data_1o5p_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1o5p _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.478 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.475 0 CA-C-O 122.327 1.061 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.546 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.9 t -111.21 108.54 18.23 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-O 123.11 1.433 . . . . 0.0 109.167 179.379 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.523 HG12 ' CG1' ' A' ' 95' ' ' VAL . 2.7 t -115.39 140.33 37.4 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.681 0 CA-C-N 114.255 -1.339 . . . . 0.0 110.08 -179.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.512 HG22 ' N ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -175.72 149.78 1.09 Allowed Pre-proline 0 N--CA 1.487 1.422 0 O-C-N 121.305 -0.872 . . . . 0.0 108.728 -179.656 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.512 ' N ' HG22 ' A' ' 8' ' ' THR . 2.2 Cg_endo -75.66 152.33 97.04 Favored 'Cis proline' 0 C--N 1.311 -1.408 0 C-N-CA 123.422 -1.491 . . . . 0.0 109.371 -0.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.493 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 10.9 m -90.69 -24.64 20.39 Favored 'General case' 0 C--N 1.293 -1.887 0 O-C-N 121.605 -0.684 . . . . 0.0 109.191 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.516 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.4 m -137.16 165.32 26.36 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.44 -0.788 . . . . 0.0 109.59 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.5 38.62 32.46 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.611 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.6 mt -92.79 -43.95 8.76 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 123.152 1.453 . . . . 0.0 110.736 -178.2 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.05 145.47 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.274 0 CA-C-N 113.597 -1.638 . . . . 0.0 110.156 -179.912 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.548 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.2 p-10 -51.16 106.84 0.15 Allowed 'General case' 0 C--N 1.301 -1.517 0 CA-C-O 121.461 0.648 . . . . 0.0 111.526 -178.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.79 14.76 9.15 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.43 -1.367 . . . . 0.0 112.969 177.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.611 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.4 t -104.24 -171.94 2.02 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 121.075 2.437 . . . . 0.0 109.544 179.152 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.544 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 16.2 t -128.59 136.05 60.89 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.392 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.116 -179.065 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.528 ' CG1' ' CG2' ' A' ' 69' ' ' VAL . 20.6 m -111.52 155.55 12.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 11.1 tttt -112.31 109.31 18.88 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.192 -0.942 . . . . 0.0 108.954 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.52 ' CG1' HG22 ' A' ' 34' ' ' VAL . 2.1 p -103.63 140.51 21.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.544 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -135.54 160.22 39.15 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.842 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.18 144.56 15.82 Favored Glycine 0 C--N 1.294 -1.783 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.51 125.11 12.47 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 120.891 -1.358 . . . . 0.0 108.844 179.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.89 26.64 26.15 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.28 -1.438 . . . . 0.0 109.864 -179.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.543 ' HB2' ' HB1' ' A' ' 57' ' ' ALA . 1.4 mt -87.79 174.89 8.11 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 120.885 -1.362 . . . . 0.0 108.596 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.559 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.79 99.58 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.4 0 O-C-N 120.987 -1.071 . . . . 0.0 109.766 -179.696 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.2 78.01 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.124 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.98 34.23 0.3 Allowed Glycine 0 N--CA 1.487 2.098 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.541 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.5 p -141.29 107.5 5.23 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 121.111 -1.229 . . . . 0.0 111.249 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.56 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -49.72 109.96 0.33 Allowed 'General case' 0 N--CA 1.498 1.938 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.638 178.076 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.45 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.6 m-30 -106.25 154.04 21.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.126 -0.984 . . . . 0.0 108.837 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.477 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.86 162.75 12.93 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.863 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.626 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.5 p -142.63 116.5 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.048 -1.032 . . . . 0.0 109.628 -178.161 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.485 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.69 -175.79 37.19 Favored Glycine 0 N--CA 1.494 2.501 0 C-N-CA 118.353 -1.879 . . . . 0.0 111.67 -179.655 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.581 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -100.73 109.65 21.69 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-O 121.899 0.857 . . . . 0.0 109.038 -179.597 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.459 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -129.94 149.88 51.47 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.275 -0.891 . . . . 0.0 109.634 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.33 139.21 53.89 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.166 -0.959 . . . . 0.0 110.796 -178.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.625 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 114.95 26.79 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.038 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.0 m -105.13 15.03 6.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 120.906 -1.121 . . . . 0.0 110.584 -178.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.589 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.78 -175.06 0.08 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.904 -1.123 . . . . 0.0 110.0 179.79 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.03 97.59 1.92 Allowed 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.465 -0.772 . . . . 0.0 109.687 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.65 27.89 33.97 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 120.258 -0.972 . . . . 0.0 111.392 178.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.589 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.38 106.41 20.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 O-C-N 120.576 -1.543 . . . . 0.0 107.313 178.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.625 HD13 ' CD1' ' A' ' 39' ' ' TRP . 11.8 tp -115.86 104.68 11.87 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 120.486 -1.384 . . . . 0.0 109.896 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.18 109.47 22.22 Favored 'General case' 0 N--CA 1.484 1.238 0 O-C-N 120.81 -1.182 . . . . 0.0 107.917 178.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.63 166.57 10.58 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.914 -1.116 . . . . 0.0 110.484 -178.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.522 ' ND2' ' HB2' ' A' ' 50' ' ' ALA . 47.6 t30 -112.06 129.77 23.93 Favored Pre-proline 0 N--CA 1.501 2.1 0 O-C-N 121.488 -0.758 . . . . 0.0 109.583 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.56 21.05 0.25 Allowed 'Trans proline' 0 C--N 1.319 -1.024 0 C-N-CA 122.132 1.888 . . . . 0.0 112.268 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.522 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -109.55 3.49 21.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.334 -1.479 . . . . 0.0 108.977 179.336 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.518 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.34 17.23 2.76 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 179.382 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -80.6 87.77 5.74 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.987 -0.685 . . . . 0.0 111.143 -178.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -104.2 -165.82 1.19 Allowed 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 178.159 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.464 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.89 137.13 0.09 Allowed 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.532 -1.355 . . . . 0.0 111.382 -179.306 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.581 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -155.5 157.09 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 178.21 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.56 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.63 142.34 30.33 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.746 -1.222 . . . . 0.0 109.911 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.687 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.34 106.83 0.96 Allowed 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 122.476 1.131 . . . . 0.0 109.406 178.481 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.526 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.6 p-10 -60.4 -139.56 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.893 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.16 -50.9 58.04 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.4 -0.813 . . . . 0.0 110.666 -178.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -103.55 -33.15 9.12 Favored 'General case' 0 C--N 1.287 -2.137 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 178.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.687 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.66 65.34 0.6 Allowed Glycine 0 C--N 1.298 -1.556 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.574 178.084 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.6 m -102.05 128.37 48.53 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 121.481 -1.011 . . . . 0.0 108.635 178.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.581 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.7 108.84 6.79 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.798 -179.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 3.8 m -121.54 119.02 30.73 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.18 -0.95 . . . . 0.0 109.428 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.456 ' CG2' HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.87 145.13 31.46 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.484 -0.76 . . . . 0.0 109.446 179.875 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.4 p -98.99 146.77 25.69 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.413 -0.804 . . . . 0.0 109.632 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.528 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -146.65 166.74 25.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.451 -0.78 . . . . 0.0 109.285 -179.431 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.544 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 4.1 p -95.24 124.87 39.5 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.075 -1.015 . . . . 0.0 109.637 -179.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.539 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.3 m -137.7 142.64 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.948 -1.095 . . . . 0.0 109.834 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.548 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 7.4 ptt180 -141.37 -165.49 1.98 Allowed 'General case' 0 N--CA 1.487 1.411 0 O-C-N 120.617 -1.302 . . . . 0.0 110.312 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.58 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 2.7 mtt180 -71.66 -78.02 0.09 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.34 -0.85 . . . . 0.0 109.096 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.441 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -69.05 137.35 53.51 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 120.21 -1.556 . . . . 0.0 107.437 179.082 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.564 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -160.78 132.8 5.93 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 117.996 -1.482 . . . . 0.0 110.167 -178.098 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.494 ' C ' ' O ' ' A' ' 73' ' ' PHE . 9.2 mp0 -30.1 121.92 0.18 Allowed 'General case' 0 N--CA 1.492 1.675 0 CA-C-O 121.627 0.727 . . . . 0.0 110.88 -178.237 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.02 45.09 3.16 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.587 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.4 m-30 -38.99 113.55 0.32 Allowed 'General case' 0 N--CA 1.508 2.461 0 O-C-N 121.123 -1.221 . . . . 0.0 110.268 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.526 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -87.57 127.45 35.26 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.035 -1.041 . . . . 0.0 109.487 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.0 t80 -64.48 58.1 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.861 -1.15 . . . . 0.0 110.118 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 77' ' ' LEU . 27.6 t0 -160.02 18.95 0.16 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.041 -1.037 . . . . 0.0 109.814 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.39 -26.42 5.71 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.56 158.6 15.62 Favored 'General case' 0 N--CA 1.485 1.307 0 O-C-N 120.959 -1.318 . . . . 0.0 110.435 -179.438 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.462 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -105.36 133.63 49.81 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 179.711 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.498 ' CD1' HD13 ' A' ' 77' ' ' LEU . 3.5 t90 -80.98 -19.52 43.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.797 -1.189 . . . . 0.0 110.281 -178.717 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.7 174.08 18.68 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.85 110.65 1.83 Allowed 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.564 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.2 t -82.06 103.56 9.41 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.389 -0.819 . . . . 0.0 108.846 -178.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.476 ' CB ' HG21 ' A' ' 90' ' ' THR . 0.4 OUTLIER -67.12 111.28 3.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.439 -0.788 . . . . 0.0 109.816 -179.174 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.53 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -63.0 -6.07 3.56 Favored 'General case' 0 N--CA 1.5 2.033 0 C-N-CA 118.361 -1.336 . . . . 0.0 109.824 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 41.4 p -84.64 -0.34 53.04 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.648 -1.282 . . . . 0.0 108.897 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.476 HG21 ' CB ' ' A' ' 87' ' ' ASP . 2.5 p -113.9 -49.7 2.86 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.338 -0.851 . . . . 0.0 109.025 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.91 -178.64 3.71 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.484 -0.76 . . . . 0.0 109.62 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.36 115.44 30.26 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.469 -0.769 . . . . 0.0 108.981 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.557 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.05 123.03 40.68 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.861 -1.15 . . . . 0.0 109.774 -179.249 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.576 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.57 146.87 27.91 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-O 122.378 1.085 . . . . 0.0 111.139 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.523 ' CG1' HG12 ' A' ' 7' ' ' VAL . 56.2 t -102.07 110.03 27.75 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.013 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 177.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.429 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.79 -170.31 16.42 Favored Glycine 0 N--CA 1.487 2.077 0 C-N-CA 118.246 -1.931 . . . . 0.0 111.631 -177.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.477 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -122.66 176.99 5.64 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.871 -0.782 . . . . 0.0 109.162 -178.854 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.459 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.5 m . . . . . 0 C--N 1.296 -1.759 0 O-C-N 121.687 -0.633 . . . . 0.0 109.386 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.404 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.482 1.722 0 N-CA-C 107.814 -2.114 . . . . 0.0 107.814 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.404 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.53 -177.17 3.86 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 122.069 0.938 . . . . 0.0 109.737 179.385 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.62 -161.44 17.14 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 108.297 -1.921 . . . . 0.0 108.297 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.4 Cg_exo -46.88 177.17 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.684 0 CA-C-N 118.794 1.297 . . . . 0.0 110.161 179.28 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -94.15 -168.92 1.95 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.054 -1.029 . . . . 0.0 110.284 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.429 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.24 162.8 18.25 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.69 129.54 48.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.457 -1.025 . . . . 0.0 109.205 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.576 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.78 122.39 21.45 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 121.74 -0.6 . . . . 0.0 109.86 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.576 HD13 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.92 170.45 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.268 -0.895 . . . . 0.0 109.191 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.516 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.23 155.07 51.27 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.211 -0.931 . . . . 0.0 109.636 -179.908 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.58 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 66.1 m-85 . . . . . 0 N--CA 1.486 1.337 0 O-C-N 121.224 -0.923 . . . . 0.0 109.457 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.475 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 122.297 1.046 . . . . 0.0 110.758 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.538 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.9 t -110.6 108.57 18.54 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 123.05 1.405 . . . . 0.0 109.073 179.275 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.502 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 2.2 t -117.02 140.42 39.76 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.713 0 CA-C-N 114.295 -1.32 . . . . 0.0 110.049 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.473 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -177.7 149.84 0.76 Allowed Pre-proline 0 N--CA 1.486 1.34 0 O-C-N 121.285 -0.884 . . . . 0.0 108.78 -179.757 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.473 ' HA ' HG22 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.86 150.39 86.5 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 123.551 -1.437 . . . . 0.0 109.239 -0.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.46 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 14.2 p -89.65 -25.74 21.1 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.466 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 8.1 m -132.75 163.22 29.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.427 -0.796 . . . . 0.0 109.527 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.16 37.72 31.6 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 -179.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.628 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 32.5 mt -92.95 -44.01 8.65 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.193 1.473 . . . . 0.0 110.695 -178.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.93 144.99 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.299 0 CA-C-N 113.515 -1.675 . . . . 0.0 109.919 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.583 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.7 p-10 -51.17 108.77 0.27 Allowed 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.433 0.635 . . . . 0.0 111.533 -178.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.84 13.38 11.28 Favored Glycine 0 N--CA 1.483 1.796 0 C-N-CA 119.45 -1.357 . . . . 0.0 112.875 177.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.628 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 11.1 t -103.12 -173.1 2.23 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 120.988 2.394 . . . . 0.0 109.571 179.333 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.535 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 20.7 t -127.2 135.11 64.42 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.968 -178.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.526 HG11 ' CG2' ' A' ' 69' ' ' VAL . 31.3 m -110.38 155.28 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 13.3 tttt -112.41 109.38 18.96 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.169 -0.957 . . . . 0.0 109.045 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.473 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.3 p -104.92 141.44 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.546 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -137.8 160.32 39.57 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.863 179.707 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.589 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.23 144.87 16.14 Favored Glycine 0 C--N 1.294 -1.775 0 N-CA-C 108.211 -1.956 . . . . 0.0 108.211 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.55 125.14 12.47 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.025 -1.28 . . . . 0.0 108.793 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.91 26.95 25.23 Favored Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.28 -1.438 . . . . 0.0 109.759 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.549 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.2 mt -86.74 175.31 8.31 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.862 -1.375 . . . . 0.0 108.529 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.09 98.04 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.914 -1.116 . . . . 0.0 109.598 -179.637 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.551 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.82 77.31 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.735 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.376 -179.099 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.43 34.29 0.32 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 179.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.543 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.2 p -146.08 112.22 5.75 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.916 -1.344 . . . . 0.0 111.202 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.542 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.85 126.85 6.03 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.823 178.223 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.493 ' CD2' ' O ' ' A' ' 30' ' ' THR . 13.8 m-85 -119.35 152.13 37.3 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.475 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.49 162.67 12.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.635 -1.291 . . . . 0.0 107.727 178.667 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.616 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.7 p -147.1 117.02 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.002 -1.061 . . . . 0.0 110.031 -177.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -170.61 -176.46 40.0 Favored Glycine 0 N--CA 1.493 2.439 0 C-N-CA 118.323 -1.894 . . . . 0.0 111.714 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.559 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -99.79 108.92 21.34 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -179.801 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.441 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -131.01 148.91 52.81 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.22 -0.925 . . . . 0.0 109.777 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.79 139.38 54.04 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.31 -0.869 . . . . 0.0 110.768 -179.014 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.621 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.28 114.7 26.51 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 178.133 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.2 m -104.37 15.06 6.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.051 -1.03 . . . . 0.0 110.523 -178.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER 173.98 -175.89 0.07 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.979 -1.075 . . . . 0.0 110.076 179.706 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.544 ' O ' ' CG2' ' A' ' 42' ' ' THR . 14.9 t -71.95 98.87 2.12 Favored 'General case' 0 N--CA 1.487 1.38 0 CA-C-O 121.77 0.795 . . . . 0.0 109.648 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.69 27.34 35.46 Favored Glycine 0 N--CA 1.493 2.475 0 C-N-CA 120.139 -1.029 . . . . 0.0 111.422 178.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.95 106.39 20.11 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 O-C-N 120.6 -1.53 . . . . 0.0 107.197 178.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.621 HD12 ' CD1' ' A' ' 39' ' ' TRP . 13.1 tp -117.64 104.57 11.15 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.426 -1.421 . . . . 0.0 109.851 -177.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.53 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.2 109.58 22.31 Favored 'General case' 0 N--CA 1.484 1.25 0 O-C-N 120.812 -1.18 . . . . 0.0 108.165 178.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -106.38 166.43 10.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.966 -1.084 . . . . 0.0 110.122 -178.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.536 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 14.3 t-20 -108.56 137.98 20.13 Favored Pre-proline 0 N--CA 1.501 2.09 0 O-C-N 121.326 -0.859 . . . . 0.0 110.04 -179.267 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.58 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.7 Cg_endo -75.38 24.29 0.41 Allowed 'Trans proline' 0 C--N 1.317 -1.08 0 C-N-CA 122.36 2.04 . . . . 0.0 111.884 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.536 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -118.01 3.66 12.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.355 -1.466 . . . . 0.0 109.298 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.495 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -139.05 17.57 2.63 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 179.328 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -82.4 90.85 6.74 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.789 -0.765 . . . . 0.0 110.834 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.616 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -111.65 -169.24 1.43 Allowed 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 178.319 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.469 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.1 135.34 0.09 Allowed 'General case' 0 N--CA 1.486 1.353 0 O-C-N 120.584 -1.322 . . . . 0.0 111.325 -179.301 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.579 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.1 p -150.62 158.49 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 178.172 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.542 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.77 145.38 26.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.804 -1.185 . . . . 0.0 109.848 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.673 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -65.77 108.05 1.99 Allowed 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 122.359 1.076 . . . . 0.0 109.61 178.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.53 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.3 p-10 -60.73 -139.46 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.802 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.551 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.22 -50.13 62.59 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.43 -0.793 . . . . 0.0 110.432 -178.849 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 37.9 t30 -103.13 -35.18 8.59 Favored 'General case' 0 C--N 1.287 -2.141 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.673 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.05 65.91 0.6 Allowed Glycine 0 C--N 1.296 -1.64 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 178.3 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.5 m -102.04 128.86 48.3 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 121.475 -1.015 . . . . 0.0 108.899 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.579 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -138.07 108.76 6.62 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.933 -179.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -121.15 119.16 31.58 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.177 -0.952 . . . . 0.0 109.537 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.469 HG23 ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -143.08 143.27 31.79 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.496 -0.753 . . . . 0.0 109.602 179.827 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.8 p -99.74 145.36 27.75 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.45 -0.781 . . . . 0.0 109.284 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.581 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -146.71 170.33 17.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.372 -0.83 . . . . 0.0 109.421 -179.286 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.529 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.9 p -99.16 125.71 44.78 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.023 -1.048 . . . . 0.0 109.532 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.533 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -137.47 143.82 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.917 -1.114 . . . . 0.0 109.768 -179.373 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.583 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.1 ptt180 -148.64 -172.04 4.0 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.434 -1.416 . . . . 0.0 110.944 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.561 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -55.8 -101.66 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 -179.358 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.463 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.58 140.52 46.35 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 120.778 -1.201 . . . . 0.0 108.215 179.587 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -162.38 136.23 6.36 Favored 'General case' 0 C--N 1.293 -1.874 0 C-N-CA 118.772 -1.171 . . . . 0.0 109.926 -178.184 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.487 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.5 mm-40 -32.09 121.02 0.3 Allowed 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.479 0.657 . . . . 0.0 110.736 -178.399 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.53 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.15 47.86 2.92 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.169 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.58 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.37 113.03 0.29 Allowed 'General case' 0 N--CA 1.506 2.365 0 O-C-N 121.076 -1.249 . . . . 0.0 110.118 179.572 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.541 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -85.14 127.02 34.09 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.959 -1.088 . . . . 0.0 109.503 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -63.57 58.36 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.905 -1.122 . . . . 0.0 110.297 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 16.7 t0 -161.53 19.74 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.995 -1.066 . . . . 0.0 109.791 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.18 -26.72 5.4 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.129 -1.189 . . . . 0.0 110.129 179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.83 159.87 15.19 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.028 -1.278 . . . . 0.0 110.32 -179.368 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.468 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.49 134.58 49.41 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.888 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.456 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.9 t90 -82.86 -19.27 37.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.773 -1.204 . . . . 0.0 110.393 -178.637 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.43 173.91 18.76 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -64.11 107.29 1.24 Allowed 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.565 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 47.5 t -78.28 105.3 7.21 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 O-C-N 121.354 -0.841 . . . . 0.0 109.304 -178.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.468 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.9 OUTLIER -65.15 110.82 2.67 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.487 -0.758 . . . . 0.0 109.777 -179.657 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.561 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.2 t -62.52 -6.36 3.35 Favored 'General case' 0 N--CA 1.499 2.001 0 C-N-CA 118.164 -1.415 . . . . 0.0 109.788 179.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.6 p -85.83 -3.17 58.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.726 -1.234 . . . . 0.0 109.272 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.468 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -109.62 -50.2 3.01 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.295 -0.878 . . . . 0.0 108.976 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.91 -179.46 3.95 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.491 -0.755 . . . . 0.0 109.374 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.2 115.98 31.17 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.363 -0.836 . . . . 0.0 108.83 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.505 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.6 123.52 40.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.815 -1.178 . . . . 0.0 109.639 -179.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.555 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.85 146.08 29.5 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 122.382 1.087 . . . . 0.0 111.042 -179.483 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.466 HG23 HG21 ' A' ' 110' ' ' ILE . 78.4 t -102.49 109.94 27.85 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.081 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 177.651 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.451 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.97 -171.52 17.79 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 118.171 -1.966 . . . . 0.0 111.812 -177.534 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.475 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -114.55 -178.39 3.36 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -179.048 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.464 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.9 OUTLIER . . . . . 0 C--N 1.296 -1.721 0 O-C-N 121.343 -0.848 . . . . 0.0 109.605 -179.26 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.718 0 N-CA-C 107.628 -2.189 . . . . 0.0 107.628 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.29 -178.48 7.31 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 121.627 -0.925 . . . . 0.0 109.682 179.238 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.84 -161.73 16.7 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 108.395 -1.882 . . . . 0.0 108.395 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.487 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.5 Cg_exo -46.93 178.3 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.634 0 CA-C-N 118.822 1.311 . . . . 0.0 110.375 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -92.69 -179.27 5.11 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.204 -0.935 . . . . 0.0 110.455 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.451 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.42 165.5 12.52 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.86 128.2 55.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.442 -1.034 . . . . 0.0 109.159 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.555 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.64 123.16 22.68 Favored 'General case' 0 C--N 1.289 -2.043 0 O-C-N 121.632 -0.667 . . . . 0.0 109.383 179.592 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.579 HD13 ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -97.69 170.85 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.214 -0.929 . . . . 0.0 109.197 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.466 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.71 153.79 49.73 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.214 -0.929 . . . . 0.0 109.609 -179.847 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CZ ' HD13 ' A' ' 110' ' ' ILE . 75.9 m-85 . . . . . 0 N--CA 1.486 1.356 0 O-C-N 121.162 -0.961 . . . . 0.0 109.494 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.184 0 CA-C-O 122.44 1.114 . . . . 0.0 110.84 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.532 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.2 p -105.65 104.86 14.67 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.427 1.108 . . . . 0.0 110.287 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.524 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 11.7 t -118.82 117.28 53.86 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.469 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.226 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.524 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.1 149.71 11.76 Favored Pre-proline 0 N--CA 1.487 1.381 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 -179.611 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.524 ' CA ' HG21 ' A' ' 8' ' ' THR . 4.9 Cg_endo -77.14 152.05 94.18 Favored 'Cis proline' 0 C--N 1.309 -1.534 0 C-N-CA 123.698 -1.376 . . . . 0.0 109.567 -0.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.441 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 18.0 p -93.15 -24.75 18.14 Favored 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.464 ' HB3' ' HB2' ' A' ' 111' ' ' SER . 3.9 m -133.61 161.83 33.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.616 -0.678 . . . . 0.0 109.382 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.31 37.02 32.86 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.614 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 35.2 mt -90.92 -42.93 10.31 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 123.283 1.516 . . . . 0.0 110.411 -178.599 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.55 144.36 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.305 0 CA-C-N 113.28 -1.782 . . . . 0.0 109.918 -179.629 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.587 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 6.3 p-10 -50.87 106.34 0.13 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.624 0.726 . . . . 0.0 111.514 -178.646 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.29 13.93 8.66 Favored Glycine 0 N--CA 1.484 1.865 0 C-N-CA 119.468 -1.349 . . . . 0.0 113.033 177.375 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.614 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -104.98 -172.73 2.15 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 121.168 2.484 . . . . 0.0 109.785 179.253 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.558 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 17.2 t -130.39 139.49 51.21 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.319 0 CA-C-N 114.794 -1.094 . . . . 0.0 111.215 -178.783 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.518 HG22 ' CD1' ' A' ' 67' ' ' LEU . 33.8 m -115.22 155.12 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 178.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.524 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.4 tttt -109.08 109.15 20.08 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.146 -0.971 . . . . 0.0 109.466 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.522 HG11 ' CG2' ' A' ' 34' ' ' VAL . 1.9 p -105.47 122.44 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.554 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -113.68 165.66 12.31 Favored 'General case' 0 C--N 1.307 -1.273 0 O-C-N 120.821 -1.174 . . . . 0.0 109.128 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.97 107.74 0.47 Allowed Glycine 0 N--CA 1.481 1.693 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.422 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.34 139.62 50.21 Favored 'General case' 0 N--CA 1.5 2.063 0 CA-C-N 119.139 1.469 . . . . 0.0 110.102 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.39 28.18 28.19 Favored Glycine 0 N--CA 1.49 2.25 0 C-N-CA 118.796 -1.669 . . . . 0.0 109.758 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.526 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -94.7 174.44 7.11 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.996 -1.297 . . . . 0.0 108.58 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.557 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.28 100.1 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.91 -1.119 . . . . 0.0 109.74 -179.597 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.86 77.75 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.101 -179.326 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.41 34.02 0.29 Allowed Glycine 0 N--CA 1.487 2.071 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.538 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.9 p -141.86 108.73 5.42 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.071 -1.253 . . . . 0.0 111.098 -179.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.547 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -47.52 109.81 0.25 Allowed 'General case' 0 N--CA 1.496 1.874 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.796 178.253 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.518 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 21.6 m-85 -99.53 153.77 18.78 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.177 -0.952 . . . . 0.0 108.835 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -102.67 158.96 15.88 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.727 -1.233 . . . . 0.0 107.829 178.553 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.636 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.0 p -141.63 118.25 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.942 -1.099 . . . . 0.0 109.92 -177.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.4 -179.81 40.48 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.937 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.558 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -101.21 108.94 20.73 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.932 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.4 146.9 52.04 Favored 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.236 -0.915 . . . . 0.0 109.808 179.675 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -119.12 137.74 53.38 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.341 -0.849 . . . . 0.0 110.647 -178.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.631 ' CE2' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.69 114.44 26.18 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 178.143 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.428 HG22 ' HB ' ' A' ' 44' ' ' VAL . 16.7 m -105.92 14.51 7.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 120.971 -1.081 . . . . 0.0 110.666 -178.665 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.596 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.33 -175.38 0.08 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.815 -1.178 . . . . 0.0 110.116 179.743 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.541 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.97 98.07 1.54 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-O 121.806 0.812 . . . . 0.0 109.91 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.97 26.61 36.81 Favored Glycine 0 N--CA 1.493 2.494 0 C-N-CA 120.17 -1.014 . . . . 0.0 111.562 178.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.596 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -115.27 105.98 19.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 O-C-N 120.549 -1.559 . . . . 0.0 107.316 178.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.631 HD13 ' CE2' ' A' ' 39' ' ' TRP . 13.1 tp -118.31 104.81 11.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.502 -1.374 . . . . 0.0 109.628 -177.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.498 ' CB ' HG23 ' A' ' 86' ' ' VAL . . . -97.92 109.67 22.38 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.755 -1.216 . . . . 0.0 108.271 179.074 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.3 t -105.51 164.44 11.88 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.996 -1.065 . . . . 0.0 110.416 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.53 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 9.6 t-20 -109.2 137.21 20.14 Favored Pre-proline 0 N--CA 1.5 2.042 0 O-C-N 121.505 -0.747 . . . . 0.0 109.972 -179.162 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.578 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.2 Cg_endo -74.39 23.9 0.36 Allowed 'Trans proline' 0 CA--C 1.544 1.004 0 C-N-CA 122.371 2.047 . . . . 0.0 112.049 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.53 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -116.91 3.61 12.85 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.364 -1.46 . . . . 0.0 109.115 179.669 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.516 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.49 13.82 3.22 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 179.356 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -79.25 91.46 5.0 Favored 'General case' 0 C--N 1.306 -1.321 0 O-C-N 121.509 -0.744 . . . . 0.0 111.052 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.636 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -112.63 -168.79 1.37 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.188 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.472 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.79 136.83 0.09 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.567 -1.333 . . . . 0.0 111.46 -179.296 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.577 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -152.19 157.01 5.31 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 178.024 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.547 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.18 143.78 28.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 120.808 -1.182 . . . . 0.0 110.081 -179.497 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.68 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.14 106.7 1.12 Allowed 'General case' 0 C--N 1.3 -1.55 0 CA-C-O 122.44 1.114 . . . . 0.0 109.278 178.609 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.527 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.8 p-10 -60.14 -139.12 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.948 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.546 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.53 -50.54 59.81 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.497 -0.752 . . . . 0.0 110.597 -178.522 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -103.91 -34.11 8.61 Favored 'General case' 0 C--N 1.286 -2.179 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 178.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.68 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.28 66.44 0.6 Allowed Glycine 0 C--N 1.296 -1.639 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.568 178.105 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 21.5 m -103.15 125.32 49.79 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.665 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.34 109.33 8.73 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.464 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.6 m -118.16 116.95 27.87 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.368 -0.833 . . . . 0.0 109.307 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.461 HG23 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -142.88 139.89 30.99 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.525 -0.734 . . . . 0.0 109.588 -179.987 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.6 p -99.62 134.55 42.33 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.465 -0.772 . . . . 0.0 109.43 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.518 ' CD1' HG22 ' A' ' 19' ' ' VAL . 0.1 OUTLIER -132.12 165.6 23.68 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.427 -0.796 . . . . 0.0 109.389 -179.549 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.558 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.8 p -96.89 125.33 41.26 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.012 -1.055 . . . . 0.0 109.25 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.527 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 15.9 m -136.01 143.47 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 120.95 -1.094 . . . . 0.0 109.81 -179.061 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.587 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.7 ptt180 -147.15 -175.48 4.84 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.534 -1.354 . . . . 0.0 111.032 -179.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.557 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.12 -101.45 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.609 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.76 141.73 43.12 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.773 -1.204 . . . . 0.0 108.114 179.437 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.596 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.74 136.03 5.06 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 118.653 -1.219 . . . . 0.0 109.96 -177.973 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' A' ' 73' ' ' PHE . 0.7 OUTLIER -33.42 121.92 0.41 Allowed 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.364 0.602 . . . . 0.0 110.313 -178.609 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.489 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.16 50.19 1.91 Allowed Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.388 -0.91 . . . . 0.0 111.343 -178.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.578 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.4 m-85 -40.15 113.5 0.36 Allowed 'General case' 0 N--CA 1.507 2.383 0 O-C-N 121.123 -1.222 . . . . 0.0 109.749 179.313 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.516 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.3 tp -85.66 127.04 34.38 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 120.903 -1.123 . . . . 0.0 109.726 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 33.3 t80 -65.25 58.06 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.971 0 O-C-N 120.85 -1.156 . . . . 0.0 109.824 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.516 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -158.69 18.67 0.21 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.004 -1.06 . . . . 0.0 109.596 -179.991 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.95 -27.23 5.56 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 42.3 p -93.98 159.87 14.98 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.962 -1.316 . . . . 0.0 110.455 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.474 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.02 135.8 46.83 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.536 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.487 ' CD1' HD13 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -83.88 -16.46 44.3 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.737 -1.227 . . . . 0.0 110.67 -178.345 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 107.62 176.23 22.44 Favored Glycine 0 N--CA 1.485 1.95 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.9 104.31 0.68 Allowed 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.582 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 39.4 t -76.37 107.19 7.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.353 -0.842 . . . . 0.0 109.096 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 1.3 m-20 -66.29 111.45 3.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.448 -0.782 . . . . 0.0 109.975 -179.236 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.557 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.74 -5.56 4.36 Favored 'General case' 0 N--CA 1.5 2.067 0 C-N-CA 118.268 -1.373 . . . . 0.0 109.78 179.357 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.0 p -86.7 -1.45 57.72 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.744 -1.222 . . . . 0.0 109.231 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.453 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.15 -49.6 3.01 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.212 -0.93 . . . . 0.0 109.019 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.89 178.42 4.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.55 -0.719 . . . . 0.0 109.398 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.83 116.45 32.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.348 -0.845 . . . . 0.0 109.115 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.561 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.59 122.89 40.0 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.853 -1.155 . . . . 0.0 109.189 -179.473 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.536 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -101.18 146.04 28.01 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 122.334 1.064 . . . . 0.0 111.338 -179.08 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.524 ' CG1' HG12 ' A' ' 7' ' ' VAL . 65.8 t -103.21 109.78 27.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.964 0 N-CA-C 106.345 -1.724 . . . . 0.0 106.345 177.45 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.87 -172.82 17.53 Favored Glycine 0 N--CA 1.486 1.968 0 C-N-CA 118.063 -2.018 . . . . 0.0 111.804 -177.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -115.98 -177.77 3.24 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -178.87 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.487 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.9 OUTLIER . . . . . 0 C--N 1.295 -1.777 0 O-C-N 121.385 -0.822 . . . . 0.0 109.098 -179.24 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.701 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.7 -179.07 7.84 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 121.448 -1.03 . . . . 0.0 109.641 178.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.58 -166.56 33.91 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 -179.49 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 104' ' ' GLY . 2.9 Cg_exo -49.8 -176.67 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.685 0 CA-C-N 118.857 1.329 . . . . 0.0 110.067 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -94.41 179.33 5.32 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.04 -1.037 . . . . 0.0 110.571 -178.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -117.97 166.77 12.76 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -108.26 128.87 63.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.246 -1.15 . . . . 0.0 109.117 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.536 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.09 119.1 16.86 Favored 'General case' 0 C--N 1.289 -2.045 0 O-C-N 121.586 -0.696 . . . . 0.0 109.356 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.579 HD13 ' CZ ' ' A' ' 112' ' ' PHE . 1.7 pt -97.81 169.9 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.151 -0.968 . . . . 0.0 108.916 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.464 ' HB2' ' HB3' ' A' ' 11' ' ' SER . 1.2 m -141.15 156.97 45.87 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.123 -0.986 . . . . 0.0 110.095 -179.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CZ ' HD13 ' A' ' 110' ' ' ILE . 97.8 m-85 . . . . . 0 N--CA 1.484 1.242 0 O-C-N 121.24 -0.912 . . . . 0.0 109.479 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.483 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.439 0 CA-C-O 122.486 1.136 . . . . 0.0 110.692 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.544 ' CG2' ' O ' ' A' ' 6' ' ' THR . 7.2 t -110.28 108.72 18.92 Favored 'General case' 0 C--N 1.296 -1.724 0 CA-C-O 123.108 1.432 . . . . 0.0 109.067 179.316 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.502 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 3.1 t -116.53 139.01 45.26 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.72 0 CA-C-N 114.246 -1.343 . . . . 0.0 110.123 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.479 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.64 149.13 1.27 Allowed Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.323 -0.861 . . . . 0.0 108.775 -179.735 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.479 ' HA ' HG22 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.79 152.52 97.07 Favored 'Cis proline' 0 C--N 1.312 -1.365 0 C-N-CA 123.476 -1.468 . . . . 0.0 109.485 -0.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.515 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 3.3 m -90.87 -24.56 20.2 Favored 'General case' 0 C--N 1.293 -1.874 0 O-C-N 121.587 -0.695 . . . . 0.0 109.175 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.51 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.2 m -137.94 165.34 26.78 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.547 -0.721 . . . . 0.0 109.515 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.05 37.98 31.34 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 108.579 -1.808 . . . . 0.0 108.579 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.621 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 33.8 mt -93.01 -43.93 8.66 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 123.102 1.43 . . . . 0.0 110.703 -178.249 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.481 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.17 145.94 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.314 0 CA-C-N 113.595 -1.639 . . . . 0.0 110.138 -179.904 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -51.23 106.95 0.15 Allowed 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 121.66 0.743 . . . . 0.0 111.638 -178.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.73 13.97 9.06 Favored Glycine 0 N--CA 1.484 1.878 0 C-N-CA 119.473 -1.346 . . . . 0.0 112.968 177.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.621 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 11.5 t -104.08 -173.96 2.43 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 121.164 2.482 . . . . 0.0 109.936 179.417 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.548 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 39.1 t -124.76 136.11 61.79 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.389 0 CA-C-N 114.563 -1.199 . . . . 0.0 110.917 -178.669 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.557 ' CG1' ' CG2' ' A' ' 69' ' ' VAL . 35.6 m -114.04 154.95 15.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.259 -0.9 . . . . 0.0 108.725 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.81 109.15 18.44 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.037 179.876 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.464 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.1 p -104.48 141.02 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.523 ' CB ' HG22 ' A' ' 6' ' ' THR . . . -137.73 160.76 38.35 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 120.735 -1.228 . . . . 0.0 110.154 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -128.46 144.6 15.42 Favored Glycine 0 C--N 1.295 -1.731 0 N-CA-C 107.973 -2.051 . . . . 0.0 107.973 179.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.13 125.71 13.3 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 120.851 -1.382 . . . . 0.0 108.864 179.053 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.454 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 89.44 26.01 26.64 Favored Glycine 0 N--CA 1.488 2.138 0 C-N-CA 119.184 -1.484 . . . . 0.0 109.874 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.556 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -89.02 170.98 10.19 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.86 -1.376 . . . . 0.0 108.477 179.892 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.559 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.02 100.88 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.082 -1.012 . . . . 0.0 110.038 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.2 78.53 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.007 -179.48 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.88 34.32 0.3 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.57 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 16.6 p -138.78 105.06 5.25 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.217 -1.166 . . . . 0.0 111.293 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.564 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.8 111.87 0.62 Allowed 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.054 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.57 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 36.9 m-85 -108.92 157.53 18.54 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.186 -0.946 . . . . 0.0 108.897 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.479 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.21 163.14 12.42 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.913 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.623 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.8 p -143.75 119.42 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.034 -1.041 . . . . 0.0 109.914 -178.044 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.89 -177.87 38.96 Favored Glycine 0 N--CA 1.495 2.602 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.851 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.559 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -102.15 108.76 20.26 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -131.14 149.56 52.54 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.241 -0.912 . . . . 0.0 109.716 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.03 138.27 54.73 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.105 -0.997 . . . . 0.0 110.803 -178.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.625 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.73 26.55 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.112 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.455 HG21 ' HB ' ' A' ' 44' ' ' VAL . 16.0 m -104.74 14.8 6.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.109 -0.994 . . . . 0.0 110.593 -178.806 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.59 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 173.97 -175.7 0.07 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.989 -1.069 . . . . 0.0 110.003 179.686 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.548 ' O ' ' CG2' ' A' ' 42' ' ' THR . 14.9 t -72.1 99.0 2.22 Favored 'General case' 0 N--CA 1.486 1.357 0 CA-C-O 121.763 0.792 . . . . 0.0 109.738 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.77 27.7 34.14 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 120.227 -0.987 . . . . 0.0 111.405 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.59 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -117.5 105.88 18.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.619 -1.518 . . . . 0.0 107.263 178.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.625 HD11 ' CD1' ' A' ' 39' ' ' TRP . 13.2 tp -117.66 104.67 11.25 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.48 -1.387 . . . . 0.0 109.739 -177.77 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.557 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.89 109.35 22.12 Favored 'General case' 0 N--CA 1.484 1.26 0 O-C-N 120.804 -1.185 . . . . 0.0 107.9 178.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.491 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -107.26 162.71 13.65 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.956 -1.09 . . . . 0.0 110.263 -178.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.486 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 39.7 t30 -105.71 134.7 19.59 Favored Pre-proline 0 N--CA 1.503 2.189 0 O-C-N 121.405 -0.809 . . . . 0.0 109.539 -179.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.586 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.2 Cg_endo -72.74 22.92 0.29 Allowed 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.322 2.015 . . . . 0.0 112.46 -179.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.486 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -118.34 10.59 12.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.349 -1.469 . . . . 0.0 108.958 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.535 ' OD1' ' CG1' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -137.99 14.59 2.86 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 179.326 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -80.15 88.64 5.43 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.564 -0.855 . . . . 0.0 111.286 -178.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.55 -167.05 1.18 Allowed 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 178.128 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.459 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.74 138.26 0.09 Allowed 'General case' 0 C--N 1.306 -1.284 0 O-C-N 120.578 -1.326 . . . . 0.0 111.239 -179.267 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.605 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -155.69 156.48 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.397 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.564 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.66 142.03 30.74 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.798 -1.189 . . . . 0.0 110.016 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.69 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -61.74 106.76 0.72 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.425 1.107 . . . . 0.0 109.287 178.091 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.519 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.0 p-10 -60.44 -138.4 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.033 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.36 -51.03 58.13 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.429 -0.794 . . . . 0.0 110.902 -178.576 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.454 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.7 t-20 -103.57 -34.54 8.62 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 178.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.69 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 110.95 63.02 0.5 Allowed Glycine 0 C--N 1.297 -1.621 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 177.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.9 m -102.48 126.9 49.68 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.6 -0.941 . . . . 0.0 108.487 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.605 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.68 109.19 7.41 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.834 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.1 m -120.83 120.56 35.92 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.284 -0.885 . . . . 0.0 109.515 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.524 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -142.04 143.65 33.23 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.526 -0.734 . . . . 0.0 109.355 179.772 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.7 p -102.0 143.41 31.89 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.423 -0.798 . . . . 0.0 109.462 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.553 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.1 OUTLIER -146.26 -178.87 6.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 109.43 -179.45 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.491 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -105.06 125.88 51.46 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.903 -1.123 . . . . 0.0 110.289 -178.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.557 ' CG2' ' CG1' ' A' ' 19' ' ' VAL . 15.3 m -134.56 144.22 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 120.965 -1.085 . . . . 0.0 109.756 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.3 ptt180 -148.66 -179.62 7.11 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 120.458 -1.401 . . . . 0.0 111.105 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.554 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.92 -100.89 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -179.661 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.73 139.54 50.35 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.82 -1.175 . . . . 0.0 107.928 179.303 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -161.44 136.18 7.25 Favored 'General case' 0 C--N 1.295 -1.803 0 C-N-CA 118.647 -1.221 . . . . 0.0 109.807 -178.105 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.476 ' C ' ' O ' ' A' ' 73' ' ' PHE . 15.7 mt-10 -33.97 121.43 0.45 Allowed 'General case' 0 N--CA 1.491 1.621 0 CA-C-O 121.419 0.628 . . . . 0.0 110.358 -178.45 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.557 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.03 50.86 1.93 Allowed Glycine 0 N--CA 1.493 2.493 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.068 -179.278 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.586 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-85 -39.22 116.69 0.62 Allowed 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.122 -1.223 . . . . 0.0 109.954 179.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.9 tp -87.37 126.16 34.7 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.006 -1.059 . . . . 0.0 109.455 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -64.8 58.47 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.925 0 O-C-N 120.804 -1.185 . . . . 0.0 110.014 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 26.4 t0 -159.33 19.54 0.18 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.054 -1.029 . . . . 0.0 109.571 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.51 -28.2 5.41 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.447 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 66.3 p -95.96 160.24 14.56 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.964 -1.315 . . . . 0.0 110.438 -179.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.467 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 4.1 ptt180 -105.73 138.77 41.37 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.466 ' HB2' HD11 ' A' ' 77' ' ' LEU . 2.0 t90 -83.55 -19.12 36.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.852 -1.155 . . . . 0.0 110.556 -178.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.59 176.1 19.24 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 108.704 -1.758 . . . . 0.0 108.704 -179.569 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -65.72 105.9 1.37 Allowed 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.553 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.0 t -77.36 105.9 6.86 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 O-C-N 121.355 -0.841 . . . . 0.0 109.144 -178.836 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.459 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.7 OUTLIER -64.97 111.1 2.7 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.373 -0.829 . . . . 0.0 109.819 -179.558 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.554 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -62.91 -5.93 3.34 Favored 'General case' 0 N--CA 1.499 2.02 0 C-N-CA 118.214 -1.394 . . . . 0.0 109.85 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.2 p -86.99 -1.25 57.72 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.729 -1.232 . . . . 0.0 109.319 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.459 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.8 p -111.49 -50.3 2.94 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.384 -0.823 . . . . 0.0 108.937 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.76 -179.94 4.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.544 -0.723 . . . . 0.0 109.238 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.93 116.11 31.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.325 -0.859 . . . . 0.0 109.057 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -96.93 121.17 38.51 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.854 -1.154 . . . . 0.0 109.278 -179.321 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.562 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.3 mt-30 -102.04 146.78 27.42 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-O 122.402 1.096 . . . . 0.0 111.311 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.458 HG21 HG21 ' A' ' 110' ' ' ILE . 62.1 t -104.65 109.86 28.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 177.479 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.45 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.0 -170.04 16.27 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 118.243 -1.932 . . . . 0.0 111.62 -177.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.479 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -112.78 179.88 3.85 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -179.065 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.2 p . . . . . 0 C--N 1.297 -1.714 0 O-C-N 121.362 -0.836 . . . . 0.0 109.546 -179.18 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.741 0 N-CA-C 107.775 -2.13 . . . . 0.0 107.775 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -164.04 -177.42 5.03 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 121.599 -0.942 . . . . 0.0 109.962 179.451 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.67 -161.72 14.25 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.518 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.48 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.5 Cg_exo -47.53 178.45 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 CA-C-N 118.997 1.398 . . . . 0.0 110.196 179.281 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -91.25 -177.56 4.9 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.056 -1.028 . . . . 0.0 110.371 -178.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.45 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.15 163.73 13.89 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.06 129.76 50.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.374 -1.074 . . . . 0.0 109.173 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.562 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.1 121.96 22.84 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.634 -0.666 . . . . 0.0 109.603 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.58 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -97.89 169.85 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.214 -0.928 . . . . 0.0 109.18 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.51 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -136.2 154.58 50.89 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.326 -0.859 . . . . 0.0 109.745 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.58 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 26.7 m-85 . . . . . 0 N--CA 1.487 1.376 0 O-C-N 121.301 -0.874 . . . . 0.0 109.421 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.496 0 CA-C-O 122.436 1.112 . . . . 0.0 110.905 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.547 ' CG2' ' O ' ' A' ' 6' ' ' THR . 7.5 t -111.74 108.71 18.24 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 123.071 1.415 . . . . 0.0 109.102 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.532 HG12 ' CG1' ' A' ' 95' ' ' VAL . 2.8 t -115.28 139.23 42.65 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.692 0 CA-C-N 114.326 -1.306 . . . . 0.0 110.196 -179.639 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.515 HG22 ' N ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.08 149.39 1.46 Allowed Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.3 -0.875 . . . . 0.0 108.783 -179.769 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.515 ' N ' HG22 ' A' ' 8' ' ' THR . 3.9 Cg_endo -77.0 151.22 93.69 Favored 'Cis proline' 0 C--N 1.312 -1.344 0 C-N-CA 123.489 -1.463 . . . . 0.0 109.238 -0.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.487 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 24.0 p -89.81 -24.36 21.47 Favored 'General case' 0 C--N 1.292 -1.924 0 O-C-N 121.46 -0.775 . . . . 0.0 109.395 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.515 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 12.4 m -136.68 164.6 27.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.35 -0.844 . . . . 0.0 109.801 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.85 38.79 30.23 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.609 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 37.2 mt -92.18 -44.1 8.98 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 123.125 1.441 . . . . 0.0 110.721 -178.325 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.488 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.88 146.17 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.364 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.329 179.989 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.561 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.9 p-10 -51.55 107.4 0.19 Allowed 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.713 0.768 . . . . 0.0 111.571 -178.633 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.8 14.95 8.98 Favored Glycine 0 N--CA 1.484 1.853 0 C-N-CA 119.445 -1.359 . . . . 0.0 112.924 177.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.609 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.5 t -105.85 -172.61 2.12 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 121.136 2.468 . . . . 0.0 109.557 179.077 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.55 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 13.3 t -129.2 136.77 58.76 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.43 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.897 -179.096 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.566 ' CG1' ' CG2' ' A' ' 69' ' ' VAL . 15.5 m -110.81 156.42 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.5 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.36 109.05 18.45 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.114 -0.991 . . . . 0.0 108.953 179.818 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.528 ' CG1' HG23 ' A' ' 34' ' ' VAL . 1.8 p -103.74 140.35 22.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.54 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -135.47 160.05 39.67 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.717 -1.239 . . . . 0.0 110.026 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.67 144.47 15.59 Favored Glycine 0 C--N 1.293 -1.806 0 N-CA-C 107.995 -2.042 . . . . 0.0 107.995 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.14 125.48 13.09 Favored 'General case' 0 C--N 1.296 -1.734 0 O-C-N 120.806 -1.408 . . . . 0.0 108.983 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.42 26.33 25.77 Favored Glycine 0 N--CA 1.488 2.121 0 C-N-CA 119.279 -1.438 . . . . 0.0 109.796 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.55 ' HB2' ' HB3' ' A' ' 57' ' ' ALA . 0.7 OUTLIER -89.36 169.59 11.28 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 120.838 -1.389 . . . . 0.0 108.347 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.562 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.84 100.99 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 122.214 1.007 . . . . 0.0 109.921 -179.438 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.82 78.18 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.618 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.904 -179.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.88 34.12 0.27 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.53 ' OG1' ' CB ' ' A' ' 27' ' ' GLN . 18.5 p -139.06 105.43 5.28 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 121.154 -1.204 . . . . 0.0 111.262 -179.433 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.567 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -51.24 111.54 0.59 Allowed 'General case' 0 N--CA 1.497 1.924 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.676 178.088 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.453 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.8 m-30 -109.48 156.35 20.2 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.109 -0.994 . . . . 0.0 108.873 179.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.49 164.98 11.86 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.821 -1.174 . . . . 0.0 107.915 179.079 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.624 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.4 p -144.95 116.52 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.036 -1.04 . . . . 0.0 109.774 -178.276 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.48 -176.23 37.43 Favored Glycine 0 N--CA 1.494 2.519 0 C-N-CA 118.348 -1.882 . . . . 0.0 111.886 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.567 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.1 pt20 -100.4 109.6 21.77 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-O 121.976 0.893 . . . . 0.0 108.978 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.61 148.75 52.44 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.212 -0.93 . . . . 0.0 109.613 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.15 138.01 54.48 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.263 -0.898 . . . . 0.0 110.875 -178.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.625 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.12 27.0 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 177.915 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 m -105.0 14.84 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 120.842 -1.162 . . . . 0.0 110.518 -178.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.42 -175.23 0.08 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 120.931 -1.106 . . . . 0.0 110.005 179.738 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.28 98.92 2.76 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.428 -0.795 . . . . 0.0 109.489 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.63 27.62 31.84 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 120.203 -0.999 . . . . 0.0 111.433 179.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -118.17 106.12 19.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 O-C-N 120.66 -1.494 . . . . 0.0 107.225 178.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.625 HD12 ' CD1' ' A' ' 39' ' ' TRP . 13.3 tp -117.94 104.53 10.99 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.475 -1.391 . . . . 0.0 109.874 -177.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.541 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.94 109.36 22.13 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 120.745 -1.222 . . . . 0.0 107.932 178.77 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.489 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 5.0 t -108.92 162.13 14.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.028 -1.045 . . . . 0.0 110.379 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.487 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 12.9 t-20 -107.36 129.18 24.64 Favored Pre-proline 0 N--CA 1.5 2.03 0 O-C-N 121.424 -0.797 . . . . 0.0 109.63 -179.404 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.0 OUTLIER -71.18 20.24 0.23 Allowed 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 122.057 1.838 . . . . 0.0 111.95 179.388 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.81 2.68 23.74 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.515 -1.366 . . . . 0.0 108.841 179.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.52 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.01 17.89 2.82 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 179.418 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -81.76 86.94 6.37 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.524 -0.735 . . . . 0.0 111.086 -178.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -102.89 -165.54 1.18 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 178.19 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.467 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.8 137.13 0.09 Allowed 'General case' 0 N--CA 1.486 1.354 0 O-C-N 120.532 -1.355 . . . . 0.0 111.212 -179.399 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.603 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -155.2 156.58 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 178.37 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.567 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.69 141.67 31.21 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.952 -1.093 . . . . 0.0 109.879 -179.802 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.688 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -62.23 107.17 0.84 Allowed 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 122.45 1.119 . . . . 0.0 109.39 178.231 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.52 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.9 t0 -62.17 -138.54 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.001 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.7 -52.42 31.34 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.391 -0.818 . . . . 0.0 110.871 -178.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -103.61 -32.81 9.24 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 178.633 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.688 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.8 62.57 0.54 Allowed Glycine 0 C--N 1.297 -1.627 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 178.04 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 37.0 m -101.04 127.14 47.7 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.603 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.13 109.2 7.2 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 119.074 -1.05 . . . . 0.0 109.877 -179.089 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 48.2 p -121.27 119.69 32.99 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.282 -0.886 . . . . 0.0 109.417 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.418 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.56 145.7 31.96 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.581 -0.699 . . . . 0.0 109.289 179.831 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.3 p -98.91 143.34 29.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.407 -0.808 . . . . 0.0 109.736 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.52 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -141.07 163.0 34.15 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.483 -0.761 . . . . 0.0 109.141 -179.486 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 5.1 p -92.77 123.98 36.44 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.045 -1.035 . . . . 0.0 109.521 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.566 ' CG2' ' CG1' ' A' ' 19' ' ' VAL . 17.8 m -137.78 144.16 31.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.001 -1.062 . . . . 0.0 109.453 -179.586 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.561 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.3 ptt180 -138.89 -168.77 2.49 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.507 -1.371 . . . . 0.0 110.544 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.658 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 3.9 mtt180 -65.48 -73.81 0.12 Allowed 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -76.72 145.43 38.66 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 178.159 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 0.9 OUTLIER -164.98 138.68 4.83 Favored 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 117.446 -1.702 . . . . 0.0 110.678 -177.478 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.486 ' O ' ' O ' ' A' ' 47' ' ' CYS . 3.7 mp0 -35.22 120.97 0.55 Allowed 'General case' 0 N--CA 1.491 1.614 0 CA-C-O 121.455 0.645 . . . . 0.0 110.361 -178.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.541 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -96.19 51.34 1.65 Allowed Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.485 -0.865 . . . . 0.0 111.018 -179.379 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-85 -40.19 114.64 0.46 Allowed 'General case' 0 N--CA 1.508 2.455 0 O-C-N 121.079 -1.248 . . . . 0.0 109.776 179.567 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.552 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.1 tp -85.73 125.67 33.39 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.855 -1.153 . . . . 0.0 109.754 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -65.24 58.04 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.908 0 O-C-N 120.789 -1.194 . . . . 0.0 109.748 179.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.552 ' N ' ' O ' ' A' ' 77' ' ' LEU . 5.6 t70 -154.97 16.7 0.43 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.13 -0.981 . . . . 0.0 109.559 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.85 -26.83 8.87 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.12 164.96 11.42 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.948 -1.325 . . . . 0.0 110.643 -179.287 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.47 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 2.1 ptm180 -105.38 137.3 43.41 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.505 ' CD1' HD12 ' A' ' 77' ' ' LEU . 1.6 t90 -81.15 -19.77 42.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.852 -1.155 . . . . 0.0 110.421 -178.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.62 176.1 19.23 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.679 -1.769 . . . . 0.0 108.679 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.97 106.44 1.24 Allowed 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.559 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 38.7 t -78.03 107.55 10.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.363 -0.836 . . . . 0.0 109.205 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -68.71 112.99 5.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.518 -0.738 . . . . 0.0 109.91 -179.371 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.658 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 7.5 m -58.43 -6.98 0.77 Allowed 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.632 -1.293 . . . . 0.0 110.424 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.8 p -87.08 -4.77 59.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.298 -1.501 . . . . 0.0 109.617 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.437 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -103.38 -47.08 4.4 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.245 -0.909 . . . . 0.0 108.94 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.08 -178.06 3.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.553 -0.717 . . . . 0.0 109.357 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.08 117.57 35.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.403 -0.811 . . . . 0.0 108.821 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.489 ' O ' HG12 ' A' ' 110' ' ' ILE . 3.2 m -96.47 121.26 38.1 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.846 -1.159 . . . . 0.0 109.724 -179.114 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.53 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.46 146.55 28.7 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 122.384 1.088 . . . . 0.0 111.37 -179.391 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.532 ' CG1' HG12 ' A' ' 7' ' ' VAL . 57.5 t -103.59 109.94 28.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 177.62 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.433 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.63 -171.54 16.8 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.221 -1.942 . . . . 0.0 111.638 -177.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.489 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.28 178.74 4.21 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 -179.067 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.1 p . . . . . 0 C--N 1.296 -1.76 0 O-C-N 121.565 -0.709 . . . . 0.0 109.406 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.65 0 N-CA-C 107.778 -2.129 . . . . 0.0 107.778 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.97 -177.74 5.99 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.64 -0.918 . . . . 0.0 109.742 179.273 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.04 -162.16 15.52 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 108.445 -1.862 . . . . 0.0 108.445 -179.439 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.2 Cg_exo -47.27 178.71 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.644 0 CA-C-N 118.789 1.295 . . . . 0.0 110.313 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -92.42 -172.97 3.25 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.007 -1.058 . . . . 0.0 110.36 -178.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.433 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.33 163.34 14.81 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.456 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.28 131.12 48.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.424 -1.045 . . . . 0.0 109.075 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.53 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.81 120.68 19.74 Favored 'General case' 0 C--N 1.29 -2.021 0 O-C-N 121.613 -0.679 . . . . 0.0 109.842 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.582 HD13 ' CZ ' ' A' ' 112' ' ' PHE . 1.4 pt -98.09 170.43 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.276 -0.89 . . . . 0.0 108.896 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.515 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.9 153.96 51.29 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.127 -0.983 . . . . 0.0 109.551 179.899 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.6 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 67.2 m-85 . . . . . 0 N--CA 1.486 1.346 0 O-C-N 121.249 -0.907 . . . . 0.0 109.527 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.522 ' CB ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.409 0 CA-C-O 122.239 1.018 . . . . 0.0 110.974 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.537 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.4 p -101.61 104.51 15.38 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 122.439 1.114 . . . . 0.0 109.864 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.518 HG11 ' CG1' ' A' ' 95' ' ' VAL . 4.1 t -118.84 118.97 59.55 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.462 179.783 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.502 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.84 147.96 9.59 Favored Pre-proline 0 C--N 1.306 -1.324 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 -179.832 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.502 ' CA ' HG21 ' A' ' 8' ' ' THR . 3.8 Cg_endo -76.17 151.31 95.02 Favored 'Cis proline' 0 C--N 1.309 -1.541 0 C-N-CA 123.593 -1.42 . . . . 0.0 109.596 -0.406 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.504 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 2.5 p -90.38 -25.37 20.46 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.426 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.469 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.1 m -136.05 165.86 24.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.609 -0.682 . . . . 0.0 109.331 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.22 37.58 36.71 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 108.463 -1.855 . . . . 0.0 108.463 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.601 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 36.0 mt -92.27 -43.0 9.53 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 123.297 1.522 . . . . 0.0 110.44 -178.33 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.487 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.48 144.35 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.29 0 CA-C-N 113.522 -1.672 . . . . 0.0 109.788 -179.62 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.551 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.7 p-10 -51.27 106.2 0.13 Allowed 'General case' 0 C--N 1.301 -1.54 0 CA-C-O 121.539 0.685 . . . . 0.0 111.597 -178.385 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.38 15.95 8.58 Favored Glycine 0 N--CA 1.484 1.884 0 C-N-CA 119.473 -1.346 . . . . 0.0 112.855 177.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.601 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.1 t -104.41 -170.88 1.83 Allowed 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 121.169 2.484 . . . . 0.0 109.727 179.176 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.571 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 14.2 t -130.38 138.92 52.65 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.166 -178.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.537 HG12 ' CG2' ' A' ' 69' ' ' VAL . 33.7 m -118.18 155.04 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tttt -109.26 109.4 20.31 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.162 -0.961 . . . . 0.0 109.509 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 1.9 p -105.86 124.59 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.489 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.537 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -117.66 167.21 11.55 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.668 -1.27 . . . . 0.0 109.253 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.61 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.07 141.05 12.38 Favored Glycine 0 C--N 1.296 -1.666 0 N-CA-C 107.466 -2.254 . . . . 0.0 107.466 179.672 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.28 123.94 11.84 Favored 'General case' 0 C--N 1.295 -1.8 0 O-C-N 120.571 -1.546 . . . . 0.0 108.819 179.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.37 27.12 23.69 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.13 -1.51 . . . . 0.0 109.899 -179.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.537 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -88.06 174.33 8.34 Favored 'General case' 0 C--N 1.308 -1.227 0 O-C-N 120.788 -1.419 . . . . 0.0 108.473 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.547 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.88 97.54 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 122.257 1.027 . . . . 0.0 109.724 -179.853 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.99 77.26 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.437 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.77 33.65 0.29 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.302 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 50.5 p -145.53 112.0 5.81 Favored 'General case' 0 C--N 1.31 -1.145 0 O-C-N 120.896 -1.355 . . . . 0.0 111.448 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.549 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -48.52 116.19 1.5 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.934 178.286 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.465 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.0 m-30 -112.28 153.87 26.51 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.225 -0.922 . . . . 0.0 108.708 179.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.459 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -98.92 165.36 11.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.849 -1.157 . . . . 0.0 108.095 179.003 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.588 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.8 p -145.15 116.64 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.114 -0.991 . . . . 0.0 109.878 -177.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.55 -175.97 39.07 Favored Glycine 0 N--CA 1.491 2.336 0 C-N-CA 118.267 -1.92 . . . . 0.0 111.754 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.567 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -100.22 113.75 26.67 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.622 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 85.0 m -131.88 153.81 49.84 Favored 'General case' 0 C--N 1.292 -1.901 0 O-C-N 121.6 -0.688 . . . . 0.0 109.602 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -129.88 136.78 49.92 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.448 -0.782 . . . . 0.0 110.565 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.639 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.69 114.45 26.38 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 178.318 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m -105.45 15.08 7.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.951 -1.093 . . . . 0.0 110.713 -178.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.597 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.22 -174.54 0.07 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.87 -1.144 . . . . 0.0 110.08 179.699 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 40.1 p -71.33 96.81 1.49 Allowed 'General case' 0 N--CA 1.485 1.323 0 O-C-N 121.382 -0.824 . . . . 0.0 109.878 -179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.26 27.95 31.92 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 120.21 -0.995 . . . . 0.0 111.564 178.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.597 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -115.54 106.38 20.36 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.54 -1.565 . . . . 0.0 107.464 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.639 HD12 ' CE2' ' A' ' 39' ' ' TRP . 11.8 tp -116.31 106.54 13.77 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.591 -1.318 . . . . 0.0 109.912 -177.621 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.576 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -96.77 113.22 24.76 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 120.821 -1.174 . . . . 0.0 108.515 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.559 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . 97.4 m -105.34 147.39 28.21 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.279 -0.888 . . . . 0.0 110.361 -178.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.465 ' OD1' ' HB2' ' A' ' 74' ' ' GLU . 32.7 t30 -97.52 135.94 21.5 Favored Pre-proline 0 N--CA 1.505 2.305 0 O-C-N 120.937 -1.102 . . . . 0.0 108.759 178.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.605 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.8 Cg_endo -74.85 26.51 0.36 Allowed 'Trans proline' 0 C--N 1.319 -1.004 0 C-N-CA 122.396 2.064 . . . . 0.0 112.29 -179.098 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.431 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -120.76 6.05 10.48 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.213 -1.554 . . . . 0.0 109.536 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.505 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -140.48 17.93 2.38 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 179.367 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.559 ' CE2' ' HB3' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -83.58 89.84 7.16 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.248 -178.437 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.588 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -109.99 -166.77 1.12 Allowed 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.153 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.477 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.66 135.61 0.09 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.421 -1.425 . . . . 0.0 111.573 -179.294 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.562 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.2 p -151.73 159.72 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 177.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.549 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.6 144.44 27.89 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.731 -1.231 . . . . 0.0 110.016 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.675 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.51 107.83 2.2 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 122.385 1.088 . . . . 0.0 109.342 178.563 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.533 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.7 t0 -62.72 -139.07 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.886 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.28 -52.09 29.7 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.427 -0.795 . . . . 0.0 110.727 -178.582 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -104.48 -32.48 8.98 Favored 'General case' 0 C--N 1.286 -2.155 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 178.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.675 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.67 68.22 0.65 Allowed Glycine 0 C--N 1.297 -1.587 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 178.294 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.61 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.0 m -103.47 128.94 50.54 Favored 'General case' 0 N--CA 1.483 1.224 0 O-C-N 121.336 -1.097 . . . . 0.0 109.15 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.562 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -135.63 108.72 7.69 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 119.469 -0.892 . . . . 0.0 109.574 -179.573 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 85.7 p -116.85 117.41 29.66 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.089 -1.007 . . . . 0.0 109.374 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.473 HG23 HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.32 142.51 28.35 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.409 -0.807 . . . . 0.0 109.956 -179.794 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.1 p -102.14 141.32 35.15 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.496 -0.752 . . . . 0.0 109.265 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.525 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -141.58 167.05 23.07 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.337 -0.852 . . . . 0.0 109.509 -179.384 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.571 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.5 p -96.17 124.74 40.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.197 -0.94 . . . . 0.0 109.349 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.537 ' CG2' HG12 ' A' ' 19' ' ' VAL . 18.7 m -138.43 142.55 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.939 -1.101 . . . . 0.0 109.922 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.551 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 8.7 ptt180 -138.56 -164.81 1.7 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.732 -1.23 . . . . 0.0 109.908 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.557 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -74.3 -82.88 0.06 Allowed 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 -179.844 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.76 136.63 57.96 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 178.698 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.567 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -161.46 133.49 5.75 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 118.058 -1.457 . . . . 0.0 110.562 -177.603 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.502 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 3.1 mm-40 -33.04 120.07 0.35 Allowed 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.619 0.723 . . . . 0.0 110.386 -178.456 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.576 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -92.9 50.74 2.54 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.484 -179.074 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.605 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -37.77 116.36 0.49 Allowed 'General case' 0 N--CA 1.507 2.381 0 O-C-N 121.136 -1.214 . . . . 0.0 110.157 179.365 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.535 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.2 tp -86.08 126.09 33.93 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 120.895 -1.128 . . . . 0.0 109.716 -179.777 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 39.3 t80 -63.62 58.42 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.015 -1.053 . . . . 0.0 110.114 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 21.2 t0 -161.01 20.27 0.13 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.904 -1.122 . . . . 0.0 109.737 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.52 -29.09 5.01 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.461 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 9.7 p -95.48 163.88 13.04 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.076 -1.249 . . . . 0.0 110.203 -179.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.453 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 3.3 ptm180 -109.25 139.85 43.64 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.465 ' HB2' HD12 ' A' ' 77' ' ' LEU . 3.6 t90 -82.0 -21.56 37.01 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.861 -1.149 . . . . 0.0 110.353 -178.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.81 175.68 18.14 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.79 110.57 2.11 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 179.037 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.542 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.1 t -82.32 102.61 8.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.652 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.475 ' CB ' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.97 111.21 2.75 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.489 -0.757 . . . . 0.0 109.632 -179.313 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.557 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.23 -4.93 5.8 Favored 'General case' 0 N--CA 1.498 1.973 0 C-N-CA 118.304 -1.358 . . . . 0.0 109.813 179.534 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.3 p -85.51 3.62 39.56 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.786 -1.196 . . . . 0.0 108.823 179.255 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.475 HG23 ' CB ' ' A' ' 87' ' ' ASP . 2.2 p -119.2 -49.82 2.38 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.402 -0.811 . . . . 0.0 108.959 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.71 -178.42 3.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.382 -0.824 . . . . 0.0 109.538 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.64 114.45 28.62 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.486 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.5 m -97.47 121.9 39.9 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.932 -1.105 . . . . 0.0 109.746 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.546 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.74 147.11 26.86 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.412 1.101 . . . . 0.0 111.245 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.518 ' CG1' HG11 ' A' ' 7' ' ' VAL . 52.9 t -103.62 110.82 31.13 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 106.913 -1.514 . . . . 0.0 106.913 177.796 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.444 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.51 -170.8 18.77 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.076 -2.012 . . . . 0.0 111.884 -177.587 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.466 HD12 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -115.96 -179.89 3.79 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 -179.167 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.465 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.4 p . . . . . 0 C--N 1.296 -1.757 0 O-C-N 121.515 -0.741 . . . . 0.0 109.317 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.624 0 N-CA-C 107.833 -2.107 . . . . 0.0 107.833 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.74 -178.16 6.87 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.572 -0.958 . . . . 0.0 109.754 179.255 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.68 -161.45 14.73 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.257 -1.937 . . . . 0.0 108.257 -179.325 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.0 Cg_exo -47.6 179.65 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.82 1.31 . . . . 0.0 110.261 179.19 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -94.05 -170.54 2.33 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.066 -1.021 . . . . 0.0 110.334 -178.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.444 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.31 162.75 18.34 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.11 128.45 50.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.381 -1.07 . . . . 0.0 109.15 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.546 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.24 119.64 15.67 Favored 'General case' 0 C--N 1.289 -2.056 0 O-C-N 121.669 -0.644 . . . . 0.0 109.738 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.577 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.7 pt -98.12 171.31 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.219 -0.926 . . . . 0.0 109.097 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.469 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.01 156.62 47.07 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.074 -1.016 . . . . 0.0 109.844 -179.822 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.577 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 96.8 m-85 . . . . . 0 N--CA 1.486 1.327 0 O-C-N 121.191 -0.943 . . . . 0.0 109.609 -179.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.477 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.441 0 CA-C-O 122.354 1.074 . . . . 1.0 110.597 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.544 ' CG2' ' O ' ' A' ' 6' ' ' THR . 7.6 t -110.31 108.67 18.83 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 123.085 1.421 . . . . 1.0 109.01 179.355 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.53 HG12 ' CG1' ' A' ' 95' ' ' VAL . 3.2 t -117.19 136.36 54.6 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.702 0 CA-C-N 114.3 -1.318 . . . . 1.0 110.002 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.484 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.31 148.76 2.43 Favored Pre-proline 0 N--CA 1.487 1.376 0 O-C-N 121.287 -0.883 . . . . 1.0 108.897 -179.64 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.484 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -79.21 148.67 82.13 Favored 'Cis proline' 0 C--N 1.311 -1.408 0 C-N-CA 123.438 -1.484 . . . . 1.0 109.52 -1.052 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.465 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 42.8 p -88.34 -25.5 22.71 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 108.981 -0.748 . . . . 1.0 108.981 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.466 ' HB3' ' CB ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -131.91 161.86 32.03 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.454 -0.779 . . . . 1.0 109.674 -179.787 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.88 37.63 29.14 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 108.592 -1.803 . . . . 1.0 108.592 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.608 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.2 mt -92.78 -43.54 8.97 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 123.099 1.428 . . . . 1.0 110.636 -178.343 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.487 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.14 145.19 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.295 0 CA-C-N 113.571 -1.65 . . . . 1.0 110.03 -179.596 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.555 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.8 p-10 -51.16 106.93 0.15 Allowed 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.462 0.648 . . . . 1.0 111.564 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.47 15.22 9.02 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 119.385 -1.388 . . . . 1.0 112.871 177.217 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.608 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 13.5 t -104.54 -171.69 1.97 Allowed 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 121.133 2.467 . . . . 1.0 109.671 179.204 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.557 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 15.1 t -128.58 137.56 56.99 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.387 0 CA-C-N 114.874 -1.057 . . . . 1.0 110.979 -179.066 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.526 HG12 ' CG2' ' A' ' 69' ' ' VAL . 35.2 m -114.13 154.75 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 108.808 -0.812 . . . . 1.0 108.808 179.036 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.5 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.65 109.23 20.37 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.226 -0.921 . . . . 1.0 108.797 179.718 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.47 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.2 p -103.82 141.6 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.727 -0.842 . . . . 1.0 108.727 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.548 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -138.24 160.23 39.99 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.72 -1.238 . . . . 1.0 109.982 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.76 144.21 15.37 Favored Glycine 0 C--N 1.295 -1.742 0 N-CA-C 108.089 -2.004 . . . . 1.0 108.089 179.811 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.11 125.53 13.16 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 120.913 -1.345 . . . . 1.0 108.828 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.08 27.09 26.89 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.216 -1.469 . . . . 1.0 109.912 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.545 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.8 mt -87.13 175.02 8.28 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 120.799 -1.412 . . . . 1.0 108.463 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.554 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.58 99.74 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.978 -1.076 . . . . 1.0 109.689 -179.79 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 77.76 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 115.226 -0.897 . . . . 1.0 110.247 -179.063 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.4 34.13 0.33 Allowed Glycine 0 N--CA 1.488 2.117 0 N-CA-C 109.496 -1.441 . . . . 1.0 109.496 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.541 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 42.9 p -141.24 108.56 5.53 Favored 'General case' 0 C--N 1.306 -1.302 0 O-C-N 121.123 -1.222 . . . . 1.0 111.311 -179.636 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.56 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.35 110.06 0.37 Allowed 'General case' 0 N--CA 1.497 1.888 0 CA-C-N 115.9 -0.591 . . . . 1.0 109.455 178.031 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.465 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.2 m-30 -106.75 155.99 19.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.133 -0.98 . . . . 1.0 108.982 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.467 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.82 165.17 11.7 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.876 -1.157 . . . . 1.0 107.876 179.045 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.622 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 7.5 p -145.7 114.85 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.066 -1.021 . . . . 1.0 109.941 -178.048 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.49 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.01 -176.41 37.3 Favored Glycine 0 N--CA 1.492 2.398 0 C-N-CA 118.499 -1.81 . . . . 1.0 111.564 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.611 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.5 pt20 -100.1 110.02 22.31 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-O 121.941 0.877 . . . . 1.0 108.966 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.451 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -130.08 150.81 51.18 Favored 'General case' 0 C--N 1.296 -1.74 0 O-C-N 121.217 -0.927 . . . . 1.0 109.837 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.83 139.78 52.84 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.222 -0.924 . . . . 1.0 110.808 -179.037 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.62 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.15 114.78 26.61 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 107.62 -1.252 . . . . 1.0 107.62 178.246 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.416 HG21 ' HB ' ' A' ' 44' ' ' VAL . 17.8 m -104.6 14.99 6.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 120.938 -1.101 . . . . 1.0 110.575 -178.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.588 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.61 -176.28 0.09 Allowed 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.863 -1.148 . . . . 1.0 110.184 179.716 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.546 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.89 97.47 1.42 Allowed 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.436 -0.79 . . . . 1.0 109.847 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.63 27.8 34.32 Favored Glycine 0 N--CA 1.493 2.493 0 C-N-CA 120.145 -1.026 . . . . 1.0 111.434 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.588 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.32 106.6 20.65 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 O-C-N 120.668 -1.489 . . . . 1.0 107.171 178.868 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.62 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.2 tp -116.06 104.67 11.8 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.449 -1.407 . . . . 1.0 109.982 -177.691 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.535 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.23 109.58 22.31 Favored 'General case' 0 N--CA 1.485 1.291 0 O-C-N 120.818 -1.176 . . . . 1.0 108.079 178.848 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.18 166.21 10.79 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.912 -1.117 . . . . 1.0 110.356 -178.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.522 ' ND2' ' HB2' ' A' ' 50' ' ' ALA . 46.0 t30 -112.01 129.85 23.84 Favored Pre-proline 0 N--CA 1.501 2.1 0 O-C-N 121.366 -0.834 . . . . 1.0 109.796 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.609 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.5 Cg_endo -71.65 22.31 0.25 Allowed 'Trans proline' 0 CA--C 1.545 1.056 0 C-N-CA 122.219 1.946 . . . . 1.0 112.342 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.522 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -109.87 2.79 20.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.415 -1.428 . . . . 1.0 109.049 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.5 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.65 18.87 2.52 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.135 -1.432 . . . . 1.0 107.135 179.41 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -82.13 89.73 6.5 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.934 -0.707 . . . . 1.0 111.127 -178.395 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -106.97 -166.87 1.21 Allowed 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 107.562 -1.273 . . . . 1.0 107.562 178.077 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.468 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.2 136.35 0.1 Allowed 'General case' 0 C--N 1.306 -1.307 0 O-C-N 120.538 -1.351 . . . . 1.0 111.304 -179.346 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.585 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -154.46 158.8 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.635 -1.246 . . . . 1.0 107.635 178.337 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.56 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.8 142.25 30.57 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.807 -1.183 . . . . 1.0 109.901 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.677 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.53 107.12 1.06 Allowed 'General case' 0 C--N 1.299 -1.602 0 CA-C-O 122.423 1.106 . . . . 1.0 109.295 178.253 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.53 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.2 p-10 -58.88 -138.84 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.583 -0.735 . . . . 1.0 110.821 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -54.65 -49.81 69.68 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.374 -0.829 . . . . 1.0 110.231 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.421 ' OD1' ' N ' ' A' ' 61' ' ' GLY . 12.3 p30 -100.23 -38.82 8.33 Favored 'General case' 0 C--N 1.285 -2.219 0 N-CA-C 106.122 -1.807 . . . . 1.0 106.122 178.492 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.677 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 109.92 65.93 0.55 Allowed Glycine 0 C--N 1.296 -1.648 0 N-CA-C 110.239 -1.144 . . . . 1.0 110.239 178.263 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.4 m -102.82 129.12 49.39 Favored 'General case' 0 N--CA 1.483 1.19 0 O-C-N 121.49 -1.006 . . . . 1.0 108.948 179.043 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.585 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -138.17 108.87 6.61 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 119.274 -0.971 . . . . 1.0 109.921 -179.371 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -124.02 120.96 33.97 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.244 -0.91 . . . . 1.0 109.801 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.48 HG21 HG13 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -146.44 149.48 33.78 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.486 -0.759 . . . . 1.0 109.07 179.587 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.5 p -100.31 145.62 27.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.312 -0.867 . . . . 1.0 109.741 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.528 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -145.95 165.81 27.87 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.472 -0.768 . . . . 1.0 109.242 -179.457 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.557 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.8 p -96.53 124.88 40.66 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.0 -1.063 . . . . 1.0 109.477 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.526 ' CG2' HG12 ' A' ' 19' ' ' VAL . 17.0 m -138.74 143.1 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 120.972 -1.08 . . . . 1.0 109.808 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.555 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 7.6 ptt180 -140.02 -163.46 1.51 Allowed 'General case' 0 N--CA 1.486 1.351 0 O-C-N 120.593 -1.317 . . . . 1.0 109.871 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.564 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -75.03 -82.28 0.07 Allowed 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.083 -1.011 . . . . 1.0 108.87 -179.609 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.44 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -62.75 137.51 58.28 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.305 -1.497 . . . . 1.0 107.357 178.861 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.563 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.2 OUTLIER -163.22 134.09 4.69 Favored 'General case' 0 C--N 1.293 -1.863 0 C-N-CA 118.045 -1.462 . . . . 1.0 110.522 -177.656 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.482 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . 3.6 mm-40 -32.56 121.21 0.33 Allowed 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 121.642 0.734 . . . . 1.0 110.773 -178.357 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.535 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.06 49.78 3.05 Favored Glycine 0 N--CA 1.496 2.649 0 C-N-CA 120.754 -0.736 . . . . 1.0 111.546 -179.139 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.609 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-30 -38.57 115.42 0.46 Allowed 'General case' 0 N--CA 1.511 2.594 0 O-C-N 121.028 -1.277 . . . . 1.0 110.14 179.318 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -87.05 125.89 34.4 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.857 -1.152 . . . . 1.0 109.744 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -64.68 58.26 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.927 0 O-C-N 120.86 -1.15 . . . . 1.0 109.869 179.403 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -158.08 18.47 0.24 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.035 -1.04 . . . . 1.0 109.677 -179.948 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.21 -27.56 6.11 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.919 -1.272 . . . . 1.0 109.919 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.407 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -98.17 164.7 12.21 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.069 -1.253 . . . . 1.0 110.337 -179.482 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.515 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.13 140.35 41.46 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.858 -0.793 . . . . 1.0 108.858 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.493 ' CD1' HD12 ' A' ' 77' ' ' LEU . 4.2 t90 -84.2 -22.34 30.95 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.845 -1.159 . . . . 1.0 110.604 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.73 175.13 17.55 Favored Glycine 0 N--CA 1.485 1.922 0 N-CA-C 108.688 -1.765 . . . . 1.0 108.688 -179.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.67 112.0 2.65 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.712 -1.218 . . . . 1.0 107.712 179.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.51 HG23 ' HA3' ' A' ' 75' ' ' GLY . 43.3 t -84.55 103.95 12.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.289 -0.882 . . . . 1.0 108.928 -179.049 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.462 ' CB ' HG22 ' A' ' 90' ' ' THR . 0.5 OUTLIER -66.58 111.65 3.74 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.357 -0.839 . . . . 1.0 109.645 -179.439 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.564 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.38 -5.3 4.97 Favored 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 118.172 -1.411 . . . . 1.0 109.948 179.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 45.5 p -84.39 0.46 49.3 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.75 -1.219 . . . . 1.0 108.772 179.195 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.462 HG22 ' CB ' ' A' ' 87' ' ' ASP . 2.3 p -115.84 -50.35 2.69 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.392 -0.817 . . . . 1.0 109.054 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.29 -178.01 3.54 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.508 -0.745 . . . . 1.0 109.514 179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.09 115.36 30.04 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.369 -0.832 . . . . 1.0 108.95 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.523 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -97.29 123.2 41.02 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.901 -1.125 . . . . 1.0 109.917 -179.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.553 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.28 148.2 26.62 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-O 122.373 1.082 . . . . 1.0 111.102 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.53 ' CG1' HG12 ' A' ' 7' ' ' VAL . 61.1 t -103.23 110.2 29.09 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 N-CA-C 106.721 -1.585 . . . . 1.0 106.721 177.618 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.416 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.46 -172.78 18.7 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 118.08 -2.01 . . . . 1.0 111.679 -177.614 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -114.77 179.88 3.82 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.945 -0.761 . . . . 1.0 108.945 -179.175 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.465 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 66.9 p . . . . . 0 C--N 1.295 -1.766 0 O-C-N 121.472 -0.768 . . . . 1.0 109.291 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.722 0 N-CA-C 107.742 -2.143 . . . . 1.0 107.742 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.43 -177.96 6.92 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.675 -0.897 . . . . 1.0 109.935 179.254 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.7 -163.84 19.94 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 108.319 -1.912 . . . . 1.0 108.319 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.4 Cg_exo -47.68 177.88 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 CA-C-N 118.763 1.281 . . . . 1.0 110.233 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -94.86 -176.25 3.8 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.236 -0.915 . . . . 1.0 110.186 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.416 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.68 163.98 13.06 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.787 -1.325 . . . . 1.0 109.787 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.5 132.35 46.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.381 -1.07 . . . . 1.0 109.063 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.553 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.0 125.44 27.62 Favored 'General case' 0 C--N 1.29 -2.017 0 O-C-N 121.649 -0.657 . . . . 1.0 109.868 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.571 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.67 171.95 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.356 -0.84 . . . . 1.0 108.953 179.611 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.466 ' CB ' ' HB3' ' A' ' 11' ' ' SER . 0.4 OUTLIER -136.51 156.27 48.83 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.118 -0.989 . . . . 1.0 109.58 -179.925 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.571 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 93.0 m-85 . . . . . 0 N--CA 1.484 1.274 0 O-C-N 121.134 -0.979 . . . . 1.0 109.506 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.398 0 CA-C-O 122.086 0.946 . . . . 0.0 111.047 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.53 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.2 p -100.88 104.32 15.53 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-O 122.407 1.099 . . . . 0.0 109.816 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.534 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 6.2 t -119.79 118.0 55.66 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.459 0 CA-C-O 121.694 0.759 . . . . 0.0 110.405 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.493 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.78 149.08 7.93 Favored Pre-proline 0 N--CA 1.488 1.425 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 -179.568 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG22 ' A' ' 8' ' ' THR . 2.2 Cg_endo -75.26 152.85 98.33 Favored 'Cis proline' 0 C--N 1.309 -1.535 0 C-N-CA 123.583 -1.424 . . . . 0.0 109.762 -0.301 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.476 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 6.5 m -91.5 -25.0 19.48 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.469 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.8 m -137.85 165.1 27.3 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.637 -0.664 . . . . 0.0 109.253 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.27 37.49 31.8 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 108.564 -1.814 . . . . 0.0 108.564 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.603 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 40.0 mt -92.07 -42.43 9.95 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 123.311 1.529 . . . . 0.0 110.522 -178.487 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.67 142.67 0.05 OUTLIER 'General case' 0 C--N 1.259 -3.327 0 CA-C-N 113.405 -1.725 . . . . 0.0 109.731 -179.644 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.587 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.6 p-10 -50.28 105.78 0.1 Allowed 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.521 0.677 . . . . 0.0 111.473 -178.549 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.49 14.22 8.33 Favored Glycine 0 N--CA 1.485 1.928 0 C-N-CA 119.413 -1.375 . . . . 0.0 113.018 177.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.603 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.0 t -106.3 -172.57 2.11 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 121.221 2.51 . . . . 0.0 109.832 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.57 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 18.8 t -129.0 139.76 51.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 CA-C-N 114.823 -1.08 . . . . 0.0 111.204 -178.644 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.504 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 27.1 m -115.88 155.61 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.7 tttt -107.86 108.79 20.11 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.021 -1.05 . . . . 0.0 109.552 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.492 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 p -106.8 122.67 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.53 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -117.83 167.48 11.36 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 120.795 -1.191 . . . . 0.0 109.064 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.594 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.86 142.44 13.95 Favored Glycine 0 C--N 1.295 -1.733 0 N-CA-C 107.935 -2.066 . . . . 0.0 107.935 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -147.16 123.7 11.07 Favored 'General case' 0 C--N 1.294 -1.834 0 O-C-N 120.812 -1.405 . . . . 0.0 108.64 179.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.19 27.25 23.72 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 119.313 -1.422 . . . . 0.0 109.838 -179.595 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.539 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.6 mt -87.73 175.14 8.0 Favored 'General case' 0 C--N 1.308 -1.236 0 O-C-N 120.877 -1.367 . . . . 0.0 108.466 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.55 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.61 96.95 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.017 -1.052 . . . . 0.0 109.541 -179.899 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.49 76.76 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.791 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.533 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.44 33.49 0.3 Allowed Glycine 0 N--CA 1.486 2.016 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.198 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.618 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.6 t -147.12 114.55 6.31 Favored 'General case' 0 C--N 1.308 -1.223 0 O-C-N 120.791 -1.417 . . . . 0.0 111.173 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.548 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.82 127.32 6.27 Favored 'General case' 0 N--CA 1.49 1.528 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.689 178.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.618 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 9.1 m-85 -116.33 148.61 40.4 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.505 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -101.21 149.33 24.11 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.805 -1.185 . . . . 0.0 107.92 179.135 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.597 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 1.0 OUTLIER -127.43 126.7 67.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.271 -0.893 . . . . 0.0 109.371 -177.935 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.491 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -174.52 174.97 46.79 Favored Glycine 0 N--CA 1.495 2.612 0 C-N-CA 117.833 -2.127 . . . . 0.0 112.42 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.561 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -101.36 108.47 20.1 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.473 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.8 m -131.24 147.92 52.64 Favored 'General case' 0 C--N 1.295 -1.772 0 O-C-N 121.251 -0.905 . . . . 0.0 109.942 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -121.02 139.04 53.84 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.394 -0.816 . . . . 0.0 110.609 -179.094 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.622 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.42 115.03 26.87 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 178.159 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -106.11 14.85 7.41 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 120.963 -1.085 . . . . 0.0 110.529 -178.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.597 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.14 -174.61 0.08 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.848 -1.157 . . . . 0.0 110.121 179.667 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 5.9 p -71.46 96.78 1.54 Allowed 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.46 -0.775 . . . . 0.0 109.931 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 27.83 32.9 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 120.171 -1.014 . . . . 0.0 111.558 178.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.597 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.26 106.28 20.24 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 O-C-N 120.552 -1.558 . . . . 0.0 107.267 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.622 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.3 tp -117.37 104.92 11.61 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.454 -1.404 . . . . 0.0 109.913 -177.686 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.84 109.61 22.33 Favored 'General case' 0 N--CA 1.485 1.287 0 O-C-N 120.706 -1.246 . . . . 0.0 108.296 178.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.3 t -105.97 163.93 12.36 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.041 -1.037 . . . . 0.0 110.198 -178.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.473 ' ND2' ' CB ' ' A' ' 50' ' ' ALA . 20.0 t30 -107.36 139.12 20.19 Favored Pre-proline 0 N--CA 1.502 2.16 0 O-C-N 121.327 -0.858 . . . . 0.0 109.81 -179.372 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.572 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 7.8 Cg_endo -75.88 27.73 0.39 Allowed 'Trans proline' 0 C--N 1.32 -0.964 0 C-N-CA 122.59 2.194 . . . . 0.0 112.135 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.473 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -124.44 9.61 8.47 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.242 -1.536 . . . . 0.0 109.679 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.523 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.46 15.63 2.76 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.403 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -77.69 86.92 3.97 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.856 -0.737 . . . . 0.0 111.421 -178.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.597 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.34 -169.77 1.85 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 177.954 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.71 134.65 0.08 Allowed 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.57 -1.331 . . . . 0.0 111.454 -179.392 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.569 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -160.47 154.73 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 178.18 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.548 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.56 144.83 26.85 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.741 -1.225 . . . . 0.0 109.572 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.677 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.07 106.74 1.69 Allowed 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 122.48 1.134 . . . . 0.0 109.476 178.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.522 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.5 p-10 -59.78 -138.83 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.982 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.893 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.546 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.37 -50.44 59.56 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.467 -0.771 . . . . 0.0 110.548 -178.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -104.97 -34.63 7.95 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 178.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.677 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 109.88 68.32 0.59 Allowed Glycine 0 C--N 1.298 -1.543 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 177.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 59.4 m -103.21 129.23 50.08 Favored 'General case' 0 N--CA 1.484 1.274 0 O-C-N 121.358 -1.084 . . . . 0.0 108.83 178.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.569 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.12 109.27 7.75 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.281 -0.967 . . . . 0.0 110.073 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.6 m -110.23 118.38 36.19 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.205 -0.934 . . . . 0.0 108.787 179.499 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.449 ' OG1' ' OG ' ' A' ' 53' ' ' SER . 0.1 OUTLIER -144.24 139.08 28.45 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.436 -0.79 . . . . 0.0 110.253 -179.514 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 78.8 p -103.18 140.79 36.9 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 179.416 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.523 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.2 OUTLIER -142.84 164.1 31.02 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.173 -0.955 . . . . 0.0 109.994 -179.148 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.8 p -97.59 125.49 42.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.339 -0.851 . . . . 0.0 109.129 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.511 ' CB ' ' OE1' ' A' ' 36' ' ' GLN . 15.2 m -136.44 143.64 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.908 -1.12 . . . . 0.0 109.803 -179.087 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.587 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -146.7 -176.12 5.06 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.44 -1.413 . . . . 0.0 111.156 -179.787 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.562 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.91 -100.54 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 -179.581 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.455 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.05 140.4 49.27 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 179.353 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.44 135.94 6.16 Favored 'General case' 0 C--N 1.294 -1.817 0 C-N-CA 118.584 -1.246 . . . . 0.0 109.764 -177.996 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.512 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 3.9 mm-40 -33.07 121.47 0.37 Allowed 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.547 0.689 . . . . 0.0 110.431 -178.482 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.533 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -91.89 48.08 2.74 Favored Glycine 0 N--CA 1.492 2.408 0 C-N-CA 120.602 -0.808 . . . . 0.0 111.195 -179.177 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.572 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -38.22 115.18 0.42 Allowed 'General case' 0 N--CA 1.511 2.623 0 O-C-N 121.118 -1.225 . . . . 0.0 109.974 179.695 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -87.29 125.76 34.42 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.944 -1.098 . . . . 0.0 109.321 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.6 t80 -64.2 58.65 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.891 -1.131 . . . . 0.0 110.215 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t0 -160.67 20.0 0.14 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.973 -1.079 . . . . 0.0 109.749 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.93 -27.8 5.3 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.439 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 80.7 p -94.22 159.42 15.14 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.038 -1.272 . . . . 0.0 110.269 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.483 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 4.4 ptt180 -107.32 137.59 45.09 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.463 ' HB2' HD12 ' A' ' 77' ' ' LEU . 1.9 t90 -83.76 -18.51 37.53 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.821 -1.174 . . . . 0.0 110.79 -178.231 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.97 175.08 19.8 Favored Glycine 0 N--CA 1.485 1.937 0 N-CA-C 108.711 -1.755 . . . . 0.0 108.711 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.21 106.77 1.15 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.562 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 43.4 t -79.1 106.41 10.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.286 -0.884 . . . . 0.0 109.264 -179.025 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.524 ' CB ' HG21 ' A' ' 90' ' ' THR . 0.9 OUTLIER -65.84 111.13 3.12 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.533 -0.73 . . . . 0.0 109.904 -179.442 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.562 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.26 -4.97 4.21 Favored 'General case' 0 N--CA 1.499 1.98 0 C-N-CA 118.246 -1.382 . . . . 0.0 109.814 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -86.39 -0.49 56.06 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.891 -1.131 . . . . 0.0 109.156 179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.524 HG21 ' CB ' ' A' ' 87' ' ' ASP . 2.2 p -113.31 -50.05 2.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.392 -0.818 . . . . 0.0 109.013 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.74 179.96 4.12 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.453 -0.779 . . . . 0.0 109.427 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.69 115.73 31.03 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.366 -0.834 . . . . 0.0 109.103 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.72 121.07 38.16 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.917 -1.114 . . . . 0.0 109.383 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.556 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.18 146.15 27.2 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-O 122.273 1.035 . . . . 0.0 111.193 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 71.7 t -105.73 112.2 38.12 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.168 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.48 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -152.49 -169.98 18.44 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 118.018 -2.039 . . . . 0.0 111.578 -178.011 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -112.64 -179.0 3.54 Favored 'General case' 0 N--CA 1.484 1.272 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -179.189 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.476 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.17 -0.956 . . . . 0.0 109.826 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.679 0 N-CA-C 107.709 -2.156 . . . . 0.0 107.709 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.26 -177.73 6.22 Favored 'General case' 0 C--N 1.307 -1.266 0 O-C-N 121.553 -0.969 . . . . 0.0 109.681 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.497 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -162.57 -159.47 10.37 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.275 -1.93 . . . . 0.0 108.275 -179.215 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.497 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.4 Cg_exo -47.21 179.98 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.675 0 CA-C-N 118.667 1.234 . . . . 0.0 110.37 179.183 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -92.57 -178.27 4.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.033 -1.042 . . . . 0.0 110.645 -178.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.48 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.02 163.57 13.25 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.407 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.08 128.79 54.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.422 -1.046 . . . . 0.0 109.214 -179.36 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.556 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.86 119.04 15.48 Favored 'General case' 0 C--N 1.29 -2.016 0 O-C-N 121.721 -0.612 . . . . 0.0 109.491 179.576 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.594 HD13 ' CZ ' ' A' ' 112' ' ' PHE . 1.7 pt -98.01 171.52 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.248 -0.908 . . . . 0.0 109.042 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.469 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -138.8 159.59 41.74 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.161 -0.962 . . . . 0.0 109.986 -179.696 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.594 ' CZ ' HD13 ' A' ' 110' ' ' ILE . 96.8 m-85 . . . . . 0 N--CA 1.485 1.312 0 O-C-N 121.18 -0.95 . . . . 0.0 109.582 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.462 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.429 0 CA-C-O 122.274 1.035 . . . . 0.0 110.429 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.542 ' CG2' ' O ' ' A' ' 6' ' ' THR . 7.4 t -109.74 108.69 19.13 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 123.05 1.405 . . . . 0.0 109.286 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.508 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.3 t -116.32 136.35 53.59 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.689 0 CA-C-N 114.164 -1.38 . . . . 0.0 109.903 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.486 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -172.88 149.05 1.78 Allowed Pre-proline 0 N--CA 1.487 1.405 0 O-C-N 121.194 -0.941 . . . . 0.0 108.883 -179.616 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.486 ' HA ' HG22 ' A' ' 8' ' ' THR . 4.2 Cg_endo -77.24 151.33 93.05 Favored 'Cis proline' 0 C--N 1.313 -1.332 0 C-N-CA 123.404 -1.498 . . . . 0.0 109.323 -0.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.52 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 16.6 p -86.83 -26.86 23.84 Favored 'General case' 0 C--N 1.295 -1.803 0 O-C-N 121.455 -0.778 . . . . 0.0 109.169 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.472 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.4 m -134.62 168.23 19.38 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.409 -0.807 . . . . 0.0 109.463 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.03 38.51 35.16 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 108.359 -1.896 . . . . 0.0 108.359 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.589 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 40.2 mt -94.81 -42.61 8.62 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 123.186 1.47 . . . . 0.0 110.65 -178.164 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.498 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.91 143.69 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.289 0 CA-C-N 113.334 -1.757 . . . . 0.0 109.889 -179.55 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.574 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 11.9 p-10 -50.3 104.62 0.08 Allowed 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.53 0.681 . . . . 0.0 111.469 -178.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.17 14.44 7.74 Favored Glycine 0 N--CA 1.485 1.91 0 C-N-CA 119.321 -1.419 . . . . 0.0 113.09 177.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.589 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.5 t -106.47 -172.47 2.09 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 121.336 2.568 . . . . 0.0 109.876 179.312 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.538 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 20.4 t -128.21 136.78 59.24 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.328 0 CA-C-N 114.733 -1.121 . . . . 0.0 111.242 -178.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.588 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 27.8 m -111.08 157.22 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.649 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.508 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 4.0 tptm -106.83 109.17 21.01 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.033 -1.042 . . . . 0.0 108.933 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.519 ' CG1' HG22 ' A' ' 34' ' ' VAL . 7.6 p -103.55 141.05 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.535 ' CB ' HG21 ' A' ' 6' ' ' THR . . . -138.79 161.52 37.03 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.718 -1.238 . . . . 0.0 110.061 179.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.591 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.46 143.69 15.01 Favored Glycine 0 C--N 1.294 -1.763 0 N-CA-C 108.355 -1.898 . . . . 0.0 108.355 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.14 125.68 13.27 Favored 'General case' 0 C--N 1.295 -1.774 0 O-C-N 120.914 -1.345 . . . . 0.0 108.996 178.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.457 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 87.45 25.92 31.82 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 119.312 -1.423 . . . . 0.0 110.116 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -86.15 172.55 10.46 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 120.937 -1.331 . . . . 0.0 108.474 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.76 100.14 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.009 -1.057 . . . . 0.0 109.651 -179.704 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 77.83 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.147 -179.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.81 34.03 0.32 Allowed Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 179.543 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.545 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.7 p -140.71 108.13 5.56 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 121.183 -1.186 . . . . 0.0 111.153 -179.508 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.98 111.64 0.59 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.535 177.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.458 ' OH ' ' HB2' ' A' ' 27' ' ' GLN . 6.0 m-30 -107.14 156.34 18.91 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.129 -0.982 . . . . 0.0 108.935 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.468 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.8 160.5 14.22 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 178.933 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.612 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.3 p -140.94 119.26 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.129 -0.982 . . . . 0.0 109.678 -177.804 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -171.64 -177.36 41.27 Favored Glycine 0 N--CA 1.494 2.513 0 C-N-CA 118.443 -1.836 . . . . 0.0 111.532 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.562 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -98.73 109.13 21.93 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.723 0.773 . . . . 0.0 108.944 -179.95 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -129.09 149.35 50.94 Favored 'General case' 0 C--N 1.295 -1.783 0 O-C-N 121.236 -0.915 . . . . 0.0 109.964 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.92 138.88 54.23 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.255 -0.903 . . . . 0.0 110.838 -179.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.625 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.05 26.9 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.037 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -105.32 15.16 6.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.903 -1.123 . . . . 0.0 110.585 -178.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.59 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.03 -175.29 0.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.886 -1.134 . . . . 0.0 110.08 179.722 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -72.37 97.41 2.04 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.394 -0.816 . . . . 0.0 109.687 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.34 27.97 31.65 Favored Glycine 0 N--CA 1.493 2.45 0 C-N-CA 120.177 -1.011 . . . . 0.0 111.385 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.59 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.92 106.43 20.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 120.534 -1.568 . . . . 0.0 107.165 178.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.625 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.5 tp -116.48 104.72 11.72 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.479 -1.388 . . . . 0.0 109.937 -177.533 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.527 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.0 109.63 22.35 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 178.649 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.486 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -108.52 162.42 14.15 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.876 -1.14 . . . . 0.0 110.54 -178.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.486 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 7.8 t30 -108.72 130.3 22.91 Favored Pre-proline 0 N--CA 1.499 2.004 0 O-C-N 121.551 -0.718 . . . . 0.0 109.553 -179.377 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.576 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.56 21.35 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.078 0 C-N-CA 122.028 1.819 . . . . 0.0 112.021 179.562 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.459 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -99.41 -3.99 32.53 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.421 -1.424 . . . . 0.0 108.995 179.409 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.535 ' CB ' ' HB3' ' A' ' 67' ' ' LEU . 5.9 m-20 -135.62 9.89 3.4 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -66.84 86.18 0.13 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.499 -0.75 . . . . 0.0 111.059 -178.291 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.612 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -108.5 -167.29 1.21 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 177.912 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.472 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.32 134.47 0.09 Allowed 'General case' 0 C--N 1.305 -1.34 0 O-C-N 120.503 -1.373 . . . . 0.0 111.451 -179.22 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.562 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -150.24 157.77 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 177.923 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.71 142.72 29.91 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.766 -1.209 . . . . 0.0 110.113 -179.685 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.68 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.67 107.12 1.09 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.398 1.094 . . . . 0.0 109.336 178.338 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.527 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -59.37 -139.08 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.056 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.856 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.73 -49.84 64.61 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.462 -0.774 . . . . 0.0 110.496 -178.641 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.457 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.6 t-20 -103.57 -35.17 8.4 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 178.454 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.68 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.95 66.78 0.58 Allowed Glycine 0 C--N 1.298 -1.579 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 177.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.591 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.9 m -104.54 128.92 52.62 Favored 'General case' 0 C--N 1.308 -1.223 0 O-C-N 121.308 -1.113 . . . . 0.0 108.683 178.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.562 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.69 109.91 8.92 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.184 -1.006 . . . . 0.0 109.668 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 91.7 p -117.75 117.77 30.24 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.367 -0.833 . . . . 0.0 109.481 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.479 HG22 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -147.31 151.29 36.34 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.422 -0.799 . . . . 0.0 109.42 -179.957 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 69.6 p -98.52 153.57 18.53 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.304 -0.872 . . . . 0.0 109.571 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.538 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.3 OUTLIER -147.92 160.1 43.17 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.339 -0.851 . . . . 0.0 109.634 -179.176 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.537 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.5 p -100.55 122.85 43.92 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.971 -1.08 . . . . 0.0 108.58 179.261 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.527 ' CG2' HG11 ' A' ' 19' ' ' VAL . 19.2 m -136.41 143.06 36.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 120.799 -1.188 . . . . 0.0 110.459 -178.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.574 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.1 ptt180 -146.43 -175.27 4.71 Favored 'General case' 0 N--CA 1.483 1.205 0 O-C-N 120.749 -1.219 . . . . 0.0 110.663 179.654 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.555 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.79 -102.03 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -179.733 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -56.02 140.27 43.99 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.761 -1.212 . . . . 0.0 108.244 179.401 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -160.74 137.93 9.13 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 118.672 -1.211 . . . . 0.0 110.009 -178.285 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -35.43 120.68 0.57 Allowed 'General case' 0 N--CA 1.49 1.563 0 CA-C-O 121.522 0.677 . . . . 0.0 110.618 -178.439 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.527 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -94.17 50.47 2.18 Favored Glycine 0 N--CA 1.493 2.486 0 O-C-N 121.551 -0.718 . . . . 0.0 111.37 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.576 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.8 m-85 -39.11 114.87 0.43 Allowed 'General case' 0 N--CA 1.511 2.616 0 O-C-N 120.947 -1.325 . . . . 0.0 109.89 179.536 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.53 ' CD2' ' OD2' ' A' ' 79' ' ' ASP . 7.9 tp -87.25 125.24 34.07 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.771 -1.206 . . . . 0.0 109.306 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -64.78 56.31 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.062 0 O-C-N 120.742 -1.224 . . . . 0.0 110.491 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.53 ' OD2' ' CD2' ' A' ' 77' ' ' LEU . 2.9 p30 -154.79 16.18 0.44 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.998 -1.064 . . . . 0.0 109.859 179.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.53 -27.03 10.18 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.41 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -100.87 161.17 13.78 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.901 -1.352 . . . . 0.0 110.38 -179.408 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.422 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 3.6 ptm180 -103.77 139.36 39.11 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.605 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.48 ' CD1' HD11 ' A' ' 77' ' ' LEU . 2.2 t90 -82.44 -19.83 38.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.917 -1.114 . . . . 0.0 110.599 -178.276 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.64 175.66 18.71 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -66.41 104.77 1.3 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.174 -1.192 . . . . 0.0 107.848 179.318 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.575 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 48.7 t -75.31 106.88 5.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.286 -0.884 . . . . 0.0 109.56 -178.736 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.53 ' CB ' HG22 ' A' ' 90' ' ' THR . 0.4 OUTLIER -64.97 110.65 2.53 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.421 -0.8 . . . . 0.0 109.759 -179.679 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.555 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.23 -5.18 4.53 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.533 -1.354 . . . . 0.0 109.766 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.7 p -86.45 -0.28 55.67 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.779 -1.2 . . . . 0.0 109.136 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.53 HG22 ' CB ' ' A' ' 87' ' ' ASP . 2.2 p -114.52 -51.24 2.76 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.326 -0.859 . . . . 0.0 109.026 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.403 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -102.85 -178.83 3.78 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.445 -0.784 . . . . 0.0 109.413 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.68 115.05 29.59 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.868 . . . . 0.0 108.983 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -96.91 122.18 39.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.855 -1.153 . . . . 0.0 109.478 -179.247 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.562 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.28 145.64 29.16 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-O 122.341 1.067 . . . . 0.0 111.284 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.493 ' CG1' HG11 ' A' ' 7' ' ' VAL . 99.5 t -101.59 109.79 26.78 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 177.637 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.471 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.95 -169.56 17.58 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.052 -2.023 . . . . 0.0 111.733 -177.536 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -120.79 177.47 5.08 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 -179.1 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 2.5 t . . . . . 0 C--N 1.292 -1.923 0 O-C-N 121.588 -0.695 . . . . 0.0 109.59 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.446 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.481 1.684 0 N-CA-C 108.143 -1.983 . . . . 0.0 108.143 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -167.78 -176.88 3.25 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 121.62 -0.93 . . . . 0.0 109.853 179.358 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.1 -160.7 16.32 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.315 -1.914 . . . . 0.0 108.315 -179.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.3 Cg_exo -47.2 179.25 0.0 OUTLIER 'Trans proline' 0 C--O 1.216 -0.607 0 CA-C-N 118.829 1.315 . . . . 0.0 110.395 179.324 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -96.22 -175.69 3.44 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.028 -1.045 . . . . 0.0 110.309 -179.099 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.471 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.91 163.82 13.74 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.0 127.36 51.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.39 -1.065 . . . . 0.0 109.062 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.562 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -70.34 120.42 15.97 Favored 'General case' 0 C--N 1.289 -2.022 0 O-C-N 121.778 -0.576 . . . . 0.0 109.662 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.582 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.98 170.55 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.234 -0.916 . . . . 0.0 109.131 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.472 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.99 157.56 45.47 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.263 -0.898 . . . . 0.0 109.895 -179.717 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.582 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 91.7 m-85 . . . . . 0 N--CA 1.486 1.343 0 O-C-N 121.271 -0.893 . . . . 0.0 109.587 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.478 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.446 0 CA-C-O 122.265 1.031 . . . . 0.0 110.762 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.546 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.9 t -111.35 108.63 18.29 Favored 'General case' 0 C--N 1.295 -1.762 0 CA-C-O 123.068 1.413 . . . . 0.0 109.084 179.201 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.523 HG13 ' CG1' ' A' ' 95' ' ' VAL . 2.5 t -115.26 140.68 35.44 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.73 0 CA-C-N 114.321 -1.308 . . . . 0.0 110.26 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.517 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -175.56 149.07 1.06 Allowed Pre-proline 0 N--CA 1.487 1.396 0 O-C-N 121.337 -0.852 . . . . 0.0 108.854 -179.751 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.517 ' CA ' HG23 ' A' ' 8' ' ' THR . 5.3 Cg_endo -78.63 150.47 87.33 Favored 'Cis proline' 0 C--N 1.311 -1.399 0 C-N-CA 123.36 -1.516 . . . . 0.0 109.09 -0.841 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.491 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 75.9 p -89.73 -24.58 21.5 Favored 'General case' 0 C--N 1.291 -1.947 0 O-C-N 121.53 -0.731 . . . . 0.0 109.358 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.507 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 12.9 m -134.83 162.8 31.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.346 -0.846 . . . . 0.0 109.757 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.88 37.67 29.06 Favored Glycine 0 N--CA 1.496 2.667 0 N-CA-C 108.604 -1.798 . . . . 0.0 108.604 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.603 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 37.0 mt -92.56 -44.24 8.72 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-O 123.19 1.472 . . . . 0.0 110.606 -178.369 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.66 144.07 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.331 0 CA-C-N 113.48 -1.691 . . . . 0.0 110.135 -179.775 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.595 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.2 p-10 -49.74 107.84 0.17 Allowed 'General case' 0 C--N 1.301 -1.526 0 CA-C-O 121.712 0.768 . . . . 0.0 111.471 -178.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.47 12.93 9.22 Favored Glycine 0 N--CA 1.484 1.855 0 C-N-CA 119.45 -1.357 . . . . 0.0 112.939 177.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.603 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.6 t -105.76 -173.05 2.21 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 121.251 2.525 . . . . 0.0 109.663 179.237 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 20.9 t -127.1 135.01 64.79 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.45 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.035 -178.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.59 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 36.0 m -108.68 155.53 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.58 109.4 18.56 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.092 -1.005 . . . . 0.0 108.945 179.885 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.474 ' HB ' ' CG1' ' A' ' 95' ' ' VAL . 2.2 p -104.58 140.56 22.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.548 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -135.24 160.09 39.48 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 118.691 -1.204 . . . . 0.0 109.699 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.594 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.23 145.28 16.52 Favored Glycine 0 C--N 1.295 -1.712 0 N-CA-C 108.109 -1.996 . . . . 0.0 108.109 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.79 124.98 12.16 Favored 'General case' 0 C--N 1.296 -1.755 0 O-C-N 120.978 -1.307 . . . . 0.0 108.779 178.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.457 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 89.36 26.58 25.24 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.264 -1.446 . . . . 0.0 109.888 -179.587 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.541 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.0 mt -87.17 175.69 7.94 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 120.872 -1.369 . . . . 0.0 108.421 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.553 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.66 98.02 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.398 0 O-C-N 120.93 -1.106 . . . . 0.0 109.702 -179.597 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.57 77.44 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.737 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.511 -179.176 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.555 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.14 34.42 0.33 Allowed Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.1 p -146.25 111.92 5.58 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.039 -1.271 . . . . 0.0 111.223 -179.686 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.54 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.08 127.76 5.57 Favored 'General case' 0 N--CA 1.492 1.659 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.683 178.207 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.515 ' CD2' ' O ' ' A' ' 30' ' ' THR . 13.2 m-85 -118.5 150.57 39.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.327 -0.858 . . . . 0.0 108.881 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.497 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -100.52 153.15 19.61 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.64 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.6 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.2 p -137.55 119.03 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.844 -1.16 . . . . 0.0 110.043 -177.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.74 -178.88 40.59 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.673 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.556 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -99.73 109.12 21.59 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 -179.943 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.48 148.78 52.33 Favored 'General case' 0 C--N 1.295 -1.795 0 O-C-N 121.285 -0.885 . . . . 0.0 109.881 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.6 137.42 54.9 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.3 -0.875 . . . . 0.0 110.883 -179.094 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.63 ' CE2' HD11 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.54 114.9 26.71 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 178.009 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.459 HG22 ' HB ' ' A' ' 44' ' ' VAL . 10.1 m -105.73 14.69 7.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.053 -1.029 . . . . 0.0 110.707 -178.712 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.592 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.6 -175.11 0.08 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.901 -1.125 . . . . 0.0 110.106 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 28.0 p -72.59 98.56 2.35 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.45 -0.781 . . . . 0.0 109.623 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.2 27.16 34.33 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 120.226 -0.988 . . . . 0.0 111.342 178.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.592 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.02 106.04 19.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.55 -1.559 . . . . 0.0 107.295 178.829 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.63 HD11 ' CE2' ' A' ' 39' ' ' TRP . 14.0 tp -118.86 104.34 10.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.458 -1.401 . . . . 0.0 109.822 -177.666 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.516 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.22 109.58 22.32 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.868 -1.145 . . . . 0.0 108.246 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.54 166.23 10.71 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.982 -1.074 . . . . 0.0 110.269 -178.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.533 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 11.0 t-20 -108.87 134.82 20.22 Favored Pre-proline 0 N--CA 1.499 2.01 0 O-C-N 121.364 -0.835 . . . . 0.0 109.639 -179.416 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.573 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.1 Cg_endo -74.85 24.66 0.38 Allowed 'Trans proline' 0 CA--C 1.545 1.055 0 C-N-CA 122.277 1.985 . . . . 0.0 111.949 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.533 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -117.18 4.34 12.66 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.498 -1.376 . . . . 0.0 109.297 179.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.514 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.26 17.54 2.78 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.285 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -81.97 86.96 6.45 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.922 -178.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.6 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -104.98 -165.89 1.18 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.334 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.464 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.01 135.77 0.09 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 120.609 -1.307 . . . . 0.0 111.449 -179.284 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.583 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -152.66 156.61 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 178.08 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.54 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.58 145.34 26.36 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.602 -1.312 . . . . 0.0 109.921 -179.611 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.677 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -65.34 107.54 1.66 Allowed 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 122.384 1.087 . . . . 0.0 109.57 178.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.519 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.2 p-10 -60.87 -138.92 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.944 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.841 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.33 -50.62 59.07 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.509 -0.744 . . . . 0.0 110.673 -178.632 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.457 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.3 t-20 -104.35 -33.99 8.45 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 178.548 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.677 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 109.13 65.41 0.56 Allowed Glycine 0 C--N 1.297 -1.617 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 178.076 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.2 m -101.6 128.48 47.85 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.505 -0.997 . . . . 0.0 108.549 178.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.583 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.68 108.8 6.78 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.057 -1.057 . . . . 0.0 109.884 -179.21 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.2 m -121.0 118.96 31.17 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.361 -0.837 . . . . 0.0 109.371 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.446 HG21 HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.63 143.74 30.91 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.392 -0.818 . . . . 0.0 109.479 179.83 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.9 p -99.06 146.97 25.52 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.4 -0.813 . . . . 0.0 109.411 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.575 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -147.42 167.97 23.05 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.393 -0.817 . . . . 0.0 109.368 -179.251 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 4.6 p -94.49 124.73 38.69 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.903 -1.123 . . . . 0.0 109.859 -179.522 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.562 ' CG2' ' CG1' ' A' ' 19' ' ' VAL . 15.8 m -136.46 144.98 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.997 -1.064 . . . . 0.0 109.206 -179.695 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.595 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.3 ptt180 -147.56 -178.49 6.28 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.327 -1.483 . . . . 0.0 111.346 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.698 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -50.07 -98.17 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -179.569 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 1.0 OUTLIER -63.79 146.69 53.45 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.57 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.609 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.8 OUTLIER -166.18 141.76 4.75 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 118.03 -1.468 . . . . 0.0 110.243 -177.276 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.492 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.9 mm-40 -36.03 120.71 0.64 Allowed 'General case' 0 N--CA 1.491 1.619 0 CA-C-O 121.475 0.655 . . . . 0.0 110.308 -178.771 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.516 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -95.59 51.46 1.79 Allowed Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.573 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -39.35 113.74 0.35 Allowed 'General case' 0 N--CA 1.507 2.401 0 O-C-N 121.093 -1.24 . . . . 0.0 110.142 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -85.28 126.35 33.64 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 120.958 -1.089 . . . . 0.0 109.415 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -64.33 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.963 0 O-C-N 120.82 -1.175 . . . . 0.0 110.105 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.7 t0 -160.07 19.76 0.16 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.982 -1.074 . . . . 0.0 109.648 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.91 -27.65 5.36 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 110.063 -1.215 . . . . 0.0 110.063 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.448 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.15 157.6 16.0 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.04 -1.27 . . . . 0.0 110.446 -179.395 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.463 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 1.8 ptm180 -104.87 136.15 44.91 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.459 ' HB2' HD12 ' A' ' 77' ' ' LEU . 1.5 t90 -82.86 -16.47 47.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.761 -1.212 . . . . 0.0 110.689 -178.26 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.08 175.43 20.83 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 108.828 -1.709 . . . . 0.0 108.828 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.72 103.51 0.7 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 179.14 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.574 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 40.8 t -74.54 107.42 5.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.384 -0.823 . . . . 0.0 109.566 -178.841 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.481 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -67.09 112.0 4.18 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.581 -0.699 . . . . 0.0 109.685 -179.556 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.698 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 11.0 m -60.96 -5.71 1.5 Allowed 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.104 -1.439 . . . . 0.0 110.35 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.02 -4.43 58.79 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.396 -1.44 . . . . 0.0 109.53 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.462 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -104.0 -48.0 4.02 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.202 -0.936 . . . . 0.0 108.886 179.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -112.55 -178.3 3.37 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.573 -0.704 . . . . 0.0 109.33 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.37 117.3 34.44 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.375 -0.828 . . . . 0.0 109.02 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.487 ' O ' HG12 ' A' ' 110' ' ' ILE . 3.9 m -96.47 122.77 39.72 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.866 -1.146 . . . . 0.0 109.344 -179.515 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.536 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mp0 -106.7 145.48 31.95 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 122.404 1.097 . . . . 0.0 111.685 -179.112 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.523 ' CG1' HG13 ' A' ' 7' ' ' VAL . 62.0 t -100.83 109.71 26.05 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 177.428 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.5 -172.2 16.58 Favored Glycine 0 N--CA 1.487 2.052 0 C-N-CA 118.257 -1.925 . . . . 0.0 111.622 -177.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.497 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.04 -179.22 3.63 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -178.874 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.483 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 8.4 p . . . . . 0 C--N 1.296 -1.727 0 O-C-N 121.369 -0.832 . . . . 0.0 109.09 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.814 0 N-CA-C 107.552 -2.219 . . . . 0.0 107.552 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.75 -179.02 7.79 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.432 -1.04 . . . . 0.0 109.561 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -174.41 -165.8 31.46 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.485 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.7 Cg_exo -49.64 -174.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 CA-C-N 118.778 1.289 . . . . 0.0 110.472 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -93.9 -179.61 5.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.113 -0.992 . . . . 0.0 110.373 -179.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -116.66 158.64 14.36 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.76 124.93 52.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.362 -1.081 . . . . 0.0 109.056 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.536 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.54 120.91 18.81 Favored 'General case' 0 C--N 1.29 -2.005 0 O-C-N 121.804 -0.56 . . . . 0.0 109.707 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.564 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -98.02 169.1 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.255 -0.903 . . . . 0.0 109.241 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.507 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.72 155.22 50.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.307 -0.871 . . . . 0.0 109.48 179.993 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.564 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 74.5 m-85 . . . . . 0 N--CA 1.486 1.349 0 O-C-N 121.164 -0.96 . . . . 0.0 109.468 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.129 0 CA-C-O 122.361 1.077 . . . . 0.0 110.672 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.529 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.6 p -104.2 104.57 14.51 Favored 'General case' 0 C--N 1.296 -1.724 0 CA-C-O 122.49 1.138 . . . . 0.0 110.115 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.532 HG12 ' CG1' ' A' ' 95' ' ' VAL . 16.2 t -119.8 115.61 47.99 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.46 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.292 179.681 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.493 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.49 148.8 13.14 Favored Pre-proline 0 N--CA 1.487 1.407 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -179.583 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG22 ' A' ' 8' ' ' THR . 6.1 Cg_endo -77.92 150.22 89.08 Favored 'Cis proline' 0 C--N 1.309 -1.528 0 C-N-CA 123.606 -1.414 . . . . 0.0 109.737 -0.397 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.49 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 40.1 p -89.05 -26.4 21.43 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.505 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 6.0 p -133.07 165.19 25.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.522 -0.736 . . . . 0.0 109.423 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.14 37.51 37.3 Favored Glycine 0 N--CA 1.496 2.652 0 N-CA-C 108.402 -1.879 . . . . 0.0 108.402 -179.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.61 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 35.6 mt -92.51 -42.98 9.41 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 123.328 1.537 . . . . 0.0 110.491 -178.26 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.28 143.94 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.29 0 CA-C-N 113.319 -1.764 . . . . 0.0 109.858 -179.548 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.578 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.0 p-10 -50.38 106.2 0.12 Allowed 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.398 0.618 . . . . 0.0 111.666 -178.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.53 14.4 8.89 Favored Glycine 0 N--CA 1.485 1.924 0 C-N-CA 119.42 -1.371 . . . . 0.0 113.022 177.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.61 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -104.96 -172.66 2.14 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 121.15 2.475 . . . . 0.0 109.864 179.246 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.583 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 18.8 t -130.4 140.19 49.46 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.285 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.24 -178.774 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.521 HG22 ' CD1' ' A' ' 67' ' ' LEU . 30.0 m -117.25 155.52 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.525 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.5 OUTLIER -107.19 109.15 20.89 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.087 -1.008 . . . . 0.0 109.572 -179.8 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.507 HG12 ' CG2' ' A' ' 34' ' ' VAL . 2.0 p -106.47 121.51 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.545 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -113.49 165.94 11.99 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.875 -1.141 . . . . 0.0 108.976 179.75 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.58 107.98 0.49 Allowed Glycine 0 N--CA 1.481 1.668 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.81 139.78 50.2 Favored 'General case' 0 N--CA 1.499 2.002 0 CA-C-N 119.218 1.509 . . . . 0.0 110.27 -179.43 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.82 28.86 30.6 Favored Glycine 0 N--CA 1.49 2.286 0 C-N-CA 118.792 -1.671 . . . . 0.0 109.782 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.523 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.4 mt -93.13 174.54 7.17 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.085 -1.244 . . . . 0.0 108.458 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.554 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.87 98.99 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.949 -1.094 . . . . 0.0 109.498 -179.718 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.05 76.59 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.282 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.33 33.96 0.26 Allowed Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 82.2 p -144.46 111.41 5.81 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 120.966 -1.314 . . . . 0.0 111.144 -179.668 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.537 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -47.49 112.65 0.57 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.895 178.308 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.53 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 14.4 m-85 -104.51 150.19 24.81 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.206 -0.933 . . . . 0.0 108.746 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.455 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -99.62 158.57 15.67 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 178.564 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.634 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 6.2 p -141.67 116.46 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.006 -1.059 . . . . 0.0 110.042 -177.69 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.509 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.45 -176.54 39.41 Favored Glycine 0 N--CA 1.493 2.462 0 C-N-CA 118.338 -1.886 . . . . 0.0 111.674 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.557 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -100.49 109.11 21.21 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 121.928 0.87 . . . . 0.0 108.82 -179.571 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.6 m -129.55 148.65 51.47 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.212 -0.93 . . . . 0.0 109.882 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.93 138.57 54.64 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.375 -0.828 . . . . 0.0 110.669 -179.027 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.621 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.91 26.73 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.039 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.402 HG22 ' HB ' ' A' ' 44' ' ' VAL . 18.1 m -105.88 14.9 7.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.894 -1.129 . . . . 0.0 110.617 -178.769 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.59 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.6 -175.81 0.08 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.844 -1.16 . . . . 0.0 110.116 179.667 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.547 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.2 t -70.57 97.28 1.29 Allowed 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.866 0.841 . . . . 0.0 109.946 -179.55 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.44 27.7 35.21 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 120.181 -1.009 . . . . 0.0 111.391 178.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.59 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.5 106.24 20.1 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.592 -1.534 . . . . 0.0 107.258 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.621 HD13 ' CD1' ' A' ' 39' ' ' TRP . 11.9 tp -116.62 104.55 11.5 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 120.428 -1.42 . . . . 0.0 109.848 -177.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.539 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.32 109.24 22.03 Favored 'General case' 0 N--CA 1.484 1.253 0 O-C-N 120.842 -1.161 . . . . 0.0 108.119 178.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.2 t -105.94 163.09 13.02 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.993 -1.067 . . . . 0.0 109.871 -179.144 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.477 ' OD1' ' HB2' ' A' ' 74' ' ' GLU . 23.6 t30 -105.66 137.02 19.19 Favored Pre-proline 0 N--CA 1.503 2.21 0 O-C-N 121.289 -0.882 . . . . 0.0 109.972 -179.055 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.459 ' HD2' ' HB2' ' A' ' 74' ' ' GLU . 4.2 Cg_endo -73.77 24.25 0.33 Allowed 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 122.467 2.111 . . . . 0.0 112.323 -179.538 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.468 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -119.74 5.07 11.0 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.278 -1.513 . . . . 0.0 109.261 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.509 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -137.8 15.37 2.89 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 179.164 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -82.43 89.33 6.61 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.815 -0.754 . . . . 0.0 110.971 -178.517 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.634 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.27 -168.83 1.45 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 178.02 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.462 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.78 135.47 0.09 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 120.496 -1.377 . . . . 0.0 111.516 -179.243 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.579 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -153.7 158.18 4.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 177.963 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.537 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.1 m -98.15 143.88 28.21 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 120.638 -1.289 . . . . 0.0 109.777 -179.662 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.663 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -65.47 107.05 1.56 Allowed 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 122.307 1.051 . . . . 0.0 109.547 178.781 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.523 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.1 t0 -61.58 -139.38 0.0 OUTLIER 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.824 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.2 -51.57 42.99 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.361 -0.837 . . . . 0.0 110.704 -178.699 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -103.96 -32.75 9.1 Favored 'General case' 0 C--N 1.288 -2.109 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 178.562 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.663 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 105.08 69.17 0.75 Allowed Glycine 0 C--N 1.297 -1.589 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 178.194 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 24.3 m -104.19 126.34 51.21 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 121.684 -0.892 . . . . 0.0 108.838 178.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.579 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.85 109.04 8.26 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 119.644 -0.822 . . . . 0.0 109.486 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 6.4 m -117.5 115.67 25.61 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.271 -0.893 . . . . 0.0 109.398 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.513 ' CG2' HG11 ' A' ' 34' ' ' VAL . 1.3 t -140.97 139.52 34.24 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.359 -0.838 . . . . 0.0 109.723 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.1 p -99.42 132.55 44.68 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.463 -0.773 . . . . 0.0 109.245 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.521 ' CD1' HG22 ' A' ' 19' ' ' VAL . 0.1 OUTLIER -132.6 165.92 23.3 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.347 -0.845 . . . . 0.0 109.808 -179.238 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.583 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -98.15 125.18 43.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.238 -0.914 . . . . 0.0 109.219 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.543 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -135.24 143.4 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.068 -1.02 . . . . 0.0 109.897 -179.03 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.578 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.7 ptt180 -145.97 -172.63 3.96 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.457 -1.402 . . . . 0.0 110.946 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.529 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -57.64 -98.15 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.359 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.64 139.54 55.82 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.27 -1.519 . . . . 0.0 107.944 179.265 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -160.29 135.24 7.79 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 118.598 -1.241 . . . . 0.0 109.847 -178.107 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.485 ' O ' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -34.95 121.44 0.53 Allowed 'General case' 0 N--CA 1.491 1.611 0 CA-C-O 121.352 0.596 . . . . 0.0 110.119 -178.49 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.539 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -92.75 50.83 2.59 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 120.404 -0.903 . . . . 0.0 110.938 -179.196 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.471 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.4 OUTLIER -37.74 116.97 0.54 Allowed 'General case' 0 N--CA 1.514 2.726 0 O-C-N 121.274 -1.133 . . . . 0.0 109.973 179.816 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.538 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.1 tp -87.04 125.96 34.45 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 120.957 -1.089 . . . . 0.0 109.14 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -64.13 58.51 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.036 0 O-C-N 120.8 -1.188 . . . . 0.0 109.922 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' LEU . 26.4 t0 -160.38 20.05 0.15 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.959 -1.088 . . . . 0.0 109.668 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.33 -28.62 5.13 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.089 -1.205 . . . . 0.0 110.089 179.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.407 ' OG1' HD22 ' A' ' 77' ' ' LEU . 70.5 p -95.25 164.2 12.95 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.043 -1.269 . . . . 0.0 110.228 -179.427 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.459 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.9 OUTLIER -109.2 138.5 45.45 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.968 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.454 ' HB2' HD11 ' A' ' 77' ' ' LEU . 4.7 t90 -81.71 -20.83 38.6 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.805 -1.184 . . . . 0.0 110.391 -178.795 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.79 175.07 17.5 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.54 107.49 1.72 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.065 -1.256 . . . . 0.0 107.684 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.557 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 48.1 t -79.38 105.3 8.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 O-C-N 121.41 -0.806 . . . . 0.0 109.182 -179.009 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.8 OUTLIER -65.74 111.59 3.29 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.467 -0.771 . . . . 0.0 109.739 -179.583 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.529 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.17 -5.62 3.42 Favored 'General case' 0 N--CA 1.499 2.01 0 C-N-CA 118.208 -1.397 . . . . 0.0 109.884 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 19.9 p -87.71 0.73 55.31 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.697 -1.252 . . . . 0.0 109.117 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.451 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.8 p -114.11 -50.82 2.8 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.367 -0.833 . . . . 0.0 108.975 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.06 179.51 4.25 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.555 -0.716 . . . . 0.0 109.331 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.94 115.62 30.95 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.465 -0.772 . . . . 0.0 108.919 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.498 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.1 m -97.04 122.42 40.01 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.894 -1.129 . . . . 0.0 109.358 -179.373 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.541 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.67 146.83 27.62 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-O 122.368 1.08 . . . . 0.0 111.215 -179.369 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.532 ' CG1' HG12 ' A' ' 7' ' ' VAL . 52.9 t -103.48 109.79 28.03 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.067 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.61 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.447 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.96 -169.94 17.36 Favored Glycine 0 N--CA 1.486 1.987 0 C-N-CA 118.229 -1.938 . . . . 0.0 111.666 -177.514 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.465 HD11 ' HB3' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -123.2 179.16 4.8 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -178.682 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 3.6 t . . . . . 0 C--N 1.293 -1.859 0 O-C-N 121.52 -0.738 . . . . 0.0 109.597 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.663 0 N-CA-C 107.874 -2.09 . . . . 0.0 107.874 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.85 -177.52 5.56 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 122.062 0.934 . . . . 0.0 109.875 179.328 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -172.43 -161.56 23.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.151 -1.98 . . . . 0.0 108.151 -179.374 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.494 ' HD2' ' CE1' ' A' ' 32' ' ' TYR . 7.1 Cg_exo -45.69 173.14 0.02 OUTLIER 'Trans proline' 0 C--O 1.216 -0.58 0 CA-C-N 118.912 1.356 . . . . 0.0 110.008 179.268 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -93.95 -178.6 4.7 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.109 -0.994 . . . . 0.0 110.428 -178.662 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.447 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.92 168.07 12.71 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -108.23 128.7 63.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.313 -1.11 . . . . 0.0 109.117 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.541 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -69.18 123.84 22.21 Favored 'General case' 0 C--N 1.29 -2.007 0 O-C-N 121.556 -0.715 . . . . 0.0 109.381 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.569 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.6 173.76 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.199 -0.938 . . . . 0.0 108.928 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.505 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.5 OUTLIER -138.28 159.61 41.6 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.129 -0.982 . . . . 0.0 109.75 -179.743 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.569 ' CE2' HD12 ' A' ' 110' ' ' ILE . 88.4 m-85 . . . . . 0 N--CA 1.485 1.298 0 O-C-N 121.267 -0.896 . . . . 0.0 109.553 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.217 0 CA-C-O 122.448 1.118 . . . . 0.0 110.434 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.545 ' CG2' ' O ' ' A' ' 6' ' ' THR . 5.9 t -115.82 109.0 17.03 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-O 123.162 1.458 . . . . 0.0 109.735 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.529 HG12 ' CG1' ' A' ' 95' ' ' VAL . 2.1 t -115.63 133.69 61.22 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.675 0 CA-C-N 114.162 -1.381 . . . . 0.0 109.593 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.498 HG21 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.45 150.66 5.0 Favored Pre-proline 0 N--CA 1.488 1.43 0 O-C-N 121.259 -0.901 . . . . 0.0 108.896 -179.419 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.498 ' HA ' HG21 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.13 150.38 88.72 Favored 'Cis proline' 0 C--N 1.311 -1.415 0 C-N-CA 123.56 -1.433 . . . . 0.0 109.454 -0.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.454 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 95.6 p -90.4 -24.93 20.64 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.586 -0.696 . . . . 0.0 109.203 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.477 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 14.6 m -131.13 161.71 31.51 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.351 -0.843 . . . . 0.0 109.71 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.44 38.16 29.43 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.611 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 32.9 mt -93.31 -43.65 8.69 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 123.178 1.466 . . . . 0.0 110.801 -178.122 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.07 144.79 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.328 0 CA-C-N 113.484 -1.689 . . . . 0.0 110.123 -179.486 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.572 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 18.6 p-10 -50.37 106.07 0.11 Allowed 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 121.53 0.681 . . . . 0.0 111.693 -178.567 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.67 15.57 8.65 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.912 177.075 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.611 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -105.41 -174.28 2.5 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 121.223 2.511 . . . . 0.0 109.981 179.225 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.541 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 31.0 t -126.41 138.09 55.75 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.36 0 CA-C-N 114.549 -1.205 . . . . 0.0 111.399 -178.339 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.531 HG12 ' CG2' ' A' ' 69' ' ' VAL . 29.0 m -114.13 154.98 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.467 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.491 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.9 tttt -106.65 109.67 21.64 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.127 -0.983 . . . . 0.0 109.041 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.528 HG12 ' CG2' ' A' ' 34' ' ' VAL . 2.3 p -101.61 140.49 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -135.46 162.08 33.64 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 118.89 -1.124 . . . . 0.0 110.094 179.485 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -138.32 140.3 11.01 Favored Glycine 0 C--N 1.299 -1.514 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.71 125.22 15.73 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-N 119.183 1.492 . . . . 0.0 109.28 179.297 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.87 29.71 17.27 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 118.702 -1.713 . . . . 0.0 109.695 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.9 mt -89.88 175.2 7.3 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 120.863 -1.375 . . . . 0.0 108.517 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.55 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.77 96.8 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.102 -0.999 . . . . 0.0 109.885 -179.608 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -58.18 74.87 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.157 -179.138 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 138.75 32.97 0.19 Allowed Glycine 0 N--CA 1.484 1.848 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 179.454 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.632 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 1.4 t -149.11 115.43 5.82 Favored 'General case' 0 C--N 1.31 -1.127 0 O-C-N 120.893 -1.357 . . . . 0.0 111.218 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.54 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -49.42 111.22 0.46 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.251 178.472 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.632 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 1.9 m-30 -101.54 152.11 21.17 Favored 'General case' 0 N--CA 1.494 1.759 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 179.123 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.469 ' HA ' ' OG ' ' A' ' 54' ' ' SER . 0.5 OUTLIER -98.89 165.01 11.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.497 -1.377 . . . . 0.0 108.327 179.26 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.621 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.1 p -145.1 119.24 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.209 -0.932 . . . . 0.0 109.534 -178.012 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.42 -178.68 41.38 Favored Glycine 0 N--CA 1.495 2.605 0 C-N-CA 118.34 -1.886 . . . . 0.0 111.616 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.559 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -100.71 108.57 20.46 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 179.833 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.441 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.6 m -130.03 148.73 51.91 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 121.228 -0.92 . . . . 0.0 110.01 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.26 138.76 54.55 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.242 -0.911 . . . . 0.0 110.644 -179.143 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.628 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.32 114.82 26.64 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 178.154 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.3 m -104.45 14.88 6.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.014 -1.054 . . . . 0.0 110.534 -178.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.02 -175.01 0.07 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.023 -1.048 . . . . 0.0 110.185 179.785 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.12 98.11 2.06 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.446 -0.784 . . . . 0.0 109.708 -179.764 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.71 27.88 33.78 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.464 178.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.75 106.24 19.85 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 O-C-N 120.536 -1.567 . . . . 0.0 107.252 178.834 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.628 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.6 tp -117.49 104.45 11.09 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.402 -1.436 . . . . 0.0 109.958 -177.714 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -97.92 109.49 22.23 Favored 'General case' 0 N--CA 1.484 1.267 0 N-CA-C 107.718 -1.215 . . . . 0.0 107.718 178.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -107.32 166.16 10.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.895 -1.128 . . . . 0.0 110.655 -178.508 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.521 ' ND2' ' HB2' ' A' ' 50' ' ' ALA . 43.7 t30 -113.14 127.92 26.26 Favored Pre-proline 0 N--CA 1.498 1.972 0 O-C-N 121.497 -0.752 . . . . 0.0 109.267 -179.661 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.584 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -70.75 21.31 0.21 Allowed 'Trans proline' 0 CA--C 1.543 0.948 0 C-N-CA 122.103 1.869 . . . . 0.0 112.396 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.521 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -97.72 -5.62 34.72 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.304 -1.497 . . . . 0.0 109.017 179.31 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.561 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 1.4 m-20 -135.62 10.76 3.43 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.488 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.7 m-85 -66.56 82.9 0.1 Allowed 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.736 -178.403 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.621 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -108.47 -171.92 1.95 Allowed 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 178.252 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.469 ' OG ' ' HA ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER 178.6 134.71 0.08 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.608 -1.308 . . . . 0.0 111.25 -179.369 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.588 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 4.1 p -143.39 159.77 17.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 177.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.54 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -97.69 144.39 27.37 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.583 -1.323 . . . . 0.0 109.767 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.659 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -70.44 108.52 4.31 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 122.312 1.053 . . . . 0.0 109.963 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.522 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.3 t0 -64.66 -139.55 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.714 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.34 -52.43 37.06 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.344 -0.848 . . . . 0.0 110.605 -178.74 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.34 -32.32 10.53 Favored 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 178.613 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.659 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 100.34 69.29 0.88 Allowed Glycine 0 C--N 1.298 -1.571 0 N-CA-C 110.562 -1.015 . . . . 0.0 110.562 178.488 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 65.6 m -98.66 132.46 44.03 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.337 -1.096 . . . . 0.0 109.016 179.119 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.604 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -133.41 109.31 9.23 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.252 -179.716 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 19.8 m -122.53 115.68 22.59 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.264 -0.897 . . . . 0.0 109.565 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.404 HG23 HG13 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.74 143.32 28.61 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.27 -0.894 . . . . 0.0 109.661 179.927 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 57.6 p -99.15 142.38 30.71 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.371 -0.831 . . . . 0.0 109.148 179.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.549 ' HB2' ' OD2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -144.49 170.63 15.67 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.397 -0.815 . . . . 0.0 109.774 -179.01 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.529 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -104.35 124.26 48.88 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.952 -1.093 . . . . 0.0 110.474 -178.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.561 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 15.7 m -132.22 143.0 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 120.907 -1.121 . . . . 0.0 110.087 -179.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.572 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -145.65 -172.51 3.91 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.604 -1.31 . . . . 0.0 110.689 179.384 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.548 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -58.52 -98.42 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 -179.35 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.4 OUTLIER -57.88 141.22 49.96 Favored 'General case' 0 N--CA 1.485 1.307 0 O-C-N 120.307 -1.496 . . . . 0.0 108.374 179.47 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -161.78 135.44 6.51 Favored 'General case' 0 C--N 1.295 -1.787 0 C-N-CA 118.75 -1.18 . . . . 0.0 109.724 -178.402 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.9 mm-40 -32.11 121.55 0.3 Allowed 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.579 0.704 . . . . 0.0 110.697 -178.351 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -90.48 45.51 2.95 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.584 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-85 -37.96 113.56 0.29 Allowed 'General case' 0 N--CA 1.507 2.39 0 O-C-N 121.193 -1.18 . . . . 0.0 110.372 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.535 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.5 tp -85.89 126.56 34.16 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 120.948 -1.095 . . . . 0.0 109.535 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 33.4 t80 -63.9 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.024 0 O-C-N 120.93 -1.106 . . . . 0.0 110.318 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 17.2 t70 -161.46 20.11 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.928 -1.107 . . . . 0.0 109.729 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.59 -28.1 4.99 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.474 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 19.2 p -93.46 159.31 15.3 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.981 -1.305 . . . . 0.0 110.231 -179.492 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.504 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 1.1 ptt180 -106.78 139.03 41.85 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.465 ' CD1' HD12 ' A' ' 77' ' ' LEU . 3.3 t90 -84.79 -19.26 32.83 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.704 -1.248 . . . . 0.0 110.524 -178.558 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.84 174.1 18.14 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.447 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.93 106.38 1.22 Allowed 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 179.137 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.578 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 48.9 t -77.02 105.84 6.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 O-C-N 121.315 -0.866 . . . . 0.0 109.398 -178.744 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.52 ' CB ' HG21 ' A' ' 90' ' ' THR . 1.0 OUTLIER -66.31 111.46 3.51 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.386 -0.821 . . . . 0.0 109.685 -179.732 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.548 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.1 t -63.54 -5.51 3.94 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.533 -1.355 . . . . 0.0 109.828 179.562 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.2 p -86.45 -1.49 57.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.787 -1.196 . . . . 0.0 109.215 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.52 HG21 ' CB ' ' A' ' 87' ' ' ASP . 2.5 p -111.38 -50.24 2.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.295 -0.878 . . . . 0.0 108.93 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.34 -178.8 3.76 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.507 -0.746 . . . . 0.0 109.482 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.05 115.52 30.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.33 -0.856 . . . . 0.0 109.001 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.91 123.02 40.51 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.77 -1.206 . . . . 0.0 109.593 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.557 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.64 146.9 27.89 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 122.445 1.116 . . . . 0.0 111.138 -179.42 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.529 ' CG1' HG12 ' A' ' 7' ' ' VAL . 48.6 t -103.58 110.53 30.26 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.978 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 177.666 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.452 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.6 -170.24 16.86 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 118.06 -2.019 . . . . 0.0 111.745 -177.523 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -115.38 -179.08 3.54 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 -178.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.466 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.2 OUTLIER . . . . . 0 C--N 1.296 -1.747 0 O-C-N 121.318 -0.864 . . . . 0.0 109.61 -179.333 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.696 0 N-CA-C 107.7 -2.16 . . . . 0.0 107.7 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.46 -178.07 6.66 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-O 122.127 0.965 . . . . 0.0 109.622 179.219 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.0 -161.28 12.88 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 108.301 -1.92 . . . . 0.0 108.301 -179.345 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.487 ' CD ' ' CE2' ' A' ' 32' ' ' TYR . 6.3 Cg_exo -46.75 177.0 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.653 0 CA-C-N 118.838 1.319 . . . . 0.0 110.179 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -92.66 -177.55 4.6 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.074 -1.016 . . . . 0.0 110.451 -178.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.452 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.45 164.48 12.91 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.92 129.23 52.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.451 -1.029 . . . . 0.0 109.103 -179.565 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.557 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.04 123.4 22.72 Favored 'General case' 0 C--N 1.289 -2.023 0 O-C-N 121.702 -0.624 . . . . 0.0 109.535 179.734 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.585 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.74 170.53 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.174 -0.954 . . . . 0.0 109.14 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.477 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -138.84 156.63 47.16 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.174 -0.954 . . . . 0.0 109.765 -179.891 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.585 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 81.2 m-85 . . . . . 0 N--CA 1.485 1.324 0 O-C-N 121.144 -0.972 . . . . 0.0 109.569 -179.683 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.151 0 CA-C-O 122.358 1.075 . . . . 1.0 110.688 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.532 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.2 p -105.63 104.87 14.67 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.457 1.122 . . . . 1.0 110.21 -179.577 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.53 HG12 ' CG1' ' A' ' 95' ' ' VAL . 13.2 t -118.34 118.8 59.25 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.446 0 CA-C-N 115.384 -0.825 . . . . 1.0 110.495 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.523 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.38 149.37 9.8 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.169 -1.049 . . . . 1.0 108.169 -179.799 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.523 ' CA ' HG23 ' A' ' 8' ' ' THR . 5.1 Cg_endo -77.38 151.83 93.17 Favored 'Cis proline' 0 C--N 1.309 -1.536 0 C-N-CA 123.654 -1.394 . . . . 1.0 109.49 -0.223 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 75.4 p -91.89 -24.99 19.15 Favored 'General case' 0 C--N 1.292 -1.904 0 O-C-N 121.501 -0.749 . . . . 1.0 109.137 179.696 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.449 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 0.9 OUTLIER -133.54 165.12 25.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.43 -0.794 . . . . 1.0 109.557 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.52 38.5 37.81 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 108.209 -1.956 . . . . 1.0 108.209 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.613 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 33.6 mt -92.13 -44.32 8.88 Favored 'General case' 0 C--N 1.298 -1.674 0 CA-C-O 123.122 1.439 . . . . 1.0 110.637 -178.214 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.481 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.3 144.75 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.279 0 CA-C-N 113.613 -1.63 . . . . 1.0 109.947 -179.603 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.575 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.2 p-10 -51.16 108.24 0.24 Allowed 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.524 0.678 . . . . 1.0 111.523 -178.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.11 14.14 10.23 Favored Glycine 0 N--CA 1.484 1.835 0 C-N-CA 119.408 -1.377 . . . . 1.0 112.824 177.283 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.613 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.1 t -104.05 -172.38 2.1 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 121.079 2.439 . . . . 1.0 109.639 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 12.1 t -131.61 138.85 52.01 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.37 0 CA-C-N 114.967 -1.015 . . . . 1.0 111.281 -178.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.493 HG12 ' CG2' ' A' ' 69' ' ' VAL . 26.9 m -114.45 154.99 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.761 -0.829 . . . . 1.0 108.761 179.155 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 21.0 tttt -109.06 108.86 19.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.053 -1.029 . . . . 1.0 109.407 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.521 ' CG1' HG23 ' A' ' 34' ' ' VAL . 1.7 p -106.86 122.53 61.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 N-CA-C 108.778 -0.823 . . . . 1.0 108.778 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.543 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -112.98 165.67 12.13 Favored 'General case' 0 C--N 1.305 -1.331 0 O-C-N 120.902 -1.124 . . . . 1.0 109.114 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.587 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.77 107.91 0.48 Allowed Glycine 0 N--CA 1.482 1.765 0 N-CA-C 108.738 -1.745 . . . . 1.0 108.738 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.44 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.43 141.05 48.68 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 120.658 -1.495 . . . . 1.0 110.168 -179.502 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.86 28.12 32.61 Favored Glycine 0 N--CA 1.488 2.109 0 C-N-CA 119.003 -1.57 . . . . 1.0 109.806 179.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.537 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -94.23 174.73 7.0 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.008 -1.29 . . . . 1.0 108.587 179.991 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.563 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.95 97.29 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.022 -1.048 . . . . 1.0 109.673 -179.831 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.541 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.19 76.63 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.345 -0.843 . . . . 1.0 110.372 -179.145 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.563 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.85 33.92 0.32 Allowed Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.751 -1.34 . . . . 1.0 109.751 179.498 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.638 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.1 t -146.66 114.15 6.34 Favored 'General case' 0 C--N 1.309 -1.174 0 O-C-N 120.838 -1.39 . . . . 1.0 110.986 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.537 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -46.12 126.2 7.35 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-N 115.31 -0.859 . . . . 1.0 110.008 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.638 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 12.2 m-85 -118.43 151.17 38.3 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.543 -0.91 . . . . 1.0 108.543 179.358 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.463 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.54 156.76 17.28 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.572 -1.33 . . . . 1.0 108.063 179.015 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.617 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 7.0 p -139.32 115.04 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.189 -0.944 . . . . 1.0 109.83 -177.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.487 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.75 -178.64 37.53 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.449 -1.834 . . . . 1.0 111.804 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.631 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -101.8 109.43 21.19 Favored 'General case' 0 C--N 1.313 -0.987 0 N-CA-C 108.799 -0.815 . . . . 1.0 108.799 -179.818 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.41 149.17 52.21 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.22 -0.925 . . . . 1.0 109.99 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.21 138.19 54.7 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.265 -0.897 . . . . 1.0 110.729 -179.081 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.625 ' CE2' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.71 26.53 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 107.432 -1.322 . . . . 1.0 107.432 178.09 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -105.63 15.3 7.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.018 -1.051 . . . . 1.0 110.589 -178.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.589 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.99 -175.63 0.09 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.875 -1.14 . . . . 1.0 110.088 179.787 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 43.8 p -71.95 97.72 1.91 Allowed 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.404 -0.81 . . . . 1.0 109.664 -179.722 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.7 27.37 35.32 Favored Glycine 0 N--CA 1.493 2.448 0 C-N-CA 120.141 -1.028 . . . . 1.0 111.302 178.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.589 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.32 106.28 20.01 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.519 -1.577 . . . . 1.0 107.203 178.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.625 HD11 ' CE2' ' A' ' 39' ' ' TRP . 13.0 tp -117.04 104.3 11.11 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 120.427 -1.42 . . . . 1.0 109.726 -177.749 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.97 109.32 22.1 Favored 'General case' 0 N--CA 1.483 1.202 0 N-CA-C 107.65 -1.241 . . . . 1.0 107.65 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -105.72 166.36 10.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.035 -1.04 . . . . 1.0 110.404 -178.678 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.454 ' OD1' ' HB2' ' A' ' 74' ' ' GLU . 59.2 t30 -111.84 131.39 22.45 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.541 -0.724 . . . . 1.0 109.736 -179.465 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.58 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 2.5 Cg_endo -73.05 22.62 0.31 Allowed 'Trans proline' 0 C--N 1.319 -1.022 0 C-N-CA 122.112 1.874 . . . . 1.0 111.737 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.436 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -110.01 2.84 19.89 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.307 -1.496 . . . . 1.0 109.19 179.562 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.524 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.5 15.56 2.75 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.471 -1.307 . . . . 1.0 107.471 179.479 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -79.22 92.96 5.16 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.898 -0.721 . . . . 1.0 111.039 -178.429 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.617 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -111.95 -167.82 1.23 Allowed 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.536 -1.283 . . . . 1.0 107.536 178.104 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.467 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.98 136.5 0.09 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.439 -1.413 . . . . 1.0 111.521 -179.332 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.585 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.12 157.51 4.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.276 -1.379 . . . . 1.0 107.276 178.019 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.537 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.1 145.49 26.51 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.76 -1.212 . . . . 1.0 109.825 -179.703 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.674 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.08 107.24 1.84 Allowed 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 122.485 1.136 . . . . 1.0 109.328 178.718 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.523 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.1 t70 -60.82 -139.37 0.0 OUTLIER 'General case' 0 C--N 1.292 -1.93 0 CA-C-N 115.558 -0.746 . . . . 1.0 110.941 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.541 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.12 -51.42 43.26 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.504 -0.747 . . . . 1.0 110.756 -178.658 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.57 -32.56 8.89 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 106.308 -1.738 . . . . 1.0 106.308 178.673 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.674 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.24 65.21 0.61 Allowed Glycine 0 C--N 1.297 -1.589 0 N-CA-C 110.542 -1.023 . . . . 1.0 110.542 178.238 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.587 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.7 m -103.0 124.66 48.93 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 108.292 -1.003 . . . . 1.0 108.292 178.604 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.585 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.58 109.36 8.62 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 119.681 -0.808 . . . . 1.0 109.726 -179.13 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.3 m -115.99 115.66 26.54 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.293 -0.879 . . . . 1.0 109.164 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.459 HG22 HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -140.68 138.86 34.59 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.425 -0.797 . . . . 1.0 109.864 179.941 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.7 p -98.98 133.48 43.19 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.448 -0.782 . . . . 1.0 109.179 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.524 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -131.22 163.71 27.14 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.302 -0.873 . . . . 1.0 109.446 -179.313 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.552 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.8 p -93.99 124.33 37.93 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.046 -1.034 . . . . 1.0 109.157 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.493 ' CG2' HG12 ' A' ' 19' ' ' VAL . 14.4 m -134.71 143.32 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 120.979 -1.076 . . . . 1.0 109.877 -178.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.575 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.2 ptt180 -145.33 -170.66 3.49 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.464 -1.397 . . . . 1.0 111.042 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.611 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -61.88 -101.64 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.851 -0.531 . . . . 1.0 110.241 -179.093 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -59.19 138.11 57.71 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.566 -1.333 . . . . 1.0 108.517 179.953 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.631 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 1.3 p90 -156.87 154.13 29.32 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 118.824 -1.15 . . . . 1.0 109.854 -178.795 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' A' ' 47' ' ' CYS . 20.4 mm-40 -47.6 122.11 4.56 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.353 -0.842 . . . . 1.0 109.577 -178.58 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -88.94 49.38 3.58 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.94 -0.864 . . . . 1.0 110.94 -179.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.58 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.4 m-85 -40.42 113.17 0.34 Allowed 'General case' 0 N--CA 1.507 2.386 0 O-C-N 121.014 -1.286 . . . . 1.0 110.224 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -86.92 127.08 35.06 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.842 -1.161 . . . . 1.0 109.358 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -63.83 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 O-C-N 120.758 -1.214 . . . . 1.0 110.213 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 1.6 t0 -160.78 19.0 0.13 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.016 -1.052 . . . . 1.0 109.801 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -25.97 5.75 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 110.15 -1.18 . . . . 1.0 110.15 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 15.4 p -93.31 157.67 16.13 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 120.964 -1.315 . . . . 1.0 110.491 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.462 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -103.86 132.71 49.85 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.482 -0.932 . . . . 1.0 108.482 179.609 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.457 ' CD1' HD11 ' A' ' 77' ' ' LEU . 3.1 t90 -81.16 -18.51 46.06 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.758 -1.213 . . . . 1.0 110.382 -178.692 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.26 174.16 19.41 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.864 -1.694 . . . . 1.0 108.864 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.43 107.93 1.22 Allowed 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.683 -1.229 . . . . 1.0 107.683 179.224 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.6 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 42.0 t -79.82 104.74 8.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.362 -0.836 . . . . 1.0 109.13 -178.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.469 ' HB3' HG22 ' A' ' 90' ' ' THR . 0.8 OUTLIER -65.04 109.15 2.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.567 -0.708 . . . . 1.0 110.15 -179.179 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.586 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.8 t -62.04 -4.1 1.51 Allowed 'General case' 0 N--CA 1.502 2.167 0 C-N-CA 118.262 -1.375 . . . . 1.0 110.334 179.265 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.1 p -91.33 5.34 49.62 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.66 -1.275 . . . . 1.0 109.384 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.469 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -117.2 -49.75 2.58 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.356 -0.84 . . . . 1.0 109.178 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.89 178.55 4.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.52 -0.737 . . . . 1.0 109.456 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.49 112.5 24.87 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.342 -0.849 . . . . 1.0 108.907 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.501 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 1.6 m -96.7 121.69 38.82 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.031 -1.043 . . . . 1.0 109.279 -179.061 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.535 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.61 147.55 26.65 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 122.454 1.121 . . . . 1.0 111.358 -179.172 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.53 ' CG1' HG12 ' A' ' 7' ' ' VAL . 58.8 t -103.38 109.52 27.22 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.492 -1.67 . . . . 1.0 106.492 177.484 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.401 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.19 -171.31 16.98 Favored Glycine 0 N--CA 1.485 1.927 0 C-N-CA 118.166 -1.969 . . . . 1.0 111.721 -177.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.463 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -115.49 -178.2 3.33 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.704 -0.85 . . . . 1.0 108.704 -178.839 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 p . . . . . 0 C--N 1.297 -1.714 0 O-C-N 121.312 -0.867 . . . . 1.0 109.574 -179.16 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.681 0 N-CA-C 107.697 -2.161 . . . . 1.0 107.697 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.02 -177.91 6.43 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 122.052 0.93 . . . . 1.0 109.844 179.255 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.48 -162.49 19.39 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 108.374 -1.89 . . . . 1.0 108.374 -179.477 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.477 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.1 Cg_exo -46.0 174.43 0.02 OUTLIER 'Trans proline' 0 C--N 1.327 -0.581 0 CA-C-N 118.854 1.327 . . . . 1.0 110.168 179.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -90.46 -178.84 5.44 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.0 -1.063 . . . . 1.0 110.611 -178.601 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.401 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.86 166.38 13.02 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.586 -1.405 . . . . 1.0 109.586 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.61 131.8 54.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.338 -1.095 . . . . 1.0 109.177 -179.225 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.535 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.3 121.94 20.28 Favored 'General case' 0 C--N 1.29 -2.002 0 O-C-N 121.59 -0.694 . . . . 1.0 109.617 179.657 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.562 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.8 pt -98.01 173.2 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.248 -0.908 . . . . 1.0 108.996 179.852 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.449 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -141.36 159.54 42.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.06 -1.025 . . . . 1.0 110.04 -179.7 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.562 ' CE2' HD12 ' A' ' 110' ' ' ILE . 88.5 m-85 . . . . . 0 N--CA 1.487 1.376 0 O-C-N 121.276 -0.89 . . . . 1.0 109.573 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.471 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.481 0 CA-C-O 122.356 1.074 . . . . 0.0 110.666 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.542 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.9 t -111.17 108.71 18.47 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 123.04 1.4 . . . . 0.0 109.096 179.273 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.506 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 4.5 t -118.31 136.44 55.5 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.761 0 CA-C-N 114.299 -1.319 . . . . 0.0 110.094 -179.685 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.528 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -176.64 150.97 1.0 Allowed Pre-proline 0 N--CA 1.488 1.431 0 O-C-N 121.279 -0.888 . . . . 0.0 108.801 -179.641 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.528 ' CA ' HG23 ' A' ' 8' ' ' THR . 5.8 Cg_endo -79.11 150.45 85.74 Favored 'Cis proline' 0 C--N 1.311 -1.432 0 C-N-CA 123.507 -1.456 . . . . 0.0 109.271 -0.735 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.459 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 78.4 p -92.23 -23.19 19.42 Favored 'General case' 0 C--N 1.291 -1.937 0 O-C-N 121.589 -0.695 . . . . 0.0 109.402 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.485 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 7.4 m -132.2 160.74 35.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.354 -0.841 . . . . 0.0 109.764 -179.785 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.77 37.39 30.21 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.616 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 30.8 mt -92.04 -44.42 8.86 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-O 123.2 1.476 . . . . 0.0 110.728 -178.363 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.4 OUTLIER 65.96 146.28 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.341 0 CA-C-N 113.628 -1.624 . . . . 0.0 109.942 -179.69 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.546 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.0 p-10 -50.85 108.08 0.21 Allowed 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 121.478 0.656 . . . . 0.0 111.882 -178.532 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.5 15.2 10.58 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.421 -1.371 . . . . 0.0 112.879 177.131 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.616 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 10.6 t -102.65 -172.42 2.12 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 121.056 2.428 . . . . 0.0 109.897 179.35 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.542 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 33.6 t -125.66 137.55 57.33 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.246 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.962 -178.726 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.526 HG11 ' CG2' ' A' ' 69' ' ' VAL . 27.4 m -116.2 155.84 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 178.768 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.506 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.4 ttpt -114.31 109.55 18.52 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.06 -1.025 . . . . 0.0 109.178 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.5 HG13 ' CG2' ' A' ' 34' ' ' VAL . 2.4 p -105.12 141.45 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.54 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -139.72 160.25 40.3 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 120.632 -1.292 . . . . 0.0 110.229 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.07 144.21 15.45 Favored Glycine 0 C--N 1.295 -1.704 0 N-CA-C 107.977 -2.049 . . . . 0.0 107.977 179.47 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.08 125.94 13.55 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 120.894 -1.356 . . . . 0.0 108.841 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.11 27.04 24.51 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 119.214 -1.469 . . . . 0.0 109.654 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.4 mt -88.58 175.01 7.74 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.887 -1.361 . . . . 0.0 108.498 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.555 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -48.55 100.15 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.002 -1.061 . . . . 0.0 109.792 -179.63 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.44 78.13 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.134 -179.24 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.91 34.08 0.31 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.72 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.539 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 34.2 p -140.79 107.29 5.3 Favored 'General case' 0 C--N 1.308 -1.218 0 O-C-N 121.24 -1.153 . . . . 0.0 110.984 -179.489 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.548 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -47.67 109.78 0.25 Allowed 'General case' 0 N--CA 1.497 1.888 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.987 178.174 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.539 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 24.9 m-85 -102.38 153.86 19.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 108.638 179.372 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.482 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.87 161.51 13.61 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.676 -1.265 . . . . 0.0 107.948 178.85 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.626 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.5 p -141.16 115.23 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.157 -0.964 . . . . 0.0 109.442 -178.205 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.521 ' HA2' ' OD1' ' A' ' 51' ' ' ASP . . . -162.75 173.99 39.05 Favored Glycine 0 N--CA 1.49 2.276 0 C-N-CA 118.06 -2.019 . . . . 0.0 112.114 -179.334 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.592 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -98.43 108.96 21.79 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 179.267 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.8 m -132.28 151.26 51.92 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.277 -0.889 . . . . 0.0 109.992 -179.513 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.82 139.65 53.64 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.248 -0.907 . . . . 0.0 110.695 -179.06 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.629 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.26 114.56 26.36 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.22 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.444 HG21 ' HB ' ' A' ' 44' ' ' VAL . 14.2 m -105.09 14.75 7.09 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 120.885 -1.135 . . . . 0.0 110.602 -178.687 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.59 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.06 -174.99 0.09 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.892 -1.13 . . . . 0.0 110.067 179.751 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.6 p -71.95 97.32 1.84 Allowed 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.344 -0.848 . . . . 0.0 109.798 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.42 26.93 34.39 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 120.241 -0.98 . . . . 0.0 111.428 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.59 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.6 106.31 20.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.55 -1.559 . . . . 0.0 107.429 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.629 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.2 tp -116.65 104.82 11.77 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.564 -1.335 . . . . 0.0 109.723 -177.862 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.542 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.98 109.53 22.27 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 120.829 -1.17 . . . . 0.0 108.204 179.092 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.6 t -105.89 165.56 11.11 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.9 -1.125 . . . . 0.0 110.295 -179.085 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.535 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 18.7 t-20 -109.33 137.0 20.13 Favored Pre-proline 0 N--CA 1.501 2.104 0 O-C-N 121.421 -0.799 . . . . 0.0 110.201 -179.08 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.579 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.2 Cg_endo -74.89 23.94 0.39 Allowed 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 122.387 2.058 . . . . 0.0 111.971 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.535 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -116.88 2.67 12.83 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.296 -1.503 . . . . 0.0 109.227 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.558 ' OD1' ' CD2' ' A' ' 67' ' ' LEU . 9.4 t70 -137.64 13.27 2.95 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 179.552 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -79.72 94.25 5.7 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 121.424 -0.798 . . . . 0.0 110.883 -178.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -115.33 -166.25 1.1 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 178.367 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.472 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.94 135.42 0.09 Allowed 'General case' 0 N--CA 1.486 1.369 0 O-C-N 120.627 -1.296 . . . . 0.0 111.429 -179.34 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.585 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -151.18 156.9 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 107.354 -1.351 . . . . 0.0 107.354 178.007 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.548 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.19 144.14 27.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.801 -1.187 . . . . 0.0 110.055 -179.574 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.685 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.72 106.91 1.06 Allowed 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 122.447 1.118 . . . . 0.0 109.436 178.27 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.521 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -60.05 -139.28 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.988 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.042 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.91 -50.1 61.74 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.498 -0.751 . . . . 0.0 110.597 -178.752 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 12.3 m-80 -103.7 -34.47 8.58 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 106.208 -1.775 . . . . 0.0 106.208 178.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.685 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.49 65.31 0.58 Allowed Glycine 0 C--N 1.297 -1.604 0 N-CA-C 110.501 -1.039 . . . . 0.0 110.501 178.141 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 46.6 m -103.62 127.05 51.11 Favored 'General case' 0 N--CA 1.483 1.19 0 O-C-N 121.381 -1.07 . . . . 0.0 108.915 178.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.585 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.72 109.15 7.37 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.424 -0.91 . . . . 0.0 109.36 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.521 ' CB ' ' HB2' ' A' ' 22' ' ' ALA . 1.4 m -124.71 121.65 35.25 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.201 -0.937 . . . . 0.0 109.663 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.71 142.05 28.61 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.596 -0.69 . . . . 0.0 109.486 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 15.6 p -98.93 136.38 39.0 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.451 -0.781 . . . . 0.0 109.186 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.558 ' CD2' ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -135.93 -178.73 5.27 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.235 -0.915 . . . . 0.0 109.544 -178.983 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.4 p -105.09 126.18 51.79 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.99 -1.069 . . . . 0.0 109.637 -179.352 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.534 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 16.9 m -139.35 142.97 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 120.888 -1.132 . . . . 0.0 110.08 -179.521 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.546 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 7.8 ptt180 -141.2 -161.42 1.21 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.671 -1.268 . . . . 0.0 110.141 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.582 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -78.15 -86.89 0.06 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.232 -0.918 . . . . 0.0 108.848 -179.584 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -60.87 138.47 58.14 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.387 -1.446 . . . . 0.0 107.204 178.809 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -165.11 136.58 4.11 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 117.901 -1.519 . . . . 0.0 110.371 -177.365 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.484 ' O ' ' O ' ' A' ' 47' ' ' CYS . 7.0 mm-40 -33.4 121.44 0.4 Allowed 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 121.352 0.596 . . . . 0.0 110.326 -178.766 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.542 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.85 51.83 1.72 Allowed Glycine 0 N--CA 1.494 2.53 0 C-N-CA 120.474 -0.869 . . . . 0.0 111.42 -179.036 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 4.2 m-85 -39.11 116.6 0.6 Allowed 'General case' 0 N--CA 1.511 2.62 0 O-C-N 121.018 -1.283 . . . . 0.0 110.05 179.526 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.544 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.9 tp -86.4 126.27 34.27 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 120.96 -1.087 . . . . 0.0 109.69 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -64.5 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 120.738 -1.226 . . . . 0.0 109.92 179.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.544 ' N ' ' O ' ' A' ' 77' ' ' LEU . 5.7 t70 -158.93 19.51 0.2 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.061 -1.025 . . . . 0.0 109.656 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.75 -27.96 5.65 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.408 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 69.7 p -97.54 162.71 13.17 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.046 -1.267 . . . . 0.0 110.307 -179.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.52 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.0 140.37 41.25 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.904 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.47 ' HB2' HD11 ' A' ' 77' ' ' LEU . 1.7 t90 -83.8 -19.21 35.42 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.771 -1.205 . . . . 0.0 110.728 -178.282 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.85 177.33 20.13 Favored Glycine 0 N--CA 1.484 1.869 0 N-CA-C 108.578 -1.809 . . . . 0.0 108.578 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -63.9 109.79 1.89 Allowed 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.214 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.521 HG23 ' CB ' ' A' ' 46' ' ' ALA . 37.3 t -82.91 105.66 12.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 121.44 -0.788 . . . . 0.0 108.947 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.507 ' CB ' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -66.14 111.73 3.56 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.428 -0.795 . . . . 0.0 109.882 -179.205 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.555 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -65.28 -5.32 6.87 Favored 'General case' 0 N--CA 1.498 1.96 0 C-N-CA 118.203 -1.399 . . . . 0.0 109.665 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.3 p -84.01 -1.24 54.37 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.799 -1.188 . . . . 0.0 108.887 179.269 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.507 HG23 ' CB ' ' A' ' 87' ' ' ASP . 2.2 p -113.5 -50.05 2.87 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.443 -0.786 . . . . 0.0 109.012 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.87 -178.0 3.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.486 -0.758 . . . . 0.0 109.45 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.09 115.77 30.76 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.451 -0.78 . . . . 0.0 109.037 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.535 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -96.87 122.76 40.19 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.894 -1.129 . . . . 0.0 109.588 -179.384 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.555 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.83 146.39 28.35 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 122.337 1.065 . . . . 0.0 111.167 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.442 HG23 HG23 ' A' ' 110' ' ' ILE . 59.3 t -103.78 109.88 28.46 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.433 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.55 -172.09 18.05 Favored Glycine 0 N--CA 1.486 2.016 0 C-N-CA 118.03 -2.033 . . . . 0.0 111.914 -177.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.482 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -112.97 -178.88 3.49 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.255 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.478 ' O ' ' N ' ' A' ' 33' ' ' ASP . 2.9 p . . . . . 0 C--N 1.296 -1.728 0 O-C-N 121.261 -0.899 . . . . 0.0 109.518 -179.373 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.631 0 N-CA-C 107.913 -2.075 . . . . 0.0 107.913 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.31 -177.76 6.23 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 122.1 0.952 . . . . 0.0 109.95 179.277 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.93 -163.89 23.71 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.149 -1.98 . . . . 0.0 108.149 -179.457 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.0 Cg_exo -46.24 172.96 0.02 OUTLIER 'Trans proline' 0 C--N 1.326 -0.616 0 CA-C-N 118.88 1.34 . . . . 0.0 109.889 179.371 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -91.7 -173.21 3.46 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.15 -0.969 . . . . 0.0 110.447 -178.712 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.433 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.81 171.29 15.54 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.416 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.1 t -106.69 132.98 52.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.536 -0.979 . . . . 0.0 109.138 -179.383 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.555 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.37 123.94 26.25 Favored 'General case' 0 C--N 1.29 -2.017 0 O-C-N 121.609 -0.682 . . . . 0.0 109.664 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.572 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.73 168.23 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.282 -0.886 . . . . 0.0 108.934 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.485 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 5.4 m -136.6 154.53 50.64 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.219 -0.926 . . . . 0.0 109.752 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.572 ' CE2' HD12 ' A' ' 110' ' ' ILE . 77.3 m-85 . . . . . 0 N--CA 1.487 1.38 0 O-C-N 121.179 -0.951 . . . . 0.0 109.417 -179.698 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.176 0 CA-C-O 122.414 1.102 . . . . 0.0 110.617 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.535 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 3.2 p -108.54 104.79 14.19 Favored 'General case' 0 C--N 1.296 -1.738 0 CA-C-O 122.491 1.139 . . . . 0.0 110.337 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.523 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 10.8 t -116.86 110.17 30.44 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.448 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.479 179.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.522 HG22 ' CA ' ' A' ' 9' ' ' PRO . 1.0 OUTLIER -152.55 146.72 18.53 Favored Pre-proline 0 N--CA 1.485 1.294 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.971 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.522 ' CA ' HG22 ' A' ' 8' ' ' THR . 9.3 Cg_endo -80.83 146.87 73.05 Favored 'Cis proline' 0 C--N 1.306 -1.675 0 O-C-N 123.666 1.351 . . . . 0.0 109.373 -0.232 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.47 ' HB2' ' HA ' ' A' ' 110' ' ' ILE . 80.4 p -91.51 -24.03 19.77 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.465 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 13.2 m -131.33 160.99 33.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.575 -0.703 . . . . 0.0 109.471 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.74 36.65 32.36 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 -179.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.604 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 35.7 mt -91.32 -42.63 10.26 Favored 'General case' 0 C--N 1.299 -1.587 0 CA-C-O 123.358 1.552 . . . . 0.0 110.46 -178.475 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.24 142.99 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.253 0 CA-C-N 113.322 -1.763 . . . . 0.0 109.795 -179.561 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.58 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.1 p-10 -50.01 105.74 0.1 Allowed 'General case' 0 C--N 1.301 -1.529 0 CA-C-O 121.448 0.642 . . . . 0.0 111.574 -178.56 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.47 13.88 8.57 Favored Glycine 0 N--CA 1.485 1.919 0 C-N-CA 119.417 -1.373 . . . . 0.0 113.16 177.211 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.604 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.0 t -106.01 -172.88 2.17 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 121.199 2.499 . . . . 0.0 109.839 179.28 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.583 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 20.8 t -128.87 140.3 49.62 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.27 0 CA-C-N 114.695 -1.139 . . . . 0.0 111.362 -178.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.531 HG11 ' CG2' ' A' ' 69' ' ' VAL . 27.8 m -114.87 156.24 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 178.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.508 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -109.29 109.72 20.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.984 -1.072 . . . . 0.0 109.553 -179.716 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.525 HG13 ' CG2' ' A' ' 34' ' ' VAL . 1.6 p -105.05 123.57 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 179.898 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.567 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -112.3 165.96 11.71 Favored 'General case' 0 N--CA 1.484 1.267 0 O-C-N 120.792 -1.192 . . . . 0.0 108.942 179.438 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -145.56 108.16 0.45 Allowed Glycine 0 N--CA 1.483 1.822 0 N-CA-C 108.36 -1.896 . . . . 0.0 108.36 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.83 137.37 52.25 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 120.519 -1.577 . . . . 0.0 110.439 -179.303 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.455 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 85.85 28.85 27.8 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.085 -1.531 . . . . 0.0 109.874 179.567 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.3 mt -90.36 175.66 7.02 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.963 -1.316 . . . . 0.0 108.373 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.553 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.69 97.94 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.858 -1.151 . . . . 0.0 109.678 -179.669 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.08 76.96 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.692 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.381 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.571 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.9 34.34 0.3 Allowed Glycine 0 N--CA 1.486 1.975 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.465 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.7 p -147.89 113.3 5.61 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 120.998 -1.296 . . . . 0.0 111.28 -179.693 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.543 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.86 126.67 5.91 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-N 115.619 -0.718 . . . . 0.0 109.567 177.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.474 ' HA ' ' O ' ' A' ' 98' ' ' SER . 10.5 m-85 -117.48 149.39 40.67 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.463 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.3 163.87 12.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.751 -1.218 . . . . 0.0 107.92 178.918 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.621 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 9.9 p -149.32 114.07 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.202 -0.936 . . . . 0.0 109.838 -177.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.01 -175.89 36.83 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 118.329 -1.891 . . . . 0.0 111.724 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.56 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -101.4 108.87 20.6 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.763 0.792 . . . . 0.0 108.951 -179.563 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.12 146.88 51.8 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.427 -0.796 . . . . 0.0 109.691 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.35 138.18 53.87 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.298 -0.877 . . . . 0.0 110.703 -179.007 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.634 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.64 114.4 26.14 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.251 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.46 HG22 ' HB ' ' A' ' 44' ' ' VAL . 15.9 m -105.89 14.85 7.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.002 -1.061 . . . . 0.0 110.603 -178.646 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.594 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.43 -174.6 0.07 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.808 -1.182 . . . . 0.0 110.164 179.756 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.8 p -71.71 97.57 1.78 Allowed 'General case' 0 N--CA 1.485 1.323 0 O-C-N 121.43 -0.794 . . . . 0.0 109.867 -179.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 26.47 37.09 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 120.251 -0.976 . . . . 0.0 111.483 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.594 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.75 106.21 20.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.556 -1.555 . . . . 0.0 107.367 178.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.634 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.9 tp -118.22 104.77 11.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.473 -1.392 . . . . 0.0 109.641 -177.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.534 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.98 109.75 22.45 Favored 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.789 -1.194 . . . . 0.0 108.345 179.138 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.5 t -106.33 164.71 11.8 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.935 -1.103 . . . . 0.0 110.426 -178.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.533 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 10.5 t-20 -108.94 139.48 20.96 Favored Pre-proline 0 N--CA 1.501 2.083 0 O-C-N 121.461 -0.775 . . . . 0.0 109.952 -179.124 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 6.8 Cg_endo -75.7 23.11 0.45 Allowed 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 125.162 3.908 . . . . 0.0 111.258 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.533 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -120.07 3.34 10.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.426 -1.421 . . . . 0.0 109.052 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.522 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.89 14.51 3.1 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 179.343 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -80.49 91.19 5.72 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.778 -0.769 . . . . 0.0 110.98 -178.487 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.621 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -113.23 -173.31 2.23 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.099 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.67 134.6 0.08 Allowed 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.482 -1.386 . . . . 0.0 111.494 -179.183 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.587 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 3.6 p -146.73 159.62 10.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 107.227 -1.398 . . . . 0.0 107.227 177.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.543 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.33 145.89 25.68 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.433 -1.417 . . . . 0.0 110.116 -179.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.674 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.47 109.36 3.67 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 122.326 1.06 . . . . 0.0 109.802 178.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -63.64 -139.31 0.0 OUTLIER 'General case' 0 C--N 1.292 -1.902 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.588 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.92 -51.59 55.91 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.391 -0.818 . . . . 0.0 110.378 -178.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.455 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.4 t-20 -101.39 -34.18 9.7 Favored 'General case' 0 C--N 1.287 -2.121 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.674 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 106.44 69.59 0.72 Allowed Glycine 0 N--CA 1.479 1.557 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 178.041 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 64.3 p -98.86 131.69 44.77 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 121.327 -1.102 . . . . 0.0 109.268 179.118 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.587 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -135.1 108.48 7.82 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.775 -0.77 . . . . 0.0 109.021 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 7.0 m -122.23 116.36 24.0 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.122 -0.986 . . . . 0.0 109.536 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.52 HG21 ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -146.13 139.48 25.99 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.428 -0.795 . . . . 0.0 109.787 179.944 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.8 p -99.97 128.83 46.01 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.369 -0.832 . . . . 0.0 108.946 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.522 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -126.54 164.42 21.24 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.227 -0.92 . . . . 0.0 109.783 -179.092 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.583 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -96.77 125.12 41.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.118 -0.989 . . . . 0.0 109.221 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.547 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.9 m -136.51 142.69 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.075 -1.016 . . . . 0.0 109.909 -179.026 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.58 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.8 ptt180 -146.37 -173.62 4.24 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.473 -1.392 . . . . 0.0 110.922 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.566 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.64 -101.94 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 -179.409 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -55.72 140.95 39.99 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 120.788 -1.195 . . . . 0.0 108.115 179.458 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.79 135.26 5.51 Favored 'General case' 0 C--N 1.294 -1.818 0 C-N-CA 118.701 -1.2 . . . . 0.0 109.813 -178.265 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.498 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 1.3 mp0 -31.53 121.16 0.25 Allowed 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 121.41 0.624 . . . . 0.0 110.699 -178.488 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.534 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.74 46.61 2.73 Favored Glycine 0 N--CA 1.495 2.572 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.136 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -38.48 113.19 0.27 Allowed 'General case' 0 N--CA 1.507 2.388 0 O-C-N 121.121 -1.223 . . . . 0.0 110.205 179.622 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.532 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -85.92 127.32 34.58 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 120.975 -1.078 . . . . 0.0 109.52 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.6 t80 -64.09 58.17 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.051 0 O-C-N 120.858 -1.151 . . . . 0.0 110.198 179.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 6.7 t70 -160.93 19.4 0.13 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.972 -1.08 . . . . 0.0 109.794 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.73 -27.17 5.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.429 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 70.7 p -93.39 157.15 16.37 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.05 -1.264 . . . . 0.0 110.349 -179.402 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.478 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -104.73 134.45 47.85 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.652 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.493 ' CD1' HD12 ' A' ' 77' ' ' LEU . 2.0 t90 -80.94 -17.97 48.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.887 -1.133 . . . . 0.0 110.413 -178.494 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.74 174.6 19.79 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.29 106.2 1.06 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.11 -1.23 . . . . 0.0 107.695 179.157 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.576 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 43.0 t -77.54 106.79 8.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.382 -0.824 . . . . 0.0 109.292 -178.787 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -65.91 111.54 3.35 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.413 -0.804 . . . . 0.0 109.801 -179.474 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.566 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.71 -5.4 4.07 Favored 'General case' 0 N--CA 1.501 2.085 0 C-N-CA 118.135 -1.426 . . . . 0.0 109.809 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 40.9 p -86.52 -1.8 57.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.799 -1.188 . . . . 0.0 109.29 179.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.455 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.14 -49.69 3.0 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.264 -0.898 . . . . 0.0 109.058 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.18 179.03 4.38 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.47 -0.769 . . . . 0.0 109.525 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.3 115.92 31.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.39 -0.819 . . . . 0.0 109.058 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.83 122.59 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.877 -1.139 . . . . 0.0 109.465 -179.448 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.532 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.92 148.03 25.82 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 122.418 1.104 . . . . 0.0 111.249 -179.266 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.481 ' CG1' HG13 ' A' ' 7' ' ' VAL . 72.3 t -104.86 109.87 28.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 177.705 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.31 -173.56 18.56 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 118.308 -1.901 . . . . 0.0 111.796 -177.545 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.468 HD11 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.49 -178.54 3.41 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.029 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.474 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.2 OUTLIER . . . . . 0 C--N 1.295 -1.794 0 O-C-N 121.357 -0.839 . . . . 0.0 109.152 -179.353 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.723 0 N-CA-C 107.588 -2.205 . . . . 0.0 107.588 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.44 -178.69 7.32 Favored 'General case' 0 C--N 1.308 -1.237 0 O-C-N 121.6 -0.941 . . . . 0.0 109.522 179.051 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -175.88 -166.53 33.46 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 108.405 -1.878 . . . . 0.0 108.405 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.2 Cg_exo -45.03 178.85 0.0 OUTLIER 'Trans proline' 0 N--CA 1.491 1.377 0 C-N-CA 123.349 2.699 . . . . 0.0 109.697 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -92.59 175.18 6.92 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.955 -1.09 . . . . 0.0 110.637 -178.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -114.76 163.66 12.16 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.35 127.38 63.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.32 -1.106 . . . . 0.0 109.155 -179.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.532 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.58 122.01 19.76 Favored 'General case' 0 C--N 1.291 -1.971 0 O-C-N 121.559 -0.713 . . . . 0.0 109.47 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.585 HD13 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.79 170.44 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.198 -0.939 . . . . 0.0 109.085 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.465 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -140.53 156.38 46.33 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.143 -0.973 . . . . 0.0 109.837 -179.657 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.585 ' CZ ' HD13 ' A' ' 110' ' ' ILE . 87.5 m-85 . . . . . 0 N--CA 1.485 1.293 0 O-C-N 121.233 -0.917 . . . . 0.0 109.572 -179.724 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.487 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 122.371 1.081 . . . . 0.0 110.391 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.55 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.1 t -114.28 109.3 18.16 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-O 123.112 1.435 . . . . 0.0 109.59 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.522 HG12 ' CB ' ' A' ' 21' ' ' VAL . 0.6 OUTLIER -116.71 129.93 72.4 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.666 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.756 -179.883 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.531 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -167.8 148.62 4.75 Favored Pre-proline 0 N--CA 1.487 1.401 0 O-C-N 121.169 -0.957 . . . . 0.0 108.943 -179.723 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.531 ' CA ' HG23 ' A' ' 8' ' ' THR . 7.4 Cg_endo -80.66 147.64 74.96 Favored 'Cis proline' 0 C--N 1.309 -1.523 0 O-C-N 123.669 1.352 . . . . 0.0 109.181 -0.656 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.479 ' HB2' ' HA ' ' A' ' 110' ' ' ILE . 86.8 p -91.08 -24.5 20.0 Favored 'General case' 0 C--N 1.294 -1.805 0 O-C-N 121.484 -0.76 . . . . 0.0 109.238 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.454 ' OG ' ' HB3' ' A' ' 111' ' ' SER . 0.7 OUTLIER -129.61 161.59 30.2 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.367 -0.833 . . . . 0.0 109.622 -179.864 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.08 37.94 31.31 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 108.499 -1.84 . . . . 0.0 108.499 -179.679 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.607 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.3 mt -92.79 -43.69 8.89 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 123.199 1.476 . . . . 0.0 110.736 -178.248 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.58 143.9 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.473 -1.694 . . . . 0.0 109.79 -179.355 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.557 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 17.9 p-10 -50.54 106.86 0.14 Allowed 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.394 0.616 . . . . 0.0 111.517 -178.558 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.62 14.34 9.65 Favored Glycine 0 N--CA 1.485 1.903 0 C-N-CA 119.38 -1.391 . . . . 0.0 112.966 177.143 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.607 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -104.18 -172.17 2.06 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 121.1 2.45 . . . . 0.0 109.821 179.246 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.553 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 17.7 t -127.94 138.7 53.95 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.796 -1.093 . . . . 0.0 111.197 -179.034 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.529 HG13 ' CG2' ' A' ' 69' ' ' VAL . 28.7 m -112.86 156.77 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.49 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.47 109.25 20.02 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.014 -1.054 . . . . 0.0 109.063 -179.933 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.531 HG12 ' CG2' ' A' ' 34' ' ' VAL . 11.2 p -103.74 140.65 21.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.707 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.576 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -138.93 160.82 38.83 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.681 -1.207 . . . . 0.0 110.142 179.635 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.582 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.03 140.25 11.55 Favored Glycine 0 C--N 1.297 -1.636 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.03 126.32 17.58 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.543 -1.563 . . . . 0.0 109.318 179.497 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.65 28.53 21.43 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 118.964 -1.588 . . . . 0.0 109.52 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.537 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.5 mt -88.0 175.92 7.55 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.003 -1.292 . . . . 0.0 108.339 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.557 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.03 97.7 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.825 -1.172 . . . . 0.0 109.707 -179.57 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.553 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.92 77.27 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.433 -179.057 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.562 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.45 34.45 0.32 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.545 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.9 p -146.07 111.92 5.63 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.016 -1.285 . . . . 0.0 111.195 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.552 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.38 126.79 5.48 Favored 'General case' 0 N--CA 1.493 1.7 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.501 178.06 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.505 ' CD2' ' O ' ' A' ' 30' ' ' THR . 13.3 m-85 -117.45 152.5 34.88 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.494 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -101.42 162.51 12.84 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 178.771 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.625 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.8 p -148.99 117.82 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.013 -1.054 . . . . 0.0 110.049 -177.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -170.86 -176.25 40.0 Favored Glycine 0 N--CA 1.493 2.48 0 C-N-CA 118.266 -1.921 . . . . 0.0 111.736 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.563 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.06 108.91 21.19 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -179.788 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.55 148.69 52.38 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.275 -0.891 . . . . 0.0 109.713 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.95 139.39 54.0 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.316 -0.865 . . . . 0.0 110.643 -178.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.625 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.31 114.55 26.34 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 178.157 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.4 m -106.34 15.43 7.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.974 -1.079 . . . . 0.0 110.771 -178.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.588 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.56 -175.31 0.1 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.894 -1.129 . . . . 0.0 110.124 179.657 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 39.2 p -71.45 96.84 1.54 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.395 -0.816 . . . . 0.0 109.691 -179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.84 27.05 35.74 Favored Glycine 0 N--CA 1.493 2.496 0 C-N-CA 120.144 -1.027 . . . . 0.0 111.499 178.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.588 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.1 106.52 20.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 O-C-N 120.595 -1.532 . . . . 0.0 107.382 178.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.625 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.0 tp -116.08 104.62 11.75 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.492 -1.38 . . . . 0.0 109.485 -177.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.532 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.09 109.57 22.31 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 120.735 -1.228 . . . . 0.0 108.295 179.062 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -107.22 163.78 12.73 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.974 -1.079 . . . . 0.0 110.303 -178.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.519 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 16.6 t30 -110.36 139.08 21.14 Favored Pre-proline 0 N--CA 1.503 2.219 0 O-C-N 121.369 -0.832 . . . . 0.0 109.89 -179.401 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.586 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 6.1 Cg_endo -74.55 23.99 0.37 Allowed 'Trans proline' 0 N--CA 1.495 1.591 0 C-N-CA 125.252 3.968 . . . . 0.0 111.445 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.412 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -116.58 1.12 12.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.474 -1.392 . . . . 0.0 109.043 179.474 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.488 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -137.75 15.39 2.9 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.399 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -79.51 90.88 5.1 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.978 -0.689 . . . . 0.0 110.831 -178.649 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.625 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.24 -170.14 1.6 Allowed 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.255 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.468 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.91 136.03 0.09 Allowed 'General case' 0 C--N 1.305 -1.331 0 O-C-N 120.657 -1.277 . . . . 0.0 111.093 -179.354 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.568 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.3 p -150.57 157.35 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 178.212 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.25 145.0 26.5 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.579 -1.325 . . . . 0.0 109.784 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.677 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.15 107.77 2.04 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 122.392 1.091 . . . . 0.0 109.56 178.793 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.528 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.9 p-10 -60.4 -139.26 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.992 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.857 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.553 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -53.01 -49.69 65.74 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.427 -0.795 . . . . 0.0 110.341 -178.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -102.56 -36.21 8.45 Favored 'General case' 0 C--N 1.287 -2.148 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 178.4 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.677 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.4 67.14 0.61 Allowed Glycine 0 N--CA 1.48 1.601 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 178.242 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.582 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.1 m -100.98 130.02 46.91 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.566 -0.961 . . . . 0.0 108.992 178.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.576 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -137.76 108.9 6.79 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.225 -0.99 . . . . 0.0 109.496 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.425 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.9 m -125.94 119.73 28.51 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.275 -0.891 . . . . 0.0 109.592 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.41 144.6 30.74 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.432 -0.793 . . . . 0.0 109.389 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.0 p -98.96 132.29 44.39 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.418 -0.801 . . . . 0.0 109.355 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.526 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -130.84 167.83 18.27 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.292 -0.88 . . . . 0.0 109.624 -179.511 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.553 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.5 p -99.33 125.54 45.01 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.183 -0.948 . . . . 0.0 109.344 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.543 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.4 m -137.7 143.04 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 120.985 -1.072 . . . . 0.0 109.857 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.557 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.8 ptt180 -145.95 -170.92 3.59 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.597 -1.314 . . . . 0.0 110.888 -179.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.565 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -56.12 -102.05 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.769 -0.582 . . . . 0.0 109.488 -179.405 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -55.38 141.0 37.9 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 120.715 -1.24 . . . . 0.0 108.266 179.554 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.577 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.06 137.13 7.16 Favored 'General case' 0 C--N 1.295 -1.777 0 C-N-CA 118.922 -1.111 . . . . 0.0 109.634 -178.357 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.543 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 9.9 mm-40 -33.03 121.62 0.37 Allowed 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.604 0.716 . . . . 0.0 110.868 -178.266 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.532 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -90.05 44.87 2.99 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -179.555 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.586 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-85 -37.88 112.6 0.22 Allowed 'General case' 0 N--CA 1.508 2.436 0 O-C-N 121.252 -1.146 . . . . 0.0 110.094 179.691 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.537 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -86.15 126.95 34.6 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.944 -1.098 . . . . 0.0 109.503 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 34.9 t80 -63.84 58.3 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.0 0 O-C-N 120.967 -1.083 . . . . 0.0 110.338 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 10.9 t0 -161.67 19.83 0.11 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.001 -1.062 . . . . 0.0 109.762 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.15 -26.93 5.25 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.427 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -92.43 157.09 16.78 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.009 -1.289 . . . . 0.0 110.322 -179.402 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.459 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -104.44 133.2 49.73 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.656 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.517 ' CD1' HD11 ' A' ' 77' ' ' LEU . 3.4 t90 -81.26 -18.96 44.14 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.835 -1.166 . . . . 0.0 110.427 -178.678 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.45 173.56 18.63 Favored Glycine 0 N--CA 1.485 1.962 0 N-CA-C 108.931 -1.668 . . . . 0.0 108.931 -179.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.37 106.83 1.19 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.156 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.572 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 50.2 t -77.9 106.17 7.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 O-C-N 121.302 -0.874 . . . . 0.0 109.504 -178.716 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -65.51 110.97 2.89 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.36 -0.837 . . . . 0.0 109.826 -179.573 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.565 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -62.5 -5.98 3.01 Favored 'General case' 0 N--CA 1.501 2.078 0 C-N-CA 118.32 -1.352 . . . . 0.0 109.901 179.383 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -87.13 -1.19 57.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.611 -1.306 . . . . 0.0 109.336 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.458 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.0 -49.54 3.02 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.253 -0.905 . . . . 0.0 108.959 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.82 -179.22 3.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.582 -0.699 . . . . 0.0 109.441 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.03 115.37 30.32 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.329 -0.857 . . . . 0.0 109.003 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.561 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.2 m -96.75 122.44 39.69 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.857 -1.152 . . . . 0.0 109.476 -179.362 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.542 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.29 147.86 26.55 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-O 122.451 1.12 . . . . 0.0 111.208 -179.354 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 60.8 t -104.18 111.09 32.44 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.973 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.07 -172.63 18.98 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 118.108 -1.996 . . . . 0.0 111.769 -177.588 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -114.4 -179.06 3.52 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 -179.11 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.494 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER . . . . . 0 C--N 1.295 -1.787 0 O-C-N 121.428 -0.795 . . . . 0.0 109.128 -179.406 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.769 0 N-CA-C 107.617 -2.193 . . . . 0.0 107.617 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.72 -178.75 7.3 Favored 'General case' 0 C--N 1.308 -1.228 0 O-C-N 121.587 -0.949 . . . . 0.0 109.457 179.036 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -175.66 -167.15 34.26 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 108.603 -1.799 . . . . 0.0 108.603 -179.577 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.482 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.7 Cg_exo -45.72 179.65 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.391 0 C-N-CA 123.262 2.641 . . . . 0.0 109.638 179.45 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.84 174.82 6.98 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.917 -1.115 . . . . 0.0 110.571 -178.759 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -115.15 163.3 12.23 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.457 HG22 HG22 ' A' ' 7' ' ' VAL . 1.2 t -105.02 129.34 57.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.23 -1.159 . . . . 0.0 109.241 -179.317 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.542 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.08 122.81 23.27 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.605 -0.684 . . . . 0.0 109.567 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.585 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -97.93 169.88 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.259 -0.9 . . . . 0.0 109.249 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.454 ' HB3' ' OG ' ' A' ' 11' ' ' SER . 1.7 t -140.02 155.4 47.1 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.158 -0.964 . . . . 0.0 109.669 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.585 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 87.4 m-85 . . . . . 0 N--CA 1.486 1.327 0 O-C-N 121.109 -0.994 . . . . 0.0 109.607 -179.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.462 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.407 0 CA-C-O 122.101 0.953 . . . . 0.0 110.609 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.547 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.8 p -107.13 104.59 14.27 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.595 1.188 . . . . 0.0 110.023 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.528 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 13.2 t -117.93 121.2 66.77 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.435 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.433 179.798 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.507 HG22 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.95 148.5 7.42 Favored Pre-proline 0 N--CA 1.487 1.379 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 -179.74 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.507 ' CA ' HG22 ' A' ' 8' ' ' THR . 2.4 Cg_endo -75.42 153.33 98.45 Favored 'Cis proline' 0 C--N 1.309 -1.501 0 C-N-CA 123.648 -1.397 . . . . 0.0 109.614 -0.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.483 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 5.1 m -97.27 -22.14 16.85 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.518 ' HB3' ' CB ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -134.43 158.65 43.33 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.543 -0.723 . . . . 0.0 109.537 179.96 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.24 36.73 30.17 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.613 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 31.5 mt -89.32 -43.89 10.61 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 123.181 1.467 . . . . 0.0 110.513 -178.512 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.74 144.94 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.335 0 CA-C-N 113.543 -1.662 . . . . 0.0 109.946 -179.646 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.567 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.4 p-10 -50.77 107.18 0.16 Allowed 'General case' 0 C--N 1.301 -1.525 0 CA-C-O 121.657 0.741 . . . . 0.0 111.788 -178.469 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.1 15.65 9.72 Favored Glycine 0 N--CA 1.486 1.997 0 C-N-CA 119.423 -1.37 . . . . 0.0 112.942 177.224 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.613 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.1 t -103.21 -172.31 2.09 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 121.103 2.451 . . . . 0.0 109.784 179.221 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 17.5 t -129.72 139.14 52.38 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.18 -178.726 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.436 HG12 HD21 ' A' ' 13' ' ' LEU . 26.8 m -118.32 154.36 20.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.528 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.64 109.21 20.35 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.233 -0.917 . . . . 0.0 109.292 -179.954 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.497 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.1 p -106.09 124.09 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.563 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -113.16 165.36 12.47 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 120.731 -1.231 . . . . 0.0 108.85 179.421 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.631 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -142.1 107.68 0.5 Allowed Glycine 0 C--O 1.203 -1.838 0 N-CA-C 108.376 -1.89 . . . . 0.0 108.376 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.1 139.09 51.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.706 -1.467 . . . . 0.0 110.83 -178.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.68 26.74 41.1 Favored Glycine 0 N--CA 1.491 2.364 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.044 179.011 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -88.34 172.97 9.01 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.975 -1.309 . . . . 0.0 108.476 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.548 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.52 99.75 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.064 -1.023 . . . . 0.0 109.602 -179.576 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.82 76.3 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.088 -179.257 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.594 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.81 33.62 0.22 Allowed Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.677 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 63.3 p -142.73 109.8 5.58 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.032 -1.275 . . . . 0.0 111.178 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.555 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -51.08 109.98 0.38 Allowed 'General case' 0 N--CA 1.497 1.894 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.361 177.79 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.476 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.0 m-30 -105.62 155.97 18.71 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.101 -0.999 . . . . 0.0 109.029 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.442 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -98.83 163.25 12.69 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.744 -1.222 . . . . 0.0 107.763 178.791 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.624 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 7.0 p -144.45 114.85 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.151 -0.968 . . . . 0.0 109.91 -177.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.65 -177.34 39.54 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 118.204 -1.95 . . . . 0.0 111.716 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.562 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -99.77 112.2 24.46 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 -179.98 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 64.4 m -130.12 154.36 47.56 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 121.428 -0.795 . . . . 0.0 109.703 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -130.89 137.77 49.49 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.507 -0.745 . . . . 0.0 110.607 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.64 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.71 114.68 26.64 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.377 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.9 m -105.85 15.2 7.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.911 -1.118 . . . . 0.0 110.703 -178.548 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.592 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.23 -175.96 0.08 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.899 -1.126 . . . . 0.0 110.117 179.598 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.552 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.2 t -69.58 97.19 1.0 Allowed 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.786 0.803 . . . . 0.0 109.985 -179.474 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.12 27.68 36.36 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.523 178.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.592 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.86 106.46 20.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 O-C-N 120.545 -1.562 . . . . 0.0 107.34 178.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.64 HD12 ' CD1' ' A' ' 39' ' ' TRP . 11.5 tp -116.03 106.7 14.05 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.529 -1.357 . . . . 0.0 109.783 -177.598 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.564 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -96.17 110.44 22.72 Favored 'General case' 0 N--CA 1.484 1.272 0 O-C-N 120.765 -1.209 . . . . 0.0 108.554 179.5 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.569 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . 60.8 m -99.71 148.06 24.77 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.337 -0.852 . . . . 0.0 109.979 -178.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.541 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 13.0 t-20 -98.92 132.61 23.35 Favored Pre-proline 0 N--CA 1.501 2.098 0 O-C-N 120.922 -1.111 . . . . 0.0 109.159 179.413 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.572 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.9 Cg_endo -73.48 24.06 0.32 Allowed 'Trans proline' 0 C--N 1.317 -1.087 0 C-N-CA 122.291 1.994 . . . . 0.0 112.011 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.541 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -115.62 1.08 13.47 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.283 -1.51 . . . . 0.0 109.215 179.492 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.521 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.68 17.46 2.34 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 179.332 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.569 ' CE2' ' HB3' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -81.26 89.75 6.07 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.726 -0.789 . . . . 0.0 110.878 -178.787 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -112.57 -170.74 1.72 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.32 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.8 134.62 0.09 Allowed 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.592 -1.318 . . . . 0.0 111.287 -179.342 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.547 ' CG1' ' HB2' ' A' ' 63' ' ' ALA . 2.5 p -149.07 161.99 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 178.163 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.555 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.29 142.62 29.72 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.685 -1.26 . . . . 0.0 110.181 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.659 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.66 108.39 2.45 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.401 1.096 . . . . 0.0 109.735 178.594 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.516 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.5 t70 -62.73 -139.39 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.995 0 CA-C-O 121.494 0.664 . . . . 0.0 110.77 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.85 -50.97 55.68 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.384 -0.823 . . . . 0.0 110.713 -178.722 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 13.6 t30 -103.16 -33.74 9.1 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 178.591 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.659 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 104.18 70.54 0.82 Allowed Glycine 0 C--N 1.298 -1.544 0 N-CA-C 110.254 -1.139 . . . . 0.0 110.254 178.415 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.631 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 36.7 m -103.34 127.55 50.66 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 121.418 -1.048 . . . . 0.0 109.322 179.566 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.563 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -132.09 108.73 9.5 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 50.8 m -118.14 115.3 24.51 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.159 -0.963 . . . . 0.0 109.39 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.45 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.22 137.08 27.09 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.397 -0.814 . . . . 0.0 109.981 -179.862 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.7 p -100.43 133.21 45.19 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.374 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.578 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -135.66 172.23 13.32 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.138 -0.976 . . . . 0.0 109.803 -179.076 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.556 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -99.63 124.68 45.08 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.139 -0.976 . . . . 0.0 109.583 -179.692 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.446 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.1 m -135.98 143.58 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.015 -1.053 . . . . 0.0 109.664 -179.415 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.567 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.3 ptt180 -141.52 -165.29 1.95 Allowed 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.563 -1.336 . . . . 0.0 110.076 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.548 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -72.65 -87.91 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.463 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -60.14 135.98 57.88 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.58 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.562 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -161.25 135.22 6.85 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 118.105 -1.438 . . . . 0.0 110.586 -177.62 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.488 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -33.29 119.42 0.35 Allowed 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.588 0.709 . . . . 0.0 110.451 -178.637 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.564 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -94.19 50.21 2.17 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.511 -178.849 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.572 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 1.1 m-85 -36.53 118.94 0.59 Allowed 'General case' 0 N--CA 1.513 2.719 0 O-C-N 121.236 -1.155 . . . . 0.0 110.214 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.533 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.4 tp -86.93 125.82 34.29 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.901 -1.124 . . . . 0.0 109.389 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.0 t80 -63.72 58.58 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.881 -1.137 . . . . 0.0 110.088 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.8 OUTLIER -161.44 21.01 0.12 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.986 -1.071 . . . . 0.0 109.651 179.879 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.02 -30.55 4.66 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.449 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -94.38 165.14 12.71 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.103 -1.234 . . . . 0.0 110.035 -179.417 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.421 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -111.24 140.39 45.84 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -179.897 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.49 ' HB2' HD11 ' A' ' 77' ' ' LEU . 3.2 t90 -81.9 -21.42 37.4 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.77 -1.207 . . . . 0.0 110.461 -178.797 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.67 176.54 18.87 Favored Glycine 0 N--CA 1.485 1.929 0 N-CA-C 108.558 -1.817 . . . . 0.0 108.558 -179.357 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.12 109.96 2.01 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.094 -1.239 . . . . 0.0 107.741 179.223 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.56 HG11 ' CE1' ' A' ' 73' ' ' PHE . 40.6 t -82.4 103.21 9.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.394 -0.816 . . . . 0.0 108.916 -178.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.9 OUTLIER -63.95 110.53 2.15 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.48 -0.762 . . . . 0.0 109.851 -179.344 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.548 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.07 -4.96 5.39 Favored 'General case' 0 N--CA 1.499 1.985 0 C-N-CA 118.269 -1.372 . . . . 0.0 109.829 179.457 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.4 p -85.31 5.1 31.99 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.779 -1.201 . . . . 0.0 108.877 179.347 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.459 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -121.11 -48.9 2.21 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.327 -0.858 . . . . 0.0 109.047 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.63 -177.78 3.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.569 -0.707 . . . . 0.0 109.38 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.14 114.09 27.93 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.391 -0.818 . . . . 0.0 108.921 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.491 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.5 m -97.4 122.74 40.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.892 -1.13 . . . . 0.0 109.756 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.565 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.66 147.73 27.33 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 122.444 1.116 . . . . 0.0 111.346 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.518 ' CG1' HG11 ' A' ' 7' ' ' VAL . 66.9 t -101.47 109.8 26.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 177.618 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -148.19 -172.52 18.23 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 118.07 -2.014 . . . . 0.0 111.59 -177.61 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.452 HD11 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.74 -178.12 3.32 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -178.904 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.476 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 30.3 p . . . . . 0 C--N 1.296 -1.738 0 O-C-N 121.352 -0.842 . . . . 0.0 109.479 -179.375 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.706 0 N-CA-C 107.567 -2.213 . . . . 0.0 107.567 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -157.91 -178.62 7.45 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.512 -0.993 . . . . 0.0 109.763 179.098 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.02 -161.76 12.85 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 108.313 -1.915 . . . . 0.0 108.313 -179.328 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.485 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.0 Cg_exo -47.17 177.69 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.701 0 CA-C-N 118.789 1.295 . . . . 0.0 110.076 179.263 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -91.79 179.79 5.53 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.059 -1.026 . . . . 0.0 110.724 -178.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -117.4 160.99 13.36 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.23 130.01 51.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.324 -1.103 . . . . 0.0 109.345 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.565 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.83 127.3 32.13 Favored 'General case' 0 C--N 1.291 -1.972 0 O-C-N 121.583 -0.698 . . . . 0.0 109.65 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.493 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 19.6 pt -97.25 178.52 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 121.24 -0.912 . . . . 0.0 109.279 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.518 ' CB ' ' HB3' ' A' ' 11' ' ' SER . 0.5 OUTLIER -143.18 152.28 41.59 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.366 -0.834 . . . . 0.0 109.571 179.838 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.493 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 97.3 m-85 . . . . . 0 N--CA 1.484 1.249 0 O-C-N 121.082 -1.011 . . . . 0.0 109.569 -179.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.276 0 CA-C-O 122.334 1.064 . . . . 0.0 110.225 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.545 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.1 t -116.38 109.01 16.77 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-O 123.105 1.431 . . . . 0.0 109.605 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.53 HG13 ' CG1' ' A' ' 95' ' ' VAL . 4.0 t -114.58 135.33 54.73 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.669 0 CA-C-N 114.194 -1.366 . . . . 0.0 109.688 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.65 149.82 4.49 Favored Pre-proline 0 N--CA 1.487 1.419 0 O-C-N 121.193 -0.942 . . . . 0.0 108.984 -179.493 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -79.3 149.38 83.08 Favored 'Cis proline' 0 C--N 1.312 -1.376 0 C-N-CA 123.511 -1.454 . . . . 0.0 109.393 -1.009 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.459 ' HB2' ' HA ' ' A' ' 110' ' ' ILE . 86.1 p -90.99 -23.83 20.28 Favored 'General case' 0 C--N 1.292 -1.929 0 O-C-N 121.551 -0.718 . . . . 0.0 109.191 179.609 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.492 ' CB ' ' HB3' ' A' ' 111' ' ' SER . 0.7 OUTLIER -129.8 158.94 38.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.496 -0.753 . . . . 0.0 109.595 -179.881 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.51 37.33 27.55 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 108.64 -1.784 . . . . 0.0 108.64 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.609 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 32.0 mt -92.11 -44.02 9.06 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.213 1.482 . . . . 0.0 110.757 -178.459 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.483 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.16 145.16 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.299 0 CA-C-N 113.505 -1.68 . . . . 0.0 110.055 -179.753 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.59 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.3 p-10 -50.32 106.4 0.12 Allowed 'General case' 0 C--N 1.3 -1.567 0 CA-C-O 121.445 0.641 . . . . 0.0 111.645 -178.694 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.46 14.93 8.53 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.515 -1.326 . . . . 0.0 112.995 177.18 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.609 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.0 t -104.97 -174.18 2.48 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 121.134 2.467 . . . . 0.0 109.919 179.348 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.538 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 21.5 t -127.09 136.11 61.69 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.437 0 CA-C-N 114.541 -1.208 . . . . 0.0 111.258 -178.84 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.521 HG12 ' CG2' ' A' ' 69' ' ' VAL . 23.3 m -112.25 154.86 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 178.61 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.492 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 18.9 tttt -107.73 109.38 20.95 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.174 -0.954 . . . . 0.0 108.949 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.512 HG11 ' CG2' ' A' ' 34' ' ' VAL . 2.3 p -101.73 139.42 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.349 -0.844 . . . . 0.0 108.79 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.586 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -134.17 161.75 34.02 Favored 'General case' 0 C--N 1.305 -1.358 0 O-C-N 120.886 -1.134 . . . . 0.0 109.848 179.483 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.592 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.57 139.7 10.86 Favored Glycine 0 C--N 1.297 -1.604 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 179.752 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.37 125.87 16.76 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.499 -1.589 . . . . 0.0 109.3 179.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.97 27.63 23.18 Favored Glycine 0 N--CA 1.488 2.146 0 C-N-CA 118.8 -1.667 . . . . 0.0 109.736 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.559 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.1 mt -87.65 174.16 8.6 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 120.825 -1.397 . . . . 0.0 108.215 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.554 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.46 97.18 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.916 -1.115 . . . . 0.0 109.888 -179.412 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.76 77.13 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.761 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.404 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.69 34.09 0.32 Allowed Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.383 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.535 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.3 p -147.13 112.8 5.67 Favored 'General case' 0 C--N 1.308 -1.209 0 O-C-N 120.819 -1.401 . . . . 0.0 111.335 -179.804 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.549 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.87 126.58 5.86 Favored 'General case' 0 N--CA 1.491 1.623 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.846 178.063 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.485 ' CD2' ' O ' ' A' ' 30' ' ' THR . 12.7 m-85 -118.5 152.26 36.29 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.478 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.474 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.93 160.34 14.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.724 -1.235 . . . . 0.0 107.825 178.911 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.626 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.7 p -142.4 119.8 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.218 -0.926 . . . . 0.0 109.451 -178.055 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.54 -178.54 41.35 Favored Glycine 0 N--CA 1.494 2.506 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.505 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.559 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -101.0 108.58 20.33 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.437 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.45 149.51 51.19 Favored 'General case' 0 C--N 1.296 -1.738 0 O-C-N 121.264 -0.898 . . . . 0.0 109.956 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.03 139.53 53.73 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.367 -0.833 . . . . 0.0 110.673 -179.146 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.623 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.29 114.92 26.75 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.199 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.8 m -105.11 15.23 6.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.093 -1.004 . . . . 0.0 110.595 -178.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.586 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.61 -176.06 0.08 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.947 -1.096 . . . . 0.0 110.038 179.631 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.546 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.93 97.75 1.48 Allowed 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.803 0.811 . . . . 0.0 109.848 -179.639 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.14 27.65 36.4 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 120.186 -1.007 . . . . 0.0 111.419 178.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.586 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -115.83 106.44 20.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 O-C-N 120.621 -1.517 . . . . 0.0 107.189 178.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.623 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.0 tp -116.03 104.69 11.83 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.461 -1.399 . . . . 0.0 109.936 -177.659 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.537 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.41 22.17 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.827 -1.17 . . . . 0.0 108.179 178.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.9 t -107.46 163.63 12.89 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.847 -1.158 . . . . 0.0 110.295 -179.006 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.5 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 13.6 t30 -108.98 134.18 20.46 Favored Pre-proline 0 N--CA 1.502 2.136 0 O-C-N 121.351 -0.843 . . . . 0.0 109.575 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.582 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.6 Cg_endo -74.38 26.85 0.34 Allowed 'Trans proline' 0 C--N 1.319 -0.98 0 C-N-CA 122.486 2.124 . . . . 0.0 112.197 -179.396 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.402 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -109.29 -3.15 17.39 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.329 -1.482 . . . . 0.0 109.299 179.664 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.56 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 1.7 m-20 -135.96 12.39 3.36 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -70.07 83.6 0.51 Allowed 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.683 -0.807 . . . . 0.0 110.74 -178.667 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -105.23 -167.92 1.4 Allowed 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 178.356 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.481 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.7 t 179.07 135.59 0.09 Allowed 'General case' 0 C--N 1.306 -1.325 0 O-C-N 120.632 -1.292 . . . . 0.0 111.231 -179.38 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.572 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.7 p -149.24 156.63 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 178.095 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.549 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.57 145.39 26.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.583 -1.323 . . . . 0.0 109.738 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.68 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.93 108.67 2.66 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 122.334 1.064 . . . . 0.0 109.592 178.756 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.543 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 p-10 -62.92 -139.58 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.054 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.641 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.92 -51.73 49.19 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.446 -0.784 . . . . 0.0 110.569 -178.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -102.51 -32.98 9.67 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 178.582 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.68 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 106.84 66.72 0.64 Allowed Glycine 0 C--N 1.299 -1.511 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 178.168 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.592 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 55.6 p -98.69 132.51 44.01 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 121.289 -1.124 . . . . 0.0 109.048 179.001 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.586 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -137.03 108.6 6.95 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.146 -1.022 . . . . 0.0 109.535 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.3 m -124.12 117.48 24.76 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.265 -0.897 . . . . 0.0 109.641 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.465 HG23 HG12 ' A' ' 34' ' ' VAL . 5.2 t -145.99 145.2 30.54 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.441 -0.787 . . . . 0.0 109.361 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 53.3 p -99.03 143.98 28.69 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.428 -0.795 . . . . 0.0 109.342 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.546 ' HB2' ' OD2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -145.35 169.86 17.45 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.305 -0.872 . . . . 0.0 109.459 -178.96 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.8 p -102.32 123.27 45.83 Favored 'General case' 0 N--CA 1.498 1.975 0 O-C-N 120.842 -1.161 . . . . 0.0 110.388 -178.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.56 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 15.2 m -131.12 143.98 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 120.996 -1.065 . . . . 0.0 110.016 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.59 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.3 ptt180 -148.93 -176.63 5.42 Favored 'General case' 0 N--CA 1.483 1.221 0 O-C-N 120.555 -1.341 . . . . 0.0 110.649 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.566 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.73 -101.5 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -179.562 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.5 OUTLIER -56.29 140.07 46.17 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.777 -1.202 . . . . 0.0 108.313 179.591 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.569 ' CZ ' ' SG ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -160.81 135.69 7.56 Favored 'General case' 0 C--N 1.296 -1.74 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.545 -178.57 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.5 ' N ' ' OD1' ' A' ' 48' ' ' ASN . 6.1 mm-40 -33.05 122.18 0.38 Allowed 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.609 0.718 . . . . 0.0 110.775 -178.038 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.537 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -90.78 45.34 2.89 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 -179.326 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.582 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-85 -37.64 114.62 0.35 Allowed 'General case' 0 N--CA 1.512 2.632 0 O-C-N 121.277 -1.131 . . . . 0.0 110.12 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.535 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.0 tp -87.44 127.22 35.22 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.115 -0.991 . . . . 0.0 109.291 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 49.8 t80 -63.54 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.061 0 O-C-N 120.862 -1.149 . . . . 0.0 110.137 179.74 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.2 t0 -161.2 19.33 0.12 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.945 -1.097 . . . . 0.0 109.805 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.55 -26.73 5.61 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 42.1 p -94.41 160.21 14.76 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.121 -1.223 . . . . 0.0 110.11 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.463 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.6 OUTLIER -106.67 136.12 47.03 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.466 ' HB2' HD12 ' A' ' 77' ' ' LEU . 4.1 t90 -81.91 -18.9 42.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.819 -1.175 . . . . 0.0 110.428 -178.653 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.46 174.38 18.43 Favored Glycine 0 N--CA 1.486 2.024 0 N-CA-C 108.772 -1.731 . . . . 0.0 108.772 -179.602 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.18 106.06 1.23 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.113 -1.228 . . . . 0.0 107.688 179.184 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.568 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 51.3 t -76.96 105.22 5.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.316 -0.865 . . . . 0.0 109.361 -178.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.524 ' CB ' HG21 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.62 110.85 2.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.468 -0.77 . . . . 0.0 109.765 -179.599 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.566 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.08 -5.73 3.39 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 120.517 -1.364 . . . . 0.0 109.846 179.422 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -86.52 -0.57 56.36 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.706 -1.246 . . . . 0.0 109.172 179.655 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.524 HG21 ' CB ' ' A' ' 87' ' ' ASP . 2.3 p -113.19 -50.13 2.88 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.322 -0.861 . . . . 0.0 108.957 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.63 -178.62 3.71 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.576 -0.703 . . . . 0.0 109.428 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.54 115.31 30.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.337 -0.852 . . . . 0.0 109.039 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.569 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.24 123.36 41.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.875 -1.14 . . . . 0.0 109.7 -179.278 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.578 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.76 145.92 29.69 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.474 1.13 . . . . 0.0 111.113 -179.424 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.53 ' CG1' HG13 ' A' ' 7' ' ' VAL . 55.6 t -101.76 110.09 27.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.049 0 N-CA-C 106.646 -1.612 . . . . 0.0 106.646 177.474 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.444 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.01 -171.29 16.83 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 118.106 -1.997 . . . . 0.0 111.694 -177.475 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.474 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -119.0 179.48 4.14 Favored 'General case' 0 N--CA 1.485 1.283 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.038 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.466 ' OG ' ' O ' ' A' ' 97' ' ' LEU . 3.5 m . . . . . 0 C--N 1.294 -1.817 0 O-C-N 121.435 -0.791 . . . . 0.0 109.666 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.409 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.482 1.721 0 N-CA-C 107.909 -2.076 . . . . 0.0 107.909 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.409 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.65 -177.15 3.8 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.603 -0.939 . . . . 0.0 109.725 179.395 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.63 -161.65 19.15 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.32 -1.912 . . . . 0.0 108.32 -179.388 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.477 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.9 Cg_exo -46.68 176.26 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.655 0 CA-C-N 118.808 1.304 . . . . 0.0 110.173 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -94.19 -174.96 3.53 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.038 -1.039 . . . . 0.0 110.403 -178.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.444 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.79 165.0 13.47 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.55 130.57 50.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.353 -1.087 . . . . 0.0 109.223 -179.416 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.578 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.84 125.48 28.26 Favored 'General case' 0 C--N 1.291 -1.964 0 O-C-N 121.669 -0.644 . . . . 0.0 109.774 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.571 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.82 170.11 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.307 -0.871 . . . . 0.0 109.22 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.492 ' HB3' ' CB ' ' A' ' 11' ' ' SER . 3.6 t -138.09 158.33 44.53 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.375 -0.828 . . . . 0.0 109.449 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.571 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 30.4 m-85 . . . . . 0 N--CA 1.487 1.417 0 O-C-N 121.184 -0.948 . . . . 0.0 109.539 -179.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.519 ' CB ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.388 0 CA-C-O 122.289 1.042 . . . . 0.0 111.109 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.529 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.4 p -101.66 104.47 15.31 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 122.413 1.101 . . . . 0.0 110.032 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.527 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 3.4 t -118.54 115.4 48.0 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.415 0 CA-C-O 121.679 0.752 . . . . 0.0 110.455 179.63 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.488 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.22 147.85 12.78 Favored Pre-proline 0 N--CA 1.487 1.397 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 -179.723 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.488 ' HA ' HG22 ' A' ' 8' ' ' THR . 4.3 Cg_endo -77.07 152.05 94.41 Favored 'Cis proline' 0 C--N 1.309 -1.506 0 C-N-CA 123.693 -1.378 . . . . 0.0 109.561 -0.328 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.507 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 13.6 p -89.71 -25.84 20.98 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.642 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.518 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.0 m -136.39 167.98 20.3 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.555 -0.715 . . . . 0.0 109.338 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.47 38.12 39.15 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.603 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 40.3 mt -93.22 -42.63 9.24 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 123.319 1.533 . . . . 0.0 110.561 -178.177 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.496 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.56 142.58 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.284 0 CA-C-N 113.402 -1.726 . . . . 0.0 109.67 -179.385 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.586 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.2 p-10 -50.61 105.95 0.11 Allowed 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.588 0.709 . . . . 0.0 111.364 -178.517 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.68 14.15 8.24 Favored Glycine 0 N--CA 1.484 1.88 0 C-N-CA 119.446 -1.359 . . . . 0.0 112.982 177.418 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.603 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.0 t -106.21 -172.24 2.05 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 121.22 2.51 . . . . 0.0 109.831 179.161 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.576 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 17.1 t -129.7 138.32 54.49 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.34 -178.786 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.52 HG22 ' CG2' ' A' ' 69' ' ' VAL . 35.8 m -114.34 155.35 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.782 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.527 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 28.2 tttt -107.13 108.87 20.53 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.184 -0.948 . . . . 0.0 109.466 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.508 ' CG2' HG21 ' A' ' 7' ' ' VAL . 2.0 p -105.64 123.29 59.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.529 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -117.66 166.55 12.28 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.716 -1.24 . . . . 0.0 109.325 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.614 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.05 142.45 13.89 Favored Glycine 0 C--N 1.294 -1.766 0 N-CA-C 107.381 -2.288 . . . . 0.0 107.381 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -147.22 123.27 10.76 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 120.747 -1.443 . . . . 0.0 108.714 179.372 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.1 27.01 22.38 Favored Glycine 0 N--CA 1.487 2.084 0 C-N-CA 119.155 -1.498 . . . . 0.0 109.802 -179.563 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.537 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -89.0 174.8 7.7 Favored 'General case' 0 C--N 1.307 -1.248 0 O-C-N 120.842 -1.387 . . . . 0.0 108.436 179.85 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.557 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.83 99.78 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.949 -1.094 . . . . 0.0 109.808 -179.8 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.541 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.18 78.09 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.191 -179.298 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.83 34.5 0.3 Allowed Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 179.627 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.543 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 35.2 p -140.99 106.9 5.15 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 121.127 -1.219 . . . . 0.0 111.361 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -49.52 110.07 0.34 Allowed 'General case' 0 N--CA 1.498 1.931 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.557 177.87 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 5.7 m-30 -108.0 154.38 21.72 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.097 -1.002 . . . . 0.0 108.854 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.466 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.64 163.03 12.53 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.864 -1.148 . . . . 0.0 108.055 179.133 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.643 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.6 p -140.89 116.71 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.133 -0.979 . . . . 0.0 109.351 -178.297 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -164.32 -176.72 36.39 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 118.325 -1.893 . . . . 0.0 111.802 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.56 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -103.15 109.44 21.02 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.862 0.839 . . . . 0.0 109.099 -179.635 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.35 147.79 51.21 Favored 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.231 -0.918 . . . . 0.0 109.578 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -121.66 138.26 54.41 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.255 -0.903 . . . . 0.0 110.823 -178.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.623 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.68 26.48 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.177 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -105.74 14.71 7.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 120.952 -1.092 . . . . 0.0 110.513 -178.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.594 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 175.09 -175.9 0.09 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 120.951 -1.093 . . . . 0.0 110.03 179.754 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.541 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.0 t -71.33 97.82 1.65 Allowed 'General case' 0 N--CA 1.487 1.379 0 CA-C-O 121.785 0.802 . . . . 0.0 109.785 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.78 27.45 34.79 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.238 -0.982 . . . . 0.0 111.524 178.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.594 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.98 106.11 19.75 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 O-C-N 120.539 -1.565 . . . . 0.0 107.236 178.836 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.623 HD12 ' CD1' ' A' ' 39' ' ' TRP . 12.5 tp -116.82 104.75 11.64 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.517 -1.365 . . . . 0.0 109.874 -177.692 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.567 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.78 109.45 22.2 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 120.845 -1.16 . . . . 0.0 108.071 178.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.4 t -107.07 162.42 13.87 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.949 -1.094 . . . . 0.0 110.393 -178.778 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 15.4 t30 -110.32 134.4 20.81 Favored Pre-proline 0 N--CA 1.503 2.199 0 O-C-N 121.453 -0.78 . . . . 0.0 109.759 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.576 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.77 25.03 0.33 Allowed 'Trans proline' 0 C--N 1.318 -1.055 0 C-N-CA 122.346 2.031 . . . . 0.0 112.192 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.417 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -113.43 4.15 16.15 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.327 -1.483 . . . . 0.0 109.233 179.538 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.529 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.78 16.04 2.69 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 179.462 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -79.85 88.86 5.25 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.541 -178.266 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.643 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -105.96 -165.85 1.14 Allowed 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 177.788 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.461 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.77 138.38 0.09 Allowed 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.508 -1.37 . . . . 0.0 111.454 -179.343 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.581 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -156.64 157.2 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.225 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.67 141.82 31.01 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.828 -1.17 . . . . 0.0 109.746 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.688 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.05 106.96 0.92 Allowed 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 122.385 1.088 . . . . 0.0 109.144 178.309 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.53 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.8 t0 -61.64 -138.9 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.987 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.016 -179.843 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.541 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.59 -52.12 32.46 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.426 -0.796 . . . . 0.0 110.81 -178.534 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -104.06 -33.05 8.91 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 106.209 -1.775 . . . . 0.0 106.209 178.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.688 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 109.31 65.41 0.56 Allowed Glycine 0 C--N 1.298 -1.542 0 N-CA-C 110.457 -1.057 . . . . 0.0 110.457 178.085 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.614 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.4 m -102.99 127.95 50.01 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 121.492 -1.004 . . . . 0.0 108.819 178.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.581 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.39 109.17 7.55 Favored 'General case' 0 C--N 1.296 -1.737 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.893 -179.312 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -116.26 117.43 29.99 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.207 -0.933 . . . . 0.0 109.291 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.464 HG21 HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.63 143.34 30.72 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.412 -0.805 . . . . 0.0 109.758 -179.978 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.9 p -101.0 140.01 35.89 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.472 -0.768 . . . . 0.0 109.5 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.529 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -139.21 161.6 37.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.36 -0.837 . . . . 0.0 109.524 -179.469 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.576 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.9 p -93.87 124.46 37.89 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.159 -0.963 . . . . 0.0 109.438 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.532 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 15.3 m -135.38 143.71 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.063 -1.023 . . . . 0.0 109.58 -179.314 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.586 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.5 ptt180 -146.79 -177.13 5.49 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 120.453 -1.405 . . . . 0.0 111.042 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.57 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.13 -100.98 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -179.674 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -56.2 140.68 43.7 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 120.769 -1.207 . . . . 0.0 108.208 179.546 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.05 136.19 6.66 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 118.82 -1.152 . . . . 0.0 109.672 -178.341 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.52 ' N ' ' OD1' ' A' ' 48' ' ' ASN . 34.6 mt-10 -34.8 122.12 0.53 Allowed 'General case' 0 N--CA 1.489 1.508 0 CA-C-O 121.491 0.662 . . . . 0.0 110.462 -178.314 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.567 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -92.74 49.14 2.55 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.576 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.1 m-85 -38.82 114.21 0.37 Allowed 'General case' 0 N--CA 1.506 2.353 0 O-C-N 121.18 -1.188 . . . . 0.0 109.915 179.541 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.532 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -86.44 126.81 34.66 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.944 -1.098 . . . . 0.0 109.46 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -64.12 58.37 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.976 0 O-C-N 120.832 -1.168 . . . . 0.0 110.133 179.718 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.2 t70 -160.54 19.49 0.14 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.125 -0.984 . . . . 0.0 109.704 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.63 -27.18 5.41 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.41 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 21.4 p -94.19 159.71 15.02 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.03 -1.277 . . . . 0.0 110.316 -179.429 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.52 136.29 46.55 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.711 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.462 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.12 -18.47 42.8 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.734 -1.228 . . . . 0.0 110.44 -178.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.94 174.92 19.31 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 108.819 -1.712 . . . . 0.0 108.819 -179.575 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -65.09 105.34 1.04 Allowed 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 179.186 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.571 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.9 t -77.28 107.06 8.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.364 -0.835 . . . . 0.0 109.267 -178.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.461 ' HB3' HG22 ' A' ' 90' ' ' THR . 1.2 m-20 -66.76 111.39 3.69 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.441 -0.787 . . . . 0.0 110.022 -179.313 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.57 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.81 -5.52 4.42 Favored 'General case' 0 N--CA 1.5 2.058 0 C-N-CA 118.171 -1.412 . . . . 0.0 109.832 179.198 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 16.6 p -87.26 1.17 53.98 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.795 -1.19 . . . . 0.0 109.171 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.461 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -115.23 -50.66 2.74 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.326 -0.859 . . . . 0.0 108.99 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.67 179.63 4.21 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.488 -0.757 . . . . 0.0 109.43 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.5 115.39 30.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.31 -0.869 . . . . 0.0 108.906 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.563 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.2 m -96.99 122.04 39.54 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.916 -1.115 . . . . 0.0 109.335 -179.368 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.531 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.17 146.37 27.58 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 122.371 1.081 . . . . 0.0 111.286 -179.292 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.433 ' HB ' HG11 ' A' ' 7' ' ' VAL . 54.6 t -105.73 111.74 36.19 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.028 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.46 -169.94 19.06 Favored Glycine 0 N--CA 1.487 2.088 0 C-N-CA 118.251 -1.928 . . . . 0.0 111.482 -177.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.482 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -117.23 173.24 6.79 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.803 -0.822 . . . . 0.0 108.858 -179.356 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.482 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER . . . . . 0 C--N 1.293 -1.888 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.519 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.482 1.744 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -173.74 -176.21 1.21 Allowed 'General case' 0 C--N 1.306 -1.29 0 O-C-N 121.562 -0.964 . . . . 0.0 109.828 179.512 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.501 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.6 -159.57 12.51 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.314 -1.914 . . . . 0.0 108.314 -179.311 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.501 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.6 Cg_exo -47.49 -178.13 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.672 0 CA-C-N 118.824 1.312 . . . . 0.0 110.574 179.215 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -94.44 -178.38 4.56 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.057 -1.027 . . . . 0.0 110.405 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.467 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.36 162.22 13.31 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.25 128.6 52.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.465 -1.021 . . . . 0.0 109.123 -179.549 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.531 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.09 118.53 15.07 Favored 'General case' 0 C--N 1.289 -2.059 0 O-C-N 121.7 -0.625 . . . . 0.0 109.555 179.75 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.577 HD11 ' CE2' ' A' ' 112' ' ' PHE . 1.8 pt -98.01 172.13 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.289 -0.882 . . . . 0.0 108.997 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.518 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -142.48 154.09 44.22 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.06 -1.025 . . . . 0.0 110.153 -179.744 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.577 ' CE2' HD11 ' A' ' 110' ' ' ILE . 97.8 m-85 . . . . . 0 N--CA 1.486 1.342 0 O-C-N 121.302 -0.873 . . . . 0.0 109.278 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.52 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.484 1.244 0 CA-C-O 122.254 1.026 . . . . 0.0 110.827 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.511 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.7 p -104.03 104.82 14.83 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-O 122.417 1.103 . . . . 0.0 110.397 -179.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.535 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 6.1 t -119.26 116.81 52.05 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.477 0 CA-C-O 121.582 0.706 . . . . 0.0 110.226 179.434 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.491 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -161.06 149.28 12.8 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.44 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.491 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.71 152.95 98.87 Favored 'Cis proline' 0 C--N 1.311 -1.428 0 C-N-CA 123.679 -1.384 . . . . 0.0 109.72 -0.507 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.497 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 3.8 m -91.46 -25.35 19.35 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.474 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.5 m -136.84 166.15 24.29 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.6 -0.688 . . . . 0.0 109.39 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.27 37.76 35.92 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 108.426 -1.87 . . . . 0.0 108.426 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.614 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.9 mt -92.47 -43.77 9.01 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 123.229 1.49 . . . . 0.0 110.676 -178.242 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.56 144.72 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.517 -1.674 . . . . 0.0 110.044 -179.57 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.582 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.7 p-10 -50.72 107.36 0.17 Allowed 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.535 0.683 . . . . 0.0 111.629 -178.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.9 14.23 9.52 Favored Glycine 0 N--CA 1.485 1.949 0 C-N-CA 119.421 -1.371 . . . . 0.0 112.927 177.357 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.614 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 13.8 t -105.09 -173.54 2.33 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 121.13 2.465 . . . . 0.0 109.899 179.265 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 20.9 t -128.41 138.97 53.17 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 CA-C-N 114.63 -1.168 . . . . 0.0 111.157 -178.639 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.492 HG11 ' CG2' ' A' ' 69' ' ' VAL . 27.9 m -116.15 154.42 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.653 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.535 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 15.0 tptp -107.21 108.68 20.22 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.168 -0.957 . . . . 0.0 109.297 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.1 p -106.14 123.54 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.538 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -118.24 168.22 10.8 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.717 -1.24 . . . . 0.0 109.504 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.608 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -137.13 136.71 8.47 Favored Glycine 0 C--O 1.207 -1.582 0 N-CA-C 107.493 -2.243 . . . . 0.0 107.493 179.515 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -141.27 125.82 17.8 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-N 119.668 1.734 . . . . 0.0 109.397 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.462 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 88.35 28.91 21.12 Favored Glycine 0 N--CA 1.488 2.146 0 C-N-CA 118.692 -1.718 . . . . 0.0 109.598 -179.715 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.522 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.8 mt -89.26 173.98 8.1 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.034 -1.274 . . . . 0.0 108.283 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.553 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.02 97.1 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.007 -1.058 . . . . 0.0 109.773 -179.871 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.552 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.34 76.86 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.39 -178.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.84 34.06 0.31 Allowed Glycine 0 N--CA 1.486 1.995 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.309 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.542 ' CG2' ' O ' ' A' ' 30' ' ' THR . 1.1 t -146.37 113.88 6.35 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.923 -1.339 . . . . 0.0 111.225 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.556 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -45.3 126.97 6.79 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.548 178.399 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.485 ' OH ' ' HB2' ' A' ' 27' ' ' GLN . 6.0 m-85 -121.32 149.41 42.97 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.454 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.45 160.06 14.65 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.697 -1.252 . . . . 0.0 108.064 178.955 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.619 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 9.0 p -142.8 116.96 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.249 -0.907 . . . . 0.0 109.908 -177.69 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.496 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.82 -176.51 38.48 Favored Glycine 0 N--CA 1.494 2.524 0 C-N-CA 118.298 -1.906 . . . . 0.0 111.756 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.557 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -101.38 109.34 21.16 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.758 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -129.6 149.85 51.18 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.235 -0.915 . . . . 0.0 109.601 179.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.93 138.3 54.5 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.241 -0.912 . . . . 0.0 110.928 -178.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.624 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.09 26.96 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 178.049 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.434 HG22 ' HB ' ' A' ' 44' ' ' VAL . 17.7 m -105.64 15.01 7.16 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.024 -1.047 . . . . 0.0 110.512 -178.755 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.586 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.96 -175.38 0.09 Allowed 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.028 -1.045 . . . . 0.0 109.987 179.715 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -72.38 97.77 2.11 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 121.381 -0.825 . . . . 0.0 109.66 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.29 28.14 31.33 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.233 -0.984 . . . . 0.0 111.383 178.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.586 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.42 106.26 19.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 O-C-N 120.586 -1.537 . . . . 0.0 107.339 178.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.624 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.4 tp -116.35 104.59 11.63 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.421 -1.424 . . . . 0.0 109.902 -177.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.553 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.5 22.25 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.776 -1.203 . . . . 0.0 107.987 178.704 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.5 161.74 14.57 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.919 -1.113 . . . . 0.0 110.189 -178.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.491 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 43.2 t30 -109.74 136.49 20.33 Favored Pre-proline 0 N--CA 1.502 2.167 0 O-C-N 121.383 -0.823 . . . . 0.0 109.807 -179.57 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.55 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.79 25.37 0.33 Allowed 'Trans proline' 0 C--N 1.318 -1.028 0 C-N-CA 122.354 2.036 . . . . 0.0 111.876 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.491 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -111.2 2.33 17.72 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.392 -1.442 . . . . 0.0 109.268 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.496 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -141.24 16.77 2.24 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.7 -1.222 . . . . 0.0 107.7 179.724 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -79.86 91.77 5.41 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.82 -0.752 . . . . 0.0 111.078 -178.57 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.619 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -111.31 -168.2 1.28 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.957 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.473 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.85 135.61 0.09 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.503 -1.373 . . . . 0.0 111.521 -179.307 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.561 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.4 p -152.41 158.32 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 178.015 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.556 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.77 145.54 26.26 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.659 -1.276 . . . . 0.0 109.672 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.67 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -67.24 108.01 2.56 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 122.394 1.092 . . . . 0.0 109.5 178.721 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.523 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 t0 -61.06 -138.73 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.923 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.552 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.57 -49.87 64.11 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.386 -0.821 . . . . 0.0 110.405 -178.747 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.462 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 16.9 t-20 -102.94 -36.99 8.01 Favored 'General case' 0 C--N 1.286 -2.194 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 178.449 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.67 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 109.31 68.36 0.61 Allowed Glycine 0 C--N 1.297 -1.601 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 178.19 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.608 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.8 m -102.96 129.12 49.59 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.496 -1.002 . . . . 0.0 109.316 179.284 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.561 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -135.56 108.54 7.63 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.533 -0.867 . . . . 0.0 109.43 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.505 ' HB2' ' NZ ' ' A' ' 20' ' ' LYS . 53.0 p -120.31 118.87 31.54 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.106 -0.996 . . . . 0.0 109.368 -179.82 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.456 HG23 HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.91 143.01 28.2 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.395 -0.815 . . . . 0.0 109.802 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.455 ' HB3' ' HD3' ' A' ' 20' ' ' LYS . 2.9 p -102.17 135.04 44.45 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.492 -0.755 . . . . 0.0 109.059 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.533 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -135.2 169.93 16.7 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.301 -0.874 . . . . 0.0 109.597 -179.24 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.554 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -99.56 125.55 45.37 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.079 -1.013 . . . . 0.0 109.581 -179.68 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.513 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 15.7 m -135.11 143.33 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.036 -1.04 . . . . 0.0 109.519 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.582 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.0 ptt180 -146.63 -174.89 4.59 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 120.417 -1.427 . . . . 0.0 111.11 -179.758 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.555 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -54.12 -101.71 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 116.032 -0.531 . . . . 0.0 109.577 -179.382 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.85 139.97 49.64 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.749 -1.22 . . . . 0.0 108.138 179.659 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.576 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -161.28 136.34 7.51 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 118.772 -1.171 . . . . 0.0 109.879 -178.068 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.579 ' OE2' ' CD1' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -34.7 121.19 0.51 Allowed 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.543 0.687 . . . . 0.0 110.249 -178.462 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.553 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -94.52 50.57 2.08 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.107 -179.199 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CD1' ' OE2' ' A' ' 74' ' ' GLU . 2.8 m-85 -38.95 116.93 0.62 Allowed 'General case' 0 N--CA 1.509 2.484 0 O-C-N 121.041 -1.27 . . . . 0.0 109.882 179.639 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.537 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -87.34 126.16 34.68 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.95 -1.094 . . . . 0.0 109.389 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -64.53 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.789 -1.194 . . . . 0.0 110.106 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -159.77 19.7 0.17 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.033 -1.042 . . . . 0.0 109.696 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.26 -28.07 5.35 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.448 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 38.4 p -95.84 160.42 14.49 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.991 -1.299 . . . . 0.0 110.404 -179.458 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.477 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 6.0 ptt180 -105.95 139.58 40.28 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.784 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.468 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.4 t90 -84.5 -18.83 34.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.653 -1.279 . . . . 0.0 110.634 -178.53 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.85 175.53 19.03 Favored Glycine 0 N--CA 1.485 1.943 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 -179.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.74 105.37 1.24 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.058 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.562 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 43.5 t -76.7 105.61 5.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.147 -178.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.464 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -65.65 110.82 2.9 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.471 -0.768 . . . . 0.0 109.813 -179.481 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.555 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.24 -5.7 3.65 Favored 'General case' 0 N--CA 1.499 1.982 0 C-N-CA 118.255 -1.378 . . . . 0.0 109.838 179.482 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.0 p -86.57 -0.11 55.47 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.766 -1.209 . . . . 0.0 109.107 179.548 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.464 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.86 -50.57 2.82 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.398 -0.814 . . . . 0.0 108.968 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.8 -178.96 3.8 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.515 -0.741 . . . . 0.0 109.443 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.97 115.84 30.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.432 -0.793 . . . . 0.0 108.929 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.8 121.55 38.78 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.797 -1.189 . . . . 0.0 109.39 -179.369 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.556 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.81 147.1 26.46 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 122.33 1.062 . . . . 0.0 111.126 -179.362 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.532 ' CG1' HG12 ' A' ' 7' ' ' VAL . 48.3 t -105.34 111.93 36.75 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.997 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.831 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.469 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.75 -170.54 19.92 Favored Glycine 0 N--CA 1.488 2.102 0 C-N-CA 118.062 -2.018 . . . . 0.0 111.751 -177.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.482 ' O ' ' OG ' ' A' ' 98' ' ' SER . 0.0 OUTLIER -116.81 177.47 4.69 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.212 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' A' ' 97' ' ' LEU . 3.9 m . . . . . 0 C--N 1.295 -1.78 0 O-C-N 121.649 -0.657 . . . . 0.0 109.269 -179.805 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.569 0 N-CA-C 108.07 -2.012 . . . . 0.0 108.07 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -164.22 -177.32 4.9 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.612 -0.934 . . . . 0.0 110.042 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.68 -161.04 19.37 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 108.117 -1.993 . . . . 0.0 108.117 -179.494 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.1 Cg_exo -47.01 177.3 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.701 0 CA-C-N 118.968 1.384 . . . . 0.0 110.249 179.228 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.2 mm-40 -94.32 -179.4 4.91 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.073 -1.017 . . . . 0.0 110.583 -178.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.469 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.94 166.13 12.72 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.59 131.19 54.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.288 -1.124 . . . . 0.0 109.258 -179.282 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.556 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.03 121.02 20.42 Favored 'General case' 0 C--N 1.29 -2.014 0 O-C-N 121.548 -0.72 . . . . 0.0 109.587 179.676 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.578 HD13 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.97 171.3 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.226 -0.922 . . . . 0.0 109.095 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.474 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.93 156.81 46.97 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.264 -0.897 . . . . 0.0 109.929 -179.635 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.578 ' CE1' HD13 ' A' ' 110' ' ' ILE . 95.9 m-85 . . . . . 0 N--CA 1.486 1.369 0 O-C-N 121.318 -0.864 . . . . 0.0 109.378 -179.779 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.472 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 122.262 1.03 . . . . 0.0 110.602 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.541 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.8 t -110.42 108.63 18.73 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 123.088 1.423 . . . . 0.0 109.088 179.34 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.505 HG13 ' CG1' ' A' ' 95' ' ' VAL . 2.5 t -118.43 137.85 51.05 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.678 0 CA-C-N 114.244 -1.344 . . . . 0.0 109.907 -179.7 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.492 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -175.4 150.33 1.19 Allowed Pre-proline 0 N--CA 1.487 1.388 0 O-C-N 121.314 -0.866 . . . . 0.0 108.712 -179.651 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.492 ' HA ' HG22 ' A' ' 8' ' ' THR . 5.7 Cg_endo -77.64 150.52 90.51 Favored 'Cis proline' 0 C--N 1.311 -1.433 0 C-N-CA 123.57 -1.429 . . . . 0.0 109.535 -0.905 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.466 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 61.8 p -91.02 -24.52 20.05 Favored 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.55 -0.718 . . . . 0.0 109.27 179.828 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.521 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 17.1 m -133.44 160.36 37.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.265 -0.897 . . . . 0.0 109.978 -179.806 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.78 36.75 24.78 Favored Glycine 0 N--CA 1.494 2.523 0 N-CA-C 108.859 -1.696 . . . . 0.0 108.859 -179.856 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.57 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 44.2 mt -93.83 -44.37 8.15 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-O 123.204 1.478 . . . . 0.0 110.353 -178.658 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.451 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.9 OUTLIER 63.81 145.35 0.02 OUTLIER 'General case' 0 C--N 1.262 -3.216 0 CA-C-N 113.62 -1.627 . . . . 0.0 109.798 -179.459 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.535 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.4 p-10 -51.61 105.33 0.1 Allowed 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.551 0.691 . . . . 0.0 110.844 -179.015 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 126.93 2.22 6.68 Favored Glycine 0 N--CA 1.485 1.949 0 C-N-CA 119.077 -1.535 . . . . 0.0 113.428 177.625 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.57 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -104.08 -171.82 2.0 Allowed 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 121.376 2.588 . . . . 0.0 110.102 179.909 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.566 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 16.0 t -131.47 141.91 44.64 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.252 0 CA-C-N 114.604 -1.18 . . . . 0.0 110.47 -179.207 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.529 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 28.6 m -115.7 154.99 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.199 -0.938 . . . . 0.0 109.023 179.321 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.492 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 45.9 tptt -107.07 109.31 21.14 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 108.892 179.918 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.507 HG11 ' CG2' ' A' ' 34' ' ' VAL . 2.1 p -103.63 141.62 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.545 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -139.05 160.41 39.84 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 118.595 -1.242 . . . . 0.0 110.04 179.714 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.42 144.26 15.58 Favored Glycine 0 C--N 1.294 -1.793 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 179.695 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.28 125.37 12.88 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.872 -1.369 . . . . 0.0 108.956 179.037 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.48 26.84 26.6 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.289 -1.434 . . . . 0.0 109.867 -179.733 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.547 ' HB2' ' HB1' ' A' ' 57' ' ' ALA . 1.4 mt -87.68 174.61 8.31 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 120.837 -1.39 . . . . 0.0 108.648 -179.879 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.559 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.58 99.79 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.99 -1.069 . . . . 0.0 109.744 -179.682 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 77.94 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.233 -179.149 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.58 34.17 0.32 Allowed Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.556 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.543 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 40.6 p -141.13 108.14 5.44 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.136 -1.214 . . . . 0.0 111.208 -179.539 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.9 110.75 0.46 Allowed 'General case' 0 N--CA 1.497 1.876 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.542 178.027 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.475 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.3 m-30 -106.75 156.02 19.09 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.122 -0.987 . . . . 0.0 108.902 179.821 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -99.13 164.16 12.27 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.822 -1.174 . . . . 0.0 107.917 178.822 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.623 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.5 p -144.99 115.2 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.982 -1.074 . . . . 0.0 109.653 -178.247 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.476 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.02 -174.48 35.52 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.42 -1.847 . . . . 0.0 111.594 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.579 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.4 pt20 -102.39 109.25 20.85 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.862 0.839 . . . . 0.0 108.839 -179.772 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.453 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -131.75 149.51 52.45 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.099 -1.001 . . . . 0.0 110.093 -179.858 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.77 139.14 54.12 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.25 -0.906 . . . . 0.0 110.867 -179.076 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.621 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.36 114.96 26.79 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 178.21 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.5 m -105.4 15.15 7.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.991 -1.068 . . . . 0.0 110.591 -178.799 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.595 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.6 -176.19 0.09 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.961 -1.087 . . . . 0.0 110.101 179.747 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.541 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.89 97.86 1.49 Allowed 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.381 -0.825 . . . . 0.0 109.856 -179.742 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.37 27.58 35.84 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.212 -0.994 . . . . 0.0 111.394 178.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.595 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.23 106.44 20.34 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.528 -1.572 . . . . 0.0 107.185 178.904 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.621 HD13 ' CD1' ' A' ' 39' ' ' TRP . 13.0 tp -116.99 104.61 11.45 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.476 -1.39 . . . . 0.0 109.752 -177.763 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.525 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.82 109.53 22.27 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.746 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.497 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -106.74 168.75 8.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.967 -1.083 . . . . 0.0 110.379 -178.565 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.536 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 20.5 t-20 -114.57 132.34 22.92 Favored Pre-proline 0 N--CA 1.498 1.963 0 O-C-N 121.64 -0.662 . . . . 0.0 109.95 -179.242 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.585 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.8 Cg_endo -74.18 25.56 0.34 Allowed 'Trans proline' 0 CA--C 1.544 0.997 0 C-N-CA 122.28 1.986 . . . . 0.0 112.139 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.536 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -111.25 -1.06 16.23 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.279 -1.513 . . . . 0.0 109.443 179.709 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.521 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.06 21.32 2.62 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.561 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -80.92 90.6 5.93 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 120.053 -0.659 . . . . 0.0 110.873 -178.646 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -109.73 -167.23 1.18 Allowed 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.157 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.467 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.96 136.25 0.09 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.61 -1.307 . . . . 0.0 111.186 -179.273 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.59 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -153.53 158.26 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.354 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.78 141.8 31.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.906 -1.121 . . . . 0.0 109.945 -179.845 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.683 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.02 106.51 0.84 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 122.45 1.119 . . . . 0.0 109.359 178.296 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.52 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -58.3 -138.47 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.03 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.918 -179.863 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.548 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -54.22 -49.19 70.01 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.367 -0.833 . . . . 0.0 110.406 -178.756 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -102.37 -38.26 7.68 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 178.333 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.683 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 111.36 65.26 0.51 Allowed Glycine 0 C--N 1.297 -1.593 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 177.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.1 m -102.98 128.73 49.68 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 121.41 -1.053 . . . . 0.0 108.703 178.851 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.59 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -138.22 109.07 6.68 Favored 'General case' 0 C--N 1.296 -1.73 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.771 -179.235 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.5 m -123.52 120.63 33.44 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.309 -0.869 . . . . 0.0 109.725 -179.902 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.467 HG23 HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.28 148.24 32.23 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.568 -0.708 . . . . 0.0 109.278 179.777 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.3 p -98.99 143.02 29.75 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.386 -0.821 . . . . 0.0 109.648 -179.839 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.536 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -146.03 157.52 43.87 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.357 -0.839 . . . . 0.0 109.368 -179.33 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.566 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 13.9 t -86.62 140.28 30.0 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.135 -0.978 . . . . 0.0 110.08 -179.792 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.47 HG11 ' HB3' ' A' ' 36' ' ' GLN . 16.9 m -145.94 137.89 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.226 -0.921 . . . . 0.0 110.148 -179.388 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.535 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 59.7 mtt180 -128.19 -162.75 1.21 Allowed 'General case' 0 N--CA 1.484 1.266 0 O-C-N 120.649 -1.282 . . . . 0.0 110.955 179.97 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.586 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.6 OUTLIER -86.66 -79.95 0.25 Allowed 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.35 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -69.78 133.02 46.97 Favored 'General case' 0 N--CA 1.486 1.34 0 N-CA-C 106.511 -1.662 . . . . 0.0 106.511 177.956 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.599 ' CE1' ' HB ' ' A' ' 86' ' ' VAL . 0.9 OUTLIER -154.42 155.32 34.75 Favored 'General case' 0 C--N 1.293 -1.875 0 C-N-CA 117.696 -1.602 . . . . 0.0 110.669 -177.938 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 47' ' ' CYS . 16.4 mt-10 -48.1 120.6 3.63 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 121.556 0.694 . . . . 0.0 109.549 -178.443 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.525 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -87.62 49.41 3.87 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -179.588 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.7 m-30 -40.59 112.38 0.28 Allowed 'General case' 0 N--CA 1.507 2.387 0 O-C-N 121.046 -1.267 . . . . 0.0 110.302 179.986 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.9 tp -86.33 126.39 34.3 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.96 -1.088 . . . . 0.0 109.415 179.848 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -64.2 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.98 0 O-C-N 120.773 -1.204 . . . . 0.0 110.192 179.72 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 1.5 t0 -159.03 18.53 0.19 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.996 -1.065 . . . . 0.0 109.794 179.865 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.92 -25.85 6.47 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 179.763 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 47.6 p -95.0 159.37 15.05 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 120.966 -1.314 . . . . 0.0 110.604 -179.33 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.46 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -104.25 131.84 51.14 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.52 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.485 ' CD1' HD11 ' A' ' 77' ' ' LEU . 3.0 t90 -79.75 -19.96 47.47 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.854 -1.154 . . . . 0.0 110.169 -178.501 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.52 174.4 18.88 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 108.666 -1.773 . . . . 0.0 108.666 -179.406 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.13 112.88 2.55 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 179.09 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.599 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 38.1 t -84.56 103.22 11.54 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.019 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.472 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.7 OUTLIER -63.88 109.26 1.7 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.54 -0.725 . . . . 0.0 110.248 -178.902 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.534 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 4.1 t -61.85 -4.19 1.44 Allowed 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.546 -1.262 . . . . 0.0 110.433 179.227 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -91.6 4.26 53.08 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.477 -1.389 . . . . 0.0 109.333 179.772 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.472 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -116.18 -50.19 2.67 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.178 -0.951 . . . . 0.0 109.144 179.936 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.89 178.73 4.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.512 -0.743 . . . . 0.0 109.396 179.871 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.85 113.37 26.24 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.324 -0.86 . . . . 0.0 108.817 179.884 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.475 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.51 119.59 35.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.017 -1.052 . . . . 0.0 109.471 -179.048 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.551 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.71 147.31 26.99 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-O 122.459 1.123 . . . . 0.0 111.43 -179.21 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.505 ' CG1' HG13 ' A' ' 7' ' ' VAL . 77.2 t -103.81 109.83 28.34 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.993 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 177.613 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.456 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.39 -170.01 17.1 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 118.246 -1.93 . . . . 0.0 111.608 -177.54 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.489 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.66 178.27 4.46 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.907 -0.761 . . . . 0.0 108.994 -178.972 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.475 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER . . . . . 0 C--N 1.295 -1.762 0 O-C-N 121.529 -0.732 . . . . 0.0 109.511 -179.653 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.714 0 N-CA-C 107.569 -2.212 . . . . 0.0 107.569 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -157.96 -178.37 7.26 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 121.569 -0.96 . . . . 0.0 109.721 179.183 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.44 -160.55 11.62 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 108.333 -1.907 . . . . 0.0 108.333 -179.344 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -47.01 178.31 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.864 1.332 . . . . 0.0 110.265 179.207 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -93.02 -174.4 3.56 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.123 -0.985 . . . . 0.0 110.341 -178.956 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.456 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.75 164.0 15.02 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.935 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.38 129.71 49.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.386 -1.067 . . . . 0.0 109.074 -179.629 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.551 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.92 121.44 19.08 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.658 -0.651 . . . . 0.0 109.804 179.836 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.475 HG12 ' O ' ' A' ' 93' ' ' CYS . 1.5 pt -97.99 169.28 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 121.379 -0.826 . . . . 0.0 108.818 179.822 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.521 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.98 160.37 38.82 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.141 -0.974 . . . . 0.0 109.693 -179.945 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CD1' ' HG2' ' A' ' 71' ' ' ARG . 39.2 m-85 . . . . . 0 N--CA 1.488 1.445 0 O-C-N 121.242 -0.911 . . . . 0.0 109.46 -179.759 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.484 1.255 0 CA-C-O 122.275 1.036 . . . . 1.0 110.561 . . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.526 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.9 p -107.0 104.93 14.73 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 122.608 1.194 . . . . 1.0 110.347 -179.587 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.522 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 15.2 t -119.37 115.35 47.43 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.468 0 CA-C-N 115.271 -0.877 . . . . 1.0 110.131 179.428 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.502 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -162.57 150.8 12.01 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.316 -0.994 . . . . 1.0 108.316 -179.378 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.502 ' HA ' HG22 ' A' ' 8' ' ' THR . 6.1 Cg_endo -77.96 150.21 88.92 Favored 'Cis proline' 0 C--N 1.308 -1.554 0 C-N-CA 123.635 -1.402 . . . . 1.0 109.74 -0.679 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.493 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 69.2 p -89.75 -25.49 21.12 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 109.031 -0.729 . . . . 1.0 109.031 179.549 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.464 ' HB2' ' HB3' ' A' ' 111' ' ' SER . 18.7 p -132.55 164.64 26.18 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.498 -0.751 . . . . 1.0 109.375 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.68 38.27 37.61 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 108.259 -1.936 . . . . 1.0 108.259 -179.531 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.605 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 33.7 mt -92.49 -43.39 9.21 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 123.264 1.507 . . . . 1.0 110.619 -178.174 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.494 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.11 143.59 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.269 0 CA-C-N 113.461 -1.7 . . . . 1.0 109.815 -179.467 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.546 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 9.9 p-10 -50.48 105.13 0.09 Allowed 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.474 0.654 . . . . 1.0 111.634 -178.484 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.4 ' H ' ' HB3' ' A' ' 70' ' ' ARG . . . 113.98 15.68 8.38 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 119.457 -1.354 . . . . 1.0 113.007 177.153 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.605 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.5 t -103.88 -171.22 1.9 Allowed 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 121.053 2.426 . . . . 1.0 109.802 179.125 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.579 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 16.6 t -131.31 140.06 49.34 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.314 0 CA-C-N 114.822 -1.081 . . . . 1.0 111.362 -178.783 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.528 HG13 ' CG2' ' A' ' 69' ' ' VAL . 30.9 m -115.9 155.48 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 N-CA-C 108.66 -0.867 . . . . 1.0 108.66 178.861 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.522 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 5.5 tptm -108.16 108.96 20.23 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.137 -0.977 . . . . 1.0 109.529 -179.759 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.518 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 p -106.39 122.5 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.853 -0.795 . . . . 1.0 108.853 179.729 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.55 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -115.21 165.45 12.92 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.943 -1.098 . . . . 1.0 109.145 179.789 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.81 108.03 0.46 Allowed Glycine 0 N--CA 1.483 1.768 0 N-CA-C 108.711 -1.756 . . . . 1.0 108.711 179.602 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.468 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.75 142.43 46.93 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.704 -1.468 . . . . 1.0 110.212 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.96 29.08 35.49 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.062 -1.542 . . . . 1.0 109.773 179.787 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.529 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -94.56 172.75 7.99 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.093 -1.239 . . . . 1.0 108.31 179.98 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.555 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.09 100.36 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.027 -1.046 . . . . 1.0 109.602 -179.799 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.85 76.44 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 115.397 -0.819 . . . . 1.0 109.955 -179.313 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 137.08 33.26 0.22 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.457 -1.457 . . . . 1.0 109.457 179.712 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.528 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 66.8 p -142.14 109.74 5.72 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.042 -1.269 . . . . 1.0 111.013 -179.803 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.537 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -47.95 109.93 0.28 Allowed 'General case' 0 N--CA 1.496 1.847 0 CA-C-N 115.7 -0.682 . . . . 1.0 109.858 178.407 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.498 ' CE1' ' HD2' ' A' ' 105' ' ' PRO . 21.1 m-85 -99.1 152.3 20.01 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.157 -0.965 . . . . 1.0 109.007 179.653 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.47 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.48 157.77 16.56 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 107.598 -1.26 . . . . 1.0 107.598 178.421 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.623 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 9.9 p -142.29 113.97 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.063 -1.023 . . . . 1.0 110.07 -177.692 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.489 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.39 -175.49 36.73 Favored Glycine 0 N--CA 1.495 2.575 0 C-N-CA 118.371 -1.871 . . . . 1.0 111.875 -179.811 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.588 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -102.25 109.41 21.09 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 108.848 -0.797 . . . . 1.0 108.848 -179.663 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -131.07 148.55 52.75 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.129 -0.982 . . . . 1.0 110.034 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.89 139.79 53.62 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.314 -0.866 . . . . 1.0 110.716 -179.016 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.621 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.25 114.66 26.47 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 107.607 -1.257 . . . . 1.0 107.607 178.161 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 m -105.25 15.01 7.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.094 -1.004 . . . . 1.0 110.469 -178.752 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.585 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 175.04 -175.76 0.09 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.044 -1.035 . . . . 1.0 110.039 179.688 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 p -72.69 98.02 2.29 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.448 -0.782 . . . . 1.0 109.508 -179.805 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.39 27.64 32.45 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.232 -0.985 . . . . 1.0 111.291 179.046 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.585 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -117.6 106.27 19.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 O-C-N 120.6 -1.53 . . . . 1.0 107.325 178.889 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.621 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.4 tp -116.1 104.8 11.92 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 120.496 -1.378 . . . . 1.0 109.567 -178.016 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.536 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.47 109.56 22.29 Favored 'General case' 0 N--CA 1.486 1.338 0 O-C-N 120.781 -1.199 . . . . 1.0 107.857 178.889 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -108.26 163.73 12.93 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.02 -1.05 . . . . 1.0 110.112 -178.656 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.485 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 36.2 t-20 -110.16 128.78 24.79 Favored Pre-proline 0 N--CA 1.502 2.141 0 O-C-N 121.437 -0.789 . . . . 1.0 109.67 -179.372 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.576 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.6 Cg_endo -69.44 17.72 0.18 Allowed 'Trans proline' 0 CA--C 1.546 1.075 0 C-N-CA 122.021 1.814 . . . . 1.0 112.108 179.444 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -104.6 3.48 31.77 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.389 -1.444 . . . . 1.0 108.528 179.065 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.518 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.45 15.91 2.75 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 107.228 -1.397 . . . . 1.0 107.228 179.487 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -81.53 92.39 6.5 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.834 -0.746 . . . . 1.0 111.099 -178.299 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -112.01 -170.94 1.75 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.133 -1.432 . . . . 1.0 107.133 177.879 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 179.18 136.91 0.1 Allowed 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.475 -1.391 . . . . 1.0 111.277 -179.197 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.59 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.56 157.14 4.78 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 107.107 -1.442 . . . . 1.0 107.107 178.194 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.537 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -97.83 143.23 28.66 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.696 -1.253 . . . . 1.0 109.965 -179.474 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.664 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.24 105.86 0.98 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 122.372 1.082 . . . . 1.0 109.392 178.704 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.522 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.5 t70 -60.21 -139.28 0.0 OUTLIER 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.719 -0.673 . . . . 1.0 110.934 -179.827 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.6 -50.48 60.1 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.297 -0.877 . . . . 1.0 110.625 -178.7 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 49.4 m-80 -102.95 -35.15 8.68 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.272 -1.751 . . . . 1.0 106.272 178.59 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.664 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 105.26 66.27 0.68 Allowed Glycine 0 C--N 1.297 -1.602 0 N-CA-C 110.522 -1.031 . . . . 1.0 110.522 178.305 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.584 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.4 m -104.09 125.54 50.51 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 108.514 -0.921 . . . . 1.0 108.514 178.833 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.59 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.46 109.54 8.8 Favored 'General case' 0 C--N 1.296 -1.748 0 C-N-CA 119.692 -0.803 . . . . 1.0 109.755 -179.266 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.481 ' OG ' ' HB1' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -116.24 122.72 45.8 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.278 -0.888 . . . . 1.0 109.019 179.709 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.461 HG21 HG13 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -148.44 140.14 23.7 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.496 -0.752 . . . . 1.0 109.884 -179.964 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.404 ' HB3' ' HD2' ' A' ' 20' ' ' LYS . 14.6 p -101.34 131.42 47.4 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.369 -0.832 . . . . 1.0 109.276 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.518 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -128.52 164.62 22.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.38 -0.825 . . . . 1.0 109.623 -179.452 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.579 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -97.36 124.59 41.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.952 -1.093 . . . . 1.0 109.249 -179.958 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.549 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 18.0 m -136.61 143.67 34.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.1 -1.0 . . . . 1.0 109.947 -179.106 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.546 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.8 ptt180 -141.86 -165.51 2.02 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.51 -1.369 . . . . 1.0 110.264 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.583 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 10.1 mtt180 -70.07 -76.85 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.425 -0.797 . . . . 1.0 109.017 -179.557 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.428 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -69.62 137.33 52.18 Favored 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.232 -1.542 . . . . 1.0 107.128 178.878 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.588 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -160.17 134.18 7.26 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 117.895 -1.522 . . . . 1.0 110.299 -178.179 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.478 ' C ' ' O ' ' A' ' 73' ' ' PHE . 4.2 mm-40 -30.57 120.97 0.2 Allowed 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.54 0.686 . . . . 1.0 110.888 -178.397 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.536 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.13 43.4 3.05 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.913 -0.875 . . . . 1.0 110.913 -179.526 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.576 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 2.1 m-85 -38.71 114.93 0.42 Allowed 'General case' 0 N--CA 1.511 2.603 0 O-C-N 121.182 -1.187 . . . . 1.0 110.123 179.959 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.529 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.4 tp -87.64 126.96 35.26 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.889 -1.132 . . . . 1.0 109.231 179.81 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -63.95 58.01 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.871 -1.143 . . . . 1.0 110.438 -179.9 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 9.3 t0 -161.97 19.96 0.1 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.924 -1.11 . . . . 1.0 109.862 179.802 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.06 -27.29 5.05 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.002 -1.239 . . . . 1.0 110.002 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.463 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 3.1 p -90.24 153.55 20.4 Favored 'General case' 0 N--CA 1.485 1.318 0 O-C-N 121.072 -1.252 . . . . 1.0 110.388 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.507 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 5.1 ptt180 -102.43 132.82 48.2 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.636 -0.875 . . . . 1.0 108.636 179.68 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.46 ' CD1' HD11 ' A' ' 77' ' ' LEU . 2.4 t90 -81.92 -21.41 37.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.659 -1.276 . . . . 1.0 110.294 -178.673 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.92 174.0 18.55 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.746 -1.742 . . . . 1.0 108.746 -179.644 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.67 110.71 1.81 Allowed 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.412 -1.329 . . . . 1.0 107.412 179.095 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.577 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 41.3 t -82.26 104.27 10.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 O-C-N 121.449 -0.782 . . . . 1.0 108.895 -178.962 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.46 ' HB3' HG22 ' A' ' 90' ' ' THR . 0.1 OUTLIER -66.47 111.81 3.76 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.306 -0.871 . . . . 1.0 109.784 -179.277 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.533 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.0 t -62.77 -5.35 2.69 Favored 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 118.416 -1.314 . . . . 1.0 110.108 179.497 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -86.23 0.6 53.36 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.611 -1.306 . . . . 1.0 109.15 179.462 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.46 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -112.71 -48.89 2.97 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.268 -0.895 . . . . 1.0 109.055 179.907 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.46 -178.31 3.56 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.483 -0.761 . . . . 1.0 109.6 -179.93 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.55 114.78 29.23 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.294 -0.879 . . . . 1.0 108.97 179.923 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.56 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.12 123.32 40.85 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.956 -1.09 . . . . 1.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.546 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.96 146.16 28.75 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 122.359 1.076 . . . . 1.0 111.059 -179.775 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.514 ' CG1' HG12 ' A' ' 7' ' ' VAL . 97.8 t -103.07 109.63 27.39 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.069 0 N-CA-C 106.604 -1.628 . . . . 1.0 106.604 177.719 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.464 ' HA3' ' CA ' ' A' ' 107' ' ' GLY . . . -149.51 -170.58 17.19 Favored Glycine 0 N--CA 1.485 1.962 0 C-N-CA 118.091 -2.004 . . . . 1.0 111.944 -177.47 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.47 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -118.16 -178.65 3.56 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 108.88 -0.785 . . . . 1.0 108.88 -178.77 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.469 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.711 0 O-C-N 121.355 -0.841 . . . . 1.0 109.254 -179.45 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.666 0 N-CA-C 107.522 -2.231 . . . . 1.0 107.522 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.46 -178.24 6.99 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.615 -0.932 . . . . 1.0 109.727 179.12 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -170.27 -162.61 22.87 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 108.248 -1.941 . . . . 1.0 108.248 -179.426 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.498 ' HD2' ' CE1' ' A' ' 32' ' ' TYR . 7.5 Cg_exo -45.69 165.81 0.06 OUTLIER 'Trans proline' 0 C--O 1.215 -0.637 0 CA-C-N 118.912 1.356 . . . . 1.0 109.656 179.392 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.73 -176.45 4.97 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.047 -1.033 . . . . 1.0 110.528 -178.473 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.464 ' CA ' ' HA3' ' A' ' 96' ' ' GLY . . . -118.57 175.26 15.64 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.723 -1.351 . . . . 1.0 109.723 -179.837 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -112.05 132.51 60.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.383 -1.069 . . . . 1.0 109.121 -179.14 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.546 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -69.88 124.58 24.39 Favored 'General case' 0 C--N 1.291 -1.95 0 O-C-N 121.556 -0.715 . . . . 1.0 109.479 179.526 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.578 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.71 171.57 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.19 -0.944 . . . . 1.0 109.043 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.464 ' HB3' ' HB2' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.53 161.21 37.01 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.237 -0.914 . . . . 1.0 109.707 -179.773 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.583 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 90.0 m-85 . . . . . 0 N--CA 1.484 1.268 0 O-C-N 121.12 -0.987 . . . . 1.0 109.532 -179.702 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.502 ' CB ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 122.281 1.038 . . . . 0.0 111.179 . . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.541 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.4 p -101.22 104.45 15.51 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 122.404 1.097 . . . . 0.0 109.907 179.859 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.54 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 3.2 t -119.37 119.3 60.21 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.393 179.588 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.495 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.8 149.92 4.41 Favored Pre-proline 0 N--CA 1.486 1.335 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -179.602 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.495 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.3 Cg_endo -78.55 149.96 86.69 Favored 'Cis proline' 0 C--N 1.309 -1.504 0 C-N-CA 123.631 -1.404 . . . . 0.0 109.439 -0.677 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.482 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 72.6 p -92.09 -23.43 19.46 Favored 'General case' 0 C--N 1.292 -1.911 0 O-C-N 121.632 -0.668 . . . . 0.0 109.245 179.677 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.522 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 12.1 p -131.81 161.19 33.53 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.376 -0.828 . . . . 0.0 109.646 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.2 37.78 31.33 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 108.386 -1.885 . . . . 0.0 108.386 -179.556 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.603 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 33.2 mt -91.85 -43.39 9.53 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 123.223 1.487 . . . . 0.0 110.53 -178.223 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.494 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.89 143.93 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.25 0 CA-C-N 113.457 -1.701 . . . . 0.0 110.017 -179.508 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.565 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 11.5 p-10 -49.83 105.69 0.1 Allowed 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 121.431 0.634 . . . . 0.0 111.737 -178.53 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.5 15.37 8.89 Favored Glycine 0 N--CA 1.485 1.94 0 C-N-CA 119.439 -1.363 . . . . 0.0 113.077 177.068 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.603 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.9 t -105.04 -173.2 2.25 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 121.123 2.461 . . . . 0.0 109.943 179.191 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.539 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 21.6 t -128.86 139.7 51.21 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.318 0 CA-C-N 114.635 -1.166 . . . . 0.0 111.508 -178.578 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.462 ' CG1' HD22 ' A' ' 13' ' ' LEU . 33.8 m -117.82 155.96 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.641 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tppp? -107.69 109.92 21.64 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.017 -1.052 . . . . 0.0 109.816 -179.681 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.527 ' CG2' HG21 ' A' ' 7' ' ' VAL . 7.3 p -105.87 123.23 60.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.086 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.541 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -119.7 166.61 12.99 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.506 -1.371 . . . . 0.0 109.397 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.582 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.42 143.31 14.97 Favored Glycine 0 C--N 1.296 -1.682 0 N-CA-C 107.802 -2.119 . . . . 0.0 107.802 179.806 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -148.08 122.54 9.73 Favored 'General case' 0 C--N 1.293 -1.858 0 O-C-N 120.828 -1.395 . . . . 0.0 108.565 179.067 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.52 27.38 20.22 Favored Glycine 0 N--CA 1.486 2.017 0 C-N-CA 119.093 -1.527 . . . . 0.0 109.707 -179.552 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.556 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.2 mt -87.23 176.51 7.53 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 120.894 -1.356 . . . . 0.0 108.373 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.582 ' CB ' ' CG2' ' A' ' 30' ' ' THR . 0.0 OUTLIER -45.42 96.76 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.001 -1.062 . . . . 0.0 109.665 -179.784 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.2 77.68 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.528 -179.0 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 129.33 36.28 0.43 Allowed Glycine 0 N--CA 1.487 2.035 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 179.409 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.648 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -148.57 114.54 5.76 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 120.913 -1.345 . . . . 0.0 111.199 -179.891 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.548 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -46.34 122.52 4.09 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 115.437 -0.802 . . . . 0.0 110.354 178.66 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.648 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 1.9 m-30 -116.97 154.43 30.9 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.084 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.503 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -100.52 167.68 10.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.499 -1.375 . . . . 0.0 108.604 179.449 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.615 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.3 p -147.78 122.46 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.165 -0.96 . . . . 0.0 109.554 -178.089 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -177.08 -178.21 46.63 Favored Glycine 0 N--CA 1.495 2.606 0 C-N-CA 118.329 -1.891 . . . . 0.0 111.71 179.977 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.564 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -100.4 108.52 20.55 Favored 'General case' 0 N--CA 1.477 0.901 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.836 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -129.59 148.63 51.51 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.179 -0.951 . . . . 0.0 109.803 179.691 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.34 139.52 53.95 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.307 -0.871 . . . . 0.0 110.675 -179.023 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.617 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.09 114.9 26.76 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 178.147 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.47 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 18.2 m -105.77 14.98 7.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.044 -1.035 . . . . 0.0 110.58 -178.652 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.553 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 175.1 -174.94 0.09 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.986 -1.071 . . . . 0.0 109.995 179.579 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.547 ' O ' ' CG2' ' A' ' 42' ' ' THR . 14.9 t -72.62 98.01 2.26 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.43 -0.794 . . . . 0.0 109.757 -179.779 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.78 28.01 33.19 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 120.161 -1.019 . . . . 0.0 111.436 179.037 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.553 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -117.16 106.39 20.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.542 -1.564 . . . . 0.0 107.149 178.798 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.617 HD12 ' CD1' ' A' ' 39' ' ' TRP . 13.2 tp -116.76 104.94 11.85 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.496 -1.378 . . . . 0.0 109.681 -177.649 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.97 109.75 22.45 Favored 'General case' 0 N--CA 1.484 1.26 0 O-C-N 120.934 -1.104 . . . . 0.0 108.387 179.237 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.0 t -106.16 163.88 12.44 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.995 -1.066 . . . . 0.0 110.268 -179.037 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.518 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 17.4 t30 -111.36 137.79 21.17 Favored Pre-proline 0 N--CA 1.502 2.129 0 O-C-N 121.496 -0.752 . . . . 0.0 109.598 -179.387 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.57 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.2 24.58 0.31 Allowed 'Trans proline' 0 C--N 1.318 -1.04 0 C-N-CA 122.504 2.136 . . . . 0.0 112.41 -179.379 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.466 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -103.34 -8.3 20.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.164 -1.585 . . . . 0.0 109.184 179.465 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.548 ' HB3' ' CB ' ' A' ' 67' ' ' LEU . 2.0 m-20 -135.69 8.85 3.33 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.54 86.46 0.08 Allowed 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.277 -0.889 . . . . 0.0 110.441 -178.797 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.615 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -115.61 -169.86 1.66 Allowed 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 178.785 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.462 ' OG ' ' O ' ' A' ' 32' ' ' TYR . 0.6 OUTLIER 178.65 133.9 0.08 Allowed 'General case' 0 C--N 1.303 -1.424 0 O-C-N 120.725 -1.235 . . . . 0.0 111.206 -179.483 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.555 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 2.0 p -143.59 159.72 16.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.548 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.89 145.33 26.54 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.649 -1.282 . . . . 0.0 109.75 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.684 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -67.56 109.75 3.38 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 122.449 1.118 . . . . 0.0 109.465 178.638 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.535 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.5 p-10 -62.11 -139.17 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.643 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.532 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.33 -51.88 50.43 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.268 -0.895 . . . . 0.0 110.445 -178.94 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.5 -33.72 9.4 Favored 'General case' 0 C--N 1.288 -2.103 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.555 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.684 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.18 65.65 0.59 Allowed Glycine 0 C--N 1.3 -1.444 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.162 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.582 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 53.5 p -99.91 131.78 45.67 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 121.354 -1.086 . . . . 0.0 109.363 179.15 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.555 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.19 108.78 6.96 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.429 -0.908 . . . . 0.0 109.535 -179.853 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.0 p -117.62 118.52 32.34 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.063 -1.023 . . . . 0.0 109.588 -179.818 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.403 HG22 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -146.67 140.89 26.31 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.473 -0.767 . . . . 0.0 109.835 -179.947 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.447 ' HB3' ' HE3' ' A' ' 20' ' ' LYS . 24.2 p -98.82 136.37 38.94 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.322 -0.861 . . . . 0.0 108.792 179.54 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.548 ' CB ' ' HB3' ' A' ' 51' ' ' ASP . 0.2 OUTLIER -132.73 168.07 18.98 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.266 -0.896 . . . . 0.0 110.322 -178.489 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.524 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.1 p -104.46 124.39 49.17 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.876 . . . . 0.0 108.688 179.464 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.52 HG12 ' CB ' ' A' ' 36' ' ' GLN . 17.4 m -136.93 142.98 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 120.873 -1.142 . . . . 0.0 110.237 -178.761 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.565 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.4 ptt180 -144.9 -169.71 3.24 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 120.575 -1.328 . . . . 0.0 110.771 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.553 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -58.35 -99.8 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -179.144 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -58.33 143.37 45.13 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.355 -1.466 . . . . 0.0 108.505 179.692 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.589 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.17 138.63 6.7 Favored 'General case' 0 C--N 1.294 -1.813 0 C-N-CA 118.848 -1.141 . . . . 0.0 109.614 -178.185 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.532 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 8.6 mm-40 -34.77 121.97 0.53 Allowed 'General case' 0 N--CA 1.49 1.53 0 CA-C-O 121.484 0.659 . . . . 0.0 110.583 -178.254 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.533 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.64 46.08 2.75 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 120.52 -0.848 . . . . 0.0 110.995 -179.298 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.57 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.7 m-85 -39.07 111.48 0.18 Allowed 'General case' 0 N--CA 1.507 2.403 0 O-C-N 121.23 -1.159 . . . . 0.0 109.887 179.589 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.542 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.5 tp -84.88 127.37 34.12 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.9 -1.125 . . . . 0.0 109.281 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.415 ' CD2' ' O ' ' A' ' 78' ' ' PHE . 57.6 t80 -63.18 58.18 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.92 -1.113 . . . . 0.0 110.527 -179.881 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t0 -163.33 20.21 0.08 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.906 -1.121 . . . . 0.0 109.997 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.77 -27.16 4.95 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.091 -1.203 . . . . 0.0 110.091 179.979 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.505 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -90.3 150.57 21.86 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 121.119 -1.224 . . . . 0.0 110.247 -179.469 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.48 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -101.19 133.06 46.31 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 179.434 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.461 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.5 t90 -81.76 -16.09 52.18 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.794 -1.191 . . . . 0.0 110.56 -178.525 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 108.74 174.36 21.52 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.856 -1.697 . . . . 0.0 108.856 -179.719 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.79 103.9 0.62 Allowed 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.613 -1.255 . . . . 0.0 107.613 179.116 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.585 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.5 t -74.52 106.53 4.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.476 -0.765 . . . . 0.0 109.224 -178.814 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -66.58 110.93 3.37 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.386 -0.821 . . . . 0.0 109.813 -179.454 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.553 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.72 -5.49 4.23 Favored 'General case' 0 N--CA 1.499 2.024 0 C-N-CA 118.329 -1.348 . . . . 0.0 109.908 179.463 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.7 p -85.61 -0.6 55.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.705 -1.247 . . . . 0.0 109.144 179.568 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.452 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -112.92 -49.17 2.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.383 -0.823 . . . . 0.0 109.002 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.45 -178.2 3.58 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.511 -0.743 . . . . 0.0 109.455 179.963 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.14 115.64 30.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.446 -0.784 . . . . 0.0 108.964 179.924 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.564 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.86 123.54 40.6 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.935 -1.103 . . . . 0.0 109.665 -179.176 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.565 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.05 147.66 26.68 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-O 122.418 1.104 . . . . 0.0 111.014 -179.522 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.459 ' HB ' HG12 ' A' ' 7' ' ' VAL . 46.4 t -106.28 113.22 42.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.993 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.017 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.472 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -155.18 -169.83 20.11 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 117.989 -2.053 . . . . 0.0 111.834 -177.943 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -110.52 -177.74 3.31 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 -179.227 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.503 ' O ' ' N ' ' A' ' 33' ' ' ASP . 12.1 p . . . . . 0 C--N 1.297 -1.715 0 O-C-N 121.367 -0.833 . . . . 0.0 109.083 -179.072 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.712 0 N-CA-C 107.878 -2.089 . . . . 0.0 107.878 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.64 -177.92 6.88 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 121.474 -1.015 . . . . 0.0 109.81 179.238 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.4 -161.2 13.01 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.589 -1.804 . . . . 0.0 108.589 -179.256 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.519 ' HD3' ' CE2' ' A' ' 32' ' ' TYR . 4.7 Cg_exo -47.41 -178.97 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.709 1.254 . . . . 0.0 110.577 179.278 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -93.75 -177.6 4.42 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.072 -1.017 . . . . 0.0 110.425 -178.93 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.472 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.79 166.39 14.55 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.68 130.41 52.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.342 -1.093 . . . . 0.0 109.165 -179.405 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.565 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.25 122.29 22.6 Favored 'General case' 0 C--N 1.289 -2.024 0 O-C-N 121.623 -0.673 . . . . 0.0 109.48 179.617 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.583 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.57 168.74 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 O-C-N 121.193 -0.942 . . . . 0.0 109.188 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.522 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.3 m -136.85 157.52 46.56 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.301 -0.875 . . . . 0.0 109.541 -179.784 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.583 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 70.8 m-85 . . . . . 0 C--N 1.306 -1.323 0 O-C-N 121.164 -0.96 . . . . 0.0 109.608 -179.614 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.283 0 CA-C-O 122.415 1.102 . . . . 0.0 110.423 . . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.552 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.1 t -114.72 109.07 17.64 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 123.075 1.417 . . . . 0.0 109.663 179.937 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.527 HG11 ' CG1' ' A' ' 95' ' ' VAL . 2.5 t -117.28 136.08 55.6 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 CA-C-N 114.297 -1.32 . . . . 0.0 109.681 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.522 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -173.08 150.8 2.0 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.273 -0.892 . . . . 0.0 108.734 -179.559 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.522 ' CA ' HG21 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.21 150.44 88.57 Favored 'Cis proline' 0 C--N 1.312 -1.387 0 C-N-CA 123.563 -1.432 . . . . 0.0 109.507 -0.761 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.467 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 38.3 p -90.01 -25.59 20.77 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 121.586 -0.696 . . . . 0.0 109.14 179.502 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.521 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 16.1 m -133.08 162.11 32.61 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.406 -0.809 . . . . 0.0 109.565 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.86 37.13 30.52 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 -179.684 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.605 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 37.5 mt -92.36 -42.34 9.85 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 123.218 1.485 . . . . 0.0 110.43 -178.482 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.487 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.94 143.27 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.323 0 CA-C-N 113.379 -1.737 . . . . 0.0 109.825 -179.542 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.573 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 18.3 p-10 -50.39 105.27 0.09 Allowed 'General case' 0 C--N 1.3 -1.586 0 CA-C-O 121.452 0.644 . . . . 0.0 111.484 -178.525 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.92 13.57 8.46 Favored Glycine 0 N--CA 1.486 2.002 0 C-N-CA 119.306 -1.426 . . . . 0.0 113.165 177.285 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.605 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -104.56 -171.71 1.97 Allowed 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 121.28 2.54 . . . . 0.0 109.78 179.18 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.571 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 18.2 t -129.26 139.01 52.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.956 -1.02 . . . . 0.0 111.224 -178.821 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.519 HG12 ' CG2' ' A' ' 69' ' ' VAL . 31.5 m -114.14 155.39 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 178.937 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.82 109.57 20.72 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.115 -0.991 . . . . 0.0 109.266 179.976 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 1.6 p -102.36 140.74 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.594 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.583 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -137.32 161.67 35.64 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 118.773 -1.171 . . . . 0.0 110.182 179.81 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.32 141.74 13.02 Favored Glycine 0 C--N 1.298 -1.572 0 N-CA-C 108.169 -1.973 . . . . 0.0 108.169 179.721 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -143.24 124.69 14.76 Favored 'General case' 0 N--CA 1.494 1.754 0 CA-C-N 119.226 1.513 . . . . 0.0 109.363 179.255 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.05 28.98 19.16 Favored Glycine 0 N--CA 1.489 2.212 0 C-N-CA 118.965 -1.588 . . . . 0.0 109.647 -179.733 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.543 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.5 mt -89.4 175.24 7.4 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.9 -1.353 . . . . 0.0 108.366 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.554 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.61 99.95 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.977 -1.077 . . . . 0.0 109.806 -179.752 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.537 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.32 77.52 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.918 -179.347 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.588 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.97 33.97 0.24 Allowed Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 179.674 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 23.1 p -139.59 105.66 5.22 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.141 -1.211 . . . . 0.0 111.283 -179.404 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.559 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.42 109.77 0.34 Allowed 'General case' 0 N--CA 1.497 1.916 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 177.853 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.501 ' HA ' ' O ' ' A' ' 98' ' ' SER . 6.8 m-30 -104.41 158.99 16.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.139 -0.975 . . . . 0.0 109.131 -179.977 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.512 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -101.63 157.75 16.59 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 178.754 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.525 ' CG1' HG21 ' A' ' 65' ' ' THR . 1.6 t -136.84 109.77 8.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.129 -0.982 . . . . 0.0 109.635 -177.573 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.481 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.38 -174.05 35.37 Favored Glycine 0 N--CA 1.497 2.727 0 C-N-CA 117.713 -2.184 . . . . 0.0 112.638 -179.928 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.567 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -102.09 109.11 20.74 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-O 121.756 0.789 . . . . 0.0 109.062 -179.495 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.428 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.42 148.8 52.27 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.21 -0.931 . . . . 0.0 109.6 179.33 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.34 138.72 54.55 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.32 -0.862 . . . . 0.0 110.774 -178.995 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.619 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.43 115.07 26.92 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.154 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.429 HG22 ' HB ' ' A' ' 44' ' ' VAL . 16.8 m -104.88 14.89 6.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 120.988 -1.07 . . . . 0.0 110.558 -178.89 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.592 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.38 -175.12 0.08 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.959 -1.088 . . . . 0.0 110.006 179.781 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.44 98.12 2.2 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.411 -0.806 . . . . 0.0 109.687 -179.78 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.99 28.11 32.22 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 120.217 -0.992 . . . . 0.0 111.355 179.014 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.592 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.54 106.25 19.61 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 O-C-N 120.603 -1.528 . . . . 0.0 107.071 178.804 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.619 HD12 ' CD1' ' A' ' 39' ' ' TRP . 13.8 tp -118.03 104.5 10.93 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.458 -1.401 . . . . 0.0 109.789 -177.719 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.542 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.21 109.37 22.14 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 120.918 -1.114 . . . . 0.0 108.051 178.84 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.502 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.1 163.47 12.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.906 -1.121 . . . . 0.0 110.281 -178.778 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.522 ' ND2' ' HB2' ' A' ' 50' ' ' ALA . 47.4 t30 -106.4 132.33 20.99 Favored Pre-proline 0 N--CA 1.504 2.23 0 O-C-N 121.394 -0.816 . . . . 0.0 109.627 -179.424 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.571 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -72.21 19.36 0.3 Allowed 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 122.296 1.997 . . . . 0.0 112.281 -179.596 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.522 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -111.2 4.13 18.99 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.38 -1.45 . . . . 0.0 108.707 179.114 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.517 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.08 20.76 3.01 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 179.303 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -81.37 85.85 6.37 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.538 -178.715 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.501 ' CB ' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.52 -171.03 2.04 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.843 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.45 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.66 134.58 0.08 Allowed 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.676 -1.265 . . . . 0.0 111.23 -179.292 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.569 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -158.12 153.6 5.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 178.359 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.559 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.28 139.95 33.29 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.875 -1.141 . . . . 0.0 109.544 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.68 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -62.35 106.32 0.73 Allowed 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.391 1.091 . . . . 0.0 109.501 178.637 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.53 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.9 t70 -61.37 -139.21 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.045 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.77 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.537 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.11 -51.2 59.32 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.401 -0.812 . . . . 0.0 110.724 -178.803 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -101.04 -34.53 9.7 Favored 'General case' 0 C--N 1.286 -2.153 0 N-CA-C 106.282 -1.747 . . . . 0.0 106.282 178.493 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.68 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 104.88 65.76 0.68 Allowed Glycine 0 C--N 1.297 -1.637 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 178.109 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.6 m -98.86 130.42 45.27 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.594 -0.945 . . . . 0.0 108.6 178.739 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.583 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -137.79 108.63 6.68 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.594 -179.329 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.8 m -124.23 120.45 32.28 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.334 -0.854 . . . . 0.0 109.47 179.927 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.525 HG21 ' CG1' ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.16 142.83 29.95 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.558 -0.714 . . . . 0.0 109.353 179.908 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 9.5 p -99.2 136.22 39.47 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.316 -0.865 . . . . 0.0 109.434 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.517 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -136.31 165.19 26.34 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.461 -0.774 . . . . 0.0 109.55 -179.343 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.571 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.2 p -96.78 125.45 41.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.073 -1.017 . . . . 0.0 109.112 179.926 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.551 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.7 m -136.53 142.7 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 120.934 -1.104 . . . . 0.0 110.09 -178.886 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.573 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 5.2 ptt180 -147.49 -173.08 4.18 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.562 -1.337 . . . . 0.0 110.884 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.551 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -54.11 -101.22 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 -179.421 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.19 141.44 46.41 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.82 -1.175 . . . . 0.0 108.128 179.479 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.8 135.44 5.58 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 118.68 -1.208 . . . . 0.0 109.665 -178.01 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.501 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 18.7 mm-40 -34.73 122.93 0.54 Allowed 'General case' 0 N--CA 1.491 1.603 0 CA-C-O 121.502 0.668 . . . . 0.0 110.088 -178.466 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.542 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.98 52.81 1.66 Allowed Glycine 0 N--CA 1.492 2.385 0 C-N-CA 120.397 -0.906 . . . . 0.0 111.108 -178.937 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.571 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-30 -39.7 113.38 0.33 Allowed 'General case' 0 N--CA 1.506 2.332 0 O-C-N 121.065 -1.256 . . . . 0.0 109.972 179.393 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.1 tp -83.45 126.12 32.43 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.947 -1.096 . . . . 0.0 109.217 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 39.5 t80 -63.7 58.66 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.918 -1.114 . . . . 0.0 110.169 179.806 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -160.92 19.91 0.13 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.996 -1.065 . . . . 0.0 109.696 179.92 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.13 -28.07 5.28 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.882 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.439 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.32 159.61 15.04 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.007 -1.29 . . . . 0.0 110.28 -179.416 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.469 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.73 135.96 47.37 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.757 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.472 ' CD1' HD11 ' A' ' 77' ' ' LEU . 1.6 t90 -80.77 -18.87 46.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.867 -1.145 . . . . 0.0 110.545 -178.504 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.46 177.47 19.84 Favored Glycine 0 N--CA 1.484 1.88 0 N-CA-C 108.671 -1.771 . . . . 0.0 108.671 -179.428 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.36 105.58 1.18 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.2 -1.176 . . . . 0.0 107.859 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.576 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 40.0 t -77.53 105.7 6.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.346 -0.846 . . . . 0.0 109.124 -179.069 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 1.5 m-20 -65.6 111.44 3.15 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.406 -0.809 . . . . 0.0 109.747 -179.372 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.551 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.13 -5.23 4.46 Favored 'General case' 0 N--CA 1.5 2.031 0 C-N-CA 118.113 -1.435 . . . . 0.0 109.876 179.386 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -86.54 -0.06 55.33 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.799 -1.188 . . . . 0.0 109.159 179.587 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.448 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -113.36 -50.01 2.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.334 -0.854 . . . . 0.0 108.969 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.5 -179.05 3.83 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.487 -0.758 . . . . 0.0 109.42 179.925 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.88 115.27 30.01 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.328 -0.857 . . . . 0.0 108.999 179.9 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -97.03 122.24 39.81 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.762 -1.211 . . . . 0.0 109.428 -179.431 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.552 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -101.91 146.89 27.21 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 122.41 1.1 . . . . 0.0 111.107 -179.372 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.527 ' CG1' HG11 ' A' ' 7' ' ' VAL . 61.1 t -104.43 110.25 29.93 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 177.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.44 -169.86 17.58 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 118.31 -1.9 . . . . 0.0 111.466 -177.786 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.497 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -113.22 179.98 3.81 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -179.333 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.512 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.6 OUTLIER . . . . . 0 C--N 1.296 -1.736 0 O-C-N 121.364 -0.835 . . . . 0.0 109.406 -179.596 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.806 0 N-CA-C 107.62 -2.192 . . . . 0.0 107.62 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.49 -178.16 6.93 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.637 -0.919 . . . . 0.0 109.622 179.194 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.85 -162.43 14.74 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 108.434 -1.866 . . . . 0.0 108.434 -179.34 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.48 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.9 Cg_exo -46.32 176.31 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.692 0 CA-C-N 118.837 1.318 . . . . 0.0 110.206 179.289 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -91.62 -176.15 4.4 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.033 -1.042 . . . . 0.0 110.573 -178.71 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.467 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.63 168.88 15.02 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.61 130.39 57.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.354 -1.086 . . . . 0.0 109.192 -179.208 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.552 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.05 122.9 20.91 Favored 'General case' 0 C--N 1.29 -1.985 0 O-C-N 121.609 -0.682 . . . . 0.0 109.505 179.543 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.527 ' CD1' ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.69 169.02 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.201 -0.937 . . . . 0.0 109.222 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.521 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -136.39 155.31 50.21 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 109.602 -179.942 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.527 ' CZ ' ' CD1' ' A' ' 110' ' ' ILE . 21.2 m-85 . . . . . 0 N--CA 1.486 1.333 0 O-C-N 121.198 -0.939 . . . . 0.0 109.482 -179.664 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.525 ' CB ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 122.303 1.049 . . . . 0.0 111.134 . . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.524 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.2 p -100.92 104.59 15.79 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 122.478 1.132 . . . . 0.0 109.76 -179.892 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.535 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 5.4 t -119.4 122.92 70.2 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.401 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.574 179.823 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.489 HG21 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -169.52 150.04 3.91 Favored Pre-proline 0 N--CA 1.487 1.413 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 -179.529 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.489 ' HA ' HG21 ' A' ' 8' ' ' THR . 4.4 Cg_endo -76.74 150.71 93.25 Favored 'Cis proline' 0 C--N 1.309 -1.533 0 C-N-CA 123.613 -1.411 . . . . 0.0 109.579 -0.339 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.483 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 89.2 p -92.49 -22.81 19.37 Favored 'General case' 0 C--N 1.292 -1.929 0 O-C-N 121.693 -0.629 . . . . 0.0 109.352 179.799 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.488 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.3 m -132.37 163.97 27.51 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.398 -0.814 . . . . 0.0 109.689 -179.822 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.05 38.88 39.14 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 -179.504 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.635 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 27.7 mt -92.02 -45.21 8.44 Favored 'General case' 0 C--N 1.297 -1.698 0 CA-C-O 123.12 1.438 . . . . 0.0 110.772 -178.09 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.13 146.42 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.349 0 CA-C-N 113.799 -1.546 . . . . 0.0 110.077 -179.615 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.566 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.6 p-10 -50.76 108.32 0.23 Allowed 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 121.542 0.687 . . . . 0.0 111.984 -178.53 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.74 16.54 9.9 Favored Glycine 0 N--CA 1.485 1.907 0 C-N-CA 119.592 -1.289 . . . . 0.0 112.768 177.07 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.635 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 8.8 t -103.45 -174.79 2.63 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 120.965 2.382 . . . . 0.0 109.98 179.426 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.553 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 17.0 t -129.89 138.9 52.91 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 CA-C-N 114.365 -1.288 . . . . 0.0 111.06 -178.799 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.515 HG21 ' CG2' ' A' ' 69' ' ' VAL . 4.1 m -118.53 154.99 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.669 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.535 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 10.2 tttt -105.95 108.99 20.79 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.175 -0.953 . . . . 0.0 109.403 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.531 HG11 ' CD1' ' A' ' 67' ' ' LEU . 2.1 p -107.04 123.38 62.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 179.611 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.531 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -117.51 167.17 11.54 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 120.69 -1.256 . . . . 0.0 109.222 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.6 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.76 140.71 12.03 Favored Glycine 0 C--N 1.295 -1.717 0 N-CA-C 107.49 -2.244 . . . . 0.0 107.49 179.718 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.31 124.1 11.92 Favored 'General case' 0 C--N 1.293 -1.889 0 O-C-N 120.748 -1.442 . . . . 0.0 108.87 179.35 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.36 25.97 26.94 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.226 -1.464 . . . . 0.0 109.913 -179.641 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.1 mt -85.6 175.44 8.77 Favored 'General case' 0 C--N 1.306 -1.321 0 O-C-N 120.891 -1.358 . . . . 0.0 108.263 -179.989 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.556 ' CB ' ' CG2' ' A' ' 30' ' ' THR . 0.0 OUTLIER -46.39 96.71 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.928 -1.108 . . . . 0.0 109.659 -179.72 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.53 76.77 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.758 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.536 -178.996 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.77 33.7 0.33 Allowed Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.253 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.587 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.3 t -149.14 116.07 6.0 Favored 'General case' 0 C--N 1.307 -1.268 0 O-C-N 120.929 -1.336 . . . . 0.0 111.138 179.919 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.543 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.83 127.55 6.4 Favored 'General case' 0 N--CA 1.492 1.653 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.902 178.453 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.587 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.9 m-85 -118.36 149.18 41.63 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.431 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -98.97 159.28 15.07 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.548 -1.345 . . . . 0.0 107.784 178.841 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.623 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.4 p -140.19 119.6 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.189 -0.944 . . . . 0.0 109.633 -177.819 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.466 ' HA2' ' HB2' ' A' ' 51' ' ' ASP . . . -170.72 -179.94 42.33 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 118.274 -1.917 . . . . 0.0 111.794 -179.799 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.556 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -100.83 108.85 20.76 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.783 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.32 148.51 51.25 Favored 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.174 -0.954 . . . . 0.0 109.953 179.887 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.19 138.99 54.51 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.359 -0.838 . . . . 0.0 110.593 -179.046 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.627 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.29 114.63 26.44 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 107.521 -1.289 . . . . 0.0 107.521 178.213 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.463 HG21 ' HB ' ' A' ' 44' ' ' VAL . 17.0 m -104.38 14.81 6.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 O-C-N 121.069 -1.019 . . . . 0.0 110.482 -178.811 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.584 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.74 -175.41 0.08 Allowed 'General case' 0 C--N 1.302 -1.482 0 O-C-N 120.935 -1.103 . . . . 0.0 110.025 179.695 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.6 p -73.54 98.28 2.78 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.413 -0.804 . . . . 0.0 109.506 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.5 27.58 29.56 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.219 -0.991 . . . . 0.0 111.326 179.128 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.584 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -118.72 106.31 19.29 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 O-C-N 120.607 -1.525 . . . . 0.0 107.342 178.999 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.627 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.9 tp -116.61 104.7 11.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.315 -1.491 . . . . 0.0 109.855 -177.815 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.535 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -97.49 109.62 22.34 Favored 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.909 -1.12 . . . . 0.0 108.1 178.885 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.0 t -107.15 165.82 11.08 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.841 -1.162 . . . . 0.0 110.612 -178.632 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.481 ' OD1' ' HB2' ' A' ' 74' ' ' GLU . 55.3 t30 -113.55 132.45 22.53 Favored Pre-proline 0 N--CA 1.501 2.092 0 C-N-CA 120.119 -0.632 . . . . 0.0 109.425 -179.486 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.577 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.8 Cg_endo -72.76 24.31 0.29 Allowed 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 122.205 1.937 . . . . 0.0 112.104 -179.743 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.405 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -99.06 -7.58 26.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.369 -1.457 . . . . 0.0 109.184 179.52 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.542 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 0.7 OUTLIER -133.61 5.8 3.72 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.346 -0.846 . . . . 0.0 108.817 -179.985 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -59.44 80.62 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.87 -178.656 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -108.48 -169.97 1.59 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 178.297 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.472 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.5 134.55 0.08 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.543 -1.348 . . . . 0.0 111.448 -179.405 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.563 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.9 p -146.31 158.92 11.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 177.741 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.543 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.48 146.6 25.08 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.572 -1.33 . . . . 0.0 109.884 -179.564 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.67 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.42 108.73 3.37 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 122.385 1.088 . . . . 0.0 109.674 178.914 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.527 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.1 p-10 -62.42 -138.85 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.862 -179.796 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.72 -51.84 35.76 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.376 -0.828 . . . . 0.0 110.641 -178.771 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -105.11 -32.73 8.55 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 178.553 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.67 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.5 69.78 0.67 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 178.246 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 69.9 m -103.63 130.09 51.01 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 121.268 -1.137 . . . . 0.0 109.337 179.267 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.563 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -135.62 108.69 7.68 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.433 -0.907 . . . . 0.0 109.676 -179.675 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 93.6 p -115.88 116.93 28.84 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 120.956 -1.09 . . . . 0.0 109.364 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.463 HG21 HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.29 141.27 27.15 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.427 -0.796 . . . . 0.0 110.125 -179.868 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.6 p -100.35 137.0 39.36 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.614 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.553 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -137.35 172.22 13.31 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.253 -0.904 . . . . 0.0 109.844 -178.979 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.536 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.2 p -104.72 123.66 48.02 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.089 -1.007 . . . . 0.0 109.908 -179.372 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.542 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 15.5 m -133.04 143.6 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 121.056 -1.027 . . . . 0.0 109.688 -179.606 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.566 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.2 ptt180 -140.78 -167.77 2.43 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.558 -1.339 . . . . 0.0 110.417 179.906 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.577 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 3.3 mtt180 -70.95 -76.61 0.1 Allowed 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -179.623 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.437 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -71.88 137.8 47.74 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 120.153 -1.592 . . . . 0.0 107.547 179.117 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.594 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -159.56 136.96 9.79 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.27 -1.372 . . . . 0.0 110.108 -178.105 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.484 ' O ' ' O ' ' A' ' 47' ' ' CYS . 9.1 mm-40 -34.71 122.54 0.53 Allowed 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.562 0.696 . . . . 0.0 110.571 -178.188 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.535 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -89.38 45.62 3.14 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.577 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 6.6 m-85 -38.41 113.82 0.32 Allowed 'General case' 0 N--CA 1.509 2.477 0 O-C-N 121.194 -1.18 . . . . 0.0 110.167 179.751 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.533 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.4 tp -87.81 125.99 34.76 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 120.913 -1.117 . . . . 0.0 109.477 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -64.26 58.6 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 O-C-N 120.972 -1.08 . . . . 0.0 110.184 179.93 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 6.3 t70 -161.0 20.02 0.13 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.047 -1.033 . . . . 0.0 109.796 179.688 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.68 -27.5 5.29 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.874 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.408 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 8.1 p -94.05 160.99 14.47 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.984 -1.303 . . . . 0.0 110.256 -179.488 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.544 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -108.98 136.63 48.2 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.897 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.482 ' CD1' HD13 ' A' ' 77' ' ' LEU . 1.7 t90 -82.67 -19.1 38.82 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.932 -1.105 . . . . 0.0 110.386 -178.368 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.64 175.2 19.97 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 -179.494 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.29 109.63 1.39 Allowed 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 179.122 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.594 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 39.4 t -81.38 104.38 9.85 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.068 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.453 ' CB ' HG22 ' A' ' 90' ' ' THR . 0.3 OUTLIER -67.42 111.14 3.91 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.433 -0.792 . . . . 0.0 109.888 -179.076 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.546 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.0 t -63.26 -5.9 3.9 Favored 'General case' 0 N--CA 1.499 2.017 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.942 179.48 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.3 p -84.76 -0.08 52.45 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.717 -1.24 . . . . 0.0 109.023 179.407 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.453 HG22 ' CB ' ' A' ' 87' ' ' ASP . 2.6 p -113.41 -49.14 2.91 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.356 -0.84 . . . . 0.0 109.024 -179.969 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.08 -178.03 3.53 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.578 -0.701 . . . . 0.0 109.539 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.11 115.26 29.92 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.466 -0.771 . . . . 0.0 108.982 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.57 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -97.09 125.2 41.4 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.948 -1.095 . . . . 0.0 109.687 -179.174 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.546 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.54 146.44 28.89 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 122.421 1.105 . . . . 0.0 111.191 -179.524 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.485 ' CG1' HG12 ' A' ' 7' ' ' VAL . 96.2 t -102.68 111.09 31.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 177.775 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.453 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.78 -171.2 18.72 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 117.97 -2.062 . . . . 0.0 111.808 -177.684 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.481 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -113.95 -177.59 3.17 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -179.075 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.465 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.299 -1.617 0 O-C-N 121.229 -0.92 . . . . 0.0 109.531 -179.378 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.699 0 N-CA-C 107.786 -2.126 . . . . 0.0 107.786 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.55 -177.67 6.09 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.534 -0.98 . . . . 0.0 109.91 179.328 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.86 -160.97 12.89 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.415 -1.874 . . . . 0.0 108.415 -179.395 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.7 Cg_exo -47.87 -178.95 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.813 1.306 . . . . 0.0 110.474 179.367 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -94.59 -179.51 4.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.068 -1.02 . . . . 0.0 110.448 -178.903 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.453 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.84 162.49 12.71 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 -179.972 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.8 129.67 50.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.397 -1.06 . . . . 0.0 109.095 -179.501 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.546 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.35 121.82 21.06 Favored 'General case' 0 C--N 1.289 -2.041 0 O-C-N 121.626 -0.671 . . . . 0.0 109.892 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.574 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.83 171.37 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.242 -0.911 . . . . 0.0 108.982 179.658 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.488 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -138.6 159.33 42.36 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.156 -0.965 . . . . 0.0 109.669 -179.845 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.577 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 79.7 m-85 . . . . . 0 N--CA 1.485 1.323 0 O-C-N 121.25 -0.907 . . . . 0.0 109.63 -179.785 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.48 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.414 0 CA-C-O 122.32 1.057 . . . . 0.0 110.778 . . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.547 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.4 t -112.82 108.71 17.79 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-O 123.108 1.432 . . . . 0.0 109.175 179.394 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 3.2 t -115.93 139.04 44.39 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.728 0 CA-C-N 114.169 -1.378 . . . . 0.0 110.088 -179.67 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.523 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -177.0 150.32 0.88 Allowed Pre-proline 0 N--CA 1.486 1.35 0 O-C-N 121.309 -0.87 . . . . 0.0 108.766 -179.673 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.523 ' CA ' HG23 ' A' ' 8' ' ' THR . 5.9 Cg_endo -78.49 150.43 87.7 Favored 'Cis proline' 0 C--N 1.312 -1.364 0 C-N-CA 123.531 -1.445 . . . . 0.0 109.334 -0.921 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.488 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 94.1 p -93.65 -22.13 18.96 Favored 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.52 -0.738 . . . . 0.0 109.558 179.821 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.469 ' HA ' ' O ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -132.2 162.62 30.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.805 -179.798 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.15 39.03 38.21 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 -179.508 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.614 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 31.8 mt -91.38 -44.58 9.06 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-O 123.093 1.425 . . . . 0.0 110.771 -178.272 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.483 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.0 OUTLIER 64.37 146.42 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.332 0 CA-C-N 113.735 -1.575 . . . . 0.0 109.63 -179.42 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.578 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.7 p-10 -52.32 110.1 0.46 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.486 0.66 . . . . 0.0 111.554 -178.523 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.71 9.76 13.75 Favored Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.301 -1.428 . . . . 0.0 112.854 177.375 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.614 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 9.8 t -101.32 -172.52 2.18 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 121.029 2.415 . . . . 0.0 109.747 179.502 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 11.2 t -134.63 141.32 43.64 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.612 -179.334 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.514 HG22 ' CG2' ' A' ' 69' ' ' VAL . 27.8 m -116.55 154.8 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.214 -0.929 . . . . 0.0 109.057 179.471 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.477 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 21.8 tttt -107.95 108.97 20.34 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.238 -0.914 . . . . 0.0 109.049 179.793 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.522 HG11 ' CG2' ' A' ' 34' ' ' VAL . 1.8 p -101.03 139.11 23.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.555 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.562 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -134.45 160.46 37.92 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 118.461 -1.296 . . . . 0.0 110.027 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.6 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.94 144.07 15.52 Favored Glycine 0 C--N 1.294 -1.758 0 N-CA-C 107.755 -2.138 . . . . 0.0 107.755 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.45 124.5 12.09 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 120.799 -1.412 . . . . 0.0 108.953 179.222 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.15 26.52 23.58 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 119.272 -1.442 . . . . 0.0 109.703 -179.702 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.553 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -89.22 170.56 10.49 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 120.857 -1.378 . . . . 0.0 108.479 179.989 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.09 100.69 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.051 -1.031 . . . . 0.0 109.988 -179.574 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.7 77.98 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.004 -179.509 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.85 34.05 0.27 Allowed Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 179.702 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 20.8 p -139.18 105.88 5.37 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.198 -1.178 . . . . 0.0 111.255 -179.485 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.569 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -52.32 114.19 1.27 Allowed 'General case' 0 N--CA 1.495 1.814 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.611 178.098 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.478 ' HA ' ' O ' ' A' ' 98' ' ' SER . 8.2 m-30 -110.67 160.06 17.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.143 -0.973 . . . . 0.0 108.949 179.834 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.507 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -100.62 168.28 9.8 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 178.93 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.627 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.8 p -150.36 117.13 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.023 -1.048 . . . . 0.0 109.827 -178.221 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.489 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.85 -175.93 39.21 Favored Glycine 0 N--CA 1.495 2.605 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.821 -179.765 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.571 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -99.33 108.44 20.97 Favored 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.811 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.0 m -132.21 148.45 52.46 Favored 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.296 -0.878 . . . . 0.0 109.784 179.657 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.2 140.25 53.02 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.241 -0.912 . . . . 0.0 110.727 -179.136 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.619 ' CE2' HD11 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.16 114.78 26.61 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.211 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.3 m -104.16 14.49 6.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.052 -1.03 . . . . 0.0 110.5 -178.798 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.93 -175.26 0.08 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.897 -1.127 . . . . 0.0 110.087 179.769 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.25 98.45 2.65 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.425 -0.797 . . . . 0.0 109.535 -179.917 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.98 27.51 31.2 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 120.244 -0.979 . . . . 0.0 111.421 179.072 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.591 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -118.01 106.33 19.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 O-C-N 120.618 -1.519 . . . . 0.0 107.303 178.846 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.619 HD11 ' CE2' ' A' ' 39' ' ' TRP . 13.4 tp -117.65 104.67 11.25 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.523 -1.36 . . . . 0.0 109.58 -177.843 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.03 109.54 22.27 Favored 'General case' 0 N--CA 1.485 1.281 0 O-C-N 120.828 -1.17 . . . . 0.0 108.251 179.068 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -107.61 166.85 10.37 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.023 -1.048 . . . . 0.0 109.989 -179.17 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.531 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 11.0 t-20 -107.3 137.33 19.58 Favored Pre-proline 0 N--CA 1.502 2.148 0 O-C-N 121.231 -0.918 . . . . 0.0 109.846 -179.286 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.574 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.6 Cg_endo -75.15 24.49 0.39 Allowed 'Trans proline' 0 C--N 1.318 -1.04 0 C-N-CA 122.383 2.056 . . . . 0.0 111.786 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.531 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -120.27 4.09 10.81 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.351 -1.468 . . . . 0.0 109.195 179.75 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.543 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.84 19.96 2.85 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 179.278 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -84.14 87.81 7.17 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.929 -0.708 . . . . 0.0 110.858 -178.618 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -107.91 -168.25 1.35 Allowed 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.436 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.472 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.92 136.22 0.09 Allowed 'General case' 0 C--N 1.305 -1.326 0 O-C-N 120.755 -1.216 . . . . 0.0 111.082 -179.401 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.577 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -151.73 157.7 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 178.391 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.569 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.91 142.26 30.64 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.835 -1.166 . . . . 0.0 110.027 -179.786 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.693 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -62.89 107.76 1.05 Allowed 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 122.441 1.115 . . . . 0.0 109.288 178.083 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.525 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.1 t0 -62.94 -138.68 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.777 179.937 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.531 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.37 -52.7 34.93 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.402 -0.811 . . . . 0.0 110.924 -178.615 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.85 -33.07 9.94 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 178.612 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.693 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.19 62.26 0.55 Allowed Glycine 0 C--N 1.296 -1.664 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 178.051 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 82.5 p -98.72 129.91 45.19 Favored 'General case' 0 C--N 1.309 -1.155 0 O-C-N 121.563 -0.963 . . . . 0.0 108.731 178.713 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.29 108.89 6.97 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.203 -0.999 . . . . 0.0 109.727 -179.343 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -122.35 119.2 30.37 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.191 -0.943 . . . . 0.0 109.533 -179.941 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.451 HG23 HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.66 142.98 30.51 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.491 -0.756 . . . . 0.0 109.329 179.876 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 27.7 p -98.82 138.09 36.46 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.416 -0.802 . . . . 0.0 109.58 -179.853 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.543 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -140.83 159.41 42.27 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.329 -0.857 . . . . 0.0 109.48 -179.502 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 13.0 t -87.91 139.14 30.82 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.147 -0.97 . . . . 0.0 110.657 -179.411 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.535 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 19.4 m -148.73 144.31 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.484 -0.76 . . . . 0.0 109.249 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.578 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.9 OUTLIER -150.72 -173.69 4.55 Favored 'General case' 0 N--CA 1.484 1.245 0 O-C-N 120.456 -1.403 . . . . 0.0 111.178 -179.641 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.701 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.28 -104.8 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.281 -179.644 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -59.43 140.23 56.37 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 120.695 -1.253 . . . . 0.0 108.072 178.948 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.609 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -158.29 138.69 12.61 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.773 -1.171 . . . . 0.0 109.713 -178.312 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.472 ' C ' ' O ' ' A' ' 73' ' ' PHE . 8.8 mm-40 -34.89 120.35 0.5 Allowed 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.539 0.685 . . . . 0.0 110.552 -178.448 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -89.96 47.91 3.2 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.415 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.574 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -38.47 113.65 0.31 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 121.241 -1.153 . . . . 0.0 110.166 179.812 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.533 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.9 tp -86.66 126.26 34.41 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.997 -1.065 . . . . 0.0 109.456 -179.982 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -64.23 58.48 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.906 -1.121 . . . . 0.0 109.949 179.541 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 9.8 t70 -158.74 18.77 0.2 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.976 -1.078 . . . . 0.0 109.645 -179.979 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.18 -26.41 6.23 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.761 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.83 163.64 12.71 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 120.99 -1.3 . . . . 0.0 110.404 -179.332 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.471 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 4.2 ptt180 -106.24 136.79 45.34 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.914 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.528 ' CD1' HD13 ' A' ' 77' ' ' LEU . 4.7 t90 -82.58 -19.6 38.15 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.79 -1.194 . . . . 0.0 110.241 -178.709 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.64 173.43 16.86 Favored Glycine 0 N--CA 1.486 2.019 0 N-CA-C 108.791 -1.723 . . . . 0.0 108.791 -179.636 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -65.14 106.1 1.22 Allowed 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 179.105 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.596 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 46.2 t -76.51 107.34 7.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.371 -0.831 . . . . 0.0 109.533 -178.694 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.482 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.9 m-20 -63.92 111.99 2.73 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.213 -0.929 . . . . 0.0 109.178 -179.919 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.701 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.2 m -65.41 -4.66 5.96 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 120.704 -1.247 . . . . 0.0 109.829 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.2 p -93.27 1.95 56.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.731 -1.23 . . . . 0.0 109.58 179.956 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.482 HG23 ' HB3' ' A' ' 87' ' ' ASP . 5.0 p -112.51 -52.79 2.76 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.241 -0.912 . . . . 0.0 108.636 179.78 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.421 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -98.47 178.77 4.92 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.492 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.07 114.0 27.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -0.89 . . . . 0.0 108.777 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.482 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.8 m -96.44 121.8 38.64 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.982 -1.074 . . . . 0.0 109.758 -178.989 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.528 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -106.2 144.28 33.12 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-O 122.355 1.074 . . . . 0.0 111.112 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.418 ' CG1' HG13 ' A' ' 7' ' ' VAL . 90.5 t -101.87 109.58 26.44 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.086 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.741 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.441 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.12 -172.01 17.65 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 118.223 -1.941 . . . . 0.0 111.741 -177.591 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.491 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -112.01 178.8 4.19 Favored 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.289 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.507 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.9 OUTLIER . . . . . 0 C--N 1.294 -1.805 0 O-C-N 121.571 -0.706 . . . . 0.0 109.424 -179.546 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.717 0 N-CA-C 107.559 -2.216 . . . . 0.0 107.559 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.75 -178.23 7.1 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.574 -0.956 . . . . 0.0 109.777 179.23 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.44 -161.9 14.4 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.488 -1.845 . . . . 0.0 108.488 -179.394 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.479 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -47.24 178.25 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.626 0 CA-C-N 118.812 1.306 . . . . 0.0 110.342 179.329 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -91.37 -174.35 3.9 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.097 -1.002 . . . . 0.0 110.401 -178.893 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.441 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.99 166.8 15.29 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.7 130.15 51.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.43 -1.041 . . . . 0.0 109.1 -179.429 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.528 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.71 125.12 28.04 Favored 'General case' 0 C--N 1.289 -2.049 0 O-C-N 121.641 -0.662 . . . . 0.0 109.606 179.782 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.488 ' CB ' ' O ' ' A' ' 10' ' ' SER . 1.5 pt -97.84 169.98 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.274 -0.891 . . . . 0.0 109.257 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.469 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -137.88 155.77 48.6 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.276 -0.89 . . . . 0.0 109.504 179.992 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.569 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 76.5 m-85 . . . . . 0 N--CA 1.487 1.398 0 O-C-N 121.11 -0.994 . . . . 0.0 109.51 -179.808 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.224 0 CA-C-O 122.465 1.126 . . . . 0.0 110.031 . . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.546 ' CG2' ' O ' ' A' ' 6' ' ' THR . 5.9 t -114.88 109.1 17.64 Favored 'General case' 0 C--N 1.294 -1.822 0 CA-C-O 123.2 1.476 . . . . 0.0 109.765 -179.807 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.527 HG11 ' CG1' ' A' ' 95' ' ' VAL . 3.1 t -116.27 136.98 51.49 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.638 0 CA-C-N 114.176 -1.374 . . . . 0.0 109.716 179.902 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.524 HG22 ' CA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -172.96 151.25 2.13 Favored Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 121.235 -0.915 . . . . 0.0 108.791 -179.534 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.524 ' CA ' HG22 ' A' ' 8' ' ' THR . 5.2 Cg_endo -77.53 151.67 92.52 Favored 'Cis proline' 0 C--N 1.311 -1.422 0 C-N-CA 123.517 -1.451 . . . . 0.0 109.433 -0.819 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.459 ' HA ' HG21 ' A' ' 110' ' ' ILE . 88.1 p -93.94 -23.2 18.16 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.576 -0.703 . . . . 0.0 109.505 179.805 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.491 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 3.0 m -130.94 160.1 35.51 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.321 -0.862 . . . . 0.0 109.96 -179.65 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.23 37.25 32.57 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 108.611 -1.796 . . . . 0.0 108.611 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.636 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 27.1 mt -90.83 -45.42 8.81 Favored 'General case' 0 C--N 1.299 -1.627 0 CA-C-O 123.113 1.435 . . . . 0.0 110.751 -178.411 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 64.03 147.23 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.311 0 CA-C-N 113.748 -1.569 . . . . 0.0 109.963 -179.612 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.595 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.4 p-10 -51.41 108.9 0.29 Allowed 'General case' 0 C--N 1.302 -1.47 0 CA-C-O 121.725 0.774 . . . . 0.0 111.809 -178.568 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.8 13.66 11.04 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 119.479 -1.343 . . . . 0.0 112.914 177.311 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.636 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 10.2 t -101.8 -174.34 2.57 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 121.059 2.43 . . . . 0.0 109.86 179.457 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.542 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 21.1 t -127.83 138.3 55.13 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.885 -178.994 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.527 HG13 ' CG2' ' A' ' 69' ' ' VAL . 30.8 m -117.34 154.17 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.877 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -109.98 109.34 19.89 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.187 -0.946 . . . . 0.0 109.195 -179.846 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 p -101.96 140.44 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.747 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.563 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -134.33 158.31 44.12 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.838 -1.164 . . . . 0.0 109.701 179.568 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.613 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -139.36 108.81 0.61 Allowed Glycine 0 N--CA 1.481 1.675 0 N-CA-C 108.658 -1.777 . . . . 0.0 108.658 179.888 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.54 139.52 50.4 Favored 'General case' 0 N--CA 1.502 2.14 0 CA-C-N 119.402 1.601 . . . . 0.0 110.564 -179.25 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.21 27.81 32.47 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.058 -1.544 . . . . 0.0 109.938 179.569 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.533 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.7 OUTLIER -93.67 170.53 9.51 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.97 -1.312 . . . . 0.0 108.522 -179.92 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.555 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.43 101.23 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.097 -1.002 . . . . 0.0 109.827 -179.566 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.54 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.42 77.93 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.705 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.888 -179.342 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.5 33.46 0.27 Allowed Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 179.896 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.564 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 12.9 p -136.96 104.75 5.55 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 121.2 -1.176 . . . . 0.0 111.057 -179.349 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.566 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -51.54 110.03 0.41 Allowed 'General case' 0 N--CA 1.497 1.914 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.621 178.087 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.564 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 38.5 m-85 -106.33 156.35 18.59 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.052 -1.03 . . . . 0.0 108.992 179.87 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.406 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.25 160.14 14.57 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.631 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.626 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.2 p -140.75 119.66 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.095 -1.003 . . . . 0.0 109.62 -177.836 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.467 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.88 -178.8 41.15 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.536 -1.792 . . . . 0.0 111.525 -179.782 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.571 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 1.1 pt20 -100.99 109.08 20.95 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.756 0.788 . . . . 0.0 108.954 -179.904 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.81 150.26 52.07 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.079 -1.013 . . . . 0.0 110.406 179.978 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.92 139.38 53.88 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.373 -0.829 . . . . 0.0 110.661 -179.054 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.62 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.3 115.02 26.87 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 178.114 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -105.92 15.44 7.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.013 -1.055 . . . . 0.0 110.605 -178.889 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.594 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.6 -176.33 0.09 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.831 -1.168 . . . . 0.0 110.147 179.759 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.55 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.2 t -70.13 97.32 1.18 Allowed 'General case' 0 N--CA 1.487 1.419 0 CA-C-O 121.791 0.805 . . . . 0.0 109.949 -179.553 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.2 28.35 37.18 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.158 -1.02 . . . . 0.0 111.349 178.957 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.594 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 2.0 t -115.61 106.46 20.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 120.625 -1.515 . . . . 0.0 107.193 178.778 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.62 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.3 tp -116.4 104.75 11.77 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.428 -1.42 . . . . 0.0 109.847 -177.612 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.524 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -97.96 109.24 22.03 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 120.763 -1.211 . . . . 0.0 107.847 178.682 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -104.17 170.0 8.16 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.933 -1.104 . . . . 0.0 110.151 -178.863 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.51 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 36.9 t30 -108.24 134.67 20.1 Favored Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.346 -0.846 . . . . 0.0 109.631 -179.376 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.583 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.1 Cg_endo -74.5 25.27 0.36 Allowed 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 122.259 1.972 . . . . 0.0 111.608 -179.962 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.51 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -120.12 2.54 10.92 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.473 -1.392 . . . . 0.0 109.307 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.526 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 5.7 m-20 -137.09 18.67 2.99 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 179.744 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -81.13 88.52 5.99 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.617 -0.833 . . . . 0.0 110.62 -178.702 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -109.43 -166.22 1.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 178.66 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.469 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.77 136.02 0.09 Allowed 'General case' 0 N--CA 1.485 1.316 0 O-C-N 120.708 -1.245 . . . . 0.0 111.07 -179.215 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.587 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.84 155.92 5.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.421 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.566 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.73 141.34 31.66 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.87 -1.144 . . . . 0.0 109.94 -179.737 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.667 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -61.76 106.18 0.65 Allowed 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 122.471 1.129 . . . . 0.0 109.379 178.331 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.535 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.2 p-10 -59.46 -140.06 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.043 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.947 179.895 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.54 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.37 -50.42 59.58 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.488 -0.758 . . . . 0.0 110.752 -178.756 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -103.65 -33.35 9.0 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 106.16 -1.792 . . . . 0.0 106.16 178.518 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.667 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 106.4 66.3 0.65 Allowed Glycine 0 C--N 1.298 -1.545 0 CA-C-N 114.897 -1.047 . . . . 0.0 110.514 177.993 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.613 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 20.0 m -103.68 125.43 50.17 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 178.657 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.587 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -135.9 109.27 7.86 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.349 -179.379 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.7 m -126.21 122.16 34.82 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.366 -0.834 . . . . 0.0 109.674 -179.717 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.453 HG21 HG12 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -143.91 141.8 30.45 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.634 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.3 p -98.55 131.63 44.62 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.192 -0.942 . . . . 0.0 109.493 -179.8 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.566 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -131.49 178.46 6.71 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.487 -0.758 . . . . 0.0 109.299 -179.387 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.5 p -102.22 123.52 46.2 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.898 -1.126 . . . . 0.0 109.739 -179.416 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.53 ' CG2' HD12 ' A' ' 13' ' ' LEU . 15.5 m -128.59 142.32 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 120.934 -1.104 . . . . 0.0 110.062 -179.389 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.595 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.5 ptt180 -148.4 -176.76 5.43 Favored 'General case' 0 N--CA 1.484 1.248 0 O-C-N 120.521 -1.362 . . . . 0.0 110.91 179.669 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.557 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.1 OUTLIER -60.56 -102.33 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.189 -179.109 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.467 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -60.09 138.12 57.95 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.443 -1.411 . . . . 0.0 107.979 179.773 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.531 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 2.4 p90 -161.72 147.33 13.57 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 118.555 -1.258 . . . . 0.0 110.033 -178.377 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.488 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 1.8 mp0 -37.68 120.44 0.82 Allowed 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 121.504 0.669 . . . . 0.0 110.516 -178.674 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.524 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -90.54 49.49 3.17 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.599 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.583 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.9 m-30 -38.07 114.45 0.36 Allowed 'General case' 0 N--CA 1.511 2.582 0 O-C-N 121.194 -1.18 . . . . 0.0 110.545 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.531 HD11 ' CD1' ' A' ' 83' ' ' TRP . 8.0 tp -87.62 127.01 35.28 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.843 -1.161 . . . . 0.0 109.546 179.78 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.6 t80 -64.36 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.872 -1.142 . . . . 0.0 109.993 179.667 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.8 t70 -159.46 19.01 0.18 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.047 -1.033 . . . . 0.0 109.72 179.893 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.89 -26.34 6.1 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.747 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 35.2 p -96.45 163.32 13.1 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 121.037 -1.273 . . . . 0.0 110.407 -179.414 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.4 136.28 46.42 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.913 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.531 ' CD1' HD11 ' A' ' 77' ' ' LEU . 4.9 t90 -82.42 -18.56 41.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.781 -1.199 . . . . 0.0 110.318 -178.757 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.83 173.36 17.85 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 -179.587 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.79 109.3 1.68 Allowed 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 179.203 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.481 HG22 ' HB1' ' A' ' 46' ' ' ALA . 50.4 t -80.06 105.23 9.37 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 121.43 -0.794 . . . . 0.0 109.349 -178.782 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.467 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.9 OUTLIER -66.14 109.69 2.7 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.661 -0.649 . . . . 0.0 109.965 -179.529 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.557 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 3.0 t -62.09 -4.41 1.67 Allowed 'General case' 0 N--CA 1.501 2.107 0 C-N-CA 118.165 -1.414 . . . . 0.0 110.162 179.348 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.0 p -90.08 3.54 53.0 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.627 -1.296 . . . . 0.0 109.306 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.466 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -116.32 -49.88 2.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.298 -0.876 . . . . 0.0 109.127 -179.899 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.9 179.37 4.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.429 -0.795 . . . . 0.0 109.46 179.969 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.42 113.6 26.85 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.286 -0.884 . . . . 0.0 108.725 179.737 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.472 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -97.16 121.41 39.02 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.929 -1.107 . . . . 0.0 109.542 -178.922 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.54 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.43 148.58 26.27 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 122.44 1.114 . . . . 0.0 111.452 -179.249 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.527 ' CG1' HG11 ' A' ' 7' ' ' VAL . 28.8 t -104.95 109.5 27.86 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.449 -1.686 . . . . 0.0 106.449 177.249 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.438 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.8 -169.53 16.77 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 118.305 -1.902 . . . . 0.0 111.691 -177.366 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.471 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -120.77 177.13 5.2 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -178.958 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.471 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 7.8 t . . . . . 0 C--N 1.292 -1.933 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 179.917 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.693 0 N-CA-C 107.857 -2.097 . . . . 0.0 107.857 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.95 -177.35 5.03 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.576 -0.955 . . . . 0.0 109.992 179.359 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.13 -161.24 20.28 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 108.074 -2.01 . . . . 0.0 108.074 -179.411 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.479 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.4 Cg_exo -47.01 176.43 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.66 0 CA-C-N 118.956 1.378 . . . . 0.0 110.061 179.297 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -95.28 178.62 5.46 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.029 -1.045 . . . . 0.0 110.725 -178.58 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.438 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.23 170.34 13.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -107.32 133.22 52.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.348 -1.089 . . . . 0.0 109.187 -179.273 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.54 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.65 124.37 26.59 Favored 'General case' 0 C--N 1.29 -2.013 0 O-C-N 121.508 -0.745 . . . . 0.0 109.704 179.709 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.563 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.7 pt -97.95 171.0 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.283 -0.886 . . . . 0.0 108.91 179.816 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.491 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 24.3 m -139.15 156.74 46.91 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.054 -1.029 . . . . 0.0 109.872 -179.794 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.563 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 45.2 m-85 . . . . . 0 N--CA 1.486 1.352 0 O-C-N 121.226 -0.921 . . . . 0.0 109.465 -179.669 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.478 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.457 0 CA-C-O 122.335 1.064 . . . . 0.0 110.768 . . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.541 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.7 t -110.87 108.9 18.85 Favored 'General case' 0 C--N 1.297 -1.7 0 CA-C-O 123.109 1.433 . . . . 0.0 109.066 179.357 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.503 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 2.6 t -118.28 139.72 44.44 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.699 0 CA-C-N 114.223 -1.353 . . . . 0.0 110.121 -179.741 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.484 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -179.07 150.88 0.64 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.239 -0.913 . . . . 0.0 108.764 -179.685 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.484 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.7 Cg_endo -77.47 151.72 92.77 Favored 'Cis proline' 0 C--N 1.313 -1.314 0 C-N-CA 123.555 -1.435 . . . . 0.0 109.332 -0.838 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.487 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 59.2 p -92.49 -23.29 19.16 Favored 'General case' 0 C--N 1.291 -1.968 0 O-C-N 121.567 -0.708 . . . . 0.0 109.664 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.464 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 23.9 p -133.26 159.14 41.09 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.197 -0.939 . . . . 0.0 110.124 -179.493 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.79 37.1 23.83 Favored Glycine 0 N--CA 1.497 2.706 0 N-CA-C 108.917 -1.673 . . . . 0.0 108.917 -179.859 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.601 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 39.0 mt -93.34 -44.57 8.23 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.162 1.458 . . . . 0.0 110.44 -178.54 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.456 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.8 OUTLIER 64.3 146.8 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.273 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.17 -179.829 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.531 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 12.7 p-10 -51.51 104.92 0.09 Allowed 'General case' 0 C--N 1.305 -1.353 0 CA-C-O 121.675 0.75 . . . . 0.0 111.04 -179.072 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.81 7.47 6.68 Favored Glycine 0 N--CA 1.484 1.848 0 C-N-CA 119.13 -1.509 . . . . 0.0 113.296 177.52 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.601 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.2 t -107.13 -177.03 3.24 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 121.444 2.622 . . . . 0.0 110.133 179.605 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.544 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 25.4 t -126.26 135.75 62.86 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.452 0 CA-C-N 114.249 -1.341 . . . . 0.0 111.073 -178.717 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.595 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 10.4 m -110.56 156.53 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.734 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.503 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.6 tttt -109.15 108.88 19.71 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.095 -1.003 . . . . 0.0 108.968 179.84 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.504 HG13 ' CG2' ' A' ' 34' ' ' VAL . 2.1 p -103.75 141.13 20.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.668 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.535 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -139.24 160.6 39.44 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 118.539 -1.265 . . . . 0.0 110.2 179.901 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.58 143.49 14.64 Favored Glycine 0 C--N 1.295 -1.731 0 N-CA-C 107.89 -2.084 . . . . 0.0 107.89 179.448 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -145.45 126.22 14.35 Favored 'General case' 0 C--N 1.295 -1.765 0 O-C-N 120.783 -1.422 . . . . 0.0 108.977 179.276 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.2 26.52 25.74 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 119.319 -1.419 . . . . 0.0 109.737 -179.744 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.546 ' HB2' ' HB1' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -89.43 169.78 11.09 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.81 -1.406 . . . . 0.0 108.392 179.861 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.557 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.95 100.98 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.039 -1.038 . . . . 0.0 110.076 -179.526 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.69 78.56 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.867 -179.529 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.41 33.9 0.3 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 179.778 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.569 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 17.2 p -138.6 105.03 5.28 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.259 -1.141 . . . . 0.0 111.146 -179.43 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.36 110.6 0.42 Allowed 'General case' 0 N--CA 1.497 1.905 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.701 178.169 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.569 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 35.5 m-85 -105.91 157.31 17.58 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.154 -0.966 . . . . 0.0 108.923 179.718 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.467 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -102.31 162.16 13.14 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.935 -1.103 . . . . 0.0 108.132 179.035 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.631 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.9 p -141.8 118.89 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.196 -0.94 . . . . 0.0 109.559 -178.186 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -166.41 -179.08 39.52 Favored Glycine 0 N--CA 1.493 2.481 0 C-N-CA 118.386 -1.864 . . . . 0.0 111.647 -179.693 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.553 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -101.38 109.01 20.77 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 179.978 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.448 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.51 148.76 52.35 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 121.164 -0.96 . . . . 0.0 109.959 179.925 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.65 138.66 54.5 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.409 -0.807 . . . . 0.0 110.656 -179.146 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.625 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.21 114.78 26.61 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 178.154 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.445 HG21 ' HB ' ' A' ' 44' ' ' VAL . 17.6 m -104.8 14.86 6.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.997 -1.065 . . . . 0.0 110.537 -178.789 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.589 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.87 -175.19 0.08 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.968 -1.083 . . . . 0.0 109.979 179.625 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 71.4 p -72.72 98.03 2.3 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.474 -0.766 . . . . 0.0 109.519 -179.704 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.57 27.65 31.92 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 120.225 -0.988 . . . . 0.0 111.413 178.943 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.589 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.25 106.18 19.59 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.653 -1.498 . . . . 0.0 107.258 178.942 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.625 HD12 ' CD1' ' A' ' 39' ' ' TRP . 12.9 tp -117.26 104.59 11.32 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.504 -1.373 . . . . 0.0 109.831 -177.771 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.531 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.7 109.3 22.08 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.641 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.17 167.11 10.13 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.941 -1.099 . . . . 0.0 110.685 -178.588 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.484 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 10.8 t-20 -115.07 129.5 25.01 Favored Pre-proline 0 N--CA 1.498 1.939 0 O-C-N 121.606 -0.684 . . . . 0.0 109.498 -179.334 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.581 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -71.8 22.38 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.081 0 C-N-CA 122.052 1.835 . . . . 0.0 111.852 179.437 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.04 -5.9 29.49 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.404 -1.435 . . . . 0.0 109.15 179.61 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.551 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 1.6 m-20 -136.4 11.44 3.24 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.861 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -67.47 86.76 0.19 Allowed 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.48 -0.763 . . . . 0.0 110.649 -178.715 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.631 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -107.89 -165.97 1.1 Allowed 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 178.576 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.476 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.73 135.89 0.09 Allowed 'General case' 0 C--N 1.306 -1.305 0 O-C-N 120.642 -1.286 . . . . 0.0 111.147 -179.334 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.587 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -151.82 156.53 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 178.168 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.38 142.58 29.83 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.773 -1.205 . . . . 0.0 110.082 -179.676 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.69 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -62.36 107.08 0.85 Allowed 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 122.446 1.117 . . . . 0.0 109.403 178.079 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.524 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 17.2 p-10 -61.14 -138.93 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.026 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.986 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.77 -51.19 52.87 Favored 'General case' 0 N--CA 1.5 2.075 0 O-C-N 121.379 -0.826 . . . . 0.0 110.845 -178.536 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -103.79 -33.29 8.96 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.167 -1.79 . . . . 0.0 106.167 178.488 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.69 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.95 63.88 0.55 Allowed Glycine 0 C--N 1.298 -1.58 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 178.102 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 43.2 m -102.38 126.96 49.56 Favored 'General case' 0 C--N 1.31 -1.148 0 O-C-N 121.479 -1.012 . . . . 0.0 108.731 178.732 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.587 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.28 109.04 7.52 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 119.411 -0.915 . . . . 0.0 109.53 -179.387 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.458 ' OG ' ' HB2' ' A' ' 22' ' ' ALA . 1.5 m -123.81 121.44 35.41 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 121.242 -0.911 . . . . 0.0 109.614 -179.768 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.58 146.54 31.42 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.558 -0.714 . . . . 0.0 109.305 179.854 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.5 p -98.83 141.15 31.98 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.351 -0.843 . . . . 0.0 109.472 -179.909 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.544 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -140.83 170.33 15.95 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.405 -0.809 . . . . 0.0 109.304 -179.206 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.523 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.5 p -101.87 124.94 48.34 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 120.878 -1.139 . . . . 0.0 110.157 -179.099 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.551 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 11.8 m -128.54 139.34 52.15 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 120.996 -1.065 . . . . 0.0 110.343 -179.601 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.531 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 56.3 mtt180 -127.11 -168.84 1.94 Allowed 'General case' 0 N--CA 1.483 1.222 0 O-C-N 120.576 -1.327 . . . . 0.0 111.156 179.673 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.567 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 1.8 mtt180 -79.08 -76.02 0.22 Allowed 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 179.001 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -73.66 135.52 43.75 Favored 'General case' 0 N--CA 1.486 1.349 0 N-CA-C 106.452 -1.684 . . . . 0.0 106.452 177.774 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.59 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -156.79 139.13 14.76 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 117.637 -1.625 . . . . 0.0 110.925 -177.331 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.9 mm-40 -37.19 118.93 0.65 Allowed 'General case' 0 N--CA 1.489 1.513 0 CA-C-O 121.408 0.623 . . . . 0.0 110.09 -178.943 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -89.78 50.13 3.43 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.175 -179.242 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.581 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-30 -38.69 113.88 0.34 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.136 -1.214 . . . . 0.0 110.073 179.514 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.537 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.0 tp -85.92 126.66 34.25 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 120.981 -1.074 . . . . 0.0 109.526 -179.885 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 29.4 t80 -63.72 58.54 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.026 0 O-C-N 120.91 -1.119 . . . . 0.0 110.142 179.608 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.59 19.5 0.14 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.036 -1.04 . . . . 0.0 109.748 179.84 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.78 -27.03 5.55 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 110.111 -1.195 . . . . 0.0 110.111 179.842 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.24 161.82 13.94 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 121.033 -1.274 . . . . 0.0 110.335 -179.499 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -107.67 136.85 46.73 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.917 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.469 ' HB2' HD12 ' A' ' 77' ' ' LEU . 3.5 t90 -82.21 -19.07 40.52 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.755 -1.216 . . . . 0.0 110.311 -178.759 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.93 173.93 19.01 Favored Glycine 0 N--CA 1.486 1.969 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.581 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.65 109.65 1.47 Allowed 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 179.202 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.59 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 40.5 t -81.92 105.12 11.43 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 O-C-N 121.354 -0.841 . . . . 0.0 108.916 -179.092 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.528 ' CB ' HG21 ' A' ' 90' ' ' THR . 0.1 OUTLIER -65.45 110.69 2.76 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.45 -0.781 . . . . 0.0 110.006 -179.1 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.565 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.6 t -64.19 -5.28 4.63 Favored 'General case' 0 N--CA 1.5 2.035 0 C-N-CA 118.452 -1.299 . . . . 0.0 109.791 179.38 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.1 p -86.88 0.6 54.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.742 -1.224 . . . . 0.0 108.961 179.427 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.528 HG21 ' CB ' ' A' ' 87' ' ' ASP . 2.5 p -114.88 -50.96 2.75 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.292 -0.88 . . . . 0.0 109.02 179.825 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -102.84 -178.99 3.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.566 -0.709 . . . . 0.0 109.394 179.84 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.5 115.32 30.05 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.312 -0.867 . . . . 0.0 109.023 179.923 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.492 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.7 m -97.11 121.91 39.52 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.998 -1.064 . . . . 0.0 109.396 -179.353 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.562 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.92 144.93 29.93 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 122.397 1.094 . . . . 0.0 111.199 -179.365 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 96.4 t -102.49 110.16 28.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 177.701 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.438 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.3 -169.91 16.92 Favored Glycine 0 N--CA 1.486 2.006 0 C-N-CA 118.071 -2.014 . . . . 0.0 111.833 -177.536 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -112.91 179.88 3.84 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -179.116 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 p . . . . . 0 C--N 1.296 -1.74 0 O-C-N 121.456 -0.777 . . . . 0.0 109.58 -179.301 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.706 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.19 -177.46 5.4 Favored 'General case' 0 C--N 1.308 -1.219 0 O-C-N 121.518 -0.989 . . . . 0.0 109.789 179.26 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.61 -162.88 19.22 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 108.27 -1.932 . . . . 0.0 108.27 -179.442 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.4 Cg_exo -46.82 176.62 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.653 0 CA-C-N 118.835 1.317 . . . . 0.0 110.16 179.305 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -91.53 -176.13 4.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.142 -0.974 . . . . 0.0 110.502 -178.752 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.438 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.9 167.24 14.55 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.78 130.92 52.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.428 -1.042 . . . . 0.0 109.186 -179.403 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.562 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.42 120.76 20.43 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.679 -0.638 . . . . 0.0 109.744 179.751 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.521 HD13 ' CE2' ' A' ' 112' ' ' PHE . 1.4 pt -98.12 167.28 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.279 -0.888 . . . . 0.0 109.201 179.89 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.464 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -133.14 159.28 40.59 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.314 -0.866 . . . . 0.0 109.412 -179.926 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.567 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 49.4 m-85 . . . . . 0 N--CA 1.487 1.384 0 O-C-N 121.117 -0.989 . . . . 0.0 109.563 -179.753 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.217 0 CA-C-O 122.584 1.183 . . . . 0.0 110.115 . . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.545 ' CG2' ' O ' ' A' ' 6' ' ' THR . 5.7 t -115.8 109.2 17.33 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 123.122 1.439 . . . . 0.0 109.607 -179.98 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.526 HG12 ' CG1' ' A' ' 95' ' ' VAL . 3.1 t -114.95 139.84 39.15 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.677 0 CA-C-N 114.234 -1.348 . . . . 0.0 109.853 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.502 HG22 ' N ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.65 149.12 2.35 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.272 -0.893 . . . . 0.0 108.695 -179.666 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.502 ' N ' HG22 ' A' ' 8' ' ' THR . 3.0 Cg_endo -75.26 152.35 97.69 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 123.491 -1.462 . . . . 0.0 109.552 -0.846 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.468 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 2.4 m -88.46 -27.36 21.57 Favored 'General case' 0 C--N 1.293 -1.863 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.62 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.529 ' CB ' ' HB3' ' A' ' 111' ' ' SER . 1.9 p -136.39 166.77 22.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.51 -0.744 . . . . 0.0 109.347 179.764 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.08 37.36 32.85 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 108.512 -1.835 . . . . 0.0 108.512 -179.626 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.601 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 41.0 mt -92.98 -42.65 9.33 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-O 123.243 1.497 . . . . 0.0 110.466 -178.352 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.67 144.08 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.243 0 CA-C-N 113.392 -1.731 . . . . 0.0 109.877 -179.669 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 13.0 p-10 -50.94 105.65 0.11 Allowed 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.457 0.646 . . . . 0.0 111.589 -178.601 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.71 14.08 8.27 Favored Glycine 0 N--CA 1.485 1.927 0 C-N-CA 119.425 -1.369 . . . . 0.0 112.995 177.35 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.601 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.9 t -105.76 -172.43 2.09 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 121.239 2.52 . . . . 0.0 109.86 179.23 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 18.1 t -128.41 139.18 52.6 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.345 0 CA-C-N 114.742 -1.117 . . . . 0.0 111.022 -178.81 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.538 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 33.2 m -114.49 154.91 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.876 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.483 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.05 109.55 21.45 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.261 -0.899 . . . . 0.0 109.19 -179.954 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.53 HG11 ' CG2' ' A' ' 34' ' ' VAL . 2.0 p -102.26 140.06 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.511 -0.743 . . . . 0.0 109.059 179.95 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.557 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -131.44 158.16 41.56 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.012 -1.055 . . . . 0.0 109.335 179.458 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.59 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.73 108.76 0.57 Allowed Glycine 0 N--CA 1.482 1.724 0 N-CA-C 108.806 -1.718 . . . . 0.0 108.806 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -115.78 139.75 49.88 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-N 119.268 1.534 . . . . 0.0 110.512 -179.317 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.47 28.84 31.74 Favored Glycine 0 N--CA 1.491 2.354 0 C-N-CA 119.13 -1.51 . . . . 0.0 109.971 179.535 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.6 mt -92.19 175.28 6.91 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.977 -1.308 . . . . 0.0 108.613 -179.875 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.11 97.03 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.287 0 O-C-N 121.014 -1.054 . . . . 0.0 109.661 -179.811 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 76.69 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.384 -178.988 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.84 33.82 0.32 Allowed Glycine 0 N--CA 1.486 2.002 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 179.451 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.613 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -147.0 114.53 6.35 Favored 'General case' 0 C--N 1.308 -1.227 0 O-C-N 120.843 -1.387 . . . . 0.0 111.084 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.532 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -45.18 127.11 6.69 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.788 178.561 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.613 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 10.2 m-85 -117.75 149.34 40.94 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.484 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.474 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -101.01 152.64 20.34 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.867 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.64 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.5 p -137.19 118.55 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.958 -1.089 . . . . 0.0 109.767 -177.759 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.34 -178.7 39.22 Favored Glycine 0 N--CA 1.495 2.607 0 C-N-CA 118.341 -1.885 . . . . 0.0 111.863 -179.733 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.561 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -100.35 109.36 21.54 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.928 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.47 149.54 52.09 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.146 -0.971 . . . . 0.0 109.839 179.84 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.24 138.49 54.4 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.234 -0.916 . . . . 0.0 110.736 -179.039 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.622 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.17 114.97 26.82 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 178.02 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.2 m -105.28 14.91 7.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 120.997 -1.064 . . . . 0.0 110.583 -178.794 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.68 -175.0 0.08 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.925 -1.11 . . . . 0.0 110.014 179.704 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -72.64 97.64 2.2 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.448 -0.782 . . . . 0.0 109.702 -179.753 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.62 28.3 29.97 Favored Glycine 0 N--CA 1.494 2.544 0 C-N-CA 120.211 -0.995 . . . . 0.0 111.341 179.005 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.591 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.43 106.11 19.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 O-C-N 120.499 -1.589 . . . . 0.0 107.207 178.854 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.622 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.1 tp -116.59 104.69 11.65 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.568 -1.332 . . . . 0.0 109.866 -177.66 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.553 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.15 109.3 22.08 Favored 'General case' 0 N--CA 1.485 1.298 0 O-C-N 120.856 -1.152 . . . . 0.0 108.06 178.633 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.79 163.36 13.18 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.985 -1.072 . . . . 0.0 110.182 -178.908 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.54 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 9.9 t-20 -108.95 135.76 20.11 Favored Pre-proline 0 N--CA 1.499 2.002 0 O-C-N 121.281 -0.887 . . . . 0.0 109.944 -179.136 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.576 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.3 Cg_endo -74.72 23.96 0.38 Allowed 'Trans proline' 0 C--N 1.319 -1.017 0 C-N-CA 122.417 2.078 . . . . 0.0 112.069 -179.992 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.54 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -114.44 3.28 14.91 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.323 -1.486 . . . . 0.0 109.198 179.632 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.505 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.67 14.77 3.15 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 179.154 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -78.7 87.77 4.6 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.039 -0.665 . . . . 0.0 110.871 -178.558 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.64 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -104.98 -167.93 1.41 Allowed 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.057 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.47 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.88 135.77 0.09 Allowed 'General case' 0 C--N 1.304 -1.404 0 O-C-N 120.555 -1.34 . . . . 0.0 111.38 -179.192 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.591 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -154.06 156.91 4.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 178.034 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.532 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.62 145.33 26.39 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.665 -1.272 . . . . 0.0 109.831 -179.612 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.668 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.05 107.09 1.78 Allowed 'General case' 0 C--N 1.298 -1.63 0 CA-C-O 122.433 1.111 . . . . 0.0 109.472 178.936 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.531 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.4 p-10 -59.62 -139.43 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.037 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.728 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.9 -50.11 64.58 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.374 -0.829 . . . . 0.0 110.361 -178.822 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -102.56 -35.54 8.7 Favored 'General case' 0 C--N 1.286 -2.186 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 178.488 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.668 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.91 67.31 0.62 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.541 -1.023 . . . . 0.0 110.541 178.166 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.59 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 38.4 m -101.6 127.86 48.13 Favored 'General case' 0 N--CA 1.485 1.325 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 178.688 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.591 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.03 108.82 7.04 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.503 -179.37 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 18.4 p -126.11 120.56 30.49 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.348 -0.845 . . . . 0.0 109.565 -179.888 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.443 HG22 HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.37 146.25 31.5 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.669 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.2 p -98.61 131.25 44.96 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.162 -0.961 . . . . 0.0 109.588 -179.663 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.528 ' CD1' HG23 ' A' ' 19' ' ' VAL . 0.0 OUTLIER -128.92 166.22 19.55 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.403 -0.811 . . . . 0.0 109.341 -179.514 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.556 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -97.65 125.1 42.23 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.986 -1.072 . . . . 0.0 109.373 -179.999 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.533 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.2 m -137.26 143.48 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.047 -1.033 . . . . 0.0 109.785 -179.149 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -146.44 -177.48 5.65 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.531 -1.355 . . . . 0.0 111.249 -179.927 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.539 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.05 -100.2 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -179.655 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.21 140.13 50.6 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 120.71 -1.244 . . . . 0.0 107.888 179.309 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.569 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -161.91 136.65 7.06 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 118.513 -1.275 . . . . 0.0 109.918 -178.015 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.476 ' C ' ' O ' ' A' ' 73' ' ' PHE . 6.4 mt-10 -34.78 121.34 0.52 Allowed 'General case' 0 N--CA 1.489 1.485 0 CA-C-O 121.434 0.635 . . . . 0.0 110.423 -178.61 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.553 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -94.75 51.54 2.0 Allowed Glycine 0 N--CA 1.495 2.593 0 C-N-CA 120.563 -0.827 . . . . 0.0 111.125 -179.22 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.576 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.23 115.63 0.51 Allowed 'General case' 0 N--CA 1.506 2.371 0 O-C-N 121.154 -1.204 . . . . 0.0 110.121 179.453 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.54 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.9 tp -86.89 126.56 34.75 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 120.831 -1.168 . . . . 0.0 109.575 -179.741 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -64.2 58.3 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.913 -1.117 . . . . 0.0 110.065 179.513 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.54 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.1 t70 -159.53 19.24 0.17 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.982 -1.074 . . . . 0.0 109.709 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.07 -27.19 5.64 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.822 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 p -95.99 161.6 13.92 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 120.994 -1.298 . . . . 0.0 110.397 -179.393 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.463 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.75 137.53 44.61 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.673 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.46 ' HB2' HD11 ' A' ' 77' ' ' LEU . 2.3 t90 -82.08 -19.65 39.76 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.747 -1.221 . . . . 0.0 110.507 -178.648 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.15 176.36 19.05 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.709 -1.757 . . . . 0.0 108.709 -179.499 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.94 105.7 1.39 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.015 -1.285 . . . . 0.0 107.783 179.158 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.556 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.9 t -77.12 105.82 6.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 O-C-N 121.367 -0.833 . . . . 0.0 109.229 -178.903 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.7 OUTLIER -65.48 111.3 3.03 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.483 -0.761 . . . . 0.0 110.012 -179.445 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.539 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.05 -5.88 3.48 Favored 'General case' 0 N--CA 1.499 2.015 0 C-N-CA 118.273 -1.371 . . . . 0.0 109.8 179.486 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -86.89 -0.18 56.05 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.713 -1.242 . . . . 0.0 109.26 179.496 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.457 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.32 -50.33 2.87 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.34 -0.85 . . . . 0.0 109.006 179.886 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.69 -179.9 4.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.581 -0.699 . . . . 0.0 109.344 179.833 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.69 115.91 31.36 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.895 . . . . 0.0 109.003 179.981 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.521 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.86 120.77 37.81 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.826 -1.171 . . . . 0.0 109.368 -179.409 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.556 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.43 145.96 28.25 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 122.355 1.074 . . . . 0.0 111.117 -179.283 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.526 ' CG1' HG12 ' A' ' 7' ' ' VAL . 60.5 t -101.25 109.77 26.47 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.013 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 177.362 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.43 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -146.64 -171.32 15.83 Favored Glycine 0 N--CA 1.486 2.0 0 C-N-CA 118.212 -1.946 . . . . 0.0 111.619 -177.284 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.474 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -123.22 179.64 4.63 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -178.631 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.296 -1.727 0 O-C-N 121.482 -0.761 . . . . 0.0 109.513 -179.862 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.845 0 N-CA-C 107.604 -2.198 . . . . 0.0 107.604 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.09 -177.67 5.91 Favored 'General case' 0 C--N 1.307 -1.282 0 O-C-N 121.668 -0.901 . . . . 0.0 109.808 179.338 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.09 -161.81 21.25 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 -179.368 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.47 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.3 Cg_exo -45.37 172.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.69 0 CA-C-N 118.81 1.305 . . . . 0.0 110.094 179.303 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -92.49 -178.7 4.98 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.084 -1.01 . . . . 0.0 110.608 -178.659 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.43 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -115.08 164.53 12.09 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.88 133.12 48.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.411 -1.052 . . . . 0.0 109.28 -179.282 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.556 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.02 119.3 17.07 Favored 'General case' 0 C--N 1.289 -2.022 0 O-C-N 121.655 -0.653 . . . . 0.0 109.474 179.646 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.589 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.7 pt -98.14 172.07 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.175 -0.953 . . . . 0.0 109.101 179.944 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.529 ' HB3' ' CB ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -138.49 155.86 48.04 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.104 -0.997 . . . . 0.0 109.892 -179.695 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.589 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 87.0 m-85 . . . . . 0 N--CA 1.485 1.303 0 O-C-N 121.325 -0.859 . . . . 0.0 109.613 -179.783 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.472 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.477 0 CA-C-O 122.372 1.082 . . . . 0.0 110.701 . . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.547 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.3 t -112.91 108.7 17.74 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 123.106 1.431 . . . . 0.0 109.19 179.367 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.525 HG12 ' CG1' ' A' ' 95' ' ' VAL . 3.7 t -116.34 142.51 29.58 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.667 0 CA-C-N 114.347 -1.297 . . . . 0.0 110.203 -179.615 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.509 HG21 ' N ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -178.16 150.45 0.74 Allowed Pre-proline 0 N--CA 1.488 1.454 0 O-C-N 121.278 -0.888 . . . . 0.0 108.715 -179.737 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.509 ' N ' HG21 ' A' ' 8' ' ' THR . 1.9 Cg_endo -75.05 153.73 99.25 Favored 'Cis proline' 0 C--N 1.312 -1.362 0 C-N-CA 123.577 -1.426 . . . . 0.0 109.471 -0.644 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.511 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 3.3 m -91.4 -25.35 19.4 Favored 'General case' 0 C--N 1.292 -1.912 0 O-C-N 121.63 -0.669 . . . . 0.0 109.428 -179.94 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.5 ' HB3' ' CB ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -137.9 163.35 31.69 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.338 -0.851 . . . . 0.0 109.905 -179.619 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.72 37.14 27.25 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 108.773 -1.731 . . . . 0.0 108.773 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.598 ' CD1' ' CG1' ' A' ' 19' ' ' VAL . 44.2 mt -93.05 -44.22 8.5 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 123.249 1.5 . . . . 0.0 110.547 -178.533 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.46 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.48 145.75 0.03 OUTLIER 'General case' 0 C--N 1.262 -3.203 0 CA-C-N 113.473 -1.694 . . . . 0.0 109.999 -179.796 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.546 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.0 p-10 -51.93 105.1 0.1 Allowed 'General case' 0 C--N 1.303 -1.451 0 CA-C-O 121.49 0.662 . . . . 0.0 111.088 -179.05 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.95 6.66 6.96 Favored Glycine 0 N--CA 1.486 1.983 0 C-N-CA 119.18 -1.486 . . . . 0.0 113.194 177.518 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.595 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.6 t -105.14 -174.45 2.54 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 121.437 2.618 . . . . 0.0 109.922 179.709 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.542 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 21.6 t -127.02 135.94 62.2 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.579 -1.191 . . . . 0.0 110.955 -178.778 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.598 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 32.5 m -109.54 154.79 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 178.795 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -110.56 109.25 19.5 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.198 -0.939 . . . . 0.0 108.825 179.776 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.521 HG12 ' CG2' ' A' ' 34' ' ' VAL . 1.8 p -104.32 140.46 22.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.568 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -135.18 160.32 38.73 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 118.74 -1.184 . . . . 0.0 109.857 179.649 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.585 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.44 143.55 15.2 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 108.021 -2.032 . . . . 0.0 108.021 179.789 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.12 125.26 12.91 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 120.843 -1.386 . . . . 0.0 108.846 179.289 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.98 26.8 25.5 Favored Glycine 0 N--CA 1.488 2.124 0 C-N-CA 119.371 -1.395 . . . . 0.0 109.704 -179.698 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.559 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.5 mt -86.27 175.83 8.25 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.921 -1.341 . . . . 0.0 108.557 -179.813 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.554 ' CB ' ' CG2' ' A' ' 30' ' ' THR . 0.0 OUTLIER -45.44 96.9 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.028 -1.045 . . . . 0.0 109.556 -179.771 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.26 76.32 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.715 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.541 -178.989 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.32 33.93 0.3 Allowed Glycine 0 N--CA 1.484 1.876 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.304 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.554 ' CG2' ' CB ' ' A' ' 27' ' ' GLN . 1.2 t -148.64 114.97 5.87 Favored 'General case' 0 C--N 1.308 -1.21 0 O-C-N 120.774 -1.427 . . . . 0.0 111.333 179.955 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.559 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.13 130.05 3.65 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.798 178.376 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.553 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 7.7 m-85 -121.41 147.93 45.06 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.583 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.48 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.96 156.71 17.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.626 -1.296 . . . . 0.0 107.771 178.719 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.627 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.5 p -140.27 117.27 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.066 -1.021 . . . . 0.0 109.867 -177.789 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.29 -176.92 39.06 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.942 -179.739 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.6 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.4 pt20 -99.83 109.96 22.35 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 121.874 0.845 . . . . 0.0 109.02 -179.648 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -130.35 150.12 51.73 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.223 -0.923 . . . . 0.0 109.679 179.703 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.69 138.29 54.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.197 -0.94 . . . . 0.0 110.968 -178.945 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.627 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.38 115.0 26.83 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 177.982 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.458 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 19.8 m -105.77 14.72 7.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 120.993 -1.067 . . . . 0.0 110.646 -178.732 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.587 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.32 -174.71 0.09 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.04 -1.037 . . . . 0.0 110.011 179.614 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.84 97.03 1.73 Allowed 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.439 -0.788 . . . . 0.0 109.709 -179.77 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.28 27.8 32.3 Favored Glycine 0 N--CA 1.493 2.492 0 C-N-CA 120.149 -1.024 . . . . 0.0 111.481 178.849 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.587 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.32 106.45 20.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 O-C-N 120.688 -1.477 . . . . 0.0 107.252 178.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.627 HD13 ' CD1' ' A' ' 39' ' ' TRP . 11.5 tp -115.38 104.8 12.15 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.4 -1.437 . . . . 0.0 110.019 -177.715 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.534 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -97.68 109.71 22.41 Favored 'General case' 0 N--CA 1.486 1.372 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.801 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.51 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -109.08 168.34 9.44 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.059 -1.026 . . . . 0.0 110.365 -178.744 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.548 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 22.3 t-20 -118.09 135.08 23.32 Favored Pre-proline 0 N--CA 1.499 2.01 0 O-C-N 121.353 -0.842 . . . . 0.0 110.101 -179.438 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.577 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.5 Cg_endo -73.66 23.33 0.33 Allowed 'Trans proline' 0 CA--C 1.545 1.045 0 C-N-CA 122.223 1.949 . . . . 0.0 112.181 179.901 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.548 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -108.82 1.99 21.31 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.345 -1.472 . . . . 0.0 109.079 179.406 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.511 ' O ' ' CD2' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.11 17.41 2.27 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.643 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -81.06 90.37 6.0 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.524 -0.735 . . . . 0.0 110.891 -178.606 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.69 -166.87 1.19 Allowed 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 178.145 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.465 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.72 134.92 0.09 Allowed 'General case' 0 C--N 1.306 -1.311 0 O-C-N 120.524 -1.36 . . . . 0.0 111.666 -179.356 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.584 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.5 p -150.94 157.38 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 177.862 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.559 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.19 146.07 25.44 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.496 -1.377 . . . . 0.0 109.741 -179.648 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.677 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.09 108.55 3.15 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 122.302 1.048 . . . . 0.0 109.589 179.009 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.524 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.7 t70 -63.69 -139.03 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.999 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.663 179.938 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.546 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.92 -51.74 49.11 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.343 -0.848 . . . . 0.0 110.679 -178.672 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -102.58 -32.7 9.78 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 106.517 -1.66 . . . . 0.0 106.517 178.662 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.677 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 105.36 66.32 0.67 Allowed Glycine 0 C--N 1.297 -1.591 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.18 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.585 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 58.0 p -98.66 131.96 44.42 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 121.378 -1.072 . . . . 0.0 109.097 179.006 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.584 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -138.43 108.32 6.32 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 119.319 -0.953 . . . . 0.0 109.52 -179.642 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.439 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.6 m -124.67 119.13 28.1 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.094 -1.004 . . . . 0.0 109.701 -179.939 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.463 HG21 HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.33 144.16 29.6 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.448 -0.782 . . . . 0.0 109.363 179.853 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.8 p -99.12 141.51 31.8 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.316 -0.865 . . . . 0.0 109.191 179.838 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.561 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.83 167.94 20.94 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.449 -0.782 . . . . 0.0 109.551 -179.23 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.542 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.0 p -98.18 126.82 43.8 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.094 -1.004 . . . . 0.0 109.319 -179.761 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.484 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 15.4 m -134.44 140.53 45.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.879 -1.138 . . . . 0.0 110.091 -179.198 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.546 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 52.2 mtt180 -127.56 -165.52 1.49 Allowed 'General case' 0 N--CA 1.485 1.315 0 O-C-N 120.676 -1.265 . . . . 0.0 111.255 -179.821 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.569 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 1.0 OUTLIER -80.48 -79.64 0.15 Allowed 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.209 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.444 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -68.85 136.45 52.7 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 177.9 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.573 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.03 137.64 9.76 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 117.803 -1.559 . . . . 0.0 110.735 -177.325 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.507 ' HB3' ' CD1' ' A' ' 76' ' ' PHE . 8.0 mm-40 -33.72 119.2 0.37 Allowed 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 121.638 0.732 . . . . 0.0 110.58 -178.69 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.534 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -87.92 48.4 3.67 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.316 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.577 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 19.0 m-85 -39.21 113.92 0.36 Allowed 'General case' 0 N--CA 1.507 2.385 0 O-C-N 121.157 -1.202 . . . . 0.0 110.136 179.591 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -87.67 127.04 35.29 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.993 -1.067 . . . . 0.0 109.474 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -64.51 58.29 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.753 -1.217 . . . . 0.0 110.056 179.674 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.7 t70 -159.52 19.0 0.17 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.042 -1.036 . . . . 0.0 109.721 179.948 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.68 -26.56 5.8 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.84 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 72.4 p -95.15 160.56 14.5 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.021 -1.281 . . . . 0.0 110.417 -179.343 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 1.3 ptt180 -105.63 134.84 48.1 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.66 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.452 ' HB2' HD12 ' A' ' 77' ' ' LEU . 4.0 t90 -81.21 -20.01 42.03 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.823 -1.173 . . . . 0.0 110.234 -178.623 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.26 173.64 18.25 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 108.739 -1.745 . . . . 0.0 108.739 -179.572 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.67 111.45 2.09 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 179.251 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.554 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.7 t -83.1 103.91 11.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 O-C-N 121.35 -0.844 . . . . 0.0 108.798 -179.062 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.464 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.8 111.41 3.24 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.448 -0.783 . . . . 0.0 109.971 -179.094 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.545 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -63.96 -5.12 4.03 Favored 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 118.426 -1.31 . . . . 0.0 109.834 179.372 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.9 p -87.89 2.09 52.41 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.841 -1.162 . . . . 0.0 109.052 179.415 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.464 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -116.72 -51.23 2.59 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.329 -0.857 . . . . 0.0 108.939 -179.99 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.1 179.5 4.25 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.512 -0.742 . . . . 0.0 109.371 179.869 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.34 116.52 32.58 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.362 -0.836 . . . . 0.0 108.925 179.917 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.484 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.9 m -96.73 120.71 37.56 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.894 -1.129 . . . . 0.0 109.357 -179.41 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.567 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.67 145.56 28.92 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 122.373 1.083 . . . . 0.0 111.283 -179.12 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.525 ' CG1' HG12 ' A' ' 7' ' ' VAL . 62.6 t -101.71 109.81 26.92 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.037 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 177.537 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.417 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.85 -170.91 16.33 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 118.174 -1.965 . . . . 0.0 111.851 -177.467 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.48 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.6 178.98 4.61 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -178.859 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.297 -1.704 0 O-C-N 121.564 -0.71 . . . . 0.0 109.562 179.999 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.698 0 N-CA-C 107.946 -2.061 . . . . 0.0 107.946 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -166.99 -177.0 3.6 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 121.609 -0.936 . . . . 0.0 109.756 179.367 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.25 -161.36 17.96 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.27 -1.932 . . . . 0.0 108.27 -179.396 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.48 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.6 Cg_exo -46.6 176.5 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.664 0 CA-C-N 118.841 1.32 . . . . 0.0 110.203 179.287 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -93.85 -168.88 1.97 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.118 -0.989 . . . . 0.0 110.39 -178.927 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.417 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -123.88 163.47 17.51 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.736 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.461 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.14 129.67 49.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.409 -1.054 . . . . 0.0 109.123 -179.679 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.567 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.58 118.97 16.15 Favored 'General case' 0 C--N 1.288 -2.085 0 O-C-N 121.703 -0.623 . . . . 0.0 109.759 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.571 HD11 ' CE2' ' A' ' 112' ' ' PHE . 1.4 pt -98.07 168.0 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 121.249 -0.907 . . . . 0.0 109.065 179.803 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.5 ' CB ' ' HB3' ' A' ' 11' ' ' SER . 0.2 OUTLIER -132.28 156.89 45.74 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.281 -0.887 . . . . 0.0 109.666 -179.876 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.571 ' CE2' HD11 ' A' ' 110' ' ' ILE . 41.4 m-85 . . . . . 0 N--CA 1.487 1.42 0 O-C-N 121.272 -0.893 . . . . 0.0 109.357 -179.852 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.412 0 CA-C-O 122.165 0.983 . . . . 1.0 110.961 . . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.523 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.4 p -102.0 104.52 15.19 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 122.408 1.099 . . . . 1.0 110.088 -179.84 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.524 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 5.9 t -119.5 123.55 71.33 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.448 0 CA-C-N 115.521 -0.763 . . . . 1.0 110.516 179.822 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.486 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -170.95 150.02 2.9 Favored Pre-proline 0 N--CA 1.488 1.451 0 N-CA-C 108.086 -1.079 . . . . 1.0 108.086 -179.649 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.486 ' HA ' HG22 ' A' ' 8' ' ' THR . 5.0 Cg_endo -76.79 151.37 94.16 Favored 'Cis proline' 0 C--N 1.311 -1.434 0 C-N-CA 123.658 -1.393 . . . . 1.0 109.533 -0.526 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.482 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 95.2 p -95.4 -21.47 18.34 Favored 'General case' 0 C--N 1.293 -1.888 0 O-C-N 121.649 -0.657 . . . . 1.0 109.643 179.954 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.466 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.3 m -131.54 157.11 44.45 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.256 -0.903 . . . . 1.0 110.221 -179.583 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.39 37.11 25.04 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 108.794 -1.722 . . . . 1.0 108.794 -179.719 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.603 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 35.4 mt -92.1 -44.78 8.63 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 123.201 1.477 . . . . 1.0 110.542 -178.59 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.458 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.1 t 63.8 147.52 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.25 0 CA-C-N 113.562 -1.654 . . . . 1.0 110.045 -179.815 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.525 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.5 p-10 -51.65 105.16 0.1 Allowed 'General case' 0 C--N 1.303 -1.438 0 CA-C-O 121.665 0.745 . . . . 1.0 111.106 -178.997 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.31 7.39 7.02 Favored Glycine 0 N--CA 1.485 1.954 0 C-N-CA 119.319 -1.42 . . . . 1.0 113.318 177.323 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.603 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.9 t -106.42 -177.46 3.37 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 121.468 2.634 . . . . 1.0 110.325 179.654 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.551 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 21.9 t -128.3 139.69 51.22 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.374 0 CA-C-N 114.076 -1.42 . . . . 1.0 111.091 -178.717 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.492 ' CG1' HD11 ' A' ' 13' ' ' LEU . 15.7 m -117.19 154.68 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.35 -0.981 . . . . 1.0 108.35 178.739 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.524 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -104.1 108.79 20.32 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.139 -0.975 . . . . 1.0 109.304 -179.886 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.532 HG12 ' CD1' ' A' ' 67' ' ' LEU . 2.4 p -106.34 123.27 61.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 N-CA-C 108.299 -1.001 . . . . 1.0 108.299 179.571 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.531 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -117.67 167.21 11.55 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 120.681 -1.262 . . . . 1.0 109.22 -179.831 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.61 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.77 139.1 10.61 Favored Glycine 0 C--N 1.294 -1.779 0 N-CA-C 107.282 -2.327 . . . . 1.0 107.282 179.51 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -145.39 125.35 13.56 Favored 'General case' 0 C--N 1.293 -1.866 0 O-C-N 120.522 -1.575 . . . . 1.0 108.991 179.613 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.23 26.35 28.62 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 119.013 -1.565 . . . . 1.0 109.952 -179.798 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.551 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -86.5 174.34 9.02 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 120.885 -1.362 . . . . 1.0 108.29 179.743 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.554 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.41 99.28 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.412 0 O-C-N 120.855 -1.153 . . . . 1.0 109.743 -179.605 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.11 77.74 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.304 -0.862 . . . . 1.0 110.246 -179.271 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.9 34.47 0.3 Allowed Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.464 -1.454 . . . . 1.0 109.464 179.587 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.534 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 53.4 p -142.82 108.75 5.17 Favored 'General case' 0 C--N 1.308 -1.221 0 O-C-N 121.039 -1.271 . . . . 1.0 111.214 -179.416 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.559 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -49.92 109.92 0.34 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 109.393 -0.595 . . . . 1.0 109.393 177.807 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.478 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.7 m-30 -104.9 155.4 18.96 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.119 -0.988 . . . . 1.0 108.878 179.874 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.474 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.82 162.01 13.33 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.804 -1.185 . . . . 1.0 108.077 178.934 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.63 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.9 p -141.91 120.36 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.166 -0.959 . . . . 1.0 109.307 -178.217 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.456 ' HA2' ' HB2' ' A' ' 51' ' ' ASP . . . -171.88 -176.48 40.83 Favored Glycine 0 N--CA 1.495 2.571 0 C-N-CA 118.412 -1.851 . . . . 1.0 111.583 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.556 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -101.15 109.19 21.03 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 108.909 -0.774 . . . . 1.0 108.909 -179.908 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.0 m -130.14 149.06 52.02 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.277 -0.89 . . . . 1.0 109.682 179.585 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.54 138.72 54.51 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.236 -0.915 . . . . 1.0 110.793 -178.93 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.626 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.2 114.77 26.6 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 107.532 -1.284 . . . . 1.0 107.532 178.047 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 m -104.85 14.72 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.931 -1.106 . . . . 1.0 110.481 -178.793 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.588 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.1 -175.24 0.09 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.98 -1.075 . . . . 1.0 110.049 179.748 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.51 97.79 2.17 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.519 -0.738 . . . . 1.0 109.577 -179.75 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.46 27.75 31.94 Favored Glycine 0 N--CA 1.492 2.414 0 C-N-CA 120.214 -0.993 . . . . 1.0 111.399 178.94 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.588 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.22 106.48 20.18 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.558 -1.554 . . . . 1.0 107.357 178.81 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.626 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.5 tp -116.4 104.72 11.74 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.475 -1.391 . . . . 1.0 109.954 -177.629 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.536 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.65 109.53 22.27 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 107.812 -1.181 . . . . 1.0 107.812 178.871 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -108.05 166.74 10.5 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.869 -1.145 . . . . 1.0 110.727 -178.455 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.52 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 46.4 t30 -118.51 136.72 24.2 Favored Pre-proline 0 N--CA 1.498 1.971 0 C-N-CA 120.098 -0.641 . . . . 1.0 109.64 -179.497 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.582 ' HD3' ' CE1' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -74.03 26.41 0.33 Allowed 'Trans proline' 0 C--N 1.317 -1.111 0 C-N-CA 122.437 2.092 . . . . 1.0 112.01 -179.89 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.52 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -98.54 -9.55 24.78 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.319 -1.488 . . . . 1.0 109.164 179.735 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.541 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 0.8 OUTLIER -135.68 7.4 3.26 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.383 -0.823 . . . . 1.0 108.872 -179.81 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -60.75 84.1 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.427 -0.796 . . . . 1.0 110.898 -178.569 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.63 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.78 -167.02 1.17 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.852 -1.166 . . . . 1.0 107.852 178.33 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.486 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.7 t 179.1 135.25 0.09 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.569 -1.332 . . . . 1.0 111.43 -179.364 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.536 HG11 ' CB ' ' A' ' 63' ' ' ALA . 1.4 p -150.46 157.77 5.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 N-CA-C 107.537 -1.283 . . . . 1.0 107.537 177.914 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.559 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.63 142.1 30.63 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.734 -1.229 . . . . 1.0 110.051 -179.747 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.679 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.36 107.68 1.41 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 122.331 1.062 . . . . 1.0 109.38 178.524 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.537 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.6 p-10 -62.04 -138.81 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 115.612 -0.722 . . . . 1.0 110.861 -179.778 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.87 -51.82 37.5 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.344 -0.847 . . . . 1.0 110.737 -178.599 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -104.57 -32.91 8.72 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 106.261 -1.755 . . . . 1.0 106.261 178.508 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.679 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.57 69.88 0.67 Allowed Glycine 0 C--N 1.298 -1.574 0 N-CA-C 110.299 -1.12 . . . . 1.0 110.299 178.104 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.61 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 63.7 m -104.07 129.98 51.75 Favored 'General case' 0 N--CA 1.483 1.175 0 O-C-N 121.259 -1.142 . . . . 1.0 109.275 179.14 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.536 ' CB ' HG11 ' A' ' 55' ' ' VAL . . . -134.4 108.96 8.46 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.535 -0.866 . . . . 1.0 109.484 -179.638 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 97.2 p -116.21 117.02 28.87 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.117 -0.989 . . . . 1.0 109.492 -179.747 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.452 HG22 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.27 139.93 26.13 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.385 -0.822 . . . . 1.0 110.077 -179.84 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 27.2 p -99.61 135.26 41.29 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.822 -0.807 . . . . 1.0 108.822 179.432 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.541 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -136.22 168.52 19.24 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.292 -0.88 . . . . 1.0 110.057 -178.931 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.551 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.2 p -104.06 126.26 51.04 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.192 -0.942 . . . . 1.0 109.329 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.541 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 12.3 m -129.41 139.99 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 120.922 -1.111 . . . . 1.0 110.209 -179.26 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.525 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 52.4 mtt180 -125.67 -168.57 1.86 Allowed 'General case' 0 N--CA 1.484 1.23 0 O-C-N 120.676 -1.265 . . . . 1.0 111.304 179.823 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.562 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 40.0 mtt180 -78.5 -75.71 0.22 Allowed 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.2 -1.037 . . . . 1.0 108.2 179.284 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.438 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -72.67 137.06 45.79 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 120.14 -1.6 . . . . 1.0 106.812 178.107 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -157.66 135.51 10.73 Favored 'General case' 0 C--N 1.295 -1.784 0 C-N-CA 118.08 -1.448 . . . . 1.0 110.308 -177.903 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.581 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 9.5 mm-40 -34.78 121.62 0.52 Allowed 'General case' 0 N--CA 1.487 1.41 0 CA-C-O 121.582 0.706 . . . . 1.0 110.364 -178.259 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.536 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -87.76 47.94 3.64 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 110.986 -0.846 . . . . 1.0 110.986 -179.377 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.582 ' CE1' ' HD3' ' A' ' 49' ' ' PRO . 36.2 m-85 -39.76 112.95 0.3 Allowed 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.07 -1.253 . . . . 1.0 110.001 179.614 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.541 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -87.03 126.64 34.88 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.995 -1.066 . . . . 1.0 109.493 -179.912 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -63.99 58.34 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.735 -1.228 . . . . 1.0 110.315 179.674 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.26 19.15 0.15 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.01 -1.056 . . . . 1.0 109.765 179.854 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.31 -26.18 5.81 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.097 -1.201 . . . . 1.0 110.097 179.78 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -94.07 160.0 14.91 Favored 'General case' 0 N--CA 1.485 1.311 0 O-C-N 121.011 -1.288 . . . . 1.0 110.49 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.459 ' CG ' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -105.89 133.39 50.69 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 108.581 -0.896 . . . . 1.0 108.581 179.701 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.45 ' HB2' HD12 ' A' ' 77' ' ' LEU . 4.1 t90 -80.93 -20.28 42.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.809 -1.182 . . . . 1.0 110.256 -178.701 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.92 174.19 18.62 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.9 -1.68 . . . . 1.0 108.9 -179.59 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.06 110.04 1.69 Allowed 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.143 -1.21 . . . . 1.0 107.743 179.269 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.595 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 44.4 t -82.32 104.45 10.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.696 0 N-CA-C 108.715 -0.846 . . . . 1.0 108.715 -179.098 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.465 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -67.11 111.07 3.69 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.322 -0.861 . . . . 1.0 109.893 -179.119 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.562 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -64.04 -5.23 4.33 Favored 'General case' 0 N--CA 1.501 2.083 0 C-N-CA 118.465 -1.294 . . . . 1.0 109.869 179.394 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -86.69 2.04 49.92 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.757 -1.214 . . . . 1.0 108.923 179.363 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.465 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -117.05 -51.11 2.56 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.478 -0.764 . . . . 1.0 108.967 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -102.57 -179.92 4.11 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.498 -0.751 . . . . 1.0 109.381 179.883 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.84 115.25 29.98 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.349 -0.845 . . . . 1.0 108.979 179.923 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.56 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.88 122.25 39.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.807 -1.183 . . . . 1.0 109.464 -179.278 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.572 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -101.75 145.35 29.26 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 122.449 1.119 . . . . 1.0 111.184 -179.3 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.466 HG12 HG11 ' A' ' 7' ' ' VAL . 65.2 t -102.68 110.59 29.76 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 N-CA-C 106.892 -1.521 . . . . 1.0 106.892 177.815 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.458 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.11 -169.63 18.47 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 118.177 -1.963 . . . . 1.0 111.75 -177.712 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.474 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -120.02 177.06 5.13 Favored 'General case' 0 N--CA 1.489 1.485 0 CA-C-O 121.69 0.757 . . . . 1.0 109.113 -178.931 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.478 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.717 0 N-CA-C 109.276 -0.639 . . . . 1.0 109.276 179.801 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.677 0 N-CA-C 107.703 -2.159 . . . . 1.0 107.703 . . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.31 -178.08 6.69 Favored 'General case' 0 C--N 1.305 -1.326 0 O-C-N 121.554 -0.968 . . . . 1.0 109.749 179.322 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.35 -161.31 18.01 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.326 -1.91 . . . . 1.0 108.326 -179.293 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.487 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.4 Cg_exo -47.33 179.82 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 CA-C-N 118.783 1.292 . . . . 1.0 110.368 179.322 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -95.59 -170.82 2.23 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.053 -1.029 . . . . 1.0 110.236 -179.075 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.458 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -125.37 164.53 18.91 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.693 -1.363 . . . . 1.0 109.693 -179.846 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.465 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.56 128.55 49.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 O-C-N 121.436 -1.038 . . . . 1.0 109.103 -179.535 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.572 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.56 120.91 19.81 Favored 'General case' 0 C--N 1.289 -2.036 0 O-C-N 121.735 -0.603 . . . . 1.0 109.835 179.957 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.538 HD13 ' CE2' ' A' ' 112' ' ' PHE . 1.4 pt -98.03 168.11 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.315 -0.866 . . . . 1.0 109.037 179.722 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.466 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -134.98 158.6 43.9 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.305 -0.872 . . . . 1.0 109.428 179.976 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.538 ' CE2' HD13 ' A' ' 110' ' ' ILE . 42.2 m-85 . . . . . 0 N--CA 1.49 1.53 0 O-C-N 121.191 -0.943 . . . . 1.0 109.392 -179.786 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.494 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.424 0 CA-C-O 122.11 0.957 . . . . 1.0 111.098 . . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.528 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.2 p -99.7 104.3 16.02 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 122.353 1.073 . . . . 1.0 109.918 -179.965 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.539 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 4.0 t -121.6 117.1 51.5 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-O 121.603 0.716 . . . . 1.0 110.341 179.587 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.526 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -165.94 150.04 7.21 Favored Pre-proline 0 N--CA 1.487 1.41 0 N-CA-C 108.213 -1.032 . . . . 1.0 108.213 -179.646 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.526 ' CA ' HG21 ' A' ' 8' ' ' THR . 5.8 Cg_endo -77.72 151.76 92.04 Favored 'Cis proline' 0 C--N 1.31 -1.463 0 C-N-CA 123.608 -1.413 . . . . 1.0 109.512 -0.615 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 85.7 p -92.85 -25.66 18.0 Favored 'General case' 0 C--N 1.293 -1.857 0 O-C-N 121.435 -0.791 . . . . 1.0 108.895 179.42 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.414 ' HA ' ' O ' ' A' ' 111' ' ' SER . 3.0 m -131.9 161.37 33.2 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.455 -0.778 . . . . 1.0 109.413 -179.912 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.59 36.55 33.19 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 108.627 -1.789 . . . . 1.0 108.627 -179.566 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.605 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.6 mt -91.19 -42.69 10.29 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.298 1.523 . . . . 1.0 110.37 -178.505 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.5 143.62 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.284 0 CA-C-N 113.292 -1.776 . . . . 1.0 109.809 -179.585 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.58 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.1 p-10 -50.76 105.59 0.1 Allowed 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.596 0.712 . . . . 1.0 111.31 -178.655 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.47 13.64 8.02 Favored Glycine 0 N--CA 1.485 1.945 0 C-N-CA 119.316 -1.421 . . . . 1.0 113.041 177.497 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.605 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.9 t -104.8 -171.96 2.01 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 121.28 2.54 . . . . 1.0 109.755 179.28 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 14.9 t -130.11 138.51 53.8 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.345 0 CA-C-N 114.857 -1.065 . . . . 1.0 111.261 -178.855 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.523 HG12 ' CG2' ' A' ' 69' ' ' VAL . 34.1 m -115.85 154.82 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.585 -0.894 . . . . 1.0 108.585 178.888 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.539 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -109.19 109.18 20.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.121 -0.987 . . . . 1.0 109.35 -179.903 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.1 p -107.4 123.16 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 108.357 -0.979 . . . . 1.0 108.357 179.67 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.528 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -120.85 167.24 12.73 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 120.721 -1.237 . . . . 1.0 109.386 -179.744 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.598 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -131.24 144.33 15.86 Favored Glycine 0 C--N 1.295 -1.723 0 N-CA-C 107.711 -2.155 . . . . 1.0 107.711 179.691 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -148.18 123.19 10.08 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 120.96 -1.317 . . . . 1.0 108.532 179.105 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.66 27.95 17.98 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.269 -1.443 . . . . 1.0 109.722 -179.464 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.53 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.0 OUTLIER -90.52 175.37 7.09 Favored 'General case' 0 C--N 1.308 -1.213 0 O-C-N 120.832 -1.393 . . . . 1.0 108.602 179.947 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.552 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -48.6 100.4 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.903 -1.123 . . . . 1.0 109.859 -179.817 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.43 78.57 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.679 0 CA-C-N 115.355 -0.839 . . . . 1.0 110.116 -179.375 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.573 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.81 34.44 0.3 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.283 -1.527 . . . . 1.0 109.283 179.711 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 21.4 p -139.75 105.69 5.19 Favored 'General case' 0 C--N 1.307 -1.252 0 O-C-N 121.185 -1.185 . . . . 1.0 111.155 -179.381 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.554 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -48.47 109.8 0.28 Allowed 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.579 -0.526 . . . . 1.0 109.579 178.057 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.406 ' CE2' ' HB3' ' A' ' 26' ' ' LEU . 8.4 m-85 -104.34 153.23 21.3 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.055 -1.028 . . . . 1.0 108.994 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.427 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.2 155.35 18.49 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.859 -1.15 . . . . 1.0 108.246 179.054 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.601 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -126.91 127.89 70.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.228 -0.92 . . . . 1.0 108.973 -178.079 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.493 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -175.6 174.36 46.8 Favored Glycine 0 N--CA 1.495 2.581 0 C-N-CA 117.726 -2.178 . . . . 1.0 112.342 -179.926 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.574 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -101.09 108.84 20.63 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 107.964 -1.124 . . . . 1.0 107.964 179.577 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.0 m -129.67 147.87 51.5 Favored 'General case' 0 C--N 1.294 -1.81 0 O-C-N 121.212 -0.93 . . . . 1.0 109.969 -179.654 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.58 139.13 54.26 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.362 -0.837 . . . . 1.0 110.523 -179.133 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.615 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.08 114.72 26.56 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.411 -1.329 . . . . 1.0 107.411 178.282 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -106.11 15.35 7.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.051 -1.031 . . . . 1.0 110.541 -178.614 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.77 -175.99 0.09 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.931 -1.106 . . . . 1.0 110.02 179.761 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.551 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.29 97.09 1.19 Allowed 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.782 0.801 . . . . 1.0 109.993 -179.631 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.56 28.23 36.43 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 120.278 -0.963 . . . . 1.0 111.413 178.856 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.591 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.18 106.27 20.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 O-C-N 120.623 -1.516 . . . . 1.0 107.186 178.846 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.615 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.5 tp -116.88 104.77 11.64 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.463 -1.398 . . . . 1.0 109.869 -177.614 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.509 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -98.01 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.782 -1.199 . . . . 1.0 108.219 178.815 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.0 t -106.35 164.85 11.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.945 -1.097 . . . . 1.0 110.288 -178.897 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.532 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 8.9 t-20 -107.52 134.29 20.05 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.386 -0.821 . . . . 1.0 109.648 -179.301 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.575 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.3 Cg_endo -74.96 22.88 0.41 Allowed 'Trans proline' 0 CA--C 1.544 0.998 0 C-N-CA 122.327 2.018 . . . . 1.0 111.811 -179.813 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.532 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -115.82 7.04 14.46 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.398 -1.439 . . . . 1.0 108.912 179.534 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.53 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.99 15.16 2.86 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.385 -1.339 . . . . 1.0 107.385 179.522 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -78.3 88.19 4.34 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.984 -0.686 . . . . 1.0 111.522 -178.132 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.601 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -97.97 -167.49 1.52 Allowed 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.718 -1.215 . . . . 1.0 107.718 177.941 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.459 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.93 135.99 0.09 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.565 -1.335 . . . . 1.0 111.542 -179.331 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.59 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -163.47 154.19 2.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 107.526 -1.287 . . . . 1.0 107.526 178.419 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.554 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.1 m -98.6 141.92 30.83 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.833 -1.167 . . . . 1.0 109.59 -179.945 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.687 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -61.82 105.69 0.59 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 122.493 1.139 . . . . 1.0 109.281 178.541 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.525 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.8 p-10 -58.55 -138.63 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.982 0 CA-C-N 115.443 -0.799 . . . . 1.0 110.966 -179.862 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -53.79 -49.4 68.37 Favored 'General case' 0 N--CA 1.5 2.042 0 CA-C-O 121.675 0.75 . . . . 1.0 110.409 -178.672 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 74.7 m-80 -102.38 -37.29 8.11 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 106.066 -1.827 . . . . 1.0 106.066 178.382 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.687 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 110.16 65.84 0.55 Allowed Glycine 0 C--N 1.297 -1.596 0 CA-C-N 114.774 -1.103 . . . . 1.0 110.438 177.964 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.7 m -104.43 127.3 52.09 Favored 'General case' 0 N--CA 1.483 1.179 0 O-C-N 121.563 -0.963 . . . . 1.0 109.07 179.05 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.59 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.54 109.02 7.38 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 119.519 -0.872 . . . . 1.0 109.764 -179.443 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 53.3 p -115.3 119.57 36.74 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.105 -0.997 . . . . 1.0 109.373 179.97 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.481 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.33 142.21 30.25 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.48 -0.762 . . . . 1.0 109.844 179.935 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 54.8 p -99.44 149.02 23.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.414 -0.803 . . . . 1.0 109.156 179.751 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.53 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.2 OUTLIER -149.87 163.71 37.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.265 -0.897 . . . . 1.0 109.763 -178.93 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.554 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.5 p -96.57 126.1 41.51 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.125 -0.984 . . . . 1.0 109.259 -179.987 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.523 ' CG2' HG12 ' A' ' 19' ' ' VAL . 16.0 m -137.44 143.19 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 120.904 -1.123 . . . . 1.0 109.856 -179.102 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.58 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.9 ptt180 -147.3 -176.51 5.26 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.519 -1.363 . . . . 1.0 111.081 -179.774 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.548 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.04 -100.19 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 109.155 -0.683 . . . . 1.0 109.155 -179.714 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.52 139.97 51.96 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.779 -1.201 . . . . 1.0 107.801 179.208 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -162.45 138.79 7.62 Favored 'General case' 0 C--N 1.293 -1.89 0 C-N-CA 118.525 -1.27 . . . . 1.0 110.074 -177.819 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.502 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.8 mm-40 -34.7 120.82 0.5 Allowed 'General case' 0 N--CA 1.491 1.6 0 CA-C-O 121.395 0.617 . . . . 1.0 110.246 -178.713 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.505 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.18 50.8 1.9 Allowed Glycine 0 N--CA 1.492 2.402 0 C-N-CA 120.477 -0.868 . . . . 1.0 111.136 -179.101 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.575 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-30 -39.39 113.35 0.32 Allowed 'General case' 0 N--CA 1.507 2.424 0 O-C-N 121.057 -1.26 . . . . 1.0 109.916 179.488 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -85.73 126.78 34.23 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.835 -1.166 . . . . 1.0 109.504 -179.915 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 30.7 t80 -64.36 58.23 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.018 0 O-C-N 120.859 -1.151 . . . . 1.0 110.104 179.764 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -160.05 19.49 0.16 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.019 -1.051 . . . . 1.0 109.674 179.905 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.38 -26.71 5.52 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.154 -1.178 . . . . 1.0 110.154 179.856 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.451 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -94.27 154.81 17.33 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.06 -1.259 . . . . 1.0 110.42 -179.431 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.465 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -102.11 134.54 45.19 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.176 -1.046 . . . . 1.0 108.176 179.476 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.482 ' HB2' HD12 ' A' ' 77' ' ' LEU . 1.2 t90 -81.49 -16.6 51.41 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.784 -1.197 . . . . 1.0 110.506 -178.34 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 108.17 175.52 22.04 Favored Glycine 0 N--CA 1.485 1.921 0 N-CA-C 108.768 -1.733 . . . . 1.0 108.768 -179.675 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.44 104.32 0.61 Allowed 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 107.615 -1.254 . . . . 1.0 107.615 179.07 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.565 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 38.1 t -76.03 106.37 5.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.316 -0.865 . . . . 1.0 109.059 -178.862 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.464 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.5 OUTLIER -64.37 110.65 2.33 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.507 -0.746 . . . . 1.0 109.835 -179.268 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.548 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.61 -5.08 4.88 Favored 'General case' 0 N--CA 1.498 1.938 0 C-N-CA 118.261 -1.375 . . . . 1.0 109.752 179.357 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.5 p -85.57 -1.44 57.11 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.806 -1.184 . . . . 1.0 109.216 179.606 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.458 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.81 -48.36 3.07 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.299 -0.875 . . . . 1.0 109.051 -179.984 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.31 -178.57 3.64 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.57 -0.706 . . . . 1.0 109.491 179.905 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.46 115.36 30.12 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.429 -0.794 . . . . 1.0 109.096 -179.956 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.76 120.99 38.12 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.894 -1.129 . . . . 1.0 109.239 -179.514 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.561 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -99.26 145.54 27.16 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 122.328 1.061 . . . . 1.0 111.105 -179.338 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.526 ' CG1' HG13 ' A' ' 7' ' ' VAL . 97.5 t -103.21 110.51 29.97 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 106.958 -1.497 . . . . 1.0 106.958 177.858 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.499 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -154.09 -169.68 19.2 Favored Glycine 0 N--CA 1.486 1.996 0 C-N-CA 118.173 -1.965 . . . . 1.0 111.579 -177.635 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.503 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -117.87 173.92 6.48 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 108.532 -0.914 . . . . 1.0 108.532 -179.506 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.503 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 7.3 t . . . . . 0 C--N 1.292 -1.913 0 N-CA-C 109.235 -0.654 . . . . 1.0 109.235 -179.808 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.525 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.482 1.757 0 N-CA-C 108.115 -1.994 . . . . 1.0 108.115 . . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -172.61 -176.69 1.56 Allowed 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.526 -0.985 . . . . 1.0 109.715 179.467 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.23 -160.8 16.73 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.159 -1.976 . . . . 1.0 108.159 -179.383 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -46.84 176.41 0.01 OUTLIER 'Trans proline' 0 C--N 1.326 -0.656 0 CA-C-N 118.973 1.386 . . . . 1.0 109.998 179.127 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -95.21 -176.88 3.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.027 -1.046 . . . . 1.0 110.376 -178.814 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.499 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.62 167.19 13.38 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.741 -1.343 . . . . 1.0 109.741 -179.963 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -101.55 129.55 52.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.417 -1.049 . . . . 1.0 109.143 -179.381 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.561 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -68.91 115.86 8.72 Favored 'General case' 0 C--N 1.289 -2.041 0 N-CA-C 109.47 -0.567 . . . . 1.0 109.47 179.474 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.589 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.8 pt -97.8 168.49 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.262 -0.899 . . . . 1.0 108.59 179.857 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.414 ' O ' ' HA ' ' A' ' 11' ' ' SER . 2.8 t -142.36 158.49 43.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.022 -1.049 . . . . 1.0 110.302 -179.375 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.589 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 84.8 m-85 . . . . . 0 N--CA 1.484 1.259 0 O-C-N 121.374 -0.829 . . . . 1.0 109.324 -179.856 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.475 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.301 0 CA-C-O 122.333 1.063 . . . . 0.0 110.388 . . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.545 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.3 t -114.54 109.35 18.13 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 123.01 1.386 . . . . 0.0 109.768 -179.929 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.521 HG13 ' CG1' ' A' ' 95' ' ' VAL . 2.5 t -115.58 139.03 44.0 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.721 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.763 179.913 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.515 HG22 ' N ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -172.42 150.71 2.31 Favored Pre-proline 0 N--CA 1.487 1.403 0 O-C-N 121.154 -0.966 . . . . 0.0 108.948 -179.533 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.515 ' N ' HG22 ' A' ' 8' ' ' THR . 2.1 Cg_endo -75.38 152.77 98.03 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.498 -1.459 . . . . 0.0 109.533 -0.674 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.521 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 3.5 m -89.89 -25.42 20.99 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.763 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.465 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.5 m -136.83 166.43 23.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.483 -0.76 . . . . 0.0 109.435 179.935 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.28 37.72 35.99 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.522 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.625 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 30.9 mt -92.77 -44.68 8.39 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 123.153 1.454 . . . . 0.0 110.767 -178.272 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.84 145.56 0.03 OUTLIER 'General case' 0 C--N 1.258 -3.392 0 CA-C-N 113.721 -1.581 . . . . 0.0 110.045 -179.819 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.575 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.6 p-10 -50.64 108.34 0.23 Allowed 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 121.562 0.696 . . . . 0.0 111.727 -178.678 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.06 15.56 9.82 Favored Glycine 0 N--CA 1.484 1.895 0 C-N-CA 119.619 -1.277 . . . . 0.0 112.78 177.263 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.625 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 8.8 t -103.56 -173.12 2.24 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 121.056 2.428 . . . . 0.0 109.839 179.348 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.543 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 21.9 t -126.8 135.71 62.91 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.944 -178.771 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.542 ' CG1' ' CG2' ' A' ' 69' ' ' VAL . 27.4 m -112.37 154.75 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 O-C-N 121.348 -0.845 . . . . 0.0 108.883 178.789 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -111.24 109.43 19.45 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.219 -0.926 . . . . 0.0 108.987 179.947 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.2 p -105.11 140.2 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -179.972 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.557 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -137.43 161.39 36.47 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.793 -1.192 . . . . 0.0 110.004 179.583 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.582 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -134.54 140.44 11.74 Favored Glycine 0 C--N 1.299 -1.518 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 179.793 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -141.74 127.04 18.66 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.563 -1.551 . . . . 0.0 109.489 179.294 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 87.47 29.26 22.35 Favored Glycine 0 N--CA 1.488 2.16 0 C-N-CA 118.915 -1.612 . . . . 0.0 109.681 -179.821 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.9 mt -89.08 173.21 8.57 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.006 -1.291 . . . . 0.0 108.334 -179.85 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.56 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.21 98.85 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.015 -1.053 . . . . 0.0 109.797 -179.715 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.549 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.38 77.02 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.251 -179.199 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.05 33.35 0.28 Allowed Glycine 0 N--CA 1.486 1.991 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.533 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.528 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.7 p -142.81 110.57 5.87 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 120.981 -1.306 . . . . 0.0 111.028 -179.832 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.545 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -48.95 112.68 0.65 Allowed 'General case' 0 N--CA 1.495 1.814 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.99 178.366 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.504 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 21.6 m-85 -101.33 155.3 18.12 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.127 -0.983 . . . . 0.0 108.88 179.665 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.478 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -102.7 150.19 23.7 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.862 -1.149 . . . . 0.0 108.205 179.014 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.591 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 1.1 t -126.34 129.97 71.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.117 -0.989 . . . . 0.0 109.121 -178.074 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.435 ' HA2' ' HB2' ' A' ' 51' ' ' ASP . . . -178.56 172.67 45.06 Favored Glycine 0 N--CA 1.495 2.573 0 C-N-CA 117.812 -2.137 . . . . 0.0 112.201 179.866 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.575 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -101.02 109.1 20.97 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.364 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.1 m -130.05 148.93 51.96 Favored 'General case' 0 C--N 1.295 -1.765 0 O-C-N 120.96 -1.087 . . . . 0.0 110.27 -179.496 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -121.54 138.34 54.34 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.364 -0.835 . . . . 0.0 110.537 -179.307 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.626 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.34 114.79 26.61 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 178.249 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.5 m -104.46 14.57 6.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.069 -1.02 . . . . 0.0 110.518 -178.915 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.55 -175.0 0.08 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.902 -1.124 . . . . 0.0 109.974 179.702 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -73.6 98.79 2.91 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.441 -0.787 . . . . 0.0 109.539 -179.814 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.99 27.62 30.86 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 120.161 -1.018 . . . . 0.0 111.362 179.09 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -118.11 105.99 18.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 O-C-N 120.597 -1.531 . . . . 0.0 107.231 178.967 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.626 HD13 ' CD1' ' A' ' 39' ' ' TRP . 13.6 tp -118.12 104.73 11.11 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 120.496 -1.378 . . . . 0.0 109.917 -177.801 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.495 ' HB1' HG23 ' A' ' 86' ' ' VAL . . . -97.64 109.33 22.11 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.729 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -105.64 165.87 10.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.915 -1.116 . . . . 0.0 110.674 -178.479 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.475 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 7.8 t30 -110.32 130.25 23.07 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 121.601 -0.687 . . . . 0.0 109.247 -179.486 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.584 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -71.59 23.28 0.24 Allowed 'Trans proline' 0 CA--C 1.545 1.055 0 C-N-CA 122.054 1.836 . . . . 0.0 111.804 179.623 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.406 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -103.32 -3.07 26.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.448 -1.408 . . . . 0.0 109.074 179.641 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.535 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 1.6 m-20 -134.93 10.41 3.6 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.943 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -63.34 81.99 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.251 -178.905 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.591 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.34 -169.57 1.82 Allowed 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.096 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.45 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.1 t 179.27 132.94 0.09 Allowed 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.865 -1.147 . . . . 0.0 111.126 -179.532 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.545 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.1 p -156.32 152.61 8.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 178.367 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.545 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -97.91 142.29 29.83 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.696 -1.253 . . . . 0.0 109.872 -179.64 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.675 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.02 106.11 0.78 Allowed 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.447 1.117 . . . . 0.0 109.497 178.792 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.526 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.6 p-10 -57.92 -139.22 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.727 -179.978 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.549 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -55.13 -49.27 72.2 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.331 -0.856 . . . . 0.0 110.093 -178.95 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.7 p-10 -100.22 -39.03 8.25 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 178.482 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.675 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.94 66.36 0.58 Allowed Glycine 0 C--N 1.297 -1.619 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 178.288 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.582 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.0 m -101.48 129.81 47.61 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 121.601 -0.941 . . . . 0.0 109.056 179.103 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.557 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -138.13 108.95 6.66 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 119.31 -0.956 . . . . 0.0 109.498 -179.554 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.449 ' OG ' ' HB1' ' A' ' 22' ' ' ALA . 2.7 m -126.0 120.92 31.58 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.205 -0.934 . . . . 0.0 109.627 -179.774 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.08 144.78 30.24 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.482 -0.761 . . . . 0.0 109.391 179.871 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.432 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 32.1 p -98.83 141.12 32.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.368 -0.832 . . . . 0.0 109.115 179.894 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.543 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -140.56 174.69 10.27 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.333 -0.854 . . . . 0.0 109.65 -178.818 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.512 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -102.34 122.37 44.11 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.019 -1.051 . . . . 0.0 109.622 -179.751 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.542 ' CG2' ' CG1' ' A' ' 19' ' ' VAL . 16.9 m -133.47 143.17 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 120.911 -1.118 . . . . 0.0 110.159 -179.411 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.575 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.0 ptt180 -142.68 -166.87 2.38 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.663 -1.273 . . . . 0.0 110.09 179.568 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.565 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -72.32 -85.91 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.321 -0.862 . . . . 0.0 108.841 -179.575 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.62 138.81 58.58 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.291 -1.506 . . . . 0.0 107.362 178.799 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -164.48 139.08 5.49 Favored 'General case' 0 C--N 1.294 -1.82 0 C-N-CA 117.982 -1.487 . . . . 0.0 110.542 -177.496 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.6 mm-40 -34.09 120.55 0.44 Allowed 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.47 0.653 . . . . 0.0 110.612 -178.625 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.488 ' HA3' HG21 ' A' ' 86' ' ' VAL . . . -95.15 50.57 1.91 Allowed Glycine 0 N--CA 1.494 2.563 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.226 -179.418 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.584 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-85 -41.05 114.18 0.46 Allowed 'General case' 0 N--CA 1.508 2.45 0 O-C-N 120.868 -1.372 . . . . 0.0 109.964 179.453 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.53 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.3 tp -84.32 126.92 33.64 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.742 -1.224 . . . . 0.0 109.624 -179.951 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -64.05 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.812 -1.18 . . . . 0.0 110.275 179.688 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' LEU . 8.7 t0 -161.35 20.0 0.12 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.944 -1.098 . . . . 0.0 109.806 179.731 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.19 -26.88 5.31 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 110.041 -1.223 . . . . 0.0 110.041 179.963 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.475 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 5.9 p -92.38 152.78 19.56 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.056 -1.261 . . . . 0.0 110.386 -179.442 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.497 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 5.4 ptt180 -101.93 133.06 47.32 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.597 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.489 ' CD1' HD13 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -81.24 -20.96 39.9 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 120.713 -1.242 . . . . 0.0 110.527 -178.269 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.88 176.04 20.45 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 108.725 -1.75 . . . . 0.0 108.725 -179.629 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.49 109.42 1.37 Allowed 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 179.148 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.53 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 31.1 t -81.83 105.74 12.05 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 121.341 -0.849 . . . . 0.0 108.94 -178.934 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.2 OUTLIER -65.3 111.82 3.19 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.446 -0.783 . . . . 0.0 109.845 -179.357 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.538 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.56 -5.09 7.13 Favored 'General case' 0 N--CA 1.499 1.984 0 C-N-CA 118.285 -1.366 . . . . 0.0 109.648 179.369 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 p -83.76 -2.18 55.74 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.876 -1.14 . . . . 0.0 108.901 179.318 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.453 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.98 -49.81 2.95 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.347 -0.846 . . . . 0.0 109.013 -179.998 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.62 -178.34 3.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.551 -0.718 . . . . 0.0 109.517 179.919 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.3 116.29 31.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.43 -0.794 . . . . 0.0 108.99 -179.971 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.568 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.1 m -96.88 124.21 40.8 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.814 -1.179 . . . . 0.0 109.747 -179.168 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.564 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.0 147.32 26.71 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 122.33 1.062 . . . . 0.0 111.202 -179.44 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.521 ' CG1' HG13 ' A' ' 7' ' ' VAL . 43.8 t -104.75 111.53 34.65 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.567 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.458 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.35 -169.81 17.47 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 117.906 -2.092 . . . . 0.0 111.845 -177.481 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.478 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.57 -179.07 3.57 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -179.094 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.464 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.296 -1.735 0 O-C-N 121.277 -0.889 . . . . 0.0 109.438 -179.73 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.658 0 N-CA-C 107.676 -2.17 . . . . 0.0 107.676 . . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.55 -178.16 6.91 Favored 'General case' 0 C--N 1.306 -1.296 0 O-C-N 121.534 -0.98 . . . . 0.0 109.671 179.253 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.5 -162.04 17.06 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 108.356 -1.897 . . . . 0.0 108.356 -179.494 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' CD ' ' CE1' ' A' ' 32' ' ' TYR . 6.8 Cg_exo -46.12 174.16 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 CA-C-N 118.784 1.292 . . . . 0.0 110.022 179.387 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -92.82 -177.69 4.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.107 -0.996 . . . . 0.0 110.528 -178.588 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.458 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.8 167.44 13.1 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.946 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.06 131.19 53.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 O-C-N 121.325 -1.103 . . . . 0.0 109.095 -179.269 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.564 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.99 122.63 22.03 Favored 'General case' 0 C--N 1.29 -2.001 0 O-C-N 121.612 -0.68 . . . . 0.0 109.529 179.707 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.573 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.72 169.84 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 O-C-N 121.225 -0.922 . . . . 0.0 109.226 -179.982 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.465 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -135.48 155.33 50.7 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.233 -0.917 . . . . 0.0 109.721 -179.753 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.573 ' CE2' HD12 ' A' ' 110' ' ' ILE . 74.9 m-85 . . . . . 0 N--CA 1.488 1.426 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.767 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.164 0 CA-C-O 122.475 1.131 . . . . 0.0 110.618 . . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.537 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.8 p -106.89 104.95 14.75 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-O 122.503 1.144 . . . . 0.0 110.331 -179.43 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.525 HG12 ' CG1' ' A' ' 95' ' ' VAL . 10.6 t -117.25 119.16 61.02 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.478 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.303 179.582 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.49 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.61 148.38 12.67 Favored Pre-proline 0 N--CA 1.487 1.415 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -179.602 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.49 ' HA ' HG22 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.49 152.85 97.95 Favored 'Cis proline' 0 C--N 1.31 -1.497 0 C-N-CA 123.603 -1.415 . . . . 0.0 109.728 -0.445 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.477 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 3.7 m -92.53 -24.94 18.6 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.505 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.502 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 1.2 m -136.53 166.05 24.43 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.656 -0.652 . . . . 0.0 109.351 179.847 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.39 37.98 39.95 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 -179.723 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.615 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.6 mt -91.7 -43.34 9.64 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 123.344 1.545 . . . . 0.0 110.649 -178.31 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.02 144.43 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.376 -1.738 . . . . 0.0 109.853 -179.653 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.589 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 6.1 p-10 -51.13 107.78 0.2 Allowed 'General case' 0 C--N 1.302 -1.492 0 CA-C-O 121.586 0.708 . . . . 0.0 111.527 -178.534 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.12 14.26 9.33 Favored Glycine 0 N--CA 1.484 1.86 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.822 177.486 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.615 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 13.3 t -105.0 -172.6 2.13 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 121.13 2.465 . . . . 0.0 109.713 179.287 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.553 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 15.0 t -130.68 139.18 51.88 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.324 -178.793 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.519 HG21 ' CD1' ' A' ' 67' ' ' LEU . 31.7 m -114.72 154.91 16.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.037 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.523 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.6 tptm -110.45 109.36 19.7 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.337 180.0 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.523 ' CG1' HG21 ' A' ' 34' ' ' VAL . 1.9 p -105.1 123.95 59.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 179.948 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.55 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -112.38 166.16 11.55 Favored 'General case' 0 N--CA 1.485 1.279 0 O-C-N 120.927 -1.108 . . . . 0.0 108.94 179.594 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.62 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.19 108.1 0.48 Allowed Glycine 0 N--CA 1.482 1.763 0 N-CA-C 108.41 -1.876 . . . . 0.0 108.41 179.917 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.19 136.81 52.78 Favored 'General case' 0 N--CA 1.501 2.078 0 CA-C-N 119.432 1.616 . . . . 0.0 110.38 -179.287 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 87.61 28.11 25.2 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 118.895 -1.621 . . . . 0.0 109.806 179.68 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.533 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -93.4 170.6 9.49 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.988 -1.301 . . . . 0.0 108.309 179.852 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.555 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.9 100.8 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.068 -1.02 . . . . 0.0 110.018 -179.495 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.541 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.75 78.17 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.675 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.018 -179.36 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.32 34.48 0.28 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.735 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.531 ' OG1' ' CB ' ' A' ' 27' ' ' GLN . 18.8 p -139.56 105.67 5.23 Favored 'General case' 0 C--N 1.307 -1.278 0 O-C-N 121.162 -1.199 . . . . 0.0 111.273 -179.258 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.566 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.74 109.88 0.36 Allowed 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 177.824 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.463 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.2 m-30 -106.38 156.11 18.85 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.049 -1.032 . . . . 0.0 108.886 179.89 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -100.36 164.51 11.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.902 -1.124 . . . . 0.0 108.081 179.035 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.637 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.2 p -144.23 117.21 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.152 -0.967 . . . . 0.0 109.61 -178.1 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.496 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.9 -176.9 38.83 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 118.364 -1.874 . . . . 0.0 111.876 -179.717 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.557 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -101.48 109.21 20.99 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.837 0.827 . . . . 0.0 109.13 -179.572 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.21 148.44 52.04 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.192 -0.943 . . . . 0.0 109.511 179.579 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.7 138.52 54.58 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.179 -0.951 . . . . 0.0 110.815 -178.969 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.624 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.97 26.8 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 178.112 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.9 m -105.64 15.07 7.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 120.994 -1.066 . . . . 0.0 110.534 -178.84 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.11 -175.38 0.09 Allowed 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.857 -1.152 . . . . 0.0 110.064 179.724 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 64.0 p -72.24 97.44 1.99 Allowed 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.428 -0.795 . . . . 0.0 109.64 -179.784 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.56 27.54 32.24 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 120.154 -1.022 . . . . 0.0 111.419 178.877 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.591 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.65 106.21 19.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.526 -1.573 . . . . 0.0 107.221 178.93 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.624 HD12 ' CD1' ' A' ' 39' ' ' TRP . 12.8 tp -117.06 104.69 11.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.52 -1.362 . . . . 0.0 109.854 -177.659 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.534 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.08 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.299 0 O-C-N 120.842 -1.161 . . . . 0.0 107.887 178.77 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -106.87 163.99 12.49 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.015 -1.053 . . . . 0.0 110.44 -178.771 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.523 ' ND2' ' HB2' ' A' ' 50' ' ' ALA . 47.0 t30 -109.59 131.04 22.12 Favored Pre-proline 0 N--CA 1.502 2.173 0 O-C-N 121.59 -0.694 . . . . 0.0 109.618 -179.345 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.61 20.76 0.25 Allowed 'Trans proline' 0 C--N 1.318 -1.029 0 C-N-CA 122.21 1.94 . . . . 0.0 112.243 -179.813 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.523 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -110.53 5.68 21.39 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.379 -1.451 . . . . 0.0 108.846 179.166 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.52 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.01 16.82 2.64 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 179.339 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -81.74 88.82 6.26 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.868 -0.733 . . . . 0.0 111.285 -178.302 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.637 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.79 -167.25 1.23 Allowed 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 177.93 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.47 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.65 136.24 0.09 Allowed 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.479 -1.388 . . . . 0.0 111.395 -179.341 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.573 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -152.67 157.29 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.169 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.566 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.89 141.76 31.25 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.732 -1.23 . . . . 0.0 109.859 -179.772 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.685 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.17 107.51 1.06 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.43 1.109 . . . . 0.0 109.399 178.199 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.54 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 14.4 p-10 -61.75 -138.91 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.001 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.812 -179.997 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.541 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.49 -51.62 53.55 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.374 -0.828 . . . . 0.0 110.664 -178.665 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -102.23 -33.75 9.5 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 178.473 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.685 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.28 64.56 0.57 Allowed Glycine 0 C--N 1.299 -1.511 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.671 178.009 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.62 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 92.7 p -98.89 128.91 45.2 Favored 'General case' 0 N--CA 1.482 1.168 0 O-C-N 121.859 -0.789 . . . . 0.0 108.92 178.804 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.573 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.28 108.78 7.4 Favored 'General case' 0 C--N 1.296 -1.742 0 C-N-CA 119.67 -0.812 . . . . 0.0 109.416 -179.524 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 80.9 p -120.5 117.44 27.65 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.298 -0.876 . . . . 0.0 109.368 -179.906 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.461 HG22 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.31 140.83 28.04 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.418 -0.801 . . . . 0.0 109.609 -179.836 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 12.6 p -100.69 136.24 40.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.377 -0.827 . . . . 0.0 109.494 -179.947 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.521 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -133.84 165.85 24.03 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.423 -0.798 . . . . 0.0 109.392 -179.473 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.553 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.2 p -96.22 125.33 40.66 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.956 -1.09 . . . . 0.0 109.349 -179.946 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.54 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.4 m -135.82 143.49 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 120.919 -1.113 . . . . 0.0 109.929 -179.116 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.589 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.63 -175.9 4.98 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.495 -1.378 . . . . 0.0 110.984 179.957 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.551 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.56 -101.73 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.762 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.51 ' OG ' ' NH1' ' A' ' 71' ' ' ARG . 0.7 OUTLIER -57.29 142.0 44.84 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.731 -1.23 . . . . 0.0 108.187 179.424 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.585 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.65 136.85 6.39 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.775 -1.17 . . . . 0.0 109.637 -177.961 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.495 ' OE1' ' N ' ' A' ' 74' ' ' GLU . 1.6 mp0 -34.46 121.89 0.5 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.431 0.634 . . . . 0.0 110.306 -178.402 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.534 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -93.58 49.91 2.34 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.236 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.5 m-85 -39.3 113.85 0.36 Allowed 'General case' 0 N--CA 1.507 2.382 0 O-C-N 121.204 -1.174 . . . . 0.0 109.992 179.555 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.539 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -85.81 126.46 34.04 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 120.944 -1.098 . . . . 0.0 109.55 -179.797 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -64.28 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.869 -1.144 . . . . 0.0 110.052 179.665 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.539 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.4 t70 -159.96 19.49 0.16 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.157 -0.964 . . . . 0.0 109.66 179.764 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.96 -27.45 5.47 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.75 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.4 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 19.5 p -94.49 160.46 14.64 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.033 -1.275 . . . . 0.0 110.362 -179.361 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.467 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.75 136.62 46.24 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.689 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.459 ' HB2' HD11 ' A' ' 77' ' ' LEU . 1.8 t90 -82.89 -17.96 41.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.765 -1.21 . . . . 0.0 110.526 -178.487 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.94 175.6 19.89 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 108.778 -1.729 . . . . 0.0 108.778 -179.632 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.05 104.74 0.92 Allowed 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 179.134 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.572 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.5 t -76.48 106.3 6.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.388 -0.82 . . . . 0.0 109.258 -178.913 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.459 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.6 OUTLIER -66.02 111.28 3.28 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.47 -0.769 . . . . 0.0 109.892 -179.41 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.551 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.75 -5.49 4.27 Favored 'General case' 0 N--CA 1.5 2.068 0 C-N-CA 118.256 -1.377 . . . . 0.0 109.816 179.484 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.6 p -86.82 -0.14 55.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.708 -1.245 . . . . 0.0 109.111 179.585 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.459 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.33 -50.59 2.85 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.398 -0.814 . . . . 0.0 108.945 179.96 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.07 -179.95 4.09 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.484 -0.76 . . . . 0.0 109.392 179.845 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.97 115.86 31.2 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.333 -0.854 . . . . 0.0 108.964 179.917 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.84 121.32 38.57 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.993 -1.067 . . . . 0.0 109.308 -179.421 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.546 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.92 145.7 28.3 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 122.355 1.074 . . . . 0.0 111.2 -179.306 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.525 ' CG1' HG12 ' A' ' 7' ' ' VAL . 58.6 t -103.12 109.78 27.83 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 177.675 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.438 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.26 -170.73 16.47 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 118.271 -1.919 . . . . 0.0 111.663 -177.738 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -114.36 -179.55 3.66 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 -178.95 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.463 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 37.1 p . . . . . 0 C--N 1.297 -1.693 0 O-C-N 121.337 -0.852 . . . . 0.0 109.321 -179.235 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.771 0 N-CA-C 107.572 -2.211 . . . . 0.0 107.572 . . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.61 -178.01 6.79 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.538 -0.977 . . . . 0.0 109.793 179.253 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.75 -163.0 16.93 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -179.321 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.473 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.4 Cg_exo -46.71 175.69 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.643 0 CA-C-N 118.77 1.285 . . . . 0.0 110.1 179.325 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -90.06 -176.04 4.75 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.019 -1.05 . . . . 0.0 110.599 -178.787 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.438 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.82 167.0 13.88 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.896 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.89 132.66 49.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.373 -1.075 . . . . 0.0 109.174 -179.334 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.546 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.27 118.88 17.73 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.547 -0.72 . . . . 0.0 109.685 179.675 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.57 HD13 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -98.02 170.07 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.211 -0.93 . . . . 0.0 108.999 179.72 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.502 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 34.4 m -140.95 156.85 45.99 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.167 -0.958 . . . . 0.0 110.094 -179.674 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.57 ' CE1' HD13 ' A' ' 110' ' ' ILE . 96.3 m-85 . . . . . 0 N--CA 1.486 1.334 0 O-C-N 121.333 -0.855 . . . . 0.0 109.541 -179.754 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.478 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.21 0 CA-C-O 122.486 1.136 . . . . 0.0 110.397 . . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.548 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.5 t -113.52 109.17 18.21 Favored 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 123.15 1.452 . . . . 0.0 109.266 179.954 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.526 HG12 ' CG1' ' A' ' 95' ' ' VAL . 4.4 t -116.25 127.38 73.87 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.709 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.94 -179.847 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.523 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.44 148.11 12.7 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.286 -0.884 . . . . 0.0 108.874 -179.696 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.523 ' CA ' HG21 ' A' ' 8' ' ' THR . 7.1 Cg_endo -79.96 147.65 77.46 Favored 'Cis proline' 0 C--N 1.31 -1.451 0 O-C-N 123.778 1.409 . . . . 0.0 109.35 -0.797 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.452 ' HB2' ' HA ' ' A' ' 110' ' ' ILE . 79.8 p -89.27 -25.8 21.5 Favored 'General case' 0 C--N 1.295 -1.785 0 O-C-N 121.563 -0.71 . . . . 0.0 109.203 179.788 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.457 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 1.0 OUTLIER -132.23 162.03 31.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.405 -0.81 . . . . 0.0 109.55 -179.927 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.9 37.29 29.98 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 -179.661 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.604 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 35.5 mt -92.39 -42.81 9.57 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 123.295 1.521 . . . . 0.0 110.516 -178.388 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.42 144.69 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.283 0 CA-C-N 113.321 -1.763 . . . . 0.0 109.936 -179.649 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.566 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 11.3 p-10 -51.2 106.11 0.12 Allowed 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.647 0.737 . . . . 0.0 111.494 -178.513 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.98 14.67 8.35 Favored Glycine 0 N--CA 1.485 1.929 0 C-N-CA 119.354 -1.403 . . . . 0.0 113.006 177.358 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.604 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.9 t -104.87 -171.2 1.88 Allowed 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 121.143 2.471 . . . . 0.0 109.516 179.218 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.54 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 17.0 t -127.63 135.88 61.95 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.128 -179.119 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.586 ' CG1' ' CG2' ' A' ' 69' ' ' VAL . 29.2 m -109.18 155.27 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.835 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.52 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -110.35 109.23 19.57 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 108.834 179.804 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.476 ' CA ' HG13 ' A' ' 7' ' ' VAL . 2.3 p -105.01 139.5 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.399 -0.813 . . . . 0.0 108.832 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.556 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -137.58 161.13 37.25 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.804 -1.185 . . . . 0.0 109.945 179.631 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.59 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -134.05 141.57 12.93 Favored Glycine 0 C--N 1.297 -1.623 0 N-CA-C 108.318 -1.913 . . . . 0.0 108.318 179.768 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.64 125.98 16.6 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.706 -1.467 . . . . 0.0 109.294 179.369 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.11 28.2 21.19 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 118.873 -1.632 . . . . 0.0 109.599 -179.625 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.544 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.8 mt -88.84 174.59 7.88 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.988 -1.301 . . . . 0.0 108.365 179.953 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.555 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.66 98.45 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.887 -1.133 . . . . 0.0 109.823 -179.521 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 77.71 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.724 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.248 -179.253 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.563 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.73 34.37 0.31 Allowed Glycine 0 N--CA 1.486 2.014 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.525 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.541 ' O ' ' CD2' ' A' ' 32' ' ' TYR . 66.6 p -144.24 109.73 5.19 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.005 -1.291 . . . . 0.0 111.211 -179.585 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.553 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -43.8 127.01 4.97 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.43 178.02 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.541 ' CD2' ' O ' ' A' ' 30' ' ' THR . 15.3 m-85 -116.98 153.48 32.56 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.388 -0.82 . . . . 0.0 108.834 179.844 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.5 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -105.24 148.97 26.38 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.816 -1.177 . . . . 0.0 108.264 179.059 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.593 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 0.9 OUTLIER -125.82 126.46 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.169 -0.957 . . . . 0.0 109.071 -178.103 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -172.77 173.29 45.47 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 117.707 -2.187 . . . . 0.0 112.527 -179.915 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.572 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -100.36 110.31 22.52 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 179.368 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 63.1 m -129.35 152.11 49.26 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 121.196 -0.94 . . . . 0.0 110.156 -179.612 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.47 135.45 51.37 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.632 -0.668 . . . . 0.0 110.046 179.585 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.64 ' CE2' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.71 114.43 26.35 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.579 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 m -106.86 15.15 7.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.915 -1.115 . . . . 0.0 110.713 -178.633 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.6 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.4 -174.52 0.07 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.819 -1.175 . . . . 0.0 110.135 179.63 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 29.5 p -70.14 96.32 1.07 Allowed 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.407 -0.808 . . . . 0.0 110.013 -179.468 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.04 28.4 34.4 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 120.166 -1.016 . . . . 0.0 111.532 178.749 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.6 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.32 106.04 19.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 120.58 -1.541 . . . . 0.0 107.327 178.83 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.64 HD13 ' CE2' ' A' ' 39' ' ' TRP . 11.7 tp -116.47 106.54 13.71 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.59 -1.319 . . . . 0.0 109.775 -177.65 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.581 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -96.13 109.76 22.14 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 120.697 -1.252 . . . . 0.0 108.381 179.281 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 86.8 m -101.48 147.59 26.2 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.346 -0.847 . . . . 0.0 110.48 -178.371 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.462 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 31.1 t30 -96.66 137.87 21.43 Favored Pre-proline 0 N--CA 1.502 2.169 0 O-C-N 121.01 -1.056 . . . . 0.0 108.826 178.878 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.585 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 8.0 Cg_endo -75.76 26.71 0.4 Allowed 'Trans proline' 0 N--CA 1.496 1.649 0 C-N-CA 125.188 3.925 . . . . 0.0 111.507 -179.068 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.454 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -126.1 9.12 7.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.424 -1.423 . . . . 0.0 109.576 179.881 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.517 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.83 15.97 2.49 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 179.502 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -77.91 87.14 4.11 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.059 -178.675 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.593 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -98.98 -168.22 1.6 Allowed 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 178.569 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.449 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 179.13 133.98 0.09 Allowed 'General case' 0 N--CA 1.486 1.329 0 O-C-N 120.766 -1.209 . . . . 0.0 111.42 -179.428 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.56 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -159.14 153.62 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.493 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.553 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.51 144.63 27.02 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.683 -1.261 . . . . 0.0 109.645 -179.86 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.682 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.67 107.42 1.41 Allowed 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 122.525 1.155 . . . . 0.0 109.502 178.7 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.536 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 p-10 -61.39 -139.97 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.782 179.98 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.06 -50.73 58.1 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.382 -0.824 . . . . 0.0 110.664 -178.799 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -103.48 -32.64 9.39 Favored 'General case' 0 C--N 1.286 -2.165 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 178.713 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.682 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 106.0 65.72 0.65 Allowed Glycine 0 C--N 1.296 -1.652 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 178.309 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.59 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.1 m -100.54 128.96 46.43 Favored 'General case' 0 N--CA 1.484 1.245 0 O-C-N 121.523 -0.987 . . . . 0.0 108.808 178.856 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.56 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.9 108.65 6.64 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.242 -0.983 . . . . 0.0 109.588 -179.516 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.44 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 27.3 p -123.82 120.24 32.04 Favored 'General case' 0 C--N 1.305 -1.33 0 O-C-N 121.246 -0.909 . . . . 0.0 109.513 -179.982 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.76 146.05 31.06 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.485 -0.759 . . . . 0.0 109.321 179.819 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 55.4 p -98.57 144.56 27.75 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.295 -0.878 . . . . 0.0 109.287 179.945 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.528 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.1 OUTLIER -144.02 165.01 28.97 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.434 -0.791 . . . . 0.0 109.413 -179.216 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.54 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 3.8 p -95.04 123.71 38.68 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.127 -0.983 . . . . 0.0 109.329 -179.887 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.586 ' CG2' ' CG1' ' A' ' 19' ' ' VAL . 16.6 m -137.89 142.49 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 120.963 -1.085 . . . . 0.0 109.701 -179.292 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.566 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 5.4 ptt180 -140.71 -166.79 2.21 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 120.677 -1.264 . . . . 0.0 109.968 -179.989 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.543 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -71.66 -80.41 0.06 Allowed 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.809 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -64.87 135.79 56.13 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 178.648 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.572 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -161.08 133.6 6.09 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 117.862 -1.535 . . . . 0.0 110.563 -177.643 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.504 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -33.64 120.74 0.41 Allowed 'General case' 0 N--CA 1.493 1.694 0 CA-C-O 121.615 0.722 . . . . 0.0 110.391 -178.472 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.581 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -93.4 50.52 2.4 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.456 -0.878 . . . . 0.0 111.611 -178.916 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.7 OUTLIER -38.42 116.88 0.58 Allowed 'General case' 0 N--CA 1.51 2.567 0 O-C-N 121.094 -1.239 . . . . 0.0 110.053 179.41 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.537 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -87.28 125.71 34.38 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 120.8 -1.187 . . . . 0.0 109.455 179.855 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.0 t80 -64.14 58.6 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.819 -1.176 . . . . 0.0 110.086 179.82 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.9 t70 -160.51 20.02 0.14 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.059 -1.026 . . . . 0.0 109.668 179.898 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.46 -28.64 5.19 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 179.813 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.444 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 40.7 p -94.23 160.57 14.63 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.066 -1.255 . . . . 0.0 110.293 -179.52 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.476 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -108.02 136.8 47.11 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.794 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.463 ' HB2' HD12 ' A' ' 77' ' ' LEU . 1.9 t90 -80.74 -20.34 42.97 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.809 -1.182 . . . . 0.0 110.351 -178.688 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.43 176.24 20.22 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 108.644 -1.782 . . . . 0.0 108.644 -179.565 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -62.55 109.97 1.55 Allowed 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.166 -1.196 . . . . 0.0 107.779 179.168 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.548 HG21 ' CB ' ' A' ' 46' ' ' ALA . 37.1 t -83.22 103.53 10.62 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -179.104 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.475 ' HB3' HG22 ' A' ' 90' ' ' THR . 0.2 OUTLIER -65.77 111.71 3.37 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.383 -0.823 . . . . 0.0 109.894 -179.257 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.543 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -65.83 -3.67 5.43 Favored 'General case' 0 N--CA 1.5 2.055 0 C-N-CA 118.334 -1.346 . . . . 0.0 109.886 179.457 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.402 ' C ' HG23 ' A' ' 90' ' ' THR . 1.4 p -86.93 11.61 13.08 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.739 -1.225 . . . . 0.0 108.794 179.487 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.475 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -127.25 -48.22 1.45 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.428 -0.795 . . . . 0.0 108.989 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.36 -179.85 4.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.559 -0.713 . . . . 0.0 109.504 -179.948 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.1 113.66 27.32 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.318 -0.864 . . . . 0.0 109.079 -179.986 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.51 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 2.6 m -97.12 124.89 41.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.879 -1.138 . . . . 0.0 109.438 -179.512 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.522 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -104.87 147.15 28.06 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 122.403 1.097 . . . . 0.0 111.38 -179.27 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.526 ' CG1' HG12 ' A' ' 7' ' ' VAL . 43.4 t -103.53 112.04 35.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.977 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 177.577 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.06 -170.44 16.73 Favored Glycine 0 N--CA 1.488 2.137 0 C-N-CA 118.076 -2.011 . . . . 0.0 111.738 -177.607 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.47 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.08 -179.43 3.7 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 -179.126 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 4.5 p . . . . . 0 C--N 1.293 -1.885 0 O-C-N 121.337 -0.852 . . . . 0.0 109.287 -179.523 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.75 0 N-CA-C 107.59 -2.204 . . . . 0.0 107.59 . . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.54 -178.74 7.49 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 121.62 -0.929 . . . . 0.0 109.355 178.9 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -173.29 -165.97 30.97 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.737 -1.745 . . . . 0.0 108.737 -179.471 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.492 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.6 Cg_exo -46.39 -175.86 0.0 OUTLIER 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 123.57 2.847 . . . . 0.0 109.923 179.512 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -94.78 172.13 8.35 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.975 -1.078 . . . . 0.0 110.574 -178.957 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -110.47 159.71 13.71 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 179.897 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.36 128.17 55.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.36 -1.082 . . . . 0.0 109.29 -179.378 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.522 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.75 119.49 17.06 Favored 'General case' 0 C--N 1.289 -2.042 0 O-C-N 121.591 -0.693 . . . . 0.0 109.358 179.569 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.583 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -97.99 171.07 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.228 -0.92 . . . . 0.0 109.116 -179.945 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.457 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.86 154.91 48.46 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.088 -1.007 . . . . 0.0 109.811 -179.763 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.583 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 76.1 m-85 . . . . . 0 N--CA 1.485 1.324 0 O-C-N 121.1 -1.0 . . . . 0.0 109.467 -179.752 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.468 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.458 0 CA-C-O 122.355 1.074 . . . . 0.0 110.613 . . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.549 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.1 t -113.19 108.66 17.58 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 123.166 1.46 . . . . 0.0 109.227 179.418 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 4.3 t -116.89 141.37 35.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.717 0 CA-C-N 114.185 -1.371 . . . . 0.0 109.953 -179.716 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.482 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -178.07 150.61 0.76 Allowed Pre-proline 0 N--CA 1.487 1.415 0 O-C-N 121.248 -0.907 . . . . 0.0 108.668 -179.613 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.482 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.67 152.24 96.92 Favored 'Cis proline' 0 C--N 1.312 -1.39 0 C-N-CA 123.485 -1.465 . . . . 0.0 109.679 -0.699 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.465 ' HA ' HG23 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -90.75 -24.85 20.25 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.768 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.507 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.7 m -136.71 164.15 28.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.451 -0.781 . . . . 0.0 109.482 179.856 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.39 37.47 31.38 Favored Glycine 0 N--CA 1.497 2.702 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 -179.717 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.608 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 36.6 mt -92.18 -43.2 9.47 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 123.203 1.477 . . . . 0.0 110.421 -178.348 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.91 144.45 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.312 0 CA-C-N 113.459 -1.7 . . . . 0.0 109.929 -179.657 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.59 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.1 p-10 -50.79 107.56 0.18 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.521 0.677 . . . . 0.0 111.458 -178.583 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.32 13.5 9.77 Favored Glycine 0 N--CA 1.485 1.938 0 C-N-CA 119.435 -1.364 . . . . 0.0 112.935 177.342 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.608 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.6 t -104.45 -172.61 2.13 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 121.213 2.507 . . . . 0.0 109.734 179.261 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.551 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 15.9 t -129.37 138.3 54.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.371 0 CA-C-N 114.761 -1.109 . . . . 0.0 111.019 -179.014 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.524 HG13 ' CG2' ' A' ' 69' ' ' VAL . 27.8 m -113.67 154.62 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.922 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.491 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -108.55 109.38 20.6 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.208 -0.932 . . . . 0.0 108.996 179.936 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.509 HG13 ' CG2' ' A' ' 34' ' ' VAL . 2.1 p -103.49 140.89 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.789 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.569 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -136.35 160.54 38.42 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 118.659 -1.216 . . . . 0.0 109.89 179.734 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.583 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.18 143.81 15.46 Favored Glycine 0 C--N 1.293 -1.814 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 179.716 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.26 124.96 12.55 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 120.908 -1.348 . . . . 0.0 108.882 179.185 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.86 27.58 23.59 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 119.339 -1.41 . . . . 0.0 109.659 -179.68 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.562 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.7 mt -86.72 175.53 8.21 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 120.909 -1.348 . . . . 0.0 108.62 -179.781 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.553 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.54 97.12 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.047 -1.033 . . . . 0.0 109.58 -179.821 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 76.19 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.495 -178.978 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.21 33.27 0.28 Allowed Glycine 0 N--CA 1.486 1.985 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.26 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.61 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.4 t -148.13 115.32 6.18 Favored 'General case' 0 C--N 1.308 -1.214 0 O-C-N 120.831 -1.394 . . . . 0.0 111.276 179.973 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.546 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.3 127.84 5.88 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.781 178.367 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.61 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.8 m-85 -119.09 149.03 42.38 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.51 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.477 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.62 163.86 12.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.61 -1.307 . . . . 0.0 107.518 178.631 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.623 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 9.2 p -149.08 114.62 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.045 -1.035 . . . . 0.0 110.143 -177.74 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.489 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.14 -175.41 37.16 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 118.365 -1.874 . . . . 0.0 111.731 -179.865 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.557 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.34 109.01 21.19 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-O 121.829 0.823 . . . . 0.0 108.819 -179.695 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.47 149.04 52.33 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.231 -0.918 . . . . 0.0 109.6 179.751 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.48 139.24 54.07 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.301 -0.875 . . . . 0.0 110.732 -179.041 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.621 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 114.78 26.6 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.174 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.4 m -105.53 15.29 6.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.999 -1.063 . . . . 0.0 110.573 -178.639 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.09 -175.42 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.955 -1.091 . . . . 0.0 110.003 179.734 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 56.8 p -71.95 97.45 1.86 Allowed 'General case' 0 N--CA 1.485 1.305 0 O-C-N 121.364 -0.835 . . . . 0.0 109.748 -179.73 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.65 27.71 34.5 Favored Glycine 0 N--CA 1.492 2.404 0 C-N-CA 120.235 -0.983 . . . . 0.0 111.423 178.985 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.591 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.05 106.24 19.98 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 O-C-N 120.59 -1.536 . . . . 0.0 107.29 178.829 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.621 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.4 tp -116.71 104.55 11.47 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.478 -1.388 . . . . 0.0 109.81 -177.715 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.544 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.2 109.45 22.21 Favored 'General case' 0 N--CA 1.485 1.276 0 O-C-N 120.834 -1.166 . . . . 0.0 107.945 178.828 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -107.4 163.9 12.65 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.964 -1.085 . . . . 0.0 110.297 -178.73 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.494 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 38.8 t30 -108.56 128.77 24.98 Favored Pre-proline 0 N--CA 1.501 2.111 0 O-C-N 121.46 -0.775 . . . . 0.0 109.503 -179.386 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.585 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -70.14 19.76 0.19 Allowed 'Trans proline' 0 CA--C 1.544 1.017 0 C-N-CA 122.088 1.859 . . . . 0.0 112.386 -179.867 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.494 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -108.96 4.85 23.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.388 -1.445 . . . . 0.0 108.868 179.157 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.518 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.79 16.7 2.68 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 179.497 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -81.67 90.58 6.33 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.974 -0.691 . . . . 0.0 111.088 -178.446 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.39 -171.08 1.77 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 178.015 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.464 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.85 134.99 0.09 Allowed 'General case' 0 C--N 1.305 -1.356 0 O-C-N 120.403 -1.435 . . . . 0.0 111.554 -179.357 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.601 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.5 p -150.07 159.11 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 177.894 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.546 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.57 146.05 25.66 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.543 -1.348 . . . . 0.0 109.726 -179.724 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.675 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.24 108.71 3.28 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 122.31 1.052 . . . . 0.0 109.629 178.999 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.524 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.5 t0 -63.02 -138.65 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.526 179.858 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -53.7 -51.45 63.2 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.289 -0.882 . . . . 0.0 110.21 -178.931 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.8 p-10 -98.58 -37.08 9.68 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 178.563 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.675 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 106.06 65.62 0.64 Allowed Glycine 0 C--N 1.297 -1.588 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.412 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.583 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 53.7 p -98.49 132.62 43.77 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 121.426 -1.043 . . . . 0.0 109.245 179.28 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.601 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -138.02 108.53 6.55 Favored 'General case' 0 C--N 1.296 -1.754 0 C-N-CA 119.235 -0.986 . . . . 0.0 109.52 -179.708 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.407 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 21.8 p -124.82 120.75 32.61 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.147 -0.97 . . . . 0.0 109.797 -179.803 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.466 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -148.04 146.72 28.99 Favored 'General case' 0 C--N 1.3 -1.587 0 O-C-N 121.581 -0.7 . . . . 0.0 109.304 179.648 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.4 p -100.61 138.88 37.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.322 -0.861 . . . . 0.0 109.404 179.975 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.526 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.1 OUTLIER -138.03 165.54 26.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.404 -0.81 . . . . 0.0 109.529 -179.405 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.551 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.2 p -96.8 125.7 41.44 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.068 -1.02 . . . . 0.0 109.354 -179.857 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.533 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -136.8 144.42 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.99 -1.069 . . . . 0.0 109.888 -179.26 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.59 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.0 OUTLIER -149.0 -174.93 4.77 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 120.455 -1.403 . . . . 0.0 110.998 -179.845 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.561 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.94 -101.84 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 -179.766 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.05 140.46 49.06 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.815 -1.178 . . . . 0.0 108.052 179.43 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.58 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -161.79 137.13 7.45 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 118.642 -1.223 . . . . 0.0 109.759 -178.118 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.481 ' C ' ' O ' ' A' ' 73' ' ' PHE . 10.3 mm-40 -34.97 122.06 0.55 Allowed 'General case' 0 N--CA 1.49 1.546 0 CA-C-O 121.387 0.613 . . . . 0.0 110.351 -178.468 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.544 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.29 51.25 1.86 Allowed Glycine 0 N--CA 1.493 2.458 0 C-N-CA 120.548 -0.835 . . . . 0.0 111.06 -179.268 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -39.24 115.39 0.49 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.04 -1.271 . . . . 0.0 110.108 179.572 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.53 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -86.49 126.46 34.45 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 120.928 -1.108 . . . . 0.0 109.495 -179.895 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.8 t80 -64.38 58.46 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.989 0 O-C-N 120.876 -1.14 . . . . 0.0 110.091 179.685 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' LEU . 17.0 t0 -160.19 19.65 0.15 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.987 -1.07 . . . . 0.0 109.664 179.83 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.05 -28.03 5.26 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.999 -1.241 . . . . 0.0 109.999 179.931 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.414 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 10.3 p -94.27 161.0 14.43 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.034 -1.274 . . . . 0.0 110.384 -179.446 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.467 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -107.97 138.13 44.77 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.84 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.462 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -83.61 -17.96 39.82 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.71 -1.244 . . . . 0.0 110.674 -178.411 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.0 176.43 19.99 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 108.644 -1.783 . . . . 0.0 108.644 -179.648 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.53 104.45 1.01 Allowed 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.188 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.565 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 41.0 t -76.09 106.62 6.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.287 -0.883 . . . . 0.0 109.133 -178.926 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.7 OUTLIER -65.68 111.24 3.1 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.493 -0.755 . . . . 0.0 110.026 -179.352 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.561 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.47 -5.71 4.07 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.813 179.353 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.5 p -86.58 -0.93 57.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.747 -1.221 . . . . 0.0 109.202 179.681 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.453 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -112.87 -50.1 2.9 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.29 -0.881 . . . . 0.0 108.995 179.977 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.94 -179.04 3.83 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.488 -0.757 . . . . 0.0 109.42 179.782 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.06 115.75 30.8 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.386 -0.821 . . . . 0.0 108.905 179.992 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.531 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -96.87 121.43 38.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.851 -1.156 . . . . 0.0 109.483 -179.455 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.85 146.29 28.5 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.437 1.113 . . . . 0.0 111.215 -179.32 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.3 t -102.46 109.77 27.35 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 177.632 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.401 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.6 -173.11 18.38 Favored Glycine 0 N--CA 1.486 2.016 0 C-N-CA 118.142 -1.98 . . . . 0.0 111.709 -177.601 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.477 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -113.71 -178.95 3.5 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.069 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.456 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.0 OUTLIER . . . . . 0 C--N 1.297 -1.711 0 O-C-N 121.219 -0.926 . . . . 0.0 109.711 -179.203 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.696 0 N-CA-C 107.776 -2.13 . . . . 0.0 107.776 . . . . . . . . . 0 0 . 1 . 036 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.61 -177.72 5.76 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-O 122.007 0.908 . . . . 0.0 109.785 179.279 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.38 -161.85 15.27 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 -179.44 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.3 Cg_exo -47.08 177.98 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.693 0 CA-C-N 118.874 1.337 . . . . 0.0 110.202 179.324 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -92.27 -175.17 3.96 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.06 -1.025 . . . . 0.0 110.511 -178.83 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.401 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.24 163.46 14.68 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.944 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.9 128.92 52.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.426 -1.044 . . . . 0.0 109.222 -179.441 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.22 123.22 23.26 Favored 'General case' 0 C--N 1.29 -2.015 0 O-C-N 121.687 -0.633 . . . . 0.0 109.562 179.672 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.596 ' CD1' ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.72 167.69 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 O-C-N 121.221 -0.924 . . . . 0.0 109.193 -179.925 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.507 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -134.73 154.26 51.65 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.277 -0.889 . . . . 0.0 109.565 -179.873 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.596 ' CZ ' ' CD1' ' A' ' 110' ' ' ILE . 30.3 m-85 . . . . . 0 N--CA 1.487 1.382 0 O-C-N 121.15 -0.969 . . . . 0.0 109.566 -179.729 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.475 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.456 0 CA-C-O 122.364 1.078 . . . . 0.0 110.863 . . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.545 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.6 t -112.46 108.58 17.76 Favored 'General case' 0 C--N 1.296 -1.738 0 CA-C-O 123.084 1.421 . . . . 0.0 109.117 179.357 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.526 ' CG2' HG21 ' A' ' 21' ' ' VAL . 2.4 t -115.31 140.38 36.99 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.699 0 CA-C-N 114.275 -1.329 . . . . 0.0 110.102 -179.521 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.519 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -176.04 149.82 1.03 Allowed Pre-proline 0 N--CA 1.487 1.375 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.772 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.519 ' CA ' HG21 ' A' ' 8' ' ' THR . 4.2 Cg_endo -77.43 152.57 93.88 Favored 'Cis proline' 0 C--N 1.312 -1.353 0 C-N-CA 123.572 -1.428 . . . . 0.0 109.313 -0.813 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.447 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 3.5 m -89.76 -26.51 20.58 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 179.761 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.476 ' HB3' ' HB2' ' A' ' 111' ' ' SER . 5.3 m -135.23 164.31 27.99 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.587 -0.696 . . . . 0.0 109.609 179.858 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.3 37.03 29.14 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 108.767 -1.733 . . . . 0.0 108.767 -179.841 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.6 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 40.6 mt -93.23 -42.69 9.21 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-O 123.242 1.496 . . . . 0.0 110.405 -178.406 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.494 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.83 145.3 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.277 0 CA-C-N 113.322 -1.763 . . . . 0.0 109.954 -179.735 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.593 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.2 p-10 -51.26 106.81 0.15 Allowed 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.493 0.663 . . . . 0.0 111.513 -178.749 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.54 13.16 9.01 Favored Glycine 0 N--CA 1.483 1.823 0 C-N-CA 119.401 -1.38 . . . . 0.0 112.986 177.317 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.6 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.2 t -105.31 -172.4 2.09 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 121.242 2.521 . . . . 0.0 109.673 179.167 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.535 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 20.2 t -126.6 135.56 63.39 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 114.866 -1.061 . . . . 0.0 111.097 -178.897 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.583 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 17.3 m -109.04 156.82 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.664 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -114.06 109.27 18.18 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.091 -1.005 . . . . 0.0 109.16 179.949 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.526 HG21 ' CG2' ' A' ' 7' ' ' VAL . 2.0 p -104.07 140.01 23.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 179.749 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.558 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -134.77 160.4 38.29 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 118.605 -1.238 . . . . 0.0 109.85 179.856 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -131.4 144.96 16.6 Favored Glycine 0 C--N 1.293 -1.807 0 N-CA-C 108.179 -1.968 . . . . 0.0 108.179 179.751 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.88 124.53 11.79 Favored 'General case' 0 C--N 1.295 -1.792 0 O-C-N 120.901 -1.352 . . . . 0.0 108.785 179.182 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.99 26.7 23.47 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.337 -1.411 . . . . 0.0 109.631 -179.623 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.544 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.9 mt -87.43 174.57 8.44 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 120.897 -1.355 . . . . 0.0 108.445 -179.901 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.556 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.42 96.96 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.04 -1.037 . . . . 0.0 109.674 -179.714 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 76.83 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.45 -179.091 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.01 33.77 0.32 Allowed Glycine 0 N--CA 1.486 2.027 0 N-CA-C 109.731 -1.347 . . . . 0.0 109.731 179.347 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.543 ' CG2' ' CB ' ' A' ' 27' ' ' GLN . 1.2 t -148.15 114.88 6.03 Favored 'General case' 0 C--N 1.309 -1.181 0 O-C-N 120.869 -1.371 . . . . 0.0 111.098 179.899 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.555 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.45 129.86 3.93 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.996 178.55 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.499 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 10.7 m-85 -119.47 150.84 39.55 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.368 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -102.05 159.39 15.41 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.703 -1.248 . . . . 0.0 107.856 178.728 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.624 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.1 p -144.03 117.27 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.075 -1.016 . . . . 0.0 109.852 -177.914 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.12 -178.73 40.18 Favored Glycine 0 N--CA 1.494 2.518 0 C-N-CA 118.324 -1.893 . . . . 0.0 111.849 -179.86 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.56 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -100.43 108.88 20.98 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -179.862 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.24 148.34 52.06 Favored 'General case' 0 C--N 1.296 -1.731 0 O-C-N 121.286 -0.884 . . . . 0.0 109.704 179.777 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -121.96 138.63 54.34 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.274 -0.891 . . . . 0.0 110.776 -179.005 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.626 ' CE2' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.45 114.75 26.55 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 178.137 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -106.12 14.79 7.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.934 -1.104 . . . . 0.0 110.64 -178.716 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.61 -175.65 0.08 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.926 -1.109 . . . . 0.0 110.101 179.694 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.546 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.3 97.53 1.26 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 121.799 0.809 . . . . 0.0 110.031 -179.605 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.26 27.11 37.64 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 120.261 -0.971 . . . . 0.0 111.429 178.785 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -114.85 106.14 20.03 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 O-C-N 120.617 -1.519 . . . . 0.0 107.375 178.818 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.626 HD13 ' CE2' ' A' ' 39' ' ' TRP . 12.4 tp -117.01 104.71 11.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.459 -1.401 . . . . 0.0 109.629 -177.803 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.94 109.55 22.28 Favored 'General case' 0 N--CA 1.485 1.316 0 O-C-N 120.808 -1.183 . . . . 0.0 108.415 179.093 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.6 t -105.98 162.83 13.25 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.952 -1.092 . . . . 0.0 110.115 -179.254 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.488 ' OD1' ' HB2' ' A' ' 74' ' ' GLU . 17.0 t30 -107.01 140.89 21.84 Favored Pre-proline 0 N--CA 1.504 2.259 0 O-C-N 121.348 -0.845 . . . . 0.0 110.13 -179.218 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.581 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 8.2 Cg_endo -76.36 27.65 0.41 Allowed 'Trans proline' 0 C--N 1.318 -1.029 0 C-N-CA 122.662 2.241 . . . . 0.0 111.636 -179.665 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.417 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -121.49 3.57 10.21 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.394 -1.441 . . . . 0.0 109.522 -179.869 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.5 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -138.48 15.41 2.75 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 179.435 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -80.11 91.68 5.55 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.508 -0.745 . . . . 0.0 110.815 -178.675 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.59 -168.53 1.33 Allowed 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.387 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.474 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.98 135.2 0.09 Allowed 'General case' 0 N--CA 1.486 1.349 0 O-C-N 120.633 -1.292 . . . . 0.0 111.486 -179.381 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.585 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.4 p -149.02 157.53 6.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 177.935 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.555 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.28 146.61 24.96 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.636 -1.29 . . . . 0.0 109.897 -179.489 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.678 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -67.26 108.31 2.68 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-O 122.361 1.077 . . . . 0.0 109.622 178.847 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.519 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.6 t0 -62.95 -138.94 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.005 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.822 -179.867 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.546 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.9 -51.99 36.42 Favored 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.349 -0.845 . . . . 0.0 110.676 -178.657 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.06 -32.36 9.24 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.714 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.678 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.07 64.89 0.61 Allowed Glycine 0 C--N 1.298 -1.583 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 178.262 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.5 m -99.57 129.31 45.72 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.465 -1.021 . . . . 0.0 108.664 178.772 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.585 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.74 108.63 6.69 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.805 -179.329 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 51.8 p -122.15 119.45 31.32 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.259 -0.901 . . . . 0.0 109.455 179.936 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.422 HG22 HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.22 143.46 30.29 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.519 -0.738 . . . . 0.0 109.417 179.894 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.9 p -100.01 140.63 33.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.406 -0.809 . . . . 0.0 109.406 179.961 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.527 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -139.37 168.82 18.97 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.405 -0.809 . . . . 0.0 109.382 -179.426 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.8 p -96.82 124.86 40.92 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.03 -1.044 . . . . 0.0 109.424 -179.823 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.531 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 15.9 m -137.05 143.54 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.932 -1.105 . . . . 0.0 109.728 -179.259 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.593 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.1 ptt180 -148.79 -175.34 4.91 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.519 -1.363 . . . . 0.0 110.9 -179.835 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.561 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.76 -101.2 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.7 -179.413 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.86 142.03 42.61 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.812 -1.18 . . . . 0.0 108.319 179.785 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.582 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.93 134.59 4.38 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 118.783 -1.167 . . . . 0.0 109.64 -178.209 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.514 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -33.81 122.82 0.46 Allowed 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.519 0.676 . . . . 0.0 110.465 -178.138 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.2 49.15 2.7 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.273 -179.187 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.581 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -38.47 115.0 0.42 Allowed 'General case' 0 N--CA 1.509 2.519 0 O-C-N 121.096 -1.237 . . . . 0.0 109.909 179.615 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.548 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -86.72 126.42 34.55 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.938 -1.101 . . . . 0.0 109.357 179.972 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 24.5 t80 -63.48 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.902 -1.124 . . . . 0.0 110.307 179.912 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.548 ' N ' ' O ' ' A' ' 77' ' ' LEU . 22.2 t0 -162.04 20.18 0.1 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.992 -1.068 . . . . 0.0 109.786 179.736 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.65 -27.76 5.17 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 179.821 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.432 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 14.3 p -93.15 160.23 14.94 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.047 -1.267 . . . . 0.0 110.26 -179.466 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.467 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.4 OUTLIER -107.63 136.69 46.96 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.835 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.456 ' CD1' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -82.56 -19.1 39.19 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.848 -1.158 . . . . 0.0 110.407 -178.667 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.54 175.41 19.14 Favored Glycine 0 N--CA 1.485 1.908 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.613 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.84 107.14 1.37 Allowed 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.271 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.561 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 47.2 t -79.62 106.71 11.11 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.362 -0.836 . . . . 0.0 109.262 -179.014 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.8 OUTLIER -67.69 111.67 4.37 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.407 -0.808 . . . . 0.0 109.805 -179.554 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.561 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.16 -5.69 3.49 Favored 'General case' 0 N--CA 1.5 2.046 0 C-N-CA 118.189 -1.404 . . . . 0.0 109.826 179.414 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.14 0.02 54.58 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.644 -1.285 . . . . 0.0 109.158 179.51 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.448 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.66 -49.72 2.87 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.366 -0.834 . . . . 0.0 109.007 -179.98 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.77 179.63 4.21 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.433 -0.792 . . . . 0.0 109.482 179.944 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.94 116.13 31.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.445 -0.785 . . . . 0.0 108.922 179.908 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.85 121.8 39.11 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.86 -1.15 . . . . 0.0 109.371 -179.381 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.55 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.68 146.51 27.63 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.411 1.101 . . . . 0.0 111.359 -179.213 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.456 HG22 HG23 ' A' ' 110' ' ' ILE . 65.7 t -102.95 110.06 28.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 177.502 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.76 -173.01 17.61 Favored Glycine 0 N--CA 1.487 2.063 0 C-N-CA 118.041 -2.028 . . . . 0.0 111.828 -177.441 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.481 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -115.98 -178.11 3.32 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 -179.057 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.47 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.0 OUTLIER . . . . . 0 C--N 1.297 -1.68 0 O-C-N 121.234 -0.916 . . . . 0.0 109.331 -179.527 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.695 0 N-CA-C 107.687 -2.165 . . . . 0.0 107.687 . . . . . . . . . 0 0 . 1 . 037 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.43 -178.49 7.18 Favored 'General case' 0 C--N 1.307 -1.245 0 O-C-N 121.527 -0.984 . . . . 0.0 109.431 179.05 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.64 -166.18 33.36 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -179.554 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.475 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.3 Cg_exo -49.09 -177.37 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.677 0 CA-C-N 118.7 1.25 . . . . 0.0 110.288 179.525 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -94.54 -176.85 4.04 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.082 -1.011 . . . . 0.0 110.419 -179.02 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -120.45 161.3 14.73 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.969 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.87 126.37 54.59 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.349 -1.089 . . . . 0.0 109.188 -179.472 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.55 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.1 119.76 16.75 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.745 -0.597 . . . . 0.0 109.431 179.669 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.548 ' CD1' ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.96 168.53 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.201 -0.937 . . . . 0.0 109.303 -179.956 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.476 ' HB2' ' HB3' ' A' ' 11' ' ' SER . 2.4 m -138.2 151.31 47.57 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.384 -0.823 . . . . 0.0 109.542 -179.955 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.548 ' CZ ' ' CD1' ' A' ' 110' ' ' ILE . 22.8 m-85 . . . . . 0 N--CA 1.487 1.382 0 O-C-N 121.146 -0.971 . . . . 0.0 109.531 -179.674 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.484 1.251 0 CA-C-O 122.43 1.109 . . . . 0.0 110.129 . . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.548 ' CG2' ' O ' ' A' ' 6' ' ' THR . 5.1 t -116.28 109.02 16.83 Favored 'General case' 0 C--N 1.293 -1.858 0 CA-C-O 123.129 1.442 . . . . 0.0 109.622 179.968 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.499 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 8.0 t -116.92 137.84 49.51 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.709 0 CA-C-N 114.074 -1.421 . . . . 0.0 109.862 -179.874 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.522 HG22 ' CA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -174.37 151.02 1.57 Allowed Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.331 -0.856 . . . . 0.0 108.804 -179.617 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.522 ' CA ' HG22 ' A' ' 8' ' ' THR . 5.3 Cg_endo -77.47 150.94 91.85 Favored 'Cis proline' 0 C--N 1.312 -1.383 0 C-N-CA 123.539 -1.442 . . . . 0.0 109.392 -0.907 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.455 ' HB2' ' HA ' ' A' ' 110' ' ' ILE . 89.6 p -92.52 -23.08 19.21 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 121.433 -0.792 . . . . 0.0 109.27 179.692 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.491 ' CB ' ' HB3' ' A' ' 111' ' ' SER . 7.0 m -132.16 159.97 37.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.484 -0.76 . . . . 0.0 109.542 -179.859 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.73 37.61 29.76 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.633 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.605 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.4 mt -91.1 -43.69 9.74 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-O 123.146 1.45 . . . . 0.0 110.641 -178.273 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.494 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.35 144.88 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.298 0 CA-C-N 113.471 -1.695 . . . . 0.0 110.224 -179.72 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.57 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.0 p-10 -50.2 106.11 0.11 Allowed 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.494 0.664 . . . . 0.0 111.626 -178.548 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.81 15.0 8.92 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 119.426 -1.368 . . . . 0.0 113.037 177.05 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.605 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.0 t -105.8 -174.02 2.44 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 121.29 2.545 . . . . 0.0 109.837 179.227 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.542 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 15.7 t -130.71 138.56 53.35 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 CA-C-N 114.702 -1.135 . . . . 0.0 111.178 -178.721 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.458 HG13 HD11 ' A' ' 13' ' ' LEU . 33.8 m -113.06 155.16 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 178.75 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.499 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -103.96 108.82 20.33 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.021 -1.05 . . . . 0.0 109.167 179.971 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.524 HG11 ' CG2' ' A' ' 34' ' ' VAL . 2.3 p -101.51 140.06 21.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.893 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.568 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -133.76 159.18 41.37 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.866 -1.146 . . . . 0.0 109.638 179.484 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.59 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -141.08 108.8 0.57 Allowed Glycine 0 N--CA 1.482 1.76 0 N-CA-C 108.753 -1.739 . . . . 0.0 108.753 179.97 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.28 140.35 49.42 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 119.259 1.529 . . . . 0.0 110.426 -179.461 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.48 26.9 34.32 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 118.945 -1.598 . . . . 0.0 109.946 179.57 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.552 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -93.0 169.88 10.09 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 120.933 -1.333 . . . . 0.0 108.534 -179.946 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.58 101.32 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.117 -0.989 . . . . 0.0 109.777 -179.426 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.92 77.88 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.864 -179.327 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.89 33.83 0.28 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.77 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.543 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 18.8 p -138.79 106.35 5.58 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.279 -1.13 . . . . 0.0 110.93 -179.465 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -51.39 109.91 0.39 Allowed 'General case' 0 N--CA 1.497 1.903 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.532 178.181 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.543 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 32.6 m-85 -102.81 155.8 18.08 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.147 -0.971 . . . . 0.0 108.901 179.74 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -100.46 158.42 15.92 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 178.696 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.63 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.3 p -139.83 120.07 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.189 -0.944 . . . . 0.0 109.472 -177.818 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -169.89 -178.34 40.86 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.23 -1.938 . . . . 0.0 111.796 -179.742 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.547 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -100.21 109.78 22.03 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.918 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 68.1 m -127.16 152.77 46.9 Favored 'General case' 0 C--N 1.293 -1.86 0 O-C-N 121.22 -0.925 . . . . 0.0 109.819 179.619 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.87 135.66 51.27 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.535 -0.728 . . . . 0.0 110.452 179.965 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.644 ' CE2' HD11 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.94 114.69 26.55 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.231 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 20.1 m -104.97 14.42 7.21 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 120.851 -1.155 . . . . 0.0 110.809 -178.65 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.596 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 173.73 -174.5 0.06 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.81 -1.181 . . . . 0.0 110.158 179.65 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 24.5 p -71.69 97.67 1.79 Allowed 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.467 -0.77 . . . . 0.0 109.827 -179.67 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.85 27.63 31.22 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 120.285 -0.959 . . . . 0.0 111.487 178.836 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.596 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.3 t -116.35 106.09 19.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 O-C-N 120.538 -1.566 . . . . 0.0 107.372 179.001 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.644 HD11 ' CE2' ' A' ' 39' ' ' TRP . 11.7 tp -116.85 106.37 13.38 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.548 -1.345 . . . . 0.0 109.989 -177.703 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.563 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -95.72 109.78 22.02 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.803 -1.185 . . . . 0.0 108.161 179.137 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 66.5 m -100.12 145.88 27.47 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.225 -0.922 . . . . 0.0 110.415 -178.354 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.475 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 7.4 t30 -99.23 129.23 29.8 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.217 -0.927 . . . . 0.0 108.673 179.097 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.4 Cg_endo -71.41 23.05 0.23 Allowed 'Trans proline' 0 C--N 1.317 -1.108 0 C-N-CA 122.102 1.868 . . . . 0.0 111.968 179.923 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.35 -5.86 22.54 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.4 -1.437 . . . . 0.0 109.106 179.68 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.534 ' CB ' ' HB3' ' A' ' 67' ' ' LEU . 5.6 m-20 -134.13 6.39 3.62 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.351 -0.843 . . . . 0.0 108.89 -179.961 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -62.42 84.18 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.336 -0.852 . . . . 0.0 110.655 -178.672 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.63 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.5 -167.87 1.32 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 178.605 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.474 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.47 135.73 0.08 Allowed 'General case' 0 C--N 1.304 -1.404 0 O-C-N 120.68 -1.262 . . . . 0.0 111.383 -179.321 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.577 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -150.83 156.13 6.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 177.94 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.69 142.0 30.8 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.721 -1.237 . . . . 0.0 110.162 -179.525 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.678 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -62.26 106.4 0.73 Allowed 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 122.559 1.171 . . . . 0.0 109.45 178.316 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.526 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.2 p-10 -59.7 -139.51 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.862 179.962 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.75 -50.87 59.78 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.454 -0.778 . . . . 0.0 110.715 -178.711 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -102.94 -33.79 9.18 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 178.462 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.678 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.43 65.9 0.61 Allowed Glycine 0 C--N 1.298 -1.548 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.575 177.941 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.59 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 23.2 m -102.81 126.49 49.97 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 178.631 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.24 109.17 8.68 Favored 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 119.457 -0.897 . . . . 0.0 109.296 -179.29 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -123.35 119.42 30.04 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.412 -0.805 . . . . 0.0 109.646 -179.73 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.55 150.31 36.17 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.698 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.2 p -98.04 136.7 37.92 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.196 -0.94 . . . . 0.0 109.484 -179.785 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.542 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.2 OUTLIER -128.99 160.65 32.06 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.442 -0.786 . . . . 0.0 109.485 -178.913 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.537 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.3 p -100.95 123.23 44.82 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.03 -1.044 . . . . 0.0 108.861 179.525 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.524 ' CB ' ' OE1' ' A' ' 36' ' ' GLN . 17.6 m -135.25 142.81 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 120.872 -1.143 . . . . 0.0 110.486 -178.579 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.57 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.4 ptt180 -145.5 -171.81 3.75 Favored 'General case' 0 N--CA 1.484 1.263 0 O-C-N 120.582 -1.324 . . . . 0.0 110.825 179.55 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.541 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -57.34 -99.67 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.197 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.79 142.23 50.8 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 120.343 -1.473 . . . . 0.0 108.218 179.517 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.591 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -162.07 135.09 6.05 Favored 'General case' 0 C--N 1.295 -1.771 0 C-N-CA 118.581 -1.248 . . . . 0.0 110.027 -178.05 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.487 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 20.5 mt-10 -35.22 120.99 0.55 Allowed 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.458 0.647 . . . . 0.0 110.231 -178.723 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.563 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -94.74 51.22 2.01 Favored Glycine 0 N--CA 1.494 2.55 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.665 -178.793 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.587 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -38.32 115.88 0.48 Allowed 'General case' 0 N--CA 1.507 2.396 0 O-C-N 121.04 -1.271 . . . . 0.0 110.012 179.26 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.1 tp -86.78 126.06 34.35 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 120.816 -1.177 . . . . 0.0 109.594 -179.623 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -64.34 58.93 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.842 -1.161 . . . . 0.0 109.837 179.519 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.6 t70 -159.68 19.76 0.17 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.984 -1.072 . . . . 0.0 109.715 179.936 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.6 -27.91 5.59 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.811 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.443 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 73.1 p -98.49 162.6 13.07 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.142 -1.21 . . . . 0.0 110.39 -179.439 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.473 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 2.1 ptt180 -106.54 142.13 36.7 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.859 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.471 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.6 t90 -85.19 -19.77 31.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.635 -1.291 . . . . 0.0 110.601 -178.505 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.1 177.12 18.77 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.631 -1.788 . . . . 0.0 108.631 -179.424 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -66.4 105.33 1.43 Allowed 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 179.198 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.591 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 44.3 t -76.13 104.83 4.52 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.24 -0.913 . . . . 0.0 109.048 -179.058 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -66.05 111.17 3.24 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.46 -0.775 . . . . 0.0 109.686 -179.508 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.541 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.77 -4.85 4.76 Favored 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 118.245 -1.382 . . . . 0.0 109.71 179.51 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -86.83 1.81 51.15 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.782 -1.199 . . . . 0.0 109.017 179.341 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.465 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -117.01 -51.14 2.56 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.376 -0.828 . . . . 0.0 108.951 179.975 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.31 -179.92 4.09 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.479 -0.763 . . . . 0.0 109.383 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.25 115.7 30.85 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.446 -0.784 . . . . 0.0 108.935 179.807 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.527 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.03 124.53 41.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.84 -1.162 . . . . 0.0 109.582 -179.264 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.52 ' HA ' ' O ' ' A' ' 108' ' ' VAL . 1.0 OUTLIER -102.97 147.73 26.57 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.344 1.069 . . . . 0.0 111.405 -179.241 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.482 ' CG1' HG12 ' A' ' 7' ' ' VAL . 44.8 t -104.6 113.12 40.78 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 177.498 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -155.08 -169.77 19.99 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 117.886 -2.102 . . . . 0.0 111.802 -177.766 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.469 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -120.56 177.59 5.0 Favored 'General case' 0 N--CA 1.484 1.245 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -179.138 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.469 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 2.1 t . . . . . 0 C--N 1.294 -1.833 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.907 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.654 0 N-CA-C 107.96 -2.056 . . . . 0.0 107.96 . . . . . . . . . 0 0 . 1 . 038 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.53 -177.65 6.08 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-O 122.1 0.952 . . . . 0.0 109.839 179.263 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.496 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.31 -161.34 21.77 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.176 -1.97 . . . . 0.0 108.176 -179.361 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.496 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.3 Cg_exo -47.73 -178.77 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.671 0 CA-C-N 118.96 1.38 . . . . 0.0 110.313 179.206 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -96.69 178.04 5.45 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.979 -1.075 . . . . 0.0 110.364 -178.958 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.467 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.7 172.64 14.32 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.983 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -110.87 153.55 12.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.495 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.52 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -95.75 122.45 38.55 Favored 'General case' 0 C--N 1.291 -1.959 0 O-C-N 121.217 -0.927 . . . . 0.0 109.392 179.79 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.577 HD13 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.99 168.98 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 121.091 -1.005 . . . . 0.0 109.032 -179.905 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.491 ' HB3' ' CB ' ' A' ' 11' ' ' SER . 13.0 t -138.92 157.9 45.18 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.175 -0.953 . . . . 0.0 109.68 -179.91 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.577 ' CE2' HD13 ' A' ' 110' ' ' ILE . 82.0 m-85 . . . . . 0 N--CA 1.485 1.32 0 O-C-N 121.23 -0.919 . . . . 0.0 109.488 -179.706 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.493 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.484 1.245 0 CA-C-O 122.366 1.079 . . . . 0.0 110.28 . . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.551 ' CG2' ' O ' ' A' ' 6' ' ' THR . 5.6 t -115.9 109.16 17.22 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 123.122 1.439 . . . . 0.0 109.829 -179.827 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.516 HG13 ' CG1' ' A' ' 95' ' ' VAL . 2.2 t -114.78 133.7 60.1 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.19 -1.368 . . . . 0.0 109.787 179.855 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.52 HG22 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -169.26 150.17 4.15 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.232 -0.917 . . . . 0.0 108.809 -179.604 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.52 ' CA ' HG22 ' A' ' 8' ' ' THR . 1.2 Cg_endo -75.33 155.31 99.56 Favored 'Cis proline' 0 C--N 1.312 -1.35 0 C-N-CA 123.521 -1.45 . . . . 0.0 109.399 -0.873 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.493 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 15.4 m -99.62 -19.83 16.63 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.754 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.51 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 19.2 m -136.02 159.07 42.84 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.426 -0.796 . . . . 0.0 109.678 -179.945 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.37 37.78 30.67 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 108.526 -1.829 . . . . 0.0 108.526 -179.688 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.613 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 30.1 mt -89.75 -44.31 10.08 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 123.056 1.407 . . . . 0.0 110.599 -178.383 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.478 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.0 144.39 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.363 0 CA-C-N 113.633 -1.622 . . . . 0.0 109.935 -179.638 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.584 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.1 p-10 -50.86 105.0 0.09 Allowed 'General case' 0 C--N 1.301 -1.504 0 CA-C-O 121.632 0.729 . . . . 0.0 111.435 -178.565 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.04 14.77 7.61 Favored Glycine 0 N--CA 1.485 1.902 0 C-N-CA 119.396 -1.383 . . . . 0.0 113.055 177.383 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.613 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 13.7 t -104.48 -173.55 2.33 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 121.264 2.532 . . . . 0.0 109.717 179.116 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.546 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 18.1 t -127.65 135.99 61.64 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.89 -1.05 . . . . 0.0 111.424 -178.598 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.526 HG11 ' CG2' ' A' ' 69' ' ' VAL . 34.7 m -111.2 154.6 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.529 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.496 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 5.4 tttt -110.31 109.28 19.66 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 108.894 179.875 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.516 HG13 ' CG2' ' A' ' 34' ' ' VAL . 2.3 p -101.27 139.17 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.347 -0.846 . . . . 0.0 108.734 -179.929 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.594 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -134.0 162.38 32.22 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 118.819 -1.153 . . . . 0.0 110.107 179.656 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.6 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.71 140.35 11.39 Favored Glycine 0 C--N 1.299 -1.525 0 N-CA-C 107.899 -2.08 . . . . 0.0 107.899 179.694 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.94 124.96 15.24 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.514 -1.58 . . . . 0.0 109.409 179.299 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.55 28.62 18.81 Favored Glycine 0 N--CA 1.488 2.107 0 C-N-CA 118.776 -1.678 . . . . 0.0 109.678 -179.705 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -89.79 171.86 9.32 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.006 -1.291 . . . . 0.0 108.249 179.875 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.552 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.92 99.6 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.969 -1.082 . . . . 0.0 109.926 -179.498 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.5 77.05 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.136 -179.333 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.91 33.83 0.22 Allowed Glycine 0 N--CA 1.486 2.022 0 N-CA-C 109.311 -1.515 . . . . 0.0 109.311 179.634 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 40.4 p -141.38 107.32 5.16 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 121.09 -1.241 . . . . 0.0 111.399 -179.35 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.83 109.79 0.36 Allowed 'General case' 0 N--CA 1.496 1.835 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.621 177.828 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.48 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.4 m-30 -105.42 157.54 17.27 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.119 -0.988 . . . . 0.0 108.798 179.745 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.474 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -100.45 167.52 10.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.762 -1.211 . . . . 0.0 108.048 179.209 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.624 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.7 p -148.13 119.59 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.132 -0.98 . . . . 0.0 109.648 -178.094 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -171.26 -176.74 40.59 Favored Glycine 0 N--CA 1.496 2.638 0 C-N-CA 118.369 -1.872 . . . . 0.0 111.5 -179.763 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.56 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -100.71 108.3 20.13 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 -179.979 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -130.01 148.32 51.85 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.306 -0.872 . . . . 0.0 109.833 179.685 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.25 139.84 53.53 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.227 -0.921 . . . . 0.0 110.739 -179.024 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.617 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.12 114.93 26.78 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.119 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.7 m -106.21 15.49 7.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.035 -1.041 . . . . 0.0 110.526 -178.724 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.594 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.7 -176.66 0.09 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.948 -1.095 . . . . 0.0 110.068 179.739 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.548 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.2 t -69.78 96.72 1.01 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.503 -0.748 . . . . 0.0 110.009 -179.61 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.93 28.82 33.39 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 120.15 -1.024 . . . . 0.0 111.355 178.892 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.594 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.25 106.42 20.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 O-C-N 120.586 -1.538 . . . . 0.0 107.221 178.769 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.617 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.7 tp -116.89 104.68 11.55 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.427 -1.421 . . . . 0.0 109.706 -177.545 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -98.23 109.54 22.28 Favored 'General case' 0 N--CA 1.484 1.244 0 O-C-N 120.827 -1.171 . . . . 0.0 108.295 178.928 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -106.27 166.13 10.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.956 -1.09 . . . . 0.0 110.209 -179.073 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.54 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 12.6 t-20 -108.22 134.45 20.18 Favored Pre-proline 0 N--CA 1.498 1.952 0 O-C-N 121.376 -0.827 . . . . 0.0 109.599 -179.411 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.1 Cg_endo -73.93 24.29 0.34 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 122.452 2.102 . . . . 0.0 112.108 -179.655 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.54 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -113.75 -0.69 14.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.322 -1.486 . . . . 0.0 109.183 179.643 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.557 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 2.2 m-20 -136.38 18.26 3.15 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 179.651 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -78.04 83.96 4.32 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.66 -0.816 . . . . 0.0 110.62 -178.525 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -106.27 -170.51 1.74 Allowed 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 178.523 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.471 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.61 136.39 0.09 Allowed 'General case' 0 C--N 1.305 -1.351 0 O-C-N 120.705 -1.247 . . . . 0.0 111.008 -179.273 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.584 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.7 p -148.58 159.07 6.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 178.259 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.56 141.6 31.2 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 120.729 -1.232 . . . . 0.0 109.802 -179.923 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.672 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -65.09 108.04 1.72 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 122.305 1.05 . . . . 0.0 109.651 178.57 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.54 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.0 t0 -64.08 -139.44 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.027 0 CA-C-O 121.377 0.608 . . . . 0.0 110.809 179.864 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.95 -52.0 36.91 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.386 -0.821 . . . . 0.0 110.821 -178.706 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -102.49 -32.17 10.08 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 178.633 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.672 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 103.3 66.6 0.73 Allowed Glycine 0 C--N 1.298 -1.572 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.262 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 52.6 m -98.82 130.73 45.26 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.603 -0.939 . . . . 0.0 108.764 178.866 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.594 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -134.09 109.13 8.74 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 119.299 -0.96 . . . . 0.0 109.335 -179.576 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.9 m -123.08 116.86 24.19 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.237 -0.914 . . . . 0.0 109.498 -179.803 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.455 HG21 HG13 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.24 143.58 29.31 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.385 -0.822 . . . . 0.0 109.523 -179.993 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.0 p -99.83 147.33 25.62 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.363 -0.835 . . . . 0.0 109.469 -179.892 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.544 ' HB2' ' OD2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -147.56 168.43 21.98 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.441 -0.787 . . . . 0.0 109.398 -179.155 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.546 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.5 p -100.19 121.81 42.03 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.84 -1.163 . . . . 0.0 110.098 -178.937 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.557 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 15.5 m -129.08 144.17 38.99 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 120.897 -1.127 . . . . 0.0 110.162 -179.404 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.584 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.7 ptt180 -149.1 -177.47 5.84 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 120.576 -1.327 . . . . 0.0 110.838 179.722 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.538 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.6 -102.58 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.702 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.508 ' OG ' ' NH1' ' A' ' 71' ' ' ARG . 0.7 OUTLIER -57.56 140.41 50.96 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 120.712 -1.242 . . . . 0.0 108.161 179.388 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.41 136.69 8.66 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.934 -178.124 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.485 ' C ' ' O ' ' A' ' 73' ' ' PHE . 8.9 mm-40 -32.28 120.15 0.29 Allowed 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.47 0.652 . . . . 0.0 110.6 -178.591 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -90.84 47.19 2.95 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.573 -0.823 . . . . 0.0 111.175 -179.195 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -38.38 113.99 0.33 Allowed 'General case' 0 N--CA 1.508 2.428 0 O-C-N 121.168 -1.195 . . . . 0.0 110.085 179.607 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.532 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -87.56 126.33 34.87 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.869 -1.145 . . . . 0.0 109.509 -179.816 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 16.4 t80 -64.26 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.856 -1.153 . . . . 0.0 110.035 179.693 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.0 t0 -159.87 19.25 0.16 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.982 -1.073 . . . . 0.0 109.735 179.895 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.93 -27.02 5.64 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.837 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.3 p -95.17 161.47 14.1 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.006 -1.29 . . . . 0.0 110.361 -179.491 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.463 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -107.66 136.32 47.61 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.832 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.483 ' CD1' HD11 ' A' ' 77' ' ' LEU . 2.3 t90 -83.03 -17.61 42.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.858 -1.151 . . . . 0.0 110.502 -178.649 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.71 174.02 19.65 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 108.862 -1.695 . . . . 0.0 108.862 -179.632 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.97 105.97 0.95 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.08 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.578 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 46.1 t -76.94 105.46 5.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.385 -0.822 . . . . 0.0 109.45 -178.682 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.467 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.9 m-20 -64.01 110.61 2.19 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.43 -0.793 . . . . 0.0 109.7 -179.624 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.538 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.3 t -65.0 -4.48 4.65 Favored 'General case' 0 N--CA 1.499 2.024 0 C-N-CA 118.289 -1.364 . . . . 0.0 109.969 179.505 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 38.7 p -86.82 -1.14 57.54 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.712 -1.242 . . . . 0.0 109.239 179.579 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.467 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -112.28 -50.27 2.91 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.34 -0.85 . . . . 0.0 108.917 -179.99 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.39 -178.27 3.61 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.596 -0.69 . . . . 0.0 109.301 179.724 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.29 115.51 30.33 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.349 -0.844 . . . . 0.0 109.14 -179.989 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.77 121.62 38.82 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.848 -1.158 . . . . 0.0 109.244 -179.578 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.608 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.31 145.26 30.22 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 122.424 1.107 . . . . 0.0 111.16 -179.176 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.516 ' CG1' HG13 ' A' ' 7' ' ' VAL . 49.1 t -101.73 109.88 27.1 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.999 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 177.68 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.453 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.7 -170.57 16.62 Favored Glycine 0 N--CA 1.486 2.012 0 C-N-CA 118.26 -1.924 . . . . 0.0 111.666 -177.569 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.474 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -112.91 179.61 3.92 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 -179.197 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.48 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 33.8 p . . . . . 0 C--N 1.295 -1.762 0 O-C-N 121.381 -0.824 . . . . 0.0 109.585 -179.328 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.772 0 N-CA-C 107.657 -2.177 . . . . 0.0 107.657 . . . . . . . . . 0 0 . 1 . 039 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.58 -178.04 6.83 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 122.104 0.954 . . . . 0.0 109.768 179.206 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.46 -162.65 14.65 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 -179.404 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.3 Cg_exo -47.09 177.09 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.608 0 CA-C-N 118.807 1.304 . . . . 0.0 110.042 179.258 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -91.81 -178.57 5.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.015 -1.053 . . . . 0.0 110.409 -178.704 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.453 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.74 165.29 12.95 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.954 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.459 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.83 129.51 51.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 O-C-N 121.458 -1.025 . . . . 0.0 109.249 -179.413 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.608 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.31 126.6 30.49 Favored 'General case' 0 C--N 1.291 -1.972 0 O-C-N 121.677 -0.639 . . . . 0.0 109.791 179.756 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.504 HG12 ' O ' ' A' ' 93' ' ' CYS . 20.8 pt -97.43 177.2 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.226 -0.921 . . . . 0.0 109.473 -179.884 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.51 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.3 m -144.2 150.96 38.81 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.464 -0.772 . . . . 0.0 109.54 179.851 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.45 ' CZ ' ' CD1' ' A' ' 110' ' ' ILE . 94.9 m-85 . . . . . 0 N--CA 1.485 1.297 0 O-C-N 121.115 -0.991 . . . . 0.0 109.506 -179.636 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.499 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.215 0 CA-C-O 122.361 1.076 . . . . 0.0 110.599 . . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.532 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.8 p -104.82 104.72 14.55 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 122.456 1.122 . . . . 0.0 110.243 -179.495 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 14.7 t -119.51 115.4 47.5 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.443 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.265 179.704 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.491 HG21 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.72 148.94 12.95 Favored Pre-proline 0 N--CA 1.488 1.451 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.547 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.491 ' HA ' HG21 ' A' ' 8' ' ' THR . 6.5 Cg_endo -78.59 149.77 86.21 Favored 'Cis proline' 0 C--N 1.31 -1.497 0 C-N-CA 123.726 -1.364 . . . . 0.0 109.558 -0.609 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.462 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 77.6 p -91.7 -24.06 19.6 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.543 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.457 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 0.9 OUTLIER -131.28 162.18 30.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.45 -0.781 . . . . 0.0 109.513 -179.921 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.17 38.37 34.78 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 -179.536 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.611 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 31.5 mt -91.51 -44.28 9.19 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 123.142 1.448 . . . . 0.0 110.691 -178.233 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.488 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.7 144.87 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.274 0 CA-C-N 113.587 -1.642 . . . . 0.0 109.915 -179.629 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.556 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 9.2 p-10 -50.81 106.29 0.12 Allowed 'General case' 0 C--N 1.302 -1.46 0 CA-C-O 121.492 0.663 . . . . 0.0 111.674 -178.575 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.55 15.51 8.77 Favored Glycine 0 N--CA 1.485 1.918 0 C-N-CA 119.523 -1.323 . . . . 0.0 112.944 177.178 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.611 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.9 t -103.93 -172.3 2.08 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 121.156 2.478 . . . . 0.0 109.835 179.304 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.569 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 15.1 t -131.56 140.23 48.75 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.301 0 CA-C-N 114.873 -1.058 . . . . 0.0 111.186 -178.817 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.526 ' CG2' HG21 ' A' ' 69' ' ' VAL . 4.1 m -117.86 154.72 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 178.948 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -106.91 108.74 20.39 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.078 -1.014 . . . . 0.0 109.311 179.927 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.496 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 1.6 p -106.23 122.16 59.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 179.775 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.547 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -114.54 165.97 12.2 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 120.913 -1.117 . . . . 0.0 109.068 179.933 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.16 108.1 0.5 Allowed Glycine 0 N--CA 1.483 1.778 0 N-CA-C 108.586 -1.806 . . . . 0.0 108.586 179.848 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.407 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.58 140.31 49.53 Favored 'General case' 0 N--CA 1.498 1.954 0 CA-C-N 119.192 1.496 . . . . 0.0 110.282 -179.274 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.73 28.1 33.07 Favored Glycine 0 N--CA 1.489 2.184 0 C-N-CA 119.025 -1.559 . . . . 0.0 109.845 179.777 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.523 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -92.55 175.08 6.96 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.931 -1.335 . . . . 0.0 108.352 179.929 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.554 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.94 98.84 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.448 0 O-C-N 120.878 -1.139 . . . . 0.0 109.601 -179.625 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.3 77.48 0.0 OUTLIER 'General case' 0 C--N 1.294 -1.807 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.269 -179.131 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.31 34.35 0.32 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.457 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.545 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 59.7 p -145.42 112.08 5.87 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.075 -1.25 . . . . 0.0 111.196 -179.691 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.544 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.42 126.84 5.56 Favored 'General case' 0 N--CA 1.491 1.615 0 CA-C-O 121.458 0.647 . . . . 0.0 109.523 178.098 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.484 ' HA ' ' O ' ' A' ' 98' ' ' SER . 12.1 m-85 -118.09 150.26 39.63 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.736 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.474 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.84 159.0 15.56 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.652 -1.28 . . . . 0.0 107.729 178.535 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.617 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 7.4 p -144.27 116.04 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.085 -1.009 . . . . 0.0 110.045 -177.637 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.2 -178.78 39.74 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.414 -1.85 . . . . 0.0 111.857 -179.919 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.564 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -100.31 109.01 21.2 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -179.872 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.58 148.02 52.33 Favored 'General case' 0 C--N 1.294 -1.81 0 O-C-N 121.357 -0.84 . . . . 0.0 109.835 179.873 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -121.9 138.94 54.21 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.375 -0.828 . . . . 0.0 110.702 -179.082 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.63 ' CE2' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.55 114.67 26.45 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 178.187 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.42 ' O ' ' OD2' ' A' ' 41' ' ' ASP . 17.1 m -105.71 14.72 7.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.971 -1.081 . . . . 0.0 110.576 -178.679 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.92 -175.17 0.08 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.923 -1.111 . . . . 0.0 110.086 179.749 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 46.2 p -71.85 97.54 1.83 Allowed 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.428 -0.795 . . . . 0.0 109.717 -179.655 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.33 27.13 34.05 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 120.293 -0.956 . . . . 0.0 111.487 178.921 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.93 106.13 19.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.222 0 O-C-N 120.566 -1.549 . . . . 0.0 107.337 178.872 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.63 HD11 ' CE2' ' A' ' 39' ' ' TRP . 12.6 tp -117.24 104.67 11.4 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.531 -1.356 . . . . 0.0 109.669 -177.839 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.539 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.76 109.36 22.13 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.787 -1.196 . . . . 0.0 108.331 178.956 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.8 t -105.39 164.51 11.81 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.05 -1.031 . . . . 0.0 110.123 -179.055 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.532 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 13.6 t-20 -106.76 138.9 19.91 Favored Pre-proline 0 N--CA 1.501 2.087 0 O-C-N 121.333 -0.854 . . . . 0.0 110.095 -179.031 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.578 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 6.9 Cg_endo -75.88 25.9 0.41 Allowed 'Trans proline' 0 C--N 1.319 -1.012 0 C-N-CA 122.537 2.158 . . . . 0.0 111.705 179.987 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.532 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -121.43 3.54 10.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.403 -1.436 . . . . 0.0 109.312 -179.915 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.498 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -137.09 14.36 3.06 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.285 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -80.18 91.83 5.61 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.799 -178.644 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.617 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.53 -169.23 1.44 Allowed 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 178.356 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.471 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.03 135.56 0.09 Allowed 'General case' 0 C--N 1.306 -1.325 0 O-C-N 120.517 -1.364 . . . . 0.0 111.439 -179.351 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.587 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -151.98 157.75 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 178.102 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.544 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.41 145.31 26.29 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.595 -1.316 . . . . 0.0 109.976 -179.578 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.667 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -65.6 107.39 1.71 Allowed 'General case' 0 C--N 1.3 -1.582 0 CA-C-O 122.375 1.083 . . . . 0.0 109.418 178.716 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.527 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.7 p-10 -60.37 -139.25 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.019 -179.914 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.21 -50.43 59.11 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.316 -0.865 . . . . 0.0 110.564 -178.71 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -104.7 -33.71 8.38 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 106.249 -1.759 . . . . 0.0 106.249 178.529 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.667 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.01 66.99 0.61 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 178.205 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.8 m -104.3 124.84 49.89 Favored 'General case' 0 N--CA 1.485 1.28 0 O-C-N 121.674 -0.898 . . . . 0.0 108.686 178.818 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.587 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.15 109.21 8.76 Favored 'General case' 0 C--N 1.296 -1.733 0 C-N-CA 119.699 -0.8 . . . . 0.0 109.479 -179.412 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.458 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 81.2 p -117.87 118.64 32.57 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.348 -0.845 . . . . 0.0 109.448 -179.924 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.458 HG23 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.02 141.24 30.01 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.513 -0.742 . . . . 0.0 109.631 179.92 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.1 p -100.46 131.65 46.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.436 -0.79 . . . . 0.0 109.352 179.955 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.527 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -130.05 166.98 19.03 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.416 -0.803 . . . . 0.0 109.477 -179.512 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.569 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -97.94 124.69 42.49 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.109 -0.994 . . . . 0.0 109.365 -179.834 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.527 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.0 m -135.45 143.28 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.082 -1.011 . . . . 0.0 109.767 -179.292 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.556 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.6 ptt180 -141.1 -165.62 2.0 Allowed 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.657 -1.277 . . . . 0.0 110.494 -179.912 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.588 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 17.5 mtp180 -72.4 -80.24 0.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.367 -0.833 . . . . 0.0 109.217 -179.498 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.442 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -68.65 138.3 54.89 Favored 'General case' 0 N--CA 1.485 1.282 0 O-C-N 120.051 -1.655 . . . . 0.0 107.284 178.874 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.567 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -162.21 133.99 5.41 Favored 'General case' 0 C--N 1.295 -1.788 0 C-N-CA 117.766 -1.573 . . . . 0.0 110.414 -177.559 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.496 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -33.83 121.95 0.44 Allowed 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.44 0.638 . . . . 0.0 110.234 -178.766 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.539 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -93.86 51.66 2.27 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 120.512 -0.852 . . . . 0.0 111.392 -178.98 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.578 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -38.97 116.17 0.55 Allowed 'General case' 0 N--CA 1.511 2.615 0 O-C-N 121.075 -1.25 . . . . 0.0 109.933 179.519 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.537 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.0 tp -87.32 126.63 34.96 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.875 -1.14 . . . . 0.0 109.328 -179.946 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -64.15 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.772 -1.205 . . . . 0.0 110.025 179.741 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 20.4 t70 -160.18 19.48 0.15 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.984 -1.072 . . . . 0.0 109.705 179.895 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.0 -27.39 5.51 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 179.785 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.404 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 2.3 p -95.22 160.93 14.32 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.004 -1.292 . . . . 0.0 110.318 -179.425 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.465 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.86 137.48 44.84 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.822 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.46 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.27 -19.2 40.03 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.748 -1.22 . . . . 0.0 110.437 -178.596 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.51 176.27 19.73 Favored Glycine 0 N--CA 1.484 1.85 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.485 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -63.82 108.8 1.55 Allowed 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 179.13 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.567 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 38.2 t -81.72 105.41 11.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 121.361 -0.837 . . . . 0.0 108.786 -179.144 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.449 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -67.68 112.16 4.63 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.39 -0.819 . . . . 0.0 109.931 -179.108 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.529 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.28 -5.09 4.41 Favored 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.286 -1.366 . . . . 0.0 109.97 179.437 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.446 HG23 ' NH2' ' A' ' 71' ' ' ARG . 41.0 p -85.63 1.44 49.24 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.769 -1.207 . . . . 0.0 109.021 179.361 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.449 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -115.73 -49.34 2.73 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.432 -0.792 . . . . 0.0 109.08 179.971 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.64 -179.63 4.0 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.458 -0.776 . . . . 0.0 109.536 179.961 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.99 115.36 30.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.338 -0.851 . . . . 0.0 109.102 179.958 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.494 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.94 123.73 40.73 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.082 -1.011 . . . . 0.0 109.54 -179.358 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.541 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.28 147.48 27.44 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 122.515 1.15 . . . . 0.0 111.356 -179.318 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.521 ' CG1' HG13 ' A' ' 7' ' ' VAL . 59.1 t -103.09 109.62 27.36 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.038 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 177.351 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.09 -174.06 17.9 Favored Glycine 0 N--CA 1.484 1.855 0 C-N-CA 118.203 -1.951 . . . . 0.0 111.815 -177.414 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.474 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -117.1 -177.59 3.24 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -178.835 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.484 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.8 OUTLIER . . . . . 0 C--N 1.297 -1.694 0 O-C-N 121.182 -0.949 . . . . 0.0 109.389 -179.344 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.73 0 N-CA-C 107.468 -2.253 . . . . 0.0 107.468 . . . . . . . . . 0 0 . 1 . 040 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -154.98 -179.66 8.27 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 121.509 -0.995 . . . . 0.0 109.406 178.786 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -179.23 -167.78 37.22 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 -179.488 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.423 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.8 Cg_exo -48.38 175.1 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.665 0 CA-C-N 118.888 1.344 . . . . 0.0 110.002 179.523 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -92.48 -175.4 3.98 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.163 -0.96 . . . . 0.0 110.435 -178.778 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -120.52 166.54 13.77 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.908 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -106.65 131.82 55.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.452 -1.028 . . . . 0.0 109.069 -179.358 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.541 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.16 125.11 27.65 Favored 'General case' 0 C--N 1.29 -2.018 0 O-C-N 121.48 -0.762 . . . . 0.0 109.782 179.733 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.574 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.72 172.18 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.158 -0.964 . . . . 0.0 108.948 179.81 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.457 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.81 158.25 44.74 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.305 -0.872 . . . . 0.0 109.605 -179.837 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.588 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 70.8 m-85 . . . . . 0 C--N 1.306 -1.297 0 O-C-N 121.19 -0.944 . . . . 0.0 109.52 -179.585 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.5 ' CB ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.486 1.366 0 CA-C-O 122.208 1.004 . . . . 0.0 111.252 . . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.528 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.2 p -100.36 104.03 15.45 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.377 1.084 . . . . 0.0 109.783 179.982 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.527 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 6.9 t -120.32 116.72 51.1 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-O 121.726 0.774 . . . . 0.0 110.466 179.863 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.517 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.81 148.7 8.86 Favored Pre-proline 0 N--CA 1.486 1.339 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.707 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.517 ' CA ' HG21 ' A' ' 8' ' ' THR . 6.0 Cg_endo -77.94 150.32 89.18 Favored 'Cis proline' 0 C--N 1.307 -1.65 0 C-N-CA 123.604 -1.415 . . . . 0.0 109.513 -0.425 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.464 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 80.1 p -91.3 -24.69 19.75 Favored 'General case' 0 C--N 1.292 -1.916 0 O-C-N 121.498 -0.751 . . . . 0.0 108.985 179.518 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.519 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 17.0 m -133.92 161.9 33.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.521 -0.737 . . . . 0.0 109.367 -179.931 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.77 37.06 31.05 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 108.571 -1.811 . . . . 0.0 108.571 -179.657 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.589 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 42.8 mt -91.12 -42.13 10.64 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-O 123.374 1.559 . . . . 0.0 110.22 -178.548 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.483 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.65 142.31 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.238 -1.801 . . . . 0.0 109.838 -179.488 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.589 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.3 p-10 -49.94 106.86 0.13 Allowed 'General case' 0 C--N 1.298 -1.656 0 CA-C-O 121.562 0.696 . . . . 0.0 111.324 -178.588 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.16 10.64 9.57 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.132 177.449 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.589 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.7 t -105.48 -171.31 1.89 Allowed 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 121.286 2.543 . . . . 0.0 109.905 179.471 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.58 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 16.8 t -132.93 143.42 39.55 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.284 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.851 -178.952 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.492 ' CG1' HD22 ' A' ' 13' ' ' LEU . 32.2 m -118.98 155.34 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.28 -0.887 . . . . 0.0 108.707 179.21 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.527 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -105.08 108.77 20.47 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.152 -0.967 . . . . 0.0 109.441 -179.897 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.5 HG22 ' CG2' ' A' ' 7' ' ' VAL . 1.8 p -106.74 121.76 59.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.434 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.528 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -118.07 167.16 11.72 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 120.688 -1.257 . . . . 0.0 109.292 -179.604 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.55 143.47 15.11 Favored Glycine 0 C--N 1.294 -1.78 0 N-CA-C 107.774 -2.131 . . . . 0.0 107.774 179.735 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -147.82 123.01 10.2 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 120.929 -1.336 . . . . 0.0 108.589 179.175 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.18 27.39 21.0 Favored Glycine 0 N--CA 1.487 2.063 0 C-N-CA 119.201 -1.476 . . . . 0.0 109.755 -179.448 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.546 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.0 mt -87.9 175.85 7.62 Favored 'General case' 0 C--N 1.308 -1.224 0 O-C-N 120.846 -1.384 . . . . 0.0 108.403 179.964 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.553 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.24 96.85 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.029 -1.044 . . . . 0.0 109.6 -179.91 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.24 76.48 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.448 -178.847 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.25 33.44 0.27 Allowed Glycine 0 N--CA 1.486 1.994 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 179.179 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.626 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.6 t -148.45 115.46 6.09 Favored 'General case' 0 C--N 1.309 -1.178 0 O-C-N 120.797 -1.414 . . . . 0.0 111.252 179.932 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.554 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.98 129.18 4.43 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.657 178.221 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.626 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 6.8 m-85 -121.5 146.82 46.54 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.727 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.48 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.95 164.31 12.24 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 107.429 -1.323 . . . . 0.0 107.429 178.54 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.624 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 7.1 p -148.95 115.11 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.979 -1.076 . . . . 0.0 110.133 -177.673 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.482 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.15 -174.29 36.85 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 118.541 -1.79 . . . . 0.0 111.563 -179.938 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.568 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -100.77 108.89 20.83 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -179.718 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.429 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.26 148.76 52.12 Favored 'General case' 0 C--N 1.296 -1.73 0 O-C-N 121.19 -0.944 . . . . 0.0 109.934 179.765 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.33 139.1 53.98 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.276 -0.89 . . . . 0.0 110.613 -179.03 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.623 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.17 114.89 26.74 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 178.116 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.416 HG23 ' HB ' ' A' ' 44' ' ' VAL . 11.2 m -106.17 15.57 7.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.014 -1.054 . . . . 0.0 110.587 -178.676 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.3 -175.59 0.09 Allowed 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.933 -1.105 . . . . 0.0 110.021 179.739 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.0 97.47 1.88 Allowed 'General case' 0 N--CA 1.486 1.33 0 O-C-N 121.423 -0.798 . . . . 0.0 109.724 -179.765 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.64 27.93 33.89 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 120.164 -1.017 . . . . 0.0 111.399 178.973 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.52 106.33 20.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 O-C-N 120.612 -1.522 . . . . 0.0 107.289 178.928 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.623 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.9 tp -116.88 104.74 11.61 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.501 -1.374 . . . . 0.0 109.684 -177.626 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.522 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.13 109.57 22.3 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.739 -1.226 . . . . 0.0 108.213 178.797 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -108.12 164.53 12.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.977 -1.077 . . . . 0.0 110.081 -178.929 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.477 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 7.5 t30 -108.62 130.02 23.27 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.357 -0.84 . . . . 0.0 109.69 -179.284 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.589 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -71.01 19.83 0.23 Allowed 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 122.178 1.919 . . . . 0.0 112.044 179.502 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.472 ' O ' HG23 ' A' ' 68' ' ' THR . . . -108.32 1.12 21.66 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.364 -1.46 . . . . 0.0 108.883 179.305 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.551 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.07 19.27 2.99 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 179.462 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -83.0 90.9 7.07 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.876 -0.73 . . . . 0.0 111.005 -178.439 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.66 -171.02 1.76 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.944 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.458 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.3 OUTLIER 178.53 137.96 0.09 Allowed 'General case' 0 C--N 1.304 -1.372 0 O-C-N 120.501 -1.374 . . . . 0.0 111.544 -179.16 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.575 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -154.79 159.51 3.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 178.07 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.554 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.28 145.78 25.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.59 -1.319 . . . . 0.0 109.722 -179.676 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.67 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -67.66 108.09 2.78 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 122.353 1.073 . . . . 0.0 109.582 179.037 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.518 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 t0 -63.03 -139.21 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.015 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.874 -179.917 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.04 -51.83 28.88 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.411 -0.806 . . . . 0.0 110.759 -178.572 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -105.09 -32.07 8.87 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 178.585 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.67 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 106.25 67.96 0.69 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 178.391 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.2 m -103.42 128.88 50.46 Favored 'General case' 0 N--CA 1.484 1.266 0 O-C-N 121.37 -1.077 . . . . 0.0 109.143 179.202 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.575 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.25 108.65 6.89 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 119.321 -0.952 . . . . 0.0 109.949 -179.486 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.484 ' HB3' ' CE ' ' A' ' 20' ' ' LYS . 3.4 m -114.48 116.58 29.07 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.995 -1.066 . . . . 0.0 109.409 179.85 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.506 HG22 ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -143.08 142.19 31.46 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 110.013 -179.971 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.9 p -100.71 136.32 40.76 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.466 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.551 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -141.08 156.82 45.93 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.935 . . . . 0.0 109.808 -179.129 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.58 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 12.9 t -87.04 138.76 31.22 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.062 -1.023 . . . . 0.0 110.676 -179.608 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.538 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 20.7 m -149.27 143.55 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.508 -0.745 . . . . 0.0 109.232 -179.852 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.589 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -147.52 -178.01 6.01 Favored 'General case' 0 N--CA 1.486 1.326 0 O-C-N 120.487 -1.383 . . . . 0.0 111.206 -179.68 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.67 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -47.52 -98.92 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -179.616 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -64.02 145.01 56.65 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.389 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.599 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -163.95 143.2 7.85 Favored 'General case' 0 C--N 1.291 -1.952 0 C-N-CA 118.045 -1.462 . . . . 0.0 110.268 -177.419 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.481 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 29.4 mm-40 -37.29 120.46 0.77 Allowed 'General case' 0 N--CA 1.489 1.477 0 CA-C-O 121.457 0.646 . . . . 0.0 110.304 -178.888 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.522 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -96.5 52.45 1.54 Allowed Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.477 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.589 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.8 m-85 -39.76 114.96 0.47 Allowed 'General case' 0 N--CA 1.508 2.465 0 O-C-N 121.181 -1.188 . . . . 0.0 110.113 179.65 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.529 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -86.13 126.55 34.3 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.866 -1.146 . . . . 0.0 109.511 -179.986 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.6 t80 -64.1 58.17 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.004 0 O-C-N 120.845 -1.159 . . . . 0.0 110.25 179.767 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.58 19.68 0.14 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.025 -1.047 . . . . 0.0 109.709 179.892 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.88 -27.5 5.4 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.871 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.419 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 11.9 p -93.36 158.53 15.69 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.02 -1.282 . . . . 0.0 110.434 -179.455 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.474 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.35 136.28 46.35 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.627 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.467 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.1 t90 -83.08 -16.72 45.81 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.669 -1.269 . . . . 0.0 110.647 -178.194 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.57 175.94 21.18 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 108.709 -1.756 . . . . 0.0 108.709 -179.618 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -64.84 103.07 0.66 Allowed 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 179.106 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.581 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 37.2 t -73.78 107.97 4.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 109.483 -178.755 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.8 OUTLIER -65.11 112.09 3.22 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.462 -0.774 . . . . 0.0 109.706 -179.58 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.67 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 4.0 m -62.81 -4.98 2.4 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.422 -1.311 . . . . 0.0 110.228 179.608 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.5 p -89.25 -2.94 58.67 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.566 -1.334 . . . . 0.0 109.555 -179.983 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.468 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -106.31 -48.65 3.52 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.071 -1.018 . . . . 0.0 108.861 179.885 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.42 -177.86 3.4 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.631 -0.668 . . . . 0.0 109.297 179.726 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.59 115.98 31.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.454 -0.779 . . . . 0.0 108.927 179.834 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.494 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 3.2 m -96.48 120.32 36.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.913 -1.117 . . . . 0.0 109.615 -179.245 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.525 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.93 145.28 30.37 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 122.409 1.099 . . . . 0.0 111.282 -179.392 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.511 ' CG1' HG13 ' A' ' 7' ' ' VAL . 92.4 t -102.22 109.86 27.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.945 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 177.788 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.459 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.49 -173.22 19.82 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 118.112 -1.995 . . . . 0.0 111.695 -177.608 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.48 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -111.93 -178.61 3.47 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 -179.345 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.473 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.1 p . . . . . 0 C--N 1.297 -1.707 0 O-C-N 121.197 -0.939 . . . . 0.0 109.751 -179.132 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.723 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 . . . . . . . . . 0 0 . 1 . 041 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.11 -177.6 5.85 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.578 -0.954 . . . . 0.0 109.713 179.242 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.31 -161.5 14.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 -179.345 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.485 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.5 Cg_exo -47.97 -179.36 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.612 0 CA-C-N 118.877 1.339 . . . . 0.0 110.304 179.328 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -93.59 -173.95 3.34 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.002 -1.061 . . . . 0.0 110.298 -178.974 . . . . . . . . 1 1 . 1 . 041 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.459 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.76 164.18 14.97 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.946 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.86 129.41 51.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.367 -1.078 . . . . 0.0 109.0 -179.46 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.525 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.79 119.25 15.7 Favored 'General case' 0 C--N 1.288 -2.101 0 O-C-N 121.746 -0.596 . . . . 0.0 109.73 179.759 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.573 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -98.09 170.04 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.188 -0.945 . . . . 0.0 108.861 179.821 . . . . . . . . 2 2 . 1 . 041 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.519 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -138.46 155.08 48.78 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.085 -1.01 . . . . 0.0 109.6 -179.908 . . . . . . . . 3 3 . 1 . 041 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.573 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 77.6 m-85 . . . . . 0 C--N 1.305 -1.327 0 O-C-N 121.271 -0.893 . . . . 0.0 109.424 -179.686 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.501 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.209 0 CA-C-O 122.327 1.06 . . . . 0.0 110.594 . . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.533 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.8 p -104.72 104.85 14.72 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-O 122.532 1.158 . . . . 0.0 110.142 -179.519 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.536 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 12.5 t -119.48 120.0 62.25 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.438 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.355 179.616 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.509 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.67 150.3 8.84 Favored Pre-proline 0 N--CA 1.489 1.492 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 -179.621 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.509 ' CA ' HG21 ' A' ' 8' ' ' THR . 1.3 Cg_endo -74.22 153.98 99.42 Favored 'Cis proline' 0 C--N 1.31 -1.493 0 C-N-CA 123.621 -1.408 . . . . 0.0 109.927 -0.482 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.479 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 4.5 m -93.64 -23.94 18.08 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.646 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.467 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 3.1 m -137.12 166.14 24.41 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.61 -0.681 . . . . 0.0 109.424 179.919 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.14 38.09 40.93 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 108.346 -1.902 . . . . 0.0 108.346 -179.6 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.63 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 29.9 mt -91.42 -45.21 8.68 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 123.131 1.444 . . . . 0.0 110.676 -178.316 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.483 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.28 146.16 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.763 -1.562 . . . . 0.0 109.942 -179.704 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.575 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.5 p-10 -51.44 110.14 0.42 Allowed 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 121.532 0.682 . . . . 0.0 111.664 -178.614 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.52 13.97 12.23 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.557 -1.306 . . . . 0.0 112.731 177.345 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.63 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 9.0 t -102.66 -173.38 2.31 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 120.929 2.364 . . . . 0.0 109.632 179.365 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.555 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 12.7 t -132.15 137.75 53.96 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.866 -1.061 . . . . 0.0 111.14 -178.995 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.511 HG13 ' CG2' ' A' ' 69' ' ' VAL . 29.2 m -114.57 154.48 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.351 -0.843 . . . . 0.0 109.07 178.934 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.3 tttt -109.33 108.93 19.68 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.266 -0.896 . . . . 0.0 109.126 179.83 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.525 ' CG1' HG23 ' A' ' 34' ' ' VAL . 2.0 p -107.25 122.92 62.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -179.954 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.538 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -114.48 165.96 12.19 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.761 -1.212 . . . . 0.0 109.136 179.694 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.591 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.15 107.84 0.49 Allowed Glycine 0 N--CA 1.483 1.793 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 179.865 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.49 141.15 48.56 Favored 'General case' 0 N--CA 1.5 2.051 0 CA-C-N 119.248 1.524 . . . . 0.0 110.273 -179.389 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.4 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 84.28 28.37 33.75 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 118.943 -1.598 . . . . 0.0 109.767 179.621 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.527 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -94.54 173.66 7.51 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.941 -1.329 . . . . 0.0 108.553 179.971 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.57 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.72 98.74 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.006 -1.059 . . . . 0.0 109.703 -179.885 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.549 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.41 76.6 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.188 -179.21 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 135.06 33.35 0.28 Allowed Glycine 0 N--CA 1.486 1.993 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.483 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.627 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -142.49 111.83 6.6 Favored 'General case' 0 C--N 1.309 -1.174 0 O-C-N 120.928 -1.336 . . . . 0.0 111.075 -179.929 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.555 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -49.5 113.34 0.8 Allowed 'General case' 0 N--CA 1.497 1.922 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.915 178.67 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.627 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 11.9 m-85 -107.14 153.06 23.21 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.263 -0.898 . . . . 0.0 108.592 179.441 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.455 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.66 159.55 15.22 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.729 -1.232 . . . . 0.0 107.994 178.884 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.627 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 6.4 p -139.84 114.66 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 109.667 -178.086 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.96 -179.51 37.55 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 118.384 -1.865 . . . . 0.0 111.733 -179.449 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.633 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.1 pt20 -101.92 109.39 21.12 Favored 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 -179.889 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.69 149.37 52.37 Favored 'General case' 0 C--N 1.296 -1.751 0 O-C-N 121.14 -0.975 . . . . 0.0 110.087 -179.867 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.07 138.2 54.73 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.276 -0.89 . . . . 0.0 110.809 -178.976 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.62 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.26 115.0 26.85 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 178.055 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.433 HG21 ' HB ' ' A' ' 44' ' ' VAL . 16.4 m -104.36 14.3 7.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.044 -1.035 . . . . 0.0 110.491 -178.853 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.29 -174.86 0.07 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.977 -1.077 . . . . 0.0 110.095 179.765 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -72.96 98.68 2.54 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.387 -0.821 . . . . 0.0 109.606 -179.803 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.61 27.41 32.5 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 120.251 -0.975 . . . . 0.0 111.394 179.011 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.591 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -117.64 105.96 19.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 O-C-N 120.571 -1.547 . . . . 0.0 107.335 178.849 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.62 HD12 ' CD1' ' A' ' 39' ' ' TRP . 13.4 tp -117.95 104.38 10.84 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.408 -1.433 . . . . 0.0 109.741 -177.772 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.53 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.15 109.36 22.13 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 178.829 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -105.56 165.82 10.88 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.029 -1.044 . . . . 0.0 110.277 -178.612 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.463 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 50.8 t30 -110.66 134.93 20.77 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 121.49 -0.756 . . . . 0.0 109.885 -179.409 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.584 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -75.32 25.46 0.39 Allowed 'Trans proline' 0 C--N 1.319 -1.011 0 C-N-CA 122.328 2.019 . . . . 0.0 111.404 179.591 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.46 ' HB1' ' ND2' ' A' ' 48' ' ' ASN . . . -112.74 0.1 15.18 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.484 -1.385 . . . . 0.0 109.373 179.944 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.524 ' O ' ' CD2' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.67 16.1 2.71 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 179.601 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -78.8 91.66 4.75 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.872 -0.731 . . . . 0.0 110.952 -178.648 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -110.1 -166.58 1.1 Allowed 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.281 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.466 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.7 136.44 0.09 Allowed 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.546 -1.346 . . . . 0.0 111.502 -179.289 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.588 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -154.39 157.15 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 178.174 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.555 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.37 143.95 28.28 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.772 -1.205 . . . . 0.0 109.91 -179.827 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.673 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.58 106.64 1.2 Allowed 'General case' 0 C--N 1.299 -1.587 0 CA-C-O 122.478 1.132 . . . . 0.0 109.325 178.556 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.524 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.9 p-10 -59.28 -139.53 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.918 -179.928 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.549 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.01 -50.0 62.25 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.434 -0.791 . . . . 0.0 110.731 -178.703 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.4 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.5 t-20 -103.77 -34.35 8.59 Favored 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 178.379 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.673 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.76 66.13 0.61 Allowed Glycine 0 C--N 1.297 -1.599 0 N-CA-C 110.459 -1.056 . . . . 0.0 110.459 178.126 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.591 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.8 m -104.36 124.23 48.83 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.683 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.588 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -133.89 109.2 8.9 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 119.692 -0.803 . . . . 0.0 109.506 -179.278 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.2 m -116.88 116.35 27.27 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.3 -0.875 . . . . 0.0 109.353 -179.93 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.468 ' CG2' HG12 ' A' ' 34' ' ' VAL . 1.2 t -140.78 139.08 34.53 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.507 -0.745 . . . . 0.0 109.762 179.998 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.6 p -99.02 138.38 36.2 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.38 -0.825 . . . . 0.0 108.982 179.631 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.526 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -138.56 166.44 24.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.269 -0.894 . . . . 0.0 109.547 -179.15 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.555 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.8 p -95.3 125.02 39.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.061 -1.025 . . . . 0.0 109.44 -179.818 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.511 ' CG2' HG13 ' A' ' 19' ' ' VAL . 15.0 m -133.29 143.32 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 120.955 -1.091 . . . . 0.0 109.798 -179.207 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.575 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.59 -170.7 3.58 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.484 -1.385 . . . . 0.0 111.092 179.992 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.603 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -63.12 -101.87 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.954 -0.466 . . . . 0.0 110.309 -179.034 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.477 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -58.95 137.98 57.64 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.595 -1.316 . . . . 0.0 108.534 -180.0 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.633 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.8 OUTLIER -156.62 156.59 33.79 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 118.807 -1.157 . . . . 0.0 109.746 -178.864 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.525 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 10.3 mm-40 -48.35 122.28 5.21 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.587 -178.603 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.53 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -88.32 46.78 3.41 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -179.555 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.584 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -38.59 112.92 0.26 Allowed 'General case' 0 N--CA 1.506 2.351 0 O-C-N 121.22 -1.164 . . . . 0.0 110.537 -179.795 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.533 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -86.79 126.89 34.92 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.986 -1.071 . . . . 0.0 109.366 179.945 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.8 t80 -63.68 58.41 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.017 0 O-C-N 120.851 -1.156 . . . . 0.0 110.21 179.761 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.1 t0 -161.1 19.52 0.12 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.927 -1.108 . . . . 0.0 109.786 179.816 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.28 -26.73 5.46 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 179.798 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 47.2 p -93.88 160.72 14.61 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.958 -1.319 . . . . 0.0 110.275 -179.508 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.473 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.9 OUTLIER -107.23 134.92 49.61 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.895 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.481 ' CD1' HD13 ' A' ' 77' ' ' LEU . 4.2 t90 -81.74 -17.46 47.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.956 -1.09 . . . . 0.0 110.327 -178.608 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.12 173.46 18.76 Favored Glycine 0 N--CA 1.485 1.936 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 -179.544 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -63.77 107.34 1.17 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 179.093 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.599 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 44.5 t -78.7 104.61 6.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 121.398 -0.814 . . . . 0.0 109.275 -178.686 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 1.2 m-20 -64.88 108.86 1.89 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.545 -0.722 . . . . 0.0 110.032 -179.377 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.559 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.6 t -60.3 -5.52 1.15 Allowed 'General case' 0 N--CA 1.501 2.113 0 C-N-CA 118.164 -1.414 . . . . 0.0 110.343 179.302 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 33.1 p -89.51 0.83 56.61 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.486 -1.384 . . . . 0.0 109.528 179.987 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.475 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -111.67 -48.61 3.06 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.201 -0.937 . . . . 0.0 109.129 -179.894 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.31 179.38 4.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.592 -0.693 . . . . 0.0 109.539 -179.896 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.28 113.31 26.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.369 -0.832 . . . . 0.0 108.925 179.826 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.49 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.8 m -96.55 121.07 37.98 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.035 -1.041 . . . . 0.0 109.43 -178.854 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.549 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.82 148.11 25.7 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-O 122.416 1.103 . . . . 0.0 111.301 -179.375 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.528 ' CG1' HG11 ' A' ' 7' ' ' VAL . 47.7 t -104.41 109.96 29.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 N-CA-C 106.697 -1.594 . . . . 0.0 106.697 177.607 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.412 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.51 -171.15 17.79 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 118.15 -1.976 . . . . 0.0 111.589 -177.686 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.462 HD13 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -115.08 -178.54 3.39 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -178.888 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.2 p . . . . . 0 C--N 1.296 -1.729 0 O-C-N 121.224 -0.923 . . . . 0.0 109.65 -179.113 . . . . . . . . 0 0 . 1 . 042 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.692 0 N-CA-C 107.915 -2.074 . . . . 0.0 107.915 . . . . . . . . . 0 0 . 1 . 042 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.23 -177.47 5.73 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.542 -0.975 . . . . 0.0 110.09 179.419 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.37 -163.69 23.82 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 108.17 -1.972 . . . . 0.0 108.17 -179.512 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.466 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.2 Cg_exo -46.09 172.78 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.693 0 CA-C-N 119.084 1.442 . . . . 0.0 109.938 179.332 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -91.16 -177.2 4.82 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.071 -1.018 . . . . 0.0 110.701 -178.632 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.412 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.27 168.36 13.81 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.842 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.47 133.57 51.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.43 -1.041 . . . . 0.0 109.176 -179.202 . . . . . . . . 1 1 . 1 . 042 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.549 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.68 123.48 24.14 Favored 'General case' 0 C--N 1.291 -1.976 0 O-C-N 121.55 -0.719 . . . . 0.0 109.874 179.72 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.555 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.97 172.77 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.137 -0.977 . . . . 0.0 108.969 179.711 . . . . . . . . 2 2 . 1 . 042 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.467 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.97 157.74 45.18 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.036 -1.04 . . . . 0.0 110.094 -179.627 . . . . . . . . 3 3 . 1 . 042 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.555 ' CE1' HD12 ' A' ' 110' ' ' ILE . 88.0 m-85 . . . . . 0 N--CA 1.487 1.412 0 O-C-N 121.224 -0.922 . . . . 0.0 109.444 -179.825 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.468 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.449 0 CA-C-O 122.345 1.069 . . . . 0.0 110.751 . . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.55 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.6 t -111.75 108.54 18.01 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-O 123.099 1.428 . . . . 0.0 109.053 179.339 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.525 HG12 ' CG1' ' A' ' 95' ' ' VAL . 5.6 t -117.71 137.39 51.78 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 0 CA-C-N 114.284 -1.326 . . . . 0.0 109.935 -179.616 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.511 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -172.85 149.11 1.8 Allowed Pre-proline 0 N--CA 1.485 1.316 0 O-C-N 121.241 -0.912 . . . . 0.0 108.815 -179.717 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.511 ' CA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -76.63 151.08 94.07 Favored 'Cis proline' 0 C--N 1.311 -1.439 0 C-N-CA 123.478 -1.468 . . . . 0.0 109.467 -0.865 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.462 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 65.3 p -90.17 -25.18 20.79 Favored 'General case' 0 C--N 1.294 -1.842 0 O-C-N 121.564 -0.71 . . . . 0.0 109.123 179.686 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.511 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.5 m -134.16 165.04 26.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.459 -0.776 . . . . 0.0 109.534 -179.904 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.22 38.28 34.79 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 -179.61 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.591 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 40.0 mt -92.4 -42.92 9.5 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 123.236 1.493 . . . . 0.0 110.525 -178.322 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.0 143.86 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.468 -1.696 . . . . 0.0 109.686 -179.534 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.557 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 6.0 p-10 -50.98 107.19 0.16 Allowed 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 121.625 0.726 . . . . 0.0 111.608 -178.437 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.46 11.61 11.59 Favored Glycine 0 N--CA 1.485 1.902 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.087 177.254 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.591 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.2 t -102.3 -169.8 1.72 Allowed 'General case' 0 C--N 1.312 -1.043 0 CA-C-N 121.111 2.455 . . . . 0.0 109.615 179.397 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.574 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 12.0 t -134.17 142.23 41.56 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.702 -179.255 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.521 HG11 ' CG2' ' A' ' 69' ' ' VAL . 35.0 m -119.88 155.21 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.276 -0.89 . . . . 0.0 108.853 179.313 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 11.1 tttt -103.96 109.24 20.93 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.207 -0.933 . . . . 0.0 109.158 -179.965 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.464 ' HB ' HG13 ' A' ' 7' ' ' VAL . 2.1 p -101.94 140.87 19.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.607 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.545 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -137.3 160.15 39.89 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 118.62 -1.232 . . . . 0.0 109.949 179.795 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.592 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.19 143.89 15.16 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 179.578 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -145.73 125.93 13.83 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 120.87 -1.371 . . . . 0.0 108.911 179.296 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.73 26.39 27.24 Favored Glycine 0 N--CA 1.488 2.137 0 C-N-CA 119.296 -1.43 . . . . 0.0 109.777 -179.692 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.55 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.0 mt -86.84 175.3 8.26 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.918 -1.342 . . . . 0.0 108.364 -179.933 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.56 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.85 97.33 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.961 -1.087 . . . . 0.0 109.737 -179.61 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.53 77.32 0.0 OUTLIER 'General case' 0 C--N 1.294 -1.813 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.42 -179.134 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.12 34.4 0.33 Allowed Glycine 0 N--CA 1.486 2.005 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.381 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.531 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.4 p -147.78 113.26 5.63 Favored 'General case' 0 C--N 1.307 -1.251 0 O-C-N 121.045 -1.267 . . . . 0.0 111.236 -179.819 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.537 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -43.53 128.41 5.06 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.823 178.263 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.49 ' CD2' ' O ' ' A' ' 30' ' ' THR . 11.3 m-85 -121.38 149.8 42.43 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.596 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.488 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.49 156.35 17.33 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.642 -1.286 . . . . 0.0 107.854 178.84 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.625 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.6 p -138.53 114.79 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.062 -1.024 . . . . 0.0 109.713 -178.06 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.476 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.08 -178.3 35.86 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.249 -1.929 . . . . 0.0 111.908 -179.529 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.55 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.7 OUTLIER -101.03 112.55 25.04 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 -179.941 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 66.8 m -130.64 153.11 49.27 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.365 -0.834 . . . . 0.0 109.615 179.746 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.43 135.91 51.1 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.482 -0.761 . . . . 0.0 110.491 -179.957 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.639 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.6 OUTLIER -94.83 114.37 26.24 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.243 -1.391 . . . . 0.0 107.243 178.137 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 m -106.27 14.86 7.47 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 O-C-N 120.966 -1.084 . . . . 0.0 110.763 -178.473 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.595 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.21 -175.47 0.08 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.856 -1.152 . . . . 0.0 110.222 179.655 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.548 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.2 t -69.75 97.09 1.04 Allowed 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 121.83 0.824 . . . . 0.0 109.952 -179.445 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.66 27.15 36.09 Favored Glycine 0 N--CA 1.494 2.546 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.515 178.679 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.595 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.4 t -114.48 106.18 20.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.233 0 O-C-N 120.6 -1.53 . . . . 0.0 107.483 178.901 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.639 HD13 ' CD1' ' A' ' 39' ' ' TRP . 11.7 tp -116.94 106.54 13.54 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.574 -1.329 . . . . 0.0 109.662 -177.724 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.552 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -95.99 111.97 23.83 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 120.676 -1.265 . . . . 0.0 108.256 179.445 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.537 ' HB3' ' CE1' ' A' ' 52' ' ' PHE . 66.8 m -101.67 147.76 26.06 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.33 -0.856 . . . . 0.0 110.71 -178.291 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.488 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 24.4 t30 -103.45 126.11 33.06 Favored Pre-proline 0 N--CA 1.503 2.198 0 O-C-N 121.248 -0.908 . . . . 0.0 108.838 179.053 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.567 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.5 Cg_endo -70.58 23.85 0.2 Allowed 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 122.108 1.872 . . . . 0.0 112.561 -179.657 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.475 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -110.15 2.15 19.21 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.252 -1.53 . . . . 0.0 109.317 179.346 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.513 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.54 16.18 2.55 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 179.628 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.537 ' CE1' ' HB3' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -79.08 91.51 4.91 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.579 -0.701 . . . . 0.0 110.885 -178.568 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.625 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.67 -165.71 1.05 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.284 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.459 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 179.04 135.3 0.09 Allowed 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.514 -1.366 . . . . 0.0 111.564 -179.339 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.581 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -153.2 157.83 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 107.116 -1.438 . . . . 0.0 107.116 178.024 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.537 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.71 145.92 25.86 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.658 -1.276 . . . . 0.0 109.865 -179.73 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.676 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.38 107.98 2.2 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 122.368 1.08 . . . . 0.0 109.478 178.733 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.515 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.2 t0 -62.02 -139.11 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.045 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.931 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.84 -51.62 38.71 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.477 -0.764 . . . . 0.0 110.733 -178.614 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.73 -32.39 8.89 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 178.726 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.676 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.15 65.38 0.59 Allowed Glycine 0 C--N 1.297 -1.59 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 178.307 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.592 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 48.4 m -101.77 127.99 48.31 Favored 'General case' 0 C--N 1.309 -1.187 0 O-C-N 121.468 -1.019 . . . . 0.0 108.711 178.858 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.581 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.92 108.77 7.08 Favored 'General case' 0 C--N 1.295 -1.768 0 C-N-CA 119.316 -0.953 . . . . 0.0 109.819 -179.214 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 40.2 p -121.95 120.11 33.47 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.322 -0.861 . . . . 0.0 109.481 179.945 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.465 HG23 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.74 147.97 32.49 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.482 -0.761 . . . . 0.0 109.245 179.845 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.3 p -98.64 139.74 33.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.355 -0.84 . . . . 0.0 109.593 -179.876 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.513 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -143.75 157.45 44.38 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.366 -0.834 . . . . 0.0 109.202 -179.466 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.574 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 14.4 t -86.25 137.73 32.39 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.056 -1.028 . . . . 0.0 110.427 -179.645 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.521 ' CG2' HG11 ' A' ' 19' ' ' VAL . 24.1 m -148.6 141.43 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.467 -0.771 . . . . 0.0 109.525 -179.444 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.557 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -143.63 -170.68 3.36 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.563 -1.335 . . . . 0.0 110.368 -179.984 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.543 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -64.4 -94.61 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 -179.812 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.77 137.73 56.27 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.776 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.19 137.96 7.49 Favored 'General case' 0 C--N 1.293 -1.886 0 C-N-CA 118.3 -1.36 . . . . 0.0 110.473 -177.683 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.483 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.8 OUTLIER -32.42 118.91 0.28 Allowed 'General case' 0 N--CA 1.493 1.682 0 CA-C-O 121.5 0.667 . . . . 0.0 110.6 -178.497 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.552 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.97 49.42 1.76 Allowed Glycine 0 N--CA 1.492 2.403 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.542 -179.028 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.567 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.8 m-85 -40.0 115.55 0.55 Allowed 'General case' 0 N--CA 1.509 2.517 0 O-C-N 121.029 -1.277 . . . . 0.0 109.731 179.347 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.542 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -85.81 127.21 34.5 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.943 -1.098 . . . . 0.0 109.66 -179.673 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -64.55 57.97 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.856 -1.153 . . . . 0.0 110.182 179.664 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.47 19.62 0.14 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.929 -1.107 . . . . 0.0 109.718 179.885 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.07 -28.12 5.23 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.952 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.454 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 34.6 p -92.59 156.28 17.21 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.06 -1.259 . . . . 0.0 110.309 -179.439 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.467 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -105.04 134.73 47.65 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.664 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.48 ' HB2' HD12 ' A' ' 77' ' ' LEU . 0.6 OUTLIER -82.55 -17.21 45.76 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.655 -1.278 . . . . 0.0 110.518 -178.372 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 106.67 176.42 23.14 Favored Glycine 0 N--CA 1.485 1.904 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -179.791 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.72 105.38 0.65 Allowed 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 179.095 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.536 HG21 ' CB ' ' A' ' 46' ' ' ALA . 36.8 t -76.43 104.08 4.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.421 -0.799 . . . . 0.0 109.046 -178.816 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.471 ' HB3' HG22 ' A' ' 90' ' ' THR . 0.5 OUTLIER -62.39 109.51 1.38 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.546 -0.721 . . . . 0.0 110.027 -179.343 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.543 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.85 -4.49 6.86 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.565 -1.335 . . . . 0.0 109.728 179.256 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.5 p -85.37 3.78 38.31 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.848 -1.158 . . . . 0.0 108.989 179.499 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.471 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -119.37 -49.08 2.38 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.409 -0.807 . . . . 0.0 109.026 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.91 -178.88 3.78 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.491 -0.756 . . . . 0.0 109.474 179.826 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.55 115.26 29.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.366 -0.833 . . . . 0.0 109.138 -179.924 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.547 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.85 124.88 40.95 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.845 -1.16 . . . . 0.0 109.201 -179.628 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.529 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -104.12 146.77 28.27 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 122.379 1.085 . . . . 0.0 111.709 -179.027 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.525 ' CG1' HG12 ' A' ' 7' ' ' VAL . 84.1 t -100.4 109.81 25.97 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 177.348 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -145.87 -174.2 17.83 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 118.064 -2.017 . . . . 0.0 111.782 -177.426 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.62 -178.8 3.56 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 -178.95 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.471 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.2 p . . . . . 0 C--N 1.297 -1.695 0 O-C-N 121.423 -0.798 . . . . 0.0 109.094 -179.425 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.709 0 N-CA-C 107.867 -2.093 . . . . 0.0 107.867 . . . . . . . . . 0 0 . 1 . 043 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.61 -178.11 6.36 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 121.504 -0.998 . . . . 0.0 109.626 179.209 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.13 -165.89 32.62 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.479 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.7 Cg_exo -49.53 -175.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.646 0 CA-C-N 118.874 1.337 . . . . 0.0 110.371 179.572 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 16.5 mm-40 -95.89 -178.85 4.5 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.093 -1.004 . . . . 0.0 110.248 -179.094 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -115.64 158.74 14.2 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 -179.906 . . . . . . . . 1 1 . 1 . 043 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.94 128.35 50.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.421 -1.046 . . . . 0.0 108.982 -179.555 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.529 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.32 119.26 16.27 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.589 -0.695 . . . . 0.0 109.959 179.964 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.583 HD13 ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -97.97 172.61 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.241 -0.912 . . . . 0.0 108.677 179.544 . . . . . . . . 2 2 . 1 . 043 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.511 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -140.7 156.91 46.09 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.945 -1.097 . . . . 0.0 110.012 -179.761 . . . . . . . . 3 3 . 1 . 043 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.583 ' CZ ' HD13 ' A' ' 110' ' ' ILE . 96.6 m-85 . . . . . 0 N--CA 1.486 1.346 0 O-C-N 121.289 -0.882 . . . . 0.0 109.506 -179.749 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.481 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.288 0 CA-C-O 122.427 1.108 . . . . 0.0 110.278 . . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.54 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.1 t -116.21 109.22 17.14 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-O 123.09 1.424 . . . . 0.0 109.767 -179.992 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.526 HG12 ' CG1' ' A' ' 95' ' ' VAL . 2.4 t -112.87 136.26 49.71 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.745 0 CA-C-N 114.24 -1.345 . . . . 0.0 109.776 179.909 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.483 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.65 148.23 5.6 Favored Pre-proline 0 N--CA 1.487 1.396 0 O-C-N 121.184 -0.947 . . . . 0.0 108.855 -179.557 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.483 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.4 Cg_endo -76.46 151.18 94.44 Favored 'Cis proline' 0 C--N 1.312 -1.352 0 C-N-CA 123.38 -1.508 . . . . 0.0 109.422 -0.812 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.459 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 2.1 m -88.35 -26.73 22.06 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.593 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.475 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.4 m -136.73 165.14 26.61 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.616 -0.678 . . . . 0.0 109.446 179.807 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.31 37.69 31.12 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 -179.631 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.605 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 38.7 mt -92.84 -41.98 9.78 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 123.362 1.553 . . . . 0.0 110.418 -178.342 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.494 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.45 143.24 0.05 OUTLIER 'General case' 0 C--N 1.261 -3.279 0 CA-C-N 113.297 -1.774 . . . . 0.0 109.808 -179.57 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.552 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.3 p-10 -50.79 104.75 0.08 Allowed 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 121.462 0.649 . . . . 0.0 111.432 -178.369 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.4 15.19 7.76 Favored Glycine 0 N--CA 1.485 1.963 0 C-N-CA 119.317 -1.421 . . . . 0.0 113.086 177.311 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.605 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.0 t -104.72 -170.33 1.75 Allowed 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 121.165 2.482 . . . . 0.0 109.579 179.09 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.55 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 17.4 t -127.4 137.41 57.81 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.116 -179.133 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.576 ' CG1' ' CG2' ' A' ' 69' ' ' VAL . 11.7 m -111.28 156.32 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.315 -0.866 . . . . 0.0 108.852 178.932 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.491 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.4 tttt -111.55 109.48 19.42 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.214 -0.929 . . . . 0.0 108.843 179.854 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.525 HG12 ' CG2' ' A' ' 34' ' ' VAL . 1.9 p -102.91 138.8 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.975 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.581 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -132.61 161.76 33.06 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.861 -1.135 . . . . 0.0 109.941 179.689 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.586 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.92 140.75 11.85 Favored Glycine 0 C--N 1.298 -1.547 0 N-CA-C 108.144 -1.983 . . . . 0.0 108.144 179.776 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.54 125.4 16.09 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.606 -1.526 . . . . 0.0 109.296 179.374 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.2 28.51 20.06 Favored Glycine 0 N--CA 1.489 2.187 0 C-N-CA 118.69 -1.719 . . . . 0.0 109.807 -179.808 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.536 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -89.53 171.95 9.34 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 120.936 -1.332 . . . . 0.0 108.301 179.852 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.557 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.0 99.33 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.96 -1.087 . . . . 0.0 109.892 -179.385 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.23 77.66 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.212 -179.337 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.19 34.02 0.3 Allowed Glycine 0 N--CA 1.487 2.099 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 179.57 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.539 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 48.2 p -141.94 108.57 5.35 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 121.048 -1.266 . . . . 0.0 111.252 -179.527 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.559 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.16 109.71 0.32 Allowed 'General case' 0 N--CA 1.496 1.843 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.584 177.944 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.514 ' CE1' ' OG1' ' A' ' 30' ' ' THR . 4.6 m-30 -104.26 156.14 18.15 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.145 -0.972 . . . . 0.0 108.774 179.752 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.48 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -99.7 165.36 11.64 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.978 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.618 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.5 p -146.66 116.23 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.085 -1.009 . . . . 0.0 109.759 -178.15 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.491 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.73 -176.89 38.17 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.175 -1.964 . . . . 0.0 111.709 -179.608 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.614 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.3 pt20 -101.47 109.77 21.65 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.979 0.895 . . . . 0.0 109.055 -179.653 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.99 150.46 52.13 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 121.224 -0.922 . . . . 0.0 109.554 179.846 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.78 139.0 54.24 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.079 -1.013 . . . . 0.0 110.775 -178.949 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.627 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.16 114.64 26.45 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 178.196 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m -105.46 15.19 7.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.068 -1.02 . . . . 0.0 110.561 -178.688 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.589 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.42 -175.38 0.1 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.894 -1.128 . . . . 0.0 110.114 179.631 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -71.6 96.81 1.6 Allowed 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.426 -0.796 . . . . 0.0 109.743 -179.696 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.01 27.5 33.89 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 120.194 -1.003 . . . . 0.0 111.482 178.877 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.589 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.42 106.29 20.23 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.523 -1.575 . . . . 0.0 107.443 178.861 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.627 HD13 ' CD1' ' A' ' 39' ' ' TRP . 11.8 tp -115.75 104.67 11.9 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 120.389 -1.445 . . . . 0.0 109.967 -177.658 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.516 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.18 109.24 22.03 Favored 'General case' 0 N--CA 1.484 1.24 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.709 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.7 t -107.26 167.93 9.57 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.985 -1.072 . . . . 0.0 110.564 -178.397 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.522 ' ND2' ' HB1' ' A' ' 50' ' ' ALA . 49.9 t30 -112.61 130.9 22.97 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.454 -0.779 . . . . 0.0 109.585 -179.435 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.49 ' CD ' ' HB3' ' A' ' 74' ' ' GLU . 2.8 Cg_endo -72.41 23.76 0.27 Allowed 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 122.189 1.926 . . . . 0.0 112.124 179.966 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.522 ' HB1' ' ND2' ' A' ' 48' ' ' ASN . . . -113.41 3.53 15.88 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.333 -1.479 . . . . 0.0 109.192 179.526 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.505 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.45 17.36 2.74 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 179.259 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -80.84 88.87 5.82 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.577 -0.702 . . . . 0.0 111.011 -178.593 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.618 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -107.27 -167.19 1.24 Allowed 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.266 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.468 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.96 135.06 0.09 Allowed 'General case' 0 C--N 1.305 -1.353 0 O-C-N 120.496 -1.377 . . . . 0.0 111.372 -179.418 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.568 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.4 p -150.3 157.72 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 178.176 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.559 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.56 142.24 30.4 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.74 -1.225 . . . . 0.0 110.054 -179.847 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.681 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.13 107.73 1.36 Allowed 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 122.469 1.128 . . . . 0.0 109.416 178.436 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.537 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.0 p-10 -61.2 -139.17 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.762 179.893 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.29 -51.07 60.66 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.431 -0.793 . . . . 0.0 110.454 -178.691 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -101.75 -34.95 9.24 Favored 'General case' 0 C--N 1.285 -2.221 0 N-CA-C 106.287 -1.745 . . . . 0.0 106.287 178.342 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.681 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.28 65.87 0.59 Allowed Glycine 0 C--N 1.298 -1.565 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.082 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.586 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.5 m -98.71 130.83 45.21 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 121.503 -0.998 . . . . 0.0 108.482 178.729 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.581 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -135.76 108.86 7.7 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 118.956 -1.098 . . . . 0.0 109.796 -179.272 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 60.0 p -121.51 117.72 27.52 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.36 -0.838 . . . . 0.0 109.421 179.949 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.499 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -144.99 142.17 29.57 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.489 -0.757 . . . . 0.0 109.593 179.981 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 34.0 p -99.87 141.59 32.48 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.436 -0.79 . . . . 0.0 109.287 179.815 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.525 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -142.04 166.18 25.42 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.354 -0.841 . . . . 0.0 109.418 -179.355 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 3.4 p -95.49 124.47 39.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.118 -0.989 . . . . 0.0 109.398 -179.852 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.576 ' CG2' ' CG1' ' A' ' 19' ' ' VAL . 18.8 m -139.76 142.56 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 120.946 -1.096 . . . . 0.0 109.964 -179.183 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.552 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 7.3 ptt180 -140.09 -166.35 2.08 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 120.627 -1.295 . . . . 0.0 109.897 179.903 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.578 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -71.93 -80.68 0.06 Allowed 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 179.952 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.5 OUTLIER -64.13 135.97 56.83 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.197 -1.409 . . . . 0.0 107.197 178.579 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.591 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -161.98 138.68 8.14 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 118.07 -1.452 . . . . 0.0 110.252 -177.692 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.49 ' HB3' ' CD ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -31.04 121.39 0.22 Allowed 'General case' 0 N--CA 1.492 1.634 0 CA-C-O 121.479 0.657 . . . . 0.0 110.851 -178.31 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.516 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -91.95 50.62 2.83 Favored Glycine 0 N--CA 1.496 2.667 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 -179.489 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.463 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.5 OUTLIER -52.97 114.13 1.33 Allowed 'General case' 0 N--CA 1.51 2.55 0 O-C-N 120.934 -1.333 . . . . 0.0 110.645 -179.886 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.517 HD12 ' CD1' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -78.94 151.95 31.37 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 120.864 -1.148 . . . . 0.0 108.231 178.114 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.416 ' O ' ' CG ' ' A' ' 78' ' ' PHE . 63.7 t80 -74.68 5.5 4.83 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 120.69 -1.256 . . . . 0.0 110.563 -179.98 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -105.16 -2.49 24.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.905 -1.122 . . . . 0.0 109.701 -179.879 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.21 -19.45 51.42 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.998 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.475 ' O ' ' HB2' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -76.35 151.56 36.61 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.147 -1.207 . . . . 0.0 109.5 -179.947 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.503 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -96.82 123.08 40.42 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.896 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.517 ' CD1' HD12 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -85.27 -16.68 39.33 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.968 -1.083 . . . . 0.0 110.046 -179.121 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 103.19 173.15 26.24 Favored Glycine 0 N--CA 1.483 1.829 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 -179.757 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -60.09 108.93 0.85 Allowed 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 178.853 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.558 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 25.5 t -78.88 101.27 4.16 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -178.844 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.458 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -62.14 110.41 1.6 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.548 -0.72 . . . . 0.0 110.046 -178.985 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.532 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -65.14 -4.78 5.38 Favored 'General case' 0 N--CA 1.499 1.993 0 C-N-CA 118.413 -1.315 . . . . 0.0 109.727 179.378 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.6 p -83.66 2.82 35.73 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.712 -1.242 . . . . 0.0 108.911 179.328 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.458 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.0 p -117.91 -48.53 2.55 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.406 -0.809 . . . . 0.0 108.974 -179.976 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.67 179.97 4.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.542 -0.724 . . . . 0.0 109.394 179.931 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.47 114.75 29.18 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.368 -0.832 . . . . 0.0 109.22 179.964 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.569 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.7 120.89 37.86 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.887 -1.133 . . . . 0.0 109.532 -179.305 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.566 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.91 148.25 25.2 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 122.38 1.086 . . . . 0.0 111.308 -179.322 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.526 ' CG1' HG12 ' A' ' 7' ' ' VAL . 43.2 t -105.06 111.56 35.04 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 177.66 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.47 -170.84 17.45 Favored Glycine 0 N--CA 1.486 2.025 0 C-N-CA 118.18 -1.962 . . . . 0.0 111.667 -177.65 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.48 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.68 178.81 4.2 Favored 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.016 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.458 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.0 OUTLIER . . . . . 0 C--N 1.296 -1.739 0 O-C-N 121.473 -0.767 . . . . 0.0 109.347 -179.517 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.763 0 N-CA-C 107.661 -2.175 . . . . 0.0 107.661 . . . . . . . . . 0 0 . 1 . 044 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.28 -177.76 6.24 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.561 -0.964 . . . . 0.0 109.715 179.28 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.82 -161.78 15.63 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 108.41 -1.876 . . . . 0.0 108.41 -179.344 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.483 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.7 Cg_exo -47.22 178.97 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.678 0 CA-C-N 118.721 1.261 . . . . 0.0 110.345 179.378 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -92.97 -172.64 3.05 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.198 -0.939 . . . . 0.0 110.357 -178.866 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -123.45 161.94 17.56 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.891 . . . . . . . . 1 1 . 1 . 044 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.73 130.53 48.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.415 -1.05 . . . . 0.0 109.244 -179.514 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.566 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.22 120.81 19.36 Favored 'General case' 0 C--N 1.289 -2.043 0 O-C-N 121.716 -0.615 . . . . 0.0 109.646 179.684 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.629 ' CD1' ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -98.14 169.67 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 O-C-N 121.138 -0.976 . . . . 0.0 109.331 -179.956 . . . . . . . . 2 2 . 1 . 044 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.475 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -136.96 151.16 48.69 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.256 -0.903 . . . . 0.0 109.694 -179.973 . . . . . . . . 3 3 . 1 . 044 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.629 ' CZ ' ' CD1' ' A' ' 110' ' ' ILE . 36.7 m-85 . . . . . 0 C--N 1.305 -1.33 0 O-C-N 121.099 -1.001 . . . . 0.0 109.539 -179.727 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.211 0 CA-C-O 122.296 1.046 . . . . 0.0 110.469 . . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.543 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.4 p -105.56 105.04 14.89 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 122.501 1.143 . . . . 0.0 110.46 -179.352 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.529 HG21 ' CG2' ' A' ' 21' ' ' VAL . 3.5 t -118.12 117.82 56.09 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.426 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.267 179.426 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.489 HG21 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -161.34 148.49 11.83 Favored Pre-proline 0 N--CA 1.487 1.412 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 -179.588 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.489 ' HA ' HG21 ' A' ' 8' ' ' THR . 6.2 Cg_endo -78.3 149.93 87.38 Favored 'Cis proline' 0 C--N 1.31 -1.491 0 C-N-CA 123.533 -1.445 . . . . 0.0 109.563 -0.573 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 88.5 p -92.23 -23.38 19.36 Favored 'General case' 0 C--N 1.291 -1.962 0 O-C-N 121.618 -0.676 . . . . 0.0 109.209 179.584 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 111' ' ' SER . 1.1 m -132.7 161.15 34.75 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.52 -0.737 . . . . 0.0 109.47 -179.91 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.01 37.76 32.07 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 -179.556 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.619 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 32.8 mt -90.83 -43.78 9.83 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 123.303 1.525 . . . . 0.0 110.674 -178.233 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.486 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.39 143.94 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.282 0 CA-C-N 113.508 -1.678 . . . . 0.0 109.899 -179.618 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.576 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -50.72 107.19 0.15 Allowed 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.683 0.754 . . . . 0.0 111.653 -178.611 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.26 15.46 8.99 Favored Glycine 0 N--CA 1.483 1.829 0 C-N-CA 119.557 -1.306 . . . . 0.0 112.801 177.461 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.619 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.7 t -105.3 -173.82 2.39 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 121.106 2.453 . . . . 0.0 109.914 179.309 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.549 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 19.0 t -130.18 138.94 52.68 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 114.666 -1.152 . . . . 0.0 111.24 -178.61 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.488 HG13 ' CG2' ' A' ' 69' ' ' VAL . 34.6 m -115.92 155.65 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.367 -0.833 . . . . 0.0 108.817 178.725 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.522 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 12.4 tttt -107.72 109.33 20.89 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.03 -1.043 . . . . 0.0 109.66 -179.789 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.529 ' CG2' HG21 ' A' ' 7' ' ' VAL . 6.5 p -104.36 125.08 59.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.528 -0.732 . . . . 0.0 109.193 179.759 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.554 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -115.53 165.21 13.26 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.741 -1.224 . . . . 0.0 108.911 179.348 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.613 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.39 107.95 0.49 Allowed Glycine 0 N--CA 1.481 1.686 0 N-CA-C 108.242 -1.943 . . . . 0.0 108.242 -179.97 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.23 139.84 50.69 Favored 'General case' 0 N--CA 1.5 2.035 0 CA-C-N 119.635 1.718 . . . . 0.0 110.464 -179.171 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.76 28.46 35.06 Favored Glycine 0 N--CA 1.489 2.219 0 C-N-CA 118.739 -1.696 . . . . 0.0 109.948 179.387 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -92.4 171.96 8.7 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.935 -1.332 . . . . 0.0 108.429 179.793 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.23 100.43 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.933 -1.104 . . . . 0.0 109.781 -179.664 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.06 77.6 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.679 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.982 -179.245 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.1 33.99 0.27 Allowed Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.721 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.573 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 24.5 p -139.53 106.98 5.55 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.17 -1.194 . . . . 0.0 111.261 -179.577 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.565 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -52.37 110.4 0.49 Allowed 'General case' 0 N--CA 1.497 1.901 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.93 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.573 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 30.0 m-85 -106.68 157.4 17.73 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.06 -1.025 . . . . 0.0 109.079 179.892 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.58 165.29 11.49 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.781 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.636 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.6 p -144.57 121.3 4.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.13 -0.981 . . . . 0.0 109.535 -177.623 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.39 -178.53 42.62 Favored Glycine 0 N--CA 1.496 2.681 0 C-N-CA 118.114 -1.993 . . . . 0.0 111.86 -179.814 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.559 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -100.73 108.86 20.81 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.874 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -129.85 149.29 51.65 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.142 -0.974 . . . . 0.0 110.11 179.849 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.34 138.73 54.35 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.363 -0.836 . . . . 0.0 110.757 -179.128 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.618 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.25 115.03 26.89 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.146 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.468 HG23 ' HB ' ' A' ' 44' ' ' VAL . 11.8 m -105.9 15.52 7.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 120.95 -1.094 . . . . 0.0 110.55 -178.895 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.59 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 173.97 -176.26 0.08 Allowed 'General case' 0 C--N 1.303 -1.417 0 O-C-N 120.902 -1.124 . . . . 0.0 110.192 179.775 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.545 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.0 t -71.16 98.45 1.69 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.426 -0.796 . . . . 0.0 109.827 -179.672 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.7 28.77 34.25 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.312 179.006 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.59 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -117.5 106.11 19.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 120.608 -1.525 . . . . 0.0 107.16 178.853 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.618 HD11 ' CD1' ' A' ' 39' ' ' TRP . 13.3 tp -117.6 104.74 11.33 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.49 -1.381 . . . . 0.0 109.756 -177.613 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.517 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.95 109.52 22.26 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.809 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -106.74 166.49 10.54 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.928 -1.108 . . . . 0.0 110.422 -178.761 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.542 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 3.0 t-20 -107.88 133.34 20.51 Favored Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.526 -0.734 . . . . 0.0 109.511 -179.247 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.581 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.3 Cg_endo -74.61 25.12 0.36 Allowed 'Trans proline' 0 C--N 1.319 -0.99 0 C-N-CA 122.376 2.05 . . . . 0.0 111.99 -179.973 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.542 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -107.12 -4.87 18.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.342 -1.474 . . . . 0.0 109.306 179.848 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.544 ' HB3' ' CB ' ' A' ' 67' ' ' LEU . 5.4 m-20 -133.24 5.94 3.83 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.264 -0.898 . . . . 0.0 108.683 179.918 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -60.35 80.06 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 110.5 -178.797 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.636 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -105.31 -169.6 1.62 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 178.55 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.474 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 177.88 135.67 0.07 Allowed 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.626 -1.296 . . . . 0.0 111.149 -179.249 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.553 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -149.58 157.83 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 177.907 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.565 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.31 140.1 33.1 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 120.837 -1.164 . . . . 0.0 110.038 -179.7 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.663 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -62.45 106.61 0.79 Allowed 'General case' 0 C--N 1.298 -1.673 0 CA-C-O 122.438 1.113 . . . . 0.0 109.448 178.418 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.535 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.5 p-10 -59.8 -139.38 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.031 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.882 -179.944 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.01 -50.4 61.46 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.344 -0.848 . . . . 0.0 110.485 -178.782 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -103.21 -35.0 8.62 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 178.433 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.663 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.34 69.86 0.71 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 178.123 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.613 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 48.3 m -105.1 127.68 53.0 Favored 'General case' 0 N--CA 1.485 1.299 0 O-C-N 121.517 -0.99 . . . . 0.0 108.96 179.256 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.554 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -133.96 109.27 8.9 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.076 -179.765 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 42.5 m -120.46 115.84 24.26 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.282 -0.886 . . . . 0.0 109.452 -179.656 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.82 143.82 29.89 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.4 -0.813 . . . . 0.0 109.502 179.967 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.427 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 21.8 p -98.76 137.21 37.69 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.467 -0.771 . . . . 0.0 109.407 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.549 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.1 OUTLIER -131.26 167.81 18.58 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.408 -0.808 . . . . 0.0 110.027 -178.673 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.522 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.2 p -102.62 123.6 46.62 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.051 -1.031 . . . . 0.0 108.863 179.396 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.529 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.7 m -135.99 143.99 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 120.899 -1.126 . . . . 0.0 109.868 -179.023 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.576 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.8 ptt180 -144.75 -176.79 5.21 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 120.637 -1.289 . . . . 0.0 111.046 -179.891 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.706 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.97 -94.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.276 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -65.32 148.28 51.98 Favored 'General case' 0 N--CA 1.485 1.282 0 O-C-N 120.566 -1.334 . . . . 0.0 107.543 178.63 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.602 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -167.44 140.66 3.45 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 117.942 -1.503 . . . . 0.0 110.126 -177.459 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' A' ' 47' ' ' CYS . 5.1 mm-40 -36.49 122.06 0.75 Allowed 'General case' 0 N--CA 1.489 1.509 0 CA-C-O 121.421 0.629 . . . . 0.0 110.235 -178.708 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.517 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -96.61 51.83 1.54 Allowed Glycine 0 N--CA 1.495 2.571 0 C-N-CA 120.496 -0.859 . . . . 0.0 111.148 -179.252 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.581 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -39.16 114.74 0.43 Allowed 'General case' 0 N--CA 1.509 2.476 0 O-C-N 121.104 -1.233 . . . . 0.0 110.18 179.446 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -85.53 126.55 33.95 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 120.791 -1.193 . . . . 0.0 109.594 -179.841 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -64.5 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.028 0 O-C-N 120.852 -1.155 . . . . 0.0 109.951 179.527 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.2 t70 -159.55 19.41 0.17 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.007 -1.058 . . . . 0.0 109.624 179.873 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.4 -27.45 5.71 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.929 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.471 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 63.1 p -97.01 158.5 15.4 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 120.963 -1.316 . . . . 0.0 110.366 -179.375 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.487 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 2.6 ptt180 -104.28 140.21 38.19 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.672 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.468 ' CD1' HD12 ' A' ' 77' ' ' LEU . 1.7 t90 -84.93 -17.51 37.54 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.683 -1.261 . . . . 0.0 110.787 -178.077 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.41 176.58 19.83 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 -179.45 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.91 104.51 1.12 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 179.198 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.574 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 39.9 t -75.93 107.92 7.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.295 -0.878 . . . . 0.0 109.387 -178.767 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.508 ' CB ' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -68.24 113.14 5.6 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.435 -0.791 . . . . 0.0 109.575 -179.777 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.706 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 8.2 m -62.48 -5.07 2.24 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 120.424 -1.423 . . . . 0.0 110.235 179.717 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 p -88.35 -2.82 58.82 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.542 -1.349 . . . . 0.0 109.489 179.825 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.508 HG23 ' CB ' ' A' ' 87' ' ' ASP . 2.6 p -106.45 -47.95 3.67 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.237 -0.914 . . . . 0.0 108.804 179.837 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -111.1 -177.67 3.27 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.642 -0.662 . . . . 0.0 109.295 179.724 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.75 116.19 31.87 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.933 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.524 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 3.4 m -96.67 122.23 39.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.823 -1.173 . . . . 0.0 109.794 -179.167 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.521 ' HA ' ' O ' ' A' ' 108' ' ' VAL . 1.1 mt-30 -104.36 148.71 26.09 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 122.393 1.092 . . . . 0.0 111.458 -179.374 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.524 ' CG1' HG13 ' A' ' 7' ' ' VAL . 48.4 t -106.3 111.51 35.55 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 106.873 -1.529 . . . . 0.0 106.873 177.534 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.465 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.51 -170.68 19.9 Favored Glycine 0 N--CA 1.488 2.106 0 C-N-CA 118.104 -1.998 . . . . 0.0 111.625 -177.743 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.485 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -115.92 175.15 5.67 Favored 'General case' 0 C--N 1.307 -1.268 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.269 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.485 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 3.3 t . . . . . 0 C--N 1.291 -1.957 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -179.857 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.672 0 N-CA-C 108.048 -2.021 . . . . 0.0 108.048 . . . . . . . . . 0 0 . 1 . 045 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -165.83 -177.16 4.15 Favored 'General case' 0 C--N 1.307 -1.282 0 O-C-N 121.501 -0.999 . . . . 0.0 109.98 179.476 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.71 -161.62 20.48 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.204 -1.958 . . . . 0.0 108.204 -179.368 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.4 Cg_exo -47.55 -179.55 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.694 0 CA-C-N 118.921 1.36 . . . . 0.0 110.442 179.239 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -96.51 174.71 6.71 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.069 -1.019 . . . . 0.0 110.361 -179.056 . . . . . . . . 1 1 . 1 . 045 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.465 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -114.65 175.69 16.29 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -110.01 153.45 11.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 -179.545 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.514 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -94.21 123.94 37.92 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 121.337 -0.852 . . . . 0.0 109.413 179.796 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.55 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.4 pt -97.91 169.72 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 O-C-N 121.092 -1.005 . . . . 0.0 109.159 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.44 154.99 48.87 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.333 -0.854 . . . . 0.0 109.455 179.93 . . . . . . . . 3 3 . 1 . 045 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.55 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 59.6 m-85 . . . . . 0 N--CA 1.486 1.332 0 O-C-N 121.084 -1.01 . . . . 0.0 109.598 -179.609 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.522 ' CB ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.386 0 CA-C-O 122.232 1.015 . . . . 0.0 111.055 . . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.536 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.3 p -101.22 104.71 15.77 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 122.453 1.121 . . . . 0.0 109.959 -179.843 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.544 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 3.2 t -118.54 124.54 73.3 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.509 179.716 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.486 HG21 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -170.8 149.96 2.99 Favored Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.509 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.486 ' HA ' HG21 ' A' ' 8' ' ' THR . 2.0 Cg_endo -75.02 152.55 98.32 Favored 'Cis proline' 0 C--N 1.309 -1.504 0 C-N-CA 123.553 -1.436 . . . . 0.0 109.714 -0.476 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.467 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 9.3 m -93.31 -23.07 18.61 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.61 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.465 ' OG ' ' HB3' ' A' ' 111' ' ' SER . 3.2 m -135.32 163.38 30.14 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.46 -0.775 . . . . 0.0 109.345 179.764 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.83 38.1 32.11 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 108.387 -1.885 . . . . 0.0 108.387 -179.513 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.614 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 32.8 mt -91.94 -44.14 9.07 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 123.122 1.439 . . . . 0.0 110.7 -178.201 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 68.14 145.24 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.338 0 CA-C-N 113.578 -1.646 . . . . 0.0 110.081 -179.707 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.56 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.5 p-10 -50.45 106.81 0.13 Allowed 'General case' 0 C--N 1.302 -1.474 0 CA-C-O 121.437 0.637 . . . . 0.0 111.793 -178.54 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.05 16.38 9.15 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.502 -1.332 . . . . 0.0 112.905 177.137 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.614 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.1 t -105.05 -173.73 2.37 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 121.069 2.434 . . . . 0.0 109.982 179.276 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.552 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 19.3 t -130.33 138.84 52.86 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.287 0 CA-C-N 114.593 -1.185 . . . . 0.0 111.183 -178.613 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.455 ' CG1' HD23 ' A' ' 13' ' ' LEU . 27.2 m -115.95 155.52 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.75 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.544 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 4.7 tttm -104.84 109.15 21.0 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.08 -1.013 . . . . 0.0 109.355 -179.954 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.524 ' CG1' HD11 ' A' ' 67' ' ' LEU . 7.2 p -106.64 124.2 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 179.671 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.536 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -118.89 166.94 12.21 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.65 -1.281 . . . . 0.0 109.296 179.848 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.76 141.8 13.2 Favored Glycine 0 C--N 1.296 -1.676 0 N-CA-C 107.594 -2.203 . . . . 0.0 107.594 179.727 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -147.42 123.21 10.59 Favored 'General case' 0 C--N 1.291 -1.956 0 O-C-N 120.832 -1.393 . . . . 0.0 108.624 179.19 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.68 26.36 25.12 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 119.222 -1.466 . . . . 0.0 109.884 -179.724 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.547 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.3 mt -85.69 176.01 8.4 Favored 'General case' 0 C--N 1.307 -1.281 0 O-C-N 120.695 -1.473 . . . . 0.0 108.245 179.908 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.561 ' CB ' ' CG2' ' A' ' 30' ' ' THR . 0.0 OUTLIER -45.76 96.87 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.013 -1.055 . . . . 0.0 109.671 -179.891 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.69 76.61 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.547 -178.91 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.01 34.59 0.33 Allowed Glycine 0 N--CA 1.486 1.984 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 179.334 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.561 ' CG2' ' CB ' ' A' ' 27' ' ' GLN . 1.2 t -149.23 115.4 5.77 Favored 'General case' 0 C--N 1.308 -1.213 0 O-C-N 120.94 -1.329 . . . . 0.0 111.263 179.949 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.557 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.68 129.54 4.15 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.819 178.262 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.541 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 7.4 m-85 -120.45 149.85 41.74 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.614 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.07 164.79 11.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.651 -1.281 . . . . 0.0 107.685 178.73 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.624 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 7.0 p -147.86 118.22 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.139 -0.976 . . . . 0.0 109.855 -177.831 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.77 -178.61 41.52 Favored Glycine 0 N--CA 1.494 2.526 0 C-N-CA 118.432 -1.842 . . . . 0.0 111.537 -179.864 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.561 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -99.16 108.48 21.09 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.822 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.453 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.19 148.31 52.02 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.257 -0.902 . . . . 0.0 110.109 179.992 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.44 139.5 53.83 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.39 -0.819 . . . . 0.0 110.736 -179.167 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.623 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.82 26.65 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.129 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.454 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 13.6 m -105.92 15.46 7.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.029 -1.044 . . . . 0.0 110.583 -178.698 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.59 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.32 -175.66 0.09 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.858 -1.151 . . . . 0.0 110.095 179.688 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -71.5 97.14 1.61 Allowed 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.47 -0.769 . . . . 0.0 109.754 -179.744 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.26 27.81 35.49 Favored Glycine 0 N--CA 1.491 2.325 0 C-N-CA 120.181 -1.009 . . . . 0.0 111.394 179.006 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.59 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 2.0 t -116.1 106.6 20.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 O-C-N 120.625 -1.515 . . . . 0.0 107.295 178.814 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.623 HD12 ' CD1' ' A' ' 39' ' ' TRP . 12.4 tp -116.21 104.66 11.74 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.483 -1.386 . . . . 0.0 109.738 -177.745 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.536 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.63 109.36 22.13 Favored 'General case' 0 N--CA 1.483 1.221 0 O-C-N 120.887 -1.133 . . . . 0.0 107.947 178.916 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.492 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -108.29 167.09 10.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.98 -1.075 . . . . 0.0 110.589 -178.535 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.519 ' ND2' ' HB1' ' A' ' 50' ' ' ALA . 43.6 t30 -114.7 128.22 26.09 Favored Pre-proline 0 N--CA 1.499 1.977 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 -179.554 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.575 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.2 Cg_endo -69.96 19.89 0.19 Allowed 'Trans proline' 0 CA--C 1.545 1.065 0 C-N-CA 122.005 1.803 . . . . 0.0 112.294 -179.804 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.519 ' HB1' ' ND2' ' A' ' 48' ' ' ASN . . . -93.79 -7.51 43.22 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.384 -1.448 . . . . 0.0 108.802 179.122 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.558 ' HB3' ' CB ' ' A' ' 67' ' ' LEU . 4.2 m-20 -131.24 2.22 4.24 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.369 -0.832 . . . . 0.0 108.802 -179.869 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -58.15 83.53 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.336 -0.853 . . . . 0.0 111.147 -178.247 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -110.97 -170.89 1.72 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 178.087 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.469 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.62 134.7 0.08 Allowed 'General case' 0 C--N 1.305 -1.363 0 O-C-N 120.446 -1.409 . . . . 0.0 111.621 -179.345 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.567 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.9 p -145.95 158.78 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 107.071 -1.455 . . . . 0.0 107.071 177.744 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.557 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.13 145.44 26.01 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.448 -1.407 . . . . 0.0 109.944 -179.613 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.669 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.04 108.84 3.23 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 122.272 1.034 . . . . 0.0 109.568 179.036 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.52 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.3 t0 -62.8 -138.89 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.979 -179.888 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.548 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.95 -51.53 40.59 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.393 -0.817 . . . . 0.0 110.559 -178.732 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -104.46 -33.54 8.55 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 178.493 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.669 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.75 70.08 0.7 Allowed Glycine 0 C--N 1.299 -1.512 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 178.482 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 70.9 m -103.57 130.81 51.05 Favored 'General case' 0 N--CA 1.484 1.255 0 O-C-N 121.248 -1.148 . . . . 0.0 109.208 179.324 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.567 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -135.57 108.86 7.79 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.471 -0.891 . . . . 0.0 109.841 -179.588 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.2 m -115.4 115.38 26.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.117 -0.99 . . . . 0.0 109.328 179.998 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.459 HG21 HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.09 144.87 30.29 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.413 -0.804 . . . . 0.0 109.829 -179.91 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.424 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 24.7 p -98.99 140.8 32.61 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.55 -0.718 . . . . 0.0 109.169 179.66 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.558 ' CB ' ' HB3' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -135.46 165.37 25.64 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.322 -0.862 . . . . 0.0 110.065 -178.924 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.2 p -104.38 123.06 46.75 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.127 -0.983 . . . . 0.0 108.807 179.463 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.517 ' CB ' ' OE1' ' A' ' 36' ' ' GLN . 18.9 m -136.06 143.48 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.838 -1.164 . . . . 0.0 110.359 -178.898 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.56 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.2 ptt180 -141.64 -166.19 2.15 Favored 'General case' 0 N--CA 1.485 1.323 0 O-C-N 120.686 -1.259 . . . . 0.0 110.331 179.688 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.547 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 1.3 mtp180 -68.98 -78.21 0.07 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.57 -0.706 . . . . 0.0 109.128 -179.419 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.43 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -71.92 139.25 48.65 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 120.122 -1.611 . . . . 0.0 107.822 179.39 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -160.32 136.36 8.52 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 118.276 -1.37 . . . . 0.0 110.058 -178.501 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.483 ' O ' ' O ' ' A' ' 47' ' ' CYS . 20.4 mm-40 -32.84 122.36 0.36 Allowed 'General case' 0 N--CA 1.491 1.598 0 CA-C-O 121.557 0.694 . . . . 0.0 110.776 -178.248 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.536 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -89.51 44.37 3.05 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 -179.502 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.575 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -39.12 112.3 0.24 Allowed 'General case' 0 N--CA 1.507 2.384 0 O-C-N 121.156 -1.202 . . . . 0.0 110.27 179.954 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.52 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.5 tp -87.41 127.73 35.21 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 120.837 -1.165 . . . . 0.0 109.412 -179.926 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -64.35 57.96 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 120.91 -1.119 . . . . 0.0 110.24 179.9 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.52 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.0 t70 -160.68 19.06 0.13 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.049 -1.032 . . . . 0.0 109.817 179.813 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.06 -26.01 5.73 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.161 -1.175 . . . . 0.0 110.161 179.865 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.424 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -92.54 153.65 18.93 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.906 -1.35 . . . . 0.0 110.384 -179.463 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -101.34 132.45 46.89 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.493 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.459 ' CD1' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -80.66 -17.44 51.2 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.813 -1.179 . . . . 0.0 110.278 -178.624 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.6 173.55 20.16 Favored Glycine 0 N--CA 1.486 1.995 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -179.682 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.38 108.05 1.03 Allowed 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 179.04 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.595 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 39.8 t -79.01 105.64 8.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 O-C-N 121.43 -0.794 . . . . 0.0 108.882 -178.834 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.45 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.2 OUTLIER -67.93 111.23 4.25 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.427 -0.795 . . . . 0.0 109.874 -179.151 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.547 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -63.88 -5.45 4.43 Favored 'General case' 0 N--CA 1.501 2.095 0 C-N-CA 118.438 -1.305 . . . . 0.0 109.862 179.529 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.452 HG22 ' HB3' ' A' ' 71' ' ' ARG . 69.7 p -84.49 0.22 50.53 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.744 -1.222 . . . . 0.0 108.909 179.324 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.45 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -114.2 -49.06 2.86 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.469 -0.77 . . . . 0.0 109.147 179.952 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.17 -178.65 3.7 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.386 -0.821 . . . . 0.0 109.58 -179.943 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.16 114.78 29.18 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.452 -0.78 . . . . 0.0 109.022 -179.991 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.563 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.04 122.12 39.68 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.919 -1.113 . . . . 0.0 109.49 -179.375 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.589 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.28 144.7 30.46 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 122.444 1.116 . . . . 0.0 111.151 -179.336 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.425 ' HB ' HG11 ' A' ' 7' ' ' VAL . 99.4 t -100.9 110.02 26.84 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.604 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.448 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.39 -172.63 19.19 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 117.899 -2.096 . . . . 0.0 111.83 -177.611 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.481 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -111.63 -177.51 3.21 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -179.268 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.486 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.0 OUTLIER . . . . . 0 C--N 1.297 -1.707 0 O-C-N 121.137 -0.977 . . . . 0.0 110.143 -179.134 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.49 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.483 1.793 0 N-CA-C 107.978 -2.049 . . . . 0.0 107.978 . . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.49 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -171.24 -179.12 2.58 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.517 -0.99 . . . . 0.0 109.567 179.156 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.36 -165.42 28.61 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 108.685 -1.766 . . . . 0.0 108.685 -179.548 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.472 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.0 Cg_exo -49.3 -178.19 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.641 0 CA-C-N 118.857 1.328 . . . . 0.0 110.076 179.556 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -96.88 -179.67 4.64 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.079 -1.013 . . . . 0.0 110.313 -179.056 . . . . . . . . 1 1 . 1 . 046 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.448 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.87 163.79 12.8 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 179.994 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.84 127.6 51.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.287 -1.125 . . . . 0.0 109.165 -179.53 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.589 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.02 121.11 18.61 Favored 'General case' 0 C--N 1.289 -2.053 0 CA-C-O 121.323 0.582 . . . . 0.0 109.743 179.825 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.574 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.98 168.76 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.238 -0.914 . . . . 0.0 109.387 179.952 . . . . . . . . 2 2 . 1 . 046 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.465 ' HB3' ' OG ' ' A' ' 11' ' ' SER . 0.0 OUTLIER -138.34 157.63 45.86 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.289 -0.882 . . . . 0.0 109.78 -179.875 . . . . . . . . 3 3 . 1 . 046 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.574 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 96.6 m-85 . . . . . 0 N--CA 1.487 1.41 0 O-C-N 121.202 -0.936 . . . . 0.0 109.565 -179.756 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.154 0 CA-C-O 122.425 1.107 . . . . 0.0 110.609 . . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.536 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.9 p -105.42 104.72 14.5 Favored 'General case' 0 C--N 1.295 -1.77 0 CA-C-O 122.57 1.176 . . . . 0.0 110.173 -179.585 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.53 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 20.5 t -119.29 122.56 69.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.317 179.804 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.487 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -166.59 150.64 6.76 Favored Pre-proline 0 N--CA 1.489 1.511 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.294 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG22 ' A' ' 8' ' ' THR . 2.6 Cg_endo -74.62 151.9 97.54 Favored 'Cis proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.651 -1.395 . . . . 0.0 110.016 -0.621 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.479 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 6.0 m -93.73 -23.07 18.34 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.518 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.479 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -135.67 160.86 37.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.474 -0.766 . . . . 0.0 109.446 -179.97 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.09 37.7 31.93 Favored Glycine 0 N--CA 1.494 2.541 0 N-CA-C 108.517 -1.833 . . . . 0.0 108.517 -179.624 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.617 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 31.0 mt -89.9 -44.7 9.73 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 123.188 1.47 . . . . 0.0 110.608 -178.439 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.486 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.4 OUTLIER 65.89 146.26 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.626 -1.624 . . . . 0.0 110.151 -179.931 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.567 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.1 p-10 -51.33 107.52 0.19 Allowed 'General case' 0 C--N 1.302 -1.485 0 CA-C-O 121.68 0.752 . . . . 0.0 111.678 -178.601 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.24 15.08 9.27 Favored Glycine 0 N--CA 1.484 1.848 0 C-N-CA 119.511 -1.328 . . . . 0.0 112.847 177.348 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.617 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 9.9 t -103.72 -172.77 2.17 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 121.146 2.473 . . . . 0.0 109.776 179.358 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.572 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 13.6 t -132.81 140.42 47.45 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.351 0 CA-C-N 114.937 -1.028 . . . . 0.0 111.136 -178.829 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.458 HG11 ' CG2' ' A' ' 69' ' ' VAL . 31.3 m -117.76 154.16 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 121.355 -0.841 . . . . 0.0 108.968 179.144 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.53 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -108.03 108.95 20.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.886 . . . . 0.0 109.148 179.966 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.51 ' CG2' HG23 ' A' ' 7' ' ' VAL . 2.3 p -106.1 122.44 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.978 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.557 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -112.84 166.23 11.57 Favored 'General case' 0 C--N 1.306 -1.3 0 O-C-N 120.857 -1.152 . . . . 0.0 108.737 179.502 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.41 108.37 0.49 Allowed Glycine 0 N--CA 1.482 1.752 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 179.952 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.94 138.83 51.28 Favored 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 119.366 1.583 . . . . 0.0 110.21 -179.454 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.88 28.92 30.29 Favored Glycine 0 N--CA 1.491 2.306 0 C-N-CA 118.941 -1.6 . . . . 0.0 109.888 179.549 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.53 ' O ' ' N ' ' A' ' 28' ' ' ALA . 2.0 mt -91.67 176.13 6.65 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.979 -1.307 . . . . 0.0 108.449 179.956 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.556 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.65 96.91 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.052 -1.03 . . . . 0.0 109.61 -179.905 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.07 76.61 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.798 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.341 -178.857 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.52 34.17 0.32 Allowed Glycine 0 N--CA 1.486 1.985 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.383 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.568 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.1 t -148.44 115.32 6.06 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 120.931 -1.335 . . . . 0.0 111.113 -179.935 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.55 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -43.36 128.83 4.94 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.777 178.38 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.568 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.0 m-85 -120.58 147.35 45.31 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.486 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.463 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -99.61 159.65 14.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.507 -1.371 . . . . 0.0 107.666 178.648 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.624 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 9.8 p -144.36 116.33 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.08 -1.012 . . . . 0.0 110.198 -177.543 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.89 -175.33 38.81 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.477 -1.82 . . . . 0.0 111.654 -179.995 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.555 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -100.91 109.22 21.14 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 121.845 0.831 . . . . 0.0 108.973 -179.717 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.448 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.79 149.44 52.43 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.254 -0.904 . . . . 0.0 110.05 179.796 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.34 139.07 54.26 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.38 -0.825 . . . . 0.0 110.813 -179.064 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.619 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 115.05 26.92 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.98 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.455 HG23 ' HB ' ' A' ' 44' ' ' VAL . 10.8 m -106.05 15.59 7.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 O-C-N 120.969 -1.082 . . . . 0.0 110.534 -178.796 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.594 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 173.79 -176.36 0.07 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.897 -1.127 . . . . 0.0 110.127 179.835 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.545 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.0 t -70.79 98.58 1.57 Allowed 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.416 -0.803 . . . . 0.0 109.914 -179.69 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.13 28.52 36.84 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.265 -0.969 . . . . 0.0 111.238 179.027 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.594 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.9 106.31 19.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.839 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.619 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.6 tp -116.94 104.83 11.68 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.409 -1.432 . . . . 0.0 109.749 -177.55 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.62 109.46 22.21 Favored 'General case' 0 N--CA 1.485 1.276 0 O-C-N 120.806 -1.184 . . . . 0.0 108.29 178.938 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.38 167.46 9.91 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.959 -1.088 . . . . 0.0 110.078 -178.959 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.529 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 15.2 t-20 -109.31 136.45 20.18 Favored Pre-proline 0 N--CA 1.5 2.06 0 O-C-N 121.369 -0.832 . . . . 0.0 109.97 -179.296 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.57 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -75.25 23.27 0.42 Allowed 'Trans proline' 0 CA--C 1.544 0.976 0 C-N-CA 122.369 2.046 . . . . 0.0 111.798 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.529 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -117.68 3.9 12.33 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.429 -1.42 . . . . 0.0 108.974 179.593 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.516 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.58 17.87 2.9 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 179.214 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -83.71 90.13 7.26 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.925 -178.473 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.81 -170.41 1.65 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 178.042 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.465 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.81 135.36 0.09 Allowed 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.402 -1.436 . . . . 0.0 111.508 -179.245 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.577 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.3 p -151.88 158.73 4.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.037 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.55 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.49 145.77 25.89 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.642 -1.286 . . . . 0.0 109.799 -179.621 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.662 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -67.22 108.01 2.55 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 122.389 1.09 . . . . 0.0 109.681 178.879 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.528 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.8 p-10 -61.23 -139.56 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.811 -179.898 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.96 -50.89 57.16 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.296 -0.877 . . . . 0.0 110.498 -178.858 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -103.98 -34.02 8.61 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 178.481 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.662 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.11 70.36 0.73 Allowed Glycine 0 C--N 1.297 -1.583 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 178.278 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 38.9 m -104.05 127.4 51.61 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.69 -0.888 . . . . 0.0 108.936 179.165 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -135.06 109.04 8.15 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.415 -179.682 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.439 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -118.69 117.07 27.94 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.264 -0.898 . . . . 0.0 109.349 -179.934 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.481 HG21 HG12 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -145.46 142.0 28.88 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.452 -0.78 . . . . 0.0 109.772 179.99 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.3 p -100.91 135.06 42.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.497 -0.752 . . . . 0.0 109.231 179.742 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.528 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.1 OUTLIER -133.39 165.52 24.65 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.314 -0.866 . . . . 0.0 109.526 -179.449 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.572 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.3 p -96.76 125.23 41.07 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.27 -0.894 . . . . 0.0 109.342 -179.903 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.54 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.3 m -136.13 144.54 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.959 -1.088 . . . . 0.0 109.584 -179.312 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.567 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.4 ptt180 -139.95 -166.37 2.08 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 120.593 -1.317 . . . . 0.0 110.338 -179.927 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.665 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 40.9 mtm180 -69.83 -73.91 0.15 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.51 -0.744 . . . . 0.0 109.298 -179.113 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -76.87 145.74 38.13 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 178.534 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -166.23 140.06 4.23 Favored 'General case' 0 C--N 1.293 -1.887 0 C-N-CA 117.507 -1.677 . . . . 0.0 110.464 -177.737 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.513 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 2.2 mm-40 -33.98 122.32 0.46 Allowed 'General case' 0 N--CA 1.49 1.533 0 CA-C-O 121.593 0.711 . . . . 0.0 110.664 -178.479 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.533 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -90.09 45.82 3.03 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 -179.338 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.57 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.9 m-30 -39.63 113.19 0.31 Allowed 'General case' 0 N--CA 1.508 2.472 0 O-C-N 121.083 -1.245 . . . . 0.0 110.169 179.673 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.518 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.2 tp -87.23 128.17 35.15 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 120.868 -1.145 . . . . 0.0 109.379 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -64.47 57.89 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 120.809 -1.182 . . . . 0.0 110.328 179.882 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.518 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.1 t70 -161.0 18.92 0.12 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.946 -1.096 . . . . 0.0 109.779 179.844 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.79 -25.85 5.65 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 179.952 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 3.4 p -91.55 153.27 19.87 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 120.895 -1.356 . . . . 0.0 110.387 -179.351 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.491 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 8.5 ptt180 -100.95 131.93 46.6 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.544 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.496 ' CD1' HD12 ' A' ' 77' ' ' LEU . 2.0 t90 -81.74 -18.61 43.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.729 -1.232 . . . . 0.0 110.495 -178.47 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.61 173.65 19.6 Favored Glycine 0 N--CA 1.486 2.014 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 -179.624 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -62.07 109.27 1.24 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 179.133 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.564 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 40.5 t -80.87 104.51 9.47 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 O-C-N 121.339 -0.851 . . . . 0.0 109.058 -178.859 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.523 ' CB ' HG21 ' A' ' 90' ' ' THR . 0.2 OUTLIER -68.07 112.69 5.19 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.628 -0.67 . . . . 0.0 109.648 -179.551 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.665 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 6.8 m -56.83 -8.4 0.6 Allowed 'General case' 0 N--CA 1.496 1.867 0 C-N-CA 118.309 -1.356 . . . . 0.0 110.466 179.816 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 p -84.52 -12.44 54.19 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.366 -1.459 . . . . 0.0 109.53 179.981 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.523 HG21 ' CB ' ' A' ' 87' ' ' ASP . 2.7 p -92.97 -47.86 6.8 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.286 -0.884 . . . . 0.0 109.032 179.934 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -117.12 -178.24 3.4 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.547 -0.72 . . . . 0.0 109.477 179.937 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.48 117.76 35.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.462 -0.774 . . . . 0.0 108.922 179.888 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.474 ' O ' HG12 ' A' ' 110' ' ' ILE . 3.2 m -96.41 121.41 38.19 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.761 -1.212 . . . . 0.0 109.791 -179.202 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.551 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.78 146.92 27.92 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 122.445 1.117 . . . . 0.0 111.022 -179.486 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.514 ' CG1' HG11 ' A' ' 7' ' ' VAL . 42.5 t -102.93 109.81 27.82 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 177.442 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.441 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.68 -170.0 16.65 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 118.263 -1.922 . . . . 0.0 111.697 -177.4 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.461 HD12 ' HB3' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -122.2 -179.41 4.16 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.608 . . . . . . . . 3 3 . 1 . 047 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.463 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.4 OUTLIER . . . . . 0 C--N 1.296 -1.725 0 O-C-N 121.362 -0.836 . . . . 0.0 109.593 -179.739 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.696 0 N-CA-C 107.713 -2.155 . . . . 0.0 107.713 . . . . . . . . . 0 0 . 1 . 047 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.52 -177.6 5.72 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.626 -0.926 . . . . 0.0 109.967 179.311 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.53 -161.55 21.31 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.41 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.468 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.2 Cg_exo -45.83 173.12 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.628 0 CA-C-N 118.919 1.359 . . . . 0.0 109.936 179.263 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -92.81 -174.87 3.74 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.127 -0.983 . . . . 0.0 110.526 -178.751 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.441 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.0 166.14 13.55 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.953 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -103.97 130.42 54.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.349 -1.089 . . . . 0.0 109.075 -179.39 . . . . . . . . 1 1 . 1 . 047 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.551 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.81 123.68 23.85 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.494 -0.753 . . . . 0.0 109.642 179.728 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.571 HD13 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.78 168.42 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 119.555 -0.858 . . . . 0.0 108.912 179.893 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.479 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 2.3 m -134.12 153.76 51.62 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.295 -0.878 . . . . 0.0 109.448 -179.882 . . . . . . . . 2 2 . 1 . 047 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.595 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 65.9 m-85 . . . . . 0 N--CA 1.485 1.314 0 O-C-N 121.193 -0.942 . . . . 0.0 109.397 -179.783 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.493 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.156 0 CA-C-O 122.359 1.076 . . . . 0.0 110.696 . . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.538 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.8 p -105.11 104.8 14.61 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 122.609 1.195 . . . . 0.0 110.141 -179.505 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.533 HG12 ' CG1' ' A' ' 95' ' ' VAL . 16.7 t -120.17 119.91 61.4 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.44 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.325 179.662 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.516 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.0 150.06 9.54 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 -179.587 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.516 ' CA ' HG21 ' A' ' 8' ' ' THR . 3.1 Cg_endo -75.11 153.57 99.06 Favored 'Cis proline' 0 C--N 1.31 -1.471 0 C-N-CA 123.721 -1.366 . . . . 0.0 109.933 -0.637 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.449 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 8.0 m -95.04 -23.51 17.32 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.461 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.446 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 3.4 m -134.24 164.21 27.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.583 -0.698 . . . . 0.0 109.649 179.95 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.36 36.85 43.39 Favored Glycine 0 N--CA 1.496 2.668 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 -179.73 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.643 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 21.9 mt -90.03 -46.18 8.67 Favored 'General case' 0 C--N 1.297 -1.705 0 CA-C-O 123.151 1.453 . . . . 0.0 110.6 -178.532 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 2.1 t 61.45 148.25 0.02 OUTLIER 'General case' 0 C--N 1.259 -3.341 0 CA-C-N 113.917 -1.492 . . . . 0.0 109.913 -179.766 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.605 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 3.9 p-10 -51.35 109.61 0.36 Allowed 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.574 0.702 . . . . 0.0 111.683 -178.834 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.94 12.68 10.95 Favored Glycine 0 N--CA 1.485 1.945 0 C-N-CA 119.403 -1.38 . . . . 0.0 112.915 177.42 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.643 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 7.9 t -101.45 -175.25 2.8 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 121.0 2.4 . . . . 0.0 109.717 179.511 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.547 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 9.4 t -132.75 137.72 53.41 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.906 -179.414 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.424 HG22 HG22 ' A' ' 69' ' ' VAL . 28.5 m -116.97 153.88 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.348 -0.845 . . . . 0.0 109.214 179.219 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.52 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -110.31 109.23 19.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.29 -0.882 . . . . 0.0 108.977 179.715 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.515 ' CG2' HG21 ' A' ' 7' ' ' VAL . 2.0 p -105.95 122.5 59.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.766 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.543 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -113.4 165.84 12.07 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.886 -1.134 . . . . 0.0 108.954 179.554 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.6 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.52 108.23 0.5 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 108.806 -1.717 . . . . 0.0 108.806 -179.976 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.425 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.31 140.8 48.95 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-N 119.204 1.502 . . . . 0.0 110.281 -179.38 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.08 28.46 34.05 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.077 -1.535 . . . . 0.0 109.964 179.653 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -92.91 175.01 6.95 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.942 -1.328 . . . . 0.0 108.367 179.977 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.555 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.54 99.19 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.913 -1.117 . . . . 0.0 109.572 -179.743 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.69 76.85 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.272 -179.101 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.17 34.26 0.29 Allowed Glycine 0 N--CA 1.486 2.005 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.574 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.541 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.9 p -145.11 111.98 5.91 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.958 -1.319 . . . . 0.0 111.167 -179.683 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.535 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -45.7 125.66 6.21 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.574 178.107 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.489 ' CD2' ' O ' ' A' ' 30' ' ' THR . 14.2 m-85 -117.33 151.11 37.67 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.682 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.49 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -101.39 153.23 19.85 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.76 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.627 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 6.2 p -136.31 115.05 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.105 -0.997 . . . . 0.0 109.756 -177.928 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.482 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -165.09 -178.45 38.35 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 118.474 -1.822 . . . . 0.0 111.696 -179.68 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.618 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -102.47 109.27 20.86 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.729 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.449 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.87 149.08 52.67 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.128 -0.982 . . . . 0.0 110.117 -179.878 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.78 138.72 54.55 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.399 -0.813 . . . . 0.0 110.609 -179.111 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.621 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 114.88 26.72 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 178.005 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 m -105.24 15.05 6.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.986 -1.071 . . . . 0.0 110.579 -178.72 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.59 -175.88 0.08 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.916 -1.115 . . . . 0.0 110.044 179.686 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.542 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.0 t -71.81 98.34 1.96 Allowed 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.418 -0.801 . . . . 0.0 109.794 -179.704 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.76 27.43 34.94 Favored Glycine 0 N--CA 1.492 2.425 0 C-N-CA 120.077 -1.058 . . . . 0.0 111.518 179.084 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.591 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.76 106.42 20.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 O-C-N 120.548 -1.56 . . . . 0.0 107.288 178.929 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.621 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.9 tp -117.36 104.64 11.33 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.38 -1.45 . . . . 0.0 109.796 -177.757 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.529 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.77 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 178.698 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -105.49 166.96 10.07 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.043 -1.036 . . . . 0.0 110.493 -178.641 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.462 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 36.8 t-20 -110.35 129.61 23.77 Favored Pre-proline 0 N--CA 1.499 1.998 0 O-C-N 121.668 -0.645 . . . . 0.0 109.499 -179.393 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.1 Cg_endo -72.39 22.34 0.28 Allowed 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 122.091 1.861 . . . . 0.0 111.808 179.581 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -110.76 2.6 18.5 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.41 -1.431 . . . . 0.0 108.997 179.626 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.496 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.58 17.83 2.71 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 179.447 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -80.73 93.11 6.13 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.916 -0.714 . . . . 0.0 111.086 -178.496 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -113.15 -167.78 1.24 Allowed 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 178.113 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.47 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.73 136.82 0.09 Allowed 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.619 -1.301 . . . . 0.0 111.524 -179.248 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.587 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -154.45 157.1 4.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.113 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.535 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.84 144.82 27.03 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.665 -1.272 . . . . 0.0 109.893 -179.636 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.667 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -65.6 107.07 1.61 Allowed 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 122.353 1.073 . . . . 0.0 109.428 178.772 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.523 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.4 t0 -60.47 -139.29 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.956 -179.895 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.548 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.01 -50.72 57.98 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.401 -0.812 . . . . 0.0 110.733 -178.749 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -104.02 -34.06 8.58 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.461 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.667 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.23 66.17 0.62 Allowed Glycine 0 C--N 1.295 -1.704 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 178.243 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 20.3 m -103.5 125.02 49.82 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.758 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.587 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.6 109.19 8.5 Favored 'General case' 0 C--N 1.296 -1.749 0 C-N-CA 119.631 -0.827 . . . . 0.0 109.649 -179.28 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 97.3 p -116.44 116.51 27.8 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.345 -0.847 . . . . 0.0 109.441 -179.987 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.451 HG23 HG11 ' A' ' 34' ' ' VAL . 1.1 t -141.3 138.5 33.21 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.438 -0.789 . . . . 0.0 109.816 179.982 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 23.4 p -99.12 141.22 32.16 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.446 -0.784 . . . . 0.0 109.127 179.814 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.531 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -142.34 169.44 17.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.33 -0.856 . . . . 0.0 109.523 -179.24 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.547 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.5 p -96.57 126.26 41.62 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.055 -1.028 . . . . 0.0 109.519 -179.712 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.447 HG13 ' HB3' ' A' ' 36' ' ' GLN . 15.6 m -133.14 142.74 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 120.916 -1.115 . . . . 0.0 109.738 -179.346 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.605 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.84 -170.68 3.59 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.517 -1.364 . . . . 0.0 110.731 -179.877 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.6 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -66.6 -102.23 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.807 -0.558 . . . . 0.0 110.171 -179.04 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.12 136.29 56.38 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.388 -1.445 . . . . 0.0 108.198 179.845 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.618 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -155.86 158.52 38.18 Favored 'General case' 0 C--N 1.295 -1.793 0 C-N-CA 118.722 -1.191 . . . . 0.0 109.894 -178.853 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' A' ' 47' ' ' CYS . 12.1 mm-40 -50.01 121.9 6.01 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.296 -0.878 . . . . 0.0 109.561 -178.651 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.529 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.12 48.32 3.43 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 -179.514 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.587 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -40.11 113.38 0.35 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.046 -1.267 . . . . 0.0 110.286 179.919 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.531 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -86.94 127.1 35.07 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 120.913 -1.117 . . . . 0.0 109.47 179.987 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -63.88 58.52 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.865 -1.147 . . . . 0.0 110.167 179.8 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.531 ' N ' ' O ' ' A' ' 77' ' ' LEU . 14.3 t0 -161.02 19.23 0.12 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.09 -1.006 . . . . 0.0 109.92 179.842 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -25.6 5.96 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 179.802 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 67.4 p -94.09 159.22 15.25 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.979 -1.307 . . . . 0.0 110.384 -179.35 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.469 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 2.7 ptt180 -104.97 133.33 49.94 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 179.796 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.476 ' CD1' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -82.38 -18.37 42.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.845 -1.159 . . . . 0.0 110.406 -178.694 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.29 174.04 19.36 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 -179.671 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.56 108.7 1.44 Allowed 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 179.137 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.602 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 42.9 t -80.28 104.38 8.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 O-C-N 121.469 -0.77 . . . . 0.0 109.278 -178.771 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.478 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.6 OUTLIER -63.78 108.35 1.42 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.517 -0.739 . . . . 0.0 110.137 -179.231 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.548 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.6 t -60.76 -5.14 1.17 Allowed 'General case' 0 N--CA 1.501 2.084 0 C-N-CA 118.141 -1.424 . . . . 0.0 110.282 179.214 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 73.2 p -89.87 2.08 55.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.486 -1.383 . . . . 0.0 109.495 179.965 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.472 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.06 -49.04 2.94 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.236 -0.915 . . . . 0.0 109.149 -179.975 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.57 179.55 4.23 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.432 -0.792 . . . . 0.0 109.48 -179.974 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.65 112.99 25.74 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.791 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.484 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.55 121.39 38.32 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.008 -1.058 . . . . 0.0 109.373 -179.004 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.548 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.61 147.03 27.3 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.369 1.08 . . . . 0.0 111.341 -179.117 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.533 ' CG1' HG12 ' A' ' 7' ' ' VAL . 54.0 t -102.82 109.24 26.15 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 177.309 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.422 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.1 -170.96 16.56 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 118.179 -1.962 . . . . 0.0 111.53 -177.378 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.49 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -118.33 -178.52 3.54 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -178.612 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.47 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER . . . . . 0 C--N 1.295 -1.783 0 O-C-N 121.423 -0.798 . . . . 0.0 109.38 -179.352 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.735 0 N-CA-C 107.645 -2.182 . . . . 0.0 107.645 . . . . . . . . . 0 0 . 1 . 048 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.18 -178.39 7.17 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.581 -0.953 . . . . 0.0 109.809 179.229 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.12 -162.08 19.32 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 108.209 -1.957 . . . . 0.0 108.209 -179.398 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.3 Cg_exo -45.68 171.99 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.632 0 CA-C-N 118.855 1.327 . . . . 0.0 109.932 179.366 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -90.6 -173.07 3.62 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.092 -1.005 . . . . 0.0 110.544 -178.567 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.422 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.68 168.26 15.04 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.874 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.33 131.44 54.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 121.414 -1.051 . . . . 0.0 109.143 -179.313 . . . . . . . . 1 1 . 1 . 048 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.548 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.16 122.51 21.13 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.662 -0.648 . . . . 0.0 109.736 179.767 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.547 HD11 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -97.95 170.99 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.279 -0.888 . . . . 0.0 108.898 179.766 . . . . . . . . 2 2 . 1 . 048 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.446 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.1 OUTLIER -137.07 162.29 33.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.216 -0.927 . . . . 0.0 109.856 -179.78 . . . . . . . . 3 3 . 1 . 048 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.547 ' CE1' HD11 ' A' ' 110' ' ' ILE . 48.3 m-85 . . . . . 0 N--CA 1.485 1.277 0 O-C-N 121.244 -0.91 . . . . 0.0 109.495 -179.817 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.486 1.34 0 CA-C-O 122.431 1.11 . . . . 0.0 110.262 . . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.546 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.0 t -115.82 109.16 17.25 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-O 123.058 1.409 . . . . 0.0 109.867 -179.893 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.507 HG12 ' CG1' ' A' ' 95' ' ' VAL . 1.6 t -114.5 136.68 50.32 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.733 0 CA-C-N 114.236 -1.347 . . . . 0.0 109.557 179.781 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.51 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -170.55 149.68 3.09 Favored Pre-proline 0 N--CA 1.488 1.432 0 O-C-N 121.135 -0.978 . . . . 0.0 109.001 -179.591 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.51 ' CA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -77.02 150.78 92.94 Favored 'Cis proline' 0 C--N 1.313 -1.302 0 C-N-CA 123.436 -1.485 . . . . 0.0 109.455 -0.931 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.48 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 79.1 p -91.31 -23.81 20.01 Favored 'General case' 0 C--N 1.292 -1.928 0 O-C-N 121.589 -0.695 . . . . 0.0 109.292 179.971 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.465 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -131.57 162.05 31.22 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.284 -0.885 . . . . 0.0 109.733 -179.839 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.76 38.38 31.72 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 108.434 -1.866 . . . . 0.0 108.434 -179.666 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.605 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 35.0 mt -91.88 -44.07 9.13 Favored 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 123.12 1.438 . . . . 0.0 110.759 -178.226 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.485 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.87 144.22 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.317 0 CA-C-N 113.568 -1.651 . . . . 0.0 109.938 -179.526 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.595 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.6 p-10 -50.55 108.43 0.23 Allowed 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 121.64 0.734 . . . . 0.0 111.759 -178.483 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.72 14.24 10.52 Favored Glycine 0 N--CA 1.484 1.841 0 C-N-CA 119.555 -1.307 . . . . 0.0 112.895 177.255 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.605 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.2 t -105.29 -173.71 2.36 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 121.011 2.406 . . . . 0.0 110.162 179.435 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.541 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 21.8 t -130.62 141.39 46.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.273 0 CA-C-N 114.45 -1.25 . . . . 0.0 111.069 -178.714 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.486 ' CG1' HD23 ' A' ' 13' ' ' LEU . 34.5 m -118.53 155.29 20.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.661 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.488 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.9 tttt -102.07 109.19 20.84 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.127 -0.983 . . . . 0.0 109.176 -179.871 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.514 HG12 ' CG2' ' A' ' 34' ' ' VAL . 10.5 p -99.05 139.6 20.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.785 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.588 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -134.84 161.49 35.05 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 120.729 -1.232 . . . . 0.0 109.94 179.45 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.582 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.98 138.01 9.46 Favored Glycine 0 C--O 1.207 -1.551 0 N-CA-C 107.839 -2.104 . . . . 0.0 107.839 179.669 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -141.04 126.89 19.19 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-N 119.484 1.642 . . . . 0.0 109.547 179.52 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 87.36 28.64 24.35 Favored Glycine 0 N--CA 1.488 2.132 0 C-N-CA 118.832 -1.651 . . . . 0.0 109.745 -179.984 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HB2' ' HB3' ' A' ' 57' ' ' ALA . 1.7 mt -88.27 173.06 8.99 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.913 -1.345 . . . . 0.0 108.235 179.894 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.557 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.56 99.26 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.954 -1.091 . . . . 0.0 109.809 -179.482 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.43 77.31 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.698 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.254 -179.221 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.62 34.18 0.28 Allowed Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.591 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.549 ' OG1' ' CE1' ' A' ' 32' ' ' TYR . 50.7 p -142.35 108.55 5.24 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.092 -1.24 . . . . 0.0 111.367 -179.52 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.557 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.23 109.71 0.33 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 177.826 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.549 ' CE1' ' OG1' ' A' ' 30' ' ' THR . 4.3 m-30 -103.13 155.53 18.34 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.094 -1.004 . . . . 0.0 108.987 179.94 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.99 161.82 13.42 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.855 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.632 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.7 p -142.66 121.61 8.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.117 -0.99 . . . . 0.0 109.538 -178.018 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.64 -176.9 41.63 Favored Glycine 0 N--CA 1.496 2.645 0 C-N-CA 118.516 -1.802 . . . . 0.0 111.548 -179.77 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.566 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -100.17 108.94 21.18 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 -179.937 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -128.66 148.53 50.82 Favored 'General case' 0 C--N 1.295 -1.767 0 O-C-N 121.229 -0.919 . . . . 0.0 109.884 179.738 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.92 139.51 53.76 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.24 -0.912 . . . . 0.0 110.674 -179.071 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.62 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.13 114.93 26.78 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 178.19 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -105.24 15.26 6.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.982 -1.074 . . . . 0.0 110.53 -178.883 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.588 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.7 -176.39 0.09 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.997 -1.064 . . . . 0.0 110.067 179.682 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.547 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.4 97.37 1.26 Allowed 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.817 0.818 . . . . 0.0 109.901 -179.656 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.13 28.23 34.62 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 120.198 -1.001 . . . . 0.0 111.387 178.833 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.588 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.03 106.41 20.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 O-C-N 120.562 -1.552 . . . . 0.0 107.278 178.891 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.62 HD12 ' CD1' ' A' ' 39' ' ' TRP . 12.0 tp -115.98 104.77 11.93 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.465 -1.397 . . . . 0.0 109.942 -177.552 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.532 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.3 109.65 22.37 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.656 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.49 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -109.06 161.9 14.75 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.863 -1.148 . . . . 0.0 110.462 -178.585 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.484 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 29.8 t-20 -108.44 131.04 22.02 Favored Pre-proline 0 N--CA 1.5 2.038 0 O-C-N 121.582 -0.699 . . . . 0.0 109.391 -179.659 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.584 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -72.19 22.15 0.27 Allowed 'Trans proline' 0 CA--C 1.545 1.074 0 C-N-CA 121.958 1.772 . . . . 0.0 111.892 179.523 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.48 ' HB3' ' CG2' ' A' ' 68' ' ' THR . . . -97.08 -7.26 33.2 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.434 -1.417 . . . . 0.0 108.994 179.555 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.555 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 1.8 m-20 -132.63 5.22 3.97 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.999 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -59.84 78.61 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.355 -0.841 . . . . 0.0 110.938 -178.385 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.632 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -101.07 -167.91 1.49 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.238 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.469 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.57 134.84 0.08 Allowed 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.55 -1.344 . . . . 0.0 111.363 -179.391 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.565 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.5 p -149.03 156.99 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.067 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.557 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.4 141.22 31.54 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.706 -1.246 . . . . 0.0 110.012 -179.776 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.678 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.26 107.54 1.34 Allowed 'General case' 0 C--N 1.298 -1.669 0 CA-C-O 122.484 1.135 . . . . 0.0 109.571 178.76 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -61.04 -139.42 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.709 179.95 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.35 -50.68 61.87 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.393 -0.817 . . . . 0.0 110.481 -178.798 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -101.95 -35.15 9.09 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 178.404 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.678 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.42 68.19 0.66 Allowed Glycine 0 C--N 1.298 -1.535 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 178.07 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.582 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 56.4 m -99.54 131.54 45.47 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.421 -1.046 . . . . 0.0 108.836 178.917 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.588 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -135.2 108.87 7.98 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.452 -179.517 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 m -123.97 117.92 25.86 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.297 -0.877 . . . . 0.0 109.651 -179.798 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.434 ' O ' HG13 ' A' ' 21' ' ' VAL . 0.2 OUTLIER -146.61 145.34 30.04 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.433 -0.792 . . . . 0.0 109.411 179.879 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.0 p -98.56 136.6 38.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.273 -0.892 . . . . 0.0 109.22 179.894 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.543 ' HB2' ' OD2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -140.69 165.9 26.23 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.396 -0.815 . . . . 0.0 109.909 -178.9 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.541 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 10.9 t -99.56 129.61 45.73 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.955 -1.09 . . . . 0.0 111.437 -178.753 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.555 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 17.3 m -136.61 143.86 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.459 -0.776 . . . . 0.0 109.956 179.68 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.595 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -148.45 -175.46 4.93 Favored 'General case' 0 N--CA 1.484 1.239 0 O-C-N 120.445 -1.409 . . . . 0.0 110.6 179.25 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.547 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.13 -102.44 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -179.539 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.447 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.4 OUTLIER -56.41 139.93 47.26 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.789 -1.194 . . . . 0.0 108.206 179.494 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.581 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -159.68 138.3 10.64 Favored 'General case' 0 C--N 1.296 -1.745 0 C-N-CA 118.717 -1.193 . . . . 0.0 109.91 -178.403 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' A' ' 47' ' ' CYS . 4.4 mm-40 -35.22 120.81 0.55 Allowed 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.473 0.654 . . . . 0.0 110.662 -178.496 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.532 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.6 48.27 2.57 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 -179.428 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.584 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-30 -39.12 114.98 0.44 Allowed 'General case' 0 N--CA 1.509 2.489 0 O-C-N 121.152 -1.205 . . . . 0.0 110.064 179.598 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.529 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.4 tp -87.3 126.48 34.87 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.796 -1.19 . . . . 0.0 109.597 -179.78 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 24.1 t80 -64.42 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.023 0 O-C-N 120.871 -1.143 . . . . 0.0 110.188 179.704 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 14.0 t0 -160.35 19.6 0.15 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.049 -1.032 . . . . 0.0 109.739 179.865 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.83 -27.43 5.41 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 179.935 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.491 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 68.1 p -95.13 157.05 16.06 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 120.978 -1.307 . . . . 0.0 110.313 -179.446 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.526 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -103.94 139.94 38.4 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.673 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.465 ' HB2' HD11 ' A' ' 77' ' ' LEU . 2.1 t90 -85.89 -19.71 30.15 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.588 -1.32 . . . . 0.0 110.766 -178.129 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.23 174.59 18.62 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -179.419 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.99 104.17 1.08 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 179.159 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.581 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 48.9 t -74.49 106.64 4.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.388 -0.82 . . . . 0.0 109.55 -178.769 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.46 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.74 110.67 2.46 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.443 -0.786 . . . . 0.0 109.654 -179.735 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.547 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.4 t -64.32 -4.98 4.29 Favored 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 118.334 -1.346 . . . . 0.0 109.891 179.58 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.0 p -87.03 0.56 55.01 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.701 -1.25 . . . . 0.0 109.111 179.511 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.46 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -114.16 -50.07 2.83 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.275 -0.891 . . . . 0.0 109.047 179.905 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.22 -178.09 3.56 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.54 -0.725 . . . . 0.0 109.495 179.769 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.09 114.94 29.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.395 -0.816 . . . . 0.0 108.998 179.937 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.567 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -97.05 122.98 40.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.911 -1.118 . . . . 0.0 109.722 -179.233 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.586 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.23 146.83 28.22 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-O 122.345 1.069 . . . . 0.0 111.224 -179.414 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.507 ' CG1' HG12 ' A' ' 7' ' ' VAL . 58.9 t -101.5 110.18 27.69 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.987 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 177.695 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.442 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.06 -171.28 16.85 Favored Glycine 0 N--CA 1.485 1.964 0 C-N-CA 118.236 -1.935 . . . . 0.0 111.78 -177.592 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.63 177.66 5.15 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 121.625 0.726 . . . . 0.0 109.047 -179.161 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.465 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.4 OUTLIER . . . . . 0 C--N 1.296 -1.741 0 O-C-N 121.641 -0.662 . . . . 0.0 109.455 179.937 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.668 0 N-CA-C 107.817 -2.113 . . . . 0.0 107.817 . . . . . . . . . 0 0 . 1 . 049 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -166.06 -177.09 4.02 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.596 -0.944 . . . . 0.0 109.795 179.336 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.18 -161.88 17.52 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 108.247 -1.941 . . . . 0.0 108.247 -179.379 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.4 Cg_exo -46.56 176.34 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.686 0 CA-C-N 118.778 1.289 . . . . 0.0 110.203 179.325 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -95.19 -177.3 4.08 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.121 -0.987 . . . . 0.0 110.417 -178.896 . . . . . . . . 1 1 . 1 . 049 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.442 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -115.37 161.63 12.75 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.871 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.8 130.55 47.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.383 -1.069 . . . . 0.0 109.041 -179.461 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.586 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.65 124.33 25.06 Favored 'General case' 0 C--N 1.291 -1.975 0 O-C-N 121.724 -0.61 . . . . 0.0 110.059 -179.937 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.573 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.65 171.21 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.298 -0.876 . . . . 0.0 108.954 179.639 . . . . . . . . 2 2 . 1 . 049 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.465 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -137.05 158.06 45.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.209 -0.932 . . . . 0.0 109.632 179.97 . . . . . . . . 3 3 . 1 . 049 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.573 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 77.7 m-85 . . . . . 0 N--CA 1.486 1.35 0 O-C-N 121.26 -0.9 . . . . 0.0 109.517 -179.551 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.501 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.168 0 CA-C-O 122.444 1.116 . . . . 0.0 110.702 . . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.532 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.8 p -104.05 104.71 14.7 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 122.39 1.09 . . . . 0.0 110.271 -179.566 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.528 HG12 ' CG1' ' A' ' 95' ' ' VAL . 11.2 t -119.68 119.19 59.65 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.514 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.244 179.625 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.508 HG22 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.51 150.51 10.49 Favored Pre-proline 0 N--CA 1.488 1.44 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 -179.561 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.508 ' CA ' HG22 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.49 153.24 99.06 Favored 'Cis proline' 0 C--N 1.309 -1.537 0 C-N-CA 123.663 -1.39 . . . . 0.0 110.014 -0.578 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.469 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 7.2 m -94.44 -23.57 17.68 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.495 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.455 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 1.3 m -136.18 163.12 31.1 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.516 -0.74 . . . . 0.0 109.33 179.825 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.41 37.66 35.49 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 -179.523 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.598 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.1 mt -90.47 -44.12 9.82 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 123.18 1.467 . . . . 0.0 110.486 -178.289 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.484 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.97 144.71 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.265 0 CA-C-N 113.613 -1.63 . . . . 0.0 109.903 -179.665 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.556 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 8.1 p-10 -51.11 106.18 0.12 Allowed 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 121.471 0.653 . . . . 0.0 111.509 -178.592 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.46 12.31 9.78 Favored Glycine 0 N--CA 1.488 2.126 0 C-N-CA 119.324 -1.417 . . . . 0.0 113.121 177.261 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.598 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 11.6 t -101.51 -169.55 1.71 Allowed 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 121.135 2.467 . . . . 0.0 109.665 179.362 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.565 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 11.4 t -136.14 142.94 37.32 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 CA-C-N 115.204 -0.907 . . . . 0.0 110.953 -179.015 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.461 HG23 HG23 ' A' ' 69' ' ' VAL . 13.3 m -120.47 154.72 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.221 -0.924 . . . . 0.0 109.255 179.438 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.519 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.3 tttt -106.28 109.08 20.9 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.233 -0.917 . . . . 0.0 109.28 179.955 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.513 HG13 ' CG2' ' A' ' 34' ' ' VAL . 1.6 p -105.61 122.26 58.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 179.885 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.535 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -114.43 165.81 12.35 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 120.886 -1.134 . . . . 0.0 109.129 179.885 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.58 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.1 107.7 0.48 Allowed Glycine 0 N--CA 1.482 1.751 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 179.792 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.452 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.6 141.24 48.45 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.598 -1.53 . . . . 0.0 110.16 -179.439 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.31 27.88 32.0 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 118.833 -1.651 . . . . 0.0 109.718 179.726 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.6 OUTLIER -95.67 170.88 9.02 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.018 -1.284 . . . . 0.0 108.45 179.831 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.556 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.07 101.18 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.407 0 O-C-N 120.947 -1.095 . . . . 0.0 109.948 -179.607 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.85 77.98 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.685 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.993 -179.411 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.42 34.15 0.29 Allowed Glycine 0 N--CA 1.486 2.021 0 N-CA-C 109.316 -1.513 . . . . 0.0 109.316 179.818 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.561 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 22.6 p -139.78 106.9 5.46 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.186 -1.185 . . . . 0.0 111.154 -179.514 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.557 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -49.67 110.0 0.34 Allowed 'General case' 0 N--CA 1.496 1.839 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.8 178.131 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.561 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 28.8 m-85 -103.89 154.51 19.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.111 -0.993 . . . . 0.0 108.95 179.8 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.455 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -102.18 158.09 16.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.767 -1.208 . . . . 0.0 107.821 178.784 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.628 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 6.0 p -139.23 115.11 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.165 -0.959 . . . . 0.0 109.722 -178.12 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.476 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.73 -178.36 36.5 Favored Glycine 0 N--CA 1.494 2.561 0 C-N-CA 118.326 -1.892 . . . . 0.0 111.729 -179.468 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.635 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.1 pt20 -103.32 109.75 21.49 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 121.8 0.81 . . . . 0.0 108.9 -179.764 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.453 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -131.3 149.2 52.66 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.005 -1.06 . . . . 0.0 110.261 -179.805 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.37 138.8 54.52 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.319 -0.863 . . . . 0.0 110.777 -179.167 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.63 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.25 114.55 26.35 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 178.108 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.437 HG21 ' HB ' ' A' ' 44' ' ' VAL . 15.6 m -104.83 14.69 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.026 -1.046 . . . . 0.0 110.663 -178.757 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.587 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 175.25 -175.17 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.923 -1.111 . . . . 0.0 110.125 179.758 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -72.0 97.64 1.92 Allowed 'General case' 0 N--CA 1.485 1.317 0 O-C-N 121.413 -0.804 . . . . 0.0 109.677 -179.757 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.3 26.76 35.31 Favored Glycine 0 N--CA 1.494 2.531 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.475 178.934 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.587 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.92 106.66 20.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 O-C-N 120.549 -1.56 . . . . 0.0 107.396 178.875 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.63 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.7 tp -117.05 104.62 11.43 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.488 -1.382 . . . . 0.0 109.629 -177.747 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.532 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.61 109.42 22.18 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 120.808 -1.182 . . . . 0.0 107.914 178.678 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -105.95 167.83 9.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.928 -1.107 . . . . 0.0 110.483 -178.68 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.473 ' HB2' ' HB2' ' A' ' 73' ' ' PHE . 11.6 t-20 -111.94 129.33 24.33 Favored Pre-proline 0 N--CA 1.499 1.986 0 O-C-N 121.532 -0.73 . . . . 0.0 109.649 -179.118 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.571 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 2.2 Cg_endo -72.72 23.06 0.29 Allowed 'Trans proline' 0 CA--C 1.545 1.059 0 C-N-CA 122.056 1.837 . . . . 0.0 111.815 179.61 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.472 ' O ' HG22 ' A' ' 68' ' ' THR . . . -110.57 -0.7 17.2 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.462 -1.399 . . . . 0.0 109.145 179.545 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.543 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.37 16.81 3.17 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 179.489 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -79.75 89.94 5.22 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.709 -178.678 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.26 -166.26 1.14 Allowed 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.948 -1.131 . . . . 0.0 107.948 178.34 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.467 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.76 136.43 0.09 Allowed 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.594 -1.316 . . . . 0.0 111.314 -179.256 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.606 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -154.74 156.63 4.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.084 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.557 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.49 142.1 30.52 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.669 -1.269 . . . . 0.0 109.977 -179.621 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.683 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -62.08 106.12 0.68 Allowed 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 122.467 1.127 . . . . 0.0 109.341 178.208 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.521 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.8 p-10 -59.29 -138.79 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.029 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.052 -179.881 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.85 -50.33 61.13 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.412 -0.805 . . . . 0.0 110.744 -178.633 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -104.08 -34.57 8.37 Favored 'General case' 0 C--N 1.286 -2.178 0 N-CA-C 106.004 -1.85 . . . . 0.0 106.004 178.505 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.683 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 109.41 64.34 0.54 Allowed Glycine 0 C--N 1.296 -1.646 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 177.928 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 18.5 m -103.85 124.05 48.23 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.501 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.606 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.01 109.48 9.01 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.821 -0.752 . . . . 0.0 109.673 -179.081 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.458 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.7 m -116.5 116.69 28.11 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.329 -0.857 . . . . 0.0 109.373 -179.959 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.495 ' CG2' HG13 ' A' ' 34' ' ' VAL . 1.3 t -140.85 140.19 34.57 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.374 -0.829 . . . . 0.0 109.822 179.908 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.1 p -98.88 137.61 37.19 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.49 -0.756 . . . . 0.0 109.242 179.849 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.543 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -140.43 159.01 43.15 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.382 -0.824 . . . . 0.0 109.452 -179.129 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.565 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 12.7 t -87.55 135.77 33.22 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.162 -0.961 . . . . 0.0 110.21 -179.837 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.461 HG23 HG23 ' A' ' 19' ' ' VAL . 18.0 m -145.51 140.36 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.74 -179.39 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.556 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.5 ptt180 -140.25 -163.83 1.59 Allowed 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.595 -1.315 . . . . 0.0 109.877 179.814 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.603 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -78.79 -81.81 0.1 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.055 -1.028 . . . . 0.0 109.6 -179.15 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -67.12 134.66 52.24 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.334 -1.479 . . . . 0.0 107.488 179.273 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.635 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.8 OUTLIER -157.7 156.58 31.94 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 117.965 -1.494 . . . . 0.0 110.568 -178.257 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.475 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.2 mm-40 -48.71 121.66 4.83 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.497 -0.752 . . . . 0.0 109.676 -178.574 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.532 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -89.08 48.78 3.48 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 -179.39 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.571 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.2 OUTLIER -40.39 114.6 0.47 Allowed 'General case' 0 N--CA 1.514 2.774 0 O-C-N 121.029 -1.277 . . . . 0.0 109.972 179.908 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.531 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -87.25 126.95 35.14 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.959 -1.088 . . . . 0.0 109.289 179.729 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -64.09 58.11 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.8 -1.187 . . . . 0.0 110.307 179.897 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.531 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -160.86 19.34 0.13 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.961 -1.087 . . . . 0.0 109.785 179.91 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.3 -26.74 5.45 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.913 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.7 p -91.88 159.32 15.83 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.12 -1.223 . . . . 0.0 110.389 -179.403 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.503 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.56 133.46 51.21 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.716 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.478 ' CD1' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -82.6 -18.13 42.35 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.88 -1.137 . . . . 0.0 110.411 -178.469 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.32 174.79 20.6 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 -179.525 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.0 112.06 2.18 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 179.14 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.574 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 38.7 t -83.44 102.39 9.35 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -178.916 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.475 ' HB3' HG22 ' A' ' 90' ' ' THR . 0.2 OUTLIER -64.49 108.53 1.68 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.659 -0.651 . . . . 0.0 109.971 -179.153 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.569 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 3.7 t -62.48 -4.25 1.82 Allowed 'General case' 0 N--CA 1.499 1.979 0 C-N-CA 118.361 -1.336 . . . . 0.0 110.34 179.341 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.6 p -88.24 10.39 19.76 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.621 -1.299 . . . . 0.0 109.097 179.622 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.475 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -124.25 -47.66 1.87 Allowed 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.399 -0.813 . . . . 0.0 109.08 -179.994 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.85 179.58 4.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.604 -0.685 . . . . 0.0 109.536 179.905 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.88 112.41 25.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.36 -0.838 . . . . 0.0 108.799 179.783 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.475 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.1 m -96.64 121.85 38.93 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.083 -1.01 . . . . 0.0 109.667 -178.786 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.544 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.34 149.2 24.98 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 122.482 1.134 . . . . 0.0 111.368 -179.199 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.528 ' CG1' HG12 ' A' ' 7' ' ' VAL . 47.4 t -105.42 109.94 29.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 177.465 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.403 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.89 -171.3 17.51 Favored Glycine 0 N--CA 1.485 1.95 0 C-N-CA 118.154 -1.974 . . . . 0.0 111.663 -177.641 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.463 HD13 ' HB3' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -115.16 -179.02 3.51 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -178.899 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.5 p . . . . . 0 C--N 1.296 -1.729 0 O-C-N 121.332 -0.855 . . . . 0.0 109.545 -179.06 . . . . . . . . 0 0 . 1 . 050 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.627 0 N-CA-C 107.753 -2.139 . . . . 0.0 107.753 . . . . . . . . . 0 0 . 1 . 050 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.35 -178.09 6.69 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 122.159 0.98 . . . . 0.0 109.898 179.326 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.42 -163.04 21.72 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 108.191 -1.963 . . . . 0.0 108.191 -179.46 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.47 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.4 Cg_exo -45.93 172.76 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.647 0 CA-C-N 119.013 1.406 . . . . 0.0 109.937 179.325 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -90.19 -177.42 5.14 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.997 -1.064 . . . . 0.0 110.695 -178.566 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.403 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.03 167.9 13.66 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.816 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.47 132.56 54.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.393 -1.063 . . . . 0.0 109.23 -179.285 . . . . . . . . 1 1 . 1 . 050 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.544 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.57 124.42 25.86 Favored 'General case' 0 C--N 1.29 -1.984 0 O-C-N 121.637 -0.664 . . . . 0.0 109.732 179.757 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.571 HD13 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.97 171.81 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.228 -0.92 . . . . 0.0 109.227 179.794 . . . . . . . . 2 2 . 1 . 050 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.455 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.23 155.96 48.15 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.209 -0.932 . . . . 0.0 109.769 -179.896 . . . . . . . . 3 3 . 1 . 050 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.571 ' CE2' HD13 ' A' ' 110' ' ' ILE . 71.6 m-85 . . . . . 0 N--CA 1.487 1.378 0 O-C-N 121.178 -0.952 . . . . 0.0 109.533 -179.733 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.468 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.431 0 CA-C-O 122.054 0.931 . . . . 0.0 110.63 . . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.539 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.9 p -104.54 104.4 14.23 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 122.453 1.12 . . . . 0.0 110.156 179.96 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.534 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 12.0 t -120.15 119.76 60.98 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.366 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.309 179.738 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.515 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.64 149.88 6.34 Favored Pre-proline 0 N--CA 1.486 1.326 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -179.674 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.515 ' CA ' HG21 ' A' ' 8' ' ' THR . 5.1 Cg_endo -76.68 151.62 94.61 Favored 'Cis proline' 0 C--N 1.309 -1.523 0 C-N-CA 123.637 -1.401 . . . . 0.0 109.501 -0.433 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.491 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 77.4 p -93.19 -23.53 18.53 Favored 'General case' 0 C--N 1.293 -1.865 0 O-C-N 121.595 -0.691 . . . . 0.0 109.305 179.765 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.46 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 1.2 m -133.89 158.2 44.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.316 -0.865 . . . . 0.0 109.957 -179.693 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 80.36 36.46 23.71 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 -179.777 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.601 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 39.2 mt -92.54 -44.36 8.66 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 123.24 1.495 . . . . 0.0 110.284 -178.634 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.46 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 64.1 147.03 0.03 OUTLIER 'General case' 0 C--N 1.263 -3.189 0 CA-C-N 113.549 -1.66 . . . . 0.0 110.138 -179.758 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.55 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.0 p-10 -51.65 104.81 0.09 Allowed 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.644 0.735 . . . . 0.0 111.048 -178.939 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.52 6.39 6.72 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.148 -1.501 . . . . 0.0 113.33 177.312 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.601 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.9 t -106.31 -175.97 2.94 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 121.491 2.646 . . . . 0.0 110.166 179.693 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 21.8 t -128.05 138.2 55.36 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.383 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.068 -178.697 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.565 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 34.6 m -114.39 154.66 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.827 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.1 108.9 20.59 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.14 -0.975 . . . . 0.0 109.314 -179.885 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.1 p -107.59 123.34 62.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.751 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.539 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -116.72 165.33 13.41 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 120.873 -1.142 . . . . 0.0 109.14 179.922 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.57 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.46 107.55 0.53 Allowed Glycine 0 C--O 1.207 -1.577 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 179.875 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.422 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.23 143.83 45.0 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.787 -1.419 . . . . 0.0 110.676 -178.964 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.445 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 80.48 27.45 51.51 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 119.576 -1.297 . . . . 0.0 109.993 179.193 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.549 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -91.95 172.25 8.58 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.086 -1.244 . . . . 0.0 108.556 -179.984 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.568 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.58 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.116 -0.99 . . . . 0.0 109.652 -179.987 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.63 76.74 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.206 -179.059 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 135.96 32.96 0.26 Allowed Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.512 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.628 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -141.98 111.45 6.54 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 120.935 -1.332 . . . . 0.0 111.027 -179.96 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.554 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.64 120.4 4.67 Favored 'General case' 0 N--CA 1.493 1.715 0 CA-C-N 115.488 -0.778 . . . . 0.0 109.674 178.7 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.628 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 9.7 m-85 -114.27 152.82 30.74 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.238 -0.914 . . . . 0.0 108.923 179.807 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.466 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.68 154.18 18.81 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.622 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.622 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 9.7 p -137.42 115.41 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.023 -1.048 . . . . 0.0 109.882 -177.753 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.87 -176.85 36.16 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 118.372 -1.87 . . . . 0.0 111.792 -179.717 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.591 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -101.21 109.86 21.79 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -179.803 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -129.61 149.38 51.39 Favored 'General case' 0 C--N 1.296 -1.74 0 O-C-N 121.221 -0.924 . . . . 0.0 109.748 179.81 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.66 137.73 54.81 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.254 -0.904 . . . . 0.0 110.907 -178.847 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.622 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.49 114.86 26.67 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.048 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 m -105.05 14.67 7.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.931 -1.105 . . . . 0.0 110.501 -178.947 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.589 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 173.9 -175.54 0.07 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 120.949 -1.094 . . . . 0.0 110.128 179.73 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.541 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.92 98.17 1.55 Allowed 'General case' 0 N--CA 1.487 1.416 0 CA-C-O 121.828 0.823 . . . . 0.0 109.969 -179.669 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.28 27.98 34.92 Favored Glycine 0 N--CA 1.493 2.441 0 C-N-CA 120.325 -0.94 . . . . 0.0 111.444 178.949 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.589 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -116.54 106.29 19.99 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 O-C-N 120.569 -1.548 . . . . 0.0 107.198 178.782 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.622 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.4 tp -117.02 104.64 11.47 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.487 -1.383 . . . . 0.0 109.942 -177.527 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.534 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.9 109.56 22.29 Favored 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.847 -1.158 . . . . 0.0 107.919 178.7 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.58 167.05 10.11 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.907 -1.12 . . . . 0.0 110.41 -178.699 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.549 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 20.7 t-20 -114.67 137.71 22.87 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 121.299 -0.876 . . . . 0.0 110.359 -179.149 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.45 ' HD2' ' ND2' ' A' ' 48' ' ' ASN . 6.1 Cg_endo -75.55 25.8 0.39 Allowed 'Trans proline' 0 C--N 1.318 -1.039 0 C-N-CA 122.346 2.031 . . . . 0.0 111.966 179.859 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.549 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -113.82 2.13 15.03 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.266 -1.521 . . . . 0.0 109.482 179.833 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.503 ' O ' ' CD2' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.22 16.72 2.42 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 179.423 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -79.38 91.74 5.12 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.598 -0.689 . . . . 0.0 111.016 -178.678 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -109.08 -166.9 1.15 Allowed 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.171 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.47 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.97 136.62 0.09 Allowed 'General case' 0 N--CA 1.485 1.301 0 O-C-N 120.519 -1.363 . . . . 0.0 111.327 -179.298 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.597 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -156.75 157.0 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 178.213 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.554 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.6 144.23 28.13 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.884 -1.135 . . . . 0.0 109.835 -179.759 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.673 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.84 105.82 0.9 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 122.436 1.112 . . . . 0.0 109.38 178.546 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.52 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.8 p-10 -58.69 -138.87 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.029 -179.869 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.32 -50.26 62.62 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.453 -0.779 . . . . 0.0 110.576 -178.718 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.445 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.7 t-20 -103.75 -35.19 8.3 Favored 'General case' 0 C--N 1.286 -2.195 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 178.442 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.673 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 109.28 67.36 0.59 Allowed Glycine 0 C--N 1.297 -1.627 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 177.936 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.57 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.0 m -106.76 123.12 47.68 Favored 'General case' 0 N--CA 1.482 1.137 0 O-C-N 121.559 -0.965 . . . . 0.0 108.623 178.829 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.597 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -132.6 109.15 9.54 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 -179.443 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.1 m -118.95 120.39 37.13 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.211 -0.93 . . . . 0.0 109.606 -179.474 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.479 HG21 HG13 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.71 141.62 29.42 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.567 -0.708 . . . . 0.0 109.691 179.779 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 17.7 p -99.93 135.89 40.66 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.395 -0.815 . . . . 0.0 109.112 179.702 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.527 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -135.59 167.84 20.35 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.941 . . . . 0.0 109.618 -179.29 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.5 p -99.4 126.89 45.38 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.077 -1.014 . . . . 0.0 109.276 -179.802 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.456 HG12 ' OD2' ' A' ' 51' ' ' ASP . 12.6 m -132.39 140.8 46.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 120.868 -1.145 . . . . 0.0 109.93 -179.134 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.55 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 56.7 mtt180 -127.61 -166.96 1.68 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.68 -1.263 . . . . 0.0 111.328 -179.674 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.577 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 46.4 mtt180 -80.59 -79.02 0.16 Allowed 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 178.946 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.442 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -69.11 136.66 52.58 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 106.386 -1.709 . . . . 0.0 106.386 177.766 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.35 136.51 8.6 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 117.666 -1.614 . . . . 0.0 110.891 -177.191 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.47 ' C ' ' O ' ' A' ' 73' ' ' PHE . 2.0 mm-40 -33.43 118.78 0.34 Allowed 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.47 0.652 . . . . 0.0 110.427 -178.742 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.534 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -88.26 48.07 3.57 Favored Glycine 0 N--CA 1.493 2.463 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.148 -179.312 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.482 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -36.99 115.93 0.41 Allowed 'General case' 0 N--CA 1.513 2.685 0 O-C-N 121.109 -1.23 . . . . 0.0 110.11 179.828 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.543 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.3 tp -87.59 126.41 34.92 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.987 -1.071 . . . . 0.0 109.121 179.742 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.8 t80 -63.64 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.836 -1.165 . . . . 0.0 110.228 179.824 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.543 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t70 -160.89 19.72 0.13 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.989 -1.069 . . . . 0.0 109.846 179.924 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.2 -28.01 5.34 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.812 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.67 163.38 13.4 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.061 -1.258 . . . . 0.0 110.184 -179.438 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.55 137.71 46.05 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.987 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.463 ' HB2' HD13 ' A' ' 77' ' ' LEU . 5.6 t90 -81.62 -20.93 38.71 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.896 -1.127 . . . . 0.0 110.157 -178.956 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.36 173.55 17.07 Favored Glycine 0 N--CA 1.486 1.968 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -179.44 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.25 111.81 2.41 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 179.069 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.564 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 46.0 t -83.67 104.25 11.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 121.378 -0.826 . . . . 0.0 108.981 -179.001 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.466 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.3 OUTLIER -66.15 111.3 3.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.355 -0.84 . . . . 0.0 109.845 -179.295 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.547 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -64.25 -4.8 4.04 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 120.587 -1.321 . . . . 0.0 109.896 179.4 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 31.6 p -87.81 2.18 52.01 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.694 -1.253 . . . . 0.0 109.097 179.325 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.466 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -116.52 -51.16 2.61 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.362 -0.836 . . . . 0.0 108.935 -179.998 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.22 -179.9 4.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.53 -0.731 . . . . 0.0 109.493 179.745 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.75 116.07 31.64 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.365 -0.834 . . . . 0.0 108.925 179.91 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.533 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 2.7 m -96.97 123.3 40.65 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.828 -1.17 . . . . 0.0 109.477 -179.298 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.531 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -103.15 149.17 24.9 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.344 1.069 . . . . 0.0 111.356 -179.142 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.527 ' CG1' HG13 ' A' ' 7' ' ' VAL . 43.2 t -104.88 112.1 37.12 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.552 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -151.77 -172.02 20.14 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 118.218 -1.944 . . . . 0.0 111.747 -177.785 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.01 178.67 4.64 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 -178.845 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.453 ' OG ' ' O ' ' A' ' 97' ' ' LEU . 3.2 m . . . . . 0 C--N 1.295 -1.786 0 O-C-N 121.581 -0.699 . . . . 0.0 109.432 -179.806 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.7 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 . . . . . . . . . 0 0 . 1 . 051 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.82 -177.48 5.15 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.544 -0.974 . . . . 0.0 109.9 179.438 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.88 -161.83 23.1 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.462 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 104' ' ' GLY . 8.0 Cg_exo -45.51 173.73 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.643 0 CA-C-N 119.003 1.401 . . . . 0.0 110.232 179.251 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 25.9 pt-20 -92.7 -173.83 3.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.072 -1.017 . . . . 0.0 110.302 -178.824 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -124.67 174.86 17.15 Favored Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 -179.89 . . . . . . . . 1 1 . 1 . 051 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.518 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -111.02 153.71 12.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -179.552 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.531 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -95.02 123.07 38.3 Favored 'General case' 0 C--N 1.292 -1.93 0 O-C-N 121.303 -0.873 . . . . 0.0 109.605 179.922 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.533 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 1.4 pt -98.08 168.32 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.209 -0.932 . . . . 0.0 109.073 179.942 . . . . . . . . 2 2 . 1 . 051 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.46 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.2 OUTLIER -135.1 156.65 48.65 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.29 -0.881 . . . . 0.0 109.456 -179.98 . . . . . . . . 3 3 . 1 . 051 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.577 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 44.6 m-85 . . . . . 0 N--CA 1.489 1.486 0 O-C-N 121.2 -0.937 . . . . 0.0 109.543 -179.767 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.483 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.283 0 CA-C-O 122.288 1.042 . . . . 0.0 110.333 . . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.547 ' CG2' ' O ' ' A' ' 6' ' ' THR . 5.8 t -115.63 109.26 17.5 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-O 123.158 1.456 . . . . 0.0 109.838 -179.866 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.502 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -115.5 136.12 53.32 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.632 0 CA-C-N 114.271 -1.331 . . . . 0.0 109.604 179.763 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.485 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -173.72 150.64 1.75 Allowed Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.181 -0.95 . . . . 0.0 109.04 -179.621 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.485 ' HA ' HG22 ' A' ' 8' ' ' THR . 5.0 Cg_endo -77.2 151.18 92.99 Favored 'Cis proline' 0 C--N 1.313 -1.335 0 C-N-CA 123.484 -1.465 . . . . 0.0 109.26 -0.902 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.453 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 72.4 p -94.43 -22.55 18.22 Favored 'General case' 0 C--N 1.293 -1.89 0 O-C-N 121.511 -0.743 . . . . 0.0 109.623 179.878 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.455 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -130.88 155.18 47.18 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.214 -0.929 . . . . 0.0 110.233 -179.602 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.33 35.59 22.96 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.002 -1.639 . . . . 0.0 109.002 179.996 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.593 ' CD1' ' CG1' ' A' ' 19' ' ' VAL . 40.4 mt -92.8 -44.19 8.63 Favored 'General case' 0 C--N 1.301 -1.529 0 CA-C-O 123.214 1.483 . . . . 0.0 110.635 -178.713 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.452 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 63.17 145.19 0.02 OUTLIER 'General case' 0 C--N 1.261 -3.247 0 CA-C-N 113.558 -1.655 . . . . 0.0 109.201 -178.939 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.533 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.6 m-20 -53.82 114.68 1.65 Allowed 'General case' 0 C--N 1.299 -1.627 0 CA-C-O 121.764 0.792 . . . . 0.0 110.436 -178.946 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 121.67 0.71 10.99 Favored Glycine 0 N--CA 1.484 1.865 0 C-N-CA 119.495 -1.336 . . . . 0.0 112.404 178.334 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.577 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.8 t -106.7 -177.34 3.33 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 121.069 2.434 . . . . 0.0 110.474 -179.944 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.541 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 25.9 t -127.48 139.09 52.88 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 CA-C-N 114.113 -1.403 . . . . 0.0 110.878 -178.865 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.593 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 4.2 m -113.01 158.37 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 178.907 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -106.45 108.77 20.44 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.088 -1.007 . . . . 0.0 109.115 179.947 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.53 HG11 ' CG2' ' A' ' 34' ' ' VAL . 13.0 p -101.23 140.02 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.651 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.584 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -137.37 161.86 35.16 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.675 -1.266 . . . . 0.0 110.154 179.642 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.587 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.6 139.32 10.53 Favored Glycine 0 C--N 1.298 -1.546 0 N-CA-C 107.882 -2.087 . . . . 0.0 107.882 179.529 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.4 125.31 16.13 Favored 'General case' 0 N--CA 1.496 1.828 0 CA-C-N 119.411 1.606 . . . . 0.0 109.434 179.446 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.67 27.77 21.01 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 118.8 -1.667 . . . . 0.0 109.634 -179.756 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -89.01 169.63 11.36 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.033 -1.275 . . . . 0.0 108.188 179.942 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.552 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -43.59 98.67 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.015 -1.053 . . . . 0.0 110.042 -179.354 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.552 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.29 77.83 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.255 -179.285 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.571 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.23 33.44 0.27 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.393 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.529 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 59.0 p -141.73 108.67 5.43 Favored 'General case' 0 C--N 1.307 -1.264 0 O-C-N 121.102 -1.234 . . . . 0.0 111.316 -179.474 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.564 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -51.79 111.49 0.61 Allowed 'General case' 0 N--CA 1.497 1.896 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.717 178.067 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.5 ' CA ' ' O ' ' A' ' 98' ' ' SER . 5.3 m-30 -105.65 160.04 15.5 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.068 -1.02 . . . . 0.0 108.817 179.662 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.482 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -100.23 167.34 10.49 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.738 -1.226 . . . . 0.0 108.003 179.061 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.612 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.9 p -149.48 120.81 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.112 -0.992 . . . . 0.0 109.531 -178.136 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -174.9 -176.63 43.36 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 118.297 -1.906 . . . . 0.0 111.702 -179.941 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.567 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -98.83 108.87 21.66 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -179.997 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.1 m -130.45 148.93 52.32 Favored 'General case' 0 C--N 1.295 -1.796 0 O-C-N 121.315 -0.866 . . . . 0.0 109.461 179.389 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.38 138.72 54.34 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.154 -0.966 . . . . 0.0 110.849 -178.872 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.622 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.14 114.64 26.46 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 178.103 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.6 m -105.16 15.14 6.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.08 -1.012 . . . . 0.0 110.466 -178.609 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.587 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.42 -175.48 0.1 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.864 -1.148 . . . . 0.0 109.998 179.705 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.65 96.83 1.63 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.473 -0.767 . . . . 0.0 109.735 -179.739 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 28.03 32.32 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.493 178.933 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.587 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.18 106.57 20.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 O-C-N 120.577 -1.543 . . . . 0.0 107.302 178.845 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.622 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.2 tp -116.23 104.45 11.52 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.449 -1.407 . . . . 0.0 110.022 -177.5 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.547 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.25 109.45 22.21 Favored 'General case' 0 N--CA 1.484 1.248 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 178.525 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 5.1 t -108.5 165.49 11.48 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.826 -1.171 . . . . 0.0 110.648 -178.468 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.486 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 52.4 t30 -115.84 134.45 22.71 Favored Pre-proline 0 N--CA 1.499 2.019 0 O-C-N 121.545 -0.722 . . . . 0.0 109.394 -179.624 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.524 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 2.5 Cg_endo -72.08 22.96 0.26 Allowed 'Trans proline' 0 C--N 1.317 -1.124 0 C-N-CA 122.289 1.993 . . . . 0.0 112.106 -179.802 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.486 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -95.28 -9.76 32.2 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.355 -1.466 . . . . 0.0 109.045 179.408 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.548 ' HB3' ' CB ' ' A' ' 67' ' ' LEU . 3.4 m-20 -134.06 6.77 3.66 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.903 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -59.72 84.04 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.495 -0.753 . . . . 0.0 110.589 -178.775 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.612 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -111.47 -168.89 1.36 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.516 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.473 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.3 t 179.01 135.17 0.09 Allowed 'General case' 0 C--N 1.305 -1.358 0 O-C-N 120.656 -1.278 . . . . 0.0 110.967 -179.476 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.53 HG12 ' CB ' ' A' ' 63' ' ' ALA . 1.6 p -147.29 157.4 9.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.288 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.564 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.53 142.01 30.66 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 120.696 -1.252 . . . . 0.0 110.024 -179.699 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.678 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.17 107.54 1.32 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 122.5 1.143 . . . . 0.0 109.533 178.462 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.535 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.2 p-10 -61.19 -139.39 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.976 -179.99 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.552 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.77 -50.83 55.0 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.399 -0.813 . . . . 0.0 110.641 -178.764 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -104.36 -33.27 8.69 Favored 'General case' 0 C--N 1.285 -2.221 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 178.498 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.678 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.47 66.49 0.62 Allowed Glycine 0 C--N 1.299 -1.498 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 178.132 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.587 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.6 m -100.68 130.09 46.67 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.491 -1.006 . . . . 0.0 108.883 178.974 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.584 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -134.49 109.51 8.76 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.217 -0.993 . . . . 0.0 109.307 -179.594 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 18.2 m -124.31 118.33 26.52 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.359 -0.838 . . . . 0.0 109.789 -179.781 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.452 HG23 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -148.36 148.26 30.17 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.436 -0.79 . . . . 0.0 109.218 179.808 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.405 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 28.2 p -98.38 136.23 38.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.33 -0.856 . . . . 0.0 109.47 179.923 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.548 ' CB ' ' HB3' ' A' ' 51' ' ' ASP . 0.2 OUTLIER -129.68 164.91 22.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.313 -0.867 . . . . 0.0 109.874 -179.023 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.522 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.1 p -104.29 127.16 51.89 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.157 -0.964 . . . . 0.0 108.679 179.529 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.496 ' CB ' ' OE1' ' A' ' 36' ' ' GLN . 16.0 m -134.53 140.21 46.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.722 -1.236 . . . . 0.0 110.471 -178.659 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.533 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 46.8 mtt180 -126.48 -168.2 1.83 Allowed 'General case' 0 N--CA 1.484 1.226 0 O-C-N 120.703 -1.248 . . . . 0.0 111.015 179.937 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.56 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 27.9 mtm180 -77.87 -75.5 0.22 Allowed 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.326 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.424 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -73.79 136.39 43.58 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 120.006 -1.684 . . . . 0.0 106.829 178.017 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.594 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -156.15 136.88 13.36 Favored 'General case' 0 C--N 1.295 -1.766 0 C-N-CA 117.987 -1.485 . . . . 0.0 110.481 -177.861 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.479 ' O ' ' O ' ' A' ' 47' ' ' CYS . 6.6 mm-40 -37.37 120.45 0.78 Allowed 'General case' 0 N--CA 1.487 1.385 0 CA-C-O 121.589 0.709 . . . . 0.0 110.129 -178.584 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.547 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -88.91 48.88 3.53 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.273 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.524 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 26.3 m-85 -38.22 113.44 0.29 Allowed 'General case' 0 N--CA 1.505 2.276 0 O-C-N 121.165 -1.197 . . . . 0.0 110.138 179.561 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.542 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.0 tp -86.07 126.93 34.54 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.003 -1.061 . . . . 0.0 109.455 -179.819 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.6 t80 -63.62 58.44 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.994 0 O-C-N 120.984 -1.073 . . . . 0.0 110.21 179.599 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -160.89 19.62 0.13 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.038 -1.038 . . . . 0.0 109.824 179.926 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.72 -27.14 5.47 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 179.767 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.438 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 15.5 p -95.57 158.91 15.24 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.994 -1.297 . . . . 0.0 110.258 -179.457 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.448 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -105.03 136.68 44.06 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 179.699 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.466 ' HB2' HD12 ' A' ' 77' ' ' LEU . 4.7 t90 -80.72 -20.13 43.5 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.914 -1.116 . . . . 0.0 110.274 -178.644 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.76 174.43 18.31 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 108.669 -1.772 . . . . 0.0 108.669 -179.392 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.53 108.73 1.44 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.011 -1.287 . . . . 0.0 107.771 179.21 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.594 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 41.5 t -81.41 105.59 11.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 O-C-N 121.375 -0.828 . . . . 0.0 108.796 -179.256 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.462 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.92 111.14 3.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.342 -0.849 . . . . 0.0 110.051 -179.085 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.56 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.5 t -63.99 -5.21 4.22 Favored 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 118.587 -1.245 . . . . 0.0 109.924 179.456 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.7 p -87.43 1.46 53.35 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.804 -1.185 . . . . 0.0 109.08 179.446 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.462 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -116.05 -51.18 2.65 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.393 -0.817 . . . . 0.0 108.965 179.868 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . 0.401 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -102.2 -178.96 3.85 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.544 -0.722 . . . . 0.0 109.384 179.736 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.49 115.61 30.54 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.389 -0.82 . . . . 0.0 109.077 179.975 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.52 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.76 121.39 38.55 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.833 -1.167 . . . . 0.0 109.324 -179.438 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.585 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.02 144.93 30.0 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 122.323 1.059 . . . . 0.0 111.262 -179.278 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.424 HG13 HG21 ' A' ' 21' ' ' VAL . 96.1 t -102.14 109.86 27.36 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.663 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.437 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.89 -171.29 17.49 Favored Glycine 0 N--CA 1.487 2.092 0 C-N-CA 118.018 -2.039 . . . . 0.0 111.894 -177.54 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.482 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -110.51 -179.21 3.7 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 -179.221 . . . . . . . . 3 3 . 1 . 052 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.5 ' O ' ' CA ' ' A' ' 32' ' ' TYR . 36.8 p . . . . . 0 C--N 1.295 -1.766 0 O-C-N 121.464 -0.772 . . . . 0.0 109.379 -179.366 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.763 0 N-CA-C 107.601 -2.199 . . . . 0.0 107.601 . . . . . . . . . 0 0 . 1 . 052 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.34 -178.3 6.84 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 121.568 -0.96 . . . . 0.0 109.587 179.202 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -158.92 -163.42 13.0 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 108.3 -1.92 . . . . 0.0 108.3 -179.558 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.0 Cg_exo -47.72 178.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.705 0 CA-C-N 118.819 1.31 . . . . 0.0 110.132 179.331 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -91.75 -175.79 4.26 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.047 -1.033 . . . . 0.0 110.415 -178.879 . . . . . . . . 1 1 . 1 . 052 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.437 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.83 168.2 14.56 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 -179.865 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.465 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.6 130.49 51.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.405 -1.056 . . . . 0.0 109.073 -179.363 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.585 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.58 121.39 21.5 Favored 'General case' 0 C--N 1.29 -1.979 0 O-C-N 121.578 -0.701 . . . . 0.0 109.914 179.85 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.495 HG12 ' O ' ' A' ' 93' ' ' CYS . 1.5 pt -98.0 166.91 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.279 -0.888 . . . . 0.0 109.04 179.765 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.455 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 1.4 m -135.25 156.52 48.83 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.322 -0.862 . . . . 0.0 109.597 -179.96 . . . . . . . . 2 2 . 1 . 052 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.56 ' CD1' ' HG2' ' A' ' 71' ' ' ARG . 53.7 m-85 . . . . . 0 N--CA 1.489 1.485 0 O-C-N 121.215 -0.928 . . . . 0.0 109.434 -179.885 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.47 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.385 0 CA-C-O 122.123 0.963 . . . . 0.0 110.717 . . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.54 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.7 p -104.16 104.38 14.3 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 122.585 1.183 . . . . 0.0 109.835 179.901 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.542 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 14.2 t -119.59 121.49 66.43 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.398 179.806 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.73 149.75 6.18 Favored Pre-proline 0 N--CA 1.486 1.354 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.557 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.8 Cg_endo -78.63 149.54 85.67 Favored 'Cis proline' 0 C--N 1.308 -1.563 0 C-N-CA 123.663 -1.39 . . . . 0.0 109.697 -0.722 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.448 ' HB2' ' HA ' ' A' ' 110' ' ' ILE . 88.7 p -91.0 -24.63 20.03 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.34 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.465 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 0.8 OUTLIER -131.23 161.17 32.85 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.381 -0.825 . . . . 0.0 109.733 -179.949 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.63 38.47 32.19 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 -179.574 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.619 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 30.9 mt -92.08 -44.46 8.82 Favored 'General case' 0 C--N 1.298 -1.665 0 CA-C-O 123.111 1.434 . . . . 0.0 110.736 -178.26 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.483 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.67 145.72 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.658 -1.61 . . . . 0.0 110.05 -179.818 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.543 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.4 p-10 -51.2 107.35 0.18 Allowed 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 121.502 0.668 . . . . 0.0 111.597 -178.693 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.25 14.36 9.91 Favored Glycine 0 N--CA 1.484 1.883 0 C-N-CA 119.335 -1.412 . . . . 0.0 112.953 177.227 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.619 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 9.7 t -102.78 -172.31 2.1 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 121.012 2.406 . . . . 0.0 109.643 179.239 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 11.8 t -131.71 137.93 54.0 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.372 0 CA-C-N 115.001 -0.999 . . . . 0.0 111.229 -179.113 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.51 HG13 ' CG2' ' A' ' 69' ' ' VAL . 33.7 m -114.69 154.4 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.965 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.542 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -109.05 109.29 20.28 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.158 -0.964 . . . . 0.0 109.186 -179.993 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.515 ' CG1' HG23 ' A' ' 34' ' ' VAL . 2.0 p -107.7 123.11 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 -179.968 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.54 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -114.43 165.12 13.07 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 120.829 -1.169 . . . . 0.0 108.873 179.55 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.579 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.85 107.67 0.53 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 108.825 -1.71 . . . . 0.0 108.825 179.944 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.442 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -115.73 142.84 46.21 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 120.876 -1.367 . . . . 0.0 110.676 -179.213 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.78 27.35 46.77 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 179.207 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.546 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -92.11 174.26 7.41 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.061 -1.258 . . . . 0.0 108.589 179.967 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.561 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.44 99.43 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.025 -1.047 . . . . 0.0 109.732 -179.79 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.06 77.4 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.246 -179.116 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.67 34.02 0.32 Allowed Glycine 0 N--CA 1.487 2.067 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.379 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 80.3 p -144.23 111.6 5.98 Favored 'General case' 0 C--N 1.306 -1.291 0 O-C-N 120.996 -1.297 . . . . 0.0 111.096 -179.803 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.54 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -47.09 124.5 6.53 Favored 'General case' 0 N--CA 1.493 1.691 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.845 178.355 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.496 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 17.8 m-85 -117.69 150.4 39.13 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.493 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.463 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.64 155.42 17.89 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 178.675 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.621 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 7.0 p -138.17 114.96 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.025 -1.047 . . . . 0.0 109.807 -177.81 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.58 -177.67 36.62 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 118.507 -1.806 . . . . 0.0 111.638 -179.648 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.642 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.2 pt20 -102.3 109.83 21.62 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-O 121.836 0.826 . . . . 0.0 108.917 -179.781 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.0 150.34 51.32 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.157 -0.964 . . . . 0.0 110.166 -179.869 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.77 139.7 53.61 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.255 -0.903 . . . . 0.0 110.633 -179.212 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.617 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.05 114.44 26.25 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 178.178 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.4 m -105.37 15.82 6.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.006 -1.059 . . . . 0.0 110.661 -178.821 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.58 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.98 -175.94 0.11 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.928 -1.108 . . . . 0.0 110.043 179.741 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 71.8 p -71.23 96.35 1.39 Allowed 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.37 -0.831 . . . . 0.0 109.759 -179.714 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.38 27.98 34.59 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.234 -0.984 . . . . 0.0 111.402 178.873 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.58 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 2.1 t -115.46 105.97 19.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 O-C-N 120.481 -1.599 . . . . 0.0 107.417 178.951 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.617 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.0 tp -114.9 104.63 12.12 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.533 -1.355 . . . . 0.0 110.062 -177.658 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.472 ' HA ' ' O ' ' A' ' 76' ' ' PHE . . . -98.21 109.52 22.26 Favored 'General case' 0 N--CA 1.483 1.225 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 178.447 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.7 t -105.49 170.47 7.87 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.968 -1.082 . . . . 0.0 110.734 -178.108 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.468 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 21.1 t-20 -114.14 126.07 28.5 Favored Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.54 -0.725 . . . . 0.0 109.546 -179.471 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.583 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -70.57 21.15 0.2 Allowed 'Trans proline' 0 CA--C 1.545 1.062 0 C-N-CA 122.098 1.865 . . . . 0.0 112.118 179.589 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.86 2.59 23.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.42 -1.425 . . . . 0.0 108.964 179.385 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.521 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.39 16.4 2.57 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.563 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -80.35 91.16 5.63 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.974 -178.537 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.621 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.35 -166.37 1.15 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.23 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.463 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.68 137.57 0.09 Allowed 'General case' 0 N--CA 1.486 1.345 0 O-C-N 120.55 -1.344 . . . . 0.0 111.369 -179.38 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.613 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -156.86 156.94 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.171 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.54 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.1 m -98.17 144.7 27.36 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 120.717 -1.239 . . . . 0.0 109.944 -179.616 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.68 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.22 106.39 1.08 Allowed 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 122.408 1.099 . . . . 0.0 109.29 178.466 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.515 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.6 p-10 -59.04 -138.49 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.992 -179.816 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.19 -50.27 62.22 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.445 -0.784 . . . . 0.0 110.618 -178.567 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 28.9 t30 -104.16 -35.53 8.0 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 106.093 -1.817 . . . . 0.0 106.093 178.376 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.68 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 111.1 64.82 0.51 Allowed Glycine 0 C--N 1.298 -1.548 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 177.924 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.579 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 18.6 m -104.72 123.11 47.06 Favored 'General case' 0 N--CA 1.484 1.254 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.545 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.613 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -133.27 109.23 9.25 Favored 'General case' 0 C--N 1.294 -1.819 0 C-N-CA 119.894 -0.722 . . . . 0.0 109.544 -179.052 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 3.6 m -114.0 115.77 28.15 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.349 -0.845 . . . . 0.0 109.358 -179.981 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.52 ' CG2' HG12 ' A' ' 34' ' ' VAL . 1.5 t -139.18 140.0 37.7 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.399 -0.813 . . . . 0.0 109.85 179.971 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 45.4 p -99.24 145.82 26.86 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.496 -0.753 . . . . 0.0 109.17 179.718 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.521 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -146.63 162.7 37.88 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.354 -0.842 . . . . 0.0 109.6 -179.134 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 3.2 p -93.94 124.76 38.16 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.936 . . . . 0.0 109.276 -179.913 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.51 ' CG2' HG13 ' A' ' 19' ' ' VAL . 15.4 m -134.66 141.94 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 120.861 -1.149 . . . . 0.0 109.99 -179.101 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.543 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 8.5 ptt180 -141.9 -163.7 1.64 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 120.473 -1.392 . . . . 0.0 110.601 -179.802 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.614 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -75.74 -92.59 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.343 -0.848 . . . . 0.0 109.79 -179.029 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -60.92 133.07 55.73 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.255 -1.528 . . . . 0.0 107.726 179.478 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.642 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -153.95 156.91 38.35 Favored 'General case' 0 C--N 1.293 -1.874 0 C-N-CA 118.367 -1.333 . . . . 0.0 110.179 -178.716 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.578 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 30.3 mm-40 -47.99 121.66 4.41 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.35 -0.844 . . . . 0.0 109.94 -178.292 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.521 ' CA ' HG23 ' A' ' 86' ' ' VAL . . . -86.79 49.89 4.1 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 -179.4 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.583 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 29.7 m-85 -52.29 110.37 0.49 Allowed 'General case' 0 N--CA 1.505 2.301 0 O-C-N 121.014 -1.286 . . . . 0.0 110.743 179.753 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.529 ' HB2' ' O ' ' A' ' 81' ' ' THR . 0.5 OUTLIER -78.67 151.57 32.14 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 120.801 -1.187 . . . . 0.0 108.748 178.64 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -63.41 -5.5 3.71 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 120.691 -1.256 . . . . 0.0 110.863 179.954 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -99.18 7.63 45.59 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.723 -1.236 . . . . 0.0 109.593 179.938 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.59 -9.81 57.77 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.967 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.529 ' O ' ' HB2' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -78.86 133.56 36.98 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.115 -1.227 . . . . 0.0 109.917 -179.8 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.519 ' NH1' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -75.74 114.66 14.6 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.294 -0.879 . . . . 0.0 109.702 179.75 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.0 t90 -80.91 -20.16 42.73 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.036 -1.04 . . . . 0.0 109.426 -179.97 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.44 172.48 18.82 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 -179.725 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.44 110.61 1.72 Allowed 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 179.192 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.598 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 41.1 t -80.84 101.17 5.55 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.989 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.535 ' CB ' HG21 ' A' ' 90' ' ' THR . 0.5 OUTLIER -61.98 108.21 1.0 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.671 -0.643 . . . . 0.0 110.066 -179.176 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.558 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 4.1 t -60.36 -5.07 1.0 Allowed 'General case' 0 N--CA 1.501 2.124 0 C-N-CA 118.334 -1.346 . . . . 0.0 110.339 179.385 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 60.8 p -89.6 0.26 57.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.461 -1.399 . . . . 0.0 109.588 179.994 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.535 HG21 ' CB ' ' A' ' 87' ' ' ASP . 2.4 p -110.24 -48.46 3.18 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.172 -0.955 . . . . 0.0 109.068 179.994 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.78 -178.07 3.54 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.604 -0.685 . . . . 0.0 109.507 179.997 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.36 112.94 26.17 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.784 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.474 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.48 122.2 39.13 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.107 -0.995 . . . . 0.0 109.675 -178.731 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.53 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.3 mt-30 -104.02 148.92 25.66 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 122.428 1.109 . . . . 0.0 111.339 -179.42 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.52 ' CG1' HG12 ' A' ' 7' ' ' VAL . 57.7 t -103.98 109.78 28.25 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.989 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 177.566 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.42 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.13 -171.46 17.83 Favored Glycine 0 N--CA 1.486 1.995 0 C-N-CA 118.239 -1.934 . . . . 0.0 111.605 -177.625 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.463 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -122.05 178.92 4.7 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -178.812 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' A' ' 97' ' ' LEU . 3.4 m . . . . . 0 C--N 1.295 -1.763 0 O-C-N 121.571 -0.705 . . . . 0.0 109.393 -179.841 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.413 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.482 1.71 0 N-CA-C 107.883 -2.087 . . . . 0.0 107.883 . . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.413 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -167.0 -177.17 3.67 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 122.079 0.942 . . . . 0.0 109.755 179.427 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.87 -162.23 21.77 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.265 -1.934 . . . . 0.0 108.265 -179.431 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.465 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.5 Cg_exo -45.27 171.91 0.02 OUTLIER 'Trans proline' 0 C--N 1.326 -0.629 0 CA-C-N 118.95 1.375 . . . . 0.0 110.035 179.319 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -93.17 -176.69 4.23 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.049 -1.032 . . . . 0.0 110.501 -178.583 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.42 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.07 166.28 12.77 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 -179.908 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -106.11 132.91 52.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.399 -1.059 . . . . 0.0 109.162 -179.251 . . . . . . . . 1 1 . 1 . 053 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.53 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.58 126.08 29.0 Favored 'General case' 0 C--N 1.289 -2.038 0 O-C-N 121.534 -0.729 . . . . 0.0 109.741 179.873 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.576 HD11 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.91 172.44 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.248 -0.907 . . . . 0.0 108.979 179.683 . . . . . . . . 2 2 . 1 . 053 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.465 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.59 158.73 43.76 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.077 -1.014 . . . . 0.0 109.462 -179.948 . . . . . . . . 3 3 . 1 . 053 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.602 ' CD1' ' HD2' ' A' ' 71' ' ' ARG . 56.0 m-85 . . . . . 0 N--CA 1.486 1.337 0 O-C-N 121.24 -0.913 . . . . 0.0 109.636 -179.639 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.482 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.291 0 CA-C-O 122.43 1.11 . . . . 0.0 110.234 . . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.55 ' CG2' ' O ' ' A' ' 6' ' ' THR . 5.9 t -115.14 109.04 17.43 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 123.127 1.441 . . . . 0.0 109.812 -179.863 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.519 HG13 ' CG1' ' A' ' 95' ' ' VAL . 2.2 t -116.18 134.18 60.36 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.659 0 CA-C-N 114.229 -1.35 . . . . 0.0 109.486 179.795 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.491 HG21 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -169.53 150.39 4.03 Favored Pre-proline 0 N--CA 1.487 1.413 0 O-C-N 121.183 -0.948 . . . . 0.0 108.876 -179.509 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.491 ' HA ' HG21 ' A' ' 8' ' ' THR . 2.5 Cg_endo -75.52 152.32 97.24 Favored 'Cis proline' 0 C--N 1.313 -1.315 0 C-N-CA 123.488 -1.463 . . . . 0.0 109.785 -0.963 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.419 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 5.8 m -93.05 -23.52 18.63 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.447 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.513 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 69.0 m -134.99 159.62 40.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.564 -0.71 . . . . 0.0 109.382 179.912 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.28 36.29 27.61 Favored Glycine 0 N--CA 1.495 2.626 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.736 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.599 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 36.7 mt -90.94 -42.65 10.45 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 123.391 1.567 . . . . 0.0 110.393 -178.482 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.11 144.34 0.05 OUTLIER 'General case' 0 C--N 1.261 -3.267 0 CA-C-N 113.282 -1.781 . . . . 0.0 110.08 -179.746 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.579 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.3 p-10 -50.46 104.75 0.08 Allowed 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.556 0.693 . . . . 0.0 111.655 -178.451 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.51 14.4 8.2 Favored Glycine 0 N--CA 1.485 1.91 0 C-N-CA 119.33 -1.414 . . . . 0.0 113.154 177.18 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.599 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.0 t -105.76 -172.99 2.19 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 121.352 2.576 . . . . 0.0 109.821 179.181 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.543 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 17.5 t -129.59 138.21 54.82 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.333 0 CA-C-N 114.67 -1.15 . . . . 0.0 111.136 -178.711 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.517 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 29.4 m -113.61 155.48 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.863 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.492 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tttm -104.32 109.05 20.75 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.208 -0.933 . . . . 0.0 109.213 -179.962 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.2 p -100.64 140.05 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.627 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.571 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -136.61 162.67 32.49 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.733 -1.229 . . . . 0.0 110.179 179.666 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.585 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.64 139.82 10.95 Favored Glycine 0 C--N 1.299 -1.527 0 N-CA-C 108.244 -1.942 . . . . 0.0 108.244 179.728 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.32 125.6 16.51 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.491 -1.593 . . . . 0.0 109.355 179.301 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.85 28.32 21.52 Favored Glycine 0 N--CA 1.49 2.264 0 C-N-CA 118.685 -1.722 . . . . 0.0 109.731 -179.824 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.4 mt -88.72 171.95 9.6 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.885 -1.362 . . . . 0.0 108.278 179.835 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.556 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.03 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.96 -1.087 . . . . 0.0 109.872 -179.476 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.57 77.54 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.677 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.178 -179.345 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.65 33.97 0.28 Allowed Glycine 0 N--CA 1.486 2.007 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.618 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.541 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 41.2 p -141.51 108.05 5.32 Favored 'General case' 0 C--N 1.307 -1.244 0 O-C-N 121.144 -1.209 . . . . 0.0 111.236 -179.476 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -51.04 109.8 0.36 Allowed 'General case' 0 N--CA 1.497 1.904 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.488 177.866 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.459 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.3 m-30 -103.89 157.99 16.71 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.054 -1.029 . . . . 0.0 108.87 179.741 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -99.81 166.54 11.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.844 -1.16 . . . . 0.0 107.969 179.007 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.628 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.8 p -148.09 120.28 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.108 -0.995 . . . . 0.0 109.605 -178.038 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -174.02 -177.02 42.89 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 118.403 -1.856 . . . . 0.0 111.641 -179.927 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.57 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -99.16 108.24 20.79 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.95 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -130.25 148.5 52.08 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.212 -0.93 . . . . 0.0 109.985 179.708 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.71 139.58 53.73 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.298 -0.877 . . . . 0.0 110.634 -179.099 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.618 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.21 114.76 26.59 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 178.207 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.432 HG23 ' HB ' ' A' ' 44' ' ' VAL . 16.4 m -104.83 15.02 6.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.92 -1.112 . . . . 0.0 110.58 -178.795 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.592 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.41 -175.96 0.08 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.872 -1.142 . . . . 0.0 110.074 179.757 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.545 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.0 t -71.36 98.0 1.7 Allowed 'General case' 0 N--CA 1.488 1.434 0 CA-C-O 121.729 0.776 . . . . 0.0 109.808 -179.696 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.48 27.86 34.64 Favored Glycine 0 N--CA 1.492 2.405 0 C-N-CA 120.174 -1.012 . . . . 0.0 111.427 178.97 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.592 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.71 106.25 19.87 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 O-C-N 120.587 -1.537 . . . . 0.0 107.192 178.887 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.618 HD12 ' CD1' ' A' ' 39' ' ' TRP . 13.1 tp -116.96 104.53 11.37 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.478 -1.389 . . . . 0.0 109.773 -177.75 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.546 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.99 109.28 22.06 Favored 'General case' 0 N--CA 1.485 1.315 0 O-C-N 120.833 -1.167 . . . . 0.0 108.152 178.92 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.0 t -106.67 164.8 11.79 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.913 -1.117 . . . . 0.0 110.233 -179.115 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.548 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 3.7 t-20 -106.56 136.21 19.42 Favored Pre-proline 0 N--CA 1.498 1.966 0 O-C-N 121.386 -0.821 . . . . 0.0 109.622 -179.179 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.575 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -74.85 23.79 0.39 Allowed 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 122.384 2.056 . . . . 0.0 111.943 -179.83 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.548 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -109.76 -4.59 15.99 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.33 -1.481 . . . . 0.0 109.143 179.615 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.538 ' CB ' ' HB3' ' A' ' 67' ' ' LEU . 6.0 m-20 -131.73 6.05 4.33 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.658 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.47 84.94 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.732 -178.502 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -110.76 -170.49 1.65 Allowed 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.448 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.469 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.58 135.22 0.08 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 120.622 -1.298 . . . . 0.0 111.136 -179.286 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.563 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.6 p -146.8 158.28 10.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 178.169 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.49 141.51 31.25 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 120.703 -1.248 . . . . 0.0 110.061 -179.791 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.678 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.21 107.91 1.43 Allowed 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.438 1.114 . . . . 0.0 109.537 178.596 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.1 p-10 -61.46 -139.45 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.97 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.864 179.849 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.89 -50.87 60.17 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.427 -0.796 . . . . 0.0 110.487 -178.843 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -102.24 -34.71 9.13 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 178.46 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.678 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.27 67.31 0.64 Allowed Glycine 0 C--N 1.299 -1.499 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 178.073 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.585 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 57.5 m -100.06 130.86 46.26 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.482 -1.011 . . . . 0.0 108.803 178.962 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.571 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -133.48 109.42 9.27 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.19 -1.004 . . . . 0.0 109.321 -179.648 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 73.2 m -121.85 117.0 25.43 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.313 -0.867 . . . . 0.0 109.61 -179.678 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.459 HG21 HG13 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -147.54 149.32 32.37 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.452 -0.78 . . . . 0.0 109.291 179.879 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.465 ' O ' HD23 ' A' ' 67' ' ' LEU . 56.3 p -98.47 145.08 27.13 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.401 -0.812 . . . . 0.0 109.284 179.969 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.543 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.3 OUTLIER -138.96 159.62 41.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.334 -0.854 . . . . 0.0 109.826 -178.717 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.543 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.4 p -101.29 124.0 46.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.011 -1.056 . . . . 0.0 108.483 179.319 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.527 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 21.1 m -137.92 143.16 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.744 -1.222 . . . . 0.0 110.783 -178.47 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.579 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.9 ptt180 -147.45 -175.14 4.73 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 120.711 -1.243 . . . . 0.0 110.742 179.68 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.549 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.43 -101.93 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -179.597 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -57.08 140.85 47.98 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.741 -1.224 . . . . 0.0 108.205 179.459 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -161.83 136.67 7.16 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 118.611 -1.235 . . . . 0.0 109.733 -178.1 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.48 ' C ' ' O ' ' A' ' 73' ' ' PHE . 4.4 mp0 -35.87 122.36 0.68 Allowed 'General case' 0 N--CA 1.491 1.576 0 CA-C-O 121.466 0.65 . . . . 0.0 110.094 -178.615 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.546 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.85 52.67 1.7 Allowed Glycine 0 N--CA 1.494 2.522 0 C-N-CA 120.539 -0.838 . . . . 0.0 111.22 -179.109 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.575 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.57 114.05 0.38 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.094 -1.239 . . . . 0.0 110.133 179.463 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.541 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.1 tp -82.79 126.19 32.14 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 120.843 -1.161 . . . . 0.0 109.313 179.787 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . 0.401 ' O ' ' CD2' ' A' ' 78' ' ' PHE . 51.8 t80 -64.02 58.59 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.955 0 O-C-N 120.89 -1.131 . . . . 0.0 110.042 179.724 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.3 t0 -160.22 20.03 0.15 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.094 -1.004 . . . . 0.0 109.608 179.942 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.54 -28.35 5.36 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.871 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.47 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.5 OUTLIER -96.72 160.42 14.38 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.058 -1.26 . . . . 0.0 110.207 -179.532 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.493 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.7 OUTLIER -106.13 141.69 37.07 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 179.896 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.475 ' HB2' HD12 ' A' ' 77' ' ' LEU . 2.6 t90 -85.15 -19.35 31.92 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.679 -1.263 . . . . 0.0 110.689 -178.289 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.42 177.5 18.59 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -179.359 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -67.02 105.79 1.75 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.146 -1.208 . . . . 0.0 107.785 179.183 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.578 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.7 t -77.2 106.33 7.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.326 -0.858 . . . . 0.0 109.232 -178.879 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 1.1 m-20 -65.96 111.63 3.42 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.363 -0.836 . . . . 0.0 109.69 -179.643 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.549 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.5 -5.36 5.26 Favored 'General case' 0 N--CA 1.5 2.045 0 C-N-CA 118.195 -1.402 . . . . 0.0 109.721 179.567 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -86.4 -0.41 55.91 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.716 -1.24 . . . . 0.0 109.079 179.482 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.452 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.6 -50.88 2.83 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.287 -0.883 . . . . 0.0 108.972 179.9 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.69 -178.73 3.74 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.509 -0.744 . . . . 0.0 109.271 179.815 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.17 115.37 30.11 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.437 -0.789 . . . . 0.0 108.888 -179.949 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.527 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.06 121.1 38.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.94 -1.1 . . . . 0.0 109.714 -179.271 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.567 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.21 146.94 27.27 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 122.449 1.119 . . . . 0.0 111.024 -179.562 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.519 ' CG1' HG13 ' A' ' 7' ' ' VAL . 61.6 t -104.23 111.72 34.94 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 177.858 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.463 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -152.91 -169.86 18.59 Favored Glycine 0 N--CA 1.487 2.089 0 C-N-CA 118.124 -1.989 . . . . 0.0 111.848 -177.71 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -114.32 179.43 3.96 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 -179.173 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.459 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 25.0 p . . . . . 0 C--N 1.295 -1.792 0 O-C-N 121.467 -0.771 . . . . 0.0 109.363 -179.513 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.34 0 N-CA-C 106.717 -2.553 . . . . 0.0 106.717 . . . . . . . . . 0 0 . 1 . 054 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -146.7 170.74 16.35 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.709 -0.877 . . . . 0.0 109.943 -179.775 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.15 -165.01 19.55 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 108.163 -1.975 . . . . 0.0 108.163 -179.857 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.9 Cg_exo -48.22 179.39 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 CA-C-N 118.889 1.344 . . . . 0.0 110.164 179.446 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -92.86 -177.71 4.61 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.183 -0.948 . . . . 0.0 110.438 -178.894 . . . . . . . . 1 1 . 1 . 054 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.463 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.61 165.62 14.53 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.923 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.431 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.0 130.13 53.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 O-C-N 121.293 -1.122 . . . . 0.0 109.209 -179.269 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.567 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.05 121.92 21.85 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.569 -0.707 . . . . 0.0 109.528 179.668 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.617 ' CD1' ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.9 167.25 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 121.188 -0.945 . . . . 0.0 109.243 179.913 . . . . . . . . 2 2 . 1 . 054 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.513 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -137.33 151.24 48.42 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.237 -0.914 . . . . 0.0 109.62 -179.97 . . . . . . . . 3 3 . 1 . 054 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.617 ' CZ ' ' CD1' ' A' ' 110' ' ' ILE . 25.2 m-85 . . . . . 0 N--CA 1.486 1.365 0 O-C-N 121.163 -0.961 . . . . 0.0 109.51 -179.693 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.471 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.478 0 CA-C-O 122.301 1.048 . . . . 0.0 110.71 . . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.542 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.7 t -110.93 108.77 18.65 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.079 1.418 . . . . 0.0 109.078 179.276 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.509 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 2.3 t -119.62 136.7 55.89 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.672 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.023 -179.637 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.527 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -177.0 150.96 0.92 Allowed Pre-proline 0 N--CA 1.487 1.421 0 O-C-N 121.286 -0.884 . . . . 0.0 108.785 -179.72 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.527 ' CA ' HG21 ' A' ' 8' ' ' THR . 5.5 Cg_endo -78.46 150.76 88.4 Favored 'Cis proline' 0 C--N 1.312 -1.35 0 C-N-CA 123.481 -1.466 . . . . 0.0 109.301 -0.828 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.453 ' HA ' HG21 ' A' ' 110' ' ' ILE . 77.9 p -89.34 -25.99 21.33 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.518 -0.739 . . . . 0.0 109.056 179.527 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.48 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -132.99 162.69 31.01 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.528 -0.733 . . . . 0.0 109.529 -179.922 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.31 36.93 29.37 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.749 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.608 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 37.5 mt -92.78 -42.97 9.27 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 123.24 1.495 . . . . 0.0 110.488 -178.327 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.492 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.29 144.35 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.265 0 CA-C-N 113.479 -1.691 . . . . 0.0 109.936 -179.521 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.555 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 15.5 p-10 -50.9 106.49 0.13 Allowed 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.515 0.674 . . . . 0.0 111.556 -178.542 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.28 14.22 9.23 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.331 -1.414 . . . . 0.0 113.007 177.311 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.608 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -104.71 -172.01 2.02 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 121.143 2.471 . . . . 0.0 109.67 179.144 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.546 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 17.2 t -127.92 135.97 61.53 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.404 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.182 -178.93 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.585 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 23.0 m -110.79 155.15 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.77 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.509 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.8 OUTLIER -109.93 109.18 19.71 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.173 -0.954 . . . . 0.0 108.973 179.958 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.473 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.1 p -105.16 141.73 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.675 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.534 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -141.0 160.2 40.59 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.144 179.886 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.592 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.95 144.72 15.91 Favored Glycine 0 C--N 1.294 -1.769 0 N-CA-C 107.996 -2.041 . . . . 0.0 107.996 179.666 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.4 125.73 13.1 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 120.884 -1.362 . . . . 0.0 108.789 179.244 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.46 27.16 23.36 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.315 -1.421 . . . . 0.0 109.608 -179.568 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.5 mt -88.8 175.33 7.53 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.946 -1.326 . . . . 0.0 108.446 -179.941 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.559 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -48.42 99.49 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.013 -1.055 . . . . 0.0 109.83 -179.623 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.11 77.98 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.759 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.149 -179.325 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.69 34.2 0.31 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.614 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.536 ' O ' ' CD2' ' A' ' 32' ' ' TYR . 62.9 p -143.21 109.09 5.18 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.034 -1.274 . . . . 0.0 111.142 -179.591 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.544 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.99 126.01 5.57 Favored 'General case' 0 N--CA 1.493 1.71 0 CA-C-O 121.403 0.62 . . . . 0.0 109.56 178.129 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.536 ' CD2' ' O ' ' A' ' 30' ' ' THR . 19.8 m-85 -117.35 152.98 33.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.349 -0.844 . . . . 0.0 108.923 179.808 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.5 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -103.14 152.66 21.17 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.627 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.637 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.0 p -136.82 116.96 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 120.885 -1.134 . . . . 0.0 109.856 -177.904 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.482 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.1 -178.28 39.35 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 118.462 -1.828 . . . . 0.0 111.828 -179.799 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.577 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.6 OUTLIER -101.74 109.56 21.36 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.928 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.53 148.4 52.33 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.098 -1.001 . . . . 0.0 110.081 179.852 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.04 138.53 54.66 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.394 -0.816 . . . . 0.0 110.701 -179.025 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.63 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.39 114.6 26.39 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 178.137 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 m -105.22 15.16 6.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.006 -1.059 . . . . 0.0 110.705 -178.596 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.14 -175.09 0.09 Allowed 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.952 -1.093 . . . . 0.0 110.097 179.736 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 35.1 p -72.0 97.54 1.9 Allowed 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.404 -0.81 . . . . 0.0 109.727 -179.673 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.13 26.53 36.61 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.173 -1.013 . . . . 0.0 111.446 178.859 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.21 106.3 20.28 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 O-C-N 120.547 -1.561 . . . . 0.0 107.482 178.93 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.63 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.9 tp -117.51 104.07 10.7 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.47 -1.393 . . . . 0.0 109.6 -177.815 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.515 ' CB ' HG23 ' A' ' 86' ' ' VAL . . . -98.32 109.24 22.03 Favored 'General case' 0 N--CA 1.483 1.179 0 O-C-N 120.767 -1.208 . . . . 0.0 107.753 178.603 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.491 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -103.5 166.01 10.69 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.924 -1.11 . . . . 0.0 110.411 -178.532 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.522 ' ND2' ' HD2' ' A' ' 49' ' ' PRO . 17.1 t-20 -106.35 129.72 24.07 Favored Pre-proline 0 N--CA 1.501 2.084 0 C-N-CA 119.945 -0.702 . . . . 0.0 109.757 -179.202 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.576 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.6 Cg_endo -72.94 23.81 0.3 Allowed 'Trans proline' 0 CA--C 1.544 0.98 0 C-N-CA 122.089 1.86 . . . . 0.0 111.813 179.634 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.4 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -115.51 3.63 14.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.498 -1.376 . . . . 0.0 109.197 179.738 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.496 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.89 17.24 2.66 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 179.49 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -80.64 91.1 5.8 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.842 -0.743 . . . . 0.0 110.814 -178.696 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.637 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -109.51 -166.71 1.12 Allowed 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.297 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.471 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.94 137.03 0.09 Allowed 'General case' 0 C--N 1.306 -1.311 0 O-C-N 120.526 -1.358 . . . . 0.0 111.404 -179.271 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.584 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -154.9 156.15 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.211 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.544 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.68 144.87 26.88 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.694 -1.254 . . . . 0.0 109.907 -179.534 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.686 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.83 107.22 1.16 Allowed 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 122.431 1.11 . . . . 0.0 109.409 178.586 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.524 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -61.07 -139.34 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.027 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.903 -179.909 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.548 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.9 -50.91 56.38 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.397 -0.814 . . . . 0.0 110.68 -178.713 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -103.94 -33.18 8.92 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 178.576 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.686 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.96 64.91 0.58 Allowed Glycine 0 C--N 1.299 -1.498 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 178.206 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.592 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 47.7 m -103.44 127.07 50.9 Favored 'General case' 0 N--CA 1.483 1.176 0 O-C-N 121.57 -0.959 . . . . 0.0 108.83 178.901 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.584 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.04 108.96 7.1 Favored 'General case' 0 C--N 1.296 -1.751 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.659 -179.396 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.513 ' CB ' ' HB2' ' A' ' 22' ' ' ALA . 1.1 m -122.44 121.01 35.6 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.359 -0.838 . . . . 0.0 109.303 -179.898 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.432 HG22 HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.83 144.84 31.34 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.426 -0.796 . . . . 0.0 109.565 179.886 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 22.1 p -99.0 141.0 32.3 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.38 -0.825 . . . . 0.0 109.297 -179.945 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.519 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -140.99 166.7 24.07 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.413 -0.804 . . . . 0.0 109.39 -179.327 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.546 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.7 p -95.96 124.38 39.95 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.005 -1.06 . . . . 0.0 109.416 -179.883 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.527 ' CG2' HG13 ' A' ' 19' ' ' VAL . 13.3 m -136.42 141.86 40.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 120.907 -1.121 . . . . 0.0 109.937 -179.12 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.555 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 7.3 ptt180 -144.35 -170.32 3.34 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.546 -1.346 . . . . 0.0 110.884 -179.882 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.583 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -62.45 -101.42 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.77 -0.581 . . . . 0.0 110.206 -179.125 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -58.94 137.15 58.0 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.574 -1.329 . . . . 0.0 108.209 179.957 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD2' ' O ' ' A' ' 71' ' ' ARG . 1.7 p90 -157.53 154.04 27.96 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.646 -1.222 . . . . 0.0 110.198 -178.514 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 47' ' ' CYS . 5.1 mm-40 -47.15 120.8 3.32 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.359 -0.838 . . . . 0.0 109.263 -179.124 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.48 ' HA3' HG21 ' A' ' 86' ' ' VAL . . . -91.5 51.34 3.01 Favored Glycine 0 N--CA 1.495 2.59 0 C-N-CA 120.414 -0.898 . . . . 0.0 111.116 -179.224 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.576 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.5 m-30 -39.0 114.0 0.36 Allowed 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.114 -1.227 . . . . 0.0 110.31 179.62 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -86.21 126.94 34.63 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.919 -1.113 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 29.2 t80 -64.25 58.44 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.911 -1.118 . . . . 0.0 110.059 179.702 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -160.33 19.52 0.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.031 -1.043 . . . . 0.0 109.733 179.824 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.74 -26.96 5.57 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 179.866 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -95.34 161.42 14.09 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 120.998 -1.295 . . . . 0.0 110.315 -179.383 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.471 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -107.24 136.78 46.49 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.813 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.507 ' CD1' HD11 ' A' ' 77' ' ' LEU . 3.0 t90 -83.64 -16.89 43.44 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.784 -1.198 . . . . 0.0 110.562 -178.423 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.14 174.27 20.0 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 108.827 -1.709 . . . . 0.0 108.827 -179.553 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -63.66 107.0 1.06 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.141 -1.211 . . . . 0.0 107.759 179.218 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.556 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 44.3 t -78.94 106.05 9.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.307 -0.871 . . . . 0.0 109.243 -178.877 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.6 OUTLIER -65.16 108.35 1.84 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.652 -0.655 . . . . 0.0 110.113 -179.408 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.545 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.5 t -61.34 -4.72 1.32 Allowed 'General case' 0 N--CA 1.502 2.133 0 O-C-N 120.479 -1.388 . . . . 0.0 110.417 179.391 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -90.43 3.68 53.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.597 -1.314 . . . . 0.0 109.481 179.944 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.461 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -114.96 -48.32 2.84 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.282 -0.886 . . . . 0.0 109.107 -179.976 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.72 -179.05 3.82 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.573 -0.704 . . . . 0.0 109.526 179.997 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.97 112.15 24.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.382 -0.824 . . . . 0.0 108.812 179.838 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.484 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 1.4 m -96.98 122.06 39.54 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.104 -0.997 . . . . 0.0 109.399 -178.922 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.529 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.08 148.66 25.45 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-O 122.439 1.114 . . . . 0.0 111.577 -179.157 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.517 ' CG2' HG22 ' A' ' 110' ' ' ILE . 84.8 t -104.22 110.78 31.43 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 177.643 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.84 -172.01 18.87 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 118.034 -2.031 . . . . 0.0 111.802 -177.604 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.5 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -114.57 -179.04 3.52 Favored 'General case' 0 N--CA 1.485 1.3 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -178.94 . . . . . . . . 3 3 . 1 . 055 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.469 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.8 OUTLIER . . . . . 0 C--N 1.298 -1.66 0 O-C-N 121.394 -0.816 . . . . 0.0 109.033 -179.418 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.688 0 N-CA-C 107.636 -2.185 . . . . 0.0 107.636 . . . . . . . . . 0 0 . 1 . 055 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.3 -178.81 7.56 Favored 'General case' 0 C--N 1.307 -1.26 0 O-C-N 121.542 -0.975 . . . . 0.0 109.623 179.022 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -177.63 -167.01 35.17 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 -179.584 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.468 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.7 Cg_exo -49.11 -179.57 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.618 0 CA-C-N 118.83 1.315 . . . . 0.0 110.07 179.529 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.87 -179.81 5.1 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.012 -1.055 . . . . 0.0 110.521 -178.765 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -118.99 162.65 13.42 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.973 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -103.55 130.62 53.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.318 -1.107 . . . . 0.0 109.216 -179.347 . . . . . . . . 1 1 . 1 . 055 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.529 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.98 121.21 18.75 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.641 -0.662 . . . . 0.0 109.606 179.62 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.584 HD13 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.04 171.43 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.239 -0.913 . . . . 0.0 109.174 179.947 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.4 m -141.1 156.55 45.96 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.151 -0.968 . . . . 0.0 109.895 -179.841 . . . . . . . . 2 2 . 1 . 055 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.584 ' CE2' HD13 ' A' ' 110' ' ' ILE . 82.8 m-85 . . . . . 0 N--CA 1.486 1.34 0 O-C-N 121.243 -0.911 . . . . 0.0 109.549 -179.74 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.494 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.217 0 CA-C-O 122.409 1.1 . . . . 0.0 110.565 . . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.541 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.4 p -106.31 104.86 14.65 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 122.461 1.124 . . . . 0.0 110.199 -179.476 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.53 HG12 ' CG1' ' A' ' 95' ' ' VAL . 12.1 t -118.53 118.69 58.8 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.439 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.364 179.596 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.497 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.87 149.17 10.28 Favored Pre-proline 0 N--CA 1.487 1.38 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 -179.65 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.497 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -77.83 151.23 91.09 Favored 'Cis proline' 0 C--N 1.31 -1.494 0 C-N-CA 123.606 -1.414 . . . . 0.0 109.51 -0.578 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.421 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 16.5 p -93.52 -23.85 18.2 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.639 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.461 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 20.2 m -132.38 162.22 31.64 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.438 -0.789 . . . . 0.0 109.585 -179.927 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.2 37.24 37.72 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 -179.733 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.617 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 30.2 mt -90.41 -44.64 9.51 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 123.127 1.441 . . . . 0.0 110.652 -178.428 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.487 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.99 145.83 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.325 0 CA-C-N 113.699 -1.591 . . . . 0.0 109.963 -179.701 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.562 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 7.3 p-10 -51.35 106.26 0.13 Allowed 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.598 0.713 . . . . 0.0 111.794 -178.471 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.45 15.7 8.71 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 119.438 -1.363 . . . . 0.0 112.98 177.302 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.617 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 9.0 t -102.72 -171.66 1.99 Allowed 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 121.13 2.465 . . . . 0.0 109.84 179.31 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.544 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 17.2 t -129.45 139.01 52.83 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.289 0 CA-C-N 114.861 -1.063 . . . . 0.0 111.195 -178.699 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.489 ' CG2' HG23 ' A' ' 69' ' ' VAL . 31.2 m -118.08 155.04 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.733 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 6.2 tttt -113.08 109.13 18.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.126 -0.984 . . . . 0.0 109.413 -179.854 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.523 HG11 ' CG2' ' A' ' 34' ' ' VAL . 2.1 p -105.33 122.97 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 179.833 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.552 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -112.88 166.09 11.71 Favored 'General case' 0 C--N 1.307 -1.243 0 O-C-N 120.799 -1.188 . . . . 0.0 109.073 179.634 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.613 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.67 108.46 0.5 Allowed Glycine 0 N--CA 1.481 1.678 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 -179.886 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.36 139.11 50.76 Favored 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 119.396 1.598 . . . . 0.0 110.424 -179.485 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.56 29.04 30.86 Favored Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.079 -1.534 . . . . 0.0 109.941 179.56 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.526 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.5 mt -92.47 176.07 6.6 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.986 -1.302 . . . . 0.0 108.562 179.935 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.559 ' CB ' ' CG2' ' A' ' 30' ' ' THR . 0.0 OUTLIER -45.39 96.98 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.023 -1.048 . . . . 0.0 109.621 -179.909 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.94 77.18 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.36 -178.93 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 131.8 34.87 0.37 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.465 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.636 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -146.51 114.4 6.51 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 120.931 -1.335 . . . . 0.0 111.109 -179.948 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.537 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -48.17 122.9 5.66 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.181 178.669 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.636 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 2.0 m-30 -116.93 151.77 35.96 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.267 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.47 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -98.91 163.75 12.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.539 -1.351 . . . . 0.0 108.216 179.247 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.622 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.8 p -144.59 117.98 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.106 -0.997 . . . . 0.0 109.643 -177.963 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.489 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.66 -179.08 41.22 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.411 -1.852 . . . . 0.0 111.738 -179.804 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.601 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -100.95 109.24 21.15 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -179.922 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.457 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.03 149.21 51.85 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.21 -0.931 . . . . 0.0 109.74 179.891 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.36 137.75 54.75 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.178 -0.951 . . . . 0.0 110.736 -178.993 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.624 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.28 114.61 26.41 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 178.038 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -104.59 14.47 7.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 120.973 -1.079 . . . . 0.0 110.585 -178.708 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.594 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.57 -174.84 0.08 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.941 -1.099 . . . . 0.0 109.988 179.747 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.92 98.22 2.43 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.379 -0.826 . . . . 0.0 109.653 -179.753 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.28 26.95 31.96 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 120.302 -0.952 . . . . 0.0 111.534 178.943 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.594 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -116.85 106.16 19.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 O-C-N 120.499 -1.589 . . . . 0.0 107.298 178.922 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.624 HD13 ' CD1' ' A' ' 39' ' ' TRP . 13.1 tp -118.17 104.37 10.75 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.358 -1.464 . . . . 0.0 109.885 -177.795 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.488 ' HA ' ' O ' ' A' ' 76' ' ' PHE . . . -98.45 109.36 22.13 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 120.821 -1.174 . . . . 0.0 108.156 178.905 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.509 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.3 t -104.42 166.63 10.27 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.844 -1.16 . . . . 0.0 110.353 -178.961 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.545 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 15.8 t-20 -109.53 137.89 20.44 Favored Pre-proline 0 N--CA 1.501 2.082 0 O-C-N 121.445 -0.785 . . . . 0.0 110.146 -179.081 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.8 Cg_endo -74.82 25.2 0.37 Allowed 'Trans proline' 0 C--N 1.318 -1.027 0 C-N-CA 122.465 2.11 . . . . 0.0 111.939 179.903 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.545 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -117.27 2.35 12.54 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.278 -1.514 . . . . 0.0 109.294 179.788 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.513 ' O ' ' O ' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -139.73 18.71 2.51 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 179.297 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -80.58 89.73 5.69 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.88 -0.728 . . . . 0.0 110.489 -179.078 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -113.65 -168.7 1.38 Allowed 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 178.647 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.471 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.5 134.96 0.08 Allowed 'General case' 0 C--N 1.305 -1.34 0 O-C-N 120.653 -1.28 . . . . 0.0 111.286 -179.337 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.575 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.3 p -149.09 158.71 6.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 177.966 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.537 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.19 145.69 26.35 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.75 -1.219 . . . . 0.0 109.908 -179.723 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.67 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.88 107.87 2.36 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-O 122.443 1.116 . . . . 0.0 109.369 178.577 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.527 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.9 p-10 -59.87 -139.47 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.829 179.996 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.64 -50.68 59.84 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.386 -0.821 . . . . 0.0 110.467 -178.775 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.5 t30 -103.63 -34.65 8.56 Favored 'General case' 0 C--N 1.285 -2.225 0 N-CA-C 106.379 -1.711 . . . . 0.0 106.379 178.481 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.67 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.5 67.92 0.62 Allowed Glycine 0 C--N 1.297 -1.584 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.055 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.613 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.8 m -103.36 126.16 50.37 Favored 'General case' 0 N--CA 1.484 1.254 0 O-C-N 121.717 -0.873 . . . . 0.0 108.677 178.817 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.575 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.87 108.86 8.14 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 119.714 -0.794 . . . . 0.0 109.511 -179.327 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 93.0 p -117.89 117.2 28.62 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 121.17 -0.956 . . . . 0.0 109.436 -179.99 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.454 HG21 HG13 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -141.85 135.31 29.44 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.467 -0.771 . . . . 0.0 109.957 179.979 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 10.0 p -100.36 133.13 45.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.423 -0.798 . . . . 0.0 108.848 179.511 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.58 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -134.3 175.19 9.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.316 -0.865 . . . . 0.0 109.683 -178.917 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -100.16 125.0 46.23 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.006 -1.059 . . . . 0.0 109.702 -179.612 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.509 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.5 m -136.87 142.15 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 120.94 -1.1 . . . . 0.0 109.761 -179.495 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.562 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.4 ptt180 -138.43 -165.3 1.79 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.652 -1.28 . . . . 0.0 110.129 -179.911 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.579 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -74.87 -83.61 0.05 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.142 -0.974 . . . . 0.0 108.782 -179.615 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -62.82 138.86 58.64 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.361 -1.462 . . . . 0.0 107.228 178.668 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD1' ' O ' ' A' ' 71' ' ' ARG . 0.3 OUTLIER -164.54 135.11 4.1 Favored 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 117.933 -1.507 . . . . 0.0 110.533 -177.443 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.481 ' C ' ' O ' ' A' ' 73' ' ' PHE . 0.6 OUTLIER -31.82 121.02 0.28 Allowed 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.463 0.649 . . . . 0.0 110.483 -178.76 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.477 ' HA3' HG22 ' A' ' 86' ' ' VAL . . . -93.28 49.87 2.42 Favored Glycine 0 N--CA 1.494 2.537 0 C-N-CA 120.353 -0.927 . . . . 0.0 111.396 -179.062 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.587 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.4 m-30 -39.68 112.46 0.26 Allowed 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.027 -1.278 . . . . 0.0 109.998 179.306 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -84.62 127.18 33.94 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.906 -1.121 . . . . 0.0 109.791 -179.804 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -63.66 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.03 0 O-C-N 120.978 -1.077 . . . . 0.0 110.195 179.58 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.4 t0 -161.26 19.51 0.12 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.022 -1.049 . . . . 0.0 109.816 179.878 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.3 -26.68 5.49 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 179.866 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.419 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 22.8 p -93.9 157.53 16.08 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.975 -1.309 . . . . 0.0 110.302 -179.442 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.482 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 4.5 ptt180 -104.73 135.54 45.92 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.701 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.469 ' HB2' HD12 ' A' ' 77' ' ' LEU . 1.6 t90 -82.57 -17.76 43.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.716 -1.24 . . . . 0.0 110.423 -178.55 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.6 175.68 21.14 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 -179.57 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.59 109.14 1.3 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 179.037 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.564 HG12 ' CE1' ' A' ' 73' ' ' PHE . 35.2 t -81.39 104.77 10.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -178.864 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.457 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.09 111.9 3.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.448 -0.782 . . . . 0.0 109.885 -179.146 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.539 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -65.98 -4.44 7.1 Favored 'General case' 0 N--CA 1.499 1.992 0 C-N-CA 118.366 -1.334 . . . . 0.0 109.839 179.324 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 p -85.02 1.18 48.76 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.835 -1.166 . . . . 0.0 108.872 179.336 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.457 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -116.13 -49.86 2.68 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.401 -0.812 . . . . 0.0 109.047 -179.957 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.7 -179.49 3.95 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.512 -0.743 . . . . 0.0 109.464 179.916 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.99 115.46 30.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.883 . . . . 0.0 109.104 179.976 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.55 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.9 m -96.8 122.54 39.87 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.909 -1.12 . . . . 0.0 109.391 -179.5 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.542 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.31 146.28 27.76 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-O 122.393 1.092 . . . . 0.0 111.368 -179.216 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.53 ' CG1' HG12 ' A' ' 7' ' ' VAL . 53.4 t -102.5 109.64 27.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 177.419 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -148.64 -169.99 16.0 Favored Glycine 0 N--CA 1.485 1.932 0 C-N-CA 118.009 -2.043 . . . . 0.0 111.729 -177.362 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.443 HD11 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -117.75 -177.89 3.36 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -178.786 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.473 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.1 p . . . . . 0 C--N 1.295 -1.765 0 O-C-N 121.35 -0.844 . . . . 0.0 109.302 -179.251 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.707 0 N-CA-C 107.599 -2.201 . . . . 0.0 107.599 . . . . . . . . . 0 0 . 1 . 056 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.94 -178.15 7.03 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.617 -0.931 . . . . 0.0 109.826 179.288 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.87 -162.6 20.13 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 108.239 -1.945 . . . . 0.0 108.239 -179.433 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.609 ' CD ' ' CE2' ' A' ' 32' ' ' TYR . 7.3 Cg_exo -45.59 172.07 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.652 0 CA-C-N 118.92 1.36 . . . . 0.0 109.926 179.354 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -90.36 -171.43 3.09 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.107 -0.995 . . . . 0.0 110.42 -178.746 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -124.65 169.65 16.67 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.751 . . . . . . . . 1 1 . 1 . 056 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.81 133.95 47.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.48 -1.012 . . . . 0.0 109.061 -179.314 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.542 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.82 119.42 18.98 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.513 -0.742 . . . . 0.0 109.696 179.791 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.578 HD13 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -98.14 168.58 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 O-C-N 121.272 -0.892 . . . . 0.0 108.845 179.708 . . . . . . . . 2 2 . 1 . 056 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.461 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -139.7 157.63 45.44 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.017 -1.052 . . . . 0.0 109.853 -179.717 . . . . . . . . 3 3 . 1 . 056 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.578 ' CE1' HD13 ' A' ' 110' ' ' ILE . 96.7 m-85 . . . . . 0 N--CA 1.486 1.37 0 O-C-N 121.236 -0.915 . . . . 0.0 109.506 -179.672 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.42 0 CA-C-O 122.253 1.025 . . . . 0.0 110.32 . . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.552 ' CG2' ' O ' ' A' ' 6' ' ' THR . 4.3 t -116.36 108.71 16.4 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 123.167 1.46 . . . . 0.0 109.23 179.29 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.503 ' CG2' HG21 ' A' ' 21' ' ' VAL . 2.5 t -117.04 138.26 48.29 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.654 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.944 -179.604 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.52 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.5 149.88 1.39 Allowed Pre-proline 0 N--CA 1.485 1.308 0 O-C-N 121.298 -0.877 . . . . 0.0 108.757 -179.782 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.52 ' CA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -77.86 150.91 90.56 Favored 'Cis proline' 0 C--N 1.311 -1.427 0 C-N-CA 123.507 -1.455 . . . . 0.0 109.461 -0.786 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.453 ' HB2' ' HA ' ' A' ' 110' ' ' ILE . 71.1 p -88.31 -26.2 22.39 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.903 -0.776 . . . . 0.0 108.903 179.564 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.543 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 0.8 OUTLIER -132.75 168.74 17.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.449 -0.782 . . . . 0.0 109.499 179.649 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.93 38.79 48.11 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 108.36 -1.896 . . . . 0.0 108.36 -179.801 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.599 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.3 mt -94.11 -43.04 8.68 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 123.285 1.517 . . . . 0.0 110.67 -178.111 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.497 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.08 143.5 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.283 0 CA-C-N 113.408 -1.723 . . . . 0.0 109.766 -179.398 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.546 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 10.8 p-10 -49.95 105.47 0.09 Allowed 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 121.57 0.7 . . . . 0.0 111.753 -178.397 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.403 ' H ' ' HB3' ' A' ' 70' ' ' ARG . . . 113.23 15.68 8.86 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.33 -1.414 . . . . 0.0 113.081 177.158 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.599 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -104.24 -171.15 1.88 Allowed 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 121.235 2.517 . . . . 0.0 109.733 179.153 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.569 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 15.9 t -129.98 139.26 51.95 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.289 0 CA-C-N 114.943 -1.026 . . . . 0.0 111.309 -178.97 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.505 HG12 ' CG2' ' A' ' 69' ' ' VAL . 33.6 m -115.59 155.74 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.881 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.486 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -106.9 109.76 21.74 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.117 -0.989 . . . . 0.0 109.187 -179.929 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.516 HG12 ' CG2' ' A' ' 34' ' ' VAL . 1.9 p -103.35 139.74 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.404 -0.81 . . . . 0.0 108.842 179.978 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.561 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -132.55 157.8 43.79 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.829 -1.169 . . . . 0.0 109.608 179.426 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.585 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -138.99 108.71 0.62 Allowed Glycine 0 N--CA 1.482 1.74 0 N-CA-C 108.688 -1.765 . . . . 0.0 108.688 -179.964 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.36 142.04 46.85 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.889 -1.359 . . . . 0.0 110.858 -179.059 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.84 27.36 46.47 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.701 -1.237 . . . . 0.0 110.131 178.942 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.567 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.6 mt -89.52 173.99 8.02 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.008 -1.289 . . . . 0.0 108.705 -179.848 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.561 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.97 99.64 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.965 -1.085 . . . . 0.0 109.579 -179.598 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.543 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.24 77.22 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.196 -179.144 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.9 34.09 0.31 Allowed Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.549 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 78.0 p -144.04 111.02 5.73 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 120.965 -1.315 . . . . 0.0 111.045 -179.741 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.538 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -46.27 125.09 6.28 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.689 178.158 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.493 ' CD2' ' O ' ' A' ' 30' ' ' THR . 16.9 m-85 -116.11 150.82 36.75 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.889 . . . . 0.0 108.97 179.699 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.485 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -101.86 151.77 21.69 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 178.547 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.601 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.5 p -136.17 117.63 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.957 -1.09 . . . . 0.0 109.787 -177.904 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.479 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -165.01 -179.35 38.93 Favored Glycine 0 N--CA 1.494 2.5 0 C-N-CA 118.348 -1.882 . . . . 0.0 111.69 -179.576 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.597 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.6 pt20 -100.44 110.79 23.0 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.927 0.87 . . . . 0.0 108.744 -179.872 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.1 m -131.08 148.98 52.8 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.265 -0.897 . . . . 0.0 109.781 -179.756 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.39 138.19 54.61 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.261 -0.9 . . . . 0.0 110.675 -179.047 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.632 ' CE2' HD11 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.63 114.64 26.41 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 178.209 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 m -105.23 14.56 7.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.028 -1.045 . . . . 0.0 110.65 -178.693 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 173.98 -175.67 0.07 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.912 -1.118 . . . . 0.0 110.198 179.706 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.542 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.34 97.99 1.34 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 121.755 0.788 . . . . 0.0 110.001 -179.633 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.62 26.47 38.62 Favored Glycine 0 N--CA 1.493 2.494 0 C-N-CA 120.252 -0.975 . . . . 0.0 111.522 178.825 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.89 106.31 20.35 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.572 -1.546 . . . . 0.0 107.382 178.931 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.632 HD11 ' CE2' ' A' ' 39' ' ' TRP . 12.8 tp -118.05 104.69 11.1 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.494 -1.379 . . . . 0.0 109.77 -177.793 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.87 109.69 22.4 Favored 'General case' 0 N--CA 1.484 1.265 0 O-C-N 120.796 -1.19 . . . . 0.0 108.246 178.903 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.9 t -107.13 166.54 10.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.93 -1.106 . . . . 0.0 110.525 -178.692 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.491 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 12.4 t-20 -114.0 129.81 24.45 Favored Pre-proline 0 N--CA 1.499 2.005 0 O-C-N 121.424 -0.797 . . . . 0.0 109.697 -179.236 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.59 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -71.28 21.08 0.23 Allowed 'Trans proline' 0 CA--C 1.546 1.082 0 C-N-CA 121.953 1.769 . . . . 0.0 111.969 179.274 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.08 1.45 24.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.442 -1.411 . . . . 0.0 108.82 179.293 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.512 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.92 15.47 2.87 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 179.372 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -79.25 85.76 5.08 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.069 -178.49 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.601 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -101.59 -166.72 1.33 Allowed 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 178.128 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.45 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.36 138.35 0.09 Allowed 'General case' 0 C--N 1.305 -1.348 0 O-C-N 120.504 -1.373 . . . . 0.0 111.417 -179.178 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.604 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -157.47 156.7 4.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 178.135 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.538 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.1 m -97.88 144.75 27.13 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.747 -1.221 . . . . 0.0 109.884 -179.664 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.684 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.46 106.69 1.19 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 122.47 1.129 . . . . 0.0 109.44 178.61 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.523 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 16.9 p-10 -58.87 -138.62 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.621 179.848 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.543 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -56.38 -49.45 74.42 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.39 -0.819 . . . . 0.0 110.103 -178.976 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.406 ' CG ' ' N ' ' A' ' 61' ' ' GLY . 10.8 p-10 -98.21 -39.84 8.66 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 106.066 -1.827 . . . . 0.0 106.066 178.372 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.684 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 110.19 64.33 0.53 Allowed Glycine 0 C--N 1.296 -1.694 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.38 178.054 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.585 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 88.6 p -100.28 128.47 46.34 Favored 'General case' 0 C--N 1.309 -1.167 0 O-C-N 121.618 -0.93 . . . . 0.0 108.945 178.915 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.604 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.26 108.47 7.26 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.604 -0.839 . . . . 0.0 108.952 -179.814 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.466 ' OG ' ' HB1' ' A' ' 22' ' ' ALA . 1.5 m -128.64 121.33 28.37 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.288 -0.883 . . . . 0.0 109.977 -179.358 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.456 HG23 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -147.06 148.08 31.28 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.62 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 9.5 p -98.28 131.01 44.96 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.173 -0.955 . . . . 0.0 109.486 -179.737 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.512 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -127.23 164.52 21.51 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.507 -0.746 . . . . 0.0 109.338 -179.347 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.569 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.9 p -96.51 124.05 40.37 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.986 -1.071 . . . . 0.0 109.333 179.969 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.522 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.5 m -137.33 143.38 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 120.997 -1.064 . . . . 0.0 109.968 -179.211 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.546 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -141.52 -166.54 2.22 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.558 -1.338 . . . . 0.0 110.214 179.986 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.575 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -69.44 -89.13 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 119.687 -0.805 . . . . 0.0 108.837 -179.737 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.49 ' HB3' ' CG2' ' A' ' 85' ' ' THR . 0.9 OUTLIER -59.67 138.27 57.79 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 120.426 -1.421 . . . . 0.0 107.451 178.89 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.12 141.09 7.99 Favored 'General case' 0 C--N 1.294 -1.819 0 C-N-CA 118.148 -1.421 . . . . 0.0 110.351 -177.682 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.464 ' O ' ' O ' ' A' ' 47' ' ' CYS . 4.5 mm-40 -33.95 120.24 0.42 Allowed 'General case' 0 N--CA 1.491 1.62 0 CA-C-O 121.561 0.696 . . . . 0.0 110.7 -178.473 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -91.33 45.21 2.79 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.713 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.59 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -39.24 113.34 0.31 Allowed 'General case' 0 N--CA 1.508 2.474 0 O-C-N 121.099 -1.236 . . . . 0.0 110.298 179.782 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.527 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -86.43 127.36 34.83 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 120.857 -1.152 . . . . 0.0 109.556 -179.972 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -64.23 58.09 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.955 0 O-C-N 120.815 -1.178 . . . . 0.0 110.286 179.849 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 77' ' ' LEU . 10.7 t0 -160.92 19.57 0.13 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.983 -1.073 . . . . 0.0 109.833 179.771 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -26.78 5.28 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.918 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -91.72 154.44 18.97 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 121.031 -1.276 . . . . 0.0 110.387 -179.471 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.473 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -102.87 131.91 49.45 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.634 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.474 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -79.89 -19.15 48.89 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.758 -1.214 . . . . 0.0 110.238 -178.635 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.24 175.05 20.13 Favored Glycine 0 N--CA 1.485 1.966 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 -179.529 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.49 ' CG2' ' HB3' ' A' ' 72' ' ' SER . 0.9 OUTLIER -63.49 110.29 1.91 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 106.903 -1.518 . . . . 0.0 106.903 178.851 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.549 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 40.1 t -81.28 104.36 9.71 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 O-C-N 121.345 -0.847 . . . . 0.0 109.162 -178.642 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.472 ' CB ' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -63.98 110.64 2.2 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.479 -0.763 . . . . 0.0 109.735 -179.414 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.536 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.61 -5.13 4.98 Favored 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 118.137 -1.425 . . . . 0.0 109.839 179.42 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -84.41 -0.7 53.73 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.834 -1.166 . . . . 0.0 108.932 179.306 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.472 HG23 ' CB ' ' A' ' 87' ' ' ASP . 2.4 p -112.66 -50.02 2.91 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.346 -0.847 . . . . 0.0 108.995 179.911 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.12 -179.88 4.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.491 -0.756 . . . . 0.0 109.572 179.96 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.91 116.12 31.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.365 -0.834 . . . . 0.0 109.103 -179.954 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -96.83 122.24 39.57 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.884 -1.135 . . . . 0.0 109.555 -179.484 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.531 ' HA ' ' O ' ' A' ' 108' ' ' VAL . 1.0 OUTLIER -102.76 149.59 24.32 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.383 1.087 . . . . 0.0 111.421 -179.149 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.511 ' CG2' HG22 ' A' ' 110' ' ' ILE . 47.2 t -102.07 111.12 30.73 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 177.194 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -145.18 -174.96 17.91 Favored Glycine 0 N--CA 1.486 1.975 0 C-N-CA 118.49 -1.814 . . . . 0.0 111.46 -177.56 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.485 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.12 -179.83 4.16 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -178.779 . . . . . . . . 3 3 . 1 . 057 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.469 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.777 0 O-C-N 121.501 -0.749 . . . . 0.0 109.063 -179.498 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.755 0 N-CA-C 107.823 -2.111 . . . . 0.0 107.823 . . . . . . . . . 0 0 . 1 . 057 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.17 -178.58 7.3 Favored 'General case' 0 C--N 1.308 -1.222 0 O-C-N 121.484 -1.01 . . . . 0.0 109.573 179.074 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -178.63 -166.45 34.8 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 108.495 -1.842 . . . . 0.0 108.495 -179.457 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.472 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.0 Cg_exo -50.22 -175.15 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.63 0 CA-C-N 118.843 1.321 . . . . 0.0 110.279 179.561 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.61 -173.66 2.81 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.119 -0.988 . . . . 0.0 110.076 -179.179 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -125.25 169.95 17.2 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.817 . . . . . . . . 1 1 . 1 . 057 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.531 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -109.25 154.23 10.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -179.597 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.529 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -97.42 122.82 40.9 Favored 'General case' 0 C--N 1.291 -1.945 0 O-C-N 121.318 -0.864 . . . . 0.0 109.703 -179.888 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.518 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 1.6 pt -98.26 168.97 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.213 -0.929 . . . . 0.0 109.033 179.83 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.543 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.7 m -142.52 155.91 45.08 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.05 -1.031 . . . . 0.0 109.811 179.979 . . . . . . . . 2 2 . 1 . 057 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.575 ' CE2' ' HA ' ' A' ' 71' ' ' ARG . 31.4 m-85 . . . . . 0 N--CA 1.486 1.327 0 O-C-N 121.138 -0.976 . . . . 0.0 109.539 -179.642 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.451 0 CA-C-O 122.129 0.966 . . . . 0.0 110.81 . . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.54 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.2 p -105.01 104.4 14.13 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 122.435 1.112 . . . . 0.0 109.997 179.833 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.533 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 13.1 t -118.85 119.75 61.97 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.543 179.841 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.514 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.75 148.55 7.68 Favored Pre-proline 0 N--CA 1.486 1.352 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 -179.695 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.514 ' CA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -77.54 150.72 91.21 Favored 'Cis proline' 0 C--N 1.31 -1.476 0 C-N-CA 123.552 -1.437 . . . . 0.0 109.495 -0.458 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.483 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 80.4 p -89.29 -26.18 21.28 Favored 'General case' 0 C--N 1.293 -1.882 0 O-C-N 121.467 -0.77 . . . . 0.0 108.993 179.625 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.507 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 4.3 p -133.47 165.91 23.77 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.474 -0.766 . . . . 0.0 109.419 -179.941 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.7 38.27 37.51 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 -179.505 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.611 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 36.8 mt -92.56 -43.24 9.24 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 123.203 1.478 . . . . 0.0 110.624 -178.167 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.498 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 70.54 143.31 0.05 Allowed 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.453 -1.703 . . . . 0.0 109.774 -179.54 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.558 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 7.4 p-10 -50.57 104.59 0.08 Allowed 'General case' 0 C--N 1.301 -1.516 0 CA-C-O 121.558 0.694 . . . . 0.0 111.772 -178.447 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.409 ' H ' ' HB3' ' A' ' 70' ' ' ARG . . . 113.89 16.61 7.85 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 119.476 -1.345 . . . . 0.0 112.97 177.272 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.611 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.2 t -104.8 -171.23 1.88 Allowed 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 121.146 2.473 . . . . 0.0 109.693 179.11 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.575 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 16.4 t -130.37 140.02 49.9 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.246 -178.845 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.523 HG12 ' CG2' ' A' ' 69' ' ' VAL . 35.1 m -117.25 155.33 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 178.933 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.533 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.1 tttt -106.73 108.97 20.75 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.047 -1.033 . . . . 0.0 109.414 -179.817 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.528 HG12 ' CG2' ' A' ' 34' ' ' VAL . 2.1 p -107.47 123.13 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.723 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.54 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -114.67 164.49 13.97 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 120.745 -1.222 . . . . 0.0 108.938 179.82 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.581 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.56 107.51 0.53 Allowed Glycine 0 C--N 1.297 -1.628 0 N-CA-C 108.595 -1.802 . . . . 0.0 108.595 179.8 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.412 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -115.72 142.67 46.44 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.978 -1.307 . . . . 0.0 110.445 -179.134 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.03 27.26 45.97 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.577 -1.297 . . . . 0.0 109.93 179.357 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.545 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -90.84 174.24 7.56 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.069 -1.254 . . . . 0.0 108.574 179.974 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.553 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.42 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.966 -1.084 . . . . 0.0 109.517 -179.65 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.552 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.82 77.21 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.77 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.409 -178.97 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.553 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 132.7 34.66 0.34 Allowed Glycine 0 N--CA 1.487 2.066 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.407 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.54 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.0 p -145.0 112.54 6.2 Favored 'General case' 0 C--N 1.307 -1.272 0 O-C-N 121.031 -1.276 . . . . 0.0 111.083 -179.676 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.537 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -45.83 125.34 6.05 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-N 115.67 -0.695 . . . . 0.0 109.606 178.096 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.475 ' HA ' ' O ' ' A' ' 98' ' ' SER . 11.8 m-85 -118.13 149.87 40.31 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.325 -0.86 . . . . 0.0 108.697 179.692 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.483 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.27 158.35 15.93 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.614 -1.304 . . . . 0.0 107.742 178.635 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.566 ' CG1' ' HB3' ' A' ' 53' ' ' SER . 7.2 p -142.12 112.24 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.035 -1.041 . . . . 0.0 109.897 -177.798 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.486 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -160.57 -178.86 34.93 Favored Glycine 0 N--CA 1.494 2.538 0 C-N-CA 118.524 -1.798 . . . . 0.0 111.722 -179.62 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.6 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.1 pt20 -101.31 110.75 22.81 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.82 0.819 . . . . 0.0 108.922 -179.82 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -131.45 148.69 52.67 Favored 'General case' 0 C--N 1.295 -1.791 0 O-C-N 121.286 -0.884 . . . . 0.0 109.672 179.893 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.97 137.59 54.55 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.174 -0.954 . . . . 0.0 110.803 -178.936 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.636 ' CE2' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.73 114.57 26.32 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.096 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -104.78 14.11 7.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 120.979 -1.076 . . . . 0.0 110.65 -178.738 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.17 -174.53 0.07 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.942 -1.099 . . . . 0.0 110.081 179.725 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.8 p -72.73 98.66 2.43 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.504 -0.748 . . . . 0.0 109.622 -179.729 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.11 26.37 34.26 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.222 -0.99 . . . . 0.0 111.553 178.939 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.3 t -116.64 106.04 19.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 O-C-N 120.47 -1.606 . . . . 0.0 107.413 178.918 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.636 HD13 ' CE2' ' A' ' 39' ' ' TRP . 13.4 tp -118.98 104.47 10.53 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.517 -1.365 . . . . 0.0 109.681 -177.896 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.5 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.93 109.57 22.3 Favored 'General case' 0 N--CA 1.485 1.279 0 O-C-N 120.852 -1.155 . . . . 0.0 108.063 178.9 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -105.88 165.06 11.46 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.966 -1.084 . . . . 0.0 110.599 -178.699 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.504 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 50.2 t30 -113.18 130.87 23.19 Favored Pre-proline 0 N--CA 1.499 2.023 0 O-C-N 121.558 -0.714 . . . . 0.0 109.714 -179.3 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.8 Cg_endo -71.85 22.2 0.26 Allowed 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 122.188 1.926 . . . . 0.0 112.288 -179.986 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.504 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -108.65 2.02 21.67 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.39 -1.444 . . . . 0.0 108.929 179.393 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.498 ' O ' ' O ' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -138.05 14.43 2.85 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 179.475 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -78.13 91.28 4.3 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.908 -0.717 . . . . 0.0 110.974 -178.475 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.566 ' HB3' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -114.09 -173.11 2.22 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 178.198 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.533 ' N ' ' OG ' ' A' ' 53' ' ' SER . 12.3 t 179.68 139.35 0.12 Allowed 'General case' 0 C--N 1.306 -1.285 0 O-C-N 120.534 -1.354 . . . . 0.0 111.303 -179.134 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.595 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -152.71 160.59 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 178.123 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.537 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -97.61 144.53 27.19 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.593 -1.317 . . . . 0.0 110.168 -179.387 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.673 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.7 107.2 1.36 Allowed 'General case' 0 C--N 1.301 -1.537 0 CA-C-O 122.44 1.114 . . . . 0.0 109.338 178.415 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.512 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 13.6 p-10 -58.53 -138.16 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.852 -179.8 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.552 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -54.58 -49.74 69.67 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.348 -0.845 . . . . 0.0 110.202 -178.771 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . 0.404 ' CG ' ' N ' ' A' ' 61' ' ' GLY . 9.9 p-10 -101.41 -38.97 7.78 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 178.454 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.673 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 111.74 65.74 0.51 Allowed Glycine 0 C--N 1.297 -1.587 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.211 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.581 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 21.0 m -105.42 124.03 48.87 Favored 'General case' 0 N--CA 1.483 1.214 0 O-C-N 121.686 -0.89 . . . . 0.0 108.734 179.005 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.595 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -133.52 109.35 9.2 Favored 'General case' 0 C--N 1.295 -1.788 0 C-N-CA 119.899 -0.72 . . . . 0.0 109.388 -179.395 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -116.5 118.28 32.23 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.178 -0.951 . . . . 0.0 109.273 -179.901 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.411 HG21 HG12 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -143.68 141.08 30.38 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.405 -0.809 . . . . 0.0 109.679 -179.907 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 21.3 p -99.36 130.75 45.66 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.441 -0.787 . . . . 0.0 109.277 179.9 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.513 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.1 OUTLIER -128.18 165.56 20.2 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.332 -0.855 . . . . 0.0 109.376 -179.503 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.575 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.8 p -96.75 123.23 40.38 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.103 -0.998 . . . . 0.0 109.213 179.953 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.523 ' CG2' HG12 ' A' ' 19' ' ' VAL . 16.3 m -135.96 142.13 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.118 -0.989 . . . . 0.0 109.899 -179.232 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.558 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.2 ptt180 -137.6 -166.12 1.89 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.62 -1.3 . . . . 0.0 110.097 -179.946 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.583 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -73.92 -83.57 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.27 -0.894 . . . . 0.0 108.665 -179.686 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.54 138.68 58.53 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.343 -1.473 . . . . 0.0 107.185 178.631 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' O ' ' A' ' 71' ' ' ARG . 0.2 OUTLIER -164.04 137.05 5.19 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 117.879 -1.528 . . . . 0.0 110.459 -177.434 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.508 ' OE1' ' N ' ' A' ' 75' ' ' GLY . 0.6 OUTLIER -34.29 121.49 0.48 Allowed 'General case' 0 N--CA 1.491 1.595 0 CA-C-O 121.478 0.656 . . . . 0.0 110.302 -178.584 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.508 ' N ' ' OE1' ' A' ' 74' ' ' GLU . . . -93.73 50.34 2.3 Favored Glycine 0 N--CA 1.494 2.544 0 C-N-CA 120.451 -0.881 . . . . 0.0 111.205 -179.223 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 4.1 m-30 -39.81 113.34 0.33 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.032 -1.275 . . . . 0.0 110.025 179.468 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.538 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -84.7 127.1 33.93 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.884 -1.135 . . . . 0.0 109.638 -179.845 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -63.54 58.33 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.004 0 O-C-N 120.874 -1.141 . . . . 0.0 110.405 179.611 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.5 t0 -161.54 19.78 0.11 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.008 -1.057 . . . . 0.0 109.807 179.849 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.22 -26.91 5.31 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 110.171 -1.172 . . . . 0.0 110.171 179.937 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 37.0 p -92.95 156.26 17.04 Favored 'General case' 0 N--CA 1.486 1.36 0 O-C-N 121.031 -1.276 . . . . 0.0 110.332 -179.489 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.471 ' O ' ' HD2' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -104.49 133.75 48.83 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.707 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.477 ' HB2' HD12 ' A' ' 77' ' ' LEU . 1.6 t90 -80.26 -18.71 48.6 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.823 -1.173 . . . . 0.0 110.41 -178.566 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.93 175.93 20.97 Favored Glycine 0 N--CA 1.485 1.93 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -179.589 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -62.43 109.59 1.41 Allowed 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 179.138 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.55 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 31.4 t -82.54 105.39 12.33 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.967 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.468 ' CB ' HG22 ' A' ' 90' ' ' THR . 0.3 OUTLIER -65.76 112.32 3.66 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.402 -0.811 . . . . 0.0 109.904 -179.215 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.554 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.97 -4.79 4.96 Favored 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 118.208 -1.397 . . . . 0.0 109.863 179.398 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 p -85.71 -0.08 54.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.774 -1.204 . . . . 0.0 109.0 179.348 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.468 HG22 ' CB ' ' A' ' 87' ' ' ASP . 2.5 p -113.03 -49.71 2.91 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.297 -0.877 . . . . 0.0 109.063 179.949 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.8 179.77 4.13 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.581 -0.7 . . . . 0.0 109.505 179.93 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.93 115.7 31.11 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.301 -0.874 . . . . 0.0 109.219 -180.0 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.547 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.92 123.7 40.7 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.87 -1.143 . . . . 0.0 109.358 -179.469 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.535 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.52 148.46 25.93 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-O 122.446 1.117 . . . . 0.0 111.457 -179.171 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.496 ' CG1' HG12 ' A' ' 7' ' ' VAL . 61.8 t -102.4 109.66 27.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 N-CA-C 106.282 -1.748 . . . . 0.0 106.282 177.249 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -144.11 -175.41 17.22 Favored Glycine 0 N--CA 1.483 1.831 0 C-N-CA 118.318 -1.896 . . . . 0.0 111.563 -177.395 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.483 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -117.22 -177.82 3.3 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 -178.853 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.475 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.1 p . . . . . 0 C--N 1.297 -1.687 0 O-C-N 121.235 -0.916 . . . . 0.0 109.143 -179.26 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.712 0 N-CA-C 107.699 -2.16 . . . . 0.0 107.699 . . . . . . . . . 0 0 . 1 . 058 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.59 -178.68 7.44 Favored 'General case' 0 C--N 1.308 -1.198 0 O-C-N 121.415 -1.05 . . . . 0.0 109.866 179.118 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -177.67 -166.52 34.43 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 108.194 -1.962 . . . . 0.0 108.194 -179.477 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.47 ' HB2' HD11 ' A' ' 97' ' ' LEU . 5.4 Cg_exo -48.42 179.26 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.659 0 CA-C-N 118.94 1.37 . . . . 0.0 110.148 179.483 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -91.85 -175.2 4.06 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.055 -1.028 . . . . 0.0 110.516 -178.717 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -122.05 161.7 16.1 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.848 . . . . . . . . 1 1 . 1 . 058 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.62 133.09 49.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.364 -1.08 . . . . 0.0 109.278 -179.242 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.535 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -76.04 122.09 23.73 Favored 'General case' 0 C--N 1.289 -2.054 0 O-C-N 121.485 -0.76 . . . . 0.0 109.716 179.703 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.566 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.99 174.0 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.924 . . . . 0.0 109.23 179.837 . . . . . . . . 2 2 . 1 . 058 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.507 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.6 OUTLIER -140.21 158.19 44.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.048 -1.032 . . . . 0.0 109.838 -179.778 . . . . . . . . 3 3 . 1 . 058 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.566 ' CE2' HD12 ' A' ' 110' ' ' ILE . 96.5 m-85 . . . . . 0 N--CA 1.485 1.282 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 -179.808 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.473 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.405 0 CA-C-O 122.173 0.987 . . . . 0.0 110.757 . . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.546 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.1 p -105.41 104.62 14.38 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 122.558 1.17 . . . . 0.0 109.911 179.983 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.531 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 14.5 t -118.97 126.34 75.27 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.407 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.535 179.875 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.487 HG21 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -170.57 149.37 2.99 Favored Pre-proline 0 N--CA 1.486 1.361 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 -179.642 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG21 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.64 153.23 99.05 Favored 'Cis proline' 0 C--N 1.31 -1.465 0 C-N-CA 123.678 -1.384 . . . . 0.0 109.894 -0.522 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.464 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 6.6 m -95.73 -22.6 17.43 Favored 'General case' 0 C--N 1.294 -1.846 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 179.564 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.43 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.9 m -135.59 162.85 31.55 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.491 -0.756 . . . . 0.0 109.496 179.921 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.11 37.6 37.23 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 108.503 -1.839 . . . . 0.0 108.503 -179.556 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.637 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 27.3 mt -90.59 -45.47 8.89 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-O 123.116 1.436 . . . . 0.0 110.644 -178.373 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 63.82 147.24 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.325 0 CA-C-N 113.69 -1.596 . . . . 0.0 109.974 -179.699 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.595 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -51.48 109.33 0.34 Allowed 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 121.556 0.694 . . . . 0.0 111.721 -178.652 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.04 12.98 11.42 Favored Glycine 0 N--CA 1.485 1.966 0 C-N-CA 119.478 -1.344 . . . . 0.0 112.873 177.339 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.637 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 9.7 t -101.42 -174.35 2.58 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 121.057 2.428 . . . . 0.0 109.763 179.479 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.546 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 14.8 t -131.28 138.48 53.14 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.38 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.813 -178.982 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.494 ' CG1' ' CG2' ' A' ' 69' ' ' VAL . 35.0 m -117.43 154.4 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.365 -0.835 . . . . 0.0 109.135 179.082 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.531 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -110.12 109.25 19.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.957 . . . . 0.0 109.149 179.881 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.537 HG12 ' CD1' ' A' ' 67' ' ' LEU . 2.4 p -107.39 124.6 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.964 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.546 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -114.08 165.08 13.0 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.845 -1.159 . . . . 0.0 108.858 179.489 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.618 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.39 107.5 0.53 Allowed Glycine 0 C--N 1.296 -1.692 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 179.971 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.41 141.09 48.63 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 120.743 -1.445 . . . . 0.0 110.796 -179.072 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.09 26.5 44.29 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.033 179.145 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -90.35 172.29 8.85 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.028 -1.278 . . . . 0.0 108.575 -179.992 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.559 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.18 99.97 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.081 -1.012 . . . . 0.0 109.652 -179.685 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.0 76.96 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.118 -179.036 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.41 33.39 0.27 Allowed Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.517 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.531 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 54.1 p -141.14 109.47 5.88 Favored 'General case' 0 C--N 1.307 -1.25 0 O-C-N 121.015 -1.285 . . . . 0.0 111.152 -179.714 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.94 110.08 0.39 Allowed 'General case' 0 N--CA 1.496 1.858 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.909 178.314 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.458 ' OH ' ' HB2' ' A' ' 27' ' ' GLN . 18.6 m-85 -104.25 154.76 19.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.146 -0.971 . . . . 0.0 108.74 179.396 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.44 ' HA ' ' OG ' ' A' ' 54' ' ' SER . 0.3 OUTLIER -98.96 165.23 11.85 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 178.545 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.62 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.0 p -143.4 120.47 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.092 -1.005 . . . . 0.0 109.493 -177.807 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -168.75 179.91 41.32 Favored Glycine 0 N--CA 1.491 2.312 0 C-N-CA 118.264 -1.922 . . . . 0.0 111.614 -179.806 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.618 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -101.96 109.79 21.6 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.715 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 58.2 m -128.87 152.75 48.17 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.347 -0.846 . . . . 0.0 110.319 -179.828 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.52 136.36 51.63 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.64 -0.662 . . . . 0.0 110.126 179.65 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.631 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.4 114.73 26.81 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 178.369 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -106.6 15.3 7.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 120.964 -1.085 . . . . 0.0 110.762 -178.636 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.596 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.24 -175.63 0.08 Allowed 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.894 -1.129 . . . . 0.0 110.112 179.604 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.551 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.3 t -69.63 97.0 0.99 Allowed 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.741 0.781 . . . . 0.0 110.02 -179.404 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.8 28.46 34.95 Favored Glycine 0 N--CA 1.492 2.415 0 C-N-CA 120.225 -0.988 . . . . 0.0 111.38 178.694 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.596 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.09 106.09 19.9 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 O-C-N 120.531 -1.57 . . . . 0.0 107.432 178.836 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.631 HD12 ' CD1' ' A' ' 39' ' ' TRP . 11.8 tp -116.31 106.66 13.9 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.541 -1.349 . . . . 0.0 109.941 -177.552 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.55 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -95.93 110.12 22.38 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 120.759 -1.213 . . . . 0.0 108.028 179.186 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 68.2 m -98.91 144.91 27.56 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.259 -0.901 . . . . 0.0 110.846 -178.132 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.511 ' ND2' ' HG2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.48 131.08 48.95 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.415 -0.803 . . . . 0.0 109.076 179.299 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.58 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 6.8 Cg_endo -75.68 31.02 0.38 Allowed 'Trans proline' 0 C--N 1.314 -1.266 0 C-N-CA 122.267 1.978 . . . . 0.0 111.323 179.898 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.465 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . -122.14 -1.69 9.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.42 -1.425 . . . . 0.0 110.299 -179.231 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.542 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 20.4 m-20 -137.55 10.31 2.93 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.039 -1.038 . . . . 0.0 109.115 -179.68 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -64.0 84.1 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.292 -179.108 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.62 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -110.82 -169.0 1.38 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.164 -0.96 . . . . 0.0 108.557 179.081 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.467 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.32 135.22 0.08 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.783 -1.198 . . . . 0.0 111.288 -179.348 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.587 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -147.48 159.29 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 177.915 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.29 142.96 29.29 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.707 -1.245 . . . . 0.0 110.246 -179.52 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.666 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.75 107.08 1.34 Allowed 'General case' 0 C--N 1.299 -1.593 0 CA-C-O 122.404 1.097 . . . . 0.0 109.367 178.323 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.526 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.5 t0 -60.59 -138.97 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.039 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.022 -179.889 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.72 -51.11 53.06 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.427 -0.796 . . . . 0.0 110.66 -178.552 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 11.9 t30 -104.19 -34.28 8.43 Favored 'General case' 0 C--N 1.286 -2.185 0 N-CA-C 106.182 -1.785 . . . . 0.0 106.182 178.472 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.666 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.72 67.93 0.61 Allowed Glycine 0 C--N 1.296 -1.647 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 178.182 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.618 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.8 m -104.67 124.48 49.44 Favored 'General case' 0 N--CA 1.483 1.194 0 O-C-N 121.612 -0.934 . . . . 0.0 108.739 179.004 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.587 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -132.88 109.21 9.45 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.906 -0.718 . . . . 0.0 109.223 -179.609 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 14.7 m -118.37 118.77 32.66 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.302 -0.874 . . . . 0.0 109.611 -179.621 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.424 HG22 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.86 140.29 28.27 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.505 -0.747 . . . . 0.0 109.684 179.805 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 66' ' ' SER . . . . . 0.427 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 19.2 p -98.83 136.05 39.4 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.466 -0.771 . . . . 0.0 109.079 179.758 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.546 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -133.35 173.79 11.09 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.339 -0.851 . . . . 0.0 109.687 -178.887 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.523 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -100.18 125.01 46.27 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.933 -1.105 . . . . 0.0 109.01 179.918 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.532 ' CG2' HD11 ' A' ' 13' ' ' LEU . 15.9 m -132.19 142.13 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 120.764 -1.21 . . . . 0.0 110.06 -178.986 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.595 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.9 ptt180 -147.71 -170.48 3.58 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 120.563 -1.336 . . . . 0.0 110.827 -179.945 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.614 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -67.22 -102.68 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.821 -0.549 . . . . 0.0 109.932 -179.329 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.08 134.98 56.92 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.359 -1.463 . . . . 0.0 108.152 179.714 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.618 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -153.78 156.92 38.6 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.584 -1.246 . . . . 0.0 110.298 -178.683 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.539 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 1.6 mm-40 -53.15 119.4 4.67 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.277 -0.889 . . . . 0.0 109.368 -178.736 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.55 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -90.39 54.04 3.5 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.311 -178.9 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.58 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 5.3 m-30 -40.35 115.92 0.61 Allowed 'General case' 0 N--CA 1.504 2.271 0 O-C-N 120.947 -1.325 . . . . 0.0 110.173 179.487 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.529 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.1 tp -87.46 126.85 35.14 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 120.806 -1.184 . . . . 0.0 109.488 -179.834 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -64.18 58.38 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.972 0 O-C-N 120.837 -1.165 . . . . 0.0 110.132 179.702 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.4 t70 -160.37 19.66 0.15 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.028 -1.045 . . . . 0.0 109.717 179.772 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.75 -27.44 5.36 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 179.856 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 46.4 p -94.9 162.44 13.75 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 120.98 -1.306 . . . . 0.0 110.402 -179.46 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.47 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 2.2 ptm180 -108.14 138.0 45.15 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.921 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.473 ' HB2' HD12 ' A' ' 77' ' ' LEU . 2.9 t90 -83.4 -18.6 38.21 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.769 -1.207 . . . . 0.0 110.443 -178.656 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.99 175.05 19.79 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 108.766 -1.734 . . . . 0.0 108.766 -179.632 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.94 106.2 0.98 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.119 -1.224 . . . . 0.0 107.898 179.227 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.618 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 40.7 t -78.25 104.35 6.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.021 -179.041 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.526 ' CB ' HG22 ' A' ' 90' ' ' THR . 0.5 OUTLIER -62.99 107.9 1.1 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.55 -0.719 . . . . 0.0 110.164 -179.141 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.566 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.4 t -61.42 -4.26 1.23 Allowed 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.255 -1.378 . . . . 0.0 110.38 179.298 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.2 p -90.98 7.09 42.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.562 -1.336 . . . . 0.0 109.407 -179.933 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.526 HG22 ' CB ' ' A' ' 87' ' ' ASP . 2.2 p -119.35 -47.76 2.44 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.292 -0.88 . . . . 0.0 109.16 179.941 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.6 -178.4 3.64 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.562 -0.711 . . . . 0.0 109.589 179.988 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.81 111.99 24.58 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.381 -0.824 . . . . 0.0 108.856 179.859 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.471 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.5 m -97.22 121.06 38.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.036 -1.04 . . . . 0.0 109.445 -178.966 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.559 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.17 147.36 27.12 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.474 1.13 . . . . 0.0 111.646 -179.05 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.484 ' CG1' HG11 ' A' ' 7' ' ' VAL . 92.3 t -102.95 109.65 27.38 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 177.259 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.453 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.84 -169.45 17.37 Favored Glycine 0 N--CA 1.484 1.88 0 C-N-CA 118.073 -2.013 . . . . 0.0 111.628 -177.258 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.487 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -121.24 176.8 5.43 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -178.897 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.487 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 6.9 t . . . . . 0 C--N 1.292 -1.897 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 -179.963 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . 0.431 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.481 1.666 0 N-CA-C 107.992 -2.043 . . . . 0.0 107.992 . . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.54 -177.08 3.82 Favored 'General case' 0 C--N 1.307 -1.262 0 O-C-N 121.574 -0.957 . . . . 0.0 109.984 179.395 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.56 -161.41 21.1 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 108.068 -2.013 . . . . 0.0 108.068 -179.397 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.9 Cg_exo -45.77 172.63 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.632 0 CA-C-N 118.978 1.389 . . . . 0.0 109.933 179.194 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -92.9 -174.49 3.61 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.092 -1.005 . . . . 0.0 110.56 -178.772 . . . . . . . . 1 1 . 1 . 059 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.453 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.48 166.31 14.35 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.876 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.424 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.0 131.16 50.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.416 -1.049 . . . . 0.0 109.124 -179.428 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.559 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.61 123.77 24.63 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.594 -0.691 . . . . 0.0 109.519 179.713 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.51 HD11 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.84 171.74 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.232 -0.917 . . . . 0.0 109.183 179.901 . . . . . . . . 2 2 . 1 . 059 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.43 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -138.15 157.78 45.62 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.279 -0.888 . . . . 0.0 109.92 -179.712 . . . . . . . . 3 3 . 1 . 059 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.51 ' CE1' HD11 ' A' ' 110' ' ' ILE . 38.8 m-85 . . . . . 0 N--CA 1.487 1.376 0 O-C-N 121.273 -0.892 . . . . 0.0 109.543 -179.741 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.278 0 CA-C-O 122.454 1.121 . . . . 0.0 110.452 . . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 6' ' ' THR . . . . . 0.544 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.3 t -115.58 109.24 17.5 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.123 1.44 . . . . 0.0 109.72 -179.935 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.1 t -114.53 135.75 53.35 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.285 -1.325 . . . . 0.0 109.582 179.886 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.524 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.69 150.42 2.62 Favored Pre-proline 0 N--CA 1.487 1.407 0 O-C-N 121.151 -0.968 . . . . 0.0 108.95 -179.639 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.524 ' CA ' HG23 ' A' ' 8' ' ' THR . 6.0 Cg_endo -78.63 150.2 86.86 Favored 'Cis proline' 0 C--N 1.313 -1.305 0 C-N-CA 123.392 -1.503 . . . . 0.0 109.341 -0.965 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.457 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 84.6 p -92.91 -22.65 19.11 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.552 -0.718 . . . . 0.0 109.306 179.894 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 11' ' ' SER . . . . . 0.493 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 4.3 m -130.91 159.64 36.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.345 -0.847 . . . . 0.0 109.644 -179.838 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.55 37.34 31.13 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 108.542 -1.823 . . . . 0.0 108.542 -179.676 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.598 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 33.6 mt -90.92 -44.29 9.46 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 123.14 1.447 . . . . 0.0 110.691 -178.479 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.478 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.26 144.41 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.249 0 CA-C-N 113.555 -1.657 . . . . 0.0 109.687 -179.538 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.59 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.4 p-10 -51.54 109.24 0.33 Allowed 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.495 0.664 . . . . 0.0 111.483 -178.612 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.43 10.85 12.56 Favored Glycine 0 N--CA 1.485 1.955 0 C-N-CA 119.391 -1.385 . . . . 0.0 112.83 177.374 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.598 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.9 t -101.97 -171.37 1.96 Allowed 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 121.051 2.425 . . . . 0.0 109.876 179.575 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.535 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 19.1 t -131.19 142.41 43.53 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.76 -179.058 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.474 HG23 ' CG2' ' A' ' 69' ' ' VAL . 35.4 m -118.55 155.58 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.277 -0.889 . . . . 0.0 108.764 179.209 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 6.1 tttt -108.02 109.23 20.64 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.162 -0.961 . . . . 0.0 109.288 -179.984 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.532 HG12 ' CG2' ' A' ' 34' ' ' VAL . 10.4 p -101.36 138.92 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.71 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.595 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -135.68 161.24 36.11 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 118.698 -1.201 . . . . 0.0 110.127 179.689 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.94 140.92 12.0 Favored Glycine 0 C--O 1.209 -1.444 0 N-CA-C 107.928 -2.069 . . . . 0.0 107.928 179.621 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -143.06 125.05 15.21 Favored 'General case' 0 N--CA 1.494 1.756 0 CA-C-N 119.266 1.533 . . . . 0.0 109.395 179.387 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.64 28.22 19.75 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 118.755 -1.688 . . . . 0.0 109.619 -179.728 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.552 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.6 mt -88.74 171.32 10.06 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.866 -1.373 . . . . 0.0 108.089 179.906 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.555 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.79 100.25 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.901 -1.124 . . . . 0.0 109.981 -179.424 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.58 77.21 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.946 -179.347 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.01 33.88 0.24 Allowed Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.717 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 30' ' ' THR . . . . . 0.556 ' OG1' ' CE1' ' A' ' 32' ' ' TYR . 36.3 p -141.26 107.47 5.23 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.082 -1.246 . . . . 0.0 111.311 -179.422 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . 0.555 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -49.49 109.78 0.31 Allowed 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 177.93 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . 0.58 ' CG ' ' O ' ' A' ' 98' ' ' SER . 4.4 m-30 -101.24 156.1 17.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.168 -0.957 . . . . 0.0 109.009 179.83 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.479 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -99.98 163.71 12.32 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 178.503 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.618 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.4 p -147.77 117.85 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.891 -1.131 . . . . 0.0 110.05 -177.928 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.478 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -171.28 -175.91 40.04 Favored Glycine 0 N--CA 1.494 2.501 0 C-N-CA 118.346 -1.883 . . . . 0.0 111.724 -179.862 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . 0.563 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -100.42 108.87 20.97 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.748 0.785 . . . . 0.0 108.946 -179.818 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.39 148.27 52.19 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.269 -0.894 . . . . 0.0 109.676 179.431 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -121.19 137.55 54.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.265 -0.897 . . . . 0.0 110.932 -178.839 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 39' ' ' TRP . . . . . 0.628 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.64 114.68 26.45 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.114 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.465 HG21 ' HB ' ' A' ' 44' ' ' VAL . 15.0 m -105.03 14.4 7.24 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 120.95 -1.094 . . . . 0.0 110.573 -178.715 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.592 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.03 -175.36 0.07 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.987 -1.071 . . . . 0.0 110.091 179.729 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.546 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.0 t -71.69 99.05 2.04 Favored 'General case' 0 N--CA 1.486 1.347 0 CA-C-O 121.829 0.823 . . . . 0.0 109.812 -179.641 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.77 26.57 37.71 Favored Glycine 0 N--CA 1.494 2.549 0 C-N-CA 120.179 -1.01 . . . . 0.0 111.46 178.957 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.592 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.4 t -116.16 106.25 19.98 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 O-C-N 120.576 -1.544 . . . . 0.0 107.356 178.891 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . 0.628 HD12 ' CD1' ' A' ' 39' ' ' TRP . 13.2 tp -117.93 104.34 10.82 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.471 -1.393 . . . . 0.0 109.73 -177.694 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.534 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.73 109.66 22.37 Favored 'General case' 0 N--CA 1.485 1.311 0 O-C-N 120.776 -1.203 . . . . 0.0 108.07 178.88 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -107.26 163.35 13.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.016 -1.053 . . . . 0.0 110.467 -178.705 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.517 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 17.0 t30 -111.29 136.77 20.91 Favored Pre-proline 0 N--CA 1.502 2.136 0 O-C-N 121.414 -0.803 . . . . 0.0 109.75 -179.463 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.577 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.7 Cg_endo -73.57 25.67 0.32 Allowed 'Trans proline' 0 C--N 1.319 -1.007 0 C-N-CA 122.463 2.109 . . . . 0.0 112.335 -179.63 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . 0.501 ' HB3' ' CG2' ' A' ' 68' ' ' THR . . . -112.66 3.07 16.41 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.272 -1.518 . . . . 0.0 109.326 179.588 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 51' ' ' ASP . . . . . 0.489 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.45 18.97 2.22 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 179.592 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -79.94 92.06 5.5 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.867 -0.733 . . . . 0.0 110.866 -178.867 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 53' ' ' SER . . . . . 0.618 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -114.47 -168.85 1.43 Allowed 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 178.367 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.471 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.9 134.88 0.09 Allowed 'General case' 0 C--N 1.304 -1.372 0 O-C-N 120.597 -1.315 . . . . 0.0 111.214 -179.402 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.572 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 2.0 p -148.98 157.2 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.233 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.555 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.26 142.62 29.69 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.709 -1.244 . . . . 0.0 109.874 -179.85 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . 0.673 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -65.36 108.15 1.86 Allowed 'General case' 0 C--N 1.299 -1.626 0 CA-C-O 122.337 1.065 . . . . 0.0 109.649 178.706 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.535 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.1 t0 -63.84 -138.8 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.003 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.816 179.888 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.81 -52.04 45.07 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.361 -0.837 . . . . 0.0 110.697 -178.677 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -101.74 -33.6 9.78 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 178.517 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.673 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 104.51 65.92 0.69 Allowed Glycine 0 C--N 1.298 -1.532 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 178.221 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 55.9 p -98.53 132.41 43.98 Favored 'General case' 0 N--CA 1.482 1.153 0 O-C-N 121.489 -1.007 . . . . 0.0 109.177 179.074 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.595 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -138.63 108.57 6.33 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 119.255 -0.978 . . . . 0.0 109.567 -179.658 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.458 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 6.0 m -127.11 120.32 28.6 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.272 -0.892 . . . . 0.0 109.681 -179.878 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.447 HG22 HG12 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.09 142.72 28.81 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.55 -0.719 . . . . 0.0 109.277 179.794 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.9 p -98.81 131.69 44.74 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.287 -0.883 . . . . 0.0 109.212 179.985 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.518 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -135.6 169.4 17.59 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.288 -0.882 . . . . 0.0 109.569 -179.349 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 68' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 11.3 t -95.29 137.74 33.93 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.091 -1.006 . . . . 0.0 110.559 -179.425 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.511 ' CB ' ' OE1' ' A' ' 36' ' ' GLN . 18.3 m -148.24 143.55 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.381 -0.824 . . . . 0.0 109.536 -179.891 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.59 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.0 OUTLIER -149.95 -174.65 4.77 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.497 -1.377 . . . . 0.0 110.807 -179.863 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 71' ' ' ARG . . . . . 0.569 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.86 -102.06 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.414 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.637 -179.458 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -56.49 141.89 40.97 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.831 -1.168 . . . . 0.0 108.577 179.814 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -163.34 137.26 5.91 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 118.836 -1.146 . . . . 0.0 109.633 -178.402 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.517 ' N ' ' OD1' ' A' ' 48' ' ' ASN . 17.4 mm-40 -33.56 122.1 0.42 Allowed 'General case' 0 N--CA 1.49 1.571 0 CA-C-O 121.559 0.695 . . . . 0.0 110.78 -178.12 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.534 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -91.32 46.91 2.83 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.321 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 76' ' ' PHE . . . . . 0.577 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.1 m-85 -39.64 112.02 0.23 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.073 -1.251 . . . . 0.0 109.856 179.568 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.9 tp -85.46 126.44 33.82 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.895 -1.128 . . . . 0.0 109.37 -179.927 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 37.5 t80 -63.89 58.39 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.933 -1.104 . . . . 0.0 110.168 179.833 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 4.9 t70 -160.38 19.3 0.14 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.037 -1.039 . . . . 0.0 109.709 179.913 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.51 -26.5 5.74 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 179.808 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 60.5 p -94.06 158.63 15.53 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.033 -1.275 . . . . 0.0 110.418 -179.346 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -105.08 133.43 49.87 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.698 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 83' ' ' TRP . . . . . 0.476 ' CD1' HD13 ' A' ' 77' ' ' LEU . 1.9 t90 -81.43 -18.9 43.76 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.883 -1.135 . . . . 0.0 110.37 -178.573 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.34 174.83 19.57 Favored Glycine 0 N--CA 1.485 1.962 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.653 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.1 105.96 0.97 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.112 -1.228 . . . . 0.0 107.72 179.085 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.578 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 43.6 t -76.95 105.99 6.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.306 -0.871 . . . . 0.0 109.27 -178.824 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -66.4 111.14 3.39 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.359 -0.838 . . . . 0.0 109.821 -179.524 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 88' ' ' CYS . . . . . 0.569 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -62.74 -6.09 3.34 Favored 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 118.225 -1.39 . . . . 0.0 109.875 179.42 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -86.13 -1.26 57.24 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.716 -1.24 . . . . 0.0 109.163 179.63 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.453 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.47 -49.6 2.99 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.338 -0.851 . . . . 0.0 109.005 179.905 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.27 179.15 4.34 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.415 -0.803 . . . . 0.0 109.438 179.924 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.54 116.22 32.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.322 -0.861 . . . . 0.0 108.952 179.928 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 93' ' ' CYS . . . . . 0.564 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.72 124.7 40.78 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.815 -1.178 . . . . 0.0 109.535 -179.478 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 94' ' ' GLN . . . . . 0.551 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -105.15 147.87 27.49 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 122.515 1.15 . . . . 0.0 111.451 -179.152 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . 0.42 HG21 HG22 ' A' ' 110' ' ' ILE . 57.6 t -104.49 110.55 30.93 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.04 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 177.43 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -148.47 -171.29 17.18 Favored Glycine 0 N--CA 1.488 2.157 0 C-N-CA 118.123 -1.989 . . . . 0.0 111.89 -177.562 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . 0.479 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.77 -179.62 3.74 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.023 . . . . . . . . 3 3 . 1 . 060 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.58 ' O ' ' CG ' ' A' ' 32' ' ' TYR . 1.5 p . . . . . 0 C--N 1.296 -1.729 0 O-C-N 121.367 -0.833 . . . . 0.0 109.715 -179.524 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.783 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 . . . . . . . . . 0 0 . 1 . 060 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -153.88 -179.62 8.01 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.466 -1.02 . . . . 0.0 109.345 178.8 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -172.45 -166.28 30.79 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 108.631 -1.788 . . . . 0.0 108.631 -179.44 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.0 Cg_exo -49.93 -175.64 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.668 0 CA-C-N 118.759 1.279 . . . . 0.0 110.32 179.603 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 -94.43 -179.27 4.85 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.059 -1.026 . . . . 0.0 110.506 -178.843 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -119.95 162.64 14.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.992 . . . . . . . . 1 1 . 1 . 060 nuclear orig core ' A' A ' 108' ' ' VAL . . . . . 0.463 HG21 HG21 ' A' ' 7' ' ' VAL . 1.2 t -101.17 128.42 53.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.334 -1.098 . . . . 0.0 109.165 -179.389 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 109' ' ' ALA . . . . . 0.551 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.71 124.02 26.56 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.59 -0.694 . . . . 0.0 109.552 179.669 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 110' ' ' ILE . . . . . 0.536 HD13 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.75 167.79 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.21 -0.931 . . . . 0.0 109.234 -179.913 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.493 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 15.2 m -137.0 156.33 48.58 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.276 -0.89 . . . . 0.0 109.481 -179.931 . . . . . . . . 2 2 . 1 . 060 nuclear orig core ' A' A ' 112' ' ' PHE . . . . . 0.536 ' CZ ' HD13 ' A' ' 110' ' ' ILE . 17.5 m-85 . . . . . 0 N--CA 1.486 1.347 0 O-C-N 121.204 -0.935 . . . . 0.0 109.523 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -87.18 160.16 49.43 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.255 -0.903 . . . . 0.0 109.417 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.529 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.2 Cg_exo -60.01 157.88 32.16 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.335 2.024 . . . . 0.0 110.585 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.539 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.62 -169.77 0.15 Allowed 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.204 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.539 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.61 130.39 2.4 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 120.859 -1.15 . . . . 0.0 110.683 -179.165 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.546 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.9 t -111.21 108.54 18.23 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-O 123.11 1.433 . . . . 0.0 109.167 179.379 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.523 HG12 ' CG1' ' A' ' 95' ' ' VAL . 2.7 t -115.39 140.33 37.4 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.681 0 CA-C-N 114.255 -1.339 . . . . 0.0 110.08 -179.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.512 HG22 ' N ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -175.72 149.78 1.09 Allowed Pre-proline 0 N--CA 1.487 1.422 0 O-C-N 121.305 -0.872 . . . . 0.0 108.728 -179.656 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.512 ' N ' HG22 ' A' ' 8' ' ' THR . 2.2 Cg_endo -75.66 152.33 97.04 Favored 'Cis proline' 0 C--N 1.311 -1.408 0 C-N-CA 123.422 -1.491 . . . . 0.0 109.371 -0.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.493 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 10.9 m -90.69 -24.64 20.39 Favored 'General case' 0 C--N 1.293 -1.887 0 O-C-N 121.605 -0.684 . . . . 0.0 109.191 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.516 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.4 m -137.16 165.32 26.36 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.44 -0.788 . . . . 0.0 109.59 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.5 38.62 32.46 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.611 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.6 mt -92.79 -43.95 8.76 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 123.152 1.453 . . . . 0.0 110.736 -178.2 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.05 145.47 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.274 0 CA-C-N 113.597 -1.638 . . . . 0.0 110.156 -179.912 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.548 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.2 p-10 -51.16 106.84 0.15 Allowed 'General case' 0 C--N 1.301 -1.517 0 CA-C-O 121.461 0.648 . . . . 0.0 111.526 -178.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.79 14.76 9.15 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.43 -1.367 . . . . 0.0 112.969 177.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.611 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.4 t -104.24 -171.94 2.02 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 121.075 2.437 . . . . 0.0 109.544 179.152 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.544 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 16.2 t -128.59 136.05 60.89 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.392 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.116 -179.065 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.528 ' CG1' ' CG2' ' A' ' 69' ' ' VAL . 20.6 m -111.52 155.55 12.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.501 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 11.1 tttt -112.31 109.31 18.88 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.192 -0.942 . . . . 0.0 108.954 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.52 HG12 ' CG2' ' A' ' 34' ' ' VAL . 2.1 p -103.63 140.51 21.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.544 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -135.54 160.22 39.15 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.842 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.18 144.56 15.82 Favored Glycine 0 C--N 1.294 -1.783 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.511 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.51 125.11 12.47 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 120.891 -1.358 . . . . 0.0 108.844 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.529 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.89 26.64 26.15 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.28 -1.438 . . . . 0.0 109.864 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.543 ' HB2' ' HB1' ' A' ' 57' ' ' ALA . 1.4 mt -87.79 174.89 8.11 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 120.885 -1.362 . . . . 0.0 108.596 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.559 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.79 99.58 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.4 0 O-C-N 120.987 -1.071 . . . . 0.0 109.766 -179.696 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.2 78.01 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.124 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.98 34.23 0.3 Allowed Glycine 0 N--CA 1.487 2.098 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.541 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.5 p -141.29 107.5 5.23 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 121.111 -1.229 . . . . 0.0 111.249 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.56 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -49.72 109.96 0.33 Allowed 'General case' 0 N--CA 1.498 1.938 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.638 178.076 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.546 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 4.6 m-30 -106.25 154.04 21.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.126 -0.984 . . . . 0.0 108.837 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.477 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.86 162.75 12.93 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.863 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.626 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.5 p -142.63 116.5 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.048 -1.032 . . . . 0.0 109.628 -178.161 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.485 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.69 -175.79 37.19 Favored Glycine 0 N--CA 1.494 2.501 0 C-N-CA 118.353 -1.879 . . . . 0.0 111.67 -179.655 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.581 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -100.73 109.65 21.69 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-O 121.899 0.857 . . . . 0.0 109.038 -179.597 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.459 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -129.94 149.88 51.47 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.275 -0.891 . . . . 0.0 109.634 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.33 139.21 53.89 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.166 -0.959 . . . . 0.0 110.796 -178.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.625 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 114.95 26.79 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.038 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.0 m -105.13 15.03 6.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 120.906 -1.121 . . . . 0.0 110.584 -178.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.589 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.78 -175.06 0.08 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.904 -1.123 . . . . 0.0 110.0 179.79 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.03 97.59 1.92 Allowed 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.465 -0.772 . . . . 0.0 109.687 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.65 27.89 33.97 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 120.258 -0.972 . . . . 0.0 111.392 178.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.589 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.38 106.41 20.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 O-C-N 120.576 -1.543 . . . . 0.0 107.313 178.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.625 HD13 ' CD1' ' A' ' 39' ' ' TRP . 11.8 tp -115.86 104.68 11.87 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 120.486 -1.384 . . . . 0.0 109.896 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.18 109.47 22.22 Favored 'General case' 0 N--CA 1.484 1.238 0 O-C-N 120.81 -1.182 . . . . 0.0 107.917 178.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.63 166.57 10.58 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.914 -1.116 . . . . 0.0 110.484 -178.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.522 ' ND2' ' HB2' ' A' ' 50' ' ' ALA . 47.6 t30 -112.06 129.77 23.93 Favored Pre-proline 0 N--CA 1.501 2.1 0 O-C-N 121.488 -0.758 . . . . 0.0 109.583 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.56 21.05 0.25 Allowed 'Trans proline' 0 C--N 1.319 -1.024 0 C-N-CA 122.132 1.888 . . . . 0.0 112.268 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.522 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -109.55 3.49 21.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.334 -1.479 . . . . 0.0 108.977 179.336 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.518 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.34 17.23 2.76 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 179.382 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -80.6 87.77 5.74 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.987 -0.685 . . . . 0.0 111.143 -178.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -104.2 -165.82 1.19 Allowed 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 178.159 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.464 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.89 137.13 0.09 Allowed 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.532 -1.355 . . . . 0.0 111.382 -179.306 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.581 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -155.5 157.09 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 178.21 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.56 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.63 142.34 30.33 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.746 -1.222 . . . . 0.0 109.911 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.687 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.34 106.83 0.96 Allowed 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 122.476 1.131 . . . . 0.0 109.406 178.481 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.526 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.6 p-10 -60.4 -139.56 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.893 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.16 -50.9 58.04 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.4 -0.813 . . . . 0.0 110.666 -178.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -103.55 -33.15 9.12 Favored 'General case' 0 C--N 1.287 -2.137 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 178.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.687 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.66 65.34 0.6 Allowed Glycine 0 C--N 1.298 -1.556 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.574 178.084 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.6 m -102.05 128.37 48.53 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 121.481 -1.011 . . . . 0.0 108.635 178.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.581 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.7 108.84 6.79 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.798 -179.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 3.8 m -121.54 119.02 30.73 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.18 -0.95 . . . . 0.0 109.428 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.456 ' CG2' HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.87 145.13 31.46 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.484 -0.76 . . . . 0.0 109.446 179.875 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.4 p -98.99 146.77 25.69 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.413 -0.804 . . . . 0.0 109.632 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.528 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -146.65 166.74 25.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.451 -0.78 . . . . 0.0 109.285 -179.431 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.544 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 4.1 p -95.24 124.87 39.5 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.075 -1.015 . . . . 0.0 109.637 -179.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.539 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.3 m -137.7 142.64 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.948 -1.095 . . . . 0.0 109.834 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.548 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 7.4 ptt180 -141.37 -165.49 1.98 Allowed 'General case' 0 N--CA 1.487 1.411 0 O-C-N 120.617 -1.302 . . . . 0.0 110.312 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.58 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 2.7 mtt180 -71.66 -78.02 0.09 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.34 -0.85 . . . . 0.0 109.096 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.441 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -69.05 137.35 53.51 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 120.21 -1.556 . . . . 0.0 107.437 179.082 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.564 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -160.78 132.8 5.93 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 117.996 -1.482 . . . . 0.0 110.167 -178.098 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.494 ' C ' ' O ' ' A' ' 73' ' ' PHE . 9.2 mp0 -30.1 121.92 0.18 Allowed 'General case' 0 N--CA 1.492 1.675 0 CA-C-O 121.627 0.727 . . . . 0.0 110.88 -178.237 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.02 45.09 3.16 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.587 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.4 m-30 -38.99 113.55 0.32 Allowed 'General case' 0 N--CA 1.508 2.461 0 O-C-N 121.123 -1.221 . . . . 0.0 110.268 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.526 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -87.57 127.45 35.26 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.035 -1.041 . . . . 0.0 109.487 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.579 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.0 t80 -64.48 58.1 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.861 -1.15 . . . . 0.0 110.118 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 77' ' ' LEU . 27.6 t0 -160.02 18.95 0.16 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.041 -1.037 . . . . 0.0 109.814 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.39 -26.42 5.71 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.56 158.6 15.62 Favored 'General case' 0 N--CA 1.485 1.307 0 O-C-N 120.959 -1.318 . . . . 0.0 110.435 -179.438 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.462 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -105.36 133.63 49.81 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 179.711 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.498 ' CD1' HD13 ' A' ' 77' ' ' LEU . 3.5 t90 -80.98 -19.52 43.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.797 -1.189 . . . . 0.0 110.281 -178.717 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.7 174.08 18.68 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.85 110.65 1.83 Allowed 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.564 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.2 t -82.06 103.56 9.41 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.389 -0.819 . . . . 0.0 108.846 -178.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.476 ' CB ' HG21 ' A' ' 90' ' ' THR . 0.4 OUTLIER -67.12 111.28 3.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.439 -0.788 . . . . 0.0 109.816 -179.174 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.53 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -63.0 -6.07 3.56 Favored 'General case' 0 N--CA 1.5 2.033 0 C-N-CA 118.361 -1.336 . . . . 0.0 109.824 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 41.4 p -84.64 -0.34 53.04 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.648 -1.282 . . . . 0.0 108.897 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.476 HG21 ' CB ' ' A' ' 87' ' ' ASP . 2.5 p -113.9 -49.7 2.86 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.338 -0.851 . . . . 0.0 109.025 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.91 -178.64 3.71 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.484 -0.76 . . . . 0.0 109.62 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.36 115.44 30.26 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.469 -0.769 . . . . 0.0 108.981 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.557 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.05 123.03 40.68 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.861 -1.15 . . . . 0.0 109.774 -179.249 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.576 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.57 146.87 27.91 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-O 122.378 1.085 . . . . 0.0 111.139 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.523 ' CG1' HG12 ' A' ' 7' ' ' VAL . 56.2 t -102.07 110.03 27.75 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.013 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 177.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.429 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.79 -170.31 16.42 Favored Glycine 0 N--CA 1.487 2.077 0 C-N-CA 118.246 -1.931 . . . . 0.0 111.631 -177.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.477 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -122.66 176.99 5.64 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.871 -0.782 . . . . 0.0 109.162 -178.854 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.553 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.5 m -176.12 176.43 1.73 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.687 -0.633 . . . . 0.0 109.386 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.546 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -123.35 -157.21 0.74 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.963 -1.086 . . . . 0.0 109.045 -179.949 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.446 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.35 35.94 4.46 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.726 -1.234 . . . . 0.0 109.249 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.436 ' HB3' ' OD2' ' A' ' 99' ' ' ASP . . . -111.07 -32.67 6.71 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.402 -0.811 . . . . 0.0 109.817 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.427 ' CA ' H192 ' A' ' 114' ' ' CHR . . . 165.02 -36.03 0.27 Allowed Glycine 0 N--CA 1.482 1.722 0 N-CA-C 107.814 -2.114 . . . . 0.0 107.814 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.404 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.53 -177.17 3.86 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 122.069 0.938 . . . . 0.0 109.737 179.385 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.62 -161.44 17.14 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 108.297 -1.921 . . . . 0.0 108.297 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.4 Cg_exo -46.88 177.17 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.684 0 CA-C-N 118.794 1.297 . . . . 0.0 110.161 179.28 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -94.15 -168.92 1.95 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.054 -1.029 . . . . 0.0 110.284 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.429 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.24 162.8 18.25 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.69 129.54 48.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.457 -1.025 . . . . 0.0 109.205 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.576 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.78 122.39 21.45 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 121.74 -0.6 . . . . 0.0 109.86 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.576 HD13 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.92 170.45 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.268 -0.895 . . . . 0.0 109.191 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.516 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.23 155.07 51.27 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.211 -0.931 . . . . 0.0 109.636 -179.908 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.58 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 66.1 m-85 -131.31 108.2 9.49 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.224 -0.923 . . . . 0.0 109.457 -179.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.415 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 13.7 p30 . . . . . 0 N--CA 1.489 1.515 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.577 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.591 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.453 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -112.05 164.83 14.24 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.195 -0.94 . . . . 0.0 109.465 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.528 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 4.9 Cg_exo -60.08 158.11 31.49 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.276 1.984 . . . . 0.0 110.534 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.528 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.46 -169.78 0.15 Allowed 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.256 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.528 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.97 130.63 2.29 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.769 -1.207 . . . . 0.0 110.758 -179.157 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.538 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.9 t -110.6 108.57 18.54 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 123.05 1.405 . . . . 0.0 109.073 179.275 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.502 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 2.2 t -117.02 140.42 39.76 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.713 0 CA-C-N 114.295 -1.32 . . . . 0.0 110.049 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.473 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -177.7 149.84 0.76 Allowed Pre-proline 0 N--CA 1.486 1.34 0 O-C-N 121.285 -0.884 . . . . 0.0 108.78 -179.757 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.473 ' HA ' HG22 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.86 150.39 86.5 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 123.551 -1.437 . . . . 0.0 109.239 -0.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.46 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 14.2 p -89.65 -25.74 21.1 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.466 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 8.1 m -132.75 163.22 29.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.427 -0.796 . . . . 0.0 109.527 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.16 37.72 31.6 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 -179.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.628 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 32.5 mt -92.95 -44.01 8.65 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.193 1.473 . . . . 0.0 110.695 -178.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.93 144.99 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.299 0 CA-C-N 113.515 -1.675 . . . . 0.0 109.919 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.583 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.7 p-10 -51.17 108.77 0.27 Allowed 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.433 0.635 . . . . 0.0 111.533 -178.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.84 13.38 11.28 Favored Glycine 0 N--CA 1.483 1.796 0 C-N-CA 119.45 -1.357 . . . . 0.0 112.875 177.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.628 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 11.1 t -103.12 -173.1 2.23 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 120.988 2.394 . . . . 0.0 109.571 179.333 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.535 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 20.7 t -127.2 135.11 64.42 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.968 -178.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.526 HG11 ' CG2' ' A' ' 69' ' ' VAL . 31.3 m -110.38 155.28 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 13.3 tttt -112.41 109.38 18.96 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.169 -0.957 . . . . 0.0 109.045 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.473 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.3 p -104.92 141.44 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.546 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -137.8 160.32 39.57 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.863 179.707 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.589 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.23 144.87 16.14 Favored Glycine 0 C--N 1.294 -1.775 0 N-CA-C 108.211 -1.956 . . . . 0.0 108.211 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.503 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.55 125.14 12.47 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.025 -1.28 . . . . 0.0 108.793 179.08 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.528 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.91 26.95 25.23 Favored Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.28 -1.438 . . . . 0.0 109.759 -179.699 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.549 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.2 mt -86.74 175.31 8.31 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.862 -1.375 . . . . 0.0 108.529 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.09 98.04 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.914 -1.116 . . . . 0.0 109.598 -179.637 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.551 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.82 77.31 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.735 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.376 -179.099 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.43 34.29 0.32 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 179.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.543 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.2 p -146.08 112.22 5.75 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.916 -1.344 . . . . 0.0 111.202 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.542 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.85 126.85 6.03 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.823 178.223 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.493 ' CD2' ' O ' ' A' ' 30' ' ' THR . 13.8 m-85 -119.35 152.13 37.3 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.475 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.49 162.67 12.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.635 -1.291 . . . . 0.0 107.727 178.667 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.616 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.7 p -147.1 117.02 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.002 -1.061 . . . . 0.0 110.031 -177.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -170.61 -176.46 40.0 Favored Glycine 0 N--CA 1.493 2.439 0 C-N-CA 118.323 -1.894 . . . . 0.0 111.714 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.559 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -99.79 108.92 21.34 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -179.801 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.441 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -131.01 148.91 52.81 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.22 -0.925 . . . . 0.0 109.777 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.79 139.38 54.04 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.31 -0.869 . . . . 0.0 110.768 -179.014 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.621 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.28 114.7 26.51 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 178.133 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.2 m -104.37 15.06 6.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.051 -1.03 . . . . 0.0 110.523 -178.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER 173.98 -175.89 0.07 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.979 -1.075 . . . . 0.0 110.076 179.706 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.544 ' O ' ' CG2' ' A' ' 42' ' ' THR . 14.9 t -71.95 98.87 2.12 Favored 'General case' 0 N--CA 1.487 1.38 0 CA-C-O 121.77 0.795 . . . . 0.0 109.648 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.69 27.34 35.46 Favored Glycine 0 N--CA 1.493 2.475 0 C-N-CA 120.139 -1.029 . . . . 0.0 111.422 178.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.95 106.39 20.11 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 O-C-N 120.6 -1.53 . . . . 0.0 107.197 178.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.621 HD12 ' CD1' ' A' ' 39' ' ' TRP . 13.1 tp -117.64 104.57 11.15 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.426 -1.421 . . . . 0.0 109.851 -177.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.53 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.2 109.58 22.31 Favored 'General case' 0 N--CA 1.484 1.25 0 O-C-N 120.812 -1.18 . . . . 0.0 108.165 178.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -106.38 166.43 10.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.966 -1.084 . . . . 0.0 110.122 -178.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.536 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 14.3 t-20 -108.56 137.98 20.13 Favored Pre-proline 0 N--CA 1.501 2.09 0 O-C-N 121.326 -0.859 . . . . 0.0 110.04 -179.267 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.58 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.7 Cg_endo -75.38 24.29 0.41 Allowed 'Trans proline' 0 C--N 1.317 -1.08 0 C-N-CA 122.36 2.04 . . . . 0.0 111.884 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.536 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -118.01 3.66 12.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.355 -1.466 . . . . 0.0 109.298 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.495 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -139.05 17.57 2.63 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 179.328 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -82.4 90.85 6.74 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.789 -0.765 . . . . 0.0 110.834 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.616 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -111.65 -169.24 1.43 Allowed 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 178.319 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.469 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.1 135.34 0.09 Allowed 'General case' 0 N--CA 1.486 1.353 0 O-C-N 120.584 -1.322 . . . . 0.0 111.325 -179.301 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.579 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.1 p -150.62 158.49 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 178.172 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.542 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.77 145.38 26.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.804 -1.185 . . . . 0.0 109.848 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.673 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -65.77 108.05 1.99 Allowed 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 122.359 1.076 . . . . 0.0 109.61 178.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.53 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.3 p-10 -60.73 -139.46 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.802 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.551 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.22 -50.13 62.59 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.43 -0.793 . . . . 0.0 110.432 -178.849 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 37.9 t30 -103.13 -35.18 8.59 Favored 'General case' 0 C--N 1.287 -2.141 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.673 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.05 65.91 0.6 Allowed Glycine 0 C--N 1.296 -1.64 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 178.3 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.5 m -102.04 128.86 48.3 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 121.475 -1.015 . . . . 0.0 108.899 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.579 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -138.07 108.76 6.62 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.933 -179.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -121.15 119.16 31.58 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.177 -0.952 . . . . 0.0 109.537 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.469 HG23 ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -143.08 143.27 31.79 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.496 -0.753 . . . . 0.0 109.602 179.827 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.8 p -99.74 145.36 27.75 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.45 -0.781 . . . . 0.0 109.284 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.581 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -146.71 170.33 17.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.372 -0.83 . . . . 0.0 109.421 -179.286 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.529 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.9 p -99.16 125.71 44.78 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.023 -1.048 . . . . 0.0 109.532 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.533 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -137.47 143.82 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.917 -1.114 . . . . 0.0 109.768 -179.373 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.583 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.1 ptt180 -148.64 -172.04 4.0 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.434 -1.416 . . . . 0.0 110.944 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.561 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -55.8 -101.66 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 -179.358 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.463 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.58 140.52 46.35 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 120.778 -1.201 . . . . 0.0 108.215 179.587 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -162.38 136.23 6.36 Favored 'General case' 0 C--N 1.293 -1.874 0 C-N-CA 118.772 -1.171 . . . . 0.0 109.926 -178.184 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.487 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.5 mm-40 -32.09 121.02 0.3 Allowed 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.479 0.657 . . . . 0.0 110.736 -178.399 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.53 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.15 47.86 2.92 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.169 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.58 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.37 113.03 0.29 Allowed 'General case' 0 N--CA 1.506 2.365 0 O-C-N 121.076 -1.249 . . . . 0.0 110.118 179.572 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.541 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -85.14 127.02 34.09 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.959 -1.088 . . . . 0.0 109.503 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.572 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 43.1 t80 -63.57 58.36 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.905 -1.122 . . . . 0.0 110.297 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 16.7 t0 -161.53 19.74 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.995 -1.066 . . . . 0.0 109.791 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.18 -26.72 5.4 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.129 -1.189 . . . . 0.0 110.129 179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.83 159.87 15.19 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.028 -1.278 . . . . 0.0 110.32 -179.368 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.468 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.49 134.58 49.41 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.888 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.456 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.9 t90 -82.86 -19.27 37.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.773 -1.204 . . . . 0.0 110.393 -178.637 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.43 173.91 18.76 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -64.11 107.29 1.24 Allowed 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.565 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 47.5 t -78.28 105.3 7.21 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 O-C-N 121.354 -0.841 . . . . 0.0 109.304 -178.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.468 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.9 OUTLIER -65.15 110.82 2.67 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.487 -0.758 . . . . 0.0 109.777 -179.657 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.561 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.2 t -62.52 -6.36 3.35 Favored 'General case' 0 N--CA 1.499 2.001 0 C-N-CA 118.164 -1.415 . . . . 0.0 109.788 179.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.6 p -85.83 -3.17 58.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.726 -1.234 . . . . 0.0 109.272 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.468 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -109.62 -50.2 3.01 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.295 -0.878 . . . . 0.0 108.976 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.91 -179.46 3.95 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.491 -0.755 . . . . 0.0 109.374 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.2 115.98 31.17 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.363 -0.836 . . . . 0.0 108.83 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.505 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.6 123.52 40.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.815 -1.178 . . . . 0.0 109.639 -179.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.555 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.85 146.08 29.5 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 122.382 1.087 . . . . 0.0 111.042 -179.483 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.466 HG23 HG21 ' A' ' 110' ' ' ILE . 78.4 t -102.49 109.94 27.85 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.081 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 177.651 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.451 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.97 -171.52 17.79 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 118.171 -1.966 . . . . 0.0 111.812 -177.534 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.475 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -114.55 -178.39 3.36 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -179.048 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.587 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.9 OUTLIER -173.36 168.1 4.65 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.343 -0.848 . . . . 0.0 109.605 -179.26 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.424 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -117.36 -159.04 0.72 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.043 -1.036 . . . . 0.0 108.916 179.685 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.424 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.05 36.05 4.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.638 -1.289 . . . . 0.0 109.287 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -116.06 -32.87 5.24 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.34 -0.85 . . . . 0.0 110.195 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.501 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 162.88 -34.42 0.32 Allowed Glycine 0 N--CA 1.482 1.718 0 N-CA-C 107.628 -2.189 . . . . 0.0 107.628 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.29 -178.48 7.31 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 121.627 -0.925 . . . . 0.0 109.682 179.238 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.84 -161.73 16.7 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 108.395 -1.882 . . . . 0.0 108.395 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.487 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.5 Cg_exo -46.93 178.3 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.634 0 CA-C-N 118.822 1.311 . . . . 0.0 110.375 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -92.69 -179.27 5.11 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.204 -0.935 . . . . 0.0 110.455 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.451 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.42 165.5 12.52 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.86 128.2 55.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.442 -1.034 . . . . 0.0 109.159 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.555 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.64 123.16 22.68 Favored 'General case' 0 C--N 1.289 -2.043 0 O-C-N 121.632 -0.667 . . . . 0.0 109.383 179.592 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.579 HD13 ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -97.69 170.85 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.214 -0.929 . . . . 0.0 109.197 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.466 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.71 153.79 49.73 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.214 -0.929 . . . . 0.0 109.609 -179.847 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CZ ' HD13 ' A' ' 110' ' ' ILE . 75.9 m-85 -130.9 100.9 5.41 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.162 -0.961 . . . . 0.0 109.494 -179.709 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.3 p30 . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.466 -179.983 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.59 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.63 155.59 59.57 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.302 -0.874 . . . . 0.0 109.501 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.48 ' CA ' ' O ' ' A' ' 25' ' ' GLY . 3.0 Cg_exo -61.24 155.65 50.23 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.212 1.941 . . . . 0.0 110.52 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.603 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -139.57 161.62 37.05 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -179.994 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.07 128.81 15.23 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 118.796 -1.162 . . . . 0.0 110.84 -179.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.532 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.2 p -105.65 104.86 14.67 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.427 1.108 . . . . 0.0 110.287 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.524 HG12 ' CG1' ' A' ' 95' ' ' VAL . 11.7 t -118.82 117.28 53.86 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.469 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.226 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.524 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.1 149.71 11.76 Favored Pre-proline 0 N--CA 1.487 1.381 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 -179.611 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.524 ' CA ' HG21 ' A' ' 8' ' ' THR . 4.9 Cg_endo -77.14 152.05 94.18 Favored 'Cis proline' 0 C--N 1.309 -1.534 0 C-N-CA 123.698 -1.376 . . . . 0.0 109.567 -0.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.441 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 18.0 p -93.15 -24.75 18.14 Favored 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.464 ' HB3' ' HB2' ' A' ' 111' ' ' SER . 3.9 m -133.61 161.83 33.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.616 -0.678 . . . . 0.0 109.382 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.31 37.02 32.86 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.614 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 35.2 mt -90.92 -42.93 10.31 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 123.283 1.516 . . . . 0.0 110.411 -178.599 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.55 144.36 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.305 0 CA-C-N 113.28 -1.782 . . . . 0.0 109.918 -179.629 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.587 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 6.3 p-10 -50.87 106.34 0.13 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.624 0.726 . . . . 0.0 111.514 -178.646 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.29 13.93 8.66 Favored Glycine 0 N--CA 1.484 1.865 0 C-N-CA 119.468 -1.349 . . . . 0.0 113.033 177.375 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.614 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -104.98 -172.73 2.15 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 121.168 2.484 . . . . 0.0 109.785 179.253 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.558 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 17.2 t -130.39 139.49 51.21 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.319 0 CA-C-N 114.794 -1.094 . . . . 0.0 111.215 -178.783 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.518 HG22 ' CD1' ' A' ' 67' ' ' LEU . 33.8 m -115.22 155.12 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 178.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.524 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.4 tttt -109.08 109.15 20.08 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.146 -0.971 . . . . 0.0 109.466 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.522 HG11 ' CG2' ' A' ' 34' ' ' VAL . 1.9 p -105.47 122.44 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.554 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -113.68 165.66 12.31 Favored 'General case' 0 C--N 1.307 -1.273 0 O-C-N 120.821 -1.174 . . . . 0.0 109.128 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.97 107.74 0.47 Allowed Glycine 0 N--CA 1.481 1.693 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.603 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.34 139.62 50.21 Favored 'General case' 0 N--CA 1.5 2.063 0 CA-C-N 119.139 1.469 . . . . 0.0 110.102 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.48 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 86.39 28.18 28.19 Favored Glycine 0 N--CA 1.49 2.25 0 C-N-CA 118.796 -1.669 . . . . 0.0 109.758 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.526 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -94.7 174.44 7.11 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.996 -1.297 . . . . 0.0 108.58 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.557 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.28 100.1 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.91 -1.119 . . . . 0.0 109.74 -179.597 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.86 77.75 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.101 -179.326 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.41 34.02 0.29 Allowed Glycine 0 N--CA 1.487 2.071 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.538 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.9 p -141.86 108.73 5.42 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.071 -1.253 . . . . 0.0 111.098 -179.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.547 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -47.52 109.81 0.25 Allowed 'General case' 0 N--CA 1.496 1.874 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.796 178.253 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.563 ' CE1' ' OD2' ' A' ' 99' ' ' ASP . 21.6 m-85 -99.53 153.77 18.78 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.177 -0.952 . . . . 0.0 108.835 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -102.67 158.96 15.88 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.727 -1.233 . . . . 0.0 107.829 178.553 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.636 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.0 p -141.63 118.25 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.942 -1.099 . . . . 0.0 109.92 -177.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.4 -179.81 40.48 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.937 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.558 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -101.21 108.94 20.73 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.932 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.4 146.9 52.04 Favored 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.236 -0.915 . . . . 0.0 109.808 179.675 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -119.12 137.74 53.38 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.341 -0.849 . . . . 0.0 110.647 -178.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.631 ' CE2' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.69 114.44 26.18 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 178.143 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.428 HG22 ' HB ' ' A' ' 44' ' ' VAL . 16.7 m -105.92 14.51 7.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 120.971 -1.081 . . . . 0.0 110.666 -178.665 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.596 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.33 -175.38 0.08 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.815 -1.178 . . . . 0.0 110.116 179.743 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.541 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.97 98.07 1.54 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-O 121.806 0.812 . . . . 0.0 109.91 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.97 26.61 36.81 Favored Glycine 0 N--CA 1.493 2.494 0 C-N-CA 120.17 -1.014 . . . . 0.0 111.562 178.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.596 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -115.27 105.98 19.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 O-C-N 120.549 -1.559 . . . . 0.0 107.316 178.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.631 HD13 ' CE2' ' A' ' 39' ' ' TRP . 13.1 tp -118.31 104.81 11.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.502 -1.374 . . . . 0.0 109.628 -177.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.498 ' CB ' HG23 ' A' ' 86' ' ' VAL . . . -97.92 109.67 22.38 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.755 -1.216 . . . . 0.0 108.271 179.074 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.3 t -105.51 164.44 11.88 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.996 -1.065 . . . . 0.0 110.416 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.53 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 9.6 t-20 -109.2 137.21 20.14 Favored Pre-proline 0 N--CA 1.5 2.042 0 O-C-N 121.505 -0.747 . . . . 0.0 109.972 -179.162 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.578 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.2 Cg_endo -74.39 23.9 0.36 Allowed 'Trans proline' 0 CA--C 1.544 1.004 0 C-N-CA 122.371 2.047 . . . . 0.0 112.049 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.53 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -116.91 3.61 12.85 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.364 -1.46 . . . . 0.0 109.115 179.669 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.516 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.49 13.82 3.22 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 179.356 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -79.25 91.46 5.0 Favored 'General case' 0 C--N 1.306 -1.321 0 O-C-N 121.509 -0.744 . . . . 0.0 111.052 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.636 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -112.63 -168.79 1.37 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.188 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.472 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.79 136.83 0.09 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.567 -1.333 . . . . 0.0 111.46 -179.296 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.577 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -152.19 157.01 5.31 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 178.024 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.547 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.18 143.78 28.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 120.808 -1.182 . . . . 0.0 110.081 -179.497 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.68 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.14 106.7 1.12 Allowed 'General case' 0 C--N 1.3 -1.55 0 CA-C-O 122.44 1.114 . . . . 0.0 109.278 178.609 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.527 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.8 p-10 -60.14 -139.12 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.948 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.546 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.53 -50.54 59.81 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.497 -0.752 . . . . 0.0 110.597 -178.522 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -103.91 -34.11 8.61 Favored 'General case' 0 C--N 1.286 -2.179 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 178.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.68 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.28 66.44 0.6 Allowed Glycine 0 C--N 1.296 -1.639 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.568 178.105 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 21.5 m -103.15 125.32 49.79 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.665 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.34 109.33 8.73 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.464 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.6 m -118.16 116.95 27.87 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.368 -0.833 . . . . 0.0 109.307 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.461 HG23 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -142.88 139.89 30.99 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.525 -0.734 . . . . 0.0 109.588 -179.987 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.6 p -99.62 134.55 42.33 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.465 -0.772 . . . . 0.0 109.43 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.518 ' CD1' HG22 ' A' ' 19' ' ' VAL . 0.1 OUTLIER -132.12 165.6 23.68 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.427 -0.796 . . . . 0.0 109.389 -179.549 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.558 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.8 p -96.89 125.33 41.26 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.012 -1.055 . . . . 0.0 109.25 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.527 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 15.9 m -136.01 143.47 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 120.95 -1.094 . . . . 0.0 109.81 -179.061 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.587 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.7 ptt180 -147.15 -175.48 4.84 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.534 -1.354 . . . . 0.0 111.032 -179.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.557 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.12 -101.45 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.609 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.76 141.73 43.12 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.773 -1.204 . . . . 0.0 108.114 179.437 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.596 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.74 136.03 5.06 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 118.653 -1.219 . . . . 0.0 109.96 -177.973 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' A' ' 73' ' ' PHE . 0.7 OUTLIER -33.42 121.92 0.41 Allowed 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.364 0.602 . . . . 0.0 110.313 -178.609 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.489 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.16 50.19 1.91 Allowed Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.388 -0.91 . . . . 0.0 111.343 -178.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.578 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.4 m-85 -40.15 113.5 0.36 Allowed 'General case' 0 N--CA 1.507 2.383 0 O-C-N 121.123 -1.222 . . . . 0.0 109.749 179.313 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.516 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.3 tp -85.66 127.04 34.38 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 120.903 -1.123 . . . . 0.0 109.726 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.575 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 33.3 t80 -65.25 58.06 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.971 0 O-C-N 120.85 -1.156 . . . . 0.0 109.824 179.611 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.516 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -158.69 18.67 0.21 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.004 -1.06 . . . . 0.0 109.596 -179.991 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.95 -27.23 5.56 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 42.3 p -93.98 159.87 14.98 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.962 -1.316 . . . . 0.0 110.455 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.474 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.02 135.8 46.83 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.536 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.487 ' CD1' HD13 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -83.88 -16.46 44.3 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.737 -1.227 . . . . 0.0 110.67 -178.345 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 107.62 176.23 22.44 Favored Glycine 0 N--CA 1.485 1.95 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.9 104.31 0.68 Allowed 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.582 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 39.4 t -76.37 107.19 7.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.353 -0.842 . . . . 0.0 109.096 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 1.3 m-20 -66.29 111.45 3.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.448 -0.782 . . . . 0.0 109.975 -179.236 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.557 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.74 -5.56 4.36 Favored 'General case' 0 N--CA 1.5 2.067 0 C-N-CA 118.268 -1.373 . . . . 0.0 109.78 179.357 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.0 p -86.7 -1.45 57.72 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.744 -1.222 . . . . 0.0 109.231 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.453 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.15 -49.6 3.01 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.212 -0.93 . . . . 0.0 109.019 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.89 178.42 4.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.55 -0.719 . . . . 0.0 109.398 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.83 116.45 32.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.348 -0.845 . . . . 0.0 109.115 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.561 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.59 122.89 40.0 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.853 -1.155 . . . . 0.0 109.189 -179.473 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.536 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -101.18 146.04 28.01 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 122.334 1.064 . . . . 0.0 111.338 -179.08 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.524 ' CG1' HG12 ' A' ' 7' ' ' VAL . 65.8 t -103.21 109.78 27.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.964 0 N-CA-C 106.345 -1.724 . . . . 0.0 106.345 177.45 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.87 -172.82 17.53 Favored Glycine 0 N--CA 1.486 1.968 0 C-N-CA 118.063 -2.018 . . . . 0.0 111.804 -177.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -115.98 -177.77 3.24 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -178.87 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.54 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.9 OUTLIER -171.11 168.78 6.75 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.385 -0.822 . . . . 0.0 109.098 -179.24 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.563 ' OD2' ' CE1' ' A' ' 32' ' ' TYR . 1.4 m-20 -104.86 -9.64 17.88 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.115 -0.991 . . . . 0.0 109.504 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.488 ' CB ' ' O ' ' A' ' 99' ' ' ASP . . . 73.6 39.02 0.59 Allowed 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.471 -0.768 . . . . 0.0 109.199 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -139.23 -34.54 0.58 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.569 -0.707 . . . . 0.0 110.715 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.491 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 179.22 -41.58 0.08 OUTLIER Glycine 0 N--CA 1.482 1.701 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 -179.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.7 -179.07 7.84 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 121.448 -1.03 . . . . 0.0 109.641 178.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.58 -166.56 33.91 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 -179.49 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 104' ' ' GLY . 2.9 Cg_exo -49.8 -176.67 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.685 0 CA-C-N 118.857 1.329 . . . . 0.0 110.067 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -94.41 179.33 5.32 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.04 -1.037 . . . . 0.0 110.571 -178.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -117.97 166.77 12.76 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -108.26 128.87 63.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.246 -1.15 . . . . 0.0 109.117 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.536 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.09 119.1 16.86 Favored 'General case' 0 C--N 1.289 -2.045 0 O-C-N 121.586 -0.696 . . . . 0.0 109.356 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.579 HD13 ' CZ ' ' A' ' 112' ' ' PHE . 1.7 pt -97.81 169.9 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.151 -0.968 . . . . 0.0 108.916 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.464 ' HB2' ' HB3' ' A' ' 11' ' ' SER . 1.2 m -141.15 156.97 45.87 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.123 -0.986 . . . . 0.0 110.095 -179.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CZ ' HD13 ' A' ' 110' ' ' ILE . 97.8 m-85 -133.17 85.49 2.22 Favored 'General case' 0 N--CA 1.484 1.242 0 O-C-N 121.24 -0.912 . . . . 0.0 109.479 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.402 ' OXT' ' OD1' ' A' ' 113' ' ' ASN . 20.5 p30 . . . . . 0 N--CA 1.489 1.502 0 CA-C-O 118.044 -0.979 . . . . 0.0 109.445 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.584 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -123.51 154.58 66.3 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.174 -0.954 . . . . 0.0 109.631 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.535 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.8 Cg_exo -59.7 159.31 24.9 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.32 2.013 . . . . 0.0 110.458 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.06 -169.73 0.16 Allowed 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 179.442 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.545 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -163.48 131.01 3.5 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.755 -1.216 . . . . 0.0 110.692 -179.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.544 ' CG2' ' O ' ' A' ' 6' ' ' THR . 7.2 t -110.28 108.72 18.92 Favored 'General case' 0 C--N 1.296 -1.724 0 CA-C-O 123.108 1.432 . . . . 0.0 109.067 179.316 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.502 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 3.1 t -116.53 139.01 45.26 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.72 0 CA-C-N 114.246 -1.343 . . . . 0.0 110.123 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.479 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.64 149.13 1.27 Allowed Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.323 -0.861 . . . . 0.0 108.775 -179.735 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.479 ' HA ' HG22 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.79 152.52 97.07 Favored 'Cis proline' 0 C--N 1.312 -1.365 0 C-N-CA 123.476 -1.468 . . . . 0.0 109.485 -0.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.515 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 3.3 m -90.87 -24.56 20.2 Favored 'General case' 0 C--N 1.293 -1.874 0 O-C-N 121.587 -0.695 . . . . 0.0 109.175 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.51 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.2 m -137.94 165.34 26.78 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.547 -0.721 . . . . 0.0 109.515 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.05 37.98 31.34 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 108.579 -1.808 . . . . 0.0 108.579 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.621 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 33.8 mt -93.01 -43.93 8.66 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 123.102 1.43 . . . . 0.0 110.703 -178.249 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.481 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.17 145.94 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.314 0 CA-C-N 113.595 -1.639 . . . . 0.0 110.138 -179.904 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -51.23 106.95 0.15 Allowed 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 121.66 0.743 . . . . 0.0 111.638 -178.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.73 13.97 9.06 Favored Glycine 0 N--CA 1.484 1.878 0 C-N-CA 119.473 -1.346 . . . . 0.0 112.968 177.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.621 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 11.5 t -104.08 -173.96 2.43 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 121.164 2.482 . . . . 0.0 109.936 179.417 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.548 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 39.1 t -124.76 136.11 61.79 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.389 0 CA-C-N 114.563 -1.199 . . . . 0.0 110.917 -178.669 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.557 ' CG1' ' CG2' ' A' ' 69' ' ' VAL . 35.6 m -114.04 154.95 15.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.259 -0.9 . . . . 0.0 108.725 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.81 109.15 18.44 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.037 179.876 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.464 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.1 p -104.48 141.02 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.523 ' CB ' HG22 ' A' ' 6' ' ' THR . . . -137.73 160.76 38.35 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 120.735 -1.228 . . . . 0.0 110.154 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -128.46 144.6 15.42 Favored Glycine 0 C--N 1.295 -1.731 0 N-CA-C 107.973 -2.051 . . . . 0.0 107.973 179.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.504 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.13 125.71 13.3 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 120.851 -1.382 . . . . 0.0 108.864 179.053 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.535 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.44 26.01 26.64 Favored Glycine 0 N--CA 1.488 2.138 0 C-N-CA 119.184 -1.484 . . . . 0.0 109.874 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.556 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -89.02 170.98 10.19 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.86 -1.376 . . . . 0.0 108.477 179.892 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.559 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.02 100.88 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.082 -1.012 . . . . 0.0 110.038 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.2 78.53 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.007 -179.48 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.88 34.32 0.3 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.57 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 16.6 p -138.78 105.06 5.25 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.217 -1.166 . . . . 0.0 111.293 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.564 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.8 111.87 0.62 Allowed 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.054 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.57 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 36.9 m-85 -108.92 157.53 18.54 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.186 -0.946 . . . . 0.0 108.897 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.479 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.21 163.14 12.42 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.913 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.623 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.8 p -143.75 119.42 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.034 -1.041 . . . . 0.0 109.914 -178.044 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.89 -177.87 38.96 Favored Glycine 0 N--CA 1.495 2.602 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.851 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.559 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -102.15 108.76 20.26 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -131.14 149.56 52.54 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.241 -0.912 . . . . 0.0 109.716 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.03 138.27 54.73 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.105 -0.997 . . . . 0.0 110.803 -178.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.625 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.73 26.55 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.112 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.455 HG21 ' HB ' ' A' ' 44' ' ' VAL . 16.0 m -104.74 14.8 6.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.109 -0.994 . . . . 0.0 110.593 -178.806 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.59 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 173.97 -175.7 0.07 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.989 -1.069 . . . . 0.0 110.003 179.686 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.548 ' O ' ' CG2' ' A' ' 42' ' ' THR . 14.9 t -72.1 99.0 2.22 Favored 'General case' 0 N--CA 1.486 1.357 0 CA-C-O 121.763 0.792 . . . . 0.0 109.738 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.77 27.7 34.14 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 120.227 -0.987 . . . . 0.0 111.405 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.59 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -117.5 105.88 18.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.619 -1.518 . . . . 0.0 107.263 178.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.625 HD11 ' CD1' ' A' ' 39' ' ' TRP . 13.2 tp -117.66 104.67 11.25 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.48 -1.387 . . . . 0.0 109.739 -177.77 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.557 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.89 109.35 22.12 Favored 'General case' 0 N--CA 1.484 1.26 0 O-C-N 120.804 -1.185 . . . . 0.0 107.9 178.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.491 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -107.26 162.71 13.65 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.956 -1.09 . . . . 0.0 110.263 -178.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.486 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 39.7 t30 -105.71 134.7 19.59 Favored Pre-proline 0 N--CA 1.503 2.189 0 O-C-N 121.405 -0.809 . . . . 0.0 109.539 -179.614 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.586 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.2 Cg_endo -72.74 22.92 0.29 Allowed 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.322 2.015 . . . . 0.0 112.46 -179.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.486 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -118.34 10.59 12.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.349 -1.469 . . . . 0.0 108.958 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.535 ' OD1' ' CG1' ' A' ' 69' ' ' VAL . 0.1 OUTLIER -137.99 14.59 2.86 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 179.326 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -80.15 88.64 5.43 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.564 -0.855 . . . . 0.0 111.286 -178.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.55 -167.05 1.18 Allowed 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 178.128 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.459 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.74 138.26 0.09 Allowed 'General case' 0 C--N 1.306 -1.284 0 O-C-N 120.578 -1.326 . . . . 0.0 111.239 -179.267 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.605 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -155.69 156.48 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.397 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.564 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.66 142.03 30.74 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.798 -1.189 . . . . 0.0 110.016 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.69 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -61.74 106.76 0.72 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.425 1.107 . . . . 0.0 109.287 178.091 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.519 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.0 p-10 -60.44 -138.4 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.033 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.36 -51.03 58.13 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.429 -0.794 . . . . 0.0 110.902 -178.576 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.454 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.7 t-20 -103.57 -34.54 8.62 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 178.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.69 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 110.95 63.02 0.5 Allowed Glycine 0 C--N 1.297 -1.621 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 177.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.9 m -102.48 126.9 49.68 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.6 -0.941 . . . . 0.0 108.487 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.605 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.68 109.19 7.41 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.834 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.1 m -120.83 120.56 35.92 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.284 -0.885 . . . . 0.0 109.515 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.524 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -142.04 143.65 33.23 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.526 -0.734 . . . . 0.0 109.355 179.772 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.7 p -102.0 143.41 31.89 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.423 -0.798 . . . . 0.0 109.462 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.553 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.1 OUTLIER -146.26 -178.87 6.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 109.43 -179.45 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.491 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -105.06 125.88 51.46 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.903 -1.123 . . . . 0.0 110.289 -178.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.557 ' CG2' ' CG1' ' A' ' 19' ' ' VAL . 15.3 m -134.56 144.22 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 120.965 -1.085 . . . . 0.0 109.756 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.3 ptt180 -148.66 -179.62 7.11 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 120.458 -1.401 . . . . 0.0 111.105 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.554 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.92 -100.89 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -179.661 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.73 139.54 50.35 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.82 -1.175 . . . . 0.0 107.928 179.303 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -161.44 136.18 7.25 Favored 'General case' 0 C--N 1.295 -1.803 0 C-N-CA 118.647 -1.221 . . . . 0.0 109.807 -178.105 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.476 ' C ' ' O ' ' A' ' 73' ' ' PHE . 15.7 mt-10 -33.97 121.43 0.45 Allowed 'General case' 0 N--CA 1.491 1.621 0 CA-C-O 121.419 0.628 . . . . 0.0 110.358 -178.45 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.557 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.03 50.86 1.93 Allowed Glycine 0 N--CA 1.493 2.493 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.068 -179.278 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.586 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-85 -39.22 116.69 0.62 Allowed 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.122 -1.223 . . . . 0.0 109.954 179.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.9 tp -87.37 126.16 34.7 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.006 -1.059 . . . . 0.0 109.455 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.57 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.1 t80 -64.8 58.47 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.925 0 O-C-N 120.804 -1.185 . . . . 0.0 110.014 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 26.4 t0 -159.33 19.54 0.18 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.054 -1.029 . . . . 0.0 109.571 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.51 -28.2 5.41 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.447 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 66.3 p -95.96 160.24 14.56 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.964 -1.315 . . . . 0.0 110.438 -179.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.467 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 4.1 ptt180 -105.73 138.77 41.37 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.466 ' HB2' HD11 ' A' ' 77' ' ' LEU . 2.0 t90 -83.55 -19.12 36.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.852 -1.155 . . . . 0.0 110.556 -178.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.59 176.1 19.24 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 108.704 -1.758 . . . . 0.0 108.704 -179.569 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -65.72 105.9 1.37 Allowed 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.553 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.0 t -77.36 105.9 6.86 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 O-C-N 121.355 -0.841 . . . . 0.0 109.144 -178.836 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.459 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.7 OUTLIER -64.97 111.1 2.7 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.373 -0.829 . . . . 0.0 109.819 -179.558 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.554 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -62.91 -5.93 3.34 Favored 'General case' 0 N--CA 1.499 2.02 0 C-N-CA 118.214 -1.394 . . . . 0.0 109.85 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.2 p -86.99 -1.25 57.72 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.729 -1.232 . . . . 0.0 109.319 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.459 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.8 p -111.49 -50.3 2.94 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.384 -0.823 . . . . 0.0 108.937 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.76 -179.94 4.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.544 -0.723 . . . . 0.0 109.238 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.93 116.11 31.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.325 -0.859 . . . . 0.0 109.057 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -96.93 121.17 38.51 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.854 -1.154 . . . . 0.0 109.278 -179.321 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.562 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.3 mt-30 -102.04 146.78 27.42 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-O 122.402 1.096 . . . . 0.0 111.311 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.458 HG21 HG21 ' A' ' 110' ' ' ILE . 62.1 t -104.65 109.86 28.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 177.479 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.45 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.0 -170.04 16.27 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 118.243 -1.932 . . . . 0.0 111.62 -177.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.479 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -112.78 179.88 3.85 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -179.065 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.581 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.2 p -177.79 171.09 1.87 Allowed 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.362 -0.836 . . . . 0.0 109.546 -179.18 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.502 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -126.67 -158.27 0.85 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.028 -1.045 . . . . 0.0 109.13 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.439 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.32 35.85 4.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.728 -1.232 . . . . 0.0 109.214 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.12 -33.79 5.57 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.341 -0.849 . . . . 0.0 109.991 -179.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 165.23 -36.37 0.27 Allowed Glycine 0 N--CA 1.482 1.741 0 N-CA-C 107.775 -2.13 . . . . 0.0 107.775 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -164.04 -177.42 5.03 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 121.599 -0.942 . . . . 0.0 109.962 179.451 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.67 -161.72 14.25 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.518 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.48 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.5 Cg_exo -47.53 178.45 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 CA-C-N 118.997 1.398 . . . . 0.0 110.196 179.281 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -91.25 -177.56 4.9 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.056 -1.028 . . . . 0.0 110.371 -178.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.45 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.15 163.73 13.89 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.06 129.76 50.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.374 -1.074 . . . . 0.0 109.173 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.562 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.1 121.96 22.84 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.634 -0.666 . . . . 0.0 109.603 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.58 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -97.89 169.85 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.214 -0.928 . . . . 0.0 109.18 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.51 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -136.2 154.58 50.89 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.326 -0.859 . . . . 0.0 109.745 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.58 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 26.7 m-85 -125.53 109.97 13.31 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.301 -0.874 . . . . 0.0 109.421 -179.78 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.421 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 13.3 p30 . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 117.926 -1.035 . . . . 0.0 109.437 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.589 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -123.72 153.23 66.67 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.241 -0.912 . . . . 0.0 109.565 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.539 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 4.7 Cg_exo -60.26 159.03 28.17 Favored 'Trans proline' 0 C--N 1.309 -1.51 0 C-N-CA 122.428 2.085 . . . . 0.0 110.535 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.544 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -173.85 -169.66 0.51 Allowed 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.092 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.544 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.94 130.58 2.71 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.888 -1.133 . . . . 0.0 110.905 -179.047 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.547 ' CG2' ' O ' ' A' ' 6' ' ' THR . 7.5 t -111.74 108.71 18.24 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 123.071 1.415 . . . . 0.0 109.102 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.532 HG12 ' CG1' ' A' ' 95' ' ' VAL . 2.8 t -115.28 139.23 42.65 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.692 0 CA-C-N 114.326 -1.306 . . . . 0.0 110.196 -179.639 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.515 HG22 ' N ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.08 149.39 1.46 Allowed Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.3 -0.875 . . . . 0.0 108.783 -179.769 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.515 ' N ' HG22 ' A' ' 8' ' ' THR . 3.9 Cg_endo -77.0 151.22 93.69 Favored 'Cis proline' 0 C--N 1.312 -1.344 0 C-N-CA 123.489 -1.463 . . . . 0.0 109.238 -0.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.487 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 24.0 p -89.81 -24.36 21.47 Favored 'General case' 0 C--N 1.292 -1.924 0 O-C-N 121.46 -0.775 . . . . 0.0 109.395 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.515 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 12.4 m -136.68 164.6 27.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.35 -0.844 . . . . 0.0 109.801 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.85 38.79 30.23 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.609 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 37.2 mt -92.18 -44.1 8.98 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 123.125 1.441 . . . . 0.0 110.721 -178.325 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.488 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.88 146.17 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.364 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.329 179.989 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.561 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.9 p-10 -51.55 107.4 0.19 Allowed 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.713 0.768 . . . . 0.0 111.571 -178.633 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.8 14.95 8.98 Favored Glycine 0 N--CA 1.484 1.853 0 C-N-CA 119.445 -1.359 . . . . 0.0 112.924 177.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.609 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.5 t -105.85 -172.61 2.12 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 121.136 2.468 . . . . 0.0 109.557 179.077 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.55 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 13.3 t -129.2 136.77 58.76 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.43 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.897 -179.096 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.566 ' CG1' ' CG2' ' A' ' 69' ' ' VAL . 15.5 m -110.81 156.42 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.5 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.36 109.05 18.45 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.114 -0.991 . . . . 0.0 108.953 179.818 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.528 ' CG1' HG23 ' A' ' 34' ' ' VAL . 1.8 p -103.74 140.35 22.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.54 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -135.47 160.05 39.67 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.717 -1.239 . . . . 0.0 110.026 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.67 144.47 15.59 Favored Glycine 0 C--N 1.293 -1.806 0 N-CA-C 107.995 -2.042 . . . . 0.0 107.995 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.14 125.48 13.09 Favored 'General case' 0 C--N 1.296 -1.734 0 O-C-N 120.806 -1.408 . . . . 0.0 108.983 179.232 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.539 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.42 26.33 25.77 Favored Glycine 0 N--CA 1.488 2.121 0 C-N-CA 119.279 -1.438 . . . . 0.0 109.796 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.55 ' HB2' ' HB3' ' A' ' 57' ' ' ALA . 0.7 OUTLIER -89.36 169.59 11.28 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 120.838 -1.389 . . . . 0.0 108.347 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.562 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.84 100.99 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 122.214 1.007 . . . . 0.0 109.921 -179.438 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.82 78.18 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.618 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.904 -179.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.88 34.12 0.27 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.53 ' OG1' ' CB ' ' A' ' 27' ' ' GLN . 18.5 p -139.06 105.43 5.28 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 121.154 -1.204 . . . . 0.0 111.262 -179.433 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.567 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -51.24 111.54 0.59 Allowed 'General case' 0 N--CA 1.497 1.924 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.676 178.088 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.573 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 5.8 m-30 -109.48 156.35 20.2 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.109 -0.994 . . . . 0.0 108.873 179.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.49 164.98 11.86 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.821 -1.174 . . . . 0.0 107.915 179.079 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.624 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.4 p -144.95 116.52 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.036 -1.04 . . . . 0.0 109.774 -178.276 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.48 -176.23 37.43 Favored Glycine 0 N--CA 1.494 2.519 0 C-N-CA 118.348 -1.882 . . . . 0.0 111.886 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.567 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.1 pt20 -100.4 109.6 21.77 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-O 121.976 0.893 . . . . 0.0 108.978 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.61 148.75 52.44 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.212 -0.93 . . . . 0.0 109.613 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.15 138.01 54.48 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.263 -0.898 . . . . 0.0 110.875 -178.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.625 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.12 27.0 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 177.915 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 m -105.0 14.84 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 120.842 -1.162 . . . . 0.0 110.518 -178.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.42 -175.23 0.08 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 120.931 -1.106 . . . . 0.0 110.005 179.738 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.28 98.92 2.76 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.428 -0.795 . . . . 0.0 109.489 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.63 27.62 31.84 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 120.203 -0.999 . . . . 0.0 111.433 179.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -118.17 106.12 19.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 O-C-N 120.66 -1.494 . . . . 0.0 107.225 178.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.625 HD12 ' CD1' ' A' ' 39' ' ' TRP . 13.3 tp -117.94 104.53 10.99 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.475 -1.391 . . . . 0.0 109.874 -177.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.541 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.94 109.36 22.13 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 120.745 -1.222 . . . . 0.0 107.932 178.77 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.489 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 5.0 t -108.92 162.13 14.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.028 -1.045 . . . . 0.0 110.379 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.487 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 12.9 t-20 -107.36 129.18 24.64 Favored Pre-proline 0 N--CA 1.5 2.03 0 O-C-N 121.424 -0.797 . . . . 0.0 109.63 -179.404 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.0 OUTLIER -71.18 20.24 0.23 Allowed 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 122.057 1.838 . . . . 0.0 111.95 179.388 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.81 2.68 23.74 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.515 -1.366 . . . . 0.0 108.841 179.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.52 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.01 17.89 2.82 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 179.418 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -81.76 86.94 6.37 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.524 -0.735 . . . . 0.0 111.086 -178.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -102.89 -165.54 1.18 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 178.19 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.467 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.8 137.13 0.09 Allowed 'General case' 0 N--CA 1.486 1.354 0 O-C-N 120.532 -1.355 . . . . 0.0 111.212 -179.399 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.603 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -155.2 156.58 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 178.37 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.567 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.69 141.67 31.21 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.952 -1.093 . . . . 0.0 109.879 -179.802 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.688 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -62.23 107.17 0.84 Allowed 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 122.45 1.119 . . . . 0.0 109.39 178.231 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.52 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.9 t0 -62.17 -138.54 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.001 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.7 -52.42 31.34 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.391 -0.818 . . . . 0.0 110.871 -178.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -103.61 -32.81 9.24 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 178.633 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.688 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.8 62.57 0.54 Allowed Glycine 0 C--N 1.297 -1.627 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 178.04 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 37.0 m -101.04 127.14 47.7 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.603 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.13 109.2 7.2 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 119.074 -1.05 . . . . 0.0 109.877 -179.089 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 48.2 p -121.27 119.69 32.99 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.282 -0.886 . . . . 0.0 109.417 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.418 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.56 145.7 31.96 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.581 -0.699 . . . . 0.0 109.289 179.831 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.3 p -98.91 143.34 29.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.407 -0.808 . . . . 0.0 109.736 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.52 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -141.07 163.0 34.15 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.483 -0.761 . . . . 0.0 109.141 -179.486 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 5.1 p -92.77 123.98 36.44 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.045 -1.035 . . . . 0.0 109.521 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.566 ' CG2' ' CG1' ' A' ' 19' ' ' VAL . 17.8 m -137.78 144.16 31.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.001 -1.062 . . . . 0.0 109.453 -179.586 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.561 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.3 ptt180 -138.89 -168.77 2.49 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.507 -1.371 . . . . 0.0 110.544 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.658 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 3.9 mtt180 -65.48 -73.81 0.12 Allowed 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -76.72 145.43 38.66 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 178.159 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 0.9 OUTLIER -164.98 138.68 4.83 Favored 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 117.446 -1.702 . . . . 0.0 110.678 -177.478 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.486 ' O ' ' O ' ' A' ' 47' ' ' CYS . 3.7 mp0 -35.22 120.97 0.55 Allowed 'General case' 0 N--CA 1.491 1.614 0 CA-C-O 121.455 0.645 . . . . 0.0 110.361 -178.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.541 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -96.19 51.34 1.65 Allowed Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.485 -0.865 . . . . 0.0 111.018 -179.379 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-85 -40.19 114.64 0.46 Allowed 'General case' 0 N--CA 1.508 2.455 0 O-C-N 121.079 -1.248 . . . . 0.0 109.776 179.567 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.552 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.1 tp -85.73 125.67 33.39 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.855 -1.153 . . . . 0.0 109.754 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.577 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 19.0 t80 -65.24 58.04 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.908 0 O-C-N 120.789 -1.194 . . . . 0.0 109.748 179.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.552 ' N ' ' O ' ' A' ' 77' ' ' LEU . 5.6 t70 -154.97 16.7 0.43 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.13 -0.981 . . . . 0.0 109.559 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.85 -26.83 8.87 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.12 164.96 11.42 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.948 -1.325 . . . . 0.0 110.643 -179.287 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.47 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 2.1 ptm180 -105.38 137.3 43.41 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.505 ' CD1' HD12 ' A' ' 77' ' ' LEU . 1.6 t90 -81.15 -19.77 42.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.852 -1.155 . . . . 0.0 110.421 -178.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.62 176.1 19.23 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.679 -1.769 . . . . 0.0 108.679 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.97 106.44 1.24 Allowed 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.559 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 38.7 t -78.03 107.55 10.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.363 -0.836 . . . . 0.0 109.205 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -68.71 112.99 5.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.518 -0.738 . . . . 0.0 109.91 -179.371 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.658 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 7.5 m -58.43 -6.98 0.77 Allowed 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.632 -1.293 . . . . 0.0 110.424 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.8 p -87.08 -4.77 59.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.298 -1.501 . . . . 0.0 109.617 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.437 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -103.38 -47.08 4.4 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.245 -0.909 . . . . 0.0 108.94 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.08 -178.06 3.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.553 -0.717 . . . . 0.0 109.357 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.08 117.57 35.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.403 -0.811 . . . . 0.0 108.821 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.489 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 3.2 m -96.47 121.26 38.1 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.846 -1.159 . . . . 0.0 109.724 -179.114 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.53 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.46 146.55 28.7 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 122.384 1.088 . . . . 0.0 111.37 -179.391 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.532 ' CG1' HG12 ' A' ' 7' ' ' VAL . 57.5 t -103.59 109.94 28.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 177.62 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.433 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.63 -171.54 16.8 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.221 -1.942 . . . . 0.0 111.638 -177.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.489 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.28 178.74 4.21 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 -179.067 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.59 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.1 p -171.58 168.54 6.32 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.565 -0.709 . . . . 0.0 109.406 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.573 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -119.35 -158.16 0.72 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.072 -1.017 . . . . 0.0 108.945 179.711 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.458 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.45 36.43 4.27 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.733 -1.23 . . . . 0.0 109.138 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.45 ' HB1' ' OD2' ' A' ' 99' ' ' ASP . . . -115.29 -32.49 5.62 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.442 -0.786 . . . . 0.0 110.075 -179.66 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.519 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 163.99 -35.69 0.3 Allowed Glycine 0 N--CA 1.481 1.65 0 N-CA-C 107.778 -2.129 . . . . 0.0 107.778 -179.561 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.97 -177.74 5.99 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.64 -0.918 . . . . 0.0 109.742 179.273 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.04 -162.16 15.52 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 108.445 -1.862 . . . . 0.0 108.445 -179.439 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.2 Cg_exo -47.27 178.71 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.644 0 CA-C-N 118.789 1.295 . . . . 0.0 110.313 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -92.42 -172.97 3.25 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.007 -1.058 . . . . 0.0 110.36 -178.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.433 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.33 163.34 14.81 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.456 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.28 131.12 48.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.424 -1.045 . . . . 0.0 109.075 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.53 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.81 120.68 19.74 Favored 'General case' 0 C--N 1.29 -2.021 0 O-C-N 121.613 -0.679 . . . . 0.0 109.842 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.582 HD13 ' CZ ' ' A' ' 112' ' ' PHE . 1.4 pt -98.09 170.43 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.276 -0.89 . . . . 0.0 108.896 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.515 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.9 153.96 51.29 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.127 -0.983 . . . . 0.0 109.551 179.899 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.6 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 67.2 m-85 -130.31 95.14 3.83 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.249 -0.907 . . . . 0.0 109.527 -179.577 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.9 p30 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 117.868 -1.063 . . . . 0.0 109.558 179.951 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.592 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.445 ' HB3' ' OD1' ' A' ' 60' ' ' ASN . . . . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.4 ' O ' HG22 ' A' ' 4' ' ' THR . . . -125.54 97.93 35.67 Favored Pre-proline 0 N--CA 1.487 1.413 0 O-C-N 121.33 -0.856 . . . . 0.0 109.398 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.524 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 6.3 Cg_exo -58.46 157.45 26.76 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.045 1.83 . . . . 0.0 110.194 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.538 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -179.92 -169.26 0.13 Allowed 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 179.543 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.538 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -166.55 133.85 2.61 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.758 -1.214 . . . . 0.0 110.974 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.537 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.4 p -101.61 104.51 15.38 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 122.439 1.114 . . . . 0.0 109.864 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.518 HG11 ' CG1' ' A' ' 95' ' ' VAL . 4.1 t -118.84 118.97 59.55 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.462 179.783 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.502 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.84 147.96 9.59 Favored Pre-proline 0 C--N 1.306 -1.324 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 -179.832 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.502 ' CA ' HG21 ' A' ' 8' ' ' THR . 3.8 Cg_endo -76.17 151.31 95.02 Favored 'Cis proline' 0 C--N 1.309 -1.541 0 C-N-CA 123.593 -1.42 . . . . 0.0 109.596 -0.406 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.504 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 2.5 p -90.38 -25.37 20.46 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.426 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.469 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.1 m -136.05 165.86 24.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.609 -0.682 . . . . 0.0 109.331 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.22 37.58 36.71 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 108.463 -1.855 . . . . 0.0 108.463 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.601 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 36.0 mt -92.27 -43.0 9.53 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 123.297 1.522 . . . . 0.0 110.44 -178.33 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.487 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.48 144.35 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.29 0 CA-C-N 113.522 -1.672 . . . . 0.0 109.788 -179.62 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.551 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.7 p-10 -51.27 106.2 0.13 Allowed 'General case' 0 C--N 1.301 -1.54 0 CA-C-O 121.539 0.685 . . . . 0.0 111.597 -178.385 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.38 15.95 8.58 Favored Glycine 0 N--CA 1.484 1.884 0 C-N-CA 119.473 -1.346 . . . . 0.0 112.855 177.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.601 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.1 t -104.41 -170.88 1.83 Allowed 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 121.169 2.484 . . . . 0.0 109.727 179.176 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.571 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 14.2 t -130.38 138.92 52.65 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.166 -178.883 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.537 HG12 ' CG2' ' A' ' 69' ' ' VAL . 33.7 m -118.18 155.04 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tttt -109.26 109.4 20.31 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.162 -0.961 . . . . 0.0 109.509 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 1.9 p -105.86 124.59 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.489 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.537 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -117.66 167.21 11.55 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.668 -1.27 . . . . 0.0 109.253 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.61 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.07 141.05 12.38 Favored Glycine 0 C--N 1.296 -1.666 0 N-CA-C 107.466 -2.254 . . . . 0.0 107.466 179.672 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.517 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.28 123.94 11.84 Favored 'General case' 0 C--N 1.295 -1.8 0 O-C-N 120.571 -1.546 . . . . 0.0 108.819 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.524 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.37 27.12 23.69 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.13 -1.51 . . . . 0.0 109.899 -179.666 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.537 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -88.06 174.33 8.34 Favored 'General case' 0 C--N 1.308 -1.227 0 O-C-N 120.788 -1.419 . . . . 0.0 108.473 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.547 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.88 97.54 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 122.257 1.027 . . . . 0.0 109.724 -179.853 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.99 77.26 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.437 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.77 33.65 0.29 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.302 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 50.5 p -145.53 112.0 5.81 Favored 'General case' 0 C--N 1.31 -1.145 0 O-C-N 120.896 -1.355 . . . . 0.0 111.448 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.549 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -48.52 116.19 1.5 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.934 178.286 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.602 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 4.0 m-30 -112.28 153.87 26.51 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.225 -0.922 . . . . 0.0 108.708 179.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.459 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -98.92 165.36 11.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.849 -1.157 . . . . 0.0 108.095 179.003 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.588 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.8 p -145.15 116.64 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.114 -0.991 . . . . 0.0 109.878 -177.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.55 -175.97 39.07 Favored Glycine 0 N--CA 1.491 2.336 0 C-N-CA 118.267 -1.92 . . . . 0.0 111.754 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.567 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -100.22 113.75 26.67 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.622 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 85.0 m -131.88 153.81 49.84 Favored 'General case' 0 C--N 1.292 -1.901 0 O-C-N 121.6 -0.688 . . . . 0.0 109.602 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -129.88 136.78 49.92 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.448 -0.782 . . . . 0.0 110.565 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.639 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.69 114.45 26.38 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 178.318 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m -105.45 15.08 7.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.951 -1.093 . . . . 0.0 110.713 -178.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.597 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.22 -174.54 0.07 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.87 -1.144 . . . . 0.0 110.08 179.699 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 40.1 p -71.33 96.81 1.49 Allowed 'General case' 0 N--CA 1.485 1.323 0 O-C-N 121.382 -0.824 . . . . 0.0 109.878 -179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.26 27.95 31.92 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 120.21 -0.995 . . . . 0.0 111.564 178.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.597 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -115.54 106.38 20.36 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.54 -1.565 . . . . 0.0 107.464 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.639 HD12 ' CE2' ' A' ' 39' ' ' TRP . 11.8 tp -116.31 106.54 13.77 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.591 -1.318 . . . . 0.0 109.912 -177.621 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.576 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -96.77 113.22 24.76 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 120.821 -1.174 . . . . 0.0 108.515 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.559 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . 97.4 m -105.34 147.39 28.21 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.279 -0.888 . . . . 0.0 110.361 -178.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.465 ' OD1' ' HB2' ' A' ' 74' ' ' GLU . 32.7 t30 -97.52 135.94 21.5 Favored Pre-proline 0 N--CA 1.505 2.305 0 O-C-N 120.937 -1.102 . . . . 0.0 108.759 178.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.605 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.8 Cg_endo -74.85 26.51 0.36 Allowed 'Trans proline' 0 C--N 1.319 -1.004 0 C-N-CA 122.396 2.064 . . . . 0.0 112.29 -179.098 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.431 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -120.76 6.05 10.48 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.213 -1.554 . . . . 0.0 109.536 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.505 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -140.48 17.93 2.38 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 179.367 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.559 ' CE2' ' HB3' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -83.58 89.84 7.16 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.248 -178.437 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.588 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -109.99 -166.77 1.12 Allowed 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.153 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.477 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.66 135.61 0.09 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.421 -1.425 . . . . 0.0 111.573 -179.294 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.562 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.2 p -151.73 159.72 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 177.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.549 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.6 144.44 27.89 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.731 -1.231 . . . . 0.0 110.016 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.675 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.51 107.83 2.2 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 122.385 1.088 . . . . 0.0 109.342 178.563 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.533 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.7 t0 -62.72 -139.07 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.886 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.28 -52.09 29.7 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.427 -0.795 . . . . 0.0 110.727 -178.582 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.445 ' OD1' ' HB3' ' A' ' 1' ' ' ALA . 1.3 m-20 -104.48 -32.48 8.98 Favored 'General case' 0 C--N 1.286 -2.155 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 178.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.675 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.67 68.22 0.65 Allowed Glycine 0 C--N 1.297 -1.587 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 178.294 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.61 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.0 m -103.47 128.94 50.54 Favored 'General case' 0 N--CA 1.483 1.224 0 O-C-N 121.336 -1.097 . . . . 0.0 109.15 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.562 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -135.63 108.72 7.69 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 119.469 -0.892 . . . . 0.0 109.574 -179.573 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 85.7 p -116.85 117.41 29.66 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.089 -1.007 . . . . 0.0 109.374 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.473 HG23 HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.32 142.51 28.35 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.409 -0.807 . . . . 0.0 109.956 -179.794 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.1 p -102.14 141.32 35.15 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.496 -0.752 . . . . 0.0 109.265 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.525 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -141.58 167.05 23.07 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.337 -0.852 . . . . 0.0 109.509 -179.384 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.571 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.5 p -96.17 124.74 40.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.197 -0.94 . . . . 0.0 109.349 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.537 ' CG2' HG12 ' A' ' 19' ' ' VAL . 18.7 m -138.43 142.55 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.939 -1.101 . . . . 0.0 109.922 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.551 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 8.7 ptt180 -138.56 -164.81 1.7 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.732 -1.23 . . . . 0.0 109.908 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.557 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -74.3 -82.88 0.06 Allowed 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 -179.844 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.76 136.63 57.96 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 178.698 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.567 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -161.46 133.49 5.75 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 118.058 -1.457 . . . . 0.0 110.562 -177.603 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.502 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 3.1 mm-40 -33.04 120.07 0.35 Allowed 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.619 0.723 . . . . 0.0 110.386 -178.456 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.576 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -92.9 50.74 2.54 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.484 -179.074 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.605 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -37.77 116.36 0.49 Allowed 'General case' 0 N--CA 1.507 2.381 0 O-C-N 121.136 -1.214 . . . . 0.0 110.157 179.365 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.535 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.2 tp -86.08 126.09 33.93 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 120.895 -1.128 . . . . 0.0 109.716 -179.777 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.568 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 39.3 t80 -63.62 58.42 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.015 -1.053 . . . . 0.0 110.114 179.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 21.2 t0 -161.01 20.27 0.13 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.904 -1.122 . . . . 0.0 109.737 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.52 -29.09 5.01 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.461 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 9.7 p -95.48 163.88 13.04 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.076 -1.249 . . . . 0.0 110.203 -179.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.453 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 3.3 ptm180 -109.25 139.85 43.64 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.465 ' HB2' HD12 ' A' ' 77' ' ' LEU . 3.6 t90 -82.0 -21.56 37.01 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.861 -1.149 . . . . 0.0 110.353 -178.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.81 175.68 18.14 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.79 110.57 2.11 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 179.037 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.542 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.1 t -82.32 102.61 8.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.652 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.475 ' CB ' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.97 111.21 2.75 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.489 -0.757 . . . . 0.0 109.632 -179.313 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.557 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.23 -4.93 5.8 Favored 'General case' 0 N--CA 1.498 1.973 0 C-N-CA 118.304 -1.358 . . . . 0.0 109.813 179.534 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.3 p -85.51 3.62 39.56 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.786 -1.196 . . . . 0.0 108.823 179.255 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.475 HG23 ' CB ' ' A' ' 87' ' ' ASP . 2.2 p -119.2 -49.82 2.38 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.402 -0.811 . . . . 0.0 108.959 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.71 -178.42 3.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.382 -0.824 . . . . 0.0 109.538 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.64 114.45 28.62 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.486 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.5 m -97.47 121.9 39.9 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.932 -1.105 . . . . 0.0 109.746 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.546 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.74 147.11 26.86 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.412 1.101 . . . . 0.0 111.245 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.518 ' CG1' HG11 ' A' ' 7' ' ' VAL . 52.9 t -103.62 110.82 31.13 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 106.913 -1.514 . . . . 0.0 106.913 177.796 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.444 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.51 -170.8 18.77 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.076 -2.012 . . . . 0.0 111.884 -177.587 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.466 HD12 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -115.96 -179.89 3.79 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 -179.167 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.586 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.4 p -171.05 167.3 7.23 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.515 -0.741 . . . . 0.0 109.317 -179.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.602 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -112.82 -160.13 0.71 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.086 -1.009 . . . . 0.0 108.962 179.806 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -118.54 36.51 4.37 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.688 -1.258 . . . . 0.0 109.222 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.03 -32.91 4.6 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.332 -0.855 . . . . 0.0 110.174 -179.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.518 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 167.52 -36.91 0.22 Allowed Glycine 0 N--CA 1.48 1.624 0 N-CA-C 107.833 -2.107 . . . . 0.0 107.833 -179.543 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.74 -178.16 6.87 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.572 -0.958 . . . . 0.0 109.754 179.255 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.68 -161.45 14.73 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.257 -1.937 . . . . 0.0 108.257 -179.325 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.0 Cg_exo -47.6 179.65 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.82 1.31 . . . . 0.0 110.261 179.19 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -94.05 -170.54 2.33 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.066 -1.021 . . . . 0.0 110.334 -178.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.444 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.31 162.75 18.34 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.11 128.45 50.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.381 -1.07 . . . . 0.0 109.15 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.546 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.24 119.64 15.67 Favored 'General case' 0 C--N 1.289 -2.056 0 O-C-N 121.669 -0.644 . . . . 0.0 109.738 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.577 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.7 pt -98.12 171.31 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.219 -0.926 . . . . 0.0 109.097 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.469 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.01 156.62 47.07 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.074 -1.016 . . . . 0.0 109.844 -179.822 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.577 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 96.8 m-85 -131.09 110.44 11.19 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.191 -0.943 . . . . 0.0 109.609 -179.686 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.2 p30 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.492 -179.929 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.586 ' C20' ' CB ' ' A' ' 98' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.445 -0.576 . . . . 1.0 109.445 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -101.32 147.58 33.97 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.317 -0.865 . . . . 1.0 109.449 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.534 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.5 Cg_exo -60.06 158.14 31.25 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.322 2.015 . . . . 1.0 110.561 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.536 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.54 -169.85 0.15 Allowed 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 108.177 -1.045 . . . . 1.0 108.177 179.206 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.536 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.35 130.0 2.44 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 120.873 -1.142 . . . . 1.0 110.597 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.544 ' CG2' ' O ' ' A' ' 6' ' ' THR . 7.6 t -110.31 108.67 18.83 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 123.085 1.421 . . . . 1.0 109.01 179.355 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.53 HG12 ' CG1' ' A' ' 95' ' ' VAL . 3.2 t -117.19 136.36 54.6 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.702 0 CA-C-N 114.3 -1.318 . . . . 1.0 110.002 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.484 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.31 148.76 2.43 Favored Pre-proline 0 N--CA 1.487 1.376 0 O-C-N 121.287 -0.883 . . . . 1.0 108.897 -179.64 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.484 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -79.21 148.67 82.13 Favored 'Cis proline' 0 C--N 1.311 -1.408 0 C-N-CA 123.438 -1.484 . . . . 1.0 109.52 -1.052 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.465 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 42.8 p -88.34 -25.5 22.71 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 108.981 -0.748 . . . . 1.0 108.981 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.466 ' HB3' ' CB ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -131.91 161.86 32.03 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.454 -0.779 . . . . 1.0 109.674 -179.787 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.88 37.63 29.14 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 108.592 -1.803 . . . . 1.0 108.592 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.608 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.2 mt -92.78 -43.54 8.97 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 123.099 1.428 . . . . 1.0 110.636 -178.343 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.487 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.14 145.19 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.295 0 CA-C-N 113.571 -1.65 . . . . 1.0 110.03 -179.596 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.555 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.8 p-10 -51.16 106.93 0.15 Allowed 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.462 0.648 . . . . 1.0 111.564 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.47 15.22 9.02 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 119.385 -1.388 . . . . 1.0 112.871 177.217 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.608 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 13.5 t -104.54 -171.69 1.97 Allowed 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 121.133 2.467 . . . . 1.0 109.671 179.204 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.557 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 15.1 t -128.58 137.56 56.99 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.387 0 CA-C-N 114.874 -1.057 . . . . 1.0 110.979 -179.066 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.526 HG12 ' CG2' ' A' ' 69' ' ' VAL . 35.2 m -114.13 154.75 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 108.808 -0.812 . . . . 1.0 108.808 179.036 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.5 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.65 109.23 20.37 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.226 -0.921 . . . . 1.0 108.797 179.718 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.47 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.2 p -103.82 141.6 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.727 -0.842 . . . . 1.0 108.727 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.548 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -138.24 160.23 39.99 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.72 -1.238 . . . . 1.0 109.982 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.76 144.21 15.37 Favored Glycine 0 C--N 1.295 -1.742 0 N-CA-C 108.089 -2.004 . . . . 1.0 108.089 179.811 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.505 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.11 125.53 13.16 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 120.913 -1.345 . . . . 1.0 108.828 179.028 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.534 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.08 27.09 26.89 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.216 -1.469 . . . . 1.0 109.912 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.545 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.8 mt -87.13 175.02 8.28 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 120.799 -1.412 . . . . 1.0 108.463 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.554 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.58 99.74 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.978 -1.076 . . . . 1.0 109.689 -179.79 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 77.76 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 115.226 -0.897 . . . . 1.0 110.247 -179.063 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.4 34.13 0.33 Allowed Glycine 0 N--CA 1.488 2.117 0 N-CA-C 109.496 -1.441 . . . . 1.0 109.496 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.541 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 42.9 p -141.24 108.56 5.53 Favored 'General case' 0 C--N 1.306 -1.302 0 O-C-N 121.123 -1.222 . . . . 1.0 111.311 -179.636 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.56 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.35 110.06 0.37 Allowed 'General case' 0 N--CA 1.497 1.888 0 CA-C-N 115.9 -0.591 . . . . 1.0 109.455 178.031 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.564 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 5.2 m-30 -106.75 155.99 19.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.133 -0.98 . . . . 1.0 108.982 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.467 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.82 165.17 11.7 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.876 -1.157 . . . . 1.0 107.876 179.045 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.622 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 7.5 p -145.7 114.85 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.066 -1.021 . . . . 1.0 109.941 -178.048 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.49 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.01 -176.41 37.3 Favored Glycine 0 N--CA 1.492 2.398 0 C-N-CA 118.499 -1.81 . . . . 1.0 111.564 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.611 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.5 pt20 -100.1 110.02 22.31 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-O 121.941 0.877 . . . . 1.0 108.966 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.451 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -130.08 150.81 51.18 Favored 'General case' 0 C--N 1.296 -1.74 0 O-C-N 121.217 -0.927 . . . . 1.0 109.837 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.83 139.78 52.84 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.222 -0.924 . . . . 1.0 110.808 -179.037 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.62 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.15 114.78 26.61 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 107.62 -1.252 . . . . 1.0 107.62 178.246 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.416 HG21 ' HB ' ' A' ' 44' ' ' VAL . 17.8 m -104.6 14.99 6.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 120.938 -1.101 . . . . 1.0 110.575 -178.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.588 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.61 -176.28 0.09 Allowed 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.863 -1.148 . . . . 1.0 110.184 179.716 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.546 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.89 97.47 1.42 Allowed 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.436 -0.79 . . . . 1.0 109.847 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.63 27.8 34.32 Favored Glycine 0 N--CA 1.493 2.493 0 C-N-CA 120.145 -1.026 . . . . 1.0 111.434 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.588 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.32 106.6 20.65 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 O-C-N 120.668 -1.489 . . . . 1.0 107.171 178.868 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.62 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.2 tp -116.06 104.67 11.8 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.449 -1.407 . . . . 1.0 109.982 -177.691 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.535 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.23 109.58 22.31 Favored 'General case' 0 N--CA 1.485 1.291 0 O-C-N 120.818 -1.176 . . . . 1.0 108.079 178.848 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.18 166.21 10.79 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.912 -1.117 . . . . 1.0 110.356 -178.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.522 ' ND2' ' HB2' ' A' ' 50' ' ' ALA . 46.0 t30 -112.01 129.85 23.84 Favored Pre-proline 0 N--CA 1.501 2.1 0 O-C-N 121.366 -0.834 . . . . 1.0 109.796 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.609 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.5 Cg_endo -71.65 22.31 0.25 Allowed 'Trans proline' 0 CA--C 1.545 1.056 0 C-N-CA 122.219 1.946 . . . . 1.0 112.342 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.522 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -109.87 2.79 20.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.415 -1.428 . . . . 1.0 109.049 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.5 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.65 18.87 2.52 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.135 -1.432 . . . . 1.0 107.135 179.41 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -82.13 89.73 6.5 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.934 -0.707 . . . . 1.0 111.127 -178.395 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -106.97 -166.87 1.21 Allowed 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 107.562 -1.273 . . . . 1.0 107.562 178.077 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.468 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.2 136.35 0.1 Allowed 'General case' 0 C--N 1.306 -1.307 0 O-C-N 120.538 -1.351 . . . . 1.0 111.304 -179.346 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.585 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -154.46 158.8 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.635 -1.246 . . . . 1.0 107.635 178.337 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.56 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.8 142.25 30.57 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.807 -1.183 . . . . 1.0 109.901 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.677 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.53 107.12 1.06 Allowed 'General case' 0 C--N 1.299 -1.602 0 CA-C-O 122.423 1.106 . . . . 1.0 109.295 178.253 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.53 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.2 p-10 -58.88 -138.84 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.583 -0.735 . . . . 1.0 110.821 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -54.65 -49.81 69.68 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.374 -0.829 . . . . 1.0 110.231 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.421 ' OD1' ' N ' ' A' ' 61' ' ' GLY . 12.3 p30 -100.23 -38.82 8.33 Favored 'General case' 0 C--N 1.285 -2.219 0 N-CA-C 106.122 -1.807 . . . . 1.0 106.122 178.492 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.677 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 109.92 65.93 0.55 Allowed Glycine 0 C--N 1.296 -1.648 0 N-CA-C 110.239 -1.144 . . . . 1.0 110.239 178.263 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.4 m -102.82 129.12 49.39 Favored 'General case' 0 N--CA 1.483 1.19 0 O-C-N 121.49 -1.006 . . . . 1.0 108.948 179.043 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.585 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -138.17 108.87 6.61 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 119.274 -0.971 . . . . 1.0 109.921 -179.371 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -124.02 120.96 33.97 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.244 -0.91 . . . . 1.0 109.801 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.48 HG21 HG13 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -146.44 149.48 33.78 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.486 -0.759 . . . . 1.0 109.07 179.587 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.5 p -100.31 145.62 27.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.312 -0.867 . . . . 1.0 109.741 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.528 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -145.95 165.81 27.87 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.472 -0.768 . . . . 1.0 109.242 -179.457 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.557 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.8 p -96.53 124.88 40.66 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.0 -1.063 . . . . 1.0 109.477 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.526 ' CG2' HG12 ' A' ' 19' ' ' VAL . 17.0 m -138.74 143.1 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 120.972 -1.08 . . . . 1.0 109.808 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.555 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 7.6 ptt180 -140.02 -163.46 1.51 Allowed 'General case' 0 N--CA 1.486 1.351 0 O-C-N 120.593 -1.317 . . . . 1.0 109.871 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.564 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -75.03 -82.28 0.07 Allowed 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.083 -1.011 . . . . 1.0 108.87 -179.609 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.44 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -62.75 137.51 58.28 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.305 -1.497 . . . . 1.0 107.357 178.861 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.563 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.2 OUTLIER -163.22 134.09 4.69 Favored 'General case' 0 C--N 1.293 -1.863 0 C-N-CA 118.045 -1.462 . . . . 1.0 110.522 -177.656 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.482 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . 3.6 mm-40 -32.56 121.21 0.33 Allowed 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 121.642 0.734 . . . . 1.0 110.773 -178.357 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.535 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.06 49.78 3.05 Favored Glycine 0 N--CA 1.496 2.649 0 C-N-CA 120.754 -0.736 . . . . 1.0 111.546 -179.139 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.609 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-30 -38.57 115.42 0.46 Allowed 'General case' 0 N--CA 1.511 2.594 0 O-C-N 121.028 -1.277 . . . . 1.0 110.14 179.318 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -87.05 125.89 34.4 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.857 -1.152 . . . . 1.0 109.744 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.581 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.3 t80 -64.68 58.26 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.927 0 O-C-N 120.86 -1.15 . . . . 1.0 109.869 179.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -158.08 18.47 0.24 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.035 -1.04 . . . . 1.0 109.677 -179.948 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.21 -27.56 6.11 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.919 -1.272 . . . . 1.0 109.919 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.407 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -98.17 164.7 12.21 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.069 -1.253 . . . . 1.0 110.337 -179.482 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.515 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.13 140.35 41.46 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.858 -0.793 . . . . 1.0 108.858 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.493 ' CD1' HD12 ' A' ' 77' ' ' LEU . 4.2 t90 -84.2 -22.34 30.95 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.845 -1.159 . . . . 1.0 110.604 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.73 175.13 17.55 Favored Glycine 0 N--CA 1.485 1.922 0 N-CA-C 108.688 -1.765 . . . . 1.0 108.688 -179.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.67 112.0 2.65 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.712 -1.218 . . . . 1.0 107.712 179.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.51 HG23 ' HA3' ' A' ' 75' ' ' GLY . 43.3 t -84.55 103.95 12.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.289 -0.882 . . . . 1.0 108.928 -179.049 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.462 ' CB ' HG22 ' A' ' 90' ' ' THR . 0.5 OUTLIER -66.58 111.65 3.74 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.357 -0.839 . . . . 1.0 109.645 -179.439 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.564 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.38 -5.3 4.97 Favored 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 118.172 -1.411 . . . . 1.0 109.948 179.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 45.5 p -84.39 0.46 49.3 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.75 -1.219 . . . . 1.0 108.772 179.195 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.462 HG22 ' CB ' ' A' ' 87' ' ' ASP . 2.3 p -115.84 -50.35 2.69 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.392 -0.817 . . . . 1.0 109.054 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.29 -178.01 3.54 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.508 -0.745 . . . . 1.0 109.514 179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.09 115.36 30.04 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.369 -0.832 . . . . 1.0 108.95 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.523 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -97.29 123.2 41.02 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.901 -1.125 . . . . 1.0 109.917 -179.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.553 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.28 148.2 26.62 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-O 122.373 1.082 . . . . 1.0 111.102 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.53 ' CG1' HG12 ' A' ' 7' ' ' VAL . 61.1 t -103.23 110.2 29.09 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 N-CA-C 106.721 -1.585 . . . . 1.0 106.721 177.618 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.416 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.46 -172.78 18.7 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 118.08 -2.01 . . . . 1.0 111.679 -177.614 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -114.77 179.88 3.82 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.945 -0.761 . . . . 1.0 108.945 -179.175 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.581 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 66.9 p -167.95 162.21 13.29 Favored 'General case' 0 C--N 1.295 -1.766 0 O-C-N 121.472 -0.768 . . . . 1.0 109.291 -179.279 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.564 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -108.9 -159.92 0.7 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.194 -0.941 . . . . 1.0 108.703 179.61 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -119.13 36.12 4.58 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.613 -1.305 . . . . 1.0 109.264 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -119.07 -31.77 4.63 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.338 -0.851 . . . . 1.0 110.372 -179.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.521 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 166.84 -36.72 0.24 Allowed Glycine 0 N--CA 1.482 1.722 0 N-CA-C 107.742 -2.143 . . . . 1.0 107.742 -179.5 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.43 -177.96 6.92 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.675 -0.897 . . . . 1.0 109.935 179.254 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.7 -163.84 19.94 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 108.319 -1.912 . . . . 1.0 108.319 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.4 Cg_exo -47.68 177.88 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 CA-C-N 118.763 1.281 . . . . 1.0 110.233 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -94.86 -176.25 3.8 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.236 -0.915 . . . . 1.0 110.186 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.416 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.68 163.98 13.06 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.787 -1.325 . . . . 1.0 109.787 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.411 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.5 132.35 46.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.381 -1.07 . . . . 1.0 109.063 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.553 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.0 125.44 27.62 Favored 'General case' 0 C--N 1.29 -2.017 0 O-C-N 121.649 -0.657 . . . . 1.0 109.868 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.571 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.67 171.95 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.356 -0.84 . . . . 1.0 108.953 179.611 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.466 ' CB ' ' HB3' ' A' ' 11' ' ' SER . 0.4 OUTLIER -136.51 156.27 48.83 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.118 -0.989 . . . . 1.0 109.58 -179.925 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.571 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 93.0 m-85 -128.27 66.46 1.38 Allowed 'General case' 0 N--CA 1.484 1.274 0 O-C-N 121.134 -0.979 . . . . 1.0 109.506 -179.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.439 ' O ' ' OD1' ' A' ' 113' ' ' ASN . 17.7 p30 . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 118.041 -0.98 . . . . 1.0 109.565 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.588 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 121.301 0.572 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.528 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . . . -123.7 173.81 4.17 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.285 -0.884 . . . . 0.0 109.505 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.53 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 4.9 Cg_exo -60.45 157.01 38.19 Favored 'Trans proline' 0 C--N 1.311 -1.442 0 C-N-CA 122.313 2.009 . . . . 0.0 110.843 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.54 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.89 -169.64 0.13 Allowed 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.228 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.54 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -167.74 133.19 1.94 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.698 -1.251 . . . . 0.0 111.047 -179.354 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.53 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.2 p -100.88 104.32 15.53 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-O 122.407 1.099 . . . . 0.0 109.816 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.534 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 6.2 t -119.79 118.0 55.66 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.459 0 CA-C-O 121.694 0.759 . . . . 0.0 110.405 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.493 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.78 149.08 7.93 Favored Pre-proline 0 N--CA 1.488 1.425 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 -179.568 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG22 ' A' ' 8' ' ' THR . 2.2 Cg_endo -75.26 152.85 98.33 Favored 'Cis proline' 0 C--N 1.309 -1.535 0 C-N-CA 123.583 -1.424 . . . . 0.0 109.762 -0.301 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.476 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 6.5 m -91.5 -25.0 19.48 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.469 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.8 m -137.85 165.1 27.3 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.637 -0.664 . . . . 0.0 109.253 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.27 37.49 31.8 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 108.564 -1.814 . . . . 0.0 108.564 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.603 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 40.0 mt -92.07 -42.43 9.95 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 123.311 1.529 . . . . 0.0 110.522 -178.487 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.67 142.67 0.05 OUTLIER 'General case' 0 C--N 1.259 -3.327 0 CA-C-N 113.405 -1.725 . . . . 0.0 109.731 -179.644 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.587 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.6 p-10 -50.28 105.78 0.1 Allowed 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.521 0.677 . . . . 0.0 111.473 -178.549 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.49 14.22 8.33 Favored Glycine 0 N--CA 1.485 1.928 0 C-N-CA 119.413 -1.375 . . . . 0.0 113.018 177.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.603 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.0 t -106.3 -172.57 2.11 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 121.221 2.51 . . . . 0.0 109.832 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.57 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 18.8 t -129.0 139.76 51.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 CA-C-N 114.823 -1.08 . . . . 0.0 111.204 -178.644 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.504 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 27.1 m -115.88 155.61 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.7 tttt -107.86 108.79 20.11 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.021 -1.05 . . . . 0.0 109.552 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.492 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 p -106.8 122.67 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.53 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -117.83 167.48 11.36 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 120.795 -1.191 . . . . 0.0 109.064 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.594 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.86 142.44 13.95 Favored Glycine 0 C--N 1.295 -1.733 0 N-CA-C 107.935 -2.066 . . . . 0.0 107.935 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.53 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -147.16 123.7 11.07 Favored 'General case' 0 C--N 1.294 -1.834 0 O-C-N 120.812 -1.405 . . . . 0.0 108.64 179.237 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.527 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.19 27.25 23.72 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 119.313 -1.422 . . . . 0.0 109.838 -179.595 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.539 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.6 mt -87.73 175.14 8.0 Favored 'General case' 0 C--N 1.308 -1.236 0 O-C-N 120.877 -1.367 . . . . 0.0 108.466 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.55 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.61 96.95 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.017 -1.052 . . . . 0.0 109.541 -179.899 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.49 76.76 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.791 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.533 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.44 33.49 0.3 Allowed Glycine 0 N--CA 1.486 2.016 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.198 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.618 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.6 t -147.12 114.55 6.31 Favored 'General case' 0 C--N 1.308 -1.223 0 O-C-N 120.791 -1.417 . . . . 0.0 111.173 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.548 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.82 127.32 6.27 Favored 'General case' 0 N--CA 1.49 1.528 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.689 178.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.618 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 9.1 m-85 -116.33 148.61 40.4 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.505 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -101.21 149.33 24.11 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.805 -1.185 . . . . 0.0 107.92 179.135 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.597 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 1.0 OUTLIER -127.43 126.7 67.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.271 -0.893 . . . . 0.0 109.371 -177.935 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.491 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -174.52 174.97 46.79 Favored Glycine 0 N--CA 1.495 2.612 0 C-N-CA 117.833 -2.127 . . . . 0.0 112.42 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.561 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -101.36 108.47 20.1 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.473 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.8 m -131.24 147.92 52.64 Favored 'General case' 0 C--N 1.295 -1.772 0 O-C-N 121.251 -0.905 . . . . 0.0 109.942 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -121.02 139.04 53.84 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.394 -0.816 . . . . 0.0 110.609 -179.094 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.622 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.42 115.03 26.87 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 178.159 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -106.11 14.85 7.41 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 120.963 -1.085 . . . . 0.0 110.529 -178.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.597 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.14 -174.61 0.08 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.848 -1.157 . . . . 0.0 110.121 179.667 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 5.9 p -71.46 96.78 1.54 Allowed 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.46 -0.775 . . . . 0.0 109.931 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 27.83 32.9 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 120.171 -1.014 . . . . 0.0 111.558 178.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.597 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.26 106.28 20.24 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 O-C-N 120.552 -1.558 . . . . 0.0 107.267 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.622 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.3 tp -117.37 104.92 11.61 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.454 -1.404 . . . . 0.0 109.913 -177.686 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.84 109.61 22.33 Favored 'General case' 0 N--CA 1.485 1.287 0 O-C-N 120.706 -1.246 . . . . 0.0 108.296 178.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.3 t -105.97 163.93 12.36 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.041 -1.037 . . . . 0.0 110.198 -178.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.473 ' ND2' ' CB ' ' A' ' 50' ' ' ALA . 20.0 t30 -107.36 139.12 20.19 Favored Pre-proline 0 N--CA 1.502 2.16 0 O-C-N 121.327 -0.858 . . . . 0.0 109.81 -179.372 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.572 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 7.8 Cg_endo -75.88 27.73 0.39 Allowed 'Trans proline' 0 C--N 1.32 -0.964 0 C-N-CA 122.59 2.194 . . . . 0.0 112.135 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.473 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -124.44 9.61 8.47 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.242 -1.536 . . . . 0.0 109.679 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.523 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.46 15.63 2.76 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.403 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -77.69 86.92 3.97 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.856 -0.737 . . . . 0.0 111.421 -178.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.597 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.34 -169.77 1.85 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 177.954 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.71 134.65 0.08 Allowed 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.57 -1.331 . . . . 0.0 111.454 -179.392 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.569 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -160.47 154.73 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 178.18 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.548 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.56 144.83 26.85 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.741 -1.225 . . . . 0.0 109.572 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.677 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.07 106.74 1.69 Allowed 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 122.48 1.134 . . . . 0.0 109.476 178.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.522 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.5 p-10 -59.78 -138.83 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.982 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.893 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.546 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.37 -50.44 59.56 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.467 -0.771 . . . . 0.0 110.548 -178.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -104.97 -34.63 7.95 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 178.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.677 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 109.88 68.32 0.59 Allowed Glycine 0 C--N 1.298 -1.543 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 177.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 59.4 m -103.21 129.23 50.08 Favored 'General case' 0 N--CA 1.484 1.274 0 O-C-N 121.358 -1.084 . . . . 0.0 108.83 178.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.569 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.12 109.27 7.75 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.281 -0.967 . . . . 0.0 110.073 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.6 m -110.23 118.38 36.19 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.205 -0.934 . . . . 0.0 108.787 179.499 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.449 ' OG1' ' OG ' ' A' ' 53' ' ' SER . 0.1 OUTLIER -144.24 139.08 28.45 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.436 -0.79 . . . . 0.0 110.253 -179.514 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 78.8 p -103.18 140.79 36.9 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 179.416 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.523 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.2 OUTLIER -142.84 164.1 31.02 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.173 -0.955 . . . . 0.0 109.994 -179.148 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.8 p -97.59 125.49 42.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.339 -0.851 . . . . 0.0 109.129 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.511 ' CB ' ' OE1' ' A' ' 36' ' ' GLN . 15.2 m -136.44 143.64 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.908 -1.12 . . . . 0.0 109.803 -179.087 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.587 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -146.7 -176.12 5.06 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.44 -1.413 . . . . 0.0 111.156 -179.787 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.562 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.91 -100.54 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 -179.581 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.455 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.05 140.4 49.27 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 179.353 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.44 135.94 6.16 Favored 'General case' 0 C--N 1.294 -1.817 0 C-N-CA 118.584 -1.246 . . . . 0.0 109.764 -177.996 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.512 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 3.9 mm-40 -33.07 121.47 0.37 Allowed 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.547 0.689 . . . . 0.0 110.431 -178.482 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.533 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -91.89 48.08 2.74 Favored Glycine 0 N--CA 1.492 2.408 0 C-N-CA 120.602 -0.808 . . . . 0.0 111.195 -179.177 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.572 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -38.22 115.18 0.42 Allowed 'General case' 0 N--CA 1.511 2.623 0 O-C-N 121.118 -1.225 . . . . 0.0 109.974 179.695 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -87.29 125.76 34.42 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.944 -1.098 . . . . 0.0 109.321 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.585 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 19.6 t80 -64.2 58.65 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.891 -1.131 . . . . 0.0 110.215 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t0 -160.67 20.0 0.14 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.973 -1.079 . . . . 0.0 109.749 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.93 -27.8 5.3 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.439 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 80.7 p -94.22 159.42 15.14 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.038 -1.272 . . . . 0.0 110.269 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.483 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 4.4 ptt180 -107.32 137.59 45.09 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.463 ' HB2' HD12 ' A' ' 77' ' ' LEU . 1.9 t90 -83.76 -18.51 37.53 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.821 -1.174 . . . . 0.0 110.79 -178.231 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.97 175.08 19.8 Favored Glycine 0 N--CA 1.485 1.937 0 N-CA-C 108.711 -1.755 . . . . 0.0 108.711 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.21 106.77 1.15 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.562 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 43.4 t -79.1 106.41 10.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.286 -0.884 . . . . 0.0 109.264 -179.025 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.524 ' CB ' HG21 ' A' ' 90' ' ' THR . 0.9 OUTLIER -65.84 111.13 3.12 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.533 -0.73 . . . . 0.0 109.904 -179.442 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.562 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.26 -4.97 4.21 Favored 'General case' 0 N--CA 1.499 1.98 0 C-N-CA 118.246 -1.382 . . . . 0.0 109.814 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -86.39 -0.49 56.06 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.891 -1.131 . . . . 0.0 109.156 179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.524 HG21 ' CB ' ' A' ' 87' ' ' ASP . 2.2 p -113.31 -50.05 2.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.392 -0.818 . . . . 0.0 109.013 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.74 179.96 4.12 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.453 -0.779 . . . . 0.0 109.427 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.69 115.73 31.03 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.366 -0.834 . . . . 0.0 109.103 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.72 121.07 38.16 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.917 -1.114 . . . . 0.0 109.383 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.556 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.18 146.15 27.2 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-O 122.273 1.035 . . . . 0.0 111.193 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 71.7 t -105.73 112.2 38.12 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.168 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.48 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -152.49 -169.98 18.44 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 118.018 -2.039 . . . . 0.0 111.578 -178.011 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -112.64 -179.0 3.54 Favored 'General case' 0 N--CA 1.484 1.272 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -179.189 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.584 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -171.83 167.35 6.33 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.17 -0.956 . . . . 0.0 109.826 -179.402 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.89 -160.04 0.71 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.108 -0.995 . . . . 0.0 108.822 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -119.69 35.64 4.78 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.614 -1.304 . . . . 0.0 109.452 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.49 -32.37 4.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.359 -0.838 . . . . 0.0 110.219 -179.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.528 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 170.18 -38.45 0.19 Allowed Glycine 0 N--CA 1.481 1.679 0 N-CA-C 107.709 -2.156 . . . . 0.0 107.709 -179.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.473 ' ND2' ' O9 ' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -161.26 -177.73 6.22 Favored 'General case' 0 C--N 1.307 -1.266 0 O-C-N 121.553 -0.969 . . . . 0.0 109.681 179.212 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.497 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -162.57 -159.47 10.37 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.275 -1.93 . . . . 0.0 108.275 -179.215 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.497 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.4 Cg_exo -47.21 179.98 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.675 0 CA-C-N 118.667 1.234 . . . . 0.0 110.37 179.183 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -92.57 -178.27 4.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.033 -1.042 . . . . 0.0 110.645 -178.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.48 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.02 163.57 13.25 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.407 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.08 128.79 54.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.422 -1.046 . . . . 0.0 109.214 -179.36 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.556 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.86 119.04 15.48 Favored 'General case' 0 C--N 1.29 -2.016 0 O-C-N 121.721 -0.612 . . . . 0.0 109.491 179.576 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.594 HD13 ' CZ ' ' A' ' 112' ' ' PHE . 1.7 pt -98.01 171.52 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.248 -0.908 . . . . 0.0 109.042 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.469 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -138.8 159.59 41.74 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.161 -0.962 . . . . 0.0 109.986 -179.696 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.594 ' CZ ' HD13 ' A' ' 110' ' ' ILE . 96.8 m-85 -135.23 103.3 5.47 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.18 -0.95 . . . . 0.0 109.582 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 16.8 p30 . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.462 179.93 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.586 ' O6 ' ' H27' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -120.27 152.36 54.67 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.337 -0.852 . . . . 0.0 109.401 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.536 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.2 Cg_exo -60.17 157.73 33.57 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 C-N-CA 122.34 2.027 . . . . 0.0 110.65 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.544 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.48 -169.9 0.15 Allowed 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.047 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.544 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.58 129.9 2.75 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.881 -1.137 . . . . 0.0 110.429 -179.218 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.542 ' CG2' ' O ' ' A' ' 6' ' ' THR . 7.4 t -109.74 108.69 19.13 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 123.05 1.405 . . . . 0.0 109.286 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.508 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.3 t -116.32 136.35 53.59 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.689 0 CA-C-N 114.164 -1.38 . . . . 0.0 109.903 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.486 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -172.88 149.05 1.78 Allowed Pre-proline 0 N--CA 1.487 1.405 0 O-C-N 121.194 -0.941 . . . . 0.0 108.883 -179.616 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.486 ' HA ' HG22 ' A' ' 8' ' ' THR . 4.2 Cg_endo -77.24 151.33 93.05 Favored 'Cis proline' 0 C--N 1.313 -1.332 0 C-N-CA 123.404 -1.498 . . . . 0.0 109.323 -0.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.52 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 16.6 p -86.83 -26.86 23.84 Favored 'General case' 0 C--N 1.295 -1.803 0 O-C-N 121.455 -0.778 . . . . 0.0 109.169 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.472 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.4 m -134.62 168.23 19.38 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.409 -0.807 . . . . 0.0 109.463 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.03 38.51 35.16 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 108.359 -1.896 . . . . 0.0 108.359 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.589 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 40.2 mt -94.81 -42.61 8.62 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 123.186 1.47 . . . . 0.0 110.65 -178.164 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.498 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.91 143.69 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.289 0 CA-C-N 113.334 -1.757 . . . . 0.0 109.889 -179.55 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.574 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 11.9 p-10 -50.3 104.62 0.08 Allowed 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.53 0.681 . . . . 0.0 111.469 -178.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.17 14.44 7.74 Favored Glycine 0 N--CA 1.485 1.91 0 C-N-CA 119.321 -1.419 . . . . 0.0 113.09 177.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.589 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.5 t -106.47 -172.47 2.09 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 121.336 2.568 . . . . 0.0 109.876 179.312 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.538 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 20.4 t -128.21 136.78 59.24 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.328 0 CA-C-N 114.733 -1.121 . . . . 0.0 111.242 -178.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.588 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 27.8 m -111.08 157.22 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.649 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.508 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 4.0 tptm -106.83 109.17 21.01 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.033 -1.042 . . . . 0.0 108.933 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.519 ' CG1' HG22 ' A' ' 34' ' ' VAL . 7.6 p -103.55 141.05 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.535 ' CB ' HG21 ' A' ' 6' ' ' THR . . . -138.79 161.52 37.03 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.718 -1.238 . . . . 0.0 110.061 179.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.591 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.46 143.69 15.01 Favored Glycine 0 C--N 1.294 -1.763 0 N-CA-C 108.355 -1.898 . . . . 0.0 108.355 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.505 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.14 125.68 13.27 Favored 'General case' 0 C--N 1.295 -1.774 0 O-C-N 120.914 -1.345 . . . . 0.0 108.996 178.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.536 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 87.45 25.92 31.82 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 119.312 -1.423 . . . . 0.0 110.116 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -86.15 172.55 10.46 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 120.937 -1.331 . . . . 0.0 108.474 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.76 100.14 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.009 -1.057 . . . . 0.0 109.651 -179.704 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 77.83 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.147 -179.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.81 34.03 0.32 Allowed Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 179.543 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.545 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.7 p -140.71 108.13 5.56 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 121.183 -1.186 . . . . 0.0 111.153 -179.508 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.98 111.64 0.59 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.535 177.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.458 ' OH ' ' HB2' ' A' ' 27' ' ' GLN . 6.0 m-30 -107.14 156.34 18.91 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.129 -0.982 . . . . 0.0 108.935 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.468 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.8 160.5 14.22 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 178.933 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.612 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.3 p -140.94 119.26 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.129 -0.982 . . . . 0.0 109.678 -177.804 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -171.64 -177.36 41.27 Favored Glycine 0 N--CA 1.494 2.513 0 C-N-CA 118.443 -1.836 . . . . 0.0 111.532 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.562 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -98.73 109.13 21.93 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.723 0.773 . . . . 0.0 108.944 -179.95 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -129.09 149.35 50.94 Favored 'General case' 0 C--N 1.295 -1.783 0 O-C-N 121.236 -0.915 . . . . 0.0 109.964 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.92 138.88 54.23 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.255 -0.903 . . . . 0.0 110.838 -179.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.625 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.05 26.9 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.037 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -105.32 15.16 6.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.903 -1.123 . . . . 0.0 110.585 -178.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.59 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.03 -175.29 0.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.886 -1.134 . . . . 0.0 110.08 179.722 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -72.37 97.41 2.04 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.394 -0.816 . . . . 0.0 109.687 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.34 27.97 31.65 Favored Glycine 0 N--CA 1.493 2.45 0 C-N-CA 120.177 -1.011 . . . . 0.0 111.385 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.59 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.92 106.43 20.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 120.534 -1.568 . . . . 0.0 107.165 178.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.625 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.5 tp -116.48 104.72 11.72 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.479 -1.388 . . . . 0.0 109.937 -177.533 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.527 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.0 109.63 22.35 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 178.649 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.486 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -108.52 162.42 14.15 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.876 -1.14 . . . . 0.0 110.54 -178.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.486 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 7.8 t30 -108.72 130.3 22.91 Favored Pre-proline 0 N--CA 1.499 2.004 0 O-C-N 121.551 -0.718 . . . . 0.0 109.553 -179.377 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.576 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.56 21.35 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.078 0 C-N-CA 122.028 1.819 . . . . 0.0 112.021 179.562 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.459 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -99.41 -3.99 32.53 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.421 -1.424 . . . . 0.0 108.995 179.409 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.535 ' CB ' ' HB3' ' A' ' 67' ' ' LEU . 5.9 m-20 -135.62 9.89 3.4 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -66.84 86.18 0.13 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.499 -0.75 . . . . 0.0 111.059 -178.291 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.612 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -108.5 -167.29 1.21 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 177.912 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.472 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.32 134.47 0.09 Allowed 'General case' 0 C--N 1.305 -1.34 0 O-C-N 120.503 -1.373 . . . . 0.0 111.451 -179.22 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.562 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -150.24 157.77 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 177.923 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.71 142.72 29.91 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.766 -1.209 . . . . 0.0 110.113 -179.685 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.68 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.67 107.12 1.09 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.398 1.094 . . . . 0.0 109.336 178.338 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.527 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -59.37 -139.08 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.056 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.856 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.73 -49.84 64.61 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.462 -0.774 . . . . 0.0 110.496 -178.641 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.457 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.6 t-20 -103.57 -35.17 8.4 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 178.454 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.68 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.95 66.78 0.58 Allowed Glycine 0 C--N 1.298 -1.579 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 177.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.591 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.9 m -104.54 128.92 52.62 Favored 'General case' 0 C--N 1.308 -1.223 0 O-C-N 121.308 -1.113 . . . . 0.0 108.683 178.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.562 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.69 109.91 8.92 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.184 -1.006 . . . . 0.0 109.668 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 91.7 p -117.75 117.77 30.24 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.367 -0.833 . . . . 0.0 109.481 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.479 HG22 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -147.31 151.29 36.34 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.422 -0.799 . . . . 0.0 109.42 -179.957 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 69.6 p -98.52 153.57 18.53 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.304 -0.872 . . . . 0.0 109.571 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.538 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.3 OUTLIER -147.92 160.1 43.17 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.339 -0.851 . . . . 0.0 109.634 -179.176 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.537 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.5 p -100.55 122.85 43.92 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.971 -1.08 . . . . 0.0 108.58 179.261 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.527 ' CG2' HG11 ' A' ' 19' ' ' VAL . 19.2 m -136.41 143.06 36.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 120.799 -1.188 . . . . 0.0 110.459 -178.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.574 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.1 ptt180 -146.43 -175.27 4.71 Favored 'General case' 0 N--CA 1.483 1.205 0 O-C-N 120.749 -1.219 . . . . 0.0 110.663 179.654 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.555 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.79 -102.03 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -179.733 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -56.02 140.27 43.99 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.761 -1.212 . . . . 0.0 108.244 179.401 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -160.74 137.93 9.13 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 118.672 -1.211 . . . . 0.0 110.009 -178.285 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -35.43 120.68 0.57 Allowed 'General case' 0 N--CA 1.49 1.563 0 CA-C-O 121.522 0.677 . . . . 0.0 110.618 -178.439 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.527 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -94.17 50.47 2.18 Favored Glycine 0 N--CA 1.493 2.486 0 O-C-N 121.551 -0.718 . . . . 0.0 111.37 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.576 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.8 m-85 -39.11 114.87 0.43 Allowed 'General case' 0 N--CA 1.511 2.616 0 O-C-N 120.947 -1.325 . . . . 0.0 109.89 179.536 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.53 ' CD2' ' OD2' ' A' ' 79' ' ' ASP . 7.9 tp -87.25 125.24 34.07 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.771 -1.206 . . . . 0.0 109.306 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.565 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 18.7 t80 -64.78 56.31 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.062 0 O-C-N 120.742 -1.224 . . . . 0.0 110.491 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.53 ' OD2' ' CD2' ' A' ' 77' ' ' LEU . 2.9 p30 -154.79 16.18 0.44 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.998 -1.064 . . . . 0.0 109.859 179.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.53 -27.03 10.18 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.41 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -100.87 161.17 13.78 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.901 -1.352 . . . . 0.0 110.38 -179.408 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.422 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 3.6 ptm180 -103.77 139.36 39.11 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.605 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.48 ' CD1' HD11 ' A' ' 77' ' ' LEU . 2.2 t90 -82.44 -19.83 38.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.917 -1.114 . . . . 0.0 110.599 -178.276 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.64 175.66 18.71 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -66.41 104.77 1.3 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.174 -1.192 . . . . 0.0 107.848 179.318 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.575 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 48.7 t -75.31 106.88 5.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.286 -0.884 . . . . 0.0 109.56 -178.736 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.53 ' CB ' HG22 ' A' ' 90' ' ' THR . 0.4 OUTLIER -64.97 110.65 2.53 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.421 -0.8 . . . . 0.0 109.759 -179.679 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.555 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.23 -5.18 4.53 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.533 -1.354 . . . . 0.0 109.766 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.7 p -86.45 -0.28 55.67 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.779 -1.2 . . . . 0.0 109.136 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.53 HG22 ' CB ' ' A' ' 87' ' ' ASP . 2.2 p -114.52 -51.24 2.76 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.326 -0.859 . . . . 0.0 109.026 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.403 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -102.85 -178.83 3.78 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.445 -0.784 . . . . 0.0 109.413 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.68 115.05 29.59 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.868 . . . . 0.0 108.983 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -96.91 122.18 39.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.855 -1.153 . . . . 0.0 109.478 -179.247 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.562 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.28 145.64 29.16 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-O 122.341 1.067 . . . . 0.0 111.284 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.493 ' CG1' HG11 ' A' ' 7' ' ' VAL . 99.5 t -101.59 109.79 26.78 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 177.637 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.471 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.95 -169.56 17.58 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.052 -2.023 . . . . 0.0 111.733 -177.536 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -120.79 177.47 5.08 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 -179.1 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.583 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 2.5 t 179.21 171.91 0.89 Allowed 'General case' 0 C--N 1.292 -1.923 0 O-C-N 121.588 -0.695 . . . . 0.0 109.59 179.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -116.01 -160.17 0.74 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.0 -1.063 . . . . 0.0 109.001 -179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -117.95 36.68 4.23 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.723 -1.236 . . . . 0.0 109.138 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -112.18 -32.38 6.56 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.324 -0.86 . . . . 0.0 109.805 -179.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.446 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . 169.4 -37.64 0.2 Allowed Glycine 0 N--CA 1.481 1.684 0 N-CA-C 108.143 -1.983 . . . . 0.0 108.143 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -167.78 -176.88 3.25 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 121.62 -0.93 . . . . 0.0 109.853 179.358 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.1 -160.7 16.32 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.315 -1.914 . . . . 0.0 108.315 -179.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.3 Cg_exo -47.2 179.25 0.0 OUTLIER 'Trans proline' 0 C--O 1.216 -0.607 0 CA-C-N 118.829 1.315 . . . . 0.0 110.395 179.324 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -96.22 -175.69 3.44 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.028 -1.045 . . . . 0.0 110.309 -179.099 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.471 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.91 163.82 13.74 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.0 127.36 51.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.39 -1.065 . . . . 0.0 109.062 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.562 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -70.34 120.42 15.97 Favored 'General case' 0 C--N 1.289 -2.022 0 O-C-N 121.778 -0.576 . . . . 0.0 109.662 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.582 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.98 170.55 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.234 -0.916 . . . . 0.0 109.131 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.472 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.99 157.56 45.47 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.263 -0.898 . . . . 0.0 109.895 -179.717 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.582 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 91.7 m-85 -134.22 113.66 12.24 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 121.271 -0.893 . . . . 0.0 109.587 -179.62 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.4 p30 . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.461 -179.863 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.588 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.447 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -120.94 157.96 53.61 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.267 -0.895 . . . . 0.0 109.486 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.528 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.9 Cg_exo -59.47 158.23 28.2 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.281 1.987 . . . . 0.0 110.455 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.539 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.47 -169.72 0.15 Allowed 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 179.275 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.539 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.89 130.55 2.31 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.754 -1.216 . . . . 0.0 110.762 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.546 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.9 t -111.35 108.63 18.29 Favored 'General case' 0 C--N 1.295 -1.762 0 CA-C-O 123.068 1.413 . . . . 0.0 109.084 179.201 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.523 HG13 ' CG1' ' A' ' 95' ' ' VAL . 2.5 t -115.26 140.68 35.44 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.73 0 CA-C-N 114.321 -1.308 . . . . 0.0 110.26 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.517 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -175.56 149.07 1.06 Allowed Pre-proline 0 N--CA 1.487 1.396 0 O-C-N 121.337 -0.852 . . . . 0.0 108.854 -179.751 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.517 ' CA ' HG23 ' A' ' 8' ' ' THR . 5.3 Cg_endo -78.63 150.47 87.33 Favored 'Cis proline' 0 C--N 1.311 -1.399 0 C-N-CA 123.36 -1.516 . . . . 0.0 109.09 -0.841 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.491 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 75.9 p -89.73 -24.58 21.5 Favored 'General case' 0 C--N 1.291 -1.947 0 O-C-N 121.53 -0.731 . . . . 0.0 109.358 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.507 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 12.9 m -134.83 162.8 31.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.346 -0.846 . . . . 0.0 109.757 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.88 37.67 29.06 Favored Glycine 0 N--CA 1.496 2.667 0 N-CA-C 108.604 -1.798 . . . . 0.0 108.604 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.603 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 37.0 mt -92.56 -44.24 8.72 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-O 123.19 1.472 . . . . 0.0 110.606 -178.369 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.66 144.07 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.331 0 CA-C-N 113.48 -1.691 . . . . 0.0 110.135 -179.775 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.595 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.2 p-10 -49.74 107.84 0.17 Allowed 'General case' 0 C--N 1.301 -1.526 0 CA-C-O 121.712 0.768 . . . . 0.0 111.471 -178.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.47 12.93 9.22 Favored Glycine 0 N--CA 1.484 1.855 0 C-N-CA 119.45 -1.357 . . . . 0.0 112.939 177.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.603 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.6 t -105.76 -173.05 2.21 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 121.251 2.525 . . . . 0.0 109.663 179.237 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 20.9 t -127.1 135.01 64.79 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.45 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.035 -178.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.59 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 36.0 m -108.68 155.53 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.58 109.4 18.56 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.092 -1.005 . . . . 0.0 108.945 179.885 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.474 ' HB ' ' CG1' ' A' ' 95' ' ' VAL . 2.2 p -104.58 140.56 22.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.548 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -135.24 160.09 39.48 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 118.691 -1.204 . . . . 0.0 109.699 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.594 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.23 145.28 16.52 Favored Glycine 0 C--N 1.295 -1.712 0 N-CA-C 108.109 -1.996 . . . . 0.0 108.109 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.511 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.79 124.98 12.16 Favored 'General case' 0 C--N 1.296 -1.755 0 O-C-N 120.978 -1.307 . . . . 0.0 108.779 178.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.528 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.36 26.58 25.24 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.264 -1.446 . . . . 0.0 109.888 -179.587 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.541 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.0 mt -87.17 175.69 7.94 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 120.872 -1.369 . . . . 0.0 108.421 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.553 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.66 98.02 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.398 0 O-C-N 120.93 -1.106 . . . . 0.0 109.702 -179.597 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.57 77.44 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.737 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.511 -179.176 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.555 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.14 34.42 0.33 Allowed Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.1 p -146.25 111.92 5.58 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.039 -1.271 . . . . 0.0 111.223 -179.686 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.54 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.08 127.76 5.57 Favored 'General case' 0 N--CA 1.492 1.659 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.683 178.207 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.567 ' CZ ' ' OD2' ' A' ' 99' ' ' ASP . 13.2 m-85 -118.5 150.57 39.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.327 -0.858 . . . . 0.0 108.881 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.497 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -100.52 153.15 19.61 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.64 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.6 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.2 p -137.55 119.03 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.844 -1.16 . . . . 0.0 110.043 -177.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.74 -178.88 40.59 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.673 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.556 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -99.73 109.12 21.59 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 -179.943 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.48 148.78 52.33 Favored 'General case' 0 C--N 1.295 -1.795 0 O-C-N 121.285 -0.885 . . . . 0.0 109.881 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.6 137.42 54.9 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.3 -0.875 . . . . 0.0 110.883 -179.094 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.63 ' CE2' HD11 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.54 114.9 26.71 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 178.009 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.459 HG22 ' HB ' ' A' ' 44' ' ' VAL . 10.1 m -105.73 14.69 7.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.053 -1.029 . . . . 0.0 110.707 -178.712 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.592 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.6 -175.11 0.08 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.901 -1.125 . . . . 0.0 110.106 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 28.0 p -72.59 98.56 2.35 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.45 -0.781 . . . . 0.0 109.623 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.2 27.16 34.33 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 120.226 -0.988 . . . . 0.0 111.342 178.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.592 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.02 106.04 19.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.55 -1.559 . . . . 0.0 107.295 178.829 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.63 HD11 ' CE2' ' A' ' 39' ' ' TRP . 14.0 tp -118.86 104.34 10.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.458 -1.401 . . . . 0.0 109.822 -177.666 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.516 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.22 109.58 22.32 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.868 -1.145 . . . . 0.0 108.246 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.54 166.23 10.71 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.982 -1.074 . . . . 0.0 110.269 -178.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.533 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 11.0 t-20 -108.87 134.82 20.22 Favored Pre-proline 0 N--CA 1.499 2.01 0 O-C-N 121.364 -0.835 . . . . 0.0 109.639 -179.416 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.573 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.1 Cg_endo -74.85 24.66 0.38 Allowed 'Trans proline' 0 CA--C 1.545 1.055 0 C-N-CA 122.277 1.985 . . . . 0.0 111.949 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.533 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -117.18 4.34 12.66 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.498 -1.376 . . . . 0.0 109.297 179.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.514 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.26 17.54 2.78 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.285 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -81.97 86.96 6.45 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.922 -178.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.6 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -104.98 -165.89 1.18 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.334 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.464 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.01 135.77 0.09 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 120.609 -1.307 . . . . 0.0 111.449 -179.284 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.583 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -152.66 156.61 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 178.08 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.54 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.58 145.34 26.36 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.602 -1.312 . . . . 0.0 109.921 -179.611 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.677 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -65.34 107.54 1.66 Allowed 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 122.384 1.087 . . . . 0.0 109.57 178.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.519 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.2 p-10 -60.87 -138.92 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.944 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.841 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.33 -50.62 59.07 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.509 -0.744 . . . . 0.0 110.673 -178.632 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.457 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.3 t-20 -104.35 -33.99 8.45 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 178.548 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.677 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 109.13 65.41 0.56 Allowed Glycine 0 C--N 1.297 -1.617 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 178.076 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.2 m -101.6 128.48 47.85 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.505 -0.997 . . . . 0.0 108.549 178.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.583 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.68 108.8 6.78 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.057 -1.057 . . . . 0.0 109.884 -179.21 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.2 m -121.0 118.96 31.17 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.361 -0.837 . . . . 0.0 109.371 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.446 HG21 HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.63 143.74 30.91 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.392 -0.818 . . . . 0.0 109.479 179.83 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.9 p -99.06 146.97 25.52 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.4 -0.813 . . . . 0.0 109.411 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.575 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -147.42 167.97 23.05 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.393 -0.817 . . . . 0.0 109.368 -179.251 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.53 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 4.6 p -94.49 124.73 38.69 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.903 -1.123 . . . . 0.0 109.859 -179.522 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.562 ' CG2' ' CG1' ' A' ' 19' ' ' VAL . 15.8 m -136.46 144.98 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.997 -1.064 . . . . 0.0 109.206 -179.695 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.595 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.3 ptt180 -147.56 -178.49 6.28 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.327 -1.483 . . . . 0.0 111.346 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.698 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -50.07 -98.17 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -179.569 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 1.0 OUTLIER -63.79 146.69 53.45 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.57 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.609 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.8 OUTLIER -166.18 141.76 4.75 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 118.03 -1.468 . . . . 0.0 110.243 -177.276 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.492 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.9 mm-40 -36.03 120.71 0.64 Allowed 'General case' 0 N--CA 1.491 1.619 0 CA-C-O 121.475 0.655 . . . . 0.0 110.308 -178.771 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.516 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -95.59 51.46 1.79 Allowed Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.573 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -39.35 113.74 0.35 Allowed 'General case' 0 N--CA 1.507 2.401 0 O-C-N 121.093 -1.24 . . . . 0.0 110.142 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -85.28 126.35 33.64 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 120.958 -1.089 . . . . 0.0 109.415 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.583 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 18.5 t80 -64.33 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.963 0 O-C-N 120.82 -1.175 . . . . 0.0 110.105 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.7 t0 -160.07 19.76 0.16 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.982 -1.074 . . . . 0.0 109.648 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.91 -27.65 5.36 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 110.063 -1.215 . . . . 0.0 110.063 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.448 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.15 157.6 16.0 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.04 -1.27 . . . . 0.0 110.446 -179.395 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.463 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 1.8 ptm180 -104.87 136.15 44.91 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.459 ' HB2' HD12 ' A' ' 77' ' ' LEU . 1.5 t90 -82.86 -16.47 47.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.761 -1.212 . . . . 0.0 110.689 -178.26 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.08 175.43 20.83 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 108.828 -1.709 . . . . 0.0 108.828 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.72 103.51 0.7 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 179.14 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.574 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 40.8 t -74.54 107.42 5.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.384 -0.823 . . . . 0.0 109.566 -178.841 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.481 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -67.09 112.0 4.18 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.581 -0.699 . . . . 0.0 109.685 -179.556 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.698 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 11.0 m -60.96 -5.71 1.5 Allowed 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.104 -1.439 . . . . 0.0 110.35 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.02 -4.43 58.79 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.396 -1.44 . . . . 0.0 109.53 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.462 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -104.0 -48.0 4.02 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.202 -0.936 . . . . 0.0 108.886 179.706 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -112.55 -178.3 3.37 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.573 -0.704 . . . . 0.0 109.33 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.37 117.3 34.44 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.375 -0.828 . . . . 0.0 109.02 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.487 ' O ' HG12 ' A' ' 110' ' ' ILE . 3.9 m -96.47 122.77 39.72 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.866 -1.146 . . . . 0.0 109.344 -179.515 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.536 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mp0 -106.7 145.48 31.95 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 122.404 1.097 . . . . 0.0 111.685 -179.112 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.523 ' CG1' HG13 ' A' ' 7' ' ' VAL . 62.0 t -100.83 109.71 26.05 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 177.428 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.5 -172.2 16.58 Favored Glycine 0 N--CA 1.487 2.052 0 C-N-CA 118.257 -1.925 . . . . 0.0 111.622 -177.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.497 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.04 -179.22 3.63 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -178.874 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.542 ' HB2' ' C20' ' A' ' 114' ' ' CHR . 8.4 p -166.17 164.14 17.91 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.369 -0.832 . . . . 0.0 109.09 -179.479 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.567 ' OD2' ' CZ ' ' A' ' 32' ' ' TYR . 1.6 m-20 -100.69 -9.97 21.33 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.084 -1.01 . . . . 0.0 109.477 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.493 ' CB ' ' O ' ' A' ' 99' ' ' ASP . . . 74.48 37.77 0.54 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.468 -0.77 . . . . 0.0 109.202 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.67 -33.74 0.78 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.523 -0.736 . . . . 0.0 110.643 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.459 ' CA ' H193 ' A' ' 114' ' ' CHR . . . 177.77 -40.94 0.09 OUTLIER Glycine 0 N--CA 1.483 1.814 0 N-CA-C 107.552 -2.219 . . . . 0.0 107.552 -179.514 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.75 -179.02 7.79 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.432 -1.04 . . . . 0.0 109.561 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -174.41 -165.8 31.46 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.485 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.7 Cg_exo -49.64 -174.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 CA-C-N 118.778 1.289 . . . . 0.0 110.472 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -93.9 -179.61 5.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.113 -0.992 . . . . 0.0 110.373 -179.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -116.66 158.64 14.36 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.76 124.93 52.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.362 -1.081 . . . . 0.0 109.056 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.536 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.54 120.91 18.81 Favored 'General case' 0 C--N 1.29 -2.005 0 O-C-N 121.804 -0.56 . . . . 0.0 109.707 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.564 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -98.02 169.1 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.255 -0.903 . . . . 0.0 109.241 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.507 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.72 155.22 50.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.307 -0.871 . . . . 0.0 109.48 179.993 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.564 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 74.5 m-85 -124.36 109.27 13.12 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.164 -0.96 . . . . 0.0 109.468 -179.622 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.402 ' C ' ' O ' ' A' ' 112' ' ' PHE . 17.0 p30 . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.196 -0.94 . . . . 0.0 109.428 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.586 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.338 0.59 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -120.26 153.91 55.95 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.186 -0.947 . . . . 0.0 109.496 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.494 ' CA ' ' O ' ' A' ' 25' ' ' GLY . 2.7 Cg_endo -61.27 155.75 49.82 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.234 1.956 . . . . 0.0 110.554 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.602 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -145.66 160.88 41.05 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 -179.862 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -146.92 128.05 14.68 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.919 -1.113 . . . . 0.0 110.672 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.529 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.6 p -104.2 104.57 14.51 Favored 'General case' 0 C--N 1.296 -1.724 0 CA-C-O 122.49 1.138 . . . . 0.0 110.115 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.532 HG12 ' CG1' ' A' ' 95' ' ' VAL . 16.2 t -119.8 115.61 47.99 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.46 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.292 179.681 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.493 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.49 148.8 13.14 Favored Pre-proline 0 N--CA 1.487 1.407 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -179.583 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG22 ' A' ' 8' ' ' THR . 6.1 Cg_endo -77.92 150.22 89.08 Favored 'Cis proline' 0 C--N 1.309 -1.528 0 C-N-CA 123.606 -1.414 . . . . 0.0 109.737 -0.397 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.49 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 40.1 p -89.05 -26.4 21.43 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.505 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 6.0 p -133.07 165.19 25.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.522 -0.736 . . . . 0.0 109.423 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.14 37.51 37.3 Favored Glycine 0 N--CA 1.496 2.652 0 N-CA-C 108.402 -1.879 . . . . 0.0 108.402 -179.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.61 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 35.6 mt -92.51 -42.98 9.41 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 123.328 1.537 . . . . 0.0 110.491 -178.26 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.28 143.94 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.29 0 CA-C-N 113.319 -1.764 . . . . 0.0 109.858 -179.548 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.578 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.0 p-10 -50.38 106.2 0.12 Allowed 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.398 0.618 . . . . 0.0 111.666 -178.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.53 14.4 8.89 Favored Glycine 0 N--CA 1.485 1.924 0 C-N-CA 119.42 -1.371 . . . . 0.0 113.022 177.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.61 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -104.96 -172.66 2.14 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 121.15 2.475 . . . . 0.0 109.864 179.246 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.583 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 18.8 t -130.4 140.19 49.46 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.285 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.24 -178.774 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.521 HG22 ' CD1' ' A' ' 67' ' ' LEU . 30.0 m -117.25 155.52 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.525 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.5 OUTLIER -107.19 109.15 20.89 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.087 -1.008 . . . . 0.0 109.572 -179.8 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.507 HG12 ' CG2' ' A' ' 34' ' ' VAL . 2.0 p -106.47 121.51 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.545 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -113.49 165.94 11.99 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.875 -1.141 . . . . 0.0 108.976 179.75 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.58 107.98 0.49 Allowed Glycine 0 N--CA 1.481 1.668 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.602 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.81 139.78 50.2 Favored 'General case' 0 N--CA 1.499 2.002 0 CA-C-N 119.218 1.509 . . . . 0.0 110.27 -179.43 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.494 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 84.82 28.86 30.6 Favored Glycine 0 N--CA 1.49 2.286 0 C-N-CA 118.792 -1.671 . . . . 0.0 109.782 179.615 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.523 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.4 mt -93.13 174.54 7.17 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.085 -1.244 . . . . 0.0 108.458 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.554 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.87 98.99 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.949 -1.094 . . . . 0.0 109.498 -179.718 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.05 76.59 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.282 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.33 33.96 0.26 Allowed Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 82.2 p -144.46 111.41 5.81 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 120.966 -1.314 . . . . 0.0 111.144 -179.668 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.537 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -47.49 112.65 0.57 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.895 178.308 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.53 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 14.4 m-85 -104.51 150.19 24.81 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.206 -0.933 . . . . 0.0 108.746 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.455 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -99.62 158.57 15.67 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 178.564 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.634 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 6.2 p -141.67 116.46 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.006 -1.059 . . . . 0.0 110.042 -177.69 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.509 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.45 -176.54 39.41 Favored Glycine 0 N--CA 1.493 2.462 0 C-N-CA 118.338 -1.886 . . . . 0.0 111.674 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.557 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -100.49 109.11 21.21 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 121.928 0.87 . . . . 0.0 108.82 -179.571 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.6 m -129.55 148.65 51.47 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.212 -0.93 . . . . 0.0 109.882 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.93 138.57 54.64 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.375 -0.828 . . . . 0.0 110.669 -179.027 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.621 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.91 26.73 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.039 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.402 HG22 ' HB ' ' A' ' 44' ' ' VAL . 18.1 m -105.88 14.9 7.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.894 -1.129 . . . . 0.0 110.617 -178.769 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.59 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.6 -175.81 0.08 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.844 -1.16 . . . . 0.0 110.116 179.667 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.547 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.2 t -70.57 97.28 1.29 Allowed 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.866 0.841 . . . . 0.0 109.946 -179.55 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.44 27.7 35.21 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 120.181 -1.009 . . . . 0.0 111.391 178.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.59 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.5 106.24 20.1 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.592 -1.534 . . . . 0.0 107.258 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.621 HD13 ' CD1' ' A' ' 39' ' ' TRP . 11.9 tp -116.62 104.55 11.5 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 120.428 -1.42 . . . . 0.0 109.848 -177.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.539 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.32 109.24 22.03 Favored 'General case' 0 N--CA 1.484 1.253 0 O-C-N 120.842 -1.161 . . . . 0.0 108.119 178.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.2 t -105.94 163.09 13.02 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.993 -1.067 . . . . 0.0 109.871 -179.144 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.477 ' OD1' ' HB2' ' A' ' 74' ' ' GLU . 23.6 t30 -105.66 137.02 19.19 Favored Pre-proline 0 N--CA 1.503 2.21 0 O-C-N 121.289 -0.882 . . . . 0.0 109.972 -179.055 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.459 ' HD2' ' HB2' ' A' ' 74' ' ' GLU . 4.2 Cg_endo -73.77 24.25 0.33 Allowed 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 122.467 2.111 . . . . 0.0 112.323 -179.538 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.468 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -119.74 5.07 11.0 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.278 -1.513 . . . . 0.0 109.261 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.509 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -137.8 15.37 2.89 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 179.164 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -82.43 89.33 6.61 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.815 -0.754 . . . . 0.0 110.971 -178.517 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.634 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.27 -168.83 1.45 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 178.02 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.462 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.78 135.47 0.09 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 120.496 -1.377 . . . . 0.0 111.516 -179.243 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.579 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -153.7 158.18 4.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 177.963 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.537 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.1 m -98.15 143.88 28.21 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 120.638 -1.289 . . . . 0.0 109.777 -179.662 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.663 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -65.47 107.05 1.56 Allowed 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 122.307 1.051 . . . . 0.0 109.547 178.781 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.523 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.1 t0 -61.58 -139.38 0.0 OUTLIER 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.824 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.2 -51.57 42.99 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.361 -0.837 . . . . 0.0 110.704 -178.699 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -103.96 -32.75 9.1 Favored 'General case' 0 C--N 1.288 -2.109 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 178.562 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.663 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 105.08 69.17 0.75 Allowed Glycine 0 C--N 1.297 -1.589 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 178.194 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 24.3 m -104.19 126.34 51.21 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 121.684 -0.892 . . . . 0.0 108.838 178.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.579 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.85 109.04 8.26 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 119.644 -0.822 . . . . 0.0 109.486 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 6.4 m -117.5 115.67 25.61 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.271 -0.893 . . . . 0.0 109.398 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.513 ' CG2' HG11 ' A' ' 34' ' ' VAL . 1.3 t -140.97 139.52 34.24 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.359 -0.838 . . . . 0.0 109.723 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.1 p -99.42 132.55 44.68 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.463 -0.773 . . . . 0.0 109.245 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.521 ' CD1' HG22 ' A' ' 19' ' ' VAL . 0.1 OUTLIER -132.6 165.92 23.3 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.347 -0.845 . . . . 0.0 109.808 -179.238 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.583 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -98.15 125.18 43.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.238 -0.914 . . . . 0.0 109.219 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.543 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -135.24 143.4 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.068 -1.02 . . . . 0.0 109.897 -179.03 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.578 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.7 ptt180 -145.97 -172.63 3.96 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.457 -1.402 . . . . 0.0 110.946 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.529 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -57.64 -98.15 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.359 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.64 139.54 55.82 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.27 -1.519 . . . . 0.0 107.944 179.265 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -160.29 135.24 7.79 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 118.598 -1.241 . . . . 0.0 109.847 -178.107 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.485 ' O ' ' O ' ' A' ' 47' ' ' CYS . 0.5 OUTLIER -34.95 121.44 0.53 Allowed 'General case' 0 N--CA 1.491 1.611 0 CA-C-O 121.352 0.596 . . . . 0.0 110.119 -178.49 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.539 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -92.75 50.83 2.59 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 120.404 -0.903 . . . . 0.0 110.938 -179.196 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.471 ' C ' ' O ' ' A' ' 75' ' ' GLY . 0.4 OUTLIER -37.74 116.97 0.54 Allowed 'General case' 0 N--CA 1.514 2.726 0 O-C-N 121.274 -1.133 . . . . 0.0 109.973 179.816 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.538 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.1 tp -87.04 125.96 34.45 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 120.957 -1.089 . . . . 0.0 109.14 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.58 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.7 t80 -64.13 58.51 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.036 0 O-C-N 120.8 -1.188 . . . . 0.0 109.922 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' LEU . 26.4 t0 -160.38 20.05 0.15 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.959 -1.088 . . . . 0.0 109.668 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.33 -28.62 5.13 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.089 -1.205 . . . . 0.0 110.089 179.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.407 ' OG1' HD22 ' A' ' 77' ' ' LEU . 70.5 p -95.25 164.2 12.95 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.043 -1.269 . . . . 0.0 110.228 -179.427 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.459 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.9 OUTLIER -109.2 138.5 45.45 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.968 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.454 ' HB2' HD11 ' A' ' 77' ' ' LEU . 4.7 t90 -81.71 -20.83 38.6 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.805 -1.184 . . . . 0.0 110.391 -178.795 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.79 175.07 17.5 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.54 107.49 1.72 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.065 -1.256 . . . . 0.0 107.684 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.557 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 48.1 t -79.38 105.3 8.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 O-C-N 121.41 -0.806 . . . . 0.0 109.182 -179.009 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.8 OUTLIER -65.74 111.59 3.29 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.467 -0.771 . . . . 0.0 109.739 -179.583 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.529 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.17 -5.62 3.42 Favored 'General case' 0 N--CA 1.499 2.01 0 C-N-CA 118.208 -1.397 . . . . 0.0 109.884 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 19.9 p -87.71 0.73 55.31 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.697 -1.252 . . . . 0.0 109.117 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.451 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.8 p -114.11 -50.82 2.8 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.367 -0.833 . . . . 0.0 108.975 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.06 179.51 4.25 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.555 -0.716 . . . . 0.0 109.331 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.94 115.62 30.95 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.465 -0.772 . . . . 0.0 108.919 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.498 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.1 m -97.04 122.42 40.01 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.894 -1.129 . . . . 0.0 109.358 -179.373 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.541 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.67 146.83 27.62 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-O 122.368 1.08 . . . . 0.0 111.215 -179.369 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.532 ' CG1' HG12 ' A' ' 7' ' ' VAL . 52.9 t -103.48 109.79 28.03 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.067 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.61 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.447 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.96 -169.94 17.36 Favored Glycine 0 N--CA 1.486 1.987 0 C-N-CA 118.229 -1.938 . . . . 0.0 111.666 -177.514 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.465 HD11 ' HB3' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -123.2 179.16 4.8 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -178.682 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.591 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 3.6 t 179.06 176.76 0.55 Allowed 'General case' 0 C--N 1.293 -1.859 0 O-C-N 121.52 -0.738 . . . . 0.0 109.597 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.43 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -120.96 -158.17 0.75 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.026 -1.047 . . . . 0.0 109.251 -179.912 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.43 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.86 35.99 4.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.855 -1.153 . . . . 0.0 109.12 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -112.25 -32.87 6.39 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.432 -0.792 . . . . 0.0 109.875 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 163.62 -34.98 0.3 Allowed Glycine 0 N--CA 1.481 1.663 0 N-CA-C 107.874 -2.09 . . . . 0.0 107.874 -179.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.85 -177.52 5.56 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 122.062 0.934 . . . . 0.0 109.875 179.328 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -172.43 -161.56 23.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.151 -1.98 . . . . 0.0 108.151 -179.374 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.494 ' HD2' ' CE1' ' A' ' 32' ' ' TYR . 7.1 Cg_exo -45.69 173.14 0.02 OUTLIER 'Trans proline' 0 C--O 1.216 -0.58 0 CA-C-N 118.912 1.356 . . . . 0.0 110.008 179.268 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -93.95 -178.6 4.7 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.109 -0.994 . . . . 0.0 110.428 -178.662 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.447 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.92 168.07 12.71 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -108.23 128.7 63.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.313 -1.11 . . . . 0.0 109.117 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.541 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -69.18 123.84 22.21 Favored 'General case' 0 C--N 1.29 -2.007 0 O-C-N 121.556 -0.715 . . . . 0.0 109.381 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.569 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.6 173.76 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.199 -0.938 . . . . 0.0 108.928 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.505 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.5 OUTLIER -138.28 159.61 41.6 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.129 -0.982 . . . . 0.0 109.75 -179.743 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.569 ' CE2' HD12 ' A' ' 110' ' ' ILE . 88.4 m-85 -137.45 81.03 1.84 Allowed 'General case' 0 N--CA 1.485 1.298 0 O-C-N 121.267 -0.896 . . . . 0.0 109.553 -179.636 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.0 p30 . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.394 -179.999 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.591 ' C21' ' CB ' ' A' ' 98' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -119.71 163.32 28.17 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.284 -0.885 . . . . 0.0 109.492 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.519 ' HB3' ' HA ' ' A' ' 26' ' ' LEU . 5.7 Cg_exo -58.77 157.66 27.32 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 122.268 1.979 . . . . 0.0 110.899 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.619 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -140.68 160.18 40.6 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 179.812 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.71 122.93 9.56 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-O 122.448 1.118 . . . . 0.0 110.434 -179.565 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.545 ' CG2' ' O ' ' A' ' 6' ' ' THR . 5.9 t -115.82 109.0 17.03 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-O 123.162 1.458 . . . . 0.0 109.735 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.529 HG12 ' CG1' ' A' ' 95' ' ' VAL . 2.1 t -115.63 133.69 61.22 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.675 0 CA-C-N 114.162 -1.381 . . . . 0.0 109.593 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.498 HG21 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.45 150.66 5.0 Favored Pre-proline 0 N--CA 1.488 1.43 0 O-C-N 121.259 -0.901 . . . . 0.0 108.896 -179.419 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.498 ' HA ' HG21 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.13 150.38 88.72 Favored 'Cis proline' 0 C--N 1.311 -1.415 0 C-N-CA 123.56 -1.433 . . . . 0.0 109.454 -0.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.454 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 95.6 p -90.4 -24.93 20.64 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.586 -0.696 . . . . 0.0 109.203 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.477 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 14.6 m -131.13 161.71 31.51 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.351 -0.843 . . . . 0.0 109.71 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.44 38.16 29.43 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.611 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 32.9 mt -93.31 -43.65 8.69 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 123.178 1.466 . . . . 0.0 110.801 -178.122 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.07 144.79 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.328 0 CA-C-N 113.484 -1.689 . . . . 0.0 110.123 -179.486 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.572 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 18.6 p-10 -50.37 106.07 0.11 Allowed 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 121.53 0.681 . . . . 0.0 111.693 -178.567 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.67 15.57 8.65 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.912 177.075 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.611 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -105.41 -174.28 2.5 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 121.223 2.511 . . . . 0.0 109.981 179.225 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.541 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 31.0 t -126.41 138.09 55.75 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.36 0 CA-C-N 114.549 -1.205 . . . . 0.0 111.399 -178.339 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.531 HG12 ' CG2' ' A' ' 69' ' ' VAL . 29.0 m -114.13 154.98 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.467 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.491 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.9 tttt -106.65 109.67 21.64 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.127 -0.983 . . . . 0.0 109.041 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.528 HG12 ' CG2' ' A' ' 34' ' ' VAL . 2.3 p -101.61 140.49 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -135.46 162.08 33.64 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 118.89 -1.124 . . . . 0.0 110.094 179.485 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -138.32 140.3 11.01 Favored Glycine 0 C--N 1.299 -1.514 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.619 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.71 125.22 15.73 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-N 119.183 1.492 . . . . 0.0 109.28 179.297 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.503 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 88.87 29.71 17.27 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 118.702 -1.713 . . . . 0.0 109.695 -179.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.9 mt -89.88 175.2 7.3 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 120.863 -1.375 . . . . 0.0 108.517 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.55 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.77 96.8 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.102 -0.999 . . . . 0.0 109.885 -179.608 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -58.18 74.87 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.157 -179.138 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 138.75 32.97 0.19 Allowed Glycine 0 N--CA 1.484 1.848 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 179.454 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.632 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 1.4 t -149.11 115.43 5.82 Favored 'General case' 0 C--N 1.31 -1.127 0 O-C-N 120.893 -1.357 . . . . 0.0 111.218 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.54 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -49.42 111.22 0.46 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.251 178.472 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.632 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 1.9 m-30 -101.54 152.11 21.17 Favored 'General case' 0 N--CA 1.494 1.759 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 179.123 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.469 ' HA ' ' OG ' ' A' ' 54' ' ' SER . 0.5 OUTLIER -98.89 165.01 11.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.497 -1.377 . . . . 0.0 108.327 179.26 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.621 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.1 p -145.1 119.24 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.209 -0.932 . . . . 0.0 109.534 -178.012 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.42 -178.68 41.38 Favored Glycine 0 N--CA 1.495 2.605 0 C-N-CA 118.34 -1.886 . . . . 0.0 111.616 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.559 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -100.71 108.57 20.46 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 179.833 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.441 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.6 m -130.03 148.73 51.91 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 121.228 -0.92 . . . . 0.0 110.01 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.26 138.76 54.55 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.242 -0.911 . . . . 0.0 110.644 -179.143 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.628 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.32 114.82 26.64 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 178.154 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.3 m -104.45 14.88 6.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.014 -1.054 . . . . 0.0 110.534 -178.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.02 -175.01 0.07 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.023 -1.048 . . . . 0.0 110.185 179.785 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.12 98.11 2.06 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.446 -0.784 . . . . 0.0 109.708 -179.764 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.71 27.88 33.78 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.464 178.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.75 106.24 19.85 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 O-C-N 120.536 -1.567 . . . . 0.0 107.252 178.834 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.628 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.6 tp -117.49 104.45 11.09 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.402 -1.436 . . . . 0.0 109.958 -177.714 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -97.92 109.49 22.23 Favored 'General case' 0 N--CA 1.484 1.267 0 N-CA-C 107.718 -1.215 . . . . 0.0 107.718 178.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -107.32 166.16 10.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.895 -1.128 . . . . 0.0 110.655 -178.508 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.521 ' ND2' ' HB2' ' A' ' 50' ' ' ALA . 43.7 t30 -113.14 127.92 26.26 Favored Pre-proline 0 N--CA 1.498 1.972 0 O-C-N 121.497 -0.752 . . . . 0.0 109.267 -179.661 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.584 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -70.75 21.31 0.21 Allowed 'Trans proline' 0 CA--C 1.543 0.948 0 C-N-CA 122.103 1.869 . . . . 0.0 112.396 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.521 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -97.72 -5.62 34.72 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.304 -1.497 . . . . 0.0 109.017 179.31 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.561 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 1.4 m-20 -135.62 10.76 3.43 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.488 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.7 m-85 -66.56 82.9 0.1 Allowed 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.736 -178.403 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.621 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -108.47 -171.92 1.95 Allowed 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 178.252 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.469 ' OG ' ' HA ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER 178.6 134.71 0.08 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.608 -1.308 . . . . 0.0 111.25 -179.369 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.588 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 4.1 p -143.39 159.77 17.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 177.897 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.54 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -97.69 144.39 27.37 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.583 -1.323 . . . . 0.0 109.767 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.659 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -70.44 108.52 4.31 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 122.312 1.053 . . . . 0.0 109.963 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.522 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.3 t0 -64.66 -139.55 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.714 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.34 -52.43 37.06 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.344 -0.848 . . . . 0.0 110.605 -178.74 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.34 -32.32 10.53 Favored 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 178.613 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.659 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 100.34 69.29 0.88 Allowed Glycine 0 C--N 1.298 -1.571 0 N-CA-C 110.562 -1.015 . . . . 0.0 110.562 178.488 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 65.6 m -98.66 132.46 44.03 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.337 -1.096 . . . . 0.0 109.016 179.119 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.604 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -133.41 109.31 9.23 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.252 -179.716 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 19.8 m -122.53 115.68 22.59 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.264 -0.897 . . . . 0.0 109.565 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.404 HG23 HG13 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.74 143.32 28.61 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.27 -0.894 . . . . 0.0 109.661 179.927 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 57.6 p -99.15 142.38 30.71 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.371 -0.831 . . . . 0.0 109.148 179.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.549 ' HB2' ' OD2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -144.49 170.63 15.67 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.397 -0.815 . . . . 0.0 109.774 -179.01 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.529 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -104.35 124.26 48.88 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.952 -1.093 . . . . 0.0 110.474 -178.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.561 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 15.7 m -132.22 143.0 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 120.907 -1.121 . . . . 0.0 110.087 -179.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.572 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -145.65 -172.51 3.91 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.604 -1.31 . . . . 0.0 110.689 179.384 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.548 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -58.52 -98.42 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 -179.35 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.4 OUTLIER -57.88 141.22 49.96 Favored 'General case' 0 N--CA 1.485 1.307 0 O-C-N 120.307 -1.496 . . . . 0.0 108.374 179.47 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -161.78 135.44 6.51 Favored 'General case' 0 C--N 1.295 -1.787 0 C-N-CA 118.75 -1.18 . . . . 0.0 109.724 -178.402 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.9 mm-40 -32.11 121.55 0.3 Allowed 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.579 0.704 . . . . 0.0 110.697 -178.351 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -90.48 45.51 2.95 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.584 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-85 -37.96 113.56 0.29 Allowed 'General case' 0 N--CA 1.507 2.39 0 O-C-N 121.193 -1.18 . . . . 0.0 110.372 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.535 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.5 tp -85.89 126.56 34.16 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 120.948 -1.095 . . . . 0.0 109.535 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.582 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 33.4 t80 -63.9 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.024 0 O-C-N 120.93 -1.106 . . . . 0.0 110.318 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 17.2 t70 -161.46 20.11 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.928 -1.107 . . . . 0.0 109.729 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.59 -28.1 4.99 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.474 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 19.2 p -93.46 159.31 15.3 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.981 -1.305 . . . . 0.0 110.231 -179.492 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.504 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 1.1 ptt180 -106.78 139.03 41.85 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.465 ' CD1' HD12 ' A' ' 77' ' ' LEU . 3.3 t90 -84.79 -19.26 32.83 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.704 -1.248 . . . . 0.0 110.524 -178.558 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.84 174.1 18.14 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.447 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.93 106.38 1.22 Allowed 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 179.137 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.578 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 48.9 t -77.02 105.84 6.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 O-C-N 121.315 -0.866 . . . . 0.0 109.398 -178.744 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.52 ' CB ' HG21 ' A' ' 90' ' ' THR . 1.0 OUTLIER -66.31 111.46 3.51 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.386 -0.821 . . . . 0.0 109.685 -179.732 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.548 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.1 t -63.54 -5.51 3.94 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.533 -1.355 . . . . 0.0 109.828 179.562 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.2 p -86.45 -1.49 57.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.787 -1.196 . . . . 0.0 109.215 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.52 HG21 ' CB ' ' A' ' 87' ' ' ASP . 2.5 p -111.38 -50.24 2.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.295 -0.878 . . . . 0.0 108.93 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.34 -178.8 3.76 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.507 -0.746 . . . . 0.0 109.482 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.05 115.52 30.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.33 -0.856 . . . . 0.0 109.001 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.91 123.02 40.51 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.77 -1.206 . . . . 0.0 109.593 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.557 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.64 146.9 27.89 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 122.445 1.116 . . . . 0.0 111.138 -179.42 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.529 ' CG1' HG12 ' A' ' 7' ' ' VAL . 48.6 t -103.58 110.53 30.26 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.978 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 177.666 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.452 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.6 -170.24 16.86 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 118.06 -2.019 . . . . 0.0 111.745 -177.523 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -115.38 -179.08 3.54 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 -178.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.592 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.2 OUTLIER -171.36 167.89 6.72 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.318 -0.864 . . . . 0.0 109.61 -179.333 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.574 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -114.73 -157.6 0.64 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.199 -0.938 . . . . 0.0 108.816 179.652 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.442 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -120.63 36.29 4.62 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.785 -1.197 . . . . 0.0 109.32 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.89 -32.77 4.4 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.339 -0.85 . . . . 0.0 110.291 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.526 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 168.59 -37.64 0.21 Allowed Glycine 0 N--CA 1.481 1.696 0 N-CA-C 107.7 -2.16 . . . . 0.0 107.7 -179.523 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.428 ' ND2' ' O9 ' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -160.46 -178.07 6.66 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-O 122.127 0.965 . . . . 0.0 109.622 179.219 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.0 -161.28 12.88 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 108.301 -1.92 . . . . 0.0 108.301 -179.345 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.487 ' CD ' ' CE2' ' A' ' 32' ' ' TYR . 6.3 Cg_exo -46.75 177.0 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.653 0 CA-C-N 118.838 1.319 . . . . 0.0 110.179 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -92.66 -177.55 4.6 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.074 -1.016 . . . . 0.0 110.451 -178.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.452 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.45 164.48 12.91 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.92 129.23 52.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.451 -1.029 . . . . 0.0 109.103 -179.565 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.557 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.04 123.4 22.72 Favored 'General case' 0 C--N 1.289 -2.023 0 O-C-N 121.702 -0.624 . . . . 0.0 109.535 179.734 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.585 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.74 170.53 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.174 -0.954 . . . . 0.0 109.14 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.477 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -138.84 156.63 47.16 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.174 -0.954 . . . . 0.0 109.765 -179.891 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.585 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 81.2 m-85 -133.31 132.87 41.84 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.144 -0.972 . . . . 0.0 109.569 -179.683 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.9 p30 . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.44 -179.938 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.592 ' C20' ' CB ' ' A' ' 98' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.489 0 N-CA-C 109.457 -0.571 . . . . 1.0 109.457 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.68 152.43 42.85 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.261 -0.899 . . . . 1.0 109.467 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.484 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 2.8 Cg_endo -61.05 156.6 43.62 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.299 1.999 . . . . 1.0 110.399 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.601 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -153.05 161.17 42.83 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 108.683 -0.858 . . . . 1.0 108.683 -179.551 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.74 128.61 14.4 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.92 -1.112 . . . . 1.0 110.688 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.532 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.2 p -105.63 104.87 14.67 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.457 1.122 . . . . 1.0 110.21 -179.577 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.53 HG12 ' CG1' ' A' ' 95' ' ' VAL . 13.2 t -118.34 118.8 59.25 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.446 0 CA-C-N 115.384 -0.825 . . . . 1.0 110.495 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.523 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.38 149.37 9.8 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.169 -1.049 . . . . 1.0 108.169 -179.799 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.523 ' CA ' HG23 ' A' ' 8' ' ' THR . 5.1 Cg_endo -77.38 151.83 93.17 Favored 'Cis proline' 0 C--N 1.309 -1.536 0 C-N-CA 123.654 -1.394 . . . . 1.0 109.49 -0.223 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 75.4 p -91.89 -24.99 19.15 Favored 'General case' 0 C--N 1.292 -1.904 0 O-C-N 121.501 -0.749 . . . . 1.0 109.137 179.696 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.449 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 0.9 OUTLIER -133.54 165.12 25.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.43 -0.794 . . . . 1.0 109.557 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.52 38.5 37.81 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 108.209 -1.956 . . . . 1.0 108.209 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.613 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 33.6 mt -92.13 -44.32 8.88 Favored 'General case' 0 C--N 1.298 -1.674 0 CA-C-O 123.122 1.439 . . . . 1.0 110.637 -178.214 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.481 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.3 144.75 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.279 0 CA-C-N 113.613 -1.63 . . . . 1.0 109.947 -179.603 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.575 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.2 p-10 -51.16 108.24 0.24 Allowed 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.524 0.678 . . . . 1.0 111.523 -178.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.11 14.14 10.23 Favored Glycine 0 N--CA 1.484 1.835 0 C-N-CA 119.408 -1.377 . . . . 1.0 112.824 177.283 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.613 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.1 t -104.05 -172.38 2.1 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 121.079 2.439 . . . . 1.0 109.639 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 12.1 t -131.61 138.85 52.01 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.37 0 CA-C-N 114.967 -1.015 . . . . 1.0 111.281 -178.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.493 HG12 ' CG2' ' A' ' 69' ' ' VAL . 26.9 m -114.45 154.99 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.761 -0.829 . . . . 1.0 108.761 179.155 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 21.0 tttt -109.06 108.86 19.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.053 -1.029 . . . . 1.0 109.407 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.521 ' CG1' HG23 ' A' ' 34' ' ' VAL . 1.7 p -106.86 122.53 61.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 N-CA-C 108.778 -0.823 . . . . 1.0 108.778 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.543 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -112.98 165.67 12.13 Favored 'General case' 0 C--N 1.305 -1.331 0 O-C-N 120.902 -1.124 . . . . 1.0 109.114 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.587 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.77 107.91 0.48 Allowed Glycine 0 N--CA 1.482 1.765 0 N-CA-C 108.738 -1.745 . . . . 1.0 108.738 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.601 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.43 141.05 48.68 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 120.658 -1.495 . . . . 1.0 110.168 -179.502 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.484 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.86 28.12 32.61 Favored Glycine 0 N--CA 1.488 2.109 0 C-N-CA 119.003 -1.57 . . . . 1.0 109.806 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.537 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -94.23 174.73 7.0 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.008 -1.29 . . . . 1.0 108.587 179.991 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.563 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.95 97.29 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.022 -1.048 . . . . 1.0 109.673 -179.831 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.541 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.19 76.63 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.345 -0.843 . . . . 1.0 110.372 -179.145 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.563 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.85 33.92 0.32 Allowed Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.751 -1.34 . . . . 1.0 109.751 179.498 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.638 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.1 t -146.66 114.15 6.34 Favored 'General case' 0 C--N 1.309 -1.174 0 O-C-N 120.838 -1.39 . . . . 1.0 110.986 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.537 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -46.12 126.2 7.35 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-N 115.31 -0.859 . . . . 1.0 110.008 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.638 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 12.2 m-85 -118.43 151.17 38.3 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.543 -0.91 . . . . 1.0 108.543 179.358 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.463 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.54 156.76 17.28 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.572 -1.33 . . . . 1.0 108.063 179.015 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.617 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 7.0 p -139.32 115.04 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.189 -0.944 . . . . 1.0 109.83 -177.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.487 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.75 -178.64 37.53 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.449 -1.834 . . . . 1.0 111.804 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.631 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -101.8 109.43 21.19 Favored 'General case' 0 C--N 1.313 -0.987 0 N-CA-C 108.799 -0.815 . . . . 1.0 108.799 -179.818 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.41 149.17 52.21 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.22 -0.925 . . . . 1.0 109.99 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.21 138.19 54.7 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.265 -0.897 . . . . 1.0 110.729 -179.081 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.625 ' CE2' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.71 26.53 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 107.432 -1.322 . . . . 1.0 107.432 178.09 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -105.63 15.3 7.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.018 -1.051 . . . . 1.0 110.589 -178.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.589 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.99 -175.63 0.09 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.875 -1.14 . . . . 1.0 110.088 179.787 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 43.8 p -71.95 97.72 1.91 Allowed 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.404 -0.81 . . . . 1.0 109.664 -179.722 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.7 27.37 35.32 Favored Glycine 0 N--CA 1.493 2.448 0 C-N-CA 120.141 -1.028 . . . . 1.0 111.302 178.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.589 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.32 106.28 20.01 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.519 -1.577 . . . . 1.0 107.203 178.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.625 HD11 ' CE2' ' A' ' 39' ' ' TRP . 13.0 tp -117.04 104.3 11.11 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 120.427 -1.42 . . . . 1.0 109.726 -177.749 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.97 109.32 22.1 Favored 'General case' 0 N--CA 1.483 1.202 0 N-CA-C 107.65 -1.241 . . . . 1.0 107.65 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -105.72 166.36 10.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.035 -1.04 . . . . 1.0 110.404 -178.678 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.454 ' OD1' ' HB2' ' A' ' 74' ' ' GLU . 59.2 t30 -111.84 131.39 22.45 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.541 -0.724 . . . . 1.0 109.736 -179.465 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.58 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 2.5 Cg_endo -73.05 22.62 0.31 Allowed 'Trans proline' 0 C--N 1.319 -1.022 0 C-N-CA 122.112 1.874 . . . . 1.0 111.737 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.436 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -110.01 2.84 19.89 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.307 -1.496 . . . . 1.0 109.19 179.562 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.524 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.5 15.56 2.75 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.471 -1.307 . . . . 1.0 107.471 179.479 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -79.22 92.96 5.16 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.898 -0.721 . . . . 1.0 111.039 -178.429 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.617 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -111.95 -167.82 1.23 Allowed 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.536 -1.283 . . . . 1.0 107.536 178.104 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.467 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.98 136.5 0.09 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.439 -1.413 . . . . 1.0 111.521 -179.332 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.585 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.12 157.51 4.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.276 -1.379 . . . . 1.0 107.276 178.019 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.537 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.1 145.49 26.51 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.76 -1.212 . . . . 1.0 109.825 -179.703 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.674 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.08 107.24 1.84 Allowed 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 122.485 1.136 . . . . 1.0 109.328 178.718 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.523 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.1 t70 -60.82 -139.37 0.0 OUTLIER 'General case' 0 C--N 1.292 -1.93 0 CA-C-N 115.558 -0.746 . . . . 1.0 110.941 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.541 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.12 -51.42 43.26 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.504 -0.747 . . . . 1.0 110.756 -178.658 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.57 -32.56 8.89 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 106.308 -1.738 . . . . 1.0 106.308 178.673 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.674 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.24 65.21 0.61 Allowed Glycine 0 C--N 1.297 -1.589 0 N-CA-C 110.542 -1.023 . . . . 1.0 110.542 178.238 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.587 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.7 m -103.0 124.66 48.93 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 108.292 -1.003 . . . . 1.0 108.292 178.604 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.585 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.58 109.36 8.62 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 119.681 -0.808 . . . . 1.0 109.726 -179.13 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.3 m -115.99 115.66 26.54 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.293 -0.879 . . . . 1.0 109.164 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.459 HG22 HG13 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -140.68 138.86 34.59 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.425 -0.797 . . . . 1.0 109.864 179.941 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.7 p -98.98 133.48 43.19 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.448 -0.782 . . . . 1.0 109.179 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.524 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -131.22 163.71 27.14 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.302 -0.873 . . . . 1.0 109.446 -179.313 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.552 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.8 p -93.99 124.33 37.93 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.046 -1.034 . . . . 1.0 109.157 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.493 ' CG2' HG12 ' A' ' 19' ' ' VAL . 14.4 m -134.71 143.32 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 120.979 -1.076 . . . . 1.0 109.877 -178.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.575 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.2 ptt180 -145.33 -170.66 3.49 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.464 -1.397 . . . . 1.0 111.042 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.611 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -61.88 -101.64 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.851 -0.531 . . . . 1.0 110.241 -179.093 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -59.19 138.11 57.71 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.566 -1.333 . . . . 1.0 108.517 179.953 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.631 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 1.3 p90 -156.87 154.13 29.32 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 118.824 -1.15 . . . . 1.0 109.854 -178.795 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' A' ' 47' ' ' CYS . 20.4 mm-40 -47.6 122.11 4.56 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.353 -0.842 . . . . 1.0 109.577 -178.58 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -88.94 49.38 3.58 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.94 -0.864 . . . . 1.0 110.94 -179.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.58 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.4 m-85 -40.42 113.17 0.34 Allowed 'General case' 0 N--CA 1.507 2.386 0 O-C-N 121.014 -1.286 . . . . 1.0 110.224 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -86.92 127.08 35.06 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.842 -1.161 . . . . 1.0 109.358 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.569 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 20.6 t80 -63.83 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 O-C-N 120.758 -1.214 . . . . 1.0 110.213 179.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 1.6 t0 -160.78 19.0 0.13 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.016 -1.052 . . . . 1.0 109.801 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -25.97 5.75 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 110.15 -1.18 . . . . 1.0 110.15 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 15.4 p -93.31 157.67 16.13 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 120.964 -1.315 . . . . 1.0 110.491 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.462 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -103.86 132.71 49.85 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.482 -0.932 . . . . 1.0 108.482 179.609 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.457 ' CD1' HD11 ' A' ' 77' ' ' LEU . 3.1 t90 -81.16 -18.51 46.06 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.758 -1.213 . . . . 1.0 110.382 -178.692 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.26 174.16 19.41 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.864 -1.694 . . . . 1.0 108.864 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.43 107.93 1.22 Allowed 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.683 -1.229 . . . . 1.0 107.683 179.224 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.6 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 42.0 t -79.82 104.74 8.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.362 -0.836 . . . . 1.0 109.13 -178.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.469 ' HB3' HG22 ' A' ' 90' ' ' THR . 0.8 OUTLIER -65.04 109.15 2.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.567 -0.708 . . . . 1.0 110.15 -179.179 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.586 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.8 t -62.04 -4.1 1.51 Allowed 'General case' 0 N--CA 1.502 2.167 0 C-N-CA 118.262 -1.375 . . . . 1.0 110.334 179.265 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.1 p -91.33 5.34 49.62 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.66 -1.275 . . . . 1.0 109.384 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.469 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -117.2 -49.75 2.58 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.356 -0.84 . . . . 1.0 109.178 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.89 178.55 4.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.52 -0.737 . . . . 1.0 109.456 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.49 112.5 24.87 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.342 -0.849 . . . . 1.0 108.907 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.501 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 1.6 m -96.7 121.69 38.82 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.031 -1.043 . . . . 1.0 109.279 -179.061 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.535 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.61 147.55 26.65 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 122.454 1.121 . . . . 1.0 111.358 -179.172 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.53 ' CG1' HG12 ' A' ' 7' ' ' VAL . 58.8 t -103.38 109.52 27.22 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.492 -1.67 . . . . 1.0 106.492 177.484 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.401 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.19 -171.31 16.98 Favored Glycine 0 N--CA 1.485 1.927 0 C-N-CA 118.166 -1.969 . . . . 1.0 111.721 -177.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.463 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -115.49 -178.2 3.33 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.704 -0.85 . . . . 1.0 108.704 -178.839 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.581 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.4 p -178.81 169.23 1.65 Allowed 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.312 -0.867 . . . . 1.0 109.574 -179.16 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.454 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -122.18 -157.69 0.75 Allowed 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.035 -1.04 . . . . 1.0 108.994 179.919 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.454 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.48 36.01 4.3 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.742 -1.224 . . . . 1.0 109.238 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.39 -33.09 5.72 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.273 -0.892 . . . . 1.0 110.026 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.447 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 162.74 -35.27 0.33 Allowed Glycine 0 N--CA 1.481 1.681 0 N-CA-C 107.697 -2.161 . . . . 1.0 107.697 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.02 -177.91 6.43 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 122.052 0.93 . . . . 1.0 109.844 179.255 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.48 -162.49 19.39 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 108.374 -1.89 . . . . 1.0 108.374 -179.477 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.477 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.1 Cg_exo -46.0 174.43 0.02 OUTLIER 'Trans proline' 0 C--N 1.327 -0.581 0 CA-C-N 118.854 1.327 . . . . 1.0 110.168 179.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -90.46 -178.84 5.44 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.0 -1.063 . . . . 1.0 110.611 -178.601 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.401 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.86 166.38 13.02 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.586 -1.405 . . . . 1.0 109.586 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.61 131.8 54.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.338 -1.095 . . . . 1.0 109.177 -179.225 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.535 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.3 121.94 20.28 Favored 'General case' 0 C--N 1.29 -2.002 0 O-C-N 121.59 -0.694 . . . . 1.0 109.617 179.657 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.562 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.8 pt -98.01 173.2 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.248 -0.908 . . . . 1.0 108.996 179.852 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.449 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -141.36 159.54 42.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.06 -1.025 . . . . 1.0 110.04 -179.7 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.562 ' CE2' HD12 ' A' ' 110' ' ' ILE . 88.5 m-85 -135.96 98.55 3.91 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.276 -0.89 . . . . 1.0 109.573 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 p30 . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 118.006 -0.997 . . . . 1.0 109.512 179.976 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.588 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.324 0.583 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.519 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . . . -85.37 172.83 7.96 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.222 -0.923 . . . . 0.0 109.525 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.519 ' HD2' ' CB ' ' A' ' 2' ' ' ALA . 5.0 Cg_exo -60.14 157.72 33.52 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.386 2.057 . . . . 0.0 110.572 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.6 -169.68 0.14 Allowed 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.15 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.545 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.93 130.06 2.22 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.83 -1.169 . . . . 0.0 110.666 -179.132 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.542 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.9 t -111.17 108.71 18.47 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 123.04 1.4 . . . . 0.0 109.096 179.273 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.506 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 4.5 t -118.31 136.44 55.5 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.761 0 CA-C-N 114.299 -1.319 . . . . 0.0 110.094 -179.685 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.528 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -176.64 150.97 1.0 Allowed Pre-proline 0 N--CA 1.488 1.431 0 O-C-N 121.279 -0.888 . . . . 0.0 108.801 -179.641 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.528 ' CA ' HG23 ' A' ' 8' ' ' THR . 5.8 Cg_endo -79.11 150.45 85.74 Favored 'Cis proline' 0 C--N 1.311 -1.432 0 C-N-CA 123.507 -1.456 . . . . 0.0 109.271 -0.735 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.459 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 78.4 p -92.23 -23.19 19.42 Favored 'General case' 0 C--N 1.291 -1.937 0 O-C-N 121.589 -0.695 . . . . 0.0 109.402 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.485 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 7.4 m -132.2 160.74 35.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.354 -0.841 . . . . 0.0 109.764 -179.785 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.77 37.39 30.21 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.616 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 30.8 mt -92.04 -44.42 8.86 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-O 123.2 1.476 . . . . 0.0 110.728 -178.363 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.4 OUTLIER 65.96 146.28 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.341 0 CA-C-N 113.628 -1.624 . . . . 0.0 109.942 -179.69 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.546 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.0 p-10 -50.85 108.08 0.21 Allowed 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 121.478 0.656 . . . . 0.0 111.882 -178.532 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.5 15.2 10.58 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.421 -1.371 . . . . 0.0 112.879 177.131 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.616 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 10.6 t -102.65 -172.42 2.12 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 121.056 2.428 . . . . 0.0 109.897 179.35 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.542 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 33.6 t -125.66 137.55 57.33 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.246 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.962 -178.726 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.526 HG11 ' CG2' ' A' ' 69' ' ' VAL . 27.4 m -116.2 155.84 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 178.768 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.506 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.4 ttpt -114.31 109.55 18.52 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.06 -1.025 . . . . 0.0 109.178 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.5 HG13 ' CG2' ' A' ' 34' ' ' VAL . 2.4 p -105.12 141.45 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.54 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -139.72 160.25 40.3 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 120.632 -1.292 . . . . 0.0 110.229 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.07 144.21 15.45 Favored Glycine 0 C--N 1.295 -1.704 0 N-CA-C 107.977 -2.049 . . . . 0.0 107.977 179.47 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.509 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.08 125.94 13.55 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 120.894 -1.356 . . . . 0.0 108.841 179.206 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.518 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.11 27.04 24.51 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 119.214 -1.469 . . . . 0.0 109.654 -179.617 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.4 mt -88.58 175.01 7.74 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.887 -1.361 . . . . 0.0 108.498 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.555 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -48.55 100.15 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.002 -1.061 . . . . 0.0 109.792 -179.63 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.44 78.13 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.134 -179.24 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.91 34.08 0.31 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.72 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.539 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 34.2 p -140.79 107.29 5.3 Favored 'General case' 0 C--N 1.308 -1.218 0 O-C-N 121.24 -1.153 . . . . 0.0 110.984 -179.489 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.548 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -47.67 109.78 0.25 Allowed 'General case' 0 N--CA 1.497 1.888 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.987 178.174 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.539 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 24.9 m-85 -102.38 153.86 19.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 108.638 179.372 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.482 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.87 161.51 13.61 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.676 -1.265 . . . . 0.0 107.948 178.85 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.626 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.5 p -141.16 115.23 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.157 -0.964 . . . . 0.0 109.442 -178.205 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.521 ' HA2' ' OD1' ' A' ' 51' ' ' ASP . . . -162.75 173.99 39.05 Favored Glycine 0 N--CA 1.49 2.276 0 C-N-CA 118.06 -2.019 . . . . 0.0 112.114 -179.334 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.592 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -98.43 108.96 21.79 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 179.267 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.8 m -132.28 151.26 51.92 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.277 -0.889 . . . . 0.0 109.992 -179.513 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.82 139.65 53.64 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.248 -0.907 . . . . 0.0 110.695 -179.06 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.629 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.26 114.56 26.36 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.22 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.444 HG21 ' HB ' ' A' ' 44' ' ' VAL . 14.2 m -105.09 14.75 7.09 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 120.885 -1.135 . . . . 0.0 110.602 -178.687 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.59 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.06 -174.99 0.09 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.892 -1.13 . . . . 0.0 110.067 179.751 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.6 p -71.95 97.32 1.84 Allowed 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.344 -0.848 . . . . 0.0 109.798 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.42 26.93 34.39 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 120.241 -0.98 . . . . 0.0 111.428 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.59 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.6 106.31 20.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.55 -1.559 . . . . 0.0 107.429 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.629 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.2 tp -116.65 104.82 11.77 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.564 -1.335 . . . . 0.0 109.723 -177.862 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.542 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.98 109.53 22.27 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 120.829 -1.17 . . . . 0.0 108.204 179.092 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.6 t -105.89 165.56 11.11 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.9 -1.125 . . . . 0.0 110.295 -179.085 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.535 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 18.7 t-20 -109.33 137.0 20.13 Favored Pre-proline 0 N--CA 1.501 2.104 0 O-C-N 121.421 -0.799 . . . . 0.0 110.201 -179.08 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.579 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.2 Cg_endo -74.89 23.94 0.39 Allowed 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 122.387 2.058 . . . . 0.0 111.971 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.535 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -116.88 2.67 12.83 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.296 -1.503 . . . . 0.0 109.227 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.558 ' OD1' ' CD2' ' A' ' 67' ' ' LEU . 9.4 t70 -137.64 13.27 2.95 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 179.552 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -79.72 94.25 5.7 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 121.424 -0.798 . . . . 0.0 110.883 -178.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -115.33 -166.25 1.1 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 178.367 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.472 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.94 135.42 0.09 Allowed 'General case' 0 N--CA 1.486 1.369 0 O-C-N 120.627 -1.296 . . . . 0.0 111.429 -179.34 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.585 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -151.18 156.9 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 107.354 -1.351 . . . . 0.0 107.354 178.007 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.548 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.19 144.14 27.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.801 -1.187 . . . . 0.0 110.055 -179.574 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.685 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.72 106.91 1.06 Allowed 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 122.447 1.118 . . . . 0.0 109.436 178.27 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.521 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -60.05 -139.28 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.988 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.042 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.91 -50.1 61.74 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.498 -0.751 . . . . 0.0 110.597 -178.752 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 12.3 m-80 -103.7 -34.47 8.58 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 106.208 -1.775 . . . . 0.0 106.208 178.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.685 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.49 65.31 0.58 Allowed Glycine 0 C--N 1.297 -1.604 0 N-CA-C 110.501 -1.039 . . . . 0.0 110.501 178.141 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 46.6 m -103.62 127.05 51.11 Favored 'General case' 0 N--CA 1.483 1.19 0 O-C-N 121.381 -1.07 . . . . 0.0 108.915 178.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.585 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.72 109.15 7.37 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.424 -0.91 . . . . 0.0 109.36 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.521 ' CB ' ' HB2' ' A' ' 22' ' ' ALA . 1.4 m -124.71 121.65 35.25 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.201 -0.937 . . . . 0.0 109.663 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.71 142.05 28.61 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.596 -0.69 . . . . 0.0 109.486 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 15.6 p -98.93 136.38 39.0 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.451 -0.781 . . . . 0.0 109.186 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.558 ' CD2' ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -135.93 -178.73 5.27 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.235 -0.915 . . . . 0.0 109.544 -178.983 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.4 p -105.09 126.18 51.79 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.99 -1.069 . . . . 0.0 109.637 -179.352 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.534 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 16.9 m -139.35 142.97 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 120.888 -1.132 . . . . 0.0 110.08 -179.521 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.546 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 7.8 ptt180 -141.2 -161.42 1.21 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.671 -1.268 . . . . 0.0 110.141 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.582 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -78.15 -86.89 0.06 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.232 -0.918 . . . . 0.0 108.848 -179.584 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -60.87 138.47 58.14 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.387 -1.446 . . . . 0.0 107.204 178.809 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -165.11 136.58 4.11 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 117.901 -1.519 . . . . 0.0 110.371 -177.365 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.484 ' O ' ' O ' ' A' ' 47' ' ' CYS . 7.0 mm-40 -33.4 121.44 0.4 Allowed 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 121.352 0.596 . . . . 0.0 110.326 -178.766 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.542 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.85 51.83 1.72 Allowed Glycine 0 N--CA 1.494 2.53 0 C-N-CA 120.474 -0.869 . . . . 0.0 111.42 -179.036 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 4.2 m-85 -39.11 116.6 0.6 Allowed 'General case' 0 N--CA 1.511 2.62 0 O-C-N 121.018 -1.283 . . . . 0.0 110.05 179.526 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.544 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.9 tp -86.4 126.27 34.27 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 120.96 -1.087 . . . . 0.0 109.69 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.568 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 32.0 t80 -64.5 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 120.738 -1.226 . . . . 0.0 109.92 179.362 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.544 ' N ' ' O ' ' A' ' 77' ' ' LEU . 5.7 t70 -158.93 19.51 0.2 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.061 -1.025 . . . . 0.0 109.656 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.75 -27.96 5.65 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.408 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 69.7 p -97.54 162.71 13.17 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.046 -1.267 . . . . 0.0 110.307 -179.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.52 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.0 140.37 41.25 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.904 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.47 ' HB2' HD11 ' A' ' 77' ' ' LEU . 1.7 t90 -83.8 -19.21 35.42 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.771 -1.205 . . . . 0.0 110.728 -178.282 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.85 177.33 20.13 Favored Glycine 0 N--CA 1.484 1.869 0 N-CA-C 108.578 -1.809 . . . . 0.0 108.578 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -63.9 109.79 1.89 Allowed 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.214 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.521 HG23 ' CB ' ' A' ' 46' ' ' ALA . 37.3 t -82.91 105.66 12.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 121.44 -0.788 . . . . 0.0 108.947 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.507 ' CB ' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -66.14 111.73 3.56 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.428 -0.795 . . . . 0.0 109.882 -179.205 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.555 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -65.28 -5.32 6.87 Favored 'General case' 0 N--CA 1.498 1.96 0 C-N-CA 118.203 -1.399 . . . . 0.0 109.665 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.3 p -84.01 -1.24 54.37 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.799 -1.188 . . . . 0.0 108.887 179.269 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.507 HG23 ' CB ' ' A' ' 87' ' ' ASP . 2.2 p -113.5 -50.05 2.87 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.443 -0.786 . . . . 0.0 109.012 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.87 -178.0 3.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.486 -0.758 . . . . 0.0 109.45 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.09 115.77 30.76 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.451 -0.78 . . . . 0.0 109.037 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.535 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -96.87 122.76 40.19 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.894 -1.129 . . . . 0.0 109.588 -179.384 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.555 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.83 146.39 28.35 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 122.337 1.065 . . . . 0.0 111.167 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.442 HG23 HG23 ' A' ' 110' ' ' ILE . 59.3 t -103.78 109.88 28.46 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.433 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.55 -172.09 18.05 Favored Glycine 0 N--CA 1.486 2.016 0 C-N-CA 118.03 -2.033 . . . . 0.0 111.914 -177.515 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.482 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -112.97 -178.88 3.49 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.255 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.548 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 2.9 p -176.57 173.03 2.08 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.261 -0.899 . . . . 0.0 109.518 -179.373 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -121.27 -161.74 0.92 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.044 -1.035 . . . . 0.0 108.785 179.841 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -117.39 36.09 4.4 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.584 -1.322 . . . . 0.0 109.302 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -117.48 -33.31 4.63 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.337 -0.852 . . . . 0.0 110.225 -179.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.439 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 167.93 -36.84 0.22 Allowed Glycine 0 N--CA 1.48 1.631 0 N-CA-C 107.913 -2.075 . . . . 0.0 107.913 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.31 -177.76 6.23 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 122.1 0.952 . . . . 0.0 109.95 179.277 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.93 -163.89 23.71 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.149 -1.98 . . . . 0.0 108.149 -179.457 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.0 Cg_exo -46.24 172.96 0.02 OUTLIER 'Trans proline' 0 C--N 1.326 -0.616 0 CA-C-N 118.88 1.34 . . . . 0.0 109.889 179.371 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -91.7 -173.21 3.46 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.15 -0.969 . . . . 0.0 110.447 -178.712 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.433 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.81 171.29 15.54 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.416 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.1 t -106.69 132.98 52.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.536 -0.979 . . . . 0.0 109.138 -179.383 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.555 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.37 123.94 26.25 Favored 'General case' 0 C--N 1.29 -2.017 0 O-C-N 121.609 -0.682 . . . . 0.0 109.664 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.572 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.73 168.23 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.282 -0.886 . . . . 0.0 108.934 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.485 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 5.4 m -136.6 154.53 50.64 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.219 -0.926 . . . . 0.0 109.752 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.572 ' CE2' HD12 ' A' ' 110' ' ' ILE . 77.3 m-85 -129.54 101.54 5.98 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.179 -0.951 . . . . 0.0 109.417 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.443 ' O ' ' OD1' ' A' ' 113' ' ' ASN . 15.0 p30 . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 117.921 -1.038 . . . . 0.0 109.48 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.588 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.625 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.523 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . . . -63.8 175.08 0.86 Allowed Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.279 -0.888 . . . . 0.0 109.258 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.523 ' HD2' ' CB ' ' A' ' 2' ' ' ALA . 6.0 Cg_exo -58.45 155.33 36.61 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 124.876 3.717 . . . . 0.0 109.784 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.591 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.2 p -165.8 160.72 17.36 Favored 'General case' 0 C--N 1.297 -1.716 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.111 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -149.51 128.29 12.5 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 122.414 1.102 . . . . 0.0 110.617 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.535 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 3.2 p -108.54 104.79 14.19 Favored 'General case' 0 C--N 1.296 -1.738 0 CA-C-O 122.491 1.139 . . . . 0.0 110.337 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.523 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 10.8 t -116.86 110.17 30.44 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.448 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.479 179.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.522 HG22 ' CA ' ' A' ' 9' ' ' PRO . 1.0 OUTLIER -152.55 146.72 18.53 Favored Pre-proline 0 N--CA 1.485 1.294 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.971 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.522 ' CA ' HG22 ' A' ' 8' ' ' THR . 9.3 Cg_endo -80.83 146.87 73.05 Favored 'Cis proline' 0 C--N 1.306 -1.675 0 O-C-N 123.666 1.351 . . . . 0.0 109.373 -0.232 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.47 ' HB2' ' HA ' ' A' ' 110' ' ' ILE . 80.4 p -91.51 -24.03 19.77 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.465 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 13.2 m -131.33 160.99 33.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.575 -0.703 . . . . 0.0 109.471 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.74 36.65 32.36 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 -179.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.604 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 35.7 mt -91.32 -42.63 10.26 Favored 'General case' 0 C--N 1.299 -1.587 0 CA-C-O 123.358 1.552 . . . . 0.0 110.46 -178.475 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.24 142.99 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.253 0 CA-C-N 113.322 -1.763 . . . . 0.0 109.795 -179.561 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.58 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.1 p-10 -50.01 105.74 0.1 Allowed 'General case' 0 C--N 1.301 -1.529 0 CA-C-O 121.448 0.642 . . . . 0.0 111.574 -178.56 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.47 13.88 8.57 Favored Glycine 0 N--CA 1.485 1.919 0 C-N-CA 119.417 -1.373 . . . . 0.0 113.16 177.211 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.604 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.0 t -106.01 -172.88 2.17 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 121.199 2.499 . . . . 0.0 109.839 179.28 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.583 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 20.8 t -128.87 140.3 49.62 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.27 0 CA-C-N 114.695 -1.139 . . . . 0.0 111.362 -178.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.531 HG11 ' CG2' ' A' ' 69' ' ' VAL . 27.8 m -114.87 156.24 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 178.876 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.508 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -109.29 109.72 20.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.984 -1.072 . . . . 0.0 109.553 -179.716 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.525 HG13 ' CG2' ' A' ' 34' ' ' VAL . 1.6 p -105.05 123.57 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 179.898 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.567 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -112.3 165.96 11.71 Favored 'General case' 0 N--CA 1.484 1.267 0 O-C-N 120.792 -1.192 . . . . 0.0 108.942 179.438 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -145.56 108.16 0.45 Allowed Glycine 0 N--CA 1.483 1.822 0 N-CA-C 108.36 -1.896 . . . . 0.0 108.36 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.591 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.83 137.37 52.25 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 120.519 -1.577 . . . . 0.0 110.439 -179.303 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.501 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 85.85 28.85 27.8 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.085 -1.531 . . . . 0.0 109.874 179.567 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.3 mt -90.36 175.66 7.02 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.963 -1.316 . . . . 0.0 108.373 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.553 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.69 97.94 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.858 -1.151 . . . . 0.0 109.678 -179.669 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.08 76.96 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.692 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.381 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.571 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.9 34.34 0.3 Allowed Glycine 0 N--CA 1.486 1.975 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.465 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.7 p -147.89 113.3 5.61 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 120.998 -1.296 . . . . 0.0 111.28 -179.693 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.543 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.86 126.67 5.91 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-N 115.619 -0.718 . . . . 0.0 109.567 177.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.551 ' CZ ' ' OD2' ' A' ' 99' ' ' ASP . 10.5 m-85 -117.48 149.39 40.67 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.463 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.3 163.87 12.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.751 -1.218 . . . . 0.0 107.92 178.918 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.621 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 9.9 p -149.32 114.07 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.202 -0.936 . . . . 0.0 109.838 -177.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.01 -175.89 36.83 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 118.329 -1.891 . . . . 0.0 111.724 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.56 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -101.4 108.87 20.6 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.763 0.792 . . . . 0.0 108.951 -179.563 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.12 146.88 51.8 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.427 -0.796 . . . . 0.0 109.691 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.35 138.18 53.87 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.298 -0.877 . . . . 0.0 110.703 -179.007 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.634 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.64 114.4 26.14 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.251 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.46 HG22 ' HB ' ' A' ' 44' ' ' VAL . 15.9 m -105.89 14.85 7.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.002 -1.061 . . . . 0.0 110.603 -178.646 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.594 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.43 -174.6 0.07 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.808 -1.182 . . . . 0.0 110.164 179.756 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.8 p -71.71 97.57 1.78 Allowed 'General case' 0 N--CA 1.485 1.323 0 O-C-N 121.43 -0.794 . . . . 0.0 109.867 -179.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 26.47 37.09 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 120.251 -0.976 . . . . 0.0 111.483 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.594 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.75 106.21 20.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.556 -1.555 . . . . 0.0 107.367 178.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.634 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.9 tp -118.22 104.77 11.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.473 -1.392 . . . . 0.0 109.641 -177.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.534 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.98 109.75 22.45 Favored 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.789 -1.194 . . . . 0.0 108.345 179.138 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.5 t -106.33 164.71 11.8 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.935 -1.103 . . . . 0.0 110.426 -178.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.533 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 10.5 t-20 -108.94 139.48 20.96 Favored Pre-proline 0 N--CA 1.501 2.083 0 O-C-N 121.461 -0.775 . . . . 0.0 109.952 -179.124 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 6.8 Cg_endo -75.7 23.11 0.45 Allowed 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 125.162 3.908 . . . . 0.0 111.258 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.533 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -120.07 3.34 10.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.426 -1.421 . . . . 0.0 109.052 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.522 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.89 14.51 3.1 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 179.343 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -80.49 91.19 5.72 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.778 -0.769 . . . . 0.0 110.98 -178.487 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.621 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -113.23 -173.31 2.23 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.099 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.67 134.6 0.08 Allowed 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.482 -1.386 . . . . 0.0 111.494 -179.183 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.587 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 3.6 p -146.73 159.62 10.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 107.227 -1.398 . . . . 0.0 107.227 177.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.543 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.33 145.89 25.68 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.433 -1.417 . . . . 0.0 110.116 -179.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.674 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.47 109.36 3.67 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 122.326 1.06 . . . . 0.0 109.802 178.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -63.64 -139.31 0.0 OUTLIER 'General case' 0 C--N 1.292 -1.902 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.588 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.92 -51.59 55.91 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.391 -0.818 . . . . 0.0 110.378 -178.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.455 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.4 t-20 -101.39 -34.18 9.7 Favored 'General case' 0 C--N 1.287 -2.121 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.674 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 106.44 69.59 0.72 Allowed Glycine 0 N--CA 1.479 1.557 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 178.041 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 64.3 p -98.86 131.69 44.77 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 121.327 -1.102 . . . . 0.0 109.268 179.118 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.587 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -135.1 108.48 7.82 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.775 -0.77 . . . . 0.0 109.021 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 7.0 m -122.23 116.36 24.0 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.122 -0.986 . . . . 0.0 109.536 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.52 HG21 ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -146.13 139.48 25.99 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.428 -0.795 . . . . 0.0 109.787 179.944 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.8 p -99.97 128.83 46.01 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.369 -0.832 . . . . 0.0 108.946 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.522 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -126.54 164.42 21.24 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.227 -0.92 . . . . 0.0 109.783 -179.092 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.583 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -96.77 125.12 41.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.118 -0.989 . . . . 0.0 109.221 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.547 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.9 m -136.51 142.69 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.075 -1.016 . . . . 0.0 109.909 -179.026 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.58 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.8 ptt180 -146.37 -173.62 4.24 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.473 -1.392 . . . . 0.0 110.922 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.566 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.64 -101.94 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 -179.409 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -55.72 140.95 39.99 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 120.788 -1.195 . . . . 0.0 108.115 179.458 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.79 135.26 5.51 Favored 'General case' 0 C--N 1.294 -1.818 0 C-N-CA 118.701 -1.2 . . . . 0.0 109.813 -178.265 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.498 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 1.3 mp0 -31.53 121.16 0.25 Allowed 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 121.41 0.624 . . . . 0.0 110.699 -178.488 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.534 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.74 46.61 2.73 Favored Glycine 0 N--CA 1.495 2.572 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.136 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -38.48 113.19 0.27 Allowed 'General case' 0 N--CA 1.507 2.388 0 O-C-N 121.121 -1.223 . . . . 0.0 110.205 179.622 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.532 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -85.92 127.32 34.58 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 120.975 -1.078 . . . . 0.0 109.52 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.586 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 25.6 t80 -64.09 58.17 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.051 0 O-C-N 120.858 -1.151 . . . . 0.0 110.198 179.73 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 6.7 t70 -160.93 19.4 0.13 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.972 -1.08 . . . . 0.0 109.794 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.73 -27.17 5.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.429 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 70.7 p -93.39 157.15 16.37 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.05 -1.264 . . . . 0.0 110.349 -179.402 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.478 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -104.73 134.45 47.85 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.652 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.493 ' CD1' HD12 ' A' ' 77' ' ' LEU . 2.0 t90 -80.94 -17.97 48.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.887 -1.133 . . . . 0.0 110.413 -178.494 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.74 174.6 19.79 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.29 106.2 1.06 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.11 -1.23 . . . . 0.0 107.695 179.157 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.576 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 43.0 t -77.54 106.79 8.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.382 -0.824 . . . . 0.0 109.292 -178.787 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -65.91 111.54 3.35 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.413 -0.804 . . . . 0.0 109.801 -179.474 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.566 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.71 -5.4 4.07 Favored 'General case' 0 N--CA 1.501 2.085 0 C-N-CA 118.135 -1.426 . . . . 0.0 109.809 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 40.9 p -86.52 -1.8 57.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.799 -1.188 . . . . 0.0 109.29 179.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.455 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.14 -49.69 3.0 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.264 -0.898 . . . . 0.0 109.058 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.18 179.03 4.38 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.47 -0.769 . . . . 0.0 109.525 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.3 115.92 31.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.39 -0.819 . . . . 0.0 109.058 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.83 122.59 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.877 -1.139 . . . . 0.0 109.465 -179.448 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.532 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.92 148.03 25.82 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 122.418 1.104 . . . . 0.0 111.249 -179.266 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.481 ' CG1' HG13 ' A' ' 7' ' ' VAL . 72.3 t -104.86 109.87 28.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 177.705 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.31 -173.56 18.56 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 118.308 -1.901 . . . . 0.0 111.796 -177.545 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.468 HD11 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.49 -178.54 3.41 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.029 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.552 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.2 OUTLIER -171.43 168.39 6.52 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.357 -0.839 . . . . 0.0 109.152 -179.353 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.551 ' OD2' ' CZ ' ' A' ' 32' ' ' TYR . 2.0 m-20 -104.11 -9.96 18.35 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.104 -0.998 . . . . 0.0 109.497 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.492 ' CB ' ' O ' ' A' ' 99' ' ' ASP . . . 73.97 38.76 0.56 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.464 -0.773 . . . . 0.0 109.317 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -137.83 -34.5 0.67 Allowed 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.543 -0.723 . . . . 0.0 110.566 -179.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.504 ' CA ' H192 ' A' ' 114' ' ' CHR . . . -178.16 -42.99 0.07 OUTLIER Glycine 0 N--CA 1.482 1.723 0 N-CA-C 107.588 -2.205 . . . . 0.0 107.588 -179.711 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.44 -178.69 7.32 Favored 'General case' 0 C--N 1.308 -1.237 0 O-C-N 121.6 -0.941 . . . . 0.0 109.522 179.051 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -175.88 -166.53 33.46 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 108.405 -1.878 . . . . 0.0 108.405 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.2 Cg_exo -45.03 178.85 0.0 OUTLIER 'Trans proline' 0 N--CA 1.491 1.377 0 C-N-CA 123.349 2.699 . . . . 0.0 109.697 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -92.59 175.18 6.92 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.955 -1.09 . . . . 0.0 110.637 -178.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -114.76 163.66 12.16 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.35 127.38 63.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.32 -1.106 . . . . 0.0 109.155 -179.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.532 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.58 122.01 19.76 Favored 'General case' 0 C--N 1.291 -1.971 0 O-C-N 121.559 -0.713 . . . . 0.0 109.47 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.585 HD13 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.79 170.44 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.198 -0.939 . . . . 0.0 109.085 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.465 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -140.53 156.38 46.33 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.143 -0.973 . . . . 0.0 109.837 -179.657 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.585 ' CZ ' HD13 ' A' ' 110' ' ' ILE . 87.5 m-85 -134.22 114.27 12.88 Favored 'General case' 0 N--CA 1.485 1.293 0 O-C-N 121.233 -0.917 . . . . 0.0 109.572 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.415 ' C ' ' O ' ' A' ' 112' ' ' PHE . 20.2 p30 . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 117.98 -1.009 . . . . 0.0 109.494 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.587 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -104.41 161.95 21.32 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.265 -0.897 . . . . 0.0 109.36 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.524 ' O ' ' CG2' ' A' ' 4' ' ' THR . 4.5 Cg_exo -59.2 154.92 42.92 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 124.932 3.755 . . . . 0.0 110.029 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.598 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.2 p -166.54 160.14 14.98 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 -179.248 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.487 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -149.63 121.79 8.33 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-O 122.371 1.081 . . . . 0.0 110.391 -179.725 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.55 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.1 t -114.28 109.3 18.16 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-O 123.112 1.435 . . . . 0.0 109.59 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.522 HG12 ' CB ' ' A' ' 21' ' ' VAL . 0.6 OUTLIER -116.71 129.93 72.4 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.666 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.756 -179.883 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.531 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -167.8 148.62 4.75 Favored Pre-proline 0 N--CA 1.487 1.401 0 O-C-N 121.169 -0.957 . . . . 0.0 108.943 -179.723 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.531 ' CA ' HG23 ' A' ' 8' ' ' THR . 7.4 Cg_endo -80.66 147.64 74.96 Favored 'Cis proline' 0 C--N 1.309 -1.523 0 O-C-N 123.669 1.352 . . . . 0.0 109.181 -0.656 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.479 ' HB2' ' HA ' ' A' ' 110' ' ' ILE . 86.8 p -91.08 -24.5 20.0 Favored 'General case' 0 C--N 1.294 -1.805 0 O-C-N 121.484 -0.76 . . . . 0.0 109.238 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.454 ' OG ' ' HB3' ' A' ' 111' ' ' SER . 0.7 OUTLIER -129.61 161.59 30.2 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.367 -0.833 . . . . 0.0 109.622 -179.864 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.08 37.94 31.31 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 108.499 -1.84 . . . . 0.0 108.499 -179.679 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.607 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.3 mt -92.79 -43.69 8.89 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 123.199 1.476 . . . . 0.0 110.736 -178.248 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.58 143.9 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.473 -1.694 . . . . 0.0 109.79 -179.355 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.557 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 17.9 p-10 -50.54 106.86 0.14 Allowed 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.394 0.616 . . . . 0.0 111.517 -178.558 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.62 14.34 9.65 Favored Glycine 0 N--CA 1.485 1.903 0 C-N-CA 119.38 -1.391 . . . . 0.0 112.966 177.143 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.607 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -104.18 -172.17 2.06 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 121.1 2.45 . . . . 0.0 109.821 179.246 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.553 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 17.7 t -127.94 138.7 53.95 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.796 -1.093 . . . . 0.0 111.197 -179.034 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.529 HG13 ' CG2' ' A' ' 69' ' ' VAL . 28.7 m -112.86 156.77 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.49 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.47 109.25 20.02 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.014 -1.054 . . . . 0.0 109.063 -179.933 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.531 HG12 ' CG2' ' A' ' 34' ' ' VAL . 11.2 p -103.74 140.65 21.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.707 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.576 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -138.93 160.82 38.83 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.681 -1.207 . . . . 0.0 110.142 179.635 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.582 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.03 140.25 11.55 Favored Glycine 0 C--N 1.297 -1.636 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.598 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.03 126.32 17.58 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.543 -1.563 . . . . 0.0 109.318 179.497 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.523 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 88.65 28.53 21.43 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 118.964 -1.588 . . . . 0.0 109.52 -179.666 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.537 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.5 mt -88.0 175.92 7.55 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.003 -1.292 . . . . 0.0 108.339 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.557 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.03 97.7 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.825 -1.172 . . . . 0.0 109.707 -179.57 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.553 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.92 77.27 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.433 -179.057 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.562 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.45 34.45 0.32 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.545 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.9 p -146.07 111.92 5.63 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.016 -1.285 . . . . 0.0 111.195 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.552 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.38 126.79 5.48 Favored 'General case' 0 N--CA 1.493 1.7 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.501 178.06 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.548 ' CE1' ' OD2' ' A' ' 99' ' ' ASP . 13.3 m-85 -117.45 152.5 34.88 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.494 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -101.42 162.51 12.84 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 178.771 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.625 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.8 p -148.99 117.82 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.013 -1.054 . . . . 0.0 110.049 -177.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -170.86 -176.25 40.0 Favored Glycine 0 N--CA 1.493 2.48 0 C-N-CA 118.266 -1.921 . . . . 0.0 111.736 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.563 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.06 108.91 21.19 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -179.788 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.55 148.69 52.38 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.275 -0.891 . . . . 0.0 109.713 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.95 139.39 54.0 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.316 -0.865 . . . . 0.0 110.643 -178.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.625 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.31 114.55 26.34 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 178.157 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.4 m -106.34 15.43 7.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.974 -1.079 . . . . 0.0 110.771 -178.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.588 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.56 -175.31 0.1 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.894 -1.129 . . . . 0.0 110.124 179.657 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 39.2 p -71.45 96.84 1.54 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.395 -0.816 . . . . 0.0 109.691 -179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.84 27.05 35.74 Favored Glycine 0 N--CA 1.493 2.496 0 C-N-CA 120.144 -1.027 . . . . 0.0 111.499 178.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.588 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.1 106.52 20.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 O-C-N 120.595 -1.532 . . . . 0.0 107.382 178.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.625 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.0 tp -116.08 104.62 11.75 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.492 -1.38 . . . . 0.0 109.485 -177.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.532 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.09 109.57 22.31 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 120.735 -1.228 . . . . 0.0 108.295 179.062 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -107.22 163.78 12.73 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.974 -1.079 . . . . 0.0 110.303 -178.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.519 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 16.6 t30 -110.36 139.08 21.14 Favored Pre-proline 0 N--CA 1.503 2.219 0 O-C-N 121.369 -0.832 . . . . 0.0 109.89 -179.401 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.586 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 6.1 Cg_endo -74.55 23.99 0.37 Allowed 'Trans proline' 0 N--CA 1.495 1.591 0 C-N-CA 125.252 3.968 . . . . 0.0 111.445 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.412 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -116.58 1.12 12.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.474 -1.392 . . . . 0.0 109.043 179.474 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.488 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -137.75 15.39 2.9 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.399 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -79.51 90.88 5.1 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.978 -0.689 . . . . 0.0 110.831 -178.649 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.625 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.24 -170.14 1.6 Allowed 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.255 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.468 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.91 136.03 0.09 Allowed 'General case' 0 C--N 1.305 -1.331 0 O-C-N 120.657 -1.277 . . . . 0.0 111.093 -179.354 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.568 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.3 p -150.57 157.35 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 178.212 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.25 145.0 26.5 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.579 -1.325 . . . . 0.0 109.784 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.677 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.15 107.77 2.04 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 122.392 1.091 . . . . 0.0 109.56 178.793 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.528 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.9 p-10 -60.4 -139.26 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.992 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.857 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.553 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -53.01 -49.69 65.74 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.427 -0.795 . . . . 0.0 110.341 -178.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -102.56 -36.21 8.45 Favored 'General case' 0 C--N 1.287 -2.148 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 178.4 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.677 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.4 67.14 0.61 Allowed Glycine 0 N--CA 1.48 1.601 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 178.242 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.582 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.1 m -100.98 130.02 46.91 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.566 -0.961 . . . . 0.0 108.992 178.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.576 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -137.76 108.9 6.79 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.225 -0.99 . . . . 0.0 109.496 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.425 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.9 m -125.94 119.73 28.51 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.275 -0.891 . . . . 0.0 109.592 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.41 144.6 30.74 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.432 -0.793 . . . . 0.0 109.389 179.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.0 p -98.96 132.29 44.39 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.418 -0.801 . . . . 0.0 109.355 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.526 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -130.84 167.83 18.27 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.292 -0.88 . . . . 0.0 109.624 -179.511 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.553 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.5 p -99.33 125.54 45.01 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.183 -0.948 . . . . 0.0 109.344 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.543 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.4 m -137.7 143.04 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 120.985 -1.072 . . . . 0.0 109.857 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.557 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.8 ptt180 -145.95 -170.92 3.59 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.597 -1.314 . . . . 0.0 110.888 -179.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.565 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -56.12 -102.05 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.769 -0.582 . . . . 0.0 109.488 -179.405 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -55.38 141.0 37.9 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 120.715 -1.24 . . . . 0.0 108.266 179.554 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.577 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.06 137.13 7.16 Favored 'General case' 0 C--N 1.295 -1.777 0 C-N-CA 118.922 -1.111 . . . . 0.0 109.634 -178.357 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.543 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 9.9 mm-40 -33.03 121.62 0.37 Allowed 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.604 0.716 . . . . 0.0 110.868 -178.266 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.532 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -90.05 44.87 2.99 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -179.555 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.586 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-85 -37.88 112.6 0.22 Allowed 'General case' 0 N--CA 1.508 2.436 0 O-C-N 121.252 -1.146 . . . . 0.0 110.094 179.691 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.537 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -86.15 126.95 34.6 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.944 -1.098 . . . . 0.0 109.503 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.573 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 34.9 t80 -63.84 58.3 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.0 0 O-C-N 120.967 -1.083 . . . . 0.0 110.338 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 10.9 t0 -161.67 19.83 0.11 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.001 -1.062 . . . . 0.0 109.762 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.15 -26.93 5.25 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.427 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -92.43 157.09 16.78 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.009 -1.289 . . . . 0.0 110.322 -179.402 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.459 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -104.44 133.2 49.73 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.656 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.517 ' CD1' HD11 ' A' ' 77' ' ' LEU . 3.4 t90 -81.26 -18.96 44.14 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.835 -1.166 . . . . 0.0 110.427 -178.678 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.45 173.56 18.63 Favored Glycine 0 N--CA 1.485 1.962 0 N-CA-C 108.931 -1.668 . . . . 0.0 108.931 -179.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.37 106.83 1.19 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.156 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.572 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 50.2 t -77.9 106.17 7.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 O-C-N 121.302 -0.874 . . . . 0.0 109.504 -178.716 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -65.51 110.97 2.89 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.36 -0.837 . . . . 0.0 109.826 -179.573 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.565 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -62.5 -5.98 3.01 Favored 'General case' 0 N--CA 1.501 2.078 0 C-N-CA 118.32 -1.352 . . . . 0.0 109.901 179.383 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -87.13 -1.19 57.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.611 -1.306 . . . . 0.0 109.336 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.458 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.0 -49.54 3.02 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.253 -0.905 . . . . 0.0 108.959 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.82 -179.22 3.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.582 -0.699 . . . . 0.0 109.441 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.03 115.37 30.32 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.329 -0.857 . . . . 0.0 109.003 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.561 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.2 m -96.75 122.44 39.69 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.857 -1.152 . . . . 0.0 109.476 -179.362 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.542 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.29 147.86 26.55 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-O 122.451 1.12 . . . . 0.0 111.208 -179.354 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 60.8 t -104.18 111.09 32.44 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.973 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.07 -172.63 18.98 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 118.108 -1.996 . . . . 0.0 111.769 -177.588 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -114.4 -179.06 3.52 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 -179.11 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.574 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -170.83 167.05 7.67 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.428 -0.795 . . . . 0.0 109.128 -179.406 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.548 ' OD2' ' CE1' ' A' ' 32' ' ' TYR . 3.3 m-20 -102.31 -12.8 17.67 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.104 -0.998 . . . . 0.0 109.51 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.512 ' CB ' ' O ' ' A' ' 99' ' ' ASP . . . 75.82 36.29 0.46 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.472 -0.768 . . . . 0.0 109.343 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -135.47 -33.17 0.89 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.548 -0.72 . . . . 0.0 110.615 -179.412 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.515 ' N ' H193 ' A' ' 114' ' ' CHR . . . -178.94 -42.58 0.07 OUTLIER Glycine 0 N--CA 1.483 1.769 0 N-CA-C 107.617 -2.193 . . . . 0.0 107.617 -179.564 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.72 -178.75 7.3 Favored 'General case' 0 C--N 1.308 -1.228 0 O-C-N 121.587 -0.949 . . . . 0.0 109.457 179.036 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -175.66 -167.15 34.26 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 108.603 -1.799 . . . . 0.0 108.603 -179.577 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.482 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.7 Cg_exo -45.72 179.65 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.391 0 C-N-CA 123.262 2.641 . . . . 0.0 109.638 179.45 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.84 174.82 6.98 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.917 -1.115 . . . . 0.0 110.571 -178.759 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -115.15 163.3 12.23 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.457 HG22 HG22 ' A' ' 7' ' ' VAL . 1.2 t -105.02 129.34 57.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.23 -1.159 . . . . 0.0 109.241 -179.317 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.542 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.08 122.81 23.27 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.605 -0.684 . . . . 0.0 109.567 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.585 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -97.93 169.88 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.259 -0.9 . . . . 0.0 109.249 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.454 ' HB3' ' OG ' ' A' ' 11' ' ' SER . 1.7 t -140.02 155.4 47.1 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.158 -0.964 . . . . 0.0 109.669 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.585 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 87.4 m-85 -131.91 88.31 2.54 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.109 -0.994 . . . . 0.0 109.607 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 16.5 p30 . . . . . 0 N--CA 1.489 1.489 0 CA-C-O 118.061 -0.971 . . . . 0.0 109.554 179.959 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.584 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.5 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . . . -114.7 171.79 4.16 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.319 -0.863 . . . . 0.0 109.459 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.535 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.8 Cg_exo -60.16 157.21 35.85 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.261 1.974 . . . . 0.0 110.693 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.543 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -175.8 -169.24 0.33 Allowed 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 178.904 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.543 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.95 133.57 2.86 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.909 -1.119 . . . . 0.0 110.609 -179.09 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.547 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.8 p -107.13 104.59 14.27 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.595 1.188 . . . . 0.0 110.023 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.528 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 13.2 t -117.93 121.2 66.77 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.435 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.433 179.798 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.507 HG22 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.95 148.5 7.42 Favored Pre-proline 0 N--CA 1.487 1.379 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 -179.74 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.507 ' CA ' HG22 ' A' ' 8' ' ' THR . 2.4 Cg_endo -75.42 153.33 98.45 Favored 'Cis proline' 0 C--N 1.309 -1.501 0 C-N-CA 123.648 -1.397 . . . . 0.0 109.614 -0.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.483 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 5.1 m -97.27 -22.14 16.85 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.518 ' HB3' ' CB ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -134.43 158.65 43.33 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.543 -0.723 . . . . 0.0 109.537 179.96 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.24 36.73 30.17 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.613 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 31.5 mt -89.32 -43.89 10.61 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 123.181 1.467 . . . . 0.0 110.513 -178.512 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.74 144.94 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.335 0 CA-C-N 113.543 -1.662 . . . . 0.0 109.946 -179.646 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.567 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.4 p-10 -50.77 107.18 0.16 Allowed 'General case' 0 C--N 1.301 -1.525 0 CA-C-O 121.657 0.741 . . . . 0.0 111.788 -178.469 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.1 15.65 9.72 Favored Glycine 0 N--CA 1.486 1.997 0 C-N-CA 119.423 -1.37 . . . . 0.0 112.942 177.224 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.613 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.1 t -103.21 -172.31 2.09 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 121.103 2.451 . . . . 0.0 109.784 179.221 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 17.5 t -129.72 139.14 52.38 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.18 -178.726 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.436 HG12 HD21 ' A' ' 13' ' ' LEU . 26.8 m -118.32 154.36 20.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.528 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.64 109.21 20.35 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.233 -0.917 . . . . 0.0 109.292 -179.954 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.497 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.1 p -106.09 124.09 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.563 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -113.16 165.36 12.47 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 120.731 -1.231 . . . . 0.0 108.85 179.421 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.631 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -142.1 107.68 0.5 Allowed Glycine 0 C--O 1.203 -1.838 0 N-CA-C 108.376 -1.89 . . . . 0.0 108.376 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.509 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -117.1 139.09 51.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.706 -1.467 . . . . 0.0 110.83 -178.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.535 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 83.68 26.74 41.1 Favored Glycine 0 N--CA 1.491 2.364 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.044 179.011 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -88.34 172.97 9.01 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.975 -1.309 . . . . 0.0 108.476 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.548 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.52 99.75 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.064 -1.023 . . . . 0.0 109.602 -179.576 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.82 76.3 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.088 -179.257 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.594 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.81 33.62 0.22 Allowed Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.677 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 63.3 p -142.73 109.8 5.58 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.032 -1.275 . . . . 0.0 111.178 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.555 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -51.08 109.98 0.38 Allowed 'General case' 0 N--CA 1.497 1.894 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.361 177.79 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.52 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 5.0 m-30 -105.62 155.97 18.71 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.101 -0.999 . . . . 0.0 109.029 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.442 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -98.83 163.25 12.69 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.744 -1.222 . . . . 0.0 107.763 178.791 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.624 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 7.0 p -144.45 114.85 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.151 -0.968 . . . . 0.0 109.91 -177.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.65 -177.34 39.54 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 118.204 -1.95 . . . . 0.0 111.716 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.562 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -99.77 112.2 24.46 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 -179.98 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 64.4 m -130.12 154.36 47.56 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 121.428 -0.795 . . . . 0.0 109.703 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -130.89 137.77 49.49 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.507 -0.745 . . . . 0.0 110.607 -179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.64 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.71 114.68 26.64 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.377 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.9 m -105.85 15.2 7.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.911 -1.118 . . . . 0.0 110.703 -178.548 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.592 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.23 -175.96 0.08 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.899 -1.126 . . . . 0.0 110.117 179.598 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.552 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.2 t -69.58 97.19 1.0 Allowed 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.786 0.803 . . . . 0.0 109.985 -179.474 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.12 27.68 36.36 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.523 178.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.592 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.86 106.46 20.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 O-C-N 120.545 -1.562 . . . . 0.0 107.34 178.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.64 HD12 ' CD1' ' A' ' 39' ' ' TRP . 11.5 tp -116.03 106.7 14.05 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.529 -1.357 . . . . 0.0 109.783 -177.598 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.564 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -96.17 110.44 22.72 Favored 'General case' 0 N--CA 1.484 1.272 0 O-C-N 120.765 -1.209 . . . . 0.0 108.554 179.5 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.569 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . 60.8 m -99.71 148.06 24.77 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.337 -0.852 . . . . 0.0 109.979 -178.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.541 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 13.0 t-20 -98.92 132.61 23.35 Favored Pre-proline 0 N--CA 1.501 2.098 0 O-C-N 120.922 -1.111 . . . . 0.0 109.159 179.413 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.572 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.9 Cg_endo -73.48 24.06 0.32 Allowed 'Trans proline' 0 C--N 1.317 -1.087 0 C-N-CA 122.291 1.994 . . . . 0.0 112.011 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.541 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -115.62 1.08 13.47 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.283 -1.51 . . . . 0.0 109.215 179.492 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.521 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.68 17.46 2.34 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 179.332 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.569 ' CE2' ' HB3' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -81.26 89.75 6.07 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.726 -0.789 . . . . 0.0 110.878 -178.787 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -112.57 -170.74 1.72 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.32 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.8 134.62 0.09 Allowed 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.592 -1.318 . . . . 0.0 111.287 -179.342 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.547 ' CG1' ' HB2' ' A' ' 63' ' ' ALA . 2.5 p -149.07 161.99 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 178.163 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.555 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.29 142.62 29.72 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.685 -1.26 . . . . 0.0 110.181 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.659 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.66 108.39 2.45 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.401 1.096 . . . . 0.0 109.735 178.594 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.516 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.5 t70 -62.73 -139.39 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.995 0 CA-C-O 121.494 0.664 . . . . 0.0 110.77 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.85 -50.97 55.68 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.384 -0.823 . . . . 0.0 110.713 -178.722 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 13.6 t30 -103.16 -33.74 9.1 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 178.591 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.659 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 104.18 70.54 0.82 Allowed Glycine 0 C--N 1.298 -1.544 0 N-CA-C 110.254 -1.139 . . . . 0.0 110.254 178.415 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.631 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 36.7 m -103.34 127.55 50.66 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 121.418 -1.048 . . . . 0.0 109.322 179.566 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.563 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -132.09 108.73 9.5 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 50.8 m -118.14 115.3 24.51 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.159 -0.963 . . . . 0.0 109.39 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.45 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.22 137.08 27.09 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.397 -0.814 . . . . 0.0 109.981 -179.862 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.7 p -100.43 133.21 45.19 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.374 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.578 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -135.66 172.23 13.32 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.138 -0.976 . . . . 0.0 109.803 -179.076 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.556 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -99.63 124.68 45.08 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.139 -0.976 . . . . 0.0 109.583 -179.692 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.446 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.1 m -135.98 143.58 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.015 -1.053 . . . . 0.0 109.664 -179.415 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.567 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.3 ptt180 -141.52 -165.29 1.95 Allowed 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.563 -1.336 . . . . 0.0 110.076 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.548 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -72.65 -87.91 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.463 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -60.14 135.98 57.88 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.58 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.562 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -161.25 135.22 6.85 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 118.105 -1.438 . . . . 0.0 110.586 -177.62 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.488 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -33.29 119.42 0.35 Allowed 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.588 0.709 . . . . 0.0 110.451 -178.637 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.564 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -94.19 50.21 2.17 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.511 -178.849 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.572 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 1.1 m-85 -36.53 118.94 0.59 Allowed 'General case' 0 N--CA 1.513 2.719 0 O-C-N 121.236 -1.155 . . . . 0.0 110.214 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.533 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.4 tp -86.93 125.82 34.29 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.901 -1.124 . . . . 0.0 109.389 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.575 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.0 t80 -63.72 58.58 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.881 -1.137 . . . . 0.0 110.088 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.8 OUTLIER -161.44 21.01 0.12 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.986 -1.071 . . . . 0.0 109.651 179.879 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.02 -30.55 4.66 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.449 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -94.38 165.14 12.71 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.103 -1.234 . . . . 0.0 110.035 -179.417 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.421 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -111.24 140.39 45.84 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -179.897 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.49 ' HB2' HD11 ' A' ' 77' ' ' LEU . 3.2 t90 -81.9 -21.42 37.4 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.77 -1.207 . . . . 0.0 110.461 -178.797 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.67 176.54 18.87 Favored Glycine 0 N--CA 1.485 1.929 0 N-CA-C 108.558 -1.817 . . . . 0.0 108.558 -179.357 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.12 109.96 2.01 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.094 -1.239 . . . . 0.0 107.741 179.223 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.56 HG11 ' CE1' ' A' ' 73' ' ' PHE . 40.6 t -82.4 103.21 9.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.394 -0.816 . . . . 0.0 108.916 -178.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.9 OUTLIER -63.95 110.53 2.15 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.48 -0.762 . . . . 0.0 109.851 -179.344 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.548 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.07 -4.96 5.39 Favored 'General case' 0 N--CA 1.499 1.985 0 C-N-CA 118.269 -1.372 . . . . 0.0 109.829 179.457 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.4 p -85.31 5.1 31.99 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.779 -1.201 . . . . 0.0 108.877 179.347 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.459 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -121.11 -48.9 2.21 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.327 -0.858 . . . . 0.0 109.047 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.63 -177.78 3.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.569 -0.707 . . . . 0.0 109.38 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.14 114.09 27.93 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.391 -0.818 . . . . 0.0 108.921 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.491 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.5 m -97.4 122.74 40.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.892 -1.13 . . . . 0.0 109.756 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.565 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.66 147.73 27.33 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 122.444 1.116 . . . . 0.0 111.346 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.518 ' CG1' HG11 ' A' ' 7' ' ' VAL . 66.9 t -101.47 109.8 26.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 177.618 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -148.19 -172.52 18.23 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 118.07 -2.014 . . . . 0.0 111.59 -177.61 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.452 HD11 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.74 -178.12 3.32 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -178.904 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.588 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 30.3 p -170.2 164.24 9.07 Favored 'General case' 0 C--N 1.296 -1.738 0 O-C-N 121.352 -0.842 . . . . 0.0 109.479 -179.375 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.52 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -114.96 -156.56 0.61 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.206 -0.934 . . . . 0.0 108.808 179.624 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.472 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -118.5 36.17 4.5 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.824 -1.172 . . . . 0.0 109.221 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.8 -32.71 4.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.298 -0.876 . . . . 0.0 110.448 -179.57 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.514 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 164.27 -36.07 0.29 Allowed Glycine 0 N--CA 1.482 1.706 0 N-CA-C 107.567 -2.213 . . . . 0.0 107.567 -179.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.479 ' ND2' ' O9 ' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -157.91 -178.62 7.45 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.512 -0.993 . . . . 0.0 109.763 179.098 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.02 -161.76 12.85 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 108.313 -1.915 . . . . 0.0 108.313 -179.328 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.485 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.0 Cg_exo -47.17 177.69 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.701 0 CA-C-N 118.789 1.295 . . . . 0.0 110.076 179.263 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -91.79 179.79 5.53 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.059 -1.026 . . . . 0.0 110.724 -178.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -117.4 160.99 13.36 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.23 130.01 51.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.324 -1.103 . . . . 0.0 109.345 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.565 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.83 127.3 32.13 Favored 'General case' 0 C--N 1.291 -1.972 0 O-C-N 121.583 -0.698 . . . . 0.0 109.65 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.493 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 19.6 pt -97.25 178.52 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 121.24 -0.912 . . . . 0.0 109.279 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.518 ' CB ' ' HB3' ' A' ' 11' ' ' SER . 0.5 OUTLIER -143.18 152.28 41.59 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.366 -0.834 . . . . 0.0 109.571 179.838 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.493 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 97.3 m-85 -132.82 68.55 1.5 Allowed 'General case' 0 N--CA 1.484 1.249 0 O-C-N 121.082 -1.011 . . . . 0.0 109.569 -179.649 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.8 p30 . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.458 -179.971 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.595 ' O6 ' ' H27' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -122.06 151.35 58.27 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.199 -0.938 . . . . 0.0 109.456 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.524 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 3.5 Cg_exo -60.79 157.24 38.81 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 122.212 1.941 . . . . 0.0 110.543 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.601 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -148.69 159.93 43.65 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -179.515 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -149.12 122.45 9.01 Favored 'General case' 0 C--N 1.295 -1.775 0 CA-C-O 122.334 1.064 . . . . 0.0 110.225 -179.69 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.545 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.1 t -116.38 109.01 16.77 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-O 123.105 1.431 . . . . 0.0 109.605 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.53 HG13 ' CG1' ' A' ' 95' ' ' VAL . 4.0 t -114.58 135.33 54.73 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.669 0 CA-C-N 114.194 -1.366 . . . . 0.0 109.688 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.65 149.82 4.49 Favored Pre-proline 0 N--CA 1.487 1.419 0 O-C-N 121.193 -0.942 . . . . 0.0 108.984 -179.493 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -79.3 149.38 83.08 Favored 'Cis proline' 0 C--N 1.312 -1.376 0 C-N-CA 123.511 -1.454 . . . . 0.0 109.393 -1.009 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.459 ' HB2' ' HA ' ' A' ' 110' ' ' ILE . 86.1 p -90.99 -23.83 20.28 Favored 'General case' 0 C--N 1.292 -1.929 0 O-C-N 121.551 -0.718 . . . . 0.0 109.191 179.609 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.492 ' CB ' ' HB3' ' A' ' 111' ' ' SER . 0.7 OUTLIER -129.8 158.94 38.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.496 -0.753 . . . . 0.0 109.595 -179.881 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.51 37.33 27.55 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 108.64 -1.784 . . . . 0.0 108.64 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.609 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 32.0 mt -92.11 -44.02 9.06 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.213 1.482 . . . . 0.0 110.757 -178.459 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.483 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.16 145.16 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.299 0 CA-C-N 113.505 -1.68 . . . . 0.0 110.055 -179.753 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.59 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.3 p-10 -50.32 106.4 0.12 Allowed 'General case' 0 C--N 1.3 -1.567 0 CA-C-O 121.445 0.641 . . . . 0.0 111.645 -178.694 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.46 14.93 8.53 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.515 -1.326 . . . . 0.0 112.995 177.18 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.609 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.0 t -104.97 -174.18 2.48 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 121.134 2.467 . . . . 0.0 109.919 179.348 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.538 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 21.5 t -127.09 136.11 61.69 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.437 0 CA-C-N 114.541 -1.208 . . . . 0.0 111.258 -178.84 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.521 HG12 ' CG2' ' A' ' 69' ' ' VAL . 23.3 m -112.25 154.86 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 178.61 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.492 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 18.9 tttt -107.73 109.38 20.95 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.174 -0.954 . . . . 0.0 108.949 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.512 HG11 ' CG2' ' A' ' 34' ' ' VAL . 2.3 p -101.73 139.42 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.349 -0.844 . . . . 0.0 108.79 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.586 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -134.17 161.75 34.02 Favored 'General case' 0 C--N 1.305 -1.358 0 O-C-N 120.886 -1.134 . . . . 0.0 109.848 179.483 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.592 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.57 139.7 10.86 Favored Glycine 0 C--N 1.297 -1.604 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 179.752 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.601 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.37 125.87 16.76 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.499 -1.589 . . . . 0.0 109.3 179.48 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.524 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 88.97 27.63 23.18 Favored Glycine 0 N--CA 1.488 2.146 0 C-N-CA 118.8 -1.667 . . . . 0.0 109.736 -179.685 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.559 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.1 mt -87.65 174.16 8.6 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 120.825 -1.397 . . . . 0.0 108.215 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.554 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.46 97.18 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.916 -1.115 . . . . 0.0 109.888 -179.412 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.76 77.13 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.761 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.404 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.69 34.09 0.32 Allowed Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.383 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.535 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.3 p -147.13 112.8 5.67 Favored 'General case' 0 C--N 1.308 -1.209 0 O-C-N 120.819 -1.401 . . . . 0.0 111.335 -179.804 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.549 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.87 126.58 5.86 Favored 'General case' 0 N--CA 1.491 1.623 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.846 178.063 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.485 ' CD2' ' O ' ' A' ' 30' ' ' THR . 12.7 m-85 -118.5 152.26 36.29 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.478 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.474 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.93 160.34 14.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.724 -1.235 . . . . 0.0 107.825 178.911 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.626 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.7 p -142.4 119.8 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.218 -0.926 . . . . 0.0 109.451 -178.055 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.54 -178.54 41.35 Favored Glycine 0 N--CA 1.494 2.506 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.505 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.559 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -101.0 108.58 20.33 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.437 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.45 149.51 51.19 Favored 'General case' 0 C--N 1.296 -1.738 0 O-C-N 121.264 -0.898 . . . . 0.0 109.956 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.03 139.53 53.73 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.367 -0.833 . . . . 0.0 110.673 -179.146 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.623 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.29 114.92 26.75 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.199 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.8 m -105.11 15.23 6.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.093 -1.004 . . . . 0.0 110.595 -178.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.586 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.61 -176.06 0.08 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.947 -1.096 . . . . 0.0 110.038 179.631 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.546 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.93 97.75 1.48 Allowed 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.803 0.811 . . . . 0.0 109.848 -179.639 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.14 27.65 36.4 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 120.186 -1.007 . . . . 0.0 111.419 178.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.586 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -115.83 106.44 20.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 O-C-N 120.621 -1.517 . . . . 0.0 107.189 178.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.623 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.0 tp -116.03 104.69 11.83 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.461 -1.399 . . . . 0.0 109.936 -177.659 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.537 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.41 22.17 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.827 -1.17 . . . . 0.0 108.179 178.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.9 t -107.46 163.63 12.89 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.847 -1.158 . . . . 0.0 110.295 -179.006 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.5 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 13.6 t30 -108.98 134.18 20.46 Favored Pre-proline 0 N--CA 1.502 2.136 0 O-C-N 121.351 -0.843 . . . . 0.0 109.575 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.582 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.6 Cg_endo -74.38 26.85 0.34 Allowed 'Trans proline' 0 C--N 1.319 -0.98 0 C-N-CA 122.486 2.124 . . . . 0.0 112.197 -179.396 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.402 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -109.29 -3.15 17.39 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.329 -1.482 . . . . 0.0 109.299 179.664 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.56 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 1.7 m-20 -135.96 12.39 3.36 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -70.07 83.6 0.51 Allowed 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.683 -0.807 . . . . 0.0 110.74 -178.667 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -105.23 -167.92 1.4 Allowed 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 178.356 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.481 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.7 t 179.07 135.59 0.09 Allowed 'General case' 0 C--N 1.306 -1.325 0 O-C-N 120.632 -1.292 . . . . 0.0 111.231 -179.38 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.572 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.7 p -149.24 156.63 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 178.095 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.549 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.57 145.39 26.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.583 -1.323 . . . . 0.0 109.738 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.68 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.93 108.67 2.66 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 122.334 1.064 . . . . 0.0 109.592 178.756 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.543 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 p-10 -62.92 -139.58 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.054 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.641 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.92 -51.73 49.19 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.446 -0.784 . . . . 0.0 110.569 -178.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -102.51 -32.98 9.67 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 178.582 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.68 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 106.84 66.72 0.64 Allowed Glycine 0 C--N 1.299 -1.511 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 178.168 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.592 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 55.6 p -98.69 132.51 44.01 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 121.289 -1.124 . . . . 0.0 109.048 179.001 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.586 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -137.03 108.6 6.95 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.146 -1.022 . . . . 0.0 109.535 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.3 m -124.12 117.48 24.76 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.265 -0.897 . . . . 0.0 109.641 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.465 HG23 HG12 ' A' ' 34' ' ' VAL . 5.2 t -145.99 145.2 30.54 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.441 -0.787 . . . . 0.0 109.361 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 53.3 p -99.03 143.98 28.69 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.428 -0.795 . . . . 0.0 109.342 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.546 ' HB2' ' OD2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -145.35 169.86 17.45 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.305 -0.872 . . . . 0.0 109.459 -178.96 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.8 p -102.32 123.27 45.83 Favored 'General case' 0 N--CA 1.498 1.975 0 O-C-N 120.842 -1.161 . . . . 0.0 110.388 -178.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.56 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 15.2 m -131.12 143.98 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 120.996 -1.065 . . . . 0.0 110.016 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.59 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.3 ptt180 -148.93 -176.63 5.42 Favored 'General case' 0 N--CA 1.483 1.221 0 O-C-N 120.555 -1.341 . . . . 0.0 110.649 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.566 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.73 -101.5 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -179.562 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.5 OUTLIER -56.29 140.07 46.17 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.777 -1.202 . . . . 0.0 108.313 179.591 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.569 ' CZ ' ' SG ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -160.81 135.69 7.56 Favored 'General case' 0 C--N 1.296 -1.74 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.545 -178.57 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.5 ' N ' ' OD1' ' A' ' 48' ' ' ASN . 6.1 mm-40 -33.05 122.18 0.38 Allowed 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.609 0.718 . . . . 0.0 110.775 -178.038 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.537 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -90.78 45.34 2.89 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 -179.326 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.582 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-85 -37.64 114.62 0.35 Allowed 'General case' 0 N--CA 1.512 2.632 0 O-C-N 121.277 -1.131 . . . . 0.0 110.12 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.535 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.0 tp -87.44 127.22 35.22 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.115 -0.991 . . . . 0.0 109.291 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.574 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 49.8 t80 -63.54 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.061 0 O-C-N 120.862 -1.149 . . . . 0.0 110.137 179.74 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.2 t0 -161.2 19.33 0.12 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.945 -1.097 . . . . 0.0 109.805 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.55 -26.73 5.61 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 42.1 p -94.41 160.21 14.76 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.121 -1.223 . . . . 0.0 110.11 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.463 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.6 OUTLIER -106.67 136.12 47.03 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.466 ' HB2' HD12 ' A' ' 77' ' ' LEU . 4.1 t90 -81.91 -18.9 42.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.819 -1.175 . . . . 0.0 110.428 -178.653 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.46 174.38 18.43 Favored Glycine 0 N--CA 1.486 2.024 0 N-CA-C 108.772 -1.731 . . . . 0.0 108.772 -179.602 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.18 106.06 1.23 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.113 -1.228 . . . . 0.0 107.688 179.184 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.568 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 51.3 t -76.96 105.22 5.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.316 -0.865 . . . . 0.0 109.361 -178.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.524 ' CB ' HG21 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.62 110.85 2.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.468 -0.77 . . . . 0.0 109.765 -179.599 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.566 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.08 -5.73 3.39 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 120.517 -1.364 . . . . 0.0 109.846 179.422 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -86.52 -0.57 56.36 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.706 -1.246 . . . . 0.0 109.172 179.655 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.524 HG21 ' CB ' ' A' ' 87' ' ' ASP . 2.3 p -113.19 -50.13 2.88 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.322 -0.861 . . . . 0.0 108.957 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.63 -178.62 3.71 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.576 -0.703 . . . . 0.0 109.428 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.54 115.31 30.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.337 -0.852 . . . . 0.0 109.039 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.569 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.24 123.36 41.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.875 -1.14 . . . . 0.0 109.7 -179.278 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.578 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.76 145.92 29.69 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.474 1.13 . . . . 0.0 111.113 -179.424 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.53 ' CG1' HG13 ' A' ' 7' ' ' VAL . 55.6 t -101.76 110.09 27.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.049 0 N-CA-C 106.646 -1.612 . . . . 0.0 106.646 177.474 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.444 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.01 -171.29 16.83 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 118.106 -1.997 . . . . 0.0 111.694 -177.475 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.474 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -119.0 179.48 4.14 Favored 'General case' 0 N--CA 1.485 1.283 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.038 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.544 ' OG ' ' C21' ' A' ' 114' ' ' CHR . 3.5 m -179.16 -179.65 0.59 Allowed 'General case' 0 C--N 1.294 -1.817 0 O-C-N 121.435 -0.791 . . . . 0.0 109.666 -179.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.415 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -128.54 -159.14 0.93 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.975 -1.078 . . . . 0.0 109.036 179.921 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.415 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.13 36.8 4.07 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.736 -1.228 . . . . 0.0 109.037 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -113.14 -32.81 6.2 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.371 -0.83 . . . . 0.0 109.958 -179.591 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.409 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . 165.13 -35.63 0.27 Allowed Glycine 0 N--CA 1.482 1.721 0 N-CA-C 107.909 -2.076 . . . . 0.0 107.909 -179.702 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.409 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.65 -177.15 3.8 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.603 -0.939 . . . . 0.0 109.725 179.395 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.63 -161.65 19.15 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.32 -1.912 . . . . 0.0 108.32 -179.388 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.477 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.9 Cg_exo -46.68 176.26 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.655 0 CA-C-N 118.808 1.304 . . . . 0.0 110.173 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -94.19 -174.96 3.53 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.038 -1.039 . . . . 0.0 110.403 -178.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.444 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.79 165.0 13.47 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.55 130.57 50.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.353 -1.087 . . . . 0.0 109.223 -179.416 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.578 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.84 125.48 28.26 Favored 'General case' 0 C--N 1.291 -1.964 0 O-C-N 121.669 -0.644 . . . . 0.0 109.774 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.571 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.82 170.11 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.307 -0.871 . . . . 0.0 109.22 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.492 ' HB3' ' CB ' ' A' ' 11' ' ' SER . 3.6 t -138.09 158.33 44.53 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.375 -0.828 . . . . 0.0 109.449 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.571 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 30.4 m-85 -123.12 125.7 45.65 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.184 -0.948 . . . . 0.0 109.539 -179.731 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.46 ' OXT' ' O ' ' A' ' 112' ' ' PHE . 19.8 p30 . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.168 -0.957 . . . . 0.0 109.457 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.587 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -120.61 148.62 48.43 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.49 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.528 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 4.4 Cg_exo -60.4 157.16 37.28 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.348 2.032 . . . . 0.0 110.581 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.552 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.8 -169.69 0.14 Allowed 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 179.209 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.552 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -166.43 133.55 2.6 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 120.614 -1.304 . . . . 0.0 111.109 -179.322 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.529 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.4 p -101.66 104.47 15.31 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 122.413 1.101 . . . . 0.0 110.032 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.527 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 3.4 t -118.54 115.4 48.0 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.415 0 CA-C-O 121.679 0.752 . . . . 0.0 110.455 179.63 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.488 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.22 147.85 12.78 Favored Pre-proline 0 N--CA 1.487 1.397 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 -179.723 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.488 ' HA ' HG22 ' A' ' 8' ' ' THR . 4.3 Cg_endo -77.07 152.05 94.41 Favored 'Cis proline' 0 C--N 1.309 -1.506 0 C-N-CA 123.693 -1.378 . . . . 0.0 109.561 -0.328 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.507 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 13.6 p -89.71 -25.84 20.98 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.642 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.518 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.0 m -136.39 167.98 20.3 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.555 -0.715 . . . . 0.0 109.338 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.47 38.12 39.15 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.603 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 40.3 mt -93.22 -42.63 9.24 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 123.319 1.533 . . . . 0.0 110.561 -178.177 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.496 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.56 142.58 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.284 0 CA-C-N 113.402 -1.726 . . . . 0.0 109.67 -179.385 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.586 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.2 p-10 -50.61 105.95 0.11 Allowed 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.588 0.709 . . . . 0.0 111.364 -178.517 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.68 14.15 8.24 Favored Glycine 0 N--CA 1.484 1.88 0 C-N-CA 119.446 -1.359 . . . . 0.0 112.982 177.418 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.603 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.0 t -106.21 -172.24 2.05 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 121.22 2.51 . . . . 0.0 109.831 179.161 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.576 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 17.1 t -129.7 138.32 54.49 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.34 -178.786 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.52 HG22 ' CG2' ' A' ' 69' ' ' VAL . 35.8 m -114.34 155.35 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.782 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.527 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 28.2 tttt -107.13 108.87 20.53 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.184 -0.948 . . . . 0.0 109.466 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.508 ' CG2' HG21 ' A' ' 7' ' ' VAL . 2.0 p -105.64 123.29 59.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.529 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -117.66 166.55 12.28 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.716 -1.24 . . . . 0.0 109.325 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.614 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.05 142.45 13.89 Favored Glycine 0 C--N 1.294 -1.766 0 N-CA-C 107.381 -2.288 . . . . 0.0 107.381 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.528 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -147.22 123.27 10.76 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 120.747 -1.443 . . . . 0.0 108.714 179.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.513 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 90.1 27.01 22.38 Favored Glycine 0 N--CA 1.487 2.084 0 C-N-CA 119.155 -1.498 . . . . 0.0 109.802 -179.563 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.537 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -89.0 174.8 7.7 Favored 'General case' 0 C--N 1.307 -1.248 0 O-C-N 120.842 -1.387 . . . . 0.0 108.436 179.85 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.557 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.83 99.78 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.949 -1.094 . . . . 0.0 109.808 -179.8 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.541 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.18 78.09 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.191 -179.298 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.83 34.5 0.3 Allowed Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 179.627 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.543 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 35.2 p -140.99 106.9 5.15 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 121.127 -1.219 . . . . 0.0 111.361 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -49.52 110.07 0.34 Allowed 'General case' 0 N--CA 1.498 1.931 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.557 177.87 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 5.7 m-30 -108.0 154.38 21.72 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.097 -1.002 . . . . 0.0 108.854 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.466 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.64 163.03 12.53 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.864 -1.148 . . . . 0.0 108.055 179.133 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.643 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.6 p -140.89 116.71 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.133 -0.979 . . . . 0.0 109.351 -178.297 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -164.32 -176.72 36.39 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 118.325 -1.893 . . . . 0.0 111.802 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.56 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -103.15 109.44 21.02 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.862 0.839 . . . . 0.0 109.099 -179.635 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.35 147.79 51.21 Favored 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.231 -0.918 . . . . 0.0 109.578 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -121.66 138.26 54.41 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.255 -0.903 . . . . 0.0 110.823 -178.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.623 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.68 26.48 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.177 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -105.74 14.71 7.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 120.952 -1.092 . . . . 0.0 110.513 -178.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.594 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 175.09 -175.9 0.09 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 120.951 -1.093 . . . . 0.0 110.03 179.754 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.541 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.0 t -71.33 97.82 1.65 Allowed 'General case' 0 N--CA 1.487 1.379 0 CA-C-O 121.785 0.802 . . . . 0.0 109.785 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.78 27.45 34.79 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.238 -0.982 . . . . 0.0 111.524 178.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.594 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.98 106.11 19.75 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 O-C-N 120.539 -1.565 . . . . 0.0 107.236 178.836 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.623 HD12 ' CD1' ' A' ' 39' ' ' TRP . 12.5 tp -116.82 104.75 11.64 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.517 -1.365 . . . . 0.0 109.874 -177.692 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.567 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.78 109.45 22.2 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 120.845 -1.16 . . . . 0.0 108.071 178.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.4 t -107.07 162.42 13.87 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.949 -1.094 . . . . 0.0 110.393 -178.778 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.52 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 15.4 t30 -110.32 134.4 20.81 Favored Pre-proline 0 N--CA 1.503 2.199 0 O-C-N 121.453 -0.78 . . . . 0.0 109.759 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.576 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.77 25.03 0.33 Allowed 'Trans proline' 0 C--N 1.318 -1.055 0 C-N-CA 122.346 2.031 . . . . 0.0 112.192 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.417 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -113.43 4.15 16.15 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.327 -1.483 . . . . 0.0 109.233 179.538 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.529 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.78 16.04 2.69 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 179.462 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -79.85 88.86 5.25 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.541 -178.266 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.643 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -105.96 -165.85 1.14 Allowed 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 177.788 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.461 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.77 138.38 0.09 Allowed 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.508 -1.37 . . . . 0.0 111.454 -179.343 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.581 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -156.64 157.2 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.225 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.67 141.82 31.01 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.828 -1.17 . . . . 0.0 109.746 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.688 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.05 106.96 0.92 Allowed 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 122.385 1.088 . . . . 0.0 109.144 178.309 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.53 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.8 t0 -61.64 -138.9 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.987 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.016 -179.843 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.541 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.59 -52.12 32.46 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.426 -0.796 . . . . 0.0 110.81 -178.534 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -104.06 -33.05 8.91 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 106.209 -1.775 . . . . 0.0 106.209 178.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.688 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 109.31 65.41 0.56 Allowed Glycine 0 C--N 1.298 -1.542 0 N-CA-C 110.457 -1.057 . . . . 0.0 110.457 178.085 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.614 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.4 m -102.99 127.95 50.01 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 121.492 -1.004 . . . . 0.0 108.819 178.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.581 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.39 109.17 7.55 Favored 'General case' 0 C--N 1.296 -1.737 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.893 -179.312 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -116.26 117.43 29.99 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.207 -0.933 . . . . 0.0 109.291 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.464 HG21 HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.63 143.34 30.72 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.412 -0.805 . . . . 0.0 109.758 -179.978 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.9 p -101.0 140.01 35.89 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.472 -0.768 . . . . 0.0 109.5 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.529 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -139.21 161.6 37.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.36 -0.837 . . . . 0.0 109.524 -179.469 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.576 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.9 p -93.87 124.46 37.89 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.159 -0.963 . . . . 0.0 109.438 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.532 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 15.3 m -135.38 143.71 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.063 -1.023 . . . . 0.0 109.58 -179.314 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.586 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.5 ptt180 -146.79 -177.13 5.49 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 120.453 -1.405 . . . . 0.0 111.042 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.57 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.13 -100.98 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -179.674 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -56.2 140.68 43.7 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 120.769 -1.207 . . . . 0.0 108.208 179.546 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.05 136.19 6.66 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 118.82 -1.152 . . . . 0.0 109.672 -178.341 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.52 ' N ' ' OD1' ' A' ' 48' ' ' ASN . 34.6 mt-10 -34.8 122.12 0.53 Allowed 'General case' 0 N--CA 1.489 1.508 0 CA-C-O 121.491 0.662 . . . . 0.0 110.462 -178.314 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.567 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -92.74 49.14 2.55 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.576 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.1 m-85 -38.82 114.21 0.37 Allowed 'General case' 0 N--CA 1.506 2.353 0 O-C-N 121.18 -1.188 . . . . 0.0 109.915 179.541 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.532 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -86.44 126.81 34.66 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.944 -1.098 . . . . 0.0 109.46 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.57 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.4 t80 -64.12 58.37 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.976 0 O-C-N 120.832 -1.168 . . . . 0.0 110.133 179.718 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.2 t70 -160.54 19.49 0.14 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.125 -0.984 . . . . 0.0 109.704 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.63 -27.18 5.41 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.41 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 21.4 p -94.19 159.71 15.02 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.03 -1.277 . . . . 0.0 110.316 -179.429 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.464 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.52 136.29 46.55 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.711 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.462 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.12 -18.47 42.8 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.734 -1.228 . . . . 0.0 110.44 -178.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.94 174.92 19.31 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 108.819 -1.712 . . . . 0.0 108.819 -179.575 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -65.09 105.34 1.04 Allowed 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 179.186 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.571 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.9 t -77.28 107.06 8.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.364 -0.835 . . . . 0.0 109.267 -178.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.461 ' HB3' HG22 ' A' ' 90' ' ' THR . 1.2 m-20 -66.76 111.39 3.69 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.441 -0.787 . . . . 0.0 110.022 -179.313 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.57 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.81 -5.52 4.42 Favored 'General case' 0 N--CA 1.5 2.058 0 C-N-CA 118.171 -1.412 . . . . 0.0 109.832 179.198 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 16.6 p -87.26 1.17 53.98 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.795 -1.19 . . . . 0.0 109.171 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.461 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -115.23 -50.66 2.74 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.326 -0.859 . . . . 0.0 108.99 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.67 179.63 4.21 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.488 -0.757 . . . . 0.0 109.43 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.5 115.39 30.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.31 -0.869 . . . . 0.0 108.906 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.563 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.2 m -96.99 122.04 39.54 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.916 -1.115 . . . . 0.0 109.335 -179.368 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.531 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.17 146.37 27.58 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 122.371 1.081 . . . . 0.0 111.286 -179.292 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.433 ' HB ' HG11 ' A' ' 7' ' ' VAL . 54.6 t -105.73 111.74 36.19 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.028 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.46 -169.94 19.06 Favored Glycine 0 N--CA 1.487 2.088 0 C-N-CA 118.251 -1.928 . . . . 0.0 111.482 -177.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.482 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -117.23 173.24 6.79 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.803 -0.822 . . . . 0.0 108.858 -179.356 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.557 ' HB3' ' C20' ' A' ' 114' ' ' CHR . 0.3 OUTLIER 173.19 163.51 0.14 Allowed 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.854 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.47 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.2 OUTLIER -112.13 -156.64 0.59 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.916 -1.115 . . . . 0.0 109.113 179.922 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.47 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.64 36.31 4.34 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 120.806 -1.184 . . . . 0.0 109.031 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.411 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -106.93 -31.4 8.35 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.436 -0.79 . . . . 0.0 109.56 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.519 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . 168.22 -37.24 0.21 Allowed Glycine 0 N--CA 1.482 1.744 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -173.74 -176.21 1.21 Allowed 'General case' 0 C--N 1.306 -1.29 0 O-C-N 121.562 -0.964 . . . . 0.0 109.828 179.512 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.501 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.6 -159.57 12.51 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.314 -1.914 . . . . 0.0 108.314 -179.311 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.501 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.6 Cg_exo -47.49 -178.13 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.672 0 CA-C-N 118.824 1.312 . . . . 0.0 110.574 179.215 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -94.44 -178.38 4.56 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.057 -1.027 . . . . 0.0 110.405 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.467 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.36 162.22 13.31 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.25 128.6 52.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.465 -1.021 . . . . 0.0 109.123 -179.549 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.531 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.09 118.53 15.07 Favored 'General case' 0 C--N 1.289 -2.059 0 O-C-N 121.7 -0.625 . . . . 0.0 109.555 179.75 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.577 HD11 ' CE2' ' A' ' 112' ' ' PHE . 1.8 pt -98.01 172.13 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.289 -0.882 . . . . 0.0 108.997 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.518 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -142.48 154.09 44.22 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.06 -1.025 . . . . 0.0 110.153 -179.744 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.577 ' CE2' HD11 ' A' ' 110' ' ' ILE . 97.8 m-85 -132.64 134.74 45.24 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.302 -0.873 . . . . 0.0 109.278 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.3 p30 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.974 -1.012 . . . . 0.0 109.445 -179.954 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.587 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -102.83 156.27 35.5 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.299 -0.875 . . . . 0.0 109.465 -179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.504 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 4.3 Cg_exo -60.1 158.0 32.08 Favored 'Trans proline' 0 C--N 1.31 -1.468 0 C-N-CA 122.29 1.993 . . . . 0.0 110.466 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.602 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -155.33 162.45 40.83 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 -179.316 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.52 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -149.21 125.75 10.98 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.875 -1.14 . . . . 0.0 110.827 -179.784 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.511 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.7 p -104.03 104.82 14.83 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-O 122.417 1.103 . . . . 0.0 110.397 -179.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.535 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 6.1 t -119.26 116.81 52.05 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.477 0 CA-C-O 121.582 0.706 . . . . 0.0 110.226 179.434 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.491 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -161.06 149.28 12.8 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.44 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.491 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.71 152.95 98.87 Favored 'Cis proline' 0 C--N 1.311 -1.428 0 C-N-CA 123.679 -1.384 . . . . 0.0 109.72 -0.507 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.497 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 3.8 m -91.46 -25.35 19.35 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.474 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.5 m -136.84 166.15 24.29 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.6 -0.688 . . . . 0.0 109.39 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.27 37.76 35.92 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 108.426 -1.87 . . . . 0.0 108.426 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.614 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.9 mt -92.47 -43.77 9.01 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 123.229 1.49 . . . . 0.0 110.676 -178.242 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.56 144.72 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.517 -1.674 . . . . 0.0 110.044 -179.57 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.582 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.7 p-10 -50.72 107.36 0.17 Allowed 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.535 0.683 . . . . 0.0 111.629 -178.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.9 14.23 9.52 Favored Glycine 0 N--CA 1.485 1.949 0 C-N-CA 119.421 -1.371 . . . . 0.0 112.927 177.357 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.614 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 13.8 t -105.09 -173.54 2.33 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 121.13 2.465 . . . . 0.0 109.899 179.265 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 20.9 t -128.41 138.97 53.17 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 CA-C-N 114.63 -1.168 . . . . 0.0 111.157 -178.639 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.492 HG11 ' CG2' ' A' ' 69' ' ' VAL . 27.9 m -116.15 154.42 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.653 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.535 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 15.0 tptp -107.21 108.68 20.22 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.168 -0.957 . . . . 0.0 109.297 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.1 p -106.14 123.54 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.538 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -118.24 168.22 10.8 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.717 -1.24 . . . . 0.0 109.504 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.608 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -137.13 136.71 8.47 Favored Glycine 0 C--O 1.207 -1.582 0 N-CA-C 107.493 -2.243 . . . . 0.0 107.493 179.515 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.602 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -141.27 125.82 17.8 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-N 119.668 1.734 . . . . 0.0 109.397 179.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.504 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 88.35 28.91 21.12 Favored Glycine 0 N--CA 1.488 2.146 0 C-N-CA 118.692 -1.718 . . . . 0.0 109.598 -179.715 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.522 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.8 mt -89.26 173.98 8.1 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.034 -1.274 . . . . 0.0 108.283 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.553 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.02 97.1 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.007 -1.058 . . . . 0.0 109.773 -179.871 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.552 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.34 76.86 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.39 -178.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.84 34.06 0.31 Allowed Glycine 0 N--CA 1.486 1.995 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.309 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.542 ' CG2' ' O ' ' A' ' 30' ' ' THR . 1.1 t -146.37 113.88 6.35 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.923 -1.339 . . . . 0.0 111.225 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.556 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -45.3 126.97 6.79 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.548 178.399 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.485 ' OH ' ' HB2' ' A' ' 27' ' ' GLN . 6.0 m-85 -121.32 149.41 42.97 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.454 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.45 160.06 14.65 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.697 -1.252 . . . . 0.0 108.064 178.955 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.619 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 9.0 p -142.8 116.96 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.249 -0.907 . . . . 0.0 109.908 -177.69 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.496 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.82 -176.51 38.48 Favored Glycine 0 N--CA 1.494 2.524 0 C-N-CA 118.298 -1.906 . . . . 0.0 111.756 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.557 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -101.38 109.34 21.16 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.758 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -129.6 149.85 51.18 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.235 -0.915 . . . . 0.0 109.601 179.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.93 138.3 54.5 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.241 -0.912 . . . . 0.0 110.928 -178.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.624 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.09 26.96 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 178.049 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.434 HG22 ' HB ' ' A' ' 44' ' ' VAL . 17.7 m -105.64 15.01 7.16 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.024 -1.047 . . . . 0.0 110.512 -178.755 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.586 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.96 -175.38 0.09 Allowed 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.028 -1.045 . . . . 0.0 109.987 179.715 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -72.38 97.77 2.11 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 121.381 -0.825 . . . . 0.0 109.66 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.29 28.14 31.33 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.233 -0.984 . . . . 0.0 111.383 178.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.586 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.42 106.26 19.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 O-C-N 120.586 -1.537 . . . . 0.0 107.339 178.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.624 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.4 tp -116.35 104.59 11.63 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.421 -1.424 . . . . 0.0 109.902 -177.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.553 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.5 22.25 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.776 -1.203 . . . . 0.0 107.987 178.704 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.5 161.74 14.57 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.919 -1.113 . . . . 0.0 110.189 -178.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.491 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 43.2 t30 -109.74 136.49 20.33 Favored Pre-proline 0 N--CA 1.502 2.167 0 O-C-N 121.383 -0.823 . . . . 0.0 109.807 -179.57 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.55 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.79 25.37 0.33 Allowed 'Trans proline' 0 C--N 1.318 -1.028 0 C-N-CA 122.354 2.036 . . . . 0.0 111.876 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.491 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -111.2 2.33 17.72 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.392 -1.442 . . . . 0.0 109.268 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.496 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -141.24 16.77 2.24 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.7 -1.222 . . . . 0.0 107.7 179.724 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -79.86 91.77 5.41 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.82 -0.752 . . . . 0.0 111.078 -178.57 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.619 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -111.31 -168.2 1.28 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.957 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.473 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.85 135.61 0.09 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.503 -1.373 . . . . 0.0 111.521 -179.307 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.561 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.4 p -152.41 158.32 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 178.015 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.556 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.77 145.54 26.26 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.659 -1.276 . . . . 0.0 109.672 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.67 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -67.24 108.01 2.56 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 122.394 1.092 . . . . 0.0 109.5 178.721 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.523 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 t0 -61.06 -138.73 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.923 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.552 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.57 -49.87 64.11 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.386 -0.821 . . . . 0.0 110.405 -178.747 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.462 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 16.9 t-20 -102.94 -36.99 8.01 Favored 'General case' 0 C--N 1.286 -2.194 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 178.449 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.67 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 109.31 68.36 0.61 Allowed Glycine 0 C--N 1.297 -1.601 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 178.19 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.608 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.8 m -102.96 129.12 49.59 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.496 -1.002 . . . . 0.0 109.316 179.284 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.561 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -135.56 108.54 7.63 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.533 -0.867 . . . . 0.0 109.43 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.505 ' HB2' ' NZ ' ' A' ' 20' ' ' LYS . 53.0 p -120.31 118.87 31.54 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.106 -0.996 . . . . 0.0 109.368 -179.82 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.456 HG23 HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.91 143.01 28.2 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.395 -0.815 . . . . 0.0 109.802 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.455 ' HB3' ' HD3' ' A' ' 20' ' ' LYS . 2.9 p -102.17 135.04 44.45 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.492 -0.755 . . . . 0.0 109.059 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.533 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -135.2 169.93 16.7 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.301 -0.874 . . . . 0.0 109.597 -179.24 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.554 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -99.56 125.55 45.37 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.079 -1.013 . . . . 0.0 109.581 -179.68 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.513 ' CB ' ' OE1' ' A' ' 36' ' ' GLN . 15.7 m -135.11 143.33 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.036 -1.04 . . . . 0.0 109.519 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.582 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.0 ptt180 -146.63 -174.89 4.59 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 120.417 -1.427 . . . . 0.0 111.11 -179.758 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.555 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -54.12 -101.71 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 116.032 -0.531 . . . . 0.0 109.577 -179.382 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.85 139.97 49.64 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.749 -1.22 . . . . 0.0 108.138 179.659 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.576 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -161.28 136.34 7.51 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 118.772 -1.171 . . . . 0.0 109.879 -178.068 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.579 ' OE2' ' CD1' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -34.7 121.19 0.51 Allowed 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.543 0.687 . . . . 0.0 110.249 -178.462 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.553 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -94.52 50.57 2.08 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.107 -179.199 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CD1' ' OE2' ' A' ' 74' ' ' GLU . 2.8 m-85 -38.95 116.93 0.62 Allowed 'General case' 0 N--CA 1.509 2.484 0 O-C-N 121.041 -1.27 . . . . 0.0 109.882 179.639 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.537 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -87.34 126.16 34.68 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.95 -1.094 . . . . 0.0 109.389 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.58 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.1 t80 -64.53 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.789 -1.194 . . . . 0.0 110.106 179.711 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -159.77 19.7 0.17 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.033 -1.042 . . . . 0.0 109.696 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.26 -28.07 5.35 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.448 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 38.4 p -95.84 160.42 14.49 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.991 -1.299 . . . . 0.0 110.404 -179.458 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.477 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 6.0 ptt180 -105.95 139.58 40.28 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.784 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.468 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.4 t90 -84.5 -18.83 34.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.653 -1.279 . . . . 0.0 110.634 -178.53 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.85 175.53 19.03 Favored Glycine 0 N--CA 1.485 1.943 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 -179.581 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.74 105.37 1.24 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.058 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.562 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 43.5 t -76.7 105.61 5.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.147 -178.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.464 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -65.65 110.82 2.9 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.471 -0.768 . . . . 0.0 109.813 -179.481 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.555 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.24 -5.7 3.65 Favored 'General case' 0 N--CA 1.499 1.982 0 C-N-CA 118.255 -1.378 . . . . 0.0 109.838 179.482 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.0 p -86.57 -0.11 55.47 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.766 -1.209 . . . . 0.0 109.107 179.548 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.464 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.86 -50.57 2.82 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.398 -0.814 . . . . 0.0 108.968 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.8 -178.96 3.8 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.515 -0.741 . . . . 0.0 109.443 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.97 115.84 30.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.432 -0.793 . . . . 0.0 108.929 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.8 121.55 38.78 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.797 -1.189 . . . . 0.0 109.39 -179.369 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.556 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.81 147.1 26.46 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 122.33 1.062 . . . . 0.0 111.126 -179.362 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.532 ' CG1' HG12 ' A' ' 7' ' ' VAL . 48.3 t -105.34 111.93 36.75 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.997 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.831 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.469 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.75 -170.54 19.92 Favored Glycine 0 N--CA 1.488 2.102 0 C-N-CA 118.062 -2.018 . . . . 0.0 111.751 -177.877 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.482 ' O ' ' OG ' ' A' ' 98' ' ' SER . 0.0 OUTLIER -116.81 177.47 4.69 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.212 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.571 ' HB2' ' C27' ' A' ' 114' ' ' CHR . 3.9 m 177.97 165.63 0.71 Allowed 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.649 -0.657 . . . . 0.0 109.269 -179.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.482 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -112.65 -159.09 0.67 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.846 -1.159 . . . . 0.0 109.065 179.95 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.93 36.01 4.38 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.757 -1.214 . . . . 0.0 109.166 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.85 -33.28 6.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.314 -0.866 . . . . 0.0 109.77 -179.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 167.08 -36.86 0.23 Allowed Glycine 0 N--CA 1.48 1.569 0 N-CA-C 108.07 -2.012 . . . . 0.0 108.07 -179.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -164.22 -177.32 4.9 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.612 -0.934 . . . . 0.0 110.042 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.68 -161.04 19.37 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 108.117 -1.993 . . . . 0.0 108.117 -179.494 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.1 Cg_exo -47.01 177.3 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.701 0 CA-C-N 118.968 1.384 . . . . 0.0 110.249 179.228 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.2 mm-40 -94.32 -179.4 4.91 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.073 -1.017 . . . . 0.0 110.583 -178.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.469 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.94 166.13 12.72 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.59 131.19 54.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.288 -1.124 . . . . 0.0 109.258 -179.282 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.556 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.03 121.02 20.42 Favored 'General case' 0 C--N 1.29 -2.014 0 O-C-N 121.548 -0.72 . . . . 0.0 109.587 179.676 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.578 HD13 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.97 171.3 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.226 -0.922 . . . . 0.0 109.095 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.474 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.93 156.81 46.97 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.264 -0.897 . . . . 0.0 109.929 -179.635 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.578 ' CE1' HD13 ' A' ' 110' ' ' ILE . 95.9 m-85 -132.03 73.55 1.54 Allowed 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.318 -0.864 . . . . 0.0 109.378 -179.779 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.421 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 13.2 p30 . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.503 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.588 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.516 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . . . -98.05 172.75 4.53 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.343 -0.848 . . . . 0.0 109.474 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.536 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.7 Cg_exo -59.71 158.0 30.22 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.214 1.943 . . . . 0.0 110.632 -179.994 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.537 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.59 -169.78 0.15 Allowed 'General case' 0 C--N 1.295 -1.779 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 179.245 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.537 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.88 130.32 2.28 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 120.841 -1.162 . . . . 0.0 110.602 -179.153 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.541 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.8 t -110.42 108.63 18.73 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 123.088 1.423 . . . . 0.0 109.088 179.34 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.505 HG13 ' CG1' ' A' ' 95' ' ' VAL . 2.5 t -118.43 137.85 51.05 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.678 0 CA-C-N 114.244 -1.344 . . . . 0.0 109.907 -179.7 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.492 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -175.4 150.33 1.19 Allowed Pre-proline 0 N--CA 1.487 1.388 0 O-C-N 121.314 -0.866 . . . . 0.0 108.712 -179.651 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.492 ' HA ' HG22 ' A' ' 8' ' ' THR . 5.7 Cg_endo -77.64 150.52 90.51 Favored 'Cis proline' 0 C--N 1.311 -1.433 0 C-N-CA 123.57 -1.429 . . . . 0.0 109.535 -0.905 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.466 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 61.8 p -91.02 -24.52 20.05 Favored 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.55 -0.718 . . . . 0.0 109.27 179.828 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.521 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 17.1 m -133.44 160.36 37.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.265 -0.897 . . . . 0.0 109.978 -179.806 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.78 36.75 24.78 Favored Glycine 0 N--CA 1.494 2.523 0 N-CA-C 108.859 -1.696 . . . . 0.0 108.859 -179.856 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.57 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 44.2 mt -93.83 -44.37 8.15 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-O 123.204 1.478 . . . . 0.0 110.353 -178.658 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.451 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.9 OUTLIER 63.81 145.35 0.02 OUTLIER 'General case' 0 C--N 1.262 -3.216 0 CA-C-N 113.62 -1.627 . . . . 0.0 109.798 -179.459 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.535 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.4 p-10 -51.61 105.33 0.1 Allowed 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.551 0.691 . . . . 0.0 110.844 -179.015 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 126.93 2.22 6.68 Favored Glycine 0 N--CA 1.485 1.949 0 C-N-CA 119.077 -1.535 . . . . 0.0 113.428 177.625 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.57 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -104.08 -171.82 2.0 Allowed 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 121.376 2.588 . . . . 0.0 110.102 179.909 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.566 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 16.0 t -131.47 141.91 44.64 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.252 0 CA-C-N 114.604 -1.18 . . . . 0.0 110.47 -179.207 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.529 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 28.6 m -115.7 154.99 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.199 -0.938 . . . . 0.0 109.023 179.321 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.492 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 45.9 tptt -107.07 109.31 21.14 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 108.892 179.918 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.507 HG11 ' CG2' ' A' ' 34' ' ' VAL . 2.1 p -103.63 141.62 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.545 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -139.05 160.41 39.84 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 118.595 -1.242 . . . . 0.0 110.04 179.714 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.42 144.26 15.58 Favored Glycine 0 C--N 1.294 -1.793 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 179.695 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.506 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.28 125.37 12.88 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.872 -1.369 . . . . 0.0 108.956 179.037 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.536 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.48 26.84 26.6 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.289 -1.434 . . . . 0.0 109.867 -179.733 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.547 ' HB2' ' HB1' ' A' ' 57' ' ' ALA . 1.4 mt -87.68 174.61 8.31 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 120.837 -1.39 . . . . 0.0 108.648 -179.879 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.559 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.58 99.79 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.99 -1.069 . . . . 0.0 109.744 -179.682 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 77.94 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.233 -179.149 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.58 34.17 0.32 Allowed Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.556 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.543 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 40.6 p -141.13 108.14 5.44 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.136 -1.214 . . . . 0.0 111.208 -179.539 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.9 110.75 0.46 Allowed 'General case' 0 N--CA 1.497 1.876 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.542 178.027 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.58 ' CE1' ' HB2' ' A' ' 99' ' ' ASP . 5.3 m-30 -106.75 156.02 19.09 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.122 -0.987 . . . . 0.0 108.902 179.821 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -99.13 164.16 12.27 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.822 -1.174 . . . . 0.0 107.917 178.822 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.623 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.5 p -144.99 115.2 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.982 -1.074 . . . . 0.0 109.653 -178.247 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.476 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.02 -174.48 35.52 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.42 -1.847 . . . . 0.0 111.594 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.579 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.4 pt20 -102.39 109.25 20.85 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.862 0.839 . . . . 0.0 108.839 -179.772 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.453 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -131.75 149.51 52.45 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.099 -1.001 . . . . 0.0 110.093 -179.858 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.77 139.14 54.12 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.25 -0.906 . . . . 0.0 110.867 -179.076 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.621 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.36 114.96 26.79 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 178.21 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.5 m -105.4 15.15 7.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.991 -1.068 . . . . 0.0 110.591 -178.799 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.595 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.6 -176.19 0.09 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.961 -1.087 . . . . 0.0 110.101 179.747 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.541 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.89 97.86 1.49 Allowed 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.381 -0.825 . . . . 0.0 109.856 -179.742 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.37 27.58 35.84 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.212 -0.994 . . . . 0.0 111.394 178.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.595 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.23 106.44 20.34 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.528 -1.572 . . . . 0.0 107.185 178.904 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.621 HD13 ' CD1' ' A' ' 39' ' ' TRP . 13.0 tp -116.99 104.61 11.45 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.476 -1.39 . . . . 0.0 109.752 -177.763 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.525 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.82 109.53 22.27 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.746 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.497 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -106.74 168.75 8.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.967 -1.083 . . . . 0.0 110.379 -178.565 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.536 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 20.5 t-20 -114.57 132.34 22.92 Favored Pre-proline 0 N--CA 1.498 1.963 0 O-C-N 121.64 -0.662 . . . . 0.0 109.95 -179.242 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.585 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.8 Cg_endo -74.18 25.56 0.34 Allowed 'Trans proline' 0 CA--C 1.544 0.997 0 C-N-CA 122.28 1.986 . . . . 0.0 112.139 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.536 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -111.25 -1.06 16.23 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.279 -1.513 . . . . 0.0 109.443 179.709 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.521 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.06 21.32 2.62 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.561 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -80.92 90.6 5.93 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 120.053 -0.659 . . . . 0.0 110.873 -178.646 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -109.73 -167.23 1.18 Allowed 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.157 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.467 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.96 136.25 0.09 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.61 -1.307 . . . . 0.0 111.186 -179.273 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.59 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -153.53 158.26 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.354 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.78 141.8 31.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.906 -1.121 . . . . 0.0 109.945 -179.845 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.683 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.02 106.51 0.84 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 122.45 1.119 . . . . 0.0 109.359 178.296 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.52 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -58.3 -138.47 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.03 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.918 -179.863 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.548 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -54.22 -49.19 70.01 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.367 -0.833 . . . . 0.0 110.406 -178.756 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -102.37 -38.26 7.68 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 178.333 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.683 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 111.36 65.26 0.51 Allowed Glycine 0 C--N 1.297 -1.593 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 177.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.1 m -102.98 128.73 49.68 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 121.41 -1.053 . . . . 0.0 108.703 178.851 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.59 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -138.22 109.07 6.68 Favored 'General case' 0 C--N 1.296 -1.73 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.771 -179.235 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.5 m -123.52 120.63 33.44 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.309 -0.869 . . . . 0.0 109.725 -179.902 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.467 HG23 HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.28 148.24 32.23 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.568 -0.708 . . . . 0.0 109.278 179.777 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.3 p -98.99 143.02 29.75 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.386 -0.821 . . . . 0.0 109.648 -179.839 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.536 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -146.03 157.52 43.87 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.357 -0.839 . . . . 0.0 109.368 -179.33 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.566 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 13.9 t -86.62 140.28 30.0 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.135 -0.978 . . . . 0.0 110.08 -179.792 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.47 HG11 ' HB3' ' A' ' 36' ' ' GLN . 16.9 m -145.94 137.89 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.226 -0.921 . . . . 0.0 110.148 -179.388 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.535 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 59.7 mtt180 -128.19 -162.75 1.21 Allowed 'General case' 0 N--CA 1.484 1.266 0 O-C-N 120.649 -1.282 . . . . 0.0 110.955 179.97 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.586 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.6 OUTLIER -86.66 -79.95 0.25 Allowed 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.35 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -69.78 133.02 46.97 Favored 'General case' 0 N--CA 1.486 1.34 0 N-CA-C 106.511 -1.662 . . . . 0.0 106.511 177.956 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.599 ' CE1' ' HB ' ' A' ' 86' ' ' VAL . 0.9 OUTLIER -154.42 155.32 34.75 Favored 'General case' 0 C--N 1.293 -1.875 0 C-N-CA 117.696 -1.602 . . . . 0.0 110.669 -177.938 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 47' ' ' CYS . 16.4 mt-10 -48.1 120.6 3.63 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 121.556 0.694 . . . . 0.0 109.549 -178.443 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.525 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -87.62 49.41 3.87 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -179.588 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.7 m-30 -40.59 112.38 0.28 Allowed 'General case' 0 N--CA 1.507 2.387 0 O-C-N 121.046 -1.267 . . . . 0.0 110.302 179.986 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.9 tp -86.33 126.39 34.3 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.96 -1.088 . . . . 0.0 109.415 179.848 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.572 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.5 t80 -64.2 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.98 0 O-C-N 120.773 -1.204 . . . . 0.0 110.192 179.72 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 1.5 t0 -159.03 18.53 0.19 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.996 -1.065 . . . . 0.0 109.794 179.865 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.92 -25.85 6.47 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 179.763 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 47.6 p -95.0 159.37 15.05 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 120.966 -1.314 . . . . 0.0 110.604 -179.33 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.46 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -104.25 131.84 51.14 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.52 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.485 ' CD1' HD11 ' A' ' 77' ' ' LEU . 3.0 t90 -79.75 -19.96 47.47 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.854 -1.154 . . . . 0.0 110.169 -178.501 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.52 174.4 18.88 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 108.666 -1.773 . . . . 0.0 108.666 -179.406 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.13 112.88 2.55 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 179.09 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.599 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 38.1 t -84.56 103.22 11.54 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.019 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.472 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.7 OUTLIER -63.88 109.26 1.7 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.54 -0.725 . . . . 0.0 110.248 -178.902 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.534 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 4.1 t -61.85 -4.19 1.44 Allowed 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.546 -1.262 . . . . 0.0 110.433 179.227 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -91.6 4.26 53.08 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.477 -1.389 . . . . 0.0 109.333 179.772 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.472 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -116.18 -50.19 2.67 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.178 -0.951 . . . . 0.0 109.144 179.936 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.89 178.73 4.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.512 -0.743 . . . . 0.0 109.396 179.871 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.85 113.37 26.24 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.324 -0.86 . . . . 0.0 108.817 179.884 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.475 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.51 119.59 35.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.017 -1.052 . . . . 0.0 109.471 -179.048 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.551 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.71 147.31 26.99 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-O 122.459 1.123 . . . . 0.0 111.43 -179.21 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.505 ' CG1' HG13 ' A' ' 7' ' ' VAL . 77.2 t -103.81 109.83 28.34 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.993 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 177.613 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.456 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.39 -170.01 17.1 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 118.246 -1.93 . . . . 0.0 111.608 -177.54 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.489 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.66 178.27 4.46 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.907 -0.761 . . . . 0.0 108.994 -178.972 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.595 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -160.93 178.43 9.4 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.529 -0.732 . . . . 0.0 109.511 -179.653 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.58 ' HB2' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -122.21 -157.41 0.73 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.21 -0.931 . . . . 0.0 108.764 179.629 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.449 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -120.23 35.91 4.71 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.66 -1.275 . . . . 0.0 109.316 -179.948 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -122.17 -32.55 3.66 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.341 -0.85 . . . . 0.0 110.464 -179.46 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.526 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 167.31 -37.29 0.23 Allowed Glycine 0 N--CA 1.482 1.714 0 N-CA-C 107.569 -2.212 . . . . 0.0 107.569 -179.395 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.473 ' ND2' ' O9 ' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -157.96 -178.37 7.26 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 121.569 -0.96 . . . . 0.0 109.721 179.183 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.44 -160.55 11.62 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 108.333 -1.907 . . . . 0.0 108.333 -179.344 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -47.01 178.31 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.864 1.332 . . . . 0.0 110.265 179.207 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -93.02 -174.4 3.56 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.123 -0.985 . . . . 0.0 110.341 -178.956 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.456 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.75 164.0 15.02 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.935 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.38 129.71 49.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.386 -1.067 . . . . 0.0 109.074 -179.629 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.551 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.92 121.44 19.08 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.658 -0.651 . . . . 0.0 109.804 179.836 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.475 HG12 ' O ' ' A' ' 93' ' ' CYS . 1.5 pt -97.99 169.28 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 121.379 -0.826 . . . . 0.0 108.818 179.822 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.521 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.98 160.37 38.82 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.141 -0.974 . . . . 0.0 109.693 -179.945 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.579 ' CD1' ' HG2' ' A' ' 71' ' ' ARG . 39.2 m-85 -134.33 76.01 1.62 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.242 -0.911 . . . . 0.0 109.46 -179.759 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.4 p30 . . . . . 0 N--CA 1.491 1.603 0 CA-C-O 117.917 -1.04 . . . . 0.0 109.42 179.99 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.595 ' C20' ' CB ' ' A' ' 98' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.497 -0.557 . . . . 1.0 109.497 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.513 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . . . -68.57 173.39 3.48 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.299 -0.876 . . . . 1.0 109.483 179.992 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.532 ' O ' ' CG2' ' A' ' 4' ' ' THR . 3.3 Cg_exo -60.84 157.2 39.27 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.233 1.955 . . . . 1.0 110.412 -179.892 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.605 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.1 p -167.9 160.49 12.32 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.824 -0.806 . . . . 1.0 108.824 -179.247 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -150.37 127.78 11.43 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.06 -1.056 . . . . 1.0 110.561 -179.869 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.526 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.9 p -107.0 104.93 14.73 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 122.608 1.194 . . . . 1.0 110.347 -179.587 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.522 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 15.2 t -119.37 115.35 47.43 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.468 0 CA-C-N 115.271 -0.877 . . . . 1.0 110.131 179.428 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.502 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -162.57 150.8 12.01 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.316 -0.994 . . . . 1.0 108.316 -179.378 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.502 ' HA ' HG22 ' A' ' 8' ' ' THR . 6.1 Cg_endo -77.96 150.21 88.92 Favored 'Cis proline' 0 C--N 1.308 -1.554 0 C-N-CA 123.635 -1.402 . . . . 1.0 109.74 -0.679 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.493 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 69.2 p -89.75 -25.49 21.12 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 109.031 -0.729 . . . . 1.0 109.031 179.549 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.464 ' HB2' ' HB3' ' A' ' 111' ' ' SER . 18.7 p -132.55 164.64 26.18 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.498 -0.751 . . . . 1.0 109.375 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.68 38.27 37.61 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 108.259 -1.936 . . . . 1.0 108.259 -179.531 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.605 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 33.7 mt -92.49 -43.39 9.21 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 123.264 1.507 . . . . 1.0 110.619 -178.174 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.494 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.11 143.59 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.269 0 CA-C-N 113.461 -1.7 . . . . 1.0 109.815 -179.467 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.546 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 9.9 p-10 -50.48 105.13 0.09 Allowed 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.474 0.654 . . . . 1.0 111.634 -178.484 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.4 ' H ' ' HB3' ' A' ' 70' ' ' ARG . . . 113.98 15.68 8.38 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 119.457 -1.354 . . . . 1.0 113.007 177.153 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.605 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.5 t -103.88 -171.22 1.9 Allowed 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 121.053 2.426 . . . . 1.0 109.802 179.125 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.579 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 16.6 t -131.31 140.06 49.34 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.314 0 CA-C-N 114.822 -1.081 . . . . 1.0 111.362 -178.783 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.528 HG13 ' CG2' ' A' ' 69' ' ' VAL . 30.9 m -115.9 155.48 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 N-CA-C 108.66 -0.867 . . . . 1.0 108.66 178.861 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.522 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 5.5 tptm -108.16 108.96 20.23 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.137 -0.977 . . . . 1.0 109.529 -179.759 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.518 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 p -106.39 122.5 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.853 -0.795 . . . . 1.0 108.853 179.729 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.55 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -115.21 165.45 12.92 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.943 -1.098 . . . . 1.0 109.145 179.789 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.81 108.03 0.46 Allowed Glycine 0 N--CA 1.483 1.768 0 N-CA-C 108.711 -1.756 . . . . 1.0 108.711 179.602 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.605 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.75 142.43 46.93 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.704 -1.468 . . . . 1.0 110.212 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.483 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 82.96 29.08 35.49 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.062 -1.542 . . . . 1.0 109.773 179.787 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.529 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -94.56 172.75 7.99 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.093 -1.239 . . . . 1.0 108.31 179.98 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.555 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.09 100.36 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.027 -1.046 . . . . 1.0 109.602 -179.799 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.85 76.44 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 115.397 -0.819 . . . . 1.0 109.955 -179.313 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 137.08 33.26 0.22 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.457 -1.457 . . . . 1.0 109.457 179.712 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.528 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 66.8 p -142.14 109.74 5.72 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.042 -1.269 . . . . 1.0 111.013 -179.803 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.537 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -47.95 109.93 0.28 Allowed 'General case' 0 N--CA 1.496 1.847 0 CA-C-N 115.7 -0.682 . . . . 1.0 109.858 178.407 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.498 ' CE1' ' HD2' ' A' ' 105' ' ' PRO . 21.1 m-85 -99.1 152.3 20.01 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.157 -0.965 . . . . 1.0 109.007 179.653 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.47 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.48 157.77 16.56 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 107.598 -1.26 . . . . 1.0 107.598 178.421 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.623 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 9.9 p -142.29 113.97 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.063 -1.023 . . . . 1.0 110.07 -177.692 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.489 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.39 -175.49 36.73 Favored Glycine 0 N--CA 1.495 2.575 0 C-N-CA 118.371 -1.871 . . . . 1.0 111.875 -179.811 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.588 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -102.25 109.41 21.09 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 108.848 -0.797 . . . . 1.0 108.848 -179.663 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -131.07 148.55 52.75 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.129 -0.982 . . . . 1.0 110.034 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.89 139.79 53.62 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.314 -0.866 . . . . 1.0 110.716 -179.016 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.621 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.25 114.66 26.47 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 107.607 -1.257 . . . . 1.0 107.607 178.161 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 m -105.25 15.01 7.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.094 -1.004 . . . . 1.0 110.469 -178.752 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.585 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 175.04 -175.76 0.09 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.044 -1.035 . . . . 1.0 110.039 179.688 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 p -72.69 98.02 2.29 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.448 -0.782 . . . . 1.0 109.508 -179.805 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.39 27.64 32.45 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.232 -0.985 . . . . 1.0 111.291 179.046 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.585 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -117.6 106.27 19.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 O-C-N 120.6 -1.53 . . . . 1.0 107.325 178.889 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.621 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.4 tp -116.1 104.8 11.92 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 120.496 -1.378 . . . . 1.0 109.567 -178.016 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.536 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.47 109.56 22.29 Favored 'General case' 0 N--CA 1.486 1.338 0 O-C-N 120.781 -1.199 . . . . 1.0 107.857 178.889 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -108.26 163.73 12.93 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.02 -1.05 . . . . 1.0 110.112 -178.656 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.485 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 36.2 t-20 -110.16 128.78 24.79 Favored Pre-proline 0 N--CA 1.502 2.141 0 O-C-N 121.437 -0.789 . . . . 1.0 109.67 -179.372 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.576 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.6 Cg_endo -69.44 17.72 0.18 Allowed 'Trans proline' 0 CA--C 1.546 1.075 0 C-N-CA 122.021 1.814 . . . . 1.0 112.108 179.444 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -104.6 3.48 31.77 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.389 -1.444 . . . . 1.0 108.528 179.065 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.518 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.45 15.91 2.75 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 107.228 -1.397 . . . . 1.0 107.228 179.487 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -81.53 92.39 6.5 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.834 -0.746 . . . . 1.0 111.099 -178.299 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -112.01 -170.94 1.75 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.133 -1.432 . . . . 1.0 107.133 177.879 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 179.18 136.91 0.1 Allowed 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.475 -1.391 . . . . 1.0 111.277 -179.197 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.59 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.56 157.14 4.78 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 107.107 -1.442 . . . . 1.0 107.107 178.194 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.537 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -97.83 143.23 28.66 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.696 -1.253 . . . . 1.0 109.965 -179.474 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.664 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.24 105.86 0.98 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 122.372 1.082 . . . . 1.0 109.392 178.704 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.522 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.5 t70 -60.21 -139.28 0.0 OUTLIER 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.719 -0.673 . . . . 1.0 110.934 -179.827 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.6 -50.48 60.1 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.297 -0.877 . . . . 1.0 110.625 -178.7 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 49.4 m-80 -102.95 -35.15 8.68 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.272 -1.751 . . . . 1.0 106.272 178.59 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.664 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 105.26 66.27 0.68 Allowed Glycine 0 C--N 1.297 -1.602 0 N-CA-C 110.522 -1.031 . . . . 1.0 110.522 178.305 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.584 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.4 m -104.09 125.54 50.51 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 108.514 -0.921 . . . . 1.0 108.514 178.833 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.59 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.46 109.54 8.8 Favored 'General case' 0 C--N 1.296 -1.748 0 C-N-CA 119.692 -0.803 . . . . 1.0 109.755 -179.266 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.481 ' OG ' ' HB1' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -116.24 122.72 45.8 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.278 -0.888 . . . . 1.0 109.019 179.709 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.461 HG21 HG13 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -148.44 140.14 23.7 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.496 -0.752 . . . . 1.0 109.884 -179.964 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.404 ' HB3' ' HD2' ' A' ' 20' ' ' LYS . 14.6 p -101.34 131.42 47.4 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.369 -0.832 . . . . 1.0 109.276 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.518 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -128.52 164.62 22.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.38 -0.825 . . . . 1.0 109.623 -179.452 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.579 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -97.36 124.59 41.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.952 -1.093 . . . . 1.0 109.249 -179.958 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.549 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 18.0 m -136.61 143.67 34.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.1 -1.0 . . . . 1.0 109.947 -179.106 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.546 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.8 ptt180 -141.86 -165.51 2.02 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.51 -1.369 . . . . 1.0 110.264 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.583 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 10.1 mtt180 -70.07 -76.85 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.425 -0.797 . . . . 1.0 109.017 -179.557 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.428 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -69.62 137.33 52.18 Favored 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.232 -1.542 . . . . 1.0 107.128 178.878 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.588 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -160.17 134.18 7.26 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 117.895 -1.522 . . . . 1.0 110.299 -178.179 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.478 ' C ' ' O ' ' A' ' 73' ' ' PHE . 4.2 mm-40 -30.57 120.97 0.2 Allowed 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.54 0.686 . . . . 1.0 110.888 -178.397 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.536 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.13 43.4 3.05 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.913 -0.875 . . . . 1.0 110.913 -179.526 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.576 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 2.1 m-85 -38.71 114.93 0.42 Allowed 'General case' 0 N--CA 1.511 2.603 0 O-C-N 121.182 -1.187 . . . . 1.0 110.123 179.959 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.529 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.4 tp -87.64 126.96 35.26 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.889 -1.132 . . . . 1.0 109.231 179.81 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.58 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.3 t80 -63.95 58.01 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.871 -1.143 . . . . 1.0 110.438 -179.9 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 9.3 t0 -161.97 19.96 0.1 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.924 -1.11 . . . . 1.0 109.862 179.802 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.06 -27.29 5.05 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.002 -1.239 . . . . 1.0 110.002 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.463 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 3.1 p -90.24 153.55 20.4 Favored 'General case' 0 N--CA 1.485 1.318 0 O-C-N 121.072 -1.252 . . . . 1.0 110.388 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.507 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 5.1 ptt180 -102.43 132.82 48.2 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.636 -0.875 . . . . 1.0 108.636 179.68 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.46 ' CD1' HD11 ' A' ' 77' ' ' LEU . 2.4 t90 -81.92 -21.41 37.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.659 -1.276 . . . . 1.0 110.294 -178.673 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.92 174.0 18.55 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.746 -1.742 . . . . 1.0 108.746 -179.644 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.67 110.71 1.81 Allowed 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.412 -1.329 . . . . 1.0 107.412 179.095 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.577 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 41.3 t -82.26 104.27 10.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 O-C-N 121.449 -0.782 . . . . 1.0 108.895 -178.962 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.46 ' HB3' HG22 ' A' ' 90' ' ' THR . 0.1 OUTLIER -66.47 111.81 3.76 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.306 -0.871 . . . . 1.0 109.784 -179.277 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.533 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.0 t -62.77 -5.35 2.69 Favored 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 118.416 -1.314 . . . . 1.0 110.108 179.497 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -86.23 0.6 53.36 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.611 -1.306 . . . . 1.0 109.15 179.462 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.46 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -112.71 -48.89 2.97 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.268 -0.895 . . . . 1.0 109.055 179.907 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.46 -178.31 3.56 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.483 -0.761 . . . . 1.0 109.6 -179.93 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.55 114.78 29.23 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.294 -0.879 . . . . 1.0 108.97 179.923 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.56 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.12 123.32 40.85 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.956 -1.09 . . . . 1.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.546 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.96 146.16 28.75 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 122.359 1.076 . . . . 1.0 111.059 -179.775 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.514 ' CG1' HG12 ' A' ' 7' ' ' VAL . 97.8 t -103.07 109.63 27.39 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.069 0 N-CA-C 106.604 -1.628 . . . . 1.0 106.604 177.719 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.464 ' HA3' ' CA ' ' A' ' 107' ' ' GLY . . . -149.51 -170.58 17.19 Favored Glycine 0 N--CA 1.485 1.962 0 C-N-CA 118.091 -2.004 . . . . 1.0 111.944 -177.47 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.47 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -118.16 -178.65 3.56 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 108.88 -0.785 . . . . 1.0 108.88 -178.77 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.535 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -174.48 173.17 2.99 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.355 -0.841 . . . . 1.0 109.254 -179.45 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.406 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -116.97 -158.54 0.7 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.162 -0.961 . . . . 1.0 108.765 179.582 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.406 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -118.91 36.11 4.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.759 -1.213 . . . . 1.0 109.288 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.45 -32.52 4.6 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.278 -0.889 . . . . 1.0 110.358 -179.502 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.512 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 167.15 -37.41 0.23 Allowed Glycine 0 N--CA 1.481 1.666 0 N-CA-C 107.522 -2.231 . . . . 1.0 107.522 -179.465 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.46 -178.24 6.99 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.615 -0.932 . . . . 1.0 109.727 179.12 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -170.27 -162.61 22.87 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 108.248 -1.941 . . . . 1.0 108.248 -179.426 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.498 ' HD2' ' CE1' ' A' ' 32' ' ' TYR . 7.5 Cg_exo -45.69 165.81 0.06 OUTLIER 'Trans proline' 0 C--O 1.215 -0.637 0 CA-C-N 118.912 1.356 . . . . 1.0 109.656 179.392 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.73 -176.45 4.97 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.047 -1.033 . . . . 1.0 110.528 -178.473 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.464 ' CA ' ' HA3' ' A' ' 96' ' ' GLY . . . -118.57 175.26 15.64 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.723 -1.351 . . . . 1.0 109.723 -179.837 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -112.05 132.51 60.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.383 -1.069 . . . . 1.0 109.121 -179.14 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.546 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -69.88 124.58 24.39 Favored 'General case' 0 C--N 1.291 -1.95 0 O-C-N 121.556 -0.715 . . . . 1.0 109.479 179.526 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.578 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.71 171.57 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.19 -0.944 . . . . 1.0 109.043 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.464 ' HB3' ' HB2' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.53 161.21 37.01 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.237 -0.914 . . . . 1.0 109.707 -179.773 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.583 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 90.0 m-85 -136.69 86.47 2.22 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 121.12 -0.987 . . . . 1.0 109.532 -179.702 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 16.2 p30 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 117.894 -1.05 . . . . 1.0 109.461 -179.954 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.588 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.46 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . . . -119.13 169.48 8.05 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.89 . . . . 0.0 109.558 -179.922 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.5 Cg_exo -59.91 158.42 29.33 Favored 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 122.416 2.077 . . . . 0.0 110.574 179.991 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.532 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.28 -169.56 0.15 Allowed 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 179.154 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.532 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -168.51 133.8 1.73 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.548 -1.345 . . . . 0.0 111.179 -179.128 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.541 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.4 p -101.22 104.45 15.51 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 122.404 1.097 . . . . 0.0 109.907 179.859 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.54 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 3.2 t -119.37 119.3 60.21 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.393 179.588 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.495 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.8 149.92 4.41 Favored Pre-proline 0 N--CA 1.486 1.335 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -179.602 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.495 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.3 Cg_endo -78.55 149.96 86.69 Favored 'Cis proline' 0 C--N 1.309 -1.504 0 C-N-CA 123.631 -1.404 . . . . 0.0 109.439 -0.677 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.482 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 72.6 p -92.09 -23.43 19.46 Favored 'General case' 0 C--N 1.292 -1.911 0 O-C-N 121.632 -0.668 . . . . 0.0 109.245 179.677 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.522 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 12.1 p -131.81 161.19 33.53 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.376 -0.828 . . . . 0.0 109.646 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.2 37.78 31.33 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 108.386 -1.885 . . . . 0.0 108.386 -179.556 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.603 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 33.2 mt -91.85 -43.39 9.53 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 123.223 1.487 . . . . 0.0 110.53 -178.223 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.494 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.89 143.93 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.25 0 CA-C-N 113.457 -1.701 . . . . 0.0 110.017 -179.508 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.565 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 11.5 p-10 -49.83 105.69 0.1 Allowed 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 121.431 0.634 . . . . 0.0 111.737 -178.53 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.5 15.37 8.89 Favored Glycine 0 N--CA 1.485 1.94 0 C-N-CA 119.439 -1.363 . . . . 0.0 113.077 177.068 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.603 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.9 t -105.04 -173.2 2.25 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 121.123 2.461 . . . . 0.0 109.943 179.191 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.539 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 21.6 t -128.86 139.7 51.21 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.318 0 CA-C-N 114.635 -1.166 . . . . 0.0 111.508 -178.578 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.462 ' CG1' HD22 ' A' ' 13' ' ' LEU . 33.8 m -117.82 155.96 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.641 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tppp? -107.69 109.92 21.64 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.017 -1.052 . . . . 0.0 109.816 -179.681 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.527 ' CG2' HG21 ' A' ' 7' ' ' VAL . 7.3 p -105.87 123.23 60.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.086 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.541 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -119.7 166.61 12.99 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.506 -1.371 . . . . 0.0 109.397 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.582 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.42 143.31 14.97 Favored Glycine 0 C--N 1.296 -1.682 0 N-CA-C 107.802 -2.119 . . . . 0.0 107.802 179.806 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.522 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -148.08 122.54 9.73 Favored 'General case' 0 C--N 1.293 -1.858 0 O-C-N 120.828 -1.395 . . . . 0.0 108.565 179.067 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.518 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 90.52 27.38 20.22 Favored Glycine 0 N--CA 1.486 2.017 0 C-N-CA 119.093 -1.527 . . . . 0.0 109.707 -179.552 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.556 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.2 mt -87.23 176.51 7.53 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 120.894 -1.356 . . . . 0.0 108.373 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.582 ' CB ' ' CG2' ' A' ' 30' ' ' THR . 0.0 OUTLIER -45.42 96.76 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.001 -1.062 . . . . 0.0 109.665 -179.784 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.2 77.68 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.528 -179.0 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 129.33 36.28 0.43 Allowed Glycine 0 N--CA 1.487 2.035 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 179.409 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.648 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -148.57 114.54 5.76 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 120.913 -1.345 . . . . 0.0 111.199 -179.891 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.548 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -46.34 122.52 4.09 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 115.437 -0.802 . . . . 0.0 110.354 178.66 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.648 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 1.9 m-30 -116.97 154.43 30.9 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.084 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.503 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -100.52 167.68 10.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.499 -1.375 . . . . 0.0 108.604 179.449 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.615 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.3 p -147.78 122.46 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.165 -0.96 . . . . 0.0 109.554 -178.089 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -177.08 -178.21 46.63 Favored Glycine 0 N--CA 1.495 2.606 0 C-N-CA 118.329 -1.891 . . . . 0.0 111.71 179.977 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.564 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -100.4 108.52 20.55 Favored 'General case' 0 N--CA 1.477 0.901 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.836 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -129.59 148.63 51.51 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.179 -0.951 . . . . 0.0 109.803 179.691 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.34 139.52 53.95 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.307 -0.871 . . . . 0.0 110.675 -179.023 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.617 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.09 114.9 26.76 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 178.147 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.47 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 18.2 m -105.77 14.98 7.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.044 -1.035 . . . . 0.0 110.58 -178.652 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.553 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 175.1 -174.94 0.09 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.986 -1.071 . . . . 0.0 109.995 179.579 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.547 ' O ' ' CG2' ' A' ' 42' ' ' THR . 14.9 t -72.62 98.01 2.26 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.43 -0.794 . . . . 0.0 109.757 -179.779 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.78 28.01 33.19 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 120.161 -1.019 . . . . 0.0 111.436 179.037 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.553 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -117.16 106.39 20.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.542 -1.564 . . . . 0.0 107.149 178.798 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.617 HD12 ' CD1' ' A' ' 39' ' ' TRP . 13.2 tp -116.76 104.94 11.85 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.496 -1.378 . . . . 0.0 109.681 -177.649 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.97 109.75 22.45 Favored 'General case' 0 N--CA 1.484 1.26 0 O-C-N 120.934 -1.104 . . . . 0.0 108.387 179.237 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.0 t -106.16 163.88 12.44 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.995 -1.066 . . . . 0.0 110.268 -179.037 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.518 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 17.4 t30 -111.36 137.79 21.17 Favored Pre-proline 0 N--CA 1.502 2.129 0 O-C-N 121.496 -0.752 . . . . 0.0 109.598 -179.387 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.57 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.2 24.58 0.31 Allowed 'Trans proline' 0 C--N 1.318 -1.04 0 C-N-CA 122.504 2.136 . . . . 0.0 112.41 -179.379 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.466 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -103.34 -8.3 20.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.164 -1.585 . . . . 0.0 109.184 179.465 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.548 ' HB3' ' CB ' ' A' ' 67' ' ' LEU . 2.0 m-20 -135.69 8.85 3.33 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.54 86.46 0.08 Allowed 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.277 -0.889 . . . . 0.0 110.441 -178.797 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.615 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -115.61 -169.86 1.66 Allowed 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 178.785 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.462 ' OG ' ' O ' ' A' ' 32' ' ' TYR . 0.6 OUTLIER 178.65 133.9 0.08 Allowed 'General case' 0 C--N 1.303 -1.424 0 O-C-N 120.725 -1.235 . . . . 0.0 111.206 -179.483 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.555 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 2.0 p -143.59 159.72 16.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.548 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.89 145.33 26.54 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.649 -1.282 . . . . 0.0 109.75 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.684 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -67.56 109.75 3.38 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 122.449 1.118 . . . . 0.0 109.465 178.638 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.535 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.5 p-10 -62.11 -139.17 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.643 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.532 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.33 -51.88 50.43 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.268 -0.895 . . . . 0.0 110.445 -178.94 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.5 -33.72 9.4 Favored 'General case' 0 C--N 1.288 -2.103 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.555 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.684 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.18 65.65 0.59 Allowed Glycine 0 C--N 1.3 -1.444 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.162 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.582 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 53.5 p -99.91 131.78 45.67 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 121.354 -1.086 . . . . 0.0 109.363 179.15 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.555 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.19 108.78 6.96 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.429 -0.908 . . . . 0.0 109.535 -179.853 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 92.0 p -117.62 118.52 32.34 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.063 -1.023 . . . . 0.0 109.588 -179.818 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.403 HG22 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -146.67 140.89 26.31 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.473 -0.767 . . . . 0.0 109.835 -179.947 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.447 ' HB3' ' HE3' ' A' ' 20' ' ' LYS . 24.2 p -98.82 136.37 38.94 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.322 -0.861 . . . . 0.0 108.792 179.54 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.548 ' CB ' ' HB3' ' A' ' 51' ' ' ASP . 0.2 OUTLIER -132.73 168.07 18.98 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.266 -0.896 . . . . 0.0 110.322 -178.489 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.524 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.1 p -104.46 124.39 49.17 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.876 . . . . 0.0 108.688 179.464 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.52 HG12 ' CB ' ' A' ' 36' ' ' GLN . 17.4 m -136.93 142.98 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 120.873 -1.142 . . . . 0.0 110.237 -178.761 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.565 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.4 ptt180 -144.9 -169.71 3.24 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 120.575 -1.328 . . . . 0.0 110.771 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.553 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -58.35 -99.8 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -179.144 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -58.33 143.37 45.13 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.355 -1.466 . . . . 0.0 108.505 179.692 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.589 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.17 138.63 6.7 Favored 'General case' 0 C--N 1.294 -1.813 0 C-N-CA 118.848 -1.141 . . . . 0.0 109.614 -178.185 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.532 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 8.6 mm-40 -34.77 121.97 0.53 Allowed 'General case' 0 N--CA 1.49 1.53 0 CA-C-O 121.484 0.659 . . . . 0.0 110.583 -178.254 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.533 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.64 46.08 2.75 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 120.52 -0.848 . . . . 0.0 110.995 -179.298 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.57 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.7 m-85 -39.07 111.48 0.18 Allowed 'General case' 0 N--CA 1.507 2.403 0 O-C-N 121.23 -1.159 . . . . 0.0 109.887 179.589 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.542 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.5 tp -84.88 127.37 34.12 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.9 -1.125 . . . . 0.0 109.281 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.565 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 57.6 t80 -63.18 58.18 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.92 -1.113 . . . . 0.0 110.527 -179.881 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t0 -163.33 20.21 0.08 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.906 -1.121 . . . . 0.0 109.997 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.77 -27.16 4.95 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.091 -1.203 . . . . 0.0 110.091 179.979 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.505 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -90.3 150.57 21.86 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 121.119 -1.224 . . . . 0.0 110.247 -179.469 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.48 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -101.19 133.06 46.31 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 179.434 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.461 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.5 t90 -81.76 -16.09 52.18 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.794 -1.191 . . . . 0.0 110.56 -178.525 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 108.74 174.36 21.52 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.856 -1.697 . . . . 0.0 108.856 -179.719 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.79 103.9 0.62 Allowed 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.613 -1.255 . . . . 0.0 107.613 179.116 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.585 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.5 t -74.52 106.53 4.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.476 -0.765 . . . . 0.0 109.224 -178.814 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -66.58 110.93 3.37 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.386 -0.821 . . . . 0.0 109.813 -179.454 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.553 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.72 -5.49 4.23 Favored 'General case' 0 N--CA 1.499 2.024 0 C-N-CA 118.329 -1.348 . . . . 0.0 109.908 179.463 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.7 p -85.61 -0.6 55.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.705 -1.247 . . . . 0.0 109.144 179.568 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.452 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -112.92 -49.17 2.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.383 -0.823 . . . . 0.0 109.002 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.45 -178.2 3.58 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.511 -0.743 . . . . 0.0 109.455 179.963 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.14 115.64 30.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.446 -0.784 . . . . 0.0 108.964 179.924 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.564 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.86 123.54 40.6 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.935 -1.103 . . . . 0.0 109.665 -179.176 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.565 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.05 147.66 26.68 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-O 122.418 1.104 . . . . 0.0 111.014 -179.522 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.459 ' HB ' HG12 ' A' ' 7' ' ' VAL . 46.4 t -106.28 113.22 42.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.993 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.017 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.472 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -155.18 -169.83 20.11 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 117.989 -2.053 . . . . 0.0 111.834 -177.943 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -110.52 -177.74 3.31 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 -179.227 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.559 ' HB3' ' C26' ' A' ' 114' ' ' CHR . 12.1 p -170.38 172.03 6.31 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.367 -0.833 . . . . 0.0 109.083 -179.072 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.461 ' OD1' ' O ' ' A' ' 103' ' ' ASN . 0.6 OUTLIER -117.64 -161.81 0.84 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.984 -1.073 . . . . 0.0 108.764 179.592 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -119.56 36.12 4.6 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.546 -1.346 . . . . 0.0 109.236 -179.919 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -121.76 -33.54 3.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.391 -0.818 . . . . 0.0 110.468 -179.598 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.514 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 171.08 -38.01 0.18 Allowed Glycine 0 N--CA 1.482 1.712 0 N-CA-C 107.878 -2.089 . . . . 0.0 107.878 -179.58 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.461 ' O ' ' OD1' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -158.64 -177.92 6.88 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 121.474 -1.015 . . . . 0.0 109.81 179.238 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.4 -161.2 13.01 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.589 -1.804 . . . . 0.0 108.589 -179.256 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.519 ' HD3' ' CE2' ' A' ' 32' ' ' TYR . 4.7 Cg_exo -47.41 -178.97 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.709 1.254 . . . . 0.0 110.577 179.278 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -93.75 -177.6 4.42 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.072 -1.017 . . . . 0.0 110.425 -178.93 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.472 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.79 166.39 14.55 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.68 130.41 52.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.342 -1.093 . . . . 0.0 109.165 -179.405 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.565 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.25 122.29 22.6 Favored 'General case' 0 C--N 1.289 -2.024 0 O-C-N 121.623 -0.673 . . . . 0.0 109.48 179.617 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.583 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.57 168.74 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 O-C-N 121.193 -0.942 . . . . 0.0 109.188 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.522 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.3 m -136.85 157.52 46.56 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.301 -0.875 . . . . 0.0 109.541 -179.784 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.583 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 70.8 m-85 -133.8 68.94 1.48 Allowed 'General case' 0 C--N 1.306 -1.323 0 O-C-N 121.164 -0.96 . . . . 0.0 109.608 -179.614 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 20.8 p30 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.491 -179.937 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.593 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.45 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -113.91 167.2 9.86 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.926 . . . . 0.0 109.429 -179.948 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.526 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 3.8 Cg_exo -60.21 157.88 33.1 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 122.194 1.929 . . . . 0.0 110.547 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.583 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.1 p -161.62 160.44 28.8 Favored 'General case' 0 C--N 1.296 -1.734 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.238 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -149.45 122.78 9.01 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-O 122.415 1.102 . . . . 0.0 110.423 -179.684 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.552 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.1 t -114.72 109.07 17.64 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 123.075 1.417 . . . . 0.0 109.663 179.937 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.527 HG11 ' CG1' ' A' ' 95' ' ' VAL . 2.5 t -117.28 136.08 55.6 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 CA-C-N 114.297 -1.32 . . . . 0.0 109.681 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.522 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -173.08 150.8 2.0 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.273 -0.892 . . . . 0.0 108.734 -179.559 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.522 ' CA ' HG21 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.21 150.44 88.57 Favored 'Cis proline' 0 C--N 1.312 -1.387 0 C-N-CA 123.563 -1.432 . . . . 0.0 109.507 -0.761 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.467 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 38.3 p -90.01 -25.59 20.77 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 121.586 -0.696 . . . . 0.0 109.14 179.502 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.521 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 16.1 m -133.08 162.11 32.61 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.406 -0.809 . . . . 0.0 109.565 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.86 37.13 30.52 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 -179.684 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.605 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 37.5 mt -92.36 -42.34 9.85 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 123.218 1.485 . . . . 0.0 110.43 -178.482 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.487 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.94 143.27 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.323 0 CA-C-N 113.379 -1.737 . . . . 0.0 109.825 -179.542 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.573 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 18.3 p-10 -50.39 105.27 0.09 Allowed 'General case' 0 C--N 1.3 -1.586 0 CA-C-O 121.452 0.644 . . . . 0.0 111.484 -178.525 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.92 13.57 8.46 Favored Glycine 0 N--CA 1.486 2.002 0 C-N-CA 119.306 -1.426 . . . . 0.0 113.165 177.285 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.605 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -104.56 -171.71 1.97 Allowed 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 121.28 2.54 . . . . 0.0 109.78 179.18 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.571 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 18.2 t -129.26 139.01 52.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.956 -1.02 . . . . 0.0 111.224 -178.821 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.519 HG12 ' CG2' ' A' ' 69' ' ' VAL . 31.5 m -114.14 155.39 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 178.937 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.82 109.57 20.72 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.115 -0.991 . . . . 0.0 109.266 179.976 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 1.6 p -102.36 140.74 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.594 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.583 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -137.32 161.67 35.64 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 118.773 -1.171 . . . . 0.0 110.182 179.81 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.32 141.74 13.02 Favored Glycine 0 C--N 1.298 -1.572 0 N-CA-C 108.169 -1.973 . . . . 0.0 108.169 179.721 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.583 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -143.24 124.69 14.76 Favored 'General case' 0 N--CA 1.494 1.754 0 CA-C-N 119.226 1.513 . . . . 0.0 109.363 179.255 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.526 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.05 28.98 19.16 Favored Glycine 0 N--CA 1.489 2.212 0 C-N-CA 118.965 -1.588 . . . . 0.0 109.647 -179.733 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.543 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.5 mt -89.4 175.24 7.4 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.9 -1.353 . . . . 0.0 108.366 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.554 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.61 99.95 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.977 -1.077 . . . . 0.0 109.806 -179.752 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.537 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.32 77.52 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.918 -179.347 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.588 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.97 33.97 0.24 Allowed Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 179.674 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 23.1 p -139.59 105.66 5.22 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.141 -1.211 . . . . 0.0 111.283 -179.404 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.559 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.42 109.77 0.34 Allowed 'General case' 0 N--CA 1.497 1.916 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 177.853 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.501 ' HA ' ' O ' ' A' ' 98' ' ' SER . 6.8 m-30 -104.41 158.99 16.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.139 -0.975 . . . . 0.0 109.131 -179.977 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.512 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -101.63 157.75 16.59 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 178.754 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.525 ' CG1' HG21 ' A' ' 65' ' ' THR . 1.6 t -136.84 109.77 8.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.129 -0.982 . . . . 0.0 109.635 -177.573 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.481 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.38 -174.05 35.37 Favored Glycine 0 N--CA 1.497 2.727 0 C-N-CA 117.713 -2.184 . . . . 0.0 112.638 -179.928 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.567 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -102.09 109.11 20.74 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-O 121.756 0.789 . . . . 0.0 109.062 -179.495 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.428 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.42 148.8 52.27 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.21 -0.931 . . . . 0.0 109.6 179.33 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.34 138.72 54.55 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.32 -0.862 . . . . 0.0 110.774 -178.995 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.619 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.43 115.07 26.92 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.154 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.429 HG22 ' HB ' ' A' ' 44' ' ' VAL . 16.8 m -104.88 14.89 6.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 120.988 -1.07 . . . . 0.0 110.558 -178.89 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.592 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.38 -175.12 0.08 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.959 -1.088 . . . . 0.0 110.006 179.781 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.44 98.12 2.2 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.411 -0.806 . . . . 0.0 109.687 -179.78 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.99 28.11 32.22 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 120.217 -0.992 . . . . 0.0 111.355 179.014 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.592 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.54 106.25 19.61 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 O-C-N 120.603 -1.528 . . . . 0.0 107.071 178.804 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.619 HD12 ' CD1' ' A' ' 39' ' ' TRP . 13.8 tp -118.03 104.5 10.93 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.458 -1.401 . . . . 0.0 109.789 -177.719 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.542 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.21 109.37 22.14 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 120.918 -1.114 . . . . 0.0 108.051 178.84 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.502 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.1 163.47 12.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.906 -1.121 . . . . 0.0 110.281 -178.778 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.522 ' ND2' ' HB2' ' A' ' 50' ' ' ALA . 47.4 t30 -106.4 132.33 20.99 Favored Pre-proline 0 N--CA 1.504 2.23 0 O-C-N 121.394 -0.816 . . . . 0.0 109.627 -179.424 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.571 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -72.21 19.36 0.3 Allowed 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 122.296 1.997 . . . . 0.0 112.281 -179.596 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.522 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -111.2 4.13 18.99 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.38 -1.45 . . . . 0.0 108.707 179.114 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.517 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.08 20.76 3.01 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 179.303 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -81.37 85.85 6.37 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.538 -178.715 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.501 ' CB ' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.52 -171.03 2.04 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.843 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.45 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.66 134.58 0.08 Allowed 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.676 -1.265 . . . . 0.0 111.23 -179.292 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.569 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -158.12 153.6 5.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 178.359 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.559 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.28 139.95 33.29 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.875 -1.141 . . . . 0.0 109.544 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.68 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -62.35 106.32 0.73 Allowed 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.391 1.091 . . . . 0.0 109.501 178.637 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.53 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.9 t70 -61.37 -139.21 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.045 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.77 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.537 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.11 -51.2 59.32 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.401 -0.812 . . . . 0.0 110.724 -178.803 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -101.04 -34.53 9.7 Favored 'General case' 0 C--N 1.286 -2.153 0 N-CA-C 106.282 -1.747 . . . . 0.0 106.282 178.493 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.68 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 104.88 65.76 0.68 Allowed Glycine 0 C--N 1.297 -1.637 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 178.109 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.6 m -98.86 130.42 45.27 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.594 -0.945 . . . . 0.0 108.6 178.739 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.583 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -137.79 108.63 6.68 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.594 -179.329 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.8 m -124.23 120.45 32.28 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.334 -0.854 . . . . 0.0 109.47 179.927 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.525 HG21 ' CG1' ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.16 142.83 29.95 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.558 -0.714 . . . . 0.0 109.353 179.908 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 9.5 p -99.2 136.22 39.47 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.316 -0.865 . . . . 0.0 109.434 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.517 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -136.31 165.19 26.34 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.461 -0.774 . . . . 0.0 109.55 -179.343 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.571 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.2 p -96.78 125.45 41.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.073 -1.017 . . . . 0.0 109.112 179.926 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.551 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.7 m -136.53 142.7 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 120.934 -1.104 . . . . 0.0 110.09 -178.886 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.573 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 5.2 ptt180 -147.49 -173.08 4.18 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.562 -1.337 . . . . 0.0 110.884 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.551 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -54.11 -101.22 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 -179.421 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.19 141.44 46.41 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.82 -1.175 . . . . 0.0 108.128 179.479 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.8 135.44 5.58 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 118.68 -1.208 . . . . 0.0 109.665 -178.01 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.501 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 18.7 mm-40 -34.73 122.93 0.54 Allowed 'General case' 0 N--CA 1.491 1.603 0 CA-C-O 121.502 0.668 . . . . 0.0 110.088 -178.466 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.542 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.98 52.81 1.66 Allowed Glycine 0 N--CA 1.492 2.385 0 C-N-CA 120.397 -0.906 . . . . 0.0 111.108 -178.937 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.571 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-30 -39.7 113.38 0.33 Allowed 'General case' 0 N--CA 1.506 2.332 0 O-C-N 121.065 -1.256 . . . . 0.0 109.972 179.393 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.1 tp -83.45 126.12 32.43 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.947 -1.096 . . . . 0.0 109.217 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.579 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 39.5 t80 -63.7 58.66 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.918 -1.114 . . . . 0.0 110.169 179.806 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -160.92 19.91 0.13 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.996 -1.065 . . . . 0.0 109.696 179.92 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.13 -28.07 5.28 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.882 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.439 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.32 159.61 15.04 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.007 -1.29 . . . . 0.0 110.28 -179.416 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.469 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.73 135.96 47.37 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.757 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.472 ' CD1' HD11 ' A' ' 77' ' ' LEU . 1.6 t90 -80.77 -18.87 46.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.867 -1.145 . . . . 0.0 110.545 -178.504 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.46 177.47 19.84 Favored Glycine 0 N--CA 1.484 1.88 0 N-CA-C 108.671 -1.771 . . . . 0.0 108.671 -179.428 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.36 105.58 1.18 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.2 -1.176 . . . . 0.0 107.859 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.576 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 40.0 t -77.53 105.7 6.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.346 -0.846 . . . . 0.0 109.124 -179.069 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 1.5 m-20 -65.6 111.44 3.15 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.406 -0.809 . . . . 0.0 109.747 -179.372 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.551 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.13 -5.23 4.46 Favored 'General case' 0 N--CA 1.5 2.031 0 C-N-CA 118.113 -1.435 . . . . 0.0 109.876 179.386 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -86.54 -0.06 55.33 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.799 -1.188 . . . . 0.0 109.159 179.587 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.448 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -113.36 -50.01 2.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.334 -0.854 . . . . 0.0 108.969 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.5 -179.05 3.83 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.487 -0.758 . . . . 0.0 109.42 179.925 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.88 115.27 30.01 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.328 -0.857 . . . . 0.0 108.999 179.9 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -97.03 122.24 39.81 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.762 -1.211 . . . . 0.0 109.428 -179.431 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.552 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -101.91 146.89 27.21 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 122.41 1.1 . . . . 0.0 111.107 -179.372 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.527 ' CG1' HG11 ' A' ' 7' ' ' VAL . 61.1 t -104.43 110.25 29.93 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 177.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.44 -169.86 17.58 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 118.31 -1.9 . . . . 0.0 111.466 -177.786 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.497 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -113.22 179.98 3.81 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -179.333 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.572 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.6 OUTLIER -169.51 163.82 10.37 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 121.364 -0.835 . . . . 0.0 109.406 -179.596 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.475 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -108.39 -160.83 0.74 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.187 -0.945 . . . . 0.0 108.804 179.673 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -120.06 35.41 4.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.554 -1.342 . . . . 0.0 109.336 -179.843 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -119.43 -32.52 4.33 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.434 -0.791 . . . . 0.0 110.215 -179.594 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.517 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 171.55 -39.17 0.17 Allowed Glycine 0 N--CA 1.483 1.806 0 N-CA-C 107.62 -2.192 . . . . 0.0 107.62 -179.536 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.501 ' ND2' ' O9 ' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -159.49 -178.16 6.93 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.637 -0.919 . . . . 0.0 109.622 179.194 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.85 -162.43 14.74 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 108.434 -1.866 . . . . 0.0 108.434 -179.34 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.48 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.9 Cg_exo -46.32 176.31 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.692 0 CA-C-N 118.837 1.318 . . . . 0.0 110.206 179.289 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -91.62 -176.15 4.4 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.033 -1.042 . . . . 0.0 110.573 -178.71 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.467 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.63 168.88 15.02 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.61 130.39 57.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.354 -1.086 . . . . 0.0 109.192 -179.208 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.552 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.05 122.9 20.91 Favored 'General case' 0 C--N 1.29 -1.985 0 O-C-N 121.609 -0.682 . . . . 0.0 109.505 179.543 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.527 ' CD1' ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.69 169.02 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.201 -0.937 . . . . 0.0 109.222 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.521 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -136.39 155.31 50.21 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 109.602 -179.942 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.527 ' CZ ' ' CD1' ' A' ' 110' ' ' ILE . 21.2 m-85 -131.12 93.86 3.47 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.198 -0.939 . . . . 0.0 109.482 -179.664 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.7 p30 . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.41 179.904 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.586 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.511 0 CA-C-O 121.262 0.553 . . . . 0.0 109.564 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.515 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . . . -114.26 172.79 3.3 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.231 -0.918 . . . . 0.0 109.411 179.987 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.533 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.7 Cg_exo -59.64 157.92 30.27 Favored 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.15 1.9 . . . . 0.0 110.539 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.7 -169.5 0.14 Allowed 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.289 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.545 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -166.3 133.97 2.76 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.7 -1.25 . . . . 0.0 111.134 -179.37 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.524 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.2 p -100.92 104.59 15.79 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 122.478 1.132 . . . . 0.0 109.76 -179.892 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.535 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 5.4 t -119.4 122.92 70.2 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.401 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.574 179.823 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.489 HG21 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -169.52 150.04 3.91 Favored Pre-proline 0 N--CA 1.487 1.413 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 -179.529 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.489 ' HA ' HG21 ' A' ' 8' ' ' THR . 4.4 Cg_endo -76.74 150.71 93.25 Favored 'Cis proline' 0 C--N 1.309 -1.533 0 C-N-CA 123.613 -1.411 . . . . 0.0 109.579 -0.339 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.483 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 89.2 p -92.49 -22.81 19.37 Favored 'General case' 0 C--N 1.292 -1.929 0 O-C-N 121.693 -0.629 . . . . 0.0 109.352 179.799 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.488 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.3 m -132.37 163.97 27.51 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.398 -0.814 . . . . 0.0 109.689 -179.822 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.05 38.88 39.14 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 -179.504 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.635 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 27.7 mt -92.02 -45.21 8.44 Favored 'General case' 0 C--N 1.297 -1.698 0 CA-C-O 123.12 1.438 . . . . 0.0 110.772 -178.09 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.13 146.42 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.349 0 CA-C-N 113.799 -1.546 . . . . 0.0 110.077 -179.615 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.566 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.6 p-10 -50.76 108.32 0.23 Allowed 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 121.542 0.687 . . . . 0.0 111.984 -178.53 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.74 16.54 9.9 Favored Glycine 0 N--CA 1.485 1.907 0 C-N-CA 119.592 -1.289 . . . . 0.0 112.768 177.07 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.635 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 8.8 t -103.45 -174.79 2.63 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 120.965 2.382 . . . . 0.0 109.98 179.426 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.553 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 17.0 t -129.89 138.9 52.91 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 CA-C-N 114.365 -1.288 . . . . 0.0 111.06 -178.799 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.515 HG21 ' CG2' ' A' ' 69' ' ' VAL . 4.1 m -118.53 154.99 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.669 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.535 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 10.2 tttt -105.95 108.99 20.79 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.175 -0.953 . . . . 0.0 109.403 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.531 HG11 ' CD1' ' A' ' 67' ' ' LEU . 2.1 p -107.04 123.38 62.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 179.611 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.531 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -117.51 167.17 11.54 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 120.69 -1.256 . . . . 0.0 109.222 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.6 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.76 140.71 12.03 Favored Glycine 0 C--N 1.295 -1.717 0 N-CA-C 107.49 -2.244 . . . . 0.0 107.49 179.718 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.31 124.1 11.92 Favored 'General case' 0 C--N 1.293 -1.889 0 O-C-N 120.748 -1.442 . . . . 0.0 108.87 179.35 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.533 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.36 25.97 26.94 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.226 -1.464 . . . . 0.0 109.913 -179.641 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.1 mt -85.6 175.44 8.77 Favored 'General case' 0 C--N 1.306 -1.321 0 O-C-N 120.891 -1.358 . . . . 0.0 108.263 -179.989 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.556 ' CB ' ' CG2' ' A' ' 30' ' ' THR . 0.0 OUTLIER -46.39 96.71 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.928 -1.108 . . . . 0.0 109.659 -179.72 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.53 76.77 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.758 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.536 -178.996 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.77 33.7 0.33 Allowed Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.253 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.587 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.3 t -149.14 116.07 6.0 Favored 'General case' 0 C--N 1.307 -1.268 0 O-C-N 120.929 -1.336 . . . . 0.0 111.138 179.919 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.543 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.83 127.55 6.4 Favored 'General case' 0 N--CA 1.492 1.653 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.902 178.453 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.587 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.9 m-85 -118.36 149.18 41.63 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.431 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -98.97 159.28 15.07 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.548 -1.345 . . . . 0.0 107.784 178.841 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.623 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.4 p -140.19 119.6 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.189 -0.944 . . . . 0.0 109.633 -177.819 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.466 ' HA2' ' HB2' ' A' ' 51' ' ' ASP . . . -170.72 -179.94 42.33 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 118.274 -1.917 . . . . 0.0 111.794 -179.799 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.556 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -100.83 108.85 20.76 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.783 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.32 148.51 51.25 Favored 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.174 -0.954 . . . . 0.0 109.953 179.887 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.19 138.99 54.51 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.359 -0.838 . . . . 0.0 110.593 -179.046 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.627 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.29 114.63 26.44 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 107.521 -1.289 . . . . 0.0 107.521 178.213 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.463 HG21 ' HB ' ' A' ' 44' ' ' VAL . 17.0 m -104.38 14.81 6.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 O-C-N 121.069 -1.019 . . . . 0.0 110.482 -178.811 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.584 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.74 -175.41 0.08 Allowed 'General case' 0 C--N 1.302 -1.482 0 O-C-N 120.935 -1.103 . . . . 0.0 110.025 179.695 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.6 p -73.54 98.28 2.78 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.413 -0.804 . . . . 0.0 109.506 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.5 27.58 29.56 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.219 -0.991 . . . . 0.0 111.326 179.128 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.584 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -118.72 106.31 19.29 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 O-C-N 120.607 -1.525 . . . . 0.0 107.342 178.999 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.627 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.9 tp -116.61 104.7 11.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.315 -1.491 . . . . 0.0 109.855 -177.815 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.535 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -97.49 109.62 22.34 Favored 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.909 -1.12 . . . . 0.0 108.1 178.885 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.0 t -107.15 165.82 11.08 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.841 -1.162 . . . . 0.0 110.612 -178.632 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.481 ' OD1' ' HB2' ' A' ' 74' ' ' GLU . 55.3 t30 -113.55 132.45 22.53 Favored Pre-proline 0 N--CA 1.501 2.092 0 C-N-CA 120.119 -0.632 . . . . 0.0 109.425 -179.486 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.577 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.8 Cg_endo -72.76 24.31 0.29 Allowed 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 122.205 1.937 . . . . 0.0 112.104 -179.743 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.405 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -99.06 -7.58 26.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.369 -1.457 . . . . 0.0 109.184 179.52 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.542 ' HB3' ' CB ' ' A' ' 67' ' ' LEU . 0.7 OUTLIER -133.61 5.8 3.72 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.346 -0.846 . . . . 0.0 108.817 -179.985 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -59.44 80.62 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.87 -178.656 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -108.48 -169.97 1.59 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 178.297 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.472 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.5 134.55 0.08 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.543 -1.348 . . . . 0.0 111.448 -179.405 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.563 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.9 p -146.31 158.92 11.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 177.741 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.543 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.48 146.6 25.08 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.572 -1.33 . . . . 0.0 109.884 -179.564 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.67 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.42 108.73 3.37 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 122.385 1.088 . . . . 0.0 109.674 178.914 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.527 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.1 p-10 -62.42 -138.85 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.862 -179.796 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.72 -51.84 35.76 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.376 -0.828 . . . . 0.0 110.641 -178.771 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -105.11 -32.73 8.55 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 178.553 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.67 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.5 69.78 0.67 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 178.246 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 69.9 m -103.63 130.09 51.01 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 121.268 -1.137 . . . . 0.0 109.337 179.267 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.563 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -135.62 108.69 7.68 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.433 -0.907 . . . . 0.0 109.676 -179.675 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 93.6 p -115.88 116.93 28.84 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 120.956 -1.09 . . . . 0.0 109.364 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.463 HG21 HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.29 141.27 27.15 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.427 -0.796 . . . . 0.0 110.125 -179.868 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.6 p -100.35 137.0 39.36 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.614 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.553 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -137.35 172.22 13.31 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.253 -0.904 . . . . 0.0 109.844 -178.979 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.536 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.2 p -104.72 123.66 48.02 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.089 -1.007 . . . . 0.0 109.908 -179.372 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.542 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 15.5 m -133.04 143.6 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 121.056 -1.027 . . . . 0.0 109.688 -179.606 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.566 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.2 ptt180 -140.78 -167.77 2.43 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.558 -1.339 . . . . 0.0 110.417 179.906 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.577 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 3.3 mtt180 -70.95 -76.61 0.1 Allowed 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -179.623 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.437 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -71.88 137.8 47.74 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 120.153 -1.592 . . . . 0.0 107.547 179.117 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.594 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -159.56 136.96 9.79 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.27 -1.372 . . . . 0.0 110.108 -178.105 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.484 ' O ' ' O ' ' A' ' 47' ' ' CYS . 9.1 mm-40 -34.71 122.54 0.53 Allowed 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.562 0.696 . . . . 0.0 110.571 -178.188 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.535 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -89.38 45.62 3.14 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.577 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 6.6 m-85 -38.41 113.82 0.32 Allowed 'General case' 0 N--CA 1.509 2.477 0 O-C-N 121.194 -1.18 . . . . 0.0 110.167 179.751 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.533 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.4 tp -87.81 125.99 34.76 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 120.913 -1.117 . . . . 0.0 109.477 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.587 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 23.4 t80 -64.26 58.6 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 O-C-N 120.972 -1.08 . . . . 0.0 110.184 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 6.3 t70 -161.0 20.02 0.13 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.047 -1.033 . . . . 0.0 109.796 179.688 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.68 -27.5 5.29 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.874 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.408 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 8.1 p -94.05 160.99 14.47 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.984 -1.303 . . . . 0.0 110.256 -179.488 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.544 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -108.98 136.63 48.2 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.897 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.482 ' CD1' HD13 ' A' ' 77' ' ' LEU . 1.7 t90 -82.67 -19.1 38.82 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.932 -1.105 . . . . 0.0 110.386 -178.368 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.64 175.2 19.97 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 -179.494 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.29 109.63 1.39 Allowed 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 179.122 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.594 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 39.4 t -81.38 104.38 9.85 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.068 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.453 ' CB ' HG22 ' A' ' 90' ' ' THR . 0.3 OUTLIER -67.42 111.14 3.91 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.433 -0.792 . . . . 0.0 109.888 -179.076 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.546 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.0 t -63.26 -5.9 3.9 Favored 'General case' 0 N--CA 1.499 2.017 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.942 179.48 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.3 p -84.76 -0.08 52.45 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.717 -1.24 . . . . 0.0 109.023 179.407 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.453 HG22 ' CB ' ' A' ' 87' ' ' ASP . 2.6 p -113.41 -49.14 2.91 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.356 -0.84 . . . . 0.0 109.024 -179.969 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.08 -178.03 3.53 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.578 -0.701 . . . . 0.0 109.539 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.11 115.26 29.92 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.466 -0.771 . . . . 0.0 108.982 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.57 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -97.09 125.2 41.4 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.948 -1.095 . . . . 0.0 109.687 -179.174 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.546 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.54 146.44 28.89 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 122.421 1.105 . . . . 0.0 111.191 -179.524 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.485 ' CG1' HG12 ' A' ' 7' ' ' VAL . 96.2 t -102.68 111.09 31.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 177.775 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.453 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.78 -171.2 18.72 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 117.97 -2.062 . . . . 0.0 111.808 -177.684 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.481 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -113.95 -177.59 3.17 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -179.075 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.594 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.0 OUTLIER -175.13 172.02 2.87 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.229 -0.92 . . . . 0.0 109.531 -179.378 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -122.05 -162.27 0.98 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.878 -1.139 . . . . 0.0 108.921 179.665 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -116.03 36.5 4.02 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.684 -1.26 . . . . 0.0 109.122 179.953 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -116.76 -33.26 4.87 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.337 -0.852 . . . . 0.0 110.159 -179.522 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.507 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 166.64 -36.65 0.24 Allowed Glycine 0 N--CA 1.481 1.699 0 N-CA-C 107.786 -2.126 . . . . 0.0 107.786 -179.667 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.55 -177.67 6.09 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.534 -0.98 . . . . 0.0 109.91 179.328 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.86 -160.97 12.89 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.415 -1.874 . . . . 0.0 108.415 -179.395 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.7 Cg_exo -47.87 -178.95 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.813 1.306 . . . . 0.0 110.474 179.367 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -94.59 -179.51 4.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.068 -1.02 . . . . 0.0 110.448 -178.903 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.453 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.84 162.49 12.71 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 -179.972 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.8 129.67 50.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.397 -1.06 . . . . 0.0 109.095 -179.501 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.546 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.35 121.82 21.06 Favored 'General case' 0 C--N 1.289 -2.041 0 O-C-N 121.626 -0.671 . . . . 0.0 109.892 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.574 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.83 171.37 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.242 -0.911 . . . . 0.0 108.982 179.658 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.488 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -138.6 159.33 42.36 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.156 -0.965 . . . . 0.0 109.669 -179.845 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.577 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 79.7 m-85 -135.09 129.31 33.76 Favored 'General case' 0 N--CA 1.485 1.323 0 O-C-N 121.25 -0.907 . . . . 0.0 109.63 -179.785 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.6 p30 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 118.093 -0.956 . . . . 0.0 109.538 -179.87 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.594 ' C20' ' CB ' ' A' ' 98' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.516 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . . . -122.56 173.02 4.59 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.254 -0.904 . . . . 0.0 109.457 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.523 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.6 Cg_exo -59.83 157.86 31.4 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.233 1.955 . . . . 0.0 110.472 179.979 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.528 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.54 -169.76 0.15 Allowed 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.292 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.528 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.77 131.0 2.43 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 120.764 -1.21 . . . . 0.0 110.778 -179.202 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.547 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.4 t -112.82 108.71 17.79 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-O 123.108 1.432 . . . . 0.0 109.175 179.394 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 3.2 t -115.93 139.04 44.39 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.728 0 CA-C-N 114.169 -1.378 . . . . 0.0 110.088 -179.67 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.523 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -177.0 150.32 0.88 Allowed Pre-proline 0 N--CA 1.486 1.35 0 O-C-N 121.309 -0.87 . . . . 0.0 108.766 -179.673 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.523 ' CA ' HG23 ' A' ' 8' ' ' THR . 5.9 Cg_endo -78.49 150.43 87.7 Favored 'Cis proline' 0 C--N 1.312 -1.364 0 C-N-CA 123.531 -1.445 . . . . 0.0 109.334 -0.921 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.488 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 94.1 p -93.65 -22.13 18.96 Favored 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.52 -0.738 . . . . 0.0 109.558 179.821 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.469 ' HA ' ' O ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -132.2 162.62 30.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.805 -179.798 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.15 39.03 38.21 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 -179.508 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.614 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 31.8 mt -91.38 -44.58 9.06 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-O 123.093 1.425 . . . . 0.0 110.771 -178.272 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.483 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.0 OUTLIER 64.37 146.42 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.332 0 CA-C-N 113.735 -1.575 . . . . 0.0 109.63 -179.42 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.578 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.7 p-10 -52.32 110.1 0.46 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.486 0.66 . . . . 0.0 111.554 -178.523 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.71 9.76 13.75 Favored Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.301 -1.428 . . . . 0.0 112.854 177.375 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.614 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 9.8 t -101.32 -172.52 2.18 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 121.029 2.415 . . . . 0.0 109.747 179.502 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 11.2 t -134.63 141.32 43.64 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.612 -179.334 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.514 HG22 ' CG2' ' A' ' 69' ' ' VAL . 27.8 m -116.55 154.8 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.214 -0.929 . . . . 0.0 109.057 179.471 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.477 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 21.8 tttt -107.95 108.97 20.34 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.238 -0.914 . . . . 0.0 109.049 179.793 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.522 HG11 ' CG2' ' A' ' 34' ' ' VAL . 1.8 p -101.03 139.11 23.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.555 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.562 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -134.45 160.46 37.92 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 118.461 -1.296 . . . . 0.0 110.027 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.6 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.94 144.07 15.52 Favored Glycine 0 C--N 1.294 -1.758 0 N-CA-C 107.755 -2.138 . . . . 0.0 107.755 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.45 124.5 12.09 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 120.799 -1.412 . . . . 0.0 108.953 179.222 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 90.15 26.52 23.58 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 119.272 -1.442 . . . . 0.0 109.703 -179.702 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.553 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -89.22 170.56 10.49 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 120.857 -1.378 . . . . 0.0 108.479 179.989 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.09 100.69 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.051 -1.031 . . . . 0.0 109.988 -179.574 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.7 77.98 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.004 -179.509 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.85 34.05 0.27 Allowed Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 179.702 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 20.8 p -139.18 105.88 5.37 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.198 -1.178 . . . . 0.0 111.255 -179.485 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.569 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -52.32 114.19 1.27 Allowed 'General case' 0 N--CA 1.495 1.814 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.611 178.098 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.489 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 8.2 m-30 -110.67 160.06 17.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.143 -0.973 . . . . 0.0 108.949 179.834 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.507 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -100.62 168.28 9.8 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 178.93 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.627 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.8 p -150.36 117.13 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.023 -1.048 . . . . 0.0 109.827 -178.221 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.489 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.85 -175.93 39.21 Favored Glycine 0 N--CA 1.495 2.605 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.821 -179.765 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.571 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -99.33 108.44 20.97 Favored 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.811 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.0 m -132.21 148.45 52.46 Favored 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.296 -0.878 . . . . 0.0 109.784 179.657 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.2 140.25 53.02 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.241 -0.912 . . . . 0.0 110.727 -179.136 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.619 ' CE2' HD11 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.16 114.78 26.61 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.211 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.3 m -104.16 14.49 6.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.052 -1.03 . . . . 0.0 110.5 -178.798 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.93 -175.26 0.08 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.897 -1.127 . . . . 0.0 110.087 179.769 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.25 98.45 2.65 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.425 -0.797 . . . . 0.0 109.535 -179.917 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.98 27.51 31.2 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 120.244 -0.979 . . . . 0.0 111.421 179.072 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.591 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -118.01 106.33 19.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 O-C-N 120.618 -1.519 . . . . 0.0 107.303 178.846 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.619 HD11 ' CE2' ' A' ' 39' ' ' TRP . 13.4 tp -117.65 104.67 11.25 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.523 -1.36 . . . . 0.0 109.58 -177.843 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.03 109.54 22.27 Favored 'General case' 0 N--CA 1.485 1.281 0 O-C-N 120.828 -1.17 . . . . 0.0 108.251 179.068 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -107.61 166.85 10.37 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.023 -1.048 . . . . 0.0 109.989 -179.17 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.531 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 11.0 t-20 -107.3 137.33 19.58 Favored Pre-proline 0 N--CA 1.502 2.148 0 O-C-N 121.231 -0.918 . . . . 0.0 109.846 -179.286 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.574 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.6 Cg_endo -75.15 24.49 0.39 Allowed 'Trans proline' 0 C--N 1.318 -1.04 0 C-N-CA 122.383 2.056 . . . . 0.0 111.786 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.531 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -120.27 4.09 10.81 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.351 -1.468 . . . . 0.0 109.195 179.75 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.543 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.84 19.96 2.85 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 179.278 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -84.14 87.81 7.17 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.929 -0.708 . . . . 0.0 110.858 -178.618 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -107.91 -168.25 1.35 Allowed 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.436 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.472 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.92 136.22 0.09 Allowed 'General case' 0 C--N 1.305 -1.326 0 O-C-N 120.755 -1.216 . . . . 0.0 111.082 -179.401 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.577 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -151.73 157.7 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 178.391 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.569 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.91 142.26 30.64 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.835 -1.166 . . . . 0.0 110.027 -179.786 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.693 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -62.89 107.76 1.05 Allowed 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 122.441 1.115 . . . . 0.0 109.288 178.083 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.525 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.1 t0 -62.94 -138.68 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.777 179.937 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.531 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.37 -52.7 34.93 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.402 -0.811 . . . . 0.0 110.924 -178.615 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.85 -33.07 9.94 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 178.612 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.693 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.19 62.26 0.55 Allowed Glycine 0 C--N 1.296 -1.664 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 178.051 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 82.5 p -98.72 129.91 45.19 Favored 'General case' 0 C--N 1.309 -1.155 0 O-C-N 121.563 -0.963 . . . . 0.0 108.731 178.713 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.29 108.89 6.97 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.203 -0.999 . . . . 0.0 109.727 -179.343 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -122.35 119.2 30.37 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.191 -0.943 . . . . 0.0 109.533 -179.941 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.451 HG23 HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.66 142.98 30.51 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.491 -0.756 . . . . 0.0 109.329 179.876 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 27.7 p -98.82 138.09 36.46 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.416 -0.802 . . . . 0.0 109.58 -179.853 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.543 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -140.83 159.41 42.27 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.329 -0.857 . . . . 0.0 109.48 -179.502 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 13.0 t -87.91 139.14 30.82 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.147 -0.97 . . . . 0.0 110.657 -179.411 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.535 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 19.4 m -148.73 144.31 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.484 -0.76 . . . . 0.0 109.249 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.578 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.9 OUTLIER -150.72 -173.69 4.55 Favored 'General case' 0 N--CA 1.484 1.245 0 O-C-N 120.456 -1.403 . . . . 0.0 111.178 -179.641 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.701 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.28 -104.8 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.281 -179.644 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -59.43 140.23 56.37 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 120.695 -1.253 . . . . 0.0 108.072 178.948 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.609 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -158.29 138.69 12.61 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.773 -1.171 . . . . 0.0 109.713 -178.312 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.472 ' C ' ' O ' ' A' ' 73' ' ' PHE . 8.8 mm-40 -34.89 120.35 0.5 Allowed 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.539 0.685 . . . . 0.0 110.552 -178.448 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -89.96 47.91 3.2 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.415 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.574 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -38.47 113.65 0.31 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 121.241 -1.153 . . . . 0.0 110.166 179.812 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.533 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.9 tp -86.66 126.26 34.41 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.997 -1.065 . . . . 0.0 109.456 -179.982 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.574 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 20.4 t80 -64.23 58.48 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.906 -1.121 . . . . 0.0 109.949 179.541 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 9.8 t70 -158.74 18.77 0.2 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.976 -1.078 . . . . 0.0 109.645 -179.979 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.18 -26.41 6.23 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.761 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.83 163.64 12.71 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 120.99 -1.3 . . . . 0.0 110.404 -179.332 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.471 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 4.2 ptt180 -106.24 136.79 45.34 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.914 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.528 ' CD1' HD13 ' A' ' 77' ' ' LEU . 4.7 t90 -82.58 -19.6 38.15 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.79 -1.194 . . . . 0.0 110.241 -178.709 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.64 173.43 16.86 Favored Glycine 0 N--CA 1.486 2.019 0 N-CA-C 108.791 -1.723 . . . . 0.0 108.791 -179.636 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -65.14 106.1 1.22 Allowed 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 179.105 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.596 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 46.2 t -76.51 107.34 7.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.371 -0.831 . . . . 0.0 109.533 -178.694 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.482 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.9 m-20 -63.92 111.99 2.73 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.213 -0.929 . . . . 0.0 109.178 -179.919 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.701 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.2 m -65.41 -4.66 5.96 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 120.704 -1.247 . . . . 0.0 109.829 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.2 p -93.27 1.95 56.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.731 -1.23 . . . . 0.0 109.58 179.956 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.482 HG23 ' HB3' ' A' ' 87' ' ' ASP . 5.0 p -112.51 -52.79 2.76 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.241 -0.912 . . . . 0.0 108.636 179.78 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.421 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -98.47 178.77 4.92 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.492 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.07 114.0 27.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -0.89 . . . . 0.0 108.777 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.482 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.8 m -96.44 121.8 38.64 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.982 -1.074 . . . . 0.0 109.758 -178.989 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.528 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -106.2 144.28 33.12 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-O 122.355 1.074 . . . . 0.0 111.112 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.418 ' CG1' HG13 ' A' ' 7' ' ' VAL . 90.5 t -101.87 109.58 26.44 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.086 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.741 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.441 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.12 -172.01 17.65 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 118.223 -1.941 . . . . 0.0 111.741 -177.591 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.491 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -112.01 178.8 4.19 Favored 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.289 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.59 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.9 OUTLIER -169.52 165.93 10.26 Favored 'General case' 0 C--N 1.294 -1.805 0 O-C-N 121.571 -0.706 . . . . 0.0 109.424 -179.546 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.489 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -115.16 -160.1 0.73 Allowed 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.043 -1.036 . . . . 0.0 108.805 179.776 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -116.82 35.76 4.47 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.636 -1.29 . . . . 0.0 109.246 -179.959 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -116.52 -33.17 4.98 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.402 -0.811 . . . . 0.0 110.143 -179.684 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.52 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 165.83 -36.81 0.26 Allowed Glycine 0 N--CA 1.482 1.717 0 N-CA-C 107.559 -2.216 . . . . 0.0 107.559 -179.544 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.75 -178.23 7.1 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.574 -0.956 . . . . 0.0 109.777 179.23 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.44 -161.9 14.4 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.488 -1.845 . . . . 0.0 108.488 -179.394 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.479 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -47.24 178.25 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.626 0 CA-C-N 118.812 1.306 . . . . 0.0 110.342 179.329 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -91.37 -174.35 3.9 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.097 -1.002 . . . . 0.0 110.401 -178.893 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.441 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.99 166.8 15.29 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.7 130.15 51.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.43 -1.041 . . . . 0.0 109.1 -179.429 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.528 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.71 125.12 28.04 Favored 'General case' 0 C--N 1.289 -2.049 0 O-C-N 121.641 -0.662 . . . . 0.0 109.606 179.782 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.488 ' CB ' ' O ' ' A' ' 10' ' ' SER . 1.5 pt -97.84 169.98 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.274 -0.891 . . . . 0.0 109.257 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.469 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -137.88 155.77 48.6 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.276 -0.89 . . . . 0.0 109.504 179.992 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.569 ' CE1' ' HB3' ' A' ' 88' ' ' CYS . 76.5 m-85 -123.55 68.98 1.02 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.11 -0.994 . . . . 0.0 109.51 -179.808 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.8 p30 . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.483 -179.961 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.59 ' C20' ' CB ' ' A' ' 98' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -117.92 157.42 48.43 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.23 -0.919 . . . . 0.0 109.493 179.96 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.523 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 2.9 Cg_endo -61.23 155.94 48.43 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.37 2.046 . . . . 0.0 110.609 -179.933 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -150.05 158.86 44.59 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -179.666 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -144.08 123.84 13.39 Favored 'General case' 0 C--N 1.294 -1.817 0 CA-C-O 122.465 1.126 . . . . 0.0 110.031 -179.918 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.546 ' CG2' ' O ' ' A' ' 6' ' ' THR . 5.9 t -114.88 109.1 17.64 Favored 'General case' 0 C--N 1.294 -1.822 0 CA-C-O 123.2 1.476 . . . . 0.0 109.765 -179.807 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.527 HG11 ' CG1' ' A' ' 95' ' ' VAL . 3.1 t -116.27 136.98 51.49 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.638 0 CA-C-N 114.176 -1.374 . . . . 0.0 109.716 179.902 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.524 HG22 ' CA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -172.96 151.25 2.13 Favored Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 121.235 -0.915 . . . . 0.0 108.791 -179.534 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.524 ' CA ' HG22 ' A' ' 8' ' ' THR . 5.2 Cg_endo -77.53 151.67 92.52 Favored 'Cis proline' 0 C--N 1.311 -1.422 0 C-N-CA 123.517 -1.451 . . . . 0.0 109.433 -0.819 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.459 ' HA ' HG21 ' A' ' 110' ' ' ILE . 88.1 p -93.94 -23.2 18.16 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.576 -0.703 . . . . 0.0 109.505 179.805 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.491 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 3.0 m -130.94 160.1 35.51 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.321 -0.862 . . . . 0.0 109.96 -179.65 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.23 37.25 32.57 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 108.611 -1.796 . . . . 0.0 108.611 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.636 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 27.1 mt -90.83 -45.42 8.81 Favored 'General case' 0 C--N 1.299 -1.627 0 CA-C-O 123.113 1.435 . . . . 0.0 110.751 -178.411 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 64.03 147.23 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.311 0 CA-C-N 113.748 -1.569 . . . . 0.0 109.963 -179.612 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.595 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.4 p-10 -51.41 108.9 0.29 Allowed 'General case' 0 C--N 1.302 -1.47 0 CA-C-O 121.725 0.774 . . . . 0.0 111.809 -178.568 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.8 13.66 11.04 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 119.479 -1.343 . . . . 0.0 112.914 177.311 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.636 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 10.2 t -101.8 -174.34 2.57 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 121.059 2.43 . . . . 0.0 109.86 179.457 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.542 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 21.1 t -127.83 138.3 55.13 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.885 -178.994 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.527 HG13 ' CG2' ' A' ' 69' ' ' VAL . 30.8 m -117.34 154.17 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.877 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -109.98 109.34 19.89 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.187 -0.946 . . . . 0.0 109.195 -179.846 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 p -101.96 140.44 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.747 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.563 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -134.33 158.31 44.12 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.838 -1.164 . . . . 0.0 109.701 179.568 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.613 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -139.36 108.81 0.61 Allowed Glycine 0 N--CA 1.481 1.675 0 N-CA-C 108.658 -1.777 . . . . 0.0 108.658 179.888 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.597 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.54 139.52 50.4 Favored 'General case' 0 N--CA 1.502 2.14 0 CA-C-N 119.402 1.601 . . . . 0.0 110.564 -179.25 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.523 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 85.21 27.81 32.47 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.058 -1.544 . . . . 0.0 109.938 179.569 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.533 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.7 OUTLIER -93.67 170.53 9.51 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.97 -1.312 . . . . 0.0 108.522 -179.92 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.555 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.43 101.23 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.097 -1.002 . . . . 0.0 109.827 -179.566 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.54 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.42 77.93 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.705 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.888 -179.342 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.5 33.46 0.27 Allowed Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 179.896 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.564 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 12.9 p -136.96 104.75 5.55 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 121.2 -1.176 . . . . 0.0 111.057 -179.349 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.566 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -51.54 110.03 0.41 Allowed 'General case' 0 N--CA 1.497 1.914 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.621 178.087 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.564 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 38.5 m-85 -106.33 156.35 18.59 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.052 -1.03 . . . . 0.0 108.992 179.87 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.453 ' HB3' H313 ' A' ' 114' ' ' CHR . 0.2 OUTLIER -100.25 160.14 14.57 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.631 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.626 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.2 p -140.75 119.66 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.095 -1.003 . . . . 0.0 109.62 -177.836 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.467 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.88 -178.8 41.15 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.536 -1.792 . . . . 0.0 111.525 -179.782 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.571 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 1.1 pt20 -100.99 109.08 20.95 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.756 0.788 . . . . 0.0 108.954 -179.904 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.81 150.26 52.07 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.079 -1.013 . . . . 0.0 110.406 179.978 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.92 139.38 53.88 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.373 -0.829 . . . . 0.0 110.661 -179.054 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.62 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.3 115.02 26.87 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 178.114 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -105.92 15.44 7.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.013 -1.055 . . . . 0.0 110.605 -178.889 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.594 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.6 -176.33 0.09 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.831 -1.168 . . . . 0.0 110.147 179.759 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.55 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.2 t -70.13 97.32 1.18 Allowed 'General case' 0 N--CA 1.487 1.419 0 CA-C-O 121.791 0.805 . . . . 0.0 109.949 -179.553 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.2 28.35 37.18 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.158 -1.02 . . . . 0.0 111.349 178.957 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.594 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 2.0 t -115.61 106.46 20.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 120.625 -1.515 . . . . 0.0 107.193 178.778 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.62 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.3 tp -116.4 104.75 11.77 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.428 -1.42 . . . . 0.0 109.847 -177.612 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.524 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -97.96 109.24 22.03 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 120.763 -1.211 . . . . 0.0 107.847 178.682 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -104.17 170.0 8.16 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.933 -1.104 . . . . 0.0 110.151 -178.863 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.51 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 36.9 t30 -108.24 134.67 20.1 Favored Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.346 -0.846 . . . . 0.0 109.631 -179.376 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.583 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.1 Cg_endo -74.5 25.27 0.36 Allowed 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 122.259 1.972 . . . . 0.0 111.608 -179.962 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.51 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -120.12 2.54 10.92 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.473 -1.392 . . . . 0.0 109.307 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.526 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 5.7 m-20 -137.09 18.67 2.99 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 179.744 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -81.13 88.52 5.99 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.617 -0.833 . . . . 0.0 110.62 -178.702 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -109.43 -166.22 1.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 178.66 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.469 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.77 136.02 0.09 Allowed 'General case' 0 N--CA 1.485 1.316 0 O-C-N 120.708 -1.245 . . . . 0.0 111.07 -179.215 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.587 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.84 155.92 5.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.421 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.566 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.73 141.34 31.66 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.87 -1.144 . . . . 0.0 109.94 -179.737 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.667 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -61.76 106.18 0.65 Allowed 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 122.471 1.129 . . . . 0.0 109.379 178.331 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.535 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.2 p-10 -59.46 -140.06 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.043 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.947 179.895 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.54 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.37 -50.42 59.58 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.488 -0.758 . . . . 0.0 110.752 -178.756 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -103.65 -33.35 9.0 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 106.16 -1.792 . . . . 0.0 106.16 178.518 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.667 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 106.4 66.3 0.65 Allowed Glycine 0 C--N 1.298 -1.545 0 CA-C-N 114.897 -1.047 . . . . 0.0 110.514 177.993 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.613 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 20.0 m -103.68 125.43 50.17 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 178.657 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.587 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -135.9 109.27 7.86 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.349 -179.379 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.7 m -126.21 122.16 34.82 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.366 -0.834 . . . . 0.0 109.674 -179.717 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.453 HG21 HG12 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -143.91 141.8 30.45 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.634 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.3 p -98.55 131.63 44.62 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.192 -0.942 . . . . 0.0 109.493 -179.8 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.566 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -131.49 178.46 6.71 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.487 -0.758 . . . . 0.0 109.299 -179.387 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.5 p -102.22 123.52 46.2 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.898 -1.126 . . . . 0.0 109.739 -179.416 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.53 ' CG2' HD12 ' A' ' 13' ' ' LEU . 15.5 m -128.59 142.32 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 120.934 -1.104 . . . . 0.0 110.062 -179.389 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.595 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.5 ptt180 -148.4 -176.76 5.43 Favored 'General case' 0 N--CA 1.484 1.248 0 O-C-N 120.521 -1.362 . . . . 0.0 110.91 179.669 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.557 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.1 OUTLIER -60.56 -102.33 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.189 -179.109 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.467 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -60.09 138.12 57.95 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.443 -1.411 . . . . 0.0 107.979 179.773 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.531 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 2.4 p90 -161.72 147.33 13.57 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 118.555 -1.258 . . . . 0.0 110.033 -178.377 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.488 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 1.8 mp0 -37.68 120.44 0.82 Allowed 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 121.504 0.669 . . . . 0.0 110.516 -178.674 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.524 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -90.54 49.49 3.17 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.599 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.583 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.9 m-30 -38.07 114.45 0.36 Allowed 'General case' 0 N--CA 1.511 2.582 0 O-C-N 121.194 -1.18 . . . . 0.0 110.545 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.531 HD11 ' CD1' ' A' ' 83' ' ' TRP . 8.0 tp -87.62 127.01 35.28 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.843 -1.161 . . . . 0.0 109.546 179.78 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.579 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 25.6 t80 -64.36 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.872 -1.142 . . . . 0.0 109.993 179.667 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.8 t70 -159.46 19.01 0.18 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.047 -1.033 . . . . 0.0 109.72 179.893 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.89 -26.34 6.1 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.747 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 35.2 p -96.45 163.32 13.1 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 121.037 -1.273 . . . . 0.0 110.407 -179.414 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.464 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.4 136.28 46.42 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.913 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.531 ' CD1' HD11 ' A' ' 77' ' ' LEU . 4.9 t90 -82.42 -18.56 41.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.781 -1.199 . . . . 0.0 110.318 -178.757 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.83 173.36 17.85 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 -179.587 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.79 109.3 1.68 Allowed 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 179.203 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.481 HG22 ' HB1' ' A' ' 46' ' ' ALA . 50.4 t -80.06 105.23 9.37 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 121.43 -0.794 . . . . 0.0 109.349 -178.782 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.467 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.9 OUTLIER -66.14 109.69 2.7 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.661 -0.649 . . . . 0.0 109.965 -179.529 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.557 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 3.0 t -62.09 -4.41 1.67 Allowed 'General case' 0 N--CA 1.501 2.107 0 C-N-CA 118.165 -1.414 . . . . 0.0 110.162 179.348 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.0 p -90.08 3.54 53.0 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.627 -1.296 . . . . 0.0 109.306 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.466 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -116.32 -49.88 2.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.298 -0.876 . . . . 0.0 109.127 -179.899 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.9 179.37 4.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.429 -0.795 . . . . 0.0 109.46 179.969 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.42 113.6 26.85 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.286 -0.884 . . . . 0.0 108.725 179.737 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.472 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -97.16 121.41 39.02 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.929 -1.107 . . . . 0.0 109.542 -178.922 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.54 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.43 148.58 26.27 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 122.44 1.114 . . . . 0.0 111.452 -179.249 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.527 ' CG1' HG11 ' A' ' 7' ' ' VAL . 28.8 t -104.95 109.5 27.86 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.449 -1.686 . . . . 0.0 106.449 177.249 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.438 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.8 -169.53 16.77 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 118.305 -1.902 . . . . 0.0 111.691 -177.366 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.471 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -120.77 177.13 5.2 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -178.958 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.594 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 7.8 t 177.81 159.15 0.45 Allowed 'General case' 0 C--N 1.292 -1.933 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 179.917 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.548 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -103.44 -158.21 0.65 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.962 -1.086 . . . . 0.0 109.266 -179.621 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.438 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.34 35.69 4.42 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.792 -1.192 . . . . 0.0 109.167 -179.973 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.75 -32.4 6.65 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.323 -0.861 . . . . 0.0 109.814 -179.677 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 165.86 -36.58 0.26 Allowed Glycine 0 N--CA 1.481 1.693 0 N-CA-C 107.857 -2.097 . . . . 0.0 107.857 -179.744 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.95 -177.35 5.03 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.576 -0.955 . . . . 0.0 109.992 179.359 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.13 -161.24 20.28 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 108.074 -2.01 . . . . 0.0 108.074 -179.411 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.479 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.4 Cg_exo -47.01 176.43 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.66 0 CA-C-N 118.956 1.378 . . . . 0.0 110.061 179.297 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -95.28 178.62 5.46 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.029 -1.045 . . . . 0.0 110.725 -178.58 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.438 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.23 170.34 13.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -107.32 133.22 52.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.348 -1.089 . . . . 0.0 109.187 -179.273 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.54 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.65 124.37 26.59 Favored 'General case' 0 C--N 1.29 -2.013 0 O-C-N 121.508 -0.745 . . . . 0.0 109.704 179.709 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.563 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.7 pt -97.95 171.0 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.283 -0.886 . . . . 0.0 108.91 179.816 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.491 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 24.3 m -139.15 156.74 46.91 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.054 -1.029 . . . . 0.0 109.872 -179.794 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.563 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 45.2 m-85 -129.15 77.33 1.78 Allowed 'General case' 0 N--CA 1.486 1.352 0 O-C-N 121.226 -0.921 . . . . 0.0 109.465 -179.669 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.402 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 17.4 p30 . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 118.018 -0.991 . . . . 0.0 109.458 -179.991 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.594 ' C21' ' CB ' ' A' ' 98' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.81 155.2 60.57 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.219 -0.926 . . . . 0.0 109.491 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.529 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.8 Cg_exo -59.49 158.88 25.57 Favored 'Trans proline' 0 C--N 1.31 -1.491 0 C-N-CA 122.246 1.964 . . . . 0.0 110.549 179.971 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.538 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.31 -169.74 0.15 Allowed 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 179.318 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.538 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.47 130.5 2.92 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.8 -1.187 . . . . 0.0 110.768 -179.051 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.541 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.7 t -110.87 108.9 18.85 Favored 'General case' 0 C--N 1.297 -1.7 0 CA-C-O 123.109 1.433 . . . . 0.0 109.066 179.357 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.503 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 2.6 t -118.28 139.72 44.44 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.699 0 CA-C-N 114.223 -1.353 . . . . 0.0 110.121 -179.741 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.484 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -179.07 150.88 0.64 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.239 -0.913 . . . . 0.0 108.764 -179.685 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.484 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.7 Cg_endo -77.47 151.72 92.77 Favored 'Cis proline' 0 C--N 1.313 -1.314 0 C-N-CA 123.555 -1.435 . . . . 0.0 109.332 -0.838 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.487 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 59.2 p -92.49 -23.29 19.16 Favored 'General case' 0 C--N 1.291 -1.968 0 O-C-N 121.567 -0.708 . . . . 0.0 109.664 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.464 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 23.9 p -133.26 159.14 41.09 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.197 -0.939 . . . . 0.0 110.124 -179.493 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.79 37.1 23.83 Favored Glycine 0 N--CA 1.497 2.706 0 N-CA-C 108.917 -1.673 . . . . 0.0 108.917 -179.859 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.601 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 39.0 mt -93.34 -44.57 8.23 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.162 1.458 . . . . 0.0 110.44 -178.54 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.456 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.8 OUTLIER 64.3 146.8 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.273 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.17 -179.829 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.531 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 12.7 p-10 -51.51 104.92 0.09 Allowed 'General case' 0 C--N 1.305 -1.353 0 CA-C-O 121.675 0.75 . . . . 0.0 111.04 -179.072 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.81 7.47 6.68 Favored Glycine 0 N--CA 1.484 1.848 0 C-N-CA 119.13 -1.509 . . . . 0.0 113.296 177.52 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.601 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.2 t -107.13 -177.03 3.24 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 121.444 2.622 . . . . 0.0 110.133 179.605 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.544 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 25.4 t -126.26 135.75 62.86 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.452 0 CA-C-N 114.249 -1.341 . . . . 0.0 111.073 -178.717 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.595 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 10.4 m -110.56 156.53 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.734 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.503 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.6 tttt -109.15 108.88 19.71 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.095 -1.003 . . . . 0.0 108.968 179.84 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.504 HG13 ' CG2' ' A' ' 34' ' ' VAL . 2.1 p -103.75 141.13 20.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.668 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.535 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -139.24 160.6 39.44 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 118.539 -1.265 . . . . 0.0 110.2 179.901 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.58 143.49 14.64 Favored Glycine 0 C--N 1.295 -1.731 0 N-CA-C 107.89 -2.084 . . . . 0.0 107.89 179.448 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.51 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -145.45 126.22 14.35 Favored 'General case' 0 C--N 1.295 -1.765 0 O-C-N 120.783 -1.422 . . . . 0.0 108.977 179.276 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.529 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.2 26.52 25.74 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 119.319 -1.419 . . . . 0.0 109.737 -179.744 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.546 ' HB2' ' HB1' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -89.43 169.78 11.09 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.81 -1.406 . . . . 0.0 108.392 179.861 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.557 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.95 100.98 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.039 -1.038 . . . . 0.0 110.076 -179.526 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.69 78.56 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.867 -179.529 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.41 33.9 0.3 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 179.778 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.569 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 17.2 p -138.6 105.03 5.28 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.259 -1.141 . . . . 0.0 111.146 -179.43 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.36 110.6 0.42 Allowed 'General case' 0 N--CA 1.497 1.905 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.701 178.169 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.569 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 35.5 m-85 -105.91 157.31 17.58 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.154 -0.966 . . . . 0.0 108.923 179.718 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.467 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -102.31 162.16 13.14 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.935 -1.103 . . . . 0.0 108.132 179.035 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.631 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.9 p -141.8 118.89 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.196 -0.94 . . . . 0.0 109.559 -178.186 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -166.41 -179.08 39.52 Favored Glycine 0 N--CA 1.493 2.481 0 C-N-CA 118.386 -1.864 . . . . 0.0 111.647 -179.693 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.553 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -101.38 109.01 20.77 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 179.978 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.448 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.51 148.76 52.35 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 121.164 -0.96 . . . . 0.0 109.959 179.925 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.65 138.66 54.5 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.409 -0.807 . . . . 0.0 110.656 -179.146 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.625 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.21 114.78 26.61 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 178.154 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.445 HG21 ' HB ' ' A' ' 44' ' ' VAL . 17.6 m -104.8 14.86 6.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.997 -1.065 . . . . 0.0 110.537 -178.789 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.589 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.87 -175.19 0.08 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.968 -1.083 . . . . 0.0 109.979 179.625 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 71.4 p -72.72 98.03 2.3 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.474 -0.766 . . . . 0.0 109.519 -179.704 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.57 27.65 31.92 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 120.225 -0.988 . . . . 0.0 111.413 178.943 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.589 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.25 106.18 19.59 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.653 -1.498 . . . . 0.0 107.258 178.942 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.625 HD12 ' CD1' ' A' ' 39' ' ' TRP . 12.9 tp -117.26 104.59 11.32 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.504 -1.373 . . . . 0.0 109.831 -177.771 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.531 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.7 109.3 22.08 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.641 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.17 167.11 10.13 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.941 -1.099 . . . . 0.0 110.685 -178.588 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.484 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 10.8 t-20 -115.07 129.5 25.01 Favored Pre-proline 0 N--CA 1.498 1.939 0 O-C-N 121.606 -0.684 . . . . 0.0 109.498 -179.334 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.581 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -71.8 22.38 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.081 0 C-N-CA 122.052 1.835 . . . . 0.0 111.852 179.437 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -99.04 -5.9 29.49 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.404 -1.435 . . . . 0.0 109.15 179.61 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.551 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 1.6 m-20 -136.4 11.44 3.24 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.861 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -67.47 86.76 0.19 Allowed 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.48 -0.763 . . . . 0.0 110.649 -178.715 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.631 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -107.89 -165.97 1.1 Allowed 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 178.576 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.476 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.73 135.89 0.09 Allowed 'General case' 0 C--N 1.306 -1.305 0 O-C-N 120.642 -1.286 . . . . 0.0 111.147 -179.334 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.587 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -151.82 156.53 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 178.168 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.38 142.58 29.83 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.773 -1.205 . . . . 0.0 110.082 -179.676 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.69 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -62.36 107.08 0.85 Allowed 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 122.446 1.117 . . . . 0.0 109.403 178.079 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.524 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 17.2 p-10 -61.14 -138.93 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.026 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.986 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.77 -51.19 52.87 Favored 'General case' 0 N--CA 1.5 2.075 0 O-C-N 121.379 -0.826 . . . . 0.0 110.845 -178.536 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -103.79 -33.29 8.96 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.167 -1.79 . . . . 0.0 106.167 178.488 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.69 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.95 63.88 0.55 Allowed Glycine 0 C--N 1.298 -1.58 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 178.102 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 43.2 m -102.38 126.96 49.56 Favored 'General case' 0 C--N 1.31 -1.148 0 O-C-N 121.479 -1.012 . . . . 0.0 108.731 178.732 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.587 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.28 109.04 7.52 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 119.411 -0.915 . . . . 0.0 109.53 -179.387 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.458 ' OG ' ' HB2' ' A' ' 22' ' ' ALA . 1.5 m -123.81 121.44 35.41 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 121.242 -0.911 . . . . 0.0 109.614 -179.768 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.58 146.54 31.42 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.558 -0.714 . . . . 0.0 109.305 179.854 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.5 p -98.83 141.15 31.98 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.351 -0.843 . . . . 0.0 109.472 -179.909 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.544 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -140.83 170.33 15.95 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.405 -0.809 . . . . 0.0 109.304 -179.206 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.523 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.5 p -101.87 124.94 48.34 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 120.878 -1.139 . . . . 0.0 110.157 -179.099 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.551 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 11.8 m -128.54 139.34 52.15 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 120.996 -1.065 . . . . 0.0 110.343 -179.601 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.531 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 56.3 mtt180 -127.11 -168.84 1.94 Allowed 'General case' 0 N--CA 1.483 1.222 0 O-C-N 120.576 -1.327 . . . . 0.0 111.156 179.673 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.567 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 1.8 mtt180 -79.08 -76.02 0.22 Allowed 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 179.001 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -73.66 135.52 43.75 Favored 'General case' 0 N--CA 1.486 1.349 0 N-CA-C 106.452 -1.684 . . . . 0.0 106.452 177.774 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.59 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -156.79 139.13 14.76 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 117.637 -1.625 . . . . 0.0 110.925 -177.331 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.9 mm-40 -37.19 118.93 0.65 Allowed 'General case' 0 N--CA 1.489 1.513 0 CA-C-O 121.408 0.623 . . . . 0.0 110.09 -178.943 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -89.78 50.13 3.43 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.175 -179.242 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.581 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-30 -38.69 113.88 0.34 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.136 -1.214 . . . . 0.0 110.073 179.514 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.537 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.0 tp -85.92 126.66 34.25 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 120.981 -1.074 . . . . 0.0 109.526 -179.885 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.577 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 29.4 t80 -63.72 58.54 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.026 0 O-C-N 120.91 -1.119 . . . . 0.0 110.142 179.608 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.59 19.5 0.14 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.036 -1.04 . . . . 0.0 109.748 179.84 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.78 -27.03 5.55 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 110.111 -1.195 . . . . 0.0 110.111 179.842 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.24 161.82 13.94 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 121.033 -1.274 . . . . 0.0 110.335 -179.499 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.464 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -107.67 136.85 46.73 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.917 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.469 ' HB2' HD12 ' A' ' 77' ' ' LEU . 3.5 t90 -82.21 -19.07 40.52 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.755 -1.216 . . . . 0.0 110.311 -178.759 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.93 173.93 19.01 Favored Glycine 0 N--CA 1.486 1.969 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.581 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.65 109.65 1.47 Allowed 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 179.202 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.59 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 40.5 t -81.92 105.12 11.43 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 O-C-N 121.354 -0.841 . . . . 0.0 108.916 -179.092 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.528 ' CB ' HG21 ' A' ' 90' ' ' THR . 0.1 OUTLIER -65.45 110.69 2.76 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.45 -0.781 . . . . 0.0 110.006 -179.1 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.565 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.6 t -64.19 -5.28 4.63 Favored 'General case' 0 N--CA 1.5 2.035 0 C-N-CA 118.452 -1.299 . . . . 0.0 109.791 179.38 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.1 p -86.88 0.6 54.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.742 -1.224 . . . . 0.0 108.961 179.427 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.528 HG21 ' CB ' ' A' ' 87' ' ' ASP . 2.5 p -114.88 -50.96 2.75 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.292 -0.88 . . . . 0.0 109.02 179.825 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -102.84 -178.99 3.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.566 -0.709 . . . . 0.0 109.394 179.84 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.5 115.32 30.05 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.312 -0.867 . . . . 0.0 109.023 179.923 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.492 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.7 m -97.11 121.91 39.52 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.998 -1.064 . . . . 0.0 109.396 -179.353 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.562 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.92 144.93 29.93 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 122.397 1.094 . . . . 0.0 111.199 -179.365 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 96.4 t -102.49 110.16 28.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 177.701 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.438 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.3 -169.91 16.92 Favored Glycine 0 N--CA 1.486 2.006 0 C-N-CA 118.071 -2.014 . . . . 0.0 111.833 -177.536 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.467 HD13 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -112.91 179.88 3.84 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -179.116 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.577 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.4 p -178.51 167.33 1.82 Allowed 'General case' 0 C--N 1.296 -1.74 0 O-C-N 121.456 -0.777 . . . . 0.0 109.58 -179.301 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.502 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -120.02 -160.07 0.81 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.013 -1.054 . . . . 0.0 109.023 -179.962 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.79 36.42 4.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.76 -1.212 . . . . 0.0 109.184 179.969 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.73 -33.19 5.58 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.344 -0.847 . . . . 0.0 110.053 -179.705 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 166.18 -36.38 0.25 Allowed Glycine 0 N--CA 1.482 1.706 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 -179.712 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.19 -177.46 5.4 Favored 'General case' 0 C--N 1.308 -1.219 0 O-C-N 121.518 -0.989 . . . . 0.0 109.789 179.26 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.61 -162.88 19.22 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 108.27 -1.932 . . . . 0.0 108.27 -179.442 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.4 Cg_exo -46.82 176.62 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.653 0 CA-C-N 118.835 1.317 . . . . 0.0 110.16 179.305 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -91.53 -176.13 4.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.142 -0.974 . . . . 0.0 110.502 -178.752 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.438 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.9 167.24 14.55 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.78 130.92 52.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.428 -1.042 . . . . 0.0 109.186 -179.403 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.562 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.42 120.76 20.43 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.679 -0.638 . . . . 0.0 109.744 179.751 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.521 HD13 ' CE2' ' A' ' 112' ' ' PHE . 1.4 pt -98.12 167.28 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.279 -0.888 . . . . 0.0 109.201 179.89 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.464 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -133.14 159.28 40.59 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.314 -0.866 . . . . 0.0 109.412 -179.926 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.567 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 49.4 m-85 -134.3 119.27 18.5 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.117 -0.989 . . . . 0.0 109.563 -179.753 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.441 ' OD1' ' OXT' ' A' ' 113' ' ' ASN . 10.2 p30 . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 118.057 -0.973 . . . . 0.0 109.41 -179.969 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.588 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.6 0 CA-C-O 121.27 0.557 . . . . 0.0 109.515 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -89.4 161.74 38.92 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.245 -0.91 . . . . 0.0 109.435 179.98 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.524 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 2.4 Cg_endo -61.39 155.75 50.44 Favored 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.114 1.876 . . . . 0.0 110.601 179.937 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -152.89 159.46 43.0 Favored 'General case' 0 C--N 1.293 -1.868 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 -179.526 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -145.19 124.99 13.37 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 122.584 1.183 . . . . 0.0 110.115 -179.749 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.545 ' CG2' ' O ' ' A' ' 6' ' ' THR . 5.7 t -115.8 109.2 17.33 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 123.122 1.439 . . . . 0.0 109.607 -179.98 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.526 HG12 ' CG1' ' A' ' 95' ' ' VAL . 3.1 t -114.95 139.84 39.15 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.677 0 CA-C-N 114.234 -1.348 . . . . 0.0 109.853 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.502 HG22 ' N ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.65 149.12 2.35 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.272 -0.893 . . . . 0.0 108.695 -179.666 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.502 ' N ' HG22 ' A' ' 8' ' ' THR . 3.0 Cg_endo -75.26 152.35 97.69 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 123.491 -1.462 . . . . 0.0 109.552 -0.846 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.468 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 2.4 m -88.46 -27.36 21.57 Favored 'General case' 0 C--N 1.293 -1.863 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.62 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.529 ' CB ' ' HB3' ' A' ' 111' ' ' SER . 1.9 p -136.39 166.77 22.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.51 -0.744 . . . . 0.0 109.347 179.764 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.08 37.36 32.85 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 108.512 -1.835 . . . . 0.0 108.512 -179.626 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.601 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 41.0 mt -92.98 -42.65 9.33 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-O 123.243 1.497 . . . . 0.0 110.466 -178.352 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.67 144.08 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.243 0 CA-C-N 113.392 -1.731 . . . . 0.0 109.877 -179.669 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 13.0 p-10 -50.94 105.65 0.11 Allowed 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.457 0.646 . . . . 0.0 111.589 -178.601 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.71 14.08 8.27 Favored Glycine 0 N--CA 1.485 1.927 0 C-N-CA 119.425 -1.369 . . . . 0.0 112.995 177.35 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.601 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.9 t -105.76 -172.43 2.09 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 121.239 2.52 . . . . 0.0 109.86 179.23 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 18.1 t -128.41 139.18 52.6 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.345 0 CA-C-N 114.742 -1.117 . . . . 0.0 111.022 -178.81 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.538 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 33.2 m -114.49 154.91 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.876 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.483 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.05 109.55 21.45 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.261 -0.899 . . . . 0.0 109.19 -179.954 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.53 HG11 ' CG2' ' A' ' 34' ' ' VAL . 2.0 p -102.26 140.06 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.511 -0.743 . . . . 0.0 109.059 179.95 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.557 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -131.44 158.16 41.56 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.012 -1.055 . . . . 0.0 109.335 179.458 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.59 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.73 108.76 0.57 Allowed Glycine 0 N--CA 1.482 1.724 0 N-CA-C 108.806 -1.718 . . . . 0.0 108.806 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.597 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -115.78 139.75 49.88 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-N 119.268 1.534 . . . . 0.0 110.512 -179.317 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.524 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.47 28.84 31.74 Favored Glycine 0 N--CA 1.491 2.354 0 C-N-CA 119.13 -1.51 . . . . 0.0 109.971 179.535 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.6 mt -92.19 175.28 6.91 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.977 -1.308 . . . . 0.0 108.613 -179.875 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.11 97.03 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.287 0 O-C-N 121.014 -1.054 . . . . 0.0 109.661 -179.811 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 76.69 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.384 -178.988 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.84 33.82 0.32 Allowed Glycine 0 N--CA 1.486 2.002 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 179.451 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.613 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -147.0 114.53 6.35 Favored 'General case' 0 C--N 1.308 -1.227 0 O-C-N 120.843 -1.387 . . . . 0.0 111.084 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.532 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -45.18 127.11 6.69 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.788 178.561 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.613 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 10.2 m-85 -117.75 149.34 40.94 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.484 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.474 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -101.01 152.64 20.34 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.867 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.64 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.5 p -137.19 118.55 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.958 -1.089 . . . . 0.0 109.767 -177.759 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.34 -178.7 39.22 Favored Glycine 0 N--CA 1.495 2.607 0 C-N-CA 118.341 -1.885 . . . . 0.0 111.863 -179.733 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.561 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -100.35 109.36 21.54 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.928 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.47 149.54 52.09 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.146 -0.971 . . . . 0.0 109.839 179.84 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.24 138.49 54.4 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.234 -0.916 . . . . 0.0 110.736 -179.039 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.622 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.17 114.97 26.82 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 178.02 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.2 m -105.28 14.91 7.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 120.997 -1.064 . . . . 0.0 110.583 -178.794 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.68 -175.0 0.08 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.925 -1.11 . . . . 0.0 110.014 179.704 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -72.64 97.64 2.2 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.448 -0.782 . . . . 0.0 109.702 -179.753 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.62 28.3 29.97 Favored Glycine 0 N--CA 1.494 2.544 0 C-N-CA 120.211 -0.995 . . . . 0.0 111.341 179.005 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.591 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.43 106.11 19.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 O-C-N 120.499 -1.589 . . . . 0.0 107.207 178.854 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.622 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.1 tp -116.59 104.69 11.65 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.568 -1.332 . . . . 0.0 109.866 -177.66 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.553 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.15 109.3 22.08 Favored 'General case' 0 N--CA 1.485 1.298 0 O-C-N 120.856 -1.152 . . . . 0.0 108.06 178.633 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.79 163.36 13.18 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.985 -1.072 . . . . 0.0 110.182 -178.908 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.54 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 9.9 t-20 -108.95 135.76 20.11 Favored Pre-proline 0 N--CA 1.499 2.002 0 O-C-N 121.281 -0.887 . . . . 0.0 109.944 -179.136 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.576 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.3 Cg_endo -74.72 23.96 0.38 Allowed 'Trans proline' 0 C--N 1.319 -1.017 0 C-N-CA 122.417 2.078 . . . . 0.0 112.069 -179.992 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.54 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -114.44 3.28 14.91 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.323 -1.486 . . . . 0.0 109.198 179.632 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.505 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.67 14.77 3.15 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 179.154 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -78.7 87.77 4.6 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.039 -0.665 . . . . 0.0 110.871 -178.558 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.64 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -104.98 -167.93 1.41 Allowed 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.057 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.47 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.88 135.77 0.09 Allowed 'General case' 0 C--N 1.304 -1.404 0 O-C-N 120.555 -1.34 . . . . 0.0 111.38 -179.192 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.591 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -154.06 156.91 4.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 178.034 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.532 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.62 145.33 26.39 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.665 -1.272 . . . . 0.0 109.831 -179.612 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.668 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.05 107.09 1.78 Allowed 'General case' 0 C--N 1.298 -1.63 0 CA-C-O 122.433 1.111 . . . . 0.0 109.472 178.936 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.531 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.4 p-10 -59.62 -139.43 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.037 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.728 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.9 -50.11 64.58 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.374 -0.829 . . . . 0.0 110.361 -178.822 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -102.56 -35.54 8.7 Favored 'General case' 0 C--N 1.286 -2.186 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 178.488 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.668 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.91 67.31 0.62 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.541 -1.023 . . . . 0.0 110.541 178.166 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.59 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 38.4 m -101.6 127.86 48.13 Favored 'General case' 0 N--CA 1.485 1.325 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 178.688 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.591 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.03 108.82 7.04 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.503 -179.37 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.459 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 18.4 p -126.11 120.56 30.49 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.348 -0.845 . . . . 0.0 109.565 -179.888 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.443 HG22 HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.37 146.25 31.5 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.669 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.2 p -98.61 131.25 44.96 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.162 -0.961 . . . . 0.0 109.588 -179.663 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.528 ' CD1' HG23 ' A' ' 19' ' ' VAL . 0.0 OUTLIER -128.92 166.22 19.55 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.403 -0.811 . . . . 0.0 109.341 -179.514 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.556 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -97.65 125.1 42.23 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.986 -1.072 . . . . 0.0 109.373 -179.999 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.533 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.2 m -137.26 143.48 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.047 -1.033 . . . . 0.0 109.785 -179.149 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -146.44 -177.48 5.65 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.531 -1.355 . . . . 0.0 111.249 -179.927 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.539 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.05 -100.2 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -179.655 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.21 140.13 50.6 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 120.71 -1.244 . . . . 0.0 107.888 179.309 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.569 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -161.91 136.65 7.06 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 118.513 -1.275 . . . . 0.0 109.918 -178.015 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.476 ' C ' ' O ' ' A' ' 73' ' ' PHE . 6.4 mt-10 -34.78 121.34 0.52 Allowed 'General case' 0 N--CA 1.489 1.485 0 CA-C-O 121.434 0.635 . . . . 0.0 110.423 -178.61 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.553 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -94.75 51.54 2.0 Allowed Glycine 0 N--CA 1.495 2.593 0 C-N-CA 120.563 -0.827 . . . . 0.0 111.125 -179.22 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.576 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.23 115.63 0.51 Allowed 'General case' 0 N--CA 1.506 2.371 0 O-C-N 121.154 -1.204 . . . . 0.0 110.121 179.453 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.54 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.9 tp -86.89 126.56 34.75 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 120.831 -1.168 . . . . 0.0 109.575 -179.741 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.578 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.5 t80 -64.2 58.3 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.913 -1.117 . . . . 0.0 110.065 179.513 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.54 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.1 t70 -159.53 19.24 0.17 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.982 -1.074 . . . . 0.0 109.709 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.07 -27.19 5.64 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.822 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 p -95.99 161.6 13.92 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 120.994 -1.298 . . . . 0.0 110.397 -179.393 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.463 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.75 137.53 44.61 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.673 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.46 ' HB2' HD11 ' A' ' 77' ' ' LEU . 2.3 t90 -82.08 -19.65 39.76 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.747 -1.221 . . . . 0.0 110.507 -178.648 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.15 176.36 19.05 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.709 -1.757 . . . . 0.0 108.709 -179.499 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.94 105.7 1.39 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.015 -1.285 . . . . 0.0 107.783 179.158 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.556 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.9 t -77.12 105.82 6.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 O-C-N 121.367 -0.833 . . . . 0.0 109.229 -178.903 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.7 OUTLIER -65.48 111.3 3.03 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.483 -0.761 . . . . 0.0 110.012 -179.445 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.539 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.05 -5.88 3.48 Favored 'General case' 0 N--CA 1.499 2.015 0 C-N-CA 118.273 -1.371 . . . . 0.0 109.8 179.486 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -86.89 -0.18 56.05 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.713 -1.242 . . . . 0.0 109.26 179.496 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.457 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.32 -50.33 2.87 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.34 -0.85 . . . . 0.0 109.006 179.886 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.69 -179.9 4.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.581 -0.699 . . . . 0.0 109.344 179.833 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.69 115.91 31.36 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.895 . . . . 0.0 109.003 179.981 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.521 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.86 120.77 37.81 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.826 -1.171 . . . . 0.0 109.368 -179.409 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.556 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.43 145.96 28.25 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 122.355 1.074 . . . . 0.0 111.117 -179.283 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.526 ' CG1' HG12 ' A' ' 7' ' ' VAL . 60.5 t -101.25 109.77 26.47 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.013 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 177.362 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.43 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -146.64 -171.32 15.83 Favored Glycine 0 N--CA 1.486 2.0 0 C-N-CA 118.212 -1.946 . . . . 0.0 111.619 -177.284 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.474 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -123.22 179.64 4.63 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -178.631 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.54 ' OG ' ' C21' ' A' ' 114' ' ' CHR . 0.8 OUTLIER -178.94 170.78 1.47 Allowed 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.482 -0.761 . . . . 0.0 109.513 -179.862 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.479 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -119.16 -156.34 0.65 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.102 -0.999 . . . . 0.0 109.036 -179.977 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.479 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -115.94 35.28 4.54 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.795 -1.191 . . . . 0.0 109.14 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -110.77 -33.2 6.61 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.352 -0.842 . . . . 0.0 109.776 -179.832 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.498 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 161.77 -34.88 0.37 Allowed Glycine 0 N--CA 1.484 1.845 0 N-CA-C 107.604 -2.198 . . . . 0.0 107.604 -179.754 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.09 -177.67 5.91 Favored 'General case' 0 C--N 1.307 -1.282 0 O-C-N 121.668 -0.901 . . . . 0.0 109.808 179.338 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.09 -161.81 21.25 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 -179.368 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.47 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.3 Cg_exo -45.37 172.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.69 0 CA-C-N 118.81 1.305 . . . . 0.0 110.094 179.303 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -92.49 -178.7 4.98 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.084 -1.01 . . . . 0.0 110.608 -178.659 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.43 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -115.08 164.53 12.09 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.88 133.12 48.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.411 -1.052 . . . . 0.0 109.28 -179.282 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.556 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.02 119.3 17.07 Favored 'General case' 0 C--N 1.289 -2.022 0 O-C-N 121.655 -0.653 . . . . 0.0 109.474 179.646 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.589 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.7 pt -98.14 172.07 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.175 -0.953 . . . . 0.0 109.101 179.944 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.529 ' HB3' ' CB ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -138.49 155.86 48.04 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.104 -0.997 . . . . 0.0 109.892 -179.695 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.589 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 87.0 m-85 -133.64 82.4 1.98 Allowed 'General case' 0 N--CA 1.485 1.303 0 O-C-N 121.325 -0.859 . . . . 0.0 109.613 -179.783 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 23.5 p30 . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.435 -179.978 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.587 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 121.307 0.575 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -110.24 166.13 11.36 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.89 . . . . 0.0 109.511 -179.986 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.53 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.9 Cg_exo -59.62 158.06 29.57 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.173 1.916 . . . . 0.0 110.513 -179.977 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.54 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.6 -169.77 0.15 Allowed 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 179.102 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.54 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -166.81 131.17 2.02 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.82 -1.175 . . . . 0.0 110.701 -179.099 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.547 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.3 t -112.91 108.7 17.74 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 123.106 1.431 . . . . 0.0 109.19 179.367 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.525 HG12 ' CG1' ' A' ' 95' ' ' VAL . 3.7 t -116.34 142.51 29.58 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.667 0 CA-C-N 114.347 -1.297 . . . . 0.0 110.203 -179.615 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.509 HG21 ' N ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -178.16 150.45 0.74 Allowed Pre-proline 0 N--CA 1.488 1.454 0 O-C-N 121.278 -0.888 . . . . 0.0 108.715 -179.737 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.509 ' N ' HG21 ' A' ' 8' ' ' THR . 1.9 Cg_endo -75.05 153.73 99.25 Favored 'Cis proline' 0 C--N 1.312 -1.362 0 C-N-CA 123.577 -1.426 . . . . 0.0 109.471 -0.644 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.511 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 3.3 m -91.4 -25.35 19.4 Favored 'General case' 0 C--N 1.292 -1.912 0 O-C-N 121.63 -0.669 . . . . 0.0 109.428 -179.94 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.5 ' HB3' ' CB ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -137.9 163.35 31.69 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.338 -0.851 . . . . 0.0 109.905 -179.619 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.72 37.14 27.25 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 108.773 -1.731 . . . . 0.0 108.773 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.598 ' CD1' ' CG1' ' A' ' 19' ' ' VAL . 44.2 mt -93.05 -44.22 8.5 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 123.249 1.5 . . . . 0.0 110.547 -178.533 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.46 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.48 145.75 0.03 OUTLIER 'General case' 0 C--N 1.262 -3.203 0 CA-C-N 113.473 -1.694 . . . . 0.0 109.999 -179.796 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.546 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.0 p-10 -51.93 105.1 0.1 Allowed 'General case' 0 C--N 1.303 -1.451 0 CA-C-O 121.49 0.662 . . . . 0.0 111.088 -179.05 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.95 6.66 6.96 Favored Glycine 0 N--CA 1.486 1.983 0 C-N-CA 119.18 -1.486 . . . . 0.0 113.194 177.518 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.595 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.6 t -105.14 -174.45 2.54 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 121.437 2.618 . . . . 0.0 109.922 179.709 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.542 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 21.6 t -127.02 135.94 62.2 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.579 -1.191 . . . . 0.0 110.955 -178.778 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.598 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 32.5 m -109.54 154.79 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 178.795 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -110.56 109.25 19.5 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.198 -0.939 . . . . 0.0 108.825 179.776 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.521 HG12 ' CG2' ' A' ' 34' ' ' VAL . 1.8 p -104.32 140.46 22.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.568 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -135.18 160.32 38.73 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 118.74 -1.184 . . . . 0.0 109.857 179.649 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.585 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.44 143.55 15.2 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 108.021 -2.032 . . . . 0.0 108.021 179.789 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.519 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.12 125.26 12.91 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 120.843 -1.386 . . . . 0.0 108.846 179.289 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.53 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.98 26.8 25.5 Favored Glycine 0 N--CA 1.488 2.124 0 C-N-CA 119.371 -1.395 . . . . 0.0 109.704 -179.698 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.559 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.5 mt -86.27 175.83 8.25 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.921 -1.341 . . . . 0.0 108.557 -179.813 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.554 ' CB ' ' CG2' ' A' ' 30' ' ' THR . 0.0 OUTLIER -45.44 96.9 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.028 -1.045 . . . . 0.0 109.556 -179.771 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.26 76.32 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.715 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.541 -178.989 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.32 33.93 0.3 Allowed Glycine 0 N--CA 1.484 1.876 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.304 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.554 ' CG2' ' CB ' ' A' ' 27' ' ' GLN . 1.2 t -148.64 114.97 5.87 Favored 'General case' 0 C--N 1.308 -1.21 0 O-C-N 120.774 -1.427 . . . . 0.0 111.333 179.955 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.559 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.13 130.05 3.65 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.798 178.376 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.553 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 7.7 m-85 -121.41 147.93 45.06 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.583 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.48 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.96 156.71 17.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.626 -1.296 . . . . 0.0 107.771 178.719 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.627 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.5 p -140.27 117.27 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.066 -1.021 . . . . 0.0 109.867 -177.789 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.29 -176.92 39.06 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.942 -179.739 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.6 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.4 pt20 -99.83 109.96 22.35 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 121.874 0.845 . . . . 0.0 109.02 -179.648 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -130.35 150.12 51.73 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.223 -0.923 . . . . 0.0 109.679 179.703 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.69 138.29 54.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.197 -0.94 . . . . 0.0 110.968 -178.945 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.627 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.38 115.0 26.83 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 177.982 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.458 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 19.8 m -105.77 14.72 7.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 120.993 -1.067 . . . . 0.0 110.646 -178.732 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.587 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.32 -174.71 0.09 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.04 -1.037 . . . . 0.0 110.011 179.614 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.84 97.03 1.73 Allowed 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.439 -0.788 . . . . 0.0 109.709 -179.77 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.28 27.8 32.3 Favored Glycine 0 N--CA 1.493 2.492 0 C-N-CA 120.149 -1.024 . . . . 0.0 111.481 178.849 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.587 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.32 106.45 20.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 O-C-N 120.688 -1.477 . . . . 0.0 107.252 178.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.627 HD13 ' CD1' ' A' ' 39' ' ' TRP . 11.5 tp -115.38 104.8 12.15 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.4 -1.437 . . . . 0.0 110.019 -177.715 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.534 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -97.68 109.71 22.41 Favored 'General case' 0 N--CA 1.486 1.372 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.801 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.51 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -109.08 168.34 9.44 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.059 -1.026 . . . . 0.0 110.365 -178.744 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.548 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 22.3 t-20 -118.09 135.08 23.32 Favored Pre-proline 0 N--CA 1.499 2.01 0 O-C-N 121.353 -0.842 . . . . 0.0 110.101 -179.438 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.577 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.5 Cg_endo -73.66 23.33 0.33 Allowed 'Trans proline' 0 CA--C 1.545 1.045 0 C-N-CA 122.223 1.949 . . . . 0.0 112.181 179.901 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.548 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -108.82 1.99 21.31 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.345 -1.472 . . . . 0.0 109.079 179.406 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.511 ' O ' ' CD2' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.11 17.41 2.27 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.643 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -81.06 90.37 6.0 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.524 -0.735 . . . . 0.0 110.891 -178.606 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.69 -166.87 1.19 Allowed 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 178.145 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.465 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.72 134.92 0.09 Allowed 'General case' 0 C--N 1.306 -1.311 0 O-C-N 120.524 -1.36 . . . . 0.0 111.666 -179.356 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.584 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.5 p -150.94 157.38 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 177.862 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.559 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.19 146.07 25.44 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.496 -1.377 . . . . 0.0 109.741 -179.648 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.677 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.09 108.55 3.15 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 122.302 1.048 . . . . 0.0 109.589 179.009 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.524 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.7 t70 -63.69 -139.03 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.999 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.663 179.938 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.546 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.92 -51.74 49.11 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.343 -0.848 . . . . 0.0 110.679 -178.672 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -102.58 -32.7 9.78 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 106.517 -1.66 . . . . 0.0 106.517 178.662 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.677 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 105.36 66.32 0.67 Allowed Glycine 0 C--N 1.297 -1.591 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.18 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.585 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 58.0 p -98.66 131.96 44.42 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 121.378 -1.072 . . . . 0.0 109.097 179.006 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.584 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -138.43 108.32 6.32 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 119.319 -0.953 . . . . 0.0 109.52 -179.642 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.439 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.6 m -124.67 119.13 28.1 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.094 -1.004 . . . . 0.0 109.701 -179.939 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.463 HG21 HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.33 144.16 29.6 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.448 -0.782 . . . . 0.0 109.363 179.853 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.8 p -99.12 141.51 31.8 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.316 -0.865 . . . . 0.0 109.191 179.838 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.561 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.83 167.94 20.94 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.449 -0.782 . . . . 0.0 109.551 -179.23 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.542 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.0 p -98.18 126.82 43.8 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.094 -1.004 . . . . 0.0 109.319 -179.761 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.484 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 15.4 m -134.44 140.53 45.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.879 -1.138 . . . . 0.0 110.091 -179.198 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.546 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 52.2 mtt180 -127.56 -165.52 1.49 Allowed 'General case' 0 N--CA 1.485 1.315 0 O-C-N 120.676 -1.265 . . . . 0.0 111.255 -179.821 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.569 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 1.0 OUTLIER -80.48 -79.64 0.15 Allowed 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.209 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.444 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -68.85 136.45 52.7 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 177.9 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.573 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.03 137.64 9.76 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 117.803 -1.559 . . . . 0.0 110.735 -177.325 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.507 ' HB3' ' CD1' ' A' ' 76' ' ' PHE . 8.0 mm-40 -33.72 119.2 0.37 Allowed 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 121.638 0.732 . . . . 0.0 110.58 -178.69 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.534 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -87.92 48.4 3.67 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.316 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.577 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 19.0 m-85 -39.21 113.92 0.36 Allowed 'General case' 0 N--CA 1.507 2.385 0 O-C-N 121.157 -1.202 . . . . 0.0 110.136 179.591 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -87.67 127.04 35.29 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.993 -1.067 . . . . 0.0 109.474 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.58 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.1 t80 -64.51 58.29 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.753 -1.217 . . . . 0.0 110.056 179.674 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.7 t70 -159.52 19.0 0.17 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.042 -1.036 . . . . 0.0 109.721 179.948 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.68 -26.56 5.8 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.84 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 72.4 p -95.15 160.56 14.5 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.021 -1.281 . . . . 0.0 110.417 -179.343 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 1.3 ptt180 -105.63 134.84 48.1 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.66 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.452 ' HB2' HD12 ' A' ' 77' ' ' LEU . 4.0 t90 -81.21 -20.01 42.03 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.823 -1.173 . . . . 0.0 110.234 -178.623 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.26 173.64 18.25 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 108.739 -1.745 . . . . 0.0 108.739 -179.572 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.67 111.45 2.09 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 179.251 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.554 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.7 t -83.1 103.91 11.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 O-C-N 121.35 -0.844 . . . . 0.0 108.798 -179.062 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.464 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.8 111.41 3.24 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.448 -0.783 . . . . 0.0 109.971 -179.094 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.545 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -63.96 -5.12 4.03 Favored 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 118.426 -1.31 . . . . 0.0 109.834 179.372 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.9 p -87.89 2.09 52.41 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.841 -1.162 . . . . 0.0 109.052 179.415 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.464 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -116.72 -51.23 2.59 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.329 -0.857 . . . . 0.0 108.939 -179.99 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.1 179.5 4.25 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.512 -0.742 . . . . 0.0 109.371 179.869 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.34 116.52 32.58 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.362 -0.836 . . . . 0.0 108.925 179.917 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.484 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.9 m -96.73 120.71 37.56 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.894 -1.129 . . . . 0.0 109.357 -179.41 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.567 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.67 145.56 28.92 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 122.373 1.083 . . . . 0.0 111.283 -179.12 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.525 ' CG1' HG12 ' A' ' 7' ' ' VAL . 62.6 t -101.71 109.81 26.92 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.037 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 177.537 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.417 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.85 -170.91 16.33 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 118.174 -1.965 . . . . 0.0 111.851 -177.467 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.48 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.6 178.98 4.61 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -178.859 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.553 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.7 OUTLIER -179.56 176.86 0.77 Allowed 'General case' 0 C--N 1.297 -1.704 0 O-C-N 121.564 -0.71 . . . . 0.0 109.562 179.999 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.459 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -124.32 -157.31 0.76 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.054 -1.029 . . . . 0.0 109.101 -179.896 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.459 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.77 36.17 4.41 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.76 -1.213 . . . . 0.0 109.2 -179.965 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.47 -32.67 6.62 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.312 -0.868 . . . . 0.0 109.8 -179.735 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 165.43 -35.92 0.26 Allowed Glycine 0 N--CA 1.481 1.698 0 N-CA-C 107.946 -2.061 . . . . 0.0 107.946 -179.765 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -166.99 -177.0 3.6 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 121.609 -0.936 . . . . 0.0 109.756 179.367 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.25 -161.36 17.96 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.27 -1.932 . . . . 0.0 108.27 -179.396 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.48 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.6 Cg_exo -46.6 176.5 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.664 0 CA-C-N 118.841 1.32 . . . . 0.0 110.203 179.287 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -93.85 -168.88 1.97 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.118 -0.989 . . . . 0.0 110.39 -178.927 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.417 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -123.88 163.47 17.51 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.736 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.461 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.14 129.67 49.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.409 -1.054 . . . . 0.0 109.123 -179.679 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.567 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.58 118.97 16.15 Favored 'General case' 0 C--N 1.288 -2.085 0 O-C-N 121.703 -0.623 . . . . 0.0 109.759 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.571 HD11 ' CE2' ' A' ' 112' ' ' PHE . 1.4 pt -98.07 168.0 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 121.249 -0.907 . . . . 0.0 109.065 179.803 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.5 ' CB ' ' HB3' ' A' ' 11' ' ' SER . 0.2 OUTLIER -132.28 156.89 45.74 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.281 -0.887 . . . . 0.0 109.666 -179.876 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.571 ' CE2' HD11 ' A' ' 110' ' ' ILE . 41.4 m-85 -131.72 117.35 18.51 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.272 -0.893 . . . . 0.0 109.357 -179.852 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.7 p30 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.496 179.931 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.594 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.466 -0.568 . . . . 1.0 109.466 . . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.16 149.0 50.59 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.309 -0.869 . . . . 1.0 109.569 179.922 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.533 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.4 Cg_exo -59.94 158.76 28.01 Favored 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.241 1.961 . . . . 1.0 110.606 179.969 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.49 -169.65 0.15 Allowed 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.092 -1.077 . . . . 1.0 108.092 179.233 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.545 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.99 133.81 2.89 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 120.735 -1.228 . . . . 1.0 110.961 -179.277 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.523 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.4 p -102.0 104.52 15.19 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 122.408 1.099 . . . . 1.0 110.088 -179.84 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.524 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 5.9 t -119.5 123.55 71.33 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.448 0 CA-C-N 115.521 -0.763 . . . . 1.0 110.516 179.822 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.486 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -170.95 150.02 2.9 Favored Pre-proline 0 N--CA 1.488 1.451 0 N-CA-C 108.086 -1.079 . . . . 1.0 108.086 -179.649 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.486 ' HA ' HG22 ' A' ' 8' ' ' THR . 5.0 Cg_endo -76.79 151.37 94.16 Favored 'Cis proline' 0 C--N 1.311 -1.434 0 C-N-CA 123.658 -1.393 . . . . 1.0 109.533 -0.526 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.482 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 95.2 p -95.4 -21.47 18.34 Favored 'General case' 0 C--N 1.293 -1.888 0 O-C-N 121.649 -0.657 . . . . 1.0 109.643 179.954 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.466 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.3 m -131.54 157.11 44.45 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.256 -0.903 . . . . 1.0 110.221 -179.583 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.39 37.11 25.04 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 108.794 -1.722 . . . . 1.0 108.794 -179.719 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.603 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 35.4 mt -92.1 -44.78 8.63 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 123.201 1.477 . . . . 1.0 110.542 -178.59 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.458 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.1 t 63.8 147.52 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.25 0 CA-C-N 113.562 -1.654 . . . . 1.0 110.045 -179.815 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.525 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.5 p-10 -51.65 105.16 0.1 Allowed 'General case' 0 C--N 1.303 -1.438 0 CA-C-O 121.665 0.745 . . . . 1.0 111.106 -178.997 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.31 7.39 7.02 Favored Glycine 0 N--CA 1.485 1.954 0 C-N-CA 119.319 -1.42 . . . . 1.0 113.318 177.323 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.603 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.9 t -106.42 -177.46 3.37 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 121.468 2.634 . . . . 1.0 110.325 179.654 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.551 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 21.9 t -128.3 139.69 51.22 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.374 0 CA-C-N 114.076 -1.42 . . . . 1.0 111.091 -178.717 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.492 ' CG1' HD11 ' A' ' 13' ' ' LEU . 15.7 m -117.19 154.68 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.35 -0.981 . . . . 1.0 108.35 178.739 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.524 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -104.1 108.79 20.32 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.139 -0.975 . . . . 1.0 109.304 -179.886 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.532 HG12 ' CD1' ' A' ' 67' ' ' LEU . 2.4 p -106.34 123.27 61.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 N-CA-C 108.299 -1.001 . . . . 1.0 108.299 179.571 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.531 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -117.67 167.21 11.55 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 120.681 -1.262 . . . . 1.0 109.22 -179.831 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.61 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.77 139.1 10.61 Favored Glycine 0 C--N 1.294 -1.779 0 N-CA-C 107.282 -2.327 . . . . 1.0 107.282 179.51 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.519 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -145.39 125.35 13.56 Favored 'General case' 0 C--N 1.293 -1.866 0 O-C-N 120.522 -1.575 . . . . 1.0 108.991 179.613 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.533 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.23 26.35 28.62 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 119.013 -1.565 . . . . 1.0 109.952 -179.798 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.551 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -86.5 174.34 9.02 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 120.885 -1.362 . . . . 1.0 108.29 179.743 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.554 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -47.41 99.28 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.412 0 O-C-N 120.855 -1.153 . . . . 1.0 109.743 -179.605 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.11 77.74 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.304 -0.862 . . . . 1.0 110.246 -179.271 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.9 34.47 0.3 Allowed Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.464 -1.454 . . . . 1.0 109.464 179.587 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.534 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 53.4 p -142.82 108.75 5.17 Favored 'General case' 0 C--N 1.308 -1.221 0 O-C-N 121.039 -1.271 . . . . 1.0 111.214 -179.416 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.559 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -49.92 109.92 0.34 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 109.393 -0.595 . . . . 1.0 109.393 177.807 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.583 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 4.7 m-30 -104.9 155.4 18.96 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.119 -0.988 . . . . 1.0 108.878 179.874 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.474 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.82 162.01 13.33 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.804 -1.185 . . . . 1.0 108.077 178.934 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.63 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.9 p -141.91 120.36 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.166 -0.959 . . . . 1.0 109.307 -178.217 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.456 ' HA2' ' HB2' ' A' ' 51' ' ' ASP . . . -171.88 -176.48 40.83 Favored Glycine 0 N--CA 1.495 2.571 0 C-N-CA 118.412 -1.851 . . . . 1.0 111.583 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.556 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -101.15 109.19 21.03 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 108.909 -0.774 . . . . 1.0 108.909 -179.908 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.0 m -130.14 149.06 52.02 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.277 -0.89 . . . . 1.0 109.682 179.585 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.54 138.72 54.51 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.236 -0.915 . . . . 1.0 110.793 -178.93 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.626 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.2 114.77 26.6 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 107.532 -1.284 . . . . 1.0 107.532 178.047 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 m -104.85 14.72 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.931 -1.106 . . . . 1.0 110.481 -178.793 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.588 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.1 -175.24 0.09 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.98 -1.075 . . . . 1.0 110.049 179.748 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.51 97.79 2.17 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.519 -0.738 . . . . 1.0 109.577 -179.75 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.46 27.75 31.94 Favored Glycine 0 N--CA 1.492 2.414 0 C-N-CA 120.214 -0.993 . . . . 1.0 111.399 178.94 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.588 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.22 106.48 20.18 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.558 -1.554 . . . . 1.0 107.357 178.81 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.626 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.5 tp -116.4 104.72 11.74 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.475 -1.391 . . . . 1.0 109.954 -177.629 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.536 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.65 109.53 22.27 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 107.812 -1.181 . . . . 1.0 107.812 178.871 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -108.05 166.74 10.5 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.869 -1.145 . . . . 1.0 110.727 -178.455 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.52 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 46.4 t30 -118.51 136.72 24.2 Favored Pre-proline 0 N--CA 1.498 1.971 0 C-N-CA 120.098 -0.641 . . . . 1.0 109.64 -179.497 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.582 ' HD3' ' CE1' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -74.03 26.41 0.33 Allowed 'Trans proline' 0 C--N 1.317 -1.111 0 C-N-CA 122.437 2.092 . . . . 1.0 112.01 -179.89 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.52 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -98.54 -9.55 24.78 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.319 -1.488 . . . . 1.0 109.164 179.735 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.541 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 0.8 OUTLIER -135.68 7.4 3.26 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.383 -0.823 . . . . 1.0 108.872 -179.81 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -60.75 84.1 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.427 -0.796 . . . . 1.0 110.898 -178.569 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.63 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.78 -167.02 1.17 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.852 -1.166 . . . . 1.0 107.852 178.33 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.486 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.7 t 179.1 135.25 0.09 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.569 -1.332 . . . . 1.0 111.43 -179.364 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.536 HG11 ' CB ' ' A' ' 63' ' ' ALA . 1.4 p -150.46 157.77 5.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 N-CA-C 107.537 -1.283 . . . . 1.0 107.537 177.914 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.559 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.63 142.1 30.63 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.734 -1.229 . . . . 1.0 110.051 -179.747 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.679 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.36 107.68 1.41 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 122.331 1.062 . . . . 1.0 109.38 178.524 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.537 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.6 p-10 -62.04 -138.81 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 115.612 -0.722 . . . . 1.0 110.861 -179.778 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.87 -51.82 37.5 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.344 -0.847 . . . . 1.0 110.737 -178.599 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -104.57 -32.91 8.72 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 106.261 -1.755 . . . . 1.0 106.261 178.508 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.679 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.57 69.88 0.67 Allowed Glycine 0 C--N 1.298 -1.574 0 N-CA-C 110.299 -1.12 . . . . 1.0 110.299 178.104 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.61 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 63.7 m -104.07 129.98 51.75 Favored 'General case' 0 N--CA 1.483 1.175 0 O-C-N 121.259 -1.142 . . . . 1.0 109.275 179.14 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.536 ' CB ' HG11 ' A' ' 55' ' ' VAL . . . -134.4 108.96 8.46 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.535 -0.866 . . . . 1.0 109.484 -179.638 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 97.2 p -116.21 117.02 28.87 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.117 -0.989 . . . . 1.0 109.492 -179.747 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.452 HG22 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.27 139.93 26.13 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.385 -0.822 . . . . 1.0 110.077 -179.84 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 27.2 p -99.61 135.26 41.29 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.822 -0.807 . . . . 1.0 108.822 179.432 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.541 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -136.22 168.52 19.24 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.292 -0.88 . . . . 1.0 110.057 -178.931 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.551 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.2 p -104.06 126.26 51.04 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.192 -0.942 . . . . 1.0 109.329 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.541 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 12.3 m -129.41 139.99 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 120.922 -1.111 . . . . 1.0 110.209 -179.26 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.525 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 52.4 mtt180 -125.67 -168.57 1.86 Allowed 'General case' 0 N--CA 1.484 1.23 0 O-C-N 120.676 -1.265 . . . . 1.0 111.304 179.823 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.562 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 40.0 mtt180 -78.5 -75.71 0.22 Allowed 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.2 -1.037 . . . . 1.0 108.2 179.284 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.438 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -72.67 137.06 45.79 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 120.14 -1.6 . . . . 1.0 106.812 178.107 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -157.66 135.51 10.73 Favored 'General case' 0 C--N 1.295 -1.784 0 C-N-CA 118.08 -1.448 . . . . 1.0 110.308 -177.903 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.581 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 9.5 mm-40 -34.78 121.62 0.52 Allowed 'General case' 0 N--CA 1.487 1.41 0 CA-C-O 121.582 0.706 . . . . 1.0 110.364 -178.259 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.536 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -87.76 47.94 3.64 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 110.986 -0.846 . . . . 1.0 110.986 -179.377 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.582 ' CE1' ' HD3' ' A' ' 49' ' ' PRO . 36.2 m-85 -39.76 112.95 0.3 Allowed 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.07 -1.253 . . . . 1.0 110.001 179.614 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.541 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -87.03 126.64 34.88 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.995 -1.066 . . . . 1.0 109.493 -179.912 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.3 t80 -63.99 58.34 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.735 -1.228 . . . . 1.0 110.315 179.674 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.26 19.15 0.15 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.01 -1.056 . . . . 1.0 109.765 179.854 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.31 -26.18 5.81 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.097 -1.201 . . . . 1.0 110.097 179.78 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -94.07 160.0 14.91 Favored 'General case' 0 N--CA 1.485 1.311 0 O-C-N 121.011 -1.288 . . . . 1.0 110.49 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.459 ' CG ' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -105.89 133.39 50.69 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 108.581 -0.896 . . . . 1.0 108.581 179.701 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.45 ' HB2' HD12 ' A' ' 77' ' ' LEU . 4.1 t90 -80.93 -20.28 42.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.809 -1.182 . . . . 1.0 110.256 -178.701 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.92 174.19 18.62 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.9 -1.68 . . . . 1.0 108.9 -179.59 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.06 110.04 1.69 Allowed 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.143 -1.21 . . . . 1.0 107.743 179.269 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.595 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 44.4 t -82.32 104.45 10.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.696 0 N-CA-C 108.715 -0.846 . . . . 1.0 108.715 -179.098 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.465 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -67.11 111.07 3.69 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.322 -0.861 . . . . 1.0 109.893 -179.119 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.562 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -64.04 -5.23 4.33 Favored 'General case' 0 N--CA 1.501 2.083 0 C-N-CA 118.465 -1.294 . . . . 1.0 109.869 179.394 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -86.69 2.04 49.92 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.757 -1.214 . . . . 1.0 108.923 179.363 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.465 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -117.05 -51.11 2.56 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.478 -0.764 . . . . 1.0 108.967 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -102.57 -179.92 4.11 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.498 -0.751 . . . . 1.0 109.381 179.883 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.84 115.25 29.98 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.349 -0.845 . . . . 1.0 108.979 179.923 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.56 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.88 122.25 39.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.807 -1.183 . . . . 1.0 109.464 -179.278 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.572 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -101.75 145.35 29.26 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 122.449 1.119 . . . . 1.0 111.184 -179.3 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.466 HG12 HG11 ' A' ' 7' ' ' VAL . 65.2 t -102.68 110.59 29.76 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 N-CA-C 106.892 -1.521 . . . . 1.0 106.892 177.815 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.458 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.11 -169.63 18.47 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 118.177 -1.963 . . . . 1.0 111.75 -177.712 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.474 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -120.02 177.06 5.13 Favored 'General case' 0 N--CA 1.489 1.485 0 CA-C-O 121.69 0.757 . . . . 1.0 109.113 -178.931 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.581 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -168.84 173.45 7.1 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 109.276 -0.639 . . . . 1.0 109.276 179.801 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.583 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -116.06 -159.92 0.74 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.103 -0.998 . . . . 1.0 108.86 179.662 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.407 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.2 36.44 4.23 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.674 -1.266 . . . . 1.0 109.152 -179.95 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -115.17 -32.67 5.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.404 -0.81 . . . . 1.0 110.173 -179.724 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.522 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 164.68 -35.53 0.28 Allowed Glycine 0 N--CA 1.481 1.677 0 N-CA-C 107.703 -2.159 . . . . 1.0 107.703 -179.573 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.31 -178.08 6.69 Favored 'General case' 0 C--N 1.305 -1.326 0 O-C-N 121.554 -0.968 . . . . 1.0 109.749 179.322 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.35 -161.31 18.01 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.326 -1.91 . . . . 1.0 108.326 -179.293 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.487 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.4 Cg_exo -47.33 179.82 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 CA-C-N 118.783 1.292 . . . . 1.0 110.368 179.322 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -95.59 -170.82 2.23 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.053 -1.029 . . . . 1.0 110.236 -179.075 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.458 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -125.37 164.53 18.91 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.693 -1.363 . . . . 1.0 109.693 -179.846 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.465 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.56 128.55 49.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 O-C-N 121.436 -1.038 . . . . 1.0 109.103 -179.535 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.572 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.56 120.91 19.81 Favored 'General case' 0 C--N 1.289 -2.036 0 O-C-N 121.735 -0.603 . . . . 1.0 109.835 179.957 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.538 HD13 ' CE2' ' A' ' 112' ' ' PHE . 1.4 pt -98.03 168.11 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.315 -0.866 . . . . 1.0 109.037 179.722 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.466 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -134.98 158.6 43.9 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.305 -0.872 . . . . 1.0 109.428 179.976 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.538 ' CE2' HD13 ' A' ' 110' ' ' ILE . 42.2 m-85 -132.33 119.62 20.99 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.191 -0.943 . . . . 1.0 109.392 -179.786 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 23.7 p30 . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.172 -0.955 . . . . 1.0 109.423 179.954 . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.593 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.328 0.585 . . . . 1.0 109.481 . . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -101.24 160.75 25.72 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.225 -0.922 . . . . 1.0 109.496 179.956 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.53 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 2.4 Cg_endo -61.79 155.22 55.66 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 C-N-CA 122.185 1.924 . . . . 1.0 110.556 -179.99 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.557 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER 179.85 -169.6 0.13 Allowed 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 108.055 -1.091 . . . . 1.0 108.055 179.063 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.557 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -167.82 132.54 1.82 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.655 -1.278 . . . . 1.0 111.098 -179.412 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.528 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.2 p -99.7 104.3 16.02 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 122.353 1.073 . . . . 1.0 109.918 -179.965 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.539 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 4.0 t -121.6 117.1 51.5 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-O 121.603 0.716 . . . . 1.0 110.341 179.587 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.526 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -165.94 150.04 7.21 Favored Pre-proline 0 N--CA 1.487 1.41 0 N-CA-C 108.213 -1.032 . . . . 1.0 108.213 -179.646 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.526 ' CA ' HG21 ' A' ' 8' ' ' THR . 5.8 Cg_endo -77.72 151.76 92.04 Favored 'Cis proline' 0 C--N 1.31 -1.463 0 C-N-CA 123.608 -1.413 . . . . 1.0 109.512 -0.615 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 85.7 p -92.85 -25.66 18.0 Favored 'General case' 0 C--N 1.293 -1.857 0 O-C-N 121.435 -0.791 . . . . 1.0 108.895 179.42 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.414 ' HA ' ' O ' ' A' ' 111' ' ' SER . 3.0 m -131.9 161.37 33.2 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.455 -0.778 . . . . 1.0 109.413 -179.912 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.59 36.55 33.19 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 108.627 -1.789 . . . . 1.0 108.627 -179.566 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.605 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.6 mt -91.19 -42.69 10.29 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.298 1.523 . . . . 1.0 110.37 -178.505 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.5 143.62 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.284 0 CA-C-N 113.292 -1.776 . . . . 1.0 109.809 -179.585 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.58 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.1 p-10 -50.76 105.59 0.1 Allowed 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.596 0.712 . . . . 1.0 111.31 -178.655 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.47 13.64 8.02 Favored Glycine 0 N--CA 1.485 1.945 0 C-N-CA 119.316 -1.421 . . . . 1.0 113.041 177.497 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.605 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.9 t -104.8 -171.96 2.01 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 121.28 2.54 . . . . 1.0 109.755 179.28 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 14.9 t -130.11 138.51 53.8 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.345 0 CA-C-N 114.857 -1.065 . . . . 1.0 111.261 -178.855 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.523 HG12 ' CG2' ' A' ' 69' ' ' VAL . 34.1 m -115.85 154.82 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.585 -0.894 . . . . 1.0 108.585 178.888 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.539 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -109.19 109.18 20.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.121 -0.987 . . . . 1.0 109.35 -179.903 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.1 p -107.4 123.16 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 108.357 -0.979 . . . . 1.0 108.357 179.67 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.528 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -120.85 167.24 12.73 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 120.721 -1.237 . . . . 1.0 109.386 -179.744 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.598 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -131.24 144.33 15.86 Favored Glycine 0 C--N 1.295 -1.723 0 N-CA-C 107.711 -2.155 . . . . 1.0 107.711 179.691 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.53 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -148.18 123.19 10.08 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 120.96 -1.317 . . . . 1.0 108.532 179.105 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.502 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 90.66 27.95 17.98 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.269 -1.443 . . . . 1.0 109.722 -179.464 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.53 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.0 OUTLIER -90.52 175.37 7.09 Favored 'General case' 0 C--N 1.308 -1.213 0 O-C-N 120.832 -1.393 . . . . 1.0 108.602 179.947 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.552 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -48.6 100.4 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.903 -1.123 . . . . 1.0 109.859 -179.817 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.43 78.57 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.679 0 CA-C-N 115.355 -0.839 . . . . 1.0 110.116 -179.375 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.573 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.81 34.44 0.3 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.283 -1.527 . . . . 1.0 109.283 179.711 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 21.4 p -139.75 105.69 5.19 Favored 'General case' 0 C--N 1.307 -1.252 0 O-C-N 121.185 -1.185 . . . . 1.0 111.155 -179.381 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.554 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -48.47 109.8 0.28 Allowed 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.579 -0.526 . . . . 1.0 109.579 178.057 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.477 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 8.4 m-85 -104.34 153.23 21.3 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.055 -1.028 . . . . 1.0 108.994 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.427 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.2 155.35 18.49 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.859 -1.15 . . . . 1.0 108.246 179.054 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.601 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 0.8 OUTLIER -126.91 127.89 70.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.228 -0.92 . . . . 1.0 108.973 -178.079 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.493 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -175.6 174.36 46.8 Favored Glycine 0 N--CA 1.495 2.581 0 C-N-CA 117.726 -2.178 . . . . 1.0 112.342 -179.926 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.574 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -101.09 108.84 20.63 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 107.964 -1.124 . . . . 1.0 107.964 179.577 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.0 m -129.67 147.87 51.5 Favored 'General case' 0 C--N 1.294 -1.81 0 O-C-N 121.212 -0.93 . . . . 1.0 109.969 -179.654 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.58 139.13 54.26 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.362 -0.837 . . . . 1.0 110.523 -179.133 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.615 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.08 114.72 26.56 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.411 -1.329 . . . . 1.0 107.411 178.282 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -106.11 15.35 7.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.051 -1.031 . . . . 1.0 110.541 -178.614 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.77 -175.99 0.09 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.931 -1.106 . . . . 1.0 110.02 179.761 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.551 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.29 97.09 1.19 Allowed 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.782 0.801 . . . . 1.0 109.993 -179.631 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.56 28.23 36.43 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 120.278 -0.963 . . . . 1.0 111.413 178.856 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.591 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.18 106.27 20.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 O-C-N 120.623 -1.516 . . . . 1.0 107.186 178.846 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.615 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.5 tp -116.88 104.77 11.64 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.463 -1.398 . . . . 1.0 109.869 -177.614 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.509 ' CB ' HG21 ' A' ' 86' ' ' VAL . . . -98.01 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.782 -1.199 . . . . 1.0 108.219 178.815 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.0 t -106.35 164.85 11.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.945 -1.097 . . . . 1.0 110.288 -178.897 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.532 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 8.9 t-20 -107.52 134.29 20.05 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.386 -0.821 . . . . 1.0 109.648 -179.301 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.575 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.3 Cg_endo -74.96 22.88 0.41 Allowed 'Trans proline' 0 CA--C 1.544 0.998 0 C-N-CA 122.327 2.018 . . . . 1.0 111.811 -179.813 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.532 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -115.82 7.04 14.46 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.398 -1.439 . . . . 1.0 108.912 179.534 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.53 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.99 15.16 2.86 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.385 -1.339 . . . . 1.0 107.385 179.522 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -78.3 88.19 4.34 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.984 -0.686 . . . . 1.0 111.522 -178.132 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.601 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -97.97 -167.49 1.52 Allowed 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.718 -1.215 . . . . 1.0 107.718 177.941 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.459 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.93 135.99 0.09 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.565 -1.335 . . . . 1.0 111.542 -179.331 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.59 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -163.47 154.19 2.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 107.526 -1.287 . . . . 1.0 107.526 178.419 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.554 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.1 m -98.6 141.92 30.83 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.833 -1.167 . . . . 1.0 109.59 -179.945 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.687 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -61.82 105.69 0.59 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 122.493 1.139 . . . . 1.0 109.281 178.541 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.525 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.8 p-10 -58.55 -138.63 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.982 0 CA-C-N 115.443 -0.799 . . . . 1.0 110.966 -179.862 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -53.79 -49.4 68.37 Favored 'General case' 0 N--CA 1.5 2.042 0 CA-C-O 121.675 0.75 . . . . 1.0 110.409 -178.672 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 74.7 m-80 -102.38 -37.29 8.11 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 106.066 -1.827 . . . . 1.0 106.066 178.382 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.687 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 110.16 65.84 0.55 Allowed Glycine 0 C--N 1.297 -1.596 0 CA-C-N 114.774 -1.103 . . . . 1.0 110.438 177.964 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.7 m -104.43 127.3 52.09 Favored 'General case' 0 N--CA 1.483 1.179 0 O-C-N 121.563 -0.963 . . . . 1.0 109.07 179.05 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.59 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.54 109.02 7.38 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 119.519 -0.872 . . . . 1.0 109.764 -179.443 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 53.3 p -115.3 119.57 36.74 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.105 -0.997 . . . . 1.0 109.373 179.97 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.481 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.33 142.21 30.25 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.48 -0.762 . . . . 1.0 109.844 179.935 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 54.8 p -99.44 149.02 23.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.414 -0.803 . . . . 1.0 109.156 179.751 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.53 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.2 OUTLIER -149.87 163.71 37.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.265 -0.897 . . . . 1.0 109.763 -178.93 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.554 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.5 p -96.57 126.1 41.51 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.125 -0.984 . . . . 1.0 109.259 -179.987 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.523 ' CG2' HG12 ' A' ' 19' ' ' VAL . 16.0 m -137.44 143.19 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 120.904 -1.123 . . . . 1.0 109.856 -179.102 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.58 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.9 ptt180 -147.3 -176.51 5.26 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.519 -1.363 . . . . 1.0 111.081 -179.774 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.548 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.04 -100.19 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 109.155 -0.683 . . . . 1.0 109.155 -179.714 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.52 139.97 51.96 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.779 -1.201 . . . . 1.0 107.801 179.208 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -162.45 138.79 7.62 Favored 'General case' 0 C--N 1.293 -1.89 0 C-N-CA 118.525 -1.27 . . . . 1.0 110.074 -177.819 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.502 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.8 mm-40 -34.7 120.82 0.5 Allowed 'General case' 0 N--CA 1.491 1.6 0 CA-C-O 121.395 0.617 . . . . 1.0 110.246 -178.713 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.505 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.18 50.8 1.9 Allowed Glycine 0 N--CA 1.492 2.402 0 C-N-CA 120.477 -0.868 . . . . 1.0 111.136 -179.101 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.575 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-30 -39.39 113.35 0.32 Allowed 'General case' 0 N--CA 1.507 2.424 0 O-C-N 121.057 -1.26 . . . . 1.0 109.916 179.488 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -85.73 126.78 34.23 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.835 -1.166 . . . . 1.0 109.504 -179.915 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.576 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 30.7 t80 -64.36 58.23 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.018 0 O-C-N 120.859 -1.151 . . . . 1.0 110.104 179.764 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -160.05 19.49 0.16 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.019 -1.051 . . . . 1.0 109.674 179.905 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.38 -26.71 5.52 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.154 -1.178 . . . . 1.0 110.154 179.856 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.451 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -94.27 154.81 17.33 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.06 -1.259 . . . . 1.0 110.42 -179.431 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.465 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -102.11 134.54 45.19 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.176 -1.046 . . . . 1.0 108.176 179.476 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.482 ' HB2' HD12 ' A' ' 77' ' ' LEU . 1.2 t90 -81.49 -16.6 51.41 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.784 -1.197 . . . . 1.0 110.506 -178.34 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 108.17 175.52 22.04 Favored Glycine 0 N--CA 1.485 1.921 0 N-CA-C 108.768 -1.733 . . . . 1.0 108.768 -179.675 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.44 104.32 0.61 Allowed 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 107.615 -1.254 . . . . 1.0 107.615 179.07 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.565 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 38.1 t -76.03 106.37 5.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.316 -0.865 . . . . 1.0 109.059 -178.862 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.464 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.5 OUTLIER -64.37 110.65 2.33 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.507 -0.746 . . . . 1.0 109.835 -179.268 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.548 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.61 -5.08 4.88 Favored 'General case' 0 N--CA 1.498 1.938 0 C-N-CA 118.261 -1.375 . . . . 1.0 109.752 179.357 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.5 p -85.57 -1.44 57.11 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.806 -1.184 . . . . 1.0 109.216 179.606 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.458 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.81 -48.36 3.07 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.299 -0.875 . . . . 1.0 109.051 -179.984 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.31 -178.57 3.64 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.57 -0.706 . . . . 1.0 109.491 179.905 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.46 115.36 30.12 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.429 -0.794 . . . . 1.0 109.096 -179.956 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.76 120.99 38.12 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.894 -1.129 . . . . 1.0 109.239 -179.514 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.561 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -99.26 145.54 27.16 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 122.328 1.061 . . . . 1.0 111.105 -179.338 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.526 ' CG1' HG13 ' A' ' 7' ' ' VAL . 97.5 t -103.21 110.51 29.97 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 106.958 -1.497 . . . . 1.0 106.958 177.858 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.499 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -154.09 -169.68 19.2 Favored Glycine 0 N--CA 1.486 1.996 0 C-N-CA 118.173 -1.965 . . . . 1.0 111.579 -177.635 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.503 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -117.87 173.92 6.48 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 108.532 -0.914 . . . . 1.0 108.532 -179.506 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.596 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 7.3 t 176.13 163.93 0.38 Allowed 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 109.235 -0.654 . . . . 1.0 109.235 -179.808 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.477 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -108.61 -160.84 0.74 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.923 -1.111 . . . . 1.0 109.092 -179.997 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -118.03 36.49 4.31 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.705 -1.247 . . . . 1.0 109.167 -179.954 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -110.18 -30.32 7.79 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.37 -0.831 . . . . 1.0 109.809 -179.713 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.525 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . 170.79 -38.45 0.18 Allowed Glycine 0 N--CA 1.482 1.757 0 N-CA-C 108.115 -1.994 . . . . 1.0 108.115 -179.82 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -172.61 -176.69 1.56 Allowed 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.526 -0.985 . . . . 1.0 109.715 179.467 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.23 -160.8 16.73 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.159 -1.976 . . . . 1.0 108.159 -179.383 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -46.84 176.41 0.01 OUTLIER 'Trans proline' 0 C--N 1.326 -0.656 0 CA-C-N 118.973 1.386 . . . . 1.0 109.998 179.127 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -95.21 -176.88 3.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.027 -1.046 . . . . 1.0 110.376 -178.814 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.499 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.62 167.19 13.38 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.741 -1.343 . . . . 1.0 109.741 -179.963 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -101.55 129.55 52.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.417 -1.049 . . . . 1.0 109.143 -179.381 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.561 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -68.91 115.86 8.72 Favored 'General case' 0 C--N 1.289 -2.041 0 N-CA-C 109.47 -0.567 . . . . 1.0 109.47 179.474 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.589 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.8 pt -97.8 168.49 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.262 -0.899 . . . . 1.0 108.59 179.857 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.414 ' O ' ' HA ' ' A' ' 11' ' ' SER . 2.8 t -142.36 158.49 43.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.022 -1.049 . . . . 1.0 110.302 -179.375 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.589 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 84.8 m-85 -133.67 98.86 4.31 Favored 'General case' 0 N--CA 1.484 1.259 0 O-C-N 121.374 -0.829 . . . . 1.0 109.324 -179.856 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 20.0 p30 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 118.033 -0.984 . . . . 1.0 109.517 -179.935 . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.596 ' C21' ' CB ' ' A' ' 98' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 121.319 0.58 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 033 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.413 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . . . -110.65 167.82 8.5 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.218 -0.926 . . . . 0.0 109.503 -179.99 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.534 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 3.3 Cg_exo -60.82 157.49 37.79 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.256 1.971 . . . . 0.0 110.464 -179.936 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.583 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.1 p -159.68 160.14 33.81 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 -179.309 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.475 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.82 121.97 9.53 Favored 'General case' 0 C--N 1.296 -1.73 0 CA-C-O 122.333 1.063 . . . . 0.0 110.388 -179.672 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.545 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.3 t -114.54 109.35 18.13 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 123.01 1.386 . . . . 0.0 109.768 -179.929 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.521 HG13 ' CG1' ' A' ' 95' ' ' VAL . 2.5 t -115.58 139.03 44.0 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.721 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.763 179.913 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.515 HG22 ' N ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -172.42 150.71 2.31 Favored Pre-proline 0 N--CA 1.487 1.403 0 O-C-N 121.154 -0.966 . . . . 0.0 108.948 -179.533 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.515 ' N ' HG22 ' A' ' 8' ' ' THR . 2.1 Cg_endo -75.38 152.77 98.03 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.498 -1.459 . . . . 0.0 109.533 -0.674 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.521 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 3.5 m -89.89 -25.42 20.99 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.763 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.465 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.5 m -136.83 166.43 23.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.483 -0.76 . . . . 0.0 109.435 179.935 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.28 37.72 35.99 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.522 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.625 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 30.9 mt -92.77 -44.68 8.39 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 123.153 1.454 . . . . 0.0 110.767 -178.272 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.84 145.56 0.03 OUTLIER 'General case' 0 C--N 1.258 -3.392 0 CA-C-N 113.721 -1.581 . . . . 0.0 110.045 -179.819 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.575 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.6 p-10 -50.64 108.34 0.23 Allowed 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 121.562 0.696 . . . . 0.0 111.727 -178.678 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.06 15.56 9.82 Favored Glycine 0 N--CA 1.484 1.895 0 C-N-CA 119.619 -1.277 . . . . 0.0 112.78 177.263 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.625 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 8.8 t -103.56 -173.12 2.24 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 121.056 2.428 . . . . 0.0 109.839 179.348 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.543 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 21.9 t -126.8 135.71 62.91 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.944 -178.771 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.542 ' CG1' ' CG2' ' A' ' 69' ' ' VAL . 27.4 m -112.37 154.75 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 O-C-N 121.348 -0.845 . . . . 0.0 108.883 178.789 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -111.24 109.43 19.45 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.219 -0.926 . . . . 0.0 108.987 179.947 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.2 p -105.11 140.2 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -179.972 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.557 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -137.43 161.39 36.47 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.793 -1.192 . . . . 0.0 110.004 179.583 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.582 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -134.54 140.44 11.74 Favored Glycine 0 C--N 1.299 -1.518 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 179.793 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.583 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -141.74 127.04 18.66 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.563 -1.551 . . . . 0.0 109.489 179.294 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.534 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 87.47 29.26 22.35 Favored Glycine 0 N--CA 1.488 2.16 0 C-N-CA 118.915 -1.612 . . . . 0.0 109.681 -179.821 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HB2' ' HB3' ' A' ' 57' ' ' ALA . 1.9 mt -89.08 173.21 8.57 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.006 -1.291 . . . . 0.0 108.334 -179.85 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.56 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.21 98.85 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.015 -1.053 . . . . 0.0 109.797 -179.715 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.549 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.38 77.02 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.251 -179.199 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.05 33.35 0.28 Allowed Glycine 0 N--CA 1.486 1.991 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.533 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.528 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.7 p -142.81 110.57 5.87 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 120.981 -1.306 . . . . 0.0 111.028 -179.832 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.545 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -48.95 112.68 0.65 Allowed 'General case' 0 N--CA 1.495 1.814 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.99 178.366 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.504 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 21.6 m-85 -101.33 155.3 18.12 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.127 -0.983 . . . . 0.0 108.88 179.665 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.478 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -102.7 150.19 23.7 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.862 -1.149 . . . . 0.0 108.205 179.014 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.591 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 1.1 t -126.34 129.97 71.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.117 -0.989 . . . . 0.0 109.121 -178.074 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.46 ' O ' ' H29' ' A' ' 114' ' ' CHR . . . -178.56 172.67 45.06 Favored Glycine 0 N--CA 1.495 2.573 0 C-N-CA 117.812 -2.137 . . . . 0.0 112.201 179.866 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.575 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -101.02 109.1 20.97 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.364 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.1 m -130.05 148.93 51.96 Favored 'General case' 0 C--N 1.295 -1.765 0 O-C-N 120.96 -1.087 . . . . 0.0 110.27 -179.496 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -121.54 138.34 54.34 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.364 -0.835 . . . . 0.0 110.537 -179.307 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.626 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.34 114.79 26.61 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 178.249 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.5 m -104.46 14.57 6.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.069 -1.02 . . . . 0.0 110.518 -178.915 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.55 -175.0 0.08 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.902 -1.124 . . . . 0.0 109.974 179.702 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -73.6 98.79 2.91 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.441 -0.787 . . . . 0.0 109.539 -179.814 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.99 27.62 30.86 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 120.161 -1.018 . . . . 0.0 111.362 179.09 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -118.11 105.99 18.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 O-C-N 120.597 -1.531 . . . . 0.0 107.231 178.967 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.626 HD13 ' CD1' ' A' ' 39' ' ' TRP . 13.6 tp -118.12 104.73 11.11 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 120.496 -1.378 . . . . 0.0 109.917 -177.801 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.495 ' HB1' HG23 ' A' ' 86' ' ' VAL . . . -97.64 109.33 22.11 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.729 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -105.64 165.87 10.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.915 -1.116 . . . . 0.0 110.674 -178.479 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.475 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 7.8 t30 -110.32 130.25 23.07 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 121.601 -0.687 . . . . 0.0 109.247 -179.486 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.584 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -71.59 23.28 0.24 Allowed 'Trans proline' 0 CA--C 1.545 1.055 0 C-N-CA 122.054 1.836 . . . . 0.0 111.804 179.623 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.406 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -103.32 -3.07 26.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.448 -1.408 . . . . 0.0 109.074 179.641 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.535 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 1.6 m-20 -134.93 10.41 3.6 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.943 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -63.34 81.99 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.251 -178.905 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.591 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.34 -169.57 1.82 Allowed 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.096 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.45 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.1 t 179.27 132.94 0.09 Allowed 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.865 -1.147 . . . . 0.0 111.126 -179.532 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.545 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.1 p -156.32 152.61 8.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 178.367 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.545 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -97.91 142.29 29.83 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.696 -1.253 . . . . 0.0 109.872 -179.64 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.675 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.02 106.11 0.78 Allowed 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.447 1.117 . . . . 0.0 109.497 178.792 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.526 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.6 p-10 -57.92 -139.22 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.727 -179.978 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.549 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -55.13 -49.27 72.2 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.331 -0.856 . . . . 0.0 110.093 -178.95 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.7 p-10 -100.22 -39.03 8.25 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 178.482 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.675 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.94 66.36 0.58 Allowed Glycine 0 C--N 1.297 -1.619 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 178.288 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.582 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.0 m -101.48 129.81 47.61 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 121.601 -0.941 . . . . 0.0 109.056 179.103 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.557 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -138.13 108.95 6.66 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 119.31 -0.956 . . . . 0.0 109.498 -179.554 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.449 ' OG ' ' HB1' ' A' ' 22' ' ' ALA . 2.7 m -126.0 120.92 31.58 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.205 -0.934 . . . . 0.0 109.627 -179.774 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.08 144.78 30.24 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.482 -0.761 . . . . 0.0 109.391 179.871 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.432 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 32.1 p -98.83 141.12 32.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.368 -0.832 . . . . 0.0 109.115 179.894 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.543 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -140.56 174.69 10.27 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.333 -0.854 . . . . 0.0 109.65 -178.818 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.512 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -102.34 122.37 44.11 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.019 -1.051 . . . . 0.0 109.622 -179.751 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.542 ' CG2' ' CG1' ' A' ' 19' ' ' VAL . 16.9 m -133.47 143.17 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 120.911 -1.118 . . . . 0.0 110.159 -179.411 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.575 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.0 ptt180 -142.68 -166.87 2.38 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.663 -1.273 . . . . 0.0 110.09 179.568 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.565 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -72.32 -85.91 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.321 -0.862 . . . . 0.0 108.841 -179.575 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.62 138.81 58.58 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.291 -1.506 . . . . 0.0 107.362 178.799 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -164.48 139.08 5.49 Favored 'General case' 0 C--N 1.294 -1.82 0 C-N-CA 117.982 -1.487 . . . . 0.0 110.542 -177.496 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.472 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.6 mm-40 -34.09 120.55 0.44 Allowed 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.47 0.653 . . . . 0.0 110.612 -178.625 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.488 ' HA3' HG21 ' A' ' 86' ' ' VAL . . . -95.15 50.57 1.91 Allowed Glycine 0 N--CA 1.494 2.563 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.226 -179.418 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.584 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-85 -41.05 114.18 0.46 Allowed 'General case' 0 N--CA 1.508 2.45 0 O-C-N 120.868 -1.372 . . . . 0.0 109.964 179.453 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.53 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.3 tp -84.32 126.92 33.64 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.742 -1.224 . . . . 0.0 109.624 -179.951 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.583 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 26.4 t80 -64.05 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.812 -1.18 . . . . 0.0 110.275 179.688 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' LEU . 8.7 t0 -161.35 20.0 0.12 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.944 -1.098 . . . . 0.0 109.806 179.731 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.19 -26.88 5.31 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 110.041 -1.223 . . . . 0.0 110.041 179.963 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.475 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 5.9 p -92.38 152.78 19.56 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.056 -1.261 . . . . 0.0 110.386 -179.442 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.497 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 5.4 ptt180 -101.93 133.06 47.32 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.597 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.489 ' CD1' HD13 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -81.24 -20.96 39.9 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 120.713 -1.242 . . . . 0.0 110.527 -178.269 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.88 176.04 20.45 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 108.725 -1.75 . . . . 0.0 108.725 -179.629 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.49 109.42 1.37 Allowed 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 179.148 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.53 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 31.1 t -81.83 105.74 12.05 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 121.341 -0.849 . . . . 0.0 108.94 -178.934 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.2 OUTLIER -65.3 111.82 3.19 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.446 -0.783 . . . . 0.0 109.845 -179.357 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.538 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.56 -5.09 7.13 Favored 'General case' 0 N--CA 1.499 1.984 0 C-N-CA 118.285 -1.366 . . . . 0.0 109.648 179.369 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 p -83.76 -2.18 55.74 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.876 -1.14 . . . . 0.0 108.901 179.318 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.453 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.98 -49.81 2.95 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.347 -0.846 . . . . 0.0 109.013 -179.998 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.62 -178.34 3.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.551 -0.718 . . . . 0.0 109.517 179.919 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.3 116.29 31.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.43 -0.794 . . . . 0.0 108.99 -179.971 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.568 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.1 m -96.88 124.21 40.8 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.814 -1.179 . . . . 0.0 109.747 -179.168 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.564 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.0 147.32 26.71 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 122.33 1.062 . . . . 0.0 111.202 -179.44 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.521 ' CG1' HG13 ' A' ' 7' ' ' VAL . 43.8 t -104.75 111.53 34.65 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.567 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.458 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.35 -169.81 17.47 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 117.906 -2.092 . . . . 0.0 111.845 -177.481 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.478 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.57 -179.07 3.57 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -179.094 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.586 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.0 OUTLIER -171.34 173.55 4.81 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.277 -0.889 . . . . 0.0 109.438 -179.73 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.413 ' OD1' ' C ' ' A' ' 99' ' ' ASP . 0.6 OUTLIER -118.43 -160.38 0.79 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.078 -1.014 . . . . 0.0 108.993 179.937 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -118.91 35.5 4.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.673 -1.267 . . . . 0.0 109.347 -179.824 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.78 -32.55 4.49 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.403 -0.811 . . . . 0.0 110.239 -179.542 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.522 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 168.32 -37.56 0.21 Allowed Glycine 0 N--CA 1.481 1.658 0 N-CA-C 107.676 -2.17 . . . . 0.0 107.676 -179.493 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.55 -178.16 6.91 Favored 'General case' 0 C--N 1.306 -1.296 0 O-C-N 121.534 -0.98 . . . . 0.0 109.671 179.253 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.5 -162.04 17.06 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 108.356 -1.897 . . . . 0.0 108.356 -179.494 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' CD ' ' CE1' ' A' ' 32' ' ' TYR . 6.8 Cg_exo -46.12 174.16 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 CA-C-N 118.784 1.292 . . . . 0.0 110.022 179.387 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -92.82 -177.69 4.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.107 -0.996 . . . . 0.0 110.528 -178.588 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.458 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.8 167.44 13.1 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.946 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.06 131.19 53.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 O-C-N 121.325 -1.103 . . . . 0.0 109.095 -179.269 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.564 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.99 122.63 22.03 Favored 'General case' 0 C--N 1.29 -2.001 0 O-C-N 121.612 -0.68 . . . . 0.0 109.529 179.707 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.573 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.72 169.84 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 O-C-N 121.225 -0.922 . . . . 0.0 109.226 -179.982 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.465 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -135.48 155.33 50.7 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.233 -0.917 . . . . 0.0 109.721 -179.753 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.573 ' CE2' HD12 ' A' ' 110' ' ' ILE . 74.9 m-85 -131.19 109.28 10.31 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.767 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.2 p30 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 117.98 -1.01 . . . . 0.0 109.443 179.99 . . . . . . . . 0 0 . 1 . 033 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.587 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.489 0 CA-C-O 121.316 0.579 . . . . 0.0 109.459 . . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -119.88 152.84 54.44 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.181 -0.949 . . . . 0.0 109.524 179.969 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.492 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 2.7 Cg_endo -61.33 156.03 48.45 Favored 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.343 2.029 . . . . 0.0 110.514 -179.941 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.602 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -146.75 161.56 40.37 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 -179.739 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -146.9 128.92 15.51 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-O 122.475 1.131 . . . . 0.0 110.618 -179.725 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.537 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.8 p -106.89 104.95 14.75 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-O 122.503 1.144 . . . . 0.0 110.331 -179.43 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.525 HG12 ' CG1' ' A' ' 95' ' ' VAL . 10.6 t -117.25 119.16 61.02 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.478 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.303 179.582 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.49 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.61 148.38 12.67 Favored Pre-proline 0 N--CA 1.487 1.415 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -179.602 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.49 ' HA ' HG22 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.49 152.85 97.95 Favored 'Cis proline' 0 C--N 1.31 -1.497 0 C-N-CA 123.603 -1.415 . . . . 0.0 109.728 -0.445 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.477 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 3.7 m -92.53 -24.94 18.6 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.505 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.502 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 1.2 m -136.53 166.05 24.43 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.656 -0.652 . . . . 0.0 109.351 179.847 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.39 37.98 39.95 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 -179.723 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.615 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.6 mt -91.7 -43.34 9.64 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 123.344 1.545 . . . . 0.0 110.649 -178.31 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.02 144.43 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.376 -1.738 . . . . 0.0 109.853 -179.653 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.589 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 6.1 p-10 -51.13 107.78 0.2 Allowed 'General case' 0 C--N 1.302 -1.492 0 CA-C-O 121.586 0.708 . . . . 0.0 111.527 -178.534 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.12 14.26 9.33 Favored Glycine 0 N--CA 1.484 1.86 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.822 177.486 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.615 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 13.3 t -105.0 -172.6 2.13 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 121.13 2.465 . . . . 0.0 109.713 179.287 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.553 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 15.0 t -130.68 139.18 51.88 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.324 -178.793 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.519 HG21 ' CD1' ' A' ' 67' ' ' LEU . 31.7 m -114.72 154.91 16.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.037 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.523 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.6 tptm -110.45 109.36 19.7 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.337 180.0 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.523 ' CG1' HG21 ' A' ' 34' ' ' VAL . 1.9 p -105.1 123.95 59.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 179.948 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.55 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -112.38 166.16 11.55 Favored 'General case' 0 N--CA 1.485 1.279 0 O-C-N 120.927 -1.108 . . . . 0.0 108.94 179.594 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.62 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.19 108.1 0.48 Allowed Glycine 0 N--CA 1.482 1.763 0 N-CA-C 108.41 -1.876 . . . . 0.0 108.41 179.917 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.602 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -117.19 136.81 52.78 Favored 'General case' 0 N--CA 1.501 2.078 0 CA-C-N 119.432 1.616 . . . . 0.0 110.38 -179.287 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.492 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 87.61 28.11 25.2 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 118.895 -1.621 . . . . 0.0 109.806 179.68 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.533 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -93.4 170.6 9.49 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.988 -1.301 . . . . 0.0 108.309 179.852 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.555 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.9 100.8 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.068 -1.02 . . . . 0.0 110.018 -179.495 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.541 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.75 78.17 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.675 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.018 -179.36 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.32 34.48 0.28 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.735 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.531 ' OG1' ' CB ' ' A' ' 27' ' ' GLN . 18.8 p -139.56 105.67 5.23 Favored 'General case' 0 C--N 1.307 -1.278 0 O-C-N 121.162 -1.199 . . . . 0.0 111.273 -179.258 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.566 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.74 109.88 0.36 Allowed 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 177.824 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.535 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 5.2 m-30 -106.38 156.11 18.85 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.049 -1.032 . . . . 0.0 108.886 179.89 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -100.36 164.51 11.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.902 -1.124 . . . . 0.0 108.081 179.035 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.637 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.2 p -144.23 117.21 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.152 -0.967 . . . . 0.0 109.61 -178.1 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.496 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.9 -176.9 38.83 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 118.364 -1.874 . . . . 0.0 111.876 -179.717 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.557 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -101.48 109.21 20.99 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.837 0.827 . . . . 0.0 109.13 -179.572 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.21 148.44 52.04 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.192 -0.943 . . . . 0.0 109.511 179.579 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.7 138.52 54.58 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.179 -0.951 . . . . 0.0 110.815 -178.969 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.624 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.97 26.8 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 178.112 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.9 m -105.64 15.07 7.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 120.994 -1.066 . . . . 0.0 110.534 -178.84 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.11 -175.38 0.09 Allowed 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.857 -1.152 . . . . 0.0 110.064 179.724 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 64.0 p -72.24 97.44 1.99 Allowed 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.428 -0.795 . . . . 0.0 109.64 -179.784 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.56 27.54 32.24 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 120.154 -1.022 . . . . 0.0 111.419 178.877 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.591 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.65 106.21 19.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.526 -1.573 . . . . 0.0 107.221 178.93 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.624 HD12 ' CD1' ' A' ' 39' ' ' TRP . 12.8 tp -117.06 104.69 11.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.52 -1.362 . . . . 0.0 109.854 -177.659 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.534 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.08 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.299 0 O-C-N 120.842 -1.161 . . . . 0.0 107.887 178.77 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -106.87 163.99 12.49 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.015 -1.053 . . . . 0.0 110.44 -178.771 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.523 ' ND2' ' HB2' ' A' ' 50' ' ' ALA . 47.0 t30 -109.59 131.04 22.12 Favored Pre-proline 0 N--CA 1.502 2.173 0 O-C-N 121.59 -0.694 . . . . 0.0 109.618 -179.345 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.61 20.76 0.25 Allowed 'Trans proline' 0 C--N 1.318 -1.029 0 C-N-CA 122.21 1.94 . . . . 0.0 112.243 -179.813 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.523 ' HB2' ' ND2' ' A' ' 48' ' ' ASN . . . -110.53 5.68 21.39 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.379 -1.451 . . . . 0.0 108.846 179.166 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.52 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.01 16.82 2.64 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 179.339 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -81.74 88.82 6.26 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.868 -0.733 . . . . 0.0 111.285 -178.302 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.637 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.79 -167.25 1.23 Allowed 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 177.93 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.47 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.65 136.24 0.09 Allowed 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.479 -1.388 . . . . 0.0 111.395 -179.341 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.573 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -152.67 157.29 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.169 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.566 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.89 141.76 31.25 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.732 -1.23 . . . . 0.0 109.859 -179.772 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.685 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.17 107.51 1.06 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.43 1.109 . . . . 0.0 109.399 178.199 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.54 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 14.4 p-10 -61.75 -138.91 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.001 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.812 -179.997 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.541 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.49 -51.62 53.55 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.374 -0.828 . . . . 0.0 110.664 -178.665 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -102.23 -33.75 9.5 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 178.473 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.685 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.28 64.56 0.57 Allowed Glycine 0 C--N 1.299 -1.511 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.671 178.009 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.62 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 92.7 p -98.89 128.91 45.2 Favored 'General case' 0 N--CA 1.482 1.168 0 O-C-N 121.859 -0.789 . . . . 0.0 108.92 178.804 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.573 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.28 108.78 7.4 Favored 'General case' 0 C--N 1.296 -1.742 0 C-N-CA 119.67 -0.812 . . . . 0.0 109.416 -179.524 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 80.9 p -120.5 117.44 27.65 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.298 -0.876 . . . . 0.0 109.368 -179.906 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.461 HG22 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.31 140.83 28.04 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.418 -0.801 . . . . 0.0 109.609 -179.836 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 12.6 p -100.69 136.24 40.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.377 -0.827 . . . . 0.0 109.494 -179.947 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.521 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -133.84 165.85 24.03 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.423 -0.798 . . . . 0.0 109.392 -179.473 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.553 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.2 p -96.22 125.33 40.66 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.956 -1.09 . . . . 0.0 109.349 -179.946 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.54 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.4 m -135.82 143.49 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 120.919 -1.113 . . . . 0.0 109.929 -179.116 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.589 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.63 -175.9 4.98 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.495 -1.378 . . . . 0.0 110.984 179.957 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.551 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.56 -101.73 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.762 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.51 ' OG ' ' NH1' ' A' ' 71' ' ' ARG . 0.7 OUTLIER -57.29 142.0 44.84 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.731 -1.23 . . . . 0.0 108.187 179.424 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.585 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.65 136.85 6.39 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.775 -1.17 . . . . 0.0 109.637 -177.961 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.495 ' OE1' ' N ' ' A' ' 74' ' ' GLU . 1.6 mp0 -34.46 121.89 0.5 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.431 0.634 . . . . 0.0 110.306 -178.402 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.534 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -93.58 49.91 2.34 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.236 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.5 m-85 -39.3 113.85 0.36 Allowed 'General case' 0 N--CA 1.507 2.382 0 O-C-N 121.204 -1.174 . . . . 0.0 109.992 179.555 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.539 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -85.81 126.46 34.04 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 120.944 -1.098 . . . . 0.0 109.55 -179.797 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.568 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 19.9 t80 -64.28 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.869 -1.144 . . . . 0.0 110.052 179.665 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.539 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.4 t70 -159.96 19.49 0.16 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.157 -0.964 . . . . 0.0 109.66 179.764 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.96 -27.45 5.47 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.75 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.4 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 19.5 p -94.49 160.46 14.64 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.033 -1.275 . . . . 0.0 110.362 -179.361 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.467 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.75 136.62 46.24 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.689 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.459 ' HB2' HD11 ' A' ' 77' ' ' LEU . 1.8 t90 -82.89 -17.96 41.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.765 -1.21 . . . . 0.0 110.526 -178.487 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.94 175.6 19.89 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 108.778 -1.729 . . . . 0.0 108.778 -179.632 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.05 104.74 0.92 Allowed 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 179.134 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.572 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.5 t -76.48 106.3 6.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.388 -0.82 . . . . 0.0 109.258 -178.913 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.459 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.6 OUTLIER -66.02 111.28 3.28 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.47 -0.769 . . . . 0.0 109.892 -179.41 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.551 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.75 -5.49 4.27 Favored 'General case' 0 N--CA 1.5 2.068 0 C-N-CA 118.256 -1.377 . . . . 0.0 109.816 179.484 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.6 p -86.82 -0.14 55.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.708 -1.245 . . . . 0.0 109.111 179.585 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.459 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.33 -50.59 2.85 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.398 -0.814 . . . . 0.0 108.945 179.96 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.07 -179.95 4.09 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.484 -0.76 . . . . 0.0 109.392 179.845 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.97 115.86 31.2 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.333 -0.854 . . . . 0.0 108.964 179.917 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.84 121.32 38.57 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.993 -1.067 . . . . 0.0 109.308 -179.421 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.546 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.92 145.7 28.3 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 122.355 1.074 . . . . 0.0 111.2 -179.306 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.525 ' CG1' HG12 ' A' ' 7' ' ' VAL . 58.6 t -103.12 109.78 27.83 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 177.675 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.438 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.26 -170.73 16.47 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 118.271 -1.919 . . . . 0.0 111.663 -177.738 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -114.36 -179.55 3.66 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 -178.95 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.562 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 37.1 p -170.85 168.33 7.23 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.337 -0.852 . . . . 0.0 109.321 -179.235 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.535 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -120.06 -158.83 0.76 Allowed 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.079 -1.013 . . . . 0.0 108.845 179.663 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.427 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.45 36.13 4.39 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.706 -1.246 . . . . 0.0 109.314 179.943 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.434 ' HB2' ' OD2' ' A' ' 99' ' ' ASP . . . -117.8 -32.76 4.72 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.452 -0.78 . . . . 0.0 110.262 -179.509 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.517 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 164.9 -36.25 0.28 Allowed Glycine 0 N--CA 1.483 1.771 0 N-CA-C 107.572 -2.211 . . . . 0.0 107.572 -179.513 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.61 -178.01 6.79 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.538 -0.977 . . . . 0.0 109.793 179.253 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.75 -163.0 16.93 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -179.321 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.473 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.4 Cg_exo -46.71 175.69 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.643 0 CA-C-N 118.77 1.285 . . . . 0.0 110.1 179.325 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -90.06 -176.04 4.75 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.019 -1.05 . . . . 0.0 110.599 -178.787 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.438 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.82 167.0 13.88 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.896 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.89 132.66 49.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.373 -1.075 . . . . 0.0 109.174 -179.334 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.546 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.27 118.88 17.73 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.547 -0.72 . . . . 0.0 109.685 179.675 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.57 HD13 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -98.02 170.07 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.211 -0.93 . . . . 0.0 108.999 179.72 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.502 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 34.4 m -140.95 156.85 45.99 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.167 -0.958 . . . . 0.0 110.094 -179.674 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.57 ' CE1' HD13 ' A' ' 110' ' ' ILE . 96.3 m-85 -131.97 106.33 7.98 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.333 -0.855 . . . . 0.0 109.541 -179.754 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 p30 . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.4 -179.928 . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.588 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.322 0.582 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 035 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -113.09 150.11 42.42 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.217 -0.927 . . . . 0.0 109.444 179.984 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.51 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 5.6 Cg_exo -58.67 154.04 45.57 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 C-N-CA 124.821 3.681 . . . . 0.0 110.086 -179.935 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.594 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -150.16 160.63 43.53 Favored 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -179.419 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.478 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.01 122.48 10.37 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 122.486 1.136 . . . . 0.0 110.397 -179.589 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.548 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.5 t -113.52 109.17 18.21 Favored 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 123.15 1.452 . . . . 0.0 109.266 179.954 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.526 HG12 ' CG1' ' A' ' 95' ' ' VAL . 4.4 t -116.25 127.38 73.87 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.709 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.94 -179.847 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.523 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.44 148.11 12.7 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.286 -0.884 . . . . 0.0 108.874 -179.696 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.523 ' CA ' HG21 ' A' ' 8' ' ' THR . 7.1 Cg_endo -79.96 147.65 77.46 Favored 'Cis proline' 0 C--N 1.31 -1.451 0 O-C-N 123.778 1.409 . . . . 0.0 109.35 -0.797 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.452 ' HB2' ' HA ' ' A' ' 110' ' ' ILE . 79.8 p -89.27 -25.8 21.5 Favored 'General case' 0 C--N 1.295 -1.785 0 O-C-N 121.563 -0.71 . . . . 0.0 109.203 179.788 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.457 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 1.0 OUTLIER -132.23 162.03 31.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.405 -0.81 . . . . 0.0 109.55 -179.927 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.9 37.29 29.98 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 -179.661 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.604 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 35.5 mt -92.39 -42.81 9.57 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 123.295 1.521 . . . . 0.0 110.516 -178.388 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.49 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.42 144.69 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.283 0 CA-C-N 113.321 -1.763 . . . . 0.0 109.936 -179.649 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.566 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 11.3 p-10 -51.2 106.11 0.12 Allowed 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.647 0.737 . . . . 0.0 111.494 -178.513 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.98 14.67 8.35 Favored Glycine 0 N--CA 1.485 1.929 0 C-N-CA 119.354 -1.403 . . . . 0.0 113.006 177.358 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.604 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.9 t -104.87 -171.2 1.88 Allowed 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 121.143 2.471 . . . . 0.0 109.516 179.218 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.54 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 17.0 t -127.63 135.88 61.95 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.128 -179.119 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.586 ' CG1' ' CG2' ' A' ' 69' ' ' VAL . 29.2 m -109.18 155.27 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.835 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.52 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -110.35 109.23 19.57 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 108.834 179.804 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.476 ' CA ' HG13 ' A' ' 7' ' ' VAL . 2.3 p -105.01 139.5 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.399 -0.813 . . . . 0.0 108.832 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.556 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -137.58 161.13 37.25 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.804 -1.185 . . . . 0.0 109.945 179.631 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.59 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -134.05 141.57 12.93 Favored Glycine 0 C--N 1.297 -1.623 0 N-CA-C 108.318 -1.913 . . . . 0.0 108.318 179.768 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.594 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.64 125.98 16.6 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.706 -1.467 . . . . 0.0 109.294 179.369 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.51 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.11 28.2 21.19 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 118.873 -1.632 . . . . 0.0 109.599 -179.625 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.544 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.8 mt -88.84 174.59 7.88 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.988 -1.301 . . . . 0.0 108.365 179.953 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.555 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.66 98.45 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.887 -1.133 . . . . 0.0 109.823 -179.521 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 77.71 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.724 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.248 -179.253 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.563 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.73 34.37 0.31 Allowed Glycine 0 N--CA 1.486 2.014 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.525 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.541 ' O ' ' CD2' ' A' ' 32' ' ' TYR . 66.6 p -144.24 109.73 5.19 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.005 -1.291 . . . . 0.0 111.211 -179.585 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.553 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -43.8 127.01 4.97 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.43 178.02 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.541 ' CD2' ' O ' ' A' ' 30' ' ' THR . 15.3 m-85 -116.98 153.48 32.56 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.388 -0.82 . . . . 0.0 108.834 179.844 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.5 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -105.24 148.97 26.38 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.816 -1.177 . . . . 0.0 108.264 179.059 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.593 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 0.9 OUTLIER -125.82 126.46 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.169 -0.957 . . . . 0.0 109.071 -178.103 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -172.77 173.29 45.47 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 117.707 -2.187 . . . . 0.0 112.527 -179.915 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.572 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -100.36 110.31 22.52 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 179.368 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 63.1 m -129.35 152.11 49.26 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 121.196 -0.94 . . . . 0.0 110.156 -179.612 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.47 135.45 51.37 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.632 -0.668 . . . . 0.0 110.046 179.585 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.64 ' CE2' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.71 114.43 26.35 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.579 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 m -106.86 15.15 7.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.915 -1.115 . . . . 0.0 110.713 -178.633 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.6 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.4 -174.52 0.07 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.819 -1.175 . . . . 0.0 110.135 179.63 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 29.5 p -70.14 96.32 1.07 Allowed 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.407 -0.808 . . . . 0.0 110.013 -179.468 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.04 28.4 34.4 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 120.166 -1.016 . . . . 0.0 111.532 178.749 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.6 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.32 106.04 19.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 120.58 -1.541 . . . . 0.0 107.327 178.83 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.64 HD13 ' CE2' ' A' ' 39' ' ' TRP . 11.7 tp -116.47 106.54 13.71 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.59 -1.319 . . . . 0.0 109.775 -177.65 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.581 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -96.13 109.76 22.14 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 120.697 -1.252 . . . . 0.0 108.381 179.281 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 86.8 m -101.48 147.59 26.2 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.346 -0.847 . . . . 0.0 110.48 -178.371 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.462 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 31.1 t30 -96.66 137.87 21.43 Favored Pre-proline 0 N--CA 1.502 2.169 0 O-C-N 121.01 -1.056 . . . . 0.0 108.826 178.878 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.585 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 8.0 Cg_endo -75.76 26.71 0.4 Allowed 'Trans proline' 0 N--CA 1.496 1.649 0 C-N-CA 125.188 3.925 . . . . 0.0 111.507 -179.068 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.454 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -126.1 9.12 7.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.424 -1.423 . . . . 0.0 109.576 179.881 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.517 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.83 15.97 2.49 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 179.502 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -77.91 87.14 4.11 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.059 -178.675 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.593 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -98.98 -168.22 1.6 Allowed 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 178.569 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.449 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 179.13 133.98 0.09 Allowed 'General case' 0 N--CA 1.486 1.329 0 O-C-N 120.766 -1.209 . . . . 0.0 111.42 -179.428 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.56 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -159.14 153.62 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.493 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.553 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.51 144.63 27.02 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.683 -1.261 . . . . 0.0 109.645 -179.86 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.682 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.67 107.42 1.41 Allowed 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 122.525 1.155 . . . . 0.0 109.502 178.7 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.536 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 p-10 -61.39 -139.97 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.782 179.98 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.06 -50.73 58.1 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.382 -0.824 . . . . 0.0 110.664 -178.799 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -103.48 -32.64 9.39 Favored 'General case' 0 C--N 1.286 -2.165 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 178.713 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.682 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 106.0 65.72 0.65 Allowed Glycine 0 C--N 1.296 -1.652 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 178.309 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.59 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.1 m -100.54 128.96 46.43 Favored 'General case' 0 N--CA 1.484 1.245 0 O-C-N 121.523 -0.987 . . . . 0.0 108.808 178.856 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.56 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.9 108.65 6.64 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.242 -0.983 . . . . 0.0 109.588 -179.516 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.44 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 27.3 p -123.82 120.24 32.04 Favored 'General case' 0 C--N 1.305 -1.33 0 O-C-N 121.246 -0.909 . . . . 0.0 109.513 -179.982 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.76 146.05 31.06 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.485 -0.759 . . . . 0.0 109.321 179.819 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 55.4 p -98.57 144.56 27.75 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.295 -0.878 . . . . 0.0 109.287 179.945 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.528 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.1 OUTLIER -144.02 165.01 28.97 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.434 -0.791 . . . . 0.0 109.413 -179.216 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.54 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 3.8 p -95.04 123.71 38.68 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.127 -0.983 . . . . 0.0 109.329 -179.887 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.586 ' CG2' ' CG1' ' A' ' 19' ' ' VAL . 16.6 m -137.89 142.49 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 120.963 -1.085 . . . . 0.0 109.701 -179.292 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.566 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 5.4 ptt180 -140.71 -166.79 2.21 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 120.677 -1.264 . . . . 0.0 109.968 -179.989 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.543 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -71.66 -80.41 0.06 Allowed 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.809 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -64.87 135.79 56.13 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 178.648 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.572 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -161.08 133.6 6.09 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 117.862 -1.535 . . . . 0.0 110.563 -177.643 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.504 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -33.64 120.74 0.41 Allowed 'General case' 0 N--CA 1.493 1.694 0 CA-C-O 121.615 0.722 . . . . 0.0 110.391 -178.472 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.581 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -93.4 50.52 2.4 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.456 -0.878 . . . . 0.0 111.611 -178.916 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.7 OUTLIER -38.42 116.88 0.58 Allowed 'General case' 0 N--CA 1.51 2.567 0 O-C-N 121.094 -1.239 . . . . 0.0 110.053 179.41 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.537 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -87.28 125.71 34.38 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 120.8 -1.187 . . . . 0.0 109.455 179.855 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.567 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.0 t80 -64.14 58.6 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.819 -1.176 . . . . 0.0 110.086 179.82 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.9 t70 -160.51 20.02 0.14 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.059 -1.026 . . . . 0.0 109.668 179.898 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.46 -28.64 5.19 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 179.813 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.444 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 40.7 p -94.23 160.57 14.63 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.066 -1.255 . . . . 0.0 110.293 -179.52 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.476 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -108.02 136.8 47.11 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.794 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.463 ' HB2' HD12 ' A' ' 77' ' ' LEU . 1.9 t90 -80.74 -20.34 42.97 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.809 -1.182 . . . . 0.0 110.351 -178.688 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.43 176.24 20.22 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 108.644 -1.782 . . . . 0.0 108.644 -179.565 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -62.55 109.97 1.55 Allowed 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.166 -1.196 . . . . 0.0 107.779 179.168 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.548 HG21 ' CB ' ' A' ' 46' ' ' ALA . 37.1 t -83.22 103.53 10.62 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -179.104 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.475 ' HB3' HG22 ' A' ' 90' ' ' THR . 0.2 OUTLIER -65.77 111.71 3.37 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.383 -0.823 . . . . 0.0 109.894 -179.257 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.543 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -65.83 -3.67 5.43 Favored 'General case' 0 N--CA 1.5 2.055 0 C-N-CA 118.334 -1.346 . . . . 0.0 109.886 179.457 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.402 ' C ' HG23 ' A' ' 90' ' ' THR . 1.4 p -86.93 11.61 13.08 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.739 -1.225 . . . . 0.0 108.794 179.487 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.475 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -127.25 -48.22 1.45 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.428 -0.795 . . . . 0.0 108.989 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.36 -179.85 4.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.559 -0.713 . . . . 0.0 109.504 -179.948 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.1 113.66 27.32 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.318 -0.864 . . . . 0.0 109.079 -179.986 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.51 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 2.6 m -97.12 124.89 41.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.879 -1.138 . . . . 0.0 109.438 -179.512 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.522 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -104.87 147.15 28.06 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 122.403 1.097 . . . . 0.0 111.38 -179.27 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.526 ' CG1' HG12 ' A' ' 7' ' ' VAL . 43.4 t -103.53 112.04 35.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.977 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 177.577 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.06 -170.44 16.73 Favored Glycine 0 N--CA 1.488 2.137 0 C-N-CA 118.076 -2.011 . . . . 0.0 111.738 -177.607 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.47 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.08 -179.43 3.7 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 -179.126 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.542 ' HB2' ' C20' ' A' ' 114' ' ' CHR . 4.5 p -166.83 167.25 15.12 Favored 'General case' 0 C--N 1.293 -1.885 0 O-C-N 121.337 -0.852 . . . . 0.0 109.287 -179.523 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.541 ' OD1' ' CE1' ' A' ' 32' ' ' TYR . 4.7 m-20 -101.6 -12.54 18.38 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.134 -0.979 . . . . 0.0 109.452 179.891 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.506 ' CB ' ' O ' ' A' ' 99' ' ' ASP . . . 74.77 38.15 0.48 Allowed 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.451 -0.781 . . . . 0.0 109.283 179.89 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -138.85 -34.28 0.61 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.525 -0.734 . . . . 0.0 110.636 -179.382 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.501 ' CA ' H192 ' A' ' 114' ' ' CHR . . . -177.82 -42.87 0.06 OUTLIER Glycine 0 N--CA 1.482 1.75 0 N-CA-C 107.59 -2.204 . . . . 0.0 107.59 -179.627 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.54 -178.74 7.49 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 121.62 -0.929 . . . . 0.0 109.355 178.9 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -173.29 -165.97 30.97 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.737 -1.745 . . . . 0.0 108.737 -179.471 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.492 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.6 Cg_exo -46.39 -175.86 0.0 OUTLIER 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 123.57 2.847 . . . . 0.0 109.923 179.512 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -94.78 172.13 8.35 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.975 -1.078 . . . . 0.0 110.574 -178.957 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -110.47 159.71 13.71 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 179.897 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.36 128.17 55.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.36 -1.082 . . . . 0.0 109.29 -179.378 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.522 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.75 119.49 17.06 Favored 'General case' 0 C--N 1.289 -2.042 0 O-C-N 121.591 -0.693 . . . . 0.0 109.358 179.569 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.583 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -97.99 171.07 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.228 -0.92 . . . . 0.0 109.116 -179.945 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.457 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.86 154.91 48.46 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.088 -1.007 . . . . 0.0 109.811 -179.763 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.583 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 76.1 m-85 -133.11 94.25 3.32 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.1 -1.0 . . . . 0.0 109.467 -179.752 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.434 ' O ' ' OD1' ' A' ' 113' ' ' ASN . 19.7 p30 . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 117.988 -1.006 . . . . 0.0 109.44 -179.967 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.584 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 036 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.69 148.86 39.03 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.227 -0.921 . . . . 0.0 109.504 179.982 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.525 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 4.8 Cg_exo -60.38 157.23 36.84 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.321 2.014 . . . . 0.0 110.581 -179.988 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.549 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.76 -169.69 0.14 Allowed 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 179.146 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.549 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -167.4 130.69 1.74 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 120.872 -1.143 . . . . 0.0 110.613 -179.16 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.549 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.1 t -113.19 108.66 17.58 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 123.166 1.46 . . . . 0.0 109.227 179.418 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 4.3 t -116.89 141.37 35.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.717 0 CA-C-N 114.185 -1.371 . . . . 0.0 109.953 -179.716 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.482 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -178.07 150.61 0.76 Allowed Pre-proline 0 N--CA 1.487 1.415 0 O-C-N 121.248 -0.907 . . . . 0.0 108.668 -179.613 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.482 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.67 152.24 96.92 Favored 'Cis proline' 0 C--N 1.312 -1.39 0 C-N-CA 123.485 -1.465 . . . . 0.0 109.679 -0.699 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.465 ' HA ' HG23 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -90.75 -24.85 20.25 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.768 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.507 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.7 m -136.71 164.15 28.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.451 -0.781 . . . . 0.0 109.482 179.856 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.39 37.47 31.38 Favored Glycine 0 N--CA 1.497 2.702 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 -179.717 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.608 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 36.6 mt -92.18 -43.2 9.47 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 123.203 1.477 . . . . 0.0 110.421 -178.348 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.91 144.45 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.312 0 CA-C-N 113.459 -1.7 . . . . 0.0 109.929 -179.657 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.59 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.1 p-10 -50.79 107.56 0.18 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.521 0.677 . . . . 0.0 111.458 -178.583 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.32 13.5 9.77 Favored Glycine 0 N--CA 1.485 1.938 0 C-N-CA 119.435 -1.364 . . . . 0.0 112.935 177.342 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.608 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.6 t -104.45 -172.61 2.13 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 121.213 2.507 . . . . 0.0 109.734 179.261 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.551 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 15.9 t -129.37 138.3 54.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.371 0 CA-C-N 114.761 -1.109 . . . . 0.0 111.019 -179.014 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.524 HG13 ' CG2' ' A' ' 69' ' ' VAL . 27.8 m -113.67 154.62 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.922 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.491 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -108.55 109.38 20.6 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.208 -0.932 . . . . 0.0 108.996 179.936 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.509 HG13 ' CG2' ' A' ' 34' ' ' VAL . 2.1 p -103.49 140.89 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.789 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.569 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -136.35 160.54 38.42 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 118.659 -1.216 . . . . 0.0 109.89 179.734 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.583 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.18 143.81 15.46 Favored Glycine 0 C--N 1.293 -1.814 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 179.716 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.518 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.26 124.96 12.55 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 120.908 -1.348 . . . . 0.0 108.882 179.185 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.525 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.86 27.58 23.59 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 119.339 -1.41 . . . . 0.0 109.659 -179.68 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.562 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.7 mt -86.72 175.53 8.21 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 120.909 -1.348 . . . . 0.0 108.62 -179.781 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.553 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.54 97.12 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.047 -1.033 . . . . 0.0 109.58 -179.821 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 76.19 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.495 -178.978 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.21 33.27 0.28 Allowed Glycine 0 N--CA 1.486 1.985 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.26 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.61 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.4 t -148.13 115.32 6.18 Favored 'General case' 0 C--N 1.308 -1.214 0 O-C-N 120.831 -1.394 . . . . 0.0 111.276 179.973 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.546 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.3 127.84 5.88 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.781 178.367 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.61 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.8 m-85 -119.09 149.03 42.38 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.51 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.477 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.62 163.86 12.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.61 -1.307 . . . . 0.0 107.518 178.631 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.623 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 9.2 p -149.08 114.62 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.045 -1.035 . . . . 0.0 110.143 -177.74 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.489 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.14 -175.41 37.16 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 118.365 -1.874 . . . . 0.0 111.731 -179.865 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.557 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.34 109.01 21.19 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-O 121.829 0.823 . . . . 0.0 108.819 -179.695 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.47 149.04 52.33 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.231 -0.918 . . . . 0.0 109.6 179.751 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.48 139.24 54.07 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.301 -0.875 . . . . 0.0 110.732 -179.041 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.621 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 114.78 26.6 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.174 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.4 m -105.53 15.29 6.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.999 -1.063 . . . . 0.0 110.573 -178.639 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.09 -175.42 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.955 -1.091 . . . . 0.0 110.003 179.734 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 56.8 p -71.95 97.45 1.86 Allowed 'General case' 0 N--CA 1.485 1.305 0 O-C-N 121.364 -0.835 . . . . 0.0 109.748 -179.73 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.65 27.71 34.5 Favored Glycine 0 N--CA 1.492 2.404 0 C-N-CA 120.235 -0.983 . . . . 0.0 111.423 178.985 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.591 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.05 106.24 19.98 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 O-C-N 120.59 -1.536 . . . . 0.0 107.29 178.829 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.621 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.4 tp -116.71 104.55 11.47 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.478 -1.388 . . . . 0.0 109.81 -177.715 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.544 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.2 109.45 22.21 Favored 'General case' 0 N--CA 1.485 1.276 0 O-C-N 120.834 -1.166 . . . . 0.0 107.945 178.828 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -107.4 163.9 12.65 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.964 -1.085 . . . . 0.0 110.297 -178.73 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.494 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 38.8 t30 -108.56 128.77 24.98 Favored Pre-proline 0 N--CA 1.501 2.111 0 O-C-N 121.46 -0.775 . . . . 0.0 109.503 -179.386 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.585 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -70.14 19.76 0.19 Allowed 'Trans proline' 0 CA--C 1.544 1.017 0 C-N-CA 122.088 1.859 . . . . 0.0 112.386 -179.867 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.494 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -108.96 4.85 23.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.388 -1.445 . . . . 0.0 108.868 179.157 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.518 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.79 16.7 2.68 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 179.497 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -81.67 90.58 6.33 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.974 -0.691 . . . . 0.0 111.088 -178.446 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.39 -171.08 1.77 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 178.015 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.464 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.85 134.99 0.09 Allowed 'General case' 0 C--N 1.305 -1.356 0 O-C-N 120.403 -1.435 . . . . 0.0 111.554 -179.357 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.601 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.5 p -150.07 159.11 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 177.894 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.546 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.57 146.05 25.66 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.543 -1.348 . . . . 0.0 109.726 -179.724 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.675 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.24 108.71 3.28 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 122.31 1.052 . . . . 0.0 109.629 178.999 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.524 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.5 t0 -63.02 -138.65 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.526 179.858 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -53.7 -51.45 63.2 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.289 -0.882 . . . . 0.0 110.21 -178.931 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.8 p-10 -98.58 -37.08 9.68 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 178.563 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.675 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 106.06 65.62 0.64 Allowed Glycine 0 C--N 1.297 -1.588 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.412 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.583 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 53.7 p -98.49 132.62 43.77 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 121.426 -1.043 . . . . 0.0 109.245 179.28 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.601 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -138.02 108.53 6.55 Favored 'General case' 0 C--N 1.296 -1.754 0 C-N-CA 119.235 -0.986 . . . . 0.0 109.52 -179.708 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.407 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 21.8 p -124.82 120.75 32.61 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.147 -0.97 . . . . 0.0 109.797 -179.803 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.466 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -148.04 146.72 28.99 Favored 'General case' 0 C--N 1.3 -1.587 0 O-C-N 121.581 -0.7 . . . . 0.0 109.304 179.648 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.4 p -100.61 138.88 37.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.322 -0.861 . . . . 0.0 109.404 179.975 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.526 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.1 OUTLIER -138.03 165.54 26.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.404 -0.81 . . . . 0.0 109.529 -179.405 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.551 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.2 p -96.8 125.7 41.44 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.068 -1.02 . . . . 0.0 109.354 -179.857 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.533 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -136.8 144.42 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.99 -1.069 . . . . 0.0 109.888 -179.26 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.59 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.0 OUTLIER -149.0 -174.93 4.77 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 120.455 -1.403 . . . . 0.0 110.998 -179.845 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.561 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.94 -101.84 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 -179.766 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.05 140.46 49.06 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.815 -1.178 . . . . 0.0 108.052 179.43 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.58 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -161.79 137.13 7.45 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 118.642 -1.223 . . . . 0.0 109.759 -178.118 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.481 ' C ' ' O ' ' A' ' 73' ' ' PHE . 10.3 mm-40 -34.97 122.06 0.55 Allowed 'General case' 0 N--CA 1.49 1.546 0 CA-C-O 121.387 0.613 . . . . 0.0 110.351 -178.468 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.544 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.29 51.25 1.86 Allowed Glycine 0 N--CA 1.493 2.458 0 C-N-CA 120.548 -0.835 . . . . 0.0 111.06 -179.268 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.585 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -39.24 115.39 0.49 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.04 -1.271 . . . . 0.0 110.108 179.572 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.53 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -86.49 126.46 34.45 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 120.928 -1.108 . . . . 0.0 109.495 -179.895 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.576 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.8 t80 -64.38 58.46 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.989 0 O-C-N 120.876 -1.14 . . . . 0.0 110.091 179.685 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' LEU . 17.0 t0 -160.19 19.65 0.15 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.987 -1.07 . . . . 0.0 109.664 179.83 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.05 -28.03 5.26 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.999 -1.241 . . . . 0.0 109.999 179.931 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.414 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 10.3 p -94.27 161.0 14.43 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.034 -1.274 . . . . 0.0 110.384 -179.446 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.467 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -107.97 138.13 44.77 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.84 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.462 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -83.61 -17.96 39.82 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.71 -1.244 . . . . 0.0 110.674 -178.411 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.0 176.43 19.99 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 108.644 -1.783 . . . . 0.0 108.644 -179.648 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.53 104.45 1.01 Allowed 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.188 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.565 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 41.0 t -76.09 106.62 6.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.287 -0.883 . . . . 0.0 109.133 -178.926 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.7 OUTLIER -65.68 111.24 3.1 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.493 -0.755 . . . . 0.0 110.026 -179.352 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.561 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.47 -5.71 4.07 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.813 179.353 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.5 p -86.58 -0.93 57.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.747 -1.221 . . . . 0.0 109.202 179.681 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.453 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -112.87 -50.1 2.9 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.29 -0.881 . . . . 0.0 108.995 179.977 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.94 -179.04 3.83 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.488 -0.757 . . . . 0.0 109.42 179.782 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.06 115.75 30.8 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.386 -0.821 . . . . 0.0 108.905 179.992 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.531 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -96.87 121.43 38.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.851 -1.156 . . . . 0.0 109.483 -179.455 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.85 146.29 28.5 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.437 1.113 . . . . 0.0 111.215 -179.32 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.3 t -102.46 109.77 27.35 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 177.632 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.401 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.6 -173.11 18.38 Favored Glycine 0 N--CA 1.486 2.016 0 C-N-CA 118.142 -1.98 . . . . 0.0 111.709 -177.601 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.477 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -113.71 -178.95 3.5 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.069 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.589 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.0 OUTLIER -175.88 170.62 2.76 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.219 -0.926 . . . . 0.0 109.711 -179.203 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.423 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -122.46 -159.33 0.82 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.025 -1.047 . . . . 0.0 108.856 179.786 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.423 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.86 36.08 4.34 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.685 -1.259 . . . . 0.0 109.2 -179.926 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.55 -33.07 5.68 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.359 -0.838 . . . . 0.0 110.034 -179.669 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.521 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 164.89 -35.64 0.27 Allowed Glycine 0 N--CA 1.481 1.696 0 N-CA-C 107.776 -2.13 . . . . 0.0 107.776 -179.673 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.61 -177.72 5.76 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-O 122.007 0.908 . . . . 0.0 109.785 179.279 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.38 -161.85 15.27 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 -179.44 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.3 Cg_exo -47.08 177.98 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.693 0 CA-C-N 118.874 1.337 . . . . 0.0 110.202 179.324 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -92.27 -175.17 3.96 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.06 -1.025 . . . . 0.0 110.511 -178.83 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.401 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.24 163.46 14.68 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.944 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.9 128.92 52.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.426 -1.044 . . . . 0.0 109.222 -179.441 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.22 123.22 23.26 Favored 'General case' 0 C--N 1.29 -2.015 0 O-C-N 121.687 -0.633 . . . . 0.0 109.562 179.672 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.596 ' CD1' ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.72 167.69 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 O-C-N 121.221 -0.924 . . . . 0.0 109.193 -179.925 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.507 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -134.73 154.26 51.65 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.277 -0.889 . . . . 0.0 109.565 -179.873 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.596 ' CZ ' ' CD1' ' A' ' 110' ' ' ILE . 30.3 m-85 -122.98 117.43 25.48 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.15 -0.969 . . . . 0.0 109.566 -179.729 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 112' ' ' PHE . 20.9 p30 . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 118.018 -0.992 . . . . 0.0 109.479 -179.972 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.589 ' C20' ' CB ' ' A' ' 98' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 121.301 0.572 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 037 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.426 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . . . -120.58 168.36 10.83 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.966 . . . . 0.0 109.516 -179.94 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.53 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.4 Cg_exo -59.89 158.34 29.62 Favored 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 122.355 2.037 . . . . 0.0 110.577 179.971 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.537 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.42 -169.81 0.15 Allowed 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 179.239 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.537 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -166.5 131.46 2.2 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 120.771 -1.206 . . . . 0.0 110.863 -179.111 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.545 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.6 t -112.46 108.58 17.76 Favored 'General case' 0 C--N 1.296 -1.738 0 CA-C-O 123.084 1.421 . . . . 0.0 109.117 179.357 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.526 ' CG2' HG21 ' A' ' 21' ' ' VAL . 2.4 t -115.31 140.38 36.99 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.699 0 CA-C-N 114.275 -1.329 . . . . 0.0 110.102 -179.521 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.519 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -176.04 149.82 1.03 Allowed Pre-proline 0 N--CA 1.487 1.375 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.772 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.519 ' CA ' HG21 ' A' ' 8' ' ' THR . 4.2 Cg_endo -77.43 152.57 93.88 Favored 'Cis proline' 0 C--N 1.312 -1.353 0 C-N-CA 123.572 -1.428 . . . . 0.0 109.313 -0.813 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.447 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 3.5 m -89.76 -26.51 20.58 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 179.761 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.476 ' HB3' ' HB2' ' A' ' 111' ' ' SER . 5.3 m -135.23 164.31 27.99 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.587 -0.696 . . . . 0.0 109.609 179.858 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.3 37.03 29.14 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 108.767 -1.733 . . . . 0.0 108.767 -179.841 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.6 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 40.6 mt -93.23 -42.69 9.21 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-O 123.242 1.496 . . . . 0.0 110.405 -178.406 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.494 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.83 145.3 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.277 0 CA-C-N 113.322 -1.763 . . . . 0.0 109.954 -179.735 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.593 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.2 p-10 -51.26 106.81 0.15 Allowed 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.493 0.663 . . . . 0.0 111.513 -178.749 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.54 13.16 9.01 Favored Glycine 0 N--CA 1.483 1.823 0 C-N-CA 119.401 -1.38 . . . . 0.0 112.986 177.317 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.6 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.2 t -105.31 -172.4 2.09 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 121.242 2.521 . . . . 0.0 109.673 179.167 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.535 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 20.2 t -126.6 135.56 63.39 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 114.866 -1.061 . . . . 0.0 111.097 -178.897 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.583 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 17.3 m -109.04 156.82 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.664 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -114.06 109.27 18.18 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.091 -1.005 . . . . 0.0 109.16 179.949 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.526 HG21 ' CG2' ' A' ' 7' ' ' VAL . 2.0 p -104.07 140.01 23.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 179.749 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.558 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -134.77 160.4 38.29 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 118.605 -1.238 . . . . 0.0 109.85 179.856 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -131.4 144.96 16.6 Favored Glycine 0 C--N 1.293 -1.807 0 N-CA-C 108.179 -1.968 . . . . 0.0 108.179 179.751 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.512 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.88 124.53 11.79 Favored 'General case' 0 C--N 1.295 -1.792 0 O-C-N 120.901 -1.352 . . . . 0.0 108.785 179.182 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.53 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.99 26.7 23.47 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.337 -1.411 . . . . 0.0 109.631 -179.623 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.544 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.9 mt -87.43 174.57 8.44 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 120.897 -1.355 . . . . 0.0 108.445 -179.901 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.556 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.42 96.96 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.04 -1.037 . . . . 0.0 109.674 -179.714 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.546 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 76.83 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.45 -179.091 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.01 33.77 0.32 Allowed Glycine 0 N--CA 1.486 2.027 0 N-CA-C 109.731 -1.347 . . . . 0.0 109.731 179.347 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.543 ' CG2' ' CB ' ' A' ' 27' ' ' GLN . 1.2 t -148.15 114.88 6.03 Favored 'General case' 0 C--N 1.309 -1.181 0 O-C-N 120.869 -1.371 . . . . 0.0 111.098 179.899 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.555 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.45 129.86 3.93 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.996 178.55 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.553 ' CE1' ' OD1' ' A' ' 99' ' ' ASP . 10.7 m-85 -119.47 150.84 39.55 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.368 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -102.05 159.39 15.41 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.703 -1.248 . . . . 0.0 107.856 178.728 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.624 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.1 p -144.03 117.27 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.075 -1.016 . . . . 0.0 109.852 -177.914 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.12 -178.73 40.18 Favored Glycine 0 N--CA 1.494 2.518 0 C-N-CA 118.324 -1.893 . . . . 0.0 111.849 -179.86 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.56 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -100.43 108.88 20.98 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -179.862 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.24 148.34 52.06 Favored 'General case' 0 C--N 1.296 -1.731 0 O-C-N 121.286 -0.884 . . . . 0.0 109.704 179.777 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -121.96 138.63 54.34 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.274 -0.891 . . . . 0.0 110.776 -179.005 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.626 ' CE2' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.45 114.75 26.55 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 178.137 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -106.12 14.79 7.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.934 -1.104 . . . . 0.0 110.64 -178.716 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.61 -175.65 0.08 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.926 -1.109 . . . . 0.0 110.101 179.694 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.546 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.3 97.53 1.26 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 121.799 0.809 . . . . 0.0 110.031 -179.605 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.26 27.11 37.64 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 120.261 -0.971 . . . . 0.0 111.429 178.785 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -114.85 106.14 20.03 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 O-C-N 120.617 -1.519 . . . . 0.0 107.375 178.818 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.626 HD13 ' CE2' ' A' ' 39' ' ' TRP . 12.4 tp -117.01 104.71 11.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.459 -1.401 . . . . 0.0 109.629 -177.803 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.94 109.55 22.28 Favored 'General case' 0 N--CA 1.485 1.316 0 O-C-N 120.808 -1.183 . . . . 0.0 108.415 179.093 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.6 t -105.98 162.83 13.25 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.952 -1.092 . . . . 0.0 110.115 -179.254 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.488 ' OD1' ' HB2' ' A' ' 74' ' ' GLU . 17.0 t30 -107.01 140.89 21.84 Favored Pre-proline 0 N--CA 1.504 2.259 0 O-C-N 121.348 -0.845 . . . . 0.0 110.13 -179.218 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.581 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 8.2 Cg_endo -76.36 27.65 0.41 Allowed 'Trans proline' 0 C--N 1.318 -1.029 0 C-N-CA 122.662 2.241 . . . . 0.0 111.636 -179.665 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.417 ' CB ' ' ND2' ' A' ' 48' ' ' ASN . . . -121.49 3.57 10.21 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.394 -1.441 . . . . 0.0 109.522 -179.869 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.5 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -138.48 15.41 2.75 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 179.435 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.413 ' CE1' H313 ' A' ' 114' ' ' CHR . 0.6 OUTLIER -80.11 91.68 5.55 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.508 -0.745 . . . . 0.0 110.815 -178.675 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.59 -168.53 1.33 Allowed 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.387 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.474 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.98 135.2 0.09 Allowed 'General case' 0 N--CA 1.486 1.349 0 O-C-N 120.633 -1.292 . . . . 0.0 111.486 -179.381 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.585 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.4 p -149.02 157.53 6.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 177.935 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.555 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.28 146.61 24.96 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.636 -1.29 . . . . 0.0 109.897 -179.489 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.678 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -67.26 108.31 2.68 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-O 122.361 1.077 . . . . 0.0 109.622 178.847 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.519 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.6 t0 -62.95 -138.94 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.005 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.822 -179.867 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.546 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.9 -51.99 36.42 Favored 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.349 -0.845 . . . . 0.0 110.676 -178.657 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.06 -32.36 9.24 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.714 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.678 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.07 64.89 0.61 Allowed Glycine 0 C--N 1.298 -1.583 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 178.262 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.5 m -99.57 129.31 45.72 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.465 -1.021 . . . . 0.0 108.664 178.772 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.585 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.74 108.63 6.69 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.805 -179.329 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.443 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 51.8 p -122.15 119.45 31.32 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.259 -0.901 . . . . 0.0 109.455 179.936 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.422 HG22 HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.22 143.46 30.29 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.519 -0.738 . . . . 0.0 109.417 179.894 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.9 p -100.01 140.63 33.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.406 -0.809 . . . . 0.0 109.406 179.961 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.527 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -139.37 168.82 18.97 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.405 -0.809 . . . . 0.0 109.382 -179.426 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.8 p -96.82 124.86 40.92 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.03 -1.044 . . . . 0.0 109.424 -179.823 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.531 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 15.9 m -137.05 143.54 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.932 -1.105 . . . . 0.0 109.728 -179.259 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.593 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.1 ptt180 -148.79 -175.34 4.91 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.519 -1.363 . . . . 0.0 110.9 -179.835 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.561 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.76 -101.2 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.7 -179.413 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.86 142.03 42.61 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.812 -1.18 . . . . 0.0 108.319 179.785 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.582 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.93 134.59 4.38 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 118.783 -1.167 . . . . 0.0 109.64 -178.209 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.514 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -33.81 122.82 0.46 Allowed 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.519 0.676 . . . . 0.0 110.465 -178.138 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.2 49.15 2.7 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.273 -179.187 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.581 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -38.47 115.0 0.42 Allowed 'General case' 0 N--CA 1.509 2.519 0 O-C-N 121.096 -1.237 . . . . 0.0 109.909 179.615 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.548 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -86.72 126.42 34.55 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.938 -1.101 . . . . 0.0 109.357 179.972 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.576 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 24.5 t80 -63.48 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.902 -1.124 . . . . 0.0 110.307 179.912 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.548 ' N ' ' O ' ' A' ' 77' ' ' LEU . 22.2 t0 -162.04 20.18 0.1 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.992 -1.068 . . . . 0.0 109.786 179.736 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.65 -27.76 5.17 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 179.821 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.432 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 14.3 p -93.15 160.23 14.94 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.047 -1.267 . . . . 0.0 110.26 -179.466 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.467 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.4 OUTLIER -107.63 136.69 46.96 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.835 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.456 ' CD1' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -82.56 -19.1 39.19 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.848 -1.158 . . . . 0.0 110.407 -178.667 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.54 175.41 19.14 Favored Glycine 0 N--CA 1.485 1.908 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.613 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.84 107.14 1.37 Allowed 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.271 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.561 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 47.2 t -79.62 106.71 11.11 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.362 -0.836 . . . . 0.0 109.262 -179.014 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.8 OUTLIER -67.69 111.67 4.37 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.407 -0.808 . . . . 0.0 109.805 -179.554 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.561 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.16 -5.69 3.49 Favored 'General case' 0 N--CA 1.5 2.046 0 C-N-CA 118.189 -1.404 . . . . 0.0 109.826 179.414 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.14 0.02 54.58 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.644 -1.285 . . . . 0.0 109.158 179.51 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.448 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.66 -49.72 2.87 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.366 -0.834 . . . . 0.0 109.007 -179.98 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.77 179.63 4.21 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.433 -0.792 . . . . 0.0 109.482 179.944 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.94 116.13 31.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.445 -0.785 . . . . 0.0 108.922 179.908 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.85 121.8 39.11 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.86 -1.15 . . . . 0.0 109.371 -179.381 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.55 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.68 146.51 27.63 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.411 1.101 . . . . 0.0 111.359 -179.213 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.456 HG22 HG23 ' A' ' 110' ' ' ILE . 65.7 t -102.95 110.06 28.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 177.502 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.76 -173.01 17.61 Favored Glycine 0 N--CA 1.487 2.063 0 C-N-CA 118.041 -2.028 . . . . 0.0 111.828 -177.441 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.481 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -115.98 -178.11 3.32 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 -179.057 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.539 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 1.0 OUTLIER -172.28 166.46 5.9 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.234 -0.916 . . . . 0.0 109.331 -179.527 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.553 ' OD1' ' CE1' ' A' ' 32' ' ' TYR . 7.9 m-20 -99.46 -13.41 19.53 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.173 -0.955 . . . . 0.0 109.402 179.882 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.517 ' CB ' ' O ' ' A' ' 99' ' ' ASP . . . 75.47 36.9 0.46 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.451 -0.78 . . . . 0.0 109.222 179.9 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.09 -33.51 0.83 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.53 -0.731 . . . . 0.0 110.704 -179.399 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.521 ' CA ' H192 ' A' ' 114' ' ' CHR . . . -177.59 -42.62 0.06 OUTLIER Glycine 0 N--CA 1.481 1.695 0 N-CA-C 107.687 -2.165 . . . . 0.0 107.687 -179.636 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.43 -178.49 7.18 Favored 'General case' 0 C--N 1.307 -1.245 0 O-C-N 121.527 -0.984 . . . . 0.0 109.431 179.05 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.64 -166.18 33.36 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -179.554 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.475 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.3 Cg_exo -49.09 -177.37 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.677 0 CA-C-N 118.7 1.25 . . . . 0.0 110.288 179.525 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -94.54 -176.85 4.04 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.082 -1.011 . . . . 0.0 110.419 -179.02 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -120.45 161.3 14.73 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.969 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.87 126.37 54.59 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.349 -1.089 . . . . 0.0 109.188 -179.472 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.55 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.1 119.76 16.75 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.745 -0.597 . . . . 0.0 109.431 179.669 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.548 ' CD1' ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.96 168.53 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.201 -0.937 . . . . 0.0 109.303 -179.956 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.476 ' HB2' ' HB3' ' A' ' 11' ' ' SER . 2.4 m -138.2 151.31 47.57 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.384 -0.823 . . . . 0.0 109.542 -179.955 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.548 ' CZ ' ' CD1' ' A' ' 110' ' ' ILE . 22.8 m-85 -126.38 104.91 8.42 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.146 -0.971 . . . . 0.0 109.531 -179.674 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.7 p30 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.502 -179.98 . . . . . . . . 0 0 . 1 . 037 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.587 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 0 0 . 1 . 038 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.63 143.99 39.42 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.206 -0.934 . . . . 0.0 109.222 179.781 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.508 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 3.2 Cg_exo -60.85 156.52 43.07 Favored 'Trans proline' 0 C--N 1.31 -1.468 0 C-N-CA 122.063 1.842 . . . . 0.0 110.415 179.984 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.607 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -146.62 159.24 43.7 Favored 'General case' 0 C--N 1.292 -1.899 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 -179.617 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -146.51 125.36 12.7 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-O 122.43 1.109 . . . . 0.0 110.129 -179.715 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.548 ' CG2' ' O ' ' A' ' 6' ' ' THR . 5.1 t -116.28 109.02 16.83 Favored 'General case' 0 C--N 1.293 -1.858 0 CA-C-O 123.129 1.442 . . . . 0.0 109.622 179.968 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.499 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 8.0 t -116.92 137.84 49.51 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.709 0 CA-C-N 114.074 -1.421 . . . . 0.0 109.862 -179.874 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.522 HG22 ' CA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -174.37 151.02 1.57 Allowed Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.331 -0.856 . . . . 0.0 108.804 -179.617 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.522 ' CA ' HG22 ' A' ' 8' ' ' THR . 5.3 Cg_endo -77.47 150.94 91.85 Favored 'Cis proline' 0 C--N 1.312 -1.383 0 C-N-CA 123.539 -1.442 . . . . 0.0 109.392 -0.907 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.455 ' HB2' ' HA ' ' A' ' 110' ' ' ILE . 89.6 p -92.52 -23.08 19.21 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 121.433 -0.792 . . . . 0.0 109.27 179.692 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.491 ' CB ' ' HB3' ' A' ' 111' ' ' SER . 7.0 m -132.16 159.97 37.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.484 -0.76 . . . . 0.0 109.542 -179.859 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.73 37.61 29.76 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.633 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.605 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.4 mt -91.1 -43.69 9.74 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-O 123.146 1.45 . . . . 0.0 110.641 -178.273 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.494 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.35 144.88 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.298 0 CA-C-N 113.471 -1.695 . . . . 0.0 110.224 -179.72 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.57 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.0 p-10 -50.2 106.11 0.11 Allowed 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.494 0.664 . . . . 0.0 111.626 -178.548 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.81 15.0 8.92 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 119.426 -1.368 . . . . 0.0 113.037 177.05 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.605 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.0 t -105.8 -174.02 2.44 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 121.29 2.545 . . . . 0.0 109.837 179.227 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.542 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 15.7 t -130.71 138.56 53.35 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 CA-C-N 114.702 -1.135 . . . . 0.0 111.178 -178.721 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.458 HG13 HD11 ' A' ' 13' ' ' LEU . 33.8 m -113.06 155.16 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 178.75 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.499 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -103.96 108.82 20.33 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.021 -1.05 . . . . 0.0 109.167 179.971 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.524 HG11 ' CG2' ' A' ' 34' ' ' VAL . 2.3 p -101.51 140.06 21.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.893 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.568 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -133.76 159.18 41.37 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.866 -1.146 . . . . 0.0 109.638 179.484 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.59 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -141.08 108.8 0.57 Allowed Glycine 0 N--CA 1.482 1.76 0 N-CA-C 108.753 -1.739 . . . . 0.0 108.753 179.97 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.607 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.28 140.35 49.42 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 119.259 1.529 . . . . 0.0 110.426 -179.461 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.508 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 85.48 26.9 34.32 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 118.945 -1.598 . . . . 0.0 109.946 179.57 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.552 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -93.0 169.88 10.09 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 120.933 -1.333 . . . . 0.0 108.534 -179.946 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.58 101.32 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.117 -0.989 . . . . 0.0 109.777 -179.426 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.92 77.88 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.864 -179.327 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.89 33.83 0.28 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.77 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.543 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 18.8 p -138.79 106.35 5.58 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.279 -1.13 . . . . 0.0 110.93 -179.465 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -51.39 109.91 0.39 Allowed 'General case' 0 N--CA 1.497 1.903 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.532 178.181 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.543 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 32.6 m-85 -102.81 155.8 18.08 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.147 -0.971 . . . . 0.0 108.901 179.74 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.439 ' HB3' H313 ' A' ' 114' ' ' CHR . 0.1 OUTLIER -100.46 158.42 15.92 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 178.696 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.63 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.3 p -139.83 120.07 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.189 -0.944 . . . . 0.0 109.472 -177.818 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -169.89 -178.34 40.86 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.23 -1.938 . . . . 0.0 111.796 -179.742 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.547 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -100.21 109.78 22.03 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.918 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 68.1 m -127.16 152.77 46.9 Favored 'General case' 0 C--N 1.293 -1.86 0 O-C-N 121.22 -0.925 . . . . 0.0 109.819 179.619 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -126.87 135.66 51.27 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.535 -0.728 . . . . 0.0 110.452 179.965 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.644 ' CE2' HD11 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.94 114.69 26.55 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.231 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 20.1 m -104.97 14.42 7.21 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 120.851 -1.155 . . . . 0.0 110.809 -178.65 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.596 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 173.73 -174.5 0.06 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.81 -1.181 . . . . 0.0 110.158 179.65 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 24.5 p -71.69 97.67 1.79 Allowed 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.467 -0.77 . . . . 0.0 109.827 -179.67 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.85 27.63 31.22 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 120.285 -0.959 . . . . 0.0 111.487 178.836 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.596 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.3 t -116.35 106.09 19.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 O-C-N 120.538 -1.566 . . . . 0.0 107.372 179.001 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.644 HD11 ' CE2' ' A' ' 39' ' ' TRP . 11.7 tp -116.85 106.37 13.38 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.548 -1.345 . . . . 0.0 109.989 -177.703 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.563 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -95.72 109.78 22.02 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.803 -1.185 . . . . 0.0 108.161 179.137 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 66.5 m -100.12 145.88 27.47 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.225 -0.922 . . . . 0.0 110.415 -178.354 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.475 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 7.4 t30 -99.23 129.23 29.8 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.217 -0.927 . . . . 0.0 108.673 179.097 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.4 Cg_endo -71.41 23.05 0.23 Allowed 'Trans proline' 0 C--N 1.317 -1.108 0 C-N-CA 122.102 1.868 . . . . 0.0 111.968 179.923 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -103.35 -5.86 22.54 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.4 -1.437 . . . . 0.0 109.106 179.68 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.534 ' CB ' ' HB3' ' A' ' 67' ' ' LEU . 5.6 m-20 -134.13 6.39 3.62 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.351 -0.843 . . . . 0.0 108.89 -179.961 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -62.42 84.18 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.336 -0.852 . . . . 0.0 110.655 -178.672 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.63 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.5 -167.87 1.32 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 178.605 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.474 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.47 135.73 0.08 Allowed 'General case' 0 C--N 1.304 -1.404 0 O-C-N 120.68 -1.262 . . . . 0.0 111.383 -179.321 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.577 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -150.83 156.13 6.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 177.94 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.69 142.0 30.8 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.721 -1.237 . . . . 0.0 110.162 -179.525 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.678 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -62.26 106.4 0.73 Allowed 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 122.559 1.171 . . . . 0.0 109.45 178.316 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.526 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.2 p-10 -59.7 -139.51 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.862 179.962 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.75 -50.87 59.78 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.454 -0.778 . . . . 0.0 110.715 -178.711 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -102.94 -33.79 9.18 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 178.462 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.678 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.43 65.9 0.61 Allowed Glycine 0 C--N 1.298 -1.548 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.575 177.941 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.59 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 23.2 m -102.81 126.49 49.97 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 178.631 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.24 109.17 8.68 Favored 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 119.457 -0.897 . . . . 0.0 109.296 -179.29 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.4 m -123.35 119.42 30.04 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.412 -0.805 . . . . 0.0 109.646 -179.73 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.55 150.31 36.17 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.698 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.2 p -98.04 136.7 37.92 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.196 -0.94 . . . . 0.0 109.484 -179.785 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.542 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.2 OUTLIER -128.99 160.65 32.06 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.442 -0.786 . . . . 0.0 109.485 -178.913 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.537 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.3 p -100.95 123.23 44.82 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.03 -1.044 . . . . 0.0 108.861 179.525 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.524 ' CB ' ' OE1' ' A' ' 36' ' ' GLN . 17.6 m -135.25 142.81 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 120.872 -1.143 . . . . 0.0 110.486 -178.579 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.57 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.4 ptt180 -145.5 -171.81 3.75 Favored 'General case' 0 N--CA 1.484 1.263 0 O-C-N 120.582 -1.324 . . . . 0.0 110.825 179.55 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.541 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -57.34 -99.67 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.197 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.465 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.79 142.23 50.8 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 120.343 -1.473 . . . . 0.0 108.218 179.517 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.591 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -162.07 135.09 6.05 Favored 'General case' 0 C--N 1.295 -1.771 0 C-N-CA 118.581 -1.248 . . . . 0.0 110.027 -178.05 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.487 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 20.5 mt-10 -35.22 120.99 0.55 Allowed 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.458 0.647 . . . . 0.0 110.231 -178.723 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.563 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -94.74 51.22 2.01 Favored Glycine 0 N--CA 1.494 2.55 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.665 -178.793 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.587 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -38.32 115.88 0.48 Allowed 'General case' 0 N--CA 1.507 2.396 0 O-C-N 121.04 -1.271 . . . . 0.0 110.012 179.26 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.1 tp -86.78 126.06 34.35 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 120.816 -1.177 . . . . 0.0 109.594 -179.623 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.581 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 30.9 t80 -64.34 58.93 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.842 -1.161 . . . . 0.0 109.837 179.519 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.6 t70 -159.68 19.76 0.17 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.984 -1.072 . . . . 0.0 109.715 179.936 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.6 -27.91 5.59 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.811 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.443 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 73.1 p -98.49 162.6 13.07 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.142 -1.21 . . . . 0.0 110.39 -179.439 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.473 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 2.1 ptt180 -106.54 142.13 36.7 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.859 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.471 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.6 t90 -85.19 -19.77 31.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.635 -1.291 . . . . 0.0 110.601 -178.505 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.1 177.12 18.77 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.631 -1.788 . . . . 0.0 108.631 -179.424 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -66.4 105.33 1.43 Allowed 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 179.198 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.591 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 44.3 t -76.13 104.83 4.52 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.24 -0.913 . . . . 0.0 109.048 -179.058 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -66.05 111.17 3.24 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.46 -0.775 . . . . 0.0 109.686 -179.508 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.541 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.77 -4.85 4.76 Favored 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 118.245 -1.382 . . . . 0.0 109.71 179.51 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -86.83 1.81 51.15 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.782 -1.199 . . . . 0.0 109.017 179.341 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.465 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -117.01 -51.14 2.56 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.376 -0.828 . . . . 0.0 108.951 179.975 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.31 -179.92 4.09 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.479 -0.763 . . . . 0.0 109.383 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.25 115.7 30.85 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.446 -0.784 . . . . 0.0 108.935 179.807 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.527 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 2.7 m -97.03 124.53 41.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.84 -1.162 . . . . 0.0 109.582 -179.264 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.52 ' HA ' ' O ' ' A' ' 108' ' ' VAL . 1.0 OUTLIER -102.97 147.73 26.57 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.344 1.069 . . . . 0.0 111.405 -179.241 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.482 ' CG1' HG12 ' A' ' 7' ' ' VAL . 44.8 t -104.6 113.12 40.78 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 177.498 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -155.08 -169.77 19.99 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 117.886 -2.102 . . . . 0.0 111.802 -177.766 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.469 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -120.56 177.59 5.0 Favored 'General case' 0 N--CA 1.484 1.245 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -179.138 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.584 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 2.1 t 177.52 163.57 0.57 Allowed 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.907 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -107.44 -162.61 0.85 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.916 -1.115 . . . . 0.0 109.138 -179.79 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -115.82 35.83 4.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.697 -1.252 . . . . 0.0 109.112 -179.969 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -112.31 -32.23 6.58 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.458 -0.776 . . . . 0.0 109.864 -179.633 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 165.1 -35.34 0.27 Allowed Glycine 0 N--CA 1.481 1.654 0 N-CA-C 107.96 -2.056 . . . . 0.0 107.96 -179.656 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.53 -177.65 6.08 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-O 122.1 0.952 . . . . 0.0 109.839 179.263 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.496 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.31 -161.34 21.77 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.176 -1.97 . . . . 0.0 108.176 -179.361 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.496 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.3 Cg_exo -47.73 -178.77 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.671 0 CA-C-N 118.96 1.38 . . . . 0.0 110.313 179.206 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -96.69 178.04 5.45 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.979 -1.075 . . . . 0.0 110.364 -178.958 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.467 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.7 172.64 14.32 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.983 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -110.87 153.55 12.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.495 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.52 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -95.75 122.45 38.55 Favored 'General case' 0 C--N 1.291 -1.959 0 O-C-N 121.217 -0.927 . . . . 0.0 109.392 179.79 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.577 HD13 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.99 168.98 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 121.091 -1.005 . . . . 0.0 109.032 -179.905 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.491 ' HB3' ' CB ' ' A' ' 11' ' ' SER . 13.0 t -138.92 157.9 45.18 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.175 -0.953 . . . . 0.0 109.68 -179.91 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.577 ' CE2' HD13 ' A' ' 110' ' ' ILE . 82.0 m-85 -134.02 93.76 3.15 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.23 -0.919 . . . . 0.0 109.488 -179.706 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 17.5 p30 . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 118.065 -0.969 . . . . 0.0 109.464 -179.957 . . . . . . . . 0 0 . 1 . 038 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.586 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 121.305 0.574 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 039 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -89.19 164.97 28.56 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.194 -0.942 . . . . 0.0 109.458 179.979 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.51 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 4.3 Cg_exo -60.58 157.03 38.8 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.256 1.971 . . . . 0.0 110.495 179.94 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.609 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -147.0 160.64 42.12 Favored 'General case' 0 C--N 1.295 -1.797 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -179.6 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.493 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.55 122.39 9.33 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 122.366 1.079 . . . . 0.0 110.28 -179.715 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.551 ' CG2' ' O ' ' A' ' 6' ' ' THR . 5.6 t -115.9 109.16 17.22 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 123.122 1.439 . . . . 0.0 109.829 -179.827 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.516 HG13 ' CG1' ' A' ' 95' ' ' VAL . 2.2 t -114.78 133.7 60.1 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.19 -1.368 . . . . 0.0 109.787 179.855 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.52 HG22 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -169.26 150.17 4.15 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.232 -0.917 . . . . 0.0 108.809 -179.604 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.52 ' CA ' HG22 ' A' ' 8' ' ' THR . 1.2 Cg_endo -75.33 155.31 99.56 Favored 'Cis proline' 0 C--N 1.312 -1.35 0 C-N-CA 123.521 -1.45 . . . . 0.0 109.399 -0.873 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.493 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 15.4 m -99.62 -19.83 16.63 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.754 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.51 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 19.2 m -136.02 159.07 42.84 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.426 -0.796 . . . . 0.0 109.678 -179.945 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.37 37.78 30.67 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 108.526 -1.829 . . . . 0.0 108.526 -179.688 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.613 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 30.1 mt -89.75 -44.31 10.08 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 123.056 1.407 . . . . 0.0 110.599 -178.383 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.478 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.0 144.39 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.363 0 CA-C-N 113.633 -1.622 . . . . 0.0 109.935 -179.638 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.584 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.1 p-10 -50.86 105.0 0.09 Allowed 'General case' 0 C--N 1.301 -1.504 0 CA-C-O 121.632 0.729 . . . . 0.0 111.435 -178.565 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.04 14.77 7.61 Favored Glycine 0 N--CA 1.485 1.902 0 C-N-CA 119.396 -1.383 . . . . 0.0 113.055 177.383 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.613 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 13.7 t -104.48 -173.55 2.33 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 121.264 2.532 . . . . 0.0 109.717 179.116 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.546 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 18.1 t -127.65 135.99 61.64 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.89 -1.05 . . . . 0.0 111.424 -178.598 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.526 HG11 ' CG2' ' A' ' 69' ' ' VAL . 34.7 m -111.2 154.6 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.529 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.496 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 5.4 tttt -110.31 109.28 19.66 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 108.894 179.875 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.516 HG13 ' CG2' ' A' ' 34' ' ' VAL . 2.3 p -101.27 139.17 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.347 -0.846 . . . . 0.0 108.734 -179.929 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.594 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -134.0 162.38 32.22 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 118.819 -1.153 . . . . 0.0 110.107 179.656 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.6 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.71 140.35 11.39 Favored Glycine 0 C--N 1.299 -1.525 0 N-CA-C 107.899 -2.08 . . . . 0.0 107.899 179.694 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.609 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.94 124.96 15.24 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.514 -1.58 . . . . 0.0 109.409 179.299 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.51 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.55 28.62 18.81 Favored Glycine 0 N--CA 1.488 2.107 0 C-N-CA 118.776 -1.678 . . . . 0.0 109.678 -179.705 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -89.79 171.86 9.32 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.006 -1.291 . . . . 0.0 108.249 179.875 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.552 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.92 99.6 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.969 -1.082 . . . . 0.0 109.926 -179.498 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.5 77.05 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.136 -179.333 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.91 33.83 0.22 Allowed Glycine 0 N--CA 1.486 2.022 0 N-CA-C 109.311 -1.515 . . . . 0.0 109.311 179.634 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 40.4 p -141.38 107.32 5.16 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 121.09 -1.241 . . . . 0.0 111.399 -179.35 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.83 109.79 0.36 Allowed 'General case' 0 N--CA 1.496 1.835 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.621 177.828 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.593 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 4.4 m-30 -105.42 157.54 17.27 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.119 -0.988 . . . . 0.0 108.798 179.745 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.474 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -100.45 167.52 10.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.762 -1.211 . . . . 0.0 108.048 179.209 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.624 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.7 p -148.13 119.59 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.132 -0.98 . . . . 0.0 109.648 -178.094 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -171.26 -176.74 40.59 Favored Glycine 0 N--CA 1.496 2.638 0 C-N-CA 118.369 -1.872 . . . . 0.0 111.5 -179.763 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.56 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -100.71 108.3 20.13 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 -179.979 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -130.01 148.32 51.85 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.306 -0.872 . . . . 0.0 109.833 179.685 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.25 139.84 53.53 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.227 -0.921 . . . . 0.0 110.739 -179.024 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.617 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.12 114.93 26.78 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.119 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.7 m -106.21 15.49 7.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.035 -1.041 . . . . 0.0 110.526 -178.724 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.594 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.7 -176.66 0.09 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.948 -1.095 . . . . 0.0 110.068 179.739 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.548 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.2 t -69.78 96.72 1.01 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.503 -0.748 . . . . 0.0 110.009 -179.61 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.93 28.82 33.39 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 120.15 -1.024 . . . . 0.0 111.355 178.892 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.594 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.25 106.42 20.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 O-C-N 120.586 -1.538 . . . . 0.0 107.221 178.769 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.617 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.7 tp -116.89 104.68 11.55 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.427 -1.421 . . . . 0.0 109.706 -177.545 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -98.23 109.54 22.28 Favored 'General case' 0 N--CA 1.484 1.244 0 O-C-N 120.827 -1.171 . . . . 0.0 108.295 178.928 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -106.27 166.13 10.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.956 -1.09 . . . . 0.0 110.209 -179.073 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.54 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 12.6 t-20 -108.22 134.45 20.18 Favored Pre-proline 0 N--CA 1.498 1.952 0 O-C-N 121.376 -0.827 . . . . 0.0 109.599 -179.411 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.1 Cg_endo -73.93 24.29 0.34 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 122.452 2.102 . . . . 0.0 112.108 -179.655 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.54 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -113.75 -0.69 14.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.322 -1.486 . . . . 0.0 109.183 179.643 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.557 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 2.2 m-20 -136.38 18.26 3.15 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 179.651 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -78.04 83.96 4.32 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.66 -0.816 . . . . 0.0 110.62 -178.525 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -106.27 -170.51 1.74 Allowed 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 178.523 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.471 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.61 136.39 0.09 Allowed 'General case' 0 C--N 1.305 -1.351 0 O-C-N 120.705 -1.247 . . . . 0.0 111.008 -179.273 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.584 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.7 p -148.58 159.07 6.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 178.259 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.56 141.6 31.2 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 120.729 -1.232 . . . . 0.0 109.802 -179.923 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.672 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -65.09 108.04 1.72 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 122.305 1.05 . . . . 0.0 109.651 178.57 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.54 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.0 t0 -64.08 -139.44 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.027 0 CA-C-O 121.377 0.608 . . . . 0.0 110.809 179.864 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.95 -52.0 36.91 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.386 -0.821 . . . . 0.0 110.821 -178.706 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -102.49 -32.17 10.08 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 178.633 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.672 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 103.3 66.6 0.73 Allowed Glycine 0 C--N 1.298 -1.572 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.262 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 52.6 m -98.82 130.73 45.26 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.603 -0.939 . . . . 0.0 108.764 178.866 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.594 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -134.09 109.13 8.74 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 119.299 -0.96 . . . . 0.0 109.335 -179.576 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.9 m -123.08 116.86 24.19 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.237 -0.914 . . . . 0.0 109.498 -179.803 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.455 HG21 HG13 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.24 143.58 29.31 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.385 -0.822 . . . . 0.0 109.523 -179.993 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.0 p -99.83 147.33 25.62 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.363 -0.835 . . . . 0.0 109.469 -179.892 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.544 ' HB2' ' OD2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -147.56 168.43 21.98 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.441 -0.787 . . . . 0.0 109.398 -179.155 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.546 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.5 p -100.19 121.81 42.03 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.84 -1.163 . . . . 0.0 110.098 -178.937 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.557 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 15.5 m -129.08 144.17 38.99 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 120.897 -1.127 . . . . 0.0 110.162 -179.404 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.584 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.7 ptt180 -149.1 -177.47 5.84 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 120.576 -1.327 . . . . 0.0 110.838 179.722 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.538 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.6 -102.58 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.702 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.508 ' OG ' ' NH1' ' A' ' 71' ' ' ARG . 0.7 OUTLIER -57.56 140.41 50.96 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 120.712 -1.242 . . . . 0.0 108.161 179.388 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.41 136.69 8.66 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.934 -178.124 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.485 ' C ' ' O ' ' A' ' 73' ' ' PHE . 8.9 mm-40 -32.28 120.15 0.29 Allowed 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.47 0.652 . . . . 0.0 110.6 -178.591 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -90.84 47.19 2.95 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.573 -0.823 . . . . 0.0 111.175 -179.195 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -38.38 113.99 0.33 Allowed 'General case' 0 N--CA 1.508 2.428 0 O-C-N 121.168 -1.195 . . . . 0.0 110.085 179.607 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.532 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -87.56 126.33 34.87 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.869 -1.145 . . . . 0.0 109.509 -179.816 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.582 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 16.4 t80 -64.26 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.856 -1.153 . . . . 0.0 110.035 179.693 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.0 t0 -159.87 19.25 0.16 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.982 -1.073 . . . . 0.0 109.735 179.895 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.93 -27.02 5.64 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.837 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 1.3 p -95.17 161.47 14.1 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.006 -1.29 . . . . 0.0 110.361 -179.491 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.463 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -107.66 136.32 47.61 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.832 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.483 ' CD1' HD11 ' A' ' 77' ' ' LEU . 2.3 t90 -83.03 -17.61 42.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.858 -1.151 . . . . 0.0 110.502 -178.649 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.71 174.02 19.65 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 108.862 -1.695 . . . . 0.0 108.862 -179.632 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.97 105.97 0.95 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.08 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.578 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 46.1 t -76.94 105.46 5.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.385 -0.822 . . . . 0.0 109.45 -178.682 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.467 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.9 m-20 -64.01 110.61 2.19 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.43 -0.793 . . . . 0.0 109.7 -179.624 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.538 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.3 t -65.0 -4.48 4.65 Favored 'General case' 0 N--CA 1.499 2.024 0 C-N-CA 118.289 -1.364 . . . . 0.0 109.969 179.505 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 38.7 p -86.82 -1.14 57.54 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.712 -1.242 . . . . 0.0 109.239 179.579 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.467 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -112.28 -50.27 2.91 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.34 -0.85 . . . . 0.0 108.917 -179.99 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.39 -178.27 3.61 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.596 -0.69 . . . . 0.0 109.301 179.724 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.29 115.51 30.33 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.349 -0.844 . . . . 0.0 109.14 -179.989 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.77 121.62 38.82 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.848 -1.158 . . . . 0.0 109.244 -179.578 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.608 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.31 145.26 30.22 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 122.424 1.107 . . . . 0.0 111.16 -179.176 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.516 ' CG1' HG13 ' A' ' 7' ' ' VAL . 49.1 t -101.73 109.88 27.1 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.999 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 177.68 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.453 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.7 -170.57 16.62 Favored Glycine 0 N--CA 1.486 2.012 0 C-N-CA 118.26 -1.924 . . . . 0.0 111.666 -177.569 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.474 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -112.91 179.61 3.92 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 -179.197 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.554 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 33.8 p -168.66 166.43 11.81 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.381 -0.824 . . . . 0.0 109.585 -179.328 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.593 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -116.71 -159.25 0.72 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.229 -0.919 . . . . 0.0 108.864 179.629 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.401 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -118.37 36.01 4.54 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.667 -1.271 . . . . 0.0 109.286 -179.911 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.66 -33.03 4.39 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.369 -0.832 . . . . 0.0 110.311 -179.572 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.5 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 167.07 -36.8 0.23 Allowed Glycine 0 N--CA 1.483 1.772 0 N-CA-C 107.657 -2.177 . . . . 0.0 107.657 -179.562 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.448 ' ND2' ' O9 ' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -159.58 -178.04 6.83 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 122.104 0.954 . . . . 0.0 109.768 179.206 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.46 -162.65 14.65 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 -179.404 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.3 Cg_exo -47.09 177.09 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.608 0 CA-C-N 118.807 1.304 . . . . 0.0 110.042 179.258 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -91.81 -178.57 5.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.015 -1.053 . . . . 0.0 110.409 -178.704 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.453 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.74 165.29 12.95 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.954 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.459 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.83 129.51 51.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 O-C-N 121.458 -1.025 . . . . 0.0 109.249 -179.413 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.608 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.31 126.6 30.49 Favored 'General case' 0 C--N 1.291 -1.972 0 O-C-N 121.677 -0.639 . . . . 0.0 109.791 179.756 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.504 HG12 ' O ' ' A' ' 93' ' ' CYS . 20.8 pt -97.43 177.2 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.226 -0.921 . . . . 0.0 109.473 -179.884 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.51 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.3 m -144.2 150.96 38.81 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.464 -0.772 . . . . 0.0 109.54 179.851 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.45 ' CZ ' ' CD1' ' A' ' 110' ' ' ILE . 94.9 m-85 -130.16 92.83 3.36 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 121.115 -0.991 . . . . 0.0 109.506 -179.636 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.419 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 13.4 p30 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.527 179.969 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.592 ' O6 ' ' H27' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 040 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.08 154.98 58.42 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.231 -0.918 . . . . 0.0 109.503 179.991 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.491 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 3.4 Cg_exo -60.76 157.37 38.09 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.252 1.968 . . . . 0.0 110.486 -179.948 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.585 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.1 p -162.04 160.71 27.85 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -179.327 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.499 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.34 128.23 14.45 Favored 'General case' 0 C--N 1.298 -1.636 0 C-N-CA 118.989 -1.084 . . . . 0.0 110.599 -179.707 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.532 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.8 p -104.82 104.72 14.55 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 122.456 1.122 . . . . 0.0 110.243 -179.495 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 14.7 t -119.51 115.4 47.5 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.443 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.265 179.704 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.491 HG21 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.72 148.94 12.95 Favored Pre-proline 0 N--CA 1.488 1.451 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.547 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.491 ' HA ' HG21 ' A' ' 8' ' ' THR . 6.5 Cg_endo -78.59 149.77 86.21 Favored 'Cis proline' 0 C--N 1.31 -1.497 0 C-N-CA 123.726 -1.364 . . . . 0.0 109.558 -0.609 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.462 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 77.6 p -91.7 -24.06 19.6 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.543 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.457 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 0.9 OUTLIER -131.28 162.18 30.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.45 -0.781 . . . . 0.0 109.513 -179.921 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.17 38.37 34.78 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 -179.536 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.611 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 31.5 mt -91.51 -44.28 9.19 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 123.142 1.448 . . . . 0.0 110.691 -178.233 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.488 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.7 144.87 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.274 0 CA-C-N 113.587 -1.642 . . . . 0.0 109.915 -179.629 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.556 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 9.2 p-10 -50.81 106.29 0.12 Allowed 'General case' 0 C--N 1.302 -1.46 0 CA-C-O 121.492 0.663 . . . . 0.0 111.674 -178.575 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.55 15.51 8.77 Favored Glycine 0 N--CA 1.485 1.918 0 C-N-CA 119.523 -1.323 . . . . 0.0 112.944 177.178 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.611 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.9 t -103.93 -172.3 2.08 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 121.156 2.478 . . . . 0.0 109.835 179.304 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.569 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 15.1 t -131.56 140.23 48.75 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.301 0 CA-C-N 114.873 -1.058 . . . . 0.0 111.186 -178.817 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.526 ' CG2' HG21 ' A' ' 69' ' ' VAL . 4.1 m -117.86 154.72 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 178.948 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -106.91 108.74 20.39 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.078 -1.014 . . . . 0.0 109.311 179.927 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.496 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 1.6 p -106.23 122.16 59.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 179.775 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.547 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -114.54 165.97 12.2 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 120.913 -1.117 . . . . 0.0 109.068 179.933 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.16 108.1 0.5 Allowed Glycine 0 N--CA 1.483 1.778 0 N-CA-C 108.586 -1.806 . . . . 0.0 108.586 179.848 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.585 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.58 140.31 49.53 Favored 'General case' 0 N--CA 1.498 1.954 0 CA-C-N 119.192 1.496 . . . . 0.0 110.282 -179.274 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.491 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.73 28.1 33.07 Favored Glycine 0 N--CA 1.489 2.184 0 C-N-CA 119.025 -1.559 . . . . 0.0 109.845 179.777 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.523 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -92.55 175.08 6.96 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.931 -1.335 . . . . 0.0 108.352 179.929 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.554 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.94 98.84 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.448 0 O-C-N 120.878 -1.139 . . . . 0.0 109.601 -179.625 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.3 77.48 0.0 OUTLIER 'General case' 0 C--N 1.294 -1.807 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.269 -179.131 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.31 34.35 0.32 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.457 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.545 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 59.7 p -145.42 112.08 5.87 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.075 -1.25 . . . . 0.0 111.196 -179.691 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.544 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.42 126.84 5.56 Favored 'General case' 0 N--CA 1.491 1.615 0 CA-C-O 121.458 0.647 . . . . 0.0 109.523 178.098 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.484 ' HA ' ' O ' ' A' ' 98' ' ' SER . 12.1 m-85 -118.09 150.26 39.63 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.736 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.474 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.84 159.0 15.56 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.652 -1.28 . . . . 0.0 107.729 178.535 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.617 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 7.4 p -144.27 116.04 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.085 -1.009 . . . . 0.0 110.045 -177.637 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.2 -178.78 39.74 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.414 -1.85 . . . . 0.0 111.857 -179.919 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.564 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -100.31 109.01 21.2 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -179.872 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.58 148.02 52.33 Favored 'General case' 0 C--N 1.294 -1.81 0 O-C-N 121.357 -0.84 . . . . 0.0 109.835 179.873 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -121.9 138.94 54.21 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.375 -0.828 . . . . 0.0 110.702 -179.082 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.63 ' CE2' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.55 114.67 26.45 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 178.187 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.42 ' O ' ' OD2' ' A' ' 41' ' ' ASP . 17.1 m -105.71 14.72 7.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.971 -1.081 . . . . 0.0 110.576 -178.679 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.92 -175.17 0.08 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.923 -1.111 . . . . 0.0 110.086 179.749 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 46.2 p -71.85 97.54 1.83 Allowed 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.428 -0.795 . . . . 0.0 109.717 -179.655 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.33 27.13 34.05 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 120.293 -0.956 . . . . 0.0 111.487 178.921 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.93 106.13 19.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.222 0 O-C-N 120.566 -1.549 . . . . 0.0 107.337 178.872 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.63 HD11 ' CE2' ' A' ' 39' ' ' TRP . 12.6 tp -117.24 104.67 11.4 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.531 -1.356 . . . . 0.0 109.669 -177.839 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.539 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.76 109.36 22.13 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.787 -1.196 . . . . 0.0 108.331 178.956 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.8 t -105.39 164.51 11.81 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.05 -1.031 . . . . 0.0 110.123 -179.055 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.532 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 13.6 t-20 -106.76 138.9 19.91 Favored Pre-proline 0 N--CA 1.501 2.087 0 O-C-N 121.333 -0.854 . . . . 0.0 110.095 -179.031 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.578 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 6.9 Cg_endo -75.88 25.9 0.41 Allowed 'Trans proline' 0 C--N 1.319 -1.012 0 C-N-CA 122.537 2.158 . . . . 0.0 111.705 179.987 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.532 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -121.43 3.54 10.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.403 -1.436 . . . . 0.0 109.312 -179.915 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.498 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -137.09 14.36 3.06 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.285 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -80.18 91.83 5.61 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.799 -178.644 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.617 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.53 -169.23 1.44 Allowed 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 178.356 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.471 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.03 135.56 0.09 Allowed 'General case' 0 C--N 1.306 -1.325 0 O-C-N 120.517 -1.364 . . . . 0.0 111.439 -179.351 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.587 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -151.98 157.75 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 178.102 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.544 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.41 145.31 26.29 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.595 -1.316 . . . . 0.0 109.976 -179.578 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.667 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -65.6 107.39 1.71 Allowed 'General case' 0 C--N 1.3 -1.582 0 CA-C-O 122.375 1.083 . . . . 0.0 109.418 178.716 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.527 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.7 p-10 -60.37 -139.25 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.019 -179.914 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.21 -50.43 59.11 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.316 -0.865 . . . . 0.0 110.564 -178.71 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -104.7 -33.71 8.38 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 106.249 -1.759 . . . . 0.0 106.249 178.529 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.667 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.01 66.99 0.61 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 178.205 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.8 m -104.3 124.84 49.89 Favored 'General case' 0 N--CA 1.485 1.28 0 O-C-N 121.674 -0.898 . . . . 0.0 108.686 178.818 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.587 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.15 109.21 8.76 Favored 'General case' 0 C--N 1.296 -1.733 0 C-N-CA 119.699 -0.8 . . . . 0.0 109.479 -179.412 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.458 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 81.2 p -117.87 118.64 32.57 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.348 -0.845 . . . . 0.0 109.448 -179.924 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.458 HG23 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.02 141.24 30.01 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.513 -0.742 . . . . 0.0 109.631 179.92 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.1 p -100.46 131.65 46.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.436 -0.79 . . . . 0.0 109.352 179.955 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.527 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -130.05 166.98 19.03 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.416 -0.803 . . . . 0.0 109.477 -179.512 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.569 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -97.94 124.69 42.49 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.109 -0.994 . . . . 0.0 109.365 -179.834 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.527 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.0 m -135.45 143.28 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.082 -1.011 . . . . 0.0 109.767 -179.292 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.556 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.6 ptt180 -141.1 -165.62 2.0 Allowed 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.657 -1.277 . . . . 0.0 110.494 -179.912 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.588 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 17.5 mtp180 -72.4 -80.24 0.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.367 -0.833 . . . . 0.0 109.217 -179.498 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.442 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -68.65 138.3 54.89 Favored 'General case' 0 N--CA 1.485 1.282 0 O-C-N 120.051 -1.655 . . . . 0.0 107.284 178.874 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.567 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -162.21 133.99 5.41 Favored 'General case' 0 C--N 1.295 -1.788 0 C-N-CA 117.766 -1.573 . . . . 0.0 110.414 -177.559 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.496 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -33.83 121.95 0.44 Allowed 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.44 0.638 . . . . 0.0 110.234 -178.766 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.539 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -93.86 51.66 2.27 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 120.512 -0.852 . . . . 0.0 111.392 -178.98 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.578 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -38.97 116.17 0.55 Allowed 'General case' 0 N--CA 1.511 2.615 0 O-C-N 121.075 -1.25 . . . . 0.0 109.933 179.519 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.537 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.0 tp -87.32 126.63 34.96 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.875 -1.14 . . . . 0.0 109.328 -179.946 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.576 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.1 t80 -64.15 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.772 -1.205 . . . . 0.0 110.025 179.741 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 20.4 t70 -160.18 19.48 0.15 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.984 -1.072 . . . . 0.0 109.705 179.895 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.0 -27.39 5.51 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 179.785 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.404 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 2.3 p -95.22 160.93 14.32 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.004 -1.292 . . . . 0.0 110.318 -179.425 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.465 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.86 137.48 44.84 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.822 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.46 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.27 -19.2 40.03 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.748 -1.22 . . . . 0.0 110.437 -178.596 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.51 176.27 19.73 Favored Glycine 0 N--CA 1.484 1.85 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.485 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -63.82 108.8 1.55 Allowed 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 179.13 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.567 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 38.2 t -81.72 105.41 11.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 121.361 -0.837 . . . . 0.0 108.786 -179.144 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.449 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -67.68 112.16 4.63 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.39 -0.819 . . . . 0.0 109.931 -179.108 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.529 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.28 -5.09 4.41 Favored 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.286 -1.366 . . . . 0.0 109.97 179.437 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.446 HG23 ' NH2' ' A' ' 71' ' ' ARG . 41.0 p -85.63 1.44 49.24 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.769 -1.207 . . . . 0.0 109.021 179.361 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.449 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -115.73 -49.34 2.73 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.432 -0.792 . . . . 0.0 109.08 179.971 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.64 -179.63 4.0 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.458 -0.776 . . . . 0.0 109.536 179.961 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.99 115.36 30.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.338 -0.851 . . . . 0.0 109.102 179.958 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.494 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.94 123.73 40.73 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.082 -1.011 . . . . 0.0 109.54 -179.358 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.541 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.28 147.48 27.44 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 122.515 1.15 . . . . 0.0 111.356 -179.318 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.521 ' CG1' HG13 ' A' ' 7' ' ' VAL . 59.1 t -103.09 109.62 27.36 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.038 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 177.351 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.09 -174.06 17.9 Favored Glycine 0 N--CA 1.484 1.855 0 C-N-CA 118.203 -1.951 . . . . 0.0 111.815 -177.414 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.474 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -117.1 -177.59 3.24 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -178.835 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.534 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.8 OUTLIER -170.3 157.36 6.15 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.182 -0.949 . . . . 0.0 109.389 -179.344 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.504 ' O ' ' CB ' ' A' ' 100' ' ' ALA . 3.6 m-20 -85.32 -14.91 45.04 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.133 -0.98 . . . . 0.0 109.483 179.959 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.504 ' CB ' ' O ' ' A' ' 99' ' ' ASP . . . 76.16 35.5 0.46 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.513 -0.742 . . . . 0.0 109.328 -179.943 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -138.73 -34.05 0.63 Allowed 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.636 -0.665 . . . . 0.0 110.651 -179.463 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.457 ' CA ' H192 ' A' ' 114' ' ' CHR . . . -176.13 -44.03 0.06 OUTLIER Glycine 0 N--CA 1.482 1.73 0 N-CA-C 107.468 -2.253 . . . . 0.0 107.468 -179.69 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -154.98 -179.66 8.27 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 121.509 -0.995 . . . . 0.0 109.406 178.786 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -179.23 -167.78 37.22 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 -179.488 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.423 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.8 Cg_exo -48.38 175.1 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.665 0 CA-C-N 118.888 1.344 . . . . 0.0 110.002 179.523 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -92.48 -175.4 3.98 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.163 -0.96 . . . . 0.0 110.435 -178.778 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -120.52 166.54 13.77 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.908 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -106.65 131.82 55.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.452 -1.028 . . . . 0.0 109.069 -179.358 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.541 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.16 125.11 27.65 Favored 'General case' 0 C--N 1.29 -2.018 0 O-C-N 121.48 -0.762 . . . . 0.0 109.782 179.733 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.574 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.72 172.18 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.158 -0.964 . . . . 0.0 108.948 179.81 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.457 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.81 158.25 44.74 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.305 -0.872 . . . . 0.0 109.605 -179.837 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.588 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 70.8 m-85 -135.75 86.16 2.21 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 121.19 -0.944 . . . . 0.0 109.52 -179.585 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 17.4 p30 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 118.013 -0.994 . . . . 0.0 109.441 -179.959 . . . . . . . . 0 0 . 1 . 040 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.587 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.321 0.581 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 041 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -117.66 152.06 49.26 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.203 -0.935 . . . . 0.0 109.512 179.981 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.527 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 4.6 Cg_exo -60.46 157.38 36.58 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.301 2.001 . . . . 0.0 110.625 -179.924 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.531 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.69 -169.57 0.14 Allowed 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.204 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.531 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -167.82 133.63 1.98 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.661 -1.274 . . . . 0.0 111.252 -179.27 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.528 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.2 p -100.36 104.03 15.45 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.377 1.084 . . . . 0.0 109.783 179.982 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.527 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 6.9 t -120.32 116.72 51.1 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-O 121.726 0.774 . . . . 0.0 110.466 179.863 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.517 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.81 148.7 8.86 Favored Pre-proline 0 N--CA 1.486 1.339 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.707 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.517 ' CA ' HG21 ' A' ' 8' ' ' THR . 6.0 Cg_endo -77.94 150.32 89.18 Favored 'Cis proline' 0 C--N 1.307 -1.65 0 C-N-CA 123.604 -1.415 . . . . 0.0 109.513 -0.425 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.464 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 80.1 p -91.3 -24.69 19.75 Favored 'General case' 0 C--N 1.292 -1.916 0 O-C-N 121.498 -0.751 . . . . 0.0 108.985 179.518 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.519 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 17.0 m -133.92 161.9 33.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.521 -0.737 . . . . 0.0 109.367 -179.931 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.77 37.06 31.05 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 108.571 -1.811 . . . . 0.0 108.571 -179.657 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.589 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 42.8 mt -91.12 -42.13 10.64 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-O 123.374 1.559 . . . . 0.0 110.22 -178.548 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.483 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.65 142.31 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.238 -1.801 . . . . 0.0 109.838 -179.488 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.589 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.3 p-10 -49.94 106.86 0.13 Allowed 'General case' 0 C--N 1.298 -1.656 0 CA-C-O 121.562 0.696 . . . . 0.0 111.324 -178.588 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.16 10.64 9.57 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.132 177.449 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.589 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.7 t -105.48 -171.31 1.89 Allowed 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 121.286 2.543 . . . . 0.0 109.905 179.471 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.58 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 16.8 t -132.93 143.42 39.55 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.284 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.851 -178.952 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.492 ' CG1' HD22 ' A' ' 13' ' ' LEU . 32.2 m -118.98 155.34 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.28 -0.887 . . . . 0.0 108.707 179.21 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.527 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -105.08 108.77 20.47 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.152 -0.967 . . . . 0.0 109.441 -179.897 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.5 HG22 ' CG2' ' A' ' 7' ' ' VAL . 1.8 p -106.74 121.76 59.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.434 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.528 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -118.07 167.16 11.72 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 120.688 -1.257 . . . . 0.0 109.292 -179.604 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.55 143.47 15.11 Favored Glycine 0 C--N 1.294 -1.78 0 N-CA-C 107.774 -2.131 . . . . 0.0 107.774 179.735 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.527 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -147.82 123.01 10.2 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 120.929 -1.336 . . . . 0.0 108.589 179.175 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.512 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 90.18 27.39 21.0 Favored Glycine 0 N--CA 1.487 2.063 0 C-N-CA 119.201 -1.476 . . . . 0.0 109.755 -179.448 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.546 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.0 mt -87.9 175.85 7.62 Favored 'General case' 0 C--N 1.308 -1.224 0 O-C-N 120.846 -1.384 . . . . 0.0 108.403 179.964 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.553 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.24 96.85 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.029 -1.044 . . . . 0.0 109.6 -179.91 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.24 76.48 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.448 -178.847 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.25 33.44 0.27 Allowed Glycine 0 N--CA 1.486 1.994 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 179.179 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.626 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.6 t -148.45 115.46 6.09 Favored 'General case' 0 C--N 1.309 -1.178 0 O-C-N 120.797 -1.414 . . . . 0.0 111.252 179.932 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.554 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.98 129.18 4.43 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.657 178.221 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.626 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 6.8 m-85 -121.5 146.82 46.54 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.727 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.48 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.95 164.31 12.24 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 107.429 -1.323 . . . . 0.0 107.429 178.54 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.624 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 7.1 p -148.95 115.11 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.979 -1.076 . . . . 0.0 110.133 -177.673 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.482 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.15 -174.29 36.85 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 118.541 -1.79 . . . . 0.0 111.563 -179.938 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.568 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -100.77 108.89 20.83 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -179.718 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.429 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.26 148.76 52.12 Favored 'General case' 0 C--N 1.296 -1.73 0 O-C-N 121.19 -0.944 . . . . 0.0 109.934 179.765 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.33 139.1 53.98 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.276 -0.89 . . . . 0.0 110.613 -179.03 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.623 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.17 114.89 26.74 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 178.116 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.416 HG23 ' HB ' ' A' ' 44' ' ' VAL . 11.2 m -106.17 15.57 7.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.014 -1.054 . . . . 0.0 110.587 -178.676 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.3 -175.59 0.09 Allowed 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.933 -1.105 . . . . 0.0 110.021 179.739 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.0 97.47 1.88 Allowed 'General case' 0 N--CA 1.486 1.33 0 O-C-N 121.423 -0.798 . . . . 0.0 109.724 -179.765 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.64 27.93 33.89 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 120.164 -1.017 . . . . 0.0 111.399 178.973 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.52 106.33 20.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 O-C-N 120.612 -1.522 . . . . 0.0 107.289 178.928 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.623 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.9 tp -116.88 104.74 11.61 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.501 -1.374 . . . . 0.0 109.684 -177.626 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.522 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.13 109.57 22.3 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.739 -1.226 . . . . 0.0 108.213 178.797 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -108.12 164.53 12.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.977 -1.077 . . . . 0.0 110.081 -178.929 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.477 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 7.5 t30 -108.62 130.02 23.27 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.357 -0.84 . . . . 0.0 109.69 -179.284 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.589 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -71.01 19.83 0.23 Allowed 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 122.178 1.919 . . . . 0.0 112.044 179.502 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.472 ' O ' HG23 ' A' ' 68' ' ' THR . . . -108.32 1.12 21.66 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.364 -1.46 . . . . 0.0 108.883 179.305 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.551 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.07 19.27 2.99 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 179.462 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -83.0 90.9 7.07 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.876 -0.73 . . . . 0.0 111.005 -178.439 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.66 -171.02 1.76 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.944 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.458 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.3 OUTLIER 178.53 137.96 0.09 Allowed 'General case' 0 C--N 1.304 -1.372 0 O-C-N 120.501 -1.374 . . . . 0.0 111.544 -179.16 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.575 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -154.79 159.51 3.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 178.07 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.554 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.28 145.78 25.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.59 -1.319 . . . . 0.0 109.722 -179.676 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.67 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -67.66 108.09 2.78 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 122.353 1.073 . . . . 0.0 109.582 179.037 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.518 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 t0 -63.03 -139.21 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.015 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.874 -179.917 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.04 -51.83 28.88 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.411 -0.806 . . . . 0.0 110.759 -178.572 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -105.09 -32.07 8.87 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 178.585 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.67 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 106.25 67.96 0.69 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 178.391 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.2 m -103.42 128.88 50.46 Favored 'General case' 0 N--CA 1.484 1.266 0 O-C-N 121.37 -1.077 . . . . 0.0 109.143 179.202 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.575 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.25 108.65 6.89 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 119.321 -0.952 . . . . 0.0 109.949 -179.486 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.484 ' HB3' ' CE ' ' A' ' 20' ' ' LYS . 3.4 m -114.48 116.58 29.07 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.995 -1.066 . . . . 0.0 109.409 179.85 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.506 HG22 ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -143.08 142.19 31.46 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 110.013 -179.971 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.9 p -100.71 136.32 40.76 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.466 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.551 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -141.08 156.82 45.93 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.935 . . . . 0.0 109.808 -179.129 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.58 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 12.9 t -87.04 138.76 31.22 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.062 -1.023 . . . . 0.0 110.676 -179.608 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.538 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 20.7 m -149.27 143.55 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.508 -0.745 . . . . 0.0 109.232 -179.852 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.589 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -147.52 -178.01 6.01 Favored 'General case' 0 N--CA 1.486 1.326 0 O-C-N 120.487 -1.383 . . . . 0.0 111.206 -179.68 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.67 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -47.52 -98.92 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -179.616 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -64.02 145.01 56.65 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.389 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.599 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -163.95 143.2 7.85 Favored 'General case' 0 C--N 1.291 -1.952 0 C-N-CA 118.045 -1.462 . . . . 0.0 110.268 -177.419 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.481 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 29.4 mm-40 -37.29 120.46 0.77 Allowed 'General case' 0 N--CA 1.489 1.477 0 CA-C-O 121.457 0.646 . . . . 0.0 110.304 -178.888 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.522 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -96.5 52.45 1.54 Allowed Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.477 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.589 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.8 m-85 -39.76 114.96 0.47 Allowed 'General case' 0 N--CA 1.508 2.465 0 O-C-N 121.181 -1.188 . . . . 0.0 110.113 179.65 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.529 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -86.13 126.55 34.3 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.866 -1.146 . . . . 0.0 109.511 -179.986 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.565 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.6 t80 -64.1 58.17 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.004 0 O-C-N 120.845 -1.159 . . . . 0.0 110.25 179.767 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.58 19.68 0.14 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.025 -1.047 . . . . 0.0 109.709 179.892 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.88 -27.5 5.4 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.871 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.419 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 11.9 p -93.36 158.53 15.69 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.02 -1.282 . . . . 0.0 110.434 -179.455 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.474 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.35 136.28 46.35 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.627 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.467 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.1 t90 -83.08 -16.72 45.81 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.669 -1.269 . . . . 0.0 110.647 -178.194 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.57 175.94 21.18 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 108.709 -1.756 . . . . 0.0 108.709 -179.618 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -64.84 103.07 0.66 Allowed 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 179.106 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.581 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 37.2 t -73.78 107.97 4.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 109.483 -178.755 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.8 OUTLIER -65.11 112.09 3.22 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.462 -0.774 . . . . 0.0 109.706 -179.58 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.67 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 4.0 m -62.81 -4.98 2.4 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.422 -1.311 . . . . 0.0 110.228 179.608 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.5 p -89.25 -2.94 58.67 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.566 -1.334 . . . . 0.0 109.555 -179.983 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.468 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -106.31 -48.65 3.52 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.071 -1.018 . . . . 0.0 108.861 179.885 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.42 -177.86 3.4 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.631 -0.668 . . . . 0.0 109.297 179.726 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.59 115.98 31.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.454 -0.779 . . . . 0.0 108.927 179.834 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.494 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 3.2 m -96.48 120.32 36.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.913 -1.117 . . . . 0.0 109.615 -179.245 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.525 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.93 145.28 30.37 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 122.409 1.099 . . . . 0.0 111.282 -179.392 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.511 ' CG1' HG13 ' A' ' 7' ' ' VAL . 92.4 t -102.22 109.86 27.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.945 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 177.788 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.459 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.49 -173.22 19.82 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 118.112 -1.995 . . . . 0.0 111.695 -177.608 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.48 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -111.93 -178.61 3.47 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 -179.345 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.586 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.1 p -175.1 167.47 3.48 Favored 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.197 -0.939 . . . . 0.0 109.751 -179.132 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -117.67 -161.46 0.82 Allowed 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.032 -1.042 . . . . 0.0 108.901 179.906 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -117.38 35.67 4.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.598 -1.314 . . . . 0.0 109.453 -179.955 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.26 -31.19 6.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.374 -0.829 . . . . 0.0 109.955 -179.705 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.41 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 164.22 -35.12 0.29 Allowed Glycine 0 N--CA 1.482 1.723 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 -179.558 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.11 -177.6 5.85 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.578 -0.954 . . . . 0.0 109.713 179.242 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.31 -161.5 14.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 -179.345 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.485 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.5 Cg_exo -47.97 -179.36 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.612 0 CA-C-N 118.877 1.339 . . . . 0.0 110.304 179.328 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -93.59 -173.95 3.34 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.002 -1.061 . . . . 0.0 110.298 -178.974 . . . . . . . . 1 1 . 1 . 041 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.459 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.76 164.18 14.97 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.946 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.86 129.41 51.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.367 -1.078 . . . . 0.0 109.0 -179.46 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.525 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.79 119.25 15.7 Favored 'General case' 0 C--N 1.288 -2.101 0 O-C-N 121.746 -0.596 . . . . 0.0 109.73 179.759 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.573 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -98.09 170.04 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.188 -0.945 . . . . 0.0 108.861 179.821 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.519 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -138.46 155.08 48.78 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.085 -1.01 . . . . 0.0 109.6 -179.908 . . . . . . . . 3 3 . 1 . 041 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.573 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 77.6 m-85 -129.67 99.11 5.03 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.271 -0.893 . . . . 0.0 109.424 -179.686 . . . . . . . . 2 2 . 1 . 041 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 14.3 p30 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 118.011 -0.995 . . . . 0.0 109.463 179.992 . . . . . . . . 0 0 . 1 . 041 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.587 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 042 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.62 152.64 44.19 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.296 -0.878 . . . . 0.0 109.498 179.933 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.489 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 2.6 Cg_endo -61.43 156.83 44.25 Favored 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 122.271 1.981 . . . . 0.0 110.534 179.981 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.6 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -155.01 160.96 41.45 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 -179.511 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.501 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -146.8 127.98 14.74 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 119.011 -1.075 . . . . 0.0 110.594 -179.731 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.533 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.8 p -104.72 104.85 14.72 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-O 122.532 1.158 . . . . 0.0 110.142 -179.519 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.536 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 12.5 t -119.48 120.0 62.25 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.438 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.355 179.616 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.509 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.67 150.3 8.84 Favored Pre-proline 0 N--CA 1.489 1.492 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 -179.621 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.509 ' CA ' HG21 ' A' ' 8' ' ' THR . 1.3 Cg_endo -74.22 153.98 99.42 Favored 'Cis proline' 0 C--N 1.31 -1.493 0 C-N-CA 123.621 -1.408 . . . . 0.0 109.927 -0.482 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.479 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 4.5 m -93.64 -23.94 18.08 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.646 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.467 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 3.1 m -137.12 166.14 24.41 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.61 -0.681 . . . . 0.0 109.424 179.919 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.14 38.09 40.93 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 108.346 -1.902 . . . . 0.0 108.346 -179.6 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.63 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 29.9 mt -91.42 -45.21 8.68 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 123.131 1.444 . . . . 0.0 110.676 -178.316 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.483 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.28 146.16 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.763 -1.562 . . . . 0.0 109.942 -179.704 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.575 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.5 p-10 -51.44 110.14 0.42 Allowed 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 121.532 0.682 . . . . 0.0 111.664 -178.614 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.52 13.97 12.23 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.557 -1.306 . . . . 0.0 112.731 177.345 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.63 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 9.0 t -102.66 -173.38 2.31 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 120.929 2.364 . . . . 0.0 109.632 179.365 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.555 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 12.7 t -132.15 137.75 53.96 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.866 -1.061 . . . . 0.0 111.14 -178.995 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.511 HG13 ' CG2' ' A' ' 69' ' ' VAL . 29.2 m -114.57 154.48 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.351 -0.843 . . . . 0.0 109.07 178.934 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.3 tttt -109.33 108.93 19.68 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.266 -0.896 . . . . 0.0 109.126 179.83 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.525 ' CG1' HG23 ' A' ' 34' ' ' VAL . 2.0 p -107.25 122.92 62.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -179.954 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.538 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -114.48 165.96 12.19 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.761 -1.212 . . . . 0.0 109.136 179.694 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.591 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.15 107.84 0.49 Allowed Glycine 0 N--CA 1.483 1.793 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 179.865 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.6 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.49 141.15 48.56 Favored 'General case' 0 N--CA 1.5 2.051 0 CA-C-N 119.248 1.524 . . . . 0.0 110.273 -179.389 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.489 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.28 28.37 33.75 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 118.943 -1.598 . . . . 0.0 109.767 179.621 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.527 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -94.54 173.66 7.51 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.941 -1.329 . . . . 0.0 108.553 179.971 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.57 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.72 98.74 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.006 -1.059 . . . . 0.0 109.703 -179.885 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.549 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.41 76.6 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.188 -179.21 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 135.06 33.35 0.28 Allowed Glycine 0 N--CA 1.486 1.993 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.483 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.627 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -142.49 111.83 6.6 Favored 'General case' 0 C--N 1.309 -1.174 0 O-C-N 120.928 -1.336 . . . . 0.0 111.075 -179.929 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.555 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -49.5 113.34 0.8 Allowed 'General case' 0 N--CA 1.497 1.922 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.915 178.67 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.627 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 11.9 m-85 -107.14 153.06 23.21 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.263 -0.898 . . . . 0.0 108.592 179.441 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.455 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.66 159.55 15.22 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.729 -1.232 . . . . 0.0 107.994 178.884 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.627 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 6.4 p -139.84 114.66 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 109.667 -178.086 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.477 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.96 -179.51 37.55 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 118.384 -1.865 . . . . 0.0 111.733 -179.449 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.633 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.1 pt20 -101.92 109.39 21.12 Favored 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 -179.889 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.69 149.37 52.37 Favored 'General case' 0 C--N 1.296 -1.751 0 O-C-N 121.14 -0.975 . . . . 0.0 110.087 -179.867 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.07 138.2 54.73 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.276 -0.89 . . . . 0.0 110.809 -178.976 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.62 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.26 115.0 26.85 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 178.055 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.433 HG21 ' HB ' ' A' ' 44' ' ' VAL . 16.4 m -104.36 14.3 7.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.044 -1.035 . . . . 0.0 110.491 -178.853 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.29 -174.86 0.07 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.977 -1.077 . . . . 0.0 110.095 179.765 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -72.96 98.68 2.54 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.387 -0.821 . . . . 0.0 109.606 -179.803 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.61 27.41 32.5 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 120.251 -0.975 . . . . 0.0 111.394 179.011 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.591 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -117.64 105.96 19.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 O-C-N 120.571 -1.547 . . . . 0.0 107.335 178.849 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.62 HD12 ' CD1' ' A' ' 39' ' ' TRP . 13.4 tp -117.95 104.38 10.84 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.408 -1.433 . . . . 0.0 109.741 -177.772 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.53 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.15 109.36 22.13 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 178.829 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -105.56 165.82 10.88 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.029 -1.044 . . . . 0.0 110.277 -178.612 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.463 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 50.8 t30 -110.66 134.93 20.77 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 121.49 -0.756 . . . . 0.0 109.885 -179.409 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.584 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -75.32 25.46 0.39 Allowed 'Trans proline' 0 C--N 1.319 -1.011 0 C-N-CA 122.328 2.019 . . . . 0.0 111.404 179.591 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.46 ' HB1' ' ND2' ' A' ' 48' ' ' ASN . . . -112.74 0.1 15.18 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.484 -1.385 . . . . 0.0 109.373 179.944 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.524 ' O ' ' CD2' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.67 16.1 2.71 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 179.601 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -78.8 91.66 4.75 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.872 -0.731 . . . . 0.0 110.952 -178.648 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -110.1 -166.58 1.1 Allowed 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.281 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.466 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.7 136.44 0.09 Allowed 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.546 -1.346 . . . . 0.0 111.502 -179.289 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.588 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -154.39 157.15 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 178.174 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.555 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.37 143.95 28.28 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.772 -1.205 . . . . 0.0 109.91 -179.827 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.673 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.58 106.64 1.2 Allowed 'General case' 0 C--N 1.299 -1.587 0 CA-C-O 122.478 1.132 . . . . 0.0 109.325 178.556 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.524 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.9 p-10 -59.28 -139.53 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.918 -179.928 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.549 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.01 -50.0 62.25 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.434 -0.791 . . . . 0.0 110.731 -178.703 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.4 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.5 t-20 -103.77 -34.35 8.59 Favored 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 178.379 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.673 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.76 66.13 0.61 Allowed Glycine 0 C--N 1.297 -1.599 0 N-CA-C 110.459 -1.056 . . . . 0.0 110.459 178.126 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.591 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.8 m -104.36 124.23 48.83 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.683 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.588 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -133.89 109.2 8.9 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 119.692 -0.803 . . . . 0.0 109.506 -179.278 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.2 m -116.88 116.35 27.27 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.3 -0.875 . . . . 0.0 109.353 -179.93 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.468 ' CG2' HG12 ' A' ' 34' ' ' VAL . 1.2 t -140.78 139.08 34.53 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.507 -0.745 . . . . 0.0 109.762 179.998 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.6 p -99.02 138.38 36.2 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.38 -0.825 . . . . 0.0 108.982 179.631 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.526 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -138.56 166.44 24.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.269 -0.894 . . . . 0.0 109.547 -179.15 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.555 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.8 p -95.3 125.02 39.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.061 -1.025 . . . . 0.0 109.44 -179.818 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.511 ' CG2' HG13 ' A' ' 19' ' ' VAL . 15.0 m -133.29 143.32 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 120.955 -1.091 . . . . 0.0 109.798 -179.207 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.575 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.59 -170.7 3.58 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.484 -1.385 . . . . 0.0 111.092 179.992 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.603 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -63.12 -101.87 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.954 -0.466 . . . . 0.0 110.309 -179.034 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.477 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -58.95 137.98 57.64 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.595 -1.316 . . . . 0.0 108.534 -180.0 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.633 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.8 OUTLIER -156.62 156.59 33.79 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 118.807 -1.157 . . . . 0.0 109.746 -178.864 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.525 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 10.3 mm-40 -48.35 122.28 5.21 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.587 -178.603 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.53 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -88.32 46.78 3.41 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -179.555 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.584 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -38.59 112.92 0.26 Allowed 'General case' 0 N--CA 1.506 2.351 0 O-C-N 121.22 -1.164 . . . . 0.0 110.537 -179.795 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.533 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.8 tp -86.79 126.89 34.92 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.986 -1.071 . . . . 0.0 109.366 179.945 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.579 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.8 t80 -63.68 58.41 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.017 0 O-C-N 120.851 -1.156 . . . . 0.0 110.21 179.761 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.1 t0 -161.1 19.52 0.12 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.927 -1.108 . . . . 0.0 109.786 179.816 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.28 -26.73 5.46 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 179.798 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 47.2 p -93.88 160.72 14.61 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.958 -1.319 . . . . 0.0 110.275 -179.508 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.473 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.9 OUTLIER -107.23 134.92 49.61 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.895 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.481 ' CD1' HD13 ' A' ' 77' ' ' LEU . 4.2 t90 -81.74 -17.46 47.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.956 -1.09 . . . . 0.0 110.327 -178.608 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.12 173.46 18.76 Favored Glycine 0 N--CA 1.485 1.936 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 -179.544 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -63.77 107.34 1.17 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 179.093 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.599 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 44.5 t -78.7 104.61 6.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 121.398 -0.814 . . . . 0.0 109.275 -178.686 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 1.2 m-20 -64.88 108.86 1.89 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.545 -0.722 . . . . 0.0 110.032 -179.377 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.559 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.6 t -60.3 -5.52 1.15 Allowed 'General case' 0 N--CA 1.501 2.113 0 C-N-CA 118.164 -1.414 . . . . 0.0 110.343 179.302 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 33.1 p -89.51 0.83 56.61 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.486 -1.384 . . . . 0.0 109.528 179.987 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.475 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -111.67 -48.61 3.06 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.201 -0.937 . . . . 0.0 109.129 -179.894 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.31 179.38 4.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.592 -0.693 . . . . 0.0 109.539 -179.896 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.28 113.31 26.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.369 -0.832 . . . . 0.0 108.925 179.826 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.49 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.8 m -96.55 121.07 37.98 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.035 -1.041 . . . . 0.0 109.43 -178.854 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.549 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.82 148.11 25.7 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-O 122.416 1.103 . . . . 0.0 111.301 -179.375 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.528 ' CG1' HG11 ' A' ' 7' ' ' VAL . 47.7 t -104.41 109.96 29.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 N-CA-C 106.697 -1.594 . . . . 0.0 106.697 177.607 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.412 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.51 -171.15 17.79 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 118.15 -1.976 . . . . 0.0 111.589 -177.686 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.462 HD13 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -115.08 -178.54 3.39 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -178.888 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.574 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.2 p 178.65 171.03 0.81 Allowed 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.224 -0.923 . . . . 0.0 109.65 -179.113 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.431 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -122.26 -159.58 0.83 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 120.902 -1.124 . . . . 0.0 108.934 179.801 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.404 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.62 36.58 4.08 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.673 -1.267 . . . . 0.0 109.134 179.985 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -116.27 -34.04 4.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.374 -0.829 . . . . 0.0 110.099 -179.686 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 167.4 -37.03 0.23 Allowed Glycine 0 N--CA 1.481 1.692 0 N-CA-C 107.915 -2.074 . . . . 0.0 107.915 -179.72 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.23 -177.47 5.73 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.542 -0.975 . . . . 0.0 110.09 179.419 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.37 -163.69 23.82 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 108.17 -1.972 . . . . 0.0 108.17 -179.512 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.466 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.2 Cg_exo -46.09 172.78 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.693 0 CA-C-N 119.084 1.442 . . . . 0.0 109.938 179.332 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -91.16 -177.2 4.82 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.071 -1.018 . . . . 0.0 110.701 -178.632 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.412 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.27 168.36 13.81 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.842 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.47 133.57 51.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.43 -1.041 . . . . 0.0 109.176 -179.202 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.549 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.68 123.48 24.14 Favored 'General case' 0 C--N 1.291 -1.976 0 O-C-N 121.55 -0.719 . . . . 0.0 109.874 179.72 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.555 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.97 172.77 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.137 -0.977 . . . . 0.0 108.969 179.711 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.467 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.97 157.74 45.18 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.036 -1.04 . . . . 0.0 110.094 -179.627 . . . . . . . . 3 3 . 1 . 042 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.555 ' CE1' HD12 ' A' ' 110' ' ' ILE . 88.0 m-85 -133.23 93.36 3.15 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.224 -0.922 . . . . 0.0 109.444 -179.825 . . . . . . . . 2 2 . 1 . 042 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.468 ' OD1' ' OXT' ' A' ' 113' ' ' ASN . 6.9 p30 . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 118.049 -0.977 . . . . 0.0 109.55 -179.904 . . . . . . . . 1 1 . 1 . 042 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.586 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 043 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.516 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . . . -122.27 173.07 4.47 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.256 -0.903 . . . . 0.0 109.406 -179.925 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.531 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 6.0 Cg_exo -59.52 158.66 26.58 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.212 1.941 . . . . 0.0 110.522 179.932 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.546 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.38 -169.7 0.15 Allowed 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 179.403 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.546 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.37 130.46 2.51 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 120.818 -1.176 . . . . 0.0 110.751 -179.083 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.55 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.6 t -111.75 108.54 18.01 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-O 123.099 1.428 . . . . 0.0 109.053 179.339 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.525 HG12 ' CG1' ' A' ' 95' ' ' VAL . 5.6 t -117.71 137.39 51.78 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 0 CA-C-N 114.284 -1.326 . . . . 0.0 109.935 -179.616 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.511 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -172.85 149.11 1.8 Allowed Pre-proline 0 N--CA 1.485 1.316 0 O-C-N 121.241 -0.912 . . . . 0.0 108.815 -179.717 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.511 ' CA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -76.63 151.08 94.07 Favored 'Cis proline' 0 C--N 1.311 -1.439 0 C-N-CA 123.478 -1.468 . . . . 0.0 109.467 -0.865 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.462 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 65.3 p -90.17 -25.18 20.79 Favored 'General case' 0 C--N 1.294 -1.842 0 O-C-N 121.564 -0.71 . . . . 0.0 109.123 179.686 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.511 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.5 m -134.16 165.04 26.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.459 -0.776 . . . . 0.0 109.534 -179.904 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.22 38.28 34.79 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 -179.61 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.591 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 40.0 mt -92.4 -42.92 9.5 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 123.236 1.493 . . . . 0.0 110.525 -178.322 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.0 143.86 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.468 -1.696 . . . . 0.0 109.686 -179.534 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.557 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 6.0 p-10 -50.98 107.19 0.16 Allowed 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 121.625 0.726 . . . . 0.0 111.608 -178.437 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.46 11.61 11.59 Favored Glycine 0 N--CA 1.485 1.902 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.087 177.254 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.591 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.2 t -102.3 -169.8 1.72 Allowed 'General case' 0 C--N 1.312 -1.043 0 CA-C-N 121.111 2.455 . . . . 0.0 109.615 179.397 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.574 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 12.0 t -134.17 142.23 41.56 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.702 -179.255 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.521 HG11 ' CG2' ' A' ' 69' ' ' VAL . 35.0 m -119.88 155.21 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.276 -0.89 . . . . 0.0 108.853 179.313 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 11.1 tttt -103.96 109.24 20.93 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.207 -0.933 . . . . 0.0 109.158 -179.965 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.464 ' HB ' HG13 ' A' ' 7' ' ' VAL . 2.1 p -101.94 140.87 19.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.607 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.545 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -137.3 160.15 39.89 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 118.62 -1.232 . . . . 0.0 109.949 179.795 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.592 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.19 143.89 15.16 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 179.578 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.518 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -145.73 125.93 13.83 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 120.87 -1.371 . . . . 0.0 108.911 179.296 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.531 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.73 26.39 27.24 Favored Glycine 0 N--CA 1.488 2.137 0 C-N-CA 119.296 -1.43 . . . . 0.0 109.777 -179.692 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.55 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.0 mt -86.84 175.3 8.26 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.918 -1.342 . . . . 0.0 108.364 -179.933 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.56 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.85 97.33 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.961 -1.087 . . . . 0.0 109.737 -179.61 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.53 77.32 0.0 OUTLIER 'General case' 0 C--N 1.294 -1.813 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.42 -179.134 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.12 34.4 0.33 Allowed Glycine 0 N--CA 1.486 2.005 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.381 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.531 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.4 p -147.78 113.26 5.63 Favored 'General case' 0 C--N 1.307 -1.251 0 O-C-N 121.045 -1.267 . . . . 0.0 111.236 -179.819 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.537 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -43.53 128.41 5.06 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.823 178.263 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.49 ' CD2' ' O ' ' A' ' 30' ' ' THR . 11.3 m-85 -121.38 149.8 42.43 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.596 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.488 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.49 156.35 17.33 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.642 -1.286 . . . . 0.0 107.854 178.84 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.625 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.6 p -138.53 114.79 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.062 -1.024 . . . . 0.0 109.713 -178.06 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.476 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.08 -178.3 35.86 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.249 -1.929 . . . . 0.0 111.908 -179.529 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.55 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.7 OUTLIER -101.03 112.55 25.04 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 -179.941 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 66.8 m -130.64 153.11 49.27 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.365 -0.834 . . . . 0.0 109.615 179.746 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.43 135.91 51.1 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.482 -0.761 . . . . 0.0 110.491 -179.957 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.639 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.6 OUTLIER -94.83 114.37 26.24 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.243 -1.391 . . . . 0.0 107.243 178.137 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 m -106.27 14.86 7.47 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 O-C-N 120.966 -1.084 . . . . 0.0 110.763 -178.473 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.595 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.21 -175.47 0.08 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.856 -1.152 . . . . 0.0 110.222 179.655 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.548 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.2 t -69.75 97.09 1.04 Allowed 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 121.83 0.824 . . . . 0.0 109.952 -179.445 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.66 27.15 36.09 Favored Glycine 0 N--CA 1.494 2.546 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.515 178.679 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.595 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.4 t -114.48 106.18 20.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.233 0 O-C-N 120.6 -1.53 . . . . 0.0 107.483 178.901 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.639 HD13 ' CD1' ' A' ' 39' ' ' TRP . 11.7 tp -116.94 106.54 13.54 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.574 -1.329 . . . . 0.0 109.662 -177.724 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.552 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -95.99 111.97 23.83 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 120.676 -1.265 . . . . 0.0 108.256 179.445 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.537 ' HB3' ' CE1' ' A' ' 52' ' ' PHE . 66.8 m -101.67 147.76 26.06 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.33 -0.856 . . . . 0.0 110.71 -178.291 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.488 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 24.4 t30 -103.45 126.11 33.06 Favored Pre-proline 0 N--CA 1.503 2.198 0 O-C-N 121.248 -0.908 . . . . 0.0 108.838 179.053 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.567 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.5 Cg_endo -70.58 23.85 0.2 Allowed 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 122.108 1.872 . . . . 0.0 112.561 -179.657 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.475 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -110.15 2.15 19.21 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.252 -1.53 . . . . 0.0 109.317 179.346 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.513 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.54 16.18 2.55 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 179.628 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.537 ' CE1' ' HB3' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -79.08 91.51 4.91 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.579 -0.701 . . . . 0.0 110.885 -178.568 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.625 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.67 -165.71 1.05 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.284 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.459 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 179.04 135.3 0.09 Allowed 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.514 -1.366 . . . . 0.0 111.564 -179.339 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.581 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -153.2 157.83 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 107.116 -1.438 . . . . 0.0 107.116 178.024 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.537 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.71 145.92 25.86 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.658 -1.276 . . . . 0.0 109.865 -179.73 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.676 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.38 107.98 2.2 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 122.368 1.08 . . . . 0.0 109.478 178.733 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.515 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.2 t0 -62.02 -139.11 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.045 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.931 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.84 -51.62 38.71 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.477 -0.764 . . . . 0.0 110.733 -178.614 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.73 -32.39 8.89 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 178.726 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.676 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.15 65.38 0.59 Allowed Glycine 0 C--N 1.297 -1.59 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 178.307 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.592 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 48.4 m -101.77 127.99 48.31 Favored 'General case' 0 C--N 1.309 -1.187 0 O-C-N 121.468 -1.019 . . . . 0.0 108.711 178.858 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.581 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.92 108.77 7.08 Favored 'General case' 0 C--N 1.295 -1.768 0 C-N-CA 119.316 -0.953 . . . . 0.0 109.819 -179.214 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 40.2 p -121.95 120.11 33.47 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.322 -0.861 . . . . 0.0 109.481 179.945 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.465 HG23 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.74 147.97 32.49 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.482 -0.761 . . . . 0.0 109.245 179.845 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.3 p -98.64 139.74 33.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.355 -0.84 . . . . 0.0 109.593 -179.876 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.513 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -143.75 157.45 44.38 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.366 -0.834 . . . . 0.0 109.202 -179.466 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.574 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 14.4 t -86.25 137.73 32.39 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.056 -1.028 . . . . 0.0 110.427 -179.645 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.521 ' CG2' HG11 ' A' ' 19' ' ' VAL . 24.1 m -148.6 141.43 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.467 -0.771 . . . . 0.0 109.525 -179.444 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.557 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -143.63 -170.68 3.36 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.563 -1.335 . . . . 0.0 110.368 -179.984 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.543 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -64.4 -94.61 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 -179.812 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.77 137.73 56.27 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.776 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.19 137.96 7.49 Favored 'General case' 0 C--N 1.293 -1.886 0 C-N-CA 118.3 -1.36 . . . . 0.0 110.473 -177.683 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.483 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.8 OUTLIER -32.42 118.91 0.28 Allowed 'General case' 0 N--CA 1.493 1.682 0 CA-C-O 121.5 0.667 . . . . 0.0 110.6 -178.497 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.552 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.97 49.42 1.76 Allowed Glycine 0 N--CA 1.492 2.403 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.542 -179.028 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.567 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.8 m-85 -40.0 115.55 0.55 Allowed 'General case' 0 N--CA 1.509 2.517 0 O-C-N 121.029 -1.277 . . . . 0.0 109.731 179.347 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.542 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -85.81 127.21 34.5 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.943 -1.098 . . . . 0.0 109.66 -179.673 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.571 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.1 t80 -64.55 57.97 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.856 -1.153 . . . . 0.0 110.182 179.664 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.47 19.62 0.14 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.929 -1.107 . . . . 0.0 109.718 179.885 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.07 -28.12 5.23 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.952 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.454 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 34.6 p -92.59 156.28 17.21 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.06 -1.259 . . . . 0.0 110.309 -179.439 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.467 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -105.04 134.73 47.65 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.664 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.48 ' HB2' HD12 ' A' ' 77' ' ' LEU . 0.6 OUTLIER -82.55 -17.21 45.76 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.655 -1.278 . . . . 0.0 110.518 -178.372 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 106.67 176.42 23.14 Favored Glycine 0 N--CA 1.485 1.904 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -179.791 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.72 105.38 0.65 Allowed 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 179.095 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.536 HG21 ' CB ' ' A' ' 46' ' ' ALA . 36.8 t -76.43 104.08 4.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.421 -0.799 . . . . 0.0 109.046 -178.816 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.471 ' HB3' HG22 ' A' ' 90' ' ' THR . 0.5 OUTLIER -62.39 109.51 1.38 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.546 -0.721 . . . . 0.0 110.027 -179.343 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.543 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.85 -4.49 6.86 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.565 -1.335 . . . . 0.0 109.728 179.256 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.5 p -85.37 3.78 38.31 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.848 -1.158 . . . . 0.0 108.989 179.499 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.471 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -119.37 -49.08 2.38 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.409 -0.807 . . . . 0.0 109.026 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.91 -178.88 3.78 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.491 -0.756 . . . . 0.0 109.474 179.826 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.55 115.26 29.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.366 -0.833 . . . . 0.0 109.138 -179.924 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.547 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.85 124.88 40.95 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.845 -1.16 . . . . 0.0 109.201 -179.628 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.529 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -104.12 146.77 28.27 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 122.379 1.085 . . . . 0.0 111.709 -179.027 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.525 ' CG1' HG12 ' A' ' 7' ' ' VAL . 84.1 t -100.4 109.81 25.97 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 177.348 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -145.87 -174.2 17.83 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 118.064 -2.017 . . . . 0.0 111.782 -177.426 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.62 -178.8 3.56 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 -178.95 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.534 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 1.2 p -173.28 170.19 4.33 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 121.423 -0.798 . . . . 0.0 109.094 -179.425 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.481 ' OD2' ' CZ ' ' A' ' 32' ' ' TYR . 1.7 m-20 -106.07 -9.34 17.04 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.107 -0.996 . . . . 0.0 109.542 179.917 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.47 ' CB ' ' O ' ' A' ' 99' ' ' ASP . . . 72.72 39.76 0.66 Allowed 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.443 -0.785 . . . . 0.0 109.121 179.991 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -137.44 -34.47 0.7 Allowed 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.629 -0.669 . . . . 0.0 110.646 -179.427 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.498 ' CA ' H192 ' A' ' 114' ' ' CHR . . . -177.09 -42.8 0.06 OUTLIER Glycine 0 N--CA 1.482 1.709 0 N-CA-C 107.867 -2.093 . . . . 0.0 107.867 -179.712 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.61 -178.11 6.36 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 121.504 -0.998 . . . . 0.0 109.626 179.209 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.13 -165.89 32.62 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.479 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.7 Cg_exo -49.53 -175.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.646 0 CA-C-N 118.874 1.337 . . . . 0.0 110.371 179.572 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 16.5 mm-40 -95.89 -178.85 4.5 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.093 -1.004 . . . . 0.0 110.248 -179.094 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -115.64 158.74 14.2 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 -179.906 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.94 128.35 50.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.421 -1.046 . . . . 0.0 108.982 -179.555 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.529 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.32 119.26 16.27 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.589 -0.695 . . . . 0.0 109.959 179.964 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.583 HD13 ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -97.97 172.61 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.241 -0.912 . . . . 0.0 108.677 179.544 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.511 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -140.7 156.91 46.09 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.945 -1.097 . . . . 0.0 110.012 -179.761 . . . . . . . . 3 3 . 1 . 043 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.583 ' CZ ' HD13 ' A' ' 110' ' ' ILE . 96.6 m-85 -132.8 114.63 14.32 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.289 -0.882 . . . . 0.0 109.506 -179.749 . . . . . . . . 2 2 . 1 . 043 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.42 ' C ' ' O ' ' A' ' 112' ' ' PHE . 23.5 p30 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.036 -0.983 . . . . 0.0 109.491 -179.984 . . . . . . . . 1 1 . 1 . 043 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.586 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 044 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -93.93 165.91 16.85 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.347 -0.846 . . . . 0.0 109.535 179.995 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.508 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 5.2 Cg_exo -59.97 157.53 33.49 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.371 2.048 . . . . 0.0 110.667 179.969 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.605 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -147.12 160.58 42.26 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 -179.681 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.481 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.44 122.42 9.43 Favored 'General case' 0 C--N 1.297 -1.705 0 CA-C-O 122.427 1.108 . . . . 0.0 110.278 -179.659 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.54 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.1 t -116.21 109.22 17.14 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-O 123.09 1.424 . . . . 0.0 109.767 -179.992 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.526 HG12 ' CG1' ' A' ' 95' ' ' VAL . 2.4 t -112.87 136.26 49.71 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.745 0 CA-C-N 114.24 -1.345 . . . . 0.0 109.776 179.909 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.483 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.65 148.23 5.6 Favored Pre-proline 0 N--CA 1.487 1.396 0 O-C-N 121.184 -0.947 . . . . 0.0 108.855 -179.557 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.483 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.4 Cg_endo -76.46 151.18 94.44 Favored 'Cis proline' 0 C--N 1.312 -1.352 0 C-N-CA 123.38 -1.508 . . . . 0.0 109.422 -0.812 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.459 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 2.1 m -88.35 -26.73 22.06 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.593 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.475 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.4 m -136.73 165.14 26.61 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.616 -0.678 . . . . 0.0 109.446 179.807 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.31 37.69 31.12 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 -179.631 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.605 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 38.7 mt -92.84 -41.98 9.78 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 123.362 1.553 . . . . 0.0 110.418 -178.342 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.494 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.45 143.24 0.05 OUTLIER 'General case' 0 C--N 1.261 -3.279 0 CA-C-N 113.297 -1.774 . . . . 0.0 109.808 -179.57 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.552 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.3 p-10 -50.79 104.75 0.08 Allowed 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 121.462 0.649 . . . . 0.0 111.432 -178.369 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.4 15.19 7.76 Favored Glycine 0 N--CA 1.485 1.963 0 C-N-CA 119.317 -1.421 . . . . 0.0 113.086 177.311 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.605 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.0 t -104.72 -170.33 1.75 Allowed 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 121.165 2.482 . . . . 0.0 109.579 179.09 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.55 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 17.4 t -127.4 137.41 57.81 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.116 -179.133 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.576 ' CG1' ' CG2' ' A' ' 69' ' ' VAL . 11.7 m -111.28 156.32 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.315 -0.866 . . . . 0.0 108.852 178.932 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.491 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.4 tttt -111.55 109.48 19.42 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.214 -0.929 . . . . 0.0 108.843 179.854 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.525 HG12 ' CG2' ' A' ' 34' ' ' VAL . 1.9 p -102.91 138.8 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.975 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.581 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -132.61 161.76 33.06 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.861 -1.135 . . . . 0.0 109.941 179.689 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.586 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.92 140.75 11.85 Favored Glycine 0 C--N 1.298 -1.547 0 N-CA-C 108.144 -1.983 . . . . 0.0 108.144 179.776 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.605 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.54 125.4 16.09 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.606 -1.526 . . . . 0.0 109.296 179.374 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.508 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.2 28.51 20.06 Favored Glycine 0 N--CA 1.489 2.187 0 C-N-CA 118.69 -1.719 . . . . 0.0 109.807 -179.808 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.536 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -89.53 171.95 9.34 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 120.936 -1.332 . . . . 0.0 108.301 179.852 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.557 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.0 99.33 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.96 -1.087 . . . . 0.0 109.892 -179.385 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.23 77.66 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.212 -179.337 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.19 34.02 0.3 Allowed Glycine 0 N--CA 1.487 2.099 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 179.57 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.539 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 48.2 p -141.94 108.57 5.35 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 121.048 -1.266 . . . . 0.0 111.252 -179.527 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.559 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.16 109.71 0.32 Allowed 'General case' 0 N--CA 1.496 1.843 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.584 177.944 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.514 ' CE1' ' OG1' ' A' ' 30' ' ' THR . 4.6 m-30 -104.26 156.14 18.15 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.145 -0.972 . . . . 0.0 108.774 179.752 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.48 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -99.7 165.36 11.64 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.978 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.618 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.5 p -146.66 116.23 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.085 -1.009 . . . . 0.0 109.759 -178.15 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.491 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.73 -176.89 38.17 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.175 -1.964 . . . . 0.0 111.709 -179.608 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.614 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.3 pt20 -101.47 109.77 21.65 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.979 0.895 . . . . 0.0 109.055 -179.653 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.99 150.46 52.13 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 121.224 -0.922 . . . . 0.0 109.554 179.846 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.78 139.0 54.24 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.079 -1.013 . . . . 0.0 110.775 -178.949 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.627 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.16 114.64 26.45 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 178.196 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m -105.46 15.19 7.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.068 -1.02 . . . . 0.0 110.561 -178.688 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.589 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.42 -175.38 0.1 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.894 -1.128 . . . . 0.0 110.114 179.631 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -71.6 96.81 1.6 Allowed 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.426 -0.796 . . . . 0.0 109.743 -179.696 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.01 27.5 33.89 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 120.194 -1.003 . . . . 0.0 111.482 178.877 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.589 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.42 106.29 20.23 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.523 -1.575 . . . . 0.0 107.443 178.861 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.627 HD13 ' CD1' ' A' ' 39' ' ' TRP . 11.8 tp -115.75 104.67 11.9 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 120.389 -1.445 . . . . 0.0 109.967 -177.658 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.516 ' HB3' ' CA ' ' A' ' 75' ' ' GLY . . . -98.18 109.24 22.03 Favored 'General case' 0 N--CA 1.484 1.24 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.709 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.7 t -107.26 167.93 9.57 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.985 -1.072 . . . . 0.0 110.564 -178.397 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.522 ' ND2' ' HB1' ' A' ' 50' ' ' ALA . 49.9 t30 -112.61 130.9 22.97 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.454 -0.779 . . . . 0.0 109.585 -179.435 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.49 ' CD ' ' HB3' ' A' ' 74' ' ' GLU . 2.8 Cg_endo -72.41 23.76 0.27 Allowed 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 122.189 1.926 . . . . 0.0 112.124 179.966 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.522 ' HB1' ' ND2' ' A' ' 48' ' ' ASN . . . -113.41 3.53 15.88 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.333 -1.479 . . . . 0.0 109.192 179.526 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.505 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.45 17.36 2.74 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 179.259 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -80.84 88.87 5.82 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.577 -0.702 . . . . 0.0 111.011 -178.593 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.618 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -107.27 -167.19 1.24 Allowed 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.266 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.468 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.96 135.06 0.09 Allowed 'General case' 0 C--N 1.305 -1.353 0 O-C-N 120.496 -1.377 . . . . 0.0 111.372 -179.418 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.568 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.4 p -150.3 157.72 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 178.176 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.559 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.56 142.24 30.4 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.74 -1.225 . . . . 0.0 110.054 -179.847 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.681 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.13 107.73 1.36 Allowed 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 122.469 1.128 . . . . 0.0 109.416 178.436 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.537 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.0 p-10 -61.2 -139.17 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.762 179.893 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.29 -51.07 60.66 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.431 -0.793 . . . . 0.0 110.454 -178.691 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -101.75 -34.95 9.24 Favored 'General case' 0 C--N 1.285 -2.221 0 N-CA-C 106.287 -1.745 . . . . 0.0 106.287 178.342 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.681 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.28 65.87 0.59 Allowed Glycine 0 C--N 1.298 -1.565 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.082 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.586 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.5 m -98.71 130.83 45.21 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 121.503 -0.998 . . . . 0.0 108.482 178.729 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.581 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -135.76 108.86 7.7 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 118.956 -1.098 . . . . 0.0 109.796 -179.272 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 60.0 p -121.51 117.72 27.52 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.36 -0.838 . . . . 0.0 109.421 179.949 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.499 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -144.99 142.17 29.57 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.489 -0.757 . . . . 0.0 109.593 179.981 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 34.0 p -99.87 141.59 32.48 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.436 -0.79 . . . . 0.0 109.287 179.815 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.525 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -142.04 166.18 25.42 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.354 -0.841 . . . . 0.0 109.418 -179.355 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 3.4 p -95.49 124.47 39.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.118 -0.989 . . . . 0.0 109.398 -179.852 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.576 ' CG2' ' CG1' ' A' ' 19' ' ' VAL . 18.8 m -139.76 142.56 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 120.946 -1.096 . . . . 0.0 109.964 -179.183 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.552 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 7.3 ptt180 -140.09 -166.35 2.08 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 120.627 -1.295 . . . . 0.0 109.897 179.903 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.578 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -71.93 -80.68 0.06 Allowed 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 179.952 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.5 OUTLIER -64.13 135.97 56.83 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.197 -1.409 . . . . 0.0 107.197 178.579 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.591 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -161.98 138.68 8.14 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 118.07 -1.452 . . . . 0.0 110.252 -177.692 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.49 ' HB3' ' CD ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -31.04 121.39 0.22 Allowed 'General case' 0 N--CA 1.492 1.634 0 CA-C-O 121.479 0.657 . . . . 0.0 110.851 -178.31 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.516 ' CA ' ' HB3' ' A' ' 46' ' ' ALA . . . -91.95 50.62 2.83 Favored Glycine 0 N--CA 1.496 2.667 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 -179.489 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.463 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.5 OUTLIER -52.97 114.13 1.33 Allowed 'General case' 0 N--CA 1.51 2.55 0 O-C-N 120.934 -1.333 . . . . 0.0 110.645 -179.886 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.517 HD12 ' CD1' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -78.94 151.95 31.37 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 120.864 -1.148 . . . . 0.0 108.231 178.114 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.564 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 63.7 t80 -74.68 5.5 4.83 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 120.69 -1.256 . . . . 0.0 110.563 -179.98 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -105.16 -2.49 24.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.905 -1.122 . . . . 0.0 109.701 -179.879 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.21 -19.45 51.42 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.998 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.475 ' O ' ' HB2' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -76.35 151.56 36.61 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.147 -1.207 . . . . 0.0 109.5 -179.947 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.503 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -96.82 123.08 40.42 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.896 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.517 ' CD1' HD12 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -85.27 -16.68 39.33 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.968 -1.083 . . . . 0.0 110.046 -179.121 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 103.19 173.15 26.24 Favored Glycine 0 N--CA 1.483 1.829 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 -179.757 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -60.09 108.93 0.85 Allowed 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 178.853 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.558 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 25.5 t -78.88 101.27 4.16 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -178.844 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.458 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -62.14 110.41 1.6 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.548 -0.72 . . . . 0.0 110.046 -178.985 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.532 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -65.14 -4.78 5.38 Favored 'General case' 0 N--CA 1.499 1.993 0 C-N-CA 118.413 -1.315 . . . . 0.0 109.727 179.378 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.6 p -83.66 2.82 35.73 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.712 -1.242 . . . . 0.0 108.911 179.328 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.458 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.0 p -117.91 -48.53 2.55 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.406 -0.809 . . . . 0.0 108.974 -179.976 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.67 179.97 4.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.542 -0.724 . . . . 0.0 109.394 179.931 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.47 114.75 29.18 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.368 -0.832 . . . . 0.0 109.22 179.964 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.569 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.7 120.89 37.86 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.887 -1.133 . . . . 0.0 109.532 -179.305 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.566 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.91 148.25 25.2 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 122.38 1.086 . . . . 0.0 111.308 -179.322 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.526 ' CG1' HG12 ' A' ' 7' ' ' VAL . 43.2 t -105.06 111.56 35.04 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 177.66 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.47 -170.84 17.45 Favored Glycine 0 N--CA 1.486 2.025 0 C-N-CA 118.18 -1.962 . . . . 0.0 111.667 -177.65 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.48 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.68 178.81 4.2 Favored 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.016 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.584 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.0 OUTLIER -171.59 168.7 6.28 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.473 -0.767 . . . . 0.0 109.347 -179.517 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.464 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -118.1 -158.28 0.71 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.067 -1.021 . . . . 0.0 108.948 179.811 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.464 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.39 36.63 4.18 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.72 -1.238 . . . . 0.0 109.156 179.999 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -115.87 -32.74 5.35 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.262 -0.899 . . . . 0.0 110.225 -179.624 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.513 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 164.13 -35.49 0.29 Allowed Glycine 0 N--CA 1.482 1.763 0 N-CA-C 107.661 -2.175 . . . . 0.0 107.661 -179.648 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.28 -177.76 6.24 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.561 -0.964 . . . . 0.0 109.715 179.28 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.82 -161.78 15.63 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 108.41 -1.876 . . . . 0.0 108.41 -179.344 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.483 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.7 Cg_exo -47.22 178.97 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.678 0 CA-C-N 118.721 1.261 . . . . 0.0 110.345 179.378 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -92.97 -172.64 3.05 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.198 -0.939 . . . . 0.0 110.357 -178.866 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -123.45 161.94 17.56 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.891 . . . . . . . . 1 1 . 1 . 044 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.73 130.53 48.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.415 -1.05 . . . . 0.0 109.244 -179.514 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.566 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.22 120.81 19.36 Favored 'General case' 0 C--N 1.289 -2.043 0 O-C-N 121.716 -0.615 . . . . 0.0 109.646 179.684 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.629 ' CD1' ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -98.14 169.67 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 O-C-N 121.138 -0.976 . . . . 0.0 109.331 -179.956 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.475 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -136.96 151.16 48.69 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.256 -0.903 . . . . 0.0 109.694 -179.973 . . . . . . . . 3 3 . 1 . 044 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.629 ' CZ ' ' CD1' ' A' ' 110' ' ' ILE . 36.7 m-85 -128.56 100.8 5.89 Favored 'General case' 0 C--N 1.305 -1.33 0 O-C-N 121.099 -1.001 . . . . 0.0 109.539 -179.727 . . . . . . . . 2 2 . 1 . 044 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 20.1 p30 . . . . . 0 N--CA 1.49 1.527 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.417 -179.986 . . . . . . . . 0 0 . 1 . 044 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.593 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 045 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -110.31 155.48 41.86 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.239 -0.913 . . . . 0.0 109.558 179.918 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.495 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 3.5 Cg_exo -60.8 156.38 43.65 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.313 2.009 . . . . 0.0 110.62 -179.872 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.601 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -148.05 160.53 42.76 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.901 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -145.64 127.05 14.96 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 120.984 -1.072 . . . . 0.0 110.469 -179.67 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.543 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.4 p -105.56 105.04 14.89 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 122.501 1.143 . . . . 0.0 110.46 -179.352 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.529 HG21 ' CG2' ' A' ' 21' ' ' VAL . 3.5 t -118.12 117.82 56.09 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.426 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.267 179.426 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.489 HG21 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -161.34 148.49 11.83 Favored Pre-proline 0 N--CA 1.487 1.412 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 -179.588 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.489 ' HA ' HG21 ' A' ' 8' ' ' THR . 6.2 Cg_endo -78.3 149.93 87.38 Favored 'Cis proline' 0 C--N 1.31 -1.491 0 C-N-CA 123.533 -1.445 . . . . 0.0 109.563 -0.573 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.473 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 88.5 p -92.23 -23.38 19.36 Favored 'General case' 0 C--N 1.291 -1.962 0 O-C-N 121.618 -0.676 . . . . 0.0 109.209 179.584 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.453 ' HA ' ' O ' ' A' ' 111' ' ' SER . 1.1 m -132.7 161.15 34.75 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.52 -0.737 . . . . 0.0 109.47 -179.91 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.01 37.76 32.07 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 -179.556 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.619 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 32.8 mt -90.83 -43.78 9.83 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 123.303 1.525 . . . . 0.0 110.674 -178.233 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.486 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.39 143.94 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.282 0 CA-C-N 113.508 -1.678 . . . . 0.0 109.899 -179.618 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.576 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -50.72 107.19 0.15 Allowed 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.683 0.754 . . . . 0.0 111.653 -178.611 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.26 15.46 8.99 Favored Glycine 0 N--CA 1.483 1.829 0 C-N-CA 119.557 -1.306 . . . . 0.0 112.801 177.461 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.619 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.7 t -105.3 -173.82 2.39 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 121.106 2.453 . . . . 0.0 109.914 179.309 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.549 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 19.0 t -130.18 138.94 52.68 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 114.666 -1.152 . . . . 0.0 111.24 -178.61 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.488 HG13 ' CG2' ' A' ' 69' ' ' VAL . 34.6 m -115.92 155.65 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.367 -0.833 . . . . 0.0 108.817 178.725 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.522 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 12.4 tttt -107.72 109.33 20.89 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.03 -1.043 . . . . 0.0 109.66 -179.789 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.529 ' CG2' HG21 ' A' ' 7' ' ' VAL . 6.5 p -104.36 125.08 59.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.528 -0.732 . . . . 0.0 109.193 179.759 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.554 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -115.53 165.21 13.26 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.741 -1.224 . . . . 0.0 108.911 179.348 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.613 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.39 107.95 0.49 Allowed Glycine 0 N--CA 1.481 1.686 0 N-CA-C 108.242 -1.943 . . . . 0.0 108.242 -179.97 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.601 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -118.23 139.84 50.69 Favored 'General case' 0 N--CA 1.5 2.035 0 CA-C-N 119.635 1.718 . . . . 0.0 110.464 -179.171 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.495 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 83.76 28.46 35.06 Favored Glycine 0 N--CA 1.489 2.219 0 C-N-CA 118.739 -1.696 . . . . 0.0 109.948 179.387 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -92.4 171.96 8.7 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.935 -1.332 . . . . 0.0 108.429 179.793 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.23 100.43 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.933 -1.104 . . . . 0.0 109.781 -179.664 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.06 77.6 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.679 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.982 -179.245 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.1 33.99 0.27 Allowed Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.721 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.573 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 24.5 p -139.53 106.98 5.55 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.17 -1.194 . . . . 0.0 111.261 -179.577 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.565 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -52.37 110.4 0.49 Allowed 'General case' 0 N--CA 1.497 1.901 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.93 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.575 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 30.0 m-85 -106.68 157.4 17.73 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.06 -1.025 . . . . 0.0 109.079 179.892 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.58 165.29 11.49 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.781 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.636 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.6 p -144.57 121.3 4.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.13 -0.981 . . . . 0.0 109.535 -177.623 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.39 -178.53 42.62 Favored Glycine 0 N--CA 1.496 2.681 0 C-N-CA 118.114 -1.993 . . . . 0.0 111.86 -179.814 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.559 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.2 OUTLIER -100.73 108.86 20.81 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.874 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.446 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -129.85 149.29 51.65 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.142 -0.974 . . . . 0.0 110.11 179.849 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.34 138.73 54.35 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.363 -0.836 . . . . 0.0 110.757 -179.128 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.618 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.25 115.03 26.89 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.146 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.468 HG23 ' HB ' ' A' ' 44' ' ' VAL . 11.8 m -105.9 15.52 7.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 120.95 -1.094 . . . . 0.0 110.55 -178.895 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.59 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 173.97 -176.26 0.08 Allowed 'General case' 0 C--N 1.303 -1.417 0 O-C-N 120.902 -1.124 . . . . 0.0 110.192 179.775 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.545 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.0 t -71.16 98.45 1.69 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.426 -0.796 . . . . 0.0 109.827 -179.672 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.7 28.77 34.25 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.312 179.006 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.59 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -117.5 106.11 19.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 120.608 -1.525 . . . . 0.0 107.16 178.853 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.618 HD11 ' CD1' ' A' ' 39' ' ' TRP . 13.3 tp -117.6 104.74 11.33 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.49 -1.381 . . . . 0.0 109.756 -177.613 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.517 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.95 109.52 22.26 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.809 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -106.74 166.49 10.54 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.928 -1.108 . . . . 0.0 110.422 -178.761 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.542 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 3.0 t-20 -107.88 133.34 20.51 Favored Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.526 -0.734 . . . . 0.0 109.511 -179.247 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.581 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.3 Cg_endo -74.61 25.12 0.36 Allowed 'Trans proline' 0 C--N 1.319 -0.99 0 C-N-CA 122.376 2.05 . . . . 0.0 111.99 -179.973 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.542 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -107.12 -4.87 18.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.342 -1.474 . . . . 0.0 109.306 179.848 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.544 ' HB3' ' CB ' ' A' ' 67' ' ' LEU . 5.4 m-20 -133.24 5.94 3.83 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.264 -0.898 . . . . 0.0 108.683 179.918 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -60.35 80.06 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 110.5 -178.797 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.636 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -105.31 -169.6 1.62 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 178.55 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.474 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 177.88 135.67 0.07 Allowed 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.626 -1.296 . . . . 0.0 111.149 -179.249 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.553 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -149.58 157.83 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 177.907 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.565 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.31 140.1 33.1 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 120.837 -1.164 . . . . 0.0 110.038 -179.7 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.663 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -62.45 106.61 0.79 Allowed 'General case' 0 C--N 1.298 -1.673 0 CA-C-O 122.438 1.113 . . . . 0.0 109.448 178.418 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.535 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.5 p-10 -59.8 -139.38 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.031 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.882 -179.944 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.01 -50.4 61.46 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.344 -0.848 . . . . 0.0 110.485 -178.782 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -103.21 -35.0 8.62 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 178.433 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.663 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.34 69.86 0.71 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 178.123 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.613 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 48.3 m -105.1 127.68 53.0 Favored 'General case' 0 N--CA 1.485 1.299 0 O-C-N 121.517 -0.99 . . . . 0.0 108.96 179.256 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.554 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -133.96 109.27 8.9 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.076 -179.765 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 42.5 m -120.46 115.84 24.26 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.282 -0.886 . . . . 0.0 109.452 -179.656 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.82 143.82 29.89 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.4 -0.813 . . . . 0.0 109.502 179.967 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.427 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 21.8 p -98.76 137.21 37.69 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.467 -0.771 . . . . 0.0 109.407 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.549 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.1 OUTLIER -131.26 167.81 18.58 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.408 -0.808 . . . . 0.0 110.027 -178.673 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.522 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.2 p -102.62 123.6 46.62 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.051 -1.031 . . . . 0.0 108.863 179.396 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.529 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.7 m -135.99 143.99 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 120.899 -1.126 . . . . 0.0 109.868 -179.023 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.576 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.8 ptt180 -144.75 -176.79 5.21 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 120.637 -1.289 . . . . 0.0 111.046 -179.891 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.706 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.97 -94.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.276 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -65.32 148.28 51.98 Favored 'General case' 0 N--CA 1.485 1.282 0 O-C-N 120.566 -1.334 . . . . 0.0 107.543 178.63 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.602 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -167.44 140.66 3.45 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 117.942 -1.503 . . . . 0.0 110.126 -177.459 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' A' ' 47' ' ' CYS . 5.1 mm-40 -36.49 122.06 0.75 Allowed 'General case' 0 N--CA 1.489 1.509 0 CA-C-O 121.421 0.629 . . . . 0.0 110.235 -178.708 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.517 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -96.61 51.83 1.54 Allowed Glycine 0 N--CA 1.495 2.571 0 C-N-CA 120.496 -0.859 . . . . 0.0 111.148 -179.252 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.581 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -39.16 114.74 0.43 Allowed 'General case' 0 N--CA 1.509 2.476 0 O-C-N 121.104 -1.233 . . . . 0.0 110.18 179.446 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -85.53 126.55 33.95 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 120.791 -1.193 . . . . 0.0 109.594 -179.841 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.579 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 32.3 t80 -64.5 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.028 0 O-C-N 120.852 -1.155 . . . . 0.0 109.951 179.527 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.2 t70 -159.55 19.41 0.17 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.007 -1.058 . . . . 0.0 109.624 179.873 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.4 -27.45 5.71 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.929 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.471 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 63.1 p -97.01 158.5 15.4 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 120.963 -1.316 . . . . 0.0 110.366 -179.375 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.487 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 2.6 ptt180 -104.28 140.21 38.19 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.672 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.468 ' CD1' HD12 ' A' ' 77' ' ' LEU . 1.7 t90 -84.93 -17.51 37.54 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.683 -1.261 . . . . 0.0 110.787 -178.077 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.41 176.58 19.83 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 -179.45 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.91 104.51 1.12 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 179.198 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.574 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 39.9 t -75.93 107.92 7.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.295 -0.878 . . . . 0.0 109.387 -178.767 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.508 ' CB ' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -68.24 113.14 5.6 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.435 -0.791 . . . . 0.0 109.575 -179.777 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.706 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 8.2 m -62.48 -5.07 2.24 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 120.424 -1.423 . . . . 0.0 110.235 179.717 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 p -88.35 -2.82 58.82 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.542 -1.349 . . . . 0.0 109.489 179.825 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.508 HG23 ' CB ' ' A' ' 87' ' ' ASP . 2.6 p -106.45 -47.95 3.67 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.237 -0.914 . . . . 0.0 108.804 179.837 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -111.1 -177.67 3.27 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.642 -0.662 . . . . 0.0 109.295 179.724 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.75 116.19 31.87 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.933 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.524 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 3.4 m -96.67 122.23 39.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.823 -1.173 . . . . 0.0 109.794 -179.167 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.521 ' HA ' ' O ' ' A' ' 108' ' ' VAL . 1.1 mt-30 -104.36 148.71 26.09 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 122.393 1.092 . . . . 0.0 111.458 -179.374 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.524 ' CG1' HG13 ' A' ' 7' ' ' VAL . 48.4 t -106.3 111.51 35.55 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 106.873 -1.529 . . . . 0.0 106.873 177.534 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.465 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.51 -170.68 19.9 Favored Glycine 0 N--CA 1.488 2.106 0 C-N-CA 118.104 -1.998 . . . . 0.0 111.625 -177.743 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.485 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -115.92 175.15 5.67 Favored 'General case' 0 C--N 1.307 -1.268 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.269 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.6 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 3.3 t 175.34 153.1 0.14 Allowed 'General case' 0 C--N 1.291 -1.957 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -179.857 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.575 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -99.72 -161.26 0.86 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.765 -1.21 . . . . 0.0 109.115 -179.819 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -115.63 35.76 4.28 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.716 -1.24 . . . . 0.0 109.15 -179.929 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -110.78 -32.17 6.94 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.358 -0.839 . . . . 0.0 109.658 -179.733 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 167.63 -36.82 0.22 Allowed Glycine 0 N--CA 1.481 1.672 0 N-CA-C 108.048 -2.021 . . . . 0.0 108.048 -179.823 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -165.83 -177.16 4.15 Favored 'General case' 0 C--N 1.307 -1.282 0 O-C-N 121.501 -0.999 . . . . 0.0 109.98 179.476 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.71 -161.62 20.48 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.204 -1.958 . . . . 0.0 108.204 -179.368 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.4 Cg_exo -47.55 -179.55 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.694 0 CA-C-N 118.921 1.36 . . . . 0.0 110.442 179.239 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -96.51 174.71 6.71 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.069 -1.019 . . . . 0.0 110.361 -179.056 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.465 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -114.65 175.69 16.29 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -110.01 153.45 11.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 -179.545 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.514 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -94.21 123.94 37.92 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 121.337 -0.852 . . . . 0.0 109.413 179.796 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.55 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.4 pt -97.91 169.72 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 O-C-N 121.092 -1.005 . . . . 0.0 109.159 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.44 154.99 48.87 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.333 -0.854 . . . . 0.0 109.455 179.93 . . . . . . . . 3 3 . 1 . 045 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.55 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 59.6 m-85 -131.39 87.85 2.51 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.084 -1.01 . . . . 0.0 109.598 -179.609 . . . . . . . . 2 2 . 1 . 045 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.407 ' C ' ' O ' ' A' ' 112' ' ' PHE . 18.6 p30 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.428 -179.971 . . . . . . . . 1 1 . 1 . 045 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.6 ' C21' ' CB ' ' A' ' 98' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 121.274 0.559 . . . . 0.0 109.492 . . . . . . . . . 0 0 . 1 . 046 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -117.8 158.41 45.71 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.18 -0.95 . . . . 0.0 109.484 179.977 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.528 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.2 Cg_exo -59.98 157.44 33.95 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.185 1.923 . . . . 0.0 110.606 -179.979 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.539 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.83 -169.75 0.14 Allowed 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 179.218 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.539 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -166.87 133.87 2.44 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.634 -1.291 . . . . 0.0 111.055 -179.529 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.536 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.3 p -101.22 104.71 15.77 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 122.453 1.121 . . . . 0.0 109.959 -179.843 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.544 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 3.2 t -118.54 124.54 73.3 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.509 179.716 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.486 HG21 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -170.8 149.96 2.99 Favored Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.509 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.486 ' HA ' HG21 ' A' ' 8' ' ' THR . 2.0 Cg_endo -75.02 152.55 98.32 Favored 'Cis proline' 0 C--N 1.309 -1.504 0 C-N-CA 123.553 -1.436 . . . . 0.0 109.714 -0.476 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.467 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 9.3 m -93.31 -23.07 18.61 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.61 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.465 ' OG ' ' HB3' ' A' ' 111' ' ' SER . 3.2 m -135.32 163.38 30.14 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.46 -0.775 . . . . 0.0 109.345 179.764 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.83 38.1 32.11 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 108.387 -1.885 . . . . 0.0 108.387 -179.513 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.614 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 32.8 mt -91.94 -44.14 9.07 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 123.122 1.439 . . . . 0.0 110.7 -178.201 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 68.14 145.24 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.338 0 CA-C-N 113.578 -1.646 . . . . 0.0 110.081 -179.707 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.56 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.5 p-10 -50.45 106.81 0.13 Allowed 'General case' 0 C--N 1.302 -1.474 0 CA-C-O 121.437 0.637 . . . . 0.0 111.793 -178.54 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.05 16.38 9.15 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.502 -1.332 . . . . 0.0 112.905 177.137 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.614 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.1 t -105.05 -173.73 2.37 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 121.069 2.434 . . . . 0.0 109.982 179.276 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.552 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 19.3 t -130.33 138.84 52.86 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.287 0 CA-C-N 114.593 -1.185 . . . . 0.0 111.183 -178.613 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.455 ' CG1' HD23 ' A' ' 13' ' ' LEU . 27.2 m -115.95 155.52 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.75 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.544 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 4.7 tttm -104.84 109.15 21.0 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.08 -1.013 . . . . 0.0 109.355 -179.954 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.524 ' CG1' HD11 ' A' ' 67' ' ' LEU . 7.2 p -106.64 124.2 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 179.671 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.536 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -118.89 166.94 12.21 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.65 -1.281 . . . . 0.0 109.296 179.848 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.76 141.8 13.2 Favored Glycine 0 C--N 1.296 -1.676 0 N-CA-C 107.594 -2.203 . . . . 0.0 107.594 179.727 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.515 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -147.42 123.21 10.59 Favored 'General case' 0 C--N 1.291 -1.956 0 O-C-N 120.832 -1.393 . . . . 0.0 108.624 179.19 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.528 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.68 26.36 25.12 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 119.222 -1.466 . . . . 0.0 109.884 -179.724 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.547 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.3 mt -85.69 176.01 8.4 Favored 'General case' 0 C--N 1.307 -1.281 0 O-C-N 120.695 -1.473 . . . . 0.0 108.245 179.908 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.561 ' CB ' ' CG2' ' A' ' 30' ' ' THR . 0.0 OUTLIER -45.76 96.87 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.013 -1.055 . . . . 0.0 109.671 -179.891 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.69 76.61 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.547 -178.91 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.01 34.59 0.33 Allowed Glycine 0 N--CA 1.486 1.984 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 179.334 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.561 ' CG2' ' CB ' ' A' ' 27' ' ' GLN . 1.2 t -149.23 115.4 5.77 Favored 'General case' 0 C--N 1.308 -1.213 0 O-C-N 120.94 -1.329 . . . . 0.0 111.263 179.949 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.557 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.68 129.54 4.15 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.819 178.262 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.541 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 7.4 m-85 -120.45 149.85 41.74 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.614 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.07 164.79 11.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.651 -1.281 . . . . 0.0 107.685 178.73 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.624 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 7.0 p -147.86 118.22 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.139 -0.976 . . . . 0.0 109.855 -177.831 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.77 -178.61 41.52 Favored Glycine 0 N--CA 1.494 2.526 0 C-N-CA 118.432 -1.842 . . . . 0.0 111.537 -179.864 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.561 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -99.16 108.48 21.09 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.822 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.453 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.19 148.31 52.02 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.257 -0.902 . . . . 0.0 110.109 179.992 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.44 139.5 53.83 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.39 -0.819 . . . . 0.0 110.736 -179.167 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.623 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.82 26.65 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.129 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.454 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 13.6 m -105.92 15.46 7.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.029 -1.044 . . . . 0.0 110.583 -178.698 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.59 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.32 -175.66 0.09 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.858 -1.151 . . . . 0.0 110.095 179.688 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -71.5 97.14 1.61 Allowed 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.47 -0.769 . . . . 0.0 109.754 -179.744 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.26 27.81 35.49 Favored Glycine 0 N--CA 1.491 2.325 0 C-N-CA 120.181 -1.009 . . . . 0.0 111.394 179.006 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.59 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 2.0 t -116.1 106.6 20.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 O-C-N 120.625 -1.515 . . . . 0.0 107.295 178.814 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.623 HD12 ' CD1' ' A' ' 39' ' ' TRP . 12.4 tp -116.21 104.66 11.74 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.483 -1.386 . . . . 0.0 109.738 -177.745 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.536 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.63 109.36 22.13 Favored 'General case' 0 N--CA 1.483 1.221 0 O-C-N 120.887 -1.133 . . . . 0.0 107.947 178.916 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.492 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -108.29 167.09 10.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.98 -1.075 . . . . 0.0 110.589 -178.535 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.519 ' ND2' ' HB1' ' A' ' 50' ' ' ALA . 43.6 t30 -114.7 128.22 26.09 Favored Pre-proline 0 N--CA 1.499 1.977 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 -179.554 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.575 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.2 Cg_endo -69.96 19.89 0.19 Allowed 'Trans proline' 0 CA--C 1.545 1.065 0 C-N-CA 122.005 1.803 . . . . 0.0 112.294 -179.804 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.519 ' HB1' ' ND2' ' A' ' 48' ' ' ASN . . . -93.79 -7.51 43.22 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.384 -1.448 . . . . 0.0 108.802 179.122 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.558 ' HB3' ' CB ' ' A' ' 67' ' ' LEU . 4.2 m-20 -131.24 2.22 4.24 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.369 -0.832 . . . . 0.0 108.802 -179.869 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -58.15 83.53 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.336 -0.853 . . . . 0.0 111.147 -178.247 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -110.97 -170.89 1.72 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 178.087 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.469 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.62 134.7 0.08 Allowed 'General case' 0 C--N 1.305 -1.363 0 O-C-N 120.446 -1.409 . . . . 0.0 111.621 -179.345 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.567 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.9 p -145.95 158.78 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 107.071 -1.455 . . . . 0.0 107.071 177.744 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.557 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.13 145.44 26.01 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.448 -1.407 . . . . 0.0 109.944 -179.613 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.669 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -68.04 108.84 3.23 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 122.272 1.034 . . . . 0.0 109.568 179.036 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.52 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.3 t0 -62.8 -138.89 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.979 -179.888 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.548 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.95 -51.53 40.59 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.393 -0.817 . . . . 0.0 110.559 -178.732 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -104.46 -33.54 8.55 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 178.493 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.669 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.75 70.08 0.7 Allowed Glycine 0 C--N 1.299 -1.512 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 178.482 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 70.9 m -103.57 130.81 51.05 Favored 'General case' 0 N--CA 1.484 1.255 0 O-C-N 121.248 -1.148 . . . . 0.0 109.208 179.324 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.567 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -135.57 108.86 7.79 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.471 -0.891 . . . . 0.0 109.841 -179.588 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.2 m -115.4 115.38 26.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.117 -0.99 . . . . 0.0 109.328 179.998 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.459 HG21 HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.09 144.87 30.29 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.413 -0.804 . . . . 0.0 109.829 -179.91 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.424 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 24.7 p -98.99 140.8 32.61 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.55 -0.718 . . . . 0.0 109.169 179.66 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.558 ' CB ' ' HB3' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -135.46 165.37 25.64 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.322 -0.862 . . . . 0.0 110.065 -178.924 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.2 p -104.38 123.06 46.75 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.127 -0.983 . . . . 0.0 108.807 179.463 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.517 ' CB ' ' OE1' ' A' ' 36' ' ' GLN . 18.9 m -136.06 143.48 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.838 -1.164 . . . . 0.0 110.359 -178.898 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.56 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.2 ptt180 -141.64 -166.19 2.15 Favored 'General case' 0 N--CA 1.485 1.323 0 O-C-N 120.686 -1.259 . . . . 0.0 110.331 179.688 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.547 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 1.3 mtp180 -68.98 -78.21 0.07 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.57 -0.706 . . . . 0.0 109.128 -179.419 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.43 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -71.92 139.25 48.65 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 120.122 -1.611 . . . . 0.0 107.822 179.39 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -160.32 136.36 8.52 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 118.276 -1.37 . . . . 0.0 110.058 -178.501 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.483 ' O ' ' O ' ' A' ' 47' ' ' CYS . 20.4 mm-40 -32.84 122.36 0.36 Allowed 'General case' 0 N--CA 1.491 1.598 0 CA-C-O 121.557 0.694 . . . . 0.0 110.776 -178.248 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.536 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -89.51 44.37 3.05 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 -179.502 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.575 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -39.12 112.3 0.24 Allowed 'General case' 0 N--CA 1.507 2.384 0 O-C-N 121.156 -1.202 . . . . 0.0 110.27 179.954 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.52 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.5 tp -87.41 127.73 35.21 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 120.837 -1.165 . . . . 0.0 109.412 -179.926 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.578 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.5 t80 -64.35 57.96 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 120.91 -1.119 . . . . 0.0 110.24 179.9 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.52 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.0 t70 -160.68 19.06 0.13 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.049 -1.032 . . . . 0.0 109.817 179.813 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.06 -26.01 5.73 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.161 -1.175 . . . . 0.0 110.161 179.865 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.424 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -92.54 153.65 18.93 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.906 -1.35 . . . . 0.0 110.384 -179.463 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.464 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -101.34 132.45 46.89 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.493 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.459 ' CD1' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -80.66 -17.44 51.2 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.813 -1.179 . . . . 0.0 110.278 -178.624 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.6 173.55 20.16 Favored Glycine 0 N--CA 1.486 1.995 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -179.682 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.38 108.05 1.03 Allowed 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 179.04 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.595 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 39.8 t -79.01 105.64 8.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 O-C-N 121.43 -0.794 . . . . 0.0 108.882 -178.834 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.45 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.2 OUTLIER -67.93 111.23 4.25 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.427 -0.795 . . . . 0.0 109.874 -179.151 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.547 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -63.88 -5.45 4.43 Favored 'General case' 0 N--CA 1.501 2.095 0 C-N-CA 118.438 -1.305 . . . . 0.0 109.862 179.529 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.452 HG22 ' HB3' ' A' ' 71' ' ' ARG . 69.7 p -84.49 0.22 50.53 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.744 -1.222 . . . . 0.0 108.909 179.324 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.45 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -114.2 -49.06 2.86 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.469 -0.77 . . . . 0.0 109.147 179.952 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.17 -178.65 3.7 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.386 -0.821 . . . . 0.0 109.58 -179.943 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.16 114.78 29.18 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.452 -0.78 . . . . 0.0 109.022 -179.991 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.563 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.04 122.12 39.68 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.919 -1.113 . . . . 0.0 109.49 -179.375 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.589 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.28 144.7 30.46 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 122.444 1.116 . . . . 0.0 111.151 -179.336 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.425 ' HB ' HG11 ' A' ' 7' ' ' VAL . 99.4 t -100.9 110.02 26.84 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.604 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.448 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.39 -172.63 19.19 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 117.899 -2.096 . . . . 0.0 111.83 -177.611 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.481 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -111.63 -177.51 3.21 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -179.268 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.578 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.0 OUTLIER -178.07 174.63 1.35 Allowed 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.137 -0.977 . . . . 0.0 110.143 -179.134 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.548 ' O ' ' CB ' ' A' ' 100' ' ' ALA . 27.1 p-10 -107.47 -33.08 7.46 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-O 122.148 0.975 . . . . 0.0 108.773 179.621 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 99' ' ' ASP . . . 86.96 13.0 0.12 Allowed 'General case' 0 C--N 1.296 -1.759 0 CA-C-N 115.079 -0.964 . . . . 0.0 110.171 -179.944 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -107.36 -21.34 12.97 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.237 -0.915 . . . . 0.0 109.395 179.385 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.514 ' CA ' H191 ' A' ' 114' ' ' CHR . . . -178.44 -43.71 0.07 OUTLIER Glycine 0 N--CA 1.483 1.793 0 N-CA-C 107.978 -2.049 . . . . 0.0 107.978 179.745 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.49 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -171.24 -179.12 2.58 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.517 -0.99 . . . . 0.0 109.567 179.156 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.36 -165.42 28.61 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 108.685 -1.766 . . . . 0.0 108.685 -179.548 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.472 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.0 Cg_exo -49.3 -178.19 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.641 0 CA-C-N 118.857 1.328 . . . . 0.0 110.076 179.556 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -96.88 -179.67 4.64 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.079 -1.013 . . . . 0.0 110.313 -179.056 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.448 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.87 163.79 12.8 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 179.994 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.84 127.6 51.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.287 -1.125 . . . . 0.0 109.165 -179.53 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.589 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.02 121.11 18.61 Favored 'General case' 0 C--N 1.289 -2.053 0 CA-C-O 121.323 0.582 . . . . 0.0 109.743 179.825 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.574 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.98 168.76 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.238 -0.914 . . . . 0.0 109.387 179.952 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.465 ' HB3' ' OG ' ' A' ' 11' ' ' SER . 0.0 OUTLIER -138.34 157.63 45.86 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.289 -0.882 . . . . 0.0 109.78 -179.875 . . . . . . . . 3 3 . 1 . 046 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.574 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 96.6 m-85 -129.89 72.27 1.48 Allowed 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.202 -0.936 . . . . 0.0 109.565 -179.756 . . . . . . . . 2 2 . 1 . 046 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.426 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 12.6 p30 . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.481 -179.986 . . . . . . . . 1 1 . 1 . 046 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.59 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 047 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -118.42 152.68 51.25 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.273 -0.892 . . . . 0.0 109.422 179.975 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.497 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 2.5 Cg_endo -61.42 155.59 51.5 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.271 1.98 . . . . 0.0 110.489 -179.901 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.596 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -148.66 161.12 42.38 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 -179.825 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.4 128.92 15.0 Favored 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 118.923 -1.111 . . . . 0.0 110.609 -179.697 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.536 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.9 p -105.42 104.72 14.5 Favored 'General case' 0 C--N 1.295 -1.77 0 CA-C-O 122.57 1.176 . . . . 0.0 110.173 -179.585 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.53 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 20.5 t -119.29 122.56 69.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.317 179.804 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.487 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -166.59 150.64 6.76 Favored Pre-proline 0 N--CA 1.489 1.511 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.294 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG22 ' A' ' 8' ' ' THR . 2.6 Cg_endo -74.62 151.9 97.54 Favored 'Cis proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.651 -1.395 . . . . 0.0 110.016 -0.621 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.479 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 6.0 m -93.73 -23.07 18.34 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.518 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.479 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -135.67 160.86 37.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.474 -0.766 . . . . 0.0 109.446 -179.97 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.09 37.7 31.93 Favored Glycine 0 N--CA 1.494 2.541 0 N-CA-C 108.517 -1.833 . . . . 0.0 108.517 -179.624 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.617 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 31.0 mt -89.9 -44.7 9.73 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 123.188 1.47 . . . . 0.0 110.608 -178.439 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.486 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.4 OUTLIER 65.89 146.26 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.626 -1.624 . . . . 0.0 110.151 -179.931 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.567 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.1 p-10 -51.33 107.52 0.19 Allowed 'General case' 0 C--N 1.302 -1.485 0 CA-C-O 121.68 0.752 . . . . 0.0 111.678 -178.601 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.24 15.08 9.27 Favored Glycine 0 N--CA 1.484 1.848 0 C-N-CA 119.511 -1.328 . . . . 0.0 112.847 177.348 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.617 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 9.9 t -103.72 -172.77 2.17 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 121.146 2.473 . . . . 0.0 109.776 179.358 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.572 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 13.6 t -132.81 140.42 47.45 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.351 0 CA-C-N 114.937 -1.028 . . . . 0.0 111.136 -178.829 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.458 HG11 ' CG2' ' A' ' 69' ' ' VAL . 31.3 m -117.76 154.16 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 121.355 -0.841 . . . . 0.0 108.968 179.144 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.53 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -108.03 108.95 20.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.886 . . . . 0.0 109.148 179.966 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.51 ' CG2' HG23 ' A' ' 7' ' ' VAL . 2.3 p -106.1 122.44 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.978 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.557 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -112.84 166.23 11.57 Favored 'General case' 0 C--N 1.306 -1.3 0 O-C-N 120.857 -1.152 . . . . 0.0 108.737 179.502 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.41 108.37 0.49 Allowed Glycine 0 N--CA 1.482 1.752 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 179.952 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.596 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.94 138.83 51.28 Favored 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 119.366 1.583 . . . . 0.0 110.21 -179.454 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.497 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.88 28.92 30.29 Favored Glycine 0 N--CA 1.491 2.306 0 C-N-CA 118.941 -1.6 . . . . 0.0 109.888 179.549 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.53 ' O ' ' N ' ' A' ' 28' ' ' ALA . 2.0 mt -91.67 176.13 6.65 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.979 -1.307 . . . . 0.0 108.449 179.956 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.556 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.65 96.91 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.052 -1.03 . . . . 0.0 109.61 -179.905 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.07 76.61 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.798 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.341 -178.857 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.52 34.17 0.32 Allowed Glycine 0 N--CA 1.486 1.985 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.383 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.568 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.1 t -148.44 115.32 6.06 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 120.931 -1.335 . . . . 0.0 111.113 -179.935 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.55 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -43.36 128.83 4.94 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.777 178.38 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.568 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.0 m-85 -120.58 147.35 45.31 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.486 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.463 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -99.61 159.65 14.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.507 -1.371 . . . . 0.0 107.666 178.648 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.624 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 9.8 p -144.36 116.33 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.08 -1.012 . . . . 0.0 110.198 -177.543 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.89 -175.33 38.81 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.477 -1.82 . . . . 0.0 111.654 -179.995 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.555 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -100.91 109.22 21.14 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 121.845 0.831 . . . . 0.0 108.973 -179.717 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.448 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.79 149.44 52.43 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.254 -0.904 . . . . 0.0 110.05 179.796 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.34 139.07 54.26 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.38 -0.825 . . . . 0.0 110.813 -179.064 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.619 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 115.05 26.92 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.98 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.455 HG23 ' HB ' ' A' ' 44' ' ' VAL . 10.8 m -106.05 15.59 7.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 O-C-N 120.969 -1.082 . . . . 0.0 110.534 -178.796 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.594 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 173.79 -176.36 0.07 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.897 -1.127 . . . . 0.0 110.127 179.835 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.545 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.0 t -70.79 98.58 1.57 Allowed 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.416 -0.803 . . . . 0.0 109.914 -179.69 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.13 28.52 36.84 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.265 -0.969 . . . . 0.0 111.238 179.027 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.594 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.9 106.31 19.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.839 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.619 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.6 tp -116.94 104.83 11.68 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.409 -1.432 . . . . 0.0 109.749 -177.55 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.62 109.46 22.21 Favored 'General case' 0 N--CA 1.485 1.276 0 O-C-N 120.806 -1.184 . . . . 0.0 108.29 178.938 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.38 167.46 9.91 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.959 -1.088 . . . . 0.0 110.078 -178.959 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.529 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 15.2 t-20 -109.31 136.45 20.18 Favored Pre-proline 0 N--CA 1.5 2.06 0 O-C-N 121.369 -0.832 . . . . 0.0 109.97 -179.296 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.57 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -75.25 23.27 0.42 Allowed 'Trans proline' 0 CA--C 1.544 0.976 0 C-N-CA 122.369 2.046 . . . . 0.0 111.798 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.529 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -117.68 3.9 12.33 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.429 -1.42 . . . . 0.0 108.974 179.593 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.516 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.58 17.87 2.9 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 179.214 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -83.71 90.13 7.26 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.925 -178.473 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.81 -170.41 1.65 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 178.042 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.465 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.81 135.36 0.09 Allowed 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.402 -1.436 . . . . 0.0 111.508 -179.245 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.577 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.3 p -151.88 158.73 4.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.037 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.55 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.49 145.77 25.89 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.642 -1.286 . . . . 0.0 109.799 -179.621 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.662 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -67.22 108.01 2.55 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 122.389 1.09 . . . . 0.0 109.681 178.879 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.528 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.8 p-10 -61.23 -139.56 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.811 -179.898 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.96 -50.89 57.16 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.296 -0.877 . . . . 0.0 110.498 -178.858 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -103.98 -34.02 8.61 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 178.481 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.662 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.11 70.36 0.73 Allowed Glycine 0 C--N 1.297 -1.583 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 178.278 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 38.9 m -104.05 127.4 51.61 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.69 -0.888 . . . . 0.0 108.936 179.165 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.577 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -135.06 109.04 8.15 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.415 -179.682 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.439 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -118.69 117.07 27.94 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.264 -0.898 . . . . 0.0 109.349 -179.934 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.481 HG21 HG12 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -145.46 142.0 28.88 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.452 -0.78 . . . . 0.0 109.772 179.99 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.3 p -100.91 135.06 42.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.497 -0.752 . . . . 0.0 109.231 179.742 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.528 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.1 OUTLIER -133.39 165.52 24.65 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.314 -0.866 . . . . 0.0 109.526 -179.449 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.572 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.3 p -96.76 125.23 41.07 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.27 -0.894 . . . . 0.0 109.342 -179.903 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.54 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.3 m -136.13 144.54 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.959 -1.088 . . . . 0.0 109.584 -179.312 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.567 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.4 ptt180 -139.95 -166.37 2.08 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 120.593 -1.317 . . . . 0.0 110.338 -179.927 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.665 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 40.9 mtm180 -69.83 -73.91 0.15 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.51 -0.744 . . . . 0.0 109.298 -179.113 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -76.87 145.74 38.13 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 178.534 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -166.23 140.06 4.23 Favored 'General case' 0 C--N 1.293 -1.887 0 C-N-CA 117.507 -1.677 . . . . 0.0 110.464 -177.737 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.513 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 2.2 mm-40 -33.98 122.32 0.46 Allowed 'General case' 0 N--CA 1.49 1.533 0 CA-C-O 121.593 0.711 . . . . 0.0 110.664 -178.479 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.533 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -90.09 45.82 3.03 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 -179.338 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.57 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.9 m-30 -39.63 113.19 0.31 Allowed 'General case' 0 N--CA 1.508 2.472 0 O-C-N 121.083 -1.245 . . . . 0.0 110.169 179.673 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.518 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.2 tp -87.23 128.17 35.15 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 120.868 -1.145 . . . . 0.0 109.379 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.566 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 24.8 t80 -64.47 57.89 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 120.809 -1.182 . . . . 0.0 110.328 179.882 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.518 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.1 t70 -161.0 18.92 0.12 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.946 -1.096 . . . . 0.0 109.779 179.844 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.79 -25.85 5.65 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 179.952 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 3.4 p -91.55 153.27 19.87 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 120.895 -1.356 . . . . 0.0 110.387 -179.351 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.491 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 8.5 ptt180 -100.95 131.93 46.6 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.544 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.496 ' CD1' HD12 ' A' ' 77' ' ' LEU . 2.0 t90 -81.74 -18.61 43.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.729 -1.232 . . . . 0.0 110.495 -178.47 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.61 173.65 19.6 Favored Glycine 0 N--CA 1.486 2.014 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 -179.624 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -62.07 109.27 1.24 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 179.133 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.564 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 40.5 t -80.87 104.51 9.47 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 O-C-N 121.339 -0.851 . . . . 0.0 109.058 -178.859 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.523 ' CB ' HG21 ' A' ' 90' ' ' THR . 0.2 OUTLIER -68.07 112.69 5.19 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.628 -0.67 . . . . 0.0 109.648 -179.551 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.665 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 6.8 m -56.83 -8.4 0.6 Allowed 'General case' 0 N--CA 1.496 1.867 0 C-N-CA 118.309 -1.356 . . . . 0.0 110.466 179.816 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 p -84.52 -12.44 54.19 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.366 -1.459 . . . . 0.0 109.53 179.981 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.523 HG21 ' CB ' ' A' ' 87' ' ' ASP . 2.7 p -92.97 -47.86 6.8 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.286 -0.884 . . . . 0.0 109.032 179.934 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -117.12 -178.24 3.4 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.547 -0.72 . . . . 0.0 109.477 179.937 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.48 117.76 35.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.462 -0.774 . . . . 0.0 108.922 179.888 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.474 ' O ' HG12 ' A' ' 110' ' ' ILE . 3.2 m -96.41 121.41 38.19 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.761 -1.212 . . . . 0.0 109.791 -179.202 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.551 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.78 146.92 27.92 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 122.445 1.117 . . . . 0.0 111.022 -179.486 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.514 ' CG1' HG11 ' A' ' 7' ' ' VAL . 42.5 t -102.93 109.81 27.82 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 177.442 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.441 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.68 -170.0 16.65 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 118.263 -1.922 . . . . 0.0 111.697 -177.4 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.461 HD12 ' HB3' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -122.2 -179.41 4.16 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.608 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.548 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -179.26 176.96 0.81 Allowed 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.362 -0.836 . . . . 0.0 109.593 -179.739 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.455 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -123.82 -157.88 0.78 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.923 -1.111 . . . . 0.0 109.067 -179.96 . . . . . . . . 3 3 . 1 . 047 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.455 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.46 35.79 4.4 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.819 -1.176 . . . . 0.0 109.223 -179.991 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -112.96 -33.08 6.17 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.363 -0.836 . . . . 0.0 109.882 -179.705 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 163.57 -35.52 0.31 Allowed Glycine 0 N--CA 1.481 1.696 0 N-CA-C 107.713 -2.155 . . . . 0.0 107.713 -179.755 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.52 -177.6 5.72 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.626 -0.926 . . . . 0.0 109.967 179.311 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.53 -161.55 21.31 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.41 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.468 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.2 Cg_exo -45.83 173.12 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.628 0 CA-C-N 118.919 1.359 . . . . 0.0 109.936 179.263 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -92.81 -174.87 3.74 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.127 -0.983 . . . . 0.0 110.526 -178.751 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.441 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.0 166.14 13.55 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.953 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -103.97 130.42 54.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.349 -1.089 . . . . 0.0 109.075 -179.39 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.551 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.81 123.68 23.85 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.494 -0.753 . . . . 0.0 109.642 179.728 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.571 HD13 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.78 168.42 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 119.555 -0.858 . . . . 0.0 108.912 179.893 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.479 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 2.3 m -134.12 153.76 51.62 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.295 -0.878 . . . . 0.0 109.448 -179.882 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.595 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 65.9 m-85 -127.35 98.17 5.16 Favored 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.193 -0.942 . . . . 0.0 109.397 -179.783 . . . . . . . . 2 2 . 1 . 047 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.467 ' O ' ' O ' ' A' ' 112' ' ' PHE . 12.4 p30 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 117.962 -1.018 . . . . 0.0 109.664 -179.905 . . . . . . . . 1 1 . 1 . 047 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.589 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 048 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.67 162.97 60.94 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.329 -0.857 . . . . 0.0 109.48 -179.982 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.516 ' O ' ' CG2' ' A' ' 4' ' ' THR . 4.1 Cg_exo -60.24 158.07 32.39 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.167 1.912 . . . . 0.0 110.443 179.921 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.589 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.2 p -165.95 160.48 16.73 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 -179.265 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.493 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.9 128.5 14.15 Favored 'General case' 0 C--N 1.297 -1.701 0 CA-C-O 122.359 1.076 . . . . 0.0 110.696 -179.782 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.538 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.8 p -105.11 104.8 14.61 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 122.609 1.195 . . . . 0.0 110.141 -179.505 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.533 HG12 ' CG1' ' A' ' 95' ' ' VAL . 16.7 t -120.17 119.91 61.4 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.44 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.325 179.662 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.516 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.0 150.06 9.54 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 -179.587 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.516 ' CA ' HG21 ' A' ' 8' ' ' THR . 3.1 Cg_endo -75.11 153.57 99.06 Favored 'Cis proline' 0 C--N 1.31 -1.471 0 C-N-CA 123.721 -1.366 . . . . 0.0 109.933 -0.637 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.449 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 8.0 m -95.04 -23.51 17.32 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.461 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.446 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 3.4 m -134.24 164.21 27.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.583 -0.698 . . . . 0.0 109.649 179.95 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.36 36.85 43.39 Favored Glycine 0 N--CA 1.496 2.668 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 -179.73 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.643 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 21.9 mt -90.03 -46.18 8.67 Favored 'General case' 0 C--N 1.297 -1.705 0 CA-C-O 123.151 1.453 . . . . 0.0 110.6 -178.532 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 2.1 t 61.45 148.25 0.02 OUTLIER 'General case' 0 C--N 1.259 -3.341 0 CA-C-N 113.917 -1.492 . . . . 0.0 109.913 -179.766 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.605 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 3.9 p-10 -51.35 109.61 0.36 Allowed 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.574 0.702 . . . . 0.0 111.683 -178.834 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.94 12.68 10.95 Favored Glycine 0 N--CA 1.485 1.945 0 C-N-CA 119.403 -1.38 . . . . 0.0 112.915 177.42 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.643 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 7.9 t -101.45 -175.25 2.8 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 121.0 2.4 . . . . 0.0 109.717 179.511 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.547 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 9.4 t -132.75 137.72 53.41 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.906 -179.414 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.424 HG22 HG22 ' A' ' 69' ' ' VAL . 28.5 m -116.97 153.88 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.348 -0.845 . . . . 0.0 109.214 179.219 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.52 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -110.31 109.23 19.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.29 -0.882 . . . . 0.0 108.977 179.715 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.515 ' CG2' HG21 ' A' ' 7' ' ' VAL . 2.0 p -105.95 122.5 59.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.766 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.543 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -113.4 165.84 12.07 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.886 -1.134 . . . . 0.0 108.954 179.554 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.6 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.52 108.23 0.5 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 108.806 -1.717 . . . . 0.0 108.806 -179.976 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.589 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.31 140.8 48.95 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-N 119.204 1.502 . . . . 0.0 110.281 -179.38 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.489 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.08 28.46 34.05 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.077 -1.535 . . . . 0.0 109.964 179.653 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -92.91 175.01 6.95 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.942 -1.328 . . . . 0.0 108.367 179.977 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.555 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.54 99.19 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.913 -1.117 . . . . 0.0 109.572 -179.743 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.69 76.85 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.272 -179.101 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.17 34.26 0.29 Allowed Glycine 0 N--CA 1.486 2.005 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.574 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.541 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.9 p -145.11 111.98 5.91 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.958 -1.319 . . . . 0.0 111.167 -179.683 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.535 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -45.7 125.66 6.21 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.574 178.107 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.489 ' CD2' ' O ' ' A' ' 30' ' ' THR . 14.2 m-85 -117.33 151.11 37.67 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.682 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.49 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -101.39 153.23 19.85 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.76 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.627 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 6.2 p -136.31 115.05 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.105 -0.997 . . . . 0.0 109.756 -177.928 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.482 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -165.09 -178.45 38.35 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 118.474 -1.822 . . . . 0.0 111.696 -179.68 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.618 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -102.47 109.27 20.86 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.729 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.449 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.87 149.08 52.67 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.128 -0.982 . . . . 0.0 110.117 -179.878 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.78 138.72 54.55 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.399 -0.813 . . . . 0.0 110.609 -179.111 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.621 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 114.88 26.72 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 178.005 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 m -105.24 15.05 6.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.986 -1.071 . . . . 0.0 110.579 -178.72 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.591 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.59 -175.88 0.08 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.916 -1.115 . . . . 0.0 110.044 179.686 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.542 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.0 t -71.81 98.34 1.96 Allowed 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.418 -0.801 . . . . 0.0 109.794 -179.704 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.76 27.43 34.94 Favored Glycine 0 N--CA 1.492 2.425 0 C-N-CA 120.077 -1.058 . . . . 0.0 111.518 179.084 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.591 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.76 106.42 20.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 O-C-N 120.548 -1.56 . . . . 0.0 107.288 178.929 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.621 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.9 tp -117.36 104.64 11.33 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.38 -1.45 . . . . 0.0 109.796 -177.757 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.529 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.77 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 178.698 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -105.49 166.96 10.07 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.043 -1.036 . . . . 0.0 110.493 -178.641 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.462 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 36.8 t-20 -110.35 129.61 23.77 Favored Pre-proline 0 N--CA 1.499 1.998 0 O-C-N 121.668 -0.645 . . . . 0.0 109.499 -179.393 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.1 Cg_endo -72.39 22.34 0.28 Allowed 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 122.091 1.861 . . . . 0.0 111.808 179.581 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -110.76 2.6 18.5 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.41 -1.431 . . . . 0.0 108.997 179.626 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.496 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.58 17.83 2.71 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 179.447 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -80.73 93.11 6.13 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.916 -0.714 . . . . 0.0 111.086 -178.496 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -113.15 -167.78 1.24 Allowed 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 178.113 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.47 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.73 136.82 0.09 Allowed 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.619 -1.301 . . . . 0.0 111.524 -179.248 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.587 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -154.45 157.1 4.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.113 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.535 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.84 144.82 27.03 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.665 -1.272 . . . . 0.0 109.893 -179.636 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.667 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -65.6 107.07 1.61 Allowed 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 122.353 1.073 . . . . 0.0 109.428 178.772 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.523 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.4 t0 -60.47 -139.29 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.956 -179.895 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.548 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.01 -50.72 57.98 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.401 -0.812 . . . . 0.0 110.733 -178.749 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -104.02 -34.06 8.58 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.461 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.667 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.23 66.17 0.62 Allowed Glycine 0 C--N 1.295 -1.704 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 178.243 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 20.3 m -103.5 125.02 49.82 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.758 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.587 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.6 109.19 8.5 Favored 'General case' 0 C--N 1.296 -1.749 0 C-N-CA 119.631 -0.827 . . . . 0.0 109.649 -179.28 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 97.3 p -116.44 116.51 27.8 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.345 -0.847 . . . . 0.0 109.441 -179.987 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.451 HG23 HG11 ' A' ' 34' ' ' VAL . 1.1 t -141.3 138.5 33.21 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.438 -0.789 . . . . 0.0 109.816 179.982 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.421 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 23.4 p -99.12 141.22 32.16 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.446 -0.784 . . . . 0.0 109.127 179.814 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.531 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -142.34 169.44 17.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.33 -0.856 . . . . 0.0 109.523 -179.24 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.547 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.5 p -96.57 126.26 41.62 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.055 -1.028 . . . . 0.0 109.519 -179.712 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.447 HG13 ' HB3' ' A' ' 36' ' ' GLN . 15.6 m -133.14 142.74 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 120.916 -1.115 . . . . 0.0 109.738 -179.346 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.605 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.84 -170.68 3.59 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.517 -1.364 . . . . 0.0 110.731 -179.877 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.6 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -66.6 -102.23 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.807 -0.558 . . . . 0.0 110.171 -179.04 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.12 136.29 56.38 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.388 -1.445 . . . . 0.0 108.198 179.845 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.618 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -155.86 158.52 38.18 Favored 'General case' 0 C--N 1.295 -1.793 0 C-N-CA 118.722 -1.191 . . . . 0.0 109.894 -178.853 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' A' ' 47' ' ' CYS . 12.1 mm-40 -50.01 121.9 6.01 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.296 -0.878 . . . . 0.0 109.561 -178.651 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.529 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.12 48.32 3.43 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 -179.514 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.587 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -40.11 113.38 0.35 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.046 -1.267 . . . . 0.0 110.286 179.919 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.531 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -86.94 127.1 35.07 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 120.913 -1.117 . . . . 0.0 109.47 179.987 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.567 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.5 t80 -63.88 58.52 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.865 -1.147 . . . . 0.0 110.167 179.8 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.531 ' N ' ' O ' ' A' ' 77' ' ' LEU . 14.3 t0 -161.02 19.23 0.12 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.09 -1.006 . . . . 0.0 109.92 179.842 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -25.6 5.96 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 179.802 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 67.4 p -94.09 159.22 15.25 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.979 -1.307 . . . . 0.0 110.384 -179.35 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.469 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 2.7 ptt180 -104.97 133.33 49.94 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 179.796 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.476 ' CD1' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -82.38 -18.37 42.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.845 -1.159 . . . . 0.0 110.406 -178.694 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.29 174.04 19.36 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 -179.671 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.56 108.7 1.44 Allowed 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 179.137 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.602 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 42.9 t -80.28 104.38 8.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 O-C-N 121.469 -0.77 . . . . 0.0 109.278 -178.771 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.478 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.6 OUTLIER -63.78 108.35 1.42 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.517 -0.739 . . . . 0.0 110.137 -179.231 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.548 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.6 t -60.76 -5.14 1.17 Allowed 'General case' 0 N--CA 1.501 2.084 0 C-N-CA 118.141 -1.424 . . . . 0.0 110.282 179.214 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 73.2 p -89.87 2.08 55.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.486 -1.383 . . . . 0.0 109.495 179.965 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.472 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.06 -49.04 2.94 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.236 -0.915 . . . . 0.0 109.149 -179.975 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.57 179.55 4.23 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.432 -0.792 . . . . 0.0 109.48 -179.974 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.65 112.99 25.74 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.791 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.484 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.55 121.39 38.32 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.008 -1.058 . . . . 0.0 109.373 -179.004 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.548 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.61 147.03 27.3 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.369 1.08 . . . . 0.0 111.341 -179.117 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.533 ' CG1' HG12 ' A' ' 7' ' ' VAL . 54.0 t -102.82 109.24 26.15 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 177.309 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.422 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.1 -170.96 16.56 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 118.179 -1.962 . . . . 0.0 111.53 -177.378 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.49 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -118.33 -178.52 3.54 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -178.612 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.537 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -173.7 172.57 3.54 Favored 'General case' 0 C--N 1.295 -1.783 0 O-C-N 121.423 -0.798 . . . . 0.0 109.38 -179.352 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.429 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -118.85 -157.87 0.7 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.188 -0.945 . . . . 0.0 108.796 179.676 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.429 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -118.07 36.34 4.38 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.705 -1.247 . . . . 0.0 109.24 179.988 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.23 -33.51 4.37 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.345 -0.847 . . . . 0.0 110.185 -179.552 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.515 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 166.26 -36.98 0.25 Allowed Glycine 0 N--CA 1.482 1.735 0 N-CA-C 107.645 -2.182 . . . . 0.0 107.645 -179.519 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.18 -178.39 7.17 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.581 -0.953 . . . . 0.0 109.809 179.229 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.12 -162.08 19.32 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 108.209 -1.957 . . . . 0.0 108.209 -179.398 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.3 Cg_exo -45.68 171.99 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.632 0 CA-C-N 118.855 1.327 . . . . 0.0 109.932 179.366 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -90.6 -173.07 3.62 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.092 -1.005 . . . . 0.0 110.544 -178.567 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.422 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.68 168.26 15.04 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.874 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.33 131.44 54.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 121.414 -1.051 . . . . 0.0 109.143 -179.313 . . . . . . . . 1 1 . 1 . 048 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.548 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.16 122.51 21.13 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.662 -0.648 . . . . 0.0 109.736 179.767 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.547 HD11 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -97.95 170.99 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.279 -0.888 . . . . 0.0 108.898 179.766 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.446 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.1 OUTLIER -137.07 162.29 33.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.216 -0.927 . . . . 0.0 109.856 -179.78 . . . . . . . . 3 3 . 1 . 048 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.547 ' CE1' HD11 ' A' ' 110' ' ' ILE . 48.3 m-85 -133.37 144.75 49.79 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.244 -0.91 . . . . 0.0 109.495 -179.817 . . . . . . . . 2 2 . 1 . 048 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.8 p30 . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.454 -179.978 . . . . . . . . 0 0 . 1 . 048 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.585 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 121.258 0.551 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 049 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -117.0 165.94 14.18 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.231 -0.918 . . . . 0.0 109.514 -179.957 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.523 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 4.2 Cg_exo -60.2 157.76 33.58 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.277 1.985 . . . . 0.0 110.54 179.932 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -153.65 160.72 42.47 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 -179.402 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.23 122.53 9.62 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-O 122.431 1.11 . . . . 0.0 110.262 -179.705 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.546 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.0 t -115.82 109.16 17.25 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-O 123.058 1.409 . . . . 0.0 109.867 -179.893 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.507 HG12 ' CG1' ' A' ' 95' ' ' VAL . 1.6 t -114.5 136.68 50.32 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.733 0 CA-C-N 114.236 -1.347 . . . . 0.0 109.557 179.781 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.51 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -170.55 149.68 3.09 Favored Pre-proline 0 N--CA 1.488 1.432 0 O-C-N 121.135 -0.978 . . . . 0.0 109.001 -179.591 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.51 ' CA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -77.02 150.78 92.94 Favored 'Cis proline' 0 C--N 1.313 -1.302 0 C-N-CA 123.436 -1.485 . . . . 0.0 109.455 -0.931 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.48 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 79.1 p -91.31 -23.81 20.01 Favored 'General case' 0 C--N 1.292 -1.928 0 O-C-N 121.589 -0.695 . . . . 0.0 109.292 179.971 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.465 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -131.57 162.05 31.22 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.284 -0.885 . . . . 0.0 109.733 -179.839 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.76 38.38 31.72 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 108.434 -1.866 . . . . 0.0 108.434 -179.666 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.605 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 35.0 mt -91.88 -44.07 9.13 Favored 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 123.12 1.438 . . . . 0.0 110.759 -178.226 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.485 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.87 144.22 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.317 0 CA-C-N 113.568 -1.651 . . . . 0.0 109.938 -179.526 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.595 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.6 p-10 -50.55 108.43 0.23 Allowed 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 121.64 0.734 . . . . 0.0 111.759 -178.483 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.72 14.24 10.52 Favored Glycine 0 N--CA 1.484 1.841 0 C-N-CA 119.555 -1.307 . . . . 0.0 112.895 177.255 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.605 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.2 t -105.29 -173.71 2.36 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 121.011 2.406 . . . . 0.0 110.162 179.435 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.541 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 21.8 t -130.62 141.39 46.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.273 0 CA-C-N 114.45 -1.25 . . . . 0.0 111.069 -178.714 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.486 ' CG1' HD23 ' A' ' 13' ' ' LEU . 34.5 m -118.53 155.29 20.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.661 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.488 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.9 tttt -102.07 109.19 20.84 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.127 -0.983 . . . . 0.0 109.176 -179.871 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.514 HG12 ' CG2' ' A' ' 34' ' ' VAL . 10.5 p -99.05 139.6 20.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.785 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.588 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -134.84 161.49 35.05 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 120.729 -1.232 . . . . 0.0 109.94 179.45 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.582 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.98 138.01 9.46 Favored Glycine 0 C--O 1.207 -1.551 0 N-CA-C 107.839 -2.104 . . . . 0.0 107.839 179.669 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.597 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -141.04 126.89 19.19 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-N 119.484 1.642 . . . . 0.0 109.547 179.52 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.523 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 87.36 28.64 24.35 Favored Glycine 0 N--CA 1.488 2.132 0 C-N-CA 118.832 -1.651 . . . . 0.0 109.745 -179.984 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HB2' ' HB3' ' A' ' 57' ' ' ALA . 1.7 mt -88.27 173.06 8.99 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.913 -1.345 . . . . 0.0 108.235 179.894 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.557 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.56 99.26 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.954 -1.091 . . . . 0.0 109.809 -179.482 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.43 77.31 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.698 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.254 -179.221 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.62 34.18 0.28 Allowed Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.591 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.549 ' OG1' ' CE1' ' A' ' 32' ' ' TYR . 50.7 p -142.35 108.55 5.24 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.092 -1.24 . . . . 0.0 111.367 -179.52 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.557 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.23 109.71 0.33 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 177.826 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.549 ' CE1' ' OG1' ' A' ' 30' ' ' THR . 4.3 m-30 -103.13 155.53 18.34 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.094 -1.004 . . . . 0.0 108.987 179.94 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.99 161.82 13.42 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.855 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.632 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.7 p -142.66 121.61 8.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.117 -0.99 . . . . 0.0 109.538 -178.018 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.64 -176.9 41.63 Favored Glycine 0 N--CA 1.496 2.645 0 C-N-CA 118.516 -1.802 . . . . 0.0 111.548 -179.77 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.566 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -100.17 108.94 21.18 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 -179.937 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -128.66 148.53 50.82 Favored 'General case' 0 C--N 1.295 -1.767 0 O-C-N 121.229 -0.919 . . . . 0.0 109.884 179.738 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.92 139.51 53.76 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.24 -0.912 . . . . 0.0 110.674 -179.071 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.62 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.13 114.93 26.78 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 178.19 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -105.24 15.26 6.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.982 -1.074 . . . . 0.0 110.53 -178.883 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.588 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.7 -176.39 0.09 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.997 -1.064 . . . . 0.0 110.067 179.682 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.547 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.4 97.37 1.26 Allowed 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.817 0.818 . . . . 0.0 109.901 -179.656 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.13 28.23 34.62 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 120.198 -1.001 . . . . 0.0 111.387 178.833 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.588 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.03 106.41 20.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 O-C-N 120.562 -1.552 . . . . 0.0 107.278 178.891 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.62 HD12 ' CD1' ' A' ' 39' ' ' TRP . 12.0 tp -115.98 104.77 11.93 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.465 -1.397 . . . . 0.0 109.942 -177.552 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.532 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.3 109.65 22.37 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.656 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.49 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -109.06 161.9 14.75 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.863 -1.148 . . . . 0.0 110.462 -178.585 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.484 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 29.8 t-20 -108.44 131.04 22.02 Favored Pre-proline 0 N--CA 1.5 2.038 0 O-C-N 121.582 -0.699 . . . . 0.0 109.391 -179.659 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.584 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -72.19 22.15 0.27 Allowed 'Trans proline' 0 CA--C 1.545 1.074 0 C-N-CA 121.958 1.772 . . . . 0.0 111.892 179.523 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.48 ' HB3' ' CG2' ' A' ' 68' ' ' THR . . . -97.08 -7.26 33.2 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.434 -1.417 . . . . 0.0 108.994 179.555 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.555 ' OD2' ' CG1' ' A' ' 69' ' ' VAL . 1.8 m-20 -132.63 5.22 3.97 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.999 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -59.84 78.61 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.355 -0.841 . . . . 0.0 110.938 -178.385 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.632 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -101.07 -167.91 1.49 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.238 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.469 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.57 134.84 0.08 Allowed 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.55 -1.344 . . . . 0.0 111.363 -179.391 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.565 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.5 p -149.03 156.99 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.067 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.557 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.4 141.22 31.54 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.706 -1.246 . . . . 0.0 110.012 -179.776 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.678 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.26 107.54 1.34 Allowed 'General case' 0 C--N 1.298 -1.669 0 CA-C-O 122.484 1.135 . . . . 0.0 109.571 178.76 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -61.04 -139.42 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.709 179.95 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.35 -50.68 61.87 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.393 -0.817 . . . . 0.0 110.481 -178.798 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -101.95 -35.15 9.09 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 178.404 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.678 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.42 68.19 0.66 Allowed Glycine 0 C--N 1.298 -1.535 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 178.07 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.582 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 56.4 m -99.54 131.54 45.47 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.421 -1.046 . . . . 0.0 108.836 178.917 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.588 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -135.2 108.87 7.98 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.452 -179.517 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 m -123.97 117.92 25.86 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.297 -0.877 . . . . 0.0 109.651 -179.798 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.434 ' O ' HG13 ' A' ' 21' ' ' VAL . 0.2 OUTLIER -146.61 145.34 30.04 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.433 -0.792 . . . . 0.0 109.411 179.879 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.0 p -98.56 136.6 38.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.273 -0.892 . . . . 0.0 109.22 179.894 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.543 ' HB2' ' OD2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -140.69 165.9 26.23 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.396 -0.815 . . . . 0.0 109.909 -178.9 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.541 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 10.9 t -99.56 129.61 45.73 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.955 -1.09 . . . . 0.0 111.437 -178.753 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.555 ' CG1' ' OD2' ' A' ' 51' ' ' ASP . 17.3 m -136.61 143.86 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.459 -0.776 . . . . 0.0 109.956 179.68 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.595 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -148.45 -175.46 4.93 Favored 'General case' 0 N--CA 1.484 1.239 0 O-C-N 120.445 -1.409 . . . . 0.0 110.6 179.25 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.547 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.13 -102.44 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -179.539 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.447 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.4 OUTLIER -56.41 139.93 47.26 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.789 -1.194 . . . . 0.0 108.206 179.494 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.581 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -159.68 138.3 10.64 Favored 'General case' 0 C--N 1.296 -1.745 0 C-N-CA 118.717 -1.193 . . . . 0.0 109.91 -178.403 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' A' ' 47' ' ' CYS . 4.4 mm-40 -35.22 120.81 0.55 Allowed 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.473 0.654 . . . . 0.0 110.662 -178.496 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.532 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.6 48.27 2.57 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 -179.428 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.584 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-30 -39.12 114.98 0.44 Allowed 'General case' 0 N--CA 1.509 2.489 0 O-C-N 121.152 -1.205 . . . . 0.0 110.064 179.598 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.529 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.4 tp -87.3 126.48 34.87 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.796 -1.19 . . . . 0.0 109.597 -179.78 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.574 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 24.1 t80 -64.42 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.023 0 O-C-N 120.871 -1.143 . . . . 0.0 110.188 179.704 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 14.0 t0 -160.35 19.6 0.15 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.049 -1.032 . . . . 0.0 109.739 179.865 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.83 -27.43 5.41 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 179.935 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.491 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 68.1 p -95.13 157.05 16.06 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 120.978 -1.307 . . . . 0.0 110.313 -179.446 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.526 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -103.94 139.94 38.4 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.673 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.465 ' HB2' HD11 ' A' ' 77' ' ' LEU . 2.1 t90 -85.89 -19.71 30.15 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.588 -1.32 . . . . 0.0 110.766 -178.129 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.23 174.59 18.62 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -179.419 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.99 104.17 1.08 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 179.159 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.581 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 48.9 t -74.49 106.64 4.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.388 -0.82 . . . . 0.0 109.55 -178.769 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.46 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.74 110.67 2.46 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.443 -0.786 . . . . 0.0 109.654 -179.735 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.547 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.4 t -64.32 -4.98 4.29 Favored 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 118.334 -1.346 . . . . 0.0 109.891 179.58 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.0 p -87.03 0.56 55.01 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.701 -1.25 . . . . 0.0 109.111 179.511 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.46 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -114.16 -50.07 2.83 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.275 -0.891 . . . . 0.0 109.047 179.905 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.22 -178.09 3.56 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.54 -0.725 . . . . 0.0 109.495 179.769 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.09 114.94 29.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.395 -0.816 . . . . 0.0 108.998 179.937 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.567 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -97.05 122.98 40.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.911 -1.118 . . . . 0.0 109.722 -179.233 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.586 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.23 146.83 28.22 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-O 122.345 1.069 . . . . 0.0 111.224 -179.414 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.507 ' CG1' HG12 ' A' ' 7' ' ' VAL . 58.9 t -101.5 110.18 27.69 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.987 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 177.695 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.442 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.06 -171.28 16.85 Favored Glycine 0 N--CA 1.485 1.964 0 C-N-CA 118.236 -1.935 . . . . 0.0 111.78 -177.592 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.63 177.66 5.15 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 121.625 0.726 . . . . 0.0 109.047 -179.161 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.585 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -175.18 176.3 2.1 Favored 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.641 -0.662 . . . . 0.0 109.455 179.937 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.476 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -124.46 -157.13 0.75 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.004 -1.06 . . . . 0.0 109.0 179.802 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.476 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.22 35.9 4.46 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.746 -1.221 . . . . 0.0 109.288 -179.982 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.88 -32.9 6.46 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.349 -0.844 . . . . 0.0 109.833 -179.765 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 165.1 -36.28 0.27 Allowed Glycine 0 N--CA 1.481 1.668 0 N-CA-C 107.817 -2.113 . . . . 0.0 107.817 -179.738 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -166.06 -177.09 4.02 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.596 -0.944 . . . . 0.0 109.795 179.336 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.18 -161.88 17.52 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 108.247 -1.941 . . . . 0.0 108.247 -179.379 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.4 Cg_exo -46.56 176.34 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.686 0 CA-C-N 118.778 1.289 . . . . 0.0 110.203 179.325 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -95.19 -177.3 4.08 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.121 -0.987 . . . . 0.0 110.417 -178.896 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.442 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -115.37 161.63 12.75 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.871 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.8 130.55 47.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.383 -1.069 . . . . 0.0 109.041 -179.461 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.586 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.65 124.33 25.06 Favored 'General case' 0 C--N 1.291 -1.975 0 O-C-N 121.724 -0.61 . . . . 0.0 110.059 -179.937 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.573 HD11 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.65 171.21 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.298 -0.876 . . . . 0.0 108.954 179.639 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.465 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -137.05 158.06 45.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.209 -0.932 . . . . 0.0 109.632 179.97 . . . . . . . . 3 3 . 1 . 049 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.573 ' CZ ' HD11 ' A' ' 110' ' ' ILE . 77.7 m-85 -129.49 79.27 1.9 Allowed 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.26 -0.9 . . . . 0.0 109.517 -179.551 . . . . . . . . 2 2 . 1 . 049 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.407 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 13.6 p30 . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.439 -179.924 . . . . . . . . 1 1 . 1 . 049 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.586 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 050 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.528 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . . . -88.8 172.97 6.68 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.267 -0.896 . . . . 0.0 109.491 -179.951 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.528 ' HD2' ' CB ' ' A' ' 2' ' ' ALA . 2.7 Cg_endo -61.31 155.63 50.7 Favored 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.304 2.002 . . . . 0.0 110.544 179.992 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.6 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -141.25 161.56 37.59 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 -179.866 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.501 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -145.77 128.67 16.4 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 118.846 -1.142 . . . . 0.0 110.702 -179.682 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.532 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.8 p -104.05 104.71 14.7 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 122.39 1.09 . . . . 0.0 110.271 -179.566 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.528 HG12 ' CG1' ' A' ' 95' ' ' VAL . 11.2 t -119.68 119.19 59.65 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.514 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.244 179.625 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.508 HG22 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.51 150.51 10.49 Favored Pre-proline 0 N--CA 1.488 1.44 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 -179.561 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.508 ' CA ' HG22 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.49 153.24 99.06 Favored 'Cis proline' 0 C--N 1.309 -1.537 0 C-N-CA 123.663 -1.39 . . . . 0.0 110.014 -0.578 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.469 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 7.2 m -94.44 -23.57 17.68 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.495 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.455 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.3 m -136.18 163.12 31.1 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.516 -0.74 . . . . 0.0 109.33 179.825 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.41 37.66 35.49 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 -179.523 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.598 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.1 mt -90.47 -44.12 9.82 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 123.18 1.467 . . . . 0.0 110.486 -178.289 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.484 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.97 144.71 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.265 0 CA-C-N 113.613 -1.63 . . . . 0.0 109.903 -179.665 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.556 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 8.1 p-10 -51.11 106.18 0.12 Allowed 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 121.471 0.653 . . . . 0.0 111.509 -178.592 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.46 12.31 9.78 Favored Glycine 0 N--CA 1.488 2.126 0 C-N-CA 119.324 -1.417 . . . . 0.0 113.121 177.261 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.598 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 11.6 t -101.51 -169.55 1.71 Allowed 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 121.135 2.467 . . . . 0.0 109.665 179.362 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.565 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 11.4 t -136.14 142.94 37.32 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 CA-C-N 115.204 -0.907 . . . . 0.0 110.953 -179.015 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.461 HG23 HG23 ' A' ' 69' ' ' VAL . 13.3 m -120.47 154.72 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.221 -0.924 . . . . 0.0 109.255 179.438 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.519 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.3 tttt -106.28 109.08 20.9 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.233 -0.917 . . . . 0.0 109.28 179.955 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.513 HG13 ' CG2' ' A' ' 34' ' ' VAL . 1.6 p -105.61 122.26 58.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 179.885 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.535 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -114.43 165.81 12.35 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 120.886 -1.134 . . . . 0.0 109.129 179.885 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.58 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.1 107.7 0.48 Allowed Glycine 0 N--CA 1.482 1.751 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 179.792 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.6 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.6 141.24 48.45 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.598 -1.53 . . . . 0.0 110.16 -179.439 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.483 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 85.31 27.88 32.0 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 118.833 -1.651 . . . . 0.0 109.718 179.726 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.6 OUTLIER -95.67 170.88 9.02 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.018 -1.284 . . . . 0.0 108.45 179.831 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.556 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.07 101.18 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.407 0 O-C-N 120.947 -1.095 . . . . 0.0 109.948 -179.607 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.85 77.98 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.685 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.993 -179.411 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.42 34.15 0.29 Allowed Glycine 0 N--CA 1.486 2.021 0 N-CA-C 109.316 -1.513 . . . . 0.0 109.316 179.818 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.561 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 22.6 p -139.78 106.9 5.46 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.186 -1.185 . . . . 0.0 111.154 -179.514 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.557 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -49.67 110.0 0.34 Allowed 'General case' 0 N--CA 1.496 1.839 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.8 178.131 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.561 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 28.8 m-85 -103.89 154.51 19.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.111 -0.993 . . . . 0.0 108.95 179.8 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.455 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -102.18 158.09 16.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.767 -1.208 . . . . 0.0 107.821 178.784 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.628 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 6.0 p -139.23 115.11 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.165 -0.959 . . . . 0.0 109.722 -178.12 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.476 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.73 -178.36 36.5 Favored Glycine 0 N--CA 1.494 2.561 0 C-N-CA 118.326 -1.892 . . . . 0.0 111.729 -179.468 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.635 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.1 pt20 -103.32 109.75 21.49 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 121.8 0.81 . . . . 0.0 108.9 -179.764 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.453 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -131.3 149.2 52.66 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.005 -1.06 . . . . 0.0 110.261 -179.805 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.37 138.8 54.52 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.319 -0.863 . . . . 0.0 110.777 -179.167 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.63 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.25 114.55 26.35 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 178.108 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.437 HG21 ' HB ' ' A' ' 44' ' ' VAL . 15.6 m -104.83 14.69 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.026 -1.046 . . . . 0.0 110.663 -178.757 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.587 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.7 OUTLIER 175.25 -175.17 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.923 -1.111 . . . . 0.0 110.125 179.758 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -72.0 97.64 1.92 Allowed 'General case' 0 N--CA 1.485 1.317 0 O-C-N 121.413 -0.804 . . . . 0.0 109.677 -179.757 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.3 26.76 35.31 Favored Glycine 0 N--CA 1.494 2.531 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.475 178.934 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.587 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.92 106.66 20.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 O-C-N 120.549 -1.56 . . . . 0.0 107.396 178.875 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.63 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.7 tp -117.05 104.62 11.43 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.488 -1.382 . . . . 0.0 109.629 -177.747 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.532 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.61 109.42 22.18 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 120.808 -1.182 . . . . 0.0 107.914 178.678 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -105.95 167.83 9.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.928 -1.107 . . . . 0.0 110.483 -178.68 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.473 ' HB2' ' HB2' ' A' ' 73' ' ' PHE . 11.6 t-20 -111.94 129.33 24.33 Favored Pre-proline 0 N--CA 1.499 1.986 0 O-C-N 121.532 -0.73 . . . . 0.0 109.649 -179.118 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.571 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 2.2 Cg_endo -72.72 23.06 0.29 Allowed 'Trans proline' 0 CA--C 1.545 1.059 0 C-N-CA 122.056 1.837 . . . . 0.0 111.815 179.61 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.472 ' O ' HG22 ' A' ' 68' ' ' THR . . . -110.57 -0.7 17.2 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.462 -1.399 . . . . 0.0 109.145 179.545 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.543 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.37 16.81 3.17 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 179.489 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -79.75 89.94 5.22 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.709 -178.678 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.26 -166.26 1.14 Allowed 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.948 -1.131 . . . . 0.0 107.948 178.34 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.467 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.76 136.43 0.09 Allowed 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.594 -1.316 . . . . 0.0 111.314 -179.256 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.606 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -154.74 156.63 4.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.084 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.557 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.49 142.1 30.52 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.669 -1.269 . . . . 0.0 109.977 -179.621 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.683 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -62.08 106.12 0.68 Allowed 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 122.467 1.127 . . . . 0.0 109.341 178.208 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.521 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.8 p-10 -59.29 -138.79 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.029 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.052 -179.881 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.85 -50.33 61.13 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.412 -0.805 . . . . 0.0 110.744 -178.633 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -104.08 -34.57 8.37 Favored 'General case' 0 C--N 1.286 -2.178 0 N-CA-C 106.004 -1.85 . . . . 0.0 106.004 178.505 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.683 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 109.41 64.34 0.54 Allowed Glycine 0 C--N 1.296 -1.646 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 177.928 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 18.5 m -103.85 124.05 48.23 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.501 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.606 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.01 109.48 9.01 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.821 -0.752 . . . . 0.0 109.673 -179.081 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.458 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.7 m -116.5 116.69 28.11 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.329 -0.857 . . . . 0.0 109.373 -179.959 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.495 ' CG2' HG13 ' A' ' 34' ' ' VAL . 1.3 t -140.85 140.19 34.57 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.374 -0.829 . . . . 0.0 109.822 179.908 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.1 p -98.88 137.61 37.19 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.49 -0.756 . . . . 0.0 109.242 179.849 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.543 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -140.43 159.01 43.15 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.382 -0.824 . . . . 0.0 109.452 -179.129 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.565 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 12.7 t -87.55 135.77 33.22 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.162 -0.961 . . . . 0.0 110.21 -179.837 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.461 HG23 HG23 ' A' ' 19' ' ' VAL . 18.0 m -145.51 140.36 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.74 -179.39 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.556 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.5 ptt180 -140.25 -163.83 1.59 Allowed 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.595 -1.315 . . . . 0.0 109.877 179.814 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.603 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -78.79 -81.81 0.1 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.055 -1.028 . . . . 0.0 109.6 -179.15 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -67.12 134.66 52.24 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.334 -1.479 . . . . 0.0 107.488 179.273 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.635 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.8 OUTLIER -157.7 156.58 31.94 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 117.965 -1.494 . . . . 0.0 110.568 -178.257 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.475 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.2 mm-40 -48.71 121.66 4.83 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.497 -0.752 . . . . 0.0 109.676 -178.574 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.532 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -89.08 48.78 3.48 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 -179.39 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.571 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.2 OUTLIER -40.39 114.6 0.47 Allowed 'General case' 0 N--CA 1.514 2.774 0 O-C-N 121.029 -1.277 . . . . 0.0 109.972 179.908 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.531 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -87.25 126.95 35.14 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.959 -1.088 . . . . 0.0 109.289 179.729 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.569 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 23.2 t80 -64.09 58.11 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.8 -1.187 . . . . 0.0 110.307 179.897 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.531 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -160.86 19.34 0.13 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.961 -1.087 . . . . 0.0 109.785 179.91 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.3 -26.74 5.45 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.913 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.7 p -91.88 159.32 15.83 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.12 -1.223 . . . . 0.0 110.389 -179.403 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.503 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.56 133.46 51.21 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.716 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.478 ' CD1' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -82.6 -18.13 42.35 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.88 -1.137 . . . . 0.0 110.411 -178.469 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.32 174.79 20.6 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 -179.525 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.0 112.06 2.18 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 179.14 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.574 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 38.7 t -83.44 102.39 9.35 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -178.916 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.475 ' HB3' HG22 ' A' ' 90' ' ' THR . 0.2 OUTLIER -64.49 108.53 1.68 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.659 -0.651 . . . . 0.0 109.971 -179.153 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.569 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 3.7 t -62.48 -4.25 1.82 Allowed 'General case' 0 N--CA 1.499 1.979 0 C-N-CA 118.361 -1.336 . . . . 0.0 110.34 179.341 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.6 p -88.24 10.39 19.76 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.621 -1.299 . . . . 0.0 109.097 179.622 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.475 HG22 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -124.25 -47.66 1.87 Allowed 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.399 -0.813 . . . . 0.0 109.08 -179.994 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.85 179.58 4.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.604 -0.685 . . . . 0.0 109.536 179.905 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.88 112.41 25.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.36 -0.838 . . . . 0.0 108.799 179.783 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.475 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.1 m -96.64 121.85 38.93 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.083 -1.01 . . . . 0.0 109.667 -178.786 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.544 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.34 149.2 24.98 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 122.482 1.134 . . . . 0.0 111.368 -179.199 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.528 ' CG1' HG12 ' A' ' 7' ' ' VAL . 47.4 t -105.42 109.94 29.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 177.465 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.403 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.89 -171.3 17.51 Favored Glycine 0 N--CA 1.485 1.95 0 C-N-CA 118.154 -1.974 . . . . 0.0 111.663 -177.641 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.463 HD13 ' HB3' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -115.16 -179.02 3.51 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -178.899 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.576 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.5 p -178.65 169.31 1.7 Allowed 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.332 -0.855 . . . . 0.0 109.545 -179.06 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.43 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -121.31 -158.8 0.78 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.961 -1.087 . . . . 0.0 108.976 179.895 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.43 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.13 36.05 4.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.663 -1.273 . . . . 0.0 109.093 -179.982 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -115.33 -33.65 5.23 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.469 -0.77 . . . . 0.0 109.994 -179.707 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.416 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 164.36 -36.06 0.29 Allowed Glycine 0 N--CA 1.48 1.627 0 N-CA-C 107.753 -2.139 . . . . 0.0 107.753 -179.7 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.35 -178.09 6.69 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 122.159 0.98 . . . . 0.0 109.898 179.326 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.42 -163.04 21.72 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 108.191 -1.963 . . . . 0.0 108.191 -179.46 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.47 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.4 Cg_exo -45.93 172.76 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.647 0 CA-C-N 119.013 1.406 . . . . 0.0 109.937 179.325 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -90.19 -177.42 5.14 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.997 -1.064 . . . . 0.0 110.695 -178.566 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.403 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.03 167.9 13.66 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.816 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.47 132.56 54.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.393 -1.063 . . . . 0.0 109.23 -179.285 . . . . . . . . 1 1 . 1 . 050 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.544 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.57 124.42 25.86 Favored 'General case' 0 C--N 1.29 -1.984 0 O-C-N 121.637 -0.664 . . . . 0.0 109.732 179.757 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.571 HD13 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.97 171.81 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.228 -0.92 . . . . 0.0 109.227 179.794 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.455 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.23 155.96 48.15 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.209 -0.932 . . . . 0.0 109.769 -179.896 . . . . . . . . 3 3 . 1 . 050 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.571 ' CE2' HD13 ' A' ' 110' ' ' ILE . 71.6 m-85 -133.25 95.05 3.44 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.178 -0.952 . . . . 0.0 109.533 -179.733 . . . . . . . . 2 2 . 1 . 050 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 14.8 p30 . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 118.077 -0.963 . . . . 0.0 109.462 -179.997 . . . . . . . . 0 0 . 1 . 050 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.586 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.307 0.575 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 051 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.457 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . . . -71.21 169.73 14.11 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.239 -0.913 . . . . 0.0 109.422 179.962 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.521 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.6 Cg_exo -60.1 156.76 37.82 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.253 1.969 . . . . 0.0 110.642 -179.928 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.574 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -177.75 -169.42 0.21 Allowed 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 179.016 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.574 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.7 132.6 3.28 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.76 -1.212 . . . . 0.0 110.63 -179.135 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.539 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.9 p -104.54 104.4 14.23 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 122.453 1.12 . . . . 0.0 110.156 179.96 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.534 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 12.0 t -120.15 119.76 60.98 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.366 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.309 179.738 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.515 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.64 149.88 6.34 Favored Pre-proline 0 N--CA 1.486 1.326 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -179.674 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.515 ' CA ' HG21 ' A' ' 8' ' ' THR . 5.1 Cg_endo -76.68 151.62 94.61 Favored 'Cis proline' 0 C--N 1.309 -1.523 0 C-N-CA 123.637 -1.401 . . . . 0.0 109.501 -0.433 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.491 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 77.4 p -93.19 -23.53 18.53 Favored 'General case' 0 C--N 1.293 -1.865 0 O-C-N 121.595 -0.691 . . . . 0.0 109.305 179.765 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.46 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 1.2 m -133.89 158.2 44.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.316 -0.865 . . . . 0.0 109.957 -179.693 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 80.36 36.46 23.71 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 -179.777 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.601 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 39.2 mt -92.54 -44.36 8.66 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 123.24 1.495 . . . . 0.0 110.284 -178.634 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.46 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 64.1 147.03 0.03 OUTLIER 'General case' 0 C--N 1.263 -3.189 0 CA-C-N 113.549 -1.66 . . . . 0.0 110.138 -179.758 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.55 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.0 p-10 -51.65 104.81 0.09 Allowed 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.644 0.735 . . . . 0.0 111.048 -178.939 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.52 6.39 6.72 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.148 -1.501 . . . . 0.0 113.33 177.312 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.601 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 14.9 t -106.31 -175.97 2.94 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 121.491 2.646 . . . . 0.0 110.166 179.693 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 21.8 t -128.05 138.2 55.36 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.383 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.068 -178.697 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.565 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 34.6 m -114.39 154.66 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.827 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.1 108.9 20.59 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.14 -0.975 . . . . 0.0 109.314 -179.885 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.1 p -107.59 123.34 62.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.751 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.539 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -116.72 165.33 13.41 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 120.873 -1.142 . . . . 0.0 109.14 179.922 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.57 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.46 107.55 0.53 Allowed Glycine 0 C--O 1.207 -1.577 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 179.875 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.521 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -116.23 143.83 45.0 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.787 -1.419 . . . . 0.0 110.676 -178.964 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.52 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 80.48 27.45 51.51 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 119.576 -1.297 . . . . 0.0 109.993 179.193 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.549 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -91.95 172.25 8.58 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.086 -1.244 . . . . 0.0 108.556 -179.984 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.568 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.58 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.116 -0.99 . . . . 0.0 109.652 -179.987 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.63 76.74 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.206 -179.059 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 135.96 32.96 0.26 Allowed Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.512 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.628 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -141.98 111.45 6.54 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 120.935 -1.332 . . . . 0.0 111.027 -179.96 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.554 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.64 120.4 4.67 Favored 'General case' 0 N--CA 1.493 1.715 0 CA-C-N 115.488 -0.778 . . . . 0.0 109.674 178.7 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.628 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 9.7 m-85 -114.27 152.82 30.74 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.238 -0.914 . . . . 0.0 108.923 179.807 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.466 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.68 154.18 18.81 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.622 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.622 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 9.7 p -137.42 115.41 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.023 -1.048 . . . . 0.0 109.882 -177.753 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.87 -176.85 36.16 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 118.372 -1.87 . . . . 0.0 111.792 -179.717 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.591 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -101.21 109.86 21.79 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -179.803 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -129.61 149.38 51.39 Favored 'General case' 0 C--N 1.296 -1.74 0 O-C-N 121.221 -0.924 . . . . 0.0 109.748 179.81 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.66 137.73 54.81 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.254 -0.904 . . . . 0.0 110.907 -178.847 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.622 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.49 114.86 26.67 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.048 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 m -105.05 14.67 7.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.931 -1.105 . . . . 0.0 110.501 -178.947 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.589 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 173.9 -175.54 0.07 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 120.949 -1.094 . . . . 0.0 110.128 179.73 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.541 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.92 98.17 1.55 Allowed 'General case' 0 N--CA 1.487 1.416 0 CA-C-O 121.828 0.823 . . . . 0.0 109.969 -179.669 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.28 27.98 34.92 Favored Glycine 0 N--CA 1.493 2.441 0 C-N-CA 120.325 -0.94 . . . . 0.0 111.444 178.949 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.589 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -116.54 106.29 19.99 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 O-C-N 120.569 -1.548 . . . . 0.0 107.198 178.782 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.622 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.4 tp -117.02 104.64 11.47 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.487 -1.383 . . . . 0.0 109.942 -177.527 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.534 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.9 109.56 22.29 Favored 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.847 -1.158 . . . . 0.0 107.919 178.7 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.58 167.05 10.11 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.907 -1.12 . . . . 0.0 110.41 -178.699 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.549 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 20.7 t-20 -114.67 137.71 22.87 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 121.299 -0.876 . . . . 0.0 110.359 -179.149 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.45 ' HD2' ' ND2' ' A' ' 48' ' ' ASN . 6.1 Cg_endo -75.55 25.8 0.39 Allowed 'Trans proline' 0 C--N 1.318 -1.039 0 C-N-CA 122.346 2.031 . . . . 0.0 111.966 179.859 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.549 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -113.82 2.13 15.03 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.266 -1.521 . . . . 0.0 109.482 179.833 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.503 ' O ' ' CD2' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.22 16.72 2.42 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 179.423 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -79.38 91.74 5.12 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.598 -0.689 . . . . 0.0 111.016 -178.678 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -109.08 -166.9 1.15 Allowed 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.171 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.47 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.97 136.62 0.09 Allowed 'General case' 0 N--CA 1.485 1.301 0 O-C-N 120.519 -1.363 . . . . 0.0 111.327 -179.298 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.597 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -156.75 157.0 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 178.213 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.554 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.6 144.23 28.13 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.884 -1.135 . . . . 0.0 109.835 -179.759 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.673 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.84 105.82 0.9 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 122.436 1.112 . . . . 0.0 109.38 178.546 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.52 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.8 p-10 -58.69 -138.87 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.029 -179.869 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.32 -50.26 62.62 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.453 -0.779 . . . . 0.0 110.576 -178.718 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.445 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.7 t-20 -103.75 -35.19 8.3 Favored 'General case' 0 C--N 1.286 -2.195 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 178.442 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.673 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 109.28 67.36 0.59 Allowed Glycine 0 C--N 1.297 -1.627 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 177.936 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.57 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.0 m -106.76 123.12 47.68 Favored 'General case' 0 N--CA 1.482 1.137 0 O-C-N 121.559 -0.965 . . . . 0.0 108.623 178.829 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.597 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -132.6 109.15 9.54 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 -179.443 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.1 m -118.95 120.39 37.13 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.211 -0.93 . . . . 0.0 109.606 -179.474 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.479 HG21 HG13 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.71 141.62 29.42 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.567 -0.708 . . . . 0.0 109.691 179.779 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 17.7 p -99.93 135.89 40.66 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.395 -0.815 . . . . 0.0 109.112 179.702 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.527 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -135.59 167.84 20.35 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.941 . . . . 0.0 109.618 -179.29 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.5 p -99.4 126.89 45.38 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.077 -1.014 . . . . 0.0 109.276 -179.802 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.456 HG12 ' OD2' ' A' ' 51' ' ' ASP . 12.6 m -132.39 140.8 46.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 120.868 -1.145 . . . . 0.0 109.93 -179.134 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.55 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 56.7 mtt180 -127.61 -166.96 1.68 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.68 -1.263 . . . . 0.0 111.328 -179.674 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.577 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 46.4 mtt180 -80.59 -79.02 0.16 Allowed 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 178.946 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.442 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -69.11 136.66 52.58 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 106.386 -1.709 . . . . 0.0 106.386 177.766 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.35 136.51 8.6 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 117.666 -1.614 . . . . 0.0 110.891 -177.191 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.47 ' C ' ' O ' ' A' ' 73' ' ' PHE . 2.0 mm-40 -33.43 118.78 0.34 Allowed 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.47 0.652 . . . . 0.0 110.427 -178.742 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.534 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -88.26 48.07 3.57 Favored Glycine 0 N--CA 1.493 2.463 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.148 -179.312 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.482 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -36.99 115.93 0.41 Allowed 'General case' 0 N--CA 1.513 2.685 0 O-C-N 121.109 -1.23 . . . . 0.0 110.11 179.828 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.543 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.3 tp -87.59 126.41 34.92 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.987 -1.071 . . . . 0.0 109.121 179.742 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.579 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 25.8 t80 -63.64 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.836 -1.165 . . . . 0.0 110.228 179.824 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.543 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t70 -160.89 19.72 0.13 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.989 -1.069 . . . . 0.0 109.846 179.924 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.2 -28.01 5.34 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.812 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -94.67 163.38 13.4 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.061 -1.258 . . . . 0.0 110.184 -179.438 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.55 137.71 46.05 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.987 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.463 ' HB2' HD13 ' A' ' 77' ' ' LEU . 5.6 t90 -81.62 -20.93 38.71 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.896 -1.127 . . . . 0.0 110.157 -178.956 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.36 173.55 17.07 Favored Glycine 0 N--CA 1.486 1.968 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -179.44 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.25 111.81 2.41 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 179.069 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.564 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 46.0 t -83.67 104.25 11.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 121.378 -0.826 . . . . 0.0 108.981 -179.001 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.466 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.3 OUTLIER -66.15 111.3 3.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.355 -0.84 . . . . 0.0 109.845 -179.295 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.547 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -64.25 -4.8 4.04 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 120.587 -1.321 . . . . 0.0 109.896 179.4 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 31.6 p -87.81 2.18 52.01 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.694 -1.253 . . . . 0.0 109.097 179.325 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.466 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -116.52 -51.16 2.61 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.362 -0.836 . . . . 0.0 108.935 -179.998 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.22 -179.9 4.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.53 -0.731 . . . . 0.0 109.493 179.745 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.75 116.07 31.64 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.365 -0.834 . . . . 0.0 108.925 179.91 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.533 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 2.7 m -96.97 123.3 40.65 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.828 -1.17 . . . . 0.0 109.477 -179.298 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.531 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -103.15 149.17 24.9 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.344 1.069 . . . . 0.0 111.356 -179.142 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.527 ' CG1' HG13 ' A' ' 7' ' ' VAL . 43.2 t -104.88 112.1 37.12 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.552 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -151.77 -172.02 20.14 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 118.218 -1.944 . . . . 0.0 111.747 -177.785 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.01 178.67 4.64 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 -178.845 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.558 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 3.2 m 177.19 178.56 0.27 Allowed 'General case' 0 C--N 1.295 -1.786 0 O-C-N 121.581 -0.699 . . . . 0.0 109.432 -179.806 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.422 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -124.74 -158.64 0.84 Allowed 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.935 -1.103 . . . . 0.0 109.063 179.796 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.72 36.02 4.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.696 -1.252 . . . . 0.0 109.134 -179.966 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.412 ' HB1' ' OD2' ' A' ' 99' ' ' ASP . . . -113.12 -33.94 5.85 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.42 -0.8 . . . . 0.0 109.855 -179.732 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 166.19 -36.35 0.25 Allowed Glycine 0 N--CA 1.482 1.7 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 -179.805 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.82 -177.48 5.15 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.544 -0.974 . . . . 0.0 109.9 179.438 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.88 -161.83 23.1 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.462 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 104' ' ' GLY . 8.0 Cg_exo -45.51 173.73 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.643 0 CA-C-N 119.003 1.401 . . . . 0.0 110.232 179.251 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 25.9 pt-20 -92.7 -173.83 3.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.072 -1.017 . . . . 0.0 110.302 -178.824 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -124.67 174.86 17.15 Favored Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 -179.89 . . . . . . . . 1 1 . 1 . 051 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.518 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -111.02 153.71 12.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -179.552 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.531 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -95.02 123.07 38.3 Favored 'General case' 0 C--N 1.292 -1.93 0 O-C-N 121.303 -0.873 . . . . 0.0 109.605 179.922 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.533 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 1.4 pt -98.08 168.32 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.209 -0.932 . . . . 0.0 109.073 179.942 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.46 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.2 OUTLIER -135.1 156.65 48.65 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.29 -0.881 . . . . 0.0 109.456 -179.98 . . . . . . . . 3 3 . 1 . 051 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.577 ' CG ' ' HG2' ' A' ' 71' ' ' ARG . 44.6 m-85 -131.97 78.46 1.82 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.2 -0.937 . . . . 0.0 109.543 -179.767 . . . . . . . . 2 2 . 1 . 051 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 20.1 p30 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 118.003 -0.999 . . . . 0.0 109.497 179.995 . . . . . . . . 0 0 . 1 . 051 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.586 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 052 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.453 ' HB3' ' HD2' ' A' ' 3' ' ' PRO . . . -122.07 159.29 52.4 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.309 -0.869 . . . . 0.0 109.446 -179.939 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.516 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 5.0 Cg_exo -59.88 157.42 33.55 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.332 2.021 . . . . 0.0 110.619 179.938 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.604 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -147.29 160.37 42.58 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.6 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.483 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.59 122.44 9.33 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-O 122.288 1.042 . . . . 0.0 110.333 -179.673 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.547 ' CG2' ' O ' ' A' ' 6' ' ' THR . 5.8 t -115.63 109.26 17.5 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-O 123.158 1.456 . . . . 0.0 109.838 -179.866 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.502 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 0.8 OUTLIER -115.5 136.12 53.32 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.632 0 CA-C-N 114.271 -1.331 . . . . 0.0 109.604 179.763 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.485 HG22 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -173.72 150.64 1.75 Allowed Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.181 -0.95 . . . . 0.0 109.04 -179.621 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.485 ' HA ' HG22 ' A' ' 8' ' ' THR . 5.0 Cg_endo -77.2 151.18 92.99 Favored 'Cis proline' 0 C--N 1.313 -1.335 0 C-N-CA 123.484 -1.465 . . . . 0.0 109.26 -0.902 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.453 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 72.4 p -94.43 -22.55 18.22 Favored 'General case' 0 C--N 1.293 -1.89 0 O-C-N 121.511 -0.743 . . . . 0.0 109.623 179.878 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.455 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -130.88 155.18 47.18 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.214 -0.929 . . . . 0.0 110.233 -179.602 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.33 35.59 22.96 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.002 -1.639 . . . . 0.0 109.002 179.996 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.593 ' CD1' ' CG1' ' A' ' 19' ' ' VAL . 40.4 mt -92.8 -44.19 8.63 Favored 'General case' 0 C--N 1.301 -1.529 0 CA-C-O 123.214 1.483 . . . . 0.0 110.635 -178.713 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.452 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 63.17 145.19 0.02 OUTLIER 'General case' 0 C--N 1.261 -3.247 0 CA-C-N 113.558 -1.655 . . . . 0.0 109.201 -178.939 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.533 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.6 m-20 -53.82 114.68 1.65 Allowed 'General case' 0 C--N 1.299 -1.627 0 CA-C-O 121.764 0.792 . . . . 0.0 110.436 -178.946 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 121.67 0.71 10.99 Favored Glycine 0 N--CA 1.484 1.865 0 C-N-CA 119.495 -1.336 . . . . 0.0 112.404 178.334 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.577 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.8 t -106.7 -177.34 3.33 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 121.069 2.434 . . . . 0.0 110.474 -179.944 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.541 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 25.9 t -127.48 139.09 52.88 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 CA-C-N 114.113 -1.403 . . . . 0.0 110.878 -178.865 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.593 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 4.2 m -113.01 158.37 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 178.907 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -106.45 108.77 20.44 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.088 -1.007 . . . . 0.0 109.115 179.947 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.53 HG11 ' CG2' ' A' ' 34' ' ' VAL . 13.0 p -101.23 140.02 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.651 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.584 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -137.37 161.86 35.16 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.675 -1.266 . . . . 0.0 110.154 179.642 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.587 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.6 139.32 10.53 Favored Glycine 0 C--N 1.298 -1.546 0 N-CA-C 107.882 -2.087 . . . . 0.0 107.882 179.529 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.604 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.4 125.31 16.13 Favored 'General case' 0 N--CA 1.496 1.828 0 CA-C-N 119.411 1.606 . . . . 0.0 109.434 179.446 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.516 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.67 27.77 21.01 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 118.8 -1.667 . . . . 0.0 109.634 -179.756 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -89.01 169.63 11.36 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.033 -1.275 . . . . 0.0 108.188 179.942 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.552 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -43.59 98.67 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.015 -1.053 . . . . 0.0 110.042 -179.354 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.552 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.29 77.83 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.255 -179.285 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.571 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.23 33.44 0.27 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.393 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.529 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 59.0 p -141.73 108.67 5.43 Favored 'General case' 0 C--N 1.307 -1.264 0 O-C-N 121.102 -1.234 . . . . 0.0 111.316 -179.474 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.564 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -51.79 111.49 0.61 Allowed 'General case' 0 N--CA 1.497 1.896 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.717 178.067 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.53 ' CE1' ' HB2' ' A' ' 99' ' ' ASP . 5.3 m-30 -105.65 160.04 15.5 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.068 -1.02 . . . . 0.0 108.817 179.662 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.482 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -100.23 167.34 10.49 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.738 -1.226 . . . . 0.0 108.003 179.061 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.612 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.9 p -149.48 120.81 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.112 -0.992 . . . . 0.0 109.531 -178.136 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -174.9 -176.63 43.36 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 118.297 -1.906 . . . . 0.0 111.702 -179.941 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.567 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -98.83 108.87 21.66 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -179.997 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.442 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.1 m -130.45 148.93 52.32 Favored 'General case' 0 C--N 1.295 -1.796 0 O-C-N 121.315 -0.866 . . . . 0.0 109.461 179.389 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.38 138.72 54.34 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.154 -0.966 . . . . 0.0 110.849 -178.872 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.622 ' CD1' HD11 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.14 114.64 26.46 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 178.103 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.6 m -105.16 15.14 6.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.08 -1.012 . . . . 0.0 110.466 -178.609 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.587 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.42 -175.48 0.1 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.864 -1.148 . . . . 0.0 109.998 179.705 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.65 96.83 1.63 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.473 -0.767 . . . . 0.0 109.735 -179.739 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 28.03 32.32 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.493 178.933 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.587 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.18 106.57 20.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 O-C-N 120.577 -1.543 . . . . 0.0 107.302 178.845 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.622 HD11 ' CD1' ' A' ' 39' ' ' TRP . 12.2 tp -116.23 104.45 11.52 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.449 -1.407 . . . . 0.0 110.022 -177.5 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.547 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -98.25 109.45 22.21 Favored 'General case' 0 N--CA 1.484 1.248 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 178.525 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 5.1 t -108.5 165.49 11.48 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.826 -1.171 . . . . 0.0 110.648 -178.468 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.486 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 52.4 t30 -115.84 134.45 22.71 Favored Pre-proline 0 N--CA 1.499 2.019 0 O-C-N 121.545 -0.722 . . . . 0.0 109.394 -179.624 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.524 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 2.5 Cg_endo -72.08 22.96 0.26 Allowed 'Trans proline' 0 C--N 1.317 -1.124 0 C-N-CA 122.289 1.993 . . . . 0.0 112.106 -179.802 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.486 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -95.28 -9.76 32.2 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.355 -1.466 . . . . 0.0 109.045 179.408 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.548 ' HB3' ' CB ' ' A' ' 67' ' ' LEU . 3.4 m-20 -134.06 6.77 3.66 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.903 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -59.72 84.04 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.495 -0.753 . . . . 0.0 110.589 -178.775 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.612 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -111.47 -168.89 1.36 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.516 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.473 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.3 t 179.01 135.17 0.09 Allowed 'General case' 0 C--N 1.305 -1.358 0 O-C-N 120.656 -1.278 . . . . 0.0 110.967 -179.476 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.53 HG12 ' CB ' ' A' ' 63' ' ' ALA . 1.6 p -147.29 157.4 9.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.288 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.564 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.53 142.01 30.66 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 120.696 -1.252 . . . . 0.0 110.024 -179.699 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.678 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.17 107.54 1.32 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 122.5 1.143 . . . . 0.0 109.533 178.462 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.535 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.2 p-10 -61.19 -139.39 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.976 -179.99 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.552 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.77 -50.83 55.0 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.399 -0.813 . . . . 0.0 110.641 -178.764 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -104.36 -33.27 8.69 Favored 'General case' 0 C--N 1.285 -2.221 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 178.498 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.678 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.47 66.49 0.62 Allowed Glycine 0 C--N 1.299 -1.498 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 178.132 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.587 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.6 m -100.68 130.09 46.67 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.491 -1.006 . . . . 0.0 108.883 178.974 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.584 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -134.49 109.51 8.76 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.217 -0.993 . . . . 0.0 109.307 -179.594 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 18.2 m -124.31 118.33 26.52 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.359 -0.838 . . . . 0.0 109.789 -179.781 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.452 HG23 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -148.36 148.26 30.17 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.436 -0.79 . . . . 0.0 109.218 179.808 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.405 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 28.2 p -98.38 136.23 38.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.33 -0.856 . . . . 0.0 109.47 179.923 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.548 ' CB ' ' HB3' ' A' ' 51' ' ' ASP . 0.2 OUTLIER -129.68 164.91 22.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.313 -0.867 . . . . 0.0 109.874 -179.023 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.522 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.1 p -104.29 127.16 51.89 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.157 -0.964 . . . . 0.0 108.679 179.529 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.496 ' CB ' ' OE1' ' A' ' 36' ' ' GLN . 16.0 m -134.53 140.21 46.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.722 -1.236 . . . . 0.0 110.471 -178.659 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.533 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 46.8 mtt180 -126.48 -168.2 1.83 Allowed 'General case' 0 N--CA 1.484 1.226 0 O-C-N 120.703 -1.248 . . . . 0.0 111.015 179.937 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.56 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 27.9 mtm180 -77.87 -75.5 0.22 Allowed 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.326 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.424 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -73.79 136.39 43.58 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 120.006 -1.684 . . . . 0.0 106.829 178.017 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.594 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -156.15 136.88 13.36 Favored 'General case' 0 C--N 1.295 -1.766 0 C-N-CA 117.987 -1.485 . . . . 0.0 110.481 -177.861 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.479 ' O ' ' O ' ' A' ' 47' ' ' CYS . 6.6 mm-40 -37.37 120.45 0.78 Allowed 'General case' 0 N--CA 1.487 1.385 0 CA-C-O 121.589 0.709 . . . . 0.0 110.129 -178.584 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.547 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -88.91 48.88 3.53 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.273 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.524 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 26.3 m-85 -38.22 113.44 0.29 Allowed 'General case' 0 N--CA 1.505 2.276 0 O-C-N 121.165 -1.197 . . . . 0.0 110.138 179.561 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.542 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.0 tp -86.07 126.93 34.54 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.003 -1.061 . . . . 0.0 109.455 -179.819 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 19.6 t80 -63.62 58.44 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.994 0 O-C-N 120.984 -1.073 . . . . 0.0 110.21 179.599 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -160.89 19.62 0.13 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.038 -1.038 . . . . 0.0 109.824 179.926 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.72 -27.14 5.47 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 179.767 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.438 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 15.5 p -95.57 158.91 15.24 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.994 -1.297 . . . . 0.0 110.258 -179.457 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.448 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -105.03 136.68 44.06 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 179.699 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.466 ' HB2' HD12 ' A' ' 77' ' ' LEU . 4.7 t90 -80.72 -20.13 43.5 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.914 -1.116 . . . . 0.0 110.274 -178.644 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.76 174.43 18.31 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 108.669 -1.772 . . . . 0.0 108.669 -179.392 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.53 108.73 1.44 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.011 -1.287 . . . . 0.0 107.771 179.21 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.594 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 41.5 t -81.41 105.59 11.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 O-C-N 121.375 -0.828 . . . . 0.0 108.796 -179.256 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.462 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.92 111.14 3.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.342 -0.849 . . . . 0.0 110.051 -179.085 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.56 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.5 t -63.99 -5.21 4.22 Favored 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 118.587 -1.245 . . . . 0.0 109.924 179.456 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.7 p -87.43 1.46 53.35 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.804 -1.185 . . . . 0.0 109.08 179.446 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.462 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -116.05 -51.18 2.65 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.393 -0.817 . . . . 0.0 108.965 179.868 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . 0.401 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -102.2 -178.96 3.85 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.544 -0.722 . . . . 0.0 109.384 179.736 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.49 115.61 30.54 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.389 -0.82 . . . . 0.0 109.077 179.975 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.52 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.76 121.39 38.55 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.833 -1.167 . . . . 0.0 109.324 -179.438 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.585 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.02 144.93 30.0 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 122.323 1.059 . . . . 0.0 111.262 -179.278 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.424 HG13 HG21 ' A' ' 21' ' ' VAL . 96.1 t -102.14 109.86 27.36 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.663 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.437 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.89 -171.29 17.49 Favored Glycine 0 N--CA 1.487 2.092 0 C-N-CA 118.018 -2.039 . . . . 0.0 111.894 -177.54 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.482 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -110.51 -179.21 3.7 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 -179.221 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.553 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 36.8 p -162.67 173.78 13.43 Favored 'General case' 0 C--N 1.295 -1.766 0 O-C-N 121.464 -0.772 . . . . 0.0 109.379 -179.366 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.53 ' HB2' ' CE1' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -123.59 -160.93 0.94 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.197 -0.939 . . . . 0.0 108.782 179.569 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -120.73 34.01 5.37 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.511 -1.368 . . . . 0.0 109.572 -179.859 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -121.48 -29.12 4.48 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.355 -0.841 . . . . 0.0 110.578 -179.63 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.489 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 167.28 -37.31 0.23 Allowed Glycine 0 N--CA 1.482 1.763 0 N-CA-C 107.601 -2.199 . . . . 0.0 107.601 -179.42 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.501 ' ND2' ' O9 ' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -160.34 -178.3 6.84 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 121.568 -0.96 . . . . 0.0 109.587 179.202 . . . . . . . . 3 3 . 1 . 052 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -158.92 -163.42 13.0 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 108.3 -1.92 . . . . 0.0 108.3 -179.558 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.0 Cg_exo -47.72 178.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.705 0 CA-C-N 118.819 1.31 . . . . 0.0 110.132 179.331 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -91.75 -175.79 4.26 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.047 -1.033 . . . . 0.0 110.415 -178.879 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.437 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.83 168.2 14.56 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 -179.865 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.465 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.6 130.49 51.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.405 -1.056 . . . . 0.0 109.073 -179.363 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.585 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.58 121.39 21.5 Favored 'General case' 0 C--N 1.29 -1.979 0 O-C-N 121.578 -0.701 . . . . 0.0 109.914 179.85 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.495 HG12 ' O ' ' A' ' 93' ' ' CYS . 1.5 pt -98.0 166.91 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.279 -0.888 . . . . 0.0 109.04 179.765 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.455 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 1.4 m -135.25 156.52 48.83 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.322 -0.862 . . . . 0.0 109.597 -179.96 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.56 ' CD1' ' HG2' ' A' ' 71' ' ' ARG . 53.7 m-85 -128.08 89.33 2.9 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.215 -0.928 . . . . 0.0 109.434 -179.885 . . . . . . . . 2 2 . 1 . 052 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.406 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 14.4 p30 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.456 -179.998 . . . . . . . . 1 1 . 1 . 052 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.587 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 053 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -122.56 108.81 33.1 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.266 -0.896 . . . . 0.0 109.407 -179.917 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.521 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 6.3 Cg_exo -58.77 156.66 31.59 Favored 'Trans proline' 0 C--N 1.311 -1.406 0 C-N-CA 122.119 1.879 . . . . 0.0 110.64 179.954 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.542 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -176.85 -169.41 0.26 Allowed 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 179.083 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.542 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.28 132.84 3.02 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.81 -1.181 . . . . 0.0 110.717 -179.059 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.54 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 1.7 p -104.16 104.38 14.3 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 122.585 1.183 . . . . 0.0 109.835 179.901 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.542 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 14.2 t -119.59 121.49 66.43 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.398 179.806 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.73 149.75 6.18 Favored Pre-proline 0 N--CA 1.486 1.354 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.557 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.8 Cg_endo -78.63 149.54 85.67 Favored 'Cis proline' 0 C--N 1.308 -1.563 0 C-N-CA 123.663 -1.39 . . . . 0.0 109.697 -0.722 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.448 ' HB2' ' HA ' ' A' ' 110' ' ' ILE . 88.7 p -91.0 -24.63 20.03 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.34 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.465 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 0.8 OUTLIER -131.23 161.17 32.85 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.381 -0.825 . . . . 0.0 109.733 -179.949 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.63 38.47 32.19 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 -179.574 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.619 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 30.9 mt -92.08 -44.46 8.82 Favored 'General case' 0 C--N 1.298 -1.665 0 CA-C-O 123.111 1.434 . . . . 0.0 110.736 -178.26 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.483 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.67 145.72 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.658 -1.61 . . . . 0.0 110.05 -179.818 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.543 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.4 p-10 -51.2 107.35 0.18 Allowed 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 121.502 0.668 . . . . 0.0 111.597 -178.693 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.25 14.36 9.91 Favored Glycine 0 N--CA 1.484 1.883 0 C-N-CA 119.335 -1.412 . . . . 0.0 112.953 177.227 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.619 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 9.7 t -102.78 -172.31 2.1 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 121.012 2.406 . . . . 0.0 109.643 179.239 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.561 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 11.8 t -131.71 137.93 54.0 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.372 0 CA-C-N 115.001 -0.999 . . . . 0.0 111.229 -179.113 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.51 HG13 ' CG2' ' A' ' 69' ' ' VAL . 33.7 m -114.69 154.4 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.965 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.542 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -109.05 109.29 20.28 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.158 -0.964 . . . . 0.0 109.186 -179.993 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.515 ' CG1' HG23 ' A' ' 34' ' ' VAL . 2.0 p -107.7 123.11 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 -179.968 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.54 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -114.43 165.12 13.07 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 120.829 -1.169 . . . . 0.0 108.873 179.55 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.579 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.85 107.67 0.53 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 108.825 -1.71 . . . . 0.0 108.825 179.944 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.516 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -115.73 142.84 46.21 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 120.876 -1.367 . . . . 0.0 110.676 -179.213 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.521 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 81.78 27.35 46.77 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 179.207 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.546 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.8 OUTLIER -92.11 174.26 7.41 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.061 -1.258 . . . . 0.0 108.589 179.967 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.561 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.44 99.43 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.025 -1.047 . . . . 0.0 109.732 -179.79 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.06 77.4 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.246 -179.116 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.67 34.02 0.32 Allowed Glycine 0 N--CA 1.487 2.067 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.379 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 80.3 p -144.23 111.6 5.98 Favored 'General case' 0 C--N 1.306 -1.291 0 O-C-N 120.996 -1.297 . . . . 0.0 111.096 -179.803 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.54 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -47.09 124.5 6.53 Favored 'General case' 0 N--CA 1.493 1.691 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.845 178.355 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.496 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 17.8 m-85 -117.69 150.4 39.13 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.493 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.463 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.64 155.42 17.89 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 178.675 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.621 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 7.0 p -138.17 114.96 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.025 -1.047 . . . . 0.0 109.807 -177.81 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.483 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.58 -177.67 36.62 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 118.507 -1.806 . . . . 0.0 111.638 -179.648 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.642 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.2 pt20 -102.3 109.83 21.62 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-O 121.836 0.826 . . . . 0.0 108.917 -179.781 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.0 150.34 51.32 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.157 -0.964 . . . . 0.0 110.166 -179.869 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.77 139.7 53.61 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.255 -0.903 . . . . 0.0 110.633 -179.212 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.617 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.05 114.44 26.25 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 178.178 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.4 m -105.37 15.82 6.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.006 -1.059 . . . . 0.0 110.661 -178.821 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.58 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.98 -175.94 0.11 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.928 -1.108 . . . . 0.0 110.043 179.741 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 71.8 p -71.23 96.35 1.39 Allowed 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.37 -0.831 . . . . 0.0 109.759 -179.714 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.38 27.98 34.59 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.234 -0.984 . . . . 0.0 111.402 178.873 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.58 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 2.1 t -115.46 105.97 19.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 O-C-N 120.481 -1.599 . . . . 0.0 107.417 178.951 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.617 HD13 ' CD1' ' A' ' 39' ' ' TRP . 12.0 tp -114.9 104.63 12.12 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.533 -1.355 . . . . 0.0 110.062 -177.658 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.472 ' HA ' ' O ' ' A' ' 76' ' ' PHE . . . -98.21 109.52 22.26 Favored 'General case' 0 N--CA 1.483 1.225 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 178.447 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.7 t -105.49 170.47 7.87 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.968 -1.082 . . . . 0.0 110.734 -178.108 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.468 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 21.1 t-20 -114.14 126.07 28.5 Favored Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.54 -0.725 . . . . 0.0 109.546 -179.471 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.583 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -70.57 21.15 0.2 Allowed 'Trans proline' 0 CA--C 1.545 1.062 0 C-N-CA 122.098 1.865 . . . . 0.0 112.118 179.589 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.86 2.59 23.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.42 -1.425 . . . . 0.0 108.964 179.385 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.521 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.39 16.4 2.57 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.563 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -80.35 91.16 5.63 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.974 -178.537 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.621 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.35 -166.37 1.15 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.23 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.463 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.68 137.57 0.09 Allowed 'General case' 0 N--CA 1.486 1.345 0 O-C-N 120.55 -1.344 . . . . 0.0 111.369 -179.38 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.613 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -156.86 156.94 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.171 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.54 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.1 m -98.17 144.7 27.36 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 120.717 -1.239 . . . . 0.0 109.944 -179.616 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.68 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.22 106.39 1.08 Allowed 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 122.408 1.099 . . . . 0.0 109.29 178.466 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.515 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.6 p-10 -59.04 -138.49 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.992 -179.816 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.19 -50.27 62.22 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.445 -0.784 . . . . 0.0 110.618 -178.567 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 28.9 t30 -104.16 -35.53 8.0 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 106.093 -1.817 . . . . 0.0 106.093 178.376 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.68 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 111.1 64.82 0.51 Allowed Glycine 0 C--N 1.298 -1.548 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 177.924 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.579 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 18.6 m -104.72 123.11 47.06 Favored 'General case' 0 N--CA 1.484 1.254 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.545 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.613 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -133.27 109.23 9.25 Favored 'General case' 0 C--N 1.294 -1.819 0 C-N-CA 119.894 -0.722 . . . . 0.0 109.544 -179.052 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 3.6 m -114.0 115.77 28.15 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.349 -0.845 . . . . 0.0 109.358 -179.981 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.52 ' CG2' HG12 ' A' ' 34' ' ' VAL . 1.5 t -139.18 140.0 37.7 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.399 -0.813 . . . . 0.0 109.85 179.971 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 45.4 p -99.24 145.82 26.86 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.496 -0.753 . . . . 0.0 109.17 179.718 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.521 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -146.63 162.7 37.88 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.354 -0.842 . . . . 0.0 109.6 -179.134 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 3.2 p -93.94 124.76 38.16 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.936 . . . . 0.0 109.276 -179.913 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.51 ' CG2' HG13 ' A' ' 19' ' ' VAL . 15.4 m -134.66 141.94 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 120.861 -1.149 . . . . 0.0 109.99 -179.101 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.543 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 8.5 ptt180 -141.9 -163.7 1.64 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 120.473 -1.392 . . . . 0.0 110.601 -179.802 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.614 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -75.74 -92.59 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.343 -0.848 . . . . 0.0 109.79 -179.029 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -60.92 133.07 55.73 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.255 -1.528 . . . . 0.0 107.726 179.478 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.642 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -153.95 156.91 38.35 Favored 'General case' 0 C--N 1.293 -1.874 0 C-N-CA 118.367 -1.333 . . . . 0.0 110.179 -178.716 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.578 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 30.3 mm-40 -47.99 121.66 4.41 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.35 -0.844 . . . . 0.0 109.94 -178.292 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.521 ' CA ' HG23 ' A' ' 86' ' ' VAL . . . -86.79 49.89 4.1 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 -179.4 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.583 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 29.7 m-85 -52.29 110.37 0.49 Allowed 'General case' 0 N--CA 1.505 2.301 0 O-C-N 121.014 -1.286 . . . . 0.0 110.743 179.753 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.529 ' HB2' ' O ' ' A' ' 81' ' ' THR . 0.5 OUTLIER -78.67 151.57 32.14 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 120.801 -1.187 . . . . 0.0 108.748 178.64 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.535 ' HA ' ' C6 ' ' A' ' 114' ' ' CHR . 40.4 t80 -63.41 -5.5 3.71 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 120.691 -1.256 . . . . 0.0 110.863 179.954 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -99.18 7.63 45.59 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.723 -1.236 . . . . 0.0 109.593 179.938 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.438 ' HA2' ' O11' ' A' ' 114' ' ' CHR . . . 82.59 -9.81 57.77 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.967 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.529 ' O ' ' HB2' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -78.86 133.56 36.98 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.115 -1.227 . . . . 0.0 109.917 -179.8 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.519 ' NH1' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -75.74 114.66 14.6 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.294 -0.879 . . . . 0.0 109.702 179.75 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . . . . . . . . . 4.0 t90 -80.91 -20.16 42.73 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.036 -1.04 . . . . 0.0 109.426 -179.97 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.44 172.48 18.82 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 -179.725 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.44 110.61 1.72 Allowed 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 179.192 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.598 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 41.1 t -80.84 101.17 5.55 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.989 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.535 ' CB ' HG21 ' A' ' 90' ' ' THR . 0.5 OUTLIER -61.98 108.21 1.0 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.671 -0.643 . . . . 0.0 110.066 -179.176 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.558 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 4.1 t -60.36 -5.07 1.0 Allowed 'General case' 0 N--CA 1.501 2.124 0 C-N-CA 118.334 -1.346 . . . . 0.0 110.339 179.385 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 60.8 p -89.6 0.26 57.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.461 -1.399 . . . . 0.0 109.588 179.994 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.535 HG21 ' CB ' ' A' ' 87' ' ' ASP . 2.4 p -110.24 -48.46 3.18 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.172 -0.955 . . . . 0.0 109.068 179.994 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.78 -178.07 3.54 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.604 -0.685 . . . . 0.0 109.507 179.997 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.36 112.94 26.17 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.784 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.474 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.48 122.2 39.13 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.107 -0.995 . . . . 0.0 109.675 -178.731 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.53 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.3 mt-30 -104.02 148.92 25.66 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 122.428 1.109 . . . . 0.0 111.339 -179.42 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.52 ' CG1' HG12 ' A' ' 7' ' ' VAL . 57.7 t -103.98 109.78 28.25 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.989 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 177.566 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.42 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.13 -171.46 17.83 Favored Glycine 0 N--CA 1.486 1.995 0 C-N-CA 118.239 -1.934 . . . . 0.0 111.605 -177.625 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.463 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -122.05 178.92 4.7 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -178.812 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.571 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 3.4 m 178.37 177.32 0.44 Allowed 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.571 -0.705 . . . . 0.0 109.393 -179.841 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.481 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -125.05 -156.95 0.75 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.058 -1.026 . . . . 0.0 109.033 179.877 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.481 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.48 36.22 4.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.781 -1.2 . . . . 0.0 109.091 179.925 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -112.19 -32.84 6.41 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.301 -0.875 . . . . 0.0 109.946 -179.671 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.413 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . 165.89 -36.86 0.26 Allowed Glycine 0 N--CA 1.482 1.71 0 N-CA-C 107.883 -2.087 . . . . 0.0 107.883 -179.704 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.413 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -167.0 -177.17 3.67 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 122.079 0.942 . . . . 0.0 109.755 179.427 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.87 -162.23 21.77 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.265 -1.934 . . . . 0.0 108.265 -179.431 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.465 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.5 Cg_exo -45.27 171.91 0.02 OUTLIER 'Trans proline' 0 C--N 1.326 -0.629 0 CA-C-N 118.95 1.375 . . . . 0.0 110.035 179.319 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -93.17 -176.69 4.23 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.049 -1.032 . . . . 0.0 110.501 -178.583 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.42 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.07 166.28 12.77 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 -179.908 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -106.11 132.91 52.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.399 -1.059 . . . . 0.0 109.162 -179.251 . . . . . . . . 1 1 . 1 . 053 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.53 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.58 126.08 29.0 Favored 'General case' 0 C--N 1.289 -2.038 0 O-C-N 121.534 -0.729 . . . . 0.0 109.741 179.873 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.576 HD11 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.91 172.44 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.248 -0.907 . . . . 0.0 108.979 179.683 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.465 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.59 158.73 43.76 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.077 -1.014 . . . . 0.0 109.462 -179.948 . . . . . . . . 3 3 . 1 . 053 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.602 ' CD1' ' HD2' ' A' ' 71' ' ' ARG . 56.0 m-85 -136.8 81.09 1.85 Allowed 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.24 -0.913 . . . . 0.0 109.636 -179.639 . . . . . . . . 2 2 . 1 . 053 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 16.6 p30 . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.516 -179.985 . . . . . . . . 0 0 . 1 . 053 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.595 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 0 0 . 1 . 054 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -119.42 152.95 53.52 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.371 -0.83 . . . . 0.0 109.49 179.969 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.519 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 5.1 Cg_exo -59.96 157.44 33.87 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.23 1.953 . . . . 0.0 110.642 -179.985 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.598 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -149.04 160.22 43.51 Favored 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 -179.542 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.482 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.41 122.69 9.61 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-O 122.43 1.11 . . . . 0.0 110.234 -179.728 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.55 ' CG2' ' O ' ' A' ' 6' ' ' THR . 5.9 t -115.14 109.04 17.43 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 123.127 1.441 . . . . 0.0 109.812 -179.863 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.519 HG13 ' CG1' ' A' ' 95' ' ' VAL . 2.2 t -116.18 134.18 60.36 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.659 0 CA-C-N 114.229 -1.35 . . . . 0.0 109.486 179.795 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.491 HG21 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -169.53 150.39 4.03 Favored Pre-proline 0 N--CA 1.487 1.413 0 O-C-N 121.183 -0.948 . . . . 0.0 108.876 -179.509 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.491 ' HA ' HG21 ' A' ' 8' ' ' THR . 2.5 Cg_endo -75.52 152.32 97.24 Favored 'Cis proline' 0 C--N 1.313 -1.315 0 C-N-CA 123.488 -1.463 . . . . 0.0 109.785 -0.963 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.419 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 5.8 m -93.05 -23.52 18.63 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.447 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.513 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 69.0 m -134.99 159.62 40.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.564 -0.71 . . . . 0.0 109.382 179.912 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.28 36.29 27.61 Favored Glycine 0 N--CA 1.495 2.626 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.736 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.599 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 36.7 mt -90.94 -42.65 10.45 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 123.391 1.567 . . . . 0.0 110.393 -178.482 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.11 144.34 0.05 OUTLIER 'General case' 0 C--N 1.261 -3.267 0 CA-C-N 113.282 -1.781 . . . . 0.0 110.08 -179.746 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.579 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.3 p-10 -50.46 104.75 0.08 Allowed 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.556 0.693 . . . . 0.0 111.655 -178.451 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.51 14.4 8.2 Favored Glycine 0 N--CA 1.485 1.91 0 C-N-CA 119.33 -1.414 . . . . 0.0 113.154 177.18 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.599 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.0 t -105.76 -172.99 2.19 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 121.352 2.576 . . . . 0.0 109.821 179.181 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.543 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 17.5 t -129.59 138.21 54.82 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.333 0 CA-C-N 114.67 -1.15 . . . . 0.0 111.136 -178.711 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.517 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 29.4 m -113.61 155.48 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.863 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.492 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tttm -104.32 109.05 20.75 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.208 -0.933 . . . . 0.0 109.213 -179.962 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.2 p -100.64 140.05 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.627 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.571 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -136.61 162.67 32.49 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.733 -1.229 . . . . 0.0 110.179 179.666 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.585 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.64 139.82 10.95 Favored Glycine 0 C--N 1.299 -1.527 0 N-CA-C 108.244 -1.942 . . . . 0.0 108.244 179.728 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.598 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.32 125.6 16.51 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.491 -1.593 . . . . 0.0 109.355 179.301 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.519 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 88.85 28.32 21.52 Favored Glycine 0 N--CA 1.49 2.264 0 C-N-CA 118.685 -1.722 . . . . 0.0 109.731 -179.824 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.4 mt -88.72 171.95 9.6 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.885 -1.362 . . . . 0.0 108.278 179.835 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.556 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.03 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.96 -1.087 . . . . 0.0 109.872 -179.476 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.57 77.54 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.677 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.178 -179.345 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.65 33.97 0.28 Allowed Glycine 0 N--CA 1.486 2.007 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.618 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.541 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 41.2 p -141.51 108.05 5.32 Favored 'General case' 0 C--N 1.307 -1.244 0 O-C-N 121.144 -1.209 . . . . 0.0 111.236 -179.476 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -51.04 109.8 0.36 Allowed 'General case' 0 N--CA 1.497 1.904 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.488 177.866 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.499 ' CE1' ' HB2' ' A' ' 99' ' ' ASP . 5.3 m-30 -103.89 157.99 16.71 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.054 -1.029 . . . . 0.0 108.87 179.741 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -99.81 166.54 11.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.844 -1.16 . . . . 0.0 107.969 179.007 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.628 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.8 p -148.09 120.28 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.108 -0.995 . . . . 0.0 109.605 -178.038 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -174.02 -177.02 42.89 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 118.403 -1.856 . . . . 0.0 111.641 -179.927 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.57 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.0 OUTLIER -99.16 108.24 20.79 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.95 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -130.25 148.5 52.08 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.212 -0.93 . . . . 0.0 109.985 179.708 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.71 139.58 53.73 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.298 -0.877 . . . . 0.0 110.634 -179.099 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.618 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.21 114.76 26.59 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 178.207 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.432 HG23 ' HB ' ' A' ' 44' ' ' VAL . 16.4 m -104.83 15.02 6.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.92 -1.112 . . . . 0.0 110.58 -178.795 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.592 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.41 -175.96 0.08 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.872 -1.142 . . . . 0.0 110.074 179.757 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.545 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.0 t -71.36 98.0 1.7 Allowed 'General case' 0 N--CA 1.488 1.434 0 CA-C-O 121.729 0.776 . . . . 0.0 109.808 -179.696 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.48 27.86 34.64 Favored Glycine 0 N--CA 1.492 2.405 0 C-N-CA 120.174 -1.012 . . . . 0.0 111.427 178.97 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.592 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.71 106.25 19.87 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 O-C-N 120.587 -1.537 . . . . 0.0 107.192 178.887 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.618 HD12 ' CD1' ' A' ' 39' ' ' TRP . 13.1 tp -116.96 104.53 11.37 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.478 -1.389 . . . . 0.0 109.773 -177.75 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.546 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.99 109.28 22.06 Favored 'General case' 0 N--CA 1.485 1.315 0 O-C-N 120.833 -1.167 . . . . 0.0 108.152 178.92 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.0 t -106.67 164.8 11.79 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.913 -1.117 . . . . 0.0 110.233 -179.115 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.548 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 3.7 t-20 -106.56 136.21 19.42 Favored Pre-proline 0 N--CA 1.498 1.966 0 O-C-N 121.386 -0.821 . . . . 0.0 109.622 -179.179 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.575 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -74.85 23.79 0.39 Allowed 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 122.384 2.056 . . . . 0.0 111.943 -179.83 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.548 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -109.76 -4.59 15.99 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.33 -1.481 . . . . 0.0 109.143 179.615 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.538 ' CB ' ' HB3' ' A' ' 67' ' ' LEU . 6.0 m-20 -131.73 6.05 4.33 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.658 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.47 84.94 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.732 -178.502 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -110.76 -170.49 1.65 Allowed 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.448 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.469 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.58 135.22 0.08 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 120.622 -1.298 . . . . 0.0 111.136 -179.286 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.563 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.6 p -146.8 158.28 10.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 178.169 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.49 141.51 31.25 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 120.703 -1.248 . . . . 0.0 110.061 -179.791 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.678 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.21 107.91 1.43 Allowed 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.438 1.114 . . . . 0.0 109.537 178.596 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.1 p-10 -61.46 -139.45 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.97 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.864 179.849 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.89 -50.87 60.17 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.427 -0.796 . . . . 0.0 110.487 -178.843 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -102.24 -34.71 9.13 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 178.46 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.678 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.27 67.31 0.64 Allowed Glycine 0 C--N 1.299 -1.499 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 178.073 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.585 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 57.5 m -100.06 130.86 46.26 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.482 -1.011 . . . . 0.0 108.803 178.962 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.571 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -133.48 109.42 9.27 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.19 -1.004 . . . . 0.0 109.321 -179.648 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 73.2 m -121.85 117.0 25.43 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.313 -0.867 . . . . 0.0 109.61 -179.678 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.459 HG21 HG13 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -147.54 149.32 32.37 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.452 -0.78 . . . . 0.0 109.291 179.879 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.465 ' O ' HD23 ' A' ' 67' ' ' LEU . 56.3 p -98.47 145.08 27.13 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.401 -0.812 . . . . 0.0 109.284 179.969 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.543 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.3 OUTLIER -138.96 159.62 41.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.334 -0.854 . . . . 0.0 109.826 -178.717 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.543 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.4 p -101.29 124.0 46.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.011 -1.056 . . . . 0.0 108.483 179.319 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.527 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 21.1 m -137.92 143.16 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.744 -1.222 . . . . 0.0 110.783 -178.47 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.579 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.9 ptt180 -147.45 -175.14 4.73 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 120.711 -1.243 . . . . 0.0 110.742 179.68 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.549 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.43 -101.93 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -179.597 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -57.08 140.85 47.98 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.741 -1.224 . . . . 0.0 108.205 179.459 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -161.83 136.67 7.16 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 118.611 -1.235 . . . . 0.0 109.733 -178.1 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.48 ' C ' ' O ' ' A' ' 73' ' ' PHE . 4.4 mp0 -35.87 122.36 0.68 Allowed 'General case' 0 N--CA 1.491 1.576 0 CA-C-O 121.466 0.65 . . . . 0.0 110.094 -178.615 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.546 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -95.85 52.67 1.7 Allowed Glycine 0 N--CA 1.494 2.522 0 C-N-CA 120.539 -0.838 . . . . 0.0 111.22 -179.109 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.575 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.57 114.05 0.38 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.094 -1.239 . . . . 0.0 110.133 179.463 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.541 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.1 tp -82.79 126.19 32.14 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 120.843 -1.161 . . . . 0.0 109.313 179.787 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.576 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 51.8 t80 -64.02 58.59 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.955 0 O-C-N 120.89 -1.131 . . . . 0.0 110.042 179.724 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.3 t0 -160.22 20.03 0.15 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.094 -1.004 . . . . 0.0 109.608 179.942 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.54 -28.35 5.36 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.871 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.47 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.5 OUTLIER -96.72 160.42 14.38 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.058 -1.26 . . . . 0.0 110.207 -179.532 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.493 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.7 OUTLIER -106.13 141.69 37.07 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 179.896 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.475 ' HB2' HD12 ' A' ' 77' ' ' LEU . 2.6 t90 -85.15 -19.35 31.92 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.679 -1.263 . . . . 0.0 110.689 -178.289 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.42 177.5 18.59 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -179.359 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -67.02 105.79 1.75 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.146 -1.208 . . . . 0.0 107.785 179.183 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.578 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 42.7 t -77.2 106.33 7.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.326 -0.858 . . . . 0.0 109.232 -178.879 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 1.1 m-20 -65.96 111.63 3.42 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.363 -0.836 . . . . 0.0 109.69 -179.643 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.549 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.5 -5.36 5.26 Favored 'General case' 0 N--CA 1.5 2.045 0 C-N-CA 118.195 -1.402 . . . . 0.0 109.721 179.567 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -86.4 -0.41 55.91 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.716 -1.24 . . . . 0.0 109.079 179.482 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.452 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.6 -50.88 2.83 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.287 -0.883 . . . . 0.0 108.972 179.9 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.69 -178.73 3.74 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.509 -0.744 . . . . 0.0 109.271 179.815 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.17 115.37 30.11 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.437 -0.789 . . . . 0.0 108.888 -179.949 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.527 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.06 121.1 38.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.94 -1.1 . . . . 0.0 109.714 -179.271 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.567 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.21 146.94 27.27 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 122.449 1.119 . . . . 0.0 111.024 -179.562 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.519 ' CG1' HG13 ' A' ' 7' ' ' VAL . 61.6 t -104.23 111.72 34.94 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 177.858 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.463 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -152.91 -169.86 18.59 Favored Glycine 0 N--CA 1.487 2.089 0 C-N-CA 118.124 -1.989 . . . . 0.0 111.848 -177.71 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -114.32 179.43 3.96 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 -179.173 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.557 ' HB2' ' C20' ' A' ' 114' ' ' CHR . 25.0 p -160.64 167.59 26.69 Favored 'General case' 0 C--N 1.295 -1.792 0 O-C-N 121.467 -0.771 . . . . 0.0 109.363 -179.513 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.499 ' HB2' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -110.25 -160.5 0.72 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.025 -1.047 . . . . 0.0 108.646 179.554 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -116.86 37.07 3.92 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.552 -1.342 . . . . 0.0 109.09 179.866 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -123.53 -36.74 2.74 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.275 -0.89 . . . . 0.0 110.449 -179.473 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.533 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 162.43 -30.9 0.3 Allowed Glycine 0 N--CA 1.476 1.34 0 N-CA-C 106.717 -2.553 . . . . 0.0 106.717 -179.348 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.451 ' O ' ' OD1' ' A' ' 99' ' ' ASP . 0.0 OUTLIER -146.7 170.74 16.35 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.709 -0.877 . . . . 0.0 109.943 -179.775 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.15 -165.01 19.55 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 108.163 -1.975 . . . . 0.0 108.163 -179.857 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.9 Cg_exo -48.22 179.39 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 CA-C-N 118.889 1.344 . . . . 0.0 110.164 179.446 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -92.86 -177.71 4.61 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.183 -0.948 . . . . 0.0 110.438 -178.894 . . . . . . . . 1 1 . 1 . 054 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.463 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.61 165.62 14.53 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.923 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.431 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.0 130.13 53.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 O-C-N 121.293 -1.122 . . . . 0.0 109.209 -179.269 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.567 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.05 121.92 21.85 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.569 -0.707 . . . . 0.0 109.528 179.668 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.617 ' CD1' ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.9 167.25 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 121.188 -0.945 . . . . 0.0 109.243 179.913 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.513 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -137.33 151.24 48.42 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.237 -0.914 . . . . 0.0 109.62 -179.97 . . . . . . . . 3 3 . 1 . 054 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.617 ' CZ ' ' CD1' ' A' ' 110' ' ' ILE . 25.2 m-85 -126.32 108.06 10.89 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.163 -0.961 . . . . 0.0 109.51 -179.693 . . . . . . . . 2 2 . 1 . 054 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 16.0 p30 . . . . . 0 N--CA 1.489 1.48 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.461 179.997 . . . . . . . . 0 0 . 1 . 054 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.602 ' O6 ' ' H27' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 121.327 0.584 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 055 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -105.56 162.99 18.03 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.199 -0.938 . . . . 0.0 109.497 179.967 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.52 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 3.2 Cg_exo -60.87 156.24 44.8 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.262 1.975 . . . . 0.0 110.672 -179.996 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.561 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.95 -169.65 0.13 Allowed 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.237 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.561 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -166.8 129.01 1.76 Allowed 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.837 -1.164 . . . . 0.0 110.71 -179.164 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.542 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.7 t -110.93 108.77 18.65 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.079 1.418 . . . . 0.0 109.078 179.276 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.509 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 2.3 t -119.62 136.7 55.89 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.672 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.023 -179.637 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.527 HG21 ' CA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -177.0 150.96 0.92 Allowed Pre-proline 0 N--CA 1.487 1.421 0 O-C-N 121.286 -0.884 . . . . 0.0 108.785 -179.72 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.527 ' CA ' HG21 ' A' ' 8' ' ' THR . 5.5 Cg_endo -78.46 150.76 88.4 Favored 'Cis proline' 0 C--N 1.312 -1.35 0 C-N-CA 123.481 -1.466 . . . . 0.0 109.301 -0.828 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.453 ' HA ' HG21 ' A' ' 110' ' ' ILE . 77.9 p -89.34 -25.99 21.33 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.518 -0.739 . . . . 0.0 109.056 179.527 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.48 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -132.99 162.69 31.01 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.528 -0.733 . . . . 0.0 109.529 -179.922 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.31 36.93 29.37 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.749 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.608 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 37.5 mt -92.78 -42.97 9.27 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 123.24 1.495 . . . . 0.0 110.488 -178.327 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.492 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.29 144.35 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.265 0 CA-C-N 113.479 -1.691 . . . . 0.0 109.936 -179.521 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.555 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 15.5 p-10 -50.9 106.49 0.13 Allowed 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.515 0.674 . . . . 0.0 111.556 -178.542 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.28 14.22 9.23 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.331 -1.414 . . . . 0.0 113.007 177.311 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.608 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -104.71 -172.01 2.02 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 121.143 2.471 . . . . 0.0 109.67 179.144 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.546 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 17.2 t -127.92 135.97 61.53 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.404 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.182 -178.93 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.585 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 23.0 m -110.79 155.15 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.77 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.509 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.8 OUTLIER -109.93 109.18 19.71 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.173 -0.954 . . . . 0.0 108.973 179.958 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.473 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 2.1 p -105.16 141.73 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.675 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.534 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -141.0 160.2 40.59 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.144 179.886 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.592 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.95 144.72 15.91 Favored Glycine 0 C--N 1.294 -1.769 0 N-CA-C 107.996 -2.041 . . . . 0.0 107.996 179.666 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.52 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.4 125.73 13.1 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 120.884 -1.362 . . . . 0.0 108.789 179.244 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.517 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.46 27.16 23.36 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.315 -1.421 . . . . 0.0 109.608 -179.568 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.5 mt -88.8 175.33 7.53 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.946 -1.326 . . . . 0.0 108.446 -179.941 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.559 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -48.42 99.49 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.013 -1.055 . . . . 0.0 109.83 -179.623 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.548 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.11 77.98 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.759 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.149 -179.325 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.69 34.2 0.31 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.614 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.536 ' O ' ' CD2' ' A' ' 32' ' ' TYR . 62.9 p -143.21 109.09 5.18 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.034 -1.274 . . . . 0.0 111.142 -179.591 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.544 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.99 126.01 5.57 Favored 'General case' 0 N--CA 1.493 1.71 0 CA-C-O 121.403 0.62 . . . . 0.0 109.56 178.129 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.566 ' CE1' ' OD2' ' A' ' 99' ' ' ASP . 19.8 m-85 -117.35 152.98 33.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.349 -0.844 . . . . 0.0 108.923 179.808 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.5 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -103.14 152.66 21.17 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.627 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.637 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.0 p -136.82 116.96 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 120.885 -1.134 . . . . 0.0 109.856 -177.904 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.482 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.1 -178.28 39.35 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 118.462 -1.828 . . . . 0.0 111.828 -179.799 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.577 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.6 OUTLIER -101.74 109.56 21.36 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.928 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.53 148.4 52.33 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.098 -1.001 . . . . 0.0 110.081 179.852 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.04 138.53 54.66 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.394 -0.816 . . . . 0.0 110.701 -179.025 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.63 ' CE2' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.39 114.6 26.39 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 178.137 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 m -105.22 15.16 6.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.006 -1.059 . . . . 0.0 110.705 -178.596 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.14 -175.09 0.09 Allowed 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.952 -1.093 . . . . 0.0 110.097 179.736 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 35.1 p -72.0 97.54 1.9 Allowed 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.404 -0.81 . . . . 0.0 109.727 -179.673 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.13 26.53 36.61 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.173 -1.013 . . . . 0.0 111.446 178.859 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.21 106.3 20.28 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 O-C-N 120.547 -1.561 . . . . 0.0 107.482 178.93 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.63 HD12 ' CE2' ' A' ' 39' ' ' TRP . 12.9 tp -117.51 104.07 10.7 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.47 -1.393 . . . . 0.0 109.6 -177.815 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.515 ' CB ' HG23 ' A' ' 86' ' ' VAL . . . -98.32 109.24 22.03 Favored 'General case' 0 N--CA 1.483 1.179 0 O-C-N 120.767 -1.208 . . . . 0.0 107.753 178.603 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.491 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -103.5 166.01 10.69 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.924 -1.11 . . . . 0.0 110.411 -178.532 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.522 ' ND2' ' HD2' ' A' ' 49' ' ' PRO . 17.1 t-20 -106.35 129.72 24.07 Favored Pre-proline 0 N--CA 1.501 2.084 0 C-N-CA 119.945 -0.702 . . . . 0.0 109.757 -179.202 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.576 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.6 Cg_endo -72.94 23.81 0.3 Allowed 'Trans proline' 0 CA--C 1.544 0.98 0 C-N-CA 122.089 1.86 . . . . 0.0 111.813 179.634 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.4 ' HB1' ' OD1' ' A' ' 48' ' ' ASN . . . -115.51 3.63 14.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.498 -1.376 . . . . 0.0 109.197 179.738 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.496 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.89 17.24 2.66 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 179.49 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -80.64 91.1 5.8 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.842 -0.743 . . . . 0.0 110.814 -178.696 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.637 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -109.51 -166.71 1.12 Allowed 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.297 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.471 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.94 137.03 0.09 Allowed 'General case' 0 C--N 1.306 -1.311 0 O-C-N 120.526 -1.358 . . . . 0.0 111.404 -179.271 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.584 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -154.9 156.15 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.211 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.544 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.68 144.87 26.88 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.694 -1.254 . . . . 0.0 109.907 -179.534 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.686 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -63.83 107.22 1.16 Allowed 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 122.431 1.11 . . . . 0.0 109.409 178.586 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.524 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -61.07 -139.34 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.027 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.903 -179.909 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.548 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.9 -50.91 56.38 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.397 -0.814 . . . . 0.0 110.68 -178.713 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -103.94 -33.18 8.92 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 178.576 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.686 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 107.96 64.91 0.58 Allowed Glycine 0 C--N 1.299 -1.498 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 178.206 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.592 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 47.7 m -103.44 127.07 50.9 Favored 'General case' 0 N--CA 1.483 1.176 0 O-C-N 121.57 -0.959 . . . . 0.0 108.83 178.901 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.584 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -137.04 108.96 7.1 Favored 'General case' 0 C--N 1.296 -1.751 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.659 -179.396 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.513 ' CB ' ' HB2' ' A' ' 22' ' ' ALA . 1.1 m -122.44 121.01 35.6 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.359 -0.838 . . . . 0.0 109.303 -179.898 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.432 HG22 HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.83 144.84 31.34 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.426 -0.796 . . . . 0.0 109.565 179.886 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 22.1 p -99.0 141.0 32.3 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.38 -0.825 . . . . 0.0 109.297 -179.945 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.519 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -140.99 166.7 24.07 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.413 -0.804 . . . . 0.0 109.39 -179.327 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.546 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.7 p -95.96 124.38 39.95 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.005 -1.06 . . . . 0.0 109.416 -179.883 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.527 ' CG2' HG13 ' A' ' 19' ' ' VAL . 13.3 m -136.42 141.86 40.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 120.907 -1.121 . . . . 0.0 109.937 -179.12 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.555 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 7.3 ptt180 -144.35 -170.32 3.34 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.546 -1.346 . . . . 0.0 110.884 -179.882 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.583 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -62.45 -101.42 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.77 -0.581 . . . . 0.0 110.206 -179.125 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -58.94 137.15 58.0 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.574 -1.329 . . . . 0.0 108.209 179.957 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD2' ' O ' ' A' ' 71' ' ' ARG . 1.7 p90 -157.53 154.04 27.96 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.646 -1.222 . . . . 0.0 110.198 -178.514 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 47' ' ' CYS . 5.1 mm-40 -47.15 120.8 3.32 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.359 -0.838 . . . . 0.0 109.263 -179.124 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.48 ' HA3' HG21 ' A' ' 86' ' ' VAL . . . -91.5 51.34 3.01 Favored Glycine 0 N--CA 1.495 2.59 0 C-N-CA 120.414 -0.898 . . . . 0.0 111.116 -179.224 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.576 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.5 m-30 -39.0 114.0 0.36 Allowed 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.114 -1.227 . . . . 0.0 110.31 179.62 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.534 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -86.21 126.94 34.63 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.919 -1.113 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.575 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 29.2 t80 -64.25 58.44 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.911 -1.118 . . . . 0.0 110.059 179.702 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -160.33 19.52 0.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.031 -1.043 . . . . 0.0 109.733 179.824 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.74 -26.96 5.57 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 179.866 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -95.34 161.42 14.09 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 120.998 -1.295 . . . . 0.0 110.315 -179.383 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.471 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -107.24 136.78 46.49 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.813 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.507 ' CD1' HD11 ' A' ' 77' ' ' LEU . 3.0 t90 -83.64 -16.89 43.44 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.784 -1.198 . . . . 0.0 110.562 -178.423 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.14 174.27 20.0 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 108.827 -1.709 . . . . 0.0 108.827 -179.553 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -63.66 107.0 1.06 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.141 -1.211 . . . . 0.0 107.759 179.218 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.556 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 44.3 t -78.94 106.05 9.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.307 -0.871 . . . . 0.0 109.243 -178.877 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.6 OUTLIER -65.16 108.35 1.84 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.652 -0.655 . . . . 0.0 110.113 -179.408 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.545 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.5 t -61.34 -4.72 1.32 Allowed 'General case' 0 N--CA 1.502 2.133 0 O-C-N 120.479 -1.388 . . . . 0.0 110.417 179.391 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -90.43 3.68 53.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.597 -1.314 . . . . 0.0 109.481 179.944 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.461 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -114.96 -48.32 2.84 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.282 -0.886 . . . . 0.0 109.107 -179.976 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.72 -179.05 3.82 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.573 -0.704 . . . . 0.0 109.526 179.997 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.97 112.15 24.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.382 -0.824 . . . . 0.0 108.812 179.838 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.484 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 1.4 m -96.98 122.06 39.54 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.104 -0.997 . . . . 0.0 109.399 -178.922 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.529 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.08 148.66 25.45 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-O 122.439 1.114 . . . . 0.0 111.577 -179.157 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.517 ' CG2' HG22 ' A' ' 110' ' ' ILE . 84.8 t -104.22 110.78 31.43 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 177.643 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.84 -172.01 18.87 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 118.034 -2.031 . . . . 0.0 111.802 -177.604 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.5 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -114.57 -179.04 3.52 Favored 'General case' 0 N--CA 1.485 1.3 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -178.94 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.545 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.8 OUTLIER -170.93 168.26 7.12 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.394 -0.816 . . . . 0.0 109.033 -179.418 . . . . . . . . 3 3 . 1 . 055 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.566 ' OD2' ' CE1' ' A' ' 32' ' ' TYR . 2.1 m-20 -103.66 -11.16 17.84 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.021 -1.05 . . . . 0.0 109.485 179.961 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.499 ' CB ' ' O ' ' A' ' 99' ' ' ASP . . . 74.29 37.67 0.58 Allowed 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.411 -0.806 . . . . 0.0 109.246 179.783 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -137.24 -33.61 0.74 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.533 -0.729 . . . . 0.0 110.715 -179.44 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.518 ' N ' H193 ' A' ' 114' ' ' CHR . . . -179.88 -41.93 0.08 OUTLIER Glycine 0 N--CA 1.481 1.688 0 N-CA-C 107.636 -2.185 . . . . 0.0 107.636 -179.573 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.3 -178.81 7.56 Favored 'General case' 0 C--N 1.307 -1.26 0 O-C-N 121.542 -0.975 . . . . 0.0 109.623 179.022 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -177.63 -167.01 35.17 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 -179.584 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.468 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.7 Cg_exo -49.11 -179.57 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.618 0 CA-C-N 118.83 1.315 . . . . 0.0 110.07 179.529 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.87 -179.81 5.1 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.012 -1.055 . . . . 0.0 110.521 -178.765 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -118.99 162.65 13.42 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.973 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -103.55 130.62 53.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.318 -1.107 . . . . 0.0 109.216 -179.347 . . . . . . . . 1 1 . 1 . 055 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.529 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.98 121.21 18.75 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.641 -0.662 . . . . 0.0 109.606 179.62 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.584 HD13 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.04 171.43 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.239 -0.913 . . . . 0.0 109.174 179.947 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.4 m -141.1 156.55 45.96 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.151 -0.968 . . . . 0.0 109.895 -179.841 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.584 ' CE2' HD13 ' A' ' 110' ' ' ILE . 82.8 m-85 -134.36 94.22 3.18 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.243 -0.911 . . . . 0.0 109.549 -179.74 . . . . . . . . 2 2 . 1 . 055 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 23.0 p30 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 118.003 -0.998 . . . . 0.0 109.459 179.931 . . . . . . . . 0 0 . 1 . 055 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.585 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.345 0.593 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 056 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.51 ' CB ' ' HD2' ' A' ' 3' ' ' PRO . . . -95.42 172.17 5.66 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.224 -0.922 . . . . 0.0 109.509 179.995 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.52 ' O ' ' CG2' ' A' ' 4' ' ' THR . 3.7 Cg_exo -60.42 158.08 33.15 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.266 1.977 . . . . 0.0 110.55 -179.98 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.583 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.1 p -166.43 160.79 15.87 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -179.341 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.494 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.11 128.61 14.03 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-O 122.409 1.1 . . . . 0.0 110.565 -179.705 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.541 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.4 p -106.31 104.86 14.65 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 122.461 1.124 . . . . 0.0 110.199 -179.476 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.53 HG12 ' CG1' ' A' ' 95' ' ' VAL . 12.1 t -118.53 118.69 58.8 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.439 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.364 179.596 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.497 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.87 149.17 10.28 Favored Pre-proline 0 N--CA 1.487 1.38 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 -179.65 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.497 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -77.83 151.23 91.09 Favored 'Cis proline' 0 C--N 1.31 -1.494 0 C-N-CA 123.606 -1.414 . . . . 0.0 109.51 -0.578 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.421 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 16.5 p -93.52 -23.85 18.2 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.639 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.461 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 20.2 m -132.38 162.22 31.64 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.438 -0.789 . . . . 0.0 109.585 -179.927 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.2 37.24 37.72 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 -179.733 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.617 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 30.2 mt -90.41 -44.64 9.51 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 123.127 1.441 . . . . 0.0 110.652 -178.428 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.487 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.99 145.83 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.325 0 CA-C-N 113.699 -1.591 . . . . 0.0 109.963 -179.701 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.562 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 7.3 p-10 -51.35 106.26 0.13 Allowed 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.598 0.713 . . . . 0.0 111.794 -178.471 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.45 15.7 8.71 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 119.438 -1.363 . . . . 0.0 112.98 177.302 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.617 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 9.0 t -102.72 -171.66 1.99 Allowed 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 121.13 2.465 . . . . 0.0 109.84 179.31 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.544 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 17.2 t -129.45 139.01 52.83 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.289 0 CA-C-N 114.861 -1.063 . . . . 0.0 111.195 -178.699 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.489 ' CG2' HG23 ' A' ' 69' ' ' VAL . 31.2 m -118.08 155.04 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.733 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.529 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 6.2 tttt -113.08 109.13 18.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.126 -0.984 . . . . 0.0 109.413 -179.854 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.523 HG11 ' CG2' ' A' ' 34' ' ' VAL . 2.1 p -105.33 122.97 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 179.833 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.552 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -112.88 166.09 11.71 Favored 'General case' 0 C--N 1.307 -1.243 0 O-C-N 120.799 -1.188 . . . . 0.0 109.073 179.634 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.613 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.67 108.46 0.5 Allowed Glycine 0 N--CA 1.481 1.678 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 -179.886 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.583 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.36 139.11 50.76 Favored 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 119.396 1.598 . . . . 0.0 110.424 -179.485 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.494 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.56 29.04 30.86 Favored Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.079 -1.534 . . . . 0.0 109.941 179.56 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.526 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.5 mt -92.47 176.07 6.6 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.986 -1.302 . . . . 0.0 108.562 179.935 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.559 ' CB ' ' CG2' ' A' ' 30' ' ' THR . 0.0 OUTLIER -45.39 96.98 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.023 -1.048 . . . . 0.0 109.621 -179.909 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.94 77.18 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.36 -178.93 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 131.8 34.87 0.37 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.465 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.636 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -146.51 114.4 6.51 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 120.931 -1.335 . . . . 0.0 111.109 -179.948 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.537 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -48.17 122.9 5.66 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.181 178.669 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.636 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 2.0 m-30 -116.93 151.77 35.96 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.267 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.47 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -98.91 163.75 12.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.539 -1.351 . . . . 0.0 108.216 179.247 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.622 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.8 p -144.59 117.98 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.106 -0.997 . . . . 0.0 109.643 -177.963 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.489 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.66 -179.08 41.22 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.411 -1.852 . . . . 0.0 111.738 -179.804 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.601 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -100.95 109.24 21.15 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -179.922 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.457 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.03 149.21 51.85 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.21 -0.931 . . . . 0.0 109.74 179.891 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.36 137.75 54.75 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.178 -0.951 . . . . 0.0 110.736 -178.993 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.624 ' CD1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.28 114.61 26.41 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 178.038 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -104.59 14.47 7.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 120.973 -1.079 . . . . 0.0 110.585 -178.708 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.594 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.57 -174.84 0.08 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.941 -1.099 . . . . 0.0 109.988 179.747 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.92 98.22 2.43 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.379 -0.826 . . . . 0.0 109.653 -179.753 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.28 26.95 31.96 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 120.302 -0.952 . . . . 0.0 111.534 178.943 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.594 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -116.85 106.16 19.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 O-C-N 120.499 -1.589 . . . . 0.0 107.298 178.922 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.624 HD13 ' CD1' ' A' ' 39' ' ' TRP . 13.1 tp -118.17 104.37 10.75 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.358 -1.464 . . . . 0.0 109.885 -177.795 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.488 ' HA ' ' O ' ' A' ' 76' ' ' PHE . . . -98.45 109.36 22.13 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 120.821 -1.174 . . . . 0.0 108.156 178.905 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.509 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.3 t -104.42 166.63 10.27 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.844 -1.16 . . . . 0.0 110.353 -178.961 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.545 ' OD1' ' CB ' ' A' ' 50' ' ' ALA . 15.8 t-20 -109.53 137.89 20.44 Favored Pre-proline 0 N--CA 1.501 2.082 0 O-C-N 121.445 -0.785 . . . . 0.0 110.146 -179.081 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.8 Cg_endo -74.82 25.2 0.37 Allowed 'Trans proline' 0 C--N 1.318 -1.027 0 C-N-CA 122.465 2.11 . . . . 0.0 111.939 179.903 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.545 ' CB ' ' OD1' ' A' ' 48' ' ' ASN . . . -117.27 2.35 12.54 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.278 -1.514 . . . . 0.0 109.294 179.788 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.513 ' O ' ' O ' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -139.73 18.71 2.51 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 179.297 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -80.58 89.73 5.69 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.88 -0.728 . . . . 0.0 110.489 -179.078 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -113.65 -168.7 1.38 Allowed 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 178.647 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.471 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.5 134.96 0.08 Allowed 'General case' 0 C--N 1.305 -1.34 0 O-C-N 120.653 -1.28 . . . . 0.0 111.286 -179.337 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.575 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 1.3 p -149.09 158.71 6.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 177.966 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.537 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.19 145.69 26.35 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.75 -1.219 . . . . 0.0 109.908 -179.723 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.67 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -66.88 107.87 2.36 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-O 122.443 1.116 . . . . 0.0 109.369 178.577 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.527 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.9 p-10 -59.87 -139.47 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.829 179.996 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.64 -50.68 59.84 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.386 -0.821 . . . . 0.0 110.467 -178.775 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.5 t30 -103.63 -34.65 8.56 Favored 'General case' 0 C--N 1.285 -2.225 0 N-CA-C 106.379 -1.711 . . . . 0.0 106.379 178.481 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.67 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.5 67.92 0.62 Allowed Glycine 0 C--N 1.297 -1.584 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.055 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.613 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.8 m -103.36 126.16 50.37 Favored 'General case' 0 N--CA 1.484 1.254 0 O-C-N 121.717 -0.873 . . . . 0.0 108.677 178.817 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.575 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -134.87 108.86 8.14 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 119.714 -0.794 . . . . 0.0 109.511 -179.327 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 93.0 p -117.89 117.2 28.62 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 121.17 -0.956 . . . . 0.0 109.436 -179.99 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.454 HG21 HG13 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -141.85 135.31 29.44 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.467 -0.771 . . . . 0.0 109.957 179.979 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 10.0 p -100.36 133.13 45.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.423 -0.798 . . . . 0.0 108.848 179.511 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.58 ' N ' ' CD1' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -134.3 175.19 9.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.316 -0.865 . . . . 0.0 109.683 -178.917 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -100.16 125.0 46.23 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.006 -1.059 . . . . 0.0 109.702 -179.612 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.509 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.5 m -136.87 142.15 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 120.94 -1.1 . . . . 0.0 109.761 -179.495 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.562 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.4 ptt180 -138.43 -165.3 1.79 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.652 -1.28 . . . . 0.0 110.129 -179.911 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.579 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -74.87 -83.61 0.05 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.142 -0.974 . . . . 0.0 108.782 -179.615 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -62.82 138.86 58.64 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.361 -1.462 . . . . 0.0 107.228 178.668 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD1' ' O ' ' A' ' 71' ' ' ARG . 0.3 OUTLIER -164.54 135.11 4.1 Favored 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 117.933 -1.507 . . . . 0.0 110.533 -177.443 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.481 ' C ' ' O ' ' A' ' 73' ' ' PHE . 0.6 OUTLIER -31.82 121.02 0.28 Allowed 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.463 0.649 . . . . 0.0 110.483 -178.76 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.477 ' HA3' HG22 ' A' ' 86' ' ' VAL . . . -93.28 49.87 2.42 Favored Glycine 0 N--CA 1.494 2.537 0 C-N-CA 120.353 -0.927 . . . . 0.0 111.396 -179.062 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.587 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.4 m-30 -39.68 112.46 0.26 Allowed 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.027 -1.278 . . . . 0.0 109.998 179.306 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.536 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -84.62 127.18 33.94 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.906 -1.121 . . . . 0.0 109.791 -179.804 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.563 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 42.0 t80 -63.66 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.03 0 O-C-N 120.978 -1.077 . . . . 0.0 110.195 179.58 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.4 t0 -161.26 19.51 0.12 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.022 -1.049 . . . . 0.0 109.816 179.878 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.3 -26.68 5.49 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 179.866 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.419 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 22.8 p -93.9 157.53 16.08 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.975 -1.309 . . . . 0.0 110.302 -179.442 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.482 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 4.5 ptt180 -104.73 135.54 45.92 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.701 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.469 ' HB2' HD12 ' A' ' 77' ' ' LEU . 1.6 t90 -82.57 -17.76 43.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.716 -1.24 . . . . 0.0 110.423 -178.55 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.6 175.68 21.14 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 -179.57 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.59 109.14 1.3 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 179.037 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.564 HG12 ' CE1' ' A' ' 73' ' ' PHE . 35.2 t -81.39 104.77 10.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -178.864 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.457 ' HB3' HG21 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.09 111.9 3.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.448 -0.782 . . . . 0.0 109.885 -179.146 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.539 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -65.98 -4.44 7.1 Favored 'General case' 0 N--CA 1.499 1.992 0 C-N-CA 118.366 -1.334 . . . . 0.0 109.839 179.324 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 p -85.02 1.18 48.76 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.835 -1.166 . . . . 0.0 108.872 179.336 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.457 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -116.13 -49.86 2.68 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.401 -0.812 . . . . 0.0 109.047 -179.957 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.7 -179.49 3.95 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.512 -0.743 . . . . 0.0 109.464 179.916 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.99 115.46 30.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.883 . . . . 0.0 109.104 179.976 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.55 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.9 m -96.8 122.54 39.87 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.909 -1.12 . . . . 0.0 109.391 -179.5 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.542 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.31 146.28 27.76 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-O 122.393 1.092 . . . . 0.0 111.368 -179.216 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.53 ' CG1' HG12 ' A' ' 7' ' ' VAL . 53.4 t -102.5 109.64 27.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 177.419 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -148.64 -169.99 16.0 Favored Glycine 0 N--CA 1.485 1.932 0 C-N-CA 118.009 -2.043 . . . . 0.0 111.729 -177.362 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.443 HD11 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -117.75 -177.89 3.36 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -178.786 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.584 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.1 p -173.15 174.28 3.45 Favored 'General case' 0 C--N 1.295 -1.765 0 O-C-N 121.35 -0.844 . . . . 0.0 109.302 -179.251 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.523 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -121.36 -159.23 0.8 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.105 -0.997 . . . . 0.0 108.839 179.663 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.406 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.63 36.01 4.46 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.63 -1.293 . . . . 0.0 109.267 179.966 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.99 -33.28 4.22 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.426 -0.796 . . . . 0.0 110.299 -179.532 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.52 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . 166.76 -37.18 0.24 Allowed Glycine 0 N--CA 1.482 1.707 0 N-CA-C 107.599 -2.201 . . . . 0.0 107.599 -179.579 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.94 -178.15 7.03 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.617 -0.931 . . . . 0.0 109.826 179.288 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.87 -162.6 20.13 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 108.239 -1.945 . . . . 0.0 108.239 -179.433 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.609 ' CD ' ' CE2' ' A' ' 32' ' ' TYR . 7.3 Cg_exo -45.59 172.07 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.652 0 CA-C-N 118.92 1.36 . . . . 0.0 109.926 179.354 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -90.36 -171.43 3.09 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.107 -0.995 . . . . 0.0 110.42 -178.746 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -124.65 169.65 16.67 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.751 . . . . . . . . 1 1 . 1 . 056 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.81 133.95 47.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.48 -1.012 . . . . 0.0 109.061 -179.314 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.542 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.82 119.42 18.98 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.513 -0.742 . . . . 0.0 109.696 179.791 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.578 HD13 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -98.14 168.58 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 O-C-N 121.272 -0.892 . . . . 0.0 108.845 179.708 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.461 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -139.7 157.63 45.44 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.017 -1.052 . . . . 0.0 109.853 -179.717 . . . . . . . . 3 3 . 1 . 056 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.578 ' CE1' HD13 ' A' ' 110' ' ' ILE . 96.7 m-85 -130.64 142.79 50.45 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.236 -0.915 . . . . 0.0 109.506 -179.672 . . . . . . . . 2 2 . 1 . 056 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 p30 . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 117.971 -1.014 . . . . 0.0 109.524 179.983 . . . . . . . . 0 0 . 1 . 056 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.586 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 057 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -125.22 98.86 34.84 Favored Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.26 -0.9 . . . . 0.0 109.311 -179.935 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.523 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 6.2 Cg_exo -58.78 156.7 31.42 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.111 1.874 . . . . 0.0 110.496 -179.992 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.584 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -176.65 -169.52 0.28 Allowed 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.222 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.584 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.81 129.87 2.24 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 120.952 -1.092 . . . . 0.0 110.32 -178.983 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.552 ' CG2' ' O ' ' A' ' 6' ' ' THR . 4.3 t -116.36 108.71 16.4 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 123.167 1.46 . . . . 0.0 109.23 179.29 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.503 ' CG2' HG21 ' A' ' 21' ' ' VAL . 2.5 t -117.04 138.26 48.29 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.654 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.944 -179.604 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.52 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.5 149.88 1.39 Allowed Pre-proline 0 N--CA 1.485 1.308 0 O-C-N 121.298 -0.877 . . . . 0.0 108.757 -179.782 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.52 ' CA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -77.86 150.91 90.56 Favored 'Cis proline' 0 C--N 1.311 -1.427 0 C-N-CA 123.507 -1.455 . . . . 0.0 109.461 -0.786 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.453 ' HB2' ' HA ' ' A' ' 110' ' ' ILE . 71.1 p -88.31 -26.2 22.39 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.903 -0.776 . . . . 0.0 108.903 179.564 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.543 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 0.8 OUTLIER -132.75 168.74 17.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.449 -0.782 . . . . 0.0 109.499 179.649 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.93 38.79 48.11 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 108.36 -1.896 . . . . 0.0 108.36 -179.801 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.599 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 34.3 mt -94.11 -43.04 8.68 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 123.285 1.517 . . . . 0.0 110.67 -178.111 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.497 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.08 143.5 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.283 0 CA-C-N 113.408 -1.723 . . . . 0.0 109.766 -179.398 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.546 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 10.8 p-10 -49.95 105.47 0.09 Allowed 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 121.57 0.7 . . . . 0.0 111.753 -178.397 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.403 ' H ' ' HB3' ' A' ' 70' ' ' ARG . . . 113.23 15.68 8.86 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.33 -1.414 . . . . 0.0 113.081 177.158 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.599 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.3 t -104.24 -171.15 1.88 Allowed 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 121.235 2.517 . . . . 0.0 109.733 179.153 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.569 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 15.9 t -129.98 139.26 51.95 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.289 0 CA-C-N 114.943 -1.026 . . . . 0.0 111.309 -178.97 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.505 HG12 ' CG2' ' A' ' 69' ' ' VAL . 33.6 m -115.59 155.74 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.881 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.486 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -106.9 109.76 21.74 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.117 -0.989 . . . . 0.0 109.187 -179.929 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.516 HG12 ' CG2' ' A' ' 34' ' ' VAL . 1.9 p -103.35 139.74 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.404 -0.81 . . . . 0.0 108.842 179.978 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.561 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -132.55 157.8 43.79 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.829 -1.169 . . . . 0.0 109.608 179.426 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.585 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -138.99 108.71 0.62 Allowed Glycine 0 N--CA 1.482 1.74 0 N-CA-C 108.688 -1.765 . . . . 0.0 108.688 -179.964 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.51 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -114.36 142.04 46.85 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.889 -1.359 . . . . 0.0 110.858 -179.059 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 81.84 27.36 46.47 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.701 -1.237 . . . . 0.0 110.131 178.942 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.567 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.6 mt -89.52 173.99 8.02 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.008 -1.289 . . . . 0.0 108.705 -179.848 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.561 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.97 99.64 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.965 -1.085 . . . . 0.0 109.579 -179.598 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.543 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.24 77.22 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.196 -179.144 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.9 34.09 0.31 Allowed Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.549 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 78.0 p -144.04 111.02 5.73 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 120.965 -1.315 . . . . 0.0 111.045 -179.741 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.538 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -46.27 125.09 6.28 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.689 178.158 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.493 ' CD2' ' O ' ' A' ' 30' ' ' THR . 16.9 m-85 -116.11 150.82 36.75 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.889 . . . . 0.0 108.97 179.699 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.485 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -101.86 151.77 21.69 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 178.547 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.601 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.5 p -136.17 117.63 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.957 -1.09 . . . . 0.0 109.787 -177.904 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.479 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -165.01 -179.35 38.93 Favored Glycine 0 N--CA 1.494 2.5 0 C-N-CA 118.348 -1.882 . . . . 0.0 111.69 -179.576 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.597 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.6 pt20 -100.44 110.79 23.0 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.927 0.87 . . . . 0.0 108.744 -179.872 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.1 m -131.08 148.98 52.8 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.265 -0.897 . . . . 0.0 109.781 -179.756 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.39 138.19 54.61 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.261 -0.9 . . . . 0.0 110.675 -179.047 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.632 ' CE2' HD11 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.63 114.64 26.41 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 178.209 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 m -105.23 14.56 7.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.028 -1.045 . . . . 0.0 110.65 -178.693 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 173.98 -175.67 0.07 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.912 -1.118 . . . . 0.0 110.198 179.706 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.542 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.1 t -70.34 97.99 1.34 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 121.755 0.788 . . . . 0.0 110.001 -179.633 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.62 26.47 38.62 Favored Glycine 0 N--CA 1.493 2.494 0 C-N-CA 120.252 -0.975 . . . . 0.0 111.522 178.825 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.89 106.31 20.35 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.572 -1.546 . . . . 0.0 107.382 178.931 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.632 HD11 ' CE2' ' A' ' 39' ' ' TRP . 12.8 tp -118.05 104.69 11.1 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.494 -1.379 . . . . 0.0 109.77 -177.793 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.531 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.87 109.69 22.4 Favored 'General case' 0 N--CA 1.484 1.265 0 O-C-N 120.796 -1.19 . . . . 0.0 108.246 178.903 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.9 t -107.13 166.54 10.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.93 -1.106 . . . . 0.0 110.525 -178.692 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.491 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 12.4 t-20 -114.0 129.81 24.45 Favored Pre-proline 0 N--CA 1.499 2.005 0 O-C-N 121.424 -0.797 . . . . 0.0 109.697 -179.236 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.59 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -71.28 21.08 0.23 Allowed 'Trans proline' 0 CA--C 1.546 1.082 0 C-N-CA 121.953 1.769 . . . . 0.0 111.969 179.274 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -107.08 1.45 24.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.442 -1.411 . . . . 0.0 108.82 179.293 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.512 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.92 15.47 2.87 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 179.372 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -79.25 85.76 5.08 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.069 -178.49 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.601 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -101.59 -166.72 1.33 Allowed 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 178.128 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.45 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.36 138.35 0.09 Allowed 'General case' 0 C--N 1.305 -1.348 0 O-C-N 120.504 -1.373 . . . . 0.0 111.417 -179.178 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.604 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -157.47 156.7 4.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 178.135 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.538 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.1 m -97.88 144.75 27.13 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.747 -1.221 . . . . 0.0 109.884 -179.664 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.684 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.46 106.69 1.19 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 122.47 1.129 . . . . 0.0 109.44 178.61 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.523 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 16.9 p-10 -58.87 -138.62 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.621 179.848 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.543 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -56.38 -49.45 74.42 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.39 -0.819 . . . . 0.0 110.103 -178.976 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.406 ' CG ' ' N ' ' A' ' 61' ' ' GLY . 10.8 p-10 -98.21 -39.84 8.66 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 106.066 -1.827 . . . . 0.0 106.066 178.372 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.684 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 110.19 64.33 0.53 Allowed Glycine 0 C--N 1.296 -1.694 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.38 178.054 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.585 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 88.6 p -100.28 128.47 46.34 Favored 'General case' 0 C--N 1.309 -1.167 0 O-C-N 121.618 -0.93 . . . . 0.0 108.945 178.915 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.604 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -136.26 108.47 7.26 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.604 -0.839 . . . . 0.0 108.952 -179.814 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.466 ' OG ' ' HB1' ' A' ' 22' ' ' ALA . 1.5 m -128.64 121.33 28.37 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.288 -0.883 . . . . 0.0 109.977 -179.358 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.456 HG23 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -147.06 148.08 31.28 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.62 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 9.5 p -98.28 131.01 44.96 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.173 -0.955 . . . . 0.0 109.486 -179.737 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.512 ' CB ' ' HA ' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -127.23 164.52 21.51 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.507 -0.746 . . . . 0.0 109.338 -179.347 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.569 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.9 p -96.51 124.05 40.37 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.986 -1.071 . . . . 0.0 109.333 179.969 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.522 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.5 m -137.33 143.38 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 120.997 -1.064 . . . . 0.0 109.968 -179.211 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.546 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -141.52 -166.54 2.22 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.558 -1.338 . . . . 0.0 110.214 179.986 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.575 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -69.44 -89.13 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 119.687 -0.805 . . . . 0.0 108.837 -179.737 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.49 ' HB3' ' CG2' ' A' ' 85' ' ' THR . 0.9 OUTLIER -59.67 138.27 57.79 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 120.426 -1.421 . . . . 0.0 107.451 178.89 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.12 141.09 7.99 Favored 'General case' 0 C--N 1.294 -1.819 0 C-N-CA 118.148 -1.421 . . . . 0.0 110.351 -177.682 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.464 ' O ' ' O ' ' A' ' 47' ' ' CYS . 4.5 mm-40 -33.95 120.24 0.42 Allowed 'General case' 0 N--CA 1.491 1.62 0 CA-C-O 121.561 0.696 . . . . 0.0 110.7 -178.473 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.531 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -91.33 45.21 2.79 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.713 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.59 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -39.24 113.34 0.31 Allowed 'General case' 0 N--CA 1.508 2.474 0 O-C-N 121.099 -1.236 . . . . 0.0 110.298 179.782 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.527 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.6 tp -86.43 127.36 34.83 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 120.857 -1.152 . . . . 0.0 109.556 -179.972 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.578 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 18.5 t80 -64.23 58.09 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.955 0 O-C-N 120.815 -1.178 . . . . 0.0 110.286 179.849 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 77' ' ' LEU . 10.7 t0 -160.92 19.57 0.13 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.983 -1.073 . . . . 0.0 109.833 179.771 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -26.78 5.28 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.918 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -91.72 154.44 18.97 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 121.031 -1.276 . . . . 0.0 110.387 -179.471 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.473 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -102.87 131.91 49.45 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.634 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.474 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -79.89 -19.15 48.89 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.758 -1.214 . . . . 0.0 110.238 -178.635 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.24 175.05 20.13 Favored Glycine 0 N--CA 1.485 1.966 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 -179.529 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.49 ' CG2' ' HB3' ' A' ' 72' ' ' SER . 0.9 OUTLIER -63.49 110.29 1.91 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 106.903 -1.518 . . . . 0.0 106.903 178.851 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.549 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 40.1 t -81.28 104.36 9.71 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 O-C-N 121.345 -0.847 . . . . 0.0 109.162 -178.642 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.472 ' CB ' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -63.98 110.64 2.2 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.479 -0.763 . . . . 0.0 109.735 -179.414 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.536 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.61 -5.13 4.98 Favored 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 118.137 -1.425 . . . . 0.0 109.839 179.42 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -84.41 -0.7 53.73 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.834 -1.166 . . . . 0.0 108.932 179.306 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.472 HG23 ' CB ' ' A' ' 87' ' ' ASP . 2.4 p -112.66 -50.02 2.91 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.346 -0.847 . . . . 0.0 108.995 179.911 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.12 -179.88 4.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.491 -0.756 . . . . 0.0 109.572 179.96 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.91 116.12 31.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.365 -0.834 . . . . 0.0 109.103 -179.954 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -96.83 122.24 39.57 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.884 -1.135 . . . . 0.0 109.555 -179.484 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.531 ' HA ' ' O ' ' A' ' 108' ' ' VAL . 1.0 OUTLIER -102.76 149.59 24.32 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.383 1.087 . . . . 0.0 111.421 -179.149 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.511 ' CG2' HG22 ' A' ' 110' ' ' ILE . 47.2 t -102.07 111.12 30.73 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 177.194 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -145.18 -174.96 17.91 Favored Glycine 0 N--CA 1.486 1.975 0 C-N-CA 118.49 -1.814 . . . . 0.0 111.46 -177.56 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.485 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.12 -179.83 4.16 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -178.779 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.584 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.0 OUTLIER -173.48 172.46 3.68 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.501 -0.749 . . . . 0.0 109.063 -179.498 . . . . . . . . 3 3 . 1 . 057 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.478 ' O ' ' CB ' ' A' ' 100' ' ' ALA . 1.5 m-20 -106.87 -9.44 16.33 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.036 -1.04 . . . . 0.0 109.425 179.947 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.478 ' CB ' ' O ' ' A' ' 99' ' ' ASP . . . 73.81 39.41 0.54 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.365 -0.834 . . . . 0.0 109.135 179.927 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.61 -33.84 0.78 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.696 -0.627 . . . . 0.0 110.631 -179.4 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.444 ' CA ' H192 ' A' ' 114' ' ' CHR . . . 178.26 -40.4 0.09 OUTLIER Glycine 0 N--CA 1.482 1.755 0 N-CA-C 107.823 -2.111 . . . . 0.0 107.823 -179.625 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.17 -178.58 7.3 Favored 'General case' 0 C--N 1.308 -1.222 0 O-C-N 121.484 -1.01 . . . . 0.0 109.573 179.074 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -178.63 -166.45 34.8 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 108.495 -1.842 . . . . 0.0 108.495 -179.457 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.472 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.0 Cg_exo -50.22 -175.15 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.63 0 CA-C-N 118.843 1.321 . . . . 0.0 110.279 179.561 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.61 -173.66 2.81 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.119 -0.988 . . . . 0.0 110.076 -179.179 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -125.25 169.95 17.2 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.817 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.531 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -109.25 154.23 10.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -179.597 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.529 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -97.42 122.82 40.9 Favored 'General case' 0 C--N 1.291 -1.945 0 O-C-N 121.318 -0.864 . . . . 0.0 109.703 -179.888 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.518 ' CG1' ' O ' ' A' ' 93' ' ' CYS . 1.6 pt -98.26 168.97 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.213 -0.929 . . . . 0.0 109.033 179.83 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.543 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.7 m -142.52 155.91 45.08 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.05 -1.031 . . . . 0.0 109.811 179.979 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.575 ' CE2' ' HA ' ' A' ' 71' ' ' ARG . 31.4 m-85 -129.48 75.61 1.66 Allowed 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.138 -0.976 . . . . 0.0 109.539 -179.642 . . . . . . . . 2 2 . 1 . 057 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.427 ' O ' ' OD1' ' A' ' 113' ' ' ASN . 21.6 p30 . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 118.022 -0.989 . . . . 0.0 109.481 -179.979 . . . . . . . . 1 1 . 1 . 057 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.589 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 058 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.63 163.23 36.27 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.188 -0.945 . . . . 0.0 109.337 179.848 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.524 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.0 Cg_exo -60.17 155.27 46.46 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.213 1.942 . . . . 0.0 110.646 179.965 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.533 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -175.41 -169.6 0.38 Allowed 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.996 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.533 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.8 133.29 3.4 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.767 -1.208 . . . . 0.0 110.81 -179.0 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.54 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.2 p -105.01 104.4 14.13 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 122.435 1.112 . . . . 0.0 109.997 179.833 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.533 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 13.1 t -118.85 119.75 61.97 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.543 179.841 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.514 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.75 148.55 7.68 Favored Pre-proline 0 N--CA 1.486 1.352 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 -179.695 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.514 ' CA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -77.54 150.72 91.21 Favored 'Cis proline' 0 C--N 1.31 -1.476 0 C-N-CA 123.552 -1.437 . . . . 0.0 109.495 -0.458 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.483 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 80.4 p -89.29 -26.18 21.28 Favored 'General case' 0 C--N 1.293 -1.882 0 O-C-N 121.467 -0.77 . . . . 0.0 108.993 179.625 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.507 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 4.3 p -133.47 165.91 23.77 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.474 -0.766 . . . . 0.0 109.419 -179.941 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.7 38.27 37.51 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 -179.505 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.611 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 36.8 mt -92.56 -43.24 9.24 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 123.203 1.478 . . . . 0.0 110.624 -178.167 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.498 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 70.54 143.31 0.05 Allowed 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.453 -1.703 . . . . 0.0 109.774 -179.54 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.558 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 7.4 p-10 -50.57 104.59 0.08 Allowed 'General case' 0 C--N 1.301 -1.516 0 CA-C-O 121.558 0.694 . . . . 0.0 111.772 -178.447 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.409 ' H ' ' HB3' ' A' ' 70' ' ' ARG . . . 113.89 16.61 7.85 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 119.476 -1.345 . . . . 0.0 112.97 177.272 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.611 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 15.2 t -104.8 -171.23 1.88 Allowed 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 121.146 2.473 . . . . 0.0 109.693 179.11 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.575 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 16.4 t -130.37 140.02 49.9 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.246 -178.845 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.523 HG12 ' CG2' ' A' ' 69' ' ' VAL . 35.1 m -117.25 155.33 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 178.933 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.533 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.1 tttt -106.73 108.97 20.75 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.047 -1.033 . . . . 0.0 109.414 -179.817 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.528 HG12 ' CG2' ' A' ' 34' ' ' VAL . 2.1 p -107.47 123.13 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.723 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.54 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -114.67 164.49 13.97 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 120.745 -1.222 . . . . 0.0 108.938 179.82 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.581 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.56 107.51 0.53 Allowed Glycine 0 C--N 1.297 -1.628 0 N-CA-C 108.595 -1.802 . . . . 0.0 108.595 179.8 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -115.72 142.67 46.44 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.978 -1.307 . . . . 0.0 110.445 -179.134 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.524 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 82.03 27.26 45.97 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.577 -1.297 . . . . 0.0 109.93 179.357 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.545 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -90.84 174.24 7.56 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.069 -1.254 . . . . 0.0 108.574 179.974 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.553 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -46.42 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.966 -1.084 . . . . 0.0 109.517 -179.65 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.552 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -55.82 77.21 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.77 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.409 -178.97 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.553 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 132.7 34.66 0.34 Allowed Glycine 0 N--CA 1.487 2.066 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.407 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.54 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.0 p -145.0 112.54 6.2 Favored 'General case' 0 C--N 1.307 -1.272 0 O-C-N 121.031 -1.276 . . . . 0.0 111.083 -179.676 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.537 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -45.83 125.34 6.05 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-N 115.67 -0.695 . . . . 0.0 109.606 178.096 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.508 ' CZ ' ' OD2' ' A' ' 99' ' ' ASP . 11.8 m-85 -118.13 149.87 40.31 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.325 -0.86 . . . . 0.0 108.697 179.692 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.483 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.27 158.35 15.93 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.614 -1.304 . . . . 0.0 107.742 178.635 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.566 ' CG1' ' HB3' ' A' ' 53' ' ' SER . 7.2 p -142.12 112.24 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.035 -1.041 . . . . 0.0 109.897 -177.798 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.486 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -160.57 -178.86 34.93 Favored Glycine 0 N--CA 1.494 2.538 0 C-N-CA 118.524 -1.798 . . . . 0.0 111.722 -179.62 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.6 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.1 pt20 -101.31 110.75 22.81 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.82 0.819 . . . . 0.0 108.922 -179.82 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -131.45 148.69 52.67 Favored 'General case' 0 C--N 1.295 -1.791 0 O-C-N 121.286 -0.884 . . . . 0.0 109.672 179.893 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -120.97 137.59 54.55 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.174 -0.954 . . . . 0.0 110.803 -178.936 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.636 ' CE2' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.73 114.57 26.32 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.096 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -104.78 14.11 7.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 120.979 -1.076 . . . . 0.0 110.65 -178.738 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.593 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.17 -174.53 0.07 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.942 -1.099 . . . . 0.0 110.081 179.725 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.8 p -72.73 98.66 2.43 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.504 -0.748 . . . . 0.0 109.622 -179.729 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.11 26.37 34.26 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.222 -0.99 . . . . 0.0 111.553 178.939 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.593 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.3 t -116.64 106.04 19.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 O-C-N 120.47 -1.606 . . . . 0.0 107.413 178.918 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.636 HD13 ' CE2' ' A' ' 39' ' ' TRP . 13.4 tp -118.98 104.47 10.53 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.517 -1.365 . . . . 0.0 109.681 -177.896 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.5 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -97.93 109.57 22.3 Favored 'General case' 0 N--CA 1.485 1.279 0 O-C-N 120.852 -1.155 . . . . 0.0 108.063 178.9 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -105.88 165.06 11.46 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.966 -1.084 . . . . 0.0 110.599 -178.699 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.504 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 50.2 t30 -113.18 130.87 23.19 Favored Pre-proline 0 N--CA 1.499 2.023 0 O-C-N 121.558 -0.714 . . . . 0.0 109.714 -179.3 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.8 Cg_endo -71.85 22.2 0.26 Allowed 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 122.188 1.926 . . . . 0.0 112.288 -179.986 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.504 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -108.65 2.02 21.67 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.39 -1.444 . . . . 0.0 108.929 179.393 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.498 ' O ' ' O ' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -138.05 14.43 2.85 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 179.475 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -78.13 91.28 4.3 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.908 -0.717 . . . . 0.0 110.974 -178.475 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.566 ' HB3' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -114.09 -173.11 2.22 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 178.198 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.533 ' N ' ' OG ' ' A' ' 53' ' ' SER . 12.3 t 179.68 139.35 0.12 Allowed 'General case' 0 C--N 1.306 -1.285 0 O-C-N 120.534 -1.354 . . . . 0.0 111.303 -179.134 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.595 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -152.71 160.59 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 178.123 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.537 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -97.61 144.53 27.19 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.593 -1.317 . . . . 0.0 110.168 -179.387 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.673 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.7 107.2 1.36 Allowed 'General case' 0 C--N 1.301 -1.537 0 CA-C-O 122.44 1.114 . . . . 0.0 109.338 178.415 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.512 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 13.6 p-10 -58.53 -138.16 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.852 -179.8 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.552 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -54.58 -49.74 69.67 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.348 -0.845 . . . . 0.0 110.202 -178.771 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . 0.404 ' CG ' ' N ' ' A' ' 61' ' ' GLY . 9.9 p-10 -101.41 -38.97 7.78 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 178.454 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.673 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 111.74 65.74 0.51 Allowed Glycine 0 C--N 1.297 -1.587 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.211 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.581 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 21.0 m -105.42 124.03 48.87 Favored 'General case' 0 N--CA 1.483 1.214 0 O-C-N 121.686 -0.89 . . . . 0.0 108.734 179.005 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.595 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -133.52 109.35 9.2 Favored 'General case' 0 C--N 1.295 -1.788 0 C-N-CA 119.899 -0.72 . . . . 0.0 109.388 -179.395 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -116.5 118.28 32.23 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.178 -0.951 . . . . 0.0 109.273 -179.901 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.411 HG21 HG12 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -143.68 141.08 30.38 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.405 -0.809 . . . . 0.0 109.679 -179.907 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 21.3 p -99.36 130.75 45.66 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.441 -0.787 . . . . 0.0 109.277 179.9 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.513 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.1 OUTLIER -128.18 165.56 20.2 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.332 -0.855 . . . . 0.0 109.376 -179.503 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.575 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.8 p -96.75 123.23 40.38 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.103 -0.998 . . . . 0.0 109.213 179.953 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.523 ' CG2' HG12 ' A' ' 19' ' ' VAL . 16.3 m -135.96 142.13 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.118 -0.989 . . . . 0.0 109.899 -179.232 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.558 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.2 ptt180 -137.6 -166.12 1.89 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.62 -1.3 . . . . 0.0 110.097 -179.946 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.583 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -73.92 -83.57 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.27 -0.894 . . . . 0.0 108.665 -179.686 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.446 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.54 138.68 58.53 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.343 -1.473 . . . . 0.0 107.185 178.631 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' O ' ' A' ' 71' ' ' ARG . 0.2 OUTLIER -164.04 137.05 5.19 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 117.879 -1.528 . . . . 0.0 110.459 -177.434 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.508 ' OE1' ' N ' ' A' ' 75' ' ' GLY . 0.6 OUTLIER -34.29 121.49 0.48 Allowed 'General case' 0 N--CA 1.491 1.595 0 CA-C-O 121.478 0.656 . . . . 0.0 110.302 -178.584 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.508 ' N ' ' OE1' ' A' ' 74' ' ' GLU . . . -93.73 50.34 2.3 Favored Glycine 0 N--CA 1.494 2.544 0 C-N-CA 120.451 -0.881 . . . . 0.0 111.205 -179.223 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 4.1 m-30 -39.81 113.34 0.33 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.032 -1.275 . . . . 0.0 110.025 179.468 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.538 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.7 tp -84.7 127.1 33.93 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.884 -1.135 . . . . 0.0 109.638 -179.845 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.569 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 29.7 t80 -63.54 58.33 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.004 0 O-C-N 120.874 -1.141 . . . . 0.0 110.405 179.611 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.5 t0 -161.54 19.78 0.11 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.008 -1.057 . . . . 0.0 109.807 179.849 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.22 -26.91 5.31 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 110.171 -1.172 . . . . 0.0 110.171 179.937 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 37.0 p -92.95 156.26 17.04 Favored 'General case' 0 N--CA 1.486 1.36 0 O-C-N 121.031 -1.276 . . . . 0.0 110.332 -179.489 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.471 ' O ' ' HD2' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -104.49 133.75 48.83 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.707 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.477 ' HB2' HD12 ' A' ' 77' ' ' LEU . 1.6 t90 -80.26 -18.71 48.6 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.823 -1.173 . . . . 0.0 110.41 -178.566 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.93 175.93 20.97 Favored Glycine 0 N--CA 1.485 1.93 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -179.589 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -62.43 109.59 1.41 Allowed 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 179.138 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.55 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 31.4 t -82.54 105.39 12.33 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.967 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.468 ' CB ' HG22 ' A' ' 90' ' ' THR . 0.3 OUTLIER -65.76 112.32 3.66 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.402 -0.811 . . . . 0.0 109.904 -179.215 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.554 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.97 -4.79 4.96 Favored 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 118.208 -1.397 . . . . 0.0 109.863 179.398 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 p -85.71 -0.08 54.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.774 -1.204 . . . . 0.0 109.0 179.348 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.468 HG22 ' CB ' ' A' ' 87' ' ' ASP . 2.5 p -113.03 -49.71 2.91 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.297 -0.877 . . . . 0.0 109.063 179.949 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.8 179.77 4.13 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.581 -0.7 . . . . 0.0 109.505 179.93 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.93 115.7 31.11 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.301 -0.874 . . . . 0.0 109.219 -180.0 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.547 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.92 123.7 40.7 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.87 -1.143 . . . . 0.0 109.358 -179.469 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.535 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.52 148.46 25.93 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-O 122.446 1.117 . . . . 0.0 111.457 -179.171 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.496 ' CG1' HG12 ' A' ' 7' ' ' VAL . 61.8 t -102.4 109.66 27.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 N-CA-C 106.282 -1.748 . . . . 0.0 106.282 177.249 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -144.11 -175.41 17.22 Favored Glycine 0 N--CA 1.483 1.831 0 C-N-CA 118.318 -1.896 . . . . 0.0 111.563 -177.395 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.483 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -117.22 -177.82 3.3 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 -178.853 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.544 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 1.1 p -173.72 169.45 4.2 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.235 -0.916 . . . . 0.0 109.143 -179.26 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.508 ' OD2' ' CZ ' ' A' ' 32' ' ' TYR . 1.7 m-20 -106.91 -9.34 16.33 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.141 -0.975 . . . . 0.0 109.487 179.92 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.502 ' CB ' ' O ' ' A' ' 99' ' ' ASP . . . 75.18 37.61 0.46 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.41 -0.806 . . . . 0.0 109.116 179.947 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.11 -34.69 0.79 Allowed 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.572 -0.705 . . . . 0.0 110.616 -179.434 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.46 ' CA ' H193 ' A' ' 114' ' ' CHR . . . 179.85 -41.95 0.08 OUTLIER Glycine 0 N--CA 1.482 1.712 0 N-CA-C 107.699 -2.16 . . . . 0.0 107.699 -179.665 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.59 -178.68 7.44 Favored 'General case' 0 C--N 1.308 -1.198 0 O-C-N 121.415 -1.05 . . . . 0.0 109.866 179.118 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -177.67 -166.52 34.43 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 108.194 -1.962 . . . . 0.0 108.194 -179.477 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.47 ' HB2' HD11 ' A' ' 97' ' ' LEU . 5.4 Cg_exo -48.42 179.26 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.659 0 CA-C-N 118.94 1.37 . . . . 0.0 110.148 179.483 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -91.85 -175.2 4.06 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.055 -1.028 . . . . 0.0 110.516 -178.717 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -122.05 161.7 16.1 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.848 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.62 133.09 49.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.364 -1.08 . . . . 0.0 109.278 -179.242 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.535 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -76.04 122.09 23.73 Favored 'General case' 0 C--N 1.289 -2.054 0 O-C-N 121.485 -0.76 . . . . 0.0 109.716 179.703 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.566 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.99 174.0 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.924 . . . . 0.0 109.23 179.837 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.507 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.6 OUTLIER -140.21 158.19 44.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.048 -1.032 . . . . 0.0 109.838 -179.778 . . . . . . . . 3 3 . 1 . 058 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.566 ' CE2' HD12 ' A' ' 110' ' ' ILE . 96.5 m-85 -135.08 131.18 36.64 Favored 'General case' 0 N--CA 1.485 1.282 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 -179.808 . . . . . . . . 2 2 . 1 . 058 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.407 ' C ' ' O ' ' A' ' 112' ' ' PHE . 21.4 p30 . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.533 -179.967 . . . . . . . . 1 1 . 1 . 058 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.585 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 121.296 0.57 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 059 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -113.06 157.03 41.92 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.245 -0.909 . . . . 0.0 109.471 -179.993 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.542 ' CB ' ' O ' ' A' ' 25' ' ' GLY . 5.7 Cg_exo -59.98 157.95 31.72 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 122.314 2.01 . . . . 0.0 110.608 179.948 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.557 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -173.71 -169.23 0.48 Allowed 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 178.989 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.557 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.6 133.84 3.68 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 120.745 -1.222 . . . . 0.0 110.757 -179.156 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.546 ' OG1' ' CB ' ' A' ' 22' ' ' ALA . 2.1 p -105.41 104.62 14.38 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 122.558 1.17 . . . . 0.0 109.911 179.983 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.531 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 14.5 t -118.97 126.34 75.27 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.407 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.535 179.875 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.487 HG21 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -170.57 149.37 2.99 Favored Pre-proline 0 N--CA 1.486 1.361 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 -179.642 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG21 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.64 153.23 99.05 Favored 'Cis proline' 0 C--N 1.31 -1.465 0 C-N-CA 123.678 -1.384 . . . . 0.0 109.894 -0.522 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.464 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 6.6 m -95.73 -22.6 17.43 Favored 'General case' 0 C--N 1.294 -1.846 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 179.564 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.43 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.9 m -135.59 162.85 31.55 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.491 -0.756 . . . . 0.0 109.496 179.921 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.11 37.6 37.23 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 108.503 -1.839 . . . . 0.0 108.503 -179.556 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.637 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 27.3 mt -90.59 -45.47 8.89 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-O 123.116 1.436 . . . . 0.0 110.644 -178.373 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 63.82 147.24 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.325 0 CA-C-N 113.69 -1.596 . . . . 0.0 109.974 -179.699 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.595 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -51.48 109.33 0.34 Allowed 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 121.556 0.694 . . . . 0.0 111.721 -178.652 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.04 12.98 11.42 Favored Glycine 0 N--CA 1.485 1.966 0 C-N-CA 119.478 -1.344 . . . . 0.0 112.873 177.339 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.637 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 9.7 t -101.42 -174.35 2.58 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 121.057 2.428 . . . . 0.0 109.763 179.479 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.546 ' CG1' ' O ' ' A' ' 67' ' ' LEU . 14.8 t -131.28 138.48 53.14 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.38 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.813 -178.982 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.494 ' CG1' ' CG2' ' A' ' 69' ' ' VAL . 35.0 m -117.43 154.4 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.365 -0.835 . . . . 0.0 109.135 179.082 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.531 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -110.12 109.25 19.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.957 . . . . 0.0 109.149 179.881 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.537 HG12 ' CD1' ' A' ' 67' ' ' LEU . 2.4 p -107.39 124.6 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.964 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.546 ' CB ' ' OG1' ' A' ' 6' ' ' THR . . . -114.08 165.08 13.0 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.845 -1.159 . . . . 0.0 108.858 179.489 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.618 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.39 107.5 0.53 Allowed Glycine 0 C--N 1.296 -1.692 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 179.971 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.494 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -116.41 141.09 48.63 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 120.743 -1.445 . . . . 0.0 110.796 -179.072 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.542 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 83.09 26.5 44.29 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.033 179.145 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -90.35 172.29 8.85 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.028 -1.278 . . . . 0.0 108.575 -179.992 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.559 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -45.18 99.97 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.081 -1.012 . . . . 0.0 109.652 -179.685 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.0 76.96 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.118 -179.036 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.41 33.39 0.27 Allowed Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.517 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.531 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 54.1 p -141.14 109.47 5.88 Favored 'General case' 0 C--N 1.307 -1.25 0 O-C-N 121.015 -1.285 . . . . 0.0 111.152 -179.714 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.562 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -50.94 110.08 0.39 Allowed 'General case' 0 N--CA 1.496 1.858 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.909 178.314 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.535 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 18.6 m-85 -104.25 154.76 19.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.146 -0.971 . . . . 0.0 108.74 179.396 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.469 ' HB3' H312 ' A' ' 114' ' ' CHR . 0.3 OUTLIER -98.96 165.23 11.85 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 178.545 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.62 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.0 p -143.4 120.47 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.092 -1.005 . . . . 0.0 109.493 -177.807 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -168.75 179.91 41.32 Favored Glycine 0 N--CA 1.491 2.312 0 C-N-CA 118.264 -1.922 . . . . 0.0 111.614 -179.806 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.618 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -101.96 109.79 21.6 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.715 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 58.2 m -128.87 152.75 48.17 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.347 -0.846 . . . . 0.0 110.319 -179.828 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.52 136.36 51.63 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.64 -0.662 . . . . 0.0 110.126 179.65 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.631 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.4 114.73 26.81 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 178.369 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -106.6 15.3 7.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 120.964 -1.085 . . . . 0.0 110.762 -178.636 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.596 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.24 -175.63 0.08 Allowed 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.894 -1.129 . . . . 0.0 110.112 179.604 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.551 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.3 t -69.63 97.0 0.99 Allowed 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.741 0.781 . . . . 0.0 110.02 -179.404 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.8 28.46 34.95 Favored Glycine 0 N--CA 1.492 2.415 0 C-N-CA 120.225 -0.988 . . . . 0.0 111.38 178.694 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.596 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.09 106.09 19.9 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 O-C-N 120.531 -1.57 . . . . 0.0 107.432 178.836 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.631 HD12 ' CD1' ' A' ' 39' ' ' TRP . 11.8 tp -116.31 106.66 13.9 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.541 -1.349 . . . . 0.0 109.941 -177.552 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.55 ' CB ' ' CA ' ' A' ' 75' ' ' GLY . . . -95.93 110.12 22.38 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 120.759 -1.213 . . . . 0.0 108.028 179.186 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 68.2 m -98.91 144.91 27.56 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.259 -0.901 . . . . 0.0 110.846 -178.132 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.511 ' ND2' ' HG2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.48 131.08 48.95 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.415 -0.803 . . . . 0.0 109.076 179.299 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.58 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 6.8 Cg_endo -75.68 31.02 0.38 Allowed 'Trans proline' 0 C--N 1.314 -1.266 0 C-N-CA 122.267 1.978 . . . . 0.0 111.323 179.898 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.465 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . -122.14 -1.69 9.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.42 -1.425 . . . . 0.0 110.299 -179.231 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.542 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 20.4 m-20 -137.55 10.31 2.93 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.039 -1.038 . . . . 0.0 109.115 -179.68 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -64.0 84.1 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.292 -179.108 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.62 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -110.82 -169.0 1.38 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.164 -0.96 . . . . 0.0 108.557 179.081 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.467 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.32 135.22 0.08 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.783 -1.198 . . . . 0.0 111.288 -179.348 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.587 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -147.48 159.29 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 177.915 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.29 142.96 29.29 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.707 -1.245 . . . . 0.0 110.246 -179.52 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.666 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -64.75 107.08 1.34 Allowed 'General case' 0 C--N 1.299 -1.593 0 CA-C-O 122.404 1.097 . . . . 0.0 109.367 178.323 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.526 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.5 t0 -60.59 -138.97 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.039 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.022 -179.889 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.72 -51.11 53.06 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.427 -0.796 . . . . 0.0 110.66 -178.552 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 11.9 t30 -104.19 -34.28 8.43 Favored 'General case' 0 C--N 1.286 -2.185 0 N-CA-C 106.182 -1.785 . . . . 0.0 106.182 178.472 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.666 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 108.72 67.93 0.61 Allowed Glycine 0 C--N 1.296 -1.647 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 178.182 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.618 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.8 m -104.67 124.48 49.44 Favored 'General case' 0 N--CA 1.483 1.194 0 O-C-N 121.612 -0.934 . . . . 0.0 108.739 179.004 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.587 ' CB ' ' CG1' ' A' ' 55' ' ' VAL . . . -132.88 109.21 9.45 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.906 -0.718 . . . . 0.0 109.223 -179.609 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.46 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 14.7 m -118.37 118.77 32.66 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.302 -0.874 . . . . 0.0 109.611 -179.621 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.424 HG22 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.86 140.29 28.27 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.505 -0.747 . . . . 0.0 109.684 179.805 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 66' ' ' SER . . . . . 0.427 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 19.2 p -98.83 136.05 39.4 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.466 -0.771 . . . . 0.0 109.079 179.758 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.546 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -133.35 173.79 11.09 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.339 -0.851 . . . . 0.0 109.687 -178.887 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.523 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -100.18 125.01 46.27 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.933 -1.105 . . . . 0.0 109.01 179.918 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.532 ' CG2' HD11 ' A' ' 13' ' ' LEU . 15.9 m -132.19 142.13 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 120.764 -1.21 . . . . 0.0 110.06 -178.986 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.595 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.9 ptt180 -147.71 -170.48 3.58 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 120.563 -1.336 . . . . 0.0 110.827 -179.945 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.614 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -67.22 -102.68 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.821 -0.549 . . . . 0.0 109.932 -179.329 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.08 134.98 56.92 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.359 -1.463 . . . . 0.0 108.152 179.714 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.618 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -153.78 156.92 38.6 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.584 -1.246 . . . . 0.0 110.298 -178.683 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.539 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 1.6 mm-40 -53.15 119.4 4.67 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.277 -0.889 . . . . 0.0 109.368 -178.736 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.55 ' CA ' ' CB ' ' A' ' 46' ' ' ALA . . . -90.39 54.04 3.5 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.311 -178.9 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.58 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 5.3 m-30 -40.35 115.92 0.61 Allowed 'General case' 0 N--CA 1.504 2.271 0 O-C-N 120.947 -1.325 . . . . 0.0 110.173 179.487 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.529 ' O ' ' N ' ' A' ' 79' ' ' ASP . 8.1 tp -87.46 126.85 35.14 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 120.806 -1.184 . . . . 0.0 109.488 -179.834 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.58 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 24.8 t80 -64.18 58.38 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.972 0 O-C-N 120.837 -1.165 . . . . 0.0 110.132 179.702 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.4 t70 -160.37 19.66 0.15 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.028 -1.045 . . . . 0.0 109.717 179.772 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.75 -27.44 5.36 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 179.856 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 46.4 p -94.9 162.44 13.75 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 120.98 -1.306 . . . . 0.0 110.402 -179.46 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.47 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 2.2 ptm180 -108.14 138.0 45.15 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.921 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.473 ' HB2' HD12 ' A' ' 77' ' ' LEU . 2.9 t90 -83.4 -18.6 38.21 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.769 -1.207 . . . . 0.0 110.443 -178.656 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.99 175.05 19.79 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 108.766 -1.734 . . . . 0.0 108.766 -179.632 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.94 106.2 0.98 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.119 -1.224 . . . . 0.0 107.898 179.227 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.618 ' HB ' ' CE1' ' A' ' 73' ' ' PHE . 40.7 t -78.25 104.35 6.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.021 -179.041 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.526 ' CB ' HG22 ' A' ' 90' ' ' THR . 0.5 OUTLIER -62.99 107.9 1.1 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.55 -0.719 . . . . 0.0 110.164 -179.141 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.566 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.4 t -61.42 -4.26 1.23 Allowed 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.255 -1.378 . . . . 0.0 110.38 179.298 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.2 p -90.98 7.09 42.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.562 -1.336 . . . . 0.0 109.407 -179.933 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.526 HG22 ' CB ' ' A' ' 87' ' ' ASP . 2.2 p -119.35 -47.76 2.44 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.292 -0.88 . . . . 0.0 109.16 179.941 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.6 -178.4 3.64 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.562 -0.711 . . . . 0.0 109.589 179.988 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.81 111.99 24.58 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.381 -0.824 . . . . 0.0 108.856 179.859 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.471 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.5 m -97.22 121.06 38.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.036 -1.04 . . . . 0.0 109.445 -178.966 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.559 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.17 147.36 27.12 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.474 1.13 . . . . 0.0 111.646 -179.05 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.484 ' CG1' HG11 ' A' ' 7' ' ' VAL . 92.3 t -102.95 109.65 27.38 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 177.259 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.453 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.84 -169.45 17.37 Favored Glycine 0 N--CA 1.484 1.88 0 C-N-CA 118.073 -2.013 . . . . 0.0 111.628 -177.258 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.487 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -121.24 176.8 5.43 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -178.897 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.592 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 6.9 t 176.84 159.71 0.36 Allowed 'General case' 0 C--N 1.292 -1.897 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 -179.963 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.535 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -103.49 -158.49 0.67 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.91 -1.119 . . . . 0.0 109.29 -179.855 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.442 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.22 36.22 4.33 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.788 -1.195 . . . . 0.0 109.238 179.984 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.89 -32.6 6.56 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.366 -0.834 . . . . 0.0 109.796 -179.736 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.431 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . 169.02 -37.94 0.2 Allowed Glycine 0 N--CA 1.481 1.666 0 N-CA-C 107.992 -2.043 . . . . 0.0 107.992 -179.78 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.54 -177.08 3.82 Favored 'General case' 0 C--N 1.307 -1.262 0 O-C-N 121.574 -0.957 . . . . 0.0 109.984 179.395 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.56 -161.41 21.1 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 108.068 -2.013 . . . . 0.0 108.068 -179.397 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.9 Cg_exo -45.77 172.63 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.632 0 CA-C-N 118.978 1.389 . . . . 0.0 109.933 179.194 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -92.9 -174.49 3.61 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.092 -1.005 . . . . 0.0 110.56 -178.772 . . . . . . . . 1 1 . 1 . 059 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.453 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.48 166.31 14.35 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.876 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.424 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.0 131.16 50.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.416 -1.049 . . . . 0.0 109.124 -179.428 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.559 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.61 123.77 24.63 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.594 -0.691 . . . . 0.0 109.519 179.713 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.51 HD11 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.84 171.74 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.232 -0.917 . . . . 0.0 109.183 179.901 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.43 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -138.15 157.78 45.62 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.279 -0.888 . . . . 0.0 109.92 -179.712 . . . . . . . . 3 3 . 1 . 059 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.51 ' CE1' HD11 ' A' ' 110' ' ' ILE . 38.8 m-85 -129.77 98.62 4.86 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.273 -0.892 . . . . 0.0 109.543 -179.741 . . . . . . . . 2 2 . 1 . 059 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 24.7 p30 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 118.048 -0.977 . . . . 0.0 109.462 -179.97 . . . . . . . . 0 0 . 1 . 059 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.592 ' C21' ' CB ' ' A' ' 98' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 060 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -103.41 161.75 22.12 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.268 -0.895 . . . . 0.0 109.446 -179.978 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.515 ' HA ' ' C ' ' A' ' 25' ' ' GLY . 4.1 Cg_exo -60.5 157.25 37.38 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.322 2.014 . . . . 0.0 110.52 -179.987 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -149.82 160.59 43.44 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -179.532 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.63 122.57 9.39 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 122.454 1.121 . . . . 0.0 110.452 -179.675 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 6' ' ' THR . . . . . 0.544 ' CG2' ' O ' ' A' ' 6' ' ' THR . 6.3 t -115.58 109.24 17.5 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.123 1.44 . . . . 0.0 109.72 -179.935 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 20' ' ' LYS . 1.1 t -114.53 135.75 53.35 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.285 -1.325 . . . . 0.0 109.582 179.886 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.524 HG23 ' CA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.69 150.42 2.62 Favored Pre-proline 0 N--CA 1.487 1.407 0 O-C-N 121.151 -0.968 . . . . 0.0 108.95 -179.639 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.524 ' CA ' HG23 ' A' ' 8' ' ' THR . 6.0 Cg_endo -78.63 150.2 86.86 Favored 'Cis proline' 0 C--N 1.313 -1.305 0 C-N-CA 123.392 -1.503 . . . . 0.0 109.341 -0.965 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.457 ' O ' ' CB ' ' A' ' 110' ' ' ILE . 84.6 p -92.91 -22.65 19.11 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.552 -0.718 . . . . 0.0 109.306 179.894 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 11' ' ' SER . . . . . 0.493 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 4.3 m -130.91 159.64 36.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.345 -0.847 . . . . 0.0 109.644 -179.838 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.55 37.34 31.13 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 108.542 -1.823 . . . . 0.0 108.542 -179.676 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.598 ' HB3' ' CG2' ' A' ' 17' ' ' THR . 33.6 mt -90.92 -44.29 9.46 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 123.14 1.447 . . . . 0.0 110.691 -178.479 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.478 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.26 144.41 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.249 0 CA-C-N 113.555 -1.657 . . . . 0.0 109.687 -179.538 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.59 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.4 p-10 -51.54 109.24 0.33 Allowed 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.495 0.664 . . . . 0.0 111.483 -178.612 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.43 10.85 12.56 Favored Glycine 0 N--CA 1.485 1.955 0 C-N-CA 119.391 -1.385 . . . . 0.0 112.83 177.374 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.598 ' CG2' ' HB3' ' A' ' 13' ' ' LEU . 12.9 t -101.97 -171.37 1.96 Allowed 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 121.051 2.425 . . . . 0.0 109.876 179.575 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.535 ' HA ' ' HA ' ' A' ' 68' ' ' THR . 19.1 t -131.19 142.41 43.53 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.76 -179.058 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.474 HG23 ' CG2' ' A' ' 69' ' ' VAL . 35.4 m -118.55 155.58 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.277 -0.889 . . . . 0.0 108.764 179.209 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 6.1 tttt -108.02 109.23 20.64 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.162 -0.961 . . . . 0.0 109.288 -179.984 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.532 HG12 ' CG2' ' A' ' 34' ' ' VAL . 10.4 p -101.36 138.92 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.71 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.595 ' HA ' ' O ' ' A' ' 63' ' ' ALA . . . -135.68 161.24 36.11 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 118.698 -1.201 . . . . 0.0 110.127 179.689 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.94 140.92 12.0 Favored Glycine 0 C--O 1.209 -1.444 0 N-CA-C 107.928 -2.069 . . . . 0.0 107.928 179.621 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.597 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -143.06 125.05 15.21 Favored 'General case' 0 N--CA 1.494 1.756 0 CA-C-N 119.266 1.533 . . . . 0.0 109.395 179.387 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.515 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.64 28.22 19.75 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 118.755 -1.688 . . . . 0.0 109.619 -179.728 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.552 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.6 mt -88.74 171.32 10.06 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.866 -1.373 . . . . 0.0 108.089 179.906 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.555 ' O ' ' N ' ' A' ' 29' ' ' GLY . 0.0 OUTLIER -44.79 100.25 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.901 -1.124 . . . . 0.0 109.981 -179.424 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.58 77.21 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.946 -179.347 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.01 33.88 0.24 Allowed Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.717 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.556 ' OG1' ' CE1' ' A' ' 32' ' ' TYR . 36.3 p -141.26 107.47 5.23 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.082 -1.246 . . . . 0.0 111.311 -179.422 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . 0.555 ' CA ' ' OG1' ' A' ' 56' ' ' THR . . . -49.49 109.78 0.31 Allowed 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 177.93 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . 0.58 ' CG ' ' O ' ' A' ' 98' ' ' SER . 4.4 m-30 -101.24 156.1 17.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.168 -0.957 . . . . 0.0 109.009 179.83 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.479 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -99.98 163.71 12.32 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 178.503 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.618 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.4 p -147.77 117.85 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.891 -1.131 . . . . 0.0 110.05 -177.928 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.478 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -171.28 -175.91 40.04 Favored Glycine 0 N--CA 1.494 2.501 0 C-N-CA 118.346 -1.883 . . . . 0.0 111.724 -179.862 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . 0.563 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -100.42 108.87 20.97 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.748 0.785 . . . . 0.0 108.946 -179.818 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.39 148.27 52.19 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.269 -0.894 . . . . 0.0 109.676 179.431 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -121.19 137.55 54.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.265 -0.897 . . . . 0.0 110.932 -178.839 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 39' ' ' TRP . . . . . 0.628 ' CD1' HD12 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.64 114.68 26.45 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.114 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.465 HG21 ' HB ' ' A' ' 44' ' ' VAL . 15.0 m -105.03 14.4 7.24 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 120.95 -1.094 . . . . 0.0 110.573 -178.715 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.592 ' CB ' ' CG2' ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.03 -175.36 0.07 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.987 -1.071 . . . . 0.0 110.091 179.729 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.546 ' O ' ' CG2' ' A' ' 42' ' ' THR . 15.0 t -71.69 99.05 2.04 Favored 'General case' 0 N--CA 1.486 1.347 0 CA-C-O 121.829 0.823 . . . . 0.0 109.812 -179.641 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.77 26.57 37.71 Favored Glycine 0 N--CA 1.494 2.549 0 C-N-CA 120.179 -1.01 . . . . 0.0 111.46 178.957 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.592 ' CG2' ' CB ' ' A' ' 41' ' ' ASP . 1.4 t -116.16 106.25 19.98 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 O-C-N 120.576 -1.544 . . . . 0.0 107.356 178.891 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . 0.628 HD12 ' CD1' ' A' ' 39' ' ' TRP . 13.2 tp -117.93 104.34 10.82 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.471 -1.393 . . . . 0.0 109.73 -177.694 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.534 ' HB2' ' CA ' ' A' ' 75' ' ' GLY . . . -97.73 109.66 22.37 Favored 'General case' 0 N--CA 1.485 1.311 0 O-C-N 120.776 -1.203 . . . . 0.0 108.07 178.88 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -107.26 163.35 13.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.016 -1.053 . . . . 0.0 110.467 -178.705 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.517 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 17.0 t30 -111.29 136.77 20.91 Favored Pre-proline 0 N--CA 1.502 2.136 0 O-C-N 121.414 -0.803 . . . . 0.0 109.75 -179.463 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.577 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.7 Cg_endo -73.57 25.67 0.32 Allowed 'Trans proline' 0 C--N 1.319 -1.007 0 C-N-CA 122.463 2.109 . . . . 0.0 112.335 -179.63 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . 0.501 ' HB3' ' CG2' ' A' ' 68' ' ' THR . . . -112.66 3.07 16.41 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.272 -1.518 . . . . 0.0 109.326 179.588 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.489 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.45 18.97 2.22 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 179.592 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -79.94 92.06 5.5 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.867 -0.733 . . . . 0.0 110.866 -178.867 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 53' ' ' SER . . . . . 0.618 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -114.47 -168.85 1.43 Allowed 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 178.367 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.471 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.9 134.88 0.09 Allowed 'General case' 0 C--N 1.304 -1.372 0 O-C-N 120.597 -1.315 . . . . 0.0 111.214 -179.402 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.572 ' CG1' ' CB ' ' A' ' 63' ' ' ALA . 2.0 p -148.98 157.2 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.233 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.555 ' OG1' ' CA ' ' A' ' 31' ' ' ALA . 1.2 m -98.26 142.62 29.69 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.709 -1.244 . . . . 0.0 109.874 -179.85 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . 0.673 ' CA ' ' HA2' ' A' ' 61' ' ' GLY . . . -65.36 108.15 1.86 Allowed 'General case' 0 C--N 1.299 -1.626 0 CA-C-O 122.337 1.065 . . . . 0.0 109.649 178.706 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.535 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.1 t0 -63.84 -138.8 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.003 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.816 179.888 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.81 -52.04 45.07 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.361 -0.837 . . . . 0.0 110.697 -178.677 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -101.74 -33.6 9.78 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 178.517 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.673 ' HA2' ' CA ' ' A' ' 57' ' ' ALA . . . 104.51 65.92 0.69 Allowed Glycine 0 C--N 1.298 -1.532 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 178.221 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 55.9 p -98.53 132.41 43.98 Favored 'General case' 0 N--CA 1.482 1.153 0 O-C-N 121.489 -1.007 . . . . 0.0 109.177 179.074 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.595 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -138.63 108.57 6.33 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 119.255 -0.978 . . . . 0.0 109.567 -179.658 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.458 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 6.0 m -127.11 120.32 28.6 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.272 -0.892 . . . . 0.0 109.681 -179.878 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.447 HG22 HG12 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.09 142.72 28.81 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.55 -0.719 . . . . 0.0 109.277 179.794 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.9 p -98.81 131.69 44.74 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.287 -0.883 . . . . 0.0 109.212 179.985 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.518 ' O ' ' CG1' ' A' ' 18' ' ' VAL . 0.0 OUTLIER -135.6 169.4 17.59 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.288 -0.882 . . . . 0.0 109.569 -179.349 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 68' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 11.3 t -95.29 137.74 33.93 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.091 -1.006 . . . . 0.0 110.559 -179.425 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.511 ' CB ' ' OE1' ' A' ' 36' ' ' GLN . 18.3 m -148.24 143.55 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.381 -0.824 . . . . 0.0 109.536 -179.891 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.59 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.0 OUTLIER -149.95 -174.65 4.77 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.497 -1.377 . . . . 0.0 110.807 -179.863 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 71' ' ' ARG . . . . . 0.569 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.86 -102.06 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.414 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.637 -179.458 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -56.49 141.89 40.97 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.831 -1.168 . . . . 0.0 108.577 179.814 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -163.34 137.26 5.91 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 118.836 -1.146 . . . . 0.0 109.633 -178.402 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.517 ' N ' ' OD1' ' A' ' 48' ' ' ASN . 17.4 mm-40 -33.56 122.1 0.42 Allowed 'General case' 0 N--CA 1.49 1.571 0 CA-C-O 121.559 0.695 . . . . 0.0 110.78 -178.12 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.534 ' CA ' ' HB2' ' A' ' 46' ' ' ALA . . . -91.32 46.91 2.83 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.321 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 76' ' ' PHE . . . . . 0.577 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.1 m-85 -39.64 112.02 0.23 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.073 -1.251 . . . . 0.0 109.856 179.568 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . 0.545 ' O ' ' N ' ' A' ' 79' ' ' ASP . 7.9 tp -85.46 126.44 33.82 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.895 -1.128 . . . . 0.0 109.37 -179.927 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . 0.578 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 37.5 t80 -63.89 58.39 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.933 -1.104 . . . . 0.0 110.168 179.833 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 4.9 t70 -160.38 19.3 0.14 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.037 -1.039 . . . . 0.0 109.709 179.913 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.51 -26.5 5.74 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 179.808 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 60.5 p -94.06 158.63 15.53 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.033 -1.275 . . . . 0.0 110.418 -179.346 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.464 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -105.08 133.43 49.87 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.698 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 83' ' ' TRP . . . . . 0.476 ' CD1' HD13 ' A' ' 77' ' ' LEU . 1.9 t90 -81.43 -18.9 43.76 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.883 -1.135 . . . . 0.0 110.37 -178.573 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.34 174.83 19.57 Favored Glycine 0 N--CA 1.485 1.962 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.653 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.1 105.96 0.97 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.112 -1.228 . . . . 0.0 107.72 179.085 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.578 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 43.6 t -76.95 105.99 6.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.306 -0.871 . . . . 0.0 109.27 -178.824 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -66.4 111.14 3.39 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.359 -0.838 . . . . 0.0 109.821 -179.524 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 88' ' ' CYS . . . . . 0.569 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -62.74 -6.09 3.34 Favored 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 118.225 -1.39 . . . . 0.0 109.875 179.42 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -86.13 -1.26 57.24 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.716 -1.24 . . . . 0.0 109.163 179.63 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.453 HG21 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.47 -49.6 2.99 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.338 -0.851 . . . . 0.0 109.005 179.905 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.27 179.15 4.34 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.415 -0.803 . . . . 0.0 109.438 179.924 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.54 116.22 32.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.322 -0.861 . . . . 0.0 108.952 179.928 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 93' ' ' CYS . . . . . 0.564 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.72 124.7 40.78 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.815 -1.178 . . . . 0.0 109.535 -179.478 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 94' ' ' GLN . . . . . 0.551 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -105.15 147.87 27.49 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 122.515 1.15 . . . . 0.0 111.451 -179.152 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . 0.42 HG21 HG22 ' A' ' 110' ' ' ILE . 57.6 t -104.49 110.55 30.93 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.04 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 177.43 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -148.47 -171.29 17.18 Favored Glycine 0 N--CA 1.488 2.157 0 C-N-CA 118.123 -1.989 . . . . 0.0 111.89 -177.562 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . 0.479 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.77 -179.62 3.74 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.023 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.58 ' O ' ' CG ' ' A' ' 32' ' ' TYR . 1.5 p -156.1 177.19 11.71 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.367 -0.833 . . . . 0.0 109.715 -179.524 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 99' ' ' ASP . . . . . 0.566 ' OD2' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -107.25 -16.27 14.45 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.387 -0.821 . . . . 0.0 109.274 179.811 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 100' ' ' ALA . . . . . 0.5 ' CB ' ' O ' ' A' ' 99' ' ' ASP . . . 76.77 36.02 0.37 Allowed 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.55 -0.718 . . . . 0.0 109.218 -179.83 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -143.13 -34.68 0.42 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.588 -0.695 . . . . 0.0 110.802 -179.411 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 102' ' ' GLY . . . . . 0.52 ' HA2' ' C19' ' A' ' 114' ' ' CHR . . . -178.79 -42.67 0.07 OUTLIER Glycine 0 N--CA 1.483 1.783 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 -179.642 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.471 ' O ' ' HB2' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -153.88 -179.62 8.01 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.466 -1.02 . . . . 0.0 109.345 178.8 . . . . . . . . 3 3 . 1 . 060 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -172.45 -166.28 30.79 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 108.631 -1.788 . . . . 0.0 108.631 -179.44 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.0 Cg_exo -49.93 -175.64 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.668 0 CA-C-N 118.759 1.279 . . . . 0.0 110.32 179.603 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 -94.43 -179.27 4.85 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.059 -1.026 . . . . 0.0 110.506 -178.843 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -119.95 162.64 14.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.992 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 108' ' ' VAL . . . . . 0.463 HG21 HG21 ' A' ' 7' ' ' VAL . 1.2 t -101.17 128.42 53.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.334 -1.098 . . . . 0.0 109.165 -179.389 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 109' ' ' ALA . . . . . 0.551 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.71 124.02 26.56 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.59 -0.694 . . . . 0.0 109.552 179.669 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 110' ' ' ILE . . . . . 0.536 HD13 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.75 167.79 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.21 -0.931 . . . . 0.0 109.234 -179.913 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.493 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 15.2 m -137.0 156.33 48.58 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.276 -0.89 . . . . 0.0 109.481 -179.931 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 112' ' ' PHE . . . . . 0.536 ' CZ ' HD13 ' A' ' 110' ' ' ILE . 17.5 m-85 -122.18 126.9 49.3 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.204 -0.935 . . . . 0.0 109.523 -179.787 . . . . . . . . 2 2 . 1 . 060 nuclear orig full ' A' A ' 113' ' ' ASN . . . . . 0.457 ' OXT' ' O ' ' A' ' 112' ' ' PHE . 20.1 p30 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.502 -179.938 . . . . . . . . 1 1 . 1 . 060 nuclear orig full ' A' A ' 114' ' ' CHR . . . . . 0.585 ' C7 ' ' C2 ' ' A' ' 114' ' ' CHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.474 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.475 0 CA-C-O 122.327 1.061 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.948 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -111.21 108.54 18.23 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-O 123.11 1.433 . . . . 0.0 109.167 179.379 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.842 HG22 HG23 ' A' ' 21' ' ' VAL . 2.7 t -115.39 140.33 37.4 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.681 0 CA-C-N 114.255 -1.339 . . . . 0.0 110.08 -179.668 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.495 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -175.72 149.78 1.09 Allowed Pre-proline 0 N--CA 1.487 1.422 0 O-C-N 121.305 -0.872 . . . . 0.0 108.728 -179.656 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.495 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -75.66 152.33 97.04 Favored 'Cis proline' 0 C--N 1.311 -1.408 0 C-N-CA 123.422 -1.491 . . . . 0.0 109.371 -0.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.647 ' HA ' HG22 ' A' ' 110' ' ' ILE . 10.9 m -90.69 -24.64 20.39 Favored 'General case' 0 C--N 1.293 -1.887 0 O-C-N 121.605 -0.684 . . . . 0.0 109.191 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.516 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.4 m -137.16 165.32 26.36 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.44 -0.788 . . . . 0.0 109.59 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.5 38.62 32.46 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.801 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.6 mt -92.79 -43.95 8.76 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 123.152 1.453 . . . . 0.0 110.736 -178.2 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.467 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.05 145.47 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.274 0 CA-C-N 113.597 -1.638 . . . . 0.0 110.156 -179.912 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.6 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 14.2 p-10 -51.16 106.84 0.15 Allowed 'General case' 0 C--N 1.301 -1.517 0 CA-C-O 121.461 0.648 . . . . 0.0 111.526 -178.692 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.79 14.76 9.15 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.43 -1.367 . . . . 0.0 112.969 177.328 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.801 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.4 t -104.24 -171.94 2.02 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 121.075 2.437 . . . . 0.0 109.544 179.152 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.727 HG13 ' C ' ' A' ' 67' ' ' LEU . 16.2 t -128.59 136.05 60.89 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.392 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.116 -179.065 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.587 HG13 ' CG2' ' A' ' 69' ' ' VAL . 20.6 m -111.52 155.55 12.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 11.1 tttt -112.31 109.31 18.88 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.192 -0.942 . . . . 0.0 108.954 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.842 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.63 140.51 21.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.948 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.54 160.22 39.15 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.842 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.18 144.56 15.82 Favored Glycine 0 C--N 1.294 -1.783 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.51 125.11 12.47 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 120.891 -1.358 . . . . 0.0 108.844 179.099 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.89 26.64 26.15 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.28 -1.438 . . . . 0.0 109.864 -179.739 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.549 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -87.79 174.89 8.11 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 120.885 -1.362 . . . . 0.0 108.596 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.79 99.58 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.4 0 O-C-N 120.987 -1.071 . . . . 0.0 109.766 -179.696 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.2 78.01 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.124 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.98 34.23 0.3 Allowed Glycine 0 N--CA 1.487 2.098 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.5 p -141.29 107.5 5.23 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 121.111 -1.229 . . . . 0.0 111.249 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.72 109.96 0.33 Allowed 'General case' 0 N--CA 1.498 1.938 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.638 178.076 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.459 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.6 m-30 -106.25 154.04 21.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.126 -0.984 . . . . 0.0 108.837 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.484 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.86 162.75 12.93 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.863 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.722 HG22 HG11 ' A' ' 21' ' ' VAL . 3.5 p -142.63 116.5 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.048 -1.032 . . . . 0.0 109.628 -178.161 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.69 -175.79 37.19 Favored Glycine 0 N--CA 1.494 2.501 0 C-N-CA 118.353 -1.879 . . . . 0.0 111.67 -179.655 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.615 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -100.73 109.65 21.69 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-O 121.899 0.857 . . . . 0.0 109.038 -179.597 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.486 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -129.94 149.88 51.47 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.275 -0.891 . . . . 0.0 109.634 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.517 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -125.33 139.21 53.89 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.166 -0.959 . . . . 0.0 110.796 -178.922 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.89 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 114.95 26.79 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.038 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.0 m -105.13 15.03 6.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 120.906 -1.121 . . . . 0.0 110.584 -178.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.76 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.78 -175.06 0.08 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.904 -1.123 . . . . 0.0 110.0 179.79 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.03 97.59 1.92 Allowed 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.465 -0.772 . . . . 0.0 109.687 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.65 27.89 33.97 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 120.258 -0.972 . . . . 0.0 111.392 178.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.76 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.38 106.41 20.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 O-C-N 120.576 -1.543 . . . . 0.0 107.313 178.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.89 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -115.86 104.68 11.87 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 120.486 -1.384 . . . . 0.0 109.896 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.959 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.18 109.47 22.22 Favored 'General case' 0 N--CA 1.484 1.238 0 O-C-N 120.81 -1.182 . . . . 0.0 107.917 178.737 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.63 166.57 10.58 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.914 -1.116 . . . . 0.0 110.484 -178.793 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.747 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 47.6 t30 -112.06 129.77 23.93 Favored Pre-proline 0 N--CA 1.501 2.1 0 O-C-N 121.488 -0.758 . . . . 0.0 109.583 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.612 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.56 21.05 0.25 Allowed 'Trans proline' 0 C--N 1.319 -1.024 0 C-N-CA 122.132 1.888 . . . . 0.0 112.268 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.747 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -109.55 3.49 21.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.334 -1.479 . . . . 0.0 108.977 179.336 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.539 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.34 17.23 2.76 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 179.382 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -80.6 87.77 5.74 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.987 -0.685 . . . . 0.0 111.143 -178.458 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -104.2 -165.82 1.19 Allowed 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 178.159 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.446 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.89 137.13 0.09 Allowed 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.532 -1.355 . . . . 0.0 111.382 -179.306 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.931 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -155.5 157.09 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 178.21 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.63 142.34 30.33 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.746 -1.222 . . . . 0.0 109.911 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.34 106.83 0.96 Allowed 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 122.476 1.131 . . . . 0.0 109.406 178.481 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.544 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.6 p-10 -60.4 -139.56 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.893 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.16 -50.9 58.04 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.4 -0.813 . . . . 0.0 110.666 -178.638 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -103.55 -33.15 9.12 Favored 'General case' 0 C--N 1.287 -2.137 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 178.535 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.016 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.66 65.34 0.6 Allowed Glycine 0 C--N 1.298 -1.556 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.574 178.084 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.6 m -102.05 128.37 48.53 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 121.481 -1.011 . . . . 0.0 108.635 178.803 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.931 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.7 108.84 6.79 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.798 -179.244 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 3.8 m -121.54 119.02 30.73 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.18 -0.95 . . . . 0.0 109.428 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.595 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.87 145.13 31.46 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.484 -0.76 . . . . 0.0 109.446 179.875 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 18.4 p -98.99 146.77 25.69 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.413 -0.804 . . . . 0.0 109.632 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.727 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -146.65 166.74 25.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.451 -0.78 . . . . 0.0 109.285 -179.431 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.664 HG22 HG22 ' A' ' 18' ' ' VAL . 4.1 p -95.24 124.87 39.5 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.075 -1.015 . . . . 0.0 109.637 -179.584 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.587 ' CG2' HG13 ' A' ' 19' ' ' VAL . 17.3 m -137.7 142.64 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.948 -1.095 . . . . 0.0 109.834 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.6 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.4 ptt180 -141.37 -165.49 1.98 Allowed 'General case' 0 N--CA 1.487 1.411 0 O-C-N 120.617 -1.302 . . . . 0.0 110.312 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.593 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 2.7 mtt180 -71.66 -78.02 0.09 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.34 -0.85 . . . . 0.0 109.096 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -69.05 137.35 53.51 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 120.21 -1.556 . . . . 0.0 107.437 179.082 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.564 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -160.78 132.8 5.93 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 117.996 -1.482 . . . . 0.0 110.167 -178.098 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.494 ' C ' ' O ' ' A' ' 73' ' ' PHE . 9.2 mp0 -30.1 121.92 0.18 Allowed 'General case' 0 N--CA 1.492 1.675 0 CA-C-O 121.627 0.727 . . . . 0.0 110.88 -178.237 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.959 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.02 45.09 3.16 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.612 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.4 m-30 -38.99 113.55 0.32 Allowed 'General case' 0 N--CA 1.508 2.461 0 O-C-N 121.123 -1.221 . . . . 0.0 110.268 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.716 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.57 127.45 35.26 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.035 -1.041 . . . . 0.0 109.487 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.0 t80 -64.48 58.1 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.861 -1.15 . . . . 0.0 110.118 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 77' ' ' LEU . 27.6 t0 -160.02 18.95 0.16 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.041 -1.037 . . . . 0.0 109.814 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.39 -26.42 5.71 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.56 158.6 15.62 Favored 'General case' 0 N--CA 1.485 1.307 0 O-C-N 120.959 -1.318 . . . . 0.0 110.435 -179.438 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.482 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -105.36 133.63 49.81 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 179.711 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.716 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.5 t90 -80.98 -19.52 43.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.797 -1.189 . . . . 0.0 110.281 -178.717 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.7 174.08 18.68 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.85 110.65 1.83 Allowed 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.666 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.2 t -82.06 103.56 9.41 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.389 -0.819 . . . . 0.0 108.846 -178.936 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.647 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -67.12 111.28 3.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.439 -0.788 . . . . 0.0 109.816 -179.174 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.553 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -63.0 -6.07 3.56 Favored 'General case' 0 N--CA 1.5 2.033 0 C-N-CA 118.361 -1.336 . . . . 0.0 109.824 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 41.4 p -84.64 -0.34 53.04 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.648 -1.282 . . . . 0.0 108.897 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.647 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -113.9 -49.7 2.86 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.338 -0.851 . . . . 0.0 109.025 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.91 -178.64 3.71 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.484 -0.76 . . . . 0.0 109.62 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.36 115.44 30.26 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.469 -0.769 . . . . 0.0 108.981 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.557 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.05 123.03 40.68 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.861 -1.15 . . . . 0.0 109.774 -179.249 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.624 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.57 146.87 27.91 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-O 122.378 1.085 . . . . 0.0 111.139 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.475 ' HB ' HG11 ' A' ' 7' ' ' VAL . 56.2 t -102.07 110.03 27.75 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.013 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 177.497 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.465 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.79 -170.31 16.42 Favored Glycine 0 N--CA 1.487 2.077 0 C-N-CA 118.246 -1.931 . . . . 0.0 111.631 -177.543 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.484 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -122.66 176.99 5.64 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.871 -0.782 . . . . 0.0 109.162 -178.854 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.459 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.5 m . . . . . 0 C--N 1.296 -1.759 0 O-C-N 121.687 -0.633 . . . . 0.0 109.386 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.404 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.482 1.722 0 N-CA-C 107.814 -2.114 . . . . 0.0 107.814 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.404 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.53 -177.17 3.86 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 122.069 0.938 . . . . 0.0 109.737 179.385 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.62 -161.44 17.14 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 108.297 -1.921 . . . . 0.0 108.297 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.497 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.4 Cg_exo -46.88 177.17 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.684 0 CA-C-N 118.794 1.297 . . . . 0.0 110.161 179.28 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -94.15 -168.92 1.95 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.054 -1.029 . . . . 0.0 110.284 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.465 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.24 162.8 18.25 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.69 129.54 48.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.457 -1.025 . . . . 0.0 109.205 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.624 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.78 122.39 21.45 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 121.74 -0.6 . . . . 0.0 109.86 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.821 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.92 170.45 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.268 -0.895 . . . . 0.0 109.191 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.516 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.23 155.07 51.27 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.211 -0.931 . . . . 0.0 109.636 -179.908 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.821 ' CE2' HD12 ' A' ' 110' ' ' ILE . 66.1 m-85 . . . . . 0 N--CA 1.486 1.337 0 O-C-N 121.224 -0.923 . . . . 0.0 109.457 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.488 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 122.297 1.046 . . . . 0.0 110.758 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.955 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -110.6 108.57 18.54 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 123.05 1.405 . . . . 0.0 109.073 179.275 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.826 HG22 HG23 ' A' ' 21' ' ' VAL . 2.2 t -117.02 140.42 39.76 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.713 0 CA-C-N 114.295 -1.32 . . . . 0.0 110.049 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.446 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -177.7 149.84 0.76 Allowed Pre-proline 0 N--CA 1.486 1.34 0 O-C-N 121.285 -0.884 . . . . 0.0 108.78 -179.757 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.446 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.86 150.39 86.5 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 123.551 -1.437 . . . . 0.0 109.239 -0.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 14.2 p -89.65 -25.74 21.1 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.473 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 8.1 m -132.75 163.22 29.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.427 -0.796 . . . . 0.0 109.527 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.16 37.72 31.6 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 -179.576 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.815 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.5 mt -92.95 -44.01 8.65 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.193 1.473 . . . . 0.0 110.695 -178.351 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.93 144.99 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.299 0 CA-C-N 113.515 -1.675 . . . . 0.0 109.919 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.602 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.7 p-10 -51.17 108.77 0.27 Allowed 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.433 0.635 . . . . 0.0 111.533 -178.58 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.84 13.38 11.28 Favored Glycine 0 N--CA 1.483 1.796 0 C-N-CA 119.45 -1.357 . . . . 0.0 112.875 177.335 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.815 HG21 ' CA ' ' A' ' 13' ' ' LEU . 11.1 t -103.12 -173.1 2.23 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 120.988 2.394 . . . . 0.0 109.571 179.333 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.751 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.7 t -127.2 135.11 64.42 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.968 -178.912 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.532 ' CG1' HD13 ' A' ' 13' ' ' LEU . 31.3 m -110.38 155.28 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 13.3 tttt -112.41 109.38 18.96 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.169 -0.957 . . . . 0.0 109.045 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.826 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -104.92 141.44 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.955 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.8 160.32 39.57 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.863 179.707 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.592 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.23 144.87 16.14 Favored Glycine 0 C--N 1.294 -1.775 0 N-CA-C 108.211 -1.956 . . . . 0.0 108.211 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.55 125.14 12.47 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.025 -1.28 . . . . 0.0 108.793 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.91 26.95 25.23 Favored Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.28 -1.438 . . . . 0.0 109.759 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.551 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.2 mt -86.74 175.31 8.31 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.862 -1.375 . . . . 0.0 108.529 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.09 98.04 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.914 -1.116 . . . . 0.0 109.598 -179.637 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.632 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.82 77.31 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.735 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.376 -179.099 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.43 34.29 0.32 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 179.384 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.558 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.2 p -146.08 112.22 5.75 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.916 -1.344 . . . . 0.0 111.202 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.85 126.85 6.03 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.823 178.223 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.493 ' CD2' ' O ' ' A' ' 30' ' ' THR . 13.8 m-85 -119.35 152.13 37.3 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -100.49 162.67 12.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.635 -1.291 . . . . 0.0 107.727 178.667 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.947 HG11 HG21 ' A' ' 65' ' ' THR . 5.7 p -147.1 117.02 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.002 -1.061 . . . . 0.0 110.031 -177.805 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -170.61 -176.46 40.0 Favored Glycine 0 N--CA 1.493 2.439 0 C-N-CA 118.323 -1.894 . . . . 0.0 111.714 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.586 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -99.79 108.92 21.34 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -179.801 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -131.01 148.91 52.81 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.22 -0.925 . . . . 0.0 109.777 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.415 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.79 139.38 54.04 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.31 -0.869 . . . . 0.0 110.768 -179.014 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.889 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.28 114.7 26.51 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 178.133 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.2 m -104.37 15.06 6.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.051 -1.03 . . . . 0.0 110.523 -178.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.767 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 173.98 -175.89 0.07 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.979 -1.075 . . . . 0.0 110.076 179.706 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.789 ' O ' HG23 ' A' ' 42' ' ' THR . 14.9 t -71.95 98.87 2.12 Favored 'General case' 0 N--CA 1.487 1.38 0 CA-C-O 121.77 0.795 . . . . 0.0 109.648 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.69 27.34 35.46 Favored Glycine 0 N--CA 1.493 2.475 0 C-N-CA 120.139 -1.029 . . . . 0.0 111.422 178.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.767 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.95 106.39 20.11 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 O-C-N 120.6 -1.53 . . . . 0.0 107.197 178.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.889 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -117.64 104.57 11.15 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.426 -1.421 . . . . 0.0 109.851 -177.684 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.988 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.2 109.58 22.31 Favored 'General case' 0 N--CA 1.484 1.25 0 O-C-N 120.812 -1.18 . . . . 0.0 108.165 178.868 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -106.38 166.43 10.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.966 -1.084 . . . . 0.0 110.122 -178.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.697 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 14.3 t-20 -108.56 137.98 20.13 Favored Pre-proline 0 N--CA 1.501 2.09 0 O-C-N 121.326 -0.859 . . . . 0.0 110.04 -179.267 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.7 Cg_endo -75.38 24.29 0.41 Allowed 'Trans proline' 0 C--N 1.317 -1.08 0 C-N-CA 122.36 2.04 . . . . 0.0 111.884 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.697 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -118.01 3.66 12.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.355 -1.466 . . . . 0.0 109.298 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.567 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.05 17.57 2.63 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 179.328 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -82.4 90.85 6.74 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.789 -0.765 . . . . 0.0 110.834 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.616 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -111.65 -169.24 1.43 Allowed 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 178.319 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.1 135.34 0.09 Allowed 'General case' 0 N--CA 1.486 1.353 0 O-C-N 120.584 -1.322 . . . . 0.0 111.325 -179.301 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.855 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.1 p -150.62 158.49 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 178.172 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.77 145.38 26.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.804 -1.185 . . . . 0.0 109.848 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.77 108.05 1.99 Allowed 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 122.359 1.076 . . . . 0.0 109.61 178.702 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.3 p-10 -60.73 -139.46 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.802 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.632 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.22 -50.13 62.59 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.43 -0.793 . . . . 0.0 110.432 -178.849 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 37.9 t30 -103.13 -35.18 8.59 Favored 'General case' 0 C--N 1.287 -2.141 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.05 65.91 0.6 Allowed Glycine 0 C--N 1.296 -1.64 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 178.3 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.592 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.5 m -102.04 128.86 48.3 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 121.475 -1.015 . . . . 0.0 108.899 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.855 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.07 108.76 6.62 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.933 -179.445 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -121.15 119.16 31.58 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.177 -0.952 . . . . 0.0 109.537 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.947 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -143.08 143.27 31.79 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.496 -0.753 . . . . 0.0 109.602 179.827 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.8 p -99.74 145.36 27.75 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.45 -0.781 . . . . 0.0 109.284 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.818 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -146.71 170.33 17.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.372 -0.83 . . . . 0.0 109.421 -179.286 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.662 HG22 HG22 ' A' ' 18' ' ' VAL . 1.9 p -99.16 125.71 44.78 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.023 -1.048 . . . . 0.0 109.532 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.562 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -137.47 143.82 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.917 -1.114 . . . . 0.0 109.768 -179.373 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.602 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.1 ptt180 -148.64 -172.04 4.0 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.434 -1.416 . . . . 0.0 110.944 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.613 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -55.8 -101.66 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 -179.358 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.508 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.58 140.52 46.35 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 120.778 -1.201 . . . . 0.0 108.215 179.587 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -162.38 136.23 6.36 Favored 'General case' 0 C--N 1.293 -1.874 0 C-N-CA 118.772 -1.171 . . . . 0.0 109.926 -178.184 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.545 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.5 mm-40 -32.09 121.02 0.3 Allowed 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.479 0.657 . . . . 0.0 110.736 -178.399 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.988 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.15 47.86 2.92 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.169 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.37 113.03 0.29 Allowed 'General case' 0 N--CA 1.506 2.365 0 O-C-N 121.076 -1.249 . . . . 0.0 110.118 179.572 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.741 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -85.14 127.02 34.09 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.959 -1.088 . . . . 0.0 109.503 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -63.57 58.36 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.905 -1.122 . . . . 0.0 110.297 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 16.7 t0 -161.53 19.74 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.995 -1.066 . . . . 0.0 109.791 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.18 -26.72 5.4 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.129 -1.189 . . . . 0.0 110.129 179.858 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.83 159.87 15.19 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.028 -1.278 . . . . 0.0 110.32 -179.368 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.485 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.49 134.58 49.41 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.888 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.741 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.9 t90 -82.86 -19.27 37.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.773 -1.204 . . . . 0.0 110.393 -178.637 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.43 173.91 18.76 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -64.11 107.29 1.24 Allowed 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.634 HG21 ' HB3' ' A' ' 46' ' ' ALA . 47.5 t -78.28 105.3 7.21 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 O-C-N 121.354 -0.841 . . . . 0.0 109.304 -178.843 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.549 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -65.15 110.82 2.67 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.487 -0.758 . . . . 0.0 109.777 -179.657 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.613 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.2 t -62.52 -6.36 3.35 Favored 'General case' 0 N--CA 1.499 2.001 0 C-N-CA 118.164 -1.415 . . . . 0.0 109.788 179.462 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.6 p -85.83 -3.17 58.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.726 -1.234 . . . . 0.0 109.272 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.549 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -109.62 -50.2 3.01 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.295 -0.878 . . . . 0.0 108.976 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.91 -179.46 3.95 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.491 -0.755 . . . . 0.0 109.374 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.2 115.98 31.17 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.363 -0.836 . . . . 0.0 108.83 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.505 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.6 123.52 40.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.815 -1.178 . . . . 0.0 109.639 -179.227 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.599 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.85 146.08 29.5 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 122.382 1.087 . . . . 0.0 111.042 -179.483 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 78.4 t -102.49 109.94 27.85 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.081 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 177.651 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.486 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.97 -171.52 17.79 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 118.171 -1.966 . . . . 0.0 111.812 -177.534 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.499 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -114.55 -178.39 3.36 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -179.048 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.515 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.9 OUTLIER . . . . . 0 C--N 1.296 -1.721 0 O-C-N 121.343 -0.848 . . . . 0.0 109.605 -179.26 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.718 0 N-CA-C 107.628 -2.189 . . . . 0.0 107.628 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.29 -178.48 7.31 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 121.627 -0.925 . . . . 0.0 109.682 179.238 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.84 -161.73 16.7 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 108.395 -1.882 . . . . 0.0 108.395 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.49 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.5 Cg_exo -46.93 178.3 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.634 0 CA-C-N 118.822 1.311 . . . . 0.0 110.375 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -92.69 -179.27 5.11 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.204 -0.935 . . . . 0.0 110.455 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.486 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.42 165.5 12.52 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.86 128.2 55.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.442 -1.034 . . . . 0.0 109.159 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.599 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.64 123.16 22.68 Favored 'General case' 0 C--N 1.289 -2.043 0 O-C-N 121.632 -0.667 . . . . 0.0 109.383 179.592 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.858 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.69 170.85 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.214 -0.929 . . . . 0.0 109.197 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.473 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.71 153.79 49.73 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.214 -0.929 . . . . 0.0 109.609 -179.847 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.858 ' CE2' HD12 ' A' ' 110' ' ' ILE . 75.9 m-85 . . . . . 0 N--CA 1.486 1.356 0 O-C-N 121.162 -0.961 . . . . 0.0 109.494 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.507 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.184 0 CA-C-O 122.44 1.114 . . . . 0.0 110.84 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.008 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.2 p -105.65 104.86 14.67 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.427 1.108 . . . . 0.0 110.287 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.951 HG22 HG23 ' A' ' 21' ' ' VAL . 11.7 t -118.82 117.28 53.86 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.469 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.226 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.522 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.1 149.71 11.76 Favored Pre-proline 0 N--CA 1.487 1.381 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 -179.611 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.522 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -77.14 152.05 94.18 Favored 'Cis proline' 0 C--N 1.309 -1.534 0 C-N-CA 123.698 -1.376 . . . . 0.0 109.567 -0.423 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.714 ' HA ' HG22 ' A' ' 110' ' ' ILE . 18.0 p -93.15 -24.75 18.14 Favored 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.468 ' HB3' ' HB2' ' A' ' 111' ' ' SER . 3.9 m -133.61 161.83 33.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.616 -0.678 . . . . 0.0 109.382 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.31 37.02 32.86 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.777 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.2 mt -90.92 -42.93 10.31 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 123.283 1.516 . . . . 0.0 110.411 -178.599 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.55 144.36 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.305 0 CA-C-N 113.28 -1.782 . . . . 0.0 109.918 -179.629 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.609 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 6.3 p-10 -50.87 106.34 0.13 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.624 0.726 . . . . 0.0 111.514 -178.646 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.29 13.93 8.66 Favored Glycine 0 N--CA 1.484 1.865 0 C-N-CA 119.468 -1.349 . . . . 0.0 113.033 177.375 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.777 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.98 -172.73 2.15 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 121.168 2.484 . . . . 0.0 109.785 179.253 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.8 HG22 HG22 ' A' ' 68' ' ' THR . 17.2 t -130.39 139.49 51.21 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.319 0 CA-C-N 114.794 -1.094 . . . . 0.0 111.215 -178.783 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.485 HG11 HD11 ' A' ' 13' ' ' LEU . 33.8 m -115.22 155.12 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 178.89 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.542 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.4 tttt -109.08 109.15 20.08 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.146 -0.971 . . . . 0.0 109.466 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.951 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -105.47 122.44 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.008 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.68 165.66 12.31 Favored 'General case' 0 C--N 1.307 -1.273 0 O-C-N 120.821 -1.174 . . . . 0.0 109.128 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.587 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.97 107.74 0.47 Allowed Glycine 0 N--CA 1.481 1.693 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.451 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.34 139.62 50.21 Favored 'General case' 0 N--CA 1.5 2.063 0 CA-C-N 119.139 1.469 . . . . 0.0 110.102 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.39 28.18 28.19 Favored Glycine 0 N--CA 1.49 2.25 0 C-N-CA 118.796 -1.669 . . . . 0.0 109.758 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.551 HD22 ' HG3' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -94.7 174.44 7.11 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.996 -1.297 . . . . 0.0 108.58 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.005 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.28 100.1 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.91 -1.119 . . . . 0.0 109.74 -179.597 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.557 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.86 77.75 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.101 -179.326 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.41 34.02 0.29 Allowed Glycine 0 N--CA 1.487 2.071 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.9 p -141.86 108.73 5.42 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.071 -1.253 . . . . 0.0 111.098 -179.627 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.579 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.52 109.81 0.25 Allowed 'General case' 0 N--CA 1.496 1.874 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.796 178.253 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.518 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 21.6 m-85 -99.53 153.77 18.78 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.177 -0.952 . . . . 0.0 108.835 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.502 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -102.67 158.96 15.88 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.727 -1.233 . . . . 0.0 107.829 178.553 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.636 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.0 p -141.63 118.25 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.942 -1.099 . . . . 0.0 109.92 -177.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.52 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.4 -179.81 40.48 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.937 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.607 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -101.21 108.94 20.73 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.932 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.488 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.4 146.9 52.04 Favored 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.236 -0.915 . . . . 0.0 109.808 179.675 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.525 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -119.12 137.74 53.38 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.341 -0.849 . . . . 0.0 110.647 -178.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.857 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.69 114.44 26.18 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 178.143 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.7 m -105.92 14.51 7.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 120.971 -1.081 . . . . 0.0 110.666 -178.665 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.773 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.33 -175.38 0.08 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.815 -1.178 . . . . 0.0 110.116 179.743 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.784 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.97 98.07 1.54 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-O 121.806 0.812 . . . . 0.0 109.91 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.97 26.61 36.81 Favored Glycine 0 N--CA 1.493 2.494 0 C-N-CA 120.17 -1.014 . . . . 0.0 111.562 178.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.773 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -115.27 105.98 19.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 O-C-N 120.549 -1.559 . . . . 0.0 107.316 178.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.857 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -118.31 104.81 11.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.502 -1.374 . . . . 0.0 109.628 -177.806 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.037 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.92 109.67 22.38 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.755 -1.216 . . . . 0.0 108.271 179.074 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.3 t -105.51 164.44 11.88 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.996 -1.065 . . . . 0.0 110.416 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.72 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 9.6 t-20 -109.2 137.21 20.14 Favored Pre-proline 0 N--CA 1.5 2.042 0 O-C-N 121.505 -0.747 . . . . 0.0 109.972 -179.162 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.59 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.2 Cg_endo -74.39 23.9 0.36 Allowed 'Trans proline' 0 CA--C 1.544 1.004 0 C-N-CA 122.371 2.047 . . . . 0.0 112.049 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.72 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -116.91 3.61 12.85 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.364 -1.46 . . . . 0.0 109.115 179.669 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.541 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.49 13.82 3.22 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 179.356 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -79.25 91.46 5.0 Favored 'General case' 0 C--N 1.306 -1.321 0 O-C-N 121.509 -0.744 . . . . 0.0 111.052 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.636 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -112.63 -168.79 1.37 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.188 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.79 136.83 0.09 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.567 -1.333 . . . . 0.0 111.46 -179.296 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.92 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -152.19 157.01 5.31 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 178.024 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.579 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.18 143.78 28.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 120.808 -1.182 . . . . 0.0 110.081 -179.497 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -64.14 106.7 1.12 Allowed 'General case' 0 C--N 1.3 -1.55 0 CA-C-O 122.44 1.114 . . . . 0.0 109.278 178.609 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.8 p-10 -60.14 -139.12 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.948 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.557 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.53 -50.54 59.81 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.497 -0.752 . . . . 0.0 110.597 -178.522 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -103.91 -34.11 8.61 Favored 'General case' 0 C--N 1.286 -2.179 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 178.492 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.012 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.28 66.44 0.6 Allowed Glycine 0 C--N 1.296 -1.639 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.568 178.105 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.587 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 21.5 m -103.15 125.32 49.79 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.665 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.92 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.34 109.33 8.73 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.464 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.6 m -118.16 116.95 27.87 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.368 -0.833 . . . . 0.0 109.307 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.587 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -142.88 139.89 30.99 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.525 -0.734 . . . . 0.0 109.588 -179.987 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.6 p -99.62 134.55 42.33 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.465 -0.772 . . . . 0.0 109.43 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.76 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -132.12 165.6 23.68 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.427 -0.796 . . . . 0.0 109.389 -179.549 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.8 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -96.89 125.33 41.26 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.012 -1.055 . . . . 0.0 109.25 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.607 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.9 m -136.01 143.47 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 120.95 -1.094 . . . . 0.0 109.81 -179.061 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.609 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.7 ptt180 -147.15 -175.48 4.84 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.534 -1.354 . . . . 0.0 111.032 -179.806 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.605 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.12 -101.45 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.609 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.76 141.73 43.12 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.773 -1.204 . . . . 0.0 108.114 179.437 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.596 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.74 136.03 5.06 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 118.653 -1.219 . . . . 0.0 109.96 -177.973 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' A' ' 73' ' ' PHE . 0.7 OUTLIER -33.42 121.92 0.41 Allowed 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.364 0.602 . . . . 0.0 110.313 -178.609 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.037 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.16 50.19 1.91 Allowed Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.388 -0.91 . . . . 0.0 111.343 -178.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.59 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.4 m-85 -40.15 113.5 0.36 Allowed 'General case' 0 N--CA 1.507 2.383 0 O-C-N 121.123 -1.222 . . . . 0.0 109.749 179.313 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.677 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.3 tp -85.66 127.04 34.38 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 120.903 -1.123 . . . . 0.0 109.726 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 33.3 t80 -65.25 58.06 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.971 0 O-C-N 120.85 -1.156 . . . . 0.0 109.824 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -158.69 18.67 0.21 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.004 -1.06 . . . . 0.0 109.596 -179.991 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.95 -27.23 5.56 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 42.3 p -93.98 159.87 14.98 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.962 -1.316 . . . . 0.0 110.455 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.02 135.8 46.83 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.536 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.677 ' HB2' HD13 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -83.88 -16.46 44.3 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.737 -1.227 . . . . 0.0 110.67 -178.345 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 107.62 176.23 22.44 Favored Glycine 0 N--CA 1.485 1.95 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.9 104.31 0.68 Allowed 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.582 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 39.4 t -76.37 107.19 7.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.353 -0.842 . . . . 0.0 109.096 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.535 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.3 m-20 -66.29 111.45 3.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.448 -0.782 . . . . 0.0 109.975 -179.236 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.605 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.74 -5.56 4.36 Favored 'General case' 0 N--CA 1.5 2.067 0 C-N-CA 118.268 -1.373 . . . . 0.0 109.78 179.357 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.0 p -86.7 -1.45 57.72 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.744 -1.222 . . . . 0.0 109.231 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.535 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.15 -49.6 3.01 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.212 -0.93 . . . . 0.0 109.019 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.89 178.42 4.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.55 -0.719 . . . . 0.0 109.398 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.83 116.45 32.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.348 -0.845 . . . . 0.0 109.115 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.561 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.59 122.89 40.0 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.853 -1.155 . . . . 0.0 109.189 -179.473 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.578 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -101.18 146.04 28.01 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 122.334 1.064 . . . . 0.0 111.338 -179.08 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.588 ' HB ' HG11 ' A' ' 7' ' ' VAL . 65.8 t -103.21 109.78 27.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.964 0 N-CA-C 106.345 -1.724 . . . . 0.0 106.345 177.45 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.87 -172.82 17.53 Favored Glycine 0 N--CA 1.486 1.968 0 C-N-CA 118.063 -2.018 . . . . 0.0 111.804 -177.505 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.5 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -115.98 -177.77 3.24 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -178.87 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.502 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.9 OUTLIER . . . . . 0 C--N 1.295 -1.777 0 O-C-N 121.385 -0.822 . . . . 0.0 109.098 -179.24 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.701 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.7 -179.07 7.84 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 121.448 -1.03 . . . . 0.0 109.641 178.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.58 -166.56 33.91 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 -179.49 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.551 ' HG3' HD22 ' A' ' 26' ' ' LEU . 2.9 Cg_exo -49.8 -176.67 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.685 0 CA-C-N 118.857 1.329 . . . . 0.0 110.067 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -94.41 179.33 5.32 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.04 -1.037 . . . . 0.0 110.571 -178.762 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -117.97 166.77 12.76 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -108.26 128.87 63.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.246 -1.15 . . . . 0.0 109.117 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.578 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.09 119.1 16.86 Favored 'General case' 0 C--N 1.289 -2.045 0 O-C-N 121.586 -0.696 . . . . 0.0 109.356 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.892 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.81 169.9 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.151 -0.968 . . . . 0.0 108.916 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.468 ' HB2' ' HB3' ' A' ' 11' ' ' SER . 1.2 m -141.15 156.97 45.87 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.123 -0.986 . . . . 0.0 110.095 -179.628 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.892 ' CE2' HD12 ' A' ' 110' ' ' ILE . 97.8 m-85 . . . . . 0 N--CA 1.484 1.242 0 O-C-N 121.24 -0.912 . . . . 0.0 109.479 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.513 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.439 0 CA-C-O 122.486 1.136 . . . . 0.0 110.692 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.941 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.2 t -110.28 108.72 18.92 Favored 'General case' 0 C--N 1.296 -1.724 0 CA-C-O 123.108 1.432 . . . . 0.0 109.067 179.316 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.839 HG22 HG23 ' A' ' 21' ' ' VAL . 3.1 t -116.53 139.01 45.26 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.72 0 CA-C-N 114.246 -1.343 . . . . 0.0 110.123 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.466 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.64 149.13 1.27 Allowed Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.323 -0.861 . . . . 0.0 108.775 -179.735 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.466 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.79 152.52 97.07 Favored 'Cis proline' 0 C--N 1.312 -1.365 0 C-N-CA 123.476 -1.468 . . . . 0.0 109.485 -0.786 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.651 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.3 m -90.87 -24.56 20.2 Favored 'General case' 0 C--N 1.293 -1.874 0 O-C-N 121.587 -0.695 . . . . 0.0 109.175 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.51 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.2 m -137.94 165.34 26.78 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.547 -0.721 . . . . 0.0 109.515 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.05 37.98 31.34 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 108.579 -1.808 . . . . 0.0 108.579 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.81 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.8 mt -93.01 -43.93 8.66 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 123.102 1.43 . . . . 0.0 110.703 -178.249 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.17 145.94 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.314 0 CA-C-N 113.595 -1.639 . . . . 0.0 110.138 -179.904 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.616 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -51.23 106.95 0.15 Allowed 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 121.66 0.743 . . . . 0.0 111.638 -178.67 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.73 13.97 9.06 Favored Glycine 0 N--CA 1.484 1.878 0 C-N-CA 119.473 -1.346 . . . . 0.0 112.968 177.438 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.81 HG21 ' CA ' ' A' ' 13' ' ' LEU . 11.5 t -104.08 -173.96 2.43 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 121.164 2.482 . . . . 0.0 109.936 179.417 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.808 HG13 ' O ' ' A' ' 67' ' ' LEU . 39.1 t -124.76 136.11 61.79 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.389 0 CA-C-N 114.563 -1.199 . . . . 0.0 110.917 -178.669 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.562 ' CG1' HD13 ' A' ' 13' ' ' LEU . 35.6 m -114.04 154.95 15.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.259 -0.9 . . . . 0.0 108.725 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.81 109.15 18.44 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.037 179.876 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.839 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -104.48 141.02 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.941 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.73 160.76 38.35 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 120.735 -1.228 . . . . 0.0 110.154 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -128.46 144.6 15.42 Favored Glycine 0 C--N 1.295 -1.731 0 N-CA-C 107.973 -2.051 . . . . 0.0 107.973 179.559 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.13 125.71 13.3 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 120.851 -1.382 . . . . 0.0 108.864 179.053 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.472 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 89.44 26.01 26.64 Favored Glycine 0 N--CA 1.488 2.138 0 C-N-CA 119.184 -1.484 . . . . 0.0 109.874 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.587 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -89.02 170.98 10.19 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.86 -1.376 . . . . 0.0 108.477 179.892 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.997 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.02 100.88 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.082 -1.012 . . . . 0.0 110.038 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.2 78.53 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.007 -179.48 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.88 34.32 0.3 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.558 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 16.6 p -138.78 105.06 5.25 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.217 -1.166 . . . . 0.0 111.293 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.8 111.87 0.62 Allowed 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.054 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.558 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 36.9 m-85 -108.92 157.53 18.54 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.186 -0.946 . . . . 0.0 108.897 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.498 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.21 163.14 12.42 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.913 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.92 HG11 HG21 ' A' ' 65' ' ' THR . 2.8 p -143.75 119.42 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.034 -1.041 . . . . 0.0 109.914 -178.044 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.89 -177.87 38.96 Favored Glycine 0 N--CA 1.495 2.602 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.851 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.572 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -102.15 108.76 20.26 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.458 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -131.14 149.56 52.54 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.241 -0.912 . . . . 0.0 109.716 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.478 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.03 138.27 54.73 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.105 -0.997 . . . . 0.0 110.803 -178.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.888 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.73 26.55 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.112 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.0 m -104.74 14.8 6.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.109 -0.994 . . . . 0.0 110.593 -178.806 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.762 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 173.97 -175.7 0.07 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.989 -1.069 . . . . 0.0 110.003 179.686 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.789 ' O ' HG23 ' A' ' 42' ' ' THR . 14.9 t -72.1 99.0 2.22 Favored 'General case' 0 N--CA 1.486 1.357 0 CA-C-O 121.763 0.792 . . . . 0.0 109.738 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.77 27.7 34.14 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 120.227 -0.987 . . . . 0.0 111.405 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.762 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -117.5 105.88 18.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.619 -1.518 . . . . 0.0 107.263 178.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.888 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.2 tp -117.66 104.67 11.25 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.48 -1.387 . . . . 0.0 109.739 -177.77 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.089 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.89 109.35 22.12 Favored 'General case' 0 N--CA 1.484 1.26 0 O-C-N 120.804 -1.185 . . . . 0.0 107.9 178.757 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.491 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -107.26 162.71 13.65 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.956 -1.09 . . . . 0.0 110.263 -178.673 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.713 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 39.7 t30 -105.71 134.7 19.59 Favored Pre-proline 0 N--CA 1.503 2.189 0 O-C-N 121.405 -0.809 . . . . 0.0 109.539 -179.614 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.599 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.2 Cg_endo -72.74 22.92 0.29 Allowed 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.322 2.015 . . . . 0.0 112.46 -179.436 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.713 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -118.34 10.59 12.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.349 -1.469 . . . . 0.0 108.958 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.854 ' OD2' HD22 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -137.99 14.59 2.86 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 179.326 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -80.15 88.64 5.43 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.564 -0.855 . . . . 0.0 111.286 -178.108 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.55 -167.05 1.18 Allowed 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 178.128 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.74 138.26 0.09 Allowed 'General case' 0 C--N 1.306 -1.284 0 O-C-N 120.578 -1.326 . . . . 0.0 111.239 -179.267 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 1.022 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -155.69 156.48 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.397 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.66 142.03 30.74 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.798 -1.189 . . . . 0.0 110.016 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.015 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -61.74 106.76 0.72 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.425 1.107 . . . . 0.0 109.287 178.091 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.544 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.0 p-10 -60.44 -138.4 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.033 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.36 -51.03 58.13 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.429 -0.794 . . . . 0.0 110.902 -178.576 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.472 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.7 t-20 -103.57 -34.54 8.62 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 178.43 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.015 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 110.95 63.02 0.5 Allowed Glycine 0 C--N 1.297 -1.621 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 177.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.9 m -102.48 126.9 49.68 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.6 -0.941 . . . . 0.0 108.487 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 1.022 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.68 109.19 7.41 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.834 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.1 m -120.83 120.56 35.92 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.284 -0.885 . . . . 0.0 109.515 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.92 HG21 HG11 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -142.04 143.65 33.23 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.526 -0.734 . . . . 0.0 109.355 179.772 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.7 p -102.0 143.41 31.89 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.423 -0.798 . . . . 0.0 109.462 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.854 HD22 ' OD2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -146.26 -178.87 6.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 109.43 -179.45 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.513 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -105.06 125.88 51.46 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.903 -1.123 . . . . 0.0 110.289 -178.894 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.761 HG13 ' OD1' ' A' ' 51' ' ' ASP . 15.3 m -134.56 144.22 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 120.965 -1.085 . . . . 0.0 109.756 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.616 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.3 ptt180 -148.66 -179.62 7.11 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 120.458 -1.401 . . . . 0.0 111.105 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.603 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.92 -100.89 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -179.661 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.511 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.73 139.54 50.35 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.82 -1.175 . . . . 0.0 107.928 179.303 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -161.44 136.18 7.25 Favored 'General case' 0 C--N 1.295 -1.803 0 C-N-CA 118.647 -1.221 . . . . 0.0 109.807 -178.105 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.523 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 15.7 mt-10 -33.97 121.43 0.45 Allowed 'General case' 0 N--CA 1.491 1.621 0 CA-C-O 121.419 0.628 . . . . 0.0 110.358 -178.45 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.089 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.03 50.86 1.93 Allowed Glycine 0 N--CA 1.493 2.493 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.068 -179.278 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.599 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-85 -39.22 116.69 0.62 Allowed 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.122 -1.223 . . . . 0.0 109.954 179.626 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.718 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -87.37 126.16 34.7 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.006 -1.059 . . . . 0.0 109.455 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -64.8 58.47 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.925 0 O-C-N 120.804 -1.185 . . . . 0.0 110.014 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 26.4 t0 -159.33 19.54 0.18 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.054 -1.029 . . . . 0.0 109.571 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.51 -28.2 5.41 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.454 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 66.3 p -95.96 160.24 14.56 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.964 -1.315 . . . . 0.0 110.438 -179.334 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.479 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 4.1 ptt180 -105.73 138.77 41.37 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.718 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -83.55 -19.12 36.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.852 -1.155 . . . . 0.0 110.556 -178.599 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.59 176.1 19.24 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 108.704 -1.758 . . . . 0.0 108.704 -179.569 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -65.72 105.9 1.37 Allowed 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.0 t -77.36 105.9 6.86 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 O-C-N 121.355 -0.841 . . . . 0.0 109.144 -178.836 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.546 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -64.97 111.1 2.7 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.373 -0.829 . . . . 0.0 109.819 -179.558 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.603 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -62.91 -5.93 3.34 Favored 'General case' 0 N--CA 1.499 2.02 0 C-N-CA 118.214 -1.394 . . . . 0.0 109.85 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.2 p -86.99 -1.25 57.72 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.729 -1.232 . . . . 0.0 109.319 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.546 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.8 p -111.49 -50.3 2.94 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.384 -0.823 . . . . 0.0 108.937 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.76 -179.94 4.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.544 -0.723 . . . . 0.0 109.238 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.93 116.11 31.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.325 -0.859 . . . . 0.0 109.057 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -96.93 121.17 38.51 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.854 -1.154 . . . . 0.0 109.278 -179.321 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.609 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.3 mt-30 -102.04 146.78 27.42 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-O 122.402 1.096 . . . . 0.0 111.311 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.415 ' CG1' ' HB ' ' A' ' 21' ' ' VAL . 62.1 t -104.65 109.86 28.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 177.479 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.485 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.0 -170.04 16.27 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 118.243 -1.932 . . . . 0.0 111.62 -177.57 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.498 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -112.78 179.88 3.85 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -179.065 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.427 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.2 p . . . . . 0 C--N 1.297 -1.714 0 O-C-N 121.362 -0.836 . . . . 0.0 109.546 -179.18 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.741 0 N-CA-C 107.775 -2.13 . . . . 0.0 107.775 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -164.04 -177.42 5.03 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 121.599 -0.942 . . . . 0.0 109.962 179.451 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.67 -161.72 14.25 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.518 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.48 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.5 Cg_exo -47.53 178.45 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 CA-C-N 118.997 1.398 . . . . 0.0 110.196 179.281 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -91.25 -177.56 4.9 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.056 -1.028 . . . . 0.0 110.371 -178.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.485 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.15 163.73 13.89 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.06 129.76 50.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.374 -1.074 . . . . 0.0 109.173 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.609 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.1 121.96 22.84 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.634 -0.666 . . . . 0.0 109.603 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.955 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -97.89 169.85 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.214 -0.928 . . . . 0.0 109.18 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.51 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -136.2 154.58 50.89 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.326 -0.859 . . . . 0.0 109.745 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.955 ' CE1' HD12 ' A' ' 110' ' ' ILE . 26.7 m-85 . . . . . 0 N--CA 1.487 1.376 0 O-C-N 121.301 -0.874 . . . . 0.0 109.421 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.478 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.496 0 CA-C-O 122.436 1.112 . . . . 0.0 110.905 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.929 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.5 t -111.74 108.71 18.24 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 123.071 1.415 . . . . 0.0 109.102 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.819 HG22 HG23 ' A' ' 21' ' ' VAL . 2.8 t -115.28 139.23 42.65 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.692 0 CA-C-N 114.326 -1.306 . . . . 0.0 110.196 -179.639 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.08 149.39 1.46 Allowed Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.3 -0.875 . . . . 0.0 108.783 -179.769 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.9 Cg_endo -77.0 151.22 93.69 Favored 'Cis proline' 0 C--N 1.312 -1.344 0 C-N-CA 123.489 -1.463 . . . . 0.0 109.238 -0.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' HG22 ' A' ' 110' ' ' ILE . 24.0 p -89.81 -24.36 21.47 Favored 'General case' 0 C--N 1.292 -1.924 0 O-C-N 121.46 -0.775 . . . . 0.0 109.395 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.515 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 12.4 m -136.68 164.6 27.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.35 -0.844 . . . . 0.0 109.801 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.85 38.79 30.23 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.79 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.2 mt -92.18 -44.1 8.98 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 123.125 1.441 . . . . 0.0 110.721 -178.325 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.88 146.17 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.364 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.329 179.989 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.9 p-10 -51.55 107.4 0.19 Allowed 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.713 0.768 . . . . 0.0 111.571 -178.633 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.8 14.95 8.98 Favored Glycine 0 N--CA 1.484 1.853 0 C-N-CA 119.445 -1.359 . . . . 0.0 112.924 177.435 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.79 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.5 t -105.85 -172.61 2.12 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 121.136 2.468 . . . . 0.0 109.557 179.077 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.73 HG13 ' C ' ' A' ' 67' ' ' LEU . 13.3 t -129.2 136.77 58.76 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.43 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.897 -179.096 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.648 HG13 ' CG2' ' A' ' 69' ' ' VAL . 15.5 m -110.81 156.42 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.512 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.36 109.05 18.45 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.114 -0.991 . . . . 0.0 108.953 179.818 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.819 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -103.74 140.35 22.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.837 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.929 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.47 160.05 39.67 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.717 -1.239 . . . . 0.0 110.026 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.604 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.67 144.47 15.59 Favored Glycine 0 C--N 1.293 -1.806 0 N-CA-C 107.995 -2.042 . . . . 0.0 107.995 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.14 125.48 13.09 Favored 'General case' 0 C--N 1.296 -1.734 0 O-C-N 120.806 -1.408 . . . . 0.0 108.983 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.42 26.33 25.77 Favored Glycine 0 N--CA 1.488 2.121 0 C-N-CA 119.279 -1.438 . . . . 0.0 109.796 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.591 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.7 OUTLIER -89.36 169.59 11.28 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 120.838 -1.389 . . . . 0.0 108.347 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.84 100.99 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 122.214 1.007 . . . . 0.0 109.921 -179.438 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.82 78.18 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.618 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.904 -179.477 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.88 34.12 0.27 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.551 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 18.5 p -139.06 105.43 5.28 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 121.154 -1.204 . . . . 0.0 111.262 -179.433 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.583 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.24 111.54 0.59 Allowed 'General case' 0 N--CA 1.497 1.924 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.676 178.088 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.466 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.8 m-30 -109.48 156.35 20.2 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.109 -0.994 . . . . 0.0 108.873 179.725 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -99.49 164.98 11.86 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.821 -1.174 . . . . 0.0 107.915 179.079 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.728 HG22 HG11 ' A' ' 21' ' ' VAL . 3.4 p -144.95 116.52 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.036 -1.04 . . . . 0.0 109.774 -178.276 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.48 -176.23 37.43 Favored Glycine 0 N--CA 1.494 2.519 0 C-N-CA 118.348 -1.882 . . . . 0.0 111.886 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.597 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.1 pt20 -100.4 109.6 21.77 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-O 121.976 0.893 . . . . 0.0 108.978 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.61 148.75 52.44 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.212 -0.93 . . . . 0.0 109.613 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.497 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.15 138.01 54.48 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.263 -0.898 . . . . 0.0 110.875 -178.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.12 27.0 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 177.915 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 m -105.0 14.84 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 120.842 -1.162 . . . . 0.0 110.518 -178.744 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.42 -175.23 0.08 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 120.931 -1.106 . . . . 0.0 110.005 179.738 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.28 98.92 2.76 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.428 -0.795 . . . . 0.0 109.489 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.63 27.62 31.84 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 120.203 -0.999 . . . . 0.0 111.433 179.096 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -118.17 106.12 19.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 O-C-N 120.66 -1.494 . . . . 0.0 107.225 178.871 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.3 tp -117.94 104.53 10.99 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.475 -1.391 . . . . 0.0 109.874 -177.829 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.085 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.94 109.36 22.13 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 120.745 -1.222 . . . . 0.0 107.932 178.77 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.489 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 5.0 t -108.92 162.13 14.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.028 -1.045 . . . . 0.0 110.379 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.505 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 12.9 t-20 -107.36 129.18 24.64 Favored Pre-proline 0 N--CA 1.5 2.03 0 O-C-N 121.424 -0.797 . . . . 0.0 109.63 -179.404 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.621 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.0 OUTLIER -71.18 20.24 0.23 Allowed 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 122.057 1.838 . . . . 0.0 111.95 179.388 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.505 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -107.81 2.68 23.74 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.515 -1.366 . . . . 0.0 108.841 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.552 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.01 17.89 2.82 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 179.418 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -81.76 86.94 6.37 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.524 -0.735 . . . . 0.0 111.086 -178.384 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -102.89 -165.54 1.18 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 178.19 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.459 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.8 137.13 0.09 Allowed 'General case' 0 N--CA 1.486 1.354 0 O-C-N 120.532 -1.355 . . . . 0.0 111.212 -179.399 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 1.013 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -155.2 156.58 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 178.37 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.583 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.69 141.67 31.21 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.952 -1.093 . . . . 0.0 109.879 -179.802 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.034 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.23 107.17 0.84 Allowed 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 122.45 1.119 . . . . 0.0 109.39 178.231 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.546 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.9 t0 -62.17 -138.54 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.001 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.7 -52.42 31.34 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.391 -0.818 . . . . 0.0 110.871 -178.443 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -103.61 -32.81 9.24 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 178.633 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.034 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.8 62.57 0.54 Allowed Glycine 0 C--N 1.297 -1.627 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 178.04 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 37.0 m -101.04 127.14 47.7 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 1.013 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -137.13 109.2 7.2 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 119.074 -1.05 . . . . 0.0 109.877 -179.089 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 48.2 p -121.27 119.69 32.99 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.282 -0.886 . . . . 0.0 109.417 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.529 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.56 145.7 31.96 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.581 -0.699 . . . . 0.0 109.289 179.831 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 20.3 p -98.91 143.34 29.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.407 -0.808 . . . . 0.0 109.736 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.73 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -141.07 163.0 34.15 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.483 -0.761 . . . . 0.0 109.141 -179.486 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.693 HG22 HG22 ' A' ' 18' ' ' VAL . 5.1 p -92.77 123.98 36.44 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.045 -1.035 . . . . 0.0 109.521 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.648 ' CG2' HG13 ' A' ' 19' ' ' VAL . 17.8 m -137.78 144.16 31.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.001 -1.062 . . . . 0.0 109.453 -179.586 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.596 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 4.3 ptt180 -138.89 -168.77 2.49 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.507 -1.371 . . . . 0.0 110.544 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.681 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 3.9 mtt180 -65.48 -73.81 0.12 Allowed 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.522 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -76.72 145.43 38.66 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 178.159 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 0.9 OUTLIER -164.98 138.68 4.83 Favored 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 117.446 -1.702 . . . . 0.0 110.678 -177.478 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.525 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 3.7 mp0 -35.22 120.97 0.55 Allowed 'General case' 0 N--CA 1.491 1.614 0 CA-C-O 121.455 0.645 . . . . 0.0 110.361 -178.726 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.085 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -96.19 51.34 1.65 Allowed Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.485 -0.865 . . . . 0.0 111.018 -179.379 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.621 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-85 -40.19 114.64 0.46 Allowed 'General case' 0 N--CA 1.508 2.455 0 O-C-N 121.079 -1.248 . . . . 0.0 109.776 179.567 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.684 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -85.73 125.67 33.39 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.855 -1.153 . . . . 0.0 109.754 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -65.24 58.04 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.908 0 O-C-N 120.789 -1.194 . . . . 0.0 109.748 179.154 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.552 ' N ' ' O ' ' A' ' 77' ' ' LEU . 5.6 t70 -154.97 16.7 0.43 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.13 -0.981 . . . . 0.0 109.559 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.85 -26.83 8.87 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.12 164.96 11.42 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.948 -1.325 . . . . 0.0 110.643 -179.287 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.482 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 2.1 ptm180 -105.38 137.3 43.41 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.684 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -81.15 -19.77 42.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.852 -1.155 . . . . 0.0 110.421 -178.598 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.62 176.1 19.23 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.679 -1.769 . . . . 0.0 108.679 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.97 106.44 1.24 Allowed 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.651 HG21 ' HB3' ' A' ' 46' ' ' ALA . 38.7 t -78.03 107.55 10.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.363 -0.836 . . . . 0.0 109.205 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.522 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -68.71 112.99 5.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.518 -0.738 . . . . 0.0 109.91 -179.371 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.681 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 7.5 m -58.43 -6.98 0.77 Allowed 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.632 -1.293 . . . . 0.0 110.424 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.8 p -87.08 -4.77 59.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.298 -1.501 . . . . 0.0 109.617 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.496 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -103.38 -47.08 4.4 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.245 -0.909 . . . . 0.0 108.94 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.08 -178.06 3.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.553 -0.717 . . . . 0.0 109.357 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.08 117.57 35.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.403 -0.811 . . . . 0.0 108.821 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.557 ' HB2' HD11 ' A' ' 110' ' ' ILE . 3.2 m -96.47 121.26 38.1 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.846 -1.159 . . . . 0.0 109.724 -179.114 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.573 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.46 146.55 28.7 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 122.384 1.088 . . . . 0.0 111.37 -179.391 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.443 ' CG1' HG11 ' A' ' 7' ' ' VAL . 57.5 t -103.59 109.94 28.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 177.62 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.469 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.63 -171.54 16.8 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.221 -1.942 . . . . 0.0 111.638 -177.653 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.28 178.74 4.21 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 -179.067 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.506 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.1 p . . . . . 0 C--N 1.296 -1.76 0 O-C-N 121.565 -0.709 . . . . 0.0 109.406 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.65 0 N-CA-C 107.778 -2.129 . . . . 0.0 107.778 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.97 -177.74 5.99 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.64 -0.918 . . . . 0.0 109.742 179.273 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.04 -162.16 15.52 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 108.445 -1.862 . . . . 0.0 108.445 -179.439 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.482 ' HG3' HD22 ' A' ' 26' ' ' LEU . 5.2 Cg_exo -47.27 178.71 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.644 0 CA-C-N 118.789 1.295 . . . . 0.0 110.313 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -92.42 -172.97 3.25 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.007 -1.058 . . . . 0.0 110.36 -178.923 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.469 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.33 163.34 14.81 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.28 131.12 48.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.424 -1.045 . . . . 0.0 109.075 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.573 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.81 120.68 19.74 Favored 'General case' 0 C--N 1.29 -2.021 0 O-C-N 121.613 -0.679 . . . . 0.0 109.842 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.818 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.4 pt -98.09 170.43 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.276 -0.89 . . . . 0.0 108.896 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.515 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.9 153.96 51.29 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.127 -0.983 . . . . 0.0 109.551 179.899 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.818 ' CE2' HD12 ' A' ' 110' ' ' ILE . 67.2 m-85 . . . . . 0 N--CA 1.486 1.346 0 O-C-N 121.249 -0.907 . . . . 0.0 109.527 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.596 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.409 0 CA-C-O 122.239 1.018 . . . . 0.0 110.974 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.019 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -101.61 104.51 15.38 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 122.439 1.114 . . . . 0.0 109.864 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.939 HG22 HG23 ' A' ' 21' ' ' VAL . 4.1 t -118.84 118.97 59.55 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.462 179.783 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.502 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.84 147.96 9.59 Favored Pre-proline 0 C--N 1.306 -1.324 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 -179.832 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.502 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.8 Cg_endo -76.17 151.31 95.02 Favored 'Cis proline' 0 C--N 1.309 -1.541 0 C-N-CA 123.593 -1.42 . . . . 0.0 109.596 -0.406 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' HG22 ' A' ' 110' ' ' ILE . 2.5 p -90.38 -25.37 20.46 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.426 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.497 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.1 m -136.05 165.86 24.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.609 -0.682 . . . . 0.0 109.331 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.22 37.58 36.71 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 108.463 -1.855 . . . . 0.0 108.463 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.0 mt -92.27 -43.0 9.53 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 123.297 1.522 . . . . 0.0 110.44 -178.33 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.48 144.35 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.29 0 CA-C-N 113.522 -1.672 . . . . 0.0 109.788 -179.62 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.608 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 4.7 p-10 -51.27 106.2 0.13 Allowed 'General case' 0 C--N 1.301 -1.54 0 CA-C-O 121.539 0.685 . . . . 0.0 111.597 -178.385 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.401 ' H ' ' HB3' ' A' ' 70' ' ' ARG . . . 113.38 15.95 8.58 Favored Glycine 0 N--CA 1.484 1.884 0 C-N-CA 119.473 -1.346 . . . . 0.0 112.855 177.297 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.1 t -104.41 -170.88 1.83 Allowed 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 121.169 2.484 . . . . 0.0 109.727 179.176 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.731 HG13 ' C ' ' A' ' 67' ' ' LEU . 14.2 t -130.38 138.92 52.65 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.166 -178.883 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.569 HG11 HD11 ' A' ' 13' ' ' LEU . 33.7 m -118.18 155.04 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tttt -109.26 109.4 20.31 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.162 -0.961 . . . . 0.0 109.509 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.939 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -105.86 124.59 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.489 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.019 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.66 167.21 11.55 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.668 -1.27 . . . . 0.0 109.253 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.615 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.07 141.05 12.38 Favored Glycine 0 C--N 1.296 -1.666 0 N-CA-C 107.466 -2.254 . . . . 0.0 107.466 179.672 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.28 123.94 11.84 Favored 'General case' 0 C--N 1.295 -1.8 0 O-C-N 120.571 -1.546 . . . . 0.0 108.819 179.363 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.37 27.12 23.69 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.13 -1.51 . . . . 0.0 109.899 -179.666 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.532 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -88.06 174.33 8.34 Favored 'General case' 0 C--N 1.308 -1.227 0 O-C-N 120.788 -1.419 . . . . 0.0 108.473 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.001 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.88 97.54 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 122.257 1.027 . . . . 0.0 109.724 -179.853 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.637 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.99 77.26 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.437 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.77 33.65 0.29 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.302 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 50.5 p -145.53 112.0 5.81 Favored 'General case' 0 C--N 1.31 -1.145 0 O-C-N 120.896 -1.355 . . . . 0.0 111.448 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.59 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.52 116.19 1.5 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.934 178.286 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.478 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.0 m-30 -112.28 153.87 26.51 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.225 -0.922 . . . . 0.0 108.708 179.521 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -98.92 165.36 11.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.849 -1.157 . . . . 0.0 108.095 179.003 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 34' ' ' VAL . 4.8 p -145.15 116.64 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.114 -0.991 . . . . 0.0 109.878 -177.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.53 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.55 -175.97 39.07 Favored Glycine 0 N--CA 1.491 2.336 0 C-N-CA 118.267 -1.92 . . . . 0.0 111.754 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.571 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -100.22 113.75 26.67 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.622 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 85.0 m -131.88 153.81 49.84 Favored 'General case' 0 C--N 1.292 -1.901 0 O-C-N 121.6 -0.688 . . . . 0.0 109.602 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.663 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -129.88 136.78 49.92 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.448 -0.782 . . . . 0.0 110.565 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.908 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.69 114.45 26.38 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 178.318 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m -105.45 15.08 7.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.951 -1.093 . . . . 0.0 110.713 -178.47 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.782 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.22 -174.54 0.07 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.87 -1.144 . . . . 0.0 110.08 179.699 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 40.1 p -71.33 96.81 1.49 Allowed 'General case' 0 N--CA 1.485 1.323 0 O-C-N 121.382 -0.824 . . . . 0.0 109.878 -179.631 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.26 27.95 31.92 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 120.21 -0.995 . . . . 0.0 111.564 178.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.782 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -115.54 106.38 20.36 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.54 -1.565 . . . . 0.0 107.464 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.908 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -116.31 106.54 13.77 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.591 -1.318 . . . . 0.0 109.912 -177.621 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.123 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -96.77 113.22 24.76 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 120.821 -1.174 . . . . 0.0 108.515 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.575 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . 97.4 m -105.34 147.39 28.21 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.279 -0.888 . . . . 0.0 110.361 -178.468 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.604 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 32.7 t30 -97.52 135.94 21.5 Favored Pre-proline 0 N--CA 1.505 2.305 0 O-C-N 120.937 -1.102 . . . . 0.0 108.759 178.797 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.62 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.8 Cg_endo -74.85 26.51 0.36 Allowed 'Trans proline' 0 C--N 1.319 -1.004 0 C-N-CA 122.396 2.064 . . . . 0.0 112.29 -179.098 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.604 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -120.76 6.05 10.48 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.213 -1.554 . . . . 0.0 109.536 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.6 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.48 17.93 2.38 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 179.367 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.575 ' CE2' ' HB3' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -83.58 89.84 7.16 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.248 -178.437 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.588 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -109.99 -166.77 1.12 Allowed 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.153 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.463 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.66 135.61 0.09 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.421 -1.425 . . . . 0.0 111.573 -179.294 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.803 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.2 p -151.73 159.72 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 177.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.6 144.44 27.89 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.731 -1.231 . . . . 0.0 110.016 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.001 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.51 107.83 2.2 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 122.385 1.088 . . . . 0.0 109.342 178.563 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.555 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.7 t0 -62.72 -139.07 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.886 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.637 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.28 -52.09 29.7 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.427 -0.795 . . . . 0.0 110.727 -178.582 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -104.48 -32.48 8.98 Favored 'General case' 0 C--N 1.286 -2.155 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 178.645 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.972 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.67 68.22 0.65 Allowed Glycine 0 C--N 1.297 -1.587 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 178.294 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.0 m -103.47 128.94 50.54 Favored 'General case' 0 N--CA 1.483 1.224 0 O-C-N 121.336 -1.097 . . . . 0.0 109.15 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.803 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.63 108.72 7.69 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 119.469 -0.892 . . . . 0.0 109.574 -179.573 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.447 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 85.7 p -116.85 117.41 29.66 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.089 -1.007 . . . . 0.0 109.374 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.618 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.32 142.51 28.35 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.409 -0.807 . . . . 0.0 109.956 -179.794 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 25.1 p -102.14 141.32 35.15 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.496 -0.752 . . . . 0.0 109.265 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.776 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.58 167.05 23.07 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.337 -0.852 . . . . 0.0 109.509 -179.384 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.699 HG22 HG22 ' A' ' 18' ' ' VAL . 2.5 p -96.17 124.74 40.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.197 -0.94 . . . . 0.0 109.349 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.537 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 18.7 m -138.43 142.55 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.939 -1.101 . . . . 0.0 109.922 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.608 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.7 ptt180 -138.56 -164.81 1.7 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.732 -1.23 . . . . 0.0 109.908 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.564 ' HG3' ' CD1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -74.3 -82.88 0.06 Allowed 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 -179.844 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.498 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.76 136.63 57.96 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 178.698 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.663 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.46 133.49 5.75 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 118.058 -1.457 . . . . 0.0 110.562 -177.603 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.56 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 3.1 mm-40 -33.04 120.07 0.35 Allowed 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.619 0.723 . . . . 0.0 110.386 -178.456 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.123 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.9 50.74 2.54 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.484 -179.074 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.62 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -37.77 116.36 0.49 Allowed 'General case' 0 N--CA 1.507 2.381 0 O-C-N 121.136 -1.214 . . . . 0.0 110.157 179.365 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.653 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.2 tp -86.08 126.09 33.93 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 120.895 -1.128 . . . . 0.0 109.716 -179.777 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 39.3 t80 -63.62 58.42 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.015 -1.053 . . . . 0.0 110.114 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 21.2 t0 -161.01 20.27 0.13 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.904 -1.122 . . . . 0.0 109.737 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.52 -29.09 5.01 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.484 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 9.7 p -95.48 163.88 13.04 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.076 -1.249 . . . . 0.0 110.203 -179.542 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 3.3 ptm180 -109.25 139.85 43.64 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.653 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.6 t90 -82.0 -21.56 37.01 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.861 -1.149 . . . . 0.0 110.353 -178.867 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.81 175.68 18.14 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.79 110.57 2.11 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 179.037 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.615 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.1 t -82.32 102.61 8.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.652 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.608 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.97 111.21 2.75 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.489 -0.757 . . . . 0.0 109.632 -179.313 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.563 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.23 -4.93 5.8 Favored 'General case' 0 N--CA 1.498 1.973 0 C-N-CA 118.304 -1.358 . . . . 0.0 109.813 179.534 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.3 p -85.51 3.62 39.56 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.786 -1.196 . . . . 0.0 108.823 179.255 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.608 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -119.2 -49.82 2.38 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.402 -0.811 . . . . 0.0 108.959 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.71 -178.42 3.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.382 -0.824 . . . . 0.0 109.538 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.64 114.45 28.62 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.511 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.5 m -97.47 121.9 39.9 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.932 -1.105 . . . . 0.0 109.746 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.592 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.74 147.11 26.86 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.412 1.101 . . . . 0.0 111.245 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.656 ' HB ' HG11 ' A' ' 7' ' ' VAL . 52.9 t -103.62 110.82 31.13 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 106.913 -1.514 . . . . 0.0 106.913 177.796 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.475 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.51 -170.8 18.77 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.076 -2.012 . . . . 0.0 111.884 -177.587 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.525 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -115.96 -179.89 3.79 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 -179.167 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.515 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.4 p . . . . . 0 C--N 1.296 -1.757 0 O-C-N 121.515 -0.741 . . . . 0.0 109.317 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.624 0 N-CA-C 107.833 -2.107 . . . . 0.0 107.833 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.74 -178.16 6.87 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.572 -0.958 . . . . 0.0 109.754 179.255 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.68 -161.45 14.73 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.257 -1.937 . . . . 0.0 108.257 -179.325 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.0 Cg_exo -47.6 179.65 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.82 1.31 . . . . 0.0 110.261 179.19 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -94.05 -170.54 2.33 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.066 -1.021 . . . . 0.0 110.334 -178.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.475 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.31 162.75 18.34 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.11 128.45 50.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.381 -1.07 . . . . 0.0 109.15 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.592 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.24 119.64 15.67 Favored 'General case' 0 C--N 1.289 -2.056 0 O-C-N 121.669 -0.644 . . . . 0.0 109.738 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.884 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.12 171.31 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.219 -0.926 . . . . 0.0 109.097 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.497 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.01 156.62 47.07 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.074 -1.016 . . . . 0.0 109.844 -179.822 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.884 ' CE2' HD12 ' A' ' 110' ' ' ILE . 96.8 m-85 . . . . . 0 N--CA 1.486 1.327 0 O-C-N 121.191 -0.943 . . . . 0.0 109.609 -179.686 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.466 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.441 0 CA-C-O 122.354 1.074 . . . . 1.0 110.597 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.948 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.6 t -110.31 108.67 18.83 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 123.085 1.421 . . . . 1.0 109.01 179.355 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.838 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -117.19 136.36 54.6 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.702 0 CA-C-N 114.3 -1.318 . . . . 1.0 110.002 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.456 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.31 148.76 2.43 Favored Pre-proline 0 N--CA 1.487 1.376 0 O-C-N 121.287 -0.883 . . . . 1.0 108.897 -179.64 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.456 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -79.21 148.67 82.13 Favored 'Cis proline' 0 C--N 1.311 -1.408 0 C-N-CA 123.438 -1.484 . . . . 1.0 109.52 -1.052 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.644 ' HA ' HG22 ' A' ' 110' ' ' ILE . 42.8 p -88.34 -25.5 22.71 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 108.981 -0.748 . . . . 1.0 108.981 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 0.7 OUTLIER -131.91 161.86 32.03 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.454 -0.779 . . . . 1.0 109.674 -179.787 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.88 37.63 29.14 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 108.592 -1.803 . . . . 1.0 108.592 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.79 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.2 mt -92.78 -43.54 8.97 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 123.099 1.428 . . . . 1.0 110.636 -178.343 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.14 145.19 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.295 0 CA-C-N 113.571 -1.65 . . . . 1.0 110.03 -179.596 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 14.8 p-10 -51.16 106.93 0.15 Allowed 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.462 0.648 . . . . 1.0 111.564 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.47 15.22 9.02 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 119.385 -1.388 . . . . 1.0 112.871 177.217 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.79 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.5 t -104.54 -171.69 1.97 Allowed 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 121.133 2.467 . . . . 1.0 109.671 179.204 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.727 HG13 ' C ' ' A' ' 67' ' ' LEU . 15.1 t -128.58 137.56 56.99 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.387 0 CA-C-N 114.874 -1.057 . . . . 1.0 110.979 -179.066 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.527 HG11 ' CD1' ' A' ' 13' ' ' LEU . 35.2 m -114.13 154.75 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 108.808 -0.812 . . . . 1.0 108.808 179.036 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.65 109.23 20.37 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.226 -0.921 . . . . 1.0 108.797 179.718 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.838 HG23 HG22 ' A' ' 7' ' ' VAL . 2.2 p -103.82 141.6 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.727 -0.842 . . . . 1.0 108.727 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.948 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -138.24 160.23 39.99 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.72 -1.238 . . . . 1.0 109.982 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.76 144.21 15.37 Favored Glycine 0 C--N 1.295 -1.742 0 N-CA-C 108.089 -2.004 . . . . 1.0 108.089 179.811 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.11 125.53 13.16 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 120.913 -1.345 . . . . 1.0 108.828 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.08 27.09 26.89 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.216 -1.469 . . . . 1.0 109.912 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.576 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.8 mt -87.13 175.02 8.28 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 120.799 -1.412 . . . . 1.0 108.463 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.016 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.58 99.74 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.978 -1.076 . . . . 1.0 109.689 -179.79 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.563 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 77.76 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 115.226 -0.897 . . . . 1.0 110.247 -179.063 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.4 34.13 0.33 Allowed Glycine 0 N--CA 1.488 2.117 0 N-CA-C 109.496 -1.441 . . . . 1.0 109.496 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.56 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 42.9 p -141.24 108.56 5.53 Favored 'General case' 0 C--N 1.306 -1.302 0 O-C-N 121.123 -1.222 . . . . 1.0 111.311 -179.636 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.589 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.35 110.06 0.37 Allowed 'General case' 0 N--CA 1.497 1.888 0 CA-C-N 115.9 -0.591 . . . . 1.0 109.455 178.031 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.2 m-30 -106.75 155.99 19.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.133 -0.98 . . . . 1.0 108.982 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.486 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -99.82 165.17 11.7 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.876 -1.157 . . . . 1.0 107.876 179.045 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.692 HG13 ' O ' ' A' ' 34' ' ' VAL . 7.5 p -145.7 114.85 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.066 -1.021 . . . . 1.0 109.941 -178.048 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.01 -176.41 37.3 Favored Glycine 0 N--CA 1.492 2.398 0 C-N-CA 118.499 -1.81 . . . . 1.0 111.564 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.646 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.5 pt20 -100.1 110.02 22.31 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-O 121.941 0.877 . . . . 1.0 108.966 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -130.08 150.81 51.18 Favored 'General case' 0 C--N 1.296 -1.74 0 O-C-N 121.217 -0.927 . . . . 1.0 109.837 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.522 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -126.83 139.78 52.84 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.222 -0.924 . . . . 1.0 110.808 -179.037 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.897 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.15 114.78 26.61 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 107.62 -1.252 . . . . 1.0 107.62 178.246 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -104.6 14.99 6.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 120.938 -1.101 . . . . 1.0 110.575 -178.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.762 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.61 -176.28 0.09 Allowed 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.863 -1.148 . . . . 1.0 110.184 179.716 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.769 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.89 97.47 1.42 Allowed 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.436 -0.79 . . . . 1.0 109.847 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.63 27.8 34.32 Favored Glycine 0 N--CA 1.493 2.493 0 C-N-CA 120.145 -1.026 . . . . 1.0 111.434 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.762 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.32 106.6 20.65 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 O-C-N 120.668 -1.489 . . . . 1.0 107.171 178.868 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.897 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.2 tp -116.06 104.67 11.8 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.449 -1.407 . . . . 1.0 109.982 -177.691 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.042 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.23 109.58 22.31 Favored 'General case' 0 N--CA 1.485 1.291 0 O-C-N 120.818 -1.176 . . . . 1.0 108.079 178.848 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.18 166.21 10.79 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.912 -1.117 . . . . 1.0 110.356 -178.814 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.73 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 46.0 t30 -112.01 129.85 23.84 Favored Pre-proline 0 N--CA 1.501 2.1 0 O-C-N 121.366 -0.834 . . . . 1.0 109.796 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.634 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.5 Cg_endo -71.65 22.31 0.25 Allowed 'Trans proline' 0 CA--C 1.545 1.056 0 C-N-CA 122.219 1.946 . . . . 1.0 112.342 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.73 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -109.87 2.79 20.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.415 -1.428 . . . . 1.0 109.049 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.571 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.65 18.87 2.52 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.135 -1.432 . . . . 1.0 107.135 179.41 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -82.13 89.73 6.5 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.934 -0.707 . . . . 1.0 111.127 -178.395 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -106.97 -166.87 1.21 Allowed 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 107.562 -1.273 . . . . 1.0 107.562 178.077 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.2 136.35 0.1 Allowed 'General case' 0 C--N 1.306 -1.307 0 O-C-N 120.538 -1.351 . . . . 1.0 111.304 -179.346 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.901 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -154.46 158.8 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.635 -1.246 . . . . 1.0 107.635 178.337 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.589 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.8 142.25 30.57 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.807 -1.183 . . . . 1.0 109.901 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.53 107.12 1.06 Allowed 'General case' 0 C--N 1.299 -1.602 0 CA-C-O 122.423 1.106 . . . . 1.0 109.295 178.253 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.552 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.2 p-10 -58.88 -138.84 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.583 -0.735 . . . . 1.0 110.821 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.563 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -54.65 -49.81 69.68 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.374 -0.829 . . . . 1.0 110.231 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.421 ' OD1' ' N ' ' A' ' 61' ' ' GLY . 12.3 p30 -100.23 -38.82 8.33 Favored 'General case' 0 C--N 1.285 -2.219 0 N-CA-C 106.122 -1.807 . . . . 1.0 106.122 178.492 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.999 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.92 65.93 0.55 Allowed Glycine 0 C--N 1.296 -1.648 0 N-CA-C 110.239 -1.144 . . . . 1.0 110.239 178.263 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.4 m -102.82 129.12 49.39 Favored 'General case' 0 N--CA 1.483 1.19 0 O-C-N 121.49 -1.006 . . . . 1.0 108.948 179.043 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.901 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.17 108.87 6.61 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 119.274 -0.971 . . . . 1.0 109.921 -179.371 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.483 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -124.02 120.96 33.97 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.244 -0.91 . . . . 1.0 109.801 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.465 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -146.44 149.48 33.78 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.486 -0.759 . . . . 1.0 109.07 179.587 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.5 p -100.31 145.62 27.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.312 -0.867 . . . . 1.0 109.741 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.727 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -145.95 165.81 27.87 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.472 -0.768 . . . . 1.0 109.242 -179.457 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.693 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -96.53 124.88 40.66 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.0 -1.063 . . . . 1.0 109.477 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.535 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.0 m -138.74 143.1 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 120.972 -1.08 . . . . 1.0 109.808 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.596 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.6 ptt180 -140.02 -163.46 1.51 Allowed 'General case' 0 N--CA 1.486 1.351 0 O-C-N 120.593 -1.317 . . . . 1.0 109.871 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.571 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -75.03 -82.28 0.07 Allowed 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.083 -1.011 . . . . 1.0 108.87 -179.609 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.491 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -62.75 137.51 58.28 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.305 -1.497 . . . . 1.0 107.357 178.861 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.563 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.2 OUTLIER -163.22 134.09 4.69 Favored 'General case' 0 C--N 1.293 -1.863 0 C-N-CA 118.045 -1.462 . . . . 1.0 110.522 -177.656 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.486 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . 3.6 mm-40 -32.56 121.21 0.33 Allowed 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 121.642 0.734 . . . . 1.0 110.773 -178.357 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.042 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.06 49.78 3.05 Favored Glycine 0 N--CA 1.496 2.649 0 C-N-CA 120.754 -0.736 . . . . 1.0 111.546 -179.139 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.634 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-30 -38.57 115.42 0.46 Allowed 'General case' 0 N--CA 1.511 2.594 0 O-C-N 121.028 -1.277 . . . . 1.0 110.14 179.318 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.794 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.05 125.89 34.4 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.857 -1.152 . . . . 1.0 109.744 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -64.68 58.26 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.927 0 O-C-N 120.86 -1.15 . . . . 1.0 109.869 179.403 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -158.08 18.47 0.24 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.035 -1.04 . . . . 1.0 109.677 -179.948 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.21 -27.56 6.11 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.919 -1.272 . . . . 1.0 109.919 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -98.17 164.7 12.21 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.069 -1.253 . . . . 1.0 110.337 -179.482 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.519 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.13 140.35 41.46 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.858 -0.793 . . . . 1.0 108.858 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.794 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.2 t90 -84.2 -22.34 30.95 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.845 -1.159 . . . . 1.0 110.604 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.73 175.13 17.55 Favored Glycine 0 N--CA 1.485 1.922 0 N-CA-C 108.688 -1.765 . . . . 1.0 108.688 -179.484 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.67 112.0 2.65 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.712 -1.218 . . . . 1.0 107.712 179.243 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.642 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.3 t -84.55 103.95 12.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.289 -0.882 . . . . 1.0 108.928 -179.049 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.622 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -66.58 111.65 3.74 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.357 -0.839 . . . . 1.0 109.645 -179.439 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.571 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.38 -5.3 4.97 Favored 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 118.172 -1.411 . . . . 1.0 109.948 179.501 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 45.5 p -84.39 0.46 49.3 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.75 -1.219 . . . . 1.0 108.772 179.195 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.622 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -115.84 -50.35 2.69 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.392 -0.817 . . . . 1.0 109.054 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.29 -178.01 3.54 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.508 -0.745 . . . . 1.0 109.514 179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.09 115.36 30.04 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.369 -0.832 . . . . 1.0 108.95 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.523 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -97.29 123.2 41.02 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.901 -1.125 . . . . 1.0 109.917 -179.094 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.6 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.28 148.2 26.62 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-O 122.373 1.082 . . . . 1.0 111.102 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.434 ' CG1' HG11 ' A' ' 7' ' ' VAL . 61.1 t -103.23 110.2 29.09 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 N-CA-C 106.721 -1.585 . . . . 1.0 106.721 177.618 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.452 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.46 -172.78 18.7 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 118.08 -2.01 . . . . 1.0 111.679 -177.614 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.483 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -114.77 179.88 3.82 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.945 -0.761 . . . . 1.0 108.945 -179.175 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.486 ' O ' ' N ' ' A' ' 33' ' ' ASP . 66.9 p . . . . . 0 C--N 1.295 -1.766 0 O-C-N 121.472 -0.768 . . . . 1.0 109.291 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.722 0 N-CA-C 107.742 -2.143 . . . . 1.0 107.742 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.43 -177.96 6.92 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.675 -0.897 . . . . 1.0 109.935 179.254 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.7 -163.84 19.94 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 108.319 -1.912 . . . . 1.0 108.319 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.4 Cg_exo -47.68 177.88 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 CA-C-N 118.763 1.281 . . . . 1.0 110.233 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -94.86 -176.25 3.8 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.236 -0.915 . . . . 1.0 110.186 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.452 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.68 163.98 13.06 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.787 -1.325 . . . . 1.0 109.787 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.5 132.35 46.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.381 -1.07 . . . . 1.0 109.063 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.6 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.0 125.44 27.62 Favored 'General case' 0 C--N 1.29 -2.017 0 O-C-N 121.649 -0.657 . . . . 1.0 109.868 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.87 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.67 171.95 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.356 -0.84 . . . . 1.0 108.953 179.611 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.4 OUTLIER -136.51 156.27 48.83 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.118 -0.989 . . . . 1.0 109.58 -179.925 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.87 ' CE1' HD12 ' A' ' 110' ' ' ILE . 93.0 m-85 . . . . . 0 N--CA 1.484 1.274 0 O-C-N 121.134 -0.979 . . . . 1.0 109.506 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.547 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.398 0 CA-C-O 122.086 0.946 . . . . 0.0 111.047 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.005 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -100.88 104.32 15.53 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-O 122.407 1.099 . . . . 0.0 109.816 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.944 HG22 HG23 ' A' ' 21' ' ' VAL . 6.2 t -119.79 118.0 55.66 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.459 0 CA-C-O 121.694 0.759 . . . . 0.0 110.405 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.78 149.08 7.93 Favored Pre-proline 0 N--CA 1.488 1.425 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 -179.568 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -75.26 152.85 98.33 Favored 'Cis proline' 0 C--N 1.309 -1.535 0 C-N-CA 123.583 -1.424 . . . . 0.0 109.762 -0.301 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.658 ' HA ' HG22 ' A' ' 110' ' ' ILE . 6.5 m -91.5 -25.0 19.48 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.498 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.8 m -137.85 165.1 27.3 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.637 -0.664 . . . . 0.0 109.253 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.27 37.49 31.8 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 108.564 -1.814 . . . . 0.0 108.564 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.741 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.0 mt -92.07 -42.43 9.95 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 123.311 1.529 . . . . 0.0 110.522 -178.487 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.67 142.67 0.05 OUTLIER 'General case' 0 C--N 1.259 -3.327 0 CA-C-N 113.405 -1.725 . . . . 0.0 109.731 -179.644 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.607 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.6 p-10 -50.28 105.78 0.1 Allowed 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.521 0.677 . . . . 0.0 111.473 -178.549 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.49 14.22 8.33 Favored Glycine 0 N--CA 1.485 1.928 0 C-N-CA 119.413 -1.375 . . . . 0.0 113.018 177.37 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.741 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -106.3 -172.57 2.11 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 121.221 2.51 . . . . 0.0 109.832 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.852 HG22 HG22 ' A' ' 68' ' ' THR . 18.8 t -129.0 139.76 51.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 CA-C-N 114.823 -1.08 . . . . 0.0 111.204 -178.644 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.63 HG11 HD11 ' A' ' 13' ' ' LEU . 27.1 m -115.88 155.61 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.553 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.7 tttt -107.86 108.79 20.11 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.021 -1.05 . . . . 0.0 109.552 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.944 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -106.8 122.67 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.005 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.83 167.48 11.36 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 120.795 -1.191 . . . . 0.0 109.064 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.86 142.44 13.95 Favored Glycine 0 C--N 1.295 -1.733 0 N-CA-C 107.935 -2.066 . . . . 0.0 107.935 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -147.16 123.7 11.07 Favored 'General case' 0 C--N 1.294 -1.834 0 O-C-N 120.812 -1.405 . . . . 0.0 108.64 179.237 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.19 27.25 23.72 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 119.313 -1.422 . . . . 0.0 109.838 -179.595 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.534 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.6 mt -87.73 175.14 8.0 Favored 'General case' 0 C--N 1.308 -1.236 0 O-C-N 120.877 -1.367 . . . . 0.0 108.466 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.61 96.95 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.017 -1.052 . . . . 0.0 109.541 -179.899 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.699 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.49 76.76 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.791 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.533 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.44 33.49 0.3 Allowed Glycine 0 N--CA 1.486 2.016 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.198 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.618 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.6 t -147.12 114.55 6.31 Favored 'General case' 0 C--N 1.308 -1.223 0 O-C-N 120.791 -1.417 . . . . 0.0 111.173 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.82 127.32 6.27 Favored 'General case' 0 N--CA 1.49 1.528 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.689 178.293 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.618 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 9.1 m-85 -116.33 148.61 40.4 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.529 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -101.21 149.33 24.11 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.805 -1.185 . . . . 0.0 107.92 179.135 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.634 HG23 HD23 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -127.43 126.7 67.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.271 -0.893 . . . . 0.0 109.371 -177.935 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -174.52 174.97 46.79 Favored Glycine 0 N--CA 1.495 2.612 0 C-N-CA 117.833 -2.127 . . . . 0.0 112.42 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.585 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -101.36 108.47 20.1 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.473 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.8 m -131.24 147.92 52.64 Favored 'General case' 0 C--N 1.295 -1.772 0 O-C-N 121.251 -0.905 . . . . 0.0 109.942 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.43 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.02 139.04 53.84 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.394 -0.816 . . . . 0.0 110.609 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.879 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.42 115.03 26.87 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 178.159 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -106.11 14.85 7.41 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 120.963 -1.085 . . . . 0.0 110.529 -178.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.776 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.14 -174.61 0.08 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.848 -1.157 . . . . 0.0 110.121 179.667 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 5.9 p -71.46 96.78 1.54 Allowed 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.46 -0.775 . . . . 0.0 109.931 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 27.83 32.9 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 120.171 -1.014 . . . . 0.0 111.558 178.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.776 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.26 106.28 20.24 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 O-C-N 120.552 -1.558 . . . . 0.0 107.267 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.879 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.3 tp -117.37 104.92 11.61 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.454 -1.404 . . . . 0.0 109.913 -177.686 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.038 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.84 109.61 22.33 Favored 'General case' 0 N--CA 1.485 1.287 0 O-C-N 120.706 -1.246 . . . . 0.0 108.296 178.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.3 t -105.97 163.93 12.36 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.041 -1.037 . . . . 0.0 110.198 -178.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.623 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 20.0 t30 -107.36 139.12 20.19 Favored Pre-proline 0 N--CA 1.502 2.16 0 O-C-N 121.327 -0.858 . . . . 0.0 109.81 -179.372 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.569 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 7.8 Cg_endo -75.88 27.73 0.39 Allowed 'Trans proline' 0 C--N 1.32 -0.964 0 C-N-CA 122.59 2.194 . . . . 0.0 112.135 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.623 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -124.44 9.61 8.47 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.242 -1.536 . . . . 0.0 109.679 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.567 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.46 15.63 2.76 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.403 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -77.69 86.92 3.97 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.856 -0.737 . . . . 0.0 111.421 -178.265 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.605 ' CB ' HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.34 -169.77 1.85 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 177.954 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.71 134.65 0.08 Allowed 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.57 -1.331 . . . . 0.0 111.454 -179.392 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.912 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -160.47 154.73 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 178.18 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.568 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.56 144.83 26.85 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.741 -1.225 . . . . 0.0 109.572 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.07 106.74 1.69 Allowed 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 122.48 1.134 . . . . 0.0 109.476 178.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.545 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.5 p-10 -59.78 -138.83 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.982 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.893 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.699 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.37 -50.44 59.56 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.467 -0.771 . . . . 0.0 110.548 -178.625 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -104.97 -34.63 7.95 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 178.585 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.966 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.88 68.32 0.59 Allowed Glycine 0 C--N 1.298 -1.543 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 177.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 59.4 m -103.21 129.23 50.08 Favored 'General case' 0 N--CA 1.484 1.274 0 O-C-N 121.358 -1.084 . . . . 0.0 108.83 178.836 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.912 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.12 109.27 7.75 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.281 -0.967 . . . . 0.0 110.073 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.6 m -110.23 118.38 36.19 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.205 -0.934 . . . . 0.0 108.787 179.499 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.458 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.24 139.08 28.45 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.436 -0.79 . . . . 0.0 110.253 -179.514 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 78.8 p -103.18 140.79 36.9 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 179.416 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.759 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -142.84 164.1 31.02 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.173 -0.955 . . . . 0.0 109.994 -179.148 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.852 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -97.59 125.49 42.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.339 -0.851 . . . . 0.0 109.129 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.553 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.2 m -136.44 143.64 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.908 -1.12 . . . . 0.0 109.803 -179.087 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.607 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -146.7 -176.12 5.06 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.44 -1.413 . . . . 0.0 111.156 -179.787 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.613 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.91 -100.54 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 -179.581 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.05 140.4 49.27 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 179.353 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.44 135.94 6.16 Favored 'General case' 0 C--N 1.294 -1.817 0 C-N-CA 118.584 -1.246 . . . . 0.0 109.764 -177.996 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.553 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 3.9 mm-40 -33.07 121.47 0.37 Allowed 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.547 0.689 . . . . 0.0 110.431 -178.482 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.038 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.89 48.08 2.74 Favored Glycine 0 N--CA 1.492 2.408 0 C-N-CA 120.602 -0.808 . . . . 0.0 111.195 -179.177 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.569 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -38.22 115.18 0.42 Allowed 'General case' 0 N--CA 1.511 2.623 0 O-C-N 121.118 -1.225 . . . . 0.0 109.974 179.695 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.689 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.29 125.76 34.42 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.944 -1.098 . . . . 0.0 109.321 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.6 t80 -64.2 58.65 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.891 -1.131 . . . . 0.0 110.215 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t0 -160.67 20.0 0.14 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.973 -1.079 . . . . 0.0 109.749 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.93 -27.8 5.3 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.439 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 80.7 p -94.22 159.42 15.14 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.038 -1.272 . . . . 0.0 110.269 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.495 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 4.4 ptt180 -107.32 137.59 45.09 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.689 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.9 t90 -83.76 -18.51 37.53 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.821 -1.174 . . . . 0.0 110.79 -178.231 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.97 175.08 19.8 Favored Glycine 0 N--CA 1.485 1.937 0 N-CA-C 108.711 -1.755 . . . . 0.0 108.711 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.21 106.77 1.15 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.604 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.4 t -79.1 106.41 10.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.286 -0.884 . . . . 0.0 109.264 -179.025 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.638 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -65.84 111.13 3.12 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.533 -0.73 . . . . 0.0 109.904 -179.442 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.613 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.26 -4.97 4.21 Favored 'General case' 0 N--CA 1.499 1.98 0 C-N-CA 118.246 -1.382 . . . . 0.0 109.814 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -86.39 -0.49 56.06 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.891 -1.131 . . . . 0.0 109.156 179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.638 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -113.31 -50.05 2.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.392 -0.818 . . . . 0.0 109.013 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.74 179.96 4.12 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.453 -0.779 . . . . 0.0 109.427 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.69 115.73 31.03 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.366 -0.834 . . . . 0.0 109.103 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.72 121.07 38.16 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.917 -1.114 . . . . 0.0 109.383 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.605 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.18 146.15 27.2 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-O 122.273 1.035 . . . . 0.0 111.193 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.447 ' HB ' HG11 ' A' ' 7' ' ' VAL . 71.7 t -105.73 112.2 38.12 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.168 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.516 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -152.49 -169.98 18.44 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 118.018 -2.039 . . . . 0.0 111.578 -178.011 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.634 HD23 HG23 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -112.64 -179.0 3.54 Favored 'General case' 0 N--CA 1.484 1.272 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -179.189 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.487 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.17 -0.956 . . . . 0.0 109.826 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.679 0 N-CA-C 107.709 -2.156 . . . . 0.0 107.709 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.26 -177.73 6.22 Favored 'General case' 0 C--N 1.307 -1.266 0 O-C-N 121.553 -0.969 . . . . 0.0 109.681 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.497 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -162.57 -159.47 10.37 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.275 -1.93 . . . . 0.0 108.275 -179.215 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.497 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.4 Cg_exo -47.21 179.98 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.675 0 CA-C-N 118.667 1.234 . . . . 0.0 110.37 179.183 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -92.57 -178.27 4.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.033 -1.042 . . . . 0.0 110.645 -178.767 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.516 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.02 163.57 13.25 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.402 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.08 128.79 54.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.422 -1.046 . . . . 0.0 109.214 -179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.605 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.86 119.04 15.48 Favored 'General case' 0 C--N 1.29 -2.016 0 O-C-N 121.721 -0.612 . . . . 0.0 109.491 179.576 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.897 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.01 171.52 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.248 -0.908 . . . . 0.0 109.042 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.498 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -138.8 159.59 41.74 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.161 -0.962 . . . . 0.0 109.986 -179.696 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.897 ' CE2' HD12 ' A' ' 110' ' ' ILE . 96.8 m-85 . . . . . 0 N--CA 1.485 1.312 0 O-C-N 121.18 -0.95 . . . . 0.0 109.582 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.545 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.429 0 CA-C-O 122.274 1.035 . . . . 0.0 110.429 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.941 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.4 t -109.74 108.69 19.13 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 123.05 1.405 . . . . 0.0 109.286 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.815 HG22 HG23 ' A' ' 21' ' ' VAL . 1.3 t -116.32 136.35 53.59 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.689 0 CA-C-N 114.164 -1.38 . . . . 0.0 109.903 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.461 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -172.88 149.05 1.78 Allowed Pre-proline 0 N--CA 1.487 1.405 0 O-C-N 121.194 -0.941 . . . . 0.0 108.883 -179.616 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.461 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.2 Cg_endo -77.24 151.33 93.05 Favored 'Cis proline' 0 C--N 1.313 -1.332 0 C-N-CA 123.404 -1.498 . . . . 0.0 109.323 -0.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 16.6 p -86.83 -26.86 23.84 Favored 'General case' 0 C--N 1.295 -1.803 0 O-C-N 121.455 -0.778 . . . . 0.0 109.169 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.498 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.4 m -134.62 168.23 19.38 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.409 -0.807 . . . . 0.0 109.463 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.03 38.51 35.16 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 108.359 -1.896 . . . . 0.0 108.359 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.744 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.2 mt -94.81 -42.61 8.62 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 123.186 1.47 . . . . 0.0 110.65 -178.164 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.91 143.69 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.289 0 CA-C-N 113.334 -1.757 . . . . 0.0 109.889 -179.55 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 11.9 p-10 -50.3 104.62 0.08 Allowed 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.53 0.681 . . . . 0.0 111.469 -178.498 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.17 14.44 7.74 Favored Glycine 0 N--CA 1.485 1.91 0 C-N-CA 119.321 -1.419 . . . . 0.0 113.09 177.164 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.744 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.5 t -106.47 -172.47 2.09 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 121.336 2.568 . . . . 0.0 109.876 179.312 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.744 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.4 t -128.21 136.78 59.24 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.328 0 CA-C-N 114.733 -1.121 . . . . 0.0 111.242 -178.741 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.64 HG11 HD11 ' A' ' 13' ' ' LEU . 27.8 m -111.08 157.22 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.649 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.521 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 4.0 tptm -106.83 109.17 21.01 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.033 -1.042 . . . . 0.0 108.933 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.815 HG23 HG22 ' A' ' 7' ' ' VAL . 7.6 p -103.55 141.05 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.941 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -138.79 161.52 37.03 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.718 -1.238 . . . . 0.0 110.061 179.678 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.594 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.46 143.69 15.01 Favored Glycine 0 C--N 1.294 -1.763 0 N-CA-C 108.355 -1.898 . . . . 0.0 108.355 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.14 125.68 13.27 Favored 'General case' 0 C--N 1.295 -1.774 0 O-C-N 120.914 -1.345 . . . . 0.0 108.996 178.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.477 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 87.45 25.92 31.82 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 119.312 -1.423 . . . . 0.0 110.116 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.601 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.2 mt -86.15 172.55 10.46 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 120.937 -1.331 . . . . 0.0 108.474 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.015 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.76 100.14 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.009 -1.057 . . . . 0.0 109.651 -179.704 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.562 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 77.83 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.147 -179.165 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.81 34.03 0.32 Allowed Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 179.543 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.565 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.7 p -140.71 108.13 5.56 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 121.183 -1.186 . . . . 0.0 111.153 -179.508 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.586 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.98 111.64 0.59 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.535 177.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.464 ' OH ' ' HB2' ' A' ' 27' ' ' GLN . 6.0 m-30 -107.14 156.34 18.91 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.129 -0.982 . . . . 0.0 108.935 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.475 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.8 160.5 14.22 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 178.933 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.632 HG22 HG11 ' A' ' 21' ' ' VAL . 5.3 p -140.94 119.26 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.129 -0.982 . . . . 0.0 109.678 -177.804 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -171.64 -177.36 41.27 Favored Glycine 0 N--CA 1.494 2.513 0 C-N-CA 118.443 -1.836 . . . . 0.0 111.532 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.684 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -98.73 109.13 21.93 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.723 0.773 . . . . 0.0 108.944 -179.95 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -129.09 149.35 50.94 Favored 'General case' 0 C--N 1.295 -1.783 0 O-C-N 121.236 -0.915 . . . . 0.0 109.964 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.586 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.92 138.88 54.23 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.255 -0.903 . . . . 0.0 110.838 -179.009 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.05 26.9 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.037 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -105.32 15.16 6.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.903 -1.123 . . . . 0.0 110.585 -178.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.751 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.03 -175.29 0.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.886 -1.134 . . . . 0.0 110.08 179.722 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -72.37 97.41 2.04 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.394 -0.816 . . . . 0.0 109.687 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.34 27.97 31.65 Favored Glycine 0 N--CA 1.493 2.45 0 C-N-CA 120.177 -1.011 . . . . 0.0 111.385 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.751 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.92 106.43 20.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 120.534 -1.568 . . . . 0.0 107.165 178.845 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.48 104.72 11.72 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.479 -1.388 . . . . 0.0 109.937 -177.533 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.058 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.0 109.63 22.35 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 178.649 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.486 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -108.52 162.42 14.15 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.876 -1.14 . . . . 0.0 110.54 -178.742 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.502 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 7.8 t30 -108.72 130.3 22.91 Favored Pre-proline 0 N--CA 1.499 2.004 0 O-C-N 121.551 -0.718 . . . . 0.0 109.553 -179.377 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.592 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.56 21.35 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.078 0 C-N-CA 122.028 1.819 . . . . 0.0 112.021 179.562 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.502 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -99.41 -3.99 32.53 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.421 -1.424 . . . . 0.0 108.995 179.409 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.68 ' OD2' HG13 ' A' ' 69' ' ' VAL . 5.9 m-20 -135.62 9.89 3.4 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -66.84 86.18 0.13 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.499 -0.75 . . . . 0.0 111.059 -178.291 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.612 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -108.5 -167.29 1.21 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 177.912 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.32 134.47 0.09 Allowed 'General case' 0 C--N 1.305 -1.34 0 O-C-N 120.503 -1.373 . . . . 0.0 111.451 -179.22 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.866 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -150.24 157.77 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 177.923 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.586 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.71 142.72 29.91 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.766 -1.209 . . . . 0.0 110.113 -179.685 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.015 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.67 107.12 1.09 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.398 1.094 . . . . 0.0 109.336 178.338 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.547 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -59.37 -139.08 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.056 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.856 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.562 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.73 -49.84 64.61 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.462 -0.774 . . . . 0.0 110.496 -178.641 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.477 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.6 t-20 -103.57 -35.17 8.4 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 178.454 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.009 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.95 66.78 0.58 Allowed Glycine 0 C--N 1.298 -1.579 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 177.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.9 m -104.54 128.92 52.62 Favored 'General case' 0 C--N 1.308 -1.223 0 O-C-N 121.308 -1.113 . . . . 0.0 108.683 178.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.866 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.69 109.91 8.92 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.184 -1.006 . . . . 0.0 109.668 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 91.7 p -117.75 117.77 30.24 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.367 -0.833 . . . . 0.0 109.481 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.547 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -147.31 151.29 36.34 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.422 -0.799 . . . . 0.0 109.42 -179.957 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.748 ' O ' HD23 ' A' ' 67' ' ' LEU . 69.6 p -98.52 153.57 18.53 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.304 -0.872 . . . . 0.0 109.571 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.785 HD11 HG11 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -147.92 160.1 43.17 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.339 -0.851 . . . . 0.0 109.634 -179.176 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.653 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -100.55 122.85 43.92 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.971 -1.08 . . . . 0.0 108.58 179.261 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.684 HG12 ' HB3' ' A' ' 36' ' ' GLN . 19.2 m -136.41 143.06 36.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 120.799 -1.188 . . . . 0.0 110.459 -178.669 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.1 ptt180 -146.43 -175.27 4.71 Favored 'General case' 0 N--CA 1.483 1.205 0 O-C-N 120.749 -1.219 . . . . 0.0 110.663 179.654 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.604 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.79 -102.03 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -179.733 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.496 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -56.02 140.27 43.99 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.761 -1.212 . . . . 0.0 108.244 179.401 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.586 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.4 OUTLIER -160.74 137.93 9.13 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 118.672 -1.211 . . . . 0.0 110.009 -178.285 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.484 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.7 OUTLIER -35.43 120.68 0.57 Allowed 'General case' 0 N--CA 1.49 1.563 0 CA-C-O 121.522 0.677 . . . . 0.0 110.618 -178.439 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.058 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.17 50.47 2.18 Favored Glycine 0 N--CA 1.493 2.486 0 O-C-N 121.551 -0.718 . . . . 0.0 111.37 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.592 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.8 m-85 -39.11 114.87 0.43 Allowed 'General case' 0 N--CA 1.511 2.616 0 O-C-N 120.947 -1.325 . . . . 0.0 109.89 179.536 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.724 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -87.25 125.24 34.07 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.771 -1.206 . . . . 0.0 109.306 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -64.78 56.31 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.062 0 O-C-N 120.742 -1.224 . . . . 0.0 110.491 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.618 ' OD2' HD23 ' A' ' 77' ' ' LEU . 2.9 p30 -154.79 16.18 0.44 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.998 -1.064 . . . . 0.0 109.859 179.742 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.53 -27.03 10.18 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.427 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -100.87 161.17 13.78 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.901 -1.352 . . . . 0.0 110.38 -179.408 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.434 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 3.6 ptm180 -103.77 139.36 39.11 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.605 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.724 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.2 t90 -82.44 -19.83 38.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.917 -1.114 . . . . 0.0 110.599 -178.276 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.64 175.66 18.71 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -66.41 104.77 1.3 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.174 -1.192 . . . . 0.0 107.848 179.318 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.648 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.7 t -75.31 106.88 5.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.286 -0.884 . . . . 0.0 109.56 -178.736 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.665 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -64.97 110.65 2.53 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.421 -0.8 . . . . 0.0 109.759 -179.679 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.604 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.23 -5.18 4.53 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.533 -1.354 . . . . 0.0 109.766 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.7 p -86.45 -0.28 55.67 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.779 -1.2 . . . . 0.0 109.136 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.665 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -114.52 -51.24 2.76 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.326 -0.859 . . . . 0.0 109.026 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.403 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -102.85 -178.83 3.78 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.445 -0.784 . . . . 0.0 109.413 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.68 115.05 29.59 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.868 . . . . 0.0 108.983 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -96.91 122.18 39.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.855 -1.153 . . . . 0.0 109.478 -179.247 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.611 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.28 145.64 29.16 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-O 122.341 1.067 . . . . 0.0 111.284 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.653 ' CG1' HG11 ' A' ' 7' ' ' VAL . 99.5 t -101.59 109.79 26.78 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 177.637 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.509 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.95 -169.56 17.58 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.052 -2.023 . . . . 0.0 111.733 -177.536 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.545 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -120.79 177.47 5.08 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 -179.1 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.432 ' O ' ' N ' ' A' ' 33' ' ' ASP . 2.5 t . . . . . 0 C--N 1.292 -1.923 0 O-C-N 121.588 -0.695 . . . . 0.0 109.59 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.446 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.481 1.684 0 N-CA-C 108.143 -1.983 . . . . 0.0 108.143 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -167.78 -176.88 3.25 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 121.62 -0.93 . . . . 0.0 109.853 179.358 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.1 -160.7 16.32 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.315 -1.914 . . . . 0.0 108.315 -179.41 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.3 Cg_exo -47.2 179.25 0.0 OUTLIER 'Trans proline' 0 C--O 1.216 -0.607 0 CA-C-N 118.829 1.315 . . . . 0.0 110.395 179.324 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -96.22 -175.69 3.44 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.028 -1.045 . . . . 0.0 110.309 -179.099 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.509 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.91 163.82 13.74 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.41 HG11 ' HB ' ' A' ' 7' ' ' VAL . 1.2 t -99.0 127.36 51.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.39 -1.065 . . . . 0.0 109.062 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.611 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -70.34 120.42 15.97 Favored 'General case' 0 C--N 1.289 -2.022 0 O-C-N 121.778 -0.576 . . . . 0.0 109.662 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.875 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.98 170.55 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.234 -0.916 . . . . 0.0 109.131 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.498 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.99 157.56 45.47 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.263 -0.898 . . . . 0.0 109.895 -179.717 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.875 ' CE2' HD12 ' A' ' 110' ' ' ILE . 91.7 m-85 . . . . . 0 N--CA 1.486 1.343 0 O-C-N 121.271 -0.893 . . . . 0.0 109.587 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.523 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.446 0 CA-C-O 122.265 1.031 . . . . 0.0 110.762 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.94 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -111.35 108.63 18.29 Favored 'General case' 0 C--N 1.295 -1.762 0 CA-C-O 123.068 1.413 . . . . 0.0 109.084 179.201 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.831 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -115.26 140.68 35.44 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.73 0 CA-C-N 114.321 -1.308 . . . . 0.0 110.26 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.476 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -175.56 149.07 1.06 Allowed Pre-proline 0 N--CA 1.487 1.396 0 O-C-N 121.337 -0.852 . . . . 0.0 108.854 -179.751 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.476 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.3 Cg_endo -78.63 150.47 87.33 Favored 'Cis proline' 0 C--N 1.311 -1.399 0 C-N-CA 123.36 -1.516 . . . . 0.0 109.09 -0.841 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.67 ' HA ' HG22 ' A' ' 110' ' ' ILE . 75.9 p -89.73 -24.58 21.5 Favored 'General case' 0 C--N 1.291 -1.947 0 O-C-N 121.53 -0.731 . . . . 0.0 109.358 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.507 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 12.9 m -134.83 162.8 31.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.346 -0.846 . . . . 0.0 109.757 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.88 37.67 29.06 Favored Glycine 0 N--CA 1.496 2.667 0 N-CA-C 108.604 -1.798 . . . . 0.0 108.604 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.78 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.0 mt -92.56 -44.24 8.72 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-O 123.19 1.472 . . . . 0.0 110.606 -178.369 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.457 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.66 144.07 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.331 0 CA-C-N 113.48 -1.691 . . . . 0.0 110.135 -179.775 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.616 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.2 p-10 -49.74 107.84 0.17 Allowed 'General case' 0 C--N 1.301 -1.526 0 CA-C-O 121.712 0.768 . . . . 0.0 111.471 -178.839 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.47 12.93 9.22 Favored Glycine 0 N--CA 1.484 1.855 0 C-N-CA 119.45 -1.357 . . . . 0.0 112.939 177.429 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.78 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.6 t -105.76 -173.05 2.21 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 121.251 2.525 . . . . 0.0 109.663 179.237 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.74 HG13 ' C ' ' A' ' 67' ' ' LEU . 20.9 t -127.1 135.01 64.79 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.45 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.035 -178.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.601 ' CG1' HD13 ' A' ' 13' ' ' LEU . 36.0 m -108.68 155.53 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.839 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.58 109.4 18.56 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.092 -1.005 . . . . 0.0 108.945 179.885 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.831 HG23 HG22 ' A' ' 7' ' ' VAL . 2.2 p -104.58 140.56 22.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.94 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.24 160.09 39.48 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 118.691 -1.204 . . . . 0.0 109.699 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.23 145.28 16.52 Favored Glycine 0 C--N 1.295 -1.712 0 N-CA-C 108.109 -1.996 . . . . 0.0 108.109 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.79 124.98 12.16 Favored 'General case' 0 C--N 1.296 -1.755 0 O-C-N 120.978 -1.307 . . . . 0.0 108.779 178.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.475 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 89.36 26.58 25.24 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.264 -1.446 . . . . 0.0 109.888 -179.587 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.592 HD22 ' HG3' ' A' ' 105' ' ' PRO . 2.0 mt -87.17 175.69 7.94 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 120.872 -1.369 . . . . 0.0 108.421 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.66 98.02 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.398 0 O-C-N 120.93 -1.106 . . . . 0.0 109.702 -179.597 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.651 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.57 77.44 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.737 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.511 -179.176 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.555 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.14 34.42 0.33 Allowed Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.55 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.1 p -146.25 111.92 5.58 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.039 -1.271 . . . . 0.0 111.223 -179.686 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.559 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.08 127.76 5.57 Favored 'General case' 0 N--CA 1.492 1.659 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.683 178.207 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.515 ' CD2' ' O ' ' A' ' 30' ' ' THR . 13.2 m-85 -118.5 150.57 39.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.327 -0.858 . . . . 0.0 108.881 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.518 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -100.52 153.15 19.61 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.64 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.655 HG22 HG11 ' A' ' 21' ' ' VAL . 4.2 p -137.55 119.03 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.844 -1.16 . . . . 0.0 110.043 -177.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.518 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.74 -178.88 40.59 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.673 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.57 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -99.73 109.12 21.59 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 -179.943 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.48 148.78 52.33 Favored 'General case' 0 C--N 1.295 -1.795 0 O-C-N 121.285 -0.885 . . . . 0.0 109.881 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.6 137.42 54.9 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.3 -0.875 . . . . 0.0 110.883 -179.094 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.868 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.54 114.9 26.71 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 178.009 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.1 m -105.73 14.69 7.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.053 -1.029 . . . . 0.0 110.707 -178.712 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.756 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.6 -175.11 0.08 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.901 -1.125 . . . . 0.0 110.106 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 28.0 p -72.59 98.56 2.35 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.45 -0.781 . . . . 0.0 109.623 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.2 27.16 34.33 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 120.226 -0.988 . . . . 0.0 111.342 178.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.756 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.02 106.04 19.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.55 -1.559 . . . . 0.0 107.295 178.829 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.868 HD13 ' NE1' ' A' ' 39' ' ' TRP . 14.0 tp -118.86 104.34 10.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.458 -1.401 . . . . 0.0 109.822 -177.666 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.027 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.22 109.58 22.32 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.868 -1.145 . . . . 0.0 108.246 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.54 166.23 10.71 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.982 -1.074 . . . . 0.0 110.269 -178.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.714 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.0 t-20 -108.87 134.82 20.22 Favored Pre-proline 0 N--CA 1.499 2.01 0 O-C-N 121.364 -0.835 . . . . 0.0 109.639 -179.416 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.589 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.1 Cg_endo -74.85 24.66 0.38 Allowed 'Trans proline' 0 CA--C 1.545 1.055 0 C-N-CA 122.277 1.985 . . . . 0.0 111.949 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.714 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -117.18 4.34 12.66 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.498 -1.376 . . . . 0.0 109.297 179.633 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.26 17.54 2.78 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.285 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -81.97 86.96 6.45 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.922 -178.562 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.6 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -104.98 -165.89 1.18 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.334 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.449 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.01 135.77 0.09 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 120.609 -1.307 . . . . 0.0 111.449 -179.284 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.904 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -152.66 156.61 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 178.08 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.559 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.58 145.34 26.36 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.602 -1.312 . . . . 0.0 109.921 -179.611 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.34 107.54 1.66 Allowed 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 122.384 1.087 . . . . 0.0 109.57 178.652 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.532 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.2 p-10 -60.87 -138.92 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.944 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.841 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.651 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.33 -50.62 59.07 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.509 -0.744 . . . . 0.0 110.673 -178.632 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.475 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.3 t-20 -104.35 -33.99 8.45 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 178.548 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.991 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.13 65.41 0.56 Allowed Glycine 0 C--N 1.297 -1.617 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 178.076 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.2 m -101.6 128.48 47.85 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.505 -0.997 . . . . 0.0 108.549 178.865 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.904 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.68 108.8 6.78 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.057 -1.057 . . . . 0.0 109.884 -179.21 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.2 m -121.0 118.96 31.17 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.361 -0.837 . . . . 0.0 109.371 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.563 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.63 143.74 30.91 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.392 -0.818 . . . . 0.0 109.479 179.83 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.423 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 28.9 p -99.06 146.97 25.52 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.4 -0.813 . . . . 0.0 109.411 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.783 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -147.42 167.97 23.05 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.393 -0.817 . . . . 0.0 109.368 -179.251 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.663 HG22 HG22 ' A' ' 18' ' ' VAL . 4.6 p -94.49 124.73 38.69 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.903 -1.123 . . . . 0.0 109.859 -179.522 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.598 ' CG2' HG13 ' A' ' 19' ' ' VAL . 15.8 m -136.46 144.98 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.997 -1.064 . . . . 0.0 109.206 -179.695 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.616 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.3 ptt180 -147.56 -178.49 6.28 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.327 -1.483 . . . . 0.0 111.346 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.727 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -50.07 -98.17 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -179.569 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.541 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 1.0 OUTLIER -63.79 146.69 53.45 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.57 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.609 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.8 OUTLIER -166.18 141.76 4.75 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 118.03 -1.468 . . . . 0.0 110.243 -177.276 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.548 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.9 mm-40 -36.03 120.71 0.64 Allowed 'General case' 0 N--CA 1.491 1.619 0 CA-C-O 121.475 0.655 . . . . 0.0 110.308 -178.771 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.027 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.59 51.46 1.79 Allowed Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.589 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -39.35 113.74 0.35 Allowed 'General case' 0 N--CA 1.507 2.401 0 O-C-N 121.093 -1.24 . . . . 0.0 110.142 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.686 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -85.28 126.35 33.64 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 120.958 -1.089 . . . . 0.0 109.415 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -64.33 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.963 0 O-C-N 120.82 -1.175 . . . . 0.0 110.105 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.7 t0 -160.07 19.76 0.16 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.982 -1.074 . . . . 0.0 109.648 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.91 -27.65 5.36 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 110.063 -1.215 . . . . 0.0 110.063 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.448 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.15 157.6 16.0 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.04 -1.27 . . . . 0.0 110.446 -179.395 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.476 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 1.8 ptm180 -104.87 136.15 44.91 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.686 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.5 t90 -82.86 -16.47 47.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.761 -1.212 . . . . 0.0 110.689 -178.26 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.08 175.43 20.83 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 108.828 -1.709 . . . . 0.0 108.828 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.72 103.51 0.7 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 179.14 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.614 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.8 t -74.54 107.42 5.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.384 -0.823 . . . . 0.0 109.566 -178.841 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.541 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -67.09 112.0 4.18 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.581 -0.699 . . . . 0.0 109.685 -179.556 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.727 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 11.0 m -60.96 -5.71 1.5 Allowed 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.104 -1.439 . . . . 0.0 110.35 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.02 -4.43 58.79 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.396 -1.44 . . . . 0.0 109.53 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.511 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -104.0 -48.0 4.02 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.202 -0.936 . . . . 0.0 108.886 179.706 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -112.55 -178.3 3.37 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.573 -0.704 . . . . 0.0 109.33 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.37 117.3 34.44 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.375 -0.828 . . . . 0.0 109.02 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.509 ' O ' HG12 ' A' ' 110' ' ' ILE . 3.9 m -96.47 122.77 39.72 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.866 -1.146 . . . . 0.0 109.344 -179.515 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.58 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mp0 -106.7 145.48 31.95 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 122.404 1.097 . . . . 0.0 111.685 -179.112 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.483 ' CG1' ' HB ' ' A' ' 21' ' ' VAL . 62.0 t -100.83 109.71 26.05 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 177.428 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.5 -172.2 16.58 Favored Glycine 0 N--CA 1.487 2.052 0 C-N-CA 118.257 -1.925 . . . . 0.0 111.622 -177.383 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.523 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -117.04 -179.22 3.63 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -178.874 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 8.4 p . . . . . 0 C--N 1.296 -1.727 0 O-C-N 121.369 -0.832 . . . . 0.0 109.09 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.814 0 N-CA-C 107.552 -2.219 . . . . 0.0 107.552 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.75 -179.02 7.79 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.432 -1.04 . . . . 0.0 109.561 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -174.41 -165.8 31.46 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.592 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.7 Cg_exo -49.64 -174.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 CA-C-N 118.778 1.289 . . . . 0.0 110.472 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -93.9 -179.61 5.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.113 -0.992 . . . . 0.0 110.373 -179.103 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -116.66 158.64 14.36 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.466 HG11 ' HB ' ' A' ' 7' ' ' VAL . 1.2 t -98.76 124.93 52.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.362 -1.081 . . . . 0.0 109.056 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.58 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.54 120.91 18.81 Favored 'General case' 0 C--N 1.29 -2.005 0 O-C-N 121.804 -0.56 . . . . 0.0 109.707 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.87 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -98.02 169.1 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.255 -0.903 . . . . 0.0 109.241 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.507 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.72 155.22 50.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.307 -0.871 . . . . 0.0 109.48 179.993 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.87 ' CE1' HD12 ' A' ' 110' ' ' ILE . 74.5 m-85 . . . . . 0 N--CA 1.486 1.349 0 O-C-N 121.164 -0.96 . . . . 0.0 109.468 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.129 0 CA-C-O 122.361 1.077 . . . . 0.0 110.672 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.012 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.6 p -104.2 104.57 14.51 Favored 'General case' 0 C--N 1.296 -1.724 0 CA-C-O 122.49 1.138 . . . . 0.0 110.115 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.959 HG22 HG23 ' A' ' 21' ' ' VAL . 16.2 t -119.8 115.61 47.99 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.46 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.292 179.681 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.49 148.8 13.14 Favored Pre-proline 0 N--CA 1.487 1.407 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -179.583 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.1 Cg_endo -77.92 150.22 89.08 Favored 'Cis proline' 0 C--N 1.309 -1.528 0 C-N-CA 123.606 -1.414 . . . . 0.0 109.737 -0.397 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.656 ' HA ' HG22 ' A' ' 110' ' ' ILE . 40.1 p -89.05 -26.4 21.43 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.403 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.535 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 6.0 p -133.07 165.19 25.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.522 -0.736 . . . . 0.0 109.423 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.14 37.51 37.3 Favored Glycine 0 N--CA 1.496 2.652 0 N-CA-C 108.402 -1.879 . . . . 0.0 108.402 -179.548 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.775 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.6 mt -92.51 -42.98 9.41 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 123.328 1.537 . . . . 0.0 110.491 -178.26 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.28 143.94 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.29 0 CA-C-N 113.319 -1.764 . . . . 0.0 109.858 -179.548 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.599 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.0 p-10 -50.38 106.2 0.12 Allowed 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.398 0.618 . . . . 0.0 111.666 -178.498 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.53 14.4 8.89 Favored Glycine 0 N--CA 1.485 1.924 0 C-N-CA 119.42 -1.371 . . . . 0.0 113.022 177.244 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.775 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.96 -172.66 2.14 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 121.15 2.475 . . . . 0.0 109.864 179.246 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.894 HG22 HG22 ' A' ' 68' ' ' THR . 18.8 t -130.4 140.19 49.46 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.285 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.24 -178.774 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.528 HG11 HD11 ' A' ' 13' ' ' LEU . 30.0 m -117.25 155.52 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.865 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.544 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.5 OUTLIER -107.19 109.15 20.89 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.087 -1.008 . . . . 0.0 109.572 -179.8 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.959 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -106.47 121.51 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.012 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.49 165.94 11.99 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.875 -1.141 . . . . 0.0 108.976 179.75 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.606 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.58 107.98 0.49 Allowed Glycine 0 N--CA 1.481 1.668 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.423 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.81 139.78 50.2 Favored 'General case' 0 N--CA 1.499 2.002 0 CA-C-N 119.218 1.509 . . . . 0.0 110.27 -179.43 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.82 28.86 30.6 Favored Glycine 0 N--CA 1.49 2.286 0 C-N-CA 118.792 -1.671 . . . . 0.0 109.782 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.527 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.4 mt -93.13 174.54 7.17 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.085 -1.244 . . . . 0.0 108.458 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.87 98.99 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.949 -1.094 . . . . 0.0 109.498 -179.718 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.588 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -57.05 76.59 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.282 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.33 33.96 0.26 Allowed Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.558 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 82.2 p -144.46 111.41 5.81 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 120.966 -1.314 . . . . 0.0 111.144 -179.668 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.588 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.49 112.65 0.57 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.895 178.308 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.53 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 14.4 m-85 -104.51 150.19 24.81 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.206 -0.933 . . . . 0.0 108.746 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.493 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -99.62 158.57 15.67 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 178.564 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.014 HG11 HG21 ' A' ' 65' ' ' THR . 6.2 p -141.67 116.46 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.006 -1.059 . . . . 0.0 110.042 -177.69 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.535 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.45 -176.54 39.41 Favored Glycine 0 N--CA 1.493 2.462 0 C-N-CA 118.338 -1.886 . . . . 0.0 111.674 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.585 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.5 OUTLIER -100.49 109.11 21.21 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 121.928 0.87 . . . . 0.0 108.82 -179.571 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.461 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.6 m -129.55 148.65 51.47 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.212 -0.93 . . . . 0.0 109.882 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.507 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.93 138.57 54.64 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.375 -0.828 . . . . 0.0 110.669 -179.027 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.882 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.91 26.73 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.039 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -105.88 14.9 7.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.894 -1.129 . . . . 0.0 110.617 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.766 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.6 -175.81 0.08 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.844 -1.16 . . . . 0.0 110.116 179.667 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.781 ' O ' HG23 ' A' ' 42' ' ' THR . 15.2 t -70.57 97.28 1.29 Allowed 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.866 0.841 . . . . 0.0 109.946 -179.55 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.44 27.7 35.21 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 120.181 -1.009 . . . . 0.0 111.391 178.831 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.766 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.5 106.24 20.1 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.592 -1.534 . . . . 0.0 107.258 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.882 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.9 tp -116.62 104.55 11.5 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 120.428 -1.42 . . . . 0.0 109.848 -177.736 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.078 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.32 109.24 22.03 Favored 'General case' 0 N--CA 1.484 1.253 0 O-C-N 120.842 -1.161 . . . . 0.0 108.119 178.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.2 t -105.94 163.09 13.02 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.993 -1.067 . . . . 0.0 109.871 -179.144 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.618 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 23.6 t30 -105.66 137.02 19.19 Favored Pre-proline 0 N--CA 1.503 2.21 0 O-C-N 121.289 -0.882 . . . . 0.0 109.972 -179.055 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.516 ' HD2' ' HB2' ' A' ' 74' ' ' GLU . 4.2 Cg_endo -73.77 24.25 0.33 Allowed 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 122.467 2.111 . . . . 0.0 112.323 -179.538 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.618 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -119.74 5.07 11.0 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.278 -1.513 . . . . 0.0 109.261 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.576 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.8 15.37 2.89 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 179.164 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -82.43 89.33 6.61 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.815 -0.754 . . . . 0.0 110.971 -178.517 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.634 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.27 -168.83 1.45 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 178.02 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.78 135.47 0.09 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 120.496 -1.377 . . . . 0.0 111.516 -179.243 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.833 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -153.7 158.18 4.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 177.963 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.588 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.15 143.88 28.21 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 120.638 -1.289 . . . . 0.0 109.777 -179.662 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.47 107.05 1.56 Allowed 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 122.307 1.051 . . . . 0.0 109.547 178.781 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.549 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.1 t0 -61.58 -139.38 0.0 OUTLIER 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.824 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.588 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.2 -51.57 42.99 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.361 -0.837 . . . . 0.0 110.704 -178.699 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -103.96 -32.75 9.1 Favored 'General case' 0 C--N 1.288 -2.109 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 178.562 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.98 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 105.08 69.17 0.75 Allowed Glycine 0 C--N 1.297 -1.589 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 178.194 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.606 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 24.3 m -104.19 126.34 51.21 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 121.684 -0.892 . . . . 0.0 108.838 178.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.833 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.85 109.04 8.26 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 119.644 -0.822 . . . . 0.0 109.486 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.477 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 6.4 m -117.5 115.67 25.61 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.271 -0.893 . . . . 0.0 109.398 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' THR . . . . . 1.014 HG21 HG11 ' A' ' 34' ' ' VAL . 1.3 t -140.97 139.52 34.24 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.359 -0.838 . . . . 0.0 109.723 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.1 p -99.42 132.55 44.68 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.463 -0.773 . . . . 0.0 109.245 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.761 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -132.6 165.92 23.3 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.347 -0.845 . . . . 0.0 109.808 -179.238 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.894 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -98.15 125.18 43.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.238 -0.914 . . . . 0.0 109.219 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.585 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -135.24 143.4 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.068 -1.02 . . . . 0.0 109.897 -179.03 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.599 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.7 ptt180 -145.97 -172.63 3.96 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.457 -1.402 . . . . 0.0 110.946 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.578 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -57.64 -98.15 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.359 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.501 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.64 139.54 55.82 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.27 -1.519 . . . . 0.0 107.944 179.265 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -160.29 135.24 7.79 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 118.598 -1.241 . . . . 0.0 109.847 -178.107 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.516 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -34.95 121.44 0.53 Allowed 'General case' 0 N--CA 1.491 1.611 0 CA-C-O 121.352 0.596 . . . . 0.0 110.119 -178.49 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.078 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.75 50.83 2.59 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 120.404 -0.903 . . . . 0.0 110.938 -179.196 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.48 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.4 OUTLIER -37.74 116.97 0.54 Allowed 'General case' 0 N--CA 1.514 2.726 0 O-C-N 121.274 -1.133 . . . . 0.0 109.973 179.816 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.703 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -87.04 125.96 34.45 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 120.957 -1.089 . . . . 0.0 109.14 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -64.13 58.51 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.036 0 O-C-N 120.8 -1.188 . . . . 0.0 109.922 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' LEU . 26.4 t0 -160.38 20.05 0.15 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.959 -1.088 . . . . 0.0 109.668 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.33 -28.62 5.13 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.089 -1.205 . . . . 0.0 110.089 179.774 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 70.5 p -95.25 164.2 12.95 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.043 -1.269 . . . . 0.0 110.228 -179.427 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.472 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.9 OUTLIER -109.2 138.5 45.45 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.968 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.703 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.7 t90 -81.71 -20.83 38.6 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.805 -1.184 . . . . 0.0 110.391 -178.795 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.79 175.07 17.5 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.54 107.49 1.72 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.065 -1.256 . . . . 0.0 107.684 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.642 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.1 t -79.38 105.3 8.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 O-C-N 121.41 -0.806 . . . . 0.0 109.182 -179.009 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.543 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -65.74 111.59 3.29 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.467 -0.771 . . . . 0.0 109.739 -179.583 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.578 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.17 -5.62 3.42 Favored 'General case' 0 N--CA 1.499 2.01 0 C-N-CA 118.208 -1.397 . . . . 0.0 109.884 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 19.9 p -87.71 0.73 55.31 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.697 -1.252 . . . . 0.0 109.117 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.543 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.8 p -114.11 -50.82 2.8 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.367 -0.833 . . . . 0.0 108.975 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.06 179.51 4.25 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.555 -0.716 . . . . 0.0 109.331 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.94 115.62 30.95 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.465 -0.772 . . . . 0.0 108.919 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.516 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.1 m -97.04 122.42 40.01 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.894 -1.129 . . . . 0.0 109.358 -179.373 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.58 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.67 146.83 27.62 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-O 122.368 1.08 . . . . 0.0 111.215 -179.369 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.608 ' HB ' HG11 ' A' ' 7' ' ' VAL . 52.9 t -103.48 109.79 28.03 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.067 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.61 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.492 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.96 -169.94 17.36 Favored Glycine 0 N--CA 1.486 1.987 0 C-N-CA 118.229 -1.938 . . . . 0.0 111.666 -177.514 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -123.2 179.16 4.8 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -178.682 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.493 ' O ' ' N ' ' A' ' 33' ' ' ASP . 3.6 t . . . . . 0 C--N 1.293 -1.859 0 O-C-N 121.52 -0.738 . . . . 0.0 109.597 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.663 0 N-CA-C 107.874 -2.09 . . . . 0.0 107.874 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.85 -177.52 5.56 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 122.062 0.934 . . . . 0.0 109.875 179.328 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -172.43 -161.56 23.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.151 -1.98 . . . . 0.0 108.151 -179.374 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.516 ' HD2' ' CE1' ' A' ' 32' ' ' TYR . 7.1 Cg_exo -45.69 173.14 0.02 OUTLIER 'Trans proline' 0 C--O 1.216 -0.58 0 CA-C-N 118.912 1.356 . . . . 0.0 110.008 179.268 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -93.95 -178.6 4.7 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.109 -0.994 . . . . 0.0 110.428 -178.662 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.492 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.92 168.07 12.71 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -108.23 128.7 63.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.313 -1.11 . . . . 0.0 109.117 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.58 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -69.18 123.84 22.21 Favored 'General case' 0 C--N 1.29 -2.007 0 O-C-N 121.556 -0.715 . . . . 0.0 109.381 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.899 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.6 173.76 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.199 -0.938 . . . . 0.0 108.928 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.535 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.5 OUTLIER -138.28 159.61 41.6 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.129 -0.982 . . . . 0.0 109.75 -179.743 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.899 ' CE2' HD12 ' A' ' 110' ' ' ILE . 88.4 m-85 . . . . . 0 N--CA 1.485 1.298 0 O-C-N 121.267 -0.896 . . . . 0.0 109.553 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.217 0 CA-C-O 122.448 1.118 . . . . 0.0 110.434 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.897 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.9 t -115.82 109.0 17.03 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-O 123.162 1.458 . . . . 0.0 109.735 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.801 HG22 HG23 ' A' ' 21' ' ' VAL . 2.1 t -115.63 133.69 61.22 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.675 0 CA-C-N 114.162 -1.381 . . . . 0.0 109.593 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.475 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.45 150.66 5.0 Favored Pre-proline 0 N--CA 1.488 1.43 0 O-C-N 121.259 -0.901 . . . . 0.0 108.896 -179.419 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.475 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.13 150.38 88.72 Favored 'Cis proline' 0 C--N 1.311 -1.415 0 C-N-CA 123.56 -1.433 . . . . 0.0 109.454 -0.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.678 ' HA ' HG22 ' A' ' 110' ' ' ILE . 95.6 p -90.4 -24.93 20.64 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.586 -0.696 . . . . 0.0 109.203 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.476 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 14.6 m -131.13 161.71 31.51 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.351 -0.843 . . . . 0.0 109.71 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.44 38.16 29.43 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.783 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.9 mt -93.31 -43.65 8.69 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 123.178 1.466 . . . . 0.0 110.801 -178.122 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.07 144.79 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.328 0 CA-C-N 113.484 -1.689 . . . . 0.0 110.123 -179.486 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 18.6 p-10 -50.37 106.07 0.11 Allowed 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 121.53 0.681 . . . . 0.0 111.693 -178.567 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.67 15.57 8.65 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.912 177.075 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.783 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -105.41 -174.28 2.5 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 121.223 2.511 . . . . 0.0 109.981 179.225 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.821 HG22 HG22 ' A' ' 68' ' ' THR . 31.0 t -126.41 138.09 55.75 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.36 0 CA-C-N 114.549 -1.205 . . . . 0.0 111.399 -178.339 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.517 HG11 HD11 ' A' ' 13' ' ' LEU . 29.0 m -114.13 154.98 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.467 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.503 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.9 tttt -106.65 109.67 21.64 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.127 -0.983 . . . . 0.0 109.041 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.801 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.61 140.49 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.897 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.46 162.08 33.64 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 118.89 -1.124 . . . . 0.0 110.094 179.485 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.598 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -138.32 140.3 11.01 Favored Glycine 0 C--N 1.299 -1.514 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.71 125.22 15.73 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-N 119.183 1.492 . . . . 0.0 109.28 179.297 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.87 29.71 17.27 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 118.702 -1.713 . . . . 0.0 109.695 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.9 mt -89.88 175.2 7.3 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 120.863 -1.375 . . . . 0.0 108.517 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.028 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.77 96.8 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.102 -0.999 . . . . 0.0 109.885 -179.608 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -58.18 74.87 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.157 -179.138 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 138.75 32.97 0.19 Allowed Glycine 0 N--CA 1.484 1.848 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 179.454 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.632 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 1.4 t -149.11 115.43 5.82 Favored 'General case' 0 C--N 1.31 -1.127 0 O-C-N 120.893 -1.357 . . . . 0.0 111.218 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.608 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.42 111.22 0.46 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.251 178.472 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.632 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 1.9 m-30 -101.54 152.11 21.17 Favored 'General case' 0 N--CA 1.494 1.759 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 179.123 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -98.89 165.01 11.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.497 -1.377 . . . . 0.0 108.327 179.26 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.621 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.1 p -145.1 119.24 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.209 -0.932 . . . . 0.0 109.534 -178.012 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.42 -178.68 41.38 Favored Glycine 0 N--CA 1.495 2.605 0 C-N-CA 118.34 -1.886 . . . . 0.0 111.616 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.698 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.71 108.57 20.46 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 179.833 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.6 m -130.03 148.73 51.91 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 121.228 -0.92 . . . . 0.0 110.01 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.482 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.26 138.76 54.55 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.242 -0.911 . . . . 0.0 110.644 -179.143 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.32 114.82 26.64 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 178.154 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.3 m -104.45 14.88 6.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.014 -1.054 . . . . 0.0 110.534 -178.848 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.765 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.02 -175.01 0.07 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.023 -1.048 . . . . 0.0 110.185 179.785 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.12 98.11 2.06 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.446 -0.784 . . . . 0.0 109.708 -179.764 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.71 27.88 33.78 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.464 178.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.765 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.75 106.24 19.85 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 O-C-N 120.536 -1.567 . . . . 0.0 107.252 178.834 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.6 tp -117.49 104.45 11.09 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.402 -1.436 . . . . 0.0 109.958 -177.714 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.01 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.92 109.49 22.23 Favored 'General case' 0 N--CA 1.484 1.267 0 N-CA-C 107.718 -1.215 . . . . 0.0 107.718 178.623 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -107.32 166.16 10.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.895 -1.128 . . . . 0.0 110.655 -178.508 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.56 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 43.7 t30 -113.14 127.92 26.26 Favored Pre-proline 0 N--CA 1.498 1.972 0 O-C-N 121.497 -0.752 . . . . 0.0 109.267 -179.661 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.611 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -70.75 21.31 0.21 Allowed 'Trans proline' 0 CA--C 1.543 0.948 0 C-N-CA 122.103 1.869 . . . . 0.0 112.396 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.56 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -97.72 -5.62 34.72 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.304 -1.497 . . . . 0.0 109.017 179.31 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.857 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.4 m-20 -135.62 10.76 3.43 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.494 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.7 m-85 -66.56 82.9 0.1 Allowed 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.736 -178.403 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.621 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -108.47 -171.92 1.95 Allowed 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 178.252 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.478 ' OG ' ' HA ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER 178.6 134.71 0.08 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.608 -1.308 . . . . 0.0 111.25 -179.369 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.625 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 4.1 p -143.39 159.77 17.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 177.897 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.69 144.39 27.37 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.583 -1.323 . . . . 0.0 109.767 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.028 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -70.44 108.52 4.31 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 122.312 1.053 . . . . 0.0 109.963 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.553 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.3 t0 -64.66 -139.55 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.714 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.34 -52.43 37.06 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.344 -0.848 . . . . 0.0 110.605 -178.74 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.34 -32.32 10.53 Favored 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 178.613 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.993 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 100.34 69.29 0.88 Allowed Glycine 0 C--N 1.298 -1.571 0 N-CA-C 110.562 -1.015 . . . . 0.0 110.562 178.488 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 65.6 m -98.66 132.46 44.03 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.337 -1.096 . . . . 0.0 109.016 179.119 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.625 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.41 109.31 9.23 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.252 -179.716 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 19.8 m -122.53 115.68 22.59 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.264 -0.897 . . . . 0.0 109.565 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.545 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.74 143.32 28.61 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.27 -0.894 . . . . 0.0 109.661 179.927 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 57.6 p -99.15 142.38 30.71 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.371 -0.831 . . . . 0.0 109.148 179.784 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.857 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -144.49 170.63 15.67 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.397 -0.815 . . . . 0.0 109.774 -179.01 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.821 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -104.35 124.26 48.88 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.952 -1.093 . . . . 0.0 110.474 -178.851 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.847 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.7 m -132.22 143.0 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 120.907 -1.121 . . . . 0.0 110.087 -179.751 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -145.65 -172.51 3.91 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.604 -1.31 . . . . 0.0 110.689 179.384 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.597 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -58.52 -98.42 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 -179.35 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.4 OUTLIER -57.88 141.22 49.96 Favored 'General case' 0 N--CA 1.485 1.307 0 O-C-N 120.307 -1.496 . . . . 0.0 108.374 179.47 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -161.78 135.44 6.51 Favored 'General case' 0 C--N 1.295 -1.787 0 C-N-CA 118.75 -1.18 . . . . 0.0 109.724 -178.402 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.9 mm-40 -32.11 121.55 0.3 Allowed 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.579 0.704 . . . . 0.0 110.697 -178.351 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.01 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.48 45.51 2.95 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.611 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-85 -37.96 113.56 0.29 Allowed 'General case' 0 N--CA 1.507 2.39 0 O-C-N 121.193 -1.18 . . . . 0.0 110.372 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.739 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.5 tp -85.89 126.56 34.16 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 120.948 -1.095 . . . . 0.0 109.535 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 33.4 t80 -63.9 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.024 0 O-C-N 120.93 -1.106 . . . . 0.0 110.318 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 17.2 t70 -161.46 20.11 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.928 -1.107 . . . . 0.0 109.729 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.59 -28.1 4.99 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.482 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 19.2 p -93.46 159.31 15.3 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.981 -1.305 . . . . 0.0 110.231 -179.492 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.515 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 1.1 ptt180 -106.78 139.03 41.85 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.739 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.3 t90 -84.79 -19.26 32.83 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.704 -1.248 . . . . 0.0 110.524 -178.558 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.84 174.1 18.14 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.447 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.93 106.38 1.22 Allowed 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 179.137 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.66 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.9 t -77.02 105.84 6.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 O-C-N 121.315 -0.866 . . . . 0.0 109.398 -178.744 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.684 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.0 OUTLIER -66.31 111.46 3.51 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.386 -0.821 . . . . 0.0 109.685 -179.732 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.597 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.1 t -63.54 -5.51 3.94 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.533 -1.355 . . . . 0.0 109.828 179.562 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.2 p -86.45 -1.49 57.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.787 -1.196 . . . . 0.0 109.215 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.684 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -111.38 -50.24 2.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.295 -0.878 . . . . 0.0 108.93 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.34 -178.8 3.76 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.507 -0.746 . . . . 0.0 109.482 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.05 115.52 30.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.33 -0.856 . . . . 0.0 109.001 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.91 123.02 40.51 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.77 -1.206 . . . . 0.0 109.593 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.64 146.9 27.89 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 122.445 1.116 . . . . 0.0 111.138 -179.42 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.585 ' CG1' HG11 ' A' ' 7' ' ' VAL . 48.6 t -103.58 110.53 30.26 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.978 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 177.666 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.489 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.6 -170.24 16.86 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 118.06 -2.019 . . . . 0.0 111.745 -177.523 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -115.38 -179.08 3.54 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 -178.986 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.51 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.2 OUTLIER . . . . . 0 C--N 1.296 -1.747 0 O-C-N 121.318 -0.864 . . . . 0.0 109.61 -179.333 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.696 0 N-CA-C 107.7 -2.16 . . . . 0.0 107.7 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.46 -178.07 6.66 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-O 122.127 0.965 . . . . 0.0 109.622 179.219 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.0 -161.28 12.88 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 108.301 -1.92 . . . . 0.0 108.301 -179.345 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.507 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.3 Cg_exo -46.75 177.0 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.653 0 CA-C-N 118.838 1.319 . . . . 0.0 110.179 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -92.66 -177.55 4.6 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.074 -1.016 . . . . 0.0 110.451 -178.788 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.489 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.45 164.48 12.91 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -100.92 129.23 52.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.451 -1.029 . . . . 0.0 109.103 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.04 123.4 22.72 Favored 'General case' 0 C--N 1.289 -2.023 0 O-C-N 121.702 -0.624 . . . . 0.0 109.535 179.734 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.855 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.74 170.53 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.174 -0.954 . . . . 0.0 109.14 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.476 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -138.84 156.63 47.16 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.174 -0.954 . . . . 0.0 109.765 -179.891 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.855 ' CE2' HD12 ' A' ' 110' ' ' ILE . 81.2 m-85 . . . . . 0 N--CA 1.485 1.324 0 O-C-N 121.144 -0.972 . . . . 0.0 109.569 -179.683 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.512 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.151 0 CA-C-O 122.358 1.075 . . . . 1.0 110.688 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.009 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.2 p -105.63 104.87 14.67 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.457 1.122 . . . . 1.0 110.21 -179.577 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.951 HG22 HG23 ' A' ' 21' ' ' VAL . 13.2 t -118.34 118.8 59.25 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.446 0 CA-C-N 115.384 -0.825 . . . . 1.0 110.495 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.521 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.38 149.37 9.8 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.169 -1.049 . . . . 1.0 108.169 -179.799 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.521 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.1 Cg_endo -77.38 151.83 93.17 Favored 'Cis proline' 0 C--N 1.309 -1.536 0 C-N-CA 123.654 -1.394 . . . . 1.0 109.49 -0.223 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.686 ' HA ' HG22 ' A' ' 110' ' ' ILE . 75.4 p -91.89 -24.99 19.15 Favored 'General case' 0 C--N 1.292 -1.904 0 O-C-N 121.501 -0.749 . . . . 1.0 109.137 179.696 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.474 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 0.9 OUTLIER -133.54 165.12 25.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.43 -0.794 . . . . 1.0 109.557 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.52 38.5 37.81 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 108.209 -1.956 . . . . 1.0 108.209 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.808 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.6 mt -92.13 -44.32 8.88 Favored 'General case' 0 C--N 1.298 -1.674 0 CA-C-O 123.122 1.439 . . . . 1.0 110.637 -178.214 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.464 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.3 144.75 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.279 0 CA-C-N 113.613 -1.63 . . . . 1.0 109.947 -179.603 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.598 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.2 p-10 -51.16 108.24 0.24 Allowed 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.524 0.678 . . . . 1.0 111.523 -178.546 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.11 14.14 10.23 Favored Glycine 0 N--CA 1.484 1.835 0 C-N-CA 119.408 -1.377 . . . . 1.0 112.824 177.283 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.808 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.1 t -104.05 -172.38 2.1 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 121.079 2.439 . . . . 1.0 109.639 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.764 HG22 HG22 ' A' ' 68' ' ' THR . 12.1 t -131.61 138.85 52.01 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.37 0 CA-C-N 114.967 -1.015 . . . . 1.0 111.281 -178.928 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.442 HG11 HD11 ' A' ' 13' ' ' LEU . 26.9 m -114.45 154.99 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.761 -0.829 . . . . 1.0 108.761 179.155 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 21.0 tttt -109.06 108.86 19.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.053 -1.029 . . . . 1.0 109.407 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.951 HG23 HG22 ' A' ' 7' ' ' VAL . 1.7 p -106.86 122.53 61.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 N-CA-C 108.778 -0.823 . . . . 1.0 108.778 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.009 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.98 165.67 12.13 Favored 'General case' 0 C--N 1.305 -1.331 0 O-C-N 120.902 -1.124 . . . . 1.0 109.114 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.582 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.77 107.91 0.48 Allowed Glycine 0 N--CA 1.482 1.765 0 N-CA-C 108.738 -1.745 . . . . 1.0 108.738 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.477 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.43 141.05 48.68 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 120.658 -1.495 . . . . 1.0 110.168 -179.502 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.86 28.12 32.61 Favored Glycine 0 N--CA 1.488 2.109 0 C-N-CA 119.003 -1.57 . . . . 1.0 109.806 179.784 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -94.23 174.73 7.0 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.008 -1.29 . . . . 1.0 108.587 179.991 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.006 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.95 97.29 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.022 -1.048 . . . . 1.0 109.673 -179.831 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.688 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.19 76.63 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.345 -0.843 . . . . 1.0 110.372 -179.145 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.563 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.85 33.92 0.32 Allowed Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.751 -1.34 . . . . 1.0 109.751 179.498 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.638 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.1 t -146.66 114.15 6.34 Favored 'General case' 0 C--N 1.309 -1.174 0 O-C-N 120.838 -1.39 . . . . 1.0 110.986 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -46.12 126.2 7.35 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-N 115.31 -0.859 . . . . 1.0 110.008 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.638 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 12.2 m-85 -118.43 151.17 38.3 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.543 -0.91 . . . . 1.0 108.543 179.358 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.491 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.54 156.76 17.28 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.572 -1.33 . . . . 1.0 108.063 179.015 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.926 HG11 HG21 ' A' ' 65' ' ' THR . 7.0 p -139.32 115.04 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.189 -0.944 . . . . 1.0 109.83 -177.908 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.75 -178.64 37.53 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.449 -1.834 . . . . 1.0 111.804 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.631 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -101.8 109.43 21.19 Favored 'General case' 0 C--N 1.313 -0.987 0 N-CA-C 108.799 -0.815 . . . . 1.0 108.799 -179.818 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.41 149.17 52.21 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.22 -0.925 . . . . 1.0 109.99 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.21 138.19 54.7 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.265 -0.897 . . . . 1.0 110.729 -179.081 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.877 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.71 26.53 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 107.432 -1.322 . . . . 1.0 107.432 178.09 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -105.63 15.3 7.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.018 -1.051 . . . . 1.0 110.589 -178.679 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.99 -175.63 0.09 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.875 -1.14 . . . . 1.0 110.088 179.787 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 43.8 p -71.95 97.72 1.91 Allowed 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.404 -0.81 . . . . 1.0 109.664 -179.722 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.7 27.37 35.32 Favored Glycine 0 N--CA 1.493 2.448 0 C-N-CA 120.141 -1.028 . . . . 1.0 111.302 178.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.32 106.28 20.01 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.519 -1.577 . . . . 1.0 107.203 178.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.877 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.0 tp -117.04 104.3 11.11 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 120.427 -1.42 . . . . 1.0 109.726 -177.749 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.904 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.97 109.32 22.1 Favored 'General case' 0 N--CA 1.483 1.202 0 N-CA-C 107.65 -1.241 . . . . 1.0 107.65 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -105.72 166.36 10.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.035 -1.04 . . . . 1.0 110.404 -178.678 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.487 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 59.2 t30 -111.84 131.39 22.45 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.541 -0.724 . . . . 1.0 109.736 -179.465 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.599 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 2.5 Cg_endo -73.05 22.62 0.31 Allowed 'Trans proline' 0 C--N 1.319 -1.022 0 C-N-CA 122.112 1.874 . . . . 1.0 111.737 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.487 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -110.01 2.84 19.89 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.307 -1.496 . . . . 1.0 109.19 179.562 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.5 15.56 2.75 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.471 -1.307 . . . . 1.0 107.471 179.479 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -79.22 92.96 5.16 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.898 -0.721 . . . . 1.0 111.039 -178.429 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.617 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -111.95 -167.82 1.23 Allowed 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.536 -1.283 . . . . 1.0 107.536 178.104 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.98 136.5 0.09 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.439 -1.413 . . . . 1.0 111.521 -179.332 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.941 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.12 157.51 4.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.276 -1.379 . . . . 1.0 107.276 178.019 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.568 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.1 145.49 26.51 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.76 -1.212 . . . . 1.0 109.825 -179.703 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -66.08 107.24 1.84 Allowed 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 122.485 1.136 . . . . 1.0 109.328 178.718 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.541 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.1 t70 -60.82 -139.37 0.0 OUTLIER 'General case' 0 C--N 1.292 -1.93 0 CA-C-N 115.558 -0.746 . . . . 1.0 110.941 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.688 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.12 -51.42 43.26 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.504 -0.747 . . . . 1.0 110.756 -178.658 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.57 -32.56 8.89 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 106.308 -1.738 . . . . 1.0 106.308 178.673 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.012 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.24 65.21 0.61 Allowed Glycine 0 C--N 1.297 -1.589 0 N-CA-C 110.542 -1.023 . . . . 1.0 110.542 178.238 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.582 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.7 m -103.0 124.66 48.93 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 108.292 -1.003 . . . . 1.0 108.292 178.604 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.941 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.58 109.36 8.62 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 119.681 -0.808 . . . . 1.0 109.726 -179.13 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.3 m -115.99 115.66 26.54 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.293 -0.879 . . . . 1.0 109.164 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.926 HG21 HG11 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -140.68 138.86 34.59 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.425 -0.797 . . . . 1.0 109.864 179.941 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.7 p -98.98 133.48 43.19 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.448 -0.782 . . . . 1.0 109.179 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.759 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -131.22 163.71 27.14 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.302 -0.873 . . . . 1.0 109.446 -179.313 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.764 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -93.99 124.33 37.93 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.046 -1.034 . . . . 1.0 109.157 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.541 HG23 HD13 ' A' ' 13' ' ' LEU . 14.4 m -134.71 143.32 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 120.979 -1.076 . . . . 1.0 109.877 -178.867 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.598 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.2 ptt180 -145.33 -170.66 3.49 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.464 -1.397 . . . . 1.0 111.042 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.637 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -61.88 -101.64 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.851 -0.531 . . . . 1.0 110.241 -179.093 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.528 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -59.19 138.11 57.71 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.566 -1.333 . . . . 1.0 108.517 179.953 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.631 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 1.3 p90 -156.87 154.13 29.32 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 118.824 -1.15 . . . . 1.0 109.854 -178.795 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.483 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 20.4 mm-40 -47.6 122.11 4.56 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.353 -0.842 . . . . 1.0 109.577 -178.58 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.904 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.94 49.38 3.58 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.94 -0.864 . . . . 1.0 110.94 -179.333 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.599 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.4 m-85 -40.42 113.17 0.34 Allowed 'General case' 0 N--CA 1.507 2.386 0 O-C-N 121.014 -1.286 . . . . 1.0 110.224 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.736 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.92 127.08 35.06 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.842 -1.161 . . . . 1.0 109.358 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -63.83 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 O-C-N 120.758 -1.214 . . . . 1.0 110.213 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 1.6 t0 -160.78 19.0 0.13 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.016 -1.052 . . . . 1.0 109.801 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -25.97 5.75 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 110.15 -1.18 . . . . 1.0 110.15 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 15.4 p -93.31 157.67 16.13 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 120.964 -1.315 . . . . 1.0 110.491 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.477 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -103.86 132.71 49.85 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.482 -0.932 . . . . 1.0 108.482 179.609 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.736 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.1 t90 -81.16 -18.51 46.06 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.758 -1.213 . . . . 1.0 110.382 -178.692 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.26 174.16 19.41 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.864 -1.694 . . . . 1.0 108.864 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.43 107.93 1.22 Allowed 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.683 -1.229 . . . . 1.0 107.683 179.224 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.639 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.0 t -79.82 104.74 8.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.362 -0.836 . . . . 1.0 109.13 -178.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.555 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -65.04 109.15 2.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.567 -0.708 . . . . 1.0 110.15 -179.179 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.637 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.8 t -62.04 -4.1 1.51 Allowed 'General case' 0 N--CA 1.502 2.167 0 C-N-CA 118.262 -1.375 . . . . 1.0 110.334 179.265 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.1 p -91.33 5.34 49.62 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.66 -1.275 . . . . 1.0 109.384 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.555 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -117.2 -49.75 2.58 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.356 -0.84 . . . . 1.0 109.178 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.89 178.55 4.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.52 -0.737 . . . . 1.0 109.456 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.49 112.5 24.87 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.342 -0.849 . . . . 1.0 108.907 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.522 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.6 m -96.7 121.69 38.82 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.031 -1.043 . . . . 1.0 109.279 -179.061 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.582 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.61 147.55 26.65 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 122.454 1.121 . . . . 1.0 111.358 -179.172 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.637 ' HB ' HG11 ' A' ' 7' ' ' VAL . 58.8 t -103.38 109.52 27.22 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.492 -1.67 . . . . 1.0 106.492 177.484 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.443 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.19 -171.31 16.98 Favored Glycine 0 N--CA 1.485 1.927 0 C-N-CA 118.166 -1.969 . . . . 1.0 111.721 -177.546 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.555 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -115.49 -178.2 3.33 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.704 -0.85 . . . . 1.0 108.704 -178.839 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 p . . . . . 0 C--N 1.297 -1.714 0 O-C-N 121.312 -0.867 . . . . 1.0 109.574 -179.16 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.681 0 N-CA-C 107.697 -2.161 . . . . 1.0 107.697 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.02 -177.91 6.43 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 122.052 0.93 . . . . 1.0 109.844 179.255 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.48 -162.49 19.39 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 108.374 -1.89 . . . . 1.0 108.374 -179.477 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.555 ' HB2' HD12 ' A' ' 97' ' ' LEU . 7.1 Cg_exo -46.0 174.43 0.02 OUTLIER 'Trans proline' 0 C--N 1.327 -0.581 0 CA-C-N 118.854 1.327 . . . . 1.0 110.168 179.301 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -90.46 -178.84 5.44 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.0 -1.063 . . . . 1.0 110.611 -178.601 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.443 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.86 166.38 13.02 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.586 -1.405 . . . . 1.0 109.586 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.61 131.8 54.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.338 -1.095 . . . . 1.0 109.177 -179.225 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.582 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.3 121.94 20.28 Favored 'General case' 0 C--N 1.29 -2.002 0 O-C-N 121.59 -0.694 . . . . 1.0 109.617 179.657 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.844 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.8 pt -98.01 173.2 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.248 -0.908 . . . . 1.0 108.996 179.852 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.474 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -141.36 159.54 42.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.06 -1.025 . . . . 1.0 110.04 -179.7 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.844 ' CE2' HD12 ' A' ' 110' ' ' ILE . 88.5 m-85 . . . . . 0 N--CA 1.487 1.376 0 O-C-N 121.276 -0.89 . . . . 1.0 109.573 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.458 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.481 0 CA-C-O 122.356 1.074 . . . . 0.0 110.666 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.962 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -111.17 108.71 18.47 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 123.04 1.4 . . . . 0.0 109.096 179.273 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.914 HG22 HG23 ' A' ' 21' ' ' VAL . 4.5 t -118.31 136.44 55.5 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.761 0 CA-C-N 114.299 -1.319 . . . . 0.0 110.094 -179.685 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.482 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -176.64 150.97 1.0 Allowed Pre-proline 0 N--CA 1.488 1.431 0 O-C-N 121.279 -0.888 . . . . 0.0 108.801 -179.641 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.482 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.8 Cg_endo -79.11 150.45 85.74 Favored 'Cis proline' 0 C--N 1.311 -1.432 0 C-N-CA 123.507 -1.456 . . . . 0.0 109.271 -0.735 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.677 ' HA ' HG22 ' A' ' 110' ' ' ILE . 78.4 p -92.23 -23.19 19.42 Favored 'General case' 0 C--N 1.291 -1.937 0 O-C-N 121.589 -0.695 . . . . 0.0 109.402 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.485 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 7.4 m -132.2 160.74 35.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.354 -0.841 . . . . 0.0 109.764 -179.785 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.77 37.39 30.21 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.824 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.8 mt -92.04 -44.42 8.86 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-O 123.2 1.476 . . . . 0.0 110.728 -178.363 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.4 OUTLIER 65.96 146.28 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.341 0 CA-C-N 113.628 -1.624 . . . . 0.0 109.942 -179.69 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.606 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.0 p-10 -50.85 108.08 0.21 Allowed 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 121.478 0.656 . . . . 0.0 111.882 -178.532 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.5 15.2 10.58 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.421 -1.371 . . . . 0.0 112.879 177.131 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.824 HG21 ' CA ' ' A' ' 13' ' ' LEU . 10.6 t -102.65 -172.42 2.12 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 121.056 2.428 . . . . 0.0 109.897 179.35 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.796 HG13 ' O ' ' A' ' 67' ' ' LEU . 33.6 t -125.66 137.55 57.33 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.246 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.962 -178.726 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.54 HG22 HG22 ' A' ' 69' ' ' VAL . 27.4 m -116.2 155.84 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 178.768 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.4 ttpt -114.31 109.55 18.52 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.06 -1.025 . . . . 0.0 109.178 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.914 HG23 HG22 ' A' ' 7' ' ' VAL . 2.4 p -105.12 141.45 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.962 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -139.72 160.25 40.3 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 120.632 -1.292 . . . . 0.0 110.229 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.07 144.21 15.45 Favored Glycine 0 C--N 1.295 -1.704 0 N-CA-C 107.977 -2.049 . . . . 0.0 107.977 179.47 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.08 125.94 13.55 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 120.894 -1.356 . . . . 0.0 108.841 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.11 27.04 24.51 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 119.214 -1.469 . . . . 0.0 109.654 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.4 mt -88.58 175.01 7.74 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.887 -1.361 . . . . 0.0 108.498 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.998 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -48.55 100.15 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.002 -1.061 . . . . 0.0 109.792 -179.63 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.44 78.13 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.134 -179.24 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.91 34.08 0.31 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.72 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.554 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 34.2 p -140.79 107.29 5.3 Favored 'General case' 0 C--N 1.308 -1.218 0 O-C-N 121.24 -1.153 . . . . 0.0 110.984 -179.489 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.575 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.67 109.78 0.25 Allowed 'General case' 0 N--CA 1.497 1.888 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.987 178.174 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.537 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 24.9 m-85 -102.38 153.86 19.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 108.638 179.372 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.505 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.87 161.51 13.61 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.676 -1.265 . . . . 0.0 107.948 178.85 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.655 HG13 ' O ' ' A' ' 34' ' ' VAL . 5.5 p -141.16 115.23 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.157 -0.964 . . . . 0.0 109.442 -178.205 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.53 ' HA2' ' OD1' ' A' ' 51' ' ' ASP . . . -162.75 173.99 39.05 Favored Glycine 0 N--CA 1.49 2.276 0 C-N-CA 118.06 -2.019 . . . . 0.0 112.114 -179.334 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.628 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -98.43 108.96 21.79 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 179.267 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.8 m -132.28 151.26 51.92 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.277 -0.889 . . . . 0.0 109.992 -179.513 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.42 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.82 139.65 53.64 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.248 -0.907 . . . . 0.0 110.695 -179.06 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.878 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.26 114.56 26.36 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.22 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.2 m -105.09 14.75 7.09 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 120.885 -1.135 . . . . 0.0 110.602 -178.687 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.759 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.06 -174.99 0.09 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.892 -1.13 . . . . 0.0 110.067 179.751 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.6 p -71.95 97.32 1.84 Allowed 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.344 -0.848 . . . . 0.0 109.798 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.42 26.93 34.39 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 120.241 -0.98 . . . . 0.0 111.428 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.6 106.31 20.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.55 -1.559 . . . . 0.0 107.429 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.878 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.2 tp -116.65 104.82 11.77 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.564 -1.335 . . . . 0.0 109.723 -177.862 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.078 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.98 109.53 22.27 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 120.829 -1.17 . . . . 0.0 108.204 179.092 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.6 t -105.89 165.56 11.11 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.9 -1.125 . . . . 0.0 110.295 -179.085 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.665 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 18.7 t-20 -109.33 137.0 20.13 Favored Pre-proline 0 N--CA 1.501 2.104 0 O-C-N 121.421 -0.799 . . . . 0.0 110.201 -179.08 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.584 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.2 Cg_endo -74.89 23.94 0.39 Allowed 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 122.387 2.058 . . . . 0.0 111.971 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.665 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -116.88 2.67 12.83 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.296 -1.503 . . . . 0.0 109.227 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.955 ' OD1' HD22 ' A' ' 67' ' ' LEU . 9.4 t70 -137.64 13.27 2.95 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 179.552 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -79.72 94.25 5.7 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 121.424 -0.798 . . . . 0.0 110.883 -178.651 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -115.33 -166.25 1.1 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 178.367 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.94 135.42 0.09 Allowed 'General case' 0 N--CA 1.486 1.369 0 O-C-N 120.627 -1.296 . . . . 0.0 111.429 -179.34 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.915 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -151.18 156.9 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 107.354 -1.351 . . . . 0.0 107.354 178.007 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.575 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.19 144.14 27.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.801 -1.187 . . . . 0.0 110.055 -179.574 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.008 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.72 106.91 1.06 Allowed 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 122.447 1.118 . . . . 0.0 109.436 178.27 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -60.05 -139.28 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.988 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.042 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.91 -50.1 61.74 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.498 -0.751 . . . . 0.0 110.597 -178.752 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 12.3 m-80 -103.7 -34.47 8.58 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 106.208 -1.775 . . . . 0.0 106.208 178.573 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.008 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.49 65.31 0.58 Allowed Glycine 0 C--N 1.297 -1.604 0 N-CA-C 110.501 -1.039 . . . . 0.0 110.501 178.141 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 46.6 m -103.62 127.05 51.11 Favored 'General case' 0 N--CA 1.483 1.19 0 O-C-N 121.381 -1.07 . . . . 0.0 108.915 178.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.915 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.72 109.15 7.37 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.424 -0.91 . . . . 0.0 109.36 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -124.71 121.65 35.25 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.201 -0.937 . . . . 0.0 109.663 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.71 142.05 28.61 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.596 -0.69 . . . . 0.0 109.486 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 15.6 p -98.93 136.38 39.0 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.451 -0.781 . . . . 0.0 109.186 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.955 HD22 ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -135.93 -178.73 5.27 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.235 -0.915 . . . . 0.0 109.544 -178.983 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.4 p -105.09 126.18 51.79 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.99 -1.069 . . . . 0.0 109.637 -179.352 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.54 HG22 HG22 ' A' ' 19' ' ' VAL . 16.9 m -139.35 142.97 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 120.888 -1.132 . . . . 0.0 110.08 -179.521 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.606 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.8 ptt180 -141.2 -161.42 1.21 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.671 -1.268 . . . . 0.0 110.141 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.582 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -78.15 -86.89 0.06 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.232 -0.918 . . . . 0.0 108.848 -179.584 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -60.87 138.47 58.14 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.387 -1.446 . . . . 0.0 107.204 178.809 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -165.11 136.58 4.11 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 117.901 -1.519 . . . . 0.0 110.371 -177.365 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.516 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 7.0 mm-40 -33.4 121.44 0.4 Allowed 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 121.352 0.596 . . . . 0.0 110.326 -178.766 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.078 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.85 51.83 1.72 Allowed Glycine 0 N--CA 1.494 2.53 0 C-N-CA 120.474 -0.869 . . . . 0.0 111.42 -179.036 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.584 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 4.2 m-85 -39.11 116.6 0.6 Allowed 'General case' 0 N--CA 1.511 2.62 0 O-C-N 121.018 -1.283 . . . . 0.0 110.05 179.526 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.682 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.4 126.27 34.27 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 120.96 -1.087 . . . . 0.0 109.69 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -64.5 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 120.738 -1.226 . . . . 0.0 109.92 179.362 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.544 ' N ' ' O ' ' A' ' 77' ' ' LEU . 5.7 t70 -158.93 19.51 0.2 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.061 -1.025 . . . . 0.0 109.656 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.75 -27.96 5.65 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.426 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 69.7 p -97.54 162.71 13.17 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.046 -1.267 . . . . 0.0 110.307 -179.525 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.525 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.0 140.37 41.25 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.904 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.682 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.7 t90 -83.8 -19.21 35.42 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.771 -1.205 . . . . 0.0 110.728 -178.282 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.85 177.33 20.13 Favored Glycine 0 N--CA 1.484 1.869 0 N-CA-C 108.578 -1.809 . . . . 0.0 108.578 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -63.9 109.79 1.89 Allowed 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.214 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.62 HG21 ' HB3' ' A' ' 46' ' ' ALA . 37.3 t -82.91 105.66 12.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 121.44 -0.788 . . . . 0.0 108.947 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.539 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -66.14 111.73 3.56 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.428 -0.795 . . . . 0.0 109.882 -179.205 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.555 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -65.28 -5.32 6.87 Favored 'General case' 0 N--CA 1.498 1.96 0 C-N-CA 118.203 -1.399 . . . . 0.0 109.665 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.3 p -84.01 -1.24 54.37 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.799 -1.188 . . . . 0.0 108.887 179.269 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.539 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -113.5 -50.05 2.87 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.443 -0.786 . . . . 0.0 109.012 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.87 -178.0 3.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.486 -0.758 . . . . 0.0 109.45 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.09 115.77 30.76 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.451 -0.78 . . . . 0.0 109.037 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.535 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -96.87 122.76 40.19 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.894 -1.129 . . . . 0.0 109.588 -179.384 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.83 146.39 28.35 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 122.337 1.065 . . . . 0.0 111.167 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 59.3 t -103.78 109.88 28.46 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.591 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.473 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.55 -172.09 18.05 Favored Glycine 0 N--CA 1.486 2.016 0 C-N-CA 118.03 -2.033 . . . . 0.0 111.914 -177.515 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -112.97 -178.88 3.49 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.255 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.478 ' O ' ' N ' ' A' ' 33' ' ' ASP . 2.9 p . . . . . 0 C--N 1.296 -1.728 0 O-C-N 121.261 -0.899 . . . . 0.0 109.518 -179.373 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.631 0 N-CA-C 107.913 -2.075 . . . . 0.0 107.913 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.31 -177.76 6.23 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 122.1 0.952 . . . . 0.0 109.95 179.277 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.93 -163.89 23.71 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.149 -1.98 . . . . 0.0 108.149 -179.457 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.0 Cg_exo -46.24 172.96 0.02 OUTLIER 'Trans proline' 0 C--N 1.326 -0.616 0 CA-C-N 118.88 1.34 . . . . 0.0 109.889 179.371 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -91.7 -173.21 3.46 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.15 -0.969 . . . . 0.0 110.447 -178.712 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.473 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.81 171.29 15.54 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.1 t -106.69 132.98 52.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.536 -0.979 . . . . 0.0 109.138 -179.383 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.37 123.94 26.25 Favored 'General case' 0 C--N 1.29 -2.017 0 O-C-N 121.609 -0.682 . . . . 0.0 109.664 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.827 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.73 168.23 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.282 -0.886 . . . . 0.0 108.934 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.485 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 5.4 m -136.6 154.53 50.64 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.219 -0.926 . . . . 0.0 109.752 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.827 ' CE2' HD12 ' A' ' 110' ' ' ILE . 77.3 m-85 . . . . . 0 N--CA 1.487 1.38 0 O-C-N 121.179 -0.951 . . . . 0.0 109.417 -179.698 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.176 0 CA-C-O 122.414 1.102 . . . . 0.0 110.617 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.989 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 3.2 p -108.54 104.79 14.19 Favored 'General case' 0 C--N 1.296 -1.738 0 CA-C-O 122.491 1.139 . . . . 0.0 110.337 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.949 HG22 HG23 ' A' ' 21' ' ' VAL . 10.8 t -116.86 110.17 30.44 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.448 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.479 179.589 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.5 HG23 ' HA ' ' A' ' 9' ' ' PRO . 1.0 OUTLIER -152.55 146.72 18.53 Favored Pre-proline 0 N--CA 1.485 1.294 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.971 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.5 ' HA ' HG23 ' A' ' 8' ' ' THR . 9.3 Cg_endo -80.83 146.87 73.05 Favored 'Cis proline' 0 C--N 1.306 -1.675 0 O-C-N 123.666 1.351 . . . . 0.0 109.373 -0.232 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.677 ' HA ' HG22 ' A' ' 110' ' ' ILE . 80.4 p -91.51 -24.03 19.77 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.493 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 13.2 m -131.33 160.99 33.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.575 -0.703 . . . . 0.0 109.471 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.74 36.65 32.36 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 -179.648 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.75 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.7 mt -91.32 -42.63 10.26 Favored 'General case' 0 C--N 1.299 -1.587 0 CA-C-O 123.358 1.552 . . . . 0.0 110.46 -178.475 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.24 142.99 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.253 0 CA-C-N 113.322 -1.763 . . . . 0.0 109.795 -179.561 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.601 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.1 p-10 -50.01 105.74 0.1 Allowed 'General case' 0 C--N 1.301 -1.529 0 CA-C-O 121.448 0.642 . . . . 0.0 111.574 -178.56 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.47 13.88 8.57 Favored Glycine 0 N--CA 1.485 1.919 0 C-N-CA 119.417 -1.373 . . . . 0.0 113.16 177.211 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.75 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -106.01 -172.88 2.17 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 121.199 2.499 . . . . 0.0 109.839 179.28 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.95 HG22 HG22 ' A' ' 68' ' ' THR . 20.8 t -128.87 140.3 49.62 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.27 0 CA-C-N 114.695 -1.139 . . . . 0.0 111.362 -178.832 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.562 HG11 HD11 ' A' ' 13' ' ' LEU . 27.8 m -114.87 156.24 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 178.876 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.526 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -109.29 109.72 20.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.984 -1.072 . . . . 0.0 109.553 -179.716 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.949 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -105.05 123.57 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 179.898 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.989 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.3 165.96 11.71 Favored 'General case' 0 N--CA 1.484 1.267 0 O-C-N 120.792 -1.192 . . . . 0.0 108.942 179.438 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.6 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -145.56 108.16 0.45 Allowed Glycine 0 N--CA 1.483 1.822 0 N-CA-C 108.36 -1.896 . . . . 0.0 108.36 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.83 137.37 52.25 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 120.519 -1.577 . . . . 0.0 110.439 -179.303 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.475 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 85.85 28.85 27.8 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.085 -1.531 . . . . 0.0 109.874 179.567 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.606 HD22 ' HG3' ' A' ' 105' ' ' PRO . 2.3 mt -90.36 175.66 7.02 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.963 -1.316 . . . . 0.0 108.373 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.012 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.69 97.94 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.858 -1.151 . . . . 0.0 109.678 -179.669 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.594 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.08 76.96 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.692 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.381 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.571 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.9 34.34 0.3 Allowed Glycine 0 N--CA 1.486 1.975 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.465 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.553 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.7 p -147.89 113.3 5.61 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 120.998 -1.296 . . . . 0.0 111.28 -179.693 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.577 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.86 126.67 5.91 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-N 115.619 -0.718 . . . . 0.0 109.567 177.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.483 ' HA ' ' O ' ' A' ' 98' ' ' SER . 10.5 m-85 -117.48 149.39 40.67 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.484 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.3 163.87 12.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.751 -1.218 . . . . 0.0 107.92 178.918 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.929 HG11 HG21 ' A' ' 65' ' ' THR . 9.9 p -149.32 114.07 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.202 -0.936 . . . . 0.0 109.838 -177.627 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.524 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.01 -175.89 36.83 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 118.329 -1.891 . . . . 0.0 111.724 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.591 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -101.4 108.87 20.6 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.763 0.792 . . . . 0.0 108.951 -179.563 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.484 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.12 146.88 51.8 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.427 -0.796 . . . . 0.0 109.691 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.493 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -120.35 138.18 53.87 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.298 -0.877 . . . . 0.0 110.703 -179.007 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.861 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.64 114.4 26.14 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.251 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -105.89 14.85 7.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.002 -1.061 . . . . 0.0 110.603 -178.646 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.766 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.43 -174.6 0.07 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.808 -1.182 . . . . 0.0 110.164 179.756 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.8 p -71.71 97.57 1.78 Allowed 'General case' 0 N--CA 1.485 1.323 0 O-C-N 121.43 -0.794 . . . . 0.0 109.867 -179.63 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 26.47 37.09 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 120.251 -0.976 . . . . 0.0 111.483 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.766 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.75 106.21 20.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.556 -1.555 . . . . 0.0 107.367 178.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.861 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -118.22 104.77 11.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.473 -1.392 . . . . 0.0 109.641 -177.729 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.012 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.98 109.75 22.45 Favored 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.789 -1.194 . . . . 0.0 108.345 179.138 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.5 t -106.33 164.71 11.8 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.935 -1.103 . . . . 0.0 110.426 -178.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.732 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 10.5 t-20 -108.94 139.48 20.96 Favored Pre-proline 0 N--CA 1.501 2.083 0 O-C-N 121.461 -0.775 . . . . 0.0 109.952 -179.124 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 6.8 Cg_endo -75.7 23.11 0.45 Allowed 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 125.162 3.908 . . . . 0.0 111.258 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.732 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -120.07 3.34 10.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.426 -1.421 . . . . 0.0 109.052 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.545 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.89 14.51 3.1 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 179.343 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -80.49 91.19 5.72 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.778 -0.769 . . . . 0.0 110.98 -178.487 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.648 ' C ' HG12 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -113.23 -173.31 2.23 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.099 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.67 134.6 0.08 Allowed 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.482 -1.386 . . . . 0.0 111.494 -179.183 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.645 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 3.6 p -146.73 159.62 10.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 107.227 -1.398 . . . . 0.0 107.227 177.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.577 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.33 145.89 25.68 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.433 -1.417 . . . . 0.0 110.116 -179.629 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.47 109.36 3.67 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 122.326 1.06 . . . . 0.0 109.802 178.899 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.574 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -63.64 -139.31 0.0 OUTLIER 'General case' 0 C--N 1.292 -1.902 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.588 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.594 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.92 -51.59 55.91 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.391 -0.818 . . . . 0.0 110.378 -178.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.475 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.4 t-20 -101.39 -34.18 9.7 Favored 'General case' 0 C--N 1.287 -2.121 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.968 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.44 69.59 0.72 Allowed Glycine 0 N--CA 1.479 1.557 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 178.041 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 64.3 p -98.86 131.69 44.77 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 121.327 -1.102 . . . . 0.0 109.268 179.118 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.645 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.1 108.48 7.82 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.775 -0.77 . . . . 0.0 109.021 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 7.0 m -122.23 116.36 24.0 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.122 -0.986 . . . . 0.0 109.536 -179.743 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.929 HG21 HG11 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -146.13 139.48 25.99 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.428 -0.795 . . . . 0.0 109.787 179.944 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.8 p -99.97 128.83 46.01 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.369 -0.832 . . . . 0.0 108.946 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.787 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -126.54 164.42 21.24 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.227 -0.92 . . . . 0.0 109.783 -179.092 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.95 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -96.77 125.12 41.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.118 -0.989 . . . . 0.0 109.221 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.591 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.9 m -136.51 142.69 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.075 -1.016 . . . . 0.0 109.909 -179.026 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.601 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.8 ptt180 -146.37 -173.62 4.24 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.473 -1.392 . . . . 0.0 110.922 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.619 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.64 -101.94 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 -179.409 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.508 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -55.72 140.95 39.99 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 120.788 -1.195 . . . . 0.0 108.115 179.458 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.79 135.26 5.51 Favored 'General case' 0 C--N 1.294 -1.818 0 C-N-CA 118.701 -1.2 . . . . 0.0 109.813 -178.265 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.519 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 1.3 mp0 -31.53 121.16 0.25 Allowed 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 121.41 0.624 . . . . 0.0 110.699 -178.488 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.012 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.74 46.61 2.73 Favored Glycine 0 N--CA 1.495 2.572 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.136 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -38.48 113.19 0.27 Allowed 'General case' 0 N--CA 1.507 2.388 0 O-C-N 121.121 -1.223 . . . . 0.0 110.205 179.622 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.654 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -85.92 127.32 34.58 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 120.975 -1.078 . . . . 0.0 109.52 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.6 t80 -64.09 58.17 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.051 0 O-C-N 120.858 -1.151 . . . . 0.0 110.198 179.73 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 6.7 t70 -160.93 19.4 0.13 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.972 -1.08 . . . . 0.0 109.794 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.73 -27.17 5.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.429 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 70.7 p -93.39 157.15 16.37 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.05 -1.264 . . . . 0.0 110.349 -179.402 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.492 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -104.73 134.45 47.85 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.652 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.654 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -80.94 -17.97 48.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.887 -1.133 . . . . 0.0 110.413 -178.494 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.74 174.6 19.79 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.29 106.2 1.06 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.11 -1.23 . . . . 0.0 107.695 179.157 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.596 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.0 t -77.54 106.79 8.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.382 -0.824 . . . . 0.0 109.292 -178.787 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.537 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.91 111.54 3.35 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.413 -0.804 . . . . 0.0 109.801 -179.474 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.619 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.71 -5.4 4.07 Favored 'General case' 0 N--CA 1.501 2.085 0 C-N-CA 118.135 -1.426 . . . . 0.0 109.809 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 40.9 p -86.52 -1.8 57.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.799 -1.188 . . . . 0.0 109.29 179.684 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.537 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.14 -49.69 3.0 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.264 -0.898 . . . . 0.0 109.058 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.18 179.03 4.38 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.47 -0.769 . . . . 0.0 109.525 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.3 115.92 31.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.39 -0.819 . . . . 0.0 109.058 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.83 122.59 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.877 -1.139 . . . . 0.0 109.465 -179.448 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.92 148.03 25.82 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 122.418 1.104 . . . . 0.0 111.249 -179.266 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.544 ' HB ' HG11 ' A' ' 7' ' ' VAL . 72.3 t -104.86 109.87 28.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 177.705 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.31 -173.56 18.56 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 118.308 -1.901 . . . . 0.0 111.796 -177.545 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.545 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.49 -178.54 3.41 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.029 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.483 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.2 OUTLIER . . . . . 0 C--N 1.295 -1.794 0 O-C-N 121.357 -0.839 . . . . 0.0 109.152 -179.353 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.723 0 N-CA-C 107.588 -2.205 . . . . 0.0 107.588 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.44 -178.69 7.32 Favored 'General case' 0 C--N 1.308 -1.237 0 O-C-N 121.6 -0.941 . . . . 0.0 109.522 179.051 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -175.88 -166.53 33.46 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 108.405 -1.878 . . . . 0.0 108.405 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.606 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.2 Cg_exo -45.03 178.85 0.0 OUTLIER 'Trans proline' 0 N--CA 1.491 1.377 0 C-N-CA 123.349 2.699 . . . . 0.0 109.697 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -92.59 175.18 6.92 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.955 -1.09 . . . . 0.0 110.637 -178.859 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -114.76 163.66 12.16 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.35 127.38 63.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.32 -1.106 . . . . 0.0 109.155 -179.285 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.58 122.01 19.76 Favored 'General case' 0 C--N 1.291 -1.971 0 O-C-N 121.559 -0.713 . . . . 0.0 109.47 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.865 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.79 170.44 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.198 -0.939 . . . . 0.0 109.085 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.493 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -140.53 156.38 46.33 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.143 -0.973 . . . . 0.0 109.837 -179.657 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.865 ' CE2' HD12 ' A' ' 110' ' ' ILE . 87.5 m-85 . . . . . 0 N--CA 1.485 1.293 0 O-C-N 121.233 -0.917 . . . . 0.0 109.572 -179.724 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.493 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 122.371 1.081 . . . . 0.0 110.391 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.873 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -114.28 109.3 18.16 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-O 123.112 1.435 . . . . 0.0 109.59 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.819 HG13 ' CA ' ' A' ' 21' ' ' VAL . 0.6 OUTLIER -116.71 129.93 72.4 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.666 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.756 -179.883 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.506 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -167.8 148.62 4.75 Favored Pre-proline 0 N--CA 1.487 1.401 0 O-C-N 121.169 -0.957 . . . . 0.0 108.943 -179.723 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.506 ' HA ' HG23 ' A' ' 8' ' ' THR . 7.4 Cg_endo -80.66 147.64 74.96 Favored 'Cis proline' 0 C--N 1.309 -1.523 0 O-C-N 123.669 1.352 . . . . 0.0 109.181 -0.656 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.685 ' HA ' HG22 ' A' ' 110' ' ' ILE . 86.8 p -91.08 -24.5 20.0 Favored 'General case' 0 C--N 1.294 -1.805 0 O-C-N 121.484 -0.76 . . . . 0.0 109.238 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.461 ' HA ' ' O ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -129.61 161.59 30.2 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.367 -0.833 . . . . 0.0 109.622 -179.864 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.08 37.94 31.31 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 108.499 -1.84 . . . . 0.0 108.499 -179.679 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.777 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.3 mt -92.79 -43.69 8.89 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 123.199 1.476 . . . . 0.0 110.736 -178.248 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.476 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.58 143.9 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.473 -1.694 . . . . 0.0 109.79 -179.355 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.577 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 17.9 p-10 -50.54 106.86 0.14 Allowed 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.394 0.616 . . . . 0.0 111.517 -178.558 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.62 14.34 9.65 Favored Glycine 0 N--CA 1.485 1.903 0 C-N-CA 119.38 -1.391 . . . . 0.0 112.966 177.143 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.777 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.18 -172.17 2.06 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 121.1 2.45 . . . . 0.0 109.821 179.246 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.766 HG22 HG22 ' A' ' 68' ' ' THR . 17.7 t -127.94 138.7 53.95 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.796 -1.093 . . . . 0.0 111.197 -179.034 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.483 HG12 ' CD2' ' A' ' 13' ' ' LEU . 28.7 m -112.86 156.77 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.5 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.47 109.25 20.02 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.014 -1.054 . . . . 0.0 109.063 -179.933 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.819 ' CA ' HG13 ' A' ' 7' ' ' VAL . 11.2 p -103.74 140.65 21.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.707 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.873 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -138.93 160.82 38.83 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.681 -1.207 . . . . 0.0 110.142 179.635 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.585 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.03 140.25 11.55 Favored Glycine 0 C--N 1.297 -1.636 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.03 126.32 17.58 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.543 -1.563 . . . . 0.0 109.318 179.497 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.65 28.53 21.43 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 118.964 -1.588 . . . . 0.0 109.52 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.589 HD22 ' HG3' ' A' ' 105' ' ' PRO . 2.5 mt -88.0 175.92 7.55 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.003 -1.292 . . . . 0.0 108.339 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.03 97.7 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.825 -1.172 . . . . 0.0 109.707 -179.57 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.639 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.92 77.27 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.433 -179.057 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.562 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.45 34.45 0.32 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.564 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.9 p -146.07 111.92 5.63 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.016 -1.285 . . . . 0.0 111.195 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.562 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.38 126.79 5.48 Favored 'General case' 0 N--CA 1.493 1.7 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.501 178.06 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.505 ' CD2' ' O ' ' A' ' 30' ' ' THR . 13.3 m-85 -117.45 152.5 34.88 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.494 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -101.42 162.51 12.84 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 178.771 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.718 HG22 HG11 ' A' ' 21' ' ' VAL . 3.8 p -148.99 117.82 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.013 -1.054 . . . . 0.0 110.049 -177.794 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.511 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -170.86 -176.25 40.0 Favored Glycine 0 N--CA 1.493 2.48 0 C-N-CA 118.266 -1.921 . . . . 0.0 111.736 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.595 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.06 108.91 21.19 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -179.788 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.55 148.69 52.38 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.275 -0.891 . . . . 0.0 109.713 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.494 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.95 139.39 54.0 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.316 -0.865 . . . . 0.0 110.643 -178.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.862 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.31 114.55 26.34 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 178.157 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.4 m -106.34 15.43 7.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.974 -1.079 . . . . 0.0 110.771 -178.587 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.751 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.56 -175.31 0.1 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.894 -1.129 . . . . 0.0 110.124 179.657 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 39.2 p -71.45 96.84 1.54 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.395 -0.816 . . . . 0.0 109.691 -179.637 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.84 27.05 35.74 Favored Glycine 0 N--CA 1.493 2.496 0 C-N-CA 120.144 -1.027 . . . . 0.0 111.499 178.848 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.751 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.1 106.52 20.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 O-C-N 120.595 -1.532 . . . . 0.0 107.382 178.987 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.862 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -116.08 104.62 11.75 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.492 -1.38 . . . . 0.0 109.485 -177.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.012 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.09 109.57 22.31 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 120.735 -1.228 . . . . 0.0 108.295 179.062 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -107.22 163.78 12.73 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.974 -1.079 . . . . 0.0 110.303 -178.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.536 HD22 ' HB3' ' A' ' 50' ' ' ALA . 16.6 t30 -110.36 139.08 21.14 Favored Pre-proline 0 N--CA 1.503 2.219 0 O-C-N 121.369 -0.832 . . . . 0.0 109.89 -179.401 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.6 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 6.1 Cg_endo -74.55 23.99 0.37 Allowed 'Trans proline' 0 N--CA 1.495 1.591 0 C-N-CA 125.252 3.968 . . . . 0.0 111.445 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.536 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -116.58 1.12 12.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.474 -1.392 . . . . 0.0 109.043 179.474 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.511 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -137.75 15.39 2.9 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.399 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -79.51 90.88 5.1 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.978 -0.689 . . . . 0.0 110.831 -178.649 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.625 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.24 -170.14 1.6 Allowed 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.255 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.451 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.91 136.03 0.09 Allowed 'General case' 0 C--N 1.305 -1.331 0 O-C-N 120.657 -1.277 . . . . 0.0 111.093 -179.354 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.804 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.3 p -150.57 157.35 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 178.212 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.25 145.0 26.5 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.579 -1.325 . . . . 0.0 109.784 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.009 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.15 107.77 2.04 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 122.392 1.091 . . . . 0.0 109.56 178.793 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.553 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.9 p-10 -60.4 -139.26 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.992 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.857 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.639 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -53.01 -49.69 65.74 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.427 -0.795 . . . . 0.0 110.341 -178.889 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -102.56 -36.21 8.45 Favored 'General case' 0 C--N 1.287 -2.148 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 178.4 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.982 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.4 67.14 0.61 Allowed Glycine 0 N--CA 1.48 1.601 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 178.242 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.585 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.1 m -100.98 130.02 46.91 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.566 -0.961 . . . . 0.0 108.992 178.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.804 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.76 108.9 6.79 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.225 -0.99 . . . . 0.0 109.496 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.9 m -125.94 119.73 28.51 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.275 -0.891 . . . . 0.0 109.592 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.455 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.41 144.6 30.74 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.432 -0.793 . . . . 0.0 109.389 179.86 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.0 p -98.96 132.29 44.39 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.418 -0.801 . . . . 0.0 109.355 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.743 ' O ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -130.84 167.83 18.27 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.292 -0.88 . . . . 0.0 109.624 -179.511 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.766 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -99.33 125.54 45.01 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.183 -0.948 . . . . 0.0 109.344 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.568 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.4 m -137.7 143.04 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 120.985 -1.072 . . . . 0.0 109.857 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.577 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.8 ptt180 -145.95 -170.92 3.59 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.597 -1.314 . . . . 0.0 110.888 -179.898 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.616 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -56.12 -102.05 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.769 -0.582 . . . . 0.0 109.488 -179.405 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -55.38 141.0 37.9 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 120.715 -1.24 . . . . 0.0 108.266 179.554 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.577 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.06 137.13 7.16 Favored 'General case' 0 C--N 1.295 -1.777 0 C-N-CA 118.922 -1.111 . . . . 0.0 109.634 -178.357 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.566 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 9.9 mm-40 -33.03 121.62 0.37 Allowed 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.604 0.716 . . . . 0.0 110.868 -178.266 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.012 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.05 44.87 2.99 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -179.555 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.6 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-85 -37.88 112.6 0.22 Allowed 'General case' 0 N--CA 1.508 2.436 0 O-C-N 121.252 -1.146 . . . . 0.0 110.094 179.691 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.739 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.15 126.95 34.6 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.944 -1.098 . . . . 0.0 109.503 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 34.9 t80 -63.84 58.3 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.0 0 O-C-N 120.967 -1.083 . . . . 0.0 110.338 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 10.9 t0 -161.67 19.83 0.11 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.001 -1.062 . . . . 0.0 109.762 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.15 -26.93 5.25 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.427 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -92.43 157.09 16.78 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.009 -1.289 . . . . 0.0 110.322 -179.402 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.473 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -104.44 133.2 49.73 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.656 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.739 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.4 t90 -81.26 -18.96 44.14 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.835 -1.166 . . . . 0.0 110.427 -178.678 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.45 173.56 18.63 Favored Glycine 0 N--CA 1.485 1.962 0 N-CA-C 108.931 -1.668 . . . . 0.0 108.931 -179.687 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.37 106.83 1.19 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.156 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.647 HG21 ' HB3' ' A' ' 46' ' ' ALA . 50.2 t -77.9 106.17 7.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 O-C-N 121.302 -0.874 . . . . 0.0 109.504 -178.716 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.543 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.51 110.97 2.89 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.36 -0.837 . . . . 0.0 109.826 -179.573 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.616 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -62.5 -5.98 3.01 Favored 'General case' 0 N--CA 1.501 2.078 0 C-N-CA 118.32 -1.352 . . . . 0.0 109.901 179.383 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -87.13 -1.19 57.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.611 -1.306 . . . . 0.0 109.336 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.543 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.0 -49.54 3.02 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.253 -0.905 . . . . 0.0 108.959 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.82 -179.22 3.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.582 -0.699 . . . . 0.0 109.441 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.03 115.37 30.32 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.329 -0.857 . . . . 0.0 109.003 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.561 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.2 m -96.75 122.44 39.69 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.857 -1.152 . . . . 0.0 109.476 -179.362 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.58 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.29 147.86 26.55 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-O 122.451 1.12 . . . . 0.0 111.208 -179.354 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.473 ' CG1' HG11 ' A' ' 7' ' ' VAL . 60.8 t -104.18 111.09 32.44 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.973 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.692 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.07 -172.63 18.98 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 118.108 -1.996 . . . . 0.0 111.769 -177.588 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.5 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -114.4 -179.06 3.52 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 -179.11 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.497 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER . . . . . 0 C--N 1.295 -1.787 0 O-C-N 121.428 -0.795 . . . . 0.0 109.128 -179.406 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.769 0 N-CA-C 107.617 -2.193 . . . . 0.0 107.617 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.72 -178.75 7.3 Favored 'General case' 0 C--N 1.308 -1.228 0 O-C-N 121.587 -0.949 . . . . 0.0 109.457 179.036 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -175.66 -167.15 34.26 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 108.603 -1.799 . . . . 0.0 108.603 -179.577 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.589 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.7 Cg_exo -45.72 179.65 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.391 0 C-N-CA 123.262 2.641 . . . . 0.0 109.638 179.45 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.84 174.82 6.98 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.917 -1.115 . . . . 0.0 110.571 -178.759 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -115.15 163.3 12.23 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.02 129.34 57.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.23 -1.159 . . . . 0.0 109.241 -179.317 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.58 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.08 122.81 23.27 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.605 -0.684 . . . . 0.0 109.567 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.855 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.93 169.88 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.259 -0.9 . . . . 0.0 109.249 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.461 ' O ' ' HA ' ' A' ' 11' ' ' SER . 1.7 t -140.02 155.4 47.1 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.158 -0.964 . . . . 0.0 109.669 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.855 ' CE2' HD12 ' A' ' 110' ' ' ILE . 87.4 m-85 . . . . . 0 N--CA 1.486 1.327 0 O-C-N 121.109 -0.994 . . . . 0.0 109.607 -179.728 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.467 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.407 0 CA-C-O 122.101 0.953 . . . . 0.0 110.609 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.995 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.8 p -107.13 104.59 14.27 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.595 1.188 . . . . 0.0 110.023 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.993 HG22 HG23 ' A' ' 21' ' ' VAL . 13.2 t -117.93 121.2 66.77 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.435 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.433 179.798 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.512 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.95 148.5 7.42 Favored Pre-proline 0 N--CA 1.487 1.379 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 -179.74 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.512 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.4 Cg_endo -75.42 153.33 98.45 Favored 'Cis proline' 0 C--N 1.309 -1.501 0 C-N-CA 123.648 -1.397 . . . . 0.0 109.614 -0.447 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.493 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 5.1 m -97.27 -22.14 16.85 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.515 ' HB3' ' CB ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -134.43 158.65 43.33 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.543 -0.723 . . . . 0.0 109.537 179.96 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.24 36.73 30.17 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.798 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.5 mt -89.32 -43.89 10.61 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 123.181 1.467 . . . . 0.0 110.513 -178.512 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.74 144.94 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.335 0 CA-C-N 113.543 -1.662 . . . . 0.0 109.946 -179.646 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.584 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.4 p-10 -50.77 107.18 0.16 Allowed 'General case' 0 C--N 1.301 -1.525 0 CA-C-O 121.657 0.741 . . . . 0.0 111.788 -178.469 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.1 15.65 9.72 Favored Glycine 0 N--CA 1.486 1.997 0 C-N-CA 119.423 -1.37 . . . . 0.0 112.942 177.224 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.798 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.1 t -103.21 -172.31 2.09 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 121.103 2.451 . . . . 0.0 109.784 179.221 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.753 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.5 t -129.72 139.14 52.38 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.18 -178.726 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.484 HG11 HD11 ' A' ' 13' ' ' LEU . 26.8 m -118.32 154.36 20.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.878 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.64 109.21 20.35 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.233 -0.917 . . . . 0.0 109.292 -179.954 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.993 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -106.09 124.09 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.995 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.16 165.36 12.47 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 120.731 -1.231 . . . . 0.0 108.85 179.421 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.636 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -142.1 107.68 0.5 Allowed Glycine 0 C--O 1.203 -1.838 0 N-CA-C 108.376 -1.89 . . . . 0.0 108.376 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.1 139.09 51.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.706 -1.467 . . . . 0.0 110.83 -178.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.68 26.74 41.1 Favored Glycine 0 N--CA 1.491 2.364 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.044 179.011 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.566 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -88.34 172.97 9.01 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.975 -1.309 . . . . 0.0 108.476 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.024 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.52 99.75 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.064 -1.023 . . . . 0.0 109.602 -179.576 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.82 76.3 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.088 -179.257 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.594 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.81 33.62 0.22 Allowed Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.677 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.556 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 63.3 p -142.73 109.8 5.58 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.032 -1.275 . . . . 0.0 111.178 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.594 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.08 109.98 0.38 Allowed 'General case' 0 N--CA 1.497 1.894 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.361 177.79 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.485 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.0 m-30 -105.62 155.97 18.71 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.101 -0.999 . . . . 0.0 109.029 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.509 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -98.83 163.25 12.69 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.744 -1.222 . . . . 0.0 107.763 178.791 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.735 HG11 HG21 ' A' ' 65' ' ' THR . 7.0 p -144.45 114.85 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.151 -0.968 . . . . 0.0 109.91 -177.882 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.65 -177.34 39.54 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 118.204 -1.95 . . . . 0.0 111.716 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.59 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.0 OUTLIER -99.77 112.2 24.46 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 -179.98 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 64.4 m -130.12 154.36 47.56 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 121.428 -0.795 . . . . 0.0 109.703 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.615 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -130.89 137.77 49.49 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.507 -0.745 . . . . 0.0 110.607 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.904 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.71 114.68 26.64 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.377 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.9 m -105.85 15.2 7.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.911 -1.118 . . . . 0.0 110.703 -178.548 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.779 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.23 -175.96 0.08 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.899 -1.126 . . . . 0.0 110.117 179.598 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.8 ' O ' HG23 ' A' ' 42' ' ' THR . 15.2 t -69.58 97.19 1.0 Allowed 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.786 0.803 . . . . 0.0 109.985 -179.474 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.12 27.68 36.36 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.523 178.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.779 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.86 106.46 20.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 O-C-N 120.545 -1.562 . . . . 0.0 107.34 178.929 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.904 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.5 tp -116.03 106.7 14.05 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.529 -1.357 . . . . 0.0 109.783 -177.598 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.112 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -96.17 110.44 22.72 Favored 'General case' 0 N--CA 1.484 1.272 0 O-C-N 120.765 -1.209 . . . . 0.0 108.554 179.5 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.584 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . 60.8 m -99.71 148.06 24.77 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.337 -0.852 . . . . 0.0 109.979 -178.812 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.749 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 13.0 t-20 -98.92 132.61 23.35 Favored Pre-proline 0 N--CA 1.501 2.098 0 O-C-N 120.922 -1.111 . . . . 0.0 109.159 179.413 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.581 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.9 Cg_endo -73.48 24.06 0.32 Allowed 'Trans proline' 0 C--N 1.317 -1.087 0 C-N-CA 122.291 1.994 . . . . 0.0 112.011 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.749 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -115.62 1.08 13.47 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.283 -1.51 . . . . 0.0 109.215 179.492 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.573 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.68 17.46 2.34 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 179.332 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.584 ' CE2' ' HB3' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -81.26 89.75 6.07 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.726 -0.789 . . . . 0.0 110.878 -178.787 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -112.57 -170.74 1.72 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.32 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.443 ' OG ' ' HA ' ' A' ' 33' ' ' ASP . 0.8 OUTLIER 178.8 134.62 0.09 Allowed 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.592 -1.318 . . . . 0.0 111.287 -179.342 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.564 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 2.5 p -149.07 161.99 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 178.163 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.29 142.62 29.72 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.685 -1.26 . . . . 0.0 110.181 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.024 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.66 108.39 2.45 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.401 1.096 . . . . 0.0 109.735 178.594 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.539 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.5 t70 -62.73 -139.39 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.995 0 CA-C-O 121.494 0.664 . . . . 0.0 110.77 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.85 -50.97 55.68 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.384 -0.823 . . . . 0.0 110.713 -178.722 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 13.6 t30 -103.16 -33.74 9.1 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 178.591 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.981 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 104.18 70.54 0.82 Allowed Glycine 0 C--N 1.298 -1.544 0 N-CA-C 110.254 -1.139 . . . . 0.0 110.254 178.415 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.636 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 36.7 m -103.34 127.55 50.66 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 121.418 -1.048 . . . . 0.0 109.322 179.566 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.567 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -132.09 108.73 9.5 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 50.8 m -118.14 115.3 24.51 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.159 -0.963 . . . . 0.0 109.39 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.735 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.22 137.08 27.09 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.397 -0.814 . . . . 0.0 109.981 -179.862 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.7 p -100.43 133.21 45.19 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.374 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.843 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -135.66 172.23 13.32 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.138 -0.976 . . . . 0.0 109.803 -179.076 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.692 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -99.63 124.68 45.08 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.139 -0.976 . . . . 0.0 109.583 -179.692 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.47 HG23 HD13 ' A' ' 13' ' ' LEU . 17.1 m -135.98 143.58 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.015 -1.053 . . . . 0.0 109.664 -179.415 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.584 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.3 ptt180 -141.52 -165.29 1.95 Allowed 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.563 -1.336 . . . . 0.0 110.076 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.548 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -72.65 -87.91 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.522 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -60.14 135.98 57.88 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.58 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.615 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.25 135.22 6.85 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 118.105 -1.438 . . . . 0.0 110.586 -177.62 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.543 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -33.29 119.42 0.35 Allowed 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.588 0.709 . . . . 0.0 110.451 -178.637 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.112 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.19 50.21 2.17 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.511 -178.849 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.581 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 1.1 m-85 -36.53 118.94 0.59 Allowed 'General case' 0 N--CA 1.513 2.719 0 O-C-N 121.236 -1.155 . . . . 0.0 110.214 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.621 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.4 tp -86.93 125.82 34.29 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.901 -1.124 . . . . 0.0 109.389 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.0 t80 -63.72 58.58 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.881 -1.137 . . . . 0.0 110.088 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.8 OUTLIER -161.44 21.01 0.12 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.986 -1.071 . . . . 0.0 109.651 179.879 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.02 -30.55 4.66 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.468 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -94.38 165.14 12.71 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.103 -1.234 . . . . 0.0 110.035 -179.417 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.433 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -111.24 140.39 45.84 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -179.897 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.621 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.2 t90 -81.9 -21.42 37.4 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.77 -1.207 . . . . 0.0 110.461 -178.797 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.67 176.54 18.87 Favored Glycine 0 N--CA 1.485 1.929 0 N-CA-C 108.558 -1.817 . . . . 0.0 108.558 -179.357 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.12 109.96 2.01 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.094 -1.239 . . . . 0.0 107.741 179.223 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.569 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.6 t -82.4 103.21 9.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.394 -0.816 . . . . 0.0 108.916 -178.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.528 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -63.95 110.53 2.15 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.48 -0.762 . . . . 0.0 109.851 -179.344 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.548 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.07 -4.96 5.39 Favored 'General case' 0 N--CA 1.499 1.985 0 C-N-CA 118.269 -1.372 . . . . 0.0 109.829 179.457 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.4 p -85.31 5.1 31.99 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.779 -1.201 . . . . 0.0 108.877 179.347 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.528 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -121.11 -48.9 2.21 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.327 -0.858 . . . . 0.0 109.047 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.63 -177.78 3.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.569 -0.707 . . . . 0.0 109.38 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.14 114.09 27.93 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.391 -0.818 . . . . 0.0 108.921 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.495 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.5 m -97.4 122.74 40.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.892 -1.13 . . . . 0.0 109.756 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.618 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.66 147.73 27.33 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 122.444 1.116 . . . . 0.0 111.346 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.551 ' HB ' HG11 ' A' ' 7' ' ' VAL . 66.9 t -101.47 109.8 26.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 177.618 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.412 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.19 -172.52 18.23 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 118.07 -2.014 . . . . 0.0 111.59 -177.61 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.492 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.74 -178.12 3.32 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -178.904 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.509 ' O ' ' N ' ' A' ' 33' ' ' ASP . 30.3 p . . . . . 0 C--N 1.296 -1.738 0 O-C-N 121.352 -0.842 . . . . 0.0 109.479 -179.375 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.706 0 N-CA-C 107.567 -2.213 . . . . 0.0 107.567 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -157.91 -178.62 7.45 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.512 -0.993 . . . . 0.0 109.763 179.098 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.02 -161.76 12.85 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 108.313 -1.915 . . . . 0.0 108.313 -179.328 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.492 ' HB2' HD12 ' A' ' 97' ' ' LEU . 5.0 Cg_exo -47.17 177.69 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.701 0 CA-C-N 118.789 1.295 . . . . 0.0 110.076 179.263 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -91.79 179.79 5.53 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.059 -1.026 . . . . 0.0 110.724 -178.576 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.412 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.4 160.99 13.36 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.23 130.01 51.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.324 -1.103 . . . . 0.0 109.345 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.618 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.83 127.3 32.13 Favored 'General case' 0 C--N 1.291 -1.972 0 O-C-N 121.583 -0.698 . . . . 0.0 109.65 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.641 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 19.6 pt -97.25 178.52 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 121.24 -0.912 . . . . 0.0 109.279 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.515 ' CB ' ' HB3' ' A' ' 11' ' ' SER . 0.5 OUTLIER -143.18 152.28 41.59 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.366 -0.834 . . . . 0.0 109.571 179.838 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.641 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 97.3 m-85 . . . . . 0 N--CA 1.484 1.249 0 O-C-N 121.082 -1.011 . . . . 0.0 109.569 -179.649 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.276 0 CA-C-O 122.334 1.064 . . . . 0.0 110.225 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.818 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -116.38 109.01 16.77 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-O 123.105 1.431 . . . . 0.0 109.605 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.925 HG22 HG23 ' A' ' 21' ' ' VAL . 4.0 t -114.58 135.33 54.73 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.669 0 CA-C-N 114.194 -1.366 . . . . 0.0 109.688 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.472 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.65 149.82 4.49 Favored Pre-proline 0 N--CA 1.487 1.419 0 O-C-N 121.193 -0.942 . . . . 0.0 108.984 -179.493 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.472 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -79.3 149.38 83.08 Favored 'Cis proline' 0 C--N 1.312 -1.376 0 C-N-CA 123.511 -1.454 . . . . 0.0 109.393 -1.009 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.661 ' HA ' HG22 ' A' ' 110' ' ' ILE . 86.1 p -90.99 -23.83 20.28 Favored 'General case' 0 C--N 1.292 -1.929 0 O-C-N 121.551 -0.718 . . . . 0.0 109.191 179.609 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.49 ' CB ' ' HB3' ' A' ' 111' ' ' SER . 0.7 OUTLIER -129.8 158.94 38.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.496 -0.753 . . . . 0.0 109.595 -179.881 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.51 37.33 27.55 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 108.64 -1.784 . . . . 0.0 108.64 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.806 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.0 mt -92.11 -44.02 9.06 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.213 1.482 . . . . 0.0 110.757 -178.459 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.463 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.16 145.16 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.299 0 CA-C-N 113.505 -1.68 . . . . 0.0 110.055 -179.753 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.613 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.3 p-10 -50.32 106.4 0.12 Allowed 'General case' 0 C--N 1.3 -1.567 0 CA-C-O 121.445 0.641 . . . . 0.0 111.645 -178.694 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.46 14.93 8.53 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.515 -1.326 . . . . 0.0 112.995 177.18 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.806 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -104.97 -174.18 2.48 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 121.134 2.467 . . . . 0.0 109.919 179.348 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.771 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.5 t -127.09 136.11 61.69 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.437 0 CA-C-N 114.541 -1.208 . . . . 0.0 111.258 -178.84 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.472 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 23.3 m -112.25 154.86 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 178.61 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.506 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 18.9 tttt -107.73 109.38 20.95 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.174 -0.954 . . . . 0.0 108.949 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.925 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.73 139.42 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.349 -0.844 . . . . 0.0 108.79 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.818 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.17 161.75 34.02 Favored 'General case' 0 C--N 1.305 -1.358 0 O-C-N 120.886 -1.134 . . . . 0.0 109.848 179.483 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.57 139.7 10.86 Favored Glycine 0 C--N 1.297 -1.604 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 179.752 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.37 125.87 16.76 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.499 -1.589 . . . . 0.0 109.3 179.48 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.97 27.63 23.18 Favored Glycine 0 N--CA 1.488 2.146 0 C-N-CA 118.8 -1.667 . . . . 0.0 109.736 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.562 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.1 mt -87.65 174.16 8.6 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 120.825 -1.397 . . . . 0.0 108.215 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.017 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.46 97.18 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.916 -1.115 . . . . 0.0 109.888 -179.412 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.623 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.76 77.13 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.761 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.404 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.69 34.09 0.32 Allowed Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.383 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.546 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.3 p -147.13 112.8 5.67 Favored 'General case' 0 C--N 1.308 -1.209 0 O-C-N 120.819 -1.401 . . . . 0.0 111.335 -179.804 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.566 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.87 126.58 5.86 Favored 'General case' 0 N--CA 1.491 1.623 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.846 178.063 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.485 ' CD2' ' O ' ' A' ' 30' ' ' THR . 12.7 m-85 -118.5 152.26 36.29 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.478 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -100.93 160.34 14.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.724 -1.235 . . . . 0.0 107.825 178.911 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.955 HG11 HG21 ' A' ' 65' ' ' THR . 3.7 p -142.4 119.8 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.218 -0.926 . . . . 0.0 109.451 -178.055 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.54 -178.54 41.35 Favored Glycine 0 N--CA 1.494 2.506 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.505 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.684 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -101.0 108.58 20.33 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.462 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.45 149.51 51.19 Favored 'General case' 0 C--N 1.296 -1.738 0 O-C-N 121.264 -0.898 . . . . 0.0 109.956 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.497 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -125.03 139.53 53.73 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.367 -0.833 . . . . 0.0 110.673 -179.146 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.29 114.92 26.75 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.199 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.8 m -105.11 15.23 6.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.093 -1.004 . . . . 0.0 110.595 -178.838 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.759 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.61 -176.06 0.08 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.947 -1.096 . . . . 0.0 110.038 179.631 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.776 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.93 97.75 1.48 Allowed 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.803 0.811 . . . . 0.0 109.848 -179.639 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.14 27.65 36.4 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 120.186 -1.007 . . . . 0.0 111.419 178.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -115.83 106.44 20.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 O-C-N 120.621 -1.517 . . . . 0.0 107.189 178.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -116.03 104.69 11.83 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.461 -1.399 . . . . 0.0 109.936 -177.659 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.045 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.41 22.17 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.827 -1.17 . . . . 0.0 108.179 178.81 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.9 t -107.46 163.63 12.89 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.847 -1.158 . . . . 0.0 110.295 -179.006 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.5 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 13.6 t30 -108.98 134.18 20.46 Favored Pre-proline 0 N--CA 1.502 2.136 0 O-C-N 121.351 -0.843 . . . . 0.0 109.575 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.598 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.6 Cg_endo -74.38 26.85 0.34 Allowed 'Trans proline' 0 C--N 1.319 -0.98 0 C-N-CA 122.486 2.124 . . . . 0.0 112.197 -179.396 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.494 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -109.29 -3.15 17.39 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.329 -1.482 . . . . 0.0 109.299 179.664 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.874 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.7 m-20 -135.96 12.39 3.36 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -70.07 83.6 0.51 Allowed 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.683 -0.807 . . . . 0.0 110.74 -178.667 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -105.23 -167.92 1.4 Allowed 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 178.356 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.473 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.7 t 179.07 135.59 0.09 Allowed 'General case' 0 C--N 1.306 -1.325 0 O-C-N 120.632 -1.292 . . . . 0.0 111.231 -179.38 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.773 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.7 p -149.24 156.63 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 178.095 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.566 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.57 145.39 26.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.583 -1.323 . . . . 0.0 109.738 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.017 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.93 108.67 2.66 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 122.334 1.064 . . . . 0.0 109.592 178.756 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.563 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 p-10 -62.92 -139.58 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.054 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.641 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.623 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.92 -51.73 49.19 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.446 -0.784 . . . . 0.0 110.569 -178.81 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -102.51 -32.98 9.67 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 178.582 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.84 66.72 0.64 Allowed Glycine 0 C--N 1.299 -1.511 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 178.168 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 55.6 p -98.69 132.51 44.01 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 121.289 -1.124 . . . . 0.0 109.048 179.001 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.773 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.03 108.6 6.95 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.146 -1.022 . . . . 0.0 109.535 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.3 m -124.12 117.48 24.76 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.265 -0.897 . . . . 0.0 109.641 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.955 HG21 HG11 ' A' ' 34' ' ' VAL . 5.2 t -145.99 145.2 30.54 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.441 -0.787 . . . . 0.0 109.361 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 53.3 p -99.03 143.98 28.69 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.428 -0.795 . . . . 0.0 109.342 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.874 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -145.35 169.86 17.45 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.305 -0.872 . . . . 0.0 109.459 -178.96 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.754 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -102.32 123.27 45.83 Favored 'General case' 0 N--CA 1.498 1.975 0 O-C-N 120.842 -1.161 . . . . 0.0 110.388 -178.878 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.842 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.2 m -131.12 143.98 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 120.996 -1.065 . . . . 0.0 110.016 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.613 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.3 ptt180 -148.93 -176.63 5.42 Favored 'General case' 0 N--CA 1.483 1.221 0 O-C-N 120.555 -1.341 . . . . 0.0 110.649 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.619 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.73 -101.5 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -179.562 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.5 OUTLIER -56.29 140.07 46.17 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.777 -1.202 . . . . 0.0 108.313 179.591 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.569 ' CZ ' ' SG ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -160.81 135.69 7.56 Favored 'General case' 0 C--N 1.296 -1.74 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.545 -178.57 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.5 ' N ' ' OD1' ' A' ' 48' ' ' ASN . 6.1 mm-40 -33.05 122.18 0.38 Allowed 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.609 0.718 . . . . 0.0 110.775 -178.038 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.045 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.78 45.34 2.89 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 -179.326 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.598 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-85 -37.64 114.62 0.35 Allowed 'General case' 0 N--CA 1.512 2.632 0 O-C-N 121.277 -1.131 . . . . 0.0 110.12 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.733 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -87.44 127.22 35.22 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.115 -0.991 . . . . 0.0 109.291 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 49.8 t80 -63.54 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.061 0 O-C-N 120.862 -1.149 . . . . 0.0 110.137 179.74 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.2 t0 -161.2 19.33 0.12 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.945 -1.097 . . . . 0.0 109.805 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.55 -26.73 5.61 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 42.1 p -94.41 160.21 14.76 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.121 -1.223 . . . . 0.0 110.11 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.477 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.6 OUTLIER -106.67 136.12 47.03 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.733 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.1 t90 -81.91 -18.9 42.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.819 -1.175 . . . . 0.0 110.428 -178.653 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.46 174.38 18.43 Favored Glycine 0 N--CA 1.486 2.024 0 N-CA-C 108.772 -1.731 . . . . 0.0 108.772 -179.602 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.18 106.06 1.23 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.113 -1.228 . . . . 0.0 107.688 179.184 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.683 HG21 ' HB3' ' A' ' 46' ' ' ALA . 51.3 t -76.96 105.22 5.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.316 -0.865 . . . . 0.0 109.361 -178.822 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.675 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.62 110.85 2.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.468 -0.77 . . . . 0.0 109.765 -179.599 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.619 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.08 -5.73 3.39 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 120.517 -1.364 . . . . 0.0 109.846 179.422 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -86.52 -0.57 56.36 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.706 -1.246 . . . . 0.0 109.172 179.655 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.675 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -113.19 -50.13 2.88 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.322 -0.861 . . . . 0.0 108.957 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.63 -178.62 3.71 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.576 -0.703 . . . . 0.0 109.428 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.54 115.31 30.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.337 -0.852 . . . . 0.0 109.039 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.569 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.24 123.36 41.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.875 -1.14 . . . . 0.0 109.7 -179.278 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.623 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.76 145.92 29.69 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.474 1.13 . . . . 0.0 111.113 -179.424 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.517 ' CG1' HG11 ' A' ' 7' ' ' VAL . 55.6 t -101.76 110.09 27.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.049 0 N-CA-C 106.646 -1.612 . . . . 0.0 106.646 177.474 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.483 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.01 -171.29 16.83 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 118.106 -1.997 . . . . 0.0 111.694 -177.475 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.49 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -119.0 179.48 4.14 Favored 'General case' 0 N--CA 1.485 1.283 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.038 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.535 ' O ' ' N ' ' A' ' 33' ' ' ASP . 3.5 m . . . . . 0 C--N 1.294 -1.817 0 O-C-N 121.435 -0.791 . . . . 0.0 109.666 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.409 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.482 1.721 0 N-CA-C 107.909 -2.076 . . . . 0.0 107.909 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.409 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.65 -177.15 3.8 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.603 -0.939 . . . . 0.0 109.725 179.395 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.63 -161.65 19.15 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.32 -1.912 . . . . 0.0 108.32 -179.388 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.495 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.9 Cg_exo -46.68 176.26 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.655 0 CA-C-N 118.808 1.304 . . . . 0.0 110.173 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -94.19 -174.96 3.53 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.038 -1.039 . . . . 0.0 110.403 -178.799 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.483 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.79 165.0 13.47 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.449 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.55 130.57 50.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.353 -1.087 . . . . 0.0 109.223 -179.416 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.623 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.84 125.48 28.26 Favored 'General case' 0 C--N 1.291 -1.964 0 O-C-N 121.669 -0.644 . . . . 0.0 109.774 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.661 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.5 pt -97.82 170.11 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.307 -0.871 . . . . 0.0 109.22 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.49 ' HB3' ' CB ' ' A' ' 11' ' ' SER . 3.6 t -138.09 158.33 44.53 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.375 -0.828 . . . . 0.0 109.449 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.633 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 30.4 m-85 . . . . . 0 N--CA 1.487 1.417 0 O-C-N 121.184 -0.948 . . . . 0.0 109.539 -179.731 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.587 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.388 0 CA-C-O 122.289 1.042 . . . . 0.0 111.109 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.007 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -101.66 104.47 15.31 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 122.413 1.101 . . . . 0.0 110.032 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.949 HG22 HG23 ' A' ' 21' ' ' VAL . 3.4 t -118.54 115.4 48.0 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.415 0 CA-C-O 121.679 0.752 . . . . 0.0 110.455 179.63 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.504 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.22 147.85 12.78 Favored Pre-proline 0 N--CA 1.487 1.397 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 -179.723 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.504 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.3 Cg_endo -77.07 152.05 94.41 Favored 'Cis proline' 0 C--N 1.309 -1.506 0 C-N-CA 123.693 -1.378 . . . . 0.0 109.561 -0.328 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.685 ' HA ' HG22 ' A' ' 110' ' ' ILE . 13.6 p -89.71 -25.84 20.98 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.642 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.518 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.0 m -136.39 167.98 20.3 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.555 -0.715 . . . . 0.0 109.338 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.47 38.12 39.15 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.747 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.3 mt -93.22 -42.63 9.24 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 123.319 1.533 . . . . 0.0 110.561 -178.177 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.56 142.58 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.284 0 CA-C-N 113.402 -1.726 . . . . 0.0 109.67 -179.385 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.606 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.2 p-10 -50.61 105.95 0.11 Allowed 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.588 0.709 . . . . 0.0 111.364 -178.517 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.68 14.15 8.24 Favored Glycine 0 N--CA 1.484 1.88 0 C-N-CA 119.446 -1.359 . . . . 0.0 112.982 177.418 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.747 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -106.21 -172.24 2.05 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 121.22 2.51 . . . . 0.0 109.831 179.161 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.985 HG22 HG22 ' A' ' 68' ' ' THR . 17.1 t -129.7 138.32 54.49 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.34 -178.786 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.62 HG11 HD11 ' A' ' 13' ' ' LEU . 35.8 m -114.34 155.35 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.782 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 28.2 tttt -107.13 108.87 20.53 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.184 -0.948 . . . . 0.0 109.466 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.949 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -105.64 123.29 59.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.372 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.007 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.66 166.55 12.28 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.716 -1.24 . . . . 0.0 109.325 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.62 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.05 142.45 13.89 Favored Glycine 0 C--N 1.294 -1.766 0 N-CA-C 107.381 -2.288 . . . . 0.0 107.381 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -147.22 123.27 10.76 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 120.747 -1.443 . . . . 0.0 108.714 179.372 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.1 27.01 22.38 Favored Glycine 0 N--CA 1.487 2.084 0 C-N-CA 119.155 -1.498 . . . . 0.0 109.802 -179.563 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.553 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.9 OUTLIER -89.0 174.8 7.7 Favored 'General case' 0 C--N 1.307 -1.248 0 O-C-N 120.842 -1.387 . . . . 0.0 108.436 179.85 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.83 99.78 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.949 -1.094 . . . . 0.0 109.808 -179.8 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.581 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.18 78.09 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.191 -179.298 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.83 34.5 0.3 Allowed Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 179.627 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.565 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 35.2 p -140.99 106.9 5.15 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 121.127 -1.219 . . . . 0.0 111.361 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.59 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.52 110.07 0.34 Allowed 'General case' 0 N--CA 1.498 1.931 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.557 177.87 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 5.7 m-30 -108.0 154.38 21.72 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.097 -1.002 . . . . 0.0 108.854 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.64 163.03 12.53 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.864 -1.148 . . . . 0.0 108.055 179.133 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.643 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.6 p -140.89 116.71 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.133 -0.979 . . . . 0.0 109.351 -178.297 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -164.32 -176.72 36.39 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 118.325 -1.893 . . . . 0.0 111.802 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.593 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -103.15 109.44 21.02 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.862 0.839 . . . . 0.0 109.099 -179.635 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.35 147.79 51.21 Favored 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.231 -0.918 . . . . 0.0 109.578 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.558 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.66 138.26 54.41 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.255 -0.903 . . . . 0.0 110.823 -178.882 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.68 26.48 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.177 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -105.74 14.71 7.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 120.952 -1.092 . . . . 0.0 110.513 -178.771 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 175.09 -175.9 0.09 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 120.951 -1.093 . . . . 0.0 110.03 179.754 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.784 ' O ' HG23 ' A' ' 42' ' ' THR . 15.0 t -71.33 97.82 1.65 Allowed 'General case' 0 N--CA 1.487 1.379 0 CA-C-O 121.785 0.802 . . . . 0.0 109.785 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.78 27.45 34.79 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.238 -0.982 . . . . 0.0 111.524 178.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.98 106.11 19.75 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 O-C-N 120.539 -1.565 . . . . 0.0 107.236 178.836 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.82 104.75 11.64 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.517 -1.365 . . . . 0.0 109.874 -177.692 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.106 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.78 109.45 22.2 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 120.845 -1.16 . . . . 0.0 108.071 178.86 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.4 t -107.07 162.42 13.87 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.949 -1.094 . . . . 0.0 110.393 -178.778 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.557 HD22 ' HB3' ' A' ' 50' ' ' ALA . 15.4 t30 -110.32 134.4 20.81 Favored Pre-proline 0 N--CA 1.503 2.199 0 O-C-N 121.453 -0.78 . . . . 0.0 109.759 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.593 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.77 25.03 0.33 Allowed 'Trans proline' 0 C--N 1.318 -1.055 0 C-N-CA 122.346 2.031 . . . . 0.0 112.192 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.557 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -113.43 4.15 16.15 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.327 -1.483 . . . . 0.0 109.233 179.538 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.56 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.78 16.04 2.69 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 179.462 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -79.85 88.86 5.25 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.541 -178.266 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.643 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -105.96 -165.85 1.14 Allowed 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 177.788 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.444 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.77 138.38 0.09 Allowed 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.508 -1.37 . . . . 0.0 111.454 -179.343 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.949 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -156.64 157.2 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.225 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.67 141.82 31.01 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.828 -1.17 . . . . 0.0 109.746 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.05 106.96 0.92 Allowed 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 122.385 1.088 . . . . 0.0 109.144 178.309 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.8 t0 -61.64 -138.9 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.987 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.016 -179.843 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.581 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.59 -52.12 32.46 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.426 -0.796 . . . . 0.0 110.81 -178.534 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -104.06 -33.05 8.91 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 106.209 -1.775 . . . . 0.0 106.209 178.571 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.016 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.31 65.41 0.56 Allowed Glycine 0 C--N 1.298 -1.542 0 N-CA-C 110.457 -1.057 . . . . 0.0 110.457 178.085 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.62 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.4 m -102.99 127.95 50.01 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 121.492 -1.004 . . . . 0.0 108.819 178.871 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.949 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.39 109.17 7.55 Favored 'General case' 0 C--N 1.296 -1.737 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.893 -179.312 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -116.26 117.43 29.99 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.207 -0.933 . . . . 0.0 109.291 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.573 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.63 143.34 30.72 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.412 -0.805 . . . . 0.0 109.758 -179.978 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.9 p -101.0 140.01 35.89 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.472 -0.768 . . . . 0.0 109.5 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.796 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -139.21 161.6 37.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.36 -0.837 . . . . 0.0 109.524 -179.469 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.985 HG22 HG22 ' A' ' 18' ' ' VAL . 2.9 p -93.87 124.46 37.89 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.159 -0.963 . . . . 0.0 109.438 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.562 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.3 m -135.38 143.71 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.063 -1.023 . . . . 0.0 109.58 -179.314 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.606 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.5 ptt180 -146.79 -177.13 5.49 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 120.453 -1.405 . . . . 0.0 111.042 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.627 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.13 -100.98 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -179.674 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -56.2 140.68 43.7 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 120.769 -1.207 . . . . 0.0 108.208 179.546 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.05 136.19 6.66 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 118.82 -1.152 . . . . 0.0 109.672 -178.341 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.52 ' N ' ' OD1' ' A' ' 48' ' ' ASN . 34.6 mt-10 -34.8 122.12 0.53 Allowed 'General case' 0 N--CA 1.489 1.508 0 CA-C-O 121.491 0.662 . . . . 0.0 110.462 -178.314 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.106 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.74 49.14 2.55 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.593 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.1 m-85 -38.82 114.21 0.37 Allowed 'General case' 0 N--CA 1.506 2.353 0 O-C-N 121.18 -1.188 . . . . 0.0 109.915 179.541 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.7 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.44 126.81 34.66 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.944 -1.098 . . . . 0.0 109.46 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -64.12 58.37 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.976 0 O-C-N 120.832 -1.168 . . . . 0.0 110.133 179.718 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.2 t70 -160.54 19.49 0.14 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.125 -0.984 . . . . 0.0 109.704 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.63 -27.18 5.41 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.41 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 21.4 p -94.19 159.71 15.02 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.03 -1.277 . . . . 0.0 110.316 -179.429 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.478 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.52 136.29 46.55 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.711 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.7 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.12 -18.47 42.8 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.734 -1.228 . . . . 0.0 110.44 -178.499 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.94 174.92 19.31 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 108.819 -1.712 . . . . 0.0 108.819 -179.575 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -65.09 105.34 1.04 Allowed 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 179.186 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.643 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.9 t -77.28 107.06 8.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.364 -0.835 . . . . 0.0 109.267 -178.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.536 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.2 m-20 -66.76 111.39 3.69 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.441 -0.787 . . . . 0.0 110.022 -179.313 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.627 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.81 -5.52 4.42 Favored 'General case' 0 N--CA 1.5 2.058 0 C-N-CA 118.171 -1.412 . . . . 0.0 109.832 179.198 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 16.6 p -87.26 1.17 53.98 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.795 -1.19 . . . . 0.0 109.171 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.536 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -115.23 -50.66 2.74 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.326 -0.859 . . . . 0.0 108.99 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.67 179.63 4.21 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.488 -0.757 . . . . 0.0 109.43 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.5 115.39 30.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.31 -0.869 . . . . 0.0 108.906 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.563 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.2 m -96.99 122.04 39.54 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.916 -1.115 . . . . 0.0 109.335 -179.368 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.578 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.17 146.37 27.58 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 122.371 1.081 . . . . 0.0 111.286 -179.292 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.607 ' HB ' HG11 ' A' ' 7' ' ' VAL . 54.6 t -105.73 111.74 36.19 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.028 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.502 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.46 -169.94 19.06 Favored Glycine 0 N--CA 1.487 2.088 0 C-N-CA 118.251 -1.928 . . . . 0.0 111.482 -177.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.479 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -117.23 173.24 6.79 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.803 -0.822 . . . . 0.0 108.858 -179.356 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.479 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER . . . . . 0 C--N 1.293 -1.888 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.519 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.482 1.744 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -173.74 -176.21 1.21 Allowed 'General case' 0 C--N 1.306 -1.29 0 O-C-N 121.562 -0.964 . . . . 0.0 109.828 179.512 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.501 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.6 -159.57 12.51 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.314 -1.914 . . . . 0.0 108.314 -179.311 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.501 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.6 Cg_exo -47.49 -178.13 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.672 0 CA-C-N 118.824 1.312 . . . . 0.0 110.574 179.215 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -94.44 -178.38 4.56 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.057 -1.027 . . . . 0.0 110.405 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.502 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.36 162.22 13.31 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.25 128.6 52.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.465 -1.021 . . . . 0.0 109.123 -179.549 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.578 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.09 118.53 15.07 Favored 'General case' 0 C--N 1.289 -2.059 0 O-C-N 121.7 -0.625 . . . . 0.0 109.555 179.75 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.899 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.8 pt -98.01 172.13 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.289 -0.882 . . . . 0.0 108.997 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.518 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -142.48 154.09 44.22 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.06 -1.025 . . . . 0.0 110.153 -179.744 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.899 ' CE2' HD12 ' A' ' 110' ' ' ILE . 97.8 m-85 . . . . . 0 N--CA 1.486 1.342 0 O-C-N 121.302 -0.873 . . . . 0.0 109.278 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.534 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.484 1.244 0 CA-C-O 122.254 1.026 . . . . 0.0 110.827 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.003 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.7 p -104.03 104.82 14.83 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-O 122.417 1.103 . . . . 0.0 110.397 -179.483 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.94 HG22 HG23 ' A' ' 21' ' ' VAL . 6.1 t -119.26 116.81 52.05 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.477 0 CA-C-O 121.582 0.706 . . . . 0.0 110.226 179.434 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.5 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -161.06 149.28 12.8 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.44 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.5 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.71 152.95 98.87 Favored 'Cis proline' 0 C--N 1.311 -1.428 0 C-N-CA 123.679 -1.384 . . . . 0.0 109.72 -0.507 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.647 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.8 m -91.46 -25.35 19.35 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.49 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 13.5 m -136.84 166.15 24.29 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.6 -0.688 . . . . 0.0 109.39 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.27 37.76 35.92 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 108.426 -1.87 . . . . 0.0 108.426 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.787 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.9 mt -92.47 -43.77 9.01 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 123.229 1.49 . . . . 0.0 110.676 -178.242 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.56 144.72 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.517 -1.674 . . . . 0.0 110.044 -179.57 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.601 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.7 p-10 -50.72 107.36 0.17 Allowed 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.535 0.683 . . . . 0.0 111.629 -178.606 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.9 14.23 9.52 Favored Glycine 0 N--CA 1.485 1.949 0 C-N-CA 119.421 -1.371 . . . . 0.0 112.927 177.357 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.787 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.8 t -105.09 -173.54 2.33 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 121.13 2.465 . . . . 0.0 109.899 179.265 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.769 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.9 t -128.41 138.97 53.17 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 CA-C-N 114.63 -1.168 . . . . 0.0 111.157 -178.639 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.551 HG11 HD11 ' A' ' 13' ' ' LEU . 27.9 m -116.15 154.42 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.653 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.554 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 15.0 tptp -107.21 108.68 20.22 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.168 -0.957 . . . . 0.0 109.297 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.94 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -106.14 123.54 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.003 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -118.24 168.22 10.8 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.717 -1.24 . . . . 0.0 109.504 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.614 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -137.13 136.71 8.47 Favored Glycine 0 C--O 1.207 -1.582 0 N-CA-C 107.493 -2.243 . . . . 0.0 107.493 179.515 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -141.27 125.82 17.8 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-N 119.668 1.734 . . . . 0.0 109.397 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.471 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 88.35 28.91 21.12 Favored Glycine 0 N--CA 1.488 2.146 0 C-N-CA 118.692 -1.718 . . . . 0.0 109.598 -179.715 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.525 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.8 mt -89.26 173.98 8.1 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.034 -1.274 . . . . 0.0 108.283 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.001 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.02 97.1 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.007 -1.058 . . . . 0.0 109.773 -179.871 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.684 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.34 76.86 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.39 -178.882 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.84 34.06 0.31 Allowed Glycine 0 N--CA 1.486 1.995 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.309 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.557 ' O ' HG23 ' A' ' 30' ' ' THR . 1.1 t -146.37 113.88 6.35 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.923 -1.339 . . . . 0.0 111.225 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.566 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -45.3 126.97 6.79 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.548 178.399 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.486 ' OH ' ' HB2' ' A' ' 27' ' ' GLN . 6.0 m-85 -121.32 149.41 42.97 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.467 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.45 160.06 14.65 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.697 -1.252 . . . . 0.0 108.064 178.955 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.682 HG13 ' O ' ' A' ' 34' ' ' VAL . 9.0 p -142.8 116.96 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.249 -0.907 . . . . 0.0 109.908 -177.69 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.521 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.82 -176.51 38.48 Favored Glycine 0 N--CA 1.494 2.524 0 C-N-CA 118.298 -1.906 . . . . 0.0 111.756 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.587 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -101.38 109.34 21.16 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.758 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -129.6 149.85 51.18 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.235 -0.915 . . . . 0.0 109.601 179.622 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.607 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.93 138.3 54.5 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.241 -0.912 . . . . 0.0 110.928 -178.928 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.09 26.96 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 178.049 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.7 m -105.64 15.01 7.16 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.024 -1.047 . . . . 0.0 110.512 -178.755 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.761 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.96 -175.38 0.09 Allowed 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.028 -1.045 . . . . 0.0 109.987 179.715 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -72.38 97.77 2.11 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 121.381 -0.825 . . . . 0.0 109.66 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.29 28.14 31.33 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.233 -0.984 . . . . 0.0 111.383 178.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.761 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.42 106.26 19.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 O-C-N 120.586 -1.537 . . . . 0.0 107.339 178.873 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -116.35 104.59 11.63 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.421 -1.424 . . . . 0.0 109.902 -177.771 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.095 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.5 22.25 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.776 -1.203 . . . . 0.0 107.987 178.704 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.5 161.74 14.57 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.919 -1.113 . . . . 0.0 110.189 -178.763 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.6 HD22 ' HB3' ' A' ' 50' ' ' ALA . 43.2 t30 -109.74 136.49 20.33 Favored Pre-proline 0 N--CA 1.502 2.167 0 O-C-N 121.383 -0.823 . . . . 0.0 109.807 -179.57 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.56 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.79 25.37 0.33 Allowed 'Trans proline' 0 C--N 1.318 -1.028 0 C-N-CA 122.354 2.036 . . . . 0.0 111.876 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.6 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -111.2 2.33 17.72 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.392 -1.442 . . . . 0.0 109.268 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.522 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.24 16.77 2.24 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.7 -1.222 . . . . 0.0 107.7 179.724 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -79.86 91.77 5.41 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.82 -0.752 . . . . 0.0 111.078 -178.57 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.619 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -111.31 -168.2 1.28 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.957 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.85 135.61 0.09 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.503 -1.373 . . . . 0.0 111.521 -179.307 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.762 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -152.41 158.32 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 178.015 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.566 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.77 145.54 26.26 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.659 -1.276 . . . . 0.0 109.672 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.001 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.24 108.01 2.56 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 122.394 1.092 . . . . 0.0 109.5 178.721 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 t0 -61.06 -138.73 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.923 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.684 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.57 -49.87 64.11 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.386 -0.821 . . . . 0.0 110.405 -178.747 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.471 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 16.9 t-20 -102.94 -36.99 8.01 Favored 'General case' 0 C--N 1.286 -2.194 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 178.449 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.978 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.31 68.36 0.61 Allowed Glycine 0 C--N 1.297 -1.601 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 178.19 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.614 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.8 m -102.96 129.12 49.59 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.496 -1.002 . . . . 0.0 109.316 179.284 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.762 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.56 108.54 7.63 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.533 -0.867 . . . . 0.0 109.43 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.497 ' HB2' ' NZ ' ' A' ' 20' ' ' LYS . 53.0 p -120.31 118.87 31.54 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.106 -0.996 . . . . 0.0 109.368 -179.82 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.58 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.91 143.01 28.2 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.395 -0.815 . . . . 0.0 109.802 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.476 ' HB3' ' HD3' ' A' ' 20' ' ' LYS . 2.9 p -102.17 135.04 44.45 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.492 -0.755 . . . . 0.0 109.059 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.836 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -135.2 169.93 16.7 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.301 -0.874 . . . . 0.0 109.597 -179.24 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.767 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -99.56 125.55 45.37 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.079 -1.013 . . . . 0.0 109.581 -179.68 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.587 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.7 m -135.11 143.33 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.036 -1.04 . . . . 0.0 109.519 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.601 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.0 ptt180 -146.63 -174.89 4.59 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 120.417 -1.427 . . . . 0.0 111.11 -179.758 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.607 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -54.12 -101.71 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 116.032 -0.531 . . . . 0.0 109.577 -179.382 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.508 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.85 139.97 49.64 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.749 -1.22 . . . . 0.0 108.138 179.659 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.607 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.28 136.34 7.51 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 118.772 -1.171 . . . . 0.0 109.879 -178.068 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.579 ' OE2' ' CD1' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -34.7 121.19 0.51 Allowed 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.543 0.687 . . . . 0.0 110.249 -178.462 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.095 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.52 50.57 2.08 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.107 -179.199 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CD1' ' OE2' ' A' ' 74' ' ' GLU . 2.8 m-85 -38.95 116.93 0.62 Allowed 'General case' 0 N--CA 1.509 2.484 0 O-C-N 121.041 -1.27 . . . . 0.0 109.882 179.639 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.74 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -87.34 126.16 34.68 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.95 -1.094 . . . . 0.0 109.389 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -64.53 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.789 -1.194 . . . . 0.0 110.106 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -159.77 19.7 0.17 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.033 -1.042 . . . . 0.0 109.696 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.26 -28.07 5.35 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.45 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 38.4 p -95.84 160.42 14.49 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.991 -1.299 . . . . 0.0 110.404 -179.458 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 6.0 ptt180 -105.95 139.58 40.28 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.784 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.74 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.4 t90 -84.5 -18.83 34.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.653 -1.279 . . . . 0.0 110.634 -178.53 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.85 175.53 19.03 Favored Glycine 0 N--CA 1.485 1.943 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 -179.581 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.74 105.37 1.24 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.058 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.674 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.5 t -76.7 105.61 5.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.147 -178.877 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.548 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -65.65 110.82 2.9 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.471 -0.768 . . . . 0.0 109.813 -179.481 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.607 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.24 -5.7 3.65 Favored 'General case' 0 N--CA 1.499 1.982 0 C-N-CA 118.255 -1.378 . . . . 0.0 109.838 179.482 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.0 p -86.57 -0.11 55.47 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.766 -1.209 . . . . 0.0 109.107 179.548 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.548 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.86 -50.57 2.82 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.398 -0.814 . . . . 0.0 108.968 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.8 -178.96 3.8 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.515 -0.741 . . . . 0.0 109.443 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.97 115.84 30.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.432 -0.793 . . . . 0.0 108.929 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.8 121.55 38.78 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.797 -1.189 . . . . 0.0 109.39 -179.369 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.81 147.1 26.46 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 122.33 1.062 . . . . 0.0 111.126 -179.362 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.701 ' HB ' HG11 ' A' ' 7' ' ' VAL . 48.3 t -105.34 111.93 36.75 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.997 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.831 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.511 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.75 -170.54 19.92 Favored Glycine 0 N--CA 1.488 2.102 0 C-N-CA 118.062 -2.018 . . . . 0.0 111.751 -177.877 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.81 177.47 4.69 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.212 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.444 ' OG ' ' O ' ' A' ' 97' ' ' LEU . 3.9 m . . . . . 0 C--N 1.295 -1.78 0 O-C-N 121.649 -0.657 . . . . 0.0 109.269 -179.805 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.569 0 N-CA-C 108.07 -2.012 . . . . 0.0 108.07 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -164.22 -177.32 4.9 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.612 -0.934 . . . . 0.0 110.042 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.68 -161.04 19.37 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 108.117 -1.993 . . . . 0.0 108.117 -179.494 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.1 Cg_exo -47.01 177.3 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.701 0 CA-C-N 118.968 1.384 . . . . 0.0 110.249 179.228 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.2 mm-40 -94.32 -179.4 4.91 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.073 -1.017 . . . . 0.0 110.583 -178.797 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.511 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.94 166.13 12.72 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.59 131.19 54.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.288 -1.124 . . . . 0.0 109.258 -179.282 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.03 121.02 20.42 Favored 'General case' 0 C--N 1.29 -2.014 0 O-C-N 121.548 -0.72 . . . . 0.0 109.587 179.676 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.92 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.97 171.3 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.226 -0.922 . . . . 0.0 109.095 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.49 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.93 156.81 46.97 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.264 -0.897 . . . . 0.0 109.929 -179.635 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.92 ' CE1' HD12 ' A' ' 110' ' ' ILE . 95.9 m-85 . . . . . 0 N--CA 1.486 1.369 0 O-C-N 121.318 -0.864 . . . . 0.0 109.378 -179.779 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.495 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 122.262 1.03 . . . . 0.0 110.602 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.957 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.8 t -110.42 108.63 18.73 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 123.088 1.423 . . . . 0.0 109.088 179.34 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.822 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -118.43 137.85 51.05 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.678 0 CA-C-N 114.244 -1.344 . . . . 0.0 109.907 -179.7 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.467 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -175.4 150.33 1.19 Allowed Pre-proline 0 N--CA 1.487 1.388 0 O-C-N 121.314 -0.866 . . . . 0.0 108.712 -179.651 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.467 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -77.64 150.52 90.51 Favored 'Cis proline' 0 C--N 1.311 -1.433 0 C-N-CA 123.57 -1.429 . . . . 0.0 109.535 -0.905 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.67 ' HA ' HG22 ' A' ' 110' ' ' ILE . 61.8 p -91.02 -24.52 20.05 Favored 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.55 -0.718 . . . . 0.0 109.27 179.828 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.521 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 17.1 m -133.44 160.36 37.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.265 -0.897 . . . . 0.0 109.978 -179.806 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.78 36.75 24.78 Favored Glycine 0 N--CA 1.494 2.523 0 N-CA-C 108.859 -1.696 . . . . 0.0 108.859 -179.856 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.755 ' HA ' HG21 ' A' ' 17' ' ' THR . 44.2 mt -93.83 -44.37 8.15 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-O 123.204 1.478 . . . . 0.0 110.353 -178.658 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.434 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.9 OUTLIER 63.81 145.35 0.02 OUTLIER 'General case' 0 C--N 1.262 -3.216 0 CA-C-N 113.62 -1.627 . . . . 0.0 109.798 -179.459 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.539 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.4 p-10 -51.61 105.33 0.1 Allowed 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.551 0.691 . . . . 0.0 110.844 -179.015 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 126.93 2.22 6.68 Favored Glycine 0 N--CA 1.485 1.949 0 C-N-CA 119.077 -1.535 . . . . 0.0 113.428 177.625 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.755 HG21 ' HA ' ' A' ' 13' ' ' LEU . 15.3 t -104.08 -171.82 2.0 Allowed 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 121.376 2.588 . . . . 0.0 110.102 179.909 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.772 HG13 ' C ' ' A' ' 67' ' ' LEU . 16.0 t -131.47 141.91 44.64 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.252 0 CA-C-N 114.604 -1.18 . . . . 0.0 110.47 -179.207 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.545 HG11 ' CD1' ' A' ' 13' ' ' LEU . 28.6 m -115.7 154.99 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.199 -0.938 . . . . 0.0 109.023 179.321 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 45.9 tptt -107.07 109.31 21.14 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 108.892 179.918 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.822 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.63 141.62 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.957 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -139.05 160.41 39.84 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 118.595 -1.242 . . . . 0.0 110.04 179.714 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.42 144.26 15.58 Favored Glycine 0 C--N 1.294 -1.793 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 179.695 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.28 125.37 12.88 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.872 -1.369 . . . . 0.0 108.956 179.037 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.48 26.84 26.6 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.289 -1.434 . . . . 0.0 109.867 -179.733 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.582 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -87.68 174.61 8.31 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 120.837 -1.39 . . . . 0.0 108.648 -179.879 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.018 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.58 99.79 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.99 -1.069 . . . . 0.0 109.744 -179.682 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.57 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 77.94 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.233 -179.149 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.58 34.17 0.32 Allowed Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.556 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 40.6 p -141.13 108.14 5.44 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.136 -1.214 . . . . 0.0 111.208 -179.539 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.9 110.75 0.46 Allowed 'General case' 0 N--CA 1.497 1.876 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.542 178.027 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.489 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.3 m-30 -106.75 156.02 19.09 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.122 -0.987 . . . . 0.0 108.902 179.821 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.503 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -99.13 164.16 12.27 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.822 -1.174 . . . . 0.0 107.917 178.822 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.666 HG13 ' O ' ' A' ' 34' ' ' VAL . 5.5 p -144.99 115.2 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.982 -1.074 . . . . 0.0 109.653 -178.247 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.02 -174.48 35.52 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.42 -1.847 . . . . 0.0 111.594 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.612 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.4 pt20 -102.39 109.25 20.85 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.862 0.839 . . . . 0.0 108.839 -179.772 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -131.75 149.51 52.45 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.099 -1.001 . . . . 0.0 110.093 -179.858 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.77 139.14 54.12 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.25 -0.906 . . . . 0.0 110.867 -179.076 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.876 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.36 114.96 26.79 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 178.21 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.5 m -105.4 15.15 7.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.991 -1.068 . . . . 0.0 110.591 -178.799 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.6 -176.19 0.09 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.961 -1.087 . . . . 0.0 110.101 179.747 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.783 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.89 97.86 1.49 Allowed 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.381 -0.825 . . . . 0.0 109.856 -179.742 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.37 27.58 35.84 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.212 -0.994 . . . . 0.0 111.394 178.948 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.23 106.44 20.34 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.528 -1.572 . . . . 0.0 107.185 178.904 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.876 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.0 tp -116.99 104.61 11.45 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.476 -1.39 . . . . 0.0 109.752 -177.763 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.86 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.82 109.53 22.27 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.746 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.497 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -106.74 168.75 8.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.967 -1.083 . . . . 0.0 110.379 -178.565 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.728 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 20.5 t-20 -114.57 132.34 22.92 Favored Pre-proline 0 N--CA 1.498 1.963 0 O-C-N 121.64 -0.662 . . . . 0.0 109.95 -179.242 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.8 Cg_endo -74.18 25.56 0.34 Allowed 'Trans proline' 0 CA--C 1.544 0.997 0 C-N-CA 122.28 1.986 . . . . 0.0 112.139 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.728 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -111.25 -1.06 16.23 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.279 -1.513 . . . . 0.0 109.443 179.709 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.572 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.06 21.32 2.62 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.561 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -80.92 90.6 5.93 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 120.053 -0.659 . . . . 0.0 110.873 -178.646 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -109.73 -167.23 1.18 Allowed 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.157 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.96 136.25 0.09 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.61 -1.307 . . . . 0.0 111.186 -179.273 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.938 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -153.53 158.26 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.354 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.78 141.8 31.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.906 -1.121 . . . . 0.0 109.945 -179.845 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.018 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.02 106.51 0.84 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 122.45 1.119 . . . . 0.0 109.359 178.296 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -58.3 -138.47 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.03 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.918 -179.863 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.57 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -54.22 -49.19 70.01 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.367 -0.833 . . . . 0.0 110.406 -178.756 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -102.37 -38.26 7.68 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 178.333 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.009 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 111.36 65.26 0.51 Allowed Glycine 0 C--N 1.297 -1.593 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 177.942 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.1 m -102.98 128.73 49.68 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 121.41 -1.053 . . . . 0.0 108.703 178.851 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.938 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -138.22 109.07 6.68 Favored 'General case' 0 C--N 1.296 -1.73 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.771 -179.235 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.5 m -123.52 120.63 33.44 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.309 -0.869 . . . . 0.0 109.725 -179.902 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.28 148.24 32.23 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.568 -0.708 . . . . 0.0 109.278 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.3 p -98.99 143.02 29.75 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.386 -0.821 . . . . 0.0 109.648 -179.839 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.782 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -146.03 157.52 43.87 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.357 -0.839 . . . . 0.0 109.368 -179.33 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.644 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 13.9 t -86.62 140.28 30.0 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.135 -0.978 . . . . 0.0 110.08 -179.792 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.554 HG12 ' OD2' ' A' ' 51' ' ' ASP . 16.9 m -145.94 137.89 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.226 -0.921 . . . . 0.0 110.148 -179.388 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.539 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 59.7 mtt180 -128.19 -162.75 1.21 Allowed 'General case' 0 N--CA 1.484 1.266 0 O-C-N 120.649 -1.282 . . . . 0.0 110.955 179.97 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.594 ' HG2' ' CD1' ' A' ' 112' ' ' PHE . 0.6 OUTLIER -86.66 -79.95 0.25 Allowed 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.35 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.538 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -69.78 133.02 46.97 Favored 'General case' 0 N--CA 1.486 1.34 0 N-CA-C 106.511 -1.662 . . . . 0.0 106.511 177.956 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.588 ' CE1' ' HB ' ' A' ' 86' ' ' VAL . 0.9 OUTLIER -154.42 155.32 34.75 Favored 'General case' 0 C--N 1.293 -1.875 0 C-N-CA 117.696 -1.602 . . . . 0.0 110.669 -177.938 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 47' ' ' CYS . 16.4 mt-10 -48.1 120.6 3.63 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 121.556 0.694 . . . . 0.0 109.549 -178.443 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.86 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -87.62 49.41 3.87 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -179.588 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.7 m-30 -40.59 112.38 0.28 Allowed 'General case' 0 N--CA 1.507 2.387 0 O-C-N 121.046 -1.267 . . . . 0.0 110.302 179.986 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.728 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.33 126.39 34.3 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.96 -1.088 . . . . 0.0 109.415 179.848 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -64.2 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.98 0 O-C-N 120.773 -1.204 . . . . 0.0 110.192 179.72 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 1.5 t0 -159.03 18.53 0.19 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.996 -1.065 . . . . 0.0 109.794 179.865 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.92 -25.85 6.47 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 179.763 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 47.6 p -95.0 159.37 15.05 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 120.966 -1.314 . . . . 0.0 110.604 -179.33 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.473 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -104.25 131.84 51.14 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.52 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.728 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -79.75 -19.96 47.47 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.854 -1.154 . . . . 0.0 110.169 -178.501 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.52 174.4 18.88 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 108.666 -1.773 . . . . 0.0 108.666 -179.406 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.13 112.88 2.55 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 179.09 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.647 HG21 ' CB ' ' A' ' 46' ' ' ALA . 38.1 t -84.56 103.22 11.54 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.019 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.561 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -63.88 109.26 1.7 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.54 -0.725 . . . . 0.0 110.248 -178.902 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.556 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 4.1 t -61.85 -4.19 1.44 Allowed 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.546 -1.262 . . . . 0.0 110.433 179.227 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -91.6 4.26 53.08 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.477 -1.389 . . . . 0.0 109.333 179.772 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.561 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -116.18 -50.19 2.67 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.178 -0.951 . . . . 0.0 109.144 179.936 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.89 178.73 4.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.512 -0.743 . . . . 0.0 109.396 179.871 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.85 113.37 26.24 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.324 -0.86 . . . . 0.0 108.817 179.884 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.498 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.51 119.59 35.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.017 -1.052 . . . . 0.0 109.471 -179.048 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.71 147.31 26.99 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-O 122.459 1.123 . . . . 0.0 111.43 -179.21 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.491 ' CG1' HG11 ' A' ' 7' ' ' VAL . 77.2 t -103.81 109.83 28.34 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.993 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 177.613 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.491 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.39 -170.01 17.1 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 118.246 -1.93 . . . . 0.0 111.608 -177.54 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.503 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.66 178.27 4.46 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.907 -0.761 . . . . 0.0 108.994 -178.972 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.489 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER . . . . . 0 C--N 1.295 -1.762 0 O-C-N 121.529 -0.732 . . . . 0.0 109.511 -179.653 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.714 0 N-CA-C 107.569 -2.212 . . . . 0.0 107.569 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -157.96 -178.37 7.26 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 121.569 -0.96 . . . . 0.0 109.721 179.183 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.44 -160.55 11.62 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 108.333 -1.907 . . . . 0.0 108.333 -179.344 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -47.01 178.31 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.864 1.332 . . . . 0.0 110.265 179.207 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -93.02 -174.4 3.56 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.123 -0.985 . . . . 0.0 110.341 -178.956 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.491 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.75 164.0 15.02 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.935 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.402 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.38 129.71 49.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.386 -1.067 . . . . 0.0 109.074 -179.629 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.92 121.44 19.08 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.658 -0.651 . . . . 0.0 109.804 179.836 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.67 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.5 pt -97.99 169.28 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 121.379 -0.826 . . . . 0.0 108.818 179.822 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.521 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.98 160.37 38.82 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.141 -0.974 . . . . 0.0 109.693 -179.945 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.594 ' CD1' ' HG2' ' A' ' 71' ' ' ARG . 39.2 m-85 . . . . . 0 N--CA 1.488 1.445 0 O-C-N 121.242 -0.911 . . . . 0.0 109.46 -179.759 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.484 1.255 0 CA-C-O 122.275 1.036 . . . . 1.0 110.561 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.974 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.9 p -107.0 104.93 14.73 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 122.608 1.194 . . . . 1.0 110.347 -179.587 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.975 HG22 HG23 ' A' ' 21' ' ' VAL . 15.2 t -119.37 115.35 47.43 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.468 0 CA-C-N 115.271 -0.877 . . . . 1.0 110.131 179.428 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -162.57 150.8 12.01 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.316 -0.994 . . . . 1.0 108.316 -179.378 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.1 Cg_endo -77.96 150.21 88.92 Favored 'Cis proline' 0 C--N 1.308 -1.554 0 C-N-CA 123.635 -1.402 . . . . 1.0 109.74 -0.679 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.655 ' HA ' HG22 ' A' ' 110' ' ' ILE . 69.2 p -89.75 -25.49 21.12 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 109.031 -0.729 . . . . 1.0 109.031 179.549 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.502 ' HB2' ' HB3' ' A' ' 111' ' ' SER . 18.7 p -132.55 164.64 26.18 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.498 -0.751 . . . . 1.0 109.375 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.68 38.27 37.61 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 108.259 -1.936 . . . . 1.0 108.259 -179.531 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.7 mt -92.49 -43.39 9.21 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 123.264 1.507 . . . . 1.0 110.619 -178.174 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.11 143.59 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.269 0 CA-C-N 113.461 -1.7 . . . . 1.0 109.815 -179.467 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.582 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 9.9 p-10 -50.48 105.13 0.09 Allowed 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.474 0.654 . . . . 1.0 111.634 -178.484 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.98 15.68 8.38 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 119.457 -1.354 . . . . 1.0 113.007 177.153 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.5 t -103.88 -171.22 1.9 Allowed 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 121.053 2.426 . . . . 1.0 109.802 179.125 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.856 HG22 HG22 ' A' ' 68' ' ' THR . 16.6 t -131.31 140.06 49.34 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.314 0 CA-C-N 114.822 -1.081 . . . . 1.0 111.362 -178.783 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.46 HG12 ' CD2' ' A' ' 13' ' ' LEU . 30.9 m -115.9 155.48 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 N-CA-C 108.66 -0.867 . . . . 1.0 108.66 178.861 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 5.5 tptm -108.16 108.96 20.23 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.137 -0.977 . . . . 1.0 109.529 -179.759 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.975 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -106.39 122.5 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.853 -0.795 . . . . 1.0 108.853 179.729 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.974 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -115.21 165.45 12.92 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.943 -1.098 . . . . 1.0 109.145 179.789 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.577 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.81 108.03 0.46 Allowed Glycine 0 N--CA 1.483 1.768 0 N-CA-C 108.711 -1.756 . . . . 1.0 108.711 179.602 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.501 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.75 142.43 46.93 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.704 -1.468 . . . . 1.0 110.212 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.96 29.08 35.49 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.062 -1.542 . . . . 1.0 109.773 179.787 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.54 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.9 OUTLIER -94.56 172.75 7.99 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.093 -1.239 . . . . 1.0 108.31 179.98 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.012 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.09 100.36 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.027 -1.046 . . . . 1.0 109.602 -179.799 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.85 76.44 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 115.397 -0.819 . . . . 1.0 109.955 -179.313 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 137.08 33.26 0.22 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.457 -1.457 . . . . 1.0 109.457 179.712 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.546 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 66.8 p -142.14 109.74 5.72 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.042 -1.269 . . . . 1.0 111.013 -179.803 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.586 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.95 109.93 0.28 Allowed 'General case' 0 N--CA 1.496 1.847 0 CA-C-N 115.7 -0.682 . . . . 1.0 109.858 178.407 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.515 ' CE1' ' HD2' ' A' ' 105' ' ' PRO . 21.1 m-85 -99.1 152.3 20.01 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.157 -0.965 . . . . 1.0 109.007 179.653 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.507 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -101.48 157.77 16.56 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 107.598 -1.26 . . . . 1.0 107.598 178.421 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.774 HG11 HG21 ' A' ' 65' ' ' THR . 9.9 p -142.29 113.97 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.063 -1.023 . . . . 1.0 110.07 -177.692 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.39 -175.49 36.73 Favored Glycine 0 N--CA 1.495 2.575 0 C-N-CA 118.371 -1.871 . . . . 1.0 111.875 -179.811 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.588 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -102.25 109.41 21.09 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 108.848 -0.797 . . . . 1.0 108.848 -179.663 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -131.07 148.55 52.75 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.129 -0.982 . . . . 1.0 110.034 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.486 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.89 139.79 53.62 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.314 -0.866 . . . . 1.0 110.716 -179.016 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.889 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.25 114.66 26.47 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 107.607 -1.257 . . . . 1.0 107.607 178.161 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 m -105.25 15.01 7.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.094 -1.004 . . . . 1.0 110.469 -178.752 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 175.04 -175.76 0.09 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.044 -1.035 . . . . 1.0 110.039 179.688 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 p -72.69 98.02 2.29 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.448 -0.782 . . . . 1.0 109.508 -179.805 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.39 27.64 32.45 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.232 -0.985 . . . . 1.0 111.291 179.046 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -117.6 106.27 19.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 O-C-N 120.6 -1.53 . . . . 1.0 107.325 178.889 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.889 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -116.1 104.8 11.92 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 120.496 -1.378 . . . . 1.0 109.567 -178.016 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.938 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.47 109.56 22.29 Favored 'General case' 0 N--CA 1.486 1.338 0 O-C-N 120.781 -1.199 . . . . 1.0 107.857 178.889 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -108.26 163.73 12.93 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.02 -1.05 . . . . 1.0 110.112 -178.656 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.49 ' HB2' ' HB2' ' A' ' 73' ' ' PHE . 36.2 t-20 -110.16 128.78 24.79 Favored Pre-proline 0 N--CA 1.502 2.141 0 O-C-N 121.437 -0.789 . . . . 1.0 109.67 -179.372 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.594 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.6 Cg_endo -69.44 17.72 0.18 Allowed 'Trans proline' 0 CA--C 1.546 1.075 0 C-N-CA 122.021 1.814 . . . . 1.0 112.108 179.444 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -104.6 3.48 31.77 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.389 -1.444 . . . . 1.0 108.528 179.065 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.45 15.91 2.75 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 107.228 -1.397 . . . . 1.0 107.228 179.487 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -81.53 92.39 6.5 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.834 -0.746 . . . . 1.0 111.099 -178.299 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -112.01 -170.94 1.75 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.133 -1.432 . . . . 1.0 107.133 177.879 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 179.18 136.91 0.1 Allowed 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.475 -1.391 . . . . 1.0 111.277 -179.197 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.9 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.56 157.14 4.78 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 107.107 -1.442 . . . . 1.0 107.107 178.194 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.586 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.83 143.23 28.66 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.696 -1.253 . . . . 1.0 109.965 -179.474 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.24 105.86 0.98 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 122.372 1.082 . . . . 1.0 109.392 178.704 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.54 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.5 t70 -60.21 -139.28 0.0 OUTLIER 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.719 -0.673 . . . . 1.0 110.934 -179.827 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.6 -50.48 60.1 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.297 -0.877 . . . . 1.0 110.625 -178.7 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 49.4 m-80 -102.95 -35.15 8.68 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.272 -1.751 . . . . 1.0 106.272 178.59 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 105.26 66.27 0.68 Allowed Glycine 0 C--N 1.297 -1.602 0 N-CA-C 110.522 -1.031 . . . . 1.0 110.522 178.305 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.577 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.4 m -104.09 125.54 50.51 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 108.514 -0.921 . . . . 1.0 108.514 178.833 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.9 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.46 109.54 8.8 Favored 'General case' 0 C--N 1.296 -1.748 0 C-N-CA 119.692 -0.803 . . . . 1.0 109.755 -179.266 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.471 ' OG ' ' HB2' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -116.24 122.72 45.8 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.278 -0.888 . . . . 1.0 109.019 179.709 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.774 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -148.44 140.14 23.7 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.496 -0.752 . . . . 1.0 109.884 -179.964 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.425 ' HB3' ' HD2' ' A' ' 20' ' ' LYS . 14.6 p -101.34 131.42 47.4 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.369 -0.832 . . . . 1.0 109.276 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.759 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -128.52 164.62 22.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.38 -0.825 . . . . 1.0 109.623 -179.452 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.856 HG22 HG22 ' A' ' 18' ' ' VAL . 1.7 p -97.36 124.59 41.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.952 -1.093 . . . . 1.0 109.249 -179.958 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.573 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 18.0 m -136.61 143.67 34.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.1 -1.0 . . . . 1.0 109.947 -179.106 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.582 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 6.8 ptt180 -141.86 -165.51 2.02 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.51 -1.369 . . . . 1.0 110.264 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.597 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 10.1 mtt180 -70.07 -76.85 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.425 -0.797 . . . . 1.0 109.017 -179.557 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.486 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -69.62 137.33 52.18 Favored 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.232 -1.542 . . . . 1.0 107.128 178.878 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.588 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -160.17 134.18 7.26 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 117.895 -1.522 . . . . 1.0 110.299 -178.179 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.527 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.2 mm-40 -30.57 120.97 0.2 Allowed 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.54 0.686 . . . . 1.0 110.888 -178.397 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.938 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.13 43.4 3.05 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.913 -0.875 . . . . 1.0 110.913 -179.526 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.594 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 2.1 m-85 -38.71 114.93 0.42 Allowed 'General case' 0 N--CA 1.511 2.603 0 O-C-N 121.182 -1.187 . . . . 1.0 110.123 179.959 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.713 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.4 tp -87.64 126.96 35.26 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.889 -1.132 . . . . 1.0 109.231 179.81 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -63.95 58.01 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.871 -1.143 . . . . 1.0 110.438 -179.9 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 9.3 t0 -161.97 19.96 0.1 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.924 -1.11 . . . . 1.0 109.862 179.802 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.06 -27.29 5.05 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.002 -1.239 . . . . 1.0 110.002 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.463 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 3.1 p -90.24 153.55 20.4 Favored 'General case' 0 N--CA 1.485 1.318 0 O-C-N 121.072 -1.252 . . . . 1.0 110.388 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.523 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 5.1 ptt180 -102.43 132.82 48.2 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.636 -0.875 . . . . 1.0 108.636 179.68 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.713 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.4 t90 -81.92 -21.41 37.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.659 -1.276 . . . . 1.0 110.294 -178.673 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.92 174.0 18.55 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.746 -1.742 . . . . 1.0 108.746 -179.644 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.67 110.71 1.81 Allowed 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.412 -1.329 . . . . 1.0 107.412 179.095 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.654 HG21 ' CB ' ' A' ' 46' ' ' ALA . 41.3 t -82.26 104.27 10.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 O-C-N 121.449 -0.782 . . . . 1.0 108.895 -178.962 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.66 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.1 OUTLIER -66.47 111.81 3.76 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.306 -0.871 . . . . 1.0 109.784 -179.277 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.555 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.0 t -62.77 -5.35 2.69 Favored 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 118.416 -1.314 . . . . 1.0 110.108 179.497 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -86.23 0.6 53.36 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.611 -1.306 . . . . 1.0 109.15 179.462 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.66 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -112.71 -48.89 2.97 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.268 -0.895 . . . . 1.0 109.055 179.907 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.46 -178.31 3.56 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.483 -0.761 . . . . 1.0 109.6 -179.93 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.55 114.78 29.23 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.294 -0.879 . . . . 1.0 108.97 179.923 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.56 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.12 123.32 40.85 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.956 -1.09 . . . . 1.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.586 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.96 146.16 28.75 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 122.359 1.076 . . . . 1.0 111.059 -179.775 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.538 ' HB ' HG11 ' A' ' 7' ' ' VAL . 97.8 t -103.07 109.63 27.39 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.069 0 N-CA-C 106.604 -1.628 . . . . 1.0 106.604 177.719 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.488 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.51 -170.58 17.19 Favored Glycine 0 N--CA 1.485 1.962 0 C-N-CA 118.091 -2.004 . . . . 1.0 111.944 -177.47 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.491 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -118.16 -178.65 3.56 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 108.88 -0.785 . . . . 1.0 108.88 -178.77 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.507 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.711 0 O-C-N 121.355 -0.841 . . . . 1.0 109.254 -179.45 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.666 0 N-CA-C 107.522 -2.231 . . . . 1.0 107.522 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.46 -178.24 6.99 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.615 -0.932 . . . . 1.0 109.727 179.12 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -170.27 -162.61 22.87 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 108.248 -1.941 . . . . 1.0 108.248 -179.426 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.515 ' HD2' ' CE1' ' A' ' 32' ' ' TYR . 7.5 Cg_exo -45.69 165.81 0.06 OUTLIER 'Trans proline' 0 C--O 1.215 -0.637 0 CA-C-N 118.912 1.356 . . . . 1.0 109.656 179.392 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.73 -176.45 4.97 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.047 -1.033 . . . . 1.0 110.528 -178.473 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.488 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.57 175.26 15.64 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.723 -1.351 . . . . 1.0 109.723 -179.837 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -112.05 132.51 60.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.383 -1.069 . . . . 1.0 109.121 -179.14 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.586 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -69.88 124.58 24.39 Favored 'General case' 0 C--N 1.291 -1.95 0 O-C-N 121.556 -0.715 . . . . 1.0 109.479 179.526 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.884 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.71 171.57 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.19 -0.944 . . . . 1.0 109.043 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.502 ' HB3' ' HB2' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.53 161.21 37.01 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.237 -0.914 . . . . 1.0 109.707 -179.773 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.884 ' CE2' HD12 ' A' ' 110' ' ' ILE . 90.0 m-85 . . . . . 0 N--CA 1.484 1.268 0 O-C-N 121.12 -0.987 . . . . 1.0 109.532 -179.702 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.582 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 122.281 1.038 . . . . 0.0 111.179 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.021 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -101.22 104.45 15.51 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 122.404 1.097 . . . . 0.0 109.907 179.859 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 1.07 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -119.37 119.3 60.21 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.393 179.588 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.481 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.8 149.92 4.41 Favored Pre-proline 0 N--CA 1.486 1.335 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -179.602 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.481 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.3 Cg_endo -78.55 149.96 86.69 Favored 'Cis proline' 0 C--N 1.309 -1.504 0 C-N-CA 123.631 -1.404 . . . . 0.0 109.439 -0.677 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.669 ' HA ' HG22 ' A' ' 110' ' ' ILE . 72.6 p -92.09 -23.43 19.46 Favored 'General case' 0 C--N 1.292 -1.911 0 O-C-N 121.632 -0.668 . . . . 0.0 109.245 179.677 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.548 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 12.1 p -131.81 161.19 33.53 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.376 -0.828 . . . . 0.0 109.646 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.2 37.78 31.33 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 108.386 -1.885 . . . . 0.0 108.386 -179.556 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.2 mt -91.85 -43.39 9.53 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 123.223 1.487 . . . . 0.0 110.53 -178.223 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.478 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.89 143.93 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.25 0 CA-C-N 113.457 -1.701 . . . . 0.0 110.017 -179.508 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.586 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 11.5 p-10 -49.83 105.69 0.1 Allowed 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 121.431 0.634 . . . . 0.0 111.737 -178.53 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.5 15.37 8.89 Favored Glycine 0 N--CA 1.485 1.94 0 C-N-CA 119.439 -1.363 . . . . 0.0 113.077 177.068 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -105.04 -173.2 2.25 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 121.123 2.461 . . . . 0.0 109.943 179.191 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.782 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.6 t -128.86 139.7 51.21 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.318 0 CA-C-N 114.635 -1.166 . . . . 0.0 111.508 -178.578 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.584 HG11 HD11 ' A' ' 13' ' ' LEU . 33.8 m -117.82 155.96 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.641 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.559 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tppp? -107.69 109.92 21.64 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.017 -1.052 . . . . 0.0 109.816 -179.681 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 1.07 HG23 HG22 ' A' ' 7' ' ' VAL . 7.3 p -105.87 123.23 60.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.086 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.021 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -119.7 166.61 12.99 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.506 -1.371 . . . . 0.0 109.397 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.589 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.42 143.31 14.97 Favored Glycine 0 C--N 1.296 -1.682 0 N-CA-C 107.802 -2.119 . . . . 0.0 107.802 179.806 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -148.08 122.54 9.73 Favored 'General case' 0 C--N 1.293 -1.858 0 O-C-N 120.828 -1.395 . . . . 0.0 108.565 179.067 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.52 27.38 20.22 Favored Glycine 0 N--CA 1.486 2.017 0 C-N-CA 119.093 -1.527 . . . . 0.0 109.707 -179.552 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.558 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.2 mt -87.23 176.51 7.53 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 120.894 -1.356 . . . . 0.0 108.373 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.42 96.76 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.001 -1.062 . . . . 0.0 109.665 -179.784 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.719 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.2 77.68 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.528 -179.0 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 129.33 36.28 0.43 Allowed Glycine 0 N--CA 1.487 2.035 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 179.409 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.648 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -148.57 114.54 5.76 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 120.913 -1.345 . . . . 0.0 111.199 -179.891 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -46.34 122.52 4.09 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 115.437 -0.802 . . . . 0.0 110.354 178.66 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.648 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 1.9 m-30 -116.97 154.43 30.9 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.084 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.503 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -100.52 167.68 10.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.499 -1.375 . . . . 0.0 108.604 179.449 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.615 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.3 p -147.78 122.46 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.165 -0.96 . . . . 0.0 109.554 -178.089 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -177.08 -178.21 46.63 Favored Glycine 0 N--CA 1.495 2.606 0 C-N-CA 118.329 -1.891 . . . . 0.0 111.71 179.977 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.67 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.4 108.52 20.55 Favored 'General case' 0 N--CA 1.477 0.901 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.836 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -129.59 148.63 51.51 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.179 -0.951 . . . . 0.0 109.803 179.691 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.542 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.34 139.52 53.95 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.307 -0.871 . . . . 0.0 110.675 -179.023 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.881 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.09 114.9 26.76 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 178.147 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.47 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 18.2 m -105.77 14.98 7.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.044 -1.035 . . . . 0.0 110.58 -178.652 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.719 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 175.1 -174.94 0.09 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.986 -1.071 . . . . 0.0 109.995 179.579 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.786 ' O ' HG23 ' A' ' 42' ' ' THR . 14.9 t -72.62 98.01 2.26 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.43 -0.794 . . . . 0.0 109.757 -179.779 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.78 28.01 33.19 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 120.161 -1.019 . . . . 0.0 111.436 179.037 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.719 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -117.16 106.39 20.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.542 -1.564 . . . . 0.0 107.149 178.798 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.881 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.2 tp -116.76 104.94 11.85 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.496 -1.378 . . . . 0.0 109.681 -177.649 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.013 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.97 109.75 22.45 Favored 'General case' 0 N--CA 1.484 1.26 0 O-C-N 120.934 -1.104 . . . . 0.0 108.387 179.237 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.0 t -106.16 163.88 12.44 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.995 -1.066 . . . . 0.0 110.268 -179.037 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.518 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 17.4 t30 -111.36 137.79 21.17 Favored Pre-proline 0 N--CA 1.502 2.129 0 O-C-N 121.496 -0.752 . . . . 0.0 109.598 -179.387 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.579 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.2 24.58 0.31 Allowed 'Trans proline' 0 C--N 1.318 -1.04 0 C-N-CA 122.504 2.136 . . . . 0.0 112.41 -179.379 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.415 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -103.34 -8.3 20.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.164 -1.585 . . . . 0.0 109.184 179.465 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.703 ' OD2' HG13 ' A' ' 69' ' ' VAL . 2.0 m-20 -135.69 8.85 3.33 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.54 86.46 0.08 Allowed 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.277 -0.889 . . . . 0.0 110.441 -178.797 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.615 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -115.61 -169.86 1.66 Allowed 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 178.785 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.465 ' OG ' ' HA ' ' A' ' 33' ' ' ASP . 0.6 OUTLIER 178.65 133.9 0.08 Allowed 'General case' 0 C--N 1.303 -1.424 0 O-C-N 120.725 -1.235 . . . . 0.0 111.206 -179.483 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.725 HG11 ' HB1' ' A' ' 63' ' ' ALA . 2.0 p -143.59 159.72 16.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.981 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.89 145.33 26.54 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.649 -1.282 . . . . 0.0 109.75 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.002 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.56 109.75 3.38 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 122.449 1.118 . . . . 0.0 109.465 178.638 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.557 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.5 p-10 -62.11 -139.17 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.643 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.719 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.33 -51.88 50.43 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.268 -0.895 . . . . 0.0 110.445 -178.94 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.5 -33.72 9.4 Favored 'General case' 0 C--N 1.288 -2.103 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.555 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.999 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.18 65.65 0.59 Allowed Glycine 0 C--N 1.3 -1.444 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.162 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 53.5 p -99.91 131.78 45.67 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 121.354 -1.086 . . . . 0.0 109.363 179.15 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.725 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -137.19 108.78 6.96 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.429 -0.908 . . . . 0.0 109.535 -179.853 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.417 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 92.0 p -117.62 118.52 32.34 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.063 -1.023 . . . . 0.0 109.588 -179.818 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.568 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -146.67 140.89 26.31 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.473 -0.767 . . . . 0.0 109.835 -179.947 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.476 ' HB3' ' HE3' ' A' ' 20' ' ' LYS . 24.2 p -98.82 136.37 38.94 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.322 -0.861 . . . . 0.0 108.792 179.54 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.971 HD11 HG12 ' A' ' 21' ' ' VAL . 0.2 OUTLIER -132.73 168.07 18.98 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.266 -0.896 . . . . 0.0 110.322 -178.489 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.647 HG22 HG22 ' A' ' 18' ' ' VAL . 1.1 p -104.46 124.39 49.17 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.876 . . . . 0.0 108.688 179.464 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.703 HG13 ' OD2' ' A' ' 51' ' ' ASP . 17.4 m -136.93 142.98 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 120.873 -1.142 . . . . 0.0 110.237 -178.761 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.586 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.4 ptt180 -144.9 -169.71 3.24 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 120.575 -1.328 . . . . 0.0 110.771 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.601 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -58.35 -99.8 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -179.144 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -58.33 143.37 45.13 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.355 -1.466 . . . . 0.0 108.505 179.692 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.589 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.17 138.63 6.7 Favored 'General case' 0 C--N 1.294 -1.813 0 C-N-CA 118.848 -1.141 . . . . 0.0 109.614 -178.185 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.556 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 8.6 mm-40 -34.77 121.97 0.53 Allowed 'General case' 0 N--CA 1.49 1.53 0 CA-C-O 121.484 0.659 . . . . 0.0 110.583 -178.254 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.013 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.64 46.08 2.75 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 120.52 -0.848 . . . . 0.0 110.995 -179.298 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.7 m-85 -39.07 111.48 0.18 Allowed 'General case' 0 N--CA 1.507 2.403 0 O-C-N 121.23 -1.159 . . . . 0.0 109.887 179.589 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.672 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.5 tp -84.88 127.37 34.12 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.9 -1.125 . . . . 0.0 109.281 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.415 ' CD2' ' O ' ' A' ' 78' ' ' PHE . 57.6 t80 -63.18 58.18 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.92 -1.113 . . . . 0.0 110.527 -179.881 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t0 -163.33 20.21 0.08 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.906 -1.121 . . . . 0.0 109.997 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.77 -27.16 4.95 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.091 -1.203 . . . . 0.0 110.091 179.979 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.505 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -90.3 150.57 21.86 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 121.119 -1.224 . . . . 0.0 110.247 -179.469 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.486 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -101.19 133.06 46.31 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 179.434 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.672 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.5 t90 -81.76 -16.09 52.18 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.794 -1.191 . . . . 0.0 110.56 -178.525 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 108.74 174.36 21.52 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.856 -1.697 . . . . 0.0 108.856 -179.719 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.79 103.9 0.62 Allowed 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.613 -1.255 . . . . 0.0 107.613 179.116 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.611 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.5 t -74.52 106.53 4.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.476 -0.765 . . . . 0.0 109.224 -178.814 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.58 110.93 3.37 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.386 -0.821 . . . . 0.0 109.813 -179.454 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.601 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.72 -5.49 4.23 Favored 'General case' 0 N--CA 1.499 2.024 0 C-N-CA 118.329 -1.348 . . . . 0.0 109.908 179.463 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.7 p -85.61 -0.6 55.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.705 -1.247 . . . . 0.0 109.144 179.568 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -112.92 -49.17 2.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.383 -0.823 . . . . 0.0 109.002 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.45 -178.2 3.58 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.511 -0.743 . . . . 0.0 109.455 179.963 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.14 115.64 30.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.446 -0.784 . . . . 0.0 108.964 179.924 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.564 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.86 123.54 40.6 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.935 -1.103 . . . . 0.0 109.665 -179.176 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.618 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.05 147.66 26.68 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-O 122.418 1.104 . . . . 0.0 111.014 -179.522 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.536 ' HB ' HG11 ' A' ' 7' ' ' VAL . 46.4 t -106.28 113.22 42.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.993 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.017 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.508 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -155.18 -169.83 20.11 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 117.989 -2.053 . . . . 0.0 111.834 -177.943 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.494 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -110.52 -177.74 3.31 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 -179.227 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.509 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 12.1 p . . . . . 0 C--N 1.297 -1.715 0 O-C-N 121.367 -0.833 . . . . 0.0 109.083 -179.072 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.712 0 N-CA-C 107.878 -2.089 . . . . 0.0 107.878 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.64 -177.92 6.88 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 121.474 -1.015 . . . . 0.0 109.81 179.238 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.4 -161.2 13.01 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.589 -1.804 . . . . 0.0 108.589 -179.256 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.544 ' HD3' ' CE2' ' A' ' 32' ' ' TYR . 4.7 Cg_exo -47.41 -178.97 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.709 1.254 . . . . 0.0 110.577 179.278 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -93.75 -177.6 4.42 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.072 -1.017 . . . . 0.0 110.425 -178.93 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.508 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.79 166.39 14.55 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.68 130.41 52.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.342 -1.093 . . . . 0.0 109.165 -179.405 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.618 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.25 122.29 22.6 Favored 'General case' 0 C--N 1.289 -2.024 0 O-C-N 121.623 -0.673 . . . . 0.0 109.48 179.617 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.833 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.57 168.74 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 O-C-N 121.193 -0.942 . . . . 0.0 109.188 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.548 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.3 m -136.85 157.52 46.56 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.301 -0.875 . . . . 0.0 109.541 -179.784 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.833 ' CE2' HD12 ' A' ' 110' ' ' ILE . 70.8 m-85 . . . . . 0 C--N 1.306 -1.323 0 O-C-N 121.164 -0.96 . . . . 0.0 109.608 -179.614 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.283 0 CA-C-O 122.415 1.102 . . . . 0.0 110.423 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.863 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -114.72 109.07 17.64 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 123.075 1.417 . . . . 0.0 109.663 179.937 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.782 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -117.28 136.08 55.6 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 CA-C-N 114.297 -1.32 . . . . 0.0 109.681 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.489 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -173.08 150.8 2.0 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.273 -0.892 . . . . 0.0 108.734 -179.559 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.489 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.21 150.44 88.57 Favored 'Cis proline' 0 C--N 1.312 -1.387 0 C-N-CA 123.563 -1.432 . . . . 0.0 109.507 -0.761 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.673 ' HA ' HG22 ' A' ' 110' ' ' ILE . 38.3 p -90.01 -25.59 20.77 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 121.586 -0.696 . . . . 0.0 109.14 179.502 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.521 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 16.1 m -133.08 162.11 32.61 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.406 -0.809 . . . . 0.0 109.565 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.86 37.13 30.52 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 -179.684 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.749 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.5 mt -92.36 -42.34 9.85 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 123.218 1.485 . . . . 0.0 110.43 -178.482 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.94 143.27 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.323 0 CA-C-N 113.379 -1.737 . . . . 0.0 109.825 -179.542 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.592 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 18.3 p-10 -50.39 105.27 0.09 Allowed 'General case' 0 C--N 1.3 -1.586 0 CA-C-O 121.452 0.644 . . . . 0.0 111.484 -178.525 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.92 13.57 8.46 Favored Glycine 0 N--CA 1.486 2.002 0 C-N-CA 119.306 -1.426 . . . . 0.0 113.165 177.285 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.749 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.56 -171.71 1.97 Allowed 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 121.28 2.54 . . . . 0.0 109.78 179.18 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.841 HG22 HG22 ' A' ' 68' ' ' THR . 18.2 t -129.26 139.01 52.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.956 -1.02 . . . . 0.0 111.224 -178.821 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.56 HG23 ' CD1' ' A' ' 67' ' ' LEU . 31.5 m -114.14 155.39 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 178.937 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.82 109.57 20.72 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.115 -0.991 . . . . 0.0 109.266 179.976 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.782 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -102.36 140.74 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.594 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.863 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.32 161.67 35.64 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 118.773 -1.171 . . . . 0.0 110.182 179.81 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.611 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.32 141.74 13.02 Favored Glycine 0 C--N 1.298 -1.572 0 N-CA-C 108.169 -1.973 . . . . 0.0 108.169 179.721 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -143.24 124.69 14.76 Favored 'General case' 0 N--CA 1.494 1.754 0 CA-C-N 119.226 1.513 . . . . 0.0 109.363 179.255 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.05 28.98 19.16 Favored Glycine 0 N--CA 1.489 2.212 0 C-N-CA 118.965 -1.588 . . . . 0.0 109.647 -179.733 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.539 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.5 mt -89.4 175.24 7.4 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.9 -1.353 . . . . 0.0 108.366 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.022 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.61 99.95 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.977 -1.077 . . . . 0.0 109.806 -179.752 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.537 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.32 77.52 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.918 -179.347 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.588 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.97 33.97 0.24 Allowed Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 179.674 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.556 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 23.1 p -139.59 105.66 5.22 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.141 -1.211 . . . . 0.0 111.283 -179.404 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.592 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.42 109.77 0.34 Allowed 'General case' 0 N--CA 1.497 1.916 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 177.853 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.512 ' HA ' ' O ' ' A' ' 98' ' ' SER . 6.8 m-30 -104.41 158.99 16.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.139 -0.975 . . . . 0.0 109.131 -179.977 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.516 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -101.63 157.75 16.59 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 178.754 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.017 HG11 HG23 ' A' ' 65' ' ' THR . 1.6 t -136.84 109.77 8.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.129 -0.982 . . . . 0.0 109.635 -177.573 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.38 -174.05 35.37 Favored Glycine 0 N--CA 1.497 2.727 0 C-N-CA 117.713 -2.184 . . . . 0.0 112.638 -179.928 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.602 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -102.09 109.11 20.74 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-O 121.756 0.789 . . . . 0.0 109.062 -179.495 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.42 148.8 52.27 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.21 -0.931 . . . . 0.0 109.6 179.33 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.503 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.34 138.72 54.55 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.32 -0.862 . . . . 0.0 110.774 -178.995 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.885 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.43 115.07 26.92 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.154 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.8 m -104.88 14.89 6.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 120.988 -1.07 . . . . 0.0 110.558 -178.89 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.764 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.38 -175.12 0.08 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.959 -1.088 . . . . 0.0 110.006 179.781 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.44 98.12 2.2 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.411 -0.806 . . . . 0.0 109.687 -179.78 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.99 28.11 32.22 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 120.217 -0.992 . . . . 0.0 111.355 179.014 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.764 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.54 106.25 19.61 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 O-C-N 120.603 -1.528 . . . . 0.0 107.071 178.804 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.885 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.8 tp -118.03 104.5 10.93 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.458 -1.401 . . . . 0.0 109.789 -177.719 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.09 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.21 109.37 22.14 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 120.918 -1.114 . . . . 0.0 108.051 178.84 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.502 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.1 163.47 12.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.906 -1.121 . . . . 0.0 110.281 -178.778 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.742 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 47.4 t30 -106.4 132.33 20.99 Favored Pre-proline 0 N--CA 1.504 2.23 0 O-C-N 121.394 -0.816 . . . . 0.0 109.627 -179.424 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -72.21 19.36 0.3 Allowed 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 122.296 1.997 . . . . 0.0 112.281 -179.596 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.742 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -111.2 4.13 18.99 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.38 -1.45 . . . . 0.0 108.707 179.114 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.657 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.08 20.76 3.01 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 179.303 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -81.37 85.85 6.37 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.538 -178.715 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.505 ' HB3' ' HB ' ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.52 -171.03 2.04 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.843 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.66 134.58 0.08 Allowed 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.676 -1.265 . . . . 0.0 111.23 -179.292 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.873 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -158.12 153.6 5.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 178.359 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.592 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.28 139.95 33.29 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.875 -1.141 . . . . 0.0 109.544 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.022 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -62.35 106.32 0.73 Allowed 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.391 1.091 . . . . 0.0 109.501 178.637 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.555 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.9 t70 -61.37 -139.21 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.045 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.77 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.537 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.11 -51.2 59.32 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.401 -0.812 . . . . 0.0 110.724 -178.803 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -101.04 -34.53 9.7 Favored 'General case' 0 C--N 1.286 -2.153 0 N-CA-C 106.282 -1.747 . . . . 0.0 106.282 178.493 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 104.88 65.76 0.68 Allowed Glycine 0 C--N 1.297 -1.637 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 178.109 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.611 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.6 m -98.86 130.42 45.27 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.594 -0.945 . . . . 0.0 108.6 178.739 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.873 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.79 108.63 6.68 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.594 -179.329 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.8 m -124.23 120.45 32.28 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.334 -0.854 . . . . 0.0 109.47 179.927 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 65' ' ' THR . . . . . 1.017 HG23 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.16 142.83 29.95 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.558 -0.714 . . . . 0.0 109.353 179.908 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 9.5 p -99.2 136.22 39.47 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.316 -0.865 . . . . 0.0 109.434 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.758 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -136.31 165.19 26.34 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.461 -0.774 . . . . 0.0 109.55 -179.343 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.841 HG22 HG22 ' A' ' 18' ' ' VAL . 2.2 p -96.78 125.45 41.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.073 -1.017 . . . . 0.0 109.112 179.926 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.602 HG12 ' HB3' ' A' ' 36' ' ' GLN . 17.7 m -136.53 142.7 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 120.934 -1.104 . . . . 0.0 110.09 -178.886 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.592 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 5.2 ptt180 -147.49 -173.08 4.18 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.562 -1.337 . . . . 0.0 110.884 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.599 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -54.11 -101.22 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 -179.421 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.514 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.19 141.44 46.41 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.82 -1.175 . . . . 0.0 108.128 179.479 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.8 135.44 5.58 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 118.68 -1.208 . . . . 0.0 109.665 -178.01 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.561 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 18.7 mm-40 -34.73 122.93 0.54 Allowed 'General case' 0 N--CA 1.491 1.603 0 CA-C-O 121.502 0.668 . . . . 0.0 110.088 -178.466 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.09 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.98 52.81 1.66 Allowed Glycine 0 N--CA 1.492 2.385 0 C-N-CA 120.397 -0.906 . . . . 0.0 111.108 -178.937 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.587 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-30 -39.7 113.38 0.33 Allowed 'General case' 0 N--CA 1.506 2.332 0 O-C-N 121.065 -1.256 . . . . 0.0 109.972 179.393 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.625 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -83.45 126.12 32.43 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.947 -1.096 . . . . 0.0 109.217 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 39.5 t80 -63.7 58.66 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.918 -1.114 . . . . 0.0 110.169 179.806 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -160.92 19.91 0.13 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.996 -1.065 . . . . 0.0 109.696 179.92 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.13 -28.07 5.28 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.882 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.463 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.32 159.61 15.04 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.007 -1.29 . . . . 0.0 110.28 -179.416 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.483 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.73 135.96 47.37 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.757 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.625 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -80.77 -18.87 46.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.867 -1.145 . . . . 0.0 110.545 -178.504 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.46 177.47 19.84 Favored Glycine 0 N--CA 1.484 1.88 0 N-CA-C 108.671 -1.771 . . . . 0.0 108.671 -179.428 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.36 105.58 1.18 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.2 -1.176 . . . . 0.0 107.859 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.665 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.0 t -77.53 105.7 6.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.346 -0.846 . . . . 0.0 109.124 -179.069 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.543 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.5 m-20 -65.6 111.44 3.15 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.406 -0.809 . . . . 0.0 109.747 -179.372 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.599 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.13 -5.23 4.46 Favored 'General case' 0 N--CA 1.5 2.031 0 C-N-CA 118.113 -1.435 . . . . 0.0 109.876 179.386 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -86.54 -0.06 55.33 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.799 -1.188 . . . . 0.0 109.159 179.587 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.543 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -113.36 -50.01 2.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.334 -0.854 . . . . 0.0 108.969 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.5 -179.05 3.83 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.487 -0.758 . . . . 0.0 109.42 179.925 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.88 115.27 30.01 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.328 -0.857 . . . . 0.0 108.999 179.9 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -97.03 122.24 39.81 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.762 -1.211 . . . . 0.0 109.428 -179.431 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -101.91 146.89 27.21 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 122.41 1.1 . . . . 0.0 111.107 -179.372 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.552 ' CG1' HG11 ' A' ' 7' ' ' VAL . 61.1 t -104.43 110.25 29.93 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 177.911 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.511 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.44 -169.86 17.58 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 118.31 -1.9 . . . . 0.0 111.466 -177.786 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.639 HD23 HG22 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -113.22 179.98 3.81 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -179.333 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.512 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.6 OUTLIER . . . . . 0 C--N 1.296 -1.736 0 O-C-N 121.364 -0.835 . . . . 0.0 109.406 -179.596 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.806 0 N-CA-C 107.62 -2.192 . . . . 0.0 107.62 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.49 -178.16 6.93 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.637 -0.919 . . . . 0.0 109.622 179.194 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.85 -162.43 14.74 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 108.434 -1.866 . . . . 0.0 108.434 -179.34 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.48 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.9 Cg_exo -46.32 176.31 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.692 0 CA-C-N 118.837 1.318 . . . . 0.0 110.206 179.289 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -91.62 -176.15 4.4 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.033 -1.042 . . . . 0.0 110.573 -178.71 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.511 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.63 168.88 15.02 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.61 130.39 57.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.354 -1.086 . . . . 0.0 109.192 -179.208 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.05 122.9 20.91 Favored 'General case' 0 C--N 1.29 -1.985 0 O-C-N 121.609 -0.682 . . . . 0.0 109.505 179.543 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.76 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.69 169.02 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.201 -0.937 . . . . 0.0 109.222 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.521 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -136.39 155.31 50.21 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 109.602 -179.942 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.76 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 21.2 m-85 . . . . . 0 N--CA 1.486 1.333 0 O-C-N 121.198 -0.939 . . . . 0.0 109.482 -179.664 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.668 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 122.303 1.049 . . . . 0.0 111.134 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.01 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -100.92 104.59 15.79 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 122.478 1.132 . . . . 0.0 109.76 -179.892 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.975 HG22 HG23 ' A' ' 21' ' ' VAL . 5.4 t -119.4 122.92 70.2 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.401 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.574 179.823 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.481 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -169.52 150.04 3.91 Favored Pre-proline 0 N--CA 1.487 1.413 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 -179.529 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.481 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.4 Cg_endo -76.74 150.71 93.25 Favored 'Cis proline' 0 C--N 1.309 -1.533 0 C-N-CA 123.613 -1.411 . . . . 0.0 109.579 -0.339 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.679 ' HA ' HG22 ' A' ' 110' ' ' ILE . 89.2 p -92.49 -22.81 19.37 Favored 'General case' 0 C--N 1.292 -1.929 0 O-C-N 121.693 -0.629 . . . . 0.0 109.352 179.799 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.488 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.3 m -132.37 163.97 27.51 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.398 -0.814 . . . . 0.0 109.689 -179.822 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.05 38.88 39.14 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 -179.504 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.857 ' CA ' HG21 ' A' ' 17' ' ' THR . 27.7 mt -92.02 -45.21 8.44 Favored 'General case' 0 C--N 1.297 -1.698 0 CA-C-O 123.12 1.438 . . . . 0.0 110.772 -178.09 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.13 146.42 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.349 0 CA-C-N 113.799 -1.546 . . . . 0.0 110.077 -179.615 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.585 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.6 p-10 -50.76 108.32 0.23 Allowed 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 121.542 0.687 . . . . 0.0 111.984 -178.53 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.74 16.54 9.9 Favored Glycine 0 N--CA 1.485 1.907 0 C-N-CA 119.592 -1.289 . . . . 0.0 112.768 177.07 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.857 HG21 ' CA ' ' A' ' 13' ' ' LEU . 8.8 t -103.45 -174.79 2.63 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 120.965 2.382 . . . . 0.0 109.98 179.426 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.772 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.0 t -129.89 138.9 52.91 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 CA-C-N 114.365 -1.288 . . . . 0.0 111.06 -178.799 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.635 HG22 HG22 ' A' ' 69' ' ' VAL . 4.1 m -118.53 154.99 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.669 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 10.2 tttt -105.95 108.99 20.79 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.175 -0.953 . . . . 0.0 109.403 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.975 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.04 123.38 62.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 179.611 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.51 167.17 11.54 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 120.69 -1.256 . . . . 0.0 109.222 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.604 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.76 140.71 12.03 Favored Glycine 0 C--N 1.295 -1.717 0 N-CA-C 107.49 -2.244 . . . . 0.0 107.49 179.718 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.31 124.1 11.92 Favored 'General case' 0 C--N 1.293 -1.889 0 O-C-N 120.748 -1.442 . . . . 0.0 108.87 179.35 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.36 25.97 26.94 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.226 -1.464 . . . . 0.0 109.913 -179.641 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.539 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.1 mt -85.6 175.44 8.77 Favored 'General case' 0 C--N 1.306 -1.321 0 O-C-N 120.891 -1.358 . . . . 0.0 108.263 -179.989 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.39 96.71 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.928 -1.108 . . . . 0.0 109.659 -179.72 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.706 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.53 76.77 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.758 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.536 -178.996 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.77 33.7 0.33 Allowed Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.253 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.587 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.3 t -149.14 116.07 6.0 Favored 'General case' 0 C--N 1.307 -1.268 0 O-C-N 120.929 -1.336 . . . . 0.0 111.138 179.919 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.565 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.83 127.55 6.4 Favored 'General case' 0 N--CA 1.492 1.653 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.902 178.453 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.587 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.9 m-85 -118.36 149.18 41.63 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.431 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.505 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -98.97 159.28 15.07 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.548 -1.345 . . . . 0.0 107.784 178.841 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.623 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.4 p -140.19 119.6 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.189 -0.944 . . . . 0.0 109.633 -177.819 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' HB2' ' A' ' 51' ' ' ASP . . . -170.72 -179.94 42.33 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 118.274 -1.917 . . . . 0.0 111.794 -179.799 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.67 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.83 108.85 20.76 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.783 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.484 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.32 148.51 51.25 Favored 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.174 -0.954 . . . . 0.0 109.953 179.887 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.513 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.19 138.99 54.51 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.359 -0.838 . . . . 0.0 110.593 -179.046 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.89 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.29 114.63 26.44 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 107.521 -1.289 . . . . 0.0 107.521 178.213 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.0 m -104.38 14.81 6.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 O-C-N 121.069 -1.019 . . . . 0.0 110.482 -178.811 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.74 -175.41 0.08 Allowed 'General case' 0 C--N 1.302 -1.482 0 O-C-N 120.935 -1.103 . . . . 0.0 110.025 179.695 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.6 p -73.54 98.28 2.78 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.413 -0.804 . . . . 0.0 109.506 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.5 27.58 29.56 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.219 -0.991 . . . . 0.0 111.326 179.128 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -118.72 106.31 19.29 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 O-C-N 120.607 -1.525 . . . . 0.0 107.342 178.999 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.89 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -116.61 104.7 11.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.315 -1.491 . . . . 0.0 109.855 -177.815 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.948 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.49 109.62 22.34 Favored 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.909 -1.12 . . . . 0.0 108.1 178.885 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.0 t -107.15 165.82 11.08 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.841 -1.162 . . . . 0.0 110.612 -178.632 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.503 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 55.3 t30 -113.55 132.45 22.53 Favored Pre-proline 0 N--CA 1.501 2.092 0 C-N-CA 120.119 -0.632 . . . . 0.0 109.425 -179.486 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.8 Cg_endo -72.76 24.31 0.29 Allowed 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 122.205 1.937 . . . . 0.0 112.104 -179.743 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.419 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -99.06 -7.58 26.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.369 -1.457 . . . . 0.0 109.184 179.52 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.792 ' HB3' HD22 ' A' ' 67' ' ' LEU . 0.7 OUTLIER -133.61 5.8 3.72 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.346 -0.846 . . . . 0.0 108.817 -179.985 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -59.44 80.62 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.87 -178.656 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -108.48 -169.97 1.59 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 178.297 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.5 134.55 0.08 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.543 -1.348 . . . . 0.0 111.448 -179.405 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.724 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.9 p -146.31 158.92 11.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 177.741 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.565 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.48 146.6 25.08 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.572 -1.33 . . . . 0.0 109.884 -179.564 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.42 108.73 3.37 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 122.385 1.088 . . . . 0.0 109.674 178.914 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.546 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.1 p-10 -62.42 -138.85 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.862 -179.796 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.706 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.72 -51.84 35.76 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.376 -0.828 . . . . 0.0 110.641 -178.771 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -105.11 -32.73 8.55 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 178.553 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.963 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.5 69.78 0.67 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 178.246 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 69.9 m -103.63 130.09 51.01 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 121.268 -1.137 . . . . 0.0 109.337 179.267 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.724 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.62 108.69 7.68 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.433 -0.907 . . . . 0.0 109.676 -179.675 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 93.6 p -115.88 116.93 28.84 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 120.956 -1.09 . . . . 0.0 109.364 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.29 141.27 27.15 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.427 -0.796 . . . . 0.0 110.125 -179.868 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.6 p -100.35 137.0 39.36 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.614 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.972 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -137.35 172.22 13.31 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.253 -0.904 . . . . 0.0 109.844 -178.979 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.581 HG22 HG22 ' A' ' 18' ' ' VAL . 1.2 p -104.72 123.66 48.02 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.089 -1.007 . . . . 0.0 109.908 -179.372 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.764 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.5 m -133.04 143.6 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 121.056 -1.027 . . . . 0.0 109.688 -179.606 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.585 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.2 ptt180 -140.78 -167.77 2.43 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.558 -1.339 . . . . 0.0 110.417 179.906 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.584 ' HG2' ' CD1' ' A' ' 112' ' ' PHE . 3.3 mtt180 -70.95 -76.61 0.1 Allowed 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -179.623 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.49 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -71.88 137.8 47.74 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 120.153 -1.592 . . . . 0.0 107.547 179.117 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.594 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -159.56 136.96 9.79 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.27 -1.372 . . . . 0.0 110.108 -178.105 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.484 ' O ' ' O ' ' A' ' 47' ' ' CYS . 9.1 mm-40 -34.71 122.54 0.53 Allowed 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.562 0.696 . . . . 0.0 110.571 -178.188 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.948 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.38 45.62 3.14 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 6.6 m-85 -38.41 113.82 0.32 Allowed 'General case' 0 N--CA 1.509 2.477 0 O-C-N 121.194 -1.18 . . . . 0.0 110.167 179.751 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.691 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.4 tp -87.81 125.99 34.76 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 120.913 -1.117 . . . . 0.0 109.477 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -64.26 58.6 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 O-C-N 120.972 -1.08 . . . . 0.0 110.184 179.93 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 6.3 t70 -161.0 20.02 0.13 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.047 -1.033 . . . . 0.0 109.796 179.688 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.68 -27.5 5.29 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.874 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 8.1 p -94.05 160.99 14.47 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.984 -1.303 . . . . 0.0 110.256 -179.488 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.544 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -108.98 136.63 48.2 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.897 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.691 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.7 t90 -82.67 -19.1 38.82 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.932 -1.105 . . . . 0.0 110.386 -178.368 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.64 175.2 19.97 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 -179.494 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.29 109.63 1.39 Allowed 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 179.122 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.677 HG21 ' CB ' ' A' ' 46' ' ' ALA . 39.4 t -81.38 104.38 9.85 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.068 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.637 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -67.42 111.14 3.91 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.433 -0.792 . . . . 0.0 109.888 -179.076 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.568 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.0 t -63.26 -5.9 3.9 Favored 'General case' 0 N--CA 1.499 2.017 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.942 179.48 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.3 p -84.76 -0.08 52.45 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.717 -1.24 . . . . 0.0 109.023 179.407 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.637 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.41 -49.14 2.91 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.356 -0.84 . . . . 0.0 109.024 -179.969 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.08 -178.03 3.53 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.578 -0.701 . . . . 0.0 109.539 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.11 115.26 29.92 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.466 -0.771 . . . . 0.0 108.982 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.57 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -97.09 125.2 41.4 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.948 -1.095 . . . . 0.0 109.687 -179.174 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.595 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.54 146.44 28.89 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 122.421 1.105 . . . . 0.0 111.191 -179.524 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.606 ' HB ' HG11 ' A' ' 7' ' ' VAL . 96.2 t -102.68 111.09 31.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 177.775 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.487 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.78 -171.2 18.72 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 117.97 -2.062 . . . . 0.0 111.808 -177.684 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.668 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -113.95 -177.59 3.17 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -179.075 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.472 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.299 -1.617 0 O-C-N 121.229 -0.92 . . . . 0.0 109.531 -179.378 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.699 0 N-CA-C 107.786 -2.126 . . . . 0.0 107.786 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.55 -177.67 6.09 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.534 -0.98 . . . . 0.0 109.91 179.328 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.86 -160.97 12.89 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.415 -1.874 . . . . 0.0 108.415 -179.395 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.7 Cg_exo -47.87 -178.95 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.813 1.306 . . . . 0.0 110.474 179.367 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -94.59 -179.51 4.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.068 -1.02 . . . . 0.0 110.448 -178.903 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.487 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.84 162.49 12.71 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 -179.972 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.8 129.67 50.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.397 -1.06 . . . . 0.0 109.095 -179.501 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.595 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.35 121.82 21.06 Favored 'General case' 0 C--N 1.289 -2.041 0 O-C-N 121.626 -0.671 . . . . 0.0 109.892 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.853 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.83 171.37 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.242 -0.911 . . . . 0.0 108.982 179.658 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.488 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -138.6 159.33 42.36 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.156 -0.965 . . . . 0.0 109.669 -179.845 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.853 ' CE2' HD12 ' A' ' 110' ' ' ILE . 79.7 m-85 . . . . . 0 N--CA 1.485 1.323 0 O-C-N 121.25 -0.907 . . . . 0.0 109.63 -179.785 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.414 0 CA-C-O 122.32 1.057 . . . . 0.0 110.778 . . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.949 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.4 t -112.82 108.71 17.79 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-O 123.108 1.432 . . . . 0.0 109.175 179.394 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.853 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -115.93 139.04 44.39 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.728 0 CA-C-N 114.169 -1.378 . . . . 0.0 110.088 -179.67 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.486 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -177.0 150.32 0.88 Allowed Pre-proline 0 N--CA 1.486 1.35 0 O-C-N 121.309 -0.87 . . . . 0.0 108.766 -179.673 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.486 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.9 Cg_endo -78.49 150.43 87.7 Favored 'Cis proline' 0 C--N 1.312 -1.364 0 C-N-CA 123.531 -1.445 . . . . 0.0 109.334 -0.921 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.646 ' HA ' HG22 ' A' ' 110' ' ' ILE . 94.1 p -93.65 -22.13 18.96 Favored 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.52 -0.738 . . . . 0.0 109.558 179.821 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.481 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -132.2 162.62 30.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.805 -179.798 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.15 39.03 38.21 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 -179.508 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.823 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.8 mt -91.38 -44.58 9.06 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-O 123.093 1.425 . . . . 0.0 110.771 -178.272 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.0 OUTLIER 64.37 146.42 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.332 0 CA-C-N 113.735 -1.575 . . . . 0.0 109.63 -179.42 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.6 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.7 p-10 -52.32 110.1 0.46 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.486 0.66 . . . . 0.0 111.554 -178.523 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.71 9.76 13.75 Favored Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.301 -1.428 . . . . 0.0 112.854 177.375 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.823 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.8 t -101.32 -172.52 2.18 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 121.029 2.415 . . . . 0.0 109.747 179.502 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.76 HG13 ' C ' ' A' ' 67' ' ' LEU . 11.2 t -134.63 141.32 43.64 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.612 -179.334 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 27.8 m -116.55 154.8 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.214 -0.929 . . . . 0.0 109.057 179.471 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.489 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 21.8 tttt -107.95 108.97 20.34 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.238 -0.914 . . . . 0.0 109.049 179.793 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.853 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -101.03 139.11 23.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.555 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.949 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.45 160.46 37.92 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 118.461 -1.296 . . . . 0.0 110.027 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.603 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.94 144.07 15.52 Favored Glycine 0 C--N 1.294 -1.758 0 N-CA-C 107.755 -2.138 . . . . 0.0 107.755 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.45 124.5 12.09 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 120.799 -1.412 . . . . 0.0 108.953 179.222 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.15 26.52 23.58 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 119.272 -1.442 . . . . 0.0 109.703 -179.702 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.577 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -89.22 170.56 10.49 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 120.857 -1.378 . . . . 0.0 108.479 179.989 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.006 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.09 100.69 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.051 -1.031 . . . . 0.0 109.988 -179.574 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.7 77.98 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.004 -179.509 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.85 34.05 0.27 Allowed Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 179.702 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.553 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 20.8 p -139.18 105.88 5.37 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.198 -1.178 . . . . 0.0 111.255 -179.485 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.589 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -52.32 114.19 1.27 Allowed 'General case' 0 N--CA 1.495 1.814 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.611 178.098 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.488 ' HA ' ' O ' ' A' ' 98' ' ' SER . 8.2 m-30 -110.67 160.06 17.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.143 -0.973 . . . . 0.0 108.949 179.834 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.507 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -100.62 168.28 9.8 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 178.93 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.704 HG22 HG11 ' A' ' 21' ' ' VAL . 3.8 p -150.36 117.13 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.023 -1.048 . . . . 0.0 109.827 -178.221 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.85 -175.93 39.21 Favored Glycine 0 N--CA 1.495 2.605 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.821 -179.765 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.609 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -99.33 108.44 20.97 Favored 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.811 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.0 m -132.21 148.45 52.46 Favored 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.296 -0.878 . . . . 0.0 109.784 179.657 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.2 140.25 53.02 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.241 -0.912 . . . . 0.0 110.727 -179.136 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.885 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.16 114.78 26.61 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.211 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.3 m -104.16 14.49 6.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.052 -1.03 . . . . 0.0 110.5 -178.798 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.75 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.93 -175.26 0.08 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.897 -1.127 . . . . 0.0 110.087 179.769 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.25 98.45 2.65 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.425 -0.797 . . . . 0.0 109.535 -179.917 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.98 27.51 31.2 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 120.244 -0.979 . . . . 0.0 111.421 179.072 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.75 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -118.01 106.33 19.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 O-C-N 120.618 -1.519 . . . . 0.0 107.303 178.846 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.885 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.4 tp -117.65 104.67 11.25 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.523 -1.36 . . . . 0.0 109.58 -177.843 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.965 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.03 109.54 22.27 Favored 'General case' 0 N--CA 1.485 1.281 0 O-C-N 120.828 -1.17 . . . . 0.0 108.251 179.068 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -107.61 166.85 10.37 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.023 -1.048 . . . . 0.0 109.989 -179.17 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.73 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.0 t-20 -107.3 137.33 19.58 Favored Pre-proline 0 N--CA 1.502 2.148 0 O-C-N 121.231 -0.918 . . . . 0.0 109.846 -179.286 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.6 Cg_endo -75.15 24.49 0.39 Allowed 'Trans proline' 0 C--N 1.318 -1.04 0 C-N-CA 122.383 2.056 . . . . 0.0 111.786 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.73 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -120.27 4.09 10.81 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.351 -1.468 . . . . 0.0 109.195 179.75 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.572 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.84 19.96 2.85 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 179.278 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -84.14 87.81 7.17 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.929 -0.708 . . . . 0.0 110.858 -178.618 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -107.91 -168.25 1.35 Allowed 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.436 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.458 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.92 136.22 0.09 Allowed 'General case' 0 C--N 1.305 -1.326 0 O-C-N 120.755 -1.216 . . . . 0.0 111.082 -179.401 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.927 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -151.73 157.7 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 178.391 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.589 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.91 142.26 30.64 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.835 -1.166 . . . . 0.0 110.027 -179.786 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.03 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.89 107.76 1.05 Allowed 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 122.441 1.115 . . . . 0.0 109.288 178.083 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.1 t0 -62.94 -138.68 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.777 179.937 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.531 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.37 -52.7 34.93 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.402 -0.811 . . . . 0.0 110.924 -178.615 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.85 -33.07 9.94 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 178.612 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.03 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.19 62.26 0.55 Allowed Glycine 0 C--N 1.296 -1.664 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 178.051 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.603 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 82.5 p -98.72 129.91 45.19 Favored 'General case' 0 C--N 1.309 -1.155 0 O-C-N 121.563 -0.963 . . . . 0.0 108.731 178.713 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.927 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.29 108.89 6.97 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.203 -0.999 . . . . 0.0 109.727 -179.343 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -122.35 119.2 30.37 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.191 -0.943 . . . . 0.0 109.533 -179.941 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.574 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.66 142.98 30.51 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.491 -0.756 . . . . 0.0 109.329 179.876 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 27.7 p -98.82 138.09 36.46 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.416 -0.802 . . . . 0.0 109.58 -179.853 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.814 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -140.83 159.41 42.27 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.329 -0.857 . . . . 0.0 109.48 -179.502 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.71 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 13.0 t -87.91 139.14 30.82 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.147 -0.97 . . . . 0.0 110.657 -179.411 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.609 HG12 ' HB3' ' A' ' 36' ' ' GLN . 19.4 m -148.73 144.31 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.484 -0.76 . . . . 0.0 109.249 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.6 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.9 OUTLIER -150.72 -173.69 4.55 Favored 'General case' 0 N--CA 1.484 1.245 0 O-C-N 120.456 -1.403 . . . . 0.0 111.178 -179.641 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.741 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.28 -104.8 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.281 -179.644 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.458 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -59.43 140.23 56.37 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 120.695 -1.253 . . . . 0.0 108.072 178.948 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.609 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -158.29 138.69 12.61 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.773 -1.171 . . . . 0.0 109.713 -178.312 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.52 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 8.8 mm-40 -34.89 120.35 0.5 Allowed 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.539 0.685 . . . . 0.0 110.552 -178.448 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.965 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.96 47.91 3.2 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.415 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -38.47 113.65 0.31 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 121.241 -1.153 . . . . 0.0 110.166 179.812 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.816 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.66 126.26 34.41 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.997 -1.065 . . . . 0.0 109.456 -179.982 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -64.23 58.48 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.906 -1.121 . . . . 0.0 109.949 179.541 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 9.8 t70 -158.74 18.77 0.2 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.976 -1.078 . . . . 0.0 109.645 -179.979 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.18 -26.41 6.23 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.761 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.83 163.64 12.71 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 120.99 -1.3 . . . . 0.0 110.404 -179.332 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.486 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 4.2 ptt180 -106.24 136.79 45.34 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.914 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.816 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.7 t90 -82.58 -19.6 38.15 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.79 -1.194 . . . . 0.0 110.241 -178.709 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.64 173.43 16.86 Favored Glycine 0 N--CA 1.486 2.019 0 N-CA-C 108.791 -1.723 . . . . 0.0 108.791 -179.636 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -65.14 106.1 1.22 Allowed 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 179.105 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.651 HG21 ' HB3' ' A' ' 46' ' ' ALA . 46.2 t -76.51 107.34 7.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.371 -0.831 . . . . 0.0 109.533 -178.694 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.603 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.9 m-20 -63.92 111.99 2.73 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.213 -0.929 . . . . 0.0 109.178 -179.919 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.741 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.2 m -65.41 -4.66 5.96 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 120.704 -1.247 . . . . 0.0 109.829 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.2 p -93.27 1.95 56.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.731 -1.23 . . . . 0.0 109.58 179.956 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.603 HG23 ' HB3' ' A' ' 87' ' ' ASP . 5.0 p -112.51 -52.79 2.76 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.241 -0.912 . . . . 0.0 108.636 179.78 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.421 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -98.47 178.77 4.92 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.492 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.07 114.0 27.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -0.89 . . . . 0.0 108.777 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.505 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.8 m -96.44 121.8 38.64 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.982 -1.074 . . . . 0.0 109.758 -178.989 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.572 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -106.2 144.28 33.12 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-O 122.355 1.074 . . . . 0.0 111.112 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 90.5 t -101.87 109.58 26.44 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.086 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.741 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.483 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.12 -172.01 17.65 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 118.223 -1.941 . . . . 0.0 111.741 -177.591 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.503 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -112.01 178.8 4.19 Favored 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.289 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.507 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.9 OUTLIER . . . . . 0 C--N 1.294 -1.805 0 O-C-N 121.571 -0.706 . . . . 0.0 109.424 -179.546 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.717 0 N-CA-C 107.559 -2.216 . . . . 0.0 107.559 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.75 -178.23 7.1 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.574 -0.956 . . . . 0.0 109.777 179.23 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.44 -161.9 14.4 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.488 -1.845 . . . . 0.0 108.488 -179.394 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.479 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -47.24 178.25 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.626 0 CA-C-N 118.812 1.306 . . . . 0.0 110.342 179.329 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -91.37 -174.35 3.9 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.097 -1.002 . . . . 0.0 110.401 -178.893 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.483 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.99 166.8 15.29 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.7 130.15 51.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.43 -1.041 . . . . 0.0 109.1 -179.429 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.572 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.71 125.12 28.04 Favored 'General case' 0 C--N 1.289 -2.049 0 O-C-N 121.641 -0.662 . . . . 0.0 109.606 179.782 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.755 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.84 169.98 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.274 -0.891 . . . . 0.0 109.257 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.481 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -137.88 155.77 48.6 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.276 -0.89 . . . . 0.0 109.504 179.992 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.755 ' CE1' HD12 ' A' ' 110' ' ' ILE . 76.5 m-85 . . . . . 0 N--CA 1.487 1.398 0 O-C-N 121.11 -0.994 . . . . 0.0 109.51 -179.808 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.499 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.224 0 CA-C-O 122.465 1.126 . . . . 0.0 110.031 . . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.92 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.9 t -114.88 109.1 17.64 Favored 'General case' 0 C--N 1.294 -1.822 0 CA-C-O 123.2 1.476 . . . . 0.0 109.765 -179.807 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.863 HG22 HG23 ' A' ' 21' ' ' VAL . 3.1 t -116.27 136.98 51.49 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.638 0 CA-C-N 114.176 -1.374 . . . . 0.0 109.716 179.902 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.497 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -172.96 151.25 2.13 Favored Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 121.235 -0.915 . . . . 0.0 108.791 -179.534 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.497 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.2 Cg_endo -77.53 151.67 92.52 Favored 'Cis proline' 0 C--N 1.311 -1.422 0 C-N-CA 123.517 -1.451 . . . . 0.0 109.433 -0.819 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.67 ' HA ' HG22 ' A' ' 110' ' ' ILE . 88.1 p -93.94 -23.2 18.16 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.576 -0.703 . . . . 0.0 109.505 179.805 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.5 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 3.0 m -130.94 160.1 35.51 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.321 -0.862 . . . . 0.0 109.96 -179.65 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.23 37.25 32.57 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 108.611 -1.796 . . . . 0.0 108.611 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.865 ' CA ' HG21 ' A' ' 17' ' ' THR . 27.1 mt -90.83 -45.42 8.81 Favored 'General case' 0 C--N 1.299 -1.627 0 CA-C-O 123.113 1.435 . . . . 0.0 110.751 -178.411 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 64.03 147.23 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.311 0 CA-C-N 113.748 -1.569 . . . . 0.0 109.963 -179.612 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.615 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.4 p-10 -51.41 108.9 0.29 Allowed 'General case' 0 C--N 1.302 -1.47 0 CA-C-O 121.725 0.774 . . . . 0.0 111.809 -178.568 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.8 13.66 11.04 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 119.479 -1.343 . . . . 0.0 112.914 177.311 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.865 HG21 ' CA ' ' A' ' 13' ' ' LEU . 10.2 t -101.8 -174.34 2.57 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 121.059 2.43 . . . . 0.0 109.86 179.457 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.766 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.1 t -127.83 138.3 55.13 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.885 -178.994 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.534 HG13 ' CG2' ' A' ' 69' ' ' VAL . 30.8 m -117.34 154.17 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.877 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -109.98 109.34 19.89 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.187 -0.946 . . . . 0.0 109.195 -179.846 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.863 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -101.96 140.44 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.747 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.92 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.33 158.31 44.12 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.838 -1.164 . . . . 0.0 109.701 179.568 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -139.36 108.81 0.61 Allowed Glycine 0 N--CA 1.481 1.675 0 N-CA-C 108.658 -1.777 . . . . 0.0 108.658 179.888 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.43 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.54 139.52 50.4 Favored 'General case' 0 N--CA 1.502 2.14 0 CA-C-N 119.402 1.601 . . . . 0.0 110.564 -179.25 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.21 27.81 32.47 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.058 -1.544 . . . . 0.0 109.938 179.569 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.7 OUTLIER -93.67 170.53 9.51 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.97 -1.312 . . . . 0.0 108.522 -179.92 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.997 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.43 101.23 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.097 -1.002 . . . . 0.0 109.827 -179.566 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.54 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.42 77.93 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.705 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.888 -179.342 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.5 33.46 0.27 Allowed Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 179.896 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.56 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 12.9 p -136.96 104.75 5.55 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 121.2 -1.176 . . . . 0.0 111.057 -179.349 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.582 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.54 110.03 0.41 Allowed 'General case' 0 N--CA 1.497 1.914 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.621 178.087 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.555 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 38.5 m-85 -106.33 156.35 18.59 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.052 -1.03 . . . . 0.0 108.992 179.87 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.415 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.25 160.14 14.57 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.631 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.626 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.2 p -140.75 119.66 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.095 -1.003 . . . . 0.0 109.62 -177.836 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.486 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.88 -178.8 41.15 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.536 -1.792 . . . . 0.0 111.525 -179.782 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.586 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.1 pt20 -100.99 109.08 20.95 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.756 0.788 . . . . 0.0 108.954 -179.904 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.493 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.81 150.26 52.07 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.079 -1.013 . . . . 0.0 110.406 179.978 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.92 139.38 53.88 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.373 -0.829 . . . . 0.0 110.661 -179.054 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.882 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.3 115.02 26.87 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 178.114 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -105.92 15.44 7.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.013 -1.055 . . . . 0.0 110.605 -178.889 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.764 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.6 -176.33 0.09 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.831 -1.168 . . . . 0.0 110.147 179.759 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.789 ' O ' HG23 ' A' ' 42' ' ' THR . 15.2 t -70.13 97.32 1.18 Allowed 'General case' 0 N--CA 1.487 1.419 0 CA-C-O 121.791 0.805 . . . . 0.0 109.949 -179.553 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.2 28.35 37.18 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.158 -1.02 . . . . 0.0 111.349 178.957 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.764 HG21 ' CB ' ' A' ' 41' ' ' ASP . 2.0 t -115.61 106.46 20.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 120.625 -1.515 . . . . 0.0 107.193 178.778 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.882 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.3 tp -116.4 104.75 11.77 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.428 -1.42 . . . . 0.0 109.847 -177.612 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.872 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.96 109.24 22.03 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 120.763 -1.211 . . . . 0.0 107.847 178.682 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -104.17 170.0 8.16 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.933 -1.104 . . . . 0.0 110.151 -178.863 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.454 ' CG ' ' HB2' ' A' ' 73' ' ' PHE . 36.9 t30 -108.24 134.67 20.1 Favored Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.346 -0.846 . . . . 0.0 109.631 -179.376 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.1 Cg_endo -74.5 25.27 0.36 Allowed 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 122.259 1.972 . . . . 0.0 111.608 -179.962 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.424 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -120.12 2.54 10.92 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.473 -1.392 . . . . 0.0 109.307 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.706 ' OD2' HG13 ' A' ' 69' ' ' VAL . 5.7 m-20 -137.09 18.67 2.99 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 179.744 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -81.13 88.52 5.99 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.617 -0.833 . . . . 0.0 110.62 -178.702 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -109.43 -166.22 1.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 178.66 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.77 136.02 0.09 Allowed 'General case' 0 N--CA 1.485 1.316 0 O-C-N 120.708 -1.245 . . . . 0.0 111.07 -179.215 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.94 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.84 155.92 5.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.421 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.582 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.73 141.34 31.66 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.87 -1.144 . . . . 0.0 109.94 -179.737 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.997 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -61.76 106.18 0.65 Allowed 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 122.471 1.129 . . . . 0.0 109.379 178.331 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.56 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.2 p-10 -59.46 -140.06 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.043 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.947 179.895 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.54 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.37 -50.42 59.58 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.488 -0.758 . . . . 0.0 110.752 -178.756 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -103.65 -33.35 9.0 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 106.16 -1.792 . . . . 0.0 106.16 178.518 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.985 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.4 66.3 0.65 Allowed Glycine 0 C--N 1.298 -1.545 0 CA-C-N 114.897 -1.047 . . . . 0.0 110.514 177.993 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 20.0 m -103.68 125.43 50.17 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 178.657 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.94 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.9 109.27 7.86 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.349 -179.379 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.7 m -126.21 122.16 34.82 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.366 -0.834 . . . . 0.0 109.674 -179.717 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.587 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -143.91 141.8 30.45 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.634 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.3 p -98.55 131.63 44.62 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.192 -0.942 . . . . 0.0 109.493 -179.8 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.839 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -131.49 178.46 6.71 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.487 -0.758 . . . . 0.0 109.299 -179.387 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.538 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.5 p -102.22 123.52 46.2 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.898 -1.126 . . . . 0.0 109.739 -179.416 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.731 HG23 HD13 ' A' ' 13' ' ' LEU . 15.5 m -128.59 142.32 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 120.934 -1.104 . . . . 0.0 110.062 -179.389 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.615 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.5 ptt180 -148.4 -176.76 5.43 Favored 'General case' 0 N--CA 1.484 1.248 0 O-C-N 120.521 -1.362 . . . . 0.0 110.91 179.669 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.569 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.1 OUTLIER -60.56 -102.33 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.189 -179.109 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.534 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -60.09 138.12 57.95 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.443 -1.411 . . . . 0.0 107.979 179.773 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.531 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 2.4 p90 -161.72 147.33 13.57 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 118.555 -1.258 . . . . 0.0 110.033 -178.377 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.541 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 1.8 mp0 -37.68 120.44 0.82 Allowed 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 121.504 0.669 . . . . 0.0 110.516 -178.674 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.872 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.54 49.49 3.17 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.599 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.9 m-30 -38.07 114.45 0.36 Allowed 'General case' 0 N--CA 1.511 2.582 0 O-C-N 121.194 -1.18 . . . . 0.0 110.545 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.816 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -87.62 127.01 35.28 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.843 -1.161 . . . . 0.0 109.546 179.78 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.6 t80 -64.36 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.872 -1.142 . . . . 0.0 109.993 179.667 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.8 t70 -159.46 19.01 0.18 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.047 -1.033 . . . . 0.0 109.72 179.893 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.89 -26.34 6.1 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.747 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 35.2 p -96.45 163.32 13.1 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 121.037 -1.273 . . . . 0.0 110.407 -179.414 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.478 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.4 136.28 46.42 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.913 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.816 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.9 t90 -82.42 -18.56 41.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.781 -1.199 . . . . 0.0 110.318 -178.757 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.83 173.36 17.85 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 -179.587 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.79 109.3 1.68 Allowed 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 179.203 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.606 HG21 ' HB3' ' A' ' 46' ' ' ALA . 50.4 t -80.06 105.23 9.37 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 121.43 -0.794 . . . . 0.0 109.349 -178.782 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.556 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -66.14 109.69 2.7 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.661 -0.649 . . . . 0.0 109.965 -179.529 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.569 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 3.0 t -62.09 -4.41 1.67 Allowed 'General case' 0 N--CA 1.501 2.107 0 C-N-CA 118.165 -1.414 . . . . 0.0 110.162 179.348 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.0 p -90.08 3.54 53.0 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.627 -1.296 . . . . 0.0 109.306 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.556 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -116.32 -49.88 2.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.298 -0.876 . . . . 0.0 109.127 -179.899 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.9 179.37 4.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.429 -0.795 . . . . 0.0 109.46 179.969 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.42 113.6 26.85 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.286 -0.884 . . . . 0.0 108.725 179.737 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.495 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -97.16 121.41 39.02 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.929 -1.107 . . . . 0.0 109.542 -178.922 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.579 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.43 148.58 26.27 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 122.44 1.114 . . . . 0.0 111.452 -179.249 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.483 ' CG1' HG11 ' A' ' 7' ' ' VAL . 28.8 t -104.95 109.5 27.86 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.449 -1.686 . . . . 0.0 106.449 177.249 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.482 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.8 -169.53 16.77 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 118.305 -1.902 . . . . 0.0 111.691 -177.366 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.468 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -120.77 177.13 5.2 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -178.958 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.468 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 7.8 t . . . . . 0 C--N 1.292 -1.933 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 179.917 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.693 0 N-CA-C 107.857 -2.097 . . . . 0.0 107.857 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.95 -177.35 5.03 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.576 -0.955 . . . . 0.0 109.992 179.359 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.13 -161.24 20.28 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 108.074 -2.01 . . . . 0.0 108.074 -179.411 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.479 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.4 Cg_exo -47.01 176.43 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.66 0 CA-C-N 118.956 1.378 . . . . 0.0 110.061 179.297 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -95.28 178.62 5.46 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.029 -1.045 . . . . 0.0 110.725 -178.58 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.482 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.23 170.34 13.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -107.32 133.22 52.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.348 -1.089 . . . . 0.0 109.187 -179.273 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.579 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.65 124.37 26.59 Favored 'General case' 0 C--N 1.29 -2.013 0 O-C-N 121.508 -0.745 . . . . 0.0 109.704 179.709 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.944 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.95 171.0 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.283 -0.886 . . . . 0.0 108.91 179.816 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.5 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 24.3 m -139.15 156.74 46.91 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.054 -1.029 . . . . 0.0 109.872 -179.794 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.944 ' CE1' HD12 ' A' ' 110' ' ' ILE . 45.2 m-85 . . . . . 0 N--CA 1.486 1.352 0 O-C-N 121.226 -0.921 . . . . 0.0 109.465 -179.669 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.488 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.457 0 CA-C-O 122.335 1.064 . . . . 0.0 110.768 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.957 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.7 t -110.87 108.9 18.85 Favored 'General case' 0 C--N 1.297 -1.7 0 CA-C-O 123.109 1.433 . . . . 0.0 109.066 179.357 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.817 HG22 HG23 ' A' ' 21' ' ' VAL . 2.6 t -118.28 139.72 44.44 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.699 0 CA-C-N 114.223 -1.353 . . . . 0.0 110.121 -179.741 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.453 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -179.07 150.88 0.64 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.239 -0.913 . . . . 0.0 108.764 -179.685 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.453 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.7 Cg_endo -77.47 151.72 92.77 Favored 'Cis proline' 0 C--N 1.313 -1.314 0 C-N-CA 123.555 -1.435 . . . . 0.0 109.332 -0.838 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.681 ' HA ' HG22 ' A' ' 110' ' ' ILE . 59.2 p -92.49 -23.29 19.16 Favored 'General case' 0 C--N 1.291 -1.968 0 O-C-N 121.567 -0.708 . . . . 0.0 109.664 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.482 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 23.9 p -133.26 159.14 41.09 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.197 -0.939 . . . . 0.0 110.124 -179.493 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.79 37.1 23.83 Favored Glycine 0 N--CA 1.497 2.706 0 N-CA-C 108.917 -1.673 . . . . 0.0 108.917 -179.859 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.777 ' HA ' HG21 ' A' ' 17' ' ' THR . 39.0 mt -93.34 -44.57 8.23 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.162 1.458 . . . . 0.0 110.44 -178.54 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.44 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.8 OUTLIER 64.3 146.8 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.273 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.17 -179.829 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.53 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 12.7 p-10 -51.51 104.92 0.09 Allowed 'General case' 0 C--N 1.305 -1.353 0 CA-C-O 121.675 0.75 . . . . 0.0 111.04 -179.072 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.81 7.47 6.68 Favored Glycine 0 N--CA 1.484 1.848 0 C-N-CA 119.13 -1.509 . . . . 0.0 113.296 177.52 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.777 HG21 ' HA ' ' A' ' 13' ' ' LEU . 15.2 t -107.13 -177.03 3.24 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 121.444 2.622 . . . . 0.0 110.133 179.605 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.784 HG13 ' O ' ' A' ' 67' ' ' LEU . 25.4 t -126.26 135.75 62.86 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.452 0 CA-C-N 114.249 -1.341 . . . . 0.0 111.073 -178.717 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.62 ' CG1' HD13 ' A' ' 13' ' ' LEU . 10.4 m -110.56 156.53 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.734 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.6 tttt -109.15 108.88 19.71 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.095 -1.003 . . . . 0.0 108.968 179.84 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.817 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.75 141.13 20.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.668 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.957 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -139.24 160.6 39.44 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 118.539 -1.265 . . . . 0.0 110.2 179.901 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.602 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.58 143.49 14.64 Favored Glycine 0 C--N 1.295 -1.731 0 N-CA-C 107.89 -2.084 . . . . 0.0 107.89 179.448 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -145.45 126.22 14.35 Favored 'General case' 0 C--N 1.295 -1.765 0 O-C-N 120.783 -1.422 . . . . 0.0 108.977 179.276 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.2 26.52 25.74 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 119.319 -1.419 . . . . 0.0 109.737 -179.744 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.576 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -89.43 169.78 11.09 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.81 -1.406 . . . . 0.0 108.392 179.861 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.999 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.95 100.98 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.039 -1.038 . . . . 0.0 110.076 -179.526 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.69 78.56 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.867 -179.529 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.41 33.9 0.3 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 179.778 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.562 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 17.2 p -138.6 105.03 5.28 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.259 -1.141 . . . . 0.0 111.146 -179.43 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.578 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.36 110.6 0.42 Allowed 'General case' 0 N--CA 1.497 1.905 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.701 178.169 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.562 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 35.5 m-85 -105.91 157.31 17.58 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.154 -0.966 . . . . 0.0 108.923 179.718 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.486 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -102.31 162.16 13.14 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.935 -1.103 . . . . 0.0 108.132 179.035 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.631 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.9 p -141.8 118.89 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.196 -0.94 . . . . 0.0 109.559 -178.186 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -166.41 -179.08 39.52 Favored Glycine 0 N--CA 1.493 2.481 0 C-N-CA 118.386 -1.864 . . . . 0.0 111.647 -179.693 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.63 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -101.38 109.01 20.77 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 179.978 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.51 148.76 52.35 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 121.164 -0.96 . . . . 0.0 109.959 179.925 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.429 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.65 138.66 54.5 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.409 -0.807 . . . . 0.0 110.656 -179.146 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.891 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.21 114.78 26.61 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 178.154 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.6 m -104.8 14.86 6.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.997 -1.065 . . . . 0.0 110.537 -178.789 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.753 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.87 -175.19 0.08 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.968 -1.083 . . . . 0.0 109.979 179.625 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 71.4 p -72.72 98.03 2.3 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.474 -0.766 . . . . 0.0 109.519 -179.704 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.57 27.65 31.92 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 120.225 -0.988 . . . . 0.0 111.413 178.943 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.753 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.25 106.18 19.59 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.653 -1.498 . . . . 0.0 107.258 178.942 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.891 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -117.26 104.59 11.32 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.504 -1.373 . . . . 0.0 109.831 -177.771 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.083 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.7 109.3 22.08 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.641 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.17 167.11 10.13 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.941 -1.099 . . . . 0.0 110.685 -178.588 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.483 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 10.8 t-20 -115.07 129.5 25.01 Favored Pre-proline 0 N--CA 1.498 1.939 0 O-C-N 121.606 -0.684 . . . . 0.0 109.498 -179.334 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.6 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -71.8 22.38 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.081 0 C-N-CA 122.052 1.835 . . . . 0.0 111.852 179.437 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.454 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -99.04 -5.9 29.49 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.404 -1.435 . . . . 0.0 109.15 179.61 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.815 ' OD2' HG13 ' A' ' 69' ' ' VAL . 1.6 m-20 -136.4 11.44 3.24 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.861 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -67.47 86.76 0.19 Allowed 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.48 -0.763 . . . . 0.0 110.649 -178.715 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.631 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -107.89 -165.97 1.1 Allowed 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 178.576 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.463 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.73 135.89 0.09 Allowed 'General case' 0 C--N 1.306 -1.305 0 O-C-N 120.642 -1.286 . . . . 0.0 111.147 -179.334 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.942 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -151.82 156.53 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 178.168 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.578 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.38 142.58 29.83 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.773 -1.205 . . . . 0.0 110.082 -179.676 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.024 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.36 107.08 0.85 Allowed 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 122.446 1.117 . . . . 0.0 109.403 178.079 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 17.2 p-10 -61.14 -138.93 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.026 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.986 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.77 -51.19 52.87 Favored 'General case' 0 N--CA 1.5 2.075 0 O-C-N 121.379 -0.826 . . . . 0.0 110.845 -178.536 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -103.79 -33.29 8.96 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.167 -1.79 . . . . 0.0 106.167 178.488 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.024 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.95 63.88 0.55 Allowed Glycine 0 C--N 1.298 -1.58 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 178.102 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.602 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 43.2 m -102.38 126.96 49.56 Favored 'General case' 0 C--N 1.31 -1.148 0 O-C-N 121.479 -1.012 . . . . 0.0 108.731 178.732 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.942 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.28 109.04 7.52 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 119.411 -0.915 . . . . 0.0 109.53 -179.387 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -123.81 121.44 35.41 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 121.242 -0.911 . . . . 0.0 109.614 -179.768 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.58 146.54 31.42 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.558 -0.714 . . . . 0.0 109.305 179.854 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.401 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 13.5 p -98.83 141.15 31.98 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.351 -0.843 . . . . 0.0 109.472 -179.909 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.784 ' O ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -140.83 170.33 15.95 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.405 -0.809 . . . . 0.0 109.304 -179.206 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.779 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -101.87 124.94 48.34 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 120.878 -1.139 . . . . 0.0 110.157 -179.099 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.815 HG13 ' OD2' ' A' ' 51' ' ' ASP . 11.8 m -128.54 139.34 52.15 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 120.996 -1.065 . . . . 0.0 110.343 -179.601 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.53 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 56.3 mtt180 -127.11 -168.84 1.94 Allowed 'General case' 0 N--CA 1.483 1.222 0 O-C-N 120.576 -1.327 . . . . 0.0 111.156 179.673 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.588 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 1.8 mtt180 -79.08 -76.02 0.22 Allowed 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 179.001 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.504 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -73.66 135.52 43.75 Favored 'General case' 0 N--CA 1.486 1.349 0 N-CA-C 106.452 -1.684 . . . . 0.0 106.452 177.774 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.59 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -156.79 139.13 14.76 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 117.637 -1.625 . . . . 0.0 110.925 -177.331 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.9 mm-40 -37.19 118.93 0.65 Allowed 'General case' 0 N--CA 1.489 1.513 0 CA-C-O 121.408 0.623 . . . . 0.0 110.09 -178.943 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.083 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.78 50.13 3.43 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.175 -179.242 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.6 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-30 -38.69 113.88 0.34 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.136 -1.214 . . . . 0.0 110.073 179.514 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.729 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -85.92 126.66 34.25 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 120.981 -1.074 . . . . 0.0 109.526 -179.885 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 29.4 t80 -63.72 58.54 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.026 0 O-C-N 120.91 -1.119 . . . . 0.0 110.142 179.608 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.59 19.5 0.14 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.036 -1.04 . . . . 0.0 109.748 179.84 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.78 -27.03 5.55 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 110.111 -1.195 . . . . 0.0 110.111 179.842 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.24 161.82 13.94 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 121.033 -1.274 . . . . 0.0 110.335 -179.499 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.476 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -107.67 136.85 46.73 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.917 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.729 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.5 t90 -82.21 -19.07 40.52 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.755 -1.216 . . . . 0.0 110.311 -178.759 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.93 173.93 19.01 Favored Glycine 0 N--CA 1.486 1.969 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.581 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.65 109.65 1.47 Allowed 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 179.202 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.5 t -81.92 105.12 11.43 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 O-C-N 121.354 -0.841 . . . . 0.0 108.916 -179.092 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.655 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.1 OUTLIER -65.45 110.69 2.76 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.45 -0.781 . . . . 0.0 110.006 -179.1 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.588 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.6 t -64.19 -5.28 4.63 Favored 'General case' 0 N--CA 1.5 2.035 0 C-N-CA 118.452 -1.299 . . . . 0.0 109.791 179.38 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.1 p -86.88 0.6 54.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.742 -1.224 . . . . 0.0 108.961 179.427 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.655 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -114.88 -50.96 2.75 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.292 -0.88 . . . . 0.0 109.02 179.825 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -102.84 -178.99 3.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.566 -0.709 . . . . 0.0 109.394 179.84 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.5 115.32 30.05 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.312 -0.867 . . . . 0.0 109.023 179.923 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.516 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.7 m -97.11 121.91 39.52 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.998 -1.064 . . . . 0.0 109.396 -179.353 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.612 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.92 144.93 29.93 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 122.397 1.094 . . . . 0.0 111.199 -179.365 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 96.4 t -102.49 110.16 28.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 177.701 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.478 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.3 -169.91 16.92 Favored Glycine 0 N--CA 1.486 2.006 0 C-N-CA 118.071 -2.014 . . . . 0.0 111.833 -177.536 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.503 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -112.91 179.88 3.84 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -179.116 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.452 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.4 p . . . . . 0 C--N 1.296 -1.74 0 O-C-N 121.456 -0.777 . . . . 0.0 109.58 -179.301 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.706 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.19 -177.46 5.4 Favored 'General case' 0 C--N 1.308 -1.219 0 O-C-N 121.518 -0.989 . . . . 0.0 109.789 179.26 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.61 -162.88 19.22 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 108.27 -1.932 . . . . 0.0 108.27 -179.442 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.503 ' HB2' HD12 ' A' ' 97' ' ' LEU . 6.4 Cg_exo -46.82 176.62 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.653 0 CA-C-N 118.835 1.317 . . . . 0.0 110.16 179.305 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -91.53 -176.13 4.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.142 -0.974 . . . . 0.0 110.502 -178.752 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.478 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.9 167.24 14.55 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.78 130.92 52.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.428 -1.042 . . . . 0.0 109.186 -179.403 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.612 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.42 120.76 20.43 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.679 -0.638 . . . . 0.0 109.744 179.751 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.733 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.4 pt -98.12 167.28 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.279 -0.888 . . . . 0.0 109.201 179.89 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.482 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -133.14 159.28 40.59 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.314 -0.866 . . . . 0.0 109.412 -179.926 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.733 ' CE2' HD12 ' A' ' 110' ' ' ILE . 49.4 m-85 . . . . . 0 N--CA 1.487 1.384 0 O-C-N 121.117 -0.989 . . . . 0.0 109.563 -179.753 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.495 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.483 1.217 0 CA-C-O 122.584 1.183 . . . . 0.0 110.115 . . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.911 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.7 t -115.8 109.2 17.33 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 123.122 1.439 . . . . 0.0 109.607 -179.98 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.882 HG22 HG23 ' A' ' 21' ' ' VAL . 3.1 t -114.95 139.84 39.15 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.677 0 CA-C-N 114.234 -1.348 . . . . 0.0 109.853 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.65 149.12 2.35 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.272 -0.893 . . . . 0.0 108.695 -179.666 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.0 Cg_endo -75.26 152.35 97.69 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 123.491 -1.462 . . . . 0.0 109.552 -0.846 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.653 ' HA ' HG22 ' A' ' 110' ' ' ILE . 2.4 m -88.46 -27.36 21.57 Favored 'General case' 0 C--N 1.293 -1.863 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.62 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.541 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 1.9 p -136.39 166.77 22.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.51 -0.744 . . . . 0.0 109.347 179.764 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.08 37.36 32.85 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 108.512 -1.835 . . . . 0.0 108.512 -179.626 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.755 ' CA ' HG21 ' A' ' 17' ' ' THR . 41.0 mt -92.98 -42.65 9.33 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-O 123.243 1.497 . . . . 0.0 110.466 -178.352 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.67 144.08 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.243 0 CA-C-N 113.392 -1.731 . . . . 0.0 109.877 -179.669 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.615 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 13.0 p-10 -50.94 105.65 0.11 Allowed 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.457 0.646 . . . . 0.0 111.589 -178.601 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.71 14.08 8.27 Favored Glycine 0 N--CA 1.485 1.927 0 C-N-CA 119.425 -1.369 . . . . 0.0 112.995 177.35 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.755 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -105.76 -172.43 2.09 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 121.239 2.52 . . . . 0.0 109.86 179.23 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.822 HG22 HG22 ' A' ' 68' ' ' THR . 18.1 t -128.41 139.18 52.6 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.345 0 CA-C-N 114.742 -1.117 . . . . 0.0 111.022 -178.81 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.6 HG11 HD11 ' A' ' 13' ' ' LEU . 33.2 m -114.49 154.91 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.876 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.05 109.55 21.45 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.261 -0.899 . . . . 0.0 109.19 -179.954 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.882 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -102.26 140.06 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.511 -0.743 . . . . 0.0 109.059 179.95 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.911 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -131.44 158.16 41.56 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.012 -1.055 . . . . 0.0 109.335 179.458 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.583 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.73 108.76 0.57 Allowed Glycine 0 N--CA 1.482 1.724 0 N-CA-C 108.806 -1.718 . . . . 0.0 108.806 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -115.78 139.75 49.88 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-N 119.268 1.534 . . . . 0.0 110.512 -179.317 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.47 28.84 31.74 Favored Glycine 0 N--CA 1.491 2.354 0 C-N-CA 119.13 -1.51 . . . . 0.0 109.971 179.535 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.549 HD22 ' HG3' ' A' ' 105' ' ' PRO . 1.6 mt -92.19 175.28 6.91 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.977 -1.308 . . . . 0.0 108.613 -179.875 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.11 97.03 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.287 0 O-C-N 121.014 -1.054 . . . . 0.0 109.661 -179.811 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.656 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 76.69 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.384 -178.988 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.84 33.82 0.32 Allowed Glycine 0 N--CA 1.486 2.002 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 179.451 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.613 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -147.0 114.53 6.35 Favored 'General case' 0 C--N 1.308 -1.227 0 O-C-N 120.843 -1.387 . . . . 0.0 111.084 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -45.18 127.11 6.69 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.788 178.561 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.613 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 10.2 m-85 -117.75 149.34 40.94 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.484 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.493 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -101.01 152.64 20.34 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.867 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.64 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.5 p -137.19 118.55 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.958 -1.089 . . . . 0.0 109.767 -177.759 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.34 -178.7 39.22 Favored Glycine 0 N--CA 1.495 2.607 0 C-N-CA 118.341 -1.885 . . . . 0.0 111.863 -179.733 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.59 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.35 109.36 21.54 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.928 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.47 149.54 52.09 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.146 -0.971 . . . . 0.0 109.839 179.84 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.538 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.24 138.49 54.4 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.234 -0.916 . . . . 0.0 110.736 -179.039 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.895 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.17 114.97 26.82 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 178.02 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.2 m -105.28 14.91 7.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 120.997 -1.064 . . . . 0.0 110.583 -178.794 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.764 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.68 -175.0 0.08 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.925 -1.11 . . . . 0.0 110.014 179.704 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -72.64 97.64 2.2 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.448 -0.782 . . . . 0.0 109.702 -179.753 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.62 28.3 29.97 Favored Glycine 0 N--CA 1.494 2.544 0 C-N-CA 120.211 -0.995 . . . . 0.0 111.341 179.005 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.764 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.43 106.11 19.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 O-C-N 120.499 -1.589 . . . . 0.0 107.207 178.854 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.895 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.1 tp -116.59 104.69 11.65 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.568 -1.332 . . . . 0.0 109.866 -177.66 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.1 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.15 109.3 22.08 Favored 'General case' 0 N--CA 1.485 1.298 0 O-C-N 120.856 -1.152 . . . . 0.0 108.06 178.633 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.79 163.36 13.18 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.985 -1.072 . . . . 0.0 110.182 -178.908 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.721 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 9.9 t-20 -108.95 135.76 20.11 Favored Pre-proline 0 N--CA 1.499 2.002 0 O-C-N 121.281 -0.887 . . . . 0.0 109.944 -179.136 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.3 Cg_endo -74.72 23.96 0.38 Allowed 'Trans proline' 0 C--N 1.319 -1.017 0 C-N-CA 122.417 2.078 . . . . 0.0 112.069 -179.992 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.721 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -114.44 3.28 14.91 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.323 -1.486 . . . . 0.0 109.198 179.632 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.529 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.67 14.77 3.15 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 179.154 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -78.7 87.77 4.6 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.039 -0.665 . . . . 0.0 110.871 -178.558 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.64 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -104.98 -167.93 1.41 Allowed 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.057 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.88 135.77 0.09 Allowed 'General case' 0 C--N 1.304 -1.404 0 O-C-N 120.555 -1.34 . . . . 0.0 111.38 -179.192 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.902 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -154.06 156.91 4.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 178.034 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.62 145.33 26.39 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.665 -1.272 . . . . 0.0 109.831 -179.612 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.009 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.05 107.09 1.78 Allowed 'General case' 0 C--N 1.298 -1.63 0 CA-C-O 122.433 1.111 . . . . 0.0 109.472 178.936 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.4 p-10 -59.62 -139.43 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.037 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.728 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.656 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.9 -50.11 64.58 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.374 -0.829 . . . . 0.0 110.361 -178.822 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -102.56 -35.54 8.7 Favored 'General case' 0 C--N 1.286 -2.186 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 178.488 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.988 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.91 67.31 0.62 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.541 -1.023 . . . . 0.0 110.541 178.166 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.583 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 38.4 m -101.6 127.86 48.13 Favored 'General case' 0 N--CA 1.485 1.325 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 178.688 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.902 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.03 108.82 7.04 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.503 -179.37 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 18.4 p -126.11 120.56 30.49 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.348 -0.845 . . . . 0.0 109.565 -179.888 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.37 146.25 31.5 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.669 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.2 p -98.61 131.25 44.96 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.162 -0.961 . . . . 0.0 109.588 -179.663 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.76 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -128.92 166.22 19.55 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.403 -0.811 . . . . 0.0 109.341 -179.514 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.822 HG22 HG22 ' A' ' 18' ' ' VAL . 1.7 p -97.65 125.1 42.23 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.986 -1.072 . . . . 0.0 109.373 -179.999 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.556 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.2 m -137.26 143.48 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.047 -1.033 . . . . 0.0 109.785 -179.149 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.615 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -146.44 -177.48 5.65 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.531 -1.355 . . . . 0.0 111.249 -179.927 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.583 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.05 -100.2 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -179.655 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.515 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.21 140.13 50.6 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 120.71 -1.244 . . . . 0.0 107.888 179.309 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.569 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -161.91 136.65 7.06 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 118.513 -1.275 . . . . 0.0 109.918 -178.015 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.508 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 6.4 mt-10 -34.78 121.34 0.52 Allowed 'General case' 0 N--CA 1.489 1.485 0 CA-C-O 121.434 0.635 . . . . 0.0 110.423 -178.61 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.1 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.75 51.54 2.0 Allowed Glycine 0 N--CA 1.495 2.593 0 C-N-CA 120.563 -0.827 . . . . 0.0 111.125 -179.22 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.23 115.63 0.51 Allowed 'General case' 0 N--CA 1.506 2.371 0 O-C-N 121.154 -1.204 . . . . 0.0 110.121 179.453 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.706 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.89 126.56 34.75 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 120.831 -1.168 . . . . 0.0 109.575 -179.741 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -64.2 58.3 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.913 -1.117 . . . . 0.0 110.065 179.513 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.54 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.1 t70 -159.53 19.24 0.17 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.982 -1.074 . . . . 0.0 109.709 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.07 -27.19 5.64 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.822 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 p -95.99 161.6 13.92 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 120.994 -1.298 . . . . 0.0 110.397 -179.393 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.478 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.75 137.53 44.61 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.673 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.706 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.08 -19.65 39.76 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.747 -1.221 . . . . 0.0 110.507 -178.648 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.15 176.36 19.05 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.709 -1.757 . . . . 0.0 108.709 -179.499 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.94 105.7 1.39 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.015 -1.285 . . . . 0.0 107.783 179.158 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.65 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.9 t -77.12 105.82 6.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 O-C-N 121.367 -0.833 . . . . 0.0 109.229 -178.903 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.547 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -65.48 111.3 3.03 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.483 -0.761 . . . . 0.0 110.012 -179.445 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.583 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.05 -5.88 3.48 Favored 'General case' 0 N--CA 1.499 2.015 0 C-N-CA 118.273 -1.371 . . . . 0.0 109.8 179.486 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -86.89 -0.18 56.05 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.713 -1.242 . . . . 0.0 109.26 179.496 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.547 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.32 -50.33 2.87 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.34 -0.85 . . . . 0.0 109.006 179.886 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.69 -179.9 4.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.581 -0.699 . . . . 0.0 109.344 179.833 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.69 115.91 31.36 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.895 . . . . 0.0 109.003 179.981 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.521 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.86 120.77 37.81 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.826 -1.171 . . . . 0.0 109.368 -179.409 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.43 145.96 28.25 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 122.355 1.074 . . . . 0.0 111.117 -179.283 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.526 ' CG1' HG11 ' A' ' 7' ' ' VAL . 60.5 t -101.25 109.77 26.47 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.013 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 177.362 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.469 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -146.64 -171.32 15.83 Favored Glycine 0 N--CA 1.486 2.0 0 C-N-CA 118.212 -1.946 . . . . 0.0 111.619 -177.284 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.495 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -123.22 179.64 4.63 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -178.631 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.296 -1.727 0 O-C-N 121.482 -0.761 . . . . 0.0 109.513 -179.862 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.845 0 N-CA-C 107.604 -2.198 . . . . 0.0 107.604 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.09 -177.67 5.91 Favored 'General case' 0 C--N 1.307 -1.282 0 O-C-N 121.668 -0.901 . . . . 0.0 109.808 179.338 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.09 -161.81 21.25 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 -179.368 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.549 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.3 Cg_exo -45.37 172.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.69 0 CA-C-N 118.81 1.305 . . . . 0.0 110.094 179.303 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -92.49 -178.7 4.98 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.084 -1.01 . . . . 0.0 110.608 -178.659 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.469 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -115.08 164.53 12.09 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.88 133.12 48.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.411 -1.052 . . . . 0.0 109.28 -179.282 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.02 119.3 17.07 Favored 'General case' 0 C--N 1.289 -2.022 0 O-C-N 121.655 -0.653 . . . . 0.0 109.474 179.646 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.876 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.14 172.07 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.175 -0.953 . . . . 0.0 109.101 179.944 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.541 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.3 OUTLIER -138.49 155.86 48.04 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.104 -0.997 . . . . 0.0 109.892 -179.695 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.876 ' CE2' HD12 ' A' ' 110' ' ' ILE . 87.0 m-85 . . . . . 0 N--CA 1.485 1.303 0 O-C-N 121.325 -0.859 . . . . 0.0 109.613 -179.783 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.526 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.489 1.477 0 CA-C-O 122.372 1.082 . . . . 0.0 110.701 . . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.951 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.3 t -112.91 108.7 17.74 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 123.106 1.431 . . . . 0.0 109.19 179.367 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.871 HG22 HG23 ' A' ' 21' ' ' VAL . 3.7 t -116.34 142.51 29.58 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.667 0 CA-C-N 114.347 -1.297 . . . . 0.0 110.203 -179.615 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.504 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -178.16 150.45 0.74 Allowed Pre-proline 0 N--CA 1.488 1.454 0 O-C-N 121.278 -0.888 . . . . 0.0 108.715 -179.737 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.504 ' HA ' HG23 ' A' ' 8' ' ' THR . 1.9 Cg_endo -75.05 153.73 99.25 Favored 'Cis proline' 0 C--N 1.312 -1.362 0 C-N-CA 123.577 -1.426 . . . . 0.0 109.471 -0.644 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.3 m -91.4 -25.35 19.4 Favored 'General case' 0 C--N 1.292 -1.912 0 O-C-N 121.63 -0.669 . . . . 0.0 109.428 -179.94 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.505 ' HB3' ' CB ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -137.9 163.35 31.69 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.338 -0.851 . . . . 0.0 109.905 -179.619 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.72 37.14 27.25 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 108.773 -1.731 . . . . 0.0 108.773 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.749 ' CA ' HG21 ' A' ' 17' ' ' THR . 44.2 mt -93.05 -44.22 8.5 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 123.249 1.5 . . . . 0.0 110.547 -178.533 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.445 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.48 145.75 0.03 OUTLIER 'General case' 0 C--N 1.262 -3.203 0 CA-C-N 113.473 -1.694 . . . . 0.0 109.999 -179.796 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.544 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.0 p-10 -51.93 105.1 0.1 Allowed 'General case' 0 C--N 1.303 -1.451 0 CA-C-O 121.49 0.662 . . . . 0.0 111.088 -179.05 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.95 6.66 6.96 Favored Glycine 0 N--CA 1.486 1.983 0 C-N-CA 119.18 -1.486 . . . . 0.0 113.194 177.518 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.749 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.6 t -105.14 -174.45 2.54 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 121.437 2.618 . . . . 0.0 109.922 179.709 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.782 HG22 HG22 ' A' ' 68' ' ' THR . 21.6 t -127.02 135.94 62.2 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.579 -1.191 . . . . 0.0 110.955 -178.778 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.622 ' CG1' HD13 ' A' ' 13' ' ' LEU . 32.5 m -109.54 154.79 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 178.795 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -110.56 109.25 19.5 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.198 -0.939 . . . . 0.0 108.825 179.776 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.871 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -104.32 140.46 22.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.951 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.18 160.32 38.73 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 118.74 -1.184 . . . . 0.0 109.857 179.649 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.59 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.44 143.55 15.2 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 108.021 -2.032 . . . . 0.0 108.021 179.789 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.12 125.26 12.91 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 120.843 -1.386 . . . . 0.0 108.846 179.289 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.98 26.8 25.5 Favored Glycine 0 N--CA 1.488 2.124 0 C-N-CA 119.371 -1.395 . . . . 0.0 109.704 -179.698 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.5 mt -86.27 175.83 8.25 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.921 -1.341 . . . . 0.0 108.557 -179.813 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.44 96.9 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.028 -1.045 . . . . 0.0 109.556 -179.771 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.637 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.26 76.32 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.715 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.541 -178.989 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.32 33.93 0.3 Allowed Glycine 0 N--CA 1.484 1.876 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.304 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.558 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 1.2 t -148.64 114.97 5.87 Favored 'General case' 0 C--N 1.308 -1.21 0 O-C-N 120.774 -1.427 . . . . 0.0 111.333 179.955 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.13 130.05 3.65 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.798 178.376 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.553 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 7.7 m-85 -121.41 147.93 45.06 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.583 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.498 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.96 156.71 17.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.626 -1.296 . . . . 0.0 107.771 178.719 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.644 HG13 ' O ' ' A' ' 34' ' ' VAL . 5.5 p -140.27 117.27 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.066 -1.021 . . . . 0.0 109.867 -177.789 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.518 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.29 -176.92 39.06 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.942 -179.739 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.64 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.4 pt20 -99.83 109.96 22.35 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 121.874 0.845 . . . . 0.0 109.02 -179.648 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.497 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -130.35 150.12 51.73 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.223 -0.923 . . . . 0.0 109.679 179.703 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.457 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.69 138.29 54.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.197 -0.94 . . . . 0.0 110.968 -178.945 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.38 115.0 26.83 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 177.982 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.458 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 19.8 m -105.77 14.72 7.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 120.993 -1.067 . . . . 0.0 110.646 -178.732 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.756 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.32 -174.71 0.09 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.04 -1.037 . . . . 0.0 110.011 179.614 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.84 97.03 1.73 Allowed 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.439 -0.788 . . . . 0.0 109.709 -179.77 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.28 27.8 32.3 Favored Glycine 0 N--CA 1.493 2.492 0 C-N-CA 120.149 -1.024 . . . . 0.0 111.481 178.849 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.756 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.32 106.45 20.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 O-C-N 120.688 -1.477 . . . . 0.0 107.252 178.975 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.5 tp -115.38 104.8 12.15 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.4 -1.437 . . . . 0.0 110.019 -177.715 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.986 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.68 109.71 22.41 Favored 'General case' 0 N--CA 1.486 1.372 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.801 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.51 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -109.08 168.34 9.44 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.059 -1.026 . . . . 0.0 110.365 -178.744 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.55 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 22.3 t-20 -118.09 135.08 23.32 Favored Pre-proline 0 N--CA 1.499 2.01 0 O-C-N 121.353 -0.842 . . . . 0.0 110.101 -179.438 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.589 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.5 Cg_endo -73.66 23.33 0.33 Allowed 'Trans proline' 0 CA--C 1.545 1.045 0 C-N-CA 122.223 1.949 . . . . 0.0 112.181 179.901 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.55 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -108.82 1.99 21.31 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.345 -1.472 . . . . 0.0 109.079 179.406 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.53 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.11 17.41 2.27 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.643 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -81.06 90.37 6.0 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.524 -0.735 . . . . 0.0 110.891 -178.606 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.69 -166.87 1.19 Allowed 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 178.145 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.448 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.72 134.92 0.09 Allowed 'General case' 0 C--N 1.306 -1.311 0 O-C-N 120.524 -1.36 . . . . 0.0 111.666 -179.356 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.803 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.5 p -150.94 157.38 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 177.862 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.57 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.19 146.07 25.44 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.496 -1.377 . . . . 0.0 109.741 -179.648 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.09 108.55 3.15 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 122.302 1.048 . . . . 0.0 109.589 179.009 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.541 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.7 t70 -63.69 -139.03 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.999 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.663 179.938 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.637 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.92 -51.74 49.11 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.343 -0.848 . . . . 0.0 110.679 -178.672 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -102.58 -32.7 9.78 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 106.517 -1.66 . . . . 0.0 106.517 178.662 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.006 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 105.36 66.32 0.67 Allowed Glycine 0 C--N 1.297 -1.591 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.18 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.59 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 58.0 p -98.66 131.96 44.42 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 121.378 -1.072 . . . . 0.0 109.097 179.006 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.803 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.43 108.32 6.32 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 119.319 -0.953 . . . . 0.0 109.52 -179.642 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.6 m -124.67 119.13 28.1 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.094 -1.004 . . . . 0.0 109.701 -179.939 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.593 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.33 144.16 29.6 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.448 -0.782 . . . . 0.0 109.363 179.853 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.8 p -99.12 141.51 31.8 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.316 -0.865 . . . . 0.0 109.191 179.838 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.827 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.83 167.94 20.94 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.449 -0.782 . . . . 0.0 109.551 -179.23 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.782 HG22 HG22 ' A' ' 18' ' ' VAL . 2.0 p -98.18 126.82 43.8 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.094 -1.004 . . . . 0.0 109.319 -179.761 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.502 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 15.4 m -134.44 140.53 45.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.879 -1.138 . . . . 0.0 110.091 -179.198 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.544 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 52.2 mtt180 -127.56 -165.52 1.49 Allowed 'General case' 0 N--CA 1.485 1.315 0 O-C-N 120.676 -1.265 . . . . 0.0 111.255 -179.821 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.574 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 1.0 OUTLIER -80.48 -79.64 0.15 Allowed 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.209 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.511 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -68.85 136.45 52.7 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 177.9 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.573 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.03 137.64 9.76 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 117.803 -1.559 . . . . 0.0 110.735 -177.325 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.526 ' HB3' ' CD1' ' A' ' 76' ' ' PHE . 8.0 mm-40 -33.72 119.2 0.37 Allowed 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 121.638 0.732 . . . . 0.0 110.58 -178.69 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.986 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -87.92 48.4 3.67 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.316 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.589 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 19.0 m-85 -39.21 113.92 0.36 Allowed 'General case' 0 N--CA 1.507 2.385 0 O-C-N 121.157 -1.202 . . . . 0.0 110.136 179.591 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.746 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -87.67 127.04 35.29 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.993 -1.067 . . . . 0.0 109.474 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -64.51 58.29 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.753 -1.217 . . . . 0.0 110.056 179.674 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.7 t70 -159.52 19.0 0.17 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.042 -1.036 . . . . 0.0 109.721 179.948 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.68 -26.56 5.8 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.84 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 72.4 p -95.15 160.56 14.5 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.021 -1.281 . . . . 0.0 110.417 -179.343 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.482 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 1.3 ptt180 -105.63 134.84 48.1 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.66 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.746 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.0 t90 -81.21 -20.01 42.03 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.823 -1.173 . . . . 0.0 110.234 -178.623 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.26 173.64 18.25 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 108.739 -1.745 . . . . 0.0 108.739 -179.572 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.67 111.45 2.09 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 179.251 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.653 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.7 t -83.1 103.91 11.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 O-C-N 121.35 -0.844 . . . . 0.0 108.798 -179.062 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.542 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.8 111.41 3.24 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.448 -0.783 . . . . 0.0 109.971 -179.094 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.57 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -63.96 -5.12 4.03 Favored 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 118.426 -1.31 . . . . 0.0 109.834 179.372 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.9 p -87.89 2.09 52.41 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.841 -1.162 . . . . 0.0 109.052 179.415 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.542 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -116.72 -51.23 2.59 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.329 -0.857 . . . . 0.0 108.939 -179.99 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.1 179.5 4.25 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.512 -0.742 . . . . 0.0 109.371 179.869 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.34 116.52 32.58 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.362 -0.836 . . . . 0.0 108.925 179.917 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.505 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.9 m -96.73 120.71 37.56 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.894 -1.129 . . . . 0.0 109.357 -179.41 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.616 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.67 145.56 28.92 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 122.373 1.083 . . . . 0.0 111.283 -179.12 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.427 ' CG1' HG11 ' A' ' 7' ' ' VAL . 62.6 t -101.71 109.81 26.92 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.037 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 177.537 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.451 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.85 -170.91 16.33 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 118.174 -1.965 . . . . 0.0 111.851 -177.467 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.526 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -121.6 178.98 4.61 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -178.859 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.472 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.7 OUTLIER . . . . . 0 C--N 1.297 -1.704 0 O-C-N 121.564 -0.71 . . . . 0.0 109.562 179.999 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.421 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.481 1.698 0 N-CA-C 107.946 -2.061 . . . . 0.0 107.946 . . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.421 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.99 -177.0 3.6 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 121.609 -0.936 . . . . 0.0 109.756 179.367 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.25 -161.36 17.96 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.27 -1.932 . . . . 0.0 108.27 -179.396 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.532 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.6 Cg_exo -46.6 176.5 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.664 0 CA-C-N 118.841 1.32 . . . . 0.0 110.203 179.287 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -93.85 -168.88 1.97 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.118 -0.989 . . . . 0.0 110.39 -178.927 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.451 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -123.88 163.47 17.51 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.736 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.14 129.67 49.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.409 -1.054 . . . . 0.0 109.123 -179.679 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.616 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.58 118.97 16.15 Favored 'General case' 0 C--N 1.288 -2.085 0 O-C-N 121.703 -0.623 . . . . 0.0 109.759 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.66 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.4 pt -98.07 168.0 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 121.249 -0.907 . . . . 0.0 109.065 179.803 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.505 ' CB ' ' HB3' ' A' ' 11' ' ' SER . 0.2 OUTLIER -132.28 156.89 45.74 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.281 -0.887 . . . . 0.0 109.666 -179.876 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.617 ' CE2' HD12 ' A' ' 110' ' ' ILE . 41.4 m-85 . . . . . 0 N--CA 1.487 1.42 0 O-C-N 121.272 -0.893 . . . . 0.0 109.357 -179.852 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.565 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.412 0 CA-C-O 122.165 0.983 . . . . 1.0 110.961 . . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.005 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -102.0 104.52 15.19 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 122.408 1.099 . . . . 1.0 110.088 -179.84 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 1.018 HG22 HG23 ' A' ' 21' ' ' VAL . 5.9 t -119.5 123.55 71.33 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.448 0 CA-C-N 115.521 -0.763 . . . . 1.0 110.516 179.822 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.48 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -170.95 150.02 2.9 Favored Pre-proline 0 N--CA 1.488 1.451 0 N-CA-C 108.086 -1.079 . . . . 1.0 108.086 -179.649 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.48 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.0 Cg_endo -76.79 151.37 94.16 Favored 'Cis proline' 0 C--N 1.311 -1.434 0 C-N-CA 123.658 -1.393 . . . . 1.0 109.533 -0.526 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.683 ' HA ' HG22 ' A' ' 110' ' ' ILE . 95.2 p -95.4 -21.47 18.34 Favored 'General case' 0 C--N 1.293 -1.888 0 O-C-N 121.649 -0.657 . . . . 1.0 109.643 179.954 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.489 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.3 m -131.54 157.11 44.45 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.256 -0.903 . . . . 1.0 110.221 -179.583 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.39 37.11 25.04 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 108.794 -1.722 . . . . 1.0 108.794 -179.719 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.807 ' HA ' HG21 ' A' ' 17' ' ' THR . 35.4 mt -92.1 -44.78 8.63 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 123.201 1.477 . . . . 1.0 110.542 -178.59 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.442 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.1 t 63.8 147.52 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.25 0 CA-C-N 113.562 -1.654 . . . . 1.0 110.045 -179.815 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.521 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.5 p-10 -51.65 105.16 0.1 Allowed 'General case' 0 C--N 1.303 -1.438 0 CA-C-O 121.665 0.745 . . . . 1.0 111.106 -178.997 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.31 7.39 7.02 Favored Glycine 0 N--CA 1.485 1.954 0 C-N-CA 119.319 -1.42 . . . . 1.0 113.318 177.323 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.807 HG21 ' HA ' ' A' ' 13' ' ' LEU . 14.9 t -106.42 -177.46 3.37 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 121.468 2.634 . . . . 1.0 110.325 179.654 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.858 HG22 HG22 ' A' ' 68' ' ' THR . 21.9 t -128.3 139.69 51.22 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.374 0 CA-C-N 114.076 -1.42 . . . . 1.0 111.091 -178.717 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.671 HG11 HD11 ' A' ' 13' ' ' LEU . 15.7 m -117.19 154.68 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.35 -0.981 . . . . 1.0 108.35 178.739 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.545 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -104.1 108.79 20.32 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.139 -0.975 . . . . 1.0 109.304 -179.886 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 1.018 HG23 HG22 ' A' ' 7' ' ' VAL . 2.4 p -106.34 123.27 61.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 N-CA-C 108.299 -1.001 . . . . 1.0 108.299 179.571 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.005 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.67 167.21 11.55 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 120.681 -1.262 . . . . 1.0 109.22 -179.831 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.617 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.77 139.1 10.61 Favored Glycine 0 C--N 1.294 -1.779 0 N-CA-C 107.282 -2.327 . . . . 1.0 107.282 179.51 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -145.39 125.35 13.56 Favored 'General case' 0 C--N 1.293 -1.866 0 O-C-N 120.522 -1.575 . . . . 1.0 108.991 179.613 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.23 26.35 28.62 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 119.013 -1.565 . . . . 1.0 109.952 -179.798 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.566 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.3 mt -86.5 174.34 9.02 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 120.885 -1.362 . . . . 1.0 108.29 179.743 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.021 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.41 99.28 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.412 0 O-C-N 120.855 -1.153 . . . . 1.0 109.743 -179.605 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.585 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.11 77.74 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.304 -0.862 . . . . 1.0 110.246 -179.271 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.9 34.47 0.3 Allowed Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.464 -1.454 . . . . 1.0 109.464 179.587 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 53.4 p -142.82 108.75 5.17 Favored 'General case' 0 C--N 1.308 -1.221 0 O-C-N 121.039 -1.271 . . . . 1.0 111.214 -179.416 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.594 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.92 109.92 0.34 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 109.393 -0.595 . . . . 1.0 109.393 177.807 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.491 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.7 m-30 -104.9 155.4 18.96 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.119 -0.988 . . . . 1.0 108.878 179.874 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.82 162.01 13.33 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.804 -1.185 . . . . 1.0 108.077 178.934 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.63 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.9 p -141.91 120.36 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.166 -0.959 . . . . 1.0 109.307 -178.217 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' HB2' ' A' ' 51' ' ' ASP . . . -171.88 -176.48 40.83 Favored Glycine 0 N--CA 1.495 2.571 0 C-N-CA 118.412 -1.851 . . . . 1.0 111.583 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.657 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -101.15 109.19 21.03 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 108.909 -0.774 . . . . 1.0 108.909 -179.908 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.492 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.0 m -130.14 149.06 52.02 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.277 -0.89 . . . . 1.0 109.682 179.585 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.525 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.54 138.72 54.51 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.236 -0.915 . . . . 1.0 110.793 -178.93 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.2 114.77 26.6 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 107.532 -1.284 . . . . 1.0 107.532 178.047 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 m -104.85 14.72 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.931 -1.106 . . . . 1.0 110.481 -178.793 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.75 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.1 -175.24 0.09 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.98 -1.075 . . . . 1.0 110.049 179.748 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.51 97.79 2.17 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.519 -0.738 . . . . 1.0 109.577 -179.75 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.46 27.75 31.94 Favored Glycine 0 N--CA 1.492 2.414 0 C-N-CA 120.214 -0.993 . . . . 1.0 111.399 178.94 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.75 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.22 106.48 20.18 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.558 -1.554 . . . . 1.0 107.357 178.81 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.4 104.72 11.74 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.475 -1.391 . . . . 1.0 109.954 -177.629 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.007 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.65 109.53 22.27 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 107.812 -1.181 . . . . 1.0 107.812 178.871 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -108.05 166.74 10.5 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.869 -1.145 . . . . 1.0 110.727 -178.455 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.487 ' OD1' ' HB2' ' A' ' 74' ' ' GLU . 46.4 t30 -118.51 136.72 24.2 Favored Pre-proline 0 N--CA 1.498 1.971 0 C-N-CA 120.098 -0.641 . . . . 1.0 109.64 -179.497 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HD3' ' CE1' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -74.03 26.41 0.33 Allowed 'Trans proline' 0 C--N 1.317 -1.111 0 C-N-CA 122.437 2.092 . . . . 1.0 112.01 -179.89 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.447 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -98.54 -9.55 24.78 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.319 -1.488 . . . . 1.0 109.164 179.735 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.801 ' HB3' HD22 ' A' ' 67' ' ' LEU . 0.8 OUTLIER -135.68 7.4 3.26 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.383 -0.823 . . . . 1.0 108.872 -179.81 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -60.75 84.1 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.427 -0.796 . . . . 1.0 110.898 -178.569 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.63 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.78 -167.02 1.17 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.852 -1.166 . . . . 1.0 107.852 178.33 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.477 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.7 t 179.1 135.25 0.09 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.569 -1.332 . . . . 1.0 111.43 -179.364 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.789 HG11 ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -150.46 157.77 5.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 N-CA-C 107.537 -1.283 . . . . 1.0 107.537 177.914 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.63 142.1 30.63 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.734 -1.229 . . . . 1.0 110.051 -179.747 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.021 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.36 107.68 1.41 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 122.331 1.062 . . . . 1.0 109.38 178.524 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.558 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.6 p-10 -62.04 -138.81 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 115.612 -0.722 . . . . 1.0 110.861 -179.778 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.585 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.87 -51.82 37.5 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.344 -0.847 . . . . 1.0 110.737 -178.599 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -104.57 -32.91 8.72 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 106.261 -1.755 . . . . 1.0 106.261 178.508 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.988 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.57 69.88 0.67 Allowed Glycine 0 C--N 1.298 -1.574 0 N-CA-C 110.299 -1.12 . . . . 1.0 110.299 178.104 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.617 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 63.7 m -104.07 129.98 51.75 Favored 'General case' 0 N--CA 1.483 1.175 0 O-C-N 121.259 -1.142 . . . . 1.0 109.275 179.14 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.789 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.4 108.96 8.46 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.535 -0.866 . . . . 1.0 109.484 -179.638 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 97.2 p -116.21 117.02 28.87 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.117 -0.989 . . . . 1.0 109.492 -179.747 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.61 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.27 139.93 26.13 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.385 -0.822 . . . . 1.0 110.077 -179.84 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 27.2 p -99.61 135.26 41.29 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.822 -0.807 . . . . 1.0 108.822 179.432 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.94 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -136.22 168.52 19.24 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.292 -0.88 . . . . 1.0 110.057 -178.931 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.858 HG22 HG22 ' A' ' 18' ' ' VAL . 1.2 p -104.06 126.26 51.04 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.192 -0.942 . . . . 1.0 109.329 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.735 HG13 ' OD2' ' A' ' 51' ' ' ASP . 12.3 m -129.41 139.99 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 120.922 -1.111 . . . . 1.0 110.209 -179.26 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.521 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 52.4 mtt180 -125.67 -168.57 1.86 Allowed 'General case' 0 N--CA 1.484 1.23 0 O-C-N 120.676 -1.265 . . . . 1.0 111.304 179.823 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.588 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 40.0 mtt180 -78.5 -75.71 0.22 Allowed 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.2 -1.037 . . . . 1.0 108.2 179.284 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -72.67 137.06 45.79 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 120.14 -1.6 . . . . 1.0 106.812 178.107 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -157.66 135.51 10.73 Favored 'General case' 0 C--N 1.295 -1.784 0 C-N-CA 118.08 -1.448 . . . . 1.0 110.308 -177.903 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.601 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 9.5 mm-40 -34.78 121.62 0.52 Allowed 'General case' 0 N--CA 1.487 1.41 0 CA-C-O 121.582 0.706 . . . . 1.0 110.364 -178.259 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.007 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -87.76 47.94 3.64 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 110.986 -0.846 . . . . 1.0 110.986 -179.377 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.601 ' CE1' ' HB3' ' A' ' 74' ' ' GLU . 36.2 m-85 -39.76 112.95 0.3 Allowed 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.07 -1.253 . . . . 1.0 110.001 179.614 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.738 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -87.03 126.64 34.88 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.995 -1.066 . . . . 1.0 109.493 -179.912 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -63.99 58.34 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.735 -1.228 . . . . 1.0 110.315 179.674 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.26 19.15 0.15 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.01 -1.056 . . . . 1.0 109.765 179.854 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.31 -26.18 5.81 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.097 -1.201 . . . . 1.0 110.097 179.78 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -94.07 160.0 14.91 Favored 'General case' 0 N--CA 1.485 1.311 0 O-C-N 121.011 -1.288 . . . . 1.0 110.49 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.476 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -105.89 133.39 50.69 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 108.581 -0.896 . . . . 1.0 108.581 179.701 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.738 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.1 t90 -80.93 -20.28 42.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.809 -1.182 . . . . 1.0 110.256 -178.701 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.92 174.19 18.62 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.9 -1.68 . . . . 1.0 108.9 -179.59 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.06 110.04 1.69 Allowed 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.143 -1.21 . . . . 1.0 107.743 179.269 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.678 HG21 ' HB3' ' A' ' 46' ' ' ALA . 44.4 t -82.32 104.45 10.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.696 0 N-CA-C 108.715 -0.846 . . . . 1.0 108.715 -179.098 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.529 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -67.11 111.07 3.69 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.322 -0.861 . . . . 1.0 109.893 -179.119 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.588 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -64.04 -5.23 4.33 Favored 'General case' 0 N--CA 1.501 2.083 0 C-N-CA 118.465 -1.294 . . . . 1.0 109.869 179.394 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -86.69 2.04 49.92 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.757 -1.214 . . . . 1.0 108.923 179.363 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.529 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -117.05 -51.11 2.56 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.478 -0.764 . . . . 1.0 108.967 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -102.57 -179.92 4.11 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.498 -0.751 . . . . 1.0 109.381 179.883 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.84 115.25 29.98 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.349 -0.845 . . . . 1.0 108.979 179.923 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.56 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.88 122.25 39.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.807 -1.183 . . . . 1.0 109.464 -179.278 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.618 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -101.75 145.35 29.26 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 122.449 1.119 . . . . 1.0 111.184 -179.3 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.614 ' HB ' HG11 ' A' ' 7' ' ' VAL . 65.2 t -102.68 110.59 29.76 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 N-CA-C 106.892 -1.521 . . . . 1.0 106.892 177.815 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.491 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.11 -169.63 18.47 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 118.177 -1.963 . . . . 1.0 111.75 -177.712 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.52 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -120.02 177.06 5.13 Favored 'General case' 0 N--CA 1.489 1.485 0 CA-C-O 121.69 0.757 . . . . 1.0 109.113 -178.931 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.491 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.717 0 N-CA-C 109.276 -0.639 . . . . 1.0 109.276 179.801 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.677 0 N-CA-C 107.703 -2.159 . . . . 1.0 107.703 . . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.31 -178.08 6.69 Favored 'General case' 0 C--N 1.305 -1.326 0 O-C-N 121.554 -0.968 . . . . 1.0 109.749 179.322 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.35 -161.31 18.01 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.326 -1.91 . . . . 1.0 108.326 -179.293 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.487 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.4 Cg_exo -47.33 179.82 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 CA-C-N 118.783 1.292 . . . . 1.0 110.368 179.322 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -95.59 -170.82 2.23 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.053 -1.029 . . . . 1.0 110.236 -179.075 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.491 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -125.37 164.53 18.91 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.693 -1.363 . . . . 1.0 109.693 -179.846 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.56 128.55 49.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 O-C-N 121.436 -1.038 . . . . 1.0 109.103 -179.535 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.618 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.56 120.91 19.81 Favored 'General case' 0 C--N 1.289 -2.036 0 O-C-N 121.735 -0.603 . . . . 1.0 109.835 179.957 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.683 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.4 pt -98.03 168.11 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.315 -0.866 . . . . 1.0 109.037 179.722 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.489 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -134.98 158.6 43.9 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.305 -0.872 . . . . 1.0 109.428 179.976 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.548 ' CE2' HD12 ' A' ' 110' ' ' ILE . 42.2 m-85 . . . . . 0 N--CA 1.49 1.53 0 O-C-N 121.191 -0.943 . . . . 1.0 109.392 -179.786 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.546 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.424 0 CA-C-O 122.11 0.957 . . . . 1.0 111.098 . . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.023 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -99.7 104.3 16.02 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 122.353 1.073 . . . . 1.0 109.918 -179.965 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.945 HG22 HG23 ' A' ' 21' ' ' VAL . 4.0 t -121.6 117.1 51.5 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-O 121.603 0.716 . . . . 1.0 110.341 179.587 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.518 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -165.94 150.04 7.21 Favored Pre-proline 0 N--CA 1.487 1.41 0 N-CA-C 108.213 -1.032 . . . . 1.0 108.213 -179.646 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.518 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.8 Cg_endo -77.72 151.76 92.04 Favored 'Cis proline' 0 C--N 1.31 -1.463 0 C-N-CA 123.608 -1.413 . . . . 1.0 109.512 -0.615 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.712 ' HA ' HG22 ' A' ' 110' ' ' ILE . 85.7 p -92.85 -25.66 18.0 Favored 'General case' 0 C--N 1.293 -1.857 0 O-C-N 121.435 -0.791 . . . . 1.0 108.895 179.42 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 111' ' ' SER . 3.0 m -131.9 161.37 33.2 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.455 -0.778 . . . . 1.0 109.413 -179.912 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.59 36.55 33.19 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 108.627 -1.789 . . . . 1.0 108.627 -179.566 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.772 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.6 mt -91.19 -42.69 10.29 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.298 1.523 . . . . 1.0 110.37 -178.505 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.5 143.62 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.284 0 CA-C-N 113.292 -1.776 . . . . 1.0 109.809 -179.585 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.602 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.1 p-10 -50.76 105.59 0.1 Allowed 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.596 0.712 . . . . 1.0 111.31 -178.655 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.47 13.64 8.02 Favored Glycine 0 N--CA 1.485 1.945 0 C-N-CA 119.316 -1.421 . . . . 1.0 113.041 177.497 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.772 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -104.8 -171.96 2.01 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 121.28 2.54 . . . . 1.0 109.755 179.28 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.739 HG13 ' C ' ' A' ' 67' ' ' LEU . 14.9 t -130.11 138.51 53.8 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.345 0 CA-C-N 114.857 -1.065 . . . . 1.0 111.261 -178.855 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.537 HG11 HD11 ' A' ' 13' ' ' LEU . 34.1 m -115.85 154.82 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.585 -0.894 . . . . 1.0 108.585 178.888 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.559 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -109.19 109.18 20.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.121 -0.987 . . . . 1.0 109.35 -179.903 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.945 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.4 123.16 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 108.357 -0.979 . . . . 1.0 108.357 179.67 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.023 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -120.85 167.24 12.73 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 120.721 -1.237 . . . . 1.0 109.386 -179.744 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -131.24 144.33 15.86 Favored Glycine 0 C--N 1.295 -1.723 0 N-CA-C 107.711 -2.155 . . . . 1.0 107.711 179.691 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -148.18 123.19 10.08 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 120.96 -1.317 . . . . 1.0 108.532 179.105 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.66 27.95 17.98 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.269 -1.443 . . . . 1.0 109.722 -179.464 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.539 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.0 OUTLIER -90.52 175.37 7.09 Favored 'General case' 0 C--N 1.308 -1.213 0 O-C-N 120.832 -1.393 . . . . 1.0 108.602 179.947 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.012 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -48.6 100.4 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.903 -1.123 . . . . 1.0 109.859 -179.817 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.43 78.57 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.679 0 CA-C-N 115.355 -0.839 . . . . 1.0 110.116 -179.375 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.573 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.81 34.44 0.3 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.283 -1.527 . . . . 1.0 109.283 179.711 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.548 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 21.4 p -139.75 105.69 5.19 Favored 'General case' 0 C--N 1.307 -1.252 0 O-C-N 121.185 -1.185 . . . . 1.0 111.155 -179.381 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.584 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.47 109.8 0.28 Allowed 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.579 -0.526 . . . . 1.0 109.579 178.057 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.429 ' CE2' ' HB3' ' A' ' 26' ' ' LEU . 8.4 m-85 -104.34 153.23 21.3 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.055 -1.028 . . . . 1.0 108.994 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.435 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.2 155.35 18.49 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.859 -1.15 . . . . 1.0 108.246 179.054 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.728 HG23 HD23 ' A' ' 97' ' ' LEU . 0.8 OUTLIER -126.91 127.89 70.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.228 -0.92 . . . . 1.0 108.973 -178.079 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -175.6 174.36 46.8 Favored Glycine 0 N--CA 1.495 2.581 0 C-N-CA 117.726 -2.178 . . . . 1.0 112.342 -179.926 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.606 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -101.09 108.84 20.63 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 107.964 -1.124 . . . . 1.0 107.964 179.577 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.461 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.0 m -129.67 147.87 51.5 Favored 'General case' 0 C--N 1.294 -1.81 0 O-C-N 121.212 -0.93 . . . . 1.0 109.969 -179.654 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.44 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.58 139.13 54.26 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.362 -0.837 . . . . 1.0 110.523 -179.133 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.876 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.08 114.72 26.56 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.411 -1.329 . . . . 1.0 107.411 178.282 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -106.11 15.35 7.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.051 -1.031 . . . . 1.0 110.541 -178.614 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.77 -175.99 0.09 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.931 -1.106 . . . . 1.0 110.02 179.761 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.79 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.29 97.09 1.19 Allowed 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.782 0.801 . . . . 1.0 109.993 -179.631 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.56 28.23 36.43 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 120.278 -0.963 . . . . 1.0 111.413 178.856 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.18 106.27 20.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 O-C-N 120.623 -1.516 . . . . 1.0 107.186 178.846 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.876 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.88 104.77 11.64 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.463 -1.398 . . . . 1.0 109.869 -177.614 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.044 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.782 -1.199 . . . . 1.0 108.219 178.815 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.0 t -106.35 164.85 11.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.945 -1.097 . . . . 1.0 110.288 -178.897 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.749 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 8.9 t-20 -107.52 134.29 20.05 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.386 -0.821 . . . . 1.0 109.648 -179.301 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.593 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.3 Cg_endo -74.96 22.88 0.41 Allowed 'Trans proline' 0 CA--C 1.544 0.998 0 C-N-CA 122.327 2.018 . . . . 1.0 111.811 -179.813 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.749 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -115.82 7.04 14.46 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.398 -1.439 . . . . 1.0 108.912 179.534 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.546 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.99 15.16 2.86 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.385 -1.339 . . . . 1.0 107.385 179.522 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -78.3 88.19 4.34 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.984 -0.686 . . . . 1.0 111.522 -178.132 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' HG12 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -97.97 -167.49 1.52 Allowed 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.718 -1.215 . . . . 1.0 107.718 177.941 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.445 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.93 135.99 0.09 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.565 -1.335 . . . . 1.0 111.542 -179.331 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.953 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -163.47 154.19 2.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 107.526 -1.287 . . . . 1.0 107.526 178.419 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.584 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.6 141.92 30.83 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.833 -1.167 . . . . 1.0 109.59 -179.945 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -61.82 105.69 0.59 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 122.493 1.139 . . . . 1.0 109.281 178.541 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.552 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.8 p-10 -58.55 -138.63 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.982 0 CA-C-N 115.443 -0.799 . . . . 1.0 110.966 -179.862 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -53.79 -49.4 68.37 Favored 'General case' 0 N--CA 1.5 2.042 0 CA-C-O 121.675 0.75 . . . . 1.0 110.409 -178.672 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 74.7 m-80 -102.38 -37.29 8.11 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 106.066 -1.827 . . . . 1.0 106.066 178.382 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.986 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 110.16 65.84 0.55 Allowed Glycine 0 C--N 1.297 -1.596 0 CA-C-N 114.774 -1.103 . . . . 1.0 110.438 177.964 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.609 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.7 m -104.43 127.3 52.09 Favored 'General case' 0 N--CA 1.483 1.179 0 O-C-N 121.563 -0.963 . . . . 1.0 109.07 179.05 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.953 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.54 109.02 7.38 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 119.519 -0.872 . . . . 1.0 109.764 -179.443 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 53.3 p -115.3 119.57 36.74 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.105 -0.997 . . . . 1.0 109.373 179.97 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.5 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.33 142.21 30.25 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.48 -0.762 . . . . 1.0 109.844 179.935 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 54.8 p -99.44 149.02 23.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.414 -0.803 . . . . 1.0 109.156 179.751 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.739 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -149.87 163.71 37.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.265 -0.897 . . . . 1.0 109.763 -178.93 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.71 HG22 HG22 ' A' ' 18' ' ' VAL . 2.5 p -96.57 126.1 41.51 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.125 -0.984 . . . . 1.0 109.259 -179.987 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.547 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.0 m -137.44 143.19 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 120.904 -1.123 . . . . 1.0 109.856 -179.102 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.602 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.9 ptt180 -147.3 -176.51 5.26 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.519 -1.363 . . . . 1.0 111.081 -179.774 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.596 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.04 -100.19 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 109.155 -0.683 . . . . 1.0 109.155 -179.714 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.52 139.97 51.96 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.779 -1.201 . . . . 1.0 107.801 179.208 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -162.45 138.79 7.62 Favored 'General case' 0 C--N 1.293 -1.89 0 C-N-CA 118.525 -1.27 . . . . 1.0 110.074 -177.819 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.564 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.8 mm-40 -34.7 120.82 0.5 Allowed 'General case' 0 N--CA 1.491 1.6 0 CA-C-O 121.395 0.617 . . . . 1.0 110.246 -178.713 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.044 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.18 50.8 1.9 Allowed Glycine 0 N--CA 1.492 2.402 0 C-N-CA 120.477 -0.868 . . . . 1.0 111.136 -179.101 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.593 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-30 -39.39 113.35 0.32 Allowed 'General case' 0 N--CA 1.507 2.424 0 O-C-N 121.057 -1.26 . . . . 1.0 109.916 179.488 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.643 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -85.73 126.78 34.23 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.835 -1.166 . . . . 1.0 109.504 -179.915 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 30.7 t80 -64.36 58.23 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.018 0 O-C-N 120.859 -1.151 . . . . 1.0 110.104 179.764 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -160.05 19.49 0.16 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.019 -1.051 . . . . 1.0 109.674 179.905 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.38 -26.71 5.52 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.154 -1.178 . . . . 1.0 110.154 179.856 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.451 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -94.27 154.81 17.33 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.06 -1.259 . . . . 1.0 110.42 -179.431 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.479 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -102.11 134.54 45.19 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.176 -1.046 . . . . 1.0 108.176 179.476 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.643 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.2 t90 -81.49 -16.6 51.41 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.784 -1.197 . . . . 1.0 110.506 -178.34 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 108.17 175.52 22.04 Favored Glycine 0 N--CA 1.485 1.921 0 N-CA-C 108.768 -1.733 . . . . 1.0 108.768 -179.675 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.44 104.32 0.61 Allowed 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 107.615 -1.254 . . . . 1.0 107.615 179.07 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.615 HG21 ' HB3' ' A' ' 46' ' ' ALA . 38.1 t -76.03 106.37 5.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.316 -0.865 . . . . 1.0 109.059 -178.862 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.37 110.65 2.33 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.507 -0.746 . . . . 1.0 109.835 -179.268 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.596 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.61 -5.08 4.88 Favored 'General case' 0 N--CA 1.498 1.938 0 C-N-CA 118.261 -1.375 . . . . 1.0 109.752 179.357 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.5 p -85.57 -1.44 57.11 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.806 -1.184 . . . . 1.0 109.216 179.606 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.81 -48.36 3.07 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.299 -0.875 . . . . 1.0 109.051 -179.984 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.31 -178.57 3.64 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.57 -0.706 . . . . 1.0 109.491 179.905 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.46 115.36 30.12 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.429 -0.794 . . . . 1.0 109.096 -179.956 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.76 120.99 38.12 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.894 -1.129 . . . . 1.0 109.239 -179.514 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.61 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -99.26 145.54 27.16 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 122.328 1.061 . . . . 1.0 111.105 -179.338 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.545 ' HB ' HG11 ' A' ' 7' ' ' VAL . 97.5 t -103.21 110.51 29.97 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 106.958 -1.497 . . . . 1.0 106.958 177.858 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.544 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -154.09 -169.68 19.2 Favored Glycine 0 N--CA 1.486 1.996 0 C-N-CA 118.173 -1.965 . . . . 1.0 111.579 -177.635 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.728 HD23 HG23 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -117.87 173.92 6.48 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 108.532 -0.914 . . . . 1.0 108.532 -179.506 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.501 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 7.3 t . . . . . 0 C--N 1.292 -1.913 0 N-CA-C 109.235 -0.654 . . . . 1.0 109.235 -179.808 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.525 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.482 1.757 0 N-CA-C 108.115 -1.994 . . . . 1.0 108.115 . . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -172.61 -176.69 1.56 Allowed 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.526 -0.985 . . . . 1.0 109.715 179.467 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.23 -160.8 16.73 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.159 -1.976 . . . . 1.0 108.159 -179.383 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -46.84 176.41 0.01 OUTLIER 'Trans proline' 0 C--N 1.326 -0.656 0 CA-C-N 118.973 1.386 . . . . 1.0 109.998 179.127 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -95.21 -176.88 3.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.027 -1.046 . . . . 1.0 110.376 -178.814 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.544 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.62 167.19 13.38 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.741 -1.343 . . . . 1.0 109.741 -179.963 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -101.55 129.55 52.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.417 -1.049 . . . . 1.0 109.143 -179.381 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.61 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -68.91 115.86 8.72 Favored 'General case' 0 C--N 1.289 -2.041 0 N-CA-C 109.47 -0.567 . . . . 1.0 109.47 179.474 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.827 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.8 pt -97.8 168.49 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.262 -0.899 . . . . 1.0 108.59 179.857 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.422 ' O ' ' HA ' ' A' ' 11' ' ' SER . 2.8 t -142.36 158.49 43.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.022 -1.049 . . . . 1.0 110.302 -179.375 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.827 ' CE1' HD12 ' A' ' 110' ' ' ILE . 84.8 m-85 . . . . . 0 N--CA 1.484 1.259 0 O-C-N 121.374 -0.829 . . . . 1.0 109.324 -179.856 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.483 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.301 0 CA-C-O 122.333 1.063 . . . . 0.0 110.388 . . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.755 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.3 t -114.54 109.35 18.13 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 123.01 1.386 . . . . 0.0 109.768 -179.929 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.83 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -115.58 139.03 44.0 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.721 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.763 179.913 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.51 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -172.42 150.71 2.31 Favored Pre-proline 0 N--CA 1.487 1.403 0 O-C-N 121.154 -0.966 . . . . 0.0 108.948 -179.533 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.51 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.1 Cg_endo -75.38 152.77 98.03 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.498 -1.459 . . . . 0.0 109.533 -0.674 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.641 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.5 m -89.89 -25.42 20.99 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.763 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.494 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.5 m -136.83 166.43 23.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.483 -0.76 . . . . 0.0 109.435 179.935 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.28 37.72 35.99 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.522 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.837 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.9 mt -92.77 -44.68 8.39 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 123.153 1.454 . . . . 0.0 110.767 -178.272 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.84 145.56 0.03 OUTLIER 'General case' 0 C--N 1.258 -3.392 0 CA-C-N 113.721 -1.581 . . . . 0.0 110.045 -179.819 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.593 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.6 p-10 -50.64 108.34 0.23 Allowed 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 121.562 0.696 . . . . 0.0 111.727 -178.678 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.06 15.56 9.82 Favored Glycine 0 N--CA 1.484 1.895 0 C-N-CA 119.619 -1.277 . . . . 0.0 112.78 177.263 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.837 HG21 ' CA ' ' A' ' 13' ' ' LEU . 8.8 t -103.56 -173.12 2.24 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 121.056 2.428 . . . . 0.0 109.839 179.348 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.77 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.9 t -126.8 135.71 62.91 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.944 -178.771 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.549 HG13 ' CG2' ' A' ' 69' ' ' VAL . 27.4 m -112.37 154.75 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 O-C-N 121.348 -0.845 . . . . 0.0 108.883 178.789 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.517 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -111.24 109.43 19.45 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.219 -0.926 . . . . 0.0 108.987 179.947 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.83 HG23 HG22 ' A' ' 7' ' ' VAL . 2.2 p -105.11 140.2 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -179.972 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.755 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.43 161.39 36.47 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.793 -1.192 . . . . 0.0 110.004 179.583 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -134.54 140.44 11.74 Favored Glycine 0 C--N 1.299 -1.518 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 179.793 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -141.74 127.04 18.66 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.563 -1.551 . . . . 0.0 109.489 179.294 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 87.47 29.26 22.35 Favored Glycine 0 N--CA 1.488 2.16 0 C-N-CA 118.915 -1.612 . . . . 0.0 109.681 -179.821 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.551 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.9 mt -89.08 173.21 8.57 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.006 -1.291 . . . . 0.0 108.334 -179.85 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.022 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.21 98.85 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.015 -1.053 . . . . 0.0 109.797 -179.715 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.549 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.38 77.02 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.251 -179.199 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.05 33.35 0.28 Allowed Glycine 0 N--CA 1.486 1.991 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.533 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.55 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.7 p -142.81 110.57 5.87 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 120.981 -1.306 . . . . 0.0 111.028 -179.832 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.588 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.95 112.68 0.65 Allowed 'General case' 0 N--CA 1.495 1.814 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.99 178.366 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.504 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 21.6 m-85 -101.33 155.3 18.12 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.127 -0.983 . . . . 0.0 108.88 179.665 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.517 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -102.7 150.19 23.7 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.862 -1.149 . . . . 0.0 108.205 179.014 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.71 ' CG1' HD21 ' A' ' 67' ' ' LEU . 1.1 t -126.34 129.97 71.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.117 -0.989 . . . . 0.0 109.121 -178.074 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.467 ' HA2' ' HB2' ' A' ' 51' ' ' ASP . . . -178.56 172.67 45.06 Favored Glycine 0 N--CA 1.495 2.573 0 C-N-CA 117.812 -2.137 . . . . 0.0 112.201 179.866 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.609 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -101.02 109.1 20.97 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.364 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.1 m -130.05 148.93 51.96 Favored 'General case' 0 C--N 1.295 -1.765 0 O-C-N 120.96 -1.087 . . . . 0.0 110.27 -179.496 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.52 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.54 138.34 54.34 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.364 -0.835 . . . . 0.0 110.537 -179.307 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.34 114.79 26.61 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 178.249 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.5 m -104.46 14.57 6.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.069 -1.02 . . . . 0.0 110.518 -178.915 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.763 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.55 -175.0 0.08 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.902 -1.124 . . . . 0.0 109.974 179.702 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -73.6 98.79 2.91 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.441 -0.787 . . . . 0.0 109.539 -179.814 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.99 27.62 30.86 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 120.161 -1.018 . . . . 0.0 111.362 179.09 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.763 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -118.11 105.99 18.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 O-C-N 120.597 -1.531 . . . . 0.0 107.231 178.967 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.6 tp -118.12 104.73 11.11 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 120.496 -1.378 . . . . 0.0 109.917 -177.801 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.013 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.64 109.33 22.11 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.729 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -105.64 165.87 10.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.915 -1.116 . . . . 0.0 110.674 -178.479 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.504 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 7.8 t30 -110.32 130.25 23.07 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 121.601 -0.687 . . . . 0.0 109.247 -179.486 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -71.59 23.28 0.24 Allowed 'Trans proline' 0 CA--C 1.545 1.055 0 C-N-CA 122.054 1.836 . . . . 0.0 111.804 179.623 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.504 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -103.32 -3.07 26.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.448 -1.408 . . . . 0.0 109.074 179.641 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.863 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.6 m-20 -134.93 10.41 3.6 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.943 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -63.34 81.99 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.251 -178.905 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.648 ' HB2' HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.34 -169.57 1.82 Allowed 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.096 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.435 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.1 t 179.27 132.94 0.09 Allowed 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.865 -1.147 . . . . 0.0 111.126 -179.532 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.855 HG11 ' HB1' ' A' ' 63' ' ' ALA . 1.1 p -156.32 152.61 8.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 178.367 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.588 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.91 142.29 29.83 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.696 -1.253 . . . . 0.0 109.872 -179.64 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.022 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.02 106.11 0.78 Allowed 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.447 1.117 . . . . 0.0 109.497 178.792 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.6 p-10 -57.92 -139.22 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.727 -179.978 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.549 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -55.13 -49.27 72.2 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.331 -0.856 . . . . 0.0 110.093 -178.95 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.7 p-10 -100.22 -39.03 8.25 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 178.482 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.978 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.94 66.36 0.58 Allowed Glycine 0 C--N 1.297 -1.619 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 178.288 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.584 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.0 m -101.48 129.81 47.61 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 121.601 -0.941 . . . . 0.0 109.056 179.103 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.855 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -138.13 108.95 6.66 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 119.31 -0.956 . . . . 0.0 109.498 -179.554 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.7 m -126.0 120.92 31.58 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.205 -0.934 . . . . 0.0 109.627 -179.774 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.08 144.78 30.24 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.482 -0.761 . . . . 0.0 109.391 179.871 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.437 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 32.1 p -98.83 141.12 32.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.368 -0.832 . . . . 0.0 109.115 179.894 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.863 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -140.56 174.69 10.27 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.333 -0.854 . . . . 0.0 109.65 -178.818 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.528 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -102.34 122.37 44.11 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.019 -1.051 . . . . 0.0 109.622 -179.751 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.671 HG13 ' OD2' ' A' ' 51' ' ' ASP . 16.9 m -133.47 143.17 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 120.911 -1.118 . . . . 0.0 110.159 -179.411 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.593 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.0 ptt180 -142.68 -166.87 2.38 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.663 -1.273 . . . . 0.0 110.09 179.568 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.565 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -72.32 -85.91 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.321 -0.862 . . . . 0.0 108.841 -179.575 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.62 138.81 58.58 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.291 -1.506 . . . . 0.0 107.362 178.799 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -164.48 139.08 5.49 Favored 'General case' 0 C--N 1.294 -1.82 0 C-N-CA 117.982 -1.487 . . . . 0.0 110.542 -177.496 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.507 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.6 mm-40 -34.09 120.55 0.44 Allowed 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.47 0.653 . . . . 0.0 110.612 -178.625 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.013 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.15 50.57 1.91 Allowed Glycine 0 N--CA 1.494 2.563 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.226 -179.418 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-85 -41.05 114.18 0.46 Allowed 'General case' 0 N--CA 1.508 2.45 0 O-C-N 120.868 -1.372 . . . . 0.0 109.964 179.453 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.637 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.3 tp -84.32 126.92 33.64 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.742 -1.224 . . . . 0.0 109.624 -179.951 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -64.05 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.812 -1.18 . . . . 0.0 110.275 179.688 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' LEU . 8.7 t0 -161.35 20.0 0.12 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.944 -1.098 . . . . 0.0 109.806 179.731 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.19 -26.88 5.31 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 110.041 -1.223 . . . . 0.0 110.041 179.963 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.475 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 5.9 p -92.38 152.78 19.56 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.056 -1.261 . . . . 0.0 110.386 -179.442 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.515 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 5.4 ptt180 -101.93 133.06 47.32 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.597 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.637 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -81.24 -20.96 39.9 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 120.713 -1.242 . . . . 0.0 110.527 -178.269 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.88 176.04 20.45 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 108.725 -1.75 . . . . 0.0 108.725 -179.629 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.49 109.42 1.37 Allowed 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 179.148 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.591 HG21 ' HB3' ' A' ' 46' ' ' ALA . 31.1 t -81.83 105.74 12.05 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 121.341 -0.849 . . . . 0.0 108.94 -178.934 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.651 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -65.3 111.82 3.19 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.446 -0.783 . . . . 0.0 109.845 -179.357 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.549 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.56 -5.09 7.13 Favored 'General case' 0 N--CA 1.499 1.984 0 C-N-CA 118.285 -1.366 . . . . 0.0 109.648 179.369 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 p -83.76 -2.18 55.74 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.876 -1.14 . . . . 0.0 108.901 179.318 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.651 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.98 -49.81 2.95 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.347 -0.846 . . . . 0.0 109.013 -179.998 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.62 -178.34 3.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.551 -0.718 . . . . 0.0 109.517 179.919 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.3 116.29 31.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.43 -0.794 . . . . 0.0 108.99 -179.971 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.568 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.1 m -96.88 124.21 40.8 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.814 -1.179 . . . . 0.0 109.747 -179.168 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.614 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.0 147.32 26.71 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 122.33 1.062 . . . . 0.0 111.202 -179.44 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.527 ' CG1' HG11 ' A' ' 7' ' ' VAL . 43.8 t -104.75 111.53 34.65 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.567 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.496 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.35 -169.81 17.47 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 117.906 -2.092 . . . . 0.0 111.845 -177.481 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.494 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.57 -179.07 3.57 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -179.094 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.517 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER . . . . . 0 C--N 1.296 -1.735 0 O-C-N 121.277 -0.889 . . . . 0.0 109.438 -179.73 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.658 0 N-CA-C 107.676 -2.17 . . . . 0.0 107.676 . . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.55 -178.16 6.91 Favored 'General case' 0 C--N 1.306 -1.296 0 O-C-N 121.534 -0.98 . . . . 0.0 109.671 179.253 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.5 -162.04 17.06 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 108.356 -1.897 . . . . 0.0 108.356 -179.494 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' CD ' ' CE1' ' A' ' 32' ' ' TYR . 6.8 Cg_exo -46.12 174.16 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 CA-C-N 118.784 1.292 . . . . 0.0 110.022 179.387 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -92.82 -177.69 4.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.107 -0.996 . . . . 0.0 110.528 -178.588 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.496 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.8 167.44 13.1 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.946 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -104.06 131.19 53.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 O-C-N 121.325 -1.103 . . . . 0.0 109.095 -179.269 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.614 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.99 122.63 22.03 Favored 'General case' 0 C--N 1.29 -2.001 0 O-C-N 121.612 -0.68 . . . . 0.0 109.529 179.707 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.848 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.72 169.84 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 O-C-N 121.225 -0.922 . . . . 0.0 109.226 -179.982 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.494 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -135.48 155.33 50.7 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.233 -0.917 . . . . 0.0 109.721 -179.753 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.848 ' CE2' HD12 ' A' ' 110' ' ' ILE . 74.9 m-85 . . . . . 0 N--CA 1.488 1.426 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.767 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.164 0 CA-C-O 122.475 1.131 . . . . 0.0 110.618 . . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.006 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.8 p -106.89 104.95 14.75 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-O 122.503 1.144 . . . . 0.0 110.331 -179.43 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.955 HG22 HG23 ' A' ' 21' ' ' VAL . 10.6 t -117.25 119.16 61.02 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.478 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.303 179.582 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.501 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.61 148.38 12.67 Favored Pre-proline 0 N--CA 1.487 1.415 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -179.602 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.501 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.49 152.85 97.95 Favored 'Cis proline' 0 C--N 1.31 -1.497 0 C-N-CA 123.603 -1.415 . . . . 0.0 109.728 -0.445 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.7 m -92.53 -24.94 18.6 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.505 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.517 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 1.2 m -136.53 166.05 24.43 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.656 -0.652 . . . . 0.0 109.351 179.847 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.39 37.98 39.95 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 -179.723 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.786 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.6 mt -91.7 -43.34 9.64 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 123.344 1.545 . . . . 0.0 110.649 -178.31 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.472 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.02 144.43 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.376 -1.738 . . . . 0.0 109.853 -179.653 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.611 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 6.1 p-10 -51.13 107.78 0.2 Allowed 'General case' 0 C--N 1.302 -1.492 0 CA-C-O 121.586 0.708 . . . . 0.0 111.527 -178.534 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.12 14.26 9.33 Favored Glycine 0 N--CA 1.484 1.86 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.822 177.486 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.786 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.3 t -105.0 -172.6 2.13 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 121.13 2.465 . . . . 0.0 109.713 179.287 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.75 HG13 ' C ' ' A' ' 67' ' ' LEU . 15.0 t -130.68 139.18 51.88 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.324 -178.793 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.472 HG23 ' CD1' ' A' ' 67' ' ' LEU . 31.7 m -114.72 154.91 16.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.037 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.541 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.6 tptm -110.45 109.36 19.7 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.337 180.0 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.955 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -105.1 123.95 59.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 179.948 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.006 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.38 166.16 11.55 Favored 'General case' 0 N--CA 1.485 1.279 0 O-C-N 120.927 -1.108 . . . . 0.0 108.94 179.594 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.622 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.19 108.1 0.48 Allowed Glycine 0 N--CA 1.482 1.763 0 N-CA-C 108.41 -1.876 . . . . 0.0 108.41 179.917 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.19 136.81 52.78 Favored 'General case' 0 N--CA 1.501 2.078 0 CA-C-N 119.432 1.616 . . . . 0.0 110.38 -179.287 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 87.61 28.11 25.2 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 118.895 -1.621 . . . . 0.0 109.806 179.68 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.566 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -93.4 170.6 9.49 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.988 -1.301 . . . . 0.0 108.309 179.852 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.008 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.9 100.8 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.068 -1.02 . . . . 0.0 110.018 -179.495 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.541 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.75 78.17 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.675 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.018 -179.36 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.32 34.48 0.28 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.735 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 18.8 p -139.56 105.67 5.23 Favored 'General case' 0 C--N 1.307 -1.278 0 O-C-N 121.162 -1.199 . . . . 0.0 111.273 -179.258 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.592 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.74 109.88 0.36 Allowed 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 177.824 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.2 m-30 -106.38 156.11 18.85 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.049 -1.032 . . . . 0.0 108.886 179.89 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.512 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -100.36 164.51 11.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.902 -1.124 . . . . 0.0 108.081 179.035 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.682 HG22 HG11 ' A' ' 21' ' ' VAL . 4.2 p -144.23 117.21 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.152 -0.967 . . . . 0.0 109.61 -178.1 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.9 -176.9 38.83 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 118.364 -1.874 . . . . 0.0 111.876 -179.717 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.601 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -101.48 109.21 20.99 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.837 0.827 . . . . 0.0 109.13 -179.572 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.21 148.44 52.04 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.192 -0.943 . . . . 0.0 109.511 179.579 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.509 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.7 138.52 54.58 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.179 -0.951 . . . . 0.0 110.815 -178.969 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.97 26.8 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 178.112 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.9 m -105.64 15.07 7.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 120.994 -1.066 . . . . 0.0 110.534 -178.84 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.754 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.11 -175.38 0.09 Allowed 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.857 -1.152 . . . . 0.0 110.064 179.724 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 64.0 p -72.24 97.44 1.99 Allowed 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.428 -0.795 . . . . 0.0 109.64 -179.784 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.56 27.54 32.24 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 120.154 -1.022 . . . . 0.0 111.419 178.877 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.754 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.65 106.21 19.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.526 -1.573 . . . . 0.0 107.221 178.93 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.8 tp -117.06 104.69 11.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.52 -1.362 . . . . 0.0 109.854 -177.659 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.072 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.08 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.299 0 O-C-N 120.842 -1.161 . . . . 0.0 107.887 178.77 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -106.87 163.99 12.49 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.015 -1.053 . . . . 0.0 110.44 -178.771 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.743 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 47.0 t30 -109.59 131.04 22.12 Favored Pre-proline 0 N--CA 1.502 2.173 0 O-C-N 121.59 -0.694 . . . . 0.0 109.618 -179.345 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.61 20.76 0.25 Allowed 'Trans proline' 0 C--N 1.318 -1.029 0 C-N-CA 122.21 1.94 . . . . 0.0 112.243 -179.813 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.743 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -110.53 5.68 21.39 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.379 -1.451 . . . . 0.0 108.846 179.166 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.543 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.01 16.82 2.64 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 179.339 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -81.74 88.82 6.26 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.868 -0.733 . . . . 0.0 111.285 -178.302 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.637 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.79 -167.25 1.23 Allowed 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 177.93 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.65 136.24 0.09 Allowed 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.479 -1.388 . . . . 0.0 111.395 -179.341 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.881 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -152.67 157.29 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.169 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.592 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.89 141.76 31.25 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.732 -1.23 . . . . 0.0 109.859 -179.772 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.008 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.17 107.51 1.06 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.43 1.109 . . . . 0.0 109.399 178.199 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.562 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 14.4 p-10 -61.75 -138.91 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.001 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.812 -179.997 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.541 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.49 -51.62 53.55 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.374 -0.828 . . . . 0.0 110.664 -178.665 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -102.23 -33.75 9.5 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 178.473 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.008 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.28 64.56 0.57 Allowed Glycine 0 C--N 1.299 -1.511 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.671 178.009 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.622 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 92.7 p -98.89 128.91 45.2 Favored 'General case' 0 N--CA 1.482 1.168 0 O-C-N 121.859 -0.789 . . . . 0.0 108.92 178.804 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.881 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.28 108.78 7.4 Favored 'General case' 0 C--N 1.296 -1.742 0 C-N-CA 119.67 -0.812 . . . . 0.0 109.416 -179.524 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 80.9 p -120.5 117.44 27.65 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.298 -0.876 . . . . 0.0 109.368 -179.906 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.569 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.31 140.83 28.04 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.418 -0.801 . . . . 0.0 109.609 -179.836 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 12.6 p -100.69 136.24 40.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.377 -0.827 . . . . 0.0 109.494 -179.947 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.75 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -133.84 165.85 24.03 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.423 -0.798 . . . . 0.0 109.392 -179.473 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.729 HG22 HG22 ' A' ' 18' ' ' VAL . 2.2 p -96.22 125.33 40.66 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.956 -1.09 . . . . 0.0 109.349 -179.946 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.601 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.4 m -135.82 143.49 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 120.919 -1.113 . . . . 0.0 109.929 -179.116 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.611 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.63 -175.9 4.98 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.495 -1.378 . . . . 0.0 110.984 179.957 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.599 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.56 -101.73 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.762 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.514 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -57.29 142.0 44.84 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.731 -1.23 . . . . 0.0 108.187 179.424 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.585 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.65 136.85 6.39 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.775 -1.17 . . . . 0.0 109.637 -177.961 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.498 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 1.6 mp0 -34.46 121.89 0.5 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.431 0.634 . . . . 0.0 110.306 -178.402 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.072 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.58 49.91 2.34 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.236 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.5 m-85 -39.3 113.85 0.36 Allowed 'General case' 0 N--CA 1.507 2.382 0 O-C-N 121.204 -1.174 . . . . 0.0 109.992 179.555 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.7 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -85.81 126.46 34.04 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 120.944 -1.098 . . . . 0.0 109.55 -179.797 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -64.28 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.869 -1.144 . . . . 0.0 110.052 179.665 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.539 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.4 t70 -159.96 19.49 0.16 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.157 -0.964 . . . . 0.0 109.66 179.764 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.96 -27.45 5.47 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.75 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.4 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 19.5 p -94.49 160.46 14.64 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.033 -1.275 . . . . 0.0 110.362 -179.361 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.48 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.75 136.62 46.24 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.689 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.7 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -82.89 -17.96 41.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.765 -1.21 . . . . 0.0 110.526 -178.487 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.94 175.6 19.89 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 108.778 -1.729 . . . . 0.0 108.778 -179.632 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.05 104.74 0.92 Allowed 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 179.134 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.633 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.5 t -76.48 106.3 6.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.388 -0.82 . . . . 0.0 109.258 -178.913 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -66.02 111.28 3.28 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.47 -0.769 . . . . 0.0 109.892 -179.41 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.599 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.75 -5.49 4.27 Favored 'General case' 0 N--CA 1.5 2.068 0 C-N-CA 118.256 -1.377 . . . . 0.0 109.816 179.484 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.6 p -86.82 -0.14 55.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.708 -1.245 . . . . 0.0 109.111 179.585 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.33 -50.59 2.85 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.398 -0.814 . . . . 0.0 108.945 179.96 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.07 -179.95 4.09 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.484 -0.76 . . . . 0.0 109.392 179.845 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.97 115.86 31.2 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.333 -0.854 . . . . 0.0 108.964 179.917 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.84 121.32 38.57 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.993 -1.067 . . . . 0.0 109.308 -179.421 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.595 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.92 145.7 28.3 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 122.355 1.074 . . . . 0.0 111.2 -179.306 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.648 ' HB ' HG11 ' A' ' 7' ' ' VAL . 58.6 t -103.12 109.78 27.83 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 177.675 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.478 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.26 -170.73 16.47 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 118.271 -1.919 . . . . 0.0 111.663 -177.738 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.503 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -114.36 -179.55 3.66 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 -178.95 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.512 ' O ' ' N ' ' A' ' 33' ' ' ASP . 37.1 p . . . . . 0 C--N 1.297 -1.693 0 O-C-N 121.337 -0.852 . . . . 0.0 109.321 -179.235 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.771 0 N-CA-C 107.572 -2.211 . . . . 0.0 107.572 . . . . . . . . . 0 0 . 1 . 034 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.61 -178.01 6.79 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.538 -0.977 . . . . 0.0 109.793 179.253 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.75 -163.0 16.93 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -179.321 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.503 ' HB2' HD12 ' A' ' 97' ' ' LEU . 6.4 Cg_exo -46.71 175.69 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.643 0 CA-C-N 118.77 1.285 . . . . 0.0 110.1 179.325 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -90.06 -176.04 4.75 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.019 -1.05 . . . . 0.0 110.599 -178.787 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.478 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.82 167.0 13.88 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.896 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.89 132.66 49.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.373 -1.075 . . . . 0.0 109.174 -179.334 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.595 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.27 118.88 17.73 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.547 -0.72 . . . . 0.0 109.685 179.675 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.911 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -98.02 170.07 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.211 -0.93 . . . . 0.0 108.999 179.72 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.517 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 34.4 m -140.95 156.85 45.99 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.167 -0.958 . . . . 0.0 110.094 -179.674 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.911 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.3 m-85 . . . . . 0 N--CA 1.486 1.334 0 O-C-N 121.333 -0.855 . . . . 0.0 109.541 -179.754 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.488 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.21 0 CA-C-O 122.486 1.136 . . . . 0.0 110.397 . . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.763 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.5 t -113.52 109.17 18.21 Favored 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 123.15 1.452 . . . . 0.0 109.266 179.954 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.889 HG22 HG23 ' A' ' 21' ' ' VAL . 4.4 t -116.25 127.38 73.87 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.709 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.94 -179.847 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.512 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.44 148.11 12.7 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.286 -0.884 . . . . 0.0 108.874 -179.696 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.512 ' HA ' HG23 ' A' ' 8' ' ' THR . 7.1 Cg_endo -79.96 147.65 77.46 Favored 'Cis proline' 0 C--N 1.31 -1.451 0 O-C-N 123.778 1.409 . . . . 0.0 109.35 -0.797 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.681 ' HA ' HG22 ' A' ' 110' ' ' ILE . 79.8 p -89.27 -25.8 21.5 Favored 'General case' 0 C--N 1.295 -1.785 0 O-C-N 121.563 -0.71 . . . . 0.0 109.203 179.788 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.476 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.0 OUTLIER -132.23 162.03 31.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.405 -0.81 . . . . 0.0 109.55 -179.927 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.9 37.29 29.98 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 -179.661 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.773 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.5 mt -92.39 -42.81 9.57 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 123.295 1.521 . . . . 0.0 110.516 -178.388 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.42 144.69 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.283 0 CA-C-N 113.321 -1.763 . . . . 0.0 109.936 -179.649 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.591 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.3 p-10 -51.2 106.11 0.12 Allowed 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.647 0.737 . . . . 0.0 111.494 -178.513 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.98 14.67 8.35 Favored Glycine 0 N--CA 1.485 1.929 0 C-N-CA 119.354 -1.403 . . . . 0.0 113.006 177.358 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.773 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -104.87 -171.2 1.88 Allowed 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 121.143 2.471 . . . . 0.0 109.516 179.218 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.732 HG13 ' C ' ' A' ' 67' ' ' LEU . 17.0 t -127.63 135.88 61.95 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.128 -179.119 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.642 HG13 ' CG2' ' A' ' 69' ' ' VAL . 29.2 m -109.18 155.27 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.835 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.533 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -110.35 109.23 19.57 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 108.834 179.804 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.889 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -105.01 139.5 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.399 -0.813 . . . . 0.0 108.832 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.763 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.58 161.13 37.25 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.804 -1.185 . . . . 0.0 109.945 179.631 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -134.05 141.57 12.93 Favored Glycine 0 C--N 1.297 -1.623 0 N-CA-C 108.318 -1.913 . . . . 0.0 108.318 179.768 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.64 125.98 16.6 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.706 -1.467 . . . . 0.0 109.294 179.369 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.11 28.2 21.19 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 118.873 -1.632 . . . . 0.0 109.599 -179.625 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.596 HD22 ' HG3' ' A' ' 105' ' ' PRO . 1.8 mt -88.84 174.59 7.88 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.988 -1.301 . . . . 0.0 108.365 179.953 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.66 98.45 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.887 -1.133 . . . . 0.0 109.823 -179.521 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.579 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 77.71 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.724 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.248 -179.253 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.563 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.73 34.37 0.31 Allowed Glycine 0 N--CA 1.486 2.014 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.525 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 66.6 p -144.24 109.73 5.19 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.005 -1.291 . . . . 0.0 111.211 -179.585 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.566 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -43.8 127.01 4.97 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.43 178.02 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.541 ' CD2' ' O ' ' A' ' 30' ' ' THR . 15.3 m-85 -116.98 153.48 32.56 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.388 -0.82 . . . . 0.0 108.834 179.844 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.5 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -105.24 148.97 26.38 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.816 -1.177 . . . . 0.0 108.264 179.059 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.648 HG13 HD21 ' A' ' 67' ' ' LEU . 0.9 OUTLIER -125.82 126.46 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.169 -0.957 . . . . 0.0 109.071 -178.103 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -172.77 173.29 45.47 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 117.707 -2.187 . . . . 0.0 112.527 -179.915 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.578 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.36 110.31 22.52 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 179.368 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 63.1 m -129.35 152.11 49.26 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 121.196 -0.94 . . . . 0.0 110.156 -179.612 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.67 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -126.47 135.45 51.37 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.632 -0.668 . . . . 0.0 110.046 179.585 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.905 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.71 114.43 26.35 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.579 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 m -106.86 15.15 7.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.915 -1.115 . . . . 0.0 110.713 -178.633 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.788 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.4 -174.52 0.07 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.819 -1.175 . . . . 0.0 110.135 179.63 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 29.5 p -70.14 96.32 1.07 Allowed 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.407 -0.808 . . . . 0.0 110.013 -179.468 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.04 28.4 34.4 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 120.166 -1.016 . . . . 0.0 111.532 178.749 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.788 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.32 106.04 19.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 120.58 -1.541 . . . . 0.0 107.327 178.83 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.905 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.7 tp -116.47 106.54 13.71 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.59 -1.319 . . . . 0.0 109.775 -177.65 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.116 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -96.13 109.76 22.14 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 120.697 -1.252 . . . . 0.0 108.381 179.281 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.41 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 86.8 m -101.48 147.59 26.2 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.346 -0.847 . . . . 0.0 110.48 -178.371 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.655 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 31.1 t30 -96.66 137.87 21.43 Favored Pre-proline 0 N--CA 1.502 2.169 0 O-C-N 121.01 -1.056 . . . . 0.0 108.826 178.878 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.582 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 8.0 Cg_endo -75.76 26.71 0.4 Allowed 'Trans proline' 0 N--CA 1.496 1.649 0 C-N-CA 125.188 3.925 . . . . 0.0 111.507 -179.068 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.655 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -126.1 9.12 7.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.424 -1.423 . . . . 0.0 109.576 179.881 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.83 15.97 2.49 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 179.502 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -77.91 87.14 4.11 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.059 -178.675 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.611 ' CB ' HG12 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -98.98 -168.22 1.6 Allowed 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 178.569 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.43 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 179.13 133.98 0.09 Allowed 'General case' 0 N--CA 1.486 1.329 0 O-C-N 120.766 -1.209 . . . . 0.0 111.42 -179.428 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.879 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -159.14 153.62 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.493 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.566 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.51 144.63 27.02 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.683 -1.261 . . . . 0.0 109.645 -179.86 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.002 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.67 107.42 1.41 Allowed 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 122.525 1.155 . . . . 0.0 109.502 178.7 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.556 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 p-10 -61.39 -139.97 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.782 179.98 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.579 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.06 -50.73 58.1 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.382 -0.824 . . . . 0.0 110.664 -178.799 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -103.48 -32.64 9.39 Favored 'General case' 0 C--N 1.286 -2.165 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 178.713 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.994 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.0 65.72 0.65 Allowed Glycine 0 C--N 1.296 -1.652 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 178.309 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.1 m -100.54 128.96 46.43 Favored 'General case' 0 N--CA 1.484 1.245 0 O-C-N 121.523 -0.987 . . . . 0.0 108.808 178.856 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.879 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -137.9 108.65 6.64 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.242 -0.983 . . . . 0.0 109.588 -179.516 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 27.3 p -123.82 120.24 32.04 Favored 'General case' 0 C--N 1.305 -1.33 0 O-C-N 121.246 -0.909 . . . . 0.0 109.513 -179.982 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.76 146.05 31.06 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.485 -0.759 . . . . 0.0 109.321 179.819 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 55.4 p -98.57 144.56 27.75 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.295 -0.878 . . . . 0.0 109.287 179.945 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.732 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -144.02 165.01 28.97 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.434 -0.791 . . . . 0.0 109.413 -179.216 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.657 HG22 HG22 ' A' ' 18' ' ' VAL . 3.8 p -95.04 123.71 38.68 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.127 -0.983 . . . . 0.0 109.329 -179.887 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.642 ' CG2' HG13 ' A' ' 19' ' ' VAL . 16.6 m -137.89 142.49 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 120.963 -1.085 . . . . 0.0 109.701 -179.292 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.591 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 5.4 ptt180 -140.71 -166.79 2.21 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 120.677 -1.264 . . . . 0.0 109.968 -179.989 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.549 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -71.66 -80.41 0.06 Allowed 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.809 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.504 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -64.87 135.79 56.13 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 178.648 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.67 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.08 133.6 6.09 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 117.862 -1.535 . . . . 0.0 110.563 -177.643 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.556 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -33.64 120.74 0.41 Allowed 'General case' 0 N--CA 1.493 1.694 0 CA-C-O 121.615 0.722 . . . . 0.0 110.391 -178.472 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.116 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.4 50.52 2.4 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.456 -0.878 . . . . 0.0 111.611 -178.916 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.582 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.7 OUTLIER -38.42 116.88 0.58 Allowed 'General case' 0 N--CA 1.51 2.567 0 O-C-N 121.094 -1.239 . . . . 0.0 110.053 179.41 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.627 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.28 125.71 34.38 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 120.8 -1.187 . . . . 0.0 109.455 179.855 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.0 t80 -64.14 58.6 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.819 -1.176 . . . . 0.0 110.086 179.82 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.9 t70 -160.51 20.02 0.14 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.059 -1.026 . . . . 0.0 109.668 179.898 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.46 -28.64 5.19 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 179.813 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.468 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 40.7 p -94.23 160.57 14.63 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.066 -1.255 . . . . 0.0 110.293 -179.52 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.49 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -108.02 136.8 47.11 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.794 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.627 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.9 t90 -80.74 -20.34 42.97 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.809 -1.182 . . . . 0.0 110.351 -178.688 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.43 176.24 20.22 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 108.644 -1.782 . . . . 0.0 108.644 -179.565 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -62.55 109.97 1.55 Allowed 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.166 -1.196 . . . . 0.0 107.779 179.168 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.63 HG21 ' CB ' ' A' ' 46' ' ' ALA . 37.1 t -83.22 103.53 10.62 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -179.104 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.575 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -65.77 111.71 3.37 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.383 -0.823 . . . . 0.0 109.894 -179.257 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.549 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -65.83 -3.67 5.43 Favored 'General case' 0 N--CA 1.5 2.055 0 C-N-CA 118.334 -1.346 . . . . 0.0 109.886 179.457 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 p -86.93 11.61 13.08 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.739 -1.225 . . . . 0.0 108.794 179.487 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.575 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -127.25 -48.22 1.45 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.428 -0.795 . . . . 0.0 108.989 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.36 -179.85 4.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.559 -0.713 . . . . 0.0 109.504 -179.948 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.1 113.66 27.32 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.318 -0.864 . . . . 0.0 109.079 -179.986 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.522 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.6 m -97.12 124.89 41.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.879 -1.138 . . . . 0.0 109.438 -179.512 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.567 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -104.87 147.15 28.06 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 122.403 1.097 . . . . 0.0 111.38 -179.27 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.497 ' CG1' HG11 ' A' ' 7' ' ' VAL . 43.4 t -103.53 112.04 35.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.977 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 177.577 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.417 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.06 -170.44 16.73 Favored Glycine 0 N--CA 1.488 2.137 0 C-N-CA 118.076 -2.011 . . . . 0.0 111.738 -177.607 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.485 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.08 -179.43 3.7 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 -179.126 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.515 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 4.5 p . . . . . 0 C--N 1.293 -1.885 0 O-C-N 121.337 -0.852 . . . . 0.0 109.287 -179.523 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.75 0 N-CA-C 107.59 -2.204 . . . . 0.0 107.59 . . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.54 -178.74 7.49 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 121.62 -0.929 . . . . 0.0 109.355 178.9 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -173.29 -165.97 30.97 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.737 -1.745 . . . . 0.0 108.737 -179.471 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.596 ' HG3' HD22 ' A' ' 26' ' ' LEU . 4.6 Cg_exo -46.39 -175.86 0.0 OUTLIER 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 123.57 2.847 . . . . 0.0 109.923 179.512 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -94.78 172.13 8.35 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.975 -1.078 . . . . 0.0 110.574 -178.957 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.417 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -110.47 159.71 13.71 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 179.897 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.36 128.17 55.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.36 -1.082 . . . . 0.0 109.29 -179.378 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.567 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.75 119.49 17.06 Favored 'General case' 0 C--N 1.289 -2.042 0 O-C-N 121.591 -0.693 . . . . 0.0 109.358 179.569 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.852 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.99 171.07 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.228 -0.92 . . . . 0.0 109.116 -179.945 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.476 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.86 154.91 48.46 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.088 -1.007 . . . . 0.0 109.811 -179.763 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.852 ' CE2' HD12 ' A' ' 110' ' ' ILE . 76.1 m-85 . . . . . 0 N--CA 1.485 1.324 0 O-C-N 121.1 -1.0 . . . . 0.0 109.467 -179.752 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.491 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.458 0 CA-C-O 122.355 1.074 . . . . 0.0 110.613 . . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.954 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -113.19 108.66 17.58 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 123.166 1.46 . . . . 0.0 109.227 179.418 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.911 HG22 HG23 ' A' ' 21' ' ' VAL . 4.3 t -116.89 141.37 35.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.717 0 CA-C-N 114.185 -1.371 . . . . 0.0 109.953 -179.716 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.47 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -178.07 150.61 0.76 Allowed Pre-proline 0 N--CA 1.487 1.415 0 O-C-N 121.248 -0.907 . . . . 0.0 108.668 -179.613 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.47 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.67 152.24 96.92 Favored 'Cis proline' 0 C--N 1.312 -1.39 0 C-N-CA 123.485 -1.465 . . . . 0.0 109.679 -0.699 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.545 ' HA ' HG22 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -90.75 -24.85 20.25 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.768 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.507 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.7 m -136.71 164.15 28.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.451 -0.781 . . . . 0.0 109.482 179.856 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.39 37.47 31.38 Favored Glycine 0 N--CA 1.497 2.702 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 -179.717 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.6 mt -92.18 -43.2 9.47 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 123.203 1.477 . . . . 0.0 110.421 -178.348 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.91 144.45 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.312 0 CA-C-N 113.459 -1.7 . . . . 0.0 109.929 -179.657 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.611 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.1 p-10 -50.79 107.56 0.18 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.521 0.677 . . . . 0.0 111.458 -178.583 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.32 13.5 9.77 Favored Glycine 0 N--CA 1.485 1.938 0 C-N-CA 119.435 -1.364 . . . . 0.0 112.935 177.342 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.6 t -104.45 -172.61 2.13 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 121.213 2.507 . . . . 0.0 109.734 179.261 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.748 HG13 ' C ' ' A' ' 67' ' ' LEU . 15.9 t -129.37 138.3 54.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.371 0 CA-C-N 114.761 -1.109 . . . . 0.0 111.019 -179.014 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.556 HG23 ' CD1' ' A' ' 67' ' ' LEU . 27.8 m -113.67 154.62 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.922 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.504 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -108.55 109.38 20.6 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.208 -0.932 . . . . 0.0 108.996 179.936 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.911 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.49 140.89 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.789 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.954 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -136.35 160.54 38.42 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 118.659 -1.216 . . . . 0.0 109.89 179.734 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.589 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.18 143.81 15.46 Favored Glycine 0 C--N 1.293 -1.814 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 179.716 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.26 124.96 12.55 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 120.908 -1.348 . . . . 0.0 108.882 179.185 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.86 27.58 23.59 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 119.339 -1.41 . . . . 0.0 109.659 -179.68 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.7 mt -86.72 175.53 8.21 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 120.909 -1.348 . . . . 0.0 108.62 -179.781 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.54 97.12 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.047 -1.033 . . . . 0.0 109.58 -179.821 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.585 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 76.19 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.495 -178.978 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.21 33.27 0.28 Allowed Glycine 0 N--CA 1.486 1.985 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.26 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.61 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.4 t -148.13 115.32 6.18 Favored 'General case' 0 C--N 1.308 -1.214 0 O-C-N 120.831 -1.394 . . . . 0.0 111.276 179.973 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.3 127.84 5.88 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.781 178.367 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.61 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.8 m-85 -119.09 149.03 42.38 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.51 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.5 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.62 163.86 12.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.61 -1.307 . . . . 0.0 107.518 178.631 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.707 HG11 HG21 ' A' ' 65' ' ' THR . 9.2 p -149.08 114.62 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.045 -1.035 . . . . 0.0 110.143 -177.74 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.14 -175.41 37.16 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 118.365 -1.874 . . . . 0.0 111.731 -179.865 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.581 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.34 109.01 21.19 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-O 121.829 0.823 . . . . 0.0 108.819 -179.695 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.47 149.04 52.33 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.231 -0.918 . . . . 0.0 109.6 179.751 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.448 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.48 139.24 54.07 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.301 -0.875 . . . . 0.0 110.732 -179.041 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 114.78 26.6 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.174 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.4 m -105.53 15.29 6.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.999 -1.063 . . . . 0.0 110.573 -178.639 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.757 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.09 -175.42 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.955 -1.091 . . . . 0.0 110.003 179.734 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 56.8 p -71.95 97.45 1.86 Allowed 'General case' 0 N--CA 1.485 1.305 0 O-C-N 121.364 -0.835 . . . . 0.0 109.748 -179.73 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.65 27.71 34.5 Favored Glycine 0 N--CA 1.492 2.404 0 C-N-CA 120.235 -0.983 . . . . 0.0 111.423 178.985 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.757 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.05 106.24 19.98 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 O-C-N 120.59 -1.536 . . . . 0.0 107.29 178.829 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -116.71 104.55 11.47 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.478 -1.388 . . . . 0.0 109.81 -177.715 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.088 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.2 109.45 22.21 Favored 'General case' 0 N--CA 1.485 1.276 0 O-C-N 120.834 -1.166 . . . . 0.0 107.945 178.828 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -107.4 163.9 12.65 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.964 -1.085 . . . . 0.0 110.297 -178.73 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.754 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 38.8 t30 -108.56 128.77 24.98 Favored Pre-proline 0 N--CA 1.501 2.111 0 O-C-N 121.46 -0.775 . . . . 0.0 109.503 -179.386 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -70.14 19.76 0.19 Allowed 'Trans proline' 0 CA--C 1.544 1.017 0 C-N-CA 122.088 1.859 . . . . 0.0 112.386 -179.867 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.754 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -108.96 4.85 23.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.388 -1.445 . . . . 0.0 108.868 179.157 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.578 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.79 16.7 2.68 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 179.497 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -81.67 90.58 6.33 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.974 -0.691 . . . . 0.0 111.088 -178.446 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.39 -171.08 1.77 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 178.015 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.446 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.85 134.99 0.09 Allowed 'General case' 0 C--N 1.305 -1.356 0 O-C-N 120.403 -1.435 . . . . 0.0 111.554 -179.357 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.777 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.5 p -150.07 159.11 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 177.894 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.57 146.05 25.66 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.543 -1.348 . . . . 0.0 109.726 -179.724 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.24 108.71 3.28 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 122.31 1.052 . . . . 0.0 109.629 178.999 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.547 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.5 t0 -63.02 -138.65 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.526 179.858 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.585 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -53.7 -51.45 63.2 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.289 -0.882 . . . . 0.0 110.21 -178.931 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.8 p-10 -98.58 -37.08 9.68 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 178.563 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.987 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.06 65.62 0.64 Allowed Glycine 0 C--N 1.297 -1.588 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.412 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 53.7 p -98.49 132.62 43.77 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 121.426 -1.043 . . . . 0.0 109.245 179.28 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.777 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.02 108.53 6.55 Favored 'General case' 0 C--N 1.296 -1.754 0 C-N-CA 119.235 -0.986 . . . . 0.0 109.52 -179.708 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.432 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 21.8 p -124.82 120.75 32.61 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.147 -0.97 . . . . 0.0 109.797 -179.803 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.707 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -148.04 146.72 28.99 Favored 'General case' 0 C--N 1.3 -1.587 0 O-C-N 121.581 -0.7 . . . . 0.0 109.304 179.648 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.4 p -100.61 138.88 37.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.322 -0.861 . . . . 0.0 109.404 179.975 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.748 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -138.03 165.54 26.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.404 -0.81 . . . . 0.0 109.529 -179.405 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.724 HG22 HG22 ' A' ' 18' ' ' VAL . 2.2 p -96.8 125.7 41.44 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.068 -1.02 . . . . 0.0 109.354 -179.857 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.572 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -136.8 144.42 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.99 -1.069 . . . . 0.0 109.888 -179.26 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.611 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.0 OUTLIER -149.0 -174.93 4.77 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 120.455 -1.403 . . . . 0.0 110.998 -179.845 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.61 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.94 -101.84 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 -179.766 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.05 140.46 49.06 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.815 -1.178 . . . . 0.0 108.052 179.43 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.58 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -161.79 137.13 7.45 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 118.642 -1.223 . . . . 0.0 109.759 -178.118 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.522 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 10.3 mm-40 -34.97 122.06 0.55 Allowed 'General case' 0 N--CA 1.49 1.546 0 CA-C-O 121.387 0.613 . . . . 0.0 110.351 -178.468 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.088 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.29 51.25 1.86 Allowed Glycine 0 N--CA 1.493 2.458 0 C-N-CA 120.548 -0.835 . . . . 0.0 111.06 -179.268 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -39.24 115.39 0.49 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.04 -1.271 . . . . 0.0 110.108 179.572 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.691 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.49 126.46 34.45 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 120.928 -1.108 . . . . 0.0 109.495 -179.895 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.8 t80 -64.38 58.46 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.989 0 O-C-N 120.876 -1.14 . . . . 0.0 110.091 179.685 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' LEU . 17.0 t0 -160.19 19.65 0.15 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.987 -1.07 . . . . 0.0 109.664 179.83 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.05 -28.03 5.26 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.999 -1.241 . . . . 0.0 109.999 179.931 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.414 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 10.3 p -94.27 161.0 14.43 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.034 -1.274 . . . . 0.0 110.384 -179.446 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.48 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -107.97 138.13 44.77 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.84 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.691 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -83.61 -17.96 39.82 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.71 -1.244 . . . . 0.0 110.674 -178.411 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.0 176.43 19.99 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 108.644 -1.783 . . . . 0.0 108.644 -179.648 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.53 104.45 1.01 Allowed 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.188 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 46' ' ' ALA . 41.0 t -76.09 106.62 6.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.287 -0.883 . . . . 0.0 109.133 -178.926 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.546 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -65.68 111.24 3.1 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.493 -0.755 . . . . 0.0 110.026 -179.352 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.61 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.47 -5.71 4.07 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.813 179.353 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.5 p -86.58 -0.93 57.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.747 -1.221 . . . . 0.0 109.202 179.681 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.546 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -112.87 -50.1 2.9 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.29 -0.881 . . . . 0.0 108.995 179.977 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.94 -179.04 3.83 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.488 -0.757 . . . . 0.0 109.42 179.782 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.06 115.75 30.8 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.386 -0.821 . . . . 0.0 108.905 179.992 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.531 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -96.87 121.43 38.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.851 -1.156 . . . . 0.0 109.483 -179.455 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.619 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.85 146.29 28.5 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.437 1.113 . . . . 0.0 111.215 -179.32 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.3 t -102.46 109.77 27.35 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 177.632 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.439 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.6 -173.11 18.38 Favored Glycine 0 N--CA 1.486 2.016 0 C-N-CA 118.142 -1.98 . . . . 0.0 111.709 -177.601 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.5 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -113.71 -178.95 3.5 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.069 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.465 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.0 OUTLIER . . . . . 0 C--N 1.297 -1.711 0 O-C-N 121.219 -0.926 . . . . 0.0 109.711 -179.203 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.696 0 N-CA-C 107.776 -2.13 . . . . 0.0 107.776 . . . . . . . . . 0 0 . 1 . 036 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.61 -177.72 5.76 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-O 122.007 0.908 . . . . 0.0 109.785 179.279 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.38 -161.85 15.27 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 -179.44 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.504 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.3 Cg_exo -47.08 177.98 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.693 0 CA-C-N 118.874 1.337 . . . . 0.0 110.202 179.324 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -92.27 -175.17 3.96 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.06 -1.025 . . . . 0.0 110.511 -178.83 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.439 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.24 163.46 14.68 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.944 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.9 128.92 52.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.426 -1.044 . . . . 0.0 109.222 -179.441 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.619 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.22 123.22 23.26 Favored 'General case' 0 C--N 1.29 -2.015 0 O-C-N 121.687 -0.633 . . . . 0.0 109.562 179.672 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.917 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.72 167.69 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 O-C-N 121.221 -0.924 . . . . 0.0 109.193 -179.925 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.507 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -134.73 154.26 51.65 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.277 -0.889 . . . . 0.0 109.565 -179.873 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.917 ' CE1' HD12 ' A' ' 110' ' ' ILE . 30.3 m-85 . . . . . 0 N--CA 1.487 1.382 0 O-C-N 121.15 -0.969 . . . . 0.0 109.566 -179.729 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.593 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.456 0 CA-C-O 122.364 1.078 . . . . 0.0 110.863 . . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.949 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.6 t -112.46 108.58 17.76 Favored 'General case' 0 C--N 1.296 -1.738 0 CA-C-O 123.084 1.421 . . . . 0.0 109.117 179.357 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.79 HG22 HG23 ' A' ' 21' ' ' VAL . 2.4 t -115.31 140.38 36.99 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.699 0 CA-C-N 114.275 -1.329 . . . . 0.0 110.102 -179.521 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.496 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -176.04 149.82 1.03 Allowed Pre-proline 0 N--CA 1.487 1.375 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.772 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.496 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.2 Cg_endo -77.43 152.57 93.88 Favored 'Cis proline' 0 C--N 1.312 -1.353 0 C-N-CA 123.572 -1.428 . . . . 0.0 109.313 -0.813 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.639 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.5 m -89.76 -26.51 20.58 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 179.761 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.48 ' HB3' ' HB2' ' A' ' 111' ' ' SER . 5.3 m -135.23 164.31 27.99 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.587 -0.696 . . . . 0.0 109.609 179.858 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.3 37.03 29.14 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 108.767 -1.733 . . . . 0.0 108.767 -179.841 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.766 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.6 mt -93.23 -42.69 9.21 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-O 123.242 1.496 . . . . 0.0 110.405 -178.406 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.83 145.3 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.277 0 CA-C-N 113.322 -1.763 . . . . 0.0 109.954 -179.735 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.613 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.2 p-10 -51.26 106.81 0.15 Allowed 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.493 0.663 . . . . 0.0 111.513 -178.749 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.54 13.16 9.01 Favored Glycine 0 N--CA 1.483 1.823 0 C-N-CA 119.401 -1.38 . . . . 0.0 112.986 177.317 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.766 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -105.31 -172.4 2.09 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 121.242 2.521 . . . . 0.0 109.673 179.167 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.738 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.2 t -126.6 135.56 63.39 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 114.866 -1.061 . . . . 0.0 111.097 -178.897 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.66 ' CG1' HD13 ' A' ' 13' ' ' LEU . 17.3 m -109.04 156.82 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.664 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -114.06 109.27 18.18 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.091 -1.005 . . . . 0.0 109.16 179.949 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.79 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -104.07 140.01 23.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 179.749 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.949 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.77 160.4 38.29 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 118.605 -1.238 . . . . 0.0 109.85 179.856 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -131.4 144.96 16.6 Favored Glycine 0 C--N 1.293 -1.807 0 N-CA-C 108.179 -1.968 . . . . 0.0 108.179 179.751 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.88 124.53 11.79 Favored 'General case' 0 C--N 1.295 -1.792 0 O-C-N 120.901 -1.352 . . . . 0.0 108.785 179.182 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.99 26.7 23.47 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.337 -1.411 . . . . 0.0 109.631 -179.623 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.603 HD22 ' HG3' ' A' ' 105' ' ' PRO . 1.9 mt -87.43 174.57 8.44 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 120.897 -1.355 . . . . 0.0 108.445 -179.901 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.42 96.96 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.04 -1.037 . . . . 0.0 109.674 -179.714 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.659 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 76.83 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.45 -179.091 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.01 33.77 0.32 Allowed Glycine 0 N--CA 1.486 2.027 0 N-CA-C 109.731 -1.347 . . . . 0.0 109.731 179.347 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.554 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 1.2 t -148.15 114.88 6.03 Favored 'General case' 0 C--N 1.309 -1.181 0 O-C-N 120.869 -1.371 . . . . 0.0 111.098 179.899 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.45 129.86 3.93 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.996 178.55 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.499 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 10.7 m-85 -119.47 150.84 39.55 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.368 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.506 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -102.05 159.39 15.41 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.703 -1.248 . . . . 0.0 107.856 178.728 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.645 HG22 HG11 ' A' ' 21' ' ' VAL . 5.1 p -144.03 117.27 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.075 -1.016 . . . . 0.0 109.852 -177.914 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.12 -178.73 40.18 Favored Glycine 0 N--CA 1.494 2.518 0 C-N-CA 118.324 -1.893 . . . . 0.0 111.849 -179.86 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.592 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -100.43 108.88 20.98 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -179.862 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.24 148.34 52.06 Favored 'General case' 0 C--N 1.296 -1.731 0 O-C-N 121.286 -0.884 . . . . 0.0 109.704 179.777 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.512 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.96 138.63 54.34 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.274 -0.891 . . . . 0.0 110.776 -179.005 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.867 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.45 114.75 26.55 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 178.137 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -106.12 14.79 7.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.934 -1.104 . . . . 0.0 110.64 -178.716 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.61 -175.65 0.08 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.926 -1.109 . . . . 0.0 110.101 179.694 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.775 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.3 97.53 1.26 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 121.799 0.809 . . . . 0.0 110.031 -179.605 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.26 27.11 37.64 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 120.261 -0.971 . . . . 0.0 111.429 178.785 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -114.85 106.14 20.03 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 O-C-N 120.617 -1.519 . . . . 0.0 107.375 178.818 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.867 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -117.01 104.71 11.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.459 -1.401 . . . . 0.0 109.629 -177.803 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.058 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.94 109.55 22.28 Favored 'General case' 0 N--CA 1.485 1.316 0 O-C-N 120.808 -1.183 . . . . 0.0 108.415 179.093 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.6 t -105.98 162.83 13.25 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.952 -1.092 . . . . 0.0 110.115 -179.254 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.548 HD22 ' HB3' ' A' ' 50' ' ' ALA . 17.0 t30 -107.01 140.89 21.84 Favored Pre-proline 0 N--CA 1.504 2.259 0 O-C-N 121.348 -0.845 . . . . 0.0 110.13 -179.218 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.573 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 8.2 Cg_endo -76.36 27.65 0.41 Allowed 'Trans proline' 0 C--N 1.318 -1.029 0 C-N-CA 122.662 2.241 . . . . 0.0 111.636 -179.665 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.548 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -121.49 3.57 10.21 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.394 -1.441 . . . . 0.0 109.522 -179.869 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.523 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -138.48 15.41 2.75 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 179.435 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -80.11 91.68 5.55 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.508 -0.745 . . . . 0.0 110.815 -178.675 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.59 -168.53 1.33 Allowed 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.387 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.98 135.2 0.09 Allowed 'General case' 0 N--CA 1.486 1.349 0 O-C-N 120.633 -1.292 . . . . 0.0 111.486 -179.381 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.872 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -149.02 157.53 6.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 177.935 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.567 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.28 146.61 24.96 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.636 -1.29 . . . . 0.0 109.897 -179.489 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.26 108.31 2.68 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-O 122.361 1.077 . . . . 0.0 109.622 178.847 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.533 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.6 t0 -62.95 -138.94 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.005 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.822 -179.867 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.659 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.9 -51.99 36.42 Favored 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.349 -0.845 . . . . 0.0 110.676 -178.657 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.06 -32.36 9.24 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.714 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.0 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.07 64.89 0.61 Allowed Glycine 0 C--N 1.298 -1.583 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 178.262 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.5 m -99.57 129.31 45.72 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.465 -1.021 . . . . 0.0 108.664 178.772 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.872 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.74 108.63 6.69 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.805 -179.329 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 51.8 p -122.15 119.45 31.32 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.259 -0.901 . . . . 0.0 109.455 179.936 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.571 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.22 143.46 30.29 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.519 -0.738 . . . . 0.0 109.417 179.894 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 15.9 p -100.01 140.63 33.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.406 -0.809 . . . . 0.0 109.406 179.961 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.789 HD12 ' H ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.37 168.82 18.97 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.405 -0.809 . . . . 0.0 109.382 -179.426 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.716 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -96.82 124.86 40.92 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.03 -1.044 . . . . 0.0 109.424 -179.823 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.598 ' CG2' HG13 ' A' ' 19' ' ' VAL . 15.9 m -137.05 143.54 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.932 -1.105 . . . . 0.0 109.728 -179.259 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.613 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.1 ptt180 -148.79 -175.34 4.91 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.519 -1.363 . . . . 0.0 110.9 -179.835 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.612 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.76 -101.2 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.7 -179.413 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.507 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.86 142.03 42.61 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.812 -1.18 . . . . 0.0 108.319 179.785 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.582 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.93 134.59 4.38 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 118.783 -1.167 . . . . 0.0 109.64 -178.209 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.554 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -33.81 122.82 0.46 Allowed 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.519 0.676 . . . . 0.0 110.465 -178.138 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.058 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.2 49.15 2.7 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.273 -179.187 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.573 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -38.47 115.0 0.42 Allowed 'General case' 0 N--CA 1.509 2.519 0 O-C-N 121.096 -1.237 . . . . 0.0 109.909 179.615 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.726 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -86.72 126.42 34.55 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.938 -1.101 . . . . 0.0 109.357 179.972 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 24.5 t80 -63.48 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.902 -1.124 . . . . 0.0 110.307 179.912 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.548 ' N ' ' O ' ' A' ' 77' ' ' LEU . 22.2 t0 -162.04 20.18 0.1 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.992 -1.068 . . . . 0.0 109.786 179.736 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.65 -27.76 5.17 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 179.821 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.445 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 14.3 p -93.15 160.23 14.94 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.047 -1.267 . . . . 0.0 110.26 -179.466 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.479 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.4 OUTLIER -107.63 136.69 46.96 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.835 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.726 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -82.56 -19.1 39.19 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.848 -1.158 . . . . 0.0 110.407 -178.667 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.54 175.41 19.14 Favored Glycine 0 N--CA 1.485 1.908 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.613 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.84 107.14 1.37 Allowed 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.271 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.622 HG21 ' HB3' ' A' ' 46' ' ' ALA . 47.2 t -79.62 106.71 11.11 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.362 -0.836 . . . . 0.0 109.262 -179.014 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.54 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -67.69 111.67 4.37 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.407 -0.808 . . . . 0.0 109.805 -179.554 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.612 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.16 -5.69 3.49 Favored 'General case' 0 N--CA 1.5 2.046 0 C-N-CA 118.189 -1.404 . . . . 0.0 109.826 179.414 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.14 0.02 54.58 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.644 -1.285 . . . . 0.0 109.158 179.51 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.54 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.66 -49.72 2.87 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.366 -0.834 . . . . 0.0 109.007 -179.98 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.77 179.63 4.21 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.433 -0.792 . . . . 0.0 109.482 179.944 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.94 116.13 31.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.445 -0.785 . . . . 0.0 108.922 179.908 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.85 121.8 39.11 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.86 -1.15 . . . . 0.0 109.371 -179.381 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.6 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.68 146.51 27.63 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.411 1.101 . . . . 0.0 111.359 -179.213 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 65.7 t -102.95 110.06 28.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 177.502 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.76 -173.01 17.61 Favored Glycine 0 N--CA 1.487 2.063 0 C-N-CA 118.041 -2.028 . . . . 0.0 111.828 -177.441 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.593 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -115.98 -178.11 3.32 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 -179.057 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.505 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER . . . . . 0 C--N 1.297 -1.68 0 O-C-N 121.234 -0.916 . . . . 0.0 109.331 -179.527 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.695 0 N-CA-C 107.687 -2.165 . . . . 0.0 107.687 . . . . . . . . . 0 0 . 1 . 037 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.43 -178.49 7.18 Favored 'General case' 0 C--N 1.307 -1.245 0 O-C-N 121.527 -0.984 . . . . 0.0 109.431 179.05 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.64 -166.18 33.36 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -179.554 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.603 ' HG3' HD22 ' A' ' 26' ' ' LEU . 4.3 Cg_exo -49.09 -177.37 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.677 0 CA-C-N 118.7 1.25 . . . . 0.0 110.288 179.525 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -94.54 -176.85 4.04 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.082 -1.011 . . . . 0.0 110.419 -179.02 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -120.45 161.3 14.73 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.969 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.409 ' O ' HG12 ' A' ' 108' ' ' VAL . 1.2 t -100.87 126.37 54.59 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.349 -1.089 . . . . 0.0 109.188 -179.472 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.6 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.1 119.76 16.75 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.745 -0.597 . . . . 0.0 109.431 179.669 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.766 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.96 168.53 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.201 -0.937 . . . . 0.0 109.303 -179.956 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB2' ' HB3' ' A' ' 11' ' ' SER . 2.4 m -138.2 151.31 47.57 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.384 -0.823 . . . . 0.0 109.542 -179.955 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.766 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 22.8 m-85 . . . . . 0 N--CA 1.487 1.382 0 O-C-N 121.146 -0.971 . . . . 0.0 109.531 -179.674 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.484 1.251 0 CA-C-O 122.43 1.109 . . . . 0.0 110.129 . . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.903 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.1 t -116.28 109.02 16.83 Favored 'General case' 0 C--N 1.293 -1.858 0 CA-C-O 123.129 1.442 . . . . 0.0 109.622 179.968 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.948 HG22 HG23 ' A' ' 21' ' ' VAL . 8.0 t -116.92 137.84 49.51 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.709 0 CA-C-N 114.074 -1.421 . . . . 0.0 109.862 -179.874 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.49 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -174.37 151.02 1.57 Allowed Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.331 -0.856 . . . . 0.0 108.804 -179.617 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.49 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.3 Cg_endo -77.47 150.94 91.85 Favored 'Cis proline' 0 C--N 1.312 -1.383 0 C-N-CA 123.539 -1.442 . . . . 0.0 109.392 -0.907 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.677 ' HA ' HG22 ' A' ' 110' ' ' ILE . 89.6 p -92.52 -23.08 19.21 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 121.433 -0.792 . . . . 0.0 109.27 179.692 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.499 ' CB ' ' HB3' ' A' ' 111' ' ' SER . 7.0 m -132.16 159.97 37.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.484 -0.76 . . . . 0.0 109.542 -179.859 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.73 37.61 29.76 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.633 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.773 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.4 mt -91.1 -43.69 9.74 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-O 123.146 1.45 . . . . 0.0 110.641 -178.273 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.35 144.88 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.298 0 CA-C-N 113.471 -1.695 . . . . 0.0 110.224 -179.72 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.594 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.0 p-10 -50.2 106.11 0.11 Allowed 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.494 0.664 . . . . 0.0 111.626 -178.548 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.81 15.0 8.92 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 119.426 -1.368 . . . . 0.0 113.037 177.05 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.773 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -105.8 -174.02 2.44 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 121.29 2.545 . . . . 0.0 109.837 179.227 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.733 HG13 ' O ' ' A' ' 67' ' ' LEU . 15.7 t -130.71 138.56 53.35 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 CA-C-N 114.702 -1.135 . . . . 0.0 111.178 -178.721 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.568 HG12 HD21 ' A' ' 13' ' ' LEU . 33.8 m -113.06 155.16 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 178.75 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -103.96 108.82 20.33 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.021 -1.05 . . . . 0.0 109.167 179.971 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.948 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.51 140.06 21.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.893 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.903 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -133.76 159.18 41.37 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.866 -1.146 . . . . 0.0 109.638 179.484 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.581 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -141.08 108.8 0.57 Allowed Glycine 0 N--CA 1.482 1.76 0 N-CA-C 108.753 -1.739 . . . . 0.0 108.753 179.97 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.426 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.28 140.35 49.42 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 119.259 1.529 . . . . 0.0 110.426 -179.461 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.48 26.9 34.32 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 118.945 -1.598 . . . . 0.0 109.946 179.57 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.583 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -93.0 169.88 10.09 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 120.933 -1.333 . . . . 0.0 108.534 -179.946 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.58 101.32 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.117 -0.989 . . . . 0.0 109.777 -179.426 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.92 77.88 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.864 -179.327 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.89 33.83 0.28 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.77 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.55 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 18.8 p -138.79 106.35 5.58 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.279 -1.13 . . . . 0.0 110.93 -179.465 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.583 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.39 109.91 0.39 Allowed 'General case' 0 N--CA 1.497 1.903 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.532 178.181 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.483 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 32.6 m-85 -102.81 155.8 18.08 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.147 -0.971 . . . . 0.0 108.901 179.74 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.407 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.46 158.42 15.92 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 178.696 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.63 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.3 p -139.83 120.07 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.189 -0.944 . . . . 0.0 109.472 -177.818 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -169.89 -178.34 40.86 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.23 -1.938 . . . . 0.0 111.796 -179.742 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.729 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.21 109.78 22.03 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.918 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 68.1 m -127.16 152.77 46.9 Favored 'General case' 0 C--N 1.293 -1.86 0 O-C-N 121.22 -0.925 . . . . 0.0 109.819 179.619 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.654 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -126.87 135.66 51.27 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.535 -0.728 . . . . 0.0 110.452 179.965 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.902 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.94 114.69 26.55 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.231 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 20.1 m -104.97 14.42 7.21 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 120.851 -1.155 . . . . 0.0 110.809 -178.65 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.785 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 173.73 -174.5 0.06 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.81 -1.181 . . . . 0.0 110.158 179.65 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 24.5 p -71.69 97.67 1.79 Allowed 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.467 -0.77 . . . . 0.0 109.827 -179.67 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.85 27.63 31.22 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 120.285 -0.959 . . . . 0.0 111.487 178.836 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.785 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.3 t -116.35 106.09 19.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 O-C-N 120.538 -1.566 . . . . 0.0 107.372 179.001 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.902 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.7 tp -116.85 106.37 13.38 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.548 -1.345 . . . . 0.0 109.989 -177.703 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.105 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -95.72 109.78 22.02 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.803 -1.185 . . . . 0.0 108.161 179.137 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.4 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 66.5 m -100.12 145.88 27.47 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.225 -0.922 . . . . 0.0 110.415 -178.354 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.502 ' HB3' ' HG2' ' A' ' 36' ' ' GLN . 7.4 t30 -99.23 129.23 29.8 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.217 -0.927 . . . . 0.0 108.673 179.097 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.4 Cg_endo -71.41 23.05 0.23 Allowed 'Trans proline' 0 C--N 1.317 -1.108 0 C-N-CA 122.102 1.868 . . . . 0.0 111.968 179.923 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.494 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -103.35 -5.86 22.54 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.4 -1.437 . . . . 0.0 109.106 179.68 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.696 ' OD2' HG13 ' A' ' 69' ' ' VAL . 5.6 m-20 -134.13 6.39 3.62 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.351 -0.843 . . . . 0.0 108.89 -179.961 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -62.42 84.18 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.336 -0.852 . . . . 0.0 110.655 -178.672 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.63 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.5 -167.87 1.32 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 178.605 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.47 135.73 0.08 Allowed 'General case' 0 C--N 1.304 -1.404 0 O-C-N 120.68 -1.262 . . . . 0.0 111.383 -179.321 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.925 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -150.83 156.13 6.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 177.94 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.583 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.69 142.0 30.8 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.721 -1.237 . . . . 0.0 110.162 -179.525 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.011 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.26 106.4 0.73 Allowed 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 122.559 1.171 . . . . 0.0 109.45 178.316 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.2 p-10 -59.7 -139.51 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.862 179.962 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.75 -50.87 59.78 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.454 -0.778 . . . . 0.0 110.715 -178.711 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -102.94 -33.79 9.18 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 178.462 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.43 65.9 0.61 Allowed Glycine 0 C--N 1.298 -1.548 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.575 177.941 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.581 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 23.2 m -102.81 126.49 49.97 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 178.631 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.925 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.24 109.17 8.68 Favored 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 119.457 -0.897 . . . . 0.0 109.296 -179.29 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.407 ' HB3' ' HE3' ' A' ' 20' ' ' LYS . 1.4 m -123.35 119.42 30.04 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.412 -0.805 . . . . 0.0 109.646 -179.73 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.55 150.31 36.17 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.698 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.2 p -98.04 136.7 37.92 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.196 -0.94 . . . . 0.0 109.484 -179.785 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.912 HD11 HG11 ' A' ' 21' ' ' VAL . 0.2 OUTLIER -128.99 160.65 32.06 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.442 -0.786 . . . . 0.0 109.485 -178.913 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.665 HG22 HG22 ' A' ' 18' ' ' VAL . 1.3 p -100.95 123.23 44.82 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.03 -1.044 . . . . 0.0 108.861 179.525 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.729 HG12 ' HB3' ' A' ' 36' ' ' GLN . 17.6 m -135.25 142.81 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 120.872 -1.143 . . . . 0.0 110.486 -178.579 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.594 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.4 ptt180 -145.5 -171.81 3.75 Favored 'General case' 0 N--CA 1.484 1.263 0 O-C-N 120.582 -1.324 . . . . 0.0 110.825 179.55 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.588 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -57.34 -99.67 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.197 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.513 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.79 142.23 50.8 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 120.343 -1.473 . . . . 0.0 108.218 179.517 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.654 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.4 OUTLIER -162.07 135.09 6.05 Favored 'General case' 0 C--N 1.295 -1.771 0 C-N-CA 118.581 -1.248 . . . . 0.0 110.027 -178.05 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.544 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 20.5 mt-10 -35.22 120.99 0.55 Allowed 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.458 0.647 . . . . 0.0 110.231 -178.723 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.105 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.74 51.22 2.01 Favored Glycine 0 N--CA 1.494 2.55 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.665 -178.793 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -38.32 115.88 0.48 Allowed 'General case' 0 N--CA 1.507 2.396 0 O-C-N 121.04 -1.271 . . . . 0.0 110.012 179.26 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.767 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -86.78 126.06 34.35 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 120.816 -1.177 . . . . 0.0 109.594 -179.623 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -64.34 58.93 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.842 -1.161 . . . . 0.0 109.837 179.519 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.6 t70 -159.68 19.76 0.17 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.984 -1.072 . . . . 0.0 109.715 179.936 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.6 -27.91 5.59 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.811 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.467 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 73.1 p -98.49 162.6 13.07 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.142 -1.21 . . . . 0.0 110.39 -179.439 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.486 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 2.1 ptt180 -106.54 142.13 36.7 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.859 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.767 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.6 t90 -85.19 -19.77 31.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.635 -1.291 . . . . 0.0 110.601 -178.505 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.1 177.12 18.77 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.631 -1.788 . . . . 0.0 108.631 -179.424 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -66.4 105.33 1.43 Allowed 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 179.198 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.591 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 44.3 t -76.13 104.83 4.52 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.24 -0.913 . . . . 0.0 109.048 -179.058 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.529 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.05 111.17 3.24 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.46 -0.775 . . . . 0.0 109.686 -179.508 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.588 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.77 -4.85 4.76 Favored 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 118.245 -1.382 . . . . 0.0 109.71 179.51 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -86.83 1.81 51.15 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.782 -1.199 . . . . 0.0 109.017 179.341 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.529 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -117.01 -51.14 2.56 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.376 -0.828 . . . . 0.0 108.951 179.975 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.31 -179.92 4.09 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.479 -0.763 . . . . 0.0 109.383 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.25 115.7 30.85 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.446 -0.784 . . . . 0.0 108.935 179.807 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.527 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.03 124.53 41.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.84 -1.162 . . . . 0.0 109.582 -179.264 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.57 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -102.97 147.73 26.57 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.344 1.069 . . . . 0.0 111.405 -179.241 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.496 ' CG1' HG11 ' A' ' 7' ' ' VAL . 44.8 t -104.6 113.12 40.78 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 177.498 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.509 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -155.08 -169.77 19.99 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 117.886 -2.102 . . . . 0.0 111.802 -177.766 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.46 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -120.56 177.59 5.0 Favored 'General case' 0 N--CA 1.484 1.245 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -179.138 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 2.1 t . . . . . 0 C--N 1.294 -1.833 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.907 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.654 0 N-CA-C 107.96 -2.056 . . . . 0.0 107.96 . . . . . . . . . 0 0 . 1 . 038 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.53 -177.65 6.08 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-O 122.1 0.952 . . . . 0.0 109.839 179.263 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.496 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.31 -161.34 21.77 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.176 -1.97 . . . . 0.0 108.176 -179.361 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.501 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.3 Cg_exo -47.73 -178.77 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.671 0 CA-C-N 118.96 1.38 . . . . 0.0 110.313 179.206 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -96.69 178.04 5.45 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.979 -1.075 . . . . 0.0 110.364 -178.958 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.509 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.7 172.64 14.32 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.983 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -110.87 153.55 12.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.495 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.57 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -95.75 122.45 38.55 Favored 'General case' 0 C--N 1.291 -1.959 0 O-C-N 121.217 -0.927 . . . . 0.0 109.392 179.79 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.852 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.99 168.98 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 121.091 -1.005 . . . . 0.0 109.032 -179.905 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.499 ' HB3' ' CB ' ' A' ' 11' ' ' SER . 13.0 t -138.92 157.9 45.18 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.175 -0.953 . . . . 0.0 109.68 -179.91 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.852 ' CE2' HD12 ' A' ' 110' ' ' ILE . 82.0 m-85 . . . . . 0 N--CA 1.485 1.32 0 O-C-N 121.23 -0.919 . . . . 0.0 109.488 -179.706 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.505 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.484 1.245 0 CA-C-O 122.366 1.079 . . . . 0.0 110.28 . . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.861 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.6 t -115.9 109.16 17.22 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 123.122 1.439 . . . . 0.0 109.829 -179.827 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.817 HG22 HG23 ' A' ' 21' ' ' VAL . 2.2 t -114.78 133.7 60.1 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.19 -1.368 . . . . 0.0 109.787 179.855 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.513 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -169.26 150.17 4.15 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.232 -0.917 . . . . 0.0 108.809 -179.604 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.513 ' HA ' HG23 ' A' ' 8' ' ' THR . 1.2 Cg_endo -75.33 155.31 99.56 Favored 'Cis proline' 0 C--N 1.312 -1.35 0 C-N-CA 123.521 -1.45 . . . . 0.0 109.399 -0.873 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.5 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 15.4 m -99.62 -19.83 16.63 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.754 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.502 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 19.2 m -136.02 159.07 42.84 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.426 -0.796 . . . . 0.0 109.678 -179.945 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.37 37.78 30.67 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 108.526 -1.829 . . . . 0.0 108.526 -179.688 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.794 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.1 mt -89.75 -44.31 10.08 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 123.056 1.407 . . . . 0.0 110.599 -178.383 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.462 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.0 144.39 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.363 0 CA-C-N 113.633 -1.622 . . . . 0.0 109.935 -179.638 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.605 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.1 p-10 -50.86 105.0 0.09 Allowed 'General case' 0 C--N 1.301 -1.504 0 CA-C-O 121.632 0.729 . . . . 0.0 111.435 -178.565 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.04 14.77 7.61 Favored Glycine 0 N--CA 1.485 1.902 0 C-N-CA 119.396 -1.383 . . . . 0.0 113.055 177.383 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.794 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.7 t -104.48 -173.55 2.33 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 121.264 2.532 . . . . 0.0 109.717 179.116 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.748 HG13 ' O ' ' A' ' 67' ' ' LEU . 18.1 t -127.65 135.99 61.64 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.89 -1.05 . . . . 0.0 111.424 -178.598 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.594 HG23 ' CD1' ' A' ' 67' ' ' LEU . 34.7 m -111.2 154.6 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.529 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 5.4 tttt -110.31 109.28 19.66 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 108.894 179.875 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.817 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.27 139.17 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.347 -0.846 . . . . 0.0 108.734 -179.929 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.861 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.0 162.38 32.22 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 118.819 -1.153 . . . . 0.0 110.107 179.656 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.603 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.71 140.35 11.39 Favored Glycine 0 C--N 1.299 -1.525 0 N-CA-C 107.899 -2.08 . . . . 0.0 107.899 179.694 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.94 124.96 15.24 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.514 -1.58 . . . . 0.0 109.409 179.299 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.55 28.62 18.81 Favored Glycine 0 N--CA 1.488 2.107 0 C-N-CA 118.776 -1.678 . . . . 0.0 109.678 -179.705 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.54 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -89.79 171.86 9.32 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.006 -1.291 . . . . 0.0 108.249 179.875 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.008 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.92 99.6 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.969 -1.082 . . . . 0.0 109.926 -179.498 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.5 77.05 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.136 -179.333 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.91 33.83 0.22 Allowed Glycine 0 N--CA 1.486 2.022 0 N-CA-C 109.311 -1.515 . . . . 0.0 109.311 179.634 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 40.4 p -141.38 107.32 5.16 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 121.09 -1.241 . . . . 0.0 111.399 -179.35 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.599 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.83 109.79 0.36 Allowed 'General case' 0 N--CA 1.496 1.835 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.621 177.828 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.494 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.4 m-30 -105.42 157.54 17.27 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.119 -0.988 . . . . 0.0 108.798 179.745 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.49 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -100.45 167.52 10.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.762 -1.211 . . . . 0.0 108.048 179.209 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.704 HG22 HG11 ' A' ' 21' ' ' VAL . 2.7 p -148.13 119.59 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.132 -0.98 . . . . 0.0 109.648 -178.094 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -171.26 -176.74 40.59 Favored Glycine 0 N--CA 1.496 2.638 0 C-N-CA 118.369 -1.872 . . . . 0.0 111.5 -179.763 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.685 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.71 108.3 20.13 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 -179.979 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -130.01 148.32 51.85 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.306 -0.872 . . . . 0.0 109.833 179.685 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.25 139.84 53.53 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.227 -0.921 . . . . 0.0 110.739 -179.024 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.88 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.12 114.93 26.78 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.119 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.7 m -106.21 15.49 7.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.035 -1.041 . . . . 0.0 110.526 -178.724 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.77 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.7 -176.66 0.09 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.948 -1.095 . . . . 0.0 110.068 179.739 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.794 ' O ' HG23 ' A' ' 42' ' ' THR . 15.2 t -69.78 96.72 1.01 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.503 -0.748 . . . . 0.0 110.009 -179.61 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.93 28.82 33.39 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 120.15 -1.024 . . . . 0.0 111.355 178.892 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.77 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.25 106.42 20.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 O-C-N 120.586 -1.538 . . . . 0.0 107.221 178.769 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.88 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.7 tp -116.89 104.68 11.55 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.427 -1.421 . . . . 0.0 109.706 -177.545 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.989 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.23 109.54 22.28 Favored 'General case' 0 N--CA 1.484 1.244 0 O-C-N 120.827 -1.171 . . . . 0.0 108.295 178.928 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -106.27 166.13 10.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.956 -1.09 . . . . 0.0 110.209 -179.073 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.684 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 12.6 t-20 -108.22 134.45 20.18 Favored Pre-proline 0 N--CA 1.498 1.952 0 O-C-N 121.376 -0.827 . . . . 0.0 109.599 -179.411 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.627 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.1 Cg_endo -73.93 24.29 0.34 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 122.452 2.102 . . . . 0.0 112.108 -179.655 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.684 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -113.75 -0.69 14.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.322 -1.486 . . . . 0.0 109.183 179.643 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.898 ' HB3' HD22 ' A' ' 67' ' ' LEU . 2.2 m-20 -136.38 18.26 3.15 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 179.651 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -78.04 83.96 4.32 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.66 -0.816 . . . . 0.0 110.62 -178.525 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -106.27 -170.51 1.74 Allowed 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 178.523 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.458 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.61 136.39 0.09 Allowed 'General case' 0 C--N 1.305 -1.351 0 O-C-N 120.705 -1.247 . . . . 0.0 111.008 -179.273 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.776 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.7 p -148.58 159.07 6.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 178.259 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.599 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.56 141.6 31.2 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 120.729 -1.232 . . . . 0.0 109.802 -179.923 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.008 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.09 108.04 1.72 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 122.305 1.05 . . . . 0.0 109.651 178.57 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.567 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.0 t0 -64.08 -139.44 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.027 0 CA-C-O 121.377 0.608 . . . . 0.0 110.809 179.864 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.95 -52.0 36.91 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.386 -0.821 . . . . 0.0 110.821 -178.706 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -102.49 -32.17 10.08 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 178.633 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.995 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 103.3 66.6 0.73 Allowed Glycine 0 C--N 1.298 -1.572 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.262 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.603 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 52.6 m -98.82 130.73 45.26 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.603 -0.939 . . . . 0.0 108.764 178.866 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.776 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.09 109.13 8.74 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 119.299 -0.96 . . . . 0.0 109.335 -179.576 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.9 m -123.08 116.86 24.19 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.237 -0.914 . . . . 0.0 109.498 -179.803 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.616 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.24 143.58 29.31 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.385 -0.822 . . . . 0.0 109.523 -179.993 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.0 p -99.83 147.33 25.62 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.363 -0.835 . . . . 0.0 109.469 -179.892 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.898 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -147.56 168.43 21.98 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.441 -0.787 . . . . 0.0 109.398 -179.155 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.696 HG22 HG22 ' A' ' 18' ' ' VAL . 2.5 p -100.19 121.81 42.03 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.84 -1.163 . . . . 0.0 110.098 -178.937 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.823 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.5 m -129.08 144.17 38.99 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 120.897 -1.127 . . . . 0.0 110.162 -179.404 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.605 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.7 ptt180 -149.1 -177.47 5.84 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 120.576 -1.327 . . . . 0.0 110.838 179.722 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.578 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.6 -102.58 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.702 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.508 ' OG ' ' NH1' ' A' ' 71' ' ' ARG . 0.7 OUTLIER -57.56 140.41 50.96 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 120.712 -1.242 . . . . 0.0 108.161 179.388 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.41 136.69 8.66 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.934 -178.124 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.522 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 8.9 mm-40 -32.28 120.15 0.29 Allowed 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.47 0.652 . . . . 0.0 110.6 -178.591 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.989 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.84 47.19 2.95 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.573 -0.823 . . . . 0.0 111.175 -179.195 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.627 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -38.38 113.99 0.33 Allowed 'General case' 0 N--CA 1.508 2.428 0 O-C-N 121.168 -1.195 . . . . 0.0 110.085 179.607 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.724 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -87.56 126.33 34.87 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.869 -1.145 . . . . 0.0 109.509 -179.816 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 16.4 t80 -64.26 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.856 -1.153 . . . . 0.0 110.035 179.693 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.0 t0 -159.87 19.25 0.16 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.982 -1.073 . . . . 0.0 109.735 179.895 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.93 -27.02 5.64 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.837 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.403 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.3 p -95.17 161.47 14.1 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.006 -1.29 . . . . 0.0 110.361 -179.491 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.475 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -107.66 136.32 47.61 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.832 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.724 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -83.03 -17.61 42.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.858 -1.151 . . . . 0.0 110.502 -178.649 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.71 174.02 19.65 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 108.862 -1.695 . . . . 0.0 108.862 -179.632 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.97 105.97 0.95 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.08 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.641 HG21 ' HB3' ' A' ' 46' ' ' ALA . 46.1 t -76.94 105.46 5.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.385 -0.822 . . . . 0.0 109.45 -178.682 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.558 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.9 m-20 -64.01 110.61 2.19 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.43 -0.793 . . . . 0.0 109.7 -179.624 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.578 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.3 t -65.0 -4.48 4.65 Favored 'General case' 0 N--CA 1.499 2.024 0 C-N-CA 118.289 -1.364 . . . . 0.0 109.969 179.505 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 38.7 p -86.82 -1.14 57.54 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.712 -1.242 . . . . 0.0 109.239 179.579 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.558 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -112.28 -50.27 2.91 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.34 -0.85 . . . . 0.0 108.917 -179.99 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.39 -178.27 3.61 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.596 -0.69 . . . . 0.0 109.301 179.724 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.29 115.51 30.33 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.349 -0.844 . . . . 0.0 109.14 -179.989 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.77 121.62 38.82 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.848 -1.158 . . . . 0.0 109.244 -179.578 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.656 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.31 145.26 30.22 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 122.424 1.107 . . . . 0.0 111.16 -179.176 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.502 ' HB ' HG11 ' A' ' 7' ' ' VAL . 49.1 t -101.73 109.88 27.1 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.999 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 177.68 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.489 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.7 -170.57 16.62 Favored Glycine 0 N--CA 1.486 2.012 0 C-N-CA 118.26 -1.924 . . . . 0.0 111.666 -177.569 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.49 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -112.91 179.61 3.92 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 -179.197 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.494 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 33.8 p . . . . . 0 C--N 1.295 -1.762 0 O-C-N 121.381 -0.824 . . . . 0.0 109.585 -179.328 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.772 0 N-CA-C 107.657 -2.177 . . . . 0.0 107.657 . . . . . . . . . 0 0 . 1 . 039 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.58 -178.04 6.83 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 122.104 0.954 . . . . 0.0 109.768 179.206 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.46 -162.65 14.65 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 -179.404 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.3 Cg_exo -47.09 177.09 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.608 0 CA-C-N 118.807 1.304 . . . . 0.0 110.042 179.258 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -91.81 -178.57 5.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.015 -1.053 . . . . 0.0 110.409 -178.704 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.489 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.74 165.29 12.95 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.954 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.456 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.83 129.51 51.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 O-C-N 121.458 -1.025 . . . . 0.0 109.249 -179.413 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.656 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.31 126.6 30.49 Favored 'General case' 0 C--N 1.291 -1.972 0 O-C-N 121.677 -0.639 . . . . 0.0 109.791 179.756 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.697 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 20.8 pt -97.43 177.2 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.226 -0.921 . . . . 0.0 109.473 -179.884 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.502 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.3 m -144.2 150.96 38.81 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.464 -0.772 . . . . 0.0 109.54 179.851 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.697 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 94.9 m-85 . . . . . 0 N--CA 1.485 1.297 0 O-C-N 121.115 -0.991 . . . . 0.0 109.506 -179.636 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.511 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.215 0 CA-C-O 122.361 1.076 . . . . 0.0 110.599 . . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.015 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -104.82 104.72 14.55 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 122.456 1.122 . . . . 0.0 110.243 -179.495 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.928 HG22 HG23 ' A' ' 21' ' ' VAL . 14.7 t -119.51 115.4 47.5 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.443 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.265 179.704 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.72 148.94 12.95 Favored Pre-proline 0 N--CA 1.488 1.451 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.547 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -78.59 149.77 86.21 Favored 'Cis proline' 0 C--N 1.31 -1.497 0 C-N-CA 123.726 -1.364 . . . . 0.0 109.558 -0.609 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.657 ' HA ' HG22 ' A' ' 110' ' ' ILE . 77.6 p -91.7 -24.06 19.6 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.543 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.479 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 0.9 OUTLIER -131.28 162.18 30.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.45 -0.781 . . . . 0.0 109.513 -179.921 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.17 38.37 34.78 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 -179.536 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.809 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.5 mt -91.51 -44.28 9.19 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 123.142 1.448 . . . . 0.0 110.691 -178.233 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.472 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.7 144.87 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.274 0 CA-C-N 113.587 -1.642 . . . . 0.0 109.915 -179.629 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.577 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 9.2 p-10 -50.81 106.29 0.12 Allowed 'General case' 0 C--N 1.302 -1.46 0 CA-C-O 121.492 0.663 . . . . 0.0 111.674 -178.575 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.55 15.51 8.77 Favored Glycine 0 N--CA 1.485 1.918 0 C-N-CA 119.523 -1.323 . . . . 0.0 112.944 177.178 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.809 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.9 t -103.93 -172.3 2.08 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 121.156 2.478 . . . . 0.0 109.835 179.304 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.761 HG22 HG22 ' A' ' 68' ' ' THR . 15.1 t -131.56 140.23 48.75 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.301 0 CA-C-N 114.873 -1.058 . . . . 0.0 111.186 -178.817 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.638 HG22 HG22 ' A' ' 69' ' ' VAL . 4.1 m -117.86 154.72 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 178.948 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -106.91 108.74 20.39 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.078 -1.014 . . . . 0.0 109.311 179.927 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.928 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -106.23 122.16 59.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 179.775 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.015 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.54 165.97 12.2 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 120.913 -1.117 . . . . 0.0 109.068 179.933 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.16 108.1 0.5 Allowed Glycine 0 N--CA 1.483 1.778 0 N-CA-C 108.586 -1.806 . . . . 0.0 108.586 179.848 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.438 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.58 140.31 49.53 Favored 'General case' 0 N--CA 1.498 1.954 0 CA-C-N 119.192 1.496 . . . . 0.0 110.282 -179.274 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.73 28.1 33.07 Favored Glycine 0 N--CA 1.489 2.184 0 C-N-CA 119.025 -1.559 . . . . 0.0 109.845 179.777 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -92.55 175.08 6.96 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.931 -1.335 . . . . 0.0 108.352 179.929 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.998 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.94 98.84 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.448 0 O-C-N 120.878 -1.139 . . . . 0.0 109.601 -179.625 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.663 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.3 77.48 0.0 OUTLIER 'General case' 0 C--N 1.294 -1.807 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.269 -179.131 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.31 34.35 0.32 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.457 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.564 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 59.7 p -145.42 112.08 5.87 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.075 -1.25 . . . . 0.0 111.196 -179.691 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.552 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.42 126.84 5.56 Favored 'General case' 0 N--CA 1.491 1.615 0 CA-C-O 121.458 0.647 . . . . 0.0 109.523 178.098 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.493 ' HA ' ' O ' ' A' ' 98' ' ' SER . 12.1 m-85 -118.09 150.26 39.63 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.736 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.512 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -100.84 159.0 15.56 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.652 -1.28 . . . . 0.0 107.729 178.535 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.68 HG13 ' O ' ' A' ' 34' ' ' VAL . 7.4 p -144.27 116.04 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.085 -1.009 . . . . 0.0 110.045 -177.637 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.2 -178.78 39.74 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.414 -1.85 . . . . 0.0 111.857 -179.919 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.598 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -100.31 109.01 21.2 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -179.872 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.58 148.02 52.33 Favored 'General case' 0 C--N 1.294 -1.81 0 O-C-N 121.357 -0.84 . . . . 0.0 109.835 179.873 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.466 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.9 138.94 54.21 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.375 -0.828 . . . . 0.0 110.702 -179.082 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.874 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.55 114.67 26.45 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 178.187 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.42 ' O ' ' OD2' ' A' ' 41' ' ' ASP . 17.1 m -105.71 14.72 7.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.971 -1.081 . . . . 0.0 110.576 -178.679 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.761 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.92 -175.17 0.08 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.923 -1.111 . . . . 0.0 110.086 179.749 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 46.2 p -71.85 97.54 1.83 Allowed 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.428 -0.795 . . . . 0.0 109.717 -179.655 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.33 27.13 34.05 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 120.293 -0.956 . . . . 0.0 111.487 178.921 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.761 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.93 106.13 19.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.222 0 O-C-N 120.566 -1.549 . . . . 0.0 107.337 178.872 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.874 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.6 tp -117.24 104.67 11.4 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.531 -1.356 . . . . 0.0 109.669 -177.839 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.077 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.76 109.36 22.13 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.787 -1.196 . . . . 0.0 108.331 178.956 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.8 t -105.39 164.51 11.81 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.05 -1.031 . . . . 0.0 110.123 -179.055 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.695 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 13.6 t-20 -106.76 138.9 19.91 Favored Pre-proline 0 N--CA 1.501 2.087 0 O-C-N 121.333 -0.854 . . . . 0.0 110.095 -179.031 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.576 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 6.9 Cg_endo -75.88 25.9 0.41 Allowed 'Trans proline' 0 C--N 1.319 -1.012 0 C-N-CA 122.537 2.158 . . . . 0.0 111.705 179.987 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.695 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -121.43 3.54 10.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.403 -1.436 . . . . 0.0 109.312 -179.915 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.538 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.09 14.36 3.06 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.285 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -80.18 91.83 5.61 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.799 -178.644 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.617 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.53 -169.23 1.44 Allowed 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 178.356 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.03 135.56 0.09 Allowed 'General case' 0 C--N 1.306 -1.325 0 O-C-N 120.517 -1.364 . . . . 0.0 111.439 -179.351 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.899 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -151.98 157.75 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 178.102 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.41 145.31 26.29 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.595 -1.316 . . . . 0.0 109.976 -179.578 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.998 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.6 107.39 1.71 Allowed 'General case' 0 C--N 1.3 -1.582 0 CA-C-O 122.375 1.083 . . . . 0.0 109.418 178.716 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.7 p-10 -60.37 -139.25 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.019 -179.914 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.663 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.21 -50.43 59.11 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.316 -0.865 . . . . 0.0 110.564 -178.71 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -104.7 -33.71 8.38 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 106.249 -1.759 . . . . 0.0 106.249 178.529 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.982 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.01 66.99 0.61 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 178.205 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.8 m -104.3 124.84 49.89 Favored 'General case' 0 N--CA 1.485 1.28 0 O-C-N 121.674 -0.898 . . . . 0.0 108.686 178.818 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.899 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.15 109.21 8.76 Favored 'General case' 0 C--N 1.296 -1.733 0 C-N-CA 119.699 -0.8 . . . . 0.0 109.479 -179.412 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 81.2 p -117.87 118.64 32.57 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.348 -0.845 . . . . 0.0 109.448 -179.924 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.636 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.02 141.24 30.01 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.513 -0.742 . . . . 0.0 109.631 179.92 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.1 p -100.46 131.65 46.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.436 -0.79 . . . . 0.0 109.352 179.955 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.746 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -130.05 166.98 19.03 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.416 -0.803 . . . . 0.0 109.477 -179.512 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.761 HG22 HG22 ' A' ' 18' ' ' VAL . 1.7 p -97.94 124.69 42.49 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.109 -0.994 . . . . 0.0 109.365 -179.834 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.638 HG22 HG22 ' A' ' 19' ' ' VAL . 16.0 m -135.45 143.28 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.082 -1.011 . . . . 0.0 109.767 -179.292 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.577 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 4.6 ptt180 -141.1 -165.62 2.0 Allowed 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.657 -1.277 . . . . 0.0 110.494 -179.912 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.597 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 17.5 mtp180 -72.4 -80.24 0.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.367 -0.833 . . . . 0.0 109.217 -179.498 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.5 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -68.65 138.3 54.89 Favored 'General case' 0 N--CA 1.485 1.282 0 O-C-N 120.051 -1.655 . . . . 0.0 107.284 178.874 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.567 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -162.21 133.99 5.41 Favored 'General case' 0 C--N 1.295 -1.788 0 C-N-CA 117.766 -1.573 . . . . 0.0 110.414 -177.559 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.55 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -33.83 121.95 0.44 Allowed 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.44 0.638 . . . . 0.0 110.234 -178.766 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.077 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.86 51.66 2.27 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 120.512 -0.852 . . . . 0.0 111.392 -178.98 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.576 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -38.97 116.17 0.55 Allowed 'General case' 0 N--CA 1.511 2.615 0 O-C-N 121.075 -1.25 . . . . 0.0 109.933 179.519 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.693 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -87.32 126.63 34.96 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.875 -1.14 . . . . 0.0 109.328 -179.946 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -64.15 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.772 -1.205 . . . . 0.0 110.025 179.741 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 20.4 t70 -160.18 19.48 0.15 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.984 -1.072 . . . . 0.0 109.705 179.895 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.0 -27.39 5.51 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 179.785 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.41 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 2.3 p -95.22 160.93 14.32 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.004 -1.292 . . . . 0.0 110.318 -179.425 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.479 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.86 137.48 44.84 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.822 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.693 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.27 -19.2 40.03 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.748 -1.22 . . . . 0.0 110.437 -178.596 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.51 176.27 19.73 Favored Glycine 0 N--CA 1.484 1.85 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.485 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -63.82 108.8 1.55 Allowed 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 179.13 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.628 HG21 ' HB3' ' A' ' 46' ' ' ALA . 38.2 t -81.72 105.41 11.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 121.361 -0.837 . . . . 0.0 108.786 -179.144 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.531 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -67.68 112.16 4.63 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.39 -0.819 . . . . 0.0 109.931 -179.108 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.546 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -64.28 -5.09 4.41 Favored 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.286 -1.366 . . . . 0.0 109.97 179.437 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.404 HG22 ' NH2' ' A' ' 71' ' ' ARG . 41.0 p -85.63 1.44 49.24 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.769 -1.207 . . . . 0.0 109.021 179.361 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -115.73 -49.34 2.73 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.432 -0.792 . . . . 0.0 109.08 179.971 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.64 -179.63 4.0 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.458 -0.776 . . . . 0.0 109.536 179.961 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.99 115.36 30.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.338 -0.851 . . . . 0.0 109.102 179.958 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.507 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.7 m -96.94 123.73 40.73 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.082 -1.011 . . . . 0.0 109.54 -179.358 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.582 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.28 147.48 27.44 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 122.515 1.15 . . . . 0.0 111.356 -179.318 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.64 ' HB ' HG11 ' A' ' 7' ' ' VAL . 59.1 t -103.09 109.62 27.36 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.038 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 177.351 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.09 -174.06 17.9 Favored Glycine 0 N--CA 1.484 1.855 0 C-N-CA 118.203 -1.951 . . . . 0.0 111.815 -177.414 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.503 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -117.1 -177.59 3.24 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -178.835 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.512 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.8 OUTLIER . . . . . 0 C--N 1.297 -1.694 0 O-C-N 121.182 -0.949 . . . . 0.0 109.389 -179.344 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.73 0 N-CA-C 107.468 -2.253 . . . . 0.0 107.468 . . . . . . . . . 0 0 . 1 . 040 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -154.98 -179.66 8.27 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 121.509 -0.995 . . . . 0.0 109.406 178.786 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -179.23 -167.78 37.22 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 -179.488 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.449 ' HG3' HD22 ' A' ' 26' ' ' LEU . 5.8 Cg_exo -48.38 175.1 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.665 0 CA-C-N 118.888 1.344 . . . . 0.0 110.002 179.523 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -92.48 -175.4 3.98 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.163 -0.96 . . . . 0.0 110.435 -178.778 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -120.52 166.54 13.77 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.908 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -106.65 131.82 55.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.452 -1.028 . . . . 0.0 109.069 -179.358 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.582 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.16 125.11 27.65 Favored 'General case' 0 C--N 1.29 -2.018 0 O-C-N 121.48 -0.762 . . . . 0.0 109.782 179.733 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.86 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.72 172.18 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.158 -0.964 . . . . 0.0 108.948 179.81 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.479 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.81 158.25 44.74 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.305 -0.872 . . . . 0.0 109.605 -179.837 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.86 ' CE2' HD12 ' A' ' 110' ' ' ILE . 70.8 m-85 . . . . . 0 C--N 1.306 -1.297 0 O-C-N 121.19 -0.944 . . . . 0.0 109.52 -179.585 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.572 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.486 1.366 0 CA-C-O 122.208 1.004 . . . . 0.0 111.252 . . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.01 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -100.36 104.03 15.45 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.377 1.084 . . . . 0.0 109.783 179.982 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.937 HG22 HG23 ' A' ' 21' ' ' VAL . 6.9 t -120.32 116.72 51.1 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-O 121.726 0.774 . . . . 0.0 110.466 179.863 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.508 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.81 148.7 8.86 Favored Pre-proline 0 N--CA 1.486 1.339 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.707 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.508 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.0 Cg_endo -77.94 150.32 89.18 Favored 'Cis proline' 0 C--N 1.307 -1.65 0 C-N-CA 123.604 -1.415 . . . . 0.0 109.513 -0.425 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.674 ' HA ' HG22 ' A' ' 110' ' ' ILE . 80.1 p -91.3 -24.69 19.75 Favored 'General case' 0 C--N 1.292 -1.916 0 O-C-N 121.498 -0.751 . . . . 0.0 108.985 179.518 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.519 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 17.0 m -133.92 161.9 33.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.521 -0.737 . . . . 0.0 109.367 -179.931 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.77 37.06 31.05 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 108.571 -1.811 . . . . 0.0 108.571 -179.657 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.725 ' CA ' HG21 ' A' ' 17' ' ' THR . 42.8 mt -91.12 -42.13 10.64 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-O 123.374 1.559 . . . . 0.0 110.22 -178.548 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.468 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.65 142.31 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.238 -1.801 . . . . 0.0 109.838 -179.488 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.61 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.3 p-10 -49.94 106.86 0.13 Allowed 'General case' 0 C--N 1.298 -1.656 0 CA-C-O 121.562 0.696 . . . . 0.0 111.324 -178.588 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.16 10.64 9.57 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.132 177.449 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.725 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.7 t -105.48 -171.31 1.89 Allowed 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 121.286 2.543 . . . . 0.0 109.905 179.471 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.81 HG13 ' C ' ' A' ' 67' ' ' LEU . 16.8 t -132.93 143.42 39.55 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.284 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.851 -178.952 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.599 HG11 HD11 ' A' ' 13' ' ' LEU . 32.2 m -118.98 155.34 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.28 -0.887 . . . . 0.0 108.707 179.21 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.547 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -105.08 108.77 20.47 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.152 -0.967 . . . . 0.0 109.441 -179.897 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.937 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -106.74 121.76 59.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.434 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -118.07 167.16 11.72 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 120.688 -1.257 . . . . 0.0 109.292 -179.604 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.602 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.55 143.47 15.11 Favored Glycine 0 C--N 1.294 -1.78 0 N-CA-C 107.774 -2.131 . . . . 0.0 107.774 179.735 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -147.82 123.01 10.2 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 120.929 -1.336 . . . . 0.0 108.589 179.175 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.18 27.39 21.0 Favored Glycine 0 N--CA 1.487 2.063 0 C-N-CA 119.201 -1.476 . . . . 0.0 109.755 -179.448 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.0 mt -87.9 175.85 7.62 Favored 'General case' 0 C--N 1.308 -1.224 0 O-C-N 120.846 -1.384 . . . . 0.0 108.403 179.964 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.996 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.24 96.85 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.029 -1.044 . . . . 0.0 109.6 -179.91 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.679 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.24 76.48 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.448 -178.847 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.25 33.44 0.27 Allowed Glycine 0 N--CA 1.486 1.994 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 179.179 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.626 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.6 t -148.45 115.46 6.09 Favored 'General case' 0 C--N 1.309 -1.178 0 O-C-N 120.797 -1.414 . . . . 0.0 111.252 179.932 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.565 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.98 129.18 4.43 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.657 178.221 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.626 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 6.8 m-85 -121.5 146.82 46.54 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.727 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.508 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.95 164.31 12.24 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 107.429 -1.323 . . . . 0.0 107.429 178.54 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.948 HG11 HG21 ' A' ' 65' ' ' THR . 7.1 p -148.95 115.11 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.979 -1.076 . . . . 0.0 110.133 -177.673 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.15 -174.29 36.85 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 118.541 -1.79 . . . . 0.0 111.563 -179.938 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.568 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -100.77 108.89 20.83 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -179.718 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.26 148.76 52.12 Favored 'General case' 0 C--N 1.296 -1.73 0 O-C-N 121.19 -0.944 . . . . 0.0 109.934 179.765 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.33 139.1 53.98 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.276 -0.89 . . . . 0.0 110.613 -179.03 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.882 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.17 114.89 26.74 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 178.116 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.2 m -106.17 15.57 7.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.014 -1.054 . . . . 0.0 110.587 -178.676 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.3 -175.59 0.09 Allowed 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.933 -1.105 . . . . 0.0 110.021 179.739 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.0 97.47 1.88 Allowed 'General case' 0 N--CA 1.486 1.33 0 O-C-N 121.423 -0.798 . . . . 0.0 109.724 -179.765 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.64 27.93 33.89 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 120.164 -1.017 . . . . 0.0 111.399 178.973 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.52 106.33 20.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 O-C-N 120.612 -1.522 . . . . 0.0 107.289 178.928 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.882 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -116.88 104.74 11.61 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.501 -1.374 . . . . 0.0 109.684 -177.626 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.068 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.13 109.57 22.3 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.739 -1.226 . . . . 0.0 108.213 178.797 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -108.12 164.53 12.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.977 -1.077 . . . . 0.0 110.081 -178.929 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.62 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 7.5 t30 -108.62 130.02 23.27 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.357 -0.84 . . . . 0.0 109.69 -179.284 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.614 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -71.01 19.83 0.23 Allowed 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 122.178 1.919 . . . . 0.0 112.044 179.502 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.634 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -108.32 1.12 21.66 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.364 -1.46 . . . . 0.0 108.883 179.305 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.576 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.07 19.27 2.99 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 179.462 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -83.0 90.9 7.07 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.876 -0.73 . . . . 0.0 111.005 -178.439 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.66 -171.02 1.76 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.944 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.437 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.3 OUTLIER 178.53 137.96 0.09 Allowed 'General case' 0 C--N 1.304 -1.372 0 O-C-N 120.501 -1.374 . . . . 0.0 111.544 -179.16 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.822 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -154.79 159.51 3.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 178.07 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.565 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.28 145.78 25.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.59 -1.319 . . . . 0.0 109.722 -179.676 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.996 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.66 108.09 2.78 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 122.353 1.073 . . . . 0.0 109.582 179.037 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.541 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 t0 -63.03 -139.21 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.015 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.874 -179.917 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.679 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.04 -51.83 28.88 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.411 -0.806 . . . . 0.0 110.759 -178.572 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -105.09 -32.07 8.87 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 178.585 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.963 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.25 67.96 0.69 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 178.391 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.602 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.2 m -103.42 128.88 50.46 Favored 'General case' 0 N--CA 1.484 1.266 0 O-C-N 121.37 -1.077 . . . . 0.0 109.143 179.202 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.822 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.25 108.65 6.89 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 119.321 -0.952 . . . . 0.0 109.949 -179.486 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.494 ' HB3' ' CE ' ' A' ' 20' ' ' LYS . 3.4 m -114.48 116.58 29.07 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.995 -1.066 . . . . 0.0 109.409 179.85 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.948 HG21 HG11 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -143.08 142.19 31.46 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 110.013 -179.971 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.9 p -100.71 136.32 40.76 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.466 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.81 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -141.08 156.82 45.93 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.935 . . . . 0.0 109.808 -179.129 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.634 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 12.9 t -87.04 138.76 31.22 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.062 -1.023 . . . . 0.0 110.676 -179.608 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.564 HG12 ' HB3' ' A' ' 36' ' ' GLN . 20.7 m -149.27 143.55 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.508 -0.745 . . . . 0.0 109.232 -179.852 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.61 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -147.52 -178.01 6.01 Favored 'General case' 0 N--CA 1.486 1.326 0 O-C-N 120.487 -1.383 . . . . 0.0 111.206 -179.68 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.697 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -47.52 -98.92 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -179.616 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.523 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -64.02 145.01 56.65 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.389 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.599 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -163.95 143.2 7.85 Favored 'General case' 0 C--N 1.291 -1.952 0 C-N-CA 118.045 -1.462 . . . . 0.0 110.268 -177.419 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.538 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 29.4 mm-40 -37.29 120.46 0.77 Allowed 'General case' 0 N--CA 1.489 1.477 0 CA-C-O 121.457 0.646 . . . . 0.0 110.304 -178.888 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.068 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -96.5 52.45 1.54 Allowed Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.477 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.614 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.8 m-85 -39.76 114.96 0.47 Allowed 'General case' 0 N--CA 1.508 2.465 0 O-C-N 121.181 -1.188 . . . . 0.0 110.113 179.65 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.656 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.13 126.55 34.3 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.866 -1.146 . . . . 0.0 109.511 -179.986 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.6 t80 -64.1 58.17 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.004 0 O-C-N 120.845 -1.159 . . . . 0.0 110.25 179.767 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.58 19.68 0.14 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.025 -1.047 . . . . 0.0 109.709 179.892 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.88 -27.5 5.4 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.871 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.419 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 11.9 p -93.36 158.53 15.69 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.02 -1.282 . . . . 0.0 110.434 -179.455 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.487 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.35 136.28 46.35 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.627 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.656 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.1 t90 -83.08 -16.72 45.81 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.669 -1.269 . . . . 0.0 110.647 -178.194 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.57 175.94 21.18 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 108.709 -1.756 . . . . 0.0 108.709 -179.618 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -64.84 103.07 0.66 Allowed 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 179.106 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.656 HG21 ' HB3' ' A' ' 46' ' ' ALA . 37.2 t -73.78 107.97 4.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 109.483 -178.755 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.523 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.8 OUTLIER -65.11 112.09 3.22 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.462 -0.774 . . . . 0.0 109.706 -179.58 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.697 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 4.0 m -62.81 -4.98 2.4 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.422 -1.311 . . . . 0.0 110.228 179.608 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.5 p -89.25 -2.94 58.67 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.566 -1.334 . . . . 0.0 109.555 -179.983 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.522 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -106.31 -48.65 3.52 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.071 -1.018 . . . . 0.0 108.861 179.885 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.42 -177.86 3.4 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.631 -0.668 . . . . 0.0 109.297 179.726 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.59 115.98 31.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.454 -0.779 . . . . 0.0 108.927 179.834 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.544 ' HB2' HD11 ' A' ' 110' ' ' ILE . 3.2 m -96.48 120.32 36.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.913 -1.117 . . . . 0.0 109.615 -179.245 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.93 145.28 30.37 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 122.409 1.099 . . . . 0.0 111.282 -179.392 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.582 ' HB ' HG11 ' A' ' 7' ' ' VAL . 92.4 t -102.22 109.86 27.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.945 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 177.788 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.494 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.49 -173.22 19.82 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 118.112 -1.995 . . . . 0.0 111.695 -177.608 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.538 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -111.93 -178.61 3.47 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 -179.345 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.482 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.1 p . . . . . 0 C--N 1.297 -1.707 0 O-C-N 121.197 -0.939 . . . . 0.0 109.751 -179.132 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.723 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 . . . . . . . . . 0 0 . 1 . 041 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.11 -177.6 5.85 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.578 -0.954 . . . . 0.0 109.713 179.242 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.31 -161.5 14.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 -179.345 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.485 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.5 Cg_exo -47.97 -179.36 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.612 0 CA-C-N 118.877 1.339 . . . . 0.0 110.304 179.328 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -93.59 -173.95 3.34 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.002 -1.061 . . . . 0.0 110.298 -178.974 . . . . . . . . 1 1 . 1 . 041 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.494 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.76 164.18 14.97 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.946 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.86 129.41 51.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.367 -1.078 . . . . 0.0 109.0 -179.46 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.79 119.25 15.7 Favored 'General case' 0 C--N 1.288 -2.101 0 O-C-N 121.746 -0.596 . . . . 0.0 109.73 179.759 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.813 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -98.09 170.04 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.188 -0.945 . . . . 0.0 108.861 179.821 . . . . . . . . 2 2 . 1 . 041 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.519 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -138.46 155.08 48.78 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.085 -1.01 . . . . 0.0 109.6 -179.908 . . . . . . . . 3 3 . 1 . 041 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.813 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 77.6 m-85 . . . . . 0 C--N 1.305 -1.327 0 O-C-N 121.271 -0.893 . . . . 0.0 109.424 -179.686 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.209 0 CA-C-O 122.327 1.06 . . . . 0.0 110.594 . . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.012 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -104.72 104.85 14.72 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-O 122.532 1.158 . . . . 0.0 110.142 -179.519 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.974 HG22 HG23 ' A' ' 21' ' ' VAL . 12.5 t -119.48 120.0 62.25 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.438 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.355 179.616 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.519 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.67 150.3 8.84 Favored Pre-proline 0 N--CA 1.489 1.492 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 -179.621 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.519 ' HA ' HG23 ' A' ' 8' ' ' THR . 1.3 Cg_endo -74.22 153.98 99.42 Favored 'Cis proline' 0 C--N 1.31 -1.493 0 C-N-CA 123.621 -1.408 . . . . 0.0 109.927 -0.482 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.628 ' HA ' HG22 ' A' ' 110' ' ' ILE . 4.5 m -93.64 -23.94 18.08 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.646 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.495 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 3.1 m -137.12 166.14 24.41 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.61 -0.681 . . . . 0.0 109.424 179.919 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.14 38.09 40.93 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 108.346 -1.902 . . . . 0.0 108.346 -179.6 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.852 ' CA ' HG21 ' A' ' 17' ' ' THR . 29.9 mt -91.42 -45.21 8.68 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 123.131 1.444 . . . . 0.0 110.676 -178.316 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.28 146.16 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.763 -1.562 . . . . 0.0 109.942 -179.704 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.592 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.5 p-10 -51.44 110.14 0.42 Allowed 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 121.532 0.682 . . . . 0.0 111.664 -178.614 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.52 13.97 12.23 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.557 -1.306 . . . . 0.0 112.731 177.345 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.852 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.0 t -102.66 -173.38 2.31 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 120.929 2.364 . . . . 0.0 109.632 179.365 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.73 HG13 ' C ' ' A' ' 67' ' ' LEU . 12.7 t -132.15 137.75 53.96 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.866 -1.061 . . . . 0.0 111.14 -178.995 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.498 HG13 ' CG2' ' A' ' 69' ' ' VAL . 29.2 m -114.57 154.48 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.351 -0.843 . . . . 0.0 109.07 178.934 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.555 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.3 tttt -109.33 108.93 19.68 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.266 -0.896 . . . . 0.0 109.126 179.83 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.974 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -107.25 122.92 62.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -179.954 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.012 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.48 165.96 12.19 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.761 -1.212 . . . . 0.0 109.136 179.694 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.58 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.15 107.84 0.49 Allowed Glycine 0 N--CA 1.483 1.793 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 179.865 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.49 141.15 48.56 Favored 'General case' 0 N--CA 1.5 2.051 0 CA-C-N 119.248 1.524 . . . . 0.0 110.273 -179.389 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.418 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 84.28 28.37 33.75 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 118.943 -1.598 . . . . 0.0 109.767 179.621 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.523 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -94.54 173.66 7.51 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.941 -1.329 . . . . 0.0 108.553 179.971 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.005 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.72 98.74 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.006 -1.059 . . . . 0.0 109.703 -179.885 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.622 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.41 76.6 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.188 -179.21 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 135.06 33.35 0.28 Allowed Glycine 0 N--CA 1.486 1.993 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.483 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.627 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -142.49 111.83 6.6 Favored 'General case' 0 C--N 1.309 -1.174 0 O-C-N 120.928 -1.336 . . . . 0.0 111.075 -179.929 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.579 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.5 113.34 0.8 Allowed 'General case' 0 N--CA 1.497 1.922 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.915 178.67 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.627 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 11.9 m-85 -107.14 153.06 23.21 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.263 -0.898 . . . . 0.0 108.592 179.441 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.482 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.66 159.55 15.22 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.729 -1.232 . . . . 0.0 107.994 178.884 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.002 HG11 HG21 ' A' ' 65' ' ' THR . 6.4 p -139.84 114.66 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 109.667 -178.086 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.96 -179.51 37.55 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 118.384 -1.865 . . . . 0.0 111.733 -179.449 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.633 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.1 pt20 -101.92 109.39 21.12 Favored 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 -179.889 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.472 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.69 149.37 52.37 Favored 'General case' 0 C--N 1.296 -1.751 0 O-C-N 121.14 -0.975 . . . . 0.0 110.087 -179.867 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.07 138.2 54.73 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.276 -0.89 . . . . 0.0 110.809 -178.976 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.887 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.26 115.0 26.85 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 178.055 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -104.36 14.3 7.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.044 -1.035 . . . . 0.0 110.491 -178.853 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.29 -174.86 0.07 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.977 -1.077 . . . . 0.0 110.095 179.765 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -72.96 98.68 2.54 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.387 -0.821 . . . . 0.0 109.606 -179.803 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.61 27.41 32.5 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 120.251 -0.975 . . . . 0.0 111.394 179.011 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -117.64 105.96 19.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 O-C-N 120.571 -1.547 . . . . 0.0 107.335 178.849 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.887 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.4 tp -117.95 104.38 10.84 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.408 -1.433 . . . . 0.0 109.741 -177.772 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.908 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.15 109.36 22.13 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 178.829 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -105.56 165.82 10.88 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.029 -1.044 . . . . 0.0 110.277 -178.612 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.614 HD22 ' HB3' ' A' ' 50' ' ' ALA . 50.8 t30 -110.66 134.93 20.77 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 121.49 -0.756 . . . . 0.0 109.885 -179.409 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.602 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -75.32 25.46 0.39 Allowed 'Trans proline' 0 C--N 1.319 -1.011 0 C-N-CA 122.328 2.019 . . . . 0.0 111.404 179.591 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.614 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -112.74 0.1 15.18 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.484 -1.385 . . . . 0.0 109.373 179.944 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.524 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.67 16.1 2.71 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 179.601 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -78.8 91.66 4.75 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.872 -0.731 . . . . 0.0 110.952 -178.648 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -110.1 -166.58 1.1 Allowed 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.281 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.448 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.7 136.44 0.09 Allowed 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.546 -1.346 . . . . 0.0 111.502 -179.289 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.957 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -154.39 157.15 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 178.174 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.579 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.37 143.95 28.28 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.772 -1.205 . . . . 0.0 109.91 -179.827 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.005 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.58 106.64 1.2 Allowed 'General case' 0 C--N 1.299 -1.587 0 CA-C-O 122.478 1.132 . . . . 0.0 109.325 178.556 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.9 p-10 -59.28 -139.53 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.918 -179.928 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.622 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.01 -50.0 62.25 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.434 -0.791 . . . . 0.0 110.731 -178.703 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.418 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.5 t-20 -103.77 -34.35 8.59 Favored 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 178.379 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.004 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.76 66.13 0.61 Allowed Glycine 0 C--N 1.297 -1.599 0 N-CA-C 110.459 -1.056 . . . . 0.0 110.459 178.126 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.8 m -104.36 124.23 48.83 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.683 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.957 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.89 109.2 8.9 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 119.692 -0.803 . . . . 0.0 109.506 -179.278 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.2 m -116.88 116.35 27.27 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.3 -0.875 . . . . 0.0 109.353 -179.93 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 65' ' ' THR . . . . . 1.002 HG21 HG11 ' A' ' 34' ' ' VAL . 1.2 t -140.78 139.08 34.53 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.507 -0.745 . . . . 0.0 109.762 179.998 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.6 p -99.02 138.38 36.2 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.38 -0.825 . . . . 0.0 108.982 179.631 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.809 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.56 166.44 24.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.269 -0.894 . . . . 0.0 109.547 -179.15 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.66 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -95.3 125.02 39.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.061 -1.025 . . . . 0.0 109.44 -179.818 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.609 HG23 HD13 ' A' ' 13' ' ' LEU . 15.0 m -133.29 143.32 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 120.955 -1.091 . . . . 0.0 109.798 -179.207 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.592 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.59 -170.7 3.58 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.484 -1.385 . . . . 0.0 111.092 179.992 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.606 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -63.12 -101.87 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.954 -0.466 . . . . 0.0 110.309 -179.034 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.535 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -58.95 137.98 57.64 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.595 -1.316 . . . . 0.0 108.534 -180.0 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.633 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.8 OUTLIER -156.62 156.59 33.79 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 118.807 -1.157 . . . . 0.0 109.746 -178.864 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.545 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 10.3 mm-40 -48.35 122.28 5.21 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.587 -178.603 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.908 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.32 46.78 3.41 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -179.555 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.602 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -38.59 112.92 0.26 Allowed 'General case' 0 N--CA 1.506 2.351 0 O-C-N 121.22 -1.164 . . . . 0.0 110.537 -179.795 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.753 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.79 126.89 34.92 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.986 -1.071 . . . . 0.0 109.366 179.945 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.8 t80 -63.68 58.41 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.017 0 O-C-N 120.851 -1.156 . . . . 0.0 110.21 179.761 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.1 t0 -161.1 19.52 0.12 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.927 -1.108 . . . . 0.0 109.786 179.816 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.28 -26.73 5.46 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 179.798 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 47.2 p -93.88 160.72 14.61 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.958 -1.319 . . . . 0.0 110.275 -179.508 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.486 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.9 OUTLIER -107.23 134.92 49.61 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.895 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.753 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.2 t90 -81.74 -17.46 47.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.956 -1.09 . . . . 0.0 110.327 -178.608 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.12 173.46 18.76 Favored Glycine 0 N--CA 1.485 1.936 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 -179.544 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -63.77 107.34 1.17 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 179.093 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.645 HG21 ' HB3' ' A' ' 46' ' ' ALA . 44.5 t -78.7 104.61 6.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 121.398 -0.814 . . . . 0.0 109.275 -178.686 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.557 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.2 m-20 -64.88 108.86 1.89 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.545 -0.722 . . . . 0.0 110.032 -179.377 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.606 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.6 t -60.3 -5.52 1.15 Allowed 'General case' 0 N--CA 1.501 2.113 0 C-N-CA 118.164 -1.414 . . . . 0.0 110.343 179.302 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 33.1 p -89.51 0.83 56.61 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.486 -1.384 . . . . 0.0 109.528 179.987 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.557 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -111.67 -48.61 3.06 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.201 -0.937 . . . . 0.0 109.129 -179.894 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.31 179.38 4.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.592 -0.693 . . . . 0.0 109.539 -179.896 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.28 113.31 26.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.369 -0.832 . . . . 0.0 108.925 179.826 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.515 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.8 m -96.55 121.07 37.98 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.035 -1.041 . . . . 0.0 109.43 -178.854 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.589 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.82 148.11 25.7 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-O 122.416 1.103 . . . . 0.0 111.301 -179.375 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.625 ' HB ' HG11 ' A' ' 7' ' ' VAL . 47.7 t -104.41 109.96 29.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 N-CA-C 106.697 -1.594 . . . . 0.0 106.697 177.607 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.457 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.51 -171.15 17.79 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 118.15 -1.976 . . . . 0.0 111.589 -177.686 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.541 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -115.08 -178.54 3.39 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -178.888 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.458 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.2 p . . . . . 0 C--N 1.296 -1.729 0 O-C-N 121.224 -0.923 . . . . 0.0 109.65 -179.113 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.692 0 N-CA-C 107.915 -2.074 . . . . 0.0 107.915 . . . . . . . . . 0 0 . 1 . 042 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.23 -177.47 5.73 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.542 -0.975 . . . . 0.0 110.09 179.419 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.37 -163.69 23.82 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 108.17 -1.972 . . . . 0.0 108.17 -179.512 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.541 ' HB2' HD12 ' A' ' 97' ' ' LEU . 7.2 Cg_exo -46.09 172.78 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.693 0 CA-C-N 119.084 1.442 . . . . 0.0 109.938 179.332 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -91.16 -177.2 4.82 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.071 -1.018 . . . . 0.0 110.701 -178.632 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.457 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.27 168.36 13.81 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.842 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.47 133.57 51.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.43 -1.041 . . . . 0.0 109.176 -179.202 . . . . . . . . 1 1 . 1 . 042 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.589 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.68 123.48 24.14 Favored 'General case' 0 C--N 1.291 -1.976 0 O-C-N 121.55 -0.719 . . . . 0.0 109.874 179.72 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.837 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.97 172.77 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.137 -0.977 . . . . 0.0 108.969 179.711 . . . . . . . . 2 2 . 1 . 042 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.495 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.97 157.74 45.18 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.036 -1.04 . . . . 0.0 110.094 -179.627 . . . . . . . . 3 3 . 1 . 042 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.837 ' CE1' HD12 ' A' ' 110' ' ' ILE . 88.0 m-85 . . . . . 0 N--CA 1.487 1.412 0 O-C-N 121.224 -0.922 . . . . 0.0 109.444 -179.825 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.553 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.449 0 CA-C-O 122.345 1.069 . . . . 0.0 110.751 . . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.936 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.6 t -111.75 108.54 18.01 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-O 123.099 1.428 . . . . 0.0 109.053 179.339 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.897 HG22 HG23 ' A' ' 21' ' ' VAL . 5.6 t -117.71 137.39 51.78 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 0 CA-C-N 114.284 -1.326 . . . . 0.0 109.935 -179.616 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -172.85 149.11 1.8 Allowed Pre-proline 0 N--CA 1.485 1.316 0 O-C-N 121.241 -0.912 . . . . 0.0 108.815 -179.717 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -76.63 151.08 94.07 Favored 'Cis proline' 0 C--N 1.311 -1.439 0 C-N-CA 123.478 -1.468 . . . . 0.0 109.467 -0.865 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.685 ' HA ' HG22 ' A' ' 110' ' ' ILE . 65.3 p -90.17 -25.18 20.79 Favored 'General case' 0 C--N 1.294 -1.842 0 O-C-N 121.564 -0.71 . . . . 0.0 109.123 179.686 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.511 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.5 m -134.16 165.04 26.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.459 -0.776 . . . . 0.0 109.534 -179.904 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.22 38.28 34.79 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 -179.61 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.76 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.0 mt -92.4 -42.92 9.5 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 123.236 1.493 . . . . 0.0 110.525 -178.322 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.0 143.86 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.468 -1.696 . . . . 0.0 109.686 -179.534 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.583 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 6.0 p-10 -50.98 107.19 0.16 Allowed 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 121.625 0.726 . . . . 0.0 111.608 -178.437 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.46 11.61 11.59 Favored Glycine 0 N--CA 1.485 1.902 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.087 177.254 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.76 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -102.3 -169.8 1.72 Allowed 'General case' 0 C--N 1.312 -1.043 0 CA-C-N 121.111 2.455 . . . . 0.0 109.615 179.397 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.765 HG13 ' C ' ' A' ' 67' ' ' LEU . 12.0 t -134.17 142.23 41.56 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.702 -179.255 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.579 HG12 HD21 ' A' ' 13' ' ' LEU . 35.0 m -119.88 155.21 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.276 -0.89 . . . . 0.0 108.853 179.313 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 11.1 tttt -103.96 109.24 20.93 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.207 -0.933 . . . . 0.0 109.158 -179.965 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.897 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -101.94 140.87 19.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.607 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.936 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.3 160.15 39.89 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 118.62 -1.232 . . . . 0.0 109.949 179.795 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.594 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.19 143.89 15.16 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 179.578 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -145.73 125.93 13.83 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 120.87 -1.371 . . . . 0.0 108.911 179.296 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.73 26.39 27.24 Favored Glycine 0 N--CA 1.488 2.137 0 C-N-CA 119.296 -1.43 . . . . 0.0 109.777 -179.692 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.554 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.0 mt -86.84 175.3 8.26 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.918 -1.342 . . . . 0.0 108.364 -179.933 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.85 97.33 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.961 -1.087 . . . . 0.0 109.737 -179.61 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.675 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.53 77.32 0.0 OUTLIER 'General case' 0 C--N 1.294 -1.813 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.42 -179.134 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.12 34.4 0.33 Allowed Glycine 0 N--CA 1.486 2.005 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.381 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.549 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.4 p -147.78 113.26 5.63 Favored 'General case' 0 C--N 1.307 -1.251 0 O-C-N 121.045 -1.267 . . . . 0.0 111.236 -179.819 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.569 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -43.53 128.41 5.06 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.823 178.263 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.49 ' CD2' ' O ' ' A' ' 30' ' ' THR . 11.3 m-85 -121.38 149.8 42.43 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.596 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.509 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.49 156.35 17.33 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.642 -1.286 . . . . 0.0 107.854 178.84 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 34' ' ' VAL . 5.6 p -138.53 114.79 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.062 -1.024 . . . . 0.0 109.713 -178.06 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.08 -178.3 35.86 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.249 -1.929 . . . . 0.0 111.908 -179.529 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.568 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -101.03 112.55 25.04 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 -179.941 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 66.8 m -130.64 153.11 49.27 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.365 -0.834 . . . . 0.0 109.615 179.746 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.694 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -127.43 135.91 51.1 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.482 -0.761 . . . . 0.0 110.491 -179.957 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.885 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.6 OUTLIER -94.83 114.37 26.24 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.243 -1.391 . . . . 0.0 107.243 178.137 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 m -106.27 14.86 7.47 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 O-C-N 120.966 -1.084 . . . . 0.0 110.763 -178.473 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.776 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.21 -175.47 0.08 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.856 -1.152 . . . . 0.0 110.222 179.655 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.789 ' O ' HG23 ' A' ' 42' ' ' THR . 15.2 t -69.75 97.09 1.04 Allowed 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 121.83 0.824 . . . . 0.0 109.952 -179.445 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.66 27.15 36.09 Favored Glycine 0 N--CA 1.494 2.546 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.515 178.679 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.776 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.4 t -114.48 106.18 20.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.233 0 O-C-N 120.6 -1.53 . . . . 0.0 107.483 178.901 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.885 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.7 tp -116.94 106.54 13.54 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.574 -1.329 . . . . 0.0 109.662 -177.724 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.096 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -95.99 111.97 23.83 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 120.676 -1.265 . . . . 0.0 108.256 179.445 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.545 ' HB3' ' CE1' ' A' ' 52' ' ' PHE . 66.8 m -101.67 147.76 26.06 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.33 -0.856 . . . . 0.0 110.71 -178.291 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.696 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 24.4 t30 -103.45 126.11 33.06 Favored Pre-proline 0 N--CA 1.503 2.198 0 O-C-N 121.248 -0.908 . . . . 0.0 108.838 179.053 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.586 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.5 Cg_endo -70.58 23.85 0.2 Allowed 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 122.108 1.872 . . . . 0.0 112.561 -179.657 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.696 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -110.15 2.15 19.21 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.252 -1.53 . . . . 0.0 109.317 179.346 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.562 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.54 16.18 2.55 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 179.628 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.545 ' CE1' ' HB3' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -79.08 91.51 4.91 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.579 -0.701 . . . . 0.0 110.885 -178.568 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.625 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.67 -165.71 1.05 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.284 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 179.04 135.3 0.09 Allowed 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.514 -1.366 . . . . 0.0 111.564 -179.339 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.899 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -153.2 157.83 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 107.116 -1.438 . . . . 0.0 107.116 178.024 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.569 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.71 145.92 25.86 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.658 -1.276 . . . . 0.0 109.865 -179.73 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.38 107.98 2.2 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 122.368 1.08 . . . . 0.0 109.478 178.733 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.526 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.2 t0 -62.02 -139.11 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.045 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.931 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.675 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.84 -51.62 38.71 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.477 -0.764 . . . . 0.0 110.733 -178.614 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.73 -32.39 8.89 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 178.726 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.978 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.15 65.38 0.59 Allowed Glycine 0 C--N 1.297 -1.59 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 178.307 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 48.4 m -101.77 127.99 48.31 Favored 'General case' 0 C--N 1.309 -1.187 0 O-C-N 121.468 -1.019 . . . . 0.0 108.711 178.858 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.899 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.92 108.77 7.08 Favored 'General case' 0 C--N 1.295 -1.768 0 C-N-CA 119.316 -0.953 . . . . 0.0 109.819 -179.214 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 40.2 p -121.95 120.11 33.47 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.322 -0.861 . . . . 0.0 109.481 179.945 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.438 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.74 147.97 32.49 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.482 -0.761 . . . . 0.0 109.245 179.845 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.3 p -98.64 139.74 33.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.355 -0.84 . . . . 0.0 109.593 -179.876 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.765 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -143.75 157.45 44.38 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.366 -0.834 . . . . 0.0 109.202 -179.466 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.641 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 14.4 t -86.25 137.73 32.39 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.056 -1.028 . . . . 0.0 110.427 -179.645 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.539 HG23 HD13 ' A' ' 13' ' ' LEU . 24.1 m -148.6 141.43 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.467 -0.771 . . . . 0.0 109.525 -179.444 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.583 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -143.63 -170.68 3.36 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.563 -1.335 . . . . 0.0 110.368 -179.984 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.577 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -64.4 -94.61 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 -179.812 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.524 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.77 137.73 56.27 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.776 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.694 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -162.19 137.96 7.49 Favored 'General case' 0 C--N 1.293 -1.886 0 C-N-CA 118.3 -1.36 . . . . 0.0 110.473 -177.683 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.541 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.8 OUTLIER -32.42 118.91 0.28 Allowed 'General case' 0 N--CA 1.493 1.682 0 CA-C-O 121.5 0.667 . . . . 0.0 110.6 -178.497 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.096 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.97 49.42 1.76 Allowed Glycine 0 N--CA 1.492 2.403 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.542 -179.028 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.586 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.8 m-85 -40.0 115.55 0.55 Allowed 'General case' 0 N--CA 1.509 2.517 0 O-C-N 121.029 -1.277 . . . . 0.0 109.731 179.347 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.709 HD11 HG12 ' A' ' 44' ' ' VAL . 7.6 tp -85.81 127.21 34.5 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.943 -1.098 . . . . 0.0 109.66 -179.673 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -64.55 57.97 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.856 -1.153 . . . . 0.0 110.182 179.664 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.47 19.62 0.14 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.929 -1.107 . . . . 0.0 109.718 179.885 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.07 -28.12 5.23 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.952 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.454 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 34.6 p -92.59 156.28 17.21 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.06 -1.259 . . . . 0.0 110.309 -179.439 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.481 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -105.04 134.73 47.65 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.664 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.616 ' HB2' HD13 ' A' ' 77' ' ' LEU . 0.6 OUTLIER -82.55 -17.21 45.76 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.655 -1.278 . . . . 0.0 110.518 -178.372 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 106.67 176.42 23.14 Favored Glycine 0 N--CA 1.485 1.904 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -179.791 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.72 105.38 0.65 Allowed 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 179.095 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.581 HG21 ' CB ' ' A' ' 46' ' ' ALA . 36.8 t -76.43 104.08 4.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.421 -0.799 . . . . 0.0 109.046 -178.816 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.545 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -62.39 109.51 1.38 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.546 -0.721 . . . . 0.0 110.027 -179.343 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.577 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.85 -4.49 6.86 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.565 -1.335 . . . . 0.0 109.728 179.256 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.5 p -85.37 3.78 38.31 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.848 -1.158 . . . . 0.0 108.989 179.499 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.545 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -119.37 -49.08 2.38 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.409 -0.807 . . . . 0.0 109.026 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.91 -178.88 3.78 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.491 -0.756 . . . . 0.0 109.474 179.826 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.55 115.26 29.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.366 -0.833 . . . . 0.0 109.138 -179.924 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.547 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.85 124.88 40.95 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.845 -1.16 . . . . 0.0 109.201 -179.628 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.572 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -104.12 146.77 28.27 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 122.379 1.085 . . . . 0.0 111.709 -179.027 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.525 ' CG1' HG11 ' A' ' 7' ' ' VAL . 84.1 t -100.4 109.81 25.97 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 177.348 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -145.87 -174.2 17.83 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 118.064 -2.017 . . . . 0.0 111.782 -177.426 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.553 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -117.62 -178.8 3.56 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 -178.95 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.496 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.2 p . . . . . 0 C--N 1.297 -1.695 0 O-C-N 121.423 -0.798 . . . . 0.0 109.094 -179.425 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.709 0 N-CA-C 107.867 -2.093 . . . . 0.0 107.867 . . . . . . . . . 0 0 . 1 . 043 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.61 -178.11 6.36 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 121.504 -0.998 . . . . 0.0 109.626 179.209 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.13 -165.89 32.62 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.479 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.539 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.7 Cg_exo -49.53 -175.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.646 0 CA-C-N 118.874 1.337 . . . . 0.0 110.371 179.572 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 16.5 mm-40 -95.89 -178.85 4.5 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.093 -1.004 . . . . 0.0 110.248 -179.094 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -115.64 158.74 14.2 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 -179.906 . . . . . . . . 1 1 . 1 . 043 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.94 128.35 50.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.421 -1.046 . . . . 0.0 108.982 -179.555 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.572 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.32 119.26 16.27 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.589 -0.695 . . . . 0.0 109.959 179.964 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.914 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -97.97 172.61 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.241 -0.912 . . . . 0.0 108.677 179.544 . . . . . . . . 2 2 . 1 . 043 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.511 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -140.7 156.91 46.09 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.945 -1.097 . . . . 0.0 110.012 -179.761 . . . . . . . . 3 3 . 1 . 043 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.914 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.6 m-85 . . . . . 0 N--CA 1.486 1.346 0 O-C-N 121.289 -0.882 . . . . 0.0 109.506 -179.749 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.288 0 CA-C-O 122.427 1.108 . . . . 0.0 110.278 . . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.793 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -116.21 109.22 17.14 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-O 123.09 1.424 . . . . 0.0 109.767 -179.992 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.836 HG22 HG23 ' A' ' 21' ' ' VAL . 2.4 t -112.87 136.26 49.71 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.745 0 CA-C-N 114.24 -1.345 . . . . 0.0 109.776 179.909 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.462 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.65 148.23 5.6 Favored Pre-proline 0 N--CA 1.487 1.396 0 O-C-N 121.184 -0.947 . . . . 0.0 108.855 -179.557 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.462 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.4 Cg_endo -76.46 151.18 94.44 Favored 'Cis proline' 0 C--N 1.312 -1.352 0 C-N-CA 123.38 -1.508 . . . . 0.0 109.422 -0.812 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.648 ' HA ' HG22 ' A' ' 110' ' ' ILE . 2.1 m -88.35 -26.73 22.06 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.593 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.484 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 13.4 m -136.73 165.14 26.61 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.616 -0.678 . . . . 0.0 109.446 179.807 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.31 37.69 31.12 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 -179.631 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.742 ' CA ' HG21 ' A' ' 17' ' ' THR . 38.7 mt -92.84 -41.98 9.78 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 123.362 1.553 . . . . 0.0 110.418 -178.342 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.476 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.45 143.24 0.05 OUTLIER 'General case' 0 C--N 1.261 -3.279 0 CA-C-N 113.297 -1.774 . . . . 0.0 109.808 -179.57 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.601 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.3 p-10 -50.79 104.75 0.08 Allowed 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 121.462 0.649 . . . . 0.0 111.432 -178.369 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.4 15.19 7.76 Favored Glycine 0 N--CA 1.485 1.963 0 C-N-CA 119.317 -1.421 . . . . 0.0 113.086 177.311 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.742 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -104.72 -170.33 1.75 Allowed 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 121.165 2.482 . . . . 0.0 109.579 179.09 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.736 HG13 ' C ' ' A' ' 67' ' ' LEU . 17.4 t -127.4 137.41 57.81 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.116 -179.133 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.633 HG13 ' CG2' ' A' ' 69' ' ' VAL . 11.7 m -111.28 156.32 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.315 -0.866 . . . . 0.0 108.852 178.932 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.504 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.4 tttt -111.55 109.48 19.42 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.214 -0.929 . . . . 0.0 108.843 179.854 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.836 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -102.91 138.8 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.975 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.793 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -132.61 161.76 33.06 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.861 -1.135 . . . . 0.0 109.941 179.689 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.588 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.92 140.75 11.85 Favored Glycine 0 C--N 1.298 -1.547 0 N-CA-C 108.144 -1.983 . . . . 0.0 108.144 179.776 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.54 125.4 16.09 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.606 -1.526 . . . . 0.0 109.296 179.374 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.2 28.51 20.06 Favored Glycine 0 N--CA 1.489 2.187 0 C-N-CA 118.69 -1.719 . . . . 0.0 109.807 -179.808 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.557 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -89.53 171.95 9.34 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 120.936 -1.332 . . . . 0.0 108.301 179.852 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.0 99.33 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.96 -1.087 . . . . 0.0 109.892 -179.385 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.549 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.23 77.66 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.212 -179.337 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.19 34.02 0.3 Allowed Glycine 0 N--CA 1.487 2.099 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 179.57 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.557 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 48.2 p -141.94 108.57 5.35 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 121.048 -1.266 . . . . 0.0 111.252 -179.527 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.59 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.16 109.71 0.32 Allowed 'General case' 0 N--CA 1.496 1.843 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.584 177.944 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.484 ' CE1' ' OG1' ' A' ' 30' ' ' THR . 4.6 m-30 -104.26 156.14 18.15 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.145 -0.972 . . . . 0.0 108.774 179.752 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.509 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -99.7 165.36 11.64 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.978 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.05 HG11 HG21 ' A' ' 65' ' ' THR . 4.5 p -146.66 116.23 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.085 -1.009 . . . . 0.0 109.759 -178.15 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.515 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.73 -176.89 38.17 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.175 -1.964 . . . . 0.0 111.709 -179.608 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.649 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.3 pt20 -101.47 109.77 21.65 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.979 0.895 . . . . 0.0 109.055 -179.653 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.488 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.99 150.46 52.13 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 121.224 -0.922 . . . . 0.0 109.554 179.846 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.48 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.78 139.0 54.24 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.079 -1.013 . . . . 0.0 110.775 -178.949 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.16 114.64 26.45 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 178.196 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m -105.46 15.19 7.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.068 -1.02 . . . . 0.0 110.561 -178.688 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.746 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.42 -175.38 0.1 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.894 -1.128 . . . . 0.0 110.114 179.631 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -71.6 96.81 1.6 Allowed 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.426 -0.796 . . . . 0.0 109.743 -179.696 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.01 27.5 33.89 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 120.194 -1.003 . . . . 0.0 111.482 178.877 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.746 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.42 106.29 20.23 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.523 -1.575 . . . . 0.0 107.443 178.861 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -115.75 104.67 11.9 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 120.389 -1.445 . . . . 0.0 109.967 -177.658 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.833 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.18 109.24 22.03 Favored 'General case' 0 N--CA 1.484 1.24 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.709 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.7 t -107.26 167.93 9.57 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.985 -1.072 . . . . 0.0 110.564 -178.397 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.74 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 49.9 t30 -112.61 130.9 22.97 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.454 -0.779 . . . . 0.0 109.585 -179.435 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.51 ' CD ' ' HB3' ' A' ' 74' ' ' GLU . 2.8 Cg_endo -72.41 23.76 0.27 Allowed 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 122.189 1.926 . . . . 0.0 112.124 179.966 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.74 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -113.41 3.53 15.88 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.333 -1.479 . . . . 0.0 109.192 179.526 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.525 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.45 17.36 2.74 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 179.259 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -80.84 88.87 5.82 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.577 -0.702 . . . . 0.0 111.011 -178.593 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.618 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -107.27 -167.19 1.24 Allowed 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.266 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.96 135.06 0.09 Allowed 'General case' 0 C--N 1.305 -1.353 0 O-C-N 120.496 -1.377 . . . . 0.0 111.372 -179.418 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.843 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -150.3 157.72 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 178.176 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.56 142.24 30.4 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.74 -1.225 . . . . 0.0 110.054 -179.847 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.13 107.73 1.36 Allowed 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 122.469 1.128 . . . . 0.0 109.416 178.436 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.555 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.0 p-10 -61.2 -139.17 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.762 179.893 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.549 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.29 -51.07 60.66 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.431 -0.793 . . . . 0.0 110.454 -178.691 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -101.75 -34.95 9.24 Favored 'General case' 0 C--N 1.285 -2.221 0 N-CA-C 106.287 -1.745 . . . . 0.0 106.287 178.342 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.28 65.87 0.59 Allowed Glycine 0 C--N 1.298 -1.565 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.082 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.5 m -98.71 130.83 45.21 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 121.503 -0.998 . . . . 0.0 108.482 178.729 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.843 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.76 108.86 7.7 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 118.956 -1.098 . . . . 0.0 109.796 -179.272 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 60.0 p -121.51 117.72 27.52 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.36 -0.838 . . . . 0.0 109.421 179.949 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 65' ' ' THR . . . . . 1.05 HG21 HG11 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -144.99 142.17 29.57 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.489 -0.757 . . . . 0.0 109.593 179.981 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 34.0 p -99.87 141.59 32.48 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.436 -0.79 . . . . 0.0 109.287 179.815 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.736 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -142.04 166.18 25.42 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.354 -0.841 . . . . 0.0 109.418 -179.355 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.701 HG22 HG22 ' A' ' 18' ' ' VAL . 3.4 p -95.49 124.47 39.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.118 -0.989 . . . . 0.0 109.398 -179.852 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.633 ' CG2' HG13 ' A' ' 19' ' ' VAL . 18.8 m -139.76 142.56 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 120.946 -1.096 . . . . 0.0 109.964 -179.183 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.601 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.3 ptt180 -140.09 -166.35 2.08 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 120.627 -1.295 . . . . 0.0 109.897 179.903 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.594 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -71.93 -80.68 0.06 Allowed 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 179.952 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.507 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.5 OUTLIER -64.13 135.97 56.83 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.197 -1.409 . . . . 0.0 107.197 178.579 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.591 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -161.98 138.68 8.14 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 118.07 -1.452 . . . . 0.0 110.252 -177.692 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.51 ' HB3' ' CD ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -31.04 121.39 0.22 Allowed 'General case' 0 N--CA 1.492 1.634 0 CA-C-O 121.479 0.657 . . . . 0.0 110.851 -178.31 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.833 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.95 50.62 2.83 Favored Glycine 0 N--CA 1.496 2.667 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 -179.489 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.47 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.5 OUTLIER -52.97 114.13 1.33 Allowed 'General case' 0 N--CA 1.51 2.55 0 O-C-N 120.934 -1.333 . . . . 0.0 110.645 -179.886 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.685 HD13 ' HB2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -78.94 151.95 31.37 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 120.864 -1.148 . . . . 0.0 108.231 178.114 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.416 ' O ' ' CG ' ' A' ' 78' ' ' PHE . 63.7 t80 -74.68 5.5 4.83 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 120.69 -1.256 . . . . 0.0 110.563 -179.98 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -105.16 -2.49 24.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.905 -1.122 . . . . 0.0 109.701 -179.879 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.21 -19.45 51.42 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.998 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.49 ' O ' ' HB2' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -76.35 151.56 36.61 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.147 -1.207 . . . . 0.0 109.5 -179.947 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.512 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -96.82 123.08 40.42 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.896 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.685 ' HB2' HD13 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -85.27 -16.68 39.33 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.968 -1.083 . . . . 0.0 110.046 -179.121 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 103.19 173.15 26.24 Favored Glycine 0 N--CA 1.483 1.829 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 -179.757 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -60.09 108.93 0.85 Allowed 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 178.853 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.635 HG23 ' HA3' ' A' ' 75' ' ' GLY . 25.5 t -78.88 101.27 4.16 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -178.844 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.531 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -62.14 110.41 1.6 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.548 -0.72 . . . . 0.0 110.046 -178.985 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.548 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -65.14 -4.78 5.38 Favored 'General case' 0 N--CA 1.499 1.993 0 C-N-CA 118.413 -1.315 . . . . 0.0 109.727 179.378 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.6 p -83.66 2.82 35.73 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.712 -1.242 . . . . 0.0 108.911 179.328 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.0 p -117.91 -48.53 2.55 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.406 -0.809 . . . . 0.0 108.974 -179.976 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.67 179.97 4.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.542 -0.724 . . . . 0.0 109.394 179.931 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.47 114.75 29.18 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.368 -0.832 . . . . 0.0 109.22 179.964 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.569 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.7 120.89 37.86 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.887 -1.133 . . . . 0.0 109.532 -179.305 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.611 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.91 148.25 25.2 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 122.38 1.086 . . . . 0.0 111.308 -179.322 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.507 ' CG1' HG11 ' A' ' 7' ' ' VAL . 43.2 t -105.06 111.56 35.04 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 177.66 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.427 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.47 -170.84 17.45 Favored Glycine 0 N--CA 1.486 2.025 0 C-N-CA 118.18 -1.962 . . . . 0.0 111.667 -177.65 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.495 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.68 178.81 4.2 Favored 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.016 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.509 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER . . . . . 0 C--N 1.296 -1.739 0 O-C-N 121.473 -0.767 . . . . 0.0 109.347 -179.517 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.763 0 N-CA-C 107.661 -2.175 . . . . 0.0 107.661 . . . . . . . . . 0 0 . 1 . 044 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.28 -177.76 6.24 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.561 -0.964 . . . . 0.0 109.715 179.28 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.82 -161.78 15.63 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 108.41 -1.876 . . . . 0.0 108.41 -179.344 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.504 ' HG3' HD22 ' A' ' 26' ' ' LEU . 5.7 Cg_exo -47.22 178.97 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.678 0 CA-C-N 118.721 1.261 . . . . 0.0 110.345 179.378 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -92.97 -172.64 3.05 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.198 -0.939 . . . . 0.0 110.357 -178.866 . . . . . . . . 1 1 . 1 . 044 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.427 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -123.45 161.94 17.56 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.891 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.424 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.73 130.53 48.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.415 -1.05 . . . . 0.0 109.244 -179.514 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.611 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.22 120.81 19.36 Favored 'General case' 0 C--N 1.289 -2.043 0 O-C-N 121.716 -0.615 . . . . 0.0 109.646 179.684 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.878 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -98.14 169.67 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 O-C-N 121.138 -0.976 . . . . 0.0 109.331 -179.956 . . . . . . . . 2 2 . 1 . 044 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.484 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -136.96 151.16 48.69 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.256 -0.903 . . . . 0.0 109.694 -179.973 . . . . . . . . 3 3 . 1 . 044 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.878 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 36.7 m-85 . . . . . 0 C--N 1.305 -1.33 0 O-C-N 121.099 -1.001 . . . . 0.0 109.539 -179.727 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.211 0 CA-C-O 122.296 1.046 . . . . 0.0 110.469 . . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.016 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.4 p -105.56 105.04 14.89 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 122.501 1.143 . . . . 0.0 110.46 -179.352 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 1.127 HG22 HG23 ' A' ' 21' ' ' VAL . 3.5 t -118.12 117.82 56.09 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.426 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.267 179.426 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.485 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -161.34 148.49 11.83 Favored Pre-proline 0 N--CA 1.487 1.412 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 -179.588 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.485 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.2 Cg_endo -78.3 149.93 87.38 Favored 'Cis proline' 0 C--N 1.31 -1.491 0 C-N-CA 123.533 -1.445 . . . . 0.0 109.563 -0.573 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 88.5 p -92.23 -23.38 19.36 Favored 'General case' 0 C--N 1.291 -1.962 0 O-C-N 121.618 -0.676 . . . . 0.0 109.209 179.584 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.472 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -132.7 161.15 34.75 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.52 -0.737 . . . . 0.0 109.47 -179.91 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.01 37.76 32.07 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 -179.556 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.789 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.8 mt -90.83 -43.78 9.83 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 123.303 1.525 . . . . 0.0 110.674 -178.233 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.47 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.39 143.94 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.282 0 CA-C-N 113.508 -1.678 . . . . 0.0 109.899 -179.618 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -50.72 107.19 0.15 Allowed 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.683 0.754 . . . . 0.0 111.653 -178.611 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.26 15.46 8.99 Favored Glycine 0 N--CA 1.483 1.829 0 C-N-CA 119.557 -1.306 . . . . 0.0 112.801 177.461 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.789 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.7 t -105.3 -173.82 2.39 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 121.106 2.453 . . . . 0.0 109.914 179.309 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.756 HG13 ' O ' ' A' ' 67' ' ' LEU . 19.0 t -130.18 138.94 52.68 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 114.666 -1.152 . . . . 0.0 111.24 -178.61 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.518 HG12 HD21 ' A' ' 13' ' ' LEU . 34.6 m -115.92 155.65 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.367 -0.833 . . . . 0.0 108.817 178.725 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.541 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 12.4 tttt -107.72 109.33 20.89 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.03 -1.043 . . . . 0.0 109.66 -179.789 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 1.127 HG23 HG22 ' A' ' 7' ' ' VAL . 6.5 p -104.36 125.08 59.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.528 -0.732 . . . . 0.0 109.193 179.759 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.016 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -115.53 165.21 13.26 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.741 -1.224 . . . . 0.0 108.911 179.348 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.614 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.39 107.95 0.49 Allowed Glycine 0 N--CA 1.481 1.686 0 N-CA-C 108.242 -1.943 . . . . 0.0 108.242 -179.97 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.23 139.84 50.69 Favored 'General case' 0 N--CA 1.5 2.035 0 CA-C-N 119.635 1.718 . . . . 0.0 110.464 -179.171 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.76 28.46 35.06 Favored Glycine 0 N--CA 1.489 2.219 0 C-N-CA 118.739 -1.696 . . . . 0.0 109.948 179.387 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.579 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.9 OUTLIER -92.4 171.96 8.7 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.935 -1.332 . . . . 0.0 108.429 179.793 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.016 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.23 100.43 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.933 -1.104 . . . . 0.0 109.781 -179.664 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.06 77.6 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.679 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.982 -179.245 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.1 33.99 0.27 Allowed Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.721 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 24.5 p -139.53 106.98 5.55 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.17 -1.194 . . . . 0.0 111.261 -179.577 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.582 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -52.37 110.4 0.49 Allowed 'General case' 0 N--CA 1.497 1.901 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.93 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.515 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 30.0 m-85 -106.68 157.4 17.73 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.06 -1.025 . . . . 0.0 109.079 179.892 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.58 165.29 11.49 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.781 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.652 HG22 HG11 ' A' ' 21' ' ' VAL . 4.6 p -144.57 121.3 4.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.13 -0.981 . . . . 0.0 109.535 -177.623 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.39 -178.53 42.62 Favored Glycine 0 N--CA 1.496 2.681 0 C-N-CA 118.114 -1.993 . . . . 0.0 111.86 -179.814 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.619 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -100.73 108.86 20.81 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.874 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -129.85 149.29 51.65 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.142 -0.974 . . . . 0.0 110.11 179.849 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.34 138.73 54.35 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.363 -0.836 . . . . 0.0 110.757 -179.128 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.25 115.03 26.89 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.146 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 m -105.9 15.52 7.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 120.95 -1.094 . . . . 0.0 110.55 -178.895 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.772 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 173.97 -176.26 0.08 Allowed 'General case' 0 C--N 1.303 -1.417 0 O-C-N 120.902 -1.124 . . . . 0.0 110.192 179.775 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.777 ' O ' HG23 ' A' ' 42' ' ' THR . 15.0 t -71.16 98.45 1.69 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.426 -0.796 . . . . 0.0 109.827 -179.672 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.7 28.77 34.25 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.312 179.006 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.772 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -117.5 106.11 19.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 120.608 -1.525 . . . . 0.0 107.16 178.853 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.3 tp -117.6 104.74 11.33 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.49 -1.381 . . . . 0.0 109.756 -177.613 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.072 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.95 109.52 22.26 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.809 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -106.74 166.49 10.54 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.928 -1.108 . . . . 0.0 110.422 -178.761 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.833 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 3.0 t-20 -107.88 133.34 20.51 Favored Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.526 -0.734 . . . . 0.0 109.511 -179.247 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.3 Cg_endo -74.61 25.12 0.36 Allowed 'Trans proline' 0 C--N 1.319 -0.99 0 C-N-CA 122.376 2.05 . . . . 0.0 111.99 -179.973 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.833 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -107.12 -4.87 18.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.342 -1.474 . . . . 0.0 109.306 179.848 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.663 ' HB3' HD22 ' A' ' 67' ' ' LEU . 5.4 m-20 -133.24 5.94 3.83 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.264 -0.898 . . . . 0.0 108.683 179.918 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -60.35 80.06 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 110.5 -178.797 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.636 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -105.31 -169.6 1.62 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 178.55 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 177.88 135.67 0.07 Allowed 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.626 -1.296 . . . . 0.0 111.149 -179.249 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.783 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -149.58 157.83 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 177.907 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.582 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.31 140.1 33.1 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 120.837 -1.164 . . . . 0.0 110.038 -179.7 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -62.45 106.61 0.79 Allowed 'General case' 0 C--N 1.298 -1.673 0 CA-C-O 122.438 1.113 . . . . 0.0 109.448 178.418 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.561 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.5 p-10 -59.8 -139.38 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.031 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.882 -179.944 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.01 -50.4 61.46 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.344 -0.848 . . . . 0.0 110.485 -178.782 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -103.21 -35.0 8.62 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 178.433 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.974 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.34 69.86 0.71 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 178.123 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.614 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 48.3 m -105.1 127.68 53.0 Favored 'General case' 0 N--CA 1.485 1.299 0 O-C-N 121.517 -0.99 . . . . 0.0 108.96 179.256 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.783 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.96 109.27 8.9 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.076 -179.765 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 42.5 m -120.46 115.84 24.26 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.282 -0.886 . . . . 0.0 109.452 -179.656 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.82 143.82 29.89 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.4 -0.813 . . . . 0.0 109.502 179.967 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.436 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 21.8 p -98.76 137.21 37.69 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.467 -0.771 . . . . 0.0 109.407 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.927 HD11 HG12 ' A' ' 21' ' ' VAL . 0.1 OUTLIER -131.26 167.81 18.58 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.408 -0.808 . . . . 0.0 110.027 -178.673 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.529 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.2 p -102.62 123.6 46.62 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.051 -1.031 . . . . 0.0 108.863 179.396 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.619 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.7 m -135.99 143.99 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 120.899 -1.126 . . . . 0.0 109.868 -179.023 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.8 ptt180 -144.75 -176.79 5.21 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 120.637 -1.289 . . . . 0.0 111.046 -179.891 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.727 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.97 -94.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.276 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.533 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -65.32 148.28 51.98 Favored 'General case' 0 N--CA 1.485 1.282 0 O-C-N 120.566 -1.334 . . . . 0.0 107.543 178.63 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.602 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -167.44 140.66 3.45 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 117.942 -1.503 . . . . 0.0 110.126 -177.459 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.523 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 5.1 mm-40 -36.49 122.06 0.75 Allowed 'General case' 0 N--CA 1.489 1.509 0 CA-C-O 121.421 0.629 . . . . 0.0 110.235 -178.708 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.072 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -96.61 51.83 1.54 Allowed Glycine 0 N--CA 1.495 2.571 0 C-N-CA 120.496 -0.859 . . . . 0.0 111.148 -179.252 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -39.16 114.74 0.43 Allowed 'General case' 0 N--CA 1.509 2.476 0 O-C-N 121.104 -1.233 . . . . 0.0 110.18 179.446 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.724 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -85.53 126.55 33.95 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 120.791 -1.193 . . . . 0.0 109.594 -179.841 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -64.5 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.028 0 O-C-N 120.852 -1.155 . . . . 0.0 109.951 179.527 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.2 t70 -159.55 19.41 0.17 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.007 -1.058 . . . . 0.0 109.624 179.873 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.4 -27.45 5.71 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.929 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.471 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 63.1 p -97.01 158.5 15.4 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 120.963 -1.316 . . . . 0.0 110.366 -179.375 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.498 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 2.6 ptt180 -104.28 140.21 38.19 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.672 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.724 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.7 t90 -84.93 -17.51 37.54 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.683 -1.261 . . . . 0.0 110.787 -178.077 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.41 176.58 19.83 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 -179.45 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.91 104.51 1.12 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 179.198 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.649 HG21 ' HB3' ' A' ' 46' ' ' ALA . 39.9 t -75.93 107.92 7.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.295 -0.878 . . . . 0.0 109.387 -178.767 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.711 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -68.24 113.14 5.6 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.435 -0.791 . . . . 0.0 109.575 -179.777 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.727 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 8.2 m -62.48 -5.07 2.24 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 120.424 -1.423 . . . . 0.0 110.235 179.717 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 p -88.35 -2.82 58.82 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.542 -1.349 . . . . 0.0 109.489 179.825 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.711 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -106.45 -47.95 3.67 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.237 -0.914 . . . . 0.0 108.804 179.837 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -111.1 -177.67 3.27 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.642 -0.662 . . . . 0.0 109.295 179.724 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.75 116.19 31.87 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.933 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.621 ' HB2' HD11 ' A' ' 110' ' ' ILE . 3.4 m -96.67 122.23 39.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.823 -1.173 . . . . 0.0 109.794 -179.167 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.561 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.36 148.71 26.09 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 122.393 1.092 . . . . 0.0 111.458 -179.374 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.556 ' HB ' HG11 ' A' ' 7' ' ' VAL . 48.4 t -106.3 111.51 35.55 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 106.873 -1.529 . . . . 0.0 106.873 177.534 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.508 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.51 -170.68 19.9 Favored Glycine 0 N--CA 1.488 2.106 0 C-N-CA 118.104 -1.998 . . . . 0.0 111.625 -177.743 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.488 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.92 175.15 5.67 Favored 'General case' 0 C--N 1.307 -1.268 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.269 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.477 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 3.3 t . . . . . 0 C--N 1.291 -1.957 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -179.857 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.672 0 N-CA-C 108.048 -2.021 . . . . 0.0 108.048 . . . . . . . . . 0 0 . 1 . 045 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -165.83 -177.16 4.15 Favored 'General case' 0 C--N 1.307 -1.282 0 O-C-N 121.501 -0.999 . . . . 0.0 109.98 179.476 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.71 -161.62 20.48 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.204 -1.958 . . . . 0.0 108.204 -179.368 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.488 ' HB2' HD12 ' A' ' 97' ' ' LEU . 6.4 Cg_exo -47.55 -179.55 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.694 0 CA-C-N 118.921 1.36 . . . . 0.0 110.442 179.239 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -96.51 174.71 6.71 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.069 -1.019 . . . . 0.0 110.361 -179.056 . . . . . . . . 1 1 . 1 . 045 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.508 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -114.65 175.69 16.29 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -110.01 153.45 11.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 -179.545 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.561 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -94.21 123.94 37.92 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 121.337 -0.852 . . . . 0.0 109.413 179.796 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.75 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.4 pt -97.91 169.72 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 O-C-N 121.092 -1.005 . . . . 0.0 109.159 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.472 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.44 154.99 48.87 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.333 -0.854 . . . . 0.0 109.455 179.93 . . . . . . . . 3 3 . 1 . 045 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.75 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 59.6 m-85 . . . . . 0 N--CA 1.486 1.332 0 O-C-N 121.084 -1.01 . . . . 0.0 109.598 -179.609 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.652 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.487 1.386 0 CA-C-O 122.232 1.015 . . . . 0.0 111.055 . . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.01 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.3 p -101.22 104.71 15.77 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 122.453 1.121 . . . . 0.0 109.959 -179.843 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 1.131 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -118.54 124.54 73.3 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.509 179.716 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.478 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -170.8 149.96 2.99 Favored Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.509 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.478 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.0 Cg_endo -75.02 152.55 98.32 Favored 'Cis proline' 0 C--N 1.309 -1.504 0 C-N-CA 123.553 -1.436 . . . . 0.0 109.714 -0.476 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.622 ' HA ' HG22 ' A' ' 110' ' ' ILE . 9.3 m -93.31 -23.07 18.61 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.61 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.469 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 3.2 m -135.32 163.38 30.14 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.46 -0.775 . . . . 0.0 109.345 179.764 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.83 38.1 32.11 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 108.387 -1.885 . . . . 0.0 108.387 -179.513 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.795 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.8 mt -91.94 -44.14 9.07 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 123.122 1.439 . . . . 0.0 110.7 -178.201 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 68.14 145.24 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.338 0 CA-C-N 113.578 -1.646 . . . . 0.0 110.081 -179.707 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.583 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.5 p-10 -50.45 106.81 0.13 Allowed 'General case' 0 C--N 1.302 -1.474 0 CA-C-O 121.437 0.637 . . . . 0.0 111.793 -178.54 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.05 16.38 9.15 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.502 -1.332 . . . . 0.0 112.905 177.137 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.795 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.1 t -105.05 -173.73 2.37 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 121.069 2.434 . . . . 0.0 109.982 179.276 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.762 HG13 ' O ' ' A' ' 67' ' ' LEU . 19.3 t -130.33 138.84 52.86 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.287 0 CA-C-N 114.593 -1.185 . . . . 0.0 111.183 -178.613 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.532 HG12 HD21 ' A' ' 13' ' ' LEU . 27.2 m -115.95 155.52 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.75 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.567 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 4.7 tttm -104.84 109.15 21.0 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.08 -1.013 . . . . 0.0 109.355 -179.954 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 1.131 HG23 HG22 ' A' ' 7' ' ' VAL . 7.2 p -106.64 124.2 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 179.671 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -118.89 166.94 12.21 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.65 -1.281 . . . . 0.0 109.296 179.848 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.603 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.76 141.8 13.2 Favored Glycine 0 C--N 1.296 -1.676 0 N-CA-C 107.594 -2.203 . . . . 0.0 107.594 179.727 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -147.42 123.21 10.59 Favored 'General case' 0 C--N 1.291 -1.956 0 O-C-N 120.832 -1.393 . . . . 0.0 108.624 179.19 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.68 26.36 25.12 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 119.222 -1.466 . . . . 0.0 109.884 -179.724 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.544 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.3 mt -85.69 176.01 8.4 Favored 'General case' 0 C--N 1.307 -1.281 0 O-C-N 120.695 -1.473 . . . . 0.0 108.245 179.908 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.76 96.87 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.013 -1.055 . . . . 0.0 109.671 -179.891 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.722 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.69 76.61 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.547 -178.91 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.01 34.59 0.33 Allowed Glycine 0 N--CA 1.486 1.984 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 179.334 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.561 ' CG2' ' CB ' ' A' ' 27' ' ' GLN . 1.2 t -149.23 115.4 5.77 Favored 'General case' 0 C--N 1.308 -1.213 0 O-C-N 120.94 -1.329 . . . . 0.0 111.263 179.949 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.68 129.54 4.15 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.819 178.262 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.541 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 7.4 m-85 -120.45 149.85 41.74 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.614 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.549 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -100.07 164.79 11.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.651 -1.281 . . . . 0.0 107.685 178.73 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.648 HG13 ' O ' ' A' ' 34' ' ' VAL . 7.0 p -147.86 118.22 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.139 -0.976 . . . . 0.0 109.855 -177.831 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.77 -178.61 41.52 Favored Glycine 0 N--CA 1.494 2.526 0 C-N-CA 118.432 -1.842 . . . . 0.0 111.537 -179.864 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.707 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -99.16 108.48 21.09 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.822 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.19 148.31 52.02 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.257 -0.902 . . . . 0.0 110.109 179.992 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.44 139.5 53.83 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.39 -0.819 . . . . 0.0 110.736 -179.167 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.878 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.82 26.65 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.129 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.454 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 13.6 m -105.92 15.46 7.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.029 -1.044 . . . . 0.0 110.583 -178.698 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.32 -175.66 0.09 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.858 -1.151 . . . . 0.0 110.095 179.688 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -71.5 97.14 1.61 Allowed 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.47 -0.769 . . . . 0.0 109.754 -179.744 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.26 27.81 35.49 Favored Glycine 0 N--CA 1.491 2.325 0 C-N-CA 120.181 -1.009 . . . . 0.0 111.394 179.006 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 2.0 t -116.1 106.6 20.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 O-C-N 120.625 -1.515 . . . . 0.0 107.295 178.814 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.878 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -116.21 104.66 11.74 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.483 -1.386 . . . . 0.0 109.738 -177.745 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.925 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.63 109.36 22.13 Favored 'General case' 0 N--CA 1.483 1.221 0 O-C-N 120.887 -1.133 . . . . 0.0 107.947 178.916 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.492 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -108.29 167.09 10.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.98 -1.075 . . . . 0.0 110.589 -178.535 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.496 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 43.6 t30 -114.7 128.22 26.09 Favored Pre-proline 0 N--CA 1.499 1.977 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 -179.554 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.603 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.2 Cg_endo -69.96 19.89 0.19 Allowed 'Trans proline' 0 CA--C 1.545 1.065 0 C-N-CA 122.005 1.803 . . . . 0.0 112.294 -179.804 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.496 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -93.79 -7.51 43.22 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.384 -1.448 . . . . 0.0 108.802 179.122 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.608 ' HB3' HD22 ' A' ' 67' ' ' LEU . 4.2 m-20 -131.24 2.22 4.24 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.369 -0.832 . . . . 0.0 108.802 -179.869 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -58.15 83.53 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.336 -0.853 . . . . 0.0 111.147 -178.247 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -110.97 -170.89 1.72 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 178.087 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.62 134.7 0.08 Allowed 'General case' 0 C--N 1.305 -1.363 0 O-C-N 120.446 -1.409 . . . . 0.0 111.621 -179.345 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.708 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.9 p -145.95 158.78 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 107.071 -1.455 . . . . 0.0 107.071 177.744 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.568 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.13 145.44 26.01 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.448 -1.407 . . . . 0.0 109.944 -179.613 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.002 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.04 108.84 3.23 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 122.272 1.034 . . . . 0.0 109.568 179.036 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.54 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.3 t0 -62.8 -138.89 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.979 -179.888 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.722 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.95 -51.53 40.59 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.393 -0.817 . . . . 0.0 110.559 -178.732 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -104.46 -33.54 8.55 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 178.493 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.971 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.75 70.08 0.7 Allowed Glycine 0 C--N 1.299 -1.512 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 178.482 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.603 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 70.9 m -103.57 130.81 51.05 Favored 'General case' 0 N--CA 1.484 1.255 0 O-C-N 121.248 -1.148 . . . . 0.0 109.208 179.324 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.708 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.57 108.86 7.79 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.471 -0.891 . . . . 0.0 109.841 -179.588 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.2 m -115.4 115.38 26.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.117 -0.99 . . . . 0.0 109.328 179.998 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.44 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.09 144.87 30.29 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.413 -0.804 . . . . 0.0 109.829 -179.91 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.426 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 24.7 p -98.99 140.8 32.61 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.55 -0.718 . . . . 0.0 109.169 179.66 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 1.128 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -135.46 165.37 25.64 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.322 -0.862 . . . . 0.0 110.065 -178.924 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.587 HG22 HG22 ' A' ' 18' ' ' VAL . 1.2 p -104.38 123.06 46.75 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.127 -0.983 . . . . 0.0 108.807 179.463 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.707 HG12 ' HB3' ' A' ' 36' ' ' GLN . 18.9 m -136.06 143.48 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.838 -1.164 . . . . 0.0 110.359 -178.898 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.583 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.2 ptt180 -141.64 -166.19 2.15 Favored 'General case' 0 N--CA 1.485 1.323 0 O-C-N 120.686 -1.259 . . . . 0.0 110.331 179.688 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.571 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 1.3 mtp180 -68.98 -78.21 0.07 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.57 -0.706 . . . . 0.0 109.128 -179.419 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -71.92 139.25 48.65 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 120.122 -1.611 . . . . 0.0 107.822 179.39 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -160.32 136.36 8.52 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 118.276 -1.37 . . . . 0.0 110.058 -178.501 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.483 ' O ' ' O ' ' A' ' 47' ' ' CYS . 20.4 mm-40 -32.84 122.36 0.36 Allowed 'General case' 0 N--CA 1.491 1.598 0 CA-C-O 121.557 0.694 . . . . 0.0 110.776 -178.248 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.925 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.51 44.37 3.05 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 -179.502 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.603 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -39.12 112.3 0.24 Allowed 'General case' 0 N--CA 1.507 2.384 0 O-C-N 121.156 -1.202 . . . . 0.0 110.27 179.954 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.696 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.5 tp -87.41 127.73 35.21 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 120.837 -1.165 . . . . 0.0 109.412 -179.926 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -64.35 57.96 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 120.91 -1.119 . . . . 0.0 110.24 179.9 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.52 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.0 t70 -160.68 19.06 0.13 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.049 -1.032 . . . . 0.0 109.817 179.813 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.06 -26.01 5.73 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.161 -1.175 . . . . 0.0 110.161 179.865 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.424 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -92.54 153.65 18.93 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.906 -1.35 . . . . 0.0 110.384 -179.463 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.482 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -101.34 132.45 46.89 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.493 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.696 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -80.66 -17.44 51.2 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.813 -1.179 . . . . 0.0 110.278 -178.624 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.6 173.55 20.16 Favored Glycine 0 N--CA 1.486 1.995 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -179.682 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.38 108.05 1.03 Allowed 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 179.04 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.676 HG21 ' CB ' ' A' ' 46' ' ' ALA . 39.8 t -79.01 105.64 8.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 O-C-N 121.43 -0.794 . . . . 0.0 108.882 -178.834 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.631 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -67.93 111.23 4.25 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.427 -0.795 . . . . 0.0 109.874 -179.151 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.571 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -63.88 -5.45 4.43 Favored 'General case' 0 N--CA 1.501 2.095 0 C-N-CA 118.438 -1.305 . . . . 0.0 109.862 179.529 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.424 HG23 ' HB3' ' A' ' 71' ' ' ARG . 69.7 p -84.49 0.22 50.53 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.744 -1.222 . . . . 0.0 108.909 179.324 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.631 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -114.2 -49.06 2.86 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.469 -0.77 . . . . 0.0 109.147 179.952 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.17 -178.65 3.7 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.386 -0.821 . . . . 0.0 109.58 -179.943 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.16 114.78 29.18 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.452 -0.78 . . . . 0.0 109.022 -179.991 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.563 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.04 122.12 39.68 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.919 -1.113 . . . . 0.0 109.49 -179.375 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.637 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.28 144.7 30.46 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 122.444 1.116 . . . . 0.0 111.151 -179.336 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.567 ' HB ' HG11 ' A' ' 7' ' ' VAL . 99.4 t -100.9 110.02 26.84 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.604 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.483 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.39 -172.63 19.19 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 117.899 -2.096 . . . . 0.0 111.83 -177.611 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.652 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -111.63 -177.51 3.21 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -179.268 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.549 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER . . . . . 0 C--N 1.297 -1.707 0 O-C-N 121.137 -0.977 . . . . 0.0 110.143 -179.134 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.49 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.483 1.793 0 N-CA-C 107.978 -2.049 . . . . 0.0 107.978 . . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.49 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -171.24 -179.12 2.58 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.517 -0.99 . . . . 0.0 109.567 179.156 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.36 -165.42 28.61 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 108.685 -1.766 . . . . 0.0 108.685 -179.548 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.472 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.0 Cg_exo -49.3 -178.19 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.641 0 CA-C-N 118.857 1.328 . . . . 0.0 110.076 179.556 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -96.88 -179.67 4.64 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.079 -1.013 . . . . 0.0 110.313 -179.056 . . . . . . . . 1 1 . 1 . 046 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.483 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.87 163.79 12.8 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 179.994 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.84 127.6 51.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.287 -1.125 . . . . 0.0 109.165 -179.53 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.637 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.02 121.11 18.61 Favored 'General case' 0 C--N 1.289 -2.053 0 CA-C-O 121.323 0.582 . . . . 0.0 109.743 179.825 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.861 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.98 168.76 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.238 -0.914 . . . . 0.0 109.387 179.952 . . . . . . . . 2 2 . 1 . 046 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.469 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.0 OUTLIER -138.34 157.63 45.86 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.289 -0.882 . . . . 0.0 109.78 -179.875 . . . . . . . . 3 3 . 1 . 046 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.861 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.6 m-85 . . . . . 0 N--CA 1.487 1.41 0 O-C-N 121.202 -0.936 . . . . 0.0 109.565 -179.756 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.526 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.482 1.154 0 CA-C-O 122.425 1.107 . . . . 0.0 110.609 . . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.005 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.9 p -105.42 104.72 14.5 Favored 'General case' 0 C--N 1.295 -1.77 0 CA-C-O 122.57 1.176 . . . . 0.0 110.173 -179.585 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.944 HG22 HG23 ' A' ' 21' ' ' VAL . 20.5 t -119.29 122.56 69.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.317 179.804 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.477 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -166.59 150.64 6.76 Favored Pre-proline 0 N--CA 1.489 1.511 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.294 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.477 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -74.62 151.9 97.54 Favored 'Cis proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.651 -1.395 . . . . 0.0 110.016 -0.621 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.635 ' HA ' HG22 ' A' ' 110' ' ' ILE . 6.0 m -93.73 -23.07 18.34 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.518 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.501 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -135.67 160.86 37.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.474 -0.766 . . . . 0.0 109.446 -179.97 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.09 37.7 31.93 Favored Glycine 0 N--CA 1.494 2.541 0 N-CA-C 108.517 -1.833 . . . . 0.0 108.517 -179.624 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.829 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.0 mt -89.9 -44.7 9.73 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 123.188 1.47 . . . . 0.0 110.608 -178.439 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.47 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.4 OUTLIER 65.89 146.26 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.626 -1.624 . . . . 0.0 110.151 -179.931 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.588 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.1 p-10 -51.33 107.52 0.19 Allowed 'General case' 0 C--N 1.302 -1.485 0 CA-C-O 121.68 0.752 . . . . 0.0 111.678 -178.601 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.24 15.08 9.27 Favored Glycine 0 N--CA 1.484 1.848 0 C-N-CA 119.511 -1.328 . . . . 0.0 112.847 177.348 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.829 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.9 t -103.72 -172.77 2.17 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 121.146 2.473 . . . . 0.0 109.776 179.358 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.721 HG13 ' C ' ' A' ' 67' ' ' LEU . 13.6 t -132.81 140.42 47.45 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.351 0 CA-C-N 114.937 -1.028 . . . . 0.0 111.136 -178.829 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.525 HG23 ' CD1' ' A' ' 67' ' ' LEU . 31.3 m -117.76 154.16 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 121.355 -0.841 . . . . 0.0 108.968 179.144 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.551 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -108.03 108.95 20.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.886 . . . . 0.0 109.148 179.966 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.944 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -106.1 122.44 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.978 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.005 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.84 166.23 11.57 Favored 'General case' 0 C--N 1.306 -1.3 0 O-C-N 120.857 -1.152 . . . . 0.0 108.737 179.502 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.605 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.41 108.37 0.49 Allowed Glycine 0 N--CA 1.482 1.752 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 179.952 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.94 138.83 51.28 Favored 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 119.366 1.583 . . . . 0.0 110.21 -179.454 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.88 28.92 30.29 Favored Glycine 0 N--CA 1.491 2.306 0 C-N-CA 118.941 -1.6 . . . . 0.0 109.888 179.549 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.53 ' O ' ' N ' ' A' ' 28' ' ' ALA . 2.0 mt -91.67 176.13 6.65 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.979 -1.307 . . . . 0.0 108.449 179.956 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.65 96.91 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.052 -1.03 . . . . 0.0 109.61 -179.905 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.7 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.07 76.61 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.798 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.341 -178.857 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.52 34.17 0.32 Allowed Glycine 0 N--CA 1.486 1.985 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.383 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.568 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.1 t -148.44 115.32 6.06 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 120.931 -1.335 . . . . 0.0 111.113 -179.935 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.559 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -43.36 128.83 4.94 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.777 178.38 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.568 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.0 m-85 -120.58 147.35 45.31 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.486 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.469 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.61 159.65 14.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.507 -1.371 . . . . 0.0 107.666 178.648 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.8 HG11 HG21 ' A' ' 65' ' ' THR . 9.8 p -144.36 116.33 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.08 -1.012 . . . . 0.0 110.198 -177.543 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.522 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.89 -175.33 38.81 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.477 -1.82 . . . . 0.0 111.654 -179.995 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.587 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -100.91 109.22 21.14 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 121.845 0.831 . . . . 0.0 108.973 -179.717 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.79 149.44 52.43 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.254 -0.904 . . . . 0.0 110.05 179.796 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.34 139.07 54.26 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.38 -0.825 . . . . 0.0 110.813 -179.064 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 115.05 26.92 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.98 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.8 m -106.05 15.59 7.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 O-C-N 120.969 -1.082 . . . . 0.0 110.534 -178.796 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.777 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 173.79 -176.36 0.07 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.897 -1.127 . . . . 0.0 110.127 179.835 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.781 ' O ' HG23 ' A' ' 42' ' ' THR . 15.0 t -70.79 98.58 1.57 Allowed 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.416 -0.803 . . . . 0.0 109.914 -179.69 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.13 28.52 36.84 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.265 -0.969 . . . . 0.0 111.238 179.027 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.777 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.9 106.31 19.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.839 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.6 tp -116.94 104.83 11.68 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.409 -1.432 . . . . 0.0 109.749 -177.55 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.895 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.62 109.46 22.21 Favored 'General case' 0 N--CA 1.485 1.276 0 O-C-N 120.806 -1.184 . . . . 0.0 108.29 178.938 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.38 167.46 9.91 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.959 -1.088 . . . . 0.0 110.078 -178.959 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.743 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 15.2 t-20 -109.31 136.45 20.18 Favored Pre-proline 0 N--CA 1.5 2.06 0 O-C-N 121.369 -0.832 . . . . 0.0 109.97 -179.296 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -75.25 23.27 0.42 Allowed 'Trans proline' 0 CA--C 1.544 0.976 0 C-N-CA 122.369 2.046 . . . . 0.0 111.798 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.743 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -117.68 3.9 12.33 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.429 -1.42 . . . . 0.0 108.974 179.593 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.583 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.58 17.87 2.9 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 179.214 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -83.71 90.13 7.26 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.925 -178.473 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.81 -170.41 1.65 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 178.042 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.445 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.81 135.36 0.09 Allowed 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.402 -1.436 . . . . 0.0 111.508 -179.245 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.788 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.3 p -151.88 158.73 4.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.037 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.559 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.49 145.77 25.89 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.642 -1.286 . . . . 0.0 109.799 -179.621 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.22 108.01 2.55 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 122.389 1.09 . . . . 0.0 109.681 178.879 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.553 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.8 p-10 -61.23 -139.56 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.811 -179.898 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.7 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.96 -50.89 57.16 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.296 -0.877 . . . . 0.0 110.498 -178.858 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -103.98 -34.02 8.61 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 178.481 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.947 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.11 70.36 0.73 Allowed Glycine 0 C--N 1.297 -1.583 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 178.278 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.605 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 38.9 m -104.05 127.4 51.61 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.69 -0.888 . . . . 0.0 108.936 179.165 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.788 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.06 109.04 8.15 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.415 -179.682 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -118.69 117.07 27.94 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.264 -0.898 . . . . 0.0 109.349 -179.934 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.8 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -145.46 142.0 28.88 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.452 -0.78 . . . . 0.0 109.772 179.99 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.3 p -100.91 135.06 42.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.497 -0.752 . . . . 0.0 109.231 179.742 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.721 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -133.39 165.52 24.65 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.314 -0.866 . . . . 0.0 109.526 -179.449 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.679 HG22 HG22 ' A' ' 18' ' ' VAL . 2.3 p -96.76 125.23 41.07 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.27 -0.894 . . . . 0.0 109.342 -179.903 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.562 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.3 m -136.13 144.54 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.959 -1.088 . . . . 0.0 109.584 -179.312 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.588 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.4 ptt180 -139.95 -166.37 2.08 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 120.593 -1.317 . . . . 0.0 110.338 -179.927 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.688 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 40.9 mtm180 -69.83 -73.91 0.15 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.51 -0.744 . . . . 0.0 109.298 -179.113 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.52 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -76.87 145.74 38.13 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 178.534 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -166.23 140.06 4.23 Favored 'General case' 0 C--N 1.293 -1.887 0 C-N-CA 117.507 -1.677 . . . . 0.0 110.464 -177.737 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.537 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 2.2 mm-40 -33.98 122.32 0.46 Allowed 'General case' 0 N--CA 1.49 1.533 0 CA-C-O 121.593 0.711 . . . . 0.0 110.664 -178.479 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.895 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.09 45.82 3.03 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 -179.338 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.9 m-30 -39.63 113.19 0.31 Allowed 'General case' 0 N--CA 1.508 2.472 0 O-C-N 121.083 -1.245 . . . . 0.0 110.169 179.673 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.737 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.2 tp -87.23 128.17 35.15 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 120.868 -1.145 . . . . 0.0 109.379 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -64.47 57.89 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 120.809 -1.182 . . . . 0.0 110.328 179.882 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.518 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.1 t70 -161.0 18.92 0.12 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.946 -1.096 . . . . 0.0 109.779 179.844 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.79 -25.85 5.65 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 179.952 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 3.4 p -91.55 153.27 19.87 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 120.895 -1.356 . . . . 0.0 110.387 -179.351 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.508 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 8.5 ptt180 -100.95 131.93 46.6 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.544 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.737 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -81.74 -18.61 43.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.729 -1.232 . . . . 0.0 110.495 -178.47 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.61 173.65 19.6 Favored Glycine 0 N--CA 1.486 2.014 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 -179.624 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -62.07 109.27 1.24 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 179.133 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.681 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.5 t -80.87 104.51 9.47 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 O-C-N 121.339 -0.851 . . . . 0.0 109.058 -178.859 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.573 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -68.07 112.69 5.19 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.628 -0.67 . . . . 0.0 109.648 -179.551 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.688 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 6.8 m -56.83 -8.4 0.6 Allowed 'General case' 0 N--CA 1.496 1.867 0 C-N-CA 118.309 -1.356 . . . . 0.0 110.466 179.816 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 p -84.52 -12.44 54.19 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.366 -1.459 . . . . 0.0 109.53 179.981 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.573 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -92.97 -47.86 6.8 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.286 -0.884 . . . . 0.0 109.032 179.934 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -117.12 -178.24 3.4 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.547 -0.72 . . . . 0.0 109.477 179.937 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.48 117.76 35.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.462 -0.774 . . . . 0.0 108.922 179.888 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.496 ' O ' HG12 ' A' ' 110' ' ' ILE . 3.2 m -96.41 121.41 38.19 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.761 -1.212 . . . . 0.0 109.791 -179.202 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.78 146.92 27.92 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 122.445 1.117 . . . . 0.0 111.022 -179.486 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.707 ' HB ' HG11 ' A' ' 7' ' ' VAL . 42.5 t -102.93 109.81 27.82 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 177.442 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.482 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.68 -170.0 16.65 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 118.263 -1.922 . . . . 0.0 111.697 -177.4 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.526 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -122.2 -179.41 4.16 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.608 . . . . . . . . 3 3 . 1 . 047 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.463 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.4 OUTLIER . . . . . 0 C--N 1.296 -1.725 0 O-C-N 121.362 -0.836 . . . . 0.0 109.593 -179.739 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.696 0 N-CA-C 107.713 -2.155 . . . . 0.0 107.713 . . . . . . . . . 0 0 . 1 . 047 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.52 -177.6 5.72 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.626 -0.926 . . . . 0.0 109.967 179.311 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.53 -161.55 21.31 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.41 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.494 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.2 Cg_exo -45.83 173.12 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.628 0 CA-C-N 118.919 1.359 . . . . 0.0 109.936 179.263 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -92.81 -174.87 3.74 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.127 -0.983 . . . . 0.0 110.526 -178.751 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.482 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.0 166.14 13.55 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.953 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -103.97 130.42 54.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.349 -1.089 . . . . 0.0 109.075 -179.39 . . . . . . . . 1 1 . 1 . 047 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.81 123.68 23.85 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.494 -0.753 . . . . 0.0 109.642 179.728 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.761 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.78 168.42 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 119.555 -0.858 . . . . 0.0 108.912 179.893 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.501 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 2.3 m -134.12 153.76 51.62 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.295 -0.878 . . . . 0.0 109.448 -179.882 . . . . . . . . 2 2 . 1 . 047 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.761 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 65.9 m-85 . . . . . 0 N--CA 1.485 1.314 0 O-C-N 121.193 -0.942 . . . . 0.0 109.397 -179.783 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.156 0 CA-C-O 122.359 1.076 . . . . 0.0 110.696 . . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.009 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -105.11 104.8 14.61 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 122.609 1.195 . . . . 0.0 110.141 -179.505 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.931 HG22 HG23 ' A' ' 21' ' ' VAL . 16.7 t -120.17 119.91 61.4 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.44 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.325 179.662 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.523 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.0 150.06 9.54 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 -179.587 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.523 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.1 Cg_endo -75.11 153.57 99.06 Favored 'Cis proline' 0 C--N 1.31 -1.471 0 C-N-CA 123.721 -1.366 . . . . 0.0 109.933 -0.637 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.646 ' HA ' HG22 ' A' ' 110' ' ' ILE . 8.0 m -95.04 -23.51 17.32 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.461 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.461 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 3.4 m -134.24 164.21 27.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.583 -0.698 . . . . 0.0 109.649 179.95 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.36 36.85 43.39 Favored Glycine 0 N--CA 1.496 2.668 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 -179.73 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.885 ' CA ' HG21 ' A' ' 17' ' ' THR . 21.9 mt -90.03 -46.18 8.67 Favored 'General case' 0 C--N 1.297 -1.705 0 CA-C-O 123.151 1.453 . . . . 0.0 110.6 -178.532 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.45 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 2.1 t 61.45 148.25 0.02 OUTLIER 'General case' 0 C--N 1.259 -3.341 0 CA-C-N 113.917 -1.492 . . . . 0.0 109.913 -179.766 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.625 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 3.9 p-10 -51.35 109.61 0.36 Allowed 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.574 0.702 . . . . 0.0 111.683 -178.834 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.94 12.68 10.95 Favored Glycine 0 N--CA 1.485 1.945 0 C-N-CA 119.403 -1.38 . . . . 0.0 112.915 177.42 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.885 HG21 ' CA ' ' A' ' 13' ' ' LEU . 7.9 t -101.45 -175.25 2.8 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 121.0 2.4 . . . . 0.0 109.717 179.511 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.673 HG13 ' O ' ' A' ' 67' ' ' LEU . 9.4 t -132.75 137.72 53.41 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.906 -179.414 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.485 ' O ' HD12 ' A' ' 67' ' ' LEU . 28.5 m -116.97 153.88 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.348 -0.845 . . . . 0.0 109.214 179.219 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -110.31 109.23 19.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.29 -0.882 . . . . 0.0 108.977 179.715 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.931 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -105.95 122.5 59.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.766 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.009 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.4 165.84 12.07 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.886 -1.134 . . . . 0.0 108.954 179.554 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.52 108.23 0.5 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 108.806 -1.717 . . . . 0.0 108.806 -179.976 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.457 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.31 140.8 48.95 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-N 119.204 1.502 . . . . 0.0 110.281 -179.38 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.08 28.46 34.05 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.077 -1.535 . . . . 0.0 109.964 179.653 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -92.91 175.01 6.95 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.942 -1.328 . . . . 0.0 108.367 179.977 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.54 99.19 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.913 -1.117 . . . . 0.0 109.572 -179.743 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.647 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.69 76.85 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.272 -179.101 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.17 34.26 0.29 Allowed Glycine 0 N--CA 1.486 2.005 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.574 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.563 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.9 p -145.11 111.98 5.91 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.958 -1.319 . . . . 0.0 111.167 -179.683 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -45.7 125.66 6.21 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.574 178.107 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.489 ' CD2' ' O ' ' A' ' 30' ' ' THR . 14.2 m-85 -117.33 151.11 37.67 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.682 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.516 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -101.39 153.23 19.85 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.76 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.002 HG11 HG21 ' A' ' 65' ' ' THR . 6.2 p -136.31 115.05 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.105 -0.997 . . . . 0.0 109.756 -177.928 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -165.09 -178.45 38.35 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 118.474 -1.822 . . . . 0.0 111.696 -179.68 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.618 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -102.47 109.27 20.86 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.729 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.87 149.08 52.67 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.128 -0.982 . . . . 0.0 110.117 -179.878 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.78 138.72 54.55 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.399 -0.813 . . . . 0.0 110.609 -179.111 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.883 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 114.88 26.72 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 178.005 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 m -105.24 15.05 6.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.986 -1.071 . . . . 0.0 110.579 -178.72 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.759 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.59 -175.88 0.08 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.916 -1.115 . . . . 0.0 110.044 179.686 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.786 ' O ' HG23 ' A' ' 42' ' ' THR . 15.0 t -71.81 98.34 1.96 Allowed 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.418 -0.801 . . . . 0.0 109.794 -179.704 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.76 27.43 34.94 Favored Glycine 0 N--CA 1.492 2.425 0 C-N-CA 120.077 -1.058 . . . . 0.0 111.518 179.084 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.76 106.42 20.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 O-C-N 120.548 -1.56 . . . . 0.0 107.288 178.929 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.883 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -117.36 104.64 11.33 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.38 -1.45 . . . . 0.0 109.796 -177.757 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.89 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.77 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 178.698 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -105.49 166.96 10.07 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.043 -1.036 . . . . 0.0 110.493 -178.641 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.465 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 36.8 t-20 -110.35 129.61 23.77 Favored Pre-proline 0 N--CA 1.499 1.998 0 O-C-N 121.668 -0.645 . . . . 0.0 109.499 -179.393 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.612 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.1 Cg_endo -72.39 22.34 0.28 Allowed 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 122.091 1.861 . . . . 0.0 111.808 179.581 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -110.76 2.6 18.5 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.41 -1.431 . . . . 0.0 108.997 179.626 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.531 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.58 17.83 2.71 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 179.447 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -80.73 93.11 6.13 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.916 -0.714 . . . . 0.0 111.086 -178.496 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -113.15 -167.78 1.24 Allowed 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 178.113 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.73 136.82 0.09 Allowed 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.619 -1.301 . . . . 0.0 111.524 -179.248 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.918 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -154.45 157.1 4.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.113 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.84 144.82 27.03 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.665 -1.272 . . . . 0.0 109.893 -179.636 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.6 107.07 1.61 Allowed 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 122.353 1.073 . . . . 0.0 109.428 178.772 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.549 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.4 t0 -60.47 -139.29 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.956 -179.895 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.647 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.01 -50.72 57.98 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.401 -0.812 . . . . 0.0 110.733 -178.749 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -104.02 -34.06 8.58 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.461 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.985 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.23 66.17 0.62 Allowed Glycine 0 C--N 1.295 -1.704 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 178.243 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 20.3 m -103.5 125.02 49.82 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.758 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.918 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.6 109.19 8.5 Favored 'General case' 0 C--N 1.296 -1.749 0 C-N-CA 119.631 -0.827 . . . . 0.0 109.649 -179.28 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 97.3 p -116.44 116.51 27.8 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.345 -0.847 . . . . 0.0 109.441 -179.987 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 65' ' ' THR . . . . . 1.002 HG21 HG11 ' A' ' 34' ' ' VAL . 1.1 t -141.3 138.5 33.21 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.438 -0.789 . . . . 0.0 109.816 179.982 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.444 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 23.4 p -99.12 141.22 32.16 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.446 -0.784 . . . . 0.0 109.127 179.814 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.776 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -142.34 169.44 17.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.33 -0.856 . . . . 0.0 109.523 -179.24 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.5 p -96.57 126.26 41.62 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.055 -1.028 . . . . 0.0 109.519 -179.712 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.676 HG23 HD13 ' A' ' 13' ' ' LEU . 15.6 m -133.14 142.74 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 120.916 -1.115 . . . . 0.0 109.738 -179.346 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.625 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.84 -170.68 3.59 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.517 -1.364 . . . . 0.0 110.731 -179.877 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.6 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -66.6 -102.23 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.807 -0.558 . . . . 0.0 110.171 -179.04 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.12 136.29 56.38 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.388 -1.445 . . . . 0.0 108.198 179.845 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.618 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -155.86 158.52 38.18 Favored 'General case' 0 C--N 1.295 -1.793 0 C-N-CA 118.722 -1.191 . . . . 0.0 109.894 -178.853 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.515 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 12.1 mm-40 -50.01 121.9 6.01 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.296 -0.878 . . . . 0.0 109.561 -178.651 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.89 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.12 48.32 3.43 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 -179.514 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.612 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -40.11 113.38 0.35 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.046 -1.267 . . . . 0.0 110.286 179.919 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.756 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -86.94 127.1 35.07 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 120.913 -1.117 . . . . 0.0 109.47 179.987 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -63.88 58.52 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.865 -1.147 . . . . 0.0 110.167 179.8 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.531 ' N ' ' O ' ' A' ' 77' ' ' LEU . 14.3 t0 -161.02 19.23 0.12 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.09 -1.006 . . . . 0.0 109.92 179.842 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -25.6 5.96 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 179.802 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 67.4 p -94.09 159.22 15.25 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.979 -1.307 . . . . 0.0 110.384 -179.35 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.483 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 2.7 ptt180 -104.97 133.33 49.94 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 179.796 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.756 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -82.38 -18.37 42.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.845 -1.159 . . . . 0.0 110.406 -178.694 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.29 174.04 19.36 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 -179.671 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.56 108.7 1.44 Allowed 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 179.137 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.642 HG21 ' CB ' ' A' ' 46' ' ' ALA . 42.9 t -80.28 104.38 8.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 O-C-N 121.469 -0.77 . . . . 0.0 109.278 -178.771 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.561 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -63.78 108.35 1.42 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.517 -0.739 . . . . 0.0 110.137 -179.231 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.597 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.6 t -60.76 -5.14 1.17 Allowed 'General case' 0 N--CA 1.501 2.084 0 C-N-CA 118.141 -1.424 . . . . 0.0 110.282 179.214 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 73.2 p -89.87 2.08 55.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.486 -1.383 . . . . 0.0 109.495 179.965 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.561 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.06 -49.04 2.94 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.236 -0.915 . . . . 0.0 109.149 -179.975 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.57 179.55 4.23 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.432 -0.792 . . . . 0.0 109.48 -179.974 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.65 112.99 25.74 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.791 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.506 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.55 121.39 38.32 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.008 -1.058 . . . . 0.0 109.373 -179.004 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.594 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.61 147.03 27.3 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.369 1.08 . . . . 0.0 111.341 -179.117 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.626 ' HB ' HG11 ' A' ' 7' ' ' VAL . 54.0 t -102.82 109.24 26.15 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 177.309 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.1 -170.96 16.56 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 118.179 -1.962 . . . . 0.0 111.53 -177.378 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.516 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -118.33 -178.52 3.54 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -178.612 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.51 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER . . . . . 0 C--N 1.295 -1.783 0 O-C-N 121.423 -0.798 . . . . 0.0 109.38 -179.352 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.735 0 N-CA-C 107.645 -2.182 . . . . 0.0 107.645 . . . . . . . . . 0 0 . 1 . 048 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.18 -178.39 7.17 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.581 -0.953 . . . . 0.0 109.809 179.229 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.12 -162.08 19.32 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 108.209 -1.957 . . . . 0.0 108.209 -179.398 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.3 Cg_exo -45.68 171.99 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.632 0 CA-C-N 118.855 1.327 . . . . 0.0 109.932 179.366 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -90.6 -173.07 3.62 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.092 -1.005 . . . . 0.0 110.544 -178.567 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.467 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.68 168.26 15.04 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.874 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.33 131.44 54.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 121.414 -1.051 . . . . 0.0 109.143 -179.313 . . . . . . . . 1 1 . 1 . 048 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.594 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.16 122.51 21.13 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.662 -0.648 . . . . 0.0 109.736 179.767 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.906 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -97.95 170.99 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.279 -0.888 . . . . 0.0 108.898 179.766 . . . . . . . . 2 2 . 1 . 048 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.461 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.1 OUTLIER -137.07 162.29 33.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.216 -0.927 . . . . 0.0 109.856 -179.78 . . . . . . . . 3 3 . 1 . 048 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.906 ' CE1' HD12 ' A' ' 110' ' ' ILE . 48.3 m-85 . . . . . 0 N--CA 1.485 1.277 0 O-C-N 121.244 -0.91 . . . . 0.0 109.495 -179.817 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.486 1.34 0 CA-C-O 122.431 1.11 . . . . 0.0 110.262 . . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.879 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.0 t -115.82 109.16 17.25 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-O 123.058 1.409 . . . . 0.0 109.867 -179.893 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.921 HG22 HG23 ' A' ' 21' ' ' VAL . 1.6 t -114.5 136.68 50.32 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.733 0 CA-C-N 114.236 -1.347 . . . . 0.0 109.557 179.781 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.486 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -170.55 149.68 3.09 Favored Pre-proline 0 N--CA 1.488 1.432 0 O-C-N 121.135 -0.978 . . . . 0.0 109.001 -179.591 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.486 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -77.02 150.78 92.94 Favored 'Cis proline' 0 C--N 1.313 -1.302 0 C-N-CA 123.436 -1.485 . . . . 0.0 109.455 -0.931 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.656 ' HA ' HG22 ' A' ' 110' ' ' ILE . 79.1 p -91.31 -23.81 20.01 Favored 'General case' 0 C--N 1.292 -1.928 0 O-C-N 121.589 -0.695 . . . . 0.0 109.292 179.971 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.493 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -131.57 162.05 31.22 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.284 -0.885 . . . . 0.0 109.733 -179.839 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.76 38.38 31.72 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 108.434 -1.866 . . . . 0.0 108.434 -179.666 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.781 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.0 mt -91.88 -44.07 9.13 Favored 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 123.12 1.438 . . . . 0.0 110.759 -178.226 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.468 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.87 144.22 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.317 0 CA-C-N 113.568 -1.651 . . . . 0.0 109.938 -179.526 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.618 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.6 p-10 -50.55 108.43 0.23 Allowed 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 121.64 0.734 . . . . 0.0 111.759 -178.483 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.72 14.24 10.52 Favored Glycine 0 N--CA 1.484 1.841 0 C-N-CA 119.555 -1.307 . . . . 0.0 112.895 177.255 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.781 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -105.29 -173.71 2.36 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 121.011 2.406 . . . . 0.0 110.162 179.435 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.779 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.8 t -130.62 141.39 46.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.273 0 CA-C-N 114.45 -1.25 . . . . 0.0 111.069 -178.714 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.572 HG12 HD21 ' A' ' 13' ' ' LEU . 34.5 m -118.53 155.29 20.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.661 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.9 tttt -102.07 109.19 20.84 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.127 -0.983 . . . . 0.0 109.176 -179.871 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.921 HG23 HG22 ' A' ' 7' ' ' VAL . 10.5 p -99.05 139.6 20.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.785 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.879 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.84 161.49 35.05 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 120.729 -1.232 . . . . 0.0 109.94 179.45 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.586 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.98 138.01 9.46 Favored Glycine 0 C--O 1.207 -1.551 0 N-CA-C 107.839 -2.104 . . . . 0.0 107.839 179.669 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -141.04 126.89 19.19 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-N 119.484 1.642 . . . . 0.0 109.547 179.52 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.416 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 87.36 28.64 24.35 Favored Glycine 0 N--CA 1.488 2.132 0 C-N-CA 118.832 -1.651 . . . . 0.0 109.745 -179.984 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.7 mt -88.27 173.06 8.99 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.913 -1.345 . . . . 0.0 108.235 179.894 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.021 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.56 99.26 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.954 -1.091 . . . . 0.0 109.809 -179.482 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.43 77.31 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.698 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.254 -179.221 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.62 34.18 0.28 Allowed Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.591 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 50.7 p -142.35 108.55 5.24 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.092 -1.24 . . . . 0.0 111.367 -179.52 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.597 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.23 109.71 0.33 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 177.826 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.536 ' CE1' ' OG1' ' A' ' 30' ' ' THR . 4.3 m-30 -103.13 155.53 18.34 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.094 -1.004 . . . . 0.0 108.987 179.94 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -98.99 161.82 13.42 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.855 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.696 HG22 HG11 ' A' ' 21' ' ' VAL . 2.7 p -142.66 121.61 8.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.117 -0.99 . . . . 0.0 109.538 -178.018 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.64 -176.9 41.63 Favored Glycine 0 N--CA 1.496 2.645 0 C-N-CA 118.516 -1.802 . . . . 0.0 111.548 -179.77 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.756 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.17 108.94 21.18 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 -179.937 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -128.66 148.53 50.82 Favored 'General case' 0 C--N 1.295 -1.767 0 O-C-N 121.229 -0.919 . . . . 0.0 109.884 179.738 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.502 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.92 139.51 53.76 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.24 -0.912 . . . . 0.0 110.674 -179.071 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.891 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.13 114.93 26.78 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 178.19 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -105.24 15.26 6.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.982 -1.074 . . . . 0.0 110.53 -178.883 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.7 -176.39 0.09 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.997 -1.064 . . . . 0.0 110.067 179.682 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.774 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.4 97.37 1.26 Allowed 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.817 0.818 . . . . 0.0 109.901 -179.656 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.13 28.23 34.62 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 120.198 -1.001 . . . . 0.0 111.387 178.833 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.03 106.41 20.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 O-C-N 120.562 -1.552 . . . . 0.0 107.278 178.891 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.891 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -115.98 104.77 11.93 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.465 -1.397 . . . . 0.0 109.942 -177.552 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.041 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.3 109.65 22.37 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.656 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.49 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -109.06 161.9 14.75 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.863 -1.148 . . . . 0.0 110.462 -178.585 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.479 ' HB2' ' HB2' ' A' ' 73' ' ' PHE . 29.8 t-20 -108.44 131.04 22.02 Favored Pre-proline 0 N--CA 1.5 2.038 0 O-C-N 121.582 -0.699 . . . . 0.0 109.391 -179.659 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -72.19 22.15 0.27 Allowed 'Trans proline' 0 CA--C 1.545 1.074 0 C-N-CA 121.958 1.772 . . . . 0.0 111.892 179.523 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.664 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -97.08 -7.26 33.2 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.434 -1.417 . . . . 0.0 108.994 179.555 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.881 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.8 m-20 -132.63 5.22 3.97 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.999 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -59.84 78.61 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.355 -0.841 . . . . 0.0 110.938 -178.385 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.632 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -101.07 -167.91 1.49 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.238 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.451 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.57 134.84 0.08 Allowed 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.55 -1.344 . . . . 0.0 111.363 -179.391 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.771 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.5 p -149.03 156.99 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.067 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.597 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.4 141.22 31.54 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.706 -1.246 . . . . 0.0 110.012 -179.776 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.021 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.26 107.54 1.34 Allowed 'General case' 0 C--N 1.298 -1.669 0 CA-C-O 122.484 1.135 . . . . 0.0 109.571 178.76 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.565 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -61.04 -139.42 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.709 179.95 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.35 -50.68 61.87 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.393 -0.817 . . . . 0.0 110.481 -178.798 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.416 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 6.2 t-20 -101.95 -35.15 9.09 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 178.404 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.998 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.42 68.19 0.66 Allowed Glycine 0 C--N 1.298 -1.535 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 178.07 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.586 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 56.4 m -99.54 131.54 45.47 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.421 -1.046 . . . . 0.0 108.836 178.917 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.771 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.2 108.87 7.98 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.452 -179.517 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 m -123.97 117.92 25.86 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.297 -0.877 . . . . 0.0 109.651 -179.798 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.525 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.61 145.34 30.04 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.433 -0.792 . . . . 0.0 109.411 179.879 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.0 p -98.56 136.6 38.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.273 -0.892 . . . . 0.0 109.22 179.894 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.881 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -140.69 165.9 26.23 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.396 -0.815 . . . . 0.0 109.909 -178.9 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.664 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 10.9 t -99.56 129.61 45.73 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.955 -1.09 . . . . 0.0 111.437 -178.753 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.83 HG13 ' OD2' ' A' ' 51' ' ' ASP . 17.3 m -136.61 143.86 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.459 -0.776 . . . . 0.0 109.956 179.68 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.618 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -148.45 -175.46 4.93 Favored 'General case' 0 N--CA 1.484 1.239 0 O-C-N 120.445 -1.409 . . . . 0.0 110.6 179.25 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.59 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.13 -102.44 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -179.539 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.4 OUTLIER -56.41 139.93 47.26 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.789 -1.194 . . . . 0.0 108.206 179.494 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.581 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -159.68 138.3 10.64 Favored 'General case' 0 C--N 1.296 -1.745 0 C-N-CA 118.717 -1.193 . . . . 0.0 109.91 -178.403 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' A' ' 47' ' ' CYS . 4.4 mm-40 -35.22 120.81 0.55 Allowed 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.473 0.654 . . . . 0.0 110.662 -178.496 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.041 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.6 48.27 2.57 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 -179.428 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-30 -39.12 114.98 0.44 Allowed 'General case' 0 N--CA 1.509 2.489 0 O-C-N 121.152 -1.205 . . . . 0.0 110.064 179.598 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.734 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.4 tp -87.3 126.48 34.87 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.796 -1.19 . . . . 0.0 109.597 -179.78 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 24.1 t80 -64.42 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.023 0 O-C-N 120.871 -1.143 . . . . 0.0 110.188 179.704 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 14.0 t0 -160.35 19.6 0.15 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.049 -1.032 . . . . 0.0 109.739 179.865 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.83 -27.43 5.41 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 179.935 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.491 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 68.1 p -95.13 157.05 16.06 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 120.978 -1.307 . . . . 0.0 110.313 -179.446 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.536 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -103.94 139.94 38.4 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.673 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.734 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.1 t90 -85.89 -19.71 30.15 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.588 -1.32 . . . . 0.0 110.766 -178.129 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.23 174.59 18.62 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -179.419 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.99 104.17 1.08 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 179.159 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.665 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.9 t -74.49 106.64 4.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.388 -0.82 . . . . 0.0 109.55 -178.769 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.74 110.67 2.46 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.443 -0.786 . . . . 0.0 109.654 -179.735 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.59 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.4 t -64.32 -4.98 4.29 Favored 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 118.334 -1.346 . . . . 0.0 109.891 179.58 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.0 p -87.03 0.56 55.01 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.701 -1.25 . . . . 0.0 109.111 179.511 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -114.16 -50.07 2.83 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.275 -0.891 . . . . 0.0 109.047 179.905 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.22 -178.09 3.56 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.54 -0.725 . . . . 0.0 109.495 179.769 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.09 114.94 29.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.395 -0.816 . . . . 0.0 108.998 179.937 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.567 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -97.05 122.98 40.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.911 -1.118 . . . . 0.0 109.722 -179.233 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.632 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.23 146.83 28.22 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-O 122.345 1.069 . . . . 0.0 111.224 -179.414 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.658 ' CG1' HG11 ' A' ' 7' ' ' VAL . 58.9 t -101.5 110.18 27.69 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.987 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 177.695 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.476 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.06 -171.28 16.85 Favored Glycine 0 N--CA 1.485 1.964 0 C-N-CA 118.236 -1.935 . . . . 0.0 111.78 -177.592 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.476 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.63 177.66 5.15 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 121.625 0.726 . . . . 0.0 109.047 -179.161 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.523 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.4 OUTLIER . . . . . 0 C--N 1.296 -1.741 0 O-C-N 121.641 -0.662 . . . . 0.0 109.455 179.937 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.668 0 N-CA-C 107.817 -2.113 . . . . 0.0 107.817 . . . . . . . . . 0 0 . 1 . 049 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -166.06 -177.09 4.02 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.596 -0.944 . . . . 0.0 109.795 179.336 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.18 -161.88 17.52 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 108.247 -1.941 . . . . 0.0 108.247 -179.379 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.521 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.4 Cg_exo -46.56 176.34 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.686 0 CA-C-N 118.778 1.289 . . . . 0.0 110.203 179.325 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -95.19 -177.3 4.08 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.121 -0.987 . . . . 0.0 110.417 -178.896 . . . . . . . . 1 1 . 1 . 049 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.476 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -115.37 161.63 12.75 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.871 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.8 130.55 47.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.383 -1.069 . . . . 0.0 109.041 -179.461 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.632 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.65 124.33 25.06 Favored 'General case' 0 C--N 1.291 -1.975 0 O-C-N 121.724 -0.61 . . . . 0.0 110.059 -179.937 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.894 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.65 171.21 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.298 -0.876 . . . . 0.0 108.954 179.639 . . . . . . . . 2 2 . 1 . 049 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.493 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -137.05 158.06 45.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.209 -0.932 . . . . 0.0 109.632 179.97 . . . . . . . . 3 3 . 1 . 049 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.894 ' CE1' HD12 ' A' ' 110' ' ' ILE . 77.7 m-85 . . . . . 0 N--CA 1.486 1.35 0 O-C-N 121.26 -0.9 . . . . 0.0 109.517 -179.551 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.566 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.482 1.168 0 CA-C-O 122.444 1.116 . . . . 0.0 110.702 . . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.015 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -104.05 104.71 14.7 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 122.39 1.09 . . . . 0.0 110.271 -179.566 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.912 HG22 HG23 ' A' ' 21' ' ' VAL . 11.2 t -119.68 119.19 59.65 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.514 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.244 179.625 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.516 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.51 150.51 10.49 Favored Pre-proline 0 N--CA 1.488 1.44 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 -179.561 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.516 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.49 153.24 99.06 Favored 'Cis proline' 0 C--N 1.309 -1.537 0 C-N-CA 123.663 -1.39 . . . . 0.0 110.014 -0.578 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.618 ' HA ' HG22 ' A' ' 110' ' ' ILE . 7.2 m -94.44 -23.57 17.68 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.495 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.481 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.3 m -136.18 163.12 31.1 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.516 -0.74 . . . . 0.0 109.33 179.825 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.41 37.66 35.49 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 -179.523 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.796 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.1 mt -90.47 -44.12 9.82 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 123.18 1.467 . . . . 0.0 110.486 -178.289 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.467 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.97 144.71 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.265 0 CA-C-N 113.613 -1.63 . . . . 0.0 109.903 -179.665 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.625 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 8.1 p-10 -51.11 106.18 0.12 Allowed 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 121.471 0.653 . . . . 0.0 111.509 -178.592 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.46 12.31 9.78 Favored Glycine 0 N--CA 1.488 2.126 0 C-N-CA 119.324 -1.417 . . . . 0.0 113.121 177.261 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.796 HG21 ' CA ' ' A' ' 13' ' ' LEU . 11.6 t -101.51 -169.55 1.71 Allowed 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 121.135 2.467 . . . . 0.0 109.665 179.362 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.74 HG13 ' C ' ' A' ' 67' ' ' LEU . 11.4 t -136.14 142.94 37.32 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 CA-C-N 115.204 -0.907 . . . . 0.0 110.953 -179.015 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.538 HG22 HG22 ' A' ' 69' ' ' VAL . 13.3 m -120.47 154.72 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.221 -0.924 . . . . 0.0 109.255 179.438 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.538 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.3 tttt -106.28 109.08 20.9 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.233 -0.917 . . . . 0.0 109.28 179.955 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.912 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -105.61 122.26 58.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 179.885 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.015 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.43 165.81 12.35 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 120.886 -1.134 . . . . 0.0 109.129 179.885 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.579 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.1 107.7 0.48 Allowed Glycine 0 N--CA 1.482 1.751 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 179.792 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.482 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.6 141.24 48.45 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.598 -1.53 . . . . 0.0 110.16 -179.439 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.31 27.88 32.0 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 118.833 -1.651 . . . . 0.0 109.718 179.726 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.562 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.6 OUTLIER -95.67 170.88 9.02 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.018 -1.284 . . . . 0.0 108.45 179.831 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.07 101.18 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.407 0 O-C-N 120.947 -1.095 . . . . 0.0 109.948 -179.607 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.85 77.98 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.685 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.993 -179.411 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.42 34.15 0.29 Allowed Glycine 0 N--CA 1.486 2.021 0 N-CA-C 109.316 -1.513 . . . . 0.0 109.316 179.818 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 22.6 p -139.78 106.9 5.46 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.186 -1.185 . . . . 0.0 111.154 -179.514 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.582 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.67 110.0 0.34 Allowed 'General case' 0 N--CA 1.496 1.839 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.8 178.131 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.525 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 28.8 m-85 -103.89 154.51 19.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.111 -0.993 . . . . 0.0 108.95 179.8 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -102.18 158.09 16.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.767 -1.208 . . . . 0.0 107.821 178.784 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.945 HG11 HG21 ' A' ' 65' ' ' THR . 6.0 p -139.23 115.11 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.165 -0.959 . . . . 0.0 109.722 -178.12 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.73 -178.36 36.5 Favored Glycine 0 N--CA 1.494 2.561 0 C-N-CA 118.326 -1.892 . . . . 0.0 111.729 -179.468 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.635 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.1 pt20 -103.32 109.75 21.49 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 121.8 0.81 . . . . 0.0 108.9 -179.764 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.478 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -131.3 149.2 52.66 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.005 -1.06 . . . . 0.0 110.261 -179.805 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.37 138.8 54.52 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.319 -0.863 . . . . 0.0 110.777 -179.167 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.876 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.25 114.55 26.35 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 178.108 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.6 m -104.83 14.69 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.026 -1.046 . . . . 0.0 110.663 -178.757 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.746 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 175.25 -175.17 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.923 -1.111 . . . . 0.0 110.125 179.758 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -72.0 97.64 1.92 Allowed 'General case' 0 N--CA 1.485 1.317 0 O-C-N 121.413 -0.804 . . . . 0.0 109.677 -179.757 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.3 26.76 35.31 Favored Glycine 0 N--CA 1.494 2.531 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.475 178.934 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.746 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.92 106.66 20.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 O-C-N 120.549 -1.56 . . . . 0.0 107.396 178.875 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.876 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.7 tp -117.05 104.62 11.43 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.488 -1.382 . . . . 0.0 109.629 -177.747 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.871 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.61 109.42 22.18 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 120.808 -1.182 . . . . 0.0 107.914 178.678 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -105.95 167.83 9.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.928 -1.107 . . . . 0.0 110.483 -178.68 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.53 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 11.6 t-20 -111.94 129.33 24.33 Favored Pre-proline 0 N--CA 1.499 1.986 0 O-C-N 121.532 -0.73 . . . . 0.0 109.649 -179.118 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.582 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 2.2 Cg_endo -72.72 23.06 0.29 Allowed 'Trans proline' 0 CA--C 1.545 1.059 0 C-N-CA 122.056 1.837 . . . . 0.0 111.815 179.61 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.611 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -110.57 -0.7 17.2 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.462 -1.399 . . . . 0.0 109.145 179.545 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.567 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.37 16.81 3.17 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 179.489 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -79.75 89.94 5.22 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.709 -178.678 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.26 -166.26 1.14 Allowed 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.948 -1.131 . . . . 0.0 107.948 178.34 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.76 136.43 0.09 Allowed 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.594 -1.316 . . . . 0.0 111.314 -179.256 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 1.016 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -154.74 156.63 4.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.084 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.582 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.49 142.1 30.52 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.669 -1.269 . . . . 0.0 109.977 -179.621 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.08 106.12 0.68 Allowed 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 122.467 1.127 . . . . 0.0 109.341 178.208 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.545 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.8 p-10 -59.29 -138.79 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.029 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.052 -179.881 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.85 -50.33 61.13 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.412 -0.805 . . . . 0.0 110.744 -178.633 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -104.08 -34.57 8.37 Favored 'General case' 0 C--N 1.286 -2.178 0 N-CA-C 106.004 -1.85 . . . . 0.0 106.004 178.505 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.013 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.41 64.34 0.54 Allowed Glycine 0 C--N 1.296 -1.646 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 177.928 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.579 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 18.5 m -103.85 124.05 48.23 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.501 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 1.016 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.01 109.48 9.01 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.821 -0.752 . . . . 0.0 109.673 -179.081 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.7 m -116.5 116.69 28.11 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.329 -0.857 . . . . 0.0 109.373 -179.959 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.945 HG21 HG11 ' A' ' 34' ' ' VAL . 1.3 t -140.85 140.19 34.57 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.374 -0.829 . . . . 0.0 109.822 179.908 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.1 p -98.88 137.61 37.19 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.49 -0.756 . . . . 0.0 109.242 179.849 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.806 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -140.43 159.01 43.15 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.382 -0.824 . . . . 0.0 109.452 -179.129 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.611 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 12.7 t -87.55 135.77 33.22 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.162 -0.961 . . . . 0.0 110.21 -179.837 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.573 HG23 HD13 ' A' ' 13' ' ' LEU . 18.0 m -145.51 140.36 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.74 -179.39 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.625 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.5 ptt180 -140.25 -163.83 1.59 Allowed 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.595 -1.315 . . . . 0.0 109.877 179.814 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.603 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -78.79 -81.81 0.1 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.055 -1.028 . . . . 0.0 109.6 -179.15 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.524 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -67.12 134.66 52.24 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.334 -1.479 . . . . 0.0 107.488 179.273 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.635 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.8 OUTLIER -157.7 156.58 31.94 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 117.965 -1.494 . . . . 0.0 110.568 -178.257 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.514 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.2 mm-40 -48.71 121.66 4.83 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.497 -0.752 . . . . 0.0 109.676 -178.574 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.871 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.08 48.78 3.48 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 -179.39 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.582 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.2 OUTLIER -40.39 114.6 0.47 Allowed 'General case' 0 N--CA 1.514 2.774 0 O-C-N 121.029 -1.277 . . . . 0.0 109.972 179.908 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.704 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.25 126.95 35.14 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.959 -1.088 . . . . 0.0 109.289 179.729 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -64.09 58.11 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.8 -1.187 . . . . 0.0 110.307 179.897 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.531 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -160.86 19.34 0.13 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.961 -1.087 . . . . 0.0 109.785 179.91 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.3 -26.74 5.45 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.913 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.7 p -91.88 159.32 15.83 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.12 -1.223 . . . . 0.0 110.389 -179.403 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.513 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.56 133.46 51.21 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.716 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.704 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -82.6 -18.13 42.35 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.88 -1.137 . . . . 0.0 110.411 -178.469 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.32 174.79 20.6 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 -179.525 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.0 112.06 2.18 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 179.14 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.664 HG21 ' CB ' ' A' ' 46' ' ' ALA . 38.7 t -83.44 102.39 9.35 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -178.916 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.547 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -64.49 108.53 1.68 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.659 -0.651 . . . . 0.0 109.971 -179.153 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.579 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 3.7 t -62.48 -4.25 1.82 Allowed 'General case' 0 N--CA 1.499 1.979 0 C-N-CA 118.361 -1.336 . . . . 0.0 110.34 179.341 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.6 p -88.24 10.39 19.76 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.621 -1.299 . . . . 0.0 109.097 179.622 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.547 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -124.25 -47.66 1.87 Allowed 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.399 -0.813 . . . . 0.0 109.08 -179.994 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.85 179.58 4.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.604 -0.685 . . . . 0.0 109.536 179.905 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.88 112.41 25.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.36 -0.838 . . . . 0.0 108.799 179.783 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.497 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.1 m -96.64 121.85 38.93 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.083 -1.01 . . . . 0.0 109.667 -178.786 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.583 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.34 149.2 24.98 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 122.482 1.134 . . . . 0.0 111.368 -179.199 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.561 ' HB ' HG11 ' A' ' 7' ' ' VAL . 47.4 t -105.42 109.94 29.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 177.465 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.449 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.89 -171.3 17.51 Favored Glycine 0 N--CA 1.485 1.95 0 C-N-CA 118.154 -1.974 . . . . 0.0 111.663 -177.641 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.602 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -115.16 -179.02 3.51 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -178.899 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.414 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.5 p . . . . . 0 C--N 1.296 -1.729 0 O-C-N 121.332 -0.855 . . . . 0.0 109.545 -179.06 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.627 0 N-CA-C 107.753 -2.139 . . . . 0.0 107.753 . . . . . . . . . 0 0 . 1 . 050 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.35 -178.09 6.69 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 122.159 0.98 . . . . 0.0 109.898 179.326 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.42 -163.04 21.72 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 108.191 -1.963 . . . . 0.0 108.191 -179.46 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.602 ' HB2' HD12 ' A' ' 97' ' ' LEU . 7.4 Cg_exo -45.93 172.76 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.647 0 CA-C-N 119.013 1.406 . . . . 0.0 109.937 179.325 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -90.19 -177.42 5.14 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.997 -1.064 . . . . 0.0 110.695 -178.566 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.449 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.03 167.9 13.66 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.816 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.47 132.56 54.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.393 -1.063 . . . . 0.0 109.23 -179.285 . . . . . . . . 1 1 . 1 . 050 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.583 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.57 124.42 25.86 Favored 'General case' 0 C--N 1.29 -1.984 0 O-C-N 121.637 -0.664 . . . . 0.0 109.732 179.757 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.842 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.97 171.81 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.228 -0.92 . . . . 0.0 109.227 179.794 . . . . . . . . 2 2 . 1 . 050 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.481 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.23 155.96 48.15 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.209 -0.932 . . . . 0.0 109.769 -179.896 . . . . . . . . 3 3 . 1 . 050 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.842 ' CE2' HD12 ' A' ' 110' ' ' ILE . 71.6 m-85 . . . . . 0 N--CA 1.487 1.378 0 O-C-N 121.178 -0.952 . . . . 0.0 109.533 -179.733 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.465 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.431 0 CA-C-O 122.054 0.931 . . . . 0.0 110.63 . . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.02 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.9 p -104.54 104.4 14.23 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 122.453 1.12 . . . . 0.0 110.156 179.96 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.952 HG22 HG23 ' A' ' 21' ' ' VAL . 12.0 t -120.15 119.76 60.98 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.366 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.309 179.738 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.512 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.64 149.88 6.34 Favored Pre-proline 0 N--CA 1.486 1.326 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -179.674 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.512 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.1 Cg_endo -76.68 151.62 94.61 Favored 'Cis proline' 0 C--N 1.309 -1.523 0 C-N-CA 123.637 -1.401 . . . . 0.0 109.501 -0.433 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.674 ' HA ' HG22 ' A' ' 110' ' ' ILE . 77.4 p -93.19 -23.53 18.53 Favored 'General case' 0 C--N 1.293 -1.865 0 O-C-N 121.595 -0.691 . . . . 0.0 109.305 179.765 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.48 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.2 m -133.89 158.2 44.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.316 -0.865 . . . . 0.0 109.957 -179.693 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 80.36 36.46 23.71 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 -179.777 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.763 ' HA ' HG21 ' A' ' 17' ' ' THR . 39.2 mt -92.54 -44.36 8.66 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 123.24 1.495 . . . . 0.0 110.284 -178.634 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.447 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 64.1 147.03 0.03 OUTLIER 'General case' 0 C--N 1.263 -3.189 0 CA-C-N 113.549 -1.66 . . . . 0.0 110.138 -179.758 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.552 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.0 p-10 -51.65 104.81 0.09 Allowed 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.644 0.735 . . . . 0.0 111.048 -178.939 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.52 6.39 6.72 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.148 -1.501 . . . . 0.0 113.33 177.312 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.763 HG21 ' HA ' ' A' ' 13' ' ' LEU . 14.9 t -106.31 -175.97 2.94 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 121.491 2.646 . . . . 0.0 110.166 179.693 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.861 HG22 HG22 ' A' ' 68' ' ' THR . 21.8 t -128.05 138.2 55.36 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.383 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.068 -178.697 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.652 HG11 HD11 ' A' ' 13' ' ' LEU . 34.6 m -114.39 154.66 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.827 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.553 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.1 108.9 20.59 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.14 -0.975 . . . . 0.0 109.314 -179.885 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.952 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.59 123.34 62.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.751 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.02 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -116.72 165.33 13.41 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 120.873 -1.142 . . . . 0.0 109.14 179.922 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.563 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.46 107.55 0.53 Allowed Glycine 0 C--O 1.207 -1.577 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 179.875 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.45 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.23 143.83 45.0 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.787 -1.419 . . . . 0.0 110.676 -178.964 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.463 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 80.48 27.45 51.51 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 119.576 -1.297 . . . . 0.0 109.993 179.193 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.571 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -91.95 172.25 8.58 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.086 -1.244 . . . . 0.0 108.556 -179.984 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.005 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.58 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.116 -0.99 . . . . 0.0 109.652 -179.987 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.578 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.63 76.74 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.206 -179.059 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 135.96 32.96 0.26 Allowed Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.512 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.628 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -141.98 111.45 6.54 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 120.935 -1.332 . . . . 0.0 111.027 -179.96 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.572 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.64 120.4 4.67 Favored 'General case' 0 N--CA 1.493 1.715 0 CA-C-N 115.488 -0.778 . . . . 0.0 109.674 178.7 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.628 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 9.7 m-85 -114.27 152.82 30.74 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.238 -0.914 . . . . 0.0 108.923 179.807 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.483 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.68 154.18 18.81 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.622 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.693 HG13 ' O ' ' A' ' 34' ' ' VAL . 9.7 p -137.42 115.41 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.023 -1.048 . . . . 0.0 109.882 -177.753 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.87 -176.85 36.16 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 118.372 -1.87 . . . . 0.0 111.792 -179.717 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.624 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -101.21 109.86 21.79 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -179.803 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.498 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -129.61 149.38 51.39 Favored 'General case' 0 C--N 1.296 -1.74 0 O-C-N 121.221 -0.924 . . . . 0.0 109.748 179.81 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.531 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.66 137.73 54.81 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.254 -0.904 . . . . 0.0 110.907 -178.847 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.887 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.49 114.86 26.67 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.048 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 m -105.05 14.67 7.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.931 -1.105 . . . . 0.0 110.501 -178.947 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.774 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 173.9 -175.54 0.07 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 120.949 -1.094 . . . . 0.0 110.128 179.73 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.779 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.92 98.17 1.55 Allowed 'General case' 0 N--CA 1.487 1.416 0 CA-C-O 121.828 0.823 . . . . 0.0 109.969 -179.669 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.28 27.98 34.92 Favored Glycine 0 N--CA 1.493 2.441 0 C-N-CA 120.325 -0.94 . . . . 0.0 111.444 178.949 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.774 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -116.54 106.29 19.99 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 O-C-N 120.569 -1.548 . . . . 0.0 107.198 178.782 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.887 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -117.02 104.64 11.47 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.487 -1.383 . . . . 0.0 109.942 -177.527 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.011 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.9 109.56 22.29 Favored 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.847 -1.158 . . . . 0.0 107.919 178.7 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.58 167.05 10.11 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.907 -1.12 . . . . 0.0 110.41 -178.699 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.585 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 20.7 t-20 -114.67 137.71 22.87 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 121.299 -0.876 . . . . 0.0 110.359 -179.149 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.464 ' HD2' ' ND2' ' A' ' 48' ' ' ASN . 6.1 Cg_endo -75.55 25.8 0.39 Allowed 'Trans proline' 0 C--N 1.318 -1.039 0 C-N-CA 122.346 2.031 . . . . 0.0 111.966 179.859 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.585 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -113.82 2.13 15.03 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.266 -1.521 . . . . 0.0 109.482 179.833 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.533 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.22 16.72 2.42 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 179.423 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -79.38 91.74 5.12 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.598 -0.689 . . . . 0.0 111.016 -178.678 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -109.08 -166.9 1.15 Allowed 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.171 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.455 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.97 136.62 0.09 Allowed 'General case' 0 N--CA 1.485 1.301 0 O-C-N 120.519 -1.363 . . . . 0.0 111.327 -179.298 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.964 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -156.75 157.0 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 178.213 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.572 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.6 144.23 28.13 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.884 -1.135 . . . . 0.0 109.835 -179.759 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.005 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.84 105.82 0.9 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 122.436 1.112 . . . . 0.0 109.38 178.546 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.546 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.8 p-10 -58.69 -138.87 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.029 -179.869 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.578 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.32 -50.26 62.62 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.453 -0.779 . . . . 0.0 110.576 -178.718 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.463 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.7 t-20 -103.75 -35.19 8.3 Favored 'General case' 0 C--N 1.286 -2.195 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 178.442 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.977 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.28 67.36 0.59 Allowed Glycine 0 C--N 1.297 -1.627 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 177.936 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.563 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.0 m -106.76 123.12 47.68 Favored 'General case' 0 N--CA 1.482 1.137 0 O-C-N 121.559 -0.965 . . . . 0.0 108.623 178.829 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.964 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -132.6 109.15 9.54 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 -179.443 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.1 m -118.95 120.39 37.13 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.211 -0.93 . . . . 0.0 109.606 -179.474 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.662 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.71 141.62 29.42 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.567 -0.708 . . . . 0.0 109.691 179.779 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 17.7 p -99.93 135.89 40.66 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.395 -0.815 . . . . 0.0 109.112 179.702 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.843 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -135.59 167.84 20.35 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.941 . . . . 0.0 109.618 -179.29 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.861 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -99.4 126.89 45.38 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.077 -1.014 . . . . 0.0 109.276 -179.802 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.491 HG12 ' HB3' ' A' ' 36' ' ' GLN . 12.6 m -132.39 140.8 46.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 120.868 -1.145 . . . . 0.0 109.93 -179.134 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.552 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 56.7 mtt180 -127.61 -166.96 1.68 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.68 -1.263 . . . . 0.0 111.328 -179.674 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.578 ' HG2' ' CD1' ' A' ' 112' ' ' PHE . 46.4 mtt180 -80.59 -79.02 0.16 Allowed 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 178.946 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -69.11 136.66 52.58 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 106.386 -1.709 . . . . 0.0 106.386 177.766 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.35 136.51 8.6 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 117.666 -1.614 . . . . 0.0 110.891 -177.191 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.47 ' C ' ' O ' ' A' ' 73' ' ' PHE . 2.0 mm-40 -33.43 118.78 0.34 Allowed 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.47 0.652 . . . . 0.0 110.427 -178.742 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.011 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.26 48.07 3.57 Favored Glycine 0 N--CA 1.493 2.463 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.148 -179.312 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.487 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -36.99 115.93 0.41 Allowed 'General case' 0 N--CA 1.513 2.685 0 O-C-N 121.109 -1.23 . . . . 0.0 110.11 179.828 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.727 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.3 tp -87.59 126.41 34.92 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.987 -1.071 . . . . 0.0 109.121 179.742 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.8 t80 -63.64 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.836 -1.165 . . . . 0.0 110.228 179.824 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.543 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t70 -160.89 19.72 0.13 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.989 -1.069 . . . . 0.0 109.846 179.924 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.2 -28.01 5.34 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.812 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.67 163.38 13.4 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.061 -1.258 . . . . 0.0 110.184 -179.438 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.478 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.55 137.71 46.05 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.987 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.727 ' HB2' HD13 ' A' ' 77' ' ' LEU . 5.6 t90 -81.62 -20.93 38.71 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.896 -1.127 . . . . 0.0 110.157 -178.956 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.36 173.55 17.07 Favored Glycine 0 N--CA 1.486 1.968 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -179.44 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.25 111.81 2.41 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 179.069 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.652 HG21 ' HB3' ' A' ' 46' ' ' ALA . 46.0 t -83.67 104.25 11.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 121.378 -0.826 . . . . 0.0 108.981 -179.001 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.531 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -66.15 111.3 3.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.355 -0.84 . . . . 0.0 109.845 -179.295 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.572 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -64.25 -4.8 4.04 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 120.587 -1.321 . . . . 0.0 109.896 179.4 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 31.6 p -87.81 2.18 52.01 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.694 -1.253 . . . . 0.0 109.097 179.325 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -116.52 -51.16 2.61 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.362 -0.836 . . . . 0.0 108.935 -179.998 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.22 -179.9 4.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.53 -0.731 . . . . 0.0 109.493 179.745 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.75 116.07 31.64 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.365 -0.834 . . . . 0.0 108.925 179.91 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.557 ' HB2' HD11 ' A' ' 110' ' ' ILE . 2.7 m -96.97 123.3 40.65 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.828 -1.17 . . . . 0.0 109.477 -179.298 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.582 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -103.15 149.17 24.9 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.344 1.069 . . . . 0.0 111.356 -179.142 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.639 ' HB ' HG11 ' A' ' 7' ' ' VAL . 43.2 t -104.88 112.1 37.12 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.552 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -151.77 -172.02 20.14 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 118.218 -1.944 . . . . 0.0 111.747 -177.785 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.483 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.01 178.67 4.64 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 -178.845 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.423 ' O ' ' N ' ' A' ' 33' ' ' ASP . 3.2 m . . . . . 0 C--N 1.295 -1.786 0 O-C-N 121.581 -0.699 . . . . 0.0 109.432 -179.806 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.7 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 . . . . . . . . . 0 0 . 1 . 051 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.82 -177.48 5.15 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.544 -0.974 . . . . 0.0 109.9 179.438 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.88 -161.83 23.1 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.462 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 104' ' ' GLY . 8.0 Cg_exo -45.51 173.73 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.643 0 CA-C-N 119.003 1.401 . . . . 0.0 110.232 179.251 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 25.9 pt-20 -92.7 -173.83 3.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.072 -1.017 . . . . 0.0 110.302 -178.824 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -124.67 174.86 17.15 Favored Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 -179.89 . . . . . . . . 1 1 . 1 . 051 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -111.02 153.71 12.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -179.552 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.582 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -95.02 123.07 38.3 Favored 'General case' 0 C--N 1.292 -1.93 0 O-C-N 121.303 -0.873 . . . . 0.0 109.605 179.922 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.674 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.4 pt -98.08 168.32 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.209 -0.932 . . . . 0.0 109.073 179.942 . . . . . . . . 2 2 . 1 . 051 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -135.1 156.65 48.65 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.29 -0.881 . . . . 0.0 109.456 -179.98 . . . . . . . . 3 3 . 1 . 051 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.658 ' CE2' HD12 ' A' ' 110' ' ' ILE . 44.6 m-85 . . . . . 0 N--CA 1.489 1.486 0 O-C-N 121.2 -0.937 . . . . 0.0 109.543 -179.767 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.495 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.283 0 CA-C-O 122.288 1.042 . . . . 0.0 110.333 . . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.908 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.8 t -115.63 109.26 17.5 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-O 123.158 1.456 . . . . 0.0 109.838 -179.866 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.795 HG13 ' CA ' ' A' ' 21' ' ' VAL . 0.8 OUTLIER -115.5 136.12 53.32 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.632 0 CA-C-N 114.271 -1.331 . . . . 0.0 109.604 179.763 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.465 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -173.72 150.64 1.75 Allowed Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.181 -0.95 . . . . 0.0 109.04 -179.621 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.465 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.0 Cg_endo -77.2 151.18 92.99 Favored 'Cis proline' 0 C--N 1.313 -1.335 0 C-N-CA 123.484 -1.465 . . . . 0.0 109.26 -0.902 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.686 ' HA ' HG22 ' A' ' 110' ' ' ILE . 72.4 p -94.43 -22.55 18.22 Favored 'General case' 0 C--N 1.293 -1.89 0 O-C-N 121.511 -0.743 . . . . 0.0 109.623 179.878 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.466 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -130.88 155.18 47.18 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.214 -0.929 . . . . 0.0 110.233 -179.602 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.33 35.59 22.96 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.002 -1.639 . . . . 0.0 109.002 179.996 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.713 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.4 mt -92.8 -44.19 8.63 Favored 'General case' 0 C--N 1.301 -1.529 0 CA-C-O 123.214 1.483 . . . . 0.0 110.635 -178.713 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.433 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 63.17 145.19 0.02 OUTLIER 'General case' 0 C--N 1.261 -3.247 0 CA-C-N 113.558 -1.655 . . . . 0.0 109.201 -178.939 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.533 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.6 m-20 -53.82 114.68 1.65 Allowed 'General case' 0 C--N 1.299 -1.627 0 CA-C-O 121.764 0.792 . . . . 0.0 110.436 -178.946 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 121.67 0.71 10.99 Favored Glycine 0 N--CA 1.484 1.865 0 C-N-CA 119.495 -1.336 . . . . 0.0 112.404 178.334 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.713 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.8 t -106.7 -177.34 3.33 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 121.069 2.434 . . . . 0.0 110.474 -179.944 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.774 HG13 ' O ' ' A' ' 67' ' ' LEU . 25.9 t -127.48 139.09 52.88 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 CA-C-N 114.113 -1.403 . . . . 0.0 110.878 -178.865 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.603 ' CG1' HD13 ' A' ' 13' ' ' LEU . 4.2 m -113.01 158.37 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 178.907 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.51 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -106.45 108.77 20.44 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.088 -1.007 . . . . 0.0 109.115 179.947 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.878 ' CG1' HD11 ' A' ' 67' ' ' LEU . 13.0 p -101.23 140.02 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.651 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.908 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.37 161.86 35.16 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.675 -1.266 . . . . 0.0 110.154 179.642 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.591 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.6 139.32 10.53 Favored Glycine 0 C--N 1.298 -1.546 0 N-CA-C 107.882 -2.087 . . . . 0.0 107.882 179.529 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.4 125.31 16.13 Favored 'General case' 0 N--CA 1.496 1.828 0 CA-C-N 119.411 1.606 . . . . 0.0 109.434 179.446 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.67 27.77 21.01 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 118.8 -1.667 . . . . 0.0 109.634 -179.756 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -89.01 169.63 11.36 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.033 -1.275 . . . . 0.0 108.188 179.942 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -43.59 98.67 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.015 -1.053 . . . . 0.0 110.042 -179.354 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.552 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.29 77.83 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.255 -179.285 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.571 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.23 33.44 0.27 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.393 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.542 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 59.0 p -141.73 108.67 5.43 Favored 'General case' 0 C--N 1.307 -1.264 0 O-C-N 121.102 -1.234 . . . . 0.0 111.316 -179.474 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.79 111.49 0.61 Allowed 'General case' 0 N--CA 1.497 1.896 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.717 178.067 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.5 ' CA ' ' O ' ' A' ' 98' ' ' SER . 5.3 m-30 -105.65 160.04 15.5 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.068 -1.02 . . . . 0.0 108.817 179.662 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.502 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -100.23 167.34 10.49 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.738 -1.226 . . . . 0.0 108.003 179.061 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.625 HG22 HG11 ' A' ' 21' ' ' VAL . 2.9 p -149.48 120.81 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.112 -0.992 . . . . 0.0 109.531 -178.136 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -174.9 -176.63 43.36 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 118.297 -1.906 . . . . 0.0 111.702 -179.941 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.711 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -98.83 108.87 21.66 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -179.997 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.1 m -130.45 148.93 52.32 Favored 'General case' 0 C--N 1.295 -1.796 0 O-C-N 121.315 -0.866 . . . . 0.0 109.461 179.389 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.494 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.38 138.72 54.34 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.154 -0.966 . . . . 0.0 110.849 -178.872 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.14 114.64 26.46 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 178.103 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.6 m -105.16 15.14 6.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.08 -1.012 . . . . 0.0 110.466 -178.609 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.75 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.42 -175.48 0.1 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.864 -1.148 . . . . 0.0 109.998 179.705 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.65 96.83 1.63 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.473 -0.767 . . . . 0.0 109.735 -179.739 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 28.03 32.32 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.493 178.933 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.75 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.18 106.57 20.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 O-C-N 120.577 -1.543 . . . . 0.0 107.302 178.845 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.2 tp -116.23 104.45 11.52 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.449 -1.407 . . . . 0.0 110.022 -177.5 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.095 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.25 109.45 22.21 Favored 'General case' 0 N--CA 1.484 1.248 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 178.525 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 5.1 t -108.5 165.49 11.48 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.826 -1.171 . . . . 0.0 110.648 -178.468 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.48 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 52.4 t30 -115.84 134.45 22.71 Favored Pre-proline 0 N--CA 1.499 2.019 0 O-C-N 121.545 -0.722 . . . . 0.0 109.394 -179.624 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.531 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 2.5 Cg_endo -72.08 22.96 0.26 Allowed 'Trans proline' 0 C--N 1.317 -1.124 0 C-N-CA 122.289 1.993 . . . . 0.0 112.106 -179.802 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.443 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -95.28 -9.76 32.2 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.355 -1.466 . . . . 0.0 109.045 179.408 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.65 ' OD2' HG13 ' A' ' 69' ' ' VAL . 3.4 m-20 -134.06 6.77 3.66 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.903 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -59.72 84.04 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.495 -0.753 . . . . 0.0 110.589 -178.775 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.612 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -111.47 -168.89 1.36 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.516 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.464 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.3 t 179.01 135.17 0.09 Allowed 'General case' 0 C--N 1.305 -1.358 0 O-C-N 120.656 -1.278 . . . . 0.0 110.967 -179.476 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.79 HG11 ' HB1' ' A' ' 63' ' ' ALA . 1.6 p -147.29 157.4 9.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.288 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.598 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.53 142.01 30.66 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 120.696 -1.252 . . . . 0.0 110.024 -179.699 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.17 107.54 1.32 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 122.5 1.143 . . . . 0.0 109.533 178.462 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.558 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.2 p-10 -61.19 -139.39 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.976 -179.99 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.552 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.77 -50.83 55.0 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.399 -0.813 . . . . 0.0 110.641 -178.764 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -104.36 -33.27 8.69 Favored 'General case' 0 C--N 1.285 -2.221 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 178.498 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.996 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.47 66.49 0.62 Allowed Glycine 0 C--N 1.299 -1.498 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 178.132 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.591 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.6 m -100.68 130.09 46.67 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.491 -1.006 . . . . 0.0 108.883 178.974 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.79 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.49 109.51 8.76 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.217 -0.993 . . . . 0.0 109.307 -179.594 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 18.2 m -124.31 118.33 26.52 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.359 -0.838 . . . . 0.0 109.789 -179.781 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -148.36 148.26 30.17 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.436 -0.79 . . . . 0.0 109.218 179.808 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.412 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 28.2 p -98.38 136.23 38.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.33 -0.856 . . . . 0.0 109.47 179.923 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.878 HD11 ' CG1' ' A' ' 21' ' ' VAL . 0.2 OUTLIER -129.68 164.91 22.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.313 -0.867 . . . . 0.0 109.874 -179.023 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.713 HG22 HG22 ' A' ' 18' ' ' VAL . 1.1 p -104.29 127.16 51.89 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.157 -0.964 . . . . 0.0 108.679 179.529 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.711 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.0 m -134.53 140.21 46.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.722 -1.236 . . . . 0.0 110.471 -178.659 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.533 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 46.8 mtt180 -126.48 -168.2 1.83 Allowed 'General case' 0 N--CA 1.484 1.226 0 O-C-N 120.703 -1.248 . . . . 0.0 111.015 179.937 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.583 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 27.9 mtm180 -77.87 -75.5 0.22 Allowed 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.326 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -73.79 136.39 43.58 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 120.006 -1.684 . . . . 0.0 106.829 178.017 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.594 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -156.15 136.88 13.36 Favored 'General case' 0 C--N 1.295 -1.766 0 C-N-CA 117.987 -1.485 . . . . 0.0 110.481 -177.861 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.479 ' O ' ' O ' ' A' ' 47' ' ' CYS . 6.6 mm-40 -37.37 120.45 0.78 Allowed 'General case' 0 N--CA 1.487 1.385 0 CA-C-O 121.589 0.709 . . . . 0.0 110.129 -178.584 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.095 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.91 48.88 3.53 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.273 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.531 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 26.3 m-85 -38.22 113.44 0.29 Allowed 'General case' 0 N--CA 1.505 2.276 0 O-C-N 121.165 -1.197 . . . . 0.0 110.138 179.561 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.717 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -86.07 126.93 34.54 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.003 -1.061 . . . . 0.0 109.455 -179.819 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.6 t80 -63.62 58.44 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.994 0 O-C-N 120.984 -1.073 . . . . 0.0 110.21 179.599 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -160.89 19.62 0.13 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.038 -1.038 . . . . 0.0 109.824 179.926 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.72 -27.14 5.47 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 179.767 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.446 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 15.5 p -95.57 158.91 15.24 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.994 -1.297 . . . . 0.0 110.258 -179.457 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.461 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -105.03 136.68 44.06 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 179.699 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.717 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.7 t90 -80.72 -20.13 43.5 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.914 -1.116 . . . . 0.0 110.274 -178.644 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.76 174.43 18.31 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 108.669 -1.772 . . . . 0.0 108.669 -179.392 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.53 108.73 1.44 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.011 -1.287 . . . . 0.0 107.771 179.21 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.674 HG21 ' HB3' ' A' ' 46' ' ' ALA . 41.5 t -81.41 105.59 11.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 O-C-N 121.375 -0.828 . . . . 0.0 108.796 -179.256 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.526 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.92 111.14 3.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.342 -0.849 . . . . 0.0 110.051 -179.085 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.583 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.5 t -63.99 -5.21 4.22 Favored 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 118.587 -1.245 . . . . 0.0 109.924 179.456 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.7 p -87.43 1.46 53.35 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.804 -1.185 . . . . 0.0 109.08 179.446 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.526 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -116.05 -51.18 2.65 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.393 -0.817 . . . . 0.0 108.965 179.868 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.401 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -102.2 -178.96 3.85 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.544 -0.722 . . . . 0.0 109.384 179.736 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.49 115.61 30.54 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.389 -0.82 . . . . 0.0 109.077 179.975 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.52 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.76 121.39 38.55 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.833 -1.167 . . . . 0.0 109.324 -179.438 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.632 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.02 144.93 30.0 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 122.323 1.059 . . . . 0.0 111.262 -179.278 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.586 ' CG1' HG11 ' A' ' 7' ' ' VAL . 96.1 t -102.14 109.86 27.36 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.663 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.476 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.89 -171.29 17.49 Favored Glycine 0 N--CA 1.487 2.092 0 C-N-CA 118.018 -2.039 . . . . 0.0 111.894 -177.54 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.502 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -110.51 -179.21 3.7 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 -179.221 . . . . . . . . 3 3 . 1 . 052 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.5 ' O ' ' CA ' ' A' ' 32' ' ' TYR . 36.8 p . . . . . 0 C--N 1.295 -1.766 0 O-C-N 121.464 -0.772 . . . . 0.0 109.379 -179.366 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.763 0 N-CA-C 107.601 -2.199 . . . . 0.0 107.601 . . . . . . . . . 0 0 . 1 . 052 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.34 -178.3 6.84 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 121.568 -0.96 . . . . 0.0 109.587 179.202 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -158.92 -163.42 13.0 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 108.3 -1.92 . . . . 0.0 108.3 -179.558 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.0 Cg_exo -47.72 178.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.705 0 CA-C-N 118.819 1.31 . . . . 0.0 110.132 179.331 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -91.75 -175.79 4.26 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.047 -1.033 . . . . 0.0 110.415 -178.879 . . . . . . . . 1 1 . 1 . 052 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.476 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.83 168.2 14.56 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 -179.865 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.6 130.49 51.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.405 -1.056 . . . . 0.0 109.073 -179.363 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.632 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.58 121.39 21.5 Favored 'General case' 0 C--N 1.29 -1.979 0 O-C-N 121.578 -0.701 . . . . 0.0 109.914 179.85 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.686 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.5 pt -98.0 166.91 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.279 -0.888 . . . . 0.0 109.04 179.765 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.466 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 1.4 m -135.25 156.52 48.83 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.322 -0.862 . . . . 0.0 109.597 -179.96 . . . . . . . . 2 2 . 1 . 052 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.648 ' CE2' HD12 ' A' ' 110' ' ' ILE . 53.7 m-85 . . . . . 0 N--CA 1.489 1.485 0 O-C-N 121.215 -0.928 . . . . 0.0 109.434 -179.885 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.49 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.487 1.385 0 CA-C-O 122.123 0.963 . . . . 0.0 110.717 . . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.017 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.7 p -104.16 104.38 14.3 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 122.585 1.183 . . . . 0.0 109.835 179.901 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.965 HG22 HG23 ' A' ' 21' ' ' VAL . 14.2 t -119.59 121.49 66.43 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.398 179.806 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.479 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.73 149.75 6.18 Favored Pre-proline 0 N--CA 1.486 1.354 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.557 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.479 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.8 Cg_endo -78.63 149.54 85.67 Favored 'Cis proline' 0 C--N 1.308 -1.563 0 C-N-CA 123.663 -1.39 . . . . 0.0 109.697 -0.722 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.641 ' HA ' HG22 ' A' ' 110' ' ' ILE . 88.7 p -91.0 -24.63 20.03 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.34 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 0.8 OUTLIER -131.23 161.17 32.85 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.381 -0.825 . . . . 0.0 109.733 -179.949 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.63 38.47 32.19 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 -179.574 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.825 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.9 mt -92.08 -44.46 8.82 Favored 'General case' 0 C--N 1.298 -1.665 0 CA-C-O 123.111 1.434 . . . . 0.0 110.736 -178.26 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.464 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.67 145.72 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.658 -1.61 . . . . 0.0 110.05 -179.818 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.607 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.4 p-10 -51.2 107.35 0.18 Allowed 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 121.502 0.668 . . . . 0.0 111.597 -178.693 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.25 14.36 9.91 Favored Glycine 0 N--CA 1.484 1.883 0 C-N-CA 119.335 -1.412 . . . . 0.0 112.953 177.227 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.825 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.7 t -102.78 -172.31 2.1 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 121.012 2.406 . . . . 0.0 109.643 179.239 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.738 HG13 ' C ' ' A' ' 67' ' ' LEU . 11.8 t -131.71 137.93 54.0 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.372 0 CA-C-N 115.001 -0.999 . . . . 0.0 111.229 -179.113 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.427 HG23 ' CD1' ' A' ' 67' ' ' LEU . 33.7 m -114.69 154.4 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.965 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.564 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -109.05 109.29 20.28 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.158 -0.964 . . . . 0.0 109.186 -179.993 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.965 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -107.7 123.11 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 -179.968 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.017 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.43 165.12 13.07 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 120.829 -1.169 . . . . 0.0 108.873 179.55 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.574 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.85 107.67 0.53 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 108.825 -1.71 . . . . 0.0 108.825 179.944 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -115.73 142.84 46.21 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 120.876 -1.367 . . . . 0.0 110.676 -179.213 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.78 27.35 46.77 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 179.207 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.561 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -92.11 174.26 7.41 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.061 -1.258 . . . . 0.0 108.589 179.967 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.004 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.44 99.43 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.025 -1.047 . . . . 0.0 109.732 -179.79 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.656 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.06 77.4 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.246 -179.116 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.67 34.02 0.32 Allowed Glycine 0 N--CA 1.487 2.067 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.379 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 80.3 p -144.23 111.6 5.98 Favored 'General case' 0 C--N 1.306 -1.291 0 O-C-N 120.996 -1.297 . . . . 0.0 111.096 -179.803 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.09 124.5 6.53 Favored 'General case' 0 N--CA 1.493 1.691 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.845 178.355 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.494 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 17.8 m-85 -117.69 150.4 39.13 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.493 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.479 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.64 155.42 17.89 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 178.675 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.012 HG11 HG21 ' A' ' 65' ' ' THR . 7.0 p -138.17 114.96 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.025 -1.047 . . . . 0.0 109.807 -177.81 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.58 -177.67 36.62 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 118.507 -1.806 . . . . 0.0 111.638 -179.648 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.642 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.2 pt20 -102.3 109.83 21.62 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-O 121.836 0.826 . . . . 0.0 108.917 -179.781 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.0 150.34 51.32 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.157 -0.964 . . . . 0.0 110.166 -179.869 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.77 139.7 53.61 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.255 -0.903 . . . . 0.0 110.633 -179.212 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.883 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.05 114.44 26.25 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 178.178 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.4 m -105.37 15.82 6.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.006 -1.059 . . . . 0.0 110.661 -178.821 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.98 -175.94 0.11 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.928 -1.108 . . . . 0.0 110.043 179.741 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 71.8 p -71.23 96.35 1.39 Allowed 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.37 -0.831 . . . . 0.0 109.759 -179.714 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.38 27.98 34.59 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.234 -0.984 . . . . 0.0 111.402 178.873 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 2.1 t -115.46 105.97 19.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 O-C-N 120.481 -1.599 . . . . 0.0 107.417 178.951 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.883 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -114.9 104.63 12.12 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.533 -1.355 . . . . 0.0 110.062 -177.658 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.745 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.21 109.52 22.26 Favored 'General case' 0 N--CA 1.483 1.225 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 178.447 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.7 t -105.49 170.47 7.87 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.968 -1.082 . . . . 0.0 110.734 -178.108 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.474 ' HB2' ' HB2' ' A' ' 73' ' ' PHE . 21.1 t-20 -114.14 126.07 28.5 Favored Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.54 -0.725 . . . . 0.0 109.546 -179.471 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.602 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -70.57 21.15 0.2 Allowed 'Trans proline' 0 CA--C 1.545 1.062 0 C-N-CA 122.098 1.865 . . . . 0.0 112.118 179.589 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.445 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -107.86 2.59 23.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.42 -1.425 . . . . 0.0 108.964 179.385 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.544 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.39 16.4 2.57 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.563 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -80.35 91.16 5.63 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.974 -178.537 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.621 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.35 -166.37 1.15 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.23 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.68 137.57 0.09 Allowed 'General case' 0 N--CA 1.486 1.345 0 O-C-N 120.55 -1.344 . . . . 0.0 111.369 -179.38 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 1.012 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -156.86 156.94 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.171 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.568 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.17 144.7 27.36 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 120.717 -1.239 . . . . 0.0 109.944 -179.616 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.004 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.22 106.39 1.08 Allowed 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 122.408 1.099 . . . . 0.0 109.29 178.466 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.536 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.6 p-10 -59.04 -138.49 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.992 -179.816 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.656 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.19 -50.27 62.22 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.445 -0.784 . . . . 0.0 110.618 -178.567 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 28.9 t30 -104.16 -35.53 8.0 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 106.093 -1.817 . . . . 0.0 106.093 178.376 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.993 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 111.1 64.82 0.51 Allowed Glycine 0 C--N 1.298 -1.548 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 177.924 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.574 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 18.6 m -104.72 123.11 47.06 Favored 'General case' 0 N--CA 1.484 1.254 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.545 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 1.012 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.27 109.23 9.25 Favored 'General case' 0 C--N 1.294 -1.819 0 C-N-CA 119.894 -0.722 . . . . 0.0 109.544 -179.052 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 3.6 m -114.0 115.77 28.15 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.349 -0.845 . . . . 0.0 109.358 -179.981 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 65' ' ' THR . . . . . 1.012 HG21 HG11 ' A' ' 34' ' ' VAL . 1.5 t -139.18 140.0 37.7 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.399 -0.813 . . . . 0.0 109.85 179.971 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 45.4 p -99.24 145.82 26.86 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.496 -0.753 . . . . 0.0 109.17 179.718 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.738 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -146.63 162.7 37.88 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.354 -0.842 . . . . 0.0 109.6 -179.134 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.714 HG22 HG22 ' A' ' 18' ' ' VAL . 3.2 p -93.94 124.76 38.16 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.936 . . . . 0.0 109.276 -179.913 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.553 HG23 HD13 ' A' ' 13' ' ' LEU . 15.4 m -134.66 141.94 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 120.861 -1.149 . . . . 0.0 109.99 -179.101 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.607 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.5 ptt180 -141.9 -163.7 1.64 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 120.473 -1.392 . . . . 0.0 110.601 -179.802 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.615 ' HD2' ' CD1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -75.74 -92.59 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.343 -0.848 . . . . 0.0 109.79 -179.029 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.539 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -60.92 133.07 55.73 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.255 -1.528 . . . . 0.0 107.726 179.478 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.642 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -153.95 156.91 38.35 Favored 'General case' 0 C--N 1.293 -1.874 0 C-N-CA 118.367 -1.333 . . . . 0.0 110.179 -178.716 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.596 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 30.3 mm-40 -47.99 121.66 4.41 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.35 -0.844 . . . . 0.0 109.94 -178.292 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.745 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -86.79 49.89 4.1 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 -179.4 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.602 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 29.7 m-85 -52.29 110.37 0.49 Allowed 'General case' 0 N--CA 1.505 2.301 0 O-C-N 121.014 -1.286 . . . . 0.0 110.743 179.753 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.775 HD13 ' HB2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -78.67 151.57 32.14 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 120.801 -1.187 . . . . 0.0 108.748 178.64 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -63.41 -5.5 3.71 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 120.691 -1.256 . . . . 0.0 110.863 179.954 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -99.18 7.63 45.59 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.723 -1.236 . . . . 0.0 109.593 179.938 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.59 -9.81 57.77 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.967 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.55 ' O ' ' HB2' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -78.86 133.56 36.98 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.115 -1.227 . . . . 0.0 109.917 -179.8 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.508 ' HG2' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -75.74 114.66 14.6 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.294 -0.879 . . . . 0.0 109.702 179.75 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.775 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.0 t90 -80.91 -20.16 42.73 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.036 -1.04 . . . . 0.0 109.426 -179.97 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.44 172.48 18.82 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 -179.725 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.44 110.61 1.72 Allowed 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 179.192 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.616 HG23 ' HA3' ' A' ' 75' ' ' GLY . 41.1 t -80.84 101.17 5.55 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.989 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.727 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -61.98 108.21 1.0 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.671 -0.643 . . . . 0.0 110.066 -179.176 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.56 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 4.1 t -60.36 -5.07 1.0 Allowed 'General case' 0 N--CA 1.501 2.124 0 C-N-CA 118.334 -1.346 . . . . 0.0 110.339 179.385 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 60.8 p -89.6 0.26 57.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.461 -1.399 . . . . 0.0 109.588 179.994 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.727 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -110.24 -48.46 3.18 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.172 -0.955 . . . . 0.0 109.068 179.994 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.78 -178.07 3.54 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.604 -0.685 . . . . 0.0 109.507 179.997 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.36 112.94 26.17 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.784 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.497 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.48 122.2 39.13 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.107 -0.995 . . . . 0.0 109.675 -178.731 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.3 mt-30 -104.02 148.92 25.66 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 122.428 1.109 . . . . 0.0 111.339 -179.42 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.549 ' HB ' HG11 ' A' ' 7' ' ' VAL . 57.7 t -103.98 109.78 28.25 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.989 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 177.566 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.46 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.13 -171.46 17.83 Favored Glycine 0 N--CA 1.486 1.995 0 C-N-CA 118.239 -1.934 . . . . 0.0 111.605 -177.625 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.49 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -122.05 178.92 4.7 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -178.812 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.4 m . . . . . 0 C--N 1.295 -1.763 0 O-C-N 121.571 -0.705 . . . . 0.0 109.393 -179.841 . . . . . . . . 0 0 . 1 . 053 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.413 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.482 1.71 0 N-CA-C 107.883 -2.087 . . . . 0.0 107.883 . . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.413 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -167.0 -177.17 3.67 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 122.079 0.942 . . . . 0.0 109.755 179.427 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.87 -162.23 21.77 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.265 -1.934 . . . . 0.0 108.265 -179.431 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.508 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.5 Cg_exo -45.27 171.91 0.02 OUTLIER 'Trans proline' 0 C--N 1.326 -0.629 0 CA-C-N 118.95 1.375 . . . . 0.0 110.035 179.319 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -93.17 -176.69 4.23 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.049 -1.032 . . . . 0.0 110.501 -178.583 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.46 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.07 166.28 12.77 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 -179.908 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -106.11 132.91 52.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.399 -1.059 . . . . 0.0 109.162 -179.251 . . . . . . . . 1 1 . 1 . 053 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.58 126.08 29.0 Favored 'General case' 0 C--N 1.289 -2.038 0 O-C-N 121.534 -0.729 . . . . 0.0 109.741 179.873 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.822 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.91 172.44 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.248 -0.907 . . . . 0.0 108.979 179.683 . . . . . . . . 2 2 . 1 . 053 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.59 158.73 43.76 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.077 -1.014 . . . . 0.0 109.462 -179.948 . . . . . . . . 3 3 . 1 . 053 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.822 ' CE2' HD12 ' A' ' 110' ' ' ILE . 56.0 m-85 . . . . . 0 N--CA 1.486 1.337 0 O-C-N 121.24 -0.913 . . . . 0.0 109.636 -179.639 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.494 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.291 0 CA-C-O 122.43 1.11 . . . . 0.0 110.234 . . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.863 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.9 t -115.14 109.04 17.43 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 123.127 1.441 . . . . 0.0 109.812 -179.863 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.795 HG22 HG23 ' A' ' 21' ' ' VAL . 2.2 t -116.18 134.18 60.36 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.659 0 CA-C-N 114.229 -1.35 . . . . 0.0 109.486 179.795 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.472 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -169.53 150.39 4.03 Favored Pre-proline 0 N--CA 1.487 1.413 0 O-C-N 121.183 -0.948 . . . . 0.0 108.876 -179.509 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.472 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.5 Cg_endo -75.52 152.32 97.24 Favored 'Cis proline' 0 C--N 1.313 -1.315 0 C-N-CA 123.488 -1.463 . . . . 0.0 109.785 -0.963 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.625 ' HA ' HG22 ' A' ' 110' ' ' ILE . 5.8 m -93.05 -23.52 18.63 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.447 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.513 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 69.0 m -134.99 159.62 40.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.564 -0.71 . . . . 0.0 109.382 179.912 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.28 36.29 27.61 Favored Glycine 0 N--CA 1.495 2.626 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.736 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.745 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.7 mt -90.94 -42.65 10.45 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 123.391 1.567 . . . . 0.0 110.393 -178.482 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.48 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.11 144.34 0.05 OUTLIER 'General case' 0 C--N 1.261 -3.267 0 CA-C-N 113.282 -1.781 . . . . 0.0 110.08 -179.746 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.599 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.3 p-10 -50.46 104.75 0.08 Allowed 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.556 0.693 . . . . 0.0 111.655 -178.451 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.51 14.4 8.2 Favored Glycine 0 N--CA 1.485 1.91 0 C-N-CA 119.33 -1.414 . . . . 0.0 113.154 177.18 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.745 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -105.76 -172.99 2.19 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 121.352 2.576 . . . . 0.0 109.821 179.181 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.731 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.5 t -129.59 138.21 54.82 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.333 0 CA-C-N 114.67 -1.15 . . . . 0.0 111.136 -178.711 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.633 HG11 HD11 ' A' ' 13' ' ' LEU . 29.4 m -113.61 155.48 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.863 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tttm -104.32 109.05 20.75 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.208 -0.933 . . . . 0.0 109.213 -179.962 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.944 HG11 HD11 ' A' ' 67' ' ' LEU . 2.2 p -100.64 140.05 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.627 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.863 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -136.61 162.67 32.49 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.733 -1.229 . . . . 0.0 110.179 179.666 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.588 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.64 139.82 10.95 Favored Glycine 0 C--N 1.299 -1.527 0 N-CA-C 108.244 -1.942 . . . . 0.0 108.244 179.728 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.32 125.6 16.51 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.491 -1.593 . . . . 0.0 109.355 179.301 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.85 28.32 21.52 Favored Glycine 0 N--CA 1.49 2.264 0 C-N-CA 118.685 -1.722 . . . . 0.0 109.731 -179.824 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.555 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -88.72 171.95 9.6 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.885 -1.362 . . . . 0.0 108.278 179.835 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.02 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.03 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.96 -1.087 . . . . 0.0 109.872 -179.476 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.57 77.54 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.677 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.178 -179.345 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.65 33.97 0.28 Allowed Glycine 0 N--CA 1.486 2.007 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.618 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.563 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 41.2 p -141.51 108.05 5.32 Favored 'General case' 0 C--N 1.307 -1.244 0 O-C-N 121.144 -1.209 . . . . 0.0 111.236 -179.476 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.04 109.8 0.36 Allowed 'General case' 0 N--CA 1.497 1.904 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.488 177.866 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.474 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.3 m-30 -103.89 157.99 16.71 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.054 -1.029 . . . . 0.0 108.87 179.741 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -99.81 166.54 11.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.844 -1.16 . . . . 0.0 107.969 179.007 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.628 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.8 p -148.09 120.28 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.108 -0.995 . . . . 0.0 109.605 -178.038 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -174.02 -177.02 42.89 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 118.403 -1.856 . . . . 0.0 111.641 -179.927 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.701 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -99.16 108.24 20.79 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.95 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -130.25 148.5 52.08 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.212 -0.93 . . . . 0.0 109.985 179.708 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.427 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.71 139.58 53.73 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.298 -0.877 . . . . 0.0 110.634 -179.099 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.888 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.21 114.76 26.59 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 178.207 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -104.83 15.02 6.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.92 -1.112 . . . . 0.0 110.58 -178.795 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.768 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.41 -175.96 0.08 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.872 -1.142 . . . . 0.0 110.074 179.757 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.781 ' O ' HG23 ' A' ' 42' ' ' THR . 15.0 t -71.36 98.0 1.7 Allowed 'General case' 0 N--CA 1.488 1.434 0 CA-C-O 121.729 0.776 . . . . 0.0 109.808 -179.696 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.48 27.86 34.64 Favored Glycine 0 N--CA 1.492 2.405 0 C-N-CA 120.174 -1.012 . . . . 0.0 111.427 178.97 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.768 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.71 106.25 19.87 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 O-C-N 120.587 -1.537 . . . . 0.0 107.192 178.887 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.888 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -116.96 104.53 11.37 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.478 -1.389 . . . . 0.0 109.773 -177.75 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.098 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.99 109.28 22.06 Favored 'General case' 0 N--CA 1.485 1.315 0 O-C-N 120.833 -1.167 . . . . 0.0 108.152 178.92 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.0 t -106.67 164.8 11.79 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.913 -1.117 . . . . 0.0 110.233 -179.115 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.793 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 3.7 t-20 -106.56 136.21 19.42 Favored Pre-proline 0 N--CA 1.498 1.966 0 O-C-N 121.386 -0.821 . . . . 0.0 109.622 -179.179 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.592 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -74.85 23.79 0.39 Allowed 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 122.384 2.056 . . . . 0.0 111.943 -179.83 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.793 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -109.76 -4.59 15.99 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.33 -1.481 . . . . 0.0 109.143 179.615 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.665 ' OD2' HG13 ' A' ' 69' ' ' VAL . 6.0 m-20 -131.73 6.05 4.33 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.658 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.47 84.94 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.732 -178.502 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -110.76 -170.49 1.65 Allowed 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.448 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.58 135.22 0.08 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 120.622 -1.298 . . . . 0.0 111.136 -179.286 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.767 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.6 p -146.8 158.28 10.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 178.169 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.598 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.49 141.51 31.25 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 120.703 -1.248 . . . . 0.0 110.061 -179.791 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.02 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.21 107.91 1.43 Allowed 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.438 1.114 . . . . 0.0 109.537 178.596 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.57 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.1 p-10 -61.46 -139.45 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.97 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.864 179.849 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.89 -50.87 60.17 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.427 -0.796 . . . . 0.0 110.487 -178.843 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -102.24 -34.71 9.13 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 178.46 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.27 67.31 0.64 Allowed Glycine 0 C--N 1.299 -1.499 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 178.073 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 57.5 m -100.06 130.86 46.26 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.482 -1.011 . . . . 0.0 108.803 178.962 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.767 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.48 109.42 9.27 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.19 -1.004 . . . . 0.0 109.321 -179.648 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 73.2 m -121.85 117.0 25.43 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.313 -0.867 . . . . 0.0 109.61 -179.678 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.589 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -147.54 149.32 32.37 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.452 -0.78 . . . . 0.0 109.291 179.879 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.434 ' O ' HD23 ' A' ' 67' ' ' LEU . 56.3 p -98.47 145.08 27.13 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.401 -0.812 . . . . 0.0 109.284 179.969 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.944 HD11 HG11 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -138.96 159.62 41.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.334 -0.854 . . . . 0.0 109.826 -178.717 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.652 HG22 HG22 ' A' ' 18' ' ' VAL . 1.4 p -101.29 124.0 46.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.011 -1.056 . . . . 0.0 108.483 179.319 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.701 HG12 ' HB3' ' A' ' 36' ' ' GLN . 21.1 m -137.92 143.16 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.744 -1.222 . . . . 0.0 110.783 -178.47 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.599 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.9 ptt180 -147.45 -175.14 4.73 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 120.711 -1.243 . . . . 0.0 110.742 179.68 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.595 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.43 -101.93 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -179.597 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.503 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -57.08 140.85 47.98 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.741 -1.224 . . . . 0.0 108.205 179.459 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -161.83 136.67 7.16 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 118.611 -1.235 . . . . 0.0 109.733 -178.1 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.532 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.4 mp0 -35.87 122.36 0.68 Allowed 'General case' 0 N--CA 1.491 1.576 0 CA-C-O 121.466 0.65 . . . . 0.0 110.094 -178.615 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.098 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.85 52.67 1.7 Allowed Glycine 0 N--CA 1.494 2.522 0 C-N-CA 120.539 -0.838 . . . . 0.0 111.22 -179.109 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.592 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.57 114.05 0.38 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.094 -1.239 . . . . 0.0 110.133 179.463 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.733 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -82.79 126.19 32.14 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 120.843 -1.161 . . . . 0.0 109.313 179.787 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.401 ' O ' ' CD2' ' A' ' 78' ' ' PHE . 51.8 t80 -64.02 58.59 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.955 0 O-C-N 120.89 -1.131 . . . . 0.0 110.042 179.724 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.3 t0 -160.22 20.03 0.15 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.094 -1.004 . . . . 0.0 109.608 179.942 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.54 -28.35 5.36 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.871 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.481 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.5 OUTLIER -96.72 160.42 14.38 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.058 -1.26 . . . . 0.0 110.207 -179.532 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.508 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.7 OUTLIER -106.13 141.69 37.07 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 179.896 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.733 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.6 t90 -85.15 -19.35 31.92 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.679 -1.263 . . . . 0.0 110.689 -178.289 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.42 177.5 18.59 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -179.359 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -67.02 105.79 1.75 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.146 -1.208 . . . . 0.0 107.785 179.183 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.65 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.7 t -77.2 106.33 7.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.326 -0.858 . . . . 0.0 109.232 -178.879 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.55 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.1 m-20 -65.96 111.63 3.42 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.363 -0.836 . . . . 0.0 109.69 -179.643 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.595 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.5 -5.36 5.26 Favored 'General case' 0 N--CA 1.5 2.045 0 C-N-CA 118.195 -1.402 . . . . 0.0 109.721 179.567 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -86.4 -0.41 55.91 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.716 -1.24 . . . . 0.0 109.079 179.482 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.55 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.6 -50.88 2.83 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.287 -0.883 . . . . 0.0 108.972 179.9 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.69 -178.73 3.74 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.509 -0.744 . . . . 0.0 109.271 179.815 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.17 115.37 30.11 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.437 -0.789 . . . . 0.0 108.888 -179.949 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.527 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.06 121.1 38.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.94 -1.1 . . . . 0.0 109.714 -179.271 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.614 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.21 146.94 27.27 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 122.449 1.119 . . . . 0.0 111.024 -179.562 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.548 ' CG1' HG11 ' A' ' 7' ' ' VAL . 61.6 t -104.23 111.72 34.94 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 177.858 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.497 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -152.91 -169.86 18.59 Favored Glycine 0 N--CA 1.487 2.089 0 C-N-CA 118.124 -1.989 . . . . 0.0 111.848 -177.71 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.489 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -114.32 179.43 3.96 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 -179.173 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.474 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 25.0 p . . . . . 0 C--N 1.295 -1.792 0 O-C-N 121.467 -0.771 . . . . 0.0 109.363 -179.513 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.34 0 N-CA-C 106.717 -2.553 . . . . 0.0 106.717 . . . . . . . . . 0 0 . 1 . 054 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -146.7 170.74 16.35 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.709 -0.877 . . . . 0.0 109.943 -179.775 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.15 -165.01 19.55 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 108.163 -1.975 . . . . 0.0 108.163 -179.857 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.9 Cg_exo -48.22 179.39 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 CA-C-N 118.889 1.344 . . . . 0.0 110.164 179.446 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -92.86 -177.71 4.61 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.183 -0.948 . . . . 0.0 110.438 -178.894 . . . . . . . . 1 1 . 1 . 054 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.497 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.61 165.62 14.53 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.923 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.0 130.13 53.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 O-C-N 121.293 -1.122 . . . . 0.0 109.209 -179.269 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.614 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.05 121.92 21.85 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.569 -0.707 . . . . 0.0 109.528 179.668 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.827 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.9 167.25 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 121.188 -0.945 . . . . 0.0 109.243 179.913 . . . . . . . . 2 2 . 1 . 054 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.513 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -137.33 151.24 48.42 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.237 -0.914 . . . . 0.0 109.62 -179.97 . . . . . . . . 3 3 . 1 . 054 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.827 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 25.2 m-85 . . . . . 0 N--CA 1.486 1.365 0 O-C-N 121.163 -0.961 . . . . 0.0 109.51 -179.693 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.458 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.478 0 CA-C-O 122.301 1.048 . . . . 0.0 110.71 . . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.968 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.7 t -110.93 108.77 18.65 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.079 1.418 . . . . 0.0 109.078 179.276 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.768 HG22 HG23 ' A' ' 21' ' ' VAL . 2.3 t -119.62 136.7 55.89 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.672 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.023 -179.637 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.488 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -177.0 150.96 0.92 Allowed Pre-proline 0 N--CA 1.487 1.421 0 O-C-N 121.286 -0.884 . . . . 0.0 108.785 -179.72 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.488 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -78.46 150.76 88.4 Favored 'Cis proline' 0 C--N 1.312 -1.35 0 C-N-CA 123.481 -1.466 . . . . 0.0 109.301 -0.828 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.689 ' HA ' HG22 ' A' ' 110' ' ' ILE . 77.9 p -89.34 -25.99 21.33 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.518 -0.739 . . . . 0.0 109.056 179.527 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.504 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -132.99 162.69 31.01 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.528 -0.733 . . . . 0.0 109.529 -179.922 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.31 36.93 29.37 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.749 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.771 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.5 mt -92.78 -42.97 9.27 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 123.24 1.495 . . . . 0.0 110.488 -178.327 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.29 144.35 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.265 0 CA-C-N 113.479 -1.691 . . . . 0.0 109.936 -179.521 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.591 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 15.5 p-10 -50.9 106.49 0.13 Allowed 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.515 0.674 . . . . 0.0 111.556 -178.542 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.28 14.22 9.23 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.331 -1.414 . . . . 0.0 113.007 177.311 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.771 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.71 -172.01 2.02 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 121.143 2.471 . . . . 0.0 109.67 179.144 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.748 HG13 ' C ' ' A' ' 67' ' ' LEU . 17.2 t -127.92 135.97 61.53 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.404 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.182 -178.93 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.591 HG11 HD11 ' A' ' 13' ' ' LEU . 23.0 m -110.79 155.15 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.77 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.523 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.8 OUTLIER -109.93 109.18 19.71 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.173 -0.954 . . . . 0.0 108.973 179.958 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.768 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -105.16 141.73 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.675 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.968 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -141.0 160.2 40.59 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.144 179.886 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.95 144.72 15.91 Favored Glycine 0 C--N 1.294 -1.769 0 N-CA-C 107.996 -2.041 . . . . 0.0 107.996 179.666 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.4 125.73 13.1 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 120.884 -1.362 . . . . 0.0 108.789 179.244 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.46 27.16 23.36 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.315 -1.421 . . . . 0.0 109.608 -179.568 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.551 HD22 ' HG3' ' A' ' 105' ' ' PRO . 1.5 mt -88.8 175.33 7.53 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.946 -1.326 . . . . 0.0 108.446 -179.941 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.998 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -48.42 99.49 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.013 -1.055 . . . . 0.0 109.83 -179.623 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.562 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.11 77.98 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.759 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.149 -179.325 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.69 34.2 0.31 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.614 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.549 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 62.9 p -143.21 109.09 5.18 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.034 -1.274 . . . . 0.0 111.142 -179.591 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.552 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.99 126.01 5.57 Favored 'General case' 0 N--CA 1.493 1.71 0 CA-C-O 121.403 0.62 . . . . 0.0 109.56 178.129 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.536 ' CD2' ' O ' ' A' ' 30' ' ' THR . 19.8 m-85 -117.35 152.98 33.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.349 -0.844 . . . . 0.0 108.923 179.808 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.523 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -103.14 152.66 21.17 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.627 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.637 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.0 p -136.82 116.96 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 120.885 -1.134 . . . . 0.0 109.856 -177.904 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.502 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.1 -178.28 39.35 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 118.462 -1.828 . . . . 0.0 111.828 -179.799 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.59 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -101.74 109.56 21.36 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.928 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.485 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.53 148.4 52.33 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.098 -1.001 . . . . 0.0 110.081 179.852 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.04 138.53 54.66 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.394 -0.816 . . . . 0.0 110.701 -179.025 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.862 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.39 114.6 26.39 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 178.137 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 m -105.22 15.16 6.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.006 -1.059 . . . . 0.0 110.705 -178.596 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.757 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.14 -175.09 0.09 Allowed 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.952 -1.093 . . . . 0.0 110.097 179.736 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 35.1 p -72.0 97.54 1.9 Allowed 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.404 -0.81 . . . . 0.0 109.727 -179.673 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.13 26.53 36.61 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.173 -1.013 . . . . 0.0 111.446 178.859 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.757 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.21 106.3 20.28 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 O-C-N 120.547 -1.561 . . . . 0.0 107.482 178.93 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.862 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -117.51 104.07 10.7 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.47 -1.393 . . . . 0.0 109.6 -177.815 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.014 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.32 109.24 22.03 Favored 'General case' 0 N--CA 1.483 1.179 0 O-C-N 120.767 -1.208 . . . . 0.0 107.753 178.603 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.491 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -103.5 166.01 10.69 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.924 -1.11 . . . . 0.0 110.411 -178.532 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.677 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 17.1 t-20 -106.35 129.72 24.07 Favored Pre-proline 0 N--CA 1.501 2.084 0 C-N-CA 119.945 -0.702 . . . . 0.0 109.757 -179.202 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.598 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.6 Cg_endo -72.94 23.81 0.3 Allowed 'Trans proline' 0 CA--C 1.544 0.98 0 C-N-CA 122.089 1.86 . . . . 0.0 111.813 179.634 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.677 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -115.51 3.63 14.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.498 -1.376 . . . . 0.0 109.197 179.738 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.543 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.89 17.24 2.66 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 179.49 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -80.64 91.1 5.8 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.842 -0.743 . . . . 0.0 110.814 -178.696 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.637 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -109.51 -166.71 1.12 Allowed 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.297 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.94 137.03 0.09 Allowed 'General case' 0 C--N 1.306 -1.311 0 O-C-N 120.526 -1.358 . . . . 0.0 111.404 -179.271 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.932 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -154.9 156.15 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.211 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.552 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.68 144.87 26.88 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.694 -1.254 . . . . 0.0 109.907 -179.534 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.83 107.22 1.16 Allowed 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 122.431 1.11 . . . . 0.0 109.409 178.586 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -61.07 -139.34 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.027 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.903 -179.909 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.562 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.9 -50.91 56.38 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.397 -0.814 . . . . 0.0 110.68 -178.713 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -103.94 -33.18 8.92 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 178.576 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.003 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.96 64.91 0.58 Allowed Glycine 0 C--N 1.299 -1.498 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 178.206 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 47.7 m -103.44 127.07 50.9 Favored 'General case' 0 N--CA 1.483 1.176 0 O-C-N 121.57 -0.959 . . . . 0.0 108.83 178.901 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.932 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.04 108.96 7.1 Favored 'General case' 0 C--N 1.296 -1.751 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.659 -179.396 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.1 m -122.44 121.01 35.6 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.359 -0.838 . . . . 0.0 109.303 -179.898 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.525 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.83 144.84 31.34 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.426 -0.796 . . . . 0.0 109.565 179.886 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 22.1 p -99.0 141.0 32.3 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.38 -0.825 . . . . 0.0 109.297 -179.945 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.777 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.99 166.7 24.07 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.413 -0.804 . . . . 0.0 109.39 -179.327 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.728 HG22 HG22 ' A' ' 18' ' ' VAL . 2.7 p -95.96 124.38 39.95 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.005 -1.06 . . . . 0.0 109.416 -179.883 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.587 HG22 HG22 ' A' ' 19' ' ' VAL . 13.3 m -136.42 141.86 40.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 120.907 -1.121 . . . . 0.0 109.937 -179.12 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.591 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.3 ptt180 -144.35 -170.32 3.34 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.546 -1.346 . . . . 0.0 110.884 -179.882 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.598 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -62.45 -101.42 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.77 -0.581 . . . . 0.0 110.206 -179.125 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.541 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -58.94 137.15 58.0 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.574 -1.329 . . . . 0.0 108.209 179.957 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD2' ' O ' ' A' ' 71' ' ' ARG . 1.7 p90 -157.53 154.04 27.96 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.646 -1.222 . . . . 0.0 110.198 -178.514 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.5 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 5.1 mm-40 -47.15 120.8 3.32 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.359 -0.838 . . . . 0.0 109.263 -179.124 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.014 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.5 51.34 3.01 Favored Glycine 0 N--CA 1.495 2.59 0 C-N-CA 120.414 -0.898 . . . . 0.0 111.116 -179.224 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.598 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.5 m-30 -39.0 114.0 0.36 Allowed 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.114 -1.227 . . . . 0.0 110.31 179.62 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.765 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.21 126.94 34.63 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.919 -1.113 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 29.2 t80 -64.25 58.44 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.911 -1.118 . . . . 0.0 110.059 179.702 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -160.33 19.52 0.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.031 -1.043 . . . . 0.0 109.733 179.824 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.74 -26.96 5.57 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 179.866 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.404 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -95.34 161.42 14.09 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 120.998 -1.295 . . . . 0.0 110.315 -179.383 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.482 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -107.24 136.78 46.49 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.813 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.765 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -83.64 -16.89 43.44 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.784 -1.198 . . . . 0.0 110.562 -178.423 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.14 174.27 20.0 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 108.827 -1.709 . . . . 0.0 108.827 -179.553 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -63.66 107.0 1.06 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.141 -1.211 . . . . 0.0 107.759 179.218 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.662 HG21 ' HB3' ' A' ' 46' ' ' ALA . 44.3 t -78.94 106.05 9.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.307 -0.871 . . . . 0.0 109.243 -178.877 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.553 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -65.16 108.35 1.84 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.652 -0.655 . . . . 0.0 110.113 -179.408 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.598 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.5 t -61.34 -4.72 1.32 Allowed 'General case' 0 N--CA 1.502 2.133 0 O-C-N 120.479 -1.388 . . . . 0.0 110.417 179.391 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -90.43 3.68 53.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.597 -1.314 . . . . 0.0 109.481 179.944 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.553 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -114.96 -48.32 2.84 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.282 -0.886 . . . . 0.0 109.107 -179.976 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.72 -179.05 3.82 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.573 -0.704 . . . . 0.0 109.526 179.997 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.97 112.15 24.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.382 -0.824 . . . . 0.0 108.812 179.838 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.505 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.4 m -96.98 122.06 39.54 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.104 -0.997 . . . . 0.0 109.399 -178.922 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.575 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.08 148.66 25.45 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-O 122.439 1.114 . . . . 0.0 111.577 -179.157 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.499 ' CG1' HG11 ' A' ' 7' ' ' VAL . 84.8 t -104.22 110.78 31.43 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 177.643 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.412 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.84 -172.01 18.87 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 118.034 -2.031 . . . . 0.0 111.802 -177.604 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.523 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -114.57 -179.04 3.52 Favored 'General case' 0 N--CA 1.485 1.3 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -178.94 . . . . . . . . 3 3 . 1 . 055 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.504 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.8 OUTLIER . . . . . 0 C--N 1.298 -1.66 0 O-C-N 121.394 -0.816 . . . . 0.0 109.033 -179.418 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.688 0 N-CA-C 107.636 -2.185 . . . . 0.0 107.636 . . . . . . . . . 0 0 . 1 . 055 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.3 -178.81 7.56 Favored 'General case' 0 C--N 1.307 -1.26 0 O-C-N 121.542 -0.975 . . . . 0.0 109.623 179.022 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -177.63 -167.01 35.17 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 -179.584 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.551 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.7 Cg_exo -49.11 -179.57 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.618 0 CA-C-N 118.83 1.315 . . . . 0.0 110.07 179.529 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.87 -179.81 5.1 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.012 -1.055 . . . . 0.0 110.521 -178.765 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.412 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.99 162.65 13.42 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.973 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -103.55 130.62 53.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.318 -1.107 . . . . 0.0 109.216 -179.347 . . . . . . . . 1 1 . 1 . 055 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.575 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.98 121.21 18.75 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.641 -0.662 . . . . 0.0 109.606 179.62 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.859 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.04 171.43 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.239 -0.913 . . . . 0.0 109.174 179.947 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.504 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.4 m -141.1 156.55 45.96 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.151 -0.968 . . . . 0.0 109.895 -179.841 . . . . . . . . 2 2 . 1 . 055 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.859 ' CE2' HD12 ' A' ' 110' ' ' ILE . 82.8 m-85 . . . . . 0 N--CA 1.486 1.34 0 O-C-N 121.243 -0.911 . . . . 0.0 109.549 -179.74 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.505 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.217 0 CA-C-O 122.409 1.1 . . . . 0.0 110.565 . . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.011 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.4 p -106.31 104.86 14.65 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 122.461 1.124 . . . . 0.0 110.199 -179.476 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.967 HG22 HG23 ' A' ' 21' ' ' VAL . 12.1 t -118.53 118.69 58.8 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.439 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.364 179.596 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.499 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.87 149.17 10.28 Favored Pre-proline 0 N--CA 1.487 1.38 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 -179.65 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.499 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -77.83 151.23 91.09 Favored 'Cis proline' 0 C--N 1.31 -1.494 0 C-N-CA 123.606 -1.414 . . . . 0.0 109.51 -0.578 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.704 ' HA ' HG22 ' A' ' 110' ' ' ILE . 16.5 p -93.52 -23.85 18.2 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.639 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.463 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 20.2 m -132.38 162.22 31.64 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.438 -0.789 . . . . 0.0 109.585 -179.927 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.2 37.24 37.72 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 -179.733 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.83 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.2 mt -90.41 -44.64 9.51 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 123.127 1.441 . . . . 0.0 110.652 -178.428 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.99 145.83 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.325 0 CA-C-N 113.699 -1.591 . . . . 0.0 109.963 -179.701 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.63 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 7.3 p-10 -51.35 106.26 0.13 Allowed 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.598 0.713 . . . . 0.0 111.794 -178.471 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.45 15.7 8.71 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 119.438 -1.363 . . . . 0.0 112.98 177.302 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.83 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.0 t -102.72 -171.66 1.99 Allowed 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 121.13 2.465 . . . . 0.0 109.84 179.31 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.755 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.2 t -129.45 139.01 52.83 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.289 0 CA-C-N 114.861 -1.063 . . . . 0.0 111.195 -178.699 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.533 HG22 HG22 ' A' ' 69' ' ' VAL . 31.2 m -118.08 155.04 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.733 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.548 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 6.2 tttt -113.08 109.13 18.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.126 -0.984 . . . . 0.0 109.413 -179.854 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.967 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -105.33 122.97 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 179.833 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.011 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.88 166.09 11.71 Favored 'General case' 0 C--N 1.307 -1.243 0 O-C-N 120.799 -1.188 . . . . 0.0 109.073 179.634 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.67 108.46 0.5 Allowed Glycine 0 N--CA 1.481 1.678 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 -179.886 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.36 139.11 50.76 Favored 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 119.396 1.598 . . . . 0.0 110.424 -179.485 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.56 29.04 30.86 Favored Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.079 -1.534 . . . . 0.0 109.941 179.56 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.523 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.5 mt -92.47 176.07 6.6 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.986 -1.302 . . . . 0.0 108.562 179.935 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.39 96.98 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.023 -1.048 . . . . 0.0 109.621 -179.909 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.711 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.94 77.18 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.36 -178.93 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 131.8 34.87 0.37 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.465 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.636 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -146.51 114.4 6.51 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 120.931 -1.335 . . . . 0.0 111.109 -179.948 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.17 122.9 5.66 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.181 178.669 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.636 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 2.0 m-30 -116.93 151.77 35.96 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.267 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -98.91 163.75 12.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.539 -1.351 . . . . 0.0 108.216 179.247 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 1.003 HG11 HG21 ' A' ' 65' ' ' THR . 3.8 p -144.59 117.98 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.106 -0.997 . . . . 0.0 109.643 -177.963 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.511 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.66 -179.08 41.22 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.411 -1.852 . . . . 0.0 111.738 -179.804 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.636 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -100.95 109.24 21.15 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -179.922 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.03 149.21 51.85 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.21 -0.931 . . . . 0.0 109.74 179.891 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.552 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.36 137.75 54.75 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.178 -0.951 . . . . 0.0 110.736 -178.993 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.883 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.28 114.61 26.41 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 178.038 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -104.59 14.47 7.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 120.973 -1.079 . . . . 0.0 110.585 -178.708 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.766 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.57 -174.84 0.08 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.941 -1.099 . . . . 0.0 109.988 179.747 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.92 98.22 2.43 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.379 -0.826 . . . . 0.0 109.653 -179.753 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.28 26.95 31.96 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 120.302 -0.952 . . . . 0.0 111.534 178.943 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.766 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -116.85 106.16 19.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 O-C-N 120.499 -1.589 . . . . 0.0 107.298 178.922 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.883 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -118.17 104.37 10.75 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.358 -1.464 . . . . 0.0 109.885 -177.795 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.023 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.45 109.36 22.13 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 120.821 -1.174 . . . . 0.0 108.156 178.905 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.509 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.3 t -104.42 166.63 10.27 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.844 -1.16 . . . . 0.0 110.353 -178.961 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.677 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 15.8 t-20 -109.53 137.89 20.44 Favored Pre-proline 0 N--CA 1.501 2.082 0 O-C-N 121.445 -0.785 . . . . 0.0 110.146 -179.081 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.8 Cg_endo -74.82 25.2 0.37 Allowed 'Trans proline' 0 C--N 1.318 -1.027 0 C-N-CA 122.465 2.11 . . . . 0.0 111.939 179.903 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.677 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -117.27 2.35 12.54 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.278 -1.514 . . . . 0.0 109.294 179.788 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.551 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.73 18.71 2.51 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 179.297 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -80.58 89.73 5.69 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.88 -0.728 . . . . 0.0 110.489 -179.078 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -113.65 -168.7 1.38 Allowed 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 178.647 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.5 134.96 0.08 Allowed 'General case' 0 C--N 1.305 -1.34 0 O-C-N 120.653 -1.28 . . . . 0.0 111.286 -179.337 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.856 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.3 p -149.09 158.71 6.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 177.966 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.19 145.69 26.35 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.75 -1.219 . . . . 0.0 109.908 -179.723 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.88 107.87 2.36 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-O 122.443 1.116 . . . . 0.0 109.369 178.577 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.9 p-10 -59.87 -139.47 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.829 179.996 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.711 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.64 -50.68 59.84 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.386 -0.821 . . . . 0.0 110.467 -178.775 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.5 t30 -103.63 -34.65 8.56 Favored 'General case' 0 C--N 1.285 -2.225 0 N-CA-C 106.379 -1.711 . . . . 0.0 106.379 178.481 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.986 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.5 67.92 0.62 Allowed Glycine 0 C--N 1.297 -1.584 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.055 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.8 m -103.36 126.16 50.37 Favored 'General case' 0 N--CA 1.484 1.254 0 O-C-N 121.717 -0.873 . . . . 0.0 108.677 178.817 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.856 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.87 108.86 8.14 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 119.714 -0.794 . . . . 0.0 109.511 -179.327 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 93.0 p -117.89 117.2 28.62 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 121.17 -0.956 . . . . 0.0 109.436 -179.99 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 65' ' ' THR . . . . . 1.003 HG21 HG11 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -141.85 135.31 29.44 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.467 -0.771 . . . . 0.0 109.957 179.979 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 10.0 p -100.36 133.13 45.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.423 -0.798 . . . . 0.0 108.848 179.511 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.817 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -134.3 175.19 9.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.316 -0.865 . . . . 0.0 109.683 -178.917 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.548 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -100.16 125.0 46.23 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.006 -1.059 . . . . 0.0 109.702 -179.612 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.533 HG22 HG22 ' A' ' 19' ' ' VAL . 16.5 m -136.87 142.15 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 120.94 -1.1 . . . . 0.0 109.761 -179.495 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.63 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.4 ptt180 -138.43 -165.3 1.79 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.652 -1.28 . . . . 0.0 110.129 -179.911 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.579 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -74.87 -83.61 0.05 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.142 -0.974 . . . . 0.0 108.782 -179.615 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.501 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -62.82 138.86 58.64 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.361 -1.462 . . . . 0.0 107.228 178.668 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD1' ' O ' ' A' ' 71' ' ' ARG . 0.3 OUTLIER -164.54 135.11 4.1 Favored 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 117.933 -1.507 . . . . 0.0 110.533 -177.443 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.51 ' HB3' ' HD3' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -31.82 121.02 0.28 Allowed 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.463 0.649 . . . . 0.0 110.483 -178.76 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.023 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.28 49.87 2.42 Favored Glycine 0 N--CA 1.494 2.537 0 C-N-CA 120.353 -0.927 . . . . 0.0 111.396 -179.062 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.4 m-30 -39.68 112.46 0.26 Allowed 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.027 -1.278 . . . . 0.0 109.998 179.306 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.668 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -84.62 127.18 33.94 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.906 -1.121 . . . . 0.0 109.791 -179.804 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -63.66 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.03 0 O-C-N 120.978 -1.077 . . . . 0.0 110.195 179.58 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.4 t0 -161.26 19.51 0.12 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.022 -1.049 . . . . 0.0 109.816 179.878 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.3 -26.68 5.49 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 179.866 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.419 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 22.8 p -93.9 157.53 16.08 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.975 -1.309 . . . . 0.0 110.302 -179.442 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.497 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 4.5 ptt180 -104.73 135.54 45.92 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.701 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.668 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -82.57 -17.76 43.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.716 -1.24 . . . . 0.0 110.423 -178.55 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.6 175.68 21.14 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 -179.57 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.59 109.14 1.3 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 179.037 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.574 HG21 ' HB3' ' A' ' 46' ' ' ALA . 35.2 t -81.39 104.77 10.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -178.864 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.529 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.09 111.9 3.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.448 -0.782 . . . . 0.0 109.885 -179.146 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.543 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -65.98 -4.44 7.1 Favored 'General case' 0 N--CA 1.499 1.992 0 C-N-CA 118.366 -1.334 . . . . 0.0 109.839 179.324 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 p -85.02 1.18 48.76 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.835 -1.166 . . . . 0.0 108.872 179.336 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.529 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -116.13 -49.86 2.68 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.401 -0.812 . . . . 0.0 109.047 -179.957 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.7 -179.49 3.95 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.512 -0.743 . . . . 0.0 109.464 179.916 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.99 115.46 30.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.883 . . . . 0.0 109.104 179.976 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.55 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.9 m -96.8 122.54 39.87 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.909 -1.12 . . . . 0.0 109.391 -179.5 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.592 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.31 146.28 27.76 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-O 122.393 1.092 . . . . 0.0 111.368 -179.216 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.722 ' HB ' HG11 ' A' ' 7' ' ' VAL . 53.4 t -102.5 109.64 27.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 177.419 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.438 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.64 -169.99 16.0 Favored Glycine 0 N--CA 1.485 1.932 0 C-N-CA 118.009 -2.043 . . . . 0.0 111.729 -177.362 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.498 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -117.75 -177.89 3.36 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -178.786 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.515 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.1 p . . . . . 0 C--N 1.295 -1.765 0 O-C-N 121.35 -0.844 . . . . 0.0 109.302 -179.251 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.707 0 N-CA-C 107.599 -2.201 . . . . 0.0 107.599 . . . . . . . . . 0 0 . 1 . 056 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.94 -178.15 7.03 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.617 -0.931 . . . . 0.0 109.826 179.288 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.87 -162.6 20.13 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 108.239 -1.945 . . . . 0.0 108.239 -179.433 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.609 ' CD ' ' CE2' ' A' ' 32' ' ' TYR . 7.3 Cg_exo -45.59 172.07 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.652 0 CA-C-N 118.92 1.36 . . . . 0.0 109.926 179.354 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -90.36 -171.43 3.09 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.107 -0.995 . . . . 0.0 110.42 -178.746 . . . . . . . . 1 1 . 1 . 056 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.438 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.65 169.65 16.67 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.751 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.445 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.81 133.95 47.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.48 -1.012 . . . . 0.0 109.061 -179.314 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.592 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.82 119.42 18.98 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.513 -0.742 . . . . 0.0 109.696 179.791 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.896 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -98.14 168.58 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 O-C-N 121.272 -0.892 . . . . 0.0 108.845 179.708 . . . . . . . . 2 2 . 1 . 056 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.463 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -139.7 157.63 45.44 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.017 -1.052 . . . . 0.0 109.853 -179.717 . . . . . . . . 3 3 . 1 . 056 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.896 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.7 m-85 . . . . . 0 N--CA 1.486 1.37 0 O-C-N 121.236 -0.915 . . . . 0.0 109.506 -179.672 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.452 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.42 0 CA-C-O 122.253 1.025 . . . . 0.0 110.32 . . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.95 HG22 ' HB3' ' A' ' 22' ' ' ALA . 4.3 t -116.36 108.71 16.4 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 123.167 1.46 . . . . 0.0 109.23 179.29 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.791 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -117.04 138.26 48.29 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.654 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.944 -179.604 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.494 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.5 149.88 1.39 Allowed Pre-proline 0 N--CA 1.485 1.308 0 O-C-N 121.298 -0.877 . . . . 0.0 108.757 -179.782 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.494 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -77.86 150.91 90.56 Favored 'Cis proline' 0 C--N 1.311 -1.427 0 C-N-CA 123.507 -1.455 . . . . 0.0 109.461 -0.786 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.673 ' HA ' HG22 ' A' ' 110' ' ' ILE . 71.1 p -88.31 -26.2 22.39 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.903 -0.776 . . . . 0.0 108.903 179.564 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.543 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 0.8 OUTLIER -132.75 168.74 17.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.449 -0.782 . . . . 0.0 109.499 179.649 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.93 38.79 48.11 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 108.36 -1.896 . . . . 0.0 108.36 -179.801 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.772 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.3 mt -94.11 -43.04 8.68 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 123.285 1.517 . . . . 0.0 110.67 -178.111 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.48 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.08 143.5 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.283 0 CA-C-N 113.408 -1.723 . . . . 0.0 109.766 -179.398 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.568 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.8 p-10 -49.95 105.47 0.09 Allowed 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 121.57 0.7 . . . . 0.0 111.753 -178.397 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.403 ' H ' ' HB3' ' A' ' 70' ' ' ARG . . . 113.23 15.68 8.86 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.33 -1.414 . . . . 0.0 113.081 177.158 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.772 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.24 -171.15 1.88 Allowed 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 121.235 2.517 . . . . 0.0 109.733 179.153 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.859 HG22 HG22 ' A' ' 68' ' ' THR . 15.9 t -129.98 139.26 51.95 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.289 0 CA-C-N 114.943 -1.026 . . . . 0.0 111.309 -178.97 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.566 HG12 HD21 ' A' ' 13' ' ' LEU . 33.6 m -115.59 155.74 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.881 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.499 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -106.9 109.76 21.74 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.117 -0.989 . . . . 0.0 109.187 -179.929 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.791 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -103.35 139.74 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.404 -0.81 . . . . 0.0 108.842 179.978 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.95 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -132.55 157.8 43.79 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.829 -1.169 . . . . 0.0 109.608 179.426 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -138.99 108.71 0.62 Allowed Glycine 0 N--CA 1.482 1.74 0 N-CA-C 108.688 -1.765 . . . . 0.0 108.688 -179.964 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.36 142.04 46.85 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.889 -1.359 . . . . 0.0 110.858 -179.059 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.84 27.36 46.47 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.701 -1.237 . . . . 0.0 110.131 178.942 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.574 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.6 mt -89.52 173.99 8.02 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.008 -1.289 . . . . 0.0 108.705 -179.848 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.97 99.64 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.965 -1.085 . . . . 0.0 109.579 -179.598 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.554 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.24 77.22 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.196 -179.144 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.9 34.09 0.31 Allowed Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.549 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.554 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 78.0 p -144.04 111.02 5.73 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 120.965 -1.315 . . . . 0.0 111.045 -179.741 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -46.27 125.09 6.28 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.689 178.158 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.493 ' CD2' ' O ' ' A' ' 30' ' ' THR . 16.9 m-85 -116.11 150.82 36.75 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.889 . . . . 0.0 108.97 179.699 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.509 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -101.86 151.77 21.69 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 178.547 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.622 HG13 ' O ' ' A' ' 34' ' ' VAL . 4.5 p -136.17 117.63 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.957 -1.09 . . . . 0.0 109.787 -177.904 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -165.01 -179.35 38.93 Favored Glycine 0 N--CA 1.494 2.5 0 C-N-CA 118.348 -1.882 . . . . 0.0 111.69 -179.576 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.629 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.6 pt20 -100.44 110.79 23.0 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.927 0.87 . . . . 0.0 108.744 -179.872 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.1 m -131.08 148.98 52.8 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.265 -0.897 . . . . 0.0 109.781 -179.756 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.478 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.39 138.19 54.61 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.261 -0.9 . . . . 0.0 110.675 -179.047 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.867 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.63 114.64 26.41 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 178.209 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 m -105.23 14.56 7.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.028 -1.045 . . . . 0.0 110.65 -178.693 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 173.98 -175.67 0.07 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.912 -1.118 . . . . 0.0 110.198 179.706 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.777 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.34 97.99 1.34 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 121.755 0.788 . . . . 0.0 110.001 -179.633 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.62 26.47 38.62 Favored Glycine 0 N--CA 1.493 2.494 0 C-N-CA 120.252 -0.975 . . . . 0.0 111.522 178.825 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.89 106.31 20.35 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.572 -1.546 . . . . 0.0 107.382 178.931 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.867 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.8 tp -118.05 104.69 11.1 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.494 -1.379 . . . . 0.0 109.77 -177.793 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.943 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.87 109.69 22.4 Favored 'General case' 0 N--CA 1.484 1.265 0 O-C-N 120.796 -1.19 . . . . 0.0 108.246 178.903 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.9 t -107.13 166.54 10.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.93 -1.106 . . . . 0.0 110.525 -178.692 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.496 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 12.4 t-20 -114.0 129.81 24.45 Favored Pre-proline 0 N--CA 1.499 2.005 0 O-C-N 121.424 -0.797 . . . . 0.0 109.697 -179.236 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.614 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -71.28 21.08 0.23 Allowed 'Trans proline' 0 CA--C 1.546 1.082 0 C-N-CA 121.953 1.769 . . . . 0.0 111.969 179.274 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.496 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -107.08 1.45 24.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.442 -1.411 . . . . 0.0 108.82 179.293 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.532 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.92 15.47 2.87 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 179.372 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -79.25 85.76 5.08 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.069 -178.49 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.601 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -101.59 -166.72 1.33 Allowed 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 178.128 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.432 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.36 138.35 0.09 Allowed 'General case' 0 C--N 1.305 -1.348 0 O-C-N 120.504 -1.373 . . . . 0.0 111.417 -179.178 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.936 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -157.47 156.7 4.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 178.135 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.88 144.75 27.13 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.747 -1.221 . . . . 0.0 109.884 -179.664 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.009 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.46 106.69 1.19 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 122.47 1.129 . . . . 0.0 109.44 178.61 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.543 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 16.9 p-10 -58.87 -138.62 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.621 179.848 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.554 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -56.38 -49.45 74.42 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.39 -0.819 . . . . 0.0 110.103 -178.976 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.406 ' CG ' ' N ' ' A' ' 61' ' ' GLY . 10.8 p-10 -98.21 -39.84 8.66 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 106.066 -1.827 . . . . 0.0 106.066 178.372 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.989 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 110.19 64.33 0.53 Allowed Glycine 0 C--N 1.296 -1.694 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.38 178.054 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.584 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 88.6 p -100.28 128.47 46.34 Favored 'General case' 0 C--N 1.309 -1.167 0 O-C-N 121.618 -0.93 . . . . 0.0 108.945 178.915 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.936 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.26 108.47 7.26 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.604 -0.839 . . . . 0.0 108.952 -179.814 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -128.64 121.33 28.37 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.288 -0.883 . . . . 0.0 109.977 -179.358 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.06 148.08 31.28 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.62 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 9.5 p -98.28 131.01 44.96 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.173 -0.955 . . . . 0.0 109.486 -179.737 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.767 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -127.23 164.52 21.51 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.507 -0.746 . . . . 0.0 109.338 -179.347 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.859 HG22 HG22 ' A' ' 18' ' ' VAL . 1.9 p -96.51 124.05 40.37 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.986 -1.071 . . . . 0.0 109.333 179.969 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.539 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.5 m -137.33 143.38 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 120.997 -1.064 . . . . 0.0 109.968 -179.211 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.568 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -141.52 -166.54 2.22 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.558 -1.338 . . . . 0.0 110.214 179.986 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.595 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -69.44 -89.13 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 119.687 -0.805 . . . . 0.0 108.837 -179.737 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.52 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -59.67 138.27 57.79 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 120.426 -1.421 . . . . 0.0 107.451 178.89 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.12 141.09 7.99 Favored 'General case' 0 C--N 1.294 -1.819 0 C-N-CA 118.148 -1.421 . . . . 0.0 110.351 -177.682 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.489 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.5 mm-40 -33.95 120.24 0.42 Allowed 'General case' 0 N--CA 1.491 1.62 0 CA-C-O 121.561 0.696 . . . . 0.0 110.7 -178.473 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.943 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.33 45.21 2.79 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.713 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.614 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -39.24 113.34 0.31 Allowed 'General case' 0 N--CA 1.508 2.474 0 O-C-N 121.099 -1.236 . . . . 0.0 110.298 179.782 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.634 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.43 127.36 34.83 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 120.857 -1.152 . . . . 0.0 109.556 -179.972 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -64.23 58.09 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.955 0 O-C-N 120.815 -1.178 . . . . 0.0 110.286 179.849 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 77' ' ' LEU . 10.7 t0 -160.92 19.57 0.13 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.983 -1.073 . . . . 0.0 109.833 179.771 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -26.78 5.28 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.918 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -91.72 154.44 18.97 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 121.031 -1.276 . . . . 0.0 110.387 -179.471 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -102.87 131.91 49.45 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.634 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.634 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -79.89 -19.15 48.89 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.758 -1.214 . . . . 0.0 110.238 -178.635 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.24 175.05 20.13 Favored Glycine 0 N--CA 1.485 1.966 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 -179.529 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.499 ' CG2' ' HB3' ' A' ' 72' ' ' SER . 0.9 OUTLIER -63.49 110.29 1.91 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 106.903 -1.518 . . . . 0.0 106.903 178.851 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.57 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.1 t -81.28 104.36 9.71 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 O-C-N 121.345 -0.847 . . . . 0.0 109.162 -178.642 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.655 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -63.98 110.64 2.2 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.479 -0.763 . . . . 0.0 109.735 -179.414 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.534 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.61 -5.13 4.98 Favored 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 118.137 -1.425 . . . . 0.0 109.839 179.42 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -84.41 -0.7 53.73 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.834 -1.166 . . . . 0.0 108.932 179.306 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.655 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -112.66 -50.02 2.91 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.346 -0.847 . . . . 0.0 108.995 179.911 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.12 -179.88 4.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.491 -0.756 . . . . 0.0 109.572 179.96 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.91 116.12 31.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.365 -0.834 . . . . 0.0 109.103 -179.954 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -96.83 122.24 39.57 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.884 -1.135 . . . . 0.0 109.555 -179.484 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.575 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -102.76 149.59 24.32 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.383 1.087 . . . . 0.0 111.421 -179.149 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.494 ' CG1' HG11 ' A' ' 7' ' ' VAL . 47.2 t -102.07 111.12 30.73 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 177.194 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -145.18 -174.96 17.91 Favored Glycine 0 N--CA 1.486 1.975 0 C-N-CA 118.49 -1.814 . . . . 0.0 111.46 -177.56 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.509 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.12 -179.83 4.16 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -178.779 . . . . . . . . 3 3 . 1 . 057 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.501 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.777 0 O-C-N 121.501 -0.749 . . . . 0.0 109.063 -179.498 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.755 0 N-CA-C 107.823 -2.111 . . . . 0.0 107.823 . . . . . . . . . 0 0 . 1 . 057 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.17 -178.58 7.3 Favored 'General case' 0 C--N 1.308 -1.222 0 O-C-N 121.484 -1.01 . . . . 0.0 109.573 179.074 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -178.63 -166.45 34.8 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 108.495 -1.842 . . . . 0.0 108.495 -179.457 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.5 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.0 Cg_exo -50.22 -175.15 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.63 0 CA-C-N 118.843 1.321 . . . . 0.0 110.279 179.561 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.61 -173.66 2.81 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.119 -0.988 . . . . 0.0 110.076 -179.179 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -125.25 169.95 17.2 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.817 . . . . . . . . 1 1 . 1 . 057 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.516 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -109.25 154.23 10.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -179.597 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.575 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -97.42 122.82 40.9 Favored 'General case' 0 C--N 1.291 -1.945 0 O-C-N 121.318 -0.864 . . . . 0.0 109.703 -179.888 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.673 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.6 pt -98.26 168.97 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.213 -0.929 . . . . 0.0 109.033 179.83 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.543 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.7 m -142.52 155.91 45.08 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.05 -1.031 . . . . 0.0 109.811 179.979 . . . . . . . . 2 2 . 1 . 057 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.669 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 31.4 m-85 . . . . . 0 N--CA 1.486 1.327 0 O-C-N 121.138 -0.976 . . . . 0.0 109.539 -179.642 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.473 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.451 0 CA-C-O 122.129 0.966 . . . . 0.0 110.81 . . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.016 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.2 p -105.01 104.4 14.13 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 122.435 1.112 . . . . 0.0 109.997 179.833 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.978 HG22 HG23 ' A' ' 21' ' ' VAL . 13.1 t -118.85 119.75 61.97 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.543 179.841 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.506 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.75 148.55 7.68 Favored Pre-proline 0 N--CA 1.486 1.352 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 -179.695 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.506 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -77.54 150.72 91.21 Favored 'Cis proline' 0 C--N 1.31 -1.476 0 C-N-CA 123.552 -1.437 . . . . 0.0 109.495 -0.458 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.668 ' HA ' HG22 ' A' ' 110' ' ' ILE . 80.4 p -89.29 -26.18 21.28 Favored 'General case' 0 C--N 1.293 -1.882 0 O-C-N 121.467 -0.77 . . . . 0.0 108.993 179.625 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.539 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 4.3 p -133.47 165.91 23.77 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.474 -0.766 . . . . 0.0 109.419 -179.941 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.7 38.27 37.51 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 -179.505 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.772 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.8 mt -92.56 -43.24 9.24 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 123.203 1.478 . . . . 0.0 110.624 -178.167 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 70.54 143.31 0.05 Allowed 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.453 -1.703 . . . . 0.0 109.774 -179.54 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.625 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 7.4 p-10 -50.57 104.59 0.08 Allowed 'General case' 0 C--N 1.301 -1.516 0 CA-C-O 121.558 0.694 . . . . 0.0 111.772 -178.447 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.89 16.61 7.85 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 119.476 -1.345 . . . . 0.0 112.97 177.272 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.772 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -104.8 -171.23 1.88 Allowed 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 121.146 2.473 . . . . 0.0 109.693 179.11 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.845 HG22 HG22 ' A' ' 68' ' ' THR . 16.4 t -130.37 140.02 49.9 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.246 -178.845 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.559 HG12 HD21 ' A' ' 13' ' ' LEU . 35.1 m -117.25 155.33 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 178.933 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.555 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.1 tttt -106.73 108.97 20.75 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.047 -1.033 . . . . 0.0 109.414 -179.817 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.978 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.47 123.13 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.723 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.016 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.67 164.49 13.97 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 120.745 -1.222 . . . . 0.0 108.938 179.82 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.583 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.56 107.51 0.53 Allowed Glycine 0 C--N 1.297 -1.628 0 N-CA-C 108.595 -1.802 . . . . 0.0 108.595 179.8 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -115.72 142.67 46.44 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.978 -1.307 . . . . 0.0 110.445 -179.134 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.03 27.26 45.97 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.577 -1.297 . . . . 0.0 109.93 179.357 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.568 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.3 mt -90.84 174.24 7.56 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.069 -1.254 . . . . 0.0 108.574 179.974 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.0 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.42 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.966 -1.084 . . . . 0.0 109.517 -179.65 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.688 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.82 77.21 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.77 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.409 -178.97 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.553 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 132.7 34.66 0.34 Allowed Glycine 0 N--CA 1.487 2.066 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.407 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.0 p -145.0 112.54 6.2 Favored 'General case' 0 C--N 1.307 -1.272 0 O-C-N 121.031 -1.276 . . . . 0.0 111.083 -179.676 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.555 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -45.83 125.34 6.05 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-N 115.67 -0.695 . . . . 0.0 109.606 178.096 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.485 ' HA ' ' O ' ' A' ' 98' ' ' SER . 11.8 m-85 -118.13 149.87 40.31 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.325 -0.86 . . . . 0.0 108.697 179.692 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.511 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.27 158.35 15.93 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.614 -1.304 . . . . 0.0 107.742 178.635 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.722 HG13 ' O ' ' A' ' 34' ' ' VAL . 7.2 p -142.12 112.24 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.035 -1.041 . . . . 0.0 109.897 -177.798 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -160.57 -178.86 34.93 Favored Glycine 0 N--CA 1.494 2.538 0 C-N-CA 118.524 -1.798 . . . . 0.0 111.722 -179.62 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.635 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.1 pt20 -101.31 110.75 22.81 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.82 0.819 . . . . 0.0 108.922 -179.82 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -131.45 148.69 52.67 Favored 'General case' 0 C--N 1.295 -1.791 0 O-C-N 121.286 -0.884 . . . . 0.0 109.672 179.893 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.533 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -120.97 137.59 54.55 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.174 -0.954 . . . . 0.0 110.803 -178.936 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.866 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.73 114.57 26.32 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.096 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -104.78 14.11 7.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 120.979 -1.076 . . . . 0.0 110.65 -178.738 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.761 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.17 -174.53 0.07 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.942 -1.099 . . . . 0.0 110.081 179.725 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.8 p -72.73 98.66 2.43 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.504 -0.748 . . . . 0.0 109.622 -179.729 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.11 26.37 34.26 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.222 -0.99 . . . . 0.0 111.553 178.939 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.761 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.3 t -116.64 106.04 19.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 O-C-N 120.47 -1.606 . . . . 0.0 107.413 178.918 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.866 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.4 tp -118.98 104.47 10.53 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.517 -1.365 . . . . 0.0 109.681 -177.896 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.042 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.93 109.57 22.3 Favored 'General case' 0 N--CA 1.485 1.279 0 O-C-N 120.852 -1.155 . . . . 0.0 108.063 178.9 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -105.88 165.06 11.46 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.966 -1.084 . . . . 0.0 110.599 -178.699 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.677 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 50.2 t30 -113.18 130.87 23.19 Favored Pre-proline 0 N--CA 1.499 2.023 0 O-C-N 121.558 -0.714 . . . . 0.0 109.714 -179.3 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.8 Cg_endo -71.85 22.2 0.26 Allowed 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 122.188 1.926 . . . . 0.0 112.288 -179.986 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.677 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -108.65 2.02 21.67 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.39 -1.444 . . . . 0.0 108.929 179.393 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.544 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.05 14.43 2.85 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 179.475 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -78.13 91.28 4.3 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.908 -0.717 . . . . 0.0 110.974 -178.475 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.641 ' C ' HG12 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -114.09 -173.11 2.22 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 178.198 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.533 ' N ' ' OG ' ' A' ' 53' ' ' SER . 12.3 t 179.68 139.35 0.12 Allowed 'General case' 0 C--N 1.306 -1.285 0 O-C-N 120.534 -1.354 . . . . 0.0 111.303 -179.134 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.934 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -152.71 160.59 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 178.123 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.555 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.61 144.53 27.19 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.593 -1.317 . . . . 0.0 110.168 -179.387 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.0 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.7 107.2 1.36 Allowed 'General case' 0 C--N 1.301 -1.537 0 CA-C-O 122.44 1.114 . . . . 0.0 109.338 178.415 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.529 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 13.6 p-10 -58.53 -138.16 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.852 -179.8 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.688 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -54.58 -49.74 69.67 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.348 -0.845 . . . . 0.0 110.202 -178.771 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 60' ' ' ASN . . . . . 0.404 ' CG ' ' N ' ' A' ' 61' ' ' GLY . 9.9 p-10 -101.41 -38.97 7.78 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 178.454 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.991 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 111.74 65.74 0.51 Allowed Glycine 0 C--N 1.297 -1.587 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.211 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.583 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 21.0 m -105.42 124.03 48.87 Favored 'General case' 0 N--CA 1.483 1.214 0 O-C-N 121.686 -0.89 . . . . 0.0 108.734 179.005 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.934 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.52 109.35 9.2 Favored 'General case' 0 C--N 1.295 -1.788 0 C-N-CA 119.899 -0.72 . . . . 0.0 109.388 -179.395 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -116.5 118.28 32.23 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.178 -0.951 . . . . 0.0 109.273 -179.901 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.544 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -143.68 141.08 30.38 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.405 -0.809 . . . . 0.0 109.679 -179.907 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 21.3 p -99.36 130.75 45.66 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.441 -0.787 . . . . 0.0 109.277 179.9 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.762 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -128.18 165.56 20.2 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.332 -0.855 . . . . 0.0 109.376 -179.503 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.845 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -96.75 123.23 40.38 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.103 -0.998 . . . . 0.0 109.213 179.953 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.535 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -135.96 142.13 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.118 -0.989 . . . . 0.0 109.899 -179.232 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.625 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.2 ptt180 -137.6 -166.12 1.89 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.62 -1.3 . . . . 0.0 110.097 -179.946 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.583 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -73.92 -83.57 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.27 -0.894 . . . . 0.0 108.665 -179.686 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.501 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.54 138.68 58.53 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.343 -1.473 . . . . 0.0 107.185 178.631 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' O ' ' A' ' 71' ' ' ARG . 0.2 OUTLIER -164.04 137.05 5.19 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 117.879 -1.528 . . . . 0.0 110.459 -177.434 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.508 ' OE1' ' N ' ' A' ' 75' ' ' GLY . 0.6 OUTLIER -34.29 121.49 0.48 Allowed 'General case' 0 N--CA 1.491 1.595 0 CA-C-O 121.478 0.656 . . . . 0.0 110.302 -178.584 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.042 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.73 50.34 2.3 Favored Glycine 0 N--CA 1.494 2.544 0 C-N-CA 120.451 -0.881 . . . . 0.0 111.205 -179.223 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 4.1 m-30 -39.81 113.34 0.33 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.032 -1.275 . . . . 0.0 110.025 179.468 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.631 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -84.7 127.1 33.93 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.884 -1.135 . . . . 0.0 109.638 -179.845 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -63.54 58.33 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.004 0 O-C-N 120.874 -1.141 . . . . 0.0 110.405 179.611 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.5 t0 -161.54 19.78 0.11 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.008 -1.057 . . . . 0.0 109.807 179.849 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.22 -26.91 5.31 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 110.171 -1.172 . . . . 0.0 110.171 179.937 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 37.0 p -92.95 156.26 17.04 Favored 'General case' 0 N--CA 1.486 1.36 0 O-C-N 121.031 -1.276 . . . . 0.0 110.332 -179.489 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.471 ' O ' ' HD2' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -104.49 133.75 48.83 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.707 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.631 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -80.26 -18.71 48.6 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.823 -1.173 . . . . 0.0 110.41 -178.566 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.93 175.93 20.97 Favored Glycine 0 N--CA 1.485 1.93 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -179.589 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -62.43 109.59 1.41 Allowed 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 179.138 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.577 HG21 ' HB3' ' A' ' 46' ' ' ALA . 31.4 t -82.54 105.39 12.33 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.967 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.656 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -65.76 112.32 3.66 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.402 -0.811 . . . . 0.0 109.904 -179.215 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.557 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.97 -4.79 4.96 Favored 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 118.208 -1.397 . . . . 0.0 109.863 179.398 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 p -85.71 -0.08 54.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.774 -1.204 . . . . 0.0 109.0 179.348 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.656 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -113.03 -49.71 2.91 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.297 -0.877 . . . . 0.0 109.063 179.949 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.8 179.77 4.13 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.581 -0.7 . . . . 0.0 109.505 179.93 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.93 115.7 31.11 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.301 -0.874 . . . . 0.0 109.219 -180.0 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.547 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.92 123.7 40.7 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.87 -1.143 . . . . 0.0 109.358 -179.469 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.52 148.46 25.93 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-O 122.446 1.117 . . . . 0.0 111.457 -179.171 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.548 ' HB ' HG11 ' A' ' 7' ' ' VAL . 61.8 t -102.4 109.66 27.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 N-CA-C 106.282 -1.748 . . . . 0.0 106.282 177.249 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -144.11 -175.41 17.22 Favored Glycine 0 N--CA 1.483 1.831 0 C-N-CA 118.318 -1.896 . . . . 0.0 111.563 -177.395 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.537 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -117.22 -177.82 3.3 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 -178.853 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.508 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.1 p . . . . . 0 C--N 1.297 -1.687 0 O-C-N 121.235 -0.916 . . . . 0.0 109.143 -179.26 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.712 0 N-CA-C 107.699 -2.16 . . . . 0.0 107.699 . . . . . . . . . 0 0 . 1 . 058 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.59 -178.68 7.44 Favored 'General case' 0 C--N 1.308 -1.198 0 O-C-N 121.415 -1.05 . . . . 0.0 109.866 179.118 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -177.67 -166.52 34.43 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 108.194 -1.962 . . . . 0.0 108.194 -179.477 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.537 ' HB2' HD12 ' A' ' 97' ' ' LEU . 5.4 Cg_exo -48.42 179.26 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.659 0 CA-C-N 118.94 1.37 . . . . 0.0 110.148 179.483 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -91.85 -175.2 4.06 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.055 -1.028 . . . . 0.0 110.516 -178.717 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -122.05 161.7 16.1 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.848 . . . . . . . . 1 1 . 1 . 058 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.62 133.09 49.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.364 -1.08 . . . . 0.0 109.278 -179.242 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -76.04 122.09 23.73 Favored 'General case' 0 C--N 1.289 -2.054 0 O-C-N 121.485 -0.76 . . . . 0.0 109.716 179.703 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.91 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.99 174.0 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.924 . . . . 0.0 109.23 179.837 . . . . . . . . 2 2 . 1 . 058 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.539 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.6 OUTLIER -140.21 158.19 44.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.048 -1.032 . . . . 0.0 109.838 -179.778 . . . . . . . . 3 3 . 1 . 058 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.91 ' CE2' HD12 ' A' ' 110' ' ' ILE . 96.5 m-85 . . . . . 0 N--CA 1.485 1.282 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 -179.808 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.477 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.405 0 CA-C-O 122.173 0.987 . . . . 0.0 110.757 . . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 6' ' ' THR . . . . . 1.016 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.1 p -105.41 104.62 14.38 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 122.558 1.17 . . . . 0.0 109.911 179.983 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 1.012 HG22 HG23 ' A' ' 21' ' ' VAL . 14.5 t -118.97 126.34 75.27 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.407 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.535 179.875 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.478 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -170.57 149.37 2.99 Favored Pre-proline 0 N--CA 1.486 1.361 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 -179.642 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.478 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.64 153.23 99.05 Favored 'Cis proline' 0 C--N 1.31 -1.465 0 C-N-CA 123.678 -1.384 . . . . 0.0 109.894 -0.522 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.626 ' HA ' HG22 ' A' ' 110' ' ' ILE . 6.6 m -95.73 -22.6 17.43 Favored 'General case' 0 C--N 1.294 -1.846 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 179.564 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.459 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.9 m -135.59 162.85 31.55 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.491 -0.756 . . . . 0.0 109.496 179.921 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.11 37.6 37.23 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 108.503 -1.839 . . . . 0.0 108.503 -179.556 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.862 ' CA ' HG21 ' A' ' 17' ' ' THR . 27.3 mt -90.59 -45.47 8.89 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-O 123.116 1.436 . . . . 0.0 110.644 -178.373 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.463 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 63.82 147.24 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.325 0 CA-C-N 113.69 -1.596 . . . . 0.0 109.974 -179.699 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.616 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -51.48 109.33 0.34 Allowed 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 121.556 0.694 . . . . 0.0 111.721 -178.652 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.04 12.98 11.42 Favored Glycine 0 N--CA 1.485 1.966 0 C-N-CA 119.478 -1.344 . . . . 0.0 112.873 177.339 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.862 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.7 t -101.42 -174.35 2.58 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 121.057 2.428 . . . . 0.0 109.763 179.479 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.728 HG13 ' O ' ' A' ' 67' ' ' LEU . 14.8 t -131.28 138.48 53.14 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.38 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.813 -178.982 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.581 HG13 ' CG2' ' A' ' 69' ' ' VAL . 35.0 m -117.43 154.4 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.365 -0.835 . . . . 0.0 109.135 179.082 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.551 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -110.12 109.25 19.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.957 . . . . 0.0 109.149 179.881 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 1.012 HG23 HG22 ' A' ' 7' ' ' VAL . 2.4 p -107.39 124.6 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.964 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 1.016 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.08 165.08 13.0 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.845 -1.159 . . . . 0.0 108.858 179.489 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.615 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.39 107.5 0.53 Allowed Glycine 0 C--N 1.296 -1.692 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 179.971 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.41 141.09 48.63 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 120.743 -1.445 . . . . 0.0 110.796 -179.072 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.09 26.5 44.29 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.033 179.145 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.564 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.9 OUTLIER -90.35 172.29 8.85 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.028 -1.278 . . . . 0.0 108.575 -179.992 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.18 99.97 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.081 -1.012 . . . . 0.0 109.652 -179.685 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.566 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -57.0 76.96 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.118 -179.036 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.41 33.39 0.27 Allowed Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.517 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.553 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 54.1 p -141.14 109.47 5.88 Favored 'General case' 0 C--N 1.307 -1.25 0 O-C-N 121.015 -1.285 . . . . 0.0 111.152 -179.714 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.584 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.94 110.08 0.39 Allowed 'General case' 0 N--CA 1.496 1.858 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.909 178.314 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.463 ' OH ' ' HB2' ' A' ' 27' ' ' GLN . 18.6 m-85 -104.25 154.76 19.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.146 -0.971 . . . . 0.0 108.74 179.396 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.45 ' HA ' ' OG ' ' A' ' 54' ' ' SER . 0.3 OUTLIER -98.96 165.23 11.85 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 178.545 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.62 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.0 p -143.4 120.47 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.092 -1.005 . . . . 0.0 109.493 -177.807 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -168.75 179.91 41.32 Favored Glycine 0 N--CA 1.491 2.312 0 C-N-CA 118.264 -1.922 . . . . 0.0 111.614 -179.806 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.618 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -101.96 109.79 21.6 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.715 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 58.2 m -128.87 152.75 48.17 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.347 -0.846 . . . . 0.0 110.319 -179.828 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.52 136.36 51.63 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.64 -0.662 . . . . 0.0 110.126 179.65 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.901 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.4 114.73 26.81 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 178.369 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -106.6 15.3 7.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 120.964 -1.085 . . . . 0.0 110.762 -178.636 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.785 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.24 -175.63 0.08 Allowed 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.894 -1.129 . . . . 0.0 110.112 179.604 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.799 ' O ' HG23 ' A' ' 42' ' ' THR . 15.3 t -69.63 97.0 0.99 Allowed 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.741 0.781 . . . . 0.0 110.02 -179.404 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.8 28.46 34.95 Favored Glycine 0 N--CA 1.492 2.415 0 C-N-CA 120.225 -0.988 . . . . 0.0 111.38 178.694 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.785 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.09 106.09 19.9 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 O-C-N 120.531 -1.57 . . . . 0.0 107.432 178.836 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.901 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -116.31 106.66 13.9 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.541 -1.349 . . . . 0.0 109.941 -177.552 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 1.1 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -95.93 110.12 22.38 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 120.759 -1.213 . . . . 0.0 108.028 179.186 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 68.2 m -98.91 144.91 27.56 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.259 -0.901 . . . . 0.0 110.846 -178.132 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.513 ' ND2' ' HG2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.48 131.08 48.95 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.415 -0.803 . . . . 0.0 109.076 179.299 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.589 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 6.8 Cg_endo -75.68 31.02 0.38 Allowed 'Trans proline' 0 C--N 1.314 -1.266 0 C-N-CA 122.267 1.978 . . . . 0.0 111.323 179.898 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.465 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . -122.14 -1.69 9.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.42 -1.425 . . . . 0.0 110.299 -179.231 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.796 ' HB3' HD22 ' A' ' 67' ' ' LEU . 20.4 m-20 -137.55 10.31 2.93 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.039 -1.038 . . . . 0.0 109.115 -179.68 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -64.0 84.1 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.292 -179.108 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.62 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -110.82 -169.0 1.38 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.164 -0.96 . . . . 0.0 108.557 179.081 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.455 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.32 135.22 0.08 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.783 -1.198 . . . . 0.0 111.288 -179.348 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.877 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -147.48 159.29 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 177.915 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.584 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.29 142.96 29.29 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.707 -1.245 . . . . 0.0 110.246 -179.52 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.75 107.08 1.34 Allowed 'General case' 0 C--N 1.299 -1.593 0 CA-C-O 122.404 1.097 . . . . 0.0 109.367 178.323 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.5 t0 -60.59 -138.97 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.039 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.022 -179.889 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.566 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.72 -51.11 53.06 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.427 -0.796 . . . . 0.0 110.66 -178.552 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 11.9 t30 -104.19 -34.28 8.43 Favored 'General case' 0 C--N 1.286 -2.185 0 N-CA-C 106.182 -1.785 . . . . 0.0 106.182 178.472 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.976 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.72 67.93 0.61 Allowed Glycine 0 C--N 1.296 -1.647 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 178.182 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.8 m -104.67 124.48 49.44 Favored 'General case' 0 N--CA 1.483 1.194 0 O-C-N 121.612 -0.934 . . . . 0.0 108.739 179.004 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.877 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -132.88 109.21 9.45 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.906 -0.718 . . . . 0.0 109.223 -179.609 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 14.7 m -118.37 118.77 32.66 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.302 -0.874 . . . . 0.0 109.611 -179.621 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.56 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.86 140.29 28.27 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.505 -0.747 . . . . 0.0 109.684 179.805 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 66' ' ' SER . . . . . 0.434 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 19.2 p -98.83 136.05 39.4 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.466 -0.771 . . . . 0.0 109.079 179.758 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.84 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -133.35 173.79 11.09 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.339 -0.851 . . . . 0.0 109.687 -178.887 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.533 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -100.18 125.01 46.27 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.933 -1.105 . . . . 0.0 109.01 179.918 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.778 HG23 HD13 ' A' ' 13' ' ' LEU . 15.9 m -132.19 142.13 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 120.764 -1.21 . . . . 0.0 110.06 -178.986 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.616 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.9 ptt180 -147.71 -170.48 3.58 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 120.563 -1.336 . . . . 0.0 110.827 -179.945 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.624 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -67.22 -102.68 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.821 -0.549 . . . . 0.0 109.932 -179.329 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.552 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.08 134.98 56.92 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.359 -1.463 . . . . 0.0 108.152 179.714 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.618 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -153.78 156.92 38.6 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.584 -1.246 . . . . 0.0 110.298 -178.683 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.564 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 1.6 mm-40 -53.15 119.4 4.67 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.277 -0.889 . . . . 0.0 109.368 -178.736 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 1.1 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.39 54.04 3.5 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.311 -178.9 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.589 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.3 m-30 -40.35 115.92 0.61 Allowed 'General case' 0 N--CA 1.504 2.271 0 O-C-N 120.947 -1.325 . . . . 0.0 110.173 179.487 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.72 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -87.46 126.85 35.14 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 120.806 -1.184 . . . . 0.0 109.488 -179.834 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -64.18 58.38 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.972 0 O-C-N 120.837 -1.165 . . . . 0.0 110.132 179.702 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.4 t70 -160.37 19.66 0.15 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.028 -1.045 . . . . 0.0 109.717 179.772 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.75 -27.44 5.36 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 179.856 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 46.4 p -94.9 162.44 13.75 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 120.98 -1.306 . . . . 0.0 110.402 -179.46 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.481 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 2.2 ptm180 -108.14 138.0 45.15 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.921 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.72 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.9 t90 -83.4 -18.6 38.21 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.769 -1.207 . . . . 0.0 110.443 -178.656 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.99 175.05 19.79 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 108.766 -1.734 . . . . 0.0 108.766 -179.632 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.94 106.2 0.98 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.119 -1.224 . . . . 0.0 107.898 179.227 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.64 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.7 t -78.25 104.35 6.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.021 -179.041 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.655 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -62.99 107.9 1.1 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.55 -0.719 . . . . 0.0 110.164 -179.141 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.624 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.4 t -61.42 -4.26 1.23 Allowed 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.255 -1.378 . . . . 0.0 110.38 179.298 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.2 p -90.98 7.09 42.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.562 -1.336 . . . . 0.0 109.407 -179.933 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.655 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -119.35 -47.76 2.44 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.292 -0.88 . . . . 0.0 109.16 179.941 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.6 -178.4 3.64 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.562 -0.711 . . . . 0.0 109.589 179.988 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.81 111.99 24.58 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.381 -0.824 . . . . 0.0 108.856 179.859 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.494 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.5 m -97.22 121.06 38.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.036 -1.04 . . . . 0.0 109.445 -178.966 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.17 147.36 27.12 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.474 1.13 . . . . 0.0 111.646 -179.05 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.584 ' HB ' HG11 ' A' ' 7' ' ' VAL . 92.3 t -102.95 109.65 27.38 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 177.259 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.496 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.84 -169.45 17.37 Favored Glycine 0 N--CA 1.484 1.88 0 C-N-CA 118.073 -2.013 . . . . 0.0 111.628 -177.258 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.485 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -121.24 176.8 5.43 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -178.897 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.485 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 6.9 t . . . . . 0 C--N 1.292 -1.897 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 -179.963 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 102' ' ' GLY . . . . . 0.431 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.481 1.666 0 N-CA-C 107.992 -2.043 . . . . 0.0 107.992 . . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.54 -177.08 3.82 Favored 'General case' 0 C--N 1.307 -1.262 0 O-C-N 121.574 -0.957 . . . . 0.0 109.984 179.395 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.56 -161.41 21.1 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 108.068 -2.013 . . . . 0.0 108.068 -179.397 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.9 Cg_exo -45.77 172.63 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.632 0 CA-C-N 118.978 1.389 . . . . 0.0 109.933 179.194 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -92.9 -174.49 3.61 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.092 -1.005 . . . . 0.0 110.56 -178.772 . . . . . . . . 1 1 . 1 . 059 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.496 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.48 166.31 14.35 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.876 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.0 131.16 50.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.416 -1.049 . . . . 0.0 109.124 -179.428 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.61 123.77 24.63 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.594 -0.691 . . . . 0.0 109.519 179.713 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.916 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.84 171.74 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.232 -0.917 . . . . 0.0 109.183 179.901 . . . . . . . . 2 2 . 1 . 059 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.459 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -138.15 157.78 45.62 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.279 -0.888 . . . . 0.0 109.92 -179.712 . . . . . . . . 3 3 . 1 . 059 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.916 ' CE1' HD12 ' A' ' 110' ' ' ILE . 38.8 m-85 . . . . . 0 N--CA 1.487 1.376 0 O-C-N 121.273 -0.892 . . . . 0.0 109.543 -179.741 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.278 0 CA-C-O 122.454 1.121 . . . . 0.0 110.452 . . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.829 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.3 t -115.58 109.24 17.5 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.123 1.44 . . . . 0.0 109.72 -179.935 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.834 HG22 HG23 ' A' ' 21' ' ' VAL . 1.1 t -114.53 135.75 53.35 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.285 -1.325 . . . . 0.0 109.582 179.886 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.69 150.42 2.62 Favored Pre-proline 0 N--CA 1.487 1.407 0 O-C-N 121.151 -0.968 . . . . 0.0 108.95 -179.639 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.0 Cg_endo -78.63 150.2 86.86 Favored 'Cis proline' 0 C--N 1.313 -1.305 0 C-N-CA 123.392 -1.503 . . . . 0.0 109.341 -0.965 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 10' ' ' SER . . . . . 0.672 ' HA ' HG22 ' A' ' 110' ' ' ILE . 84.6 p -92.91 -22.65 19.11 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.552 -0.718 . . . . 0.0 109.306 179.894 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 11' ' ' SER . . . . . 0.495 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 4.3 m -130.91 159.64 36.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.345 -0.847 . . . . 0.0 109.644 -179.838 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.55 37.34 31.13 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 108.542 -1.823 . . . . 0.0 108.542 -179.676 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.8 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.6 mt -90.92 -44.29 9.46 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 123.14 1.447 . . . . 0.0 110.691 -178.479 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.26 144.41 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.249 0 CA-C-N 113.555 -1.657 . . . . 0.0 109.687 -179.538 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.607 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.4 p-10 -51.54 109.24 0.33 Allowed 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.495 0.664 . . . . 0.0 111.483 -178.612 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.43 10.85 12.56 Favored Glycine 0 N--CA 1.485 1.955 0 C-N-CA 119.391 -1.385 . . . . 0.0 112.83 177.374 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.8 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.9 t -101.97 -171.37 1.96 Allowed 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 121.051 2.425 . . . . 0.0 109.876 179.575 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.753 HG13 ' C ' ' A' ' 67' ' ' LEU . 19.1 t -131.19 142.41 43.53 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.76 -179.058 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.417 HG11 HD11 ' A' ' 13' ' ' LEU . 35.4 m -118.55 155.58 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.277 -0.889 . . . . 0.0 108.764 179.209 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.489 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 6.1 tttt -108.02 109.23 20.64 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.162 -0.961 . . . . 0.0 109.288 -179.984 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.834 HG23 HG22 ' A' ' 7' ' ' VAL . 10.4 p -101.36 138.92 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.71 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.829 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.68 161.24 36.11 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 118.698 -1.201 . . . . 0.0 110.127 179.689 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 23' ' ' GLY . . . . . 0.604 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.94 140.92 12.0 Favored Glycine 0 C--O 1.209 -1.444 0 N-CA-C 107.928 -2.069 . . . . 0.0 107.928 179.621 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -143.06 125.05 15.21 Favored 'General case' 0 N--CA 1.494 1.756 0 CA-C-N 119.266 1.533 . . . . 0.0 109.395 179.387 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.64 28.22 19.75 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 118.755 -1.688 . . . . 0.0 109.619 -179.728 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.55 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.6 mt -88.74 171.32 10.06 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.866 -1.373 . . . . 0.0 108.089 179.906 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 1.014 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.79 100.25 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.901 -1.124 . . . . 0.0 109.981 -179.424 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.58 77.21 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.946 -179.347 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.01 33.88 0.24 Allowed Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.717 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.557 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 36.3 p -141.26 107.47 5.23 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.082 -1.246 . . . . 0.0 111.311 -179.422 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 31' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.49 109.78 0.31 Allowed 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 177.93 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 32' ' ' TYR . . . . . 0.58 ' CG ' ' O ' ' A' ' 98' ' ' SER . 4.4 m-30 -101.24 156.1 17.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.168 -0.957 . . . . 0.0 109.009 179.83 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.499 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -99.98 163.71 12.32 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 178.503 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.752 HG22 HG11 ' A' ' 21' ' ' VAL . 2.4 p -147.77 117.85 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.891 -1.131 . . . . 0.0 110.05 -177.928 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.497 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -171.28 -175.91 40.04 Favored Glycine 0 N--CA 1.494 2.501 0 C-N-CA 118.346 -1.883 . . . . 0.0 111.724 -179.862 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.573 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -100.42 108.87 20.97 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.748 0.785 . . . . 0.0 108.946 -179.818 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.489 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.39 148.27 52.19 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.269 -0.894 . . . . 0.0 109.676 179.431 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.556 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.19 137.55 54.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.265 -0.897 . . . . 0.0 110.932 -178.839 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 39' ' ' TRP . . . . . 0.869 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.64 114.68 26.45 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.114 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.0 m -105.03 14.4 7.24 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 120.95 -1.094 . . . . 0.0 110.573 -178.715 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.76 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.03 -175.36 0.07 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.987 -1.071 . . . . 0.0 110.091 179.729 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.788 ' O ' HG23 ' A' ' 42' ' ' THR . 15.0 t -71.69 99.05 2.04 Favored 'General case' 0 N--CA 1.486 1.347 0 CA-C-O 121.829 0.823 . . . . 0.0 109.812 -179.641 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.77 26.57 37.71 Favored Glycine 0 N--CA 1.494 2.549 0 C-N-CA 120.179 -1.01 . . . . 0.0 111.46 178.957 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.76 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.4 t -116.16 106.25 19.98 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 O-C-N 120.576 -1.544 . . . . 0.0 107.356 178.891 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 45' ' ' LEU . . . . . 0.869 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.2 tp -117.93 104.34 10.82 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.471 -1.393 . . . . 0.0 109.73 -177.694 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.976 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.73 109.66 22.37 Favored 'General case' 0 N--CA 1.485 1.311 0 O-C-N 120.776 -1.203 . . . . 0.0 108.07 178.88 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -107.26 163.35 13.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.016 -1.053 . . . . 0.0 110.467 -178.705 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.528 HD22 ' HB3' ' A' ' 50' ' ' ALA . 17.0 t30 -111.29 136.77 20.91 Favored Pre-proline 0 N--CA 1.502 2.136 0 O-C-N 121.414 -0.803 . . . . 0.0 109.75 -179.463 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.7 Cg_endo -73.57 25.67 0.32 Allowed 'Trans proline' 0 C--N 1.319 -1.007 0 C-N-CA 122.463 2.109 . . . . 0.0 112.335 -179.63 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 50' ' ' ALA . . . . . 0.631 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -112.66 3.07 16.41 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.272 -1.518 . . . . 0.0 109.326 179.588 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 51' ' ' ASP . . . . . 0.534 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.45 18.97 2.22 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 179.592 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -79.94 92.06 5.5 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.867 -0.733 . . . . 0.0 110.866 -178.867 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 53' ' ' SER . . . . . 0.618 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -114.47 -168.85 1.43 Allowed 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 178.367 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.9 134.88 0.09 Allowed 'General case' 0 C--N 1.304 -1.372 0 O-C-N 120.597 -1.315 . . . . 0.0 111.214 -179.402 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.763 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 2.0 p -148.98 157.2 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.233 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.26 142.62 29.69 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.709 -1.244 . . . . 0.0 109.874 -179.85 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 1.014 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.36 108.15 1.86 Allowed 'General case' 0 C--N 1.299 -1.626 0 CA-C-O 122.337 1.065 . . . . 0.0 109.649 178.706 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.561 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.1 t0 -63.84 -138.8 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.003 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.816 179.888 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.81 -52.04 45.07 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.361 -0.837 . . . . 0.0 110.697 -178.677 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -101.74 -33.6 9.78 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 178.517 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 104.51 65.92 0.69 Allowed Glycine 0 C--N 1.298 -1.532 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 178.221 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 55.9 p -98.53 132.41 43.98 Favored 'General case' 0 N--CA 1.482 1.153 0 O-C-N 121.489 -1.007 . . . . 0.0 109.177 179.074 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.763 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.63 108.57 6.33 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 119.255 -0.978 . . . . 0.0 109.567 -179.658 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 6.0 m -127.11 120.32 28.6 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.272 -0.892 . . . . 0.0 109.681 -179.878 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.535 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.09 142.72 28.81 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.55 -0.719 . . . . 0.0 109.277 179.794 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.9 p -98.81 131.69 44.74 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.287 -0.883 . . . . 0.0 109.212 179.985 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.753 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -135.6 169.4 17.59 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.288 -0.882 . . . . 0.0 109.569 -179.349 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 68' ' ' THR . . . . . 0.631 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 11.3 t -95.29 137.74 33.93 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.091 -1.006 . . . . 0.0 110.559 -179.425 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.573 HG12 ' HB3' ' A' ' 36' ' ' GLN . 18.3 m -148.24 143.55 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.381 -0.824 . . . . 0.0 109.536 -179.891 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.607 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.0 OUTLIER -149.95 -174.65 4.77 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.497 -1.377 . . . . 0.0 110.807 -179.863 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 71' ' ' ARG . . . . . 0.62 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.86 -102.06 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.414 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.637 -179.458 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.5 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -56.49 141.89 40.97 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.831 -1.168 . . . . 0.0 108.577 179.814 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -163.34 137.26 5.91 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 118.836 -1.146 . . . . 0.0 109.633 -178.402 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.52 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 17.4 mm-40 -33.56 122.1 0.42 Allowed 'General case' 0 N--CA 1.49 1.571 0 CA-C-O 121.559 0.695 . . . . 0.0 110.78 -178.12 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.976 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.32 46.91 2.83 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.321 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.1 m-85 -39.64 112.02 0.23 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.073 -1.251 . . . . 0.0 109.856 179.568 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.696 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -85.46 126.44 33.82 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.895 -1.128 . . . . 0.0 109.37 -179.927 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 37.5 t80 -63.89 58.39 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.933 -1.104 . . . . 0.0 110.168 179.833 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 4.9 t70 -160.38 19.3 0.14 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.037 -1.039 . . . . 0.0 109.709 179.913 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.51 -26.5 5.74 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 179.808 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 60.5 p -94.06 158.63 15.53 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.033 -1.275 . . . . 0.0 110.418 -179.346 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.477 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -105.08 133.43 49.87 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.698 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 83' ' ' TRP . . . . . 0.696 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.9 t90 -81.43 -18.9 43.76 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.883 -1.135 . . . . 0.0 110.37 -178.573 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.34 174.83 19.57 Favored Glycine 0 N--CA 1.485 1.962 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.653 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.1 105.96 0.97 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.112 -1.228 . . . . 0.0 107.72 179.085 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.644 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.6 t -76.95 105.99 6.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.306 -0.871 . . . . 0.0 109.27 -178.824 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 87' ' ' ASP . . . . . 0.539 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.4 111.14 3.39 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.359 -0.838 . . . . 0.0 109.821 -179.524 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 88' ' ' CYS . . . . . 0.62 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -62.74 -6.09 3.34 Favored 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 118.225 -1.39 . . . . 0.0 109.875 179.42 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -86.13 -1.26 57.24 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.716 -1.24 . . . . 0.0 109.163 179.63 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.539 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.47 -49.6 2.99 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.338 -0.851 . . . . 0.0 109.005 179.905 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.27 179.15 4.34 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.415 -0.803 . . . . 0.0 109.438 179.924 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.54 116.22 32.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.322 -0.861 . . . . 0.0 108.952 179.928 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 93' ' ' CYS . . . . . 0.564 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.72 124.7 40.78 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.815 -1.178 . . . . 0.0 109.535 -179.478 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 94' ' ' GLN . . . . . 0.594 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -105.15 147.87 27.49 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 122.515 1.15 . . . . 0.0 111.451 -179.152 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.595 ' CG1' HG11 ' A' ' 7' ' ' VAL . 57.6 t -104.49 110.55 30.93 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.04 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 177.43 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.408 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.47 -171.29 17.18 Favored Glycine 0 N--CA 1.488 2.157 0 C-N-CA 118.123 -1.989 . . . . 0.0 111.89 -177.562 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.499 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.77 -179.62 3.74 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.023 . . . . . . . . 3 3 . 1 . 060 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.58 ' O ' ' CG ' ' A' ' 32' ' ' TYR . 1.5 p . . . . . 0 C--N 1.296 -1.729 0 O-C-N 121.367 -0.833 . . . . 0.0 109.715 -179.524 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.783 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 . . . . . . . . . 0 0 . 1 . 060 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -153.88 -179.62 8.01 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.466 -1.02 . . . . 0.0 109.345 178.8 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -172.45 -166.28 30.79 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 108.631 -1.788 . . . . 0.0 108.631 -179.44 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 105' ' ' PRO . . . . . 0.517 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.0 Cg_exo -49.93 -175.64 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.668 0 CA-C-N 118.759 1.279 . . . . 0.0 110.32 179.603 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 -94.43 -179.27 4.85 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.059 -1.026 . . . . 0.0 110.506 -178.843 . . . . . . . . 1 1 . 1 . 060 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.408 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.95 162.64 14.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.992 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.17 128.42 53.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.334 -1.098 . . . . 0.0 109.165 -179.389 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 109' ' ' ALA . . . . . 0.594 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.71 124.02 26.56 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.59 -0.694 . . . . 0.0 109.552 179.669 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 110' ' ' ILE . . . . . 0.758 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.75 167.79 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.21 -0.931 . . . . 0.0 109.234 -179.913 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.495 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 15.2 m -137.0 156.33 48.58 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.276 -0.89 . . . . 0.0 109.481 -179.931 . . . . . . . . 2 2 . 1 . 060 nuclear build core ' A' A ' 112' ' ' PHE . . . . . 0.758 ' CE1' HD12 ' A' ' 110' ' ' ILE . 17.5 m-85 . . . . . 0 N--CA 1.486 1.347 0 O-C-N 121.204 -0.935 . . . . 0.0 109.523 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.543 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -87.18 160.16 49.43 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.255 -0.903 . . . . 0.0 109.417 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.567 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.2 Cg_exo -60.01 157.88 32.16 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.335 2.024 . . . . 0.0 110.585 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.542 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.62 -169.77 0.15 Allowed 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.204 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.542 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.61 130.39 2.4 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 120.859 -1.15 . . . . 0.0 110.683 -179.165 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.948 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -111.21 108.54 18.23 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-O 123.11 1.433 . . . . 0.0 109.167 179.379 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.842 HG22 HG23 ' A' ' 21' ' ' VAL . 2.7 t -115.39 140.33 37.4 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.681 0 CA-C-N 114.255 -1.339 . . . . 0.0 110.08 -179.668 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.495 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -175.72 149.78 1.09 Allowed Pre-proline 0 N--CA 1.487 1.422 0 O-C-N 121.305 -0.872 . . . . 0.0 108.728 -179.656 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.495 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -75.66 152.33 97.04 Favored 'Cis proline' 0 C--N 1.311 -1.408 0 C-N-CA 123.422 -1.491 . . . . 0.0 109.371 -0.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.647 ' HA ' HG22 ' A' ' 110' ' ' ILE . 10.9 m -90.69 -24.64 20.39 Favored 'General case' 0 C--N 1.293 -1.887 0 O-C-N 121.605 -0.684 . . . . 0.0 109.191 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.516 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.4 m -137.16 165.32 26.36 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.44 -0.788 . . . . 0.0 109.59 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.5 38.62 32.46 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.801 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.6 mt -92.79 -43.95 8.76 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 123.152 1.453 . . . . 0.0 110.736 -178.2 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.467 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.05 145.47 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.274 0 CA-C-N 113.597 -1.638 . . . . 0.0 110.156 -179.912 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.6 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 14.2 p-10 -51.16 106.84 0.15 Allowed 'General case' 0 C--N 1.301 -1.517 0 CA-C-O 121.461 0.648 . . . . 0.0 111.526 -178.692 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.79 14.76 9.15 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.43 -1.367 . . . . 0.0 112.969 177.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.801 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.4 t -104.24 -171.94 2.02 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 121.075 2.437 . . . . 0.0 109.544 179.152 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.727 HG13 ' C ' ' A' ' 67' ' ' LEU . 16.2 t -128.59 136.05 60.89 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.392 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.116 -179.065 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.587 HG13 ' CG2' ' A' ' 69' ' ' VAL . 20.6 m -111.52 155.55 12.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 11.1 tttt -112.31 109.31 18.88 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.192 -0.942 . . . . 0.0 108.954 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.842 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.63 140.51 21.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.948 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.54 160.22 39.15 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.842 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.18 144.56 15.82 Favored Glycine 0 C--N 1.294 -1.783 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.567 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.51 125.11 12.47 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 120.891 -1.358 . . . . 0.0 108.844 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.529 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.89 26.64 26.15 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.28 -1.438 . . . . 0.0 109.864 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.549 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -87.79 174.89 8.11 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 120.885 -1.362 . . . . 0.0 108.596 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.79 99.58 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.4 0 O-C-N 120.987 -1.071 . . . . 0.0 109.766 -179.696 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.2 78.01 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.124 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.98 34.23 0.3 Allowed Glycine 0 N--CA 1.487 2.098 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.5 p -141.29 107.5 5.23 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 121.111 -1.229 . . . . 0.0 111.249 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.72 109.96 0.33 Allowed 'General case' 0 N--CA 1.498 1.938 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.638 178.076 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.575 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 4.6 m-30 -106.25 154.04 21.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.126 -0.984 . . . . 0.0 108.837 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.484 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.86 162.75 12.93 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.863 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.722 HG22 HG11 ' A' ' 21' ' ' VAL . 3.5 p -142.63 116.5 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.048 -1.032 . . . . 0.0 109.628 -178.161 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.69 -175.79 37.19 Favored Glycine 0 N--CA 1.494 2.501 0 C-N-CA 118.353 -1.879 . . . . 0.0 111.67 -179.655 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.615 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -100.73 109.65 21.69 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-O 121.899 0.857 . . . . 0.0 109.038 -179.597 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.486 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -129.94 149.88 51.47 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.275 -0.891 . . . . 0.0 109.634 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.517 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -125.33 139.21 53.89 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.166 -0.959 . . . . 0.0 110.796 -178.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.89 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 114.95 26.79 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.038 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.0 m -105.13 15.03 6.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 120.906 -1.121 . . . . 0.0 110.584 -178.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.76 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.78 -175.06 0.08 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.904 -1.123 . . . . 0.0 110.0 179.79 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.03 97.59 1.92 Allowed 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.465 -0.772 . . . . 0.0 109.687 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.65 27.89 33.97 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 120.258 -0.972 . . . . 0.0 111.392 178.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.76 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.38 106.41 20.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 O-C-N 120.576 -1.543 . . . . 0.0 107.313 178.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.89 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -115.86 104.68 11.87 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 120.486 -1.384 . . . . 0.0 109.896 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.959 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.18 109.47 22.22 Favored 'General case' 0 N--CA 1.484 1.238 0 O-C-N 120.81 -1.182 . . . . 0.0 107.917 178.737 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.63 166.57 10.58 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.914 -1.116 . . . . 0.0 110.484 -178.793 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.747 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 47.6 t30 -112.06 129.77 23.93 Favored Pre-proline 0 N--CA 1.501 2.1 0 O-C-N 121.488 -0.758 . . . . 0.0 109.583 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.612 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.56 21.05 0.25 Allowed 'Trans proline' 0 C--N 1.319 -1.024 0 C-N-CA 122.132 1.888 . . . . 0.0 112.268 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.747 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -109.55 3.49 21.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.334 -1.479 . . . . 0.0 108.977 179.336 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.539 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.34 17.23 2.76 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 179.382 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -80.6 87.77 5.74 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.987 -0.685 . . . . 0.0 111.143 -178.458 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -104.2 -165.82 1.19 Allowed 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 178.159 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.446 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.89 137.13 0.09 Allowed 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.532 -1.355 . . . . 0.0 111.382 -179.306 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.931 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -155.5 157.09 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 178.21 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.63 142.34 30.33 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.746 -1.222 . . . . 0.0 109.911 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.34 106.83 0.96 Allowed 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 122.476 1.131 . . . . 0.0 109.406 178.481 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.544 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.6 p-10 -60.4 -139.56 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.893 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.16 -50.9 58.04 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.4 -0.813 . . . . 0.0 110.666 -178.638 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -103.55 -33.15 9.12 Favored 'General case' 0 C--N 1.287 -2.137 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 178.535 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.016 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.66 65.34 0.6 Allowed Glycine 0 C--N 1.298 -1.556 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.574 178.084 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.6 m -102.05 128.37 48.53 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 121.481 -1.011 . . . . 0.0 108.635 178.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.931 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.7 108.84 6.79 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.798 -179.244 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 3.8 m -121.54 119.02 30.73 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.18 -0.95 . . . . 0.0 109.428 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.595 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.87 145.13 31.46 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.484 -0.76 . . . . 0.0 109.446 179.875 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 18.4 p -98.99 146.77 25.69 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.413 -0.804 . . . . 0.0 109.632 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.727 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -146.65 166.74 25.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.451 -0.78 . . . . 0.0 109.285 -179.431 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.664 HG22 HG22 ' A' ' 18' ' ' VAL . 4.1 p -95.24 124.87 39.5 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.075 -1.015 . . . . 0.0 109.637 -179.584 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.587 ' CG2' HG13 ' A' ' 19' ' ' VAL . 17.3 m -137.7 142.64 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.948 -1.095 . . . . 0.0 109.834 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.6 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.4 ptt180 -141.37 -165.49 1.98 Allowed 'General case' 0 N--CA 1.487 1.411 0 O-C-N 120.617 -1.302 . . . . 0.0 110.312 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.593 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 2.7 mtt180 -71.66 -78.02 0.09 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.34 -0.85 . . . . 0.0 109.096 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -69.05 137.35 53.51 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 120.21 -1.556 . . . . 0.0 107.437 179.082 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.564 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -160.78 132.8 5.93 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 117.996 -1.482 . . . . 0.0 110.167 -178.098 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.494 ' C ' ' O ' ' A' ' 73' ' ' PHE . 9.2 mp0 -30.1 121.92 0.18 Allowed 'General case' 0 N--CA 1.492 1.675 0 CA-C-O 121.627 0.727 . . . . 0.0 110.88 -178.237 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.959 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.02 45.09 3.16 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.612 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.4 m-30 -38.99 113.55 0.32 Allowed 'General case' 0 N--CA 1.508 2.461 0 O-C-N 121.123 -1.221 . . . . 0.0 110.268 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.716 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.57 127.45 35.26 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.035 -1.041 . . . . 0.0 109.487 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.587 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.0 t80 -64.48 58.1 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.861 -1.15 . . . . 0.0 110.118 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 77' ' ' LEU . 27.6 t0 -160.02 18.95 0.16 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.041 -1.037 . . . . 0.0 109.814 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.39 -26.42 5.71 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.56 158.6 15.62 Favored 'General case' 0 N--CA 1.485 1.307 0 O-C-N 120.959 -1.318 . . . . 0.0 110.435 -179.438 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.482 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -105.36 133.63 49.81 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 179.711 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.716 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.5 t90 -80.98 -19.52 43.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.797 -1.189 . . . . 0.0 110.281 -178.717 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.7 174.08 18.68 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.85 110.65 1.83 Allowed 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.666 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.2 t -82.06 103.56 9.41 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.389 -0.819 . . . . 0.0 108.846 -178.936 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.647 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -67.12 111.28 3.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.439 -0.788 . . . . 0.0 109.816 -179.174 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.553 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -63.0 -6.07 3.56 Favored 'General case' 0 N--CA 1.5 2.033 0 C-N-CA 118.361 -1.336 . . . . 0.0 109.824 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 41.4 p -84.64 -0.34 53.04 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.648 -1.282 . . . . 0.0 108.897 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.647 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -113.9 -49.7 2.86 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.338 -0.851 . . . . 0.0 109.025 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.91 -178.64 3.71 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.484 -0.76 . . . . 0.0 109.62 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.36 115.44 30.26 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.469 -0.769 . . . . 0.0 108.981 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.557 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.05 123.03 40.68 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.861 -1.15 . . . . 0.0 109.774 -179.249 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.624 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.57 146.87 27.91 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-O 122.378 1.085 . . . . 0.0 111.139 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.475 ' HB ' HG11 ' A' ' 7' ' ' VAL . 56.2 t -102.07 110.03 27.75 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.013 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 177.497 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.465 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.79 -170.31 16.42 Favored Glycine 0 N--CA 1.487 2.077 0 C-N-CA 118.246 -1.931 . . . . 0.0 111.631 -177.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.484 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -122.66 176.99 5.64 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.871 -0.782 . . . . 0.0 109.162 -178.854 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.553 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.5 m -176.12 176.43 1.73 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.687 -0.633 . . . . 0.0 109.386 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.575 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -123.35 -157.21 0.74 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.963 -1.086 . . . . 0.0 109.045 -179.949 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.446 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.35 35.94 4.46 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.726 -1.234 . . . . 0.0 109.249 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.07 -32.67 6.71 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.402 -0.811 . . . . 0.0 109.817 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.804 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.02 -36.03 0.27 Allowed Glycine 0 N--CA 1.482 1.722 0 N-CA-C 107.814 -2.114 . . . . 0.0 107.814 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.404 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.53 -177.17 3.86 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 122.069 0.938 . . . . 0.0 109.737 179.385 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.62 -161.44 17.14 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 108.297 -1.921 . . . . 0.0 108.297 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.497 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.4 Cg_exo -46.88 177.17 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.684 0 CA-C-N 118.794 1.297 . . . . 0.0 110.161 179.28 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -94.15 -168.92 1.95 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.054 -1.029 . . . . 0.0 110.284 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.465 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.24 162.8 18.25 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.69 129.54 48.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.457 -1.025 . . . . 0.0 109.205 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.624 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.78 122.39 21.45 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 121.74 -0.6 . . . . 0.0 109.86 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.821 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.92 170.45 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.268 -0.895 . . . . 0.0 109.191 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.516 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.23 155.07 51.27 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.211 -0.931 . . . . 0.0 109.636 -179.908 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.821 ' CE2' HD12 ' A' ' 110' ' ' ILE . 66.1 m-85 -131.31 108.2 9.49 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.224 -0.923 . . . . 0.0 109.457 -179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.415 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 13.7 p30 . . . . . 0 N--CA 1.489 1.515 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.577 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.804 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.702 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -112.05 164.83 14.24 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.195 -0.94 . . . . 0.0 109.465 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.702 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 4.9 Cg_exo -60.08 158.11 31.49 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.276 1.984 . . . . 0.0 110.534 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.532 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.46 -169.78 0.15 Allowed 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.256 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.532 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.97 130.63 2.29 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.769 -1.207 . . . . 0.0 110.758 -179.157 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.955 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -110.6 108.57 18.54 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 123.05 1.405 . . . . 0.0 109.073 179.275 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.826 HG22 HG23 ' A' ' 21' ' ' VAL . 2.2 t -117.02 140.42 39.76 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.713 0 CA-C-N 114.295 -1.32 . . . . 0.0 110.049 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.446 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -177.7 149.84 0.76 Allowed Pre-proline 0 N--CA 1.486 1.34 0 O-C-N 121.285 -0.884 . . . . 0.0 108.78 -179.757 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.446 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.86 150.39 86.5 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 123.551 -1.437 . . . . 0.0 109.239 -0.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 14.2 p -89.65 -25.74 21.1 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.473 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 8.1 m -132.75 163.22 29.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.427 -0.796 . . . . 0.0 109.527 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.16 37.72 31.6 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 -179.576 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.815 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.5 mt -92.95 -44.01 8.65 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.193 1.473 . . . . 0.0 110.695 -178.351 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.93 144.99 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.299 0 CA-C-N 113.515 -1.675 . . . . 0.0 109.919 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.602 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.7 p-10 -51.17 108.77 0.27 Allowed 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.433 0.635 . . . . 0.0 111.533 -178.58 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.84 13.38 11.28 Favored Glycine 0 N--CA 1.483 1.796 0 C-N-CA 119.45 -1.357 . . . . 0.0 112.875 177.335 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.815 HG21 ' CA ' ' A' ' 13' ' ' LEU . 11.1 t -103.12 -173.1 2.23 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 120.988 2.394 . . . . 0.0 109.571 179.333 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.751 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.7 t -127.2 135.11 64.42 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.968 -178.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.532 ' CG1' HD13 ' A' ' 13' ' ' LEU . 31.3 m -110.38 155.28 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 13.3 tttt -112.41 109.38 18.96 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.169 -0.957 . . . . 0.0 109.045 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.826 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -104.92 141.44 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.955 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.8 160.32 39.57 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.863 179.707 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.592 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.23 144.87 16.14 Favored Glycine 0 C--N 1.294 -1.775 0 N-CA-C 108.211 -1.956 . . . . 0.0 108.211 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.56 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.55 125.14 12.47 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.025 -1.28 . . . . 0.0 108.793 179.08 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.528 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.91 26.95 25.23 Favored Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.28 -1.438 . . . . 0.0 109.759 -179.699 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.551 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.2 mt -86.74 175.31 8.31 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.862 -1.375 . . . . 0.0 108.529 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.09 98.04 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.914 -1.116 . . . . 0.0 109.598 -179.637 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.632 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.82 77.31 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.735 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.376 -179.099 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.43 34.29 0.32 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 179.384 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.558 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.2 p -146.08 112.22 5.75 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.916 -1.344 . . . . 0.0 111.202 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.85 126.85 6.03 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.823 178.223 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.493 ' CD2' ' O ' ' A' ' 30' ' ' THR . 13.8 m-85 -119.35 152.13 37.3 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -100.49 162.67 12.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.635 -1.291 . . . . 0.0 107.727 178.667 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.947 HG11 HG21 ' A' ' 65' ' ' THR . 5.7 p -147.1 117.02 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.002 -1.061 . . . . 0.0 110.031 -177.805 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -170.61 -176.46 40.0 Favored Glycine 0 N--CA 1.493 2.439 0 C-N-CA 118.323 -1.894 . . . . 0.0 111.714 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.586 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -99.79 108.92 21.34 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -179.801 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -131.01 148.91 52.81 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.22 -0.925 . . . . 0.0 109.777 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.415 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.79 139.38 54.04 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.31 -0.869 . . . . 0.0 110.768 -179.014 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.889 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.28 114.7 26.51 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 178.133 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.2 m -104.37 15.06 6.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.051 -1.03 . . . . 0.0 110.523 -178.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.767 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 173.98 -175.89 0.07 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.979 -1.075 . . . . 0.0 110.076 179.706 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.789 ' O ' HG23 ' A' ' 42' ' ' THR . 14.9 t -71.95 98.87 2.12 Favored 'General case' 0 N--CA 1.487 1.38 0 CA-C-O 121.77 0.795 . . . . 0.0 109.648 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.69 27.34 35.46 Favored Glycine 0 N--CA 1.493 2.475 0 C-N-CA 120.139 -1.029 . . . . 0.0 111.422 178.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.767 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.95 106.39 20.11 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 O-C-N 120.6 -1.53 . . . . 0.0 107.197 178.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.889 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -117.64 104.57 11.15 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.426 -1.421 . . . . 0.0 109.851 -177.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.988 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.2 109.58 22.31 Favored 'General case' 0 N--CA 1.484 1.25 0 O-C-N 120.812 -1.18 . . . . 0.0 108.165 178.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -106.38 166.43 10.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.966 -1.084 . . . . 0.0 110.122 -178.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.697 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 14.3 t-20 -108.56 137.98 20.13 Favored Pre-proline 0 N--CA 1.501 2.09 0 O-C-N 121.326 -0.859 . . . . 0.0 110.04 -179.267 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.7 Cg_endo -75.38 24.29 0.41 Allowed 'Trans proline' 0 C--N 1.317 -1.08 0 C-N-CA 122.36 2.04 . . . . 0.0 111.884 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.697 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -118.01 3.66 12.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.355 -1.466 . . . . 0.0 109.298 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.567 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.05 17.57 2.63 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 179.328 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -82.4 90.85 6.74 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.789 -0.765 . . . . 0.0 110.834 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.616 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -111.65 -169.24 1.43 Allowed 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 178.319 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.1 135.34 0.09 Allowed 'General case' 0 N--CA 1.486 1.353 0 O-C-N 120.584 -1.322 . . . . 0.0 111.325 -179.301 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.855 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.1 p -150.62 158.49 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 178.172 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.77 145.38 26.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.804 -1.185 . . . . 0.0 109.848 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.77 108.05 1.99 Allowed 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 122.359 1.076 . . . . 0.0 109.61 178.702 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.3 p-10 -60.73 -139.46 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.802 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.632 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.22 -50.13 62.59 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.43 -0.793 . . . . 0.0 110.432 -178.849 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 37.9 t30 -103.13 -35.18 8.59 Favored 'General case' 0 C--N 1.287 -2.141 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.05 65.91 0.6 Allowed Glycine 0 C--N 1.296 -1.64 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 178.3 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.592 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.5 m -102.04 128.86 48.3 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 121.475 -1.015 . . . . 0.0 108.899 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.855 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.07 108.76 6.62 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.933 -179.445 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -121.15 119.16 31.58 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.177 -0.952 . . . . 0.0 109.537 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.947 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -143.08 143.27 31.79 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.496 -0.753 . . . . 0.0 109.602 179.827 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.8 p -99.74 145.36 27.75 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.45 -0.781 . . . . 0.0 109.284 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.818 HD12 ' H ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -146.71 170.33 17.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.372 -0.83 . . . . 0.0 109.421 -179.286 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.662 HG22 HG22 ' A' ' 18' ' ' VAL . 1.9 p -99.16 125.71 44.78 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.023 -1.048 . . . . 0.0 109.532 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.562 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -137.47 143.82 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.917 -1.114 . . . . 0.0 109.768 -179.373 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.602 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.1 ptt180 -148.64 -172.04 4.0 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.434 -1.416 . . . . 0.0 110.944 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.613 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -55.8 -101.66 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 -179.358 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.508 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.58 140.52 46.35 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 120.778 -1.201 . . . . 0.0 108.215 179.587 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -162.38 136.23 6.36 Favored 'General case' 0 C--N 1.293 -1.874 0 C-N-CA 118.772 -1.171 . . . . 0.0 109.926 -178.184 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.545 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.5 mm-40 -32.09 121.02 0.3 Allowed 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.479 0.657 . . . . 0.0 110.736 -178.399 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.988 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.15 47.86 2.92 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.169 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.37 113.03 0.29 Allowed 'General case' 0 N--CA 1.506 2.365 0 O-C-N 121.076 -1.249 . . . . 0.0 110.118 179.572 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.741 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -85.14 127.02 34.09 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.959 -1.088 . . . . 0.0 109.503 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 43.1 t80 -63.57 58.36 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.905 -1.122 . . . . 0.0 110.297 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 16.7 t0 -161.53 19.74 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.995 -1.066 . . . . 0.0 109.791 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.18 -26.72 5.4 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.129 -1.189 . . . . 0.0 110.129 179.858 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.83 159.87 15.19 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.028 -1.278 . . . . 0.0 110.32 -179.368 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.485 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.49 134.58 49.41 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.888 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.741 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.9 t90 -82.86 -19.27 37.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.773 -1.204 . . . . 0.0 110.393 -178.637 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.43 173.91 18.76 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -64.11 107.29 1.24 Allowed 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.634 HG21 ' HB3' ' A' ' 46' ' ' ALA . 47.5 t -78.28 105.3 7.21 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 O-C-N 121.354 -0.841 . . . . 0.0 109.304 -178.843 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.549 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -65.15 110.82 2.67 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.487 -0.758 . . . . 0.0 109.777 -179.657 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.613 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.2 t -62.52 -6.36 3.35 Favored 'General case' 0 N--CA 1.499 2.001 0 C-N-CA 118.164 -1.415 . . . . 0.0 109.788 179.462 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.6 p -85.83 -3.17 58.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.726 -1.234 . . . . 0.0 109.272 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.549 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -109.62 -50.2 3.01 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.295 -0.878 . . . . 0.0 108.976 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.91 -179.46 3.95 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.491 -0.755 . . . . 0.0 109.374 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.2 115.98 31.17 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.363 -0.836 . . . . 0.0 108.83 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.505 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.6 123.52 40.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.815 -1.178 . . . . 0.0 109.639 -179.227 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.599 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.85 146.08 29.5 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 122.382 1.087 . . . . 0.0 111.042 -179.483 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 78.4 t -102.49 109.94 27.85 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.081 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 177.651 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.486 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.97 -171.52 17.79 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 118.171 -1.966 . . . . 0.0 111.812 -177.534 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.499 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -114.55 -178.39 3.36 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -179.048 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.587 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.9 OUTLIER -173.36 168.1 4.65 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.343 -0.848 . . . . 0.0 109.605 -179.26 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.424 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -117.36 -159.04 0.72 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.043 -1.036 . . . . 0.0 108.916 179.685 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.424 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.05 36.05 4.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.638 -1.289 . . . . 0.0 109.287 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -116.06 -32.87 5.24 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.34 -0.85 . . . . 0.0 110.195 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.965 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 162.88 -34.42 0.32 Allowed Glycine 0 N--CA 1.482 1.718 0 N-CA-C 107.628 -2.189 . . . . 0.0 107.628 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.29 -178.48 7.31 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 121.627 -0.925 . . . . 0.0 109.682 179.238 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.84 -161.73 16.7 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 108.395 -1.882 . . . . 0.0 108.395 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.49 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.5 Cg_exo -46.93 178.3 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.634 0 CA-C-N 118.822 1.311 . . . . 0.0 110.375 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -92.69 -179.27 5.11 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.204 -0.935 . . . . 0.0 110.455 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.486 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.42 165.5 12.52 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.86 128.2 55.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.442 -1.034 . . . . 0.0 109.159 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.599 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.64 123.16 22.68 Favored 'General case' 0 C--N 1.289 -2.043 0 O-C-N 121.632 -0.667 . . . . 0.0 109.383 179.592 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.858 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.69 170.85 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.214 -0.929 . . . . 0.0 109.197 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.473 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.71 153.79 49.73 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.214 -0.929 . . . . 0.0 109.609 -179.847 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.858 ' CE2' HD12 ' A' ' 110' ' ' ILE . 75.9 m-85 -130.9 100.9 5.41 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.162 -0.961 . . . . 0.0 109.494 -179.709 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.3 p30 . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.466 -179.983 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.965 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.402 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -121.63 155.59 59.57 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.302 -0.874 . . . . 0.0 109.501 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.914 ' HB3' HD23 ' A' ' 26' ' ' LEU . 3.0 Cg_exo -61.24 155.65 50.23 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.212 1.941 . . . . 0.0 110.52 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.617 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -139.57 161.62 37.05 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -179.994 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.507 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.07 128.81 15.23 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 118.796 -1.162 . . . . 0.0 110.84 -179.664 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.008 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.2 p -105.65 104.86 14.67 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.427 1.108 . . . . 0.0 110.287 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.951 HG22 HG23 ' A' ' 21' ' ' VAL . 11.7 t -118.82 117.28 53.86 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.469 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.226 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.522 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.1 149.71 11.76 Favored Pre-proline 0 N--CA 1.487 1.381 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 -179.611 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.522 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -77.14 152.05 94.18 Favored 'Cis proline' 0 C--N 1.309 -1.534 0 C-N-CA 123.698 -1.376 . . . . 0.0 109.567 -0.423 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.714 ' HA ' HG22 ' A' ' 110' ' ' ILE . 18.0 p -93.15 -24.75 18.14 Favored 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.468 ' HB3' ' HB2' ' A' ' 111' ' ' SER . 3.9 m -133.61 161.83 33.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.616 -0.678 . . . . 0.0 109.382 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.31 37.02 32.86 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.777 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.2 mt -90.92 -42.93 10.31 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 123.283 1.516 . . . . 0.0 110.411 -178.599 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.55 144.36 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.305 0 CA-C-N 113.28 -1.782 . . . . 0.0 109.918 -179.629 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.609 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 6.3 p-10 -50.87 106.34 0.13 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.624 0.726 . . . . 0.0 111.514 -178.646 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.29 13.93 8.66 Favored Glycine 0 N--CA 1.484 1.865 0 C-N-CA 119.468 -1.349 . . . . 0.0 113.033 177.375 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.777 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.98 -172.73 2.15 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 121.168 2.484 . . . . 0.0 109.785 179.253 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.8 HG22 HG22 ' A' ' 68' ' ' THR . 17.2 t -130.39 139.49 51.21 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.319 0 CA-C-N 114.794 -1.094 . . . . 0.0 111.215 -178.783 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.485 HG11 HD11 ' A' ' 13' ' ' LEU . 33.8 m -115.22 155.12 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 178.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.542 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.4 tttt -109.08 109.15 20.08 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.146 -0.971 . . . . 0.0 109.466 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.951 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -105.47 122.44 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.008 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.68 165.66 12.31 Favored 'General case' 0 C--N 1.307 -1.273 0 O-C-N 120.821 -1.174 . . . . 0.0 109.128 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.587 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.97 107.74 0.47 Allowed Glycine 0 N--CA 1.481 1.693 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.617 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.34 139.62 50.21 Favored 'General case' 0 N--CA 1.5 2.063 0 CA-C-N 119.139 1.469 . . . . 0.0 110.102 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.48 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 86.39 28.18 28.19 Favored Glycine 0 N--CA 1.49 2.25 0 C-N-CA 118.796 -1.669 . . . . 0.0 109.758 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.914 HD23 ' HB3' ' A' ' 3' ' ' PRO . 0.9 OUTLIER -94.7 174.44 7.11 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.996 -1.297 . . . . 0.0 108.58 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.005 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.28 100.1 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.91 -1.119 . . . . 0.0 109.74 -179.597 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.557 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.86 77.75 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.101 -179.326 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.41 34.02 0.29 Allowed Glycine 0 N--CA 1.487 2.071 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.9 p -141.86 108.73 5.42 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.071 -1.253 . . . . 0.0 111.098 -179.627 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.579 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.52 109.81 0.25 Allowed 'General case' 0 N--CA 1.496 1.874 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.796 178.253 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.563 ' CE1' ' OD2' ' A' ' 99' ' ' ASP . 21.6 m-85 -99.53 153.77 18.78 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.177 -0.952 . . . . 0.0 108.835 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.502 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -102.67 158.96 15.88 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.727 -1.233 . . . . 0.0 107.829 178.553 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.636 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.0 p -141.63 118.25 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.942 -1.099 . . . . 0.0 109.92 -177.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.52 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.4 -179.81 40.48 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.937 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.607 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -101.21 108.94 20.73 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.932 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.488 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.4 146.9 52.04 Favored 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.236 -0.915 . . . . 0.0 109.808 179.675 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.525 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -119.12 137.74 53.38 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.341 -0.849 . . . . 0.0 110.647 -178.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.857 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.69 114.44 26.18 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 178.143 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.7 m -105.92 14.51 7.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 120.971 -1.081 . . . . 0.0 110.666 -178.665 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.773 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.33 -175.38 0.08 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.815 -1.178 . . . . 0.0 110.116 179.743 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.784 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.97 98.07 1.54 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-O 121.806 0.812 . . . . 0.0 109.91 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.97 26.61 36.81 Favored Glycine 0 N--CA 1.493 2.494 0 C-N-CA 120.17 -1.014 . . . . 0.0 111.562 178.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.773 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -115.27 105.98 19.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 O-C-N 120.549 -1.559 . . . . 0.0 107.316 178.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.857 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -118.31 104.81 11.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.502 -1.374 . . . . 0.0 109.628 -177.806 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.037 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.92 109.67 22.38 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.755 -1.216 . . . . 0.0 108.271 179.074 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.3 t -105.51 164.44 11.88 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.996 -1.065 . . . . 0.0 110.416 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.72 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 9.6 t-20 -109.2 137.21 20.14 Favored Pre-proline 0 N--CA 1.5 2.042 0 O-C-N 121.505 -0.747 . . . . 0.0 109.972 -179.162 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.59 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.2 Cg_endo -74.39 23.9 0.36 Allowed 'Trans proline' 0 CA--C 1.544 1.004 0 C-N-CA 122.371 2.047 . . . . 0.0 112.049 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.72 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -116.91 3.61 12.85 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.364 -1.46 . . . . 0.0 109.115 179.669 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.541 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.49 13.82 3.22 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 179.356 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -79.25 91.46 5.0 Favored 'General case' 0 C--N 1.306 -1.321 0 O-C-N 121.509 -0.744 . . . . 0.0 111.052 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.636 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -112.63 -168.79 1.37 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.188 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.79 136.83 0.09 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.567 -1.333 . . . . 0.0 111.46 -179.296 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.92 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -152.19 157.01 5.31 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 178.024 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.579 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.18 143.78 28.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 120.808 -1.182 . . . . 0.0 110.081 -179.497 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -64.14 106.7 1.12 Allowed 'General case' 0 C--N 1.3 -1.55 0 CA-C-O 122.44 1.114 . . . . 0.0 109.278 178.609 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.8 p-10 -60.14 -139.12 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.948 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.557 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.53 -50.54 59.81 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.497 -0.752 . . . . 0.0 110.597 -178.522 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -103.91 -34.11 8.61 Favored 'General case' 0 C--N 1.286 -2.179 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 178.492 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.012 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.28 66.44 0.6 Allowed Glycine 0 C--N 1.296 -1.639 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.568 178.105 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.587 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 21.5 m -103.15 125.32 49.79 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.665 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.92 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.34 109.33 8.73 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.464 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.6 m -118.16 116.95 27.87 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.368 -0.833 . . . . 0.0 109.307 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.587 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -142.88 139.89 30.99 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.525 -0.734 . . . . 0.0 109.588 -179.987 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.6 p -99.62 134.55 42.33 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.465 -0.772 . . . . 0.0 109.43 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.76 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -132.12 165.6 23.68 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.427 -0.796 . . . . 0.0 109.389 -179.549 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.8 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -96.89 125.33 41.26 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.012 -1.055 . . . . 0.0 109.25 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.607 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.9 m -136.01 143.47 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 120.95 -1.094 . . . . 0.0 109.81 -179.061 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.609 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.7 ptt180 -147.15 -175.48 4.84 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.534 -1.354 . . . . 0.0 111.032 -179.806 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.605 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.12 -101.45 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.609 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.76 141.73 43.12 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.773 -1.204 . . . . 0.0 108.114 179.437 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.596 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.74 136.03 5.06 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 118.653 -1.219 . . . . 0.0 109.96 -177.973 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' A' ' 73' ' ' PHE . 0.7 OUTLIER -33.42 121.92 0.41 Allowed 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.364 0.602 . . . . 0.0 110.313 -178.609 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.037 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.16 50.19 1.91 Allowed Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.388 -0.91 . . . . 0.0 111.343 -178.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.59 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.4 m-85 -40.15 113.5 0.36 Allowed 'General case' 0 N--CA 1.507 2.383 0 O-C-N 121.123 -1.222 . . . . 0.0 109.749 179.313 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.677 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.3 tp -85.66 127.04 34.38 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 120.903 -1.123 . . . . 0.0 109.726 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 33.3 t80 -65.25 58.06 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.971 0 O-C-N 120.85 -1.156 . . . . 0.0 109.824 179.611 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -158.69 18.67 0.21 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.004 -1.06 . . . . 0.0 109.596 -179.991 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.95 -27.23 5.56 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 42.3 p -93.98 159.87 14.98 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.962 -1.316 . . . . 0.0 110.455 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.489 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.02 135.8 46.83 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.536 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.677 ' HB2' HD13 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -83.88 -16.46 44.3 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.737 -1.227 . . . . 0.0 110.67 -178.345 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 107.62 176.23 22.44 Favored Glycine 0 N--CA 1.485 1.95 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.9 104.31 0.68 Allowed 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.582 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 39.4 t -76.37 107.19 7.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.353 -0.842 . . . . 0.0 109.096 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.535 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.3 m-20 -66.29 111.45 3.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.448 -0.782 . . . . 0.0 109.975 -179.236 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.605 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.74 -5.56 4.36 Favored 'General case' 0 N--CA 1.5 2.067 0 C-N-CA 118.268 -1.373 . . . . 0.0 109.78 179.357 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.0 p -86.7 -1.45 57.72 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.744 -1.222 . . . . 0.0 109.231 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.535 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.15 -49.6 3.01 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.212 -0.93 . . . . 0.0 109.019 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.89 178.42 4.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.55 -0.719 . . . . 0.0 109.398 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.83 116.45 32.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.348 -0.845 . . . . 0.0 109.115 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.561 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.59 122.89 40.0 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.853 -1.155 . . . . 0.0 109.189 -179.473 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.578 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -101.18 146.04 28.01 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 122.334 1.064 . . . . 0.0 111.338 -179.08 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.588 ' HB ' HG11 ' A' ' 7' ' ' VAL . 65.8 t -103.21 109.78 27.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.964 0 N-CA-C 106.345 -1.724 . . . . 0.0 106.345 177.45 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.87 -172.82 17.53 Favored Glycine 0 N--CA 1.486 1.968 0 C-N-CA 118.063 -2.018 . . . . 0.0 111.804 -177.505 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.5 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -115.98 -177.77 3.24 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -178.87 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.559 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.9 OUTLIER -171.11 168.78 6.75 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.385 -0.822 . . . . 0.0 109.098 -179.24 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.683 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 1.4 m-20 -104.86 -9.64 17.88 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.115 -0.991 . . . . 0.0 109.504 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.683 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 73.6 39.02 0.59 Allowed 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.471 -0.768 . . . . 0.0 109.199 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -139.23 -34.54 0.58 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.569 -0.707 . . . . 0.0 110.715 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.544 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 179.22 -41.58 0.08 OUTLIER Glycine 0 N--CA 1.482 1.701 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 -179.644 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.7 -179.07 7.84 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 121.448 -1.03 . . . . 0.0 109.641 178.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.58 -166.56 33.91 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 -179.49 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.551 ' HG3' HD22 ' A' ' 26' ' ' LEU . 2.9 Cg_exo -49.8 -176.67 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.685 0 CA-C-N 118.857 1.329 . . . . 0.0 110.067 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -94.41 179.33 5.32 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.04 -1.037 . . . . 0.0 110.571 -178.762 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -117.97 166.77 12.76 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -108.26 128.87 63.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.246 -1.15 . . . . 0.0 109.117 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.578 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.09 119.1 16.86 Favored 'General case' 0 C--N 1.289 -2.045 0 O-C-N 121.586 -0.696 . . . . 0.0 109.356 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.892 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.81 169.9 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.151 -0.968 . . . . 0.0 108.916 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.468 ' HB2' ' HB3' ' A' ' 11' ' ' SER . 1.2 m -141.15 156.97 45.87 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.123 -0.986 . . . . 0.0 110.095 -179.628 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.892 ' CE2' HD12 ' A' ' 110' ' ' ILE . 97.8 m-85 -133.17 85.49 2.22 Favored 'General case' 0 N--CA 1.484 1.242 0 O-C-N 121.24 -0.912 . . . . 0.0 109.479 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.402 ' OXT' ' OD1' ' A' ' 113' ' ' ASN . 20.5 p30 . . . . . 0 N--CA 1.489 1.502 0 CA-C-O 118.044 -0.979 . . . . 0.0 109.445 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.674 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -123.51 154.58 66.3 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.174 -0.954 . . . . 0.0 109.631 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.562 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.8 Cg_exo -59.7 159.31 24.9 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.32 2.013 . . . . 0.0 110.458 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.06 -169.73 0.16 Allowed 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 179.442 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.545 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -163.48 131.01 3.5 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.755 -1.216 . . . . 0.0 110.692 -179.198 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.941 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.2 t -110.28 108.72 18.92 Favored 'General case' 0 C--N 1.296 -1.724 0 CA-C-O 123.108 1.432 . . . . 0.0 109.067 179.316 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.839 HG22 HG23 ' A' ' 21' ' ' VAL . 3.1 t -116.53 139.01 45.26 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.72 0 CA-C-N 114.246 -1.343 . . . . 0.0 110.123 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.466 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.64 149.13 1.27 Allowed Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.323 -0.861 . . . . 0.0 108.775 -179.735 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.466 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.79 152.52 97.07 Favored 'Cis proline' 0 C--N 1.312 -1.365 0 C-N-CA 123.476 -1.468 . . . . 0.0 109.485 -0.786 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.651 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.3 m -90.87 -24.56 20.2 Favored 'General case' 0 C--N 1.293 -1.874 0 O-C-N 121.587 -0.695 . . . . 0.0 109.175 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.51 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.2 m -137.94 165.34 26.78 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.547 -0.721 . . . . 0.0 109.515 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.05 37.98 31.34 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 108.579 -1.808 . . . . 0.0 108.579 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.81 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.8 mt -93.01 -43.93 8.66 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 123.102 1.43 . . . . 0.0 110.703 -178.249 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.17 145.94 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.314 0 CA-C-N 113.595 -1.639 . . . . 0.0 110.138 -179.904 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.616 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -51.23 106.95 0.15 Allowed 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 121.66 0.743 . . . . 0.0 111.638 -178.67 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.73 13.97 9.06 Favored Glycine 0 N--CA 1.484 1.878 0 C-N-CA 119.473 -1.346 . . . . 0.0 112.968 177.438 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.81 HG21 ' CA ' ' A' ' 13' ' ' LEU . 11.5 t -104.08 -173.96 2.43 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 121.164 2.482 . . . . 0.0 109.936 179.417 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.808 HG13 ' O ' ' A' ' 67' ' ' LEU . 39.1 t -124.76 136.11 61.79 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.389 0 CA-C-N 114.563 -1.199 . . . . 0.0 110.917 -178.669 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.562 ' CG1' HD13 ' A' ' 13' ' ' LEU . 35.6 m -114.04 154.95 15.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.259 -0.9 . . . . 0.0 108.725 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.81 109.15 18.44 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.037 179.876 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.839 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -104.48 141.02 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.941 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.73 160.76 38.35 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 120.735 -1.228 . . . . 0.0 110.154 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -128.46 144.6 15.42 Favored Glycine 0 C--N 1.295 -1.731 0 N-CA-C 107.973 -2.051 . . . . 0.0 107.973 179.559 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.562 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.13 125.71 13.3 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 120.851 -1.382 . . . . 0.0 108.864 179.053 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.535 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.44 26.01 26.64 Favored Glycine 0 N--CA 1.488 2.138 0 C-N-CA 119.184 -1.484 . . . . 0.0 109.874 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.587 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -89.02 170.98 10.19 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.86 -1.376 . . . . 0.0 108.477 179.892 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.997 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.02 100.88 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.082 -1.012 . . . . 0.0 110.038 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.2 78.53 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.007 -179.48 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.88 34.32 0.3 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.558 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 16.6 p -138.78 105.06 5.25 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.217 -1.166 . . . . 0.0 111.293 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.8 111.87 0.62 Allowed 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.054 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.558 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 36.9 m-85 -108.92 157.53 18.54 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.186 -0.946 . . . . 0.0 108.897 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.498 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.21 163.14 12.42 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.913 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.92 HG11 HG21 ' A' ' 65' ' ' THR . 2.8 p -143.75 119.42 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.034 -1.041 . . . . 0.0 109.914 -178.044 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.89 -177.87 38.96 Favored Glycine 0 N--CA 1.495 2.602 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.851 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.572 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -102.15 108.76 20.26 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.458 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -131.14 149.56 52.54 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.241 -0.912 . . . . 0.0 109.716 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.478 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.03 138.27 54.73 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.105 -0.997 . . . . 0.0 110.803 -178.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.888 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.73 26.55 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.112 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.0 m -104.74 14.8 6.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.109 -0.994 . . . . 0.0 110.593 -178.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.762 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 173.97 -175.7 0.07 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.989 -1.069 . . . . 0.0 110.003 179.686 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.789 ' O ' HG23 ' A' ' 42' ' ' THR . 14.9 t -72.1 99.0 2.22 Favored 'General case' 0 N--CA 1.486 1.357 0 CA-C-O 121.763 0.792 . . . . 0.0 109.738 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.77 27.7 34.14 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 120.227 -0.987 . . . . 0.0 111.405 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.762 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -117.5 105.88 18.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.619 -1.518 . . . . 0.0 107.263 178.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.888 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.2 tp -117.66 104.67 11.25 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.48 -1.387 . . . . 0.0 109.739 -177.77 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.089 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.89 109.35 22.12 Favored 'General case' 0 N--CA 1.484 1.26 0 O-C-N 120.804 -1.185 . . . . 0.0 107.9 178.757 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.491 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -107.26 162.71 13.65 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.956 -1.09 . . . . 0.0 110.263 -178.673 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.713 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 39.7 t30 -105.71 134.7 19.59 Favored Pre-proline 0 N--CA 1.503 2.189 0 O-C-N 121.405 -0.809 . . . . 0.0 109.539 -179.614 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.599 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.2 Cg_endo -72.74 22.92 0.29 Allowed 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.322 2.015 . . . . 0.0 112.46 -179.436 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.713 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -118.34 10.59 12.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.349 -1.469 . . . . 0.0 108.958 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.854 ' OD2' HD22 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -137.99 14.59 2.86 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 179.326 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -80.15 88.64 5.43 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.564 -0.855 . . . . 0.0 111.286 -178.108 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.55 -167.05 1.18 Allowed 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 178.128 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.74 138.26 0.09 Allowed 'General case' 0 C--N 1.306 -1.284 0 O-C-N 120.578 -1.326 . . . . 0.0 111.239 -179.267 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 1.022 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -155.69 156.48 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.397 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.66 142.03 30.74 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.798 -1.189 . . . . 0.0 110.016 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.015 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -61.74 106.76 0.72 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.425 1.107 . . . . 0.0 109.287 178.091 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.544 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.0 p-10 -60.44 -138.4 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.033 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.36 -51.03 58.13 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.429 -0.794 . . . . 0.0 110.902 -178.576 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.472 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.7 t-20 -103.57 -34.54 8.62 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 178.43 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.015 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 110.95 63.02 0.5 Allowed Glycine 0 C--N 1.297 -1.621 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 177.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.9 m -102.48 126.9 49.68 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.6 -0.941 . . . . 0.0 108.487 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 1.022 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.68 109.19 7.41 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.834 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.1 m -120.83 120.56 35.92 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.284 -0.885 . . . . 0.0 109.515 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.92 HG21 HG11 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -142.04 143.65 33.23 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.526 -0.734 . . . . 0.0 109.355 179.772 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.7 p -102.0 143.41 31.89 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.423 -0.798 . . . . 0.0 109.462 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.854 HD22 ' OD2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -146.26 -178.87 6.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 109.43 -179.45 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.513 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -105.06 125.88 51.46 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.903 -1.123 . . . . 0.0 110.289 -178.894 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.761 HG13 ' OD1' ' A' ' 51' ' ' ASP . 15.3 m -134.56 144.22 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 120.965 -1.085 . . . . 0.0 109.756 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.616 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.3 ptt180 -148.66 -179.62 7.11 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 120.458 -1.401 . . . . 0.0 111.105 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.603 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.92 -100.89 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -179.661 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.511 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.73 139.54 50.35 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.82 -1.175 . . . . 0.0 107.928 179.303 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -161.44 136.18 7.25 Favored 'General case' 0 C--N 1.295 -1.803 0 C-N-CA 118.647 -1.221 . . . . 0.0 109.807 -178.105 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.523 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 15.7 mt-10 -33.97 121.43 0.45 Allowed 'General case' 0 N--CA 1.491 1.621 0 CA-C-O 121.419 0.628 . . . . 0.0 110.358 -178.45 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.089 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.03 50.86 1.93 Allowed Glycine 0 N--CA 1.493 2.493 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.068 -179.278 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.599 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-85 -39.22 116.69 0.62 Allowed 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.122 -1.223 . . . . 0.0 109.954 179.626 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.718 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -87.37 126.16 34.7 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.006 -1.059 . . . . 0.0 109.455 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.579 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.1 t80 -64.8 58.47 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.925 0 O-C-N 120.804 -1.185 . . . . 0.0 110.014 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 26.4 t0 -159.33 19.54 0.18 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.054 -1.029 . . . . 0.0 109.571 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.51 -28.2 5.41 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.454 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 66.3 p -95.96 160.24 14.56 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.964 -1.315 . . . . 0.0 110.438 -179.334 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.479 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 4.1 ptt180 -105.73 138.77 41.37 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.718 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -83.55 -19.12 36.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.852 -1.155 . . . . 0.0 110.556 -178.599 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.59 176.1 19.24 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 108.704 -1.758 . . . . 0.0 108.704 -179.569 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -65.72 105.9 1.37 Allowed 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.0 t -77.36 105.9 6.86 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 O-C-N 121.355 -0.841 . . . . 0.0 109.144 -178.836 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.546 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -64.97 111.1 2.7 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.373 -0.829 . . . . 0.0 109.819 -179.558 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.603 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -62.91 -5.93 3.34 Favored 'General case' 0 N--CA 1.499 2.02 0 C-N-CA 118.214 -1.394 . . . . 0.0 109.85 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.2 p -86.99 -1.25 57.72 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.729 -1.232 . . . . 0.0 109.319 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.546 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.8 p -111.49 -50.3 2.94 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.384 -0.823 . . . . 0.0 108.937 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.76 -179.94 4.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.544 -0.723 . . . . 0.0 109.238 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.93 116.11 31.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.325 -0.859 . . . . 0.0 109.057 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -96.93 121.17 38.51 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.854 -1.154 . . . . 0.0 109.278 -179.321 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.609 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.3 mt-30 -102.04 146.78 27.42 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-O 122.402 1.096 . . . . 0.0 111.311 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.415 ' CG1' ' HB ' ' A' ' 21' ' ' VAL . 62.1 t -104.65 109.86 28.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 177.479 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.485 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.0 -170.04 16.27 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 118.243 -1.932 . . . . 0.0 111.62 -177.57 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.498 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -112.78 179.88 3.85 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -179.065 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.581 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.2 p -177.79 171.09 1.87 Allowed 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.362 -0.836 . . . . 0.0 109.546 -179.18 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.525 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -126.67 -158.27 0.85 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.028 -1.045 . . . . 0.0 109.13 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.439 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.32 35.85 4.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.728 -1.232 . . . . 0.0 109.214 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.12 -33.79 5.57 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.341 -0.849 . . . . 0.0 109.991 -179.737 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.789 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.23 -36.37 0.27 Allowed Glycine 0 N--CA 1.482 1.741 0 N-CA-C 107.775 -2.13 . . . . 0.0 107.775 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -164.04 -177.42 5.03 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 121.599 -0.942 . . . . 0.0 109.962 179.451 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.67 -161.72 14.25 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.518 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.48 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.5 Cg_exo -47.53 178.45 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 CA-C-N 118.997 1.398 . . . . 0.0 110.196 179.281 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -91.25 -177.56 4.9 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.056 -1.028 . . . . 0.0 110.371 -178.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.485 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.15 163.73 13.89 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.06 129.76 50.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.374 -1.074 . . . . 0.0 109.173 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.609 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.1 121.96 22.84 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.634 -0.666 . . . . 0.0 109.603 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.955 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -97.89 169.85 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.214 -0.928 . . . . 0.0 109.18 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.51 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -136.2 154.58 50.89 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.326 -0.859 . . . . 0.0 109.745 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.955 ' CE1' HD12 ' A' ' 110' ' ' ILE . 26.7 m-85 -125.53 109.97 13.31 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.301 -0.874 . . . . 0.0 109.421 -179.78 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.421 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 13.3 p30 . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 117.926 -1.035 . . . . 0.0 109.437 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.789 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -123.72 153.23 66.67 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.241 -0.912 . . . . 0.0 109.565 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.561 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 4.7 Cg_exo -60.26 159.03 28.17 Favored 'Trans proline' 0 C--N 1.309 -1.51 0 C-N-CA 122.428 2.085 . . . . 0.0 110.535 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.544 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -173.85 -169.66 0.51 Allowed 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.092 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.544 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.94 130.58 2.71 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.888 -1.133 . . . . 0.0 110.905 -179.047 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.929 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.5 t -111.74 108.71 18.24 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 123.071 1.415 . . . . 0.0 109.102 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.819 HG22 HG23 ' A' ' 21' ' ' VAL . 2.8 t -115.28 139.23 42.65 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.692 0 CA-C-N 114.326 -1.306 . . . . 0.0 110.196 -179.639 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.08 149.39 1.46 Allowed Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.3 -0.875 . . . . 0.0 108.783 -179.769 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.9 Cg_endo -77.0 151.22 93.69 Favored 'Cis proline' 0 C--N 1.312 -1.344 0 C-N-CA 123.489 -1.463 . . . . 0.0 109.238 -0.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' HG22 ' A' ' 110' ' ' ILE . 24.0 p -89.81 -24.36 21.47 Favored 'General case' 0 C--N 1.292 -1.924 0 O-C-N 121.46 -0.775 . . . . 0.0 109.395 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.515 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 12.4 m -136.68 164.6 27.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.35 -0.844 . . . . 0.0 109.801 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.85 38.79 30.23 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.79 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.2 mt -92.18 -44.1 8.98 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 123.125 1.441 . . . . 0.0 110.721 -178.325 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.88 146.17 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.364 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.329 179.989 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.9 p-10 -51.55 107.4 0.19 Allowed 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.713 0.768 . . . . 0.0 111.571 -178.633 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.8 14.95 8.98 Favored Glycine 0 N--CA 1.484 1.853 0 C-N-CA 119.445 -1.359 . . . . 0.0 112.924 177.435 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.79 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.5 t -105.85 -172.61 2.12 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 121.136 2.468 . . . . 0.0 109.557 179.077 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.73 HG13 ' C ' ' A' ' 67' ' ' LEU . 13.3 t -129.2 136.77 58.76 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.43 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.897 -179.096 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.648 HG13 ' CG2' ' A' ' 69' ' ' VAL . 15.5 m -110.81 156.42 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.512 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.36 109.05 18.45 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.114 -0.991 . . . . 0.0 108.953 179.818 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.819 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -103.74 140.35 22.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.837 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.929 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.47 160.05 39.67 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.717 -1.239 . . . . 0.0 110.026 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.604 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.67 144.47 15.59 Favored Glycine 0 C--N 1.293 -1.806 0 N-CA-C 107.995 -2.042 . . . . 0.0 107.995 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.561 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.14 125.48 13.09 Favored 'General case' 0 C--N 1.296 -1.734 0 O-C-N 120.806 -1.408 . . . . 0.0 108.983 179.232 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.539 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.42 26.33 25.77 Favored Glycine 0 N--CA 1.488 2.121 0 C-N-CA 119.279 -1.438 . . . . 0.0 109.796 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.591 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.7 OUTLIER -89.36 169.59 11.28 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 120.838 -1.389 . . . . 0.0 108.347 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.84 100.99 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 122.214 1.007 . . . . 0.0 109.921 -179.438 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.82 78.18 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.618 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.904 -179.477 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.88 34.12 0.27 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.551 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 18.5 p -139.06 105.43 5.28 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 121.154 -1.204 . . . . 0.0 111.262 -179.433 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.583 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.24 111.54 0.59 Allowed 'General case' 0 N--CA 1.497 1.924 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.676 178.088 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.594 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 5.8 m-30 -109.48 156.35 20.2 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.109 -0.994 . . . . 0.0 108.873 179.725 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -99.49 164.98 11.86 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.821 -1.174 . . . . 0.0 107.915 179.079 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.728 HG22 HG11 ' A' ' 21' ' ' VAL . 3.4 p -144.95 116.52 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.036 -1.04 . . . . 0.0 109.774 -178.276 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.48 -176.23 37.43 Favored Glycine 0 N--CA 1.494 2.519 0 C-N-CA 118.348 -1.882 . . . . 0.0 111.886 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.597 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.1 pt20 -100.4 109.6 21.77 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-O 121.976 0.893 . . . . 0.0 108.978 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.61 148.75 52.44 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.212 -0.93 . . . . 0.0 109.613 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.497 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.15 138.01 54.48 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.263 -0.898 . . . . 0.0 110.875 -178.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.12 27.0 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 177.915 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 m -105.0 14.84 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 120.842 -1.162 . . . . 0.0 110.518 -178.744 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.42 -175.23 0.08 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 120.931 -1.106 . . . . 0.0 110.005 179.738 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.28 98.92 2.76 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.428 -0.795 . . . . 0.0 109.489 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.63 27.62 31.84 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 120.203 -0.999 . . . . 0.0 111.433 179.096 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -118.17 106.12 19.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 O-C-N 120.66 -1.494 . . . . 0.0 107.225 178.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.3 tp -117.94 104.53 10.99 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.475 -1.391 . . . . 0.0 109.874 -177.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.085 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.94 109.36 22.13 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 120.745 -1.222 . . . . 0.0 107.932 178.77 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.489 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 5.0 t -108.92 162.13 14.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.028 -1.045 . . . . 0.0 110.379 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.505 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 12.9 t-20 -107.36 129.18 24.64 Favored Pre-proline 0 N--CA 1.5 2.03 0 O-C-N 121.424 -0.797 . . . . 0.0 109.63 -179.404 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.621 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.0 OUTLIER -71.18 20.24 0.23 Allowed 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 122.057 1.838 . . . . 0.0 111.95 179.388 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.505 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -107.81 2.68 23.74 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.515 -1.366 . . . . 0.0 108.841 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.552 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.01 17.89 2.82 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 179.418 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -81.76 86.94 6.37 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.524 -0.735 . . . . 0.0 111.086 -178.384 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -102.89 -165.54 1.18 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 178.19 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.459 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.8 137.13 0.09 Allowed 'General case' 0 N--CA 1.486 1.354 0 O-C-N 120.532 -1.355 . . . . 0.0 111.212 -179.399 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 1.013 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -155.2 156.58 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 178.37 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.583 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.69 141.67 31.21 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.952 -1.093 . . . . 0.0 109.879 -179.802 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.034 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.23 107.17 0.84 Allowed 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 122.45 1.119 . . . . 0.0 109.39 178.231 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.546 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.9 t0 -62.17 -138.54 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.001 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.7 -52.42 31.34 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.391 -0.818 . . . . 0.0 110.871 -178.443 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -103.61 -32.81 9.24 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 178.633 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.034 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.8 62.57 0.54 Allowed Glycine 0 C--N 1.297 -1.627 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 178.04 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 37.0 m -101.04 127.14 47.7 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 1.013 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -137.13 109.2 7.2 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 119.074 -1.05 . . . . 0.0 109.877 -179.089 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 48.2 p -121.27 119.69 32.99 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.282 -0.886 . . . . 0.0 109.417 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.529 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.56 145.7 31.96 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.581 -0.699 . . . . 0.0 109.289 179.831 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 20.3 p -98.91 143.34 29.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.407 -0.808 . . . . 0.0 109.736 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.73 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -141.07 163.0 34.15 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.483 -0.761 . . . . 0.0 109.141 -179.486 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.693 HG22 HG22 ' A' ' 18' ' ' VAL . 5.1 p -92.77 123.98 36.44 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.045 -1.035 . . . . 0.0 109.521 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.648 ' CG2' HG13 ' A' ' 19' ' ' VAL . 17.8 m -137.78 144.16 31.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.001 -1.062 . . . . 0.0 109.453 -179.586 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.596 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 4.3 ptt180 -138.89 -168.77 2.49 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.507 -1.371 . . . . 0.0 110.544 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.681 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 3.9 mtt180 -65.48 -73.81 0.12 Allowed 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.522 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -76.72 145.43 38.66 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 178.159 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 0.9 OUTLIER -164.98 138.68 4.83 Favored 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 117.446 -1.702 . . . . 0.0 110.678 -177.478 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.525 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 3.7 mp0 -35.22 120.97 0.55 Allowed 'General case' 0 N--CA 1.491 1.614 0 CA-C-O 121.455 0.645 . . . . 0.0 110.361 -178.726 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.085 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -96.19 51.34 1.65 Allowed Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.485 -0.865 . . . . 0.0 111.018 -179.379 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.621 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-85 -40.19 114.64 0.46 Allowed 'General case' 0 N--CA 1.508 2.455 0 O-C-N 121.079 -1.248 . . . . 0.0 109.776 179.567 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.684 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -85.73 125.67 33.39 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.855 -1.153 . . . . 0.0 109.754 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.586 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 19.0 t80 -65.24 58.04 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.908 0 O-C-N 120.789 -1.194 . . . . 0.0 109.748 179.154 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.552 ' N ' ' O ' ' A' ' 77' ' ' LEU . 5.6 t70 -154.97 16.7 0.43 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.13 -0.981 . . . . 0.0 109.559 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.85 -26.83 8.87 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.12 164.96 11.42 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.948 -1.325 . . . . 0.0 110.643 -179.287 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.482 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 2.1 ptm180 -105.38 137.3 43.41 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.684 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -81.15 -19.77 42.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.852 -1.155 . . . . 0.0 110.421 -178.598 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.62 176.1 19.23 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.679 -1.769 . . . . 0.0 108.679 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.97 106.44 1.24 Allowed 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.651 HG21 ' HB3' ' A' ' 46' ' ' ALA . 38.7 t -78.03 107.55 10.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.363 -0.836 . . . . 0.0 109.205 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.522 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -68.71 112.99 5.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.518 -0.738 . . . . 0.0 109.91 -179.371 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.681 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 7.5 m -58.43 -6.98 0.77 Allowed 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.632 -1.293 . . . . 0.0 110.424 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.8 p -87.08 -4.77 59.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.298 -1.501 . . . . 0.0 109.617 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.496 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -103.38 -47.08 4.4 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.245 -0.909 . . . . 0.0 108.94 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.08 -178.06 3.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.553 -0.717 . . . . 0.0 109.357 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.08 117.57 35.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.403 -0.811 . . . . 0.0 108.821 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.557 ' HB2' HD11 ' A' ' 110' ' ' ILE . 3.2 m -96.47 121.26 38.1 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.846 -1.159 . . . . 0.0 109.724 -179.114 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.573 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.46 146.55 28.7 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 122.384 1.088 . . . . 0.0 111.37 -179.391 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.443 ' CG1' HG11 ' A' ' 7' ' ' VAL . 57.5 t -103.59 109.94 28.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 177.62 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.469 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.63 -171.54 16.8 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.221 -1.942 . . . . 0.0 111.638 -177.653 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.28 178.74 4.21 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 -179.067 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.59 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.1 p -171.58 168.54 6.32 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.565 -0.709 . . . . 0.0 109.406 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.594 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -119.35 -158.16 0.72 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.072 -1.017 . . . . 0.0 108.945 179.711 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.458 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.45 36.43 4.27 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.733 -1.23 . . . . 0.0 109.138 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -115.29 -32.49 5.62 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.442 -0.786 . . . . 0.0 110.075 -179.66 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 1.002 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 163.99 -35.69 0.3 Allowed Glycine 0 N--CA 1.481 1.65 0 N-CA-C 107.778 -2.129 . . . . 0.0 107.778 -179.561 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.97 -177.74 5.99 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.64 -0.918 . . . . 0.0 109.742 179.273 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.04 -162.16 15.52 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 108.445 -1.862 . . . . 0.0 108.445 -179.439 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.482 ' HG3' HD22 ' A' ' 26' ' ' LEU . 5.2 Cg_exo -47.27 178.71 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.644 0 CA-C-N 118.789 1.295 . . . . 0.0 110.313 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -92.42 -172.97 3.25 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.007 -1.058 . . . . 0.0 110.36 -178.923 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.469 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.33 163.34 14.81 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.28 131.12 48.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.424 -1.045 . . . . 0.0 109.075 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.573 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.81 120.68 19.74 Favored 'General case' 0 C--N 1.29 -2.021 0 O-C-N 121.613 -0.679 . . . . 0.0 109.842 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.818 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.4 pt -98.09 170.43 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.276 -0.89 . . . . 0.0 108.896 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.515 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.9 153.96 51.29 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.127 -0.983 . . . . 0.0 109.551 179.899 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.818 ' CE2' HD12 ' A' ' 110' ' ' ILE . 67.2 m-85 -130.31 95.14 3.83 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.249 -0.907 . . . . 0.0 109.527 -179.577 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.9 p30 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 117.868 -1.063 . . . . 0.0 109.558 179.951 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 1.002 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -125.54 97.93 35.67 Favored Pre-proline 0 N--CA 1.487 1.413 0 O-C-N 121.33 -0.856 . . . . 0.0 109.398 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.577 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 6.3 Cg_exo -58.46 157.45 26.76 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.045 1.83 . . . . 0.0 110.194 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.551 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -179.92 -169.26 0.13 Allowed 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 179.543 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.596 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . -166.55 133.85 2.61 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.758 -1.214 . . . . 0.0 110.974 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.019 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -101.61 104.51 15.38 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 122.439 1.114 . . . . 0.0 109.864 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.939 HG22 HG23 ' A' ' 21' ' ' VAL . 4.1 t -118.84 118.97 59.55 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.462 179.783 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.502 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.84 147.96 9.59 Favored Pre-proline 0 C--N 1.306 -1.324 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 -179.832 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.502 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.8 Cg_endo -76.17 151.31 95.02 Favored 'Cis proline' 0 C--N 1.309 -1.541 0 C-N-CA 123.593 -1.42 . . . . 0.0 109.596 -0.406 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' HG22 ' A' ' 110' ' ' ILE . 2.5 p -90.38 -25.37 20.46 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.426 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.497 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.1 m -136.05 165.86 24.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.609 -0.682 . . . . 0.0 109.331 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.22 37.58 36.71 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 108.463 -1.855 . . . . 0.0 108.463 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.0 mt -92.27 -43.0 9.53 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 123.297 1.522 . . . . 0.0 110.44 -178.33 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.48 144.35 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.29 0 CA-C-N 113.522 -1.672 . . . . 0.0 109.788 -179.62 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.608 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 4.7 p-10 -51.27 106.2 0.13 Allowed 'General case' 0 C--N 1.301 -1.54 0 CA-C-O 121.539 0.685 . . . . 0.0 111.597 -178.385 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.401 ' H ' ' HB3' ' A' ' 70' ' ' ARG . . . 113.38 15.95 8.58 Favored Glycine 0 N--CA 1.484 1.884 0 C-N-CA 119.473 -1.346 . . . . 0.0 112.855 177.297 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.1 t -104.41 -170.88 1.83 Allowed 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 121.169 2.484 . . . . 0.0 109.727 179.176 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.731 HG13 ' C ' ' A' ' 67' ' ' LEU . 14.2 t -130.38 138.92 52.65 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.166 -178.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.569 HG11 HD11 ' A' ' 13' ' ' LEU . 33.7 m -118.18 155.04 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tttt -109.26 109.4 20.31 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.162 -0.961 . . . . 0.0 109.509 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.939 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -105.86 124.59 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.489 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.019 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.66 167.21 11.55 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.668 -1.27 . . . . 0.0 109.253 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.615 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.07 141.05 12.38 Favored Glycine 0 C--N 1.296 -1.666 0 N-CA-C 107.466 -2.254 . . . . 0.0 107.466 179.672 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.577 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.28 123.94 11.84 Favored 'General case' 0 C--N 1.295 -1.8 0 O-C-N 120.571 -1.546 . . . . 0.0 108.819 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.524 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.37 27.12 23.69 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.13 -1.51 . . . . 0.0 109.899 -179.666 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.532 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -88.06 174.33 8.34 Favored 'General case' 0 C--N 1.308 -1.227 0 O-C-N 120.788 -1.419 . . . . 0.0 108.473 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.001 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.88 97.54 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 122.257 1.027 . . . . 0.0 109.724 -179.853 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.637 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.99 77.26 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.437 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.77 33.65 0.29 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.302 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 50.5 p -145.53 112.0 5.81 Favored 'General case' 0 C--N 1.31 -1.145 0 O-C-N 120.896 -1.355 . . . . 0.0 111.448 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.59 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.52 116.19 1.5 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.934 178.286 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.602 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 4.0 m-30 -112.28 153.87 26.51 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.225 -0.922 . . . . 0.0 108.708 179.521 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -98.92 165.36 11.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.849 -1.157 . . . . 0.0 108.095 179.003 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 34' ' ' VAL . 4.8 p -145.15 116.64 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.114 -0.991 . . . . 0.0 109.878 -177.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.53 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.55 -175.97 39.07 Favored Glycine 0 N--CA 1.491 2.336 0 C-N-CA 118.267 -1.92 . . . . 0.0 111.754 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.571 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -100.22 113.75 26.67 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.622 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 85.0 m -131.88 153.81 49.84 Favored 'General case' 0 C--N 1.292 -1.901 0 O-C-N 121.6 -0.688 . . . . 0.0 109.602 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.663 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -129.88 136.78 49.92 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.448 -0.782 . . . . 0.0 110.565 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.908 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.69 114.45 26.38 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 178.318 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m -105.45 15.08 7.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.951 -1.093 . . . . 0.0 110.713 -178.47 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.782 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.22 -174.54 0.07 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.87 -1.144 . . . . 0.0 110.08 179.699 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 40.1 p -71.33 96.81 1.49 Allowed 'General case' 0 N--CA 1.485 1.323 0 O-C-N 121.382 -0.824 . . . . 0.0 109.878 -179.631 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.26 27.95 31.92 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 120.21 -0.995 . . . . 0.0 111.564 178.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.782 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -115.54 106.38 20.36 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.54 -1.565 . . . . 0.0 107.464 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.908 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -116.31 106.54 13.77 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.591 -1.318 . . . . 0.0 109.912 -177.621 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.123 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -96.77 113.22 24.76 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 120.821 -1.174 . . . . 0.0 108.515 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.575 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . 97.4 m -105.34 147.39 28.21 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.279 -0.888 . . . . 0.0 110.361 -178.468 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.604 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 32.7 t30 -97.52 135.94 21.5 Favored Pre-proline 0 N--CA 1.505 2.305 0 O-C-N 120.937 -1.102 . . . . 0.0 108.759 178.797 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.62 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.8 Cg_endo -74.85 26.51 0.36 Allowed 'Trans proline' 0 C--N 1.319 -1.004 0 C-N-CA 122.396 2.064 . . . . 0.0 112.29 -179.098 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.604 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -120.76 6.05 10.48 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.213 -1.554 . . . . 0.0 109.536 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.6 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.48 17.93 2.38 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 179.367 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.575 ' CE2' ' HB3' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -83.58 89.84 7.16 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.248 -178.437 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.588 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -109.99 -166.77 1.12 Allowed 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.153 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.463 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.66 135.61 0.09 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.421 -1.425 . . . . 0.0 111.573 -179.294 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.803 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.2 p -151.73 159.72 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 177.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.6 144.44 27.89 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.731 -1.231 . . . . 0.0 110.016 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.001 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.51 107.83 2.2 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 122.385 1.088 . . . . 0.0 109.342 178.563 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.555 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.7 t0 -62.72 -139.07 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.886 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.637 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.28 -52.09 29.7 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.427 -0.795 . . . . 0.0 110.727 -178.582 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -104.48 -32.48 8.98 Favored 'General case' 0 C--N 1.286 -2.155 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 178.645 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.972 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.67 68.22 0.65 Allowed Glycine 0 C--N 1.297 -1.587 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 178.294 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.0 m -103.47 128.94 50.54 Favored 'General case' 0 N--CA 1.483 1.224 0 O-C-N 121.336 -1.097 . . . . 0.0 109.15 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.803 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.63 108.72 7.69 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 119.469 -0.892 . . . . 0.0 109.574 -179.573 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.447 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 85.7 p -116.85 117.41 29.66 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.089 -1.007 . . . . 0.0 109.374 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.618 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.32 142.51 28.35 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.409 -0.807 . . . . 0.0 109.956 -179.794 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 25.1 p -102.14 141.32 35.15 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.496 -0.752 . . . . 0.0 109.265 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.776 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.58 167.05 23.07 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.337 -0.852 . . . . 0.0 109.509 -179.384 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.699 HG22 HG22 ' A' ' 18' ' ' VAL . 2.5 p -96.17 124.74 40.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.197 -0.94 . . . . 0.0 109.349 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.537 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 18.7 m -138.43 142.55 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.939 -1.101 . . . . 0.0 109.922 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.608 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.7 ptt180 -138.56 -164.81 1.7 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.732 -1.23 . . . . 0.0 109.908 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.564 ' HG3' ' CD1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -74.3 -82.88 0.06 Allowed 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 -179.844 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.498 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.76 136.63 57.96 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 178.698 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.663 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.46 133.49 5.75 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 118.058 -1.457 . . . . 0.0 110.562 -177.603 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.56 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 3.1 mm-40 -33.04 120.07 0.35 Allowed 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.619 0.723 . . . . 0.0 110.386 -178.456 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.123 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.9 50.74 2.54 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.484 -179.074 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.62 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -37.77 116.36 0.49 Allowed 'General case' 0 N--CA 1.507 2.381 0 O-C-N 121.136 -1.214 . . . . 0.0 110.157 179.365 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.653 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.2 tp -86.08 126.09 33.93 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 120.895 -1.128 . . . . 0.0 109.716 -179.777 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.578 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 39.3 t80 -63.62 58.42 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.015 -1.053 . . . . 0.0 110.114 179.507 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 21.2 t0 -161.01 20.27 0.13 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.904 -1.122 . . . . 0.0 109.737 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.52 -29.09 5.01 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.484 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 9.7 p -95.48 163.88 13.04 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.076 -1.249 . . . . 0.0 110.203 -179.542 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 3.3 ptm180 -109.25 139.85 43.64 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.653 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.6 t90 -82.0 -21.56 37.01 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.861 -1.149 . . . . 0.0 110.353 -178.867 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.81 175.68 18.14 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.79 110.57 2.11 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 179.037 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.615 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.1 t -82.32 102.61 8.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.652 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.608 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.97 111.21 2.75 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.489 -0.757 . . . . 0.0 109.632 -179.313 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.563 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.23 -4.93 5.8 Favored 'General case' 0 N--CA 1.498 1.973 0 C-N-CA 118.304 -1.358 . . . . 0.0 109.813 179.534 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.3 p -85.51 3.62 39.56 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.786 -1.196 . . . . 0.0 108.823 179.255 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.608 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -119.2 -49.82 2.38 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.402 -0.811 . . . . 0.0 108.959 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.71 -178.42 3.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.382 -0.824 . . . . 0.0 109.538 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.64 114.45 28.62 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.511 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.5 m -97.47 121.9 39.9 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.932 -1.105 . . . . 0.0 109.746 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.592 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.74 147.11 26.86 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.412 1.101 . . . . 0.0 111.245 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.656 ' HB ' HG11 ' A' ' 7' ' ' VAL . 52.9 t -103.62 110.82 31.13 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 106.913 -1.514 . . . . 0.0 106.913 177.796 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.475 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.51 -170.8 18.77 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.076 -2.012 . . . . 0.0 111.884 -177.587 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.525 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -115.96 -179.89 3.79 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 -179.167 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.586 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.4 p -171.05 167.3 7.23 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.515 -0.741 . . . . 0.0 109.317 -179.363 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.602 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -112.82 -160.13 0.71 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.086 -1.009 . . . . 0.0 108.962 179.806 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -118.54 36.51 4.37 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.688 -1.258 . . . . 0.0 109.222 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.03 -32.91 4.6 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.332 -0.855 . . . . 0.0 110.174 -179.556 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.963 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.52 -36.91 0.22 Allowed Glycine 0 N--CA 1.48 1.624 0 N-CA-C 107.833 -2.107 . . . . 0.0 107.833 -179.543 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.74 -178.16 6.87 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.572 -0.958 . . . . 0.0 109.754 179.255 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.68 -161.45 14.73 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.257 -1.937 . . . . 0.0 108.257 -179.325 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.0 Cg_exo -47.6 179.65 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.82 1.31 . . . . 0.0 110.261 179.19 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -94.05 -170.54 2.33 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.066 -1.021 . . . . 0.0 110.334 -178.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.475 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.31 162.75 18.34 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.11 128.45 50.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.381 -1.07 . . . . 0.0 109.15 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.592 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.24 119.64 15.67 Favored 'General case' 0 C--N 1.289 -2.056 0 O-C-N 121.669 -0.644 . . . . 0.0 109.738 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.884 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.12 171.31 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.219 -0.926 . . . . 0.0 109.097 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.497 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.01 156.62 47.07 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.074 -1.016 . . . . 0.0 109.844 -179.822 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.884 ' CE2' HD12 ' A' ' 110' ' ' ILE . 96.8 m-85 -131.09 110.44 11.19 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.191 -0.943 . . . . 0.0 109.609 -179.686 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.2 p30 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.492 -179.929 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.963 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.445 -0.576 . . . . 1.0 109.445 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -101.32 147.58 33.97 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.317 -0.865 . . . . 1.0 109.449 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.559 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.5 Cg_exo -60.06 158.14 31.25 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.322 2.015 . . . . 1.0 110.561 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.542 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.54 -169.85 0.15 Allowed 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 108.177 -1.045 . . . . 1.0 108.177 179.206 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.542 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.35 130.0 2.44 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 120.873 -1.142 . . . . 1.0 110.597 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.948 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.6 t -110.31 108.67 18.83 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 123.085 1.421 . . . . 1.0 109.01 179.355 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.838 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -117.19 136.36 54.6 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.702 0 CA-C-N 114.3 -1.318 . . . . 1.0 110.002 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.456 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.31 148.76 2.43 Favored Pre-proline 0 N--CA 1.487 1.376 0 O-C-N 121.287 -0.883 . . . . 1.0 108.897 -179.64 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.456 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -79.21 148.67 82.13 Favored 'Cis proline' 0 C--N 1.311 -1.408 0 C-N-CA 123.438 -1.484 . . . . 1.0 109.52 -1.052 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.644 ' HA ' HG22 ' A' ' 110' ' ' ILE . 42.8 p -88.34 -25.5 22.71 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 108.981 -0.748 . . . . 1.0 108.981 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 0.7 OUTLIER -131.91 161.86 32.03 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.454 -0.779 . . . . 1.0 109.674 -179.787 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.88 37.63 29.14 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 108.592 -1.803 . . . . 1.0 108.592 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.79 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.2 mt -92.78 -43.54 8.97 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 123.099 1.428 . . . . 1.0 110.636 -178.343 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.14 145.19 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.295 0 CA-C-N 113.571 -1.65 . . . . 1.0 110.03 -179.596 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 14.8 p-10 -51.16 106.93 0.15 Allowed 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.462 0.648 . . . . 1.0 111.564 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.47 15.22 9.02 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 119.385 -1.388 . . . . 1.0 112.871 177.217 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.79 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.5 t -104.54 -171.69 1.97 Allowed 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 121.133 2.467 . . . . 1.0 109.671 179.204 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.727 HG13 ' C ' ' A' ' 67' ' ' LEU . 15.1 t -128.58 137.56 56.99 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.387 0 CA-C-N 114.874 -1.057 . . . . 1.0 110.979 -179.066 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.527 HG11 ' CD1' ' A' ' 13' ' ' LEU . 35.2 m -114.13 154.75 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 108.808 -0.812 . . . . 1.0 108.808 179.036 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.65 109.23 20.37 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.226 -0.921 . . . . 1.0 108.797 179.718 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.838 HG23 HG22 ' A' ' 7' ' ' VAL . 2.2 p -103.82 141.6 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.727 -0.842 . . . . 1.0 108.727 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.948 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -138.24 160.23 39.99 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.72 -1.238 . . . . 1.0 109.982 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.76 144.21 15.37 Favored Glycine 0 C--N 1.295 -1.742 0 N-CA-C 108.089 -2.004 . . . . 1.0 108.089 179.811 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.559 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.11 125.53 13.16 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 120.913 -1.345 . . . . 1.0 108.828 179.028 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.534 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.08 27.09 26.89 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.216 -1.469 . . . . 1.0 109.912 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.576 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.8 mt -87.13 175.02 8.28 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 120.799 -1.412 . . . . 1.0 108.463 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.016 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.58 99.74 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.978 -1.076 . . . . 1.0 109.689 -179.79 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.563 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 77.76 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 115.226 -0.897 . . . . 1.0 110.247 -179.063 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.4 34.13 0.33 Allowed Glycine 0 N--CA 1.488 2.117 0 N-CA-C 109.496 -1.441 . . . . 1.0 109.496 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.56 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 42.9 p -141.24 108.56 5.53 Favored 'General case' 0 C--N 1.306 -1.302 0 O-C-N 121.123 -1.222 . . . . 1.0 111.311 -179.636 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.589 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.35 110.06 0.37 Allowed 'General case' 0 N--CA 1.497 1.888 0 CA-C-N 115.9 -0.591 . . . . 1.0 109.455 178.031 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.564 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 5.2 m-30 -106.75 155.99 19.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.133 -0.98 . . . . 1.0 108.982 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.486 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -99.82 165.17 11.7 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.876 -1.157 . . . . 1.0 107.876 179.045 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.692 ' O ' HG13 ' A' ' 34' ' ' VAL . 7.5 p -145.7 114.85 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.066 -1.021 . . . . 1.0 109.941 -178.048 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.01 -176.41 37.3 Favored Glycine 0 N--CA 1.492 2.398 0 C-N-CA 118.499 -1.81 . . . . 1.0 111.564 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.646 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.5 pt20 -100.1 110.02 22.31 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-O 121.941 0.877 . . . . 1.0 108.966 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -130.08 150.81 51.18 Favored 'General case' 0 C--N 1.296 -1.74 0 O-C-N 121.217 -0.927 . . . . 1.0 109.837 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.522 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -126.83 139.78 52.84 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.222 -0.924 . . . . 1.0 110.808 -179.037 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.897 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.15 114.78 26.61 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 107.62 -1.252 . . . . 1.0 107.62 178.246 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -104.6 14.99 6.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 120.938 -1.101 . . . . 1.0 110.575 -178.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.762 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.61 -176.28 0.09 Allowed 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.863 -1.148 . . . . 1.0 110.184 179.716 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.769 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.89 97.47 1.42 Allowed 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.436 -0.79 . . . . 1.0 109.847 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.63 27.8 34.32 Favored Glycine 0 N--CA 1.493 2.493 0 C-N-CA 120.145 -1.026 . . . . 1.0 111.434 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.762 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.32 106.6 20.65 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 O-C-N 120.668 -1.489 . . . . 1.0 107.171 178.868 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.897 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.2 tp -116.06 104.67 11.8 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.449 -1.407 . . . . 1.0 109.982 -177.691 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.042 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.23 109.58 22.31 Favored 'General case' 0 N--CA 1.485 1.291 0 O-C-N 120.818 -1.176 . . . . 1.0 108.079 178.848 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.18 166.21 10.79 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.912 -1.117 . . . . 1.0 110.356 -178.814 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.73 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 46.0 t30 -112.01 129.85 23.84 Favored Pre-proline 0 N--CA 1.501 2.1 0 O-C-N 121.366 -0.834 . . . . 1.0 109.796 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.634 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.5 Cg_endo -71.65 22.31 0.25 Allowed 'Trans proline' 0 CA--C 1.545 1.056 0 C-N-CA 122.219 1.946 . . . . 1.0 112.342 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.73 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -109.87 2.79 20.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.415 -1.428 . . . . 1.0 109.049 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.571 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.65 18.87 2.52 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.135 -1.432 . . . . 1.0 107.135 179.41 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -82.13 89.73 6.5 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.934 -0.707 . . . . 1.0 111.127 -178.395 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -106.97 -166.87 1.21 Allowed 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 107.562 -1.273 . . . . 1.0 107.562 178.077 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.2 136.35 0.1 Allowed 'General case' 0 C--N 1.306 -1.307 0 O-C-N 120.538 -1.351 . . . . 1.0 111.304 -179.346 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.901 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -154.46 158.8 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.635 -1.246 . . . . 1.0 107.635 178.337 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.589 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.8 142.25 30.57 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.807 -1.183 . . . . 1.0 109.901 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.53 107.12 1.06 Allowed 'General case' 0 C--N 1.299 -1.602 0 CA-C-O 122.423 1.106 . . . . 1.0 109.295 178.253 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.552 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.2 p-10 -58.88 -138.84 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.583 -0.735 . . . . 1.0 110.821 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.563 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -54.65 -49.81 69.68 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.374 -0.829 . . . . 1.0 110.231 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.421 ' OD1' ' N ' ' A' ' 61' ' ' GLY . 12.3 p30 -100.23 -38.82 8.33 Favored 'General case' 0 C--N 1.285 -2.219 0 N-CA-C 106.122 -1.807 . . . . 1.0 106.122 178.492 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.999 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.92 65.93 0.55 Allowed Glycine 0 C--N 1.296 -1.648 0 N-CA-C 110.239 -1.144 . . . . 1.0 110.239 178.263 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.4 m -102.82 129.12 49.39 Favored 'General case' 0 N--CA 1.483 1.19 0 O-C-N 121.49 -1.006 . . . . 1.0 108.948 179.043 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.901 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.17 108.87 6.61 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 119.274 -0.971 . . . . 1.0 109.921 -179.371 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.483 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -124.02 120.96 33.97 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.244 -0.91 . . . . 1.0 109.801 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.465 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -146.44 149.48 33.78 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.486 -0.759 . . . . 1.0 109.07 179.587 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.5 p -100.31 145.62 27.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.312 -0.867 . . . . 1.0 109.741 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.727 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -145.95 165.81 27.87 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.472 -0.768 . . . . 1.0 109.242 -179.457 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.693 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -96.53 124.88 40.66 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.0 -1.063 . . . . 1.0 109.477 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.535 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.0 m -138.74 143.1 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 120.972 -1.08 . . . . 1.0 109.808 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.596 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.6 ptt180 -140.02 -163.46 1.51 Allowed 'General case' 0 N--CA 1.486 1.351 0 O-C-N 120.593 -1.317 . . . . 1.0 109.871 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.571 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -75.03 -82.28 0.07 Allowed 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.083 -1.011 . . . . 1.0 108.87 -179.609 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.491 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -62.75 137.51 58.28 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.305 -1.497 . . . . 1.0 107.357 178.861 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.563 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.2 OUTLIER -163.22 134.09 4.69 Favored 'General case' 0 C--N 1.293 -1.863 0 C-N-CA 118.045 -1.462 . . . . 1.0 110.522 -177.656 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.486 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . 3.6 mm-40 -32.56 121.21 0.33 Allowed 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 121.642 0.734 . . . . 1.0 110.773 -178.357 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.042 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.06 49.78 3.05 Favored Glycine 0 N--CA 1.496 2.649 0 C-N-CA 120.754 -0.736 . . . . 1.0 111.546 -179.139 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.634 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-30 -38.57 115.42 0.46 Allowed 'General case' 0 N--CA 1.511 2.594 0 O-C-N 121.028 -1.277 . . . . 1.0 110.14 179.318 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.794 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.05 125.89 34.4 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.857 -1.152 . . . . 1.0 109.744 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.59 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.3 t80 -64.68 58.26 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.927 0 O-C-N 120.86 -1.15 . . . . 1.0 109.869 179.403 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -158.08 18.47 0.24 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.035 -1.04 . . . . 1.0 109.677 -179.948 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.21 -27.56 6.11 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.919 -1.272 . . . . 1.0 109.919 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -98.17 164.7 12.21 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.069 -1.253 . . . . 1.0 110.337 -179.482 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.519 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.13 140.35 41.46 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.858 -0.793 . . . . 1.0 108.858 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.794 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.2 t90 -84.2 -22.34 30.95 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.845 -1.159 . . . . 1.0 110.604 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.73 175.13 17.55 Favored Glycine 0 N--CA 1.485 1.922 0 N-CA-C 108.688 -1.765 . . . . 1.0 108.688 -179.484 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.67 112.0 2.65 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.712 -1.218 . . . . 1.0 107.712 179.243 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.642 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.3 t -84.55 103.95 12.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.289 -0.882 . . . . 1.0 108.928 -179.049 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.622 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -66.58 111.65 3.74 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.357 -0.839 . . . . 1.0 109.645 -179.439 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.571 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.38 -5.3 4.97 Favored 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 118.172 -1.411 . . . . 1.0 109.948 179.501 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 45.5 p -84.39 0.46 49.3 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.75 -1.219 . . . . 1.0 108.772 179.195 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.622 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -115.84 -50.35 2.69 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.392 -0.817 . . . . 1.0 109.054 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.29 -178.01 3.54 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.508 -0.745 . . . . 1.0 109.514 179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.09 115.36 30.04 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.369 -0.832 . . . . 1.0 108.95 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.523 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -97.29 123.2 41.02 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.901 -1.125 . . . . 1.0 109.917 -179.094 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.6 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.28 148.2 26.62 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-O 122.373 1.082 . . . . 1.0 111.102 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.434 ' CG1' HG11 ' A' ' 7' ' ' VAL . 61.1 t -103.23 110.2 29.09 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 N-CA-C 106.721 -1.585 . . . . 1.0 106.721 177.618 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.452 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.46 -172.78 18.7 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 118.08 -2.01 . . . . 1.0 111.679 -177.614 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.483 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -114.77 179.88 3.82 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.945 -0.761 . . . . 1.0 108.945 -179.175 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.581 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 66.9 p -167.95 162.21 13.29 Favored 'General case' 0 C--N 1.295 -1.766 0 O-C-N 121.472 -0.768 . . . . 1.0 109.291 -179.279 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.564 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -108.9 -159.92 0.7 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.194 -0.941 . . . . 1.0 108.703 179.61 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -119.13 36.12 4.58 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.613 -1.305 . . . . 1.0 109.264 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -119.07 -31.77 4.63 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.338 -0.851 . . . . 1.0 110.372 -179.549 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 1.021 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 166.84 -36.72 0.24 Allowed Glycine 0 N--CA 1.482 1.722 0 N-CA-C 107.742 -2.143 . . . . 1.0 107.742 -179.5 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.43 -177.96 6.92 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.675 -0.897 . . . . 1.0 109.935 179.254 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.7 -163.84 19.94 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 108.319 -1.912 . . . . 1.0 108.319 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.4 Cg_exo -47.68 177.88 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 CA-C-N 118.763 1.281 . . . . 1.0 110.233 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -94.86 -176.25 3.8 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.236 -0.915 . . . . 1.0 110.186 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.452 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.68 163.98 13.06 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.787 -1.325 . . . . 1.0 109.787 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.5 132.35 46.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.381 -1.07 . . . . 1.0 109.063 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.6 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.0 125.44 27.62 Favored 'General case' 0 C--N 1.29 -2.017 0 O-C-N 121.649 -0.657 . . . . 1.0 109.868 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.87 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.67 171.95 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.356 -0.84 . . . . 1.0 108.953 179.611 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.4 OUTLIER -136.51 156.27 48.83 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.118 -0.989 . . . . 1.0 109.58 -179.925 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.87 ' CE1' HD12 ' A' ' 110' ' ' ILE . 93.0 m-85 -128.27 66.46 1.38 Allowed 'General case' 0 N--CA 1.484 1.274 0 O-C-N 121.134 -0.979 . . . . 1.0 109.506 -179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.439 ' OD1' ' O ' ' A' ' 113' ' ' ASN . 17.7 p30 . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 118.041 -0.98 . . . . 1.0 109.565 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 1.021 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 121.301 0.572 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.951 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -123.7 173.81 4.17 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.285 -0.884 . . . . 0.0 109.505 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.951 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 4.9 Cg_exo -60.45 157.01 38.19 Favored 'Trans proline' 0 C--N 1.311 -1.442 0 C-N-CA 122.313 2.009 . . . . 0.0 110.843 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.554 HG23 ' HB3' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -179.89 -169.64 0.13 Allowed 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.228 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.547 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . -167.74 133.19 1.94 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.698 -1.251 . . . . 0.0 111.047 -179.354 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.005 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -100.88 104.32 15.53 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-O 122.407 1.099 . . . . 0.0 109.816 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.944 HG22 HG23 ' A' ' 21' ' ' VAL . 6.2 t -119.79 118.0 55.66 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.459 0 CA-C-O 121.694 0.759 . . . . 0.0 110.405 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.78 149.08 7.93 Favored Pre-proline 0 N--CA 1.488 1.425 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 -179.568 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -75.26 152.85 98.33 Favored 'Cis proline' 0 C--N 1.309 -1.535 0 C-N-CA 123.583 -1.424 . . . . 0.0 109.762 -0.301 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.658 ' HA ' HG22 ' A' ' 110' ' ' ILE . 6.5 m -91.5 -25.0 19.48 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.498 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.8 m -137.85 165.1 27.3 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.637 -0.664 . . . . 0.0 109.253 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.27 37.49 31.8 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 108.564 -1.814 . . . . 0.0 108.564 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.741 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.0 mt -92.07 -42.43 9.95 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 123.311 1.529 . . . . 0.0 110.522 -178.487 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.67 142.67 0.05 OUTLIER 'General case' 0 C--N 1.259 -3.327 0 CA-C-N 113.405 -1.725 . . . . 0.0 109.731 -179.644 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.607 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.6 p-10 -50.28 105.78 0.1 Allowed 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.521 0.677 . . . . 0.0 111.473 -178.549 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.49 14.22 8.33 Favored Glycine 0 N--CA 1.485 1.928 0 C-N-CA 119.413 -1.375 . . . . 0.0 113.018 177.37 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.741 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -106.3 -172.57 2.11 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 121.221 2.51 . . . . 0.0 109.832 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.852 HG22 HG22 ' A' ' 68' ' ' THR . 18.8 t -129.0 139.76 51.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 CA-C-N 114.823 -1.08 . . . . 0.0 111.204 -178.644 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.63 HG11 HD11 ' A' ' 13' ' ' LEU . 27.1 m -115.88 155.61 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.553 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.7 tttt -107.86 108.79 20.11 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.021 -1.05 . . . . 0.0 109.552 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.944 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -106.8 122.67 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.005 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.83 167.48 11.36 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 120.795 -1.191 . . . . 0.0 109.064 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.86 142.44 13.95 Favored Glycine 0 C--N 1.295 -1.733 0 N-CA-C 107.935 -2.066 . . . . 0.0 107.935 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.595 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -147.16 123.7 11.07 Favored 'General case' 0 C--N 1.294 -1.834 0 O-C-N 120.812 -1.405 . . . . 0.0 108.64 179.237 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.19 27.25 23.72 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 119.313 -1.422 . . . . 0.0 109.838 -179.595 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.534 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.6 mt -87.73 175.14 8.0 Favored 'General case' 0 C--N 1.308 -1.236 0 O-C-N 120.877 -1.367 . . . . 0.0 108.466 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.61 96.95 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.017 -1.052 . . . . 0.0 109.541 -179.899 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.699 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.49 76.76 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.791 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.533 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.44 33.49 0.3 Allowed Glycine 0 N--CA 1.486 2.016 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.198 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.618 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.6 t -147.12 114.55 6.31 Favored 'General case' 0 C--N 1.308 -1.223 0 O-C-N 120.791 -1.417 . . . . 0.0 111.173 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.82 127.32 6.27 Favored 'General case' 0 N--CA 1.49 1.528 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.689 178.293 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.618 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 9.1 m-85 -116.33 148.61 40.4 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.529 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -101.21 149.33 24.11 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.805 -1.185 . . . . 0.0 107.92 179.135 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.634 HG23 HD23 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -127.43 126.7 67.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.271 -0.893 . . . . 0.0 109.371 -177.935 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -174.52 174.97 46.79 Favored Glycine 0 N--CA 1.495 2.612 0 C-N-CA 117.833 -2.127 . . . . 0.0 112.42 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.585 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -101.36 108.47 20.1 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.473 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.8 m -131.24 147.92 52.64 Favored 'General case' 0 C--N 1.295 -1.772 0 O-C-N 121.251 -0.905 . . . . 0.0 109.942 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.43 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.02 139.04 53.84 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.394 -0.816 . . . . 0.0 110.609 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.879 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.42 115.03 26.87 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 178.159 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -106.11 14.85 7.41 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 120.963 -1.085 . . . . 0.0 110.529 -178.839 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.776 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.14 -174.61 0.08 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.848 -1.157 . . . . 0.0 110.121 179.667 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 5.9 p -71.46 96.78 1.54 Allowed 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.46 -0.775 . . . . 0.0 109.931 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 27.83 32.9 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 120.171 -1.014 . . . . 0.0 111.558 178.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.776 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.26 106.28 20.24 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 O-C-N 120.552 -1.558 . . . . 0.0 107.267 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.879 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.3 tp -117.37 104.92 11.61 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.454 -1.404 . . . . 0.0 109.913 -177.686 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.038 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.84 109.61 22.33 Favored 'General case' 0 N--CA 1.485 1.287 0 O-C-N 120.706 -1.246 . . . . 0.0 108.296 178.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.3 t -105.97 163.93 12.36 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.041 -1.037 . . . . 0.0 110.198 -178.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.623 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 20.0 t30 -107.36 139.12 20.19 Favored Pre-proline 0 N--CA 1.502 2.16 0 O-C-N 121.327 -0.858 . . . . 0.0 109.81 -179.372 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.569 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 7.8 Cg_endo -75.88 27.73 0.39 Allowed 'Trans proline' 0 C--N 1.32 -0.964 0 C-N-CA 122.59 2.194 . . . . 0.0 112.135 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.623 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -124.44 9.61 8.47 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.242 -1.536 . . . . 0.0 109.679 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.567 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.46 15.63 2.76 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.403 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -77.69 86.92 3.97 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.856 -0.737 . . . . 0.0 111.421 -178.265 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.605 ' CB ' HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.34 -169.77 1.85 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 177.954 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.71 134.65 0.08 Allowed 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.57 -1.331 . . . . 0.0 111.454 -179.392 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.912 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -160.47 154.73 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 178.18 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.568 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.56 144.83 26.85 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.741 -1.225 . . . . 0.0 109.572 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.07 106.74 1.69 Allowed 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 122.48 1.134 . . . . 0.0 109.476 178.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.545 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.5 p-10 -59.78 -138.83 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.982 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.893 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.699 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.37 -50.44 59.56 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.467 -0.771 . . . . 0.0 110.548 -178.625 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -104.97 -34.63 7.95 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 178.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.966 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.88 68.32 0.59 Allowed Glycine 0 C--N 1.298 -1.543 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 177.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 59.4 m -103.21 129.23 50.08 Favored 'General case' 0 N--CA 1.484 1.274 0 O-C-N 121.358 -1.084 . . . . 0.0 108.83 178.836 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.912 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.12 109.27 7.75 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.281 -0.967 . . . . 0.0 110.073 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.6 m -110.23 118.38 36.19 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.205 -0.934 . . . . 0.0 108.787 179.499 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.458 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.24 139.08 28.45 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.436 -0.79 . . . . 0.0 110.253 -179.514 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 78.8 p -103.18 140.79 36.9 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 179.416 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.759 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -142.84 164.1 31.02 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.173 -0.955 . . . . 0.0 109.994 -179.148 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.852 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -97.59 125.49 42.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.339 -0.851 . . . . 0.0 109.129 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.553 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.2 m -136.44 143.64 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.908 -1.12 . . . . 0.0 109.803 -179.087 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.607 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -146.7 -176.12 5.06 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.44 -1.413 . . . . 0.0 111.156 -179.787 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.613 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.91 -100.54 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 -179.581 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.05 140.4 49.27 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 179.353 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.44 135.94 6.16 Favored 'General case' 0 C--N 1.294 -1.817 0 C-N-CA 118.584 -1.246 . . . . 0.0 109.764 -177.996 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.553 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 3.9 mm-40 -33.07 121.47 0.37 Allowed 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.547 0.689 . . . . 0.0 110.431 -178.482 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.038 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.89 48.08 2.74 Favored Glycine 0 N--CA 1.492 2.408 0 C-N-CA 120.602 -0.808 . . . . 0.0 111.195 -179.177 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.569 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -38.22 115.18 0.42 Allowed 'General case' 0 N--CA 1.511 2.623 0 O-C-N 121.118 -1.225 . . . . 0.0 109.974 179.695 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.689 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.29 125.76 34.42 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.944 -1.098 . . . . 0.0 109.321 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.595 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 19.6 t80 -64.2 58.65 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.891 -1.131 . . . . 0.0 110.215 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t0 -160.67 20.0 0.14 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.973 -1.079 . . . . 0.0 109.749 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.93 -27.8 5.3 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.439 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 80.7 p -94.22 159.42 15.14 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.038 -1.272 . . . . 0.0 110.269 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.495 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 4.4 ptt180 -107.32 137.59 45.09 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.689 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.9 t90 -83.76 -18.51 37.53 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.821 -1.174 . . . . 0.0 110.79 -178.231 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.97 175.08 19.8 Favored Glycine 0 N--CA 1.485 1.937 0 N-CA-C 108.711 -1.755 . . . . 0.0 108.711 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.21 106.77 1.15 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.604 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.4 t -79.1 106.41 10.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.286 -0.884 . . . . 0.0 109.264 -179.025 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.638 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -65.84 111.13 3.12 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.533 -0.73 . . . . 0.0 109.904 -179.442 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.613 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.26 -4.97 4.21 Favored 'General case' 0 N--CA 1.499 1.98 0 C-N-CA 118.246 -1.382 . . . . 0.0 109.814 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -86.39 -0.49 56.06 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.891 -1.131 . . . . 0.0 109.156 179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.638 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -113.31 -50.05 2.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.392 -0.818 . . . . 0.0 109.013 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.74 179.96 4.12 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.453 -0.779 . . . . 0.0 109.427 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.69 115.73 31.03 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.366 -0.834 . . . . 0.0 109.103 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.72 121.07 38.16 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.917 -1.114 . . . . 0.0 109.383 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.605 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.18 146.15 27.2 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-O 122.273 1.035 . . . . 0.0 111.193 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.447 ' HB ' HG11 ' A' ' 7' ' ' VAL . 71.7 t -105.73 112.2 38.12 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.168 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.516 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -152.49 -169.98 18.44 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 118.018 -2.039 . . . . 0.0 111.578 -178.011 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.634 HD23 HG23 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -112.64 -179.0 3.54 Favored 'General case' 0 N--CA 1.484 1.272 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -179.189 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.584 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -171.83 167.35 6.33 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.17 -0.956 . . . . 0.0 109.826 -179.402 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.89 -160.04 0.71 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.108 -0.995 . . . . 0.0 108.822 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -119.69 35.64 4.78 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.614 -1.304 . . . . 0.0 109.452 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.49 -32.37 4.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.359 -0.838 . . . . 0.0 110.219 -179.575 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.94 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 170.18 -38.45 0.19 Allowed Glycine 0 N--CA 1.481 1.679 0 N-CA-C 107.709 -2.156 . . . . 0.0 107.709 -179.554 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -161.26 -177.73 6.22 Favored 'General case' 0 C--N 1.307 -1.266 0 O-C-N 121.553 -0.969 . . . . 0.0 109.681 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.497 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -162.57 -159.47 10.37 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.275 -1.93 . . . . 0.0 108.275 -179.215 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.497 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.4 Cg_exo -47.21 179.98 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.675 0 CA-C-N 118.667 1.234 . . . . 0.0 110.37 179.183 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -92.57 -178.27 4.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.033 -1.042 . . . . 0.0 110.645 -178.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.516 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.02 163.57 13.25 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.402 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.08 128.79 54.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.422 -1.046 . . . . 0.0 109.214 -179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.605 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.86 119.04 15.48 Favored 'General case' 0 C--N 1.29 -2.016 0 O-C-N 121.721 -0.612 . . . . 0.0 109.491 179.576 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.897 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.01 171.52 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.248 -0.908 . . . . 0.0 109.042 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.498 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -138.8 159.59 41.74 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.161 -0.962 . . . . 0.0 109.986 -179.696 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.897 ' CE2' HD12 ' A' ' 110' ' ' ILE . 96.8 m-85 -135.23 103.3 5.47 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.18 -0.95 . . . . 0.0 109.582 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 16.8 p30 . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.462 179.93 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.94 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -120.27 152.36 54.67 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.337 -0.852 . . . . 0.0 109.401 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.559 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.2 Cg_exo -60.17 157.73 33.57 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 C-N-CA 122.34 2.027 . . . . 0.0 110.65 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.544 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.48 -169.9 0.15 Allowed 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.047 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.545 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -164.58 129.9 2.75 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.881 -1.137 . . . . 0.0 110.429 -179.218 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.941 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.4 t -109.74 108.69 19.13 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 123.05 1.405 . . . . 0.0 109.286 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.815 HG22 HG23 ' A' ' 21' ' ' VAL . 1.3 t -116.32 136.35 53.59 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.689 0 CA-C-N 114.164 -1.38 . . . . 0.0 109.903 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.461 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -172.88 149.05 1.78 Allowed Pre-proline 0 N--CA 1.487 1.405 0 O-C-N 121.194 -0.941 . . . . 0.0 108.883 -179.616 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.461 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.2 Cg_endo -77.24 151.33 93.05 Favored 'Cis proline' 0 C--N 1.313 -1.332 0 C-N-CA 123.404 -1.498 . . . . 0.0 109.323 -0.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 16.6 p -86.83 -26.86 23.84 Favored 'General case' 0 C--N 1.295 -1.803 0 O-C-N 121.455 -0.778 . . . . 0.0 109.169 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.498 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.4 m -134.62 168.23 19.38 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.409 -0.807 . . . . 0.0 109.463 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.03 38.51 35.16 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 108.359 -1.896 . . . . 0.0 108.359 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.744 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.2 mt -94.81 -42.61 8.62 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 123.186 1.47 . . . . 0.0 110.65 -178.164 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.91 143.69 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.289 0 CA-C-N 113.334 -1.757 . . . . 0.0 109.889 -179.55 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 11.9 p-10 -50.3 104.62 0.08 Allowed 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.53 0.681 . . . . 0.0 111.469 -178.498 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.17 14.44 7.74 Favored Glycine 0 N--CA 1.485 1.91 0 C-N-CA 119.321 -1.419 . . . . 0.0 113.09 177.164 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.744 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.5 t -106.47 -172.47 2.09 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 121.336 2.568 . . . . 0.0 109.876 179.312 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.744 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.4 t -128.21 136.78 59.24 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.328 0 CA-C-N 114.733 -1.121 . . . . 0.0 111.242 -178.741 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.64 HG11 HD11 ' A' ' 13' ' ' LEU . 27.8 m -111.08 157.22 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.649 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.521 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 4.0 tptm -106.83 109.17 21.01 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.033 -1.042 . . . . 0.0 108.933 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.815 HG23 HG22 ' A' ' 7' ' ' VAL . 7.6 p -103.55 141.05 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.941 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -138.79 161.52 37.03 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.718 -1.238 . . . . 0.0 110.061 179.678 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.594 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.46 143.69 15.01 Favored Glycine 0 C--N 1.294 -1.763 0 N-CA-C 108.355 -1.898 . . . . 0.0 108.355 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.559 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.14 125.68 13.27 Favored 'General case' 0 C--N 1.295 -1.774 0 O-C-N 120.914 -1.345 . . . . 0.0 108.996 178.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.536 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 87.45 25.92 31.82 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 119.312 -1.423 . . . . 0.0 110.116 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.601 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.2 mt -86.15 172.55 10.46 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 120.937 -1.331 . . . . 0.0 108.474 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.015 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.76 100.14 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.009 -1.057 . . . . 0.0 109.651 -179.704 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.562 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 77.83 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.147 -179.165 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.81 34.03 0.32 Allowed Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 179.543 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.565 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.7 p -140.71 108.13 5.56 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 121.183 -1.186 . . . . 0.0 111.153 -179.508 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.586 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.98 111.64 0.59 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.535 177.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.464 ' OH ' ' HB2' ' A' ' 27' ' ' GLN . 6.0 m-30 -107.14 156.34 18.91 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.129 -0.982 . . . . 0.0 108.935 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.475 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.8 160.5 14.22 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 178.933 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.632 HG22 HG11 ' A' ' 21' ' ' VAL . 5.3 p -140.94 119.26 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.129 -0.982 . . . . 0.0 109.678 -177.804 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -171.64 -177.36 41.27 Favored Glycine 0 N--CA 1.494 2.513 0 C-N-CA 118.443 -1.836 . . . . 0.0 111.532 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.684 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -98.73 109.13 21.93 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.723 0.773 . . . . 0.0 108.944 -179.95 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -129.09 149.35 50.94 Favored 'General case' 0 C--N 1.295 -1.783 0 O-C-N 121.236 -0.915 . . . . 0.0 109.964 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.586 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.92 138.88 54.23 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.255 -0.903 . . . . 0.0 110.838 -179.009 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.05 26.9 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.037 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -105.32 15.16 6.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.903 -1.123 . . . . 0.0 110.585 -178.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.751 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.03 -175.29 0.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.886 -1.134 . . . . 0.0 110.08 179.722 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -72.37 97.41 2.04 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.394 -0.816 . . . . 0.0 109.687 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.34 27.97 31.65 Favored Glycine 0 N--CA 1.493 2.45 0 C-N-CA 120.177 -1.011 . . . . 0.0 111.385 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.751 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.92 106.43 20.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 120.534 -1.568 . . . . 0.0 107.165 178.845 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.48 104.72 11.72 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.479 -1.388 . . . . 0.0 109.937 -177.533 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.058 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.0 109.63 22.35 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 178.649 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.486 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -108.52 162.42 14.15 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.876 -1.14 . . . . 0.0 110.54 -178.742 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.502 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 7.8 t30 -108.72 130.3 22.91 Favored Pre-proline 0 N--CA 1.499 2.004 0 O-C-N 121.551 -0.718 . . . . 0.0 109.553 -179.377 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.592 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.56 21.35 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.078 0 C-N-CA 122.028 1.819 . . . . 0.0 112.021 179.562 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.502 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -99.41 -3.99 32.53 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.421 -1.424 . . . . 0.0 108.995 179.409 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.68 ' OD2' HG13 ' A' ' 69' ' ' VAL . 5.9 m-20 -135.62 9.89 3.4 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -66.84 86.18 0.13 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.499 -0.75 . . . . 0.0 111.059 -178.291 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.612 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -108.5 -167.29 1.21 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 177.912 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.32 134.47 0.09 Allowed 'General case' 0 C--N 1.305 -1.34 0 O-C-N 120.503 -1.373 . . . . 0.0 111.451 -179.22 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.866 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -150.24 157.77 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 177.923 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.586 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.71 142.72 29.91 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.766 -1.209 . . . . 0.0 110.113 -179.685 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.015 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.67 107.12 1.09 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.398 1.094 . . . . 0.0 109.336 178.338 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.547 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -59.37 -139.08 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.056 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.856 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.562 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.73 -49.84 64.61 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.462 -0.774 . . . . 0.0 110.496 -178.641 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.477 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.6 t-20 -103.57 -35.17 8.4 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 178.454 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.009 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.95 66.78 0.58 Allowed Glycine 0 C--N 1.298 -1.579 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 177.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.9 m -104.54 128.92 52.62 Favored 'General case' 0 C--N 1.308 -1.223 0 O-C-N 121.308 -1.113 . . . . 0.0 108.683 178.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.866 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.69 109.91 8.92 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.184 -1.006 . . . . 0.0 109.668 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 91.7 p -117.75 117.77 30.24 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.367 -0.833 . . . . 0.0 109.481 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.547 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -147.31 151.29 36.34 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.422 -0.799 . . . . 0.0 109.42 -179.957 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.748 ' O ' HD23 ' A' ' 67' ' ' LEU . 69.6 p -98.52 153.57 18.53 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.304 -0.872 . . . . 0.0 109.571 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.785 HD11 HG11 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -147.92 160.1 43.17 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.339 -0.851 . . . . 0.0 109.634 -179.176 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.653 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -100.55 122.85 43.92 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.971 -1.08 . . . . 0.0 108.58 179.261 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.684 HG12 ' HB3' ' A' ' 36' ' ' GLN . 19.2 m -136.41 143.06 36.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 120.799 -1.188 . . . . 0.0 110.459 -178.669 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.1 ptt180 -146.43 -175.27 4.71 Favored 'General case' 0 N--CA 1.483 1.205 0 O-C-N 120.749 -1.219 . . . . 0.0 110.663 179.654 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.604 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.79 -102.03 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -179.733 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.496 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -56.02 140.27 43.99 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.761 -1.212 . . . . 0.0 108.244 179.401 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.586 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.4 OUTLIER -160.74 137.93 9.13 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 118.672 -1.211 . . . . 0.0 110.009 -178.285 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.484 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.7 OUTLIER -35.43 120.68 0.57 Allowed 'General case' 0 N--CA 1.49 1.563 0 CA-C-O 121.522 0.677 . . . . 0.0 110.618 -178.439 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.058 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.17 50.47 2.18 Favored Glycine 0 N--CA 1.493 2.486 0 O-C-N 121.551 -0.718 . . . . 0.0 111.37 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.592 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.8 m-85 -39.11 114.87 0.43 Allowed 'General case' 0 N--CA 1.511 2.616 0 O-C-N 120.947 -1.325 . . . . 0.0 109.89 179.536 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.724 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -87.25 125.24 34.07 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.771 -1.206 . . . . 0.0 109.306 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.573 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 18.7 t80 -64.78 56.31 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.062 0 O-C-N 120.742 -1.224 . . . . 0.0 110.491 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.618 ' OD2' HD23 ' A' ' 77' ' ' LEU . 2.9 p30 -154.79 16.18 0.44 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.998 -1.064 . . . . 0.0 109.859 179.742 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.53 -27.03 10.18 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.427 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -100.87 161.17 13.78 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.901 -1.352 . . . . 0.0 110.38 -179.408 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.434 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 3.6 ptm180 -103.77 139.36 39.11 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.605 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.724 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.2 t90 -82.44 -19.83 38.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.917 -1.114 . . . . 0.0 110.599 -178.276 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.64 175.66 18.71 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -66.41 104.77 1.3 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.174 -1.192 . . . . 0.0 107.848 179.318 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.648 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.7 t -75.31 106.88 5.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.286 -0.884 . . . . 0.0 109.56 -178.736 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.665 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -64.97 110.65 2.53 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.421 -0.8 . . . . 0.0 109.759 -179.679 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.604 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.23 -5.18 4.53 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.533 -1.354 . . . . 0.0 109.766 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.7 p -86.45 -0.28 55.67 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.779 -1.2 . . . . 0.0 109.136 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.665 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -114.52 -51.24 2.76 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.326 -0.859 . . . . 0.0 109.026 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.403 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -102.85 -178.83 3.78 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.445 -0.784 . . . . 0.0 109.413 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.68 115.05 29.59 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.868 . . . . 0.0 108.983 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -96.91 122.18 39.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.855 -1.153 . . . . 0.0 109.478 -179.247 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.611 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.28 145.64 29.16 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-O 122.341 1.067 . . . . 0.0 111.284 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.653 ' CG1' HG11 ' A' ' 7' ' ' VAL . 99.5 t -101.59 109.79 26.78 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 177.637 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.509 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.95 -169.56 17.58 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.052 -2.023 . . . . 0.0 111.733 -177.536 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.545 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -120.79 177.47 5.08 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 -179.1 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.583 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 2.5 t 179.21 171.91 0.89 Allowed 'General case' 0 C--N 1.292 -1.923 0 O-C-N 121.588 -0.695 . . . . 0.0 109.59 179.831 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -116.01 -160.17 0.74 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.0 -1.063 . . . . 0.0 109.001 -179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -117.95 36.68 4.23 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.723 -1.236 . . . . 0.0 109.138 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -112.18 -32.38 6.56 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.324 -0.86 . . . . 0.0 109.805 -179.672 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.519 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 169.4 -37.64 0.2 Allowed Glycine 0 N--CA 1.481 1.684 0 N-CA-C 108.143 -1.983 . . . . 0.0 108.143 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -167.78 -176.88 3.25 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 121.62 -0.93 . . . . 0.0 109.853 179.358 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.1 -160.7 16.32 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.315 -1.914 . . . . 0.0 108.315 -179.41 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.3 Cg_exo -47.2 179.25 0.0 OUTLIER 'Trans proline' 0 C--O 1.216 -0.607 0 CA-C-N 118.829 1.315 . . . . 0.0 110.395 179.324 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -96.22 -175.69 3.44 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.028 -1.045 . . . . 0.0 110.309 -179.099 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.509 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.91 163.82 13.74 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.41 HG11 ' HB ' ' A' ' 7' ' ' VAL . 1.2 t -99.0 127.36 51.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.39 -1.065 . . . . 0.0 109.062 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.611 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -70.34 120.42 15.97 Favored 'General case' 0 C--N 1.289 -2.022 0 O-C-N 121.778 -0.576 . . . . 0.0 109.662 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.875 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.98 170.55 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.234 -0.916 . . . . 0.0 109.131 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.498 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.99 157.56 45.47 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.263 -0.898 . . . . 0.0 109.895 -179.717 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.875 ' CE2' HD12 ' A' ' 110' ' ' ILE . 91.7 m-85 -134.22 113.66 12.24 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 121.271 -0.893 . . . . 0.0 109.587 -179.62 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.4 p30 . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.461 -179.863 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.852 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.468 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -120.94 157.96 53.61 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.267 -0.895 . . . . 0.0 109.486 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.569 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.9 Cg_exo -59.47 158.23 28.2 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.281 1.987 . . . . 0.0 110.455 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.539 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.47 -169.72 0.15 Allowed 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 179.275 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.539 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.89 130.55 2.31 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.754 -1.216 . . . . 0.0 110.762 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.94 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -111.35 108.63 18.29 Favored 'General case' 0 C--N 1.295 -1.762 0 CA-C-O 123.068 1.413 . . . . 0.0 109.084 179.201 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.831 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -115.26 140.68 35.44 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.73 0 CA-C-N 114.321 -1.308 . . . . 0.0 110.26 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.476 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -175.56 149.07 1.06 Allowed Pre-proline 0 N--CA 1.487 1.396 0 O-C-N 121.337 -0.852 . . . . 0.0 108.854 -179.751 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.476 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.3 Cg_endo -78.63 150.47 87.33 Favored 'Cis proline' 0 C--N 1.311 -1.399 0 C-N-CA 123.36 -1.516 . . . . 0.0 109.09 -0.841 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.67 ' HA ' HG22 ' A' ' 110' ' ' ILE . 75.9 p -89.73 -24.58 21.5 Favored 'General case' 0 C--N 1.291 -1.947 0 O-C-N 121.53 -0.731 . . . . 0.0 109.358 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.507 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 12.9 m -134.83 162.8 31.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.346 -0.846 . . . . 0.0 109.757 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.88 37.67 29.06 Favored Glycine 0 N--CA 1.496 2.667 0 N-CA-C 108.604 -1.798 . . . . 0.0 108.604 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.78 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.0 mt -92.56 -44.24 8.72 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-O 123.19 1.472 . . . . 0.0 110.606 -178.369 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.457 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.66 144.07 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.331 0 CA-C-N 113.48 -1.691 . . . . 0.0 110.135 -179.775 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.616 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.2 p-10 -49.74 107.84 0.17 Allowed 'General case' 0 C--N 1.301 -1.526 0 CA-C-O 121.712 0.768 . . . . 0.0 111.471 -178.839 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.47 12.93 9.22 Favored Glycine 0 N--CA 1.484 1.855 0 C-N-CA 119.45 -1.357 . . . . 0.0 112.939 177.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.78 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.6 t -105.76 -173.05 2.21 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 121.251 2.525 . . . . 0.0 109.663 179.237 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.74 HG13 ' C ' ' A' ' 67' ' ' LEU . 20.9 t -127.1 135.01 64.79 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.45 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.035 -178.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.601 ' CG1' HD13 ' A' ' 13' ' ' LEU . 36.0 m -108.68 155.53 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.839 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.58 109.4 18.56 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.092 -1.005 . . . . 0.0 108.945 179.885 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.831 HG23 HG22 ' A' ' 7' ' ' VAL . 2.2 p -104.58 140.56 22.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.94 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.24 160.09 39.48 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 118.691 -1.204 . . . . 0.0 109.699 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.23 145.28 16.52 Favored Glycine 0 C--N 1.295 -1.712 0 N-CA-C 108.109 -1.996 . . . . 0.0 108.109 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.569 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.79 124.98 12.16 Favored 'General case' 0 C--N 1.296 -1.755 0 O-C-N 120.978 -1.307 . . . . 0.0 108.779 178.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.528 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.36 26.58 25.24 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.264 -1.446 . . . . 0.0 109.888 -179.587 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.592 HD22 ' HG3' ' A' ' 105' ' ' PRO . 2.0 mt -87.17 175.69 7.94 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 120.872 -1.369 . . . . 0.0 108.421 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.66 98.02 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.398 0 O-C-N 120.93 -1.106 . . . . 0.0 109.702 -179.597 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.651 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.57 77.44 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.737 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.511 -179.176 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.555 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.14 34.42 0.33 Allowed Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.55 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.1 p -146.25 111.92 5.58 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.039 -1.271 . . . . 0.0 111.223 -179.686 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.559 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.08 127.76 5.57 Favored 'General case' 0 N--CA 1.492 1.659 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.683 178.207 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.567 ' CZ ' ' OD2' ' A' ' 99' ' ' ASP . 13.2 m-85 -118.5 150.57 39.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.327 -0.858 . . . . 0.0 108.881 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.518 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -100.52 153.15 19.61 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.64 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.655 HG22 HG11 ' A' ' 21' ' ' VAL . 4.2 p -137.55 119.03 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.844 -1.16 . . . . 0.0 110.043 -177.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.518 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.74 -178.88 40.59 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.673 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.57 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -99.73 109.12 21.59 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 -179.943 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.48 148.78 52.33 Favored 'General case' 0 C--N 1.295 -1.795 0 O-C-N 121.285 -0.885 . . . . 0.0 109.881 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.6 137.42 54.9 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.3 -0.875 . . . . 0.0 110.883 -179.094 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.868 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.54 114.9 26.71 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 178.009 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.1 m -105.73 14.69 7.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.053 -1.029 . . . . 0.0 110.707 -178.712 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.756 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.6 -175.11 0.08 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.901 -1.125 . . . . 0.0 110.106 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 28.0 p -72.59 98.56 2.35 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.45 -0.781 . . . . 0.0 109.623 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.2 27.16 34.33 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 120.226 -0.988 . . . . 0.0 111.342 178.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.756 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.02 106.04 19.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.55 -1.559 . . . . 0.0 107.295 178.829 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.868 HD13 ' NE1' ' A' ' 39' ' ' TRP . 14.0 tp -118.86 104.34 10.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.458 -1.401 . . . . 0.0 109.822 -177.666 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.027 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.22 109.58 22.32 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.868 -1.145 . . . . 0.0 108.246 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.54 166.23 10.71 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.982 -1.074 . . . . 0.0 110.269 -178.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.714 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.0 t-20 -108.87 134.82 20.22 Favored Pre-proline 0 N--CA 1.499 2.01 0 O-C-N 121.364 -0.835 . . . . 0.0 109.639 -179.416 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.589 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.1 Cg_endo -74.85 24.66 0.38 Allowed 'Trans proline' 0 CA--C 1.545 1.055 0 C-N-CA 122.277 1.985 . . . . 0.0 111.949 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.714 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -117.18 4.34 12.66 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.498 -1.376 . . . . 0.0 109.297 179.633 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.26 17.54 2.78 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.285 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -81.97 86.96 6.45 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.922 -178.562 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.6 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -104.98 -165.89 1.18 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.334 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.449 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.01 135.77 0.09 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 120.609 -1.307 . . . . 0.0 111.449 -179.284 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.904 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -152.66 156.61 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 178.08 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.559 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.58 145.34 26.36 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.602 -1.312 . . . . 0.0 109.921 -179.611 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.34 107.54 1.66 Allowed 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 122.384 1.087 . . . . 0.0 109.57 178.652 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.532 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.2 p-10 -60.87 -138.92 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.944 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.841 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.651 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.33 -50.62 59.07 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.509 -0.744 . . . . 0.0 110.673 -178.632 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.475 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.3 t-20 -104.35 -33.99 8.45 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 178.548 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.991 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.13 65.41 0.56 Allowed Glycine 0 C--N 1.297 -1.617 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 178.076 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.2 m -101.6 128.48 47.85 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.505 -0.997 . . . . 0.0 108.549 178.865 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.904 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.68 108.8 6.78 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.057 -1.057 . . . . 0.0 109.884 -179.21 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.2 m -121.0 118.96 31.17 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.361 -0.837 . . . . 0.0 109.371 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.563 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.63 143.74 30.91 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.392 -0.818 . . . . 0.0 109.479 179.83 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.423 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 28.9 p -99.06 146.97 25.52 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.4 -0.813 . . . . 0.0 109.411 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.783 HD12 ' H ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -147.42 167.97 23.05 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.393 -0.817 . . . . 0.0 109.368 -179.251 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.663 HG22 HG22 ' A' ' 18' ' ' VAL . 4.6 p -94.49 124.73 38.69 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.903 -1.123 . . . . 0.0 109.859 -179.522 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.598 ' CG2' HG13 ' A' ' 19' ' ' VAL . 15.8 m -136.46 144.98 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.997 -1.064 . . . . 0.0 109.206 -179.695 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.616 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.3 ptt180 -147.56 -178.49 6.28 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.327 -1.483 . . . . 0.0 111.346 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.727 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -50.07 -98.17 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -179.569 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.541 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 1.0 OUTLIER -63.79 146.69 53.45 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.57 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.609 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.8 OUTLIER -166.18 141.76 4.75 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 118.03 -1.468 . . . . 0.0 110.243 -177.276 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.548 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.9 mm-40 -36.03 120.71 0.64 Allowed 'General case' 0 N--CA 1.491 1.619 0 CA-C-O 121.475 0.655 . . . . 0.0 110.308 -178.771 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.027 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.59 51.46 1.79 Allowed Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.589 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -39.35 113.74 0.35 Allowed 'General case' 0 N--CA 1.507 2.401 0 O-C-N 121.093 -1.24 . . . . 0.0 110.142 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.686 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -85.28 126.35 33.64 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 120.958 -1.089 . . . . 0.0 109.415 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.592 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 18.5 t80 -64.33 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.963 0 O-C-N 120.82 -1.175 . . . . 0.0 110.105 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.7 t0 -160.07 19.76 0.16 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.982 -1.074 . . . . 0.0 109.648 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.91 -27.65 5.36 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 110.063 -1.215 . . . . 0.0 110.063 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.448 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.15 157.6 16.0 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.04 -1.27 . . . . 0.0 110.446 -179.395 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.476 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 1.8 ptm180 -104.87 136.15 44.91 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.686 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.5 t90 -82.86 -16.47 47.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.761 -1.212 . . . . 0.0 110.689 -178.26 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.08 175.43 20.83 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 108.828 -1.709 . . . . 0.0 108.828 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.72 103.51 0.7 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 179.14 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.614 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.8 t -74.54 107.42 5.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.384 -0.823 . . . . 0.0 109.566 -178.841 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.541 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -67.09 112.0 4.18 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.581 -0.699 . . . . 0.0 109.685 -179.556 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.727 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 11.0 m -60.96 -5.71 1.5 Allowed 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.104 -1.439 . . . . 0.0 110.35 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.02 -4.43 58.79 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.396 -1.44 . . . . 0.0 109.53 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.511 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -104.0 -48.0 4.02 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.202 -0.936 . . . . 0.0 108.886 179.706 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -112.55 -178.3 3.37 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.573 -0.704 . . . . 0.0 109.33 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.37 117.3 34.44 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.375 -0.828 . . . . 0.0 109.02 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.509 ' O ' HG12 ' A' ' 110' ' ' ILE . 3.9 m -96.47 122.77 39.72 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.866 -1.146 . . . . 0.0 109.344 -179.515 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.58 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mp0 -106.7 145.48 31.95 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 122.404 1.097 . . . . 0.0 111.685 -179.112 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.483 ' CG1' ' HB ' ' A' ' 21' ' ' VAL . 62.0 t -100.83 109.71 26.05 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 177.428 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.5 -172.2 16.58 Favored Glycine 0 N--CA 1.487 2.052 0 C-N-CA 118.257 -1.925 . . . . 0.0 111.622 -177.383 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.523 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -117.04 -179.22 3.63 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -178.874 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.56 ' HB2' ' C20' ' A' ' 114' ' ' CHR . 8.4 p -166.17 164.14 17.91 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.369 -0.832 . . . . 0.0 109.09 -179.479 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.684 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 1.6 m-20 -100.69 -9.97 21.33 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.084 -1.01 . . . . 0.0 109.477 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.684 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 74.48 37.77 0.54 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.468 -0.77 . . . . 0.0 109.202 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.67 -33.74 0.78 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.523 -0.736 . . . . 0.0 110.643 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.479 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 177.77 -40.94 0.09 OUTLIER Glycine 0 N--CA 1.483 1.814 0 N-CA-C 107.552 -2.219 . . . . 0.0 107.552 -179.514 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.75 -179.02 7.79 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.432 -1.04 . . . . 0.0 109.561 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -174.41 -165.8 31.46 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.592 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.7 Cg_exo -49.64 -174.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 CA-C-N 118.778 1.289 . . . . 0.0 110.472 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -93.9 -179.61 5.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.113 -0.992 . . . . 0.0 110.373 -179.103 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -116.66 158.64 14.36 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.466 HG11 ' HB ' ' A' ' 7' ' ' VAL . 1.2 t -98.76 124.93 52.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.362 -1.081 . . . . 0.0 109.056 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.58 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.54 120.91 18.81 Favored 'General case' 0 C--N 1.29 -2.005 0 O-C-N 121.804 -0.56 . . . . 0.0 109.707 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.87 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -98.02 169.1 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.255 -0.903 . . . . 0.0 109.241 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.507 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.72 155.22 50.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.307 -0.871 . . . . 0.0 109.48 179.993 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.87 ' CE1' HD12 ' A' ' 110' ' ' ILE . 74.5 m-85 -124.36 109.27 13.12 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.164 -0.96 . . . . 0.0 109.468 -179.622 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.402 ' C ' ' O ' ' A' ' 112' ' ' PHE . 17.0 p30 . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.196 -0.94 . . . . 0.0 109.428 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.687 ' H10' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.338 0.59 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -120.26 153.91 55.95 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.186 -0.947 . . . . 0.0 109.496 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.691 ' HB3' HD23 ' A' ' 26' ' ' LEU . 2.7 Cg_endo -61.27 155.75 49.82 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.234 1.956 . . . . 0.0 110.554 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.602 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -145.66 160.88 41.05 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 -179.862 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -146.92 128.05 14.68 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.919 -1.113 . . . . 0.0 110.672 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.012 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.6 p -104.2 104.57 14.51 Favored 'General case' 0 C--N 1.296 -1.724 0 CA-C-O 122.49 1.138 . . . . 0.0 110.115 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.959 HG22 HG23 ' A' ' 21' ' ' VAL . 16.2 t -119.8 115.61 47.99 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.46 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.292 179.681 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.49 148.8 13.14 Favored Pre-proline 0 N--CA 1.487 1.407 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -179.583 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.1 Cg_endo -77.92 150.22 89.08 Favored 'Cis proline' 0 C--N 1.309 -1.528 0 C-N-CA 123.606 -1.414 . . . . 0.0 109.737 -0.397 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.656 ' HA ' HG22 ' A' ' 110' ' ' ILE . 40.1 p -89.05 -26.4 21.43 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.403 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.535 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 6.0 p -133.07 165.19 25.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.522 -0.736 . . . . 0.0 109.423 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.14 37.51 37.3 Favored Glycine 0 N--CA 1.496 2.652 0 N-CA-C 108.402 -1.879 . . . . 0.0 108.402 -179.548 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.775 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.6 mt -92.51 -42.98 9.41 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 123.328 1.537 . . . . 0.0 110.491 -178.26 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.28 143.94 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.29 0 CA-C-N 113.319 -1.764 . . . . 0.0 109.858 -179.548 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.599 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.0 p-10 -50.38 106.2 0.12 Allowed 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.398 0.618 . . . . 0.0 111.666 -178.498 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.53 14.4 8.89 Favored Glycine 0 N--CA 1.485 1.924 0 C-N-CA 119.42 -1.371 . . . . 0.0 113.022 177.244 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.775 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.96 -172.66 2.14 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 121.15 2.475 . . . . 0.0 109.864 179.246 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.894 HG22 HG22 ' A' ' 68' ' ' THR . 18.8 t -130.4 140.19 49.46 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.285 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.24 -178.774 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.528 HG11 HD11 ' A' ' 13' ' ' LEU . 30.0 m -117.25 155.52 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.544 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.5 OUTLIER -107.19 109.15 20.89 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.087 -1.008 . . . . 0.0 109.572 -179.8 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.959 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -106.47 121.51 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.012 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.49 165.94 11.99 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.875 -1.141 . . . . 0.0 108.976 179.75 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.606 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.58 107.98 0.49 Allowed Glycine 0 N--CA 1.481 1.668 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.602 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.81 139.78 50.2 Favored 'General case' 0 N--CA 1.499 2.002 0 CA-C-N 119.218 1.509 . . . . 0.0 110.27 -179.43 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.494 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 84.82 28.86 30.6 Favored Glycine 0 N--CA 1.49 2.286 0 C-N-CA 118.792 -1.671 . . . . 0.0 109.782 179.615 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.691 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.4 mt -93.13 174.54 7.17 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.085 -1.244 . . . . 0.0 108.458 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.87 98.99 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.949 -1.094 . . . . 0.0 109.498 -179.718 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.588 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -57.05 76.59 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.282 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.33 33.96 0.26 Allowed Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.558 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 82.2 p -144.46 111.41 5.81 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 120.966 -1.314 . . . . 0.0 111.144 -179.668 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.588 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.49 112.65 0.57 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.895 178.308 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.53 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 14.4 m-85 -104.51 150.19 24.81 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.206 -0.933 . . . . 0.0 108.746 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.493 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -99.62 158.57 15.67 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 178.564 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.014 HG11 HG21 ' A' ' 65' ' ' THR . 6.2 p -141.67 116.46 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.006 -1.059 . . . . 0.0 110.042 -177.69 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.535 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.45 -176.54 39.41 Favored Glycine 0 N--CA 1.493 2.462 0 C-N-CA 118.338 -1.886 . . . . 0.0 111.674 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.585 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.5 OUTLIER -100.49 109.11 21.21 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 121.928 0.87 . . . . 0.0 108.82 -179.571 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.461 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.6 m -129.55 148.65 51.47 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.212 -0.93 . . . . 0.0 109.882 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.507 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.93 138.57 54.64 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.375 -0.828 . . . . 0.0 110.669 -179.027 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.882 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.91 26.73 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.039 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -105.88 14.9 7.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.894 -1.129 . . . . 0.0 110.617 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.766 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.6 -175.81 0.08 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.844 -1.16 . . . . 0.0 110.116 179.667 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.781 ' O ' HG23 ' A' ' 42' ' ' THR . 15.2 t -70.57 97.28 1.29 Allowed 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.866 0.841 . . . . 0.0 109.946 -179.55 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.44 27.7 35.21 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 120.181 -1.009 . . . . 0.0 111.391 178.831 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.766 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.5 106.24 20.1 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.592 -1.534 . . . . 0.0 107.258 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.882 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.9 tp -116.62 104.55 11.5 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 120.428 -1.42 . . . . 0.0 109.848 -177.736 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.078 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.32 109.24 22.03 Favored 'General case' 0 N--CA 1.484 1.253 0 O-C-N 120.842 -1.161 . . . . 0.0 108.119 178.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.2 t -105.94 163.09 13.02 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.993 -1.067 . . . . 0.0 109.871 -179.144 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.618 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 23.6 t30 -105.66 137.02 19.19 Favored Pre-proline 0 N--CA 1.503 2.21 0 O-C-N 121.289 -0.882 . . . . 0.0 109.972 -179.055 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.516 ' HD2' ' HB2' ' A' ' 74' ' ' GLU . 4.2 Cg_endo -73.77 24.25 0.33 Allowed 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 122.467 2.111 . . . . 0.0 112.323 -179.538 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.618 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -119.74 5.07 11.0 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.278 -1.513 . . . . 0.0 109.261 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.576 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.8 15.37 2.89 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 179.164 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -82.43 89.33 6.61 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.815 -0.754 . . . . 0.0 110.971 -178.517 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.634 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.27 -168.83 1.45 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 178.02 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.78 135.47 0.09 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 120.496 -1.377 . . . . 0.0 111.516 -179.243 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.833 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -153.7 158.18 4.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 177.963 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.588 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.15 143.88 28.21 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 120.638 -1.289 . . . . 0.0 109.777 -179.662 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.47 107.05 1.56 Allowed 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 122.307 1.051 . . . . 0.0 109.547 178.781 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.549 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.1 t0 -61.58 -139.38 0.0 OUTLIER 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.824 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.588 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.2 -51.57 42.99 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.361 -0.837 . . . . 0.0 110.704 -178.699 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -103.96 -32.75 9.1 Favored 'General case' 0 C--N 1.288 -2.109 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 178.562 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.98 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 105.08 69.17 0.75 Allowed Glycine 0 C--N 1.297 -1.589 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 178.194 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.606 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 24.3 m -104.19 126.34 51.21 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 121.684 -0.892 . . . . 0.0 108.838 178.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.833 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.85 109.04 8.26 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 119.644 -0.822 . . . . 0.0 109.486 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.477 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 6.4 m -117.5 115.67 25.61 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.271 -0.893 . . . . 0.0 109.398 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' THR . . . . . 1.014 HG21 HG11 ' A' ' 34' ' ' VAL . 1.3 t -140.97 139.52 34.24 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.359 -0.838 . . . . 0.0 109.723 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.1 p -99.42 132.55 44.68 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.463 -0.773 . . . . 0.0 109.245 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.761 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -132.6 165.92 23.3 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.347 -0.845 . . . . 0.0 109.808 -179.238 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.894 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -98.15 125.18 43.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.238 -0.914 . . . . 0.0 109.219 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.585 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -135.24 143.4 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.068 -1.02 . . . . 0.0 109.897 -179.03 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.599 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.7 ptt180 -145.97 -172.63 3.96 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.457 -1.402 . . . . 0.0 110.946 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.578 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -57.64 -98.15 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.359 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.501 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.64 139.54 55.82 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.27 -1.519 . . . . 0.0 107.944 179.265 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -160.29 135.24 7.79 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 118.598 -1.241 . . . . 0.0 109.847 -178.107 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.516 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -34.95 121.44 0.53 Allowed 'General case' 0 N--CA 1.491 1.611 0 CA-C-O 121.352 0.596 . . . . 0.0 110.119 -178.49 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.078 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.75 50.83 2.59 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 120.404 -0.903 . . . . 0.0 110.938 -179.196 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.48 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.4 OUTLIER -37.74 116.97 0.54 Allowed 'General case' 0 N--CA 1.514 2.726 0 O-C-N 121.274 -1.133 . . . . 0.0 109.973 179.816 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.703 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -87.04 125.96 34.45 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 120.957 -1.089 . . . . 0.0 109.14 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.7 t80 -64.13 58.51 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.036 0 O-C-N 120.8 -1.188 . . . . 0.0 109.922 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' LEU . 26.4 t0 -160.38 20.05 0.15 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.959 -1.088 . . . . 0.0 109.668 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.33 -28.62 5.13 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.089 -1.205 . . . . 0.0 110.089 179.774 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 70.5 p -95.25 164.2 12.95 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.043 -1.269 . . . . 0.0 110.228 -179.427 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.472 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.9 OUTLIER -109.2 138.5 45.45 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.968 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.703 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.7 t90 -81.71 -20.83 38.6 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.805 -1.184 . . . . 0.0 110.391 -178.795 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.79 175.07 17.5 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.54 107.49 1.72 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.065 -1.256 . . . . 0.0 107.684 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.642 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.1 t -79.38 105.3 8.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 O-C-N 121.41 -0.806 . . . . 0.0 109.182 -179.009 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.543 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -65.74 111.59 3.29 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.467 -0.771 . . . . 0.0 109.739 -179.583 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.578 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.17 -5.62 3.42 Favored 'General case' 0 N--CA 1.499 2.01 0 C-N-CA 118.208 -1.397 . . . . 0.0 109.884 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 19.9 p -87.71 0.73 55.31 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.697 -1.252 . . . . 0.0 109.117 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.543 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.8 p -114.11 -50.82 2.8 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.367 -0.833 . . . . 0.0 108.975 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.06 179.51 4.25 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.555 -0.716 . . . . 0.0 109.331 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.94 115.62 30.95 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.465 -0.772 . . . . 0.0 108.919 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.516 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.1 m -97.04 122.42 40.01 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.894 -1.129 . . . . 0.0 109.358 -179.373 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.58 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.67 146.83 27.62 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-O 122.368 1.08 . . . . 0.0 111.215 -179.369 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.608 ' HB ' HG11 ' A' ' 7' ' ' VAL . 52.9 t -103.48 109.79 28.03 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.067 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.61 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.492 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.96 -169.94 17.36 Favored Glycine 0 N--CA 1.486 1.987 0 C-N-CA 118.229 -1.938 . . . . 0.0 111.666 -177.514 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -123.2 179.16 4.8 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -178.682 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.591 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 3.6 t 179.06 176.76 0.55 Allowed 'General case' 0 C--N 1.293 -1.859 0 O-C-N 121.52 -0.738 . . . . 0.0 109.597 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.43 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -120.96 -158.17 0.75 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.026 -1.047 . . . . 0.0 109.251 -179.912 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.43 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.86 35.99 4.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.855 -1.153 . . . . 0.0 109.12 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -112.25 -32.87 6.39 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.432 -0.792 . . . . 0.0 109.875 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.565 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 163.62 -34.98 0.3 Allowed Glycine 0 N--CA 1.481 1.663 0 N-CA-C 107.874 -2.09 . . . . 0.0 107.874 -179.704 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.85 -177.52 5.56 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 122.062 0.934 . . . . 0.0 109.875 179.328 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -172.43 -161.56 23.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.151 -1.98 . . . . 0.0 108.151 -179.374 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.516 ' HD2' ' CE1' ' A' ' 32' ' ' TYR . 7.1 Cg_exo -45.69 173.14 0.02 OUTLIER 'Trans proline' 0 C--O 1.216 -0.58 0 CA-C-N 118.912 1.356 . . . . 0.0 110.008 179.268 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -93.95 -178.6 4.7 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.109 -0.994 . . . . 0.0 110.428 -178.662 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.492 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.92 168.07 12.71 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -108.23 128.7 63.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.313 -1.11 . . . . 0.0 109.117 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.58 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -69.18 123.84 22.21 Favored 'General case' 0 C--N 1.29 -2.007 0 O-C-N 121.556 -0.715 . . . . 0.0 109.381 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.899 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.6 173.76 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.199 -0.938 . . . . 0.0 108.928 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.535 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.5 OUTLIER -138.28 159.61 41.6 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.129 -0.982 . . . . 0.0 109.75 -179.743 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.899 ' CE2' HD12 ' A' ' 110' ' ' ILE . 88.4 m-85 -137.45 81.03 1.84 Allowed 'General case' 0 N--CA 1.485 1.298 0 O-C-N 121.267 -0.896 . . . . 0.0 109.553 -179.636 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.0 p30 . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.394 -179.999 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.738 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.662 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -119.71 163.32 28.17 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.284 -0.885 . . . . 0.0 109.492 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.923 ' HB3' HD23 ' A' ' 26' ' ' LEU . 5.7 Cg_exo -58.77 157.66 27.32 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 122.268 1.979 . . . . 0.0 110.899 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.619 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -140.68 160.18 40.6 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 179.812 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.71 122.93 9.56 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-O 122.448 1.118 . . . . 0.0 110.434 -179.565 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.897 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.9 t -115.82 109.0 17.03 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-O 123.162 1.458 . . . . 0.0 109.735 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.801 HG22 HG23 ' A' ' 21' ' ' VAL . 2.1 t -115.63 133.69 61.22 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.675 0 CA-C-N 114.162 -1.381 . . . . 0.0 109.593 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.475 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.45 150.66 5.0 Favored Pre-proline 0 N--CA 1.488 1.43 0 O-C-N 121.259 -0.901 . . . . 0.0 108.896 -179.419 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.475 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.13 150.38 88.72 Favored 'Cis proline' 0 C--N 1.311 -1.415 0 C-N-CA 123.56 -1.433 . . . . 0.0 109.454 -0.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.678 ' HA ' HG22 ' A' ' 110' ' ' ILE . 95.6 p -90.4 -24.93 20.64 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.586 -0.696 . . . . 0.0 109.203 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.476 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 14.6 m -131.13 161.71 31.51 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.351 -0.843 . . . . 0.0 109.71 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.44 38.16 29.43 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.783 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.9 mt -93.31 -43.65 8.69 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 123.178 1.466 . . . . 0.0 110.801 -178.122 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.07 144.79 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.328 0 CA-C-N 113.484 -1.689 . . . . 0.0 110.123 -179.486 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 18.6 p-10 -50.37 106.07 0.11 Allowed 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 121.53 0.681 . . . . 0.0 111.693 -178.567 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.67 15.57 8.65 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.912 177.075 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.783 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -105.41 -174.28 2.5 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 121.223 2.511 . . . . 0.0 109.981 179.225 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.821 HG22 HG22 ' A' ' 68' ' ' THR . 31.0 t -126.41 138.09 55.75 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.36 0 CA-C-N 114.549 -1.205 . . . . 0.0 111.399 -178.339 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.517 HG11 HD11 ' A' ' 13' ' ' LEU . 29.0 m -114.13 154.98 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.467 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.503 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.9 tttt -106.65 109.67 21.64 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.127 -0.983 . . . . 0.0 109.041 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.801 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.61 140.49 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.897 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.46 162.08 33.64 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 118.89 -1.124 . . . . 0.0 110.094 179.485 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.598 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -138.32 140.3 11.01 Favored Glycine 0 C--N 1.299 -1.514 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.619 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.71 125.22 15.73 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-N 119.183 1.492 . . . . 0.0 109.28 179.297 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.466 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 88.87 29.71 17.27 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 118.702 -1.713 . . . . 0.0 109.695 -179.786 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.923 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.9 mt -89.88 175.2 7.3 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 120.863 -1.375 . . . . 0.0 108.517 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.028 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.77 96.8 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.102 -0.999 . . . . 0.0 109.885 -179.608 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -58.18 74.87 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.157 -179.138 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 138.75 32.97 0.19 Allowed Glycine 0 N--CA 1.484 1.848 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 179.454 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.632 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 1.4 t -149.11 115.43 5.82 Favored 'General case' 0 C--N 1.31 -1.127 0 O-C-N 120.893 -1.357 . . . . 0.0 111.218 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.608 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.42 111.22 0.46 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.251 178.472 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.632 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 1.9 m-30 -101.54 152.11 21.17 Favored 'General case' 0 N--CA 1.494 1.759 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 179.123 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -98.89 165.01 11.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.497 -1.377 . . . . 0.0 108.327 179.26 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.621 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.1 p -145.1 119.24 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.209 -0.932 . . . . 0.0 109.534 -178.012 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.42 -178.68 41.38 Favored Glycine 0 N--CA 1.495 2.605 0 C-N-CA 118.34 -1.886 . . . . 0.0 111.616 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.698 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.71 108.57 20.46 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 179.833 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.6 m -130.03 148.73 51.91 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 121.228 -0.92 . . . . 0.0 110.01 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.482 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.26 138.76 54.55 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.242 -0.911 . . . . 0.0 110.644 -179.143 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.32 114.82 26.64 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 178.154 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.3 m -104.45 14.88 6.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.014 -1.054 . . . . 0.0 110.534 -178.848 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.765 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.02 -175.01 0.07 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.023 -1.048 . . . . 0.0 110.185 179.785 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.12 98.11 2.06 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.446 -0.784 . . . . 0.0 109.708 -179.764 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.71 27.88 33.78 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.464 178.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.765 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.75 106.24 19.85 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 O-C-N 120.536 -1.567 . . . . 0.0 107.252 178.834 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.6 tp -117.49 104.45 11.09 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.402 -1.436 . . . . 0.0 109.958 -177.714 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.01 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.92 109.49 22.23 Favored 'General case' 0 N--CA 1.484 1.267 0 N-CA-C 107.718 -1.215 . . . . 0.0 107.718 178.623 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -107.32 166.16 10.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.895 -1.128 . . . . 0.0 110.655 -178.508 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.56 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 43.7 t30 -113.14 127.92 26.26 Favored Pre-proline 0 N--CA 1.498 1.972 0 O-C-N 121.497 -0.752 . . . . 0.0 109.267 -179.661 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.611 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -70.75 21.31 0.21 Allowed 'Trans proline' 0 CA--C 1.543 0.948 0 C-N-CA 122.103 1.869 . . . . 0.0 112.396 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.56 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -97.72 -5.62 34.72 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.304 -1.497 . . . . 0.0 109.017 179.31 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.857 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.4 m-20 -135.62 10.76 3.43 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.494 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.7 m-85 -66.56 82.9 0.1 Allowed 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.736 -178.403 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.621 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -108.47 -171.92 1.95 Allowed 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 178.252 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.478 ' OG ' ' HA ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER 178.6 134.71 0.08 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.608 -1.308 . . . . 0.0 111.25 -179.369 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.625 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 4.1 p -143.39 159.77 17.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 177.897 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.69 144.39 27.37 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.583 -1.323 . . . . 0.0 109.767 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.028 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -70.44 108.52 4.31 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 122.312 1.053 . . . . 0.0 109.963 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.553 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.3 t0 -64.66 -139.55 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.714 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.34 -52.43 37.06 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.344 -0.848 . . . . 0.0 110.605 -178.74 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.34 -32.32 10.53 Favored 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 178.613 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.993 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 100.34 69.29 0.88 Allowed Glycine 0 C--N 1.298 -1.571 0 N-CA-C 110.562 -1.015 . . . . 0.0 110.562 178.488 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 65.6 m -98.66 132.46 44.03 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.337 -1.096 . . . . 0.0 109.016 179.119 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.625 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.41 109.31 9.23 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.252 -179.716 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 19.8 m -122.53 115.68 22.59 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.264 -0.897 . . . . 0.0 109.565 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.545 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.74 143.32 28.61 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.27 -0.894 . . . . 0.0 109.661 179.927 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 57.6 p -99.15 142.38 30.71 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.371 -0.831 . . . . 0.0 109.148 179.784 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.857 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -144.49 170.63 15.67 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.397 -0.815 . . . . 0.0 109.774 -179.01 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.821 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -104.35 124.26 48.88 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.952 -1.093 . . . . 0.0 110.474 -178.851 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.847 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.7 m -132.22 143.0 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 120.907 -1.121 . . . . 0.0 110.087 -179.751 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -145.65 -172.51 3.91 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.604 -1.31 . . . . 0.0 110.689 179.384 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.597 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -58.52 -98.42 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 -179.35 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.4 OUTLIER -57.88 141.22 49.96 Favored 'General case' 0 N--CA 1.485 1.307 0 O-C-N 120.307 -1.496 . . . . 0.0 108.374 179.47 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -161.78 135.44 6.51 Favored 'General case' 0 C--N 1.295 -1.787 0 C-N-CA 118.75 -1.18 . . . . 0.0 109.724 -178.402 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.9 mm-40 -32.11 121.55 0.3 Allowed 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.579 0.704 . . . . 0.0 110.697 -178.351 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.01 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.48 45.51 2.95 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.611 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-85 -37.96 113.56 0.29 Allowed 'General case' 0 N--CA 1.507 2.39 0 O-C-N 121.193 -1.18 . . . . 0.0 110.372 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.739 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.5 tp -85.89 126.56 34.16 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 120.948 -1.095 . . . . 0.0 109.535 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.593 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 33.4 t80 -63.9 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.024 0 O-C-N 120.93 -1.106 . . . . 0.0 110.318 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 17.2 t70 -161.46 20.11 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.928 -1.107 . . . . 0.0 109.729 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.59 -28.1 4.99 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.482 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 19.2 p -93.46 159.31 15.3 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.981 -1.305 . . . . 0.0 110.231 -179.492 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.515 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 1.1 ptt180 -106.78 139.03 41.85 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.739 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.3 t90 -84.79 -19.26 32.83 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.704 -1.248 . . . . 0.0 110.524 -178.558 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.84 174.1 18.14 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.447 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.93 106.38 1.22 Allowed 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 179.137 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.66 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.9 t -77.02 105.84 6.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 O-C-N 121.315 -0.866 . . . . 0.0 109.398 -178.744 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.684 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.0 OUTLIER -66.31 111.46 3.51 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.386 -0.821 . . . . 0.0 109.685 -179.732 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.597 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.1 t -63.54 -5.51 3.94 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.533 -1.355 . . . . 0.0 109.828 179.562 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.2 p -86.45 -1.49 57.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.787 -1.196 . . . . 0.0 109.215 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.684 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -111.38 -50.24 2.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.295 -0.878 . . . . 0.0 108.93 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.34 -178.8 3.76 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.507 -0.746 . . . . 0.0 109.482 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.05 115.52 30.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.33 -0.856 . . . . 0.0 109.001 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.91 123.02 40.51 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.77 -1.206 . . . . 0.0 109.593 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.64 146.9 27.89 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 122.445 1.116 . . . . 0.0 111.138 -179.42 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.585 ' CG1' HG11 ' A' ' 7' ' ' VAL . 48.6 t -103.58 110.53 30.26 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.978 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 177.666 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.489 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.6 -170.24 16.86 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 118.06 -2.019 . . . . 0.0 111.745 -177.523 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -115.38 -179.08 3.54 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 -178.986 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.592 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.2 OUTLIER -171.36 167.89 6.72 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.318 -0.864 . . . . 0.0 109.61 -179.333 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.6 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -114.73 -157.6 0.64 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.199 -0.938 . . . . 0.0 108.816 179.652 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.442 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -120.63 36.29 4.62 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.785 -1.197 . . . . 0.0 109.32 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.89 -32.77 4.4 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.339 -0.85 . . . . 0.0 110.291 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.952 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 168.59 -37.64 0.21 Allowed Glycine 0 N--CA 1.481 1.696 0 N-CA-C 107.7 -2.16 . . . . 0.0 107.7 -179.523 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -160.46 -178.07 6.66 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-O 122.127 0.965 . . . . 0.0 109.622 179.219 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.0 -161.28 12.88 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 108.301 -1.92 . . . . 0.0 108.301 -179.345 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.507 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.3 Cg_exo -46.75 177.0 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.653 0 CA-C-N 118.838 1.319 . . . . 0.0 110.179 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -92.66 -177.55 4.6 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.074 -1.016 . . . . 0.0 110.451 -178.788 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.489 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.45 164.48 12.91 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -100.92 129.23 52.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.451 -1.029 . . . . 0.0 109.103 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.04 123.4 22.72 Favored 'General case' 0 C--N 1.289 -2.023 0 O-C-N 121.702 -0.624 . . . . 0.0 109.535 179.734 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.855 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.74 170.53 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.174 -0.954 . . . . 0.0 109.14 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.476 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -138.84 156.63 47.16 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.174 -0.954 . . . . 0.0 109.765 -179.891 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.855 ' CE2' HD12 ' A' ' 110' ' ' ILE . 81.2 m-85 -133.31 132.87 41.84 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.144 -0.972 . . . . 0.0 109.569 -179.683 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.9 p30 . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.44 -179.938 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.952 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.489 0 N-CA-C 109.457 -0.571 . . . . 1.0 109.457 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.68 152.43 42.85 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.261 -0.899 . . . . 1.0 109.467 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.505 ' HB3' HD23 ' A' ' 26' ' ' LEU . 2.8 Cg_endo -61.05 156.6 43.62 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.299 1.999 . . . . 1.0 110.399 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.601 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -153.05 161.17 42.83 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 108.683 -0.858 . . . . 1.0 108.683 -179.551 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.512 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.74 128.61 14.4 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.92 -1.112 . . . . 1.0 110.688 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.009 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.2 p -105.63 104.87 14.67 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.457 1.122 . . . . 1.0 110.21 -179.577 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.951 HG22 HG23 ' A' ' 21' ' ' VAL . 13.2 t -118.34 118.8 59.25 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.446 0 CA-C-N 115.384 -0.825 . . . . 1.0 110.495 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.521 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.38 149.37 9.8 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.169 -1.049 . . . . 1.0 108.169 -179.799 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.521 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.1 Cg_endo -77.38 151.83 93.17 Favored 'Cis proline' 0 C--N 1.309 -1.536 0 C-N-CA 123.654 -1.394 . . . . 1.0 109.49 -0.223 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.686 ' HA ' HG22 ' A' ' 110' ' ' ILE . 75.4 p -91.89 -24.99 19.15 Favored 'General case' 0 C--N 1.292 -1.904 0 O-C-N 121.501 -0.749 . . . . 1.0 109.137 179.696 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.474 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 0.9 OUTLIER -133.54 165.12 25.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.43 -0.794 . . . . 1.0 109.557 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.52 38.5 37.81 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 108.209 -1.956 . . . . 1.0 108.209 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.808 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.6 mt -92.13 -44.32 8.88 Favored 'General case' 0 C--N 1.298 -1.674 0 CA-C-O 123.122 1.439 . . . . 1.0 110.637 -178.214 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.464 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.3 144.75 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.279 0 CA-C-N 113.613 -1.63 . . . . 1.0 109.947 -179.603 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.598 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.2 p-10 -51.16 108.24 0.24 Allowed 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.524 0.678 . . . . 1.0 111.523 -178.546 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.11 14.14 10.23 Favored Glycine 0 N--CA 1.484 1.835 0 C-N-CA 119.408 -1.377 . . . . 1.0 112.824 177.283 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.808 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.1 t -104.05 -172.38 2.1 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 121.079 2.439 . . . . 1.0 109.639 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.764 HG22 HG22 ' A' ' 68' ' ' THR . 12.1 t -131.61 138.85 52.01 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.37 0 CA-C-N 114.967 -1.015 . . . . 1.0 111.281 -178.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.442 HG11 HD11 ' A' ' 13' ' ' LEU . 26.9 m -114.45 154.99 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.761 -0.829 . . . . 1.0 108.761 179.155 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 21.0 tttt -109.06 108.86 19.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.053 -1.029 . . . . 1.0 109.407 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.951 HG23 HG22 ' A' ' 7' ' ' VAL . 1.7 p -106.86 122.53 61.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 N-CA-C 108.778 -0.823 . . . . 1.0 108.778 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.009 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.98 165.67 12.13 Favored 'General case' 0 C--N 1.305 -1.331 0 O-C-N 120.902 -1.124 . . . . 1.0 109.114 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.582 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.77 107.91 0.48 Allowed Glycine 0 N--CA 1.482 1.765 0 N-CA-C 108.738 -1.745 . . . . 1.0 108.738 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.601 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.43 141.05 48.68 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 120.658 -1.495 . . . . 1.0 110.168 -179.502 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.436 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.86 28.12 32.61 Favored Glycine 0 N--CA 1.488 2.109 0 C-N-CA 119.003 -1.57 . . . . 1.0 109.806 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -94.23 174.73 7.0 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.008 -1.29 . . . . 1.0 108.587 179.991 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.006 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.95 97.29 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.022 -1.048 . . . . 1.0 109.673 -179.831 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.688 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.19 76.63 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.345 -0.843 . . . . 1.0 110.372 -179.145 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.563 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.85 33.92 0.32 Allowed Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.751 -1.34 . . . . 1.0 109.751 179.498 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.638 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.1 t -146.66 114.15 6.34 Favored 'General case' 0 C--N 1.309 -1.174 0 O-C-N 120.838 -1.39 . . . . 1.0 110.986 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -46.12 126.2 7.35 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-N 115.31 -0.859 . . . . 1.0 110.008 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.638 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 12.2 m-85 -118.43 151.17 38.3 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.543 -0.91 . . . . 1.0 108.543 179.358 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.491 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.54 156.76 17.28 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.572 -1.33 . . . . 1.0 108.063 179.015 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.926 HG11 HG21 ' A' ' 65' ' ' THR . 7.0 p -139.32 115.04 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.189 -0.944 . . . . 1.0 109.83 -177.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.75 -178.64 37.53 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.449 -1.834 . . . . 1.0 111.804 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.631 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -101.8 109.43 21.19 Favored 'General case' 0 C--N 1.313 -0.987 0 N-CA-C 108.799 -0.815 . . . . 1.0 108.799 -179.818 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.41 149.17 52.21 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.22 -0.925 . . . . 1.0 109.99 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.21 138.19 54.7 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.265 -0.897 . . . . 1.0 110.729 -179.081 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.877 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.71 26.53 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 107.432 -1.322 . . . . 1.0 107.432 178.09 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -105.63 15.3 7.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.018 -1.051 . . . . 1.0 110.589 -178.679 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.99 -175.63 0.09 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.875 -1.14 . . . . 1.0 110.088 179.787 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 43.8 p -71.95 97.72 1.91 Allowed 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.404 -0.81 . . . . 1.0 109.664 -179.722 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.7 27.37 35.32 Favored Glycine 0 N--CA 1.493 2.448 0 C-N-CA 120.141 -1.028 . . . . 1.0 111.302 178.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.32 106.28 20.01 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.519 -1.577 . . . . 1.0 107.203 178.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.877 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.0 tp -117.04 104.3 11.11 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 120.427 -1.42 . . . . 1.0 109.726 -177.749 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.904 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.97 109.32 22.1 Favored 'General case' 0 N--CA 1.483 1.202 0 N-CA-C 107.65 -1.241 . . . . 1.0 107.65 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -105.72 166.36 10.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.035 -1.04 . . . . 1.0 110.404 -178.678 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.487 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 59.2 t30 -111.84 131.39 22.45 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.541 -0.724 . . . . 1.0 109.736 -179.465 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.599 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 2.5 Cg_endo -73.05 22.62 0.31 Allowed 'Trans proline' 0 C--N 1.319 -1.022 0 C-N-CA 122.112 1.874 . . . . 1.0 111.737 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.487 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -110.01 2.84 19.89 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.307 -1.496 . . . . 1.0 109.19 179.562 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.5 15.56 2.75 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.471 -1.307 . . . . 1.0 107.471 179.479 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -79.22 92.96 5.16 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.898 -0.721 . . . . 1.0 111.039 -178.429 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.617 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -111.95 -167.82 1.23 Allowed 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.536 -1.283 . . . . 1.0 107.536 178.104 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.98 136.5 0.09 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.439 -1.413 . . . . 1.0 111.521 -179.332 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.941 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.12 157.51 4.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.276 -1.379 . . . . 1.0 107.276 178.019 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.568 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.1 145.49 26.51 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.76 -1.212 . . . . 1.0 109.825 -179.703 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -66.08 107.24 1.84 Allowed 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 122.485 1.136 . . . . 1.0 109.328 178.718 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.541 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.1 t70 -60.82 -139.37 0.0 OUTLIER 'General case' 0 C--N 1.292 -1.93 0 CA-C-N 115.558 -0.746 . . . . 1.0 110.941 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.688 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.12 -51.42 43.26 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.504 -0.747 . . . . 1.0 110.756 -178.658 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.57 -32.56 8.89 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 106.308 -1.738 . . . . 1.0 106.308 178.673 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.012 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.24 65.21 0.61 Allowed Glycine 0 C--N 1.297 -1.589 0 N-CA-C 110.542 -1.023 . . . . 1.0 110.542 178.238 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.582 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.7 m -103.0 124.66 48.93 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 108.292 -1.003 . . . . 1.0 108.292 178.604 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.941 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.58 109.36 8.62 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 119.681 -0.808 . . . . 1.0 109.726 -179.13 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.3 m -115.99 115.66 26.54 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.293 -0.879 . . . . 1.0 109.164 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.926 HG21 HG11 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -140.68 138.86 34.59 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.425 -0.797 . . . . 1.0 109.864 179.941 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.7 p -98.98 133.48 43.19 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.448 -0.782 . . . . 1.0 109.179 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.759 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -131.22 163.71 27.14 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.302 -0.873 . . . . 1.0 109.446 -179.313 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.764 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -93.99 124.33 37.93 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.046 -1.034 . . . . 1.0 109.157 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.541 HG23 HD13 ' A' ' 13' ' ' LEU . 14.4 m -134.71 143.32 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 120.979 -1.076 . . . . 1.0 109.877 -178.867 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.598 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.2 ptt180 -145.33 -170.66 3.49 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.464 -1.397 . . . . 1.0 111.042 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.637 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -61.88 -101.64 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.851 -0.531 . . . . 1.0 110.241 -179.093 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.528 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -59.19 138.11 57.71 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.566 -1.333 . . . . 1.0 108.517 179.953 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.631 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 1.3 p90 -156.87 154.13 29.32 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 118.824 -1.15 . . . . 1.0 109.854 -178.795 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.483 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 20.4 mm-40 -47.6 122.11 4.56 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.353 -0.842 . . . . 1.0 109.577 -178.58 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.904 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.94 49.38 3.58 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.94 -0.864 . . . . 1.0 110.94 -179.333 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.599 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.4 m-85 -40.42 113.17 0.34 Allowed 'General case' 0 N--CA 1.507 2.386 0 O-C-N 121.014 -1.286 . . . . 1.0 110.224 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.736 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.92 127.08 35.06 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.842 -1.161 . . . . 1.0 109.358 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.58 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 20.6 t80 -63.83 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 O-C-N 120.758 -1.214 . . . . 1.0 110.213 179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 1.6 t0 -160.78 19.0 0.13 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.016 -1.052 . . . . 1.0 109.801 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -25.97 5.75 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 110.15 -1.18 . . . . 1.0 110.15 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 15.4 p -93.31 157.67 16.13 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 120.964 -1.315 . . . . 1.0 110.491 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.477 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -103.86 132.71 49.85 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.482 -0.932 . . . . 1.0 108.482 179.609 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.736 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.1 t90 -81.16 -18.51 46.06 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.758 -1.213 . . . . 1.0 110.382 -178.692 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.26 174.16 19.41 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.864 -1.694 . . . . 1.0 108.864 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.43 107.93 1.22 Allowed 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.683 -1.229 . . . . 1.0 107.683 179.224 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.639 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.0 t -79.82 104.74 8.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.362 -0.836 . . . . 1.0 109.13 -178.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.555 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -65.04 109.15 2.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.567 -0.708 . . . . 1.0 110.15 -179.179 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.637 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.8 t -62.04 -4.1 1.51 Allowed 'General case' 0 N--CA 1.502 2.167 0 C-N-CA 118.262 -1.375 . . . . 1.0 110.334 179.265 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.1 p -91.33 5.34 49.62 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.66 -1.275 . . . . 1.0 109.384 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.555 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -117.2 -49.75 2.58 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.356 -0.84 . . . . 1.0 109.178 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.89 178.55 4.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.52 -0.737 . . . . 1.0 109.456 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.49 112.5 24.87 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.342 -0.849 . . . . 1.0 108.907 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.522 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.6 m -96.7 121.69 38.82 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.031 -1.043 . . . . 1.0 109.279 -179.061 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.582 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.61 147.55 26.65 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 122.454 1.121 . . . . 1.0 111.358 -179.172 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.637 ' HB ' HG11 ' A' ' 7' ' ' VAL . 58.8 t -103.38 109.52 27.22 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.492 -1.67 . . . . 1.0 106.492 177.484 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.443 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.19 -171.31 16.98 Favored Glycine 0 N--CA 1.485 1.927 0 C-N-CA 118.166 -1.969 . . . . 1.0 111.721 -177.546 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.555 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -115.49 -178.2 3.33 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.704 -0.85 . . . . 1.0 108.704 -178.839 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.581 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.4 p -178.81 169.23 1.65 Allowed 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.312 -0.867 . . . . 1.0 109.574 -179.16 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.454 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -122.18 -157.69 0.75 Allowed 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.035 -1.04 . . . . 1.0 108.994 179.919 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.454 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.48 36.01 4.3 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.742 -1.224 . . . . 1.0 109.238 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.39 -33.09 5.72 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.273 -0.892 . . . . 1.0 110.026 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.858 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 162.74 -35.27 0.33 Allowed Glycine 0 N--CA 1.481 1.681 0 N-CA-C 107.697 -2.161 . . . . 1.0 107.697 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.02 -177.91 6.43 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 122.052 0.93 . . . . 1.0 109.844 179.255 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.48 -162.49 19.39 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 108.374 -1.89 . . . . 1.0 108.374 -179.477 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.555 ' HB2' HD12 ' A' ' 97' ' ' LEU . 7.1 Cg_exo -46.0 174.43 0.02 OUTLIER 'Trans proline' 0 C--N 1.327 -0.581 0 CA-C-N 118.854 1.327 . . . . 1.0 110.168 179.301 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -90.46 -178.84 5.44 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.0 -1.063 . . . . 1.0 110.611 -178.601 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.443 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.86 166.38 13.02 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.586 -1.405 . . . . 1.0 109.586 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.61 131.8 54.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.338 -1.095 . . . . 1.0 109.177 -179.225 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.582 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.3 121.94 20.28 Favored 'General case' 0 C--N 1.29 -2.002 0 O-C-N 121.59 -0.694 . . . . 1.0 109.617 179.657 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.844 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.8 pt -98.01 173.2 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.248 -0.908 . . . . 1.0 108.996 179.852 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.474 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -141.36 159.54 42.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.06 -1.025 . . . . 1.0 110.04 -179.7 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.844 ' CE2' HD12 ' A' ' 110' ' ' ILE . 88.5 m-85 -135.96 98.55 3.91 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.276 -0.89 . . . . 1.0 109.573 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 p30 . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 118.006 -0.997 . . . . 1.0 109.512 179.976 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.858 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.324 0.583 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.909 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -85.37 172.83 7.96 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.222 -0.923 . . . . 0.0 109.525 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.909 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.0 Cg_exo -60.14 157.72 33.52 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.386 2.057 . . . . 0.0 110.572 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.6 -169.68 0.14 Allowed 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.15 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.545 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.93 130.06 2.22 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.83 -1.169 . . . . 0.0 110.666 -179.132 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.962 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -111.17 108.71 18.47 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 123.04 1.4 . . . . 0.0 109.096 179.273 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.914 HG22 HG23 ' A' ' 21' ' ' VAL . 4.5 t -118.31 136.44 55.5 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.761 0 CA-C-N 114.299 -1.319 . . . . 0.0 110.094 -179.685 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.482 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -176.64 150.97 1.0 Allowed Pre-proline 0 N--CA 1.488 1.431 0 O-C-N 121.279 -0.888 . . . . 0.0 108.801 -179.641 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.482 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.8 Cg_endo -79.11 150.45 85.74 Favored 'Cis proline' 0 C--N 1.311 -1.432 0 C-N-CA 123.507 -1.456 . . . . 0.0 109.271 -0.735 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.677 ' HA ' HG22 ' A' ' 110' ' ' ILE . 78.4 p -92.23 -23.19 19.42 Favored 'General case' 0 C--N 1.291 -1.937 0 O-C-N 121.589 -0.695 . . . . 0.0 109.402 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.485 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 7.4 m -132.2 160.74 35.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.354 -0.841 . . . . 0.0 109.764 -179.785 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.77 37.39 30.21 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.824 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.8 mt -92.04 -44.42 8.86 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-O 123.2 1.476 . . . . 0.0 110.728 -178.363 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.4 OUTLIER 65.96 146.28 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.341 0 CA-C-N 113.628 -1.624 . . . . 0.0 109.942 -179.69 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.606 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.0 p-10 -50.85 108.08 0.21 Allowed 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 121.478 0.656 . . . . 0.0 111.882 -178.532 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.5 15.2 10.58 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.421 -1.371 . . . . 0.0 112.879 177.131 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.824 HG21 ' CA ' ' A' ' 13' ' ' LEU . 10.6 t -102.65 -172.42 2.12 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 121.056 2.428 . . . . 0.0 109.897 179.35 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.796 HG13 ' O ' ' A' ' 67' ' ' LEU . 33.6 t -125.66 137.55 57.33 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.246 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.962 -178.726 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.54 HG22 HG22 ' A' ' 69' ' ' VAL . 27.4 m -116.2 155.84 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 178.768 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.4 ttpt -114.31 109.55 18.52 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.06 -1.025 . . . . 0.0 109.178 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.914 HG23 HG22 ' A' ' 7' ' ' VAL . 2.4 p -105.12 141.45 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.962 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -139.72 160.25 40.3 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 120.632 -1.292 . . . . 0.0 110.229 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.07 144.21 15.45 Favored Glycine 0 C--N 1.295 -1.704 0 N-CA-C 107.977 -2.049 . . . . 0.0 107.977 179.47 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.565 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.08 125.94 13.55 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 120.894 -1.356 . . . . 0.0 108.841 179.206 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.518 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.11 27.04 24.51 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 119.214 -1.469 . . . . 0.0 109.654 -179.617 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.4 mt -88.58 175.01 7.74 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.887 -1.361 . . . . 0.0 108.498 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.998 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -48.55 100.15 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.002 -1.061 . . . . 0.0 109.792 -179.63 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.44 78.13 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.134 -179.24 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.91 34.08 0.31 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.72 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.554 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 34.2 p -140.79 107.29 5.3 Favored 'General case' 0 C--N 1.308 -1.218 0 O-C-N 121.24 -1.153 . . . . 0.0 110.984 -179.489 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.575 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.67 109.78 0.25 Allowed 'General case' 0 N--CA 1.497 1.888 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.987 178.174 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.537 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 24.9 m-85 -102.38 153.86 19.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 108.638 179.372 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.505 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.87 161.51 13.61 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.676 -1.265 . . . . 0.0 107.948 178.85 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.655 ' O ' HG13 ' A' ' 34' ' ' VAL . 5.5 p -141.16 115.23 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.157 -0.964 . . . . 0.0 109.442 -178.205 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.53 ' HA2' ' OD1' ' A' ' 51' ' ' ASP . . . -162.75 173.99 39.05 Favored Glycine 0 N--CA 1.49 2.276 0 C-N-CA 118.06 -2.019 . . . . 0.0 112.114 -179.334 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.628 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -98.43 108.96 21.79 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 179.267 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.8 m -132.28 151.26 51.92 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.277 -0.889 . . . . 0.0 109.992 -179.513 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.42 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.82 139.65 53.64 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.248 -0.907 . . . . 0.0 110.695 -179.06 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.878 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.26 114.56 26.36 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.22 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.2 m -105.09 14.75 7.09 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 120.885 -1.135 . . . . 0.0 110.602 -178.687 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.759 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.06 -174.99 0.09 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.892 -1.13 . . . . 0.0 110.067 179.751 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.6 p -71.95 97.32 1.84 Allowed 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.344 -0.848 . . . . 0.0 109.798 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.42 26.93 34.39 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 120.241 -0.98 . . . . 0.0 111.428 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.6 106.31 20.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.55 -1.559 . . . . 0.0 107.429 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.878 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.2 tp -116.65 104.82 11.77 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.564 -1.335 . . . . 0.0 109.723 -177.862 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.078 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.98 109.53 22.27 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 120.829 -1.17 . . . . 0.0 108.204 179.092 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.6 t -105.89 165.56 11.11 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.9 -1.125 . . . . 0.0 110.295 -179.085 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.665 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 18.7 t-20 -109.33 137.0 20.13 Favored Pre-proline 0 N--CA 1.501 2.104 0 O-C-N 121.421 -0.799 . . . . 0.0 110.201 -179.08 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.584 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.2 Cg_endo -74.89 23.94 0.39 Allowed 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 122.387 2.058 . . . . 0.0 111.971 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.665 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -116.88 2.67 12.83 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.296 -1.503 . . . . 0.0 109.227 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.955 ' OD1' HD22 ' A' ' 67' ' ' LEU . 9.4 t70 -137.64 13.27 2.95 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 179.552 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -79.72 94.25 5.7 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 121.424 -0.798 . . . . 0.0 110.883 -178.651 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -115.33 -166.25 1.1 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 178.367 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.94 135.42 0.09 Allowed 'General case' 0 N--CA 1.486 1.369 0 O-C-N 120.627 -1.296 . . . . 0.0 111.429 -179.34 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.915 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -151.18 156.9 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 107.354 -1.351 . . . . 0.0 107.354 178.007 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.575 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.19 144.14 27.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.801 -1.187 . . . . 0.0 110.055 -179.574 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.008 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.72 106.91 1.06 Allowed 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 122.447 1.118 . . . . 0.0 109.436 178.27 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -60.05 -139.28 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.988 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.042 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.91 -50.1 61.74 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.498 -0.751 . . . . 0.0 110.597 -178.752 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 12.3 m-80 -103.7 -34.47 8.58 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 106.208 -1.775 . . . . 0.0 106.208 178.573 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.008 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.49 65.31 0.58 Allowed Glycine 0 C--N 1.297 -1.604 0 N-CA-C 110.501 -1.039 . . . . 0.0 110.501 178.141 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 46.6 m -103.62 127.05 51.11 Favored 'General case' 0 N--CA 1.483 1.19 0 O-C-N 121.381 -1.07 . . . . 0.0 108.915 178.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.915 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.72 109.15 7.37 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.424 -0.91 . . . . 0.0 109.36 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -124.71 121.65 35.25 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.201 -0.937 . . . . 0.0 109.663 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.71 142.05 28.61 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.596 -0.69 . . . . 0.0 109.486 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 15.6 p -98.93 136.38 39.0 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.451 -0.781 . . . . 0.0 109.186 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.955 HD22 ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -135.93 -178.73 5.27 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.235 -0.915 . . . . 0.0 109.544 -178.983 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.4 p -105.09 126.18 51.79 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.99 -1.069 . . . . 0.0 109.637 -179.352 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.54 HG22 HG22 ' A' ' 19' ' ' VAL . 16.9 m -139.35 142.97 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 120.888 -1.132 . . . . 0.0 110.08 -179.521 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.606 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.8 ptt180 -141.2 -161.42 1.21 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.671 -1.268 . . . . 0.0 110.141 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.582 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -78.15 -86.89 0.06 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.232 -0.918 . . . . 0.0 108.848 -179.584 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -60.87 138.47 58.14 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.387 -1.446 . . . . 0.0 107.204 178.809 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -165.11 136.58 4.11 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 117.901 -1.519 . . . . 0.0 110.371 -177.365 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.516 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 7.0 mm-40 -33.4 121.44 0.4 Allowed 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 121.352 0.596 . . . . 0.0 110.326 -178.766 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.078 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.85 51.83 1.72 Allowed Glycine 0 N--CA 1.494 2.53 0 C-N-CA 120.474 -0.869 . . . . 0.0 111.42 -179.036 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.584 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 4.2 m-85 -39.11 116.6 0.6 Allowed 'General case' 0 N--CA 1.511 2.62 0 O-C-N 121.018 -1.283 . . . . 0.0 110.05 179.526 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.682 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.4 126.27 34.27 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 120.96 -1.087 . . . . 0.0 109.69 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.577 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 32.0 t80 -64.5 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 120.738 -1.226 . . . . 0.0 109.92 179.362 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.544 ' N ' ' O ' ' A' ' 77' ' ' LEU . 5.7 t70 -158.93 19.51 0.2 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.061 -1.025 . . . . 0.0 109.656 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.75 -27.96 5.65 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.426 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 69.7 p -97.54 162.71 13.17 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.046 -1.267 . . . . 0.0 110.307 -179.525 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.525 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.0 140.37 41.25 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.904 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.682 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.7 t90 -83.8 -19.21 35.42 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.771 -1.205 . . . . 0.0 110.728 -178.282 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.85 177.33 20.13 Favored Glycine 0 N--CA 1.484 1.869 0 N-CA-C 108.578 -1.809 . . . . 0.0 108.578 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -63.9 109.79 1.89 Allowed 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.214 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.62 HG21 ' HB3' ' A' ' 46' ' ' ALA . 37.3 t -82.91 105.66 12.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 121.44 -0.788 . . . . 0.0 108.947 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.539 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -66.14 111.73 3.56 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.428 -0.795 . . . . 0.0 109.882 -179.205 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.555 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -65.28 -5.32 6.87 Favored 'General case' 0 N--CA 1.498 1.96 0 C-N-CA 118.203 -1.399 . . . . 0.0 109.665 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.3 p -84.01 -1.24 54.37 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.799 -1.188 . . . . 0.0 108.887 179.269 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.539 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -113.5 -50.05 2.87 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.443 -0.786 . . . . 0.0 109.012 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.87 -178.0 3.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.486 -0.758 . . . . 0.0 109.45 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.09 115.77 30.76 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.451 -0.78 . . . . 0.0 109.037 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.535 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -96.87 122.76 40.19 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.894 -1.129 . . . . 0.0 109.588 -179.384 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.83 146.39 28.35 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 122.337 1.065 . . . . 0.0 111.167 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 59.3 t -103.78 109.88 28.46 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.591 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.473 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.55 -172.09 18.05 Favored Glycine 0 N--CA 1.486 2.016 0 C-N-CA 118.03 -2.033 . . . . 0.0 111.914 -177.515 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -112.97 -178.88 3.49 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.255 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.562 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 2.9 p -176.57 173.03 2.08 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.261 -0.899 . . . . 0.0 109.518 -179.373 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -121.27 -161.74 0.92 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.044 -1.035 . . . . 0.0 108.785 179.841 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -117.39 36.09 4.4 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.584 -1.322 . . . . 0.0 109.302 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -117.48 -33.31 4.63 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.337 -0.852 . . . . 0.0 110.225 -179.528 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.907 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.93 -36.84 0.22 Allowed Glycine 0 N--CA 1.48 1.631 0 N-CA-C 107.913 -2.075 . . . . 0.0 107.913 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.31 -177.76 6.23 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 122.1 0.952 . . . . 0.0 109.95 179.277 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.93 -163.89 23.71 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.149 -1.98 . . . . 0.0 108.149 -179.457 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.0 Cg_exo -46.24 172.96 0.02 OUTLIER 'Trans proline' 0 C--N 1.326 -0.616 0 CA-C-N 118.88 1.34 . . . . 0.0 109.889 179.371 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -91.7 -173.21 3.46 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.15 -0.969 . . . . 0.0 110.447 -178.712 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.473 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.81 171.29 15.54 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.1 t -106.69 132.98 52.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.536 -0.979 . . . . 0.0 109.138 -179.383 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.37 123.94 26.25 Favored 'General case' 0 C--N 1.29 -2.017 0 O-C-N 121.609 -0.682 . . . . 0.0 109.664 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.827 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.73 168.23 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.282 -0.886 . . . . 0.0 108.934 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.485 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 5.4 m -136.6 154.53 50.64 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.219 -0.926 . . . . 0.0 109.752 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.827 ' CE2' HD12 ' A' ' 110' ' ' ILE . 77.3 m-85 -129.54 101.54 5.98 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.179 -0.951 . . . . 0.0 109.417 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.443 ' OD1' ' O ' ' A' ' 113' ' ' ASN . 15.0 p30 . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 117.921 -1.038 . . . . 0.0 109.48 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.907 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.625 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.945 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -63.8 175.08 0.86 Allowed Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.279 -0.888 . . . . 0.0 109.258 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.945 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 6.0 Cg_exo -58.45 155.33 36.61 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 124.876 3.717 . . . . 0.0 109.784 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.869 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.2 p -165.8 160.72 17.36 Favored 'General case' 0 C--N 1.297 -1.716 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.111 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -149.51 128.29 12.5 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 122.414 1.102 . . . . 0.0 110.617 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.989 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 3.2 p -108.54 104.79 14.19 Favored 'General case' 0 C--N 1.296 -1.738 0 CA-C-O 122.491 1.139 . . . . 0.0 110.337 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.949 HG22 HG23 ' A' ' 21' ' ' VAL . 10.8 t -116.86 110.17 30.44 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.448 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.479 179.589 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.5 HG23 ' HA ' ' A' ' 9' ' ' PRO . 1.0 OUTLIER -152.55 146.72 18.53 Favored Pre-proline 0 N--CA 1.485 1.294 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.971 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.5 ' HA ' HG23 ' A' ' 8' ' ' THR . 9.3 Cg_endo -80.83 146.87 73.05 Favored 'Cis proline' 0 C--N 1.306 -1.675 0 O-C-N 123.666 1.351 . . . . 0.0 109.373 -0.232 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.677 ' HA ' HG22 ' A' ' 110' ' ' ILE . 80.4 p -91.51 -24.03 19.77 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.493 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 13.2 m -131.33 160.99 33.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.575 -0.703 . . . . 0.0 109.471 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.74 36.65 32.36 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 -179.648 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.75 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.7 mt -91.32 -42.63 10.26 Favored 'General case' 0 C--N 1.299 -1.587 0 CA-C-O 123.358 1.552 . . . . 0.0 110.46 -178.475 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.24 142.99 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.253 0 CA-C-N 113.322 -1.763 . . . . 0.0 109.795 -179.561 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.601 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.1 p-10 -50.01 105.74 0.1 Allowed 'General case' 0 C--N 1.301 -1.529 0 CA-C-O 121.448 0.642 . . . . 0.0 111.574 -178.56 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.47 13.88 8.57 Favored Glycine 0 N--CA 1.485 1.919 0 C-N-CA 119.417 -1.373 . . . . 0.0 113.16 177.211 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.75 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -106.01 -172.88 2.17 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 121.199 2.499 . . . . 0.0 109.839 179.28 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.95 HG22 HG22 ' A' ' 68' ' ' THR . 20.8 t -128.87 140.3 49.62 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.27 0 CA-C-N 114.695 -1.139 . . . . 0.0 111.362 -178.832 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.562 HG11 HD11 ' A' ' 13' ' ' LEU . 27.8 m -114.87 156.24 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 178.876 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.526 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -109.29 109.72 20.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.984 -1.072 . . . . 0.0 109.553 -179.716 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.949 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -105.05 123.57 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 179.898 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.989 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.3 165.96 11.71 Favored 'General case' 0 N--CA 1.484 1.267 0 O-C-N 120.792 -1.192 . . . . 0.0 108.942 179.438 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.6 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -145.56 108.16 0.45 Allowed Glycine 0 N--CA 1.483 1.822 0 N-CA-C 108.36 -1.896 . . . . 0.0 108.36 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.591 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.83 137.37 52.25 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 120.519 -1.577 . . . . 0.0 110.439 -179.303 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.486 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 85.85 28.85 27.8 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.085 -1.531 . . . . 0.0 109.874 179.567 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.606 HD22 ' HG3' ' A' ' 105' ' ' PRO . 2.3 mt -90.36 175.66 7.02 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.963 -1.316 . . . . 0.0 108.373 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.012 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.69 97.94 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.858 -1.151 . . . . 0.0 109.678 -179.669 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.594 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.08 76.96 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.692 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.381 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.571 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.9 34.34 0.3 Allowed Glycine 0 N--CA 1.486 1.975 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.465 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.553 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.7 p -147.89 113.3 5.61 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 120.998 -1.296 . . . . 0.0 111.28 -179.693 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.577 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.86 126.67 5.91 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-N 115.619 -0.718 . . . . 0.0 109.567 177.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.551 ' CZ ' ' OD2' ' A' ' 99' ' ' ASP . 10.5 m-85 -117.48 149.39 40.67 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.484 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.3 163.87 12.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.751 -1.218 . . . . 0.0 107.92 178.918 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.929 HG11 HG21 ' A' ' 65' ' ' THR . 9.9 p -149.32 114.07 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.202 -0.936 . . . . 0.0 109.838 -177.627 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.524 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.01 -175.89 36.83 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 118.329 -1.891 . . . . 0.0 111.724 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.591 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -101.4 108.87 20.6 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.763 0.792 . . . . 0.0 108.951 -179.563 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.484 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.12 146.88 51.8 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.427 -0.796 . . . . 0.0 109.691 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.493 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -120.35 138.18 53.87 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.298 -0.877 . . . . 0.0 110.703 -179.007 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.861 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.64 114.4 26.14 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.251 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -105.89 14.85 7.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.002 -1.061 . . . . 0.0 110.603 -178.646 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.766 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.43 -174.6 0.07 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.808 -1.182 . . . . 0.0 110.164 179.756 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.8 p -71.71 97.57 1.78 Allowed 'General case' 0 N--CA 1.485 1.323 0 O-C-N 121.43 -0.794 . . . . 0.0 109.867 -179.63 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 26.47 37.09 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 120.251 -0.976 . . . . 0.0 111.483 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.766 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.75 106.21 20.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.556 -1.555 . . . . 0.0 107.367 178.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.861 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -118.22 104.77 11.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.473 -1.392 . . . . 0.0 109.641 -177.729 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.012 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.98 109.75 22.45 Favored 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.789 -1.194 . . . . 0.0 108.345 179.138 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.5 t -106.33 164.71 11.8 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.935 -1.103 . . . . 0.0 110.426 -178.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.732 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 10.5 t-20 -108.94 139.48 20.96 Favored Pre-proline 0 N--CA 1.501 2.083 0 O-C-N 121.461 -0.775 . . . . 0.0 109.952 -179.124 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 6.8 Cg_endo -75.7 23.11 0.45 Allowed 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 125.162 3.908 . . . . 0.0 111.258 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.732 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -120.07 3.34 10.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.426 -1.421 . . . . 0.0 109.052 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.545 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.89 14.51 3.1 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 179.343 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -80.49 91.19 5.72 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.778 -0.769 . . . . 0.0 110.98 -178.487 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.648 ' C ' HG12 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -113.23 -173.31 2.23 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.099 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.67 134.6 0.08 Allowed 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.482 -1.386 . . . . 0.0 111.494 -179.183 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.645 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 3.6 p -146.73 159.62 10.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 107.227 -1.398 . . . . 0.0 107.227 177.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.577 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.33 145.89 25.68 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.433 -1.417 . . . . 0.0 110.116 -179.629 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.47 109.36 3.67 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 122.326 1.06 . . . . 0.0 109.802 178.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.574 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -63.64 -139.31 0.0 OUTLIER 'General case' 0 C--N 1.292 -1.902 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.588 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.594 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.92 -51.59 55.91 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.391 -0.818 . . . . 0.0 110.378 -178.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.475 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.4 t-20 -101.39 -34.18 9.7 Favored 'General case' 0 C--N 1.287 -2.121 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.968 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.44 69.59 0.72 Allowed Glycine 0 N--CA 1.479 1.557 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 178.041 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 64.3 p -98.86 131.69 44.77 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 121.327 -1.102 . . . . 0.0 109.268 179.118 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.645 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.1 108.48 7.82 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.775 -0.77 . . . . 0.0 109.021 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 7.0 m -122.23 116.36 24.0 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.122 -0.986 . . . . 0.0 109.536 -179.743 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.929 HG21 HG11 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -146.13 139.48 25.99 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.428 -0.795 . . . . 0.0 109.787 179.944 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.8 p -99.97 128.83 46.01 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.369 -0.832 . . . . 0.0 108.946 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.787 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -126.54 164.42 21.24 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.227 -0.92 . . . . 0.0 109.783 -179.092 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.95 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -96.77 125.12 41.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.118 -0.989 . . . . 0.0 109.221 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.591 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.9 m -136.51 142.69 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.075 -1.016 . . . . 0.0 109.909 -179.026 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.601 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.8 ptt180 -146.37 -173.62 4.24 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.473 -1.392 . . . . 0.0 110.922 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.619 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.64 -101.94 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 -179.409 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.508 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -55.72 140.95 39.99 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 120.788 -1.195 . . . . 0.0 108.115 179.458 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.79 135.26 5.51 Favored 'General case' 0 C--N 1.294 -1.818 0 C-N-CA 118.701 -1.2 . . . . 0.0 109.813 -178.265 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.519 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 1.3 mp0 -31.53 121.16 0.25 Allowed 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 121.41 0.624 . . . . 0.0 110.699 -178.488 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.012 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.74 46.61 2.73 Favored Glycine 0 N--CA 1.495 2.572 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.136 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -38.48 113.19 0.27 Allowed 'General case' 0 N--CA 1.507 2.388 0 O-C-N 121.121 -1.223 . . . . 0.0 110.205 179.622 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.654 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -85.92 127.32 34.58 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 120.975 -1.078 . . . . 0.0 109.52 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.598 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 25.6 t80 -64.09 58.17 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.051 0 O-C-N 120.858 -1.151 . . . . 0.0 110.198 179.73 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 6.7 t70 -160.93 19.4 0.13 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.972 -1.08 . . . . 0.0 109.794 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.73 -27.17 5.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.429 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 70.7 p -93.39 157.15 16.37 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.05 -1.264 . . . . 0.0 110.349 -179.402 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.492 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -104.73 134.45 47.85 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.652 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.654 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -80.94 -17.97 48.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.887 -1.133 . . . . 0.0 110.413 -178.494 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.74 174.6 19.79 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.29 106.2 1.06 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.11 -1.23 . . . . 0.0 107.695 179.157 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.596 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.0 t -77.54 106.79 8.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.382 -0.824 . . . . 0.0 109.292 -178.787 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.537 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.91 111.54 3.35 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.413 -0.804 . . . . 0.0 109.801 -179.474 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.619 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.71 -5.4 4.07 Favored 'General case' 0 N--CA 1.501 2.085 0 C-N-CA 118.135 -1.426 . . . . 0.0 109.809 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 40.9 p -86.52 -1.8 57.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.799 -1.188 . . . . 0.0 109.29 179.684 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.537 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.14 -49.69 3.0 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.264 -0.898 . . . . 0.0 109.058 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.18 179.03 4.38 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.47 -0.769 . . . . 0.0 109.525 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.3 115.92 31.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.39 -0.819 . . . . 0.0 109.058 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.83 122.59 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.877 -1.139 . . . . 0.0 109.465 -179.448 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.92 148.03 25.82 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 122.418 1.104 . . . . 0.0 111.249 -179.266 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.544 ' HB ' HG11 ' A' ' 7' ' ' VAL . 72.3 t -104.86 109.87 28.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 177.705 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.31 -173.56 18.56 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 118.308 -1.901 . . . . 0.0 111.796 -177.545 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.545 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.49 -178.54 3.41 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.029 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.553 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.2 OUTLIER -171.43 168.39 6.52 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.357 -0.839 . . . . 0.0 109.152 -179.353 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.699 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 2.0 m-20 -104.11 -9.96 18.35 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.104 -0.998 . . . . 0.0 109.497 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.699 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 73.97 38.76 0.56 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.464 -0.773 . . . . 0.0 109.317 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -137.83 -34.5 0.67 Allowed 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.543 -0.723 . . . . 0.0 110.566 -179.444 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.483 ' N ' H193 ' A' ' 114' ' ' CHR . . . -178.16 -42.99 0.07 OUTLIER Glycine 0 N--CA 1.482 1.723 0 N-CA-C 107.588 -2.205 . . . . 0.0 107.588 -179.711 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.44 -178.69 7.32 Favored 'General case' 0 C--N 1.308 -1.237 0 O-C-N 121.6 -0.941 . . . . 0.0 109.522 179.051 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -175.88 -166.53 33.46 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 108.405 -1.878 . . . . 0.0 108.405 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.606 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.2 Cg_exo -45.03 178.85 0.0 OUTLIER 'Trans proline' 0 N--CA 1.491 1.377 0 C-N-CA 123.349 2.699 . . . . 0.0 109.697 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -92.59 175.18 6.92 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.955 -1.09 . . . . 0.0 110.637 -178.859 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -114.76 163.66 12.16 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.35 127.38 63.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.32 -1.106 . . . . 0.0 109.155 -179.285 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.58 122.01 19.76 Favored 'General case' 0 C--N 1.291 -1.971 0 O-C-N 121.559 -0.713 . . . . 0.0 109.47 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.865 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.79 170.44 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.198 -0.939 . . . . 0.0 109.085 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.493 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -140.53 156.38 46.33 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.143 -0.973 . . . . 0.0 109.837 -179.657 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.865 ' CE2' HD12 ' A' ' 110' ' ' ILE . 87.5 m-85 -134.22 114.27 12.88 Favored 'General case' 0 N--CA 1.485 1.293 0 O-C-N 121.233 -0.917 . . . . 0.0 109.572 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.415 ' C ' ' O ' ' A' ' 112' ' ' PHE . 20.2 p30 . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 117.98 -1.009 . . . . 0.0 109.494 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.704 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.571 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -104.41 161.95 21.32 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.265 -0.897 . . . . 0.0 109.36 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.876 ' O ' HG23 ' A' ' 4' ' ' THR . 4.5 Cg_exo -59.2 154.92 42.92 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 124.932 3.755 . . . . 0.0 110.029 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.876 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.2 p -166.54 160.14 14.98 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 -179.248 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.493 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -149.63 121.79 8.33 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-O 122.371 1.081 . . . . 0.0 110.391 -179.725 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.873 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -114.28 109.3 18.16 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-O 123.112 1.435 . . . . 0.0 109.59 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.819 HG13 ' CA ' ' A' ' 21' ' ' VAL . 0.6 OUTLIER -116.71 129.93 72.4 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.666 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.756 -179.883 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.506 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -167.8 148.62 4.75 Favored Pre-proline 0 N--CA 1.487 1.401 0 O-C-N 121.169 -0.957 . . . . 0.0 108.943 -179.723 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.506 ' HA ' HG23 ' A' ' 8' ' ' THR . 7.4 Cg_endo -80.66 147.64 74.96 Favored 'Cis proline' 0 C--N 1.309 -1.523 0 O-C-N 123.669 1.352 . . . . 0.0 109.181 -0.656 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.685 ' HA ' HG22 ' A' ' 110' ' ' ILE . 86.8 p -91.08 -24.5 20.0 Favored 'General case' 0 C--N 1.294 -1.805 0 O-C-N 121.484 -0.76 . . . . 0.0 109.238 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.461 ' HA ' ' O ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -129.61 161.59 30.2 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.367 -0.833 . . . . 0.0 109.622 -179.864 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.08 37.94 31.31 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 108.499 -1.84 . . . . 0.0 108.499 -179.679 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.777 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.3 mt -92.79 -43.69 8.89 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 123.199 1.476 . . . . 0.0 110.736 -178.248 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.476 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.58 143.9 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.473 -1.694 . . . . 0.0 109.79 -179.355 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.577 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 17.9 p-10 -50.54 106.86 0.14 Allowed 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.394 0.616 . . . . 0.0 111.517 -178.558 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.62 14.34 9.65 Favored Glycine 0 N--CA 1.485 1.903 0 C-N-CA 119.38 -1.391 . . . . 0.0 112.966 177.143 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.777 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.18 -172.17 2.06 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 121.1 2.45 . . . . 0.0 109.821 179.246 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.766 HG22 HG22 ' A' ' 68' ' ' THR . 17.7 t -127.94 138.7 53.95 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.796 -1.093 . . . . 0.0 111.197 -179.034 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.483 HG12 ' CD2' ' A' ' 13' ' ' LEU . 28.7 m -112.86 156.77 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.5 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.47 109.25 20.02 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.014 -1.054 . . . . 0.0 109.063 -179.933 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.819 ' CA ' HG13 ' A' ' 7' ' ' VAL . 11.2 p -103.74 140.65 21.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.707 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.873 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -138.93 160.82 38.83 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.681 -1.207 . . . . 0.0 110.142 179.635 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.585 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.03 140.25 11.55 Favored Glycine 0 C--N 1.297 -1.636 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.656 ' HB3' ' OG1' ' A' ' 4' ' ' THR . . . -142.03 126.32 17.58 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.543 -1.563 . . . . 0.0 109.318 179.497 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.508 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 88.65 28.53 21.43 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 118.964 -1.588 . . . . 0.0 109.52 -179.666 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.589 HD22 ' HG3' ' A' ' 105' ' ' PRO . 2.5 mt -88.0 175.92 7.55 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.003 -1.292 . . . . 0.0 108.339 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.03 97.7 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.825 -1.172 . . . . 0.0 109.707 -179.57 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.639 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.92 77.27 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.433 -179.057 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.562 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.45 34.45 0.32 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.564 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.9 p -146.07 111.92 5.63 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.016 -1.285 . . . . 0.0 111.195 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.562 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.38 126.79 5.48 Favored 'General case' 0 N--CA 1.493 1.7 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.501 178.06 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.548 ' CE1' ' OD2' ' A' ' 99' ' ' ASP . 13.3 m-85 -117.45 152.5 34.88 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.494 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -101.42 162.51 12.84 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 178.771 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.718 HG22 HG11 ' A' ' 21' ' ' VAL . 3.8 p -148.99 117.82 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.013 -1.054 . . . . 0.0 110.049 -177.794 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.511 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -170.86 -176.25 40.0 Favored Glycine 0 N--CA 1.493 2.48 0 C-N-CA 118.266 -1.921 . . . . 0.0 111.736 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.595 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.06 108.91 21.19 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -179.788 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.55 148.69 52.38 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.275 -0.891 . . . . 0.0 109.713 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.494 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.95 139.39 54.0 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.316 -0.865 . . . . 0.0 110.643 -178.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.862 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.31 114.55 26.34 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 178.157 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.4 m -106.34 15.43 7.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.974 -1.079 . . . . 0.0 110.771 -178.587 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.751 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.56 -175.31 0.1 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.894 -1.129 . . . . 0.0 110.124 179.657 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 39.2 p -71.45 96.84 1.54 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.395 -0.816 . . . . 0.0 109.691 -179.637 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.84 27.05 35.74 Favored Glycine 0 N--CA 1.493 2.496 0 C-N-CA 120.144 -1.027 . . . . 0.0 111.499 178.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.751 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.1 106.52 20.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 O-C-N 120.595 -1.532 . . . . 0.0 107.382 178.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.862 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -116.08 104.62 11.75 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.492 -1.38 . . . . 0.0 109.485 -177.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.012 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.09 109.57 22.31 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 120.735 -1.228 . . . . 0.0 108.295 179.062 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -107.22 163.78 12.73 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.974 -1.079 . . . . 0.0 110.303 -178.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.536 HD22 ' HB3' ' A' ' 50' ' ' ALA . 16.6 t30 -110.36 139.08 21.14 Favored Pre-proline 0 N--CA 1.503 2.219 0 O-C-N 121.369 -0.832 . . . . 0.0 109.89 -179.401 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.6 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 6.1 Cg_endo -74.55 23.99 0.37 Allowed 'Trans proline' 0 N--CA 1.495 1.591 0 C-N-CA 125.252 3.968 . . . . 0.0 111.445 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.536 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -116.58 1.12 12.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.474 -1.392 . . . . 0.0 109.043 179.474 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.511 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -137.75 15.39 2.9 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.399 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -79.51 90.88 5.1 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.978 -0.689 . . . . 0.0 110.831 -178.649 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.625 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.24 -170.14 1.6 Allowed 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.255 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.451 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.91 136.03 0.09 Allowed 'General case' 0 C--N 1.305 -1.331 0 O-C-N 120.657 -1.277 . . . . 0.0 111.093 -179.354 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.804 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.3 p -150.57 157.35 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 178.212 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.25 145.0 26.5 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.579 -1.325 . . . . 0.0 109.784 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.009 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.15 107.77 2.04 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 122.392 1.091 . . . . 0.0 109.56 178.793 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.553 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.9 p-10 -60.4 -139.26 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.992 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.857 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.639 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -53.01 -49.69 65.74 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.427 -0.795 . . . . 0.0 110.341 -178.889 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -102.56 -36.21 8.45 Favored 'General case' 0 C--N 1.287 -2.148 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 178.4 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.982 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.4 67.14 0.61 Allowed Glycine 0 N--CA 1.48 1.601 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 178.242 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.585 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.1 m -100.98 130.02 46.91 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.566 -0.961 . . . . 0.0 108.992 178.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.804 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.76 108.9 6.79 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.225 -0.99 . . . . 0.0 109.496 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.9 m -125.94 119.73 28.51 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.275 -0.891 . . . . 0.0 109.592 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.455 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.41 144.6 30.74 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.432 -0.793 . . . . 0.0 109.389 179.86 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.0 p -98.96 132.29 44.39 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.418 -0.801 . . . . 0.0 109.355 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.743 ' O ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -130.84 167.83 18.27 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.292 -0.88 . . . . 0.0 109.624 -179.511 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.766 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -99.33 125.54 45.01 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.183 -0.948 . . . . 0.0 109.344 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.568 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.4 m -137.7 143.04 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 120.985 -1.072 . . . . 0.0 109.857 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.577 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.8 ptt180 -145.95 -170.92 3.59 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.597 -1.314 . . . . 0.0 110.888 -179.898 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.616 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -56.12 -102.05 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.769 -0.582 . . . . 0.0 109.488 -179.405 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -55.38 141.0 37.9 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 120.715 -1.24 . . . . 0.0 108.266 179.554 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.577 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.06 137.13 7.16 Favored 'General case' 0 C--N 1.295 -1.777 0 C-N-CA 118.922 -1.111 . . . . 0.0 109.634 -178.357 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.566 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 9.9 mm-40 -33.03 121.62 0.37 Allowed 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.604 0.716 . . . . 0.0 110.868 -178.266 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.012 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.05 44.87 2.99 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -179.555 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.6 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-85 -37.88 112.6 0.22 Allowed 'General case' 0 N--CA 1.508 2.436 0 O-C-N 121.252 -1.146 . . . . 0.0 110.094 179.691 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.739 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.15 126.95 34.6 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.944 -1.098 . . . . 0.0 109.503 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.582 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 34.9 t80 -63.84 58.3 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.0 0 O-C-N 120.967 -1.083 . . . . 0.0 110.338 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 10.9 t0 -161.67 19.83 0.11 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.001 -1.062 . . . . 0.0 109.762 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.15 -26.93 5.25 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.427 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -92.43 157.09 16.78 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.009 -1.289 . . . . 0.0 110.322 -179.402 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.473 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -104.44 133.2 49.73 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.656 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.739 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.4 t90 -81.26 -18.96 44.14 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.835 -1.166 . . . . 0.0 110.427 -178.678 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.45 173.56 18.63 Favored Glycine 0 N--CA 1.485 1.962 0 N-CA-C 108.931 -1.668 . . . . 0.0 108.931 -179.687 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.37 106.83 1.19 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.156 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.647 HG21 ' HB3' ' A' ' 46' ' ' ALA . 50.2 t -77.9 106.17 7.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 O-C-N 121.302 -0.874 . . . . 0.0 109.504 -178.716 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.543 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.51 110.97 2.89 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.36 -0.837 . . . . 0.0 109.826 -179.573 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.616 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -62.5 -5.98 3.01 Favored 'General case' 0 N--CA 1.501 2.078 0 C-N-CA 118.32 -1.352 . . . . 0.0 109.901 179.383 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -87.13 -1.19 57.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.611 -1.306 . . . . 0.0 109.336 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.543 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.0 -49.54 3.02 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.253 -0.905 . . . . 0.0 108.959 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.82 -179.22 3.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.582 -0.699 . . . . 0.0 109.441 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.03 115.37 30.32 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.329 -0.857 . . . . 0.0 109.003 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.561 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.2 m -96.75 122.44 39.69 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.857 -1.152 . . . . 0.0 109.476 -179.362 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.58 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.29 147.86 26.55 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-O 122.451 1.12 . . . . 0.0 111.208 -179.354 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.473 ' CG1' HG11 ' A' ' 7' ' ' VAL . 60.8 t -104.18 111.09 32.44 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.973 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.692 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.07 -172.63 18.98 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 118.108 -1.996 . . . . 0.0 111.769 -177.588 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.5 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -114.4 -179.06 3.52 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 -179.11 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.574 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -170.83 167.05 7.67 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.428 -0.795 . . . . 0.0 109.128 -179.406 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.72 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 3.3 m-20 -102.31 -12.8 17.67 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.104 -0.998 . . . . 0.0 109.51 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.72 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 75.82 36.29 0.46 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.472 -0.768 . . . . 0.0 109.343 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -135.47 -33.17 0.89 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.548 -0.72 . . . . 0.0 110.615 -179.412 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.573 ' N ' H193 ' A' ' 114' ' ' CHR . . . -178.94 -42.58 0.07 OUTLIER Glycine 0 N--CA 1.483 1.769 0 N-CA-C 107.617 -2.193 . . . . 0.0 107.617 -179.564 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.72 -178.75 7.3 Favored 'General case' 0 C--N 1.308 -1.228 0 O-C-N 121.587 -0.949 . . . . 0.0 109.457 179.036 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -175.66 -167.15 34.26 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 108.603 -1.799 . . . . 0.0 108.603 -179.577 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.589 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.7 Cg_exo -45.72 179.65 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.391 0 C-N-CA 123.262 2.641 . . . . 0.0 109.638 179.45 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.84 174.82 6.98 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.917 -1.115 . . . . 0.0 110.571 -178.759 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -115.15 163.3 12.23 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.02 129.34 57.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.23 -1.159 . . . . 0.0 109.241 -179.317 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.58 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.08 122.81 23.27 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.605 -0.684 . . . . 0.0 109.567 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.855 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.93 169.88 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.259 -0.9 . . . . 0.0 109.249 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.461 ' O ' ' HA ' ' A' ' 11' ' ' SER . 1.7 t -140.02 155.4 47.1 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.158 -0.964 . . . . 0.0 109.669 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.855 ' CE2' HD12 ' A' ' 110' ' ' ILE . 87.4 m-85 -131.91 88.31 2.54 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.109 -0.994 . . . . 0.0 109.607 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 16.5 p30 . . . . . 0 N--CA 1.489 1.489 0 CA-C-O 118.061 -0.971 . . . . 0.0 109.554 179.959 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.736 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.883 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -114.7 171.79 4.16 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.319 -0.863 . . . . 0.0 109.459 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.883 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.8 Cg_exo -60.16 157.21 35.85 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.261 1.974 . . . . 0.0 110.693 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.543 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -175.8 -169.24 0.33 Allowed 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 178.904 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.543 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.95 133.57 2.86 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.909 -1.119 . . . . 0.0 110.609 -179.09 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.995 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.8 p -107.13 104.59 14.27 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.595 1.188 . . . . 0.0 110.023 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.993 HG22 HG23 ' A' ' 21' ' ' VAL . 13.2 t -117.93 121.2 66.77 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.435 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.433 179.798 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.512 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.95 148.5 7.42 Favored Pre-proline 0 N--CA 1.487 1.379 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 -179.74 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.512 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.4 Cg_endo -75.42 153.33 98.45 Favored 'Cis proline' 0 C--N 1.309 -1.501 0 C-N-CA 123.648 -1.397 . . . . 0.0 109.614 -0.447 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.493 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 5.1 m -97.27 -22.14 16.85 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.515 ' HB3' ' CB ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -134.43 158.65 43.33 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.543 -0.723 . . . . 0.0 109.537 179.96 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.24 36.73 30.17 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.798 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.5 mt -89.32 -43.89 10.61 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 123.181 1.467 . . . . 0.0 110.513 -178.512 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.74 144.94 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.335 0 CA-C-N 113.543 -1.662 . . . . 0.0 109.946 -179.646 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.584 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.4 p-10 -50.77 107.18 0.16 Allowed 'General case' 0 C--N 1.301 -1.525 0 CA-C-O 121.657 0.741 . . . . 0.0 111.788 -178.469 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.1 15.65 9.72 Favored Glycine 0 N--CA 1.486 1.997 0 C-N-CA 119.423 -1.37 . . . . 0.0 112.942 177.224 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.798 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.1 t -103.21 -172.31 2.09 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 121.103 2.451 . . . . 0.0 109.784 179.221 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.753 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.5 t -129.72 139.14 52.38 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.18 -178.726 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.484 HG11 HD11 ' A' ' 13' ' ' LEU . 26.8 m -118.32 154.36 20.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.64 109.21 20.35 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.233 -0.917 . . . . 0.0 109.292 -179.954 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.993 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -106.09 124.09 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.995 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.16 165.36 12.47 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 120.731 -1.231 . . . . 0.0 108.85 179.421 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.636 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -142.1 107.68 0.5 Allowed Glycine 0 C--O 1.203 -1.838 0 N-CA-C 108.376 -1.89 . . . . 0.0 108.376 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.564 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -117.1 139.09 51.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.706 -1.467 . . . . 0.0 110.83 -178.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.535 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 83.68 26.74 41.1 Favored Glycine 0 N--CA 1.491 2.364 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.044 179.011 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.566 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -88.34 172.97 9.01 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.975 -1.309 . . . . 0.0 108.476 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.024 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.52 99.75 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.064 -1.023 . . . . 0.0 109.602 -179.576 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.82 76.3 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.088 -179.257 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.594 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.81 33.62 0.22 Allowed Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.677 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.556 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 63.3 p -142.73 109.8 5.58 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.032 -1.275 . . . . 0.0 111.178 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.594 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.08 109.98 0.38 Allowed 'General case' 0 N--CA 1.497 1.894 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.361 177.79 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.52 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 5.0 m-30 -105.62 155.97 18.71 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.101 -0.999 . . . . 0.0 109.029 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.509 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -98.83 163.25 12.69 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.744 -1.222 . . . . 0.0 107.763 178.791 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.735 HG11 HG21 ' A' ' 65' ' ' THR . 7.0 p -144.45 114.85 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.151 -0.968 . . . . 0.0 109.91 -177.882 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.65 -177.34 39.54 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 118.204 -1.95 . . . . 0.0 111.716 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.59 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.0 OUTLIER -99.77 112.2 24.46 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 -179.98 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 64.4 m -130.12 154.36 47.56 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 121.428 -0.795 . . . . 0.0 109.703 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.615 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -130.89 137.77 49.49 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.507 -0.745 . . . . 0.0 110.607 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.904 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.71 114.68 26.64 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.377 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.9 m -105.85 15.2 7.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.911 -1.118 . . . . 0.0 110.703 -178.548 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.779 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.23 -175.96 0.08 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.899 -1.126 . . . . 0.0 110.117 179.598 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.8 ' O ' HG23 ' A' ' 42' ' ' THR . 15.2 t -69.58 97.19 1.0 Allowed 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.786 0.803 . . . . 0.0 109.985 -179.474 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.12 27.68 36.36 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.523 178.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.779 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.86 106.46 20.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 O-C-N 120.545 -1.562 . . . . 0.0 107.34 178.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.904 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.5 tp -116.03 106.7 14.05 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.529 -1.357 . . . . 0.0 109.783 -177.598 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.112 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -96.17 110.44 22.72 Favored 'General case' 0 N--CA 1.484 1.272 0 O-C-N 120.765 -1.209 . . . . 0.0 108.554 179.5 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.584 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . 60.8 m -99.71 148.06 24.77 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.337 -0.852 . . . . 0.0 109.979 -178.812 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.749 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 13.0 t-20 -98.92 132.61 23.35 Favored Pre-proline 0 N--CA 1.501 2.098 0 O-C-N 120.922 -1.111 . . . . 0.0 109.159 179.413 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.581 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.9 Cg_endo -73.48 24.06 0.32 Allowed 'Trans proline' 0 C--N 1.317 -1.087 0 C-N-CA 122.291 1.994 . . . . 0.0 112.011 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.749 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -115.62 1.08 13.47 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.283 -1.51 . . . . 0.0 109.215 179.492 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.573 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.68 17.46 2.34 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 179.332 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.584 ' CE2' ' HB3' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -81.26 89.75 6.07 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.726 -0.789 . . . . 0.0 110.878 -178.787 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -112.57 -170.74 1.72 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.32 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.443 ' OG ' ' HA ' ' A' ' 33' ' ' ASP . 0.8 OUTLIER 178.8 134.62 0.09 Allowed 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.592 -1.318 . . . . 0.0 111.287 -179.342 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.564 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 2.5 p -149.07 161.99 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 178.163 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.29 142.62 29.72 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.685 -1.26 . . . . 0.0 110.181 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.024 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.66 108.39 2.45 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.401 1.096 . . . . 0.0 109.735 178.594 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.539 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.5 t70 -62.73 -139.39 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.995 0 CA-C-O 121.494 0.664 . . . . 0.0 110.77 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.85 -50.97 55.68 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.384 -0.823 . . . . 0.0 110.713 -178.722 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 13.6 t30 -103.16 -33.74 9.1 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 178.591 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.981 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 104.18 70.54 0.82 Allowed Glycine 0 C--N 1.298 -1.544 0 N-CA-C 110.254 -1.139 . . . . 0.0 110.254 178.415 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.636 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 36.7 m -103.34 127.55 50.66 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 121.418 -1.048 . . . . 0.0 109.322 179.566 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.567 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -132.09 108.73 9.5 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 50.8 m -118.14 115.3 24.51 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.159 -0.963 . . . . 0.0 109.39 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.735 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.22 137.08 27.09 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.397 -0.814 . . . . 0.0 109.981 -179.862 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.7 p -100.43 133.21 45.19 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.374 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.843 HD12 ' H ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -135.66 172.23 13.32 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.138 -0.976 . . . . 0.0 109.803 -179.076 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.692 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -99.63 124.68 45.08 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.139 -0.976 . . . . 0.0 109.583 -179.692 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.47 HG23 HD13 ' A' ' 13' ' ' LEU . 17.1 m -135.98 143.58 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.015 -1.053 . . . . 0.0 109.664 -179.415 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.584 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.3 ptt180 -141.52 -165.29 1.95 Allowed 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.563 -1.336 . . . . 0.0 110.076 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.548 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -72.65 -87.91 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.522 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -60.14 135.98 57.88 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.58 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.615 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.25 135.22 6.85 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 118.105 -1.438 . . . . 0.0 110.586 -177.62 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.543 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -33.29 119.42 0.35 Allowed 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.588 0.709 . . . . 0.0 110.451 -178.637 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.112 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.19 50.21 2.17 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.511 -178.849 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.581 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 1.1 m-85 -36.53 118.94 0.59 Allowed 'General case' 0 N--CA 1.513 2.719 0 O-C-N 121.236 -1.155 . . . . 0.0 110.214 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.621 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.4 tp -86.93 125.82 34.29 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.901 -1.124 . . . . 0.0 109.389 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.0 t80 -63.72 58.58 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.881 -1.137 . . . . 0.0 110.088 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.8 OUTLIER -161.44 21.01 0.12 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.986 -1.071 . . . . 0.0 109.651 179.879 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.02 -30.55 4.66 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.468 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -94.38 165.14 12.71 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.103 -1.234 . . . . 0.0 110.035 -179.417 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.433 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -111.24 140.39 45.84 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -179.897 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.621 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.2 t90 -81.9 -21.42 37.4 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.77 -1.207 . . . . 0.0 110.461 -178.797 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.67 176.54 18.87 Favored Glycine 0 N--CA 1.485 1.929 0 N-CA-C 108.558 -1.817 . . . . 0.0 108.558 -179.357 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.12 109.96 2.01 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.094 -1.239 . . . . 0.0 107.741 179.223 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.569 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.6 t -82.4 103.21 9.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.394 -0.816 . . . . 0.0 108.916 -178.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.528 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -63.95 110.53 2.15 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.48 -0.762 . . . . 0.0 109.851 -179.344 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.548 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.07 -4.96 5.39 Favored 'General case' 0 N--CA 1.499 1.985 0 C-N-CA 118.269 -1.372 . . . . 0.0 109.829 179.457 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.4 p -85.31 5.1 31.99 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.779 -1.201 . . . . 0.0 108.877 179.347 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.528 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -121.11 -48.9 2.21 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.327 -0.858 . . . . 0.0 109.047 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.63 -177.78 3.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.569 -0.707 . . . . 0.0 109.38 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.14 114.09 27.93 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.391 -0.818 . . . . 0.0 108.921 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.495 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.5 m -97.4 122.74 40.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.892 -1.13 . . . . 0.0 109.756 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.618 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.66 147.73 27.33 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 122.444 1.116 . . . . 0.0 111.346 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.551 ' HB ' HG11 ' A' ' 7' ' ' VAL . 66.9 t -101.47 109.8 26.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 177.618 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.412 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.19 -172.52 18.23 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 118.07 -2.014 . . . . 0.0 111.59 -177.61 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.492 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.74 -178.12 3.32 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -178.904 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.588 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 30.3 p -170.2 164.24 9.07 Favored 'General case' 0 C--N 1.296 -1.738 0 O-C-N 121.352 -0.842 . . . . 0.0 109.479 -179.375 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.52 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -114.96 -156.56 0.61 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.206 -0.934 . . . . 0.0 108.808 179.624 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.472 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -118.5 36.17 4.5 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.824 -1.172 . . . . 0.0 109.221 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.8 -32.71 4.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.298 -0.876 . . . . 0.0 110.448 -179.57 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.993 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 164.27 -36.07 0.29 Allowed Glycine 0 N--CA 1.482 1.706 0 N-CA-C 107.567 -2.213 . . . . 0.0 107.567 -179.518 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -157.91 -178.62 7.45 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.512 -0.993 . . . . 0.0 109.763 179.098 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.02 -161.76 12.85 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 108.313 -1.915 . . . . 0.0 108.313 -179.328 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.492 ' HB2' HD12 ' A' ' 97' ' ' LEU . 5.0 Cg_exo -47.17 177.69 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.701 0 CA-C-N 118.789 1.295 . . . . 0.0 110.076 179.263 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -91.79 179.79 5.53 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.059 -1.026 . . . . 0.0 110.724 -178.576 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.412 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.4 160.99 13.36 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.23 130.01 51.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.324 -1.103 . . . . 0.0 109.345 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.618 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.83 127.3 32.13 Favored 'General case' 0 C--N 1.291 -1.972 0 O-C-N 121.583 -0.698 . . . . 0.0 109.65 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.641 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 19.6 pt -97.25 178.52 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 121.24 -0.912 . . . . 0.0 109.279 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.515 ' CB ' ' HB3' ' A' ' 11' ' ' SER . 0.5 OUTLIER -143.18 152.28 41.59 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.366 -0.834 . . . . 0.0 109.571 179.838 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.641 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 97.3 m-85 -132.82 68.55 1.5 Allowed 'General case' 0 N--CA 1.484 1.249 0 O-C-N 121.082 -1.011 . . . . 0.0 109.569 -179.649 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.8 p30 . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.458 -179.971 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.993 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -122.06 151.35 58.27 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.199 -0.938 . . . . 0.0 109.456 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.523 ' HB3' HD23 ' A' ' 26' ' ' LEU . 3.5 Cg_exo -60.79 157.24 38.81 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 122.212 1.941 . . . . 0.0 110.543 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.601 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -148.69 159.93 43.65 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -179.515 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -149.12 122.45 9.01 Favored 'General case' 0 C--N 1.295 -1.775 0 CA-C-O 122.334 1.064 . . . . 0.0 110.225 -179.69 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.818 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -116.38 109.01 16.77 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-O 123.105 1.431 . . . . 0.0 109.605 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.925 HG22 HG23 ' A' ' 21' ' ' VAL . 4.0 t -114.58 135.33 54.73 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.669 0 CA-C-N 114.194 -1.366 . . . . 0.0 109.688 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.472 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.65 149.82 4.49 Favored Pre-proline 0 N--CA 1.487 1.419 0 O-C-N 121.193 -0.942 . . . . 0.0 108.984 -179.493 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.472 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -79.3 149.38 83.08 Favored 'Cis proline' 0 C--N 1.312 -1.376 0 C-N-CA 123.511 -1.454 . . . . 0.0 109.393 -1.009 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.661 ' HA ' HG22 ' A' ' 110' ' ' ILE . 86.1 p -90.99 -23.83 20.28 Favored 'General case' 0 C--N 1.292 -1.929 0 O-C-N 121.551 -0.718 . . . . 0.0 109.191 179.609 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.49 ' CB ' ' HB3' ' A' ' 111' ' ' SER . 0.7 OUTLIER -129.8 158.94 38.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.496 -0.753 . . . . 0.0 109.595 -179.881 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.51 37.33 27.55 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 108.64 -1.784 . . . . 0.0 108.64 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.806 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.0 mt -92.11 -44.02 9.06 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.213 1.482 . . . . 0.0 110.757 -178.459 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.463 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.16 145.16 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.299 0 CA-C-N 113.505 -1.68 . . . . 0.0 110.055 -179.753 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.613 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.3 p-10 -50.32 106.4 0.12 Allowed 'General case' 0 C--N 1.3 -1.567 0 CA-C-O 121.445 0.641 . . . . 0.0 111.645 -178.694 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.46 14.93 8.53 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.515 -1.326 . . . . 0.0 112.995 177.18 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.806 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -104.97 -174.18 2.48 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 121.134 2.467 . . . . 0.0 109.919 179.348 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.771 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.5 t -127.09 136.11 61.69 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.437 0 CA-C-N 114.541 -1.208 . . . . 0.0 111.258 -178.84 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.472 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 23.3 m -112.25 154.86 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 178.61 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.506 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 18.9 tttt -107.73 109.38 20.95 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.174 -0.954 . . . . 0.0 108.949 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.925 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.73 139.42 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.349 -0.844 . . . . 0.0 108.79 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.818 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.17 161.75 34.02 Favored 'General case' 0 C--N 1.305 -1.358 0 O-C-N 120.886 -1.134 . . . . 0.0 109.848 179.483 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.57 139.7 10.86 Favored Glycine 0 C--N 1.297 -1.604 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 179.752 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.601 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.37 125.87 16.76 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.499 -1.589 . . . . 0.0 109.3 179.48 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.477 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 88.97 27.63 23.18 Favored Glycine 0 N--CA 1.488 2.146 0 C-N-CA 118.8 -1.667 . . . . 0.0 109.736 -179.685 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.562 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.1 mt -87.65 174.16 8.6 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 120.825 -1.397 . . . . 0.0 108.215 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.017 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.46 97.18 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.916 -1.115 . . . . 0.0 109.888 -179.412 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.623 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.76 77.13 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.761 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.404 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.69 34.09 0.32 Allowed Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.383 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.546 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.3 p -147.13 112.8 5.67 Favored 'General case' 0 C--N 1.308 -1.209 0 O-C-N 120.819 -1.401 . . . . 0.0 111.335 -179.804 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.566 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.87 126.58 5.86 Favored 'General case' 0 N--CA 1.491 1.623 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.846 178.063 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.485 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 12.7 m-85 -118.5 152.26 36.29 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.478 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -100.93 160.34 14.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.724 -1.235 . . . . 0.0 107.825 178.911 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.955 HG11 HG21 ' A' ' 65' ' ' THR . 3.7 p -142.4 119.8 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.218 -0.926 . . . . 0.0 109.451 -178.055 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.54 -178.54 41.35 Favored Glycine 0 N--CA 1.494 2.506 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.505 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.684 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -101.0 108.58 20.33 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.462 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.45 149.51 51.19 Favored 'General case' 0 C--N 1.296 -1.738 0 O-C-N 121.264 -0.898 . . . . 0.0 109.956 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.497 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -125.03 139.53 53.73 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.367 -0.833 . . . . 0.0 110.673 -179.146 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.29 114.92 26.75 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.199 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.8 m -105.11 15.23 6.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.093 -1.004 . . . . 0.0 110.595 -178.838 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.759 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.61 -176.06 0.08 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.947 -1.096 . . . . 0.0 110.038 179.631 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.776 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.93 97.75 1.48 Allowed 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.803 0.811 . . . . 0.0 109.848 -179.639 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.14 27.65 36.4 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 120.186 -1.007 . . . . 0.0 111.419 178.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -115.83 106.44 20.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 O-C-N 120.621 -1.517 . . . . 0.0 107.189 178.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -116.03 104.69 11.83 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.461 -1.399 . . . . 0.0 109.936 -177.659 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.045 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.41 22.17 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.827 -1.17 . . . . 0.0 108.179 178.81 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.9 t -107.46 163.63 12.89 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.847 -1.158 . . . . 0.0 110.295 -179.006 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.5 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 13.6 t30 -108.98 134.18 20.46 Favored Pre-proline 0 N--CA 1.502 2.136 0 O-C-N 121.351 -0.843 . . . . 0.0 109.575 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.598 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.6 Cg_endo -74.38 26.85 0.34 Allowed 'Trans proline' 0 C--N 1.319 -0.98 0 C-N-CA 122.486 2.124 . . . . 0.0 112.197 -179.396 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.494 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -109.29 -3.15 17.39 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.329 -1.482 . . . . 0.0 109.299 179.664 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.874 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.7 m-20 -135.96 12.39 3.36 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -70.07 83.6 0.51 Allowed 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.683 -0.807 . . . . 0.0 110.74 -178.667 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -105.23 -167.92 1.4 Allowed 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 178.356 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.473 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.7 t 179.07 135.59 0.09 Allowed 'General case' 0 C--N 1.306 -1.325 0 O-C-N 120.632 -1.292 . . . . 0.0 111.231 -179.38 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.773 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.7 p -149.24 156.63 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 178.095 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.566 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.57 145.39 26.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.583 -1.323 . . . . 0.0 109.738 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.017 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.93 108.67 2.66 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 122.334 1.064 . . . . 0.0 109.592 178.756 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.563 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 p-10 -62.92 -139.58 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.054 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.641 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.623 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.92 -51.73 49.19 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.446 -0.784 . . . . 0.0 110.569 -178.81 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -102.51 -32.98 9.67 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 178.582 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.84 66.72 0.64 Allowed Glycine 0 C--N 1.299 -1.511 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 178.168 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 55.6 p -98.69 132.51 44.01 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 121.289 -1.124 . . . . 0.0 109.048 179.001 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.773 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.03 108.6 6.95 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.146 -1.022 . . . . 0.0 109.535 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.3 m -124.12 117.48 24.76 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.265 -0.897 . . . . 0.0 109.641 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.955 HG21 HG11 ' A' ' 34' ' ' VAL . 5.2 t -145.99 145.2 30.54 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.441 -0.787 . . . . 0.0 109.361 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 53.3 p -99.03 143.98 28.69 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.428 -0.795 . . . . 0.0 109.342 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.874 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -145.35 169.86 17.45 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.305 -0.872 . . . . 0.0 109.459 -178.96 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.754 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -102.32 123.27 45.83 Favored 'General case' 0 N--CA 1.498 1.975 0 O-C-N 120.842 -1.161 . . . . 0.0 110.388 -178.878 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.842 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.2 m -131.12 143.98 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 120.996 -1.065 . . . . 0.0 110.016 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.613 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.3 ptt180 -148.93 -176.63 5.42 Favored 'General case' 0 N--CA 1.483 1.221 0 O-C-N 120.555 -1.341 . . . . 0.0 110.649 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.619 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.73 -101.5 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -179.562 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.5 OUTLIER -56.29 140.07 46.17 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.777 -1.202 . . . . 0.0 108.313 179.591 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.569 ' CZ ' ' SG ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -160.81 135.69 7.56 Favored 'General case' 0 C--N 1.296 -1.74 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.545 -178.57 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.5 ' N ' ' OD1' ' A' ' 48' ' ' ASN . 6.1 mm-40 -33.05 122.18 0.38 Allowed 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.609 0.718 . . . . 0.0 110.775 -178.038 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.045 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.78 45.34 2.89 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 -179.326 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.598 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-85 -37.64 114.62 0.35 Allowed 'General case' 0 N--CA 1.512 2.632 0 O-C-N 121.277 -1.131 . . . . 0.0 110.12 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.733 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -87.44 127.22 35.22 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.115 -0.991 . . . . 0.0 109.291 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 49.8 t80 -63.54 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.061 0 O-C-N 120.862 -1.149 . . . . 0.0 110.137 179.74 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.2 t0 -161.2 19.33 0.12 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.945 -1.097 . . . . 0.0 109.805 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.55 -26.73 5.61 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 42.1 p -94.41 160.21 14.76 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.121 -1.223 . . . . 0.0 110.11 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.477 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.6 OUTLIER -106.67 136.12 47.03 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.733 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.1 t90 -81.91 -18.9 42.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.819 -1.175 . . . . 0.0 110.428 -178.653 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.46 174.38 18.43 Favored Glycine 0 N--CA 1.486 2.024 0 N-CA-C 108.772 -1.731 . . . . 0.0 108.772 -179.602 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.18 106.06 1.23 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.113 -1.228 . . . . 0.0 107.688 179.184 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.683 HG21 ' HB3' ' A' ' 46' ' ' ALA . 51.3 t -76.96 105.22 5.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.316 -0.865 . . . . 0.0 109.361 -178.822 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.675 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.62 110.85 2.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.468 -0.77 . . . . 0.0 109.765 -179.599 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.619 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.08 -5.73 3.39 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 120.517 -1.364 . . . . 0.0 109.846 179.422 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -86.52 -0.57 56.36 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.706 -1.246 . . . . 0.0 109.172 179.655 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.675 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -113.19 -50.13 2.88 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.322 -0.861 . . . . 0.0 108.957 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.63 -178.62 3.71 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.576 -0.703 . . . . 0.0 109.428 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.54 115.31 30.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.337 -0.852 . . . . 0.0 109.039 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.569 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.24 123.36 41.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.875 -1.14 . . . . 0.0 109.7 -179.278 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.623 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.76 145.92 29.69 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.474 1.13 . . . . 0.0 111.113 -179.424 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.517 ' CG1' HG11 ' A' ' 7' ' ' VAL . 55.6 t -101.76 110.09 27.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.049 0 N-CA-C 106.646 -1.612 . . . . 0.0 106.646 177.474 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.483 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.01 -171.29 16.83 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 118.106 -1.997 . . . . 0.0 111.694 -177.475 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.49 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -119.0 179.48 4.14 Favored 'General case' 0 N--CA 1.485 1.283 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.038 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.544 ' OG ' ' C21' ' A' ' 114' ' ' CHR . 3.5 m -179.16 -179.65 0.59 Allowed 'General case' 0 C--N 1.294 -1.817 0 O-C-N 121.435 -0.791 . . . . 0.0 109.666 -179.867 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.415 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -128.54 -159.14 0.93 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.975 -1.078 . . . . 0.0 109.036 179.921 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.415 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.13 36.8 4.07 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.736 -1.228 . . . . 0.0 109.037 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -113.14 -32.81 6.2 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.371 -0.83 . . . . 0.0 109.958 -179.591 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.768 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.13 -35.63 0.27 Allowed Glycine 0 N--CA 1.482 1.721 0 N-CA-C 107.909 -2.076 . . . . 0.0 107.909 -179.702 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.409 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.65 -177.15 3.8 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.603 -0.939 . . . . 0.0 109.725 179.395 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.63 -161.65 19.15 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.32 -1.912 . . . . 0.0 108.32 -179.388 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.495 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.9 Cg_exo -46.68 176.26 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.655 0 CA-C-N 118.808 1.304 . . . . 0.0 110.173 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -94.19 -174.96 3.53 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.038 -1.039 . . . . 0.0 110.403 -178.799 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.483 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.79 165.0 13.47 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.449 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.55 130.57 50.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.353 -1.087 . . . . 0.0 109.223 -179.416 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.623 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.84 125.48 28.26 Favored 'General case' 0 C--N 1.291 -1.964 0 O-C-N 121.669 -0.644 . . . . 0.0 109.774 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.661 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.5 pt -97.82 170.11 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.307 -0.871 . . . . 0.0 109.22 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.49 ' HB3' ' CB ' ' A' ' 11' ' ' SER . 3.6 t -138.09 158.33 44.53 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.375 -0.828 . . . . 0.0 109.449 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.633 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 30.4 m-85 -123.12 125.7 45.65 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.184 -0.948 . . . . 0.0 109.539 -179.731 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.46 ' OXT' ' O ' ' A' ' 112' ' ' PHE . 19.8 p30 . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.168 -0.957 . . . . 0.0 109.457 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.768 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -120.61 148.62 48.43 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.49 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.588 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 4.4 Cg_exo -60.4 157.16 37.28 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.348 2.032 . . . . 0.0 110.581 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.552 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.8 -169.69 0.14 Allowed 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 179.209 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.587 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . -166.43 133.55 2.6 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 120.614 -1.304 . . . . 0.0 111.109 -179.322 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.007 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -101.66 104.47 15.31 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 122.413 1.101 . . . . 0.0 110.032 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.949 HG22 HG23 ' A' ' 21' ' ' VAL . 3.4 t -118.54 115.4 48.0 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.415 0 CA-C-O 121.679 0.752 . . . . 0.0 110.455 179.63 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.504 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.22 147.85 12.78 Favored Pre-proline 0 N--CA 1.487 1.397 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 -179.723 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.504 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.3 Cg_endo -77.07 152.05 94.41 Favored 'Cis proline' 0 C--N 1.309 -1.506 0 C-N-CA 123.693 -1.378 . . . . 0.0 109.561 -0.328 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.685 ' HA ' HG22 ' A' ' 110' ' ' ILE . 13.6 p -89.71 -25.84 20.98 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.642 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.518 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.0 m -136.39 167.98 20.3 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.555 -0.715 . . . . 0.0 109.338 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.47 38.12 39.15 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.747 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.3 mt -93.22 -42.63 9.24 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 123.319 1.533 . . . . 0.0 110.561 -178.177 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.56 142.58 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.284 0 CA-C-N 113.402 -1.726 . . . . 0.0 109.67 -179.385 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.606 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.2 p-10 -50.61 105.95 0.11 Allowed 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.588 0.709 . . . . 0.0 111.364 -178.517 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.68 14.15 8.24 Favored Glycine 0 N--CA 1.484 1.88 0 C-N-CA 119.446 -1.359 . . . . 0.0 112.982 177.418 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.747 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -106.21 -172.24 2.05 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 121.22 2.51 . . . . 0.0 109.831 179.161 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.985 HG22 HG22 ' A' ' 68' ' ' THR . 17.1 t -129.7 138.32 54.49 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.34 -178.786 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.62 HG11 HD11 ' A' ' 13' ' ' LEU . 35.8 m -114.34 155.35 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.782 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 28.2 tttt -107.13 108.87 20.53 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.184 -0.948 . . . . 0.0 109.466 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.949 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -105.64 123.29 59.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.372 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.007 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.66 166.55 12.28 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.716 -1.24 . . . . 0.0 109.325 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.62 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.05 142.45 13.89 Favored Glycine 0 C--N 1.294 -1.766 0 N-CA-C 107.381 -2.288 . . . . 0.0 107.381 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.588 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -147.22 123.27 10.76 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 120.747 -1.443 . . . . 0.0 108.714 179.372 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.513 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 90.1 27.01 22.38 Favored Glycine 0 N--CA 1.487 2.084 0 C-N-CA 119.155 -1.498 . . . . 0.0 109.802 -179.563 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.553 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.9 OUTLIER -89.0 174.8 7.7 Favored 'General case' 0 C--N 1.307 -1.248 0 O-C-N 120.842 -1.387 . . . . 0.0 108.436 179.85 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.83 99.78 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.949 -1.094 . . . . 0.0 109.808 -179.8 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.581 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.18 78.09 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.191 -179.298 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.83 34.5 0.3 Allowed Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 179.627 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.565 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 35.2 p -140.99 106.9 5.15 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 121.127 -1.219 . . . . 0.0 111.361 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.59 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.52 110.07 0.34 Allowed 'General case' 0 N--CA 1.498 1.931 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.557 177.87 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 5.7 m-30 -108.0 154.38 21.72 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.097 -1.002 . . . . 0.0 108.854 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.64 163.03 12.53 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.864 -1.148 . . . . 0.0 108.055 179.133 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.643 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.6 p -140.89 116.71 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.133 -0.979 . . . . 0.0 109.351 -178.297 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -164.32 -176.72 36.39 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 118.325 -1.893 . . . . 0.0 111.802 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.593 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -103.15 109.44 21.02 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.862 0.839 . . . . 0.0 109.099 -179.635 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.35 147.79 51.21 Favored 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.231 -0.918 . . . . 0.0 109.578 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.558 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.66 138.26 54.41 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.255 -0.903 . . . . 0.0 110.823 -178.882 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.68 26.48 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.177 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -105.74 14.71 7.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 120.952 -1.092 . . . . 0.0 110.513 -178.771 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 175.09 -175.9 0.09 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 120.951 -1.093 . . . . 0.0 110.03 179.754 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.784 ' O ' HG23 ' A' ' 42' ' ' THR . 15.0 t -71.33 97.82 1.65 Allowed 'General case' 0 N--CA 1.487 1.379 0 CA-C-O 121.785 0.802 . . . . 0.0 109.785 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.78 27.45 34.79 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.238 -0.982 . . . . 0.0 111.524 178.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.98 106.11 19.75 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 O-C-N 120.539 -1.565 . . . . 0.0 107.236 178.836 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.82 104.75 11.64 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.517 -1.365 . . . . 0.0 109.874 -177.692 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.106 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.78 109.45 22.2 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 120.845 -1.16 . . . . 0.0 108.071 178.86 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.4 t -107.07 162.42 13.87 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.949 -1.094 . . . . 0.0 110.393 -178.778 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.557 HD22 ' HB3' ' A' ' 50' ' ' ALA . 15.4 t30 -110.32 134.4 20.81 Favored Pre-proline 0 N--CA 1.503 2.199 0 O-C-N 121.453 -0.78 . . . . 0.0 109.759 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.593 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.77 25.03 0.33 Allowed 'Trans proline' 0 C--N 1.318 -1.055 0 C-N-CA 122.346 2.031 . . . . 0.0 112.192 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.557 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -113.43 4.15 16.15 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.327 -1.483 . . . . 0.0 109.233 179.538 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.56 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.78 16.04 2.69 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 179.462 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -79.85 88.86 5.25 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.541 -178.266 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.643 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -105.96 -165.85 1.14 Allowed 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 177.788 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.444 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.77 138.38 0.09 Allowed 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.508 -1.37 . . . . 0.0 111.454 -179.343 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.949 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -156.64 157.2 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.225 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.67 141.82 31.01 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.828 -1.17 . . . . 0.0 109.746 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.05 106.96 0.92 Allowed 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 122.385 1.088 . . . . 0.0 109.144 178.309 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.8 t0 -61.64 -138.9 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.987 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.016 -179.843 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.581 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.59 -52.12 32.46 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.426 -0.796 . . . . 0.0 110.81 -178.534 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -104.06 -33.05 8.91 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 106.209 -1.775 . . . . 0.0 106.209 178.571 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.016 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.31 65.41 0.56 Allowed Glycine 0 C--N 1.298 -1.542 0 N-CA-C 110.457 -1.057 . . . . 0.0 110.457 178.085 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.62 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.4 m -102.99 127.95 50.01 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 121.492 -1.004 . . . . 0.0 108.819 178.871 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.949 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.39 109.17 7.55 Favored 'General case' 0 C--N 1.296 -1.737 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.893 -179.312 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -116.26 117.43 29.99 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.207 -0.933 . . . . 0.0 109.291 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.573 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.63 143.34 30.72 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.412 -0.805 . . . . 0.0 109.758 -179.978 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.9 p -101.0 140.01 35.89 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.472 -0.768 . . . . 0.0 109.5 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.796 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -139.21 161.6 37.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.36 -0.837 . . . . 0.0 109.524 -179.469 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.985 HG22 HG22 ' A' ' 18' ' ' VAL . 2.9 p -93.87 124.46 37.89 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.159 -0.963 . . . . 0.0 109.438 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.562 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.3 m -135.38 143.71 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.063 -1.023 . . . . 0.0 109.58 -179.314 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.606 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.5 ptt180 -146.79 -177.13 5.49 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 120.453 -1.405 . . . . 0.0 111.042 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.627 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.13 -100.98 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -179.674 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -56.2 140.68 43.7 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 120.769 -1.207 . . . . 0.0 108.208 179.546 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.05 136.19 6.66 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 118.82 -1.152 . . . . 0.0 109.672 -178.341 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.52 ' N ' ' OD1' ' A' ' 48' ' ' ASN . 34.6 mt-10 -34.8 122.12 0.53 Allowed 'General case' 0 N--CA 1.489 1.508 0 CA-C-O 121.491 0.662 . . . . 0.0 110.462 -178.314 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.106 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.74 49.14 2.55 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.593 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.1 m-85 -38.82 114.21 0.37 Allowed 'General case' 0 N--CA 1.506 2.353 0 O-C-N 121.18 -1.188 . . . . 0.0 109.915 179.541 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.7 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.44 126.81 34.66 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.944 -1.098 . . . . 0.0 109.46 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.577 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.4 t80 -64.12 58.37 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.976 0 O-C-N 120.832 -1.168 . . . . 0.0 110.133 179.718 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.2 t70 -160.54 19.49 0.14 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.125 -0.984 . . . . 0.0 109.704 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.63 -27.18 5.41 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.41 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 21.4 p -94.19 159.71 15.02 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.03 -1.277 . . . . 0.0 110.316 -179.429 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.478 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.52 136.29 46.55 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.711 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.7 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.12 -18.47 42.8 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.734 -1.228 . . . . 0.0 110.44 -178.499 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.94 174.92 19.31 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 108.819 -1.712 . . . . 0.0 108.819 -179.575 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -65.09 105.34 1.04 Allowed 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 179.186 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.643 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.9 t -77.28 107.06 8.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.364 -0.835 . . . . 0.0 109.267 -178.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.536 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.2 m-20 -66.76 111.39 3.69 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.441 -0.787 . . . . 0.0 110.022 -179.313 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.627 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.81 -5.52 4.42 Favored 'General case' 0 N--CA 1.5 2.058 0 C-N-CA 118.171 -1.412 . . . . 0.0 109.832 179.198 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 16.6 p -87.26 1.17 53.98 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.795 -1.19 . . . . 0.0 109.171 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.536 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -115.23 -50.66 2.74 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.326 -0.859 . . . . 0.0 108.99 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.67 179.63 4.21 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.488 -0.757 . . . . 0.0 109.43 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.5 115.39 30.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.31 -0.869 . . . . 0.0 108.906 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.563 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.2 m -96.99 122.04 39.54 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.916 -1.115 . . . . 0.0 109.335 -179.368 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.578 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.17 146.37 27.58 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 122.371 1.081 . . . . 0.0 111.286 -179.292 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.607 ' HB ' HG11 ' A' ' 7' ' ' VAL . 54.6 t -105.73 111.74 36.19 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.028 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.502 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.46 -169.94 19.06 Favored Glycine 0 N--CA 1.487 2.088 0 C-N-CA 118.251 -1.928 . . . . 0.0 111.482 -177.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.479 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -117.23 173.24 6.79 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.803 -0.822 . . . . 0.0 108.858 -179.356 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.574 ' HB3' ' C20' ' A' ' 114' ' ' CHR . 0.3 OUTLIER 173.19 163.51 0.14 Allowed 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.854 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.47 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.2 OUTLIER -112.13 -156.64 0.59 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.916 -1.115 . . . . 0.0 109.113 179.922 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.47 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.64 36.31 4.34 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 120.806 -1.184 . . . . 0.0 109.031 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.411 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -106.93 -31.4 8.35 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.436 -0.79 . . . . 0.0 109.56 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.561 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 168.22 -37.24 0.21 Allowed Glycine 0 N--CA 1.482 1.744 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -173.74 -176.21 1.21 Allowed 'General case' 0 C--N 1.306 -1.29 0 O-C-N 121.562 -0.964 . . . . 0.0 109.828 179.512 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.501 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.6 -159.57 12.51 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.314 -1.914 . . . . 0.0 108.314 -179.311 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.501 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.6 Cg_exo -47.49 -178.13 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.672 0 CA-C-N 118.824 1.312 . . . . 0.0 110.574 179.215 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -94.44 -178.38 4.56 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.057 -1.027 . . . . 0.0 110.405 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.502 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.36 162.22 13.31 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.25 128.6 52.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.465 -1.021 . . . . 0.0 109.123 -179.549 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.578 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.09 118.53 15.07 Favored 'General case' 0 C--N 1.289 -2.059 0 O-C-N 121.7 -0.625 . . . . 0.0 109.555 179.75 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.899 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.8 pt -98.01 172.13 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.289 -0.882 . . . . 0.0 108.997 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.518 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -142.48 154.09 44.22 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.06 -1.025 . . . . 0.0 110.153 -179.744 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.899 ' CE2' HD12 ' A' ' 110' ' ' ILE . 97.8 m-85 -132.64 134.74 45.24 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.302 -0.873 . . . . 0.0 109.278 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.3 p30 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.974 -1.012 . . . . 0.0 109.445 -179.954 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.834 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.44 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -102.83 156.27 35.5 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.299 -0.875 . . . . 0.0 109.465 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.54 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 4.3 Cg_exo -60.1 158.0 32.08 Favored 'Trans proline' 0 C--N 1.31 -1.468 0 C-N-CA 122.29 1.993 . . . . 0.0 110.466 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.619 ' OG1' ' HB3' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -155.33 162.45 40.83 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 -179.316 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.534 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -149.21 125.75 10.98 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.875 -1.14 . . . . 0.0 110.827 -179.784 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.003 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.7 p -104.03 104.82 14.83 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-O 122.417 1.103 . . . . 0.0 110.397 -179.483 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.94 HG22 HG23 ' A' ' 21' ' ' VAL . 6.1 t -119.26 116.81 52.05 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.477 0 CA-C-O 121.582 0.706 . . . . 0.0 110.226 179.434 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.5 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -161.06 149.28 12.8 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.44 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.5 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.71 152.95 98.87 Favored 'Cis proline' 0 C--N 1.311 -1.428 0 C-N-CA 123.679 -1.384 . . . . 0.0 109.72 -0.507 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.647 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.8 m -91.46 -25.35 19.35 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.49 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 13.5 m -136.84 166.15 24.29 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.6 -0.688 . . . . 0.0 109.39 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.27 37.76 35.92 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 108.426 -1.87 . . . . 0.0 108.426 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.787 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.9 mt -92.47 -43.77 9.01 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 123.229 1.49 . . . . 0.0 110.676 -178.242 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.56 144.72 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.517 -1.674 . . . . 0.0 110.044 -179.57 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.601 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.7 p-10 -50.72 107.36 0.17 Allowed 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.535 0.683 . . . . 0.0 111.629 -178.606 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.9 14.23 9.52 Favored Glycine 0 N--CA 1.485 1.949 0 C-N-CA 119.421 -1.371 . . . . 0.0 112.927 177.357 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.787 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.8 t -105.09 -173.54 2.33 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 121.13 2.465 . . . . 0.0 109.899 179.265 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.769 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.9 t -128.41 138.97 53.17 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 CA-C-N 114.63 -1.168 . . . . 0.0 111.157 -178.639 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.551 HG11 HD11 ' A' ' 13' ' ' LEU . 27.9 m -116.15 154.42 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.653 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.554 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 15.0 tptp -107.21 108.68 20.22 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.168 -0.957 . . . . 0.0 109.297 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.94 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -106.14 123.54 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.003 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -118.24 168.22 10.8 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.717 -1.24 . . . . 0.0 109.504 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.614 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -137.13 136.71 8.47 Favored Glycine 0 C--O 1.207 -1.582 0 N-CA-C 107.493 -2.243 . . . . 0.0 107.493 179.515 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.619 ' HB3' ' OG1' ' A' ' 4' ' ' THR . . . -141.27 125.82 17.8 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-N 119.668 1.734 . . . . 0.0 109.397 179.794 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.471 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 88.35 28.91 21.12 Favored Glycine 0 N--CA 1.488 2.146 0 C-N-CA 118.692 -1.718 . . . . 0.0 109.598 -179.715 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.525 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.8 mt -89.26 173.98 8.1 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.034 -1.274 . . . . 0.0 108.283 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.001 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.02 97.1 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.007 -1.058 . . . . 0.0 109.773 -179.871 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.684 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.34 76.86 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.39 -178.882 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.84 34.06 0.31 Allowed Glycine 0 N--CA 1.486 1.995 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.309 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.557 ' O ' HG23 ' A' ' 30' ' ' THR . 1.1 t -146.37 113.88 6.35 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.923 -1.339 . . . . 0.0 111.225 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.566 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -45.3 126.97 6.79 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.548 178.399 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.498 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 6.0 m-85 -121.32 149.41 42.97 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.467 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.45 160.06 14.65 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.697 -1.252 . . . . 0.0 108.064 178.955 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.682 ' O ' HG13 ' A' ' 34' ' ' VAL . 9.0 p -142.8 116.96 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.249 -0.907 . . . . 0.0 109.908 -177.69 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.521 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.82 -176.51 38.48 Favored Glycine 0 N--CA 1.494 2.524 0 C-N-CA 118.298 -1.906 . . . . 0.0 111.756 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.587 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -101.38 109.34 21.16 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.758 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -129.6 149.85 51.18 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.235 -0.915 . . . . 0.0 109.601 179.622 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.607 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.93 138.3 54.5 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.241 -0.912 . . . . 0.0 110.928 -178.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.09 26.96 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 178.049 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.7 m -105.64 15.01 7.16 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.024 -1.047 . . . . 0.0 110.512 -178.755 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.761 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.96 -175.38 0.09 Allowed 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.028 -1.045 . . . . 0.0 109.987 179.715 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -72.38 97.77 2.11 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 121.381 -0.825 . . . . 0.0 109.66 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.29 28.14 31.33 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.233 -0.984 . . . . 0.0 111.383 178.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.761 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.42 106.26 19.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 O-C-N 120.586 -1.537 . . . . 0.0 107.339 178.873 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -116.35 104.59 11.63 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.421 -1.424 . . . . 0.0 109.902 -177.771 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.095 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.5 22.25 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.776 -1.203 . . . . 0.0 107.987 178.704 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.5 161.74 14.57 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.919 -1.113 . . . . 0.0 110.189 -178.763 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.6 HD22 ' HB3' ' A' ' 50' ' ' ALA . 43.2 t30 -109.74 136.49 20.33 Favored Pre-proline 0 N--CA 1.502 2.167 0 O-C-N 121.383 -0.823 . . . . 0.0 109.807 -179.57 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.56 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.79 25.37 0.33 Allowed 'Trans proline' 0 C--N 1.318 -1.028 0 C-N-CA 122.354 2.036 . . . . 0.0 111.876 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.6 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -111.2 2.33 17.72 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.392 -1.442 . . . . 0.0 109.268 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.522 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.24 16.77 2.24 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.7 -1.222 . . . . 0.0 107.7 179.724 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -79.86 91.77 5.41 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.82 -0.752 . . . . 0.0 111.078 -178.57 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.619 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -111.31 -168.2 1.28 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.957 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.85 135.61 0.09 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.503 -1.373 . . . . 0.0 111.521 -179.307 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.762 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -152.41 158.32 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 178.015 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.566 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.77 145.54 26.26 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.659 -1.276 . . . . 0.0 109.672 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.001 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.24 108.01 2.56 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 122.394 1.092 . . . . 0.0 109.5 178.721 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 t0 -61.06 -138.73 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.923 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.684 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.57 -49.87 64.11 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.386 -0.821 . . . . 0.0 110.405 -178.747 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.471 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 16.9 t-20 -102.94 -36.99 8.01 Favored 'General case' 0 C--N 1.286 -2.194 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 178.449 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.978 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.31 68.36 0.61 Allowed Glycine 0 C--N 1.297 -1.601 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 178.19 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.614 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.8 m -102.96 129.12 49.59 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.496 -1.002 . . . . 0.0 109.316 179.284 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.762 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.56 108.54 7.63 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.533 -0.867 . . . . 0.0 109.43 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.497 ' HB2' ' NZ ' ' A' ' 20' ' ' LYS . 53.0 p -120.31 118.87 31.54 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.106 -0.996 . . . . 0.0 109.368 -179.82 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.58 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.91 143.01 28.2 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.395 -0.815 . . . . 0.0 109.802 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.476 ' HB3' ' HD3' ' A' ' 20' ' ' LYS . 2.9 p -102.17 135.04 44.45 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.492 -0.755 . . . . 0.0 109.059 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.836 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -135.2 169.93 16.7 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.301 -0.874 . . . . 0.0 109.597 -179.24 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.767 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -99.56 125.55 45.37 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.079 -1.013 . . . . 0.0 109.581 -179.68 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.587 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.7 m -135.11 143.33 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.036 -1.04 . . . . 0.0 109.519 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.601 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.0 ptt180 -146.63 -174.89 4.59 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 120.417 -1.427 . . . . 0.0 111.11 -179.758 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.607 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -54.12 -101.71 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 116.032 -0.531 . . . . 0.0 109.577 -179.382 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.508 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.85 139.97 49.64 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.749 -1.22 . . . . 0.0 108.138 179.659 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.607 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.28 136.34 7.51 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 118.772 -1.171 . . . . 0.0 109.879 -178.068 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.579 ' OE2' ' CD1' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -34.7 121.19 0.51 Allowed 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.543 0.687 . . . . 0.0 110.249 -178.462 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.095 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.52 50.57 2.08 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.107 -179.199 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CD1' ' OE2' ' A' ' 74' ' ' GLU . 2.8 m-85 -38.95 116.93 0.62 Allowed 'General case' 0 N--CA 1.509 2.484 0 O-C-N 121.041 -1.27 . . . . 0.0 109.882 179.639 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.74 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -87.34 126.16 34.68 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.95 -1.094 . . . . 0.0 109.389 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.1 t80 -64.53 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.789 -1.194 . . . . 0.0 110.106 179.711 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -159.77 19.7 0.17 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.033 -1.042 . . . . 0.0 109.696 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.26 -28.07 5.35 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.45 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 38.4 p -95.84 160.42 14.49 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.991 -1.299 . . . . 0.0 110.404 -179.458 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.489 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 6.0 ptt180 -105.95 139.58 40.28 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.784 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.74 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.4 t90 -84.5 -18.83 34.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.653 -1.279 . . . . 0.0 110.634 -178.53 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.85 175.53 19.03 Favored Glycine 0 N--CA 1.485 1.943 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 -179.581 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.74 105.37 1.24 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.058 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.674 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.5 t -76.7 105.61 5.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.147 -178.877 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.548 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -65.65 110.82 2.9 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.471 -0.768 . . . . 0.0 109.813 -179.481 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.607 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.24 -5.7 3.65 Favored 'General case' 0 N--CA 1.499 1.982 0 C-N-CA 118.255 -1.378 . . . . 0.0 109.838 179.482 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.0 p -86.57 -0.11 55.47 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.766 -1.209 . . . . 0.0 109.107 179.548 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.548 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.86 -50.57 2.82 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.398 -0.814 . . . . 0.0 108.968 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.8 -178.96 3.8 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.515 -0.741 . . . . 0.0 109.443 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.97 115.84 30.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.432 -0.793 . . . . 0.0 108.929 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.8 121.55 38.78 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.797 -1.189 . . . . 0.0 109.39 -179.369 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.81 147.1 26.46 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 122.33 1.062 . . . . 0.0 111.126 -179.362 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.701 ' HB ' HG11 ' A' ' 7' ' ' VAL . 48.3 t -105.34 111.93 36.75 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.997 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.831 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.511 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.75 -170.54 19.92 Favored Glycine 0 N--CA 1.488 2.102 0 C-N-CA 118.062 -2.018 . . . . 0.0 111.751 -177.877 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.81 177.47 4.69 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.212 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.583 ' HB2' ' C27' ' A' ' 114' ' ' CHR . 3.9 m 177.97 165.63 0.71 Allowed 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.649 -0.657 . . . . 0.0 109.269 -179.805 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.498 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -112.65 -159.09 0.67 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.846 -1.159 . . . . 0.0 109.065 179.95 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.93 36.01 4.38 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.757 -1.214 . . . . 0.0 109.166 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.85 -33.28 6.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.314 -0.866 . . . . 0.0 109.77 -179.691 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.661 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.08 -36.86 0.23 Allowed Glycine 0 N--CA 1.48 1.569 0 N-CA-C 108.07 -2.012 . . . . 0.0 108.07 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -164.22 -177.32 4.9 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.612 -0.934 . . . . 0.0 110.042 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.68 -161.04 19.37 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 108.117 -1.993 . . . . 0.0 108.117 -179.494 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.1 Cg_exo -47.01 177.3 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.701 0 CA-C-N 118.968 1.384 . . . . 0.0 110.249 179.228 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.2 mm-40 -94.32 -179.4 4.91 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.073 -1.017 . . . . 0.0 110.583 -178.797 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.511 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.94 166.13 12.72 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.59 131.19 54.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.288 -1.124 . . . . 0.0 109.258 -179.282 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.03 121.02 20.42 Favored 'General case' 0 C--N 1.29 -2.014 0 O-C-N 121.548 -0.72 . . . . 0.0 109.587 179.676 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.92 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.97 171.3 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.226 -0.922 . . . . 0.0 109.095 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.49 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.93 156.81 46.97 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.264 -0.897 . . . . 0.0 109.929 -179.635 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.92 ' CE1' HD12 ' A' ' 110' ' ' ILE . 95.9 m-85 -132.03 73.55 1.54 Allowed 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.318 -0.864 . . . . 0.0 109.378 -179.779 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.421 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 13.2 p30 . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.503 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.779 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.917 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -98.05 172.75 4.53 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.343 -0.848 . . . . 0.0 109.474 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.917 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.7 Cg_exo -59.71 158.0 30.22 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.214 1.943 . . . . 0.0 110.632 -179.994 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.59 -169.78 0.15 Allowed 'General case' 0 C--N 1.295 -1.779 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 179.245 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.545 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.88 130.32 2.28 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 120.841 -1.162 . . . . 0.0 110.602 -179.153 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.957 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.8 t -110.42 108.63 18.73 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 123.088 1.423 . . . . 0.0 109.088 179.34 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.822 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -118.43 137.85 51.05 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.678 0 CA-C-N 114.244 -1.344 . . . . 0.0 109.907 -179.7 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.467 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -175.4 150.33 1.19 Allowed Pre-proline 0 N--CA 1.487 1.388 0 O-C-N 121.314 -0.866 . . . . 0.0 108.712 -179.651 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.467 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -77.64 150.52 90.51 Favored 'Cis proline' 0 C--N 1.311 -1.433 0 C-N-CA 123.57 -1.429 . . . . 0.0 109.535 -0.905 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.67 ' HA ' HG22 ' A' ' 110' ' ' ILE . 61.8 p -91.02 -24.52 20.05 Favored 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.55 -0.718 . . . . 0.0 109.27 179.828 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.521 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 17.1 m -133.44 160.36 37.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.265 -0.897 . . . . 0.0 109.978 -179.806 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.78 36.75 24.78 Favored Glycine 0 N--CA 1.494 2.523 0 N-CA-C 108.859 -1.696 . . . . 0.0 108.859 -179.856 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.755 ' HA ' HG21 ' A' ' 17' ' ' THR . 44.2 mt -93.83 -44.37 8.15 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-O 123.204 1.478 . . . . 0.0 110.353 -178.658 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.434 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.9 OUTLIER 63.81 145.35 0.02 OUTLIER 'General case' 0 C--N 1.262 -3.216 0 CA-C-N 113.62 -1.627 . . . . 0.0 109.798 -179.459 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.539 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.4 p-10 -51.61 105.33 0.1 Allowed 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.551 0.691 . . . . 0.0 110.844 -179.015 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 126.93 2.22 6.68 Favored Glycine 0 N--CA 1.485 1.949 0 C-N-CA 119.077 -1.535 . . . . 0.0 113.428 177.625 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.755 HG21 ' HA ' ' A' ' 13' ' ' LEU . 15.3 t -104.08 -171.82 2.0 Allowed 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 121.376 2.588 . . . . 0.0 110.102 179.909 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.772 HG13 ' C ' ' A' ' 67' ' ' LEU . 16.0 t -131.47 141.91 44.64 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.252 0 CA-C-N 114.604 -1.18 . . . . 0.0 110.47 -179.207 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.545 HG11 ' CD1' ' A' ' 13' ' ' LEU . 28.6 m -115.7 154.99 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.199 -0.938 . . . . 0.0 109.023 179.321 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 45.9 tptt -107.07 109.31 21.14 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 108.892 179.918 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.822 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.63 141.62 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.957 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -139.05 160.41 39.84 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 118.595 -1.242 . . . . 0.0 110.04 179.714 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.42 144.26 15.58 Favored Glycine 0 C--N 1.294 -1.793 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 179.695 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.564 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.28 125.37 12.88 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.872 -1.369 . . . . 0.0 108.956 179.037 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.536 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.48 26.84 26.6 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.289 -1.434 . . . . 0.0 109.867 -179.733 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.582 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -87.68 174.61 8.31 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 120.837 -1.39 . . . . 0.0 108.648 -179.879 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.018 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.58 99.79 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.99 -1.069 . . . . 0.0 109.744 -179.682 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.57 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 77.94 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.233 -179.149 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.58 34.17 0.32 Allowed Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.556 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 40.6 p -141.13 108.14 5.44 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.136 -1.214 . . . . 0.0 111.208 -179.539 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.9 110.75 0.46 Allowed 'General case' 0 N--CA 1.497 1.876 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.542 178.027 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.589 ' CE1' ' HB2' ' A' ' 99' ' ' ASP . 5.3 m-30 -106.75 156.02 19.09 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.122 -0.987 . . . . 0.0 108.902 179.821 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.503 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -99.13 164.16 12.27 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.822 -1.174 . . . . 0.0 107.917 178.822 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.666 HG13 ' O ' ' A' ' 34' ' ' VAL . 5.5 p -144.99 115.2 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.982 -1.074 . . . . 0.0 109.653 -178.247 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.02 -174.48 35.52 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.42 -1.847 . . . . 0.0 111.594 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.612 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.4 pt20 -102.39 109.25 20.85 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.862 0.839 . . . . 0.0 108.839 -179.772 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -131.75 149.51 52.45 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.099 -1.001 . . . . 0.0 110.093 -179.858 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.77 139.14 54.12 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.25 -0.906 . . . . 0.0 110.867 -179.076 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.876 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.36 114.96 26.79 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 178.21 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.5 m -105.4 15.15 7.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.991 -1.068 . . . . 0.0 110.591 -178.799 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.6 -176.19 0.09 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.961 -1.087 . . . . 0.0 110.101 179.747 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.783 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.89 97.86 1.49 Allowed 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.381 -0.825 . . . . 0.0 109.856 -179.742 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.37 27.58 35.84 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.212 -0.994 . . . . 0.0 111.394 178.948 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.23 106.44 20.34 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.528 -1.572 . . . . 0.0 107.185 178.904 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.876 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.0 tp -116.99 104.61 11.45 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.476 -1.39 . . . . 0.0 109.752 -177.763 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.86 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.82 109.53 22.27 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.746 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.497 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -106.74 168.75 8.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.967 -1.083 . . . . 0.0 110.379 -178.565 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.728 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 20.5 t-20 -114.57 132.34 22.92 Favored Pre-proline 0 N--CA 1.498 1.963 0 O-C-N 121.64 -0.662 . . . . 0.0 109.95 -179.242 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.8 Cg_endo -74.18 25.56 0.34 Allowed 'Trans proline' 0 CA--C 1.544 0.997 0 C-N-CA 122.28 1.986 . . . . 0.0 112.139 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.728 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -111.25 -1.06 16.23 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.279 -1.513 . . . . 0.0 109.443 179.709 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.572 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.06 21.32 2.62 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.561 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -80.92 90.6 5.93 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 120.053 -0.659 . . . . 0.0 110.873 -178.646 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -109.73 -167.23 1.18 Allowed 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.157 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.96 136.25 0.09 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.61 -1.307 . . . . 0.0 111.186 -179.273 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.938 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -153.53 158.26 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.354 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.78 141.8 31.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.906 -1.121 . . . . 0.0 109.945 -179.845 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.018 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.02 106.51 0.84 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 122.45 1.119 . . . . 0.0 109.359 178.296 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -58.3 -138.47 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.03 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.918 -179.863 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.57 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -54.22 -49.19 70.01 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.367 -0.833 . . . . 0.0 110.406 -178.756 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -102.37 -38.26 7.68 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 178.333 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.009 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 111.36 65.26 0.51 Allowed Glycine 0 C--N 1.297 -1.593 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 177.942 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.1 m -102.98 128.73 49.68 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 121.41 -1.053 . . . . 0.0 108.703 178.851 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.938 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -138.22 109.07 6.68 Favored 'General case' 0 C--N 1.296 -1.73 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.771 -179.235 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.5 m -123.52 120.63 33.44 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.309 -0.869 . . . . 0.0 109.725 -179.902 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.28 148.24 32.23 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.568 -0.708 . . . . 0.0 109.278 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.3 p -98.99 143.02 29.75 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.386 -0.821 . . . . 0.0 109.648 -179.839 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.782 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -146.03 157.52 43.87 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.357 -0.839 . . . . 0.0 109.368 -179.33 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.644 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 13.9 t -86.62 140.28 30.0 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.135 -0.978 . . . . 0.0 110.08 -179.792 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.554 HG12 ' OD2' ' A' ' 51' ' ' ASP . 16.9 m -145.94 137.89 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.226 -0.921 . . . . 0.0 110.148 -179.388 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.539 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 59.7 mtt180 -128.19 -162.75 1.21 Allowed 'General case' 0 N--CA 1.484 1.266 0 O-C-N 120.649 -1.282 . . . . 0.0 110.955 179.97 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.594 ' HG2' ' CD1' ' A' ' 112' ' ' PHE . 0.6 OUTLIER -86.66 -79.95 0.25 Allowed 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.35 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.538 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -69.78 133.02 46.97 Favored 'General case' 0 N--CA 1.486 1.34 0 N-CA-C 106.511 -1.662 . . . . 0.0 106.511 177.956 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.588 ' CE1' ' HB ' ' A' ' 86' ' ' VAL . 0.9 OUTLIER -154.42 155.32 34.75 Favored 'General case' 0 C--N 1.293 -1.875 0 C-N-CA 117.696 -1.602 . . . . 0.0 110.669 -177.938 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 47' ' ' CYS . 16.4 mt-10 -48.1 120.6 3.63 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 121.556 0.694 . . . . 0.0 109.549 -178.443 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.86 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -87.62 49.41 3.87 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -179.588 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.7 m-30 -40.59 112.38 0.28 Allowed 'General case' 0 N--CA 1.507 2.387 0 O-C-N 121.046 -1.267 . . . . 0.0 110.302 179.986 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.728 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.33 126.39 34.3 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.96 -1.088 . . . . 0.0 109.415 179.848 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.581 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.5 t80 -64.2 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.98 0 O-C-N 120.773 -1.204 . . . . 0.0 110.192 179.72 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 1.5 t0 -159.03 18.53 0.19 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.996 -1.065 . . . . 0.0 109.794 179.865 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.92 -25.85 6.47 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 179.763 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 47.6 p -95.0 159.37 15.05 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 120.966 -1.314 . . . . 0.0 110.604 -179.33 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.473 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -104.25 131.84 51.14 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.52 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.728 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -79.75 -19.96 47.47 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.854 -1.154 . . . . 0.0 110.169 -178.501 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.52 174.4 18.88 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 108.666 -1.773 . . . . 0.0 108.666 -179.406 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.13 112.88 2.55 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 179.09 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.647 HG21 ' CB ' ' A' ' 46' ' ' ALA . 38.1 t -84.56 103.22 11.54 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.019 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.561 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -63.88 109.26 1.7 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.54 -0.725 . . . . 0.0 110.248 -178.902 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.556 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 4.1 t -61.85 -4.19 1.44 Allowed 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.546 -1.262 . . . . 0.0 110.433 179.227 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -91.6 4.26 53.08 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.477 -1.389 . . . . 0.0 109.333 179.772 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.561 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -116.18 -50.19 2.67 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.178 -0.951 . . . . 0.0 109.144 179.936 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.89 178.73 4.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.512 -0.743 . . . . 0.0 109.396 179.871 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.85 113.37 26.24 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.324 -0.86 . . . . 0.0 108.817 179.884 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.498 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.51 119.59 35.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.017 -1.052 . . . . 0.0 109.471 -179.048 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.71 147.31 26.99 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-O 122.459 1.123 . . . . 0.0 111.43 -179.21 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.491 ' CG1' HG11 ' A' ' 7' ' ' VAL . 77.2 t -103.81 109.83 28.34 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.993 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 177.613 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.491 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.39 -170.01 17.1 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 118.246 -1.93 . . . . 0.0 111.608 -177.54 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.503 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.66 178.27 4.46 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.907 -0.761 . . . . 0.0 108.994 -178.972 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.595 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -160.93 178.43 9.4 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.529 -0.732 . . . . 0.0 109.511 -179.653 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.589 ' HB2' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -122.21 -157.41 0.73 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.21 -0.931 . . . . 0.0 108.764 179.629 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.449 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -120.23 35.91 4.71 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.66 -1.275 . . . . 0.0 109.316 -179.948 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -122.17 -32.55 3.66 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.341 -0.85 . . . . 0.0 110.464 -179.46 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 1.052 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.31 -37.29 0.23 Allowed Glycine 0 N--CA 1.482 1.714 0 N-CA-C 107.569 -2.212 . . . . 0.0 107.569 -179.395 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -157.96 -178.37 7.26 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 121.569 -0.96 . . . . 0.0 109.721 179.183 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.44 -160.55 11.62 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 108.333 -1.907 . . . . 0.0 108.333 -179.344 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -47.01 178.31 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.864 1.332 . . . . 0.0 110.265 179.207 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -93.02 -174.4 3.56 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.123 -0.985 . . . . 0.0 110.341 -178.956 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.491 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.75 164.0 15.02 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.935 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.402 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.38 129.71 49.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.386 -1.067 . . . . 0.0 109.074 -179.629 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.92 121.44 19.08 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.658 -0.651 . . . . 0.0 109.804 179.836 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.67 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.5 pt -97.99 169.28 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 121.379 -0.826 . . . . 0.0 108.818 179.822 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.521 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.98 160.37 38.82 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.141 -0.974 . . . . 0.0 109.693 -179.945 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.594 ' CD1' ' HG2' ' A' ' 71' ' ' ARG . 39.2 m-85 -134.33 76.01 1.62 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.242 -0.911 . . . . 0.0 109.46 -179.759 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.4 p30 . . . . . 0 N--CA 1.491 1.603 0 CA-C-O 117.917 -1.04 . . . . 0.0 109.42 179.99 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 1.052 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.497 -0.557 . . . . 1.0 109.497 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.964 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -68.57 173.39 3.48 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.299 -0.876 . . . . 1.0 109.483 179.992 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.964 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 3.3 Cg_exo -60.84 157.2 39.27 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.233 1.955 . . . . 1.0 110.412 -179.892 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.898 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.1 p -167.9 160.49 12.32 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.824 -0.806 . . . . 1.0 108.824 -179.247 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -150.37 127.78 11.43 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.06 -1.056 . . . . 1.0 110.561 -179.869 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.974 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.9 p -107.0 104.93 14.73 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 122.608 1.194 . . . . 1.0 110.347 -179.587 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.975 HG22 HG23 ' A' ' 21' ' ' VAL . 15.2 t -119.37 115.35 47.43 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.468 0 CA-C-N 115.271 -0.877 . . . . 1.0 110.131 179.428 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -162.57 150.8 12.01 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.316 -0.994 . . . . 1.0 108.316 -179.378 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.1 Cg_endo -77.96 150.21 88.92 Favored 'Cis proline' 0 C--N 1.308 -1.554 0 C-N-CA 123.635 -1.402 . . . . 1.0 109.74 -0.679 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.655 ' HA ' HG22 ' A' ' 110' ' ' ILE . 69.2 p -89.75 -25.49 21.12 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 109.031 -0.729 . . . . 1.0 109.031 179.549 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.502 ' HB2' ' HB3' ' A' ' 111' ' ' SER . 18.7 p -132.55 164.64 26.18 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.498 -0.751 . . . . 1.0 109.375 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.68 38.27 37.61 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 108.259 -1.936 . . . . 1.0 108.259 -179.531 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.7 mt -92.49 -43.39 9.21 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 123.264 1.507 . . . . 1.0 110.619 -178.174 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.11 143.59 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.269 0 CA-C-N 113.461 -1.7 . . . . 1.0 109.815 -179.467 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.582 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 9.9 p-10 -50.48 105.13 0.09 Allowed 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.474 0.654 . . . . 1.0 111.634 -178.484 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.98 15.68 8.38 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 119.457 -1.354 . . . . 1.0 113.007 177.153 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.5 t -103.88 -171.22 1.9 Allowed 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 121.053 2.426 . . . . 1.0 109.802 179.125 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.856 HG22 HG22 ' A' ' 68' ' ' THR . 16.6 t -131.31 140.06 49.34 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.314 0 CA-C-N 114.822 -1.081 . . . . 1.0 111.362 -178.783 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.46 HG12 ' CD2' ' A' ' 13' ' ' LEU . 30.9 m -115.9 155.48 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 N-CA-C 108.66 -0.867 . . . . 1.0 108.66 178.861 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 5.5 tptm -108.16 108.96 20.23 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.137 -0.977 . . . . 1.0 109.529 -179.759 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.975 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -106.39 122.5 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.853 -0.795 . . . . 1.0 108.853 179.729 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.974 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -115.21 165.45 12.92 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.943 -1.098 . . . . 1.0 109.145 179.789 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.577 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.81 108.03 0.46 Allowed Glycine 0 N--CA 1.483 1.768 0 N-CA-C 108.711 -1.756 . . . . 1.0 108.711 179.602 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.605 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.75 142.43 46.93 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.704 -1.468 . . . . 1.0 110.212 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.458 ' CA ' ' HA ' ' A' ' 3' ' ' PRO . . . 82.96 29.08 35.49 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.062 -1.542 . . . . 1.0 109.773 179.787 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.54 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.9 OUTLIER -94.56 172.75 7.99 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.093 -1.239 . . . . 1.0 108.31 179.98 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.012 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.09 100.36 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.027 -1.046 . . . . 1.0 109.602 -179.799 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.85 76.44 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 115.397 -0.819 . . . . 1.0 109.955 -179.313 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 137.08 33.26 0.22 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.457 -1.457 . . . . 1.0 109.457 179.712 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.546 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 66.8 p -142.14 109.74 5.72 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.042 -1.269 . . . . 1.0 111.013 -179.803 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.586 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.95 109.93 0.28 Allowed 'General case' 0 N--CA 1.496 1.847 0 CA-C-N 115.7 -0.682 . . . . 1.0 109.858 178.407 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.515 ' CE1' ' HD2' ' A' ' 105' ' ' PRO . 21.1 m-85 -99.1 152.3 20.01 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.157 -0.965 . . . . 1.0 109.007 179.653 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.507 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -101.48 157.77 16.56 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 107.598 -1.26 . . . . 1.0 107.598 178.421 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.774 HG11 HG21 ' A' ' 65' ' ' THR . 9.9 p -142.29 113.97 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.063 -1.023 . . . . 1.0 110.07 -177.692 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.39 -175.49 36.73 Favored Glycine 0 N--CA 1.495 2.575 0 C-N-CA 118.371 -1.871 . . . . 1.0 111.875 -179.811 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.588 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -102.25 109.41 21.09 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 108.848 -0.797 . . . . 1.0 108.848 -179.663 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -131.07 148.55 52.75 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.129 -0.982 . . . . 1.0 110.034 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.486 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.89 139.79 53.62 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.314 -0.866 . . . . 1.0 110.716 -179.016 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.889 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.25 114.66 26.47 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 107.607 -1.257 . . . . 1.0 107.607 178.161 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 m -105.25 15.01 7.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.094 -1.004 . . . . 1.0 110.469 -178.752 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 175.04 -175.76 0.09 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.044 -1.035 . . . . 1.0 110.039 179.688 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 p -72.69 98.02 2.29 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.448 -0.782 . . . . 1.0 109.508 -179.805 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.39 27.64 32.45 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.232 -0.985 . . . . 1.0 111.291 179.046 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -117.6 106.27 19.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 O-C-N 120.6 -1.53 . . . . 1.0 107.325 178.889 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.889 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -116.1 104.8 11.92 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 120.496 -1.378 . . . . 1.0 109.567 -178.016 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.938 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.47 109.56 22.29 Favored 'General case' 0 N--CA 1.486 1.338 0 O-C-N 120.781 -1.199 . . . . 1.0 107.857 178.889 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -108.26 163.73 12.93 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.02 -1.05 . . . . 1.0 110.112 -178.656 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.49 ' HB2' ' HB2' ' A' ' 73' ' ' PHE . 36.2 t-20 -110.16 128.78 24.79 Favored Pre-proline 0 N--CA 1.502 2.141 0 O-C-N 121.437 -0.789 . . . . 1.0 109.67 -179.372 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.594 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.6 Cg_endo -69.44 17.72 0.18 Allowed 'Trans proline' 0 CA--C 1.546 1.075 0 C-N-CA 122.021 1.814 . . . . 1.0 112.108 179.444 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -104.6 3.48 31.77 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.389 -1.444 . . . . 1.0 108.528 179.065 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.45 15.91 2.75 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 107.228 -1.397 . . . . 1.0 107.228 179.487 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -81.53 92.39 6.5 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.834 -0.746 . . . . 1.0 111.099 -178.299 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -112.01 -170.94 1.75 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.133 -1.432 . . . . 1.0 107.133 177.879 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 179.18 136.91 0.1 Allowed 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.475 -1.391 . . . . 1.0 111.277 -179.197 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.9 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.56 157.14 4.78 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 107.107 -1.442 . . . . 1.0 107.107 178.194 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.586 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.83 143.23 28.66 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.696 -1.253 . . . . 1.0 109.965 -179.474 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.24 105.86 0.98 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 122.372 1.082 . . . . 1.0 109.392 178.704 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.54 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.5 t70 -60.21 -139.28 0.0 OUTLIER 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.719 -0.673 . . . . 1.0 110.934 -179.827 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.6 -50.48 60.1 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.297 -0.877 . . . . 1.0 110.625 -178.7 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 49.4 m-80 -102.95 -35.15 8.68 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.272 -1.751 . . . . 1.0 106.272 178.59 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 105.26 66.27 0.68 Allowed Glycine 0 C--N 1.297 -1.602 0 N-CA-C 110.522 -1.031 . . . . 1.0 110.522 178.305 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.577 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.4 m -104.09 125.54 50.51 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 108.514 -0.921 . . . . 1.0 108.514 178.833 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.9 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.46 109.54 8.8 Favored 'General case' 0 C--N 1.296 -1.748 0 C-N-CA 119.692 -0.803 . . . . 1.0 109.755 -179.266 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.471 ' OG ' ' HB2' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -116.24 122.72 45.8 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.278 -0.888 . . . . 1.0 109.019 179.709 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.774 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -148.44 140.14 23.7 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.496 -0.752 . . . . 1.0 109.884 -179.964 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.425 ' HB3' ' HD2' ' A' ' 20' ' ' LYS . 14.6 p -101.34 131.42 47.4 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.369 -0.832 . . . . 1.0 109.276 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.759 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -128.52 164.62 22.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.38 -0.825 . . . . 1.0 109.623 -179.452 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.856 HG22 HG22 ' A' ' 18' ' ' VAL . 1.7 p -97.36 124.59 41.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.952 -1.093 . . . . 1.0 109.249 -179.958 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.573 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 18.0 m -136.61 143.67 34.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.1 -1.0 . . . . 1.0 109.947 -179.106 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.582 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 6.8 ptt180 -141.86 -165.51 2.02 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.51 -1.369 . . . . 1.0 110.264 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.597 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 10.1 mtt180 -70.07 -76.85 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.425 -0.797 . . . . 1.0 109.017 -179.557 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.486 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -69.62 137.33 52.18 Favored 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.232 -1.542 . . . . 1.0 107.128 178.878 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.588 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -160.17 134.18 7.26 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 117.895 -1.522 . . . . 1.0 110.299 -178.179 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.527 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.2 mm-40 -30.57 120.97 0.2 Allowed 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.54 0.686 . . . . 1.0 110.888 -178.397 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.938 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.13 43.4 3.05 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.913 -0.875 . . . . 1.0 110.913 -179.526 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.594 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 2.1 m-85 -38.71 114.93 0.42 Allowed 'General case' 0 N--CA 1.511 2.603 0 O-C-N 121.182 -1.187 . . . . 1.0 110.123 179.959 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.713 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.4 tp -87.64 126.96 35.26 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.889 -1.132 . . . . 1.0 109.231 179.81 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.59 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.3 t80 -63.95 58.01 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.871 -1.143 . . . . 1.0 110.438 -179.9 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 9.3 t0 -161.97 19.96 0.1 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.924 -1.11 . . . . 1.0 109.862 179.802 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.06 -27.29 5.05 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.002 -1.239 . . . . 1.0 110.002 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.463 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 3.1 p -90.24 153.55 20.4 Favored 'General case' 0 N--CA 1.485 1.318 0 O-C-N 121.072 -1.252 . . . . 1.0 110.388 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.523 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 5.1 ptt180 -102.43 132.82 48.2 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.636 -0.875 . . . . 1.0 108.636 179.68 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.713 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.4 t90 -81.92 -21.41 37.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.659 -1.276 . . . . 1.0 110.294 -178.673 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.92 174.0 18.55 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.746 -1.742 . . . . 1.0 108.746 -179.644 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.67 110.71 1.81 Allowed 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.412 -1.329 . . . . 1.0 107.412 179.095 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.654 HG21 ' CB ' ' A' ' 46' ' ' ALA . 41.3 t -82.26 104.27 10.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 O-C-N 121.449 -0.782 . . . . 1.0 108.895 -178.962 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.66 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.1 OUTLIER -66.47 111.81 3.76 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.306 -0.871 . . . . 1.0 109.784 -179.277 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.555 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.0 t -62.77 -5.35 2.69 Favored 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 118.416 -1.314 . . . . 1.0 110.108 179.497 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -86.23 0.6 53.36 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.611 -1.306 . . . . 1.0 109.15 179.462 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.66 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -112.71 -48.89 2.97 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.268 -0.895 . . . . 1.0 109.055 179.907 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.46 -178.31 3.56 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.483 -0.761 . . . . 1.0 109.6 -179.93 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.55 114.78 29.23 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.294 -0.879 . . . . 1.0 108.97 179.923 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.56 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.12 123.32 40.85 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.956 -1.09 . . . . 1.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.586 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.96 146.16 28.75 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 122.359 1.076 . . . . 1.0 111.059 -179.775 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.538 ' HB ' HG11 ' A' ' 7' ' ' VAL . 97.8 t -103.07 109.63 27.39 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.069 0 N-CA-C 106.604 -1.628 . . . . 1.0 106.604 177.719 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.488 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.51 -170.58 17.19 Favored Glycine 0 N--CA 1.485 1.962 0 C-N-CA 118.091 -2.004 . . . . 1.0 111.944 -177.47 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.491 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -118.16 -178.65 3.56 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 108.88 -0.785 . . . . 1.0 108.88 -178.77 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.556 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -174.48 173.17 2.99 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.355 -0.841 . . . . 1.0 109.254 -179.45 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.406 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -116.97 -158.54 0.7 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.162 -0.961 . . . . 1.0 108.765 179.582 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.406 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -118.91 36.11 4.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.759 -1.213 . . . . 1.0 109.288 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.45 -32.52 4.6 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.278 -0.889 . . . . 1.0 110.358 -179.502 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.993 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.15 -37.41 0.23 Allowed Glycine 0 N--CA 1.481 1.666 0 N-CA-C 107.522 -2.231 . . . . 1.0 107.522 -179.465 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.46 -178.24 6.99 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.615 -0.932 . . . . 1.0 109.727 179.12 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -170.27 -162.61 22.87 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 108.248 -1.941 . . . . 1.0 108.248 -179.426 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.515 ' HD2' ' CE1' ' A' ' 32' ' ' TYR . 7.5 Cg_exo -45.69 165.81 0.06 OUTLIER 'Trans proline' 0 C--O 1.215 -0.637 0 CA-C-N 118.912 1.356 . . . . 1.0 109.656 179.392 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.73 -176.45 4.97 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.047 -1.033 . . . . 1.0 110.528 -178.473 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.488 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.57 175.26 15.64 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.723 -1.351 . . . . 1.0 109.723 -179.837 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -112.05 132.51 60.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.383 -1.069 . . . . 1.0 109.121 -179.14 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.586 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -69.88 124.58 24.39 Favored 'General case' 0 C--N 1.291 -1.95 0 O-C-N 121.556 -0.715 . . . . 1.0 109.479 179.526 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.884 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.71 171.57 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.19 -0.944 . . . . 1.0 109.043 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.502 ' HB3' ' HB2' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.53 161.21 37.01 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.237 -0.914 . . . . 1.0 109.707 -179.773 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.884 ' CE2' HD12 ' A' ' 110' ' ' ILE . 90.0 m-85 -136.69 86.47 2.22 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 121.12 -0.987 . . . . 1.0 109.532 -179.702 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 16.2 p30 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 117.894 -1.05 . . . . 1.0 109.461 -179.954 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.993 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.836 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -119.13 169.48 8.05 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.89 . . . . 0.0 109.558 -179.922 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.836 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.5 Cg_exo -59.91 158.42 29.33 Favored 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 122.416 2.077 . . . . 0.0 110.574 179.991 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.532 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.28 -169.56 0.15 Allowed 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 179.154 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.582 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . -168.51 133.8 1.73 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.548 -1.345 . . . . 0.0 111.179 -179.128 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.021 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -101.22 104.45 15.51 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 122.404 1.097 . . . . 0.0 109.907 179.859 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 1.07 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -119.37 119.3 60.21 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.393 179.588 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.481 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.8 149.92 4.41 Favored Pre-proline 0 N--CA 1.486 1.335 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -179.602 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.481 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.3 Cg_endo -78.55 149.96 86.69 Favored 'Cis proline' 0 C--N 1.309 -1.504 0 C-N-CA 123.631 -1.404 . . . . 0.0 109.439 -0.677 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.669 ' HA ' HG22 ' A' ' 110' ' ' ILE . 72.6 p -92.09 -23.43 19.46 Favored 'General case' 0 C--N 1.292 -1.911 0 O-C-N 121.632 -0.668 . . . . 0.0 109.245 179.677 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.548 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 12.1 p -131.81 161.19 33.53 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.376 -0.828 . . . . 0.0 109.646 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.2 37.78 31.33 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 108.386 -1.885 . . . . 0.0 108.386 -179.556 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.2 mt -91.85 -43.39 9.53 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 123.223 1.487 . . . . 0.0 110.53 -178.223 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.478 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.89 143.93 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.25 0 CA-C-N 113.457 -1.701 . . . . 0.0 110.017 -179.508 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.586 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 11.5 p-10 -49.83 105.69 0.1 Allowed 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 121.431 0.634 . . . . 0.0 111.737 -178.53 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.5 15.37 8.89 Favored Glycine 0 N--CA 1.485 1.94 0 C-N-CA 119.439 -1.363 . . . . 0.0 113.077 177.068 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -105.04 -173.2 2.25 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 121.123 2.461 . . . . 0.0 109.943 179.191 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.782 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.6 t -128.86 139.7 51.21 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.318 0 CA-C-N 114.635 -1.166 . . . . 0.0 111.508 -178.578 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.584 HG11 HD11 ' A' ' 13' ' ' LEU . 33.8 m -117.82 155.96 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.641 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.559 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tppp? -107.69 109.92 21.64 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.017 -1.052 . . . . 0.0 109.816 -179.681 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 1.07 HG23 HG22 ' A' ' 7' ' ' VAL . 7.3 p -105.87 123.23 60.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.086 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.021 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -119.7 166.61 12.99 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.506 -1.371 . . . . 0.0 109.397 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.589 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.42 143.31 14.97 Favored Glycine 0 C--N 1.296 -1.682 0 N-CA-C 107.802 -2.119 . . . . 0.0 107.802 179.806 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.585 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -148.08 122.54 9.73 Favored 'General case' 0 C--N 1.293 -1.858 0 O-C-N 120.828 -1.395 . . . . 0.0 108.565 179.067 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.518 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 90.52 27.38 20.22 Favored Glycine 0 N--CA 1.486 2.017 0 C-N-CA 119.093 -1.527 . . . . 0.0 109.707 -179.552 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.558 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.2 mt -87.23 176.51 7.53 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 120.894 -1.356 . . . . 0.0 108.373 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.42 96.76 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.001 -1.062 . . . . 0.0 109.665 -179.784 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.719 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.2 77.68 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.528 -179.0 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 129.33 36.28 0.43 Allowed Glycine 0 N--CA 1.487 2.035 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 179.409 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.648 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -148.57 114.54 5.76 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 120.913 -1.345 . . . . 0.0 111.199 -179.891 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -46.34 122.52 4.09 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 115.437 -0.802 . . . . 0.0 110.354 178.66 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.648 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 1.9 m-30 -116.97 154.43 30.9 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.084 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.503 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -100.52 167.68 10.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.499 -1.375 . . . . 0.0 108.604 179.449 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.615 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.3 p -147.78 122.46 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.165 -0.96 . . . . 0.0 109.554 -178.089 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -177.08 -178.21 46.63 Favored Glycine 0 N--CA 1.495 2.606 0 C-N-CA 118.329 -1.891 . . . . 0.0 111.71 179.977 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.67 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.4 108.52 20.55 Favored 'General case' 0 N--CA 1.477 0.901 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.836 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -129.59 148.63 51.51 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.179 -0.951 . . . . 0.0 109.803 179.691 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.542 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.34 139.52 53.95 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.307 -0.871 . . . . 0.0 110.675 -179.023 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.881 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.09 114.9 26.76 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 178.147 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.47 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 18.2 m -105.77 14.98 7.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.044 -1.035 . . . . 0.0 110.58 -178.652 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.719 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 175.1 -174.94 0.09 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.986 -1.071 . . . . 0.0 109.995 179.579 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.786 ' O ' HG23 ' A' ' 42' ' ' THR . 14.9 t -72.62 98.01 2.26 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.43 -0.794 . . . . 0.0 109.757 -179.779 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.78 28.01 33.19 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 120.161 -1.019 . . . . 0.0 111.436 179.037 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.719 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -117.16 106.39 20.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.542 -1.564 . . . . 0.0 107.149 178.798 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.881 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.2 tp -116.76 104.94 11.85 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.496 -1.378 . . . . 0.0 109.681 -177.649 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.013 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.97 109.75 22.45 Favored 'General case' 0 N--CA 1.484 1.26 0 O-C-N 120.934 -1.104 . . . . 0.0 108.387 179.237 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.0 t -106.16 163.88 12.44 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.995 -1.066 . . . . 0.0 110.268 -179.037 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.518 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 17.4 t30 -111.36 137.79 21.17 Favored Pre-proline 0 N--CA 1.502 2.129 0 O-C-N 121.496 -0.752 . . . . 0.0 109.598 -179.387 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.579 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.2 24.58 0.31 Allowed 'Trans proline' 0 C--N 1.318 -1.04 0 C-N-CA 122.504 2.136 . . . . 0.0 112.41 -179.379 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.415 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -103.34 -8.3 20.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.164 -1.585 . . . . 0.0 109.184 179.465 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.703 ' OD2' HG13 ' A' ' 69' ' ' VAL . 2.0 m-20 -135.69 8.85 3.33 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.54 86.46 0.08 Allowed 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.277 -0.889 . . . . 0.0 110.441 -178.797 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.615 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -115.61 -169.86 1.66 Allowed 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 178.785 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.465 ' OG ' ' HA ' ' A' ' 33' ' ' ASP . 0.6 OUTLIER 178.65 133.9 0.08 Allowed 'General case' 0 C--N 1.303 -1.424 0 O-C-N 120.725 -1.235 . . . . 0.0 111.206 -179.483 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.725 HG11 ' HB1' ' A' ' 63' ' ' ALA . 2.0 p -143.59 159.72 16.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.981 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.89 145.33 26.54 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.649 -1.282 . . . . 0.0 109.75 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.002 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.56 109.75 3.38 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 122.449 1.118 . . . . 0.0 109.465 178.638 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.557 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.5 p-10 -62.11 -139.17 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.643 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.719 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.33 -51.88 50.43 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.268 -0.895 . . . . 0.0 110.445 -178.94 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.5 -33.72 9.4 Favored 'General case' 0 C--N 1.288 -2.103 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.555 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.999 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.18 65.65 0.59 Allowed Glycine 0 C--N 1.3 -1.444 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.162 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 53.5 p -99.91 131.78 45.67 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 121.354 -1.086 . . . . 0.0 109.363 179.15 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.725 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -137.19 108.78 6.96 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.429 -0.908 . . . . 0.0 109.535 -179.853 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.417 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 92.0 p -117.62 118.52 32.34 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.063 -1.023 . . . . 0.0 109.588 -179.818 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.568 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -146.67 140.89 26.31 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.473 -0.767 . . . . 0.0 109.835 -179.947 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.476 ' HB3' ' HE3' ' A' ' 20' ' ' LYS . 24.2 p -98.82 136.37 38.94 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.322 -0.861 . . . . 0.0 108.792 179.54 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.971 HD11 HG12 ' A' ' 21' ' ' VAL . 0.2 OUTLIER -132.73 168.07 18.98 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.266 -0.896 . . . . 0.0 110.322 -178.489 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.647 HG22 HG22 ' A' ' 18' ' ' VAL . 1.1 p -104.46 124.39 49.17 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.876 . . . . 0.0 108.688 179.464 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.703 HG13 ' OD2' ' A' ' 51' ' ' ASP . 17.4 m -136.93 142.98 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 120.873 -1.142 . . . . 0.0 110.237 -178.761 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.586 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.4 ptt180 -144.9 -169.71 3.24 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 120.575 -1.328 . . . . 0.0 110.771 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.601 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -58.35 -99.8 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -179.144 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -58.33 143.37 45.13 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.355 -1.466 . . . . 0.0 108.505 179.692 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.589 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.17 138.63 6.7 Favored 'General case' 0 C--N 1.294 -1.813 0 C-N-CA 118.848 -1.141 . . . . 0.0 109.614 -178.185 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.556 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 8.6 mm-40 -34.77 121.97 0.53 Allowed 'General case' 0 N--CA 1.49 1.53 0 CA-C-O 121.484 0.659 . . . . 0.0 110.583 -178.254 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.013 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.64 46.08 2.75 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 120.52 -0.848 . . . . 0.0 110.995 -179.298 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.7 m-85 -39.07 111.48 0.18 Allowed 'General case' 0 N--CA 1.507 2.403 0 O-C-N 121.23 -1.159 . . . . 0.0 109.887 179.589 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.672 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.5 tp -84.88 127.37 34.12 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.9 -1.125 . . . . 0.0 109.281 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.573 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 57.6 t80 -63.18 58.18 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.92 -1.113 . . . . 0.0 110.527 -179.881 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t0 -163.33 20.21 0.08 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.906 -1.121 . . . . 0.0 109.997 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.77 -27.16 4.95 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.091 -1.203 . . . . 0.0 110.091 179.979 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.505 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -90.3 150.57 21.86 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 121.119 -1.224 . . . . 0.0 110.247 -179.469 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.486 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -101.19 133.06 46.31 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 179.434 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.672 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.5 t90 -81.76 -16.09 52.18 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.794 -1.191 . . . . 0.0 110.56 -178.525 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 108.74 174.36 21.52 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.856 -1.697 . . . . 0.0 108.856 -179.719 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.79 103.9 0.62 Allowed 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.613 -1.255 . . . . 0.0 107.613 179.116 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.611 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.5 t -74.52 106.53 4.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.476 -0.765 . . . . 0.0 109.224 -178.814 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.58 110.93 3.37 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.386 -0.821 . . . . 0.0 109.813 -179.454 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.601 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.72 -5.49 4.23 Favored 'General case' 0 N--CA 1.499 2.024 0 C-N-CA 118.329 -1.348 . . . . 0.0 109.908 179.463 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.7 p -85.61 -0.6 55.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.705 -1.247 . . . . 0.0 109.144 179.568 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -112.92 -49.17 2.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.383 -0.823 . . . . 0.0 109.002 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.45 -178.2 3.58 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.511 -0.743 . . . . 0.0 109.455 179.963 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.14 115.64 30.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.446 -0.784 . . . . 0.0 108.964 179.924 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.564 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.86 123.54 40.6 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.935 -1.103 . . . . 0.0 109.665 -179.176 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.618 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.05 147.66 26.68 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-O 122.418 1.104 . . . . 0.0 111.014 -179.522 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.536 ' HB ' HG11 ' A' ' 7' ' ' VAL . 46.4 t -106.28 113.22 42.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.993 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.017 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.508 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -155.18 -169.83 20.11 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 117.989 -2.053 . . . . 0.0 111.834 -177.943 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.494 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -110.52 -177.74 3.31 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 -179.227 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.574 ' HB3' ' C26' ' A' ' 114' ' ' CHR . 12.1 p -170.38 172.03 6.31 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.367 -0.833 . . . . 0.0 109.083 -179.072 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.461 ' OD1' ' O ' ' A' ' 103' ' ' ASN . 0.6 OUTLIER -117.64 -161.81 0.84 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.984 -1.073 . . . . 0.0 108.764 179.592 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -119.56 36.12 4.6 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.546 -1.346 . . . . 0.0 109.236 -179.919 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -121.76 -33.54 3.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.391 -0.818 . . . . 0.0 110.468 -179.598 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 1.042 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 171.08 -38.01 0.18 Allowed Glycine 0 N--CA 1.482 1.712 0 N-CA-C 107.878 -2.089 . . . . 0.0 107.878 -179.58 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.461 ' O ' ' OD1' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -158.64 -177.92 6.88 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 121.474 -1.015 . . . . 0.0 109.81 179.238 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.4 -161.2 13.01 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.589 -1.804 . . . . 0.0 108.589 -179.256 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.544 ' HD3' ' CE2' ' A' ' 32' ' ' TYR . 4.7 Cg_exo -47.41 -178.97 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.709 1.254 . . . . 0.0 110.577 179.278 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -93.75 -177.6 4.42 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.072 -1.017 . . . . 0.0 110.425 -178.93 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.508 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.79 166.39 14.55 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.68 130.41 52.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.342 -1.093 . . . . 0.0 109.165 -179.405 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.618 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.25 122.29 22.6 Favored 'General case' 0 C--N 1.289 -2.024 0 O-C-N 121.623 -0.673 . . . . 0.0 109.48 179.617 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.833 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.57 168.74 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 O-C-N 121.193 -0.942 . . . . 0.0 109.188 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.548 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.3 m -136.85 157.52 46.56 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.301 -0.875 . . . . 0.0 109.541 -179.784 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.833 ' CE2' HD12 ' A' ' 110' ' ' ILE . 70.8 m-85 -133.8 68.94 1.48 Allowed 'General case' 0 C--N 1.306 -1.323 0 O-C-N 121.164 -0.96 . . . . 0.0 109.608 -179.614 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 20.8 p30 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.491 -179.937 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 1.042 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.75 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -113.91 167.2 9.86 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.926 . . . . 0.0 109.429 -179.948 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.75 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 3.8 Cg_exo -60.21 157.88 33.1 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 122.194 1.929 . . . . 0.0 110.547 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.733 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.1 p -161.62 160.44 28.8 Favored 'General case' 0 C--N 1.296 -1.734 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.238 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -149.45 122.78 9.01 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-O 122.415 1.102 . . . . 0.0 110.423 -179.684 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.863 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -114.72 109.07 17.64 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 123.075 1.417 . . . . 0.0 109.663 179.937 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.782 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -117.28 136.08 55.6 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 CA-C-N 114.297 -1.32 . . . . 0.0 109.681 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.489 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -173.08 150.8 2.0 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.273 -0.892 . . . . 0.0 108.734 -179.559 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.489 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.21 150.44 88.57 Favored 'Cis proline' 0 C--N 1.312 -1.387 0 C-N-CA 123.563 -1.432 . . . . 0.0 109.507 -0.761 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.673 ' HA ' HG22 ' A' ' 110' ' ' ILE . 38.3 p -90.01 -25.59 20.77 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 121.586 -0.696 . . . . 0.0 109.14 179.502 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.521 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 16.1 m -133.08 162.11 32.61 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.406 -0.809 . . . . 0.0 109.565 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.86 37.13 30.52 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 -179.684 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.749 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.5 mt -92.36 -42.34 9.85 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 123.218 1.485 . . . . 0.0 110.43 -178.482 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.94 143.27 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.323 0 CA-C-N 113.379 -1.737 . . . . 0.0 109.825 -179.542 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.592 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 18.3 p-10 -50.39 105.27 0.09 Allowed 'General case' 0 C--N 1.3 -1.586 0 CA-C-O 121.452 0.644 . . . . 0.0 111.484 -178.525 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.92 13.57 8.46 Favored Glycine 0 N--CA 1.486 2.002 0 C-N-CA 119.306 -1.426 . . . . 0.0 113.165 177.285 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.749 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.56 -171.71 1.97 Allowed 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 121.28 2.54 . . . . 0.0 109.78 179.18 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.841 HG22 HG22 ' A' ' 68' ' ' THR . 18.2 t -129.26 139.01 52.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.956 -1.02 . . . . 0.0 111.224 -178.821 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.56 HG23 ' CD1' ' A' ' 67' ' ' LEU . 31.5 m -114.14 155.39 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 178.937 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.82 109.57 20.72 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.115 -0.991 . . . . 0.0 109.266 179.976 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.782 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -102.36 140.74 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.594 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.863 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.32 161.67 35.64 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 118.773 -1.171 . . . . 0.0 110.182 179.81 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.611 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.32 141.74 13.02 Favored Glycine 0 C--N 1.298 -1.572 0 N-CA-C 108.169 -1.973 . . . . 0.0 108.169 179.721 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.623 ' HB3' ' OG1' ' A' ' 4' ' ' THR . . . -143.24 124.69 14.76 Favored 'General case' 0 N--CA 1.494 1.754 0 CA-C-N 119.226 1.513 . . . . 0.0 109.363 179.255 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.48 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.05 28.98 19.16 Favored Glycine 0 N--CA 1.489 2.212 0 C-N-CA 118.965 -1.588 . . . . 0.0 109.647 -179.733 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.539 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.5 mt -89.4 175.24 7.4 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.9 -1.353 . . . . 0.0 108.366 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.022 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.61 99.95 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.977 -1.077 . . . . 0.0 109.806 -179.752 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.537 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.32 77.52 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.918 -179.347 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.588 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.97 33.97 0.24 Allowed Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 179.674 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.556 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 23.1 p -139.59 105.66 5.22 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.141 -1.211 . . . . 0.0 111.283 -179.404 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.592 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.42 109.77 0.34 Allowed 'General case' 0 N--CA 1.497 1.916 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 177.853 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.512 ' HA ' ' O ' ' A' ' 98' ' ' SER . 6.8 m-30 -104.41 158.99 16.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.139 -0.975 . . . . 0.0 109.131 -179.977 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.516 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -101.63 157.75 16.59 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 178.754 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.017 HG11 HG23 ' A' ' 65' ' ' THR . 1.6 t -136.84 109.77 8.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.129 -0.982 . . . . 0.0 109.635 -177.573 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.38 -174.05 35.37 Favored Glycine 0 N--CA 1.497 2.727 0 C-N-CA 117.713 -2.184 . . . . 0.0 112.638 -179.928 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.602 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -102.09 109.11 20.74 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-O 121.756 0.789 . . . . 0.0 109.062 -179.495 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.42 148.8 52.27 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.21 -0.931 . . . . 0.0 109.6 179.33 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.503 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.34 138.72 54.55 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.32 -0.862 . . . . 0.0 110.774 -178.995 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.885 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.43 115.07 26.92 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.154 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.8 m -104.88 14.89 6.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 120.988 -1.07 . . . . 0.0 110.558 -178.89 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.764 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.38 -175.12 0.08 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.959 -1.088 . . . . 0.0 110.006 179.781 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.44 98.12 2.2 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.411 -0.806 . . . . 0.0 109.687 -179.78 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.99 28.11 32.22 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 120.217 -0.992 . . . . 0.0 111.355 179.014 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.764 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.54 106.25 19.61 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 O-C-N 120.603 -1.528 . . . . 0.0 107.071 178.804 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.885 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.8 tp -118.03 104.5 10.93 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.458 -1.401 . . . . 0.0 109.789 -177.719 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.09 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.21 109.37 22.14 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 120.918 -1.114 . . . . 0.0 108.051 178.84 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.502 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.1 163.47 12.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.906 -1.121 . . . . 0.0 110.281 -178.778 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.742 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 47.4 t30 -106.4 132.33 20.99 Favored Pre-proline 0 N--CA 1.504 2.23 0 O-C-N 121.394 -0.816 . . . . 0.0 109.627 -179.424 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -72.21 19.36 0.3 Allowed 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 122.296 1.997 . . . . 0.0 112.281 -179.596 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.742 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -111.2 4.13 18.99 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.38 -1.45 . . . . 0.0 108.707 179.114 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.657 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.08 20.76 3.01 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 179.303 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -81.37 85.85 6.37 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.538 -178.715 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.505 ' HB3' ' HB ' ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.52 -171.03 2.04 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.843 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.66 134.58 0.08 Allowed 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.676 -1.265 . . . . 0.0 111.23 -179.292 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.873 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -158.12 153.6 5.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 178.359 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.592 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.28 139.95 33.29 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.875 -1.141 . . . . 0.0 109.544 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.022 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -62.35 106.32 0.73 Allowed 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.391 1.091 . . . . 0.0 109.501 178.637 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.555 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.9 t70 -61.37 -139.21 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.045 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.77 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.537 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.11 -51.2 59.32 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.401 -0.812 . . . . 0.0 110.724 -178.803 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -101.04 -34.53 9.7 Favored 'General case' 0 C--N 1.286 -2.153 0 N-CA-C 106.282 -1.747 . . . . 0.0 106.282 178.493 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 104.88 65.76 0.68 Allowed Glycine 0 C--N 1.297 -1.637 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 178.109 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.611 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.6 m -98.86 130.42 45.27 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.594 -0.945 . . . . 0.0 108.6 178.739 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.873 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.79 108.63 6.68 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.594 -179.329 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.8 m -124.23 120.45 32.28 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.334 -0.854 . . . . 0.0 109.47 179.927 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 65' ' ' THR . . . . . 1.017 HG23 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.16 142.83 29.95 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.558 -0.714 . . . . 0.0 109.353 179.908 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 9.5 p -99.2 136.22 39.47 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.316 -0.865 . . . . 0.0 109.434 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.758 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -136.31 165.19 26.34 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.461 -0.774 . . . . 0.0 109.55 -179.343 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.841 HG22 HG22 ' A' ' 18' ' ' VAL . 2.2 p -96.78 125.45 41.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.073 -1.017 . . . . 0.0 109.112 179.926 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.602 HG12 ' HB3' ' A' ' 36' ' ' GLN . 17.7 m -136.53 142.7 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 120.934 -1.104 . . . . 0.0 110.09 -178.886 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.592 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 5.2 ptt180 -147.49 -173.08 4.18 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.562 -1.337 . . . . 0.0 110.884 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.599 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -54.11 -101.22 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 -179.421 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.514 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.19 141.44 46.41 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.82 -1.175 . . . . 0.0 108.128 179.479 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.8 135.44 5.58 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 118.68 -1.208 . . . . 0.0 109.665 -178.01 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.561 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 18.7 mm-40 -34.73 122.93 0.54 Allowed 'General case' 0 N--CA 1.491 1.603 0 CA-C-O 121.502 0.668 . . . . 0.0 110.088 -178.466 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.09 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.98 52.81 1.66 Allowed Glycine 0 N--CA 1.492 2.385 0 C-N-CA 120.397 -0.906 . . . . 0.0 111.108 -178.937 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.587 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-30 -39.7 113.38 0.33 Allowed 'General case' 0 N--CA 1.506 2.332 0 O-C-N 121.065 -1.256 . . . . 0.0 109.972 179.393 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.625 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -83.45 126.12 32.43 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.947 -1.096 . . . . 0.0 109.217 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 39.5 t80 -63.7 58.66 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.918 -1.114 . . . . 0.0 110.169 179.806 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -160.92 19.91 0.13 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.996 -1.065 . . . . 0.0 109.696 179.92 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.13 -28.07 5.28 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.882 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.463 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.32 159.61 15.04 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.007 -1.29 . . . . 0.0 110.28 -179.416 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.483 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.73 135.96 47.37 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.757 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.625 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -80.77 -18.87 46.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.867 -1.145 . . . . 0.0 110.545 -178.504 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.46 177.47 19.84 Favored Glycine 0 N--CA 1.484 1.88 0 N-CA-C 108.671 -1.771 . . . . 0.0 108.671 -179.428 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.36 105.58 1.18 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.2 -1.176 . . . . 0.0 107.859 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.665 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.0 t -77.53 105.7 6.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.346 -0.846 . . . . 0.0 109.124 -179.069 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.543 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.5 m-20 -65.6 111.44 3.15 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.406 -0.809 . . . . 0.0 109.747 -179.372 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.599 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.13 -5.23 4.46 Favored 'General case' 0 N--CA 1.5 2.031 0 C-N-CA 118.113 -1.435 . . . . 0.0 109.876 179.386 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -86.54 -0.06 55.33 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.799 -1.188 . . . . 0.0 109.159 179.587 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.543 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -113.36 -50.01 2.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.334 -0.854 . . . . 0.0 108.969 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.5 -179.05 3.83 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.487 -0.758 . . . . 0.0 109.42 179.925 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.88 115.27 30.01 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.328 -0.857 . . . . 0.0 108.999 179.9 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -97.03 122.24 39.81 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.762 -1.211 . . . . 0.0 109.428 -179.431 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -101.91 146.89 27.21 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 122.41 1.1 . . . . 0.0 111.107 -179.372 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.552 ' CG1' HG11 ' A' ' 7' ' ' VAL . 61.1 t -104.43 110.25 29.93 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 177.911 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.511 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.44 -169.86 17.58 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 118.31 -1.9 . . . . 0.0 111.466 -177.786 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.639 HD23 HG22 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -113.22 179.98 3.81 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -179.333 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.591 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.6 OUTLIER -169.51 163.82 10.37 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 121.364 -0.835 . . . . 0.0 109.406 -179.596 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.475 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -108.39 -160.83 0.74 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.187 -0.945 . . . . 0.0 108.804 179.673 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -120.06 35.41 4.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.554 -1.342 . . . . 0.0 109.336 -179.843 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -119.43 -32.52 4.33 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.434 -0.791 . . . . 0.0 110.215 -179.594 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 1.041 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 171.55 -39.17 0.17 Allowed Glycine 0 N--CA 1.483 1.806 0 N-CA-C 107.62 -2.192 . . . . 0.0 107.62 -179.536 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -159.49 -178.16 6.93 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.637 -0.919 . . . . 0.0 109.622 179.194 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.85 -162.43 14.74 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 108.434 -1.866 . . . . 0.0 108.434 -179.34 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.48 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.9 Cg_exo -46.32 176.31 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.692 0 CA-C-N 118.837 1.318 . . . . 0.0 110.206 179.289 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -91.62 -176.15 4.4 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.033 -1.042 . . . . 0.0 110.573 -178.71 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.511 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.63 168.88 15.02 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.61 130.39 57.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.354 -1.086 . . . . 0.0 109.192 -179.208 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.05 122.9 20.91 Favored 'General case' 0 C--N 1.29 -1.985 0 O-C-N 121.609 -0.682 . . . . 0.0 109.505 179.543 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.76 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.69 169.02 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.201 -0.937 . . . . 0.0 109.222 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.521 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -136.39 155.31 50.21 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 109.602 -179.942 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.76 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 21.2 m-85 -131.12 93.86 3.47 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.198 -0.939 . . . . 0.0 109.482 -179.664 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.7 p30 . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.41 179.904 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 1.041 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.511 0 CA-C-O 121.262 0.553 . . . . 0.0 109.564 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.929 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -114.26 172.79 3.3 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.231 -0.918 . . . . 0.0 109.411 179.987 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.929 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.7 Cg_exo -59.64 157.92 30.27 Favored 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.15 1.9 . . . . 0.0 110.539 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.7 -169.5 0.14 Allowed 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.289 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.668 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -166.3 133.97 2.76 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.7 -1.25 . . . . 0.0 111.134 -179.37 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.01 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -100.92 104.59 15.79 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 122.478 1.132 . . . . 0.0 109.76 -179.892 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.975 HG22 HG23 ' A' ' 21' ' ' VAL . 5.4 t -119.4 122.92 70.2 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.401 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.574 179.823 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.481 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -169.52 150.04 3.91 Favored Pre-proline 0 N--CA 1.487 1.413 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 -179.529 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.481 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.4 Cg_endo -76.74 150.71 93.25 Favored 'Cis proline' 0 C--N 1.309 -1.533 0 C-N-CA 123.613 -1.411 . . . . 0.0 109.579 -0.339 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.679 ' HA ' HG22 ' A' ' 110' ' ' ILE . 89.2 p -92.49 -22.81 19.37 Favored 'General case' 0 C--N 1.292 -1.929 0 O-C-N 121.693 -0.629 . . . . 0.0 109.352 179.799 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.488 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.3 m -132.37 163.97 27.51 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.398 -0.814 . . . . 0.0 109.689 -179.822 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.05 38.88 39.14 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 -179.504 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.857 ' CA ' HG21 ' A' ' 17' ' ' THR . 27.7 mt -92.02 -45.21 8.44 Favored 'General case' 0 C--N 1.297 -1.698 0 CA-C-O 123.12 1.438 . . . . 0.0 110.772 -178.09 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.13 146.42 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.349 0 CA-C-N 113.799 -1.546 . . . . 0.0 110.077 -179.615 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.585 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.6 p-10 -50.76 108.32 0.23 Allowed 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 121.542 0.687 . . . . 0.0 111.984 -178.53 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.74 16.54 9.9 Favored Glycine 0 N--CA 1.485 1.907 0 C-N-CA 119.592 -1.289 . . . . 0.0 112.768 177.07 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.857 HG21 ' CA ' ' A' ' 13' ' ' LEU . 8.8 t -103.45 -174.79 2.63 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 120.965 2.382 . . . . 0.0 109.98 179.426 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.772 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.0 t -129.89 138.9 52.91 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 CA-C-N 114.365 -1.288 . . . . 0.0 111.06 -178.799 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.635 HG22 HG22 ' A' ' 69' ' ' VAL . 4.1 m -118.53 154.99 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.669 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 10.2 tttt -105.95 108.99 20.79 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.175 -0.953 . . . . 0.0 109.403 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.975 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.04 123.38 62.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 179.611 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.51 167.17 11.54 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 120.69 -1.256 . . . . 0.0 109.222 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.604 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.76 140.71 12.03 Favored Glycine 0 C--N 1.295 -1.717 0 N-CA-C 107.49 -2.244 . . . . 0.0 107.49 179.718 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.575 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.31 124.1 11.92 Favored 'General case' 0 C--N 1.293 -1.889 0 O-C-N 120.748 -1.442 . . . . 0.0 108.87 179.35 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.533 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.36 25.97 26.94 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.226 -1.464 . . . . 0.0 109.913 -179.641 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.539 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.1 mt -85.6 175.44 8.77 Favored 'General case' 0 C--N 1.306 -1.321 0 O-C-N 120.891 -1.358 . . . . 0.0 108.263 -179.989 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.39 96.71 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.928 -1.108 . . . . 0.0 109.659 -179.72 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.706 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.53 76.77 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.758 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.536 -178.996 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.77 33.7 0.33 Allowed Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.253 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.587 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.3 t -149.14 116.07 6.0 Favored 'General case' 0 C--N 1.307 -1.268 0 O-C-N 120.929 -1.336 . . . . 0.0 111.138 179.919 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.565 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.83 127.55 6.4 Favored 'General case' 0 N--CA 1.492 1.653 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.902 178.453 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.587 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.9 m-85 -118.36 149.18 41.63 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.431 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.505 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -98.97 159.28 15.07 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.548 -1.345 . . . . 0.0 107.784 178.841 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.623 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.4 p -140.19 119.6 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.189 -0.944 . . . . 0.0 109.633 -177.819 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' HB2' ' A' ' 51' ' ' ASP . . . -170.72 -179.94 42.33 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 118.274 -1.917 . . . . 0.0 111.794 -179.799 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.67 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.83 108.85 20.76 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.783 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.484 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.32 148.51 51.25 Favored 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.174 -0.954 . . . . 0.0 109.953 179.887 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.513 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.19 138.99 54.51 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.359 -0.838 . . . . 0.0 110.593 -179.046 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.89 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.29 114.63 26.44 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 107.521 -1.289 . . . . 0.0 107.521 178.213 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.0 m -104.38 14.81 6.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 O-C-N 121.069 -1.019 . . . . 0.0 110.482 -178.811 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.74 -175.41 0.08 Allowed 'General case' 0 C--N 1.302 -1.482 0 O-C-N 120.935 -1.103 . . . . 0.0 110.025 179.695 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.6 p -73.54 98.28 2.78 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.413 -0.804 . . . . 0.0 109.506 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.5 27.58 29.56 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.219 -0.991 . . . . 0.0 111.326 179.128 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -118.72 106.31 19.29 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 O-C-N 120.607 -1.525 . . . . 0.0 107.342 178.999 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.89 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -116.61 104.7 11.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.315 -1.491 . . . . 0.0 109.855 -177.815 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.948 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.49 109.62 22.34 Favored 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.909 -1.12 . . . . 0.0 108.1 178.885 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.0 t -107.15 165.82 11.08 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.841 -1.162 . . . . 0.0 110.612 -178.632 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.503 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 55.3 t30 -113.55 132.45 22.53 Favored Pre-proline 0 N--CA 1.501 2.092 0 C-N-CA 120.119 -0.632 . . . . 0.0 109.425 -179.486 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.8 Cg_endo -72.76 24.31 0.29 Allowed 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 122.205 1.937 . . . . 0.0 112.104 -179.743 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.419 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -99.06 -7.58 26.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.369 -1.457 . . . . 0.0 109.184 179.52 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.792 ' HB3' HD22 ' A' ' 67' ' ' LEU . 0.7 OUTLIER -133.61 5.8 3.72 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.346 -0.846 . . . . 0.0 108.817 -179.985 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -59.44 80.62 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.87 -178.656 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -108.48 -169.97 1.59 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 178.297 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.5 134.55 0.08 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.543 -1.348 . . . . 0.0 111.448 -179.405 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.724 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.9 p -146.31 158.92 11.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 177.741 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.565 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.48 146.6 25.08 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.572 -1.33 . . . . 0.0 109.884 -179.564 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.42 108.73 3.37 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 122.385 1.088 . . . . 0.0 109.674 178.914 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.546 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.1 p-10 -62.42 -138.85 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.862 -179.796 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.706 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.72 -51.84 35.76 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.376 -0.828 . . . . 0.0 110.641 -178.771 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -105.11 -32.73 8.55 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 178.553 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.963 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.5 69.78 0.67 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 178.246 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 69.9 m -103.63 130.09 51.01 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 121.268 -1.137 . . . . 0.0 109.337 179.267 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.724 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.62 108.69 7.68 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.433 -0.907 . . . . 0.0 109.676 -179.675 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 93.6 p -115.88 116.93 28.84 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 120.956 -1.09 . . . . 0.0 109.364 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.29 141.27 27.15 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.427 -0.796 . . . . 0.0 110.125 -179.868 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.6 p -100.35 137.0 39.36 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.614 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.972 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -137.35 172.22 13.31 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.253 -0.904 . . . . 0.0 109.844 -178.979 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.581 HG22 HG22 ' A' ' 18' ' ' VAL . 1.2 p -104.72 123.66 48.02 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.089 -1.007 . . . . 0.0 109.908 -179.372 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.764 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.5 m -133.04 143.6 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 121.056 -1.027 . . . . 0.0 109.688 -179.606 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.585 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.2 ptt180 -140.78 -167.77 2.43 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.558 -1.339 . . . . 0.0 110.417 179.906 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.584 ' HG2' ' CD1' ' A' ' 112' ' ' PHE . 3.3 mtt180 -70.95 -76.61 0.1 Allowed 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -179.623 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.49 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -71.88 137.8 47.74 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 120.153 -1.592 . . . . 0.0 107.547 179.117 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.594 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -159.56 136.96 9.79 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.27 -1.372 . . . . 0.0 110.108 -178.105 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.484 ' O ' ' O ' ' A' ' 47' ' ' CYS . 9.1 mm-40 -34.71 122.54 0.53 Allowed 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.562 0.696 . . . . 0.0 110.571 -178.188 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.948 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.38 45.62 3.14 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 6.6 m-85 -38.41 113.82 0.32 Allowed 'General case' 0 N--CA 1.509 2.477 0 O-C-N 121.194 -1.18 . . . . 0.0 110.167 179.751 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.691 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.4 tp -87.81 125.99 34.76 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 120.913 -1.117 . . . . 0.0 109.477 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.596 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 23.4 t80 -64.26 58.6 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 O-C-N 120.972 -1.08 . . . . 0.0 110.184 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 6.3 t70 -161.0 20.02 0.13 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.047 -1.033 . . . . 0.0 109.796 179.688 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.68 -27.5 5.29 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.874 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 8.1 p -94.05 160.99 14.47 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.984 -1.303 . . . . 0.0 110.256 -179.488 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.544 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -108.98 136.63 48.2 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.897 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.691 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.7 t90 -82.67 -19.1 38.82 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.932 -1.105 . . . . 0.0 110.386 -178.368 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.64 175.2 19.97 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 -179.494 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.29 109.63 1.39 Allowed 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 179.122 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.677 HG21 ' CB ' ' A' ' 46' ' ' ALA . 39.4 t -81.38 104.38 9.85 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.068 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.637 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -67.42 111.14 3.91 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.433 -0.792 . . . . 0.0 109.888 -179.076 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.568 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.0 t -63.26 -5.9 3.9 Favored 'General case' 0 N--CA 1.499 2.017 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.942 179.48 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.3 p -84.76 -0.08 52.45 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.717 -1.24 . . . . 0.0 109.023 179.407 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.637 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.41 -49.14 2.91 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.356 -0.84 . . . . 0.0 109.024 -179.969 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.08 -178.03 3.53 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.578 -0.701 . . . . 0.0 109.539 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.11 115.26 29.92 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.466 -0.771 . . . . 0.0 108.982 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.57 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -97.09 125.2 41.4 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.948 -1.095 . . . . 0.0 109.687 -179.174 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.595 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.54 146.44 28.89 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 122.421 1.105 . . . . 0.0 111.191 -179.524 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.606 ' HB ' HG11 ' A' ' 7' ' ' VAL . 96.2 t -102.68 111.09 31.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 177.775 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.487 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.78 -171.2 18.72 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 117.97 -2.062 . . . . 0.0 111.808 -177.684 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.668 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -113.95 -177.59 3.17 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -179.075 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.594 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.0 OUTLIER -175.13 172.02 2.87 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.229 -0.92 . . . . 0.0 109.531 -179.378 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -122.05 -162.27 0.98 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.878 -1.139 . . . . 0.0 108.921 179.665 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -116.03 36.5 4.02 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.684 -1.26 . . . . 0.0 109.122 179.953 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -116.76 -33.26 4.87 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.337 -0.852 . . . . 0.0 110.159 -179.522 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 1.026 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 166.64 -36.65 0.24 Allowed Glycine 0 N--CA 1.481 1.699 0 N-CA-C 107.786 -2.126 . . . . 0.0 107.786 -179.667 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.55 -177.67 6.09 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.534 -0.98 . . . . 0.0 109.91 179.328 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.86 -160.97 12.89 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.415 -1.874 . . . . 0.0 108.415 -179.395 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.7 Cg_exo -47.87 -178.95 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.813 1.306 . . . . 0.0 110.474 179.367 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -94.59 -179.51 4.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.068 -1.02 . . . . 0.0 110.448 -178.903 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.487 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.84 162.49 12.71 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 -179.972 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.8 129.67 50.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.397 -1.06 . . . . 0.0 109.095 -179.501 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.595 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.35 121.82 21.06 Favored 'General case' 0 C--N 1.289 -2.041 0 O-C-N 121.626 -0.671 . . . . 0.0 109.892 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.853 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.83 171.37 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.242 -0.911 . . . . 0.0 108.982 179.658 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.488 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -138.6 159.33 42.36 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.156 -0.965 . . . . 0.0 109.669 -179.845 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.853 ' CE2' HD12 ' A' ' 110' ' ' ILE . 79.7 m-85 -135.09 129.31 33.76 Favored 'General case' 0 N--CA 1.485 1.323 0 O-C-N 121.25 -0.907 . . . . 0.0 109.63 -179.785 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.6 p30 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 118.093 -0.956 . . . . 0.0 109.538 -179.87 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 1.026 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.913 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -122.56 173.02 4.59 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.254 -0.904 . . . . 0.0 109.457 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.913 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.6 Cg_exo -59.83 157.86 31.4 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.233 1.955 . . . . 0.0 110.472 179.979 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.544 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.54 -169.76 0.15 Allowed 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.292 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.544 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.77 131.0 2.43 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 120.764 -1.21 . . . . 0.0 110.778 -179.202 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.949 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.4 t -112.82 108.71 17.79 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-O 123.108 1.432 . . . . 0.0 109.175 179.394 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.853 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -115.93 139.04 44.39 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.728 0 CA-C-N 114.169 -1.378 . . . . 0.0 110.088 -179.67 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.486 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -177.0 150.32 0.88 Allowed Pre-proline 0 N--CA 1.486 1.35 0 O-C-N 121.309 -0.87 . . . . 0.0 108.766 -179.673 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.486 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.9 Cg_endo -78.49 150.43 87.7 Favored 'Cis proline' 0 C--N 1.312 -1.364 0 C-N-CA 123.531 -1.445 . . . . 0.0 109.334 -0.921 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.646 ' HA ' HG22 ' A' ' 110' ' ' ILE . 94.1 p -93.65 -22.13 18.96 Favored 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.52 -0.738 . . . . 0.0 109.558 179.821 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.481 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -132.2 162.62 30.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.805 -179.798 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.15 39.03 38.21 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 -179.508 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.823 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.8 mt -91.38 -44.58 9.06 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-O 123.093 1.425 . . . . 0.0 110.771 -178.272 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.0 OUTLIER 64.37 146.42 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.332 0 CA-C-N 113.735 -1.575 . . . . 0.0 109.63 -179.42 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.6 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.7 p-10 -52.32 110.1 0.46 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.486 0.66 . . . . 0.0 111.554 -178.523 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.71 9.76 13.75 Favored Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.301 -1.428 . . . . 0.0 112.854 177.375 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.823 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.8 t -101.32 -172.52 2.18 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 121.029 2.415 . . . . 0.0 109.747 179.502 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.76 HG13 ' C ' ' A' ' 67' ' ' LEU . 11.2 t -134.63 141.32 43.64 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.612 -179.334 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 27.8 m -116.55 154.8 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.214 -0.929 . . . . 0.0 109.057 179.471 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.489 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 21.8 tttt -107.95 108.97 20.34 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.238 -0.914 . . . . 0.0 109.049 179.793 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.853 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -101.03 139.11 23.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.555 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.949 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.45 160.46 37.92 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 118.461 -1.296 . . . . 0.0 110.027 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.603 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.94 144.07 15.52 Favored Glycine 0 C--N 1.294 -1.758 0 N-CA-C 107.755 -2.138 . . . . 0.0 107.755 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.572 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.45 124.5 12.09 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 120.799 -1.412 . . . . 0.0 108.953 179.222 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 90.15 26.52 23.58 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 119.272 -1.442 . . . . 0.0 109.703 -179.702 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.577 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -89.22 170.56 10.49 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 120.857 -1.378 . . . . 0.0 108.479 179.989 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.006 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.09 100.69 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.051 -1.031 . . . . 0.0 109.988 -179.574 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.7 77.98 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.004 -179.509 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.85 34.05 0.27 Allowed Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 179.702 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.553 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 20.8 p -139.18 105.88 5.37 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.198 -1.178 . . . . 0.0 111.255 -179.485 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.589 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -52.32 114.19 1.27 Allowed 'General case' 0 N--CA 1.495 1.814 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.611 178.098 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.489 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 8.2 m-30 -110.67 160.06 17.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.143 -0.973 . . . . 0.0 108.949 179.834 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.507 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -100.62 168.28 9.8 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 178.93 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.704 HG22 HG11 ' A' ' 21' ' ' VAL . 3.8 p -150.36 117.13 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.023 -1.048 . . . . 0.0 109.827 -178.221 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.85 -175.93 39.21 Favored Glycine 0 N--CA 1.495 2.605 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.821 -179.765 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.609 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -99.33 108.44 20.97 Favored 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.811 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.0 m -132.21 148.45 52.46 Favored 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.296 -0.878 . . . . 0.0 109.784 179.657 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.2 140.25 53.02 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.241 -0.912 . . . . 0.0 110.727 -179.136 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.885 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.16 114.78 26.61 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.211 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.3 m -104.16 14.49 6.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.052 -1.03 . . . . 0.0 110.5 -178.798 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.75 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.93 -175.26 0.08 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.897 -1.127 . . . . 0.0 110.087 179.769 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.25 98.45 2.65 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.425 -0.797 . . . . 0.0 109.535 -179.917 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.98 27.51 31.2 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 120.244 -0.979 . . . . 0.0 111.421 179.072 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.75 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -118.01 106.33 19.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 O-C-N 120.618 -1.519 . . . . 0.0 107.303 178.846 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.885 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.4 tp -117.65 104.67 11.25 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.523 -1.36 . . . . 0.0 109.58 -177.843 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.965 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.03 109.54 22.27 Favored 'General case' 0 N--CA 1.485 1.281 0 O-C-N 120.828 -1.17 . . . . 0.0 108.251 179.068 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -107.61 166.85 10.37 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.023 -1.048 . . . . 0.0 109.989 -179.17 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.73 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.0 t-20 -107.3 137.33 19.58 Favored Pre-proline 0 N--CA 1.502 2.148 0 O-C-N 121.231 -0.918 . . . . 0.0 109.846 -179.286 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.6 Cg_endo -75.15 24.49 0.39 Allowed 'Trans proline' 0 C--N 1.318 -1.04 0 C-N-CA 122.383 2.056 . . . . 0.0 111.786 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.73 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -120.27 4.09 10.81 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.351 -1.468 . . . . 0.0 109.195 179.75 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.572 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.84 19.96 2.85 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 179.278 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -84.14 87.81 7.17 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.929 -0.708 . . . . 0.0 110.858 -178.618 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -107.91 -168.25 1.35 Allowed 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.436 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.458 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.92 136.22 0.09 Allowed 'General case' 0 C--N 1.305 -1.326 0 O-C-N 120.755 -1.216 . . . . 0.0 111.082 -179.401 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.927 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -151.73 157.7 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 178.391 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.589 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.91 142.26 30.64 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.835 -1.166 . . . . 0.0 110.027 -179.786 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.03 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.89 107.76 1.05 Allowed 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 122.441 1.115 . . . . 0.0 109.288 178.083 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.1 t0 -62.94 -138.68 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.777 179.937 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.531 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.37 -52.7 34.93 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.402 -0.811 . . . . 0.0 110.924 -178.615 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.85 -33.07 9.94 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 178.612 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.03 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.19 62.26 0.55 Allowed Glycine 0 C--N 1.296 -1.664 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 178.051 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.603 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 82.5 p -98.72 129.91 45.19 Favored 'General case' 0 C--N 1.309 -1.155 0 O-C-N 121.563 -0.963 . . . . 0.0 108.731 178.713 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.927 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.29 108.89 6.97 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.203 -0.999 . . . . 0.0 109.727 -179.343 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -122.35 119.2 30.37 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.191 -0.943 . . . . 0.0 109.533 -179.941 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.574 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.66 142.98 30.51 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.491 -0.756 . . . . 0.0 109.329 179.876 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 27.7 p -98.82 138.09 36.46 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.416 -0.802 . . . . 0.0 109.58 -179.853 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.814 HD12 ' H ' ' A' ' 67' ' ' LEU . 0.1 OUTLIER -140.83 159.41 42.27 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.329 -0.857 . . . . 0.0 109.48 -179.502 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.71 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 13.0 t -87.91 139.14 30.82 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.147 -0.97 . . . . 0.0 110.657 -179.411 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.609 HG12 ' HB3' ' A' ' 36' ' ' GLN . 19.4 m -148.73 144.31 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.484 -0.76 . . . . 0.0 109.249 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.6 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.9 OUTLIER -150.72 -173.69 4.55 Favored 'General case' 0 N--CA 1.484 1.245 0 O-C-N 120.456 -1.403 . . . . 0.0 111.178 -179.641 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.741 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.28 -104.8 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.281 -179.644 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.458 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -59.43 140.23 56.37 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 120.695 -1.253 . . . . 0.0 108.072 178.948 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.609 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -158.29 138.69 12.61 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.773 -1.171 . . . . 0.0 109.713 -178.312 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.52 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 8.8 mm-40 -34.89 120.35 0.5 Allowed 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.539 0.685 . . . . 0.0 110.552 -178.448 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.965 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.96 47.91 3.2 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.415 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -38.47 113.65 0.31 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 121.241 -1.153 . . . . 0.0 110.166 179.812 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.816 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.66 126.26 34.41 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.997 -1.065 . . . . 0.0 109.456 -179.982 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 20.4 t80 -64.23 58.48 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.906 -1.121 . . . . 0.0 109.949 179.541 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 9.8 t70 -158.74 18.77 0.2 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.976 -1.078 . . . . 0.0 109.645 -179.979 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.18 -26.41 6.23 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.761 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.83 163.64 12.71 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 120.99 -1.3 . . . . 0.0 110.404 -179.332 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.486 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 4.2 ptt180 -106.24 136.79 45.34 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.914 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.816 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.7 t90 -82.58 -19.6 38.15 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.79 -1.194 . . . . 0.0 110.241 -178.709 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.64 173.43 16.86 Favored Glycine 0 N--CA 1.486 2.019 0 N-CA-C 108.791 -1.723 . . . . 0.0 108.791 -179.636 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -65.14 106.1 1.22 Allowed 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 179.105 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.651 HG21 ' HB3' ' A' ' 46' ' ' ALA . 46.2 t -76.51 107.34 7.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.371 -0.831 . . . . 0.0 109.533 -178.694 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.603 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.9 m-20 -63.92 111.99 2.73 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.213 -0.929 . . . . 0.0 109.178 -179.919 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.741 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.2 m -65.41 -4.66 5.96 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 120.704 -1.247 . . . . 0.0 109.829 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.2 p -93.27 1.95 56.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.731 -1.23 . . . . 0.0 109.58 179.956 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.603 HG23 ' HB3' ' A' ' 87' ' ' ASP . 5.0 p -112.51 -52.79 2.76 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.241 -0.912 . . . . 0.0 108.636 179.78 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.421 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -98.47 178.77 4.92 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.492 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.07 114.0 27.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -0.89 . . . . 0.0 108.777 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.505 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.8 m -96.44 121.8 38.64 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.982 -1.074 . . . . 0.0 109.758 -178.989 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.572 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -106.2 144.28 33.12 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-O 122.355 1.074 . . . . 0.0 111.112 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 90.5 t -101.87 109.58 26.44 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.086 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.741 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.483 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.12 -172.01 17.65 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 118.223 -1.941 . . . . 0.0 111.741 -177.591 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.503 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -112.01 178.8 4.19 Favored 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.289 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.59 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.9 OUTLIER -169.52 165.93 10.26 Favored 'General case' 0 C--N 1.294 -1.805 0 O-C-N 121.571 -0.706 . . . . 0.0 109.424 -179.546 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.489 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -115.16 -160.1 0.73 Allowed 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.043 -1.036 . . . . 0.0 108.805 179.776 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -116.82 35.76 4.47 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.636 -1.29 . . . . 0.0 109.246 -179.959 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -116.52 -33.17 4.98 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.402 -0.811 . . . . 0.0 110.143 -179.684 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.976 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.83 -36.81 0.26 Allowed Glycine 0 N--CA 1.482 1.717 0 N-CA-C 107.559 -2.216 . . . . 0.0 107.559 -179.544 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -158.75 -178.23 7.1 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.574 -0.956 . . . . 0.0 109.777 179.23 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.44 -161.9 14.4 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.488 -1.845 . . . . 0.0 108.488 -179.394 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.479 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -47.24 178.25 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.626 0 CA-C-N 118.812 1.306 . . . . 0.0 110.342 179.329 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -91.37 -174.35 3.9 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.097 -1.002 . . . . 0.0 110.401 -178.893 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.483 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.99 166.8 15.29 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.7 130.15 51.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.43 -1.041 . . . . 0.0 109.1 -179.429 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.572 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.71 125.12 28.04 Favored 'General case' 0 C--N 1.289 -2.049 0 O-C-N 121.641 -0.662 . . . . 0.0 109.606 179.782 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.755 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.84 169.98 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.274 -0.891 . . . . 0.0 109.257 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.481 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -137.88 155.77 48.6 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.276 -0.89 . . . . 0.0 109.504 179.992 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.755 ' CE1' HD12 ' A' ' 110' ' ' ILE . 76.5 m-85 -123.55 68.98 1.02 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.11 -0.994 . . . . 0.0 109.51 -179.808 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.8 p30 . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.483 -179.961 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.976 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.464 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -117.92 157.42 48.43 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.23 -0.919 . . . . 0.0 109.493 179.96 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.53 ' HB3' HD23 ' A' ' 26' ' ' LEU . 2.9 Cg_endo -61.23 155.94 48.43 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.37 2.046 . . . . 0.0 110.609 -179.933 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -150.05 158.86 44.59 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -179.666 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.499 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -144.08 123.84 13.39 Favored 'General case' 0 C--N 1.294 -1.817 0 CA-C-O 122.465 1.126 . . . . 0.0 110.031 -179.918 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.92 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.9 t -114.88 109.1 17.64 Favored 'General case' 0 C--N 1.294 -1.822 0 CA-C-O 123.2 1.476 . . . . 0.0 109.765 -179.807 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.863 HG22 HG23 ' A' ' 21' ' ' VAL . 3.1 t -116.27 136.98 51.49 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.638 0 CA-C-N 114.176 -1.374 . . . . 0.0 109.716 179.902 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.497 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -172.96 151.25 2.13 Favored Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 121.235 -0.915 . . . . 0.0 108.791 -179.534 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.497 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.2 Cg_endo -77.53 151.67 92.52 Favored 'Cis proline' 0 C--N 1.311 -1.422 0 C-N-CA 123.517 -1.451 . . . . 0.0 109.433 -0.819 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.67 ' HA ' HG22 ' A' ' 110' ' ' ILE . 88.1 p -93.94 -23.2 18.16 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.576 -0.703 . . . . 0.0 109.505 179.805 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.5 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 3.0 m -130.94 160.1 35.51 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.321 -0.862 . . . . 0.0 109.96 -179.65 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.23 37.25 32.57 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 108.611 -1.796 . . . . 0.0 108.611 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.865 ' CA ' HG21 ' A' ' 17' ' ' THR . 27.1 mt -90.83 -45.42 8.81 Favored 'General case' 0 C--N 1.299 -1.627 0 CA-C-O 123.113 1.435 . . . . 0.0 110.751 -178.411 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 64.03 147.23 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.311 0 CA-C-N 113.748 -1.569 . . . . 0.0 109.963 -179.612 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.615 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.4 p-10 -51.41 108.9 0.29 Allowed 'General case' 0 C--N 1.302 -1.47 0 CA-C-O 121.725 0.774 . . . . 0.0 111.809 -178.568 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.8 13.66 11.04 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 119.479 -1.343 . . . . 0.0 112.914 177.311 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.865 HG21 ' CA ' ' A' ' 13' ' ' LEU . 10.2 t -101.8 -174.34 2.57 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 121.059 2.43 . . . . 0.0 109.86 179.457 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.766 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.1 t -127.83 138.3 55.13 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.885 -178.994 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.534 HG13 ' CG2' ' A' ' 69' ' ' VAL . 30.8 m -117.34 154.17 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.877 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -109.98 109.34 19.89 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.187 -0.946 . . . . 0.0 109.195 -179.846 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.863 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -101.96 140.44 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.747 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.92 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.33 158.31 44.12 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.838 -1.164 . . . . 0.0 109.701 179.568 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -139.36 108.81 0.61 Allowed Glycine 0 N--CA 1.481 1.675 0 N-CA-C 108.658 -1.777 . . . . 0.0 108.658 179.888 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.597 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.54 139.52 50.4 Favored 'General case' 0 N--CA 1.502 2.14 0 CA-C-N 119.402 1.601 . . . . 0.0 110.564 -179.25 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.506 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 85.21 27.81 32.47 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.058 -1.544 . . . . 0.0 109.938 179.569 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.7 OUTLIER -93.67 170.53 9.51 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.97 -1.312 . . . . 0.0 108.522 -179.92 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.997 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.43 101.23 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.097 -1.002 . . . . 0.0 109.827 -179.566 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.54 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.42 77.93 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.705 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.888 -179.342 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.5 33.46 0.27 Allowed Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 179.896 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.56 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 12.9 p -136.96 104.75 5.55 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 121.2 -1.176 . . . . 0.0 111.057 -179.349 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.582 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.54 110.03 0.41 Allowed 'General case' 0 N--CA 1.497 1.914 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.621 178.087 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.567 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 38.5 m-85 -106.33 156.35 18.59 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.052 -1.03 . . . . 0.0 108.992 179.87 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.415 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.25 160.14 14.57 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.631 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.626 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.2 p -140.75 119.66 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.095 -1.003 . . . . 0.0 109.62 -177.836 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.486 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.88 -178.8 41.15 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.536 -1.792 . . . . 0.0 111.525 -179.782 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.586 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.1 pt20 -100.99 109.08 20.95 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.756 0.788 . . . . 0.0 108.954 -179.904 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.493 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.81 150.26 52.07 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.079 -1.013 . . . . 0.0 110.406 179.978 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.92 139.38 53.88 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.373 -0.829 . . . . 0.0 110.661 -179.054 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.882 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.3 115.02 26.87 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 178.114 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -105.92 15.44 7.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.013 -1.055 . . . . 0.0 110.605 -178.889 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.764 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.6 -176.33 0.09 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.831 -1.168 . . . . 0.0 110.147 179.759 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.789 ' O ' HG23 ' A' ' 42' ' ' THR . 15.2 t -70.13 97.32 1.18 Allowed 'General case' 0 N--CA 1.487 1.419 0 CA-C-O 121.791 0.805 . . . . 0.0 109.949 -179.553 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.2 28.35 37.18 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.158 -1.02 . . . . 0.0 111.349 178.957 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.764 HG21 ' CB ' ' A' ' 41' ' ' ASP . 2.0 t -115.61 106.46 20.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 120.625 -1.515 . . . . 0.0 107.193 178.778 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.882 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.3 tp -116.4 104.75 11.77 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.428 -1.42 . . . . 0.0 109.847 -177.612 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.872 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.96 109.24 22.03 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 120.763 -1.211 . . . . 0.0 107.847 178.682 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -104.17 170.0 8.16 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.933 -1.104 . . . . 0.0 110.151 -178.863 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.454 ' CG ' ' HB2' ' A' ' 73' ' ' PHE . 36.9 t30 -108.24 134.67 20.1 Favored Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.346 -0.846 . . . . 0.0 109.631 -179.376 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.1 Cg_endo -74.5 25.27 0.36 Allowed 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 122.259 1.972 . . . . 0.0 111.608 -179.962 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.424 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -120.12 2.54 10.92 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.473 -1.392 . . . . 0.0 109.307 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.706 ' OD2' HG13 ' A' ' 69' ' ' VAL . 5.7 m-20 -137.09 18.67 2.99 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 179.744 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -81.13 88.52 5.99 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.617 -0.833 . . . . 0.0 110.62 -178.702 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -109.43 -166.22 1.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 178.66 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.77 136.02 0.09 Allowed 'General case' 0 N--CA 1.485 1.316 0 O-C-N 120.708 -1.245 . . . . 0.0 111.07 -179.215 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.94 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.84 155.92 5.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.421 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.582 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.73 141.34 31.66 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.87 -1.144 . . . . 0.0 109.94 -179.737 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.997 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -61.76 106.18 0.65 Allowed 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 122.471 1.129 . . . . 0.0 109.379 178.331 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.56 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.2 p-10 -59.46 -140.06 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.043 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.947 179.895 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.54 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.37 -50.42 59.58 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.488 -0.758 . . . . 0.0 110.752 -178.756 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -103.65 -33.35 9.0 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 106.16 -1.792 . . . . 0.0 106.16 178.518 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.985 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.4 66.3 0.65 Allowed Glycine 0 C--N 1.298 -1.545 0 CA-C-N 114.897 -1.047 . . . . 0.0 110.514 177.993 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 20.0 m -103.68 125.43 50.17 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 178.657 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.94 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.9 109.27 7.86 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.349 -179.379 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.7 m -126.21 122.16 34.82 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.366 -0.834 . . . . 0.0 109.674 -179.717 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.587 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -143.91 141.8 30.45 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.634 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.3 p -98.55 131.63 44.62 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.192 -0.942 . . . . 0.0 109.493 -179.8 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.839 HD12 ' H ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -131.49 178.46 6.71 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.487 -0.758 . . . . 0.0 109.299 -179.387 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.538 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.5 p -102.22 123.52 46.2 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.898 -1.126 . . . . 0.0 109.739 -179.416 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.731 HG23 HD13 ' A' ' 13' ' ' LEU . 15.5 m -128.59 142.32 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 120.934 -1.104 . . . . 0.0 110.062 -179.389 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.615 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.5 ptt180 -148.4 -176.76 5.43 Favored 'General case' 0 N--CA 1.484 1.248 0 O-C-N 120.521 -1.362 . . . . 0.0 110.91 179.669 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.569 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.1 OUTLIER -60.56 -102.33 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.189 -179.109 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.534 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -60.09 138.12 57.95 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.443 -1.411 . . . . 0.0 107.979 179.773 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.531 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 2.4 p90 -161.72 147.33 13.57 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 118.555 -1.258 . . . . 0.0 110.033 -178.377 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.541 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 1.8 mp0 -37.68 120.44 0.82 Allowed 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 121.504 0.669 . . . . 0.0 110.516 -178.674 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.872 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.54 49.49 3.17 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.599 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.9 m-30 -38.07 114.45 0.36 Allowed 'General case' 0 N--CA 1.511 2.582 0 O-C-N 121.194 -1.18 . . . . 0.0 110.545 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.816 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -87.62 127.01 35.28 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.843 -1.161 . . . . 0.0 109.546 179.78 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 25.6 t80 -64.36 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.872 -1.142 . . . . 0.0 109.993 179.667 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.8 t70 -159.46 19.01 0.18 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.047 -1.033 . . . . 0.0 109.72 179.893 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.89 -26.34 6.1 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.747 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 35.2 p -96.45 163.32 13.1 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 121.037 -1.273 . . . . 0.0 110.407 -179.414 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.478 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.4 136.28 46.42 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.913 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.816 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.9 t90 -82.42 -18.56 41.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.781 -1.199 . . . . 0.0 110.318 -178.757 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.83 173.36 17.85 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 -179.587 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.79 109.3 1.68 Allowed 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 179.203 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.606 HG21 ' HB3' ' A' ' 46' ' ' ALA . 50.4 t -80.06 105.23 9.37 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 121.43 -0.794 . . . . 0.0 109.349 -178.782 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.556 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -66.14 109.69 2.7 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.661 -0.649 . . . . 0.0 109.965 -179.529 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.569 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 3.0 t -62.09 -4.41 1.67 Allowed 'General case' 0 N--CA 1.501 2.107 0 C-N-CA 118.165 -1.414 . . . . 0.0 110.162 179.348 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.0 p -90.08 3.54 53.0 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.627 -1.296 . . . . 0.0 109.306 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.556 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -116.32 -49.88 2.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.298 -0.876 . . . . 0.0 109.127 -179.899 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.9 179.37 4.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.429 -0.795 . . . . 0.0 109.46 179.969 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.42 113.6 26.85 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.286 -0.884 . . . . 0.0 108.725 179.737 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.495 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -97.16 121.41 39.02 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.929 -1.107 . . . . 0.0 109.542 -178.922 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.579 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.43 148.58 26.27 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 122.44 1.114 . . . . 0.0 111.452 -179.249 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.483 ' CG1' HG11 ' A' ' 7' ' ' VAL . 28.8 t -104.95 109.5 27.86 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.449 -1.686 . . . . 0.0 106.449 177.249 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.482 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.8 -169.53 16.77 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 118.305 -1.902 . . . . 0.0 111.691 -177.366 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.468 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -120.77 177.13 5.2 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -178.958 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.594 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 7.8 t 177.81 159.15 0.45 Allowed 'General case' 0 C--N 1.292 -1.933 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 179.917 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.567 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -103.44 -158.21 0.65 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.962 -1.086 . . . . 0.0 109.266 -179.621 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.438 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.34 35.69 4.42 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.792 -1.192 . . . . 0.0 109.167 -179.973 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.75 -32.4 6.65 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.323 -0.861 . . . . 0.0 109.814 -179.677 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.557 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.86 -36.58 0.26 Allowed Glycine 0 N--CA 1.481 1.693 0 N-CA-C 107.857 -2.097 . . . . 0.0 107.857 -179.744 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.95 -177.35 5.03 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.576 -0.955 . . . . 0.0 109.992 179.359 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.13 -161.24 20.28 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 108.074 -2.01 . . . . 0.0 108.074 -179.411 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.479 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.4 Cg_exo -47.01 176.43 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.66 0 CA-C-N 118.956 1.378 . . . . 0.0 110.061 179.297 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -95.28 178.62 5.46 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.029 -1.045 . . . . 0.0 110.725 -178.58 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.482 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.23 170.34 13.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -107.32 133.22 52.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.348 -1.089 . . . . 0.0 109.187 -179.273 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.579 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.65 124.37 26.59 Favored 'General case' 0 C--N 1.29 -2.013 0 O-C-N 121.508 -0.745 . . . . 0.0 109.704 179.709 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.944 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.95 171.0 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.283 -0.886 . . . . 0.0 108.91 179.816 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.5 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 24.3 m -139.15 156.74 46.91 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.054 -1.029 . . . . 0.0 109.872 -179.794 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.944 ' CE1' HD12 ' A' ' 110' ' ' ILE . 45.2 m-85 -129.15 77.33 1.78 Allowed 'General case' 0 N--CA 1.486 1.352 0 O-C-N 121.226 -0.921 . . . . 0.0 109.465 -179.669 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.402 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 17.4 p30 . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 118.018 -0.991 . . . . 0.0 109.458 -179.991 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.765 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.81 155.2 60.57 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.219 -0.926 . . . . 0.0 109.491 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.569 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.8 Cg_exo -59.49 158.88 25.57 Favored 'Trans proline' 0 C--N 1.31 -1.491 0 C-N-CA 122.246 1.964 . . . . 0.0 110.549 179.971 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.543 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.31 -169.74 0.15 Allowed 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 179.318 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.543 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.47 130.5 2.92 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.8 -1.187 . . . . 0.0 110.768 -179.051 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.957 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.7 t -110.87 108.9 18.85 Favored 'General case' 0 C--N 1.297 -1.7 0 CA-C-O 123.109 1.433 . . . . 0.0 109.066 179.357 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.817 HG22 HG23 ' A' ' 21' ' ' VAL . 2.6 t -118.28 139.72 44.44 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.699 0 CA-C-N 114.223 -1.353 . . . . 0.0 110.121 -179.741 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.453 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -179.07 150.88 0.64 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.239 -0.913 . . . . 0.0 108.764 -179.685 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.453 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.7 Cg_endo -77.47 151.72 92.77 Favored 'Cis proline' 0 C--N 1.313 -1.314 0 C-N-CA 123.555 -1.435 . . . . 0.0 109.332 -0.838 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.681 ' HA ' HG22 ' A' ' 110' ' ' ILE . 59.2 p -92.49 -23.29 19.16 Favored 'General case' 0 C--N 1.291 -1.968 0 O-C-N 121.567 -0.708 . . . . 0.0 109.664 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.482 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 23.9 p -133.26 159.14 41.09 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.197 -0.939 . . . . 0.0 110.124 -179.493 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.79 37.1 23.83 Favored Glycine 0 N--CA 1.497 2.706 0 N-CA-C 108.917 -1.673 . . . . 0.0 108.917 -179.859 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.777 ' HA ' HG21 ' A' ' 17' ' ' THR . 39.0 mt -93.34 -44.57 8.23 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.162 1.458 . . . . 0.0 110.44 -178.54 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.44 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.8 OUTLIER 64.3 146.8 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.273 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.17 -179.829 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.53 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 12.7 p-10 -51.51 104.92 0.09 Allowed 'General case' 0 C--N 1.305 -1.353 0 CA-C-O 121.675 0.75 . . . . 0.0 111.04 -179.072 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.81 7.47 6.68 Favored Glycine 0 N--CA 1.484 1.848 0 C-N-CA 119.13 -1.509 . . . . 0.0 113.296 177.52 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.777 HG21 ' HA ' ' A' ' 13' ' ' LEU . 15.2 t -107.13 -177.03 3.24 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 121.444 2.622 . . . . 0.0 110.133 179.605 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.784 HG13 ' O ' ' A' ' 67' ' ' LEU . 25.4 t -126.26 135.75 62.86 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.452 0 CA-C-N 114.249 -1.341 . . . . 0.0 111.073 -178.717 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.62 ' CG1' HD13 ' A' ' 13' ' ' LEU . 10.4 m -110.56 156.53 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.734 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.6 tttt -109.15 108.88 19.71 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.095 -1.003 . . . . 0.0 108.968 179.84 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.817 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.75 141.13 20.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.668 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.957 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -139.24 160.6 39.44 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 118.539 -1.265 . . . . 0.0 110.2 179.901 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.602 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.58 143.49 14.64 Favored Glycine 0 C--N 1.295 -1.731 0 N-CA-C 107.89 -2.084 . . . . 0.0 107.89 179.448 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.569 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -145.45 126.22 14.35 Favored 'General case' 0 C--N 1.295 -1.765 0 O-C-N 120.783 -1.422 . . . . 0.0 108.977 179.276 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.529 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.2 26.52 25.74 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 119.319 -1.419 . . . . 0.0 109.737 -179.744 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.576 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -89.43 169.78 11.09 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.81 -1.406 . . . . 0.0 108.392 179.861 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.999 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.95 100.98 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.039 -1.038 . . . . 0.0 110.076 -179.526 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.69 78.56 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.867 -179.529 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.41 33.9 0.3 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 179.778 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.562 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 17.2 p -138.6 105.03 5.28 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.259 -1.141 . . . . 0.0 111.146 -179.43 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.578 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.36 110.6 0.42 Allowed 'General case' 0 N--CA 1.497 1.905 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.701 178.169 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.562 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 35.5 m-85 -105.91 157.31 17.58 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.154 -0.966 . . . . 0.0 108.923 179.718 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.486 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -102.31 162.16 13.14 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.935 -1.103 . . . . 0.0 108.132 179.035 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.631 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.9 p -141.8 118.89 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.196 -0.94 . . . . 0.0 109.559 -178.186 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -166.41 -179.08 39.52 Favored Glycine 0 N--CA 1.493 2.481 0 C-N-CA 118.386 -1.864 . . . . 0.0 111.647 -179.693 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.63 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -101.38 109.01 20.77 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 179.978 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.51 148.76 52.35 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 121.164 -0.96 . . . . 0.0 109.959 179.925 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.429 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.65 138.66 54.5 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.409 -0.807 . . . . 0.0 110.656 -179.146 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.891 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.21 114.78 26.61 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 178.154 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.6 m -104.8 14.86 6.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.997 -1.065 . . . . 0.0 110.537 -178.789 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.753 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.87 -175.19 0.08 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.968 -1.083 . . . . 0.0 109.979 179.625 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 71.4 p -72.72 98.03 2.3 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.474 -0.766 . . . . 0.0 109.519 -179.704 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.57 27.65 31.92 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 120.225 -0.988 . . . . 0.0 111.413 178.943 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.753 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.25 106.18 19.59 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.653 -1.498 . . . . 0.0 107.258 178.942 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.891 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -117.26 104.59 11.32 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.504 -1.373 . . . . 0.0 109.831 -177.771 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.083 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.7 109.3 22.08 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.641 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.17 167.11 10.13 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.941 -1.099 . . . . 0.0 110.685 -178.588 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.483 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 10.8 t-20 -115.07 129.5 25.01 Favored Pre-proline 0 N--CA 1.498 1.939 0 O-C-N 121.606 -0.684 . . . . 0.0 109.498 -179.334 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.6 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -71.8 22.38 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.081 0 C-N-CA 122.052 1.835 . . . . 0.0 111.852 179.437 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.454 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -99.04 -5.9 29.49 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.404 -1.435 . . . . 0.0 109.15 179.61 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.815 ' OD2' HG13 ' A' ' 69' ' ' VAL . 1.6 m-20 -136.4 11.44 3.24 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.861 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -67.47 86.76 0.19 Allowed 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.48 -0.763 . . . . 0.0 110.649 -178.715 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.631 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -107.89 -165.97 1.1 Allowed 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 178.576 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.463 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.73 135.89 0.09 Allowed 'General case' 0 C--N 1.306 -1.305 0 O-C-N 120.642 -1.286 . . . . 0.0 111.147 -179.334 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.942 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -151.82 156.53 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 178.168 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.578 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.38 142.58 29.83 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.773 -1.205 . . . . 0.0 110.082 -179.676 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.024 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.36 107.08 0.85 Allowed 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 122.446 1.117 . . . . 0.0 109.403 178.079 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 17.2 p-10 -61.14 -138.93 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.026 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.986 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.77 -51.19 52.87 Favored 'General case' 0 N--CA 1.5 2.075 0 O-C-N 121.379 -0.826 . . . . 0.0 110.845 -178.536 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -103.79 -33.29 8.96 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.167 -1.79 . . . . 0.0 106.167 178.488 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.024 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.95 63.88 0.55 Allowed Glycine 0 C--N 1.298 -1.58 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 178.102 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.602 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 43.2 m -102.38 126.96 49.56 Favored 'General case' 0 C--N 1.31 -1.148 0 O-C-N 121.479 -1.012 . . . . 0.0 108.731 178.732 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.942 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.28 109.04 7.52 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 119.411 -0.915 . . . . 0.0 109.53 -179.387 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -123.81 121.44 35.41 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 121.242 -0.911 . . . . 0.0 109.614 -179.768 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.58 146.54 31.42 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.558 -0.714 . . . . 0.0 109.305 179.854 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.401 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 13.5 p -98.83 141.15 31.98 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.351 -0.843 . . . . 0.0 109.472 -179.909 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.784 ' O ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -140.83 170.33 15.95 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.405 -0.809 . . . . 0.0 109.304 -179.206 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.779 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -101.87 124.94 48.34 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 120.878 -1.139 . . . . 0.0 110.157 -179.099 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.815 HG13 ' OD2' ' A' ' 51' ' ' ASP . 11.8 m -128.54 139.34 52.15 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 120.996 -1.065 . . . . 0.0 110.343 -179.601 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.53 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 56.3 mtt180 -127.11 -168.84 1.94 Allowed 'General case' 0 N--CA 1.483 1.222 0 O-C-N 120.576 -1.327 . . . . 0.0 111.156 179.673 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.588 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 1.8 mtt180 -79.08 -76.02 0.22 Allowed 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 179.001 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.504 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -73.66 135.52 43.75 Favored 'General case' 0 N--CA 1.486 1.349 0 N-CA-C 106.452 -1.684 . . . . 0.0 106.452 177.774 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.59 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -156.79 139.13 14.76 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 117.637 -1.625 . . . . 0.0 110.925 -177.331 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.9 mm-40 -37.19 118.93 0.65 Allowed 'General case' 0 N--CA 1.489 1.513 0 CA-C-O 121.408 0.623 . . . . 0.0 110.09 -178.943 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.083 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.78 50.13 3.43 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.175 -179.242 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.6 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-30 -38.69 113.88 0.34 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.136 -1.214 . . . . 0.0 110.073 179.514 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.729 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -85.92 126.66 34.25 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 120.981 -1.074 . . . . 0.0 109.526 -179.885 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 29.4 t80 -63.72 58.54 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.026 0 O-C-N 120.91 -1.119 . . . . 0.0 110.142 179.608 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.59 19.5 0.14 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.036 -1.04 . . . . 0.0 109.748 179.84 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.78 -27.03 5.55 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 110.111 -1.195 . . . . 0.0 110.111 179.842 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.24 161.82 13.94 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 121.033 -1.274 . . . . 0.0 110.335 -179.499 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.476 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -107.67 136.85 46.73 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.917 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.729 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.5 t90 -82.21 -19.07 40.52 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.755 -1.216 . . . . 0.0 110.311 -178.759 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.93 173.93 19.01 Favored Glycine 0 N--CA 1.486 1.969 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.581 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.65 109.65 1.47 Allowed 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 179.202 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.5 t -81.92 105.12 11.43 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 O-C-N 121.354 -0.841 . . . . 0.0 108.916 -179.092 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.655 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.1 OUTLIER -65.45 110.69 2.76 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.45 -0.781 . . . . 0.0 110.006 -179.1 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.588 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.6 t -64.19 -5.28 4.63 Favored 'General case' 0 N--CA 1.5 2.035 0 C-N-CA 118.452 -1.299 . . . . 0.0 109.791 179.38 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.1 p -86.88 0.6 54.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.742 -1.224 . . . . 0.0 108.961 179.427 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.655 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -114.88 -50.96 2.75 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.292 -0.88 . . . . 0.0 109.02 179.825 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -102.84 -178.99 3.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.566 -0.709 . . . . 0.0 109.394 179.84 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.5 115.32 30.05 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.312 -0.867 . . . . 0.0 109.023 179.923 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.516 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.7 m -97.11 121.91 39.52 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.998 -1.064 . . . . 0.0 109.396 -179.353 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.612 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.92 144.93 29.93 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 122.397 1.094 . . . . 0.0 111.199 -179.365 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 96.4 t -102.49 110.16 28.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 177.701 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.478 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.3 -169.91 16.92 Favored Glycine 0 N--CA 1.486 2.006 0 C-N-CA 118.071 -2.014 . . . . 0.0 111.833 -177.536 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.503 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -112.91 179.88 3.84 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -179.116 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.577 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.4 p -178.51 167.33 1.82 Allowed 'General case' 0 C--N 1.296 -1.74 0 O-C-N 121.456 -0.777 . . . . 0.0 109.58 -179.301 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.524 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -120.02 -160.07 0.81 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.013 -1.054 . . . . 0.0 109.023 -179.962 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.79 36.42 4.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.76 -1.212 . . . . 0.0 109.184 179.969 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.73 -33.19 5.58 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.344 -0.847 . . . . 0.0 110.053 -179.705 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.787 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 166.18 -36.38 0.25 Allowed Glycine 0 N--CA 1.482 1.706 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 -179.712 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.19 -177.46 5.4 Favored 'General case' 0 C--N 1.308 -1.219 0 O-C-N 121.518 -0.989 . . . . 0.0 109.789 179.26 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.61 -162.88 19.22 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 108.27 -1.932 . . . . 0.0 108.27 -179.442 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.503 ' HB2' HD12 ' A' ' 97' ' ' LEU . 6.4 Cg_exo -46.82 176.62 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.653 0 CA-C-N 118.835 1.317 . . . . 0.0 110.16 179.305 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -91.53 -176.13 4.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.142 -0.974 . . . . 0.0 110.502 -178.752 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.478 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.9 167.24 14.55 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.78 130.92 52.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.428 -1.042 . . . . 0.0 109.186 -179.403 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.612 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.42 120.76 20.43 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.679 -0.638 . . . . 0.0 109.744 179.751 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.733 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.4 pt -98.12 167.28 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.279 -0.888 . . . . 0.0 109.201 179.89 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.482 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -133.14 159.28 40.59 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.314 -0.866 . . . . 0.0 109.412 -179.926 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.733 ' CE2' HD12 ' A' ' 110' ' ' ILE . 49.4 m-85 -134.3 119.27 18.5 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.117 -0.989 . . . . 0.0 109.563 -179.753 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.54 ' OXT' ' ND2' ' A' ' 113' ' ' ASN . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 118.057 -0.973 . . . . 0.0 109.41 -179.969 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.787 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.6 0 CA-C-O 121.27 0.557 . . . . 0.0 109.515 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.594 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -89.4 161.74 38.92 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.245 -0.91 . . . . 0.0 109.435 179.98 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.594 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 2.4 Cg_endo -61.39 155.75 50.44 Favored 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.114 1.876 . . . . 0.0 110.601 179.937 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -152.89 159.46 43.0 Favored 'General case' 0 C--N 1.293 -1.868 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 -179.526 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.495 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -145.19 124.99 13.37 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 122.584 1.183 . . . . 0.0 110.115 -179.749 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.911 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.7 t -115.8 109.2 17.33 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 123.122 1.439 . . . . 0.0 109.607 -179.98 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.882 HG22 HG23 ' A' ' 21' ' ' VAL . 3.1 t -114.95 139.84 39.15 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.677 0 CA-C-N 114.234 -1.348 . . . . 0.0 109.853 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.65 149.12 2.35 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.272 -0.893 . . . . 0.0 108.695 -179.666 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.0 Cg_endo -75.26 152.35 97.69 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 123.491 -1.462 . . . . 0.0 109.552 -0.846 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.653 ' HA ' HG22 ' A' ' 110' ' ' ILE . 2.4 m -88.46 -27.36 21.57 Favored 'General case' 0 C--N 1.293 -1.863 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.62 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.541 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 1.9 p -136.39 166.77 22.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.51 -0.744 . . . . 0.0 109.347 179.764 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.08 37.36 32.85 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 108.512 -1.835 . . . . 0.0 108.512 -179.626 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.755 ' CA ' HG21 ' A' ' 17' ' ' THR . 41.0 mt -92.98 -42.65 9.33 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-O 123.243 1.497 . . . . 0.0 110.466 -178.352 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.67 144.08 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.243 0 CA-C-N 113.392 -1.731 . . . . 0.0 109.877 -179.669 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.615 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 13.0 p-10 -50.94 105.65 0.11 Allowed 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.457 0.646 . . . . 0.0 111.589 -178.601 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.71 14.08 8.27 Favored Glycine 0 N--CA 1.485 1.927 0 C-N-CA 119.425 -1.369 . . . . 0.0 112.995 177.35 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.755 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -105.76 -172.43 2.09 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 121.239 2.52 . . . . 0.0 109.86 179.23 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.822 HG22 HG22 ' A' ' 68' ' ' THR . 18.1 t -128.41 139.18 52.6 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.345 0 CA-C-N 114.742 -1.117 . . . . 0.0 111.022 -178.81 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.6 HG11 HD11 ' A' ' 13' ' ' LEU . 33.2 m -114.49 154.91 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.876 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.05 109.55 21.45 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.261 -0.899 . . . . 0.0 109.19 -179.954 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.882 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -102.26 140.06 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.511 -0.743 . . . . 0.0 109.059 179.95 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.911 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -131.44 158.16 41.56 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.012 -1.055 . . . . 0.0 109.335 179.458 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.583 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.73 108.76 0.57 Allowed Glycine 0 N--CA 1.482 1.724 0 N-CA-C 108.806 -1.718 . . . . 0.0 108.806 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.597 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -115.78 139.75 49.88 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-N 119.268 1.534 . . . . 0.0 110.512 -179.317 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.511 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 84.47 28.84 31.74 Favored Glycine 0 N--CA 1.491 2.354 0 C-N-CA 119.13 -1.51 . . . . 0.0 109.971 179.535 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.549 HD22 ' HG3' ' A' ' 105' ' ' PRO . 1.6 mt -92.19 175.28 6.91 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.977 -1.308 . . . . 0.0 108.613 -179.875 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.11 97.03 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.287 0 O-C-N 121.014 -1.054 . . . . 0.0 109.661 -179.811 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.656 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 76.69 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.384 -178.988 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.84 33.82 0.32 Allowed Glycine 0 N--CA 1.486 2.002 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 179.451 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.613 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -147.0 114.53 6.35 Favored 'General case' 0 C--N 1.308 -1.227 0 O-C-N 120.843 -1.387 . . . . 0.0 111.084 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -45.18 127.11 6.69 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.788 178.561 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.613 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 10.2 m-85 -117.75 149.34 40.94 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.484 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.493 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -101.01 152.64 20.34 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.867 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.64 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.5 p -137.19 118.55 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.958 -1.089 . . . . 0.0 109.767 -177.759 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.34 -178.7 39.22 Favored Glycine 0 N--CA 1.495 2.607 0 C-N-CA 118.341 -1.885 . . . . 0.0 111.863 -179.733 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.59 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.35 109.36 21.54 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.928 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.47 149.54 52.09 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.146 -0.971 . . . . 0.0 109.839 179.84 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.538 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.24 138.49 54.4 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.234 -0.916 . . . . 0.0 110.736 -179.039 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.895 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.17 114.97 26.82 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 178.02 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.2 m -105.28 14.91 7.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 120.997 -1.064 . . . . 0.0 110.583 -178.794 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.764 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.68 -175.0 0.08 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.925 -1.11 . . . . 0.0 110.014 179.704 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -72.64 97.64 2.2 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.448 -0.782 . . . . 0.0 109.702 -179.753 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.62 28.3 29.97 Favored Glycine 0 N--CA 1.494 2.544 0 C-N-CA 120.211 -0.995 . . . . 0.0 111.341 179.005 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.764 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.43 106.11 19.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 O-C-N 120.499 -1.589 . . . . 0.0 107.207 178.854 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.895 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.1 tp -116.59 104.69 11.65 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.568 -1.332 . . . . 0.0 109.866 -177.66 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.1 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.15 109.3 22.08 Favored 'General case' 0 N--CA 1.485 1.298 0 O-C-N 120.856 -1.152 . . . . 0.0 108.06 178.633 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.79 163.36 13.18 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.985 -1.072 . . . . 0.0 110.182 -178.908 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.721 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 9.9 t-20 -108.95 135.76 20.11 Favored Pre-proline 0 N--CA 1.499 2.002 0 O-C-N 121.281 -0.887 . . . . 0.0 109.944 -179.136 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.3 Cg_endo -74.72 23.96 0.38 Allowed 'Trans proline' 0 C--N 1.319 -1.017 0 C-N-CA 122.417 2.078 . . . . 0.0 112.069 -179.992 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.721 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -114.44 3.28 14.91 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.323 -1.486 . . . . 0.0 109.198 179.632 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.529 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.67 14.77 3.15 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 179.154 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -78.7 87.77 4.6 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.039 -0.665 . . . . 0.0 110.871 -178.558 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.64 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -104.98 -167.93 1.41 Allowed 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.057 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.88 135.77 0.09 Allowed 'General case' 0 C--N 1.304 -1.404 0 O-C-N 120.555 -1.34 . . . . 0.0 111.38 -179.192 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.902 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -154.06 156.91 4.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 178.034 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.62 145.33 26.39 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.665 -1.272 . . . . 0.0 109.831 -179.612 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.009 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.05 107.09 1.78 Allowed 'General case' 0 C--N 1.298 -1.63 0 CA-C-O 122.433 1.111 . . . . 0.0 109.472 178.936 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.4 p-10 -59.62 -139.43 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.037 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.728 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.656 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.9 -50.11 64.58 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.374 -0.829 . . . . 0.0 110.361 -178.822 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -102.56 -35.54 8.7 Favored 'General case' 0 C--N 1.286 -2.186 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 178.488 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.988 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.91 67.31 0.62 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.541 -1.023 . . . . 0.0 110.541 178.166 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.583 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 38.4 m -101.6 127.86 48.13 Favored 'General case' 0 N--CA 1.485 1.325 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 178.688 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.902 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.03 108.82 7.04 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.503 -179.37 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 18.4 p -126.11 120.56 30.49 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.348 -0.845 . . . . 0.0 109.565 -179.888 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.37 146.25 31.5 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.669 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.2 p -98.61 131.25 44.96 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.162 -0.961 . . . . 0.0 109.588 -179.663 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.76 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -128.92 166.22 19.55 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.403 -0.811 . . . . 0.0 109.341 -179.514 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.822 HG22 HG22 ' A' ' 18' ' ' VAL . 1.7 p -97.65 125.1 42.23 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.986 -1.072 . . . . 0.0 109.373 -179.999 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.556 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.2 m -137.26 143.48 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.047 -1.033 . . . . 0.0 109.785 -179.149 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.615 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -146.44 -177.48 5.65 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.531 -1.355 . . . . 0.0 111.249 -179.927 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.583 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.05 -100.2 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -179.655 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.515 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.21 140.13 50.6 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 120.71 -1.244 . . . . 0.0 107.888 179.309 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.569 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -161.91 136.65 7.06 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 118.513 -1.275 . . . . 0.0 109.918 -178.015 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.508 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 6.4 mt-10 -34.78 121.34 0.52 Allowed 'General case' 0 N--CA 1.489 1.485 0 CA-C-O 121.434 0.635 . . . . 0.0 110.423 -178.61 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.1 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.75 51.54 2.0 Allowed Glycine 0 N--CA 1.495 2.593 0 C-N-CA 120.563 -0.827 . . . . 0.0 111.125 -179.22 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.23 115.63 0.51 Allowed 'General case' 0 N--CA 1.506 2.371 0 O-C-N 121.154 -1.204 . . . . 0.0 110.121 179.453 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.706 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.89 126.56 34.75 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 120.831 -1.168 . . . . 0.0 109.575 -179.741 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.587 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.5 t80 -64.2 58.3 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.913 -1.117 . . . . 0.0 110.065 179.513 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.54 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.1 t70 -159.53 19.24 0.17 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.982 -1.074 . . . . 0.0 109.709 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.07 -27.19 5.64 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.822 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 p -95.99 161.6 13.92 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 120.994 -1.298 . . . . 0.0 110.397 -179.393 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.478 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.75 137.53 44.61 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.673 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.706 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.08 -19.65 39.76 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.747 -1.221 . . . . 0.0 110.507 -178.648 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.15 176.36 19.05 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.709 -1.757 . . . . 0.0 108.709 -179.499 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.94 105.7 1.39 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.015 -1.285 . . . . 0.0 107.783 179.158 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.65 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.9 t -77.12 105.82 6.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 O-C-N 121.367 -0.833 . . . . 0.0 109.229 -178.903 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.547 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -65.48 111.3 3.03 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.483 -0.761 . . . . 0.0 110.012 -179.445 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.583 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.05 -5.88 3.48 Favored 'General case' 0 N--CA 1.499 2.015 0 C-N-CA 118.273 -1.371 . . . . 0.0 109.8 179.486 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -86.89 -0.18 56.05 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.713 -1.242 . . . . 0.0 109.26 179.496 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.547 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.32 -50.33 2.87 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.34 -0.85 . . . . 0.0 109.006 179.886 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.69 -179.9 4.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.581 -0.699 . . . . 0.0 109.344 179.833 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.69 115.91 31.36 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.895 . . . . 0.0 109.003 179.981 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.521 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.86 120.77 37.81 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.826 -1.171 . . . . 0.0 109.368 -179.409 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.43 145.96 28.25 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 122.355 1.074 . . . . 0.0 111.117 -179.283 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.526 ' CG1' HG11 ' A' ' 7' ' ' VAL . 60.5 t -101.25 109.77 26.47 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.013 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 177.362 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.469 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -146.64 -171.32 15.83 Favored Glycine 0 N--CA 1.486 2.0 0 C-N-CA 118.212 -1.946 . . . . 0.0 111.619 -177.284 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.495 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -123.22 179.64 4.63 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -178.631 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.54 ' OG ' ' C21' ' A' ' 114' ' ' CHR . 0.8 OUTLIER -178.94 170.78 1.47 Allowed 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.482 -0.761 . . . . 0.0 109.513 -179.862 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.479 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -119.16 -156.34 0.65 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.102 -0.999 . . . . 0.0 109.036 -179.977 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.479 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -115.94 35.28 4.54 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.795 -1.191 . . . . 0.0 109.14 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -110.77 -33.2 6.61 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.352 -0.842 . . . . 0.0 109.776 -179.832 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 1.026 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 161.77 -34.88 0.37 Allowed Glycine 0 N--CA 1.484 1.845 0 N-CA-C 107.604 -2.198 . . . . 0.0 107.604 -179.754 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.09 -177.67 5.91 Favored 'General case' 0 C--N 1.307 -1.282 0 O-C-N 121.668 -0.901 . . . . 0.0 109.808 179.338 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.09 -161.81 21.25 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 -179.368 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.549 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.3 Cg_exo -45.37 172.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.69 0 CA-C-N 118.81 1.305 . . . . 0.0 110.094 179.303 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -92.49 -178.7 4.98 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.084 -1.01 . . . . 0.0 110.608 -178.659 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.469 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -115.08 164.53 12.09 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.88 133.12 48.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.411 -1.052 . . . . 0.0 109.28 -179.282 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.02 119.3 17.07 Favored 'General case' 0 C--N 1.289 -2.022 0 O-C-N 121.655 -0.653 . . . . 0.0 109.474 179.646 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.876 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.14 172.07 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.175 -0.953 . . . . 0.0 109.101 179.944 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.541 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.3 OUTLIER -138.49 155.86 48.04 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.104 -0.997 . . . . 0.0 109.892 -179.695 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.876 ' CE2' HD12 ' A' ' 110' ' ' ILE . 87.0 m-85 -133.64 82.4 1.98 Allowed 'General case' 0 N--CA 1.485 1.303 0 O-C-N 121.325 -0.859 . . . . 0.0 109.613 -179.783 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 23.5 p30 . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.435 -179.978 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 1.026 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 121.307 0.575 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.747 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -110.24 166.13 11.36 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.89 . . . . 0.0 109.511 -179.986 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.747 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.9 Cg_exo -59.62 158.06 29.57 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.173 1.916 . . . . 0.0 110.513 -179.977 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.54 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.6 -169.77 0.15 Allowed 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 179.102 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.54 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -166.81 131.17 2.02 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.82 -1.175 . . . . 0.0 110.701 -179.099 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.951 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.3 t -112.91 108.7 17.74 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 123.106 1.431 . . . . 0.0 109.19 179.367 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.871 HG22 HG23 ' A' ' 21' ' ' VAL . 3.7 t -116.34 142.51 29.58 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.667 0 CA-C-N 114.347 -1.297 . . . . 0.0 110.203 -179.615 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.504 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -178.16 150.45 0.74 Allowed Pre-proline 0 N--CA 1.488 1.454 0 O-C-N 121.278 -0.888 . . . . 0.0 108.715 -179.737 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.504 ' HA ' HG23 ' A' ' 8' ' ' THR . 1.9 Cg_endo -75.05 153.73 99.25 Favored 'Cis proline' 0 C--N 1.312 -1.362 0 C-N-CA 123.577 -1.426 . . . . 0.0 109.471 -0.644 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.3 m -91.4 -25.35 19.4 Favored 'General case' 0 C--N 1.292 -1.912 0 O-C-N 121.63 -0.669 . . . . 0.0 109.428 -179.94 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.505 ' HB3' ' CB ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -137.9 163.35 31.69 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.338 -0.851 . . . . 0.0 109.905 -179.619 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.72 37.14 27.25 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 108.773 -1.731 . . . . 0.0 108.773 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.749 ' CA ' HG21 ' A' ' 17' ' ' THR . 44.2 mt -93.05 -44.22 8.5 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 123.249 1.5 . . . . 0.0 110.547 -178.533 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.445 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.48 145.75 0.03 OUTLIER 'General case' 0 C--N 1.262 -3.203 0 CA-C-N 113.473 -1.694 . . . . 0.0 109.999 -179.796 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.544 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.0 p-10 -51.93 105.1 0.1 Allowed 'General case' 0 C--N 1.303 -1.451 0 CA-C-O 121.49 0.662 . . . . 0.0 111.088 -179.05 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.95 6.66 6.96 Favored Glycine 0 N--CA 1.486 1.983 0 C-N-CA 119.18 -1.486 . . . . 0.0 113.194 177.518 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.749 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.6 t -105.14 -174.45 2.54 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 121.437 2.618 . . . . 0.0 109.922 179.709 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.782 HG22 HG22 ' A' ' 68' ' ' THR . 21.6 t -127.02 135.94 62.2 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.579 -1.191 . . . . 0.0 110.955 -178.778 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.622 ' CG1' HD13 ' A' ' 13' ' ' LEU . 32.5 m -109.54 154.79 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 178.795 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -110.56 109.25 19.5 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.198 -0.939 . . . . 0.0 108.825 179.776 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.871 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -104.32 140.46 22.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.951 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.18 160.32 38.73 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 118.74 -1.184 . . . . 0.0 109.857 179.649 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.59 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.44 143.55 15.2 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 108.021 -2.032 . . . . 0.0 108.021 179.789 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.578 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.12 125.26 12.91 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 120.843 -1.386 . . . . 0.0 108.846 179.289 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.53 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.98 26.8 25.5 Favored Glycine 0 N--CA 1.488 2.124 0 C-N-CA 119.371 -1.395 . . . . 0.0 109.704 -179.698 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.5 mt -86.27 175.83 8.25 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.921 -1.341 . . . . 0.0 108.557 -179.813 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.44 96.9 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.028 -1.045 . . . . 0.0 109.556 -179.771 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.637 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.26 76.32 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.715 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.541 -178.989 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.32 33.93 0.3 Allowed Glycine 0 N--CA 1.484 1.876 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.304 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.558 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 1.2 t -148.64 114.97 5.87 Favored 'General case' 0 C--N 1.308 -1.21 0 O-C-N 120.774 -1.427 . . . . 0.0 111.333 179.955 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.13 130.05 3.65 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.798 178.376 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.553 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 7.7 m-85 -121.41 147.93 45.06 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.583 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.498 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.96 156.71 17.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.626 -1.296 . . . . 0.0 107.771 178.719 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.644 ' O ' HG13 ' A' ' 34' ' ' VAL . 5.5 p -140.27 117.27 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.066 -1.021 . . . . 0.0 109.867 -177.789 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.518 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.29 -176.92 39.06 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.942 -179.739 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.64 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.4 pt20 -99.83 109.96 22.35 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 121.874 0.845 . . . . 0.0 109.02 -179.648 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.497 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -130.35 150.12 51.73 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.223 -0.923 . . . . 0.0 109.679 179.703 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.457 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.69 138.29 54.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.197 -0.94 . . . . 0.0 110.968 -178.945 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.38 115.0 26.83 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 177.982 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.458 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 19.8 m -105.77 14.72 7.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 120.993 -1.067 . . . . 0.0 110.646 -178.732 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.756 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.32 -174.71 0.09 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.04 -1.037 . . . . 0.0 110.011 179.614 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.84 97.03 1.73 Allowed 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.439 -0.788 . . . . 0.0 109.709 -179.77 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.28 27.8 32.3 Favored Glycine 0 N--CA 1.493 2.492 0 C-N-CA 120.149 -1.024 . . . . 0.0 111.481 178.849 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.756 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.32 106.45 20.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 O-C-N 120.688 -1.477 . . . . 0.0 107.252 178.975 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.5 tp -115.38 104.8 12.15 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.4 -1.437 . . . . 0.0 110.019 -177.715 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.986 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.68 109.71 22.41 Favored 'General case' 0 N--CA 1.486 1.372 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.801 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.51 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -109.08 168.34 9.44 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.059 -1.026 . . . . 0.0 110.365 -178.744 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.55 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 22.3 t-20 -118.09 135.08 23.32 Favored Pre-proline 0 N--CA 1.499 2.01 0 O-C-N 121.353 -0.842 . . . . 0.0 110.101 -179.438 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.589 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.5 Cg_endo -73.66 23.33 0.33 Allowed 'Trans proline' 0 CA--C 1.545 1.045 0 C-N-CA 122.223 1.949 . . . . 0.0 112.181 179.901 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.55 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -108.82 1.99 21.31 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.345 -1.472 . . . . 0.0 109.079 179.406 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.53 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.11 17.41 2.27 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.643 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -81.06 90.37 6.0 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.524 -0.735 . . . . 0.0 110.891 -178.606 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.69 -166.87 1.19 Allowed 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 178.145 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.448 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.72 134.92 0.09 Allowed 'General case' 0 C--N 1.306 -1.311 0 O-C-N 120.524 -1.36 . . . . 0.0 111.666 -179.356 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.803 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.5 p -150.94 157.38 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 177.862 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.57 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.19 146.07 25.44 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.496 -1.377 . . . . 0.0 109.741 -179.648 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.09 108.55 3.15 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 122.302 1.048 . . . . 0.0 109.589 179.009 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.541 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.7 t70 -63.69 -139.03 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.999 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.663 179.938 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.637 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.92 -51.74 49.11 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.343 -0.848 . . . . 0.0 110.679 -178.672 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -102.58 -32.7 9.78 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 106.517 -1.66 . . . . 0.0 106.517 178.662 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.006 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 105.36 66.32 0.67 Allowed Glycine 0 C--N 1.297 -1.591 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.18 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.59 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 58.0 p -98.66 131.96 44.42 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 121.378 -1.072 . . . . 0.0 109.097 179.006 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.803 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.43 108.32 6.32 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 119.319 -0.953 . . . . 0.0 109.52 -179.642 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.6 m -124.67 119.13 28.1 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.094 -1.004 . . . . 0.0 109.701 -179.939 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.593 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.33 144.16 29.6 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.448 -0.782 . . . . 0.0 109.363 179.853 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.8 p -99.12 141.51 31.8 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.316 -0.865 . . . . 0.0 109.191 179.838 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.827 HD12 ' H ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.83 167.94 20.94 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.449 -0.782 . . . . 0.0 109.551 -179.23 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.782 HG22 HG22 ' A' ' 18' ' ' VAL . 2.0 p -98.18 126.82 43.8 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.094 -1.004 . . . . 0.0 109.319 -179.761 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.502 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 15.4 m -134.44 140.53 45.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.879 -1.138 . . . . 0.0 110.091 -179.198 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.544 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 52.2 mtt180 -127.56 -165.52 1.49 Allowed 'General case' 0 N--CA 1.485 1.315 0 O-C-N 120.676 -1.265 . . . . 0.0 111.255 -179.821 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.574 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 1.0 OUTLIER -80.48 -79.64 0.15 Allowed 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.209 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.511 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -68.85 136.45 52.7 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 177.9 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.573 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.03 137.64 9.76 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 117.803 -1.559 . . . . 0.0 110.735 -177.325 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.526 ' HB3' ' CD1' ' A' ' 76' ' ' PHE . 8.0 mm-40 -33.72 119.2 0.37 Allowed 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 121.638 0.732 . . . . 0.0 110.58 -178.69 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.986 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -87.92 48.4 3.67 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.316 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.589 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 19.0 m-85 -39.21 113.92 0.36 Allowed 'General case' 0 N--CA 1.507 2.385 0 O-C-N 121.157 -1.202 . . . . 0.0 110.136 179.591 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.746 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -87.67 127.04 35.29 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.993 -1.067 . . . . 0.0 109.474 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.588 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.1 t80 -64.51 58.29 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.753 -1.217 . . . . 0.0 110.056 179.674 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.7 t70 -159.52 19.0 0.17 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.042 -1.036 . . . . 0.0 109.721 179.948 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.68 -26.56 5.8 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.84 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 72.4 p -95.15 160.56 14.5 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.021 -1.281 . . . . 0.0 110.417 -179.343 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.482 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 1.3 ptt180 -105.63 134.84 48.1 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.66 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.746 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.0 t90 -81.21 -20.01 42.03 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.823 -1.173 . . . . 0.0 110.234 -178.623 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.26 173.64 18.25 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 108.739 -1.745 . . . . 0.0 108.739 -179.572 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.67 111.45 2.09 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 179.251 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.653 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.7 t -83.1 103.91 11.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 O-C-N 121.35 -0.844 . . . . 0.0 108.798 -179.062 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.542 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.8 111.41 3.24 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.448 -0.783 . . . . 0.0 109.971 -179.094 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.57 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -63.96 -5.12 4.03 Favored 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 118.426 -1.31 . . . . 0.0 109.834 179.372 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.9 p -87.89 2.09 52.41 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.841 -1.162 . . . . 0.0 109.052 179.415 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.542 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -116.72 -51.23 2.59 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.329 -0.857 . . . . 0.0 108.939 -179.99 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.1 179.5 4.25 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.512 -0.742 . . . . 0.0 109.371 179.869 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.34 116.52 32.58 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.362 -0.836 . . . . 0.0 108.925 179.917 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.505 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.9 m -96.73 120.71 37.56 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.894 -1.129 . . . . 0.0 109.357 -179.41 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.616 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.67 145.56 28.92 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 122.373 1.083 . . . . 0.0 111.283 -179.12 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.427 ' CG1' HG11 ' A' ' 7' ' ' VAL . 62.6 t -101.71 109.81 26.92 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.037 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 177.537 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.451 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.85 -170.91 16.33 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 118.174 -1.965 . . . . 0.0 111.851 -177.467 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.526 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -121.6 178.98 4.61 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -178.859 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.553 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.7 OUTLIER -179.56 176.86 0.77 Allowed 'General case' 0 C--N 1.297 -1.704 0 O-C-N 121.564 -0.71 . . . . 0.0 109.562 179.999 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.459 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -124.32 -157.31 0.76 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.054 -1.029 . . . . 0.0 109.101 -179.896 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.459 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.77 36.17 4.41 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.76 -1.213 . . . . 0.0 109.2 -179.965 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.47 -32.67 6.62 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.312 -0.868 . . . . 0.0 109.8 -179.735 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.77 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.43 -35.92 0.26 Allowed Glycine 0 N--CA 1.481 1.698 0 N-CA-C 107.946 -2.061 . . . . 0.0 107.946 -179.765 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.421 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.99 -177.0 3.6 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 121.609 -0.936 . . . . 0.0 109.756 179.367 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.25 -161.36 17.96 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.27 -1.932 . . . . 0.0 108.27 -179.396 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.532 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.6 Cg_exo -46.6 176.5 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.664 0 CA-C-N 118.841 1.32 . . . . 0.0 110.203 179.287 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -93.85 -168.88 1.97 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.118 -0.989 . . . . 0.0 110.39 -178.927 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.451 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -123.88 163.47 17.51 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.736 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.14 129.67 49.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.409 -1.054 . . . . 0.0 109.123 -179.679 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.616 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.58 118.97 16.15 Favored 'General case' 0 C--N 1.288 -2.085 0 O-C-N 121.703 -0.623 . . . . 0.0 109.759 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.66 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.4 pt -98.07 168.0 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 121.249 -0.907 . . . . 0.0 109.065 179.803 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.505 ' CB ' ' HB3' ' A' ' 11' ' ' SER . 0.2 OUTLIER -132.28 156.89 45.74 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.281 -0.887 . . . . 0.0 109.666 -179.876 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.617 ' CE2' HD12 ' A' ' 110' ' ' ILE . 41.4 m-85 -131.72 117.35 18.51 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.272 -0.893 . . . . 0.0 109.357 -179.852 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.7 p30 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.496 179.931 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.77 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.466 -0.568 . . . . 1.0 109.466 . . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.16 149.0 50.59 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.309 -0.869 . . . . 1.0 109.569 179.922 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.581 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.4 Cg_exo -59.94 158.76 28.01 Favored 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.241 1.961 . . . . 1.0 110.606 179.969 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.49 -169.65 0.15 Allowed 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.092 -1.077 . . . . 1.0 108.092 179.233 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.565 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . -165.99 133.81 2.89 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 120.735 -1.228 . . . . 1.0 110.961 -179.277 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.005 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -102.0 104.52 15.19 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 122.408 1.099 . . . . 1.0 110.088 -179.84 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 1.018 HG22 HG23 ' A' ' 21' ' ' VAL . 5.9 t -119.5 123.55 71.33 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.448 0 CA-C-N 115.521 -0.763 . . . . 1.0 110.516 179.822 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.48 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -170.95 150.02 2.9 Favored Pre-proline 0 N--CA 1.488 1.451 0 N-CA-C 108.086 -1.079 . . . . 1.0 108.086 -179.649 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.48 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.0 Cg_endo -76.79 151.37 94.16 Favored 'Cis proline' 0 C--N 1.311 -1.434 0 C-N-CA 123.658 -1.393 . . . . 1.0 109.533 -0.526 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.683 ' HA ' HG22 ' A' ' 110' ' ' ILE . 95.2 p -95.4 -21.47 18.34 Favored 'General case' 0 C--N 1.293 -1.888 0 O-C-N 121.649 -0.657 . . . . 1.0 109.643 179.954 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.489 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.3 m -131.54 157.11 44.45 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.256 -0.903 . . . . 1.0 110.221 -179.583 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.39 37.11 25.04 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 108.794 -1.722 . . . . 1.0 108.794 -179.719 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.807 ' HA ' HG21 ' A' ' 17' ' ' THR . 35.4 mt -92.1 -44.78 8.63 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 123.201 1.477 . . . . 1.0 110.542 -178.59 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.442 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.1 t 63.8 147.52 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.25 0 CA-C-N 113.562 -1.654 . . . . 1.0 110.045 -179.815 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.521 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.5 p-10 -51.65 105.16 0.1 Allowed 'General case' 0 C--N 1.303 -1.438 0 CA-C-O 121.665 0.745 . . . . 1.0 111.106 -178.997 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.31 7.39 7.02 Favored Glycine 0 N--CA 1.485 1.954 0 C-N-CA 119.319 -1.42 . . . . 1.0 113.318 177.323 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.807 HG21 ' HA ' ' A' ' 13' ' ' LEU . 14.9 t -106.42 -177.46 3.37 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 121.468 2.634 . . . . 1.0 110.325 179.654 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.858 HG22 HG22 ' A' ' 68' ' ' THR . 21.9 t -128.3 139.69 51.22 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.374 0 CA-C-N 114.076 -1.42 . . . . 1.0 111.091 -178.717 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.671 HG11 HD11 ' A' ' 13' ' ' LEU . 15.7 m -117.19 154.68 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.35 -0.981 . . . . 1.0 108.35 178.739 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.545 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -104.1 108.79 20.32 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.139 -0.975 . . . . 1.0 109.304 -179.886 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 1.018 HG23 HG22 ' A' ' 7' ' ' VAL . 2.4 p -106.34 123.27 61.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 N-CA-C 108.299 -1.001 . . . . 1.0 108.299 179.571 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.005 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.67 167.21 11.55 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 120.681 -1.262 . . . . 1.0 109.22 -179.831 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.617 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.77 139.1 10.61 Favored Glycine 0 C--N 1.294 -1.779 0 N-CA-C 107.282 -2.327 . . . . 1.0 107.282 179.51 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.581 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -145.39 125.35 13.56 Favored 'General case' 0 C--N 1.293 -1.866 0 O-C-N 120.522 -1.575 . . . . 1.0 108.991 179.613 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.533 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.23 26.35 28.62 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 119.013 -1.565 . . . . 1.0 109.952 -179.798 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.566 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.3 mt -86.5 174.34 9.02 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 120.885 -1.362 . . . . 1.0 108.29 179.743 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.021 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.41 99.28 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.412 0 O-C-N 120.855 -1.153 . . . . 1.0 109.743 -179.605 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.585 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.11 77.74 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.304 -0.862 . . . . 1.0 110.246 -179.271 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.9 34.47 0.3 Allowed Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.464 -1.454 . . . . 1.0 109.464 179.587 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 53.4 p -142.82 108.75 5.17 Favored 'General case' 0 C--N 1.308 -1.221 0 O-C-N 121.039 -1.271 . . . . 1.0 111.214 -179.416 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.594 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.92 109.92 0.34 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 109.393 -0.595 . . . . 1.0 109.393 177.807 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.583 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 4.7 m-30 -104.9 155.4 18.96 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.119 -0.988 . . . . 1.0 108.878 179.874 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.82 162.01 13.33 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.804 -1.185 . . . . 1.0 108.077 178.934 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.63 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.9 p -141.91 120.36 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.166 -0.959 . . . . 1.0 109.307 -178.217 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' HB2' ' A' ' 51' ' ' ASP . . . -171.88 -176.48 40.83 Favored Glycine 0 N--CA 1.495 2.571 0 C-N-CA 118.412 -1.851 . . . . 1.0 111.583 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.657 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -101.15 109.19 21.03 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 108.909 -0.774 . . . . 1.0 108.909 -179.908 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.492 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.0 m -130.14 149.06 52.02 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.277 -0.89 . . . . 1.0 109.682 179.585 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.525 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.54 138.72 54.51 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.236 -0.915 . . . . 1.0 110.793 -178.93 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.2 114.77 26.6 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 107.532 -1.284 . . . . 1.0 107.532 178.047 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 m -104.85 14.72 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.931 -1.106 . . . . 1.0 110.481 -178.793 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.75 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.1 -175.24 0.09 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.98 -1.075 . . . . 1.0 110.049 179.748 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.51 97.79 2.17 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.519 -0.738 . . . . 1.0 109.577 -179.75 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.46 27.75 31.94 Favored Glycine 0 N--CA 1.492 2.414 0 C-N-CA 120.214 -0.993 . . . . 1.0 111.399 178.94 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.75 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.22 106.48 20.18 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.558 -1.554 . . . . 1.0 107.357 178.81 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.4 104.72 11.74 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.475 -1.391 . . . . 1.0 109.954 -177.629 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.007 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.65 109.53 22.27 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 107.812 -1.181 . . . . 1.0 107.812 178.871 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -108.05 166.74 10.5 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.869 -1.145 . . . . 1.0 110.727 -178.455 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.487 ' OD1' ' HB2' ' A' ' 74' ' ' GLU . 46.4 t30 -118.51 136.72 24.2 Favored Pre-proline 0 N--CA 1.498 1.971 0 C-N-CA 120.098 -0.641 . . . . 1.0 109.64 -179.497 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HD3' ' CE1' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -74.03 26.41 0.33 Allowed 'Trans proline' 0 C--N 1.317 -1.111 0 C-N-CA 122.437 2.092 . . . . 1.0 112.01 -179.89 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.447 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -98.54 -9.55 24.78 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.319 -1.488 . . . . 1.0 109.164 179.735 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.801 ' HB3' HD22 ' A' ' 67' ' ' LEU . 0.8 OUTLIER -135.68 7.4 3.26 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.383 -0.823 . . . . 1.0 108.872 -179.81 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -60.75 84.1 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.427 -0.796 . . . . 1.0 110.898 -178.569 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.63 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.78 -167.02 1.17 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.852 -1.166 . . . . 1.0 107.852 178.33 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.477 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.7 t 179.1 135.25 0.09 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.569 -1.332 . . . . 1.0 111.43 -179.364 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.789 HG11 ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -150.46 157.77 5.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 N-CA-C 107.537 -1.283 . . . . 1.0 107.537 177.914 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.63 142.1 30.63 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.734 -1.229 . . . . 1.0 110.051 -179.747 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.021 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.36 107.68 1.41 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 122.331 1.062 . . . . 1.0 109.38 178.524 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.558 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.6 p-10 -62.04 -138.81 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 115.612 -0.722 . . . . 1.0 110.861 -179.778 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.585 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.87 -51.82 37.5 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.344 -0.847 . . . . 1.0 110.737 -178.599 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -104.57 -32.91 8.72 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 106.261 -1.755 . . . . 1.0 106.261 178.508 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.988 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.57 69.88 0.67 Allowed Glycine 0 C--N 1.298 -1.574 0 N-CA-C 110.299 -1.12 . . . . 1.0 110.299 178.104 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.617 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 63.7 m -104.07 129.98 51.75 Favored 'General case' 0 N--CA 1.483 1.175 0 O-C-N 121.259 -1.142 . . . . 1.0 109.275 179.14 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.789 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.4 108.96 8.46 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.535 -0.866 . . . . 1.0 109.484 -179.638 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 97.2 p -116.21 117.02 28.87 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.117 -0.989 . . . . 1.0 109.492 -179.747 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.61 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.27 139.93 26.13 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.385 -0.822 . . . . 1.0 110.077 -179.84 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 27.2 p -99.61 135.26 41.29 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.822 -0.807 . . . . 1.0 108.822 179.432 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.94 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -136.22 168.52 19.24 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.292 -0.88 . . . . 1.0 110.057 -178.931 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.858 HG22 HG22 ' A' ' 18' ' ' VAL . 1.2 p -104.06 126.26 51.04 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.192 -0.942 . . . . 1.0 109.329 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.735 HG13 ' OD2' ' A' ' 51' ' ' ASP . 12.3 m -129.41 139.99 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 120.922 -1.111 . . . . 1.0 110.209 -179.26 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.521 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 52.4 mtt180 -125.67 -168.57 1.86 Allowed 'General case' 0 N--CA 1.484 1.23 0 O-C-N 120.676 -1.265 . . . . 1.0 111.304 179.823 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.588 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 40.0 mtt180 -78.5 -75.71 0.22 Allowed 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.2 -1.037 . . . . 1.0 108.2 179.284 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -72.67 137.06 45.79 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 120.14 -1.6 . . . . 1.0 106.812 178.107 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -157.66 135.51 10.73 Favored 'General case' 0 C--N 1.295 -1.784 0 C-N-CA 118.08 -1.448 . . . . 1.0 110.308 -177.903 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.601 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 9.5 mm-40 -34.78 121.62 0.52 Allowed 'General case' 0 N--CA 1.487 1.41 0 CA-C-O 121.582 0.706 . . . . 1.0 110.364 -178.259 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.007 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -87.76 47.94 3.64 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 110.986 -0.846 . . . . 1.0 110.986 -179.377 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.601 ' CE1' ' HB3' ' A' ' 74' ' ' GLU . 36.2 m-85 -39.76 112.95 0.3 Allowed 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.07 -1.253 . . . . 1.0 110.001 179.614 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.738 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -87.03 126.64 34.88 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.995 -1.066 . . . . 1.0 109.493 -179.912 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.594 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.3 t80 -63.99 58.34 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.735 -1.228 . . . . 1.0 110.315 179.674 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.26 19.15 0.15 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.01 -1.056 . . . . 1.0 109.765 179.854 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.31 -26.18 5.81 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.097 -1.201 . . . . 1.0 110.097 179.78 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -94.07 160.0 14.91 Favored 'General case' 0 N--CA 1.485 1.311 0 O-C-N 121.011 -1.288 . . . . 1.0 110.49 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.476 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -105.89 133.39 50.69 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 108.581 -0.896 . . . . 1.0 108.581 179.701 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.738 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.1 t90 -80.93 -20.28 42.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.809 -1.182 . . . . 1.0 110.256 -178.701 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.92 174.19 18.62 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.9 -1.68 . . . . 1.0 108.9 -179.59 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.06 110.04 1.69 Allowed 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.143 -1.21 . . . . 1.0 107.743 179.269 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.678 HG21 ' HB3' ' A' ' 46' ' ' ALA . 44.4 t -82.32 104.45 10.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.696 0 N-CA-C 108.715 -0.846 . . . . 1.0 108.715 -179.098 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.529 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -67.11 111.07 3.69 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.322 -0.861 . . . . 1.0 109.893 -179.119 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.588 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -64.04 -5.23 4.33 Favored 'General case' 0 N--CA 1.501 2.083 0 C-N-CA 118.465 -1.294 . . . . 1.0 109.869 179.394 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -86.69 2.04 49.92 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.757 -1.214 . . . . 1.0 108.923 179.363 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.529 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -117.05 -51.11 2.56 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.478 -0.764 . . . . 1.0 108.967 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -102.57 -179.92 4.11 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.498 -0.751 . . . . 1.0 109.381 179.883 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.84 115.25 29.98 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.349 -0.845 . . . . 1.0 108.979 179.923 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.56 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.88 122.25 39.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.807 -1.183 . . . . 1.0 109.464 -179.278 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.618 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -101.75 145.35 29.26 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 122.449 1.119 . . . . 1.0 111.184 -179.3 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.614 ' HB ' HG11 ' A' ' 7' ' ' VAL . 65.2 t -102.68 110.59 29.76 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 N-CA-C 106.892 -1.521 . . . . 1.0 106.892 177.815 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.491 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.11 -169.63 18.47 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 118.177 -1.963 . . . . 1.0 111.75 -177.712 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.52 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -120.02 177.06 5.13 Favored 'General case' 0 N--CA 1.489 1.485 0 CA-C-O 121.69 0.757 . . . . 1.0 109.113 -178.931 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.581 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -168.84 173.45 7.1 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 109.276 -0.639 . . . . 1.0 109.276 179.801 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.583 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -116.06 -159.92 0.74 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.103 -0.998 . . . . 1.0 108.86 179.662 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.407 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.2 36.44 4.23 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.674 -1.266 . . . . 1.0 109.152 -179.95 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -115.17 -32.67 5.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.404 -0.81 . . . . 1.0 110.173 -179.724 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.952 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 164.68 -35.53 0.28 Allowed Glycine 0 N--CA 1.481 1.677 0 N-CA-C 107.703 -2.159 . . . . 1.0 107.703 -179.573 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.31 -178.08 6.69 Favored 'General case' 0 C--N 1.305 -1.326 0 O-C-N 121.554 -0.968 . . . . 1.0 109.749 179.322 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.35 -161.31 18.01 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.326 -1.91 . . . . 1.0 108.326 -179.293 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.487 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.4 Cg_exo -47.33 179.82 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 CA-C-N 118.783 1.292 . . . . 1.0 110.368 179.322 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -95.59 -170.82 2.23 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.053 -1.029 . . . . 1.0 110.236 -179.075 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.491 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -125.37 164.53 18.91 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.693 -1.363 . . . . 1.0 109.693 -179.846 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.56 128.55 49.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 O-C-N 121.436 -1.038 . . . . 1.0 109.103 -179.535 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.618 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.56 120.91 19.81 Favored 'General case' 0 C--N 1.289 -2.036 0 O-C-N 121.735 -0.603 . . . . 1.0 109.835 179.957 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.683 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.4 pt -98.03 168.11 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.315 -0.866 . . . . 1.0 109.037 179.722 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.489 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -134.98 158.6 43.9 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.305 -0.872 . . . . 1.0 109.428 179.976 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.548 ' CE2' HD12 ' A' ' 110' ' ' ILE . 42.2 m-85 -132.33 119.62 20.99 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.191 -0.943 . . . . 1.0 109.392 -179.786 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 23.7 p30 . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.172 -0.955 . . . . 1.0 109.423 179.954 . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.952 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.328 0.585 . . . . 1.0 109.481 . . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.564 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -101.24 160.75 25.72 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.225 -0.922 . . . . 1.0 109.496 179.956 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.591 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 2.4 Cg_endo -61.79 155.22 55.66 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 C-N-CA 122.185 1.924 . . . . 1.0 110.556 -179.99 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.636 HG23 ' HB3' ' A' ' 24' ' ' ALA . 0.0 OUTLIER 179.85 -169.6 0.13 Allowed 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 108.055 -1.091 . . . . 1.0 108.055 179.063 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.557 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -167.82 132.54 1.82 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.655 -1.278 . . . . 1.0 111.098 -179.412 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.023 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -99.7 104.3 16.02 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 122.353 1.073 . . . . 1.0 109.918 -179.965 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.945 HG22 HG23 ' A' ' 21' ' ' VAL . 4.0 t -121.6 117.1 51.5 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-O 121.603 0.716 . . . . 1.0 110.341 179.587 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.518 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -165.94 150.04 7.21 Favored Pre-proline 0 N--CA 1.487 1.41 0 N-CA-C 108.213 -1.032 . . . . 1.0 108.213 -179.646 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.518 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.8 Cg_endo -77.72 151.76 92.04 Favored 'Cis proline' 0 C--N 1.31 -1.463 0 C-N-CA 123.608 -1.413 . . . . 1.0 109.512 -0.615 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.712 ' HA ' HG22 ' A' ' 110' ' ' ILE . 85.7 p -92.85 -25.66 18.0 Favored 'General case' 0 C--N 1.293 -1.857 0 O-C-N 121.435 -0.791 . . . . 1.0 108.895 179.42 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 111' ' ' SER . 3.0 m -131.9 161.37 33.2 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.455 -0.778 . . . . 1.0 109.413 -179.912 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.59 36.55 33.19 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 108.627 -1.789 . . . . 1.0 108.627 -179.566 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.772 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.6 mt -91.19 -42.69 10.29 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.298 1.523 . . . . 1.0 110.37 -178.505 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.5 143.62 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.284 0 CA-C-N 113.292 -1.776 . . . . 1.0 109.809 -179.585 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.602 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.1 p-10 -50.76 105.59 0.1 Allowed 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.596 0.712 . . . . 1.0 111.31 -178.655 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.47 13.64 8.02 Favored Glycine 0 N--CA 1.485 1.945 0 C-N-CA 119.316 -1.421 . . . . 1.0 113.041 177.497 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.772 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -104.8 -171.96 2.01 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 121.28 2.54 . . . . 1.0 109.755 179.28 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.739 HG13 ' C ' ' A' ' 67' ' ' LEU . 14.9 t -130.11 138.51 53.8 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.345 0 CA-C-N 114.857 -1.065 . . . . 1.0 111.261 -178.855 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.537 HG11 HD11 ' A' ' 13' ' ' LEU . 34.1 m -115.85 154.82 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.585 -0.894 . . . . 1.0 108.585 178.888 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.559 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -109.19 109.18 20.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.121 -0.987 . . . . 1.0 109.35 -179.903 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.945 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.4 123.16 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 108.357 -0.979 . . . . 1.0 108.357 179.67 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.023 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -120.85 167.24 12.73 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 120.721 -1.237 . . . . 1.0 109.386 -179.744 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -131.24 144.33 15.86 Favored Glycine 0 C--N 1.295 -1.723 0 N-CA-C 107.711 -2.155 . . . . 1.0 107.711 179.691 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.636 ' HB3' HG23 ' A' ' 4' ' ' THR . . . -148.18 123.19 10.08 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 120.96 -1.317 . . . . 1.0 108.532 179.105 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.481 ' CA ' ' HA ' ' A' ' 3' ' ' PRO . . . 90.66 27.95 17.98 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.269 -1.443 . . . . 1.0 109.722 -179.464 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.539 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.0 OUTLIER -90.52 175.37 7.09 Favored 'General case' 0 C--N 1.308 -1.213 0 O-C-N 120.832 -1.393 . . . . 1.0 108.602 179.947 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.012 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -48.6 100.4 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.903 -1.123 . . . . 1.0 109.859 -179.817 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.43 78.57 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.679 0 CA-C-N 115.355 -0.839 . . . . 1.0 110.116 -179.375 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.573 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.81 34.44 0.3 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.283 -1.527 . . . . 1.0 109.283 179.711 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.548 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 21.4 p -139.75 105.69 5.19 Favored 'General case' 0 C--N 1.307 -1.252 0 O-C-N 121.185 -1.185 . . . . 1.0 111.155 -179.381 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.584 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.47 109.8 0.28 Allowed 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.579 -0.526 . . . . 1.0 109.579 178.057 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.491 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 8.4 m-85 -104.34 153.23 21.3 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.055 -1.028 . . . . 1.0 108.994 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.435 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.2 155.35 18.49 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.859 -1.15 . . . . 1.0 108.246 179.054 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.728 HG23 HD23 ' A' ' 97' ' ' LEU . 0.8 OUTLIER -126.91 127.89 70.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.228 -0.92 . . . . 1.0 108.973 -178.079 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -175.6 174.36 46.8 Favored Glycine 0 N--CA 1.495 2.581 0 C-N-CA 117.726 -2.178 . . . . 1.0 112.342 -179.926 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.606 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -101.09 108.84 20.63 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 107.964 -1.124 . . . . 1.0 107.964 179.577 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.461 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.0 m -129.67 147.87 51.5 Favored 'General case' 0 C--N 1.294 -1.81 0 O-C-N 121.212 -0.93 . . . . 1.0 109.969 -179.654 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.44 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.58 139.13 54.26 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.362 -0.837 . . . . 1.0 110.523 -179.133 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.876 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.08 114.72 26.56 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.411 -1.329 . . . . 1.0 107.411 178.282 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -106.11 15.35 7.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.051 -1.031 . . . . 1.0 110.541 -178.614 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.77 -175.99 0.09 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.931 -1.106 . . . . 1.0 110.02 179.761 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.79 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.29 97.09 1.19 Allowed 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.782 0.801 . . . . 1.0 109.993 -179.631 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.56 28.23 36.43 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 120.278 -0.963 . . . . 1.0 111.413 178.856 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.18 106.27 20.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 O-C-N 120.623 -1.516 . . . . 1.0 107.186 178.846 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.876 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.88 104.77 11.64 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.463 -1.398 . . . . 1.0 109.869 -177.614 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.044 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.782 -1.199 . . . . 1.0 108.219 178.815 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.0 t -106.35 164.85 11.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.945 -1.097 . . . . 1.0 110.288 -178.897 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.749 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 8.9 t-20 -107.52 134.29 20.05 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.386 -0.821 . . . . 1.0 109.648 -179.301 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.593 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.3 Cg_endo -74.96 22.88 0.41 Allowed 'Trans proline' 0 CA--C 1.544 0.998 0 C-N-CA 122.327 2.018 . . . . 1.0 111.811 -179.813 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.749 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -115.82 7.04 14.46 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.398 -1.439 . . . . 1.0 108.912 179.534 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.546 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.99 15.16 2.86 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.385 -1.339 . . . . 1.0 107.385 179.522 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -78.3 88.19 4.34 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.984 -0.686 . . . . 1.0 111.522 -178.132 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' HG12 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -97.97 -167.49 1.52 Allowed 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.718 -1.215 . . . . 1.0 107.718 177.941 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.445 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.93 135.99 0.09 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.565 -1.335 . . . . 1.0 111.542 -179.331 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.953 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -163.47 154.19 2.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 107.526 -1.287 . . . . 1.0 107.526 178.419 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.584 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.6 141.92 30.83 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.833 -1.167 . . . . 1.0 109.59 -179.945 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -61.82 105.69 0.59 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 122.493 1.139 . . . . 1.0 109.281 178.541 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.552 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.8 p-10 -58.55 -138.63 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.982 0 CA-C-N 115.443 -0.799 . . . . 1.0 110.966 -179.862 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -53.79 -49.4 68.37 Favored 'General case' 0 N--CA 1.5 2.042 0 CA-C-O 121.675 0.75 . . . . 1.0 110.409 -178.672 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 74.7 m-80 -102.38 -37.29 8.11 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 106.066 -1.827 . . . . 1.0 106.066 178.382 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.986 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 110.16 65.84 0.55 Allowed Glycine 0 C--N 1.297 -1.596 0 CA-C-N 114.774 -1.103 . . . . 1.0 110.438 177.964 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.609 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.7 m -104.43 127.3 52.09 Favored 'General case' 0 N--CA 1.483 1.179 0 O-C-N 121.563 -0.963 . . . . 1.0 109.07 179.05 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.953 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.54 109.02 7.38 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 119.519 -0.872 . . . . 1.0 109.764 -179.443 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 53.3 p -115.3 119.57 36.74 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.105 -0.997 . . . . 1.0 109.373 179.97 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.5 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.33 142.21 30.25 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.48 -0.762 . . . . 1.0 109.844 179.935 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 54.8 p -99.44 149.02 23.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.414 -0.803 . . . . 1.0 109.156 179.751 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.739 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -149.87 163.71 37.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.265 -0.897 . . . . 1.0 109.763 -178.93 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.71 HG22 HG22 ' A' ' 18' ' ' VAL . 2.5 p -96.57 126.1 41.51 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.125 -0.984 . . . . 1.0 109.259 -179.987 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.547 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.0 m -137.44 143.19 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 120.904 -1.123 . . . . 1.0 109.856 -179.102 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.602 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.9 ptt180 -147.3 -176.51 5.26 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.519 -1.363 . . . . 1.0 111.081 -179.774 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.596 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.04 -100.19 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 109.155 -0.683 . . . . 1.0 109.155 -179.714 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.52 139.97 51.96 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.779 -1.201 . . . . 1.0 107.801 179.208 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -162.45 138.79 7.62 Favored 'General case' 0 C--N 1.293 -1.89 0 C-N-CA 118.525 -1.27 . . . . 1.0 110.074 -177.819 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.564 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.8 mm-40 -34.7 120.82 0.5 Allowed 'General case' 0 N--CA 1.491 1.6 0 CA-C-O 121.395 0.617 . . . . 1.0 110.246 -178.713 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.044 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.18 50.8 1.9 Allowed Glycine 0 N--CA 1.492 2.402 0 C-N-CA 120.477 -0.868 . . . . 1.0 111.136 -179.101 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.593 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-30 -39.39 113.35 0.32 Allowed 'General case' 0 N--CA 1.507 2.424 0 O-C-N 121.057 -1.26 . . . . 1.0 109.916 179.488 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.643 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -85.73 126.78 34.23 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.835 -1.166 . . . . 1.0 109.504 -179.915 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.585 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 30.7 t80 -64.36 58.23 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.018 0 O-C-N 120.859 -1.151 . . . . 1.0 110.104 179.764 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -160.05 19.49 0.16 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.019 -1.051 . . . . 1.0 109.674 179.905 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.38 -26.71 5.52 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.154 -1.178 . . . . 1.0 110.154 179.856 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.451 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -94.27 154.81 17.33 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.06 -1.259 . . . . 1.0 110.42 -179.431 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.479 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -102.11 134.54 45.19 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.176 -1.046 . . . . 1.0 108.176 179.476 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.643 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.2 t90 -81.49 -16.6 51.41 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.784 -1.197 . . . . 1.0 110.506 -178.34 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 108.17 175.52 22.04 Favored Glycine 0 N--CA 1.485 1.921 0 N-CA-C 108.768 -1.733 . . . . 1.0 108.768 -179.675 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.44 104.32 0.61 Allowed 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 107.615 -1.254 . . . . 1.0 107.615 179.07 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.615 HG21 ' HB3' ' A' ' 46' ' ' ALA . 38.1 t -76.03 106.37 5.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.316 -0.865 . . . . 1.0 109.059 -178.862 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.37 110.65 2.33 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.507 -0.746 . . . . 1.0 109.835 -179.268 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.596 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.61 -5.08 4.88 Favored 'General case' 0 N--CA 1.498 1.938 0 C-N-CA 118.261 -1.375 . . . . 1.0 109.752 179.357 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.5 p -85.57 -1.44 57.11 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.806 -1.184 . . . . 1.0 109.216 179.606 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.81 -48.36 3.07 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.299 -0.875 . . . . 1.0 109.051 -179.984 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.31 -178.57 3.64 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.57 -0.706 . . . . 1.0 109.491 179.905 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.46 115.36 30.12 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.429 -0.794 . . . . 1.0 109.096 -179.956 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.76 120.99 38.12 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.894 -1.129 . . . . 1.0 109.239 -179.514 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.61 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -99.26 145.54 27.16 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 122.328 1.061 . . . . 1.0 111.105 -179.338 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.545 ' HB ' HG11 ' A' ' 7' ' ' VAL . 97.5 t -103.21 110.51 29.97 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 106.958 -1.497 . . . . 1.0 106.958 177.858 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.544 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -154.09 -169.68 19.2 Favored Glycine 0 N--CA 1.486 1.996 0 C-N-CA 118.173 -1.965 . . . . 1.0 111.579 -177.635 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.728 HD23 HG23 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -117.87 173.92 6.48 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 108.532 -0.914 . . . . 1.0 108.532 -179.506 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.596 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 7.3 t 176.13 163.93 0.38 Allowed 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 109.235 -0.654 . . . . 1.0 109.235 -179.808 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.491 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -108.61 -160.84 0.74 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.923 -1.111 . . . . 1.0 109.092 -179.997 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -118.03 36.49 4.31 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.705 -1.247 . . . . 1.0 109.167 -179.954 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -110.18 -30.32 7.79 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.37 -0.831 . . . . 1.0 109.809 -179.713 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . 170.79 -38.45 0.18 Allowed Glycine 0 N--CA 1.482 1.757 0 N-CA-C 108.115 -1.994 . . . . 1.0 108.115 -179.82 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -172.61 -176.69 1.56 Allowed 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.526 -0.985 . . . . 1.0 109.715 179.467 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.23 -160.8 16.73 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.159 -1.976 . . . . 1.0 108.159 -179.383 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -46.84 176.41 0.01 OUTLIER 'Trans proline' 0 C--N 1.326 -0.656 0 CA-C-N 118.973 1.386 . . . . 1.0 109.998 179.127 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -95.21 -176.88 3.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.027 -1.046 . . . . 1.0 110.376 -178.814 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.544 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.62 167.19 13.38 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.741 -1.343 . . . . 1.0 109.741 -179.963 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -101.55 129.55 52.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.417 -1.049 . . . . 1.0 109.143 -179.381 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.61 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -68.91 115.86 8.72 Favored 'General case' 0 C--N 1.289 -2.041 0 N-CA-C 109.47 -0.567 . . . . 1.0 109.47 179.474 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.827 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.8 pt -97.8 168.49 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.262 -0.899 . . . . 1.0 108.59 179.857 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.422 ' O ' ' HA ' ' A' ' 11' ' ' SER . 2.8 t -142.36 158.49 43.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.022 -1.049 . . . . 1.0 110.302 -179.375 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.827 ' CE1' HD12 ' A' ' 110' ' ' ILE . 84.8 m-85 -133.67 98.86 4.31 Favored 'General case' 0 N--CA 1.484 1.259 0 O-C-N 121.374 -0.829 . . . . 1.0 109.324 -179.856 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 20.0 p30 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 118.033 -0.984 . . . . 1.0 109.517 -179.935 . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.864 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 121.319 0.58 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 033 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.783 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -110.65 167.82 8.5 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.218 -0.926 . . . . 0.0 109.503 -179.99 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.783 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 3.3 Cg_exo -60.82 157.49 37.79 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.256 1.971 . . . . 0.0 110.464 -179.936 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.672 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.1 p -159.68 160.14 33.81 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 -179.309 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.483 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.82 121.97 9.53 Favored 'General case' 0 C--N 1.296 -1.73 0 CA-C-O 122.333 1.063 . . . . 0.0 110.388 -179.672 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.755 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.3 t -114.54 109.35 18.13 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 123.01 1.386 . . . . 0.0 109.768 -179.929 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.83 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -115.58 139.03 44.0 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.721 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.763 179.913 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.51 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -172.42 150.71 2.31 Favored Pre-proline 0 N--CA 1.487 1.403 0 O-C-N 121.154 -0.966 . . . . 0.0 108.948 -179.533 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.51 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.1 Cg_endo -75.38 152.77 98.03 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.498 -1.459 . . . . 0.0 109.533 -0.674 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.641 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.5 m -89.89 -25.42 20.99 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.763 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.494 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.5 m -136.83 166.43 23.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.483 -0.76 . . . . 0.0 109.435 179.935 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.28 37.72 35.99 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.522 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.837 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.9 mt -92.77 -44.68 8.39 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 123.153 1.454 . . . . 0.0 110.767 -178.272 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.84 145.56 0.03 OUTLIER 'General case' 0 C--N 1.258 -3.392 0 CA-C-N 113.721 -1.581 . . . . 0.0 110.045 -179.819 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.593 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.6 p-10 -50.64 108.34 0.23 Allowed 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 121.562 0.696 . . . . 0.0 111.727 -178.678 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.06 15.56 9.82 Favored Glycine 0 N--CA 1.484 1.895 0 C-N-CA 119.619 -1.277 . . . . 0.0 112.78 177.263 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.837 HG21 ' CA ' ' A' ' 13' ' ' LEU . 8.8 t -103.56 -173.12 2.24 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 121.056 2.428 . . . . 0.0 109.839 179.348 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.77 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.9 t -126.8 135.71 62.91 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.944 -178.771 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.549 HG13 ' CG2' ' A' ' 69' ' ' VAL . 27.4 m -112.37 154.75 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 O-C-N 121.348 -0.845 . . . . 0.0 108.883 178.789 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.517 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -111.24 109.43 19.45 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.219 -0.926 . . . . 0.0 108.987 179.947 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.83 HG23 HG22 ' A' ' 7' ' ' VAL . 2.2 p -105.11 140.2 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -179.972 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.755 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.43 161.39 36.47 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.793 -1.192 . . . . 0.0 110.004 179.583 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -134.54 140.44 11.74 Favored Glycine 0 C--N 1.299 -1.518 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 179.793 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.583 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -141.74 127.04 18.66 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.563 -1.551 . . . . 0.0 109.489 179.294 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.489 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 87.47 29.26 22.35 Favored Glycine 0 N--CA 1.488 2.16 0 C-N-CA 118.915 -1.612 . . . . 0.0 109.681 -179.821 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.551 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.9 mt -89.08 173.21 8.57 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.006 -1.291 . . . . 0.0 108.334 -179.85 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.022 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.21 98.85 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.015 -1.053 . . . . 0.0 109.797 -179.715 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.549 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.38 77.02 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.251 -179.199 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.05 33.35 0.28 Allowed Glycine 0 N--CA 1.486 1.991 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.533 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.55 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.7 p -142.81 110.57 5.87 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 120.981 -1.306 . . . . 0.0 111.028 -179.832 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.588 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.95 112.68 0.65 Allowed 'General case' 0 N--CA 1.495 1.814 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.99 178.366 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.504 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 21.6 m-85 -101.33 155.3 18.12 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.127 -0.983 . . . . 0.0 108.88 179.665 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.517 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -102.7 150.19 23.7 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.862 -1.149 . . . . 0.0 108.205 179.014 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.71 ' CG1' HD21 ' A' ' 67' ' ' LEU . 1.1 t -126.34 129.97 71.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.117 -0.989 . . . . 0.0 109.121 -178.074 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.47 ' O ' ' H29' ' A' ' 114' ' ' CHR . . . -178.56 172.67 45.06 Favored Glycine 0 N--CA 1.495 2.573 0 C-N-CA 117.812 -2.137 . . . . 0.0 112.201 179.866 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.609 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -101.02 109.1 20.97 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.364 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.1 m -130.05 148.93 51.96 Favored 'General case' 0 C--N 1.295 -1.765 0 O-C-N 120.96 -1.087 . . . . 0.0 110.27 -179.496 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.52 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.54 138.34 54.34 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.364 -0.835 . . . . 0.0 110.537 -179.307 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.34 114.79 26.61 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 178.249 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.5 m -104.46 14.57 6.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.069 -1.02 . . . . 0.0 110.518 -178.915 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.763 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.55 -175.0 0.08 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.902 -1.124 . . . . 0.0 109.974 179.702 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -73.6 98.79 2.91 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.441 -0.787 . . . . 0.0 109.539 -179.814 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.99 27.62 30.86 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 120.161 -1.018 . . . . 0.0 111.362 179.09 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.763 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -118.11 105.99 18.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 O-C-N 120.597 -1.531 . . . . 0.0 107.231 178.967 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.6 tp -118.12 104.73 11.11 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 120.496 -1.378 . . . . 0.0 109.917 -177.801 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.013 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.64 109.33 22.11 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.729 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -105.64 165.87 10.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.915 -1.116 . . . . 0.0 110.674 -178.479 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.504 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 7.8 t30 -110.32 130.25 23.07 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 121.601 -0.687 . . . . 0.0 109.247 -179.486 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -71.59 23.28 0.24 Allowed 'Trans proline' 0 CA--C 1.545 1.055 0 C-N-CA 122.054 1.836 . . . . 0.0 111.804 179.623 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.504 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -103.32 -3.07 26.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.448 -1.408 . . . . 0.0 109.074 179.641 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.863 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.6 m-20 -134.93 10.41 3.6 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.943 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -63.34 81.99 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.251 -178.905 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.648 ' HB2' HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.34 -169.57 1.82 Allowed 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.096 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.435 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.1 t 179.27 132.94 0.09 Allowed 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.865 -1.147 . . . . 0.0 111.126 -179.532 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.855 HG11 ' HB1' ' A' ' 63' ' ' ALA . 1.1 p -156.32 152.61 8.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 178.367 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.588 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.91 142.29 29.83 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.696 -1.253 . . . . 0.0 109.872 -179.64 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.022 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.02 106.11 0.78 Allowed 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.447 1.117 . . . . 0.0 109.497 178.792 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.6 p-10 -57.92 -139.22 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.727 -179.978 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.549 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -55.13 -49.27 72.2 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.331 -0.856 . . . . 0.0 110.093 -178.95 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.7 p-10 -100.22 -39.03 8.25 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 178.482 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.978 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.94 66.36 0.58 Allowed Glycine 0 C--N 1.297 -1.619 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 178.288 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.584 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.0 m -101.48 129.81 47.61 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 121.601 -0.941 . . . . 0.0 109.056 179.103 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.855 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -138.13 108.95 6.66 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 119.31 -0.956 . . . . 0.0 109.498 -179.554 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.7 m -126.0 120.92 31.58 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.205 -0.934 . . . . 0.0 109.627 -179.774 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.08 144.78 30.24 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.482 -0.761 . . . . 0.0 109.391 179.871 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.437 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 32.1 p -98.83 141.12 32.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.368 -0.832 . . . . 0.0 109.115 179.894 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.863 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -140.56 174.69 10.27 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.333 -0.854 . . . . 0.0 109.65 -178.818 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.528 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -102.34 122.37 44.11 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.019 -1.051 . . . . 0.0 109.622 -179.751 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.671 HG13 ' OD2' ' A' ' 51' ' ' ASP . 16.9 m -133.47 143.17 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 120.911 -1.118 . . . . 0.0 110.159 -179.411 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.593 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.0 ptt180 -142.68 -166.87 2.38 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.663 -1.273 . . . . 0.0 110.09 179.568 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.565 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -72.32 -85.91 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.321 -0.862 . . . . 0.0 108.841 -179.575 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.62 138.81 58.58 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.291 -1.506 . . . . 0.0 107.362 178.799 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -164.48 139.08 5.49 Favored 'General case' 0 C--N 1.294 -1.82 0 C-N-CA 117.982 -1.487 . . . . 0.0 110.542 -177.496 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.507 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.6 mm-40 -34.09 120.55 0.44 Allowed 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.47 0.653 . . . . 0.0 110.612 -178.625 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.013 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.15 50.57 1.91 Allowed Glycine 0 N--CA 1.494 2.563 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.226 -179.418 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-85 -41.05 114.18 0.46 Allowed 'General case' 0 N--CA 1.508 2.45 0 O-C-N 120.868 -1.372 . . . . 0.0 109.964 179.453 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.637 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.3 tp -84.32 126.92 33.64 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.742 -1.224 . . . . 0.0 109.624 -179.951 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.592 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 26.4 t80 -64.05 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.812 -1.18 . . . . 0.0 110.275 179.688 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' LEU . 8.7 t0 -161.35 20.0 0.12 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.944 -1.098 . . . . 0.0 109.806 179.731 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.19 -26.88 5.31 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 110.041 -1.223 . . . . 0.0 110.041 179.963 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.475 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 5.9 p -92.38 152.78 19.56 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.056 -1.261 . . . . 0.0 110.386 -179.442 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.515 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 5.4 ptt180 -101.93 133.06 47.32 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.597 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.637 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -81.24 -20.96 39.9 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 120.713 -1.242 . . . . 0.0 110.527 -178.269 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.88 176.04 20.45 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 108.725 -1.75 . . . . 0.0 108.725 -179.629 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.49 109.42 1.37 Allowed 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 179.148 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.591 HG21 ' HB3' ' A' ' 46' ' ' ALA . 31.1 t -81.83 105.74 12.05 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 121.341 -0.849 . . . . 0.0 108.94 -178.934 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.651 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -65.3 111.82 3.19 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.446 -0.783 . . . . 0.0 109.845 -179.357 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.549 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.56 -5.09 7.13 Favored 'General case' 0 N--CA 1.499 1.984 0 C-N-CA 118.285 -1.366 . . . . 0.0 109.648 179.369 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 p -83.76 -2.18 55.74 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.876 -1.14 . . . . 0.0 108.901 179.318 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.651 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.98 -49.81 2.95 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.347 -0.846 . . . . 0.0 109.013 -179.998 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.62 -178.34 3.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.551 -0.718 . . . . 0.0 109.517 179.919 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.3 116.29 31.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.43 -0.794 . . . . 0.0 108.99 -179.971 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.568 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.1 m -96.88 124.21 40.8 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.814 -1.179 . . . . 0.0 109.747 -179.168 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.614 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.0 147.32 26.71 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 122.33 1.062 . . . . 0.0 111.202 -179.44 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.527 ' CG1' HG11 ' A' ' 7' ' ' VAL . 43.8 t -104.75 111.53 34.65 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.567 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.496 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.35 -169.81 17.47 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 117.906 -2.092 . . . . 0.0 111.845 -177.481 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.494 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.57 -179.07 3.57 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -179.094 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.586 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.0 OUTLIER -171.34 173.55 4.81 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.277 -0.889 . . . . 0.0 109.438 -179.73 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.413 ' OD1' ' C ' ' A' ' 99' ' ' ASP . 0.6 OUTLIER -118.43 -160.38 0.79 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.078 -1.014 . . . . 0.0 108.993 179.937 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -118.91 35.5 4.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.673 -1.267 . . . . 0.0 109.347 -179.824 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.78 -32.55 4.49 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.403 -0.811 . . . . 0.0 110.239 -179.542 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 1.018 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 168.32 -37.56 0.21 Allowed Glycine 0 N--CA 1.481 1.658 0 N-CA-C 107.676 -2.17 . . . . 0.0 107.676 -179.493 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.55 -178.16 6.91 Favored 'General case' 0 C--N 1.306 -1.296 0 O-C-N 121.534 -0.98 . . . . 0.0 109.671 179.253 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.5 -162.04 17.06 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 108.356 -1.897 . . . . 0.0 108.356 -179.494 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' CD ' ' CE1' ' A' ' 32' ' ' TYR . 6.8 Cg_exo -46.12 174.16 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 CA-C-N 118.784 1.292 . . . . 0.0 110.022 179.387 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -92.82 -177.69 4.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.107 -0.996 . . . . 0.0 110.528 -178.588 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.496 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.8 167.44 13.1 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.946 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -104.06 131.19 53.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 O-C-N 121.325 -1.103 . . . . 0.0 109.095 -179.269 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.614 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.99 122.63 22.03 Favored 'General case' 0 C--N 1.29 -2.001 0 O-C-N 121.612 -0.68 . . . . 0.0 109.529 179.707 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.848 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.72 169.84 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 O-C-N 121.225 -0.922 . . . . 0.0 109.226 -179.982 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.494 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -135.48 155.33 50.7 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.233 -0.917 . . . . 0.0 109.721 -179.753 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.848 ' CE2' HD12 ' A' ' 110' ' ' ILE . 74.9 m-85 -131.19 109.28 10.31 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.767 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.2 p30 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 117.98 -1.01 . . . . 0.0 109.443 179.99 . . . . . . . . 0 0 . 1 . 033 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 1.018 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.489 0 CA-C-O 121.316 0.579 . . . . 0.0 109.459 . . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -119.88 152.84 54.44 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.181 -0.949 . . . . 0.0 109.524 179.969 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.701 ' HB3' HD23 ' A' ' 26' ' ' LEU . 2.7 Cg_endo -61.33 156.03 48.45 Favored 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.343 2.029 . . . . 0.0 110.514 -179.941 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.602 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -146.75 161.56 40.37 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 -179.739 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -146.9 128.92 15.51 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-O 122.475 1.131 . . . . 0.0 110.618 -179.725 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.006 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.8 p -106.89 104.95 14.75 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-O 122.503 1.144 . . . . 0.0 110.331 -179.43 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.955 HG22 HG23 ' A' ' 21' ' ' VAL . 10.6 t -117.25 119.16 61.02 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.478 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.303 179.582 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.501 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.61 148.38 12.67 Favored Pre-proline 0 N--CA 1.487 1.415 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -179.602 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.501 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.49 152.85 97.95 Favored 'Cis proline' 0 C--N 1.31 -1.497 0 C-N-CA 123.603 -1.415 . . . . 0.0 109.728 -0.445 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.7 m -92.53 -24.94 18.6 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.505 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.517 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 1.2 m -136.53 166.05 24.43 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.656 -0.652 . . . . 0.0 109.351 179.847 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.39 37.98 39.95 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 -179.723 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.786 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.6 mt -91.7 -43.34 9.64 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 123.344 1.545 . . . . 0.0 110.649 -178.31 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.472 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.02 144.43 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.376 -1.738 . . . . 0.0 109.853 -179.653 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.611 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 6.1 p-10 -51.13 107.78 0.2 Allowed 'General case' 0 C--N 1.302 -1.492 0 CA-C-O 121.586 0.708 . . . . 0.0 111.527 -178.534 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.12 14.26 9.33 Favored Glycine 0 N--CA 1.484 1.86 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.822 177.486 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.786 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.3 t -105.0 -172.6 2.13 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 121.13 2.465 . . . . 0.0 109.713 179.287 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.75 HG13 ' C ' ' A' ' 67' ' ' LEU . 15.0 t -130.68 139.18 51.88 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.324 -178.793 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.472 HG23 ' CD1' ' A' ' 67' ' ' LEU . 31.7 m -114.72 154.91 16.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.037 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.541 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.6 tptm -110.45 109.36 19.7 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.337 180.0 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.955 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -105.1 123.95 59.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 179.948 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.006 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.38 166.16 11.55 Favored 'General case' 0 N--CA 1.485 1.279 0 O-C-N 120.927 -1.108 . . . . 0.0 108.94 179.594 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.622 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.19 108.1 0.48 Allowed Glycine 0 N--CA 1.482 1.763 0 N-CA-C 108.41 -1.876 . . . . 0.0 108.41 179.917 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.602 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -117.19 136.81 52.78 Favored 'General case' 0 N--CA 1.501 2.078 0 CA-C-N 119.432 1.616 . . . . 0.0 110.38 -179.287 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.466 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 87.61 28.11 25.2 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 118.895 -1.621 . . . . 0.0 109.806 179.68 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.701 HD23 ' HB3' ' A' ' 3' ' ' PRO . 0.8 OUTLIER -93.4 170.6 9.49 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.988 -1.301 . . . . 0.0 108.309 179.852 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.008 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.9 100.8 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.068 -1.02 . . . . 0.0 110.018 -179.495 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.541 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.75 78.17 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.675 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.018 -179.36 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.32 34.48 0.28 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.735 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 18.8 p -139.56 105.67 5.23 Favored 'General case' 0 C--N 1.307 -1.278 0 O-C-N 121.162 -1.199 . . . . 0.0 111.273 -179.258 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.592 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.74 109.88 0.36 Allowed 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 177.824 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.535 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 5.2 m-30 -106.38 156.11 18.85 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.049 -1.032 . . . . 0.0 108.886 179.89 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.512 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -100.36 164.51 11.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.902 -1.124 . . . . 0.0 108.081 179.035 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.682 HG22 HG11 ' A' ' 21' ' ' VAL . 4.2 p -144.23 117.21 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.152 -0.967 . . . . 0.0 109.61 -178.1 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.9 -176.9 38.83 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 118.364 -1.874 . . . . 0.0 111.876 -179.717 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.601 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -101.48 109.21 20.99 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.837 0.827 . . . . 0.0 109.13 -179.572 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.21 148.44 52.04 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.192 -0.943 . . . . 0.0 109.511 179.579 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.509 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.7 138.52 54.58 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.179 -0.951 . . . . 0.0 110.815 -178.969 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.97 26.8 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 178.112 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.9 m -105.64 15.07 7.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 120.994 -1.066 . . . . 0.0 110.534 -178.84 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.754 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.11 -175.38 0.09 Allowed 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.857 -1.152 . . . . 0.0 110.064 179.724 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 64.0 p -72.24 97.44 1.99 Allowed 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.428 -0.795 . . . . 0.0 109.64 -179.784 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.56 27.54 32.24 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 120.154 -1.022 . . . . 0.0 111.419 178.877 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.754 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.65 106.21 19.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.526 -1.573 . . . . 0.0 107.221 178.93 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.8 tp -117.06 104.69 11.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.52 -1.362 . . . . 0.0 109.854 -177.659 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.072 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.08 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.299 0 O-C-N 120.842 -1.161 . . . . 0.0 107.887 178.77 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -106.87 163.99 12.49 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.015 -1.053 . . . . 0.0 110.44 -178.771 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.743 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 47.0 t30 -109.59 131.04 22.12 Favored Pre-proline 0 N--CA 1.502 2.173 0 O-C-N 121.59 -0.694 . . . . 0.0 109.618 -179.345 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.61 20.76 0.25 Allowed 'Trans proline' 0 C--N 1.318 -1.029 0 C-N-CA 122.21 1.94 . . . . 0.0 112.243 -179.813 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.743 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -110.53 5.68 21.39 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.379 -1.451 . . . . 0.0 108.846 179.166 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.543 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.01 16.82 2.64 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 179.339 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -81.74 88.82 6.26 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.868 -0.733 . . . . 0.0 111.285 -178.302 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.637 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.79 -167.25 1.23 Allowed 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 177.93 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.65 136.24 0.09 Allowed 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.479 -1.388 . . . . 0.0 111.395 -179.341 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.881 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -152.67 157.29 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.169 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.592 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.89 141.76 31.25 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.732 -1.23 . . . . 0.0 109.859 -179.772 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.008 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.17 107.51 1.06 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.43 1.109 . . . . 0.0 109.399 178.199 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.562 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 14.4 p-10 -61.75 -138.91 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.001 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.812 -179.997 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.541 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.49 -51.62 53.55 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.374 -0.828 . . . . 0.0 110.664 -178.665 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -102.23 -33.75 9.5 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 178.473 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.008 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.28 64.56 0.57 Allowed Glycine 0 C--N 1.299 -1.511 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.671 178.009 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.622 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 92.7 p -98.89 128.91 45.2 Favored 'General case' 0 N--CA 1.482 1.168 0 O-C-N 121.859 -0.789 . . . . 0.0 108.92 178.804 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.881 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.28 108.78 7.4 Favored 'General case' 0 C--N 1.296 -1.742 0 C-N-CA 119.67 -0.812 . . . . 0.0 109.416 -179.524 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 80.9 p -120.5 117.44 27.65 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.298 -0.876 . . . . 0.0 109.368 -179.906 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.569 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.31 140.83 28.04 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.418 -0.801 . . . . 0.0 109.609 -179.836 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 12.6 p -100.69 136.24 40.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.377 -0.827 . . . . 0.0 109.494 -179.947 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.75 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -133.84 165.85 24.03 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.423 -0.798 . . . . 0.0 109.392 -179.473 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.729 HG22 HG22 ' A' ' 18' ' ' VAL . 2.2 p -96.22 125.33 40.66 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.956 -1.09 . . . . 0.0 109.349 -179.946 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.601 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.4 m -135.82 143.49 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 120.919 -1.113 . . . . 0.0 109.929 -179.116 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.611 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.63 -175.9 4.98 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.495 -1.378 . . . . 0.0 110.984 179.957 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.599 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.56 -101.73 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.762 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.514 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -57.29 142.0 44.84 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.731 -1.23 . . . . 0.0 108.187 179.424 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.585 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.65 136.85 6.39 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.775 -1.17 . . . . 0.0 109.637 -177.961 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.498 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 1.6 mp0 -34.46 121.89 0.5 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.431 0.634 . . . . 0.0 110.306 -178.402 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.072 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.58 49.91 2.34 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.236 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.5 m-85 -39.3 113.85 0.36 Allowed 'General case' 0 N--CA 1.507 2.382 0 O-C-N 121.204 -1.174 . . . . 0.0 109.992 179.555 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.7 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -85.81 126.46 34.04 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 120.944 -1.098 . . . . 0.0 109.55 -179.797 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.576 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 19.9 t80 -64.28 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.869 -1.144 . . . . 0.0 110.052 179.665 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.539 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.4 t70 -159.96 19.49 0.16 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.157 -0.964 . . . . 0.0 109.66 179.764 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.96 -27.45 5.47 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.75 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.4 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 19.5 p -94.49 160.46 14.64 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.033 -1.275 . . . . 0.0 110.362 -179.361 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.48 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.75 136.62 46.24 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.689 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.7 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -82.89 -17.96 41.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.765 -1.21 . . . . 0.0 110.526 -178.487 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.94 175.6 19.89 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 108.778 -1.729 . . . . 0.0 108.778 -179.632 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.05 104.74 0.92 Allowed 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 179.134 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.633 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.5 t -76.48 106.3 6.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.388 -0.82 . . . . 0.0 109.258 -178.913 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -66.02 111.28 3.28 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.47 -0.769 . . . . 0.0 109.892 -179.41 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.599 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.75 -5.49 4.27 Favored 'General case' 0 N--CA 1.5 2.068 0 C-N-CA 118.256 -1.377 . . . . 0.0 109.816 179.484 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.6 p -86.82 -0.14 55.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.708 -1.245 . . . . 0.0 109.111 179.585 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.33 -50.59 2.85 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.398 -0.814 . . . . 0.0 108.945 179.96 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.07 -179.95 4.09 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.484 -0.76 . . . . 0.0 109.392 179.845 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.97 115.86 31.2 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.333 -0.854 . . . . 0.0 108.964 179.917 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.84 121.32 38.57 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.993 -1.067 . . . . 0.0 109.308 -179.421 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.595 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.92 145.7 28.3 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 122.355 1.074 . . . . 0.0 111.2 -179.306 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.648 ' HB ' HG11 ' A' ' 7' ' ' VAL . 58.6 t -103.12 109.78 27.83 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 177.675 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.478 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.26 -170.73 16.47 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 118.271 -1.919 . . . . 0.0 111.663 -177.738 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.503 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -114.36 -179.55 3.66 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 -178.95 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.562 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 37.1 p -170.85 168.33 7.23 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.337 -0.852 . . . . 0.0 109.321 -179.235 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.535 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -120.06 -158.83 0.76 Allowed 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.079 -1.013 . . . . 0.0 108.845 179.663 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.427 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.45 36.13 4.39 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.706 -1.246 . . . . 0.0 109.314 179.943 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -117.8 -32.76 4.72 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.452 -0.78 . . . . 0.0 110.262 -179.509 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 1.023 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 164.9 -36.25 0.28 Allowed Glycine 0 N--CA 1.483 1.771 0 N-CA-C 107.572 -2.211 . . . . 0.0 107.572 -179.513 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.61 -178.01 6.79 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.538 -0.977 . . . . 0.0 109.793 179.253 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.75 -163.0 16.93 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -179.321 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.503 ' HB2' HD12 ' A' ' 97' ' ' LEU . 6.4 Cg_exo -46.71 175.69 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.643 0 CA-C-N 118.77 1.285 . . . . 0.0 110.1 179.325 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -90.06 -176.04 4.75 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.019 -1.05 . . . . 0.0 110.599 -178.787 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.478 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.82 167.0 13.88 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.896 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.89 132.66 49.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.373 -1.075 . . . . 0.0 109.174 -179.334 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.595 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.27 118.88 17.73 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.547 -0.72 . . . . 0.0 109.685 179.675 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.911 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -98.02 170.07 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.211 -0.93 . . . . 0.0 108.999 179.72 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.517 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 34.4 m -140.95 156.85 45.99 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.167 -0.958 . . . . 0.0 110.094 -179.674 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.911 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.3 m-85 -131.97 106.33 7.98 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.333 -0.855 . . . . 0.0 109.541 -179.754 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 p30 . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.4 -179.928 . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 1.023 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.322 0.582 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 035 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -113.09 150.11 42.42 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.217 -0.927 . . . . 0.0 109.444 179.984 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.61 ' HB3' HD23 ' A' ' 26' ' ' LEU . 5.6 Cg_exo -58.67 154.04 45.57 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 C-N-CA 124.821 3.681 . . . . 0.0 110.086 -179.935 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.594 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -150.16 160.63 43.53 Favored 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -179.419 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.488 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.01 122.48 10.37 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 122.486 1.136 . . . . 0.0 110.397 -179.589 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.763 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.5 t -113.52 109.17 18.21 Favored 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 123.15 1.452 . . . . 0.0 109.266 179.954 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.889 HG22 HG23 ' A' ' 21' ' ' VAL . 4.4 t -116.25 127.38 73.87 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.709 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.94 -179.847 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.512 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.44 148.11 12.7 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.286 -0.884 . . . . 0.0 108.874 -179.696 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.512 ' HA ' HG23 ' A' ' 8' ' ' THR . 7.1 Cg_endo -79.96 147.65 77.46 Favored 'Cis proline' 0 C--N 1.31 -1.451 0 O-C-N 123.778 1.409 . . . . 0.0 109.35 -0.797 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.681 ' HA ' HG22 ' A' ' 110' ' ' ILE . 79.8 p -89.27 -25.8 21.5 Favored 'General case' 0 C--N 1.295 -1.785 0 O-C-N 121.563 -0.71 . . . . 0.0 109.203 179.788 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.476 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.0 OUTLIER -132.23 162.03 31.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.405 -0.81 . . . . 0.0 109.55 -179.927 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.9 37.29 29.98 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 -179.661 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.773 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.5 mt -92.39 -42.81 9.57 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 123.295 1.521 . . . . 0.0 110.516 -178.388 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.42 144.69 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.283 0 CA-C-N 113.321 -1.763 . . . . 0.0 109.936 -179.649 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.591 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.3 p-10 -51.2 106.11 0.12 Allowed 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.647 0.737 . . . . 0.0 111.494 -178.513 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.98 14.67 8.35 Favored Glycine 0 N--CA 1.485 1.929 0 C-N-CA 119.354 -1.403 . . . . 0.0 113.006 177.358 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.773 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -104.87 -171.2 1.88 Allowed 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 121.143 2.471 . . . . 0.0 109.516 179.218 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.732 HG13 ' C ' ' A' ' 67' ' ' LEU . 17.0 t -127.63 135.88 61.95 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.128 -179.119 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.642 HG13 ' CG2' ' A' ' 69' ' ' VAL . 29.2 m -109.18 155.27 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.835 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.533 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -110.35 109.23 19.57 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 108.834 179.804 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.889 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -105.01 139.5 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.399 -0.813 . . . . 0.0 108.832 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.763 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.58 161.13 37.25 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.804 -1.185 . . . . 0.0 109.945 179.631 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -134.05 141.57 12.93 Favored Glycine 0 C--N 1.297 -1.623 0 N-CA-C 108.318 -1.913 . . . . 0.0 108.318 179.768 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.594 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.64 125.98 16.6 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.706 -1.467 . . . . 0.0 109.294 179.369 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.49 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.11 28.2 21.19 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 118.873 -1.632 . . . . 0.0 109.599 -179.625 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.61 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.8 mt -88.84 174.59 7.88 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.988 -1.301 . . . . 0.0 108.365 179.953 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.66 98.45 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.887 -1.133 . . . . 0.0 109.823 -179.521 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.579 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 77.71 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.724 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.248 -179.253 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.563 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.73 34.37 0.31 Allowed Glycine 0 N--CA 1.486 2.014 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.525 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 66.6 p -144.24 109.73 5.19 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.005 -1.291 . . . . 0.0 111.211 -179.585 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.566 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -43.8 127.01 4.97 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.43 178.02 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.541 ' CD2' ' O ' ' A' ' 30' ' ' THR . 15.3 m-85 -116.98 153.48 32.56 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.388 -0.82 . . . . 0.0 108.834 179.844 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.5 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -105.24 148.97 26.38 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.816 -1.177 . . . . 0.0 108.264 179.059 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.648 HG13 HD21 ' A' ' 67' ' ' LEU . 0.9 OUTLIER -125.82 126.46 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.169 -0.957 . . . . 0.0 109.071 -178.103 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -172.77 173.29 45.47 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 117.707 -2.187 . . . . 0.0 112.527 -179.915 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.578 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.36 110.31 22.52 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 179.368 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 63.1 m -129.35 152.11 49.26 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 121.196 -0.94 . . . . 0.0 110.156 -179.612 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.67 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -126.47 135.45 51.37 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.632 -0.668 . . . . 0.0 110.046 179.585 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.905 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.71 114.43 26.35 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.579 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 m -106.86 15.15 7.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.915 -1.115 . . . . 0.0 110.713 -178.633 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.788 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.4 -174.52 0.07 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.819 -1.175 . . . . 0.0 110.135 179.63 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 29.5 p -70.14 96.32 1.07 Allowed 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.407 -0.808 . . . . 0.0 110.013 -179.468 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.04 28.4 34.4 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 120.166 -1.016 . . . . 0.0 111.532 178.749 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.788 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.32 106.04 19.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 120.58 -1.541 . . . . 0.0 107.327 178.83 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.905 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.7 tp -116.47 106.54 13.71 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.59 -1.319 . . . . 0.0 109.775 -177.65 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.116 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -96.13 109.76 22.14 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 120.697 -1.252 . . . . 0.0 108.381 179.281 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.41 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 86.8 m -101.48 147.59 26.2 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.346 -0.847 . . . . 0.0 110.48 -178.371 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.655 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 31.1 t30 -96.66 137.87 21.43 Favored Pre-proline 0 N--CA 1.502 2.169 0 O-C-N 121.01 -1.056 . . . . 0.0 108.826 178.878 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.582 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 8.0 Cg_endo -75.76 26.71 0.4 Allowed 'Trans proline' 0 N--CA 1.496 1.649 0 C-N-CA 125.188 3.925 . . . . 0.0 111.507 -179.068 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.655 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -126.1 9.12 7.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.424 -1.423 . . . . 0.0 109.576 179.881 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.83 15.97 2.49 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 179.502 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -77.91 87.14 4.11 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.059 -178.675 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.611 ' CB ' HG12 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -98.98 -168.22 1.6 Allowed 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 178.569 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.43 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 179.13 133.98 0.09 Allowed 'General case' 0 N--CA 1.486 1.329 0 O-C-N 120.766 -1.209 . . . . 0.0 111.42 -179.428 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.879 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -159.14 153.62 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.493 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.566 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.51 144.63 27.02 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.683 -1.261 . . . . 0.0 109.645 -179.86 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.002 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.67 107.42 1.41 Allowed 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 122.525 1.155 . . . . 0.0 109.502 178.7 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.556 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 p-10 -61.39 -139.97 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.782 179.98 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.579 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.06 -50.73 58.1 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.382 -0.824 . . . . 0.0 110.664 -178.799 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -103.48 -32.64 9.39 Favored 'General case' 0 C--N 1.286 -2.165 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 178.713 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.994 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.0 65.72 0.65 Allowed Glycine 0 C--N 1.296 -1.652 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 178.309 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.1 m -100.54 128.96 46.43 Favored 'General case' 0 N--CA 1.484 1.245 0 O-C-N 121.523 -0.987 . . . . 0.0 108.808 178.856 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.879 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -137.9 108.65 6.64 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.242 -0.983 . . . . 0.0 109.588 -179.516 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 27.3 p -123.82 120.24 32.04 Favored 'General case' 0 C--N 1.305 -1.33 0 O-C-N 121.246 -0.909 . . . . 0.0 109.513 -179.982 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.76 146.05 31.06 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.485 -0.759 . . . . 0.0 109.321 179.819 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 55.4 p -98.57 144.56 27.75 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.295 -0.878 . . . . 0.0 109.287 179.945 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.732 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -144.02 165.01 28.97 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.434 -0.791 . . . . 0.0 109.413 -179.216 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.657 HG22 HG22 ' A' ' 18' ' ' VAL . 3.8 p -95.04 123.71 38.68 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.127 -0.983 . . . . 0.0 109.329 -179.887 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.642 ' CG2' HG13 ' A' ' 19' ' ' VAL . 16.6 m -137.89 142.49 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 120.963 -1.085 . . . . 0.0 109.701 -179.292 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.591 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 5.4 ptt180 -140.71 -166.79 2.21 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 120.677 -1.264 . . . . 0.0 109.968 -179.989 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.549 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -71.66 -80.41 0.06 Allowed 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.809 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.504 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -64.87 135.79 56.13 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 178.648 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.67 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.08 133.6 6.09 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 117.862 -1.535 . . . . 0.0 110.563 -177.643 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.556 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -33.64 120.74 0.41 Allowed 'General case' 0 N--CA 1.493 1.694 0 CA-C-O 121.615 0.722 . . . . 0.0 110.391 -178.472 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.116 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.4 50.52 2.4 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.456 -0.878 . . . . 0.0 111.611 -178.916 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.582 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.7 OUTLIER -38.42 116.88 0.58 Allowed 'General case' 0 N--CA 1.51 2.567 0 O-C-N 121.094 -1.239 . . . . 0.0 110.053 179.41 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.627 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.28 125.71 34.38 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 120.8 -1.187 . . . . 0.0 109.455 179.855 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.575 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.0 t80 -64.14 58.6 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.819 -1.176 . . . . 0.0 110.086 179.82 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.9 t70 -160.51 20.02 0.14 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.059 -1.026 . . . . 0.0 109.668 179.898 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.46 -28.64 5.19 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 179.813 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.468 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 40.7 p -94.23 160.57 14.63 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.066 -1.255 . . . . 0.0 110.293 -179.52 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.49 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -108.02 136.8 47.11 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.794 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.627 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.9 t90 -80.74 -20.34 42.97 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.809 -1.182 . . . . 0.0 110.351 -178.688 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.43 176.24 20.22 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 108.644 -1.782 . . . . 0.0 108.644 -179.565 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -62.55 109.97 1.55 Allowed 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.166 -1.196 . . . . 0.0 107.779 179.168 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.63 HG21 ' CB ' ' A' ' 46' ' ' ALA . 37.1 t -83.22 103.53 10.62 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -179.104 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.575 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -65.77 111.71 3.37 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.383 -0.823 . . . . 0.0 109.894 -179.257 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.549 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -65.83 -3.67 5.43 Favored 'General case' 0 N--CA 1.5 2.055 0 C-N-CA 118.334 -1.346 . . . . 0.0 109.886 179.457 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 p -86.93 11.61 13.08 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.739 -1.225 . . . . 0.0 108.794 179.487 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.575 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -127.25 -48.22 1.45 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.428 -0.795 . . . . 0.0 108.989 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.36 -179.85 4.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.559 -0.713 . . . . 0.0 109.504 -179.948 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.1 113.66 27.32 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.318 -0.864 . . . . 0.0 109.079 -179.986 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.522 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.6 m -97.12 124.89 41.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.879 -1.138 . . . . 0.0 109.438 -179.512 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.567 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -104.87 147.15 28.06 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 122.403 1.097 . . . . 0.0 111.38 -179.27 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.497 ' CG1' HG11 ' A' ' 7' ' ' VAL . 43.4 t -103.53 112.04 35.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.977 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 177.577 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.417 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.06 -170.44 16.73 Favored Glycine 0 N--CA 1.488 2.137 0 C-N-CA 118.076 -2.011 . . . . 0.0 111.738 -177.607 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.485 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.08 -179.43 3.7 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 -179.126 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.559 ' HB2' ' C20' ' A' ' 114' ' ' CHR . 4.5 p -166.83 167.25 15.12 Favored 'General case' 0 C--N 1.293 -1.885 0 O-C-N 121.337 -0.852 . . . . 0.0 109.287 -179.523 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.7 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 4.7 m-20 -101.6 -12.54 18.38 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.134 -0.979 . . . . 0.0 109.452 179.891 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.7 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 74.77 38.15 0.48 Allowed 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.451 -0.781 . . . . 0.0 109.283 179.89 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -138.85 -34.28 0.61 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.525 -0.734 . . . . 0.0 110.636 -179.382 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.607 ' HA2' H192 ' A' ' 114' ' ' CHR . . . -177.82 -42.87 0.06 OUTLIER Glycine 0 N--CA 1.482 1.75 0 N-CA-C 107.59 -2.204 . . . . 0.0 107.59 -179.627 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.54 -178.74 7.49 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 121.62 -0.929 . . . . 0.0 109.355 178.9 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -173.29 -165.97 30.97 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.737 -1.745 . . . . 0.0 108.737 -179.471 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.596 ' HG3' HD22 ' A' ' 26' ' ' LEU . 4.6 Cg_exo -46.39 -175.86 0.0 OUTLIER 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 123.57 2.847 . . . . 0.0 109.923 179.512 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -94.78 172.13 8.35 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.975 -1.078 . . . . 0.0 110.574 -178.957 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.417 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -110.47 159.71 13.71 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 179.897 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.36 128.17 55.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.36 -1.082 . . . . 0.0 109.29 -179.378 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.567 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.75 119.49 17.06 Favored 'General case' 0 C--N 1.289 -2.042 0 O-C-N 121.591 -0.693 . . . . 0.0 109.358 179.569 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.852 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.99 171.07 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.228 -0.92 . . . . 0.0 109.116 -179.945 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.476 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.86 154.91 48.46 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.088 -1.007 . . . . 0.0 109.811 -179.763 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.852 ' CE2' HD12 ' A' ' 110' ' ' ILE . 76.1 m-85 -133.11 94.25 3.32 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.1 -1.0 . . . . 0.0 109.467 -179.752 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.434 ' OD1' ' O ' ' A' ' 113' ' ' ASN . 19.7 p30 . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 117.988 -1.006 . . . . 0.0 109.44 -179.967 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.853 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 036 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.69 148.86 39.03 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.227 -0.921 . . . . 0.0 109.504 179.982 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.575 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 4.8 Cg_exo -60.38 157.23 36.84 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.321 2.014 . . . . 0.0 110.581 -179.988 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.549 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.76 -169.69 0.14 Allowed 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 179.146 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.549 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -167.4 130.69 1.74 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 120.872 -1.143 . . . . 0.0 110.613 -179.16 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.954 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -113.19 108.66 17.58 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 123.166 1.46 . . . . 0.0 109.227 179.418 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.911 HG22 HG23 ' A' ' 21' ' ' VAL . 4.3 t -116.89 141.37 35.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.717 0 CA-C-N 114.185 -1.371 . . . . 0.0 109.953 -179.716 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.47 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -178.07 150.61 0.76 Allowed Pre-proline 0 N--CA 1.487 1.415 0 O-C-N 121.248 -0.907 . . . . 0.0 108.668 -179.613 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.47 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.67 152.24 96.92 Favored 'Cis proline' 0 C--N 1.312 -1.39 0 C-N-CA 123.485 -1.465 . . . . 0.0 109.679 -0.699 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.545 ' HA ' HG22 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -90.75 -24.85 20.25 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.768 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.507 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.7 m -136.71 164.15 28.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.451 -0.781 . . . . 0.0 109.482 179.856 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.39 37.47 31.38 Favored Glycine 0 N--CA 1.497 2.702 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 -179.717 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.6 mt -92.18 -43.2 9.47 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 123.203 1.477 . . . . 0.0 110.421 -178.348 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.91 144.45 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.312 0 CA-C-N 113.459 -1.7 . . . . 0.0 109.929 -179.657 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.611 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.1 p-10 -50.79 107.56 0.18 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.521 0.677 . . . . 0.0 111.458 -178.583 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.32 13.5 9.77 Favored Glycine 0 N--CA 1.485 1.938 0 C-N-CA 119.435 -1.364 . . . . 0.0 112.935 177.342 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.6 t -104.45 -172.61 2.13 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 121.213 2.507 . . . . 0.0 109.734 179.261 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.748 HG13 ' C ' ' A' ' 67' ' ' LEU . 15.9 t -129.37 138.3 54.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.371 0 CA-C-N 114.761 -1.109 . . . . 0.0 111.019 -179.014 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.556 HG23 ' CD1' ' A' ' 67' ' ' LEU . 27.8 m -113.67 154.62 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.922 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.504 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -108.55 109.38 20.6 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.208 -0.932 . . . . 0.0 108.996 179.936 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.911 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.49 140.89 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.789 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.954 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -136.35 160.54 38.42 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 118.659 -1.216 . . . . 0.0 109.89 179.734 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.589 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.18 143.81 15.46 Favored Glycine 0 C--N 1.293 -1.814 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 179.716 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.575 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.26 124.96 12.55 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 120.908 -1.348 . . . . 0.0 108.882 179.185 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.525 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.86 27.58 23.59 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 119.339 -1.41 . . . . 0.0 109.659 -179.68 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.7 mt -86.72 175.53 8.21 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 120.909 -1.348 . . . . 0.0 108.62 -179.781 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.54 97.12 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.047 -1.033 . . . . 0.0 109.58 -179.821 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.585 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 76.19 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.495 -178.978 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.21 33.27 0.28 Allowed Glycine 0 N--CA 1.486 1.985 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.26 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.61 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.4 t -148.13 115.32 6.18 Favored 'General case' 0 C--N 1.308 -1.214 0 O-C-N 120.831 -1.394 . . . . 0.0 111.276 179.973 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.3 127.84 5.88 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.781 178.367 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.61 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.8 m-85 -119.09 149.03 42.38 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.51 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.5 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.62 163.86 12.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.61 -1.307 . . . . 0.0 107.518 178.631 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.707 HG11 HG21 ' A' ' 65' ' ' THR . 9.2 p -149.08 114.62 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.045 -1.035 . . . . 0.0 110.143 -177.74 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.14 -175.41 37.16 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 118.365 -1.874 . . . . 0.0 111.731 -179.865 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.581 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.34 109.01 21.19 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-O 121.829 0.823 . . . . 0.0 108.819 -179.695 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.47 149.04 52.33 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.231 -0.918 . . . . 0.0 109.6 179.751 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.448 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.48 139.24 54.07 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.301 -0.875 . . . . 0.0 110.732 -179.041 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 114.78 26.6 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.174 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.4 m -105.53 15.29 6.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.999 -1.063 . . . . 0.0 110.573 -178.639 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.757 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.09 -175.42 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.955 -1.091 . . . . 0.0 110.003 179.734 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 56.8 p -71.95 97.45 1.86 Allowed 'General case' 0 N--CA 1.485 1.305 0 O-C-N 121.364 -0.835 . . . . 0.0 109.748 -179.73 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.65 27.71 34.5 Favored Glycine 0 N--CA 1.492 2.404 0 C-N-CA 120.235 -0.983 . . . . 0.0 111.423 178.985 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.757 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.05 106.24 19.98 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 O-C-N 120.59 -1.536 . . . . 0.0 107.29 178.829 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -116.71 104.55 11.47 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.478 -1.388 . . . . 0.0 109.81 -177.715 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.088 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.2 109.45 22.21 Favored 'General case' 0 N--CA 1.485 1.276 0 O-C-N 120.834 -1.166 . . . . 0.0 107.945 178.828 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -107.4 163.9 12.65 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.964 -1.085 . . . . 0.0 110.297 -178.73 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.754 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 38.8 t30 -108.56 128.77 24.98 Favored Pre-proline 0 N--CA 1.501 2.111 0 O-C-N 121.46 -0.775 . . . . 0.0 109.503 -179.386 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -70.14 19.76 0.19 Allowed 'Trans proline' 0 CA--C 1.544 1.017 0 C-N-CA 122.088 1.859 . . . . 0.0 112.386 -179.867 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.754 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -108.96 4.85 23.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.388 -1.445 . . . . 0.0 108.868 179.157 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.578 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.79 16.7 2.68 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 179.497 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -81.67 90.58 6.33 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.974 -0.691 . . . . 0.0 111.088 -178.446 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.39 -171.08 1.77 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 178.015 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.446 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.85 134.99 0.09 Allowed 'General case' 0 C--N 1.305 -1.356 0 O-C-N 120.403 -1.435 . . . . 0.0 111.554 -179.357 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.777 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.5 p -150.07 159.11 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 177.894 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.57 146.05 25.66 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.543 -1.348 . . . . 0.0 109.726 -179.724 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.24 108.71 3.28 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 122.31 1.052 . . . . 0.0 109.629 178.999 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.547 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.5 t0 -63.02 -138.65 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.526 179.858 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.585 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -53.7 -51.45 63.2 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.289 -0.882 . . . . 0.0 110.21 -178.931 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.8 p-10 -98.58 -37.08 9.68 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 178.563 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.987 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.06 65.62 0.64 Allowed Glycine 0 C--N 1.297 -1.588 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.412 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 53.7 p -98.49 132.62 43.77 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 121.426 -1.043 . . . . 0.0 109.245 179.28 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.777 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.02 108.53 6.55 Favored 'General case' 0 C--N 1.296 -1.754 0 C-N-CA 119.235 -0.986 . . . . 0.0 109.52 -179.708 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.432 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 21.8 p -124.82 120.75 32.61 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.147 -0.97 . . . . 0.0 109.797 -179.803 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.707 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -148.04 146.72 28.99 Favored 'General case' 0 C--N 1.3 -1.587 0 O-C-N 121.581 -0.7 . . . . 0.0 109.304 179.648 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.4 p -100.61 138.88 37.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.322 -0.861 . . . . 0.0 109.404 179.975 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.748 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -138.03 165.54 26.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.404 -0.81 . . . . 0.0 109.529 -179.405 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.724 HG22 HG22 ' A' ' 18' ' ' VAL . 2.2 p -96.8 125.7 41.44 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.068 -1.02 . . . . 0.0 109.354 -179.857 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.572 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -136.8 144.42 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.99 -1.069 . . . . 0.0 109.888 -179.26 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.611 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.0 OUTLIER -149.0 -174.93 4.77 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 120.455 -1.403 . . . . 0.0 110.998 -179.845 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.61 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.94 -101.84 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 -179.766 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.05 140.46 49.06 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.815 -1.178 . . . . 0.0 108.052 179.43 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.58 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -161.79 137.13 7.45 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 118.642 -1.223 . . . . 0.0 109.759 -178.118 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.522 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 10.3 mm-40 -34.97 122.06 0.55 Allowed 'General case' 0 N--CA 1.49 1.546 0 CA-C-O 121.387 0.613 . . . . 0.0 110.351 -178.468 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.088 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.29 51.25 1.86 Allowed Glycine 0 N--CA 1.493 2.458 0 C-N-CA 120.548 -0.835 . . . . 0.0 111.06 -179.268 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -39.24 115.39 0.49 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.04 -1.271 . . . . 0.0 110.108 179.572 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.691 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.49 126.46 34.45 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 120.928 -1.108 . . . . 0.0 109.495 -179.895 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.586 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.8 t80 -64.38 58.46 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.989 0 O-C-N 120.876 -1.14 . . . . 0.0 110.091 179.685 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' LEU . 17.0 t0 -160.19 19.65 0.15 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.987 -1.07 . . . . 0.0 109.664 179.83 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.05 -28.03 5.26 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.999 -1.241 . . . . 0.0 109.999 179.931 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.414 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 10.3 p -94.27 161.0 14.43 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.034 -1.274 . . . . 0.0 110.384 -179.446 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.48 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -107.97 138.13 44.77 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.84 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.691 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -83.61 -17.96 39.82 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.71 -1.244 . . . . 0.0 110.674 -178.411 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.0 176.43 19.99 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 108.644 -1.783 . . . . 0.0 108.644 -179.648 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.53 104.45 1.01 Allowed 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.188 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 46' ' ' ALA . 41.0 t -76.09 106.62 6.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.287 -0.883 . . . . 0.0 109.133 -178.926 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.546 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -65.68 111.24 3.1 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.493 -0.755 . . . . 0.0 110.026 -179.352 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.61 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.47 -5.71 4.07 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.813 179.353 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.5 p -86.58 -0.93 57.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.747 -1.221 . . . . 0.0 109.202 179.681 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.546 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -112.87 -50.1 2.9 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.29 -0.881 . . . . 0.0 108.995 179.977 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.94 -179.04 3.83 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.488 -0.757 . . . . 0.0 109.42 179.782 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.06 115.75 30.8 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.386 -0.821 . . . . 0.0 108.905 179.992 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.531 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -96.87 121.43 38.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.851 -1.156 . . . . 0.0 109.483 -179.455 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.619 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.85 146.29 28.5 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.437 1.113 . . . . 0.0 111.215 -179.32 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.3 t -102.46 109.77 27.35 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 177.632 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.439 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.6 -173.11 18.38 Favored Glycine 0 N--CA 1.486 2.016 0 C-N-CA 118.142 -1.98 . . . . 0.0 111.709 -177.601 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.5 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -113.71 -178.95 3.5 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.069 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.589 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.0 OUTLIER -175.88 170.62 2.76 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.219 -0.926 . . . . 0.0 109.711 -179.203 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.423 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -122.46 -159.33 0.82 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.025 -1.047 . . . . 0.0 108.856 179.786 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.423 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.86 36.08 4.34 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.685 -1.259 . . . . 0.0 109.2 -179.926 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.55 -33.07 5.68 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.359 -0.838 . . . . 0.0 110.034 -179.669 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.965 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 164.89 -35.64 0.27 Allowed Glycine 0 N--CA 1.481 1.696 0 N-CA-C 107.776 -2.13 . . . . 0.0 107.776 -179.673 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -162.61 -177.72 5.76 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-O 122.007 0.908 . . . . 0.0 109.785 179.279 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.38 -161.85 15.27 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 -179.44 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.504 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.3 Cg_exo -47.08 177.98 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.693 0 CA-C-N 118.874 1.337 . . . . 0.0 110.202 179.324 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -92.27 -175.17 3.96 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.06 -1.025 . . . . 0.0 110.511 -178.83 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.439 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.24 163.46 14.68 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.944 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.9 128.92 52.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.426 -1.044 . . . . 0.0 109.222 -179.441 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.619 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.22 123.22 23.26 Favored 'General case' 0 C--N 1.29 -2.015 0 O-C-N 121.687 -0.633 . . . . 0.0 109.562 179.672 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.917 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.72 167.69 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 O-C-N 121.221 -0.924 . . . . 0.0 109.193 -179.925 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.507 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -134.73 154.26 51.65 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.277 -0.889 . . . . 0.0 109.565 -179.873 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.917 ' CE1' HD12 ' A' ' 110' ' ' ILE . 30.3 m-85 -122.98 117.43 25.48 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.15 -0.969 . . . . 0.0 109.566 -179.729 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 112' ' ' PHE . 20.9 p30 . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 118.018 -0.992 . . . . 0.0 109.479 -179.972 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.965 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 121.301 0.572 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 037 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.819 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -120.58 168.36 10.83 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.966 . . . . 0.0 109.516 -179.94 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.819 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.4 Cg_exo -59.89 158.34 29.62 Favored 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 122.355 2.037 . . . . 0.0 110.577 179.971 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.537 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.42 -169.81 0.15 Allowed 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 179.239 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.593 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -166.5 131.46 2.2 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 120.771 -1.206 . . . . 0.0 110.863 -179.111 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.949 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.6 t -112.46 108.58 17.76 Favored 'General case' 0 C--N 1.296 -1.738 0 CA-C-O 123.084 1.421 . . . . 0.0 109.117 179.357 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.79 HG22 HG23 ' A' ' 21' ' ' VAL . 2.4 t -115.31 140.38 36.99 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.699 0 CA-C-N 114.275 -1.329 . . . . 0.0 110.102 -179.521 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.496 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -176.04 149.82 1.03 Allowed Pre-proline 0 N--CA 1.487 1.375 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.772 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.496 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.2 Cg_endo -77.43 152.57 93.88 Favored 'Cis proline' 0 C--N 1.312 -1.353 0 C-N-CA 123.572 -1.428 . . . . 0.0 109.313 -0.813 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.639 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.5 m -89.76 -26.51 20.58 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 179.761 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.48 ' HB3' ' HB2' ' A' ' 111' ' ' SER . 5.3 m -135.23 164.31 27.99 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.587 -0.696 . . . . 0.0 109.609 179.858 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.3 37.03 29.14 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 108.767 -1.733 . . . . 0.0 108.767 -179.841 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.766 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.6 mt -93.23 -42.69 9.21 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-O 123.242 1.496 . . . . 0.0 110.405 -178.406 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.83 145.3 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.277 0 CA-C-N 113.322 -1.763 . . . . 0.0 109.954 -179.735 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.613 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.2 p-10 -51.26 106.81 0.15 Allowed 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.493 0.663 . . . . 0.0 111.513 -178.749 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.54 13.16 9.01 Favored Glycine 0 N--CA 1.483 1.823 0 C-N-CA 119.401 -1.38 . . . . 0.0 112.986 177.317 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.766 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -105.31 -172.4 2.09 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 121.242 2.521 . . . . 0.0 109.673 179.167 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.738 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.2 t -126.6 135.56 63.39 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 114.866 -1.061 . . . . 0.0 111.097 -178.897 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.66 ' CG1' HD13 ' A' ' 13' ' ' LEU . 17.3 m -109.04 156.82 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.664 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -114.06 109.27 18.18 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.091 -1.005 . . . . 0.0 109.16 179.949 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.79 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -104.07 140.01 23.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 179.749 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.949 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.77 160.4 38.29 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 118.605 -1.238 . . . . 0.0 109.85 179.856 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -131.4 144.96 16.6 Favored Glycine 0 C--N 1.293 -1.807 0 N-CA-C 108.179 -1.968 . . . . 0.0 108.179 179.751 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.571 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.88 124.53 11.79 Favored 'General case' 0 C--N 1.295 -1.792 0 O-C-N 120.901 -1.352 . . . . 0.0 108.785 179.182 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.53 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.99 26.7 23.47 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.337 -1.411 . . . . 0.0 109.631 -179.623 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.603 HD22 ' HG3' ' A' ' 105' ' ' PRO . 1.9 mt -87.43 174.57 8.44 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 120.897 -1.355 . . . . 0.0 108.445 -179.901 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.42 96.96 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.04 -1.037 . . . . 0.0 109.674 -179.714 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.659 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 76.83 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.45 -179.091 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.01 33.77 0.32 Allowed Glycine 0 N--CA 1.486 2.027 0 N-CA-C 109.731 -1.347 . . . . 0.0 109.731 179.347 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.554 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 1.2 t -148.15 114.88 6.03 Favored 'General case' 0 C--N 1.309 -1.181 0 O-C-N 120.869 -1.371 . . . . 0.0 111.098 179.899 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.45 129.86 3.93 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.996 178.55 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.553 ' CE1' ' OD1' ' A' ' 99' ' ' ASP . 10.7 m-85 -119.47 150.84 39.55 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.368 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.506 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -102.05 159.39 15.41 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.703 -1.248 . . . . 0.0 107.856 178.728 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.645 HG22 HG11 ' A' ' 21' ' ' VAL . 5.1 p -144.03 117.27 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.075 -1.016 . . . . 0.0 109.852 -177.914 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.12 -178.73 40.18 Favored Glycine 0 N--CA 1.494 2.518 0 C-N-CA 118.324 -1.893 . . . . 0.0 111.849 -179.86 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.592 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -100.43 108.88 20.98 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -179.862 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.24 148.34 52.06 Favored 'General case' 0 C--N 1.296 -1.731 0 O-C-N 121.286 -0.884 . . . . 0.0 109.704 179.777 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.512 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.96 138.63 54.34 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.274 -0.891 . . . . 0.0 110.776 -179.005 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.867 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.45 114.75 26.55 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 178.137 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -106.12 14.79 7.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.934 -1.104 . . . . 0.0 110.64 -178.716 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.61 -175.65 0.08 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.926 -1.109 . . . . 0.0 110.101 179.694 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.775 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.3 97.53 1.26 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 121.799 0.809 . . . . 0.0 110.031 -179.605 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.26 27.11 37.64 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 120.261 -0.971 . . . . 0.0 111.429 178.785 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -114.85 106.14 20.03 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 O-C-N 120.617 -1.519 . . . . 0.0 107.375 178.818 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.867 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -117.01 104.71 11.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.459 -1.401 . . . . 0.0 109.629 -177.803 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.058 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.94 109.55 22.28 Favored 'General case' 0 N--CA 1.485 1.316 0 O-C-N 120.808 -1.183 . . . . 0.0 108.415 179.093 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.6 t -105.98 162.83 13.25 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.952 -1.092 . . . . 0.0 110.115 -179.254 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.548 HD22 ' HB3' ' A' ' 50' ' ' ALA . 17.0 t30 -107.01 140.89 21.84 Favored Pre-proline 0 N--CA 1.504 2.259 0 O-C-N 121.348 -0.845 . . . . 0.0 110.13 -179.218 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.573 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 8.2 Cg_endo -76.36 27.65 0.41 Allowed 'Trans proline' 0 C--N 1.318 -1.029 0 C-N-CA 122.662 2.241 . . . . 0.0 111.636 -179.665 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.548 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -121.49 3.57 10.21 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.394 -1.441 . . . . 0.0 109.522 -179.869 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.523 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -138.48 15.41 2.75 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 179.435 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -80.11 91.68 5.55 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.508 -0.745 . . . . 0.0 110.815 -178.675 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.59 -168.53 1.33 Allowed 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.387 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.98 135.2 0.09 Allowed 'General case' 0 N--CA 1.486 1.349 0 O-C-N 120.633 -1.292 . . . . 0.0 111.486 -179.381 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.872 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -149.02 157.53 6.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 177.935 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.567 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.28 146.61 24.96 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.636 -1.29 . . . . 0.0 109.897 -179.489 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.26 108.31 2.68 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-O 122.361 1.077 . . . . 0.0 109.622 178.847 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.533 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.6 t0 -62.95 -138.94 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.005 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.822 -179.867 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.659 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.9 -51.99 36.42 Favored 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.349 -0.845 . . . . 0.0 110.676 -178.657 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.06 -32.36 9.24 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.714 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.0 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.07 64.89 0.61 Allowed Glycine 0 C--N 1.298 -1.583 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 178.262 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.5 m -99.57 129.31 45.72 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.465 -1.021 . . . . 0.0 108.664 178.772 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.872 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.74 108.63 6.69 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.805 -179.329 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 51.8 p -122.15 119.45 31.32 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.259 -0.901 . . . . 0.0 109.455 179.936 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.571 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.22 143.46 30.29 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.519 -0.738 . . . . 0.0 109.417 179.894 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 15.9 p -100.01 140.63 33.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.406 -0.809 . . . . 0.0 109.406 179.961 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.789 HD12 ' H ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.37 168.82 18.97 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.405 -0.809 . . . . 0.0 109.382 -179.426 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.716 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -96.82 124.86 40.92 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.03 -1.044 . . . . 0.0 109.424 -179.823 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.598 ' CG2' HG13 ' A' ' 19' ' ' VAL . 15.9 m -137.05 143.54 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.932 -1.105 . . . . 0.0 109.728 -179.259 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.613 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.1 ptt180 -148.79 -175.34 4.91 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.519 -1.363 . . . . 0.0 110.9 -179.835 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.612 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.76 -101.2 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.7 -179.413 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.507 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.86 142.03 42.61 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.812 -1.18 . . . . 0.0 108.319 179.785 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.582 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.93 134.59 4.38 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 118.783 -1.167 . . . . 0.0 109.64 -178.209 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.554 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -33.81 122.82 0.46 Allowed 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.519 0.676 . . . . 0.0 110.465 -178.138 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.058 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.2 49.15 2.7 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.273 -179.187 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.573 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -38.47 115.0 0.42 Allowed 'General case' 0 N--CA 1.509 2.519 0 O-C-N 121.096 -1.237 . . . . 0.0 109.909 179.615 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.726 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -86.72 126.42 34.55 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.938 -1.101 . . . . 0.0 109.357 179.972 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.585 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 24.5 t80 -63.48 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.902 -1.124 . . . . 0.0 110.307 179.912 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.548 ' N ' ' O ' ' A' ' 77' ' ' LEU . 22.2 t0 -162.04 20.18 0.1 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.992 -1.068 . . . . 0.0 109.786 179.736 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.65 -27.76 5.17 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 179.821 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.445 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 14.3 p -93.15 160.23 14.94 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.047 -1.267 . . . . 0.0 110.26 -179.466 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.479 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.4 OUTLIER -107.63 136.69 46.96 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.835 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.726 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -82.56 -19.1 39.19 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.848 -1.158 . . . . 0.0 110.407 -178.667 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.54 175.41 19.14 Favored Glycine 0 N--CA 1.485 1.908 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.613 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.84 107.14 1.37 Allowed 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.271 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.622 HG21 ' HB3' ' A' ' 46' ' ' ALA . 47.2 t -79.62 106.71 11.11 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.362 -0.836 . . . . 0.0 109.262 -179.014 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.54 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -67.69 111.67 4.37 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.407 -0.808 . . . . 0.0 109.805 -179.554 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.612 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.16 -5.69 3.49 Favored 'General case' 0 N--CA 1.5 2.046 0 C-N-CA 118.189 -1.404 . . . . 0.0 109.826 179.414 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.14 0.02 54.58 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.644 -1.285 . . . . 0.0 109.158 179.51 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.54 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.66 -49.72 2.87 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.366 -0.834 . . . . 0.0 109.007 -179.98 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.77 179.63 4.21 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.433 -0.792 . . . . 0.0 109.482 179.944 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.94 116.13 31.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.445 -0.785 . . . . 0.0 108.922 179.908 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.85 121.8 39.11 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.86 -1.15 . . . . 0.0 109.371 -179.381 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.6 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.68 146.51 27.63 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.411 1.101 . . . . 0.0 111.359 -179.213 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 65.7 t -102.95 110.06 28.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 177.502 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.76 -173.01 17.61 Favored Glycine 0 N--CA 1.487 2.063 0 C-N-CA 118.041 -2.028 . . . . 0.0 111.828 -177.441 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.593 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -115.98 -178.11 3.32 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 -179.057 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.554 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 1.0 OUTLIER -172.28 166.46 5.9 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.234 -0.916 . . . . 0.0 109.331 -179.527 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.719 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 7.9 m-20 -99.46 -13.41 19.53 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.173 -0.955 . . . . 0.0 109.402 179.882 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.719 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 75.47 36.9 0.46 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.451 -0.78 . . . . 0.0 109.222 179.9 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.09 -33.51 0.83 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.53 -0.731 . . . . 0.0 110.704 -179.399 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.476 ' HA2' H192 ' A' ' 114' ' ' CHR . . . -177.59 -42.62 0.06 OUTLIER Glycine 0 N--CA 1.481 1.695 0 N-CA-C 107.687 -2.165 . . . . 0.0 107.687 -179.636 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.43 -178.49 7.18 Favored 'General case' 0 C--N 1.307 -1.245 0 O-C-N 121.527 -0.984 . . . . 0.0 109.431 179.05 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.64 -166.18 33.36 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -179.554 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.603 ' HG3' HD22 ' A' ' 26' ' ' LEU . 4.3 Cg_exo -49.09 -177.37 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.677 0 CA-C-N 118.7 1.25 . . . . 0.0 110.288 179.525 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -94.54 -176.85 4.04 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.082 -1.011 . . . . 0.0 110.419 -179.02 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -120.45 161.3 14.73 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.969 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.409 ' O ' HG12 ' A' ' 108' ' ' VAL . 1.2 t -100.87 126.37 54.59 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.349 -1.089 . . . . 0.0 109.188 -179.472 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.6 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.1 119.76 16.75 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.745 -0.597 . . . . 0.0 109.431 179.669 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.766 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.96 168.53 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.201 -0.937 . . . . 0.0 109.303 -179.956 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB2' ' HB3' ' A' ' 11' ' ' SER . 2.4 m -138.2 151.31 47.57 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.384 -0.823 . . . . 0.0 109.542 -179.955 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.766 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 22.8 m-85 -126.38 104.91 8.42 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.146 -0.971 . . . . 0.0 109.531 -179.674 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.7 p30 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.502 -179.98 . . . . . . . . 0 0 . 1 . 037 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.659 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 0 0 . 1 . 038 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.63 143.99 39.42 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.206 -0.934 . . . . 0.0 109.222 179.781 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.612 ' HB3' HD23 ' A' ' 26' ' ' LEU . 3.2 Cg_exo -60.85 156.52 43.07 Favored 'Trans proline' 0 C--N 1.31 -1.468 0 C-N-CA 122.063 1.842 . . . . 0.0 110.415 179.984 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.607 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -146.62 159.24 43.7 Favored 'General case' 0 C--N 1.292 -1.899 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 -179.617 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -146.51 125.36 12.7 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-O 122.43 1.109 . . . . 0.0 110.129 -179.715 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.903 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.1 t -116.28 109.02 16.83 Favored 'General case' 0 C--N 1.293 -1.858 0 CA-C-O 123.129 1.442 . . . . 0.0 109.622 179.968 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.948 HG22 HG23 ' A' ' 21' ' ' VAL . 8.0 t -116.92 137.84 49.51 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.709 0 CA-C-N 114.074 -1.421 . . . . 0.0 109.862 -179.874 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.49 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -174.37 151.02 1.57 Allowed Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.331 -0.856 . . . . 0.0 108.804 -179.617 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.49 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.3 Cg_endo -77.47 150.94 91.85 Favored 'Cis proline' 0 C--N 1.312 -1.383 0 C-N-CA 123.539 -1.442 . . . . 0.0 109.392 -0.907 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.677 ' HA ' HG22 ' A' ' 110' ' ' ILE . 89.6 p -92.52 -23.08 19.21 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 121.433 -0.792 . . . . 0.0 109.27 179.692 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.499 ' CB ' ' HB3' ' A' ' 111' ' ' SER . 7.0 m -132.16 159.97 37.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.484 -0.76 . . . . 0.0 109.542 -179.859 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.73 37.61 29.76 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.633 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.773 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.4 mt -91.1 -43.69 9.74 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-O 123.146 1.45 . . . . 0.0 110.641 -178.273 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.35 144.88 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.298 0 CA-C-N 113.471 -1.695 . . . . 0.0 110.224 -179.72 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.594 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.0 p-10 -50.2 106.11 0.11 Allowed 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.494 0.664 . . . . 0.0 111.626 -178.548 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.81 15.0 8.92 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 119.426 -1.368 . . . . 0.0 113.037 177.05 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.773 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -105.8 -174.02 2.44 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 121.29 2.545 . . . . 0.0 109.837 179.227 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.733 HG13 ' O ' ' A' ' 67' ' ' LEU . 15.7 t -130.71 138.56 53.35 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 CA-C-N 114.702 -1.135 . . . . 0.0 111.178 -178.721 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.568 HG12 HD21 ' A' ' 13' ' ' LEU . 33.8 m -113.06 155.16 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 178.75 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -103.96 108.82 20.33 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.021 -1.05 . . . . 0.0 109.167 179.971 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.948 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.51 140.06 21.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.893 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.903 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -133.76 159.18 41.37 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.866 -1.146 . . . . 0.0 109.638 179.484 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.581 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -141.08 108.8 0.57 Allowed Glycine 0 N--CA 1.482 1.76 0 N-CA-C 108.753 -1.739 . . . . 0.0 108.753 179.97 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.607 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.28 140.35 49.42 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 119.259 1.529 . . . . 0.0 110.426 -179.461 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.471 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 85.48 26.9 34.32 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 118.945 -1.598 . . . . 0.0 109.946 179.57 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.612 HD23 ' HB3' ' A' ' 3' ' ' PRO . 0.8 OUTLIER -93.0 169.88 10.09 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 120.933 -1.333 . . . . 0.0 108.534 -179.946 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.58 101.32 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.117 -0.989 . . . . 0.0 109.777 -179.426 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.92 77.88 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.864 -179.327 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.89 33.83 0.28 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.77 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.55 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 18.8 p -138.79 106.35 5.58 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.279 -1.13 . . . . 0.0 110.93 -179.465 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.583 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.39 109.91 0.39 Allowed 'General case' 0 N--CA 1.497 1.903 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.532 178.181 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.483 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 32.6 m-85 -102.81 155.8 18.08 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.147 -0.971 . . . . 0.0 108.901 179.74 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.407 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.46 158.42 15.92 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 178.696 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.63 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.3 p -139.83 120.07 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.189 -0.944 . . . . 0.0 109.472 -177.818 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -169.89 -178.34 40.86 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.23 -1.938 . . . . 0.0 111.796 -179.742 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.729 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.21 109.78 22.03 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.918 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 68.1 m -127.16 152.77 46.9 Favored 'General case' 0 C--N 1.293 -1.86 0 O-C-N 121.22 -0.925 . . . . 0.0 109.819 179.619 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.654 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -126.87 135.66 51.27 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.535 -0.728 . . . . 0.0 110.452 179.965 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.902 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.94 114.69 26.55 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.231 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 20.1 m -104.97 14.42 7.21 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 120.851 -1.155 . . . . 0.0 110.809 -178.65 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.785 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 173.73 -174.5 0.06 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.81 -1.181 . . . . 0.0 110.158 179.65 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 24.5 p -71.69 97.67 1.79 Allowed 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.467 -0.77 . . . . 0.0 109.827 -179.67 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.85 27.63 31.22 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 120.285 -0.959 . . . . 0.0 111.487 178.836 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.785 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.3 t -116.35 106.09 19.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 O-C-N 120.538 -1.566 . . . . 0.0 107.372 179.001 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.902 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.7 tp -116.85 106.37 13.38 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.548 -1.345 . . . . 0.0 109.989 -177.703 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.105 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -95.72 109.78 22.02 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.803 -1.185 . . . . 0.0 108.161 179.137 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.4 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 66.5 m -100.12 145.88 27.47 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.225 -0.922 . . . . 0.0 110.415 -178.354 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.502 ' HB3' ' HG2' ' A' ' 36' ' ' GLN . 7.4 t30 -99.23 129.23 29.8 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.217 -0.927 . . . . 0.0 108.673 179.097 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.4 Cg_endo -71.41 23.05 0.23 Allowed 'Trans proline' 0 C--N 1.317 -1.108 0 C-N-CA 122.102 1.868 . . . . 0.0 111.968 179.923 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.494 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -103.35 -5.86 22.54 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.4 -1.437 . . . . 0.0 109.106 179.68 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.696 ' OD2' HG13 ' A' ' 69' ' ' VAL . 5.6 m-20 -134.13 6.39 3.62 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.351 -0.843 . . . . 0.0 108.89 -179.961 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -62.42 84.18 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.336 -0.852 . . . . 0.0 110.655 -178.672 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.63 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.5 -167.87 1.32 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 178.605 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.47 135.73 0.08 Allowed 'General case' 0 C--N 1.304 -1.404 0 O-C-N 120.68 -1.262 . . . . 0.0 111.383 -179.321 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.925 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -150.83 156.13 6.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 177.94 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.583 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.69 142.0 30.8 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.721 -1.237 . . . . 0.0 110.162 -179.525 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.011 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.26 106.4 0.73 Allowed 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 122.559 1.171 . . . . 0.0 109.45 178.316 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.2 p-10 -59.7 -139.51 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.862 179.962 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.75 -50.87 59.78 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.454 -0.778 . . . . 0.0 110.715 -178.711 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -102.94 -33.79 9.18 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 178.462 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.43 65.9 0.61 Allowed Glycine 0 C--N 1.298 -1.548 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.575 177.941 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.581 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 23.2 m -102.81 126.49 49.97 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 178.631 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.925 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.24 109.17 8.68 Favored 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 119.457 -0.897 . . . . 0.0 109.296 -179.29 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.407 ' HB3' ' HE3' ' A' ' 20' ' ' LYS . 1.4 m -123.35 119.42 30.04 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.412 -0.805 . . . . 0.0 109.646 -179.73 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.55 150.31 36.17 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.698 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.2 p -98.04 136.7 37.92 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.196 -0.94 . . . . 0.0 109.484 -179.785 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.912 HD11 HG11 ' A' ' 21' ' ' VAL . 0.2 OUTLIER -128.99 160.65 32.06 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.442 -0.786 . . . . 0.0 109.485 -178.913 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.665 HG22 HG22 ' A' ' 18' ' ' VAL . 1.3 p -100.95 123.23 44.82 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.03 -1.044 . . . . 0.0 108.861 179.525 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.729 HG12 ' HB3' ' A' ' 36' ' ' GLN . 17.6 m -135.25 142.81 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 120.872 -1.143 . . . . 0.0 110.486 -178.579 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.594 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.4 ptt180 -145.5 -171.81 3.75 Favored 'General case' 0 N--CA 1.484 1.263 0 O-C-N 120.582 -1.324 . . . . 0.0 110.825 179.55 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.588 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -57.34 -99.67 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.197 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.513 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.79 142.23 50.8 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 120.343 -1.473 . . . . 0.0 108.218 179.517 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.654 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.4 OUTLIER -162.07 135.09 6.05 Favored 'General case' 0 C--N 1.295 -1.771 0 C-N-CA 118.581 -1.248 . . . . 0.0 110.027 -178.05 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.544 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 20.5 mt-10 -35.22 120.99 0.55 Allowed 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.458 0.647 . . . . 0.0 110.231 -178.723 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.105 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.74 51.22 2.01 Favored Glycine 0 N--CA 1.494 2.55 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.665 -178.793 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -38.32 115.88 0.48 Allowed 'General case' 0 N--CA 1.507 2.396 0 O-C-N 121.04 -1.271 . . . . 0.0 110.012 179.26 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.767 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -86.78 126.06 34.35 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 120.816 -1.177 . . . . 0.0 109.594 -179.623 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 30.9 t80 -64.34 58.93 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.842 -1.161 . . . . 0.0 109.837 179.519 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.6 t70 -159.68 19.76 0.17 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.984 -1.072 . . . . 0.0 109.715 179.936 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.6 -27.91 5.59 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.811 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.467 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 73.1 p -98.49 162.6 13.07 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.142 -1.21 . . . . 0.0 110.39 -179.439 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.486 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 2.1 ptt180 -106.54 142.13 36.7 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.859 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.767 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.6 t90 -85.19 -19.77 31.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.635 -1.291 . . . . 0.0 110.601 -178.505 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.1 177.12 18.77 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.631 -1.788 . . . . 0.0 108.631 -179.424 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -66.4 105.33 1.43 Allowed 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 179.198 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.591 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 44.3 t -76.13 104.83 4.52 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.24 -0.913 . . . . 0.0 109.048 -179.058 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.529 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.05 111.17 3.24 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.46 -0.775 . . . . 0.0 109.686 -179.508 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.588 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.77 -4.85 4.76 Favored 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 118.245 -1.382 . . . . 0.0 109.71 179.51 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -86.83 1.81 51.15 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.782 -1.199 . . . . 0.0 109.017 179.341 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.529 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -117.01 -51.14 2.56 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.376 -0.828 . . . . 0.0 108.951 179.975 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.31 -179.92 4.09 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.479 -0.763 . . . . 0.0 109.383 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.25 115.7 30.85 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.446 -0.784 . . . . 0.0 108.935 179.807 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.527 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.03 124.53 41.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.84 -1.162 . . . . 0.0 109.582 -179.264 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.57 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -102.97 147.73 26.57 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.344 1.069 . . . . 0.0 111.405 -179.241 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.496 ' CG1' HG11 ' A' ' 7' ' ' VAL . 44.8 t -104.6 113.12 40.78 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 177.498 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.509 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -155.08 -169.77 19.99 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 117.886 -2.102 . . . . 0.0 111.802 -177.766 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.46 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -120.56 177.59 5.0 Favored 'General case' 0 N--CA 1.484 1.245 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -179.138 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.584 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 2.1 t 177.52 163.57 0.57 Allowed 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.907 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -107.44 -162.61 0.85 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.916 -1.115 . . . . 0.0 109.138 -179.79 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -115.82 35.83 4.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.697 -1.252 . . . . 0.0 109.112 -179.969 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -112.31 -32.23 6.58 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.458 -0.776 . . . . 0.0 109.864 -179.633 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.703 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.1 -35.34 0.27 Allowed Glycine 0 N--CA 1.481 1.654 0 N-CA-C 107.96 -2.056 . . . . 0.0 107.96 -179.656 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.53 -177.65 6.08 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-O 122.1 0.952 . . . . 0.0 109.839 179.263 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.496 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.31 -161.34 21.77 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.176 -1.97 . . . . 0.0 108.176 -179.361 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.501 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.3 Cg_exo -47.73 -178.77 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.671 0 CA-C-N 118.96 1.38 . . . . 0.0 110.313 179.206 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -96.69 178.04 5.45 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.979 -1.075 . . . . 0.0 110.364 -178.958 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.509 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.7 172.64 14.32 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.983 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -110.87 153.55 12.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.495 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.57 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -95.75 122.45 38.55 Favored 'General case' 0 C--N 1.291 -1.959 0 O-C-N 121.217 -0.927 . . . . 0.0 109.392 179.79 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.852 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.99 168.98 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 121.091 -1.005 . . . . 0.0 109.032 -179.905 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.499 ' HB3' ' CB ' ' A' ' 11' ' ' SER . 13.0 t -138.92 157.9 45.18 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.175 -0.953 . . . . 0.0 109.68 -179.91 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.852 ' CE2' HD12 ' A' ' 110' ' ' ILE . 82.0 m-85 -134.02 93.76 3.15 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.23 -0.919 . . . . 0.0 109.488 -179.706 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 17.5 p30 . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 118.065 -0.969 . . . . 0.0 109.464 -179.957 . . . . . . . . 0 0 . 1 . 038 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.859 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 121.305 0.574 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 039 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.708 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -89.19 164.97 28.56 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.194 -0.942 . . . . 0.0 109.458 179.979 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.708 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 4.3 Cg_exo -60.58 157.03 38.8 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.256 1.971 . . . . 0.0 110.495 179.94 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.609 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -147.0 160.64 42.12 Favored 'General case' 0 C--N 1.295 -1.797 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -179.6 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.505 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.55 122.39 9.33 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 122.366 1.079 . . . . 0.0 110.28 -179.715 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.861 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.6 t -115.9 109.16 17.22 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 123.122 1.439 . . . . 0.0 109.829 -179.827 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.817 HG22 HG23 ' A' ' 21' ' ' VAL . 2.2 t -114.78 133.7 60.1 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.19 -1.368 . . . . 0.0 109.787 179.855 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.513 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -169.26 150.17 4.15 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.232 -0.917 . . . . 0.0 108.809 -179.604 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.513 ' HA ' HG23 ' A' ' 8' ' ' THR . 1.2 Cg_endo -75.33 155.31 99.56 Favored 'Cis proline' 0 C--N 1.312 -1.35 0 C-N-CA 123.521 -1.45 . . . . 0.0 109.399 -0.873 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.5 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 15.4 m -99.62 -19.83 16.63 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.754 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.502 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 19.2 m -136.02 159.07 42.84 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.426 -0.796 . . . . 0.0 109.678 -179.945 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.37 37.78 30.67 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 108.526 -1.829 . . . . 0.0 108.526 -179.688 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.794 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.1 mt -89.75 -44.31 10.08 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 123.056 1.407 . . . . 0.0 110.599 -178.383 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.462 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.0 144.39 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.363 0 CA-C-N 113.633 -1.622 . . . . 0.0 109.935 -179.638 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.605 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.1 p-10 -50.86 105.0 0.09 Allowed 'General case' 0 C--N 1.301 -1.504 0 CA-C-O 121.632 0.729 . . . . 0.0 111.435 -178.565 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.04 14.77 7.61 Favored Glycine 0 N--CA 1.485 1.902 0 C-N-CA 119.396 -1.383 . . . . 0.0 113.055 177.383 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.794 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.7 t -104.48 -173.55 2.33 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 121.264 2.532 . . . . 0.0 109.717 179.116 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.748 HG13 ' O ' ' A' ' 67' ' ' LEU . 18.1 t -127.65 135.99 61.64 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.89 -1.05 . . . . 0.0 111.424 -178.598 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.594 HG23 ' CD1' ' A' ' 67' ' ' LEU . 34.7 m -111.2 154.6 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.529 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 5.4 tttt -110.31 109.28 19.66 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 108.894 179.875 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.817 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.27 139.17 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.347 -0.846 . . . . 0.0 108.734 -179.929 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.861 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.0 162.38 32.22 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 118.819 -1.153 . . . . 0.0 110.107 179.656 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.603 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.71 140.35 11.39 Favored Glycine 0 C--N 1.299 -1.525 0 N-CA-C 107.899 -2.08 . . . . 0.0 107.899 179.694 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.609 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.94 124.96 15.24 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.514 -1.58 . . . . 0.0 109.409 179.299 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.46 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.55 28.62 18.81 Favored Glycine 0 N--CA 1.488 2.107 0 C-N-CA 118.776 -1.678 . . . . 0.0 109.678 -179.705 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.659 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.2 mt -89.79 171.86 9.32 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.006 -1.291 . . . . 0.0 108.249 179.875 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.008 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.92 99.6 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.969 -1.082 . . . . 0.0 109.926 -179.498 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.5 77.05 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.136 -179.333 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.91 33.83 0.22 Allowed Glycine 0 N--CA 1.486 2.022 0 N-CA-C 109.311 -1.515 . . . . 0.0 109.311 179.634 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 40.4 p -141.38 107.32 5.16 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 121.09 -1.241 . . . . 0.0 111.399 -179.35 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.599 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.83 109.79 0.36 Allowed 'General case' 0 N--CA 1.496 1.835 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.621 177.828 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.593 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 4.4 m-30 -105.42 157.54 17.27 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.119 -0.988 . . . . 0.0 108.798 179.745 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.49 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -100.45 167.52 10.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.762 -1.211 . . . . 0.0 108.048 179.209 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.704 HG22 HG11 ' A' ' 21' ' ' VAL . 2.7 p -148.13 119.59 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.132 -0.98 . . . . 0.0 109.648 -178.094 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -171.26 -176.74 40.59 Favored Glycine 0 N--CA 1.496 2.638 0 C-N-CA 118.369 -1.872 . . . . 0.0 111.5 -179.763 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.685 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.71 108.3 20.13 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 -179.979 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -130.01 148.32 51.85 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.306 -0.872 . . . . 0.0 109.833 179.685 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.25 139.84 53.53 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.227 -0.921 . . . . 0.0 110.739 -179.024 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.88 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.12 114.93 26.78 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.119 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.7 m -106.21 15.49 7.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.035 -1.041 . . . . 0.0 110.526 -178.724 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.77 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.7 -176.66 0.09 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.948 -1.095 . . . . 0.0 110.068 179.739 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.794 ' O ' HG23 ' A' ' 42' ' ' THR . 15.2 t -69.78 96.72 1.01 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.503 -0.748 . . . . 0.0 110.009 -179.61 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.93 28.82 33.39 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 120.15 -1.024 . . . . 0.0 111.355 178.892 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.77 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.25 106.42 20.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 O-C-N 120.586 -1.538 . . . . 0.0 107.221 178.769 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.88 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.7 tp -116.89 104.68 11.55 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.427 -1.421 . . . . 0.0 109.706 -177.545 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.989 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.23 109.54 22.28 Favored 'General case' 0 N--CA 1.484 1.244 0 O-C-N 120.827 -1.171 . . . . 0.0 108.295 178.928 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -106.27 166.13 10.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.956 -1.09 . . . . 0.0 110.209 -179.073 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.684 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 12.6 t-20 -108.22 134.45 20.18 Favored Pre-proline 0 N--CA 1.498 1.952 0 O-C-N 121.376 -0.827 . . . . 0.0 109.599 -179.411 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.627 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.1 Cg_endo -73.93 24.29 0.34 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 122.452 2.102 . . . . 0.0 112.108 -179.655 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.684 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -113.75 -0.69 14.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.322 -1.486 . . . . 0.0 109.183 179.643 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.898 ' HB3' HD22 ' A' ' 67' ' ' LEU . 2.2 m-20 -136.38 18.26 3.15 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 179.651 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -78.04 83.96 4.32 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.66 -0.816 . . . . 0.0 110.62 -178.525 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -106.27 -170.51 1.74 Allowed 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 178.523 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.458 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.61 136.39 0.09 Allowed 'General case' 0 C--N 1.305 -1.351 0 O-C-N 120.705 -1.247 . . . . 0.0 111.008 -179.273 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.776 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.7 p -148.58 159.07 6.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 178.259 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.599 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.56 141.6 31.2 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 120.729 -1.232 . . . . 0.0 109.802 -179.923 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.008 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.09 108.04 1.72 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 122.305 1.05 . . . . 0.0 109.651 178.57 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.567 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.0 t0 -64.08 -139.44 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.027 0 CA-C-O 121.377 0.608 . . . . 0.0 110.809 179.864 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.95 -52.0 36.91 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.386 -0.821 . . . . 0.0 110.821 -178.706 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -102.49 -32.17 10.08 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 178.633 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.995 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 103.3 66.6 0.73 Allowed Glycine 0 C--N 1.298 -1.572 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.262 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.603 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 52.6 m -98.82 130.73 45.26 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.603 -0.939 . . . . 0.0 108.764 178.866 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.776 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.09 109.13 8.74 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 119.299 -0.96 . . . . 0.0 109.335 -179.576 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.9 m -123.08 116.86 24.19 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.237 -0.914 . . . . 0.0 109.498 -179.803 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.616 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.24 143.58 29.31 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.385 -0.822 . . . . 0.0 109.523 -179.993 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.0 p -99.83 147.33 25.62 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.363 -0.835 . . . . 0.0 109.469 -179.892 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.898 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -147.56 168.43 21.98 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.441 -0.787 . . . . 0.0 109.398 -179.155 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.696 HG22 HG22 ' A' ' 18' ' ' VAL . 2.5 p -100.19 121.81 42.03 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.84 -1.163 . . . . 0.0 110.098 -178.937 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.823 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.5 m -129.08 144.17 38.99 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 120.897 -1.127 . . . . 0.0 110.162 -179.404 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.605 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.7 ptt180 -149.1 -177.47 5.84 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 120.576 -1.327 . . . . 0.0 110.838 179.722 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.578 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.6 -102.58 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.702 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.508 ' OG ' ' NH1' ' A' ' 71' ' ' ARG . 0.7 OUTLIER -57.56 140.41 50.96 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 120.712 -1.242 . . . . 0.0 108.161 179.388 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.41 136.69 8.66 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.934 -178.124 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.522 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 8.9 mm-40 -32.28 120.15 0.29 Allowed 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.47 0.652 . . . . 0.0 110.6 -178.591 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.989 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.84 47.19 2.95 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.573 -0.823 . . . . 0.0 111.175 -179.195 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.627 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -38.38 113.99 0.33 Allowed 'General case' 0 N--CA 1.508 2.428 0 O-C-N 121.168 -1.195 . . . . 0.0 110.085 179.607 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.724 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -87.56 126.33 34.87 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.869 -1.145 . . . . 0.0 109.509 -179.816 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.594 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 16.4 t80 -64.26 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.856 -1.153 . . . . 0.0 110.035 179.693 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.0 t0 -159.87 19.25 0.16 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.982 -1.073 . . . . 0.0 109.735 179.895 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.93 -27.02 5.64 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.837 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.403 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.3 p -95.17 161.47 14.1 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.006 -1.29 . . . . 0.0 110.361 -179.491 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.475 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -107.66 136.32 47.61 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.832 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.724 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -83.03 -17.61 42.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.858 -1.151 . . . . 0.0 110.502 -178.649 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.71 174.02 19.65 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 108.862 -1.695 . . . . 0.0 108.862 -179.632 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.97 105.97 0.95 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.08 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.641 HG21 ' HB3' ' A' ' 46' ' ' ALA . 46.1 t -76.94 105.46 5.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.385 -0.822 . . . . 0.0 109.45 -178.682 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.558 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.9 m-20 -64.01 110.61 2.19 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.43 -0.793 . . . . 0.0 109.7 -179.624 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.578 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.3 t -65.0 -4.48 4.65 Favored 'General case' 0 N--CA 1.499 2.024 0 C-N-CA 118.289 -1.364 . . . . 0.0 109.969 179.505 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 38.7 p -86.82 -1.14 57.54 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.712 -1.242 . . . . 0.0 109.239 179.579 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.558 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -112.28 -50.27 2.91 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.34 -0.85 . . . . 0.0 108.917 -179.99 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.39 -178.27 3.61 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.596 -0.69 . . . . 0.0 109.301 179.724 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.29 115.51 30.33 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.349 -0.844 . . . . 0.0 109.14 -179.989 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.77 121.62 38.82 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.848 -1.158 . . . . 0.0 109.244 -179.578 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.656 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.31 145.26 30.22 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 122.424 1.107 . . . . 0.0 111.16 -179.176 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.502 ' HB ' HG11 ' A' ' 7' ' ' VAL . 49.1 t -101.73 109.88 27.1 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.999 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 177.68 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.489 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.7 -170.57 16.62 Favored Glycine 0 N--CA 1.486 2.012 0 C-N-CA 118.26 -1.924 . . . . 0.0 111.666 -177.569 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.49 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -112.91 179.61 3.92 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 -179.197 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.567 ' HB3' ' C26' ' A' ' 114' ' ' CHR . 33.8 p -168.66 166.43 11.81 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.381 -0.824 . . . . 0.0 109.585 -179.328 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.593 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -116.71 -159.25 0.72 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.229 -0.919 . . . . 0.0 108.864 179.629 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.401 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -118.37 36.01 4.54 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.667 -1.271 . . . . 0.0 109.286 -179.911 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.66 -33.03 4.39 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.369 -0.832 . . . . 0.0 110.311 -179.572 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 1.002 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.07 -36.8 0.23 Allowed Glycine 0 N--CA 1.483 1.772 0 N-CA-C 107.657 -2.177 . . . . 0.0 107.657 -179.562 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -159.58 -178.04 6.83 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 122.104 0.954 . . . . 0.0 109.768 179.206 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.46 -162.65 14.65 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 -179.404 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.3 Cg_exo -47.09 177.09 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.608 0 CA-C-N 118.807 1.304 . . . . 0.0 110.042 179.258 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -91.81 -178.57 5.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.015 -1.053 . . . . 0.0 110.409 -178.704 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.489 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.74 165.29 12.95 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.954 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.456 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.83 129.51 51.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 O-C-N 121.458 -1.025 . . . . 0.0 109.249 -179.413 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.656 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.31 126.6 30.49 Favored 'General case' 0 C--N 1.291 -1.972 0 O-C-N 121.677 -0.639 . . . . 0.0 109.791 179.756 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.697 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 20.8 pt -97.43 177.2 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.226 -0.921 . . . . 0.0 109.473 -179.884 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.502 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.3 m -144.2 150.96 38.81 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.464 -0.772 . . . . 0.0 109.54 179.851 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.697 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 94.9 m-85 -130.16 92.83 3.36 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 121.115 -0.991 . . . . 0.0 109.506 -179.636 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.419 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 13.4 p30 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.527 179.969 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 1.002 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 040 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.08 154.98 58.42 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.231 -0.918 . . . . 0.0 109.503 179.991 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.736 ' O ' HG23 ' A' ' 4' ' ' THR . 3.4 Cg_exo -60.76 157.37 38.09 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.252 1.968 . . . . 0.0 110.486 -179.948 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.736 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.1 p -162.04 160.71 27.85 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -179.327 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.511 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.34 128.23 14.45 Favored 'General case' 0 C--N 1.298 -1.636 0 C-N-CA 118.989 -1.084 . . . . 0.0 110.599 -179.707 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.015 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -104.82 104.72 14.55 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 122.456 1.122 . . . . 0.0 110.243 -179.495 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.928 HG22 HG23 ' A' ' 21' ' ' VAL . 14.7 t -119.51 115.4 47.5 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.443 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.265 179.704 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.72 148.94 12.95 Favored Pre-proline 0 N--CA 1.488 1.451 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.547 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -78.59 149.77 86.21 Favored 'Cis proline' 0 C--N 1.31 -1.497 0 C-N-CA 123.726 -1.364 . . . . 0.0 109.558 -0.609 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.657 ' HA ' HG22 ' A' ' 110' ' ' ILE . 77.6 p -91.7 -24.06 19.6 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.543 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.479 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 0.9 OUTLIER -131.28 162.18 30.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.45 -0.781 . . . . 0.0 109.513 -179.921 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.17 38.37 34.78 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 -179.536 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.809 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.5 mt -91.51 -44.28 9.19 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 123.142 1.448 . . . . 0.0 110.691 -178.233 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.472 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.7 144.87 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.274 0 CA-C-N 113.587 -1.642 . . . . 0.0 109.915 -179.629 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.577 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 9.2 p-10 -50.81 106.29 0.12 Allowed 'General case' 0 C--N 1.302 -1.46 0 CA-C-O 121.492 0.663 . . . . 0.0 111.674 -178.575 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.55 15.51 8.77 Favored Glycine 0 N--CA 1.485 1.918 0 C-N-CA 119.523 -1.323 . . . . 0.0 112.944 177.178 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.809 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.9 t -103.93 -172.3 2.08 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 121.156 2.478 . . . . 0.0 109.835 179.304 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.761 HG22 HG22 ' A' ' 68' ' ' THR . 15.1 t -131.56 140.23 48.75 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.301 0 CA-C-N 114.873 -1.058 . . . . 0.0 111.186 -178.817 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.638 HG22 HG22 ' A' ' 69' ' ' VAL . 4.1 m -117.86 154.72 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 178.948 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -106.91 108.74 20.39 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.078 -1.014 . . . . 0.0 109.311 179.927 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.928 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -106.23 122.16 59.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 179.775 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.015 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.54 165.97 12.2 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 120.913 -1.117 . . . . 0.0 109.068 179.933 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.16 108.1 0.5 Allowed Glycine 0 N--CA 1.483 1.778 0 N-CA-C 108.586 -1.806 . . . . 0.0 108.586 179.848 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.585 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.58 140.31 49.53 Favored 'General case' 0 N--CA 1.498 1.954 0 CA-C-N 119.192 1.496 . . . . 0.0 110.282 -179.274 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.452 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.73 28.1 33.07 Favored Glycine 0 N--CA 1.489 2.184 0 C-N-CA 119.025 -1.559 . . . . 0.0 109.845 179.777 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -92.55 175.08 6.96 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.931 -1.335 . . . . 0.0 108.352 179.929 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.998 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.94 98.84 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.448 0 O-C-N 120.878 -1.139 . . . . 0.0 109.601 -179.625 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.663 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.3 77.48 0.0 OUTLIER 'General case' 0 C--N 1.294 -1.807 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.269 -179.131 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.31 34.35 0.32 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.457 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.564 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 59.7 p -145.42 112.08 5.87 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.075 -1.25 . . . . 0.0 111.196 -179.691 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.552 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.42 126.84 5.56 Favored 'General case' 0 N--CA 1.491 1.615 0 CA-C-O 121.458 0.647 . . . . 0.0 109.523 178.098 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.493 ' HA ' ' O ' ' A' ' 98' ' ' SER . 12.1 m-85 -118.09 150.26 39.63 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.736 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.512 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -100.84 159.0 15.56 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.652 -1.28 . . . . 0.0 107.729 178.535 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.68 ' O ' HG13 ' A' ' 34' ' ' VAL . 7.4 p -144.27 116.04 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.085 -1.009 . . . . 0.0 110.045 -177.637 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.2 -178.78 39.74 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.414 -1.85 . . . . 0.0 111.857 -179.919 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.598 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -100.31 109.01 21.2 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -179.872 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.58 148.02 52.33 Favored 'General case' 0 C--N 1.294 -1.81 0 O-C-N 121.357 -0.84 . . . . 0.0 109.835 179.873 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.466 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.9 138.94 54.21 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.375 -0.828 . . . . 0.0 110.702 -179.082 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.874 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.55 114.67 26.45 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 178.187 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.42 ' O ' ' OD2' ' A' ' 41' ' ' ASP . 17.1 m -105.71 14.72 7.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.971 -1.081 . . . . 0.0 110.576 -178.679 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.761 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.92 -175.17 0.08 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.923 -1.111 . . . . 0.0 110.086 179.749 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 46.2 p -71.85 97.54 1.83 Allowed 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.428 -0.795 . . . . 0.0 109.717 -179.655 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.33 27.13 34.05 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 120.293 -0.956 . . . . 0.0 111.487 178.921 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.761 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.93 106.13 19.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.222 0 O-C-N 120.566 -1.549 . . . . 0.0 107.337 178.872 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.874 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.6 tp -117.24 104.67 11.4 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.531 -1.356 . . . . 0.0 109.669 -177.839 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.077 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.76 109.36 22.13 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.787 -1.196 . . . . 0.0 108.331 178.956 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.8 t -105.39 164.51 11.81 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.05 -1.031 . . . . 0.0 110.123 -179.055 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.695 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 13.6 t-20 -106.76 138.9 19.91 Favored Pre-proline 0 N--CA 1.501 2.087 0 O-C-N 121.333 -0.854 . . . . 0.0 110.095 -179.031 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.576 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 6.9 Cg_endo -75.88 25.9 0.41 Allowed 'Trans proline' 0 C--N 1.319 -1.012 0 C-N-CA 122.537 2.158 . . . . 0.0 111.705 179.987 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.695 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -121.43 3.54 10.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.403 -1.436 . . . . 0.0 109.312 -179.915 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.538 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.09 14.36 3.06 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.285 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -80.18 91.83 5.61 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.799 -178.644 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.617 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.53 -169.23 1.44 Allowed 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 178.356 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.03 135.56 0.09 Allowed 'General case' 0 C--N 1.306 -1.325 0 O-C-N 120.517 -1.364 . . . . 0.0 111.439 -179.351 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.899 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -151.98 157.75 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 178.102 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.41 145.31 26.29 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.595 -1.316 . . . . 0.0 109.976 -179.578 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.998 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.6 107.39 1.71 Allowed 'General case' 0 C--N 1.3 -1.582 0 CA-C-O 122.375 1.083 . . . . 0.0 109.418 178.716 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.7 p-10 -60.37 -139.25 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.019 -179.914 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.663 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.21 -50.43 59.11 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.316 -0.865 . . . . 0.0 110.564 -178.71 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -104.7 -33.71 8.38 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 106.249 -1.759 . . . . 0.0 106.249 178.529 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.982 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.01 66.99 0.61 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 178.205 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.8 m -104.3 124.84 49.89 Favored 'General case' 0 N--CA 1.485 1.28 0 O-C-N 121.674 -0.898 . . . . 0.0 108.686 178.818 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.899 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.15 109.21 8.76 Favored 'General case' 0 C--N 1.296 -1.733 0 C-N-CA 119.699 -0.8 . . . . 0.0 109.479 -179.412 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 81.2 p -117.87 118.64 32.57 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.348 -0.845 . . . . 0.0 109.448 -179.924 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.636 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.02 141.24 30.01 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.513 -0.742 . . . . 0.0 109.631 179.92 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.1 p -100.46 131.65 46.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.436 -0.79 . . . . 0.0 109.352 179.955 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.746 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -130.05 166.98 19.03 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.416 -0.803 . . . . 0.0 109.477 -179.512 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.761 HG22 HG22 ' A' ' 18' ' ' VAL . 1.7 p -97.94 124.69 42.49 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.109 -0.994 . . . . 0.0 109.365 -179.834 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.638 HG22 HG22 ' A' ' 19' ' ' VAL . 16.0 m -135.45 143.28 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.082 -1.011 . . . . 0.0 109.767 -179.292 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.577 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 4.6 ptt180 -141.1 -165.62 2.0 Allowed 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.657 -1.277 . . . . 0.0 110.494 -179.912 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.597 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 17.5 mtp180 -72.4 -80.24 0.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.367 -0.833 . . . . 0.0 109.217 -179.498 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.5 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -68.65 138.3 54.89 Favored 'General case' 0 N--CA 1.485 1.282 0 O-C-N 120.051 -1.655 . . . . 0.0 107.284 178.874 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.567 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -162.21 133.99 5.41 Favored 'General case' 0 C--N 1.295 -1.788 0 C-N-CA 117.766 -1.573 . . . . 0.0 110.414 -177.559 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.55 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -33.83 121.95 0.44 Allowed 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.44 0.638 . . . . 0.0 110.234 -178.766 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.077 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.86 51.66 2.27 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 120.512 -0.852 . . . . 0.0 111.392 -178.98 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.576 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -38.97 116.17 0.55 Allowed 'General case' 0 N--CA 1.511 2.615 0 O-C-N 121.075 -1.25 . . . . 0.0 109.933 179.519 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.693 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -87.32 126.63 34.96 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.875 -1.14 . . . . 0.0 109.328 -179.946 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.586 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.1 t80 -64.15 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.772 -1.205 . . . . 0.0 110.025 179.741 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 20.4 t70 -160.18 19.48 0.15 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.984 -1.072 . . . . 0.0 109.705 179.895 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.0 -27.39 5.51 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 179.785 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.41 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 2.3 p -95.22 160.93 14.32 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.004 -1.292 . . . . 0.0 110.318 -179.425 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.479 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.86 137.48 44.84 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.822 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.693 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.27 -19.2 40.03 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.748 -1.22 . . . . 0.0 110.437 -178.596 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.51 176.27 19.73 Favored Glycine 0 N--CA 1.484 1.85 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.485 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -63.82 108.8 1.55 Allowed 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 179.13 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.628 HG21 ' HB3' ' A' ' 46' ' ' ALA . 38.2 t -81.72 105.41 11.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 121.361 -0.837 . . . . 0.0 108.786 -179.144 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.531 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -67.68 112.16 4.63 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.39 -0.819 . . . . 0.0 109.931 -179.108 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.546 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -64.28 -5.09 4.41 Favored 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.286 -1.366 . . . . 0.0 109.97 179.437 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.404 HG22 ' NH2' ' A' ' 71' ' ' ARG . 41.0 p -85.63 1.44 49.24 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.769 -1.207 . . . . 0.0 109.021 179.361 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -115.73 -49.34 2.73 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.432 -0.792 . . . . 0.0 109.08 179.971 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.64 -179.63 4.0 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.458 -0.776 . . . . 0.0 109.536 179.961 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.99 115.36 30.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.338 -0.851 . . . . 0.0 109.102 179.958 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.507 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.7 m -96.94 123.73 40.73 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.082 -1.011 . . . . 0.0 109.54 -179.358 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.582 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.28 147.48 27.44 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 122.515 1.15 . . . . 0.0 111.356 -179.318 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.64 ' HB ' HG11 ' A' ' 7' ' ' VAL . 59.1 t -103.09 109.62 27.36 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.038 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 177.351 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.09 -174.06 17.9 Favored Glycine 0 N--CA 1.484 1.855 0 C-N-CA 118.203 -1.951 . . . . 0.0 111.815 -177.414 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.503 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -117.1 -177.59 3.24 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -178.835 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.549 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.8 OUTLIER -170.3 157.36 6.15 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.182 -0.949 . . . . 0.0 109.389 -179.344 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.696 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 3.6 m-20 -85.32 -14.91 45.04 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.133 -0.98 . . . . 0.0 109.483 179.959 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.696 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 76.16 35.5 0.46 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.513 -0.742 . . . . 0.0 109.328 -179.943 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -138.73 -34.05 0.63 Allowed 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.636 -0.665 . . . . 0.0 110.651 -179.463 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.802 ' HA2' H192 ' A' ' 114' ' ' CHR . . . -176.13 -44.03 0.06 OUTLIER Glycine 0 N--CA 1.482 1.73 0 N-CA-C 107.468 -2.253 . . . . 0.0 107.468 -179.69 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -154.98 -179.66 8.27 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 121.509 -0.995 . . . . 0.0 109.406 178.786 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -179.23 -167.78 37.22 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 -179.488 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.449 ' HG3' HD22 ' A' ' 26' ' ' LEU . 5.8 Cg_exo -48.38 175.1 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.665 0 CA-C-N 118.888 1.344 . . . . 0.0 110.002 179.523 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -92.48 -175.4 3.98 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.163 -0.96 . . . . 0.0 110.435 -178.778 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -120.52 166.54 13.77 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.908 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -106.65 131.82 55.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.452 -1.028 . . . . 0.0 109.069 -179.358 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.582 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.16 125.11 27.65 Favored 'General case' 0 C--N 1.29 -2.018 0 O-C-N 121.48 -0.762 . . . . 0.0 109.782 179.733 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.86 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.72 172.18 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.158 -0.964 . . . . 0.0 108.948 179.81 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.479 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.81 158.25 44.74 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.305 -0.872 . . . . 0.0 109.605 -179.837 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.86 ' CE2' HD12 ' A' ' 110' ' ' ILE . 70.8 m-85 -135.75 86.16 2.21 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 121.19 -0.944 . . . . 0.0 109.52 -179.585 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 17.4 p30 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 118.013 -0.994 . . . . 0.0 109.441 -179.959 . . . . . . . . 0 0 . 1 . 040 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.802 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.508 ' HB3' ' OD1' ' A' ' 60' ' ' ASN . . . . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.321 0.581 . . . . 0.0 109.479 . . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -117.66 152.06 49.26 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.203 -0.935 . . . . 0.0 109.512 179.981 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.589 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 4.6 Cg_exo -60.46 157.38 36.58 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.301 2.001 . . . . 0.0 110.625 -179.924 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.535 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.69 -169.57 0.14 Allowed 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.204 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.572 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . -167.82 133.63 1.98 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.661 -1.274 . . . . 0.0 111.252 -179.27 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.01 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -100.36 104.03 15.45 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.377 1.084 . . . . 0.0 109.783 179.982 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.937 HG22 HG23 ' A' ' 21' ' ' VAL . 6.9 t -120.32 116.72 51.1 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-O 121.726 0.774 . . . . 0.0 110.466 179.863 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.508 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.81 148.7 8.86 Favored Pre-proline 0 N--CA 1.486 1.339 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.707 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.508 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.0 Cg_endo -77.94 150.32 89.18 Favored 'Cis proline' 0 C--N 1.307 -1.65 0 C-N-CA 123.604 -1.415 . . . . 0.0 109.513 -0.425 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.674 ' HA ' HG22 ' A' ' 110' ' ' ILE . 80.1 p -91.3 -24.69 19.75 Favored 'General case' 0 C--N 1.292 -1.916 0 O-C-N 121.498 -0.751 . . . . 0.0 108.985 179.518 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.519 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 17.0 m -133.92 161.9 33.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.521 -0.737 . . . . 0.0 109.367 -179.931 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.77 37.06 31.05 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 108.571 -1.811 . . . . 0.0 108.571 -179.657 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.725 ' CA ' HG21 ' A' ' 17' ' ' THR . 42.8 mt -91.12 -42.13 10.64 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-O 123.374 1.559 . . . . 0.0 110.22 -178.548 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.468 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.65 142.31 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.238 -1.801 . . . . 0.0 109.838 -179.488 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.61 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.3 p-10 -49.94 106.86 0.13 Allowed 'General case' 0 C--N 1.298 -1.656 0 CA-C-O 121.562 0.696 . . . . 0.0 111.324 -178.588 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.16 10.64 9.57 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.132 177.449 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.725 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.7 t -105.48 -171.31 1.89 Allowed 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 121.286 2.543 . . . . 0.0 109.905 179.471 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.81 HG13 ' C ' ' A' ' 67' ' ' LEU . 16.8 t -132.93 143.42 39.55 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.284 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.851 -178.952 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.599 HG11 HD11 ' A' ' 13' ' ' LEU . 32.2 m -118.98 155.34 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.28 -0.887 . . . . 0.0 108.707 179.21 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.547 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -105.08 108.77 20.47 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.152 -0.967 . . . . 0.0 109.441 -179.897 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.937 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -106.74 121.76 59.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.434 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -118.07 167.16 11.72 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 120.688 -1.257 . . . . 0.0 109.292 -179.604 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.602 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.55 143.47 15.11 Favored Glycine 0 C--N 1.294 -1.78 0 N-CA-C 107.774 -2.131 . . . . 0.0 107.774 179.735 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.589 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -147.82 123.01 10.2 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 120.929 -1.336 . . . . 0.0 108.589 179.175 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.51 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 90.18 27.39 21.0 Favored Glycine 0 N--CA 1.487 2.063 0 C-N-CA 119.201 -1.476 . . . . 0.0 109.755 -179.448 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.0 mt -87.9 175.85 7.62 Favored 'General case' 0 C--N 1.308 -1.224 0 O-C-N 120.846 -1.384 . . . . 0.0 108.403 179.964 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.996 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.24 96.85 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.029 -1.044 . . . . 0.0 109.6 -179.91 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.679 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.24 76.48 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.448 -178.847 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.25 33.44 0.27 Allowed Glycine 0 N--CA 1.486 1.994 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 179.179 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.626 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.6 t -148.45 115.46 6.09 Favored 'General case' 0 C--N 1.309 -1.178 0 O-C-N 120.797 -1.414 . . . . 0.0 111.252 179.932 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.565 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.98 129.18 4.43 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.657 178.221 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.626 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 6.8 m-85 -121.5 146.82 46.54 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.727 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.508 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.95 164.31 12.24 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 107.429 -1.323 . . . . 0.0 107.429 178.54 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.948 HG11 HG21 ' A' ' 65' ' ' THR . 7.1 p -148.95 115.11 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.979 -1.076 . . . . 0.0 110.133 -177.673 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.15 -174.29 36.85 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 118.541 -1.79 . . . . 0.0 111.563 -179.938 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.568 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -100.77 108.89 20.83 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -179.718 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.26 148.76 52.12 Favored 'General case' 0 C--N 1.296 -1.73 0 O-C-N 121.19 -0.944 . . . . 0.0 109.934 179.765 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.33 139.1 53.98 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.276 -0.89 . . . . 0.0 110.613 -179.03 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.882 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.17 114.89 26.74 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 178.116 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.2 m -106.17 15.57 7.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.014 -1.054 . . . . 0.0 110.587 -178.676 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.3 -175.59 0.09 Allowed 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.933 -1.105 . . . . 0.0 110.021 179.739 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.0 97.47 1.88 Allowed 'General case' 0 N--CA 1.486 1.33 0 O-C-N 121.423 -0.798 . . . . 0.0 109.724 -179.765 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.64 27.93 33.89 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 120.164 -1.017 . . . . 0.0 111.399 178.973 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.52 106.33 20.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 O-C-N 120.612 -1.522 . . . . 0.0 107.289 178.928 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.882 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -116.88 104.74 11.61 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.501 -1.374 . . . . 0.0 109.684 -177.626 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.068 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.13 109.57 22.3 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.739 -1.226 . . . . 0.0 108.213 178.797 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -108.12 164.53 12.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.977 -1.077 . . . . 0.0 110.081 -178.929 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.62 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 7.5 t30 -108.62 130.02 23.27 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.357 -0.84 . . . . 0.0 109.69 -179.284 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.614 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -71.01 19.83 0.23 Allowed 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 122.178 1.919 . . . . 0.0 112.044 179.502 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.634 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -108.32 1.12 21.66 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.364 -1.46 . . . . 0.0 108.883 179.305 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.576 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.07 19.27 2.99 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 179.462 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -83.0 90.9 7.07 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.876 -0.73 . . . . 0.0 111.005 -178.439 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.66 -171.02 1.76 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.944 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.437 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.3 OUTLIER 178.53 137.96 0.09 Allowed 'General case' 0 C--N 1.304 -1.372 0 O-C-N 120.501 -1.374 . . . . 0.0 111.544 -179.16 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.822 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -154.79 159.51 3.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 178.07 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.565 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.28 145.78 25.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.59 -1.319 . . . . 0.0 109.722 -179.676 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.996 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.66 108.09 2.78 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 122.353 1.073 . . . . 0.0 109.582 179.037 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.541 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 t0 -63.03 -139.21 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.015 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.874 -179.917 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.679 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.04 -51.83 28.88 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.411 -0.806 . . . . 0.0 110.759 -178.572 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.508 ' OD1' ' HB3' ' A' ' 1' ' ' ALA . 0.8 OUTLIER -105.09 -32.07 8.87 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 178.585 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.963 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.25 67.96 0.69 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 178.391 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.602 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.2 m -103.42 128.88 50.46 Favored 'General case' 0 N--CA 1.484 1.266 0 O-C-N 121.37 -1.077 . . . . 0.0 109.143 179.202 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.822 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.25 108.65 6.89 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 119.321 -0.952 . . . . 0.0 109.949 -179.486 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.494 ' HB3' ' CE ' ' A' ' 20' ' ' LYS . 3.4 m -114.48 116.58 29.07 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.995 -1.066 . . . . 0.0 109.409 179.85 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.948 HG21 HG11 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -143.08 142.19 31.46 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 110.013 -179.971 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.9 p -100.71 136.32 40.76 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.466 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.81 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -141.08 156.82 45.93 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.935 . . . . 0.0 109.808 -179.129 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.634 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 12.9 t -87.04 138.76 31.22 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.062 -1.023 . . . . 0.0 110.676 -179.608 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.564 HG12 ' HB3' ' A' ' 36' ' ' GLN . 20.7 m -149.27 143.55 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.508 -0.745 . . . . 0.0 109.232 -179.852 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.61 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -147.52 -178.01 6.01 Favored 'General case' 0 N--CA 1.486 1.326 0 O-C-N 120.487 -1.383 . . . . 0.0 111.206 -179.68 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.697 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -47.52 -98.92 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -179.616 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.523 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -64.02 145.01 56.65 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.389 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.599 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -163.95 143.2 7.85 Favored 'General case' 0 C--N 1.291 -1.952 0 C-N-CA 118.045 -1.462 . . . . 0.0 110.268 -177.419 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.538 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 29.4 mm-40 -37.29 120.46 0.77 Allowed 'General case' 0 N--CA 1.489 1.477 0 CA-C-O 121.457 0.646 . . . . 0.0 110.304 -178.888 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.068 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -96.5 52.45 1.54 Allowed Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.477 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.614 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.8 m-85 -39.76 114.96 0.47 Allowed 'General case' 0 N--CA 1.508 2.465 0 O-C-N 121.181 -1.188 . . . . 0.0 110.113 179.65 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.656 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.13 126.55 34.3 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.866 -1.146 . . . . 0.0 109.511 -179.986 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.576 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.6 t80 -64.1 58.17 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.004 0 O-C-N 120.845 -1.159 . . . . 0.0 110.25 179.767 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.58 19.68 0.14 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.025 -1.047 . . . . 0.0 109.709 179.892 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.88 -27.5 5.4 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.871 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.419 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 11.9 p -93.36 158.53 15.69 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.02 -1.282 . . . . 0.0 110.434 -179.455 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.487 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.35 136.28 46.35 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.627 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.656 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.1 t90 -83.08 -16.72 45.81 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.669 -1.269 . . . . 0.0 110.647 -178.194 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.57 175.94 21.18 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 108.709 -1.756 . . . . 0.0 108.709 -179.618 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -64.84 103.07 0.66 Allowed 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 179.106 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.656 HG21 ' HB3' ' A' ' 46' ' ' ALA . 37.2 t -73.78 107.97 4.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 109.483 -178.755 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.523 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.8 OUTLIER -65.11 112.09 3.22 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.462 -0.774 . . . . 0.0 109.706 -179.58 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.697 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 4.0 m -62.81 -4.98 2.4 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.422 -1.311 . . . . 0.0 110.228 179.608 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.5 p -89.25 -2.94 58.67 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.566 -1.334 . . . . 0.0 109.555 -179.983 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.522 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -106.31 -48.65 3.52 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.071 -1.018 . . . . 0.0 108.861 179.885 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.42 -177.86 3.4 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.631 -0.668 . . . . 0.0 109.297 179.726 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.59 115.98 31.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.454 -0.779 . . . . 0.0 108.927 179.834 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.544 ' HB2' HD11 ' A' ' 110' ' ' ILE . 3.2 m -96.48 120.32 36.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.913 -1.117 . . . . 0.0 109.615 -179.245 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.93 145.28 30.37 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 122.409 1.099 . . . . 0.0 111.282 -179.392 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.582 ' HB ' HG11 ' A' ' 7' ' ' VAL . 92.4 t -102.22 109.86 27.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.945 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 177.788 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.494 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.49 -173.22 19.82 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 118.112 -1.995 . . . . 0.0 111.695 -177.608 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.538 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -111.93 -178.61 3.47 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 -179.345 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.586 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.1 p -175.1 167.47 3.48 Favored 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.197 -0.939 . . . . 0.0 109.751 -179.132 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -117.67 -161.46 0.82 Allowed 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.032 -1.042 . . . . 0.0 108.901 179.906 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -117.38 35.67 4.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.598 -1.314 . . . . 0.0 109.453 -179.955 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.26 -31.19 6.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.374 -0.829 . . . . 0.0 109.955 -179.705 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.868 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 164.22 -35.12 0.29 Allowed Glycine 0 N--CA 1.482 1.723 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 -179.558 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.11 -177.6 5.85 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.578 -0.954 . . . . 0.0 109.713 179.242 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.31 -161.5 14.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 -179.345 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.485 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.5 Cg_exo -47.97 -179.36 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.612 0 CA-C-N 118.877 1.339 . . . . 0.0 110.304 179.328 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -93.59 -173.95 3.34 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.002 -1.061 . . . . 0.0 110.298 -178.974 . . . . . . . . 1 1 . 1 . 041 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.494 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.76 164.18 14.97 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.946 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.86 129.41 51.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.367 -1.078 . . . . 0.0 109.0 -179.46 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.79 119.25 15.7 Favored 'General case' 0 C--N 1.288 -2.101 0 O-C-N 121.746 -0.596 . . . . 0.0 109.73 179.759 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.813 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -98.09 170.04 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.188 -0.945 . . . . 0.0 108.861 179.821 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.519 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -138.46 155.08 48.78 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.085 -1.01 . . . . 0.0 109.6 -179.908 . . . . . . . . 3 3 . 1 . 041 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.813 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 77.6 m-85 -129.67 99.11 5.03 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.271 -0.893 . . . . 0.0 109.424 -179.686 . . . . . . . . 2 2 . 1 . 041 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 14.3 p30 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 118.011 -0.995 . . . . 0.0 109.463 179.992 . . . . . . . . 0 0 . 1 . 041 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.868 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 042 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.62 152.64 44.19 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.296 -0.878 . . . . 0.0 109.498 179.933 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.497 ' O ' HG23 ' A' ' 4' ' ' THR . 2.6 Cg_endo -61.43 156.83 44.25 Favored 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 122.271 1.981 . . . . 0.0 110.534 179.981 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.6 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -155.01 160.96 41.45 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 -179.511 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -146.8 127.98 14.74 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 119.011 -1.075 . . . . 0.0 110.594 -179.731 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.012 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -104.72 104.85 14.72 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-O 122.532 1.158 . . . . 0.0 110.142 -179.519 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.974 HG22 HG23 ' A' ' 21' ' ' VAL . 12.5 t -119.48 120.0 62.25 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.438 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.355 179.616 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.519 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.67 150.3 8.84 Favored Pre-proline 0 N--CA 1.489 1.492 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 -179.621 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.519 ' HA ' HG23 ' A' ' 8' ' ' THR . 1.3 Cg_endo -74.22 153.98 99.42 Favored 'Cis proline' 0 C--N 1.31 -1.493 0 C-N-CA 123.621 -1.408 . . . . 0.0 109.927 -0.482 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.628 ' HA ' HG22 ' A' ' 110' ' ' ILE . 4.5 m -93.64 -23.94 18.08 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.646 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.495 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 3.1 m -137.12 166.14 24.41 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.61 -0.681 . . . . 0.0 109.424 179.919 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.14 38.09 40.93 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 108.346 -1.902 . . . . 0.0 108.346 -179.6 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.852 ' CA ' HG21 ' A' ' 17' ' ' THR . 29.9 mt -91.42 -45.21 8.68 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 123.131 1.444 . . . . 0.0 110.676 -178.316 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.28 146.16 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.763 -1.562 . . . . 0.0 109.942 -179.704 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.592 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.5 p-10 -51.44 110.14 0.42 Allowed 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 121.532 0.682 . . . . 0.0 111.664 -178.614 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.52 13.97 12.23 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.557 -1.306 . . . . 0.0 112.731 177.345 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.852 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.0 t -102.66 -173.38 2.31 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 120.929 2.364 . . . . 0.0 109.632 179.365 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.73 HG13 ' C ' ' A' ' 67' ' ' LEU . 12.7 t -132.15 137.75 53.96 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.866 -1.061 . . . . 0.0 111.14 -178.995 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.498 HG13 ' CG2' ' A' ' 69' ' ' VAL . 29.2 m -114.57 154.48 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.351 -0.843 . . . . 0.0 109.07 178.934 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.555 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.3 tttt -109.33 108.93 19.68 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.266 -0.896 . . . . 0.0 109.126 179.83 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.974 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -107.25 122.92 62.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -179.954 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.012 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.48 165.96 12.19 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.761 -1.212 . . . . 0.0 109.136 179.694 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.58 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.15 107.84 0.49 Allowed Glycine 0 N--CA 1.483 1.793 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 179.865 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.6 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.49 141.15 48.56 Favored 'General case' 0 N--CA 1.5 2.051 0 CA-C-N 119.248 1.524 . . . . 0.0 110.273 -179.389 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.44 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.28 28.37 33.75 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 118.943 -1.598 . . . . 0.0 109.767 179.621 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.523 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -94.54 173.66 7.51 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.941 -1.329 . . . . 0.0 108.553 179.971 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.005 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.72 98.74 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.006 -1.059 . . . . 0.0 109.703 -179.885 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.622 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.41 76.6 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.188 -179.21 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 135.06 33.35 0.28 Allowed Glycine 0 N--CA 1.486 1.993 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.483 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.627 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -142.49 111.83 6.6 Favored 'General case' 0 C--N 1.309 -1.174 0 O-C-N 120.928 -1.336 . . . . 0.0 111.075 -179.929 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.579 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.5 113.34 0.8 Allowed 'General case' 0 N--CA 1.497 1.922 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.915 178.67 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.627 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 11.9 m-85 -107.14 153.06 23.21 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.263 -0.898 . . . . 0.0 108.592 179.441 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.482 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.66 159.55 15.22 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.729 -1.232 . . . . 0.0 107.994 178.884 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.002 HG11 HG21 ' A' ' 65' ' ' THR . 6.4 p -139.84 114.66 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 109.667 -178.086 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.96 -179.51 37.55 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 118.384 -1.865 . . . . 0.0 111.733 -179.449 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.633 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.1 pt20 -101.92 109.39 21.12 Favored 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 -179.889 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.472 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.69 149.37 52.37 Favored 'General case' 0 C--N 1.296 -1.751 0 O-C-N 121.14 -0.975 . . . . 0.0 110.087 -179.867 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.07 138.2 54.73 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.276 -0.89 . . . . 0.0 110.809 -178.976 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.887 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.26 115.0 26.85 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 178.055 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -104.36 14.3 7.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.044 -1.035 . . . . 0.0 110.491 -178.853 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.29 -174.86 0.07 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.977 -1.077 . . . . 0.0 110.095 179.765 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -72.96 98.68 2.54 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.387 -0.821 . . . . 0.0 109.606 -179.803 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.61 27.41 32.5 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 120.251 -0.975 . . . . 0.0 111.394 179.011 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -117.64 105.96 19.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 O-C-N 120.571 -1.547 . . . . 0.0 107.335 178.849 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.887 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.4 tp -117.95 104.38 10.84 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.408 -1.433 . . . . 0.0 109.741 -177.772 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.908 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.15 109.36 22.13 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 178.829 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -105.56 165.82 10.88 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.029 -1.044 . . . . 0.0 110.277 -178.612 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.614 HD22 ' HB3' ' A' ' 50' ' ' ALA . 50.8 t30 -110.66 134.93 20.77 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 121.49 -0.756 . . . . 0.0 109.885 -179.409 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.602 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -75.32 25.46 0.39 Allowed 'Trans proline' 0 C--N 1.319 -1.011 0 C-N-CA 122.328 2.019 . . . . 0.0 111.404 179.591 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.614 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -112.74 0.1 15.18 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.484 -1.385 . . . . 0.0 109.373 179.944 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.524 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.67 16.1 2.71 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 179.601 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -78.8 91.66 4.75 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.872 -0.731 . . . . 0.0 110.952 -178.648 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -110.1 -166.58 1.1 Allowed 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.281 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.448 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.7 136.44 0.09 Allowed 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.546 -1.346 . . . . 0.0 111.502 -179.289 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.957 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -154.39 157.15 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 178.174 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.579 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.37 143.95 28.28 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.772 -1.205 . . . . 0.0 109.91 -179.827 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.005 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.58 106.64 1.2 Allowed 'General case' 0 C--N 1.299 -1.587 0 CA-C-O 122.478 1.132 . . . . 0.0 109.325 178.556 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.9 p-10 -59.28 -139.53 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.918 -179.928 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.622 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.01 -50.0 62.25 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.434 -0.791 . . . . 0.0 110.731 -178.703 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.418 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.5 t-20 -103.77 -34.35 8.59 Favored 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 178.379 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.004 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.76 66.13 0.61 Allowed Glycine 0 C--N 1.297 -1.599 0 N-CA-C 110.459 -1.056 . . . . 0.0 110.459 178.126 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.8 m -104.36 124.23 48.83 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.683 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.957 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.89 109.2 8.9 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 119.692 -0.803 . . . . 0.0 109.506 -179.278 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.2 m -116.88 116.35 27.27 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.3 -0.875 . . . . 0.0 109.353 -179.93 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 65' ' ' THR . . . . . 1.002 HG21 HG11 ' A' ' 34' ' ' VAL . 1.2 t -140.78 139.08 34.53 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.507 -0.745 . . . . 0.0 109.762 179.998 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.6 p -99.02 138.38 36.2 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.38 -0.825 . . . . 0.0 108.982 179.631 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.809 HD12 ' H ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.56 166.44 24.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.269 -0.894 . . . . 0.0 109.547 -179.15 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.66 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -95.3 125.02 39.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.061 -1.025 . . . . 0.0 109.44 -179.818 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.609 HG23 HD13 ' A' ' 13' ' ' LEU . 15.0 m -133.29 143.32 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 120.955 -1.091 . . . . 0.0 109.798 -179.207 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.592 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.59 -170.7 3.58 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.484 -1.385 . . . . 0.0 111.092 179.992 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.606 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -63.12 -101.87 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.954 -0.466 . . . . 0.0 110.309 -179.034 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.535 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -58.95 137.98 57.64 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.595 -1.316 . . . . 0.0 108.534 -180.0 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.633 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.8 OUTLIER -156.62 156.59 33.79 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 118.807 -1.157 . . . . 0.0 109.746 -178.864 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.545 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 10.3 mm-40 -48.35 122.28 5.21 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.587 -178.603 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.908 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.32 46.78 3.41 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -179.555 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.602 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -38.59 112.92 0.26 Allowed 'General case' 0 N--CA 1.506 2.351 0 O-C-N 121.22 -1.164 . . . . 0.0 110.537 -179.795 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.753 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.79 126.89 34.92 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.986 -1.071 . . . . 0.0 109.366 179.945 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.588 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.8 t80 -63.68 58.41 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.017 0 O-C-N 120.851 -1.156 . . . . 0.0 110.21 179.761 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.1 t0 -161.1 19.52 0.12 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.927 -1.108 . . . . 0.0 109.786 179.816 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.28 -26.73 5.46 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 179.798 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 47.2 p -93.88 160.72 14.61 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.958 -1.319 . . . . 0.0 110.275 -179.508 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.486 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.9 OUTLIER -107.23 134.92 49.61 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.895 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.753 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.2 t90 -81.74 -17.46 47.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.956 -1.09 . . . . 0.0 110.327 -178.608 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.12 173.46 18.76 Favored Glycine 0 N--CA 1.485 1.936 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 -179.544 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -63.77 107.34 1.17 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 179.093 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.645 HG21 ' HB3' ' A' ' 46' ' ' ALA . 44.5 t -78.7 104.61 6.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 121.398 -0.814 . . . . 0.0 109.275 -178.686 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.557 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.2 m-20 -64.88 108.86 1.89 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.545 -0.722 . . . . 0.0 110.032 -179.377 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.606 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.6 t -60.3 -5.52 1.15 Allowed 'General case' 0 N--CA 1.501 2.113 0 C-N-CA 118.164 -1.414 . . . . 0.0 110.343 179.302 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 33.1 p -89.51 0.83 56.61 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.486 -1.384 . . . . 0.0 109.528 179.987 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.557 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -111.67 -48.61 3.06 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.201 -0.937 . . . . 0.0 109.129 -179.894 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.31 179.38 4.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.592 -0.693 . . . . 0.0 109.539 -179.896 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.28 113.31 26.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.369 -0.832 . . . . 0.0 108.925 179.826 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.515 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.8 m -96.55 121.07 37.98 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.035 -1.041 . . . . 0.0 109.43 -178.854 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.589 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.82 148.11 25.7 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-O 122.416 1.103 . . . . 0.0 111.301 -179.375 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.625 ' HB ' HG11 ' A' ' 7' ' ' VAL . 47.7 t -104.41 109.96 29.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 N-CA-C 106.697 -1.594 . . . . 0.0 106.697 177.607 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.457 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.51 -171.15 17.79 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 118.15 -1.976 . . . . 0.0 111.589 -177.686 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.541 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -115.08 -178.54 3.39 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -178.888 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.574 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.2 p 178.65 171.03 0.81 Allowed 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.224 -0.923 . . . . 0.0 109.65 -179.113 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.451 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -122.26 -159.58 0.83 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 120.902 -1.124 . . . . 0.0 108.934 179.801 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.404 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.62 36.58 4.08 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.673 -1.267 . . . . 0.0 109.134 179.985 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -116.27 -34.04 4.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.374 -0.829 . . . . 0.0 110.099 -179.686 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.791 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.4 -37.03 0.23 Allowed Glycine 0 N--CA 1.481 1.692 0 N-CA-C 107.915 -2.074 . . . . 0.0 107.915 -179.72 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.23 -177.47 5.73 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.542 -0.975 . . . . 0.0 110.09 179.419 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.37 -163.69 23.82 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 108.17 -1.972 . . . . 0.0 108.17 -179.512 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.541 ' HB2' HD12 ' A' ' 97' ' ' LEU . 7.2 Cg_exo -46.09 172.78 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.693 0 CA-C-N 119.084 1.442 . . . . 0.0 109.938 179.332 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -91.16 -177.2 4.82 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.071 -1.018 . . . . 0.0 110.701 -178.632 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.457 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.27 168.36 13.81 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.842 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.47 133.57 51.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.43 -1.041 . . . . 0.0 109.176 -179.202 . . . . . . . . 1 1 . 1 . 042 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.589 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.68 123.48 24.14 Favored 'General case' 0 C--N 1.291 -1.976 0 O-C-N 121.55 -0.719 . . . . 0.0 109.874 179.72 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.837 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.97 172.77 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.137 -0.977 . . . . 0.0 108.969 179.711 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.495 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.97 157.74 45.18 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.036 -1.04 . . . . 0.0 110.094 -179.627 . . . . . . . . 3 3 . 1 . 042 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.837 ' CE1' HD12 ' A' ' 110' ' ' ILE . 88.0 m-85 -133.23 93.36 3.15 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.224 -0.922 . . . . 0.0 109.444 -179.825 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.563 ' OXT' ' ND2' ' A' ' 113' ' ' ASN . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 118.049 -0.977 . . . . 0.0 109.55 -179.904 . . . . . . . . 2 2 . 1 . 042 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.791 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 043 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.934 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -122.27 173.07 4.47 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.256 -0.903 . . . . 0.0 109.406 -179.925 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.934 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 6.0 Cg_exo -59.52 158.66 26.58 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.212 1.941 . . . . 0.0 110.522 179.932 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.546 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.38 -169.7 0.15 Allowed 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 179.403 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.553 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -165.37 130.46 2.51 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 120.818 -1.176 . . . . 0.0 110.751 -179.083 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.936 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.6 t -111.75 108.54 18.01 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-O 123.099 1.428 . . . . 0.0 109.053 179.339 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.897 HG22 HG23 ' A' ' 21' ' ' VAL . 5.6 t -117.71 137.39 51.78 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 0 CA-C-N 114.284 -1.326 . . . . 0.0 109.935 -179.616 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -172.85 149.11 1.8 Allowed Pre-proline 0 N--CA 1.485 1.316 0 O-C-N 121.241 -0.912 . . . . 0.0 108.815 -179.717 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -76.63 151.08 94.07 Favored 'Cis proline' 0 C--N 1.311 -1.439 0 C-N-CA 123.478 -1.468 . . . . 0.0 109.467 -0.865 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.685 ' HA ' HG22 ' A' ' 110' ' ' ILE . 65.3 p -90.17 -25.18 20.79 Favored 'General case' 0 C--N 1.294 -1.842 0 O-C-N 121.564 -0.71 . . . . 0.0 109.123 179.686 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.511 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.5 m -134.16 165.04 26.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.459 -0.776 . . . . 0.0 109.534 -179.904 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.22 38.28 34.79 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 -179.61 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.76 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.0 mt -92.4 -42.92 9.5 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 123.236 1.493 . . . . 0.0 110.525 -178.322 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.0 143.86 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.468 -1.696 . . . . 0.0 109.686 -179.534 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.583 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 6.0 p-10 -50.98 107.19 0.16 Allowed 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 121.625 0.726 . . . . 0.0 111.608 -178.437 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.46 11.61 11.59 Favored Glycine 0 N--CA 1.485 1.902 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.087 177.254 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.76 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -102.3 -169.8 1.72 Allowed 'General case' 0 C--N 1.312 -1.043 0 CA-C-N 121.111 2.455 . . . . 0.0 109.615 179.397 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.765 HG13 ' C ' ' A' ' 67' ' ' LEU . 12.0 t -134.17 142.23 41.56 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.702 -179.255 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.579 HG12 HD21 ' A' ' 13' ' ' LEU . 35.0 m -119.88 155.21 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.276 -0.89 . . . . 0.0 108.853 179.313 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 11.1 tttt -103.96 109.24 20.93 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.207 -0.933 . . . . 0.0 109.158 -179.965 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.897 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -101.94 140.87 19.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.607 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.936 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.3 160.15 39.89 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 118.62 -1.232 . . . . 0.0 109.949 179.795 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.594 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.19 143.89 15.16 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 179.578 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.576 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -145.73 125.93 13.83 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 120.87 -1.371 . . . . 0.0 108.911 179.296 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.531 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.73 26.39 27.24 Favored Glycine 0 N--CA 1.488 2.137 0 C-N-CA 119.296 -1.43 . . . . 0.0 109.777 -179.692 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.554 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.0 mt -86.84 175.3 8.26 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.918 -1.342 . . . . 0.0 108.364 -179.933 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.85 97.33 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.961 -1.087 . . . . 0.0 109.737 -179.61 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.675 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.53 77.32 0.0 OUTLIER 'General case' 0 C--N 1.294 -1.813 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.42 -179.134 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.12 34.4 0.33 Allowed Glycine 0 N--CA 1.486 2.005 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.381 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.549 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.4 p -147.78 113.26 5.63 Favored 'General case' 0 C--N 1.307 -1.251 0 O-C-N 121.045 -1.267 . . . . 0.0 111.236 -179.819 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.569 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -43.53 128.41 5.06 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.823 178.263 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.49 ' CD2' ' O ' ' A' ' 30' ' ' THR . 11.3 m-85 -121.38 149.8 42.43 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.596 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.509 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.49 156.35 17.33 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.642 -1.286 . . . . 0.0 107.854 178.84 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.649 ' O ' HG13 ' A' ' 34' ' ' VAL . 5.6 p -138.53 114.79 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.062 -1.024 . . . . 0.0 109.713 -178.06 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.08 -178.3 35.86 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.249 -1.929 . . . . 0.0 111.908 -179.529 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.568 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -101.03 112.55 25.04 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 -179.941 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 66.8 m -130.64 153.11 49.27 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.365 -0.834 . . . . 0.0 109.615 179.746 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.694 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -127.43 135.91 51.1 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.482 -0.761 . . . . 0.0 110.491 -179.957 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.885 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.6 OUTLIER -94.83 114.37 26.24 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.243 -1.391 . . . . 0.0 107.243 178.137 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 m -106.27 14.86 7.47 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 O-C-N 120.966 -1.084 . . . . 0.0 110.763 -178.473 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.776 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.21 -175.47 0.08 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.856 -1.152 . . . . 0.0 110.222 179.655 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.789 ' O ' HG23 ' A' ' 42' ' ' THR . 15.2 t -69.75 97.09 1.04 Allowed 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 121.83 0.824 . . . . 0.0 109.952 -179.445 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.66 27.15 36.09 Favored Glycine 0 N--CA 1.494 2.546 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.515 178.679 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.776 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.4 t -114.48 106.18 20.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.233 0 O-C-N 120.6 -1.53 . . . . 0.0 107.483 178.901 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.92 HD22 H182 ' A' ' 114' ' ' CHR . 11.7 tp -116.94 106.54 13.54 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.574 -1.329 . . . . 0.0 109.662 -177.724 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.096 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -95.99 111.97 23.83 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 120.676 -1.265 . . . . 0.0 108.256 179.445 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.545 ' HB3' ' CE1' ' A' ' 52' ' ' PHE . 66.8 m -101.67 147.76 26.06 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.33 -0.856 . . . . 0.0 110.71 -178.291 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.696 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 24.4 t30 -103.45 126.11 33.06 Favored Pre-proline 0 N--CA 1.503 2.198 0 O-C-N 121.248 -0.908 . . . . 0.0 108.838 179.053 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.586 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.5 Cg_endo -70.58 23.85 0.2 Allowed 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 122.108 1.872 . . . . 0.0 112.561 -179.657 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.696 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -110.15 2.15 19.21 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.252 -1.53 . . . . 0.0 109.317 179.346 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.562 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.54 16.18 2.55 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 179.628 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.545 ' CE1' ' HB3' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -79.08 91.51 4.91 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.579 -0.701 . . . . 0.0 110.885 -178.568 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.625 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.67 -165.71 1.05 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.284 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 179.04 135.3 0.09 Allowed 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.514 -1.366 . . . . 0.0 111.564 -179.339 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.899 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -153.2 157.83 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 107.116 -1.438 . . . . 0.0 107.116 178.024 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.569 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.71 145.92 25.86 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.658 -1.276 . . . . 0.0 109.865 -179.73 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.38 107.98 2.2 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 122.368 1.08 . . . . 0.0 109.478 178.733 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.526 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.2 t0 -62.02 -139.11 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.045 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.931 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.675 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.84 -51.62 38.71 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.477 -0.764 . . . . 0.0 110.733 -178.614 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.73 -32.39 8.89 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 178.726 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.978 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.15 65.38 0.59 Allowed Glycine 0 C--N 1.297 -1.59 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 178.307 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 48.4 m -101.77 127.99 48.31 Favored 'General case' 0 C--N 1.309 -1.187 0 O-C-N 121.468 -1.019 . . . . 0.0 108.711 178.858 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.899 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.92 108.77 7.08 Favored 'General case' 0 C--N 1.295 -1.768 0 C-N-CA 119.316 -0.953 . . . . 0.0 109.819 -179.214 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 40.2 p -121.95 120.11 33.47 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.322 -0.861 . . . . 0.0 109.481 179.945 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.438 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.74 147.97 32.49 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.482 -0.761 . . . . 0.0 109.245 179.845 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.3 p -98.64 139.74 33.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.355 -0.84 . . . . 0.0 109.593 -179.876 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.765 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -143.75 157.45 44.38 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.366 -0.834 . . . . 0.0 109.202 -179.466 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.641 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 14.4 t -86.25 137.73 32.39 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.056 -1.028 . . . . 0.0 110.427 -179.645 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.539 HG23 HD13 ' A' ' 13' ' ' LEU . 24.1 m -148.6 141.43 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.467 -0.771 . . . . 0.0 109.525 -179.444 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.583 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -143.63 -170.68 3.36 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.563 -1.335 . . . . 0.0 110.368 -179.984 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.577 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -64.4 -94.61 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 -179.812 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.524 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.77 137.73 56.27 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.776 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.694 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -162.19 137.96 7.49 Favored 'General case' 0 C--N 1.293 -1.886 0 C-N-CA 118.3 -1.36 . . . . 0.0 110.473 -177.683 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.541 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.8 OUTLIER -32.42 118.91 0.28 Allowed 'General case' 0 N--CA 1.493 1.682 0 CA-C-O 121.5 0.667 . . . . 0.0 110.6 -178.497 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.096 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.97 49.42 1.76 Allowed Glycine 0 N--CA 1.492 2.403 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.542 -179.028 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.586 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.8 m-85 -40.0 115.55 0.55 Allowed 'General case' 0 N--CA 1.509 2.517 0 O-C-N 121.029 -1.277 . . . . 0.0 109.731 179.347 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.709 HD11 HG12 ' A' ' 44' ' ' VAL . 7.6 tp -85.81 127.21 34.5 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.943 -1.098 . . . . 0.0 109.66 -179.673 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.579 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.1 t80 -64.55 57.97 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.856 -1.153 . . . . 0.0 110.182 179.664 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.47 19.62 0.14 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.929 -1.107 . . . . 0.0 109.718 179.885 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.07 -28.12 5.23 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.952 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.454 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 34.6 p -92.59 156.28 17.21 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.06 -1.259 . . . . 0.0 110.309 -179.439 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.481 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -105.04 134.73 47.65 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.664 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.616 ' HB2' HD13 ' A' ' 77' ' ' LEU . 0.6 OUTLIER -82.55 -17.21 45.76 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.655 -1.278 . . . . 0.0 110.518 -178.372 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 106.67 176.42 23.14 Favored Glycine 0 N--CA 1.485 1.904 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -179.791 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.72 105.38 0.65 Allowed 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 179.095 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.581 HG21 ' CB ' ' A' ' 46' ' ' ALA . 36.8 t -76.43 104.08 4.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.421 -0.799 . . . . 0.0 109.046 -178.816 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.545 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -62.39 109.51 1.38 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.546 -0.721 . . . . 0.0 110.027 -179.343 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.577 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.85 -4.49 6.86 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.565 -1.335 . . . . 0.0 109.728 179.256 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.5 p -85.37 3.78 38.31 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.848 -1.158 . . . . 0.0 108.989 179.499 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.545 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -119.37 -49.08 2.38 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.409 -0.807 . . . . 0.0 109.026 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.91 -178.88 3.78 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.491 -0.756 . . . . 0.0 109.474 179.826 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.55 115.26 29.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.366 -0.833 . . . . 0.0 109.138 -179.924 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.547 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.85 124.88 40.95 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.845 -1.16 . . . . 0.0 109.201 -179.628 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.572 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -104.12 146.77 28.27 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 122.379 1.085 . . . . 0.0 111.709 -179.027 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.525 ' CG1' HG11 ' A' ' 7' ' ' VAL . 84.1 t -100.4 109.81 25.97 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 177.348 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -145.87 -174.2 17.83 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 118.064 -2.017 . . . . 0.0 111.782 -177.426 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.553 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -117.62 -178.8 3.56 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 -178.95 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.548 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 1.2 p -173.28 170.19 4.33 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 121.423 -0.798 . . . . 0.0 109.094 -179.425 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.671 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 1.7 m-20 -106.07 -9.34 17.04 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.107 -0.996 . . . . 0.0 109.542 179.917 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.671 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 72.72 39.76 0.66 Allowed 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.443 -0.785 . . . . 0.0 109.121 179.991 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -137.44 -34.47 0.7 Allowed 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.629 -0.669 . . . . 0.0 110.646 -179.427 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.693 ' HA2' H192 ' A' ' 114' ' ' CHR . . . -177.09 -42.8 0.06 OUTLIER Glycine 0 N--CA 1.482 1.709 0 N-CA-C 107.867 -2.093 . . . . 0.0 107.867 -179.712 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.61 -178.11 6.36 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 121.504 -0.998 . . . . 0.0 109.626 179.209 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.13 -165.89 32.62 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.479 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.539 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.7 Cg_exo -49.53 -175.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.646 0 CA-C-N 118.874 1.337 . . . . 0.0 110.371 179.572 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 16.5 mm-40 -95.89 -178.85 4.5 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.093 -1.004 . . . . 0.0 110.248 -179.094 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -115.64 158.74 14.2 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 -179.906 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.94 128.35 50.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.421 -1.046 . . . . 0.0 108.982 -179.555 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.572 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.32 119.26 16.27 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.589 -0.695 . . . . 0.0 109.959 179.964 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.914 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -97.97 172.61 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.241 -0.912 . . . . 0.0 108.677 179.544 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.511 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -140.7 156.91 46.09 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.945 -1.097 . . . . 0.0 110.012 -179.761 . . . . . . . . 3 3 . 1 . 043 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.914 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.6 m-85 -132.8 114.63 14.32 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.289 -0.882 . . . . 0.0 109.506 -179.749 . . . . . . . . 2 2 . 1 . 043 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.42 ' C ' ' O ' ' A' ' 112' ' ' PHE . 23.5 p30 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.036 -0.983 . . . . 0.0 109.491 -179.984 . . . . . . . . 1 1 . 1 . 043 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.92 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 044 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.756 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -93.93 165.91 16.85 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.347 -0.846 . . . . 0.0 109.535 179.995 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.756 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.2 Cg_exo -59.97 157.53 33.49 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.371 2.048 . . . . 0.0 110.667 179.969 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.605 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -147.12 160.58 42.26 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 -179.681 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.44 122.42 9.43 Favored 'General case' 0 C--N 1.297 -1.705 0 CA-C-O 122.427 1.108 . . . . 0.0 110.278 -179.659 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.793 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -116.21 109.22 17.14 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-O 123.09 1.424 . . . . 0.0 109.767 -179.992 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.836 HG22 HG23 ' A' ' 21' ' ' VAL . 2.4 t -112.87 136.26 49.71 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.745 0 CA-C-N 114.24 -1.345 . . . . 0.0 109.776 179.909 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.462 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.65 148.23 5.6 Favored Pre-proline 0 N--CA 1.487 1.396 0 O-C-N 121.184 -0.947 . . . . 0.0 108.855 -179.557 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.462 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.4 Cg_endo -76.46 151.18 94.44 Favored 'Cis proline' 0 C--N 1.312 -1.352 0 C-N-CA 123.38 -1.508 . . . . 0.0 109.422 -0.812 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.648 ' HA ' HG22 ' A' ' 110' ' ' ILE . 2.1 m -88.35 -26.73 22.06 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.593 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.484 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 13.4 m -136.73 165.14 26.61 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.616 -0.678 . . . . 0.0 109.446 179.807 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.31 37.69 31.12 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 -179.631 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.742 ' CA ' HG21 ' A' ' 17' ' ' THR . 38.7 mt -92.84 -41.98 9.78 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 123.362 1.553 . . . . 0.0 110.418 -178.342 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.476 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.45 143.24 0.05 OUTLIER 'General case' 0 C--N 1.261 -3.279 0 CA-C-N 113.297 -1.774 . . . . 0.0 109.808 -179.57 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.601 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.3 p-10 -50.79 104.75 0.08 Allowed 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 121.462 0.649 . . . . 0.0 111.432 -178.369 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.4 15.19 7.76 Favored Glycine 0 N--CA 1.485 1.963 0 C-N-CA 119.317 -1.421 . . . . 0.0 113.086 177.311 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.742 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -104.72 -170.33 1.75 Allowed 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 121.165 2.482 . . . . 0.0 109.579 179.09 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.736 HG13 ' C ' ' A' ' 67' ' ' LEU . 17.4 t -127.4 137.41 57.81 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.116 -179.133 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.633 HG13 ' CG2' ' A' ' 69' ' ' VAL . 11.7 m -111.28 156.32 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.315 -0.866 . . . . 0.0 108.852 178.932 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.504 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.4 tttt -111.55 109.48 19.42 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.214 -0.929 . . . . 0.0 108.843 179.854 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.836 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -102.91 138.8 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.975 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.793 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -132.61 161.76 33.06 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.861 -1.135 . . . . 0.0 109.941 179.689 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.588 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.92 140.75 11.85 Favored Glycine 0 C--N 1.298 -1.547 0 N-CA-C 108.144 -1.983 . . . . 0.0 108.144 179.776 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.605 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.54 125.4 16.09 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.606 -1.526 . . . . 0.0 109.296 179.374 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.46 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.2 28.51 20.06 Favored Glycine 0 N--CA 1.489 2.187 0 C-N-CA 118.69 -1.719 . . . . 0.0 109.807 -179.808 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.681 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.4 mt -89.53 171.95 9.34 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 120.936 -1.332 . . . . 0.0 108.301 179.852 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.0 99.33 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.96 -1.087 . . . . 0.0 109.892 -179.385 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.549 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.23 77.66 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.212 -179.337 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.19 34.02 0.3 Allowed Glycine 0 N--CA 1.487 2.099 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 179.57 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.557 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 48.2 p -141.94 108.57 5.35 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 121.048 -1.266 . . . . 0.0 111.252 -179.527 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.59 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.16 109.71 0.32 Allowed 'General case' 0 N--CA 1.496 1.843 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.584 177.944 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.484 ' CE1' ' OG1' ' A' ' 30' ' ' THR . 4.6 m-30 -104.26 156.14 18.15 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.145 -0.972 . . . . 0.0 108.774 179.752 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.509 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -99.7 165.36 11.64 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.978 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.05 HG11 HG21 ' A' ' 65' ' ' THR . 4.5 p -146.66 116.23 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.085 -1.009 . . . . 0.0 109.759 -178.15 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.515 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.73 -176.89 38.17 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.175 -1.964 . . . . 0.0 111.709 -179.608 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.649 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.3 pt20 -101.47 109.77 21.65 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.979 0.895 . . . . 0.0 109.055 -179.653 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.488 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.99 150.46 52.13 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 121.224 -0.922 . . . . 0.0 109.554 179.846 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.48 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.78 139.0 54.24 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.079 -1.013 . . . . 0.0 110.775 -178.949 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.16 114.64 26.45 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 178.196 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m -105.46 15.19 7.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.068 -1.02 . . . . 0.0 110.561 -178.688 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.746 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.42 -175.38 0.1 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.894 -1.128 . . . . 0.0 110.114 179.631 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -71.6 96.81 1.6 Allowed 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.426 -0.796 . . . . 0.0 109.743 -179.696 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.01 27.5 33.89 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 120.194 -1.003 . . . . 0.0 111.482 178.877 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.746 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.42 106.29 20.23 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.523 -1.575 . . . . 0.0 107.443 178.861 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -115.75 104.67 11.9 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 120.389 -1.445 . . . . 0.0 109.967 -177.658 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.833 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.18 109.24 22.03 Favored 'General case' 0 N--CA 1.484 1.24 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.709 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.7 t -107.26 167.93 9.57 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.985 -1.072 . . . . 0.0 110.564 -178.397 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.74 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 49.9 t30 -112.61 130.9 22.97 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.454 -0.779 . . . . 0.0 109.585 -179.435 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.51 ' CD ' ' HB3' ' A' ' 74' ' ' GLU . 2.8 Cg_endo -72.41 23.76 0.27 Allowed 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 122.189 1.926 . . . . 0.0 112.124 179.966 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.74 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -113.41 3.53 15.88 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.333 -1.479 . . . . 0.0 109.192 179.526 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.525 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.45 17.36 2.74 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 179.259 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -80.84 88.87 5.82 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.577 -0.702 . . . . 0.0 111.011 -178.593 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.618 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -107.27 -167.19 1.24 Allowed 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.266 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.96 135.06 0.09 Allowed 'General case' 0 C--N 1.305 -1.353 0 O-C-N 120.496 -1.377 . . . . 0.0 111.372 -179.418 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.843 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -150.3 157.72 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 178.176 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.56 142.24 30.4 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.74 -1.225 . . . . 0.0 110.054 -179.847 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.13 107.73 1.36 Allowed 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 122.469 1.128 . . . . 0.0 109.416 178.436 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.555 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.0 p-10 -61.2 -139.17 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.762 179.893 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.549 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.29 -51.07 60.66 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.431 -0.793 . . . . 0.0 110.454 -178.691 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -101.75 -34.95 9.24 Favored 'General case' 0 C--N 1.285 -2.221 0 N-CA-C 106.287 -1.745 . . . . 0.0 106.287 178.342 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.28 65.87 0.59 Allowed Glycine 0 C--N 1.298 -1.565 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.082 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.5 m -98.71 130.83 45.21 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 121.503 -0.998 . . . . 0.0 108.482 178.729 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.843 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.76 108.86 7.7 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 118.956 -1.098 . . . . 0.0 109.796 -179.272 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 60.0 p -121.51 117.72 27.52 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.36 -0.838 . . . . 0.0 109.421 179.949 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 65' ' ' THR . . . . . 1.05 HG21 HG11 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -144.99 142.17 29.57 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.489 -0.757 . . . . 0.0 109.593 179.981 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 34.0 p -99.87 141.59 32.48 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.436 -0.79 . . . . 0.0 109.287 179.815 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.736 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -142.04 166.18 25.42 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.354 -0.841 . . . . 0.0 109.418 -179.355 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.701 HG22 HG22 ' A' ' 18' ' ' VAL . 3.4 p -95.49 124.47 39.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.118 -0.989 . . . . 0.0 109.398 -179.852 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.633 ' CG2' HG13 ' A' ' 19' ' ' VAL . 18.8 m -139.76 142.56 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 120.946 -1.096 . . . . 0.0 109.964 -179.183 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.601 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.3 ptt180 -140.09 -166.35 2.08 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 120.627 -1.295 . . . . 0.0 109.897 179.903 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.594 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -71.93 -80.68 0.06 Allowed 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 179.952 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.507 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.5 OUTLIER -64.13 135.97 56.83 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.197 -1.409 . . . . 0.0 107.197 178.579 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.591 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -161.98 138.68 8.14 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 118.07 -1.452 . . . . 0.0 110.252 -177.692 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.51 ' HB3' ' CD ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -31.04 121.39 0.22 Allowed 'General case' 0 N--CA 1.492 1.634 0 CA-C-O 121.479 0.657 . . . . 0.0 110.851 -178.31 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.833 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.95 50.62 2.83 Favored Glycine 0 N--CA 1.496 2.667 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 -179.489 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.47 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.5 OUTLIER -52.97 114.13 1.33 Allowed 'General case' 0 N--CA 1.51 2.55 0 O-C-N 120.934 -1.333 . . . . 0.0 110.645 -179.886 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.685 HD13 ' HB2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -78.94 151.95 31.37 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 120.864 -1.148 . . . . 0.0 108.231 178.114 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.575 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 63.7 t80 -74.68 5.5 4.83 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 120.69 -1.256 . . . . 0.0 110.563 -179.98 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -105.16 -2.49 24.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.905 -1.122 . . . . 0.0 109.701 -179.879 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.21 -19.45 51.42 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.998 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.49 ' O ' ' HB2' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -76.35 151.56 36.61 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.147 -1.207 . . . . 0.0 109.5 -179.947 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.512 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -96.82 123.08 40.42 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.896 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.685 ' HB2' HD13 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -85.27 -16.68 39.33 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.968 -1.083 . . . . 0.0 110.046 -179.121 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 103.19 173.15 26.24 Favored Glycine 0 N--CA 1.483 1.829 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 -179.757 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -60.09 108.93 0.85 Allowed 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 178.853 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.635 HG23 ' HA3' ' A' ' 75' ' ' GLY . 25.5 t -78.88 101.27 4.16 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -178.844 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.531 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -62.14 110.41 1.6 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.548 -0.72 . . . . 0.0 110.046 -178.985 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.548 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -65.14 -4.78 5.38 Favored 'General case' 0 N--CA 1.499 1.993 0 C-N-CA 118.413 -1.315 . . . . 0.0 109.727 179.378 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.6 p -83.66 2.82 35.73 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.712 -1.242 . . . . 0.0 108.911 179.328 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.0 p -117.91 -48.53 2.55 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.406 -0.809 . . . . 0.0 108.974 -179.976 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.67 179.97 4.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.542 -0.724 . . . . 0.0 109.394 179.931 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.47 114.75 29.18 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.368 -0.832 . . . . 0.0 109.22 179.964 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.569 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.7 120.89 37.86 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.887 -1.133 . . . . 0.0 109.532 -179.305 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.611 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.91 148.25 25.2 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 122.38 1.086 . . . . 0.0 111.308 -179.322 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.507 ' CG1' HG11 ' A' ' 7' ' ' VAL . 43.2 t -105.06 111.56 35.04 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 177.66 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.427 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.47 -170.84 17.45 Favored Glycine 0 N--CA 1.486 2.025 0 C-N-CA 118.18 -1.962 . . . . 0.0 111.667 -177.65 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.495 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.68 178.81 4.2 Favored 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.016 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.584 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.0 OUTLIER -171.59 168.7 6.28 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.473 -0.767 . . . . 0.0 109.347 -179.517 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.464 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -118.1 -158.28 0.71 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.067 -1.021 . . . . 0.0 108.948 179.811 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.464 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.39 36.63 4.18 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.72 -1.238 . . . . 0.0 109.156 179.999 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -115.87 -32.74 5.35 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.262 -0.899 . . . . 0.0 110.225 -179.624 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.983 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 164.13 -35.49 0.29 Allowed Glycine 0 N--CA 1.482 1.763 0 N-CA-C 107.661 -2.175 . . . . 0.0 107.661 -179.648 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.28 -177.76 6.24 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.561 -0.964 . . . . 0.0 109.715 179.28 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.82 -161.78 15.63 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 108.41 -1.876 . . . . 0.0 108.41 -179.344 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.504 ' HG3' HD22 ' A' ' 26' ' ' LEU . 5.7 Cg_exo -47.22 178.97 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.678 0 CA-C-N 118.721 1.261 . . . . 0.0 110.345 179.378 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -92.97 -172.64 3.05 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.198 -0.939 . . . . 0.0 110.357 -178.866 . . . . . . . . 1 1 . 1 . 044 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.427 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -123.45 161.94 17.56 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.891 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.424 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.73 130.53 48.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.415 -1.05 . . . . 0.0 109.244 -179.514 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.611 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.22 120.81 19.36 Favored 'General case' 0 C--N 1.289 -2.043 0 O-C-N 121.716 -0.615 . . . . 0.0 109.646 179.684 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.878 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -98.14 169.67 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 O-C-N 121.138 -0.976 . . . . 0.0 109.331 -179.956 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.484 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -136.96 151.16 48.69 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.256 -0.903 . . . . 0.0 109.694 -179.973 . . . . . . . . 3 3 . 1 . 044 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.878 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 36.7 m-85 -128.56 100.8 5.89 Favored 'General case' 0 C--N 1.305 -1.33 0 O-C-N 121.099 -1.001 . . . . 0.0 109.539 -179.727 . . . . . . . . 2 2 . 1 . 044 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 20.1 p30 . . . . . 0 N--CA 1.49 1.527 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.417 -179.986 . . . . . . . . 0 0 . 1 . 044 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.983 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 045 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -110.31 155.48 41.86 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.239 -0.913 . . . . 0.0 109.558 179.918 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.656 ' HB3' HD23 ' A' ' 26' ' ' LEU . 3.5 Cg_exo -60.8 156.38 43.65 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.313 2.009 . . . . 0.0 110.62 -179.872 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.601 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -148.05 160.53 42.76 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.901 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -145.64 127.05 14.96 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 120.984 -1.072 . . . . 0.0 110.469 -179.67 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.016 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.4 p -105.56 105.04 14.89 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 122.501 1.143 . . . . 0.0 110.46 -179.352 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 1.127 HG22 HG23 ' A' ' 21' ' ' VAL . 3.5 t -118.12 117.82 56.09 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.426 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.267 179.426 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.485 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -161.34 148.49 11.83 Favored Pre-proline 0 N--CA 1.487 1.412 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 -179.588 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.485 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.2 Cg_endo -78.3 149.93 87.38 Favored 'Cis proline' 0 C--N 1.31 -1.491 0 C-N-CA 123.533 -1.445 . . . . 0.0 109.563 -0.573 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 88.5 p -92.23 -23.38 19.36 Favored 'General case' 0 C--N 1.291 -1.962 0 O-C-N 121.618 -0.676 . . . . 0.0 109.209 179.584 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.472 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -132.7 161.15 34.75 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.52 -0.737 . . . . 0.0 109.47 -179.91 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.01 37.76 32.07 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 -179.556 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.789 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.8 mt -90.83 -43.78 9.83 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 123.303 1.525 . . . . 0.0 110.674 -178.233 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.47 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.39 143.94 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.282 0 CA-C-N 113.508 -1.678 . . . . 0.0 109.899 -179.618 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -50.72 107.19 0.15 Allowed 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.683 0.754 . . . . 0.0 111.653 -178.611 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.26 15.46 8.99 Favored Glycine 0 N--CA 1.483 1.829 0 C-N-CA 119.557 -1.306 . . . . 0.0 112.801 177.461 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.789 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.7 t -105.3 -173.82 2.39 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 121.106 2.453 . . . . 0.0 109.914 179.309 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.756 HG13 ' O ' ' A' ' 67' ' ' LEU . 19.0 t -130.18 138.94 52.68 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 114.666 -1.152 . . . . 0.0 111.24 -178.61 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.518 HG12 HD21 ' A' ' 13' ' ' LEU . 34.6 m -115.92 155.65 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.367 -0.833 . . . . 0.0 108.817 178.725 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.541 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 12.4 tttt -107.72 109.33 20.89 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.03 -1.043 . . . . 0.0 109.66 -179.789 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 1.127 HG23 HG22 ' A' ' 7' ' ' VAL . 6.5 p -104.36 125.08 59.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.528 -0.732 . . . . 0.0 109.193 179.759 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.016 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -115.53 165.21 13.26 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.741 -1.224 . . . . 0.0 108.911 179.348 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.614 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.39 107.95 0.49 Allowed Glycine 0 N--CA 1.481 1.686 0 N-CA-C 108.242 -1.943 . . . . 0.0 108.242 -179.97 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.601 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -118.23 139.84 50.69 Favored 'General case' 0 N--CA 1.5 2.035 0 CA-C-N 119.635 1.718 . . . . 0.0 110.464 -179.171 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.48 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 83.76 28.46 35.06 Favored Glycine 0 N--CA 1.489 2.219 0 C-N-CA 118.739 -1.696 . . . . 0.0 109.948 179.387 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.656 HD23 ' HB3' ' A' ' 3' ' ' PRO . 0.9 OUTLIER -92.4 171.96 8.7 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.935 -1.332 . . . . 0.0 108.429 179.793 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.016 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.23 100.43 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.933 -1.104 . . . . 0.0 109.781 -179.664 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.06 77.6 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.679 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.982 -179.245 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.1 33.99 0.27 Allowed Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.721 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 24.5 p -139.53 106.98 5.55 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.17 -1.194 . . . . 0.0 111.261 -179.577 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.582 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -52.37 110.4 0.49 Allowed 'General case' 0 N--CA 1.497 1.901 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.93 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.588 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 30.0 m-85 -106.68 157.4 17.73 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.06 -1.025 . . . . 0.0 109.079 179.892 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.58 165.29 11.49 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.781 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.652 HG22 HG11 ' A' ' 21' ' ' VAL . 4.6 p -144.57 121.3 4.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.13 -0.981 . . . . 0.0 109.535 -177.623 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.39 -178.53 42.62 Favored Glycine 0 N--CA 1.496 2.681 0 C-N-CA 118.114 -1.993 . . . . 0.0 111.86 -179.814 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.619 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -100.73 108.86 20.81 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.874 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -129.85 149.29 51.65 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.142 -0.974 . . . . 0.0 110.11 179.849 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.34 138.73 54.35 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.363 -0.836 . . . . 0.0 110.757 -179.128 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.25 115.03 26.89 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.146 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 m -105.9 15.52 7.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 120.95 -1.094 . . . . 0.0 110.55 -178.895 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.772 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 173.97 -176.26 0.08 Allowed 'General case' 0 C--N 1.303 -1.417 0 O-C-N 120.902 -1.124 . . . . 0.0 110.192 179.775 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.777 ' O ' HG23 ' A' ' 42' ' ' THR . 15.0 t -71.16 98.45 1.69 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.426 -0.796 . . . . 0.0 109.827 -179.672 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.7 28.77 34.25 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.312 179.006 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.772 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -117.5 106.11 19.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 120.608 -1.525 . . . . 0.0 107.16 178.853 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.3 tp -117.6 104.74 11.33 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.49 -1.381 . . . . 0.0 109.756 -177.613 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.072 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.95 109.52 22.26 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.809 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -106.74 166.49 10.54 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.928 -1.108 . . . . 0.0 110.422 -178.761 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.833 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 3.0 t-20 -107.88 133.34 20.51 Favored Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.526 -0.734 . . . . 0.0 109.511 -179.247 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.3 Cg_endo -74.61 25.12 0.36 Allowed 'Trans proline' 0 C--N 1.319 -0.99 0 C-N-CA 122.376 2.05 . . . . 0.0 111.99 -179.973 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.833 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -107.12 -4.87 18.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.342 -1.474 . . . . 0.0 109.306 179.848 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.663 ' HB3' HD22 ' A' ' 67' ' ' LEU . 5.4 m-20 -133.24 5.94 3.83 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.264 -0.898 . . . . 0.0 108.683 179.918 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -60.35 80.06 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 110.5 -178.797 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.636 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -105.31 -169.6 1.62 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 178.55 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 177.88 135.67 0.07 Allowed 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.626 -1.296 . . . . 0.0 111.149 -179.249 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.783 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -149.58 157.83 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 177.907 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.582 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.31 140.1 33.1 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 120.837 -1.164 . . . . 0.0 110.038 -179.7 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -62.45 106.61 0.79 Allowed 'General case' 0 C--N 1.298 -1.673 0 CA-C-O 122.438 1.113 . . . . 0.0 109.448 178.418 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.561 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.5 p-10 -59.8 -139.38 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.031 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.882 -179.944 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.01 -50.4 61.46 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.344 -0.848 . . . . 0.0 110.485 -178.782 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -103.21 -35.0 8.62 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 178.433 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.974 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.34 69.86 0.71 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 178.123 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.614 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 48.3 m -105.1 127.68 53.0 Favored 'General case' 0 N--CA 1.485 1.299 0 O-C-N 121.517 -0.99 . . . . 0.0 108.96 179.256 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.783 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.96 109.27 8.9 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.076 -179.765 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 42.5 m -120.46 115.84 24.26 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.282 -0.886 . . . . 0.0 109.452 -179.656 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.82 143.82 29.89 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.4 -0.813 . . . . 0.0 109.502 179.967 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.436 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 21.8 p -98.76 137.21 37.69 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.467 -0.771 . . . . 0.0 109.407 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.927 HD11 HG12 ' A' ' 21' ' ' VAL . 0.1 OUTLIER -131.26 167.81 18.58 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.408 -0.808 . . . . 0.0 110.027 -178.673 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.529 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.2 p -102.62 123.6 46.62 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.051 -1.031 . . . . 0.0 108.863 179.396 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.619 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.7 m -135.99 143.99 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 120.899 -1.126 . . . . 0.0 109.868 -179.023 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.8 ptt180 -144.75 -176.79 5.21 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 120.637 -1.289 . . . . 0.0 111.046 -179.891 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.727 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.97 -94.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.276 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.533 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -65.32 148.28 51.98 Favored 'General case' 0 N--CA 1.485 1.282 0 O-C-N 120.566 -1.334 . . . . 0.0 107.543 178.63 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.602 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -167.44 140.66 3.45 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 117.942 -1.503 . . . . 0.0 110.126 -177.459 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.523 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 5.1 mm-40 -36.49 122.06 0.75 Allowed 'General case' 0 N--CA 1.489 1.509 0 CA-C-O 121.421 0.629 . . . . 0.0 110.235 -178.708 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.072 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -96.61 51.83 1.54 Allowed Glycine 0 N--CA 1.495 2.571 0 C-N-CA 120.496 -0.859 . . . . 0.0 111.148 -179.252 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -39.16 114.74 0.43 Allowed 'General case' 0 N--CA 1.509 2.476 0 O-C-N 121.104 -1.233 . . . . 0.0 110.18 179.446 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.724 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -85.53 126.55 33.95 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 120.791 -1.193 . . . . 0.0 109.594 -179.841 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 32.3 t80 -64.5 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.028 0 O-C-N 120.852 -1.155 . . . . 0.0 109.951 179.527 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.2 t70 -159.55 19.41 0.17 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.007 -1.058 . . . . 0.0 109.624 179.873 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.4 -27.45 5.71 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.929 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.471 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 63.1 p -97.01 158.5 15.4 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 120.963 -1.316 . . . . 0.0 110.366 -179.375 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.498 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 2.6 ptt180 -104.28 140.21 38.19 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.672 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.724 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.7 t90 -84.93 -17.51 37.54 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.683 -1.261 . . . . 0.0 110.787 -178.077 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.41 176.58 19.83 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 -179.45 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.91 104.51 1.12 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 179.198 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.649 HG21 ' HB3' ' A' ' 46' ' ' ALA . 39.9 t -75.93 107.92 7.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.295 -0.878 . . . . 0.0 109.387 -178.767 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.711 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -68.24 113.14 5.6 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.435 -0.791 . . . . 0.0 109.575 -179.777 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.727 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 8.2 m -62.48 -5.07 2.24 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 120.424 -1.423 . . . . 0.0 110.235 179.717 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 p -88.35 -2.82 58.82 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.542 -1.349 . . . . 0.0 109.489 179.825 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.711 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -106.45 -47.95 3.67 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.237 -0.914 . . . . 0.0 108.804 179.837 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -111.1 -177.67 3.27 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.642 -0.662 . . . . 0.0 109.295 179.724 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.75 116.19 31.87 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.933 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.621 ' HB2' HD11 ' A' ' 110' ' ' ILE . 3.4 m -96.67 122.23 39.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.823 -1.173 . . . . 0.0 109.794 -179.167 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.561 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.36 148.71 26.09 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 122.393 1.092 . . . . 0.0 111.458 -179.374 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.556 ' HB ' HG11 ' A' ' 7' ' ' VAL . 48.4 t -106.3 111.51 35.55 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 106.873 -1.529 . . . . 0.0 106.873 177.534 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.508 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.51 -170.68 19.9 Favored Glycine 0 N--CA 1.488 2.106 0 C-N-CA 118.104 -1.998 . . . . 0.0 111.625 -177.743 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.488 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.92 175.15 5.67 Favored 'General case' 0 C--N 1.307 -1.268 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.269 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.6 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 3.3 t 175.34 153.1 0.14 Allowed 'General case' 0 C--N 1.291 -1.957 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -179.857 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.588 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -99.72 -161.26 0.86 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.765 -1.21 . . . . 0.0 109.115 -179.819 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -115.63 35.76 4.28 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.716 -1.24 . . . . 0.0 109.15 -179.929 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -110.78 -32.17 6.94 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.358 -0.839 . . . . 0.0 109.658 -179.733 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.559 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.63 -36.82 0.22 Allowed Glycine 0 N--CA 1.481 1.672 0 N-CA-C 108.048 -2.021 . . . . 0.0 108.048 -179.823 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -165.83 -177.16 4.15 Favored 'General case' 0 C--N 1.307 -1.282 0 O-C-N 121.501 -0.999 . . . . 0.0 109.98 179.476 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.71 -161.62 20.48 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.204 -1.958 . . . . 0.0 108.204 -179.368 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.488 ' HB2' HD12 ' A' ' 97' ' ' LEU . 6.4 Cg_exo -47.55 -179.55 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.694 0 CA-C-N 118.921 1.36 . . . . 0.0 110.442 179.239 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -96.51 174.71 6.71 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.069 -1.019 . . . . 0.0 110.361 -179.056 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.508 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -114.65 175.69 16.29 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -110.01 153.45 11.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 -179.545 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.561 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -94.21 123.94 37.92 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 121.337 -0.852 . . . . 0.0 109.413 179.796 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.75 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.4 pt -97.91 169.72 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 O-C-N 121.092 -1.005 . . . . 0.0 109.159 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.472 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.44 154.99 48.87 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.333 -0.854 . . . . 0.0 109.455 179.93 . . . . . . . . 3 3 . 1 . 045 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.75 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 59.6 m-85 -131.39 87.85 2.51 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.084 -1.01 . . . . 0.0 109.598 -179.609 . . . . . . . . 2 2 . 1 . 045 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.407 ' C ' ' O ' ' A' ' 112' ' ' PHE . 18.6 p30 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.428 -179.971 . . . . . . . . 1 1 . 1 . 045 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.707 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 121.274 0.559 . . . . 0.0 109.492 . . . . . . . . . 0 0 . 1 . 046 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.493 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -117.8 158.41 45.71 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.18 -0.95 . . . . 0.0 109.484 179.977 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.577 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.2 Cg_exo -59.98 157.44 33.95 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.185 1.923 . . . . 0.0 110.606 -179.979 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.539 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.83 -169.75 0.14 Allowed 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 179.218 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.652 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -166.87 133.87 2.44 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.634 -1.291 . . . . 0.0 111.055 -179.529 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.01 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.3 p -101.22 104.71 15.77 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 122.453 1.121 . . . . 0.0 109.959 -179.843 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 1.131 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -118.54 124.54 73.3 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.509 179.716 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.478 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -170.8 149.96 2.99 Favored Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.509 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.478 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.0 Cg_endo -75.02 152.55 98.32 Favored 'Cis proline' 0 C--N 1.309 -1.504 0 C-N-CA 123.553 -1.436 . . . . 0.0 109.714 -0.476 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.622 ' HA ' HG22 ' A' ' 110' ' ' ILE . 9.3 m -93.31 -23.07 18.61 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.61 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.469 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 3.2 m -135.32 163.38 30.14 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.46 -0.775 . . . . 0.0 109.345 179.764 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.83 38.1 32.11 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 108.387 -1.885 . . . . 0.0 108.387 -179.513 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.795 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.8 mt -91.94 -44.14 9.07 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 123.122 1.439 . . . . 0.0 110.7 -178.201 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 68.14 145.24 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.338 0 CA-C-N 113.578 -1.646 . . . . 0.0 110.081 -179.707 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.583 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.5 p-10 -50.45 106.81 0.13 Allowed 'General case' 0 C--N 1.302 -1.474 0 CA-C-O 121.437 0.637 . . . . 0.0 111.793 -178.54 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.05 16.38 9.15 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.502 -1.332 . . . . 0.0 112.905 177.137 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.795 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.1 t -105.05 -173.73 2.37 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 121.069 2.434 . . . . 0.0 109.982 179.276 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.762 HG13 ' O ' ' A' ' 67' ' ' LEU . 19.3 t -130.33 138.84 52.86 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.287 0 CA-C-N 114.593 -1.185 . . . . 0.0 111.183 -178.613 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.532 HG12 HD21 ' A' ' 13' ' ' LEU . 27.2 m -115.95 155.52 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.75 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.567 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 4.7 tttm -104.84 109.15 21.0 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.08 -1.013 . . . . 0.0 109.355 -179.954 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 1.131 HG23 HG22 ' A' ' 7' ' ' VAL . 7.2 p -106.64 124.2 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 179.671 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -118.89 166.94 12.21 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.65 -1.281 . . . . 0.0 109.296 179.848 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.603 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.76 141.8 13.2 Favored Glycine 0 C--N 1.296 -1.676 0 N-CA-C 107.594 -2.203 . . . . 0.0 107.594 179.727 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.577 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -147.42 123.21 10.59 Favored 'General case' 0 C--N 1.291 -1.956 0 O-C-N 120.832 -1.393 . . . . 0.0 108.624 179.19 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.528 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.68 26.36 25.12 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 119.222 -1.466 . . . . 0.0 109.884 -179.724 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.544 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.3 mt -85.69 176.01 8.4 Favored 'General case' 0 C--N 1.307 -1.281 0 O-C-N 120.695 -1.473 . . . . 0.0 108.245 179.908 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.76 96.87 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.013 -1.055 . . . . 0.0 109.671 -179.891 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.722 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.69 76.61 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.547 -178.91 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.01 34.59 0.33 Allowed Glycine 0 N--CA 1.486 1.984 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 179.334 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.561 ' CG2' ' CB ' ' A' ' 27' ' ' GLN . 1.2 t -149.23 115.4 5.77 Favored 'General case' 0 C--N 1.308 -1.213 0 O-C-N 120.94 -1.329 . . . . 0.0 111.263 179.949 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.68 129.54 4.15 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.819 178.262 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.541 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 7.4 m-85 -120.45 149.85 41.74 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.614 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.549 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -100.07 164.79 11.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.651 -1.281 . . . . 0.0 107.685 178.73 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.648 ' O ' HG13 ' A' ' 34' ' ' VAL . 7.0 p -147.86 118.22 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.139 -0.976 . . . . 0.0 109.855 -177.831 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.77 -178.61 41.52 Favored Glycine 0 N--CA 1.494 2.526 0 C-N-CA 118.432 -1.842 . . . . 0.0 111.537 -179.864 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.707 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -99.16 108.48 21.09 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.822 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.19 148.31 52.02 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.257 -0.902 . . . . 0.0 110.109 179.992 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.44 139.5 53.83 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.39 -0.819 . . . . 0.0 110.736 -179.167 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.878 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.82 26.65 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.129 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.454 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 13.6 m -105.92 15.46 7.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.029 -1.044 . . . . 0.0 110.583 -178.698 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.32 -175.66 0.09 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.858 -1.151 . . . . 0.0 110.095 179.688 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -71.5 97.14 1.61 Allowed 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.47 -0.769 . . . . 0.0 109.754 -179.744 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.26 27.81 35.49 Favored Glycine 0 N--CA 1.491 2.325 0 C-N-CA 120.181 -1.009 . . . . 0.0 111.394 179.006 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 2.0 t -116.1 106.6 20.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 O-C-N 120.625 -1.515 . . . . 0.0 107.295 178.814 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.927 HD22 H182 ' A' ' 114' ' ' CHR . 12.4 tp -116.21 104.66 11.74 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.483 -1.386 . . . . 0.0 109.738 -177.745 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.925 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.63 109.36 22.13 Favored 'General case' 0 N--CA 1.483 1.221 0 O-C-N 120.887 -1.133 . . . . 0.0 107.947 178.916 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.492 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -108.29 167.09 10.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.98 -1.075 . . . . 0.0 110.589 -178.535 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.496 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 43.6 t30 -114.7 128.22 26.09 Favored Pre-proline 0 N--CA 1.499 1.977 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 -179.554 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.603 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.2 Cg_endo -69.96 19.89 0.19 Allowed 'Trans proline' 0 CA--C 1.545 1.065 0 C-N-CA 122.005 1.803 . . . . 0.0 112.294 -179.804 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.496 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -93.79 -7.51 43.22 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.384 -1.448 . . . . 0.0 108.802 179.122 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.608 ' HB3' HD22 ' A' ' 67' ' ' LEU . 4.2 m-20 -131.24 2.22 4.24 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.369 -0.832 . . . . 0.0 108.802 -179.869 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -58.15 83.53 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.336 -0.853 . . . . 0.0 111.147 -178.247 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -110.97 -170.89 1.72 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 178.087 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.62 134.7 0.08 Allowed 'General case' 0 C--N 1.305 -1.363 0 O-C-N 120.446 -1.409 . . . . 0.0 111.621 -179.345 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.708 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.9 p -145.95 158.78 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 107.071 -1.455 . . . . 0.0 107.071 177.744 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.568 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.13 145.44 26.01 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.448 -1.407 . . . . 0.0 109.944 -179.613 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.002 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.04 108.84 3.23 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 122.272 1.034 . . . . 0.0 109.568 179.036 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.54 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.3 t0 -62.8 -138.89 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.979 -179.888 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.722 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.95 -51.53 40.59 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.393 -0.817 . . . . 0.0 110.559 -178.732 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -104.46 -33.54 8.55 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 178.493 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.971 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.75 70.08 0.7 Allowed Glycine 0 C--N 1.299 -1.512 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 178.482 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.603 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 70.9 m -103.57 130.81 51.05 Favored 'General case' 0 N--CA 1.484 1.255 0 O-C-N 121.248 -1.148 . . . . 0.0 109.208 179.324 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.708 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.57 108.86 7.79 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.471 -0.891 . . . . 0.0 109.841 -179.588 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.2 m -115.4 115.38 26.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.117 -0.99 . . . . 0.0 109.328 179.998 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.44 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.09 144.87 30.29 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.413 -0.804 . . . . 0.0 109.829 -179.91 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.426 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 24.7 p -98.99 140.8 32.61 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.55 -0.718 . . . . 0.0 109.169 179.66 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 1.128 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -135.46 165.37 25.64 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.322 -0.862 . . . . 0.0 110.065 -178.924 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.587 HG22 HG22 ' A' ' 18' ' ' VAL . 1.2 p -104.38 123.06 46.75 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.127 -0.983 . . . . 0.0 108.807 179.463 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.707 HG12 ' HB3' ' A' ' 36' ' ' GLN . 18.9 m -136.06 143.48 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.838 -1.164 . . . . 0.0 110.359 -178.898 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.583 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.2 ptt180 -141.64 -166.19 2.15 Favored 'General case' 0 N--CA 1.485 1.323 0 O-C-N 120.686 -1.259 . . . . 0.0 110.331 179.688 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.571 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 1.3 mtp180 -68.98 -78.21 0.07 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.57 -0.706 . . . . 0.0 109.128 -179.419 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -71.92 139.25 48.65 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 120.122 -1.611 . . . . 0.0 107.822 179.39 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -160.32 136.36 8.52 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 118.276 -1.37 . . . . 0.0 110.058 -178.501 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.483 ' O ' ' O ' ' A' ' 47' ' ' CYS . 20.4 mm-40 -32.84 122.36 0.36 Allowed 'General case' 0 N--CA 1.491 1.598 0 CA-C-O 121.557 0.694 . . . . 0.0 110.776 -178.248 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.925 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.51 44.37 3.05 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 -179.502 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.603 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -39.12 112.3 0.24 Allowed 'General case' 0 N--CA 1.507 2.384 0 O-C-N 121.156 -1.202 . . . . 0.0 110.27 179.954 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.696 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.5 tp -87.41 127.73 35.21 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 120.837 -1.165 . . . . 0.0 109.412 -179.926 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.586 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.5 t80 -64.35 57.96 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 120.91 -1.119 . . . . 0.0 110.24 179.9 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.52 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.0 t70 -160.68 19.06 0.13 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.049 -1.032 . . . . 0.0 109.817 179.813 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.06 -26.01 5.73 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.161 -1.175 . . . . 0.0 110.161 179.865 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.424 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -92.54 153.65 18.93 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.906 -1.35 . . . . 0.0 110.384 -179.463 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.482 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -101.34 132.45 46.89 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.493 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.696 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -80.66 -17.44 51.2 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.813 -1.179 . . . . 0.0 110.278 -178.624 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.6 173.55 20.16 Favored Glycine 0 N--CA 1.486 1.995 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -179.682 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.38 108.05 1.03 Allowed 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 179.04 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.676 HG21 ' CB ' ' A' ' 46' ' ' ALA . 39.8 t -79.01 105.64 8.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 O-C-N 121.43 -0.794 . . . . 0.0 108.882 -178.834 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.631 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -67.93 111.23 4.25 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.427 -0.795 . . . . 0.0 109.874 -179.151 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.571 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -63.88 -5.45 4.43 Favored 'General case' 0 N--CA 1.501 2.095 0 C-N-CA 118.438 -1.305 . . . . 0.0 109.862 179.529 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.424 HG23 ' HB3' ' A' ' 71' ' ' ARG . 69.7 p -84.49 0.22 50.53 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.744 -1.222 . . . . 0.0 108.909 179.324 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.631 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -114.2 -49.06 2.86 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.469 -0.77 . . . . 0.0 109.147 179.952 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.17 -178.65 3.7 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.386 -0.821 . . . . 0.0 109.58 -179.943 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.16 114.78 29.18 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.452 -0.78 . . . . 0.0 109.022 -179.991 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.563 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.04 122.12 39.68 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.919 -1.113 . . . . 0.0 109.49 -179.375 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.637 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.28 144.7 30.46 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 122.444 1.116 . . . . 0.0 111.151 -179.336 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.567 ' HB ' HG11 ' A' ' 7' ' ' VAL . 99.4 t -100.9 110.02 26.84 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.604 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.483 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.39 -172.63 19.19 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 117.899 -2.096 . . . . 0.0 111.83 -177.611 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.652 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -111.63 -177.51 3.21 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -179.268 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.578 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.0 OUTLIER -178.07 174.63 1.35 Allowed 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.137 -0.977 . . . . 0.0 110.143 -179.134 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.724 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 27.1 p-10 -107.47 -33.08 7.46 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-O 122.148 0.975 . . . . 0.0 108.773 179.621 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.724 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 86.96 13.0 0.12 Allowed 'General case' 0 C--N 1.296 -1.759 0 CA-C-N 115.079 -0.964 . . . . 0.0 110.171 -179.944 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -107.36 -21.34 12.97 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.237 -0.915 . . . . 0.0 109.395 179.385 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.593 ' N ' H193 ' A' ' 114' ' ' CHR . . . -178.44 -43.71 0.07 OUTLIER Glycine 0 N--CA 1.483 1.793 0 N-CA-C 107.978 -2.049 . . . . 0.0 107.978 179.745 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.49 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -171.24 -179.12 2.58 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.517 -0.99 . . . . 0.0 109.567 179.156 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.36 -165.42 28.61 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 108.685 -1.766 . . . . 0.0 108.685 -179.548 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.472 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.0 Cg_exo -49.3 -178.19 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.641 0 CA-C-N 118.857 1.328 . . . . 0.0 110.076 179.556 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -96.88 -179.67 4.64 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.079 -1.013 . . . . 0.0 110.313 -179.056 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.483 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.87 163.79 12.8 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 179.994 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.84 127.6 51.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.287 -1.125 . . . . 0.0 109.165 -179.53 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.637 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.02 121.11 18.61 Favored 'General case' 0 C--N 1.289 -2.053 0 CA-C-O 121.323 0.582 . . . . 0.0 109.743 179.825 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.861 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.98 168.76 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.238 -0.914 . . . . 0.0 109.387 179.952 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.469 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.0 OUTLIER -138.34 157.63 45.86 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.289 -0.882 . . . . 0.0 109.78 -179.875 . . . . . . . . 3 3 . 1 . 046 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.861 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.6 m-85 -129.89 72.27 1.48 Allowed 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.202 -0.936 . . . . 0.0 109.565 -179.756 . . . . . . . . 2 2 . 1 . 046 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.426 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 12.6 p30 . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.481 -179.986 . . . . . . . . 1 1 . 1 . 046 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.927 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 047 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -118.42 152.68 51.25 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.273 -0.892 . . . . 0.0 109.422 179.975 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.615 ' HB3' HD23 ' A' ' 26' ' ' LEU . 2.5 Cg_endo -61.42 155.59 51.5 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.271 1.98 . . . . 0.0 110.489 -179.901 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.596 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -148.66 161.12 42.38 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 -179.825 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.526 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -147.4 128.92 15.0 Favored 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 118.923 -1.111 . . . . 0.0 110.609 -179.697 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.005 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.9 p -105.42 104.72 14.5 Favored 'General case' 0 C--N 1.295 -1.77 0 CA-C-O 122.57 1.176 . . . . 0.0 110.173 -179.585 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.944 HG22 HG23 ' A' ' 21' ' ' VAL . 20.5 t -119.29 122.56 69.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.317 179.804 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.477 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -166.59 150.64 6.76 Favored Pre-proline 0 N--CA 1.489 1.511 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.294 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.477 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -74.62 151.9 97.54 Favored 'Cis proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.651 -1.395 . . . . 0.0 110.016 -0.621 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.635 ' HA ' HG22 ' A' ' 110' ' ' ILE . 6.0 m -93.73 -23.07 18.34 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.518 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.501 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -135.67 160.86 37.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.474 -0.766 . . . . 0.0 109.446 -179.97 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.09 37.7 31.93 Favored Glycine 0 N--CA 1.494 2.541 0 N-CA-C 108.517 -1.833 . . . . 0.0 108.517 -179.624 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.829 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.0 mt -89.9 -44.7 9.73 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 123.188 1.47 . . . . 0.0 110.608 -178.439 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.47 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.4 OUTLIER 65.89 146.26 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.626 -1.624 . . . . 0.0 110.151 -179.931 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.588 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.1 p-10 -51.33 107.52 0.19 Allowed 'General case' 0 C--N 1.302 -1.485 0 CA-C-O 121.68 0.752 . . . . 0.0 111.678 -178.601 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.24 15.08 9.27 Favored Glycine 0 N--CA 1.484 1.848 0 C-N-CA 119.511 -1.328 . . . . 0.0 112.847 177.348 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.829 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.9 t -103.72 -172.77 2.17 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 121.146 2.473 . . . . 0.0 109.776 179.358 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.721 HG13 ' C ' ' A' ' 67' ' ' LEU . 13.6 t -132.81 140.42 47.45 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.351 0 CA-C-N 114.937 -1.028 . . . . 0.0 111.136 -178.829 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.525 HG23 ' CD1' ' A' ' 67' ' ' LEU . 31.3 m -117.76 154.16 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 121.355 -0.841 . . . . 0.0 108.968 179.144 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.551 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -108.03 108.95 20.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.886 . . . . 0.0 109.148 179.966 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.944 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -106.1 122.44 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.978 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.005 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.84 166.23 11.57 Favored 'General case' 0 C--N 1.306 -1.3 0 O-C-N 120.857 -1.152 . . . . 0.0 108.737 179.502 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.605 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.41 108.37 0.49 Allowed Glycine 0 N--CA 1.482 1.752 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 179.952 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.596 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.94 138.83 51.28 Favored 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 119.366 1.583 . . . . 0.0 110.21 -179.454 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.48 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 84.88 28.92 30.29 Favored Glycine 0 N--CA 1.491 2.306 0 C-N-CA 118.941 -1.6 . . . . 0.0 109.888 179.549 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.615 HD23 ' HB3' ' A' ' 3' ' ' PRO . 2.0 mt -91.67 176.13 6.65 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.979 -1.307 . . . . 0.0 108.449 179.956 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.65 96.91 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.052 -1.03 . . . . 0.0 109.61 -179.905 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.7 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.07 76.61 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.798 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.341 -178.857 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.52 34.17 0.32 Allowed Glycine 0 N--CA 1.486 1.985 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.383 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.568 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.1 t -148.44 115.32 6.06 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 120.931 -1.335 . . . . 0.0 111.113 -179.935 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.559 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -43.36 128.83 4.94 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.777 178.38 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.568 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.0 m-85 -120.58 147.35 45.31 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.486 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.469 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.61 159.65 14.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.507 -1.371 . . . . 0.0 107.666 178.648 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.8 HG11 HG21 ' A' ' 65' ' ' THR . 9.8 p -144.36 116.33 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.08 -1.012 . . . . 0.0 110.198 -177.543 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.522 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.89 -175.33 38.81 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.477 -1.82 . . . . 0.0 111.654 -179.995 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.587 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -100.91 109.22 21.14 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 121.845 0.831 . . . . 0.0 108.973 -179.717 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.79 149.44 52.43 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.254 -0.904 . . . . 0.0 110.05 179.796 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.34 139.07 54.26 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.38 -0.825 . . . . 0.0 110.813 -179.064 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 115.05 26.92 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.98 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.8 m -106.05 15.59 7.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 O-C-N 120.969 -1.082 . . . . 0.0 110.534 -178.796 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.777 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 173.79 -176.36 0.07 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.897 -1.127 . . . . 0.0 110.127 179.835 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.781 ' O ' HG23 ' A' ' 42' ' ' THR . 15.0 t -70.79 98.58 1.57 Allowed 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.416 -0.803 . . . . 0.0 109.914 -179.69 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.13 28.52 36.84 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.265 -0.969 . . . . 0.0 111.238 179.027 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.777 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.9 106.31 19.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.839 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.6 tp -116.94 104.83 11.68 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.409 -1.432 . . . . 0.0 109.749 -177.55 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.895 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.62 109.46 22.21 Favored 'General case' 0 N--CA 1.485 1.276 0 O-C-N 120.806 -1.184 . . . . 0.0 108.29 178.938 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.38 167.46 9.91 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.959 -1.088 . . . . 0.0 110.078 -178.959 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.743 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 15.2 t-20 -109.31 136.45 20.18 Favored Pre-proline 0 N--CA 1.5 2.06 0 O-C-N 121.369 -0.832 . . . . 0.0 109.97 -179.296 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -75.25 23.27 0.42 Allowed 'Trans proline' 0 CA--C 1.544 0.976 0 C-N-CA 122.369 2.046 . . . . 0.0 111.798 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.743 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -117.68 3.9 12.33 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.429 -1.42 . . . . 0.0 108.974 179.593 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.583 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.58 17.87 2.9 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 179.214 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -83.71 90.13 7.26 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.925 -178.473 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.81 -170.41 1.65 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 178.042 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.445 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.81 135.36 0.09 Allowed 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.402 -1.436 . . . . 0.0 111.508 -179.245 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.788 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.3 p -151.88 158.73 4.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.037 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.559 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.49 145.77 25.89 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.642 -1.286 . . . . 0.0 109.799 -179.621 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.22 108.01 2.55 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 122.389 1.09 . . . . 0.0 109.681 178.879 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.553 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.8 p-10 -61.23 -139.56 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.811 -179.898 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.7 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.96 -50.89 57.16 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.296 -0.877 . . . . 0.0 110.498 -178.858 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -103.98 -34.02 8.61 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 178.481 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.947 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.11 70.36 0.73 Allowed Glycine 0 C--N 1.297 -1.583 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 178.278 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.605 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 38.9 m -104.05 127.4 51.61 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.69 -0.888 . . . . 0.0 108.936 179.165 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.788 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.06 109.04 8.15 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.415 -179.682 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -118.69 117.07 27.94 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.264 -0.898 . . . . 0.0 109.349 -179.934 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.8 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -145.46 142.0 28.88 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.452 -0.78 . . . . 0.0 109.772 179.99 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.3 p -100.91 135.06 42.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.497 -0.752 . . . . 0.0 109.231 179.742 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.721 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -133.39 165.52 24.65 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.314 -0.866 . . . . 0.0 109.526 -179.449 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.679 HG22 HG22 ' A' ' 18' ' ' VAL . 2.3 p -96.76 125.23 41.07 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.27 -0.894 . . . . 0.0 109.342 -179.903 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.562 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.3 m -136.13 144.54 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.959 -1.088 . . . . 0.0 109.584 -179.312 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.588 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.4 ptt180 -139.95 -166.37 2.08 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 120.593 -1.317 . . . . 0.0 110.338 -179.927 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.688 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 40.9 mtm180 -69.83 -73.91 0.15 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.51 -0.744 . . . . 0.0 109.298 -179.113 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.52 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -76.87 145.74 38.13 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 178.534 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -166.23 140.06 4.23 Favored 'General case' 0 C--N 1.293 -1.887 0 C-N-CA 117.507 -1.677 . . . . 0.0 110.464 -177.737 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.537 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 2.2 mm-40 -33.98 122.32 0.46 Allowed 'General case' 0 N--CA 1.49 1.533 0 CA-C-O 121.593 0.711 . . . . 0.0 110.664 -178.479 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.895 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.09 45.82 3.03 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 -179.338 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.9 m-30 -39.63 113.19 0.31 Allowed 'General case' 0 N--CA 1.508 2.472 0 O-C-N 121.083 -1.245 . . . . 0.0 110.169 179.673 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.737 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.2 tp -87.23 128.17 35.15 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 120.868 -1.145 . . . . 0.0 109.379 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.576 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 24.8 t80 -64.47 57.89 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 120.809 -1.182 . . . . 0.0 110.328 179.882 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.518 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.1 t70 -161.0 18.92 0.12 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.946 -1.096 . . . . 0.0 109.779 179.844 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.79 -25.85 5.65 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 179.952 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 3.4 p -91.55 153.27 19.87 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 120.895 -1.356 . . . . 0.0 110.387 -179.351 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.508 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 8.5 ptt180 -100.95 131.93 46.6 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.544 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.737 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -81.74 -18.61 43.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.729 -1.232 . . . . 0.0 110.495 -178.47 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.61 173.65 19.6 Favored Glycine 0 N--CA 1.486 2.014 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 -179.624 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -62.07 109.27 1.24 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 179.133 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.681 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.5 t -80.87 104.51 9.47 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 O-C-N 121.339 -0.851 . . . . 0.0 109.058 -178.859 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.573 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -68.07 112.69 5.19 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.628 -0.67 . . . . 0.0 109.648 -179.551 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.688 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 6.8 m -56.83 -8.4 0.6 Allowed 'General case' 0 N--CA 1.496 1.867 0 C-N-CA 118.309 -1.356 . . . . 0.0 110.466 179.816 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 p -84.52 -12.44 54.19 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.366 -1.459 . . . . 0.0 109.53 179.981 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.573 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -92.97 -47.86 6.8 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.286 -0.884 . . . . 0.0 109.032 179.934 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -117.12 -178.24 3.4 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.547 -0.72 . . . . 0.0 109.477 179.937 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.48 117.76 35.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.462 -0.774 . . . . 0.0 108.922 179.888 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.496 ' O ' HG12 ' A' ' 110' ' ' ILE . 3.2 m -96.41 121.41 38.19 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.761 -1.212 . . . . 0.0 109.791 -179.202 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.78 146.92 27.92 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 122.445 1.117 . . . . 0.0 111.022 -179.486 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.707 ' HB ' HG11 ' A' ' 7' ' ' VAL . 42.5 t -102.93 109.81 27.82 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 177.442 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.482 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.68 -170.0 16.65 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 118.263 -1.922 . . . . 0.0 111.697 -177.4 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.526 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -122.2 -179.41 4.16 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.608 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.55 ' HB2' ' C27' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -179.26 176.96 0.81 Allowed 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.362 -0.836 . . . . 0.0 109.593 -179.739 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.455 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -123.82 -157.88 0.78 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.923 -1.111 . . . . 0.0 109.067 -179.96 . . . . . . . . 3 3 . 1 . 047 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.455 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.46 35.79 4.4 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.819 -1.176 . . . . 0.0 109.223 -179.991 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -112.96 -33.08 6.17 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.363 -0.836 . . . . 0.0 109.882 -179.705 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.707 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 163.57 -35.52 0.31 Allowed Glycine 0 N--CA 1.481 1.696 0 N-CA-C 107.713 -2.155 . . . . 0.0 107.713 -179.755 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.52 -177.6 5.72 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.626 -0.926 . . . . 0.0 109.967 179.311 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.53 -161.55 21.31 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.41 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.494 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.2 Cg_exo -45.83 173.12 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.628 0 CA-C-N 118.919 1.359 . . . . 0.0 109.936 179.263 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -92.81 -174.87 3.74 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.127 -0.983 . . . . 0.0 110.526 -178.751 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.482 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.0 166.14 13.55 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.953 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -103.97 130.42 54.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.349 -1.089 . . . . 0.0 109.075 -179.39 . . . . . . . . 1 1 . 1 . 047 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.81 123.68 23.85 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.494 -0.753 . . . . 0.0 109.642 179.728 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.761 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.78 168.42 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 119.555 -0.858 . . . . 0.0 108.912 179.893 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.501 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 2.3 m -134.12 153.76 51.62 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.295 -0.878 . . . . 0.0 109.448 -179.882 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.761 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 65.9 m-85 -127.35 98.17 5.16 Favored 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.193 -0.942 . . . . 0.0 109.397 -179.783 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.592 ' OXT' ' ND2' ' A' ' 113' ' ' ASN . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 117.962 -1.018 . . . . 0.0 109.664 -179.905 . . . . . . . . 2 2 . 1 . 047 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.789 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 048 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.645 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -79.67 162.97 60.94 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.329 -0.857 . . . . 0.0 109.48 -179.982 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.865 ' O ' HG23 ' A' ' 4' ' ' THR . 4.1 Cg_exo -60.24 158.07 32.39 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.167 1.912 . . . . 0.0 110.443 179.921 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.865 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.2 p -165.95 160.48 16.73 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 -179.265 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.9 128.5 14.15 Favored 'General case' 0 C--N 1.297 -1.701 0 CA-C-O 122.359 1.076 . . . . 0.0 110.696 -179.782 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.009 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -105.11 104.8 14.61 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 122.609 1.195 . . . . 0.0 110.141 -179.505 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.931 HG22 HG23 ' A' ' 21' ' ' VAL . 16.7 t -120.17 119.91 61.4 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.44 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.325 179.662 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.523 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.0 150.06 9.54 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 -179.587 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.523 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.1 Cg_endo -75.11 153.57 99.06 Favored 'Cis proline' 0 C--N 1.31 -1.471 0 C-N-CA 123.721 -1.366 . . . . 0.0 109.933 -0.637 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.646 ' HA ' HG22 ' A' ' 110' ' ' ILE . 8.0 m -95.04 -23.51 17.32 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.461 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.461 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 3.4 m -134.24 164.21 27.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.583 -0.698 . . . . 0.0 109.649 179.95 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.36 36.85 43.39 Favored Glycine 0 N--CA 1.496 2.668 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 -179.73 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.885 ' CA ' HG21 ' A' ' 17' ' ' THR . 21.9 mt -90.03 -46.18 8.67 Favored 'General case' 0 C--N 1.297 -1.705 0 CA-C-O 123.151 1.453 . . . . 0.0 110.6 -178.532 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.45 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 2.1 t 61.45 148.25 0.02 OUTLIER 'General case' 0 C--N 1.259 -3.341 0 CA-C-N 113.917 -1.492 . . . . 0.0 109.913 -179.766 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.625 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 3.9 p-10 -51.35 109.61 0.36 Allowed 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.574 0.702 . . . . 0.0 111.683 -178.834 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.94 12.68 10.95 Favored Glycine 0 N--CA 1.485 1.945 0 C-N-CA 119.403 -1.38 . . . . 0.0 112.915 177.42 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.885 HG21 ' CA ' ' A' ' 13' ' ' LEU . 7.9 t -101.45 -175.25 2.8 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 121.0 2.4 . . . . 0.0 109.717 179.511 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.673 HG13 ' O ' ' A' ' 67' ' ' LEU . 9.4 t -132.75 137.72 53.41 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.906 -179.414 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.485 ' O ' HD12 ' A' ' 67' ' ' LEU . 28.5 m -116.97 153.88 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.348 -0.845 . . . . 0.0 109.214 179.219 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -110.31 109.23 19.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.29 -0.882 . . . . 0.0 108.977 179.715 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.931 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -105.95 122.5 59.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.766 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.009 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.4 165.84 12.07 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.886 -1.134 . . . . 0.0 108.954 179.554 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.52 108.23 0.5 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 108.806 -1.717 . . . . 0.0 108.806 -179.976 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.589 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.31 140.8 48.95 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-N 119.204 1.502 . . . . 0.0 110.281 -179.38 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.451 ' CA ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.08 28.46 34.05 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.077 -1.535 . . . . 0.0 109.964 179.653 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -92.91 175.01 6.95 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.942 -1.328 . . . . 0.0 108.367 179.977 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.54 99.19 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.913 -1.117 . . . . 0.0 109.572 -179.743 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.647 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.69 76.85 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.272 -179.101 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.17 34.26 0.29 Allowed Glycine 0 N--CA 1.486 2.005 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.574 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.563 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.9 p -145.11 111.98 5.91 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.958 -1.319 . . . . 0.0 111.167 -179.683 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -45.7 125.66 6.21 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.574 178.107 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.489 ' CD2' ' O ' ' A' ' 30' ' ' THR . 14.2 m-85 -117.33 151.11 37.67 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.682 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.516 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -101.39 153.23 19.85 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.76 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.002 HG11 HG21 ' A' ' 65' ' ' THR . 6.2 p -136.31 115.05 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.105 -0.997 . . . . 0.0 109.756 -177.928 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -165.09 -178.45 38.35 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 118.474 -1.822 . . . . 0.0 111.696 -179.68 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.618 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -102.47 109.27 20.86 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.729 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.87 149.08 52.67 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.128 -0.982 . . . . 0.0 110.117 -179.878 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.78 138.72 54.55 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.399 -0.813 . . . . 0.0 110.609 -179.111 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.883 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 114.88 26.72 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 178.005 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 m -105.24 15.05 6.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.986 -1.071 . . . . 0.0 110.579 -178.72 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.759 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.59 -175.88 0.08 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.916 -1.115 . . . . 0.0 110.044 179.686 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.786 ' O ' HG23 ' A' ' 42' ' ' THR . 15.0 t -71.81 98.34 1.96 Allowed 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.418 -0.801 . . . . 0.0 109.794 -179.704 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.76 27.43 34.94 Favored Glycine 0 N--CA 1.492 2.425 0 C-N-CA 120.077 -1.058 . . . . 0.0 111.518 179.084 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.76 106.42 20.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 O-C-N 120.548 -1.56 . . . . 0.0 107.288 178.929 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.883 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -117.36 104.64 11.33 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.38 -1.45 . . . . 0.0 109.796 -177.757 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.89 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.77 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 178.698 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -105.49 166.96 10.07 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.043 -1.036 . . . . 0.0 110.493 -178.641 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.465 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 36.8 t-20 -110.35 129.61 23.77 Favored Pre-proline 0 N--CA 1.499 1.998 0 O-C-N 121.668 -0.645 . . . . 0.0 109.499 -179.393 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.612 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.1 Cg_endo -72.39 22.34 0.28 Allowed 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 122.091 1.861 . . . . 0.0 111.808 179.581 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -110.76 2.6 18.5 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.41 -1.431 . . . . 0.0 108.997 179.626 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.531 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.58 17.83 2.71 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 179.447 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -80.73 93.11 6.13 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.916 -0.714 . . . . 0.0 111.086 -178.496 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -113.15 -167.78 1.24 Allowed 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 178.113 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.73 136.82 0.09 Allowed 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.619 -1.301 . . . . 0.0 111.524 -179.248 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.918 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -154.45 157.1 4.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.113 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.84 144.82 27.03 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.665 -1.272 . . . . 0.0 109.893 -179.636 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.6 107.07 1.61 Allowed 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 122.353 1.073 . . . . 0.0 109.428 178.772 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.549 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.4 t0 -60.47 -139.29 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.956 -179.895 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.647 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.01 -50.72 57.98 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.401 -0.812 . . . . 0.0 110.733 -178.749 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -104.02 -34.06 8.58 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.461 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.985 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.23 66.17 0.62 Allowed Glycine 0 C--N 1.295 -1.704 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 178.243 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 20.3 m -103.5 125.02 49.82 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.758 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.918 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.6 109.19 8.5 Favored 'General case' 0 C--N 1.296 -1.749 0 C-N-CA 119.631 -0.827 . . . . 0.0 109.649 -179.28 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 97.3 p -116.44 116.51 27.8 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.345 -0.847 . . . . 0.0 109.441 -179.987 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 65' ' ' THR . . . . . 1.002 HG21 HG11 ' A' ' 34' ' ' VAL . 1.1 t -141.3 138.5 33.21 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.438 -0.789 . . . . 0.0 109.816 179.982 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.444 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 23.4 p -99.12 141.22 32.16 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.446 -0.784 . . . . 0.0 109.127 179.814 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.776 HD12 ' H ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -142.34 169.44 17.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.33 -0.856 . . . . 0.0 109.523 -179.24 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.5 p -96.57 126.26 41.62 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.055 -1.028 . . . . 0.0 109.519 -179.712 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.676 HG23 HD13 ' A' ' 13' ' ' LEU . 15.6 m -133.14 142.74 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 120.916 -1.115 . . . . 0.0 109.738 -179.346 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.625 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.84 -170.68 3.59 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.517 -1.364 . . . . 0.0 110.731 -179.877 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.6 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -66.6 -102.23 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.807 -0.558 . . . . 0.0 110.171 -179.04 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.12 136.29 56.38 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.388 -1.445 . . . . 0.0 108.198 179.845 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.618 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -155.86 158.52 38.18 Favored 'General case' 0 C--N 1.295 -1.793 0 C-N-CA 118.722 -1.191 . . . . 0.0 109.894 -178.853 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.515 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 12.1 mm-40 -50.01 121.9 6.01 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.296 -0.878 . . . . 0.0 109.561 -178.651 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.89 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.12 48.32 3.43 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 -179.514 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.612 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -40.11 113.38 0.35 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.046 -1.267 . . . . 0.0 110.286 179.919 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.756 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -86.94 127.1 35.07 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 120.913 -1.117 . . . . 0.0 109.47 179.987 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.577 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.5 t80 -63.88 58.52 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.865 -1.147 . . . . 0.0 110.167 179.8 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.531 ' N ' ' O ' ' A' ' 77' ' ' LEU . 14.3 t0 -161.02 19.23 0.12 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.09 -1.006 . . . . 0.0 109.92 179.842 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -25.6 5.96 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 179.802 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 67.4 p -94.09 159.22 15.25 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.979 -1.307 . . . . 0.0 110.384 -179.35 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.483 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 2.7 ptt180 -104.97 133.33 49.94 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 179.796 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.756 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -82.38 -18.37 42.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.845 -1.159 . . . . 0.0 110.406 -178.694 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.29 174.04 19.36 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 -179.671 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.56 108.7 1.44 Allowed 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 179.137 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.642 HG21 ' CB ' ' A' ' 46' ' ' ALA . 42.9 t -80.28 104.38 8.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 O-C-N 121.469 -0.77 . . . . 0.0 109.278 -178.771 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.561 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -63.78 108.35 1.42 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.517 -0.739 . . . . 0.0 110.137 -179.231 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.597 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.6 t -60.76 -5.14 1.17 Allowed 'General case' 0 N--CA 1.501 2.084 0 C-N-CA 118.141 -1.424 . . . . 0.0 110.282 179.214 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 73.2 p -89.87 2.08 55.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.486 -1.383 . . . . 0.0 109.495 179.965 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.561 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.06 -49.04 2.94 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.236 -0.915 . . . . 0.0 109.149 -179.975 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.57 179.55 4.23 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.432 -0.792 . . . . 0.0 109.48 -179.974 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.65 112.99 25.74 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.791 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.506 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.55 121.39 38.32 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.008 -1.058 . . . . 0.0 109.373 -179.004 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.594 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.61 147.03 27.3 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.369 1.08 . . . . 0.0 111.341 -179.117 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.626 ' HB ' HG11 ' A' ' 7' ' ' VAL . 54.0 t -102.82 109.24 26.15 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 177.309 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.1 -170.96 16.56 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 118.179 -1.962 . . . . 0.0 111.53 -177.378 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.516 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -118.33 -178.52 3.54 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -178.612 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.559 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -173.7 172.57 3.54 Favored 'General case' 0 C--N 1.295 -1.783 0 O-C-N 121.423 -0.798 . . . . 0.0 109.38 -179.352 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.429 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -118.85 -157.87 0.7 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.188 -0.945 . . . . 0.0 108.796 179.676 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.429 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -118.07 36.34 4.38 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.705 -1.247 . . . . 0.0 109.24 179.988 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.23 -33.51 4.37 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.345 -0.847 . . . . 0.0 110.185 -179.552 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 1.024 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 166.26 -36.98 0.25 Allowed Glycine 0 N--CA 1.482 1.735 0 N-CA-C 107.645 -2.182 . . . . 0.0 107.645 -179.519 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -159.18 -178.39 7.17 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.581 -0.953 . . . . 0.0 109.809 179.229 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.12 -162.08 19.32 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 108.209 -1.957 . . . . 0.0 108.209 -179.398 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.3 Cg_exo -45.68 171.99 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.632 0 CA-C-N 118.855 1.327 . . . . 0.0 109.932 179.366 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -90.6 -173.07 3.62 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.092 -1.005 . . . . 0.0 110.544 -178.567 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.467 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.68 168.26 15.04 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.874 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.33 131.44 54.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 121.414 -1.051 . . . . 0.0 109.143 -179.313 . . . . . . . . 1 1 . 1 . 048 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.594 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.16 122.51 21.13 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.662 -0.648 . . . . 0.0 109.736 179.767 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.906 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -97.95 170.99 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.279 -0.888 . . . . 0.0 108.898 179.766 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.461 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.1 OUTLIER -137.07 162.29 33.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.216 -0.927 . . . . 0.0 109.856 -179.78 . . . . . . . . 3 3 . 1 . 048 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.906 ' CE1' HD12 ' A' ' 110' ' ' ILE . 48.3 m-85 -133.37 144.75 49.79 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.244 -0.91 . . . . 0.0 109.495 -179.817 . . . . . . . . 2 2 . 1 . 048 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.8 p30 . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.454 -179.978 . . . . . . . . 0 0 . 1 . 048 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 1.024 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 121.258 0.551 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 049 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.733 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -117.0 165.94 14.18 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.231 -0.918 . . . . 0.0 109.514 -179.957 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.733 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 4.2 Cg_exo -60.2 157.76 33.58 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.277 1.985 . . . . 0.0 110.54 179.932 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -153.65 160.72 42.47 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 -179.402 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.23 122.53 9.62 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-O 122.431 1.11 . . . . 0.0 110.262 -179.705 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.879 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.0 t -115.82 109.16 17.25 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-O 123.058 1.409 . . . . 0.0 109.867 -179.893 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.921 HG22 HG23 ' A' ' 21' ' ' VAL . 1.6 t -114.5 136.68 50.32 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.733 0 CA-C-N 114.236 -1.347 . . . . 0.0 109.557 179.781 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.486 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -170.55 149.68 3.09 Favored Pre-proline 0 N--CA 1.488 1.432 0 O-C-N 121.135 -0.978 . . . . 0.0 109.001 -179.591 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.486 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -77.02 150.78 92.94 Favored 'Cis proline' 0 C--N 1.313 -1.302 0 C-N-CA 123.436 -1.485 . . . . 0.0 109.455 -0.931 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.656 ' HA ' HG22 ' A' ' 110' ' ' ILE . 79.1 p -91.31 -23.81 20.01 Favored 'General case' 0 C--N 1.292 -1.928 0 O-C-N 121.589 -0.695 . . . . 0.0 109.292 179.971 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.493 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -131.57 162.05 31.22 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.284 -0.885 . . . . 0.0 109.733 -179.839 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.76 38.38 31.72 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 108.434 -1.866 . . . . 0.0 108.434 -179.666 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.781 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.0 mt -91.88 -44.07 9.13 Favored 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 123.12 1.438 . . . . 0.0 110.759 -178.226 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.468 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.87 144.22 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.317 0 CA-C-N 113.568 -1.651 . . . . 0.0 109.938 -179.526 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.618 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.6 p-10 -50.55 108.43 0.23 Allowed 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 121.64 0.734 . . . . 0.0 111.759 -178.483 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.72 14.24 10.52 Favored Glycine 0 N--CA 1.484 1.841 0 C-N-CA 119.555 -1.307 . . . . 0.0 112.895 177.255 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.781 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -105.29 -173.71 2.36 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 121.011 2.406 . . . . 0.0 110.162 179.435 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.779 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.8 t -130.62 141.39 46.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.273 0 CA-C-N 114.45 -1.25 . . . . 0.0 111.069 -178.714 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.572 HG12 HD21 ' A' ' 13' ' ' LEU . 34.5 m -118.53 155.29 20.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.661 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.9 tttt -102.07 109.19 20.84 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.127 -0.983 . . . . 0.0 109.176 -179.871 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.921 HG23 HG22 ' A' ' 7' ' ' VAL . 10.5 p -99.05 139.6 20.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.785 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.879 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.84 161.49 35.05 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 120.729 -1.232 . . . . 0.0 109.94 179.45 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.586 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.98 138.01 9.46 Favored Glycine 0 C--O 1.207 -1.551 0 N-CA-C 107.839 -2.104 . . . . 0.0 107.839 179.669 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.597 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -141.04 126.89 19.19 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-N 119.484 1.642 . . . . 0.0 109.547 179.52 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.476 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 87.36 28.64 24.35 Favored Glycine 0 N--CA 1.488 2.132 0 C-N-CA 118.832 -1.651 . . . . 0.0 109.745 -179.984 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.7 mt -88.27 173.06 8.99 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.913 -1.345 . . . . 0.0 108.235 179.894 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.021 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.56 99.26 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.954 -1.091 . . . . 0.0 109.809 -179.482 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.43 77.31 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.698 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.254 -179.221 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.62 34.18 0.28 Allowed Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.591 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 50.7 p -142.35 108.55 5.24 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.092 -1.24 . . . . 0.0 111.367 -179.52 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.597 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.23 109.71 0.33 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 177.826 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.536 ' CE1' ' OG1' ' A' ' 30' ' ' THR . 4.3 m-30 -103.13 155.53 18.34 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.094 -1.004 . . . . 0.0 108.987 179.94 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -98.99 161.82 13.42 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.855 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.696 HG22 HG11 ' A' ' 21' ' ' VAL . 2.7 p -142.66 121.61 8.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.117 -0.99 . . . . 0.0 109.538 -178.018 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.64 -176.9 41.63 Favored Glycine 0 N--CA 1.496 2.645 0 C-N-CA 118.516 -1.802 . . . . 0.0 111.548 -179.77 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.756 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.17 108.94 21.18 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 -179.937 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -128.66 148.53 50.82 Favored 'General case' 0 C--N 1.295 -1.767 0 O-C-N 121.229 -0.919 . . . . 0.0 109.884 179.738 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.502 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.92 139.51 53.76 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.24 -0.912 . . . . 0.0 110.674 -179.071 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.891 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.13 114.93 26.78 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 178.19 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -105.24 15.26 6.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.982 -1.074 . . . . 0.0 110.53 -178.883 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.7 -176.39 0.09 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.997 -1.064 . . . . 0.0 110.067 179.682 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.774 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.4 97.37 1.26 Allowed 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.817 0.818 . . . . 0.0 109.901 -179.656 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.13 28.23 34.62 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 120.198 -1.001 . . . . 0.0 111.387 178.833 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.03 106.41 20.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 O-C-N 120.562 -1.552 . . . . 0.0 107.278 178.891 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.891 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -115.98 104.77 11.93 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.465 -1.397 . . . . 0.0 109.942 -177.552 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.041 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.3 109.65 22.37 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.656 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.49 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -109.06 161.9 14.75 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.863 -1.148 . . . . 0.0 110.462 -178.585 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.479 ' HB2' ' HB2' ' A' ' 73' ' ' PHE . 29.8 t-20 -108.44 131.04 22.02 Favored Pre-proline 0 N--CA 1.5 2.038 0 O-C-N 121.582 -0.699 . . . . 0.0 109.391 -179.659 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -72.19 22.15 0.27 Allowed 'Trans proline' 0 CA--C 1.545 1.074 0 C-N-CA 121.958 1.772 . . . . 0.0 111.892 179.523 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.664 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -97.08 -7.26 33.2 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.434 -1.417 . . . . 0.0 108.994 179.555 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.881 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.8 m-20 -132.63 5.22 3.97 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.999 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -59.84 78.61 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.355 -0.841 . . . . 0.0 110.938 -178.385 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.632 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -101.07 -167.91 1.49 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.238 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.451 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.57 134.84 0.08 Allowed 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.55 -1.344 . . . . 0.0 111.363 -179.391 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.771 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.5 p -149.03 156.99 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.067 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.597 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.4 141.22 31.54 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.706 -1.246 . . . . 0.0 110.012 -179.776 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.021 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.26 107.54 1.34 Allowed 'General case' 0 C--N 1.298 -1.669 0 CA-C-O 122.484 1.135 . . . . 0.0 109.571 178.76 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.565 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -61.04 -139.42 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.709 179.95 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.35 -50.68 61.87 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.393 -0.817 . . . . 0.0 110.481 -178.798 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.416 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 6.2 t-20 -101.95 -35.15 9.09 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 178.404 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.998 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.42 68.19 0.66 Allowed Glycine 0 C--N 1.298 -1.535 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 178.07 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.586 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 56.4 m -99.54 131.54 45.47 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.421 -1.046 . . . . 0.0 108.836 178.917 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.771 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.2 108.87 7.98 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.452 -179.517 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 m -123.97 117.92 25.86 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.297 -0.877 . . . . 0.0 109.651 -179.798 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.525 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.61 145.34 30.04 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.433 -0.792 . . . . 0.0 109.411 179.879 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.0 p -98.56 136.6 38.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.273 -0.892 . . . . 0.0 109.22 179.894 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.881 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -140.69 165.9 26.23 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.396 -0.815 . . . . 0.0 109.909 -178.9 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.664 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 10.9 t -99.56 129.61 45.73 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.955 -1.09 . . . . 0.0 111.437 -178.753 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.83 HG13 ' OD2' ' A' ' 51' ' ' ASP . 17.3 m -136.61 143.86 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.459 -0.776 . . . . 0.0 109.956 179.68 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.618 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -148.45 -175.46 4.93 Favored 'General case' 0 N--CA 1.484 1.239 0 O-C-N 120.445 -1.409 . . . . 0.0 110.6 179.25 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.59 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.13 -102.44 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -179.539 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.4 OUTLIER -56.41 139.93 47.26 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.789 -1.194 . . . . 0.0 108.206 179.494 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.581 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -159.68 138.3 10.64 Favored 'General case' 0 C--N 1.296 -1.745 0 C-N-CA 118.717 -1.193 . . . . 0.0 109.91 -178.403 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' A' ' 47' ' ' CYS . 4.4 mm-40 -35.22 120.81 0.55 Allowed 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.473 0.654 . . . . 0.0 110.662 -178.496 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.041 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.6 48.27 2.57 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 -179.428 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-30 -39.12 114.98 0.44 Allowed 'General case' 0 N--CA 1.509 2.489 0 O-C-N 121.152 -1.205 . . . . 0.0 110.064 179.598 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.734 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.4 tp -87.3 126.48 34.87 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.796 -1.19 . . . . 0.0 109.597 -179.78 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 24.1 t80 -64.42 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.023 0 O-C-N 120.871 -1.143 . . . . 0.0 110.188 179.704 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 14.0 t0 -160.35 19.6 0.15 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.049 -1.032 . . . . 0.0 109.739 179.865 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.83 -27.43 5.41 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 179.935 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.491 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 68.1 p -95.13 157.05 16.06 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 120.978 -1.307 . . . . 0.0 110.313 -179.446 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.536 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -103.94 139.94 38.4 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.673 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.734 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.1 t90 -85.89 -19.71 30.15 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.588 -1.32 . . . . 0.0 110.766 -178.129 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.23 174.59 18.62 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -179.419 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.99 104.17 1.08 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 179.159 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.665 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.9 t -74.49 106.64 4.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.388 -0.82 . . . . 0.0 109.55 -178.769 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.74 110.67 2.46 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.443 -0.786 . . . . 0.0 109.654 -179.735 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.59 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.4 t -64.32 -4.98 4.29 Favored 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 118.334 -1.346 . . . . 0.0 109.891 179.58 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.0 p -87.03 0.56 55.01 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.701 -1.25 . . . . 0.0 109.111 179.511 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -114.16 -50.07 2.83 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.275 -0.891 . . . . 0.0 109.047 179.905 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.22 -178.09 3.56 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.54 -0.725 . . . . 0.0 109.495 179.769 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.09 114.94 29.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.395 -0.816 . . . . 0.0 108.998 179.937 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.567 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -97.05 122.98 40.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.911 -1.118 . . . . 0.0 109.722 -179.233 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.632 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.23 146.83 28.22 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-O 122.345 1.069 . . . . 0.0 111.224 -179.414 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.658 ' CG1' HG11 ' A' ' 7' ' ' VAL . 58.9 t -101.5 110.18 27.69 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.987 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 177.695 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.476 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.06 -171.28 16.85 Favored Glycine 0 N--CA 1.485 1.964 0 C-N-CA 118.236 -1.935 . . . . 0.0 111.78 -177.592 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.476 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.63 177.66 5.15 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 121.625 0.726 . . . . 0.0 109.047 -179.161 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.585 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -175.18 176.3 2.1 Favored 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.641 -0.662 . . . . 0.0 109.455 179.937 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.5 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -124.46 -157.13 0.75 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.004 -1.06 . . . . 0.0 109.0 179.802 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.476 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.22 35.9 4.46 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.746 -1.221 . . . . 0.0 109.288 -179.982 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.88 -32.9 6.46 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.349 -0.844 . . . . 0.0 109.833 -179.765 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.812 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.1 -36.28 0.27 Allowed Glycine 0 N--CA 1.481 1.668 0 N-CA-C 107.817 -2.113 . . . . 0.0 107.817 -179.738 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -166.06 -177.09 4.02 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.596 -0.944 . . . . 0.0 109.795 179.336 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.18 -161.88 17.52 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 108.247 -1.941 . . . . 0.0 108.247 -179.379 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.521 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.4 Cg_exo -46.56 176.34 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.686 0 CA-C-N 118.778 1.289 . . . . 0.0 110.203 179.325 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -95.19 -177.3 4.08 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.121 -0.987 . . . . 0.0 110.417 -178.896 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.476 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -115.37 161.63 12.75 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.871 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.8 130.55 47.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.383 -1.069 . . . . 0.0 109.041 -179.461 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.632 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.65 124.33 25.06 Favored 'General case' 0 C--N 1.291 -1.975 0 O-C-N 121.724 -0.61 . . . . 0.0 110.059 -179.937 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.894 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.65 171.21 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.298 -0.876 . . . . 0.0 108.954 179.639 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.493 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -137.05 158.06 45.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.209 -0.932 . . . . 0.0 109.632 179.97 . . . . . . . . 3 3 . 1 . 049 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.894 ' CE1' HD12 ' A' ' 110' ' ' ILE . 77.7 m-85 -129.49 79.27 1.9 Allowed 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.26 -0.9 . . . . 0.0 109.517 -179.551 . . . . . . . . 2 2 . 1 . 049 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.407 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 13.6 p30 . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.439 -179.924 . . . . . . . . 1 1 . 1 . 049 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.812 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 050 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.922 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -88.8 172.97 6.68 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.267 -0.896 . . . . 0.0 109.491 -179.951 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.922 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 2.7 Cg_endo -61.31 155.63 50.7 Favored 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.304 2.002 . . . . 0.0 110.544 179.992 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.61 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -141.25 161.56 37.59 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 -179.866 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.566 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -145.77 128.67 16.4 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 118.846 -1.142 . . . . 0.0 110.702 -179.682 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.015 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -104.05 104.71 14.7 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 122.39 1.09 . . . . 0.0 110.271 -179.566 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.912 HG22 HG23 ' A' ' 21' ' ' VAL . 11.2 t -119.68 119.19 59.65 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.514 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.244 179.625 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.516 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.51 150.51 10.49 Favored Pre-proline 0 N--CA 1.488 1.44 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 -179.561 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.516 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.49 153.24 99.06 Favored 'Cis proline' 0 C--N 1.309 -1.537 0 C-N-CA 123.663 -1.39 . . . . 0.0 110.014 -0.578 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.618 ' HA ' HG22 ' A' ' 110' ' ' ILE . 7.2 m -94.44 -23.57 17.68 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.495 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.481 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.3 m -136.18 163.12 31.1 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.516 -0.74 . . . . 0.0 109.33 179.825 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.41 37.66 35.49 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 -179.523 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.796 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.1 mt -90.47 -44.12 9.82 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 123.18 1.467 . . . . 0.0 110.486 -178.289 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.467 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.97 144.71 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.265 0 CA-C-N 113.613 -1.63 . . . . 0.0 109.903 -179.665 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.625 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 8.1 p-10 -51.11 106.18 0.12 Allowed 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 121.471 0.653 . . . . 0.0 111.509 -178.592 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.46 12.31 9.78 Favored Glycine 0 N--CA 1.488 2.126 0 C-N-CA 119.324 -1.417 . . . . 0.0 113.121 177.261 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.796 HG21 ' CA ' ' A' ' 13' ' ' LEU . 11.6 t -101.51 -169.55 1.71 Allowed 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 121.135 2.467 . . . . 0.0 109.665 179.362 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.74 HG13 ' C ' ' A' ' 67' ' ' LEU . 11.4 t -136.14 142.94 37.32 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 CA-C-N 115.204 -0.907 . . . . 0.0 110.953 -179.015 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.538 HG22 HG22 ' A' ' 69' ' ' VAL . 13.3 m -120.47 154.72 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.221 -0.924 . . . . 0.0 109.255 179.438 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.538 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.3 tttt -106.28 109.08 20.9 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.233 -0.917 . . . . 0.0 109.28 179.955 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.912 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -105.61 122.26 58.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 179.885 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.015 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.43 165.81 12.35 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 120.886 -1.134 . . . . 0.0 109.129 179.885 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.579 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.1 107.7 0.48 Allowed Glycine 0 N--CA 1.482 1.751 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 179.792 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.61 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.6 141.24 48.45 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.598 -1.53 . . . . 0.0 110.16 -179.439 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.483 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 85.31 27.88 32.0 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 118.833 -1.651 . . . . 0.0 109.718 179.726 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.874 HD23 ' HB3' ' A' ' 3' ' ' PRO . 0.6 OUTLIER -95.67 170.88 9.02 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.018 -1.284 . . . . 0.0 108.45 179.831 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.07 101.18 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.407 0 O-C-N 120.947 -1.095 . . . . 0.0 109.948 -179.607 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.85 77.98 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.685 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.993 -179.411 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.42 34.15 0.29 Allowed Glycine 0 N--CA 1.486 2.021 0 N-CA-C 109.316 -1.513 . . . . 0.0 109.316 179.818 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 22.6 p -139.78 106.9 5.46 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.186 -1.185 . . . . 0.0 111.154 -179.514 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.582 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.67 110.0 0.34 Allowed 'General case' 0 N--CA 1.496 1.839 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.8 178.131 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.525 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 28.8 m-85 -103.89 154.51 19.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.111 -0.993 . . . . 0.0 108.95 179.8 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -102.18 158.09 16.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.767 -1.208 . . . . 0.0 107.821 178.784 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.945 HG11 HG21 ' A' ' 65' ' ' THR . 6.0 p -139.23 115.11 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.165 -0.959 . . . . 0.0 109.722 -178.12 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.73 -178.36 36.5 Favored Glycine 0 N--CA 1.494 2.561 0 C-N-CA 118.326 -1.892 . . . . 0.0 111.729 -179.468 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.635 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.1 pt20 -103.32 109.75 21.49 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 121.8 0.81 . . . . 0.0 108.9 -179.764 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.478 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -131.3 149.2 52.66 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.005 -1.06 . . . . 0.0 110.261 -179.805 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.37 138.8 54.52 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.319 -0.863 . . . . 0.0 110.777 -179.167 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.876 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.25 114.55 26.35 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 178.108 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.6 m -104.83 14.69 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.026 -1.046 . . . . 0.0 110.663 -178.757 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.746 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 175.25 -175.17 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.923 -1.111 . . . . 0.0 110.125 179.758 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -72.0 97.64 1.92 Allowed 'General case' 0 N--CA 1.485 1.317 0 O-C-N 121.413 -0.804 . . . . 0.0 109.677 -179.757 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.3 26.76 35.31 Favored Glycine 0 N--CA 1.494 2.531 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.475 178.934 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.746 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.92 106.66 20.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 O-C-N 120.549 -1.56 . . . . 0.0 107.396 178.875 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.876 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.7 tp -117.05 104.62 11.43 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.488 -1.382 . . . . 0.0 109.629 -177.747 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.871 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.61 109.42 22.18 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 120.808 -1.182 . . . . 0.0 107.914 178.678 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -105.95 167.83 9.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.928 -1.107 . . . . 0.0 110.483 -178.68 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.53 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 11.6 t-20 -111.94 129.33 24.33 Favored Pre-proline 0 N--CA 1.499 1.986 0 O-C-N 121.532 -0.73 . . . . 0.0 109.649 -179.118 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.582 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 2.2 Cg_endo -72.72 23.06 0.29 Allowed 'Trans proline' 0 CA--C 1.545 1.059 0 C-N-CA 122.056 1.837 . . . . 0.0 111.815 179.61 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.611 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -110.57 -0.7 17.2 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.462 -1.399 . . . . 0.0 109.145 179.545 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.567 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.37 16.81 3.17 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 179.489 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -79.75 89.94 5.22 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.709 -178.678 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.26 -166.26 1.14 Allowed 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.948 -1.131 . . . . 0.0 107.948 178.34 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.76 136.43 0.09 Allowed 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.594 -1.316 . . . . 0.0 111.314 -179.256 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 1.016 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -154.74 156.63 4.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.084 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.582 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.49 142.1 30.52 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.669 -1.269 . . . . 0.0 109.977 -179.621 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.08 106.12 0.68 Allowed 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 122.467 1.127 . . . . 0.0 109.341 178.208 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.545 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.8 p-10 -59.29 -138.79 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.029 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.052 -179.881 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.85 -50.33 61.13 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.412 -0.805 . . . . 0.0 110.744 -178.633 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -104.08 -34.57 8.37 Favored 'General case' 0 C--N 1.286 -2.178 0 N-CA-C 106.004 -1.85 . . . . 0.0 106.004 178.505 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.013 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.41 64.34 0.54 Allowed Glycine 0 C--N 1.296 -1.646 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 177.928 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.579 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 18.5 m -103.85 124.05 48.23 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.501 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 1.016 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.01 109.48 9.01 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.821 -0.752 . . . . 0.0 109.673 -179.081 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.7 m -116.5 116.69 28.11 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.329 -0.857 . . . . 0.0 109.373 -179.959 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.945 HG21 HG11 ' A' ' 34' ' ' VAL . 1.3 t -140.85 140.19 34.57 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.374 -0.829 . . . . 0.0 109.822 179.908 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.1 p -98.88 137.61 37.19 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.49 -0.756 . . . . 0.0 109.242 179.849 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.806 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -140.43 159.01 43.15 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.382 -0.824 . . . . 0.0 109.452 -179.129 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.611 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 12.7 t -87.55 135.77 33.22 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.162 -0.961 . . . . 0.0 110.21 -179.837 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.573 HG23 HD13 ' A' ' 13' ' ' LEU . 18.0 m -145.51 140.36 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.74 -179.39 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.625 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.5 ptt180 -140.25 -163.83 1.59 Allowed 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.595 -1.315 . . . . 0.0 109.877 179.814 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.603 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -78.79 -81.81 0.1 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.055 -1.028 . . . . 0.0 109.6 -179.15 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.524 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -67.12 134.66 52.24 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.334 -1.479 . . . . 0.0 107.488 179.273 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.635 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.8 OUTLIER -157.7 156.58 31.94 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 117.965 -1.494 . . . . 0.0 110.568 -178.257 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.514 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.2 mm-40 -48.71 121.66 4.83 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.497 -0.752 . . . . 0.0 109.676 -178.574 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.871 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.08 48.78 3.48 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 -179.39 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.582 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.2 OUTLIER -40.39 114.6 0.47 Allowed 'General case' 0 N--CA 1.514 2.774 0 O-C-N 121.029 -1.277 . . . . 0.0 109.972 179.908 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.704 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.25 126.95 35.14 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.959 -1.088 . . . . 0.0 109.289 179.729 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.578 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 23.2 t80 -64.09 58.11 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.8 -1.187 . . . . 0.0 110.307 179.897 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.531 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -160.86 19.34 0.13 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.961 -1.087 . . . . 0.0 109.785 179.91 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.3 -26.74 5.45 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.913 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.7 p -91.88 159.32 15.83 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.12 -1.223 . . . . 0.0 110.389 -179.403 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.513 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.56 133.46 51.21 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.716 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.704 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -82.6 -18.13 42.35 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.88 -1.137 . . . . 0.0 110.411 -178.469 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.32 174.79 20.6 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 -179.525 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.0 112.06 2.18 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 179.14 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.664 HG21 ' CB ' ' A' ' 46' ' ' ALA . 38.7 t -83.44 102.39 9.35 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -178.916 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.547 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -64.49 108.53 1.68 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.659 -0.651 . . . . 0.0 109.971 -179.153 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.579 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 3.7 t -62.48 -4.25 1.82 Allowed 'General case' 0 N--CA 1.499 1.979 0 C-N-CA 118.361 -1.336 . . . . 0.0 110.34 179.341 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.6 p -88.24 10.39 19.76 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.621 -1.299 . . . . 0.0 109.097 179.622 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.547 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -124.25 -47.66 1.87 Allowed 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.399 -0.813 . . . . 0.0 109.08 -179.994 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.85 179.58 4.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.604 -0.685 . . . . 0.0 109.536 179.905 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.88 112.41 25.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.36 -0.838 . . . . 0.0 108.799 179.783 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.497 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.1 m -96.64 121.85 38.93 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.083 -1.01 . . . . 0.0 109.667 -178.786 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.583 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.34 149.2 24.98 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 122.482 1.134 . . . . 0.0 111.368 -179.199 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.561 ' HB ' HG11 ' A' ' 7' ' ' VAL . 47.4 t -105.42 109.94 29.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 177.465 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.449 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.89 -171.3 17.51 Favored Glycine 0 N--CA 1.485 1.95 0 C-N-CA 118.154 -1.974 . . . . 0.0 111.663 -177.641 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.602 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -115.16 -179.02 3.51 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -178.899 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.576 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.5 p -178.65 169.31 1.7 Allowed 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.332 -0.855 . . . . 0.0 109.545 -179.06 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.43 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -121.31 -158.8 0.78 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.961 -1.087 . . . . 0.0 108.976 179.895 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.43 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.13 36.05 4.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.663 -1.273 . . . . 0.0 109.093 -179.982 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -115.33 -33.65 5.23 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.469 -0.77 . . . . 0.0 109.994 -179.707 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.863 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 164.36 -36.06 0.29 Allowed Glycine 0 N--CA 1.48 1.627 0 N-CA-C 107.753 -2.139 . . . . 0.0 107.753 -179.7 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.35 -178.09 6.69 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 122.159 0.98 . . . . 0.0 109.898 179.326 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.42 -163.04 21.72 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 108.191 -1.963 . . . . 0.0 108.191 -179.46 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.602 ' HB2' HD12 ' A' ' 97' ' ' LEU . 7.4 Cg_exo -45.93 172.76 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.647 0 CA-C-N 119.013 1.406 . . . . 0.0 109.937 179.325 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -90.19 -177.42 5.14 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.997 -1.064 . . . . 0.0 110.695 -178.566 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.449 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.03 167.9 13.66 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.816 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.47 132.56 54.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.393 -1.063 . . . . 0.0 109.23 -179.285 . . . . . . . . 1 1 . 1 . 050 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.583 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.57 124.42 25.86 Favored 'General case' 0 C--N 1.29 -1.984 0 O-C-N 121.637 -0.664 . . . . 0.0 109.732 179.757 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.842 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.97 171.81 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.228 -0.92 . . . . 0.0 109.227 179.794 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.481 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.23 155.96 48.15 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.209 -0.932 . . . . 0.0 109.769 -179.896 . . . . . . . . 3 3 . 1 . 050 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.842 ' CE2' HD12 ' A' ' 110' ' ' ILE . 71.6 m-85 -133.25 95.05 3.44 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.178 -0.952 . . . . 0.0 109.533 -179.733 . . . . . . . . 2 2 . 1 . 050 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 14.8 p30 . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 118.077 -0.963 . . . . 0.0 109.462 -179.997 . . . . . . . . 0 0 . 1 . 050 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.863 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.307 0.575 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 051 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.856 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -71.21 169.73 14.11 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.239 -0.913 . . . . 0.0 109.422 179.962 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.856 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.6 Cg_exo -60.1 156.76 37.82 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.253 1.969 . . . . 0.0 110.642 -179.928 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.574 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -177.75 -169.42 0.21 Allowed 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 179.016 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.574 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.7 132.6 3.28 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.76 -1.212 . . . . 0.0 110.63 -179.135 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.02 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.9 p -104.54 104.4 14.23 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 122.453 1.12 . . . . 0.0 110.156 179.96 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.952 HG22 HG23 ' A' ' 21' ' ' VAL . 12.0 t -120.15 119.76 60.98 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.366 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.309 179.738 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.512 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.64 149.88 6.34 Favored Pre-proline 0 N--CA 1.486 1.326 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -179.674 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.512 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.1 Cg_endo -76.68 151.62 94.61 Favored 'Cis proline' 0 C--N 1.309 -1.523 0 C-N-CA 123.637 -1.401 . . . . 0.0 109.501 -0.433 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.674 ' HA ' HG22 ' A' ' 110' ' ' ILE . 77.4 p -93.19 -23.53 18.53 Favored 'General case' 0 C--N 1.293 -1.865 0 O-C-N 121.595 -0.691 . . . . 0.0 109.305 179.765 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.48 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.2 m -133.89 158.2 44.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.316 -0.865 . . . . 0.0 109.957 -179.693 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 80.36 36.46 23.71 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 -179.777 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.763 ' HA ' HG21 ' A' ' 17' ' ' THR . 39.2 mt -92.54 -44.36 8.66 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 123.24 1.495 . . . . 0.0 110.284 -178.634 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.447 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 64.1 147.03 0.03 OUTLIER 'General case' 0 C--N 1.263 -3.189 0 CA-C-N 113.549 -1.66 . . . . 0.0 110.138 -179.758 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.552 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.0 p-10 -51.65 104.81 0.09 Allowed 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.644 0.735 . . . . 0.0 111.048 -178.939 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.52 6.39 6.72 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.148 -1.501 . . . . 0.0 113.33 177.312 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.763 HG21 ' HA ' ' A' ' 13' ' ' LEU . 14.9 t -106.31 -175.97 2.94 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 121.491 2.646 . . . . 0.0 110.166 179.693 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.861 HG22 HG22 ' A' ' 68' ' ' THR . 21.8 t -128.05 138.2 55.36 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.383 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.068 -178.697 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.652 HG11 HD11 ' A' ' 13' ' ' LEU . 34.6 m -114.39 154.66 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.827 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.553 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.1 108.9 20.59 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.14 -0.975 . . . . 0.0 109.314 -179.885 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.952 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.59 123.34 62.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.751 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.02 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -116.72 165.33 13.41 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 120.873 -1.142 . . . . 0.0 109.14 179.922 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.563 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.46 107.55 0.53 Allowed Glycine 0 C--O 1.207 -1.577 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 179.875 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.582 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -116.23 143.83 45.0 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.787 -1.419 . . . . 0.0 110.676 -178.964 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.52 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 80.48 27.45 51.51 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 119.576 -1.297 . . . . 0.0 109.993 179.193 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.571 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -91.95 172.25 8.58 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.086 -1.244 . . . . 0.0 108.556 -179.984 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.005 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.58 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.116 -0.99 . . . . 0.0 109.652 -179.987 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.578 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.63 76.74 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.206 -179.059 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 135.96 32.96 0.26 Allowed Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.512 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.628 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -141.98 111.45 6.54 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 120.935 -1.332 . . . . 0.0 111.027 -179.96 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.572 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.64 120.4 4.67 Favored 'General case' 0 N--CA 1.493 1.715 0 CA-C-N 115.488 -0.778 . . . . 0.0 109.674 178.7 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.628 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 9.7 m-85 -114.27 152.82 30.74 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.238 -0.914 . . . . 0.0 108.923 179.807 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.483 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.68 154.18 18.81 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.622 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.693 ' O ' HG13 ' A' ' 34' ' ' VAL . 9.7 p -137.42 115.41 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.023 -1.048 . . . . 0.0 109.882 -177.753 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.87 -176.85 36.16 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 118.372 -1.87 . . . . 0.0 111.792 -179.717 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.624 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -101.21 109.86 21.79 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -179.803 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.498 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -129.61 149.38 51.39 Favored 'General case' 0 C--N 1.296 -1.74 0 O-C-N 121.221 -0.924 . . . . 0.0 109.748 179.81 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.531 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.66 137.73 54.81 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.254 -0.904 . . . . 0.0 110.907 -178.847 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.887 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.49 114.86 26.67 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.048 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 m -105.05 14.67 7.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.931 -1.105 . . . . 0.0 110.501 -178.947 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.774 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 173.9 -175.54 0.07 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 120.949 -1.094 . . . . 0.0 110.128 179.73 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.779 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.92 98.17 1.55 Allowed 'General case' 0 N--CA 1.487 1.416 0 CA-C-O 121.828 0.823 . . . . 0.0 109.969 -179.669 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.28 27.98 34.92 Favored Glycine 0 N--CA 1.493 2.441 0 C-N-CA 120.325 -0.94 . . . . 0.0 111.444 178.949 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.774 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -116.54 106.29 19.99 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 O-C-N 120.569 -1.548 . . . . 0.0 107.198 178.782 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.887 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -117.02 104.64 11.47 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.487 -1.383 . . . . 0.0 109.942 -177.527 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.011 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.9 109.56 22.29 Favored 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.847 -1.158 . . . . 0.0 107.919 178.7 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.58 167.05 10.11 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.907 -1.12 . . . . 0.0 110.41 -178.699 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.585 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 20.7 t-20 -114.67 137.71 22.87 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 121.299 -0.876 . . . . 0.0 110.359 -179.149 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.464 ' HD2' ' ND2' ' A' ' 48' ' ' ASN . 6.1 Cg_endo -75.55 25.8 0.39 Allowed 'Trans proline' 0 C--N 1.318 -1.039 0 C-N-CA 122.346 2.031 . . . . 0.0 111.966 179.859 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.585 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -113.82 2.13 15.03 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.266 -1.521 . . . . 0.0 109.482 179.833 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.533 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.22 16.72 2.42 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 179.423 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -79.38 91.74 5.12 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.598 -0.689 . . . . 0.0 111.016 -178.678 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -109.08 -166.9 1.15 Allowed 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.171 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.455 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.97 136.62 0.09 Allowed 'General case' 0 N--CA 1.485 1.301 0 O-C-N 120.519 -1.363 . . . . 0.0 111.327 -179.298 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.964 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -156.75 157.0 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 178.213 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.572 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.6 144.23 28.13 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.884 -1.135 . . . . 0.0 109.835 -179.759 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.005 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.84 105.82 0.9 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 122.436 1.112 . . . . 0.0 109.38 178.546 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.546 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.8 p-10 -58.69 -138.87 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.029 -179.869 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.578 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.32 -50.26 62.62 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.453 -0.779 . . . . 0.0 110.576 -178.718 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.463 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.7 t-20 -103.75 -35.19 8.3 Favored 'General case' 0 C--N 1.286 -2.195 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 178.442 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.977 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.28 67.36 0.59 Allowed Glycine 0 C--N 1.297 -1.627 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 177.936 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.563 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.0 m -106.76 123.12 47.68 Favored 'General case' 0 N--CA 1.482 1.137 0 O-C-N 121.559 -0.965 . . . . 0.0 108.623 178.829 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.964 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -132.6 109.15 9.54 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 -179.443 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.1 m -118.95 120.39 37.13 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.211 -0.93 . . . . 0.0 109.606 -179.474 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.662 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.71 141.62 29.42 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.567 -0.708 . . . . 0.0 109.691 179.779 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 17.7 p -99.93 135.89 40.66 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.395 -0.815 . . . . 0.0 109.112 179.702 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.843 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -135.59 167.84 20.35 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.941 . . . . 0.0 109.618 -179.29 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.861 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -99.4 126.89 45.38 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.077 -1.014 . . . . 0.0 109.276 -179.802 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.491 HG12 ' HB3' ' A' ' 36' ' ' GLN . 12.6 m -132.39 140.8 46.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 120.868 -1.145 . . . . 0.0 109.93 -179.134 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.552 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 56.7 mtt180 -127.61 -166.96 1.68 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.68 -1.263 . . . . 0.0 111.328 -179.674 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.578 ' HG2' ' CD1' ' A' ' 112' ' ' PHE . 46.4 mtt180 -80.59 -79.02 0.16 Allowed 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 178.946 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -69.11 136.66 52.58 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 106.386 -1.709 . . . . 0.0 106.386 177.766 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.35 136.51 8.6 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 117.666 -1.614 . . . . 0.0 110.891 -177.191 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.47 ' C ' ' O ' ' A' ' 73' ' ' PHE . 2.0 mm-40 -33.43 118.78 0.34 Allowed 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.47 0.652 . . . . 0.0 110.427 -178.742 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.011 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.26 48.07 3.57 Favored Glycine 0 N--CA 1.493 2.463 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.148 -179.312 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.487 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -36.99 115.93 0.41 Allowed 'General case' 0 N--CA 1.513 2.685 0 O-C-N 121.109 -1.23 . . . . 0.0 110.11 179.828 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.727 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.3 tp -87.59 126.41 34.92 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.987 -1.071 . . . . 0.0 109.121 179.742 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 25.8 t80 -63.64 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.836 -1.165 . . . . 0.0 110.228 179.824 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.543 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t70 -160.89 19.72 0.13 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.989 -1.069 . . . . 0.0 109.846 179.924 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.2 -28.01 5.34 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.812 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.67 163.38 13.4 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.061 -1.258 . . . . 0.0 110.184 -179.438 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.478 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.55 137.71 46.05 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.987 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.727 ' HB2' HD13 ' A' ' 77' ' ' LEU . 5.6 t90 -81.62 -20.93 38.71 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.896 -1.127 . . . . 0.0 110.157 -178.956 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.36 173.55 17.07 Favored Glycine 0 N--CA 1.486 1.968 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -179.44 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.25 111.81 2.41 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 179.069 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.652 HG21 ' HB3' ' A' ' 46' ' ' ALA . 46.0 t -83.67 104.25 11.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 121.378 -0.826 . . . . 0.0 108.981 -179.001 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.531 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -66.15 111.3 3.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.355 -0.84 . . . . 0.0 109.845 -179.295 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.572 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -64.25 -4.8 4.04 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 120.587 -1.321 . . . . 0.0 109.896 179.4 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 31.6 p -87.81 2.18 52.01 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.694 -1.253 . . . . 0.0 109.097 179.325 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -116.52 -51.16 2.61 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.362 -0.836 . . . . 0.0 108.935 -179.998 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.22 -179.9 4.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.53 -0.731 . . . . 0.0 109.493 179.745 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.75 116.07 31.64 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.365 -0.834 . . . . 0.0 108.925 179.91 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.557 ' HB2' HD11 ' A' ' 110' ' ' ILE . 2.7 m -96.97 123.3 40.65 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.828 -1.17 . . . . 0.0 109.477 -179.298 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.582 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -103.15 149.17 24.9 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.344 1.069 . . . . 0.0 111.356 -179.142 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.639 ' HB ' HG11 ' A' ' 7' ' ' VAL . 43.2 t -104.88 112.1 37.12 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.552 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -151.77 -172.02 20.14 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 118.218 -1.944 . . . . 0.0 111.747 -177.785 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.483 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.01 178.67 4.64 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 -178.845 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.558 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 3.2 m 177.19 178.56 0.27 Allowed 'General case' 0 C--N 1.295 -1.786 0 O-C-N 121.581 -0.699 . . . . 0.0 109.432 -179.806 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.423 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -124.74 -158.64 0.84 Allowed 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.935 -1.103 . . . . 0.0 109.063 179.796 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.72 36.02 4.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.696 -1.252 . . . . 0.0 109.134 -179.966 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -113.12 -33.94 5.85 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.42 -0.8 . . . . 0.0 109.855 -179.732 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.8 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 166.19 -36.35 0.25 Allowed Glycine 0 N--CA 1.482 1.7 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 -179.805 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.82 -177.48 5.15 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.544 -0.974 . . . . 0.0 109.9 179.438 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.88 -161.83 23.1 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.462 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 104' ' ' GLY . 8.0 Cg_exo -45.51 173.73 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.643 0 CA-C-N 119.003 1.401 . . . . 0.0 110.232 179.251 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 25.9 pt-20 -92.7 -173.83 3.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.072 -1.017 . . . . 0.0 110.302 -178.824 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -124.67 174.86 17.15 Favored Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 -179.89 . . . . . . . . 1 1 . 1 . 051 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -111.02 153.71 12.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -179.552 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.582 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -95.02 123.07 38.3 Favored 'General case' 0 C--N 1.292 -1.93 0 O-C-N 121.303 -0.873 . . . . 0.0 109.605 179.922 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.674 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.4 pt -98.08 168.32 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.209 -0.932 . . . . 0.0 109.073 179.942 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -135.1 156.65 48.65 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.29 -0.881 . . . . 0.0 109.456 -179.98 . . . . . . . . 3 3 . 1 . 051 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.658 ' CE2' HD12 ' A' ' 110' ' ' ILE . 44.6 m-85 -131.97 78.46 1.82 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.2 -0.937 . . . . 0.0 109.543 -179.767 . . . . . . . . 2 2 . 1 . 051 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 20.1 p30 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 118.003 -0.999 . . . . 0.0 109.497 179.995 . . . . . . . . 0 0 . 1 . 051 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.8 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 052 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.527 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -122.07 159.29 52.4 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.309 -0.869 . . . . 0.0 109.446 -179.939 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.637 ' HB3' HD23 ' A' ' 26' ' ' LEU . 5.0 Cg_exo -59.88 157.42 33.55 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.332 2.021 . . . . 0.0 110.619 179.938 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.604 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -147.29 160.37 42.58 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.6 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.495 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.59 122.44 9.33 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-O 122.288 1.042 . . . . 0.0 110.333 -179.673 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.908 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.8 t -115.63 109.26 17.5 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-O 123.158 1.456 . . . . 0.0 109.838 -179.866 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.795 HG13 ' CA ' ' A' ' 21' ' ' VAL . 0.8 OUTLIER -115.5 136.12 53.32 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.632 0 CA-C-N 114.271 -1.331 . . . . 0.0 109.604 179.763 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.465 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -173.72 150.64 1.75 Allowed Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.181 -0.95 . . . . 0.0 109.04 -179.621 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.465 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.0 Cg_endo -77.2 151.18 92.99 Favored 'Cis proline' 0 C--N 1.313 -1.335 0 C-N-CA 123.484 -1.465 . . . . 0.0 109.26 -0.902 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.686 ' HA ' HG22 ' A' ' 110' ' ' ILE . 72.4 p -94.43 -22.55 18.22 Favored 'General case' 0 C--N 1.293 -1.89 0 O-C-N 121.511 -0.743 . . . . 0.0 109.623 179.878 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.466 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -130.88 155.18 47.18 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.214 -0.929 . . . . 0.0 110.233 -179.602 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.33 35.59 22.96 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.002 -1.639 . . . . 0.0 109.002 179.996 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.713 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.4 mt -92.8 -44.19 8.63 Favored 'General case' 0 C--N 1.301 -1.529 0 CA-C-O 123.214 1.483 . . . . 0.0 110.635 -178.713 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.433 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 63.17 145.19 0.02 OUTLIER 'General case' 0 C--N 1.261 -3.247 0 CA-C-N 113.558 -1.655 . . . . 0.0 109.201 -178.939 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.533 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.6 m-20 -53.82 114.68 1.65 Allowed 'General case' 0 C--N 1.299 -1.627 0 CA-C-O 121.764 0.792 . . . . 0.0 110.436 -178.946 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 121.67 0.71 10.99 Favored Glycine 0 N--CA 1.484 1.865 0 C-N-CA 119.495 -1.336 . . . . 0.0 112.404 178.334 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.713 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.8 t -106.7 -177.34 3.33 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 121.069 2.434 . . . . 0.0 110.474 -179.944 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.774 HG13 ' O ' ' A' ' 67' ' ' LEU . 25.9 t -127.48 139.09 52.88 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 CA-C-N 114.113 -1.403 . . . . 0.0 110.878 -178.865 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.603 ' CG1' HD13 ' A' ' 13' ' ' LEU . 4.2 m -113.01 158.37 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 178.907 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.51 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -106.45 108.77 20.44 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.088 -1.007 . . . . 0.0 109.115 179.947 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.878 ' CG1' HD11 ' A' ' 67' ' ' LEU . 13.0 p -101.23 140.02 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.651 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.908 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.37 161.86 35.16 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.675 -1.266 . . . . 0.0 110.154 179.642 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.591 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.6 139.32 10.53 Favored Glycine 0 C--N 1.298 -1.546 0 N-CA-C 107.882 -2.087 . . . . 0.0 107.882 179.529 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.604 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.4 125.31 16.13 Favored 'General case' 0 N--CA 1.496 1.828 0 CA-C-N 119.411 1.606 . . . . 0.0 109.434 179.446 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.465 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.67 27.77 21.01 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 118.8 -1.667 . . . . 0.0 109.634 -179.756 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.637 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.2 mt -89.01 169.63 11.36 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.033 -1.275 . . . . 0.0 108.188 179.942 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -43.59 98.67 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.015 -1.053 . . . . 0.0 110.042 -179.354 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.552 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.29 77.83 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.255 -179.285 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.571 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.23 33.44 0.27 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.393 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.542 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 59.0 p -141.73 108.67 5.43 Favored 'General case' 0 C--N 1.307 -1.264 0 O-C-N 121.102 -1.234 . . . . 0.0 111.316 -179.474 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.79 111.49 0.61 Allowed 'General case' 0 N--CA 1.497 1.896 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.717 178.067 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.539 ' CE1' ' HB2' ' A' ' 99' ' ' ASP . 5.3 m-30 -105.65 160.04 15.5 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.068 -1.02 . . . . 0.0 108.817 179.662 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.502 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -100.23 167.34 10.49 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.738 -1.226 . . . . 0.0 108.003 179.061 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.625 HG22 HG11 ' A' ' 21' ' ' VAL . 2.9 p -149.48 120.81 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.112 -0.992 . . . . 0.0 109.531 -178.136 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -174.9 -176.63 43.36 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 118.297 -1.906 . . . . 0.0 111.702 -179.941 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.711 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -98.83 108.87 21.66 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -179.997 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.1 m -130.45 148.93 52.32 Favored 'General case' 0 C--N 1.295 -1.796 0 O-C-N 121.315 -0.866 . . . . 0.0 109.461 179.389 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.494 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.38 138.72 54.34 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.154 -0.966 . . . . 0.0 110.849 -178.872 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.14 114.64 26.46 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 178.103 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.6 m -105.16 15.14 6.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.08 -1.012 . . . . 0.0 110.466 -178.609 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.75 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.42 -175.48 0.1 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.864 -1.148 . . . . 0.0 109.998 179.705 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.65 96.83 1.63 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.473 -0.767 . . . . 0.0 109.735 -179.739 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 28.03 32.32 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.493 178.933 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.75 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.18 106.57 20.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 O-C-N 120.577 -1.543 . . . . 0.0 107.302 178.845 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.2 tp -116.23 104.45 11.52 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.449 -1.407 . . . . 0.0 110.022 -177.5 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.095 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.25 109.45 22.21 Favored 'General case' 0 N--CA 1.484 1.248 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 178.525 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 5.1 t -108.5 165.49 11.48 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.826 -1.171 . . . . 0.0 110.648 -178.468 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.48 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 52.4 t30 -115.84 134.45 22.71 Favored Pre-proline 0 N--CA 1.499 2.019 0 O-C-N 121.545 -0.722 . . . . 0.0 109.394 -179.624 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.531 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 2.5 Cg_endo -72.08 22.96 0.26 Allowed 'Trans proline' 0 C--N 1.317 -1.124 0 C-N-CA 122.289 1.993 . . . . 0.0 112.106 -179.802 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.443 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -95.28 -9.76 32.2 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.355 -1.466 . . . . 0.0 109.045 179.408 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.65 ' OD2' HG13 ' A' ' 69' ' ' VAL . 3.4 m-20 -134.06 6.77 3.66 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.903 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -59.72 84.04 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.495 -0.753 . . . . 0.0 110.589 -178.775 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.612 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -111.47 -168.89 1.36 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.516 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.464 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.3 t 179.01 135.17 0.09 Allowed 'General case' 0 C--N 1.305 -1.358 0 O-C-N 120.656 -1.278 . . . . 0.0 110.967 -179.476 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.79 HG11 ' HB1' ' A' ' 63' ' ' ALA . 1.6 p -147.29 157.4 9.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.288 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.598 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.53 142.01 30.66 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 120.696 -1.252 . . . . 0.0 110.024 -179.699 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.17 107.54 1.32 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 122.5 1.143 . . . . 0.0 109.533 178.462 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.558 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.2 p-10 -61.19 -139.39 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.976 -179.99 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.552 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.77 -50.83 55.0 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.399 -0.813 . . . . 0.0 110.641 -178.764 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -104.36 -33.27 8.69 Favored 'General case' 0 C--N 1.285 -2.221 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 178.498 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.996 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.47 66.49 0.62 Allowed Glycine 0 C--N 1.299 -1.498 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 178.132 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.591 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.6 m -100.68 130.09 46.67 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.491 -1.006 . . . . 0.0 108.883 178.974 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.79 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.49 109.51 8.76 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.217 -0.993 . . . . 0.0 109.307 -179.594 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 18.2 m -124.31 118.33 26.52 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.359 -0.838 . . . . 0.0 109.789 -179.781 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -148.36 148.26 30.17 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.436 -0.79 . . . . 0.0 109.218 179.808 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.412 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 28.2 p -98.38 136.23 38.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.33 -0.856 . . . . 0.0 109.47 179.923 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.878 HD11 ' CG1' ' A' ' 21' ' ' VAL . 0.2 OUTLIER -129.68 164.91 22.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.313 -0.867 . . . . 0.0 109.874 -179.023 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.713 HG22 HG22 ' A' ' 18' ' ' VAL . 1.1 p -104.29 127.16 51.89 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.157 -0.964 . . . . 0.0 108.679 179.529 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.711 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.0 m -134.53 140.21 46.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.722 -1.236 . . . . 0.0 110.471 -178.659 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.533 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 46.8 mtt180 -126.48 -168.2 1.83 Allowed 'General case' 0 N--CA 1.484 1.226 0 O-C-N 120.703 -1.248 . . . . 0.0 111.015 179.937 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.583 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 27.9 mtm180 -77.87 -75.5 0.22 Allowed 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.326 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -73.79 136.39 43.58 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 120.006 -1.684 . . . . 0.0 106.829 178.017 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.594 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -156.15 136.88 13.36 Favored 'General case' 0 C--N 1.295 -1.766 0 C-N-CA 117.987 -1.485 . . . . 0.0 110.481 -177.861 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.479 ' O ' ' O ' ' A' ' 47' ' ' CYS . 6.6 mm-40 -37.37 120.45 0.78 Allowed 'General case' 0 N--CA 1.487 1.385 0 CA-C-O 121.589 0.709 . . . . 0.0 110.129 -178.584 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.095 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.91 48.88 3.53 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.273 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.531 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 26.3 m-85 -38.22 113.44 0.29 Allowed 'General case' 0 N--CA 1.505 2.276 0 O-C-N 121.165 -1.197 . . . . 0.0 110.138 179.561 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.717 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -86.07 126.93 34.54 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.003 -1.061 . . . . 0.0 109.455 -179.819 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.595 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 19.6 t80 -63.62 58.44 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.994 0 O-C-N 120.984 -1.073 . . . . 0.0 110.21 179.599 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -160.89 19.62 0.13 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.038 -1.038 . . . . 0.0 109.824 179.926 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.72 -27.14 5.47 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 179.767 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.446 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 15.5 p -95.57 158.91 15.24 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.994 -1.297 . . . . 0.0 110.258 -179.457 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.461 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -105.03 136.68 44.06 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 179.699 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.717 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.7 t90 -80.72 -20.13 43.5 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.914 -1.116 . . . . 0.0 110.274 -178.644 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.76 174.43 18.31 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 108.669 -1.772 . . . . 0.0 108.669 -179.392 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.53 108.73 1.44 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.011 -1.287 . . . . 0.0 107.771 179.21 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.674 HG21 ' HB3' ' A' ' 46' ' ' ALA . 41.5 t -81.41 105.59 11.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 O-C-N 121.375 -0.828 . . . . 0.0 108.796 -179.256 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.526 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.92 111.14 3.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.342 -0.849 . . . . 0.0 110.051 -179.085 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.583 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.5 t -63.99 -5.21 4.22 Favored 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 118.587 -1.245 . . . . 0.0 109.924 179.456 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.7 p -87.43 1.46 53.35 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.804 -1.185 . . . . 0.0 109.08 179.446 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.526 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -116.05 -51.18 2.65 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.393 -0.817 . . . . 0.0 108.965 179.868 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.401 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -102.2 -178.96 3.85 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.544 -0.722 . . . . 0.0 109.384 179.736 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.49 115.61 30.54 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.389 -0.82 . . . . 0.0 109.077 179.975 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.52 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.76 121.39 38.55 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.833 -1.167 . . . . 0.0 109.324 -179.438 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.632 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.02 144.93 30.0 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 122.323 1.059 . . . . 0.0 111.262 -179.278 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.586 ' CG1' HG11 ' A' ' 7' ' ' VAL . 96.1 t -102.14 109.86 27.36 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.663 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.476 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.89 -171.29 17.49 Favored Glycine 0 N--CA 1.487 2.092 0 C-N-CA 118.018 -2.039 . . . . 0.0 111.894 -177.54 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.502 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -110.51 -179.21 3.7 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 -179.221 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.554 ' HB3' ' C21' ' A' ' 114' ' ' CHR . 36.8 p -162.67 173.78 13.43 Favored 'General case' 0 C--N 1.295 -1.766 0 O-C-N 121.464 -0.772 . . . . 0.0 109.379 -179.366 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.539 ' HB2' ' CE1' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -123.59 -160.93 0.94 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.197 -0.939 . . . . 0.0 108.782 179.569 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -120.73 34.01 5.37 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.511 -1.368 . . . . 0.0 109.572 -179.859 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -121.48 -29.12 4.48 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.355 -0.841 . . . . 0.0 110.578 -179.63 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.983 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.28 -37.31 0.23 Allowed Glycine 0 N--CA 1.482 1.763 0 N-CA-C 107.601 -2.199 . . . . 0.0 107.601 -179.42 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.428 ' O ' ' OD1' ' A' ' 99' ' ' ASP . 0.8 OUTLIER -160.34 -178.3 6.84 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 121.568 -0.96 . . . . 0.0 109.587 179.202 . . . . . . . . 3 3 . 1 . 052 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -158.92 -163.42 13.0 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 108.3 -1.92 . . . . 0.0 108.3 -179.558 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.0 Cg_exo -47.72 178.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.705 0 CA-C-N 118.819 1.31 . . . . 0.0 110.132 179.331 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -91.75 -175.79 4.26 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.047 -1.033 . . . . 0.0 110.415 -178.879 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.476 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.83 168.2 14.56 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 -179.865 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.6 130.49 51.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.405 -1.056 . . . . 0.0 109.073 -179.363 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.632 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.58 121.39 21.5 Favored 'General case' 0 C--N 1.29 -1.979 0 O-C-N 121.578 -0.701 . . . . 0.0 109.914 179.85 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.686 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.5 pt -98.0 166.91 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.279 -0.888 . . . . 0.0 109.04 179.765 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.466 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 1.4 m -135.25 156.52 48.83 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.322 -0.862 . . . . 0.0 109.597 -179.96 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.648 ' CE2' HD12 ' A' ' 110' ' ' ILE . 53.7 m-85 -128.08 89.33 2.9 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.215 -0.928 . . . . 0.0 109.434 -179.885 . . . . . . . . 2 2 . 1 . 052 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.406 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 14.4 p30 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.456 -179.998 . . . . . . . . 1 1 . 1 . 052 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.983 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 053 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -122.56 108.81 33.1 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.266 -0.896 . . . . 0.0 109.407 -179.917 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.572 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 6.3 Cg_exo -58.77 156.66 31.59 Favored 'Trans proline' 0 C--N 1.311 -1.406 0 C-N-CA 122.119 1.879 . . . . 0.0 110.64 179.954 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.542 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -176.85 -169.41 0.26 Allowed 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 179.083 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.542 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.28 132.84 3.02 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.81 -1.181 . . . . 0.0 110.717 -179.059 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.017 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.7 p -104.16 104.38 14.3 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 122.585 1.183 . . . . 0.0 109.835 179.901 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.965 HG22 HG23 ' A' ' 21' ' ' VAL . 14.2 t -119.59 121.49 66.43 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.398 179.806 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.479 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.73 149.75 6.18 Favored Pre-proline 0 N--CA 1.486 1.354 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.557 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.479 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.8 Cg_endo -78.63 149.54 85.67 Favored 'Cis proline' 0 C--N 1.308 -1.563 0 C-N-CA 123.663 -1.39 . . . . 0.0 109.697 -0.722 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.641 ' HA ' HG22 ' A' ' 110' ' ' ILE . 88.7 p -91.0 -24.63 20.03 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.34 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 0.8 OUTLIER -131.23 161.17 32.85 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.381 -0.825 . . . . 0.0 109.733 -179.949 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.63 38.47 32.19 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 -179.574 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.825 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.9 mt -92.08 -44.46 8.82 Favored 'General case' 0 C--N 1.298 -1.665 0 CA-C-O 123.111 1.434 . . . . 0.0 110.736 -178.26 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.464 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.67 145.72 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.658 -1.61 . . . . 0.0 110.05 -179.818 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.607 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.4 p-10 -51.2 107.35 0.18 Allowed 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 121.502 0.668 . . . . 0.0 111.597 -178.693 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.25 14.36 9.91 Favored Glycine 0 N--CA 1.484 1.883 0 C-N-CA 119.335 -1.412 . . . . 0.0 112.953 177.227 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.825 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.7 t -102.78 -172.31 2.1 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 121.012 2.406 . . . . 0.0 109.643 179.239 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.738 HG13 ' C ' ' A' ' 67' ' ' LEU . 11.8 t -131.71 137.93 54.0 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.372 0 CA-C-N 115.001 -0.999 . . . . 0.0 111.229 -179.113 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.427 HG23 ' CD1' ' A' ' 67' ' ' LEU . 33.7 m -114.69 154.4 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.965 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.564 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -109.05 109.29 20.28 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.158 -0.964 . . . . 0.0 109.186 -179.993 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.965 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -107.7 123.11 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 -179.968 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.017 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.43 165.12 13.07 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 120.829 -1.169 . . . . 0.0 108.873 179.55 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.574 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.85 107.67 0.53 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 108.825 -1.71 . . . . 0.0 108.825 179.944 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.572 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -115.73 142.84 46.21 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 120.876 -1.367 . . . . 0.0 110.676 -179.213 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.521 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 81.78 27.35 46.77 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 179.207 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.561 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -92.11 174.26 7.41 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.061 -1.258 . . . . 0.0 108.589 179.967 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.004 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.44 99.43 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.025 -1.047 . . . . 0.0 109.732 -179.79 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.656 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.06 77.4 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.246 -179.116 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.67 34.02 0.32 Allowed Glycine 0 N--CA 1.487 2.067 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.379 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 80.3 p -144.23 111.6 5.98 Favored 'General case' 0 C--N 1.306 -1.291 0 O-C-N 120.996 -1.297 . . . . 0.0 111.096 -179.803 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.09 124.5 6.53 Favored 'General case' 0 N--CA 1.493 1.691 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.845 178.355 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.494 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 17.8 m-85 -117.69 150.4 39.13 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.493 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.479 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.64 155.42 17.89 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 178.675 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.012 HG11 HG21 ' A' ' 65' ' ' THR . 7.0 p -138.17 114.96 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.025 -1.047 . . . . 0.0 109.807 -177.81 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.58 -177.67 36.62 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 118.507 -1.806 . . . . 0.0 111.638 -179.648 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.642 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.2 pt20 -102.3 109.83 21.62 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-O 121.836 0.826 . . . . 0.0 108.917 -179.781 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.0 150.34 51.32 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.157 -0.964 . . . . 0.0 110.166 -179.869 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.77 139.7 53.61 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.255 -0.903 . . . . 0.0 110.633 -179.212 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.883 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.05 114.44 26.25 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 178.178 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.4 m -105.37 15.82 6.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.006 -1.059 . . . . 0.0 110.661 -178.821 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.98 -175.94 0.11 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.928 -1.108 . . . . 0.0 110.043 179.741 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 71.8 p -71.23 96.35 1.39 Allowed 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.37 -0.831 . . . . 0.0 109.759 -179.714 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.38 27.98 34.59 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.234 -0.984 . . . . 0.0 111.402 178.873 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 2.1 t -115.46 105.97 19.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 O-C-N 120.481 -1.599 . . . . 0.0 107.417 178.951 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.883 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -114.9 104.63 12.12 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.533 -1.355 . . . . 0.0 110.062 -177.658 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.745 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.21 109.52 22.26 Favored 'General case' 0 N--CA 1.483 1.225 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 178.447 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.7 t -105.49 170.47 7.87 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.968 -1.082 . . . . 0.0 110.734 -178.108 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.474 ' HB2' ' HB2' ' A' ' 73' ' ' PHE . 21.1 t-20 -114.14 126.07 28.5 Favored Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.54 -0.725 . . . . 0.0 109.546 -179.471 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.602 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -70.57 21.15 0.2 Allowed 'Trans proline' 0 CA--C 1.545 1.062 0 C-N-CA 122.098 1.865 . . . . 0.0 112.118 179.589 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.445 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -107.86 2.59 23.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.42 -1.425 . . . . 0.0 108.964 179.385 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.544 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.39 16.4 2.57 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.563 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -80.35 91.16 5.63 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.974 -178.537 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.621 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.35 -166.37 1.15 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.23 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.68 137.57 0.09 Allowed 'General case' 0 N--CA 1.486 1.345 0 O-C-N 120.55 -1.344 . . . . 0.0 111.369 -179.38 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 1.012 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -156.86 156.94 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.171 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.568 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.17 144.7 27.36 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 120.717 -1.239 . . . . 0.0 109.944 -179.616 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.004 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.22 106.39 1.08 Allowed 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 122.408 1.099 . . . . 0.0 109.29 178.466 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.536 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.6 p-10 -59.04 -138.49 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.992 -179.816 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.656 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.19 -50.27 62.22 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.445 -0.784 . . . . 0.0 110.618 -178.567 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 28.9 t30 -104.16 -35.53 8.0 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 106.093 -1.817 . . . . 0.0 106.093 178.376 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.993 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 111.1 64.82 0.51 Allowed Glycine 0 C--N 1.298 -1.548 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 177.924 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.574 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 18.6 m -104.72 123.11 47.06 Favored 'General case' 0 N--CA 1.484 1.254 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.545 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 1.012 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.27 109.23 9.25 Favored 'General case' 0 C--N 1.294 -1.819 0 C-N-CA 119.894 -0.722 . . . . 0.0 109.544 -179.052 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 3.6 m -114.0 115.77 28.15 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.349 -0.845 . . . . 0.0 109.358 -179.981 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 65' ' ' THR . . . . . 1.012 HG21 HG11 ' A' ' 34' ' ' VAL . 1.5 t -139.18 140.0 37.7 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.399 -0.813 . . . . 0.0 109.85 179.971 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 45.4 p -99.24 145.82 26.86 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.496 -0.753 . . . . 0.0 109.17 179.718 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.738 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -146.63 162.7 37.88 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.354 -0.842 . . . . 0.0 109.6 -179.134 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.714 HG22 HG22 ' A' ' 18' ' ' VAL . 3.2 p -93.94 124.76 38.16 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.936 . . . . 0.0 109.276 -179.913 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.553 HG23 HD13 ' A' ' 13' ' ' LEU . 15.4 m -134.66 141.94 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 120.861 -1.149 . . . . 0.0 109.99 -179.101 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.607 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.5 ptt180 -141.9 -163.7 1.64 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 120.473 -1.392 . . . . 0.0 110.601 -179.802 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.615 ' HD2' ' CD1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -75.74 -92.59 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.343 -0.848 . . . . 0.0 109.79 -179.029 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.539 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -60.92 133.07 55.73 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.255 -1.528 . . . . 0.0 107.726 179.478 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.642 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -153.95 156.91 38.35 Favored 'General case' 0 C--N 1.293 -1.874 0 C-N-CA 118.367 -1.333 . . . . 0.0 110.179 -178.716 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.596 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 30.3 mm-40 -47.99 121.66 4.41 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.35 -0.844 . . . . 0.0 109.94 -178.292 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.745 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -86.79 49.89 4.1 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 -179.4 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.602 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 29.7 m-85 -52.29 110.37 0.49 Allowed 'General case' 0 N--CA 1.505 2.301 0 O-C-N 121.014 -1.286 . . . . 0.0 110.743 179.753 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.775 HD13 ' HB2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -78.67 151.57 32.14 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 120.801 -1.187 . . . . 0.0 108.748 178.64 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.55 ' HA ' ' C6 ' ' A' ' 114' ' ' CHR . 40.4 t80 -63.41 -5.5 3.71 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 120.691 -1.256 . . . . 0.0 110.863 179.954 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -99.18 7.63 45.59 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.723 -1.236 . . . . 0.0 109.593 179.938 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.447 ' HA2' ' O11' ' A' ' 114' ' ' CHR . . . 82.59 -9.81 57.77 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.967 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.55 ' O ' ' HB2' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -78.86 133.56 36.98 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.115 -1.227 . . . . 0.0 109.917 -179.8 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.508 ' NH1' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -75.74 114.66 14.6 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.294 -0.879 . . . . 0.0 109.702 179.75 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.775 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.0 t90 -80.91 -20.16 42.73 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.036 -1.04 . . . . 0.0 109.426 -179.97 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.44 172.48 18.82 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 -179.725 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.44 110.61 1.72 Allowed 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 179.192 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.616 HG23 ' HA3' ' A' ' 75' ' ' GLY . 41.1 t -80.84 101.17 5.55 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.989 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.727 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -61.98 108.21 1.0 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.671 -0.643 . . . . 0.0 110.066 -179.176 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.56 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 4.1 t -60.36 -5.07 1.0 Allowed 'General case' 0 N--CA 1.501 2.124 0 C-N-CA 118.334 -1.346 . . . . 0.0 110.339 179.385 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 60.8 p -89.6 0.26 57.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.461 -1.399 . . . . 0.0 109.588 179.994 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.727 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -110.24 -48.46 3.18 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.172 -0.955 . . . . 0.0 109.068 179.994 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.78 -178.07 3.54 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.604 -0.685 . . . . 0.0 109.507 179.997 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.36 112.94 26.17 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.784 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.497 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.48 122.2 39.13 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.107 -0.995 . . . . 0.0 109.675 -178.731 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.3 mt-30 -104.02 148.92 25.66 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 122.428 1.109 . . . . 0.0 111.339 -179.42 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.549 ' HB ' HG11 ' A' ' 7' ' ' VAL . 57.7 t -103.98 109.78 28.25 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.989 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 177.566 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.46 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.13 -171.46 17.83 Favored Glycine 0 N--CA 1.486 1.995 0 C-N-CA 118.239 -1.934 . . . . 0.0 111.605 -177.625 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.49 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -122.05 178.92 4.7 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -178.812 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.571 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 3.4 m 178.37 177.32 0.44 Allowed 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.571 -0.705 . . . . 0.0 109.393 -179.841 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.481 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -125.05 -156.95 0.75 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.058 -1.026 . . . . 0.0 109.033 179.877 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.481 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.48 36.22 4.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.781 -1.2 . . . . 0.0 109.091 179.925 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -112.19 -32.84 6.41 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.301 -0.875 . . . . 0.0 109.946 -179.671 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.725 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.89 -36.86 0.26 Allowed Glycine 0 N--CA 1.482 1.71 0 N-CA-C 107.883 -2.087 . . . . 0.0 107.883 -179.704 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.413 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -167.0 -177.17 3.67 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 122.079 0.942 . . . . 0.0 109.755 179.427 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.87 -162.23 21.77 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.265 -1.934 . . . . 0.0 108.265 -179.431 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.508 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.5 Cg_exo -45.27 171.91 0.02 OUTLIER 'Trans proline' 0 C--N 1.326 -0.629 0 CA-C-N 118.95 1.375 . . . . 0.0 110.035 179.319 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -93.17 -176.69 4.23 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.049 -1.032 . . . . 0.0 110.501 -178.583 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.46 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.07 166.28 12.77 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 -179.908 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -106.11 132.91 52.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.399 -1.059 . . . . 0.0 109.162 -179.251 . . . . . . . . 1 1 . 1 . 053 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.58 126.08 29.0 Favored 'General case' 0 C--N 1.289 -2.038 0 O-C-N 121.534 -0.729 . . . . 0.0 109.741 179.873 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.822 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.91 172.44 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.248 -0.907 . . . . 0.0 108.979 179.683 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.59 158.73 43.76 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.077 -1.014 . . . . 0.0 109.462 -179.948 . . . . . . . . 3 3 . 1 . 053 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.822 ' CE2' HD12 ' A' ' 110' ' ' ILE . 56.0 m-85 -136.8 81.09 1.85 Allowed 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.24 -0.913 . . . . 0.0 109.636 -179.639 . . . . . . . . 2 2 . 1 . 053 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 16.6 p30 . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.516 -179.985 . . . . . . . . 0 0 . 1 . 053 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.811 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 0 0 . 1 . 054 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -119.42 152.95 53.52 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.371 -0.83 . . . . 0.0 109.49 179.969 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.583 ' HB3' HD23 ' A' ' 26' ' ' LEU . 5.1 Cg_exo -59.96 157.44 33.87 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.23 1.953 . . . . 0.0 110.642 -179.985 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.598 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -149.04 160.22 43.51 Favored 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 -179.542 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.494 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.41 122.69 9.61 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-O 122.43 1.11 . . . . 0.0 110.234 -179.728 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.863 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.9 t -115.14 109.04 17.43 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 123.127 1.441 . . . . 0.0 109.812 -179.863 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.795 HG22 HG23 ' A' ' 21' ' ' VAL . 2.2 t -116.18 134.18 60.36 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.659 0 CA-C-N 114.229 -1.35 . . . . 0.0 109.486 179.795 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.472 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -169.53 150.39 4.03 Favored Pre-proline 0 N--CA 1.487 1.413 0 O-C-N 121.183 -0.948 . . . . 0.0 108.876 -179.509 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.472 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.5 Cg_endo -75.52 152.32 97.24 Favored 'Cis proline' 0 C--N 1.313 -1.315 0 C-N-CA 123.488 -1.463 . . . . 0.0 109.785 -0.963 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.625 ' HA ' HG22 ' A' ' 110' ' ' ILE . 5.8 m -93.05 -23.52 18.63 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.447 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.513 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 69.0 m -134.99 159.62 40.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.564 -0.71 . . . . 0.0 109.382 179.912 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.28 36.29 27.61 Favored Glycine 0 N--CA 1.495 2.626 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.736 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.745 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.7 mt -90.94 -42.65 10.45 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 123.391 1.567 . . . . 0.0 110.393 -178.482 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.48 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.11 144.34 0.05 OUTLIER 'General case' 0 C--N 1.261 -3.267 0 CA-C-N 113.282 -1.781 . . . . 0.0 110.08 -179.746 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.599 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.3 p-10 -50.46 104.75 0.08 Allowed 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.556 0.693 . . . . 0.0 111.655 -178.451 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.51 14.4 8.2 Favored Glycine 0 N--CA 1.485 1.91 0 C-N-CA 119.33 -1.414 . . . . 0.0 113.154 177.18 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.745 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -105.76 -172.99 2.19 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 121.352 2.576 . . . . 0.0 109.821 179.181 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.731 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.5 t -129.59 138.21 54.82 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.333 0 CA-C-N 114.67 -1.15 . . . . 0.0 111.136 -178.711 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.633 HG11 HD11 ' A' ' 13' ' ' LEU . 29.4 m -113.61 155.48 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.863 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tttm -104.32 109.05 20.75 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.208 -0.933 . . . . 0.0 109.213 -179.962 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.944 HG11 HD11 ' A' ' 67' ' ' LEU . 2.2 p -100.64 140.05 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.627 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.863 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -136.61 162.67 32.49 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.733 -1.229 . . . . 0.0 110.179 179.666 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.588 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.64 139.82 10.95 Favored Glycine 0 C--N 1.299 -1.527 0 N-CA-C 108.244 -1.942 . . . . 0.0 108.244 179.728 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.598 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.32 125.6 16.51 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.491 -1.593 . . . . 0.0 109.355 179.301 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.469 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 88.85 28.32 21.52 Favored Glycine 0 N--CA 1.49 2.264 0 C-N-CA 118.685 -1.722 . . . . 0.0 109.731 -179.824 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.583 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.4 mt -88.72 171.95 9.6 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.885 -1.362 . . . . 0.0 108.278 179.835 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.02 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.03 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.96 -1.087 . . . . 0.0 109.872 -179.476 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.57 77.54 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.677 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.178 -179.345 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.65 33.97 0.28 Allowed Glycine 0 N--CA 1.486 2.007 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.618 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.563 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 41.2 p -141.51 108.05 5.32 Favored 'General case' 0 C--N 1.307 -1.244 0 O-C-N 121.144 -1.209 . . . . 0.0 111.236 -179.476 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.04 109.8 0.36 Allowed 'General case' 0 N--CA 1.497 1.904 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.488 177.866 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.511 ' CE1' ' HB2' ' A' ' 99' ' ' ASP . 5.3 m-30 -103.89 157.99 16.71 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.054 -1.029 . . . . 0.0 108.87 179.741 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -99.81 166.54 11.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.844 -1.16 . . . . 0.0 107.969 179.007 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.628 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.8 p -148.09 120.28 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.108 -0.995 . . . . 0.0 109.605 -178.038 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -174.02 -177.02 42.89 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 118.403 -1.856 . . . . 0.0 111.641 -179.927 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.701 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -99.16 108.24 20.79 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.95 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -130.25 148.5 52.08 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.212 -0.93 . . . . 0.0 109.985 179.708 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.427 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.71 139.58 53.73 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.298 -0.877 . . . . 0.0 110.634 -179.099 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.888 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.21 114.76 26.59 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 178.207 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -104.83 15.02 6.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.92 -1.112 . . . . 0.0 110.58 -178.795 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.768 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.41 -175.96 0.08 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.872 -1.142 . . . . 0.0 110.074 179.757 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.781 ' O ' HG23 ' A' ' 42' ' ' THR . 15.0 t -71.36 98.0 1.7 Allowed 'General case' 0 N--CA 1.488 1.434 0 CA-C-O 121.729 0.776 . . . . 0.0 109.808 -179.696 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.48 27.86 34.64 Favored Glycine 0 N--CA 1.492 2.405 0 C-N-CA 120.174 -1.012 . . . . 0.0 111.427 178.97 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.768 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.71 106.25 19.87 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 O-C-N 120.587 -1.537 . . . . 0.0 107.192 178.887 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.888 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -116.96 104.53 11.37 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.478 -1.389 . . . . 0.0 109.773 -177.75 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.098 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.99 109.28 22.06 Favored 'General case' 0 N--CA 1.485 1.315 0 O-C-N 120.833 -1.167 . . . . 0.0 108.152 178.92 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.0 t -106.67 164.8 11.79 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.913 -1.117 . . . . 0.0 110.233 -179.115 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.793 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 3.7 t-20 -106.56 136.21 19.42 Favored Pre-proline 0 N--CA 1.498 1.966 0 O-C-N 121.386 -0.821 . . . . 0.0 109.622 -179.179 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.592 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -74.85 23.79 0.39 Allowed 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 122.384 2.056 . . . . 0.0 111.943 -179.83 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.793 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -109.76 -4.59 15.99 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.33 -1.481 . . . . 0.0 109.143 179.615 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.665 ' OD2' HG13 ' A' ' 69' ' ' VAL . 6.0 m-20 -131.73 6.05 4.33 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.658 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.47 84.94 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.732 -178.502 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -110.76 -170.49 1.65 Allowed 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.448 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.58 135.22 0.08 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 120.622 -1.298 . . . . 0.0 111.136 -179.286 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.767 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.6 p -146.8 158.28 10.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 178.169 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.598 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.49 141.51 31.25 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 120.703 -1.248 . . . . 0.0 110.061 -179.791 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.02 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.21 107.91 1.43 Allowed 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.438 1.114 . . . . 0.0 109.537 178.596 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.57 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.1 p-10 -61.46 -139.45 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.97 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.864 179.849 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.89 -50.87 60.17 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.427 -0.796 . . . . 0.0 110.487 -178.843 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -102.24 -34.71 9.13 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 178.46 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.27 67.31 0.64 Allowed Glycine 0 C--N 1.299 -1.499 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 178.073 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 57.5 m -100.06 130.86 46.26 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.482 -1.011 . . . . 0.0 108.803 178.962 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.767 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.48 109.42 9.27 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.19 -1.004 . . . . 0.0 109.321 -179.648 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 73.2 m -121.85 117.0 25.43 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.313 -0.867 . . . . 0.0 109.61 -179.678 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.589 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -147.54 149.32 32.37 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.452 -0.78 . . . . 0.0 109.291 179.879 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.434 ' O ' HD23 ' A' ' 67' ' ' LEU . 56.3 p -98.47 145.08 27.13 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.401 -0.812 . . . . 0.0 109.284 179.969 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.944 HD11 HG11 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -138.96 159.62 41.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.334 -0.854 . . . . 0.0 109.826 -178.717 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.652 HG22 HG22 ' A' ' 18' ' ' VAL . 1.4 p -101.29 124.0 46.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.011 -1.056 . . . . 0.0 108.483 179.319 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.701 HG12 ' HB3' ' A' ' 36' ' ' GLN . 21.1 m -137.92 143.16 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.744 -1.222 . . . . 0.0 110.783 -178.47 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.599 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.9 ptt180 -147.45 -175.14 4.73 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 120.711 -1.243 . . . . 0.0 110.742 179.68 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.595 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.43 -101.93 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -179.597 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.503 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -57.08 140.85 47.98 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.741 -1.224 . . . . 0.0 108.205 179.459 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -161.83 136.67 7.16 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 118.611 -1.235 . . . . 0.0 109.733 -178.1 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.532 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.4 mp0 -35.87 122.36 0.68 Allowed 'General case' 0 N--CA 1.491 1.576 0 CA-C-O 121.466 0.65 . . . . 0.0 110.094 -178.615 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.098 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.85 52.67 1.7 Allowed Glycine 0 N--CA 1.494 2.522 0 C-N-CA 120.539 -0.838 . . . . 0.0 111.22 -179.109 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.592 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.57 114.05 0.38 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.094 -1.239 . . . . 0.0 110.133 179.463 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.733 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -82.79 126.19 32.14 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 120.843 -1.161 . . . . 0.0 109.313 179.787 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.585 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 51.8 t80 -64.02 58.59 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.955 0 O-C-N 120.89 -1.131 . . . . 0.0 110.042 179.724 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.3 t0 -160.22 20.03 0.15 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.094 -1.004 . . . . 0.0 109.608 179.942 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.54 -28.35 5.36 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.871 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.481 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.5 OUTLIER -96.72 160.42 14.38 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.058 -1.26 . . . . 0.0 110.207 -179.532 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.508 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.7 OUTLIER -106.13 141.69 37.07 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 179.896 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.733 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.6 t90 -85.15 -19.35 31.92 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.679 -1.263 . . . . 0.0 110.689 -178.289 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.42 177.5 18.59 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -179.359 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -67.02 105.79 1.75 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.146 -1.208 . . . . 0.0 107.785 179.183 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.65 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.7 t -77.2 106.33 7.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.326 -0.858 . . . . 0.0 109.232 -178.879 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.55 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.1 m-20 -65.96 111.63 3.42 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.363 -0.836 . . . . 0.0 109.69 -179.643 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.595 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.5 -5.36 5.26 Favored 'General case' 0 N--CA 1.5 2.045 0 C-N-CA 118.195 -1.402 . . . . 0.0 109.721 179.567 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -86.4 -0.41 55.91 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.716 -1.24 . . . . 0.0 109.079 179.482 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.55 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.6 -50.88 2.83 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.287 -0.883 . . . . 0.0 108.972 179.9 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.69 -178.73 3.74 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.509 -0.744 . . . . 0.0 109.271 179.815 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.17 115.37 30.11 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.437 -0.789 . . . . 0.0 108.888 -179.949 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.527 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.06 121.1 38.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.94 -1.1 . . . . 0.0 109.714 -179.271 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.614 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.21 146.94 27.27 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 122.449 1.119 . . . . 0.0 111.024 -179.562 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.548 ' CG1' HG11 ' A' ' 7' ' ' VAL . 61.6 t -104.23 111.72 34.94 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 177.858 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.497 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -152.91 -169.86 18.59 Favored Glycine 0 N--CA 1.487 2.089 0 C-N-CA 118.124 -1.989 . . . . 0.0 111.848 -177.71 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.489 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -114.32 179.43 3.96 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 -179.173 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.576 ' HB2' ' C20' ' A' ' 114' ' ' CHR . 25.0 p -160.64 167.59 26.69 Favored 'General case' 0 C--N 1.295 -1.792 0 O-C-N 121.467 -0.771 . . . . 0.0 109.363 -179.513 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.511 ' HB2' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -110.25 -160.5 0.72 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.025 -1.047 . . . . 0.0 108.646 179.554 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -116.86 37.07 3.92 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.552 -1.342 . . . . 0.0 109.09 179.866 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -123.53 -36.74 2.74 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.275 -0.89 . . . . 0.0 110.449 -179.473 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.977 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 162.43 -30.9 0.3 Allowed Glycine 0 N--CA 1.476 1.34 0 N-CA-C 106.717 -2.553 . . . . 0.0 106.717 -179.348 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.451 ' O ' ' OD1' ' A' ' 99' ' ' ASP . 0.0 OUTLIER -146.7 170.74 16.35 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.709 -0.877 . . . . 0.0 109.943 -179.775 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.15 -165.01 19.55 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 108.163 -1.975 . . . . 0.0 108.163 -179.857 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.9 Cg_exo -48.22 179.39 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 CA-C-N 118.889 1.344 . . . . 0.0 110.164 179.446 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -92.86 -177.71 4.61 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.183 -0.948 . . . . 0.0 110.438 -178.894 . . . . . . . . 1 1 . 1 . 054 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.497 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.61 165.62 14.53 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.923 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.0 130.13 53.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 O-C-N 121.293 -1.122 . . . . 0.0 109.209 -179.269 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.614 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.05 121.92 21.85 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.569 -0.707 . . . . 0.0 109.528 179.668 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.827 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.9 167.25 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 121.188 -0.945 . . . . 0.0 109.243 179.913 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.513 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -137.33 151.24 48.42 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.237 -0.914 . . . . 0.0 109.62 -179.97 . . . . . . . . 3 3 . 1 . 054 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.827 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 25.2 m-85 -126.32 108.06 10.89 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.163 -0.961 . . . . 0.0 109.51 -179.693 . . . . . . . . 2 2 . 1 . 054 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 16.0 p30 . . . . . 0 N--CA 1.489 1.48 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.461 179.997 . . . . . . . . 0 0 . 1 . 054 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.977 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 121.327 0.584 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 055 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.656 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -105.56 162.99 18.03 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.199 -0.938 . . . . 0.0 109.497 179.967 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.656 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 3.2 Cg_exo -60.87 156.24 44.8 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.262 1.975 . . . . 0.0 110.672 -179.996 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.561 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.95 -169.65 0.13 Allowed 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.237 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.561 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -166.8 129.01 1.76 Allowed 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.837 -1.164 . . . . 0.0 110.71 -179.164 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.968 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.7 t -110.93 108.77 18.65 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.079 1.418 . . . . 0.0 109.078 179.276 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.768 HG22 HG23 ' A' ' 21' ' ' VAL . 2.3 t -119.62 136.7 55.89 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.672 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.023 -179.637 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.488 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -177.0 150.96 0.92 Allowed Pre-proline 0 N--CA 1.487 1.421 0 O-C-N 121.286 -0.884 . . . . 0.0 108.785 -179.72 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.488 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -78.46 150.76 88.4 Favored 'Cis proline' 0 C--N 1.312 -1.35 0 C-N-CA 123.481 -1.466 . . . . 0.0 109.301 -0.828 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.689 ' HA ' HG22 ' A' ' 110' ' ' ILE . 77.9 p -89.34 -25.99 21.33 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.518 -0.739 . . . . 0.0 109.056 179.527 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.504 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -132.99 162.69 31.01 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.528 -0.733 . . . . 0.0 109.529 -179.922 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.31 36.93 29.37 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.749 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.771 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.5 mt -92.78 -42.97 9.27 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 123.24 1.495 . . . . 0.0 110.488 -178.327 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.29 144.35 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.265 0 CA-C-N 113.479 -1.691 . . . . 0.0 109.936 -179.521 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.591 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 15.5 p-10 -50.9 106.49 0.13 Allowed 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.515 0.674 . . . . 0.0 111.556 -178.542 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.28 14.22 9.23 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.331 -1.414 . . . . 0.0 113.007 177.311 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.771 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.71 -172.01 2.02 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 121.143 2.471 . . . . 0.0 109.67 179.144 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.748 HG13 ' C ' ' A' ' 67' ' ' LEU . 17.2 t -127.92 135.97 61.53 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.404 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.182 -178.93 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.591 HG11 HD11 ' A' ' 13' ' ' LEU . 23.0 m -110.79 155.15 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.77 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.523 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.8 OUTLIER -109.93 109.18 19.71 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.173 -0.954 . . . . 0.0 108.973 179.958 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.768 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -105.16 141.73 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.675 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.968 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -141.0 160.2 40.59 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.144 179.886 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.95 144.72 15.91 Favored Glycine 0 C--N 1.294 -1.769 0 N-CA-C 107.996 -2.041 . . . . 0.0 107.996 179.666 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.579 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.4 125.73 13.1 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 120.884 -1.362 . . . . 0.0 108.789 179.244 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.496 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.46 27.16 23.36 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.315 -1.421 . . . . 0.0 109.608 -179.568 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.551 HD22 ' HG3' ' A' ' 105' ' ' PRO . 1.5 mt -88.8 175.33 7.53 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.946 -1.326 . . . . 0.0 108.446 -179.941 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.998 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -48.42 99.49 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.013 -1.055 . . . . 0.0 109.83 -179.623 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.562 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.11 77.98 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.759 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.149 -179.325 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.69 34.2 0.31 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.614 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.549 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 62.9 p -143.21 109.09 5.18 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.034 -1.274 . . . . 0.0 111.142 -179.591 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.552 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.99 126.01 5.57 Favored 'General case' 0 N--CA 1.493 1.71 0 CA-C-O 121.403 0.62 . . . . 0.0 109.56 178.129 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.566 ' CE1' ' OD2' ' A' ' 99' ' ' ASP . 19.8 m-85 -117.35 152.98 33.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.349 -0.844 . . . . 0.0 108.923 179.808 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.523 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -103.14 152.66 21.17 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.627 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.637 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.0 p -136.82 116.96 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 120.885 -1.134 . . . . 0.0 109.856 -177.904 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.502 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.1 -178.28 39.35 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 118.462 -1.828 . . . . 0.0 111.828 -179.799 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.59 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -101.74 109.56 21.36 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.928 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.485 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.53 148.4 52.33 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.098 -1.001 . . . . 0.0 110.081 179.852 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.04 138.53 54.66 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.394 -0.816 . . . . 0.0 110.701 -179.025 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.862 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.39 114.6 26.39 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 178.137 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 m -105.22 15.16 6.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.006 -1.059 . . . . 0.0 110.705 -178.596 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.757 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.14 -175.09 0.09 Allowed 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.952 -1.093 . . . . 0.0 110.097 179.736 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 35.1 p -72.0 97.54 1.9 Allowed 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.404 -0.81 . . . . 0.0 109.727 -179.673 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.13 26.53 36.61 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.173 -1.013 . . . . 0.0 111.446 178.859 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.757 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.21 106.3 20.28 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 O-C-N 120.547 -1.561 . . . . 0.0 107.482 178.93 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.862 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -117.51 104.07 10.7 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.47 -1.393 . . . . 0.0 109.6 -177.815 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.014 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.32 109.24 22.03 Favored 'General case' 0 N--CA 1.483 1.179 0 O-C-N 120.767 -1.208 . . . . 0.0 107.753 178.603 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.491 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -103.5 166.01 10.69 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.924 -1.11 . . . . 0.0 110.411 -178.532 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.677 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 17.1 t-20 -106.35 129.72 24.07 Favored Pre-proline 0 N--CA 1.501 2.084 0 C-N-CA 119.945 -0.702 . . . . 0.0 109.757 -179.202 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.598 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.6 Cg_endo -72.94 23.81 0.3 Allowed 'Trans proline' 0 CA--C 1.544 0.98 0 C-N-CA 122.089 1.86 . . . . 0.0 111.813 179.634 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.677 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -115.51 3.63 14.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.498 -1.376 . . . . 0.0 109.197 179.738 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.543 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.89 17.24 2.66 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 179.49 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -80.64 91.1 5.8 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.842 -0.743 . . . . 0.0 110.814 -178.696 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.637 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -109.51 -166.71 1.12 Allowed 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.297 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.94 137.03 0.09 Allowed 'General case' 0 C--N 1.306 -1.311 0 O-C-N 120.526 -1.358 . . . . 0.0 111.404 -179.271 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.932 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -154.9 156.15 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.211 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.552 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.68 144.87 26.88 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.694 -1.254 . . . . 0.0 109.907 -179.534 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.83 107.22 1.16 Allowed 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 122.431 1.11 . . . . 0.0 109.409 178.586 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -61.07 -139.34 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.027 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.903 -179.909 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.562 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.9 -50.91 56.38 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.397 -0.814 . . . . 0.0 110.68 -178.713 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -103.94 -33.18 8.92 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 178.576 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.003 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.96 64.91 0.58 Allowed Glycine 0 C--N 1.299 -1.498 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 178.206 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 47.7 m -103.44 127.07 50.9 Favored 'General case' 0 N--CA 1.483 1.176 0 O-C-N 121.57 -0.959 . . . . 0.0 108.83 178.901 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.932 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.04 108.96 7.1 Favored 'General case' 0 C--N 1.296 -1.751 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.659 -179.396 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.1 m -122.44 121.01 35.6 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.359 -0.838 . . . . 0.0 109.303 -179.898 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.525 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.83 144.84 31.34 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.426 -0.796 . . . . 0.0 109.565 179.886 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 22.1 p -99.0 141.0 32.3 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.38 -0.825 . . . . 0.0 109.297 -179.945 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.777 HD12 ' H ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.99 166.7 24.07 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.413 -0.804 . . . . 0.0 109.39 -179.327 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.728 HG22 HG22 ' A' ' 18' ' ' VAL . 2.7 p -95.96 124.38 39.95 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.005 -1.06 . . . . 0.0 109.416 -179.883 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.587 HG22 HG22 ' A' ' 19' ' ' VAL . 13.3 m -136.42 141.86 40.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 120.907 -1.121 . . . . 0.0 109.937 -179.12 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.591 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.3 ptt180 -144.35 -170.32 3.34 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.546 -1.346 . . . . 0.0 110.884 -179.882 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.598 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -62.45 -101.42 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.77 -0.581 . . . . 0.0 110.206 -179.125 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.541 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -58.94 137.15 58.0 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.574 -1.329 . . . . 0.0 108.209 179.957 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD2' ' O ' ' A' ' 71' ' ' ARG . 1.7 p90 -157.53 154.04 27.96 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.646 -1.222 . . . . 0.0 110.198 -178.514 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.5 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 5.1 mm-40 -47.15 120.8 3.32 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.359 -0.838 . . . . 0.0 109.263 -179.124 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.014 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.5 51.34 3.01 Favored Glycine 0 N--CA 1.495 2.59 0 C-N-CA 120.414 -0.898 . . . . 0.0 111.116 -179.224 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.598 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.5 m-30 -39.0 114.0 0.36 Allowed 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.114 -1.227 . . . . 0.0 110.31 179.62 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.765 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.21 126.94 34.63 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.919 -1.113 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.585 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 29.2 t80 -64.25 58.44 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.911 -1.118 . . . . 0.0 110.059 179.702 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -160.33 19.52 0.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.031 -1.043 . . . . 0.0 109.733 179.824 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.74 -26.96 5.57 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 179.866 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.404 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -95.34 161.42 14.09 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 120.998 -1.295 . . . . 0.0 110.315 -179.383 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.482 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -107.24 136.78 46.49 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.813 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.765 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -83.64 -16.89 43.44 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.784 -1.198 . . . . 0.0 110.562 -178.423 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.14 174.27 20.0 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 108.827 -1.709 . . . . 0.0 108.827 -179.553 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -63.66 107.0 1.06 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.141 -1.211 . . . . 0.0 107.759 179.218 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.662 HG21 ' HB3' ' A' ' 46' ' ' ALA . 44.3 t -78.94 106.05 9.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.307 -0.871 . . . . 0.0 109.243 -178.877 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.553 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -65.16 108.35 1.84 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.652 -0.655 . . . . 0.0 110.113 -179.408 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.598 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.5 t -61.34 -4.72 1.32 Allowed 'General case' 0 N--CA 1.502 2.133 0 O-C-N 120.479 -1.388 . . . . 0.0 110.417 179.391 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -90.43 3.68 53.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.597 -1.314 . . . . 0.0 109.481 179.944 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.553 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -114.96 -48.32 2.84 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.282 -0.886 . . . . 0.0 109.107 -179.976 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.72 -179.05 3.82 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.573 -0.704 . . . . 0.0 109.526 179.997 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.97 112.15 24.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.382 -0.824 . . . . 0.0 108.812 179.838 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.505 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.4 m -96.98 122.06 39.54 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.104 -0.997 . . . . 0.0 109.399 -178.922 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.575 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.08 148.66 25.45 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-O 122.439 1.114 . . . . 0.0 111.577 -179.157 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.499 ' CG1' HG11 ' A' ' 7' ' ' VAL . 84.8 t -104.22 110.78 31.43 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 177.643 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.412 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.84 -172.01 18.87 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 118.034 -2.031 . . . . 0.0 111.802 -177.604 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.523 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -114.57 -179.04 3.52 Favored 'General case' 0 N--CA 1.485 1.3 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -178.94 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.563 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.8 OUTLIER -170.93 168.26 7.12 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.394 -0.816 . . . . 0.0 109.033 -179.418 . . . . . . . . 3 3 . 1 . 055 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.7 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 2.1 m-20 -103.66 -11.16 17.84 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.021 -1.05 . . . . 0.0 109.485 179.961 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.7 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 74.29 37.67 0.58 Allowed 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.411 -0.806 . . . . 0.0 109.246 179.783 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -137.24 -33.61 0.74 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.533 -0.729 . . . . 0.0 110.715 -179.44 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.515 ' N ' H193 ' A' ' 114' ' ' CHR . . . -179.88 -41.93 0.08 OUTLIER Glycine 0 N--CA 1.481 1.688 0 N-CA-C 107.636 -2.185 . . . . 0.0 107.636 -179.573 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.3 -178.81 7.56 Favored 'General case' 0 C--N 1.307 -1.26 0 O-C-N 121.542 -0.975 . . . . 0.0 109.623 179.022 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -177.63 -167.01 35.17 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 -179.584 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.551 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.7 Cg_exo -49.11 -179.57 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.618 0 CA-C-N 118.83 1.315 . . . . 0.0 110.07 179.529 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.87 -179.81 5.1 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.012 -1.055 . . . . 0.0 110.521 -178.765 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.412 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.99 162.65 13.42 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.973 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -103.55 130.62 53.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.318 -1.107 . . . . 0.0 109.216 -179.347 . . . . . . . . 1 1 . 1 . 055 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.575 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.98 121.21 18.75 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.641 -0.662 . . . . 0.0 109.606 179.62 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.859 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.04 171.43 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.239 -0.913 . . . . 0.0 109.174 179.947 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.504 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.4 m -141.1 156.55 45.96 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.151 -0.968 . . . . 0.0 109.895 -179.841 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.859 ' CE2' HD12 ' A' ' 110' ' ' ILE . 82.8 m-85 -134.36 94.22 3.18 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.243 -0.911 . . . . 0.0 109.549 -179.74 . . . . . . . . 2 2 . 1 . 055 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 23.0 p30 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 118.003 -0.998 . . . . 0.0 109.459 179.931 . . . . . . . . 0 0 . 1 . 055 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.676 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.345 0.593 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 056 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.911 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -95.42 172.17 5.66 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.224 -0.922 . . . . 0.0 109.509 179.995 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.911 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 3.7 Cg_exo -60.42 158.08 33.15 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.266 1.977 . . . . 0.0 110.55 -179.98 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.873 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.1 p -166.43 160.79 15.87 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -179.341 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.505 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.11 128.61 14.03 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-O 122.409 1.1 . . . . 0.0 110.565 -179.705 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.011 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.4 p -106.31 104.86 14.65 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 122.461 1.124 . . . . 0.0 110.199 -179.476 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.967 HG22 HG23 ' A' ' 21' ' ' VAL . 12.1 t -118.53 118.69 58.8 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.439 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.364 179.596 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.499 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.87 149.17 10.28 Favored Pre-proline 0 N--CA 1.487 1.38 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 -179.65 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.499 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -77.83 151.23 91.09 Favored 'Cis proline' 0 C--N 1.31 -1.494 0 C-N-CA 123.606 -1.414 . . . . 0.0 109.51 -0.578 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.704 ' HA ' HG22 ' A' ' 110' ' ' ILE . 16.5 p -93.52 -23.85 18.2 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.639 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.463 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 20.2 m -132.38 162.22 31.64 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.438 -0.789 . . . . 0.0 109.585 -179.927 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.2 37.24 37.72 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 -179.733 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.83 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.2 mt -90.41 -44.64 9.51 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 123.127 1.441 . . . . 0.0 110.652 -178.428 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.99 145.83 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.325 0 CA-C-N 113.699 -1.591 . . . . 0.0 109.963 -179.701 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.63 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 7.3 p-10 -51.35 106.26 0.13 Allowed 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.598 0.713 . . . . 0.0 111.794 -178.471 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.45 15.7 8.71 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 119.438 -1.363 . . . . 0.0 112.98 177.302 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.83 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.0 t -102.72 -171.66 1.99 Allowed 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 121.13 2.465 . . . . 0.0 109.84 179.31 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.755 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.2 t -129.45 139.01 52.83 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.289 0 CA-C-N 114.861 -1.063 . . . . 0.0 111.195 -178.699 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.533 HG22 HG22 ' A' ' 69' ' ' VAL . 31.2 m -118.08 155.04 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.733 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.548 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 6.2 tttt -113.08 109.13 18.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.126 -0.984 . . . . 0.0 109.413 -179.854 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.967 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -105.33 122.97 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 179.833 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.011 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.88 166.09 11.71 Favored 'General case' 0 C--N 1.307 -1.243 0 O-C-N 120.799 -1.188 . . . . 0.0 109.073 179.634 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.67 108.46 0.5 Allowed Glycine 0 N--CA 1.481 1.678 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 -179.886 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.583 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.36 139.11 50.76 Favored 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 119.396 1.598 . . . . 0.0 110.424 -179.485 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.452 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.56 29.04 30.86 Favored Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.079 -1.534 . . . . 0.0 109.941 179.56 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.523 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.5 mt -92.47 176.07 6.6 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.986 -1.302 . . . . 0.0 108.562 179.935 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.39 96.98 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.023 -1.048 . . . . 0.0 109.621 -179.909 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.711 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.94 77.18 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.36 -178.93 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 131.8 34.87 0.37 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.465 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.636 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -146.51 114.4 6.51 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 120.931 -1.335 . . . . 0.0 111.109 -179.948 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.17 122.9 5.66 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.181 178.669 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.636 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 2.0 m-30 -116.93 151.77 35.96 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.267 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -98.91 163.75 12.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.539 -1.351 . . . . 0.0 108.216 179.247 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.003 HG11 HG21 ' A' ' 65' ' ' THR . 3.8 p -144.59 117.98 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.106 -0.997 . . . . 0.0 109.643 -177.963 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.511 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.66 -179.08 41.22 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.411 -1.852 . . . . 0.0 111.738 -179.804 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.636 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -100.95 109.24 21.15 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -179.922 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.03 149.21 51.85 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.21 -0.931 . . . . 0.0 109.74 179.891 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.552 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.36 137.75 54.75 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.178 -0.951 . . . . 0.0 110.736 -178.993 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.883 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.28 114.61 26.41 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 178.038 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -104.59 14.47 7.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 120.973 -1.079 . . . . 0.0 110.585 -178.708 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.766 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.57 -174.84 0.08 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.941 -1.099 . . . . 0.0 109.988 179.747 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.92 98.22 2.43 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.379 -0.826 . . . . 0.0 109.653 -179.753 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.28 26.95 31.96 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 120.302 -0.952 . . . . 0.0 111.534 178.943 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.766 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -116.85 106.16 19.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 O-C-N 120.499 -1.589 . . . . 0.0 107.298 178.922 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.883 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -118.17 104.37 10.75 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.358 -1.464 . . . . 0.0 109.885 -177.795 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.023 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.45 109.36 22.13 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 120.821 -1.174 . . . . 0.0 108.156 178.905 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.509 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.3 t -104.42 166.63 10.27 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.844 -1.16 . . . . 0.0 110.353 -178.961 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.677 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 15.8 t-20 -109.53 137.89 20.44 Favored Pre-proline 0 N--CA 1.501 2.082 0 O-C-N 121.445 -0.785 . . . . 0.0 110.146 -179.081 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.8 Cg_endo -74.82 25.2 0.37 Allowed 'Trans proline' 0 C--N 1.318 -1.027 0 C-N-CA 122.465 2.11 . . . . 0.0 111.939 179.903 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.677 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -117.27 2.35 12.54 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.278 -1.514 . . . . 0.0 109.294 179.788 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.551 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.73 18.71 2.51 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 179.297 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -80.58 89.73 5.69 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.88 -0.728 . . . . 0.0 110.489 -179.078 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -113.65 -168.7 1.38 Allowed 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 178.647 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.5 134.96 0.08 Allowed 'General case' 0 C--N 1.305 -1.34 0 O-C-N 120.653 -1.28 . . . . 0.0 111.286 -179.337 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.856 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.3 p -149.09 158.71 6.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 177.966 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.19 145.69 26.35 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.75 -1.219 . . . . 0.0 109.908 -179.723 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.88 107.87 2.36 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-O 122.443 1.116 . . . . 0.0 109.369 178.577 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.9 p-10 -59.87 -139.47 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.829 179.996 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.711 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.64 -50.68 59.84 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.386 -0.821 . . . . 0.0 110.467 -178.775 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.5 t30 -103.63 -34.65 8.56 Favored 'General case' 0 C--N 1.285 -2.225 0 N-CA-C 106.379 -1.711 . . . . 0.0 106.379 178.481 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.986 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.5 67.92 0.62 Allowed Glycine 0 C--N 1.297 -1.584 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.055 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.8 m -103.36 126.16 50.37 Favored 'General case' 0 N--CA 1.484 1.254 0 O-C-N 121.717 -0.873 . . . . 0.0 108.677 178.817 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.856 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.87 108.86 8.14 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 119.714 -0.794 . . . . 0.0 109.511 -179.327 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 93.0 p -117.89 117.2 28.62 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 121.17 -0.956 . . . . 0.0 109.436 -179.99 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 65' ' ' THR . . . . . 1.003 HG21 HG11 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -141.85 135.31 29.44 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.467 -0.771 . . . . 0.0 109.957 179.979 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 10.0 p -100.36 133.13 45.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.423 -0.798 . . . . 0.0 108.848 179.511 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.817 HD12 ' H ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -134.3 175.19 9.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.316 -0.865 . . . . 0.0 109.683 -178.917 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.548 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -100.16 125.0 46.23 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.006 -1.059 . . . . 0.0 109.702 -179.612 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.533 HG22 HG22 ' A' ' 19' ' ' VAL . 16.5 m -136.87 142.15 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 120.94 -1.1 . . . . 0.0 109.761 -179.495 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.63 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.4 ptt180 -138.43 -165.3 1.79 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.652 -1.28 . . . . 0.0 110.129 -179.911 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.579 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -74.87 -83.61 0.05 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.142 -0.974 . . . . 0.0 108.782 -179.615 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.501 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -62.82 138.86 58.64 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.361 -1.462 . . . . 0.0 107.228 178.668 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD1' ' O ' ' A' ' 71' ' ' ARG . 0.3 OUTLIER -164.54 135.11 4.1 Favored 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 117.933 -1.507 . . . . 0.0 110.533 -177.443 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.51 ' HB3' ' HD3' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -31.82 121.02 0.28 Allowed 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.463 0.649 . . . . 0.0 110.483 -178.76 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.023 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.28 49.87 2.42 Favored Glycine 0 N--CA 1.494 2.537 0 C-N-CA 120.353 -0.927 . . . . 0.0 111.396 -179.062 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.4 m-30 -39.68 112.46 0.26 Allowed 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.027 -1.278 . . . . 0.0 109.998 179.306 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.668 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -84.62 127.18 33.94 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.906 -1.121 . . . . 0.0 109.791 -179.804 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.573 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 42.0 t80 -63.66 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.03 0 O-C-N 120.978 -1.077 . . . . 0.0 110.195 179.58 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.4 t0 -161.26 19.51 0.12 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.022 -1.049 . . . . 0.0 109.816 179.878 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.3 -26.68 5.49 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 179.866 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.419 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 22.8 p -93.9 157.53 16.08 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.975 -1.309 . . . . 0.0 110.302 -179.442 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.497 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 4.5 ptt180 -104.73 135.54 45.92 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.701 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.668 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -82.57 -17.76 43.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.716 -1.24 . . . . 0.0 110.423 -178.55 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.6 175.68 21.14 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 -179.57 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.59 109.14 1.3 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 179.037 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.574 HG21 ' HB3' ' A' ' 46' ' ' ALA . 35.2 t -81.39 104.77 10.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -178.864 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.529 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.09 111.9 3.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.448 -0.782 . . . . 0.0 109.885 -179.146 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.543 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -65.98 -4.44 7.1 Favored 'General case' 0 N--CA 1.499 1.992 0 C-N-CA 118.366 -1.334 . . . . 0.0 109.839 179.324 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 p -85.02 1.18 48.76 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.835 -1.166 . . . . 0.0 108.872 179.336 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.529 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -116.13 -49.86 2.68 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.401 -0.812 . . . . 0.0 109.047 -179.957 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.7 -179.49 3.95 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.512 -0.743 . . . . 0.0 109.464 179.916 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.99 115.46 30.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.883 . . . . 0.0 109.104 179.976 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.55 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.9 m -96.8 122.54 39.87 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.909 -1.12 . . . . 0.0 109.391 -179.5 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.592 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.31 146.28 27.76 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-O 122.393 1.092 . . . . 0.0 111.368 -179.216 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.722 ' HB ' HG11 ' A' ' 7' ' ' VAL . 53.4 t -102.5 109.64 27.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 177.419 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.438 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.64 -169.99 16.0 Favored Glycine 0 N--CA 1.485 1.932 0 C-N-CA 118.009 -2.043 . . . . 0.0 111.729 -177.362 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.498 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -117.75 -177.89 3.36 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -178.786 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.584 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.1 p -173.15 174.28 3.45 Favored 'General case' 0 C--N 1.295 -1.765 0 O-C-N 121.35 -0.844 . . . . 0.0 109.302 -179.251 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.551 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -121.36 -159.23 0.8 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.105 -0.997 . . . . 0.0 108.839 179.663 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.406 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.63 36.01 4.46 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.63 -1.293 . . . . 0.0 109.267 179.966 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.99 -33.28 4.22 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.426 -0.796 . . . . 0.0 110.299 -179.532 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 1.03 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 166.76 -37.18 0.24 Allowed Glycine 0 N--CA 1.482 1.707 0 N-CA-C 107.599 -2.201 . . . . 0.0 107.599 -179.579 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.94 -178.15 7.03 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.617 -0.931 . . . . 0.0 109.826 179.288 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.87 -162.6 20.13 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 108.239 -1.945 . . . . 0.0 108.239 -179.433 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.609 ' CD ' ' CE2' ' A' ' 32' ' ' TYR . 7.3 Cg_exo -45.59 172.07 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.652 0 CA-C-N 118.92 1.36 . . . . 0.0 109.926 179.354 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -90.36 -171.43 3.09 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.107 -0.995 . . . . 0.0 110.42 -178.746 . . . . . . . . 1 1 . 1 . 056 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.438 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.65 169.65 16.67 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.751 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.445 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.81 133.95 47.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.48 -1.012 . . . . 0.0 109.061 -179.314 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.592 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.82 119.42 18.98 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.513 -0.742 . . . . 0.0 109.696 179.791 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.896 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -98.14 168.58 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 O-C-N 121.272 -0.892 . . . . 0.0 108.845 179.708 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.463 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -139.7 157.63 45.44 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.017 -1.052 . . . . 0.0 109.853 -179.717 . . . . . . . . 3 3 . 1 . 056 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.896 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.7 m-85 -130.64 142.79 50.45 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.236 -0.915 . . . . 0.0 109.506 -179.672 . . . . . . . . 2 2 . 1 . 056 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 p30 . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 117.971 -1.014 . . . . 0.0 109.524 179.983 . . . . . . . . 0 0 . 1 . 056 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 1.03 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 057 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -125.22 98.86 34.84 Favored Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.26 -0.9 . . . . 0.0 109.311 -179.935 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.566 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 6.2 Cg_exo -58.78 156.7 31.42 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.111 1.874 . . . . 0.0 110.496 -179.992 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.584 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -176.65 -169.52 0.28 Allowed 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.222 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.584 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.81 129.87 2.24 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 120.952 -1.092 . . . . 0.0 110.32 -178.983 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.95 HG22 ' HB3' ' A' ' 22' ' ' ALA . 4.3 t -116.36 108.71 16.4 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 123.167 1.46 . . . . 0.0 109.23 179.29 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.791 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -117.04 138.26 48.29 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.654 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.944 -179.604 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.494 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.5 149.88 1.39 Allowed Pre-proline 0 N--CA 1.485 1.308 0 O-C-N 121.298 -0.877 . . . . 0.0 108.757 -179.782 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.494 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -77.86 150.91 90.56 Favored 'Cis proline' 0 C--N 1.311 -1.427 0 C-N-CA 123.507 -1.455 . . . . 0.0 109.461 -0.786 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.673 ' HA ' HG22 ' A' ' 110' ' ' ILE . 71.1 p -88.31 -26.2 22.39 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.903 -0.776 . . . . 0.0 108.903 179.564 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.543 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 0.8 OUTLIER -132.75 168.74 17.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.449 -0.782 . . . . 0.0 109.499 179.649 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.93 38.79 48.11 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 108.36 -1.896 . . . . 0.0 108.36 -179.801 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.772 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.3 mt -94.11 -43.04 8.68 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 123.285 1.517 . . . . 0.0 110.67 -178.111 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.48 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.08 143.5 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.283 0 CA-C-N 113.408 -1.723 . . . . 0.0 109.766 -179.398 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.568 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.8 p-10 -49.95 105.47 0.09 Allowed 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 121.57 0.7 . . . . 0.0 111.753 -178.397 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.403 ' H ' ' HB3' ' A' ' 70' ' ' ARG . . . 113.23 15.68 8.86 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.33 -1.414 . . . . 0.0 113.081 177.158 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.772 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.24 -171.15 1.88 Allowed 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 121.235 2.517 . . . . 0.0 109.733 179.153 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.859 HG22 HG22 ' A' ' 68' ' ' THR . 15.9 t -129.98 139.26 51.95 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.289 0 CA-C-N 114.943 -1.026 . . . . 0.0 111.309 -178.97 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.566 HG12 HD21 ' A' ' 13' ' ' LEU . 33.6 m -115.59 155.74 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.881 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.499 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -106.9 109.76 21.74 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.117 -0.989 . . . . 0.0 109.187 -179.929 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.791 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -103.35 139.74 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.404 -0.81 . . . . 0.0 108.842 179.978 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.95 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -132.55 157.8 43.79 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.829 -1.169 . . . . 0.0 109.608 179.426 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -138.99 108.71 0.62 Allowed Glycine 0 N--CA 1.482 1.74 0 N-CA-C 108.688 -1.765 . . . . 0.0 108.688 -179.964 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.566 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -114.36 142.04 46.85 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.889 -1.359 . . . . 0.0 110.858 -179.059 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 81.84 27.36 46.47 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.701 -1.237 . . . . 0.0 110.131 178.942 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.574 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.6 mt -89.52 173.99 8.02 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.008 -1.289 . . . . 0.0 108.705 -179.848 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.97 99.64 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.965 -1.085 . . . . 0.0 109.579 -179.598 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.554 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.24 77.22 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.196 -179.144 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.9 34.09 0.31 Allowed Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.549 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.554 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 78.0 p -144.04 111.02 5.73 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 120.965 -1.315 . . . . 0.0 111.045 -179.741 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -46.27 125.09 6.28 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.689 178.158 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.493 ' CD2' ' O ' ' A' ' 30' ' ' THR . 16.9 m-85 -116.11 150.82 36.75 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.889 . . . . 0.0 108.97 179.699 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.509 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -101.86 151.77 21.69 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 178.547 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.622 ' O ' HG13 ' A' ' 34' ' ' VAL . 4.5 p -136.17 117.63 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.957 -1.09 . . . . 0.0 109.787 -177.904 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -165.01 -179.35 38.93 Favored Glycine 0 N--CA 1.494 2.5 0 C-N-CA 118.348 -1.882 . . . . 0.0 111.69 -179.576 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.629 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.6 pt20 -100.44 110.79 23.0 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.927 0.87 . . . . 0.0 108.744 -179.872 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.1 m -131.08 148.98 52.8 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.265 -0.897 . . . . 0.0 109.781 -179.756 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.478 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.39 138.19 54.61 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.261 -0.9 . . . . 0.0 110.675 -179.047 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.867 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.63 114.64 26.41 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 178.209 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 m -105.23 14.56 7.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.028 -1.045 . . . . 0.0 110.65 -178.693 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 173.98 -175.67 0.07 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.912 -1.118 . . . . 0.0 110.198 179.706 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.777 ' O ' HG23 ' A' ' 42' ' ' THR . 15.1 t -70.34 97.99 1.34 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 121.755 0.788 . . . . 0.0 110.001 -179.633 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.62 26.47 38.62 Favored Glycine 0 N--CA 1.493 2.494 0 C-N-CA 120.252 -0.975 . . . . 0.0 111.522 178.825 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.89 106.31 20.35 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.572 -1.546 . . . . 0.0 107.382 178.931 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.867 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.8 tp -118.05 104.69 11.1 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.494 -1.379 . . . . 0.0 109.77 -177.793 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.943 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.87 109.69 22.4 Favored 'General case' 0 N--CA 1.484 1.265 0 O-C-N 120.796 -1.19 . . . . 0.0 108.246 178.903 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.9 t -107.13 166.54 10.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.93 -1.106 . . . . 0.0 110.525 -178.692 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.496 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 12.4 t-20 -114.0 129.81 24.45 Favored Pre-proline 0 N--CA 1.499 2.005 0 O-C-N 121.424 -0.797 . . . . 0.0 109.697 -179.236 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.614 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -71.28 21.08 0.23 Allowed 'Trans proline' 0 CA--C 1.546 1.082 0 C-N-CA 121.953 1.769 . . . . 0.0 111.969 179.274 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.496 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -107.08 1.45 24.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.442 -1.411 . . . . 0.0 108.82 179.293 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.532 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.92 15.47 2.87 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 179.372 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -79.25 85.76 5.08 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.069 -178.49 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.601 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -101.59 -166.72 1.33 Allowed 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 178.128 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.432 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.36 138.35 0.09 Allowed 'General case' 0 C--N 1.305 -1.348 0 O-C-N 120.504 -1.373 . . . . 0.0 111.417 -179.178 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.936 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -157.47 156.7 4.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 178.135 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.88 144.75 27.13 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.747 -1.221 . . . . 0.0 109.884 -179.664 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.009 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.46 106.69 1.19 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 122.47 1.129 . . . . 0.0 109.44 178.61 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.543 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 16.9 p-10 -58.87 -138.62 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.621 179.848 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.554 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -56.38 -49.45 74.42 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.39 -0.819 . . . . 0.0 110.103 -178.976 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.406 ' CG ' ' N ' ' A' ' 61' ' ' GLY . 10.8 p-10 -98.21 -39.84 8.66 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 106.066 -1.827 . . . . 0.0 106.066 178.372 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.989 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 110.19 64.33 0.53 Allowed Glycine 0 C--N 1.296 -1.694 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.38 178.054 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.584 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 88.6 p -100.28 128.47 46.34 Favored 'General case' 0 C--N 1.309 -1.167 0 O-C-N 121.618 -0.93 . . . . 0.0 108.945 178.915 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.936 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.26 108.47 7.26 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.604 -0.839 . . . . 0.0 108.952 -179.814 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -128.64 121.33 28.37 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.288 -0.883 . . . . 0.0 109.977 -179.358 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.06 148.08 31.28 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.62 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 9.5 p -98.28 131.01 44.96 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.173 -0.955 . . . . 0.0 109.486 -179.737 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.767 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -127.23 164.52 21.51 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.507 -0.746 . . . . 0.0 109.338 -179.347 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.859 HG22 HG22 ' A' ' 18' ' ' VAL . 1.9 p -96.51 124.05 40.37 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.986 -1.071 . . . . 0.0 109.333 179.969 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.539 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.5 m -137.33 143.38 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 120.997 -1.064 . . . . 0.0 109.968 -179.211 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.568 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -141.52 -166.54 2.22 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.558 -1.338 . . . . 0.0 110.214 179.986 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.595 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -69.44 -89.13 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 119.687 -0.805 . . . . 0.0 108.837 -179.737 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.52 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -59.67 138.27 57.79 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 120.426 -1.421 . . . . 0.0 107.451 178.89 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.12 141.09 7.99 Favored 'General case' 0 C--N 1.294 -1.819 0 C-N-CA 118.148 -1.421 . . . . 0.0 110.351 -177.682 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.489 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.5 mm-40 -33.95 120.24 0.42 Allowed 'General case' 0 N--CA 1.491 1.62 0 CA-C-O 121.561 0.696 . . . . 0.0 110.7 -178.473 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.943 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.33 45.21 2.79 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.713 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.614 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -39.24 113.34 0.31 Allowed 'General case' 0 N--CA 1.508 2.474 0 O-C-N 121.099 -1.236 . . . . 0.0 110.298 179.782 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.634 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.43 127.36 34.83 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 120.857 -1.152 . . . . 0.0 109.556 -179.972 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 18.5 t80 -64.23 58.09 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.955 0 O-C-N 120.815 -1.178 . . . . 0.0 110.286 179.849 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 77' ' ' LEU . 10.7 t0 -160.92 19.57 0.13 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.983 -1.073 . . . . 0.0 109.833 179.771 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -26.78 5.28 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.918 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -91.72 154.44 18.97 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 121.031 -1.276 . . . . 0.0 110.387 -179.471 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.489 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -102.87 131.91 49.45 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.634 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.634 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -79.89 -19.15 48.89 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.758 -1.214 . . . . 0.0 110.238 -178.635 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.24 175.05 20.13 Favored Glycine 0 N--CA 1.485 1.966 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 -179.529 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.499 ' CG2' ' HB3' ' A' ' 72' ' ' SER . 0.9 OUTLIER -63.49 110.29 1.91 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 106.903 -1.518 . . . . 0.0 106.903 178.851 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.57 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.1 t -81.28 104.36 9.71 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 O-C-N 121.345 -0.847 . . . . 0.0 109.162 -178.642 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.655 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -63.98 110.64 2.2 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.479 -0.763 . . . . 0.0 109.735 -179.414 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.534 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.61 -5.13 4.98 Favored 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 118.137 -1.425 . . . . 0.0 109.839 179.42 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -84.41 -0.7 53.73 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.834 -1.166 . . . . 0.0 108.932 179.306 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.655 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -112.66 -50.02 2.91 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.346 -0.847 . . . . 0.0 108.995 179.911 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.12 -179.88 4.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.491 -0.756 . . . . 0.0 109.572 179.96 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.91 116.12 31.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.365 -0.834 . . . . 0.0 109.103 -179.954 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -96.83 122.24 39.57 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.884 -1.135 . . . . 0.0 109.555 -179.484 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.575 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -102.76 149.59 24.32 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.383 1.087 . . . . 0.0 111.421 -179.149 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.494 ' CG1' HG11 ' A' ' 7' ' ' VAL . 47.2 t -102.07 111.12 30.73 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 177.194 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -145.18 -174.96 17.91 Favored Glycine 0 N--CA 1.486 1.975 0 C-N-CA 118.49 -1.814 . . . . 0.0 111.46 -177.56 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.509 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.12 -179.83 4.16 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -178.779 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.584 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.0 OUTLIER -173.48 172.46 3.68 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.501 -0.749 . . . . 0.0 109.063 -179.498 . . . . . . . . 3 3 . 1 . 057 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.69 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 1.5 m-20 -106.87 -9.44 16.33 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.036 -1.04 . . . . 0.0 109.425 179.947 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.69 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 73.81 39.41 0.54 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.365 -0.834 . . . . 0.0 109.135 179.927 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.61 -33.84 0.78 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.696 -0.627 . . . . 0.0 110.631 -179.4 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.563 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 178.26 -40.4 0.09 OUTLIER Glycine 0 N--CA 1.482 1.755 0 N-CA-C 107.823 -2.111 . . . . 0.0 107.823 -179.625 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.17 -178.58 7.3 Favored 'General case' 0 C--N 1.308 -1.222 0 O-C-N 121.484 -1.01 . . . . 0.0 109.573 179.074 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -178.63 -166.45 34.8 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 108.495 -1.842 . . . . 0.0 108.495 -179.457 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.5 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.0 Cg_exo -50.22 -175.15 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.63 0 CA-C-N 118.843 1.321 . . . . 0.0 110.279 179.561 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.61 -173.66 2.81 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.119 -0.988 . . . . 0.0 110.076 -179.179 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -125.25 169.95 17.2 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.817 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.516 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -109.25 154.23 10.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -179.597 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.575 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -97.42 122.82 40.9 Favored 'General case' 0 C--N 1.291 -1.945 0 O-C-N 121.318 -0.864 . . . . 0.0 109.703 -179.888 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.673 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.6 pt -98.26 168.97 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.213 -0.929 . . . . 0.0 109.033 179.83 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.543 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.7 m -142.52 155.91 45.08 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.05 -1.031 . . . . 0.0 109.811 179.979 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.669 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 31.4 m-85 -129.48 75.61 1.66 Allowed 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.138 -0.976 . . . . 0.0 109.539 -179.642 . . . . . . . . 2 2 . 1 . 057 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.427 ' OD1' ' O ' ' A' ' 113' ' ' ASN . 21.6 p30 . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 118.022 -0.989 . . . . 0.0 109.481 -179.979 . . . . . . . . 1 1 . 1 . 057 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.674 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 058 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.645 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -65.63 163.23 36.27 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.188 -0.945 . . . . 0.0 109.337 179.848 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.645 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.0 Cg_exo -60.17 155.27 46.46 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.213 1.942 . . . . 0.0 110.646 179.965 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -175.41 -169.6 0.38 Allowed 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.996 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.545 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.8 133.29 3.4 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.767 -1.208 . . . . 0.0 110.81 -179.0 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.016 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.2 p -105.01 104.4 14.13 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 122.435 1.112 . . . . 0.0 109.997 179.833 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.978 HG22 HG23 ' A' ' 21' ' ' VAL . 13.1 t -118.85 119.75 61.97 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.543 179.841 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.506 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.75 148.55 7.68 Favored Pre-proline 0 N--CA 1.486 1.352 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 -179.695 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.506 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -77.54 150.72 91.21 Favored 'Cis proline' 0 C--N 1.31 -1.476 0 C-N-CA 123.552 -1.437 . . . . 0.0 109.495 -0.458 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.668 ' HA ' HG22 ' A' ' 110' ' ' ILE . 80.4 p -89.29 -26.18 21.28 Favored 'General case' 0 C--N 1.293 -1.882 0 O-C-N 121.467 -0.77 . . . . 0.0 108.993 179.625 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.539 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 4.3 p -133.47 165.91 23.77 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.474 -0.766 . . . . 0.0 109.419 -179.941 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.7 38.27 37.51 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 -179.505 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.772 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.8 mt -92.56 -43.24 9.24 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 123.203 1.478 . . . . 0.0 110.624 -178.167 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 70.54 143.31 0.05 Allowed 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.453 -1.703 . . . . 0.0 109.774 -179.54 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.625 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 7.4 p-10 -50.57 104.59 0.08 Allowed 'General case' 0 C--N 1.301 -1.516 0 CA-C-O 121.558 0.694 . . . . 0.0 111.772 -178.447 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.89 16.61 7.85 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 119.476 -1.345 . . . . 0.0 112.97 177.272 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.772 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -104.8 -171.23 1.88 Allowed 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 121.146 2.473 . . . . 0.0 109.693 179.11 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.845 HG22 HG22 ' A' ' 68' ' ' THR . 16.4 t -130.37 140.02 49.9 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.246 -178.845 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.559 HG12 HD21 ' A' ' 13' ' ' LEU . 35.1 m -117.25 155.33 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 178.933 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.555 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.1 tttt -106.73 108.97 20.75 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.047 -1.033 . . . . 0.0 109.414 -179.817 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.978 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.47 123.13 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.723 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.016 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.67 164.49 13.97 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 120.745 -1.222 . . . . 0.0 108.938 179.82 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.583 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.56 107.51 0.53 Allowed Glycine 0 C--N 1.297 -1.628 0 N-CA-C 108.595 -1.802 . . . . 0.0 108.595 179.8 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.566 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -115.72 142.67 46.44 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.978 -1.307 . . . . 0.0 110.445 -179.134 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.524 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 82.03 27.26 45.97 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.577 -1.297 . . . . 0.0 109.93 179.357 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.568 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.3 mt -90.84 174.24 7.56 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.069 -1.254 . . . . 0.0 108.574 179.974 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.0 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.42 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.966 -1.084 . . . . 0.0 109.517 -179.65 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.688 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.82 77.21 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.77 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.409 -178.97 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.553 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 132.7 34.66 0.34 Allowed Glycine 0 N--CA 1.487 2.066 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.407 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.0 p -145.0 112.54 6.2 Favored 'General case' 0 C--N 1.307 -1.272 0 O-C-N 121.031 -1.276 . . . . 0.0 111.083 -179.676 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.555 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -45.83 125.34 6.05 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-N 115.67 -0.695 . . . . 0.0 109.606 178.096 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.508 ' CZ ' ' OD2' ' A' ' 99' ' ' ASP . 11.8 m-85 -118.13 149.87 40.31 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.325 -0.86 . . . . 0.0 108.697 179.692 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.511 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.27 158.35 15.93 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.614 -1.304 . . . . 0.0 107.742 178.635 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.722 ' O ' HG13 ' A' ' 34' ' ' VAL . 7.2 p -142.12 112.24 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.035 -1.041 . . . . 0.0 109.897 -177.798 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -160.57 -178.86 34.93 Favored Glycine 0 N--CA 1.494 2.538 0 C-N-CA 118.524 -1.798 . . . . 0.0 111.722 -179.62 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.635 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.1 pt20 -101.31 110.75 22.81 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.82 0.819 . . . . 0.0 108.922 -179.82 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -131.45 148.69 52.67 Favored 'General case' 0 C--N 1.295 -1.791 0 O-C-N 121.286 -0.884 . . . . 0.0 109.672 179.893 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.533 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -120.97 137.59 54.55 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.174 -0.954 . . . . 0.0 110.803 -178.936 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.866 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.73 114.57 26.32 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.096 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -104.78 14.11 7.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 120.979 -1.076 . . . . 0.0 110.65 -178.738 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.761 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.17 -174.53 0.07 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.942 -1.099 . . . . 0.0 110.081 179.725 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.8 p -72.73 98.66 2.43 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.504 -0.748 . . . . 0.0 109.622 -179.729 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.11 26.37 34.26 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.222 -0.99 . . . . 0.0 111.553 178.939 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.761 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.3 t -116.64 106.04 19.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 O-C-N 120.47 -1.606 . . . . 0.0 107.413 178.918 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.866 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.4 tp -118.98 104.47 10.53 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.517 -1.365 . . . . 0.0 109.681 -177.896 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.042 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.93 109.57 22.3 Favored 'General case' 0 N--CA 1.485 1.279 0 O-C-N 120.852 -1.155 . . . . 0.0 108.063 178.9 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -105.88 165.06 11.46 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.966 -1.084 . . . . 0.0 110.599 -178.699 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.677 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 50.2 t30 -113.18 130.87 23.19 Favored Pre-proline 0 N--CA 1.499 2.023 0 O-C-N 121.558 -0.714 . . . . 0.0 109.714 -179.3 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.8 Cg_endo -71.85 22.2 0.26 Allowed 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 122.188 1.926 . . . . 0.0 112.288 -179.986 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.677 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -108.65 2.02 21.67 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.39 -1.444 . . . . 0.0 108.929 179.393 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.544 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.05 14.43 2.85 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 179.475 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -78.13 91.28 4.3 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.908 -0.717 . . . . 0.0 110.974 -178.475 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.641 ' C ' HG12 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -114.09 -173.11 2.22 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 178.198 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.533 ' N ' ' OG ' ' A' ' 53' ' ' SER . 12.3 t 179.68 139.35 0.12 Allowed 'General case' 0 C--N 1.306 -1.285 0 O-C-N 120.534 -1.354 . . . . 0.0 111.303 -179.134 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.934 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -152.71 160.59 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 178.123 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.555 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.61 144.53 27.19 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.593 -1.317 . . . . 0.0 110.168 -179.387 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.0 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.7 107.2 1.36 Allowed 'General case' 0 C--N 1.301 -1.537 0 CA-C-O 122.44 1.114 . . . . 0.0 109.338 178.415 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.529 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 13.6 p-10 -58.53 -138.16 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.852 -179.8 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.688 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -54.58 -49.74 69.67 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.348 -0.845 . . . . 0.0 110.202 -178.771 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.404 ' CG ' ' N ' ' A' ' 61' ' ' GLY . 9.9 p-10 -101.41 -38.97 7.78 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 178.454 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.991 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 111.74 65.74 0.51 Allowed Glycine 0 C--N 1.297 -1.587 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.211 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.583 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 21.0 m -105.42 124.03 48.87 Favored 'General case' 0 N--CA 1.483 1.214 0 O-C-N 121.686 -0.89 . . . . 0.0 108.734 179.005 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.934 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.52 109.35 9.2 Favored 'General case' 0 C--N 1.295 -1.788 0 C-N-CA 119.899 -0.72 . . . . 0.0 109.388 -179.395 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -116.5 118.28 32.23 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.178 -0.951 . . . . 0.0 109.273 -179.901 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.544 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -143.68 141.08 30.38 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.405 -0.809 . . . . 0.0 109.679 -179.907 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 21.3 p -99.36 130.75 45.66 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.441 -0.787 . . . . 0.0 109.277 179.9 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.762 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -128.18 165.56 20.2 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.332 -0.855 . . . . 0.0 109.376 -179.503 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.845 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -96.75 123.23 40.38 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.103 -0.998 . . . . 0.0 109.213 179.953 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.535 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -135.96 142.13 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.118 -0.989 . . . . 0.0 109.899 -179.232 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.625 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.2 ptt180 -137.6 -166.12 1.89 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.62 -1.3 . . . . 0.0 110.097 -179.946 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.583 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -73.92 -83.57 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.27 -0.894 . . . . 0.0 108.665 -179.686 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.501 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.54 138.68 58.53 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.343 -1.473 . . . . 0.0 107.185 178.631 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' O ' ' A' ' 71' ' ' ARG . 0.2 OUTLIER -164.04 137.05 5.19 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 117.879 -1.528 . . . . 0.0 110.459 -177.434 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.508 ' OE1' ' N ' ' A' ' 75' ' ' GLY . 0.6 OUTLIER -34.29 121.49 0.48 Allowed 'General case' 0 N--CA 1.491 1.595 0 CA-C-O 121.478 0.656 . . . . 0.0 110.302 -178.584 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.042 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.73 50.34 2.3 Favored Glycine 0 N--CA 1.494 2.544 0 C-N-CA 120.451 -0.881 . . . . 0.0 111.205 -179.223 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 4.1 m-30 -39.81 113.34 0.33 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.032 -1.275 . . . . 0.0 110.025 179.468 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.631 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -84.7 127.1 33.93 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.884 -1.135 . . . . 0.0 109.638 -179.845 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.577 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 29.7 t80 -63.54 58.33 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.004 0 O-C-N 120.874 -1.141 . . . . 0.0 110.405 179.611 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.5 t0 -161.54 19.78 0.11 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.008 -1.057 . . . . 0.0 109.807 179.849 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.22 -26.91 5.31 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 110.171 -1.172 . . . . 0.0 110.171 179.937 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 37.0 p -92.95 156.26 17.04 Favored 'General case' 0 N--CA 1.486 1.36 0 O-C-N 121.031 -1.276 . . . . 0.0 110.332 -179.489 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.471 ' O ' ' HD2' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -104.49 133.75 48.83 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.707 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.631 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -80.26 -18.71 48.6 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.823 -1.173 . . . . 0.0 110.41 -178.566 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.93 175.93 20.97 Favored Glycine 0 N--CA 1.485 1.93 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -179.589 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -62.43 109.59 1.41 Allowed 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 179.138 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.577 HG21 ' HB3' ' A' ' 46' ' ' ALA . 31.4 t -82.54 105.39 12.33 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.967 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.656 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -65.76 112.32 3.66 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.402 -0.811 . . . . 0.0 109.904 -179.215 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.557 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.97 -4.79 4.96 Favored 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 118.208 -1.397 . . . . 0.0 109.863 179.398 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 p -85.71 -0.08 54.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.774 -1.204 . . . . 0.0 109.0 179.348 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.656 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -113.03 -49.71 2.91 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.297 -0.877 . . . . 0.0 109.063 179.949 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.8 179.77 4.13 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.581 -0.7 . . . . 0.0 109.505 179.93 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.93 115.7 31.11 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.301 -0.874 . . . . 0.0 109.219 -180.0 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.547 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.92 123.7 40.7 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.87 -1.143 . . . . 0.0 109.358 -179.469 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.52 148.46 25.93 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-O 122.446 1.117 . . . . 0.0 111.457 -179.171 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.548 ' HB ' HG11 ' A' ' 7' ' ' VAL . 61.8 t -102.4 109.66 27.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 N-CA-C 106.282 -1.748 . . . . 0.0 106.282 177.249 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -144.11 -175.41 17.22 Favored Glycine 0 N--CA 1.483 1.831 0 C-N-CA 118.318 -1.896 . . . . 0.0 111.563 -177.395 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.537 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -117.22 -177.82 3.3 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 -178.853 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.56 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 1.1 p -173.72 169.45 4.2 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.235 -0.916 . . . . 0.0 109.143 -179.26 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.714 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 1.7 m-20 -106.91 -9.34 16.33 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.141 -0.975 . . . . 0.0 109.487 179.92 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.714 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 75.18 37.61 0.46 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.41 -0.806 . . . . 0.0 109.116 179.947 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.11 -34.69 0.79 Allowed 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.572 -0.705 . . . . 0.0 110.616 -179.434 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.614 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 179.85 -41.95 0.08 OUTLIER Glycine 0 N--CA 1.482 1.712 0 N-CA-C 107.699 -2.16 . . . . 0.0 107.699 -179.665 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.59 -178.68 7.44 Favored 'General case' 0 C--N 1.308 -1.198 0 O-C-N 121.415 -1.05 . . . . 0.0 109.866 179.118 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -177.67 -166.52 34.43 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 108.194 -1.962 . . . . 0.0 108.194 -179.477 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.537 ' HB2' HD12 ' A' ' 97' ' ' LEU . 5.4 Cg_exo -48.42 179.26 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.659 0 CA-C-N 118.94 1.37 . . . . 0.0 110.148 179.483 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -91.85 -175.2 4.06 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.055 -1.028 . . . . 0.0 110.516 -178.717 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -122.05 161.7 16.1 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.848 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.62 133.09 49.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.364 -1.08 . . . . 0.0 109.278 -179.242 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -76.04 122.09 23.73 Favored 'General case' 0 C--N 1.289 -2.054 0 O-C-N 121.485 -0.76 . . . . 0.0 109.716 179.703 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.91 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.99 174.0 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.924 . . . . 0.0 109.23 179.837 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.539 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.6 OUTLIER -140.21 158.19 44.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.048 -1.032 . . . . 0.0 109.838 -179.778 . . . . . . . . 3 3 . 1 . 058 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.91 ' CE2' HD12 ' A' ' 110' ' ' ILE . 96.5 m-85 -135.08 131.18 36.64 Favored 'General case' 0 N--CA 1.485 1.282 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 -179.808 . . . . . . . . 2 2 . 1 . 058 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.407 ' C ' ' O ' ' A' ' 112' ' ' PHE . 21.4 p30 . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.533 -179.967 . . . . . . . . 1 1 . 1 . 058 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.74 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.491 ' HB1' HD21 ' A' ' 60' ' ' ASN . . . . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 121.296 0.57 . . . . 0.0 109.5 . . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.438 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -113.06 157.03 41.92 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.245 -0.909 . . . . 0.0 109.471 -179.993 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.545 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.7 Cg_exo -59.98 157.95 31.72 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 122.314 2.01 . . . . 0.0 110.608 179.948 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.557 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -173.71 -169.23 0.48 Allowed 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 178.989 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.557 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.6 133.84 3.68 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 120.745 -1.222 . . . . 0.0 110.757 -179.156 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 6' ' ' THR . . . . . 1.016 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.1 p -105.41 104.62 14.38 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 122.558 1.17 . . . . 0.0 109.911 179.983 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 1.012 HG22 HG23 ' A' ' 21' ' ' VAL . 14.5 t -118.97 126.34 75.27 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.407 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.535 179.875 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.478 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -170.57 149.37 2.99 Favored Pre-proline 0 N--CA 1.486 1.361 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 -179.642 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.478 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.64 153.23 99.05 Favored 'Cis proline' 0 C--N 1.31 -1.465 0 C-N-CA 123.678 -1.384 . . . . 0.0 109.894 -0.522 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.626 ' HA ' HG22 ' A' ' 110' ' ' ILE . 6.6 m -95.73 -22.6 17.43 Favored 'General case' 0 C--N 1.294 -1.846 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 179.564 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.459 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.9 m -135.59 162.85 31.55 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.491 -0.756 . . . . 0.0 109.496 179.921 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.11 37.6 37.23 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 108.503 -1.839 . . . . 0.0 108.503 -179.556 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.862 ' CA ' HG21 ' A' ' 17' ' ' THR . 27.3 mt -90.59 -45.47 8.89 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-O 123.116 1.436 . . . . 0.0 110.644 -178.373 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.463 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 63.82 147.24 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.325 0 CA-C-N 113.69 -1.596 . . . . 0.0 109.974 -179.699 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.616 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -51.48 109.33 0.34 Allowed 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 121.556 0.694 . . . . 0.0 111.721 -178.652 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.04 12.98 11.42 Favored Glycine 0 N--CA 1.485 1.966 0 C-N-CA 119.478 -1.344 . . . . 0.0 112.873 177.339 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.862 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.7 t -101.42 -174.35 2.58 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 121.057 2.428 . . . . 0.0 109.763 179.479 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.728 HG13 ' O ' ' A' ' 67' ' ' LEU . 14.8 t -131.28 138.48 53.14 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.38 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.813 -178.982 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.581 HG13 ' CG2' ' A' ' 69' ' ' VAL . 35.0 m -117.43 154.4 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.365 -0.835 . . . . 0.0 109.135 179.082 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.551 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -110.12 109.25 19.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.957 . . . . 0.0 109.149 179.881 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 1.012 HG23 HG22 ' A' ' 7' ' ' VAL . 2.4 p -107.39 124.6 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.964 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 1.016 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.08 165.08 13.0 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.845 -1.159 . . . . 0.0 108.858 179.489 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.615 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.39 107.5 0.53 Allowed Glycine 0 C--N 1.296 -1.692 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 179.971 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.545 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -116.41 141.09 48.63 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 120.743 -1.445 . . . . 0.0 110.796 -179.072 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.542 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 83.09 26.5 44.29 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.033 179.145 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.564 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.9 OUTLIER -90.35 172.29 8.85 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.028 -1.278 . . . . 0.0 108.575 -179.992 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.18 99.97 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.081 -1.012 . . . . 0.0 109.652 -179.685 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.566 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -57.0 76.96 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.118 -179.036 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.41 33.39 0.27 Allowed Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.517 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.553 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 54.1 p -141.14 109.47 5.88 Favored 'General case' 0 C--N 1.307 -1.25 0 O-C-N 121.015 -1.285 . . . . 0.0 111.152 -179.714 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.584 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.94 110.08 0.39 Allowed 'General case' 0 N--CA 1.496 1.858 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.909 178.314 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.555 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 18.6 m-85 -104.25 154.76 19.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.146 -0.971 . . . . 0.0 108.74 179.396 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.45 ' HA ' ' OG ' ' A' ' 54' ' ' SER . 0.3 OUTLIER -98.96 165.23 11.85 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 178.545 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.62 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.0 p -143.4 120.47 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.092 -1.005 . . . . 0.0 109.493 -177.807 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -168.75 179.91 41.32 Favored Glycine 0 N--CA 1.491 2.312 0 C-N-CA 118.264 -1.922 . . . . 0.0 111.614 -179.806 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.618 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -101.96 109.79 21.6 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.715 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 58.2 m -128.87 152.75 48.17 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.347 -0.846 . . . . 0.0 110.319 -179.828 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.52 136.36 51.63 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.64 -0.662 . . . . 0.0 110.126 179.65 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.901 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.4 114.73 26.81 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 178.369 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -106.6 15.3 7.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 120.964 -1.085 . . . . 0.0 110.762 -178.636 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.785 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.24 -175.63 0.08 Allowed 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.894 -1.129 . . . . 0.0 110.112 179.604 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.799 ' O ' HG23 ' A' ' 42' ' ' THR . 15.3 t -69.63 97.0 0.99 Allowed 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.741 0.781 . . . . 0.0 110.02 -179.404 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.8 28.46 34.95 Favored Glycine 0 N--CA 1.492 2.415 0 C-N-CA 120.225 -0.988 . . . . 0.0 111.38 178.694 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.785 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.09 106.09 19.9 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 O-C-N 120.531 -1.57 . . . . 0.0 107.432 178.836 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.901 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -116.31 106.66 13.9 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.541 -1.349 . . . . 0.0 109.941 -177.552 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 1.1 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -95.93 110.12 22.38 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 120.759 -1.213 . . . . 0.0 108.028 179.186 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 68.2 m -98.91 144.91 27.56 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.259 -0.901 . . . . 0.0 110.846 -178.132 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.513 ' ND2' ' HG2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.48 131.08 48.95 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.415 -0.803 . . . . 0.0 109.076 179.299 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.589 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 6.8 Cg_endo -75.68 31.02 0.38 Allowed 'Trans proline' 0 C--N 1.314 -1.266 0 C-N-CA 122.267 1.978 . . . . 0.0 111.323 179.898 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.465 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . -122.14 -1.69 9.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.42 -1.425 . . . . 0.0 110.299 -179.231 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.796 ' HB3' HD22 ' A' ' 67' ' ' LEU . 20.4 m-20 -137.55 10.31 2.93 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.039 -1.038 . . . . 0.0 109.115 -179.68 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -64.0 84.1 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.292 -179.108 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.62 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -110.82 -169.0 1.38 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.164 -0.96 . . . . 0.0 108.557 179.081 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.455 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.32 135.22 0.08 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.783 -1.198 . . . . 0.0 111.288 -179.348 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.877 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -147.48 159.29 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 177.915 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.584 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.29 142.96 29.29 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.707 -1.245 . . . . 0.0 110.246 -179.52 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.75 107.08 1.34 Allowed 'General case' 0 C--N 1.299 -1.593 0 CA-C-O 122.404 1.097 . . . . 0.0 109.367 178.323 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.5 t0 -60.59 -138.97 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.039 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.022 -179.889 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.566 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.72 -51.11 53.06 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.427 -0.796 . . . . 0.0 110.66 -178.552 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 60' ' ' ASN . . . . . 0.491 HD21 ' HB1' ' A' ' 1' ' ' ALA . 11.9 t30 -104.19 -34.28 8.43 Favored 'General case' 0 C--N 1.286 -2.185 0 N-CA-C 106.182 -1.785 . . . . 0.0 106.182 178.472 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.976 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.72 67.93 0.61 Allowed Glycine 0 C--N 1.296 -1.647 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 178.182 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.8 m -104.67 124.48 49.44 Favored 'General case' 0 N--CA 1.483 1.194 0 O-C-N 121.612 -0.934 . . . . 0.0 108.739 179.004 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.877 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -132.88 109.21 9.45 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.906 -0.718 . . . . 0.0 109.223 -179.609 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 14.7 m -118.37 118.77 32.66 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.302 -0.874 . . . . 0.0 109.611 -179.621 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.56 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.86 140.29 28.27 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.505 -0.747 . . . . 0.0 109.684 179.805 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 66' ' ' SER . . . . . 0.434 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 19.2 p -98.83 136.05 39.4 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.466 -0.771 . . . . 0.0 109.079 179.758 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.84 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -133.35 173.79 11.09 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.339 -0.851 . . . . 0.0 109.687 -178.887 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.533 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -100.18 125.01 46.27 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.933 -1.105 . . . . 0.0 109.01 179.918 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.778 HG23 HD13 ' A' ' 13' ' ' LEU . 15.9 m -132.19 142.13 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 120.764 -1.21 . . . . 0.0 110.06 -178.986 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.616 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.9 ptt180 -147.71 -170.48 3.58 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 120.563 -1.336 . . . . 0.0 110.827 -179.945 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.624 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -67.22 -102.68 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.821 -0.549 . . . . 0.0 109.932 -179.329 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.552 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.08 134.98 56.92 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.359 -1.463 . . . . 0.0 108.152 179.714 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.618 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -153.78 156.92 38.6 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.584 -1.246 . . . . 0.0 110.298 -178.683 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.564 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 1.6 mm-40 -53.15 119.4 4.67 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.277 -0.889 . . . . 0.0 109.368 -178.736 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 1.1 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.39 54.04 3.5 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.311 -178.9 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.589 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.3 m-30 -40.35 115.92 0.61 Allowed 'General case' 0 N--CA 1.504 2.271 0 O-C-N 120.947 -1.325 . . . . 0.0 110.173 179.487 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.72 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -87.46 126.85 35.14 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 120.806 -1.184 . . . . 0.0 109.488 -179.834 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 24.8 t80 -64.18 58.38 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.972 0 O-C-N 120.837 -1.165 . . . . 0.0 110.132 179.702 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.4 t70 -160.37 19.66 0.15 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.028 -1.045 . . . . 0.0 109.717 179.772 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.75 -27.44 5.36 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 179.856 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 46.4 p -94.9 162.44 13.75 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 120.98 -1.306 . . . . 0.0 110.402 -179.46 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.481 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 2.2 ptm180 -108.14 138.0 45.15 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.921 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.72 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.9 t90 -83.4 -18.6 38.21 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.769 -1.207 . . . . 0.0 110.443 -178.656 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.99 175.05 19.79 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 108.766 -1.734 . . . . 0.0 108.766 -179.632 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.94 106.2 0.98 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.119 -1.224 . . . . 0.0 107.898 179.227 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.64 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.7 t -78.25 104.35 6.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.021 -179.041 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.655 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -62.99 107.9 1.1 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.55 -0.719 . . . . 0.0 110.164 -179.141 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.624 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.4 t -61.42 -4.26 1.23 Allowed 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.255 -1.378 . . . . 0.0 110.38 179.298 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.2 p -90.98 7.09 42.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.562 -1.336 . . . . 0.0 109.407 -179.933 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.655 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -119.35 -47.76 2.44 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.292 -0.88 . . . . 0.0 109.16 179.941 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.6 -178.4 3.64 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.562 -0.711 . . . . 0.0 109.589 179.988 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.81 111.99 24.58 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.381 -0.824 . . . . 0.0 108.856 179.859 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.494 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.5 m -97.22 121.06 38.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.036 -1.04 . . . . 0.0 109.445 -178.966 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.17 147.36 27.12 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.474 1.13 . . . . 0.0 111.646 -179.05 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.584 ' HB ' HG11 ' A' ' 7' ' ' VAL . 92.3 t -102.95 109.65 27.38 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 177.259 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.496 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.84 -169.45 17.37 Favored Glycine 0 N--CA 1.484 1.88 0 C-N-CA 118.073 -2.013 . . . . 0.0 111.628 -177.258 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.485 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -121.24 176.8 5.43 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -178.897 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.592 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 6.9 t 176.84 159.71 0.36 Allowed 'General case' 0 C--N 1.292 -1.897 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 -179.963 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.555 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -103.49 -158.49 0.67 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.91 -1.119 . . . . 0.0 109.29 -179.855 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.442 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.22 36.22 4.33 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.788 -1.195 . . . . 0.0 109.238 179.984 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.89 -32.6 6.56 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.366 -0.834 . . . . 0.0 109.796 -179.736 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.572 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 169.02 -37.94 0.2 Allowed Glycine 0 N--CA 1.481 1.666 0 N-CA-C 107.992 -2.043 . . . . 0.0 107.992 -179.78 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.54 -177.08 3.82 Favored 'General case' 0 C--N 1.307 -1.262 0 O-C-N 121.574 -0.957 . . . . 0.0 109.984 179.395 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.56 -161.41 21.1 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 108.068 -2.013 . . . . 0.0 108.068 -179.397 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.9 Cg_exo -45.77 172.63 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.632 0 CA-C-N 118.978 1.389 . . . . 0.0 109.933 179.194 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -92.9 -174.49 3.61 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.092 -1.005 . . . . 0.0 110.56 -178.772 . . . . . . . . 1 1 . 1 . 059 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.496 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.48 166.31 14.35 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.876 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.0 131.16 50.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.416 -1.049 . . . . 0.0 109.124 -179.428 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.61 123.77 24.63 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.594 -0.691 . . . . 0.0 109.519 179.713 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.916 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.84 171.74 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.232 -0.917 . . . . 0.0 109.183 179.901 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.459 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -138.15 157.78 45.62 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.279 -0.888 . . . . 0.0 109.92 -179.712 . . . . . . . . 3 3 . 1 . 059 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.916 ' CE1' HD12 ' A' ' 110' ' ' ILE . 38.8 m-85 -129.77 98.62 4.86 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.273 -0.892 . . . . 0.0 109.543 -179.741 . . . . . . . . 2 2 . 1 . 059 nuclear build full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 24.7 p30 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 118.048 -0.977 . . . . 0.0 109.462 -179.97 . . . . . . . . 0 0 . 1 . 059 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.794 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 060 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.6 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -103.41 161.75 22.12 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.268 -0.895 . . . . 0.0 109.446 -179.978 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.6 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 4.1 Cg_exo -60.5 157.25 37.38 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.322 2.014 . . . . 0.0 110.52 -179.987 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -149.82 160.59 43.44 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -179.532 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.63 122.57 9.39 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 122.454 1.121 . . . . 0.0 110.452 -179.675 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.829 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.3 t -115.58 109.24 17.5 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.123 1.44 . . . . 0.0 109.72 -179.935 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.834 HG22 HG23 ' A' ' 21' ' ' VAL . 1.1 t -114.53 135.75 53.35 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.285 -1.325 . . . . 0.0 109.582 179.886 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.69 150.42 2.62 Favored Pre-proline 0 N--CA 1.487 1.407 0 O-C-N 121.151 -0.968 . . . . 0.0 108.95 -179.639 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.0 Cg_endo -78.63 150.2 86.86 Favored 'Cis proline' 0 C--N 1.313 -1.305 0 C-N-CA 123.392 -1.503 . . . . 0.0 109.341 -0.965 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.672 ' HA ' HG22 ' A' ' 110' ' ' ILE . 84.6 p -92.91 -22.65 19.11 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.552 -0.718 . . . . 0.0 109.306 179.894 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 11' ' ' SER . . . . . 0.495 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 4.3 m -130.91 159.64 36.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.345 -0.847 . . . . 0.0 109.644 -179.838 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.55 37.34 31.13 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 108.542 -1.823 . . . . 0.0 108.542 -179.676 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.8 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.6 mt -90.92 -44.29 9.46 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 123.14 1.447 . . . . 0.0 110.691 -178.479 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.26 144.41 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.249 0 CA-C-N 113.555 -1.657 . . . . 0.0 109.687 -179.538 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.607 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.4 p-10 -51.54 109.24 0.33 Allowed 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.495 0.664 . . . . 0.0 111.483 -178.612 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.43 10.85 12.56 Favored Glycine 0 N--CA 1.485 1.955 0 C-N-CA 119.391 -1.385 . . . . 0.0 112.83 177.374 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.8 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.9 t -101.97 -171.37 1.96 Allowed 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 121.051 2.425 . . . . 0.0 109.876 179.575 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.753 HG13 ' C ' ' A' ' 67' ' ' LEU . 19.1 t -131.19 142.41 43.53 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.76 -179.058 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.417 HG11 HD11 ' A' ' 13' ' ' LEU . 35.4 m -118.55 155.58 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.277 -0.889 . . . . 0.0 108.764 179.209 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.489 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 6.1 tttt -108.02 109.23 20.64 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.162 -0.961 . . . . 0.0 109.288 -179.984 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.834 HG23 HG22 ' A' ' 7' ' ' VAL . 10.4 p -101.36 138.92 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.71 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.829 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.68 161.24 36.11 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 118.698 -1.201 . . . . 0.0 110.127 179.689 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 23' ' ' GLY . . . . . 0.604 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.94 140.92 12.0 Favored Glycine 0 C--O 1.209 -1.444 0 N-CA-C 107.928 -2.069 . . . . 0.0 107.928 179.621 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.597 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -143.06 125.05 15.21 Favored 'General case' 0 N--CA 1.494 1.756 0 CA-C-N 119.266 1.533 . . . . 0.0 109.395 179.387 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.465 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.64 28.22 19.75 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 118.755 -1.688 . . . . 0.0 109.619 -179.728 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.595 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.6 mt -88.74 171.32 10.06 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.866 -1.373 . . . . 0.0 108.089 179.906 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 1.014 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.79 100.25 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.901 -1.124 . . . . 0.0 109.981 -179.424 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.58 77.21 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.946 -179.347 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.01 33.88 0.24 Allowed Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.717 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.557 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 36.3 p -141.26 107.47 5.23 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.082 -1.246 . . . . 0.0 111.311 -179.422 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 31' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.49 109.78 0.31 Allowed 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 177.93 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 32' ' ' TYR . . . . . 0.58 ' CG ' ' O ' ' A' ' 98' ' ' SER . 4.4 m-30 -101.24 156.1 17.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.168 -0.957 . . . . 0.0 109.009 179.83 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.499 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -99.98 163.71 12.32 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 178.503 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.752 HG22 HG11 ' A' ' 21' ' ' VAL . 2.4 p -147.77 117.85 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.891 -1.131 . . . . 0.0 110.05 -177.928 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.497 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -171.28 -175.91 40.04 Favored Glycine 0 N--CA 1.494 2.501 0 C-N-CA 118.346 -1.883 . . . . 0.0 111.724 -179.862 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.573 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -100.42 108.87 20.97 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.748 0.785 . . . . 0.0 108.946 -179.818 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.489 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.39 148.27 52.19 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.269 -0.894 . . . . 0.0 109.676 179.431 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.556 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.19 137.55 54.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.265 -0.897 . . . . 0.0 110.932 -178.839 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 39' ' ' TRP . . . . . 0.869 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.64 114.68 26.45 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.114 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.0 m -105.03 14.4 7.24 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 120.95 -1.094 . . . . 0.0 110.573 -178.715 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.76 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.03 -175.36 0.07 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.987 -1.071 . . . . 0.0 110.091 179.729 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.788 ' O ' HG23 ' A' ' 42' ' ' THR . 15.0 t -71.69 99.05 2.04 Favored 'General case' 0 N--CA 1.486 1.347 0 CA-C-O 121.829 0.823 . . . . 0.0 109.812 -179.641 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.77 26.57 37.71 Favored Glycine 0 N--CA 1.494 2.549 0 C-N-CA 120.179 -1.01 . . . . 0.0 111.46 178.957 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.76 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.4 t -116.16 106.25 19.98 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 O-C-N 120.576 -1.544 . . . . 0.0 107.356 178.891 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 45' ' ' LEU . . . . . 0.869 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.2 tp -117.93 104.34 10.82 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.471 -1.393 . . . . 0.0 109.73 -177.694 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.976 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.73 109.66 22.37 Favored 'General case' 0 N--CA 1.485 1.311 0 O-C-N 120.776 -1.203 . . . . 0.0 108.07 178.88 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -107.26 163.35 13.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.016 -1.053 . . . . 0.0 110.467 -178.705 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.528 HD22 ' HB3' ' A' ' 50' ' ' ALA . 17.0 t30 -111.29 136.77 20.91 Favored Pre-proline 0 N--CA 1.502 2.136 0 O-C-N 121.414 -0.803 . . . . 0.0 109.75 -179.463 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.7 Cg_endo -73.57 25.67 0.32 Allowed 'Trans proline' 0 C--N 1.319 -1.007 0 C-N-CA 122.463 2.109 . . . . 0.0 112.335 -179.63 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 50' ' ' ALA . . . . . 0.631 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -112.66 3.07 16.41 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.272 -1.518 . . . . 0.0 109.326 179.588 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.534 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.45 18.97 2.22 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 179.592 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -79.94 92.06 5.5 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.867 -0.733 . . . . 0.0 110.866 -178.867 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 53' ' ' SER . . . . . 0.618 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -114.47 -168.85 1.43 Allowed 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 178.367 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.9 134.88 0.09 Allowed 'General case' 0 C--N 1.304 -1.372 0 O-C-N 120.597 -1.315 . . . . 0.0 111.214 -179.402 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.763 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 2.0 p -148.98 157.2 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.233 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.26 142.62 29.69 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.709 -1.244 . . . . 0.0 109.874 -179.85 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 1.014 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.36 108.15 1.86 Allowed 'General case' 0 C--N 1.299 -1.626 0 CA-C-O 122.337 1.065 . . . . 0.0 109.649 178.706 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.561 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.1 t0 -63.84 -138.8 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.003 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.816 179.888 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.81 -52.04 45.07 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.361 -0.837 . . . . 0.0 110.697 -178.677 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -101.74 -33.6 9.78 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 178.517 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 104.51 65.92 0.69 Allowed Glycine 0 C--N 1.298 -1.532 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 178.221 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 55.9 p -98.53 132.41 43.98 Favored 'General case' 0 N--CA 1.482 1.153 0 O-C-N 121.489 -1.007 . . . . 0.0 109.177 179.074 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.763 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.63 108.57 6.33 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 119.255 -0.978 . . . . 0.0 109.567 -179.658 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 6.0 m -127.11 120.32 28.6 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.272 -0.892 . . . . 0.0 109.681 -179.878 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.535 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.09 142.72 28.81 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.55 -0.719 . . . . 0.0 109.277 179.794 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.9 p -98.81 131.69 44.74 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.287 -0.883 . . . . 0.0 109.212 179.985 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.753 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -135.6 169.4 17.59 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.288 -0.882 . . . . 0.0 109.569 -179.349 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 68' ' ' THR . . . . . 0.631 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 11.3 t -95.29 137.74 33.93 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.091 -1.006 . . . . 0.0 110.559 -179.425 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.573 HG12 ' HB3' ' A' ' 36' ' ' GLN . 18.3 m -148.24 143.55 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.381 -0.824 . . . . 0.0 109.536 -179.891 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.607 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.0 OUTLIER -149.95 -174.65 4.77 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.497 -1.377 . . . . 0.0 110.807 -179.863 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 71' ' ' ARG . . . . . 0.62 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.86 -102.06 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.414 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.637 -179.458 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.5 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -56.49 141.89 40.97 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.831 -1.168 . . . . 0.0 108.577 179.814 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -163.34 137.26 5.91 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 118.836 -1.146 . . . . 0.0 109.633 -178.402 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.52 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 17.4 mm-40 -33.56 122.1 0.42 Allowed 'General case' 0 N--CA 1.49 1.571 0 CA-C-O 121.559 0.695 . . . . 0.0 110.78 -178.12 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.976 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.32 46.91 2.83 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.321 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.1 m-85 -39.64 112.02 0.23 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.073 -1.251 . . . . 0.0 109.856 179.568 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.696 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -85.46 126.44 33.82 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.895 -1.128 . . . . 0.0 109.37 -179.927 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.588 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 37.5 t80 -63.89 58.39 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.933 -1.104 . . . . 0.0 110.168 179.833 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 4.9 t70 -160.38 19.3 0.14 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.037 -1.039 . . . . 0.0 109.709 179.913 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.51 -26.5 5.74 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 179.808 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 60.5 p -94.06 158.63 15.53 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.033 -1.275 . . . . 0.0 110.418 -179.346 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.477 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -105.08 133.43 49.87 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.698 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 83' ' ' TRP . . . . . 0.696 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.9 t90 -81.43 -18.9 43.76 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.883 -1.135 . . . . 0.0 110.37 -178.573 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.34 174.83 19.57 Favored Glycine 0 N--CA 1.485 1.962 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.653 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.1 105.96 0.97 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.112 -1.228 . . . . 0.0 107.72 179.085 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.644 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.6 t -76.95 105.99 6.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.306 -0.871 . . . . 0.0 109.27 -178.824 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 87' ' ' ASP . . . . . 0.539 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.4 111.14 3.39 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.359 -0.838 . . . . 0.0 109.821 -179.524 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 88' ' ' CYS . . . . . 0.62 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -62.74 -6.09 3.34 Favored 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 118.225 -1.39 . . . . 0.0 109.875 179.42 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -86.13 -1.26 57.24 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.716 -1.24 . . . . 0.0 109.163 179.63 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.539 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.47 -49.6 2.99 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.338 -0.851 . . . . 0.0 109.005 179.905 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.27 179.15 4.34 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.415 -0.803 . . . . 0.0 109.438 179.924 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.54 116.22 32.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.322 -0.861 . . . . 0.0 108.952 179.928 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 93' ' ' CYS . . . . . 0.564 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.72 124.7 40.78 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.815 -1.178 . . . . 0.0 109.535 -179.478 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 94' ' ' GLN . . . . . 0.594 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -105.15 147.87 27.49 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 122.515 1.15 . . . . 0.0 111.451 -179.152 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.595 ' CG1' HG11 ' A' ' 7' ' ' VAL . 57.6 t -104.49 110.55 30.93 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.04 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 177.43 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.408 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.47 -171.29 17.18 Favored Glycine 0 N--CA 1.488 2.157 0 C-N-CA 118.123 -1.989 . . . . 0.0 111.89 -177.562 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.499 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.77 -179.62 3.74 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.023 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.58 ' O ' ' CG ' ' A' ' 32' ' ' TYR . 1.5 p -156.1 177.19 11.71 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.367 -0.833 . . . . 0.0 109.715 -179.524 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 99' ' ' ASP . . . . . 0.708 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 0.7 OUTLIER -107.25 -16.27 14.45 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.387 -0.821 . . . . 0.0 109.274 179.811 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 100' ' ' ALA . . . . . 0.708 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 76.77 36.02 0.37 Allowed 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.55 -0.718 . . . . 0.0 109.218 -179.83 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -143.13 -34.68 0.42 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.588 -0.695 . . . . 0.0 110.802 -179.411 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 102' ' ' GLY . . . . . 0.758 ' HA2' H192 ' A' ' 114' ' ' CHR . . . -178.79 -42.67 0.07 OUTLIER Glycine 0 N--CA 1.483 1.783 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 -179.642 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.471 ' O ' ' HB2' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -153.88 -179.62 8.01 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.466 -1.02 . . . . 0.0 109.345 178.8 . . . . . . . . 3 3 . 1 . 060 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -172.45 -166.28 30.79 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 108.631 -1.788 . . . . 0.0 108.631 -179.44 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 105' ' ' PRO . . . . . 0.517 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.0 Cg_exo -49.93 -175.64 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.668 0 CA-C-N 118.759 1.279 . . . . 0.0 110.32 179.603 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 -94.43 -179.27 4.85 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.059 -1.026 . . . . 0.0 110.506 -178.843 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.408 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.95 162.64 14.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.992 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.17 128.42 53.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.334 -1.098 . . . . 0.0 109.165 -179.389 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 109' ' ' ALA . . . . . 0.594 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.71 124.02 26.56 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.59 -0.694 . . . . 0.0 109.552 179.669 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 110' ' ' ILE . . . . . 0.758 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.75 167.79 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.21 -0.931 . . . . 0.0 109.234 -179.913 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.495 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 15.2 m -137.0 156.33 48.58 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.276 -0.89 . . . . 0.0 109.481 -179.931 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 112' ' ' PHE . . . . . 0.758 ' CE1' HD12 ' A' ' 110' ' ' ILE . 17.5 m-85 -122.18 126.9 49.3 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.204 -0.935 . . . . 0.0 109.523 -179.787 . . . . . . . . 2 2 . 1 . 060 nuclear build full ' A' A ' 113' ' ' ASN . . . . . 0.457 ' OXT' ' O ' ' A' ' 112' ' ' PHE . 20.1 p30 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.502 -179.938 . . . . . . . . 1 1 . 1 . 060 nuclear build full ' A' A ' 114' ' ' CHR . . . . . 0.758 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.474 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.475 0 CA-C-O 122.327 1.061 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.948 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -111.21 108.54 18.23 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-O 123.11 1.433 . . . . 0.0 109.167 179.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.842 HG22 HG23 ' A' ' 21' ' ' VAL . 2.7 t -115.39 140.33 37.4 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.681 0 CA-C-N 114.255 -1.339 . . . . 0.0 110.08 -179.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.495 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -175.72 149.78 1.09 Allowed Pre-proline 0 N--CA 1.487 1.422 0 O-C-N 121.305 -0.872 . . . . 0.0 108.728 -179.656 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.495 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -75.66 152.33 97.04 Favored 'Cis proline' 0 C--N 1.311 -1.408 0 C-N-CA 123.422 -1.491 . . . . 0.0 109.371 -0.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.647 ' HA ' HG22 ' A' ' 110' ' ' ILE . 10.9 m -90.69 -24.64 20.39 Favored 'General case' 0 C--N 1.293 -1.887 0 O-C-N 121.605 -0.684 . . . . 0.0 109.191 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.516 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.4 m -137.16 165.32 26.36 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.44 -0.788 . . . . 0.0 109.59 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.5 38.62 32.46 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.801 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.6 mt -92.79 -43.95 8.76 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 123.152 1.453 . . . . 0.0 110.736 -178.2 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.467 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.05 145.47 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.274 0 CA-C-N 113.597 -1.638 . . . . 0.0 110.156 -179.912 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.6 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 14.2 p-10 -51.16 106.84 0.15 Allowed 'General case' 0 C--N 1.301 -1.517 0 CA-C-O 121.461 0.648 . . . . 0.0 111.526 -178.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.79 14.76 9.15 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.43 -1.367 . . . . 0.0 112.969 177.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.801 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.4 t -104.24 -171.94 2.02 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 121.075 2.437 . . . . 0.0 109.544 179.152 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.727 HG13 ' C ' ' A' ' 67' ' ' LEU . 16.2 t -128.59 136.05 60.89 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.392 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.116 -179.065 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.587 HG13 ' CG2' ' A' ' 69' ' ' VAL . 20.6 m -111.52 155.55 12.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 11.1 tttt -112.31 109.31 18.88 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.192 -0.942 . . . . 0.0 108.954 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.842 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.63 140.51 21.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.948 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.54 160.22 39.15 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.842 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.18 144.56 15.82 Favored Glycine 0 C--N 1.294 -1.783 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.51 125.11 12.47 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 120.891 -1.358 . . . . 0.0 108.844 179.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.89 26.64 26.15 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.28 -1.438 . . . . 0.0 109.864 -179.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.549 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -87.79 174.89 8.11 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 120.885 -1.362 . . . . 0.0 108.596 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.79 99.58 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.4 0 O-C-N 120.987 -1.071 . . . . 0.0 109.766 -179.696 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.2 78.01 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.124 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.98 34.23 0.3 Allowed Glycine 0 N--CA 1.487 2.098 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.5 p -141.29 107.5 5.23 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 121.111 -1.229 . . . . 0.0 111.249 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.72 109.96 0.33 Allowed 'General case' 0 N--CA 1.498 1.938 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.638 178.076 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.459 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.6 m-30 -106.25 154.04 21.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.126 -0.984 . . . . 0.0 108.837 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.484 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.86 162.75 12.93 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.863 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.722 HG22 HG11 ' A' ' 21' ' ' VAL . 3.5 p -142.63 116.5 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.048 -1.032 . . . . 0.0 109.628 -178.161 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.69 -175.79 37.19 Favored Glycine 0 N--CA 1.494 2.501 0 C-N-CA 118.353 -1.879 . . . . 0.0 111.67 -179.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.615 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -100.73 109.65 21.69 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-O 121.899 0.857 . . . . 0.0 109.038 -179.597 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.486 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -129.94 149.88 51.47 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.275 -0.891 . . . . 0.0 109.634 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.517 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -125.33 139.21 53.89 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.166 -0.959 . . . . 0.0 110.796 -178.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.89 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 114.95 26.79 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.038 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.0 m -105.13 15.03 6.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 120.906 -1.121 . . . . 0.0 110.584 -178.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.76 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.78 -175.06 0.08 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.904 -1.123 . . . . 0.0 110.0 179.79 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.03 97.59 1.92 Allowed 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.465 -0.772 . . . . 0.0 109.687 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.65 27.89 33.97 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 120.258 -0.972 . . . . 0.0 111.392 178.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.76 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.38 106.41 20.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 O-C-N 120.576 -1.543 . . . . 0.0 107.313 178.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.89 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -115.86 104.68 11.87 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 120.486 -1.384 . . . . 0.0 109.896 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.959 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.18 109.47 22.22 Favored 'General case' 0 N--CA 1.484 1.238 0 O-C-N 120.81 -1.182 . . . . 0.0 107.917 178.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.63 166.57 10.58 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.914 -1.116 . . . . 0.0 110.484 -178.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.747 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 47.6 t30 -112.06 129.77 23.93 Favored Pre-proline 0 N--CA 1.501 2.1 0 O-C-N 121.488 -0.758 . . . . 0.0 109.583 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.612 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.56 21.05 0.25 Allowed 'Trans proline' 0 C--N 1.319 -1.024 0 C-N-CA 122.132 1.888 . . . . 0.0 112.268 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.747 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -109.55 3.49 21.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.334 -1.479 . . . . 0.0 108.977 179.336 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.539 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.34 17.23 2.76 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 179.382 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -80.6 87.77 5.74 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.987 -0.685 . . . . 0.0 111.143 -178.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -104.2 -165.82 1.19 Allowed 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 178.159 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.446 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.89 137.13 0.09 Allowed 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.532 -1.355 . . . . 0.0 111.382 -179.306 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.931 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -155.5 157.09 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 178.21 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.63 142.34 30.33 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.746 -1.222 . . . . 0.0 109.911 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.34 106.83 0.96 Allowed 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 122.476 1.131 . . . . 0.0 109.406 178.481 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.544 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.6 p-10 -60.4 -139.56 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.893 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.16 -50.9 58.04 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.4 -0.813 . . . . 0.0 110.666 -178.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -103.55 -33.15 9.12 Favored 'General case' 0 C--N 1.287 -2.137 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 178.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.016 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.66 65.34 0.6 Allowed Glycine 0 C--N 1.298 -1.556 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.574 178.084 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.6 m -102.05 128.37 48.53 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 121.481 -1.011 . . . . 0.0 108.635 178.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.931 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.7 108.84 6.79 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.798 -179.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 3.8 m -121.54 119.02 30.73 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.18 -0.95 . . . . 0.0 109.428 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.595 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.87 145.13 31.46 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.484 -0.76 . . . . 0.0 109.446 179.875 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 18.4 p -98.99 146.77 25.69 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.413 -0.804 . . . . 0.0 109.632 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.727 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -146.65 166.74 25.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.451 -0.78 . . . . 0.0 109.285 -179.431 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.664 HG22 HG22 ' A' ' 18' ' ' VAL . 4.1 p -95.24 124.87 39.5 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.075 -1.015 . . . . 0.0 109.637 -179.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.587 ' CG2' HG13 ' A' ' 19' ' ' VAL . 17.3 m -137.7 142.64 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.948 -1.095 . . . . 0.0 109.834 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.6 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.4 ptt180 -141.37 -165.49 1.98 Allowed 'General case' 0 N--CA 1.487 1.411 0 O-C-N 120.617 -1.302 . . . . 0.0 110.312 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.593 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 2.7 mtt180 -71.66 -78.02 0.09 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.34 -0.85 . . . . 0.0 109.096 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -69.05 137.35 53.51 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 120.21 -1.556 . . . . 0.0 107.437 179.082 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.564 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -160.78 132.8 5.93 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 117.996 -1.482 . . . . 0.0 110.167 -178.098 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.494 ' C ' ' O ' ' A' ' 73' ' ' PHE . 9.2 mp0 -30.1 121.92 0.18 Allowed 'General case' 0 N--CA 1.492 1.675 0 CA-C-O 121.627 0.727 . . . . 0.0 110.88 -178.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.959 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.02 45.09 3.16 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.612 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.4 m-30 -38.99 113.55 0.32 Allowed 'General case' 0 N--CA 1.508 2.461 0 O-C-N 121.123 -1.221 . . . . 0.0 110.268 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.716 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.57 127.45 35.26 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.035 -1.041 . . . . 0.0 109.487 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.0 t80 -64.48 58.1 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.861 -1.15 . . . . 0.0 110.118 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 77' ' ' LEU . 27.6 t0 -160.02 18.95 0.16 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.041 -1.037 . . . . 0.0 109.814 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.39 -26.42 5.71 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.56 158.6 15.62 Favored 'General case' 0 N--CA 1.485 1.307 0 O-C-N 120.959 -1.318 . . . . 0.0 110.435 -179.438 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.482 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -105.36 133.63 49.81 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 179.711 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.716 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.5 t90 -80.98 -19.52 43.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.797 -1.189 . . . . 0.0 110.281 -178.717 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.7 174.08 18.68 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.85 110.65 1.83 Allowed 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.666 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.2 t -82.06 103.56 9.41 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.389 -0.819 . . . . 0.0 108.846 -178.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.647 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -67.12 111.28 3.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.439 -0.788 . . . . 0.0 109.816 -179.174 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.553 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -63.0 -6.07 3.56 Favored 'General case' 0 N--CA 1.5 2.033 0 C-N-CA 118.361 -1.336 . . . . 0.0 109.824 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 41.4 p -84.64 -0.34 53.04 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.648 -1.282 . . . . 0.0 108.897 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.647 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -113.9 -49.7 2.86 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.338 -0.851 . . . . 0.0 109.025 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.91 -178.64 3.71 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.484 -0.76 . . . . 0.0 109.62 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.36 115.44 30.26 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.469 -0.769 . . . . 0.0 108.981 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.557 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.05 123.03 40.68 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.861 -1.15 . . . . 0.0 109.774 -179.249 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.624 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.57 146.87 27.91 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-O 122.378 1.085 . . . . 0.0 111.139 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.475 ' HB ' HG11 ' A' ' 7' ' ' VAL . 56.2 t -102.07 110.03 27.75 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.013 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 177.497 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.465 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.79 -170.31 16.42 Favored Glycine 0 N--CA 1.487 2.077 0 C-N-CA 118.246 -1.931 . . . . 0.0 111.631 -177.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.484 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -122.66 176.99 5.64 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.871 -0.782 . . . . 0.0 109.162 -178.854 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.459 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.5 m . . . . . 0 C--N 1.296 -1.759 0 O-C-N 121.687 -0.633 . . . . 0.0 109.386 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.404 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.482 1.722 0 N-CA-C 107.814 -2.114 . . . . 0.0 107.814 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.404 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.53 -177.17 3.86 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 122.069 0.938 . . . . 0.0 109.737 179.385 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.62 -161.44 17.14 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 108.297 -1.921 . . . . 0.0 108.297 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.497 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.4 Cg_exo -46.88 177.17 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.684 0 CA-C-N 118.794 1.297 . . . . 0.0 110.161 179.28 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -94.15 -168.92 1.95 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.054 -1.029 . . . . 0.0 110.284 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.465 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.24 162.8 18.25 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.69 129.54 48.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.457 -1.025 . . . . 0.0 109.205 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.624 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.78 122.39 21.45 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 121.74 -0.6 . . . . 0.0 109.86 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.821 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.92 170.45 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.268 -0.895 . . . . 0.0 109.191 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.516 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.23 155.07 51.27 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.211 -0.931 . . . . 0.0 109.636 -179.908 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.821 ' CE2' HD12 ' A' ' 110' ' ' ILE . 66.1 m-85 . . . . . 0 N--CA 1.486 1.337 0 O-C-N 121.224 -0.923 . . . . 0.0 109.457 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.488 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 122.297 1.046 . . . . 0.0 110.758 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.955 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -110.6 108.57 18.54 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 123.05 1.405 . . . . 0.0 109.073 179.275 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.826 HG22 HG23 ' A' ' 21' ' ' VAL . 2.2 t -117.02 140.42 39.76 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.713 0 CA-C-N 114.295 -1.32 . . . . 0.0 110.049 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.446 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -177.7 149.84 0.76 Allowed Pre-proline 0 N--CA 1.486 1.34 0 O-C-N 121.285 -0.884 . . . . 0.0 108.78 -179.757 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.446 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.86 150.39 86.5 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 123.551 -1.437 . . . . 0.0 109.239 -0.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 14.2 p -89.65 -25.74 21.1 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.473 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 8.1 m -132.75 163.22 29.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.427 -0.796 . . . . 0.0 109.527 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.16 37.72 31.6 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 -179.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.815 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.5 mt -92.95 -44.01 8.65 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.193 1.473 . . . . 0.0 110.695 -178.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.93 144.99 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.299 0 CA-C-N 113.515 -1.675 . . . . 0.0 109.919 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.602 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.7 p-10 -51.17 108.77 0.27 Allowed 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.433 0.635 . . . . 0.0 111.533 -178.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.84 13.38 11.28 Favored Glycine 0 N--CA 1.483 1.796 0 C-N-CA 119.45 -1.357 . . . . 0.0 112.875 177.335 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.815 HG21 ' CA ' ' A' ' 13' ' ' LEU . 11.1 t -103.12 -173.1 2.23 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 120.988 2.394 . . . . 0.0 109.571 179.333 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.751 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.7 t -127.2 135.11 64.42 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.968 -178.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.532 ' CG1' HD13 ' A' ' 13' ' ' LEU . 31.3 m -110.38 155.28 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 13.3 tttt -112.41 109.38 18.96 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.169 -0.957 . . . . 0.0 109.045 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.826 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -104.92 141.44 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.955 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.8 160.32 39.57 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.863 179.707 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.592 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.23 144.87 16.14 Favored Glycine 0 C--N 1.294 -1.775 0 N-CA-C 108.211 -1.956 . . . . 0.0 108.211 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.55 125.14 12.47 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.025 -1.28 . . . . 0.0 108.793 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.91 26.95 25.23 Favored Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.28 -1.438 . . . . 0.0 109.759 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.551 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.2 mt -86.74 175.31 8.31 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.862 -1.375 . . . . 0.0 108.529 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.09 98.04 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.914 -1.116 . . . . 0.0 109.598 -179.637 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.632 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.82 77.31 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.735 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.376 -179.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.43 34.29 0.32 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 179.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.558 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.2 p -146.08 112.22 5.75 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.916 -1.344 . . . . 0.0 111.202 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.85 126.85 6.03 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.823 178.223 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.493 ' CD2' ' O ' ' A' ' 30' ' ' THR . 13.8 m-85 -119.35 152.13 37.3 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -100.49 162.67 12.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.635 -1.291 . . . . 0.0 107.727 178.667 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.947 HG11 HG21 ' A' ' 65' ' ' THR . 5.7 p -147.1 117.02 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.002 -1.061 . . . . 0.0 110.031 -177.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -170.61 -176.46 40.0 Favored Glycine 0 N--CA 1.493 2.439 0 C-N-CA 118.323 -1.894 . . . . 0.0 111.714 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.586 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -99.79 108.92 21.34 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -179.801 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -131.01 148.91 52.81 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.22 -0.925 . . . . 0.0 109.777 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.415 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.79 139.38 54.04 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.31 -0.869 . . . . 0.0 110.768 -179.014 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.889 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.28 114.7 26.51 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 178.133 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.2 m -104.37 15.06 6.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.051 -1.03 . . . . 0.0 110.523 -178.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.767 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 173.98 -175.89 0.07 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.979 -1.075 . . . . 0.0 110.076 179.706 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 42' ' ' THR . 14.9 t -71.95 98.87 2.12 Favored 'General case' 0 N--CA 1.487 1.38 0 CA-C-O 121.77 0.795 . . . . 0.0 109.648 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.69 27.34 35.46 Favored Glycine 0 N--CA 1.493 2.475 0 C-N-CA 120.139 -1.029 . . . . 0.0 111.422 178.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.767 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.95 106.39 20.11 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 O-C-N 120.6 -1.53 . . . . 0.0 107.197 178.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.889 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -117.64 104.57 11.15 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.426 -1.421 . . . . 0.0 109.851 -177.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.988 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.2 109.58 22.31 Favored 'General case' 0 N--CA 1.484 1.25 0 O-C-N 120.812 -1.18 . . . . 0.0 108.165 178.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -106.38 166.43 10.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.966 -1.084 . . . . 0.0 110.122 -178.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.697 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 14.3 t-20 -108.56 137.98 20.13 Favored Pre-proline 0 N--CA 1.501 2.09 0 O-C-N 121.326 -0.859 . . . . 0.0 110.04 -179.267 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.7 Cg_endo -75.38 24.29 0.41 Allowed 'Trans proline' 0 C--N 1.317 -1.08 0 C-N-CA 122.36 2.04 . . . . 0.0 111.884 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.697 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -118.01 3.66 12.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.355 -1.466 . . . . 0.0 109.298 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.567 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.05 17.57 2.63 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 179.328 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -82.4 90.85 6.74 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.789 -0.765 . . . . 0.0 110.834 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.616 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -111.65 -169.24 1.43 Allowed 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 178.319 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.1 135.34 0.09 Allowed 'General case' 0 N--CA 1.486 1.353 0 O-C-N 120.584 -1.322 . . . . 0.0 111.325 -179.301 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.855 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.1 p -150.62 158.49 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 178.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.77 145.38 26.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.804 -1.185 . . . . 0.0 109.848 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.77 108.05 1.99 Allowed 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 122.359 1.076 . . . . 0.0 109.61 178.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.3 p-10 -60.73 -139.46 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.802 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.632 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.22 -50.13 62.59 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.43 -0.793 . . . . 0.0 110.432 -178.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 37.9 t30 -103.13 -35.18 8.59 Favored 'General case' 0 C--N 1.287 -2.141 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.05 65.91 0.6 Allowed Glycine 0 C--N 1.296 -1.64 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 178.3 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.592 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.5 m -102.04 128.86 48.3 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 121.475 -1.015 . . . . 0.0 108.899 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.855 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.07 108.76 6.62 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.933 -179.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -121.15 119.16 31.58 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.177 -0.952 . . . . 0.0 109.537 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.947 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -143.08 143.27 31.79 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.496 -0.753 . . . . 0.0 109.602 179.827 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.8 p -99.74 145.36 27.75 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.45 -0.781 . . . . 0.0 109.284 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.818 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -146.71 170.33 17.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.372 -0.83 . . . . 0.0 109.421 -179.286 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.662 HG22 HG22 ' A' ' 18' ' ' VAL . 1.9 p -99.16 125.71 44.78 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.023 -1.048 . . . . 0.0 109.532 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.562 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -137.47 143.82 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.917 -1.114 . . . . 0.0 109.768 -179.373 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.602 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.1 ptt180 -148.64 -172.04 4.0 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.434 -1.416 . . . . 0.0 110.944 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.613 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -55.8 -101.66 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 -179.358 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.508 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.58 140.52 46.35 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 120.778 -1.201 . . . . 0.0 108.215 179.587 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -162.38 136.23 6.36 Favored 'General case' 0 C--N 1.293 -1.874 0 C-N-CA 118.772 -1.171 . . . . 0.0 109.926 -178.184 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.545 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.5 mm-40 -32.09 121.02 0.3 Allowed 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.479 0.657 . . . . 0.0 110.736 -178.399 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.988 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.15 47.86 2.92 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.169 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.37 113.03 0.29 Allowed 'General case' 0 N--CA 1.506 2.365 0 O-C-N 121.076 -1.249 . . . . 0.0 110.118 179.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.741 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -85.14 127.02 34.09 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.959 -1.088 . . . . 0.0 109.503 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -63.57 58.36 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.905 -1.122 . . . . 0.0 110.297 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 16.7 t0 -161.53 19.74 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.995 -1.066 . . . . 0.0 109.791 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.18 -26.72 5.4 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.129 -1.189 . . . . 0.0 110.129 179.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.83 159.87 15.19 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.028 -1.278 . . . . 0.0 110.32 -179.368 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.485 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.49 134.58 49.41 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.888 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.741 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.9 t90 -82.86 -19.27 37.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.773 -1.204 . . . . 0.0 110.393 -178.637 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.43 173.91 18.76 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -64.11 107.29 1.24 Allowed 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.634 HG21 ' HB3' ' A' ' 46' ' ' ALA . 47.5 t -78.28 105.3 7.21 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 O-C-N 121.354 -0.841 . . . . 0.0 109.304 -178.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.549 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -65.15 110.82 2.67 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.487 -0.758 . . . . 0.0 109.777 -179.657 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.613 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.2 t -62.52 -6.36 3.35 Favored 'General case' 0 N--CA 1.499 2.001 0 C-N-CA 118.164 -1.415 . . . . 0.0 109.788 179.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.6 p -85.83 -3.17 58.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.726 -1.234 . . . . 0.0 109.272 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.549 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -109.62 -50.2 3.01 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.295 -0.878 . . . . 0.0 108.976 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.91 -179.46 3.95 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.491 -0.755 . . . . 0.0 109.374 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.2 115.98 31.17 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.363 -0.836 . . . . 0.0 108.83 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.505 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.6 123.52 40.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.815 -1.178 . . . . 0.0 109.639 -179.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.599 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.85 146.08 29.5 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 122.382 1.087 . . . . 0.0 111.042 -179.483 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 78.4 t -102.49 109.94 27.85 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.081 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 177.651 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.486 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.97 -171.52 17.79 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 118.171 -1.966 . . . . 0.0 111.812 -177.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.499 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -114.55 -178.39 3.36 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -179.048 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.515 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.9 OUTLIER . . . . . 0 C--N 1.296 -1.721 0 O-C-N 121.343 -0.848 . . . . 0.0 109.605 -179.26 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.718 0 N-CA-C 107.628 -2.189 . . . . 0.0 107.628 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.29 -178.48 7.31 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 121.627 -0.925 . . . . 0.0 109.682 179.238 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.84 -161.73 16.7 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 108.395 -1.882 . . . . 0.0 108.395 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.49 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.5 Cg_exo -46.93 178.3 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.634 0 CA-C-N 118.822 1.311 . . . . 0.0 110.375 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -92.69 -179.27 5.11 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.204 -0.935 . . . . 0.0 110.455 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.486 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.42 165.5 12.52 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.86 128.2 55.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.442 -1.034 . . . . 0.0 109.159 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.599 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.64 123.16 22.68 Favored 'General case' 0 C--N 1.289 -2.043 0 O-C-N 121.632 -0.667 . . . . 0.0 109.383 179.592 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.858 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.69 170.85 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.214 -0.929 . . . . 0.0 109.197 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.473 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.71 153.79 49.73 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.214 -0.929 . . . . 0.0 109.609 -179.847 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.858 ' CE2' HD12 ' A' ' 110' ' ' ILE . 75.9 m-85 . . . . . 0 N--CA 1.486 1.356 0 O-C-N 121.162 -0.961 . . . . 0.0 109.494 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.507 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.184 0 CA-C-O 122.44 1.114 . . . . 0.0 110.84 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.008 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.2 p -105.65 104.86 14.67 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.427 1.108 . . . . 0.0 110.287 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.951 HG22 HG23 ' A' ' 21' ' ' VAL . 11.7 t -118.82 117.28 53.86 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.469 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.226 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.522 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.1 149.71 11.76 Favored Pre-proline 0 N--CA 1.487 1.381 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 -179.611 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.522 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -77.14 152.05 94.18 Favored 'Cis proline' 0 C--N 1.309 -1.534 0 C-N-CA 123.698 -1.376 . . . . 0.0 109.567 -0.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.714 ' HA ' HG22 ' A' ' 110' ' ' ILE . 18.0 p -93.15 -24.75 18.14 Favored 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.468 ' HB3' ' HB2' ' A' ' 111' ' ' SER . 3.9 m -133.61 161.83 33.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.616 -0.678 . . . . 0.0 109.382 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.31 37.02 32.86 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.777 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.2 mt -90.92 -42.93 10.31 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 123.283 1.516 . . . . 0.0 110.411 -178.599 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.55 144.36 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.305 0 CA-C-N 113.28 -1.782 . . . . 0.0 109.918 -179.629 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.609 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 6.3 p-10 -50.87 106.34 0.13 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.624 0.726 . . . . 0.0 111.514 -178.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.29 13.93 8.66 Favored Glycine 0 N--CA 1.484 1.865 0 C-N-CA 119.468 -1.349 . . . . 0.0 113.033 177.375 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.777 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.98 -172.73 2.15 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 121.168 2.484 . . . . 0.0 109.785 179.253 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.8 HG22 HG22 ' A' ' 68' ' ' THR . 17.2 t -130.39 139.49 51.21 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.319 0 CA-C-N 114.794 -1.094 . . . . 0.0 111.215 -178.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.485 HG11 HD11 ' A' ' 13' ' ' LEU . 33.8 m -115.22 155.12 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 178.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.542 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.4 tttt -109.08 109.15 20.08 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.146 -0.971 . . . . 0.0 109.466 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.951 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -105.47 122.44 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.008 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.68 165.66 12.31 Favored 'General case' 0 C--N 1.307 -1.273 0 O-C-N 120.821 -1.174 . . . . 0.0 109.128 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.587 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.97 107.74 0.47 Allowed Glycine 0 N--CA 1.481 1.693 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.451 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.34 139.62 50.21 Favored 'General case' 0 N--CA 1.5 2.063 0 CA-C-N 119.139 1.469 . . . . 0.0 110.102 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 86.39 28.18 28.19 Favored Glycine 0 N--CA 1.49 2.25 0 C-N-CA 118.796 -1.669 . . . . 0.0 109.758 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.551 HD22 ' HG3' ' A' ' 105' ' ' PRO . 0.9 OUTLIER -94.7 174.44 7.11 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.996 -1.297 . . . . 0.0 108.58 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.005 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.28 100.1 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.91 -1.119 . . . . 0.0 109.74 -179.597 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.557 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.86 77.75 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.101 -179.326 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.41 34.02 0.29 Allowed Glycine 0 N--CA 1.487 2.071 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.9 p -141.86 108.73 5.42 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.071 -1.253 . . . . 0.0 111.098 -179.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.579 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.52 109.81 0.25 Allowed 'General case' 0 N--CA 1.496 1.874 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.796 178.253 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.518 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 21.6 m-85 -99.53 153.77 18.78 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.177 -0.952 . . . . 0.0 108.835 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.502 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -102.67 158.96 15.88 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.727 -1.233 . . . . 0.0 107.829 178.553 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.636 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.0 p -141.63 118.25 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.942 -1.099 . . . . 0.0 109.92 -177.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.52 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.4 -179.81 40.48 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.937 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.607 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -101.21 108.94 20.73 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.932 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.488 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.4 146.9 52.04 Favored 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.236 -0.915 . . . . 0.0 109.808 179.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.525 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -119.12 137.74 53.38 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.341 -0.849 . . . . 0.0 110.647 -178.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.857 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.69 114.44 26.18 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 178.143 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.7 m -105.92 14.51 7.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 120.971 -1.081 . . . . 0.0 110.666 -178.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.773 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.33 -175.38 0.08 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.815 -1.178 . . . . 0.0 110.116 179.743 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.784 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.97 98.07 1.54 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-O 121.806 0.812 . . . . 0.0 109.91 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.97 26.61 36.81 Favored Glycine 0 N--CA 1.493 2.494 0 C-N-CA 120.17 -1.014 . . . . 0.0 111.562 178.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.773 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -115.27 105.98 19.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 O-C-N 120.549 -1.559 . . . . 0.0 107.316 178.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.857 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -118.31 104.81 11.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.502 -1.374 . . . . 0.0 109.628 -177.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.037 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.92 109.67 22.38 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.755 -1.216 . . . . 0.0 108.271 179.074 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.3 t -105.51 164.44 11.88 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.996 -1.065 . . . . 0.0 110.416 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.72 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 9.6 t-20 -109.2 137.21 20.14 Favored Pre-proline 0 N--CA 1.5 2.042 0 O-C-N 121.505 -0.747 . . . . 0.0 109.972 -179.162 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.59 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.2 Cg_endo -74.39 23.9 0.36 Allowed 'Trans proline' 0 CA--C 1.544 1.004 0 C-N-CA 122.371 2.047 . . . . 0.0 112.049 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.72 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -116.91 3.61 12.85 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.364 -1.46 . . . . 0.0 109.115 179.669 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.541 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.49 13.82 3.22 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 179.356 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -79.25 91.46 5.0 Favored 'General case' 0 C--N 1.306 -1.321 0 O-C-N 121.509 -0.744 . . . . 0.0 111.052 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.636 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -112.63 -168.79 1.37 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.188 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.79 136.83 0.09 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.567 -1.333 . . . . 0.0 111.46 -179.296 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.92 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -152.19 157.01 5.31 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 178.024 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.579 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.18 143.78 28.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 120.808 -1.182 . . . . 0.0 110.081 -179.497 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -64.14 106.7 1.12 Allowed 'General case' 0 C--N 1.3 -1.55 0 CA-C-O 122.44 1.114 . . . . 0.0 109.278 178.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.8 p-10 -60.14 -139.12 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.948 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.557 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.53 -50.54 59.81 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.497 -0.752 . . . . 0.0 110.597 -178.522 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -103.91 -34.11 8.61 Favored 'General case' 0 C--N 1.286 -2.179 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 178.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.012 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.28 66.44 0.6 Allowed Glycine 0 C--N 1.296 -1.639 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.568 178.105 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.587 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 21.5 m -103.15 125.32 49.79 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.665 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.92 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.34 109.33 8.73 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.464 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.6 m -118.16 116.95 27.87 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.368 -0.833 . . . . 0.0 109.307 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.587 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -142.88 139.89 30.99 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.525 -0.734 . . . . 0.0 109.588 -179.987 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.6 p -99.62 134.55 42.33 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.465 -0.772 . . . . 0.0 109.43 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.76 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -132.12 165.6 23.68 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.427 -0.796 . . . . 0.0 109.389 -179.549 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.8 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -96.89 125.33 41.26 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.012 -1.055 . . . . 0.0 109.25 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.607 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.9 m -136.01 143.47 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 120.95 -1.094 . . . . 0.0 109.81 -179.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.609 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.7 ptt180 -147.15 -175.48 4.84 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.534 -1.354 . . . . 0.0 111.032 -179.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.605 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.12 -101.45 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.609 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.76 141.73 43.12 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.773 -1.204 . . . . 0.0 108.114 179.437 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.596 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.74 136.03 5.06 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 118.653 -1.219 . . . . 0.0 109.96 -177.973 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' A' ' 73' ' ' PHE . 0.7 OUTLIER -33.42 121.92 0.41 Allowed 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.364 0.602 . . . . 0.0 110.313 -178.609 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.037 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.16 50.19 1.91 Allowed Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.388 -0.91 . . . . 0.0 111.343 -178.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.59 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.4 m-85 -40.15 113.5 0.36 Allowed 'General case' 0 N--CA 1.507 2.383 0 O-C-N 121.123 -1.222 . . . . 0.0 109.749 179.313 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.677 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.3 tp -85.66 127.04 34.38 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 120.903 -1.123 . . . . 0.0 109.726 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 33.3 t80 -65.25 58.06 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.971 0 O-C-N 120.85 -1.156 . . . . 0.0 109.824 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -158.69 18.67 0.21 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.004 -1.06 . . . . 0.0 109.596 -179.991 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.95 -27.23 5.56 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 42.3 p -93.98 159.87 14.98 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.962 -1.316 . . . . 0.0 110.455 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.02 135.8 46.83 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.536 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.677 ' HB2' HD13 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -83.88 -16.46 44.3 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.737 -1.227 . . . . 0.0 110.67 -178.345 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 107.62 176.23 22.44 Favored Glycine 0 N--CA 1.485 1.95 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.9 104.31 0.68 Allowed 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.582 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 39.4 t -76.37 107.19 7.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.353 -0.842 . . . . 0.0 109.096 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.535 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.3 m-20 -66.29 111.45 3.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.448 -0.782 . . . . 0.0 109.975 -179.236 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.605 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.74 -5.56 4.36 Favored 'General case' 0 N--CA 1.5 2.067 0 C-N-CA 118.268 -1.373 . . . . 0.0 109.78 179.357 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.0 p -86.7 -1.45 57.72 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.744 -1.222 . . . . 0.0 109.231 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.535 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.15 -49.6 3.01 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.212 -0.93 . . . . 0.0 109.019 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.89 178.42 4.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.55 -0.719 . . . . 0.0 109.398 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.83 116.45 32.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.348 -0.845 . . . . 0.0 109.115 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.561 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.59 122.89 40.0 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.853 -1.155 . . . . 0.0 109.189 -179.473 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.578 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -101.18 146.04 28.01 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 122.334 1.064 . . . . 0.0 111.338 -179.08 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.588 ' HB ' HG11 ' A' ' 7' ' ' VAL . 65.8 t -103.21 109.78 27.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.964 0 N-CA-C 106.345 -1.724 . . . . 0.0 106.345 177.45 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.87 -172.82 17.53 Favored Glycine 0 N--CA 1.486 1.968 0 C-N-CA 118.063 -2.018 . . . . 0.0 111.804 -177.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.5 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -115.98 -177.77 3.24 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -178.87 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.502 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.9 OUTLIER . . . . . 0 C--N 1.295 -1.777 0 O-C-N 121.385 -0.822 . . . . 0.0 109.098 -179.24 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.701 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.7 -179.07 7.84 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 121.448 -1.03 . . . . 0.0 109.641 178.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.58 -166.56 33.91 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 -179.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.551 ' HG3' HD22 ' A' ' 26' ' ' LEU . 2.9 Cg_exo -49.8 -176.67 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.685 0 CA-C-N 118.857 1.329 . . . . 0.0 110.067 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -94.41 179.33 5.32 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.04 -1.037 . . . . 0.0 110.571 -178.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -117.97 166.77 12.76 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -108.26 128.87 63.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.246 -1.15 . . . . 0.0 109.117 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.578 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.09 119.1 16.86 Favored 'General case' 0 C--N 1.289 -2.045 0 O-C-N 121.586 -0.696 . . . . 0.0 109.356 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.892 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.81 169.9 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.151 -0.968 . . . . 0.0 108.916 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.468 ' HB2' ' HB3' ' A' ' 11' ' ' SER . 1.2 m -141.15 156.97 45.87 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.123 -0.986 . . . . 0.0 110.095 -179.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.892 ' CE2' HD12 ' A' ' 110' ' ' ILE . 97.8 m-85 . . . . . 0 N--CA 1.484 1.242 0 O-C-N 121.24 -0.912 . . . . 0.0 109.479 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.513 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.439 0 CA-C-O 122.486 1.136 . . . . 0.0 110.692 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.941 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.2 t -110.28 108.72 18.92 Favored 'General case' 0 C--N 1.296 -1.724 0 CA-C-O 123.108 1.432 . . . . 0.0 109.067 179.316 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.839 HG22 HG23 ' A' ' 21' ' ' VAL . 3.1 t -116.53 139.01 45.26 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.72 0 CA-C-N 114.246 -1.343 . . . . 0.0 110.123 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.466 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.64 149.13 1.27 Allowed Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.323 -0.861 . . . . 0.0 108.775 -179.735 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.466 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.79 152.52 97.07 Favored 'Cis proline' 0 C--N 1.312 -1.365 0 C-N-CA 123.476 -1.468 . . . . 0.0 109.485 -0.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.651 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.3 m -90.87 -24.56 20.2 Favored 'General case' 0 C--N 1.293 -1.874 0 O-C-N 121.587 -0.695 . . . . 0.0 109.175 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.51 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.2 m -137.94 165.34 26.78 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.547 -0.721 . . . . 0.0 109.515 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.05 37.98 31.34 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 108.579 -1.808 . . . . 0.0 108.579 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.81 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.8 mt -93.01 -43.93 8.66 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 123.102 1.43 . . . . 0.0 110.703 -178.249 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.17 145.94 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.314 0 CA-C-N 113.595 -1.639 . . . . 0.0 110.138 -179.904 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.616 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -51.23 106.95 0.15 Allowed 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 121.66 0.743 . . . . 0.0 111.638 -178.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.73 13.97 9.06 Favored Glycine 0 N--CA 1.484 1.878 0 C-N-CA 119.473 -1.346 . . . . 0.0 112.968 177.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.81 HG21 ' CA ' ' A' ' 13' ' ' LEU . 11.5 t -104.08 -173.96 2.43 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 121.164 2.482 . . . . 0.0 109.936 179.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.808 HG13 ' O ' ' A' ' 67' ' ' LEU . 39.1 t -124.76 136.11 61.79 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.389 0 CA-C-N 114.563 -1.199 . . . . 0.0 110.917 -178.669 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.562 ' CG1' HD13 ' A' ' 13' ' ' LEU . 35.6 m -114.04 154.95 15.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.259 -0.9 . . . . 0.0 108.725 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.81 109.15 18.44 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.037 179.876 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.839 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -104.48 141.02 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.941 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.73 160.76 38.35 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 120.735 -1.228 . . . . 0.0 110.154 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -128.46 144.6 15.42 Favored Glycine 0 C--N 1.295 -1.731 0 N-CA-C 107.973 -2.051 . . . . 0.0 107.973 179.559 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.13 125.71 13.3 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 120.851 -1.382 . . . . 0.0 108.864 179.053 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.472 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 89.44 26.01 26.64 Favored Glycine 0 N--CA 1.488 2.138 0 C-N-CA 119.184 -1.484 . . . . 0.0 109.874 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.587 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -89.02 170.98 10.19 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.86 -1.376 . . . . 0.0 108.477 179.892 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.997 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.02 100.88 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.082 -1.012 . . . . 0.0 110.038 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.2 78.53 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.007 -179.48 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.88 34.32 0.3 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.558 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 16.6 p -138.78 105.06 5.25 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.217 -1.166 . . . . 0.0 111.293 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.8 111.87 0.62 Allowed 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.054 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.558 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 36.9 m-85 -108.92 157.53 18.54 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.186 -0.946 . . . . 0.0 108.897 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.498 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.21 163.14 12.42 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.913 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.92 HG11 HG21 ' A' ' 65' ' ' THR . 2.8 p -143.75 119.42 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.034 -1.041 . . . . 0.0 109.914 -178.044 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.89 -177.87 38.96 Favored Glycine 0 N--CA 1.495 2.602 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.851 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.572 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -102.15 108.76 20.26 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.458 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -131.14 149.56 52.54 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.241 -0.912 . . . . 0.0 109.716 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.478 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.03 138.27 54.73 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.105 -0.997 . . . . 0.0 110.803 -178.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.888 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.73 26.55 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.112 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.0 m -104.74 14.8 6.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.109 -0.994 . . . . 0.0 110.593 -178.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.762 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 173.97 -175.7 0.07 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.989 -1.069 . . . . 0.0 110.003 179.686 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 42' ' ' THR . 14.9 t -72.1 99.0 2.22 Favored 'General case' 0 N--CA 1.486 1.357 0 CA-C-O 121.763 0.792 . . . . 0.0 109.738 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.77 27.7 34.14 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 120.227 -0.987 . . . . 0.0 111.405 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.762 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -117.5 105.88 18.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.619 -1.518 . . . . 0.0 107.263 178.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.888 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.2 tp -117.66 104.67 11.25 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.48 -1.387 . . . . 0.0 109.739 -177.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.089 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.89 109.35 22.12 Favored 'General case' 0 N--CA 1.484 1.26 0 O-C-N 120.804 -1.185 . . . . 0.0 107.9 178.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.491 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -107.26 162.71 13.65 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.956 -1.09 . . . . 0.0 110.263 -178.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.713 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 39.7 t30 -105.71 134.7 19.59 Favored Pre-proline 0 N--CA 1.503 2.189 0 O-C-N 121.405 -0.809 . . . . 0.0 109.539 -179.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.599 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.2 Cg_endo -72.74 22.92 0.29 Allowed 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.322 2.015 . . . . 0.0 112.46 -179.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.713 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -118.34 10.59 12.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.349 -1.469 . . . . 0.0 108.958 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.854 ' OD2' HD22 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -137.99 14.59 2.86 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 179.326 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -80.15 88.64 5.43 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.564 -0.855 . . . . 0.0 111.286 -178.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.55 -167.05 1.18 Allowed 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 178.128 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.74 138.26 0.09 Allowed 'General case' 0 C--N 1.306 -1.284 0 O-C-N 120.578 -1.326 . . . . 0.0 111.239 -179.267 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 1.022 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -155.69 156.48 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.397 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.66 142.03 30.74 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.798 -1.189 . . . . 0.0 110.016 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.015 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -61.74 106.76 0.72 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.425 1.107 . . . . 0.0 109.287 178.091 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.544 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.0 p-10 -60.44 -138.4 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.033 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.36 -51.03 58.13 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.429 -0.794 . . . . 0.0 110.902 -178.576 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.472 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.7 t-20 -103.57 -34.54 8.62 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 178.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.015 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 110.95 63.02 0.5 Allowed Glycine 0 C--N 1.297 -1.621 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 177.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.9 m -102.48 126.9 49.68 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.6 -0.941 . . . . 0.0 108.487 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 1.022 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.68 109.19 7.41 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.834 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.1 m -120.83 120.56 35.92 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.284 -0.885 . . . . 0.0 109.515 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.92 HG21 HG11 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -142.04 143.65 33.23 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.526 -0.734 . . . . 0.0 109.355 179.772 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.7 p -102.0 143.41 31.89 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.423 -0.798 . . . . 0.0 109.462 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.854 HD22 ' OD2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -146.26 -178.87 6.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 109.43 -179.45 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.513 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -105.06 125.88 51.46 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.903 -1.123 . . . . 0.0 110.289 -178.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.761 HG13 ' OD1' ' A' ' 51' ' ' ASP . 15.3 m -134.56 144.22 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 120.965 -1.085 . . . . 0.0 109.756 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.616 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.3 ptt180 -148.66 -179.62 7.11 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 120.458 -1.401 . . . . 0.0 111.105 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.603 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.92 -100.89 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -179.661 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.511 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.73 139.54 50.35 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.82 -1.175 . . . . 0.0 107.928 179.303 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -161.44 136.18 7.25 Favored 'General case' 0 C--N 1.295 -1.803 0 C-N-CA 118.647 -1.221 . . . . 0.0 109.807 -178.105 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.523 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 15.7 mt-10 -33.97 121.43 0.45 Allowed 'General case' 0 N--CA 1.491 1.621 0 CA-C-O 121.419 0.628 . . . . 0.0 110.358 -178.45 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.089 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.03 50.86 1.93 Allowed Glycine 0 N--CA 1.493 2.493 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.068 -179.278 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.599 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-85 -39.22 116.69 0.62 Allowed 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.122 -1.223 . . . . 0.0 109.954 179.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.718 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -87.37 126.16 34.7 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.006 -1.059 . . . . 0.0 109.455 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -64.8 58.47 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.925 0 O-C-N 120.804 -1.185 . . . . 0.0 110.014 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 26.4 t0 -159.33 19.54 0.18 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.054 -1.029 . . . . 0.0 109.571 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.51 -28.2 5.41 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.454 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 66.3 p -95.96 160.24 14.56 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.964 -1.315 . . . . 0.0 110.438 -179.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.479 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 4.1 ptt180 -105.73 138.77 41.37 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.718 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -83.55 -19.12 36.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.852 -1.155 . . . . 0.0 110.556 -178.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.59 176.1 19.24 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 108.704 -1.758 . . . . 0.0 108.704 -179.569 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -65.72 105.9 1.37 Allowed 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.0 t -77.36 105.9 6.86 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 O-C-N 121.355 -0.841 . . . . 0.0 109.144 -178.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.546 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -64.97 111.1 2.7 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.373 -0.829 . . . . 0.0 109.819 -179.558 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.603 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -62.91 -5.93 3.34 Favored 'General case' 0 N--CA 1.499 2.02 0 C-N-CA 118.214 -1.394 . . . . 0.0 109.85 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.2 p -86.99 -1.25 57.72 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.729 -1.232 . . . . 0.0 109.319 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.546 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.8 p -111.49 -50.3 2.94 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.384 -0.823 . . . . 0.0 108.937 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.76 -179.94 4.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.544 -0.723 . . . . 0.0 109.238 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.93 116.11 31.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.325 -0.859 . . . . 0.0 109.057 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -96.93 121.17 38.51 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.854 -1.154 . . . . 0.0 109.278 -179.321 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.609 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.3 mt-30 -102.04 146.78 27.42 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-O 122.402 1.096 . . . . 0.0 111.311 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.415 ' CG1' ' HB ' ' A' ' 21' ' ' VAL . 62.1 t -104.65 109.86 28.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 177.479 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.485 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.0 -170.04 16.27 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 118.243 -1.932 . . . . 0.0 111.62 -177.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.498 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -112.78 179.88 3.85 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -179.065 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.427 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.2 p . . . . . 0 C--N 1.297 -1.714 0 O-C-N 121.362 -0.836 . . . . 0.0 109.546 -179.18 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.741 0 N-CA-C 107.775 -2.13 . . . . 0.0 107.775 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -164.04 -177.42 5.03 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 121.599 -0.942 . . . . 0.0 109.962 179.451 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.67 -161.72 14.25 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.518 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.48 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.5 Cg_exo -47.53 178.45 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 CA-C-N 118.997 1.398 . . . . 0.0 110.196 179.281 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -91.25 -177.56 4.9 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.056 -1.028 . . . . 0.0 110.371 -178.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.485 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.15 163.73 13.89 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.06 129.76 50.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.374 -1.074 . . . . 0.0 109.173 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.609 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.1 121.96 22.84 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.634 -0.666 . . . . 0.0 109.603 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.955 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -97.89 169.85 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.214 -0.928 . . . . 0.0 109.18 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.51 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -136.2 154.58 50.89 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.326 -0.859 . . . . 0.0 109.745 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.955 ' CE1' HD12 ' A' ' 110' ' ' ILE . 26.7 m-85 . . . . . 0 N--CA 1.487 1.376 0 O-C-N 121.301 -0.874 . . . . 0.0 109.421 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.478 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.496 0 CA-C-O 122.436 1.112 . . . . 0.0 110.905 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.929 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.5 t -111.74 108.71 18.24 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 123.071 1.415 . . . . 0.0 109.102 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.819 HG22 HG23 ' A' ' 21' ' ' VAL . 2.8 t -115.28 139.23 42.65 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.692 0 CA-C-N 114.326 -1.306 . . . . 0.0 110.196 -179.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.08 149.39 1.46 Allowed Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.3 -0.875 . . . . 0.0 108.783 -179.769 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.9 Cg_endo -77.0 151.22 93.69 Favored 'Cis proline' 0 C--N 1.312 -1.344 0 C-N-CA 123.489 -1.463 . . . . 0.0 109.238 -0.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' HG22 ' A' ' 110' ' ' ILE . 24.0 p -89.81 -24.36 21.47 Favored 'General case' 0 C--N 1.292 -1.924 0 O-C-N 121.46 -0.775 . . . . 0.0 109.395 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.515 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 12.4 m -136.68 164.6 27.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.35 -0.844 . . . . 0.0 109.801 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.85 38.79 30.23 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.79 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.2 mt -92.18 -44.1 8.98 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 123.125 1.441 . . . . 0.0 110.721 -178.325 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.88 146.17 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.364 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.329 179.989 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.9 p-10 -51.55 107.4 0.19 Allowed 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.713 0.768 . . . . 0.0 111.571 -178.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.8 14.95 8.98 Favored Glycine 0 N--CA 1.484 1.853 0 C-N-CA 119.445 -1.359 . . . . 0.0 112.924 177.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.79 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.5 t -105.85 -172.61 2.12 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 121.136 2.468 . . . . 0.0 109.557 179.077 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.73 HG13 ' C ' ' A' ' 67' ' ' LEU . 13.3 t -129.2 136.77 58.76 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.43 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.897 -179.096 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.648 HG13 ' CG2' ' A' ' 69' ' ' VAL . 15.5 m -110.81 156.42 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.512 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.36 109.05 18.45 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.114 -0.991 . . . . 0.0 108.953 179.818 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.819 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -103.74 140.35 22.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.929 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.47 160.05 39.67 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.717 -1.239 . . . . 0.0 110.026 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.604 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.67 144.47 15.59 Favored Glycine 0 C--N 1.293 -1.806 0 N-CA-C 107.995 -2.042 . . . . 0.0 107.995 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.14 125.48 13.09 Favored 'General case' 0 C--N 1.296 -1.734 0 O-C-N 120.806 -1.408 . . . . 0.0 108.983 179.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.42 26.33 25.77 Favored Glycine 0 N--CA 1.488 2.121 0 C-N-CA 119.279 -1.438 . . . . 0.0 109.796 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.591 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.7 OUTLIER -89.36 169.59 11.28 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 120.838 -1.389 . . . . 0.0 108.347 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.84 100.99 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 122.214 1.007 . . . . 0.0 109.921 -179.438 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.82 78.18 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.618 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.904 -179.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.88 34.12 0.27 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.551 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 18.5 p -139.06 105.43 5.28 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 121.154 -1.204 . . . . 0.0 111.262 -179.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.583 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.24 111.54 0.59 Allowed 'General case' 0 N--CA 1.497 1.924 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.676 178.088 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.466 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.8 m-30 -109.48 156.35 20.2 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.109 -0.994 . . . . 0.0 108.873 179.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -99.49 164.98 11.86 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.821 -1.174 . . . . 0.0 107.915 179.079 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.728 HG22 HG11 ' A' ' 21' ' ' VAL . 3.4 p -144.95 116.52 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.036 -1.04 . . . . 0.0 109.774 -178.276 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.48 -176.23 37.43 Favored Glycine 0 N--CA 1.494 2.519 0 C-N-CA 118.348 -1.882 . . . . 0.0 111.886 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.597 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.1 pt20 -100.4 109.6 21.77 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-O 121.976 0.893 . . . . 0.0 108.978 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.61 148.75 52.44 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.212 -0.93 . . . . 0.0 109.613 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.497 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.15 138.01 54.48 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.263 -0.898 . . . . 0.0 110.875 -178.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.12 27.0 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 177.915 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 m -105.0 14.84 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 120.842 -1.162 . . . . 0.0 110.518 -178.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.42 -175.23 0.08 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 120.931 -1.106 . . . . 0.0 110.005 179.738 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.28 98.92 2.76 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.428 -0.795 . . . . 0.0 109.489 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.63 27.62 31.84 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 120.203 -0.999 . . . . 0.0 111.433 179.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -118.17 106.12 19.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 O-C-N 120.66 -1.494 . . . . 0.0 107.225 178.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.3 tp -117.94 104.53 10.99 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.475 -1.391 . . . . 0.0 109.874 -177.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.085 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.94 109.36 22.13 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 120.745 -1.222 . . . . 0.0 107.932 178.77 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.489 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 5.0 t -108.92 162.13 14.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.028 -1.045 . . . . 0.0 110.379 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.505 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 12.9 t-20 -107.36 129.18 24.64 Favored Pre-proline 0 N--CA 1.5 2.03 0 O-C-N 121.424 -0.797 . . . . 0.0 109.63 -179.404 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.621 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.0 OUTLIER -71.18 20.24 0.23 Allowed 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 122.057 1.838 . . . . 0.0 111.95 179.388 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.505 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -107.81 2.68 23.74 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.515 -1.366 . . . . 0.0 108.841 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.552 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.01 17.89 2.82 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 179.418 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -81.76 86.94 6.37 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.524 -0.735 . . . . 0.0 111.086 -178.384 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -102.89 -165.54 1.18 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 178.19 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.459 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.8 137.13 0.09 Allowed 'General case' 0 N--CA 1.486 1.354 0 O-C-N 120.532 -1.355 . . . . 0.0 111.212 -179.399 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 1.013 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -155.2 156.58 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 178.37 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.583 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.69 141.67 31.21 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.952 -1.093 . . . . 0.0 109.879 -179.802 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.034 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.23 107.17 0.84 Allowed 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 122.45 1.119 . . . . 0.0 109.39 178.231 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.546 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.9 t0 -62.17 -138.54 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.001 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.7 -52.42 31.34 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.391 -0.818 . . . . 0.0 110.871 -178.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -103.61 -32.81 9.24 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 178.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.034 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.8 62.57 0.54 Allowed Glycine 0 C--N 1.297 -1.627 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 178.04 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 37.0 m -101.04 127.14 47.7 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 1.013 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -137.13 109.2 7.2 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 119.074 -1.05 . . . . 0.0 109.877 -179.089 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 48.2 p -121.27 119.69 32.99 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.282 -0.886 . . . . 0.0 109.417 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.529 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.56 145.7 31.96 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.581 -0.699 . . . . 0.0 109.289 179.831 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 20.3 p -98.91 143.34 29.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.407 -0.808 . . . . 0.0 109.736 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.73 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -141.07 163.0 34.15 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.483 -0.761 . . . . 0.0 109.141 -179.486 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.693 HG22 HG22 ' A' ' 18' ' ' VAL . 5.1 p -92.77 123.98 36.44 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.045 -1.035 . . . . 0.0 109.521 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.648 ' CG2' HG13 ' A' ' 19' ' ' VAL . 17.8 m -137.78 144.16 31.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.001 -1.062 . . . . 0.0 109.453 -179.586 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.596 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 4.3 ptt180 -138.89 -168.77 2.49 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.507 -1.371 . . . . 0.0 110.544 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.681 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 3.9 mtt180 -65.48 -73.81 0.12 Allowed 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.522 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -76.72 145.43 38.66 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 178.159 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 0.9 OUTLIER -164.98 138.68 4.83 Favored 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 117.446 -1.702 . . . . 0.0 110.678 -177.478 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.525 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 3.7 mp0 -35.22 120.97 0.55 Allowed 'General case' 0 N--CA 1.491 1.614 0 CA-C-O 121.455 0.645 . . . . 0.0 110.361 -178.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.085 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -96.19 51.34 1.65 Allowed Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.485 -0.865 . . . . 0.0 111.018 -179.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.621 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-85 -40.19 114.64 0.46 Allowed 'General case' 0 N--CA 1.508 2.455 0 O-C-N 121.079 -1.248 . . . . 0.0 109.776 179.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.684 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -85.73 125.67 33.39 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.855 -1.153 . . . . 0.0 109.754 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -65.24 58.04 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.908 0 O-C-N 120.789 -1.194 . . . . 0.0 109.748 179.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.552 ' N ' ' O ' ' A' ' 77' ' ' LEU . 5.6 t70 -154.97 16.7 0.43 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.13 -0.981 . . . . 0.0 109.559 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.85 -26.83 8.87 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.12 164.96 11.42 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.948 -1.325 . . . . 0.0 110.643 -179.287 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.482 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 2.1 ptm180 -105.38 137.3 43.41 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.684 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -81.15 -19.77 42.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.852 -1.155 . . . . 0.0 110.421 -178.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.62 176.1 19.23 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.679 -1.769 . . . . 0.0 108.679 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.97 106.44 1.24 Allowed 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.651 HG21 ' HB3' ' A' ' 46' ' ' ALA . 38.7 t -78.03 107.55 10.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.363 -0.836 . . . . 0.0 109.205 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.522 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -68.71 112.99 5.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.518 -0.738 . . . . 0.0 109.91 -179.371 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.681 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 7.5 m -58.43 -6.98 0.77 Allowed 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.632 -1.293 . . . . 0.0 110.424 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.8 p -87.08 -4.77 59.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.298 -1.501 . . . . 0.0 109.617 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.496 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -103.38 -47.08 4.4 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.245 -0.909 . . . . 0.0 108.94 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.08 -178.06 3.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.553 -0.717 . . . . 0.0 109.357 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.08 117.57 35.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.403 -0.811 . . . . 0.0 108.821 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.557 ' HB2' HD11 ' A' ' 110' ' ' ILE . 3.2 m -96.47 121.26 38.1 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.846 -1.159 . . . . 0.0 109.724 -179.114 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.573 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.46 146.55 28.7 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 122.384 1.088 . . . . 0.0 111.37 -179.391 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.443 ' CG1' HG11 ' A' ' 7' ' ' VAL . 57.5 t -103.59 109.94 28.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 177.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.469 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.63 -171.54 16.8 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.221 -1.942 . . . . 0.0 111.638 -177.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.28 178.74 4.21 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 -179.067 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.506 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.1 p . . . . . 0 C--N 1.296 -1.76 0 O-C-N 121.565 -0.709 . . . . 0.0 109.406 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.65 0 N-CA-C 107.778 -2.129 . . . . 0.0 107.778 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.97 -177.74 5.99 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.64 -0.918 . . . . 0.0 109.742 179.273 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.04 -162.16 15.52 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 108.445 -1.862 . . . . 0.0 108.445 -179.439 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.482 ' HG3' HD22 ' A' ' 26' ' ' LEU . 5.2 Cg_exo -47.27 178.71 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.644 0 CA-C-N 118.789 1.295 . . . . 0.0 110.313 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -92.42 -172.97 3.25 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.007 -1.058 . . . . 0.0 110.36 -178.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.469 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.33 163.34 14.81 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.28 131.12 48.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.424 -1.045 . . . . 0.0 109.075 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.573 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.81 120.68 19.74 Favored 'General case' 0 C--N 1.29 -2.021 0 O-C-N 121.613 -0.679 . . . . 0.0 109.842 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.818 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.4 pt -98.09 170.43 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.276 -0.89 . . . . 0.0 108.896 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.515 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.9 153.96 51.29 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.127 -0.983 . . . . 0.0 109.551 179.899 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.818 ' CE2' HD12 ' A' ' 110' ' ' ILE . 67.2 m-85 . . . . . 0 N--CA 1.486 1.346 0 O-C-N 121.249 -0.907 . . . . 0.0 109.527 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.596 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.409 0 CA-C-O 122.239 1.018 . . . . 0.0 110.974 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.019 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -101.61 104.51 15.38 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 122.439 1.114 . . . . 0.0 109.864 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.939 HG22 HG23 ' A' ' 21' ' ' VAL . 4.1 t -118.84 118.97 59.55 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.462 179.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.502 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.84 147.96 9.59 Favored Pre-proline 0 C--N 1.306 -1.324 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 -179.832 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.502 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.8 Cg_endo -76.17 151.31 95.02 Favored 'Cis proline' 0 C--N 1.309 -1.541 0 C-N-CA 123.593 -1.42 . . . . 0.0 109.596 -0.406 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' HG22 ' A' ' 110' ' ' ILE . 2.5 p -90.38 -25.37 20.46 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.497 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.1 m -136.05 165.86 24.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.609 -0.682 . . . . 0.0 109.331 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.22 37.58 36.71 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 108.463 -1.855 . . . . 0.0 108.463 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.0 mt -92.27 -43.0 9.53 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 123.297 1.522 . . . . 0.0 110.44 -178.33 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.48 144.35 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.29 0 CA-C-N 113.522 -1.672 . . . . 0.0 109.788 -179.62 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.608 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 4.7 p-10 -51.27 106.2 0.13 Allowed 'General case' 0 C--N 1.301 -1.54 0 CA-C-O 121.539 0.685 . . . . 0.0 111.597 -178.385 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.401 ' H ' ' HB3' ' A' ' 70' ' ' ARG . . . 113.38 15.95 8.58 Favored Glycine 0 N--CA 1.484 1.884 0 C-N-CA 119.473 -1.346 . . . . 0.0 112.855 177.297 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.1 t -104.41 -170.88 1.83 Allowed 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 121.169 2.484 . . . . 0.0 109.727 179.176 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.731 HG13 ' C ' ' A' ' 67' ' ' LEU . 14.2 t -130.38 138.92 52.65 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.166 -178.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.569 HG11 HD11 ' A' ' 13' ' ' LEU . 33.7 m -118.18 155.04 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tttt -109.26 109.4 20.31 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.162 -0.961 . . . . 0.0 109.509 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.939 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -105.86 124.59 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.489 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.019 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.66 167.21 11.55 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.668 -1.27 . . . . 0.0 109.253 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.615 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.07 141.05 12.38 Favored Glycine 0 C--N 1.296 -1.666 0 N-CA-C 107.466 -2.254 . . . . 0.0 107.466 179.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.28 123.94 11.84 Favored 'General case' 0 C--N 1.295 -1.8 0 O-C-N 120.571 -1.546 . . . . 0.0 108.819 179.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.37 27.12 23.69 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.13 -1.51 . . . . 0.0 109.899 -179.666 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.532 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -88.06 174.33 8.34 Favored 'General case' 0 C--N 1.308 -1.227 0 O-C-N 120.788 -1.419 . . . . 0.0 108.473 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.001 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.88 97.54 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 122.257 1.027 . . . . 0.0 109.724 -179.853 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.637 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.99 77.26 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.437 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.77 33.65 0.29 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.302 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 50.5 p -145.53 112.0 5.81 Favored 'General case' 0 C--N 1.31 -1.145 0 O-C-N 120.896 -1.355 . . . . 0.0 111.448 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.59 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.52 116.19 1.5 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.934 178.286 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.478 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.0 m-30 -112.28 153.87 26.51 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.225 -0.922 . . . . 0.0 108.708 179.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -98.92 165.36 11.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.849 -1.157 . . . . 0.0 108.095 179.003 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 34' ' ' VAL . 4.8 p -145.15 116.64 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.114 -0.991 . . . . 0.0 109.878 -177.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.53 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.55 -175.97 39.07 Favored Glycine 0 N--CA 1.491 2.336 0 C-N-CA 118.267 -1.92 . . . . 0.0 111.754 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.571 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -100.22 113.75 26.67 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.622 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 85.0 m -131.88 153.81 49.84 Favored 'General case' 0 C--N 1.292 -1.901 0 O-C-N 121.6 -0.688 . . . . 0.0 109.602 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.663 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -129.88 136.78 49.92 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.448 -0.782 . . . . 0.0 110.565 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.908 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.69 114.45 26.38 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 178.318 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m -105.45 15.08 7.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.951 -1.093 . . . . 0.0 110.713 -178.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.782 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.22 -174.54 0.07 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.87 -1.144 . . . . 0.0 110.08 179.699 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 40.1 p -71.33 96.81 1.49 Allowed 'General case' 0 N--CA 1.485 1.323 0 O-C-N 121.382 -0.824 . . . . 0.0 109.878 -179.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.26 27.95 31.92 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 120.21 -0.995 . . . . 0.0 111.564 178.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.782 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -115.54 106.38 20.36 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.54 -1.565 . . . . 0.0 107.464 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.908 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -116.31 106.54 13.77 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.591 -1.318 . . . . 0.0 109.912 -177.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.123 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -96.77 113.22 24.76 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 120.821 -1.174 . . . . 0.0 108.515 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.575 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . 97.4 m -105.34 147.39 28.21 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.279 -0.888 . . . . 0.0 110.361 -178.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.604 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 32.7 t30 -97.52 135.94 21.5 Favored Pre-proline 0 N--CA 1.505 2.305 0 O-C-N 120.937 -1.102 . . . . 0.0 108.759 178.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.62 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.8 Cg_endo -74.85 26.51 0.36 Allowed 'Trans proline' 0 C--N 1.319 -1.004 0 C-N-CA 122.396 2.064 . . . . 0.0 112.29 -179.098 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.604 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -120.76 6.05 10.48 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.213 -1.554 . . . . 0.0 109.536 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.6 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.48 17.93 2.38 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 179.367 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.575 ' CE2' ' HB3' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -83.58 89.84 7.16 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.248 -178.437 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.588 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -109.99 -166.77 1.12 Allowed 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.153 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.463 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.66 135.61 0.09 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.421 -1.425 . . . . 0.0 111.573 -179.294 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.803 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.2 p -151.73 159.72 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 177.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.6 144.44 27.89 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.731 -1.231 . . . . 0.0 110.016 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.001 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.51 107.83 2.2 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 122.385 1.088 . . . . 0.0 109.342 178.563 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.555 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.7 t0 -62.72 -139.07 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.886 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.637 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.28 -52.09 29.7 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.427 -0.795 . . . . 0.0 110.727 -178.582 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -104.48 -32.48 8.98 Favored 'General case' 0 C--N 1.286 -2.155 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 178.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.972 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.67 68.22 0.65 Allowed Glycine 0 C--N 1.297 -1.587 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 178.294 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.0 m -103.47 128.94 50.54 Favored 'General case' 0 N--CA 1.483 1.224 0 O-C-N 121.336 -1.097 . . . . 0.0 109.15 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.803 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.63 108.72 7.69 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 119.469 -0.892 . . . . 0.0 109.574 -179.573 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.447 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 85.7 p -116.85 117.41 29.66 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.089 -1.007 . . . . 0.0 109.374 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.618 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.32 142.51 28.35 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.409 -0.807 . . . . 0.0 109.956 -179.794 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 25.1 p -102.14 141.32 35.15 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.496 -0.752 . . . . 0.0 109.265 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.776 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.58 167.05 23.07 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.337 -0.852 . . . . 0.0 109.509 -179.384 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.699 HG22 HG22 ' A' ' 18' ' ' VAL . 2.5 p -96.17 124.74 40.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.197 -0.94 . . . . 0.0 109.349 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.537 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 18.7 m -138.43 142.55 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.939 -1.101 . . . . 0.0 109.922 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.608 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.7 ptt180 -138.56 -164.81 1.7 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.732 -1.23 . . . . 0.0 109.908 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.564 ' HG3' ' CD1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -74.3 -82.88 0.06 Allowed 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 -179.844 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.498 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.76 136.63 57.96 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 178.698 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.663 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.46 133.49 5.75 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 118.058 -1.457 . . . . 0.0 110.562 -177.603 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.56 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 3.1 mm-40 -33.04 120.07 0.35 Allowed 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.619 0.723 . . . . 0.0 110.386 -178.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.123 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.9 50.74 2.54 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.484 -179.074 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.62 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -37.77 116.36 0.49 Allowed 'General case' 0 N--CA 1.507 2.381 0 O-C-N 121.136 -1.214 . . . . 0.0 110.157 179.365 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.653 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.2 tp -86.08 126.09 33.93 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 120.895 -1.128 . . . . 0.0 109.716 -179.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 39.3 t80 -63.62 58.42 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.015 -1.053 . . . . 0.0 110.114 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 21.2 t0 -161.01 20.27 0.13 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.904 -1.122 . . . . 0.0 109.737 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.52 -29.09 5.01 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.484 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 9.7 p -95.48 163.88 13.04 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.076 -1.249 . . . . 0.0 110.203 -179.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 3.3 ptm180 -109.25 139.85 43.64 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.653 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.6 t90 -82.0 -21.56 37.01 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.861 -1.149 . . . . 0.0 110.353 -178.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.81 175.68 18.14 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.79 110.57 2.11 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 179.037 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.615 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.1 t -82.32 102.61 8.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.652 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.608 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.97 111.21 2.75 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.489 -0.757 . . . . 0.0 109.632 -179.313 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.563 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.23 -4.93 5.8 Favored 'General case' 0 N--CA 1.498 1.973 0 C-N-CA 118.304 -1.358 . . . . 0.0 109.813 179.534 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.3 p -85.51 3.62 39.56 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.786 -1.196 . . . . 0.0 108.823 179.255 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.608 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -119.2 -49.82 2.38 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.402 -0.811 . . . . 0.0 108.959 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.71 -178.42 3.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.382 -0.824 . . . . 0.0 109.538 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.64 114.45 28.62 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.511 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.5 m -97.47 121.9 39.9 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.932 -1.105 . . . . 0.0 109.746 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.592 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.74 147.11 26.86 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.412 1.101 . . . . 0.0 111.245 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.656 ' HB ' HG11 ' A' ' 7' ' ' VAL . 52.9 t -103.62 110.82 31.13 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 106.913 -1.514 . . . . 0.0 106.913 177.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.475 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.51 -170.8 18.77 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.076 -2.012 . . . . 0.0 111.884 -177.587 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.525 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -115.96 -179.89 3.79 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 -179.167 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.515 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.4 p . . . . . 0 C--N 1.296 -1.757 0 O-C-N 121.515 -0.741 . . . . 0.0 109.317 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.624 0 N-CA-C 107.833 -2.107 . . . . 0.0 107.833 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.74 -178.16 6.87 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.572 -0.958 . . . . 0.0 109.754 179.255 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.68 -161.45 14.73 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.257 -1.937 . . . . 0.0 108.257 -179.325 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.0 Cg_exo -47.6 179.65 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.82 1.31 . . . . 0.0 110.261 179.19 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -94.05 -170.54 2.33 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.066 -1.021 . . . . 0.0 110.334 -178.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.475 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.31 162.75 18.34 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.11 128.45 50.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.381 -1.07 . . . . 0.0 109.15 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.592 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.24 119.64 15.67 Favored 'General case' 0 C--N 1.289 -2.056 0 O-C-N 121.669 -0.644 . . . . 0.0 109.738 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.884 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.12 171.31 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.219 -0.926 . . . . 0.0 109.097 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.497 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.01 156.62 47.07 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.074 -1.016 . . . . 0.0 109.844 -179.822 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.884 ' CE2' HD12 ' A' ' 110' ' ' ILE . 96.8 m-85 . . . . . 0 N--CA 1.486 1.327 0 O-C-N 121.191 -0.943 . . . . 0.0 109.609 -179.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.466 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.441 0 CA-C-O 122.354 1.074 . . . . 1.0 110.597 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.948 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.6 t -110.31 108.67 18.83 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 123.085 1.421 . . . . 1.0 109.01 179.355 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.838 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -117.19 136.36 54.6 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.702 0 CA-C-N 114.3 -1.318 . . . . 1.0 110.002 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.456 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.31 148.76 2.43 Favored Pre-proline 0 N--CA 1.487 1.376 0 O-C-N 121.287 -0.883 . . . . 1.0 108.897 -179.64 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.456 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -79.21 148.67 82.13 Favored 'Cis proline' 0 C--N 1.311 -1.408 0 C-N-CA 123.438 -1.484 . . . . 1.0 109.52 -1.052 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.644 ' HA ' HG22 ' A' ' 110' ' ' ILE . 42.8 p -88.34 -25.5 22.71 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 108.981 -0.748 . . . . 1.0 108.981 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 0.7 OUTLIER -131.91 161.86 32.03 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.454 -0.779 . . . . 1.0 109.674 -179.787 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.88 37.63 29.14 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 108.592 -1.803 . . . . 1.0 108.592 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.79 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.2 mt -92.78 -43.54 8.97 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 123.099 1.428 . . . . 1.0 110.636 -178.343 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.14 145.19 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.295 0 CA-C-N 113.571 -1.65 . . . . 1.0 110.03 -179.596 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 14.8 p-10 -51.16 106.93 0.15 Allowed 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.462 0.648 . . . . 1.0 111.564 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.47 15.22 9.02 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 119.385 -1.388 . . . . 1.0 112.871 177.217 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.79 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.5 t -104.54 -171.69 1.97 Allowed 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 121.133 2.467 . . . . 1.0 109.671 179.204 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.727 HG13 ' C ' ' A' ' 67' ' ' LEU . 15.1 t -128.58 137.56 56.99 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.387 0 CA-C-N 114.874 -1.057 . . . . 1.0 110.979 -179.066 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.527 HG11 ' CD1' ' A' ' 13' ' ' LEU . 35.2 m -114.13 154.75 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 108.808 -0.812 . . . . 1.0 108.808 179.036 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.65 109.23 20.37 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.226 -0.921 . . . . 1.0 108.797 179.718 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.838 HG23 HG22 ' A' ' 7' ' ' VAL . 2.2 p -103.82 141.6 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.727 -0.842 . . . . 1.0 108.727 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.948 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -138.24 160.23 39.99 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.72 -1.238 . . . . 1.0 109.982 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.76 144.21 15.37 Favored Glycine 0 C--N 1.295 -1.742 0 N-CA-C 108.089 -2.004 . . . . 1.0 108.089 179.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.11 125.53 13.16 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 120.913 -1.345 . . . . 1.0 108.828 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.08 27.09 26.89 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.216 -1.469 . . . . 1.0 109.912 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.576 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.8 mt -87.13 175.02 8.28 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 120.799 -1.412 . . . . 1.0 108.463 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.016 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.58 99.74 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.978 -1.076 . . . . 1.0 109.689 -179.79 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.563 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 77.76 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 115.226 -0.897 . . . . 1.0 110.247 -179.063 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.4 34.13 0.33 Allowed Glycine 0 N--CA 1.488 2.117 0 N-CA-C 109.496 -1.441 . . . . 1.0 109.496 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.56 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 42.9 p -141.24 108.56 5.53 Favored 'General case' 0 C--N 1.306 -1.302 0 O-C-N 121.123 -1.222 . . . . 1.0 111.311 -179.636 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.589 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.35 110.06 0.37 Allowed 'General case' 0 N--CA 1.497 1.888 0 CA-C-N 115.9 -0.591 . . . . 1.0 109.455 178.031 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.2 m-30 -106.75 155.99 19.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.133 -0.98 . . . . 1.0 108.982 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.486 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -99.82 165.17 11.7 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.876 -1.157 . . . . 1.0 107.876 179.045 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.692 HG13 ' O ' ' A' ' 34' ' ' VAL . 7.5 p -145.7 114.85 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.066 -1.021 . . . . 1.0 109.941 -178.048 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.01 -176.41 37.3 Favored Glycine 0 N--CA 1.492 2.398 0 C-N-CA 118.499 -1.81 . . . . 1.0 111.564 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.646 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.5 pt20 -100.1 110.02 22.31 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-O 121.941 0.877 . . . . 1.0 108.966 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -130.08 150.81 51.18 Favored 'General case' 0 C--N 1.296 -1.74 0 O-C-N 121.217 -0.927 . . . . 1.0 109.837 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.522 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -126.83 139.78 52.84 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.222 -0.924 . . . . 1.0 110.808 -179.037 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.897 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.15 114.78 26.61 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 107.62 -1.252 . . . . 1.0 107.62 178.246 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -104.6 14.99 6.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 120.938 -1.101 . . . . 1.0 110.575 -178.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.762 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.61 -176.28 0.09 Allowed 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.863 -1.148 . . . . 1.0 110.184 179.716 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.769 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.89 97.47 1.42 Allowed 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.436 -0.79 . . . . 1.0 109.847 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.63 27.8 34.32 Favored Glycine 0 N--CA 1.493 2.493 0 C-N-CA 120.145 -1.026 . . . . 1.0 111.434 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.762 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.32 106.6 20.65 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 O-C-N 120.668 -1.489 . . . . 1.0 107.171 178.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.897 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.2 tp -116.06 104.67 11.8 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.449 -1.407 . . . . 1.0 109.982 -177.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.042 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.23 109.58 22.31 Favored 'General case' 0 N--CA 1.485 1.291 0 O-C-N 120.818 -1.176 . . . . 1.0 108.079 178.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.18 166.21 10.79 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.912 -1.117 . . . . 1.0 110.356 -178.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.73 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 46.0 t30 -112.01 129.85 23.84 Favored Pre-proline 0 N--CA 1.501 2.1 0 O-C-N 121.366 -0.834 . . . . 1.0 109.796 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.634 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.5 Cg_endo -71.65 22.31 0.25 Allowed 'Trans proline' 0 CA--C 1.545 1.056 0 C-N-CA 122.219 1.946 . . . . 1.0 112.342 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.73 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -109.87 2.79 20.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.415 -1.428 . . . . 1.0 109.049 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.571 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.65 18.87 2.52 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.135 -1.432 . . . . 1.0 107.135 179.41 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -82.13 89.73 6.5 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.934 -0.707 . . . . 1.0 111.127 -178.395 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -106.97 -166.87 1.21 Allowed 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 107.562 -1.273 . . . . 1.0 107.562 178.077 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.2 136.35 0.1 Allowed 'General case' 0 C--N 1.306 -1.307 0 O-C-N 120.538 -1.351 . . . . 1.0 111.304 -179.346 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.901 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -154.46 158.8 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.635 -1.246 . . . . 1.0 107.635 178.337 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.589 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.8 142.25 30.57 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.807 -1.183 . . . . 1.0 109.901 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.53 107.12 1.06 Allowed 'General case' 0 C--N 1.299 -1.602 0 CA-C-O 122.423 1.106 . . . . 1.0 109.295 178.253 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.552 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.2 p-10 -58.88 -138.84 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.583 -0.735 . . . . 1.0 110.821 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.563 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -54.65 -49.81 69.68 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.374 -0.829 . . . . 1.0 110.231 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.421 ' OD1' ' N ' ' A' ' 61' ' ' GLY . 12.3 p30 -100.23 -38.82 8.33 Favored 'General case' 0 C--N 1.285 -2.219 0 N-CA-C 106.122 -1.807 . . . . 1.0 106.122 178.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.999 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.92 65.93 0.55 Allowed Glycine 0 C--N 1.296 -1.648 0 N-CA-C 110.239 -1.144 . . . . 1.0 110.239 178.263 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.4 m -102.82 129.12 49.39 Favored 'General case' 0 N--CA 1.483 1.19 0 O-C-N 121.49 -1.006 . . . . 1.0 108.948 179.043 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.901 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.17 108.87 6.61 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 119.274 -0.971 . . . . 1.0 109.921 -179.371 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.483 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -124.02 120.96 33.97 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.244 -0.91 . . . . 1.0 109.801 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.465 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -146.44 149.48 33.78 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.486 -0.759 . . . . 1.0 109.07 179.587 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.5 p -100.31 145.62 27.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.312 -0.867 . . . . 1.0 109.741 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.727 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -145.95 165.81 27.87 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.472 -0.768 . . . . 1.0 109.242 -179.457 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.693 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -96.53 124.88 40.66 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.0 -1.063 . . . . 1.0 109.477 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.535 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.0 m -138.74 143.1 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 120.972 -1.08 . . . . 1.0 109.808 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.596 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.6 ptt180 -140.02 -163.46 1.51 Allowed 'General case' 0 N--CA 1.486 1.351 0 O-C-N 120.593 -1.317 . . . . 1.0 109.871 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.571 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -75.03 -82.28 0.07 Allowed 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.083 -1.011 . . . . 1.0 108.87 -179.609 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.491 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -62.75 137.51 58.28 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.305 -1.497 . . . . 1.0 107.357 178.861 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.563 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.2 OUTLIER -163.22 134.09 4.69 Favored 'General case' 0 C--N 1.293 -1.863 0 C-N-CA 118.045 -1.462 . . . . 1.0 110.522 -177.656 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.486 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . 3.6 mm-40 -32.56 121.21 0.33 Allowed 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 121.642 0.734 . . . . 1.0 110.773 -178.357 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.042 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.06 49.78 3.05 Favored Glycine 0 N--CA 1.496 2.649 0 C-N-CA 120.754 -0.736 . . . . 1.0 111.546 -179.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.634 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-30 -38.57 115.42 0.46 Allowed 'General case' 0 N--CA 1.511 2.594 0 O-C-N 121.028 -1.277 . . . . 1.0 110.14 179.318 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.794 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.05 125.89 34.4 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.857 -1.152 . . . . 1.0 109.744 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -64.68 58.26 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.927 0 O-C-N 120.86 -1.15 . . . . 1.0 109.869 179.403 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -158.08 18.47 0.24 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.035 -1.04 . . . . 1.0 109.677 -179.948 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.21 -27.56 6.11 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.919 -1.272 . . . . 1.0 109.919 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -98.17 164.7 12.21 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.069 -1.253 . . . . 1.0 110.337 -179.482 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.519 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.13 140.35 41.46 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.858 -0.793 . . . . 1.0 108.858 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.794 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.2 t90 -84.2 -22.34 30.95 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.845 -1.159 . . . . 1.0 110.604 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.73 175.13 17.55 Favored Glycine 0 N--CA 1.485 1.922 0 N-CA-C 108.688 -1.765 . . . . 1.0 108.688 -179.484 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.67 112.0 2.65 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.712 -1.218 . . . . 1.0 107.712 179.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.642 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.3 t -84.55 103.95 12.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.289 -0.882 . . . . 1.0 108.928 -179.049 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.622 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -66.58 111.65 3.74 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.357 -0.839 . . . . 1.0 109.645 -179.439 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.571 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.38 -5.3 4.97 Favored 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 118.172 -1.411 . . . . 1.0 109.948 179.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 45.5 p -84.39 0.46 49.3 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.75 -1.219 . . . . 1.0 108.772 179.195 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.622 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -115.84 -50.35 2.69 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.392 -0.817 . . . . 1.0 109.054 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.29 -178.01 3.54 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.508 -0.745 . . . . 1.0 109.514 179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.09 115.36 30.04 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.369 -0.832 . . . . 1.0 108.95 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.523 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -97.29 123.2 41.02 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.901 -1.125 . . . . 1.0 109.917 -179.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.6 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.28 148.2 26.62 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-O 122.373 1.082 . . . . 1.0 111.102 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.434 ' CG1' HG11 ' A' ' 7' ' ' VAL . 61.1 t -103.23 110.2 29.09 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 N-CA-C 106.721 -1.585 . . . . 1.0 106.721 177.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.452 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.46 -172.78 18.7 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 118.08 -2.01 . . . . 1.0 111.679 -177.614 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.483 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -114.77 179.88 3.82 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.945 -0.761 . . . . 1.0 108.945 -179.175 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.486 ' O ' ' N ' ' A' ' 33' ' ' ASP . 66.9 p . . . . . 0 C--N 1.295 -1.766 0 O-C-N 121.472 -0.768 . . . . 1.0 109.291 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.722 0 N-CA-C 107.742 -2.143 . . . . 1.0 107.742 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.43 -177.96 6.92 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.675 -0.897 . . . . 1.0 109.935 179.254 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.7 -163.84 19.94 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 108.319 -1.912 . . . . 1.0 108.319 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.4 Cg_exo -47.68 177.88 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 CA-C-N 118.763 1.281 . . . . 1.0 110.233 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -94.86 -176.25 3.8 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.236 -0.915 . . . . 1.0 110.186 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.452 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.68 163.98 13.06 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.787 -1.325 . . . . 1.0 109.787 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.5 132.35 46.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.381 -1.07 . . . . 1.0 109.063 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.6 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.0 125.44 27.62 Favored 'General case' 0 C--N 1.29 -2.017 0 O-C-N 121.649 -0.657 . . . . 1.0 109.868 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.87 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.67 171.95 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.356 -0.84 . . . . 1.0 108.953 179.611 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.4 OUTLIER -136.51 156.27 48.83 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.118 -0.989 . . . . 1.0 109.58 -179.925 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.87 ' CE1' HD12 ' A' ' 110' ' ' ILE . 93.0 m-85 . . . . . 0 N--CA 1.484 1.274 0 O-C-N 121.134 -0.979 . . . . 1.0 109.506 -179.627 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.547 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.398 0 CA-C-O 122.086 0.946 . . . . 0.0 111.047 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.005 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -100.88 104.32 15.53 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-O 122.407 1.099 . . . . 0.0 109.816 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.944 HG22 HG23 ' A' ' 21' ' ' VAL . 6.2 t -119.79 118.0 55.66 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.459 0 CA-C-O 121.694 0.759 . . . . 0.0 110.405 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.78 149.08 7.93 Favored Pre-proline 0 N--CA 1.488 1.425 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 -179.568 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -75.26 152.85 98.33 Favored 'Cis proline' 0 C--N 1.309 -1.535 0 C-N-CA 123.583 -1.424 . . . . 0.0 109.762 -0.301 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.658 ' HA ' HG22 ' A' ' 110' ' ' ILE . 6.5 m -91.5 -25.0 19.48 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.498 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.8 m -137.85 165.1 27.3 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.637 -0.664 . . . . 0.0 109.253 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.27 37.49 31.8 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 108.564 -1.814 . . . . 0.0 108.564 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.741 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.0 mt -92.07 -42.43 9.95 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 123.311 1.529 . . . . 0.0 110.522 -178.487 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.67 142.67 0.05 OUTLIER 'General case' 0 C--N 1.259 -3.327 0 CA-C-N 113.405 -1.725 . . . . 0.0 109.731 -179.644 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.607 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.6 p-10 -50.28 105.78 0.1 Allowed 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.521 0.677 . . . . 0.0 111.473 -178.549 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.49 14.22 8.33 Favored Glycine 0 N--CA 1.485 1.928 0 C-N-CA 119.413 -1.375 . . . . 0.0 113.018 177.37 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.741 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -106.3 -172.57 2.11 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 121.221 2.51 . . . . 0.0 109.832 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.852 HG22 HG22 ' A' ' 68' ' ' THR . 18.8 t -129.0 139.76 51.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 CA-C-N 114.823 -1.08 . . . . 0.0 111.204 -178.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.63 HG11 HD11 ' A' ' 13' ' ' LEU . 27.1 m -115.88 155.61 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.553 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.7 tttt -107.86 108.79 20.11 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.021 -1.05 . . . . 0.0 109.552 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.944 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -106.8 122.67 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.005 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.83 167.48 11.36 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 120.795 -1.191 . . . . 0.0 109.064 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.86 142.44 13.95 Favored Glycine 0 C--N 1.295 -1.733 0 N-CA-C 107.935 -2.066 . . . . 0.0 107.935 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -147.16 123.7 11.07 Favored 'General case' 0 C--N 1.294 -1.834 0 O-C-N 120.812 -1.405 . . . . 0.0 108.64 179.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.19 27.25 23.72 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 119.313 -1.422 . . . . 0.0 109.838 -179.595 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.534 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.6 mt -87.73 175.14 8.0 Favored 'General case' 0 C--N 1.308 -1.236 0 O-C-N 120.877 -1.367 . . . . 0.0 108.466 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.61 96.95 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.017 -1.052 . . . . 0.0 109.541 -179.899 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.699 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.49 76.76 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.791 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.533 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.44 33.49 0.3 Allowed Glycine 0 N--CA 1.486 2.016 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.198 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.618 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.6 t -147.12 114.55 6.31 Favored 'General case' 0 C--N 1.308 -1.223 0 O-C-N 120.791 -1.417 . . . . 0.0 111.173 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.82 127.32 6.27 Favored 'General case' 0 N--CA 1.49 1.528 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.689 178.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.618 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 9.1 m-85 -116.33 148.61 40.4 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.529 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -101.21 149.33 24.11 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.805 -1.185 . . . . 0.0 107.92 179.135 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.634 HG23 HD23 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -127.43 126.7 67.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.271 -0.893 . . . . 0.0 109.371 -177.935 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -174.52 174.97 46.79 Favored Glycine 0 N--CA 1.495 2.612 0 C-N-CA 117.833 -2.127 . . . . 0.0 112.42 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.585 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -101.36 108.47 20.1 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.473 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.8 m -131.24 147.92 52.64 Favored 'General case' 0 C--N 1.295 -1.772 0 O-C-N 121.251 -0.905 . . . . 0.0 109.942 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.43 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.02 139.04 53.84 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.394 -0.816 . . . . 0.0 110.609 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.879 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.42 115.03 26.87 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 178.159 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -106.11 14.85 7.41 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 120.963 -1.085 . . . . 0.0 110.529 -178.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.776 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.14 -174.61 0.08 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.848 -1.157 . . . . 0.0 110.121 179.667 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 5.9 p -71.46 96.78 1.54 Allowed 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.46 -0.775 . . . . 0.0 109.931 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 27.83 32.9 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 120.171 -1.014 . . . . 0.0 111.558 178.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.776 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.26 106.28 20.24 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 O-C-N 120.552 -1.558 . . . . 0.0 107.267 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.879 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.3 tp -117.37 104.92 11.61 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.454 -1.404 . . . . 0.0 109.913 -177.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.038 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.84 109.61 22.33 Favored 'General case' 0 N--CA 1.485 1.287 0 O-C-N 120.706 -1.246 . . . . 0.0 108.296 178.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.3 t -105.97 163.93 12.36 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.041 -1.037 . . . . 0.0 110.198 -178.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.623 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 20.0 t30 -107.36 139.12 20.19 Favored Pre-proline 0 N--CA 1.502 2.16 0 O-C-N 121.327 -0.858 . . . . 0.0 109.81 -179.372 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.569 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 7.8 Cg_endo -75.88 27.73 0.39 Allowed 'Trans proline' 0 C--N 1.32 -0.964 0 C-N-CA 122.59 2.194 . . . . 0.0 112.135 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.623 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -124.44 9.61 8.47 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.242 -1.536 . . . . 0.0 109.679 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.567 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.46 15.63 2.76 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.403 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -77.69 86.92 3.97 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.856 -0.737 . . . . 0.0 111.421 -178.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.605 ' CB ' HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.34 -169.77 1.85 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 177.954 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.71 134.65 0.08 Allowed 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.57 -1.331 . . . . 0.0 111.454 -179.392 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.912 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -160.47 154.73 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 178.18 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.568 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.56 144.83 26.85 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.741 -1.225 . . . . 0.0 109.572 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.07 106.74 1.69 Allowed 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 122.48 1.134 . . . . 0.0 109.476 178.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.545 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.5 p-10 -59.78 -138.83 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.982 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.893 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.699 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.37 -50.44 59.56 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.467 -0.771 . . . . 0.0 110.548 -178.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -104.97 -34.63 7.95 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 178.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.966 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.88 68.32 0.59 Allowed Glycine 0 C--N 1.298 -1.543 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 177.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 59.4 m -103.21 129.23 50.08 Favored 'General case' 0 N--CA 1.484 1.274 0 O-C-N 121.358 -1.084 . . . . 0.0 108.83 178.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.912 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.12 109.27 7.75 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.281 -0.967 . . . . 0.0 110.073 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.6 m -110.23 118.38 36.19 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.205 -0.934 . . . . 0.0 108.787 179.499 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.458 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.24 139.08 28.45 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.436 -0.79 . . . . 0.0 110.253 -179.514 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 78.8 p -103.18 140.79 36.9 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 179.416 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.759 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -142.84 164.1 31.02 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.173 -0.955 . . . . 0.0 109.994 -179.148 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.852 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -97.59 125.49 42.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.339 -0.851 . . . . 0.0 109.129 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.553 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.2 m -136.44 143.64 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.908 -1.12 . . . . 0.0 109.803 -179.087 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.607 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -146.7 -176.12 5.06 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.44 -1.413 . . . . 0.0 111.156 -179.787 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.613 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.91 -100.54 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 -179.581 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.05 140.4 49.27 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 179.353 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.44 135.94 6.16 Favored 'General case' 0 C--N 1.294 -1.817 0 C-N-CA 118.584 -1.246 . . . . 0.0 109.764 -177.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.553 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 3.9 mm-40 -33.07 121.47 0.37 Allowed 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.547 0.689 . . . . 0.0 110.431 -178.482 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.038 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.89 48.08 2.74 Favored Glycine 0 N--CA 1.492 2.408 0 C-N-CA 120.602 -0.808 . . . . 0.0 111.195 -179.177 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.569 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -38.22 115.18 0.42 Allowed 'General case' 0 N--CA 1.511 2.623 0 O-C-N 121.118 -1.225 . . . . 0.0 109.974 179.695 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.689 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.29 125.76 34.42 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.944 -1.098 . . . . 0.0 109.321 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.6 t80 -64.2 58.65 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.891 -1.131 . . . . 0.0 110.215 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t0 -160.67 20.0 0.14 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.973 -1.079 . . . . 0.0 109.749 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.93 -27.8 5.3 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.439 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 80.7 p -94.22 159.42 15.14 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.038 -1.272 . . . . 0.0 110.269 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.495 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 4.4 ptt180 -107.32 137.59 45.09 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.689 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.9 t90 -83.76 -18.51 37.53 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.821 -1.174 . . . . 0.0 110.79 -178.231 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.97 175.08 19.8 Favored Glycine 0 N--CA 1.485 1.937 0 N-CA-C 108.711 -1.755 . . . . 0.0 108.711 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.21 106.77 1.15 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.604 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.4 t -79.1 106.41 10.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.286 -0.884 . . . . 0.0 109.264 -179.025 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.638 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -65.84 111.13 3.12 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.533 -0.73 . . . . 0.0 109.904 -179.442 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.613 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.26 -4.97 4.21 Favored 'General case' 0 N--CA 1.499 1.98 0 C-N-CA 118.246 -1.382 . . . . 0.0 109.814 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -86.39 -0.49 56.06 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.891 -1.131 . . . . 0.0 109.156 179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.638 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -113.31 -50.05 2.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.392 -0.818 . . . . 0.0 109.013 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.74 179.96 4.12 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.453 -0.779 . . . . 0.0 109.427 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.69 115.73 31.03 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.366 -0.834 . . . . 0.0 109.103 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.72 121.07 38.16 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.917 -1.114 . . . . 0.0 109.383 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.605 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.18 146.15 27.2 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-O 122.273 1.035 . . . . 0.0 111.193 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.447 ' HB ' HG11 ' A' ' 7' ' ' VAL . 71.7 t -105.73 112.2 38.12 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.168 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.516 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -152.49 -169.98 18.44 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 118.018 -2.039 . . . . 0.0 111.578 -178.011 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.634 HD23 HG23 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -112.64 -179.0 3.54 Favored 'General case' 0 N--CA 1.484 1.272 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -179.189 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.487 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.637 0 O-C-N 121.17 -0.956 . . . . 0.0 109.826 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.679 0 N-CA-C 107.709 -2.156 . . . . 0.0 107.709 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.26 -177.73 6.22 Favored 'General case' 0 C--N 1.307 -1.266 0 O-C-N 121.553 -0.969 . . . . 0.0 109.681 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.497 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -162.57 -159.47 10.37 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.275 -1.93 . . . . 0.0 108.275 -179.215 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.497 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.4 Cg_exo -47.21 179.98 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.675 0 CA-C-N 118.667 1.234 . . . . 0.0 110.37 179.183 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -92.57 -178.27 4.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.033 -1.042 . . . . 0.0 110.645 -178.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.516 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.02 163.57 13.25 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.402 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.08 128.79 54.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.422 -1.046 . . . . 0.0 109.214 -179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.605 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.86 119.04 15.48 Favored 'General case' 0 C--N 1.29 -2.016 0 O-C-N 121.721 -0.612 . . . . 0.0 109.491 179.576 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.897 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.01 171.52 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.248 -0.908 . . . . 0.0 109.042 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.498 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -138.8 159.59 41.74 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.161 -0.962 . . . . 0.0 109.986 -179.696 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.897 ' CE2' HD12 ' A' ' 110' ' ' ILE . 96.8 m-85 . . . . . 0 N--CA 1.485 1.312 0 O-C-N 121.18 -0.95 . . . . 0.0 109.582 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.545 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.429 0 CA-C-O 122.274 1.035 . . . . 0.0 110.429 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.941 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.4 t -109.74 108.69 19.13 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 123.05 1.405 . . . . 0.0 109.286 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.815 HG22 HG23 ' A' ' 21' ' ' VAL . 1.3 t -116.32 136.35 53.59 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.689 0 CA-C-N 114.164 -1.38 . . . . 0.0 109.903 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.461 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -172.88 149.05 1.78 Allowed Pre-proline 0 N--CA 1.487 1.405 0 O-C-N 121.194 -0.941 . . . . 0.0 108.883 -179.616 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.461 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.2 Cg_endo -77.24 151.33 93.05 Favored 'Cis proline' 0 C--N 1.313 -1.332 0 C-N-CA 123.404 -1.498 . . . . 0.0 109.323 -0.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 16.6 p -86.83 -26.86 23.84 Favored 'General case' 0 C--N 1.295 -1.803 0 O-C-N 121.455 -0.778 . . . . 0.0 109.169 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.498 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.4 m -134.62 168.23 19.38 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.409 -0.807 . . . . 0.0 109.463 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.03 38.51 35.16 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 108.359 -1.896 . . . . 0.0 108.359 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.744 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.2 mt -94.81 -42.61 8.62 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 123.186 1.47 . . . . 0.0 110.65 -178.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.91 143.69 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.289 0 CA-C-N 113.334 -1.757 . . . . 0.0 109.889 -179.55 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 11.9 p-10 -50.3 104.62 0.08 Allowed 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.53 0.681 . . . . 0.0 111.469 -178.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.17 14.44 7.74 Favored Glycine 0 N--CA 1.485 1.91 0 C-N-CA 119.321 -1.419 . . . . 0.0 113.09 177.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.744 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.5 t -106.47 -172.47 2.09 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 121.336 2.568 . . . . 0.0 109.876 179.312 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.744 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.4 t -128.21 136.78 59.24 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.328 0 CA-C-N 114.733 -1.121 . . . . 0.0 111.242 -178.741 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.64 HG11 HD11 ' A' ' 13' ' ' LEU . 27.8 m -111.08 157.22 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.521 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 4.0 tptm -106.83 109.17 21.01 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.033 -1.042 . . . . 0.0 108.933 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.815 HG23 HG22 ' A' ' 7' ' ' VAL . 7.6 p -103.55 141.05 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.941 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -138.79 161.52 37.03 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.718 -1.238 . . . . 0.0 110.061 179.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.594 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.46 143.69 15.01 Favored Glycine 0 C--N 1.294 -1.763 0 N-CA-C 108.355 -1.898 . . . . 0.0 108.355 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.14 125.68 13.27 Favored 'General case' 0 C--N 1.295 -1.774 0 O-C-N 120.914 -1.345 . . . . 0.0 108.996 178.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.477 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 87.45 25.92 31.82 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 119.312 -1.423 . . . . 0.0 110.116 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.601 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.2 mt -86.15 172.55 10.46 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 120.937 -1.331 . . . . 0.0 108.474 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.015 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.76 100.14 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.009 -1.057 . . . . 0.0 109.651 -179.704 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.562 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 77.83 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.147 -179.165 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.81 34.03 0.32 Allowed Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 179.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.565 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.7 p -140.71 108.13 5.56 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 121.183 -1.186 . . . . 0.0 111.153 -179.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.586 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.98 111.64 0.59 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.535 177.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.464 ' OH ' ' HB2' ' A' ' 27' ' ' GLN . 6.0 m-30 -107.14 156.34 18.91 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.129 -0.982 . . . . 0.0 108.935 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.475 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.8 160.5 14.22 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 178.933 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.632 HG22 HG11 ' A' ' 21' ' ' VAL . 5.3 p -140.94 119.26 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.129 -0.982 . . . . 0.0 109.678 -177.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -171.64 -177.36 41.27 Favored Glycine 0 N--CA 1.494 2.513 0 C-N-CA 118.443 -1.836 . . . . 0.0 111.532 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.684 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -98.73 109.13 21.93 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.723 0.773 . . . . 0.0 108.944 -179.95 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -129.09 149.35 50.94 Favored 'General case' 0 C--N 1.295 -1.783 0 O-C-N 121.236 -0.915 . . . . 0.0 109.964 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.586 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.92 138.88 54.23 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.255 -0.903 . . . . 0.0 110.838 -179.009 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.05 26.9 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.037 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -105.32 15.16 6.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.903 -1.123 . . . . 0.0 110.585 -178.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.751 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.03 -175.29 0.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.886 -1.134 . . . . 0.0 110.08 179.722 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -72.37 97.41 2.04 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.394 -0.816 . . . . 0.0 109.687 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.34 27.97 31.65 Favored Glycine 0 N--CA 1.493 2.45 0 C-N-CA 120.177 -1.011 . . . . 0.0 111.385 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.751 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.92 106.43 20.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 120.534 -1.568 . . . . 0.0 107.165 178.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.48 104.72 11.72 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.479 -1.388 . . . . 0.0 109.937 -177.533 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.058 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.0 109.63 22.35 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 178.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.486 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -108.52 162.42 14.15 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.876 -1.14 . . . . 0.0 110.54 -178.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.502 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 7.8 t30 -108.72 130.3 22.91 Favored Pre-proline 0 N--CA 1.499 2.004 0 O-C-N 121.551 -0.718 . . . . 0.0 109.553 -179.377 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.592 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.56 21.35 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.078 0 C-N-CA 122.028 1.819 . . . . 0.0 112.021 179.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.502 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -99.41 -3.99 32.53 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.421 -1.424 . . . . 0.0 108.995 179.409 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.68 ' OD2' HG13 ' A' ' 69' ' ' VAL . 5.9 m-20 -135.62 9.89 3.4 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -66.84 86.18 0.13 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.499 -0.75 . . . . 0.0 111.059 -178.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.612 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -108.5 -167.29 1.21 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 177.912 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.32 134.47 0.09 Allowed 'General case' 0 C--N 1.305 -1.34 0 O-C-N 120.503 -1.373 . . . . 0.0 111.451 -179.22 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.866 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -150.24 157.77 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 177.923 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.586 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.71 142.72 29.91 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.766 -1.209 . . . . 0.0 110.113 -179.685 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.015 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.67 107.12 1.09 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.398 1.094 . . . . 0.0 109.336 178.338 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.547 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -59.37 -139.08 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.056 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.856 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.562 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.73 -49.84 64.61 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.462 -0.774 . . . . 0.0 110.496 -178.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.477 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.6 t-20 -103.57 -35.17 8.4 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 178.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.009 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.95 66.78 0.58 Allowed Glycine 0 C--N 1.298 -1.579 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 177.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.9 m -104.54 128.92 52.62 Favored 'General case' 0 C--N 1.308 -1.223 0 O-C-N 121.308 -1.113 . . . . 0.0 108.683 178.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.866 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.69 109.91 8.92 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.184 -1.006 . . . . 0.0 109.668 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 91.7 p -117.75 117.77 30.24 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.367 -0.833 . . . . 0.0 109.481 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.547 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -147.31 151.29 36.34 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.422 -0.799 . . . . 0.0 109.42 -179.957 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.748 ' O ' HD23 ' A' ' 67' ' ' LEU . 69.6 p -98.52 153.57 18.53 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.304 -0.872 . . . . 0.0 109.571 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.785 HD11 HG11 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -147.92 160.1 43.17 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.339 -0.851 . . . . 0.0 109.634 -179.176 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.653 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -100.55 122.85 43.92 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.971 -1.08 . . . . 0.0 108.58 179.261 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.684 HG12 ' HB3' ' A' ' 36' ' ' GLN . 19.2 m -136.41 143.06 36.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 120.799 -1.188 . . . . 0.0 110.459 -178.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.1 ptt180 -146.43 -175.27 4.71 Favored 'General case' 0 N--CA 1.483 1.205 0 O-C-N 120.749 -1.219 . . . . 0.0 110.663 179.654 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.604 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.79 -102.03 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -179.733 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.496 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -56.02 140.27 43.99 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.761 -1.212 . . . . 0.0 108.244 179.401 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.586 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.4 OUTLIER -160.74 137.93 9.13 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 118.672 -1.211 . . . . 0.0 110.009 -178.285 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.484 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.7 OUTLIER -35.43 120.68 0.57 Allowed 'General case' 0 N--CA 1.49 1.563 0 CA-C-O 121.522 0.677 . . . . 0.0 110.618 -178.439 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.058 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.17 50.47 2.18 Favored Glycine 0 N--CA 1.493 2.486 0 O-C-N 121.551 -0.718 . . . . 0.0 111.37 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.592 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.8 m-85 -39.11 114.87 0.43 Allowed 'General case' 0 N--CA 1.511 2.616 0 O-C-N 120.947 -1.325 . . . . 0.0 109.89 179.536 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.724 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -87.25 125.24 34.07 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.771 -1.206 . . . . 0.0 109.306 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 18.7 t80 -64.78 56.31 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.062 0 O-C-N 120.742 -1.224 . . . . 0.0 110.491 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.618 ' OD2' HD23 ' A' ' 77' ' ' LEU . 2.9 p30 -154.79 16.18 0.44 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.998 -1.064 . . . . 0.0 109.859 179.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.53 -27.03 10.18 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.427 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -100.87 161.17 13.78 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.901 -1.352 . . . . 0.0 110.38 -179.408 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.434 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 3.6 ptm180 -103.77 139.36 39.11 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.605 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.724 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.2 t90 -82.44 -19.83 38.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.917 -1.114 . . . . 0.0 110.599 -178.276 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.64 175.66 18.71 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -66.41 104.77 1.3 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.174 -1.192 . . . . 0.0 107.848 179.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.648 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.7 t -75.31 106.88 5.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.286 -0.884 . . . . 0.0 109.56 -178.736 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.665 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -64.97 110.65 2.53 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.421 -0.8 . . . . 0.0 109.759 -179.679 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.604 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.23 -5.18 4.53 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.533 -1.354 . . . . 0.0 109.766 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.7 p -86.45 -0.28 55.67 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.779 -1.2 . . . . 0.0 109.136 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.665 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -114.52 -51.24 2.76 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.326 -0.859 . . . . 0.0 109.026 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.403 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -102.85 -178.83 3.78 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.445 -0.784 . . . . 0.0 109.413 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.68 115.05 29.59 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.868 . . . . 0.0 108.983 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -96.91 122.18 39.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.855 -1.153 . . . . 0.0 109.478 -179.247 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.611 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.28 145.64 29.16 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-O 122.341 1.067 . . . . 0.0 111.284 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.653 ' CG1' HG11 ' A' ' 7' ' ' VAL . 99.5 t -101.59 109.79 26.78 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 177.637 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.509 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.95 -169.56 17.58 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.052 -2.023 . . . . 0.0 111.733 -177.536 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.545 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -120.79 177.47 5.08 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 -179.1 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.432 ' O ' ' N ' ' A' ' 33' ' ' ASP . 2.5 t . . . . . 0 C--N 1.292 -1.923 0 O-C-N 121.588 -0.695 . . . . 0.0 109.59 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.446 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.481 1.684 0 N-CA-C 108.143 -1.983 . . . . 0.0 108.143 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -167.78 -176.88 3.25 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 121.62 -0.93 . . . . 0.0 109.853 179.358 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.1 -160.7 16.32 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.315 -1.914 . . . . 0.0 108.315 -179.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.3 Cg_exo -47.2 179.25 0.0 OUTLIER 'Trans proline' 0 C--O 1.216 -0.607 0 CA-C-N 118.829 1.315 . . . . 0.0 110.395 179.324 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -96.22 -175.69 3.44 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.028 -1.045 . . . . 0.0 110.309 -179.099 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.509 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.91 163.82 13.74 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.41 HG11 ' HB ' ' A' ' 7' ' ' VAL . 1.2 t -99.0 127.36 51.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.39 -1.065 . . . . 0.0 109.062 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.611 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -70.34 120.42 15.97 Favored 'General case' 0 C--N 1.289 -2.022 0 O-C-N 121.778 -0.576 . . . . 0.0 109.662 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.875 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.98 170.55 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.234 -0.916 . . . . 0.0 109.131 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.498 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.99 157.56 45.47 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.263 -0.898 . . . . 0.0 109.895 -179.717 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.875 ' CE2' HD12 ' A' ' 110' ' ' ILE . 91.7 m-85 . . . . . 0 N--CA 1.486 1.343 0 O-C-N 121.271 -0.893 . . . . 0.0 109.587 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.523 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.446 0 CA-C-O 122.265 1.031 . . . . 0.0 110.762 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.94 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -111.35 108.63 18.29 Favored 'General case' 0 C--N 1.295 -1.762 0 CA-C-O 123.068 1.413 . . . . 0.0 109.084 179.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.831 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -115.26 140.68 35.44 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.73 0 CA-C-N 114.321 -1.308 . . . . 0.0 110.26 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.476 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -175.56 149.07 1.06 Allowed Pre-proline 0 N--CA 1.487 1.396 0 O-C-N 121.337 -0.852 . . . . 0.0 108.854 -179.751 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.476 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.3 Cg_endo -78.63 150.47 87.33 Favored 'Cis proline' 0 C--N 1.311 -1.399 0 C-N-CA 123.36 -1.516 . . . . 0.0 109.09 -0.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.67 ' HA ' HG22 ' A' ' 110' ' ' ILE . 75.9 p -89.73 -24.58 21.5 Favored 'General case' 0 C--N 1.291 -1.947 0 O-C-N 121.53 -0.731 . . . . 0.0 109.358 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.507 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 12.9 m -134.83 162.8 31.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.346 -0.846 . . . . 0.0 109.757 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.88 37.67 29.06 Favored Glycine 0 N--CA 1.496 2.667 0 N-CA-C 108.604 -1.798 . . . . 0.0 108.604 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.78 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.0 mt -92.56 -44.24 8.72 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-O 123.19 1.472 . . . . 0.0 110.606 -178.369 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.457 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.66 144.07 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.331 0 CA-C-N 113.48 -1.691 . . . . 0.0 110.135 -179.775 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.616 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.2 p-10 -49.74 107.84 0.17 Allowed 'General case' 0 C--N 1.301 -1.526 0 CA-C-O 121.712 0.768 . . . . 0.0 111.471 -178.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.47 12.93 9.22 Favored Glycine 0 N--CA 1.484 1.855 0 C-N-CA 119.45 -1.357 . . . . 0.0 112.939 177.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.78 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.6 t -105.76 -173.05 2.21 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 121.251 2.525 . . . . 0.0 109.663 179.237 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.74 HG13 ' C ' ' A' ' 67' ' ' LEU . 20.9 t -127.1 135.01 64.79 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.45 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.035 -178.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.601 ' CG1' HD13 ' A' ' 13' ' ' LEU . 36.0 m -108.68 155.53 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.58 109.4 18.56 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.092 -1.005 . . . . 0.0 108.945 179.885 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.831 HG23 HG22 ' A' ' 7' ' ' VAL . 2.2 p -104.58 140.56 22.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.94 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.24 160.09 39.48 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 118.691 -1.204 . . . . 0.0 109.699 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.23 145.28 16.52 Favored Glycine 0 C--N 1.295 -1.712 0 N-CA-C 108.109 -1.996 . . . . 0.0 108.109 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.79 124.98 12.16 Favored 'General case' 0 C--N 1.296 -1.755 0 O-C-N 120.978 -1.307 . . . . 0.0 108.779 178.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.475 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 89.36 26.58 25.24 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.264 -1.446 . . . . 0.0 109.888 -179.587 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.592 HD22 ' HG3' ' A' ' 105' ' ' PRO . 2.0 mt -87.17 175.69 7.94 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 120.872 -1.369 . . . . 0.0 108.421 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.66 98.02 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.398 0 O-C-N 120.93 -1.106 . . . . 0.0 109.702 -179.597 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.651 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.57 77.44 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.737 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.511 -179.176 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.555 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.14 34.42 0.33 Allowed Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.55 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.1 p -146.25 111.92 5.58 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.039 -1.271 . . . . 0.0 111.223 -179.686 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.559 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.08 127.76 5.57 Favored 'General case' 0 N--CA 1.492 1.659 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.683 178.207 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.515 ' CD2' ' O ' ' A' ' 30' ' ' THR . 13.2 m-85 -118.5 150.57 39.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.327 -0.858 . . . . 0.0 108.881 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.518 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -100.52 153.15 19.61 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.64 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.655 HG22 HG11 ' A' ' 21' ' ' VAL . 4.2 p -137.55 119.03 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.844 -1.16 . . . . 0.0 110.043 -177.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.518 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.74 -178.88 40.59 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.673 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.57 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -99.73 109.12 21.59 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 -179.943 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.48 148.78 52.33 Favored 'General case' 0 C--N 1.295 -1.795 0 O-C-N 121.285 -0.885 . . . . 0.0 109.881 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.6 137.42 54.9 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.3 -0.875 . . . . 0.0 110.883 -179.094 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.868 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.54 114.9 26.71 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 178.009 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.1 m -105.73 14.69 7.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.053 -1.029 . . . . 0.0 110.707 -178.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.756 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.6 -175.11 0.08 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.901 -1.125 . . . . 0.0 110.106 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 28.0 p -72.59 98.56 2.35 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.45 -0.781 . . . . 0.0 109.623 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.2 27.16 34.33 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 120.226 -0.988 . . . . 0.0 111.342 178.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.756 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.02 106.04 19.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.55 -1.559 . . . . 0.0 107.295 178.829 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.868 HD13 ' NE1' ' A' ' 39' ' ' TRP . 14.0 tp -118.86 104.34 10.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.458 -1.401 . . . . 0.0 109.822 -177.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.027 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.22 109.58 22.32 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.868 -1.145 . . . . 0.0 108.246 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.54 166.23 10.71 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.982 -1.074 . . . . 0.0 110.269 -178.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.714 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.0 t-20 -108.87 134.82 20.22 Favored Pre-proline 0 N--CA 1.499 2.01 0 O-C-N 121.364 -0.835 . . . . 0.0 109.639 -179.416 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.589 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.1 Cg_endo -74.85 24.66 0.38 Allowed 'Trans proline' 0 CA--C 1.545 1.055 0 C-N-CA 122.277 1.985 . . . . 0.0 111.949 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.714 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -117.18 4.34 12.66 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.498 -1.376 . . . . 0.0 109.297 179.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.26 17.54 2.78 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.285 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -81.97 86.96 6.45 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.922 -178.562 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.6 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -104.98 -165.89 1.18 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.334 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.449 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.01 135.77 0.09 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 120.609 -1.307 . . . . 0.0 111.449 -179.284 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.904 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -152.66 156.61 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 178.08 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.559 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.58 145.34 26.36 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.602 -1.312 . . . . 0.0 109.921 -179.611 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.34 107.54 1.66 Allowed 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 122.384 1.087 . . . . 0.0 109.57 178.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.532 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.2 p-10 -60.87 -138.92 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.944 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.841 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.651 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.33 -50.62 59.07 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.509 -0.744 . . . . 0.0 110.673 -178.632 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.475 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.3 t-20 -104.35 -33.99 8.45 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 178.548 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.991 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.13 65.41 0.56 Allowed Glycine 0 C--N 1.297 -1.617 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 178.076 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.2 m -101.6 128.48 47.85 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.505 -0.997 . . . . 0.0 108.549 178.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.904 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.68 108.8 6.78 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.057 -1.057 . . . . 0.0 109.884 -179.21 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.2 m -121.0 118.96 31.17 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.361 -0.837 . . . . 0.0 109.371 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.563 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.63 143.74 30.91 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.392 -0.818 . . . . 0.0 109.479 179.83 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.423 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 28.9 p -99.06 146.97 25.52 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.4 -0.813 . . . . 0.0 109.411 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.783 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -147.42 167.97 23.05 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.393 -0.817 . . . . 0.0 109.368 -179.251 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.663 HG22 HG22 ' A' ' 18' ' ' VAL . 4.6 p -94.49 124.73 38.69 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.903 -1.123 . . . . 0.0 109.859 -179.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.598 ' CG2' HG13 ' A' ' 19' ' ' VAL . 15.8 m -136.46 144.98 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.997 -1.064 . . . . 0.0 109.206 -179.695 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.616 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.3 ptt180 -147.56 -178.49 6.28 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.327 -1.483 . . . . 0.0 111.346 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.727 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -50.07 -98.17 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -179.569 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.541 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 1.0 OUTLIER -63.79 146.69 53.45 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.57 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.609 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.8 OUTLIER -166.18 141.76 4.75 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 118.03 -1.468 . . . . 0.0 110.243 -177.276 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.548 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.9 mm-40 -36.03 120.71 0.64 Allowed 'General case' 0 N--CA 1.491 1.619 0 CA-C-O 121.475 0.655 . . . . 0.0 110.308 -178.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.027 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.59 51.46 1.79 Allowed Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.589 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -39.35 113.74 0.35 Allowed 'General case' 0 N--CA 1.507 2.401 0 O-C-N 121.093 -1.24 . . . . 0.0 110.142 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.686 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -85.28 126.35 33.64 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 120.958 -1.089 . . . . 0.0 109.415 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -64.33 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.963 0 O-C-N 120.82 -1.175 . . . . 0.0 110.105 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.7 t0 -160.07 19.76 0.16 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.982 -1.074 . . . . 0.0 109.648 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.91 -27.65 5.36 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 110.063 -1.215 . . . . 0.0 110.063 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.448 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.15 157.6 16.0 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.04 -1.27 . . . . 0.0 110.446 -179.395 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.476 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 1.8 ptm180 -104.87 136.15 44.91 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.686 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.5 t90 -82.86 -16.47 47.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.761 -1.212 . . . . 0.0 110.689 -178.26 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.08 175.43 20.83 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 108.828 -1.709 . . . . 0.0 108.828 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.72 103.51 0.7 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 179.14 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.614 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.8 t -74.54 107.42 5.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.384 -0.823 . . . . 0.0 109.566 -178.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.541 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -67.09 112.0 4.18 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.581 -0.699 . . . . 0.0 109.685 -179.556 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.727 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 11.0 m -60.96 -5.71 1.5 Allowed 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.104 -1.439 . . . . 0.0 110.35 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.02 -4.43 58.79 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.396 -1.44 . . . . 0.0 109.53 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.511 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -104.0 -48.0 4.02 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.202 -0.936 . . . . 0.0 108.886 179.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -112.55 -178.3 3.37 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.573 -0.704 . . . . 0.0 109.33 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.37 117.3 34.44 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.375 -0.828 . . . . 0.0 109.02 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.509 ' O ' HG12 ' A' ' 110' ' ' ILE . 3.9 m -96.47 122.77 39.72 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.866 -1.146 . . . . 0.0 109.344 -179.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.58 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mp0 -106.7 145.48 31.95 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 122.404 1.097 . . . . 0.0 111.685 -179.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.483 ' CG1' ' HB ' ' A' ' 21' ' ' VAL . 62.0 t -100.83 109.71 26.05 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 177.428 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.5 -172.2 16.58 Favored Glycine 0 N--CA 1.487 2.052 0 C-N-CA 118.257 -1.925 . . . . 0.0 111.622 -177.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.523 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -117.04 -179.22 3.63 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -178.874 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 8.4 p . . . . . 0 C--N 1.296 -1.727 0 O-C-N 121.369 -0.832 . . . . 0.0 109.09 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.814 0 N-CA-C 107.552 -2.219 . . . . 0.0 107.552 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.75 -179.02 7.79 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.432 -1.04 . . . . 0.0 109.561 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -174.41 -165.8 31.46 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.592 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.7 Cg_exo -49.64 -174.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 CA-C-N 118.778 1.289 . . . . 0.0 110.472 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -93.9 -179.61 5.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.113 -0.992 . . . . 0.0 110.373 -179.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -116.66 158.64 14.36 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.466 HG11 ' HB ' ' A' ' 7' ' ' VAL . 1.2 t -98.76 124.93 52.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.362 -1.081 . . . . 0.0 109.056 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.58 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.54 120.91 18.81 Favored 'General case' 0 C--N 1.29 -2.005 0 O-C-N 121.804 -0.56 . . . . 0.0 109.707 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.87 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -98.02 169.1 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.255 -0.903 . . . . 0.0 109.241 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.507 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.72 155.22 50.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.307 -0.871 . . . . 0.0 109.48 179.993 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.87 ' CE1' HD12 ' A' ' 110' ' ' ILE . 74.5 m-85 . . . . . 0 N--CA 1.486 1.349 0 O-C-N 121.164 -0.96 . . . . 0.0 109.468 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.129 0 CA-C-O 122.361 1.077 . . . . 0.0 110.672 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.012 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.6 p -104.2 104.57 14.51 Favored 'General case' 0 C--N 1.296 -1.724 0 CA-C-O 122.49 1.138 . . . . 0.0 110.115 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.959 HG22 HG23 ' A' ' 21' ' ' VAL . 16.2 t -119.8 115.61 47.99 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.46 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.292 179.681 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.49 148.8 13.14 Favored Pre-proline 0 N--CA 1.487 1.407 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -179.583 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.1 Cg_endo -77.92 150.22 89.08 Favored 'Cis proline' 0 C--N 1.309 -1.528 0 C-N-CA 123.606 -1.414 . . . . 0.0 109.737 -0.397 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.656 ' HA ' HG22 ' A' ' 110' ' ' ILE . 40.1 p -89.05 -26.4 21.43 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.535 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 6.0 p -133.07 165.19 25.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.522 -0.736 . . . . 0.0 109.423 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.14 37.51 37.3 Favored Glycine 0 N--CA 1.496 2.652 0 N-CA-C 108.402 -1.879 . . . . 0.0 108.402 -179.548 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.775 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.6 mt -92.51 -42.98 9.41 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 123.328 1.537 . . . . 0.0 110.491 -178.26 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.28 143.94 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.29 0 CA-C-N 113.319 -1.764 . . . . 0.0 109.858 -179.548 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.599 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.0 p-10 -50.38 106.2 0.12 Allowed 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.398 0.618 . . . . 0.0 111.666 -178.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.53 14.4 8.89 Favored Glycine 0 N--CA 1.485 1.924 0 C-N-CA 119.42 -1.371 . . . . 0.0 113.022 177.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.775 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.96 -172.66 2.14 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 121.15 2.475 . . . . 0.0 109.864 179.246 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.894 HG22 HG22 ' A' ' 68' ' ' THR . 18.8 t -130.4 140.19 49.46 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.285 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.24 -178.774 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.528 HG11 HD11 ' A' ' 13' ' ' LEU . 30.0 m -117.25 155.52 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.544 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.5 OUTLIER -107.19 109.15 20.89 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.087 -1.008 . . . . 0.0 109.572 -179.8 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.959 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -106.47 121.51 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.012 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.49 165.94 11.99 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.875 -1.141 . . . . 0.0 108.976 179.75 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.606 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.58 107.98 0.49 Allowed Glycine 0 N--CA 1.481 1.668 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.423 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.81 139.78 50.2 Favored 'General case' 0 N--CA 1.499 2.002 0 CA-C-N 119.218 1.509 . . . . 0.0 110.27 -179.43 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.82 28.86 30.6 Favored Glycine 0 N--CA 1.49 2.286 0 C-N-CA 118.792 -1.671 . . . . 0.0 109.782 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.527 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.4 mt -93.13 174.54 7.17 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.085 -1.244 . . . . 0.0 108.458 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.87 98.99 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.949 -1.094 . . . . 0.0 109.498 -179.718 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.588 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -57.05 76.59 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.282 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.33 33.96 0.26 Allowed Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.558 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 82.2 p -144.46 111.41 5.81 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 120.966 -1.314 . . . . 0.0 111.144 -179.668 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.588 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.49 112.65 0.57 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.895 178.308 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.53 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 14.4 m-85 -104.51 150.19 24.81 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.206 -0.933 . . . . 0.0 108.746 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.493 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -99.62 158.57 15.67 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 178.564 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.014 HG11 HG21 ' A' ' 65' ' ' THR . 6.2 p -141.67 116.46 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.006 -1.059 . . . . 0.0 110.042 -177.69 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.535 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.45 -176.54 39.41 Favored Glycine 0 N--CA 1.493 2.462 0 C-N-CA 118.338 -1.886 . . . . 0.0 111.674 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.585 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.5 OUTLIER -100.49 109.11 21.21 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 121.928 0.87 . . . . 0.0 108.82 -179.571 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.461 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.6 m -129.55 148.65 51.47 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.212 -0.93 . . . . 0.0 109.882 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.507 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.93 138.57 54.64 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.375 -0.828 . . . . 0.0 110.669 -179.027 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.882 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.91 26.73 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.039 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -105.88 14.9 7.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.894 -1.129 . . . . 0.0 110.617 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.766 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.6 -175.81 0.08 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.844 -1.16 . . . . 0.0 110.116 179.667 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.781 HG23 ' O ' ' A' ' 42' ' ' THR . 15.2 t -70.57 97.28 1.29 Allowed 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.866 0.841 . . . . 0.0 109.946 -179.55 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.44 27.7 35.21 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 120.181 -1.009 . . . . 0.0 111.391 178.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.766 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.5 106.24 20.1 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.592 -1.534 . . . . 0.0 107.258 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.882 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.9 tp -116.62 104.55 11.5 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 120.428 -1.42 . . . . 0.0 109.848 -177.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.078 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.32 109.24 22.03 Favored 'General case' 0 N--CA 1.484 1.253 0 O-C-N 120.842 -1.161 . . . . 0.0 108.119 178.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.2 t -105.94 163.09 13.02 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.993 -1.067 . . . . 0.0 109.871 -179.144 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.618 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 23.6 t30 -105.66 137.02 19.19 Favored Pre-proline 0 N--CA 1.503 2.21 0 O-C-N 121.289 -0.882 . . . . 0.0 109.972 -179.055 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.516 ' HD2' ' HB2' ' A' ' 74' ' ' GLU . 4.2 Cg_endo -73.77 24.25 0.33 Allowed 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 122.467 2.111 . . . . 0.0 112.323 -179.538 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.618 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -119.74 5.07 11.0 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.278 -1.513 . . . . 0.0 109.261 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.576 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.8 15.37 2.89 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 179.164 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -82.43 89.33 6.61 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.815 -0.754 . . . . 0.0 110.971 -178.517 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.634 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.27 -168.83 1.45 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 178.02 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.78 135.47 0.09 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 120.496 -1.377 . . . . 0.0 111.516 -179.243 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.833 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -153.7 158.18 4.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 177.963 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.588 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.15 143.88 28.21 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 120.638 -1.289 . . . . 0.0 109.777 -179.662 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.47 107.05 1.56 Allowed 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 122.307 1.051 . . . . 0.0 109.547 178.781 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.549 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.1 t0 -61.58 -139.38 0.0 OUTLIER 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.824 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.588 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.2 -51.57 42.99 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.361 -0.837 . . . . 0.0 110.704 -178.699 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -103.96 -32.75 9.1 Favored 'General case' 0 C--N 1.288 -2.109 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 178.562 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.98 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 105.08 69.17 0.75 Allowed Glycine 0 C--N 1.297 -1.589 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 178.194 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.606 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 24.3 m -104.19 126.34 51.21 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 121.684 -0.892 . . . . 0.0 108.838 178.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.833 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.85 109.04 8.26 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 119.644 -0.822 . . . . 0.0 109.486 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.477 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 6.4 m -117.5 115.67 25.61 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.271 -0.893 . . . . 0.0 109.398 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 1.014 HG21 HG11 ' A' ' 34' ' ' VAL . 1.3 t -140.97 139.52 34.24 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.359 -0.838 . . . . 0.0 109.723 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.1 p -99.42 132.55 44.68 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.463 -0.773 . . . . 0.0 109.245 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.761 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -132.6 165.92 23.3 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.347 -0.845 . . . . 0.0 109.808 -179.238 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.894 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -98.15 125.18 43.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.238 -0.914 . . . . 0.0 109.219 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.585 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -135.24 143.4 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.068 -1.02 . . . . 0.0 109.897 -179.03 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.599 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.7 ptt180 -145.97 -172.63 3.96 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.457 -1.402 . . . . 0.0 110.946 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.578 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -57.64 -98.15 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.359 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.501 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.64 139.54 55.82 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.27 -1.519 . . . . 0.0 107.944 179.265 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -160.29 135.24 7.79 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 118.598 -1.241 . . . . 0.0 109.847 -178.107 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.516 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -34.95 121.44 0.53 Allowed 'General case' 0 N--CA 1.491 1.611 0 CA-C-O 121.352 0.596 . . . . 0.0 110.119 -178.49 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.078 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.75 50.83 2.59 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 120.404 -0.903 . . . . 0.0 110.938 -179.196 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.48 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.4 OUTLIER -37.74 116.97 0.54 Allowed 'General case' 0 N--CA 1.514 2.726 0 O-C-N 121.274 -1.133 . . . . 0.0 109.973 179.816 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.703 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -87.04 125.96 34.45 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 120.957 -1.089 . . . . 0.0 109.14 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.7 t80 -64.13 58.51 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.036 0 O-C-N 120.8 -1.188 . . . . 0.0 109.922 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' LEU . 26.4 t0 -160.38 20.05 0.15 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.959 -1.088 . . . . 0.0 109.668 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.33 -28.62 5.13 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.089 -1.205 . . . . 0.0 110.089 179.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 70.5 p -95.25 164.2 12.95 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.043 -1.269 . . . . 0.0 110.228 -179.427 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.472 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.9 OUTLIER -109.2 138.5 45.45 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.968 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.703 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.7 t90 -81.71 -20.83 38.6 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.805 -1.184 . . . . 0.0 110.391 -178.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.79 175.07 17.5 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.54 107.49 1.72 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.065 -1.256 . . . . 0.0 107.684 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.642 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.1 t -79.38 105.3 8.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 O-C-N 121.41 -0.806 . . . . 0.0 109.182 -179.009 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.543 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -65.74 111.59 3.29 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.467 -0.771 . . . . 0.0 109.739 -179.583 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.578 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.17 -5.62 3.42 Favored 'General case' 0 N--CA 1.499 2.01 0 C-N-CA 118.208 -1.397 . . . . 0.0 109.884 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 19.9 p -87.71 0.73 55.31 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.697 -1.252 . . . . 0.0 109.117 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.543 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.8 p -114.11 -50.82 2.8 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.367 -0.833 . . . . 0.0 108.975 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.06 179.51 4.25 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.555 -0.716 . . . . 0.0 109.331 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.94 115.62 30.95 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.465 -0.772 . . . . 0.0 108.919 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.516 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.1 m -97.04 122.42 40.01 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.894 -1.129 . . . . 0.0 109.358 -179.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.58 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.67 146.83 27.62 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-O 122.368 1.08 . . . . 0.0 111.215 -179.369 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.608 ' HB ' HG11 ' A' ' 7' ' ' VAL . 52.9 t -103.48 109.79 28.03 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.067 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.61 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.492 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.96 -169.94 17.36 Favored Glycine 0 N--CA 1.486 1.987 0 C-N-CA 118.229 -1.938 . . . . 0.0 111.666 -177.514 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -123.2 179.16 4.8 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -178.682 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.493 ' O ' ' N ' ' A' ' 33' ' ' ASP . 3.6 t . . . . . 0 C--N 1.293 -1.859 0 O-C-N 121.52 -0.738 . . . . 0.0 109.597 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.663 0 N-CA-C 107.874 -2.09 . . . . 0.0 107.874 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.85 -177.52 5.56 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 122.062 0.934 . . . . 0.0 109.875 179.328 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -172.43 -161.56 23.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.151 -1.98 . . . . 0.0 108.151 -179.374 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.516 ' HD2' ' CE1' ' A' ' 32' ' ' TYR . 7.1 Cg_exo -45.69 173.14 0.02 OUTLIER 'Trans proline' 0 C--O 1.216 -0.58 0 CA-C-N 118.912 1.356 . . . . 0.0 110.008 179.268 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -93.95 -178.6 4.7 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.109 -0.994 . . . . 0.0 110.428 -178.662 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.492 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.92 168.07 12.71 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -108.23 128.7 63.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.313 -1.11 . . . . 0.0 109.117 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.58 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -69.18 123.84 22.21 Favored 'General case' 0 C--N 1.29 -2.007 0 O-C-N 121.556 -0.715 . . . . 0.0 109.381 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.899 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.6 173.76 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.199 -0.938 . . . . 0.0 108.928 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.535 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.5 OUTLIER -138.28 159.61 41.6 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.129 -0.982 . . . . 0.0 109.75 -179.743 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.899 ' CE2' HD12 ' A' ' 110' ' ' ILE . 88.4 m-85 . . . . . 0 N--CA 1.485 1.298 0 O-C-N 121.267 -0.896 . . . . 0.0 109.553 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.217 0 CA-C-O 122.448 1.118 . . . . 0.0 110.434 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.897 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.9 t -115.82 109.0 17.03 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-O 123.162 1.458 . . . . 0.0 109.735 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.801 HG22 HG23 ' A' ' 21' ' ' VAL . 2.1 t -115.63 133.69 61.22 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.675 0 CA-C-N 114.162 -1.381 . . . . 0.0 109.593 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.475 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.45 150.66 5.0 Favored Pre-proline 0 N--CA 1.488 1.43 0 O-C-N 121.259 -0.901 . . . . 0.0 108.896 -179.419 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.475 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.13 150.38 88.72 Favored 'Cis proline' 0 C--N 1.311 -1.415 0 C-N-CA 123.56 -1.433 . . . . 0.0 109.454 -0.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.678 ' HA ' HG22 ' A' ' 110' ' ' ILE . 95.6 p -90.4 -24.93 20.64 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.586 -0.696 . . . . 0.0 109.203 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.476 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 14.6 m -131.13 161.71 31.51 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.351 -0.843 . . . . 0.0 109.71 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.44 38.16 29.43 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.783 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.9 mt -93.31 -43.65 8.69 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 123.178 1.466 . . . . 0.0 110.801 -178.122 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.07 144.79 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.328 0 CA-C-N 113.484 -1.689 . . . . 0.0 110.123 -179.486 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 18.6 p-10 -50.37 106.07 0.11 Allowed 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 121.53 0.681 . . . . 0.0 111.693 -178.567 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.67 15.57 8.65 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.912 177.075 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.783 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -105.41 -174.28 2.5 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 121.223 2.511 . . . . 0.0 109.981 179.225 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.821 HG22 HG22 ' A' ' 68' ' ' THR . 31.0 t -126.41 138.09 55.75 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.36 0 CA-C-N 114.549 -1.205 . . . . 0.0 111.399 -178.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.517 HG11 HD11 ' A' ' 13' ' ' LEU . 29.0 m -114.13 154.98 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.467 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.503 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.9 tttt -106.65 109.67 21.64 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.127 -0.983 . . . . 0.0 109.041 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.801 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.61 140.49 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.897 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.46 162.08 33.64 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 118.89 -1.124 . . . . 0.0 110.094 179.485 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.598 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -138.32 140.3 11.01 Favored Glycine 0 C--N 1.299 -1.514 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.71 125.22 15.73 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-N 119.183 1.492 . . . . 0.0 109.28 179.297 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.87 29.71 17.27 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 118.702 -1.713 . . . . 0.0 109.695 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.9 mt -89.88 175.2 7.3 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 120.863 -1.375 . . . . 0.0 108.517 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.028 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.77 96.8 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.102 -0.999 . . . . 0.0 109.885 -179.608 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -58.18 74.87 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.157 -179.138 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 138.75 32.97 0.19 Allowed Glycine 0 N--CA 1.484 1.848 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 179.454 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.632 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 1.4 t -149.11 115.43 5.82 Favored 'General case' 0 C--N 1.31 -1.127 0 O-C-N 120.893 -1.357 . . . . 0.0 111.218 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.608 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.42 111.22 0.46 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.251 178.472 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.632 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 1.9 m-30 -101.54 152.11 21.17 Favored 'General case' 0 N--CA 1.494 1.759 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 179.123 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -98.89 165.01 11.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.497 -1.377 . . . . 0.0 108.327 179.26 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.621 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.1 p -145.1 119.24 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.209 -0.932 . . . . 0.0 109.534 -178.012 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.42 -178.68 41.38 Favored Glycine 0 N--CA 1.495 2.605 0 C-N-CA 118.34 -1.886 . . . . 0.0 111.616 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.698 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.71 108.57 20.46 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 179.833 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.6 m -130.03 148.73 51.91 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 121.228 -0.92 . . . . 0.0 110.01 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.482 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.26 138.76 54.55 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.242 -0.911 . . . . 0.0 110.644 -179.143 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.32 114.82 26.64 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 178.154 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.3 m -104.45 14.88 6.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.014 -1.054 . . . . 0.0 110.534 -178.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.765 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.02 -175.01 0.07 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.023 -1.048 . . . . 0.0 110.185 179.785 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.12 98.11 2.06 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.446 -0.784 . . . . 0.0 109.708 -179.764 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.71 27.88 33.78 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.464 178.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.765 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.75 106.24 19.85 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 O-C-N 120.536 -1.567 . . . . 0.0 107.252 178.834 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.6 tp -117.49 104.45 11.09 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.402 -1.436 . . . . 0.0 109.958 -177.714 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.01 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.92 109.49 22.23 Favored 'General case' 0 N--CA 1.484 1.267 0 N-CA-C 107.718 -1.215 . . . . 0.0 107.718 178.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -107.32 166.16 10.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.895 -1.128 . . . . 0.0 110.655 -178.508 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.56 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 43.7 t30 -113.14 127.92 26.26 Favored Pre-proline 0 N--CA 1.498 1.972 0 O-C-N 121.497 -0.752 . . . . 0.0 109.267 -179.661 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.611 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -70.75 21.31 0.21 Allowed 'Trans proline' 0 CA--C 1.543 0.948 0 C-N-CA 122.103 1.869 . . . . 0.0 112.396 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.56 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -97.72 -5.62 34.72 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.304 -1.497 . . . . 0.0 109.017 179.31 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.857 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.4 m-20 -135.62 10.76 3.43 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.494 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.7 m-85 -66.56 82.9 0.1 Allowed 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.736 -178.403 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.621 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -108.47 -171.92 1.95 Allowed 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 178.252 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.478 ' OG ' ' HA ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER 178.6 134.71 0.08 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.608 -1.308 . . . . 0.0 111.25 -179.369 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.625 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 4.1 p -143.39 159.77 17.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 177.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.69 144.39 27.37 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.583 -1.323 . . . . 0.0 109.767 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.028 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -70.44 108.52 4.31 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 122.312 1.053 . . . . 0.0 109.963 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.553 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.3 t0 -64.66 -139.55 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.714 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.34 -52.43 37.06 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.344 -0.848 . . . . 0.0 110.605 -178.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.34 -32.32 10.53 Favored 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 178.613 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.993 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 100.34 69.29 0.88 Allowed Glycine 0 C--N 1.298 -1.571 0 N-CA-C 110.562 -1.015 . . . . 0.0 110.562 178.488 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 65.6 m -98.66 132.46 44.03 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.337 -1.096 . . . . 0.0 109.016 179.119 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.625 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.41 109.31 9.23 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.252 -179.716 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 19.8 m -122.53 115.68 22.59 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.264 -0.897 . . . . 0.0 109.565 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.545 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.74 143.32 28.61 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.27 -0.894 . . . . 0.0 109.661 179.927 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 57.6 p -99.15 142.38 30.71 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.371 -0.831 . . . . 0.0 109.148 179.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.857 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -144.49 170.63 15.67 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.397 -0.815 . . . . 0.0 109.774 -179.01 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.821 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -104.35 124.26 48.88 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.952 -1.093 . . . . 0.0 110.474 -178.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.847 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.7 m -132.22 143.0 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 120.907 -1.121 . . . . 0.0 110.087 -179.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -145.65 -172.51 3.91 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.604 -1.31 . . . . 0.0 110.689 179.384 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.597 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -58.52 -98.42 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 -179.35 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.4 OUTLIER -57.88 141.22 49.96 Favored 'General case' 0 N--CA 1.485 1.307 0 O-C-N 120.307 -1.496 . . . . 0.0 108.374 179.47 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -161.78 135.44 6.51 Favored 'General case' 0 C--N 1.295 -1.787 0 C-N-CA 118.75 -1.18 . . . . 0.0 109.724 -178.402 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.9 mm-40 -32.11 121.55 0.3 Allowed 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.579 0.704 . . . . 0.0 110.697 -178.351 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.01 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.48 45.51 2.95 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.611 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-85 -37.96 113.56 0.29 Allowed 'General case' 0 N--CA 1.507 2.39 0 O-C-N 121.193 -1.18 . . . . 0.0 110.372 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.739 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.5 tp -85.89 126.56 34.16 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 120.948 -1.095 . . . . 0.0 109.535 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 33.4 t80 -63.9 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.024 0 O-C-N 120.93 -1.106 . . . . 0.0 110.318 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 17.2 t70 -161.46 20.11 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.928 -1.107 . . . . 0.0 109.729 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.59 -28.1 4.99 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.482 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 19.2 p -93.46 159.31 15.3 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.981 -1.305 . . . . 0.0 110.231 -179.492 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.515 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 1.1 ptt180 -106.78 139.03 41.85 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.739 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.3 t90 -84.79 -19.26 32.83 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.704 -1.248 . . . . 0.0 110.524 -178.558 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.84 174.1 18.14 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.447 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.93 106.38 1.22 Allowed 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 179.137 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.66 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.9 t -77.02 105.84 6.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 O-C-N 121.315 -0.866 . . . . 0.0 109.398 -178.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.684 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.0 OUTLIER -66.31 111.46 3.51 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.386 -0.821 . . . . 0.0 109.685 -179.732 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.597 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.1 t -63.54 -5.51 3.94 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.533 -1.355 . . . . 0.0 109.828 179.562 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.2 p -86.45 -1.49 57.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.787 -1.196 . . . . 0.0 109.215 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.684 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -111.38 -50.24 2.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.295 -0.878 . . . . 0.0 108.93 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.34 -178.8 3.76 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.507 -0.746 . . . . 0.0 109.482 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.05 115.52 30.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.33 -0.856 . . . . 0.0 109.001 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.91 123.02 40.51 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.77 -1.206 . . . . 0.0 109.593 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.64 146.9 27.89 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 122.445 1.116 . . . . 0.0 111.138 -179.42 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.585 ' CG1' HG11 ' A' ' 7' ' ' VAL . 48.6 t -103.58 110.53 30.26 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.978 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 177.666 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.489 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.6 -170.24 16.86 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 118.06 -2.019 . . . . 0.0 111.745 -177.523 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -115.38 -179.08 3.54 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 -178.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.51 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.2 OUTLIER . . . . . 0 C--N 1.296 -1.747 0 O-C-N 121.318 -0.864 . . . . 0.0 109.61 -179.333 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.696 0 N-CA-C 107.7 -2.16 . . . . 0.0 107.7 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.46 -178.07 6.66 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-O 122.127 0.965 . . . . 0.0 109.622 179.219 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.0 -161.28 12.88 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 108.301 -1.92 . . . . 0.0 108.301 -179.345 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.507 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.3 Cg_exo -46.75 177.0 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.653 0 CA-C-N 118.838 1.319 . . . . 0.0 110.179 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -92.66 -177.55 4.6 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.074 -1.016 . . . . 0.0 110.451 -178.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.489 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.45 164.48 12.91 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -100.92 129.23 52.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.451 -1.029 . . . . 0.0 109.103 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.04 123.4 22.72 Favored 'General case' 0 C--N 1.289 -2.023 0 O-C-N 121.702 -0.624 . . . . 0.0 109.535 179.734 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.855 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.74 170.53 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.174 -0.954 . . . . 0.0 109.14 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.476 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -138.84 156.63 47.16 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.174 -0.954 . . . . 0.0 109.765 -179.891 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.855 ' CE2' HD12 ' A' ' 110' ' ' ILE . 81.2 m-85 . . . . . 0 N--CA 1.485 1.324 0 O-C-N 121.144 -0.972 . . . . 0.0 109.569 -179.683 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.512 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.151 0 CA-C-O 122.358 1.075 . . . . 1.0 110.688 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.009 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.2 p -105.63 104.87 14.67 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.457 1.122 . . . . 1.0 110.21 -179.577 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.951 HG22 HG23 ' A' ' 21' ' ' VAL . 13.2 t -118.34 118.8 59.25 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.446 0 CA-C-N 115.384 -0.825 . . . . 1.0 110.495 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.521 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.38 149.37 9.8 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.169 -1.049 . . . . 1.0 108.169 -179.799 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.521 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.1 Cg_endo -77.38 151.83 93.17 Favored 'Cis proline' 0 C--N 1.309 -1.536 0 C-N-CA 123.654 -1.394 . . . . 1.0 109.49 -0.223 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.686 ' HA ' HG22 ' A' ' 110' ' ' ILE . 75.4 p -91.89 -24.99 19.15 Favored 'General case' 0 C--N 1.292 -1.904 0 O-C-N 121.501 -0.749 . . . . 1.0 109.137 179.696 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.474 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 0.9 OUTLIER -133.54 165.12 25.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.43 -0.794 . . . . 1.0 109.557 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.52 38.5 37.81 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 108.209 -1.956 . . . . 1.0 108.209 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.808 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.6 mt -92.13 -44.32 8.88 Favored 'General case' 0 C--N 1.298 -1.674 0 CA-C-O 123.122 1.439 . . . . 1.0 110.637 -178.214 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.464 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.3 144.75 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.279 0 CA-C-N 113.613 -1.63 . . . . 1.0 109.947 -179.603 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.598 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.2 p-10 -51.16 108.24 0.24 Allowed 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.524 0.678 . . . . 1.0 111.523 -178.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.11 14.14 10.23 Favored Glycine 0 N--CA 1.484 1.835 0 C-N-CA 119.408 -1.377 . . . . 1.0 112.824 177.283 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.808 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.1 t -104.05 -172.38 2.1 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 121.079 2.439 . . . . 1.0 109.639 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.764 HG22 HG22 ' A' ' 68' ' ' THR . 12.1 t -131.61 138.85 52.01 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.37 0 CA-C-N 114.967 -1.015 . . . . 1.0 111.281 -178.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.442 HG11 HD11 ' A' ' 13' ' ' LEU . 26.9 m -114.45 154.99 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.761 -0.829 . . . . 1.0 108.761 179.155 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 21.0 tttt -109.06 108.86 19.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.053 -1.029 . . . . 1.0 109.407 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.951 HG23 HG22 ' A' ' 7' ' ' VAL . 1.7 p -106.86 122.53 61.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 N-CA-C 108.778 -0.823 . . . . 1.0 108.778 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.009 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.98 165.67 12.13 Favored 'General case' 0 C--N 1.305 -1.331 0 O-C-N 120.902 -1.124 . . . . 1.0 109.114 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.582 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.77 107.91 0.48 Allowed Glycine 0 N--CA 1.482 1.765 0 N-CA-C 108.738 -1.745 . . . . 1.0 108.738 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.477 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.43 141.05 48.68 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 120.658 -1.495 . . . . 1.0 110.168 -179.502 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.86 28.12 32.61 Favored Glycine 0 N--CA 1.488 2.109 0 C-N-CA 119.003 -1.57 . . . . 1.0 109.806 179.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -94.23 174.73 7.0 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.008 -1.29 . . . . 1.0 108.587 179.991 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.006 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.95 97.29 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.022 -1.048 . . . . 1.0 109.673 -179.831 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.688 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.19 76.63 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.345 -0.843 . . . . 1.0 110.372 -179.145 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.563 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.85 33.92 0.32 Allowed Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.751 -1.34 . . . . 1.0 109.751 179.498 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.638 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.1 t -146.66 114.15 6.34 Favored 'General case' 0 C--N 1.309 -1.174 0 O-C-N 120.838 -1.39 . . . . 1.0 110.986 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -46.12 126.2 7.35 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-N 115.31 -0.859 . . . . 1.0 110.008 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.638 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 12.2 m-85 -118.43 151.17 38.3 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.543 -0.91 . . . . 1.0 108.543 179.358 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.491 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.54 156.76 17.28 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.572 -1.33 . . . . 1.0 108.063 179.015 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.926 HG11 HG21 ' A' ' 65' ' ' THR . 7.0 p -139.32 115.04 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.189 -0.944 . . . . 1.0 109.83 -177.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.75 -178.64 37.53 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.449 -1.834 . . . . 1.0 111.804 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.631 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -101.8 109.43 21.19 Favored 'General case' 0 C--N 1.313 -0.987 0 N-CA-C 108.799 -0.815 . . . . 1.0 108.799 -179.818 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.41 149.17 52.21 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.22 -0.925 . . . . 1.0 109.99 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.21 138.19 54.7 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.265 -0.897 . . . . 1.0 110.729 -179.081 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.877 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.71 26.53 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 107.432 -1.322 . . . . 1.0 107.432 178.09 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -105.63 15.3 7.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.018 -1.051 . . . . 1.0 110.589 -178.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.99 -175.63 0.09 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.875 -1.14 . . . . 1.0 110.088 179.787 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 43.8 p -71.95 97.72 1.91 Allowed 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.404 -0.81 . . . . 1.0 109.664 -179.722 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.7 27.37 35.32 Favored Glycine 0 N--CA 1.493 2.448 0 C-N-CA 120.141 -1.028 . . . . 1.0 111.302 178.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.32 106.28 20.01 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.519 -1.577 . . . . 1.0 107.203 178.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.877 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.0 tp -117.04 104.3 11.11 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 120.427 -1.42 . . . . 1.0 109.726 -177.749 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.904 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.97 109.32 22.1 Favored 'General case' 0 N--CA 1.483 1.202 0 N-CA-C 107.65 -1.241 . . . . 1.0 107.65 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -105.72 166.36 10.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.035 -1.04 . . . . 1.0 110.404 -178.678 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.487 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 59.2 t30 -111.84 131.39 22.45 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.541 -0.724 . . . . 1.0 109.736 -179.465 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.599 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 2.5 Cg_endo -73.05 22.62 0.31 Allowed 'Trans proline' 0 C--N 1.319 -1.022 0 C-N-CA 122.112 1.874 . . . . 1.0 111.737 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.487 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -110.01 2.84 19.89 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.307 -1.496 . . . . 1.0 109.19 179.562 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.5 15.56 2.75 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.471 -1.307 . . . . 1.0 107.471 179.479 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -79.22 92.96 5.16 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.898 -0.721 . . . . 1.0 111.039 -178.429 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.617 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -111.95 -167.82 1.23 Allowed 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.536 -1.283 . . . . 1.0 107.536 178.104 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.98 136.5 0.09 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.439 -1.413 . . . . 1.0 111.521 -179.332 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.941 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.12 157.51 4.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.276 -1.379 . . . . 1.0 107.276 178.019 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.568 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.1 145.49 26.51 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.76 -1.212 . . . . 1.0 109.825 -179.703 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -66.08 107.24 1.84 Allowed 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 122.485 1.136 . . . . 1.0 109.328 178.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.541 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.1 t70 -60.82 -139.37 0.0 OUTLIER 'General case' 0 C--N 1.292 -1.93 0 CA-C-N 115.558 -0.746 . . . . 1.0 110.941 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.688 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.12 -51.42 43.26 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.504 -0.747 . . . . 1.0 110.756 -178.658 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.57 -32.56 8.89 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 106.308 -1.738 . . . . 1.0 106.308 178.673 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.012 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.24 65.21 0.61 Allowed Glycine 0 C--N 1.297 -1.589 0 N-CA-C 110.542 -1.023 . . . . 1.0 110.542 178.238 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.582 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.7 m -103.0 124.66 48.93 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 108.292 -1.003 . . . . 1.0 108.292 178.604 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.941 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.58 109.36 8.62 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 119.681 -0.808 . . . . 1.0 109.726 -179.13 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.3 m -115.99 115.66 26.54 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.293 -0.879 . . . . 1.0 109.164 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.926 HG21 HG11 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -140.68 138.86 34.59 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.425 -0.797 . . . . 1.0 109.864 179.941 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.7 p -98.98 133.48 43.19 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.448 -0.782 . . . . 1.0 109.179 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.759 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -131.22 163.71 27.14 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.302 -0.873 . . . . 1.0 109.446 -179.313 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.764 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -93.99 124.33 37.93 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.046 -1.034 . . . . 1.0 109.157 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.541 HG23 HD13 ' A' ' 13' ' ' LEU . 14.4 m -134.71 143.32 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 120.979 -1.076 . . . . 1.0 109.877 -178.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.598 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.2 ptt180 -145.33 -170.66 3.49 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.464 -1.397 . . . . 1.0 111.042 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.637 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -61.88 -101.64 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.851 -0.531 . . . . 1.0 110.241 -179.093 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.528 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -59.19 138.11 57.71 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.566 -1.333 . . . . 1.0 108.517 179.953 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.631 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 1.3 p90 -156.87 154.13 29.32 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 118.824 -1.15 . . . . 1.0 109.854 -178.795 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.483 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 20.4 mm-40 -47.6 122.11 4.56 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.353 -0.842 . . . . 1.0 109.577 -178.58 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.904 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.94 49.38 3.58 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.94 -0.864 . . . . 1.0 110.94 -179.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.599 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.4 m-85 -40.42 113.17 0.34 Allowed 'General case' 0 N--CA 1.507 2.386 0 O-C-N 121.014 -1.286 . . . . 1.0 110.224 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.736 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.92 127.08 35.06 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.842 -1.161 . . . . 1.0 109.358 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -63.83 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 O-C-N 120.758 -1.214 . . . . 1.0 110.213 179.785 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 1.6 t0 -160.78 19.0 0.13 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.016 -1.052 . . . . 1.0 109.801 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -25.97 5.75 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 110.15 -1.18 . . . . 1.0 110.15 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 15.4 p -93.31 157.67 16.13 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 120.964 -1.315 . . . . 1.0 110.491 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.477 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -103.86 132.71 49.85 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.482 -0.932 . . . . 1.0 108.482 179.609 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.736 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.1 t90 -81.16 -18.51 46.06 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.758 -1.213 . . . . 1.0 110.382 -178.692 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.26 174.16 19.41 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.864 -1.694 . . . . 1.0 108.864 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.43 107.93 1.22 Allowed 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.683 -1.229 . . . . 1.0 107.683 179.224 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.639 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.0 t -79.82 104.74 8.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.362 -0.836 . . . . 1.0 109.13 -178.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.555 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -65.04 109.15 2.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.567 -0.708 . . . . 1.0 110.15 -179.179 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.637 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.8 t -62.04 -4.1 1.51 Allowed 'General case' 0 N--CA 1.502 2.167 0 C-N-CA 118.262 -1.375 . . . . 1.0 110.334 179.265 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.1 p -91.33 5.34 49.62 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.66 -1.275 . . . . 1.0 109.384 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.555 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -117.2 -49.75 2.58 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.356 -0.84 . . . . 1.0 109.178 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.89 178.55 4.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.52 -0.737 . . . . 1.0 109.456 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.49 112.5 24.87 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.342 -0.849 . . . . 1.0 108.907 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.522 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.6 m -96.7 121.69 38.82 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.031 -1.043 . . . . 1.0 109.279 -179.061 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.582 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.61 147.55 26.65 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 122.454 1.121 . . . . 1.0 111.358 -179.172 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.637 ' HB ' HG11 ' A' ' 7' ' ' VAL . 58.8 t -103.38 109.52 27.22 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.492 -1.67 . . . . 1.0 106.492 177.484 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.443 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.19 -171.31 16.98 Favored Glycine 0 N--CA 1.485 1.927 0 C-N-CA 118.166 -1.969 . . . . 1.0 111.721 -177.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.555 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -115.49 -178.2 3.33 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.704 -0.85 . . . . 1.0 108.704 -178.839 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 1.4 p . . . . . 0 C--N 1.297 -1.714 0 O-C-N 121.312 -0.867 . . . . 1.0 109.574 -179.16 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.681 0 N-CA-C 107.697 -2.161 . . . . 1.0 107.697 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.02 -177.91 6.43 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 122.052 0.93 . . . . 1.0 109.844 179.255 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.48 -162.49 19.39 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 108.374 -1.89 . . . . 1.0 108.374 -179.477 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.555 ' HB2' HD12 ' A' ' 97' ' ' LEU . 7.1 Cg_exo -46.0 174.43 0.02 OUTLIER 'Trans proline' 0 C--N 1.327 -0.581 0 CA-C-N 118.854 1.327 . . . . 1.0 110.168 179.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -90.46 -178.84 5.44 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.0 -1.063 . . . . 1.0 110.611 -178.601 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.443 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.86 166.38 13.02 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.586 -1.405 . . . . 1.0 109.586 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.61 131.8 54.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.338 -1.095 . . . . 1.0 109.177 -179.225 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.582 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.3 121.94 20.28 Favored 'General case' 0 C--N 1.29 -2.002 0 O-C-N 121.59 -0.694 . . . . 1.0 109.617 179.657 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.844 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.8 pt -98.01 173.2 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.248 -0.908 . . . . 1.0 108.996 179.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.474 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -141.36 159.54 42.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.06 -1.025 . . . . 1.0 110.04 -179.7 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.844 ' CE2' HD12 ' A' ' 110' ' ' ILE . 88.5 m-85 . . . . . 0 N--CA 1.487 1.376 0 O-C-N 121.276 -0.89 . . . . 1.0 109.573 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.458 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.481 0 CA-C-O 122.356 1.074 . . . . 0.0 110.666 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.962 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -111.17 108.71 18.47 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 123.04 1.4 . . . . 0.0 109.096 179.273 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.914 HG22 HG23 ' A' ' 21' ' ' VAL . 4.5 t -118.31 136.44 55.5 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.761 0 CA-C-N 114.299 -1.319 . . . . 0.0 110.094 -179.685 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.482 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -176.64 150.97 1.0 Allowed Pre-proline 0 N--CA 1.488 1.431 0 O-C-N 121.279 -0.888 . . . . 0.0 108.801 -179.641 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.482 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.8 Cg_endo -79.11 150.45 85.74 Favored 'Cis proline' 0 C--N 1.311 -1.432 0 C-N-CA 123.507 -1.456 . . . . 0.0 109.271 -0.735 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.677 ' HA ' HG22 ' A' ' 110' ' ' ILE . 78.4 p -92.23 -23.19 19.42 Favored 'General case' 0 C--N 1.291 -1.937 0 O-C-N 121.589 -0.695 . . . . 0.0 109.402 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.485 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 7.4 m -132.2 160.74 35.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.354 -0.841 . . . . 0.0 109.764 -179.785 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.77 37.39 30.21 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.824 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.8 mt -92.04 -44.42 8.86 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-O 123.2 1.476 . . . . 0.0 110.728 -178.363 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.4 OUTLIER 65.96 146.28 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.341 0 CA-C-N 113.628 -1.624 . . . . 0.0 109.942 -179.69 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.606 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.0 p-10 -50.85 108.08 0.21 Allowed 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 121.478 0.656 . . . . 0.0 111.882 -178.532 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.5 15.2 10.58 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.421 -1.371 . . . . 0.0 112.879 177.131 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.824 HG21 ' CA ' ' A' ' 13' ' ' LEU . 10.6 t -102.65 -172.42 2.12 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 121.056 2.428 . . . . 0.0 109.897 179.35 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.796 HG13 ' O ' ' A' ' 67' ' ' LEU . 33.6 t -125.66 137.55 57.33 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.246 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.962 -178.726 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.54 HG22 HG22 ' A' ' 69' ' ' VAL . 27.4 m -116.2 155.84 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 178.768 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.4 ttpt -114.31 109.55 18.52 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.06 -1.025 . . . . 0.0 109.178 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.914 HG23 HG22 ' A' ' 7' ' ' VAL . 2.4 p -105.12 141.45 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.962 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -139.72 160.25 40.3 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 120.632 -1.292 . . . . 0.0 110.229 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.07 144.21 15.45 Favored Glycine 0 C--N 1.295 -1.704 0 N-CA-C 107.977 -2.049 . . . . 0.0 107.977 179.47 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.08 125.94 13.55 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 120.894 -1.356 . . . . 0.0 108.841 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.11 27.04 24.51 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 119.214 -1.469 . . . . 0.0 109.654 -179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.4 mt -88.58 175.01 7.74 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.887 -1.361 . . . . 0.0 108.498 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.998 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -48.55 100.15 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.002 -1.061 . . . . 0.0 109.792 -179.63 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.44 78.13 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.134 -179.24 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.91 34.08 0.31 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.72 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.554 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 34.2 p -140.79 107.29 5.3 Favored 'General case' 0 C--N 1.308 -1.218 0 O-C-N 121.24 -1.153 . . . . 0.0 110.984 -179.489 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.575 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.67 109.78 0.25 Allowed 'General case' 0 N--CA 1.497 1.888 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.987 178.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.537 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 24.9 m-85 -102.38 153.86 19.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 108.638 179.372 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.505 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.87 161.51 13.61 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.676 -1.265 . . . . 0.0 107.948 178.85 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.655 HG13 ' O ' ' A' ' 34' ' ' VAL . 5.5 p -141.16 115.23 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.157 -0.964 . . . . 0.0 109.442 -178.205 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.53 ' HA2' ' OD1' ' A' ' 51' ' ' ASP . . . -162.75 173.99 39.05 Favored Glycine 0 N--CA 1.49 2.276 0 C-N-CA 118.06 -2.019 . . . . 0.0 112.114 -179.334 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.628 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -98.43 108.96 21.79 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 179.267 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.8 m -132.28 151.26 51.92 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.277 -0.889 . . . . 0.0 109.992 -179.513 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.42 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.82 139.65 53.64 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.248 -0.907 . . . . 0.0 110.695 -179.06 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.878 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.26 114.56 26.36 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.22 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.2 m -105.09 14.75 7.09 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 120.885 -1.135 . . . . 0.0 110.602 -178.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.759 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.06 -174.99 0.09 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.892 -1.13 . . . . 0.0 110.067 179.751 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.6 p -71.95 97.32 1.84 Allowed 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.344 -0.848 . . . . 0.0 109.798 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.42 26.93 34.39 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 120.241 -0.98 . . . . 0.0 111.428 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.6 106.31 20.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.55 -1.559 . . . . 0.0 107.429 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.878 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.2 tp -116.65 104.82 11.77 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.564 -1.335 . . . . 0.0 109.723 -177.862 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.078 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.98 109.53 22.27 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 120.829 -1.17 . . . . 0.0 108.204 179.092 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.6 t -105.89 165.56 11.11 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.9 -1.125 . . . . 0.0 110.295 -179.085 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.665 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 18.7 t-20 -109.33 137.0 20.13 Favored Pre-proline 0 N--CA 1.501 2.104 0 O-C-N 121.421 -0.799 . . . . 0.0 110.201 -179.08 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.584 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.2 Cg_endo -74.89 23.94 0.39 Allowed 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 122.387 2.058 . . . . 0.0 111.971 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.665 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -116.88 2.67 12.83 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.296 -1.503 . . . . 0.0 109.227 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.955 ' OD1' HD22 ' A' ' 67' ' ' LEU . 9.4 t70 -137.64 13.27 2.95 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 179.552 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -79.72 94.25 5.7 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 121.424 -0.798 . . . . 0.0 110.883 -178.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -115.33 -166.25 1.1 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 178.367 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.94 135.42 0.09 Allowed 'General case' 0 N--CA 1.486 1.369 0 O-C-N 120.627 -1.296 . . . . 0.0 111.429 -179.34 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.915 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -151.18 156.9 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 107.354 -1.351 . . . . 0.0 107.354 178.007 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.575 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.19 144.14 27.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.801 -1.187 . . . . 0.0 110.055 -179.574 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.008 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.72 106.91 1.06 Allowed 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 122.447 1.118 . . . . 0.0 109.436 178.27 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -60.05 -139.28 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.988 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.042 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.91 -50.1 61.74 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.498 -0.751 . . . . 0.0 110.597 -178.752 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 12.3 m-80 -103.7 -34.47 8.58 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 106.208 -1.775 . . . . 0.0 106.208 178.573 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.008 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.49 65.31 0.58 Allowed Glycine 0 C--N 1.297 -1.604 0 N-CA-C 110.501 -1.039 . . . . 0.0 110.501 178.141 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 46.6 m -103.62 127.05 51.11 Favored 'General case' 0 N--CA 1.483 1.19 0 O-C-N 121.381 -1.07 . . . . 0.0 108.915 178.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.915 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.72 109.15 7.37 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.424 -0.91 . . . . 0.0 109.36 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -124.71 121.65 35.25 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.201 -0.937 . . . . 0.0 109.663 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.71 142.05 28.61 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.596 -0.69 . . . . 0.0 109.486 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 15.6 p -98.93 136.38 39.0 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.451 -0.781 . . . . 0.0 109.186 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.955 HD22 ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -135.93 -178.73 5.27 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.235 -0.915 . . . . 0.0 109.544 -178.983 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.4 p -105.09 126.18 51.79 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.99 -1.069 . . . . 0.0 109.637 -179.352 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.54 HG22 HG22 ' A' ' 19' ' ' VAL . 16.9 m -139.35 142.97 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 120.888 -1.132 . . . . 0.0 110.08 -179.521 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.606 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.8 ptt180 -141.2 -161.42 1.21 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.671 -1.268 . . . . 0.0 110.141 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.582 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -78.15 -86.89 0.06 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.232 -0.918 . . . . 0.0 108.848 -179.584 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -60.87 138.47 58.14 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.387 -1.446 . . . . 0.0 107.204 178.809 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -165.11 136.58 4.11 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 117.901 -1.519 . . . . 0.0 110.371 -177.365 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.516 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 7.0 mm-40 -33.4 121.44 0.4 Allowed 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 121.352 0.596 . . . . 0.0 110.326 -178.766 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.078 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.85 51.83 1.72 Allowed Glycine 0 N--CA 1.494 2.53 0 C-N-CA 120.474 -0.869 . . . . 0.0 111.42 -179.036 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.584 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 4.2 m-85 -39.11 116.6 0.6 Allowed 'General case' 0 N--CA 1.511 2.62 0 O-C-N 121.018 -1.283 . . . . 0.0 110.05 179.526 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.682 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.4 126.27 34.27 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 120.96 -1.087 . . . . 0.0 109.69 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -64.5 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 120.738 -1.226 . . . . 0.0 109.92 179.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.544 ' N ' ' O ' ' A' ' 77' ' ' LEU . 5.7 t70 -158.93 19.51 0.2 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.061 -1.025 . . . . 0.0 109.656 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.75 -27.96 5.65 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.426 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 69.7 p -97.54 162.71 13.17 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.046 -1.267 . . . . 0.0 110.307 -179.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.525 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.0 140.37 41.25 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.904 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.682 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.7 t90 -83.8 -19.21 35.42 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.771 -1.205 . . . . 0.0 110.728 -178.282 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.85 177.33 20.13 Favored Glycine 0 N--CA 1.484 1.869 0 N-CA-C 108.578 -1.809 . . . . 0.0 108.578 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -63.9 109.79 1.89 Allowed 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.214 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.62 HG21 ' HB3' ' A' ' 46' ' ' ALA . 37.3 t -82.91 105.66 12.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 121.44 -0.788 . . . . 0.0 108.947 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.539 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -66.14 111.73 3.56 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.428 -0.795 . . . . 0.0 109.882 -179.205 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.555 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -65.28 -5.32 6.87 Favored 'General case' 0 N--CA 1.498 1.96 0 C-N-CA 118.203 -1.399 . . . . 0.0 109.665 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.3 p -84.01 -1.24 54.37 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.799 -1.188 . . . . 0.0 108.887 179.269 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.539 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -113.5 -50.05 2.87 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.443 -0.786 . . . . 0.0 109.012 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.87 -178.0 3.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.486 -0.758 . . . . 0.0 109.45 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.09 115.77 30.76 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.451 -0.78 . . . . 0.0 109.037 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.535 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -96.87 122.76 40.19 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.894 -1.129 . . . . 0.0 109.588 -179.384 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.83 146.39 28.35 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 122.337 1.065 . . . . 0.0 111.167 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 59.3 t -103.78 109.88 28.46 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.591 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.473 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.55 -172.09 18.05 Favored Glycine 0 N--CA 1.486 2.016 0 C-N-CA 118.03 -2.033 . . . . 0.0 111.914 -177.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -112.97 -178.88 3.49 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.255 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.478 ' O ' ' N ' ' A' ' 33' ' ' ASP . 2.9 p . . . . . 0 C--N 1.296 -1.728 0 O-C-N 121.261 -0.899 . . . . 0.0 109.518 -179.373 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.631 0 N-CA-C 107.913 -2.075 . . . . 0.0 107.913 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.31 -177.76 6.23 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 122.1 0.952 . . . . 0.0 109.95 179.277 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.93 -163.89 23.71 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.149 -1.98 . . . . 0.0 108.149 -179.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.0 Cg_exo -46.24 172.96 0.02 OUTLIER 'Trans proline' 0 C--N 1.326 -0.616 0 CA-C-N 118.88 1.34 . . . . 0.0 109.889 179.371 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -91.7 -173.21 3.46 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.15 -0.969 . . . . 0.0 110.447 -178.712 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.473 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.81 171.29 15.54 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.1 t -106.69 132.98 52.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.536 -0.979 . . . . 0.0 109.138 -179.383 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.37 123.94 26.25 Favored 'General case' 0 C--N 1.29 -2.017 0 O-C-N 121.609 -0.682 . . . . 0.0 109.664 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.827 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.73 168.23 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.282 -0.886 . . . . 0.0 108.934 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.485 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 5.4 m -136.6 154.53 50.64 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.219 -0.926 . . . . 0.0 109.752 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.827 ' CE2' HD12 ' A' ' 110' ' ' ILE . 77.3 m-85 . . . . . 0 N--CA 1.487 1.38 0 O-C-N 121.179 -0.951 . . . . 0.0 109.417 -179.698 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.176 0 CA-C-O 122.414 1.102 . . . . 0.0 110.617 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.989 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 3.2 p -108.54 104.79 14.19 Favored 'General case' 0 C--N 1.296 -1.738 0 CA-C-O 122.491 1.139 . . . . 0.0 110.337 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.949 HG22 HG23 ' A' ' 21' ' ' VAL . 10.8 t -116.86 110.17 30.44 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.448 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.479 179.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.5 HG23 ' HA ' ' A' ' 9' ' ' PRO . 1.0 OUTLIER -152.55 146.72 18.53 Favored Pre-proline 0 N--CA 1.485 1.294 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.971 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.5 ' HA ' HG23 ' A' ' 8' ' ' THR . 9.3 Cg_endo -80.83 146.87 73.05 Favored 'Cis proline' 0 C--N 1.306 -1.675 0 O-C-N 123.666 1.351 . . . . 0.0 109.373 -0.232 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.677 ' HA ' HG22 ' A' ' 110' ' ' ILE . 80.4 p -91.51 -24.03 19.77 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.493 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 13.2 m -131.33 160.99 33.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.575 -0.703 . . . . 0.0 109.471 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.74 36.65 32.36 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 -179.648 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.75 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.7 mt -91.32 -42.63 10.26 Favored 'General case' 0 C--N 1.299 -1.587 0 CA-C-O 123.358 1.552 . . . . 0.0 110.46 -178.475 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.24 142.99 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.253 0 CA-C-N 113.322 -1.763 . . . . 0.0 109.795 -179.561 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.601 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.1 p-10 -50.01 105.74 0.1 Allowed 'General case' 0 C--N 1.301 -1.529 0 CA-C-O 121.448 0.642 . . . . 0.0 111.574 -178.56 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.47 13.88 8.57 Favored Glycine 0 N--CA 1.485 1.919 0 C-N-CA 119.417 -1.373 . . . . 0.0 113.16 177.211 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.75 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -106.01 -172.88 2.17 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 121.199 2.499 . . . . 0.0 109.839 179.28 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.95 HG22 HG22 ' A' ' 68' ' ' THR . 20.8 t -128.87 140.3 49.62 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.27 0 CA-C-N 114.695 -1.139 . . . . 0.0 111.362 -178.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.562 HG11 HD11 ' A' ' 13' ' ' LEU . 27.8 m -114.87 156.24 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 178.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.526 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -109.29 109.72 20.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.984 -1.072 . . . . 0.0 109.553 -179.716 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.949 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -105.05 123.57 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 179.898 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.989 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.3 165.96 11.71 Favored 'General case' 0 N--CA 1.484 1.267 0 O-C-N 120.792 -1.192 . . . . 0.0 108.942 179.438 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.6 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -145.56 108.16 0.45 Allowed Glycine 0 N--CA 1.483 1.822 0 N-CA-C 108.36 -1.896 . . . . 0.0 108.36 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.83 137.37 52.25 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 120.519 -1.577 . . . . 0.0 110.439 -179.303 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.475 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 85.85 28.85 27.8 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.085 -1.531 . . . . 0.0 109.874 179.567 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.606 HD22 ' HG3' ' A' ' 105' ' ' PRO . 2.3 mt -90.36 175.66 7.02 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.963 -1.316 . . . . 0.0 108.373 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.012 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.69 97.94 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.858 -1.151 . . . . 0.0 109.678 -179.669 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.594 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.08 76.96 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.692 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.381 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.571 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.9 34.34 0.3 Allowed Glycine 0 N--CA 1.486 1.975 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.465 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.553 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.7 p -147.89 113.3 5.61 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 120.998 -1.296 . . . . 0.0 111.28 -179.693 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.577 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.86 126.67 5.91 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-N 115.619 -0.718 . . . . 0.0 109.567 177.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.483 ' HA ' ' O ' ' A' ' 98' ' ' SER . 10.5 m-85 -117.48 149.39 40.67 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.484 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.3 163.87 12.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.751 -1.218 . . . . 0.0 107.92 178.918 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.929 HG11 HG21 ' A' ' 65' ' ' THR . 9.9 p -149.32 114.07 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.202 -0.936 . . . . 0.0 109.838 -177.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.524 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.01 -175.89 36.83 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 118.329 -1.891 . . . . 0.0 111.724 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.591 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -101.4 108.87 20.6 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.763 0.792 . . . . 0.0 108.951 -179.563 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.484 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.12 146.88 51.8 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.427 -0.796 . . . . 0.0 109.691 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.493 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -120.35 138.18 53.87 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.298 -0.877 . . . . 0.0 110.703 -179.007 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.861 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.64 114.4 26.14 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.251 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -105.89 14.85 7.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.002 -1.061 . . . . 0.0 110.603 -178.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.766 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.43 -174.6 0.07 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.808 -1.182 . . . . 0.0 110.164 179.756 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.8 p -71.71 97.57 1.78 Allowed 'General case' 0 N--CA 1.485 1.323 0 O-C-N 121.43 -0.794 . . . . 0.0 109.867 -179.63 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 26.47 37.09 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 120.251 -0.976 . . . . 0.0 111.483 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.766 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.75 106.21 20.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.556 -1.555 . . . . 0.0 107.367 178.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.861 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -118.22 104.77 11.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.473 -1.392 . . . . 0.0 109.641 -177.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.012 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.98 109.75 22.45 Favored 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.789 -1.194 . . . . 0.0 108.345 179.138 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.5 t -106.33 164.71 11.8 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.935 -1.103 . . . . 0.0 110.426 -178.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.732 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 10.5 t-20 -108.94 139.48 20.96 Favored Pre-proline 0 N--CA 1.501 2.083 0 O-C-N 121.461 -0.775 . . . . 0.0 109.952 -179.124 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 6.8 Cg_endo -75.7 23.11 0.45 Allowed 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 125.162 3.908 . . . . 0.0 111.258 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.732 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -120.07 3.34 10.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.426 -1.421 . . . . 0.0 109.052 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.545 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.89 14.51 3.1 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 179.343 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -80.49 91.19 5.72 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.778 -0.769 . . . . 0.0 110.98 -178.487 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.648 ' C ' HG12 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -113.23 -173.31 2.23 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.099 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.67 134.6 0.08 Allowed 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.482 -1.386 . . . . 0.0 111.494 -179.183 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.645 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 3.6 p -146.73 159.62 10.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 107.227 -1.398 . . . . 0.0 107.227 177.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.577 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.33 145.89 25.68 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.433 -1.417 . . . . 0.0 110.116 -179.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.47 109.36 3.67 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 122.326 1.06 . . . . 0.0 109.802 178.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.574 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -63.64 -139.31 0.0 OUTLIER 'General case' 0 C--N 1.292 -1.902 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.588 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.594 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.92 -51.59 55.91 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.391 -0.818 . . . . 0.0 110.378 -178.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.475 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.4 t-20 -101.39 -34.18 9.7 Favored 'General case' 0 C--N 1.287 -2.121 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.968 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.44 69.59 0.72 Allowed Glycine 0 N--CA 1.479 1.557 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 178.041 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 64.3 p -98.86 131.69 44.77 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 121.327 -1.102 . . . . 0.0 109.268 179.118 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.645 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.1 108.48 7.82 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.775 -0.77 . . . . 0.0 109.021 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 7.0 m -122.23 116.36 24.0 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.122 -0.986 . . . . 0.0 109.536 -179.743 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.929 HG21 HG11 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -146.13 139.48 25.99 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.428 -0.795 . . . . 0.0 109.787 179.944 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.8 p -99.97 128.83 46.01 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.369 -0.832 . . . . 0.0 108.946 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.787 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -126.54 164.42 21.24 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.227 -0.92 . . . . 0.0 109.783 -179.092 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.95 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -96.77 125.12 41.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.118 -0.989 . . . . 0.0 109.221 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.591 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.9 m -136.51 142.69 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.075 -1.016 . . . . 0.0 109.909 -179.026 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.601 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.8 ptt180 -146.37 -173.62 4.24 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.473 -1.392 . . . . 0.0 110.922 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.619 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.64 -101.94 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 -179.409 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.508 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -55.72 140.95 39.99 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 120.788 -1.195 . . . . 0.0 108.115 179.458 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.79 135.26 5.51 Favored 'General case' 0 C--N 1.294 -1.818 0 C-N-CA 118.701 -1.2 . . . . 0.0 109.813 -178.265 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.519 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 1.3 mp0 -31.53 121.16 0.25 Allowed 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 121.41 0.624 . . . . 0.0 110.699 -178.488 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.012 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.74 46.61 2.73 Favored Glycine 0 N--CA 1.495 2.572 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.136 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -38.48 113.19 0.27 Allowed 'General case' 0 N--CA 1.507 2.388 0 O-C-N 121.121 -1.223 . . . . 0.0 110.205 179.622 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.654 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -85.92 127.32 34.58 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 120.975 -1.078 . . . . 0.0 109.52 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.6 t80 -64.09 58.17 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.051 0 O-C-N 120.858 -1.151 . . . . 0.0 110.198 179.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 6.7 t70 -160.93 19.4 0.13 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.972 -1.08 . . . . 0.0 109.794 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.73 -27.17 5.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.429 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 70.7 p -93.39 157.15 16.37 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.05 -1.264 . . . . 0.0 110.349 -179.402 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.492 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -104.73 134.45 47.85 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.652 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.654 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -80.94 -17.97 48.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.887 -1.133 . . . . 0.0 110.413 -178.494 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.74 174.6 19.79 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.29 106.2 1.06 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.11 -1.23 . . . . 0.0 107.695 179.157 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.596 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.0 t -77.54 106.79 8.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.382 -0.824 . . . . 0.0 109.292 -178.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.537 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.91 111.54 3.35 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.413 -0.804 . . . . 0.0 109.801 -179.474 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.619 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.71 -5.4 4.07 Favored 'General case' 0 N--CA 1.501 2.085 0 C-N-CA 118.135 -1.426 . . . . 0.0 109.809 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 40.9 p -86.52 -1.8 57.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.799 -1.188 . . . . 0.0 109.29 179.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.537 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.14 -49.69 3.0 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.264 -0.898 . . . . 0.0 109.058 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.18 179.03 4.38 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.47 -0.769 . . . . 0.0 109.525 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.3 115.92 31.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.39 -0.819 . . . . 0.0 109.058 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.83 122.59 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.877 -1.139 . . . . 0.0 109.465 -179.448 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.92 148.03 25.82 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 122.418 1.104 . . . . 0.0 111.249 -179.266 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.544 ' HB ' HG11 ' A' ' 7' ' ' VAL . 72.3 t -104.86 109.87 28.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 177.705 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.31 -173.56 18.56 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 118.308 -1.901 . . . . 0.0 111.796 -177.545 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.545 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.49 -178.54 3.41 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.029 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.483 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.2 OUTLIER . . . . . 0 C--N 1.295 -1.794 0 O-C-N 121.357 -0.839 . . . . 0.0 109.152 -179.353 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.723 0 N-CA-C 107.588 -2.205 . . . . 0.0 107.588 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.44 -178.69 7.32 Favored 'General case' 0 C--N 1.308 -1.237 0 O-C-N 121.6 -0.941 . . . . 0.0 109.522 179.051 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -175.88 -166.53 33.46 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 108.405 -1.878 . . . . 0.0 108.405 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.606 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.2 Cg_exo -45.03 178.85 0.0 OUTLIER 'Trans proline' 0 N--CA 1.491 1.377 0 C-N-CA 123.349 2.699 . . . . 0.0 109.697 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -92.59 175.18 6.92 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.955 -1.09 . . . . 0.0 110.637 -178.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -114.76 163.66 12.16 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.35 127.38 63.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.32 -1.106 . . . . 0.0 109.155 -179.285 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.58 122.01 19.76 Favored 'General case' 0 C--N 1.291 -1.971 0 O-C-N 121.559 -0.713 . . . . 0.0 109.47 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.865 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.79 170.44 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.198 -0.939 . . . . 0.0 109.085 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.493 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -140.53 156.38 46.33 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.143 -0.973 . . . . 0.0 109.837 -179.657 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.865 ' CE2' HD12 ' A' ' 110' ' ' ILE . 87.5 m-85 . . . . . 0 N--CA 1.485 1.293 0 O-C-N 121.233 -0.917 . . . . 0.0 109.572 -179.724 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.493 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 122.371 1.081 . . . . 0.0 110.391 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.873 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -114.28 109.3 18.16 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-O 123.112 1.435 . . . . 0.0 109.59 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.819 HG13 ' CA ' ' A' ' 21' ' ' VAL . 0.6 OUTLIER -116.71 129.93 72.4 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.666 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.756 -179.883 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.506 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -167.8 148.62 4.75 Favored Pre-proline 0 N--CA 1.487 1.401 0 O-C-N 121.169 -0.957 . . . . 0.0 108.943 -179.723 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.506 ' HA ' HG23 ' A' ' 8' ' ' THR . 7.4 Cg_endo -80.66 147.64 74.96 Favored 'Cis proline' 0 C--N 1.309 -1.523 0 O-C-N 123.669 1.352 . . . . 0.0 109.181 -0.656 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.685 ' HA ' HG22 ' A' ' 110' ' ' ILE . 86.8 p -91.08 -24.5 20.0 Favored 'General case' 0 C--N 1.294 -1.805 0 O-C-N 121.484 -0.76 . . . . 0.0 109.238 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.461 ' HA ' ' O ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -129.61 161.59 30.2 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.367 -0.833 . . . . 0.0 109.622 -179.864 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.08 37.94 31.31 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 108.499 -1.84 . . . . 0.0 108.499 -179.679 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.777 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.3 mt -92.79 -43.69 8.89 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 123.199 1.476 . . . . 0.0 110.736 -178.248 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.476 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.58 143.9 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.473 -1.694 . . . . 0.0 109.79 -179.355 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.577 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 17.9 p-10 -50.54 106.86 0.14 Allowed 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.394 0.616 . . . . 0.0 111.517 -178.558 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.62 14.34 9.65 Favored Glycine 0 N--CA 1.485 1.903 0 C-N-CA 119.38 -1.391 . . . . 0.0 112.966 177.143 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.777 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.18 -172.17 2.06 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 121.1 2.45 . . . . 0.0 109.821 179.246 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.766 HG22 HG22 ' A' ' 68' ' ' THR . 17.7 t -127.94 138.7 53.95 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.796 -1.093 . . . . 0.0 111.197 -179.034 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.483 HG12 ' CD2' ' A' ' 13' ' ' LEU . 28.7 m -112.86 156.77 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.5 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.47 109.25 20.02 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.014 -1.054 . . . . 0.0 109.063 -179.933 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.819 ' CA ' HG13 ' A' ' 7' ' ' VAL . 11.2 p -103.74 140.65 21.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.707 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.873 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -138.93 160.82 38.83 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.681 -1.207 . . . . 0.0 110.142 179.635 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.585 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.03 140.25 11.55 Favored Glycine 0 C--N 1.297 -1.636 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.03 126.32 17.58 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.543 -1.563 . . . . 0.0 109.318 179.497 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.65 28.53 21.43 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 118.964 -1.588 . . . . 0.0 109.52 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.589 HD22 ' HG3' ' A' ' 105' ' ' PRO . 2.5 mt -88.0 175.92 7.55 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.003 -1.292 . . . . 0.0 108.339 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.03 97.7 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.825 -1.172 . . . . 0.0 109.707 -179.57 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.639 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.92 77.27 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.433 -179.057 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.562 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.45 34.45 0.32 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.564 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.9 p -146.07 111.92 5.63 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.016 -1.285 . . . . 0.0 111.195 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.562 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.38 126.79 5.48 Favored 'General case' 0 N--CA 1.493 1.7 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.501 178.06 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.505 ' CD2' ' O ' ' A' ' 30' ' ' THR . 13.3 m-85 -117.45 152.5 34.88 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.494 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -101.42 162.51 12.84 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 178.771 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.718 HG22 HG11 ' A' ' 21' ' ' VAL . 3.8 p -148.99 117.82 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.013 -1.054 . . . . 0.0 110.049 -177.794 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.511 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -170.86 -176.25 40.0 Favored Glycine 0 N--CA 1.493 2.48 0 C-N-CA 118.266 -1.921 . . . . 0.0 111.736 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.595 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.06 108.91 21.19 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -179.788 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.55 148.69 52.38 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.275 -0.891 . . . . 0.0 109.713 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.494 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.95 139.39 54.0 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.316 -0.865 . . . . 0.0 110.643 -178.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.862 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.31 114.55 26.34 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 178.157 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.4 m -106.34 15.43 7.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.974 -1.079 . . . . 0.0 110.771 -178.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.751 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.56 -175.31 0.1 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.894 -1.129 . . . . 0.0 110.124 179.657 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 39.2 p -71.45 96.84 1.54 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.395 -0.816 . . . . 0.0 109.691 -179.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.84 27.05 35.74 Favored Glycine 0 N--CA 1.493 2.496 0 C-N-CA 120.144 -1.027 . . . . 0.0 111.499 178.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.751 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.1 106.52 20.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 O-C-N 120.595 -1.532 . . . . 0.0 107.382 178.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.862 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -116.08 104.62 11.75 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.492 -1.38 . . . . 0.0 109.485 -177.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.012 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.09 109.57 22.31 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 120.735 -1.228 . . . . 0.0 108.295 179.062 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -107.22 163.78 12.73 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.974 -1.079 . . . . 0.0 110.303 -178.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.536 HD22 ' HB3' ' A' ' 50' ' ' ALA . 16.6 t30 -110.36 139.08 21.14 Favored Pre-proline 0 N--CA 1.503 2.219 0 O-C-N 121.369 -0.832 . . . . 0.0 109.89 -179.401 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.6 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 6.1 Cg_endo -74.55 23.99 0.37 Allowed 'Trans proline' 0 N--CA 1.495 1.591 0 C-N-CA 125.252 3.968 . . . . 0.0 111.445 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.536 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -116.58 1.12 12.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.474 -1.392 . . . . 0.0 109.043 179.474 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.511 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -137.75 15.39 2.9 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.399 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -79.51 90.88 5.1 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.978 -0.689 . . . . 0.0 110.831 -178.649 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.625 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.24 -170.14 1.6 Allowed 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.255 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.451 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.91 136.03 0.09 Allowed 'General case' 0 C--N 1.305 -1.331 0 O-C-N 120.657 -1.277 . . . . 0.0 111.093 -179.354 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.804 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.3 p -150.57 157.35 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 178.212 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.25 145.0 26.5 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.579 -1.325 . . . . 0.0 109.784 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.009 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.15 107.77 2.04 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 122.392 1.091 . . . . 0.0 109.56 178.793 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.553 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.9 p-10 -60.4 -139.26 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.992 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.857 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.639 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -53.01 -49.69 65.74 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.427 -0.795 . . . . 0.0 110.341 -178.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -102.56 -36.21 8.45 Favored 'General case' 0 C--N 1.287 -2.148 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 178.4 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.982 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.4 67.14 0.61 Allowed Glycine 0 N--CA 1.48 1.601 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 178.242 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.585 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.1 m -100.98 130.02 46.91 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.566 -0.961 . . . . 0.0 108.992 178.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.804 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.76 108.9 6.79 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.225 -0.99 . . . . 0.0 109.496 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.9 m -125.94 119.73 28.51 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.275 -0.891 . . . . 0.0 109.592 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.455 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.41 144.6 30.74 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.432 -0.793 . . . . 0.0 109.389 179.86 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.0 p -98.96 132.29 44.39 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.418 -0.801 . . . . 0.0 109.355 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.743 ' O ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -130.84 167.83 18.27 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.292 -0.88 . . . . 0.0 109.624 -179.511 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.766 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -99.33 125.54 45.01 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.183 -0.948 . . . . 0.0 109.344 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.568 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.4 m -137.7 143.04 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 120.985 -1.072 . . . . 0.0 109.857 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.577 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.8 ptt180 -145.95 -170.92 3.59 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.597 -1.314 . . . . 0.0 110.888 -179.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.616 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -56.12 -102.05 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.769 -0.582 . . . . 0.0 109.488 -179.405 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -55.38 141.0 37.9 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 120.715 -1.24 . . . . 0.0 108.266 179.554 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.577 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.06 137.13 7.16 Favored 'General case' 0 C--N 1.295 -1.777 0 C-N-CA 118.922 -1.111 . . . . 0.0 109.634 -178.357 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.566 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 9.9 mm-40 -33.03 121.62 0.37 Allowed 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.604 0.716 . . . . 0.0 110.868 -178.266 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.012 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.05 44.87 2.99 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -179.555 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.6 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-85 -37.88 112.6 0.22 Allowed 'General case' 0 N--CA 1.508 2.436 0 O-C-N 121.252 -1.146 . . . . 0.0 110.094 179.691 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.739 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.15 126.95 34.6 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.944 -1.098 . . . . 0.0 109.503 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 34.9 t80 -63.84 58.3 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.0 0 O-C-N 120.967 -1.083 . . . . 0.0 110.338 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 10.9 t0 -161.67 19.83 0.11 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.001 -1.062 . . . . 0.0 109.762 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.15 -26.93 5.25 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.427 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -92.43 157.09 16.78 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.009 -1.289 . . . . 0.0 110.322 -179.402 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.473 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -104.44 133.2 49.73 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.656 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.739 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.4 t90 -81.26 -18.96 44.14 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.835 -1.166 . . . . 0.0 110.427 -178.678 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.45 173.56 18.63 Favored Glycine 0 N--CA 1.485 1.962 0 N-CA-C 108.931 -1.668 . . . . 0.0 108.931 -179.687 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.37 106.83 1.19 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.156 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.647 HG21 ' HB3' ' A' ' 46' ' ' ALA . 50.2 t -77.9 106.17 7.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 O-C-N 121.302 -0.874 . . . . 0.0 109.504 -178.716 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.543 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.51 110.97 2.89 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.36 -0.837 . . . . 0.0 109.826 -179.573 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.616 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -62.5 -5.98 3.01 Favored 'General case' 0 N--CA 1.501 2.078 0 C-N-CA 118.32 -1.352 . . . . 0.0 109.901 179.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -87.13 -1.19 57.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.611 -1.306 . . . . 0.0 109.336 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.543 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.0 -49.54 3.02 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.253 -0.905 . . . . 0.0 108.959 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.82 -179.22 3.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.582 -0.699 . . . . 0.0 109.441 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.03 115.37 30.32 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.329 -0.857 . . . . 0.0 109.003 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.561 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.2 m -96.75 122.44 39.69 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.857 -1.152 . . . . 0.0 109.476 -179.362 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.58 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.29 147.86 26.55 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-O 122.451 1.12 . . . . 0.0 111.208 -179.354 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.473 ' CG1' HG11 ' A' ' 7' ' ' VAL . 60.8 t -104.18 111.09 32.44 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.973 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.07 -172.63 18.98 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 118.108 -1.996 . . . . 0.0 111.769 -177.588 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.5 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -114.4 -179.06 3.52 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 -179.11 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.497 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER . . . . . 0 C--N 1.295 -1.787 0 O-C-N 121.428 -0.795 . . . . 0.0 109.128 -179.406 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.769 0 N-CA-C 107.617 -2.193 . . . . 0.0 107.617 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.72 -178.75 7.3 Favored 'General case' 0 C--N 1.308 -1.228 0 O-C-N 121.587 -0.949 . . . . 0.0 109.457 179.036 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -175.66 -167.15 34.26 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 108.603 -1.799 . . . . 0.0 108.603 -179.577 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.589 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.7 Cg_exo -45.72 179.65 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.391 0 C-N-CA 123.262 2.641 . . . . 0.0 109.638 179.45 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.84 174.82 6.98 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.917 -1.115 . . . . 0.0 110.571 -178.759 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -115.15 163.3 12.23 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.02 129.34 57.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.23 -1.159 . . . . 0.0 109.241 -179.317 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.58 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.08 122.81 23.27 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.605 -0.684 . . . . 0.0 109.567 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.855 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.93 169.88 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.259 -0.9 . . . . 0.0 109.249 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.461 ' O ' ' HA ' ' A' ' 11' ' ' SER . 1.7 t -140.02 155.4 47.1 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.158 -0.964 . . . . 0.0 109.669 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.855 ' CE2' HD12 ' A' ' 110' ' ' ILE . 87.4 m-85 . . . . . 0 N--CA 1.486 1.327 0 O-C-N 121.109 -0.994 . . . . 0.0 109.607 -179.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.467 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.407 0 CA-C-O 122.101 0.953 . . . . 0.0 110.609 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.995 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.8 p -107.13 104.59 14.27 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.595 1.188 . . . . 0.0 110.023 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.993 HG22 HG23 ' A' ' 21' ' ' VAL . 13.2 t -117.93 121.2 66.77 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.435 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.433 179.798 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.512 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.95 148.5 7.42 Favored Pre-proline 0 N--CA 1.487 1.379 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 -179.74 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.512 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.4 Cg_endo -75.42 153.33 98.45 Favored 'Cis proline' 0 C--N 1.309 -1.501 0 C-N-CA 123.648 -1.397 . . . . 0.0 109.614 -0.447 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.493 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 5.1 m -97.27 -22.14 16.85 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.515 ' HB3' ' CB ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -134.43 158.65 43.33 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.543 -0.723 . . . . 0.0 109.537 179.96 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.24 36.73 30.17 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.798 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.5 mt -89.32 -43.89 10.61 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 123.181 1.467 . . . . 0.0 110.513 -178.512 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.74 144.94 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.335 0 CA-C-N 113.543 -1.662 . . . . 0.0 109.946 -179.646 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.584 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.4 p-10 -50.77 107.18 0.16 Allowed 'General case' 0 C--N 1.301 -1.525 0 CA-C-O 121.657 0.741 . . . . 0.0 111.788 -178.469 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.1 15.65 9.72 Favored Glycine 0 N--CA 1.486 1.997 0 C-N-CA 119.423 -1.37 . . . . 0.0 112.942 177.224 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.798 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.1 t -103.21 -172.31 2.09 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 121.103 2.451 . . . . 0.0 109.784 179.221 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.753 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.5 t -129.72 139.14 52.38 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.18 -178.726 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.484 HG11 HD11 ' A' ' 13' ' ' LEU . 26.8 m -118.32 154.36 20.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.64 109.21 20.35 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.233 -0.917 . . . . 0.0 109.292 -179.954 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.993 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -106.09 124.09 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.995 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.16 165.36 12.47 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 120.731 -1.231 . . . . 0.0 108.85 179.421 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.636 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -142.1 107.68 0.5 Allowed Glycine 0 C--O 1.203 -1.838 0 N-CA-C 108.376 -1.89 . . . . 0.0 108.376 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.1 139.09 51.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.706 -1.467 . . . . 0.0 110.83 -178.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.68 26.74 41.1 Favored Glycine 0 N--CA 1.491 2.364 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.044 179.011 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.566 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -88.34 172.97 9.01 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.975 -1.309 . . . . 0.0 108.476 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.024 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.52 99.75 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.064 -1.023 . . . . 0.0 109.602 -179.576 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.82 76.3 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.088 -179.257 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.594 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.81 33.62 0.22 Allowed Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.677 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.556 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 63.3 p -142.73 109.8 5.58 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.032 -1.275 . . . . 0.0 111.178 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.594 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.08 109.98 0.38 Allowed 'General case' 0 N--CA 1.497 1.894 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.361 177.79 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.485 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.0 m-30 -105.62 155.97 18.71 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.101 -0.999 . . . . 0.0 109.029 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.509 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -98.83 163.25 12.69 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.744 -1.222 . . . . 0.0 107.763 178.791 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.735 HG11 HG21 ' A' ' 65' ' ' THR . 7.0 p -144.45 114.85 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.151 -0.968 . . . . 0.0 109.91 -177.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.65 -177.34 39.54 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 118.204 -1.95 . . . . 0.0 111.716 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.59 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.0 OUTLIER -99.77 112.2 24.46 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 -179.98 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 64.4 m -130.12 154.36 47.56 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 121.428 -0.795 . . . . 0.0 109.703 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.615 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -130.89 137.77 49.49 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.507 -0.745 . . . . 0.0 110.607 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.904 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.71 114.68 26.64 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.377 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.9 m -105.85 15.2 7.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.911 -1.118 . . . . 0.0 110.703 -178.548 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.779 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.23 -175.96 0.08 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.899 -1.126 . . . . 0.0 110.117 179.598 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.8 HG23 ' O ' ' A' ' 42' ' ' THR . 15.2 t -69.58 97.19 1.0 Allowed 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.786 0.803 . . . . 0.0 109.985 -179.474 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.12 27.68 36.36 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.523 178.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.779 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.86 106.46 20.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 O-C-N 120.545 -1.562 . . . . 0.0 107.34 178.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.904 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.5 tp -116.03 106.7 14.05 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.529 -1.357 . . . . 0.0 109.783 -177.598 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.112 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -96.17 110.44 22.72 Favored 'General case' 0 N--CA 1.484 1.272 0 O-C-N 120.765 -1.209 . . . . 0.0 108.554 179.5 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.584 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . 60.8 m -99.71 148.06 24.77 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.337 -0.852 . . . . 0.0 109.979 -178.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.749 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 13.0 t-20 -98.92 132.61 23.35 Favored Pre-proline 0 N--CA 1.501 2.098 0 O-C-N 120.922 -1.111 . . . . 0.0 109.159 179.413 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.581 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.9 Cg_endo -73.48 24.06 0.32 Allowed 'Trans proline' 0 C--N 1.317 -1.087 0 C-N-CA 122.291 1.994 . . . . 0.0 112.011 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.749 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -115.62 1.08 13.47 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.283 -1.51 . . . . 0.0 109.215 179.492 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.573 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.68 17.46 2.34 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 179.332 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.584 ' CE2' ' HB3' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -81.26 89.75 6.07 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.726 -0.789 . . . . 0.0 110.878 -178.787 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -112.57 -170.74 1.72 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.32 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.443 ' OG ' ' HA ' ' A' ' 33' ' ' ASP . 0.8 OUTLIER 178.8 134.62 0.09 Allowed 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.592 -1.318 . . . . 0.0 111.287 -179.342 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.564 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 2.5 p -149.07 161.99 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 178.163 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.29 142.62 29.72 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.685 -1.26 . . . . 0.0 110.181 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.024 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.66 108.39 2.45 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.401 1.096 . . . . 0.0 109.735 178.594 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.539 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.5 t70 -62.73 -139.39 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.995 0 CA-C-O 121.494 0.664 . . . . 0.0 110.77 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.85 -50.97 55.68 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.384 -0.823 . . . . 0.0 110.713 -178.722 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 13.6 t30 -103.16 -33.74 9.1 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 178.591 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.981 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 104.18 70.54 0.82 Allowed Glycine 0 C--N 1.298 -1.544 0 N-CA-C 110.254 -1.139 . . . . 0.0 110.254 178.415 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.636 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 36.7 m -103.34 127.55 50.66 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 121.418 -1.048 . . . . 0.0 109.322 179.566 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.567 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -132.09 108.73 9.5 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 50.8 m -118.14 115.3 24.51 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.159 -0.963 . . . . 0.0 109.39 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.735 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.22 137.08 27.09 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.397 -0.814 . . . . 0.0 109.981 -179.862 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.7 p -100.43 133.21 45.19 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.374 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.843 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -135.66 172.23 13.32 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.138 -0.976 . . . . 0.0 109.803 -179.076 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.692 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -99.63 124.68 45.08 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.139 -0.976 . . . . 0.0 109.583 -179.692 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.47 HG23 HD13 ' A' ' 13' ' ' LEU . 17.1 m -135.98 143.58 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.015 -1.053 . . . . 0.0 109.664 -179.415 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.584 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.3 ptt180 -141.52 -165.29 1.95 Allowed 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.563 -1.336 . . . . 0.0 110.076 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.548 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -72.65 -87.91 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.522 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -60.14 135.98 57.88 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.58 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.615 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.25 135.22 6.85 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 118.105 -1.438 . . . . 0.0 110.586 -177.62 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.543 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -33.29 119.42 0.35 Allowed 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.588 0.709 . . . . 0.0 110.451 -178.637 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.112 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.19 50.21 2.17 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.511 -178.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.581 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 1.1 m-85 -36.53 118.94 0.59 Allowed 'General case' 0 N--CA 1.513 2.719 0 O-C-N 121.236 -1.155 . . . . 0.0 110.214 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.621 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.4 tp -86.93 125.82 34.29 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.901 -1.124 . . . . 0.0 109.389 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.0 t80 -63.72 58.58 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.881 -1.137 . . . . 0.0 110.088 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.8 OUTLIER -161.44 21.01 0.12 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.986 -1.071 . . . . 0.0 109.651 179.879 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.02 -30.55 4.66 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.468 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -94.38 165.14 12.71 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.103 -1.234 . . . . 0.0 110.035 -179.417 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.433 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -111.24 140.39 45.84 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -179.897 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.621 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.2 t90 -81.9 -21.42 37.4 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.77 -1.207 . . . . 0.0 110.461 -178.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.67 176.54 18.87 Favored Glycine 0 N--CA 1.485 1.929 0 N-CA-C 108.558 -1.817 . . . . 0.0 108.558 -179.357 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.12 109.96 2.01 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.094 -1.239 . . . . 0.0 107.741 179.223 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.569 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.6 t -82.4 103.21 9.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.394 -0.816 . . . . 0.0 108.916 -178.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.528 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -63.95 110.53 2.15 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.48 -0.762 . . . . 0.0 109.851 -179.344 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.548 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.07 -4.96 5.39 Favored 'General case' 0 N--CA 1.499 1.985 0 C-N-CA 118.269 -1.372 . . . . 0.0 109.829 179.457 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.4 p -85.31 5.1 31.99 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.779 -1.201 . . . . 0.0 108.877 179.347 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.528 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -121.11 -48.9 2.21 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.327 -0.858 . . . . 0.0 109.047 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.63 -177.78 3.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.569 -0.707 . . . . 0.0 109.38 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.14 114.09 27.93 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.391 -0.818 . . . . 0.0 108.921 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.495 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.5 m -97.4 122.74 40.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.892 -1.13 . . . . 0.0 109.756 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.618 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.66 147.73 27.33 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 122.444 1.116 . . . . 0.0 111.346 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.551 ' HB ' HG11 ' A' ' 7' ' ' VAL . 66.9 t -101.47 109.8 26.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 177.618 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.412 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.19 -172.52 18.23 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 118.07 -2.014 . . . . 0.0 111.59 -177.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.492 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.74 -178.12 3.32 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -178.904 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.509 ' O ' ' N ' ' A' ' 33' ' ' ASP . 30.3 p . . . . . 0 C--N 1.296 -1.738 0 O-C-N 121.352 -0.842 . . . . 0.0 109.479 -179.375 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.706 0 N-CA-C 107.567 -2.213 . . . . 0.0 107.567 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -157.91 -178.62 7.45 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.512 -0.993 . . . . 0.0 109.763 179.098 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.02 -161.76 12.85 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 108.313 -1.915 . . . . 0.0 108.313 -179.328 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.492 ' HB2' HD12 ' A' ' 97' ' ' LEU . 5.0 Cg_exo -47.17 177.69 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.701 0 CA-C-N 118.789 1.295 . . . . 0.0 110.076 179.263 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -91.79 179.79 5.53 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.059 -1.026 . . . . 0.0 110.724 -178.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.412 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.4 160.99 13.36 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.23 130.01 51.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.324 -1.103 . . . . 0.0 109.345 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.618 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.83 127.3 32.13 Favored 'General case' 0 C--N 1.291 -1.972 0 O-C-N 121.583 -0.698 . . . . 0.0 109.65 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.641 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 19.6 pt -97.25 178.52 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 121.24 -0.912 . . . . 0.0 109.279 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.515 ' CB ' ' HB3' ' A' ' 11' ' ' SER . 0.5 OUTLIER -143.18 152.28 41.59 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.366 -0.834 . . . . 0.0 109.571 179.838 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.641 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 97.3 m-85 . . . . . 0 N--CA 1.484 1.249 0 O-C-N 121.082 -1.011 . . . . 0.0 109.569 -179.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.276 0 CA-C-O 122.334 1.064 . . . . 0.0 110.225 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.818 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -116.38 109.01 16.77 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-O 123.105 1.431 . . . . 0.0 109.605 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.925 HG22 HG23 ' A' ' 21' ' ' VAL . 4.0 t -114.58 135.33 54.73 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.669 0 CA-C-N 114.194 -1.366 . . . . 0.0 109.688 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.472 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.65 149.82 4.49 Favored Pre-proline 0 N--CA 1.487 1.419 0 O-C-N 121.193 -0.942 . . . . 0.0 108.984 -179.493 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.472 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -79.3 149.38 83.08 Favored 'Cis proline' 0 C--N 1.312 -1.376 0 C-N-CA 123.511 -1.454 . . . . 0.0 109.393 -1.009 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.661 ' HA ' HG22 ' A' ' 110' ' ' ILE . 86.1 p -90.99 -23.83 20.28 Favored 'General case' 0 C--N 1.292 -1.929 0 O-C-N 121.551 -0.718 . . . . 0.0 109.191 179.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.49 ' CB ' ' HB3' ' A' ' 111' ' ' SER . 0.7 OUTLIER -129.8 158.94 38.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.496 -0.753 . . . . 0.0 109.595 -179.881 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.51 37.33 27.55 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 108.64 -1.784 . . . . 0.0 108.64 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.806 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.0 mt -92.11 -44.02 9.06 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.213 1.482 . . . . 0.0 110.757 -178.459 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.463 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.16 145.16 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.299 0 CA-C-N 113.505 -1.68 . . . . 0.0 110.055 -179.753 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.613 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.3 p-10 -50.32 106.4 0.12 Allowed 'General case' 0 C--N 1.3 -1.567 0 CA-C-O 121.445 0.641 . . . . 0.0 111.645 -178.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.46 14.93 8.53 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.515 -1.326 . . . . 0.0 112.995 177.18 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.806 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -104.97 -174.18 2.48 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 121.134 2.467 . . . . 0.0 109.919 179.348 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.771 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.5 t -127.09 136.11 61.69 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.437 0 CA-C-N 114.541 -1.208 . . . . 0.0 111.258 -178.84 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.472 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 23.3 m -112.25 154.86 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 178.61 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.506 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 18.9 tttt -107.73 109.38 20.95 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.174 -0.954 . . . . 0.0 108.949 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.925 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.73 139.42 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.349 -0.844 . . . . 0.0 108.79 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.818 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.17 161.75 34.02 Favored 'General case' 0 C--N 1.305 -1.358 0 O-C-N 120.886 -1.134 . . . . 0.0 109.848 179.483 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.57 139.7 10.86 Favored Glycine 0 C--N 1.297 -1.604 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 179.752 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.37 125.87 16.76 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.499 -1.589 . . . . 0.0 109.3 179.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.97 27.63 23.18 Favored Glycine 0 N--CA 1.488 2.146 0 C-N-CA 118.8 -1.667 . . . . 0.0 109.736 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.562 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.1 mt -87.65 174.16 8.6 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 120.825 -1.397 . . . . 0.0 108.215 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.017 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.46 97.18 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.916 -1.115 . . . . 0.0 109.888 -179.412 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.623 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.76 77.13 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.761 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.404 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.69 34.09 0.32 Allowed Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.383 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.546 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.3 p -147.13 112.8 5.67 Favored 'General case' 0 C--N 1.308 -1.209 0 O-C-N 120.819 -1.401 . . . . 0.0 111.335 -179.804 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.566 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.87 126.58 5.86 Favored 'General case' 0 N--CA 1.491 1.623 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.846 178.063 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.485 ' CD2' ' O ' ' A' ' 30' ' ' THR . 12.7 m-85 -118.5 152.26 36.29 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.478 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -100.93 160.34 14.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.724 -1.235 . . . . 0.0 107.825 178.911 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.955 HG11 HG21 ' A' ' 65' ' ' THR . 3.7 p -142.4 119.8 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.218 -0.926 . . . . 0.0 109.451 -178.055 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.54 -178.54 41.35 Favored Glycine 0 N--CA 1.494 2.506 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.505 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.684 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -101.0 108.58 20.33 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.462 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.45 149.51 51.19 Favored 'General case' 0 C--N 1.296 -1.738 0 O-C-N 121.264 -0.898 . . . . 0.0 109.956 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.497 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -125.03 139.53 53.73 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.367 -0.833 . . . . 0.0 110.673 -179.146 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.29 114.92 26.75 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.199 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.8 m -105.11 15.23 6.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.093 -1.004 . . . . 0.0 110.595 -178.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.759 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.61 -176.06 0.08 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.947 -1.096 . . . . 0.0 110.038 179.631 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.776 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.93 97.75 1.48 Allowed 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.803 0.811 . . . . 0.0 109.848 -179.639 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.14 27.65 36.4 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 120.186 -1.007 . . . . 0.0 111.419 178.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -115.83 106.44 20.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 O-C-N 120.621 -1.517 . . . . 0.0 107.189 178.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -116.03 104.69 11.83 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.461 -1.399 . . . . 0.0 109.936 -177.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.045 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.41 22.17 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.827 -1.17 . . . . 0.0 108.179 178.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.9 t -107.46 163.63 12.89 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.847 -1.158 . . . . 0.0 110.295 -179.006 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.5 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 13.6 t30 -108.98 134.18 20.46 Favored Pre-proline 0 N--CA 1.502 2.136 0 O-C-N 121.351 -0.843 . . . . 0.0 109.575 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.598 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.6 Cg_endo -74.38 26.85 0.34 Allowed 'Trans proline' 0 C--N 1.319 -0.98 0 C-N-CA 122.486 2.124 . . . . 0.0 112.197 -179.396 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.494 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -109.29 -3.15 17.39 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.329 -1.482 . . . . 0.0 109.299 179.664 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.874 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.7 m-20 -135.96 12.39 3.36 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -70.07 83.6 0.51 Allowed 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.683 -0.807 . . . . 0.0 110.74 -178.667 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -105.23 -167.92 1.4 Allowed 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 178.356 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.473 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.7 t 179.07 135.59 0.09 Allowed 'General case' 0 C--N 1.306 -1.325 0 O-C-N 120.632 -1.292 . . . . 0.0 111.231 -179.38 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.773 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.7 p -149.24 156.63 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 178.095 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.566 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.57 145.39 26.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.583 -1.323 . . . . 0.0 109.738 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.017 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.93 108.67 2.66 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 122.334 1.064 . . . . 0.0 109.592 178.756 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.563 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 p-10 -62.92 -139.58 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.054 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.641 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.623 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.92 -51.73 49.19 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.446 -0.784 . . . . 0.0 110.569 -178.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -102.51 -32.98 9.67 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 178.582 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.84 66.72 0.64 Allowed Glycine 0 C--N 1.299 -1.511 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 178.168 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 55.6 p -98.69 132.51 44.01 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 121.289 -1.124 . . . . 0.0 109.048 179.001 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.773 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.03 108.6 6.95 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.146 -1.022 . . . . 0.0 109.535 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.3 m -124.12 117.48 24.76 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.265 -0.897 . . . . 0.0 109.641 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.955 HG21 HG11 ' A' ' 34' ' ' VAL . 5.2 t -145.99 145.2 30.54 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.441 -0.787 . . . . 0.0 109.361 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 53.3 p -99.03 143.98 28.69 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.428 -0.795 . . . . 0.0 109.342 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.874 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -145.35 169.86 17.45 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.305 -0.872 . . . . 0.0 109.459 -178.96 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.754 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -102.32 123.27 45.83 Favored 'General case' 0 N--CA 1.498 1.975 0 O-C-N 120.842 -1.161 . . . . 0.0 110.388 -178.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.842 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.2 m -131.12 143.98 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 120.996 -1.065 . . . . 0.0 110.016 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.613 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.3 ptt180 -148.93 -176.63 5.42 Favored 'General case' 0 N--CA 1.483 1.221 0 O-C-N 120.555 -1.341 . . . . 0.0 110.649 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.619 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.73 -101.5 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -179.562 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.5 OUTLIER -56.29 140.07 46.17 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.777 -1.202 . . . . 0.0 108.313 179.591 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.569 ' CZ ' ' SG ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -160.81 135.69 7.56 Favored 'General case' 0 C--N 1.296 -1.74 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.545 -178.57 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.5 ' N ' ' OD1' ' A' ' 48' ' ' ASN . 6.1 mm-40 -33.05 122.18 0.38 Allowed 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.609 0.718 . . . . 0.0 110.775 -178.038 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.045 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.78 45.34 2.89 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 -179.326 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.598 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-85 -37.64 114.62 0.35 Allowed 'General case' 0 N--CA 1.512 2.632 0 O-C-N 121.277 -1.131 . . . . 0.0 110.12 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.733 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -87.44 127.22 35.22 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.115 -0.991 . . . . 0.0 109.291 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 49.8 t80 -63.54 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.061 0 O-C-N 120.862 -1.149 . . . . 0.0 110.137 179.74 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.2 t0 -161.2 19.33 0.12 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.945 -1.097 . . . . 0.0 109.805 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.55 -26.73 5.61 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 42.1 p -94.41 160.21 14.76 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.121 -1.223 . . . . 0.0 110.11 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.477 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.6 OUTLIER -106.67 136.12 47.03 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.733 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.1 t90 -81.91 -18.9 42.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.819 -1.175 . . . . 0.0 110.428 -178.653 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.46 174.38 18.43 Favored Glycine 0 N--CA 1.486 2.024 0 N-CA-C 108.772 -1.731 . . . . 0.0 108.772 -179.602 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.18 106.06 1.23 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.113 -1.228 . . . . 0.0 107.688 179.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.683 HG21 ' HB3' ' A' ' 46' ' ' ALA . 51.3 t -76.96 105.22 5.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.316 -0.865 . . . . 0.0 109.361 -178.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.675 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.62 110.85 2.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.468 -0.77 . . . . 0.0 109.765 -179.599 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.619 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.08 -5.73 3.39 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 120.517 -1.364 . . . . 0.0 109.846 179.422 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -86.52 -0.57 56.36 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.706 -1.246 . . . . 0.0 109.172 179.655 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.675 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -113.19 -50.13 2.88 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.322 -0.861 . . . . 0.0 108.957 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.63 -178.62 3.71 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.576 -0.703 . . . . 0.0 109.428 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.54 115.31 30.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.337 -0.852 . . . . 0.0 109.039 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.569 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.24 123.36 41.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.875 -1.14 . . . . 0.0 109.7 -179.278 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.623 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.76 145.92 29.69 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.474 1.13 . . . . 0.0 111.113 -179.424 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.517 ' CG1' HG11 ' A' ' 7' ' ' VAL . 55.6 t -101.76 110.09 27.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.049 0 N-CA-C 106.646 -1.612 . . . . 0.0 106.646 177.474 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.483 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.01 -171.29 16.83 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 118.106 -1.997 . . . . 0.0 111.694 -177.475 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.49 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -119.0 179.48 4.14 Favored 'General case' 0 N--CA 1.485 1.283 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.038 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.535 ' O ' ' N ' ' A' ' 33' ' ' ASP . 3.5 m . . . . . 0 C--N 1.294 -1.817 0 O-C-N 121.435 -0.791 . . . . 0.0 109.666 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.409 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.482 1.721 0 N-CA-C 107.909 -2.076 . . . . 0.0 107.909 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.409 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.65 -177.15 3.8 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.603 -0.939 . . . . 0.0 109.725 179.395 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.63 -161.65 19.15 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.32 -1.912 . . . . 0.0 108.32 -179.388 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.495 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.9 Cg_exo -46.68 176.26 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.655 0 CA-C-N 118.808 1.304 . . . . 0.0 110.173 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -94.19 -174.96 3.53 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.038 -1.039 . . . . 0.0 110.403 -178.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.483 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.79 165.0 13.47 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.449 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.55 130.57 50.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.353 -1.087 . . . . 0.0 109.223 -179.416 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.623 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.84 125.48 28.26 Favored 'General case' 0 C--N 1.291 -1.964 0 O-C-N 121.669 -0.644 . . . . 0.0 109.774 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.661 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.5 pt -97.82 170.11 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.307 -0.871 . . . . 0.0 109.22 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.49 ' HB3' ' CB ' ' A' ' 11' ' ' SER . 3.6 t -138.09 158.33 44.53 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.375 -0.828 . . . . 0.0 109.449 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.633 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 30.4 m-85 . . . . . 0 N--CA 1.487 1.417 0 O-C-N 121.184 -0.948 . . . . 0.0 109.539 -179.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.587 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.388 0 CA-C-O 122.289 1.042 . . . . 0.0 111.109 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.007 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -101.66 104.47 15.31 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 122.413 1.101 . . . . 0.0 110.032 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.949 HG22 HG23 ' A' ' 21' ' ' VAL . 3.4 t -118.54 115.4 48.0 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.415 0 CA-C-O 121.679 0.752 . . . . 0.0 110.455 179.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.504 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.22 147.85 12.78 Favored Pre-proline 0 N--CA 1.487 1.397 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 -179.723 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.504 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.3 Cg_endo -77.07 152.05 94.41 Favored 'Cis proline' 0 C--N 1.309 -1.506 0 C-N-CA 123.693 -1.378 . . . . 0.0 109.561 -0.328 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.685 ' HA ' HG22 ' A' ' 110' ' ' ILE . 13.6 p -89.71 -25.84 20.98 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.642 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.518 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.0 m -136.39 167.98 20.3 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.555 -0.715 . . . . 0.0 109.338 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.47 38.12 39.15 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.747 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.3 mt -93.22 -42.63 9.24 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 123.319 1.533 . . . . 0.0 110.561 -178.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.56 142.58 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.284 0 CA-C-N 113.402 -1.726 . . . . 0.0 109.67 -179.385 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.606 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.2 p-10 -50.61 105.95 0.11 Allowed 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.588 0.709 . . . . 0.0 111.364 -178.517 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.68 14.15 8.24 Favored Glycine 0 N--CA 1.484 1.88 0 C-N-CA 119.446 -1.359 . . . . 0.0 112.982 177.418 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.747 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -106.21 -172.24 2.05 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 121.22 2.51 . . . . 0.0 109.831 179.161 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.985 HG22 HG22 ' A' ' 68' ' ' THR . 17.1 t -129.7 138.32 54.49 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.34 -178.786 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.62 HG11 HD11 ' A' ' 13' ' ' LEU . 35.8 m -114.34 155.35 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.782 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 28.2 tttt -107.13 108.87 20.53 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.184 -0.948 . . . . 0.0 109.466 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.949 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -105.64 123.29 59.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.007 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.66 166.55 12.28 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.716 -1.24 . . . . 0.0 109.325 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.62 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.05 142.45 13.89 Favored Glycine 0 C--N 1.294 -1.766 0 N-CA-C 107.381 -2.288 . . . . 0.0 107.381 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -147.22 123.27 10.76 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 120.747 -1.443 . . . . 0.0 108.714 179.372 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.1 27.01 22.38 Favored Glycine 0 N--CA 1.487 2.084 0 C-N-CA 119.155 -1.498 . . . . 0.0 109.802 -179.563 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.553 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.9 OUTLIER -89.0 174.8 7.7 Favored 'General case' 0 C--N 1.307 -1.248 0 O-C-N 120.842 -1.387 . . . . 0.0 108.436 179.85 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.83 99.78 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.949 -1.094 . . . . 0.0 109.808 -179.8 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.581 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.18 78.09 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.191 -179.298 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.83 34.5 0.3 Allowed Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 179.627 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.565 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 35.2 p -140.99 106.9 5.15 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 121.127 -1.219 . . . . 0.0 111.361 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.59 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.52 110.07 0.34 Allowed 'General case' 0 N--CA 1.498 1.931 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.557 177.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 5.7 m-30 -108.0 154.38 21.72 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.097 -1.002 . . . . 0.0 108.854 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.64 163.03 12.53 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.864 -1.148 . . . . 0.0 108.055 179.133 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.643 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.6 p -140.89 116.71 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.133 -0.979 . . . . 0.0 109.351 -178.297 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -164.32 -176.72 36.39 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 118.325 -1.893 . . . . 0.0 111.802 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.593 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -103.15 109.44 21.02 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.862 0.839 . . . . 0.0 109.099 -179.635 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.35 147.79 51.21 Favored 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.231 -0.918 . . . . 0.0 109.578 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.558 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.66 138.26 54.41 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.255 -0.903 . . . . 0.0 110.823 -178.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.68 26.48 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.177 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -105.74 14.71 7.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 120.952 -1.092 . . . . 0.0 110.513 -178.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 175.09 -175.9 0.09 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 120.951 -1.093 . . . . 0.0 110.03 179.754 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.784 HG23 ' O ' ' A' ' 42' ' ' THR . 15.0 t -71.33 97.82 1.65 Allowed 'General case' 0 N--CA 1.487 1.379 0 CA-C-O 121.785 0.802 . . . . 0.0 109.785 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.78 27.45 34.79 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.238 -0.982 . . . . 0.0 111.524 178.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.98 106.11 19.75 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 O-C-N 120.539 -1.565 . . . . 0.0 107.236 178.836 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.82 104.75 11.64 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.517 -1.365 . . . . 0.0 109.874 -177.692 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.106 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.78 109.45 22.2 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 120.845 -1.16 . . . . 0.0 108.071 178.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.4 t -107.07 162.42 13.87 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.949 -1.094 . . . . 0.0 110.393 -178.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.557 HD22 ' HB3' ' A' ' 50' ' ' ALA . 15.4 t30 -110.32 134.4 20.81 Favored Pre-proline 0 N--CA 1.503 2.199 0 O-C-N 121.453 -0.78 . . . . 0.0 109.759 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.593 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.77 25.03 0.33 Allowed 'Trans proline' 0 C--N 1.318 -1.055 0 C-N-CA 122.346 2.031 . . . . 0.0 112.192 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.557 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -113.43 4.15 16.15 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.327 -1.483 . . . . 0.0 109.233 179.538 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.56 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.78 16.04 2.69 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 179.462 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -79.85 88.86 5.25 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.541 -178.266 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.643 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -105.96 -165.85 1.14 Allowed 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 177.788 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.444 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.77 138.38 0.09 Allowed 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.508 -1.37 . . . . 0.0 111.454 -179.343 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.949 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -156.64 157.2 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.225 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.67 141.82 31.01 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.828 -1.17 . . . . 0.0 109.746 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.05 106.96 0.92 Allowed 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 122.385 1.088 . . . . 0.0 109.144 178.309 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.8 t0 -61.64 -138.9 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.987 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.016 -179.843 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.581 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.59 -52.12 32.46 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.426 -0.796 . . . . 0.0 110.81 -178.534 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -104.06 -33.05 8.91 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 106.209 -1.775 . . . . 0.0 106.209 178.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.016 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.31 65.41 0.56 Allowed Glycine 0 C--N 1.298 -1.542 0 N-CA-C 110.457 -1.057 . . . . 0.0 110.457 178.085 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.62 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.4 m -102.99 127.95 50.01 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 121.492 -1.004 . . . . 0.0 108.819 178.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.949 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.39 109.17 7.55 Favored 'General case' 0 C--N 1.296 -1.737 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.893 -179.312 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -116.26 117.43 29.99 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.207 -0.933 . . . . 0.0 109.291 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.573 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.63 143.34 30.72 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.412 -0.805 . . . . 0.0 109.758 -179.978 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.9 p -101.0 140.01 35.89 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.472 -0.768 . . . . 0.0 109.5 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.796 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -139.21 161.6 37.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.36 -0.837 . . . . 0.0 109.524 -179.469 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.985 HG22 HG22 ' A' ' 18' ' ' VAL . 2.9 p -93.87 124.46 37.89 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.159 -0.963 . . . . 0.0 109.438 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.562 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.3 m -135.38 143.71 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.063 -1.023 . . . . 0.0 109.58 -179.314 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.606 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.5 ptt180 -146.79 -177.13 5.49 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 120.453 -1.405 . . . . 0.0 111.042 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.627 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.13 -100.98 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -179.674 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -56.2 140.68 43.7 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 120.769 -1.207 . . . . 0.0 108.208 179.546 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.05 136.19 6.66 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 118.82 -1.152 . . . . 0.0 109.672 -178.341 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.52 ' N ' ' OD1' ' A' ' 48' ' ' ASN . 34.6 mt-10 -34.8 122.12 0.53 Allowed 'General case' 0 N--CA 1.489 1.508 0 CA-C-O 121.491 0.662 . . . . 0.0 110.462 -178.314 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.106 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.74 49.14 2.55 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.593 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.1 m-85 -38.82 114.21 0.37 Allowed 'General case' 0 N--CA 1.506 2.353 0 O-C-N 121.18 -1.188 . . . . 0.0 109.915 179.541 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.7 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.44 126.81 34.66 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.944 -1.098 . . . . 0.0 109.46 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -64.12 58.37 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.976 0 O-C-N 120.832 -1.168 . . . . 0.0 110.133 179.718 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.2 t70 -160.54 19.49 0.14 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.125 -0.984 . . . . 0.0 109.704 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.63 -27.18 5.41 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.41 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 21.4 p -94.19 159.71 15.02 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.03 -1.277 . . . . 0.0 110.316 -179.429 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.478 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.52 136.29 46.55 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.711 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.7 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.12 -18.47 42.8 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.734 -1.228 . . . . 0.0 110.44 -178.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.94 174.92 19.31 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 108.819 -1.712 . . . . 0.0 108.819 -179.575 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -65.09 105.34 1.04 Allowed 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 179.186 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.643 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.9 t -77.28 107.06 8.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.364 -0.835 . . . . 0.0 109.267 -178.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.536 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.2 m-20 -66.76 111.39 3.69 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.441 -0.787 . . . . 0.0 110.022 -179.313 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.627 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.81 -5.52 4.42 Favored 'General case' 0 N--CA 1.5 2.058 0 C-N-CA 118.171 -1.412 . . . . 0.0 109.832 179.198 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 16.6 p -87.26 1.17 53.98 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.795 -1.19 . . . . 0.0 109.171 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.536 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -115.23 -50.66 2.74 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.326 -0.859 . . . . 0.0 108.99 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.67 179.63 4.21 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.488 -0.757 . . . . 0.0 109.43 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.5 115.39 30.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.31 -0.869 . . . . 0.0 108.906 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.563 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.2 m -96.99 122.04 39.54 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.916 -1.115 . . . . 0.0 109.335 -179.368 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.578 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.17 146.37 27.58 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 122.371 1.081 . . . . 0.0 111.286 -179.292 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.607 ' HB ' HG11 ' A' ' 7' ' ' VAL . 54.6 t -105.73 111.74 36.19 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.028 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.502 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.46 -169.94 19.06 Favored Glycine 0 N--CA 1.487 2.088 0 C-N-CA 118.251 -1.928 . . . . 0.0 111.482 -177.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.479 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -117.23 173.24 6.79 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.803 -0.822 . . . . 0.0 108.858 -179.356 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.479 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER . . . . . 0 C--N 1.293 -1.888 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.519 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.482 1.744 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -173.74 -176.21 1.21 Allowed 'General case' 0 C--N 1.306 -1.29 0 O-C-N 121.562 -0.964 . . . . 0.0 109.828 179.512 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.501 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.6 -159.57 12.51 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.314 -1.914 . . . . 0.0 108.314 -179.311 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.501 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.6 Cg_exo -47.49 -178.13 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.672 0 CA-C-N 118.824 1.312 . . . . 0.0 110.574 179.215 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -94.44 -178.38 4.56 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.057 -1.027 . . . . 0.0 110.405 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.502 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.36 162.22 13.31 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.25 128.6 52.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.465 -1.021 . . . . 0.0 109.123 -179.549 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.578 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.09 118.53 15.07 Favored 'General case' 0 C--N 1.289 -2.059 0 O-C-N 121.7 -0.625 . . . . 0.0 109.555 179.75 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.899 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.8 pt -98.01 172.13 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.289 -0.882 . . . . 0.0 108.997 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.518 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -142.48 154.09 44.22 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.06 -1.025 . . . . 0.0 110.153 -179.744 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.899 ' CE2' HD12 ' A' ' 110' ' ' ILE . 97.8 m-85 . . . . . 0 N--CA 1.486 1.342 0 O-C-N 121.302 -0.873 . . . . 0.0 109.278 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.534 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.484 1.244 0 CA-C-O 122.254 1.026 . . . . 0.0 110.827 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.003 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.7 p -104.03 104.82 14.83 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-O 122.417 1.103 . . . . 0.0 110.397 -179.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.94 HG22 HG23 ' A' ' 21' ' ' VAL . 6.1 t -119.26 116.81 52.05 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.477 0 CA-C-O 121.582 0.706 . . . . 0.0 110.226 179.434 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.5 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -161.06 149.28 12.8 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.44 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.5 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.71 152.95 98.87 Favored 'Cis proline' 0 C--N 1.311 -1.428 0 C-N-CA 123.679 -1.384 . . . . 0.0 109.72 -0.507 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.647 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.8 m -91.46 -25.35 19.35 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.49 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 13.5 m -136.84 166.15 24.29 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.6 -0.688 . . . . 0.0 109.39 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.27 37.76 35.92 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 108.426 -1.87 . . . . 0.0 108.426 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.787 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.9 mt -92.47 -43.77 9.01 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 123.229 1.49 . . . . 0.0 110.676 -178.242 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.56 144.72 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.517 -1.674 . . . . 0.0 110.044 -179.57 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.601 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.7 p-10 -50.72 107.36 0.17 Allowed 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.535 0.683 . . . . 0.0 111.629 -178.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.9 14.23 9.52 Favored Glycine 0 N--CA 1.485 1.949 0 C-N-CA 119.421 -1.371 . . . . 0.0 112.927 177.357 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.787 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.8 t -105.09 -173.54 2.33 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 121.13 2.465 . . . . 0.0 109.899 179.265 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.769 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.9 t -128.41 138.97 53.17 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 CA-C-N 114.63 -1.168 . . . . 0.0 111.157 -178.639 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.551 HG11 HD11 ' A' ' 13' ' ' LEU . 27.9 m -116.15 154.42 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.653 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.554 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 15.0 tptp -107.21 108.68 20.22 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.168 -0.957 . . . . 0.0 109.297 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.94 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -106.14 123.54 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.003 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -118.24 168.22 10.8 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.717 -1.24 . . . . 0.0 109.504 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.614 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -137.13 136.71 8.47 Favored Glycine 0 C--O 1.207 -1.582 0 N-CA-C 107.493 -2.243 . . . . 0.0 107.493 179.515 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -141.27 125.82 17.8 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-N 119.668 1.734 . . . . 0.0 109.397 179.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.471 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 88.35 28.91 21.12 Favored Glycine 0 N--CA 1.488 2.146 0 C-N-CA 118.692 -1.718 . . . . 0.0 109.598 -179.715 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.525 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.8 mt -89.26 173.98 8.1 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.034 -1.274 . . . . 0.0 108.283 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.001 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.02 97.1 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.007 -1.058 . . . . 0.0 109.773 -179.871 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.684 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.34 76.86 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.39 -178.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.84 34.06 0.31 Allowed Glycine 0 N--CA 1.486 1.995 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.309 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.557 HG23 ' O ' ' A' ' 30' ' ' THR . 1.1 t -146.37 113.88 6.35 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.923 -1.339 . . . . 0.0 111.225 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.566 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -45.3 126.97 6.79 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.548 178.399 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.486 ' OH ' ' HB2' ' A' ' 27' ' ' GLN . 6.0 m-85 -121.32 149.41 42.97 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.467 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.45 160.06 14.65 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.697 -1.252 . . . . 0.0 108.064 178.955 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.682 HG13 ' O ' ' A' ' 34' ' ' VAL . 9.0 p -142.8 116.96 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.249 -0.907 . . . . 0.0 109.908 -177.69 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.521 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.82 -176.51 38.48 Favored Glycine 0 N--CA 1.494 2.524 0 C-N-CA 118.298 -1.906 . . . . 0.0 111.756 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.587 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -101.38 109.34 21.16 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.758 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -129.6 149.85 51.18 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.235 -0.915 . . . . 0.0 109.601 179.622 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.607 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.93 138.3 54.5 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.241 -0.912 . . . . 0.0 110.928 -178.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.09 26.96 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 178.049 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.7 m -105.64 15.01 7.16 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.024 -1.047 . . . . 0.0 110.512 -178.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.761 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.96 -175.38 0.09 Allowed 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.028 -1.045 . . . . 0.0 109.987 179.715 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -72.38 97.77 2.11 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 121.381 -0.825 . . . . 0.0 109.66 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.29 28.14 31.33 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.233 -0.984 . . . . 0.0 111.383 178.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.761 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.42 106.26 19.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 O-C-N 120.586 -1.537 . . . . 0.0 107.339 178.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -116.35 104.59 11.63 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.421 -1.424 . . . . 0.0 109.902 -177.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.095 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.5 22.25 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.776 -1.203 . . . . 0.0 107.987 178.704 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.5 161.74 14.57 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.919 -1.113 . . . . 0.0 110.189 -178.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.6 HD22 ' HB3' ' A' ' 50' ' ' ALA . 43.2 t30 -109.74 136.49 20.33 Favored Pre-proline 0 N--CA 1.502 2.167 0 O-C-N 121.383 -0.823 . . . . 0.0 109.807 -179.57 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.56 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.79 25.37 0.33 Allowed 'Trans proline' 0 C--N 1.318 -1.028 0 C-N-CA 122.354 2.036 . . . . 0.0 111.876 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.6 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -111.2 2.33 17.72 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.392 -1.442 . . . . 0.0 109.268 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.522 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.24 16.77 2.24 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.7 -1.222 . . . . 0.0 107.7 179.724 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -79.86 91.77 5.41 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.82 -0.752 . . . . 0.0 111.078 -178.57 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.619 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -111.31 -168.2 1.28 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.957 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.85 135.61 0.09 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.503 -1.373 . . . . 0.0 111.521 -179.307 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.762 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -152.41 158.32 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 178.015 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.566 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.77 145.54 26.26 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.659 -1.276 . . . . 0.0 109.672 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.001 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.24 108.01 2.56 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 122.394 1.092 . . . . 0.0 109.5 178.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 t0 -61.06 -138.73 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.923 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.684 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.57 -49.87 64.11 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.386 -0.821 . . . . 0.0 110.405 -178.747 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.471 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 16.9 t-20 -102.94 -36.99 8.01 Favored 'General case' 0 C--N 1.286 -2.194 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 178.449 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.978 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.31 68.36 0.61 Allowed Glycine 0 C--N 1.297 -1.601 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 178.19 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.614 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.8 m -102.96 129.12 49.59 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.496 -1.002 . . . . 0.0 109.316 179.284 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.762 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.56 108.54 7.63 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.533 -0.867 . . . . 0.0 109.43 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.497 ' HB2' ' NZ ' ' A' ' 20' ' ' LYS . 53.0 p -120.31 118.87 31.54 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.106 -0.996 . . . . 0.0 109.368 -179.82 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.58 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.91 143.01 28.2 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.395 -0.815 . . . . 0.0 109.802 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.476 ' HB3' ' HD3' ' A' ' 20' ' ' LYS . 2.9 p -102.17 135.04 44.45 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.492 -0.755 . . . . 0.0 109.059 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.836 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -135.2 169.93 16.7 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.301 -0.874 . . . . 0.0 109.597 -179.24 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.767 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -99.56 125.55 45.37 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.079 -1.013 . . . . 0.0 109.581 -179.68 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.587 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.7 m -135.11 143.33 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.036 -1.04 . . . . 0.0 109.519 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.601 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.0 ptt180 -146.63 -174.89 4.59 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 120.417 -1.427 . . . . 0.0 111.11 -179.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.607 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -54.12 -101.71 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 116.032 -0.531 . . . . 0.0 109.577 -179.382 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.508 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.85 139.97 49.64 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.749 -1.22 . . . . 0.0 108.138 179.659 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.607 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.28 136.34 7.51 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 118.772 -1.171 . . . . 0.0 109.879 -178.068 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.579 ' OE2' ' CD1' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -34.7 121.19 0.51 Allowed 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.543 0.687 . . . . 0.0 110.249 -178.462 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.095 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.52 50.57 2.08 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.107 -179.199 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CD1' ' OE2' ' A' ' 74' ' ' GLU . 2.8 m-85 -38.95 116.93 0.62 Allowed 'General case' 0 N--CA 1.509 2.484 0 O-C-N 121.041 -1.27 . . . . 0.0 109.882 179.639 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.74 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -87.34 126.16 34.68 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.95 -1.094 . . . . 0.0 109.389 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -64.53 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.789 -1.194 . . . . 0.0 110.106 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -159.77 19.7 0.17 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.033 -1.042 . . . . 0.0 109.696 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.26 -28.07 5.35 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.45 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 38.4 p -95.84 160.42 14.49 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.991 -1.299 . . . . 0.0 110.404 -179.458 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 6.0 ptt180 -105.95 139.58 40.28 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.784 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.74 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.4 t90 -84.5 -18.83 34.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.653 -1.279 . . . . 0.0 110.634 -178.53 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.85 175.53 19.03 Favored Glycine 0 N--CA 1.485 1.943 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 -179.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.74 105.37 1.24 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.058 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.674 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.5 t -76.7 105.61 5.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.147 -178.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.548 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -65.65 110.82 2.9 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.471 -0.768 . . . . 0.0 109.813 -179.481 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.607 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.24 -5.7 3.65 Favored 'General case' 0 N--CA 1.499 1.982 0 C-N-CA 118.255 -1.378 . . . . 0.0 109.838 179.482 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.0 p -86.57 -0.11 55.47 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.766 -1.209 . . . . 0.0 109.107 179.548 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.548 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.86 -50.57 2.82 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.398 -0.814 . . . . 0.0 108.968 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.8 -178.96 3.8 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.515 -0.741 . . . . 0.0 109.443 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.97 115.84 30.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.432 -0.793 . . . . 0.0 108.929 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.8 121.55 38.78 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.797 -1.189 . . . . 0.0 109.39 -179.369 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.81 147.1 26.46 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 122.33 1.062 . . . . 0.0 111.126 -179.362 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.701 ' HB ' HG11 ' A' ' 7' ' ' VAL . 48.3 t -105.34 111.93 36.75 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.997 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.831 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.511 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.75 -170.54 19.92 Favored Glycine 0 N--CA 1.488 2.102 0 C-N-CA 118.062 -2.018 . . . . 0.0 111.751 -177.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.81 177.47 4.69 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.212 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.444 ' OG ' ' O ' ' A' ' 97' ' ' LEU . 3.9 m . . . . . 0 C--N 1.295 -1.78 0 O-C-N 121.649 -0.657 . . . . 0.0 109.269 -179.805 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.569 0 N-CA-C 108.07 -2.012 . . . . 0.0 108.07 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -164.22 -177.32 4.9 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.612 -0.934 . . . . 0.0 110.042 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.68 -161.04 19.37 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 108.117 -1.993 . . . . 0.0 108.117 -179.494 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.1 Cg_exo -47.01 177.3 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.701 0 CA-C-N 118.968 1.384 . . . . 0.0 110.249 179.228 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.2 mm-40 -94.32 -179.4 4.91 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.073 -1.017 . . . . 0.0 110.583 -178.797 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.511 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.94 166.13 12.72 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.59 131.19 54.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.288 -1.124 . . . . 0.0 109.258 -179.282 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.03 121.02 20.42 Favored 'General case' 0 C--N 1.29 -2.014 0 O-C-N 121.548 -0.72 . . . . 0.0 109.587 179.676 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.92 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.97 171.3 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.226 -0.922 . . . . 0.0 109.095 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.49 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.93 156.81 46.97 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.264 -0.897 . . . . 0.0 109.929 -179.635 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.92 ' CE1' HD12 ' A' ' 110' ' ' ILE . 95.9 m-85 . . . . . 0 N--CA 1.486 1.369 0 O-C-N 121.318 -0.864 . . . . 0.0 109.378 -179.779 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.495 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 122.262 1.03 . . . . 0.0 110.602 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.957 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.8 t -110.42 108.63 18.73 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 123.088 1.423 . . . . 0.0 109.088 179.34 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.822 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -118.43 137.85 51.05 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.678 0 CA-C-N 114.244 -1.344 . . . . 0.0 109.907 -179.7 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.467 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -175.4 150.33 1.19 Allowed Pre-proline 0 N--CA 1.487 1.388 0 O-C-N 121.314 -0.866 . . . . 0.0 108.712 -179.651 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.467 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -77.64 150.52 90.51 Favored 'Cis proline' 0 C--N 1.311 -1.433 0 C-N-CA 123.57 -1.429 . . . . 0.0 109.535 -0.905 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.67 ' HA ' HG22 ' A' ' 110' ' ' ILE . 61.8 p -91.02 -24.52 20.05 Favored 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.55 -0.718 . . . . 0.0 109.27 179.828 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.521 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 17.1 m -133.44 160.36 37.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.265 -0.897 . . . . 0.0 109.978 -179.806 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.78 36.75 24.78 Favored Glycine 0 N--CA 1.494 2.523 0 N-CA-C 108.859 -1.696 . . . . 0.0 108.859 -179.856 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.755 ' HA ' HG21 ' A' ' 17' ' ' THR . 44.2 mt -93.83 -44.37 8.15 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-O 123.204 1.478 . . . . 0.0 110.353 -178.658 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.434 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.9 OUTLIER 63.81 145.35 0.02 OUTLIER 'General case' 0 C--N 1.262 -3.216 0 CA-C-N 113.62 -1.627 . . . . 0.0 109.798 -179.459 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.539 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.4 p-10 -51.61 105.33 0.1 Allowed 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.551 0.691 . . . . 0.0 110.844 -179.015 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 126.93 2.22 6.68 Favored Glycine 0 N--CA 1.485 1.949 0 C-N-CA 119.077 -1.535 . . . . 0.0 113.428 177.625 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.755 HG21 ' HA ' ' A' ' 13' ' ' LEU . 15.3 t -104.08 -171.82 2.0 Allowed 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 121.376 2.588 . . . . 0.0 110.102 179.909 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.772 HG13 ' C ' ' A' ' 67' ' ' LEU . 16.0 t -131.47 141.91 44.64 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.252 0 CA-C-N 114.604 -1.18 . . . . 0.0 110.47 -179.207 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.545 HG11 ' CD1' ' A' ' 13' ' ' LEU . 28.6 m -115.7 154.99 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.199 -0.938 . . . . 0.0 109.023 179.321 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 45.9 tptt -107.07 109.31 21.14 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 108.892 179.918 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.822 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.63 141.62 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.957 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -139.05 160.41 39.84 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 118.595 -1.242 . . . . 0.0 110.04 179.714 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.42 144.26 15.58 Favored Glycine 0 C--N 1.294 -1.793 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 179.695 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.28 125.37 12.88 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.872 -1.369 . . . . 0.0 108.956 179.037 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.48 26.84 26.6 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.289 -1.434 . . . . 0.0 109.867 -179.733 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.582 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -87.68 174.61 8.31 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 120.837 -1.39 . . . . 0.0 108.648 -179.879 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.018 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.58 99.79 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.99 -1.069 . . . . 0.0 109.744 -179.682 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.57 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 77.94 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.233 -179.149 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.58 34.17 0.32 Allowed Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.556 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 40.6 p -141.13 108.14 5.44 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.136 -1.214 . . . . 0.0 111.208 -179.539 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.9 110.75 0.46 Allowed 'General case' 0 N--CA 1.497 1.876 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.542 178.027 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.489 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.3 m-30 -106.75 156.02 19.09 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.122 -0.987 . . . . 0.0 108.902 179.821 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.503 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -99.13 164.16 12.27 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.822 -1.174 . . . . 0.0 107.917 178.822 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.666 HG13 ' O ' ' A' ' 34' ' ' VAL . 5.5 p -144.99 115.2 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.982 -1.074 . . . . 0.0 109.653 -178.247 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.02 -174.48 35.52 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.42 -1.847 . . . . 0.0 111.594 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.612 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.4 pt20 -102.39 109.25 20.85 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.862 0.839 . . . . 0.0 108.839 -179.772 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -131.75 149.51 52.45 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.099 -1.001 . . . . 0.0 110.093 -179.858 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.77 139.14 54.12 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.25 -0.906 . . . . 0.0 110.867 -179.076 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.876 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.36 114.96 26.79 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 178.21 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.5 m -105.4 15.15 7.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.991 -1.068 . . . . 0.0 110.591 -178.799 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.6 -176.19 0.09 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.961 -1.087 . . . . 0.0 110.101 179.747 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.783 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.89 97.86 1.49 Allowed 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.381 -0.825 . . . . 0.0 109.856 -179.742 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.37 27.58 35.84 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.212 -0.994 . . . . 0.0 111.394 178.948 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.23 106.44 20.34 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.528 -1.572 . . . . 0.0 107.185 178.904 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.876 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.0 tp -116.99 104.61 11.45 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.476 -1.39 . . . . 0.0 109.752 -177.763 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.86 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.82 109.53 22.27 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.746 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.497 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -106.74 168.75 8.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.967 -1.083 . . . . 0.0 110.379 -178.565 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.728 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 20.5 t-20 -114.57 132.34 22.92 Favored Pre-proline 0 N--CA 1.498 1.963 0 O-C-N 121.64 -0.662 . . . . 0.0 109.95 -179.242 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.8 Cg_endo -74.18 25.56 0.34 Allowed 'Trans proline' 0 CA--C 1.544 0.997 0 C-N-CA 122.28 1.986 . . . . 0.0 112.139 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.728 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -111.25 -1.06 16.23 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.279 -1.513 . . . . 0.0 109.443 179.709 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.572 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.06 21.32 2.62 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.561 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -80.92 90.6 5.93 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 120.053 -0.659 . . . . 0.0 110.873 -178.646 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -109.73 -167.23 1.18 Allowed 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.157 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.96 136.25 0.09 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.61 -1.307 . . . . 0.0 111.186 -179.273 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.938 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -153.53 158.26 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.354 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.78 141.8 31.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.906 -1.121 . . . . 0.0 109.945 -179.845 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.018 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.02 106.51 0.84 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 122.45 1.119 . . . . 0.0 109.359 178.296 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -58.3 -138.47 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.03 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.918 -179.863 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.57 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -54.22 -49.19 70.01 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.367 -0.833 . . . . 0.0 110.406 -178.756 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -102.37 -38.26 7.68 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 178.333 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.009 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 111.36 65.26 0.51 Allowed Glycine 0 C--N 1.297 -1.593 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 177.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.1 m -102.98 128.73 49.68 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 121.41 -1.053 . . . . 0.0 108.703 178.851 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.938 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -138.22 109.07 6.68 Favored 'General case' 0 C--N 1.296 -1.73 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.771 -179.235 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.5 m -123.52 120.63 33.44 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.309 -0.869 . . . . 0.0 109.725 -179.902 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.28 148.24 32.23 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.568 -0.708 . . . . 0.0 109.278 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.3 p -98.99 143.02 29.75 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.386 -0.821 . . . . 0.0 109.648 -179.839 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.782 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -146.03 157.52 43.87 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.357 -0.839 . . . . 0.0 109.368 -179.33 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.644 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 13.9 t -86.62 140.28 30.0 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.135 -0.978 . . . . 0.0 110.08 -179.792 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.554 HG12 ' OD2' ' A' ' 51' ' ' ASP . 16.9 m -145.94 137.89 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.226 -0.921 . . . . 0.0 110.148 -179.388 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.539 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 59.7 mtt180 -128.19 -162.75 1.21 Allowed 'General case' 0 N--CA 1.484 1.266 0 O-C-N 120.649 -1.282 . . . . 0.0 110.955 179.97 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.594 ' HG2' ' CD1' ' A' ' 112' ' ' PHE . 0.6 OUTLIER -86.66 -79.95 0.25 Allowed 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.35 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.538 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -69.78 133.02 46.97 Favored 'General case' 0 N--CA 1.486 1.34 0 N-CA-C 106.511 -1.662 . . . . 0.0 106.511 177.956 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.588 ' CE1' ' HB ' ' A' ' 86' ' ' VAL . 0.9 OUTLIER -154.42 155.32 34.75 Favored 'General case' 0 C--N 1.293 -1.875 0 C-N-CA 117.696 -1.602 . . . . 0.0 110.669 -177.938 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 47' ' ' CYS . 16.4 mt-10 -48.1 120.6 3.63 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 121.556 0.694 . . . . 0.0 109.549 -178.443 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.86 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -87.62 49.41 3.87 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -179.588 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.7 m-30 -40.59 112.38 0.28 Allowed 'General case' 0 N--CA 1.507 2.387 0 O-C-N 121.046 -1.267 . . . . 0.0 110.302 179.986 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.728 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.33 126.39 34.3 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.96 -1.088 . . . . 0.0 109.415 179.848 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -64.2 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.98 0 O-C-N 120.773 -1.204 . . . . 0.0 110.192 179.72 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 1.5 t0 -159.03 18.53 0.19 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.996 -1.065 . . . . 0.0 109.794 179.865 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.92 -25.85 6.47 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 179.763 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 47.6 p -95.0 159.37 15.05 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 120.966 -1.314 . . . . 0.0 110.604 -179.33 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.473 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -104.25 131.84 51.14 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.52 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.728 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -79.75 -19.96 47.47 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.854 -1.154 . . . . 0.0 110.169 -178.501 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.52 174.4 18.88 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 108.666 -1.773 . . . . 0.0 108.666 -179.406 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.13 112.88 2.55 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 179.09 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.647 HG21 ' CB ' ' A' ' 46' ' ' ALA . 38.1 t -84.56 103.22 11.54 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.019 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.561 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -63.88 109.26 1.7 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.54 -0.725 . . . . 0.0 110.248 -178.902 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.556 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 4.1 t -61.85 -4.19 1.44 Allowed 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.546 -1.262 . . . . 0.0 110.433 179.227 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -91.6 4.26 53.08 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.477 -1.389 . . . . 0.0 109.333 179.772 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.561 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -116.18 -50.19 2.67 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.178 -0.951 . . . . 0.0 109.144 179.936 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.89 178.73 4.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.512 -0.743 . . . . 0.0 109.396 179.871 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.85 113.37 26.24 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.324 -0.86 . . . . 0.0 108.817 179.884 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.498 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.51 119.59 35.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.017 -1.052 . . . . 0.0 109.471 -179.048 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.71 147.31 26.99 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-O 122.459 1.123 . . . . 0.0 111.43 -179.21 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.491 ' CG1' HG11 ' A' ' 7' ' ' VAL . 77.2 t -103.81 109.83 28.34 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.993 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 177.613 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.491 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.39 -170.01 17.1 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 118.246 -1.93 . . . . 0.0 111.608 -177.54 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.503 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.66 178.27 4.46 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.907 -0.761 . . . . 0.0 108.994 -178.972 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.489 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER . . . . . 0 C--N 1.295 -1.762 0 O-C-N 121.529 -0.732 . . . . 0.0 109.511 -179.653 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.714 0 N-CA-C 107.569 -2.212 . . . . 0.0 107.569 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -157.96 -178.37 7.26 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 121.569 -0.96 . . . . 0.0 109.721 179.183 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.44 -160.55 11.62 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 108.333 -1.907 . . . . 0.0 108.333 -179.344 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -47.01 178.31 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.864 1.332 . . . . 0.0 110.265 179.207 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -93.02 -174.4 3.56 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.123 -0.985 . . . . 0.0 110.341 -178.956 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.491 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.75 164.0 15.02 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.935 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.402 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.38 129.71 49.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.386 -1.067 . . . . 0.0 109.074 -179.629 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.92 121.44 19.08 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.658 -0.651 . . . . 0.0 109.804 179.836 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.67 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.5 pt -97.99 169.28 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 121.379 -0.826 . . . . 0.0 108.818 179.822 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.521 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.98 160.37 38.82 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.141 -0.974 . . . . 0.0 109.693 -179.945 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.594 ' CD1' ' HG2' ' A' ' 71' ' ' ARG . 39.2 m-85 . . . . . 0 N--CA 1.488 1.445 0 O-C-N 121.242 -0.911 . . . . 0.0 109.46 -179.759 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.484 1.255 0 CA-C-O 122.275 1.036 . . . . 1.0 110.561 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.974 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.9 p -107.0 104.93 14.73 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 122.608 1.194 . . . . 1.0 110.347 -179.587 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.975 HG22 HG23 ' A' ' 21' ' ' VAL . 15.2 t -119.37 115.35 47.43 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.468 0 CA-C-N 115.271 -0.877 . . . . 1.0 110.131 179.428 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -162.57 150.8 12.01 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.316 -0.994 . . . . 1.0 108.316 -179.378 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.1 Cg_endo -77.96 150.21 88.92 Favored 'Cis proline' 0 C--N 1.308 -1.554 0 C-N-CA 123.635 -1.402 . . . . 1.0 109.74 -0.679 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.655 ' HA ' HG22 ' A' ' 110' ' ' ILE . 69.2 p -89.75 -25.49 21.12 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 109.031 -0.729 . . . . 1.0 109.031 179.549 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.502 ' HB2' ' HB3' ' A' ' 111' ' ' SER . 18.7 p -132.55 164.64 26.18 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.498 -0.751 . . . . 1.0 109.375 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.68 38.27 37.61 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 108.259 -1.936 . . . . 1.0 108.259 -179.531 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.7 mt -92.49 -43.39 9.21 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 123.264 1.507 . . . . 1.0 110.619 -178.174 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.11 143.59 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.269 0 CA-C-N 113.461 -1.7 . . . . 1.0 109.815 -179.467 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.582 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 9.9 p-10 -50.48 105.13 0.09 Allowed 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.474 0.654 . . . . 1.0 111.634 -178.484 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.98 15.68 8.38 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 119.457 -1.354 . . . . 1.0 113.007 177.153 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.5 t -103.88 -171.22 1.9 Allowed 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 121.053 2.426 . . . . 1.0 109.802 179.125 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.856 HG22 HG22 ' A' ' 68' ' ' THR . 16.6 t -131.31 140.06 49.34 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.314 0 CA-C-N 114.822 -1.081 . . . . 1.0 111.362 -178.783 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.46 HG12 ' CD2' ' A' ' 13' ' ' LEU . 30.9 m -115.9 155.48 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 N-CA-C 108.66 -0.867 . . . . 1.0 108.66 178.861 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 5.5 tptm -108.16 108.96 20.23 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.137 -0.977 . . . . 1.0 109.529 -179.759 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.975 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -106.39 122.5 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.853 -0.795 . . . . 1.0 108.853 179.729 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.974 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -115.21 165.45 12.92 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.943 -1.098 . . . . 1.0 109.145 179.789 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.577 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.81 108.03 0.46 Allowed Glycine 0 N--CA 1.483 1.768 0 N-CA-C 108.711 -1.756 . . . . 1.0 108.711 179.602 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.501 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.75 142.43 46.93 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.704 -1.468 . . . . 1.0 110.212 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.96 29.08 35.49 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.062 -1.542 . . . . 1.0 109.773 179.787 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.54 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.9 OUTLIER -94.56 172.75 7.99 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.093 -1.239 . . . . 1.0 108.31 179.98 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.012 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.09 100.36 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.027 -1.046 . . . . 1.0 109.602 -179.799 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.85 76.44 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 115.397 -0.819 . . . . 1.0 109.955 -179.313 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 137.08 33.26 0.22 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.457 -1.457 . . . . 1.0 109.457 179.712 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.546 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 66.8 p -142.14 109.74 5.72 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.042 -1.269 . . . . 1.0 111.013 -179.803 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.586 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.95 109.93 0.28 Allowed 'General case' 0 N--CA 1.496 1.847 0 CA-C-N 115.7 -0.682 . . . . 1.0 109.858 178.407 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.515 ' CE1' ' HD2' ' A' ' 105' ' ' PRO . 21.1 m-85 -99.1 152.3 20.01 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.157 -0.965 . . . . 1.0 109.007 179.653 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.507 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -101.48 157.77 16.56 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 107.598 -1.26 . . . . 1.0 107.598 178.421 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.774 HG11 HG21 ' A' ' 65' ' ' THR . 9.9 p -142.29 113.97 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.063 -1.023 . . . . 1.0 110.07 -177.692 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.39 -175.49 36.73 Favored Glycine 0 N--CA 1.495 2.575 0 C-N-CA 118.371 -1.871 . . . . 1.0 111.875 -179.811 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.588 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -102.25 109.41 21.09 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 108.848 -0.797 . . . . 1.0 108.848 -179.663 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -131.07 148.55 52.75 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.129 -0.982 . . . . 1.0 110.034 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.486 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.89 139.79 53.62 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.314 -0.866 . . . . 1.0 110.716 -179.016 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.889 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.25 114.66 26.47 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 107.607 -1.257 . . . . 1.0 107.607 178.161 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 m -105.25 15.01 7.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.094 -1.004 . . . . 1.0 110.469 -178.752 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 175.04 -175.76 0.09 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.044 -1.035 . . . . 1.0 110.039 179.688 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 p -72.69 98.02 2.29 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.448 -0.782 . . . . 1.0 109.508 -179.805 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.39 27.64 32.45 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.232 -0.985 . . . . 1.0 111.291 179.046 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -117.6 106.27 19.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 O-C-N 120.6 -1.53 . . . . 1.0 107.325 178.889 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.889 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -116.1 104.8 11.92 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 120.496 -1.378 . . . . 1.0 109.567 -178.016 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.938 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.47 109.56 22.29 Favored 'General case' 0 N--CA 1.486 1.338 0 O-C-N 120.781 -1.199 . . . . 1.0 107.857 178.889 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -108.26 163.73 12.93 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.02 -1.05 . . . . 1.0 110.112 -178.656 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.49 ' HB2' ' HB2' ' A' ' 73' ' ' PHE . 36.2 t-20 -110.16 128.78 24.79 Favored Pre-proline 0 N--CA 1.502 2.141 0 O-C-N 121.437 -0.789 . . . . 1.0 109.67 -179.372 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.594 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.6 Cg_endo -69.44 17.72 0.18 Allowed 'Trans proline' 0 CA--C 1.546 1.075 0 C-N-CA 122.021 1.814 . . . . 1.0 112.108 179.444 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -104.6 3.48 31.77 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.389 -1.444 . . . . 1.0 108.528 179.065 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.45 15.91 2.75 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 107.228 -1.397 . . . . 1.0 107.228 179.487 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -81.53 92.39 6.5 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.834 -0.746 . . . . 1.0 111.099 -178.299 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -112.01 -170.94 1.75 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.133 -1.432 . . . . 1.0 107.133 177.879 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 179.18 136.91 0.1 Allowed 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.475 -1.391 . . . . 1.0 111.277 -179.197 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.9 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.56 157.14 4.78 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 107.107 -1.442 . . . . 1.0 107.107 178.194 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.586 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.83 143.23 28.66 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.696 -1.253 . . . . 1.0 109.965 -179.474 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.24 105.86 0.98 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 122.372 1.082 . . . . 1.0 109.392 178.704 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.54 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.5 t70 -60.21 -139.28 0.0 OUTLIER 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.719 -0.673 . . . . 1.0 110.934 -179.827 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.6 -50.48 60.1 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.297 -0.877 . . . . 1.0 110.625 -178.7 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 49.4 m-80 -102.95 -35.15 8.68 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.272 -1.751 . . . . 1.0 106.272 178.59 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 105.26 66.27 0.68 Allowed Glycine 0 C--N 1.297 -1.602 0 N-CA-C 110.522 -1.031 . . . . 1.0 110.522 178.305 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.577 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.4 m -104.09 125.54 50.51 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 108.514 -0.921 . . . . 1.0 108.514 178.833 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.9 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.46 109.54 8.8 Favored 'General case' 0 C--N 1.296 -1.748 0 C-N-CA 119.692 -0.803 . . . . 1.0 109.755 -179.266 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.471 ' OG ' ' HB2' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -116.24 122.72 45.8 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.278 -0.888 . . . . 1.0 109.019 179.709 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.774 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -148.44 140.14 23.7 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.496 -0.752 . . . . 1.0 109.884 -179.964 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.425 ' HB3' ' HD2' ' A' ' 20' ' ' LYS . 14.6 p -101.34 131.42 47.4 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.369 -0.832 . . . . 1.0 109.276 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.759 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -128.52 164.62 22.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.38 -0.825 . . . . 1.0 109.623 -179.452 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.856 HG22 HG22 ' A' ' 18' ' ' VAL . 1.7 p -97.36 124.59 41.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.952 -1.093 . . . . 1.0 109.249 -179.958 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.573 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 18.0 m -136.61 143.67 34.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.1 -1.0 . . . . 1.0 109.947 -179.106 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.582 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 6.8 ptt180 -141.86 -165.51 2.02 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.51 -1.369 . . . . 1.0 110.264 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.597 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 10.1 mtt180 -70.07 -76.85 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.425 -0.797 . . . . 1.0 109.017 -179.557 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.486 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -69.62 137.33 52.18 Favored 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.232 -1.542 . . . . 1.0 107.128 178.878 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.588 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -160.17 134.18 7.26 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 117.895 -1.522 . . . . 1.0 110.299 -178.179 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.527 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.2 mm-40 -30.57 120.97 0.2 Allowed 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.54 0.686 . . . . 1.0 110.888 -178.397 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.938 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.13 43.4 3.05 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.913 -0.875 . . . . 1.0 110.913 -179.526 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.594 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 2.1 m-85 -38.71 114.93 0.42 Allowed 'General case' 0 N--CA 1.511 2.603 0 O-C-N 121.182 -1.187 . . . . 1.0 110.123 179.959 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.713 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.4 tp -87.64 126.96 35.26 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.889 -1.132 . . . . 1.0 109.231 179.81 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -63.95 58.01 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.871 -1.143 . . . . 1.0 110.438 -179.9 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 9.3 t0 -161.97 19.96 0.1 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.924 -1.11 . . . . 1.0 109.862 179.802 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.06 -27.29 5.05 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.002 -1.239 . . . . 1.0 110.002 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.463 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 3.1 p -90.24 153.55 20.4 Favored 'General case' 0 N--CA 1.485 1.318 0 O-C-N 121.072 -1.252 . . . . 1.0 110.388 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.523 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 5.1 ptt180 -102.43 132.82 48.2 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.636 -0.875 . . . . 1.0 108.636 179.68 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.713 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.4 t90 -81.92 -21.41 37.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.659 -1.276 . . . . 1.0 110.294 -178.673 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.92 174.0 18.55 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.746 -1.742 . . . . 1.0 108.746 -179.644 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.67 110.71 1.81 Allowed 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.412 -1.329 . . . . 1.0 107.412 179.095 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.654 HG21 ' CB ' ' A' ' 46' ' ' ALA . 41.3 t -82.26 104.27 10.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 O-C-N 121.449 -0.782 . . . . 1.0 108.895 -178.962 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.66 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.1 OUTLIER -66.47 111.81 3.76 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.306 -0.871 . . . . 1.0 109.784 -179.277 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.555 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.0 t -62.77 -5.35 2.69 Favored 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 118.416 -1.314 . . . . 1.0 110.108 179.497 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -86.23 0.6 53.36 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.611 -1.306 . . . . 1.0 109.15 179.462 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.66 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -112.71 -48.89 2.97 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.268 -0.895 . . . . 1.0 109.055 179.907 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.46 -178.31 3.56 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.483 -0.761 . . . . 1.0 109.6 -179.93 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.55 114.78 29.23 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.294 -0.879 . . . . 1.0 108.97 179.923 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.56 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.12 123.32 40.85 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.956 -1.09 . . . . 1.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.586 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.96 146.16 28.75 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 122.359 1.076 . . . . 1.0 111.059 -179.775 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.538 ' HB ' HG11 ' A' ' 7' ' ' VAL . 97.8 t -103.07 109.63 27.39 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.069 0 N-CA-C 106.604 -1.628 . . . . 1.0 106.604 177.719 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.488 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.51 -170.58 17.19 Favored Glycine 0 N--CA 1.485 1.962 0 C-N-CA 118.091 -2.004 . . . . 1.0 111.944 -177.47 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.491 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -118.16 -178.65 3.56 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 108.88 -0.785 . . . . 1.0 108.88 -178.77 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.507 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.711 0 O-C-N 121.355 -0.841 . . . . 1.0 109.254 -179.45 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.666 0 N-CA-C 107.522 -2.231 . . . . 1.0 107.522 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.46 -178.24 6.99 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.615 -0.932 . . . . 1.0 109.727 179.12 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -170.27 -162.61 22.87 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 108.248 -1.941 . . . . 1.0 108.248 -179.426 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.515 ' HD2' ' CE1' ' A' ' 32' ' ' TYR . 7.5 Cg_exo -45.69 165.81 0.06 OUTLIER 'Trans proline' 0 C--O 1.215 -0.637 0 CA-C-N 118.912 1.356 . . . . 1.0 109.656 179.392 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.73 -176.45 4.97 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.047 -1.033 . . . . 1.0 110.528 -178.473 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.488 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.57 175.26 15.64 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.723 -1.351 . . . . 1.0 109.723 -179.837 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -112.05 132.51 60.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.383 -1.069 . . . . 1.0 109.121 -179.14 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.586 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -69.88 124.58 24.39 Favored 'General case' 0 C--N 1.291 -1.95 0 O-C-N 121.556 -0.715 . . . . 1.0 109.479 179.526 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.884 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.71 171.57 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.19 -0.944 . . . . 1.0 109.043 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.502 ' HB3' ' HB2' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.53 161.21 37.01 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.237 -0.914 . . . . 1.0 109.707 -179.773 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.884 ' CE2' HD12 ' A' ' 110' ' ' ILE . 90.0 m-85 . . . . . 0 N--CA 1.484 1.268 0 O-C-N 121.12 -0.987 . . . . 1.0 109.532 -179.702 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.582 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.486 1.371 0 CA-C-O 122.281 1.038 . . . . 0.0 111.179 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.021 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -101.22 104.45 15.51 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 122.404 1.097 . . . . 0.0 109.907 179.859 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 1.07 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -119.37 119.3 60.21 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.393 179.588 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.481 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.8 149.92 4.41 Favored Pre-proline 0 N--CA 1.486 1.335 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -179.602 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.481 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.3 Cg_endo -78.55 149.96 86.69 Favored 'Cis proline' 0 C--N 1.309 -1.504 0 C-N-CA 123.631 -1.404 . . . . 0.0 109.439 -0.677 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.669 ' HA ' HG22 ' A' ' 110' ' ' ILE . 72.6 p -92.09 -23.43 19.46 Favored 'General case' 0 C--N 1.292 -1.911 0 O-C-N 121.632 -0.668 . . . . 0.0 109.245 179.677 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.548 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 12.1 p -131.81 161.19 33.53 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.376 -0.828 . . . . 0.0 109.646 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.2 37.78 31.33 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 108.386 -1.885 . . . . 0.0 108.386 -179.556 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.2 mt -91.85 -43.39 9.53 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 123.223 1.487 . . . . 0.0 110.53 -178.223 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.478 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.89 143.93 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.25 0 CA-C-N 113.457 -1.701 . . . . 0.0 110.017 -179.508 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.586 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 11.5 p-10 -49.83 105.69 0.1 Allowed 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 121.431 0.634 . . . . 0.0 111.737 -178.53 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.5 15.37 8.89 Favored Glycine 0 N--CA 1.485 1.94 0 C-N-CA 119.439 -1.363 . . . . 0.0 113.077 177.068 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -105.04 -173.2 2.25 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 121.123 2.461 . . . . 0.0 109.943 179.191 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.782 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.6 t -128.86 139.7 51.21 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.318 0 CA-C-N 114.635 -1.166 . . . . 0.0 111.508 -178.578 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.584 HG11 HD11 ' A' ' 13' ' ' LEU . 33.8 m -117.82 155.96 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.641 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.559 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tppp? -107.69 109.92 21.64 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.017 -1.052 . . . . 0.0 109.816 -179.681 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 1.07 HG23 HG22 ' A' ' 7' ' ' VAL . 7.3 p -105.87 123.23 60.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.086 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.021 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -119.7 166.61 12.99 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.506 -1.371 . . . . 0.0 109.397 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.589 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.42 143.31 14.97 Favored Glycine 0 C--N 1.296 -1.682 0 N-CA-C 107.802 -2.119 . . . . 0.0 107.802 179.806 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -148.08 122.54 9.73 Favored 'General case' 0 C--N 1.293 -1.858 0 O-C-N 120.828 -1.395 . . . . 0.0 108.565 179.067 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.52 27.38 20.22 Favored Glycine 0 N--CA 1.486 2.017 0 C-N-CA 119.093 -1.527 . . . . 0.0 109.707 -179.552 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.558 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.2 mt -87.23 176.51 7.53 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 120.894 -1.356 . . . . 0.0 108.373 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.42 96.76 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.001 -1.062 . . . . 0.0 109.665 -179.784 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.719 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.2 77.68 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.528 -179.0 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 129.33 36.28 0.43 Allowed Glycine 0 N--CA 1.487 2.035 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 179.409 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.648 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -148.57 114.54 5.76 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 120.913 -1.345 . . . . 0.0 111.199 -179.891 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -46.34 122.52 4.09 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 115.437 -0.802 . . . . 0.0 110.354 178.66 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.648 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 1.9 m-30 -116.97 154.43 30.9 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.084 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.503 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -100.52 167.68 10.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.499 -1.375 . . . . 0.0 108.604 179.449 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.615 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.3 p -147.78 122.46 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.165 -0.96 . . . . 0.0 109.554 -178.089 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -177.08 -178.21 46.63 Favored Glycine 0 N--CA 1.495 2.606 0 C-N-CA 118.329 -1.891 . . . . 0.0 111.71 179.977 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.67 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.4 108.52 20.55 Favored 'General case' 0 N--CA 1.477 0.901 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.836 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -129.59 148.63 51.51 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.179 -0.951 . . . . 0.0 109.803 179.691 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.542 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.34 139.52 53.95 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.307 -0.871 . . . . 0.0 110.675 -179.023 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.881 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.09 114.9 26.76 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 178.147 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.47 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 18.2 m -105.77 14.98 7.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.044 -1.035 . . . . 0.0 110.58 -178.652 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.719 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 175.1 -174.94 0.09 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.986 -1.071 . . . . 0.0 109.995 179.579 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.786 HG23 ' O ' ' A' ' 42' ' ' THR . 14.9 t -72.62 98.01 2.26 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.43 -0.794 . . . . 0.0 109.757 -179.779 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.78 28.01 33.19 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 120.161 -1.019 . . . . 0.0 111.436 179.037 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.719 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -117.16 106.39 20.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.542 -1.564 . . . . 0.0 107.149 178.798 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.881 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.2 tp -116.76 104.94 11.85 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.496 -1.378 . . . . 0.0 109.681 -177.649 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.013 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.97 109.75 22.45 Favored 'General case' 0 N--CA 1.484 1.26 0 O-C-N 120.934 -1.104 . . . . 0.0 108.387 179.237 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.0 t -106.16 163.88 12.44 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.995 -1.066 . . . . 0.0 110.268 -179.037 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.518 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 17.4 t30 -111.36 137.79 21.17 Favored Pre-proline 0 N--CA 1.502 2.129 0 O-C-N 121.496 -0.752 . . . . 0.0 109.598 -179.387 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.579 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.2 24.58 0.31 Allowed 'Trans proline' 0 C--N 1.318 -1.04 0 C-N-CA 122.504 2.136 . . . . 0.0 112.41 -179.379 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.415 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -103.34 -8.3 20.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.164 -1.585 . . . . 0.0 109.184 179.465 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.703 ' OD2' HG13 ' A' ' 69' ' ' VAL . 2.0 m-20 -135.69 8.85 3.33 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.54 86.46 0.08 Allowed 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.277 -0.889 . . . . 0.0 110.441 -178.797 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.615 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -115.61 -169.86 1.66 Allowed 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 178.785 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.465 ' OG ' ' HA ' ' A' ' 33' ' ' ASP . 0.6 OUTLIER 178.65 133.9 0.08 Allowed 'General case' 0 C--N 1.303 -1.424 0 O-C-N 120.725 -1.235 . . . . 0.0 111.206 -179.483 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.725 HG11 ' HB1' ' A' ' 63' ' ' ALA . 2.0 p -143.59 159.72 16.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.89 145.33 26.54 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.649 -1.282 . . . . 0.0 109.75 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.002 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.56 109.75 3.38 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 122.449 1.118 . . . . 0.0 109.465 178.638 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.557 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.5 p-10 -62.11 -139.17 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.643 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.719 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.33 -51.88 50.43 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.268 -0.895 . . . . 0.0 110.445 -178.94 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.5 -33.72 9.4 Favored 'General case' 0 C--N 1.288 -2.103 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.555 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.999 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.18 65.65 0.59 Allowed Glycine 0 C--N 1.3 -1.444 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.162 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 53.5 p -99.91 131.78 45.67 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 121.354 -1.086 . . . . 0.0 109.363 179.15 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.725 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -137.19 108.78 6.96 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.429 -0.908 . . . . 0.0 109.535 -179.853 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.417 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 92.0 p -117.62 118.52 32.34 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.063 -1.023 . . . . 0.0 109.588 -179.818 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.568 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -146.67 140.89 26.31 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.473 -0.767 . . . . 0.0 109.835 -179.947 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.476 ' HB3' ' HE3' ' A' ' 20' ' ' LYS . 24.2 p -98.82 136.37 38.94 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.322 -0.861 . . . . 0.0 108.792 179.54 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.971 HD11 HG12 ' A' ' 21' ' ' VAL . 0.2 OUTLIER -132.73 168.07 18.98 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.266 -0.896 . . . . 0.0 110.322 -178.489 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.647 HG22 HG22 ' A' ' 18' ' ' VAL . 1.1 p -104.46 124.39 49.17 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.876 . . . . 0.0 108.688 179.464 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.703 HG13 ' OD2' ' A' ' 51' ' ' ASP . 17.4 m -136.93 142.98 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 120.873 -1.142 . . . . 0.0 110.237 -178.761 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.586 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.4 ptt180 -144.9 -169.71 3.24 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 120.575 -1.328 . . . . 0.0 110.771 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.601 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -58.35 -99.8 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -179.144 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -58.33 143.37 45.13 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.355 -1.466 . . . . 0.0 108.505 179.692 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.589 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.17 138.63 6.7 Favored 'General case' 0 C--N 1.294 -1.813 0 C-N-CA 118.848 -1.141 . . . . 0.0 109.614 -178.185 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.556 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 8.6 mm-40 -34.77 121.97 0.53 Allowed 'General case' 0 N--CA 1.49 1.53 0 CA-C-O 121.484 0.659 . . . . 0.0 110.583 -178.254 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.013 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.64 46.08 2.75 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 120.52 -0.848 . . . . 0.0 110.995 -179.298 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.7 m-85 -39.07 111.48 0.18 Allowed 'General case' 0 N--CA 1.507 2.403 0 O-C-N 121.23 -1.159 . . . . 0.0 109.887 179.589 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.672 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.5 tp -84.88 127.37 34.12 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.9 -1.125 . . . . 0.0 109.281 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.415 ' CD2' ' O ' ' A' ' 78' ' ' PHE . 57.6 t80 -63.18 58.18 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.92 -1.113 . . . . 0.0 110.527 -179.881 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t0 -163.33 20.21 0.08 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.906 -1.121 . . . . 0.0 109.997 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.77 -27.16 4.95 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.091 -1.203 . . . . 0.0 110.091 179.979 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.505 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -90.3 150.57 21.86 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 121.119 -1.224 . . . . 0.0 110.247 -179.469 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.486 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -101.19 133.06 46.31 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 179.434 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.672 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.5 t90 -81.76 -16.09 52.18 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.794 -1.191 . . . . 0.0 110.56 -178.525 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 108.74 174.36 21.52 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.856 -1.697 . . . . 0.0 108.856 -179.719 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.79 103.9 0.62 Allowed 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.613 -1.255 . . . . 0.0 107.613 179.116 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.611 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.5 t -74.52 106.53 4.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.476 -0.765 . . . . 0.0 109.224 -178.814 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.58 110.93 3.37 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.386 -0.821 . . . . 0.0 109.813 -179.454 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.601 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.72 -5.49 4.23 Favored 'General case' 0 N--CA 1.499 2.024 0 C-N-CA 118.329 -1.348 . . . . 0.0 109.908 179.463 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.7 p -85.61 -0.6 55.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.705 -1.247 . . . . 0.0 109.144 179.568 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -112.92 -49.17 2.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.383 -0.823 . . . . 0.0 109.002 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.45 -178.2 3.58 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.511 -0.743 . . . . 0.0 109.455 179.963 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.14 115.64 30.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.446 -0.784 . . . . 0.0 108.964 179.924 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.564 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.86 123.54 40.6 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.935 -1.103 . . . . 0.0 109.665 -179.176 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.618 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.05 147.66 26.68 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-O 122.418 1.104 . . . . 0.0 111.014 -179.522 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.536 ' HB ' HG11 ' A' ' 7' ' ' VAL . 46.4 t -106.28 113.22 42.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.993 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.017 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.508 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -155.18 -169.83 20.11 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 117.989 -2.053 . . . . 0.0 111.834 -177.943 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.494 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -110.52 -177.74 3.31 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 -179.227 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.509 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 12.1 p . . . . . 0 C--N 1.297 -1.715 0 O-C-N 121.367 -0.833 . . . . 0.0 109.083 -179.072 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.712 0 N-CA-C 107.878 -2.089 . . . . 0.0 107.878 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.64 -177.92 6.88 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 121.474 -1.015 . . . . 0.0 109.81 179.238 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.4 -161.2 13.01 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.589 -1.804 . . . . 0.0 108.589 -179.256 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.544 ' HD3' ' CE2' ' A' ' 32' ' ' TYR . 4.7 Cg_exo -47.41 -178.97 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.709 1.254 . . . . 0.0 110.577 179.278 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -93.75 -177.6 4.42 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.072 -1.017 . . . . 0.0 110.425 -178.93 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.508 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.79 166.39 14.55 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.68 130.41 52.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.342 -1.093 . . . . 0.0 109.165 -179.405 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.618 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.25 122.29 22.6 Favored 'General case' 0 C--N 1.289 -2.024 0 O-C-N 121.623 -0.673 . . . . 0.0 109.48 179.617 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.833 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.57 168.74 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 O-C-N 121.193 -0.942 . . . . 0.0 109.188 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.548 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.3 m -136.85 157.52 46.56 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.301 -0.875 . . . . 0.0 109.541 -179.784 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.833 ' CE2' HD12 ' A' ' 110' ' ' ILE . 70.8 m-85 . . . . . 0 C--N 1.306 -1.323 0 O-C-N 121.164 -0.96 . . . . 0.0 109.608 -179.614 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.283 0 CA-C-O 122.415 1.102 . . . . 0.0 110.423 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.863 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -114.72 109.07 17.64 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 123.075 1.417 . . . . 0.0 109.663 179.937 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.782 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -117.28 136.08 55.6 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 CA-C-N 114.297 -1.32 . . . . 0.0 109.681 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.489 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -173.08 150.8 2.0 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.273 -0.892 . . . . 0.0 108.734 -179.559 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.489 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.21 150.44 88.57 Favored 'Cis proline' 0 C--N 1.312 -1.387 0 C-N-CA 123.563 -1.432 . . . . 0.0 109.507 -0.761 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.673 ' HA ' HG22 ' A' ' 110' ' ' ILE . 38.3 p -90.01 -25.59 20.77 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 121.586 -0.696 . . . . 0.0 109.14 179.502 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.521 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 16.1 m -133.08 162.11 32.61 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.406 -0.809 . . . . 0.0 109.565 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.86 37.13 30.52 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 -179.684 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.749 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.5 mt -92.36 -42.34 9.85 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 123.218 1.485 . . . . 0.0 110.43 -178.482 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.94 143.27 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.323 0 CA-C-N 113.379 -1.737 . . . . 0.0 109.825 -179.542 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.592 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 18.3 p-10 -50.39 105.27 0.09 Allowed 'General case' 0 C--N 1.3 -1.586 0 CA-C-O 121.452 0.644 . . . . 0.0 111.484 -178.525 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.92 13.57 8.46 Favored Glycine 0 N--CA 1.486 2.002 0 C-N-CA 119.306 -1.426 . . . . 0.0 113.165 177.285 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.749 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.56 -171.71 1.97 Allowed 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 121.28 2.54 . . . . 0.0 109.78 179.18 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.841 HG22 HG22 ' A' ' 68' ' ' THR . 18.2 t -129.26 139.01 52.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.956 -1.02 . . . . 0.0 111.224 -178.821 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.56 HG23 ' CD1' ' A' ' 67' ' ' LEU . 31.5 m -114.14 155.39 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 178.937 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.82 109.57 20.72 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.115 -0.991 . . . . 0.0 109.266 179.976 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.782 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -102.36 140.74 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.594 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.863 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.32 161.67 35.64 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 118.773 -1.171 . . . . 0.0 110.182 179.81 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.611 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.32 141.74 13.02 Favored Glycine 0 C--N 1.298 -1.572 0 N-CA-C 108.169 -1.973 . . . . 0.0 108.169 179.721 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -143.24 124.69 14.76 Favored 'General case' 0 N--CA 1.494 1.754 0 CA-C-N 119.226 1.513 . . . . 0.0 109.363 179.255 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.05 28.98 19.16 Favored Glycine 0 N--CA 1.489 2.212 0 C-N-CA 118.965 -1.588 . . . . 0.0 109.647 -179.733 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.539 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.5 mt -89.4 175.24 7.4 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.9 -1.353 . . . . 0.0 108.366 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.022 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.61 99.95 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.977 -1.077 . . . . 0.0 109.806 -179.752 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.537 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.32 77.52 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.918 -179.347 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.588 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.97 33.97 0.24 Allowed Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 179.674 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.556 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 23.1 p -139.59 105.66 5.22 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.141 -1.211 . . . . 0.0 111.283 -179.404 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.592 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.42 109.77 0.34 Allowed 'General case' 0 N--CA 1.497 1.916 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 177.853 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.512 ' HA ' ' O ' ' A' ' 98' ' ' SER . 6.8 m-30 -104.41 158.99 16.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.139 -0.975 . . . . 0.0 109.131 -179.977 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.516 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -101.63 157.75 16.59 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 178.754 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.017 HG11 HG23 ' A' ' 65' ' ' THR . 1.6 t -136.84 109.77 8.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.129 -0.982 . . . . 0.0 109.635 -177.573 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.38 -174.05 35.37 Favored Glycine 0 N--CA 1.497 2.727 0 C-N-CA 117.713 -2.184 . . . . 0.0 112.638 -179.928 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.602 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -102.09 109.11 20.74 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-O 121.756 0.789 . . . . 0.0 109.062 -179.495 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.42 148.8 52.27 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.21 -0.931 . . . . 0.0 109.6 179.33 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.503 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.34 138.72 54.55 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.32 -0.862 . . . . 0.0 110.774 -178.995 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.885 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.43 115.07 26.92 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.154 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.8 m -104.88 14.89 6.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 120.988 -1.07 . . . . 0.0 110.558 -178.89 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.764 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.38 -175.12 0.08 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.959 -1.088 . . . . 0.0 110.006 179.781 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.44 98.12 2.2 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.411 -0.806 . . . . 0.0 109.687 -179.78 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.99 28.11 32.22 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 120.217 -0.992 . . . . 0.0 111.355 179.014 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.764 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.54 106.25 19.61 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 O-C-N 120.603 -1.528 . . . . 0.0 107.071 178.804 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.885 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.8 tp -118.03 104.5 10.93 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.458 -1.401 . . . . 0.0 109.789 -177.719 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.09 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.21 109.37 22.14 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 120.918 -1.114 . . . . 0.0 108.051 178.84 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.502 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.1 163.47 12.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.906 -1.121 . . . . 0.0 110.281 -178.778 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.742 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 47.4 t30 -106.4 132.33 20.99 Favored Pre-proline 0 N--CA 1.504 2.23 0 O-C-N 121.394 -0.816 . . . . 0.0 109.627 -179.424 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -72.21 19.36 0.3 Allowed 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 122.296 1.997 . . . . 0.0 112.281 -179.596 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.742 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -111.2 4.13 18.99 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.38 -1.45 . . . . 0.0 108.707 179.114 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.657 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.08 20.76 3.01 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 179.303 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -81.37 85.85 6.37 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.538 -178.715 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.505 ' HB3' ' HB ' ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.52 -171.03 2.04 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.843 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.66 134.58 0.08 Allowed 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.676 -1.265 . . . . 0.0 111.23 -179.292 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.873 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -158.12 153.6 5.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 178.359 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.592 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.28 139.95 33.29 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.875 -1.141 . . . . 0.0 109.544 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.022 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -62.35 106.32 0.73 Allowed 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.391 1.091 . . . . 0.0 109.501 178.637 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.555 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.9 t70 -61.37 -139.21 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.045 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.77 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.537 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.11 -51.2 59.32 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.401 -0.812 . . . . 0.0 110.724 -178.803 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -101.04 -34.53 9.7 Favored 'General case' 0 C--N 1.286 -2.153 0 N-CA-C 106.282 -1.747 . . . . 0.0 106.282 178.493 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 104.88 65.76 0.68 Allowed Glycine 0 C--N 1.297 -1.637 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 178.109 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.611 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.6 m -98.86 130.42 45.27 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.594 -0.945 . . . . 0.0 108.6 178.739 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.873 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.79 108.63 6.68 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.594 -179.329 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.8 m -124.23 120.45 32.28 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.334 -0.854 . . . . 0.0 109.47 179.927 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 1.017 HG23 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.16 142.83 29.95 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.558 -0.714 . . . . 0.0 109.353 179.908 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 9.5 p -99.2 136.22 39.47 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.316 -0.865 . . . . 0.0 109.434 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.758 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -136.31 165.19 26.34 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.461 -0.774 . . . . 0.0 109.55 -179.343 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.841 HG22 HG22 ' A' ' 18' ' ' VAL . 2.2 p -96.78 125.45 41.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.073 -1.017 . . . . 0.0 109.112 179.926 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.602 HG12 ' HB3' ' A' ' 36' ' ' GLN . 17.7 m -136.53 142.7 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 120.934 -1.104 . . . . 0.0 110.09 -178.886 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.592 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 5.2 ptt180 -147.49 -173.08 4.18 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.562 -1.337 . . . . 0.0 110.884 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.599 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -54.11 -101.22 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 -179.421 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.514 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.19 141.44 46.41 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.82 -1.175 . . . . 0.0 108.128 179.479 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.8 135.44 5.58 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 118.68 -1.208 . . . . 0.0 109.665 -178.01 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.561 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 18.7 mm-40 -34.73 122.93 0.54 Allowed 'General case' 0 N--CA 1.491 1.603 0 CA-C-O 121.502 0.668 . . . . 0.0 110.088 -178.466 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.09 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.98 52.81 1.66 Allowed Glycine 0 N--CA 1.492 2.385 0 C-N-CA 120.397 -0.906 . . . . 0.0 111.108 -178.937 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.587 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-30 -39.7 113.38 0.33 Allowed 'General case' 0 N--CA 1.506 2.332 0 O-C-N 121.065 -1.256 . . . . 0.0 109.972 179.393 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.625 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -83.45 126.12 32.43 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.947 -1.096 . . . . 0.0 109.217 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 39.5 t80 -63.7 58.66 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.918 -1.114 . . . . 0.0 110.169 179.806 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -160.92 19.91 0.13 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.996 -1.065 . . . . 0.0 109.696 179.92 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.13 -28.07 5.28 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.882 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.463 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.32 159.61 15.04 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.007 -1.29 . . . . 0.0 110.28 -179.416 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.483 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.73 135.96 47.37 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.757 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.625 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -80.77 -18.87 46.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.867 -1.145 . . . . 0.0 110.545 -178.504 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.46 177.47 19.84 Favored Glycine 0 N--CA 1.484 1.88 0 N-CA-C 108.671 -1.771 . . . . 0.0 108.671 -179.428 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.36 105.58 1.18 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.2 -1.176 . . . . 0.0 107.859 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.665 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.0 t -77.53 105.7 6.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.346 -0.846 . . . . 0.0 109.124 -179.069 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.543 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.5 m-20 -65.6 111.44 3.15 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.406 -0.809 . . . . 0.0 109.747 -179.372 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.599 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.13 -5.23 4.46 Favored 'General case' 0 N--CA 1.5 2.031 0 C-N-CA 118.113 -1.435 . . . . 0.0 109.876 179.386 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -86.54 -0.06 55.33 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.799 -1.188 . . . . 0.0 109.159 179.587 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.543 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -113.36 -50.01 2.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.334 -0.854 . . . . 0.0 108.969 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.5 -179.05 3.83 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.487 -0.758 . . . . 0.0 109.42 179.925 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.88 115.27 30.01 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.328 -0.857 . . . . 0.0 108.999 179.9 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -97.03 122.24 39.81 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.762 -1.211 . . . . 0.0 109.428 -179.431 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -101.91 146.89 27.21 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 122.41 1.1 . . . . 0.0 111.107 -179.372 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.552 ' CG1' HG11 ' A' ' 7' ' ' VAL . 61.1 t -104.43 110.25 29.93 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 177.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.511 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.44 -169.86 17.58 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 118.31 -1.9 . . . . 0.0 111.466 -177.786 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.639 HD23 HG22 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -113.22 179.98 3.81 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -179.333 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.512 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.6 OUTLIER . . . . . 0 C--N 1.296 -1.736 0 O-C-N 121.364 -0.835 . . . . 0.0 109.406 -179.596 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.806 0 N-CA-C 107.62 -2.192 . . . . 0.0 107.62 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.49 -178.16 6.93 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.637 -0.919 . . . . 0.0 109.622 179.194 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.85 -162.43 14.74 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 108.434 -1.866 . . . . 0.0 108.434 -179.34 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.48 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.9 Cg_exo -46.32 176.31 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.692 0 CA-C-N 118.837 1.318 . . . . 0.0 110.206 179.289 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -91.62 -176.15 4.4 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.033 -1.042 . . . . 0.0 110.573 -178.71 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.511 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.63 168.88 15.02 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.61 130.39 57.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.354 -1.086 . . . . 0.0 109.192 -179.208 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.05 122.9 20.91 Favored 'General case' 0 C--N 1.29 -1.985 0 O-C-N 121.609 -0.682 . . . . 0.0 109.505 179.543 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.76 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.69 169.02 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.201 -0.937 . . . . 0.0 109.222 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.521 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -136.39 155.31 50.21 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 109.602 -179.942 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.76 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 21.2 m-85 . . . . . 0 N--CA 1.486 1.333 0 O-C-N 121.198 -0.939 . . . . 0.0 109.482 -179.664 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.668 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.486 1.36 0 CA-C-O 122.303 1.049 . . . . 0.0 111.134 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.01 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -100.92 104.59 15.79 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 122.478 1.132 . . . . 0.0 109.76 -179.892 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.975 HG22 HG23 ' A' ' 21' ' ' VAL . 5.4 t -119.4 122.92 70.2 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.401 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.574 179.823 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.481 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -169.52 150.04 3.91 Favored Pre-proline 0 N--CA 1.487 1.413 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 -179.529 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.481 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.4 Cg_endo -76.74 150.71 93.25 Favored 'Cis proline' 0 C--N 1.309 -1.533 0 C-N-CA 123.613 -1.411 . . . . 0.0 109.579 -0.339 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.679 ' HA ' HG22 ' A' ' 110' ' ' ILE . 89.2 p -92.49 -22.81 19.37 Favored 'General case' 0 C--N 1.292 -1.929 0 O-C-N 121.693 -0.629 . . . . 0.0 109.352 179.799 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.488 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.3 m -132.37 163.97 27.51 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.398 -0.814 . . . . 0.0 109.689 -179.822 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.05 38.88 39.14 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 -179.504 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.857 ' CA ' HG21 ' A' ' 17' ' ' THR . 27.7 mt -92.02 -45.21 8.44 Favored 'General case' 0 C--N 1.297 -1.698 0 CA-C-O 123.12 1.438 . . . . 0.0 110.772 -178.09 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.13 146.42 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.349 0 CA-C-N 113.799 -1.546 . . . . 0.0 110.077 -179.615 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.585 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.6 p-10 -50.76 108.32 0.23 Allowed 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 121.542 0.687 . . . . 0.0 111.984 -178.53 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.74 16.54 9.9 Favored Glycine 0 N--CA 1.485 1.907 0 C-N-CA 119.592 -1.289 . . . . 0.0 112.768 177.07 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.857 HG21 ' CA ' ' A' ' 13' ' ' LEU . 8.8 t -103.45 -174.79 2.63 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 120.965 2.382 . . . . 0.0 109.98 179.426 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.772 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.0 t -129.89 138.9 52.91 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 CA-C-N 114.365 -1.288 . . . . 0.0 111.06 -178.799 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.635 HG22 HG22 ' A' ' 69' ' ' VAL . 4.1 m -118.53 154.99 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.669 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 10.2 tttt -105.95 108.99 20.79 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.175 -0.953 . . . . 0.0 109.403 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.975 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.04 123.38 62.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 179.611 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.51 167.17 11.54 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 120.69 -1.256 . . . . 0.0 109.222 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.604 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.76 140.71 12.03 Favored Glycine 0 C--N 1.295 -1.717 0 N-CA-C 107.49 -2.244 . . . . 0.0 107.49 179.718 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.31 124.1 11.92 Favored 'General case' 0 C--N 1.293 -1.889 0 O-C-N 120.748 -1.442 . . . . 0.0 108.87 179.35 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.36 25.97 26.94 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.226 -1.464 . . . . 0.0 109.913 -179.641 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.539 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.1 mt -85.6 175.44 8.77 Favored 'General case' 0 C--N 1.306 -1.321 0 O-C-N 120.891 -1.358 . . . . 0.0 108.263 -179.989 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.39 96.71 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.928 -1.108 . . . . 0.0 109.659 -179.72 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.706 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.53 76.77 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.758 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.536 -178.996 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.77 33.7 0.33 Allowed Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.253 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.587 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.3 t -149.14 116.07 6.0 Favored 'General case' 0 C--N 1.307 -1.268 0 O-C-N 120.929 -1.336 . . . . 0.0 111.138 179.919 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.565 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.83 127.55 6.4 Favored 'General case' 0 N--CA 1.492 1.653 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.902 178.453 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.587 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.9 m-85 -118.36 149.18 41.63 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.431 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.505 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -98.97 159.28 15.07 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.548 -1.345 . . . . 0.0 107.784 178.841 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.623 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.4 p -140.19 119.6 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.189 -0.944 . . . . 0.0 109.633 -177.819 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' HB2' ' A' ' 51' ' ' ASP . . . -170.72 -179.94 42.33 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 118.274 -1.917 . . . . 0.0 111.794 -179.799 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.67 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.83 108.85 20.76 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.783 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.484 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.32 148.51 51.25 Favored 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.174 -0.954 . . . . 0.0 109.953 179.887 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.513 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.19 138.99 54.51 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.359 -0.838 . . . . 0.0 110.593 -179.046 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.89 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.29 114.63 26.44 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 107.521 -1.289 . . . . 0.0 107.521 178.213 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.0 m -104.38 14.81 6.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 O-C-N 121.069 -1.019 . . . . 0.0 110.482 -178.811 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.74 -175.41 0.08 Allowed 'General case' 0 C--N 1.302 -1.482 0 O-C-N 120.935 -1.103 . . . . 0.0 110.025 179.695 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.6 p -73.54 98.28 2.78 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.413 -0.804 . . . . 0.0 109.506 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.5 27.58 29.56 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.219 -0.991 . . . . 0.0 111.326 179.128 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -118.72 106.31 19.29 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 O-C-N 120.607 -1.525 . . . . 0.0 107.342 178.999 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.89 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -116.61 104.7 11.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.315 -1.491 . . . . 0.0 109.855 -177.815 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.948 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.49 109.62 22.34 Favored 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.909 -1.12 . . . . 0.0 108.1 178.885 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.0 t -107.15 165.82 11.08 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.841 -1.162 . . . . 0.0 110.612 -178.632 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.503 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 55.3 t30 -113.55 132.45 22.53 Favored Pre-proline 0 N--CA 1.501 2.092 0 C-N-CA 120.119 -0.632 . . . . 0.0 109.425 -179.486 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.8 Cg_endo -72.76 24.31 0.29 Allowed 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 122.205 1.937 . . . . 0.0 112.104 -179.743 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.419 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -99.06 -7.58 26.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.369 -1.457 . . . . 0.0 109.184 179.52 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.792 ' HB3' HD22 ' A' ' 67' ' ' LEU . 0.7 OUTLIER -133.61 5.8 3.72 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.346 -0.846 . . . . 0.0 108.817 -179.985 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -59.44 80.62 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.87 -178.656 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -108.48 -169.97 1.59 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 178.297 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.5 134.55 0.08 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.543 -1.348 . . . . 0.0 111.448 -179.405 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.724 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.9 p -146.31 158.92 11.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 177.741 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.565 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.48 146.6 25.08 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.572 -1.33 . . . . 0.0 109.884 -179.564 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.42 108.73 3.37 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 122.385 1.088 . . . . 0.0 109.674 178.914 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.546 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.1 p-10 -62.42 -138.85 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.862 -179.796 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.706 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.72 -51.84 35.76 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.376 -0.828 . . . . 0.0 110.641 -178.771 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -105.11 -32.73 8.55 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 178.553 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.963 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.5 69.78 0.67 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 178.246 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 69.9 m -103.63 130.09 51.01 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 121.268 -1.137 . . . . 0.0 109.337 179.267 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.724 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.62 108.69 7.68 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.433 -0.907 . . . . 0.0 109.676 -179.675 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 93.6 p -115.88 116.93 28.84 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 120.956 -1.09 . . . . 0.0 109.364 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.29 141.27 27.15 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.427 -0.796 . . . . 0.0 110.125 -179.868 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.6 p -100.35 137.0 39.36 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.614 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.972 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -137.35 172.22 13.31 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.253 -0.904 . . . . 0.0 109.844 -178.979 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.581 HG22 HG22 ' A' ' 18' ' ' VAL . 1.2 p -104.72 123.66 48.02 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.089 -1.007 . . . . 0.0 109.908 -179.372 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.764 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.5 m -133.04 143.6 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 121.056 -1.027 . . . . 0.0 109.688 -179.606 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.585 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.2 ptt180 -140.78 -167.77 2.43 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.558 -1.339 . . . . 0.0 110.417 179.906 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.584 ' HG2' ' CD1' ' A' ' 112' ' ' PHE . 3.3 mtt180 -70.95 -76.61 0.1 Allowed 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -179.623 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.49 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -71.88 137.8 47.74 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 120.153 -1.592 . . . . 0.0 107.547 179.117 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.594 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -159.56 136.96 9.79 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.27 -1.372 . . . . 0.0 110.108 -178.105 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.484 ' O ' ' O ' ' A' ' 47' ' ' CYS . 9.1 mm-40 -34.71 122.54 0.53 Allowed 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.562 0.696 . . . . 0.0 110.571 -178.188 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.948 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.38 45.62 3.14 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 6.6 m-85 -38.41 113.82 0.32 Allowed 'General case' 0 N--CA 1.509 2.477 0 O-C-N 121.194 -1.18 . . . . 0.0 110.167 179.751 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.691 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.4 tp -87.81 125.99 34.76 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 120.913 -1.117 . . . . 0.0 109.477 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 23.4 t80 -64.26 58.6 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 O-C-N 120.972 -1.08 . . . . 0.0 110.184 179.93 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 6.3 t70 -161.0 20.02 0.13 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.047 -1.033 . . . . 0.0 109.796 179.688 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.68 -27.5 5.29 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.874 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 8.1 p -94.05 160.99 14.47 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.984 -1.303 . . . . 0.0 110.256 -179.488 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.544 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -108.98 136.63 48.2 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.897 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.691 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.7 t90 -82.67 -19.1 38.82 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.932 -1.105 . . . . 0.0 110.386 -178.368 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.64 175.2 19.97 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 -179.494 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.29 109.63 1.39 Allowed 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 179.122 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.677 HG21 ' CB ' ' A' ' 46' ' ' ALA . 39.4 t -81.38 104.38 9.85 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.068 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.637 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -67.42 111.14 3.91 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.433 -0.792 . . . . 0.0 109.888 -179.076 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.568 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.0 t -63.26 -5.9 3.9 Favored 'General case' 0 N--CA 1.499 2.017 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.942 179.48 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.3 p -84.76 -0.08 52.45 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.717 -1.24 . . . . 0.0 109.023 179.407 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.637 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.41 -49.14 2.91 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.356 -0.84 . . . . 0.0 109.024 -179.969 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.08 -178.03 3.53 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.578 -0.701 . . . . 0.0 109.539 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.11 115.26 29.92 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.466 -0.771 . . . . 0.0 108.982 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.57 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -97.09 125.2 41.4 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.948 -1.095 . . . . 0.0 109.687 -179.174 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.595 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.54 146.44 28.89 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 122.421 1.105 . . . . 0.0 111.191 -179.524 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.606 ' HB ' HG11 ' A' ' 7' ' ' VAL . 96.2 t -102.68 111.09 31.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 177.775 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.487 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.78 -171.2 18.72 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 117.97 -2.062 . . . . 0.0 111.808 -177.684 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.668 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -113.95 -177.59 3.17 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -179.075 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.472 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.0 OUTLIER . . . . . 0 C--N 1.299 -1.617 0 O-C-N 121.229 -0.92 . . . . 0.0 109.531 -179.378 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.699 0 N-CA-C 107.786 -2.126 . . . . 0.0 107.786 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.55 -177.67 6.09 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.534 -0.98 . . . . 0.0 109.91 179.328 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.86 -160.97 12.89 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.415 -1.874 . . . . 0.0 108.415 -179.395 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.7 Cg_exo -47.87 -178.95 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.813 1.306 . . . . 0.0 110.474 179.367 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -94.59 -179.51 4.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.068 -1.02 . . . . 0.0 110.448 -178.903 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.487 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.84 162.49 12.71 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 -179.972 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.8 129.67 50.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.397 -1.06 . . . . 0.0 109.095 -179.501 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.595 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.35 121.82 21.06 Favored 'General case' 0 C--N 1.289 -2.041 0 O-C-N 121.626 -0.671 . . . . 0.0 109.892 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.853 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.83 171.37 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.242 -0.911 . . . . 0.0 108.982 179.658 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.488 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -138.6 159.33 42.36 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.156 -0.965 . . . . 0.0 109.669 -179.845 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.853 ' CE2' HD12 ' A' ' 110' ' ' ILE . 79.7 m-85 . . . . . 0 N--CA 1.485 1.323 0 O-C-N 121.25 -0.907 . . . . 0.0 109.63 -179.785 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.414 0 CA-C-O 122.32 1.057 . . . . 0.0 110.778 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.949 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.4 t -112.82 108.71 17.79 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-O 123.108 1.432 . . . . 0.0 109.175 179.394 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.853 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -115.93 139.04 44.39 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.728 0 CA-C-N 114.169 -1.378 . . . . 0.0 110.088 -179.67 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.486 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -177.0 150.32 0.88 Allowed Pre-proline 0 N--CA 1.486 1.35 0 O-C-N 121.309 -0.87 . . . . 0.0 108.766 -179.673 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.486 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.9 Cg_endo -78.49 150.43 87.7 Favored 'Cis proline' 0 C--N 1.312 -1.364 0 C-N-CA 123.531 -1.445 . . . . 0.0 109.334 -0.921 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.646 ' HA ' HG22 ' A' ' 110' ' ' ILE . 94.1 p -93.65 -22.13 18.96 Favored 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.52 -0.738 . . . . 0.0 109.558 179.821 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.481 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -132.2 162.62 30.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.805 -179.798 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.15 39.03 38.21 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 -179.508 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.823 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.8 mt -91.38 -44.58 9.06 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-O 123.093 1.425 . . . . 0.0 110.771 -178.272 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.0 OUTLIER 64.37 146.42 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.332 0 CA-C-N 113.735 -1.575 . . . . 0.0 109.63 -179.42 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.6 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.7 p-10 -52.32 110.1 0.46 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.486 0.66 . . . . 0.0 111.554 -178.523 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.71 9.76 13.75 Favored Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.301 -1.428 . . . . 0.0 112.854 177.375 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.823 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.8 t -101.32 -172.52 2.18 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 121.029 2.415 . . . . 0.0 109.747 179.502 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.76 HG13 ' C ' ' A' ' 67' ' ' LEU . 11.2 t -134.63 141.32 43.64 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.612 -179.334 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 27.8 m -116.55 154.8 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.214 -0.929 . . . . 0.0 109.057 179.471 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.489 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 21.8 tttt -107.95 108.97 20.34 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.238 -0.914 . . . . 0.0 109.049 179.793 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.853 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -101.03 139.11 23.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.555 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.949 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.45 160.46 37.92 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 118.461 -1.296 . . . . 0.0 110.027 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.603 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.94 144.07 15.52 Favored Glycine 0 C--N 1.294 -1.758 0 N-CA-C 107.755 -2.138 . . . . 0.0 107.755 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.45 124.5 12.09 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 120.799 -1.412 . . . . 0.0 108.953 179.222 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.15 26.52 23.58 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 119.272 -1.442 . . . . 0.0 109.703 -179.702 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.577 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -89.22 170.56 10.49 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 120.857 -1.378 . . . . 0.0 108.479 179.989 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.006 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.09 100.69 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.051 -1.031 . . . . 0.0 109.988 -179.574 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.7 77.98 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.004 -179.509 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.85 34.05 0.27 Allowed Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 179.702 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.553 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 20.8 p -139.18 105.88 5.37 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.198 -1.178 . . . . 0.0 111.255 -179.485 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.589 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -52.32 114.19 1.27 Allowed 'General case' 0 N--CA 1.495 1.814 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.611 178.098 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.488 ' HA ' ' O ' ' A' ' 98' ' ' SER . 8.2 m-30 -110.67 160.06 17.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.143 -0.973 . . . . 0.0 108.949 179.834 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.507 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -100.62 168.28 9.8 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 178.93 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.704 HG22 HG11 ' A' ' 21' ' ' VAL . 3.8 p -150.36 117.13 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.023 -1.048 . . . . 0.0 109.827 -178.221 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.85 -175.93 39.21 Favored Glycine 0 N--CA 1.495 2.605 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.821 -179.765 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.609 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -99.33 108.44 20.97 Favored 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.811 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.0 m -132.21 148.45 52.46 Favored 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.296 -0.878 . . . . 0.0 109.784 179.657 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.2 140.25 53.02 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.241 -0.912 . . . . 0.0 110.727 -179.136 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.885 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.16 114.78 26.61 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.211 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.3 m -104.16 14.49 6.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.052 -1.03 . . . . 0.0 110.5 -178.798 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.75 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.93 -175.26 0.08 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.897 -1.127 . . . . 0.0 110.087 179.769 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.25 98.45 2.65 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.425 -0.797 . . . . 0.0 109.535 -179.917 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.98 27.51 31.2 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 120.244 -0.979 . . . . 0.0 111.421 179.072 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.75 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -118.01 106.33 19.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 O-C-N 120.618 -1.519 . . . . 0.0 107.303 178.846 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.885 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.4 tp -117.65 104.67 11.25 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.523 -1.36 . . . . 0.0 109.58 -177.843 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.965 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.03 109.54 22.27 Favored 'General case' 0 N--CA 1.485 1.281 0 O-C-N 120.828 -1.17 . . . . 0.0 108.251 179.068 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -107.61 166.85 10.37 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.023 -1.048 . . . . 0.0 109.989 -179.17 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.73 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.0 t-20 -107.3 137.33 19.58 Favored Pre-proline 0 N--CA 1.502 2.148 0 O-C-N 121.231 -0.918 . . . . 0.0 109.846 -179.286 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.6 Cg_endo -75.15 24.49 0.39 Allowed 'Trans proline' 0 C--N 1.318 -1.04 0 C-N-CA 122.383 2.056 . . . . 0.0 111.786 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.73 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -120.27 4.09 10.81 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.351 -1.468 . . . . 0.0 109.195 179.75 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.572 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.84 19.96 2.85 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 179.278 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -84.14 87.81 7.17 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.929 -0.708 . . . . 0.0 110.858 -178.618 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -107.91 -168.25 1.35 Allowed 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.436 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.458 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.92 136.22 0.09 Allowed 'General case' 0 C--N 1.305 -1.326 0 O-C-N 120.755 -1.216 . . . . 0.0 111.082 -179.401 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.927 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -151.73 157.7 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 178.391 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.589 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.91 142.26 30.64 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.835 -1.166 . . . . 0.0 110.027 -179.786 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.03 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.89 107.76 1.05 Allowed 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 122.441 1.115 . . . . 0.0 109.288 178.083 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.1 t0 -62.94 -138.68 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.777 179.937 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.531 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.37 -52.7 34.93 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.402 -0.811 . . . . 0.0 110.924 -178.615 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.85 -33.07 9.94 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 178.612 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.03 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.19 62.26 0.55 Allowed Glycine 0 C--N 1.296 -1.664 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 178.051 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.603 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 82.5 p -98.72 129.91 45.19 Favored 'General case' 0 C--N 1.309 -1.155 0 O-C-N 121.563 -0.963 . . . . 0.0 108.731 178.713 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.927 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.29 108.89 6.97 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.203 -0.999 . . . . 0.0 109.727 -179.343 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -122.35 119.2 30.37 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.191 -0.943 . . . . 0.0 109.533 -179.941 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.574 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.66 142.98 30.51 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.491 -0.756 . . . . 0.0 109.329 179.876 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 27.7 p -98.82 138.09 36.46 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.416 -0.802 . . . . 0.0 109.58 -179.853 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.814 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -140.83 159.41 42.27 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.329 -0.857 . . . . 0.0 109.48 -179.502 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.71 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 13.0 t -87.91 139.14 30.82 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.147 -0.97 . . . . 0.0 110.657 -179.411 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.609 HG12 ' HB3' ' A' ' 36' ' ' GLN . 19.4 m -148.73 144.31 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.484 -0.76 . . . . 0.0 109.249 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.6 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.9 OUTLIER -150.72 -173.69 4.55 Favored 'General case' 0 N--CA 1.484 1.245 0 O-C-N 120.456 -1.403 . . . . 0.0 111.178 -179.641 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.741 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.28 -104.8 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.281 -179.644 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.458 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -59.43 140.23 56.37 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 120.695 -1.253 . . . . 0.0 108.072 178.948 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.609 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -158.29 138.69 12.61 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.773 -1.171 . . . . 0.0 109.713 -178.312 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.52 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 8.8 mm-40 -34.89 120.35 0.5 Allowed 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.539 0.685 . . . . 0.0 110.552 -178.448 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.965 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.96 47.91 3.2 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.415 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -38.47 113.65 0.31 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 121.241 -1.153 . . . . 0.0 110.166 179.812 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.816 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.66 126.26 34.41 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.997 -1.065 . . . . 0.0 109.456 -179.982 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 20.4 t80 -64.23 58.48 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.906 -1.121 . . . . 0.0 109.949 179.541 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 9.8 t70 -158.74 18.77 0.2 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.976 -1.078 . . . . 0.0 109.645 -179.979 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.18 -26.41 6.23 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.761 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.83 163.64 12.71 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 120.99 -1.3 . . . . 0.0 110.404 -179.332 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.486 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 4.2 ptt180 -106.24 136.79 45.34 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.914 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.816 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.7 t90 -82.58 -19.6 38.15 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.79 -1.194 . . . . 0.0 110.241 -178.709 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.64 173.43 16.86 Favored Glycine 0 N--CA 1.486 2.019 0 N-CA-C 108.791 -1.723 . . . . 0.0 108.791 -179.636 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -65.14 106.1 1.22 Allowed 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 179.105 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.651 HG21 ' HB3' ' A' ' 46' ' ' ALA . 46.2 t -76.51 107.34 7.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.371 -0.831 . . . . 0.0 109.533 -178.694 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.603 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.9 m-20 -63.92 111.99 2.73 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.213 -0.929 . . . . 0.0 109.178 -179.919 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.741 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.2 m -65.41 -4.66 5.96 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 120.704 -1.247 . . . . 0.0 109.829 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.2 p -93.27 1.95 56.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.731 -1.23 . . . . 0.0 109.58 179.956 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.603 HG23 ' HB3' ' A' ' 87' ' ' ASP . 5.0 p -112.51 -52.79 2.76 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.241 -0.912 . . . . 0.0 108.636 179.78 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.421 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -98.47 178.77 4.92 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.492 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.07 114.0 27.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -0.89 . . . . 0.0 108.777 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.505 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.8 m -96.44 121.8 38.64 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.982 -1.074 . . . . 0.0 109.758 -178.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.572 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -106.2 144.28 33.12 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-O 122.355 1.074 . . . . 0.0 111.112 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 90.5 t -101.87 109.58 26.44 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.086 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.741 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.483 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.12 -172.01 17.65 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 118.223 -1.941 . . . . 0.0 111.741 -177.591 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.503 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -112.01 178.8 4.19 Favored 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.289 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.507 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.9 OUTLIER . . . . . 0 C--N 1.294 -1.805 0 O-C-N 121.571 -0.706 . . . . 0.0 109.424 -179.546 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.717 0 N-CA-C 107.559 -2.216 . . . . 0.0 107.559 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.75 -178.23 7.1 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.574 -0.956 . . . . 0.0 109.777 179.23 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.44 -161.9 14.4 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.488 -1.845 . . . . 0.0 108.488 -179.394 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.479 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -47.24 178.25 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.626 0 CA-C-N 118.812 1.306 . . . . 0.0 110.342 179.329 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -91.37 -174.35 3.9 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.097 -1.002 . . . . 0.0 110.401 -178.893 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.483 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.99 166.8 15.29 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.7 130.15 51.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.43 -1.041 . . . . 0.0 109.1 -179.429 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.572 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.71 125.12 28.04 Favored 'General case' 0 C--N 1.289 -2.049 0 O-C-N 121.641 -0.662 . . . . 0.0 109.606 179.782 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.755 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.84 169.98 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.274 -0.891 . . . . 0.0 109.257 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.481 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -137.88 155.77 48.6 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.276 -0.89 . . . . 0.0 109.504 179.992 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.755 ' CE1' HD12 ' A' ' 110' ' ' ILE . 76.5 m-85 . . . . . 0 N--CA 1.487 1.398 0 O-C-N 121.11 -0.994 . . . . 0.0 109.51 -179.808 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.499 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.224 0 CA-C-O 122.465 1.126 . . . . 0.0 110.031 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.92 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.9 t -114.88 109.1 17.64 Favored 'General case' 0 C--N 1.294 -1.822 0 CA-C-O 123.2 1.476 . . . . 0.0 109.765 -179.807 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.863 HG22 HG23 ' A' ' 21' ' ' VAL . 3.1 t -116.27 136.98 51.49 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.638 0 CA-C-N 114.176 -1.374 . . . . 0.0 109.716 179.902 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.497 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -172.96 151.25 2.13 Favored Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 121.235 -0.915 . . . . 0.0 108.791 -179.534 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.497 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.2 Cg_endo -77.53 151.67 92.52 Favored 'Cis proline' 0 C--N 1.311 -1.422 0 C-N-CA 123.517 -1.451 . . . . 0.0 109.433 -0.819 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.67 ' HA ' HG22 ' A' ' 110' ' ' ILE . 88.1 p -93.94 -23.2 18.16 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.576 -0.703 . . . . 0.0 109.505 179.805 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.5 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 3.0 m -130.94 160.1 35.51 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.321 -0.862 . . . . 0.0 109.96 -179.65 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.23 37.25 32.57 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 108.611 -1.796 . . . . 0.0 108.611 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.865 ' CA ' HG21 ' A' ' 17' ' ' THR . 27.1 mt -90.83 -45.42 8.81 Favored 'General case' 0 C--N 1.299 -1.627 0 CA-C-O 123.113 1.435 . . . . 0.0 110.751 -178.411 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 64.03 147.23 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.311 0 CA-C-N 113.748 -1.569 . . . . 0.0 109.963 -179.612 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.615 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.4 p-10 -51.41 108.9 0.29 Allowed 'General case' 0 C--N 1.302 -1.47 0 CA-C-O 121.725 0.774 . . . . 0.0 111.809 -178.568 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.8 13.66 11.04 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 119.479 -1.343 . . . . 0.0 112.914 177.311 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.865 HG21 ' CA ' ' A' ' 13' ' ' LEU . 10.2 t -101.8 -174.34 2.57 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 121.059 2.43 . . . . 0.0 109.86 179.457 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.766 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.1 t -127.83 138.3 55.13 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.885 -178.994 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.534 HG13 ' CG2' ' A' ' 69' ' ' VAL . 30.8 m -117.34 154.17 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.877 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -109.98 109.34 19.89 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.187 -0.946 . . . . 0.0 109.195 -179.846 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.863 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -101.96 140.44 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.747 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.92 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.33 158.31 44.12 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.838 -1.164 . . . . 0.0 109.701 179.568 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -139.36 108.81 0.61 Allowed Glycine 0 N--CA 1.481 1.675 0 N-CA-C 108.658 -1.777 . . . . 0.0 108.658 179.888 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.43 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.54 139.52 50.4 Favored 'General case' 0 N--CA 1.502 2.14 0 CA-C-N 119.402 1.601 . . . . 0.0 110.564 -179.25 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.21 27.81 32.47 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.058 -1.544 . . . . 0.0 109.938 179.569 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.7 OUTLIER -93.67 170.53 9.51 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.97 -1.312 . . . . 0.0 108.522 -179.92 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.997 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.43 101.23 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.097 -1.002 . . . . 0.0 109.827 -179.566 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.54 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.42 77.93 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.705 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.888 -179.342 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.5 33.46 0.27 Allowed Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 179.896 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.56 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 12.9 p -136.96 104.75 5.55 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 121.2 -1.176 . . . . 0.0 111.057 -179.349 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.582 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.54 110.03 0.41 Allowed 'General case' 0 N--CA 1.497 1.914 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.621 178.087 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.555 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 38.5 m-85 -106.33 156.35 18.59 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.052 -1.03 . . . . 0.0 108.992 179.87 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.415 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.25 160.14 14.57 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.631 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.626 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.2 p -140.75 119.66 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.095 -1.003 . . . . 0.0 109.62 -177.836 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.486 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.88 -178.8 41.15 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.536 -1.792 . . . . 0.0 111.525 -179.782 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.586 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.1 pt20 -100.99 109.08 20.95 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.756 0.788 . . . . 0.0 108.954 -179.904 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.493 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.81 150.26 52.07 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.079 -1.013 . . . . 0.0 110.406 179.978 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.92 139.38 53.88 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.373 -0.829 . . . . 0.0 110.661 -179.054 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.882 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.3 115.02 26.87 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 178.114 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -105.92 15.44 7.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.013 -1.055 . . . . 0.0 110.605 -178.889 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.764 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.6 -176.33 0.09 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.831 -1.168 . . . . 0.0 110.147 179.759 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 42' ' ' THR . 15.2 t -70.13 97.32 1.18 Allowed 'General case' 0 N--CA 1.487 1.419 0 CA-C-O 121.791 0.805 . . . . 0.0 109.949 -179.553 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.2 28.35 37.18 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.158 -1.02 . . . . 0.0 111.349 178.957 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.764 HG21 ' CB ' ' A' ' 41' ' ' ASP . 2.0 t -115.61 106.46 20.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 120.625 -1.515 . . . . 0.0 107.193 178.778 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.882 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.3 tp -116.4 104.75 11.77 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.428 -1.42 . . . . 0.0 109.847 -177.612 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.872 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.96 109.24 22.03 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 120.763 -1.211 . . . . 0.0 107.847 178.682 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -104.17 170.0 8.16 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.933 -1.104 . . . . 0.0 110.151 -178.863 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.454 ' CG ' ' HB2' ' A' ' 73' ' ' PHE . 36.9 t30 -108.24 134.67 20.1 Favored Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.346 -0.846 . . . . 0.0 109.631 -179.376 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.1 Cg_endo -74.5 25.27 0.36 Allowed 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 122.259 1.972 . . . . 0.0 111.608 -179.962 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.424 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -120.12 2.54 10.92 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.473 -1.392 . . . . 0.0 109.307 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.706 ' OD2' HG13 ' A' ' 69' ' ' VAL . 5.7 m-20 -137.09 18.67 2.99 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 179.744 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -81.13 88.52 5.99 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.617 -0.833 . . . . 0.0 110.62 -178.702 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -109.43 -166.22 1.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 178.66 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.77 136.02 0.09 Allowed 'General case' 0 N--CA 1.485 1.316 0 O-C-N 120.708 -1.245 . . . . 0.0 111.07 -179.215 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.94 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.84 155.92 5.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.421 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.582 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.73 141.34 31.66 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.87 -1.144 . . . . 0.0 109.94 -179.737 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.997 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -61.76 106.18 0.65 Allowed 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 122.471 1.129 . . . . 0.0 109.379 178.331 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.56 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.2 p-10 -59.46 -140.06 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.043 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.947 179.895 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.54 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.37 -50.42 59.58 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.488 -0.758 . . . . 0.0 110.752 -178.756 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -103.65 -33.35 9.0 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 106.16 -1.792 . . . . 0.0 106.16 178.518 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.985 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.4 66.3 0.65 Allowed Glycine 0 C--N 1.298 -1.545 0 CA-C-N 114.897 -1.047 . . . . 0.0 110.514 177.993 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 20.0 m -103.68 125.43 50.17 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 178.657 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.94 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.9 109.27 7.86 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.349 -179.379 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.7 m -126.21 122.16 34.82 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.366 -0.834 . . . . 0.0 109.674 -179.717 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.587 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -143.91 141.8 30.45 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.634 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.3 p -98.55 131.63 44.62 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.192 -0.942 . . . . 0.0 109.493 -179.8 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.839 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -131.49 178.46 6.71 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.487 -0.758 . . . . 0.0 109.299 -179.387 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.538 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.5 p -102.22 123.52 46.2 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.898 -1.126 . . . . 0.0 109.739 -179.416 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.731 HG23 HD13 ' A' ' 13' ' ' LEU . 15.5 m -128.59 142.32 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 120.934 -1.104 . . . . 0.0 110.062 -179.389 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.615 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.5 ptt180 -148.4 -176.76 5.43 Favored 'General case' 0 N--CA 1.484 1.248 0 O-C-N 120.521 -1.362 . . . . 0.0 110.91 179.669 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.569 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.1 OUTLIER -60.56 -102.33 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.189 -179.109 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.534 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -60.09 138.12 57.95 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.443 -1.411 . . . . 0.0 107.979 179.773 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.531 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 2.4 p90 -161.72 147.33 13.57 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 118.555 -1.258 . . . . 0.0 110.033 -178.377 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.541 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 1.8 mp0 -37.68 120.44 0.82 Allowed 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 121.504 0.669 . . . . 0.0 110.516 -178.674 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.872 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.54 49.49 3.17 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.599 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.9 m-30 -38.07 114.45 0.36 Allowed 'General case' 0 N--CA 1.511 2.582 0 O-C-N 121.194 -1.18 . . . . 0.0 110.545 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.816 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -87.62 127.01 35.28 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.843 -1.161 . . . . 0.0 109.546 179.78 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.6 t80 -64.36 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.872 -1.142 . . . . 0.0 109.993 179.667 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.8 t70 -159.46 19.01 0.18 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.047 -1.033 . . . . 0.0 109.72 179.893 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.89 -26.34 6.1 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.747 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 35.2 p -96.45 163.32 13.1 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 121.037 -1.273 . . . . 0.0 110.407 -179.414 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.478 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.4 136.28 46.42 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.913 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.816 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.9 t90 -82.42 -18.56 41.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.781 -1.199 . . . . 0.0 110.318 -178.757 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.83 173.36 17.85 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 -179.587 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.79 109.3 1.68 Allowed 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 179.203 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.606 HG21 ' HB3' ' A' ' 46' ' ' ALA . 50.4 t -80.06 105.23 9.37 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 121.43 -0.794 . . . . 0.0 109.349 -178.782 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.556 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -66.14 109.69 2.7 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.661 -0.649 . . . . 0.0 109.965 -179.529 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.569 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 3.0 t -62.09 -4.41 1.67 Allowed 'General case' 0 N--CA 1.501 2.107 0 C-N-CA 118.165 -1.414 . . . . 0.0 110.162 179.348 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.0 p -90.08 3.54 53.0 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.627 -1.296 . . . . 0.0 109.306 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.556 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -116.32 -49.88 2.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.298 -0.876 . . . . 0.0 109.127 -179.899 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.9 179.37 4.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.429 -0.795 . . . . 0.0 109.46 179.969 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.42 113.6 26.85 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.286 -0.884 . . . . 0.0 108.725 179.737 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.495 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -97.16 121.41 39.02 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.929 -1.107 . . . . 0.0 109.542 -178.922 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.579 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.43 148.58 26.27 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 122.44 1.114 . . . . 0.0 111.452 -179.249 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.483 ' CG1' HG11 ' A' ' 7' ' ' VAL . 28.8 t -104.95 109.5 27.86 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.449 -1.686 . . . . 0.0 106.449 177.249 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.482 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.8 -169.53 16.77 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 118.305 -1.902 . . . . 0.0 111.691 -177.366 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.468 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -120.77 177.13 5.2 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -178.958 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.468 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 7.8 t . . . . . 0 C--N 1.292 -1.933 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 179.917 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.693 0 N-CA-C 107.857 -2.097 . . . . 0.0 107.857 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.95 -177.35 5.03 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.576 -0.955 . . . . 0.0 109.992 179.359 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.13 -161.24 20.28 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 108.074 -2.01 . . . . 0.0 108.074 -179.411 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.479 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.4 Cg_exo -47.01 176.43 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.66 0 CA-C-N 118.956 1.378 . . . . 0.0 110.061 179.297 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -95.28 178.62 5.46 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.029 -1.045 . . . . 0.0 110.725 -178.58 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.482 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.23 170.34 13.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -107.32 133.22 52.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.348 -1.089 . . . . 0.0 109.187 -179.273 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.579 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.65 124.37 26.59 Favored 'General case' 0 C--N 1.29 -2.013 0 O-C-N 121.508 -0.745 . . . . 0.0 109.704 179.709 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.944 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.95 171.0 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.283 -0.886 . . . . 0.0 108.91 179.816 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.5 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 24.3 m -139.15 156.74 46.91 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.054 -1.029 . . . . 0.0 109.872 -179.794 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.944 ' CE1' HD12 ' A' ' 110' ' ' ILE . 45.2 m-85 . . . . . 0 N--CA 1.486 1.352 0 O-C-N 121.226 -0.921 . . . . 0.0 109.465 -179.669 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.488 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.457 0 CA-C-O 122.335 1.064 . . . . 0.0 110.768 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.957 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.7 t -110.87 108.9 18.85 Favored 'General case' 0 C--N 1.297 -1.7 0 CA-C-O 123.109 1.433 . . . . 0.0 109.066 179.357 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.817 HG22 HG23 ' A' ' 21' ' ' VAL . 2.6 t -118.28 139.72 44.44 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.699 0 CA-C-N 114.223 -1.353 . . . . 0.0 110.121 -179.741 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.453 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -179.07 150.88 0.64 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.239 -0.913 . . . . 0.0 108.764 -179.685 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.453 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.7 Cg_endo -77.47 151.72 92.77 Favored 'Cis proline' 0 C--N 1.313 -1.314 0 C-N-CA 123.555 -1.435 . . . . 0.0 109.332 -0.838 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.681 ' HA ' HG22 ' A' ' 110' ' ' ILE . 59.2 p -92.49 -23.29 19.16 Favored 'General case' 0 C--N 1.291 -1.968 0 O-C-N 121.567 -0.708 . . . . 0.0 109.664 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.482 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 23.9 p -133.26 159.14 41.09 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.197 -0.939 . . . . 0.0 110.124 -179.493 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.79 37.1 23.83 Favored Glycine 0 N--CA 1.497 2.706 0 N-CA-C 108.917 -1.673 . . . . 0.0 108.917 -179.859 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.777 ' HA ' HG21 ' A' ' 17' ' ' THR . 39.0 mt -93.34 -44.57 8.23 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.162 1.458 . . . . 0.0 110.44 -178.54 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.44 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.8 OUTLIER 64.3 146.8 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.273 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.17 -179.829 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.53 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 12.7 p-10 -51.51 104.92 0.09 Allowed 'General case' 0 C--N 1.305 -1.353 0 CA-C-O 121.675 0.75 . . . . 0.0 111.04 -179.072 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.81 7.47 6.68 Favored Glycine 0 N--CA 1.484 1.848 0 C-N-CA 119.13 -1.509 . . . . 0.0 113.296 177.52 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.777 HG21 ' HA ' ' A' ' 13' ' ' LEU . 15.2 t -107.13 -177.03 3.24 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 121.444 2.622 . . . . 0.0 110.133 179.605 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.784 HG13 ' O ' ' A' ' 67' ' ' LEU . 25.4 t -126.26 135.75 62.86 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.452 0 CA-C-N 114.249 -1.341 . . . . 0.0 111.073 -178.717 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.62 ' CG1' HD13 ' A' ' 13' ' ' LEU . 10.4 m -110.56 156.53 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.734 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.6 tttt -109.15 108.88 19.71 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.095 -1.003 . . . . 0.0 108.968 179.84 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.817 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.75 141.13 20.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.668 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.957 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -139.24 160.6 39.44 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 118.539 -1.265 . . . . 0.0 110.2 179.901 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.602 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.58 143.49 14.64 Favored Glycine 0 C--N 1.295 -1.731 0 N-CA-C 107.89 -2.084 . . . . 0.0 107.89 179.448 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -145.45 126.22 14.35 Favored 'General case' 0 C--N 1.295 -1.765 0 O-C-N 120.783 -1.422 . . . . 0.0 108.977 179.276 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.2 26.52 25.74 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 119.319 -1.419 . . . . 0.0 109.737 -179.744 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.576 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -89.43 169.78 11.09 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.81 -1.406 . . . . 0.0 108.392 179.861 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.999 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.95 100.98 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.039 -1.038 . . . . 0.0 110.076 -179.526 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.69 78.56 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.867 -179.529 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.41 33.9 0.3 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 179.778 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.562 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 17.2 p -138.6 105.03 5.28 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.259 -1.141 . . . . 0.0 111.146 -179.43 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.578 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.36 110.6 0.42 Allowed 'General case' 0 N--CA 1.497 1.905 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.701 178.169 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.562 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 35.5 m-85 -105.91 157.31 17.58 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.154 -0.966 . . . . 0.0 108.923 179.718 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.486 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -102.31 162.16 13.14 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.935 -1.103 . . . . 0.0 108.132 179.035 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.631 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.9 p -141.8 118.89 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.196 -0.94 . . . . 0.0 109.559 -178.186 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -166.41 -179.08 39.52 Favored Glycine 0 N--CA 1.493 2.481 0 C-N-CA 118.386 -1.864 . . . . 0.0 111.647 -179.693 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.63 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -101.38 109.01 20.77 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 179.978 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.51 148.76 52.35 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 121.164 -0.96 . . . . 0.0 109.959 179.925 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.429 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.65 138.66 54.5 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.409 -0.807 . . . . 0.0 110.656 -179.146 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.891 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.21 114.78 26.61 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 178.154 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.6 m -104.8 14.86 6.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.997 -1.065 . . . . 0.0 110.537 -178.789 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.753 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.87 -175.19 0.08 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.968 -1.083 . . . . 0.0 109.979 179.625 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 71.4 p -72.72 98.03 2.3 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.474 -0.766 . . . . 0.0 109.519 -179.704 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.57 27.65 31.92 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 120.225 -0.988 . . . . 0.0 111.413 178.943 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.753 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.25 106.18 19.59 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.653 -1.498 . . . . 0.0 107.258 178.942 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.891 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -117.26 104.59 11.32 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.504 -1.373 . . . . 0.0 109.831 -177.771 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.083 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.7 109.3 22.08 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.641 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.17 167.11 10.13 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.941 -1.099 . . . . 0.0 110.685 -178.588 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.483 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 10.8 t-20 -115.07 129.5 25.01 Favored Pre-proline 0 N--CA 1.498 1.939 0 O-C-N 121.606 -0.684 . . . . 0.0 109.498 -179.334 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.6 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -71.8 22.38 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.081 0 C-N-CA 122.052 1.835 . . . . 0.0 111.852 179.437 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.454 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -99.04 -5.9 29.49 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.404 -1.435 . . . . 0.0 109.15 179.61 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.815 ' OD2' HG13 ' A' ' 69' ' ' VAL . 1.6 m-20 -136.4 11.44 3.24 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.861 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -67.47 86.76 0.19 Allowed 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.48 -0.763 . . . . 0.0 110.649 -178.715 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.631 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -107.89 -165.97 1.1 Allowed 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 178.576 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.463 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.73 135.89 0.09 Allowed 'General case' 0 C--N 1.306 -1.305 0 O-C-N 120.642 -1.286 . . . . 0.0 111.147 -179.334 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.942 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -151.82 156.53 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 178.168 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.578 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.38 142.58 29.83 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.773 -1.205 . . . . 0.0 110.082 -179.676 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.024 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.36 107.08 0.85 Allowed 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 122.446 1.117 . . . . 0.0 109.403 178.079 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 17.2 p-10 -61.14 -138.93 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.026 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.986 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.77 -51.19 52.87 Favored 'General case' 0 N--CA 1.5 2.075 0 O-C-N 121.379 -0.826 . . . . 0.0 110.845 -178.536 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -103.79 -33.29 8.96 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.167 -1.79 . . . . 0.0 106.167 178.488 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.024 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.95 63.88 0.55 Allowed Glycine 0 C--N 1.298 -1.58 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 178.102 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.602 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 43.2 m -102.38 126.96 49.56 Favored 'General case' 0 C--N 1.31 -1.148 0 O-C-N 121.479 -1.012 . . . . 0.0 108.731 178.732 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.942 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.28 109.04 7.52 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 119.411 -0.915 . . . . 0.0 109.53 -179.387 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -123.81 121.44 35.41 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 121.242 -0.911 . . . . 0.0 109.614 -179.768 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.58 146.54 31.42 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.558 -0.714 . . . . 0.0 109.305 179.854 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.401 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 13.5 p -98.83 141.15 31.98 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.351 -0.843 . . . . 0.0 109.472 -179.909 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.784 ' O ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -140.83 170.33 15.95 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.405 -0.809 . . . . 0.0 109.304 -179.206 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.779 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -101.87 124.94 48.34 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 120.878 -1.139 . . . . 0.0 110.157 -179.099 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.815 HG13 ' OD2' ' A' ' 51' ' ' ASP . 11.8 m -128.54 139.34 52.15 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 120.996 -1.065 . . . . 0.0 110.343 -179.601 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.53 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 56.3 mtt180 -127.11 -168.84 1.94 Allowed 'General case' 0 N--CA 1.483 1.222 0 O-C-N 120.576 -1.327 . . . . 0.0 111.156 179.673 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.588 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 1.8 mtt180 -79.08 -76.02 0.22 Allowed 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 179.001 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.504 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -73.66 135.52 43.75 Favored 'General case' 0 N--CA 1.486 1.349 0 N-CA-C 106.452 -1.684 . . . . 0.0 106.452 177.774 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.59 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -156.79 139.13 14.76 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 117.637 -1.625 . . . . 0.0 110.925 -177.331 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.9 mm-40 -37.19 118.93 0.65 Allowed 'General case' 0 N--CA 1.489 1.513 0 CA-C-O 121.408 0.623 . . . . 0.0 110.09 -178.943 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.083 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.78 50.13 3.43 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.175 -179.242 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.6 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-30 -38.69 113.88 0.34 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.136 -1.214 . . . . 0.0 110.073 179.514 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.729 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -85.92 126.66 34.25 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 120.981 -1.074 . . . . 0.0 109.526 -179.885 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 29.4 t80 -63.72 58.54 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.026 0 O-C-N 120.91 -1.119 . . . . 0.0 110.142 179.608 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.59 19.5 0.14 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.036 -1.04 . . . . 0.0 109.748 179.84 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.78 -27.03 5.55 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 110.111 -1.195 . . . . 0.0 110.111 179.842 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.24 161.82 13.94 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 121.033 -1.274 . . . . 0.0 110.335 -179.499 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.476 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -107.67 136.85 46.73 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.917 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.729 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.5 t90 -82.21 -19.07 40.52 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.755 -1.216 . . . . 0.0 110.311 -178.759 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.93 173.93 19.01 Favored Glycine 0 N--CA 1.486 1.969 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.581 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.65 109.65 1.47 Allowed 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 179.202 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.5 t -81.92 105.12 11.43 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 O-C-N 121.354 -0.841 . . . . 0.0 108.916 -179.092 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.655 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.1 OUTLIER -65.45 110.69 2.76 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.45 -0.781 . . . . 0.0 110.006 -179.1 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.588 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.6 t -64.19 -5.28 4.63 Favored 'General case' 0 N--CA 1.5 2.035 0 C-N-CA 118.452 -1.299 . . . . 0.0 109.791 179.38 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.1 p -86.88 0.6 54.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.742 -1.224 . . . . 0.0 108.961 179.427 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.655 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -114.88 -50.96 2.75 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.292 -0.88 . . . . 0.0 109.02 179.825 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -102.84 -178.99 3.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.566 -0.709 . . . . 0.0 109.394 179.84 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.5 115.32 30.05 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.312 -0.867 . . . . 0.0 109.023 179.923 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.516 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.7 m -97.11 121.91 39.52 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.998 -1.064 . . . . 0.0 109.396 -179.353 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.612 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.92 144.93 29.93 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 122.397 1.094 . . . . 0.0 111.199 -179.365 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 96.4 t -102.49 110.16 28.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 177.701 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.478 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.3 -169.91 16.92 Favored Glycine 0 N--CA 1.486 2.006 0 C-N-CA 118.071 -2.014 . . . . 0.0 111.833 -177.536 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.503 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -112.91 179.88 3.84 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -179.116 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.452 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.4 p . . . . . 0 C--N 1.296 -1.74 0 O-C-N 121.456 -0.777 . . . . 0.0 109.58 -179.301 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.706 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.19 -177.46 5.4 Favored 'General case' 0 C--N 1.308 -1.219 0 O-C-N 121.518 -0.989 . . . . 0.0 109.789 179.26 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.61 -162.88 19.22 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 108.27 -1.932 . . . . 0.0 108.27 -179.442 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.503 ' HB2' HD12 ' A' ' 97' ' ' LEU . 6.4 Cg_exo -46.82 176.62 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.653 0 CA-C-N 118.835 1.317 . . . . 0.0 110.16 179.305 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -91.53 -176.13 4.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.142 -0.974 . . . . 0.0 110.502 -178.752 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.478 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.9 167.24 14.55 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.78 130.92 52.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.428 -1.042 . . . . 0.0 109.186 -179.403 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.612 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.42 120.76 20.43 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.679 -0.638 . . . . 0.0 109.744 179.751 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.733 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.4 pt -98.12 167.28 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.279 -0.888 . . . . 0.0 109.201 179.89 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.482 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -133.14 159.28 40.59 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.314 -0.866 . . . . 0.0 109.412 -179.926 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.733 ' CE2' HD12 ' A' ' 110' ' ' ILE . 49.4 m-85 . . . . . 0 N--CA 1.487 1.384 0 O-C-N 121.117 -0.989 . . . . 0.0 109.563 -179.753 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.495 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.483 1.217 0 CA-C-O 122.584 1.183 . . . . 0.0 110.115 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.911 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.7 t -115.8 109.2 17.33 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 123.122 1.439 . . . . 0.0 109.607 -179.98 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.882 HG22 HG23 ' A' ' 21' ' ' VAL . 3.1 t -114.95 139.84 39.15 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.677 0 CA-C-N 114.234 -1.348 . . . . 0.0 109.853 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.65 149.12 2.35 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.272 -0.893 . . . . 0.0 108.695 -179.666 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.0 Cg_endo -75.26 152.35 97.69 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 123.491 -1.462 . . . . 0.0 109.552 -0.846 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.653 ' HA ' HG22 ' A' ' 110' ' ' ILE . 2.4 m -88.46 -27.36 21.57 Favored 'General case' 0 C--N 1.293 -1.863 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.62 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.541 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 1.9 p -136.39 166.77 22.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.51 -0.744 . . . . 0.0 109.347 179.764 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.08 37.36 32.85 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 108.512 -1.835 . . . . 0.0 108.512 -179.626 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.755 ' CA ' HG21 ' A' ' 17' ' ' THR . 41.0 mt -92.98 -42.65 9.33 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-O 123.243 1.497 . . . . 0.0 110.466 -178.352 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.67 144.08 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.243 0 CA-C-N 113.392 -1.731 . . . . 0.0 109.877 -179.669 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.615 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 13.0 p-10 -50.94 105.65 0.11 Allowed 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.457 0.646 . . . . 0.0 111.589 -178.601 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.71 14.08 8.27 Favored Glycine 0 N--CA 1.485 1.927 0 C-N-CA 119.425 -1.369 . . . . 0.0 112.995 177.35 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.755 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -105.76 -172.43 2.09 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 121.239 2.52 . . . . 0.0 109.86 179.23 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.822 HG22 HG22 ' A' ' 68' ' ' THR . 18.1 t -128.41 139.18 52.6 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.345 0 CA-C-N 114.742 -1.117 . . . . 0.0 111.022 -178.81 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.6 HG11 HD11 ' A' ' 13' ' ' LEU . 33.2 m -114.49 154.91 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.876 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.05 109.55 21.45 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.261 -0.899 . . . . 0.0 109.19 -179.954 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.882 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -102.26 140.06 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.511 -0.743 . . . . 0.0 109.059 179.95 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.911 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -131.44 158.16 41.56 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.012 -1.055 . . . . 0.0 109.335 179.458 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.583 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.73 108.76 0.57 Allowed Glycine 0 N--CA 1.482 1.724 0 N-CA-C 108.806 -1.718 . . . . 0.0 108.806 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -115.78 139.75 49.88 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-N 119.268 1.534 . . . . 0.0 110.512 -179.317 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.47 28.84 31.74 Favored Glycine 0 N--CA 1.491 2.354 0 C-N-CA 119.13 -1.51 . . . . 0.0 109.971 179.535 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.549 HD22 ' HG3' ' A' ' 105' ' ' PRO . 1.6 mt -92.19 175.28 6.91 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.977 -1.308 . . . . 0.0 108.613 -179.875 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.11 97.03 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.287 0 O-C-N 121.014 -1.054 . . . . 0.0 109.661 -179.811 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.656 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 76.69 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.384 -178.988 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.84 33.82 0.32 Allowed Glycine 0 N--CA 1.486 2.002 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 179.451 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.613 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -147.0 114.53 6.35 Favored 'General case' 0 C--N 1.308 -1.227 0 O-C-N 120.843 -1.387 . . . . 0.0 111.084 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -45.18 127.11 6.69 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.788 178.561 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.613 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 10.2 m-85 -117.75 149.34 40.94 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.484 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.493 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -101.01 152.64 20.34 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.867 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.64 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.5 p -137.19 118.55 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.958 -1.089 . . . . 0.0 109.767 -177.759 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.34 -178.7 39.22 Favored Glycine 0 N--CA 1.495 2.607 0 C-N-CA 118.341 -1.885 . . . . 0.0 111.863 -179.733 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.59 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.35 109.36 21.54 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.928 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.47 149.54 52.09 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.146 -0.971 . . . . 0.0 109.839 179.84 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.538 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.24 138.49 54.4 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.234 -0.916 . . . . 0.0 110.736 -179.039 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.895 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.17 114.97 26.82 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 178.02 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.2 m -105.28 14.91 7.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 120.997 -1.064 . . . . 0.0 110.583 -178.794 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.764 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.68 -175.0 0.08 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.925 -1.11 . . . . 0.0 110.014 179.704 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -72.64 97.64 2.2 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.448 -0.782 . . . . 0.0 109.702 -179.753 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.62 28.3 29.97 Favored Glycine 0 N--CA 1.494 2.544 0 C-N-CA 120.211 -0.995 . . . . 0.0 111.341 179.005 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.764 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.43 106.11 19.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 O-C-N 120.499 -1.589 . . . . 0.0 107.207 178.854 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.895 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.1 tp -116.59 104.69 11.65 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.568 -1.332 . . . . 0.0 109.866 -177.66 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.1 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.15 109.3 22.08 Favored 'General case' 0 N--CA 1.485 1.298 0 O-C-N 120.856 -1.152 . . . . 0.0 108.06 178.633 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.79 163.36 13.18 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.985 -1.072 . . . . 0.0 110.182 -178.908 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.721 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 9.9 t-20 -108.95 135.76 20.11 Favored Pre-proline 0 N--CA 1.499 2.002 0 O-C-N 121.281 -0.887 . . . . 0.0 109.944 -179.136 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.3 Cg_endo -74.72 23.96 0.38 Allowed 'Trans proline' 0 C--N 1.319 -1.017 0 C-N-CA 122.417 2.078 . . . . 0.0 112.069 -179.992 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.721 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -114.44 3.28 14.91 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.323 -1.486 . . . . 0.0 109.198 179.632 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.529 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.67 14.77 3.15 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 179.154 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -78.7 87.77 4.6 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.039 -0.665 . . . . 0.0 110.871 -178.558 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.64 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -104.98 -167.93 1.41 Allowed 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.057 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.88 135.77 0.09 Allowed 'General case' 0 C--N 1.304 -1.404 0 O-C-N 120.555 -1.34 . . . . 0.0 111.38 -179.192 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.902 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -154.06 156.91 4.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 178.034 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.62 145.33 26.39 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.665 -1.272 . . . . 0.0 109.831 -179.612 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.009 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.05 107.09 1.78 Allowed 'General case' 0 C--N 1.298 -1.63 0 CA-C-O 122.433 1.111 . . . . 0.0 109.472 178.936 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.4 p-10 -59.62 -139.43 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.037 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.728 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.656 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.9 -50.11 64.58 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.374 -0.829 . . . . 0.0 110.361 -178.822 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -102.56 -35.54 8.7 Favored 'General case' 0 C--N 1.286 -2.186 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 178.488 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.988 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.91 67.31 0.62 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.541 -1.023 . . . . 0.0 110.541 178.166 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.583 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 38.4 m -101.6 127.86 48.13 Favored 'General case' 0 N--CA 1.485 1.325 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 178.688 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.902 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.03 108.82 7.04 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.503 -179.37 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 18.4 p -126.11 120.56 30.49 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.348 -0.845 . . . . 0.0 109.565 -179.888 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.37 146.25 31.5 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.669 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.2 p -98.61 131.25 44.96 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.162 -0.961 . . . . 0.0 109.588 -179.663 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.76 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -128.92 166.22 19.55 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.403 -0.811 . . . . 0.0 109.341 -179.514 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.822 HG22 HG22 ' A' ' 18' ' ' VAL . 1.7 p -97.65 125.1 42.23 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.986 -1.072 . . . . 0.0 109.373 -179.999 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.556 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.2 m -137.26 143.48 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.047 -1.033 . . . . 0.0 109.785 -179.149 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.615 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -146.44 -177.48 5.65 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.531 -1.355 . . . . 0.0 111.249 -179.927 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.583 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.05 -100.2 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -179.655 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.515 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.21 140.13 50.6 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 120.71 -1.244 . . . . 0.0 107.888 179.309 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.569 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -161.91 136.65 7.06 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 118.513 -1.275 . . . . 0.0 109.918 -178.015 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.508 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 6.4 mt-10 -34.78 121.34 0.52 Allowed 'General case' 0 N--CA 1.489 1.485 0 CA-C-O 121.434 0.635 . . . . 0.0 110.423 -178.61 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.1 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.75 51.54 2.0 Allowed Glycine 0 N--CA 1.495 2.593 0 C-N-CA 120.563 -0.827 . . . . 0.0 111.125 -179.22 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.23 115.63 0.51 Allowed 'General case' 0 N--CA 1.506 2.371 0 O-C-N 121.154 -1.204 . . . . 0.0 110.121 179.453 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.706 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.89 126.56 34.75 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 120.831 -1.168 . . . . 0.0 109.575 -179.741 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -64.2 58.3 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.913 -1.117 . . . . 0.0 110.065 179.513 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.54 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.1 t70 -159.53 19.24 0.17 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.982 -1.074 . . . . 0.0 109.709 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.07 -27.19 5.64 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.822 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 p -95.99 161.6 13.92 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 120.994 -1.298 . . . . 0.0 110.397 -179.393 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.478 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.75 137.53 44.61 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.673 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.706 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.08 -19.65 39.76 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.747 -1.221 . . . . 0.0 110.507 -178.648 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.15 176.36 19.05 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.709 -1.757 . . . . 0.0 108.709 -179.499 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.94 105.7 1.39 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.015 -1.285 . . . . 0.0 107.783 179.158 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.65 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.9 t -77.12 105.82 6.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 O-C-N 121.367 -0.833 . . . . 0.0 109.229 -178.903 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.547 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -65.48 111.3 3.03 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.483 -0.761 . . . . 0.0 110.012 -179.445 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.583 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.05 -5.88 3.48 Favored 'General case' 0 N--CA 1.499 2.015 0 C-N-CA 118.273 -1.371 . . . . 0.0 109.8 179.486 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -86.89 -0.18 56.05 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.713 -1.242 . . . . 0.0 109.26 179.496 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.547 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.32 -50.33 2.87 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.34 -0.85 . . . . 0.0 109.006 179.886 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.69 -179.9 4.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.581 -0.699 . . . . 0.0 109.344 179.833 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.69 115.91 31.36 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.895 . . . . 0.0 109.003 179.981 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.521 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.86 120.77 37.81 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.826 -1.171 . . . . 0.0 109.368 -179.409 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.43 145.96 28.25 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 122.355 1.074 . . . . 0.0 111.117 -179.283 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.526 ' CG1' HG11 ' A' ' 7' ' ' VAL . 60.5 t -101.25 109.77 26.47 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.013 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 177.362 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.469 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -146.64 -171.32 15.83 Favored Glycine 0 N--CA 1.486 2.0 0 C-N-CA 118.212 -1.946 . . . . 0.0 111.619 -177.284 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.495 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -123.22 179.64 4.63 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -178.631 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.296 -1.727 0 O-C-N 121.482 -0.761 . . . . 0.0 109.513 -179.862 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.845 0 N-CA-C 107.604 -2.198 . . . . 0.0 107.604 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.09 -177.67 5.91 Favored 'General case' 0 C--N 1.307 -1.282 0 O-C-N 121.668 -0.901 . . . . 0.0 109.808 179.338 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.09 -161.81 21.25 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 -179.368 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.549 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.3 Cg_exo -45.37 172.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.69 0 CA-C-N 118.81 1.305 . . . . 0.0 110.094 179.303 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -92.49 -178.7 4.98 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.084 -1.01 . . . . 0.0 110.608 -178.659 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.469 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -115.08 164.53 12.09 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.88 133.12 48.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.411 -1.052 . . . . 0.0 109.28 -179.282 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.02 119.3 17.07 Favored 'General case' 0 C--N 1.289 -2.022 0 O-C-N 121.655 -0.653 . . . . 0.0 109.474 179.646 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.876 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.14 172.07 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.175 -0.953 . . . . 0.0 109.101 179.944 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.541 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.3 OUTLIER -138.49 155.86 48.04 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.104 -0.997 . . . . 0.0 109.892 -179.695 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.876 ' CE2' HD12 ' A' ' 110' ' ' ILE . 87.0 m-85 . . . . . 0 N--CA 1.485 1.303 0 O-C-N 121.325 -0.859 . . . . 0.0 109.613 -179.783 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.526 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.489 1.477 0 CA-C-O 122.372 1.082 . . . . 0.0 110.701 . . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.951 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.3 t -112.91 108.7 17.74 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 123.106 1.431 . . . . 0.0 109.19 179.367 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.871 HG22 HG23 ' A' ' 21' ' ' VAL . 3.7 t -116.34 142.51 29.58 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.667 0 CA-C-N 114.347 -1.297 . . . . 0.0 110.203 -179.615 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.504 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -178.16 150.45 0.74 Allowed Pre-proline 0 N--CA 1.488 1.454 0 O-C-N 121.278 -0.888 . . . . 0.0 108.715 -179.737 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.504 ' HA ' HG23 ' A' ' 8' ' ' THR . 1.9 Cg_endo -75.05 153.73 99.25 Favored 'Cis proline' 0 C--N 1.312 -1.362 0 C-N-CA 123.577 -1.426 . . . . 0.0 109.471 -0.644 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.3 m -91.4 -25.35 19.4 Favored 'General case' 0 C--N 1.292 -1.912 0 O-C-N 121.63 -0.669 . . . . 0.0 109.428 -179.94 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.505 ' HB3' ' CB ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -137.9 163.35 31.69 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.338 -0.851 . . . . 0.0 109.905 -179.619 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.72 37.14 27.25 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 108.773 -1.731 . . . . 0.0 108.773 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.749 ' CA ' HG21 ' A' ' 17' ' ' THR . 44.2 mt -93.05 -44.22 8.5 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 123.249 1.5 . . . . 0.0 110.547 -178.533 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.445 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.48 145.75 0.03 OUTLIER 'General case' 0 C--N 1.262 -3.203 0 CA-C-N 113.473 -1.694 . . . . 0.0 109.999 -179.796 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.544 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.0 p-10 -51.93 105.1 0.1 Allowed 'General case' 0 C--N 1.303 -1.451 0 CA-C-O 121.49 0.662 . . . . 0.0 111.088 -179.05 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.95 6.66 6.96 Favored Glycine 0 N--CA 1.486 1.983 0 C-N-CA 119.18 -1.486 . . . . 0.0 113.194 177.518 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.749 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.6 t -105.14 -174.45 2.54 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 121.437 2.618 . . . . 0.0 109.922 179.709 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.782 HG22 HG22 ' A' ' 68' ' ' THR . 21.6 t -127.02 135.94 62.2 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.579 -1.191 . . . . 0.0 110.955 -178.778 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.622 ' CG1' HD13 ' A' ' 13' ' ' LEU . 32.5 m -109.54 154.79 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 178.795 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -110.56 109.25 19.5 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.198 -0.939 . . . . 0.0 108.825 179.776 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.871 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -104.32 140.46 22.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.951 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.18 160.32 38.73 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 118.74 -1.184 . . . . 0.0 109.857 179.649 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.59 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.44 143.55 15.2 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 108.021 -2.032 . . . . 0.0 108.021 179.789 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.12 125.26 12.91 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 120.843 -1.386 . . . . 0.0 108.846 179.289 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.98 26.8 25.5 Favored Glycine 0 N--CA 1.488 2.124 0 C-N-CA 119.371 -1.395 . . . . 0.0 109.704 -179.698 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.5 mt -86.27 175.83 8.25 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.921 -1.341 . . . . 0.0 108.557 -179.813 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.44 96.9 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.028 -1.045 . . . . 0.0 109.556 -179.771 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.637 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.26 76.32 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.715 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.541 -178.989 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.32 33.93 0.3 Allowed Glycine 0 N--CA 1.484 1.876 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.304 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.558 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 1.2 t -148.64 114.97 5.87 Favored 'General case' 0 C--N 1.308 -1.21 0 O-C-N 120.774 -1.427 . . . . 0.0 111.333 179.955 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.13 130.05 3.65 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.798 178.376 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.553 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 7.7 m-85 -121.41 147.93 45.06 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.583 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.498 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.96 156.71 17.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.626 -1.296 . . . . 0.0 107.771 178.719 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.644 HG13 ' O ' ' A' ' 34' ' ' VAL . 5.5 p -140.27 117.27 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.066 -1.021 . . . . 0.0 109.867 -177.789 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.518 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.29 -176.92 39.06 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.942 -179.739 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.64 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.4 pt20 -99.83 109.96 22.35 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 121.874 0.845 . . . . 0.0 109.02 -179.648 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.497 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -130.35 150.12 51.73 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.223 -0.923 . . . . 0.0 109.679 179.703 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.457 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.69 138.29 54.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.197 -0.94 . . . . 0.0 110.968 -178.945 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.38 115.0 26.83 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 177.982 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.458 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 19.8 m -105.77 14.72 7.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 120.993 -1.067 . . . . 0.0 110.646 -178.732 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.756 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.32 -174.71 0.09 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.04 -1.037 . . . . 0.0 110.011 179.614 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.84 97.03 1.73 Allowed 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.439 -0.788 . . . . 0.0 109.709 -179.77 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.28 27.8 32.3 Favored Glycine 0 N--CA 1.493 2.492 0 C-N-CA 120.149 -1.024 . . . . 0.0 111.481 178.849 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.756 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.32 106.45 20.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 O-C-N 120.688 -1.477 . . . . 0.0 107.252 178.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.5 tp -115.38 104.8 12.15 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.4 -1.437 . . . . 0.0 110.019 -177.715 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.986 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.68 109.71 22.41 Favored 'General case' 0 N--CA 1.486 1.372 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.801 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.51 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -109.08 168.34 9.44 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.059 -1.026 . . . . 0.0 110.365 -178.744 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.55 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 22.3 t-20 -118.09 135.08 23.32 Favored Pre-proline 0 N--CA 1.499 2.01 0 O-C-N 121.353 -0.842 . . . . 0.0 110.101 -179.438 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.589 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.5 Cg_endo -73.66 23.33 0.33 Allowed 'Trans proline' 0 CA--C 1.545 1.045 0 C-N-CA 122.223 1.949 . . . . 0.0 112.181 179.901 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.55 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -108.82 1.99 21.31 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.345 -1.472 . . . . 0.0 109.079 179.406 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.53 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.11 17.41 2.27 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.643 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -81.06 90.37 6.0 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.524 -0.735 . . . . 0.0 110.891 -178.606 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.69 -166.87 1.19 Allowed 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 178.145 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.448 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.72 134.92 0.09 Allowed 'General case' 0 C--N 1.306 -1.311 0 O-C-N 120.524 -1.36 . . . . 0.0 111.666 -179.356 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.803 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.5 p -150.94 157.38 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 177.862 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.57 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.19 146.07 25.44 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.496 -1.377 . . . . 0.0 109.741 -179.648 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.09 108.55 3.15 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 122.302 1.048 . . . . 0.0 109.589 179.009 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.541 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.7 t70 -63.69 -139.03 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.999 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.663 179.938 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.637 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.92 -51.74 49.11 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.343 -0.848 . . . . 0.0 110.679 -178.672 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -102.58 -32.7 9.78 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 106.517 -1.66 . . . . 0.0 106.517 178.662 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.006 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 105.36 66.32 0.67 Allowed Glycine 0 C--N 1.297 -1.591 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.18 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.59 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 58.0 p -98.66 131.96 44.42 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 121.378 -1.072 . . . . 0.0 109.097 179.006 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.803 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.43 108.32 6.32 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 119.319 -0.953 . . . . 0.0 109.52 -179.642 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.6 m -124.67 119.13 28.1 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.094 -1.004 . . . . 0.0 109.701 -179.939 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.593 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.33 144.16 29.6 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.448 -0.782 . . . . 0.0 109.363 179.853 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.8 p -99.12 141.51 31.8 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.316 -0.865 . . . . 0.0 109.191 179.838 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.827 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.83 167.94 20.94 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.449 -0.782 . . . . 0.0 109.551 -179.23 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.782 HG22 HG22 ' A' ' 18' ' ' VAL . 2.0 p -98.18 126.82 43.8 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.094 -1.004 . . . . 0.0 109.319 -179.761 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.502 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 15.4 m -134.44 140.53 45.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.879 -1.138 . . . . 0.0 110.091 -179.198 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.544 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 52.2 mtt180 -127.56 -165.52 1.49 Allowed 'General case' 0 N--CA 1.485 1.315 0 O-C-N 120.676 -1.265 . . . . 0.0 111.255 -179.821 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.574 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 1.0 OUTLIER -80.48 -79.64 0.15 Allowed 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.209 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.511 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -68.85 136.45 52.7 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 177.9 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.573 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.03 137.64 9.76 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 117.803 -1.559 . . . . 0.0 110.735 -177.325 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.526 ' HB3' ' CD1' ' A' ' 76' ' ' PHE . 8.0 mm-40 -33.72 119.2 0.37 Allowed 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 121.638 0.732 . . . . 0.0 110.58 -178.69 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.986 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -87.92 48.4 3.67 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.316 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.589 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 19.0 m-85 -39.21 113.92 0.36 Allowed 'General case' 0 N--CA 1.507 2.385 0 O-C-N 121.157 -1.202 . . . . 0.0 110.136 179.591 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.746 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -87.67 127.04 35.29 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.993 -1.067 . . . . 0.0 109.474 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -64.51 58.29 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.753 -1.217 . . . . 0.0 110.056 179.674 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.7 t70 -159.52 19.0 0.17 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.042 -1.036 . . . . 0.0 109.721 179.948 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.68 -26.56 5.8 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.84 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 72.4 p -95.15 160.56 14.5 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.021 -1.281 . . . . 0.0 110.417 -179.343 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.482 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 1.3 ptt180 -105.63 134.84 48.1 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.66 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.746 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.0 t90 -81.21 -20.01 42.03 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.823 -1.173 . . . . 0.0 110.234 -178.623 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.26 173.64 18.25 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 108.739 -1.745 . . . . 0.0 108.739 -179.572 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.67 111.45 2.09 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 179.251 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.653 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.7 t -83.1 103.91 11.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 O-C-N 121.35 -0.844 . . . . 0.0 108.798 -179.062 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.542 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.8 111.41 3.24 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.448 -0.783 . . . . 0.0 109.971 -179.094 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.57 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -63.96 -5.12 4.03 Favored 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 118.426 -1.31 . . . . 0.0 109.834 179.372 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.9 p -87.89 2.09 52.41 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.841 -1.162 . . . . 0.0 109.052 179.415 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.542 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -116.72 -51.23 2.59 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.329 -0.857 . . . . 0.0 108.939 -179.99 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.1 179.5 4.25 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.512 -0.742 . . . . 0.0 109.371 179.869 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.34 116.52 32.58 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.362 -0.836 . . . . 0.0 108.925 179.917 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.505 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.9 m -96.73 120.71 37.56 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.894 -1.129 . . . . 0.0 109.357 -179.41 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.616 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.67 145.56 28.92 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 122.373 1.083 . . . . 0.0 111.283 -179.12 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.427 ' CG1' HG11 ' A' ' 7' ' ' VAL . 62.6 t -101.71 109.81 26.92 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.037 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 177.537 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.451 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.85 -170.91 16.33 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 118.174 -1.965 . . . . 0.0 111.851 -177.467 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.526 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -121.6 178.98 4.61 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -178.859 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.472 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.7 OUTLIER . . . . . 0 C--N 1.297 -1.704 0 O-C-N 121.564 -0.71 . . . . 0.0 109.562 179.999 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.421 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.481 1.698 0 N-CA-C 107.946 -2.061 . . . . 0.0 107.946 . . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.421 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.99 -177.0 3.6 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 121.609 -0.936 . . . . 0.0 109.756 179.367 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.25 -161.36 17.96 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.27 -1.932 . . . . 0.0 108.27 -179.396 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.532 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.6 Cg_exo -46.6 176.5 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.664 0 CA-C-N 118.841 1.32 . . . . 0.0 110.203 179.287 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -93.85 -168.88 1.97 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.118 -0.989 . . . . 0.0 110.39 -178.927 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.451 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -123.88 163.47 17.51 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.736 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.14 129.67 49.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.409 -1.054 . . . . 0.0 109.123 -179.679 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.616 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.58 118.97 16.15 Favored 'General case' 0 C--N 1.288 -2.085 0 O-C-N 121.703 -0.623 . . . . 0.0 109.759 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.66 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.4 pt -98.07 168.0 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 121.249 -0.907 . . . . 0.0 109.065 179.803 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.505 ' CB ' ' HB3' ' A' ' 11' ' ' SER . 0.2 OUTLIER -132.28 156.89 45.74 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.281 -0.887 . . . . 0.0 109.666 -179.876 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.617 ' CE2' HD12 ' A' ' 110' ' ' ILE . 41.4 m-85 . . . . . 0 N--CA 1.487 1.42 0 O-C-N 121.272 -0.893 . . . . 0.0 109.357 -179.852 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.565 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.412 0 CA-C-O 122.165 0.983 . . . . 1.0 110.961 . . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.005 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -102.0 104.52 15.19 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 122.408 1.099 . . . . 1.0 110.088 -179.84 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 1.018 HG22 HG23 ' A' ' 21' ' ' VAL . 5.9 t -119.5 123.55 71.33 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.448 0 CA-C-N 115.521 -0.763 . . . . 1.0 110.516 179.822 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.48 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -170.95 150.02 2.9 Favored Pre-proline 0 N--CA 1.488 1.451 0 N-CA-C 108.086 -1.079 . . . . 1.0 108.086 -179.649 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.48 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.0 Cg_endo -76.79 151.37 94.16 Favored 'Cis proline' 0 C--N 1.311 -1.434 0 C-N-CA 123.658 -1.393 . . . . 1.0 109.533 -0.526 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.683 ' HA ' HG22 ' A' ' 110' ' ' ILE . 95.2 p -95.4 -21.47 18.34 Favored 'General case' 0 C--N 1.293 -1.888 0 O-C-N 121.649 -0.657 . . . . 1.0 109.643 179.954 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.489 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.3 m -131.54 157.11 44.45 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.256 -0.903 . . . . 1.0 110.221 -179.583 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.39 37.11 25.04 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 108.794 -1.722 . . . . 1.0 108.794 -179.719 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.807 ' HA ' HG21 ' A' ' 17' ' ' THR . 35.4 mt -92.1 -44.78 8.63 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 123.201 1.477 . . . . 1.0 110.542 -178.59 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.442 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.1 t 63.8 147.52 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.25 0 CA-C-N 113.562 -1.654 . . . . 1.0 110.045 -179.815 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.521 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.5 p-10 -51.65 105.16 0.1 Allowed 'General case' 0 C--N 1.303 -1.438 0 CA-C-O 121.665 0.745 . . . . 1.0 111.106 -178.997 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.31 7.39 7.02 Favored Glycine 0 N--CA 1.485 1.954 0 C-N-CA 119.319 -1.42 . . . . 1.0 113.318 177.323 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.807 HG21 ' HA ' ' A' ' 13' ' ' LEU . 14.9 t -106.42 -177.46 3.37 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 121.468 2.634 . . . . 1.0 110.325 179.654 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.858 HG22 HG22 ' A' ' 68' ' ' THR . 21.9 t -128.3 139.69 51.22 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.374 0 CA-C-N 114.076 -1.42 . . . . 1.0 111.091 -178.717 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.671 HG11 HD11 ' A' ' 13' ' ' LEU . 15.7 m -117.19 154.68 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.35 -0.981 . . . . 1.0 108.35 178.739 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.545 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -104.1 108.79 20.32 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.139 -0.975 . . . . 1.0 109.304 -179.886 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 1.018 HG23 HG22 ' A' ' 7' ' ' VAL . 2.4 p -106.34 123.27 61.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 N-CA-C 108.299 -1.001 . . . . 1.0 108.299 179.571 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.005 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.67 167.21 11.55 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 120.681 -1.262 . . . . 1.0 109.22 -179.831 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.617 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.77 139.1 10.61 Favored Glycine 0 C--N 1.294 -1.779 0 N-CA-C 107.282 -2.327 . . . . 1.0 107.282 179.51 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -145.39 125.35 13.56 Favored 'General case' 0 C--N 1.293 -1.866 0 O-C-N 120.522 -1.575 . . . . 1.0 108.991 179.613 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.23 26.35 28.62 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 119.013 -1.565 . . . . 1.0 109.952 -179.798 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.566 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.3 mt -86.5 174.34 9.02 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 120.885 -1.362 . . . . 1.0 108.29 179.743 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.021 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.41 99.28 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.412 0 O-C-N 120.855 -1.153 . . . . 1.0 109.743 -179.605 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.585 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.11 77.74 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.304 -0.862 . . . . 1.0 110.246 -179.271 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.9 34.47 0.3 Allowed Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.464 -1.454 . . . . 1.0 109.464 179.587 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 53.4 p -142.82 108.75 5.17 Favored 'General case' 0 C--N 1.308 -1.221 0 O-C-N 121.039 -1.271 . . . . 1.0 111.214 -179.416 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.594 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.92 109.92 0.34 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 109.393 -0.595 . . . . 1.0 109.393 177.807 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.491 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.7 m-30 -104.9 155.4 18.96 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.119 -0.988 . . . . 1.0 108.878 179.874 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.82 162.01 13.33 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.804 -1.185 . . . . 1.0 108.077 178.934 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.63 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.9 p -141.91 120.36 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.166 -0.959 . . . . 1.0 109.307 -178.217 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' HB2' ' A' ' 51' ' ' ASP . . . -171.88 -176.48 40.83 Favored Glycine 0 N--CA 1.495 2.571 0 C-N-CA 118.412 -1.851 . . . . 1.0 111.583 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.657 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -101.15 109.19 21.03 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 108.909 -0.774 . . . . 1.0 108.909 -179.908 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.492 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.0 m -130.14 149.06 52.02 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.277 -0.89 . . . . 1.0 109.682 179.585 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.525 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.54 138.72 54.51 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.236 -0.915 . . . . 1.0 110.793 -178.93 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.2 114.77 26.6 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 107.532 -1.284 . . . . 1.0 107.532 178.047 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 m -104.85 14.72 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.931 -1.106 . . . . 1.0 110.481 -178.793 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.75 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.1 -175.24 0.09 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.98 -1.075 . . . . 1.0 110.049 179.748 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.51 97.79 2.17 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.519 -0.738 . . . . 1.0 109.577 -179.75 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.46 27.75 31.94 Favored Glycine 0 N--CA 1.492 2.414 0 C-N-CA 120.214 -0.993 . . . . 1.0 111.399 178.94 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.75 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.22 106.48 20.18 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.558 -1.554 . . . . 1.0 107.357 178.81 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.4 104.72 11.74 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.475 -1.391 . . . . 1.0 109.954 -177.629 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.007 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.65 109.53 22.27 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 107.812 -1.181 . . . . 1.0 107.812 178.871 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -108.05 166.74 10.5 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.869 -1.145 . . . . 1.0 110.727 -178.455 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.487 ' OD1' ' HB2' ' A' ' 74' ' ' GLU . 46.4 t30 -118.51 136.72 24.2 Favored Pre-proline 0 N--CA 1.498 1.971 0 C-N-CA 120.098 -0.641 . . . . 1.0 109.64 -179.497 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HD3' ' CE1' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -74.03 26.41 0.33 Allowed 'Trans proline' 0 C--N 1.317 -1.111 0 C-N-CA 122.437 2.092 . . . . 1.0 112.01 -179.89 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.447 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -98.54 -9.55 24.78 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.319 -1.488 . . . . 1.0 109.164 179.735 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.801 ' HB3' HD22 ' A' ' 67' ' ' LEU . 0.8 OUTLIER -135.68 7.4 3.26 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.383 -0.823 . . . . 1.0 108.872 -179.81 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -60.75 84.1 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.427 -0.796 . . . . 1.0 110.898 -178.569 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.63 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.78 -167.02 1.17 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.852 -1.166 . . . . 1.0 107.852 178.33 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.477 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.7 t 179.1 135.25 0.09 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.569 -1.332 . . . . 1.0 111.43 -179.364 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.789 HG11 ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -150.46 157.77 5.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 N-CA-C 107.537 -1.283 . . . . 1.0 107.537 177.914 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.63 142.1 30.63 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.734 -1.229 . . . . 1.0 110.051 -179.747 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.021 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.36 107.68 1.41 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 122.331 1.062 . . . . 1.0 109.38 178.524 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.558 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.6 p-10 -62.04 -138.81 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 115.612 -0.722 . . . . 1.0 110.861 -179.778 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.585 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.87 -51.82 37.5 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.344 -0.847 . . . . 1.0 110.737 -178.599 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -104.57 -32.91 8.72 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 106.261 -1.755 . . . . 1.0 106.261 178.508 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.988 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.57 69.88 0.67 Allowed Glycine 0 C--N 1.298 -1.574 0 N-CA-C 110.299 -1.12 . . . . 1.0 110.299 178.104 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.617 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 63.7 m -104.07 129.98 51.75 Favored 'General case' 0 N--CA 1.483 1.175 0 O-C-N 121.259 -1.142 . . . . 1.0 109.275 179.14 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.789 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.4 108.96 8.46 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.535 -0.866 . . . . 1.0 109.484 -179.638 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 97.2 p -116.21 117.02 28.87 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.117 -0.989 . . . . 1.0 109.492 -179.747 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.61 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.27 139.93 26.13 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.385 -0.822 . . . . 1.0 110.077 -179.84 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 27.2 p -99.61 135.26 41.29 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.822 -0.807 . . . . 1.0 108.822 179.432 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.94 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -136.22 168.52 19.24 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.292 -0.88 . . . . 1.0 110.057 -178.931 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.858 HG22 HG22 ' A' ' 18' ' ' VAL . 1.2 p -104.06 126.26 51.04 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.192 -0.942 . . . . 1.0 109.329 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.735 HG13 ' OD2' ' A' ' 51' ' ' ASP . 12.3 m -129.41 139.99 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 120.922 -1.111 . . . . 1.0 110.209 -179.26 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.521 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 52.4 mtt180 -125.67 -168.57 1.86 Allowed 'General case' 0 N--CA 1.484 1.23 0 O-C-N 120.676 -1.265 . . . . 1.0 111.304 179.823 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.588 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 40.0 mtt180 -78.5 -75.71 0.22 Allowed 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.2 -1.037 . . . . 1.0 108.2 179.284 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -72.67 137.06 45.79 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 120.14 -1.6 . . . . 1.0 106.812 178.107 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -157.66 135.51 10.73 Favored 'General case' 0 C--N 1.295 -1.784 0 C-N-CA 118.08 -1.448 . . . . 1.0 110.308 -177.903 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.601 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 9.5 mm-40 -34.78 121.62 0.52 Allowed 'General case' 0 N--CA 1.487 1.41 0 CA-C-O 121.582 0.706 . . . . 1.0 110.364 -178.259 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.007 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -87.76 47.94 3.64 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 110.986 -0.846 . . . . 1.0 110.986 -179.377 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.601 ' CE1' ' HB3' ' A' ' 74' ' ' GLU . 36.2 m-85 -39.76 112.95 0.3 Allowed 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.07 -1.253 . . . . 1.0 110.001 179.614 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.738 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -87.03 126.64 34.88 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.995 -1.066 . . . . 1.0 109.493 -179.912 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -63.99 58.34 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.735 -1.228 . . . . 1.0 110.315 179.674 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.26 19.15 0.15 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.01 -1.056 . . . . 1.0 109.765 179.854 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.31 -26.18 5.81 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.097 -1.201 . . . . 1.0 110.097 179.78 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -94.07 160.0 14.91 Favored 'General case' 0 N--CA 1.485 1.311 0 O-C-N 121.011 -1.288 . . . . 1.0 110.49 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.476 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -105.89 133.39 50.69 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 108.581 -0.896 . . . . 1.0 108.581 179.701 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.738 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.1 t90 -80.93 -20.28 42.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.809 -1.182 . . . . 1.0 110.256 -178.701 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.92 174.19 18.62 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.9 -1.68 . . . . 1.0 108.9 -179.59 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.06 110.04 1.69 Allowed 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.143 -1.21 . . . . 1.0 107.743 179.269 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.678 HG21 ' HB3' ' A' ' 46' ' ' ALA . 44.4 t -82.32 104.45 10.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.696 0 N-CA-C 108.715 -0.846 . . . . 1.0 108.715 -179.098 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.529 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -67.11 111.07 3.69 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.322 -0.861 . . . . 1.0 109.893 -179.119 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.588 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -64.04 -5.23 4.33 Favored 'General case' 0 N--CA 1.501 2.083 0 C-N-CA 118.465 -1.294 . . . . 1.0 109.869 179.394 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -86.69 2.04 49.92 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.757 -1.214 . . . . 1.0 108.923 179.363 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.529 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -117.05 -51.11 2.56 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.478 -0.764 . . . . 1.0 108.967 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -102.57 -179.92 4.11 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.498 -0.751 . . . . 1.0 109.381 179.883 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.84 115.25 29.98 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.349 -0.845 . . . . 1.0 108.979 179.923 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.56 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.88 122.25 39.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.807 -1.183 . . . . 1.0 109.464 -179.278 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.618 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -101.75 145.35 29.26 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 122.449 1.119 . . . . 1.0 111.184 -179.3 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.614 ' HB ' HG11 ' A' ' 7' ' ' VAL . 65.2 t -102.68 110.59 29.76 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 N-CA-C 106.892 -1.521 . . . . 1.0 106.892 177.815 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.491 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.11 -169.63 18.47 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 118.177 -1.963 . . . . 1.0 111.75 -177.712 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.52 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -120.02 177.06 5.13 Favored 'General case' 0 N--CA 1.489 1.485 0 CA-C-O 121.69 0.757 . . . . 1.0 109.113 -178.931 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.491 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 0.1 OUTLIER . . . . . 0 C--N 1.297 -1.717 0 N-CA-C 109.276 -0.639 . . . . 1.0 109.276 179.801 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.677 0 N-CA-C 107.703 -2.159 . . . . 1.0 107.703 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.31 -178.08 6.69 Favored 'General case' 0 C--N 1.305 -1.326 0 O-C-N 121.554 -0.968 . . . . 1.0 109.749 179.322 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.35 -161.31 18.01 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.326 -1.91 . . . . 1.0 108.326 -179.293 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.487 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.4 Cg_exo -47.33 179.82 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 CA-C-N 118.783 1.292 . . . . 1.0 110.368 179.322 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -95.59 -170.82 2.23 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.053 -1.029 . . . . 1.0 110.236 -179.075 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.491 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -125.37 164.53 18.91 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.693 -1.363 . . . . 1.0 109.693 -179.846 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.56 128.55 49.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 O-C-N 121.436 -1.038 . . . . 1.0 109.103 -179.535 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.618 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.56 120.91 19.81 Favored 'General case' 0 C--N 1.289 -2.036 0 O-C-N 121.735 -0.603 . . . . 1.0 109.835 179.957 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.683 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.4 pt -98.03 168.11 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.315 -0.866 . . . . 1.0 109.037 179.722 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.489 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -134.98 158.6 43.9 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.305 -0.872 . . . . 1.0 109.428 179.976 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.548 ' CE2' HD12 ' A' ' 110' ' ' ILE . 42.2 m-85 . . . . . 0 N--CA 1.49 1.53 0 O-C-N 121.191 -0.943 . . . . 1.0 109.392 -179.786 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.546 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.424 0 CA-C-O 122.11 0.957 . . . . 1.0 111.098 . . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.023 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -99.7 104.3 16.02 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 122.353 1.073 . . . . 1.0 109.918 -179.965 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.945 HG22 HG23 ' A' ' 21' ' ' VAL . 4.0 t -121.6 117.1 51.5 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-O 121.603 0.716 . . . . 1.0 110.341 179.587 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.518 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -165.94 150.04 7.21 Favored Pre-proline 0 N--CA 1.487 1.41 0 N-CA-C 108.213 -1.032 . . . . 1.0 108.213 -179.646 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.518 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.8 Cg_endo -77.72 151.76 92.04 Favored 'Cis proline' 0 C--N 1.31 -1.463 0 C-N-CA 123.608 -1.413 . . . . 1.0 109.512 -0.615 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.712 ' HA ' HG22 ' A' ' 110' ' ' ILE . 85.7 p -92.85 -25.66 18.0 Favored 'General case' 0 C--N 1.293 -1.857 0 O-C-N 121.435 -0.791 . . . . 1.0 108.895 179.42 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 111' ' ' SER . 3.0 m -131.9 161.37 33.2 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.455 -0.778 . . . . 1.0 109.413 -179.912 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.59 36.55 33.19 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 108.627 -1.789 . . . . 1.0 108.627 -179.566 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.772 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.6 mt -91.19 -42.69 10.29 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.298 1.523 . . . . 1.0 110.37 -178.505 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.5 143.62 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.284 0 CA-C-N 113.292 -1.776 . . . . 1.0 109.809 -179.585 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.602 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.1 p-10 -50.76 105.59 0.1 Allowed 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.596 0.712 . . . . 1.0 111.31 -178.655 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.47 13.64 8.02 Favored Glycine 0 N--CA 1.485 1.945 0 C-N-CA 119.316 -1.421 . . . . 1.0 113.041 177.497 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.772 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -104.8 -171.96 2.01 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 121.28 2.54 . . . . 1.0 109.755 179.28 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.739 HG13 ' C ' ' A' ' 67' ' ' LEU . 14.9 t -130.11 138.51 53.8 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.345 0 CA-C-N 114.857 -1.065 . . . . 1.0 111.261 -178.855 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.537 HG11 HD11 ' A' ' 13' ' ' LEU . 34.1 m -115.85 154.82 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.585 -0.894 . . . . 1.0 108.585 178.888 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.559 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -109.19 109.18 20.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.121 -0.987 . . . . 1.0 109.35 -179.903 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.945 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.4 123.16 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 108.357 -0.979 . . . . 1.0 108.357 179.67 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.023 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -120.85 167.24 12.73 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 120.721 -1.237 . . . . 1.0 109.386 -179.744 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -131.24 144.33 15.86 Favored Glycine 0 C--N 1.295 -1.723 0 N-CA-C 107.711 -2.155 . . . . 1.0 107.711 179.691 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -148.18 123.19 10.08 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 120.96 -1.317 . . . . 1.0 108.532 179.105 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.66 27.95 17.98 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.269 -1.443 . . . . 1.0 109.722 -179.464 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.539 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.0 OUTLIER -90.52 175.37 7.09 Favored 'General case' 0 C--N 1.308 -1.213 0 O-C-N 120.832 -1.393 . . . . 1.0 108.602 179.947 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.012 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -48.6 100.4 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.903 -1.123 . . . . 1.0 109.859 -179.817 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.43 78.57 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.679 0 CA-C-N 115.355 -0.839 . . . . 1.0 110.116 -179.375 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.573 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.81 34.44 0.3 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.283 -1.527 . . . . 1.0 109.283 179.711 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.548 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 21.4 p -139.75 105.69 5.19 Favored 'General case' 0 C--N 1.307 -1.252 0 O-C-N 121.185 -1.185 . . . . 1.0 111.155 -179.381 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.584 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.47 109.8 0.28 Allowed 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.579 -0.526 . . . . 1.0 109.579 178.057 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.429 ' CE2' ' HB3' ' A' ' 26' ' ' LEU . 8.4 m-85 -104.34 153.23 21.3 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.055 -1.028 . . . . 1.0 108.994 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.435 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.2 155.35 18.49 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.859 -1.15 . . . . 1.0 108.246 179.054 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.728 HG23 HD23 ' A' ' 97' ' ' LEU . 0.8 OUTLIER -126.91 127.89 70.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.228 -0.92 . . . . 1.0 108.973 -178.079 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -175.6 174.36 46.8 Favored Glycine 0 N--CA 1.495 2.581 0 C-N-CA 117.726 -2.178 . . . . 1.0 112.342 -179.926 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.606 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -101.09 108.84 20.63 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 107.964 -1.124 . . . . 1.0 107.964 179.577 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.461 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.0 m -129.67 147.87 51.5 Favored 'General case' 0 C--N 1.294 -1.81 0 O-C-N 121.212 -0.93 . . . . 1.0 109.969 -179.654 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.44 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.58 139.13 54.26 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.362 -0.837 . . . . 1.0 110.523 -179.133 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.876 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.08 114.72 26.56 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.411 -1.329 . . . . 1.0 107.411 178.282 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -106.11 15.35 7.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.051 -1.031 . . . . 1.0 110.541 -178.614 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.77 -175.99 0.09 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.931 -1.106 . . . . 1.0 110.02 179.761 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.79 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.29 97.09 1.19 Allowed 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.782 0.801 . . . . 1.0 109.993 -179.631 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.56 28.23 36.43 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 120.278 -0.963 . . . . 1.0 111.413 178.856 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.18 106.27 20.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 O-C-N 120.623 -1.516 . . . . 1.0 107.186 178.846 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.876 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.88 104.77 11.64 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.463 -1.398 . . . . 1.0 109.869 -177.614 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.044 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.782 -1.199 . . . . 1.0 108.219 178.815 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.0 t -106.35 164.85 11.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.945 -1.097 . . . . 1.0 110.288 -178.897 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.749 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 8.9 t-20 -107.52 134.29 20.05 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.386 -0.821 . . . . 1.0 109.648 -179.301 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.593 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.3 Cg_endo -74.96 22.88 0.41 Allowed 'Trans proline' 0 CA--C 1.544 0.998 0 C-N-CA 122.327 2.018 . . . . 1.0 111.811 -179.813 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.749 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -115.82 7.04 14.46 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.398 -1.439 . . . . 1.0 108.912 179.534 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.546 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.99 15.16 2.86 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.385 -1.339 . . . . 1.0 107.385 179.522 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -78.3 88.19 4.34 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.984 -0.686 . . . . 1.0 111.522 -178.132 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' HG12 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -97.97 -167.49 1.52 Allowed 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.718 -1.215 . . . . 1.0 107.718 177.941 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.445 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.93 135.99 0.09 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.565 -1.335 . . . . 1.0 111.542 -179.331 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.953 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -163.47 154.19 2.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 107.526 -1.287 . . . . 1.0 107.526 178.419 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.584 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.6 141.92 30.83 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.833 -1.167 . . . . 1.0 109.59 -179.945 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -61.82 105.69 0.59 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 122.493 1.139 . . . . 1.0 109.281 178.541 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.552 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.8 p-10 -58.55 -138.63 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.982 0 CA-C-N 115.443 -0.799 . . . . 1.0 110.966 -179.862 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -53.79 -49.4 68.37 Favored 'General case' 0 N--CA 1.5 2.042 0 CA-C-O 121.675 0.75 . . . . 1.0 110.409 -178.672 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 74.7 m-80 -102.38 -37.29 8.11 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 106.066 -1.827 . . . . 1.0 106.066 178.382 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.986 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 110.16 65.84 0.55 Allowed Glycine 0 C--N 1.297 -1.596 0 CA-C-N 114.774 -1.103 . . . . 1.0 110.438 177.964 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.609 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.7 m -104.43 127.3 52.09 Favored 'General case' 0 N--CA 1.483 1.179 0 O-C-N 121.563 -0.963 . . . . 1.0 109.07 179.05 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.953 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.54 109.02 7.38 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 119.519 -0.872 . . . . 1.0 109.764 -179.443 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 53.3 p -115.3 119.57 36.74 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.105 -0.997 . . . . 1.0 109.373 179.97 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.5 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.33 142.21 30.25 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.48 -0.762 . . . . 1.0 109.844 179.935 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 54.8 p -99.44 149.02 23.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.414 -0.803 . . . . 1.0 109.156 179.751 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.739 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -149.87 163.71 37.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.265 -0.897 . . . . 1.0 109.763 -178.93 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.71 HG22 HG22 ' A' ' 18' ' ' VAL . 2.5 p -96.57 126.1 41.51 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.125 -0.984 . . . . 1.0 109.259 -179.987 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.547 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.0 m -137.44 143.19 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 120.904 -1.123 . . . . 1.0 109.856 -179.102 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.602 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.9 ptt180 -147.3 -176.51 5.26 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.519 -1.363 . . . . 1.0 111.081 -179.774 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.596 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.04 -100.19 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 109.155 -0.683 . . . . 1.0 109.155 -179.714 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.52 139.97 51.96 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.779 -1.201 . . . . 1.0 107.801 179.208 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -162.45 138.79 7.62 Favored 'General case' 0 C--N 1.293 -1.89 0 C-N-CA 118.525 -1.27 . . . . 1.0 110.074 -177.819 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.564 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.8 mm-40 -34.7 120.82 0.5 Allowed 'General case' 0 N--CA 1.491 1.6 0 CA-C-O 121.395 0.617 . . . . 1.0 110.246 -178.713 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.044 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.18 50.8 1.9 Allowed Glycine 0 N--CA 1.492 2.402 0 C-N-CA 120.477 -0.868 . . . . 1.0 111.136 -179.101 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.593 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-30 -39.39 113.35 0.32 Allowed 'General case' 0 N--CA 1.507 2.424 0 O-C-N 121.057 -1.26 . . . . 1.0 109.916 179.488 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.643 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -85.73 126.78 34.23 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.835 -1.166 . . . . 1.0 109.504 -179.915 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 30.7 t80 -64.36 58.23 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.018 0 O-C-N 120.859 -1.151 . . . . 1.0 110.104 179.764 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -160.05 19.49 0.16 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.019 -1.051 . . . . 1.0 109.674 179.905 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.38 -26.71 5.52 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.154 -1.178 . . . . 1.0 110.154 179.856 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.451 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -94.27 154.81 17.33 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.06 -1.259 . . . . 1.0 110.42 -179.431 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.479 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -102.11 134.54 45.19 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.176 -1.046 . . . . 1.0 108.176 179.476 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.643 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.2 t90 -81.49 -16.6 51.41 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.784 -1.197 . . . . 1.0 110.506 -178.34 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 108.17 175.52 22.04 Favored Glycine 0 N--CA 1.485 1.921 0 N-CA-C 108.768 -1.733 . . . . 1.0 108.768 -179.675 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.44 104.32 0.61 Allowed 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 107.615 -1.254 . . . . 1.0 107.615 179.07 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.615 HG21 ' HB3' ' A' ' 46' ' ' ALA . 38.1 t -76.03 106.37 5.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.316 -0.865 . . . . 1.0 109.059 -178.862 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.37 110.65 2.33 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.507 -0.746 . . . . 1.0 109.835 -179.268 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.596 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.61 -5.08 4.88 Favored 'General case' 0 N--CA 1.498 1.938 0 C-N-CA 118.261 -1.375 . . . . 1.0 109.752 179.357 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.5 p -85.57 -1.44 57.11 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.806 -1.184 . . . . 1.0 109.216 179.606 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.81 -48.36 3.07 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.299 -0.875 . . . . 1.0 109.051 -179.984 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.31 -178.57 3.64 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.57 -0.706 . . . . 1.0 109.491 179.905 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.46 115.36 30.12 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.429 -0.794 . . . . 1.0 109.096 -179.956 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.76 120.99 38.12 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.894 -1.129 . . . . 1.0 109.239 -179.514 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.61 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -99.26 145.54 27.16 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 122.328 1.061 . . . . 1.0 111.105 -179.338 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.545 ' HB ' HG11 ' A' ' 7' ' ' VAL . 97.5 t -103.21 110.51 29.97 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 106.958 -1.497 . . . . 1.0 106.958 177.858 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.544 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -154.09 -169.68 19.2 Favored Glycine 0 N--CA 1.486 1.996 0 C-N-CA 118.173 -1.965 . . . . 1.0 111.579 -177.635 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.728 HD23 HG23 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -117.87 173.92 6.48 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 108.532 -0.914 . . . . 1.0 108.532 -179.506 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.501 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 7.3 t . . . . . 0 C--N 1.292 -1.913 0 N-CA-C 109.235 -0.654 . . . . 1.0 109.235 -179.808 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.525 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.482 1.757 0 N-CA-C 108.115 -1.994 . . . . 1.0 108.115 . . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -172.61 -176.69 1.56 Allowed 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.526 -0.985 . . . . 1.0 109.715 179.467 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.23 -160.8 16.73 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.159 -1.976 . . . . 1.0 108.159 -179.383 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -46.84 176.41 0.01 OUTLIER 'Trans proline' 0 C--N 1.326 -0.656 0 CA-C-N 118.973 1.386 . . . . 1.0 109.998 179.127 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -95.21 -176.88 3.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.027 -1.046 . . . . 1.0 110.376 -178.814 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.544 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.62 167.19 13.38 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.741 -1.343 . . . . 1.0 109.741 -179.963 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -101.55 129.55 52.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.417 -1.049 . . . . 1.0 109.143 -179.381 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.61 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -68.91 115.86 8.72 Favored 'General case' 0 C--N 1.289 -2.041 0 N-CA-C 109.47 -0.567 . . . . 1.0 109.47 179.474 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.827 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.8 pt -97.8 168.49 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.262 -0.899 . . . . 1.0 108.59 179.857 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.422 ' O ' ' HA ' ' A' ' 11' ' ' SER . 2.8 t -142.36 158.49 43.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.022 -1.049 . . . . 1.0 110.302 -179.375 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.827 ' CE1' HD12 ' A' ' 110' ' ' ILE . 84.8 m-85 . . . . . 0 N--CA 1.484 1.259 0 O-C-N 121.374 -0.829 . . . . 1.0 109.324 -179.856 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.483 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.301 0 CA-C-O 122.333 1.063 . . . . 0.0 110.388 . . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.755 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.3 t -114.54 109.35 18.13 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 123.01 1.386 . . . . 0.0 109.768 -179.929 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.83 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -115.58 139.03 44.0 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.721 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.763 179.913 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.51 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -172.42 150.71 2.31 Favored Pre-proline 0 N--CA 1.487 1.403 0 O-C-N 121.154 -0.966 . . . . 0.0 108.948 -179.533 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.51 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.1 Cg_endo -75.38 152.77 98.03 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.498 -1.459 . . . . 0.0 109.533 -0.674 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.641 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.5 m -89.89 -25.42 20.99 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.763 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.494 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.5 m -136.83 166.43 23.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.483 -0.76 . . . . 0.0 109.435 179.935 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.28 37.72 35.99 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.522 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.837 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.9 mt -92.77 -44.68 8.39 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 123.153 1.454 . . . . 0.0 110.767 -178.272 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.84 145.56 0.03 OUTLIER 'General case' 0 C--N 1.258 -3.392 0 CA-C-N 113.721 -1.581 . . . . 0.0 110.045 -179.819 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.593 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.6 p-10 -50.64 108.34 0.23 Allowed 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 121.562 0.696 . . . . 0.0 111.727 -178.678 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.06 15.56 9.82 Favored Glycine 0 N--CA 1.484 1.895 0 C-N-CA 119.619 -1.277 . . . . 0.0 112.78 177.263 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.837 HG21 ' CA ' ' A' ' 13' ' ' LEU . 8.8 t -103.56 -173.12 2.24 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 121.056 2.428 . . . . 0.0 109.839 179.348 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.77 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.9 t -126.8 135.71 62.91 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.944 -178.771 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.549 HG13 ' CG2' ' A' ' 69' ' ' VAL . 27.4 m -112.37 154.75 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 O-C-N 121.348 -0.845 . . . . 0.0 108.883 178.789 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.517 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -111.24 109.43 19.45 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.219 -0.926 . . . . 0.0 108.987 179.947 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.83 HG23 HG22 ' A' ' 7' ' ' VAL . 2.2 p -105.11 140.2 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -179.972 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.755 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.43 161.39 36.47 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.793 -1.192 . . . . 0.0 110.004 179.583 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -134.54 140.44 11.74 Favored Glycine 0 C--N 1.299 -1.518 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 179.793 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -141.74 127.04 18.66 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.563 -1.551 . . . . 0.0 109.489 179.294 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 87.47 29.26 22.35 Favored Glycine 0 N--CA 1.488 2.16 0 C-N-CA 118.915 -1.612 . . . . 0.0 109.681 -179.821 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.551 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.9 mt -89.08 173.21 8.57 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.006 -1.291 . . . . 0.0 108.334 -179.85 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.022 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.21 98.85 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.015 -1.053 . . . . 0.0 109.797 -179.715 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.549 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.38 77.02 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.251 -179.199 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.05 33.35 0.28 Allowed Glycine 0 N--CA 1.486 1.991 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.533 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.55 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.7 p -142.81 110.57 5.87 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 120.981 -1.306 . . . . 0.0 111.028 -179.832 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.588 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.95 112.68 0.65 Allowed 'General case' 0 N--CA 1.495 1.814 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.99 178.366 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.504 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 21.6 m-85 -101.33 155.3 18.12 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.127 -0.983 . . . . 0.0 108.88 179.665 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.517 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -102.7 150.19 23.7 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.862 -1.149 . . . . 0.0 108.205 179.014 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.71 ' CG1' HD21 ' A' ' 67' ' ' LEU . 1.1 t -126.34 129.97 71.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.117 -0.989 . . . . 0.0 109.121 -178.074 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.467 ' HA2' ' HB2' ' A' ' 51' ' ' ASP . . . -178.56 172.67 45.06 Favored Glycine 0 N--CA 1.495 2.573 0 C-N-CA 117.812 -2.137 . . . . 0.0 112.201 179.866 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.609 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -101.02 109.1 20.97 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.364 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.1 m -130.05 148.93 51.96 Favored 'General case' 0 C--N 1.295 -1.765 0 O-C-N 120.96 -1.087 . . . . 0.0 110.27 -179.496 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.52 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.54 138.34 54.34 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.364 -0.835 . . . . 0.0 110.537 -179.307 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.34 114.79 26.61 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 178.249 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.5 m -104.46 14.57 6.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.069 -1.02 . . . . 0.0 110.518 -178.915 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.763 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.55 -175.0 0.08 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.902 -1.124 . . . . 0.0 109.974 179.702 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -73.6 98.79 2.91 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.441 -0.787 . . . . 0.0 109.539 -179.814 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.99 27.62 30.86 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 120.161 -1.018 . . . . 0.0 111.362 179.09 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.763 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -118.11 105.99 18.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 O-C-N 120.597 -1.531 . . . . 0.0 107.231 178.967 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.6 tp -118.12 104.73 11.11 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 120.496 -1.378 . . . . 0.0 109.917 -177.801 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.013 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.64 109.33 22.11 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.729 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -105.64 165.87 10.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.915 -1.116 . . . . 0.0 110.674 -178.479 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.504 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 7.8 t30 -110.32 130.25 23.07 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 121.601 -0.687 . . . . 0.0 109.247 -179.486 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -71.59 23.28 0.24 Allowed 'Trans proline' 0 CA--C 1.545 1.055 0 C-N-CA 122.054 1.836 . . . . 0.0 111.804 179.623 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.504 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -103.32 -3.07 26.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.448 -1.408 . . . . 0.0 109.074 179.641 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.863 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.6 m-20 -134.93 10.41 3.6 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.943 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -63.34 81.99 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.251 -178.905 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.648 ' HB2' HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.34 -169.57 1.82 Allowed 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.096 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.435 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.1 t 179.27 132.94 0.09 Allowed 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.865 -1.147 . . . . 0.0 111.126 -179.532 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.855 HG11 ' HB1' ' A' ' 63' ' ' ALA . 1.1 p -156.32 152.61 8.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 178.367 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.588 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.91 142.29 29.83 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.696 -1.253 . . . . 0.0 109.872 -179.64 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.022 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.02 106.11 0.78 Allowed 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.447 1.117 . . . . 0.0 109.497 178.792 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.6 p-10 -57.92 -139.22 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.727 -179.978 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.549 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -55.13 -49.27 72.2 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.331 -0.856 . . . . 0.0 110.093 -178.95 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.7 p-10 -100.22 -39.03 8.25 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 178.482 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.978 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.94 66.36 0.58 Allowed Glycine 0 C--N 1.297 -1.619 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 178.288 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.584 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.0 m -101.48 129.81 47.61 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 121.601 -0.941 . . . . 0.0 109.056 179.103 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.855 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -138.13 108.95 6.66 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 119.31 -0.956 . . . . 0.0 109.498 -179.554 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.7 m -126.0 120.92 31.58 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.205 -0.934 . . . . 0.0 109.627 -179.774 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.08 144.78 30.24 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.482 -0.761 . . . . 0.0 109.391 179.871 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.437 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 32.1 p -98.83 141.12 32.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.368 -0.832 . . . . 0.0 109.115 179.894 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.863 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -140.56 174.69 10.27 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.333 -0.854 . . . . 0.0 109.65 -178.818 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.528 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -102.34 122.37 44.11 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.019 -1.051 . . . . 0.0 109.622 -179.751 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.671 HG13 ' OD2' ' A' ' 51' ' ' ASP . 16.9 m -133.47 143.17 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 120.911 -1.118 . . . . 0.0 110.159 -179.411 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.593 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.0 ptt180 -142.68 -166.87 2.38 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.663 -1.273 . . . . 0.0 110.09 179.568 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.565 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -72.32 -85.91 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.321 -0.862 . . . . 0.0 108.841 -179.575 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.62 138.81 58.58 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.291 -1.506 . . . . 0.0 107.362 178.799 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -164.48 139.08 5.49 Favored 'General case' 0 C--N 1.294 -1.82 0 C-N-CA 117.982 -1.487 . . . . 0.0 110.542 -177.496 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.507 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.6 mm-40 -34.09 120.55 0.44 Allowed 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.47 0.653 . . . . 0.0 110.612 -178.625 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.013 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.15 50.57 1.91 Allowed Glycine 0 N--CA 1.494 2.563 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.226 -179.418 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-85 -41.05 114.18 0.46 Allowed 'General case' 0 N--CA 1.508 2.45 0 O-C-N 120.868 -1.372 . . . . 0.0 109.964 179.453 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.637 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.3 tp -84.32 126.92 33.64 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.742 -1.224 . . . . 0.0 109.624 -179.951 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -64.05 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.812 -1.18 . . . . 0.0 110.275 179.688 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' LEU . 8.7 t0 -161.35 20.0 0.12 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.944 -1.098 . . . . 0.0 109.806 179.731 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.19 -26.88 5.31 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 110.041 -1.223 . . . . 0.0 110.041 179.963 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.475 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 5.9 p -92.38 152.78 19.56 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.056 -1.261 . . . . 0.0 110.386 -179.442 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.515 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 5.4 ptt180 -101.93 133.06 47.32 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.597 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.637 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -81.24 -20.96 39.9 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 120.713 -1.242 . . . . 0.0 110.527 -178.269 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.88 176.04 20.45 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 108.725 -1.75 . . . . 0.0 108.725 -179.629 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.49 109.42 1.37 Allowed 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 179.148 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.591 HG21 ' HB3' ' A' ' 46' ' ' ALA . 31.1 t -81.83 105.74 12.05 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 121.341 -0.849 . . . . 0.0 108.94 -178.934 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.651 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -65.3 111.82 3.19 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.446 -0.783 . . . . 0.0 109.845 -179.357 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.549 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.56 -5.09 7.13 Favored 'General case' 0 N--CA 1.499 1.984 0 C-N-CA 118.285 -1.366 . . . . 0.0 109.648 179.369 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 p -83.76 -2.18 55.74 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.876 -1.14 . . . . 0.0 108.901 179.318 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.651 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.98 -49.81 2.95 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.347 -0.846 . . . . 0.0 109.013 -179.998 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.62 -178.34 3.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.551 -0.718 . . . . 0.0 109.517 179.919 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.3 116.29 31.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.43 -0.794 . . . . 0.0 108.99 -179.971 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.568 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.1 m -96.88 124.21 40.8 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.814 -1.179 . . . . 0.0 109.747 -179.168 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.614 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.0 147.32 26.71 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 122.33 1.062 . . . . 0.0 111.202 -179.44 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.527 ' CG1' HG11 ' A' ' 7' ' ' VAL . 43.8 t -104.75 111.53 34.65 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.567 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.496 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.35 -169.81 17.47 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 117.906 -2.092 . . . . 0.0 111.845 -177.481 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.494 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.57 -179.07 3.57 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -179.094 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.517 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER . . . . . 0 C--N 1.296 -1.735 0 O-C-N 121.277 -0.889 . . . . 0.0 109.438 -179.73 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.658 0 N-CA-C 107.676 -2.17 . . . . 0.0 107.676 . . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.55 -178.16 6.91 Favored 'General case' 0 C--N 1.306 -1.296 0 O-C-N 121.534 -0.98 . . . . 0.0 109.671 179.253 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.5 -162.04 17.06 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 108.356 -1.897 . . . . 0.0 108.356 -179.494 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.484 ' CD ' ' CE1' ' A' ' 32' ' ' TYR . 6.8 Cg_exo -46.12 174.16 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 CA-C-N 118.784 1.292 . . . . 0.0 110.022 179.387 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -92.82 -177.69 4.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.107 -0.996 . . . . 0.0 110.528 -178.588 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.496 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.8 167.44 13.1 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.946 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -104.06 131.19 53.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 O-C-N 121.325 -1.103 . . . . 0.0 109.095 -179.269 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.614 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.99 122.63 22.03 Favored 'General case' 0 C--N 1.29 -2.001 0 O-C-N 121.612 -0.68 . . . . 0.0 109.529 179.707 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.848 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.72 169.84 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 O-C-N 121.225 -0.922 . . . . 0.0 109.226 -179.982 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.494 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -135.48 155.33 50.7 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.233 -0.917 . . . . 0.0 109.721 -179.753 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.848 ' CE2' HD12 ' A' ' 110' ' ' ILE . 74.9 m-85 . . . . . 0 N--CA 1.488 1.426 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.767 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.164 0 CA-C-O 122.475 1.131 . . . . 0.0 110.618 . . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.006 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.8 p -106.89 104.95 14.75 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-O 122.503 1.144 . . . . 0.0 110.331 -179.43 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.955 HG22 HG23 ' A' ' 21' ' ' VAL . 10.6 t -117.25 119.16 61.02 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.478 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.303 179.582 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.501 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.61 148.38 12.67 Favored Pre-proline 0 N--CA 1.487 1.415 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -179.602 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.501 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.49 152.85 97.95 Favored 'Cis proline' 0 C--N 1.31 -1.497 0 C-N-CA 123.603 -1.415 . . . . 0.0 109.728 -0.445 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.7 m -92.53 -24.94 18.6 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.505 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.517 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 1.2 m -136.53 166.05 24.43 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.656 -0.652 . . . . 0.0 109.351 179.847 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.39 37.98 39.95 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 -179.723 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.786 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.6 mt -91.7 -43.34 9.64 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 123.344 1.545 . . . . 0.0 110.649 -178.31 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.472 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.02 144.43 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.376 -1.738 . . . . 0.0 109.853 -179.653 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.611 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 6.1 p-10 -51.13 107.78 0.2 Allowed 'General case' 0 C--N 1.302 -1.492 0 CA-C-O 121.586 0.708 . . . . 0.0 111.527 -178.534 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.12 14.26 9.33 Favored Glycine 0 N--CA 1.484 1.86 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.822 177.486 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.786 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.3 t -105.0 -172.6 2.13 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 121.13 2.465 . . . . 0.0 109.713 179.287 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.75 HG13 ' C ' ' A' ' 67' ' ' LEU . 15.0 t -130.68 139.18 51.88 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.324 -178.793 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.472 HG23 ' CD1' ' A' ' 67' ' ' LEU . 31.7 m -114.72 154.91 16.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.037 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.541 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.6 tptm -110.45 109.36 19.7 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.337 180.0 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.955 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -105.1 123.95 59.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 179.948 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.006 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.38 166.16 11.55 Favored 'General case' 0 N--CA 1.485 1.279 0 O-C-N 120.927 -1.108 . . . . 0.0 108.94 179.594 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.622 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.19 108.1 0.48 Allowed Glycine 0 N--CA 1.482 1.763 0 N-CA-C 108.41 -1.876 . . . . 0.0 108.41 179.917 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -117.19 136.81 52.78 Favored 'General case' 0 N--CA 1.501 2.078 0 CA-C-N 119.432 1.616 . . . . 0.0 110.38 -179.287 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 87.61 28.11 25.2 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 118.895 -1.621 . . . . 0.0 109.806 179.68 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.566 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -93.4 170.6 9.49 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.988 -1.301 . . . . 0.0 108.309 179.852 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.008 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.9 100.8 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.068 -1.02 . . . . 0.0 110.018 -179.495 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.541 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.75 78.17 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.675 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.018 -179.36 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.32 34.48 0.28 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.735 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 18.8 p -139.56 105.67 5.23 Favored 'General case' 0 C--N 1.307 -1.278 0 O-C-N 121.162 -1.199 . . . . 0.0 111.273 -179.258 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.592 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.74 109.88 0.36 Allowed 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 177.824 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.473 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.2 m-30 -106.38 156.11 18.85 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.049 -1.032 . . . . 0.0 108.886 179.89 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.512 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -100.36 164.51 11.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.902 -1.124 . . . . 0.0 108.081 179.035 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.682 HG22 HG11 ' A' ' 21' ' ' VAL . 4.2 p -144.23 117.21 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.152 -0.967 . . . . 0.0 109.61 -178.1 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.9 -176.9 38.83 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 118.364 -1.874 . . . . 0.0 111.876 -179.717 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.601 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -101.48 109.21 20.99 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.837 0.827 . . . . 0.0 109.13 -179.572 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.21 148.44 52.04 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.192 -0.943 . . . . 0.0 109.511 179.579 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.509 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.7 138.52 54.58 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.179 -0.951 . . . . 0.0 110.815 -178.969 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.97 26.8 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 178.112 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.9 m -105.64 15.07 7.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 120.994 -1.066 . . . . 0.0 110.534 -178.84 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.754 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.11 -175.38 0.09 Allowed 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.857 -1.152 . . . . 0.0 110.064 179.724 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 64.0 p -72.24 97.44 1.99 Allowed 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.428 -0.795 . . . . 0.0 109.64 -179.784 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.56 27.54 32.24 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 120.154 -1.022 . . . . 0.0 111.419 178.877 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.754 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.65 106.21 19.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.526 -1.573 . . . . 0.0 107.221 178.93 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.8 tp -117.06 104.69 11.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.52 -1.362 . . . . 0.0 109.854 -177.659 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.072 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.08 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.299 0 O-C-N 120.842 -1.161 . . . . 0.0 107.887 178.77 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -106.87 163.99 12.49 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.015 -1.053 . . . . 0.0 110.44 -178.771 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.743 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 47.0 t30 -109.59 131.04 22.12 Favored Pre-proline 0 N--CA 1.502 2.173 0 O-C-N 121.59 -0.694 . . . . 0.0 109.618 -179.345 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.61 20.76 0.25 Allowed 'Trans proline' 0 C--N 1.318 -1.029 0 C-N-CA 122.21 1.94 . . . . 0.0 112.243 -179.813 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.743 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -110.53 5.68 21.39 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.379 -1.451 . . . . 0.0 108.846 179.166 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.543 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.01 16.82 2.64 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 179.339 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -81.74 88.82 6.26 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.868 -0.733 . . . . 0.0 111.285 -178.302 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.637 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.79 -167.25 1.23 Allowed 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 177.93 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.65 136.24 0.09 Allowed 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.479 -1.388 . . . . 0.0 111.395 -179.341 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.881 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -152.67 157.29 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.169 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.592 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.89 141.76 31.25 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.732 -1.23 . . . . 0.0 109.859 -179.772 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.008 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.17 107.51 1.06 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.43 1.109 . . . . 0.0 109.399 178.199 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.562 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 14.4 p-10 -61.75 -138.91 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.001 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.812 -179.997 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.541 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.49 -51.62 53.55 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.374 -0.828 . . . . 0.0 110.664 -178.665 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -102.23 -33.75 9.5 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 178.473 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.008 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.28 64.56 0.57 Allowed Glycine 0 C--N 1.299 -1.511 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.671 178.009 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.622 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 92.7 p -98.89 128.91 45.2 Favored 'General case' 0 N--CA 1.482 1.168 0 O-C-N 121.859 -0.789 . . . . 0.0 108.92 178.804 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.881 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.28 108.78 7.4 Favored 'General case' 0 C--N 1.296 -1.742 0 C-N-CA 119.67 -0.812 . . . . 0.0 109.416 -179.524 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 80.9 p -120.5 117.44 27.65 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.298 -0.876 . . . . 0.0 109.368 -179.906 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.569 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.31 140.83 28.04 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.418 -0.801 . . . . 0.0 109.609 -179.836 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 12.6 p -100.69 136.24 40.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.377 -0.827 . . . . 0.0 109.494 -179.947 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.75 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -133.84 165.85 24.03 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.423 -0.798 . . . . 0.0 109.392 -179.473 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.729 HG22 HG22 ' A' ' 18' ' ' VAL . 2.2 p -96.22 125.33 40.66 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.956 -1.09 . . . . 0.0 109.349 -179.946 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.601 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.4 m -135.82 143.49 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 120.919 -1.113 . . . . 0.0 109.929 -179.116 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.611 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.63 -175.9 4.98 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.495 -1.378 . . . . 0.0 110.984 179.957 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.599 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.56 -101.73 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.762 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.514 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -57.29 142.0 44.84 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.731 -1.23 . . . . 0.0 108.187 179.424 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.585 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.65 136.85 6.39 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.775 -1.17 . . . . 0.0 109.637 -177.961 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.498 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 1.6 mp0 -34.46 121.89 0.5 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.431 0.634 . . . . 0.0 110.306 -178.402 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.072 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.58 49.91 2.34 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.236 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.5 m-85 -39.3 113.85 0.36 Allowed 'General case' 0 N--CA 1.507 2.382 0 O-C-N 121.204 -1.174 . . . . 0.0 109.992 179.555 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.7 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -85.81 126.46 34.04 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 120.944 -1.098 . . . . 0.0 109.55 -179.797 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -64.28 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.869 -1.144 . . . . 0.0 110.052 179.665 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.539 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.4 t70 -159.96 19.49 0.16 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.157 -0.964 . . . . 0.0 109.66 179.764 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.96 -27.45 5.47 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.75 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.4 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 19.5 p -94.49 160.46 14.64 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.033 -1.275 . . . . 0.0 110.362 -179.361 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.48 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.75 136.62 46.24 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.689 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.7 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -82.89 -17.96 41.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.765 -1.21 . . . . 0.0 110.526 -178.487 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.94 175.6 19.89 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 108.778 -1.729 . . . . 0.0 108.778 -179.632 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.05 104.74 0.92 Allowed 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 179.134 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.633 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.5 t -76.48 106.3 6.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.388 -0.82 . . . . 0.0 109.258 -178.913 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -66.02 111.28 3.28 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.47 -0.769 . . . . 0.0 109.892 -179.41 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.599 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.75 -5.49 4.27 Favored 'General case' 0 N--CA 1.5 2.068 0 C-N-CA 118.256 -1.377 . . . . 0.0 109.816 179.484 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.6 p -86.82 -0.14 55.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.708 -1.245 . . . . 0.0 109.111 179.585 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.33 -50.59 2.85 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.398 -0.814 . . . . 0.0 108.945 179.96 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.07 -179.95 4.09 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.484 -0.76 . . . . 0.0 109.392 179.845 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.97 115.86 31.2 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.333 -0.854 . . . . 0.0 108.964 179.917 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.84 121.32 38.57 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.993 -1.067 . . . . 0.0 109.308 -179.421 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.595 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.92 145.7 28.3 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 122.355 1.074 . . . . 0.0 111.2 -179.306 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.648 ' HB ' HG11 ' A' ' 7' ' ' VAL . 58.6 t -103.12 109.78 27.83 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 177.675 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.478 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.26 -170.73 16.47 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 118.271 -1.919 . . . . 0.0 111.663 -177.738 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.503 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -114.36 -179.55 3.66 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 -178.95 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.512 ' O ' ' N ' ' A' ' 33' ' ' ASP . 37.1 p . . . . . 0 C--N 1.297 -1.693 0 O-C-N 121.337 -0.852 . . . . 0.0 109.321 -179.235 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.771 0 N-CA-C 107.572 -2.211 . . . . 0.0 107.572 . . . . . . . . . 0 0 . 1 . 034 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.61 -178.01 6.79 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.538 -0.977 . . . . 0.0 109.793 179.253 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.75 -163.0 16.93 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -179.321 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.503 ' HB2' HD12 ' A' ' 97' ' ' LEU . 6.4 Cg_exo -46.71 175.69 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.643 0 CA-C-N 118.77 1.285 . . . . 0.0 110.1 179.325 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -90.06 -176.04 4.75 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.019 -1.05 . . . . 0.0 110.599 -178.787 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.478 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.82 167.0 13.88 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.896 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.89 132.66 49.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.373 -1.075 . . . . 0.0 109.174 -179.334 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.595 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.27 118.88 17.73 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.547 -0.72 . . . . 0.0 109.685 179.675 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.911 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -98.02 170.07 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.211 -0.93 . . . . 0.0 108.999 179.72 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.517 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 34.4 m -140.95 156.85 45.99 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.167 -0.958 . . . . 0.0 110.094 -179.674 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.911 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.3 m-85 . . . . . 0 N--CA 1.486 1.334 0 O-C-N 121.333 -0.855 . . . . 0.0 109.541 -179.754 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.488 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.21 0 CA-C-O 122.486 1.136 . . . . 0.0 110.397 . . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.763 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.5 t -113.52 109.17 18.21 Favored 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 123.15 1.452 . . . . 0.0 109.266 179.954 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.889 HG22 HG23 ' A' ' 21' ' ' VAL . 4.4 t -116.25 127.38 73.87 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.709 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.94 -179.847 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.512 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.44 148.11 12.7 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.286 -0.884 . . . . 0.0 108.874 -179.696 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.512 ' HA ' HG23 ' A' ' 8' ' ' THR . 7.1 Cg_endo -79.96 147.65 77.46 Favored 'Cis proline' 0 C--N 1.31 -1.451 0 O-C-N 123.778 1.409 . . . . 0.0 109.35 -0.797 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.681 ' HA ' HG22 ' A' ' 110' ' ' ILE . 79.8 p -89.27 -25.8 21.5 Favored 'General case' 0 C--N 1.295 -1.785 0 O-C-N 121.563 -0.71 . . . . 0.0 109.203 179.788 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.476 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.0 OUTLIER -132.23 162.03 31.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.405 -0.81 . . . . 0.0 109.55 -179.927 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.9 37.29 29.98 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 -179.661 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.773 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.5 mt -92.39 -42.81 9.57 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 123.295 1.521 . . . . 0.0 110.516 -178.388 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.42 144.69 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.283 0 CA-C-N 113.321 -1.763 . . . . 0.0 109.936 -179.649 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.591 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.3 p-10 -51.2 106.11 0.12 Allowed 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.647 0.737 . . . . 0.0 111.494 -178.513 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.98 14.67 8.35 Favored Glycine 0 N--CA 1.485 1.929 0 C-N-CA 119.354 -1.403 . . . . 0.0 113.006 177.358 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.773 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -104.87 -171.2 1.88 Allowed 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 121.143 2.471 . . . . 0.0 109.516 179.218 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.732 HG13 ' C ' ' A' ' 67' ' ' LEU . 17.0 t -127.63 135.88 61.95 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.128 -179.119 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.642 HG13 ' CG2' ' A' ' 69' ' ' VAL . 29.2 m -109.18 155.27 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.835 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.533 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -110.35 109.23 19.57 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 108.834 179.804 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.889 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -105.01 139.5 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.399 -0.813 . . . . 0.0 108.832 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.763 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.58 161.13 37.25 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.804 -1.185 . . . . 0.0 109.945 179.631 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -134.05 141.57 12.93 Favored Glycine 0 C--N 1.297 -1.623 0 N-CA-C 108.318 -1.913 . . . . 0.0 108.318 179.768 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.64 125.98 16.6 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.706 -1.467 . . . . 0.0 109.294 179.369 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.11 28.2 21.19 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 118.873 -1.632 . . . . 0.0 109.599 -179.625 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.596 HD22 ' HG3' ' A' ' 105' ' ' PRO . 1.8 mt -88.84 174.59 7.88 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.988 -1.301 . . . . 0.0 108.365 179.953 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.66 98.45 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.887 -1.133 . . . . 0.0 109.823 -179.521 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.579 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 77.71 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.724 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.248 -179.253 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.563 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.73 34.37 0.31 Allowed Glycine 0 N--CA 1.486 2.014 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.525 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 66.6 p -144.24 109.73 5.19 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.005 -1.291 . . . . 0.0 111.211 -179.585 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.566 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -43.8 127.01 4.97 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.43 178.02 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.541 ' CD2' ' O ' ' A' ' 30' ' ' THR . 15.3 m-85 -116.98 153.48 32.56 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.388 -0.82 . . . . 0.0 108.834 179.844 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.5 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -105.24 148.97 26.38 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.816 -1.177 . . . . 0.0 108.264 179.059 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.648 HG13 HD21 ' A' ' 67' ' ' LEU . 0.9 OUTLIER -125.82 126.46 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.169 -0.957 . . . . 0.0 109.071 -178.103 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -172.77 173.29 45.47 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 117.707 -2.187 . . . . 0.0 112.527 -179.915 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.578 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.36 110.31 22.52 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 179.368 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 63.1 m -129.35 152.11 49.26 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 121.196 -0.94 . . . . 0.0 110.156 -179.612 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.67 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -126.47 135.45 51.37 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.632 -0.668 . . . . 0.0 110.046 179.585 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.905 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.71 114.43 26.35 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.579 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 m -106.86 15.15 7.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.915 -1.115 . . . . 0.0 110.713 -178.633 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.788 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.4 -174.52 0.07 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.819 -1.175 . . . . 0.0 110.135 179.63 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 29.5 p -70.14 96.32 1.07 Allowed 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.407 -0.808 . . . . 0.0 110.013 -179.468 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.04 28.4 34.4 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 120.166 -1.016 . . . . 0.0 111.532 178.749 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.788 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.32 106.04 19.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 120.58 -1.541 . . . . 0.0 107.327 178.83 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.905 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.7 tp -116.47 106.54 13.71 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.59 -1.319 . . . . 0.0 109.775 -177.65 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.116 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -96.13 109.76 22.14 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 120.697 -1.252 . . . . 0.0 108.381 179.281 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.41 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 86.8 m -101.48 147.59 26.2 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.346 -0.847 . . . . 0.0 110.48 -178.371 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.655 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 31.1 t30 -96.66 137.87 21.43 Favored Pre-proline 0 N--CA 1.502 2.169 0 O-C-N 121.01 -1.056 . . . . 0.0 108.826 178.878 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.582 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 8.0 Cg_endo -75.76 26.71 0.4 Allowed 'Trans proline' 0 N--CA 1.496 1.649 0 C-N-CA 125.188 3.925 . . . . 0.0 111.507 -179.068 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.655 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -126.1 9.12 7.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.424 -1.423 . . . . 0.0 109.576 179.881 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.83 15.97 2.49 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 179.502 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -77.91 87.14 4.11 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.059 -178.675 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.611 ' CB ' HG12 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -98.98 -168.22 1.6 Allowed 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 178.569 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.43 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 179.13 133.98 0.09 Allowed 'General case' 0 N--CA 1.486 1.329 0 O-C-N 120.766 -1.209 . . . . 0.0 111.42 -179.428 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.879 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -159.14 153.62 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.493 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.566 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.51 144.63 27.02 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.683 -1.261 . . . . 0.0 109.645 -179.86 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.002 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.67 107.42 1.41 Allowed 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 122.525 1.155 . . . . 0.0 109.502 178.7 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.556 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 p-10 -61.39 -139.97 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.782 179.98 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.579 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.06 -50.73 58.1 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.382 -0.824 . . . . 0.0 110.664 -178.799 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -103.48 -32.64 9.39 Favored 'General case' 0 C--N 1.286 -2.165 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 178.713 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.994 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.0 65.72 0.65 Allowed Glycine 0 C--N 1.296 -1.652 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 178.309 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.1 m -100.54 128.96 46.43 Favored 'General case' 0 N--CA 1.484 1.245 0 O-C-N 121.523 -0.987 . . . . 0.0 108.808 178.856 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.879 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -137.9 108.65 6.64 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.242 -0.983 . . . . 0.0 109.588 -179.516 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 27.3 p -123.82 120.24 32.04 Favored 'General case' 0 C--N 1.305 -1.33 0 O-C-N 121.246 -0.909 . . . . 0.0 109.513 -179.982 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.76 146.05 31.06 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.485 -0.759 . . . . 0.0 109.321 179.819 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 55.4 p -98.57 144.56 27.75 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.295 -0.878 . . . . 0.0 109.287 179.945 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.732 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -144.02 165.01 28.97 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.434 -0.791 . . . . 0.0 109.413 -179.216 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.657 HG22 HG22 ' A' ' 18' ' ' VAL . 3.8 p -95.04 123.71 38.68 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.127 -0.983 . . . . 0.0 109.329 -179.887 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.642 ' CG2' HG13 ' A' ' 19' ' ' VAL . 16.6 m -137.89 142.49 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 120.963 -1.085 . . . . 0.0 109.701 -179.292 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.591 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 5.4 ptt180 -140.71 -166.79 2.21 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 120.677 -1.264 . . . . 0.0 109.968 -179.989 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.549 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -71.66 -80.41 0.06 Allowed 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.809 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.504 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -64.87 135.79 56.13 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 178.648 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.67 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.08 133.6 6.09 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 117.862 -1.535 . . . . 0.0 110.563 -177.643 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.556 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -33.64 120.74 0.41 Allowed 'General case' 0 N--CA 1.493 1.694 0 CA-C-O 121.615 0.722 . . . . 0.0 110.391 -178.472 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.116 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.4 50.52 2.4 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.456 -0.878 . . . . 0.0 111.611 -178.916 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.582 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.7 OUTLIER -38.42 116.88 0.58 Allowed 'General case' 0 N--CA 1.51 2.567 0 O-C-N 121.094 -1.239 . . . . 0.0 110.053 179.41 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.627 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.28 125.71 34.38 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 120.8 -1.187 . . . . 0.0 109.455 179.855 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.0 t80 -64.14 58.6 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.819 -1.176 . . . . 0.0 110.086 179.82 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.9 t70 -160.51 20.02 0.14 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.059 -1.026 . . . . 0.0 109.668 179.898 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.46 -28.64 5.19 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 179.813 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.468 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 40.7 p -94.23 160.57 14.63 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.066 -1.255 . . . . 0.0 110.293 -179.52 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.49 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -108.02 136.8 47.11 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.794 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.627 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.9 t90 -80.74 -20.34 42.97 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.809 -1.182 . . . . 0.0 110.351 -178.688 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.43 176.24 20.22 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 108.644 -1.782 . . . . 0.0 108.644 -179.565 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -62.55 109.97 1.55 Allowed 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.166 -1.196 . . . . 0.0 107.779 179.168 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.63 HG21 ' CB ' ' A' ' 46' ' ' ALA . 37.1 t -83.22 103.53 10.62 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -179.104 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.575 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -65.77 111.71 3.37 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.383 -0.823 . . . . 0.0 109.894 -179.257 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.549 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -65.83 -3.67 5.43 Favored 'General case' 0 N--CA 1.5 2.055 0 C-N-CA 118.334 -1.346 . . . . 0.0 109.886 179.457 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 p -86.93 11.61 13.08 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.739 -1.225 . . . . 0.0 108.794 179.487 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.575 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -127.25 -48.22 1.45 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.428 -0.795 . . . . 0.0 108.989 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.36 -179.85 4.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.559 -0.713 . . . . 0.0 109.504 -179.948 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.1 113.66 27.32 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.318 -0.864 . . . . 0.0 109.079 -179.986 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.522 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.6 m -97.12 124.89 41.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.879 -1.138 . . . . 0.0 109.438 -179.512 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.567 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -104.87 147.15 28.06 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 122.403 1.097 . . . . 0.0 111.38 -179.27 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.497 ' CG1' HG11 ' A' ' 7' ' ' VAL . 43.4 t -103.53 112.04 35.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.977 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 177.577 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.417 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.06 -170.44 16.73 Favored Glycine 0 N--CA 1.488 2.137 0 C-N-CA 118.076 -2.011 . . . . 0.0 111.738 -177.607 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.485 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.08 -179.43 3.7 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 -179.126 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.515 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 4.5 p . . . . . 0 C--N 1.293 -1.885 0 O-C-N 121.337 -0.852 . . . . 0.0 109.287 -179.523 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.75 0 N-CA-C 107.59 -2.204 . . . . 0.0 107.59 . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.54 -178.74 7.49 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 121.62 -0.929 . . . . 0.0 109.355 178.9 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -173.29 -165.97 30.97 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.737 -1.745 . . . . 0.0 108.737 -179.471 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.596 ' HG3' HD22 ' A' ' 26' ' ' LEU . 4.6 Cg_exo -46.39 -175.86 0.0 OUTLIER 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 123.57 2.847 . . . . 0.0 109.923 179.512 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -94.78 172.13 8.35 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.975 -1.078 . . . . 0.0 110.574 -178.957 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.417 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -110.47 159.71 13.71 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 179.897 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.36 128.17 55.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.36 -1.082 . . . . 0.0 109.29 -179.378 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.567 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.75 119.49 17.06 Favored 'General case' 0 C--N 1.289 -2.042 0 O-C-N 121.591 -0.693 . . . . 0.0 109.358 179.569 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.852 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.99 171.07 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.228 -0.92 . . . . 0.0 109.116 -179.945 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.476 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.86 154.91 48.46 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.088 -1.007 . . . . 0.0 109.811 -179.763 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.852 ' CE2' HD12 ' A' ' 110' ' ' ILE . 76.1 m-85 . . . . . 0 N--CA 1.485 1.324 0 O-C-N 121.1 -1.0 . . . . 0.0 109.467 -179.752 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.491 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.458 0 CA-C-O 122.355 1.074 . . . . 0.0 110.613 . . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.954 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -113.19 108.66 17.58 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 123.166 1.46 . . . . 0.0 109.227 179.418 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.911 HG22 HG23 ' A' ' 21' ' ' VAL . 4.3 t -116.89 141.37 35.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.717 0 CA-C-N 114.185 -1.371 . . . . 0.0 109.953 -179.716 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.47 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -178.07 150.61 0.76 Allowed Pre-proline 0 N--CA 1.487 1.415 0 O-C-N 121.248 -0.907 . . . . 0.0 108.668 -179.613 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.47 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.67 152.24 96.92 Favored 'Cis proline' 0 C--N 1.312 -1.39 0 C-N-CA 123.485 -1.465 . . . . 0.0 109.679 -0.699 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.545 ' HA ' HG22 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -90.75 -24.85 20.25 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.768 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.507 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.7 m -136.71 164.15 28.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.451 -0.781 . . . . 0.0 109.482 179.856 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.39 37.47 31.38 Favored Glycine 0 N--CA 1.497 2.702 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 -179.717 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.6 mt -92.18 -43.2 9.47 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 123.203 1.477 . . . . 0.0 110.421 -178.348 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.91 144.45 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.312 0 CA-C-N 113.459 -1.7 . . . . 0.0 109.929 -179.657 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.611 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.1 p-10 -50.79 107.56 0.18 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.521 0.677 . . . . 0.0 111.458 -178.583 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.32 13.5 9.77 Favored Glycine 0 N--CA 1.485 1.938 0 C-N-CA 119.435 -1.364 . . . . 0.0 112.935 177.342 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.6 t -104.45 -172.61 2.13 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 121.213 2.507 . . . . 0.0 109.734 179.261 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.748 HG13 ' C ' ' A' ' 67' ' ' LEU . 15.9 t -129.37 138.3 54.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.371 0 CA-C-N 114.761 -1.109 . . . . 0.0 111.019 -179.014 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.556 HG23 ' CD1' ' A' ' 67' ' ' LEU . 27.8 m -113.67 154.62 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.922 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.504 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -108.55 109.38 20.6 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.208 -0.932 . . . . 0.0 108.996 179.936 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.911 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.49 140.89 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.789 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.954 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -136.35 160.54 38.42 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 118.659 -1.216 . . . . 0.0 109.89 179.734 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.589 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.18 143.81 15.46 Favored Glycine 0 C--N 1.293 -1.814 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 179.716 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.26 124.96 12.55 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 120.908 -1.348 . . . . 0.0 108.882 179.185 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.86 27.58 23.59 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 119.339 -1.41 . . . . 0.0 109.659 -179.68 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.7 mt -86.72 175.53 8.21 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 120.909 -1.348 . . . . 0.0 108.62 -179.781 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.54 97.12 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.047 -1.033 . . . . 0.0 109.58 -179.821 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.585 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 76.19 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.495 -178.978 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.21 33.27 0.28 Allowed Glycine 0 N--CA 1.486 1.985 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.26 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.61 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.4 t -148.13 115.32 6.18 Favored 'General case' 0 C--N 1.308 -1.214 0 O-C-N 120.831 -1.394 . . . . 0.0 111.276 179.973 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.3 127.84 5.88 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.781 178.367 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.61 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.8 m-85 -119.09 149.03 42.38 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.51 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.5 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.62 163.86 12.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.61 -1.307 . . . . 0.0 107.518 178.631 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.707 HG11 HG21 ' A' ' 65' ' ' THR . 9.2 p -149.08 114.62 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.045 -1.035 . . . . 0.0 110.143 -177.74 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.14 -175.41 37.16 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 118.365 -1.874 . . . . 0.0 111.731 -179.865 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.581 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.34 109.01 21.19 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-O 121.829 0.823 . . . . 0.0 108.819 -179.695 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.47 149.04 52.33 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.231 -0.918 . . . . 0.0 109.6 179.751 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.448 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.48 139.24 54.07 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.301 -0.875 . . . . 0.0 110.732 -179.041 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 114.78 26.6 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.174 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.4 m -105.53 15.29 6.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.999 -1.063 . . . . 0.0 110.573 -178.639 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.757 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.09 -175.42 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.955 -1.091 . . . . 0.0 110.003 179.734 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 56.8 p -71.95 97.45 1.86 Allowed 'General case' 0 N--CA 1.485 1.305 0 O-C-N 121.364 -0.835 . . . . 0.0 109.748 -179.73 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.65 27.71 34.5 Favored Glycine 0 N--CA 1.492 2.404 0 C-N-CA 120.235 -0.983 . . . . 0.0 111.423 178.985 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.757 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.05 106.24 19.98 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 O-C-N 120.59 -1.536 . . . . 0.0 107.29 178.829 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -116.71 104.55 11.47 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.478 -1.388 . . . . 0.0 109.81 -177.715 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.088 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.2 109.45 22.21 Favored 'General case' 0 N--CA 1.485 1.276 0 O-C-N 120.834 -1.166 . . . . 0.0 107.945 178.828 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -107.4 163.9 12.65 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.964 -1.085 . . . . 0.0 110.297 -178.73 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.754 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 38.8 t30 -108.56 128.77 24.98 Favored Pre-proline 0 N--CA 1.501 2.111 0 O-C-N 121.46 -0.775 . . . . 0.0 109.503 -179.386 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -70.14 19.76 0.19 Allowed 'Trans proline' 0 CA--C 1.544 1.017 0 C-N-CA 122.088 1.859 . . . . 0.0 112.386 -179.867 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.754 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -108.96 4.85 23.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.388 -1.445 . . . . 0.0 108.868 179.157 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.578 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.79 16.7 2.68 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 179.497 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -81.67 90.58 6.33 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.974 -0.691 . . . . 0.0 111.088 -178.446 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.39 -171.08 1.77 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 178.015 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.446 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.85 134.99 0.09 Allowed 'General case' 0 C--N 1.305 -1.356 0 O-C-N 120.403 -1.435 . . . . 0.0 111.554 -179.357 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.777 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.5 p -150.07 159.11 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 177.894 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.57 146.05 25.66 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.543 -1.348 . . . . 0.0 109.726 -179.724 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.24 108.71 3.28 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 122.31 1.052 . . . . 0.0 109.629 178.999 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.547 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.5 t0 -63.02 -138.65 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.526 179.858 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.585 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -53.7 -51.45 63.2 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.289 -0.882 . . . . 0.0 110.21 -178.931 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.8 p-10 -98.58 -37.08 9.68 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 178.563 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.987 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.06 65.62 0.64 Allowed Glycine 0 C--N 1.297 -1.588 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.412 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 53.7 p -98.49 132.62 43.77 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 121.426 -1.043 . . . . 0.0 109.245 179.28 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.777 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.02 108.53 6.55 Favored 'General case' 0 C--N 1.296 -1.754 0 C-N-CA 119.235 -0.986 . . . . 0.0 109.52 -179.708 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.432 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 21.8 p -124.82 120.75 32.61 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.147 -0.97 . . . . 0.0 109.797 -179.803 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.707 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -148.04 146.72 28.99 Favored 'General case' 0 C--N 1.3 -1.587 0 O-C-N 121.581 -0.7 . . . . 0.0 109.304 179.648 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.4 p -100.61 138.88 37.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.322 -0.861 . . . . 0.0 109.404 179.975 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.748 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -138.03 165.54 26.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.404 -0.81 . . . . 0.0 109.529 -179.405 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.724 HG22 HG22 ' A' ' 18' ' ' VAL . 2.2 p -96.8 125.7 41.44 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.068 -1.02 . . . . 0.0 109.354 -179.857 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.572 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -136.8 144.42 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.99 -1.069 . . . . 0.0 109.888 -179.26 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.611 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.0 OUTLIER -149.0 -174.93 4.77 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 120.455 -1.403 . . . . 0.0 110.998 -179.845 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.61 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.94 -101.84 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 -179.766 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.05 140.46 49.06 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.815 -1.178 . . . . 0.0 108.052 179.43 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.58 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -161.79 137.13 7.45 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 118.642 -1.223 . . . . 0.0 109.759 -178.118 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.522 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 10.3 mm-40 -34.97 122.06 0.55 Allowed 'General case' 0 N--CA 1.49 1.546 0 CA-C-O 121.387 0.613 . . . . 0.0 110.351 -178.468 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.088 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.29 51.25 1.86 Allowed Glycine 0 N--CA 1.493 2.458 0 C-N-CA 120.548 -0.835 . . . . 0.0 111.06 -179.268 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -39.24 115.39 0.49 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.04 -1.271 . . . . 0.0 110.108 179.572 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.691 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.49 126.46 34.45 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 120.928 -1.108 . . . . 0.0 109.495 -179.895 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.8 t80 -64.38 58.46 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.989 0 O-C-N 120.876 -1.14 . . . . 0.0 110.091 179.685 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' LEU . 17.0 t0 -160.19 19.65 0.15 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.987 -1.07 . . . . 0.0 109.664 179.83 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.05 -28.03 5.26 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.999 -1.241 . . . . 0.0 109.999 179.931 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.414 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 10.3 p -94.27 161.0 14.43 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.034 -1.274 . . . . 0.0 110.384 -179.446 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.48 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -107.97 138.13 44.77 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.84 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.691 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -83.61 -17.96 39.82 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.71 -1.244 . . . . 0.0 110.674 -178.411 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.0 176.43 19.99 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 108.644 -1.783 . . . . 0.0 108.644 -179.648 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.53 104.45 1.01 Allowed 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.188 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 46' ' ' ALA . 41.0 t -76.09 106.62 6.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.287 -0.883 . . . . 0.0 109.133 -178.926 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.546 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -65.68 111.24 3.1 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.493 -0.755 . . . . 0.0 110.026 -179.352 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.61 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.47 -5.71 4.07 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.813 179.353 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.5 p -86.58 -0.93 57.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.747 -1.221 . . . . 0.0 109.202 179.681 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.546 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -112.87 -50.1 2.9 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.29 -0.881 . . . . 0.0 108.995 179.977 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.94 -179.04 3.83 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.488 -0.757 . . . . 0.0 109.42 179.782 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.06 115.75 30.8 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.386 -0.821 . . . . 0.0 108.905 179.992 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.531 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -96.87 121.43 38.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.851 -1.156 . . . . 0.0 109.483 -179.455 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.619 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.85 146.29 28.5 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.437 1.113 . . . . 0.0 111.215 -179.32 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.3 t -102.46 109.77 27.35 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 177.632 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.439 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.6 -173.11 18.38 Favored Glycine 0 N--CA 1.486 2.016 0 C-N-CA 118.142 -1.98 . . . . 0.0 111.709 -177.601 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.5 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -113.71 -178.95 3.5 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.069 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.465 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.0 OUTLIER . . . . . 0 C--N 1.297 -1.711 0 O-C-N 121.219 -0.926 . . . . 0.0 109.711 -179.203 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.696 0 N-CA-C 107.776 -2.13 . . . . 0.0 107.776 . . . . . . . . . 0 0 . 1 . 036 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.61 -177.72 5.76 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-O 122.007 0.908 . . . . 0.0 109.785 179.279 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.38 -161.85 15.27 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 -179.44 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.504 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.3 Cg_exo -47.08 177.98 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.693 0 CA-C-N 118.874 1.337 . . . . 0.0 110.202 179.324 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -92.27 -175.17 3.96 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.06 -1.025 . . . . 0.0 110.511 -178.83 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.439 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.24 163.46 14.68 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.944 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.9 128.92 52.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.426 -1.044 . . . . 0.0 109.222 -179.441 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.619 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.22 123.22 23.26 Favored 'General case' 0 C--N 1.29 -2.015 0 O-C-N 121.687 -0.633 . . . . 0.0 109.562 179.672 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.917 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.72 167.69 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 O-C-N 121.221 -0.924 . . . . 0.0 109.193 -179.925 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.507 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -134.73 154.26 51.65 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.277 -0.889 . . . . 0.0 109.565 -179.873 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.917 ' CE1' HD12 ' A' ' 110' ' ' ILE . 30.3 m-85 . . . . . 0 N--CA 1.487 1.382 0 O-C-N 121.15 -0.969 . . . . 0.0 109.566 -179.729 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.593 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.456 0 CA-C-O 122.364 1.078 . . . . 0.0 110.863 . . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.949 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.6 t -112.46 108.58 17.76 Favored 'General case' 0 C--N 1.296 -1.738 0 CA-C-O 123.084 1.421 . . . . 0.0 109.117 179.357 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.79 HG22 HG23 ' A' ' 21' ' ' VAL . 2.4 t -115.31 140.38 36.99 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.699 0 CA-C-N 114.275 -1.329 . . . . 0.0 110.102 -179.521 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.496 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -176.04 149.82 1.03 Allowed Pre-proline 0 N--CA 1.487 1.375 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.772 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.496 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.2 Cg_endo -77.43 152.57 93.88 Favored 'Cis proline' 0 C--N 1.312 -1.353 0 C-N-CA 123.572 -1.428 . . . . 0.0 109.313 -0.813 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.639 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.5 m -89.76 -26.51 20.58 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 179.761 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.48 ' HB3' ' HB2' ' A' ' 111' ' ' SER . 5.3 m -135.23 164.31 27.99 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.587 -0.696 . . . . 0.0 109.609 179.858 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.3 37.03 29.14 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 108.767 -1.733 . . . . 0.0 108.767 -179.841 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.766 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.6 mt -93.23 -42.69 9.21 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-O 123.242 1.496 . . . . 0.0 110.405 -178.406 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.83 145.3 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.277 0 CA-C-N 113.322 -1.763 . . . . 0.0 109.954 -179.735 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.613 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.2 p-10 -51.26 106.81 0.15 Allowed 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.493 0.663 . . . . 0.0 111.513 -178.749 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.54 13.16 9.01 Favored Glycine 0 N--CA 1.483 1.823 0 C-N-CA 119.401 -1.38 . . . . 0.0 112.986 177.317 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.766 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -105.31 -172.4 2.09 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 121.242 2.521 . . . . 0.0 109.673 179.167 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.738 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.2 t -126.6 135.56 63.39 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 114.866 -1.061 . . . . 0.0 111.097 -178.897 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.66 ' CG1' HD13 ' A' ' 13' ' ' LEU . 17.3 m -109.04 156.82 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.664 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -114.06 109.27 18.18 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.091 -1.005 . . . . 0.0 109.16 179.949 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.79 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -104.07 140.01 23.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 179.749 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.949 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.77 160.4 38.29 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 118.605 -1.238 . . . . 0.0 109.85 179.856 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -131.4 144.96 16.6 Favored Glycine 0 C--N 1.293 -1.807 0 N-CA-C 108.179 -1.968 . . . . 0.0 108.179 179.751 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.88 124.53 11.79 Favored 'General case' 0 C--N 1.295 -1.792 0 O-C-N 120.901 -1.352 . . . . 0.0 108.785 179.182 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.99 26.7 23.47 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.337 -1.411 . . . . 0.0 109.631 -179.623 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.603 HD22 ' HG3' ' A' ' 105' ' ' PRO . 1.9 mt -87.43 174.57 8.44 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 120.897 -1.355 . . . . 0.0 108.445 -179.901 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.42 96.96 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.04 -1.037 . . . . 0.0 109.674 -179.714 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.659 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 76.83 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.45 -179.091 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.01 33.77 0.32 Allowed Glycine 0 N--CA 1.486 2.027 0 N-CA-C 109.731 -1.347 . . . . 0.0 109.731 179.347 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.554 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 1.2 t -148.15 114.88 6.03 Favored 'General case' 0 C--N 1.309 -1.181 0 O-C-N 120.869 -1.371 . . . . 0.0 111.098 179.899 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.45 129.86 3.93 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.996 178.55 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.499 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 10.7 m-85 -119.47 150.84 39.55 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.368 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.506 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -102.05 159.39 15.41 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.703 -1.248 . . . . 0.0 107.856 178.728 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.645 HG22 HG11 ' A' ' 21' ' ' VAL . 5.1 p -144.03 117.27 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.075 -1.016 . . . . 0.0 109.852 -177.914 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.12 -178.73 40.18 Favored Glycine 0 N--CA 1.494 2.518 0 C-N-CA 118.324 -1.893 . . . . 0.0 111.849 -179.86 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.592 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -100.43 108.88 20.98 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -179.862 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.24 148.34 52.06 Favored 'General case' 0 C--N 1.296 -1.731 0 O-C-N 121.286 -0.884 . . . . 0.0 109.704 179.777 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.512 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.96 138.63 54.34 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.274 -0.891 . . . . 0.0 110.776 -179.005 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.867 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.45 114.75 26.55 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 178.137 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -106.12 14.79 7.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.934 -1.104 . . . . 0.0 110.64 -178.716 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.61 -175.65 0.08 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.926 -1.109 . . . . 0.0 110.101 179.694 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.775 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.3 97.53 1.26 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 121.799 0.809 . . . . 0.0 110.031 -179.605 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.26 27.11 37.64 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 120.261 -0.971 . . . . 0.0 111.429 178.785 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -114.85 106.14 20.03 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 O-C-N 120.617 -1.519 . . . . 0.0 107.375 178.818 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.867 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -117.01 104.71 11.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.459 -1.401 . . . . 0.0 109.629 -177.803 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.058 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.94 109.55 22.28 Favored 'General case' 0 N--CA 1.485 1.316 0 O-C-N 120.808 -1.183 . . . . 0.0 108.415 179.093 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.6 t -105.98 162.83 13.25 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.952 -1.092 . . . . 0.0 110.115 -179.254 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.548 HD22 ' HB3' ' A' ' 50' ' ' ALA . 17.0 t30 -107.01 140.89 21.84 Favored Pre-proline 0 N--CA 1.504 2.259 0 O-C-N 121.348 -0.845 . . . . 0.0 110.13 -179.218 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.573 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 8.2 Cg_endo -76.36 27.65 0.41 Allowed 'Trans proline' 0 C--N 1.318 -1.029 0 C-N-CA 122.662 2.241 . . . . 0.0 111.636 -179.665 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.548 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -121.49 3.57 10.21 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.394 -1.441 . . . . 0.0 109.522 -179.869 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.523 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -138.48 15.41 2.75 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 179.435 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -80.11 91.68 5.55 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.508 -0.745 . . . . 0.0 110.815 -178.675 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.59 -168.53 1.33 Allowed 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.387 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.98 135.2 0.09 Allowed 'General case' 0 N--CA 1.486 1.349 0 O-C-N 120.633 -1.292 . . . . 0.0 111.486 -179.381 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.872 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -149.02 157.53 6.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 177.935 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.567 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.28 146.61 24.96 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.636 -1.29 . . . . 0.0 109.897 -179.489 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.26 108.31 2.68 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-O 122.361 1.077 . . . . 0.0 109.622 178.847 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.533 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.6 t0 -62.95 -138.94 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.005 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.822 -179.867 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.659 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.9 -51.99 36.42 Favored 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.349 -0.845 . . . . 0.0 110.676 -178.657 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.06 -32.36 9.24 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.714 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.0 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.07 64.89 0.61 Allowed Glycine 0 C--N 1.298 -1.583 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 178.262 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.5 m -99.57 129.31 45.72 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.465 -1.021 . . . . 0.0 108.664 178.772 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.872 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.74 108.63 6.69 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.805 -179.329 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 51.8 p -122.15 119.45 31.32 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.259 -0.901 . . . . 0.0 109.455 179.936 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.571 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.22 143.46 30.29 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.519 -0.738 . . . . 0.0 109.417 179.894 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 15.9 p -100.01 140.63 33.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.406 -0.809 . . . . 0.0 109.406 179.961 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.789 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.37 168.82 18.97 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.405 -0.809 . . . . 0.0 109.382 -179.426 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.716 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -96.82 124.86 40.92 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.03 -1.044 . . . . 0.0 109.424 -179.823 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.598 ' CG2' HG13 ' A' ' 19' ' ' VAL . 15.9 m -137.05 143.54 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.932 -1.105 . . . . 0.0 109.728 -179.259 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.613 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.1 ptt180 -148.79 -175.34 4.91 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.519 -1.363 . . . . 0.0 110.9 -179.835 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.612 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.76 -101.2 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.7 -179.413 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.507 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.86 142.03 42.61 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.812 -1.18 . . . . 0.0 108.319 179.785 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.582 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.93 134.59 4.38 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 118.783 -1.167 . . . . 0.0 109.64 -178.209 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.554 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -33.81 122.82 0.46 Allowed 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.519 0.676 . . . . 0.0 110.465 -178.138 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.058 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.2 49.15 2.7 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.273 -179.187 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.573 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -38.47 115.0 0.42 Allowed 'General case' 0 N--CA 1.509 2.519 0 O-C-N 121.096 -1.237 . . . . 0.0 109.909 179.615 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.726 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -86.72 126.42 34.55 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.938 -1.101 . . . . 0.0 109.357 179.972 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 24.5 t80 -63.48 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.902 -1.124 . . . . 0.0 110.307 179.912 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.548 ' N ' ' O ' ' A' ' 77' ' ' LEU . 22.2 t0 -162.04 20.18 0.1 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.992 -1.068 . . . . 0.0 109.786 179.736 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.65 -27.76 5.17 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 179.821 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.445 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 14.3 p -93.15 160.23 14.94 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.047 -1.267 . . . . 0.0 110.26 -179.466 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.479 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.4 OUTLIER -107.63 136.69 46.96 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.835 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.726 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -82.56 -19.1 39.19 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.848 -1.158 . . . . 0.0 110.407 -178.667 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.54 175.41 19.14 Favored Glycine 0 N--CA 1.485 1.908 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.613 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.84 107.14 1.37 Allowed 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.271 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.622 HG21 ' HB3' ' A' ' 46' ' ' ALA . 47.2 t -79.62 106.71 11.11 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.362 -0.836 . . . . 0.0 109.262 -179.014 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.54 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -67.69 111.67 4.37 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.407 -0.808 . . . . 0.0 109.805 -179.554 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.612 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.16 -5.69 3.49 Favored 'General case' 0 N--CA 1.5 2.046 0 C-N-CA 118.189 -1.404 . . . . 0.0 109.826 179.414 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.14 0.02 54.58 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.644 -1.285 . . . . 0.0 109.158 179.51 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.54 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.66 -49.72 2.87 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.366 -0.834 . . . . 0.0 109.007 -179.98 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.77 179.63 4.21 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.433 -0.792 . . . . 0.0 109.482 179.944 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.94 116.13 31.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.445 -0.785 . . . . 0.0 108.922 179.908 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.85 121.8 39.11 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.86 -1.15 . . . . 0.0 109.371 -179.381 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.6 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.68 146.51 27.63 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.411 1.101 . . . . 0.0 111.359 -179.213 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 65.7 t -102.95 110.06 28.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 177.502 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.76 -173.01 17.61 Favored Glycine 0 N--CA 1.487 2.063 0 C-N-CA 118.041 -2.028 . . . . 0.0 111.828 -177.441 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.593 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -115.98 -178.11 3.32 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 -179.057 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.505 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER . . . . . 0 C--N 1.297 -1.68 0 O-C-N 121.234 -0.916 . . . . 0.0 109.331 -179.527 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.695 0 N-CA-C 107.687 -2.165 . . . . 0.0 107.687 . . . . . . . . . 0 0 . 1 . 037 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.43 -178.49 7.18 Favored 'General case' 0 C--N 1.307 -1.245 0 O-C-N 121.527 -0.984 . . . . 0.0 109.431 179.05 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.64 -166.18 33.36 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -179.554 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.603 ' HG3' HD22 ' A' ' 26' ' ' LEU . 4.3 Cg_exo -49.09 -177.37 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.677 0 CA-C-N 118.7 1.25 . . . . 0.0 110.288 179.525 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -94.54 -176.85 4.04 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.082 -1.011 . . . . 0.0 110.419 -179.02 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -120.45 161.3 14.73 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.969 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.409 ' O ' HG12 ' A' ' 108' ' ' VAL . 1.2 t -100.87 126.37 54.59 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.349 -1.089 . . . . 0.0 109.188 -179.472 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.6 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.1 119.76 16.75 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.745 -0.597 . . . . 0.0 109.431 179.669 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.766 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.96 168.53 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.201 -0.937 . . . . 0.0 109.303 -179.956 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB2' ' HB3' ' A' ' 11' ' ' SER . 2.4 m -138.2 151.31 47.57 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.384 -0.823 . . . . 0.0 109.542 -179.955 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.766 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 22.8 m-85 . . . . . 0 N--CA 1.487 1.382 0 O-C-N 121.146 -0.971 . . . . 0.0 109.531 -179.674 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.484 1.251 0 CA-C-O 122.43 1.109 . . . . 0.0 110.129 . . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.903 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.1 t -116.28 109.02 16.83 Favored 'General case' 0 C--N 1.293 -1.858 0 CA-C-O 123.129 1.442 . . . . 0.0 109.622 179.968 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.948 HG22 HG23 ' A' ' 21' ' ' VAL . 8.0 t -116.92 137.84 49.51 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.709 0 CA-C-N 114.074 -1.421 . . . . 0.0 109.862 -179.874 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.49 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -174.37 151.02 1.57 Allowed Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.331 -0.856 . . . . 0.0 108.804 -179.617 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.49 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.3 Cg_endo -77.47 150.94 91.85 Favored 'Cis proline' 0 C--N 1.312 -1.383 0 C-N-CA 123.539 -1.442 . . . . 0.0 109.392 -0.907 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.677 ' HA ' HG22 ' A' ' 110' ' ' ILE . 89.6 p -92.52 -23.08 19.21 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 121.433 -0.792 . . . . 0.0 109.27 179.692 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.499 ' CB ' ' HB3' ' A' ' 111' ' ' SER . 7.0 m -132.16 159.97 37.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.484 -0.76 . . . . 0.0 109.542 -179.859 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.73 37.61 29.76 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.633 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.773 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.4 mt -91.1 -43.69 9.74 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-O 123.146 1.45 . . . . 0.0 110.641 -178.273 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.35 144.88 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.298 0 CA-C-N 113.471 -1.695 . . . . 0.0 110.224 -179.72 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.594 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.0 p-10 -50.2 106.11 0.11 Allowed 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.494 0.664 . . . . 0.0 111.626 -178.548 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.81 15.0 8.92 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 119.426 -1.368 . . . . 0.0 113.037 177.05 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.773 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -105.8 -174.02 2.44 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 121.29 2.545 . . . . 0.0 109.837 179.227 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.733 HG13 ' O ' ' A' ' 67' ' ' LEU . 15.7 t -130.71 138.56 53.35 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 CA-C-N 114.702 -1.135 . . . . 0.0 111.178 -178.721 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.568 HG12 HD21 ' A' ' 13' ' ' LEU . 33.8 m -113.06 155.16 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 178.75 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -103.96 108.82 20.33 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.021 -1.05 . . . . 0.0 109.167 179.971 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.948 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.51 140.06 21.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.893 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.903 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -133.76 159.18 41.37 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.866 -1.146 . . . . 0.0 109.638 179.484 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.581 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -141.08 108.8 0.57 Allowed Glycine 0 N--CA 1.482 1.76 0 N-CA-C 108.753 -1.739 . . . . 0.0 108.753 179.97 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.426 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.28 140.35 49.42 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 119.259 1.529 . . . . 0.0 110.426 -179.461 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.48 26.9 34.32 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 118.945 -1.598 . . . . 0.0 109.946 179.57 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.583 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -93.0 169.88 10.09 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 120.933 -1.333 . . . . 0.0 108.534 -179.946 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.58 101.32 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.117 -0.989 . . . . 0.0 109.777 -179.426 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.92 77.88 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.864 -179.327 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.89 33.83 0.28 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.77 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.55 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 18.8 p -138.79 106.35 5.58 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.279 -1.13 . . . . 0.0 110.93 -179.465 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.583 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.39 109.91 0.39 Allowed 'General case' 0 N--CA 1.497 1.903 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.532 178.181 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.483 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 32.6 m-85 -102.81 155.8 18.08 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.147 -0.971 . . . . 0.0 108.901 179.74 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.407 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.46 158.42 15.92 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 178.696 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.63 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.3 p -139.83 120.07 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.189 -0.944 . . . . 0.0 109.472 -177.818 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -169.89 -178.34 40.86 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.23 -1.938 . . . . 0.0 111.796 -179.742 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.729 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.21 109.78 22.03 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.918 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 68.1 m -127.16 152.77 46.9 Favored 'General case' 0 C--N 1.293 -1.86 0 O-C-N 121.22 -0.925 . . . . 0.0 109.819 179.619 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.654 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -126.87 135.66 51.27 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.535 -0.728 . . . . 0.0 110.452 179.965 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.902 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.94 114.69 26.55 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.231 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 20.1 m -104.97 14.42 7.21 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 120.851 -1.155 . . . . 0.0 110.809 -178.65 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.785 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 173.73 -174.5 0.06 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.81 -1.181 . . . . 0.0 110.158 179.65 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 24.5 p -71.69 97.67 1.79 Allowed 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.467 -0.77 . . . . 0.0 109.827 -179.67 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.85 27.63 31.22 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 120.285 -0.959 . . . . 0.0 111.487 178.836 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.785 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.3 t -116.35 106.09 19.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 O-C-N 120.538 -1.566 . . . . 0.0 107.372 179.001 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.902 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.7 tp -116.85 106.37 13.38 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.548 -1.345 . . . . 0.0 109.989 -177.703 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.105 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -95.72 109.78 22.02 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.803 -1.185 . . . . 0.0 108.161 179.137 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.4 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 66.5 m -100.12 145.88 27.47 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.225 -0.922 . . . . 0.0 110.415 -178.354 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.502 ' HB3' ' HG2' ' A' ' 36' ' ' GLN . 7.4 t30 -99.23 129.23 29.8 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.217 -0.927 . . . . 0.0 108.673 179.097 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.4 Cg_endo -71.41 23.05 0.23 Allowed 'Trans proline' 0 C--N 1.317 -1.108 0 C-N-CA 122.102 1.868 . . . . 0.0 111.968 179.923 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.494 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -103.35 -5.86 22.54 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.4 -1.437 . . . . 0.0 109.106 179.68 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.696 ' OD2' HG13 ' A' ' 69' ' ' VAL . 5.6 m-20 -134.13 6.39 3.62 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.351 -0.843 . . . . 0.0 108.89 -179.961 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -62.42 84.18 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.336 -0.852 . . . . 0.0 110.655 -178.672 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.63 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.5 -167.87 1.32 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 178.605 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.47 135.73 0.08 Allowed 'General case' 0 C--N 1.304 -1.404 0 O-C-N 120.68 -1.262 . . . . 0.0 111.383 -179.321 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.925 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -150.83 156.13 6.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 177.94 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.583 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.69 142.0 30.8 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.721 -1.237 . . . . 0.0 110.162 -179.525 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.011 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.26 106.4 0.73 Allowed 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 122.559 1.171 . . . . 0.0 109.45 178.316 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.2 p-10 -59.7 -139.51 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.862 179.962 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.75 -50.87 59.78 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.454 -0.778 . . . . 0.0 110.715 -178.711 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -102.94 -33.79 9.18 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 178.462 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.43 65.9 0.61 Allowed Glycine 0 C--N 1.298 -1.548 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.575 177.941 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.581 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 23.2 m -102.81 126.49 49.97 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 178.631 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.925 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.24 109.17 8.68 Favored 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 119.457 -0.897 . . . . 0.0 109.296 -179.29 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.407 ' HB3' ' HE3' ' A' ' 20' ' ' LYS . 1.4 m -123.35 119.42 30.04 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.412 -0.805 . . . . 0.0 109.646 -179.73 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.55 150.31 36.17 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.698 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.2 p -98.04 136.7 37.92 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.196 -0.94 . . . . 0.0 109.484 -179.785 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.912 HD11 HG11 ' A' ' 21' ' ' VAL . 0.2 OUTLIER -128.99 160.65 32.06 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.442 -0.786 . . . . 0.0 109.485 -178.913 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.665 HG22 HG22 ' A' ' 18' ' ' VAL . 1.3 p -100.95 123.23 44.82 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.03 -1.044 . . . . 0.0 108.861 179.525 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.729 HG12 ' HB3' ' A' ' 36' ' ' GLN . 17.6 m -135.25 142.81 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 120.872 -1.143 . . . . 0.0 110.486 -178.579 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.594 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.4 ptt180 -145.5 -171.81 3.75 Favored 'General case' 0 N--CA 1.484 1.263 0 O-C-N 120.582 -1.324 . . . . 0.0 110.825 179.55 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.588 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -57.34 -99.67 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.197 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.513 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.79 142.23 50.8 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 120.343 -1.473 . . . . 0.0 108.218 179.517 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.654 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.4 OUTLIER -162.07 135.09 6.05 Favored 'General case' 0 C--N 1.295 -1.771 0 C-N-CA 118.581 -1.248 . . . . 0.0 110.027 -178.05 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.544 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 20.5 mt-10 -35.22 120.99 0.55 Allowed 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.458 0.647 . . . . 0.0 110.231 -178.723 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.105 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.74 51.22 2.01 Favored Glycine 0 N--CA 1.494 2.55 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.665 -178.793 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -38.32 115.88 0.48 Allowed 'General case' 0 N--CA 1.507 2.396 0 O-C-N 121.04 -1.271 . . . . 0.0 110.012 179.26 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.767 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -86.78 126.06 34.35 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 120.816 -1.177 . . . . 0.0 109.594 -179.623 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 30.9 t80 -64.34 58.93 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.842 -1.161 . . . . 0.0 109.837 179.519 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.6 t70 -159.68 19.76 0.17 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.984 -1.072 . . . . 0.0 109.715 179.936 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.6 -27.91 5.59 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.811 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.467 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 73.1 p -98.49 162.6 13.07 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.142 -1.21 . . . . 0.0 110.39 -179.439 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.486 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 2.1 ptt180 -106.54 142.13 36.7 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.859 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.767 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.6 t90 -85.19 -19.77 31.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.635 -1.291 . . . . 0.0 110.601 -178.505 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.1 177.12 18.77 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.631 -1.788 . . . . 0.0 108.631 -179.424 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -66.4 105.33 1.43 Allowed 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 179.198 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.591 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 44.3 t -76.13 104.83 4.52 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.24 -0.913 . . . . 0.0 109.048 -179.058 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.529 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.05 111.17 3.24 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.46 -0.775 . . . . 0.0 109.686 -179.508 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.588 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.77 -4.85 4.76 Favored 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 118.245 -1.382 . . . . 0.0 109.71 179.51 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -86.83 1.81 51.15 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.782 -1.199 . . . . 0.0 109.017 179.341 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.529 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -117.01 -51.14 2.56 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.376 -0.828 . . . . 0.0 108.951 179.975 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.31 -179.92 4.09 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.479 -0.763 . . . . 0.0 109.383 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.25 115.7 30.85 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.446 -0.784 . . . . 0.0 108.935 179.807 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.527 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.03 124.53 41.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.84 -1.162 . . . . 0.0 109.582 -179.264 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.57 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -102.97 147.73 26.57 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.344 1.069 . . . . 0.0 111.405 -179.241 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.496 ' CG1' HG11 ' A' ' 7' ' ' VAL . 44.8 t -104.6 113.12 40.78 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 177.498 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.509 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -155.08 -169.77 19.99 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 117.886 -2.102 . . . . 0.0 111.802 -177.766 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.46 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -120.56 177.59 5.0 Favored 'General case' 0 N--CA 1.484 1.245 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -179.138 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 2.1 t . . . . . 0 C--N 1.294 -1.833 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.907 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.654 0 N-CA-C 107.96 -2.056 . . . . 0.0 107.96 . . . . . . . . . 0 0 . 1 . 038 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.53 -177.65 6.08 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-O 122.1 0.952 . . . . 0.0 109.839 179.263 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.496 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.31 -161.34 21.77 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.176 -1.97 . . . . 0.0 108.176 -179.361 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.501 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.3 Cg_exo -47.73 -178.77 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.671 0 CA-C-N 118.96 1.38 . . . . 0.0 110.313 179.206 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -96.69 178.04 5.45 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.979 -1.075 . . . . 0.0 110.364 -178.958 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.509 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.7 172.64 14.32 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.983 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -110.87 153.55 12.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.495 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.57 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -95.75 122.45 38.55 Favored 'General case' 0 C--N 1.291 -1.959 0 O-C-N 121.217 -0.927 . . . . 0.0 109.392 179.79 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.852 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.99 168.98 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 121.091 -1.005 . . . . 0.0 109.032 -179.905 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.499 ' HB3' ' CB ' ' A' ' 11' ' ' SER . 13.0 t -138.92 157.9 45.18 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.175 -0.953 . . . . 0.0 109.68 -179.91 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.852 ' CE2' HD12 ' A' ' 110' ' ' ILE . 82.0 m-85 . . . . . 0 N--CA 1.485 1.32 0 O-C-N 121.23 -0.919 . . . . 0.0 109.488 -179.706 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.505 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.484 1.245 0 CA-C-O 122.366 1.079 . . . . 0.0 110.28 . . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.861 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.6 t -115.9 109.16 17.22 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 123.122 1.439 . . . . 0.0 109.829 -179.827 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.817 HG22 HG23 ' A' ' 21' ' ' VAL . 2.2 t -114.78 133.7 60.1 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.19 -1.368 . . . . 0.0 109.787 179.855 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.513 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -169.26 150.17 4.15 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.232 -0.917 . . . . 0.0 108.809 -179.604 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.513 ' HA ' HG23 ' A' ' 8' ' ' THR . 1.2 Cg_endo -75.33 155.31 99.56 Favored 'Cis proline' 0 C--N 1.312 -1.35 0 C-N-CA 123.521 -1.45 . . . . 0.0 109.399 -0.873 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.5 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 15.4 m -99.62 -19.83 16.63 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.754 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.502 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 19.2 m -136.02 159.07 42.84 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.426 -0.796 . . . . 0.0 109.678 -179.945 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.37 37.78 30.67 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 108.526 -1.829 . . . . 0.0 108.526 -179.688 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.794 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.1 mt -89.75 -44.31 10.08 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 123.056 1.407 . . . . 0.0 110.599 -178.383 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.462 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.0 144.39 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.363 0 CA-C-N 113.633 -1.622 . . . . 0.0 109.935 -179.638 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.605 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.1 p-10 -50.86 105.0 0.09 Allowed 'General case' 0 C--N 1.301 -1.504 0 CA-C-O 121.632 0.729 . . . . 0.0 111.435 -178.565 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.04 14.77 7.61 Favored Glycine 0 N--CA 1.485 1.902 0 C-N-CA 119.396 -1.383 . . . . 0.0 113.055 177.383 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.794 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.7 t -104.48 -173.55 2.33 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 121.264 2.532 . . . . 0.0 109.717 179.116 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.748 HG13 ' O ' ' A' ' 67' ' ' LEU . 18.1 t -127.65 135.99 61.64 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.89 -1.05 . . . . 0.0 111.424 -178.598 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.594 HG23 ' CD1' ' A' ' 67' ' ' LEU . 34.7 m -111.2 154.6 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.529 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 5.4 tttt -110.31 109.28 19.66 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 108.894 179.875 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.817 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.27 139.17 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.347 -0.846 . . . . 0.0 108.734 -179.929 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.861 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.0 162.38 32.22 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 118.819 -1.153 . . . . 0.0 110.107 179.656 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.603 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.71 140.35 11.39 Favored Glycine 0 C--N 1.299 -1.525 0 N-CA-C 107.899 -2.08 . . . . 0.0 107.899 179.694 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.94 124.96 15.24 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.514 -1.58 . . . . 0.0 109.409 179.299 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.55 28.62 18.81 Favored Glycine 0 N--CA 1.488 2.107 0 C-N-CA 118.776 -1.678 . . . . 0.0 109.678 -179.705 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.54 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -89.79 171.86 9.32 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.006 -1.291 . . . . 0.0 108.249 179.875 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.008 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.92 99.6 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.969 -1.082 . . . . 0.0 109.926 -179.498 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.5 77.05 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.136 -179.333 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.91 33.83 0.22 Allowed Glycine 0 N--CA 1.486 2.022 0 N-CA-C 109.311 -1.515 . . . . 0.0 109.311 179.634 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 40.4 p -141.38 107.32 5.16 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 121.09 -1.241 . . . . 0.0 111.399 -179.35 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.599 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.83 109.79 0.36 Allowed 'General case' 0 N--CA 1.496 1.835 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.621 177.828 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.494 ' HA ' ' O ' ' A' ' 98' ' ' SER . 4.4 m-30 -105.42 157.54 17.27 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.119 -0.988 . . . . 0.0 108.798 179.745 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.49 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -100.45 167.52 10.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.762 -1.211 . . . . 0.0 108.048 179.209 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.704 HG22 HG11 ' A' ' 21' ' ' VAL . 2.7 p -148.13 119.59 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.132 -0.98 . . . . 0.0 109.648 -178.094 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -171.26 -176.74 40.59 Favored Glycine 0 N--CA 1.496 2.638 0 C-N-CA 118.369 -1.872 . . . . 0.0 111.5 -179.763 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.685 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.71 108.3 20.13 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 -179.979 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -130.01 148.32 51.85 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.306 -0.872 . . . . 0.0 109.833 179.685 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.25 139.84 53.53 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.227 -0.921 . . . . 0.0 110.739 -179.024 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.88 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.12 114.93 26.78 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.119 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.7 m -106.21 15.49 7.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.035 -1.041 . . . . 0.0 110.526 -178.724 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.77 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.7 -176.66 0.09 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.948 -1.095 . . . . 0.0 110.068 179.739 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.794 HG23 ' O ' ' A' ' 42' ' ' THR . 15.2 t -69.78 96.72 1.01 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.503 -0.748 . . . . 0.0 110.009 -179.61 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.93 28.82 33.39 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 120.15 -1.024 . . . . 0.0 111.355 178.892 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.77 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.25 106.42 20.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 O-C-N 120.586 -1.538 . . . . 0.0 107.221 178.769 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.88 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.7 tp -116.89 104.68 11.55 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.427 -1.421 . . . . 0.0 109.706 -177.545 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.989 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.23 109.54 22.28 Favored 'General case' 0 N--CA 1.484 1.244 0 O-C-N 120.827 -1.171 . . . . 0.0 108.295 178.928 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -106.27 166.13 10.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.956 -1.09 . . . . 0.0 110.209 -179.073 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.684 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 12.6 t-20 -108.22 134.45 20.18 Favored Pre-proline 0 N--CA 1.498 1.952 0 O-C-N 121.376 -0.827 . . . . 0.0 109.599 -179.411 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.627 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.1 Cg_endo -73.93 24.29 0.34 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 122.452 2.102 . . . . 0.0 112.108 -179.655 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.684 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -113.75 -0.69 14.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.322 -1.486 . . . . 0.0 109.183 179.643 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.898 ' HB3' HD22 ' A' ' 67' ' ' LEU . 2.2 m-20 -136.38 18.26 3.15 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 179.651 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -78.04 83.96 4.32 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.66 -0.816 . . . . 0.0 110.62 -178.525 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -106.27 -170.51 1.74 Allowed 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 178.523 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.458 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.61 136.39 0.09 Allowed 'General case' 0 C--N 1.305 -1.351 0 O-C-N 120.705 -1.247 . . . . 0.0 111.008 -179.273 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.776 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.7 p -148.58 159.07 6.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 178.259 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.599 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.56 141.6 31.2 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 120.729 -1.232 . . . . 0.0 109.802 -179.923 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.008 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.09 108.04 1.72 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 122.305 1.05 . . . . 0.0 109.651 178.57 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.567 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.0 t0 -64.08 -139.44 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.027 0 CA-C-O 121.377 0.608 . . . . 0.0 110.809 179.864 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.95 -52.0 36.91 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.386 -0.821 . . . . 0.0 110.821 -178.706 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -102.49 -32.17 10.08 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 178.633 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.995 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 103.3 66.6 0.73 Allowed Glycine 0 C--N 1.298 -1.572 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.262 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.603 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 52.6 m -98.82 130.73 45.26 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.603 -0.939 . . . . 0.0 108.764 178.866 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.776 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.09 109.13 8.74 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 119.299 -0.96 . . . . 0.0 109.335 -179.576 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.9 m -123.08 116.86 24.19 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.237 -0.914 . . . . 0.0 109.498 -179.803 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.616 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.24 143.58 29.31 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.385 -0.822 . . . . 0.0 109.523 -179.993 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.0 p -99.83 147.33 25.62 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.363 -0.835 . . . . 0.0 109.469 -179.892 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.898 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -147.56 168.43 21.98 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.441 -0.787 . . . . 0.0 109.398 -179.155 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.696 HG22 HG22 ' A' ' 18' ' ' VAL . 2.5 p -100.19 121.81 42.03 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.84 -1.163 . . . . 0.0 110.098 -178.937 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.823 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.5 m -129.08 144.17 38.99 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 120.897 -1.127 . . . . 0.0 110.162 -179.404 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.605 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.7 ptt180 -149.1 -177.47 5.84 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 120.576 -1.327 . . . . 0.0 110.838 179.722 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.578 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.6 -102.58 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.702 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.508 ' OG ' ' NH1' ' A' ' 71' ' ' ARG . 0.7 OUTLIER -57.56 140.41 50.96 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 120.712 -1.242 . . . . 0.0 108.161 179.388 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.41 136.69 8.66 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.934 -178.124 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.522 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 8.9 mm-40 -32.28 120.15 0.29 Allowed 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.47 0.652 . . . . 0.0 110.6 -178.591 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.989 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.84 47.19 2.95 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.573 -0.823 . . . . 0.0 111.175 -179.195 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.627 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -38.38 113.99 0.33 Allowed 'General case' 0 N--CA 1.508 2.428 0 O-C-N 121.168 -1.195 . . . . 0.0 110.085 179.607 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.724 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -87.56 126.33 34.87 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.869 -1.145 . . . . 0.0 109.509 -179.816 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 16.4 t80 -64.26 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.856 -1.153 . . . . 0.0 110.035 179.693 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.0 t0 -159.87 19.25 0.16 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.982 -1.073 . . . . 0.0 109.735 179.895 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.93 -27.02 5.64 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.837 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.403 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.3 p -95.17 161.47 14.1 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.006 -1.29 . . . . 0.0 110.361 -179.491 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.475 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -107.66 136.32 47.61 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.832 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.724 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -83.03 -17.61 42.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.858 -1.151 . . . . 0.0 110.502 -178.649 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.71 174.02 19.65 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 108.862 -1.695 . . . . 0.0 108.862 -179.632 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.97 105.97 0.95 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.08 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.641 HG21 ' HB3' ' A' ' 46' ' ' ALA . 46.1 t -76.94 105.46 5.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.385 -0.822 . . . . 0.0 109.45 -178.682 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.558 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.9 m-20 -64.01 110.61 2.19 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.43 -0.793 . . . . 0.0 109.7 -179.624 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.578 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.3 t -65.0 -4.48 4.65 Favored 'General case' 0 N--CA 1.499 2.024 0 C-N-CA 118.289 -1.364 . . . . 0.0 109.969 179.505 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 38.7 p -86.82 -1.14 57.54 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.712 -1.242 . . . . 0.0 109.239 179.579 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.558 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -112.28 -50.27 2.91 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.34 -0.85 . . . . 0.0 108.917 -179.99 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.39 -178.27 3.61 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.596 -0.69 . . . . 0.0 109.301 179.724 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.29 115.51 30.33 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.349 -0.844 . . . . 0.0 109.14 -179.989 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.77 121.62 38.82 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.848 -1.158 . . . . 0.0 109.244 -179.578 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.656 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.31 145.26 30.22 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 122.424 1.107 . . . . 0.0 111.16 -179.176 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.502 ' HB ' HG11 ' A' ' 7' ' ' VAL . 49.1 t -101.73 109.88 27.1 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.999 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 177.68 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.489 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.7 -170.57 16.62 Favored Glycine 0 N--CA 1.486 2.012 0 C-N-CA 118.26 -1.924 . . . . 0.0 111.666 -177.569 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.49 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -112.91 179.61 3.92 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 -179.197 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.494 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 33.8 p . . . . . 0 C--N 1.295 -1.762 0 O-C-N 121.381 -0.824 . . . . 0.0 109.585 -179.328 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.772 0 N-CA-C 107.657 -2.177 . . . . 0.0 107.657 . . . . . . . . . 0 0 . 1 . 039 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.58 -178.04 6.83 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 122.104 0.954 . . . . 0.0 109.768 179.206 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.46 -162.65 14.65 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 -179.404 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.3 Cg_exo -47.09 177.09 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.608 0 CA-C-N 118.807 1.304 . . . . 0.0 110.042 179.258 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -91.81 -178.57 5.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.015 -1.053 . . . . 0.0 110.409 -178.704 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.489 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.74 165.29 12.95 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.954 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.456 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.83 129.51 51.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 O-C-N 121.458 -1.025 . . . . 0.0 109.249 -179.413 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.656 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.31 126.6 30.49 Favored 'General case' 0 C--N 1.291 -1.972 0 O-C-N 121.677 -0.639 . . . . 0.0 109.791 179.756 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.697 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 20.8 pt -97.43 177.2 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.226 -0.921 . . . . 0.0 109.473 -179.884 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.502 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.3 m -144.2 150.96 38.81 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.464 -0.772 . . . . 0.0 109.54 179.851 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.697 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 94.9 m-85 . . . . . 0 N--CA 1.485 1.297 0 O-C-N 121.115 -0.991 . . . . 0.0 109.506 -179.636 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.511 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.215 0 CA-C-O 122.361 1.076 . . . . 0.0 110.599 . . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.015 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -104.82 104.72 14.55 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 122.456 1.122 . . . . 0.0 110.243 -179.495 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.928 HG22 HG23 ' A' ' 21' ' ' VAL . 14.7 t -119.51 115.4 47.5 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.443 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.265 179.704 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.72 148.94 12.95 Favored Pre-proline 0 N--CA 1.488 1.451 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.547 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -78.59 149.77 86.21 Favored 'Cis proline' 0 C--N 1.31 -1.497 0 C-N-CA 123.726 -1.364 . . . . 0.0 109.558 -0.609 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.657 ' HA ' HG22 ' A' ' 110' ' ' ILE . 77.6 p -91.7 -24.06 19.6 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.543 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.479 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 0.9 OUTLIER -131.28 162.18 30.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.45 -0.781 . . . . 0.0 109.513 -179.921 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.17 38.37 34.78 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 -179.536 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.809 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.5 mt -91.51 -44.28 9.19 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 123.142 1.448 . . . . 0.0 110.691 -178.233 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.472 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.7 144.87 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.274 0 CA-C-N 113.587 -1.642 . . . . 0.0 109.915 -179.629 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.577 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 9.2 p-10 -50.81 106.29 0.12 Allowed 'General case' 0 C--N 1.302 -1.46 0 CA-C-O 121.492 0.663 . . . . 0.0 111.674 -178.575 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.55 15.51 8.77 Favored Glycine 0 N--CA 1.485 1.918 0 C-N-CA 119.523 -1.323 . . . . 0.0 112.944 177.178 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.809 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.9 t -103.93 -172.3 2.08 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 121.156 2.478 . . . . 0.0 109.835 179.304 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.761 HG22 HG22 ' A' ' 68' ' ' THR . 15.1 t -131.56 140.23 48.75 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.301 0 CA-C-N 114.873 -1.058 . . . . 0.0 111.186 -178.817 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.638 HG22 HG22 ' A' ' 69' ' ' VAL . 4.1 m -117.86 154.72 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 178.948 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -106.91 108.74 20.39 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.078 -1.014 . . . . 0.0 109.311 179.927 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.928 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -106.23 122.16 59.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 179.775 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.015 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.54 165.97 12.2 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 120.913 -1.117 . . . . 0.0 109.068 179.933 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.16 108.1 0.5 Allowed Glycine 0 N--CA 1.483 1.778 0 N-CA-C 108.586 -1.806 . . . . 0.0 108.586 179.848 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.438 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.58 140.31 49.53 Favored 'General case' 0 N--CA 1.498 1.954 0 CA-C-N 119.192 1.496 . . . . 0.0 110.282 -179.274 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.73 28.1 33.07 Favored Glycine 0 N--CA 1.489 2.184 0 C-N-CA 119.025 -1.559 . . . . 0.0 109.845 179.777 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -92.55 175.08 6.96 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.931 -1.335 . . . . 0.0 108.352 179.929 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.998 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.94 98.84 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.448 0 O-C-N 120.878 -1.139 . . . . 0.0 109.601 -179.625 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.663 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.3 77.48 0.0 OUTLIER 'General case' 0 C--N 1.294 -1.807 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.269 -179.131 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.31 34.35 0.32 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.457 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.564 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 59.7 p -145.42 112.08 5.87 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.075 -1.25 . . . . 0.0 111.196 -179.691 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.552 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.42 126.84 5.56 Favored 'General case' 0 N--CA 1.491 1.615 0 CA-C-O 121.458 0.647 . . . . 0.0 109.523 178.098 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.493 ' HA ' ' O ' ' A' ' 98' ' ' SER . 12.1 m-85 -118.09 150.26 39.63 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.736 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.512 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -100.84 159.0 15.56 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.652 -1.28 . . . . 0.0 107.729 178.535 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.68 HG13 ' O ' ' A' ' 34' ' ' VAL . 7.4 p -144.27 116.04 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.085 -1.009 . . . . 0.0 110.045 -177.637 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.2 -178.78 39.74 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.414 -1.85 . . . . 0.0 111.857 -179.919 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.598 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -100.31 109.01 21.2 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -179.872 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.58 148.02 52.33 Favored 'General case' 0 C--N 1.294 -1.81 0 O-C-N 121.357 -0.84 . . . . 0.0 109.835 179.873 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.466 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.9 138.94 54.21 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.375 -0.828 . . . . 0.0 110.702 -179.082 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.874 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.55 114.67 26.45 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 178.187 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.42 ' O ' ' OD2' ' A' ' 41' ' ' ASP . 17.1 m -105.71 14.72 7.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.971 -1.081 . . . . 0.0 110.576 -178.679 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.761 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.92 -175.17 0.08 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.923 -1.111 . . . . 0.0 110.086 179.749 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 46.2 p -71.85 97.54 1.83 Allowed 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.428 -0.795 . . . . 0.0 109.717 -179.655 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.33 27.13 34.05 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 120.293 -0.956 . . . . 0.0 111.487 178.921 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.761 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.93 106.13 19.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.222 0 O-C-N 120.566 -1.549 . . . . 0.0 107.337 178.872 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.874 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.6 tp -117.24 104.67 11.4 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.531 -1.356 . . . . 0.0 109.669 -177.839 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.077 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.76 109.36 22.13 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.787 -1.196 . . . . 0.0 108.331 178.956 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.8 t -105.39 164.51 11.81 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.05 -1.031 . . . . 0.0 110.123 -179.055 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.695 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 13.6 t-20 -106.76 138.9 19.91 Favored Pre-proline 0 N--CA 1.501 2.087 0 O-C-N 121.333 -0.854 . . . . 0.0 110.095 -179.031 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.576 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 6.9 Cg_endo -75.88 25.9 0.41 Allowed 'Trans proline' 0 C--N 1.319 -1.012 0 C-N-CA 122.537 2.158 . . . . 0.0 111.705 179.987 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.695 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -121.43 3.54 10.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.403 -1.436 . . . . 0.0 109.312 -179.915 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.538 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.09 14.36 3.06 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.285 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -80.18 91.83 5.61 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.799 -178.644 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.617 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.53 -169.23 1.44 Allowed 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 178.356 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.03 135.56 0.09 Allowed 'General case' 0 C--N 1.306 -1.325 0 O-C-N 120.517 -1.364 . . . . 0.0 111.439 -179.351 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.899 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -151.98 157.75 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 178.102 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.41 145.31 26.29 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.595 -1.316 . . . . 0.0 109.976 -179.578 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.998 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.6 107.39 1.71 Allowed 'General case' 0 C--N 1.3 -1.582 0 CA-C-O 122.375 1.083 . . . . 0.0 109.418 178.716 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.7 p-10 -60.37 -139.25 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.019 -179.914 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.663 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.21 -50.43 59.11 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.316 -0.865 . . . . 0.0 110.564 -178.71 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -104.7 -33.71 8.38 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 106.249 -1.759 . . . . 0.0 106.249 178.529 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.982 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.01 66.99 0.61 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 178.205 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.8 m -104.3 124.84 49.89 Favored 'General case' 0 N--CA 1.485 1.28 0 O-C-N 121.674 -0.898 . . . . 0.0 108.686 178.818 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.899 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.15 109.21 8.76 Favored 'General case' 0 C--N 1.296 -1.733 0 C-N-CA 119.699 -0.8 . . . . 0.0 109.479 -179.412 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 81.2 p -117.87 118.64 32.57 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.348 -0.845 . . . . 0.0 109.448 -179.924 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.636 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.02 141.24 30.01 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.513 -0.742 . . . . 0.0 109.631 179.92 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.1 p -100.46 131.65 46.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.436 -0.79 . . . . 0.0 109.352 179.955 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.746 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -130.05 166.98 19.03 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.416 -0.803 . . . . 0.0 109.477 -179.512 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.761 HG22 HG22 ' A' ' 18' ' ' VAL . 1.7 p -97.94 124.69 42.49 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.109 -0.994 . . . . 0.0 109.365 -179.834 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.638 HG22 HG22 ' A' ' 19' ' ' VAL . 16.0 m -135.45 143.28 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.082 -1.011 . . . . 0.0 109.767 -179.292 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.577 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 4.6 ptt180 -141.1 -165.62 2.0 Allowed 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.657 -1.277 . . . . 0.0 110.494 -179.912 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.597 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 17.5 mtp180 -72.4 -80.24 0.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.367 -0.833 . . . . 0.0 109.217 -179.498 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.5 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -68.65 138.3 54.89 Favored 'General case' 0 N--CA 1.485 1.282 0 O-C-N 120.051 -1.655 . . . . 0.0 107.284 178.874 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.567 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -162.21 133.99 5.41 Favored 'General case' 0 C--N 1.295 -1.788 0 C-N-CA 117.766 -1.573 . . . . 0.0 110.414 -177.559 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.55 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -33.83 121.95 0.44 Allowed 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.44 0.638 . . . . 0.0 110.234 -178.766 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.077 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.86 51.66 2.27 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 120.512 -0.852 . . . . 0.0 111.392 -178.98 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.576 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -38.97 116.17 0.55 Allowed 'General case' 0 N--CA 1.511 2.615 0 O-C-N 121.075 -1.25 . . . . 0.0 109.933 179.519 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.693 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -87.32 126.63 34.96 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.875 -1.14 . . . . 0.0 109.328 -179.946 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -64.15 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.772 -1.205 . . . . 0.0 110.025 179.741 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 20.4 t70 -160.18 19.48 0.15 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.984 -1.072 . . . . 0.0 109.705 179.895 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.0 -27.39 5.51 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 179.785 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.41 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 2.3 p -95.22 160.93 14.32 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.004 -1.292 . . . . 0.0 110.318 -179.425 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.479 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.86 137.48 44.84 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.822 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.693 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.27 -19.2 40.03 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.748 -1.22 . . . . 0.0 110.437 -178.596 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.51 176.27 19.73 Favored Glycine 0 N--CA 1.484 1.85 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.485 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -63.82 108.8 1.55 Allowed 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 179.13 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.628 HG21 ' HB3' ' A' ' 46' ' ' ALA . 38.2 t -81.72 105.41 11.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 121.361 -0.837 . . . . 0.0 108.786 -179.144 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.531 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -67.68 112.16 4.63 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.39 -0.819 . . . . 0.0 109.931 -179.108 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.546 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -64.28 -5.09 4.41 Favored 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.286 -1.366 . . . . 0.0 109.97 179.437 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.404 HG22 ' NH2' ' A' ' 71' ' ' ARG . 41.0 p -85.63 1.44 49.24 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.769 -1.207 . . . . 0.0 109.021 179.361 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -115.73 -49.34 2.73 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.432 -0.792 . . . . 0.0 109.08 179.971 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.64 -179.63 4.0 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.458 -0.776 . . . . 0.0 109.536 179.961 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.99 115.36 30.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.338 -0.851 . . . . 0.0 109.102 179.958 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.507 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.7 m -96.94 123.73 40.73 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.082 -1.011 . . . . 0.0 109.54 -179.358 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.582 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.28 147.48 27.44 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 122.515 1.15 . . . . 0.0 111.356 -179.318 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.64 ' HB ' HG11 ' A' ' 7' ' ' VAL . 59.1 t -103.09 109.62 27.36 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.038 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 177.351 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.09 -174.06 17.9 Favored Glycine 0 N--CA 1.484 1.855 0 C-N-CA 118.203 -1.951 . . . . 0.0 111.815 -177.414 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.503 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -117.1 -177.59 3.24 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -178.835 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.512 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.8 OUTLIER . . . . . 0 C--N 1.297 -1.694 0 O-C-N 121.182 -0.949 . . . . 0.0 109.389 -179.344 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.73 0 N-CA-C 107.468 -2.253 . . . . 0.0 107.468 . . . . . . . . . 0 0 . 1 . 040 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -154.98 -179.66 8.27 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 121.509 -0.995 . . . . 0.0 109.406 178.786 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -179.23 -167.78 37.22 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 -179.488 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.449 ' HG3' HD22 ' A' ' 26' ' ' LEU . 5.8 Cg_exo -48.38 175.1 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.665 0 CA-C-N 118.888 1.344 . . . . 0.0 110.002 179.523 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -92.48 -175.4 3.98 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.163 -0.96 . . . . 0.0 110.435 -178.778 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -120.52 166.54 13.77 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.908 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -106.65 131.82 55.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.452 -1.028 . . . . 0.0 109.069 -179.358 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.582 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.16 125.11 27.65 Favored 'General case' 0 C--N 1.29 -2.018 0 O-C-N 121.48 -0.762 . . . . 0.0 109.782 179.733 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.86 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.72 172.18 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.158 -0.964 . . . . 0.0 108.948 179.81 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.479 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.81 158.25 44.74 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.305 -0.872 . . . . 0.0 109.605 -179.837 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.86 ' CE2' HD12 ' A' ' 110' ' ' ILE . 70.8 m-85 . . . . . 0 C--N 1.306 -1.297 0 O-C-N 121.19 -0.944 . . . . 0.0 109.52 -179.585 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.572 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.486 1.366 0 CA-C-O 122.208 1.004 . . . . 0.0 111.252 . . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.01 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -100.36 104.03 15.45 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.377 1.084 . . . . 0.0 109.783 179.982 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.937 HG22 HG23 ' A' ' 21' ' ' VAL . 6.9 t -120.32 116.72 51.1 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-O 121.726 0.774 . . . . 0.0 110.466 179.863 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.508 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.81 148.7 8.86 Favored Pre-proline 0 N--CA 1.486 1.339 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.707 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.508 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.0 Cg_endo -77.94 150.32 89.18 Favored 'Cis proline' 0 C--N 1.307 -1.65 0 C-N-CA 123.604 -1.415 . . . . 0.0 109.513 -0.425 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.674 ' HA ' HG22 ' A' ' 110' ' ' ILE . 80.1 p -91.3 -24.69 19.75 Favored 'General case' 0 C--N 1.292 -1.916 0 O-C-N 121.498 -0.751 . . . . 0.0 108.985 179.518 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.519 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 17.0 m -133.92 161.9 33.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.521 -0.737 . . . . 0.0 109.367 -179.931 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.77 37.06 31.05 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 108.571 -1.811 . . . . 0.0 108.571 -179.657 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.725 ' CA ' HG21 ' A' ' 17' ' ' THR . 42.8 mt -91.12 -42.13 10.64 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-O 123.374 1.559 . . . . 0.0 110.22 -178.548 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.468 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.65 142.31 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.238 -1.801 . . . . 0.0 109.838 -179.488 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.61 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.3 p-10 -49.94 106.86 0.13 Allowed 'General case' 0 C--N 1.298 -1.656 0 CA-C-O 121.562 0.696 . . . . 0.0 111.324 -178.588 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.16 10.64 9.57 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.132 177.449 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.725 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.7 t -105.48 -171.31 1.89 Allowed 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 121.286 2.543 . . . . 0.0 109.905 179.471 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.81 HG13 ' C ' ' A' ' 67' ' ' LEU . 16.8 t -132.93 143.42 39.55 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.284 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.851 -178.952 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.599 HG11 HD11 ' A' ' 13' ' ' LEU . 32.2 m -118.98 155.34 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.28 -0.887 . . . . 0.0 108.707 179.21 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.547 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -105.08 108.77 20.47 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.152 -0.967 . . . . 0.0 109.441 -179.897 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.937 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -106.74 121.76 59.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.434 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -118.07 167.16 11.72 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 120.688 -1.257 . . . . 0.0 109.292 -179.604 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.602 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.55 143.47 15.11 Favored Glycine 0 C--N 1.294 -1.78 0 N-CA-C 107.774 -2.131 . . . . 0.0 107.774 179.735 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -147.82 123.01 10.2 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 120.929 -1.336 . . . . 0.0 108.589 179.175 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 90.18 27.39 21.0 Favored Glycine 0 N--CA 1.487 2.063 0 C-N-CA 119.201 -1.476 . . . . 0.0 109.755 -179.448 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.0 mt -87.9 175.85 7.62 Favored 'General case' 0 C--N 1.308 -1.224 0 O-C-N 120.846 -1.384 . . . . 0.0 108.403 179.964 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.996 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.24 96.85 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.029 -1.044 . . . . 0.0 109.6 -179.91 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.679 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.24 76.48 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.448 -178.847 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.25 33.44 0.27 Allowed Glycine 0 N--CA 1.486 1.994 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 179.179 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.626 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.6 t -148.45 115.46 6.09 Favored 'General case' 0 C--N 1.309 -1.178 0 O-C-N 120.797 -1.414 . . . . 0.0 111.252 179.932 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.565 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.98 129.18 4.43 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.657 178.221 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.626 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 6.8 m-85 -121.5 146.82 46.54 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.727 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.508 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.95 164.31 12.24 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 107.429 -1.323 . . . . 0.0 107.429 178.54 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.948 HG11 HG21 ' A' ' 65' ' ' THR . 7.1 p -148.95 115.11 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.979 -1.076 . . . . 0.0 110.133 -177.673 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.15 -174.29 36.85 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 118.541 -1.79 . . . . 0.0 111.563 -179.938 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.568 ' CG ' ' O ' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -100.77 108.89 20.83 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -179.718 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.26 148.76 52.12 Favored 'General case' 0 C--N 1.296 -1.73 0 O-C-N 121.19 -0.944 . . . . 0.0 109.934 179.765 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.33 139.1 53.98 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.276 -0.89 . . . . 0.0 110.613 -179.03 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.882 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.17 114.89 26.74 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 178.116 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.2 m -106.17 15.57 7.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.014 -1.054 . . . . 0.0 110.587 -178.676 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.3 -175.59 0.09 Allowed 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.933 -1.105 . . . . 0.0 110.021 179.739 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.0 97.47 1.88 Allowed 'General case' 0 N--CA 1.486 1.33 0 O-C-N 121.423 -0.798 . . . . 0.0 109.724 -179.765 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.64 27.93 33.89 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 120.164 -1.017 . . . . 0.0 111.399 178.973 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.52 106.33 20.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 O-C-N 120.612 -1.522 . . . . 0.0 107.289 178.928 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.882 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -116.88 104.74 11.61 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.501 -1.374 . . . . 0.0 109.684 -177.626 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.068 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.13 109.57 22.3 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.739 -1.226 . . . . 0.0 108.213 178.797 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -108.12 164.53 12.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.977 -1.077 . . . . 0.0 110.081 -178.929 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.62 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 7.5 t30 -108.62 130.02 23.27 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.357 -0.84 . . . . 0.0 109.69 -179.284 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.614 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -71.01 19.83 0.23 Allowed 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 122.178 1.919 . . . . 0.0 112.044 179.502 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.634 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -108.32 1.12 21.66 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.364 -1.46 . . . . 0.0 108.883 179.305 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.576 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.07 19.27 2.99 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 179.462 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -83.0 90.9 7.07 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.876 -0.73 . . . . 0.0 111.005 -178.439 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.66 -171.02 1.76 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.944 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.437 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.3 OUTLIER 178.53 137.96 0.09 Allowed 'General case' 0 C--N 1.304 -1.372 0 O-C-N 120.501 -1.374 . . . . 0.0 111.544 -179.16 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.822 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -154.79 159.51 3.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 178.07 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.565 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.28 145.78 25.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.59 -1.319 . . . . 0.0 109.722 -179.676 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.996 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.66 108.09 2.78 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 122.353 1.073 . . . . 0.0 109.582 179.037 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.541 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 t0 -63.03 -139.21 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.015 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.874 -179.917 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.679 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.04 -51.83 28.88 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.411 -0.806 . . . . 0.0 110.759 -178.572 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -105.09 -32.07 8.87 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 178.585 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.963 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.25 67.96 0.69 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 178.391 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.602 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.2 m -103.42 128.88 50.46 Favored 'General case' 0 N--CA 1.484 1.266 0 O-C-N 121.37 -1.077 . . . . 0.0 109.143 179.202 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.822 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.25 108.65 6.89 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 119.321 -0.952 . . . . 0.0 109.949 -179.486 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.494 ' HB3' ' CE ' ' A' ' 20' ' ' LYS . 3.4 m -114.48 116.58 29.07 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.995 -1.066 . . . . 0.0 109.409 179.85 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.948 HG21 HG11 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -143.08 142.19 31.46 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 110.013 -179.971 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.9 p -100.71 136.32 40.76 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.466 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.81 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -141.08 156.82 45.93 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.935 . . . . 0.0 109.808 -179.129 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.634 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 12.9 t -87.04 138.76 31.22 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.062 -1.023 . . . . 0.0 110.676 -179.608 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.564 HG12 ' HB3' ' A' ' 36' ' ' GLN . 20.7 m -149.27 143.55 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.508 -0.745 . . . . 0.0 109.232 -179.852 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.61 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -147.52 -178.01 6.01 Favored 'General case' 0 N--CA 1.486 1.326 0 O-C-N 120.487 -1.383 . . . . 0.0 111.206 -179.68 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.697 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -47.52 -98.92 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -179.616 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.523 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -64.02 145.01 56.65 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.389 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.599 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -163.95 143.2 7.85 Favored 'General case' 0 C--N 1.291 -1.952 0 C-N-CA 118.045 -1.462 . . . . 0.0 110.268 -177.419 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.538 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 29.4 mm-40 -37.29 120.46 0.77 Allowed 'General case' 0 N--CA 1.489 1.477 0 CA-C-O 121.457 0.646 . . . . 0.0 110.304 -178.888 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.068 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -96.5 52.45 1.54 Allowed Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.477 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.614 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.8 m-85 -39.76 114.96 0.47 Allowed 'General case' 0 N--CA 1.508 2.465 0 O-C-N 121.181 -1.188 . . . . 0.0 110.113 179.65 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.656 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.13 126.55 34.3 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.866 -1.146 . . . . 0.0 109.511 -179.986 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.6 t80 -64.1 58.17 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.004 0 O-C-N 120.845 -1.159 . . . . 0.0 110.25 179.767 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.58 19.68 0.14 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.025 -1.047 . . . . 0.0 109.709 179.892 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.88 -27.5 5.4 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.871 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.419 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 11.9 p -93.36 158.53 15.69 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.02 -1.282 . . . . 0.0 110.434 -179.455 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.487 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.35 136.28 46.35 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.627 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.656 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.1 t90 -83.08 -16.72 45.81 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.669 -1.269 . . . . 0.0 110.647 -178.194 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.57 175.94 21.18 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 108.709 -1.756 . . . . 0.0 108.709 -179.618 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -64.84 103.07 0.66 Allowed 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 179.106 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.656 HG21 ' HB3' ' A' ' 46' ' ' ALA . 37.2 t -73.78 107.97 4.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 109.483 -178.755 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.523 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.8 OUTLIER -65.11 112.09 3.22 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.462 -0.774 . . . . 0.0 109.706 -179.58 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.697 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 4.0 m -62.81 -4.98 2.4 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.422 -1.311 . . . . 0.0 110.228 179.608 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.5 p -89.25 -2.94 58.67 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.566 -1.334 . . . . 0.0 109.555 -179.983 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.522 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -106.31 -48.65 3.52 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.071 -1.018 . . . . 0.0 108.861 179.885 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.42 -177.86 3.4 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.631 -0.668 . . . . 0.0 109.297 179.726 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.59 115.98 31.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.454 -0.779 . . . . 0.0 108.927 179.834 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.544 ' HB2' HD11 ' A' ' 110' ' ' ILE . 3.2 m -96.48 120.32 36.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.913 -1.117 . . . . 0.0 109.615 -179.245 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.93 145.28 30.37 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 122.409 1.099 . . . . 0.0 111.282 -179.392 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.582 ' HB ' HG11 ' A' ' 7' ' ' VAL . 92.4 t -102.22 109.86 27.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.945 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 177.788 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.494 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.49 -173.22 19.82 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 118.112 -1.995 . . . . 0.0 111.695 -177.608 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.538 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -111.93 -178.61 3.47 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 -179.345 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.482 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 1.1 p . . . . . 0 C--N 1.297 -1.707 0 O-C-N 121.197 -0.939 . . . . 0.0 109.751 -179.132 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.723 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 . . . . . . . . . 0 0 . 1 . 041 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.11 -177.6 5.85 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.578 -0.954 . . . . 0.0 109.713 179.242 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.31 -161.5 14.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 -179.345 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.485 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.5 Cg_exo -47.97 -179.36 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.612 0 CA-C-N 118.877 1.339 . . . . 0.0 110.304 179.328 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -93.59 -173.95 3.34 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.002 -1.061 . . . . 0.0 110.298 -178.974 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.494 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.76 164.18 14.97 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.946 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.86 129.41 51.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.367 -1.078 . . . . 0.0 109.0 -179.46 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.79 119.25 15.7 Favored 'General case' 0 C--N 1.288 -2.101 0 O-C-N 121.746 -0.596 . . . . 0.0 109.73 179.759 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.813 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -98.09 170.04 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.188 -0.945 . . . . 0.0 108.861 179.821 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.519 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -138.46 155.08 48.78 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.085 -1.01 . . . . 0.0 109.6 -179.908 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.813 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 77.6 m-85 . . . . . 0 C--N 1.305 -1.327 0 O-C-N 121.271 -0.893 . . . . 0.0 109.424 -179.686 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.209 0 CA-C-O 122.327 1.06 . . . . 0.0 110.594 . . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.012 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -104.72 104.85 14.72 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-O 122.532 1.158 . . . . 0.0 110.142 -179.519 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.974 HG22 HG23 ' A' ' 21' ' ' VAL . 12.5 t -119.48 120.0 62.25 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.438 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.355 179.616 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.519 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.67 150.3 8.84 Favored Pre-proline 0 N--CA 1.489 1.492 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 -179.621 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.519 ' HA ' HG23 ' A' ' 8' ' ' THR . 1.3 Cg_endo -74.22 153.98 99.42 Favored 'Cis proline' 0 C--N 1.31 -1.493 0 C-N-CA 123.621 -1.408 . . . . 0.0 109.927 -0.482 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.628 ' HA ' HG22 ' A' ' 110' ' ' ILE . 4.5 m -93.64 -23.94 18.08 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.646 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.495 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 3.1 m -137.12 166.14 24.41 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.61 -0.681 . . . . 0.0 109.424 179.919 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.14 38.09 40.93 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 108.346 -1.902 . . . . 0.0 108.346 -179.6 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.852 ' CA ' HG21 ' A' ' 17' ' ' THR . 29.9 mt -91.42 -45.21 8.68 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 123.131 1.444 . . . . 0.0 110.676 -178.316 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.28 146.16 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.763 -1.562 . . . . 0.0 109.942 -179.704 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.592 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.5 p-10 -51.44 110.14 0.42 Allowed 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 121.532 0.682 . . . . 0.0 111.664 -178.614 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.52 13.97 12.23 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.557 -1.306 . . . . 0.0 112.731 177.345 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.852 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.0 t -102.66 -173.38 2.31 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 120.929 2.364 . . . . 0.0 109.632 179.365 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.73 HG13 ' C ' ' A' ' 67' ' ' LEU . 12.7 t -132.15 137.75 53.96 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.866 -1.061 . . . . 0.0 111.14 -178.995 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.498 HG13 ' CG2' ' A' ' 69' ' ' VAL . 29.2 m -114.57 154.48 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.351 -0.843 . . . . 0.0 109.07 178.934 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.555 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.3 tttt -109.33 108.93 19.68 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.266 -0.896 . . . . 0.0 109.126 179.83 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.974 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -107.25 122.92 62.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -179.954 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.012 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.48 165.96 12.19 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.761 -1.212 . . . . 0.0 109.136 179.694 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.58 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.15 107.84 0.49 Allowed Glycine 0 N--CA 1.483 1.793 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 179.865 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.49 141.15 48.56 Favored 'General case' 0 N--CA 1.5 2.051 0 CA-C-N 119.248 1.524 . . . . 0.0 110.273 -179.389 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.418 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 84.28 28.37 33.75 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 118.943 -1.598 . . . . 0.0 109.767 179.621 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.523 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -94.54 173.66 7.51 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.941 -1.329 . . . . 0.0 108.553 179.971 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.005 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.72 98.74 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.006 -1.059 . . . . 0.0 109.703 -179.885 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.622 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.41 76.6 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.188 -179.21 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 135.06 33.35 0.28 Allowed Glycine 0 N--CA 1.486 1.993 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.483 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.627 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -142.49 111.83 6.6 Favored 'General case' 0 C--N 1.309 -1.174 0 O-C-N 120.928 -1.336 . . . . 0.0 111.075 -179.929 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.579 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.5 113.34 0.8 Allowed 'General case' 0 N--CA 1.497 1.922 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.915 178.67 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.627 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 11.9 m-85 -107.14 153.06 23.21 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.263 -0.898 . . . . 0.0 108.592 179.441 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.482 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.66 159.55 15.22 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.729 -1.232 . . . . 0.0 107.994 178.884 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.002 HG11 HG21 ' A' ' 65' ' ' THR . 6.4 p -139.84 114.66 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 109.667 -178.086 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.96 -179.51 37.55 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 118.384 -1.865 . . . . 0.0 111.733 -179.449 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.633 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.1 pt20 -101.92 109.39 21.12 Favored 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 -179.889 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.472 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.69 149.37 52.37 Favored 'General case' 0 C--N 1.296 -1.751 0 O-C-N 121.14 -0.975 . . . . 0.0 110.087 -179.867 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.07 138.2 54.73 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.276 -0.89 . . . . 0.0 110.809 -178.976 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.887 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.26 115.0 26.85 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 178.055 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -104.36 14.3 7.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.044 -1.035 . . . . 0.0 110.491 -178.853 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.29 -174.86 0.07 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.977 -1.077 . . . . 0.0 110.095 179.765 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -72.96 98.68 2.54 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.387 -0.821 . . . . 0.0 109.606 -179.803 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.61 27.41 32.5 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 120.251 -0.975 . . . . 0.0 111.394 179.011 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -117.64 105.96 19.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 O-C-N 120.571 -1.547 . . . . 0.0 107.335 178.849 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.887 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.4 tp -117.95 104.38 10.84 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.408 -1.433 . . . . 0.0 109.741 -177.772 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.908 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.15 109.36 22.13 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 178.829 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -105.56 165.82 10.88 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.029 -1.044 . . . . 0.0 110.277 -178.612 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.614 HD22 ' HB3' ' A' ' 50' ' ' ALA . 50.8 t30 -110.66 134.93 20.77 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 121.49 -0.756 . . . . 0.0 109.885 -179.409 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.602 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -75.32 25.46 0.39 Allowed 'Trans proline' 0 C--N 1.319 -1.011 0 C-N-CA 122.328 2.019 . . . . 0.0 111.404 179.591 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.614 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -112.74 0.1 15.18 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.484 -1.385 . . . . 0.0 109.373 179.944 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.524 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.67 16.1 2.71 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 179.601 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -78.8 91.66 4.75 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.872 -0.731 . . . . 0.0 110.952 -178.648 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -110.1 -166.58 1.1 Allowed 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.281 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.448 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.7 136.44 0.09 Allowed 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.546 -1.346 . . . . 0.0 111.502 -179.289 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.957 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -154.39 157.15 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 178.174 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.579 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.37 143.95 28.28 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.772 -1.205 . . . . 0.0 109.91 -179.827 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.005 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.58 106.64 1.2 Allowed 'General case' 0 C--N 1.299 -1.587 0 CA-C-O 122.478 1.132 . . . . 0.0 109.325 178.556 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.9 p-10 -59.28 -139.53 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.918 -179.928 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.622 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.01 -50.0 62.25 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.434 -0.791 . . . . 0.0 110.731 -178.703 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.418 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.5 t-20 -103.77 -34.35 8.59 Favored 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 178.379 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.004 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.76 66.13 0.61 Allowed Glycine 0 C--N 1.297 -1.599 0 N-CA-C 110.459 -1.056 . . . . 0.0 110.459 178.126 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.8 m -104.36 124.23 48.83 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.683 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.957 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.89 109.2 8.9 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 119.692 -0.803 . . . . 0.0 109.506 -179.278 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.2 m -116.88 116.35 27.27 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.3 -0.875 . . . . 0.0 109.353 -179.93 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 1.002 HG21 HG11 ' A' ' 34' ' ' VAL . 1.2 t -140.78 139.08 34.53 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.507 -0.745 . . . . 0.0 109.762 179.998 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.6 p -99.02 138.38 36.2 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.38 -0.825 . . . . 0.0 108.982 179.631 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.809 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.56 166.44 24.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.269 -0.894 . . . . 0.0 109.547 -179.15 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.66 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -95.3 125.02 39.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.061 -1.025 . . . . 0.0 109.44 -179.818 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.609 HG23 HD13 ' A' ' 13' ' ' LEU . 15.0 m -133.29 143.32 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 120.955 -1.091 . . . . 0.0 109.798 -179.207 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.592 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.59 -170.7 3.58 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.484 -1.385 . . . . 0.0 111.092 179.992 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.606 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -63.12 -101.87 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.954 -0.466 . . . . 0.0 110.309 -179.034 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.535 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -58.95 137.98 57.64 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.595 -1.316 . . . . 0.0 108.534 -180.0 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.633 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.8 OUTLIER -156.62 156.59 33.79 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 118.807 -1.157 . . . . 0.0 109.746 -178.864 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.545 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 10.3 mm-40 -48.35 122.28 5.21 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.587 -178.603 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.908 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.32 46.78 3.41 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -179.555 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.602 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -38.59 112.92 0.26 Allowed 'General case' 0 N--CA 1.506 2.351 0 O-C-N 121.22 -1.164 . . . . 0.0 110.537 -179.795 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.753 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.79 126.89 34.92 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.986 -1.071 . . . . 0.0 109.366 179.945 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.8 t80 -63.68 58.41 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.017 0 O-C-N 120.851 -1.156 . . . . 0.0 110.21 179.761 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.1 t0 -161.1 19.52 0.12 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.927 -1.108 . . . . 0.0 109.786 179.816 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.28 -26.73 5.46 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 179.798 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 47.2 p -93.88 160.72 14.61 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.958 -1.319 . . . . 0.0 110.275 -179.508 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.486 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.9 OUTLIER -107.23 134.92 49.61 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.895 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.753 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.2 t90 -81.74 -17.46 47.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.956 -1.09 . . . . 0.0 110.327 -178.608 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.12 173.46 18.76 Favored Glycine 0 N--CA 1.485 1.936 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 -179.544 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -63.77 107.34 1.17 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 179.093 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.645 HG21 ' HB3' ' A' ' 46' ' ' ALA . 44.5 t -78.7 104.61 6.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 121.398 -0.814 . . . . 0.0 109.275 -178.686 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.557 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.2 m-20 -64.88 108.86 1.89 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.545 -0.722 . . . . 0.0 110.032 -179.377 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.606 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.6 t -60.3 -5.52 1.15 Allowed 'General case' 0 N--CA 1.501 2.113 0 C-N-CA 118.164 -1.414 . . . . 0.0 110.343 179.302 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 33.1 p -89.51 0.83 56.61 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.486 -1.384 . . . . 0.0 109.528 179.987 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.557 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -111.67 -48.61 3.06 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.201 -0.937 . . . . 0.0 109.129 -179.894 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.31 179.38 4.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.592 -0.693 . . . . 0.0 109.539 -179.896 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.28 113.31 26.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.369 -0.832 . . . . 0.0 108.925 179.826 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.515 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.8 m -96.55 121.07 37.98 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.035 -1.041 . . . . 0.0 109.43 -178.854 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.589 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.82 148.11 25.7 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-O 122.416 1.103 . . . . 0.0 111.301 -179.375 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.625 ' HB ' HG11 ' A' ' 7' ' ' VAL . 47.7 t -104.41 109.96 29.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 N-CA-C 106.697 -1.594 . . . . 0.0 106.697 177.607 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.457 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.51 -171.15 17.79 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 118.15 -1.976 . . . . 0.0 111.589 -177.686 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.541 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -115.08 -178.54 3.39 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -178.888 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.458 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.2 p . . . . . 0 C--N 1.296 -1.729 0 O-C-N 121.224 -0.923 . . . . 0.0 109.65 -179.113 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.692 0 N-CA-C 107.915 -2.074 . . . . 0.0 107.915 . . . . . . . . . 0 0 . 1 . 042 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.23 -177.47 5.73 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.542 -0.975 . . . . 0.0 110.09 179.419 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.37 -163.69 23.82 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 108.17 -1.972 . . . . 0.0 108.17 -179.512 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.541 ' HB2' HD12 ' A' ' 97' ' ' LEU . 7.2 Cg_exo -46.09 172.78 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.693 0 CA-C-N 119.084 1.442 . . . . 0.0 109.938 179.332 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -91.16 -177.2 4.82 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.071 -1.018 . . . . 0.0 110.701 -178.632 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.457 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.27 168.36 13.81 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.842 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.47 133.57 51.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.43 -1.041 . . . . 0.0 109.176 -179.202 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.589 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.68 123.48 24.14 Favored 'General case' 0 C--N 1.291 -1.976 0 O-C-N 121.55 -0.719 . . . . 0.0 109.874 179.72 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.837 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.97 172.77 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.137 -0.977 . . . . 0.0 108.969 179.711 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.495 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.97 157.74 45.18 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.036 -1.04 . . . . 0.0 110.094 -179.627 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.837 ' CE1' HD12 ' A' ' 110' ' ' ILE . 88.0 m-85 . . . . . 0 N--CA 1.487 1.412 0 O-C-N 121.224 -0.922 . . . . 0.0 109.444 -179.825 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.553 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.449 0 CA-C-O 122.345 1.069 . . . . 0.0 110.751 . . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.936 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.6 t -111.75 108.54 18.01 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-O 123.099 1.428 . . . . 0.0 109.053 179.339 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.897 HG22 HG23 ' A' ' 21' ' ' VAL . 5.6 t -117.71 137.39 51.78 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 0 CA-C-N 114.284 -1.326 . . . . 0.0 109.935 -179.616 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -172.85 149.11 1.8 Allowed Pre-proline 0 N--CA 1.485 1.316 0 O-C-N 121.241 -0.912 . . . . 0.0 108.815 -179.717 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -76.63 151.08 94.07 Favored 'Cis proline' 0 C--N 1.311 -1.439 0 C-N-CA 123.478 -1.468 . . . . 0.0 109.467 -0.865 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.685 ' HA ' HG22 ' A' ' 110' ' ' ILE . 65.3 p -90.17 -25.18 20.79 Favored 'General case' 0 C--N 1.294 -1.842 0 O-C-N 121.564 -0.71 . . . . 0.0 109.123 179.686 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.511 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.5 m -134.16 165.04 26.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.459 -0.776 . . . . 0.0 109.534 -179.904 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.22 38.28 34.79 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 -179.61 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.76 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.0 mt -92.4 -42.92 9.5 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 123.236 1.493 . . . . 0.0 110.525 -178.322 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.0 143.86 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.468 -1.696 . . . . 0.0 109.686 -179.534 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.583 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 6.0 p-10 -50.98 107.19 0.16 Allowed 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 121.625 0.726 . . . . 0.0 111.608 -178.437 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.46 11.61 11.59 Favored Glycine 0 N--CA 1.485 1.902 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.087 177.254 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.76 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -102.3 -169.8 1.72 Allowed 'General case' 0 C--N 1.312 -1.043 0 CA-C-N 121.111 2.455 . . . . 0.0 109.615 179.397 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.765 HG13 ' C ' ' A' ' 67' ' ' LEU . 12.0 t -134.17 142.23 41.56 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.702 -179.255 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.579 HG12 HD21 ' A' ' 13' ' ' LEU . 35.0 m -119.88 155.21 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.276 -0.89 . . . . 0.0 108.853 179.313 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 11.1 tttt -103.96 109.24 20.93 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.207 -0.933 . . . . 0.0 109.158 -179.965 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.897 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -101.94 140.87 19.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.607 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.936 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.3 160.15 39.89 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 118.62 -1.232 . . . . 0.0 109.949 179.795 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.594 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.19 143.89 15.16 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 179.578 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -145.73 125.93 13.83 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 120.87 -1.371 . . . . 0.0 108.911 179.296 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.73 26.39 27.24 Favored Glycine 0 N--CA 1.488 2.137 0 C-N-CA 119.296 -1.43 . . . . 0.0 109.777 -179.692 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.554 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.0 mt -86.84 175.3 8.26 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.918 -1.342 . . . . 0.0 108.364 -179.933 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.85 97.33 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.961 -1.087 . . . . 0.0 109.737 -179.61 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.675 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.53 77.32 0.0 OUTLIER 'General case' 0 C--N 1.294 -1.813 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.42 -179.134 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.12 34.4 0.33 Allowed Glycine 0 N--CA 1.486 2.005 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.381 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.549 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.4 p -147.78 113.26 5.63 Favored 'General case' 0 C--N 1.307 -1.251 0 O-C-N 121.045 -1.267 . . . . 0.0 111.236 -179.819 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.569 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -43.53 128.41 5.06 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.823 178.263 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.49 ' CD2' ' O ' ' A' ' 30' ' ' THR . 11.3 m-85 -121.38 149.8 42.43 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.596 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.509 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.49 156.35 17.33 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.642 -1.286 . . . . 0.0 107.854 178.84 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 34' ' ' VAL . 5.6 p -138.53 114.79 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.062 -1.024 . . . . 0.0 109.713 -178.06 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.08 -178.3 35.86 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.249 -1.929 . . . . 0.0 111.908 -179.529 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.568 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -101.03 112.55 25.04 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 -179.941 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 66.8 m -130.64 153.11 49.27 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.365 -0.834 . . . . 0.0 109.615 179.746 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.694 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -127.43 135.91 51.1 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.482 -0.761 . . . . 0.0 110.491 -179.957 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.885 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.6 OUTLIER -94.83 114.37 26.24 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.243 -1.391 . . . . 0.0 107.243 178.137 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 m -106.27 14.86 7.47 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 O-C-N 120.966 -1.084 . . . . 0.0 110.763 -178.473 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.776 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.21 -175.47 0.08 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.856 -1.152 . . . . 0.0 110.222 179.655 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 42' ' ' THR . 15.2 t -69.75 97.09 1.04 Allowed 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 121.83 0.824 . . . . 0.0 109.952 -179.445 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.66 27.15 36.09 Favored Glycine 0 N--CA 1.494 2.546 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.515 178.679 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.776 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.4 t -114.48 106.18 20.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.233 0 O-C-N 120.6 -1.53 . . . . 0.0 107.483 178.901 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.885 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.7 tp -116.94 106.54 13.54 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.574 -1.329 . . . . 0.0 109.662 -177.724 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.096 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -95.99 111.97 23.83 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 120.676 -1.265 . . . . 0.0 108.256 179.445 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.545 ' HB3' ' CE1' ' A' ' 52' ' ' PHE . 66.8 m -101.67 147.76 26.06 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.33 -0.856 . . . . 0.0 110.71 -178.291 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.696 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 24.4 t30 -103.45 126.11 33.06 Favored Pre-proline 0 N--CA 1.503 2.198 0 O-C-N 121.248 -0.908 . . . . 0.0 108.838 179.053 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.586 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.5 Cg_endo -70.58 23.85 0.2 Allowed 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 122.108 1.872 . . . . 0.0 112.561 -179.657 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.696 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -110.15 2.15 19.21 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.252 -1.53 . . . . 0.0 109.317 179.346 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.562 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.54 16.18 2.55 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 179.628 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.545 ' CE1' ' HB3' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -79.08 91.51 4.91 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.579 -0.701 . . . . 0.0 110.885 -178.568 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.625 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.67 -165.71 1.05 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.284 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 179.04 135.3 0.09 Allowed 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.514 -1.366 . . . . 0.0 111.564 -179.339 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.899 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -153.2 157.83 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 107.116 -1.438 . . . . 0.0 107.116 178.024 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.569 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.71 145.92 25.86 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.658 -1.276 . . . . 0.0 109.865 -179.73 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.38 107.98 2.2 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 122.368 1.08 . . . . 0.0 109.478 178.733 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.526 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.2 t0 -62.02 -139.11 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.045 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.931 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.675 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.84 -51.62 38.71 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.477 -0.764 . . . . 0.0 110.733 -178.614 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.73 -32.39 8.89 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 178.726 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.978 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.15 65.38 0.59 Allowed Glycine 0 C--N 1.297 -1.59 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 178.307 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 48.4 m -101.77 127.99 48.31 Favored 'General case' 0 C--N 1.309 -1.187 0 O-C-N 121.468 -1.019 . . . . 0.0 108.711 178.858 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.899 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.92 108.77 7.08 Favored 'General case' 0 C--N 1.295 -1.768 0 C-N-CA 119.316 -0.953 . . . . 0.0 109.819 -179.214 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 40.2 p -121.95 120.11 33.47 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.322 -0.861 . . . . 0.0 109.481 179.945 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.438 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.74 147.97 32.49 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.482 -0.761 . . . . 0.0 109.245 179.845 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.3 p -98.64 139.74 33.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.355 -0.84 . . . . 0.0 109.593 -179.876 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.765 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -143.75 157.45 44.38 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.366 -0.834 . . . . 0.0 109.202 -179.466 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.641 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 14.4 t -86.25 137.73 32.39 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.056 -1.028 . . . . 0.0 110.427 -179.645 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.539 HG23 HD13 ' A' ' 13' ' ' LEU . 24.1 m -148.6 141.43 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.467 -0.771 . . . . 0.0 109.525 -179.444 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.583 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -143.63 -170.68 3.36 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.563 -1.335 . . . . 0.0 110.368 -179.984 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.577 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -64.4 -94.61 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 -179.812 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.524 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.77 137.73 56.27 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.776 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.694 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -162.19 137.96 7.49 Favored 'General case' 0 C--N 1.293 -1.886 0 C-N-CA 118.3 -1.36 . . . . 0.0 110.473 -177.683 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.541 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.8 OUTLIER -32.42 118.91 0.28 Allowed 'General case' 0 N--CA 1.493 1.682 0 CA-C-O 121.5 0.667 . . . . 0.0 110.6 -178.497 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.096 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.97 49.42 1.76 Allowed Glycine 0 N--CA 1.492 2.403 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.542 -179.028 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.586 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.8 m-85 -40.0 115.55 0.55 Allowed 'General case' 0 N--CA 1.509 2.517 0 O-C-N 121.029 -1.277 . . . . 0.0 109.731 179.347 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.709 HD11 HG12 ' A' ' 44' ' ' VAL . 7.6 tp -85.81 127.21 34.5 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.943 -1.098 . . . . 0.0 109.66 -179.673 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -64.55 57.97 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.856 -1.153 . . . . 0.0 110.182 179.664 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.47 19.62 0.14 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.929 -1.107 . . . . 0.0 109.718 179.885 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.07 -28.12 5.23 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.952 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.454 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 34.6 p -92.59 156.28 17.21 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.06 -1.259 . . . . 0.0 110.309 -179.439 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.481 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -105.04 134.73 47.65 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.664 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.616 ' HB2' HD13 ' A' ' 77' ' ' LEU . 0.6 OUTLIER -82.55 -17.21 45.76 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.655 -1.278 . . . . 0.0 110.518 -178.372 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 106.67 176.42 23.14 Favored Glycine 0 N--CA 1.485 1.904 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -179.791 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.72 105.38 0.65 Allowed 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 179.095 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.581 HG21 ' CB ' ' A' ' 46' ' ' ALA . 36.8 t -76.43 104.08 4.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.421 -0.799 . . . . 0.0 109.046 -178.816 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.545 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -62.39 109.51 1.38 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.546 -0.721 . . . . 0.0 110.027 -179.343 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.577 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.85 -4.49 6.86 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.565 -1.335 . . . . 0.0 109.728 179.256 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.5 p -85.37 3.78 38.31 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.848 -1.158 . . . . 0.0 108.989 179.499 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.545 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -119.37 -49.08 2.38 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.409 -0.807 . . . . 0.0 109.026 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.91 -178.88 3.78 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.491 -0.756 . . . . 0.0 109.474 179.826 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.55 115.26 29.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.366 -0.833 . . . . 0.0 109.138 -179.924 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.547 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.85 124.88 40.95 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.845 -1.16 . . . . 0.0 109.201 -179.628 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.572 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -104.12 146.77 28.27 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 122.379 1.085 . . . . 0.0 111.709 -179.027 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.525 ' CG1' HG11 ' A' ' 7' ' ' VAL . 84.1 t -100.4 109.81 25.97 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 177.348 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -145.87 -174.2 17.83 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 118.064 -2.017 . . . . 0.0 111.782 -177.426 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.553 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -117.62 -178.8 3.56 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 -178.95 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.496 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.2 p . . . . . 0 C--N 1.297 -1.695 0 O-C-N 121.423 -0.798 . . . . 0.0 109.094 -179.425 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.709 0 N-CA-C 107.867 -2.093 . . . . 0.0 107.867 . . . . . . . . . 0 0 . 1 . 043 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.61 -178.11 6.36 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 121.504 -0.998 . . . . 0.0 109.626 179.209 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.13 -165.89 32.62 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.479 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.539 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.7 Cg_exo -49.53 -175.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.646 0 CA-C-N 118.874 1.337 . . . . 0.0 110.371 179.572 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 16.5 mm-40 -95.89 -178.85 4.5 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.093 -1.004 . . . . 0.0 110.248 -179.094 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -115.64 158.74 14.2 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 -179.906 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.94 128.35 50.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.421 -1.046 . . . . 0.0 108.982 -179.555 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.572 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.32 119.26 16.27 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.589 -0.695 . . . . 0.0 109.959 179.964 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.914 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -97.97 172.61 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.241 -0.912 . . . . 0.0 108.677 179.544 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.511 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -140.7 156.91 46.09 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.945 -1.097 . . . . 0.0 110.012 -179.761 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.914 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.6 m-85 . . . . . 0 N--CA 1.486 1.346 0 O-C-N 121.289 -0.882 . . . . 0.0 109.506 -179.749 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.288 0 CA-C-O 122.427 1.108 . . . . 0.0 110.278 . . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.793 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -116.21 109.22 17.14 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-O 123.09 1.424 . . . . 0.0 109.767 -179.992 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.836 HG22 HG23 ' A' ' 21' ' ' VAL . 2.4 t -112.87 136.26 49.71 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.745 0 CA-C-N 114.24 -1.345 . . . . 0.0 109.776 179.909 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.462 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.65 148.23 5.6 Favored Pre-proline 0 N--CA 1.487 1.396 0 O-C-N 121.184 -0.947 . . . . 0.0 108.855 -179.557 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.462 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.4 Cg_endo -76.46 151.18 94.44 Favored 'Cis proline' 0 C--N 1.312 -1.352 0 C-N-CA 123.38 -1.508 . . . . 0.0 109.422 -0.812 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.648 ' HA ' HG22 ' A' ' 110' ' ' ILE . 2.1 m -88.35 -26.73 22.06 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.593 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.484 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 13.4 m -136.73 165.14 26.61 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.616 -0.678 . . . . 0.0 109.446 179.807 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.31 37.69 31.12 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 -179.631 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.742 ' CA ' HG21 ' A' ' 17' ' ' THR . 38.7 mt -92.84 -41.98 9.78 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 123.362 1.553 . . . . 0.0 110.418 -178.342 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.476 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.45 143.24 0.05 OUTLIER 'General case' 0 C--N 1.261 -3.279 0 CA-C-N 113.297 -1.774 . . . . 0.0 109.808 -179.57 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.601 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.3 p-10 -50.79 104.75 0.08 Allowed 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 121.462 0.649 . . . . 0.0 111.432 -178.369 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.4 15.19 7.76 Favored Glycine 0 N--CA 1.485 1.963 0 C-N-CA 119.317 -1.421 . . . . 0.0 113.086 177.311 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.742 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -104.72 -170.33 1.75 Allowed 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 121.165 2.482 . . . . 0.0 109.579 179.09 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.736 HG13 ' C ' ' A' ' 67' ' ' LEU . 17.4 t -127.4 137.41 57.81 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.116 -179.133 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.633 HG13 ' CG2' ' A' ' 69' ' ' VAL . 11.7 m -111.28 156.32 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.315 -0.866 . . . . 0.0 108.852 178.932 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.504 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.4 tttt -111.55 109.48 19.42 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.214 -0.929 . . . . 0.0 108.843 179.854 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.836 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -102.91 138.8 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.975 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.793 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -132.61 161.76 33.06 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.861 -1.135 . . . . 0.0 109.941 179.689 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.588 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.92 140.75 11.85 Favored Glycine 0 C--N 1.298 -1.547 0 N-CA-C 108.144 -1.983 . . . . 0.0 108.144 179.776 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.54 125.4 16.09 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.606 -1.526 . . . . 0.0 109.296 179.374 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.2 28.51 20.06 Favored Glycine 0 N--CA 1.489 2.187 0 C-N-CA 118.69 -1.719 . . . . 0.0 109.807 -179.808 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.557 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -89.53 171.95 9.34 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 120.936 -1.332 . . . . 0.0 108.301 179.852 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.0 99.33 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.96 -1.087 . . . . 0.0 109.892 -179.385 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.549 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.23 77.66 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.212 -179.337 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.19 34.02 0.3 Allowed Glycine 0 N--CA 1.487 2.099 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 179.57 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.557 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 48.2 p -141.94 108.57 5.35 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 121.048 -1.266 . . . . 0.0 111.252 -179.527 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.59 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.16 109.71 0.32 Allowed 'General case' 0 N--CA 1.496 1.843 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.584 177.944 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.484 ' CE1' ' OG1' ' A' ' 30' ' ' THR . 4.6 m-30 -104.26 156.14 18.15 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.145 -0.972 . . . . 0.0 108.774 179.752 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.509 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -99.7 165.36 11.64 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.978 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.05 HG11 HG21 ' A' ' 65' ' ' THR . 4.5 p -146.66 116.23 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.085 -1.009 . . . . 0.0 109.759 -178.15 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.515 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.73 -176.89 38.17 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.175 -1.964 . . . . 0.0 111.709 -179.608 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.649 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.3 pt20 -101.47 109.77 21.65 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.979 0.895 . . . . 0.0 109.055 -179.653 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.488 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.99 150.46 52.13 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 121.224 -0.922 . . . . 0.0 109.554 179.846 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.48 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.78 139.0 54.24 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.079 -1.013 . . . . 0.0 110.775 -178.949 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.16 114.64 26.45 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 178.196 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m -105.46 15.19 7.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.068 -1.02 . . . . 0.0 110.561 -178.688 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.746 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.42 -175.38 0.1 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.894 -1.128 . . . . 0.0 110.114 179.631 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -71.6 96.81 1.6 Allowed 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.426 -0.796 . . . . 0.0 109.743 -179.696 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.01 27.5 33.89 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 120.194 -1.003 . . . . 0.0 111.482 178.877 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.746 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.42 106.29 20.23 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.523 -1.575 . . . . 0.0 107.443 178.861 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -115.75 104.67 11.9 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 120.389 -1.445 . . . . 0.0 109.967 -177.658 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.833 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.18 109.24 22.03 Favored 'General case' 0 N--CA 1.484 1.24 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.709 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.7 t -107.26 167.93 9.57 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.985 -1.072 . . . . 0.0 110.564 -178.397 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.74 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 49.9 t30 -112.61 130.9 22.97 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.454 -0.779 . . . . 0.0 109.585 -179.435 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.51 ' CD ' ' HB3' ' A' ' 74' ' ' GLU . 2.8 Cg_endo -72.41 23.76 0.27 Allowed 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 122.189 1.926 . . . . 0.0 112.124 179.966 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.74 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -113.41 3.53 15.88 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.333 -1.479 . . . . 0.0 109.192 179.526 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.525 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.45 17.36 2.74 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 179.259 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -80.84 88.87 5.82 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.577 -0.702 . . . . 0.0 111.011 -178.593 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.618 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -107.27 -167.19 1.24 Allowed 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.266 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.96 135.06 0.09 Allowed 'General case' 0 C--N 1.305 -1.353 0 O-C-N 120.496 -1.377 . . . . 0.0 111.372 -179.418 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.843 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -150.3 157.72 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 178.176 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.56 142.24 30.4 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.74 -1.225 . . . . 0.0 110.054 -179.847 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.13 107.73 1.36 Allowed 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 122.469 1.128 . . . . 0.0 109.416 178.436 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.555 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.0 p-10 -61.2 -139.17 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.762 179.893 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.549 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.29 -51.07 60.66 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.431 -0.793 . . . . 0.0 110.454 -178.691 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -101.75 -34.95 9.24 Favored 'General case' 0 C--N 1.285 -2.221 0 N-CA-C 106.287 -1.745 . . . . 0.0 106.287 178.342 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.28 65.87 0.59 Allowed Glycine 0 C--N 1.298 -1.565 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.082 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.5 m -98.71 130.83 45.21 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 121.503 -0.998 . . . . 0.0 108.482 178.729 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.843 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.76 108.86 7.7 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 118.956 -1.098 . . . . 0.0 109.796 -179.272 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 60.0 p -121.51 117.72 27.52 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.36 -0.838 . . . . 0.0 109.421 179.949 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 1.05 HG21 HG11 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -144.99 142.17 29.57 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.489 -0.757 . . . . 0.0 109.593 179.981 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 34.0 p -99.87 141.59 32.48 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.436 -0.79 . . . . 0.0 109.287 179.815 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.736 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -142.04 166.18 25.42 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.354 -0.841 . . . . 0.0 109.418 -179.355 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.701 HG22 HG22 ' A' ' 18' ' ' VAL . 3.4 p -95.49 124.47 39.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.118 -0.989 . . . . 0.0 109.398 -179.852 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.633 ' CG2' HG13 ' A' ' 19' ' ' VAL . 18.8 m -139.76 142.56 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 120.946 -1.096 . . . . 0.0 109.964 -179.183 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.601 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.3 ptt180 -140.09 -166.35 2.08 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 120.627 -1.295 . . . . 0.0 109.897 179.903 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.594 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -71.93 -80.68 0.06 Allowed 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 179.952 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.507 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.5 OUTLIER -64.13 135.97 56.83 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.197 -1.409 . . . . 0.0 107.197 178.579 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.591 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -161.98 138.68 8.14 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 118.07 -1.452 . . . . 0.0 110.252 -177.692 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.51 ' HB3' ' CD ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -31.04 121.39 0.22 Allowed 'General case' 0 N--CA 1.492 1.634 0 CA-C-O 121.479 0.657 . . . . 0.0 110.851 -178.31 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.833 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.95 50.62 2.83 Favored Glycine 0 N--CA 1.496 2.667 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 -179.489 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.47 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.5 OUTLIER -52.97 114.13 1.33 Allowed 'General case' 0 N--CA 1.51 2.55 0 O-C-N 120.934 -1.333 . . . . 0.0 110.645 -179.886 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.685 HD13 ' HB2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -78.94 151.95 31.37 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 120.864 -1.148 . . . . 0.0 108.231 178.114 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.416 ' O ' ' CG ' ' A' ' 78' ' ' PHE . 63.7 t80 -74.68 5.5 4.83 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 120.69 -1.256 . . . . 0.0 110.563 -179.98 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -105.16 -2.49 24.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.905 -1.122 . . . . 0.0 109.701 -179.879 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.21 -19.45 51.42 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.998 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.49 ' O ' ' HB2' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -76.35 151.56 36.61 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.147 -1.207 . . . . 0.0 109.5 -179.947 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.512 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -96.82 123.08 40.42 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.896 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.685 ' HB2' HD13 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -85.27 -16.68 39.33 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.968 -1.083 . . . . 0.0 110.046 -179.121 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 103.19 173.15 26.24 Favored Glycine 0 N--CA 1.483 1.829 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 -179.757 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -60.09 108.93 0.85 Allowed 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 178.853 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.635 HG23 ' HA3' ' A' ' 75' ' ' GLY . 25.5 t -78.88 101.27 4.16 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -178.844 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.531 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -62.14 110.41 1.6 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.548 -0.72 . . . . 0.0 110.046 -178.985 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.548 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -65.14 -4.78 5.38 Favored 'General case' 0 N--CA 1.499 1.993 0 C-N-CA 118.413 -1.315 . . . . 0.0 109.727 179.378 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.6 p -83.66 2.82 35.73 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.712 -1.242 . . . . 0.0 108.911 179.328 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.0 p -117.91 -48.53 2.55 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.406 -0.809 . . . . 0.0 108.974 -179.976 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.67 179.97 4.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.542 -0.724 . . . . 0.0 109.394 179.931 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.47 114.75 29.18 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.368 -0.832 . . . . 0.0 109.22 179.964 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.569 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.7 120.89 37.86 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.887 -1.133 . . . . 0.0 109.532 -179.305 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.611 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.91 148.25 25.2 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 122.38 1.086 . . . . 0.0 111.308 -179.322 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.507 ' CG1' HG11 ' A' ' 7' ' ' VAL . 43.2 t -105.06 111.56 35.04 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 177.66 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.427 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.47 -170.84 17.45 Favored Glycine 0 N--CA 1.486 2.025 0 C-N-CA 118.18 -1.962 . . . . 0.0 111.667 -177.65 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.495 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.68 178.81 4.2 Favored 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.016 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.509 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER . . . . . 0 C--N 1.296 -1.739 0 O-C-N 121.473 -0.767 . . . . 0.0 109.347 -179.517 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.763 0 N-CA-C 107.661 -2.175 . . . . 0.0 107.661 . . . . . . . . . 0 0 . 1 . 044 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.28 -177.76 6.24 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.561 -0.964 . . . . 0.0 109.715 179.28 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.82 -161.78 15.63 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 108.41 -1.876 . . . . 0.0 108.41 -179.344 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.504 ' HG3' HD22 ' A' ' 26' ' ' LEU . 5.7 Cg_exo -47.22 178.97 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.678 0 CA-C-N 118.721 1.261 . . . . 0.0 110.345 179.378 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -92.97 -172.64 3.05 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.198 -0.939 . . . . 0.0 110.357 -178.866 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.427 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -123.45 161.94 17.56 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.891 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.424 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.73 130.53 48.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.415 -1.05 . . . . 0.0 109.244 -179.514 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.611 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.22 120.81 19.36 Favored 'General case' 0 C--N 1.289 -2.043 0 O-C-N 121.716 -0.615 . . . . 0.0 109.646 179.684 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.878 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -98.14 169.67 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 O-C-N 121.138 -0.976 . . . . 0.0 109.331 -179.956 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.484 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -136.96 151.16 48.69 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.256 -0.903 . . . . 0.0 109.694 -179.973 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.878 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 36.7 m-85 . . . . . 0 C--N 1.305 -1.33 0 O-C-N 121.099 -1.001 . . . . 0.0 109.539 -179.727 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.211 0 CA-C-O 122.296 1.046 . . . . 0.0 110.469 . . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.016 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.4 p -105.56 105.04 14.89 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 122.501 1.143 . . . . 0.0 110.46 -179.352 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 1.127 HG22 HG23 ' A' ' 21' ' ' VAL . 3.5 t -118.12 117.82 56.09 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.426 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.267 179.426 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.485 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -161.34 148.49 11.83 Favored Pre-proline 0 N--CA 1.487 1.412 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 -179.588 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.485 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.2 Cg_endo -78.3 149.93 87.38 Favored 'Cis proline' 0 C--N 1.31 -1.491 0 C-N-CA 123.533 -1.445 . . . . 0.0 109.563 -0.573 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 88.5 p -92.23 -23.38 19.36 Favored 'General case' 0 C--N 1.291 -1.962 0 O-C-N 121.618 -0.676 . . . . 0.0 109.209 179.584 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.472 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -132.7 161.15 34.75 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.52 -0.737 . . . . 0.0 109.47 -179.91 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.01 37.76 32.07 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 -179.556 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.789 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.8 mt -90.83 -43.78 9.83 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 123.303 1.525 . . . . 0.0 110.674 -178.233 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.47 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.39 143.94 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.282 0 CA-C-N 113.508 -1.678 . . . . 0.0 109.899 -179.618 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -50.72 107.19 0.15 Allowed 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.683 0.754 . . . . 0.0 111.653 -178.611 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.26 15.46 8.99 Favored Glycine 0 N--CA 1.483 1.829 0 C-N-CA 119.557 -1.306 . . . . 0.0 112.801 177.461 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.789 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.7 t -105.3 -173.82 2.39 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 121.106 2.453 . . . . 0.0 109.914 179.309 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.756 HG13 ' O ' ' A' ' 67' ' ' LEU . 19.0 t -130.18 138.94 52.68 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 114.666 -1.152 . . . . 0.0 111.24 -178.61 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.518 HG12 HD21 ' A' ' 13' ' ' LEU . 34.6 m -115.92 155.65 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.367 -0.833 . . . . 0.0 108.817 178.725 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.541 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 12.4 tttt -107.72 109.33 20.89 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.03 -1.043 . . . . 0.0 109.66 -179.789 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 1.127 HG23 HG22 ' A' ' 7' ' ' VAL . 6.5 p -104.36 125.08 59.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.528 -0.732 . . . . 0.0 109.193 179.759 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.016 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -115.53 165.21 13.26 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.741 -1.224 . . . . 0.0 108.911 179.348 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.614 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.39 107.95 0.49 Allowed Glycine 0 N--CA 1.481 1.686 0 N-CA-C 108.242 -1.943 . . . . 0.0 108.242 -179.97 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -118.23 139.84 50.69 Favored 'General case' 0 N--CA 1.5 2.035 0 CA-C-N 119.635 1.718 . . . . 0.0 110.464 -179.171 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.76 28.46 35.06 Favored Glycine 0 N--CA 1.489 2.219 0 C-N-CA 118.739 -1.696 . . . . 0.0 109.948 179.387 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.579 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.9 OUTLIER -92.4 171.96 8.7 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.935 -1.332 . . . . 0.0 108.429 179.793 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.016 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.23 100.43 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.933 -1.104 . . . . 0.0 109.781 -179.664 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.06 77.6 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.679 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.982 -179.245 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.1 33.99 0.27 Allowed Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.721 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 24.5 p -139.53 106.98 5.55 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.17 -1.194 . . . . 0.0 111.261 -179.577 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.582 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -52.37 110.4 0.49 Allowed 'General case' 0 N--CA 1.497 1.901 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.93 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.515 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 30.0 m-85 -106.68 157.4 17.73 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.06 -1.025 . . . . 0.0 109.079 179.892 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.58 165.29 11.49 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.781 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.652 HG22 HG11 ' A' ' 21' ' ' VAL . 4.6 p -144.57 121.3 4.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.13 -0.981 . . . . 0.0 109.535 -177.623 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.39 -178.53 42.62 Favored Glycine 0 N--CA 1.496 2.681 0 C-N-CA 118.114 -1.993 . . . . 0.0 111.86 -179.814 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.619 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -100.73 108.86 20.81 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.874 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -129.85 149.29 51.65 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.142 -0.974 . . . . 0.0 110.11 179.849 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.34 138.73 54.35 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.363 -0.836 . . . . 0.0 110.757 -179.128 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.25 115.03 26.89 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.146 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 m -105.9 15.52 7.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 120.95 -1.094 . . . . 0.0 110.55 -178.895 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.772 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 173.97 -176.26 0.08 Allowed 'General case' 0 C--N 1.303 -1.417 0 O-C-N 120.902 -1.124 . . . . 0.0 110.192 179.775 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.777 HG23 ' O ' ' A' ' 42' ' ' THR . 15.0 t -71.16 98.45 1.69 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.426 -0.796 . . . . 0.0 109.827 -179.672 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.7 28.77 34.25 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.312 179.006 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.772 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -117.5 106.11 19.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 120.608 -1.525 . . . . 0.0 107.16 178.853 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.3 tp -117.6 104.74 11.33 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.49 -1.381 . . . . 0.0 109.756 -177.613 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.072 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.95 109.52 22.26 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.809 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -106.74 166.49 10.54 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.928 -1.108 . . . . 0.0 110.422 -178.761 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.833 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 3.0 t-20 -107.88 133.34 20.51 Favored Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.526 -0.734 . . . . 0.0 109.511 -179.247 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.3 Cg_endo -74.61 25.12 0.36 Allowed 'Trans proline' 0 C--N 1.319 -0.99 0 C-N-CA 122.376 2.05 . . . . 0.0 111.99 -179.973 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.833 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -107.12 -4.87 18.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.342 -1.474 . . . . 0.0 109.306 179.848 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.663 ' HB3' HD22 ' A' ' 67' ' ' LEU . 5.4 m-20 -133.24 5.94 3.83 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.264 -0.898 . . . . 0.0 108.683 179.918 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -60.35 80.06 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 110.5 -178.797 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.636 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -105.31 -169.6 1.62 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 178.55 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 177.88 135.67 0.07 Allowed 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.626 -1.296 . . . . 0.0 111.149 -179.249 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.783 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -149.58 157.83 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 177.907 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.582 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.31 140.1 33.1 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 120.837 -1.164 . . . . 0.0 110.038 -179.7 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -62.45 106.61 0.79 Allowed 'General case' 0 C--N 1.298 -1.673 0 CA-C-O 122.438 1.113 . . . . 0.0 109.448 178.418 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.561 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.5 p-10 -59.8 -139.38 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.031 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.882 -179.944 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.01 -50.4 61.46 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.344 -0.848 . . . . 0.0 110.485 -178.782 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -103.21 -35.0 8.62 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 178.433 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.974 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.34 69.86 0.71 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 178.123 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.614 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 48.3 m -105.1 127.68 53.0 Favored 'General case' 0 N--CA 1.485 1.299 0 O-C-N 121.517 -0.99 . . . . 0.0 108.96 179.256 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.783 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.96 109.27 8.9 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.076 -179.765 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 42.5 m -120.46 115.84 24.26 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.282 -0.886 . . . . 0.0 109.452 -179.656 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.82 143.82 29.89 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.4 -0.813 . . . . 0.0 109.502 179.967 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.436 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 21.8 p -98.76 137.21 37.69 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.467 -0.771 . . . . 0.0 109.407 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.927 HD11 HG12 ' A' ' 21' ' ' VAL . 0.1 OUTLIER -131.26 167.81 18.58 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.408 -0.808 . . . . 0.0 110.027 -178.673 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.529 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.2 p -102.62 123.6 46.62 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.051 -1.031 . . . . 0.0 108.863 179.396 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.619 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.7 m -135.99 143.99 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 120.899 -1.126 . . . . 0.0 109.868 -179.023 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.8 ptt180 -144.75 -176.79 5.21 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 120.637 -1.289 . . . . 0.0 111.046 -179.891 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.727 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.97 -94.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.276 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.533 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -65.32 148.28 51.98 Favored 'General case' 0 N--CA 1.485 1.282 0 O-C-N 120.566 -1.334 . . . . 0.0 107.543 178.63 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.602 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -167.44 140.66 3.45 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 117.942 -1.503 . . . . 0.0 110.126 -177.459 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.523 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 5.1 mm-40 -36.49 122.06 0.75 Allowed 'General case' 0 N--CA 1.489 1.509 0 CA-C-O 121.421 0.629 . . . . 0.0 110.235 -178.708 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.072 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -96.61 51.83 1.54 Allowed Glycine 0 N--CA 1.495 2.571 0 C-N-CA 120.496 -0.859 . . . . 0.0 111.148 -179.252 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -39.16 114.74 0.43 Allowed 'General case' 0 N--CA 1.509 2.476 0 O-C-N 121.104 -1.233 . . . . 0.0 110.18 179.446 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.724 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -85.53 126.55 33.95 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 120.791 -1.193 . . . . 0.0 109.594 -179.841 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -64.5 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.028 0 O-C-N 120.852 -1.155 . . . . 0.0 109.951 179.527 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.2 t70 -159.55 19.41 0.17 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.007 -1.058 . . . . 0.0 109.624 179.873 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.4 -27.45 5.71 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.929 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.471 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 63.1 p -97.01 158.5 15.4 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 120.963 -1.316 . . . . 0.0 110.366 -179.375 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.498 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 2.6 ptt180 -104.28 140.21 38.19 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.672 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.724 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.7 t90 -84.93 -17.51 37.54 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.683 -1.261 . . . . 0.0 110.787 -178.077 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.41 176.58 19.83 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 -179.45 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.91 104.51 1.12 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 179.198 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.649 HG21 ' HB3' ' A' ' 46' ' ' ALA . 39.9 t -75.93 107.92 7.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.295 -0.878 . . . . 0.0 109.387 -178.767 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.711 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -68.24 113.14 5.6 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.435 -0.791 . . . . 0.0 109.575 -179.777 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.727 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 8.2 m -62.48 -5.07 2.24 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 120.424 -1.423 . . . . 0.0 110.235 179.717 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 p -88.35 -2.82 58.82 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.542 -1.349 . . . . 0.0 109.489 179.825 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.711 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -106.45 -47.95 3.67 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.237 -0.914 . . . . 0.0 108.804 179.837 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -111.1 -177.67 3.27 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.642 -0.662 . . . . 0.0 109.295 179.724 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.75 116.19 31.87 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.933 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.621 ' HB2' HD11 ' A' ' 110' ' ' ILE . 3.4 m -96.67 122.23 39.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.823 -1.173 . . . . 0.0 109.794 -179.167 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.561 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.36 148.71 26.09 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 122.393 1.092 . . . . 0.0 111.458 -179.374 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.556 ' HB ' HG11 ' A' ' 7' ' ' VAL . 48.4 t -106.3 111.51 35.55 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 106.873 -1.529 . . . . 0.0 106.873 177.534 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.508 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.51 -170.68 19.9 Favored Glycine 0 N--CA 1.488 2.106 0 C-N-CA 118.104 -1.998 . . . . 0.0 111.625 -177.743 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.488 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.92 175.15 5.67 Favored 'General case' 0 C--N 1.307 -1.268 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.269 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.477 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 3.3 t . . . . . 0 C--N 1.291 -1.957 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -179.857 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.672 0 N-CA-C 108.048 -2.021 . . . . 0.0 108.048 . . . . . . . . . 0 0 . 1 . 045 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -165.83 -177.16 4.15 Favored 'General case' 0 C--N 1.307 -1.282 0 O-C-N 121.501 -0.999 . . . . 0.0 109.98 179.476 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.71 -161.62 20.48 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.204 -1.958 . . . . 0.0 108.204 -179.368 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.4 Cg_exo -47.55 -179.55 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.694 0 CA-C-N 118.921 1.36 . . . . 0.0 110.442 179.239 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -96.51 174.71 6.71 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.069 -1.019 . . . . 0.0 110.361 -179.056 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.508 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -114.65 175.69 16.29 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -110.01 153.45 11.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 -179.545 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.561 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -94.21 123.94 37.92 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 121.337 -0.852 . . . . 0.0 109.413 179.796 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.75 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.4 pt -97.91 169.72 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 O-C-N 121.092 -1.005 . . . . 0.0 109.159 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.472 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.44 154.99 48.87 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.333 -0.854 . . . . 0.0 109.455 179.93 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.75 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 59.6 m-85 . . . . . 0 N--CA 1.486 1.332 0 O-C-N 121.084 -1.01 . . . . 0.0 109.598 -179.609 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.652 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.487 1.386 0 CA-C-O 122.232 1.015 . . . . 0.0 111.055 . . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.01 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.3 p -101.22 104.71 15.77 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 122.453 1.121 . . . . 0.0 109.959 -179.843 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 1.131 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -118.54 124.54 73.3 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.509 179.716 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.478 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -170.8 149.96 2.99 Favored Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.509 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.478 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.0 Cg_endo -75.02 152.55 98.32 Favored 'Cis proline' 0 C--N 1.309 -1.504 0 C-N-CA 123.553 -1.436 . . . . 0.0 109.714 -0.476 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.622 ' HA ' HG22 ' A' ' 110' ' ' ILE . 9.3 m -93.31 -23.07 18.61 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.61 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.469 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 3.2 m -135.32 163.38 30.14 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.46 -0.775 . . . . 0.0 109.345 179.764 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.83 38.1 32.11 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 108.387 -1.885 . . . . 0.0 108.387 -179.513 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.795 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.8 mt -91.94 -44.14 9.07 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 123.122 1.439 . . . . 0.0 110.7 -178.201 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 68.14 145.24 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.338 0 CA-C-N 113.578 -1.646 . . . . 0.0 110.081 -179.707 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.583 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.5 p-10 -50.45 106.81 0.13 Allowed 'General case' 0 C--N 1.302 -1.474 0 CA-C-O 121.437 0.637 . . . . 0.0 111.793 -178.54 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.05 16.38 9.15 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.502 -1.332 . . . . 0.0 112.905 177.137 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.795 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.1 t -105.05 -173.73 2.37 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 121.069 2.434 . . . . 0.0 109.982 179.276 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.762 HG13 ' O ' ' A' ' 67' ' ' LEU . 19.3 t -130.33 138.84 52.86 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.287 0 CA-C-N 114.593 -1.185 . . . . 0.0 111.183 -178.613 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.532 HG12 HD21 ' A' ' 13' ' ' LEU . 27.2 m -115.95 155.52 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.75 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.567 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 4.7 tttm -104.84 109.15 21.0 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.08 -1.013 . . . . 0.0 109.355 -179.954 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 1.131 HG23 HG22 ' A' ' 7' ' ' VAL . 7.2 p -106.64 124.2 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 179.671 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -118.89 166.94 12.21 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.65 -1.281 . . . . 0.0 109.296 179.848 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.603 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.76 141.8 13.2 Favored Glycine 0 C--N 1.296 -1.676 0 N-CA-C 107.594 -2.203 . . . . 0.0 107.594 179.727 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -147.42 123.21 10.59 Favored 'General case' 0 C--N 1.291 -1.956 0 O-C-N 120.832 -1.393 . . . . 0.0 108.624 179.19 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.68 26.36 25.12 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 119.222 -1.466 . . . . 0.0 109.884 -179.724 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.544 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.3 mt -85.69 176.01 8.4 Favored 'General case' 0 C--N 1.307 -1.281 0 O-C-N 120.695 -1.473 . . . . 0.0 108.245 179.908 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.76 96.87 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.013 -1.055 . . . . 0.0 109.671 -179.891 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.722 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.69 76.61 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.547 -178.91 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.01 34.59 0.33 Allowed Glycine 0 N--CA 1.486 1.984 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 179.334 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.561 ' CG2' ' CB ' ' A' ' 27' ' ' GLN . 1.2 t -149.23 115.4 5.77 Favored 'General case' 0 C--N 1.308 -1.213 0 O-C-N 120.94 -1.329 . . . . 0.0 111.263 179.949 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.68 129.54 4.15 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.819 178.262 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.541 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 7.4 m-85 -120.45 149.85 41.74 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.614 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.549 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -100.07 164.79 11.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.651 -1.281 . . . . 0.0 107.685 178.73 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.648 HG13 ' O ' ' A' ' 34' ' ' VAL . 7.0 p -147.86 118.22 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.139 -0.976 . . . . 0.0 109.855 -177.831 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.77 -178.61 41.52 Favored Glycine 0 N--CA 1.494 2.526 0 C-N-CA 118.432 -1.842 . . . . 0.0 111.537 -179.864 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.707 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -99.16 108.48 21.09 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.822 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.19 148.31 52.02 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.257 -0.902 . . . . 0.0 110.109 179.992 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.44 139.5 53.83 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.39 -0.819 . . . . 0.0 110.736 -179.167 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.878 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.82 26.65 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.129 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.454 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 13.6 m -105.92 15.46 7.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.029 -1.044 . . . . 0.0 110.583 -178.698 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.32 -175.66 0.09 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.858 -1.151 . . . . 0.0 110.095 179.688 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -71.5 97.14 1.61 Allowed 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.47 -0.769 . . . . 0.0 109.754 -179.744 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.26 27.81 35.49 Favored Glycine 0 N--CA 1.491 2.325 0 C-N-CA 120.181 -1.009 . . . . 0.0 111.394 179.006 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 2.0 t -116.1 106.6 20.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 O-C-N 120.625 -1.515 . . . . 0.0 107.295 178.814 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.878 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -116.21 104.66 11.74 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.483 -1.386 . . . . 0.0 109.738 -177.745 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.925 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.63 109.36 22.13 Favored 'General case' 0 N--CA 1.483 1.221 0 O-C-N 120.887 -1.133 . . . . 0.0 107.947 178.916 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.492 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -108.29 167.09 10.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.98 -1.075 . . . . 0.0 110.589 -178.535 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.496 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 43.6 t30 -114.7 128.22 26.09 Favored Pre-proline 0 N--CA 1.499 1.977 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 -179.554 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.603 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.2 Cg_endo -69.96 19.89 0.19 Allowed 'Trans proline' 0 CA--C 1.545 1.065 0 C-N-CA 122.005 1.803 . . . . 0.0 112.294 -179.804 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.496 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -93.79 -7.51 43.22 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.384 -1.448 . . . . 0.0 108.802 179.122 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.608 ' HB3' HD22 ' A' ' 67' ' ' LEU . 4.2 m-20 -131.24 2.22 4.24 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.369 -0.832 . . . . 0.0 108.802 -179.869 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -58.15 83.53 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.336 -0.853 . . . . 0.0 111.147 -178.247 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -110.97 -170.89 1.72 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 178.087 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.62 134.7 0.08 Allowed 'General case' 0 C--N 1.305 -1.363 0 O-C-N 120.446 -1.409 . . . . 0.0 111.621 -179.345 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.708 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.9 p -145.95 158.78 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 107.071 -1.455 . . . . 0.0 107.071 177.744 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.568 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.13 145.44 26.01 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.448 -1.407 . . . . 0.0 109.944 -179.613 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.002 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.04 108.84 3.23 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 122.272 1.034 . . . . 0.0 109.568 179.036 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.54 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.3 t0 -62.8 -138.89 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.979 -179.888 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.722 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.95 -51.53 40.59 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.393 -0.817 . . . . 0.0 110.559 -178.732 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -104.46 -33.54 8.55 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 178.493 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.971 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.75 70.08 0.7 Allowed Glycine 0 C--N 1.299 -1.512 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 178.482 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.603 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 70.9 m -103.57 130.81 51.05 Favored 'General case' 0 N--CA 1.484 1.255 0 O-C-N 121.248 -1.148 . . . . 0.0 109.208 179.324 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.708 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.57 108.86 7.79 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.471 -0.891 . . . . 0.0 109.841 -179.588 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.2 m -115.4 115.38 26.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.117 -0.99 . . . . 0.0 109.328 179.998 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.44 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.09 144.87 30.29 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.413 -0.804 . . . . 0.0 109.829 -179.91 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.426 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 24.7 p -98.99 140.8 32.61 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.55 -0.718 . . . . 0.0 109.169 179.66 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 1.128 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -135.46 165.37 25.64 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.322 -0.862 . . . . 0.0 110.065 -178.924 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.587 HG22 HG22 ' A' ' 18' ' ' VAL . 1.2 p -104.38 123.06 46.75 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.127 -0.983 . . . . 0.0 108.807 179.463 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.707 HG12 ' HB3' ' A' ' 36' ' ' GLN . 18.9 m -136.06 143.48 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.838 -1.164 . . . . 0.0 110.359 -178.898 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.583 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.2 ptt180 -141.64 -166.19 2.15 Favored 'General case' 0 N--CA 1.485 1.323 0 O-C-N 120.686 -1.259 . . . . 0.0 110.331 179.688 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.571 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 1.3 mtp180 -68.98 -78.21 0.07 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.57 -0.706 . . . . 0.0 109.128 -179.419 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -71.92 139.25 48.65 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 120.122 -1.611 . . . . 0.0 107.822 179.39 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -160.32 136.36 8.52 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 118.276 -1.37 . . . . 0.0 110.058 -178.501 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.483 ' O ' ' O ' ' A' ' 47' ' ' CYS . 20.4 mm-40 -32.84 122.36 0.36 Allowed 'General case' 0 N--CA 1.491 1.598 0 CA-C-O 121.557 0.694 . . . . 0.0 110.776 -178.248 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.925 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.51 44.37 3.05 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 -179.502 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.603 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -39.12 112.3 0.24 Allowed 'General case' 0 N--CA 1.507 2.384 0 O-C-N 121.156 -1.202 . . . . 0.0 110.27 179.954 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.696 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.5 tp -87.41 127.73 35.21 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 120.837 -1.165 . . . . 0.0 109.412 -179.926 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -64.35 57.96 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 120.91 -1.119 . . . . 0.0 110.24 179.9 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.52 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.0 t70 -160.68 19.06 0.13 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.049 -1.032 . . . . 0.0 109.817 179.813 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.06 -26.01 5.73 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.161 -1.175 . . . . 0.0 110.161 179.865 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.424 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -92.54 153.65 18.93 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.906 -1.35 . . . . 0.0 110.384 -179.463 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.482 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -101.34 132.45 46.89 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.493 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.696 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -80.66 -17.44 51.2 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.813 -1.179 . . . . 0.0 110.278 -178.624 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.6 173.55 20.16 Favored Glycine 0 N--CA 1.486 1.995 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -179.682 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.38 108.05 1.03 Allowed 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 179.04 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.676 HG21 ' CB ' ' A' ' 46' ' ' ALA . 39.8 t -79.01 105.64 8.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 O-C-N 121.43 -0.794 . . . . 0.0 108.882 -178.834 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.631 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -67.93 111.23 4.25 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.427 -0.795 . . . . 0.0 109.874 -179.151 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.571 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -63.88 -5.45 4.43 Favored 'General case' 0 N--CA 1.501 2.095 0 C-N-CA 118.438 -1.305 . . . . 0.0 109.862 179.529 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.424 HG23 ' HB3' ' A' ' 71' ' ' ARG . 69.7 p -84.49 0.22 50.53 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.744 -1.222 . . . . 0.0 108.909 179.324 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.631 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -114.2 -49.06 2.86 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.469 -0.77 . . . . 0.0 109.147 179.952 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.17 -178.65 3.7 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.386 -0.821 . . . . 0.0 109.58 -179.943 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.16 114.78 29.18 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.452 -0.78 . . . . 0.0 109.022 -179.991 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.563 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.04 122.12 39.68 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.919 -1.113 . . . . 0.0 109.49 -179.375 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.637 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.28 144.7 30.46 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 122.444 1.116 . . . . 0.0 111.151 -179.336 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.567 ' HB ' HG11 ' A' ' 7' ' ' VAL . 99.4 t -100.9 110.02 26.84 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.604 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.483 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.39 -172.63 19.19 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 117.899 -2.096 . . . . 0.0 111.83 -177.611 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.652 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -111.63 -177.51 3.21 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -179.268 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.549 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER . . . . . 0 C--N 1.297 -1.707 0 O-C-N 121.137 -0.977 . . . . 0.0 110.143 -179.134 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.49 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.483 1.793 0 N-CA-C 107.978 -2.049 . . . . 0.0 107.978 . . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.49 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -171.24 -179.12 2.58 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.517 -0.99 . . . . 0.0 109.567 179.156 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.36 -165.42 28.61 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 108.685 -1.766 . . . . 0.0 108.685 -179.548 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.472 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.0 Cg_exo -49.3 -178.19 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.641 0 CA-C-N 118.857 1.328 . . . . 0.0 110.076 179.556 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -96.88 -179.67 4.64 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.079 -1.013 . . . . 0.0 110.313 -179.056 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.483 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.87 163.79 12.8 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 179.994 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.84 127.6 51.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.287 -1.125 . . . . 0.0 109.165 -179.53 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.637 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.02 121.11 18.61 Favored 'General case' 0 C--N 1.289 -2.053 0 CA-C-O 121.323 0.582 . . . . 0.0 109.743 179.825 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.861 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.98 168.76 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.238 -0.914 . . . . 0.0 109.387 179.952 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.469 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.0 OUTLIER -138.34 157.63 45.86 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.289 -0.882 . . . . 0.0 109.78 -179.875 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.861 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.6 m-85 . . . . . 0 N--CA 1.487 1.41 0 O-C-N 121.202 -0.936 . . . . 0.0 109.565 -179.756 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.526 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.482 1.154 0 CA-C-O 122.425 1.107 . . . . 0.0 110.609 . . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.005 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.9 p -105.42 104.72 14.5 Favored 'General case' 0 C--N 1.295 -1.77 0 CA-C-O 122.57 1.176 . . . . 0.0 110.173 -179.585 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.944 HG22 HG23 ' A' ' 21' ' ' VAL . 20.5 t -119.29 122.56 69.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.317 179.804 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.477 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -166.59 150.64 6.76 Favored Pre-proline 0 N--CA 1.489 1.511 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.294 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.477 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -74.62 151.9 97.54 Favored 'Cis proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.651 -1.395 . . . . 0.0 110.016 -0.621 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.635 ' HA ' HG22 ' A' ' 110' ' ' ILE . 6.0 m -93.73 -23.07 18.34 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.518 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.501 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -135.67 160.86 37.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.474 -0.766 . . . . 0.0 109.446 -179.97 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.09 37.7 31.93 Favored Glycine 0 N--CA 1.494 2.541 0 N-CA-C 108.517 -1.833 . . . . 0.0 108.517 -179.624 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.829 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.0 mt -89.9 -44.7 9.73 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 123.188 1.47 . . . . 0.0 110.608 -178.439 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.47 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.4 OUTLIER 65.89 146.26 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.626 -1.624 . . . . 0.0 110.151 -179.931 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.588 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.1 p-10 -51.33 107.52 0.19 Allowed 'General case' 0 C--N 1.302 -1.485 0 CA-C-O 121.68 0.752 . . . . 0.0 111.678 -178.601 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.24 15.08 9.27 Favored Glycine 0 N--CA 1.484 1.848 0 C-N-CA 119.511 -1.328 . . . . 0.0 112.847 177.348 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.829 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.9 t -103.72 -172.77 2.17 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 121.146 2.473 . . . . 0.0 109.776 179.358 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.721 HG13 ' C ' ' A' ' 67' ' ' LEU . 13.6 t -132.81 140.42 47.45 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.351 0 CA-C-N 114.937 -1.028 . . . . 0.0 111.136 -178.829 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.525 HG23 ' CD1' ' A' ' 67' ' ' LEU . 31.3 m -117.76 154.16 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 121.355 -0.841 . . . . 0.0 108.968 179.144 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.551 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -108.03 108.95 20.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.886 . . . . 0.0 109.148 179.966 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.944 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -106.1 122.44 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.978 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.005 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.84 166.23 11.57 Favored 'General case' 0 C--N 1.306 -1.3 0 O-C-N 120.857 -1.152 . . . . 0.0 108.737 179.502 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.605 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.41 108.37 0.49 Allowed Glycine 0 N--CA 1.482 1.752 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 179.952 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.94 138.83 51.28 Favored 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 119.366 1.583 . . . . 0.0 110.21 -179.454 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.406 ' HA2' ' ND2' ' A' ' 60' ' ' ASN . . . 84.88 28.92 30.29 Favored Glycine 0 N--CA 1.491 2.306 0 C-N-CA 118.941 -1.6 . . . . 0.0 109.888 179.549 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.53 ' O ' ' N ' ' A' ' 28' ' ' ALA . 2.0 mt -91.67 176.13 6.65 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.979 -1.307 . . . . 0.0 108.449 179.956 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.65 96.91 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.052 -1.03 . . . . 0.0 109.61 -179.905 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.7 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.07 76.61 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.798 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.341 -178.857 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.52 34.17 0.32 Allowed Glycine 0 N--CA 1.486 1.985 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.383 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.568 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.1 t -148.44 115.32 6.06 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 120.931 -1.335 . . . . 0.0 111.113 -179.935 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.559 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -43.36 128.83 4.94 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.777 178.38 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.568 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.0 m-85 -120.58 147.35 45.31 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.486 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.469 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.61 159.65 14.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.507 -1.371 . . . . 0.0 107.666 178.648 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.8 HG11 HG21 ' A' ' 65' ' ' THR . 9.8 p -144.36 116.33 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.08 -1.012 . . . . 0.0 110.198 -177.543 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.522 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.89 -175.33 38.81 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.477 -1.82 . . . . 0.0 111.654 -179.995 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.587 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -100.91 109.22 21.14 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 121.845 0.831 . . . . 0.0 108.973 -179.717 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.79 149.44 52.43 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.254 -0.904 . . . . 0.0 110.05 179.796 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.34 139.07 54.26 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.38 -0.825 . . . . 0.0 110.813 -179.064 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 115.05 26.92 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.98 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.8 m -106.05 15.59 7.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 O-C-N 120.969 -1.082 . . . . 0.0 110.534 -178.796 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.777 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 173.79 -176.36 0.07 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.897 -1.127 . . . . 0.0 110.127 179.835 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.781 HG23 ' O ' ' A' ' 42' ' ' THR . 15.0 t -70.79 98.58 1.57 Allowed 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.416 -0.803 . . . . 0.0 109.914 -179.69 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.13 28.52 36.84 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.265 -0.969 . . . . 0.0 111.238 179.027 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.777 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.9 106.31 19.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.839 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.6 tp -116.94 104.83 11.68 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.409 -1.432 . . . . 0.0 109.749 -177.55 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.895 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.62 109.46 22.21 Favored 'General case' 0 N--CA 1.485 1.276 0 O-C-N 120.806 -1.184 . . . . 0.0 108.29 178.938 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.38 167.46 9.91 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.959 -1.088 . . . . 0.0 110.078 -178.959 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.743 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 15.2 t-20 -109.31 136.45 20.18 Favored Pre-proline 0 N--CA 1.5 2.06 0 O-C-N 121.369 -0.832 . . . . 0.0 109.97 -179.296 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -75.25 23.27 0.42 Allowed 'Trans proline' 0 CA--C 1.544 0.976 0 C-N-CA 122.369 2.046 . . . . 0.0 111.798 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.743 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -117.68 3.9 12.33 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.429 -1.42 . . . . 0.0 108.974 179.593 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.583 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.58 17.87 2.9 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 179.214 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -83.71 90.13 7.26 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.925 -178.473 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.81 -170.41 1.65 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 178.042 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.445 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.81 135.36 0.09 Allowed 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.402 -1.436 . . . . 0.0 111.508 -179.245 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.788 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.3 p -151.88 158.73 4.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.037 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.559 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.49 145.77 25.89 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.642 -1.286 . . . . 0.0 109.799 -179.621 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.22 108.01 2.55 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 122.389 1.09 . . . . 0.0 109.681 178.879 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.553 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.8 p-10 -61.23 -139.56 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.811 -179.898 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.7 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.96 -50.89 57.16 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.296 -0.877 . . . . 0.0 110.498 -178.858 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.406 ' ND2' ' HA2' ' A' ' 25' ' ' GLY . 0.2 OUTLIER -103.98 -34.02 8.61 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 178.481 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.947 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.11 70.36 0.73 Allowed Glycine 0 C--N 1.297 -1.583 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 178.278 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.605 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 38.9 m -104.05 127.4 51.61 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.69 -0.888 . . . . 0.0 108.936 179.165 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.788 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.06 109.04 8.15 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.415 -179.682 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -118.69 117.07 27.94 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.264 -0.898 . . . . 0.0 109.349 -179.934 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.8 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -145.46 142.0 28.88 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.452 -0.78 . . . . 0.0 109.772 179.99 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.3 p -100.91 135.06 42.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.497 -0.752 . . . . 0.0 109.231 179.742 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.721 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -133.39 165.52 24.65 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.314 -0.866 . . . . 0.0 109.526 -179.449 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.679 HG22 HG22 ' A' ' 18' ' ' VAL . 2.3 p -96.76 125.23 41.07 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.27 -0.894 . . . . 0.0 109.342 -179.903 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.562 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.3 m -136.13 144.54 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.959 -1.088 . . . . 0.0 109.584 -179.312 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.588 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.4 ptt180 -139.95 -166.37 2.08 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 120.593 -1.317 . . . . 0.0 110.338 -179.927 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.688 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 40.9 mtm180 -69.83 -73.91 0.15 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.51 -0.744 . . . . 0.0 109.298 -179.113 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.52 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -76.87 145.74 38.13 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 178.534 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -166.23 140.06 4.23 Favored 'General case' 0 C--N 1.293 -1.887 0 C-N-CA 117.507 -1.677 . . . . 0.0 110.464 -177.737 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.537 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 2.2 mm-40 -33.98 122.32 0.46 Allowed 'General case' 0 N--CA 1.49 1.533 0 CA-C-O 121.593 0.711 . . . . 0.0 110.664 -178.479 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.895 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.09 45.82 3.03 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 -179.338 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.9 m-30 -39.63 113.19 0.31 Allowed 'General case' 0 N--CA 1.508 2.472 0 O-C-N 121.083 -1.245 . . . . 0.0 110.169 179.673 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.737 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.2 tp -87.23 128.17 35.15 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 120.868 -1.145 . . . . 0.0 109.379 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -64.47 57.89 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 120.809 -1.182 . . . . 0.0 110.328 179.882 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.518 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.1 t70 -161.0 18.92 0.12 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.946 -1.096 . . . . 0.0 109.779 179.844 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.79 -25.85 5.65 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 179.952 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 3.4 p -91.55 153.27 19.87 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 120.895 -1.356 . . . . 0.0 110.387 -179.351 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.508 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 8.5 ptt180 -100.95 131.93 46.6 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.544 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.737 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -81.74 -18.61 43.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.729 -1.232 . . . . 0.0 110.495 -178.47 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.61 173.65 19.6 Favored Glycine 0 N--CA 1.486 2.014 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 -179.624 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -62.07 109.27 1.24 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 179.133 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.681 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.5 t -80.87 104.51 9.47 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 O-C-N 121.339 -0.851 . . . . 0.0 109.058 -178.859 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.573 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -68.07 112.69 5.19 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.628 -0.67 . . . . 0.0 109.648 -179.551 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.688 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 6.8 m -56.83 -8.4 0.6 Allowed 'General case' 0 N--CA 1.496 1.867 0 C-N-CA 118.309 -1.356 . . . . 0.0 110.466 179.816 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 p -84.52 -12.44 54.19 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.366 -1.459 . . . . 0.0 109.53 179.981 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.573 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -92.97 -47.86 6.8 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.286 -0.884 . . . . 0.0 109.032 179.934 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -117.12 -178.24 3.4 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.547 -0.72 . . . . 0.0 109.477 179.937 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.48 117.76 35.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.462 -0.774 . . . . 0.0 108.922 179.888 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.496 ' O ' HG12 ' A' ' 110' ' ' ILE . 3.2 m -96.41 121.41 38.19 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.761 -1.212 . . . . 0.0 109.791 -179.202 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.78 146.92 27.92 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 122.445 1.117 . . . . 0.0 111.022 -179.486 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.707 ' HB ' HG11 ' A' ' 7' ' ' VAL . 42.5 t -102.93 109.81 27.82 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 177.442 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.482 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.68 -170.0 16.65 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 118.263 -1.922 . . . . 0.0 111.697 -177.4 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.526 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -122.2 -179.41 4.16 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.608 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.463 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.4 OUTLIER . . . . . 0 C--N 1.296 -1.725 0 O-C-N 121.362 -0.836 . . . . 0.0 109.593 -179.739 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.696 0 N-CA-C 107.713 -2.155 . . . . 0.0 107.713 . . . . . . . . . 0 0 . 1 . 047 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.52 -177.6 5.72 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.626 -0.926 . . . . 0.0 109.967 179.311 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.53 -161.55 21.31 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.41 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.494 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.2 Cg_exo -45.83 173.12 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.628 0 CA-C-N 118.919 1.359 . . . . 0.0 109.936 179.263 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -92.81 -174.87 3.74 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.127 -0.983 . . . . 0.0 110.526 -178.751 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.482 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.0 166.14 13.55 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.953 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -103.97 130.42 54.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.349 -1.089 . . . . 0.0 109.075 -179.39 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.81 123.68 23.85 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.494 -0.753 . . . . 0.0 109.642 179.728 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.761 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.78 168.42 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 119.555 -0.858 . . . . 0.0 108.912 179.893 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.501 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 2.3 m -134.12 153.76 51.62 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.295 -0.878 . . . . 0.0 109.448 -179.882 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.761 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 65.9 m-85 . . . . . 0 N--CA 1.485 1.314 0 O-C-N 121.193 -0.942 . . . . 0.0 109.397 -179.783 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.482 1.156 0 CA-C-O 122.359 1.076 . . . . 0.0 110.696 . . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.009 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -105.11 104.8 14.61 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 122.609 1.195 . . . . 0.0 110.141 -179.505 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.931 HG22 HG23 ' A' ' 21' ' ' VAL . 16.7 t -120.17 119.91 61.4 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.44 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.325 179.662 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.523 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.0 150.06 9.54 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 -179.587 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.523 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.1 Cg_endo -75.11 153.57 99.06 Favored 'Cis proline' 0 C--N 1.31 -1.471 0 C-N-CA 123.721 -1.366 . . . . 0.0 109.933 -0.637 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.646 ' HA ' HG22 ' A' ' 110' ' ' ILE . 8.0 m -95.04 -23.51 17.32 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.461 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.461 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 3.4 m -134.24 164.21 27.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.583 -0.698 . . . . 0.0 109.649 179.95 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.36 36.85 43.39 Favored Glycine 0 N--CA 1.496 2.668 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 -179.73 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.885 ' CA ' HG21 ' A' ' 17' ' ' THR . 21.9 mt -90.03 -46.18 8.67 Favored 'General case' 0 C--N 1.297 -1.705 0 CA-C-O 123.151 1.453 . . . . 0.0 110.6 -178.532 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.45 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 2.1 t 61.45 148.25 0.02 OUTLIER 'General case' 0 C--N 1.259 -3.341 0 CA-C-N 113.917 -1.492 . . . . 0.0 109.913 -179.766 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.625 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 3.9 p-10 -51.35 109.61 0.36 Allowed 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.574 0.702 . . . . 0.0 111.683 -178.834 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.94 12.68 10.95 Favored Glycine 0 N--CA 1.485 1.945 0 C-N-CA 119.403 -1.38 . . . . 0.0 112.915 177.42 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.885 HG21 ' CA ' ' A' ' 13' ' ' LEU . 7.9 t -101.45 -175.25 2.8 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 121.0 2.4 . . . . 0.0 109.717 179.511 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.673 HG13 ' O ' ' A' ' 67' ' ' LEU . 9.4 t -132.75 137.72 53.41 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.906 -179.414 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.485 ' O ' HD12 ' A' ' 67' ' ' LEU . 28.5 m -116.97 153.88 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.348 -0.845 . . . . 0.0 109.214 179.219 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -110.31 109.23 19.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.29 -0.882 . . . . 0.0 108.977 179.715 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.931 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -105.95 122.5 59.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.766 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.009 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.4 165.84 12.07 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.886 -1.134 . . . . 0.0 108.954 179.554 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.52 108.23 0.5 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 108.806 -1.717 . . . . 0.0 108.806 -179.976 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.457 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.31 140.8 48.95 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-N 119.204 1.502 . . . . 0.0 110.281 -179.38 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.08 28.46 34.05 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.077 -1.535 . . . . 0.0 109.964 179.653 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -92.91 175.01 6.95 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.942 -1.328 . . . . 0.0 108.367 179.977 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.54 99.19 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.913 -1.117 . . . . 0.0 109.572 -179.743 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.647 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.69 76.85 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.272 -179.101 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.17 34.26 0.29 Allowed Glycine 0 N--CA 1.486 2.005 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.574 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.563 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.9 p -145.11 111.98 5.91 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.958 -1.319 . . . . 0.0 111.167 -179.683 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -45.7 125.66 6.21 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.574 178.107 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.489 ' CD2' ' O ' ' A' ' 30' ' ' THR . 14.2 m-85 -117.33 151.11 37.67 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.682 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.516 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -101.39 153.23 19.85 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.76 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.002 HG11 HG21 ' A' ' 65' ' ' THR . 6.2 p -136.31 115.05 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.105 -0.997 . . . . 0.0 109.756 -177.928 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -165.09 -178.45 38.35 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 118.474 -1.822 . . . . 0.0 111.696 -179.68 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.618 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -102.47 109.27 20.86 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.729 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.87 149.08 52.67 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.128 -0.982 . . . . 0.0 110.117 -179.878 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.78 138.72 54.55 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.399 -0.813 . . . . 0.0 110.609 -179.111 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.883 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 114.88 26.72 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 178.005 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 m -105.24 15.05 6.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.986 -1.071 . . . . 0.0 110.579 -178.72 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.759 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.59 -175.88 0.08 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.916 -1.115 . . . . 0.0 110.044 179.686 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.786 HG23 ' O ' ' A' ' 42' ' ' THR . 15.0 t -71.81 98.34 1.96 Allowed 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.418 -0.801 . . . . 0.0 109.794 -179.704 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.76 27.43 34.94 Favored Glycine 0 N--CA 1.492 2.425 0 C-N-CA 120.077 -1.058 . . . . 0.0 111.518 179.084 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.76 106.42 20.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 O-C-N 120.548 -1.56 . . . . 0.0 107.288 178.929 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.883 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -117.36 104.64 11.33 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.38 -1.45 . . . . 0.0 109.796 -177.757 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.89 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.77 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 178.698 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -105.49 166.96 10.07 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.043 -1.036 . . . . 0.0 110.493 -178.641 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.465 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 36.8 t-20 -110.35 129.61 23.77 Favored Pre-proline 0 N--CA 1.499 1.998 0 O-C-N 121.668 -0.645 . . . . 0.0 109.499 -179.393 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.612 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.1 Cg_endo -72.39 22.34 0.28 Allowed 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 122.091 1.861 . . . . 0.0 111.808 179.581 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -110.76 2.6 18.5 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.41 -1.431 . . . . 0.0 108.997 179.626 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.531 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.58 17.83 2.71 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 179.447 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -80.73 93.11 6.13 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.916 -0.714 . . . . 0.0 111.086 -178.496 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -113.15 -167.78 1.24 Allowed 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 178.113 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.73 136.82 0.09 Allowed 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.619 -1.301 . . . . 0.0 111.524 -179.248 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.918 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -154.45 157.1 4.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.113 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.84 144.82 27.03 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.665 -1.272 . . . . 0.0 109.893 -179.636 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.6 107.07 1.61 Allowed 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 122.353 1.073 . . . . 0.0 109.428 178.772 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.549 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.4 t0 -60.47 -139.29 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.956 -179.895 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.647 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.01 -50.72 57.98 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.401 -0.812 . . . . 0.0 110.733 -178.749 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -104.02 -34.06 8.58 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.461 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.985 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.23 66.17 0.62 Allowed Glycine 0 C--N 1.295 -1.704 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 178.243 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 20.3 m -103.5 125.02 49.82 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.758 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.918 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.6 109.19 8.5 Favored 'General case' 0 C--N 1.296 -1.749 0 C-N-CA 119.631 -0.827 . . . . 0.0 109.649 -179.28 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 97.3 p -116.44 116.51 27.8 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.345 -0.847 . . . . 0.0 109.441 -179.987 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 1.002 HG21 HG11 ' A' ' 34' ' ' VAL . 1.1 t -141.3 138.5 33.21 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.438 -0.789 . . . . 0.0 109.816 179.982 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.444 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 23.4 p -99.12 141.22 32.16 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.446 -0.784 . . . . 0.0 109.127 179.814 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.776 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -142.34 169.44 17.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.33 -0.856 . . . . 0.0 109.523 -179.24 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.5 p -96.57 126.26 41.62 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.055 -1.028 . . . . 0.0 109.519 -179.712 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.676 HG23 HD13 ' A' ' 13' ' ' LEU . 15.6 m -133.14 142.74 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 120.916 -1.115 . . . . 0.0 109.738 -179.346 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.625 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.84 -170.68 3.59 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.517 -1.364 . . . . 0.0 110.731 -179.877 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.6 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -66.6 -102.23 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.807 -0.558 . . . . 0.0 110.171 -179.04 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.12 136.29 56.38 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.388 -1.445 . . . . 0.0 108.198 179.845 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.618 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -155.86 158.52 38.18 Favored 'General case' 0 C--N 1.295 -1.793 0 C-N-CA 118.722 -1.191 . . . . 0.0 109.894 -178.853 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.515 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 12.1 mm-40 -50.01 121.9 6.01 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.296 -0.878 . . . . 0.0 109.561 -178.651 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.89 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.12 48.32 3.43 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 -179.514 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.612 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -40.11 113.38 0.35 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.046 -1.267 . . . . 0.0 110.286 179.919 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.756 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -86.94 127.1 35.07 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 120.913 -1.117 . . . . 0.0 109.47 179.987 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -63.88 58.52 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.865 -1.147 . . . . 0.0 110.167 179.8 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.531 ' N ' ' O ' ' A' ' 77' ' ' LEU . 14.3 t0 -161.02 19.23 0.12 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.09 -1.006 . . . . 0.0 109.92 179.842 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -25.6 5.96 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 179.802 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 67.4 p -94.09 159.22 15.25 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.979 -1.307 . . . . 0.0 110.384 -179.35 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.483 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 2.7 ptt180 -104.97 133.33 49.94 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 179.796 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.756 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -82.38 -18.37 42.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.845 -1.159 . . . . 0.0 110.406 -178.694 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.29 174.04 19.36 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 -179.671 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.56 108.7 1.44 Allowed 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 179.137 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.642 HG21 ' CB ' ' A' ' 46' ' ' ALA . 42.9 t -80.28 104.38 8.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 O-C-N 121.469 -0.77 . . . . 0.0 109.278 -178.771 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.561 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -63.78 108.35 1.42 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.517 -0.739 . . . . 0.0 110.137 -179.231 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.597 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.6 t -60.76 -5.14 1.17 Allowed 'General case' 0 N--CA 1.501 2.084 0 C-N-CA 118.141 -1.424 . . . . 0.0 110.282 179.214 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 73.2 p -89.87 2.08 55.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.486 -1.383 . . . . 0.0 109.495 179.965 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.561 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.06 -49.04 2.94 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.236 -0.915 . . . . 0.0 109.149 -179.975 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.57 179.55 4.23 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.432 -0.792 . . . . 0.0 109.48 -179.974 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.65 112.99 25.74 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.791 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.506 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.55 121.39 38.32 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.008 -1.058 . . . . 0.0 109.373 -179.004 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.594 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.61 147.03 27.3 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.369 1.08 . . . . 0.0 111.341 -179.117 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.626 ' HB ' HG11 ' A' ' 7' ' ' VAL . 54.0 t -102.82 109.24 26.15 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 177.309 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.1 -170.96 16.56 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 118.179 -1.962 . . . . 0.0 111.53 -177.378 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.516 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -118.33 -178.52 3.54 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -178.612 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.51 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER . . . . . 0 C--N 1.295 -1.783 0 O-C-N 121.423 -0.798 . . . . 0.0 109.38 -179.352 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.735 0 N-CA-C 107.645 -2.182 . . . . 0.0 107.645 . . . . . . . . . 0 0 . 1 . 048 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.18 -178.39 7.17 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.581 -0.953 . . . . 0.0 109.809 179.229 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.12 -162.08 19.32 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 108.209 -1.957 . . . . 0.0 108.209 -179.398 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.3 Cg_exo -45.68 171.99 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.632 0 CA-C-N 118.855 1.327 . . . . 0.0 109.932 179.366 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -90.6 -173.07 3.62 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.092 -1.005 . . . . 0.0 110.544 -178.567 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.467 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.68 168.26 15.04 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.874 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.33 131.44 54.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 121.414 -1.051 . . . . 0.0 109.143 -179.313 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.594 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.16 122.51 21.13 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.662 -0.648 . . . . 0.0 109.736 179.767 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.906 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -97.95 170.99 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.279 -0.888 . . . . 0.0 108.898 179.766 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.461 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.1 OUTLIER -137.07 162.29 33.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.216 -0.927 . . . . 0.0 109.856 -179.78 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.906 ' CE1' HD12 ' A' ' 110' ' ' ILE . 48.3 m-85 . . . . . 0 N--CA 1.485 1.277 0 O-C-N 121.244 -0.91 . . . . 0.0 109.495 -179.817 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.486 1.34 0 CA-C-O 122.431 1.11 . . . . 0.0 110.262 . . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.879 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.0 t -115.82 109.16 17.25 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-O 123.058 1.409 . . . . 0.0 109.867 -179.893 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.921 HG22 HG23 ' A' ' 21' ' ' VAL . 1.6 t -114.5 136.68 50.32 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.733 0 CA-C-N 114.236 -1.347 . . . . 0.0 109.557 179.781 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.486 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -170.55 149.68 3.09 Favored Pre-proline 0 N--CA 1.488 1.432 0 O-C-N 121.135 -0.978 . . . . 0.0 109.001 -179.591 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.486 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -77.02 150.78 92.94 Favored 'Cis proline' 0 C--N 1.313 -1.302 0 C-N-CA 123.436 -1.485 . . . . 0.0 109.455 -0.931 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.656 ' HA ' HG22 ' A' ' 110' ' ' ILE . 79.1 p -91.31 -23.81 20.01 Favored 'General case' 0 C--N 1.292 -1.928 0 O-C-N 121.589 -0.695 . . . . 0.0 109.292 179.971 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.493 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -131.57 162.05 31.22 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.284 -0.885 . . . . 0.0 109.733 -179.839 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.76 38.38 31.72 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 108.434 -1.866 . . . . 0.0 108.434 -179.666 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.781 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.0 mt -91.88 -44.07 9.13 Favored 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 123.12 1.438 . . . . 0.0 110.759 -178.226 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.468 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.87 144.22 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.317 0 CA-C-N 113.568 -1.651 . . . . 0.0 109.938 -179.526 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.618 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.6 p-10 -50.55 108.43 0.23 Allowed 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 121.64 0.734 . . . . 0.0 111.759 -178.483 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.72 14.24 10.52 Favored Glycine 0 N--CA 1.484 1.841 0 C-N-CA 119.555 -1.307 . . . . 0.0 112.895 177.255 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.781 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -105.29 -173.71 2.36 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 121.011 2.406 . . . . 0.0 110.162 179.435 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.779 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.8 t -130.62 141.39 46.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.273 0 CA-C-N 114.45 -1.25 . . . . 0.0 111.069 -178.714 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.572 HG12 HD21 ' A' ' 13' ' ' LEU . 34.5 m -118.53 155.29 20.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.661 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.9 tttt -102.07 109.19 20.84 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.127 -0.983 . . . . 0.0 109.176 -179.871 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.921 HG23 HG22 ' A' ' 7' ' ' VAL . 10.5 p -99.05 139.6 20.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.785 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.879 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.84 161.49 35.05 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 120.729 -1.232 . . . . 0.0 109.94 179.45 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.586 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.98 138.01 9.46 Favored Glycine 0 C--O 1.207 -1.551 0 N-CA-C 107.839 -2.104 . . . . 0.0 107.839 179.669 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -141.04 126.89 19.19 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-N 119.484 1.642 . . . . 0.0 109.547 179.52 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.416 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 87.36 28.64 24.35 Favored Glycine 0 N--CA 1.488 2.132 0 C-N-CA 118.832 -1.651 . . . . 0.0 109.745 -179.984 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.7 mt -88.27 173.06 8.99 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.913 -1.345 . . . . 0.0 108.235 179.894 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.021 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.56 99.26 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.954 -1.091 . . . . 0.0 109.809 -179.482 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.43 77.31 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.698 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.254 -179.221 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.62 34.18 0.28 Allowed Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.591 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 50.7 p -142.35 108.55 5.24 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.092 -1.24 . . . . 0.0 111.367 -179.52 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.597 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.23 109.71 0.33 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 177.826 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.536 ' CE1' ' OG1' ' A' ' 30' ' ' THR . 4.3 m-30 -103.13 155.53 18.34 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.094 -1.004 . . . . 0.0 108.987 179.94 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -98.99 161.82 13.42 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.855 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.696 HG22 HG11 ' A' ' 21' ' ' VAL . 2.7 p -142.66 121.61 8.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.117 -0.99 . . . . 0.0 109.538 -178.018 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.64 -176.9 41.63 Favored Glycine 0 N--CA 1.496 2.645 0 C-N-CA 118.516 -1.802 . . . . 0.0 111.548 -179.77 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.756 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.17 108.94 21.18 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 -179.937 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -128.66 148.53 50.82 Favored 'General case' 0 C--N 1.295 -1.767 0 O-C-N 121.229 -0.919 . . . . 0.0 109.884 179.738 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.502 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.92 139.51 53.76 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.24 -0.912 . . . . 0.0 110.674 -179.071 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.891 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.13 114.93 26.78 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 178.19 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -105.24 15.26 6.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.982 -1.074 . . . . 0.0 110.53 -178.883 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.7 -176.39 0.09 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.997 -1.064 . . . . 0.0 110.067 179.682 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.774 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.4 97.37 1.26 Allowed 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.817 0.818 . . . . 0.0 109.901 -179.656 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.13 28.23 34.62 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 120.198 -1.001 . . . . 0.0 111.387 178.833 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.03 106.41 20.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 O-C-N 120.562 -1.552 . . . . 0.0 107.278 178.891 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.891 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -115.98 104.77 11.93 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.465 -1.397 . . . . 0.0 109.942 -177.552 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.041 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.3 109.65 22.37 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.656 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.49 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -109.06 161.9 14.75 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.863 -1.148 . . . . 0.0 110.462 -178.585 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.479 ' HB2' ' HB2' ' A' ' 73' ' ' PHE . 29.8 t-20 -108.44 131.04 22.02 Favored Pre-proline 0 N--CA 1.5 2.038 0 O-C-N 121.582 -0.699 . . . . 0.0 109.391 -179.659 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -72.19 22.15 0.27 Allowed 'Trans proline' 0 CA--C 1.545 1.074 0 C-N-CA 121.958 1.772 . . . . 0.0 111.892 179.523 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.664 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -97.08 -7.26 33.2 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.434 -1.417 . . . . 0.0 108.994 179.555 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.881 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.8 m-20 -132.63 5.22 3.97 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.999 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -59.84 78.61 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.355 -0.841 . . . . 0.0 110.938 -178.385 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.632 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -101.07 -167.91 1.49 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.238 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.451 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.57 134.84 0.08 Allowed 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.55 -1.344 . . . . 0.0 111.363 -179.391 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.771 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.5 p -149.03 156.99 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.067 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.597 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.4 141.22 31.54 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.706 -1.246 . . . . 0.0 110.012 -179.776 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.021 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.26 107.54 1.34 Allowed 'General case' 0 C--N 1.298 -1.669 0 CA-C-O 122.484 1.135 . . . . 0.0 109.571 178.76 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.565 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -61.04 -139.42 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.709 179.95 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.35 -50.68 61.87 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.393 -0.817 . . . . 0.0 110.481 -178.798 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.416 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 6.2 t-20 -101.95 -35.15 9.09 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 178.404 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.998 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.42 68.19 0.66 Allowed Glycine 0 C--N 1.298 -1.535 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 178.07 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.586 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 56.4 m -99.54 131.54 45.47 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.421 -1.046 . . . . 0.0 108.836 178.917 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.771 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.2 108.87 7.98 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.452 -179.517 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 m -123.97 117.92 25.86 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.297 -0.877 . . . . 0.0 109.651 -179.798 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.525 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.61 145.34 30.04 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.433 -0.792 . . . . 0.0 109.411 179.879 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.0 p -98.56 136.6 38.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.273 -0.892 . . . . 0.0 109.22 179.894 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.881 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -140.69 165.9 26.23 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.396 -0.815 . . . . 0.0 109.909 -178.9 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.664 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 10.9 t -99.56 129.61 45.73 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.955 -1.09 . . . . 0.0 111.437 -178.753 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.83 HG13 ' OD2' ' A' ' 51' ' ' ASP . 17.3 m -136.61 143.86 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.459 -0.776 . . . . 0.0 109.956 179.68 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.618 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -148.45 -175.46 4.93 Favored 'General case' 0 N--CA 1.484 1.239 0 O-C-N 120.445 -1.409 . . . . 0.0 110.6 179.25 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.59 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.13 -102.44 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -179.539 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.4 OUTLIER -56.41 139.93 47.26 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.789 -1.194 . . . . 0.0 108.206 179.494 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.581 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -159.68 138.3 10.64 Favored 'General case' 0 C--N 1.296 -1.745 0 C-N-CA 118.717 -1.193 . . . . 0.0 109.91 -178.403 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' A' ' 47' ' ' CYS . 4.4 mm-40 -35.22 120.81 0.55 Allowed 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.473 0.654 . . . . 0.0 110.662 -178.496 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.041 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.6 48.27 2.57 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 -179.428 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-30 -39.12 114.98 0.44 Allowed 'General case' 0 N--CA 1.509 2.489 0 O-C-N 121.152 -1.205 . . . . 0.0 110.064 179.598 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.734 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.4 tp -87.3 126.48 34.87 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.796 -1.19 . . . . 0.0 109.597 -179.78 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 24.1 t80 -64.42 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.023 0 O-C-N 120.871 -1.143 . . . . 0.0 110.188 179.704 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 14.0 t0 -160.35 19.6 0.15 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.049 -1.032 . . . . 0.0 109.739 179.865 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.83 -27.43 5.41 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 179.935 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.491 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 68.1 p -95.13 157.05 16.06 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 120.978 -1.307 . . . . 0.0 110.313 -179.446 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.536 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -103.94 139.94 38.4 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.673 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.734 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.1 t90 -85.89 -19.71 30.15 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.588 -1.32 . . . . 0.0 110.766 -178.129 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.23 174.59 18.62 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -179.419 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.99 104.17 1.08 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 179.159 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.665 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.9 t -74.49 106.64 4.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.388 -0.82 . . . . 0.0 109.55 -178.769 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.74 110.67 2.46 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.443 -0.786 . . . . 0.0 109.654 -179.735 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.59 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.4 t -64.32 -4.98 4.29 Favored 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 118.334 -1.346 . . . . 0.0 109.891 179.58 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.0 p -87.03 0.56 55.01 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.701 -1.25 . . . . 0.0 109.111 179.511 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -114.16 -50.07 2.83 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.275 -0.891 . . . . 0.0 109.047 179.905 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.22 -178.09 3.56 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.54 -0.725 . . . . 0.0 109.495 179.769 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.09 114.94 29.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.395 -0.816 . . . . 0.0 108.998 179.937 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.567 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -97.05 122.98 40.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.911 -1.118 . . . . 0.0 109.722 -179.233 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.632 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.23 146.83 28.22 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-O 122.345 1.069 . . . . 0.0 111.224 -179.414 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.658 ' CG1' HG11 ' A' ' 7' ' ' VAL . 58.9 t -101.5 110.18 27.69 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.987 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 177.695 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.476 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.06 -171.28 16.85 Favored Glycine 0 N--CA 1.485 1.964 0 C-N-CA 118.236 -1.935 . . . . 0.0 111.78 -177.592 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.476 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.63 177.66 5.15 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 121.625 0.726 . . . . 0.0 109.047 -179.161 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.523 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.4 OUTLIER . . . . . 0 C--N 1.296 -1.741 0 O-C-N 121.641 -0.662 . . . . 0.0 109.455 179.937 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.668 0 N-CA-C 107.817 -2.113 . . . . 0.0 107.817 . . . . . . . . . 0 0 . 1 . 049 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -166.06 -177.09 4.02 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.596 -0.944 . . . . 0.0 109.795 179.336 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.18 -161.88 17.52 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 108.247 -1.941 . . . . 0.0 108.247 -179.379 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.521 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.4 Cg_exo -46.56 176.34 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.686 0 CA-C-N 118.778 1.289 . . . . 0.0 110.203 179.325 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -95.19 -177.3 4.08 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.121 -0.987 . . . . 0.0 110.417 -178.896 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.476 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -115.37 161.63 12.75 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.871 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.8 130.55 47.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.383 -1.069 . . . . 0.0 109.041 -179.461 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.632 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.65 124.33 25.06 Favored 'General case' 0 C--N 1.291 -1.975 0 O-C-N 121.724 -0.61 . . . . 0.0 110.059 -179.937 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.894 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.65 171.21 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.298 -0.876 . . . . 0.0 108.954 179.639 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.493 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -137.05 158.06 45.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.209 -0.932 . . . . 0.0 109.632 179.97 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.894 ' CE1' HD12 ' A' ' 110' ' ' ILE . 77.7 m-85 . . . . . 0 N--CA 1.486 1.35 0 O-C-N 121.26 -0.9 . . . . 0.0 109.517 -179.551 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.566 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.482 1.168 0 CA-C-O 122.444 1.116 . . . . 0.0 110.702 . . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.015 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -104.05 104.71 14.7 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 122.39 1.09 . . . . 0.0 110.271 -179.566 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.912 HG22 HG23 ' A' ' 21' ' ' VAL . 11.2 t -119.68 119.19 59.65 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.514 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.244 179.625 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.516 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.51 150.51 10.49 Favored Pre-proline 0 N--CA 1.488 1.44 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 -179.561 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.516 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.49 153.24 99.06 Favored 'Cis proline' 0 C--N 1.309 -1.537 0 C-N-CA 123.663 -1.39 . . . . 0.0 110.014 -0.578 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.618 ' HA ' HG22 ' A' ' 110' ' ' ILE . 7.2 m -94.44 -23.57 17.68 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.495 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.481 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.3 m -136.18 163.12 31.1 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.516 -0.74 . . . . 0.0 109.33 179.825 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.41 37.66 35.49 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 -179.523 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.796 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.1 mt -90.47 -44.12 9.82 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 123.18 1.467 . . . . 0.0 110.486 -178.289 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.467 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.97 144.71 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.265 0 CA-C-N 113.613 -1.63 . . . . 0.0 109.903 -179.665 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.625 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 8.1 p-10 -51.11 106.18 0.12 Allowed 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 121.471 0.653 . . . . 0.0 111.509 -178.592 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.46 12.31 9.78 Favored Glycine 0 N--CA 1.488 2.126 0 C-N-CA 119.324 -1.417 . . . . 0.0 113.121 177.261 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.796 HG21 ' CA ' ' A' ' 13' ' ' LEU . 11.6 t -101.51 -169.55 1.71 Allowed 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 121.135 2.467 . . . . 0.0 109.665 179.362 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.74 HG13 ' C ' ' A' ' 67' ' ' LEU . 11.4 t -136.14 142.94 37.32 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 CA-C-N 115.204 -0.907 . . . . 0.0 110.953 -179.015 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.538 HG22 HG22 ' A' ' 69' ' ' VAL . 13.3 m -120.47 154.72 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.221 -0.924 . . . . 0.0 109.255 179.438 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.538 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.3 tttt -106.28 109.08 20.9 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.233 -0.917 . . . . 0.0 109.28 179.955 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.912 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -105.61 122.26 58.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 179.885 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.015 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.43 165.81 12.35 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 120.886 -1.134 . . . . 0.0 109.129 179.885 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.579 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.1 107.7 0.48 Allowed Glycine 0 N--CA 1.482 1.751 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 179.792 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.482 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.6 141.24 48.45 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.598 -1.53 . . . . 0.0 110.16 -179.439 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 85.31 27.88 32.0 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 118.833 -1.651 . . . . 0.0 109.718 179.726 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.562 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.6 OUTLIER -95.67 170.88 9.02 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.018 -1.284 . . . . 0.0 108.45 179.831 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.07 101.18 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.407 0 O-C-N 120.947 -1.095 . . . . 0.0 109.948 -179.607 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.85 77.98 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.685 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.993 -179.411 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.42 34.15 0.29 Allowed Glycine 0 N--CA 1.486 2.021 0 N-CA-C 109.316 -1.513 . . . . 0.0 109.316 179.818 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 22.6 p -139.78 106.9 5.46 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.186 -1.185 . . . . 0.0 111.154 -179.514 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.582 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.67 110.0 0.34 Allowed 'General case' 0 N--CA 1.496 1.839 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.8 178.131 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.525 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 28.8 m-85 -103.89 154.51 19.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.111 -0.993 . . . . 0.0 108.95 179.8 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -102.18 158.09 16.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.767 -1.208 . . . . 0.0 107.821 178.784 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.945 HG11 HG21 ' A' ' 65' ' ' THR . 6.0 p -139.23 115.11 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.165 -0.959 . . . . 0.0 109.722 -178.12 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.73 -178.36 36.5 Favored Glycine 0 N--CA 1.494 2.561 0 C-N-CA 118.326 -1.892 . . . . 0.0 111.729 -179.468 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.635 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.1 pt20 -103.32 109.75 21.49 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 121.8 0.81 . . . . 0.0 108.9 -179.764 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.478 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -131.3 149.2 52.66 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.005 -1.06 . . . . 0.0 110.261 -179.805 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.37 138.8 54.52 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.319 -0.863 . . . . 0.0 110.777 -179.167 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.876 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.25 114.55 26.35 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 178.108 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.6 m -104.83 14.69 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.026 -1.046 . . . . 0.0 110.663 -178.757 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.746 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 175.25 -175.17 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.923 -1.111 . . . . 0.0 110.125 179.758 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -72.0 97.64 1.92 Allowed 'General case' 0 N--CA 1.485 1.317 0 O-C-N 121.413 -0.804 . . . . 0.0 109.677 -179.757 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.3 26.76 35.31 Favored Glycine 0 N--CA 1.494 2.531 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.475 178.934 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.746 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.92 106.66 20.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 O-C-N 120.549 -1.56 . . . . 0.0 107.396 178.875 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.876 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.7 tp -117.05 104.62 11.43 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.488 -1.382 . . . . 0.0 109.629 -177.747 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.871 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.61 109.42 22.18 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 120.808 -1.182 . . . . 0.0 107.914 178.678 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -105.95 167.83 9.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.928 -1.107 . . . . 0.0 110.483 -178.68 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.53 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 11.6 t-20 -111.94 129.33 24.33 Favored Pre-proline 0 N--CA 1.499 1.986 0 O-C-N 121.532 -0.73 . . . . 0.0 109.649 -179.118 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.582 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 2.2 Cg_endo -72.72 23.06 0.29 Allowed 'Trans proline' 0 CA--C 1.545 1.059 0 C-N-CA 122.056 1.837 . . . . 0.0 111.815 179.61 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.611 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -110.57 -0.7 17.2 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.462 -1.399 . . . . 0.0 109.145 179.545 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.567 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.37 16.81 3.17 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 179.489 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -79.75 89.94 5.22 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.709 -178.678 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.26 -166.26 1.14 Allowed 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.948 -1.131 . . . . 0.0 107.948 178.34 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.76 136.43 0.09 Allowed 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.594 -1.316 . . . . 0.0 111.314 -179.256 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 1.016 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -154.74 156.63 4.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.084 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.582 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.49 142.1 30.52 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.669 -1.269 . . . . 0.0 109.977 -179.621 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.08 106.12 0.68 Allowed 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 122.467 1.127 . . . . 0.0 109.341 178.208 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.545 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.8 p-10 -59.29 -138.79 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.029 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.052 -179.881 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.85 -50.33 61.13 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.412 -0.805 . . . . 0.0 110.744 -178.633 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -104.08 -34.57 8.37 Favored 'General case' 0 C--N 1.286 -2.178 0 N-CA-C 106.004 -1.85 . . . . 0.0 106.004 178.505 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.013 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.41 64.34 0.54 Allowed Glycine 0 C--N 1.296 -1.646 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 177.928 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.579 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 18.5 m -103.85 124.05 48.23 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.501 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 1.016 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.01 109.48 9.01 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.821 -0.752 . . . . 0.0 109.673 -179.081 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.7 m -116.5 116.69 28.11 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.329 -0.857 . . . . 0.0 109.373 -179.959 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.945 HG21 HG11 ' A' ' 34' ' ' VAL . 1.3 t -140.85 140.19 34.57 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.374 -0.829 . . . . 0.0 109.822 179.908 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.1 p -98.88 137.61 37.19 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.49 -0.756 . . . . 0.0 109.242 179.849 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.806 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -140.43 159.01 43.15 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.382 -0.824 . . . . 0.0 109.452 -179.129 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.611 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 12.7 t -87.55 135.77 33.22 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.162 -0.961 . . . . 0.0 110.21 -179.837 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.573 HG23 HD13 ' A' ' 13' ' ' LEU . 18.0 m -145.51 140.36 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.74 -179.39 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.625 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.5 ptt180 -140.25 -163.83 1.59 Allowed 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.595 -1.315 . . . . 0.0 109.877 179.814 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.603 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -78.79 -81.81 0.1 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.055 -1.028 . . . . 0.0 109.6 -179.15 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.524 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -67.12 134.66 52.24 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.334 -1.479 . . . . 0.0 107.488 179.273 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.635 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.8 OUTLIER -157.7 156.58 31.94 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 117.965 -1.494 . . . . 0.0 110.568 -178.257 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.514 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.2 mm-40 -48.71 121.66 4.83 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.497 -0.752 . . . . 0.0 109.676 -178.574 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.871 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.08 48.78 3.48 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 -179.39 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.582 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.2 OUTLIER -40.39 114.6 0.47 Allowed 'General case' 0 N--CA 1.514 2.774 0 O-C-N 121.029 -1.277 . . . . 0.0 109.972 179.908 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.704 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.25 126.95 35.14 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.959 -1.088 . . . . 0.0 109.289 179.729 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -64.09 58.11 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.8 -1.187 . . . . 0.0 110.307 179.897 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.531 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -160.86 19.34 0.13 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.961 -1.087 . . . . 0.0 109.785 179.91 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.3 -26.74 5.45 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.913 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.7 p -91.88 159.32 15.83 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.12 -1.223 . . . . 0.0 110.389 -179.403 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.513 ' NH1' ' HG3' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.56 133.46 51.21 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.716 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.704 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -82.6 -18.13 42.35 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.88 -1.137 . . . . 0.0 110.411 -178.469 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.32 174.79 20.6 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 -179.525 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.0 112.06 2.18 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 179.14 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.664 HG21 ' CB ' ' A' ' 46' ' ' ALA . 38.7 t -83.44 102.39 9.35 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -178.916 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.547 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -64.49 108.53 1.68 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.659 -0.651 . . . . 0.0 109.971 -179.153 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.579 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 3.7 t -62.48 -4.25 1.82 Allowed 'General case' 0 N--CA 1.499 1.979 0 C-N-CA 118.361 -1.336 . . . . 0.0 110.34 179.341 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.6 p -88.24 10.39 19.76 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.621 -1.299 . . . . 0.0 109.097 179.622 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.547 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -124.25 -47.66 1.87 Allowed 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.399 -0.813 . . . . 0.0 109.08 -179.994 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.85 179.58 4.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.604 -0.685 . . . . 0.0 109.536 179.905 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.88 112.41 25.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.36 -0.838 . . . . 0.0 108.799 179.783 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.497 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.1 m -96.64 121.85 38.93 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.083 -1.01 . . . . 0.0 109.667 -178.786 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.583 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.34 149.2 24.98 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 122.482 1.134 . . . . 0.0 111.368 -179.199 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.561 ' HB ' HG11 ' A' ' 7' ' ' VAL . 47.4 t -105.42 109.94 29.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 177.465 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.449 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.89 -171.3 17.51 Favored Glycine 0 N--CA 1.485 1.95 0 C-N-CA 118.154 -1.974 . . . . 0.0 111.663 -177.641 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.602 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -115.16 -179.02 3.51 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -178.899 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.414 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.5 p . . . . . 0 C--N 1.296 -1.729 0 O-C-N 121.332 -0.855 . . . . 0.0 109.545 -179.06 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.627 0 N-CA-C 107.753 -2.139 . . . . 0.0 107.753 . . . . . . . . . 0 0 . 1 . 050 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.35 -178.09 6.69 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 122.159 0.98 . . . . 0.0 109.898 179.326 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.42 -163.04 21.72 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 108.191 -1.963 . . . . 0.0 108.191 -179.46 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.602 ' HB2' HD12 ' A' ' 97' ' ' LEU . 7.4 Cg_exo -45.93 172.76 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.647 0 CA-C-N 119.013 1.406 . . . . 0.0 109.937 179.325 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -90.19 -177.42 5.14 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.997 -1.064 . . . . 0.0 110.695 -178.566 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.449 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.03 167.9 13.66 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.816 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.47 132.56 54.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.393 -1.063 . . . . 0.0 109.23 -179.285 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.583 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.57 124.42 25.86 Favored 'General case' 0 C--N 1.29 -1.984 0 O-C-N 121.637 -0.664 . . . . 0.0 109.732 179.757 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.842 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.97 171.81 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.228 -0.92 . . . . 0.0 109.227 179.794 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.481 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.23 155.96 48.15 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.209 -0.932 . . . . 0.0 109.769 -179.896 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.842 ' CE2' HD12 ' A' ' 110' ' ' ILE . 71.6 m-85 . . . . . 0 N--CA 1.487 1.378 0 O-C-N 121.178 -0.952 . . . . 0.0 109.533 -179.733 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.465 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.488 1.431 0 CA-C-O 122.054 0.931 . . . . 0.0 110.63 . . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.02 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.9 p -104.54 104.4 14.23 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 122.453 1.12 . . . . 0.0 110.156 179.96 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.952 HG22 HG23 ' A' ' 21' ' ' VAL . 12.0 t -120.15 119.76 60.98 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.366 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.309 179.738 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.512 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.64 149.88 6.34 Favored Pre-proline 0 N--CA 1.486 1.326 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -179.674 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.512 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.1 Cg_endo -76.68 151.62 94.61 Favored 'Cis proline' 0 C--N 1.309 -1.523 0 C-N-CA 123.637 -1.401 . . . . 0.0 109.501 -0.433 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.674 ' HA ' HG22 ' A' ' 110' ' ' ILE . 77.4 p -93.19 -23.53 18.53 Favored 'General case' 0 C--N 1.293 -1.865 0 O-C-N 121.595 -0.691 . . . . 0.0 109.305 179.765 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.48 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.2 m -133.89 158.2 44.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.316 -0.865 . . . . 0.0 109.957 -179.693 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 80.36 36.46 23.71 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 -179.777 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.763 ' HA ' HG21 ' A' ' 17' ' ' THR . 39.2 mt -92.54 -44.36 8.66 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 123.24 1.495 . . . . 0.0 110.284 -178.634 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.447 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 64.1 147.03 0.03 OUTLIER 'General case' 0 C--N 1.263 -3.189 0 CA-C-N 113.549 -1.66 . . . . 0.0 110.138 -179.758 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.552 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.0 p-10 -51.65 104.81 0.09 Allowed 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.644 0.735 . . . . 0.0 111.048 -178.939 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.52 6.39 6.72 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.148 -1.501 . . . . 0.0 113.33 177.312 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.763 HG21 ' HA ' ' A' ' 13' ' ' LEU . 14.9 t -106.31 -175.97 2.94 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 121.491 2.646 . . . . 0.0 110.166 179.693 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.861 HG22 HG22 ' A' ' 68' ' ' THR . 21.8 t -128.05 138.2 55.36 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.383 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.068 -178.697 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.652 HG11 HD11 ' A' ' 13' ' ' LEU . 34.6 m -114.39 154.66 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.827 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.553 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.1 108.9 20.59 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.14 -0.975 . . . . 0.0 109.314 -179.885 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.952 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.59 123.34 62.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.751 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.02 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -116.72 165.33 13.41 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 120.873 -1.142 . . . . 0.0 109.14 179.922 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.563 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.46 107.55 0.53 Allowed Glycine 0 C--O 1.207 -1.577 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 179.875 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.45 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -116.23 143.83 45.0 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.787 -1.419 . . . . 0.0 110.676 -178.964 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.463 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 80.48 27.45 51.51 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 119.576 -1.297 . . . . 0.0 109.993 179.193 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.571 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -91.95 172.25 8.58 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.086 -1.244 . . . . 0.0 108.556 -179.984 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.005 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.58 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.116 -0.99 . . . . 0.0 109.652 -179.987 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.578 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.63 76.74 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.206 -179.059 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 135.96 32.96 0.26 Allowed Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.512 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.628 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -141.98 111.45 6.54 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 120.935 -1.332 . . . . 0.0 111.027 -179.96 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.572 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.64 120.4 4.67 Favored 'General case' 0 N--CA 1.493 1.715 0 CA-C-N 115.488 -0.778 . . . . 0.0 109.674 178.7 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.628 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 9.7 m-85 -114.27 152.82 30.74 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.238 -0.914 . . . . 0.0 108.923 179.807 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.483 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.68 154.18 18.81 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.622 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.693 HG13 ' O ' ' A' ' 34' ' ' VAL . 9.7 p -137.42 115.41 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.023 -1.048 . . . . 0.0 109.882 -177.753 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.87 -176.85 36.16 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 118.372 -1.87 . . . . 0.0 111.792 -179.717 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.624 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -101.21 109.86 21.79 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -179.803 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.498 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -129.61 149.38 51.39 Favored 'General case' 0 C--N 1.296 -1.74 0 O-C-N 121.221 -0.924 . . . . 0.0 109.748 179.81 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.531 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.66 137.73 54.81 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.254 -0.904 . . . . 0.0 110.907 -178.847 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.887 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.49 114.86 26.67 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.048 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 m -105.05 14.67 7.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.931 -1.105 . . . . 0.0 110.501 -178.947 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.774 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 173.9 -175.54 0.07 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 120.949 -1.094 . . . . 0.0 110.128 179.73 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.779 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.92 98.17 1.55 Allowed 'General case' 0 N--CA 1.487 1.416 0 CA-C-O 121.828 0.823 . . . . 0.0 109.969 -179.669 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.28 27.98 34.92 Favored Glycine 0 N--CA 1.493 2.441 0 C-N-CA 120.325 -0.94 . . . . 0.0 111.444 178.949 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.774 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -116.54 106.29 19.99 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 O-C-N 120.569 -1.548 . . . . 0.0 107.198 178.782 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.887 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -117.02 104.64 11.47 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.487 -1.383 . . . . 0.0 109.942 -177.527 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.011 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.9 109.56 22.29 Favored 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.847 -1.158 . . . . 0.0 107.919 178.7 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.58 167.05 10.11 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.907 -1.12 . . . . 0.0 110.41 -178.699 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.585 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 20.7 t-20 -114.67 137.71 22.87 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 121.299 -0.876 . . . . 0.0 110.359 -179.149 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.464 ' HD2' ' ND2' ' A' ' 48' ' ' ASN . 6.1 Cg_endo -75.55 25.8 0.39 Allowed 'Trans proline' 0 C--N 1.318 -1.039 0 C-N-CA 122.346 2.031 . . . . 0.0 111.966 179.859 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.585 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -113.82 2.13 15.03 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.266 -1.521 . . . . 0.0 109.482 179.833 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.533 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.22 16.72 2.42 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 179.423 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -79.38 91.74 5.12 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.598 -0.689 . . . . 0.0 111.016 -178.678 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -109.08 -166.9 1.15 Allowed 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.171 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.455 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.97 136.62 0.09 Allowed 'General case' 0 N--CA 1.485 1.301 0 O-C-N 120.519 -1.363 . . . . 0.0 111.327 -179.298 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.964 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -156.75 157.0 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 178.213 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.572 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.6 144.23 28.13 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.884 -1.135 . . . . 0.0 109.835 -179.759 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.005 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.84 105.82 0.9 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 122.436 1.112 . . . . 0.0 109.38 178.546 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.546 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.8 p-10 -58.69 -138.87 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.029 -179.869 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.578 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.32 -50.26 62.62 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.453 -0.779 . . . . 0.0 110.576 -178.718 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.463 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.7 t-20 -103.75 -35.19 8.3 Favored 'General case' 0 C--N 1.286 -2.195 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 178.442 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.977 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.28 67.36 0.59 Allowed Glycine 0 C--N 1.297 -1.627 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 177.936 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.563 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.0 m -106.76 123.12 47.68 Favored 'General case' 0 N--CA 1.482 1.137 0 O-C-N 121.559 -0.965 . . . . 0.0 108.623 178.829 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.964 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -132.6 109.15 9.54 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 -179.443 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.1 m -118.95 120.39 37.13 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.211 -0.93 . . . . 0.0 109.606 -179.474 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.662 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.71 141.62 29.42 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.567 -0.708 . . . . 0.0 109.691 179.779 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 17.7 p -99.93 135.89 40.66 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.395 -0.815 . . . . 0.0 109.112 179.702 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.843 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -135.59 167.84 20.35 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.941 . . . . 0.0 109.618 -179.29 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.861 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -99.4 126.89 45.38 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.077 -1.014 . . . . 0.0 109.276 -179.802 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.491 HG12 ' HB3' ' A' ' 36' ' ' GLN . 12.6 m -132.39 140.8 46.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 120.868 -1.145 . . . . 0.0 109.93 -179.134 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.552 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 56.7 mtt180 -127.61 -166.96 1.68 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.68 -1.263 . . . . 0.0 111.328 -179.674 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.578 ' HG2' ' CD1' ' A' ' 112' ' ' PHE . 46.4 mtt180 -80.59 -79.02 0.16 Allowed 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 178.946 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -69.11 136.66 52.58 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 106.386 -1.709 . . . . 0.0 106.386 177.766 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.35 136.51 8.6 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 117.666 -1.614 . . . . 0.0 110.891 -177.191 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.47 ' C ' ' O ' ' A' ' 73' ' ' PHE . 2.0 mm-40 -33.43 118.78 0.34 Allowed 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.47 0.652 . . . . 0.0 110.427 -178.742 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.011 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.26 48.07 3.57 Favored Glycine 0 N--CA 1.493 2.463 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.148 -179.312 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.487 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -36.99 115.93 0.41 Allowed 'General case' 0 N--CA 1.513 2.685 0 O-C-N 121.109 -1.23 . . . . 0.0 110.11 179.828 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.727 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.3 tp -87.59 126.41 34.92 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.987 -1.071 . . . . 0.0 109.121 179.742 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 25.8 t80 -63.64 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.836 -1.165 . . . . 0.0 110.228 179.824 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.543 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t70 -160.89 19.72 0.13 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.989 -1.069 . . . . 0.0 109.846 179.924 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.2 -28.01 5.34 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.812 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.67 163.38 13.4 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.061 -1.258 . . . . 0.0 110.184 -179.438 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.478 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.55 137.71 46.05 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.987 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.727 ' HB2' HD13 ' A' ' 77' ' ' LEU . 5.6 t90 -81.62 -20.93 38.71 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.896 -1.127 . . . . 0.0 110.157 -178.956 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.36 173.55 17.07 Favored Glycine 0 N--CA 1.486 1.968 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -179.44 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.25 111.81 2.41 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 179.069 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.652 HG21 ' HB3' ' A' ' 46' ' ' ALA . 46.0 t -83.67 104.25 11.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 121.378 -0.826 . . . . 0.0 108.981 -179.001 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.531 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -66.15 111.3 3.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.355 -0.84 . . . . 0.0 109.845 -179.295 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.572 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -64.25 -4.8 4.04 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 120.587 -1.321 . . . . 0.0 109.896 179.4 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 31.6 p -87.81 2.18 52.01 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.694 -1.253 . . . . 0.0 109.097 179.325 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -116.52 -51.16 2.61 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.362 -0.836 . . . . 0.0 108.935 -179.998 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.22 -179.9 4.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.53 -0.731 . . . . 0.0 109.493 179.745 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.75 116.07 31.64 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.365 -0.834 . . . . 0.0 108.925 179.91 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.557 ' HB2' HD11 ' A' ' 110' ' ' ILE . 2.7 m -96.97 123.3 40.65 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.828 -1.17 . . . . 0.0 109.477 -179.298 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.582 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -103.15 149.17 24.9 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.344 1.069 . . . . 0.0 111.356 -179.142 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.639 ' HB ' HG11 ' A' ' 7' ' ' VAL . 43.2 t -104.88 112.1 37.12 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.552 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -151.77 -172.02 20.14 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 118.218 -1.944 . . . . 0.0 111.747 -177.785 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.483 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.01 178.67 4.64 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 -178.845 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.423 ' O ' ' N ' ' A' ' 33' ' ' ASP . 3.2 m . . . . . 0 C--N 1.295 -1.786 0 O-C-N 121.581 -0.699 . . . . 0.0 109.432 -179.806 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.7 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 . . . . . . . . . 0 0 . 1 . 051 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.82 -177.48 5.15 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.544 -0.974 . . . . 0.0 109.9 179.438 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.88 -161.83 23.1 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.462 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 104' ' ' GLY . 8.0 Cg_exo -45.51 173.73 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.643 0 CA-C-N 119.003 1.401 . . . . 0.0 110.232 179.251 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 25.9 pt-20 -92.7 -173.83 3.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.072 -1.017 . . . . 0.0 110.302 -178.824 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -124.67 174.86 17.15 Favored Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 -179.89 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -111.02 153.71 12.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -179.552 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.582 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -95.02 123.07 38.3 Favored 'General case' 0 C--N 1.292 -1.93 0 O-C-N 121.303 -0.873 . . . . 0.0 109.605 179.922 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.674 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.4 pt -98.08 168.32 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.209 -0.932 . . . . 0.0 109.073 179.942 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -135.1 156.65 48.65 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.29 -0.881 . . . . 0.0 109.456 -179.98 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.658 ' CE2' HD12 ' A' ' 110' ' ' ILE . 44.6 m-85 . . . . . 0 N--CA 1.489 1.486 0 O-C-N 121.2 -0.937 . . . . 0.0 109.543 -179.767 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.495 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.283 0 CA-C-O 122.288 1.042 . . . . 0.0 110.333 . . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.908 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.8 t -115.63 109.26 17.5 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-O 123.158 1.456 . . . . 0.0 109.838 -179.866 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.795 HG13 ' CA ' ' A' ' 21' ' ' VAL . 0.8 OUTLIER -115.5 136.12 53.32 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.632 0 CA-C-N 114.271 -1.331 . . . . 0.0 109.604 179.763 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.465 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -173.72 150.64 1.75 Allowed Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.181 -0.95 . . . . 0.0 109.04 -179.621 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.465 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.0 Cg_endo -77.2 151.18 92.99 Favored 'Cis proline' 0 C--N 1.313 -1.335 0 C-N-CA 123.484 -1.465 . . . . 0.0 109.26 -0.902 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.686 ' HA ' HG22 ' A' ' 110' ' ' ILE . 72.4 p -94.43 -22.55 18.22 Favored 'General case' 0 C--N 1.293 -1.89 0 O-C-N 121.511 -0.743 . . . . 0.0 109.623 179.878 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.466 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -130.88 155.18 47.18 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.214 -0.929 . . . . 0.0 110.233 -179.602 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.33 35.59 22.96 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.002 -1.639 . . . . 0.0 109.002 179.996 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.713 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.4 mt -92.8 -44.19 8.63 Favored 'General case' 0 C--N 1.301 -1.529 0 CA-C-O 123.214 1.483 . . . . 0.0 110.635 -178.713 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.433 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 63.17 145.19 0.02 OUTLIER 'General case' 0 C--N 1.261 -3.247 0 CA-C-N 113.558 -1.655 . . . . 0.0 109.201 -178.939 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.533 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.6 m-20 -53.82 114.68 1.65 Allowed 'General case' 0 C--N 1.299 -1.627 0 CA-C-O 121.764 0.792 . . . . 0.0 110.436 -178.946 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 121.67 0.71 10.99 Favored Glycine 0 N--CA 1.484 1.865 0 C-N-CA 119.495 -1.336 . . . . 0.0 112.404 178.334 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.713 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.8 t -106.7 -177.34 3.33 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 121.069 2.434 . . . . 0.0 110.474 -179.944 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.774 HG13 ' O ' ' A' ' 67' ' ' LEU . 25.9 t -127.48 139.09 52.88 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 CA-C-N 114.113 -1.403 . . . . 0.0 110.878 -178.865 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.603 ' CG1' HD13 ' A' ' 13' ' ' LEU . 4.2 m -113.01 158.37 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 178.907 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.51 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -106.45 108.77 20.44 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.088 -1.007 . . . . 0.0 109.115 179.947 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.878 ' CG1' HD11 ' A' ' 67' ' ' LEU . 13.0 p -101.23 140.02 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.651 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.908 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.37 161.86 35.16 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.675 -1.266 . . . . 0.0 110.154 179.642 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.591 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.6 139.32 10.53 Favored Glycine 0 C--N 1.298 -1.546 0 N-CA-C 107.882 -2.087 . . . . 0.0 107.882 179.529 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.4 125.31 16.13 Favored 'General case' 0 N--CA 1.496 1.828 0 CA-C-N 119.411 1.606 . . . . 0.0 109.434 179.446 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.67 27.77 21.01 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 118.8 -1.667 . . . . 0.0 109.634 -179.756 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -89.01 169.63 11.36 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.033 -1.275 . . . . 0.0 108.188 179.942 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -43.59 98.67 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.015 -1.053 . . . . 0.0 110.042 -179.354 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.552 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.29 77.83 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.255 -179.285 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.571 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.23 33.44 0.27 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.393 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.542 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 59.0 p -141.73 108.67 5.43 Favored 'General case' 0 C--N 1.307 -1.264 0 O-C-N 121.102 -1.234 . . . . 0.0 111.316 -179.474 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.79 111.49 0.61 Allowed 'General case' 0 N--CA 1.497 1.896 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.717 178.067 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.5 ' CA ' ' O ' ' A' ' 98' ' ' SER . 5.3 m-30 -105.65 160.04 15.5 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.068 -1.02 . . . . 0.0 108.817 179.662 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.502 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -100.23 167.34 10.49 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.738 -1.226 . . . . 0.0 108.003 179.061 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.625 HG22 HG11 ' A' ' 21' ' ' VAL . 2.9 p -149.48 120.81 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.112 -0.992 . . . . 0.0 109.531 -178.136 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -174.9 -176.63 43.36 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 118.297 -1.906 . . . . 0.0 111.702 -179.941 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.711 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -98.83 108.87 21.66 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -179.997 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.1 m -130.45 148.93 52.32 Favored 'General case' 0 C--N 1.295 -1.796 0 O-C-N 121.315 -0.866 . . . . 0.0 109.461 179.389 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.494 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.38 138.72 54.34 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.154 -0.966 . . . . 0.0 110.849 -178.872 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.14 114.64 26.46 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 178.103 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.6 m -105.16 15.14 6.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.08 -1.012 . . . . 0.0 110.466 -178.609 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.75 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.42 -175.48 0.1 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.864 -1.148 . . . . 0.0 109.998 179.705 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.65 96.83 1.63 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.473 -0.767 . . . . 0.0 109.735 -179.739 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 28.03 32.32 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.493 178.933 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.75 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.18 106.57 20.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 O-C-N 120.577 -1.543 . . . . 0.0 107.302 178.845 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.2 tp -116.23 104.45 11.52 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.449 -1.407 . . . . 0.0 110.022 -177.5 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.095 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.25 109.45 22.21 Favored 'General case' 0 N--CA 1.484 1.248 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 178.525 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 5.1 t -108.5 165.49 11.48 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.826 -1.171 . . . . 0.0 110.648 -178.468 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.48 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 52.4 t30 -115.84 134.45 22.71 Favored Pre-proline 0 N--CA 1.499 2.019 0 O-C-N 121.545 -0.722 . . . . 0.0 109.394 -179.624 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.531 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 2.5 Cg_endo -72.08 22.96 0.26 Allowed 'Trans proline' 0 C--N 1.317 -1.124 0 C-N-CA 122.289 1.993 . . . . 0.0 112.106 -179.802 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.443 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -95.28 -9.76 32.2 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.355 -1.466 . . . . 0.0 109.045 179.408 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.65 ' OD2' HG13 ' A' ' 69' ' ' VAL . 3.4 m-20 -134.06 6.77 3.66 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.903 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -59.72 84.04 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.495 -0.753 . . . . 0.0 110.589 -178.775 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.612 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -111.47 -168.89 1.36 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.516 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.464 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.3 t 179.01 135.17 0.09 Allowed 'General case' 0 C--N 1.305 -1.358 0 O-C-N 120.656 -1.278 . . . . 0.0 110.967 -179.476 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.79 HG11 ' HB1' ' A' ' 63' ' ' ALA . 1.6 p -147.29 157.4 9.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.288 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.598 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.53 142.01 30.66 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 120.696 -1.252 . . . . 0.0 110.024 -179.699 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.17 107.54 1.32 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 122.5 1.143 . . . . 0.0 109.533 178.462 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.558 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.2 p-10 -61.19 -139.39 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.976 -179.99 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.552 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.77 -50.83 55.0 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.399 -0.813 . . . . 0.0 110.641 -178.764 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -104.36 -33.27 8.69 Favored 'General case' 0 C--N 1.285 -2.221 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 178.498 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.996 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.47 66.49 0.62 Allowed Glycine 0 C--N 1.299 -1.498 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 178.132 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.591 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.6 m -100.68 130.09 46.67 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.491 -1.006 . . . . 0.0 108.883 178.974 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.79 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.49 109.51 8.76 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.217 -0.993 . . . . 0.0 109.307 -179.594 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 18.2 m -124.31 118.33 26.52 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.359 -0.838 . . . . 0.0 109.789 -179.781 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -148.36 148.26 30.17 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.436 -0.79 . . . . 0.0 109.218 179.808 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.412 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 28.2 p -98.38 136.23 38.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.33 -0.856 . . . . 0.0 109.47 179.923 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.878 HD11 ' CG1' ' A' ' 21' ' ' VAL . 0.2 OUTLIER -129.68 164.91 22.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.313 -0.867 . . . . 0.0 109.874 -179.023 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.713 HG22 HG22 ' A' ' 18' ' ' VAL . 1.1 p -104.29 127.16 51.89 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.157 -0.964 . . . . 0.0 108.679 179.529 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.711 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.0 m -134.53 140.21 46.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.722 -1.236 . . . . 0.0 110.471 -178.659 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.533 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 46.8 mtt180 -126.48 -168.2 1.83 Allowed 'General case' 0 N--CA 1.484 1.226 0 O-C-N 120.703 -1.248 . . . . 0.0 111.015 179.937 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.583 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 27.9 mtm180 -77.87 -75.5 0.22 Allowed 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.326 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -73.79 136.39 43.58 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 120.006 -1.684 . . . . 0.0 106.829 178.017 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.594 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -156.15 136.88 13.36 Favored 'General case' 0 C--N 1.295 -1.766 0 C-N-CA 117.987 -1.485 . . . . 0.0 110.481 -177.861 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.479 ' O ' ' O ' ' A' ' 47' ' ' CYS . 6.6 mm-40 -37.37 120.45 0.78 Allowed 'General case' 0 N--CA 1.487 1.385 0 CA-C-O 121.589 0.709 . . . . 0.0 110.129 -178.584 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.095 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.91 48.88 3.53 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.273 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.531 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 26.3 m-85 -38.22 113.44 0.29 Allowed 'General case' 0 N--CA 1.505 2.276 0 O-C-N 121.165 -1.197 . . . . 0.0 110.138 179.561 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.717 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -86.07 126.93 34.54 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.003 -1.061 . . . . 0.0 109.455 -179.819 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 19.6 t80 -63.62 58.44 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.994 0 O-C-N 120.984 -1.073 . . . . 0.0 110.21 179.599 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -160.89 19.62 0.13 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.038 -1.038 . . . . 0.0 109.824 179.926 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.72 -27.14 5.47 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 179.767 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.446 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 15.5 p -95.57 158.91 15.24 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.994 -1.297 . . . . 0.0 110.258 -179.457 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.461 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -105.03 136.68 44.06 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 179.699 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.717 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.7 t90 -80.72 -20.13 43.5 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.914 -1.116 . . . . 0.0 110.274 -178.644 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.76 174.43 18.31 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 108.669 -1.772 . . . . 0.0 108.669 -179.392 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.53 108.73 1.44 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.011 -1.287 . . . . 0.0 107.771 179.21 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.674 HG21 ' HB3' ' A' ' 46' ' ' ALA . 41.5 t -81.41 105.59 11.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 O-C-N 121.375 -0.828 . . . . 0.0 108.796 -179.256 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.526 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.92 111.14 3.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.342 -0.849 . . . . 0.0 110.051 -179.085 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.583 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.5 t -63.99 -5.21 4.22 Favored 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 118.587 -1.245 . . . . 0.0 109.924 179.456 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.7 p -87.43 1.46 53.35 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.804 -1.185 . . . . 0.0 109.08 179.446 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.526 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -116.05 -51.18 2.65 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.393 -0.817 . . . . 0.0 108.965 179.868 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.401 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -102.2 -178.96 3.85 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.544 -0.722 . . . . 0.0 109.384 179.736 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.49 115.61 30.54 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.389 -0.82 . . . . 0.0 109.077 179.975 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.52 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.76 121.39 38.55 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.833 -1.167 . . . . 0.0 109.324 -179.438 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.632 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.02 144.93 30.0 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 122.323 1.059 . . . . 0.0 111.262 -179.278 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.586 ' CG1' HG11 ' A' ' 7' ' ' VAL . 96.1 t -102.14 109.86 27.36 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.663 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.476 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.89 -171.29 17.49 Favored Glycine 0 N--CA 1.487 2.092 0 C-N-CA 118.018 -2.039 . . . . 0.0 111.894 -177.54 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.502 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -110.51 -179.21 3.7 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 -179.221 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.5 ' O ' ' CA ' ' A' ' 32' ' ' TYR . 36.8 p . . . . . 0 C--N 1.295 -1.766 0 O-C-N 121.464 -0.772 . . . . 0.0 109.379 -179.366 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.763 0 N-CA-C 107.601 -2.199 . . . . 0.0 107.601 . . . . . . . . . 0 0 . 1 . 052 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.34 -178.3 6.84 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 121.568 -0.96 . . . . 0.0 109.587 179.202 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -158.92 -163.42 13.0 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 108.3 -1.92 . . . . 0.0 108.3 -179.558 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.0 Cg_exo -47.72 178.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.705 0 CA-C-N 118.819 1.31 . . . . 0.0 110.132 179.331 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -91.75 -175.79 4.26 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.047 -1.033 . . . . 0.0 110.415 -178.879 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.476 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.83 168.2 14.56 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 -179.865 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.6 130.49 51.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.405 -1.056 . . . . 0.0 109.073 -179.363 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.632 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.58 121.39 21.5 Favored 'General case' 0 C--N 1.29 -1.979 0 O-C-N 121.578 -0.701 . . . . 0.0 109.914 179.85 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.686 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.5 pt -98.0 166.91 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.279 -0.888 . . . . 0.0 109.04 179.765 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.466 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 1.4 m -135.25 156.52 48.83 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.322 -0.862 . . . . 0.0 109.597 -179.96 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.648 ' CE2' HD12 ' A' ' 110' ' ' ILE . 53.7 m-85 . . . . . 0 N--CA 1.489 1.485 0 O-C-N 121.215 -0.928 . . . . 0.0 109.434 -179.885 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.49 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.487 1.385 0 CA-C-O 122.123 0.963 . . . . 0.0 110.717 . . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.017 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.7 p -104.16 104.38 14.3 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 122.585 1.183 . . . . 0.0 109.835 179.901 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.965 HG22 HG23 ' A' ' 21' ' ' VAL . 14.2 t -119.59 121.49 66.43 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.398 179.806 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.479 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.73 149.75 6.18 Favored Pre-proline 0 N--CA 1.486 1.354 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.557 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.479 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.8 Cg_endo -78.63 149.54 85.67 Favored 'Cis proline' 0 C--N 1.308 -1.563 0 C-N-CA 123.663 -1.39 . . . . 0.0 109.697 -0.722 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.641 ' HA ' HG22 ' A' ' 110' ' ' ILE . 88.7 p -91.0 -24.63 20.03 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.34 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 0.8 OUTLIER -131.23 161.17 32.85 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.381 -0.825 . . . . 0.0 109.733 -179.949 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.63 38.47 32.19 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 -179.574 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.825 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.9 mt -92.08 -44.46 8.82 Favored 'General case' 0 C--N 1.298 -1.665 0 CA-C-O 123.111 1.434 . . . . 0.0 110.736 -178.26 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.464 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.67 145.72 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.658 -1.61 . . . . 0.0 110.05 -179.818 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.607 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.4 p-10 -51.2 107.35 0.18 Allowed 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 121.502 0.668 . . . . 0.0 111.597 -178.693 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.25 14.36 9.91 Favored Glycine 0 N--CA 1.484 1.883 0 C-N-CA 119.335 -1.412 . . . . 0.0 112.953 177.227 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.825 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.7 t -102.78 -172.31 2.1 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 121.012 2.406 . . . . 0.0 109.643 179.239 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.738 HG13 ' C ' ' A' ' 67' ' ' LEU . 11.8 t -131.71 137.93 54.0 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.372 0 CA-C-N 115.001 -0.999 . . . . 0.0 111.229 -179.113 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.427 HG23 ' CD1' ' A' ' 67' ' ' LEU . 33.7 m -114.69 154.4 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.965 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.564 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -109.05 109.29 20.28 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.158 -0.964 . . . . 0.0 109.186 -179.993 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.965 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -107.7 123.11 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 -179.968 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.017 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.43 165.12 13.07 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 120.829 -1.169 . . . . 0.0 108.873 179.55 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.574 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.85 107.67 0.53 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 108.825 -1.71 . . . . 0.0 108.825 179.944 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.466 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -115.73 142.84 46.21 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 120.876 -1.367 . . . . 0.0 110.676 -179.213 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.78 27.35 46.77 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 179.207 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.561 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -92.11 174.26 7.41 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.061 -1.258 . . . . 0.0 108.589 179.967 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.004 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.44 99.43 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.025 -1.047 . . . . 0.0 109.732 -179.79 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.656 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.06 77.4 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.246 -179.116 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.67 34.02 0.32 Allowed Glycine 0 N--CA 1.487 2.067 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.379 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 80.3 p -144.23 111.6 5.98 Favored 'General case' 0 C--N 1.306 -1.291 0 O-C-N 120.996 -1.297 . . . . 0.0 111.096 -179.803 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.09 124.5 6.53 Favored 'General case' 0 N--CA 1.493 1.691 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.845 178.355 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.494 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 17.8 m-85 -117.69 150.4 39.13 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.493 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.479 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.64 155.42 17.89 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 178.675 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.012 HG11 HG21 ' A' ' 65' ' ' THR . 7.0 p -138.17 114.96 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.025 -1.047 . . . . 0.0 109.807 -177.81 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.58 -177.67 36.62 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 118.507 -1.806 . . . . 0.0 111.638 -179.648 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.642 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.2 pt20 -102.3 109.83 21.62 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-O 121.836 0.826 . . . . 0.0 108.917 -179.781 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.0 150.34 51.32 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.157 -0.964 . . . . 0.0 110.166 -179.869 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.77 139.7 53.61 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.255 -0.903 . . . . 0.0 110.633 -179.212 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.883 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.05 114.44 26.25 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 178.178 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.4 m -105.37 15.82 6.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.006 -1.059 . . . . 0.0 110.661 -178.821 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.98 -175.94 0.11 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.928 -1.108 . . . . 0.0 110.043 179.741 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 71.8 p -71.23 96.35 1.39 Allowed 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.37 -0.831 . . . . 0.0 109.759 -179.714 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.38 27.98 34.59 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.234 -0.984 . . . . 0.0 111.402 178.873 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 2.1 t -115.46 105.97 19.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 O-C-N 120.481 -1.599 . . . . 0.0 107.417 178.951 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.883 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -114.9 104.63 12.12 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.533 -1.355 . . . . 0.0 110.062 -177.658 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.745 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.21 109.52 22.26 Favored 'General case' 0 N--CA 1.483 1.225 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 178.447 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.7 t -105.49 170.47 7.87 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.968 -1.082 . . . . 0.0 110.734 -178.108 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.474 ' HB2' ' HB2' ' A' ' 73' ' ' PHE . 21.1 t-20 -114.14 126.07 28.5 Favored Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.54 -0.725 . . . . 0.0 109.546 -179.471 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.602 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -70.57 21.15 0.2 Allowed 'Trans proline' 0 CA--C 1.545 1.062 0 C-N-CA 122.098 1.865 . . . . 0.0 112.118 179.589 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.445 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -107.86 2.59 23.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.42 -1.425 . . . . 0.0 108.964 179.385 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.544 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.39 16.4 2.57 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.563 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -80.35 91.16 5.63 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.974 -178.537 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.621 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.35 -166.37 1.15 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.23 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.68 137.57 0.09 Allowed 'General case' 0 N--CA 1.486 1.345 0 O-C-N 120.55 -1.344 . . . . 0.0 111.369 -179.38 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 1.012 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -156.86 156.94 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.171 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.568 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.17 144.7 27.36 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 120.717 -1.239 . . . . 0.0 109.944 -179.616 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.004 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.22 106.39 1.08 Allowed 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 122.408 1.099 . . . . 0.0 109.29 178.466 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.536 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.6 p-10 -59.04 -138.49 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.992 -179.816 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.656 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.19 -50.27 62.22 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.445 -0.784 . . . . 0.0 110.618 -178.567 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 28.9 t30 -104.16 -35.53 8.0 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 106.093 -1.817 . . . . 0.0 106.093 178.376 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.993 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 111.1 64.82 0.51 Allowed Glycine 0 C--N 1.298 -1.548 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 177.924 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.574 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 18.6 m -104.72 123.11 47.06 Favored 'General case' 0 N--CA 1.484 1.254 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.545 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 1.012 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.27 109.23 9.25 Favored 'General case' 0 C--N 1.294 -1.819 0 C-N-CA 119.894 -0.722 . . . . 0.0 109.544 -179.052 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 3.6 m -114.0 115.77 28.15 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.349 -0.845 . . . . 0.0 109.358 -179.981 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 1.012 HG21 HG11 ' A' ' 34' ' ' VAL . 1.5 t -139.18 140.0 37.7 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.399 -0.813 . . . . 0.0 109.85 179.971 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 45.4 p -99.24 145.82 26.86 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.496 -0.753 . . . . 0.0 109.17 179.718 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.738 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -146.63 162.7 37.88 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.354 -0.842 . . . . 0.0 109.6 -179.134 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.714 HG22 HG22 ' A' ' 18' ' ' VAL . 3.2 p -93.94 124.76 38.16 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.936 . . . . 0.0 109.276 -179.913 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.553 HG23 HD13 ' A' ' 13' ' ' LEU . 15.4 m -134.66 141.94 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 120.861 -1.149 . . . . 0.0 109.99 -179.101 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.607 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.5 ptt180 -141.9 -163.7 1.64 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 120.473 -1.392 . . . . 0.0 110.601 -179.802 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.615 ' HD2' ' CD1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -75.74 -92.59 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.343 -0.848 . . . . 0.0 109.79 -179.029 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.539 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -60.92 133.07 55.73 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.255 -1.528 . . . . 0.0 107.726 179.478 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.642 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -153.95 156.91 38.35 Favored 'General case' 0 C--N 1.293 -1.874 0 C-N-CA 118.367 -1.333 . . . . 0.0 110.179 -178.716 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.596 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 30.3 mm-40 -47.99 121.66 4.41 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.35 -0.844 . . . . 0.0 109.94 -178.292 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.745 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -86.79 49.89 4.1 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 -179.4 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.602 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 29.7 m-85 -52.29 110.37 0.49 Allowed 'General case' 0 N--CA 1.505 2.301 0 O-C-N 121.014 -1.286 . . . . 0.0 110.743 179.753 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.775 HD13 ' HB2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -78.67 151.57 32.14 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 120.801 -1.187 . . . . 0.0 108.748 178.64 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -63.41 -5.5 3.71 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 120.691 -1.256 . . . . 0.0 110.863 179.954 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -99.18 7.63 45.59 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.723 -1.236 . . . . 0.0 109.593 179.938 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 82.59 -9.81 57.77 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.967 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.55 ' O ' ' HB2' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -78.86 133.56 36.98 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.115 -1.227 . . . . 0.0 109.917 -179.8 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.508 ' NH1' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -75.74 114.66 14.6 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.294 -0.879 . . . . 0.0 109.702 179.75 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.775 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.0 t90 -80.91 -20.16 42.73 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.036 -1.04 . . . . 0.0 109.426 -179.97 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.44 172.48 18.82 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 -179.725 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.44 110.61 1.72 Allowed 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 179.192 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.616 HG23 ' HA3' ' A' ' 75' ' ' GLY . 41.1 t -80.84 101.17 5.55 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.989 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.727 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -61.98 108.21 1.0 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.671 -0.643 . . . . 0.0 110.066 -179.176 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.56 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 4.1 t -60.36 -5.07 1.0 Allowed 'General case' 0 N--CA 1.501 2.124 0 C-N-CA 118.334 -1.346 . . . . 0.0 110.339 179.385 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 60.8 p -89.6 0.26 57.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.461 -1.399 . . . . 0.0 109.588 179.994 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.727 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -110.24 -48.46 3.18 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.172 -0.955 . . . . 0.0 109.068 179.994 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.78 -178.07 3.54 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.604 -0.685 . . . . 0.0 109.507 179.997 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.36 112.94 26.17 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.784 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.497 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.48 122.2 39.13 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.107 -0.995 . . . . 0.0 109.675 -178.731 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.3 mt-30 -104.02 148.92 25.66 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 122.428 1.109 . . . . 0.0 111.339 -179.42 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.549 ' HB ' HG11 ' A' ' 7' ' ' VAL . 57.7 t -103.98 109.78 28.25 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.989 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 177.566 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.46 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.13 -171.46 17.83 Favored Glycine 0 N--CA 1.486 1.995 0 C-N-CA 118.239 -1.934 . . . . 0.0 111.605 -177.625 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.49 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -122.05 178.92 4.7 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -178.812 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.4 m . . . . . 0 C--N 1.295 -1.763 0 O-C-N 121.571 -0.705 . . . . 0.0 109.393 -179.841 . . . . . . . . 0 0 . 1 . 053 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.413 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.482 1.71 0 N-CA-C 107.883 -2.087 . . . . 0.0 107.883 . . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.413 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -167.0 -177.17 3.67 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 122.079 0.942 . . . . 0.0 109.755 179.427 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.87 -162.23 21.77 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.265 -1.934 . . . . 0.0 108.265 -179.431 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.508 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.5 Cg_exo -45.27 171.91 0.02 OUTLIER 'Trans proline' 0 C--N 1.326 -0.629 0 CA-C-N 118.95 1.375 . . . . 0.0 110.035 179.319 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -93.17 -176.69 4.23 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.049 -1.032 . . . . 0.0 110.501 -178.583 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.46 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.07 166.28 12.77 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 -179.908 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -106.11 132.91 52.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.399 -1.059 . . . . 0.0 109.162 -179.251 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.58 126.08 29.0 Favored 'General case' 0 C--N 1.289 -2.038 0 O-C-N 121.534 -0.729 . . . . 0.0 109.741 179.873 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.822 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.91 172.44 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.248 -0.907 . . . . 0.0 108.979 179.683 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.59 158.73 43.76 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.077 -1.014 . . . . 0.0 109.462 -179.948 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.822 ' CE2' HD12 ' A' ' 110' ' ' ILE . 56.0 m-85 . . . . . 0 N--CA 1.486 1.337 0 O-C-N 121.24 -0.913 . . . . 0.0 109.636 -179.639 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.494 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.291 0 CA-C-O 122.43 1.11 . . . . 0.0 110.234 . . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.863 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.9 t -115.14 109.04 17.43 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 123.127 1.441 . . . . 0.0 109.812 -179.863 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.795 HG22 HG23 ' A' ' 21' ' ' VAL . 2.2 t -116.18 134.18 60.36 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.659 0 CA-C-N 114.229 -1.35 . . . . 0.0 109.486 179.795 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.472 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -169.53 150.39 4.03 Favored Pre-proline 0 N--CA 1.487 1.413 0 O-C-N 121.183 -0.948 . . . . 0.0 108.876 -179.509 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.472 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.5 Cg_endo -75.52 152.32 97.24 Favored 'Cis proline' 0 C--N 1.313 -1.315 0 C-N-CA 123.488 -1.463 . . . . 0.0 109.785 -0.963 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.625 ' HA ' HG22 ' A' ' 110' ' ' ILE . 5.8 m -93.05 -23.52 18.63 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.447 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.513 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 69.0 m -134.99 159.62 40.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.564 -0.71 . . . . 0.0 109.382 179.912 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.28 36.29 27.61 Favored Glycine 0 N--CA 1.495 2.626 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.736 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.745 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.7 mt -90.94 -42.65 10.45 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 123.391 1.567 . . . . 0.0 110.393 -178.482 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.48 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.11 144.34 0.05 OUTLIER 'General case' 0 C--N 1.261 -3.267 0 CA-C-N 113.282 -1.781 . . . . 0.0 110.08 -179.746 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.599 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.3 p-10 -50.46 104.75 0.08 Allowed 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.556 0.693 . . . . 0.0 111.655 -178.451 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.51 14.4 8.2 Favored Glycine 0 N--CA 1.485 1.91 0 C-N-CA 119.33 -1.414 . . . . 0.0 113.154 177.18 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.745 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -105.76 -172.99 2.19 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 121.352 2.576 . . . . 0.0 109.821 179.181 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.731 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.5 t -129.59 138.21 54.82 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.333 0 CA-C-N 114.67 -1.15 . . . . 0.0 111.136 -178.711 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.633 HG11 HD11 ' A' ' 13' ' ' LEU . 29.4 m -113.61 155.48 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.863 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tttm -104.32 109.05 20.75 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.208 -0.933 . . . . 0.0 109.213 -179.962 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.944 HG11 HD11 ' A' ' 67' ' ' LEU . 2.2 p -100.64 140.05 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.627 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.863 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -136.61 162.67 32.49 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.733 -1.229 . . . . 0.0 110.179 179.666 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.588 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.64 139.82 10.95 Favored Glycine 0 C--N 1.299 -1.527 0 N-CA-C 108.244 -1.942 . . . . 0.0 108.244 179.728 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -142.32 125.6 16.51 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.491 -1.593 . . . . 0.0 109.355 179.301 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 88.85 28.32 21.52 Favored Glycine 0 N--CA 1.49 2.264 0 C-N-CA 118.685 -1.722 . . . . 0.0 109.731 -179.824 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.555 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -88.72 171.95 9.6 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.885 -1.362 . . . . 0.0 108.278 179.835 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.02 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.03 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.96 -1.087 . . . . 0.0 109.872 -179.476 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.57 77.54 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.677 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.178 -179.345 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.65 33.97 0.28 Allowed Glycine 0 N--CA 1.486 2.007 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.618 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.563 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 41.2 p -141.51 108.05 5.32 Favored 'General case' 0 C--N 1.307 -1.244 0 O-C-N 121.144 -1.209 . . . . 0.0 111.236 -179.476 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.04 109.8 0.36 Allowed 'General case' 0 N--CA 1.497 1.904 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.488 177.866 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.474 ' HA ' ' O ' ' A' ' 98' ' ' SER . 5.3 m-30 -103.89 157.99 16.71 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.054 -1.029 . . . . 0.0 108.87 179.741 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -99.81 166.54 11.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.844 -1.16 . . . . 0.0 107.969 179.007 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.628 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.8 p -148.09 120.28 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.108 -0.995 . . . . 0.0 109.605 -178.038 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -174.02 -177.02 42.89 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 118.403 -1.856 . . . . 0.0 111.641 -179.927 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.701 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -99.16 108.24 20.79 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.95 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -130.25 148.5 52.08 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.212 -0.93 . . . . 0.0 109.985 179.708 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.427 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.71 139.58 53.73 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.298 -0.877 . . . . 0.0 110.634 -179.099 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.888 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.21 114.76 26.59 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 178.207 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -104.83 15.02 6.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.92 -1.112 . . . . 0.0 110.58 -178.795 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.768 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.41 -175.96 0.08 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.872 -1.142 . . . . 0.0 110.074 179.757 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.781 HG23 ' O ' ' A' ' 42' ' ' THR . 15.0 t -71.36 98.0 1.7 Allowed 'General case' 0 N--CA 1.488 1.434 0 CA-C-O 121.729 0.776 . . . . 0.0 109.808 -179.696 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.48 27.86 34.64 Favored Glycine 0 N--CA 1.492 2.405 0 C-N-CA 120.174 -1.012 . . . . 0.0 111.427 178.97 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.768 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.71 106.25 19.87 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 O-C-N 120.587 -1.537 . . . . 0.0 107.192 178.887 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.888 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -116.96 104.53 11.37 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.478 -1.389 . . . . 0.0 109.773 -177.75 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.098 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.99 109.28 22.06 Favored 'General case' 0 N--CA 1.485 1.315 0 O-C-N 120.833 -1.167 . . . . 0.0 108.152 178.92 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.0 t -106.67 164.8 11.79 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.913 -1.117 . . . . 0.0 110.233 -179.115 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.793 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 3.7 t-20 -106.56 136.21 19.42 Favored Pre-proline 0 N--CA 1.498 1.966 0 O-C-N 121.386 -0.821 . . . . 0.0 109.622 -179.179 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.592 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -74.85 23.79 0.39 Allowed 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 122.384 2.056 . . . . 0.0 111.943 -179.83 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.793 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -109.76 -4.59 15.99 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.33 -1.481 . . . . 0.0 109.143 179.615 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.665 ' OD2' HG13 ' A' ' 69' ' ' VAL . 6.0 m-20 -131.73 6.05 4.33 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.658 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.47 84.94 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.732 -178.502 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -110.76 -170.49 1.65 Allowed 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.448 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.58 135.22 0.08 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 120.622 -1.298 . . . . 0.0 111.136 -179.286 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.767 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.6 p -146.8 158.28 10.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 178.169 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.598 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.49 141.51 31.25 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 120.703 -1.248 . . . . 0.0 110.061 -179.791 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.02 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.21 107.91 1.43 Allowed 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.438 1.114 . . . . 0.0 109.537 178.596 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.57 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.1 p-10 -61.46 -139.45 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.97 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.864 179.849 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.89 -50.87 60.17 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.427 -0.796 . . . . 0.0 110.487 -178.843 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -102.24 -34.71 9.13 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 178.46 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.27 67.31 0.64 Allowed Glycine 0 C--N 1.299 -1.499 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 178.073 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 57.5 m -100.06 130.86 46.26 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.482 -1.011 . . . . 0.0 108.803 178.962 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.767 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.48 109.42 9.27 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.19 -1.004 . . . . 0.0 109.321 -179.648 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 73.2 m -121.85 117.0 25.43 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.313 -0.867 . . . . 0.0 109.61 -179.678 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.589 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -147.54 149.32 32.37 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.452 -0.78 . . . . 0.0 109.291 179.879 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.434 ' O ' HD23 ' A' ' 67' ' ' LEU . 56.3 p -98.47 145.08 27.13 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.401 -0.812 . . . . 0.0 109.284 179.969 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.944 HD11 HG11 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -138.96 159.62 41.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.334 -0.854 . . . . 0.0 109.826 -178.717 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.652 HG22 HG22 ' A' ' 18' ' ' VAL . 1.4 p -101.29 124.0 46.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.011 -1.056 . . . . 0.0 108.483 179.319 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.701 HG12 ' HB3' ' A' ' 36' ' ' GLN . 21.1 m -137.92 143.16 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.744 -1.222 . . . . 0.0 110.783 -178.47 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.599 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.9 ptt180 -147.45 -175.14 4.73 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 120.711 -1.243 . . . . 0.0 110.742 179.68 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.595 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.43 -101.93 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -179.597 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.503 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -57.08 140.85 47.98 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.741 -1.224 . . . . 0.0 108.205 179.459 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -161.83 136.67 7.16 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 118.611 -1.235 . . . . 0.0 109.733 -178.1 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.532 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.4 mp0 -35.87 122.36 0.68 Allowed 'General case' 0 N--CA 1.491 1.576 0 CA-C-O 121.466 0.65 . . . . 0.0 110.094 -178.615 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.098 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.85 52.67 1.7 Allowed Glycine 0 N--CA 1.494 2.522 0 C-N-CA 120.539 -0.838 . . . . 0.0 111.22 -179.109 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.592 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.57 114.05 0.38 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.094 -1.239 . . . . 0.0 110.133 179.463 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.733 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -82.79 126.19 32.14 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 120.843 -1.161 . . . . 0.0 109.313 179.787 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.401 ' O ' ' CD2' ' A' ' 78' ' ' PHE . 51.8 t80 -64.02 58.59 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.955 0 O-C-N 120.89 -1.131 . . . . 0.0 110.042 179.724 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.3 t0 -160.22 20.03 0.15 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.094 -1.004 . . . . 0.0 109.608 179.942 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.54 -28.35 5.36 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.871 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.481 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.5 OUTLIER -96.72 160.42 14.38 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.058 -1.26 . . . . 0.0 110.207 -179.532 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.508 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.7 OUTLIER -106.13 141.69 37.07 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 179.896 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.733 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.6 t90 -85.15 -19.35 31.92 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.679 -1.263 . . . . 0.0 110.689 -178.289 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.42 177.5 18.59 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -179.359 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -67.02 105.79 1.75 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.146 -1.208 . . . . 0.0 107.785 179.183 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.65 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.7 t -77.2 106.33 7.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.326 -0.858 . . . . 0.0 109.232 -178.879 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.55 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.1 m-20 -65.96 111.63 3.42 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.363 -0.836 . . . . 0.0 109.69 -179.643 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.595 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.5 -5.36 5.26 Favored 'General case' 0 N--CA 1.5 2.045 0 C-N-CA 118.195 -1.402 . . . . 0.0 109.721 179.567 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -86.4 -0.41 55.91 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.716 -1.24 . . . . 0.0 109.079 179.482 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.55 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.6 -50.88 2.83 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.287 -0.883 . . . . 0.0 108.972 179.9 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.69 -178.73 3.74 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.509 -0.744 . . . . 0.0 109.271 179.815 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.17 115.37 30.11 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.437 -0.789 . . . . 0.0 108.888 -179.949 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.527 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.06 121.1 38.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.94 -1.1 . . . . 0.0 109.714 -179.271 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.614 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.21 146.94 27.27 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 122.449 1.119 . . . . 0.0 111.024 -179.562 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.548 ' CG1' HG11 ' A' ' 7' ' ' VAL . 61.6 t -104.23 111.72 34.94 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 177.858 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.497 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -152.91 -169.86 18.59 Favored Glycine 0 N--CA 1.487 2.089 0 C-N-CA 118.124 -1.989 . . . . 0.0 111.848 -177.71 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.489 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -114.32 179.43 3.96 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 -179.173 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.474 ' O ' ' HA ' ' A' ' 32' ' ' TYR . 25.0 p . . . . . 0 C--N 1.295 -1.792 0 O-C-N 121.467 -0.771 . . . . 0.0 109.363 -179.513 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.34 0 N-CA-C 106.717 -2.553 . . . . 0.0 106.717 . . . . . . . . . 0 0 . 1 . 054 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -146.7 170.74 16.35 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.709 -0.877 . . . . 0.0 109.943 -179.775 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.15 -165.01 19.55 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 108.163 -1.975 . . . . 0.0 108.163 -179.857 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.9 Cg_exo -48.22 179.39 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 CA-C-N 118.889 1.344 . . . . 0.0 110.164 179.446 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -92.86 -177.71 4.61 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.183 -0.948 . . . . 0.0 110.438 -178.894 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.497 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.61 165.62 14.53 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.923 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.0 130.13 53.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 O-C-N 121.293 -1.122 . . . . 0.0 109.209 -179.269 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.614 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.05 121.92 21.85 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.569 -0.707 . . . . 0.0 109.528 179.668 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.827 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.9 167.25 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 121.188 -0.945 . . . . 0.0 109.243 179.913 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.513 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -137.33 151.24 48.42 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.237 -0.914 . . . . 0.0 109.62 -179.97 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.827 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 25.2 m-85 . . . . . 0 N--CA 1.486 1.365 0 O-C-N 121.163 -0.961 . . . . 0.0 109.51 -179.693 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.458 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.478 0 CA-C-O 122.301 1.048 . . . . 0.0 110.71 . . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.968 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.7 t -110.93 108.77 18.65 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.079 1.418 . . . . 0.0 109.078 179.276 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.768 HG22 HG23 ' A' ' 21' ' ' VAL . 2.3 t -119.62 136.7 55.89 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.672 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.023 -179.637 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.488 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -177.0 150.96 0.92 Allowed Pre-proline 0 N--CA 1.487 1.421 0 O-C-N 121.286 -0.884 . . . . 0.0 108.785 -179.72 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.488 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -78.46 150.76 88.4 Favored 'Cis proline' 0 C--N 1.312 -1.35 0 C-N-CA 123.481 -1.466 . . . . 0.0 109.301 -0.828 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.689 ' HA ' HG22 ' A' ' 110' ' ' ILE . 77.9 p -89.34 -25.99 21.33 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.518 -0.739 . . . . 0.0 109.056 179.527 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.504 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -132.99 162.69 31.01 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.528 -0.733 . . . . 0.0 109.529 -179.922 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.31 36.93 29.37 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.749 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.771 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.5 mt -92.78 -42.97 9.27 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 123.24 1.495 . . . . 0.0 110.488 -178.327 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.29 144.35 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.265 0 CA-C-N 113.479 -1.691 . . . . 0.0 109.936 -179.521 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.591 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 15.5 p-10 -50.9 106.49 0.13 Allowed 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.515 0.674 . . . . 0.0 111.556 -178.542 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.28 14.22 9.23 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.331 -1.414 . . . . 0.0 113.007 177.311 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.771 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.71 -172.01 2.02 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 121.143 2.471 . . . . 0.0 109.67 179.144 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.748 HG13 ' C ' ' A' ' 67' ' ' LEU . 17.2 t -127.92 135.97 61.53 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.404 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.182 -178.93 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.591 HG11 HD11 ' A' ' 13' ' ' LEU . 23.0 m -110.79 155.15 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.77 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.523 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.8 OUTLIER -109.93 109.18 19.71 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.173 -0.954 . . . . 0.0 108.973 179.958 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.768 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -105.16 141.73 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.675 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.968 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -141.0 160.2 40.59 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.144 179.886 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.95 144.72 15.91 Favored Glycine 0 C--N 1.294 -1.769 0 N-CA-C 107.996 -2.041 . . . . 0.0 107.996 179.666 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -146.4 125.73 13.1 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 120.884 -1.362 . . . . 0.0 108.789 179.244 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.46 27.16 23.36 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.315 -1.421 . . . . 0.0 109.608 -179.568 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.551 HD22 ' HG3' ' A' ' 105' ' ' PRO . 1.5 mt -88.8 175.33 7.53 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.946 -1.326 . . . . 0.0 108.446 -179.941 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.998 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -48.42 99.49 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.013 -1.055 . . . . 0.0 109.83 -179.623 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.562 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.11 77.98 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.759 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.149 -179.325 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.69 34.2 0.31 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.614 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.549 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 62.9 p -143.21 109.09 5.18 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.034 -1.274 . . . . 0.0 111.142 -179.591 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.552 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.99 126.01 5.57 Favored 'General case' 0 N--CA 1.493 1.71 0 CA-C-O 121.403 0.62 . . . . 0.0 109.56 178.129 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.536 ' CD2' ' O ' ' A' ' 30' ' ' THR . 19.8 m-85 -117.35 152.98 33.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.349 -0.844 . . . . 0.0 108.923 179.808 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.523 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -103.14 152.66 21.17 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.627 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.637 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.0 p -136.82 116.96 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 120.885 -1.134 . . . . 0.0 109.856 -177.904 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.502 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.1 -178.28 39.35 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 118.462 -1.828 . . . . 0.0 111.828 -179.799 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.59 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -101.74 109.56 21.36 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.928 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.485 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.53 148.4 52.33 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.098 -1.001 . . . . 0.0 110.081 179.852 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.04 138.53 54.66 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.394 -0.816 . . . . 0.0 110.701 -179.025 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.862 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.39 114.6 26.39 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 178.137 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 m -105.22 15.16 6.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.006 -1.059 . . . . 0.0 110.705 -178.596 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.757 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.14 -175.09 0.09 Allowed 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.952 -1.093 . . . . 0.0 110.097 179.736 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 35.1 p -72.0 97.54 1.9 Allowed 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.404 -0.81 . . . . 0.0 109.727 -179.673 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.13 26.53 36.61 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.173 -1.013 . . . . 0.0 111.446 178.859 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.757 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.21 106.3 20.28 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 O-C-N 120.547 -1.561 . . . . 0.0 107.482 178.93 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.862 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -117.51 104.07 10.7 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.47 -1.393 . . . . 0.0 109.6 -177.815 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.014 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.32 109.24 22.03 Favored 'General case' 0 N--CA 1.483 1.179 0 O-C-N 120.767 -1.208 . . . . 0.0 107.753 178.603 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.491 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -103.5 166.01 10.69 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.924 -1.11 . . . . 0.0 110.411 -178.532 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.677 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 17.1 t-20 -106.35 129.72 24.07 Favored Pre-proline 0 N--CA 1.501 2.084 0 C-N-CA 119.945 -0.702 . . . . 0.0 109.757 -179.202 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.598 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.6 Cg_endo -72.94 23.81 0.3 Allowed 'Trans proline' 0 CA--C 1.544 0.98 0 C-N-CA 122.089 1.86 . . . . 0.0 111.813 179.634 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.677 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -115.51 3.63 14.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.498 -1.376 . . . . 0.0 109.197 179.738 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.543 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.89 17.24 2.66 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 179.49 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -80.64 91.1 5.8 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.842 -0.743 . . . . 0.0 110.814 -178.696 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.637 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -109.51 -166.71 1.12 Allowed 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.297 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.94 137.03 0.09 Allowed 'General case' 0 C--N 1.306 -1.311 0 O-C-N 120.526 -1.358 . . . . 0.0 111.404 -179.271 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.932 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -154.9 156.15 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.211 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.552 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.68 144.87 26.88 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.694 -1.254 . . . . 0.0 109.907 -179.534 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.83 107.22 1.16 Allowed 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 122.431 1.11 . . . . 0.0 109.409 178.586 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -61.07 -139.34 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.027 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.903 -179.909 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.562 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.9 -50.91 56.38 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.397 -0.814 . . . . 0.0 110.68 -178.713 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -103.94 -33.18 8.92 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 178.576 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.003 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.96 64.91 0.58 Allowed Glycine 0 C--N 1.299 -1.498 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 178.206 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 47.7 m -103.44 127.07 50.9 Favored 'General case' 0 N--CA 1.483 1.176 0 O-C-N 121.57 -0.959 . . . . 0.0 108.83 178.901 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.932 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.04 108.96 7.1 Favored 'General case' 0 C--N 1.296 -1.751 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.659 -179.396 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.1 m -122.44 121.01 35.6 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.359 -0.838 . . . . 0.0 109.303 -179.898 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.525 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.83 144.84 31.34 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.426 -0.796 . . . . 0.0 109.565 179.886 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 22.1 p -99.0 141.0 32.3 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.38 -0.825 . . . . 0.0 109.297 -179.945 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.777 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.99 166.7 24.07 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.413 -0.804 . . . . 0.0 109.39 -179.327 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.728 HG22 HG22 ' A' ' 18' ' ' VAL . 2.7 p -95.96 124.38 39.95 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.005 -1.06 . . . . 0.0 109.416 -179.883 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.587 HG22 HG22 ' A' ' 19' ' ' VAL . 13.3 m -136.42 141.86 40.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 120.907 -1.121 . . . . 0.0 109.937 -179.12 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.591 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.3 ptt180 -144.35 -170.32 3.34 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.546 -1.346 . . . . 0.0 110.884 -179.882 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.598 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -62.45 -101.42 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.77 -0.581 . . . . 0.0 110.206 -179.125 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.541 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -58.94 137.15 58.0 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.574 -1.329 . . . . 0.0 108.209 179.957 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD2' ' O ' ' A' ' 71' ' ' ARG . 1.7 p90 -157.53 154.04 27.96 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.646 -1.222 . . . . 0.0 110.198 -178.514 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.5 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 5.1 mm-40 -47.15 120.8 3.32 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.359 -0.838 . . . . 0.0 109.263 -179.124 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.014 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.5 51.34 3.01 Favored Glycine 0 N--CA 1.495 2.59 0 C-N-CA 120.414 -0.898 . . . . 0.0 111.116 -179.224 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.598 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.5 m-30 -39.0 114.0 0.36 Allowed 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.114 -1.227 . . . . 0.0 110.31 179.62 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.765 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.21 126.94 34.63 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.919 -1.113 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 29.2 t80 -64.25 58.44 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.911 -1.118 . . . . 0.0 110.059 179.702 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -160.33 19.52 0.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.031 -1.043 . . . . 0.0 109.733 179.824 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.74 -26.96 5.57 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 179.866 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.404 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -95.34 161.42 14.09 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 120.998 -1.295 . . . . 0.0 110.315 -179.383 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.482 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -107.24 136.78 46.49 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.813 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.765 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -83.64 -16.89 43.44 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.784 -1.198 . . . . 0.0 110.562 -178.423 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.14 174.27 20.0 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 108.827 -1.709 . . . . 0.0 108.827 -179.553 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -63.66 107.0 1.06 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.141 -1.211 . . . . 0.0 107.759 179.218 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.662 HG21 ' HB3' ' A' ' 46' ' ' ALA . 44.3 t -78.94 106.05 9.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.307 -0.871 . . . . 0.0 109.243 -178.877 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.553 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -65.16 108.35 1.84 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.652 -0.655 . . . . 0.0 110.113 -179.408 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.598 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.5 t -61.34 -4.72 1.32 Allowed 'General case' 0 N--CA 1.502 2.133 0 O-C-N 120.479 -1.388 . . . . 0.0 110.417 179.391 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -90.43 3.68 53.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.597 -1.314 . . . . 0.0 109.481 179.944 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.553 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -114.96 -48.32 2.84 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.282 -0.886 . . . . 0.0 109.107 -179.976 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.72 -179.05 3.82 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.573 -0.704 . . . . 0.0 109.526 179.997 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.97 112.15 24.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.382 -0.824 . . . . 0.0 108.812 179.838 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.505 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.4 m -96.98 122.06 39.54 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.104 -0.997 . . . . 0.0 109.399 -178.922 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.575 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.08 148.66 25.45 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-O 122.439 1.114 . . . . 0.0 111.577 -179.157 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.499 ' CG1' HG11 ' A' ' 7' ' ' VAL . 84.8 t -104.22 110.78 31.43 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 177.643 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.412 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.84 -172.01 18.87 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 118.034 -2.031 . . . . 0.0 111.802 -177.604 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.523 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -114.57 -179.04 3.52 Favored 'General case' 0 N--CA 1.485 1.3 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -178.94 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.504 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.8 OUTLIER . . . . . 0 C--N 1.298 -1.66 0 O-C-N 121.394 -0.816 . . . . 0.0 109.033 -179.418 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.688 0 N-CA-C 107.636 -2.185 . . . . 0.0 107.636 . . . . . . . . . 0 0 . 1 . 055 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.3 -178.81 7.56 Favored 'General case' 0 C--N 1.307 -1.26 0 O-C-N 121.542 -0.975 . . . . 0.0 109.623 179.022 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -177.63 -167.01 35.17 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 -179.584 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.551 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.7 Cg_exo -49.11 -179.57 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.618 0 CA-C-N 118.83 1.315 . . . . 0.0 110.07 179.529 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.87 -179.81 5.1 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.012 -1.055 . . . . 0.0 110.521 -178.765 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.412 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.99 162.65 13.42 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.973 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -103.55 130.62 53.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.318 -1.107 . . . . 0.0 109.216 -179.347 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.575 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.98 121.21 18.75 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.641 -0.662 . . . . 0.0 109.606 179.62 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.859 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.04 171.43 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.239 -0.913 . . . . 0.0 109.174 179.947 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.504 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.4 m -141.1 156.55 45.96 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.151 -0.968 . . . . 0.0 109.895 -179.841 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.859 ' CE2' HD12 ' A' ' 110' ' ' ILE . 82.8 m-85 . . . . . 0 N--CA 1.486 1.34 0 O-C-N 121.243 -0.911 . . . . 0.0 109.549 -179.74 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.505 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.483 1.217 0 CA-C-O 122.409 1.1 . . . . 0.0 110.565 . . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.011 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.4 p -106.31 104.86 14.65 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 122.461 1.124 . . . . 0.0 110.199 -179.476 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.967 HG22 HG23 ' A' ' 21' ' ' VAL . 12.1 t -118.53 118.69 58.8 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.439 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.364 179.596 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.499 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.87 149.17 10.28 Favored Pre-proline 0 N--CA 1.487 1.38 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 -179.65 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.499 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -77.83 151.23 91.09 Favored 'Cis proline' 0 C--N 1.31 -1.494 0 C-N-CA 123.606 -1.414 . . . . 0.0 109.51 -0.578 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.704 ' HA ' HG22 ' A' ' 110' ' ' ILE . 16.5 p -93.52 -23.85 18.2 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.639 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.463 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 20.2 m -132.38 162.22 31.64 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.438 -0.789 . . . . 0.0 109.585 -179.927 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.2 37.24 37.72 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 -179.733 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.83 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.2 mt -90.41 -44.64 9.51 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 123.127 1.441 . . . . 0.0 110.652 -178.428 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.99 145.83 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.325 0 CA-C-N 113.699 -1.591 . . . . 0.0 109.963 -179.701 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.63 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 7.3 p-10 -51.35 106.26 0.13 Allowed 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.598 0.713 . . . . 0.0 111.794 -178.471 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.45 15.7 8.71 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 119.438 -1.363 . . . . 0.0 112.98 177.302 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.83 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.0 t -102.72 -171.66 1.99 Allowed 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 121.13 2.465 . . . . 0.0 109.84 179.31 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.755 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.2 t -129.45 139.01 52.83 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.289 0 CA-C-N 114.861 -1.063 . . . . 0.0 111.195 -178.699 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.533 HG22 HG22 ' A' ' 69' ' ' VAL . 31.2 m -118.08 155.04 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.733 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.548 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 6.2 tttt -113.08 109.13 18.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.126 -0.984 . . . . 0.0 109.413 -179.854 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.967 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -105.33 122.97 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 179.833 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.011 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.88 166.09 11.71 Favored 'General case' 0 C--N 1.307 -1.243 0 O-C-N 120.799 -1.188 . . . . 0.0 109.073 179.634 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.67 108.46 0.5 Allowed Glycine 0 N--CA 1.481 1.678 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 -179.886 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.36 139.11 50.76 Favored 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 119.396 1.598 . . . . 0.0 110.424 -179.485 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 84.56 29.04 30.86 Favored Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.079 -1.534 . . . . 0.0 109.941 179.56 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.523 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.5 mt -92.47 176.07 6.6 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.986 -1.302 . . . . 0.0 108.562 179.935 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.39 96.98 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.023 -1.048 . . . . 0.0 109.621 -179.909 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.711 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.94 77.18 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.36 -178.93 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 131.8 34.87 0.37 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.465 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.636 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -146.51 114.4 6.51 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 120.931 -1.335 . . . . 0.0 111.109 -179.948 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.17 122.9 5.66 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.181 178.669 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.636 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 2.0 m-30 -116.93 151.77 35.96 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.267 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -98.91 163.75 12.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.539 -1.351 . . . . 0.0 108.216 179.247 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 1.003 HG11 HG21 ' A' ' 65' ' ' THR . 3.8 p -144.59 117.98 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.106 -0.997 . . . . 0.0 109.643 -177.963 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.511 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.66 -179.08 41.22 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.411 -1.852 . . . . 0.0 111.738 -179.804 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.636 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -100.95 109.24 21.15 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -179.922 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.03 149.21 51.85 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.21 -0.931 . . . . 0.0 109.74 179.891 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.552 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.36 137.75 54.75 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.178 -0.951 . . . . 0.0 110.736 -178.993 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.883 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.28 114.61 26.41 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 178.038 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -104.59 14.47 7.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 120.973 -1.079 . . . . 0.0 110.585 -178.708 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.766 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.57 -174.84 0.08 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.941 -1.099 . . . . 0.0 109.988 179.747 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.92 98.22 2.43 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.379 -0.826 . . . . 0.0 109.653 -179.753 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.28 26.95 31.96 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 120.302 -0.952 . . . . 0.0 111.534 178.943 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.766 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -116.85 106.16 19.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 O-C-N 120.499 -1.589 . . . . 0.0 107.298 178.922 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.883 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -118.17 104.37 10.75 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.358 -1.464 . . . . 0.0 109.885 -177.795 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.023 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.45 109.36 22.13 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 120.821 -1.174 . . . . 0.0 108.156 178.905 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.509 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.3 t -104.42 166.63 10.27 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.844 -1.16 . . . . 0.0 110.353 -178.961 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.677 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 15.8 t-20 -109.53 137.89 20.44 Favored Pre-proline 0 N--CA 1.501 2.082 0 O-C-N 121.445 -0.785 . . . . 0.0 110.146 -179.081 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.8 Cg_endo -74.82 25.2 0.37 Allowed 'Trans proline' 0 C--N 1.318 -1.027 0 C-N-CA 122.465 2.11 . . . . 0.0 111.939 179.903 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.677 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -117.27 2.35 12.54 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.278 -1.514 . . . . 0.0 109.294 179.788 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.551 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.73 18.71 2.51 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 179.297 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -80.58 89.73 5.69 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.88 -0.728 . . . . 0.0 110.489 -179.078 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -113.65 -168.7 1.38 Allowed 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 178.647 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.5 134.96 0.08 Allowed 'General case' 0 C--N 1.305 -1.34 0 O-C-N 120.653 -1.28 . . . . 0.0 111.286 -179.337 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.856 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.3 p -149.09 158.71 6.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 177.966 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.19 145.69 26.35 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.75 -1.219 . . . . 0.0 109.908 -179.723 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.88 107.87 2.36 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-O 122.443 1.116 . . . . 0.0 109.369 178.577 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.9 p-10 -59.87 -139.47 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.829 179.996 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.711 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.64 -50.68 59.84 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.386 -0.821 . . . . 0.0 110.467 -178.775 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.5 t30 -103.63 -34.65 8.56 Favored 'General case' 0 C--N 1.285 -2.225 0 N-CA-C 106.379 -1.711 . . . . 0.0 106.379 178.481 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.986 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.5 67.92 0.62 Allowed Glycine 0 C--N 1.297 -1.584 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.055 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.8 m -103.36 126.16 50.37 Favored 'General case' 0 N--CA 1.484 1.254 0 O-C-N 121.717 -0.873 . . . . 0.0 108.677 178.817 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.856 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.87 108.86 8.14 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 119.714 -0.794 . . . . 0.0 109.511 -179.327 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 93.0 p -117.89 117.2 28.62 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 121.17 -0.956 . . . . 0.0 109.436 -179.99 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 1.003 HG21 HG11 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -141.85 135.31 29.44 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.467 -0.771 . . . . 0.0 109.957 179.979 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 10.0 p -100.36 133.13 45.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.423 -0.798 . . . . 0.0 108.848 179.511 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.817 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -134.3 175.19 9.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.316 -0.865 . . . . 0.0 109.683 -178.917 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.548 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -100.16 125.0 46.23 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.006 -1.059 . . . . 0.0 109.702 -179.612 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.533 HG22 HG22 ' A' ' 19' ' ' VAL . 16.5 m -136.87 142.15 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 120.94 -1.1 . . . . 0.0 109.761 -179.495 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.63 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.4 ptt180 -138.43 -165.3 1.79 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.652 -1.28 . . . . 0.0 110.129 -179.911 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.579 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -74.87 -83.61 0.05 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.142 -0.974 . . . . 0.0 108.782 -179.615 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.501 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -62.82 138.86 58.64 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.361 -1.462 . . . . 0.0 107.228 178.668 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD1' ' O ' ' A' ' 71' ' ' ARG . 0.3 OUTLIER -164.54 135.11 4.1 Favored 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 117.933 -1.507 . . . . 0.0 110.533 -177.443 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.51 ' HB3' ' HD3' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -31.82 121.02 0.28 Allowed 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.463 0.649 . . . . 0.0 110.483 -178.76 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.023 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.28 49.87 2.42 Favored Glycine 0 N--CA 1.494 2.537 0 C-N-CA 120.353 -0.927 . . . . 0.0 111.396 -179.062 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.4 m-30 -39.68 112.46 0.26 Allowed 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.027 -1.278 . . . . 0.0 109.998 179.306 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.668 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -84.62 127.18 33.94 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.906 -1.121 . . . . 0.0 109.791 -179.804 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -63.66 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.03 0 O-C-N 120.978 -1.077 . . . . 0.0 110.195 179.58 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.4 t0 -161.26 19.51 0.12 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.022 -1.049 . . . . 0.0 109.816 179.878 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.3 -26.68 5.49 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 179.866 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.419 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 22.8 p -93.9 157.53 16.08 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.975 -1.309 . . . . 0.0 110.302 -179.442 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.497 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 4.5 ptt180 -104.73 135.54 45.92 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.701 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.668 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -82.57 -17.76 43.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.716 -1.24 . . . . 0.0 110.423 -178.55 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.6 175.68 21.14 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 -179.57 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.59 109.14 1.3 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 179.037 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.574 HG21 ' HB3' ' A' ' 46' ' ' ALA . 35.2 t -81.39 104.77 10.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -178.864 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.529 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.09 111.9 3.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.448 -0.782 . . . . 0.0 109.885 -179.146 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.543 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -65.98 -4.44 7.1 Favored 'General case' 0 N--CA 1.499 1.992 0 C-N-CA 118.366 -1.334 . . . . 0.0 109.839 179.324 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 p -85.02 1.18 48.76 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.835 -1.166 . . . . 0.0 108.872 179.336 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.529 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -116.13 -49.86 2.68 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.401 -0.812 . . . . 0.0 109.047 -179.957 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.7 -179.49 3.95 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.512 -0.743 . . . . 0.0 109.464 179.916 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.99 115.46 30.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.883 . . . . 0.0 109.104 179.976 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.55 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.9 m -96.8 122.54 39.87 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.909 -1.12 . . . . 0.0 109.391 -179.5 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.592 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.31 146.28 27.76 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-O 122.393 1.092 . . . . 0.0 111.368 -179.216 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.722 ' HB ' HG11 ' A' ' 7' ' ' VAL . 53.4 t -102.5 109.64 27.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 177.419 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.438 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.64 -169.99 16.0 Favored Glycine 0 N--CA 1.485 1.932 0 C-N-CA 118.009 -2.043 . . . . 0.0 111.729 -177.362 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.498 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -117.75 -177.89 3.36 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -178.786 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.515 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.1 p . . . . . 0 C--N 1.295 -1.765 0 O-C-N 121.35 -0.844 . . . . 0.0 109.302 -179.251 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.707 0 N-CA-C 107.599 -2.201 . . . . 0.0 107.599 . . . . . . . . . 0 0 . 1 . 056 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.94 -178.15 7.03 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.617 -0.931 . . . . 0.0 109.826 179.288 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.87 -162.6 20.13 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 108.239 -1.945 . . . . 0.0 108.239 -179.433 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.609 ' CD ' ' CE2' ' A' ' 32' ' ' TYR . 7.3 Cg_exo -45.59 172.07 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.652 0 CA-C-N 118.92 1.36 . . . . 0.0 109.926 179.354 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -90.36 -171.43 3.09 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.107 -0.995 . . . . 0.0 110.42 -178.746 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.438 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.65 169.65 16.67 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.751 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.445 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.81 133.95 47.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.48 -1.012 . . . . 0.0 109.061 -179.314 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.592 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.82 119.42 18.98 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.513 -0.742 . . . . 0.0 109.696 179.791 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.896 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -98.14 168.58 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 O-C-N 121.272 -0.892 . . . . 0.0 108.845 179.708 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.463 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -139.7 157.63 45.44 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.017 -1.052 . . . . 0.0 109.853 -179.717 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.896 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.7 m-85 . . . . . 0 N--CA 1.486 1.37 0 O-C-N 121.236 -0.915 . . . . 0.0 109.506 -179.672 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.452 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.42 0 CA-C-O 122.253 1.025 . . . . 0.0 110.32 . . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.95 HG22 ' HB3' ' A' ' 22' ' ' ALA . 4.3 t -116.36 108.71 16.4 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 123.167 1.46 . . . . 0.0 109.23 179.29 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.791 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -117.04 138.26 48.29 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.654 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.944 -179.604 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.494 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.5 149.88 1.39 Allowed Pre-proline 0 N--CA 1.485 1.308 0 O-C-N 121.298 -0.877 . . . . 0.0 108.757 -179.782 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.494 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -77.86 150.91 90.56 Favored 'Cis proline' 0 C--N 1.311 -1.427 0 C-N-CA 123.507 -1.455 . . . . 0.0 109.461 -0.786 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.673 ' HA ' HG22 ' A' ' 110' ' ' ILE . 71.1 p -88.31 -26.2 22.39 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.903 -0.776 . . . . 0.0 108.903 179.564 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.543 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 0.8 OUTLIER -132.75 168.74 17.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.449 -0.782 . . . . 0.0 109.499 179.649 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.93 38.79 48.11 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 108.36 -1.896 . . . . 0.0 108.36 -179.801 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.772 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.3 mt -94.11 -43.04 8.68 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 123.285 1.517 . . . . 0.0 110.67 -178.111 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.48 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.08 143.5 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.283 0 CA-C-N 113.408 -1.723 . . . . 0.0 109.766 -179.398 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.568 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.8 p-10 -49.95 105.47 0.09 Allowed 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 121.57 0.7 . . . . 0.0 111.753 -178.397 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.403 ' H ' ' HB3' ' A' ' 70' ' ' ARG . . . 113.23 15.68 8.86 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.33 -1.414 . . . . 0.0 113.081 177.158 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.772 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.24 -171.15 1.88 Allowed 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 121.235 2.517 . . . . 0.0 109.733 179.153 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.859 HG22 HG22 ' A' ' 68' ' ' THR . 15.9 t -129.98 139.26 51.95 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.289 0 CA-C-N 114.943 -1.026 . . . . 0.0 111.309 -178.97 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.566 HG12 HD21 ' A' ' 13' ' ' LEU . 33.6 m -115.59 155.74 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.881 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.499 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -106.9 109.76 21.74 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.117 -0.989 . . . . 0.0 109.187 -179.929 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.791 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -103.35 139.74 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.404 -0.81 . . . . 0.0 108.842 179.978 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.95 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -132.55 157.8 43.79 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.829 -1.169 . . . . 0.0 109.608 179.426 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -138.99 108.71 0.62 Allowed Glycine 0 N--CA 1.482 1.74 0 N-CA-C 108.688 -1.765 . . . . 0.0 108.688 -179.964 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -114.36 142.04 46.85 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.889 -1.359 . . . . 0.0 110.858 -179.059 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 81.84 27.36 46.47 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.701 -1.237 . . . . 0.0 110.131 178.942 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.574 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.6 mt -89.52 173.99 8.02 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.008 -1.289 . . . . 0.0 108.705 -179.848 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.97 99.64 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.965 -1.085 . . . . 0.0 109.579 -179.598 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.554 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.24 77.22 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.196 -179.144 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.9 34.09 0.31 Allowed Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.549 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.554 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 78.0 p -144.04 111.02 5.73 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 120.965 -1.315 . . . . 0.0 111.045 -179.741 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -46.27 125.09 6.28 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.689 178.158 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.493 ' CD2' ' O ' ' A' ' 30' ' ' THR . 16.9 m-85 -116.11 150.82 36.75 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.889 . . . . 0.0 108.97 179.699 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.509 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -101.86 151.77 21.69 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 178.547 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.622 HG13 ' O ' ' A' ' 34' ' ' VAL . 4.5 p -136.17 117.63 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.957 -1.09 . . . . 0.0 109.787 -177.904 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -165.01 -179.35 38.93 Favored Glycine 0 N--CA 1.494 2.5 0 C-N-CA 118.348 -1.882 . . . . 0.0 111.69 -179.576 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.629 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.6 pt20 -100.44 110.79 23.0 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.927 0.87 . . . . 0.0 108.744 -179.872 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.1 m -131.08 148.98 52.8 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.265 -0.897 . . . . 0.0 109.781 -179.756 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.478 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.39 138.19 54.61 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.261 -0.9 . . . . 0.0 110.675 -179.047 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.867 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.63 114.64 26.41 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 178.209 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 m -105.23 14.56 7.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.028 -1.045 . . . . 0.0 110.65 -178.693 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 173.98 -175.67 0.07 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.912 -1.118 . . . . 0.0 110.198 179.706 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.777 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.34 97.99 1.34 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 121.755 0.788 . . . . 0.0 110.001 -179.633 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.62 26.47 38.62 Favored Glycine 0 N--CA 1.493 2.494 0 C-N-CA 120.252 -0.975 . . . . 0.0 111.522 178.825 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.89 106.31 20.35 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.572 -1.546 . . . . 0.0 107.382 178.931 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.867 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.8 tp -118.05 104.69 11.1 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.494 -1.379 . . . . 0.0 109.77 -177.793 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.943 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.87 109.69 22.4 Favored 'General case' 0 N--CA 1.484 1.265 0 O-C-N 120.796 -1.19 . . . . 0.0 108.246 178.903 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.9 t -107.13 166.54 10.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.93 -1.106 . . . . 0.0 110.525 -178.692 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.496 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 12.4 t-20 -114.0 129.81 24.45 Favored Pre-proline 0 N--CA 1.499 2.005 0 O-C-N 121.424 -0.797 . . . . 0.0 109.697 -179.236 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.614 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -71.28 21.08 0.23 Allowed 'Trans proline' 0 CA--C 1.546 1.082 0 C-N-CA 121.953 1.769 . . . . 0.0 111.969 179.274 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.496 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -107.08 1.45 24.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.442 -1.411 . . . . 0.0 108.82 179.293 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.532 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.92 15.47 2.87 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 179.372 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -79.25 85.76 5.08 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.069 -178.49 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.601 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -101.59 -166.72 1.33 Allowed 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 178.128 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.432 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.36 138.35 0.09 Allowed 'General case' 0 C--N 1.305 -1.348 0 O-C-N 120.504 -1.373 . . . . 0.0 111.417 -179.178 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.936 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -157.47 156.7 4.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 178.135 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.88 144.75 27.13 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.747 -1.221 . . . . 0.0 109.884 -179.664 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.009 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.46 106.69 1.19 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 122.47 1.129 . . . . 0.0 109.44 178.61 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.543 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 16.9 p-10 -58.87 -138.62 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.621 179.848 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.554 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -56.38 -49.45 74.42 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.39 -0.819 . . . . 0.0 110.103 -178.976 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.406 ' CG ' ' N ' ' A' ' 61' ' ' GLY . 10.8 p-10 -98.21 -39.84 8.66 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 106.066 -1.827 . . . . 0.0 106.066 178.372 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.989 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 110.19 64.33 0.53 Allowed Glycine 0 C--N 1.296 -1.694 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.38 178.054 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.584 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 88.6 p -100.28 128.47 46.34 Favored 'General case' 0 C--N 1.309 -1.167 0 O-C-N 121.618 -0.93 . . . . 0.0 108.945 178.915 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.936 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.26 108.47 7.26 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.604 -0.839 . . . . 0.0 108.952 -179.814 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -128.64 121.33 28.37 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.288 -0.883 . . . . 0.0 109.977 -179.358 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.06 148.08 31.28 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.62 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 9.5 p -98.28 131.01 44.96 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.173 -0.955 . . . . 0.0 109.486 -179.737 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.767 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -127.23 164.52 21.51 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.507 -0.746 . . . . 0.0 109.338 -179.347 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.859 HG22 HG22 ' A' ' 18' ' ' VAL . 1.9 p -96.51 124.05 40.37 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.986 -1.071 . . . . 0.0 109.333 179.969 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.539 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.5 m -137.33 143.38 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 120.997 -1.064 . . . . 0.0 109.968 -179.211 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.568 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -141.52 -166.54 2.22 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.558 -1.338 . . . . 0.0 110.214 179.986 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.595 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -69.44 -89.13 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 119.687 -0.805 . . . . 0.0 108.837 -179.737 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.52 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -59.67 138.27 57.79 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 120.426 -1.421 . . . . 0.0 107.451 178.89 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.12 141.09 7.99 Favored 'General case' 0 C--N 1.294 -1.819 0 C-N-CA 118.148 -1.421 . . . . 0.0 110.351 -177.682 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.489 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.5 mm-40 -33.95 120.24 0.42 Allowed 'General case' 0 N--CA 1.491 1.62 0 CA-C-O 121.561 0.696 . . . . 0.0 110.7 -178.473 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.943 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.33 45.21 2.79 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.713 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.614 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -39.24 113.34 0.31 Allowed 'General case' 0 N--CA 1.508 2.474 0 O-C-N 121.099 -1.236 . . . . 0.0 110.298 179.782 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.634 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.43 127.36 34.83 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 120.857 -1.152 . . . . 0.0 109.556 -179.972 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -64.23 58.09 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.955 0 O-C-N 120.815 -1.178 . . . . 0.0 110.286 179.849 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 77' ' ' LEU . 10.7 t0 -160.92 19.57 0.13 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.983 -1.073 . . . . 0.0 109.833 179.771 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -26.78 5.28 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.918 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -91.72 154.44 18.97 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 121.031 -1.276 . . . . 0.0 110.387 -179.471 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.489 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -102.87 131.91 49.45 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.634 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.634 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -79.89 -19.15 48.89 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.758 -1.214 . . . . 0.0 110.238 -178.635 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.24 175.05 20.13 Favored Glycine 0 N--CA 1.485 1.966 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 -179.529 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.499 ' CG2' ' HB3' ' A' ' 72' ' ' SER . 0.9 OUTLIER -63.49 110.29 1.91 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 106.903 -1.518 . . . . 0.0 106.903 178.851 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.57 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.1 t -81.28 104.36 9.71 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 O-C-N 121.345 -0.847 . . . . 0.0 109.162 -178.642 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.655 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -63.98 110.64 2.2 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.479 -0.763 . . . . 0.0 109.735 -179.414 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.534 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.61 -5.13 4.98 Favored 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 118.137 -1.425 . . . . 0.0 109.839 179.42 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -84.41 -0.7 53.73 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.834 -1.166 . . . . 0.0 108.932 179.306 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.655 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -112.66 -50.02 2.91 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.346 -0.847 . . . . 0.0 108.995 179.911 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.12 -179.88 4.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.491 -0.756 . . . . 0.0 109.572 179.96 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.91 116.12 31.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.365 -0.834 . . . . 0.0 109.103 -179.954 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -96.83 122.24 39.57 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.884 -1.135 . . . . 0.0 109.555 -179.484 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.575 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -102.76 149.59 24.32 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.383 1.087 . . . . 0.0 111.421 -179.149 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.494 ' CG1' HG11 ' A' ' 7' ' ' VAL . 47.2 t -102.07 111.12 30.73 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 177.194 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -145.18 -174.96 17.91 Favored Glycine 0 N--CA 1.486 1.975 0 C-N-CA 118.49 -1.814 . . . . 0.0 111.46 -177.56 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.509 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.12 -179.83 4.16 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -178.779 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.501 ' O ' ' N ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.777 0 O-C-N 121.501 -0.749 . . . . 0.0 109.063 -179.498 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.755 0 N-CA-C 107.823 -2.111 . . . . 0.0 107.823 . . . . . . . . . 0 0 . 1 . 057 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.17 -178.58 7.3 Favored 'General case' 0 C--N 1.308 -1.222 0 O-C-N 121.484 -1.01 . . . . 0.0 109.573 179.074 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -178.63 -166.45 34.8 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 108.495 -1.842 . . . . 0.0 108.495 -179.457 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.5 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.0 Cg_exo -50.22 -175.15 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.63 0 CA-C-N 118.843 1.321 . . . . 0.0 110.279 179.561 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.61 -173.66 2.81 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.119 -0.988 . . . . 0.0 110.076 -179.179 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -125.25 169.95 17.2 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.817 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.516 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -109.25 154.23 10.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -179.597 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.575 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -97.42 122.82 40.9 Favored 'General case' 0 C--N 1.291 -1.945 0 O-C-N 121.318 -0.864 . . . . 0.0 109.703 -179.888 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.673 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.6 pt -98.26 168.97 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.213 -0.929 . . . . 0.0 109.033 179.83 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.543 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.7 m -142.52 155.91 45.08 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.05 -1.031 . . . . 0.0 109.811 179.979 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.669 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 31.4 m-85 . . . . . 0 N--CA 1.486 1.327 0 O-C-N 121.138 -0.976 . . . . 0.0 109.539 -179.642 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.473 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . . . . . . 0 N--CA 1.488 1.451 0 CA-C-O 122.129 0.966 . . . . 0.0 110.81 . . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.016 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.2 p -105.01 104.4 14.13 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 122.435 1.112 . . . . 0.0 109.997 179.833 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.978 HG22 HG23 ' A' ' 21' ' ' VAL . 13.1 t -118.85 119.75 61.97 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.543 179.841 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.506 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.75 148.55 7.68 Favored Pre-proline 0 N--CA 1.486 1.352 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 -179.695 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.506 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -77.54 150.72 91.21 Favored 'Cis proline' 0 C--N 1.31 -1.476 0 C-N-CA 123.552 -1.437 . . . . 0.0 109.495 -0.458 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.668 ' HA ' HG22 ' A' ' 110' ' ' ILE . 80.4 p -89.29 -26.18 21.28 Favored 'General case' 0 C--N 1.293 -1.882 0 O-C-N 121.467 -0.77 . . . . 0.0 108.993 179.625 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.539 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 4.3 p -133.47 165.91 23.77 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.474 -0.766 . . . . 0.0 109.419 -179.941 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.7 38.27 37.51 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 -179.505 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.772 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.8 mt -92.56 -43.24 9.24 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 123.203 1.478 . . . . 0.0 110.624 -178.167 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 70.54 143.31 0.05 Allowed 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.453 -1.703 . . . . 0.0 109.774 -179.54 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.625 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 7.4 p-10 -50.57 104.59 0.08 Allowed 'General case' 0 C--N 1.301 -1.516 0 CA-C-O 121.558 0.694 . . . . 0.0 111.772 -178.447 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.89 16.61 7.85 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 119.476 -1.345 . . . . 0.0 112.97 177.272 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.772 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -104.8 -171.23 1.88 Allowed 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 121.146 2.473 . . . . 0.0 109.693 179.11 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.845 HG22 HG22 ' A' ' 68' ' ' THR . 16.4 t -130.37 140.02 49.9 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.246 -178.845 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.559 HG12 HD21 ' A' ' 13' ' ' LEU . 35.1 m -117.25 155.33 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 178.933 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.555 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.1 tttt -106.73 108.97 20.75 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.047 -1.033 . . . . 0.0 109.414 -179.817 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.978 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.47 123.13 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.723 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.016 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.67 164.49 13.97 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 120.745 -1.222 . . . . 0.0 108.938 179.82 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.583 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.56 107.51 0.53 Allowed Glycine 0 C--N 1.297 -1.628 0 N-CA-C 108.595 -1.802 . . . . 0.0 108.595 179.8 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' A' ' 62' ' ' SER . . . -115.72 142.67 46.44 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.978 -1.307 . . . . 0.0 110.445 -179.134 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 82.03 27.26 45.97 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.577 -1.297 . . . . 0.0 109.93 179.357 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.568 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.3 mt -90.84 174.24 7.56 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.069 -1.254 . . . . 0.0 108.574 179.974 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.0 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.42 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.966 -1.084 . . . . 0.0 109.517 -179.65 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.688 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.82 77.21 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.77 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.409 -178.97 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.553 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 132.7 34.66 0.34 Allowed Glycine 0 N--CA 1.487 2.066 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.407 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.0 p -145.0 112.54 6.2 Favored 'General case' 0 C--N 1.307 -1.272 0 O-C-N 121.031 -1.276 . . . . 0.0 111.083 -179.676 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.555 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -45.83 125.34 6.05 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-N 115.67 -0.695 . . . . 0.0 109.606 178.096 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.485 ' HA ' ' O ' ' A' ' 98' ' ' SER . 11.8 m-85 -118.13 149.87 40.31 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.325 -0.86 . . . . 0.0 108.697 179.692 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.511 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.27 158.35 15.93 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.614 -1.304 . . . . 0.0 107.742 178.635 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.722 HG13 ' O ' ' A' ' 34' ' ' VAL . 7.2 p -142.12 112.24 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.035 -1.041 . . . . 0.0 109.897 -177.798 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -160.57 -178.86 34.93 Favored Glycine 0 N--CA 1.494 2.538 0 C-N-CA 118.524 -1.798 . . . . 0.0 111.722 -179.62 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.635 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.1 pt20 -101.31 110.75 22.81 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.82 0.819 . . . . 0.0 108.922 -179.82 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -131.45 148.69 52.67 Favored 'General case' 0 C--N 1.295 -1.791 0 O-C-N 121.286 -0.884 . . . . 0.0 109.672 179.893 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.533 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -120.97 137.59 54.55 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.174 -0.954 . . . . 0.0 110.803 -178.936 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.866 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.73 114.57 26.32 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.096 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -104.78 14.11 7.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 120.979 -1.076 . . . . 0.0 110.65 -178.738 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.761 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.17 -174.53 0.07 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.942 -1.099 . . . . 0.0 110.081 179.725 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.8 p -72.73 98.66 2.43 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.504 -0.748 . . . . 0.0 109.622 -179.729 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.11 26.37 34.26 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.222 -0.99 . . . . 0.0 111.553 178.939 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.761 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.3 t -116.64 106.04 19.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 O-C-N 120.47 -1.606 . . . . 0.0 107.413 178.918 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.866 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.4 tp -118.98 104.47 10.53 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.517 -1.365 . . . . 0.0 109.681 -177.896 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.042 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.93 109.57 22.3 Favored 'General case' 0 N--CA 1.485 1.279 0 O-C-N 120.852 -1.155 . . . . 0.0 108.063 178.9 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -105.88 165.06 11.46 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.966 -1.084 . . . . 0.0 110.599 -178.699 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.677 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 50.2 t30 -113.18 130.87 23.19 Favored Pre-proline 0 N--CA 1.499 2.023 0 O-C-N 121.558 -0.714 . . . . 0.0 109.714 -179.3 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.8 Cg_endo -71.85 22.2 0.26 Allowed 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 122.188 1.926 . . . . 0.0 112.288 -179.986 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.677 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -108.65 2.02 21.67 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.39 -1.444 . . . . 0.0 108.929 179.393 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.544 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.05 14.43 2.85 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 179.475 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -78.13 91.28 4.3 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.908 -0.717 . . . . 0.0 110.974 -178.475 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.641 ' C ' HG12 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -114.09 -173.11 2.22 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 178.198 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.533 ' N ' ' OG ' ' A' ' 53' ' ' SER . 12.3 t 179.68 139.35 0.12 Allowed 'General case' 0 C--N 1.306 -1.285 0 O-C-N 120.534 -1.354 . . . . 0.0 111.303 -179.134 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.934 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -152.71 160.59 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 178.123 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.555 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.61 144.53 27.19 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.593 -1.317 . . . . 0.0 110.168 -179.387 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.0 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.7 107.2 1.36 Allowed 'General case' 0 C--N 1.301 -1.537 0 CA-C-O 122.44 1.114 . . . . 0.0 109.338 178.415 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.529 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 13.6 p-10 -58.53 -138.16 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.852 -179.8 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.688 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -54.58 -49.74 69.67 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.348 -0.845 . . . . 0.0 110.202 -178.771 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . 0.404 ' CG ' ' N ' ' A' ' 61' ' ' GLY . 9.9 p-10 -101.41 -38.97 7.78 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 178.454 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.991 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 111.74 65.74 0.51 Allowed Glycine 0 C--N 1.297 -1.587 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.211 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.583 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 21.0 m -105.42 124.03 48.87 Favored 'General case' 0 N--CA 1.483 1.214 0 O-C-N 121.686 -0.89 . . . . 0.0 108.734 179.005 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.934 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.52 109.35 9.2 Favored 'General case' 0 C--N 1.295 -1.788 0 C-N-CA 119.899 -0.72 . . . . 0.0 109.388 -179.395 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -116.5 118.28 32.23 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.178 -0.951 . . . . 0.0 109.273 -179.901 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.544 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -143.68 141.08 30.38 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.405 -0.809 . . . . 0.0 109.679 -179.907 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 21.3 p -99.36 130.75 45.66 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.441 -0.787 . . . . 0.0 109.277 179.9 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.762 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -128.18 165.56 20.2 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.332 -0.855 . . . . 0.0 109.376 -179.503 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.845 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -96.75 123.23 40.38 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.103 -0.998 . . . . 0.0 109.213 179.953 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.535 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -135.96 142.13 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.118 -0.989 . . . . 0.0 109.899 -179.232 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.625 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.2 ptt180 -137.6 -166.12 1.89 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.62 -1.3 . . . . 0.0 110.097 -179.946 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.583 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -73.92 -83.57 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.27 -0.894 . . . . 0.0 108.665 -179.686 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.501 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.54 138.68 58.53 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.343 -1.473 . . . . 0.0 107.185 178.631 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' O ' ' A' ' 71' ' ' ARG . 0.2 OUTLIER -164.04 137.05 5.19 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 117.879 -1.528 . . . . 0.0 110.459 -177.434 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.508 ' OE1' ' N ' ' A' ' 75' ' ' GLY . 0.6 OUTLIER -34.29 121.49 0.48 Allowed 'General case' 0 N--CA 1.491 1.595 0 CA-C-O 121.478 0.656 . . . . 0.0 110.302 -178.584 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.042 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.73 50.34 2.3 Favored Glycine 0 N--CA 1.494 2.544 0 C-N-CA 120.451 -0.881 . . . . 0.0 111.205 -179.223 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 4.1 m-30 -39.81 113.34 0.33 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.032 -1.275 . . . . 0.0 110.025 179.468 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.631 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -84.7 127.1 33.93 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.884 -1.135 . . . . 0.0 109.638 -179.845 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 29.7 t80 -63.54 58.33 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.004 0 O-C-N 120.874 -1.141 . . . . 0.0 110.405 179.611 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.5 t0 -161.54 19.78 0.11 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.008 -1.057 . . . . 0.0 109.807 179.849 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.22 -26.91 5.31 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 110.171 -1.172 . . . . 0.0 110.171 179.937 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 37.0 p -92.95 156.26 17.04 Favored 'General case' 0 N--CA 1.486 1.36 0 O-C-N 121.031 -1.276 . . . . 0.0 110.332 -179.489 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.471 ' O ' ' HD2' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -104.49 133.75 48.83 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.707 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.631 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -80.26 -18.71 48.6 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.823 -1.173 . . . . 0.0 110.41 -178.566 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.93 175.93 20.97 Favored Glycine 0 N--CA 1.485 1.93 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -179.589 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -62.43 109.59 1.41 Allowed 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 179.138 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.577 HG21 ' HB3' ' A' ' 46' ' ' ALA . 31.4 t -82.54 105.39 12.33 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.967 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.656 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -65.76 112.32 3.66 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.402 -0.811 . . . . 0.0 109.904 -179.215 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.557 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.97 -4.79 4.96 Favored 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 118.208 -1.397 . . . . 0.0 109.863 179.398 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 p -85.71 -0.08 54.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.774 -1.204 . . . . 0.0 109.0 179.348 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.656 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -113.03 -49.71 2.91 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.297 -0.877 . . . . 0.0 109.063 179.949 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.8 179.77 4.13 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.581 -0.7 . . . . 0.0 109.505 179.93 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.93 115.7 31.11 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.301 -0.874 . . . . 0.0 109.219 -180.0 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.547 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.92 123.7 40.7 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.87 -1.143 . . . . 0.0 109.358 -179.469 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.52 148.46 25.93 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-O 122.446 1.117 . . . . 0.0 111.457 -179.171 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.548 ' HB ' HG11 ' A' ' 7' ' ' VAL . 61.8 t -102.4 109.66 27.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 N-CA-C 106.282 -1.748 . . . . 0.0 106.282 177.249 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -144.11 -175.41 17.22 Favored Glycine 0 N--CA 1.483 1.831 0 C-N-CA 118.318 -1.896 . . . . 0.0 111.563 -177.395 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.537 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -117.22 -177.82 3.3 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 -178.853 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.508 ' O ' ' N ' ' A' ' 33' ' ' ASP . 1.1 p . . . . . 0 C--N 1.297 -1.687 0 O-C-N 121.235 -0.916 . . . . 0.0 109.143 -179.26 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.712 0 N-CA-C 107.699 -2.16 . . . . 0.0 107.699 . . . . . . . . . 0 0 . 1 . 058 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.59 -178.68 7.44 Favored 'General case' 0 C--N 1.308 -1.198 0 O-C-N 121.415 -1.05 . . . . 0.0 109.866 179.118 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -177.67 -166.52 34.43 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 108.194 -1.962 . . . . 0.0 108.194 -179.477 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.537 ' HB2' HD12 ' A' ' 97' ' ' LEU . 5.4 Cg_exo -48.42 179.26 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.659 0 CA-C-N 118.94 1.37 . . . . 0.0 110.148 179.483 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -91.85 -175.2 4.06 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.055 -1.028 . . . . 0.0 110.516 -178.717 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -122.05 161.7 16.1 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.848 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.62 133.09 49.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.364 -1.08 . . . . 0.0 109.278 -179.242 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -76.04 122.09 23.73 Favored 'General case' 0 C--N 1.289 -2.054 0 O-C-N 121.485 -0.76 . . . . 0.0 109.716 179.703 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.91 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.99 174.0 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.924 . . . . 0.0 109.23 179.837 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.539 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.6 OUTLIER -140.21 158.19 44.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.048 -1.032 . . . . 0.0 109.838 -179.778 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.91 ' CE2' HD12 ' A' ' 110' ' ' ILE . 96.5 m-85 . . . . . 0 N--CA 1.485 1.282 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 -179.808 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.477 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.487 1.405 0 CA-C-O 122.173 0.987 . . . . 0.0 110.757 . . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 1.016 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.1 p -105.41 104.62 14.38 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 122.558 1.17 . . . . 0.0 109.911 179.983 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 1.012 HG22 HG23 ' A' ' 21' ' ' VAL . 14.5 t -118.97 126.34 75.27 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.407 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.535 179.875 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.478 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -170.57 149.37 2.99 Favored Pre-proline 0 N--CA 1.486 1.361 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 -179.642 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.478 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.64 153.23 99.05 Favored 'Cis proline' 0 C--N 1.31 -1.465 0 C-N-CA 123.678 -1.384 . . . . 0.0 109.894 -0.522 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.626 ' HA ' HG22 ' A' ' 110' ' ' ILE . 6.6 m -95.73 -22.6 17.43 Favored 'General case' 0 C--N 1.294 -1.846 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 179.564 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.459 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.9 m -135.59 162.85 31.55 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.491 -0.756 . . . . 0.0 109.496 179.921 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.11 37.6 37.23 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 108.503 -1.839 . . . . 0.0 108.503 -179.556 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.862 ' CA ' HG21 ' A' ' 17' ' ' THR . 27.3 mt -90.59 -45.47 8.89 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-O 123.116 1.436 . . . . 0.0 110.644 -178.373 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.463 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 63.82 147.24 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.325 0 CA-C-N 113.69 -1.596 . . . . 0.0 109.974 -179.699 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.616 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -51.48 109.33 0.34 Allowed 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 121.556 0.694 . . . . 0.0 111.721 -178.652 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.04 12.98 11.42 Favored Glycine 0 N--CA 1.485 1.966 0 C-N-CA 119.478 -1.344 . . . . 0.0 112.873 177.339 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.862 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.7 t -101.42 -174.35 2.58 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 121.057 2.428 . . . . 0.0 109.763 179.479 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.728 HG13 ' O ' ' A' ' 67' ' ' LEU . 14.8 t -131.28 138.48 53.14 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.38 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.813 -178.982 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.581 HG13 ' CG2' ' A' ' 69' ' ' VAL . 35.0 m -117.43 154.4 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.365 -0.835 . . . . 0.0 109.135 179.082 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.551 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -110.12 109.25 19.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.957 . . . . 0.0 109.149 179.881 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 1.012 HG23 HG22 ' A' ' 7' ' ' VAL . 2.4 p -107.39 124.6 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.964 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 1.016 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.08 165.08 13.0 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.845 -1.159 . . . . 0.0 108.858 179.489 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.615 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.39 107.5 0.53 Allowed Glycine 0 C--N 1.296 -1.692 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 179.971 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -116.41 141.09 48.63 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 120.743 -1.445 . . . . 0.0 110.796 -179.072 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 83.09 26.5 44.29 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.033 179.145 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.564 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.9 OUTLIER -90.35 172.29 8.85 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.028 -1.278 . . . . 0.0 108.575 -179.992 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.18 99.97 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.081 -1.012 . . . . 0.0 109.652 -179.685 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.566 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -57.0 76.96 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.118 -179.036 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.41 33.39 0.27 Allowed Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.517 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.553 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 54.1 p -141.14 109.47 5.88 Favored 'General case' 0 C--N 1.307 -1.25 0 O-C-N 121.015 -1.285 . . . . 0.0 111.152 -179.714 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.584 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.94 110.08 0.39 Allowed 'General case' 0 N--CA 1.496 1.858 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.909 178.314 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.463 ' OH ' ' HB2' ' A' ' 27' ' ' GLN . 18.6 m-85 -104.25 154.76 19.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.146 -0.971 . . . . 0.0 108.74 179.396 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.45 ' HA ' ' OG ' ' A' ' 54' ' ' SER . 0.3 OUTLIER -98.96 165.23 11.85 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 178.545 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.62 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.0 p -143.4 120.47 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.092 -1.005 . . . . 0.0 109.493 -177.807 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -168.75 179.91 41.32 Favored Glycine 0 N--CA 1.491 2.312 0 C-N-CA 118.264 -1.922 . . . . 0.0 111.614 -179.806 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.618 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -101.96 109.79 21.6 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.715 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 58.2 m -128.87 152.75 48.17 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.347 -0.846 . . . . 0.0 110.319 -179.828 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.52 136.36 51.63 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.64 -0.662 . . . . 0.0 110.126 179.65 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.901 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.4 114.73 26.81 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 178.369 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -106.6 15.3 7.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 120.964 -1.085 . . . . 0.0 110.762 -178.636 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.785 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.24 -175.63 0.08 Allowed 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.894 -1.129 . . . . 0.0 110.112 179.604 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.799 HG23 ' O ' ' A' ' 42' ' ' THR . 15.3 t -69.63 97.0 0.99 Allowed 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.741 0.781 . . . . 0.0 110.02 -179.404 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.8 28.46 34.95 Favored Glycine 0 N--CA 1.492 2.415 0 C-N-CA 120.225 -0.988 . . . . 0.0 111.38 178.694 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.785 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.09 106.09 19.9 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 O-C-N 120.531 -1.57 . . . . 0.0 107.432 178.836 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.901 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -116.31 106.66 13.9 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.541 -1.349 . . . . 0.0 109.941 -177.552 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 1.1 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -95.93 110.12 22.38 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 120.759 -1.213 . . . . 0.0 108.028 179.186 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 68.2 m -98.91 144.91 27.56 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.259 -0.901 . . . . 0.0 110.846 -178.132 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.513 ' ND2' ' HG2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.48 131.08 48.95 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.415 -0.803 . . . . 0.0 109.076 179.299 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.589 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 6.8 Cg_endo -75.68 31.02 0.38 Allowed 'Trans proline' 0 C--N 1.314 -1.266 0 C-N-CA 122.267 1.978 . . . . 0.0 111.323 179.898 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.465 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . -122.14 -1.69 9.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.42 -1.425 . . . . 0.0 110.299 -179.231 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.796 ' HB3' HD22 ' A' ' 67' ' ' LEU . 20.4 m-20 -137.55 10.31 2.93 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.039 -1.038 . . . . 0.0 109.115 -179.68 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -64.0 84.1 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.292 -179.108 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.62 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -110.82 -169.0 1.38 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.164 -0.96 . . . . 0.0 108.557 179.081 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.455 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.32 135.22 0.08 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.783 -1.198 . . . . 0.0 111.288 -179.348 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.877 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -147.48 159.29 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 177.915 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.584 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.29 142.96 29.29 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.707 -1.245 . . . . 0.0 110.246 -179.52 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.75 107.08 1.34 Allowed 'General case' 0 C--N 1.299 -1.593 0 CA-C-O 122.404 1.097 . . . . 0.0 109.367 178.323 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.5 t0 -60.59 -138.97 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.039 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.022 -179.889 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.566 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.72 -51.11 53.06 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.427 -0.796 . . . . 0.0 110.66 -178.552 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 11.9 t30 -104.19 -34.28 8.43 Favored 'General case' 0 C--N 1.286 -2.185 0 N-CA-C 106.182 -1.785 . . . . 0.0 106.182 178.472 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.976 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.72 67.93 0.61 Allowed Glycine 0 C--N 1.296 -1.647 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 178.182 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.8 m -104.67 124.48 49.44 Favored 'General case' 0 N--CA 1.483 1.194 0 O-C-N 121.612 -0.934 . . . . 0.0 108.739 179.004 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.877 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -132.88 109.21 9.45 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.906 -0.718 . . . . 0.0 109.223 -179.609 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 14.7 m -118.37 118.77 32.66 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.302 -0.874 . . . . 0.0 109.611 -179.621 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.56 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.86 140.29 28.27 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.505 -0.747 . . . . 0.0 109.684 179.805 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . 0.434 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 19.2 p -98.83 136.05 39.4 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.466 -0.771 . . . . 0.0 109.079 179.758 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.84 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -133.35 173.79 11.09 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.339 -0.851 . . . . 0.0 109.687 -178.887 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.533 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -100.18 125.01 46.27 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.933 -1.105 . . . . 0.0 109.01 179.918 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.778 HG23 HD13 ' A' ' 13' ' ' LEU . 15.9 m -132.19 142.13 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 120.764 -1.21 . . . . 0.0 110.06 -178.986 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.616 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.9 ptt180 -147.71 -170.48 3.58 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 120.563 -1.336 . . . . 0.0 110.827 -179.945 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.624 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -67.22 -102.68 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.821 -0.549 . . . . 0.0 109.932 -179.329 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.552 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.08 134.98 56.92 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.359 -1.463 . . . . 0.0 108.152 179.714 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.618 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -153.78 156.92 38.6 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.584 -1.246 . . . . 0.0 110.298 -178.683 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.564 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 1.6 mm-40 -53.15 119.4 4.67 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.277 -0.889 . . . . 0.0 109.368 -178.736 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 1.1 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.39 54.04 3.5 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.311 -178.9 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.589 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.3 m-30 -40.35 115.92 0.61 Allowed 'General case' 0 N--CA 1.504 2.271 0 O-C-N 120.947 -1.325 . . . . 0.0 110.173 179.487 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.72 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -87.46 126.85 35.14 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 120.806 -1.184 . . . . 0.0 109.488 -179.834 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -64.18 58.38 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.972 0 O-C-N 120.837 -1.165 . . . . 0.0 110.132 179.702 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.4 t70 -160.37 19.66 0.15 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.028 -1.045 . . . . 0.0 109.717 179.772 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.75 -27.44 5.36 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 179.856 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 46.4 p -94.9 162.44 13.75 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 120.98 -1.306 . . . . 0.0 110.402 -179.46 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.481 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 2.2 ptm180 -108.14 138.0 45.15 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.921 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.72 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.9 t90 -83.4 -18.6 38.21 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.769 -1.207 . . . . 0.0 110.443 -178.656 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.99 175.05 19.79 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 108.766 -1.734 . . . . 0.0 108.766 -179.632 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.94 106.2 0.98 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.119 -1.224 . . . . 0.0 107.898 179.227 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.64 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.7 t -78.25 104.35 6.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.021 -179.041 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.655 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -62.99 107.9 1.1 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.55 -0.719 . . . . 0.0 110.164 -179.141 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.624 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.4 t -61.42 -4.26 1.23 Allowed 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.255 -1.378 . . . . 0.0 110.38 179.298 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.2 p -90.98 7.09 42.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.562 -1.336 . . . . 0.0 109.407 -179.933 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.655 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -119.35 -47.76 2.44 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.292 -0.88 . . . . 0.0 109.16 179.941 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.6 -178.4 3.64 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.562 -0.711 . . . . 0.0 109.589 179.988 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.81 111.99 24.58 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.381 -0.824 . . . . 0.0 108.856 179.859 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.494 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.5 m -97.22 121.06 38.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.036 -1.04 . . . . 0.0 109.445 -178.966 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.17 147.36 27.12 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.474 1.13 . . . . 0.0 111.646 -179.05 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.584 ' HB ' HG11 ' A' ' 7' ' ' VAL . 92.3 t -102.95 109.65 27.38 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 177.259 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.496 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.84 -169.45 17.37 Favored Glycine 0 N--CA 1.484 1.88 0 C-N-CA 118.073 -2.013 . . . . 0.0 111.628 -177.258 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.485 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -121.24 176.8 5.43 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -178.897 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.485 ' HB2' ' O ' ' A' ' 97' ' ' LEU . 6.9 t . . . . . 0 C--N 1.292 -1.897 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 -179.963 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . 0.431 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . . . . . . 0 N--CA 1.481 1.666 0 N-CA-C 107.992 -2.043 . . . . 0.0 107.992 . . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.54 -177.08 3.82 Favored 'General case' 0 C--N 1.307 -1.262 0 O-C-N 121.574 -0.957 . . . . 0.0 109.984 179.395 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.56 -161.41 21.1 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 108.068 -2.013 . . . . 0.0 108.068 -179.397 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.9 Cg_exo -45.77 172.63 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.632 0 CA-C-N 118.978 1.389 . . . . 0.0 109.933 179.194 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -92.9 -174.49 3.61 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.092 -1.005 . . . . 0.0 110.56 -178.772 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.496 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.48 166.31 14.35 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.876 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.0 131.16 50.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.416 -1.049 . . . . 0.0 109.124 -179.428 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.61 123.77 24.63 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.594 -0.691 . . . . 0.0 109.519 179.713 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.916 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.84 171.74 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.232 -0.917 . . . . 0.0 109.183 179.901 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.459 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -138.15 157.78 45.62 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.279 -0.888 . . . . 0.0 109.92 -179.712 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.916 ' CE1' HD12 ' A' ' 110' ' ' ILE . 38.8 m-85 . . . . . 0 N--CA 1.487 1.376 0 O-C-N 121.273 -0.892 . . . . 0.0 109.543 -179.741 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . . . . . . 0 N--CA 1.485 1.278 0 CA-C-O 122.454 1.121 . . . . 0.0 110.452 . . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.829 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.3 t -115.58 109.24 17.5 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.123 1.44 . . . . 0.0 109.72 -179.935 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.834 HG22 HG23 ' A' ' 21' ' ' VAL . 1.1 t -114.53 135.75 53.35 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.285 -1.325 . . . . 0.0 109.582 179.886 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.69 150.42 2.62 Favored Pre-proline 0 N--CA 1.487 1.407 0 O-C-N 121.151 -0.968 . . . . 0.0 108.95 -179.639 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.0 Cg_endo -78.63 150.2 86.86 Favored 'Cis proline' 0 C--N 1.313 -1.305 0 C-N-CA 123.392 -1.503 . . . . 0.0 109.341 -0.965 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . 0.672 ' HA ' HG22 ' A' ' 110' ' ' ILE . 84.6 p -92.91 -22.65 19.11 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.552 -0.718 . . . . 0.0 109.306 179.894 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . 0.495 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 4.3 m -130.91 159.64 36.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.345 -0.847 . . . . 0.0 109.644 -179.838 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.55 37.34 31.13 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 108.542 -1.823 . . . . 0.0 108.542 -179.676 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.8 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.6 mt -90.92 -44.29 9.46 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 123.14 1.447 . . . . 0.0 110.691 -178.479 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.26 144.41 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.249 0 CA-C-N 113.555 -1.657 . . . . 0.0 109.687 -179.538 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.607 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.4 p-10 -51.54 109.24 0.33 Allowed 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.495 0.664 . . . . 0.0 111.483 -178.612 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.43 10.85 12.56 Favored Glycine 0 N--CA 1.485 1.955 0 C-N-CA 119.391 -1.385 . . . . 0.0 112.83 177.374 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.8 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.9 t -101.97 -171.37 1.96 Allowed 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 121.051 2.425 . . . . 0.0 109.876 179.575 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.753 HG13 ' C ' ' A' ' 67' ' ' LEU . 19.1 t -131.19 142.41 43.53 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.76 -179.058 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.417 HG11 HD11 ' A' ' 13' ' ' LEU . 35.4 m -118.55 155.58 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.277 -0.889 . . . . 0.0 108.764 179.209 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.489 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 6.1 tttt -108.02 109.23 20.64 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.162 -0.961 . . . . 0.0 109.288 -179.984 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.834 HG23 HG22 ' A' ' 7' ' ' VAL . 10.4 p -101.36 138.92 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.71 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.829 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.68 161.24 36.11 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 118.698 -1.201 . . . . 0.0 110.127 179.689 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . 0.604 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.94 140.92 12.0 Favored Glycine 0 C--O 1.209 -1.444 0 N-CA-C 107.928 -2.069 . . . . 0.0 107.928 179.621 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -143.06 125.05 15.21 Favored 'General case' 0 N--CA 1.494 1.756 0 CA-C-N 119.266 1.533 . . . . 0.0 109.395 179.387 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.64 28.22 19.75 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 118.755 -1.688 . . . . 0.0 109.619 -179.728 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.55 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.6 mt -88.74 171.32 10.06 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.866 -1.373 . . . . 0.0 108.089 179.906 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 1.014 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.79 100.25 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.901 -1.124 . . . . 0.0 109.981 -179.424 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.58 77.21 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.946 -179.347 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.01 33.88 0.24 Allowed Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.717 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.557 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 36.3 p -141.26 107.47 5.23 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.082 -1.246 . . . . 0.0 111.311 -179.422 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.49 109.78 0.31 Allowed 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 177.93 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . 0.58 ' CG ' ' O ' ' A' ' 98' ' ' SER . 4.4 m-30 -101.24 156.1 17.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.168 -0.957 . . . . 0.0 109.009 179.83 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.499 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -99.98 163.71 12.32 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 178.503 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.752 HG22 HG11 ' A' ' 21' ' ' VAL . 2.4 p -147.77 117.85 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.891 -1.131 . . . . 0.0 110.05 -177.928 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.497 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -171.28 -175.91 40.04 Favored Glycine 0 N--CA 1.494 2.501 0 C-N-CA 118.346 -1.883 . . . . 0.0 111.724 -179.862 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.573 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -100.42 108.87 20.97 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.748 0.785 . . . . 0.0 108.946 -179.818 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.489 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.39 148.27 52.19 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.269 -0.894 . . . . 0.0 109.676 179.431 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.556 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.19 137.55 54.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.265 -0.897 . . . . 0.0 110.932 -178.839 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 39' ' ' TRP . . . . . 0.869 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.64 114.68 26.45 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.114 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.0 m -105.03 14.4 7.24 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 120.95 -1.094 . . . . 0.0 110.573 -178.715 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.76 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.03 -175.36 0.07 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.987 -1.071 . . . . 0.0 110.091 179.729 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.788 HG23 ' O ' ' A' ' 42' ' ' THR . 15.0 t -71.69 99.05 2.04 Favored 'General case' 0 N--CA 1.486 1.347 0 CA-C-O 121.829 0.823 . . . . 0.0 109.812 -179.641 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.77 26.57 37.71 Favored Glycine 0 N--CA 1.494 2.549 0 C-N-CA 120.179 -1.01 . . . . 0.0 111.46 178.957 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.76 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.4 t -116.16 106.25 19.98 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 O-C-N 120.576 -1.544 . . . . 0.0 107.356 178.891 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . 0.869 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.2 tp -117.93 104.34 10.82 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.471 -1.393 . . . . 0.0 109.73 -177.694 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.976 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.73 109.66 22.37 Favored 'General case' 0 N--CA 1.485 1.311 0 O-C-N 120.776 -1.203 . . . . 0.0 108.07 178.88 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -107.26 163.35 13.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.016 -1.053 . . . . 0.0 110.467 -178.705 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.528 HD22 ' HB3' ' A' ' 50' ' ' ALA . 17.0 t30 -111.29 136.77 20.91 Favored Pre-proline 0 N--CA 1.502 2.136 0 O-C-N 121.414 -0.803 . . . . 0.0 109.75 -179.463 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.7 Cg_endo -73.57 25.67 0.32 Allowed 'Trans proline' 0 C--N 1.319 -1.007 0 C-N-CA 122.463 2.109 . . . . 0.0 112.335 -179.63 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . 0.631 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -112.66 3.07 16.41 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.272 -1.518 . . . . 0.0 109.326 179.588 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 51' ' ' ASP . . . . . 0.534 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.45 18.97 2.22 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 179.592 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -79.94 92.06 5.5 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.867 -0.733 . . . . 0.0 110.866 -178.867 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 53' ' ' SER . . . . . 0.618 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -114.47 -168.85 1.43 Allowed 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 178.367 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.9 134.88 0.09 Allowed 'General case' 0 C--N 1.304 -1.372 0 O-C-N 120.597 -1.315 . . . . 0.0 111.214 -179.402 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.763 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 2.0 p -148.98 157.2 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.233 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.26 142.62 29.69 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.709 -1.244 . . . . 0.0 109.874 -179.85 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 1.014 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.36 108.15 1.86 Allowed 'General case' 0 C--N 1.299 -1.626 0 CA-C-O 122.337 1.065 . . . . 0.0 109.649 178.706 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.561 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.1 t0 -63.84 -138.8 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.003 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.816 179.888 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.81 -52.04 45.07 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.361 -0.837 . . . . 0.0 110.697 -178.677 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -101.74 -33.6 9.78 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 178.517 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 104.51 65.92 0.69 Allowed Glycine 0 C--N 1.298 -1.532 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 178.221 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 55.9 p -98.53 132.41 43.98 Favored 'General case' 0 N--CA 1.482 1.153 0 O-C-N 121.489 -1.007 . . . . 0.0 109.177 179.074 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.763 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.63 108.57 6.33 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 119.255 -0.978 . . . . 0.0 109.567 -179.658 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 6.0 m -127.11 120.32 28.6 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.272 -0.892 . . . . 0.0 109.681 -179.878 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.535 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.09 142.72 28.81 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.55 -0.719 . . . . 0.0 109.277 179.794 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.9 p -98.81 131.69 44.74 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.287 -0.883 . . . . 0.0 109.212 179.985 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.753 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -135.6 169.4 17.59 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.288 -0.882 . . . . 0.0 109.569 -179.349 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . 0.631 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 11.3 t -95.29 137.74 33.93 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.091 -1.006 . . . . 0.0 110.559 -179.425 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.573 HG12 ' HB3' ' A' ' 36' ' ' GLN . 18.3 m -148.24 143.55 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.381 -0.824 . . . . 0.0 109.536 -179.891 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.607 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.0 OUTLIER -149.95 -174.65 4.77 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.497 -1.377 . . . . 0.0 110.807 -179.863 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 71' ' ' ARG . . . . . 0.62 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.86 -102.06 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.414 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.637 -179.458 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.5 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -56.49 141.89 40.97 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.831 -1.168 . . . . 0.0 108.577 179.814 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -163.34 137.26 5.91 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 118.836 -1.146 . . . . 0.0 109.633 -178.402 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.52 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 17.4 mm-40 -33.56 122.1 0.42 Allowed 'General case' 0 N--CA 1.49 1.571 0 CA-C-O 121.559 0.695 . . . . 0.0 110.78 -178.12 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.976 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.32 46.91 2.83 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.321 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.1 m-85 -39.64 112.02 0.23 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.073 -1.251 . . . . 0.0 109.856 179.568 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.696 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -85.46 126.44 33.82 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.895 -1.128 . . . . 0.0 109.37 -179.927 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 37.5 t80 -63.89 58.39 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.933 -1.104 . . . . 0.0 110.168 179.833 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 4.9 t70 -160.38 19.3 0.14 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.037 -1.039 . . . . 0.0 109.709 179.913 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.51 -26.5 5.74 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 179.808 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 60.5 p -94.06 158.63 15.53 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.033 -1.275 . . . . 0.0 110.418 -179.346 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.477 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -105.08 133.43 49.87 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.698 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 83' ' ' TRP . . . . . 0.696 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.9 t90 -81.43 -18.9 43.76 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.883 -1.135 . . . . 0.0 110.37 -178.573 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.34 174.83 19.57 Favored Glycine 0 N--CA 1.485 1.962 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.653 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.1 105.96 0.97 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.112 -1.228 . . . . 0.0 107.72 179.085 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.644 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.6 t -76.95 105.99 6.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.306 -0.871 . . . . 0.0 109.27 -178.824 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . 0.539 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.4 111.14 3.39 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.359 -0.838 . . . . 0.0 109.821 -179.524 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 88' ' ' CYS . . . . . 0.62 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -62.74 -6.09 3.34 Favored 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 118.225 -1.39 . . . . 0.0 109.875 179.42 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -86.13 -1.26 57.24 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.716 -1.24 . . . . 0.0 109.163 179.63 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.539 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.47 -49.6 2.99 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.338 -0.851 . . . . 0.0 109.005 179.905 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.27 179.15 4.34 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.415 -0.803 . . . . 0.0 109.438 179.924 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.54 116.22 32.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.322 -0.861 . . . . 0.0 108.952 179.928 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 93' ' ' CYS . . . . . 0.564 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.72 124.7 40.78 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.815 -1.178 . . . . 0.0 109.535 -179.478 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 94' ' ' GLN . . . . . 0.594 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -105.15 147.87 27.49 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 122.515 1.15 . . . . 0.0 111.451 -179.152 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.595 ' CG1' HG11 ' A' ' 7' ' ' VAL . 57.6 t -104.49 110.55 30.93 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.04 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 177.43 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.408 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.47 -171.29 17.18 Favored Glycine 0 N--CA 1.488 2.157 0 C-N-CA 118.123 -1.989 . . . . 0.0 111.89 -177.562 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.499 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.77 -179.62 3.74 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.023 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.58 ' O ' ' CG ' ' A' ' 32' ' ' TYR . 1.5 p . . . . . 0 C--N 1.296 -1.729 0 O-C-N 121.367 -0.833 . . . . 0.0 109.715 -179.524 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.783 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 . . . . . . . . . 0 0 . 1 . 060 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -153.88 -179.62 8.01 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.466 -1.02 . . . . 0.0 109.345 178.8 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -172.45 -166.28 30.79 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 108.631 -1.788 . . . . 0.0 108.631 -179.44 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . 0.517 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.0 Cg_exo -49.93 -175.64 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.668 0 CA-C-N 118.759 1.279 . . . . 0.0 110.32 179.603 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 -94.43 -179.27 4.85 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.059 -1.026 . . . . 0.0 110.506 -178.843 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.408 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.95 162.64 14.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.992 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.17 128.42 53.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.334 -1.098 . . . . 0.0 109.165 -179.389 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 109' ' ' ALA . . . . . 0.594 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.71 124.02 26.56 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.59 -0.694 . . . . 0.0 109.552 179.669 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 110' ' ' ILE . . . . . 0.758 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.75 167.79 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.21 -0.931 . . . . 0.0 109.234 -179.913 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.495 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 15.2 m -137.0 156.33 48.58 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.276 -0.89 . . . . 0.0 109.481 -179.931 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild core ' A' A ' 112' ' ' PHE . . . . . 0.758 ' CE1' HD12 ' A' ' 110' ' ' ILE . 17.5 m-85 . . . . . 0 N--CA 1.486 1.347 0 O-C-N 121.204 -0.935 . . . . 0.0 109.523 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.543 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -87.18 160.16 49.43 Favored Pre-proline 0 N--CA 1.49 1.532 0 O-C-N 121.255 -0.903 . . . . 0.0 109.417 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.567 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.2 Cg_exo -60.01 157.88 32.16 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.335 2.024 . . . . 0.0 110.585 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.542 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.62 -169.77 0.15 Allowed 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.204 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.542 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.61 130.39 2.4 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 120.859 -1.15 . . . . 0.0 110.683 -179.165 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.948 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -111.21 108.54 18.23 Favored 'General case' 0 C--N 1.296 -1.74 0 CA-C-O 123.11 1.433 . . . . 0.0 109.167 179.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.842 HG22 HG23 ' A' ' 21' ' ' VAL . 2.7 t -115.39 140.33 37.4 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.681 0 CA-C-N 114.255 -1.339 . . . . 0.0 110.08 -179.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.495 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -175.72 149.78 1.09 Allowed Pre-proline 0 N--CA 1.487 1.422 0 O-C-N 121.305 -0.872 . . . . 0.0 108.728 -179.656 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.495 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -75.66 152.33 97.04 Favored 'Cis proline' 0 C--N 1.311 -1.408 0 C-N-CA 123.422 -1.491 . . . . 0.0 109.371 -0.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.647 ' HA ' HG22 ' A' ' 110' ' ' ILE . 10.9 m -90.69 -24.64 20.39 Favored 'General case' 0 C--N 1.293 -1.887 0 O-C-N 121.605 -0.684 . . . . 0.0 109.191 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.516 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.4 m -137.16 165.32 26.36 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.44 -0.788 . . . . 0.0 109.59 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.5 38.62 32.46 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 108.471 -1.852 . . . . 0.0 108.471 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.801 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.6 mt -92.79 -43.95 8.76 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 123.152 1.453 . . . . 0.0 110.736 -178.2 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.467 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.05 145.47 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.274 0 CA-C-N 113.597 -1.638 . . . . 0.0 110.156 -179.912 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.6 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 14.2 p-10 -51.16 106.84 0.15 Allowed 'General case' 0 C--N 1.301 -1.517 0 CA-C-O 121.461 0.648 . . . . 0.0 111.526 -178.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.79 14.76 9.15 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.43 -1.367 . . . . 0.0 112.969 177.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.801 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.4 t -104.24 -171.94 2.02 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 121.075 2.437 . . . . 0.0 109.544 179.152 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.727 HG13 ' C ' ' A' ' 67' ' ' LEU . 16.2 t -128.59 136.05 60.89 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.392 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.116 -179.065 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.587 HG13 ' CG2' ' A' ' 69' ' ' VAL . 20.6 m -111.52 155.55 12.86 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 11.1 tttt -112.31 109.31 18.88 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.192 -0.942 . . . . 0.0 108.954 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.842 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.63 140.51 21.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.948 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.54 160.22 39.15 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.842 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.18 144.56 15.82 Favored Glycine 0 C--N 1.294 -1.783 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.567 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.51 125.11 12.47 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 120.891 -1.358 . . . . 0.0 108.844 179.099 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.529 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.89 26.64 26.15 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.28 -1.438 . . . . 0.0 109.864 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.549 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -87.79 174.89 8.11 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 120.885 -1.362 . . . . 0.0 108.596 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.79 99.58 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.4 0 O-C-N 120.987 -1.071 . . . . 0.0 109.766 -179.696 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.2 78.01 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.124 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.98 34.23 0.3 Allowed Glycine 0 N--CA 1.487 2.098 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.5 p -141.29 107.5 5.23 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 121.111 -1.229 . . . . 0.0 111.249 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.72 109.96 0.33 Allowed 'General case' 0 N--CA 1.498 1.938 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.638 178.076 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.575 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 4.6 m-30 -106.25 154.04 21.3 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.126 -0.984 . . . . 0.0 108.837 179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.484 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.86 162.75 12.93 Favored 'General case' 0 N--CA 1.488 1.444 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.863 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.722 HG22 HG11 ' A' ' 21' ' ' VAL . 3.5 p -142.63 116.5 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.048 -1.032 . . . . 0.0 109.628 -178.161 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.69 -175.79 37.19 Favored Glycine 0 N--CA 1.494 2.501 0 C-N-CA 118.353 -1.879 . . . . 0.0 111.67 -179.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.615 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -100.73 109.65 21.69 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-O 121.899 0.857 . . . . 0.0 109.038 -179.597 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.486 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -129.94 149.88 51.47 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 121.275 -0.891 . . . . 0.0 109.634 179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.517 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -125.33 139.21 53.89 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.166 -0.959 . . . . 0.0 110.796 -178.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.89 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 114.95 26.79 Favored 'General case' 0 N--CA 1.493 1.718 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.038 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.0 m -105.13 15.03 6.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 120.906 -1.121 . . . . 0.0 110.584 -178.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.76 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.78 -175.06 0.08 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.904 -1.123 . . . . 0.0 110.0 179.79 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.03 97.59 1.92 Allowed 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.465 -0.772 . . . . 0.0 109.687 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.65 27.89 33.97 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 120.258 -0.972 . . . . 0.0 111.392 178.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.76 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.38 106.41 20.26 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 O-C-N 120.576 -1.543 . . . . 0.0 107.313 178.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.89 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -115.86 104.68 11.87 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 120.486 -1.384 . . . . 0.0 109.896 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.959 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.18 109.47 22.22 Favored 'General case' 0 N--CA 1.484 1.238 0 O-C-N 120.81 -1.182 . . . . 0.0 107.917 178.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.63 166.57 10.58 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.914 -1.116 . . . . 0.0 110.484 -178.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.747 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 47.6 t30 -112.06 129.77 23.93 Favored Pre-proline 0 N--CA 1.501 2.1 0 O-C-N 121.488 -0.758 . . . . 0.0 109.583 -179.418 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.612 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.56 21.05 0.25 Allowed 'Trans proline' 0 C--N 1.319 -1.024 0 C-N-CA 122.132 1.888 . . . . 0.0 112.268 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.747 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -109.55 3.49 21.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.334 -1.479 . . . . 0.0 108.977 179.336 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.539 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.34 17.23 2.76 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 179.382 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -80.6 87.77 5.74 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.987 -0.685 . . . . 0.0 111.143 -178.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -104.2 -165.82 1.19 Allowed 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 178.159 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.446 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.89 137.13 0.09 Allowed 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.532 -1.355 . . . . 0.0 111.382 -179.306 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.931 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -155.5 157.09 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 107.494 -1.299 . . . . 0.0 107.494 178.21 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.63 142.34 30.33 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.746 -1.222 . . . . 0.0 109.911 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.34 106.83 0.96 Allowed 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 122.476 1.131 . . . . 0.0 109.406 178.481 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.544 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.6 p-10 -60.4 -139.56 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.893 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.16 -50.9 58.04 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.4 -0.813 . . . . 0.0 110.666 -178.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -103.55 -33.15 9.12 Favored 'General case' 0 C--N 1.287 -2.137 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 178.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.016 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.66 65.34 0.6 Allowed Glycine 0 C--N 1.298 -1.556 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.574 178.084 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.6 m -102.05 128.37 48.53 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 121.481 -1.011 . . . . 0.0 108.635 178.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.931 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.7 108.84 6.79 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.798 -179.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 3.8 m -121.54 119.02 30.73 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.18 -0.95 . . . . 0.0 109.428 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.595 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.87 145.13 31.46 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.484 -0.76 . . . . 0.0 109.446 179.875 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 18.4 p -98.99 146.77 25.69 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.413 -0.804 . . . . 0.0 109.632 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.727 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -146.65 166.74 25.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.451 -0.78 . . . . 0.0 109.285 -179.431 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.664 HG22 HG22 ' A' ' 18' ' ' VAL . 4.1 p -95.24 124.87 39.5 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.075 -1.015 . . . . 0.0 109.637 -179.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.587 ' CG2' HG13 ' A' ' 19' ' ' VAL . 17.3 m -137.7 142.64 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.948 -1.095 . . . . 0.0 109.834 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.6 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.4 ptt180 -141.37 -165.49 1.98 Allowed 'General case' 0 N--CA 1.487 1.411 0 O-C-N 120.617 -1.302 . . . . 0.0 110.312 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.593 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 2.7 mtt180 -71.66 -78.02 0.09 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.34 -0.85 . . . . 0.0 109.096 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -69.05 137.35 53.51 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 120.21 -1.556 . . . . 0.0 107.437 179.082 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.564 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -160.78 132.8 5.93 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 117.996 -1.482 . . . . 0.0 110.167 -178.098 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.494 ' C ' ' O ' ' A' ' 73' ' ' PHE . 9.2 mp0 -30.1 121.92 0.18 Allowed 'General case' 0 N--CA 1.492 1.675 0 CA-C-O 121.627 0.727 . . . . 0.0 110.88 -178.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.959 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.02 45.09 3.16 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.612 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.4 m-30 -38.99 113.55 0.32 Allowed 'General case' 0 N--CA 1.508 2.461 0 O-C-N 121.123 -1.221 . . . . 0.0 110.268 179.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.716 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.57 127.45 35.26 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.035 -1.041 . . . . 0.0 109.487 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.587 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.0 t80 -64.48 58.1 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.861 -1.15 . . . . 0.0 110.118 179.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.526 ' N ' ' O ' ' A' ' 77' ' ' LEU . 27.6 t0 -160.02 18.95 0.16 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.041 -1.037 . . . . 0.0 109.814 179.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.39 -26.42 5.71 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -93.56 158.6 15.62 Favored 'General case' 0 N--CA 1.485 1.307 0 O-C-N 120.959 -1.318 . . . . 0.0 110.435 -179.438 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.482 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -105.36 133.63 49.81 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 179.711 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.716 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.5 t90 -80.98 -19.52 43.86 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.797 -1.189 . . . . 0.0 110.281 -178.717 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.7 174.08 18.68 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 -179.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.85 110.65 1.83 Allowed 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 179.124 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.666 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.2 t -82.06 103.56 9.41 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.389 -0.819 . . . . 0.0 108.846 -178.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.647 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -67.12 111.28 3.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.439 -0.788 . . . . 0.0 109.816 -179.174 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.553 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -63.0 -6.07 3.56 Favored 'General case' 0 N--CA 1.5 2.033 0 C-N-CA 118.361 -1.336 . . . . 0.0 109.824 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 41.4 p -84.64 -0.34 53.04 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.648 -1.282 . . . . 0.0 108.897 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.647 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -113.9 -49.7 2.86 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.338 -0.851 . . . . 0.0 109.025 -179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.91 -178.64 3.71 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.484 -0.76 . . . . 0.0 109.62 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.36 115.44 30.26 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.469 -0.769 . . . . 0.0 108.981 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.557 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.05 123.03 40.68 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.861 -1.15 . . . . 0.0 109.774 -179.249 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.624 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.57 146.87 27.91 Favored 'General case' 0 C--N 1.304 -1.4 0 CA-C-O 122.378 1.085 . . . . 0.0 111.139 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.475 ' HB ' HG11 ' A' ' 7' ' ' VAL . 56.2 t -102.07 110.03 27.75 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.013 0 N-CA-C 106.665 -1.606 . . . . 0.0 106.665 177.497 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.465 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.79 -170.31 16.42 Favored Glycine 0 N--CA 1.487 2.077 0 C-N-CA 118.246 -1.931 . . . . 0.0 111.631 -177.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.484 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -122.66 176.99 5.64 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.871 -0.782 . . . . 0.0 109.162 -178.854 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.553 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.5 m -176.12 176.43 1.73 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.687 -0.633 . . . . 0.0 109.386 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.575 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -123.35 -157.21 0.74 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.963 -1.086 . . . . 0.0 109.045 -179.949 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.446 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.35 35.94 4.46 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.726 -1.234 . . . . 0.0 109.249 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.07 -32.67 6.71 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.402 -0.811 . . . . 0.0 109.817 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.804 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.02 -36.03 0.27 Allowed Glycine 0 N--CA 1.482 1.722 0 N-CA-C 107.814 -2.114 . . . . 0.0 107.814 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.404 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.53 -177.17 3.86 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 122.069 0.938 . . . . 0.0 109.737 179.385 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.62 -161.44 17.14 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 108.297 -1.921 . . . . 0.0 108.297 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.497 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.4 Cg_exo -46.88 177.17 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.684 0 CA-C-N 118.794 1.297 . . . . 0.0 110.161 179.28 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -94.15 -168.92 1.95 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.054 -1.029 . . . . 0.0 110.284 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.465 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.24 162.8 18.25 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.69 129.54 48.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.457 -1.025 . . . . 0.0 109.205 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.624 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.78 122.39 21.45 Favored 'General case' 0 C--N 1.29 -2.006 0 O-C-N 121.74 -0.6 . . . . 0.0 109.86 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.821 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.92 170.45 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.268 -0.895 . . . . 0.0 109.191 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.516 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.23 155.07 51.27 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.211 -0.931 . . . . 0.0 109.636 -179.908 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.821 ' CE2' HD12 ' A' ' 110' ' ' ILE . 66.1 m-85 -131.31 108.2 9.49 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.224 -0.923 . . . . 0.0 109.457 -179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.415 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 13.7 p30 . . . . . 0 N--CA 1.489 1.515 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.577 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.804 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.702 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -112.05 164.83 14.24 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.195 -0.94 . . . . 0.0 109.465 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.702 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 4.9 Cg_exo -60.08 158.11 31.49 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.276 1.984 . . . . 0.0 110.534 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.532 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.46 -169.78 0.15 Allowed 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.256 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.532 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.97 130.63 2.29 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.769 -1.207 . . . . 0.0 110.758 -179.157 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.955 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -110.6 108.57 18.54 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 123.05 1.405 . . . . 0.0 109.073 179.275 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.826 HG22 HG23 ' A' ' 21' ' ' VAL . 2.2 t -117.02 140.42 39.76 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.713 0 CA-C-N 114.295 -1.32 . . . . 0.0 110.049 -179.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.446 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -177.7 149.84 0.76 Allowed Pre-proline 0 N--CA 1.486 1.34 0 O-C-N 121.285 -0.884 . . . . 0.0 108.78 -179.757 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.446 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.86 150.39 86.5 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 123.551 -1.437 . . . . 0.0 109.239 -0.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 14.2 p -89.65 -25.74 21.1 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 179.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.473 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 8.1 m -132.75 163.22 29.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.427 -0.796 . . . . 0.0 109.527 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.16 37.72 31.6 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 -179.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.815 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.5 mt -92.95 -44.01 8.65 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.193 1.473 . . . . 0.0 110.695 -178.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.93 144.99 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.299 0 CA-C-N 113.515 -1.675 . . . . 0.0 109.919 -179.684 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.602 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.7 p-10 -51.17 108.77 0.27 Allowed 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.433 0.635 . . . . 0.0 111.533 -178.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.84 13.38 11.28 Favored Glycine 0 N--CA 1.483 1.796 0 C-N-CA 119.45 -1.357 . . . . 0.0 112.875 177.335 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.815 HG21 ' CA ' ' A' ' 13' ' ' LEU . 11.1 t -103.12 -173.1 2.23 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 120.988 2.394 . . . . 0.0 109.571 179.333 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.751 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.7 t -127.2 135.11 64.42 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.968 -178.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.532 ' CG1' HD13 ' A' ' 13' ' ' LEU . 31.3 m -110.38 155.28 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 13.3 tttt -112.41 109.38 18.96 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.169 -0.957 . . . . 0.0 109.045 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.826 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -104.92 141.44 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 179.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.955 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.8 160.32 39.57 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.863 179.707 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.592 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.23 144.87 16.14 Favored Glycine 0 C--N 1.294 -1.775 0 N-CA-C 108.211 -1.956 . . . . 0.0 108.211 179.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.56 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.55 125.14 12.47 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.025 -1.28 . . . . 0.0 108.793 179.08 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.528 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.91 26.95 25.23 Favored Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.28 -1.438 . . . . 0.0 109.759 -179.699 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.551 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.2 mt -86.74 175.31 8.31 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.862 -1.375 . . . . 0.0 108.529 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.09 98.04 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.914 -1.116 . . . . 0.0 109.598 -179.637 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.632 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.82 77.31 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.735 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.376 -179.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.43 34.29 0.32 Allowed Glycine 0 N--CA 1.487 2.078 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 179.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.558 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.2 p -146.08 112.22 5.75 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.916 -1.344 . . . . 0.0 111.202 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.85 126.85 6.03 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.823 178.223 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.493 ' CD2' ' O ' ' A' ' 30' ' ' THR . 13.8 m-85 -119.35 152.13 37.3 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -100.49 162.67 12.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.635 -1.291 . . . . 0.0 107.727 178.667 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.947 HG11 HG21 ' A' ' 65' ' ' THR . 5.7 p -147.1 117.02 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.002 -1.061 . . . . 0.0 110.031 -177.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -170.61 -176.46 40.0 Favored Glycine 0 N--CA 1.493 2.439 0 C-N-CA 118.323 -1.894 . . . . 0.0 111.714 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.586 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -99.79 108.92 21.34 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -179.801 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -131.01 148.91 52.81 Favored 'General case' 0 C--N 1.297 -1.688 0 O-C-N 121.22 -0.925 . . . . 0.0 109.777 179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.415 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.79 139.38 54.04 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.31 -0.869 . . . . 0.0 110.768 -179.014 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.889 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.28 114.7 26.51 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 178.133 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.2 m -104.37 15.06 6.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.051 -1.03 . . . . 0.0 110.523 -178.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.767 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 173.98 -175.89 0.07 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.979 -1.075 . . . . 0.0 110.076 179.706 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 42' ' ' THR . 14.9 t -71.95 98.87 2.12 Favored 'General case' 0 N--CA 1.487 1.38 0 CA-C-O 121.77 0.795 . . . . 0.0 109.648 -179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.69 27.34 35.46 Favored Glycine 0 N--CA 1.493 2.475 0 C-N-CA 120.139 -1.029 . . . . 0.0 111.422 178.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.767 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.95 106.39 20.11 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 O-C-N 120.6 -1.53 . . . . 0.0 107.197 178.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.889 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -117.64 104.57 11.15 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.426 -1.421 . . . . 0.0 109.851 -177.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.988 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.2 109.58 22.31 Favored 'General case' 0 N--CA 1.484 1.25 0 O-C-N 120.812 -1.18 . . . . 0.0 108.165 178.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -106.38 166.43 10.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.966 -1.084 . . . . 0.0 110.122 -178.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.697 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 14.3 t-20 -108.56 137.98 20.13 Favored Pre-proline 0 N--CA 1.501 2.09 0 O-C-N 121.326 -0.859 . . . . 0.0 110.04 -179.267 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.7 Cg_endo -75.38 24.29 0.41 Allowed 'Trans proline' 0 C--N 1.317 -1.08 0 C-N-CA 122.36 2.04 . . . . 0.0 111.884 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.697 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -118.01 3.66 12.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.355 -1.466 . . . . 0.0 109.298 179.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.567 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.05 17.57 2.63 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 179.328 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -82.4 90.85 6.74 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.789 -0.765 . . . . 0.0 110.834 -178.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.616 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -111.65 -169.24 1.43 Allowed 'General case' 0 N--CA 1.488 1.449 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 178.319 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.1 135.34 0.09 Allowed 'General case' 0 N--CA 1.486 1.353 0 O-C-N 120.584 -1.322 . . . . 0.0 111.325 -179.301 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.855 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.1 p -150.62 158.49 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 178.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.77 145.38 26.43 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.804 -1.185 . . . . 0.0 109.848 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.77 108.05 1.99 Allowed 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 122.359 1.076 . . . . 0.0 109.61 178.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.3 p-10 -60.73 -139.46 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.802 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.632 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.22 -50.13 62.59 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.43 -0.793 . . . . 0.0 110.432 -178.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 37.9 t30 -103.13 -35.18 8.59 Favored 'General case' 0 C--N 1.287 -2.141 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.05 65.91 0.6 Allowed Glycine 0 C--N 1.296 -1.64 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 178.3 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.592 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.5 m -102.04 128.86 48.3 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 121.475 -1.015 . . . . 0.0 108.899 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.855 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.07 108.76 6.62 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 119.199 -1.0 . . . . 0.0 109.933 -179.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -121.15 119.16 31.58 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.177 -0.952 . . . . 0.0 109.537 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.947 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -143.08 143.27 31.79 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.496 -0.753 . . . . 0.0 109.602 179.827 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.8 p -99.74 145.36 27.75 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.45 -0.781 . . . . 0.0 109.284 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.818 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -146.71 170.33 17.19 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.372 -0.83 . . . . 0.0 109.421 -179.286 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.662 HG22 HG22 ' A' ' 18' ' ' VAL . 1.9 p -99.16 125.71 44.78 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.023 -1.048 . . . . 0.0 109.532 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.562 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -137.47 143.82 33.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 120.917 -1.114 . . . . 0.0 109.768 -179.373 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.602 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.1 ptt180 -148.64 -172.04 4.0 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.434 -1.416 . . . . 0.0 110.944 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.613 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -55.8 -101.66 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 -179.358 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.508 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.58 140.52 46.35 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 120.778 -1.201 . . . . 0.0 108.215 179.587 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -162.38 136.23 6.36 Favored 'General case' 0 C--N 1.293 -1.874 0 C-N-CA 118.772 -1.171 . . . . 0.0 109.926 -178.184 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.545 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.5 mm-40 -32.09 121.02 0.3 Allowed 'General case' 0 N--CA 1.493 1.72 0 CA-C-O 121.479 0.657 . . . . 0.0 110.736 -178.399 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.988 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.15 47.86 2.92 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.169 -179.285 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.37 113.03 0.29 Allowed 'General case' 0 N--CA 1.506 2.365 0 O-C-N 121.076 -1.249 . . . . 0.0 110.118 179.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.741 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -85.14 127.02 34.09 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.959 -1.088 . . . . 0.0 109.503 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 43.1 t80 -63.57 58.36 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.905 -1.122 . . . . 0.0 110.297 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 16.7 t0 -161.53 19.74 0.11 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.995 -1.066 . . . . 0.0 109.791 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.18 -26.72 5.4 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.129 -1.189 . . . . 0.0 110.129 179.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -92.83 159.87 15.19 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.028 -1.278 . . . . 0.0 110.32 -179.368 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.485 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.49 134.58 49.41 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.888 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.741 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.9 t90 -82.86 -19.27 37.79 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.773 -1.204 . . . . 0.0 110.393 -178.637 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.43 173.91 18.76 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -64.11 107.29 1.24 Allowed 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.634 HG21 ' HB3' ' A' ' 46' ' ' ALA . 47.5 t -78.28 105.3 7.21 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 O-C-N 121.354 -0.841 . . . . 0.0 109.304 -178.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.549 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -65.15 110.82 2.67 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.487 -0.758 . . . . 0.0 109.777 -179.657 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.613 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.2 t -62.52 -6.36 3.35 Favored 'General case' 0 N--CA 1.499 2.001 0 C-N-CA 118.164 -1.415 . . . . 0.0 109.788 179.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.6 p -85.83 -3.17 58.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.726 -1.234 . . . . 0.0 109.272 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.549 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -109.62 -50.2 3.01 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.295 -0.878 . . . . 0.0 108.976 179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.91 -179.46 3.95 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.491 -0.755 . . . . 0.0 109.374 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.2 115.98 31.17 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.363 -0.836 . . . . 0.0 108.83 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.505 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.6 123.52 40.3 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.815 -1.178 . . . . 0.0 109.639 -179.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.599 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.85 146.08 29.5 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 122.382 1.087 . . . . 0.0 111.042 -179.483 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 78.4 t -102.49 109.94 27.85 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.081 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 177.651 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.486 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.97 -171.52 17.79 Favored Glycine 0 N--CA 1.486 2.029 0 C-N-CA 118.171 -1.966 . . . . 0.0 111.812 -177.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.499 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -114.55 -178.39 3.36 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -179.048 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.587 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.9 OUTLIER -173.36 168.1 4.65 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.343 -0.848 . . . . 0.0 109.605 -179.26 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.424 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -117.36 -159.04 0.72 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.043 -1.036 . . . . 0.0 108.916 179.685 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.424 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.05 36.05 4.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.638 -1.289 . . . . 0.0 109.287 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -116.06 -32.87 5.24 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.34 -0.85 . . . . 0.0 110.195 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.965 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 162.88 -34.42 0.32 Allowed Glycine 0 N--CA 1.482 1.718 0 N-CA-C 107.628 -2.189 . . . . 0.0 107.628 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.29 -178.48 7.31 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 121.627 -0.925 . . . . 0.0 109.682 179.238 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.84 -161.73 16.7 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 108.395 -1.882 . . . . 0.0 108.395 -179.412 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.49 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.5 Cg_exo -46.93 178.3 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.634 0 CA-C-N 118.822 1.311 . . . . 0.0 110.375 179.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -92.69 -179.27 5.11 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.204 -0.935 . . . . 0.0 110.455 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.486 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.42 165.5 12.52 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.86 128.2 55.94 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.442 -1.034 . . . . 0.0 109.159 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.599 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.64 123.16 22.68 Favored 'General case' 0 C--N 1.289 -2.043 0 O-C-N 121.632 -0.667 . . . . 0.0 109.383 179.592 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.858 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.69 170.85 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.214 -0.929 . . . . 0.0 109.197 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.473 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.71 153.79 49.73 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.214 -0.929 . . . . 0.0 109.609 -179.847 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.858 ' CE2' HD12 ' A' ' 110' ' ' ILE . 75.9 m-85 -130.9 100.9 5.41 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.162 -0.961 . . . . 0.0 109.494 -179.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.3 p30 . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.466 -179.983 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.965 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.402 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -121.63 155.59 59.57 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.302 -0.874 . . . . 0.0 109.501 179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.914 ' HB3' HD23 ' A' ' 26' ' ' LEU . 3.0 Cg_exo -61.24 155.65 50.23 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.212 1.941 . . . . 0.0 110.52 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.617 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -139.57 161.62 37.05 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -179.994 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.507 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.07 128.81 15.23 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 118.796 -1.162 . . . . 0.0 110.84 -179.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.008 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.2 p -105.65 104.86 14.67 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.427 1.108 . . . . 0.0 110.287 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.951 HG22 HG23 ' A' ' 21' ' ' VAL . 11.7 t -118.82 117.28 53.86 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.469 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.226 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.522 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.1 149.71 11.76 Favored Pre-proline 0 N--CA 1.487 1.381 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 -179.611 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.522 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -77.14 152.05 94.18 Favored 'Cis proline' 0 C--N 1.309 -1.534 0 C-N-CA 123.698 -1.376 . . . . 0.0 109.567 -0.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.714 ' HA ' HG22 ' A' ' 110' ' ' ILE . 18.0 p -93.15 -24.75 18.14 Favored 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.468 ' HB3' ' HB2' ' A' ' 111' ' ' SER . 3.9 m -133.61 161.83 33.58 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.616 -0.678 . . . . 0.0 109.382 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.31 37.02 32.86 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 -179.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.777 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.2 mt -90.92 -42.93 10.31 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 123.283 1.516 . . . . 0.0 110.411 -178.599 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.55 144.36 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.305 0 CA-C-N 113.28 -1.782 . . . . 0.0 109.918 -179.629 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.609 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 6.3 p-10 -50.87 106.34 0.13 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.624 0.726 . . . . 0.0 111.514 -178.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.29 13.93 8.66 Favored Glycine 0 N--CA 1.484 1.865 0 C-N-CA 119.468 -1.349 . . . . 0.0 113.033 177.375 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.777 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.98 -172.73 2.15 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 121.168 2.484 . . . . 0.0 109.785 179.253 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.8 HG22 HG22 ' A' ' 68' ' ' THR . 17.2 t -130.39 139.49 51.21 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.319 0 CA-C-N 114.794 -1.094 . . . . 0.0 111.215 -178.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.485 HG11 HD11 ' A' ' 13' ' ' LEU . 33.8 m -115.22 155.12 16.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 178.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.542 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.4 tttt -109.08 109.15 20.08 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.146 -0.971 . . . . 0.0 109.466 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.951 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -105.47 122.44 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.008 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.68 165.66 12.31 Favored 'General case' 0 C--N 1.307 -1.273 0 O-C-N 120.821 -1.174 . . . . 0.0 109.128 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.587 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.97 107.74 0.47 Allowed Glycine 0 N--CA 1.481 1.693 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.617 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.34 139.62 50.21 Favored 'General case' 0 N--CA 1.5 2.063 0 CA-C-N 119.139 1.469 . . . . 0.0 110.102 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.48 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 86.39 28.18 28.19 Favored Glycine 0 N--CA 1.49 2.25 0 C-N-CA 118.796 -1.669 . . . . 0.0 109.758 179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.914 HD23 ' HB3' ' A' ' 3' ' ' PRO . 0.9 OUTLIER -94.7 174.44 7.11 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 120.996 -1.297 . . . . 0.0 108.58 179.906 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.005 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.28 100.1 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.91 -1.119 . . . . 0.0 109.74 -179.597 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.557 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.86 77.75 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.101 -179.326 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.41 34.02 0.29 Allowed Glycine 0 N--CA 1.487 2.071 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.9 p -141.86 108.73 5.42 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.071 -1.253 . . . . 0.0 111.098 -179.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.579 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.52 109.81 0.25 Allowed 'General case' 0 N--CA 1.496 1.874 0 CA-C-N 115.857 -0.611 . . . . 0.0 109.796 178.253 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.563 ' CE1' ' OD2' ' A' ' 99' ' ' ASP . 21.6 m-85 -99.53 153.77 18.78 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.177 -0.952 . . . . 0.0 108.835 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.502 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -102.67 158.96 15.88 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.727 -1.233 . . . . 0.0 107.829 178.553 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.636 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.0 p -141.63 118.25 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.942 -1.099 . . . . 0.0 109.92 -177.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.52 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.4 -179.81 40.48 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.937 -179.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.607 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -101.21 108.94 20.73 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.932 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.488 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.4 146.9 52.04 Favored 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.236 -0.915 . . . . 0.0 109.808 179.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.525 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -119.12 137.74 53.38 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.341 -0.849 . . . . 0.0 110.647 -178.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.857 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.69 114.44 26.18 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 178.143 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.7 m -105.92 14.51 7.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 120.971 -1.081 . . . . 0.0 110.666 -178.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.773 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.33 -175.38 0.08 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.815 -1.178 . . . . 0.0 110.116 179.743 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.784 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.97 98.07 1.54 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-O 121.806 0.812 . . . . 0.0 109.91 -179.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.97 26.61 36.81 Favored Glycine 0 N--CA 1.493 2.494 0 C-N-CA 120.17 -1.014 . . . . 0.0 111.562 178.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.773 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -115.27 105.98 19.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 O-C-N 120.549 -1.559 . . . . 0.0 107.316 178.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.857 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -118.31 104.81 11.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.502 -1.374 . . . . 0.0 109.628 -177.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.037 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.92 109.67 22.38 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.755 -1.216 . . . . 0.0 108.271 179.074 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.3 t -105.51 164.44 11.88 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.996 -1.065 . . . . 0.0 110.416 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.72 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 9.6 t-20 -109.2 137.21 20.14 Favored Pre-proline 0 N--CA 1.5 2.042 0 O-C-N 121.505 -0.747 . . . . 0.0 109.972 -179.162 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.59 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.2 Cg_endo -74.39 23.9 0.36 Allowed 'Trans proline' 0 CA--C 1.544 1.004 0 C-N-CA 122.371 2.047 . . . . 0.0 112.049 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.72 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -116.91 3.61 12.85 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.364 -1.46 . . . . 0.0 109.115 179.669 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.541 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.49 13.82 3.22 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 179.356 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -79.25 91.46 5.0 Favored 'General case' 0 C--N 1.306 -1.321 0 O-C-N 121.509 -0.744 . . . . 0.0 111.052 -178.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.636 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -112.63 -168.79 1.37 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.188 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.79 136.83 0.09 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.567 -1.333 . . . . 0.0 111.46 -179.296 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.92 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -152.19 157.01 5.31 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 178.024 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.579 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.18 143.78 28.33 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 120.808 -1.182 . . . . 0.0 110.081 -179.497 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -64.14 106.7 1.12 Allowed 'General case' 0 C--N 1.3 -1.55 0 CA-C-O 122.44 1.114 . . . . 0.0 109.278 178.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.8 p-10 -60.14 -139.12 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.985 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.948 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.557 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.53 -50.54 59.81 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.497 -0.752 . . . . 0.0 110.597 -178.522 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 -103.91 -34.11 8.61 Favored 'General case' 0 C--N 1.286 -2.179 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 178.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.012 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.28 66.44 0.6 Allowed Glycine 0 C--N 1.296 -1.639 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.568 178.105 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.587 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 21.5 m -103.15 125.32 49.79 Favored 'General case' 0 N--CA 1.484 1.257 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.665 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.92 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.34 109.33 8.73 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.464 -179.289 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.6 m -118.16 116.95 27.87 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.368 -0.833 . . . . 0.0 109.307 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.587 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -142.88 139.89 30.99 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.525 -0.734 . . . . 0.0 109.588 -179.987 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.6 p -99.62 134.55 42.33 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.465 -0.772 . . . . 0.0 109.43 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.76 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -132.12 165.6 23.68 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.427 -0.796 . . . . 0.0 109.389 -179.549 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.8 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -96.89 125.33 41.26 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.012 -1.055 . . . . 0.0 109.25 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.607 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.9 m -136.01 143.47 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 120.95 -1.094 . . . . 0.0 109.81 -179.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.609 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.7 ptt180 -147.15 -175.48 4.84 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.534 -1.354 . . . . 0.0 111.032 -179.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.605 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.12 -101.45 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.609 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.76 141.73 43.12 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.773 -1.204 . . . . 0.0 108.114 179.437 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.596 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.74 136.03 5.06 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 118.653 -1.219 . . . . 0.0 109.96 -177.973 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.487 ' C ' ' O ' ' A' ' 73' ' ' PHE . 0.7 OUTLIER -33.42 121.92 0.41 Allowed 'General case' 0 N--CA 1.492 1.648 0 CA-C-O 121.364 0.602 . . . . 0.0 110.313 -178.609 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.037 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.16 50.19 1.91 Allowed Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.388 -0.91 . . . . 0.0 111.343 -178.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.59 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.4 m-85 -40.15 113.5 0.36 Allowed 'General case' 0 N--CA 1.507 2.383 0 O-C-N 121.123 -1.222 . . . . 0.0 109.749 179.313 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.677 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.3 tp -85.66 127.04 34.38 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 120.903 -1.123 . . . . 0.0 109.726 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 33.3 t80 -65.25 58.06 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.971 0 O-C-N 120.85 -1.156 . . . . 0.0 109.824 179.611 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -158.69 18.67 0.21 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.004 -1.06 . . . . 0.0 109.596 -179.991 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.95 -27.23 5.56 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 42.3 p -93.98 159.87 14.98 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.962 -1.316 . . . . 0.0 110.455 -179.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.489 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.02 135.8 46.83 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.536 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.677 ' HB2' HD13 ' A' ' 77' ' ' LEU . 0.9 OUTLIER -83.88 -16.46 44.3 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.737 -1.227 . . . . 0.0 110.67 -178.345 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 107.62 176.23 22.44 Favored Glycine 0 N--CA 1.485 1.95 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.9 104.31 0.68 Allowed 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.582 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 39.4 t -76.37 107.19 7.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.353 -0.842 . . . . 0.0 109.096 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.535 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.3 m-20 -66.29 111.45 3.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.448 -0.782 . . . . 0.0 109.975 -179.236 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.605 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.74 -5.56 4.36 Favored 'General case' 0 N--CA 1.5 2.067 0 C-N-CA 118.268 -1.373 . . . . 0.0 109.78 179.357 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.0 p -86.7 -1.45 57.72 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.744 -1.222 . . . . 0.0 109.231 179.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.535 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.15 -49.6 3.01 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.212 -0.93 . . . . 0.0 109.019 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.89 178.42 4.52 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.55 -0.719 . . . . 0.0 109.398 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.83 116.45 32.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.348 -0.845 . . . . 0.0 109.115 179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.561 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.59 122.89 40.0 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.853 -1.155 . . . . 0.0 109.189 -179.473 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.578 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -101.18 146.04 28.01 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 122.334 1.064 . . . . 0.0 111.338 -179.08 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.588 ' HB ' HG11 ' A' ' 7' ' ' VAL . 65.8 t -103.21 109.78 27.88 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.964 0 N-CA-C 106.345 -1.724 . . . . 0.0 106.345 177.45 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.87 -172.82 17.53 Favored Glycine 0 N--CA 1.486 1.968 0 C-N-CA 118.063 -2.018 . . . . 0.0 111.804 -177.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.5 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -115.98 -177.77 3.24 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -178.87 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.559 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.9 OUTLIER -171.11 168.78 6.75 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.385 -0.822 . . . . 0.0 109.098 -179.24 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.683 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 1.4 m-20 -104.86 -9.64 17.88 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.115 -0.991 . . . . 0.0 109.504 179.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.683 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 73.6 39.02 0.59 Allowed 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.471 -0.768 . . . . 0.0 109.199 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -139.23 -34.54 0.58 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.569 -0.707 . . . . 0.0 110.715 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.544 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 179.22 -41.58 0.08 OUTLIER Glycine 0 N--CA 1.482 1.701 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 -179.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.7 -179.07 7.84 Favored 'General case' 0 C--N 1.308 -1.231 0 O-C-N 121.448 -1.03 . . . . 0.0 109.641 178.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.58 -166.56 33.91 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 -179.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.551 ' HG3' HD22 ' A' ' 26' ' ' LEU . 2.9 Cg_exo -49.8 -176.67 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.685 0 CA-C-N 118.857 1.329 . . . . 0.0 110.067 179.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -94.41 179.33 5.32 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.04 -1.037 . . . . 0.0 110.571 -178.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -117.97 166.77 12.76 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -108.26 128.87 63.4 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.246 -1.15 . . . . 0.0 109.117 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.578 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.09 119.1 16.86 Favored 'General case' 0 C--N 1.289 -2.045 0 O-C-N 121.586 -0.696 . . . . 0.0 109.356 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.892 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.81 169.9 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.151 -0.968 . . . . 0.0 108.916 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.468 ' HB2' ' HB3' ' A' ' 11' ' ' SER . 1.2 m -141.15 156.97 45.87 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.123 -0.986 . . . . 0.0 110.095 -179.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.892 ' CE2' HD12 ' A' ' 110' ' ' ILE . 97.8 m-85 -133.17 85.49 2.22 Favored 'General case' 0 N--CA 1.484 1.242 0 O-C-N 121.24 -0.912 . . . . 0.0 109.479 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.402 ' OXT' ' OD1' ' A' ' 113' ' ' ASN . 20.5 p30 . . . . . 0 N--CA 1.489 1.502 0 CA-C-O 118.044 -0.979 . . . . 0.0 109.445 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.674 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -123.51 154.58 66.3 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.174 -0.954 . . . . 0.0 109.631 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.562 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.8 Cg_exo -59.7 159.31 24.9 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.32 2.013 . . . . 0.0 110.458 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.06 -169.73 0.16 Allowed 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 179.442 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.545 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -163.48 131.01 3.5 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.755 -1.216 . . . . 0.0 110.692 -179.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.941 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.2 t -110.28 108.72 18.92 Favored 'General case' 0 C--N 1.296 -1.724 0 CA-C-O 123.108 1.432 . . . . 0.0 109.067 179.316 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.839 HG22 HG23 ' A' ' 21' ' ' VAL . 3.1 t -116.53 139.01 45.26 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.72 0 CA-C-N 114.246 -1.343 . . . . 0.0 110.123 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.466 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.64 149.13 1.27 Allowed Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.323 -0.861 . . . . 0.0 108.775 -179.735 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.466 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.79 152.52 97.07 Favored 'Cis proline' 0 C--N 1.312 -1.365 0 C-N-CA 123.476 -1.468 . . . . 0.0 109.485 -0.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.651 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.3 m -90.87 -24.56 20.2 Favored 'General case' 0 C--N 1.293 -1.874 0 O-C-N 121.587 -0.695 . . . . 0.0 109.175 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.51 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.2 m -137.94 165.34 26.78 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.547 -0.721 . . . . 0.0 109.515 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.05 37.98 31.34 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 108.579 -1.808 . . . . 0.0 108.579 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.81 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.8 mt -93.01 -43.93 8.66 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 123.102 1.43 . . . . 0.0 110.703 -178.249 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.17 145.94 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.314 0 CA-C-N 113.595 -1.639 . . . . 0.0 110.138 -179.904 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.616 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -51.23 106.95 0.15 Allowed 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 121.66 0.743 . . . . 0.0 111.638 -178.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.73 13.97 9.06 Favored Glycine 0 N--CA 1.484 1.878 0 C-N-CA 119.473 -1.346 . . . . 0.0 112.968 177.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.81 HG21 ' CA ' ' A' ' 13' ' ' LEU . 11.5 t -104.08 -173.96 2.43 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 121.164 2.482 . . . . 0.0 109.936 179.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.808 HG13 ' O ' ' A' ' 67' ' ' LEU . 39.1 t -124.76 136.11 61.79 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.389 0 CA-C-N 114.563 -1.199 . . . . 0.0 110.917 -178.669 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.562 ' CG1' HD13 ' A' ' 13' ' ' LEU . 35.6 m -114.04 154.95 15.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.259 -0.9 . . . . 0.0 108.725 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.516 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.81 109.15 18.44 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.209 -0.932 . . . . 0.0 109.037 179.876 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.839 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -104.48 141.02 20.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.941 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.73 160.76 38.35 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 120.735 -1.228 . . . . 0.0 110.154 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -128.46 144.6 15.42 Favored Glycine 0 C--N 1.295 -1.731 0 N-CA-C 107.973 -2.051 . . . . 0.0 107.973 179.559 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.562 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.13 125.71 13.3 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 120.851 -1.382 . . . . 0.0 108.864 179.053 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.535 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.44 26.01 26.64 Favored Glycine 0 N--CA 1.488 2.138 0 C-N-CA 119.184 -1.484 . . . . 0.0 109.874 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.587 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -89.02 170.98 10.19 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.86 -1.376 . . . . 0.0 108.477 179.892 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.997 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.02 100.88 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.082 -1.012 . . . . 0.0 110.038 -179.531 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.2 78.53 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.007 -179.48 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.88 34.32 0.3 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.558 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 16.6 p -138.78 105.06 5.25 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.217 -1.166 . . . . 0.0 111.293 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.8 111.87 0.62 Allowed 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 178.054 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.558 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 36.9 m-85 -108.92 157.53 18.54 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.186 -0.946 . . . . 0.0 108.897 179.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.498 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.21 163.14 12.42 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.913 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.92 HG11 HG21 ' A' ' 65' ' ' THR . 2.8 p -143.75 119.42 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.034 -1.041 . . . . 0.0 109.914 -178.044 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.89 -177.87 38.96 Favored Glycine 0 N--CA 1.495 2.602 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.851 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.572 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -102.15 108.76 20.26 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 -179.842 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.458 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -131.14 149.56 52.54 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.241 -0.912 . . . . 0.0 109.716 179.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.478 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.03 138.27 54.73 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.105 -0.997 . . . . 0.0 110.803 -178.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.888 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.73 26.55 Favored 'General case' 0 N--CA 1.491 1.615 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.112 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.0 m -104.74 14.8 6.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.109 -0.994 . . . . 0.0 110.593 -178.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.762 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 173.97 -175.7 0.07 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.989 -1.069 . . . . 0.0 110.003 179.686 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 42' ' ' THR . 14.9 t -72.1 99.0 2.22 Favored 'General case' 0 N--CA 1.486 1.357 0 CA-C-O 121.763 0.792 . . . . 0.0 109.738 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.77 27.7 34.14 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 120.227 -0.987 . . . . 0.0 111.405 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.762 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -117.5 105.88 18.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.619 -1.518 . . . . 0.0 107.263 178.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.888 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.2 tp -117.66 104.67 11.25 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.48 -1.387 . . . . 0.0 109.739 -177.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.089 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.89 109.35 22.12 Favored 'General case' 0 N--CA 1.484 1.26 0 O-C-N 120.804 -1.185 . . . . 0.0 107.9 178.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.491 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -107.26 162.71 13.65 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.956 -1.09 . . . . 0.0 110.263 -178.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.713 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 39.7 t30 -105.71 134.7 19.59 Favored Pre-proline 0 N--CA 1.503 2.189 0 O-C-N 121.405 -0.809 . . . . 0.0 109.539 -179.614 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.599 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.2 Cg_endo -72.74 22.92 0.29 Allowed 'Trans proline' 0 CA--C 1.543 0.965 0 C-N-CA 122.322 2.015 . . . . 0.0 112.46 -179.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.713 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -118.34 10.59 12.82 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.349 -1.469 . . . . 0.0 108.958 179.455 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.854 ' OD2' HD22 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -137.99 14.59 2.86 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 179.326 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -80.15 88.64 5.43 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.564 -0.855 . . . . 0.0 111.286 -178.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.55 -167.05 1.18 Allowed 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 178.128 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.74 138.26 0.09 Allowed 'General case' 0 C--N 1.306 -1.284 0 O-C-N 120.578 -1.326 . . . . 0.0 111.239 -179.267 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 1.022 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -155.69 156.48 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 N-CA-C 107.794 -1.187 . . . . 0.0 107.794 178.397 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.66 142.03 30.74 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.798 -1.189 . . . . 0.0 110.016 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.015 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -61.74 106.76 0.72 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.425 1.107 . . . . 0.0 109.287 178.091 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.544 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.0 p-10 -60.44 -138.4 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.033 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.36 -51.03 58.13 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.429 -0.794 . . . . 0.0 110.902 -178.576 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.472 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.7 t-20 -103.57 -34.54 8.62 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 178.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.015 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 110.95 63.02 0.5 Allowed Glycine 0 C--N 1.297 -1.621 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 177.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.9 m -102.48 126.9 49.68 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.6 -0.941 . . . . 0.0 108.487 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 1.022 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.68 109.19 7.41 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 119.27 -0.972 . . . . 0.0 109.834 -179.097 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.1 m -120.83 120.56 35.92 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.284 -0.885 . . . . 0.0 109.515 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.92 HG21 HG11 ' A' ' 34' ' ' VAL . 0.8 OUTLIER -142.04 143.65 33.23 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.526 -0.734 . . . . 0.0 109.355 179.772 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.7 p -102.0 143.41 31.89 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.423 -0.798 . . . . 0.0 109.462 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.854 HD22 ' OD2' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -146.26 -178.87 6.37 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 109.43 -179.45 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.513 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -105.06 125.88 51.46 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 120.903 -1.123 . . . . 0.0 110.289 -178.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.761 HG13 ' OD1' ' A' ' 51' ' ' ASP . 15.3 m -134.56 144.22 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 120.965 -1.085 . . . . 0.0 109.756 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.616 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.3 ptt180 -148.66 -179.62 7.11 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 120.458 -1.401 . . . . 0.0 111.105 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.603 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.92 -100.89 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -179.661 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.511 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.73 139.54 50.35 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.82 -1.175 . . . . 0.0 107.928 179.303 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -161.44 136.18 7.25 Favored 'General case' 0 C--N 1.295 -1.803 0 C-N-CA 118.647 -1.221 . . . . 0.0 109.807 -178.105 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.523 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 15.7 mt-10 -33.97 121.43 0.45 Allowed 'General case' 0 N--CA 1.491 1.621 0 CA-C-O 121.419 0.628 . . . . 0.0 110.358 -178.45 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.089 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.03 50.86 1.93 Allowed Glycine 0 N--CA 1.493 2.493 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.068 -179.278 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.599 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-85 -39.22 116.69 0.62 Allowed 'General case' 0 N--CA 1.509 2.492 0 O-C-N 121.122 -1.223 . . . . 0.0 109.954 179.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.718 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -87.37 126.16 34.7 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.006 -1.059 . . . . 0.0 109.455 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.579 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.1 t80 -64.8 58.47 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.925 0 O-C-N 120.804 -1.185 . . . . 0.0 110.014 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 26.4 t0 -159.33 19.54 0.18 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.054 -1.029 . . . . 0.0 109.571 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.51 -28.2 5.41 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.454 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 66.3 p -95.96 160.24 14.56 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.964 -1.315 . . . . 0.0 110.438 -179.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.479 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 4.1 ptt180 -105.73 138.77 41.37 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.718 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -83.55 -19.12 36.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.852 -1.155 . . . . 0.0 110.556 -178.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.59 176.1 19.24 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 108.704 -1.758 . . . . 0.0 108.704 -179.569 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -65.72 105.9 1.37 Allowed 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.0 t -77.36 105.9 6.86 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.599 0 O-C-N 121.355 -0.841 . . . . 0.0 109.144 -178.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.546 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -64.97 111.1 2.7 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.373 -0.829 . . . . 0.0 109.819 -179.558 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.603 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -62.91 -5.93 3.34 Favored 'General case' 0 N--CA 1.499 2.02 0 C-N-CA 118.214 -1.394 . . . . 0.0 109.85 179.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.2 p -86.99 -1.25 57.72 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.729 -1.232 . . . . 0.0 109.319 179.523 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.546 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.8 p -111.49 -50.3 2.94 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.384 -0.823 . . . . 0.0 108.937 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.76 -179.94 4.09 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.544 -0.723 . . . . 0.0 109.238 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.93 116.11 31.66 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.325 -0.859 . . . . 0.0 109.057 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -96.93 121.17 38.51 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.854 -1.154 . . . . 0.0 109.278 -179.321 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.609 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.3 mt-30 -102.04 146.78 27.42 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-O 122.402 1.096 . . . . 0.0 111.311 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.415 ' CG1' ' HB ' ' A' ' 21' ' ' VAL . 62.1 t -104.65 109.86 28.86 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 N-CA-C 106.787 -1.56 . . . . 0.0 106.787 177.479 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.485 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.0 -170.04 16.27 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 118.243 -1.932 . . . . 0.0 111.62 -177.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.498 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -112.78 179.88 3.85 Favored 'General case' 0 N--CA 1.486 1.333 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -179.065 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.581 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.2 p -177.79 171.09 1.87 Allowed 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.362 -0.836 . . . . 0.0 109.546 -179.18 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.525 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -126.67 -158.27 0.85 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.028 -1.045 . . . . 0.0 109.13 179.961 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.439 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.32 35.85 4.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.728 -1.232 . . . . 0.0 109.214 -179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.12 -33.79 5.57 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.341 -0.849 . . . . 0.0 109.991 -179.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.789 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.23 -36.37 0.27 Allowed Glycine 0 N--CA 1.482 1.741 0 N-CA-C 107.775 -2.13 . . . . 0.0 107.775 -179.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -164.04 -177.42 5.03 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 121.599 -0.942 . . . . 0.0 109.962 179.451 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.67 -161.72 14.25 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.518 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.48 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.5 Cg_exo -47.53 178.45 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 CA-C-N 118.997 1.398 . . . . 0.0 110.196 179.281 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -91.25 -177.56 4.9 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.056 -1.028 . . . . 0.0 110.371 -178.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.485 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.15 163.73 13.89 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.06 129.76 50.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.374 -1.074 . . . . 0.0 109.173 -179.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.609 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.1 121.96 22.84 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.634 -0.666 . . . . 0.0 109.603 179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.955 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -97.89 169.85 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.214 -0.928 . . . . 0.0 109.18 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.51 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -136.2 154.58 50.89 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.326 -0.859 . . . . 0.0 109.745 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.955 ' CE1' HD12 ' A' ' 110' ' ' ILE . 26.7 m-85 -125.53 109.97 13.31 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.301 -0.874 . . . . 0.0 109.421 -179.78 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.421 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 13.3 p30 . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 117.926 -1.035 . . . . 0.0 109.437 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.789 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -123.72 153.23 66.67 Favored Pre-proline 0 N--CA 1.489 1.492 0 O-C-N 121.241 -0.912 . . . . 0.0 109.565 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.561 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 4.7 Cg_exo -60.26 159.03 28.17 Favored 'Trans proline' 0 C--N 1.309 -1.51 0 C-N-CA 122.428 2.085 . . . . 0.0 110.535 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.544 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -173.85 -169.66 0.51 Allowed 'General case' 0 C--N 1.298 -1.633 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.092 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.544 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.94 130.58 2.71 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 120.888 -1.133 . . . . 0.0 110.905 -179.047 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.929 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.5 t -111.74 108.71 18.24 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 123.071 1.415 . . . . 0.0 109.102 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.819 HG22 HG23 ' A' ' 21' ' ' VAL . 2.8 t -115.28 139.23 42.65 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.692 0 CA-C-N 114.326 -1.306 . . . . 0.0 110.196 -179.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.08 149.39 1.46 Allowed Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.3 -0.875 . . . . 0.0 108.783 -179.769 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.9 Cg_endo -77.0 151.22 93.69 Favored 'Cis proline' 0 C--N 1.312 -1.344 0 C-N-CA 123.489 -1.463 . . . . 0.0 109.238 -0.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' HG22 ' A' ' 110' ' ' ILE . 24.0 p -89.81 -24.36 21.47 Favored 'General case' 0 C--N 1.292 -1.924 0 O-C-N 121.46 -0.775 . . . . 0.0 109.395 179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.515 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 12.4 m -136.68 164.6 27.87 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.35 -0.844 . . . . 0.0 109.801 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.85 38.79 30.23 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.79 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.2 mt -92.18 -44.1 8.98 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 123.125 1.441 . . . . 0.0 110.721 -178.325 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.88 146.17 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.364 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.329 179.989 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.9 p-10 -51.55 107.4 0.19 Allowed 'General case' 0 C--N 1.303 -1.445 0 CA-C-O 121.713 0.768 . . . . 0.0 111.571 -178.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.8 14.95 8.98 Favored Glycine 0 N--CA 1.484 1.853 0 C-N-CA 119.445 -1.359 . . . . 0.0 112.924 177.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.79 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.5 t -105.85 -172.61 2.12 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 121.136 2.468 . . . . 0.0 109.557 179.077 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.73 HG13 ' C ' ' A' ' 67' ' ' LEU . 13.3 t -129.2 136.77 58.76 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.43 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.897 -179.096 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.648 HG13 ' CG2' ' A' ' 69' ' ' VAL . 15.5 m -110.81 156.42 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.512 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -112.36 109.05 18.45 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.114 -0.991 . . . . 0.0 108.953 179.818 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.819 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -103.74 140.35 22.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.929 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.47 160.05 39.67 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.717 -1.239 . . . . 0.0 110.026 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.604 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.67 144.47 15.59 Favored Glycine 0 C--N 1.293 -1.806 0 N-CA-C 107.995 -2.042 . . . . 0.0 107.995 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.561 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.14 125.48 13.09 Favored 'General case' 0 C--N 1.296 -1.734 0 O-C-N 120.806 -1.408 . . . . 0.0 108.983 179.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.539 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.42 26.33 25.77 Favored Glycine 0 N--CA 1.488 2.121 0 C-N-CA 119.279 -1.438 . . . . 0.0 109.796 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.591 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.7 OUTLIER -89.36 169.59 11.28 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 120.838 -1.389 . . . . 0.0 108.347 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.84 100.99 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 122.214 1.007 . . . . 0.0 109.921 -179.438 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.82 78.18 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.618 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.904 -179.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.88 34.12 0.27 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.551 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 18.5 p -139.06 105.43 5.28 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 121.154 -1.204 . . . . 0.0 111.262 -179.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.583 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.24 111.54 0.59 Allowed 'General case' 0 N--CA 1.497 1.924 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.676 178.088 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.594 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 5.8 m-30 -109.48 156.35 20.2 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.109 -0.994 . . . . 0.0 108.873 179.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -99.49 164.98 11.86 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.821 -1.174 . . . . 0.0 107.915 179.079 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.728 HG22 HG11 ' A' ' 21' ' ' VAL . 3.4 p -144.95 116.52 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.036 -1.04 . . . . 0.0 109.774 -178.276 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.48 -176.23 37.43 Favored Glycine 0 N--CA 1.494 2.519 0 C-N-CA 118.348 -1.882 . . . . 0.0 111.886 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.597 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.1 pt20 -100.4 109.6 21.77 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-O 121.976 0.893 . . . . 0.0 108.978 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.61 148.75 52.44 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.212 -0.93 . . . . 0.0 109.613 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.497 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.15 138.01 54.48 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.263 -0.898 . . . . 0.0 110.875 -178.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.12 27.0 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 177.915 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 m -105.0 14.84 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 120.842 -1.162 . . . . 0.0 110.518 -178.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.42 -175.23 0.08 Allowed 'General case' 0 C--N 1.301 -1.501 0 O-C-N 120.931 -1.106 . . . . 0.0 110.005 179.738 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.28 98.92 2.76 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.428 -0.795 . . . . 0.0 109.489 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.63 27.62 31.84 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 120.203 -0.999 . . . . 0.0 111.433 179.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -118.17 106.12 19.14 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 O-C-N 120.66 -1.494 . . . . 0.0 107.225 178.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.3 tp -117.94 104.53 10.99 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.475 -1.391 . . . . 0.0 109.874 -177.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.085 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.94 109.36 22.13 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 120.745 -1.222 . . . . 0.0 107.932 178.77 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.489 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 5.0 t -108.92 162.13 14.49 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.028 -1.045 . . . . 0.0 110.379 -178.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.505 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 12.9 t-20 -107.36 129.18 24.64 Favored Pre-proline 0 N--CA 1.5 2.03 0 O-C-N 121.424 -0.797 . . . . 0.0 109.63 -179.404 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.621 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.0 OUTLIER -71.18 20.24 0.23 Allowed 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 122.057 1.838 . . . . 0.0 111.95 179.388 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.505 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -107.81 2.68 23.74 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.515 -1.366 . . . . 0.0 108.841 179.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.552 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.01 17.89 2.82 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 179.418 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -81.76 86.94 6.37 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.524 -0.735 . . . . 0.0 111.086 -178.384 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -102.89 -165.54 1.18 Allowed 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 178.19 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.459 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.8 137.13 0.09 Allowed 'General case' 0 N--CA 1.486 1.354 0 O-C-N 120.532 -1.355 . . . . 0.0 111.212 -179.399 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 1.013 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -155.2 156.58 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 178.37 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.583 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.69 141.67 31.21 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.952 -1.093 . . . . 0.0 109.879 -179.802 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.034 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.23 107.17 0.84 Allowed 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 122.45 1.119 . . . . 0.0 109.39 178.231 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.546 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.9 t0 -62.17 -138.54 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.011 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.001 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.7 -52.42 31.34 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.391 -0.818 . . . . 0.0 110.871 -178.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -103.61 -32.81 9.24 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 178.633 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.034 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.8 62.57 0.54 Allowed Glycine 0 C--N 1.297 -1.627 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 178.04 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 37.0 m -101.04 127.14 47.7 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.597 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 1.013 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -137.13 109.2 7.2 Favored 'General case' 0 C--N 1.297 -1.713 0 C-N-CA 119.074 -1.05 . . . . 0.0 109.877 -179.089 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.476 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 48.2 p -121.27 119.69 32.99 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.282 -0.886 . . . . 0.0 109.417 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.529 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.56 145.7 31.96 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.581 -0.699 . . . . 0.0 109.289 179.831 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 20.3 p -98.91 143.34 29.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.407 -0.808 . . . . 0.0 109.736 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.73 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -141.07 163.0 34.15 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.483 -0.761 . . . . 0.0 109.141 -179.486 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.693 HG22 HG22 ' A' ' 18' ' ' VAL . 5.1 p -92.77 123.98 36.44 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.045 -1.035 . . . . 0.0 109.521 -179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.648 ' CG2' HG13 ' A' ' 19' ' ' VAL . 17.8 m -137.78 144.16 31.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 121.001 -1.062 . . . . 0.0 109.453 -179.586 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.596 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 4.3 ptt180 -138.89 -168.77 2.49 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.507 -1.371 . . . . 0.0 110.544 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.681 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 3.9 mtt180 -65.48 -73.81 0.12 Allowed 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.522 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -76.72 145.43 38.66 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 178.159 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 0.9 OUTLIER -164.98 138.68 4.83 Favored 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 117.446 -1.702 . . . . 0.0 110.678 -177.478 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.525 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 3.7 mp0 -35.22 120.97 0.55 Allowed 'General case' 0 N--CA 1.491 1.614 0 CA-C-O 121.455 0.645 . . . . 0.0 110.361 -178.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.085 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -96.19 51.34 1.65 Allowed Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.485 -0.865 . . . . 0.0 111.018 -179.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.621 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-85 -40.19 114.64 0.46 Allowed 'General case' 0 N--CA 1.508 2.455 0 O-C-N 121.079 -1.248 . . . . 0.0 109.776 179.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.684 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -85.73 125.67 33.39 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.855 -1.153 . . . . 0.0 109.754 -179.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.586 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 19.0 t80 -65.24 58.04 0.03 OUTLIER 'General case' 0 N--CA 1.497 1.908 0 O-C-N 120.789 -1.194 . . . . 0.0 109.748 179.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.552 ' N ' ' O ' ' A' ' 77' ' ' LEU . 5.6 t70 -154.97 16.7 0.43 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.13 -0.981 . . . . 0.0 109.559 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.85 -26.83 8.87 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.12 164.96 11.42 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.948 -1.325 . . . . 0.0 110.643 -179.287 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.482 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 2.1 ptm180 -105.38 137.3 43.41 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.684 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -81.15 -19.77 42.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.852 -1.155 . . . . 0.0 110.421 -178.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.62 176.1 19.23 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.679 -1.769 . . . . 0.0 108.679 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.97 106.44 1.24 Allowed 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 179.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.651 HG21 ' HB3' ' A' ' 46' ' ' ALA . 38.7 t -78.03 107.55 10.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.363 -0.836 . . . . 0.0 109.205 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.522 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.4 OUTLIER -68.71 112.99 5.79 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.518 -0.738 . . . . 0.0 109.91 -179.371 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.681 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 7.5 m -58.43 -6.98 0.77 Allowed 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.632 -1.293 . . . . 0.0 110.424 179.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.8 p -87.08 -4.77 59.17 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.298 -1.501 . . . . 0.0 109.617 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.496 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -103.38 -47.08 4.4 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.245 -0.909 . . . . 0.0 108.94 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -115.08 -178.06 3.28 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.553 -0.717 . . . . 0.0 109.357 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.08 117.57 35.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.403 -0.811 . . . . 0.0 108.821 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.557 ' HB2' HD11 ' A' ' 110' ' ' ILE . 3.2 m -96.47 121.26 38.1 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.846 -1.159 . . . . 0.0 109.724 -179.114 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.573 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.46 146.55 28.7 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-O 122.384 1.088 . . . . 0.0 111.37 -179.391 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.443 ' CG1' HG11 ' A' ' 7' ' ' VAL . 57.5 t -103.59 109.94 28.52 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 177.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.469 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.63 -171.54 16.8 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 118.221 -1.942 . . . . 0.0 111.638 -177.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.28 178.74 4.21 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 -179.067 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.59 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.1 p -171.58 168.54 6.32 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.565 -0.709 . . . . 0.0 109.406 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.594 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -119.35 -158.16 0.72 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.072 -1.017 . . . . 0.0 108.945 179.711 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.458 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.45 36.43 4.27 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.733 -1.23 . . . . 0.0 109.138 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -115.29 -32.49 5.62 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.442 -0.786 . . . . 0.0 110.075 -179.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 1.002 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 163.99 -35.69 0.3 Allowed Glycine 0 N--CA 1.481 1.65 0 N-CA-C 107.778 -2.129 . . . . 0.0 107.778 -179.561 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.97 -177.74 5.99 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.64 -0.918 . . . . 0.0 109.742 179.273 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.04 -162.16 15.52 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 108.445 -1.862 . . . . 0.0 108.445 -179.439 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.482 ' HG3' HD22 ' A' ' 26' ' ' LEU . 5.2 Cg_exo -47.27 178.71 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.644 0 CA-C-N 118.789 1.295 . . . . 0.0 110.313 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -92.42 -172.97 3.25 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.007 -1.058 . . . . 0.0 110.36 -178.923 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.469 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.33 163.34 14.81 Favored Glycine 0 N--CA 1.488 2.152 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.28 131.12 48.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.424 -1.045 . . . . 0.0 109.075 -179.52 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.573 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.81 120.68 19.74 Favored 'General case' 0 C--N 1.29 -2.021 0 O-C-N 121.613 -0.679 . . . . 0.0 109.842 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.818 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.4 pt -98.09 170.43 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.276 -0.89 . . . . 0.0 108.896 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.515 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.9 153.96 51.29 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.127 -0.983 . . . . 0.0 109.551 179.899 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.818 ' CE2' HD12 ' A' ' 110' ' ' ILE . 67.2 m-85 -130.31 95.14 3.83 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.249 -0.907 . . . . 0.0 109.527 -179.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.9 p30 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 117.868 -1.063 . . . . 0.0 109.558 179.951 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 1.002 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -125.54 97.93 35.67 Favored Pre-proline 0 N--CA 1.487 1.413 0 O-C-N 121.33 -0.856 . . . . 0.0 109.398 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.577 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 6.3 Cg_exo -58.46 157.45 26.76 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.045 1.83 . . . . 0.0 110.194 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.551 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -179.92 -169.26 0.13 Allowed 'General case' 0 C--N 1.297 -1.693 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 179.543 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.596 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . -166.55 133.85 2.61 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.758 -1.214 . . . . 0.0 110.974 -179.537 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.019 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -101.61 104.51 15.38 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 122.439 1.114 . . . . 0.0 109.864 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.939 HG22 HG23 ' A' ' 21' ' ' VAL . 4.1 t -118.84 118.97 59.55 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.462 179.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.502 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.84 147.96 9.59 Favored Pre-proline 0 C--N 1.306 -1.324 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 -179.832 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.502 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.8 Cg_endo -76.17 151.31 95.02 Favored 'Cis proline' 0 C--N 1.309 -1.541 0 C-N-CA 123.593 -1.42 . . . . 0.0 109.596 -0.406 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' HG22 ' A' ' 110' ' ' ILE . 2.5 p -90.38 -25.37 20.46 Favored 'General case' 0 C--N 1.294 -1.822 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.497 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.1 m -136.05 165.86 24.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.609 -0.682 . . . . 0.0 109.331 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.22 37.58 36.71 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 108.463 -1.855 . . . . 0.0 108.463 -179.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.0 mt -92.27 -43.0 9.53 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 123.297 1.522 . . . . 0.0 110.44 -178.33 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.48 144.35 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.29 0 CA-C-N 113.522 -1.672 . . . . 0.0 109.788 -179.62 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.608 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 4.7 p-10 -51.27 106.2 0.13 Allowed 'General case' 0 C--N 1.301 -1.54 0 CA-C-O 121.539 0.685 . . . . 0.0 111.597 -178.385 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.401 ' H ' ' HB3' ' A' ' 70' ' ' ARG . . . 113.38 15.95 8.58 Favored Glycine 0 N--CA 1.484 1.884 0 C-N-CA 119.473 -1.346 . . . . 0.0 112.855 177.297 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.1 t -104.41 -170.88 1.83 Allowed 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 121.169 2.484 . . . . 0.0 109.727 179.176 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.731 HG13 ' C ' ' A' ' 67' ' ' LEU . 14.2 t -130.38 138.92 52.65 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.166 -178.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.569 HG11 HD11 ' A' ' 13' ' ' LEU . 33.7 m -118.18 155.04 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tttt -109.26 109.4 20.31 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.162 -0.961 . . . . 0.0 109.509 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.939 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -105.86 124.59 61.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.489 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.019 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.66 167.21 11.55 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.668 -1.27 . . . . 0.0 109.253 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.615 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.07 141.05 12.38 Favored Glycine 0 C--N 1.296 -1.666 0 N-CA-C 107.466 -2.254 . . . . 0.0 107.466 179.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.577 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.28 123.94 11.84 Favored 'General case' 0 C--N 1.295 -1.8 0 O-C-N 120.571 -1.546 . . . . 0.0 108.819 179.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.524 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.37 27.12 23.69 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.13 -1.51 . . . . 0.0 109.899 -179.666 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.532 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -88.06 174.33 8.34 Favored 'General case' 0 C--N 1.308 -1.227 0 O-C-N 120.788 -1.419 . . . . 0.0 108.473 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.001 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.88 97.54 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 122.257 1.027 . . . . 0.0 109.724 -179.853 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.637 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.99 77.26 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.437 -179.088 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.77 33.65 0.29 Allowed Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.302 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 50.5 p -145.53 112.0 5.81 Favored 'General case' 0 C--N 1.31 -1.145 0 O-C-N 120.896 -1.355 . . . . 0.0 111.448 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.59 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.52 116.19 1.5 Allowed 'General case' 0 N--CA 1.495 1.816 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.934 178.286 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.602 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 4.0 m-30 -112.28 153.87 26.51 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.225 -0.922 . . . . 0.0 108.708 179.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.6 OUTLIER -98.92 165.36 11.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.849 -1.157 . . . . 0.0 108.095 179.003 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 34' ' ' VAL . 4.8 p -145.15 116.64 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.114 -0.991 . . . . 0.0 109.878 -177.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.53 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.55 -175.97 39.07 Favored Glycine 0 N--CA 1.491 2.336 0 C-N-CA 118.267 -1.92 . . . . 0.0 111.754 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.571 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -100.22 113.75 26.67 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.622 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 85.0 m -131.88 153.81 49.84 Favored 'General case' 0 C--N 1.292 -1.901 0 O-C-N 121.6 -0.688 . . . . 0.0 109.602 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.663 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -129.88 136.78 49.92 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 121.448 -0.782 . . . . 0.0 110.565 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.908 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.69 114.45 26.38 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 178.318 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m -105.45 15.08 7.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 120.951 -1.093 . . . . 0.0 110.713 -178.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.782 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.22 -174.54 0.07 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.87 -1.144 . . . . 0.0 110.08 179.699 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 40.1 p -71.33 96.81 1.49 Allowed 'General case' 0 N--CA 1.485 1.323 0 O-C-N 121.382 -0.824 . . . . 0.0 109.878 -179.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.26 27.95 31.92 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 120.21 -0.995 . . . . 0.0 111.564 178.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.782 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -115.54 106.38 20.36 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.54 -1.565 . . . . 0.0 107.464 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.908 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -116.31 106.54 13.77 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.591 -1.318 . . . . 0.0 109.912 -177.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.123 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -96.77 113.22 24.76 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 120.821 -1.174 . . . . 0.0 108.515 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.575 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . 97.4 m -105.34 147.39 28.21 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.279 -0.888 . . . . 0.0 110.361 -178.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.604 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 32.7 t30 -97.52 135.94 21.5 Favored Pre-proline 0 N--CA 1.505 2.305 0 O-C-N 120.937 -1.102 . . . . 0.0 108.759 178.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.62 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.8 Cg_endo -74.85 26.51 0.36 Allowed 'Trans proline' 0 C--N 1.319 -1.004 0 C-N-CA 122.396 2.064 . . . . 0.0 112.29 -179.098 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.604 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -120.76 6.05 10.48 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.213 -1.554 . . . . 0.0 109.536 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.6 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.48 17.93 2.38 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 179.367 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.575 ' CE2' ' HB3' ' A' ' 47' ' ' CYS . 0.7 OUTLIER -83.58 89.84 7.16 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.248 -178.437 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.588 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -109.99 -166.77 1.12 Allowed 'General case' 0 N--CA 1.488 1.438 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.153 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.463 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.66 135.61 0.09 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.421 -1.425 . . . . 0.0 111.573 -179.294 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.803 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.2 p -151.73 159.72 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 177.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.6 144.44 27.89 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.731 -1.231 . . . . 0.0 110.016 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.001 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.51 107.83 2.2 Favored 'General case' 0 C--N 1.301 -1.542 0 CA-C-O 122.385 1.088 . . . . 0.0 109.342 178.563 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.555 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.7 t0 -62.72 -139.07 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.886 -179.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.637 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.28 -52.09 29.7 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.427 -0.795 . . . . 0.0 110.727 -178.582 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 -104.48 -32.48 8.98 Favored 'General case' 0 C--N 1.286 -2.155 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 178.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.972 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.67 68.22 0.65 Allowed Glycine 0 C--N 1.297 -1.587 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 178.294 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.0 m -103.47 128.94 50.54 Favored 'General case' 0 N--CA 1.483 1.224 0 O-C-N 121.336 -1.097 . . . . 0.0 109.15 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.803 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.63 108.72 7.69 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 119.469 -0.892 . . . . 0.0 109.574 -179.573 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.447 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 85.7 p -116.85 117.41 29.66 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.089 -1.007 . . . . 0.0 109.374 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.618 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.32 142.51 28.35 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.409 -0.807 . . . . 0.0 109.956 -179.794 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 25.1 p -102.14 141.32 35.15 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.496 -0.752 . . . . 0.0 109.265 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.776 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.58 167.05 23.07 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.337 -0.852 . . . . 0.0 109.509 -179.384 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.699 HG22 HG22 ' A' ' 18' ' ' VAL . 2.5 p -96.17 124.74 40.29 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.197 -0.94 . . . . 0.0 109.349 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.537 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 18.7 m -138.43 142.55 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 120.939 -1.101 . . . . 0.0 109.922 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.608 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.7 ptt180 -138.56 -164.81 1.7 Allowed 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.732 -1.23 . . . . 0.0 109.908 -179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.564 ' HG3' ' CD1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -74.3 -82.88 0.06 Allowed 'General case' 0 N--CA 1.486 1.341 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 -179.844 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.498 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.76 136.63 57.96 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 178.698 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.663 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.46 133.49 5.75 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 118.058 -1.457 . . . . 0.0 110.562 -177.603 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.56 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 3.1 mm-40 -33.04 120.07 0.35 Allowed 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.619 0.723 . . . . 0.0 110.386 -178.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.123 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.9 50.74 2.54 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.484 -179.074 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.62 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -37.77 116.36 0.49 Allowed 'General case' 0 N--CA 1.507 2.381 0 O-C-N 121.136 -1.214 . . . . 0.0 110.157 179.365 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.653 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.2 tp -86.08 126.09 33.93 Favored 'General case' 0 N--CA 1.499 2.011 0 O-C-N 120.895 -1.128 . . . . 0.0 109.716 -179.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.578 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 39.3 t80 -63.62 58.42 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.015 -1.053 . . . . 0.0 110.114 179.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 21.2 t0 -161.01 20.27 0.13 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.904 -1.122 . . . . 0.0 109.737 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.52 -29.09 5.01 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.484 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 9.7 p -95.48 163.88 13.04 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.076 -1.249 . . . . 0.0 110.203 -179.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.464 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 3.3 ptm180 -109.25 139.85 43.64 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.653 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.6 t90 -82.0 -21.56 37.01 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.861 -1.149 . . . . 0.0 110.353 -178.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.81 175.68 18.14 Favored Glycine 0 N--CA 1.486 1.985 0 N-CA-C 108.487 -1.845 . . . . 0.0 108.487 -179.442 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.79 110.57 2.11 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 179.037 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.615 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.1 t -82.32 102.61 8.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.652 0 N-CA-C 108.774 -0.825 . . . . 0.0 108.774 -179.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.608 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.97 111.21 2.75 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.489 -0.757 . . . . 0.0 109.632 -179.313 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.563 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.23 -4.93 5.8 Favored 'General case' 0 N--CA 1.498 1.973 0 C-N-CA 118.304 -1.358 . . . . 0.0 109.813 179.534 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.3 p -85.51 3.62 39.56 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.786 -1.196 . . . . 0.0 108.823 179.255 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.608 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -119.2 -49.82 2.38 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.402 -0.811 . . . . 0.0 108.959 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.71 -178.42 3.65 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.382 -0.824 . . . . 0.0 109.538 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.64 114.45 28.62 Favored 'General case' 0 N--CA 1.493 1.705 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.511 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.5 m -97.47 121.9 39.9 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.932 -1.105 . . . . 0.0 109.746 -179.396 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.592 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.74 147.11 26.86 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.412 1.101 . . . . 0.0 111.245 -179.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.656 ' HB ' HG11 ' A' ' 7' ' ' VAL . 52.9 t -103.62 110.82 31.13 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.954 0 N-CA-C 106.913 -1.514 . . . . 0.0 106.913 177.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.475 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.51 -170.8 18.77 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.076 -2.012 . . . . 0.0 111.884 -177.587 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.525 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -115.96 -179.89 3.79 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 -179.167 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.586 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.4 p -171.05 167.3 7.23 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.515 -0.741 . . . . 0.0 109.317 -179.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.602 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -112.82 -160.13 0.71 Allowed 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.086 -1.009 . . . . 0.0 108.962 179.806 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -118.54 36.51 4.37 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.688 -1.258 . . . . 0.0 109.222 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.03 -32.91 4.6 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.332 -0.855 . . . . 0.0 110.174 -179.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.963 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.52 -36.91 0.22 Allowed Glycine 0 N--CA 1.48 1.624 0 N-CA-C 107.833 -2.107 . . . . 0.0 107.833 -179.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.74 -178.16 6.87 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.572 -0.958 . . . . 0.0 109.754 179.255 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.68 -161.45 14.73 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.257 -1.937 . . . . 0.0 108.257 -179.325 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.0 Cg_exo -47.6 179.65 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.82 1.31 . . . . 0.0 110.261 179.19 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -94.05 -170.54 2.33 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.066 -1.021 . . . . 0.0 110.334 -178.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.475 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.31 162.75 18.34 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.11 128.45 50.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.381 -1.07 . . . . 0.0 109.15 -179.536 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.592 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.24 119.64 15.67 Favored 'General case' 0 C--N 1.289 -2.056 0 O-C-N 121.669 -0.644 . . . . 0.0 109.738 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.884 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.12 171.31 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.219 -0.926 . . . . 0.0 109.097 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.497 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.01 156.62 47.07 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.074 -1.016 . . . . 0.0 109.844 -179.822 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.884 ' CE2' HD12 ' A' ' 110' ' ' ILE . 96.8 m-85 -131.09 110.44 11.19 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.191 -0.943 . . . . 0.0 109.609 -179.686 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.2 p30 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.492 -179.929 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.963 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.445 -0.576 . . . . 1.0 109.445 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -101.32 147.58 33.97 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.317 -0.865 . . . . 1.0 109.449 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.559 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.5 Cg_exo -60.06 158.14 31.25 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.322 2.015 . . . . 1.0 110.561 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.542 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.54 -169.85 0.15 Allowed 'General case' 0 C--N 1.297 -1.701 0 N-CA-C 108.177 -1.045 . . . . 1.0 108.177 179.206 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.542 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.35 130.0 2.44 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 120.873 -1.142 . . . . 1.0 110.597 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.948 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.6 t -110.31 108.67 18.83 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-O 123.085 1.421 . . . . 1.0 109.01 179.355 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.838 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -117.19 136.36 54.6 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.702 0 CA-C-N 114.3 -1.318 . . . . 1.0 110.002 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.456 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.31 148.76 2.43 Favored Pre-proline 0 N--CA 1.487 1.376 0 O-C-N 121.287 -0.883 . . . . 1.0 108.897 -179.64 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.456 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -79.21 148.67 82.13 Favored 'Cis proline' 0 C--N 1.311 -1.408 0 C-N-CA 123.438 -1.484 . . . . 1.0 109.52 -1.052 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.644 ' HA ' HG22 ' A' ' 110' ' ' ILE . 42.8 p -88.34 -25.5 22.71 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 108.981 -0.748 . . . . 1.0 108.981 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 0.7 OUTLIER -131.91 161.86 32.03 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.454 -0.779 . . . . 1.0 109.674 -179.787 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.88 37.63 29.14 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 108.592 -1.803 . . . . 1.0 108.592 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.79 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.2 mt -92.78 -43.54 8.97 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 123.099 1.428 . . . . 1.0 110.636 -178.343 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.14 145.19 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.295 0 CA-C-N 113.571 -1.65 . . . . 1.0 110.03 -179.596 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 14.8 p-10 -51.16 106.93 0.15 Allowed 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.462 0.648 . . . . 1.0 111.564 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.47 15.22 9.02 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 119.385 -1.388 . . . . 1.0 112.871 177.217 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.79 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.5 t -104.54 -171.69 1.97 Allowed 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 121.133 2.467 . . . . 1.0 109.671 179.204 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.727 HG13 ' C ' ' A' ' 67' ' ' LEU . 15.1 t -128.58 137.56 56.99 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.387 0 CA-C-N 114.874 -1.057 . . . . 1.0 110.979 -179.066 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.527 HG11 ' CD1' ' A' ' 13' ' ' LEU . 35.2 m -114.13 154.75 15.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 N-CA-C 108.808 -0.812 . . . . 1.0 108.808 179.036 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.65 109.23 20.37 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.226 -0.921 . . . . 1.0 108.797 179.718 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.838 HG23 HG22 ' A' ' 7' ' ' VAL . 2.2 p -103.82 141.6 19.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 108.727 -0.842 . . . . 1.0 108.727 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.948 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -138.24 160.23 39.99 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.72 -1.238 . . . . 1.0 109.982 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.76 144.21 15.37 Favored Glycine 0 C--N 1.295 -1.742 0 N-CA-C 108.089 -2.004 . . . . 1.0 108.089 179.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.559 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.11 125.53 13.16 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 120.913 -1.345 . . . . 1.0 108.828 179.028 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.534 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.08 27.09 26.89 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.216 -1.469 . . . . 1.0 109.912 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.576 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.8 mt -87.13 175.02 8.28 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 120.799 -1.412 . . . . 1.0 108.463 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.016 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.58 99.74 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.978 -1.076 . . . . 1.0 109.689 -179.79 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.563 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 77.76 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 115.226 -0.897 . . . . 1.0 110.247 -179.063 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.4 34.13 0.33 Allowed Glycine 0 N--CA 1.488 2.117 0 N-CA-C 109.496 -1.441 . . . . 1.0 109.496 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.56 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 42.9 p -141.24 108.56 5.53 Favored 'General case' 0 C--N 1.306 -1.302 0 O-C-N 121.123 -1.222 . . . . 1.0 111.311 -179.636 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.589 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.35 110.06 0.37 Allowed 'General case' 0 N--CA 1.497 1.888 0 CA-C-N 115.9 -0.591 . . . . 1.0 109.455 178.031 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.564 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 5.2 m-30 -106.75 155.99 19.12 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.133 -0.98 . . . . 1.0 108.982 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.486 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -99.82 165.17 11.7 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 107.876 -1.157 . . . . 1.0 107.876 179.045 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.692 HG13 ' O ' ' A' ' 34' ' ' VAL . 7.5 p -145.7 114.85 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.066 -1.021 . . . . 1.0 109.941 -178.048 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.01 -176.41 37.3 Favored Glycine 0 N--CA 1.492 2.398 0 C-N-CA 118.499 -1.81 . . . . 1.0 111.564 -179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.646 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.5 pt20 -100.1 110.02 22.31 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-O 121.941 0.877 . . . . 1.0 108.966 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -130.08 150.81 51.18 Favored 'General case' 0 C--N 1.296 -1.74 0 O-C-N 121.217 -0.927 . . . . 1.0 109.837 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.522 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -126.83 139.78 52.84 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.222 -0.924 . . . . 1.0 110.808 -179.037 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.897 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.15 114.78 26.61 Favored 'General case' 0 N--CA 1.494 1.726 0 N-CA-C 107.62 -1.252 . . . . 1.0 107.62 178.246 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -104.6 14.99 6.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 120.938 -1.101 . . . . 1.0 110.575 -178.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.762 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.61 -176.28 0.09 Allowed 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.863 -1.148 . . . . 1.0 110.184 179.716 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.769 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.89 97.47 1.42 Allowed 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.436 -0.79 . . . . 1.0 109.847 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.63 27.8 34.32 Favored Glycine 0 N--CA 1.493 2.493 0 C-N-CA 120.145 -1.026 . . . . 1.0 111.434 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.762 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.32 106.6 20.65 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 O-C-N 120.668 -1.489 . . . . 1.0 107.171 178.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.897 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.2 tp -116.06 104.67 11.8 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.449 -1.407 . . . . 1.0 109.982 -177.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.042 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.23 109.58 22.31 Favored 'General case' 0 N--CA 1.485 1.291 0 O-C-N 120.818 -1.176 . . . . 1.0 108.079 178.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.18 166.21 10.79 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.912 -1.117 . . . . 1.0 110.356 -178.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.73 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 46.0 t30 -112.01 129.85 23.84 Favored Pre-proline 0 N--CA 1.501 2.1 0 O-C-N 121.366 -0.834 . . . . 1.0 109.796 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.634 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.5 Cg_endo -71.65 22.31 0.25 Allowed 'Trans proline' 0 CA--C 1.545 1.056 0 C-N-CA 122.219 1.946 . . . . 1.0 112.342 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.73 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -109.87 2.79 20.08 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.415 -1.428 . . . . 1.0 109.049 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.571 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.65 18.87 2.52 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.135 -1.432 . . . . 1.0 107.135 179.41 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -82.13 89.73 6.5 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.934 -0.707 . . . . 1.0 111.127 -178.395 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -106.97 -166.87 1.21 Allowed 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 107.562 -1.273 . . . . 1.0 107.562 178.077 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.2 136.35 0.1 Allowed 'General case' 0 C--N 1.306 -1.307 0 O-C-N 120.538 -1.351 . . . . 1.0 111.304 -179.346 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.901 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -154.46 158.8 3.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.635 -1.246 . . . . 1.0 107.635 178.337 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.589 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.8 142.25 30.57 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.807 -1.183 . . . . 1.0 109.901 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.53 107.12 1.06 Allowed 'General case' 0 C--N 1.299 -1.602 0 CA-C-O 122.423 1.106 . . . . 1.0 109.295 178.253 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.552 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.2 p-10 -58.88 -138.84 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.583 -0.735 . . . . 1.0 110.821 179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.563 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -54.65 -49.81 69.68 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.374 -0.829 . . . . 1.0 110.231 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.421 ' OD1' ' N ' ' A' ' 61' ' ' GLY . 12.3 p30 -100.23 -38.82 8.33 Favored 'General case' 0 C--N 1.285 -2.219 0 N-CA-C 106.122 -1.807 . . . . 1.0 106.122 178.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.999 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.92 65.93 0.55 Allowed Glycine 0 C--N 1.296 -1.648 0 N-CA-C 110.239 -1.144 . . . . 1.0 110.239 178.263 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.4 m -102.82 129.12 49.39 Favored 'General case' 0 N--CA 1.483 1.19 0 O-C-N 121.49 -1.006 . . . . 1.0 108.948 179.043 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.901 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.17 108.87 6.61 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 119.274 -0.971 . . . . 1.0 109.921 -179.371 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.483 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -124.02 120.96 33.97 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.244 -0.91 . . . . 1.0 109.801 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.465 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -146.44 149.48 33.78 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.486 -0.759 . . . . 1.0 109.07 179.587 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.5 p -100.31 145.62 27.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.312 -0.867 . . . . 1.0 109.741 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.727 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -145.95 165.81 27.87 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.472 -0.768 . . . . 1.0 109.242 -179.457 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.693 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -96.53 124.88 40.66 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.0 -1.063 . . . . 1.0 109.477 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.535 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.0 m -138.74 143.1 32.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 120.972 -1.08 . . . . 1.0 109.808 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.596 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.6 ptt180 -140.02 -163.46 1.51 Allowed 'General case' 0 N--CA 1.486 1.351 0 O-C-N 120.593 -1.317 . . . . 1.0 109.871 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.571 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -75.03 -82.28 0.07 Allowed 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.083 -1.011 . . . . 1.0 108.87 -179.609 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.491 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -62.75 137.51 58.28 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.305 -1.497 . . . . 1.0 107.357 178.861 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.563 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.2 OUTLIER -163.22 134.09 4.69 Favored 'General case' 0 C--N 1.293 -1.863 0 C-N-CA 118.045 -1.462 . . . . 1.0 110.522 -177.656 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.486 ' HB2' ' OD1' ' A' ' 48' ' ' ASN . 3.6 mm-40 -32.56 121.21 0.33 Allowed 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 121.642 0.734 . . . . 1.0 110.773 -178.357 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.042 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.06 49.78 3.05 Favored Glycine 0 N--CA 1.496 2.649 0 C-N-CA 120.754 -0.736 . . . . 1.0 111.546 -179.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.634 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-30 -38.57 115.42 0.46 Allowed 'General case' 0 N--CA 1.511 2.594 0 O-C-N 121.028 -1.277 . . . . 1.0 110.14 179.318 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.794 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.05 125.89 34.4 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.857 -1.152 . . . . 1.0 109.744 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.59 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.3 t80 -64.68 58.26 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.927 0 O-C-N 120.86 -1.15 . . . . 1.0 109.869 179.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -158.08 18.47 0.24 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.035 -1.04 . . . . 1.0 109.677 -179.948 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.21 -27.56 6.11 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.919 -1.272 . . . . 1.0 109.919 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -98.17 164.7 12.21 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.069 -1.253 . . . . 1.0 110.337 -179.482 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.519 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.13 140.35 41.46 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.858 -0.793 . . . . 1.0 108.858 179.958 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.794 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.2 t90 -84.2 -22.34 30.95 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.845 -1.159 . . . . 1.0 110.604 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.73 175.13 17.55 Favored Glycine 0 N--CA 1.485 1.922 0 N-CA-C 108.688 -1.765 . . . . 1.0 108.688 -179.484 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.67 112.0 2.65 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.712 -1.218 . . . . 1.0 107.712 179.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.642 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.3 t -84.55 103.95 12.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 O-C-N 121.289 -0.882 . . . . 1.0 108.928 -179.049 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.622 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -66.58 111.65 3.74 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.357 -0.839 . . . . 1.0 109.645 -179.439 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.571 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.38 -5.3 4.97 Favored 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 118.172 -1.411 . . . . 1.0 109.948 179.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 45.5 p -84.39 0.46 49.3 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.75 -1.219 . . . . 1.0 108.772 179.195 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.622 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -115.84 -50.35 2.69 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.392 -0.817 . . . . 1.0 109.054 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.29 -178.01 3.54 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.508 -0.745 . . . . 1.0 109.514 179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.09 115.36 30.04 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.369 -0.832 . . . . 1.0 108.95 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.523 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -97.29 123.2 41.02 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.901 -1.125 . . . . 1.0 109.917 -179.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.6 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.28 148.2 26.62 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-O 122.373 1.082 . . . . 1.0 111.102 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.434 ' CG1' HG11 ' A' ' 7' ' ' VAL . 61.1 t -103.23 110.2 29.09 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 N-CA-C 106.721 -1.585 . . . . 1.0 106.721 177.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.452 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.46 -172.78 18.7 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 118.08 -2.01 . . . . 1.0 111.679 -177.614 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.483 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -114.77 179.88 3.82 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 108.945 -0.761 . . . . 1.0 108.945 -179.175 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.581 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 66.9 p -167.95 162.21 13.29 Favored 'General case' 0 C--N 1.295 -1.766 0 O-C-N 121.472 -0.768 . . . . 1.0 109.291 -179.279 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.564 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -108.9 -159.92 0.7 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.194 -0.941 . . . . 1.0 108.703 179.61 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -119.13 36.12 4.58 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.613 -1.305 . . . . 1.0 109.264 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -119.07 -31.77 4.63 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.338 -0.851 . . . . 1.0 110.372 -179.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 1.021 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 166.84 -36.72 0.24 Allowed Glycine 0 N--CA 1.482 1.722 0 N-CA-C 107.742 -2.143 . . . . 1.0 107.742 -179.5 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.43 -177.96 6.92 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.675 -0.897 . . . . 1.0 109.935 179.254 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.7 -163.84 19.94 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 108.319 -1.912 . . . . 1.0 108.319 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.4 Cg_exo -47.68 177.88 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.67 0 CA-C-N 118.763 1.281 . . . . 1.0 110.233 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -94.86 -176.25 3.8 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.236 -0.915 . . . . 1.0 110.186 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.452 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.68 163.98 13.06 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.787 -1.325 . . . . 1.0 109.787 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.5 132.35 46.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.381 -1.07 . . . . 1.0 109.063 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.6 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.0 125.44 27.62 Favored 'General case' 0 C--N 1.29 -2.017 0 O-C-N 121.649 -0.657 . . . . 1.0 109.868 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.87 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.67 171.95 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.356 -0.84 . . . . 1.0 108.953 179.611 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.4 OUTLIER -136.51 156.27 48.83 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.118 -0.989 . . . . 1.0 109.58 -179.925 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.87 ' CE1' HD12 ' A' ' 110' ' ' ILE . 93.0 m-85 -128.27 66.46 1.38 Allowed 'General case' 0 N--CA 1.484 1.274 0 O-C-N 121.134 -0.979 . . . . 1.0 109.506 -179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.439 ' O ' ' OD1' ' A' ' 113' ' ' ASN . 17.7 p30 . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 118.041 -0.98 . . . . 1.0 109.565 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 1.021 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 121.301 0.572 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.951 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -123.7 173.81 4.17 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.285 -0.884 . . . . 0.0 109.505 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.951 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 4.9 Cg_exo -60.45 157.01 38.19 Favored 'Trans proline' 0 C--N 1.311 -1.442 0 C-N-CA 122.313 2.009 . . . . 0.0 110.843 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.554 HG23 ' HB3' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -179.89 -169.64 0.13 Allowed 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 179.228 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.547 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . -167.74 133.19 1.94 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.698 -1.251 . . . . 0.0 111.047 -179.354 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.005 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -100.88 104.32 15.53 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-O 122.407 1.099 . . . . 0.0 109.816 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.944 HG22 HG23 ' A' ' 21' ' ' VAL . 6.2 t -119.79 118.0 55.66 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.459 0 CA-C-O 121.694 0.759 . . . . 0.0 110.405 179.795 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.78 149.08 7.93 Favored Pre-proline 0 N--CA 1.488 1.425 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 -179.568 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -75.26 152.85 98.33 Favored 'Cis proline' 0 C--N 1.309 -1.535 0 C-N-CA 123.583 -1.424 . . . . 0.0 109.762 -0.301 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.658 ' HA ' HG22 ' A' ' 110' ' ' ILE . 6.5 m -91.5 -25.0 19.48 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.498 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.8 m -137.85 165.1 27.3 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.637 -0.664 . . . . 0.0 109.253 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.27 37.49 31.8 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 108.564 -1.814 . . . . 0.0 108.564 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.741 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.0 mt -92.07 -42.43 9.95 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 123.311 1.529 . . . . 0.0 110.522 -178.487 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.67 142.67 0.05 OUTLIER 'General case' 0 C--N 1.259 -3.327 0 CA-C-N 113.405 -1.725 . . . . 0.0 109.731 -179.644 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.607 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.6 p-10 -50.28 105.78 0.1 Allowed 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.521 0.677 . . . . 0.0 111.473 -178.549 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.49 14.22 8.33 Favored Glycine 0 N--CA 1.485 1.928 0 C-N-CA 119.413 -1.375 . . . . 0.0 113.018 177.37 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.741 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -106.3 -172.57 2.11 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-N 121.221 2.51 . . . . 0.0 109.832 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.852 HG22 HG22 ' A' ' 68' ' ' THR . 18.8 t -129.0 139.76 51.04 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.279 0 CA-C-N 114.823 -1.08 . . . . 0.0 111.204 -178.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.63 HG11 HD11 ' A' ' 13' ' ' LEU . 27.1 m -115.88 155.61 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.553 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.7 tttt -107.86 108.79 20.11 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.021 -1.05 . . . . 0.0 109.552 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.944 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -106.8 122.67 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.005 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.83 167.48 11.36 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 120.795 -1.191 . . . . 0.0 109.064 -179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.86 142.44 13.95 Favored Glycine 0 C--N 1.295 -1.733 0 N-CA-C 107.935 -2.066 . . . . 0.0 107.935 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.595 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -147.16 123.7 11.07 Favored 'General case' 0 C--N 1.294 -1.834 0 O-C-N 120.812 -1.405 . . . . 0.0 108.64 179.237 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.19 27.25 23.72 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 119.313 -1.422 . . . . 0.0 109.838 -179.595 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.534 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.6 mt -87.73 175.14 8.0 Favored 'General case' 0 C--N 1.308 -1.236 0 O-C-N 120.877 -1.367 . . . . 0.0 108.466 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.61 96.95 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.017 -1.052 . . . . 0.0 109.541 -179.899 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.699 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.49 76.76 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.791 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.533 -178.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.44 33.49 0.3 Allowed Glycine 0 N--CA 1.486 2.016 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.198 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.618 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.6 t -147.12 114.55 6.31 Favored 'General case' 0 C--N 1.308 -1.223 0 O-C-N 120.791 -1.417 . . . . 0.0 111.173 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.82 127.32 6.27 Favored 'General case' 0 N--CA 1.49 1.528 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.689 178.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.618 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 9.1 m-85 -116.33 148.61 40.4 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.529 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -101.21 149.33 24.11 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.805 -1.185 . . . . 0.0 107.92 179.135 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.634 HG23 HD23 ' A' ' 97' ' ' LEU . 1.0 OUTLIER -127.43 126.7 67.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.271 -0.893 . . . . 0.0 109.371 -177.935 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -174.52 174.97 46.79 Favored Glycine 0 N--CA 1.495 2.612 0 C-N-CA 117.833 -2.127 . . . . 0.0 112.42 -179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.585 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -101.36 108.47 20.1 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.473 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.8 m -131.24 147.92 52.64 Favored 'General case' 0 C--N 1.295 -1.772 0 O-C-N 121.251 -0.905 . . . . 0.0 109.942 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.43 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.02 139.04 53.84 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.394 -0.816 . . . . 0.0 110.609 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.879 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.42 115.03 26.87 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 178.159 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -106.11 14.85 7.41 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 120.963 -1.085 . . . . 0.0 110.529 -178.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.776 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.14 -174.61 0.08 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.848 -1.157 . . . . 0.0 110.121 179.667 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 5.9 p -71.46 96.78 1.54 Allowed 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.46 -0.775 . . . . 0.0 109.931 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 27.83 32.9 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 120.171 -1.014 . . . . 0.0 111.558 178.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.776 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.26 106.28 20.24 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 O-C-N 120.552 -1.558 . . . . 0.0 107.267 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.879 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.3 tp -117.37 104.92 11.61 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.454 -1.404 . . . . 0.0 109.913 -177.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.038 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.84 109.61 22.33 Favored 'General case' 0 N--CA 1.485 1.287 0 O-C-N 120.706 -1.246 . . . . 0.0 108.296 178.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.3 t -105.97 163.93 12.36 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.041 -1.037 . . . . 0.0 110.198 -178.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.623 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 20.0 t30 -107.36 139.12 20.19 Favored Pre-proline 0 N--CA 1.502 2.16 0 O-C-N 121.327 -0.858 . . . . 0.0 109.81 -179.372 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.569 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 7.8 Cg_endo -75.88 27.73 0.39 Allowed 'Trans proline' 0 C--N 1.32 -0.964 0 C-N-CA 122.59 2.194 . . . . 0.0 112.135 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.623 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -124.44 9.61 8.47 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.242 -1.536 . . . . 0.0 109.679 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.567 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.46 15.63 2.76 Favored 'General case' 0 C--N 1.297 -1.688 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.403 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -77.69 86.92 3.97 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.856 -0.737 . . . . 0.0 111.421 -178.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.605 ' CB ' HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.34 -169.77 1.85 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 177.954 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.71 134.65 0.08 Allowed 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.57 -1.331 . . . . 0.0 111.454 -179.392 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.912 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -160.47 154.73 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 178.18 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.568 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.56 144.83 26.85 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.741 -1.225 . . . . 0.0 109.572 -179.853 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.07 106.74 1.69 Allowed 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 122.48 1.134 . . . . 0.0 109.476 178.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.545 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.5 p-10 -59.78 -138.83 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.982 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.893 -179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.699 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.37 -50.44 59.56 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.467 -0.771 . . . . 0.0 110.548 -178.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 5.3 t-20 -104.97 -34.63 7.95 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 178.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.966 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.88 68.32 0.59 Allowed Glycine 0 C--N 1.298 -1.543 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 177.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 59.4 m -103.21 129.23 50.08 Favored 'General case' 0 N--CA 1.484 1.274 0 O-C-N 121.358 -1.084 . . . . 0.0 108.83 178.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.912 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.12 109.27 7.75 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.281 -0.967 . . . . 0.0 110.073 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 10.6 m -110.23 118.38 36.19 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.205 -0.934 . . . . 0.0 108.787 179.499 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.458 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.24 139.08 28.45 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.436 -0.79 . . . . 0.0 110.253 -179.514 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 78.8 p -103.18 140.79 36.9 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 179.416 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.759 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -142.84 164.1 31.02 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.173 -0.955 . . . . 0.0 109.994 -179.148 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.852 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -97.59 125.49 42.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.339 -0.851 . . . . 0.0 109.129 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.553 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.2 m -136.44 143.64 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.908 -1.12 . . . . 0.0 109.803 -179.087 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.607 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -146.7 -176.12 5.06 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.44 -1.413 . . . . 0.0 111.156 -179.787 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.613 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.91 -100.54 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 -179.581 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.05 140.4 49.27 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 179.353 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.586 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.44 135.94 6.16 Favored 'General case' 0 C--N 1.294 -1.817 0 C-N-CA 118.584 -1.246 . . . . 0.0 109.764 -177.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.553 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 3.9 mm-40 -33.07 121.47 0.37 Allowed 'General case' 0 N--CA 1.493 1.677 0 CA-C-O 121.547 0.689 . . . . 0.0 110.431 -178.482 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.038 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.89 48.08 2.74 Favored Glycine 0 N--CA 1.492 2.408 0 C-N-CA 120.602 -0.808 . . . . 0.0 111.195 -179.177 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.569 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -38.22 115.18 0.42 Allowed 'General case' 0 N--CA 1.511 2.623 0 O-C-N 121.118 -1.225 . . . . 0.0 109.974 179.695 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.689 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.29 125.76 34.42 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.944 -1.098 . . . . 0.0 109.321 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.595 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 19.6 t80 -64.2 58.65 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.891 -1.131 . . . . 0.0 110.215 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t0 -160.67 20.0 0.14 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.973 -1.079 . . . . 0.0 109.749 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.93 -27.8 5.3 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.439 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 80.7 p -94.22 159.42 15.14 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.038 -1.272 . . . . 0.0 110.269 -179.386 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.495 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 4.4 ptt180 -107.32 137.59 45.09 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.689 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.9 t90 -83.76 -18.51 37.53 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.821 -1.174 . . . . 0.0 110.79 -178.231 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.97 175.08 19.8 Favored Glycine 0 N--CA 1.485 1.937 0 N-CA-C 108.711 -1.755 . . . . 0.0 108.711 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.21 106.77 1.15 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.604 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.4 t -79.1 106.41 10.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.286 -0.884 . . . . 0.0 109.264 -179.025 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.638 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -65.84 111.13 3.12 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.533 -0.73 . . . . 0.0 109.904 -179.442 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.613 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.26 -4.97 4.21 Favored 'General case' 0 N--CA 1.499 1.98 0 C-N-CA 118.246 -1.382 . . . . 0.0 109.814 179.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -86.39 -0.49 56.06 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.891 -1.131 . . . . 0.0 109.156 179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.638 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -113.31 -50.05 2.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.392 -0.818 . . . . 0.0 109.013 -179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.74 179.96 4.12 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.453 -0.779 . . . . 0.0 109.427 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.69 115.73 31.03 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.366 -0.834 . . . . 0.0 109.103 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.72 121.07 38.16 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.917 -1.114 . . . . 0.0 109.383 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.605 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.18 146.15 27.2 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-O 122.273 1.035 . . . . 0.0 111.193 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.447 ' HB ' HG11 ' A' ' 7' ' ' VAL . 71.7 t -105.73 112.2 38.12 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.001 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 178.168 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.516 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -152.49 -169.98 18.44 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 118.018 -2.039 . . . . 0.0 111.578 -178.011 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.634 HD23 HG23 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -112.64 -179.0 3.54 Favored 'General case' 0 N--CA 1.484 1.272 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -179.189 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.584 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -171.83 167.35 6.33 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.17 -0.956 . . . . 0.0 109.826 -179.402 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.89 -160.04 0.71 Allowed 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.108 -0.995 . . . . 0.0 108.822 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -119.69 35.64 4.78 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.614 -1.304 . . . . 0.0 109.452 -179.805 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.49 -32.37 4.63 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.359 -0.838 . . . . 0.0 110.219 -179.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.94 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 170.18 -38.45 0.19 Allowed Glycine 0 N--CA 1.481 1.679 0 N-CA-C 107.709 -2.156 . . . . 0.0 107.709 -179.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.473 ' ND2' ' O9 ' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -161.26 -177.73 6.22 Favored 'General case' 0 C--N 1.307 -1.266 0 O-C-N 121.553 -0.969 . . . . 0.0 109.681 179.212 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.497 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -162.57 -159.47 10.37 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 108.275 -1.93 . . . . 0.0 108.275 -179.215 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.497 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.4 Cg_exo -47.21 179.98 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.675 0 CA-C-N 118.667 1.234 . . . . 0.0 110.37 179.183 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.6 mt-10 -92.57 -178.27 4.84 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.033 -1.042 . . . . 0.0 110.645 -178.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.516 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.02 163.57 13.25 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.402 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.08 128.79 54.34 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.422 -1.046 . . . . 0.0 109.214 -179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.605 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.86 119.04 15.48 Favored 'General case' 0 C--N 1.29 -2.016 0 O-C-N 121.721 -0.612 . . . . 0.0 109.491 179.576 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.897 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.01 171.52 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.248 -0.908 . . . . 0.0 109.042 179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.498 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -138.8 159.59 41.74 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.161 -0.962 . . . . 0.0 109.986 -179.696 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.897 ' CE2' HD12 ' A' ' 110' ' ' ILE . 96.8 m-85 -135.23 103.3 5.47 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.18 -0.95 . . . . 0.0 109.582 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 16.8 p30 . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.462 179.93 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.94 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -120.27 152.36 54.67 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.337 -0.852 . . . . 0.0 109.401 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.559 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.2 Cg_exo -60.17 157.73 33.57 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 C-N-CA 122.34 2.027 . . . . 0.0 110.65 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.544 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.48 -169.9 0.15 Allowed 'General case' 0 C--N 1.296 -1.728 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.047 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.545 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -164.58 129.9 2.75 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 120.881 -1.137 . . . . 0.0 110.429 -179.218 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.941 HG22 ' HB3' ' A' ' 22' ' ' ALA . 7.4 t -109.74 108.69 19.13 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 123.05 1.405 . . . . 0.0 109.286 179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.815 HG22 HG23 ' A' ' 21' ' ' VAL . 1.3 t -116.32 136.35 53.59 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.689 0 CA-C-N 114.164 -1.38 . . . . 0.0 109.903 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.461 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -172.88 149.05 1.78 Allowed Pre-proline 0 N--CA 1.487 1.405 0 O-C-N 121.194 -0.941 . . . . 0.0 108.883 -179.616 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.461 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.2 Cg_endo -77.24 151.33 93.05 Favored 'Cis proline' 0 C--N 1.313 -1.332 0 C-N-CA 123.404 -1.498 . . . . 0.0 109.323 -0.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 16.6 p -86.83 -26.86 23.84 Favored 'General case' 0 C--N 1.295 -1.803 0 O-C-N 121.455 -0.778 . . . . 0.0 109.169 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.498 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.4 m -134.62 168.23 19.38 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.409 -0.807 . . . . 0.0 109.463 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.03 38.51 35.16 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 108.359 -1.896 . . . . 0.0 108.359 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.744 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.2 mt -94.81 -42.61 8.62 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 123.186 1.47 . . . . 0.0 110.65 -178.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.91 143.69 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.289 0 CA-C-N 113.334 -1.757 . . . . 0.0 109.889 -179.55 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 11.9 p-10 -50.3 104.62 0.08 Allowed 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 121.53 0.681 . . . . 0.0 111.469 -178.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.17 14.44 7.74 Favored Glycine 0 N--CA 1.485 1.91 0 C-N-CA 119.321 -1.419 . . . . 0.0 113.09 177.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.744 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.5 t -106.47 -172.47 2.09 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 121.336 2.568 . . . . 0.0 109.876 179.312 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.744 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.4 t -128.21 136.78 59.24 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.328 0 CA-C-N 114.733 -1.121 . . . . 0.0 111.242 -178.741 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.64 HG11 HD11 ' A' ' 13' ' ' LEU . 27.8 m -111.08 157.22 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.521 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 4.0 tptm -106.83 109.17 21.01 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.033 -1.042 . . . . 0.0 108.933 179.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.815 HG23 HG22 ' A' ' 7' ' ' VAL . 7.6 p -103.55 141.05 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.941 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -138.79 161.52 37.03 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.718 -1.238 . . . . 0.0 110.061 179.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.594 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.46 143.69 15.01 Favored Glycine 0 C--N 1.294 -1.763 0 N-CA-C 108.355 -1.898 . . . . 0.0 108.355 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.559 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.14 125.68 13.27 Favored 'General case' 0 C--N 1.295 -1.774 0 O-C-N 120.914 -1.345 . . . . 0.0 108.996 178.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.536 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 87.45 25.92 31.82 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 119.312 -1.423 . . . . 0.0 110.116 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.601 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.2 mt -86.15 172.55 10.46 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 120.937 -1.331 . . . . 0.0 108.474 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.015 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.76 100.14 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.009 -1.057 . . . . 0.0 109.651 -179.704 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.562 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 77.83 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.147 -179.165 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.81 34.03 0.32 Allowed Glycine 0 N--CA 1.487 2.079 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 179.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.565 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.7 p -140.71 108.13 5.56 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 121.183 -1.186 . . . . 0.0 111.153 -179.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.586 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.98 111.64 0.59 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.769 -0.651 . . . . 0.0 109.535 177.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.464 ' OH ' ' HB2' ' A' ' 27' ' ' GLN . 6.0 m-30 -107.14 156.34 18.91 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.129 -0.982 . . . . 0.0 108.935 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.475 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.8 160.5 14.22 Favored 'General case' 0 N--CA 1.488 1.431 0 N-CA-C 107.856 -1.165 . . . . 0.0 107.856 178.933 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.632 HG22 HG11 ' A' ' 21' ' ' VAL . 5.3 p -140.94 119.26 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.129 -0.982 . . . . 0.0 109.678 -177.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -171.64 -177.36 41.27 Favored Glycine 0 N--CA 1.494 2.513 0 C-N-CA 118.443 -1.836 . . . . 0.0 111.532 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.684 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -98.73 109.13 21.93 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.723 0.773 . . . . 0.0 108.944 -179.95 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -129.09 149.35 50.94 Favored 'General case' 0 C--N 1.295 -1.783 0 O-C-N 121.236 -0.915 . . . . 0.0 109.964 179.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.586 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.92 138.88 54.23 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.255 -0.903 . . . . 0.0 110.838 -179.009 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.05 26.9 Favored 'General case' 0 N--CA 1.494 1.734 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.037 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -105.32 15.16 6.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.903 -1.123 . . . . 0.0 110.585 -178.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.751 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.03 -175.29 0.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.886 -1.134 . . . . 0.0 110.08 179.722 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -72.37 97.41 2.04 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.394 -0.816 . . . . 0.0 109.687 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.34 27.97 31.65 Favored Glycine 0 N--CA 1.493 2.45 0 C-N-CA 120.177 -1.011 . . . . 0.0 111.385 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.751 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.92 106.43 20.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 O-C-N 120.534 -1.568 . . . . 0.0 107.165 178.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.48 104.72 11.72 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.479 -1.388 . . . . 0.0 109.937 -177.533 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.058 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.0 109.63 22.35 Favored 'General case' 0 N--CA 1.486 1.363 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 178.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.486 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -108.52 162.42 14.15 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.876 -1.14 . . . . 0.0 110.54 -178.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.502 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 7.8 t30 -108.72 130.3 22.91 Favored Pre-proline 0 N--CA 1.499 2.004 0 O-C-N 121.551 -0.718 . . . . 0.0 109.553 -179.377 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.592 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.56 21.35 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.078 0 C-N-CA 122.028 1.819 . . . . 0.0 112.021 179.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.502 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -99.41 -3.99 32.53 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.421 -1.424 . . . . 0.0 108.995 179.409 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.68 ' OD2' HG13 ' A' ' 69' ' ' VAL . 5.9 m-20 -135.62 9.89 3.4 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -66.84 86.18 0.13 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.499 -0.75 . . . . 0.0 111.059 -178.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.612 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -108.5 -167.29 1.21 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 177.912 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.32 134.47 0.09 Allowed 'General case' 0 C--N 1.305 -1.34 0 O-C-N 120.503 -1.373 . . . . 0.0 111.451 -179.22 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.866 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -150.24 157.77 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 177.923 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.586 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.71 142.72 29.91 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.766 -1.209 . . . . 0.0 110.113 -179.685 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.015 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.67 107.12 1.09 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.398 1.094 . . . . 0.0 109.336 178.338 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.547 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -59.37 -139.08 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.056 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.856 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.562 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.73 -49.84 64.61 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.462 -0.774 . . . . 0.0 110.496 -178.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.477 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.6 t-20 -103.57 -35.17 8.4 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 178.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.009 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.95 66.78 0.58 Allowed Glycine 0 C--N 1.298 -1.579 0 N-CA-C 110.388 -1.085 . . . . 0.0 110.388 177.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.9 m -104.54 128.92 52.62 Favored 'General case' 0 C--N 1.308 -1.223 0 O-C-N 121.308 -1.113 . . . . 0.0 108.683 178.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.866 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.69 109.91 8.92 Favored 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.184 -1.006 . . . . 0.0 109.668 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 91.7 p -117.75 117.77 30.24 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.367 -0.833 . . . . 0.0 109.481 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.547 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -147.31 151.29 36.34 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.422 -0.799 . . . . 0.0 109.42 -179.957 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.748 ' O ' HD23 ' A' ' 67' ' ' LEU . 69.6 p -98.52 153.57 18.53 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.304 -0.872 . . . . 0.0 109.571 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.785 HD11 HG11 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -147.92 160.1 43.17 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.339 -0.851 . . . . 0.0 109.634 -179.176 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.653 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -100.55 122.85 43.92 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.971 -1.08 . . . . 0.0 108.58 179.261 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.684 HG12 ' HB3' ' A' ' 36' ' ' GLN . 19.2 m -136.41 143.06 36.64 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 120.799 -1.188 . . . . 0.0 110.459 -178.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.1 ptt180 -146.43 -175.27 4.71 Favored 'General case' 0 N--CA 1.483 1.205 0 O-C-N 120.749 -1.219 . . . . 0.0 110.663 179.654 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.604 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.79 -102.03 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 -179.733 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.496 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -56.02 140.27 43.99 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.761 -1.212 . . . . 0.0 108.244 179.401 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.586 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.4 OUTLIER -160.74 137.93 9.13 Favored 'General case' 0 C--N 1.295 -1.764 0 C-N-CA 118.672 -1.211 . . . . 0.0 110.009 -178.285 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.484 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.7 OUTLIER -35.43 120.68 0.57 Allowed 'General case' 0 N--CA 1.49 1.563 0 CA-C-O 121.522 0.677 . . . . 0.0 110.618 -178.439 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.058 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.17 50.47 2.18 Favored Glycine 0 N--CA 1.493 2.486 0 O-C-N 121.551 -0.718 . . . . 0.0 111.37 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.592 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.8 m-85 -39.11 114.87 0.43 Allowed 'General case' 0 N--CA 1.511 2.616 0 O-C-N 120.947 -1.325 . . . . 0.0 109.89 179.536 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.724 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -87.25 125.24 34.07 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 120.771 -1.206 . . . . 0.0 109.306 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.573 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 18.7 t80 -64.78 56.31 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.062 0 O-C-N 120.742 -1.224 . . . . 0.0 110.491 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.618 ' OD2' HD23 ' A' ' 77' ' ' LEU . 2.9 p30 -154.79 16.18 0.44 Allowed 'General case' 0 C--N 1.303 -1.421 0 O-C-N 120.998 -1.064 . . . . 0.0 109.859 179.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 91.53 -27.03 10.18 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 179.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.427 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -100.87 161.17 13.78 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.901 -1.352 . . . . 0.0 110.38 -179.408 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.434 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 3.6 ptm180 -103.77 139.36 39.11 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.605 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.724 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.2 t90 -82.44 -19.83 38.17 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.917 -1.114 . . . . 0.0 110.599 -178.276 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.64 175.66 18.71 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -66.41 104.77 1.3 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.174 -1.192 . . . . 0.0 107.848 179.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.648 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.7 t -75.31 106.88 5.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.286 -0.884 . . . . 0.0 109.56 -178.736 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.665 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -64.97 110.65 2.53 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.421 -0.8 . . . . 0.0 109.759 -179.679 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.604 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.23 -5.18 4.53 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 120.533 -1.354 . . . . 0.0 109.766 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.7 p -86.45 -0.28 55.67 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.779 -1.2 . . . . 0.0 109.136 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.665 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -114.52 -51.24 2.76 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.326 -0.859 . . . . 0.0 109.026 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.403 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -102.85 -178.83 3.78 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.445 -0.784 . . . . 0.0 109.413 179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.68 115.05 29.59 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.868 . . . . 0.0 108.983 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -96.91 122.18 39.6 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.855 -1.153 . . . . 0.0 109.478 -179.247 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.611 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.28 145.64 29.16 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-O 122.341 1.067 . . . . 0.0 111.284 -179.321 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.653 ' CG1' HG11 ' A' ' 7' ' ' VAL . 99.5 t -101.59 109.79 26.78 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.685 -1.598 . . . . 0.0 106.685 177.637 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.509 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.95 -169.56 17.58 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.052 -2.023 . . . . 0.0 111.733 -177.536 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.545 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -120.79 177.47 5.08 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 -179.1 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.583 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 2.5 t 179.21 171.91 0.89 Allowed 'General case' 0 C--N 1.292 -1.923 0 O-C-N 121.588 -0.695 . . . . 0.0 109.59 179.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -116.01 -160.17 0.74 Allowed 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.0 -1.063 . . . . 0.0 109.001 -179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -117.95 36.68 4.23 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.723 -1.236 . . . . 0.0 109.138 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -112.18 -32.38 6.56 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.324 -0.86 . . . . 0.0 109.805 -179.672 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.519 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 169.4 -37.64 0.2 Allowed Glycine 0 N--CA 1.481 1.684 0 N-CA-C 108.143 -1.983 . . . . 0.0 108.143 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -167.78 -176.88 3.25 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 121.62 -0.93 . . . . 0.0 109.853 179.358 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.1 -160.7 16.32 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.315 -1.914 . . . . 0.0 108.315 -179.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.3 Cg_exo -47.2 179.25 0.0 OUTLIER 'Trans proline' 0 C--O 1.216 -0.607 0 CA-C-N 118.829 1.315 . . . . 0.0 110.395 179.324 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.3 pt-20 -96.22 -175.69 3.44 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.028 -1.045 . . . . 0.0 110.309 -179.099 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.509 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.91 163.82 13.74 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.41 HG11 ' HB ' ' A' ' 7' ' ' VAL . 1.2 t -99.0 127.36 51.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.39 -1.065 . . . . 0.0 109.062 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.611 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -70.34 120.42 15.97 Favored 'General case' 0 C--N 1.289 -2.022 0 O-C-N 121.778 -0.576 . . . . 0.0 109.662 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.875 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.98 170.55 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 O-C-N 121.234 -0.916 . . . . 0.0 109.131 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.498 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.99 157.56 45.47 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.263 -0.898 . . . . 0.0 109.895 -179.717 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.875 ' CE2' HD12 ' A' ' 110' ' ' ILE . 91.7 m-85 -134.22 113.66 12.24 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 121.271 -0.893 . . . . 0.0 109.587 -179.62 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.4 p30 . . . . . 0 N--CA 1.489 1.5 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.461 -179.863 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.852 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.468 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -120.94 157.96 53.61 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.267 -0.895 . . . . 0.0 109.486 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.569 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.9 Cg_exo -59.47 158.23 28.2 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.281 1.987 . . . . 0.0 110.455 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.539 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.47 -169.72 0.15 Allowed 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 179.275 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.539 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.89 130.55 2.31 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.754 -1.216 . . . . 0.0 110.762 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.94 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -111.35 108.63 18.29 Favored 'General case' 0 C--N 1.295 -1.762 0 CA-C-O 123.068 1.413 . . . . 0.0 109.084 179.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.831 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -115.26 140.68 35.44 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.73 0 CA-C-N 114.321 -1.308 . . . . 0.0 110.26 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.476 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -175.56 149.07 1.06 Allowed Pre-proline 0 N--CA 1.487 1.396 0 O-C-N 121.337 -0.852 . . . . 0.0 108.854 -179.751 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.476 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.3 Cg_endo -78.63 150.47 87.33 Favored 'Cis proline' 0 C--N 1.311 -1.399 0 C-N-CA 123.36 -1.516 . . . . 0.0 109.09 -0.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.67 ' HA ' HG22 ' A' ' 110' ' ' ILE . 75.9 p -89.73 -24.58 21.5 Favored 'General case' 0 C--N 1.291 -1.947 0 O-C-N 121.53 -0.731 . . . . 0.0 109.358 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.507 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 12.9 m -134.83 162.8 31.35 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.346 -0.846 . . . . 0.0 109.757 -179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.88 37.67 29.06 Favored Glycine 0 N--CA 1.496 2.667 0 N-CA-C 108.604 -1.798 . . . . 0.0 108.604 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.78 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.0 mt -92.56 -44.24 8.72 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-O 123.19 1.472 . . . . 0.0 110.606 -178.369 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.457 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.66 144.07 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.331 0 CA-C-N 113.48 -1.691 . . . . 0.0 110.135 -179.775 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.616 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.2 p-10 -49.74 107.84 0.17 Allowed 'General case' 0 C--N 1.301 -1.526 0 CA-C-O 121.712 0.768 . . . . 0.0 111.471 -178.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.47 12.93 9.22 Favored Glycine 0 N--CA 1.484 1.855 0 C-N-CA 119.45 -1.357 . . . . 0.0 112.939 177.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.78 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.6 t -105.76 -173.05 2.21 Favored 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 121.251 2.525 . . . . 0.0 109.663 179.237 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.74 HG13 ' C ' ' A' ' 67' ' ' LEU . 20.9 t -127.1 135.01 64.79 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.45 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.035 -178.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.601 ' CG1' HD13 ' A' ' 13' ' ' LEU . 36.0 m -108.68 155.53 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 178.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -113.58 109.4 18.56 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.092 -1.005 . . . . 0.0 108.945 179.885 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.831 HG23 HG22 ' A' ' 7' ' ' VAL . 2.2 p -104.58 140.56 22.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.94 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.24 160.09 39.48 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 118.691 -1.204 . . . . 0.0 109.699 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.23 145.28 16.52 Favored Glycine 0 C--N 1.295 -1.712 0 N-CA-C 108.109 -1.996 . . . . 0.0 108.109 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.569 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.79 124.98 12.16 Favored 'General case' 0 C--N 1.296 -1.755 0 O-C-N 120.978 -1.307 . . . . 0.0 108.779 178.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.528 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.36 26.58 25.24 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.264 -1.446 . . . . 0.0 109.888 -179.587 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.592 HD22 ' HG3' ' A' ' 105' ' ' PRO . 2.0 mt -87.17 175.69 7.94 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 120.872 -1.369 . . . . 0.0 108.421 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.66 98.02 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.398 0 O-C-N 120.93 -1.106 . . . . 0.0 109.702 -179.597 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.651 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.57 77.44 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.737 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.511 -179.176 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.555 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.14 34.42 0.33 Allowed Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.55 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.1 p -146.25 111.92 5.58 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 121.039 -1.271 . . . . 0.0 111.223 -179.686 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.559 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.08 127.76 5.57 Favored 'General case' 0 N--CA 1.492 1.659 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.683 178.207 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.567 ' CZ ' ' OD2' ' A' ' 99' ' ' ASP . 13.2 m-85 -118.5 150.57 39.39 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.327 -0.858 . . . . 0.0 108.881 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.518 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -100.52 153.15 19.61 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.64 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.655 HG22 HG11 ' A' ' 21' ' ' VAL . 4.2 p -137.55 119.03 17.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.844 -1.16 . . . . 0.0 110.043 -177.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.518 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.74 -178.88 40.59 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.673 -179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.57 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -99.73 109.12 21.59 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 -179.943 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.48 148.78 52.33 Favored 'General case' 0 C--N 1.295 -1.795 0 O-C-N 121.285 -0.885 . . . . 0.0 109.881 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.6 137.42 54.9 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.3 -0.875 . . . . 0.0 110.883 -179.094 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.868 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.54 114.9 26.71 Favored 'General case' 0 N--CA 1.493 1.689 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 178.009 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.1 m -105.73 14.69 7.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.053 -1.029 . . . . 0.0 110.707 -178.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.756 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.6 -175.11 0.08 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.901 -1.125 . . . . 0.0 110.106 179.86 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 28.0 p -72.59 98.56 2.35 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.45 -0.781 . . . . 0.0 109.623 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.2 27.16 34.33 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 120.226 -0.988 . . . . 0.0 111.342 178.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.756 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.02 106.04 19.4 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.55 -1.559 . . . . 0.0 107.295 178.829 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.868 HD13 ' NE1' ' A' ' 39' ' ' TRP . 14.0 tp -118.86 104.34 10.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.458 -1.401 . . . . 0.0 109.822 -177.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.027 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.22 109.58 22.32 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.868 -1.145 . . . . 0.0 108.246 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.54 166.23 10.71 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.982 -1.074 . . . . 0.0 110.269 -178.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.714 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.0 t-20 -108.87 134.82 20.22 Favored Pre-proline 0 N--CA 1.499 2.01 0 O-C-N 121.364 -0.835 . . . . 0.0 109.639 -179.416 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.589 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.1 Cg_endo -74.85 24.66 0.38 Allowed 'Trans proline' 0 CA--C 1.545 1.055 0 C-N-CA 122.277 1.985 . . . . 0.0 111.949 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.714 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -117.18 4.34 12.66 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.498 -1.376 . . . . 0.0 109.297 179.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.26 17.54 2.78 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.285 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -81.97 86.96 6.45 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.922 -178.562 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.6 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -104.98 -165.89 1.18 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.334 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.449 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.01 135.77 0.09 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 120.609 -1.307 . . . . 0.0 111.449 -179.284 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.904 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -152.66 156.61 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 178.08 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.559 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.58 145.34 26.36 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.602 -1.312 . . . . 0.0 109.921 -179.611 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.34 107.54 1.66 Allowed 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 122.384 1.087 . . . . 0.0 109.57 178.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.532 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.2 p-10 -60.87 -138.92 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.944 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.841 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.651 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.33 -50.62 59.07 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.509 -0.744 . . . . 0.0 110.673 -178.632 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.475 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.3 t-20 -104.35 -33.99 8.45 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 178.548 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.991 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.13 65.41 0.56 Allowed Glycine 0 C--N 1.297 -1.617 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 178.076 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.2 m -101.6 128.48 47.85 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.505 -0.997 . . . . 0.0 108.549 178.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.904 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.68 108.8 6.78 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.057 -1.057 . . . . 0.0 109.884 -179.21 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.2 m -121.0 118.96 31.17 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.361 -0.837 . . . . 0.0 109.371 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.563 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.63 143.74 30.91 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.392 -0.818 . . . . 0.0 109.479 179.83 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.423 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 28.9 p -99.06 146.97 25.52 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.4 -0.813 . . . . 0.0 109.411 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.783 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -147.42 167.97 23.05 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.393 -0.817 . . . . 0.0 109.368 -179.251 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.663 HG22 HG22 ' A' ' 18' ' ' VAL . 4.6 p -94.49 124.73 38.69 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.903 -1.123 . . . . 0.0 109.859 -179.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.598 ' CG2' HG13 ' A' ' 19' ' ' VAL . 15.8 m -136.46 144.98 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.997 -1.064 . . . . 0.0 109.206 -179.695 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.616 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.3 ptt180 -147.56 -178.49 6.28 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.327 -1.483 . . . . 0.0 111.346 -179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.727 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -50.07 -98.17 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -179.569 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.541 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 1.0 OUTLIER -63.79 146.69 53.45 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 178.57 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.609 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.8 OUTLIER -166.18 141.76 4.75 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 118.03 -1.468 . . . . 0.0 110.243 -177.276 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.548 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.9 mm-40 -36.03 120.71 0.64 Allowed 'General case' 0 N--CA 1.491 1.619 0 CA-C-O 121.475 0.655 . . . . 0.0 110.308 -178.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.027 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.59 51.46 1.79 Allowed Glycine 0 N--CA 1.493 2.469 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.589 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -39.35 113.74 0.35 Allowed 'General case' 0 N--CA 1.507 2.401 0 O-C-N 121.093 -1.24 . . . . 0.0 110.142 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.686 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -85.28 126.35 33.64 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 120.958 -1.089 . . . . 0.0 109.415 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.592 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 18.5 t80 -64.33 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.963 0 O-C-N 120.82 -1.175 . . . . 0.0 110.105 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.7 t0 -160.07 19.76 0.16 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.982 -1.074 . . . . 0.0 109.648 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.91 -27.65 5.36 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 110.063 -1.215 . . . . 0.0 110.063 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.448 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.15 157.6 16.0 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.04 -1.27 . . . . 0.0 110.446 -179.395 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.476 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 1.8 ptm180 -104.87 136.15 44.91 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.686 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.5 t90 -82.86 -16.47 47.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.761 -1.212 . . . . 0.0 110.689 -178.26 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.08 175.43 20.83 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 108.828 -1.709 . . . . 0.0 108.828 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.72 103.51 0.7 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 179.14 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.614 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.8 t -74.54 107.42 5.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.384 -0.823 . . . . 0.0 109.566 -178.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.541 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -67.09 112.0 4.18 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.581 -0.699 . . . . 0.0 109.685 -179.556 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.727 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 11.0 m -60.96 -5.71 1.5 Allowed 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 118.104 -1.439 . . . . 0.0 110.35 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -88.02 -4.43 58.79 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.396 -1.44 . . . . 0.0 109.53 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.511 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -104.0 -48.0 4.02 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.202 -0.936 . . . . 0.0 108.886 179.706 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -112.55 -178.3 3.37 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.573 -0.704 . . . . 0.0 109.33 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.37 117.3 34.44 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.375 -0.828 . . . . 0.0 109.02 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.509 ' O ' HG12 ' A' ' 110' ' ' ILE . 3.9 m -96.47 122.77 39.72 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.866 -1.146 . . . . 0.0 109.344 -179.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.58 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mp0 -106.7 145.48 31.95 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 122.404 1.097 . . . . 0.0 111.685 -179.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.483 ' CG1' ' HB ' ' A' ' 21' ' ' VAL . 62.0 t -100.83 109.71 26.05 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.02 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 177.428 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.5 -172.2 16.58 Favored Glycine 0 N--CA 1.487 2.052 0 C-N-CA 118.257 -1.925 . . . . 0.0 111.622 -177.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.523 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -117.04 -179.22 3.63 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -178.874 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.56 ' HB2' ' C20' ' A' ' 114' ' ' CHR . 8.4 p -166.17 164.14 17.91 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.369 -0.832 . . . . 0.0 109.09 -179.479 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.684 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 1.6 m-20 -100.69 -9.97 21.33 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.084 -1.01 . . . . 0.0 109.477 179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.684 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 74.48 37.77 0.54 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.468 -0.77 . . . . 0.0 109.202 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.67 -33.74 0.78 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.523 -0.736 . . . . 0.0 110.643 -179.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.479 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 177.77 -40.94 0.09 OUTLIER Glycine 0 N--CA 1.483 1.814 0 N-CA-C 107.552 -2.219 . . . . 0.0 107.552 -179.514 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -156.75 -179.02 7.79 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.432 -1.04 . . . . 0.0 109.561 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -174.41 -165.8 31.46 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.592 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.7 Cg_exo -49.64 -174.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 CA-C-N 118.778 1.289 . . . . 0.0 110.472 179.425 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -93.9 -179.61 5.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.113 -0.992 . . . . 0.0 110.373 -179.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -116.66 158.64 14.36 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.466 HG11 ' HB ' ' A' ' 7' ' ' VAL . 1.2 t -98.76 124.93 52.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 O-C-N 121.362 -1.081 . . . . 0.0 109.056 -179.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.58 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.54 120.91 18.81 Favored 'General case' 0 C--N 1.29 -2.005 0 O-C-N 121.804 -0.56 . . . . 0.0 109.707 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.87 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -98.02 169.1 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.255 -0.903 . . . . 0.0 109.241 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.507 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.72 155.22 50.73 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.307 -0.871 . . . . 0.0 109.48 179.993 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.87 ' CE1' HD12 ' A' ' 110' ' ' ILE . 74.5 m-85 -124.36 109.27 13.12 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.164 -0.96 . . . . 0.0 109.468 -179.622 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.402 ' C ' ' O ' ' A' ' 112' ' ' PHE . 17.0 p30 . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.196 -0.94 . . . . 0.0 109.428 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.687 ' H10' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 121.338 0.59 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -120.26 153.91 55.95 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.186 -0.947 . . . . 0.0 109.496 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.691 ' HB3' HD23 ' A' ' 26' ' ' LEU . 2.7 Cg_endo -61.27 155.75 49.82 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.234 1.956 . . . . 0.0 110.554 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.602 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -145.66 160.88 41.05 Favored 'General case' 0 C--N 1.293 -1.878 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 -179.862 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -146.92 128.05 14.68 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.919 -1.113 . . . . 0.0 110.672 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.012 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.6 p -104.2 104.57 14.51 Favored 'General case' 0 C--N 1.296 -1.724 0 CA-C-O 122.49 1.138 . . . . 0.0 110.115 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.959 HG22 HG23 ' A' ' 21' ' ' VAL . 16.2 t -119.8 115.61 47.99 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.46 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.292 179.681 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.49 148.8 13.14 Favored Pre-proline 0 N--CA 1.487 1.407 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -179.583 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.1 Cg_endo -77.92 150.22 89.08 Favored 'Cis proline' 0 C--N 1.309 -1.528 0 C-N-CA 123.606 -1.414 . . . . 0.0 109.737 -0.397 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.656 ' HA ' HG22 ' A' ' 110' ' ' ILE . 40.1 p -89.05 -26.4 21.43 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.535 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 6.0 p -133.07 165.19 25.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.522 -0.736 . . . . 0.0 109.423 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.14 37.51 37.3 Favored Glycine 0 N--CA 1.496 2.652 0 N-CA-C 108.402 -1.879 . . . . 0.0 108.402 -179.548 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.775 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.6 mt -92.51 -42.98 9.41 Favored 'General case' 0 C--N 1.298 -1.647 0 CA-C-O 123.328 1.537 . . . . 0.0 110.491 -178.26 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.28 143.94 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.29 0 CA-C-N 113.319 -1.764 . . . . 0.0 109.858 -179.548 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.599 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.0 p-10 -50.38 106.2 0.12 Allowed 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.398 0.618 . . . . 0.0 111.666 -178.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.53 14.4 8.89 Favored Glycine 0 N--CA 1.485 1.924 0 C-N-CA 119.42 -1.371 . . . . 0.0 113.022 177.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.775 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.96 -172.66 2.14 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 121.15 2.475 . . . . 0.0 109.864 179.246 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.894 HG22 HG22 ' A' ' 68' ' ' THR . 18.8 t -130.4 140.19 49.46 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.285 0 CA-C-N 114.696 -1.138 . . . . 0.0 111.24 -178.774 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.528 HG11 HD11 ' A' ' 13' ' ' LEU . 30.0 m -117.25 155.52 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.544 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.5 OUTLIER -107.19 109.15 20.89 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.087 -1.008 . . . . 0.0 109.572 -179.8 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.959 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -106.47 121.51 59.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.012 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.49 165.94 11.99 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.875 -1.141 . . . . 0.0 108.976 179.75 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.606 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.58 107.98 0.49 Allowed Glycine 0 N--CA 1.481 1.668 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.602 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.81 139.78 50.2 Favored 'General case' 0 N--CA 1.499 2.002 0 CA-C-N 119.218 1.509 . . . . 0.0 110.27 -179.43 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.494 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 84.82 28.86 30.6 Favored Glycine 0 N--CA 1.49 2.286 0 C-N-CA 118.792 -1.671 . . . . 0.0 109.782 179.615 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.691 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.4 mt -93.13 174.54 7.17 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.085 -1.244 . . . . 0.0 108.458 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.87 98.99 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.949 -1.094 . . . . 0.0 109.498 -179.718 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.588 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -57.05 76.59 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.282 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.33 33.96 0.26 Allowed Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.558 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 82.2 p -144.46 111.41 5.81 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 120.966 -1.314 . . . . 0.0 111.144 -179.668 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.588 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.49 112.65 0.57 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.895 178.308 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.53 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 14.4 m-85 -104.51 150.19 24.81 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.206 -0.933 . . . . 0.0 108.746 179.448 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.493 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -99.62 158.57 15.67 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 178.564 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.014 HG11 HG21 ' A' ' 65' ' ' THR . 6.2 p -141.67 116.46 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.006 -1.059 . . . . 0.0 110.042 -177.69 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.535 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.45 -176.54 39.41 Favored Glycine 0 N--CA 1.493 2.462 0 C-N-CA 118.338 -1.886 . . . . 0.0 111.674 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.585 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.5 OUTLIER -100.49 109.11 21.21 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 121.928 0.87 . . . . 0.0 108.82 -179.571 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.461 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.6 m -129.55 148.65 51.47 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.212 -0.93 . . . . 0.0 109.882 179.74 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.507 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.93 138.57 54.64 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.375 -0.828 . . . . 0.0 110.669 -179.027 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.882 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.91 26.73 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 178.039 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -105.88 14.9 7.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.894 -1.129 . . . . 0.0 110.617 -178.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.766 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.6 -175.81 0.08 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.844 -1.16 . . . . 0.0 110.116 179.667 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.781 HG23 ' O ' ' A' ' 42' ' ' THR . 15.2 t -70.57 97.28 1.29 Allowed 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.866 0.841 . . . . 0.0 109.946 -179.55 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.44 27.7 35.21 Favored Glycine 0 N--CA 1.492 2.406 0 C-N-CA 120.181 -1.009 . . . . 0.0 111.391 178.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.766 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.5 106.24 20.1 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.592 -1.534 . . . . 0.0 107.258 178.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.882 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.9 tp -116.62 104.55 11.5 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 120.428 -1.42 . . . . 0.0 109.848 -177.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.078 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.32 109.24 22.03 Favored 'General case' 0 N--CA 1.484 1.253 0 O-C-N 120.842 -1.161 . . . . 0.0 108.119 178.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.2 t -105.94 163.09 13.02 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.993 -1.067 . . . . 0.0 109.871 -179.144 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.618 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 23.6 t30 -105.66 137.02 19.19 Favored Pre-proline 0 N--CA 1.503 2.21 0 O-C-N 121.289 -0.882 . . . . 0.0 109.972 -179.055 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.516 ' HD2' ' HB2' ' A' ' 74' ' ' GLU . 4.2 Cg_endo -73.77 24.25 0.33 Allowed 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 122.467 2.111 . . . . 0.0 112.323 -179.538 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.618 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -119.74 5.07 11.0 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.278 -1.513 . . . . 0.0 109.261 179.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.576 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.8 15.37 2.89 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.274 -1.38 . . . . 0.0 107.274 179.164 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -82.43 89.33 6.61 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.815 -0.754 . . . . 0.0 110.971 -178.517 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.634 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.27 -168.83 1.45 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 178.02 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.78 135.47 0.09 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 120.496 -1.377 . . . . 0.0 111.516 -179.243 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.833 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -153.7 158.18 4.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 177.963 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.588 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.15 143.88 28.21 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 120.638 -1.289 . . . . 0.0 109.777 -179.662 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.47 107.05 1.56 Allowed 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 122.307 1.051 . . . . 0.0 109.547 178.781 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.549 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.1 t0 -61.58 -139.38 0.0 OUTLIER 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.824 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.588 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.2 -51.57 42.99 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.361 -0.837 . . . . 0.0 110.704 -178.699 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -103.96 -32.75 9.1 Favored 'General case' 0 C--N 1.288 -2.109 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 178.562 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.98 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 105.08 69.17 0.75 Allowed Glycine 0 C--N 1.297 -1.589 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 178.194 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.606 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 24.3 m -104.19 126.34 51.21 Favored 'General case' 0 N--CA 1.486 1.343 0 O-C-N 121.684 -0.892 . . . . 0.0 108.838 178.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.833 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.85 109.04 8.26 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 119.644 -0.822 . . . . 0.0 109.486 -179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.477 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 6.4 m -117.5 115.67 25.61 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.271 -0.893 . . . . 0.0 109.398 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 1.014 HG21 HG11 ' A' ' 34' ' ' VAL . 1.3 t -140.97 139.52 34.24 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.359 -0.838 . . . . 0.0 109.723 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.1 p -99.42 132.55 44.68 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.463 -0.773 . . . . 0.0 109.245 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.761 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -132.6 165.92 23.3 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.347 -0.845 . . . . 0.0 109.808 -179.238 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.894 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -98.15 125.18 43.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.238 -0.914 . . . . 0.0 109.219 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.585 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -135.24 143.4 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.068 -1.02 . . . . 0.0 109.897 -179.03 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.599 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.7 ptt180 -145.97 -172.63 3.96 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.457 -1.402 . . . . 0.0 110.946 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.578 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -57.64 -98.15 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.359 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.501 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.64 139.54 55.82 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.27 -1.519 . . . . 0.0 107.944 179.265 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.571 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -160.29 135.24 7.79 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 118.598 -1.241 . . . . 0.0 109.847 -178.107 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.516 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -34.95 121.44 0.53 Allowed 'General case' 0 N--CA 1.491 1.611 0 CA-C-O 121.352 0.596 . . . . 0.0 110.119 -178.49 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.078 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.75 50.83 2.59 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 120.404 -0.903 . . . . 0.0 110.938 -179.196 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.48 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.4 OUTLIER -37.74 116.97 0.54 Allowed 'General case' 0 N--CA 1.514 2.726 0 O-C-N 121.274 -1.133 . . . . 0.0 109.973 179.816 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.703 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -87.04 125.96 34.45 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 120.957 -1.089 . . . . 0.0 109.14 179.724 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.7 t80 -64.13 58.51 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.036 0 O-C-N 120.8 -1.188 . . . . 0.0 109.922 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' LEU . 26.4 t0 -160.38 20.05 0.15 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.959 -1.088 . . . . 0.0 109.668 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.33 -28.62 5.13 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.089 -1.205 . . . . 0.0 110.089 179.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 70.5 p -95.25 164.2 12.95 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.043 -1.269 . . . . 0.0 110.228 -179.427 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.472 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.9 OUTLIER -109.2 138.5 45.45 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.968 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.703 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.7 t90 -81.71 -20.83 38.6 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.805 -1.184 . . . . 0.0 110.391 -178.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.79 175.07 17.5 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 -179.477 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.54 107.49 1.72 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.065 -1.256 . . . . 0.0 107.684 179.221 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.642 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.1 t -79.38 105.3 8.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 O-C-N 121.41 -0.806 . . . . 0.0 109.182 -179.009 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.543 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -65.74 111.59 3.29 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.467 -0.771 . . . . 0.0 109.739 -179.583 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.578 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.17 -5.62 3.42 Favored 'General case' 0 N--CA 1.499 2.01 0 C-N-CA 118.208 -1.397 . . . . 0.0 109.884 179.465 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 19.9 p -87.71 0.73 55.31 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.697 -1.252 . . . . 0.0 109.117 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.543 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.8 p -114.11 -50.82 2.8 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.367 -0.833 . . . . 0.0 108.975 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.06 179.51 4.25 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.555 -0.716 . . . . 0.0 109.331 179.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.94 115.62 30.95 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.465 -0.772 . . . . 0.0 108.919 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.516 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.1 m -97.04 122.42 40.01 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.894 -1.129 . . . . 0.0 109.358 -179.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.58 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.67 146.83 27.62 Favored 'General case' 0 C--N 1.305 -1.329 0 CA-C-O 122.368 1.08 . . . . 0.0 111.215 -179.369 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.608 ' HB ' HG11 ' A' ' 7' ' ' VAL . 52.9 t -103.48 109.79 28.03 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.067 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.61 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.492 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.96 -169.94 17.36 Favored Glycine 0 N--CA 1.486 1.987 0 C-N-CA 118.229 -1.938 . . . . 0.0 111.666 -177.514 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.472 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -123.2 179.16 4.8 Favored 'General case' 0 C--N 1.305 -1.334 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -178.682 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.591 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 3.6 t 179.06 176.76 0.55 Allowed 'General case' 0 C--N 1.293 -1.859 0 O-C-N 121.52 -0.738 . . . . 0.0 109.597 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.43 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -120.96 -158.17 0.75 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.026 -1.047 . . . . 0.0 109.251 -179.912 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.43 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.86 35.99 4.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.855 -1.153 . . . . 0.0 109.12 179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -112.25 -32.87 6.39 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.432 -0.792 . . . . 0.0 109.875 -179.688 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.565 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 163.62 -34.98 0.3 Allowed Glycine 0 N--CA 1.481 1.663 0 N-CA-C 107.874 -2.09 . . . . 0.0 107.874 -179.704 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.85 -177.52 5.56 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 122.062 0.934 . . . . 0.0 109.875 179.328 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -172.43 -161.56 23.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.151 -1.98 . . . . 0.0 108.151 -179.374 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.516 ' HD2' ' CE1' ' A' ' 32' ' ' TYR . 7.1 Cg_exo -45.69 173.14 0.02 OUTLIER 'Trans proline' 0 C--O 1.216 -0.58 0 CA-C-N 118.912 1.356 . . . . 0.0 110.008 179.268 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -93.95 -178.6 4.7 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.109 -0.994 . . . . 0.0 110.428 -178.662 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.492 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.92 168.07 12.71 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 -179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -108.23 128.7 63.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.313 -1.11 . . . . 0.0 109.117 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.58 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -69.18 123.84 22.21 Favored 'General case' 0 C--N 1.29 -2.007 0 O-C-N 121.556 -0.715 . . . . 0.0 109.381 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.899 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.6 173.76 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.199 -0.938 . . . . 0.0 108.928 179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.535 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.5 OUTLIER -138.28 159.61 41.6 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.129 -0.982 . . . . 0.0 109.75 -179.743 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.899 ' CE2' HD12 ' A' ' 110' ' ' ILE . 88.4 m-85 -137.45 81.03 1.84 Allowed 'General case' 0 N--CA 1.485 1.298 0 O-C-N 121.267 -0.896 . . . . 0.0 109.553 -179.636 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.0 p30 . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 118.028 -0.987 . . . . 0.0 109.394 -179.999 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.738 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.662 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -119.71 163.32 28.17 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.284 -0.885 . . . . 0.0 109.492 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.923 ' HB3' HD23 ' A' ' 26' ' ' LEU . 5.7 Cg_exo -58.77 157.66 27.32 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 122.268 1.979 . . . . 0.0 110.899 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.619 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -140.68 160.18 40.6 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 179.812 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.71 122.93 9.56 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-O 122.448 1.118 . . . . 0.0 110.434 -179.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.897 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.9 t -115.82 109.0 17.03 Favored 'General case' 0 C--N 1.297 -1.688 0 CA-C-O 123.162 1.458 . . . . 0.0 109.735 -179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.801 HG22 HG23 ' A' ' 21' ' ' VAL . 2.1 t -115.63 133.69 61.22 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.675 0 CA-C-N 114.162 -1.381 . . . . 0.0 109.593 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.475 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.45 150.66 5.0 Favored Pre-proline 0 N--CA 1.488 1.43 0 O-C-N 121.259 -0.901 . . . . 0.0 108.896 -179.419 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.475 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.13 150.38 88.72 Favored 'Cis proline' 0 C--N 1.311 -1.415 0 C-N-CA 123.56 -1.433 . . . . 0.0 109.454 -0.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.678 ' HA ' HG22 ' A' ' 110' ' ' ILE . 95.6 p -90.4 -24.93 20.64 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.586 -0.696 . . . . 0.0 109.203 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.476 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 14.6 m -131.13 161.71 31.51 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.351 -0.843 . . . . 0.0 109.71 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.44 38.16 29.43 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.58 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.783 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.9 mt -93.31 -43.65 8.69 Favored 'General case' 0 C--N 1.301 -1.53 0 CA-C-O 123.178 1.466 . . . . 0.0 110.801 -178.122 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.07 144.79 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.328 0 CA-C-N 113.484 -1.689 . . . . 0.0 110.123 -179.486 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 18.6 p-10 -50.37 106.07 0.11 Allowed 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 121.53 0.681 . . . . 0.0 111.693 -178.567 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.67 15.57 8.65 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.912 177.075 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.783 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -105.41 -174.28 2.5 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 121.223 2.511 . . . . 0.0 109.981 179.225 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.821 HG22 HG22 ' A' ' 68' ' ' THR . 31.0 t -126.41 138.09 55.75 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.36 0 CA-C-N 114.549 -1.205 . . . . 0.0 111.399 -178.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.517 HG11 HD11 ' A' ' 13' ' ' LEU . 29.0 m -114.13 154.98 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.467 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.503 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.9 tttt -106.65 109.67 21.64 Favored 'General case' 0 C--N 1.3 -1.582 0 O-C-N 121.127 -0.983 . . . . 0.0 109.041 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.801 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.61 140.49 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.897 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.46 162.08 33.64 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 118.89 -1.124 . . . . 0.0 110.094 179.485 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.598 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -138.32 140.3 11.01 Favored Glycine 0 C--N 1.299 -1.514 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.619 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.71 125.22 15.73 Favored 'General case' 0 N--CA 1.494 1.731 0 CA-C-N 119.183 1.492 . . . . 0.0 109.28 179.297 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.466 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 88.87 29.71 17.27 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 118.702 -1.713 . . . . 0.0 109.695 -179.786 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.923 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.9 mt -89.88 175.2 7.3 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 120.863 -1.375 . . . . 0.0 108.517 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.028 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.77 96.8 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.102 -0.999 . . . . 0.0 109.885 -179.608 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.535 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -58.18 74.87 0.01 OUTLIER 'General case' 0 C--N 1.296 -1.739 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.157 -179.138 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 138.75 32.97 0.19 Allowed Glycine 0 N--CA 1.484 1.848 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 179.454 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.632 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 1.4 t -149.11 115.43 5.82 Favored 'General case' 0 C--N 1.31 -1.127 0 O-C-N 120.893 -1.357 . . . . 0.0 111.218 -179.848 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.608 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.42 111.22 0.46 Allowed 'General case' 0 N--CA 1.497 1.901 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.251 178.472 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.632 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 1.9 m-30 -101.54 152.11 21.17 Favored 'General case' 0 N--CA 1.494 1.759 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 179.123 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.51 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -98.89 165.01 11.97 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.497 -1.377 . . . . 0.0 108.327 179.26 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.621 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.1 p -145.1 119.24 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.209 -0.932 . . . . 0.0 109.534 -178.012 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.42 -178.68 41.38 Favored Glycine 0 N--CA 1.495 2.605 0 C-N-CA 118.34 -1.886 . . . . 0.0 111.616 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.698 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.71 108.57 20.46 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 179.833 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.6 m -130.03 148.73 51.91 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 121.228 -0.92 . . . . 0.0 110.01 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.482 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.26 138.76 54.55 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.242 -0.911 . . . . 0.0 110.644 -179.143 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.32 114.82 26.64 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 178.154 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.3 m -104.45 14.88 6.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.014 -1.054 . . . . 0.0 110.534 -178.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.765 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.02 -175.01 0.07 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.023 -1.048 . . . . 0.0 110.185 179.785 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.12 98.11 2.06 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.446 -0.784 . . . . 0.0 109.708 -179.764 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.71 27.88 33.78 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.464 178.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.765 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.75 106.24 19.85 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 O-C-N 120.536 -1.567 . . . . 0.0 107.252 178.834 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.6 tp -117.49 104.45 11.09 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.402 -1.436 . . . . 0.0 109.958 -177.714 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.01 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.92 109.49 22.23 Favored 'General case' 0 N--CA 1.484 1.267 0 N-CA-C 107.718 -1.215 . . . . 0.0 107.718 178.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -107.32 166.16 10.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.895 -1.128 . . . . 0.0 110.655 -178.508 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.56 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 43.7 t30 -113.14 127.92 26.26 Favored Pre-proline 0 N--CA 1.498 1.972 0 O-C-N 121.497 -0.752 . . . . 0.0 109.267 -179.661 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.611 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -70.75 21.31 0.21 Allowed 'Trans proline' 0 CA--C 1.543 0.948 0 C-N-CA 122.103 1.869 . . . . 0.0 112.396 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.56 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -97.72 -5.62 34.72 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.304 -1.497 . . . . 0.0 109.017 179.31 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.857 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.4 m-20 -135.62 10.76 3.43 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.494 ' CD1' ' HA ' ' A' ' 49' ' ' PRO . 1.7 m-85 -66.56 82.9 0.1 Allowed 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.736 -178.403 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.621 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -108.47 -171.92 1.95 Allowed 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 178.252 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.478 ' OG ' ' HA ' ' A' ' 33' ' ' ASP . 1.0 OUTLIER 178.6 134.71 0.08 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.608 -1.308 . . . . 0.0 111.25 -179.369 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.625 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 4.1 p -143.39 159.77 17.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 N-CA-C 107.335 -1.357 . . . . 0.0 107.335 177.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.69 144.39 27.37 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.583 -1.323 . . . . 0.0 109.767 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.028 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -70.44 108.52 4.31 Favored 'General case' 0 C--N 1.297 -1.695 0 CA-C-O 122.312 1.053 . . . . 0.0 109.963 179.312 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.553 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.3 t0 -64.66 -139.55 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.016 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.714 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.535 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.34 -52.43 37.06 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.344 -0.848 . . . . 0.0 110.605 -178.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.34 -32.32 10.53 Favored 'General case' 0 C--N 1.286 -2.18 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 178.613 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.993 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 100.34 69.29 0.88 Allowed Glycine 0 C--N 1.298 -1.571 0 N-CA-C 110.562 -1.015 . . . . 0.0 110.562 178.488 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.598 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 65.6 m -98.66 132.46 44.03 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.337 -1.096 . . . . 0.0 109.016 179.119 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.625 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.41 109.31 9.23 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.252 -179.716 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 19.8 m -122.53 115.68 22.59 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.264 -0.897 . . . . 0.0 109.565 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.545 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.74 143.32 28.61 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.27 -0.894 . . . . 0.0 109.661 179.927 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 57.6 p -99.15 142.38 30.71 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.371 -0.831 . . . . 0.0 109.148 179.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.857 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -144.49 170.63 15.67 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.397 -0.815 . . . . 0.0 109.774 -179.01 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.821 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -104.35 124.26 48.88 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.952 -1.093 . . . . 0.0 110.474 -178.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.847 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.7 m -132.22 143.0 41.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 120.907 -1.121 . . . . 0.0 110.087 -179.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -145.65 -172.51 3.91 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.604 -1.31 . . . . 0.0 110.689 179.384 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.597 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -58.52 -98.42 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.748 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 -179.35 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.4 OUTLIER -57.88 141.22 49.96 Favored 'General case' 0 N--CA 1.485 1.307 0 O-C-N 120.307 -1.496 . . . . 0.0 108.374 179.47 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -161.78 135.44 6.51 Favored 'General case' 0 C--N 1.295 -1.787 0 C-N-CA 118.75 -1.18 . . . . 0.0 109.724 -178.402 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.9 mm-40 -32.11 121.55 0.3 Allowed 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.579 0.704 . . . . 0.0 110.697 -178.351 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.01 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.48 45.51 2.95 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.611 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-85 -37.96 113.56 0.29 Allowed 'General case' 0 N--CA 1.507 2.39 0 O-C-N 121.193 -1.18 . . . . 0.0 110.372 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.739 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.5 tp -85.89 126.56 34.16 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 120.948 -1.095 . . . . 0.0 109.535 -179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.593 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 33.4 t80 -63.9 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.024 0 O-C-N 120.93 -1.106 . . . . 0.0 110.318 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 17.2 t70 -161.46 20.11 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.928 -1.107 . . . . 0.0 109.729 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.59 -28.1 4.99 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.482 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 19.2 p -93.46 159.31 15.3 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 120.981 -1.305 . . . . 0.0 110.231 -179.492 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.515 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 1.1 ptt180 -106.78 139.03 41.85 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.739 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.3 t90 -84.79 -19.26 32.83 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.704 -1.248 . . . . 0.0 110.524 -178.558 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.84 174.1 18.14 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.447 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.93 106.38 1.22 Allowed 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 179.137 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.66 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.9 t -77.02 105.84 6.33 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 O-C-N 121.315 -0.866 . . . . 0.0 109.398 -178.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.684 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.0 OUTLIER -66.31 111.46 3.51 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.386 -0.821 . . . . 0.0 109.685 -179.732 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.597 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.1 t -63.54 -5.51 3.94 Favored 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.533 -1.355 . . . . 0.0 109.828 179.562 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.2 p -86.45 -1.49 57.63 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.787 -1.196 . . . . 0.0 109.215 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.684 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -111.38 -50.24 2.95 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.295 -0.878 . . . . 0.0 108.93 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.34 -178.8 3.76 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.507 -0.746 . . . . 0.0 109.482 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.05 115.52 30.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.33 -0.856 . . . . 0.0 109.001 179.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.91 123.02 40.51 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.77 -1.206 . . . . 0.0 109.593 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.64 146.9 27.89 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 122.445 1.116 . . . . 0.0 111.138 -179.42 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.585 ' CG1' HG11 ' A' ' 7' ' ' VAL . 48.6 t -103.58 110.53 30.26 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.978 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 177.666 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.489 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.6 -170.24 16.86 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 118.06 -2.019 . . . . 0.0 111.745 -177.523 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.488 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -115.38 -179.08 3.54 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 -178.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.592 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.2 OUTLIER -171.36 167.89 6.72 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.318 -0.864 . . . . 0.0 109.61 -179.333 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.6 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -114.73 -157.6 0.64 Allowed 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.199 -0.938 . . . . 0.0 108.816 179.652 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.442 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -120.63 36.29 4.62 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.785 -1.197 . . . . 0.0 109.32 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.89 -32.77 4.4 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.339 -0.85 . . . . 0.0 110.291 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.952 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 168.59 -37.64 0.21 Allowed Glycine 0 N--CA 1.481 1.696 0 N-CA-C 107.7 -2.16 . . . . 0.0 107.7 -179.523 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.428 ' ND2' ' O9 ' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -160.46 -178.07 6.66 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-O 122.127 0.965 . . . . 0.0 109.622 179.219 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.0 -161.28 12.88 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 108.301 -1.92 . . . . 0.0 108.301 -179.345 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.507 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.3 Cg_exo -46.75 177.0 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.653 0 CA-C-N 118.838 1.319 . . . . 0.0 110.179 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -92.66 -177.55 4.6 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.074 -1.016 . . . . 0.0 110.451 -178.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.489 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.45 164.48 12.91 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -100.92 129.23 52.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 O-C-N 121.451 -1.029 . . . . 0.0 109.103 -179.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.04 123.4 22.72 Favored 'General case' 0 C--N 1.289 -2.023 0 O-C-N 121.702 -0.624 . . . . 0.0 109.535 179.734 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.855 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.74 170.53 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.174 -0.954 . . . . 0.0 109.14 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.476 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -138.84 156.63 47.16 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.174 -0.954 . . . . 0.0 109.765 -179.891 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.855 ' CE2' HD12 ' A' ' 110' ' ' ILE . 81.2 m-85 -133.31 132.87 41.84 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.144 -0.972 . . . . 0.0 109.569 -179.683 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.9 p30 . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.44 -179.938 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.952 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.489 0 N-CA-C 109.457 -0.571 . . . . 1.0 109.457 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.68 152.43 42.85 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.261 -0.899 . . . . 1.0 109.467 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.505 ' HB3' HD23 ' A' ' 26' ' ' LEU . 2.8 Cg_endo -61.05 156.6 43.62 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.299 1.999 . . . . 1.0 110.399 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.601 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -153.05 161.17 42.83 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 108.683 -0.858 . . . . 1.0 108.683 -179.551 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.512 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.74 128.61 14.4 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 118.92 -1.112 . . . . 1.0 110.688 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.009 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.2 p -105.63 104.87 14.67 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.457 1.122 . . . . 1.0 110.21 -179.577 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.951 HG22 HG23 ' A' ' 21' ' ' VAL . 13.2 t -118.34 118.8 59.25 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.446 0 CA-C-N 115.384 -0.825 . . . . 1.0 110.495 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.521 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.38 149.37 9.8 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.169 -1.049 . . . . 1.0 108.169 -179.799 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.521 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.1 Cg_endo -77.38 151.83 93.17 Favored 'Cis proline' 0 C--N 1.309 -1.536 0 C-N-CA 123.654 -1.394 . . . . 1.0 109.49 -0.223 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.686 ' HA ' HG22 ' A' ' 110' ' ' ILE . 75.4 p -91.89 -24.99 19.15 Favored 'General case' 0 C--N 1.292 -1.904 0 O-C-N 121.501 -0.749 . . . . 1.0 109.137 179.696 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.474 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 0.9 OUTLIER -133.54 165.12 25.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.43 -0.794 . . . . 1.0 109.557 -179.981 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.52 38.5 37.81 Favored Glycine 0 N--CA 1.497 2.703 0 N-CA-C 108.209 -1.956 . . . . 1.0 108.209 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.808 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.6 mt -92.13 -44.32 8.88 Favored 'General case' 0 C--N 1.298 -1.674 0 CA-C-O 123.122 1.439 . . . . 1.0 110.637 -178.214 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.464 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.3 144.75 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.279 0 CA-C-N 113.613 -1.63 . . . . 1.0 109.947 -179.603 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.598 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.2 p-10 -51.16 108.24 0.24 Allowed 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.524 0.678 . . . . 1.0 111.523 -178.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.11 14.14 10.23 Favored Glycine 0 N--CA 1.484 1.835 0 C-N-CA 119.408 -1.377 . . . . 1.0 112.824 177.283 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.808 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.1 t -104.05 -172.38 2.1 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 121.079 2.439 . . . . 1.0 109.639 179.251 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.764 HG22 HG22 ' A' ' 68' ' ' THR . 12.1 t -131.61 138.85 52.01 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.37 0 CA-C-N 114.967 -1.015 . . . . 1.0 111.281 -178.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.442 HG11 HD11 ' A' ' 13' ' ' LEU . 26.9 m -114.45 154.99 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 N-CA-C 108.761 -0.829 . . . . 1.0 108.761 179.155 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 21.0 tttt -109.06 108.86 19.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.053 -1.029 . . . . 1.0 109.407 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.951 HG23 HG22 ' A' ' 7' ' ' VAL . 1.7 p -106.86 122.53 61.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 N-CA-C 108.778 -0.823 . . . . 1.0 108.778 179.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.009 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.98 165.67 12.13 Favored 'General case' 0 C--N 1.305 -1.331 0 O-C-N 120.902 -1.124 . . . . 1.0 109.114 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.582 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.77 107.91 0.48 Allowed Glycine 0 N--CA 1.482 1.765 0 N-CA-C 108.738 -1.745 . . . . 1.0 108.738 179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.601 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.43 141.05 48.68 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 120.658 -1.495 . . . . 1.0 110.168 -179.502 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.436 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.86 28.12 32.61 Favored Glycine 0 N--CA 1.488 2.109 0 C-N-CA 119.003 -1.57 . . . . 1.0 109.806 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 0.9 OUTLIER -94.23 174.73 7.0 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.008 -1.29 . . . . 1.0 108.587 179.991 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.006 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.95 97.29 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.022 -1.048 . . . . 1.0 109.673 -179.831 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.688 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.19 76.63 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.345 -0.843 . . . . 1.0 110.372 -179.145 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.563 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.85 33.92 0.32 Allowed Glycine 0 N--CA 1.486 1.987 0 N-CA-C 109.751 -1.34 . . . . 1.0 109.751 179.498 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.638 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.1 t -146.66 114.15 6.34 Favored 'General case' 0 C--N 1.309 -1.174 0 O-C-N 120.838 -1.39 . . . . 1.0 110.986 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -46.12 126.2 7.35 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-N 115.31 -0.859 . . . . 1.0 110.008 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.638 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 12.2 m-85 -118.43 151.17 38.3 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 108.543 -0.91 . . . . 1.0 108.543 179.358 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.491 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.54 156.76 17.28 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.572 -1.33 . . . . 1.0 108.063 179.015 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.926 HG11 HG21 ' A' ' 65' ' ' THR . 7.0 p -139.32 115.04 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.189 -0.944 . . . . 1.0 109.83 -177.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.75 -178.64 37.53 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.449 -1.834 . . . . 1.0 111.804 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.631 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -101.8 109.43 21.19 Favored 'General case' 0 C--N 1.313 -0.987 0 N-CA-C 108.799 -0.815 . . . . 1.0 108.799 -179.818 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.41 149.17 52.21 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.22 -0.925 . . . . 1.0 109.99 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.21 138.19 54.7 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.265 -0.897 . . . . 1.0 110.729 -179.081 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.877 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.71 26.53 Favored 'General case' 0 N--CA 1.492 1.631 0 N-CA-C 107.432 -1.322 . . . . 1.0 107.432 178.09 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -105.63 15.3 7.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.018 -1.051 . . . . 1.0 110.589 -178.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.99 -175.63 0.09 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.875 -1.14 . . . . 1.0 110.088 179.787 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 43.8 p -71.95 97.72 1.91 Allowed 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.404 -0.81 . . . . 1.0 109.664 -179.722 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.7 27.37 35.32 Favored Glycine 0 N--CA 1.493 2.448 0 C-N-CA 120.141 -1.028 . . . . 1.0 111.302 178.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.32 106.28 20.01 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.519 -1.577 . . . . 1.0 107.203 178.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.877 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.0 tp -117.04 104.3 11.11 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 120.427 -1.42 . . . . 1.0 109.726 -177.749 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.904 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.97 109.32 22.1 Favored 'General case' 0 N--CA 1.483 1.202 0 N-CA-C 107.65 -1.241 . . . . 1.0 107.65 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -105.72 166.36 10.52 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.035 -1.04 . . . . 1.0 110.404 -178.678 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.487 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 59.2 t30 -111.84 131.39 22.45 Favored Pre-proline 0 N--CA 1.498 1.935 0 O-C-N 121.541 -0.724 . . . . 1.0 109.736 -179.465 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.599 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 2.5 Cg_endo -73.05 22.62 0.31 Allowed 'Trans proline' 0 C--N 1.319 -1.022 0 C-N-CA 122.112 1.874 . . . . 1.0 111.737 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.487 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -110.01 2.84 19.89 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.307 -1.496 . . . . 1.0 109.19 179.562 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.5 15.56 2.75 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.471 -1.307 . . . . 1.0 107.471 179.479 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -79.22 92.96 5.16 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.898 -0.721 . . . . 1.0 111.039 -178.429 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.617 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -111.95 -167.82 1.23 Allowed 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.536 -1.283 . . . . 1.0 107.536 178.104 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.98 136.5 0.09 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.439 -1.413 . . . . 1.0 111.521 -179.332 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.941 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.12 157.51 4.65 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.276 -1.379 . . . . 1.0 107.276 178.019 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.568 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.1 145.49 26.51 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.76 -1.212 . . . . 1.0 109.825 -179.703 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -66.08 107.24 1.84 Allowed 'General case' 0 C--N 1.299 -1.605 0 CA-C-O 122.485 1.136 . . . . 1.0 109.328 178.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.541 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.1 t70 -60.82 -139.37 0.0 OUTLIER 'General case' 0 C--N 1.292 -1.93 0 CA-C-N 115.558 -0.746 . . . . 1.0 110.941 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.688 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.12 -51.42 43.26 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.504 -0.747 . . . . 1.0 110.756 -178.658 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.57 -32.56 8.89 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 106.308 -1.738 . . . . 1.0 106.308 178.673 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.012 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.24 65.21 0.61 Allowed Glycine 0 C--N 1.297 -1.589 0 N-CA-C 110.542 -1.023 . . . . 1.0 110.542 178.238 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.582 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.7 m -103.0 124.66 48.93 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 108.292 -1.003 . . . . 1.0 108.292 178.604 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.941 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.58 109.36 8.62 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 119.681 -0.808 . . . . 1.0 109.726 -179.13 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.3 m -115.99 115.66 26.54 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.293 -0.879 . . . . 1.0 109.164 179.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.926 HG21 HG11 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -140.68 138.86 34.59 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.425 -0.797 . . . . 1.0 109.864 179.941 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.7 p -98.98 133.48 43.19 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.448 -0.782 . . . . 1.0 109.179 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.759 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -131.22 163.71 27.14 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.302 -0.873 . . . . 1.0 109.446 -179.313 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.764 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -93.99 124.33 37.93 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.046 -1.034 . . . . 1.0 109.157 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.541 HG23 HD13 ' A' ' 13' ' ' LEU . 14.4 m -134.71 143.32 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 120.979 -1.076 . . . . 1.0 109.877 -178.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.598 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.2 ptt180 -145.33 -170.66 3.49 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.464 -1.397 . . . . 1.0 111.042 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.637 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -61.88 -101.64 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.851 -0.531 . . . . 1.0 110.241 -179.093 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.528 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -59.19 138.11 57.71 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.566 -1.333 . . . . 1.0 108.517 179.953 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.631 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 1.3 p90 -156.87 154.13 29.32 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 118.824 -1.15 . . . . 1.0 109.854 -178.795 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.483 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 20.4 mm-40 -47.6 122.11 4.56 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.353 -0.842 . . . . 1.0 109.577 -178.58 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.904 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.94 49.38 3.58 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.94 -0.864 . . . . 1.0 110.94 -179.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.599 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.4 m-85 -40.42 113.17 0.34 Allowed 'General case' 0 N--CA 1.507 2.386 0 O-C-N 121.014 -1.286 . . . . 1.0 110.224 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.736 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.92 127.08 35.06 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 120.842 -1.161 . . . . 1.0 109.358 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.58 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 20.6 t80 -63.83 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 O-C-N 120.758 -1.214 . . . . 1.0 110.213 179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 1.6 t0 -160.78 19.0 0.13 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.016 -1.052 . . . . 1.0 109.801 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -25.97 5.75 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 110.15 -1.18 . . . . 1.0 110.15 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 15.4 p -93.31 157.67 16.13 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 120.964 -1.315 . . . . 1.0 110.491 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.477 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -103.86 132.71 49.85 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.482 -0.932 . . . . 1.0 108.482 179.609 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.736 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.1 t90 -81.16 -18.51 46.06 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.758 -1.213 . . . . 1.0 110.382 -178.692 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.26 174.16 19.41 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.864 -1.694 . . . . 1.0 108.864 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.43 107.93 1.22 Allowed 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.683 -1.229 . . . . 1.0 107.683 179.224 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.639 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.0 t -79.82 104.74 8.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.362 -0.836 . . . . 1.0 109.13 -178.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.555 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -65.04 109.15 2.04 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.567 -0.708 . . . . 1.0 110.15 -179.179 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.637 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.8 t -62.04 -4.1 1.51 Allowed 'General case' 0 N--CA 1.502 2.167 0 C-N-CA 118.262 -1.375 . . . . 1.0 110.334 179.265 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 32.1 p -91.33 5.34 49.62 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.66 -1.275 . . . . 1.0 109.384 179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.555 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -117.2 -49.75 2.58 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.356 -0.84 . . . . 1.0 109.178 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.89 178.55 4.53 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.52 -0.737 . . . . 1.0 109.456 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.49 112.5 24.87 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.342 -0.849 . . . . 1.0 108.907 179.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.522 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.6 m -96.7 121.69 38.82 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.031 -1.043 . . . . 1.0 109.279 -179.061 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.582 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.61 147.55 26.65 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 122.454 1.121 . . . . 1.0 111.358 -179.172 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.637 ' HB ' HG11 ' A' ' 7' ' ' VAL . 58.8 t -103.38 109.52 27.22 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.492 -1.67 . . . . 1.0 106.492 177.484 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.443 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.19 -171.31 16.98 Favored Glycine 0 N--CA 1.485 1.927 0 C-N-CA 118.166 -1.969 . . . . 1.0 111.721 -177.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.555 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -115.49 -178.2 3.33 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.704 -0.85 . . . . 1.0 108.704 -178.839 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.581 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.4 p -178.81 169.23 1.65 Allowed 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.312 -0.867 . . . . 1.0 109.574 -179.16 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.454 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -122.18 -157.69 0.75 Allowed 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.035 -1.04 . . . . 1.0 108.994 179.919 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.454 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.48 36.01 4.3 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.742 -1.224 . . . . 1.0 109.238 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.39 -33.09 5.72 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.273 -0.892 . . . . 1.0 110.026 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.858 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 162.74 -35.27 0.33 Allowed Glycine 0 N--CA 1.481 1.681 0 N-CA-C 107.697 -2.161 . . . . 1.0 107.697 -179.606 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.02 -177.91 6.43 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 122.052 0.93 . . . . 1.0 109.844 179.255 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.48 -162.49 19.39 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 108.374 -1.89 . . . . 1.0 108.374 -179.477 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.555 ' HB2' HD12 ' A' ' 97' ' ' LEU . 7.1 Cg_exo -46.0 174.43 0.02 OUTLIER 'Trans proline' 0 C--N 1.327 -0.581 0 CA-C-N 118.854 1.327 . . . . 1.0 110.168 179.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -90.46 -178.84 5.44 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.0 -1.063 . . . . 1.0 110.611 -178.601 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.443 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.86 166.38 13.02 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.586 -1.405 . . . . 1.0 109.586 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.61 131.8 54.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.338 -1.095 . . . . 1.0 109.177 -179.225 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.582 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.3 121.94 20.28 Favored 'General case' 0 C--N 1.29 -2.002 0 O-C-N 121.59 -0.694 . . . . 1.0 109.617 179.657 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.844 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.8 pt -98.01 173.2 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.248 -0.908 . . . . 1.0 108.996 179.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.474 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -141.36 159.54 42.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.06 -1.025 . . . . 1.0 110.04 -179.7 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.844 ' CE2' HD12 ' A' ' 110' ' ' ILE . 88.5 m-85 -135.96 98.55 3.91 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.276 -0.89 . . . . 1.0 109.573 -179.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 p30 . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 118.006 -0.997 . . . . 1.0 109.512 179.976 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.858 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.324 0.583 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.909 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -85.37 172.83 7.96 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.222 -0.923 . . . . 0.0 109.525 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.909 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.0 Cg_exo -60.14 157.72 33.52 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.386 2.057 . . . . 0.0 110.572 -179.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.6 -169.68 0.14 Allowed 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.15 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.545 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.93 130.06 2.22 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.83 -1.169 . . . . 0.0 110.666 -179.132 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.962 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.9 t -111.17 108.71 18.47 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 123.04 1.4 . . . . 0.0 109.096 179.273 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.914 HG22 HG23 ' A' ' 21' ' ' VAL . 4.5 t -118.31 136.44 55.5 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.761 0 CA-C-N 114.299 -1.319 . . . . 0.0 110.094 -179.685 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.482 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -176.64 150.97 1.0 Allowed Pre-proline 0 N--CA 1.488 1.431 0 O-C-N 121.279 -0.888 . . . . 0.0 108.801 -179.641 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.482 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.8 Cg_endo -79.11 150.45 85.74 Favored 'Cis proline' 0 C--N 1.311 -1.432 0 C-N-CA 123.507 -1.456 . . . . 0.0 109.271 -0.735 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.677 ' HA ' HG22 ' A' ' 110' ' ' ILE . 78.4 p -92.23 -23.19 19.42 Favored 'General case' 0 C--N 1.291 -1.937 0 O-C-N 121.589 -0.695 . . . . 0.0 109.402 179.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.485 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 7.4 m -132.2 160.74 35.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.354 -0.841 . . . . 0.0 109.764 -179.785 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.77 37.39 30.21 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.824 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.8 mt -92.04 -44.42 8.86 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-O 123.2 1.476 . . . . 0.0 110.728 -178.363 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.4 OUTLIER 65.96 146.28 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.341 0 CA-C-N 113.628 -1.624 . . . . 0.0 109.942 -179.69 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.606 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.0 p-10 -50.85 108.08 0.21 Allowed 'General case' 0 C--N 1.3 -1.556 0 CA-C-O 121.478 0.656 . . . . 0.0 111.882 -178.532 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.5 15.2 10.58 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.421 -1.371 . . . . 0.0 112.879 177.131 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.824 HG21 ' CA ' ' A' ' 13' ' ' LEU . 10.6 t -102.65 -172.42 2.12 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 121.056 2.428 . . . . 0.0 109.897 179.35 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.796 HG13 ' O ' ' A' ' 67' ' ' LEU . 33.6 t -125.66 137.55 57.33 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.246 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.962 -178.726 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.54 HG22 HG22 ' A' ' 69' ' ' VAL . 27.4 m -116.2 155.84 17.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 178.768 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.4 ttpt -114.31 109.55 18.52 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.06 -1.025 . . . . 0.0 109.178 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.914 HG23 HG22 ' A' ' 7' ' ' VAL . 2.4 p -105.12 141.45 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.962 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -139.72 160.25 40.3 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 120.632 -1.292 . . . . 0.0 110.229 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.07 144.21 15.45 Favored Glycine 0 C--N 1.295 -1.704 0 N-CA-C 107.977 -2.049 . . . . 0.0 107.977 179.47 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.565 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.08 125.94 13.55 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 120.894 -1.356 . . . . 0.0 108.841 179.206 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.518 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.11 27.04 24.51 Favored Glycine 0 N--CA 1.488 2.103 0 C-N-CA 119.214 -1.469 . . . . 0.0 109.654 -179.617 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.4 mt -88.58 175.01 7.74 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.887 -1.361 . . . . 0.0 108.498 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.998 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -48.55 100.15 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.002 -1.061 . . . . 0.0 109.792 -179.63 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.44 78.13 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.134 -179.24 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.91 34.08 0.31 Allowed Glycine 0 N--CA 1.487 2.09 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.72 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.554 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 34.2 p -140.79 107.29 5.3 Favored 'General case' 0 C--N 1.308 -1.218 0 O-C-N 121.24 -1.153 . . . . 0.0 110.984 -179.489 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.575 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.67 109.78 0.25 Allowed 'General case' 0 N--CA 1.497 1.888 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.987 178.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.537 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 24.9 m-85 -102.38 153.86 19.62 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 108.638 179.372 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.505 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.87 161.51 13.61 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.676 -1.265 . . . . 0.0 107.948 178.85 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.655 HG13 ' O ' ' A' ' 34' ' ' VAL . 5.5 p -141.16 115.23 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.157 -0.964 . . . . 0.0 109.442 -178.205 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.53 ' HA2' ' OD1' ' A' ' 51' ' ' ASP . . . -162.75 173.99 39.05 Favored Glycine 0 N--CA 1.49 2.276 0 C-N-CA 118.06 -2.019 . . . . 0.0 112.114 -179.334 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.628 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -98.43 108.96 21.79 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 179.267 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.8 m -132.28 151.26 51.92 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.277 -0.889 . . . . 0.0 109.992 -179.513 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.42 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.82 139.65 53.64 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.248 -0.907 . . . . 0.0 110.695 -179.06 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.878 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.26 114.56 26.36 Favored 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.22 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.2 m -105.09 14.75 7.09 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 O-C-N 120.885 -1.135 . . . . 0.0 110.602 -178.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.759 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.06 -174.99 0.09 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.892 -1.13 . . . . 0.0 110.067 179.751 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 14.6 p -71.95 97.32 1.84 Allowed 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.344 -0.848 . . . . 0.0 109.798 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.42 26.93 34.39 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 120.241 -0.98 . . . . 0.0 111.428 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.6 106.31 20.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 O-C-N 120.55 -1.559 . . . . 0.0 107.429 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.878 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.2 tp -116.65 104.82 11.77 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.564 -1.335 . . . . 0.0 109.723 -177.862 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.078 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.98 109.53 22.27 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 120.829 -1.17 . . . . 0.0 108.204 179.092 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.6 t -105.89 165.56 11.11 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.9 -1.125 . . . . 0.0 110.295 -179.085 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.665 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 18.7 t-20 -109.33 137.0 20.13 Favored Pre-proline 0 N--CA 1.501 2.104 0 O-C-N 121.421 -0.799 . . . . 0.0 110.201 -179.08 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.584 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.2 Cg_endo -74.89 23.94 0.39 Allowed 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 122.387 2.058 . . . . 0.0 111.971 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.665 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -116.88 2.67 12.83 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.296 -1.503 . . . . 0.0 109.227 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.955 ' OD1' HD22 ' A' ' 67' ' ' LEU . 9.4 t70 -137.64 13.27 2.95 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 179.552 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -79.72 94.25 5.7 Favored 'General case' 0 N--CA 1.484 1.27 0 O-C-N 121.424 -0.798 . . . . 0.0 110.883 -178.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -115.33 -166.25 1.1 Allowed 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 178.367 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.94 135.42 0.09 Allowed 'General case' 0 N--CA 1.486 1.369 0 O-C-N 120.627 -1.296 . . . . 0.0 111.429 -179.34 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.915 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -151.18 156.9 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 N-CA-C 107.354 -1.351 . . . . 0.0 107.354 178.007 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.575 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.19 144.14 27.95 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.801 -1.187 . . . . 0.0 110.055 -179.574 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.008 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.72 106.91 1.06 Allowed 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 122.447 1.118 . . . . 0.0 109.436 178.27 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -60.05 -139.28 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.988 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.042 -179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.91 -50.1 61.74 Favored 'General case' 0 N--CA 1.499 2.01 0 O-C-N 121.498 -0.751 . . . . 0.0 110.597 -178.752 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 12.3 m-80 -103.7 -34.47 8.58 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 106.208 -1.775 . . . . 0.0 106.208 178.573 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.008 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.49 65.31 0.58 Allowed Glycine 0 C--N 1.297 -1.604 0 N-CA-C 110.501 -1.039 . . . . 0.0 110.501 178.141 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 46.6 m -103.62 127.05 51.11 Favored 'General case' 0 N--CA 1.483 1.19 0 O-C-N 121.381 -1.07 . . . . 0.0 108.915 178.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.915 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.72 109.15 7.37 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.424 -0.91 . . . . 0.0 109.36 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -124.71 121.65 35.25 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.201 -0.937 . . . . 0.0 109.663 -179.736 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.71 142.05 28.61 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.596 -0.69 . . . . 0.0 109.486 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 15.6 p -98.93 136.38 39.0 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.451 -0.781 . . . . 0.0 109.186 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.955 HD22 ' OD1' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -135.93 -178.73 5.27 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.235 -0.915 . . . . 0.0 109.544 -178.983 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.509 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.4 p -105.09 126.18 51.79 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.99 -1.069 . . . . 0.0 109.637 -179.352 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.54 HG22 HG22 ' A' ' 19' ' ' VAL . 16.9 m -139.35 142.97 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 120.888 -1.132 . . . . 0.0 110.08 -179.521 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.606 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.8 ptt180 -141.2 -161.42 1.21 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.671 -1.268 . . . . 0.0 110.141 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.582 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -78.15 -86.89 0.06 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.232 -0.918 . . . . 0.0 108.848 -179.584 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -60.87 138.47 58.14 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.387 -1.446 . . . . 0.0 107.204 178.809 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -165.11 136.58 4.11 Favored 'General case' 0 C--N 1.294 -1.834 0 C-N-CA 117.901 -1.519 . . . . 0.0 110.371 -177.365 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.516 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 7.0 mm-40 -33.4 121.44 0.4 Allowed 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 121.352 0.596 . . . . 0.0 110.326 -178.766 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.078 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.85 51.83 1.72 Allowed Glycine 0 N--CA 1.494 2.53 0 C-N-CA 120.474 -0.869 . . . . 0.0 111.42 -179.036 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.584 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 4.2 m-85 -39.11 116.6 0.6 Allowed 'General case' 0 N--CA 1.511 2.62 0 O-C-N 121.018 -1.283 . . . . 0.0 110.05 179.526 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.682 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.4 126.27 34.27 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 120.96 -1.087 . . . . 0.0 109.69 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.577 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 32.0 t80 -64.5 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.933 0 O-C-N 120.738 -1.226 . . . . 0.0 109.92 179.362 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.544 ' N ' ' O ' ' A' ' 77' ' ' LEU . 5.7 t70 -158.93 19.51 0.2 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.061 -1.025 . . . . 0.0 109.656 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.75 -27.96 5.65 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.426 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 69.7 p -97.54 162.71 13.17 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.046 -1.267 . . . . 0.0 110.307 -179.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.525 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.0 140.37 41.25 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.904 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.682 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.7 t90 -83.8 -19.21 35.42 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.771 -1.205 . . . . 0.0 110.728 -178.282 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.85 177.33 20.13 Favored Glycine 0 N--CA 1.484 1.869 0 N-CA-C 108.578 -1.809 . . . . 0.0 108.578 -179.374 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -63.9 109.79 1.89 Allowed 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.214 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.62 HG21 ' HB3' ' A' ' 46' ' ' ALA . 37.3 t -82.91 105.66 12.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 O-C-N 121.44 -0.788 . . . . 0.0 108.947 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.539 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -66.14 111.73 3.56 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.428 -0.795 . . . . 0.0 109.882 -179.205 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.555 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -65.28 -5.32 6.87 Favored 'General case' 0 N--CA 1.498 1.96 0 C-N-CA 118.203 -1.399 . . . . 0.0 109.665 179.379 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 12.3 p -84.01 -1.24 54.37 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.799 -1.188 . . . . 0.0 108.887 179.269 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.539 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -113.5 -50.05 2.87 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.443 -0.786 . . . . 0.0 109.012 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.87 -178.0 3.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.486 -0.758 . . . . 0.0 109.45 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.09 115.77 30.76 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.451 -0.78 . . . . 0.0 109.037 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.535 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -96.87 122.76 40.19 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.894 -1.129 . . . . 0.0 109.588 -179.384 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.83 146.39 28.35 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-O 122.337 1.065 . . . . 0.0 111.167 -179.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 59.3 t -103.78 109.88 28.46 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.591 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.473 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.55 -172.09 18.05 Favored Glycine 0 N--CA 1.486 2.016 0 C-N-CA 118.03 -2.033 . . . . 0.0 111.914 -177.515 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.505 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -112.97 -178.88 3.49 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.255 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.562 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 2.9 p -176.57 173.03 2.08 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.261 -0.899 . . . . 0.0 109.518 -179.373 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -121.27 -161.74 0.92 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.044 -1.035 . . . . 0.0 108.785 179.841 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -117.39 36.09 4.4 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.584 -1.322 . . . . 0.0 109.302 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -117.48 -33.31 4.63 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.337 -0.852 . . . . 0.0 110.225 -179.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.907 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.93 -36.84 0.22 Allowed Glycine 0 N--CA 1.48 1.631 0 N-CA-C 107.913 -2.075 . . . . 0.0 107.913 -179.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.31 -177.76 6.23 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 122.1 0.952 . . . . 0.0 109.95 179.277 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.93 -163.89 23.71 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.149 -1.98 . . . . 0.0 108.149 -179.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.463 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.0 Cg_exo -46.24 172.96 0.02 OUTLIER 'Trans proline' 0 C--N 1.326 -0.616 0 CA-C-N 118.88 1.34 . . . . 0.0 109.889 179.371 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -91.7 -173.21 3.46 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.15 -0.969 . . . . 0.0 110.447 -178.712 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.473 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.81 171.29 15.54 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.1 t -106.69 132.98 52.58 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 O-C-N 121.536 -0.979 . . . . 0.0 109.138 -179.383 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.37 123.94 26.25 Favored 'General case' 0 C--N 1.29 -2.017 0 O-C-N 121.609 -0.682 . . . . 0.0 109.664 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.827 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.73 168.23 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.282 -0.886 . . . . 0.0 108.934 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.485 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 5.4 m -136.6 154.53 50.64 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.219 -0.926 . . . . 0.0 109.752 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.827 ' CE2' HD12 ' A' ' 110' ' ' ILE . 77.3 m-85 -129.54 101.54 5.98 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.179 -0.951 . . . . 0.0 109.417 -179.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.443 ' O ' ' OD1' ' A' ' 113' ' ' ASN . 15.0 p30 . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 117.921 -1.038 . . . . 0.0 109.48 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.907 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.625 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.945 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -63.8 175.08 0.86 Allowed Pre-proline 0 N--CA 1.49 1.526 0 O-C-N 121.279 -0.888 . . . . 0.0 109.258 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.945 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 6.0 Cg_exo -58.45 155.33 36.61 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 124.876 3.717 . . . . 0.0 109.784 -179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.869 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.2 p -165.8 160.72 17.36 Favored 'General case' 0 C--N 1.297 -1.716 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.111 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -149.51 128.29 12.5 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-O 122.414 1.102 . . . . 0.0 110.617 -179.782 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.989 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 3.2 p -108.54 104.79 14.19 Favored 'General case' 0 C--N 1.296 -1.738 0 CA-C-O 122.491 1.139 . . . . 0.0 110.337 -179.624 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.949 HG22 HG23 ' A' ' 21' ' ' VAL . 10.8 t -116.86 110.17 30.44 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.448 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.479 179.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.5 HG23 ' HA ' ' A' ' 9' ' ' PRO . 1.0 OUTLIER -152.55 146.72 18.53 Favored Pre-proline 0 N--CA 1.485 1.294 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.971 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.5 ' HA ' HG23 ' A' ' 8' ' ' THR . 9.3 Cg_endo -80.83 146.87 73.05 Favored 'Cis proline' 0 C--N 1.306 -1.675 0 O-C-N 123.666 1.351 . . . . 0.0 109.373 -0.232 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.677 ' HA ' HG22 ' A' ' 110' ' ' ILE . 80.4 p -91.51 -24.03 19.77 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.493 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 13.2 m -131.33 160.99 33.38 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.575 -0.703 . . . . 0.0 109.471 179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.74 36.65 32.36 Favored Glycine 0 N--CA 1.495 2.589 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 -179.648 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.75 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.7 mt -91.32 -42.63 10.26 Favored 'General case' 0 C--N 1.299 -1.587 0 CA-C-O 123.358 1.552 . . . . 0.0 110.46 -178.475 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.24 142.99 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.253 0 CA-C-N 113.322 -1.763 . . . . 0.0 109.795 -179.561 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.601 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.1 p-10 -50.01 105.74 0.1 Allowed 'General case' 0 C--N 1.301 -1.529 0 CA-C-O 121.448 0.642 . . . . 0.0 111.574 -178.56 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.47 13.88 8.57 Favored Glycine 0 N--CA 1.485 1.919 0 C-N-CA 119.417 -1.373 . . . . 0.0 113.16 177.211 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.75 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -106.01 -172.88 2.17 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 121.199 2.499 . . . . 0.0 109.839 179.28 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.95 HG22 HG22 ' A' ' 68' ' ' THR . 20.8 t -128.87 140.3 49.62 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.27 0 CA-C-N 114.695 -1.139 . . . . 0.0 111.362 -178.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.562 HG11 HD11 ' A' ' 13' ' ' LEU . 27.8 m -114.87 156.24 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 178.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.526 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -109.29 109.72 20.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.984 -1.072 . . . . 0.0 109.553 -179.716 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.949 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -105.05 123.57 59.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 179.898 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.989 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.3 165.96 11.71 Favored 'General case' 0 N--CA 1.484 1.267 0 O-C-N 120.792 -1.192 . . . . 0.0 108.942 179.438 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.6 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -145.56 108.16 0.45 Allowed Glycine 0 N--CA 1.483 1.822 0 N-CA-C 108.36 -1.896 . . . . 0.0 108.36 179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.591 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.83 137.37 52.25 Favored 'General case' 0 N--CA 1.5 2.029 0 O-C-N 120.519 -1.577 . . . . 0.0 110.439 -179.303 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.486 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 85.85 28.85 27.8 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.085 -1.531 . . . . 0.0 109.874 179.567 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.606 HD22 ' HG3' ' A' ' 105' ' ' PRO . 2.3 mt -90.36 175.66 7.02 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 120.963 -1.316 . . . . 0.0 108.373 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.012 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.69 97.94 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.858 -1.151 . . . . 0.0 109.678 -179.669 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.594 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.08 76.96 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.692 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.381 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.571 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.9 34.34 0.3 Allowed Glycine 0 N--CA 1.486 1.975 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 179.465 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.553 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.7 p -147.89 113.3 5.61 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 120.998 -1.296 . . . . 0.0 111.28 -179.693 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.577 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.86 126.67 5.91 Favored 'General case' 0 N--CA 1.491 1.602 0 CA-C-N 115.619 -0.718 . . . . 0.0 109.567 177.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.551 ' CZ ' ' OD2' ' A' ' 99' ' ' ASP . 10.5 m-85 -117.48 149.39 40.67 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.484 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.3 163.87 12.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.751 -1.218 . . . . 0.0 107.92 178.918 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.929 HG11 HG21 ' A' ' 65' ' ' THR . 9.9 p -149.32 114.07 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.202 -0.936 . . . . 0.0 109.838 -177.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.524 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.01 -175.89 36.83 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 118.329 -1.891 . . . . 0.0 111.724 -179.813 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.591 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -101.4 108.87 20.6 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.763 0.792 . . . . 0.0 108.951 -179.563 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.484 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.12 146.88 51.8 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.427 -0.796 . . . . 0.0 109.691 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.493 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -120.35 138.18 53.87 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.298 -0.877 . . . . 0.0 110.703 -179.007 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.861 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.64 114.4 26.14 Favored 'General case' 0 N--CA 1.493 1.716 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 178.251 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -105.89 14.85 7.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.002 -1.061 . . . . 0.0 110.603 -178.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.766 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.43 -174.6 0.07 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.808 -1.182 . . . . 0.0 110.164 179.756 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 23.8 p -71.71 97.57 1.78 Allowed 'General case' 0 N--CA 1.485 1.323 0 O-C-N 121.43 -0.794 . . . . 0.0 109.867 -179.63 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 26.47 37.09 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 120.251 -0.976 . . . . 0.0 111.483 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.766 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.75 106.21 20.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.2 0 O-C-N 120.556 -1.555 . . . . 0.0 107.367 178.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.861 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -118.22 104.77 11.11 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.473 -1.392 . . . . 0.0 109.641 -177.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.012 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.98 109.75 22.45 Favored 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.789 -1.194 . . . . 0.0 108.345 179.138 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.5 t -106.33 164.71 11.8 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.935 -1.103 . . . . 0.0 110.426 -178.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.732 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 10.5 t-20 -108.94 139.48 20.96 Favored Pre-proline 0 N--CA 1.501 2.083 0 O-C-N 121.461 -0.775 . . . . 0.0 109.952 -179.124 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 6.8 Cg_endo -75.7 23.11 0.45 Allowed 'Trans proline' 0 N--CA 1.496 1.637 0 C-N-CA 125.162 3.908 . . . . 0.0 111.258 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.732 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -120.07 3.34 10.95 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.426 -1.421 . . . . 0.0 109.052 179.636 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.545 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.89 14.51 3.1 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 179.343 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -80.49 91.19 5.72 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.778 -0.769 . . . . 0.0 110.98 -178.487 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.648 ' C ' HG12 ' A' ' 34' ' ' VAL . 0.6 OUTLIER -113.23 -173.31 2.23 Favored 'General case' 0 N--CA 1.489 1.51 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.099 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.67 134.6 0.08 Allowed 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.482 -1.386 . . . . 0.0 111.494 -179.183 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.645 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 3.6 p -146.73 159.62 10.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 107.227 -1.398 . . . . 0.0 107.227 177.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.577 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.33 145.89 25.68 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.433 -1.417 . . . . 0.0 110.116 -179.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.47 109.36 3.67 Favored 'General case' 0 C--N 1.3 -1.56 0 CA-C-O 122.326 1.06 . . . . 0.0 109.802 178.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.574 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -63.64 -139.31 0.0 OUTLIER 'General case' 0 C--N 1.292 -1.902 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.588 179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.594 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.92 -51.59 55.91 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.391 -0.818 . . . . 0.0 110.378 -178.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.475 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.4 t-20 -101.39 -34.18 9.7 Favored 'General case' 0 C--N 1.287 -2.121 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.968 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.44 69.59 0.72 Allowed Glycine 0 N--CA 1.479 1.557 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 178.041 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.6 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 64.3 p -98.86 131.69 44.77 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 121.327 -1.102 . . . . 0.0 109.268 179.118 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.645 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.1 108.48 7.82 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.775 -0.77 . . . . 0.0 109.021 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 7.0 m -122.23 116.36 24.0 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.122 -0.986 . . . . 0.0 109.536 -179.743 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.929 HG21 HG11 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -146.13 139.48 25.99 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.428 -0.795 . . . . 0.0 109.787 179.944 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.8 p -99.97 128.83 46.01 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.369 -0.832 . . . . 0.0 108.946 179.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.787 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -126.54 164.42 21.24 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.227 -0.92 . . . . 0.0 109.783 -179.092 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.95 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -96.77 125.12 41.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.118 -0.989 . . . . 0.0 109.221 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.591 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.9 m -136.51 142.69 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.075 -1.016 . . . . 0.0 109.909 -179.026 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.601 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.8 ptt180 -146.37 -173.62 4.24 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 120.473 -1.392 . . . . 0.0 110.922 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.619 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.64 -101.94 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 -179.409 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.508 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -55.72 140.95 39.99 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 120.788 -1.195 . . . . 0.0 108.115 179.458 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.79 135.26 5.51 Favored 'General case' 0 C--N 1.294 -1.818 0 C-N-CA 118.701 -1.2 . . . . 0.0 109.813 -178.265 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.519 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 1.3 mp0 -31.53 121.16 0.25 Allowed 'General case' 0 N--CA 1.493 1.679 0 CA-C-O 121.41 0.624 . . . . 0.0 110.699 -178.488 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.012 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.74 46.61 2.73 Favored Glycine 0 N--CA 1.495 2.572 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.136 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -38.48 113.19 0.27 Allowed 'General case' 0 N--CA 1.507 2.388 0 O-C-N 121.121 -1.223 . . . . 0.0 110.205 179.622 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.654 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -85.92 127.32 34.58 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 120.975 -1.078 . . . . 0.0 109.52 -179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.598 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 25.6 t80 -64.09 58.17 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.051 0 O-C-N 120.858 -1.151 . . . . 0.0 110.198 179.73 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 6.7 t70 -160.93 19.4 0.13 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.972 -1.08 . . . . 0.0 109.794 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.73 -27.17 5.46 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.429 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 70.7 p -93.39 157.15 16.37 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.05 -1.264 . . . . 0.0 110.349 -179.402 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.492 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -104.73 134.45 47.85 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.652 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.654 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -80.94 -17.97 48.69 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.887 -1.133 . . . . 0.0 110.413 -178.494 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.74 174.6 19.79 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.29 106.2 1.06 Allowed 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.11 -1.23 . . . . 0.0 107.695 179.157 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.596 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.0 t -77.54 106.79 8.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.382 -0.824 . . . . 0.0 109.292 -178.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.537 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.91 111.54 3.35 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.413 -0.804 . . . . 0.0 109.801 -179.474 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.619 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.71 -5.4 4.07 Favored 'General case' 0 N--CA 1.501 2.085 0 C-N-CA 118.135 -1.426 . . . . 0.0 109.809 179.269 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 40.9 p -86.52 -1.8 57.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.799 -1.188 . . . . 0.0 109.29 179.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.537 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.14 -49.69 3.0 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.264 -0.898 . . . . 0.0 109.058 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.18 179.03 4.38 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.47 -0.769 . . . . 0.0 109.525 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.3 115.92 31.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.39 -0.819 . . . . 0.0 109.058 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.83 122.59 39.96 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.877 -1.139 . . . . 0.0 109.465 -179.448 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.92 148.03 25.82 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 122.418 1.104 . . . . 0.0 111.249 -179.266 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.544 ' HB ' HG11 ' A' ' 7' ' ' VAL . 72.3 t -104.86 109.87 28.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 177.705 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -147.31 -173.56 18.56 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 118.308 -1.901 . . . . 0.0 111.796 -177.545 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.545 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.49 -178.54 3.41 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.029 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.553 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.2 OUTLIER -171.43 168.39 6.52 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.357 -0.839 . . . . 0.0 109.152 -179.353 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.699 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 2.0 m-20 -104.11 -9.96 18.35 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.104 -0.998 . . . . 0.0 109.497 179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.699 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 73.97 38.76 0.56 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.464 -0.773 . . . . 0.0 109.317 179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -137.83 -34.5 0.67 Allowed 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.543 -0.723 . . . . 0.0 110.566 -179.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.483 ' N ' H193 ' A' ' 114' ' ' CHR . . . -178.16 -42.99 0.07 OUTLIER Glycine 0 N--CA 1.482 1.723 0 N-CA-C 107.588 -2.205 . . . . 0.0 107.588 -179.711 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.44 -178.69 7.32 Favored 'General case' 0 C--N 1.308 -1.237 0 O-C-N 121.6 -0.941 . . . . 0.0 109.522 179.051 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -175.88 -166.53 33.46 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 108.405 -1.878 . . . . 0.0 108.405 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.606 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.2 Cg_exo -45.03 178.85 0.0 OUTLIER 'Trans proline' 0 N--CA 1.491 1.377 0 C-N-CA 123.349 2.699 . . . . 0.0 109.697 179.452 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -92.59 175.18 6.92 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.955 -1.09 . . . . 0.0 110.637 -178.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -114.76 163.66 12.16 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.35 127.38 63.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.32 -1.106 . . . . 0.0 109.155 -179.285 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.58 122.01 19.76 Favored 'General case' 0 C--N 1.291 -1.971 0 O-C-N 121.559 -0.713 . . . . 0.0 109.47 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.865 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.79 170.44 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.198 -0.939 . . . . 0.0 109.085 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.493 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -140.53 156.38 46.33 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.143 -0.973 . . . . 0.0 109.837 -179.657 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.865 ' CE2' HD12 ' A' ' 110' ' ' ILE . 87.5 m-85 -134.22 114.27 12.88 Favored 'General case' 0 N--CA 1.485 1.293 0 O-C-N 121.233 -0.917 . . . . 0.0 109.572 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.415 ' C ' ' O ' ' A' ' 112' ' ' PHE . 20.2 p30 . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 117.98 -1.009 . . . . 0.0 109.494 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.704 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.571 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -104.41 161.95 21.32 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.265 -0.897 . . . . 0.0 109.36 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.876 ' O ' HG23 ' A' ' 4' ' ' THR . 4.5 Cg_exo -59.2 154.92 42.92 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 124.932 3.755 . . . . 0.0 110.029 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.876 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.2 p -166.54 160.14 14.98 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 -179.248 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.493 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -149.63 121.79 8.33 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-O 122.371 1.081 . . . . 0.0 110.391 -179.725 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.873 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -114.28 109.3 18.16 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-O 123.112 1.435 . . . . 0.0 109.59 179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.819 HG13 ' CA ' ' A' ' 21' ' ' VAL . 0.6 OUTLIER -116.71 129.93 72.4 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.666 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.756 -179.883 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.506 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -167.8 148.62 4.75 Favored Pre-proline 0 N--CA 1.487 1.401 0 O-C-N 121.169 -0.957 . . . . 0.0 108.943 -179.723 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.506 ' HA ' HG23 ' A' ' 8' ' ' THR . 7.4 Cg_endo -80.66 147.64 74.96 Favored 'Cis proline' 0 C--N 1.309 -1.523 0 O-C-N 123.669 1.352 . . . . 0.0 109.181 -0.656 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.685 ' HA ' HG22 ' A' ' 110' ' ' ILE . 86.8 p -91.08 -24.5 20.0 Favored 'General case' 0 C--N 1.294 -1.805 0 O-C-N 121.484 -0.76 . . . . 0.0 109.238 179.774 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.461 ' HA ' ' O ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -129.61 161.59 30.2 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.367 -0.833 . . . . 0.0 109.622 -179.864 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.08 37.94 31.31 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 108.499 -1.84 . . . . 0.0 108.499 -179.679 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.777 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.3 mt -92.79 -43.69 8.89 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 123.199 1.476 . . . . 0.0 110.736 -178.248 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.476 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.58 143.9 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.473 -1.694 . . . . 0.0 109.79 -179.355 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.577 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 17.9 p-10 -50.54 106.86 0.14 Allowed 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.394 0.616 . . . . 0.0 111.517 -178.558 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.62 14.34 9.65 Favored Glycine 0 N--CA 1.485 1.903 0 C-N-CA 119.38 -1.391 . . . . 0.0 112.966 177.143 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.777 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.18 -172.17 2.06 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 121.1 2.45 . . . . 0.0 109.821 179.246 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.766 HG22 HG22 ' A' ' 68' ' ' THR . 17.7 t -127.94 138.7 53.95 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.796 -1.093 . . . . 0.0 111.197 -179.034 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.483 HG12 ' CD2' ' A' ' 13' ' ' LEU . 28.7 m -112.86 156.77 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 178.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.5 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -109.47 109.25 20.02 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.014 -1.054 . . . . 0.0 109.063 -179.933 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.819 ' CA ' HG13 ' A' ' 7' ' ' VAL . 11.2 p -103.74 140.65 21.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.707 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.873 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -138.93 160.82 38.83 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 118.681 -1.207 . . . . 0.0 110.142 179.635 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.585 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.03 140.25 11.55 Favored Glycine 0 C--N 1.297 -1.636 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.656 ' HB3' ' OG1' ' A' ' 4' ' ' THR . . . -142.03 126.32 17.58 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 120.543 -1.563 . . . . 0.0 109.318 179.497 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.508 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 88.65 28.53 21.43 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 118.964 -1.588 . . . . 0.0 109.52 -179.666 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.589 HD22 ' HG3' ' A' ' 105' ' ' PRO . 2.5 mt -88.0 175.92 7.55 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.003 -1.292 . . . . 0.0 108.339 -179.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.03 97.7 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.402 0 O-C-N 120.825 -1.172 . . . . 0.0 109.707 -179.57 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.639 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.92 77.27 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.433 -179.057 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.562 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.45 34.45 0.32 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.564 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.9 p -146.07 111.92 5.63 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.016 -1.285 . . . . 0.0 111.195 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.562 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.38 126.79 5.48 Favored 'General case' 0 N--CA 1.493 1.7 0 CA-C-N 115.687 -0.688 . . . . 0.0 109.501 178.06 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.548 ' CE1' ' OD2' ' A' ' 99' ' ' ASP . 13.3 m-85 -117.45 152.5 34.88 Favored 'General case' 0 N--CA 1.491 1.618 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.494 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -101.42 162.51 12.84 Favored 'General case' 0 N--CA 1.492 1.655 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 178.771 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.718 HG22 HG11 ' A' ' 21' ' ' VAL . 3.8 p -148.99 117.82 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.013 -1.054 . . . . 0.0 110.049 -177.794 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.511 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -170.86 -176.25 40.0 Favored Glycine 0 N--CA 1.493 2.48 0 C-N-CA 118.266 -1.921 . . . . 0.0 111.736 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.595 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.06 108.91 21.19 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -179.788 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.467 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.55 148.69 52.38 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.275 -0.891 . . . . 0.0 109.713 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.494 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.95 139.39 54.0 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.316 -0.865 . . . . 0.0 110.643 -178.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.862 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.31 114.55 26.34 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 178.157 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 12.4 m -106.34 15.43 7.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 120.974 -1.079 . . . . 0.0 110.771 -178.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.751 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.56 -175.31 0.1 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.894 -1.129 . . . . 0.0 110.124 179.657 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 39.2 p -71.45 96.84 1.54 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.395 -0.816 . . . . 0.0 109.691 -179.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.84 27.05 35.74 Favored Glycine 0 N--CA 1.493 2.496 0 C-N-CA 120.144 -1.027 . . . . 0.0 111.499 178.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.751 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.1 106.52 20.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 O-C-N 120.595 -1.532 . . . . 0.0 107.382 178.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.862 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -116.08 104.62 11.75 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.492 -1.38 . . . . 0.0 109.485 -177.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.012 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.09 109.57 22.31 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 120.735 -1.228 . . . . 0.0 108.295 179.062 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -107.22 163.78 12.73 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.974 -1.079 . . . . 0.0 110.303 -178.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.536 HD22 ' HB3' ' A' ' 50' ' ' ALA . 16.6 t30 -110.36 139.08 21.14 Favored Pre-proline 0 N--CA 1.503 2.219 0 O-C-N 121.369 -0.832 . . . . 0.0 109.89 -179.401 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.6 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 6.1 Cg_endo -74.55 23.99 0.37 Allowed 'Trans proline' 0 N--CA 1.495 1.591 0 C-N-CA 125.252 3.968 . . . . 0.0 111.445 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.536 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -116.58 1.12 12.84 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.474 -1.392 . . . . 0.0 109.043 179.474 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.511 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -137.75 15.39 2.9 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.399 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -79.51 90.88 5.1 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.978 -0.689 . . . . 0.0 110.831 -178.649 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.625 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.24 -170.14 1.6 Allowed 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.255 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.451 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.91 136.03 0.09 Allowed 'General case' 0 C--N 1.305 -1.331 0 O-C-N 120.657 -1.277 . . . . 0.0 111.093 -179.354 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.804 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.3 p -150.57 157.35 5.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 178.212 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.562 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.25 145.0 26.5 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.579 -1.325 . . . . 0.0 109.784 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.009 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.15 107.77 2.04 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 122.392 1.091 . . . . 0.0 109.56 178.793 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.553 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.9 p-10 -60.4 -139.26 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.992 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.857 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.639 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -53.01 -49.69 65.74 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.427 -0.795 . . . . 0.0 110.341 -178.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -102.56 -36.21 8.45 Favored 'General case' 0 C--N 1.287 -2.148 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 178.4 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.982 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.4 67.14 0.61 Allowed Glycine 0 N--CA 1.48 1.601 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 178.242 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.585 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.1 m -100.98 130.02 46.91 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.566 -0.961 . . . . 0.0 108.992 178.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.804 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.76 108.9 6.79 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.225 -0.99 . . . . 0.0 109.496 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.445 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.9 m -125.94 119.73 28.51 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.275 -0.891 . . . . 0.0 109.592 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.455 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.41 144.6 30.74 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.432 -0.793 . . . . 0.0 109.389 179.86 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.0 p -98.96 132.29 44.39 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.418 -0.801 . . . . 0.0 109.355 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.743 ' O ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -130.84 167.83 18.27 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.292 -0.88 . . . . 0.0 109.624 -179.511 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.766 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -99.33 125.54 45.01 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.183 -0.948 . . . . 0.0 109.344 -179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.568 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.4 m -137.7 143.04 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 120.985 -1.072 . . . . 0.0 109.857 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.577 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.8 ptt180 -145.95 -170.92 3.59 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.597 -1.314 . . . . 0.0 110.888 -179.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.616 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -56.12 -102.05 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.769 -0.582 . . . . 0.0 109.488 -179.405 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.505 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -55.38 141.0 37.9 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 120.715 -1.24 . . . . 0.0 108.266 179.554 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.577 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.06 137.13 7.16 Favored 'General case' 0 C--N 1.295 -1.777 0 C-N-CA 118.922 -1.111 . . . . 0.0 109.634 -178.357 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.566 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 9.9 mm-40 -33.03 121.62 0.37 Allowed 'General case' 0 N--CA 1.488 1.471 0 CA-C-O 121.604 0.716 . . . . 0.0 110.868 -178.266 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.012 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.05 44.87 2.99 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -179.555 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.6 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-85 -37.88 112.6 0.22 Allowed 'General case' 0 N--CA 1.508 2.436 0 O-C-N 121.252 -1.146 . . . . 0.0 110.094 179.691 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.739 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.15 126.95 34.6 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 120.944 -1.098 . . . . 0.0 109.503 -179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.582 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 34.9 t80 -63.84 58.3 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.0 0 O-C-N 120.967 -1.083 . . . . 0.0 110.338 179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 10.9 t0 -161.67 19.83 0.11 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.001 -1.062 . . . . 0.0 109.762 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.15 -26.93 5.25 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.427 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.1 OUTLIER -92.43 157.09 16.78 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.009 -1.289 . . . . 0.0 110.322 -179.402 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.473 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -104.44 133.2 49.73 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.656 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.739 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.4 t90 -81.26 -18.96 44.14 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 120.835 -1.166 . . . . 0.0 110.427 -178.678 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.45 173.56 18.63 Favored Glycine 0 N--CA 1.485 1.962 0 N-CA-C 108.931 -1.668 . . . . 0.0 108.931 -179.687 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.37 106.83 1.19 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 179.156 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.647 HG21 ' HB3' ' A' ' 46' ' ' ALA . 50.2 t -77.9 106.17 7.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 O-C-N 121.302 -0.874 . . . . 0.0 109.504 -178.716 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.543 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.51 110.97 2.89 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.36 -0.837 . . . . 0.0 109.826 -179.573 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.616 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -62.5 -5.98 3.01 Favored 'General case' 0 N--CA 1.501 2.078 0 C-N-CA 118.32 -1.352 . . . . 0.0 109.901 179.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -87.13 -1.19 57.71 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.611 -1.306 . . . . 0.0 109.336 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.543 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.0 -49.54 3.02 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.253 -0.905 . . . . 0.0 108.959 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.82 -179.22 3.87 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.582 -0.699 . . . . 0.0 109.441 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.03 115.37 30.32 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.329 -0.857 . . . . 0.0 109.003 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.561 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.2 m -96.75 122.44 39.69 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.857 -1.152 . . . . 0.0 109.476 -179.362 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.58 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.29 147.86 26.55 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-O 122.451 1.12 . . . . 0.0 111.208 -179.354 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.473 ' CG1' HG11 ' A' ' 7' ' ' VAL . 60.8 t -104.18 111.09 32.44 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.973 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -149.07 -172.63 18.98 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 118.108 -1.996 . . . . 0.0 111.769 -177.588 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.5 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -114.4 -179.06 3.52 Favored 'General case' 0 N--CA 1.485 1.319 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 -179.11 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.574 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -170.83 167.05 7.67 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.428 -0.795 . . . . 0.0 109.128 -179.406 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.72 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 3.3 m-20 -102.31 -12.8 17.67 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.104 -0.998 . . . . 0.0 109.51 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.72 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 75.82 36.29 0.46 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.472 -0.768 . . . . 0.0 109.343 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -135.47 -33.17 0.89 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.548 -0.72 . . . . 0.0 110.615 -179.412 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.573 ' N ' H193 ' A' ' 114' ' ' CHR . . . -178.94 -42.58 0.07 OUTLIER Glycine 0 N--CA 1.483 1.769 0 N-CA-C 107.617 -2.193 . . . . 0.0 107.617 -179.564 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.72 -178.75 7.3 Favored 'General case' 0 C--N 1.308 -1.228 0 O-C-N 121.587 -0.949 . . . . 0.0 109.457 179.036 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.482 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -175.66 -167.15 34.26 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 108.603 -1.799 . . . . 0.0 108.603 -179.577 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.589 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.7 Cg_exo -45.72 179.65 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.391 0 C-N-CA 123.262 2.641 . . . . 0.0 109.638 179.45 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.84 174.82 6.98 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.917 -1.115 . . . . 0.0 110.571 -178.759 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -115.15 163.3 12.23 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.02 129.34 57.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.23 -1.159 . . . . 0.0 109.241 -179.317 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.58 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.08 122.81 23.27 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.605 -0.684 . . . . 0.0 109.567 179.496 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.855 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.93 169.88 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.259 -0.9 . . . . 0.0 109.249 -179.866 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.461 ' O ' ' HA ' ' A' ' 11' ' ' SER . 1.7 t -140.02 155.4 47.1 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.158 -0.964 . . . . 0.0 109.669 -179.803 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.855 ' CE2' HD12 ' A' ' 110' ' ' ILE . 87.4 m-85 -131.91 88.31 2.54 Favored 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.109 -0.994 . . . . 0.0 109.607 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 16.5 p30 . . . . . 0 N--CA 1.489 1.489 0 CA-C-O 118.061 -0.971 . . . . 0.0 109.554 179.959 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.736 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.883 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -114.7 171.79 4.16 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.319 -0.863 . . . . 0.0 109.459 -179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.883 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.8 Cg_exo -60.16 157.21 35.85 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.261 1.974 . . . . 0.0 110.693 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.543 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -175.8 -169.24 0.33 Allowed 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 178.904 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.543 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.95 133.57 2.86 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.909 -1.119 . . . . 0.0 110.609 -179.09 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.995 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.8 p -107.13 104.59 14.27 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 122.595 1.188 . . . . 0.0 110.023 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.993 HG22 HG23 ' A' ' 21' ' ' VAL . 13.2 t -117.93 121.2 66.77 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.435 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.433 179.798 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.512 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.95 148.5 7.42 Favored Pre-proline 0 N--CA 1.487 1.379 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 -179.74 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.512 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.4 Cg_endo -75.42 153.33 98.45 Favored 'Cis proline' 0 C--N 1.309 -1.501 0 C-N-CA 123.648 -1.397 . . . . 0.0 109.614 -0.447 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.493 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 5.1 m -97.27 -22.14 16.85 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.515 ' HB3' ' CB ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -134.43 158.65 43.33 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.543 -0.723 . . . . 0.0 109.537 179.96 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.24 36.73 30.17 Favored Glycine 0 N--CA 1.495 2.598 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.798 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.5 mt -89.32 -43.89 10.61 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 123.181 1.467 . . . . 0.0 110.513 -178.512 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.74 144.94 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.335 0 CA-C-N 113.543 -1.662 . . . . 0.0 109.946 -179.646 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.584 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.4 p-10 -50.77 107.18 0.16 Allowed 'General case' 0 C--N 1.301 -1.525 0 CA-C-O 121.657 0.741 . . . . 0.0 111.788 -178.469 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.1 15.65 9.72 Favored Glycine 0 N--CA 1.486 1.997 0 C-N-CA 119.423 -1.37 . . . . 0.0 112.942 177.224 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.798 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.1 t -103.21 -172.31 2.09 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 121.103 2.451 . . . . 0.0 109.784 179.221 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.753 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.5 t -129.72 139.14 52.38 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.18 -178.726 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.484 HG11 HD11 ' A' ' 13' ' ' LEU . 26.8 m -118.32 154.36 20.42 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.64 109.21 20.35 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.233 -0.917 . . . . 0.0 109.292 -179.954 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.993 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -106.09 124.09 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.732 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.995 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.16 165.36 12.47 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 120.731 -1.231 . . . . 0.0 108.85 179.421 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.636 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -142.1 107.68 0.5 Allowed Glycine 0 C--O 1.203 -1.838 0 N-CA-C 108.376 -1.89 . . . . 0.0 108.376 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.564 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -117.1 139.09 51.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.706 -1.467 . . . . 0.0 110.83 -178.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.535 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 83.68 26.74 41.1 Favored Glycine 0 N--CA 1.491 2.364 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.044 179.011 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.566 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -88.34 172.97 9.01 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.975 -1.309 . . . . 0.0 108.476 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.024 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.52 99.75 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.064 -1.023 . . . . 0.0 109.602 -179.576 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.82 76.3 0.01 OUTLIER 'General case' 0 C--N 1.295 -1.769 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.088 -179.257 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.594 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.81 33.62 0.22 Allowed Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.677 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.556 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 63.3 p -142.73 109.8 5.58 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.032 -1.275 . . . . 0.0 111.178 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.594 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.08 109.98 0.38 Allowed 'General case' 0 N--CA 1.497 1.894 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.361 177.79 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.52 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 5.0 m-30 -105.62 155.97 18.71 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.101 -0.999 . . . . 0.0 109.029 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.509 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -98.83 163.25 12.69 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.744 -1.222 . . . . 0.0 107.763 178.791 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.735 HG11 HG21 ' A' ' 65' ' ' THR . 7.0 p -144.45 114.85 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.151 -0.968 . . . . 0.0 109.91 -177.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.65 -177.34 39.54 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 118.204 -1.95 . . . . 0.0 111.716 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.59 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.0 OUTLIER -99.77 112.2 24.46 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 -179.98 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 64.4 m -130.12 154.36 47.56 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 121.428 -0.795 . . . . 0.0 109.703 -179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.615 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -130.89 137.77 49.49 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.507 -0.745 . . . . 0.0 110.607 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.904 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.71 114.68 26.64 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 178.377 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.9 m -105.85 15.2 7.14 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 120.911 -1.118 . . . . 0.0 110.703 -178.548 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.779 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.23 -175.96 0.08 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.899 -1.126 . . . . 0.0 110.117 179.598 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.8 HG23 ' O ' ' A' ' 42' ' ' THR . 15.2 t -69.58 97.19 1.0 Allowed 'General case' 0 N--CA 1.487 1.402 0 CA-C-O 121.786 0.803 . . . . 0.0 109.985 -179.474 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.12 27.68 36.36 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.25 -0.976 . . . . 0.0 111.523 178.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.779 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.86 106.46 20.66 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 O-C-N 120.545 -1.562 . . . . 0.0 107.34 178.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.904 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.5 tp -116.03 106.7 14.05 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.529 -1.357 . . . . 0.0 109.783 -177.598 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.112 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -96.17 110.44 22.72 Favored 'General case' 0 N--CA 1.484 1.272 0 O-C-N 120.765 -1.209 . . . . 0.0 108.554 179.5 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.584 ' HB3' ' CE2' ' A' ' 52' ' ' PHE . 60.8 m -99.71 148.06 24.77 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.337 -0.852 . . . . 0.0 109.979 -178.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.749 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 13.0 t-20 -98.92 132.61 23.35 Favored Pre-proline 0 N--CA 1.501 2.098 0 O-C-N 120.922 -1.111 . . . . 0.0 109.159 179.413 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.581 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.9 Cg_endo -73.48 24.06 0.32 Allowed 'Trans proline' 0 C--N 1.317 -1.087 0 C-N-CA 122.291 1.994 . . . . 0.0 112.011 -179.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.749 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -115.62 1.08 13.47 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.283 -1.51 . . . . 0.0 109.215 179.492 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.573 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.68 17.46 2.34 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 179.332 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.584 ' CE2' ' HB3' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -81.26 89.75 6.07 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.726 -0.789 . . . . 0.0 110.878 -178.787 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -112.57 -170.74 1.72 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.32 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.443 ' OG ' ' HA ' ' A' ' 33' ' ' ASP . 0.8 OUTLIER 178.8 134.62 0.09 Allowed 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.592 -1.318 . . . . 0.0 111.287 -179.342 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.564 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 2.5 p -149.07 161.99 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 178.163 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.29 142.62 29.72 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 120.685 -1.26 . . . . 0.0 110.181 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.024 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.66 108.39 2.45 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.401 1.096 . . . . 0.0 109.735 178.594 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.539 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.5 t70 -62.73 -139.39 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.995 0 CA-C-O 121.494 0.664 . . . . 0.0 110.77 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.85 -50.97 55.68 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.384 -0.823 . . . . 0.0 110.713 -178.722 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 13.6 t30 -103.16 -33.74 9.1 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 106.398 -1.704 . . . . 0.0 106.398 178.591 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.981 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 104.18 70.54 0.82 Allowed Glycine 0 C--N 1.298 -1.544 0 N-CA-C 110.254 -1.139 . . . . 0.0 110.254 178.415 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.636 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 36.7 m -103.34 127.55 50.66 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 121.418 -1.048 . . . . 0.0 109.322 179.566 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.567 ' O ' ' HA ' ' A' ' 22' ' ' ALA . . . -132.09 108.73 9.5 Favored 'General case' 0 N--CA 1.491 1.585 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 50.8 m -118.14 115.3 24.51 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.159 -0.963 . . . . 0.0 109.39 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.735 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.22 137.08 27.09 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.397 -0.814 . . . . 0.0 109.981 -179.862 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.7 p -100.43 133.21 45.19 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.374 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.843 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -135.66 172.23 13.32 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.138 -0.976 . . . . 0.0 109.803 -179.076 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.692 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -99.63 124.68 45.08 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.139 -0.976 . . . . 0.0 109.583 -179.692 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.47 HG23 HD13 ' A' ' 13' ' ' LEU . 17.1 m -135.98 143.58 35.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.015 -1.053 . . . . 0.0 109.664 -179.415 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.584 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.3 ptt180 -141.52 -165.29 1.95 Allowed 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.563 -1.336 . . . . 0.0 110.076 -179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.548 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -72.65 -87.91 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.522 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -60.14 135.98 57.88 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.58 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.615 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.25 135.22 6.85 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 118.105 -1.438 . . . . 0.0 110.586 -177.62 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.543 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -33.29 119.42 0.35 Allowed 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.588 0.709 . . . . 0.0 110.451 -178.637 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.112 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.19 50.21 2.17 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 120.577 -0.82 . . . . 0.0 111.511 -178.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.581 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 1.1 m-85 -36.53 118.94 0.59 Allowed 'General case' 0 N--CA 1.513 2.719 0 O-C-N 121.236 -1.155 . . . . 0.0 110.214 179.568 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.621 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.4 tp -86.93 125.82 34.29 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 120.901 -1.124 . . . . 0.0 109.389 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.0 t80 -63.72 58.58 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.881 -1.137 . . . . 0.0 110.088 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.8 OUTLIER -161.44 21.01 0.12 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.986 -1.071 . . . . 0.0 109.651 179.879 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.02 -30.55 4.66 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.468 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -94.38 165.14 12.71 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.103 -1.234 . . . . 0.0 110.035 -179.417 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.433 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -111.24 140.39 45.84 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -179.897 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.621 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.2 t90 -81.9 -21.42 37.4 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.77 -1.207 . . . . 0.0 110.461 -178.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.67 176.54 18.87 Favored Glycine 0 N--CA 1.485 1.929 0 N-CA-C 108.558 -1.817 . . . . 0.0 108.558 -179.357 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -64.12 109.96 2.01 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.094 -1.239 . . . . 0.0 107.741 179.223 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.569 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.6 t -82.4 103.21 9.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.394 -0.816 . . . . 0.0 108.916 -178.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.528 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -63.95 110.53 2.15 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.48 -0.762 . . . . 0.0 109.851 -179.344 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.548 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.07 -4.96 5.39 Favored 'General case' 0 N--CA 1.499 1.985 0 C-N-CA 118.269 -1.372 . . . . 0.0 109.829 179.457 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.4 p -85.31 5.1 31.99 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.779 -1.201 . . . . 0.0 108.877 179.347 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.528 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -121.11 -48.9 2.21 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.327 -0.858 . . . . 0.0 109.047 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.63 -177.78 3.47 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.569 -0.707 . . . . 0.0 109.38 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -107.14 114.09 27.93 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.391 -0.818 . . . . 0.0 108.921 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.495 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.5 m -97.4 122.74 40.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.892 -1.13 . . . . 0.0 109.756 -179.259 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.618 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.66 147.73 27.33 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 122.444 1.116 . . . . 0.0 111.346 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.551 ' HB ' HG11 ' A' ' 7' ' ' VAL . 66.9 t -101.47 109.8 26.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.944 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 177.618 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.412 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.19 -172.52 18.23 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 118.07 -2.014 . . . . 0.0 111.59 -177.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.492 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.74 -178.12 3.32 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -178.904 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.588 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 30.3 p -170.2 164.24 9.07 Favored 'General case' 0 C--N 1.296 -1.738 0 O-C-N 121.352 -0.842 . . . . 0.0 109.479 -179.375 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.52 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -114.96 -156.56 0.61 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.206 -0.934 . . . . 0.0 108.808 179.624 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.472 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -118.5 36.17 4.5 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.824 -1.172 . . . . 0.0 109.221 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.8 -32.71 4.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.298 -0.876 . . . . 0.0 110.448 -179.57 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.993 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 164.27 -36.07 0.29 Allowed Glycine 0 N--CA 1.482 1.706 0 N-CA-C 107.567 -2.213 . . . . 0.0 107.567 -179.518 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.479 ' ND2' ' O9 ' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -157.91 -178.62 7.45 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.512 -0.993 . . . . 0.0 109.763 179.098 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.02 -161.76 12.85 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 108.313 -1.915 . . . . 0.0 108.313 -179.328 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.492 ' HB2' HD12 ' A' ' 97' ' ' LEU . 5.0 Cg_exo -47.17 177.69 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.701 0 CA-C-N 118.789 1.295 . . . . 0.0 110.076 179.263 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -91.79 179.79 5.53 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.059 -1.026 . . . . 0.0 110.724 -178.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.412 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.4 160.99 13.36 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.23 130.01 51.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 O-C-N 121.324 -1.103 . . . . 0.0 109.345 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.618 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.83 127.3 32.13 Favored 'General case' 0 C--N 1.291 -1.972 0 O-C-N 121.583 -0.698 . . . . 0.0 109.65 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.641 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 19.6 pt -97.25 178.52 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 O-C-N 121.24 -0.912 . . . . 0.0 109.279 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.515 ' CB ' ' HB3' ' A' ' 11' ' ' SER . 0.5 OUTLIER -143.18 152.28 41.59 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.366 -0.834 . . . . 0.0 109.571 179.838 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.641 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 97.3 m-85 -132.82 68.55 1.5 Allowed 'General case' 0 N--CA 1.484 1.249 0 O-C-N 121.082 -1.011 . . . . 0.0 109.569 -179.649 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.8 p30 . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 117.998 -1.001 . . . . 0.0 109.458 -179.971 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.993 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -122.06 151.35 58.27 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.199 -0.938 . . . . 0.0 109.456 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.523 ' HB3' HD23 ' A' ' 26' ' ' LEU . 3.5 Cg_exo -60.79 157.24 38.81 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 122.212 1.941 . . . . 0.0 110.543 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.601 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -148.69 159.93 43.65 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -179.515 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -149.12 122.45 9.01 Favored 'General case' 0 C--N 1.295 -1.775 0 CA-C-O 122.334 1.064 . . . . 0.0 110.225 -179.69 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.818 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -116.38 109.01 16.77 Favored 'General case' 0 C--N 1.297 -1.676 0 CA-C-O 123.105 1.431 . . . . 0.0 109.605 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.925 HG22 HG23 ' A' ' 21' ' ' VAL . 4.0 t -114.58 135.33 54.73 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.669 0 CA-C-N 114.194 -1.366 . . . . 0.0 109.688 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.472 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.65 149.82 4.49 Favored Pre-proline 0 N--CA 1.487 1.419 0 O-C-N 121.193 -0.942 . . . . 0.0 108.984 -179.493 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.472 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -79.3 149.38 83.08 Favored 'Cis proline' 0 C--N 1.312 -1.376 0 C-N-CA 123.511 -1.454 . . . . 0.0 109.393 -1.009 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.661 ' HA ' HG22 ' A' ' 110' ' ' ILE . 86.1 p -90.99 -23.83 20.28 Favored 'General case' 0 C--N 1.292 -1.929 0 O-C-N 121.551 -0.718 . . . . 0.0 109.191 179.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.49 ' CB ' ' HB3' ' A' ' 111' ' ' SER . 0.7 OUTLIER -129.8 158.94 38.05 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.496 -0.753 . . . . 0.0 109.595 -179.881 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.51 37.33 27.55 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 108.64 -1.784 . . . . 0.0 108.64 -179.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.806 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.0 mt -92.11 -44.02 9.06 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.213 1.482 . . . . 0.0 110.757 -178.459 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.463 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.16 145.16 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.299 0 CA-C-N 113.505 -1.68 . . . . 0.0 110.055 -179.753 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.613 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.3 p-10 -50.32 106.4 0.12 Allowed 'General case' 0 C--N 1.3 -1.567 0 CA-C-O 121.445 0.641 . . . . 0.0 111.645 -178.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.46 14.93 8.53 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.515 -1.326 . . . . 0.0 112.995 177.18 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.806 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -104.97 -174.18 2.48 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 121.134 2.467 . . . . 0.0 109.919 179.348 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.771 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.5 t -127.09 136.11 61.69 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.437 0 CA-C-N 114.541 -1.208 . . . . 0.0 111.258 -178.84 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.472 ' CG1' ' CD1' ' A' ' 13' ' ' LEU . 23.3 m -112.25 154.86 13.66 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 178.61 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.506 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 18.9 tttt -107.73 109.38 20.95 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.174 -0.954 . . . . 0.0 108.949 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.925 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.73 139.42 22.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.349 -0.844 . . . . 0.0 108.79 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.818 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.17 161.75 34.02 Favored 'General case' 0 C--N 1.305 -1.358 0 O-C-N 120.886 -1.134 . . . . 0.0 109.848 179.483 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.597 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.57 139.7 10.86 Favored Glycine 0 C--N 1.297 -1.604 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 179.752 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.601 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.37 125.87 16.76 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.499 -1.589 . . . . 0.0 109.3 179.48 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.477 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 88.97 27.63 23.18 Favored Glycine 0 N--CA 1.488 2.146 0 C-N-CA 118.8 -1.667 . . . . 0.0 109.736 -179.685 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.562 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.1 mt -87.65 174.16 8.6 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 120.825 -1.397 . . . . 0.0 108.215 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.017 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.46 97.18 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.916 -1.115 . . . . 0.0 109.888 -179.412 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.623 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.76 77.13 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.761 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.404 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.69 34.09 0.32 Allowed Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.383 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.546 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 43.3 p -147.13 112.8 5.67 Favored 'General case' 0 C--N 1.308 -1.209 0 O-C-N 120.819 -1.401 . . . . 0.0 111.335 -179.804 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.566 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.87 126.58 5.86 Favored 'General case' 0 N--CA 1.491 1.623 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.846 178.063 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.485 ' CD2' ' O ' ' A' ' 30' ' ' THR . 12.7 m-85 -118.5 152.26 36.29 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.478 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -100.93 160.34 14.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.724 -1.235 . . . . 0.0 107.825 178.911 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.955 HG11 HG21 ' A' ' 65' ' ' THR . 3.7 p -142.4 119.8 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.218 -0.926 . . . . 0.0 109.451 -178.055 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.54 -178.54 41.35 Favored Glycine 0 N--CA 1.494 2.506 0 C-N-CA 118.409 -1.853 . . . . 0.0 111.505 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.684 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -101.0 108.58 20.33 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.867 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.462 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.45 149.51 51.19 Favored 'General case' 0 C--N 1.296 -1.738 0 O-C-N 121.264 -0.898 . . . . 0.0 109.956 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.497 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -125.03 139.53 53.73 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.367 -0.833 . . . . 0.0 110.673 -179.146 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.29 114.92 26.75 Favored 'General case' 0 N--CA 1.494 1.763 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.199 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.8 m -105.11 15.23 6.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.093 -1.004 . . . . 0.0 110.595 -178.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.759 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.61 -176.06 0.08 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.947 -1.096 . . . . 0.0 110.038 179.631 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.776 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.93 97.75 1.48 Allowed 'General case' 0 C--N 1.304 -1.386 0 CA-C-O 121.803 0.811 . . . . 0.0 109.848 -179.639 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.14 27.65 36.4 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 120.186 -1.007 . . . . 0.0 111.419 178.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -115.83 106.44 20.43 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 O-C-N 120.621 -1.517 . . . . 0.0 107.189 178.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -116.03 104.69 11.83 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.461 -1.399 . . . . 0.0 109.936 -177.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.045 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.41 22.17 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.827 -1.17 . . . . 0.0 108.179 178.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.9 t -107.46 163.63 12.89 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.847 -1.158 . . . . 0.0 110.295 -179.006 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.5 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 13.6 t30 -108.98 134.18 20.46 Favored Pre-proline 0 N--CA 1.502 2.136 0 O-C-N 121.351 -0.843 . . . . 0.0 109.575 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.598 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.6 Cg_endo -74.38 26.85 0.34 Allowed 'Trans proline' 0 C--N 1.319 -0.98 0 C-N-CA 122.486 2.124 . . . . 0.0 112.197 -179.396 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.494 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -109.29 -3.15 17.39 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.329 -1.482 . . . . 0.0 109.299 179.664 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.874 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.7 m-20 -135.96 12.39 3.36 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -70.07 83.6 0.51 Allowed 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.683 -0.807 . . . . 0.0 110.74 -178.667 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -105.23 -167.92 1.4 Allowed 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 178.356 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.473 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.7 t 179.07 135.59 0.09 Allowed 'General case' 0 C--N 1.306 -1.325 0 O-C-N 120.632 -1.292 . . . . 0.0 111.231 -179.38 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.773 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.7 p -149.24 156.63 7.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 178.095 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.566 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.57 145.39 26.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.583 -1.323 . . . . 0.0 109.738 -179.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.017 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.93 108.67 2.66 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-O 122.334 1.064 . . . . 0.0 109.592 178.756 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.563 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 p-10 -62.92 -139.58 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.054 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.641 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.623 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.92 -51.73 49.19 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.446 -0.784 . . . . 0.0 110.569 -178.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -102.51 -32.98 9.67 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 178.582 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.84 66.72 0.64 Allowed Glycine 0 C--N 1.299 -1.511 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 178.168 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.597 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 55.6 p -98.69 132.51 44.01 Favored 'General case' 0 N--CA 1.482 1.144 0 O-C-N 121.289 -1.124 . . . . 0.0 109.048 179.001 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.773 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.03 108.6 6.95 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.146 -1.022 . . . . 0.0 109.535 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 5.3 m -124.12 117.48 24.76 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.265 -0.897 . . . . 0.0 109.641 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.955 HG21 HG11 ' A' ' 34' ' ' VAL . 5.2 t -145.99 145.2 30.54 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.441 -0.787 . . . . 0.0 109.361 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 53.3 p -99.03 143.98 28.69 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.428 -0.795 . . . . 0.0 109.342 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.874 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -145.35 169.86 17.45 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.305 -0.872 . . . . 0.0 109.459 -178.96 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.754 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -102.32 123.27 45.83 Favored 'General case' 0 N--CA 1.498 1.975 0 O-C-N 120.842 -1.161 . . . . 0.0 110.388 -178.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.842 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.2 m -131.12 143.98 39.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.99 0 O-C-N 120.996 -1.065 . . . . 0.0 110.016 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.613 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.3 ptt180 -148.93 -176.63 5.42 Favored 'General case' 0 N--CA 1.483 1.221 0 O-C-N 120.555 -1.341 . . . . 0.0 110.649 179.621 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.619 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.73 -101.5 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -179.562 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.5 OUTLIER -56.29 140.07 46.17 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 120.777 -1.202 . . . . 0.0 108.313 179.591 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.569 ' CZ ' ' SG ' ' A' ' 93' ' ' CYS . 0.3 OUTLIER -160.81 135.69 7.56 Favored 'General case' 0 C--N 1.296 -1.74 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.545 -178.57 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.5 ' N ' ' OD1' ' A' ' 48' ' ' ASN . 6.1 mm-40 -33.05 122.18 0.38 Allowed 'General case' 0 N--CA 1.491 1.624 0 CA-C-O 121.609 0.718 . . . . 0.0 110.775 -178.038 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.045 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.78 45.34 2.89 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 -179.326 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.598 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-85 -37.64 114.62 0.35 Allowed 'General case' 0 N--CA 1.512 2.632 0 O-C-N 121.277 -1.131 . . . . 0.0 110.12 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.733 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -87.44 127.22 35.22 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.115 -0.991 . . . . 0.0 109.291 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 49.8 t80 -63.54 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.061 0 O-C-N 120.862 -1.149 . . . . 0.0 110.137 179.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.535 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.2 t0 -161.2 19.33 0.12 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.945 -1.097 . . . . 0.0 109.805 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.55 -26.73 5.61 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 42.1 p -94.41 160.21 14.76 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.121 -1.223 . . . . 0.0 110.11 -179.458 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.477 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.6 OUTLIER -106.67 136.12 47.03 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 179.899 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.733 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.1 t90 -81.91 -18.9 42.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.819 -1.175 . . . . 0.0 110.428 -178.653 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.46 174.38 18.43 Favored Glycine 0 N--CA 1.486 2.024 0 N-CA-C 108.772 -1.731 . . . . 0.0 108.772 -179.602 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.18 106.06 1.23 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.113 -1.228 . . . . 0.0 107.688 179.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.683 HG21 ' HB3' ' A' ' 46' ' ' ALA . 51.3 t -76.96 105.22 5.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.316 -0.865 . . . . 0.0 109.361 -178.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.675 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.62 110.85 2.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.468 -0.77 . . . . 0.0 109.765 -179.599 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.619 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.08 -5.73 3.39 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 120.517 -1.364 . . . . 0.0 109.846 179.422 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -86.52 -0.57 56.36 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.706 -1.246 . . . . 0.0 109.172 179.655 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.675 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -113.19 -50.13 2.88 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.322 -0.861 . . . . 0.0 108.957 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.63 -178.62 3.71 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.576 -0.703 . . . . 0.0 109.428 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.54 115.31 30.02 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.337 -0.852 . . . . 0.0 109.039 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.569 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.24 123.36 41.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.875 -1.14 . . . . 0.0 109.7 -179.278 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.623 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.76 145.92 29.69 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.474 1.13 . . . . 0.0 111.113 -179.424 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.517 ' CG1' HG11 ' A' ' 7' ' ' VAL . 55.6 t -101.76 110.09 27.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.049 0 N-CA-C 106.646 -1.612 . . . . 0.0 106.646 177.474 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.483 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.01 -171.29 16.83 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 118.106 -1.997 . . . . 0.0 111.694 -177.475 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.49 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -119.0 179.48 4.14 Favored 'General case' 0 N--CA 1.485 1.283 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.038 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.544 ' OG ' ' C21' ' A' ' 114' ' ' CHR . 3.5 m -179.16 -179.65 0.59 Allowed 'General case' 0 C--N 1.294 -1.817 0 O-C-N 121.435 -0.791 . . . . 0.0 109.666 -179.867 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.415 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -128.54 -159.14 0.93 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.975 -1.078 . . . . 0.0 109.036 179.921 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.415 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.13 36.8 4.07 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.736 -1.228 . . . . 0.0 109.037 179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -113.14 -32.81 6.2 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.371 -0.83 . . . . 0.0 109.958 -179.591 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.768 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.13 -35.63 0.27 Allowed Glycine 0 N--CA 1.482 1.721 0 N-CA-C 107.909 -2.076 . . . . 0.0 107.909 -179.702 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.409 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.65 -177.15 3.8 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.603 -0.939 . . . . 0.0 109.725 179.395 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.63 -161.65 19.15 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 108.32 -1.912 . . . . 0.0 108.32 -179.388 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.495 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.9 Cg_exo -46.68 176.26 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.655 0 CA-C-N 118.808 1.304 . . . . 0.0 110.173 179.32 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -94.19 -174.96 3.53 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.038 -1.039 . . . . 0.0 110.403 -178.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.483 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.79 165.0 13.47 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.449 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.55 130.57 50.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.353 -1.087 . . . . 0.0 109.223 -179.416 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.623 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.84 125.48 28.26 Favored 'General case' 0 C--N 1.291 -1.964 0 O-C-N 121.669 -0.644 . . . . 0.0 109.774 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.661 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.5 pt -97.82 170.11 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.307 -0.871 . . . . 0.0 109.22 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.49 ' HB3' ' CB ' ' A' ' 11' ' ' SER . 3.6 t -138.09 158.33 44.53 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.375 -0.828 . . . . 0.0 109.449 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.633 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 30.4 m-85 -123.12 125.7 45.65 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.184 -0.948 . . . . 0.0 109.539 -179.731 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.46 ' OXT' ' O ' ' A' ' 112' ' ' PHE . 19.8 p30 . . . . . 0 N--CA 1.488 1.454 0 O-C-N 121.168 -0.957 . . . . 0.0 109.457 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.768 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -120.61 148.62 48.43 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 121.215 -0.928 . . . . 0.0 109.49 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.588 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 4.4 Cg_exo -60.4 157.16 37.28 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 122.348 2.032 . . . . 0.0 110.581 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.552 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.8 -169.69 0.14 Allowed 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 179.209 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.587 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . -166.43 133.55 2.6 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 120.614 -1.304 . . . . 0.0 111.109 -179.322 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.007 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -101.66 104.47 15.31 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 122.413 1.101 . . . . 0.0 110.032 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.949 HG22 HG23 ' A' ' 21' ' ' VAL . 3.4 t -118.54 115.4 48.0 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.415 0 CA-C-O 121.679 0.752 . . . . 0.0 110.455 179.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.504 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.22 147.85 12.78 Favored Pre-proline 0 N--CA 1.487 1.397 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 -179.723 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.504 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.3 Cg_endo -77.07 152.05 94.41 Favored 'Cis proline' 0 C--N 1.309 -1.506 0 C-N-CA 123.693 -1.378 . . . . 0.0 109.561 -0.328 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.685 ' HA ' HG22 ' A' ' 110' ' ' ILE . 13.6 p -89.71 -25.84 20.98 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.642 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.518 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.0 m -136.39 167.98 20.3 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.555 -0.715 . . . . 0.0 109.338 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.47 38.12 39.15 Favored Glycine 0 N--CA 1.497 2.716 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.747 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.3 mt -93.22 -42.63 9.24 Favored 'General case' 0 C--N 1.299 -1.628 0 CA-C-O 123.319 1.533 . . . . 0.0 110.561 -178.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.56 142.58 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.284 0 CA-C-N 113.402 -1.726 . . . . 0.0 109.67 -179.385 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.606 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.2 p-10 -50.61 105.95 0.11 Allowed 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.588 0.709 . . . . 0.0 111.364 -178.517 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.68 14.15 8.24 Favored Glycine 0 N--CA 1.484 1.88 0 C-N-CA 119.446 -1.359 . . . . 0.0 112.982 177.418 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.747 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -106.21 -172.24 2.05 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 121.22 2.51 . . . . 0.0 109.831 179.161 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.985 HG22 HG22 ' A' ' 68' ' ' THR . 17.1 t -129.7 138.32 54.49 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 CA-C-N 114.844 -1.071 . . . . 0.0 111.34 -178.786 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.62 HG11 HD11 ' A' ' 13' ' ' LEU . 35.8 m -114.34 155.35 15.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.782 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 28.2 tttt -107.13 108.87 20.53 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.184 -0.948 . . . . 0.0 109.466 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.949 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -105.64 123.29 59.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 179.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.007 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.66 166.55 12.28 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.716 -1.24 . . . . 0.0 109.325 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.62 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.05 142.45 13.89 Favored Glycine 0 C--N 1.294 -1.766 0 N-CA-C 107.381 -2.288 . . . . 0.0 107.381 179.494 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.588 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -147.22 123.27 10.76 Favored 'General case' 0 C--N 1.294 -1.827 0 O-C-N 120.747 -1.443 . . . . 0.0 108.714 179.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.513 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 90.1 27.01 22.38 Favored Glycine 0 N--CA 1.487 2.084 0 C-N-CA 119.155 -1.498 . . . . 0.0 109.802 -179.563 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.553 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.9 OUTLIER -89.0 174.8 7.7 Favored 'General case' 0 C--N 1.307 -1.248 0 O-C-N 120.842 -1.387 . . . . 0.0 108.436 179.85 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.83 99.78 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.949 -1.094 . . . . 0.0 109.808 -179.8 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.581 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.18 78.09 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.191 -179.298 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.83 34.5 0.3 Allowed Glycine 0 N--CA 1.487 2.057 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 179.627 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.565 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 35.2 p -140.99 106.9 5.15 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 121.127 -1.219 . . . . 0.0 111.361 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.59 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.52 110.07 0.34 Allowed 'General case' 0 N--CA 1.498 1.931 0 CA-C-N 115.993 -0.548 . . . . 0.0 109.557 177.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 5.7 m-30 -108.0 154.38 21.72 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.097 -1.002 . . . . 0.0 108.854 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.64 163.03 12.53 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.864 -1.148 . . . . 0.0 108.055 179.133 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.643 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.6 p -140.89 116.71 6.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.133 -0.979 . . . . 0.0 109.351 -178.297 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -164.32 -176.72 36.39 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 118.325 -1.893 . . . . 0.0 111.802 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.593 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -103.15 109.44 21.02 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.862 0.839 . . . . 0.0 109.099 -179.635 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.35 147.79 51.21 Favored 'General case' 0 C--N 1.295 -1.784 0 O-C-N 121.231 -0.918 . . . . 0.0 109.578 179.434 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.558 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.66 138.26 54.41 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.255 -0.903 . . . . 0.0 110.823 -178.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.68 26.48 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.177 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -105.74 14.71 7.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 120.952 -1.092 . . . . 0.0 110.513 -178.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 175.09 -175.9 0.09 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 120.951 -1.093 . . . . 0.0 110.03 179.754 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.784 HG23 ' O ' ' A' ' 42' ' ' THR . 15.0 t -71.33 97.82 1.65 Allowed 'General case' 0 N--CA 1.487 1.379 0 CA-C-O 121.785 0.802 . . . . 0.0 109.785 -179.694 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.78 27.45 34.79 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.238 -0.982 . . . . 0.0 111.524 178.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.98 106.11 19.75 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 O-C-N 120.539 -1.565 . . . . 0.0 107.236 178.836 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.82 104.75 11.64 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.517 -1.365 . . . . 0.0 109.874 -177.692 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.106 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.78 109.45 22.2 Favored 'General case' 0 N--CA 1.485 1.278 0 O-C-N 120.845 -1.16 . . . . 0.0 108.071 178.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.4 t -107.07 162.42 13.87 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.949 -1.094 . . . . 0.0 110.393 -178.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.557 HD22 ' HB3' ' A' ' 50' ' ' ALA . 15.4 t30 -110.32 134.4 20.81 Favored Pre-proline 0 N--CA 1.503 2.199 0 O-C-N 121.453 -0.78 . . . . 0.0 109.759 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.593 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.77 25.03 0.33 Allowed 'Trans proline' 0 C--N 1.318 -1.055 0 C-N-CA 122.346 2.031 . . . . 0.0 112.192 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.557 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -113.43 4.15 16.15 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.327 -1.483 . . . . 0.0 109.233 179.538 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.56 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.78 16.04 2.69 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 179.462 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -79.85 88.86 5.25 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.541 -178.266 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.643 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -105.96 -165.85 1.14 Allowed 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 177.788 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.444 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.77 138.38 0.09 Allowed 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.508 -1.37 . . . . 0.0 111.454 -179.343 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.949 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -156.64 157.2 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.225 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.67 141.82 31.01 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.828 -1.17 . . . . 0.0 109.746 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.05 106.96 0.92 Allowed 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 122.385 1.088 . . . . 0.0 109.144 178.309 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.8 t0 -61.64 -138.9 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.987 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.016 -179.843 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.581 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.59 -52.12 32.46 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.426 -0.796 . . . . 0.0 110.81 -178.534 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -104.06 -33.05 8.91 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 106.209 -1.775 . . . . 0.0 106.209 178.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.016 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.31 65.41 0.56 Allowed Glycine 0 C--N 1.298 -1.542 0 N-CA-C 110.457 -1.057 . . . . 0.0 110.457 178.085 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.62 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.4 m -102.99 127.95 50.01 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 121.492 -1.004 . . . . 0.0 108.819 178.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.949 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.39 109.17 7.55 Favored 'General case' 0 C--N 1.296 -1.737 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.893 -179.312 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 0.8 OUTLIER -116.26 117.43 29.99 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.207 -0.933 . . . . 0.0 109.291 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.573 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.63 143.34 30.72 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.412 -0.805 . . . . 0.0 109.758 -179.978 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.9 p -101.0 140.01 35.89 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.472 -0.768 . . . . 0.0 109.5 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.796 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -139.21 161.6 37.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.36 -0.837 . . . . 0.0 109.524 -179.469 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.985 HG22 HG22 ' A' ' 18' ' ' VAL . 2.9 p -93.87 124.46 37.89 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.159 -0.963 . . . . 0.0 109.438 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.562 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.3 m -135.38 143.71 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.063 -1.023 . . . . 0.0 109.58 -179.314 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.606 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.5 ptt180 -146.79 -177.13 5.49 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 120.453 -1.405 . . . . 0.0 111.042 -179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.627 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.13 -100.98 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -179.674 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -56.2 140.68 43.7 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 120.769 -1.207 . . . . 0.0 108.208 179.546 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.05 136.19 6.66 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 118.82 -1.152 . . . . 0.0 109.672 -178.341 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.52 ' N ' ' OD1' ' A' ' 48' ' ' ASN . 34.6 mt-10 -34.8 122.12 0.53 Allowed 'General case' 0 N--CA 1.489 1.508 0 CA-C-O 121.491 0.662 . . . . 0.0 110.462 -178.314 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.106 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.74 49.14 2.55 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.593 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.1 m-85 -38.82 114.21 0.37 Allowed 'General case' 0 N--CA 1.506 2.353 0 O-C-N 121.18 -1.188 . . . . 0.0 109.915 179.541 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.7 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.44 126.81 34.66 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 120.944 -1.098 . . . . 0.0 109.46 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.577 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.4 t80 -64.12 58.37 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.976 0 O-C-N 120.832 -1.168 . . . . 0.0 110.133 179.718 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.2 t70 -160.54 19.49 0.14 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.125 -0.984 . . . . 0.0 109.704 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.63 -27.18 5.41 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 110.046 -1.221 . . . . 0.0 110.046 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.41 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 21.4 p -94.19 159.71 15.02 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.03 -1.277 . . . . 0.0 110.316 -179.429 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.478 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.52 136.29 46.55 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 179.711 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.7 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.12 -18.47 42.8 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.734 -1.228 . . . . 0.0 110.44 -178.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.94 174.92 19.31 Favored Glycine 0 N--CA 1.485 1.907 0 N-CA-C 108.819 -1.712 . . . . 0.0 108.819 -179.575 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -65.09 105.34 1.04 Allowed 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 179.186 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.643 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.9 t -77.28 107.06 8.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.364 -0.835 . . . . 0.0 109.267 -178.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.536 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.2 m-20 -66.76 111.39 3.69 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.441 -0.787 . . . . 0.0 110.022 -179.313 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.627 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.81 -5.52 4.42 Favored 'General case' 0 N--CA 1.5 2.058 0 C-N-CA 118.171 -1.412 . . . . 0.0 109.832 179.198 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 16.6 p -87.26 1.17 53.98 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.795 -1.19 . . . . 0.0 109.171 179.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.536 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -115.23 -50.66 2.74 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.326 -0.859 . . . . 0.0 108.99 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.67 179.63 4.21 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.488 -0.757 . . . . 0.0 109.43 179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.5 115.39 30.43 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.31 -0.869 . . . . 0.0 108.906 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.563 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.2 m -96.99 122.04 39.54 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.916 -1.115 . . . . 0.0 109.335 -179.368 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.578 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.17 146.37 27.58 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 122.371 1.081 . . . . 0.0 111.286 -179.292 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.607 ' HB ' HG11 ' A' ' 7' ' ' VAL . 54.6 t -105.73 111.74 36.19 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 178.028 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.502 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.46 -169.94 19.06 Favored Glycine 0 N--CA 1.487 2.088 0 C-N-CA 118.251 -1.928 . . . . 0.0 111.482 -177.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.479 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -117.23 173.24 6.79 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.803 -0.822 . . . . 0.0 108.858 -179.356 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.574 ' HB3' ' C20' ' A' ' 114' ' ' CHR . 0.3 OUTLIER 173.19 163.51 0.14 Allowed 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.854 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.47 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.2 OUTLIER -112.13 -156.64 0.59 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.916 -1.115 . . . . 0.0 109.113 179.922 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.47 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.64 36.31 4.34 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 120.806 -1.184 . . . . 0.0 109.031 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.411 ' N ' ' OD2' ' A' ' 99' ' ' ASP . . . -106.93 -31.4 8.35 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.436 -0.79 . . . . 0.0 109.56 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.561 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 168.22 -37.24 0.21 Allowed Glycine 0 N--CA 1.482 1.744 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -173.74 -176.21 1.21 Allowed 'General case' 0 C--N 1.306 -1.29 0 O-C-N 121.562 -0.964 . . . . 0.0 109.828 179.512 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.501 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.6 -159.57 12.51 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.314 -1.914 . . . . 0.0 108.314 -179.311 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.501 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.6 Cg_exo -47.49 -178.13 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.672 0 CA-C-N 118.824 1.312 . . . . 0.0 110.574 179.215 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -94.44 -178.38 4.56 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.057 -1.027 . . . . 0.0 110.405 -178.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.502 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.36 162.22 13.31 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 -179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.25 128.6 52.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 O-C-N 121.465 -1.021 . . . . 0.0 109.123 -179.549 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.578 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.09 118.53 15.07 Favored 'General case' 0 C--N 1.289 -2.059 0 O-C-N 121.7 -0.625 . . . . 0.0 109.555 179.75 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.899 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.8 pt -98.01 172.13 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 O-C-N 121.289 -0.882 . . . . 0.0 108.997 179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.518 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -142.48 154.09 44.22 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.06 -1.025 . . . . 0.0 110.153 -179.744 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.899 ' CE2' HD12 ' A' ' 110' ' ' ILE . 97.8 m-85 -132.64 134.74 45.24 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.302 -0.873 . . . . 0.0 109.278 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.3 p30 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.974 -1.012 . . . . 0.0 109.445 -179.954 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.834 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.44 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -102.83 156.27 35.5 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.299 -0.875 . . . . 0.0 109.465 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.54 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 4.3 Cg_exo -60.1 158.0 32.08 Favored 'Trans proline' 0 C--N 1.31 -1.468 0 C-N-CA 122.29 1.993 . . . . 0.0 110.466 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.619 ' OG1' ' HB3' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -155.33 162.45 40.83 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 -179.316 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.534 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -149.21 125.75 10.98 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.875 -1.14 . . . . 0.0 110.827 -179.784 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.003 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.7 p -104.03 104.82 14.83 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-O 122.417 1.103 . . . . 0.0 110.397 -179.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.94 HG22 HG23 ' A' ' 21' ' ' VAL . 6.1 t -119.26 116.81 52.05 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.477 0 CA-C-O 121.582 0.706 . . . . 0.0 110.226 179.434 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.5 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -161.06 149.28 12.8 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.44 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.5 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.71 152.95 98.87 Favored 'Cis proline' 0 C--N 1.311 -1.428 0 C-N-CA 123.679 -1.384 . . . . 0.0 109.72 -0.507 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.647 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.8 m -91.46 -25.35 19.35 Favored 'General case' 0 C--N 1.292 -1.894 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.49 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 13.5 m -136.84 166.15 24.29 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.6 -0.688 . . . . 0.0 109.39 179.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.27 37.76 35.92 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 108.426 -1.87 . . . . 0.0 108.426 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.787 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.9 mt -92.47 -43.77 9.01 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 123.229 1.49 . . . . 0.0 110.676 -178.242 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.56 144.72 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.517 -1.674 . . . . 0.0 110.044 -179.57 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.601 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.7 p-10 -50.72 107.36 0.17 Allowed 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.535 0.683 . . . . 0.0 111.629 -178.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.9 14.23 9.52 Favored Glycine 0 N--CA 1.485 1.949 0 C-N-CA 119.421 -1.371 . . . . 0.0 112.927 177.357 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.787 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.8 t -105.09 -173.54 2.33 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 121.13 2.465 . . . . 0.0 109.899 179.265 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.769 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.9 t -128.41 138.97 53.17 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 CA-C-N 114.63 -1.168 . . . . 0.0 111.157 -178.639 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.551 HG11 HD11 ' A' ' 13' ' ' LEU . 27.9 m -116.15 154.42 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.653 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.554 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 15.0 tptp -107.21 108.68 20.22 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.168 -0.957 . . . . 0.0 109.297 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.94 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -106.14 123.54 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.003 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -118.24 168.22 10.8 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.717 -1.24 . . . . 0.0 109.504 -179.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.614 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -137.13 136.71 8.47 Favored Glycine 0 C--O 1.207 -1.582 0 N-CA-C 107.493 -2.243 . . . . 0.0 107.493 179.515 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.619 ' HB3' ' OG1' ' A' ' 4' ' ' THR . . . -141.27 125.82 17.8 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-N 119.668 1.734 . . . . 0.0 109.397 179.794 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.471 ' HA2' ' OD1' ' A' ' 60' ' ' ASN . . . 88.35 28.91 21.12 Favored Glycine 0 N--CA 1.488 2.146 0 C-N-CA 118.692 -1.718 . . . . 0.0 109.598 -179.715 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.525 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.8 mt -89.26 173.98 8.1 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.034 -1.274 . . . . 0.0 108.283 179.818 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.001 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.02 97.1 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.007 -1.058 . . . . 0.0 109.773 -179.871 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.684 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.34 76.86 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.39 -178.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.84 34.06 0.31 Allowed Glycine 0 N--CA 1.486 1.995 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 179.309 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.557 HG23 ' O ' ' A' ' 30' ' ' THR . 1.1 t -146.37 113.88 6.35 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 120.923 -1.339 . . . . 0.0 111.225 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.566 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -45.3 126.97 6.79 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.548 178.399 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.498 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 6.0 m-85 -121.32 149.41 42.97 Favored 'General case' 0 N--CA 1.491 1.606 0 N-CA-C 108.752 -0.832 . . . . 0.0 108.752 179.754 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.467 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.45 160.06 14.65 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.697 -1.252 . . . . 0.0 108.064 178.955 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.682 HG13 ' O ' ' A' ' 34' ' ' VAL . 9.0 p -142.8 116.96 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.249 -0.907 . . . . 0.0 109.908 -177.69 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.521 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.82 -176.51 38.48 Favored Glycine 0 N--CA 1.494 2.524 0 C-N-CA 118.298 -1.906 . . . . 0.0 111.756 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.587 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -101.38 109.34 21.16 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.758 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -129.6 149.85 51.18 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.235 -0.915 . . . . 0.0 109.601 179.622 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.607 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.93 138.3 54.5 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.241 -0.912 . . . . 0.0 110.928 -178.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.31 115.09 26.96 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 178.049 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.7 m -105.64 15.01 7.16 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.024 -1.047 . . . . 0.0 110.512 -178.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.761 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.96 -175.38 0.09 Allowed 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.028 -1.045 . . . . 0.0 109.987 179.715 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -72.38 97.77 2.11 Favored 'General case' 0 N--CA 1.485 1.285 0 O-C-N 121.381 -0.825 . . . . 0.0 109.66 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.29 28.14 31.33 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.233 -0.984 . . . . 0.0 111.383 178.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.761 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.42 106.26 19.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 O-C-N 120.586 -1.537 . . . . 0.0 107.339 178.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -116.35 104.59 11.63 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.421 -1.424 . . . . 0.0 109.902 -177.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.095 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.5 22.25 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.776 -1.203 . . . . 0.0 107.987 178.704 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.5 161.74 14.57 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.919 -1.113 . . . . 0.0 110.189 -178.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.6 HD22 ' HB3' ' A' ' 50' ' ' ALA . 43.2 t30 -109.74 136.49 20.33 Favored Pre-proline 0 N--CA 1.502 2.167 0 O-C-N 121.383 -0.823 . . . . 0.0 109.807 -179.57 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.56 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.79 25.37 0.33 Allowed 'Trans proline' 0 C--N 1.318 -1.028 0 C-N-CA 122.354 2.036 . . . . 0.0 111.876 179.878 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.6 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -111.2 2.33 17.72 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.392 -1.442 . . . . 0.0 109.268 179.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.522 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.24 16.77 2.24 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 107.7 -1.222 . . . . 0.0 107.7 179.724 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -79.86 91.77 5.41 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.82 -0.752 . . . . 0.0 111.078 -178.57 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.619 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -111.31 -168.2 1.28 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.957 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.85 135.61 0.09 Allowed 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.503 -1.373 . . . . 0.0 111.521 -179.307 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.762 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -152.41 158.32 4.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 178.015 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.566 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.77 145.54 26.26 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.659 -1.276 . . . . 0.0 109.672 -179.796 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.001 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.24 108.01 2.56 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 122.394 1.092 . . . . 0.0 109.5 178.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 t0 -61.06 -138.73 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.923 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.684 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.57 -49.87 64.11 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.386 -0.821 . . . . 0.0 110.405 -178.747 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.471 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 16.9 t-20 -102.94 -36.99 8.01 Favored 'General case' 0 C--N 1.286 -2.194 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 178.449 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.978 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.31 68.36 0.61 Allowed Glycine 0 C--N 1.297 -1.601 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 178.19 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.614 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.8 m -102.96 129.12 49.59 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.496 -1.002 . . . . 0.0 109.316 179.284 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.762 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.56 108.54 7.63 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.533 -0.867 . . . . 0.0 109.43 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.497 ' HB2' ' NZ ' ' A' ' 20' ' ' LYS . 53.0 p -120.31 118.87 31.54 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.106 -0.996 . . . . 0.0 109.368 -179.82 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.58 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.91 143.01 28.2 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.395 -0.815 . . . . 0.0 109.802 -179.99 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.476 ' HB3' ' HD3' ' A' ' 20' ' ' LYS . 2.9 p -102.17 135.04 44.45 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.492 -0.755 . . . . 0.0 109.059 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.836 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -135.2 169.93 16.7 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.301 -0.874 . . . . 0.0 109.597 -179.24 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.767 HG22 HG22 ' A' ' 18' ' ' VAL . 1.6 p -99.56 125.55 45.37 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.079 -1.013 . . . . 0.0 109.581 -179.68 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.587 HG12 ' HB3' ' A' ' 36' ' ' GLN . 15.7 m -135.11 143.33 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.036 -1.04 . . . . 0.0 109.519 -179.565 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.601 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.0 ptt180 -146.63 -174.89 4.59 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 120.417 -1.427 . . . . 0.0 111.11 -179.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.607 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -54.12 -101.71 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 116.032 -0.531 . . . . 0.0 109.577 -179.382 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.508 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.85 139.97 49.64 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 120.749 -1.22 . . . . 0.0 108.138 179.659 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.607 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.28 136.34 7.51 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 118.772 -1.171 . . . . 0.0 109.879 -178.068 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.579 ' OE2' ' CD1' ' A' ' 76' ' ' PHE . 0.0 OUTLIER -34.7 121.19 0.51 Allowed 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.543 0.687 . . . . 0.0 110.249 -178.462 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.095 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.52 50.57 2.08 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 120.39 -0.91 . . . . 0.0 111.107 -179.199 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CD1' ' OE2' ' A' ' 74' ' ' GLU . 2.8 m-85 -38.95 116.93 0.62 Allowed 'General case' 0 N--CA 1.509 2.484 0 O-C-N 121.041 -1.27 . . . . 0.0 109.882 179.639 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.74 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -87.34 126.16 34.68 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.95 -1.094 . . . . 0.0 109.389 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.1 t80 -64.53 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.789 -1.194 . . . . 0.0 110.106 179.711 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -159.77 19.7 0.17 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.033 -1.042 . . . . 0.0 109.696 179.984 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.26 -28.07 5.35 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.45 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 38.4 p -95.84 160.42 14.49 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.991 -1.299 . . . . 0.0 110.404 -179.458 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.489 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 6.0 ptt180 -105.95 139.58 40.28 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.784 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.74 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.4 t90 -84.5 -18.83 34.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.653 -1.279 . . . . 0.0 110.634 -178.53 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.85 175.53 19.03 Favored Glycine 0 N--CA 1.485 1.943 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 -179.581 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.74 105.37 1.24 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 179.058 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.674 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.5 t -76.7 105.61 5.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.241 -0.912 . . . . 0.0 109.147 -178.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.548 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -65.65 110.82 2.9 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.471 -0.768 . . . . 0.0 109.813 -179.481 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.607 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.24 -5.7 3.65 Favored 'General case' 0 N--CA 1.499 1.982 0 C-N-CA 118.255 -1.378 . . . . 0.0 109.838 179.482 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.0 p -86.57 -0.11 55.47 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.766 -1.209 . . . . 0.0 109.107 179.548 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.548 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.86 -50.57 2.82 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.398 -0.814 . . . . 0.0 108.968 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.8 -178.96 3.8 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.515 -0.741 . . . . 0.0 109.443 179.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.97 115.84 30.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.432 -0.793 . . . . 0.0 108.929 179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.8 121.55 38.78 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.797 -1.189 . . . . 0.0 109.39 -179.369 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.81 147.1 26.46 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 122.33 1.062 . . . . 0.0 111.126 -179.362 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.701 ' HB ' HG11 ' A' ' 7' ' ' VAL . 48.3 t -105.34 111.93 36.75 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.997 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.831 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.511 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.75 -170.54 19.92 Favored Glycine 0 N--CA 1.488 2.102 0 C-N-CA 118.062 -2.018 . . . . 0.0 111.751 -177.877 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.81 177.47 4.69 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.212 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.583 ' HB2' ' C27' ' A' ' 114' ' ' CHR . 3.9 m 177.97 165.63 0.71 Allowed 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.649 -0.657 . . . . 0.0 109.269 -179.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.498 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -112.65 -159.09 0.67 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.846 -1.159 . . . . 0.0 109.065 179.95 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.93 36.01 4.38 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.757 -1.214 . . . . 0.0 109.166 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.85 -33.28 6.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.314 -0.866 . . . . 0.0 109.77 -179.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.661 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.08 -36.86 0.23 Allowed Glycine 0 N--CA 1.48 1.569 0 N-CA-C 108.07 -2.012 . . . . 0.0 108.07 -179.777 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -164.22 -177.32 4.9 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.612 -0.934 . . . . 0.0 110.042 179.47 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.68 -161.04 19.37 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 108.117 -1.993 . . . . 0.0 108.117 -179.494 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.1 Cg_exo -47.01 177.3 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.701 0 CA-C-N 118.968 1.384 . . . . 0.0 110.249 179.228 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 20.2 mm-40 -94.32 -179.4 4.91 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.073 -1.017 . . . . 0.0 110.583 -178.797 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.511 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.94 166.13 12.72 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.59 131.19 54.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.288 -1.124 . . . . 0.0 109.258 -179.282 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.03 121.02 20.42 Favored 'General case' 0 C--N 1.29 -2.014 0 O-C-N 121.548 -0.72 . . . . 0.0 109.587 179.676 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.92 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.97 171.3 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.226 -0.922 . . . . 0.0 109.095 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.49 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.93 156.81 46.97 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.264 -0.897 . . . . 0.0 109.929 -179.635 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.92 ' CE1' HD12 ' A' ' 110' ' ' ILE . 95.9 m-85 -132.03 73.55 1.54 Allowed 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.318 -0.864 . . . . 0.0 109.378 -179.779 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.421 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 13.2 p30 . . . . . 0 N--CA 1.489 1.523 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.503 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.779 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.917 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -98.05 172.75 4.53 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.343 -0.848 . . . . 0.0 109.474 180.0 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.917 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.7 Cg_exo -59.71 158.0 30.22 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.214 1.943 . . . . 0.0 110.632 -179.994 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.59 -169.78 0.15 Allowed 'General case' 0 C--N 1.295 -1.779 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 179.245 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.545 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.88 130.32 2.28 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 120.841 -1.162 . . . . 0.0 110.602 -179.153 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.957 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.8 t -110.42 108.63 18.73 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 123.088 1.423 . . . . 0.0 109.088 179.34 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.822 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -118.43 137.85 51.05 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.678 0 CA-C-N 114.244 -1.344 . . . . 0.0 109.907 -179.7 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.467 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -175.4 150.33 1.19 Allowed Pre-proline 0 N--CA 1.487 1.388 0 O-C-N 121.314 -0.866 . . . . 0.0 108.712 -179.651 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.467 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -77.64 150.52 90.51 Favored 'Cis proline' 0 C--N 1.311 -1.433 0 C-N-CA 123.57 -1.429 . . . . 0.0 109.535 -0.905 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.67 ' HA ' HG22 ' A' ' 110' ' ' ILE . 61.8 p -91.02 -24.52 20.05 Favored 'General case' 0 C--N 1.293 -1.873 0 O-C-N 121.55 -0.718 . . . . 0.0 109.27 179.828 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.521 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 17.1 m -133.44 160.36 37.63 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.265 -0.897 . . . . 0.0 109.978 -179.806 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.78 36.75 24.78 Favored Glycine 0 N--CA 1.494 2.523 0 N-CA-C 108.859 -1.696 . . . . 0.0 108.859 -179.856 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.755 ' HA ' HG21 ' A' ' 17' ' ' THR . 44.2 mt -93.83 -44.37 8.15 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-O 123.204 1.478 . . . . 0.0 110.353 -178.658 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.434 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.9 OUTLIER 63.81 145.35 0.02 OUTLIER 'General case' 0 C--N 1.262 -3.216 0 CA-C-N 113.62 -1.627 . . . . 0.0 109.798 -179.459 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.539 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.4 p-10 -51.61 105.33 0.1 Allowed 'General case' 0 C--N 1.3 -1.544 0 CA-C-O 121.551 0.691 . . . . 0.0 110.844 -179.015 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 126.93 2.22 6.68 Favored Glycine 0 N--CA 1.485 1.949 0 C-N-CA 119.077 -1.535 . . . . 0.0 113.428 177.625 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.755 HG21 ' HA ' ' A' ' 13' ' ' LEU . 15.3 t -104.08 -171.82 2.0 Allowed 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 121.376 2.588 . . . . 0.0 110.102 179.909 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.772 HG13 ' C ' ' A' ' 67' ' ' LEU . 16.0 t -131.47 141.91 44.64 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.252 0 CA-C-N 114.604 -1.18 . . . . 0.0 110.47 -179.207 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.545 HG11 ' CD1' ' A' ' 13' ' ' LEU . 28.6 m -115.7 154.99 17.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.199 -0.938 . . . . 0.0 109.023 179.321 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 45.9 tptt -107.07 109.31 21.14 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 108.892 179.918 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.822 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.63 141.62 18.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 179.784 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.957 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -139.05 160.41 39.84 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 118.595 -1.242 . . . . 0.0 110.04 179.714 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.42 144.26 15.58 Favored Glycine 0 C--N 1.294 -1.793 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 179.695 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.564 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.28 125.37 12.88 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.872 -1.369 . . . . 0.0 108.956 179.037 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.536 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.48 26.84 26.6 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.289 -1.434 . . . . 0.0 109.867 -179.733 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.582 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.4 mt -87.68 174.61 8.31 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 120.837 -1.39 . . . . 0.0 108.648 -179.879 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.018 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.58 99.79 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.99 -1.069 . . . . 0.0 109.744 -179.682 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.57 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 77.94 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.233 -179.149 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.58 34.17 0.32 Allowed Glycine 0 N--CA 1.488 2.111 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 179.556 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 40.6 p -141.13 108.14 5.44 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.136 -1.214 . . . . 0.0 111.208 -179.539 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.9 110.75 0.46 Allowed 'General case' 0 N--CA 1.497 1.876 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.542 178.027 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.589 ' CE1' ' HB2' ' A' ' 99' ' ' ASP . 5.3 m-30 -106.75 156.02 19.09 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.122 -0.987 . . . . 0.0 108.902 179.821 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.503 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -99.13 164.16 12.27 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.822 -1.174 . . . . 0.0 107.917 178.822 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.666 HG13 ' O ' ' A' ' 34' ' ' VAL . 5.5 p -144.99 115.2 1.79 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.982 -1.074 . . . . 0.0 109.653 -178.247 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.02 -174.48 35.52 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.42 -1.847 . . . . 0.0 111.594 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.612 ' O ' ' HG3' ' A' ' 36' ' ' GLN . 1.4 pt20 -102.39 109.25 20.85 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.862 0.839 . . . . 0.0 108.839 -179.772 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -131.75 149.51 52.45 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.099 -1.001 . . . . 0.0 110.093 -179.858 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.77 139.14 54.12 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.25 -0.906 . . . . 0.0 110.867 -179.076 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.876 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.36 114.96 26.79 Favored 'General case' 0 N--CA 1.493 1.677 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 178.21 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.5 m -105.4 15.15 7.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.991 -1.068 . . . . 0.0 110.591 -178.799 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.6 -176.19 0.09 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.961 -1.087 . . . . 0.0 110.101 179.747 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.783 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.89 97.86 1.49 Allowed 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.381 -0.825 . . . . 0.0 109.856 -179.742 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.37 27.58 35.84 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.212 -0.994 . . . . 0.0 111.394 178.948 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.23 106.44 20.34 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.528 -1.572 . . . . 0.0 107.185 178.904 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.876 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.0 tp -116.99 104.61 11.45 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.476 -1.39 . . . . 0.0 109.752 -177.763 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.86 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.82 109.53 22.27 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.746 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.497 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -106.74 168.75 8.97 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.967 -1.083 . . . . 0.0 110.379 -178.565 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.728 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 20.5 t-20 -114.57 132.34 22.92 Favored Pre-proline 0 N--CA 1.498 1.963 0 O-C-N 121.64 -0.662 . . . . 0.0 109.95 -179.242 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.8 Cg_endo -74.18 25.56 0.34 Allowed 'Trans proline' 0 CA--C 1.544 0.997 0 C-N-CA 122.28 1.986 . . . . 0.0 112.139 -179.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.728 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -111.25 -1.06 16.23 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.279 -1.513 . . . . 0.0 109.443 179.709 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.572 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.06 21.32 2.62 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 179.561 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -80.92 90.6 5.93 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 120.053 -0.659 . . . . 0.0 110.873 -178.646 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -109.73 -167.23 1.18 Allowed 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 178.157 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.96 136.25 0.09 Allowed 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.61 -1.307 . . . . 0.0 111.186 -179.273 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.938 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -153.53 158.26 4.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.354 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.78 141.8 31.13 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.906 -1.121 . . . . 0.0 109.945 -179.845 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.018 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.02 106.51 0.84 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 122.45 1.119 . . . . 0.0 109.359 178.296 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -58.3 -138.47 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.03 0 CA-C-N 115.525 -0.762 . . . . 0.0 110.918 -179.863 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.57 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -54.22 -49.19 70.01 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.367 -0.833 . . . . 0.0 110.406 -178.756 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 10.5 t-20 -102.37 -38.26 7.68 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 178.333 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.009 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 111.36 65.26 0.51 Allowed Glycine 0 C--N 1.297 -1.593 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 177.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.596 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.1 m -102.98 128.73 49.68 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 121.41 -1.053 . . . . 0.0 108.703 178.851 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.938 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -138.22 109.07 6.68 Favored 'General case' 0 C--N 1.296 -1.73 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.771 -179.235 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.5 m -123.52 120.63 33.44 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.309 -0.869 . . . . 0.0 109.725 -179.902 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.28 148.24 32.23 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.568 -0.708 . . . . 0.0 109.278 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.3 p -98.99 143.02 29.75 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.386 -0.821 . . . . 0.0 109.648 -179.839 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.782 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -146.03 157.52 43.87 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.357 -0.839 . . . . 0.0 109.368 -179.33 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.644 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 13.9 t -86.62 140.28 30.0 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.135 -0.978 . . . . 0.0 110.08 -179.792 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.554 HG12 ' OD2' ' A' ' 51' ' ' ASP . 16.9 m -145.94 137.89 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.226 -0.921 . . . . 0.0 110.148 -179.388 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.539 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 59.7 mtt180 -128.19 -162.75 1.21 Allowed 'General case' 0 N--CA 1.484 1.266 0 O-C-N 120.649 -1.282 . . . . 0.0 110.955 179.97 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.594 ' HG2' ' CD1' ' A' ' 112' ' ' PHE . 0.6 OUTLIER -86.66 -79.95 0.25 Allowed 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 179.35 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.538 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -69.78 133.02 46.97 Favored 'General case' 0 N--CA 1.486 1.34 0 N-CA-C 106.511 -1.662 . . . . 0.0 106.511 177.956 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.588 ' CE1' ' HB ' ' A' ' 86' ' ' VAL . 0.9 OUTLIER -154.42 155.32 34.75 Favored 'General case' 0 C--N 1.293 -1.875 0 C-N-CA 117.696 -1.602 . . . . 0.0 110.669 -177.938 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 47' ' ' CYS . 16.4 mt-10 -48.1 120.6 3.63 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-O 121.556 0.694 . . . . 0.0 109.549 -178.443 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.86 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -87.62 49.41 3.87 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -179.588 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.7 m-30 -40.59 112.38 0.28 Allowed 'General case' 0 N--CA 1.507 2.387 0 O-C-N 121.046 -1.267 . . . . 0.0 110.302 179.986 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.728 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.33 126.39 34.3 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 120.96 -1.088 . . . . 0.0 109.415 179.848 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.581 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.5 t80 -64.2 58.21 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.98 0 O-C-N 120.773 -1.204 . . . . 0.0 110.192 179.72 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 1.5 t0 -159.03 18.53 0.19 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.996 -1.065 . . . . 0.0 109.794 179.865 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.92 -25.85 6.47 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 179.763 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 47.6 p -95.0 159.37 15.05 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 120.966 -1.314 . . . . 0.0 110.604 -179.33 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.473 ' HG2' ' O ' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -104.25 131.84 51.14 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.52 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.728 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -79.75 -19.96 47.47 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.854 -1.154 . . . . 0.0 110.169 -178.501 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.52 174.4 18.88 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 108.666 -1.773 . . . . 0.0 108.666 -179.406 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.13 112.88 2.55 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 179.09 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.647 HG21 ' CB ' ' A' ' 46' ' ' ALA . 38.1 t -84.56 103.22 11.54 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.019 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.561 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -63.88 109.26 1.7 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.54 -0.725 . . . . 0.0 110.248 -178.902 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.556 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 4.1 t -61.85 -4.19 1.44 Allowed 'General case' 0 N--CA 1.5 2.057 0 C-N-CA 118.546 -1.262 . . . . 0.0 110.433 179.227 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -91.6 4.26 53.08 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.477 -1.389 . . . . 0.0 109.333 179.772 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.561 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -116.18 -50.19 2.67 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.178 -0.951 . . . . 0.0 109.144 179.936 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.89 178.73 4.47 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.512 -0.743 . . . . 0.0 109.396 179.871 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -100.85 113.37 26.24 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.324 -0.86 . . . . 0.0 108.817 179.884 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.498 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.51 119.59 35.27 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.017 -1.052 . . . . 0.0 109.471 -179.048 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.71 147.31 26.99 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-O 122.459 1.123 . . . . 0.0 111.43 -179.21 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.491 ' CG1' HG11 ' A' ' 7' ' ' VAL . 77.2 t -103.81 109.83 28.34 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.993 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 177.613 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.491 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.39 -170.01 17.1 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 118.246 -1.93 . . . . 0.0 111.608 -177.54 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.503 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.66 178.27 4.46 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.907 -0.761 . . . . 0.0 108.994 -178.972 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.595 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -160.93 178.43 9.4 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.529 -0.732 . . . . 0.0 109.511 -179.653 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.589 ' HB2' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -122.21 -157.41 0.73 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.21 -0.931 . . . . 0.0 108.764 179.629 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.449 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -120.23 35.91 4.71 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.66 -1.275 . . . . 0.0 109.316 -179.948 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -122.17 -32.55 3.66 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.341 -0.85 . . . . 0.0 110.464 -179.46 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 1.052 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.31 -37.29 0.23 Allowed Glycine 0 N--CA 1.482 1.714 0 N-CA-C 107.569 -2.212 . . . . 0.0 107.569 -179.395 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.473 ' ND2' ' O9 ' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -157.96 -178.37 7.26 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 121.569 -0.96 . . . . 0.0 109.721 179.183 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.44 -160.55 11.62 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 108.333 -1.907 . . . . 0.0 108.333 -179.344 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -47.01 178.31 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.864 1.332 . . . . 0.0 110.265 179.207 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -93.02 -174.4 3.56 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.123 -0.985 . . . . 0.0 110.341 -178.956 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.491 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.75 164.0 15.02 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.935 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.402 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.38 129.71 49.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.386 -1.067 . . . . 0.0 109.074 -179.629 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.92 121.44 19.08 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.658 -0.651 . . . . 0.0 109.804 179.836 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.67 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.5 pt -97.99 169.28 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 O-C-N 121.379 -0.826 . . . . 0.0 108.818 179.822 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.521 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -135.98 160.37 38.82 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.141 -0.974 . . . . 0.0 109.693 -179.945 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.594 ' CD1' ' HG2' ' A' ' 71' ' ' ARG . 39.2 m-85 -134.33 76.01 1.62 Allowed 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.242 -0.911 . . . . 0.0 109.46 -179.759 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.4 p30 . . . . . 0 N--CA 1.491 1.603 0 CA-C-O 117.917 -1.04 . . . . 0.0 109.42 179.99 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 1.052 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.497 -0.557 . . . . 1.0 109.497 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.964 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -68.57 173.39 3.48 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.299 -0.876 . . . . 1.0 109.483 179.992 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.964 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 3.3 Cg_exo -60.84 157.2 39.27 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.233 1.955 . . . . 1.0 110.412 -179.892 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.898 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.1 p -167.9 160.49 12.32 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.824 -0.806 . . . . 1.0 108.824 -179.247 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -150.37 127.78 11.43 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.06 -1.056 . . . . 1.0 110.561 -179.869 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.974 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.9 p -107.0 104.93 14.73 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 122.608 1.194 . . . . 1.0 110.347 -179.587 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.975 HG22 HG23 ' A' ' 21' ' ' VAL . 15.2 t -119.37 115.35 47.43 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.468 0 CA-C-N 115.271 -0.877 . . . . 1.0 110.131 179.428 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -162.57 150.8 12.01 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.316 -0.994 . . . . 1.0 108.316 -179.378 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.1 Cg_endo -77.96 150.21 88.92 Favored 'Cis proline' 0 C--N 1.308 -1.554 0 C-N-CA 123.635 -1.402 . . . . 1.0 109.74 -0.679 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.655 ' HA ' HG22 ' A' ' 110' ' ' ILE . 69.2 p -89.75 -25.49 21.12 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 109.031 -0.729 . . . . 1.0 109.031 179.549 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.502 ' HB2' ' HB3' ' A' ' 111' ' ' SER . 18.7 p -132.55 164.64 26.18 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.498 -0.751 . . . . 1.0 109.375 179.954 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.68 38.27 37.61 Favored Glycine 0 N--CA 1.495 2.595 0 N-CA-C 108.259 -1.936 . . . . 1.0 108.259 -179.531 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.7 mt -92.49 -43.39 9.21 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 123.264 1.507 . . . . 1.0 110.619 -178.174 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.11 143.59 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.269 0 CA-C-N 113.461 -1.7 . . . . 1.0 109.815 -179.467 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.582 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 9.9 p-10 -50.48 105.13 0.09 Allowed 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.474 0.654 . . . . 1.0 111.634 -178.484 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.98 15.68 8.38 Favored Glycine 0 N--CA 1.485 1.917 0 C-N-CA 119.457 -1.354 . . . . 1.0 113.007 177.153 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.5 t -103.88 -171.22 1.9 Allowed 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 121.053 2.426 . . . . 1.0 109.802 179.125 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.856 HG22 HG22 ' A' ' 68' ' ' THR . 16.6 t -131.31 140.06 49.34 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.314 0 CA-C-N 114.822 -1.081 . . . . 1.0 111.362 -178.783 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.46 HG12 ' CD2' ' A' ' 13' ' ' LEU . 30.9 m -115.9 155.48 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 N-CA-C 108.66 -0.867 . . . . 1.0 108.66 178.861 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 5.5 tptm -108.16 108.96 20.23 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.137 -0.977 . . . . 1.0 109.529 -179.759 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.975 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -106.39 122.5 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 N-CA-C 108.853 -0.795 . . . . 1.0 108.853 179.729 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.974 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -115.21 165.45 12.92 Favored 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.943 -1.098 . . . . 1.0 109.145 179.789 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.577 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.81 108.03 0.46 Allowed Glycine 0 N--CA 1.483 1.768 0 N-CA-C 108.711 -1.756 . . . . 1.0 108.711 179.602 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.605 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.75 142.43 46.93 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.704 -1.468 . . . . 1.0 110.212 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.458 ' CA ' ' HA ' ' A' ' 3' ' ' PRO . . . 82.96 29.08 35.49 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.062 -1.542 . . . . 1.0 109.773 179.787 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.54 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.9 OUTLIER -94.56 172.75 7.99 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.093 -1.239 . . . . 1.0 108.31 179.98 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.012 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.09 100.36 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.027 -1.046 . . . . 1.0 109.602 -179.799 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.85 76.44 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 115.397 -0.819 . . . . 1.0 109.955 -179.313 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 137.08 33.26 0.22 Allowed Glycine 0 N--CA 1.487 2.091 0 N-CA-C 109.457 -1.457 . . . . 1.0 109.457 179.712 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.546 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 66.8 p -142.14 109.74 5.72 Favored 'General case' 0 C--N 1.307 -1.24 0 O-C-N 121.042 -1.269 . . . . 1.0 111.013 -179.803 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.586 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.95 109.93 0.28 Allowed 'General case' 0 N--CA 1.496 1.847 0 CA-C-N 115.7 -0.682 . . . . 1.0 109.858 178.407 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.515 ' CE1' ' HD2' ' A' ' 105' ' ' PRO . 21.1 m-85 -99.1 152.3 20.01 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.157 -0.965 . . . . 1.0 109.007 179.653 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.507 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -101.48 157.77 16.56 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 107.598 -1.26 . . . . 1.0 107.598 178.421 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.774 HG11 HG21 ' A' ' 65' ' ' THR . 9.9 p -142.29 113.97 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.063 -1.023 . . . . 1.0 110.07 -177.692 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.39 -175.49 36.73 Favored Glycine 0 N--CA 1.495 2.575 0 C-N-CA 118.371 -1.871 . . . . 1.0 111.875 -179.811 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.588 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -102.25 109.41 21.09 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 108.848 -0.797 . . . . 1.0 108.848 -179.663 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.452 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -131.07 148.55 52.75 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.129 -0.982 . . . . 1.0 110.034 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.486 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.89 139.79 53.62 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.314 -0.866 . . . . 1.0 110.716 -179.016 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.889 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.25 114.66 26.47 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 107.607 -1.257 . . . . 1.0 107.607 178.161 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 m -105.25 15.01 7.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.094 -1.004 . . . . 1.0 110.469 -178.752 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 175.04 -175.76 0.09 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.044 -1.035 . . . . 1.0 110.039 179.688 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.5 p -72.69 98.02 2.29 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.448 -0.782 . . . . 1.0 109.508 -179.805 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.39 27.64 32.45 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.232 -0.985 . . . . 1.0 111.291 179.046 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -117.6 106.27 19.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 O-C-N 120.6 -1.53 . . . . 1.0 107.325 178.889 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.889 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -116.1 104.8 11.92 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 120.496 -1.378 . . . . 1.0 109.567 -178.016 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.938 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.47 109.56 22.29 Favored 'General case' 0 N--CA 1.486 1.338 0 O-C-N 120.781 -1.199 . . . . 1.0 107.857 178.889 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -108.26 163.73 12.93 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.02 -1.05 . . . . 1.0 110.112 -178.656 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.49 ' HB2' ' HB2' ' A' ' 73' ' ' PHE . 36.2 t-20 -110.16 128.78 24.79 Favored Pre-proline 0 N--CA 1.502 2.141 0 O-C-N 121.437 -0.789 . . . . 1.0 109.67 -179.372 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.594 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.6 Cg_endo -69.44 17.72 0.18 Allowed 'Trans proline' 0 CA--C 1.546 1.075 0 C-N-CA 122.021 1.814 . . . . 1.0 112.108 179.444 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -104.6 3.48 31.77 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.389 -1.444 . . . . 1.0 108.528 179.065 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.45 15.91 2.75 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 107.228 -1.397 . . . . 1.0 107.228 179.487 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -81.53 92.39 6.5 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.834 -0.746 . . . . 1.0 111.099 -178.299 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -112.01 -170.94 1.75 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.133 -1.432 . . . . 1.0 107.133 177.879 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.443 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 179.18 136.91 0.1 Allowed 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.475 -1.391 . . . . 1.0 111.277 -179.197 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.9 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.56 157.14 4.78 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 107.107 -1.442 . . . . 1.0 107.107 178.194 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.586 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.83 143.23 28.66 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.696 -1.253 . . . . 1.0 109.965 -179.474 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.24 105.86 0.98 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 122.372 1.082 . . . . 1.0 109.392 178.704 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.54 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.5 t70 -60.21 -139.28 0.0 OUTLIER 'General case' 0 C--N 1.288 -2.078 0 CA-C-N 115.719 -0.673 . . . . 1.0 110.934 -179.827 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.6 -50.48 60.1 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.297 -0.877 . . . . 1.0 110.625 -178.7 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 49.4 m-80 -102.95 -35.15 8.68 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.272 -1.751 . . . . 1.0 106.272 178.59 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 105.26 66.27 0.68 Allowed Glycine 0 C--N 1.297 -1.602 0 N-CA-C 110.522 -1.031 . . . . 1.0 110.522 178.305 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.577 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.4 m -104.09 125.54 50.51 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 108.514 -0.921 . . . . 1.0 108.514 178.833 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.9 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.46 109.54 8.8 Favored 'General case' 0 C--N 1.296 -1.748 0 C-N-CA 119.692 -0.803 . . . . 1.0 109.755 -179.266 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.471 ' OG ' ' HB2' ' A' ' 22' ' ' ALA . 0.5 OUTLIER -116.24 122.72 45.8 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.278 -0.888 . . . . 1.0 109.019 179.709 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.774 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -148.44 140.14 23.7 Favored 'General case' 0 C--N 1.295 -1.787 0 O-C-N 121.496 -0.752 . . . . 1.0 109.884 -179.964 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.425 ' HB3' ' HD2' ' A' ' 20' ' ' LYS . 14.6 p -101.34 131.42 47.4 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.369 -0.832 . . . . 1.0 109.276 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.759 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -128.52 164.62 22.39 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.38 -0.825 . . . . 1.0 109.623 -179.452 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.856 HG22 HG22 ' A' ' 18' ' ' VAL . 1.7 p -97.36 124.59 41.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.952 -1.093 . . . . 1.0 109.249 -179.958 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.573 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 18.0 m -136.61 143.67 34.73 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.1 -1.0 . . . . 1.0 109.947 -179.106 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.582 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 6.8 ptt180 -141.86 -165.51 2.02 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.51 -1.369 . . . . 1.0 110.264 -179.966 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.597 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 10.1 mtt180 -70.07 -76.85 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.425 -0.797 . . . . 1.0 109.017 -179.557 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.486 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -69.62 137.33 52.18 Favored 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.232 -1.542 . . . . 1.0 107.128 178.878 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.588 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -160.17 134.18 7.26 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 117.895 -1.522 . . . . 1.0 110.299 -178.179 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.527 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.2 mm-40 -30.57 120.97 0.2 Allowed 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.54 0.686 . . . . 1.0 110.888 -178.397 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.938 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.13 43.4 3.05 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.913 -0.875 . . . . 1.0 110.913 -179.526 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.594 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 2.1 m-85 -38.71 114.93 0.42 Allowed 'General case' 0 N--CA 1.511 2.603 0 O-C-N 121.182 -1.187 . . . . 1.0 110.123 179.959 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.713 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.4 tp -87.64 126.96 35.26 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.889 -1.132 . . . . 1.0 109.231 179.81 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.59 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.3 t80 -63.95 58.01 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.974 0 O-C-N 120.871 -1.143 . . . . 1.0 110.438 -179.9 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 9.3 t0 -161.97 19.96 0.1 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.924 -1.11 . . . . 1.0 109.862 179.802 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.06 -27.29 5.05 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.002 -1.239 . . . . 1.0 110.002 179.979 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.463 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 3.1 p -90.24 153.55 20.4 Favored 'General case' 0 N--CA 1.485 1.318 0 O-C-N 121.072 -1.252 . . . . 1.0 110.388 -179.426 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.523 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 5.1 ptt180 -102.43 132.82 48.2 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.636 -0.875 . . . . 1.0 108.636 179.68 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.713 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.4 t90 -81.92 -21.41 37.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.659 -1.276 . . . . 1.0 110.294 -178.673 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.92 174.0 18.55 Favored Glycine 0 N--CA 1.486 1.997 0 N-CA-C 108.746 -1.742 . . . . 1.0 108.746 -179.644 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.67 110.71 1.81 Allowed 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 107.412 -1.329 . . . . 1.0 107.412 179.095 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.654 HG21 ' CB ' ' A' ' 46' ' ' ALA . 41.3 t -82.26 104.27 10.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 O-C-N 121.449 -0.782 . . . . 1.0 108.895 -178.962 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.66 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.1 OUTLIER -66.47 111.81 3.76 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.306 -0.871 . . . . 1.0 109.784 -179.277 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.555 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.0 t -62.77 -5.35 2.69 Favored 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 118.416 -1.314 . . . . 1.0 110.108 179.497 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.5 p -86.23 0.6 53.36 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.611 -1.306 . . . . 1.0 109.15 179.462 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.66 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -112.71 -48.89 2.97 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.268 -0.895 . . . . 1.0 109.055 179.907 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.46 -178.31 3.56 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.483 -0.761 . . . . 1.0 109.6 -179.93 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.55 114.78 29.23 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.294 -0.879 . . . . 1.0 108.97 179.923 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.56 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.12 123.32 40.85 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.956 -1.09 . . . . 1.0 109.759 -179.084 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.586 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.96 146.16 28.75 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 122.359 1.076 . . . . 1.0 111.059 -179.775 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.538 ' HB ' HG11 ' A' ' 7' ' ' VAL . 97.8 t -103.07 109.63 27.39 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.069 0 N-CA-C 106.604 -1.628 . . . . 1.0 106.604 177.719 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.488 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.51 -170.58 17.19 Favored Glycine 0 N--CA 1.485 1.962 0 C-N-CA 118.091 -2.004 . . . . 1.0 111.944 -177.47 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.491 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -118.16 -178.65 3.56 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 108.88 -0.785 . . . . 1.0 108.88 -178.77 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.556 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -174.48 173.17 2.99 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.355 -0.841 . . . . 1.0 109.254 -179.45 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.406 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -116.97 -158.54 0.7 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.162 -0.961 . . . . 1.0 108.765 179.582 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.406 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -118.91 36.11 4.56 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.759 -1.213 . . . . 1.0 109.288 -179.949 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.45 -32.52 4.6 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.278 -0.889 . . . . 1.0 110.358 -179.502 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.993 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.15 -37.41 0.23 Allowed Glycine 0 N--CA 1.481 1.666 0 N-CA-C 107.522 -2.231 . . . . 1.0 107.522 -179.465 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.46 -178.24 6.99 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.615 -0.932 . . . . 1.0 109.727 179.12 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -170.27 -162.61 22.87 Favored Glycine 0 N--CA 1.491 2.358 0 N-CA-C 108.248 -1.941 . . . . 1.0 108.248 -179.426 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.515 ' HD2' ' CE1' ' A' ' 32' ' ' TYR . 7.5 Cg_exo -45.69 165.81 0.06 OUTLIER 'Trans proline' 0 C--O 1.215 -0.637 0 CA-C-N 118.912 1.356 . . . . 1.0 109.656 179.392 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -89.73 -176.45 4.97 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.047 -1.033 . . . . 1.0 110.528 -178.473 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.488 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.57 175.26 15.64 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.723 -1.351 . . . . 1.0 109.723 -179.837 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -112.05 132.51 60.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.383 -1.069 . . . . 1.0 109.121 -179.14 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.586 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -69.88 124.58 24.39 Favored 'General case' 0 C--N 1.291 -1.95 0 O-C-N 121.556 -0.715 . . . . 1.0 109.479 179.526 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.884 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.71 171.57 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.19 -0.944 . . . . 1.0 109.043 179.969 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.502 ' HB3' ' HB2' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.53 161.21 37.01 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.237 -0.914 . . . . 1.0 109.707 -179.773 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.884 ' CE2' HD12 ' A' ' 110' ' ' ILE . 90.0 m-85 -136.69 86.47 2.22 Favored 'General case' 0 N--CA 1.484 1.268 0 O-C-N 121.12 -0.987 . . . . 1.0 109.532 -179.702 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 16.2 p30 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 117.894 -1.05 . . . . 1.0 109.461 -179.954 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.993 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.836 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -119.13 169.48 8.05 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.275 -0.89 . . . . 0.0 109.558 -179.922 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.836 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.5 Cg_exo -59.91 158.42 29.33 Favored 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 122.416 2.077 . . . . 0.0 110.574 179.991 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.532 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.28 -169.56 0.15 Allowed 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 179.154 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.582 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . -168.51 133.8 1.73 Allowed 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.548 -1.345 . . . . 0.0 111.179 -179.128 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.021 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -101.22 104.45 15.51 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 122.404 1.097 . . . . 0.0 109.907 179.859 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 1.07 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -119.37 119.3 60.21 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.412 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.393 179.588 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.481 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -168.8 149.92 4.41 Favored Pre-proline 0 N--CA 1.486 1.335 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -179.602 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.481 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.3 Cg_endo -78.55 149.96 86.69 Favored 'Cis proline' 0 C--N 1.309 -1.504 0 C-N-CA 123.631 -1.404 . . . . 0.0 109.439 -0.677 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.669 ' HA ' HG22 ' A' ' 110' ' ' ILE . 72.6 p -92.09 -23.43 19.46 Favored 'General case' 0 C--N 1.292 -1.911 0 O-C-N 121.632 -0.668 . . . . 0.0 109.245 179.677 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.548 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 12.1 p -131.81 161.19 33.53 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.376 -0.828 . . . . 0.0 109.646 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.2 37.78 31.33 Favored Glycine 0 N--CA 1.496 2.635 0 N-CA-C 108.386 -1.885 . . . . 0.0 108.386 -179.556 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.2 mt -91.85 -43.39 9.53 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 123.223 1.487 . . . . 0.0 110.53 -178.223 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.478 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.89 143.93 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.25 0 CA-C-N 113.457 -1.701 . . . . 0.0 110.017 -179.508 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.586 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 11.5 p-10 -49.83 105.69 0.1 Allowed 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 121.431 0.634 . . . . 0.0 111.737 -178.53 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.5 15.37 8.89 Favored Glycine 0 N--CA 1.485 1.94 0 C-N-CA 119.439 -1.363 . . . . 0.0 113.077 177.068 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -105.04 -173.2 2.25 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 121.123 2.461 . . . . 0.0 109.943 179.191 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.782 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.6 t -128.86 139.7 51.21 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.318 0 CA-C-N 114.635 -1.166 . . . . 0.0 111.508 -178.578 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.584 HG11 HD11 ' A' ' 13' ' ' LEU . 33.8 m -117.82 155.96 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.641 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.559 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tppp? -107.69 109.92 21.64 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.017 -1.052 . . . . 0.0 109.816 -179.681 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 1.07 HG23 HG22 ' A' ' 7' ' ' VAL . 7.3 p -105.87 123.23 60.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.086 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.021 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -119.7 166.61 12.99 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.506 -1.371 . . . . 0.0 109.397 -179.987 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.589 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.42 143.31 14.97 Favored Glycine 0 C--N 1.296 -1.682 0 N-CA-C 107.802 -2.119 . . . . 0.0 107.802 179.806 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.585 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -148.08 122.54 9.73 Favored 'General case' 0 C--N 1.293 -1.858 0 O-C-N 120.828 -1.395 . . . . 0.0 108.565 179.067 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.518 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 90.52 27.38 20.22 Favored Glycine 0 N--CA 1.486 2.017 0 C-N-CA 119.093 -1.527 . . . . 0.0 109.707 -179.552 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.558 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.2 mt -87.23 176.51 7.53 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 120.894 -1.356 . . . . 0.0 108.373 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.42 96.76 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.001 -1.062 . . . . 0.0 109.665 -179.784 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.719 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.2 77.68 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.528 -179.0 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 129.33 36.28 0.43 Allowed Glycine 0 N--CA 1.487 2.035 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 179.409 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.648 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -148.57 114.54 5.76 Favored 'General case' 0 C--N 1.309 -1.188 0 O-C-N 120.913 -1.345 . . . . 0.0 111.199 -179.891 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -46.34 122.52 4.09 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 115.437 -0.802 . . . . 0.0 110.354 178.66 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.648 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 1.9 m-30 -116.97 154.43 30.9 Favored 'General case' 0 N--CA 1.493 1.701 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.084 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.503 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -100.52 167.68 10.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.499 -1.375 . . . . 0.0 108.604 179.449 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.615 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.3 p -147.78 122.46 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.165 -0.96 . . . . 0.0 109.554 -178.089 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -177.08 -178.21 46.63 Favored Glycine 0 N--CA 1.495 2.606 0 C-N-CA 118.329 -1.891 . . . . 0.0 111.71 179.977 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.67 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.4 108.52 20.55 Favored 'General case' 0 N--CA 1.477 0.901 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.836 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -129.59 148.63 51.51 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.179 -0.951 . . . . 0.0 109.803 179.691 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.542 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.34 139.52 53.95 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.307 -0.871 . . . . 0.0 110.675 -179.023 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.881 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.09 114.9 26.76 Favored 'General case' 0 N--CA 1.491 1.589 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 178.147 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.47 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 18.2 m -105.77 14.98 7.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.044 -1.035 . . . . 0.0 110.58 -178.652 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.719 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 175.1 -174.94 0.09 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.986 -1.071 . . . . 0.0 109.995 179.579 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.786 HG23 ' O ' ' A' ' 42' ' ' THR . 14.9 t -72.62 98.01 2.26 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.43 -0.794 . . . . 0.0 109.757 -179.779 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.78 28.01 33.19 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 120.161 -1.019 . . . . 0.0 111.436 179.037 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.719 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -117.16 106.39 20.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 O-C-N 120.542 -1.564 . . . . 0.0 107.149 178.798 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.881 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.2 tp -116.76 104.94 11.85 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.496 -1.378 . . . . 0.0 109.681 -177.649 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.013 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.97 109.75 22.45 Favored 'General case' 0 N--CA 1.484 1.26 0 O-C-N 120.934 -1.104 . . . . 0.0 108.387 179.237 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.0 t -106.16 163.88 12.44 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.995 -1.066 . . . . 0.0 110.268 -179.037 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.518 ' OD1' ' N ' ' A' ' 74' ' ' GLU . 17.4 t30 -111.36 137.79 21.17 Favored Pre-proline 0 N--CA 1.502 2.129 0 O-C-N 121.496 -0.752 . . . . 0.0 109.598 -179.387 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.579 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -73.2 24.58 0.31 Allowed 'Trans proline' 0 C--N 1.318 -1.04 0 C-N-CA 122.504 2.136 . . . . 0.0 112.41 -179.379 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.415 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -103.34 -8.3 20.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.164 -1.585 . . . . 0.0 109.184 179.465 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.703 ' OD2' HG13 ' A' ' 69' ' ' VAL . 2.0 m-20 -135.69 8.85 3.33 Favored 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 179.902 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -65.54 86.46 0.08 Allowed 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.277 -0.889 . . . . 0.0 110.441 -178.797 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.615 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -115.61 -169.86 1.66 Allowed 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 178.785 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.465 ' OG ' ' HA ' ' A' ' 33' ' ' ASP . 0.6 OUTLIER 178.65 133.9 0.08 Allowed 'General case' 0 C--N 1.303 -1.424 0 O-C-N 120.725 -1.235 . . . . 0.0 111.206 -179.483 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.725 HG11 ' HB1' ' A' ' 63' ' ' ALA . 2.0 p -143.59 159.72 16.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.89 145.33 26.54 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 120.649 -1.282 . . . . 0.0 109.75 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.002 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.56 109.75 3.38 Favored 'General case' 0 C--N 1.3 -1.585 0 CA-C-O 122.449 1.118 . . . . 0.0 109.465 178.638 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.557 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.5 p-10 -62.11 -139.17 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.956 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.643 -179.989 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.719 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.33 -51.88 50.43 Favored 'General case' 0 N--CA 1.498 1.949 0 O-C-N 121.268 -0.895 . . . . 0.0 110.445 -178.94 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.5 -33.72 9.4 Favored 'General case' 0 C--N 1.288 -2.103 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.555 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.999 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.18 65.65 0.59 Allowed Glycine 0 C--N 1.3 -1.444 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.162 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 53.5 p -99.91 131.78 45.67 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 121.354 -1.086 . . . . 0.0 109.363 179.15 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.725 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -137.19 108.78 6.96 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.429 -0.908 . . . . 0.0 109.535 -179.853 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.417 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 92.0 p -117.62 118.52 32.34 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.063 -1.023 . . . . 0.0 109.588 -179.818 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.568 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -146.67 140.89 26.31 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.473 -0.767 . . . . 0.0 109.835 -179.947 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.476 ' HB3' ' HE3' ' A' ' 20' ' ' LYS . 24.2 p -98.82 136.37 38.94 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.322 -0.861 . . . . 0.0 108.792 179.54 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.971 HD11 HG12 ' A' ' 21' ' ' VAL . 0.2 OUTLIER -132.73 168.07 18.98 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.266 -0.896 . . . . 0.0 110.322 -178.489 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.647 HG22 HG22 ' A' ' 18' ' ' VAL . 1.1 p -104.46 124.39 49.17 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.876 . . . . 0.0 108.688 179.464 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.703 HG13 ' OD2' ' A' ' 51' ' ' ASP . 17.4 m -136.93 142.98 36.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 120.873 -1.142 . . . . 0.0 110.237 -178.761 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.586 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.4 ptt180 -144.9 -169.71 3.24 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 120.575 -1.328 . . . . 0.0 110.771 179.879 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.601 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -58.35 -99.8 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 -179.144 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -58.33 143.37 45.13 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.355 -1.466 . . . . 0.0 108.505 179.692 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.589 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.17 138.63 6.7 Favored 'General case' 0 C--N 1.294 -1.813 0 C-N-CA 118.848 -1.141 . . . . 0.0 109.614 -178.185 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.556 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 8.6 mm-40 -34.77 121.97 0.53 Allowed 'General case' 0 N--CA 1.49 1.53 0 CA-C-O 121.484 0.659 . . . . 0.0 110.583 -178.254 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.013 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.64 46.08 2.75 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 120.52 -0.848 . . . . 0.0 110.995 -179.298 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.579 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.7 m-85 -39.07 111.48 0.18 Allowed 'General case' 0 N--CA 1.507 2.403 0 O-C-N 121.23 -1.159 . . . . 0.0 109.887 179.589 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.672 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.5 tp -84.88 127.37 34.12 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.9 -1.125 . . . . 0.0 109.281 179.96 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.573 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 57.6 t80 -63.18 58.18 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.92 -1.113 . . . . 0.0 110.527 -179.881 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t0 -163.33 20.21 0.08 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.906 -1.121 . . . . 0.0 109.997 179.808 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.77 -27.16 4.95 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.091 -1.203 . . . . 0.0 110.091 179.979 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.505 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -90.3 150.57 21.86 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 121.119 -1.224 . . . . 0.0 110.247 -179.469 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.486 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -101.19 133.06 46.31 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 179.434 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.672 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.5 t90 -81.76 -16.09 52.18 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.794 -1.191 . . . . 0.0 110.56 -178.525 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 108.74 174.36 21.52 Favored Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.856 -1.697 . . . . 0.0 108.856 -179.719 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.79 103.9 0.62 Allowed 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.613 -1.255 . . . . 0.0 107.613 179.116 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.611 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.5 t -74.52 106.53 4.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.476 -0.765 . . . . 0.0 109.224 -178.814 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.58 110.93 3.37 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.386 -0.821 . . . . 0.0 109.813 -179.454 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.601 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.72 -5.49 4.23 Favored 'General case' 0 N--CA 1.499 2.024 0 C-N-CA 118.329 -1.348 . . . . 0.0 109.908 179.463 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.7 p -85.61 -0.6 55.53 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.705 -1.247 . . . . 0.0 109.144 179.568 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -112.92 -49.17 2.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.383 -0.823 . . . . 0.0 109.002 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.45 -178.2 3.58 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.511 -0.743 . . . . 0.0 109.455 179.963 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.14 115.64 30.57 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.446 -0.784 . . . . 0.0 108.964 179.924 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.564 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.86 123.54 40.6 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.935 -1.103 . . . . 0.0 109.665 -179.176 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.618 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.05 147.66 26.68 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-O 122.418 1.104 . . . . 0.0 111.014 -179.522 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.536 ' HB ' HG11 ' A' ' 7' ' ' VAL . 46.4 t -106.28 113.22 42.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.993 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 178.017 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.508 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -155.18 -169.83 20.11 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 117.989 -2.053 . . . . 0.0 111.834 -177.943 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.494 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -110.52 -177.74 3.31 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 -179.227 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.574 ' HB3' ' C26' ' A' ' 114' ' ' CHR . 12.1 p -170.38 172.03 6.31 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.367 -0.833 . . . . 0.0 109.083 -179.072 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.461 ' OD1' ' O ' ' A' ' 103' ' ' ASN . 0.6 OUTLIER -117.64 -161.81 0.84 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.984 -1.073 . . . . 0.0 108.764 179.592 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -119.56 36.12 4.6 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.546 -1.346 . . . . 0.0 109.236 -179.919 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -121.76 -33.54 3.56 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.391 -0.818 . . . . 0.0 110.468 -179.598 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 1.042 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 171.08 -38.01 0.18 Allowed Glycine 0 N--CA 1.482 1.712 0 N-CA-C 107.878 -2.089 . . . . 0.0 107.878 -179.58 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.461 ' O ' ' OD1' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -158.64 -177.92 6.88 Favored 'General case' 0 C--N 1.307 -1.277 0 O-C-N 121.474 -1.015 . . . . 0.0 109.81 179.238 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.4 -161.2 13.01 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.589 -1.804 . . . . 0.0 108.589 -179.256 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.544 ' HD3' ' CE2' ' A' ' 32' ' ' TYR . 4.7 Cg_exo -47.41 -178.97 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.709 1.254 . . . . 0.0 110.577 179.278 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -93.75 -177.6 4.42 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.072 -1.017 . . . . 0.0 110.425 -178.93 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.508 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.79 166.39 14.55 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 -179.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.68 130.41 52.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.342 -1.093 . . . . 0.0 109.165 -179.405 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.618 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.25 122.29 22.6 Favored 'General case' 0 C--N 1.289 -2.024 0 O-C-N 121.623 -0.673 . . . . 0.0 109.48 179.617 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.833 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.57 168.74 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 O-C-N 121.193 -0.942 . . . . 0.0 109.188 179.938 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.548 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.3 m -136.85 157.52 46.56 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.301 -0.875 . . . . 0.0 109.541 -179.784 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.833 ' CE2' HD12 ' A' ' 110' ' ' ILE . 70.8 m-85 -133.8 68.94 1.48 Allowed 'General case' 0 C--N 1.306 -1.323 0 O-C-N 121.164 -0.96 . . . . 0.0 109.608 -179.614 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 20.8 p30 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 117.995 -1.002 . . . . 0.0 109.491 -179.937 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 1.042 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.75 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -113.91 167.2 9.86 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.926 . . . . 0.0 109.429 -179.948 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.75 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 3.8 Cg_exo -60.21 157.88 33.1 Favored 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 122.194 1.929 . . . . 0.0 110.547 179.947 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.733 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.1 p -161.62 160.44 28.8 Favored 'General case' 0 C--N 1.296 -1.734 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 -179.238 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -149.45 122.78 9.01 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-O 122.415 1.102 . . . . 0.0 110.423 -179.684 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.863 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -114.72 109.07 17.64 Favored 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 123.075 1.417 . . . . 0.0 109.663 179.937 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.782 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -117.28 136.08 55.6 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.712 0 CA-C-N 114.297 -1.32 . . . . 0.0 109.681 179.99 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.489 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -173.08 150.8 2.0 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.273 -0.892 . . . . 0.0 108.734 -179.559 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.489 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -78.21 150.44 88.57 Favored 'Cis proline' 0 C--N 1.312 -1.387 0 C-N-CA 123.563 -1.432 . . . . 0.0 109.507 -0.761 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.673 ' HA ' HG22 ' A' ' 110' ' ' ILE . 38.3 p -90.01 -25.59 20.77 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 121.586 -0.696 . . . . 0.0 109.14 179.502 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.521 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 16.1 m -133.08 162.11 32.61 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.406 -0.809 . . . . 0.0 109.565 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.86 37.13 30.52 Favored Glycine 0 N--CA 1.496 2.678 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 -179.684 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.749 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.5 mt -92.36 -42.34 9.85 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 123.218 1.485 . . . . 0.0 110.43 -178.482 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.94 143.27 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.323 0 CA-C-N 113.379 -1.737 . . . . 0.0 109.825 -179.542 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.592 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 18.3 p-10 -50.39 105.27 0.09 Allowed 'General case' 0 C--N 1.3 -1.586 0 CA-C-O 121.452 0.644 . . . . 0.0 111.484 -178.525 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.92 13.57 8.46 Favored Glycine 0 N--CA 1.486 2.002 0 C-N-CA 119.306 -1.426 . . . . 0.0 113.165 177.285 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.749 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.56 -171.71 1.97 Allowed 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 121.28 2.54 . . . . 0.0 109.78 179.18 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.841 HG22 HG22 ' A' ' 68' ' ' THR . 18.2 t -129.26 139.01 52.91 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.956 -1.02 . . . . 0.0 111.224 -178.821 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.56 HG23 ' CD1' ' A' ' 67' ' ' LEU . 31.5 m -114.14 155.39 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 178.937 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -108.82 109.57 20.72 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.115 -0.991 . . . . 0.0 109.266 179.976 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.782 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -102.36 140.74 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 179.594 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.863 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.32 161.67 35.64 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 118.773 -1.171 . . . . 0.0 110.182 179.81 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.611 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.32 141.74 13.02 Favored Glycine 0 C--N 1.298 -1.572 0 N-CA-C 108.169 -1.973 . . . . 0.0 108.169 179.721 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.623 ' HB3' ' OG1' ' A' ' 4' ' ' THR . . . -143.24 124.69 14.76 Favored 'General case' 0 N--CA 1.494 1.754 0 CA-C-N 119.226 1.513 . . . . 0.0 109.363 179.255 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.48 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.05 28.98 19.16 Favored Glycine 0 N--CA 1.489 2.212 0 C-N-CA 118.965 -1.588 . . . . 0.0 109.647 -179.733 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.539 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.5 mt -89.4 175.24 7.4 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 120.9 -1.353 . . . . 0.0 108.366 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.022 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.61 99.95 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.414 0 O-C-N 120.977 -1.077 . . . . 0.0 109.806 -179.752 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.537 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.32 77.52 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.918 -179.347 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.588 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.97 33.97 0.24 Allowed Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 179.674 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.556 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 23.1 p -139.59 105.66 5.22 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.141 -1.211 . . . . 0.0 111.283 -179.404 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.592 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.42 109.77 0.34 Allowed 'General case' 0 N--CA 1.497 1.916 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 177.853 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.512 ' HA ' ' O ' ' A' ' 98' ' ' SER . 6.8 m-30 -104.41 158.99 16.09 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.139 -0.975 . . . . 0.0 109.131 -179.977 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.516 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -101.63 157.75 16.59 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 178.754 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.017 HG11 HG23 ' A' ' 65' ' ' THR . 1.6 t -136.84 109.77 8.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.129 -0.982 . . . . 0.0 109.635 -177.573 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.38 -174.05 35.37 Favored Glycine 0 N--CA 1.497 2.727 0 C-N-CA 117.713 -2.184 . . . . 0.0 112.638 -179.928 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.602 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -102.09 109.11 20.74 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-O 121.756 0.789 . . . . 0.0 109.062 -179.495 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.42 148.8 52.27 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.21 -0.931 . . . . 0.0 109.6 179.33 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.503 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.34 138.72 54.55 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.32 -0.862 . . . . 0.0 110.774 -178.995 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.885 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.43 115.07 26.92 Favored 'General case' 0 N--CA 1.493 1.694 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 178.154 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.8 m -104.88 14.89 6.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 120.988 -1.07 . . . . 0.0 110.558 -178.89 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.764 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.38 -175.12 0.08 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.959 -1.088 . . . . 0.0 110.006 179.781 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.44 98.12 2.2 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.411 -0.806 . . . . 0.0 109.687 -179.78 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.99 28.11 32.22 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 120.217 -0.992 . . . . 0.0 111.355 179.014 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.764 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.54 106.25 19.61 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 O-C-N 120.603 -1.528 . . . . 0.0 107.071 178.804 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.885 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.8 tp -118.03 104.5 10.93 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 120.458 -1.401 . . . . 0.0 109.789 -177.719 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.09 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.21 109.37 22.14 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 120.918 -1.114 . . . . 0.0 108.051 178.84 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.502 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.1 163.47 12.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.906 -1.121 . . . . 0.0 110.281 -178.778 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.742 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 47.4 t30 -106.4 132.33 20.99 Favored Pre-proline 0 N--CA 1.504 2.23 0 O-C-N 121.394 -0.816 . . . . 0.0 109.627 -179.424 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -72.21 19.36 0.3 Allowed 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 122.296 1.997 . . . . 0.0 112.281 -179.596 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.742 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -111.2 4.13 18.99 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.38 -1.45 . . . . 0.0 108.707 179.114 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.657 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.08 20.76 3.01 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 179.303 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -81.37 85.85 6.37 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.538 -178.715 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.505 ' HB3' ' HB ' ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.52 -171.03 2.04 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.843 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.66 134.58 0.08 Allowed 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.676 -1.265 . . . . 0.0 111.23 -179.292 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.873 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -158.12 153.6 5.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 178.359 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.592 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.28 139.95 33.29 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.875 -1.141 . . . . 0.0 109.544 -179.924 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.022 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -62.35 106.32 0.73 Allowed 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.391 1.091 . . . . 0.0 109.501 178.637 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.555 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.9 t70 -61.37 -139.21 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.045 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.77 179.976 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.537 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.11 -51.2 59.32 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.401 -0.812 . . . . 0.0 110.724 -178.803 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -101.04 -34.53 9.7 Favored 'General case' 0 C--N 1.286 -2.153 0 N-CA-C 106.282 -1.747 . . . . 0.0 106.282 178.493 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 104.88 65.76 0.68 Allowed Glycine 0 C--N 1.297 -1.637 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 178.109 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.611 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.6 m -98.86 130.42 45.27 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.594 -0.945 . . . . 0.0 108.6 178.739 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.873 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.79 108.63 6.68 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.594 -179.329 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.8 m -124.23 120.45 32.28 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.334 -0.854 . . . . 0.0 109.47 179.927 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 1.017 HG23 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.16 142.83 29.95 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.558 -0.714 . . . . 0.0 109.353 179.908 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 9.5 p -99.2 136.22 39.47 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.316 -0.865 . . . . 0.0 109.434 -179.949 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.758 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -136.31 165.19 26.34 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.461 -0.774 . . . . 0.0 109.55 -179.343 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.841 HG22 HG22 ' A' ' 18' ' ' VAL . 2.2 p -96.78 125.45 41.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.073 -1.017 . . . . 0.0 109.112 179.926 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.602 HG12 ' HB3' ' A' ' 36' ' ' GLN . 17.7 m -136.53 142.7 37.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 120.934 -1.104 . . . . 0.0 110.09 -178.886 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.592 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 5.2 ptt180 -147.49 -173.08 4.18 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 120.562 -1.337 . . . . 0.0 110.884 179.98 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.599 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -54.11 -101.22 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 -179.421 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.514 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.19 141.44 46.41 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.82 -1.175 . . . . 0.0 108.128 179.479 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.8 135.44 5.58 Favored 'General case' 0 C--N 1.294 -1.827 0 C-N-CA 118.68 -1.208 . . . . 0.0 109.665 -178.01 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.561 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 18.7 mm-40 -34.73 122.93 0.54 Allowed 'General case' 0 N--CA 1.491 1.603 0 CA-C-O 121.502 0.668 . . . . 0.0 110.088 -178.466 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.09 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.98 52.81 1.66 Allowed Glycine 0 N--CA 1.492 2.385 0 C-N-CA 120.397 -0.906 . . . . 0.0 111.108 -178.937 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.587 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-30 -39.7 113.38 0.33 Allowed 'General case' 0 N--CA 1.506 2.332 0 O-C-N 121.065 -1.256 . . . . 0.0 109.972 179.393 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.625 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -83.45 126.12 32.43 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.947 -1.096 . . . . 0.0 109.217 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 39.5 t80 -63.7 58.66 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.918 -1.114 . . . . 0.0 110.169 179.806 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -160.92 19.91 0.13 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.996 -1.065 . . . . 0.0 109.696 179.92 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.13 -28.07 5.28 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.882 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.463 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.32 159.61 15.04 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.007 -1.29 . . . . 0.0 110.28 -179.416 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.483 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.73 135.96 47.37 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 179.757 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.625 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -80.77 -18.87 46.25 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.867 -1.145 . . . . 0.0 110.545 -178.504 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.46 177.47 19.84 Favored Glycine 0 N--CA 1.484 1.88 0 N-CA-C 108.671 -1.771 . . . . 0.0 108.671 -179.428 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.36 105.58 1.18 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.2 -1.176 . . . . 0.0 107.859 179.206 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.665 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.0 t -77.53 105.7 6.83 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.346 -0.846 . . . . 0.0 109.124 -179.069 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.543 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.5 m-20 -65.6 111.44 3.15 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.406 -0.809 . . . . 0.0 109.747 -179.372 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.599 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.13 -5.23 4.46 Favored 'General case' 0 N--CA 1.5 2.031 0 C-N-CA 118.113 -1.435 . . . . 0.0 109.876 179.386 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -86.54 -0.06 55.33 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.799 -1.188 . . . . 0.0 109.159 179.587 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.543 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -113.36 -50.01 2.88 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.334 -0.854 . . . . 0.0 108.969 179.968 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.5 -179.05 3.83 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.487 -0.758 . . . . 0.0 109.42 179.925 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.88 115.27 30.01 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.328 -0.857 . . . . 0.0 108.999 179.9 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -97.03 122.24 39.81 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.762 -1.211 . . . . 0.0 109.428 -179.431 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -101.91 146.89 27.21 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 122.41 1.1 . . . . 0.0 111.107 -179.372 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.552 ' CG1' HG11 ' A' ' 7' ' ' VAL . 61.1 t -104.43 110.25 29.93 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 177.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.511 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.44 -169.86 17.58 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 118.31 -1.9 . . . . 0.0 111.466 -177.786 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.639 HD23 HG22 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -113.22 179.98 3.81 Favored 'General case' 0 N--CA 1.486 1.332 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -179.333 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.591 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.6 OUTLIER -169.51 163.82 10.37 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 121.364 -0.835 . . . . 0.0 109.406 -179.596 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.475 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -108.39 -160.83 0.74 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.187 -0.945 . . . . 0.0 108.804 179.673 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -120.06 35.41 4.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.554 -1.342 . . . . 0.0 109.336 -179.843 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -119.43 -32.52 4.33 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.434 -0.791 . . . . 0.0 110.215 -179.594 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 1.041 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 171.55 -39.17 0.17 Allowed Glycine 0 N--CA 1.483 1.806 0 N-CA-C 107.62 -2.192 . . . . 0.0 107.62 -179.536 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.501 ' ND2' ' O9 ' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -159.49 -178.16 6.93 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.637 -0.919 . . . . 0.0 109.622 179.194 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.85 -162.43 14.74 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 108.434 -1.866 . . . . 0.0 108.434 -179.34 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.48 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.9 Cg_exo -46.32 176.31 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.692 0 CA-C-N 118.837 1.318 . . . . 0.0 110.206 179.289 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -91.62 -176.15 4.4 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.033 -1.042 . . . . 0.0 110.573 -178.71 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.511 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.63 168.88 15.02 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.991 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.61 130.39 57.07 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.354 -1.086 . . . . 0.0 109.192 -179.208 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.05 122.9 20.91 Favored 'General case' 0 C--N 1.29 -1.985 0 O-C-N 121.609 -0.682 . . . . 0.0 109.505 179.543 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.76 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.69 169.02 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.201 -0.937 . . . . 0.0 109.222 179.922 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.521 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -136.39 155.31 50.21 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.18 -0.95 . . . . 0.0 109.602 -179.942 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.76 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 21.2 m-85 -131.12 93.86 3.47 Favored 'General case' 0 N--CA 1.486 1.333 0 O-C-N 121.198 -0.939 . . . . 0.0 109.482 -179.664 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 21.7 p30 . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.41 179.904 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 1.041 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.511 0 CA-C-O 121.262 0.553 . . . . 0.0 109.564 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.929 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -114.26 172.79 3.3 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.231 -0.918 . . . . 0.0 109.411 179.987 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.929 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.7 Cg_exo -59.64 157.92 30.27 Favored 'Trans proline' 0 C--N 1.309 -1.526 0 C-N-CA 122.15 1.9 . . . . 0.0 110.539 -179.977 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.7 -169.5 0.14 Allowed 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.289 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.668 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -166.3 133.97 2.76 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.7 -1.25 . . . . 0.0 111.134 -179.37 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.01 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -100.92 104.59 15.79 Favored 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 122.478 1.132 . . . . 0.0 109.76 -179.892 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.975 HG22 HG23 ' A' ' 21' ' ' VAL . 5.4 t -119.4 122.92 70.2 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.401 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.574 179.823 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.481 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -169.52 150.04 3.91 Favored Pre-proline 0 N--CA 1.487 1.413 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 -179.529 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.481 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.4 Cg_endo -76.74 150.71 93.25 Favored 'Cis proline' 0 C--N 1.309 -1.533 0 C-N-CA 123.613 -1.411 . . . . 0.0 109.579 -0.339 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.679 ' HA ' HG22 ' A' ' 110' ' ' ILE . 89.2 p -92.49 -22.81 19.37 Favored 'General case' 0 C--N 1.292 -1.929 0 O-C-N 121.693 -0.629 . . . . 0.0 109.352 179.799 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.488 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.3 m -132.37 163.97 27.51 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.398 -0.814 . . . . 0.0 109.689 -179.822 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.05 38.88 39.14 Favored Glycine 0 N--CA 1.495 2.574 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 -179.504 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.857 ' CA ' HG21 ' A' ' 17' ' ' THR . 27.7 mt -92.02 -45.21 8.44 Favored 'General case' 0 C--N 1.297 -1.698 0 CA-C-O 123.12 1.438 . . . . 0.0 110.772 -178.09 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.13 146.42 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.349 0 CA-C-N 113.799 -1.546 . . . . 0.0 110.077 -179.615 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.585 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.6 p-10 -50.76 108.32 0.23 Allowed 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 121.542 0.687 . . . . 0.0 111.984 -178.53 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 110.74 16.54 9.9 Favored Glycine 0 N--CA 1.485 1.907 0 C-N-CA 119.592 -1.289 . . . . 0.0 112.768 177.07 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.857 HG21 ' CA ' ' A' ' 13' ' ' LEU . 8.8 t -103.45 -174.79 2.63 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 120.965 2.382 . . . . 0.0 109.98 179.426 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.772 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.0 t -129.89 138.9 52.91 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 CA-C-N 114.365 -1.288 . . . . 0.0 111.06 -178.799 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.635 HG22 HG22 ' A' ' 69' ' ' VAL . 4.1 m -118.53 154.99 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.669 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 10.2 tttt -105.95 108.99 20.79 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.175 -0.953 . . . . 0.0 109.403 -179.99 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.975 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.04 123.38 62.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 N-CA-C 108.412 -0.959 . . . . 0.0 108.412 179.611 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.51 167.17 11.54 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 120.69 -1.256 . . . . 0.0 109.222 -179.917 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.604 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.76 140.71 12.03 Favored Glycine 0 C--N 1.295 -1.717 0 N-CA-C 107.49 -2.244 . . . . 0.0 107.49 179.718 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.575 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.31 124.1 11.92 Favored 'General case' 0 C--N 1.293 -1.889 0 O-C-N 120.748 -1.442 . . . . 0.0 108.87 179.35 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.533 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.36 25.97 26.94 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.226 -1.464 . . . . 0.0 109.913 -179.641 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.539 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.1 mt -85.6 175.44 8.77 Favored 'General case' 0 C--N 1.306 -1.321 0 O-C-N 120.891 -1.358 . . . . 0.0 108.263 -179.989 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.39 96.71 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.928 -1.108 . . . . 0.0 109.659 -179.72 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.706 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.53 76.77 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.758 0 CA-C-N 115.177 -0.92 . . . . 0.0 110.536 -178.996 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.77 33.7 0.33 Allowed Glycine 0 N--CA 1.487 2.047 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.253 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.587 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.3 t -149.14 116.07 6.0 Favored 'General case' 0 C--N 1.307 -1.268 0 O-C-N 120.929 -1.336 . . . . 0.0 111.138 179.919 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.565 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.83 127.55 6.4 Favored 'General case' 0 N--CA 1.492 1.653 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.902 178.453 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.587 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.9 m-85 -118.36 149.18 41.63 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.431 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.505 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -98.97 159.28 15.07 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.548 -1.345 . . . . 0.0 107.784 178.841 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.623 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.4 p -140.19 119.6 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.189 -0.944 . . . . 0.0 109.633 -177.819 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' HB2' ' A' ' 51' ' ' ASP . . . -170.72 -179.94 42.33 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 118.274 -1.917 . . . . 0.0 111.794 -179.799 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.67 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.83 108.85 20.76 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.783 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.484 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -129.32 148.51 51.25 Favored 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.174 -0.954 . . . . 0.0 109.953 179.887 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.513 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.19 138.99 54.51 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.359 -0.838 . . . . 0.0 110.593 -179.046 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.89 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.29 114.63 26.44 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 107.521 -1.289 . . . . 0.0 107.521 178.213 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.0 m -104.38 14.81 6.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 O-C-N 121.069 -1.019 . . . . 0.0 110.482 -178.811 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.74 -175.41 0.08 Allowed 'General case' 0 C--N 1.302 -1.482 0 O-C-N 120.935 -1.103 . . . . 0.0 110.025 179.695 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.6 p -73.54 98.28 2.78 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.413 -0.804 . . . . 0.0 109.506 -179.858 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.5 27.58 29.56 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 120.219 -0.991 . . . . 0.0 111.326 179.128 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -118.72 106.31 19.29 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 O-C-N 120.607 -1.525 . . . . 0.0 107.342 178.999 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.89 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -116.61 104.7 11.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.315 -1.491 . . . . 0.0 109.855 -177.815 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.948 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.49 109.62 22.34 Favored 'General case' 0 N--CA 1.485 1.288 0 O-C-N 120.909 -1.12 . . . . 0.0 108.1 178.885 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.0 t -107.15 165.82 11.08 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.841 -1.162 . . . . 0.0 110.612 -178.632 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.503 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 55.3 t30 -113.55 132.45 22.53 Favored Pre-proline 0 N--CA 1.501 2.092 0 C-N-CA 120.119 -0.632 . . . . 0.0 109.425 -179.486 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.8 Cg_endo -72.76 24.31 0.29 Allowed 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 122.205 1.937 . . . . 0.0 112.104 -179.743 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.419 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -99.06 -7.58 26.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.369 -1.457 . . . . 0.0 109.184 179.52 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.792 ' HB3' HD22 ' A' ' 67' ' ' LEU . 0.7 OUTLIER -133.61 5.8 3.72 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.346 -0.846 . . . . 0.0 108.817 -179.985 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -59.44 80.62 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.87 -178.656 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -108.48 -169.97 1.59 Allowed 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 178.297 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.5 134.55 0.08 Allowed 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.543 -1.348 . . . . 0.0 111.448 -179.405 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.724 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.9 p -146.31 158.92 11.14 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 177.741 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.565 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.48 146.6 25.08 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.572 -1.33 . . . . 0.0 109.884 -179.564 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.42 108.73 3.37 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-O 122.385 1.088 . . . . 0.0 109.674 178.914 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.546 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.1 p-10 -62.42 -138.85 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.017 0 CA-C-N 115.584 -0.734 . . . . 0.0 110.862 -179.796 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.706 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.72 -51.84 35.76 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.376 -0.828 . . . . 0.0 110.641 -178.771 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -105.11 -32.73 8.55 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 178.553 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.963 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.5 69.78 0.67 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.367 -1.093 . . . . 0.0 110.367 178.246 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 69.9 m -103.63 130.09 51.01 Favored 'General case' 0 N--CA 1.484 1.234 0 O-C-N 121.268 -1.137 . . . . 0.0 109.337 179.267 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.724 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.62 108.69 7.68 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.433 -0.907 . . . . 0.0 109.676 -179.675 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 93.6 p -115.88 116.93 28.84 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 120.956 -1.09 . . . . 0.0 109.364 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.29 141.27 27.15 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.427 -0.796 . . . . 0.0 110.125 -179.868 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.6 p -100.35 137.0 39.36 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 179.614 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.972 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -137.35 172.22 13.31 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.253 -0.904 . . . . 0.0 109.844 -178.979 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.581 HG22 HG22 ' A' ' 18' ' ' VAL . 1.2 p -104.72 123.66 48.02 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.089 -1.007 . . . . 0.0 109.908 -179.372 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.764 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.5 m -133.04 143.6 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.848 0 O-C-N 121.056 -1.027 . . . . 0.0 109.688 -179.606 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.585 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.2 ptt180 -140.78 -167.77 2.43 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.558 -1.339 . . . . 0.0 110.417 179.906 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.584 ' HG2' ' CD1' ' A' ' 112' ' ' PHE . 3.3 mtt180 -70.95 -76.61 0.1 Allowed 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -179.623 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.49 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -71.88 137.8 47.74 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 120.153 -1.592 . . . . 0.0 107.547 179.117 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.594 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -159.56 136.96 9.79 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.27 -1.372 . . . . 0.0 110.108 -178.105 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.484 ' O ' ' O ' ' A' ' 47' ' ' CYS . 9.1 mm-40 -34.71 122.54 0.53 Allowed 'General case' 0 N--CA 1.487 1.413 0 CA-C-O 121.562 0.696 . . . . 0.0 110.571 -178.188 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.948 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.38 45.62 3.14 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 -179.333 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 6.6 m-85 -38.41 113.82 0.32 Allowed 'General case' 0 N--CA 1.509 2.477 0 O-C-N 121.194 -1.18 . . . . 0.0 110.167 179.751 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.691 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.4 tp -87.81 125.99 34.76 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 120.913 -1.117 . . . . 0.0 109.477 -179.89 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.596 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 23.4 t80 -64.26 58.6 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 O-C-N 120.972 -1.08 . . . . 0.0 110.184 179.93 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 6.3 t70 -161.0 20.02 0.13 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.047 -1.033 . . . . 0.0 109.796 179.688 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.68 -27.5 5.29 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.874 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 8.1 p -94.05 160.99 14.47 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.984 -1.303 . . . . 0.0 110.256 -179.488 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.544 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -108.98 136.63 48.2 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.897 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.691 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.7 t90 -82.67 -19.1 38.82 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.932 -1.105 . . . . 0.0 110.386 -178.368 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.64 175.2 19.97 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 -179.494 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.29 109.63 1.39 Allowed 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 179.122 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.677 HG21 ' CB ' ' A' ' 46' ' ' ALA . 39.4 t -81.38 104.38 9.85 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.068 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.637 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -67.42 111.14 3.91 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.433 -0.792 . . . . 0.0 109.888 -179.076 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.568 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.0 t -63.26 -5.9 3.9 Favored 'General case' 0 N--CA 1.499 2.017 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.942 179.48 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.3 p -84.76 -0.08 52.45 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.717 -1.24 . . . . 0.0 109.023 179.407 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.637 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.41 -49.14 2.91 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.356 -0.84 . . . . 0.0 109.024 -179.969 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.08 -178.03 3.53 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.578 -0.701 . . . . 0.0 109.539 -179.996 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.11 115.26 29.92 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.466 -0.771 . . . . 0.0 108.982 -179.97 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.57 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -97.09 125.2 41.4 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 120.948 -1.095 . . . . 0.0 109.687 -179.174 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.595 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.54 146.44 28.89 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 122.421 1.105 . . . . 0.0 111.191 -179.524 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.606 ' HB ' HG11 ' A' ' 7' ' ' VAL . 96.2 t -102.68 111.09 31.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 177.775 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.487 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.78 -171.2 18.72 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 117.97 -2.062 . . . . 0.0 111.808 -177.684 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.668 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -113.95 -177.59 3.17 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -179.075 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.594 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.0 OUTLIER -175.13 172.02 2.87 Favored 'General case' 0 C--N 1.299 -1.617 0 O-C-N 121.229 -0.92 . . . . 0.0 109.531 -179.378 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -122.05 -162.27 0.98 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.878 -1.139 . . . . 0.0 108.921 179.665 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -116.03 36.5 4.02 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.684 -1.26 . . . . 0.0 109.122 179.953 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -116.76 -33.26 4.87 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.337 -0.852 . . . . 0.0 110.159 -179.522 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 1.026 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 166.64 -36.65 0.24 Allowed Glycine 0 N--CA 1.481 1.699 0 N-CA-C 107.786 -2.126 . . . . 0.0 107.786 -179.667 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.55 -177.67 6.09 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 121.534 -0.98 . . . . 0.0 109.91 179.328 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.86 -160.97 12.89 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.415 -1.874 . . . . 0.0 108.415 -179.395 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.488 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.7 Cg_exo -47.87 -178.95 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.679 0 CA-C-N 118.813 1.306 . . . . 0.0 110.474 179.367 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.9 mm-40 -94.59 -179.51 4.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.068 -1.02 . . . . 0.0 110.448 -178.903 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.487 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.84 162.49 12.71 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 -179.972 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.8 129.67 50.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.397 -1.06 . . . . 0.0 109.095 -179.501 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.595 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.35 121.82 21.06 Favored 'General case' 0 C--N 1.289 -2.041 0 O-C-N 121.626 -0.671 . . . . 0.0 109.892 179.963 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.853 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.83 171.37 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.242 -0.911 . . . . 0.0 108.982 179.658 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.488 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.0 OUTLIER -138.6 159.33 42.36 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.156 -0.965 . . . . 0.0 109.669 -179.845 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.853 ' CE2' HD12 ' A' ' 110' ' ' ILE . 79.7 m-85 -135.09 129.31 33.76 Favored 'General case' 0 N--CA 1.485 1.323 0 O-C-N 121.25 -0.907 . . . . 0.0 109.63 -179.785 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.6 p30 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 118.093 -0.956 . . . . 0.0 109.538 -179.87 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 1.026 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.913 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -122.56 173.02 4.59 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.254 -0.904 . . . . 0.0 109.457 -179.986 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.913 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.6 Cg_exo -59.83 157.86 31.4 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.233 1.955 . . . . 0.0 110.472 179.979 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.544 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.54 -169.76 0.15 Allowed 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.292 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.544 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.77 131.0 2.43 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 120.764 -1.21 . . . . 0.0 110.778 -179.202 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.949 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.4 t -112.82 108.71 17.79 Favored 'General case' 0 C--N 1.296 -1.753 0 CA-C-O 123.108 1.432 . . . . 0.0 109.175 179.394 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.853 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -115.93 139.04 44.39 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.728 0 CA-C-N 114.169 -1.378 . . . . 0.0 110.088 -179.67 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.486 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -177.0 150.32 0.88 Allowed Pre-proline 0 N--CA 1.486 1.35 0 O-C-N 121.309 -0.87 . . . . 0.0 108.766 -179.673 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.486 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.9 Cg_endo -78.49 150.43 87.7 Favored 'Cis proline' 0 C--N 1.312 -1.364 0 C-N-CA 123.531 -1.445 . . . . 0.0 109.334 -0.921 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.646 ' HA ' HG22 ' A' ' 110' ' ' ILE . 94.1 p -93.65 -22.13 18.96 Favored 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.52 -0.738 . . . . 0.0 109.558 179.821 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.481 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -132.2 162.62 30.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.805 -179.798 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.15 39.03 38.21 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 108.279 -1.928 . . . . 0.0 108.279 -179.508 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.823 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.8 mt -91.38 -44.58 9.06 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-O 123.093 1.425 . . . . 0.0 110.771 -178.272 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.0 OUTLIER 64.37 146.42 0.03 OUTLIER 'General case' 0 C--N 1.259 -3.332 0 CA-C-N 113.735 -1.575 . . . . 0.0 109.63 -179.42 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.6 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.7 p-10 -52.32 110.1 0.46 Allowed 'General case' 0 C--N 1.3 -1.547 0 CA-C-O 121.486 0.66 . . . . 0.0 111.554 -178.523 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.71 9.76 13.75 Favored Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.301 -1.428 . . . . 0.0 112.854 177.375 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.823 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.8 t -101.32 -172.52 2.18 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 121.029 2.415 . . . . 0.0 109.747 179.502 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.76 HG13 ' C ' ' A' ' 67' ' ' LEU . 11.2 t -134.63 141.32 43.64 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.612 -179.334 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 27.8 m -116.55 154.8 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.214 -0.929 . . . . 0.0 109.057 179.471 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.489 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 21.8 tttt -107.95 108.97 20.34 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.238 -0.914 . . . . 0.0 109.049 179.793 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.853 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -101.03 139.11 23.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.555 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.949 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.45 160.46 37.92 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 118.461 -1.296 . . . . 0.0 110.027 -179.974 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.603 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.94 144.07 15.52 Favored Glycine 0 C--N 1.294 -1.758 0 N-CA-C 107.755 -2.138 . . . . 0.0 107.755 179.608 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.572 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.45 124.5 12.09 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 120.799 -1.412 . . . . 0.0 108.953 179.222 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 90.15 26.52 23.58 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 119.272 -1.442 . . . . 0.0 109.703 -179.702 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.577 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -89.22 170.56 10.49 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 120.857 -1.378 . . . . 0.0 108.479 179.989 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.006 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.09 100.69 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.051 -1.031 . . . . 0.0 109.988 -179.574 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.7 77.98 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.625 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.004 -179.509 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.85 34.05 0.27 Allowed Glycine 0 N--CA 1.487 2.046 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 179.702 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.553 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 20.8 p -139.18 105.88 5.37 Favored 'General case' 0 C--N 1.306 -1.285 0 O-C-N 121.198 -1.178 . . . . 0.0 111.255 -179.485 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.589 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -52.32 114.19 1.27 Allowed 'General case' 0 N--CA 1.495 1.814 0 CA-C-N 115.936 -0.574 . . . . 0.0 109.611 178.098 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.489 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 8.2 m-30 -110.67 160.06 17.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.143 -0.973 . . . . 0.0 108.949 179.834 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.507 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -100.62 168.28 9.8 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 178.93 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.704 HG22 HG11 ' A' ' 21' ' ' VAL . 3.8 p -150.36 117.13 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.023 -1.048 . . . . 0.0 109.827 -178.221 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.85 -175.93 39.21 Favored Glycine 0 N--CA 1.495 2.605 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.821 -179.765 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.609 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -99.33 108.44 20.97 Favored 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.811 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.0 m -132.21 148.45 52.46 Favored 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.296 -0.878 . . . . 0.0 109.784 179.657 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.2 140.25 53.02 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.241 -0.912 . . . . 0.0 110.727 -179.136 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.885 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.16 114.78 26.61 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 178.211 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.3 m -104.16 14.49 6.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.052 -1.03 . . . . 0.0 110.5 -178.798 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.75 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 174.93 -175.26 0.08 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.897 -1.127 . . . . 0.0 110.087 179.769 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -73.25 98.45 2.65 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.425 -0.797 . . . . 0.0 109.535 -179.917 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.98 27.51 31.2 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 120.244 -0.979 . . . . 0.0 111.421 179.072 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.75 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -118.01 106.33 19.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 O-C-N 120.618 -1.519 . . . . 0.0 107.303 178.846 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.885 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.4 tp -117.65 104.67 11.25 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.523 -1.36 . . . . 0.0 109.58 -177.843 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.965 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.03 109.54 22.27 Favored 'General case' 0 N--CA 1.485 1.281 0 O-C-N 120.828 -1.17 . . . . 0.0 108.251 179.068 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -107.61 166.85 10.37 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.023 -1.048 . . . . 0.0 109.989 -179.17 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.73 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 11.0 t-20 -107.3 137.33 19.58 Favored Pre-proline 0 N--CA 1.502 2.148 0 O-C-N 121.231 -0.918 . . . . 0.0 109.846 -179.286 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 5.6 Cg_endo -75.15 24.49 0.39 Allowed 'Trans proline' 0 C--N 1.318 -1.04 0 C-N-CA 122.383 2.056 . . . . 0.0 111.786 179.845 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.73 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -120.27 4.09 10.81 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.351 -1.468 . . . . 0.0 109.195 179.75 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.572 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.84 19.96 2.85 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 179.278 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -84.14 87.81 7.17 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.929 -0.708 . . . . 0.0 110.858 -178.618 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -107.91 -168.25 1.35 Allowed 'General case' 0 N--CA 1.491 1.601 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.436 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.458 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.92 136.22 0.09 Allowed 'General case' 0 C--N 1.305 -1.326 0 O-C-N 120.755 -1.216 . . . . 0.0 111.082 -179.401 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.927 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -151.73 157.7 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 178.391 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.589 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.91 142.26 30.64 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 120.835 -1.166 . . . . 0.0 110.027 -179.786 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.03 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.89 107.76 1.05 Allowed 'General case' 0 C--N 1.298 -1.67 0 CA-C-O 122.441 1.115 . . . . 0.0 109.288 178.083 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.1 t0 -62.94 -138.68 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.777 179.937 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.531 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.37 -52.7 34.93 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 121.402 -0.811 . . . . 0.0 110.924 -178.615 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.85 -33.07 9.94 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 178.612 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.03 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.19 62.26 0.55 Allowed Glycine 0 C--N 1.296 -1.664 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 178.051 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.603 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 82.5 p -98.72 129.91 45.19 Favored 'General case' 0 C--N 1.309 -1.155 0 O-C-N 121.563 -0.963 . . . . 0.0 108.731 178.713 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.927 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.29 108.89 6.97 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.203 -0.999 . . . . 0.0 109.727 -179.343 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.435 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -122.35 119.2 30.37 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.191 -0.943 . . . . 0.0 109.533 -179.941 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.574 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.66 142.98 30.51 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.491 -0.756 . . . . 0.0 109.329 179.876 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 27.7 p -98.82 138.09 36.46 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.416 -0.802 . . . . 0.0 109.58 -179.853 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.814 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.1 OUTLIER -140.83 159.41 42.27 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.329 -0.857 . . . . 0.0 109.48 -179.502 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.71 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 13.0 t -87.91 139.14 30.82 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.147 -0.97 . . . . 0.0 110.657 -179.411 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.609 HG12 ' HB3' ' A' ' 36' ' ' GLN . 19.4 m -148.73 144.31 18.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.484 -0.76 . . . . 0.0 109.249 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.6 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.9 OUTLIER -150.72 -173.69 4.55 Favored 'General case' 0 N--CA 1.484 1.245 0 O-C-N 120.456 -1.403 . . . . 0.0 111.178 -179.641 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.741 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.28 -104.8 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.281 -179.644 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.458 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -59.43 140.23 56.37 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 120.695 -1.253 . . . . 0.0 108.072 178.948 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.609 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 0.5 OUTLIER -158.29 138.69 12.61 Favored 'General case' 0 C--N 1.295 -1.795 0 C-N-CA 118.773 -1.171 . . . . 0.0 109.713 -178.312 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.52 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 8.8 mm-40 -34.89 120.35 0.5 Allowed 'General case' 0 N--CA 1.492 1.652 0 CA-C-O 121.539 0.685 . . . . 0.0 110.552 -178.448 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.965 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.96 47.91 3.2 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.415 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -38.47 113.65 0.31 Allowed 'General case' 0 N--CA 1.507 2.394 0 O-C-N 121.241 -1.153 . . . . 0.0 110.166 179.812 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.816 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.66 126.26 34.41 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.997 -1.065 . . . . 0.0 109.456 -179.982 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 20.4 t80 -64.23 58.48 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.973 0 O-C-N 120.906 -1.121 . . . . 0.0 109.949 179.541 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 9.8 t70 -158.74 18.77 0.2 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.976 -1.078 . . . . 0.0 109.645 -179.979 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.18 -26.41 6.23 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.761 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -97.83 163.64 12.71 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 120.99 -1.3 . . . . 0.0 110.404 -179.332 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.486 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 4.2 ptt180 -106.24 136.79 45.34 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.914 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.816 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.7 t90 -82.58 -19.6 38.15 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.79 -1.194 . . . . 0.0 110.241 -178.709 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.64 173.43 16.86 Favored Glycine 0 N--CA 1.486 2.019 0 N-CA-C 108.791 -1.723 . . . . 0.0 108.791 -179.636 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -65.14 106.1 1.22 Allowed 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 179.105 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.651 HG21 ' HB3' ' A' ' 46' ' ' ALA . 46.2 t -76.51 107.34 7.51 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.371 -0.831 . . . . 0.0 109.533 -178.694 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.603 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.9 m-20 -63.92 111.99 2.73 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.213 -0.929 . . . . 0.0 109.178 -179.919 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.741 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 1.2 m -65.41 -4.66 5.96 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 120.704 -1.247 . . . . 0.0 109.829 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.2 p -93.27 1.95 56.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.731 -1.23 . . . . 0.0 109.58 179.956 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.603 HG23 ' HB3' ' A' ' 87' ' ' ASP . 5.0 p -112.51 -52.79 2.76 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.241 -0.912 . . . . 0.0 108.636 179.78 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.421 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -98.47 178.77 4.92 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.492 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.07 114.0 27.74 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.275 -0.89 . . . . 0.0 108.777 179.825 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.505 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.8 m -96.44 121.8 38.64 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.982 -1.074 . . . . 0.0 109.758 -178.989 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.572 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -106.2 144.28 33.12 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-O 122.355 1.074 . . . . 0.0 111.112 -179.798 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 90.5 t -101.87 109.58 26.44 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.086 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 177.741 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.483 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.12 -172.01 17.65 Favored Glycine 0 N--CA 1.487 2.054 0 C-N-CA 118.223 -1.941 . . . . 0.0 111.741 -177.591 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.503 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -112.01 178.8 4.19 Favored 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.289 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.59 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.9 OUTLIER -169.52 165.93 10.26 Favored 'General case' 0 C--N 1.294 -1.805 0 O-C-N 121.571 -0.706 . . . . 0.0 109.424 -179.546 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.489 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -115.16 -160.1 0.73 Allowed 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.043 -1.036 . . . . 0.0 108.805 179.776 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -116.82 35.76 4.47 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.636 -1.29 . . . . 0.0 109.246 -179.959 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -116.52 -33.17 4.98 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.402 -0.811 . . . . 0.0 110.143 -179.684 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.976 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.83 -36.81 0.26 Allowed Glycine 0 N--CA 1.482 1.717 0 N-CA-C 107.559 -2.216 . . . . 0.0 107.559 -179.544 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.75 -178.23 7.1 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.574 -0.956 . . . . 0.0 109.777 179.23 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.44 -161.9 14.4 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.488 -1.845 . . . . 0.0 108.488 -179.394 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.479 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -47.24 178.25 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.626 0 CA-C-N 118.812 1.306 . . . . 0.0 110.342 179.329 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -91.37 -174.35 3.9 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.097 -1.002 . . . . 0.0 110.401 -178.893 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.483 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.99 166.8 15.29 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.829 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.7 130.15 51.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.43 -1.041 . . . . 0.0 109.1 -179.429 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.572 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.71 125.12 28.04 Favored 'General case' 0 C--N 1.289 -2.049 0 O-C-N 121.641 -0.662 . . . . 0.0 109.606 179.782 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.755 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.84 169.98 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.274 -0.891 . . . . 0.0 109.257 179.976 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.481 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -137.88 155.77 48.6 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.276 -0.89 . . . . 0.0 109.504 179.992 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.755 ' CE1' HD12 ' A' ' 110' ' ' ILE . 76.5 m-85 -123.55 68.98 1.02 Allowed 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.11 -0.994 . . . . 0.0 109.51 -179.808 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 15.8 p30 . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 117.944 -1.027 . . . . 0.0 109.483 -179.961 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.976 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.464 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -117.92 157.42 48.43 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.23 -0.919 . . . . 0.0 109.493 179.96 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.53 ' HB3' HD23 ' A' ' 26' ' ' LEU . 2.9 Cg_endo -61.23 155.94 48.43 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.37 2.046 . . . . 0.0 110.609 -179.933 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -150.05 158.86 44.59 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -179.666 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.499 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -144.08 123.84 13.39 Favored 'General case' 0 C--N 1.294 -1.817 0 CA-C-O 122.465 1.126 . . . . 0.0 110.031 -179.918 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.92 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.9 t -114.88 109.1 17.64 Favored 'General case' 0 C--N 1.294 -1.822 0 CA-C-O 123.2 1.476 . . . . 0.0 109.765 -179.807 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.863 HG22 HG23 ' A' ' 21' ' ' VAL . 3.1 t -116.27 136.98 51.49 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.638 0 CA-C-N 114.176 -1.374 . . . . 0.0 109.716 179.902 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.497 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -172.96 151.25 2.13 Favored Pre-proline 0 N--CA 1.488 1.469 0 O-C-N 121.235 -0.915 . . . . 0.0 108.791 -179.534 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.497 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.2 Cg_endo -77.53 151.67 92.52 Favored 'Cis proline' 0 C--N 1.311 -1.422 0 C-N-CA 123.517 -1.451 . . . . 0.0 109.433 -0.819 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.67 ' HA ' HG22 ' A' ' 110' ' ' ILE . 88.1 p -93.94 -23.2 18.16 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.576 -0.703 . . . . 0.0 109.505 179.805 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.5 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 3.0 m -130.94 160.1 35.51 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.321 -0.862 . . . . 0.0 109.96 -179.65 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.23 37.25 32.57 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 108.611 -1.796 . . . . 0.0 108.611 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.865 ' CA ' HG21 ' A' ' 17' ' ' THR . 27.1 mt -90.83 -45.42 8.81 Favored 'General case' 0 C--N 1.299 -1.627 0 CA-C-O 123.113 1.435 . . . . 0.0 110.751 -178.411 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 64.03 147.23 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.311 0 CA-C-N 113.748 -1.569 . . . . 0.0 109.963 -179.612 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.615 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.4 p-10 -51.41 108.9 0.29 Allowed 'General case' 0 C--N 1.302 -1.47 0 CA-C-O 121.725 0.774 . . . . 0.0 111.809 -178.568 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.8 13.66 11.04 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 119.479 -1.343 . . . . 0.0 112.914 177.311 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.865 HG21 ' CA ' ' A' ' 13' ' ' LEU . 10.2 t -101.8 -174.34 2.57 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 121.059 2.43 . . . . 0.0 109.86 179.457 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.766 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.1 t -127.83 138.3 55.13 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.885 -178.994 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.534 HG13 ' CG2' ' A' ' 69' ' ' VAL . 30.8 m -117.34 154.17 19.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.877 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -109.98 109.34 19.89 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.187 -0.946 . . . . 0.0 109.195 -179.846 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.863 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -101.96 140.44 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.747 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.92 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.33 158.31 44.12 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.838 -1.164 . . . . 0.0 109.701 179.568 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -139.36 108.81 0.61 Allowed Glycine 0 N--CA 1.481 1.675 0 N-CA-C 108.658 -1.777 . . . . 0.0 108.658 179.888 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.597 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.54 139.52 50.4 Favored 'General case' 0 N--CA 1.502 2.14 0 CA-C-N 119.402 1.601 . . . . 0.0 110.564 -179.25 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.506 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 85.21 27.81 32.47 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.058 -1.544 . . . . 0.0 109.938 179.569 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.7 OUTLIER -93.67 170.53 9.51 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 120.97 -1.312 . . . . 0.0 108.522 -179.92 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.997 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.43 101.23 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.097 -1.002 . . . . 0.0 109.827 -179.566 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.54 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.42 77.93 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.705 0 CA-C-N 115.491 -0.777 . . . . 0.0 109.888 -179.342 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.5 33.46 0.27 Allowed Glycine 0 N--CA 1.488 2.138 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 179.896 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.56 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 12.9 p -136.96 104.75 5.55 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 121.2 -1.176 . . . . 0.0 111.057 -179.349 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.582 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.54 110.03 0.41 Allowed 'General case' 0 N--CA 1.497 1.914 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.621 178.087 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.567 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 38.5 m-85 -106.33 156.35 18.59 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.052 -1.03 . . . . 0.0 108.992 179.87 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.415 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.25 160.14 14.57 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.631 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.626 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.2 p -140.75 119.66 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.095 -1.003 . . . . 0.0 109.62 -177.836 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.486 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.88 -178.8 41.15 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.536 -1.792 . . . . 0.0 111.525 -179.782 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.586 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.1 pt20 -100.99 109.08 20.95 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.756 0.788 . . . . 0.0 108.954 -179.904 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.493 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.81 150.26 52.07 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.079 -1.013 . . . . 0.0 110.406 179.978 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.92 139.38 53.88 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.373 -0.829 . . . . 0.0 110.661 -179.054 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.882 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.3 115.02 26.87 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 178.114 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -105.92 15.44 7.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.013 -1.055 . . . . 0.0 110.605 -178.889 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.764 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.6 -176.33 0.09 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.831 -1.168 . . . . 0.0 110.147 179.759 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 42' ' ' THR . 15.2 t -70.13 97.32 1.18 Allowed 'General case' 0 N--CA 1.487 1.419 0 CA-C-O 121.791 0.805 . . . . 0.0 109.949 -179.553 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.2 28.35 37.18 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.158 -1.02 . . . . 0.0 111.349 178.957 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.764 HG21 ' CB ' ' A' ' 41' ' ' ASP . 2.0 t -115.61 106.46 20.52 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 O-C-N 120.625 -1.515 . . . . 0.0 107.193 178.778 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.882 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.3 tp -116.4 104.75 11.77 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.428 -1.42 . . . . 0.0 109.847 -177.612 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.872 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.96 109.24 22.03 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 120.763 -1.211 . . . . 0.0 107.847 178.682 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.508 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -104.17 170.0 8.16 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.933 -1.104 . . . . 0.0 110.151 -178.863 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.454 ' CG ' ' HB2' ' A' ' 73' ' ' PHE . 36.9 t30 -108.24 134.67 20.1 Favored Pre-proline 0 N--CA 1.499 1.985 0 O-C-N 121.346 -0.846 . . . . 0.0 109.631 -179.376 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.596 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.1 Cg_endo -74.5 25.27 0.36 Allowed 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 122.259 1.972 . . . . 0.0 111.608 -179.962 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.424 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -120.12 2.54 10.92 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.473 -1.392 . . . . 0.0 109.307 179.956 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.706 ' OD2' HG13 ' A' ' 69' ' ' VAL . 5.7 m-20 -137.09 18.67 2.99 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 179.744 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -81.13 88.52 5.99 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.617 -0.833 . . . . 0.0 110.62 -178.702 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.626 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -109.43 -166.22 1.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 178.66 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.77 136.02 0.09 Allowed 'General case' 0 N--CA 1.485 1.316 0 O-C-N 120.708 -1.245 . . . . 0.0 111.07 -179.215 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.94 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -153.84 155.92 5.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.421 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.582 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.73 141.34 31.66 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.87 -1.144 . . . . 0.0 109.94 -179.737 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.997 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -61.76 106.18 0.65 Allowed 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 122.471 1.129 . . . . 0.0 109.379 178.331 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.56 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.2 p-10 -59.46 -140.06 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.043 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.947 179.895 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.54 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.37 -50.42 59.58 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.488 -0.758 . . . . 0.0 110.752 -178.756 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -103.65 -33.35 9.0 Favored 'General case' 0 C--N 1.285 -2.217 0 N-CA-C 106.16 -1.792 . . . . 0.0 106.16 178.518 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.985 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.4 66.3 0.65 Allowed Glycine 0 C--N 1.298 -1.545 0 CA-C-N 114.897 -1.047 . . . . 0.0 110.514 177.993 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 20.0 m -103.68 125.43 50.17 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 178.657 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.94 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.9 109.27 7.86 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.349 -179.379 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.7 m -126.21 122.16 34.82 Favored 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.366 -0.834 . . . . 0.0 109.674 -179.717 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.587 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -143.91 141.8 30.45 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.634 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.3 p -98.55 131.63 44.62 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.192 -0.942 . . . . 0.0 109.493 -179.8 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.839 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -131.49 178.46 6.71 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.487 -0.758 . . . . 0.0 109.299 -179.387 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.538 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.5 p -102.22 123.52 46.2 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.898 -1.126 . . . . 0.0 109.739 -179.416 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.731 HG23 HD13 ' A' ' 13' ' ' LEU . 15.5 m -128.59 142.32 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 120.934 -1.104 . . . . 0.0 110.062 -179.389 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.615 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.5 ptt180 -148.4 -176.76 5.43 Favored 'General case' 0 N--CA 1.484 1.248 0 O-C-N 120.521 -1.362 . . . . 0.0 110.91 179.669 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.569 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.1 OUTLIER -60.56 -102.33 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.189 -179.109 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.534 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -60.09 138.12 57.95 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.443 -1.411 . . . . 0.0 107.979 179.773 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.531 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 2.4 p90 -161.72 147.33 13.57 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 118.555 -1.258 . . . . 0.0 110.033 -178.377 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.541 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 1.8 mp0 -37.68 120.44 0.82 Allowed 'General case' 0 N--CA 1.49 1.54 0 CA-C-O 121.504 0.669 . . . . 0.0 110.516 -178.674 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.872 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.54 49.49 3.17 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.599 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.596 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.9 m-30 -38.07 114.45 0.36 Allowed 'General case' 0 N--CA 1.511 2.582 0 O-C-N 121.194 -1.18 . . . . 0.0 110.545 179.921 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.816 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -87.62 127.01 35.28 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 120.843 -1.161 . . . . 0.0 109.546 179.78 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 25.6 t80 -64.36 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.872 -1.142 . . . . 0.0 109.993 179.667 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.522 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.8 t70 -159.46 19.01 0.18 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.047 -1.033 . . . . 0.0 109.72 179.893 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.89 -26.34 6.1 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 110.234 -1.146 . . . . 0.0 110.234 179.747 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 35.2 p -96.45 163.32 13.1 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 121.037 -1.273 . . . . 0.0 110.407 -179.414 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.478 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -106.4 136.28 46.42 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.913 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.816 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.9 t90 -82.42 -18.56 41.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.781 -1.199 . . . . 0.0 110.318 -178.757 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.83 173.36 17.85 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 -179.587 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.79 109.3 1.68 Allowed 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 179.203 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.606 HG21 ' HB3' ' A' ' 46' ' ' ALA . 50.4 t -80.06 105.23 9.37 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 121.43 -0.794 . . . . 0.0 109.349 -178.782 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.556 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.9 OUTLIER -66.14 109.69 2.7 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.661 -0.649 . . . . 0.0 109.965 -179.529 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.569 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 3.0 t -62.09 -4.41 1.67 Allowed 'General case' 0 N--CA 1.501 2.107 0 C-N-CA 118.165 -1.414 . . . . 0.0 110.162 179.348 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.0 p -90.08 3.54 53.0 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.627 -1.296 . . . . 0.0 109.306 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.556 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -116.32 -49.88 2.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.298 -0.876 . . . . 0.0 109.127 -179.899 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.9 179.37 4.29 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.429 -0.795 . . . . 0.0 109.46 179.969 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.42 113.6 26.85 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.286 -0.884 . . . . 0.0 108.725 179.737 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.495 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -97.16 121.41 39.02 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.929 -1.107 . . . . 0.0 109.542 -178.922 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.579 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.43 148.58 26.27 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 122.44 1.114 . . . . 0.0 111.452 -179.249 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.483 ' CG1' HG11 ' A' ' 7' ' ' VAL . 28.8 t -104.95 109.5 27.86 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.449 -1.686 . . . . 0.0 106.449 177.249 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.482 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.8 -169.53 16.77 Favored Glycine 0 N--CA 1.486 1.992 0 C-N-CA 118.305 -1.902 . . . . 0.0 111.691 -177.366 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.468 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -120.77 177.13 5.2 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 -178.958 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.594 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 7.8 t 177.81 159.15 0.45 Allowed 'General case' 0 C--N 1.292 -1.933 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 179.917 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.567 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -103.44 -158.21 0.65 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.962 -1.086 . . . . 0.0 109.266 -179.621 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.438 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.34 35.69 4.42 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.792 -1.192 . . . . 0.0 109.167 -179.973 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.75 -32.4 6.65 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.323 -0.861 . . . . 0.0 109.814 -179.677 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.557 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.86 -36.58 0.26 Allowed Glycine 0 N--CA 1.481 1.693 0 N-CA-C 107.857 -2.097 . . . . 0.0 107.857 -179.744 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.95 -177.35 5.03 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.576 -0.955 . . . . 0.0 109.992 179.359 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.13 -161.24 20.28 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 108.074 -2.01 . . . . 0.0 108.074 -179.411 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.479 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.4 Cg_exo -47.01 176.43 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.66 0 CA-C-N 118.956 1.378 . . . . 0.0 110.061 179.297 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -95.28 178.62 5.46 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.029 -1.045 . . . . 0.0 110.725 -178.58 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.482 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.23 170.34 13.32 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.988 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -107.32 133.22 52.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.348 -1.089 . . . . 0.0 109.187 -179.273 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.579 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.65 124.37 26.59 Favored 'General case' 0 C--N 1.29 -2.013 0 O-C-N 121.508 -0.745 . . . . 0.0 109.704 179.709 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.944 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.95 171.0 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.283 -0.886 . . . . 0.0 108.91 179.816 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.5 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 24.3 m -139.15 156.74 46.91 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.054 -1.029 . . . . 0.0 109.872 -179.794 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.944 ' CE1' HD12 ' A' ' 110' ' ' ILE . 45.2 m-85 -129.15 77.33 1.78 Allowed 'General case' 0 N--CA 1.486 1.352 0 O-C-N 121.226 -0.921 . . . . 0.0 109.465 -179.669 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.402 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 17.4 p30 . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 118.018 -0.991 . . . . 0.0 109.458 -179.991 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.765 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.81 155.2 60.57 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.219 -0.926 . . . . 0.0 109.491 -179.988 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.569 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.8 Cg_exo -59.49 158.88 25.57 Favored 'Trans proline' 0 C--N 1.31 -1.491 0 C-N-CA 122.246 1.964 . . . . 0.0 110.549 179.971 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.543 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.31 -169.74 0.15 Allowed 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 179.318 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.543 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.47 130.5 2.92 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.8 -1.187 . . . . 0.0 110.768 -179.051 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.957 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.7 t -110.87 108.9 18.85 Favored 'General case' 0 C--N 1.297 -1.7 0 CA-C-O 123.109 1.433 . . . . 0.0 109.066 179.357 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.817 HG22 HG23 ' A' ' 21' ' ' VAL . 2.6 t -118.28 139.72 44.44 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.699 0 CA-C-N 114.223 -1.353 . . . . 0.0 110.121 -179.741 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.453 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -179.07 150.88 0.64 Allowed Pre-proline 0 N--CA 1.488 1.464 0 O-C-N 121.239 -0.913 . . . . 0.0 108.764 -179.685 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.453 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.7 Cg_endo -77.47 151.72 92.77 Favored 'Cis proline' 0 C--N 1.313 -1.314 0 C-N-CA 123.555 -1.435 . . . . 0.0 109.332 -0.838 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.681 ' HA ' HG22 ' A' ' 110' ' ' ILE . 59.2 p -92.49 -23.29 19.16 Favored 'General case' 0 C--N 1.291 -1.968 0 O-C-N 121.567 -0.708 . . . . 0.0 109.664 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.482 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 23.9 p -133.26 159.14 41.09 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.197 -0.939 . . . . 0.0 110.124 -179.493 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.79 37.1 23.83 Favored Glycine 0 N--CA 1.497 2.706 0 N-CA-C 108.917 -1.673 . . . . 0.0 108.917 -179.859 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.777 ' HA ' HG21 ' A' ' 17' ' ' THR . 39.0 mt -93.34 -44.57 8.23 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.162 1.458 . . . . 0.0 110.44 -178.54 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.44 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.8 OUTLIER 64.3 146.8 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.273 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.17 -179.829 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.53 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 12.7 p-10 -51.51 104.92 0.09 Allowed 'General case' 0 C--N 1.305 -1.353 0 CA-C-O 121.675 0.75 . . . . 0.0 111.04 -179.072 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.81 7.47 6.68 Favored Glycine 0 N--CA 1.484 1.848 0 C-N-CA 119.13 -1.509 . . . . 0.0 113.296 177.52 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.777 HG21 ' HA ' ' A' ' 13' ' ' LEU . 15.2 t -107.13 -177.03 3.24 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 121.444 2.622 . . . . 0.0 110.133 179.605 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.784 HG13 ' O ' ' A' ' 67' ' ' LEU . 25.4 t -126.26 135.75 62.86 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.452 0 CA-C-N 114.249 -1.341 . . . . 0.0 111.073 -178.717 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.62 ' CG1' HD13 ' A' ' 13' ' ' LEU . 10.4 m -110.56 156.53 11.6 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.734 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.6 tttt -109.15 108.88 19.71 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.095 -1.003 . . . . 0.0 108.968 179.84 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.817 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.75 141.13 20.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.668 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.957 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -139.24 160.6 39.44 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 118.539 -1.265 . . . . 0.0 110.2 179.901 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.602 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.58 143.49 14.64 Favored Glycine 0 C--N 1.295 -1.731 0 N-CA-C 107.89 -2.084 . . . . 0.0 107.89 179.448 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.569 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -145.45 126.22 14.35 Favored 'General case' 0 C--N 1.295 -1.765 0 O-C-N 120.783 -1.422 . . . . 0.0 108.977 179.276 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.529 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.2 26.52 25.74 Favored Glycine 0 N--CA 1.488 2.108 0 C-N-CA 119.319 -1.419 . . . . 0.0 109.737 -179.744 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.576 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -89.43 169.78 11.09 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.81 -1.406 . . . . 0.0 108.392 179.861 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.999 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.95 100.98 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.039 -1.038 . . . . 0.0 110.076 -179.526 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.69 78.56 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.867 -179.529 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.41 33.9 0.3 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 179.778 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.562 ' OG1' ' CE2' ' A' ' 32' ' ' TYR . 17.2 p -138.6 105.03 5.28 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.259 -1.141 . . . . 0.0 111.146 -179.43 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.578 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.36 110.6 0.42 Allowed 'General case' 0 N--CA 1.497 1.905 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.701 178.169 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.562 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 35.5 m-85 -105.91 157.31 17.58 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.154 -0.966 . . . . 0.0 108.923 179.718 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.486 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -102.31 162.16 13.14 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.935 -1.103 . . . . 0.0 108.132 179.035 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.631 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.9 p -141.8 118.89 7.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.196 -0.94 . . . . 0.0 109.559 -178.186 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -166.41 -179.08 39.52 Favored Glycine 0 N--CA 1.493 2.481 0 C-N-CA 118.386 -1.864 . . . . 0.0 111.647 -179.693 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.63 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -101.38 109.01 20.77 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 179.978 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.51 148.76 52.35 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 121.164 -0.96 . . . . 0.0 109.959 179.925 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.429 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.65 138.66 54.5 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.409 -0.807 . . . . 0.0 110.656 -179.146 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.891 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.21 114.78 26.61 Favored 'General case' 0 N--CA 1.493 1.715 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 178.154 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.6 m -104.8 14.86 6.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 120.997 -1.065 . . . . 0.0 110.537 -178.789 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.753 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.87 -175.19 0.08 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.968 -1.083 . . . . 0.0 109.979 179.625 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 71.4 p -72.72 98.03 2.3 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.474 -0.766 . . . . 0.0 109.519 -179.704 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.57 27.65 31.92 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 120.225 -0.988 . . . . 0.0 111.413 178.943 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.753 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.25 106.18 19.59 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 O-C-N 120.653 -1.498 . . . . 0.0 107.258 178.942 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.891 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -117.26 104.59 11.32 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.504 -1.373 . . . . 0.0 109.831 -177.771 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.083 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.7 109.3 22.08 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 178.641 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -107.17 167.11 10.13 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.941 -1.099 . . . . 0.0 110.685 -178.588 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.483 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 10.8 t-20 -115.07 129.5 25.01 Favored Pre-proline 0 N--CA 1.498 1.939 0 O-C-N 121.606 -0.684 . . . . 0.0 109.498 -179.334 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.6 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -71.8 22.38 0.25 Allowed 'Trans proline' 0 CA--C 1.546 1.081 0 C-N-CA 122.052 1.835 . . . . 0.0 111.852 179.437 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.454 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -99.04 -5.9 29.49 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.404 -1.435 . . . . 0.0 109.15 179.61 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.815 ' OD2' HG13 ' A' ' 69' ' ' VAL . 1.6 m-20 -136.4 11.44 3.24 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.861 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -67.47 86.76 0.19 Allowed 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.48 -0.763 . . . . 0.0 110.649 -178.715 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.631 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -107.89 -165.97 1.1 Allowed 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 178.576 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.463 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.73 135.89 0.09 Allowed 'General case' 0 C--N 1.306 -1.305 0 O-C-N 120.642 -1.286 . . . . 0.0 111.147 -179.334 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.942 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.6 OUTLIER -151.82 156.53 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 178.168 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.578 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.38 142.58 29.83 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.773 -1.205 . . . . 0.0 110.082 -179.676 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.024 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.36 107.08 0.85 Allowed 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 122.446 1.117 . . . . 0.0 109.403 178.079 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 17.2 p-10 -61.14 -138.93 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.026 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.986 -179.917 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.77 -51.19 52.87 Favored 'General case' 0 N--CA 1.5 2.075 0 O-C-N 121.379 -0.826 . . . . 0.0 110.845 -178.536 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -103.79 -33.29 8.96 Favored 'General case' 0 C--N 1.285 -2.203 0 N-CA-C 106.167 -1.79 . . . . 0.0 106.167 178.488 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.024 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.95 63.88 0.55 Allowed Glycine 0 C--N 1.298 -1.58 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 178.102 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.602 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 43.2 m -102.38 126.96 49.56 Favored 'General case' 0 C--N 1.31 -1.148 0 O-C-N 121.479 -1.012 . . . . 0.0 108.731 178.732 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.942 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.28 109.04 7.52 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 119.411 -0.915 . . . . 0.0 109.53 -179.387 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -123.81 121.44 35.41 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 121.242 -0.911 . . . . 0.0 109.614 -179.768 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.58 146.54 31.42 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.558 -0.714 . . . . 0.0 109.305 179.854 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.401 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 13.5 p -98.83 141.15 31.98 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.351 -0.843 . . . . 0.0 109.472 -179.909 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.784 ' O ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -140.83 170.33 15.95 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.405 -0.809 . . . . 0.0 109.304 -179.206 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.779 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -101.87 124.94 48.34 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 120.878 -1.139 . . . . 0.0 110.157 -179.099 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.815 HG13 ' OD2' ' A' ' 51' ' ' ASP . 11.8 m -128.54 139.34 52.15 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.938 0 O-C-N 120.996 -1.065 . . . . 0.0 110.343 -179.601 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.53 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 56.3 mtt180 -127.11 -168.84 1.94 Allowed 'General case' 0 N--CA 1.483 1.222 0 O-C-N 120.576 -1.327 . . . . 0.0 111.156 179.673 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.588 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 1.8 mtt180 -79.08 -76.02 0.22 Allowed 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 179.001 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.504 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -73.66 135.52 43.75 Favored 'General case' 0 N--CA 1.486 1.349 0 N-CA-C 106.452 -1.684 . . . . 0.0 106.452 177.774 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.59 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -156.79 139.13 14.76 Favored 'General case' 0 C--N 1.298 -1.674 0 C-N-CA 117.637 -1.625 . . . . 0.0 110.925 -177.331 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 47' ' ' CYS . 2.9 mm-40 -37.19 118.93 0.65 Allowed 'General case' 0 N--CA 1.489 1.513 0 CA-C-O 121.408 0.623 . . . . 0.0 110.09 -178.943 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.083 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.78 50.13 3.43 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.175 -179.242 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.6 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-30 -38.69 113.88 0.34 Allowed 'General case' 0 N--CA 1.506 2.367 0 O-C-N 121.136 -1.214 . . . . 0.0 110.073 179.514 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.729 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -85.92 126.66 34.25 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 120.981 -1.074 . . . . 0.0 109.526 -179.885 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 29.4 t80 -63.72 58.54 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.026 0 O-C-N 120.91 -1.119 . . . . 0.0 110.142 179.608 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.59 19.5 0.14 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.036 -1.04 . . . . 0.0 109.748 179.84 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.78 -27.03 5.55 Favored Glycine 0 N--CA 1.49 2.249 0 N-CA-C 110.111 -1.195 . . . . 0.0 110.111 179.842 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -95.24 161.82 13.94 Favored 'General case' 0 N--CA 1.486 1.325 0 O-C-N 121.033 -1.274 . . . . 0.0 110.335 -179.499 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.476 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -107.67 136.85 46.73 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.917 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.729 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.5 t90 -82.21 -19.07 40.52 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.755 -1.216 . . . . 0.0 110.311 -178.759 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.93 173.93 19.01 Favored Glycine 0 N--CA 1.486 1.969 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.581 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.65 109.65 1.47 Allowed 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 179.202 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.5 t -81.92 105.12 11.43 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 O-C-N 121.354 -0.841 . . . . 0.0 108.916 -179.092 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.655 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.1 OUTLIER -65.45 110.69 2.76 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.45 -0.781 . . . . 0.0 110.006 -179.1 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.588 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.6 t -64.19 -5.28 4.63 Favored 'General case' 0 N--CA 1.5 2.035 0 C-N-CA 118.452 -1.299 . . . . 0.0 109.791 179.38 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 2.1 p -86.88 0.6 54.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.742 -1.224 . . . . 0.0 108.961 179.427 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.655 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -114.88 -50.96 2.75 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.292 -0.88 . . . . 0.0 109.02 179.825 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -102.84 -178.99 3.83 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.566 -0.709 . . . . 0.0 109.394 179.84 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.5 115.32 30.05 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.312 -0.867 . . . . 0.0 109.023 179.923 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.516 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.7 m -97.11 121.91 39.52 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 120.998 -1.064 . . . . 0.0 109.396 -179.353 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.612 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.92 144.93 29.93 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 122.397 1.094 . . . . 0.0 111.199 -179.365 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 96.4 t -102.49 110.16 28.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 177.701 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.478 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -150.3 -169.91 16.92 Favored Glycine 0 N--CA 1.486 2.006 0 C-N-CA 118.071 -2.014 . . . . 0.0 111.833 -177.536 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.503 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -112.91 179.88 3.84 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 -179.116 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.577 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.4 p -178.51 167.33 1.82 Allowed 'General case' 0 C--N 1.296 -1.74 0 O-C-N 121.456 -0.777 . . . . 0.0 109.58 -179.301 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.524 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -120.02 -160.07 0.81 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.013 -1.054 . . . . 0.0 109.023 -179.962 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.403 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.79 36.42 4.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.76 -1.212 . . . . 0.0 109.184 179.969 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.73 -33.19 5.58 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.344 -0.847 . . . . 0.0 110.053 -179.705 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.787 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 166.18 -36.38 0.25 Allowed Glycine 0 N--CA 1.482 1.706 0 N-CA-C 107.933 -2.067 . . . . 0.0 107.933 -179.712 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.19 -177.46 5.4 Favored 'General case' 0 C--N 1.308 -1.219 0 O-C-N 121.518 -0.989 . . . . 0.0 109.789 179.26 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.61 -162.88 19.22 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 108.27 -1.932 . . . . 0.0 108.27 -179.442 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.503 ' HB2' HD12 ' A' ' 97' ' ' LEU . 6.4 Cg_exo -46.82 176.62 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.653 0 CA-C-N 118.835 1.317 . . . . 0.0 110.16 179.305 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -91.53 -176.13 4.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.142 -0.974 . . . . 0.0 110.502 -178.752 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.478 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.9 167.24 14.55 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.78 130.92 52.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.428 -1.042 . . . . 0.0 109.186 -179.403 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.612 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.42 120.76 20.43 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.679 -0.638 . . . . 0.0 109.744 179.751 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.733 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.4 pt -98.12 167.28 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 O-C-N 121.279 -0.888 . . . . 0.0 109.201 179.89 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.482 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -133.14 159.28 40.59 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.314 -0.866 . . . . 0.0 109.412 -179.926 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.733 ' CE2' HD12 ' A' ' 110' ' ' ILE . 49.4 m-85 -134.3 119.27 18.5 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.117 -0.989 . . . . 0.0 109.563 -179.753 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.441 ' OD1' ' OXT' ' A' ' 113' ' ' ASN . 10.2 p30 . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 118.057 -0.973 . . . . 0.0 109.41 -179.969 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.787 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.6 0 CA-C-O 121.27 0.557 . . . . 0.0 109.515 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.594 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -89.4 161.74 38.92 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.245 -0.91 . . . . 0.0 109.435 179.98 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.594 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 2.4 Cg_endo -61.39 155.75 50.44 Favored 'Trans proline' 0 C--N 1.31 -1.49 0 C-N-CA 122.114 1.876 . . . . 0.0 110.601 179.937 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -152.89 159.46 43.0 Favored 'General case' 0 C--N 1.293 -1.868 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 -179.526 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.495 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -145.19 124.99 13.37 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 122.584 1.183 . . . . 0.0 110.115 -179.749 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.911 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.7 t -115.8 109.2 17.33 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 123.122 1.439 . . . . 0.0 109.607 -179.98 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.882 HG22 HG23 ' A' ' 21' ' ' VAL . 3.1 t -114.95 139.84 39.15 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.677 0 CA-C-N 114.234 -1.348 . . . . 0.0 109.853 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.65 149.12 2.35 Favored Pre-proline 0 N--CA 1.488 1.433 0 O-C-N 121.272 -0.893 . . . . 0.0 108.695 -179.666 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.0 Cg_endo -75.26 152.35 97.69 Favored 'Cis proline' 0 C--N 1.311 -1.424 0 C-N-CA 123.491 -1.462 . . . . 0.0 109.552 -0.846 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.653 ' HA ' HG22 ' A' ' 110' ' ' ILE . 2.4 m -88.46 -27.36 21.57 Favored 'General case' 0 C--N 1.293 -1.863 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.62 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.541 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 1.9 p -136.39 166.77 22.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.51 -0.744 . . . . 0.0 109.347 179.764 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.08 37.36 32.85 Favored Glycine 0 N--CA 1.496 2.677 0 N-CA-C 108.512 -1.835 . . . . 0.0 108.512 -179.626 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.755 ' CA ' HG21 ' A' ' 17' ' ' THR . 41.0 mt -92.98 -42.65 9.33 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-O 123.243 1.497 . . . . 0.0 110.466 -178.352 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.67 144.08 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.243 0 CA-C-N 113.392 -1.731 . . . . 0.0 109.877 -179.669 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.615 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 13.0 p-10 -50.94 105.65 0.11 Allowed 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.457 0.646 . . . . 0.0 111.589 -178.601 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.71 14.08 8.27 Favored Glycine 0 N--CA 1.485 1.927 0 C-N-CA 119.425 -1.369 . . . . 0.0 112.995 177.35 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.755 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -105.76 -172.43 2.09 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 121.239 2.52 . . . . 0.0 109.86 179.23 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.822 HG22 HG22 ' A' ' 68' ' ' THR . 18.1 t -128.41 139.18 52.6 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.345 0 CA-C-N 114.742 -1.117 . . . . 0.0 111.022 -178.81 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.6 HG11 HD11 ' A' ' 13' ' ' LEU . 33.2 m -114.49 154.91 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 178.876 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.05 109.55 21.45 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.261 -0.899 . . . . 0.0 109.19 -179.954 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.882 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -102.26 140.06 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.511 -0.743 . . . . 0.0 109.059 179.95 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.911 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -131.44 158.16 41.56 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.012 -1.055 . . . . 0.0 109.335 179.458 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.583 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.73 108.76 0.57 Allowed Glycine 0 N--CA 1.482 1.724 0 N-CA-C 108.806 -1.718 . . . . 0.0 108.806 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.597 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -115.78 139.75 49.88 Favored 'General case' 0 N--CA 1.5 2.054 0 CA-C-N 119.268 1.534 . . . . 0.0 110.512 -179.317 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.511 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 84.47 28.84 31.74 Favored Glycine 0 N--CA 1.491 2.354 0 C-N-CA 119.13 -1.51 . . . . 0.0 109.971 179.535 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.549 HD22 ' HG3' ' A' ' 105' ' ' PRO . 1.6 mt -92.19 175.28 6.91 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.977 -1.308 . . . . 0.0 108.613 -179.875 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.11 97.03 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.287 0 O-C-N 121.014 -1.054 . . . . 0.0 109.661 -179.811 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.656 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 76.69 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.384 -178.988 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.84 33.82 0.32 Allowed Glycine 0 N--CA 1.486 2.002 0 N-CA-C 109.671 -1.371 . . . . 0.0 109.671 179.451 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.613 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -147.0 114.53 6.35 Favored 'General case' 0 C--N 1.308 -1.227 0 O-C-N 120.843 -1.387 . . . . 0.0 111.084 179.966 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -45.18 127.11 6.69 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.788 178.561 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.613 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 10.2 m-85 -117.75 149.34 40.94 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.484 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.493 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -101.01 152.64 20.34 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.867 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.64 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.5 p -137.19 118.55 18.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.958 -1.089 . . . . 0.0 109.767 -177.759 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.34 -178.7 39.22 Favored Glycine 0 N--CA 1.495 2.607 0 C-N-CA 118.341 -1.885 . . . . 0.0 111.863 -179.733 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.59 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.35 109.36 21.54 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.928 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.47 149.54 52.09 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.146 -0.971 . . . . 0.0 109.839 179.84 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.538 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.24 138.49 54.4 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.234 -0.916 . . . . 0.0 110.736 -179.039 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.895 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.17 114.97 26.82 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 178.02 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.2 m -105.28 14.91 7.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 120.997 -1.064 . . . . 0.0 110.583 -178.794 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.764 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.68 -175.0 0.08 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.925 -1.11 . . . . 0.0 110.014 179.704 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -72.64 97.64 2.2 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.448 -0.782 . . . . 0.0 109.702 -179.753 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.62 28.3 29.97 Favored Glycine 0 N--CA 1.494 2.544 0 C-N-CA 120.211 -0.995 . . . . 0.0 111.341 179.005 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.764 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -117.43 106.11 19.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 O-C-N 120.499 -1.589 . . . . 0.0 107.207 178.854 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.895 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.1 tp -116.59 104.69 11.65 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.568 -1.332 . . . . 0.0 109.866 -177.66 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.1 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.15 109.3 22.08 Favored 'General case' 0 N--CA 1.485 1.298 0 O-C-N 120.856 -1.152 . . . . 0.0 108.06 178.633 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.79 163.36 13.18 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.985 -1.072 . . . . 0.0 110.182 -178.908 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.721 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 9.9 t-20 -108.95 135.76 20.11 Favored Pre-proline 0 N--CA 1.499 2.002 0 O-C-N 121.281 -0.887 . . . . 0.0 109.944 -179.136 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.3 Cg_endo -74.72 23.96 0.38 Allowed 'Trans proline' 0 C--N 1.319 -1.017 0 C-N-CA 122.417 2.078 . . . . 0.0 112.069 -179.992 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.721 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -114.44 3.28 14.91 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.323 -1.486 . . . . 0.0 109.198 179.632 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.529 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.67 14.77 3.15 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 179.154 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -78.7 87.77 4.6 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.039 -0.665 . . . . 0.0 110.871 -178.558 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.64 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -104.98 -167.93 1.41 Allowed 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.683 -1.229 . . . . 0.0 107.683 178.057 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.88 135.77 0.09 Allowed 'General case' 0 C--N 1.304 -1.404 0 O-C-N 120.555 -1.34 . . . . 0.0 111.38 -179.192 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.902 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -154.06 156.91 4.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 178.034 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.62 145.33 26.39 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.665 -1.272 . . . . 0.0 109.831 -179.612 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.009 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.05 107.09 1.78 Allowed 'General case' 0 C--N 1.298 -1.63 0 CA-C-O 122.433 1.111 . . . . 0.0 109.472 178.936 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.548 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.4 p-10 -59.62 -139.43 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.037 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.728 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.656 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.9 -50.11 64.58 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.374 -0.829 . . . . 0.0 110.361 -178.822 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -102.56 -35.54 8.7 Favored 'General case' 0 C--N 1.286 -2.186 0 N-CA-C 106.328 -1.73 . . . . 0.0 106.328 178.488 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.988 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.91 67.31 0.62 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.541 -1.023 . . . . 0.0 110.541 178.166 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.583 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 38.4 m -101.6 127.86 48.13 Favored 'General case' 0 N--CA 1.485 1.325 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 178.688 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.902 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.03 108.82 7.04 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.503 -179.37 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 18.4 p -126.11 120.56 30.49 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.348 -0.845 . . . . 0.0 109.565 -179.888 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.37 146.25 31.5 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.669 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.2 p -98.61 131.25 44.96 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.162 -0.961 . . . . 0.0 109.588 -179.663 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.76 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -128.92 166.22 19.55 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.403 -0.811 . . . . 0.0 109.341 -179.514 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.822 HG22 HG22 ' A' ' 18' ' ' VAL . 1.7 p -97.65 125.1 42.23 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.986 -1.072 . . . . 0.0 109.373 -179.999 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.556 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.2 m -137.26 143.48 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.047 -1.033 . . . . 0.0 109.785 -179.149 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.615 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -146.44 -177.48 5.65 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.531 -1.355 . . . . 0.0 111.249 -179.927 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.583 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.05 -100.2 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 -179.655 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.515 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.21 140.13 50.6 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 120.71 -1.244 . . . . 0.0 107.888 179.309 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.569 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -161.91 136.65 7.06 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 118.513 -1.275 . . . . 0.0 109.918 -178.015 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.508 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 6.4 mt-10 -34.78 121.34 0.52 Allowed 'General case' 0 N--CA 1.489 1.485 0 CA-C-O 121.434 0.635 . . . . 0.0 110.423 -178.61 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.1 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.75 51.54 2.0 Allowed Glycine 0 N--CA 1.495 2.593 0 C-N-CA 120.563 -0.827 . . . . 0.0 111.125 -179.22 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.23 115.63 0.51 Allowed 'General case' 0 N--CA 1.506 2.371 0 O-C-N 121.154 -1.204 . . . . 0.0 110.121 179.453 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.706 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -86.89 126.56 34.75 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 120.831 -1.168 . . . . 0.0 109.575 -179.741 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.587 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.5 t80 -64.2 58.3 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.008 0 O-C-N 120.913 -1.117 . . . . 0.0 110.065 179.513 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.54 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.1 t70 -159.53 19.24 0.17 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.982 -1.074 . . . . 0.0 109.709 179.913 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.07 -27.19 5.64 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.822 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 3.2 p -95.99 161.6 13.92 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 120.994 -1.298 . . . . 0.0 110.397 -179.393 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.478 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.75 137.53 44.61 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.673 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.706 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.08 -19.65 39.76 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.747 -1.221 . . . . 0.0 110.507 -178.648 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.15 176.36 19.05 Favored Glycine 0 N--CA 1.485 1.963 0 N-CA-C 108.709 -1.757 . . . . 0.0 108.709 -179.499 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.94 105.7 1.39 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.015 -1.285 . . . . 0.0 107.783 179.158 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.65 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.9 t -77.12 105.82 6.44 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 O-C-N 121.367 -0.833 . . . . 0.0 109.229 -178.903 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.547 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -65.48 111.3 3.03 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.483 -0.761 . . . . 0.0 110.012 -179.445 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.583 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.05 -5.88 3.48 Favored 'General case' 0 N--CA 1.499 2.015 0 C-N-CA 118.273 -1.371 . . . . 0.0 109.8 179.486 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -86.89 -0.18 56.05 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.713 -1.242 . . . . 0.0 109.26 179.496 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.547 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.32 -50.33 2.87 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.34 -0.85 . . . . 0.0 109.006 179.886 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.69 -179.9 4.07 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.581 -0.699 . . . . 0.0 109.344 179.833 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.69 115.91 31.36 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.895 . . . . 0.0 109.003 179.981 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.521 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.4 m -96.86 120.77 37.81 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.826 -1.171 . . . . 0.0 109.368 -179.409 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.43 145.96 28.25 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 122.355 1.074 . . . . 0.0 111.117 -179.283 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.526 ' CG1' HG11 ' A' ' 7' ' ' VAL . 60.5 t -101.25 109.77 26.47 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.013 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 177.362 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.469 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -146.64 -171.32 15.83 Favored Glycine 0 N--CA 1.486 2.0 0 C-N-CA 118.212 -1.946 . . . . 0.0 111.619 -177.284 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.495 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -123.22 179.64 4.63 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -178.631 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.54 ' OG ' ' C21' ' A' ' 114' ' ' CHR . 0.8 OUTLIER -178.94 170.78 1.47 Allowed 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.482 -0.761 . . . . 0.0 109.513 -179.862 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.479 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -119.16 -156.34 0.65 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.102 -0.999 . . . . 0.0 109.036 -179.977 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.479 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -115.94 35.28 4.54 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.795 -1.191 . . . . 0.0 109.14 179.965 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -110.77 -33.2 6.61 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.352 -0.842 . . . . 0.0 109.776 -179.832 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 1.026 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 161.77 -34.88 0.37 Allowed Glycine 0 N--CA 1.484 1.845 0 N-CA-C 107.604 -2.198 . . . . 0.0 107.604 -179.754 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.09 -177.67 5.91 Favored 'General case' 0 C--N 1.307 -1.282 0 O-C-N 121.668 -0.901 . . . . 0.0 109.808 179.338 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.09 -161.81 21.25 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 -179.368 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.549 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.3 Cg_exo -45.37 172.55 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.69 0 CA-C-N 118.81 1.305 . . . . 0.0 110.094 179.303 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 16.7 mt-10 -92.49 -178.7 4.98 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.084 -1.01 . . . . 0.0 110.608 -178.659 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.469 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -115.08 164.53 12.09 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.949 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.88 133.12 48.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.411 -1.052 . . . . 0.0 109.28 -179.282 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.02 119.3 17.07 Favored 'General case' 0 C--N 1.289 -2.022 0 O-C-N 121.655 -0.653 . . . . 0.0 109.474 179.646 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.876 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.14 172.07 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.175 -0.953 . . . . 0.0 109.101 179.944 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.541 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.3 OUTLIER -138.49 155.86 48.04 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.104 -0.997 . . . . 0.0 109.892 -179.695 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.876 ' CE2' HD12 ' A' ' 110' ' ' ILE . 87.0 m-85 -133.64 82.4 1.98 Allowed 'General case' 0 N--CA 1.485 1.303 0 O-C-N 121.325 -0.859 . . . . 0.0 109.613 -179.783 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 23.5 p30 . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.435 -179.978 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 1.026 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 121.307 0.575 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.747 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -110.24 166.13 11.36 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.89 . . . . 0.0 109.511 -179.986 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.747 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.9 Cg_exo -59.62 158.06 29.57 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.173 1.916 . . . . 0.0 110.513 -179.977 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.54 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.6 -169.77 0.15 Allowed 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 179.102 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.54 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -166.81 131.17 2.02 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 120.82 -1.175 . . . . 0.0 110.701 -179.099 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.951 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.3 t -112.91 108.7 17.74 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-O 123.106 1.431 . . . . 0.0 109.19 179.367 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.871 HG22 HG23 ' A' ' 21' ' ' VAL . 3.7 t -116.34 142.51 29.58 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.667 0 CA-C-N 114.347 -1.297 . . . . 0.0 110.203 -179.615 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.504 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -178.16 150.45 0.74 Allowed Pre-proline 0 N--CA 1.488 1.454 0 O-C-N 121.278 -0.888 . . . . 0.0 108.715 -179.737 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.504 ' HA ' HG23 ' A' ' 8' ' ' THR . 1.9 Cg_endo -75.05 153.73 99.25 Favored 'Cis proline' 0 C--N 1.312 -1.362 0 C-N-CA 123.577 -1.426 . . . . 0.0 109.471 -0.644 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.3 m -91.4 -25.35 19.4 Favored 'General case' 0 C--N 1.292 -1.912 0 O-C-N 121.63 -0.669 . . . . 0.0 109.428 -179.94 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.505 ' HB3' ' CB ' ' A' ' 111' ' ' SER . 0.7 OUTLIER -137.9 163.35 31.69 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.338 -0.851 . . . . 0.0 109.905 -179.619 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.72 37.14 27.25 Favored Glycine 0 N--CA 1.496 2.681 0 N-CA-C 108.773 -1.731 . . . . 0.0 108.773 -179.931 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.749 ' CA ' HG21 ' A' ' 17' ' ' THR . 44.2 mt -93.05 -44.22 8.5 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-O 123.249 1.5 . . . . 0.0 110.547 -178.533 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.445 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.48 145.75 0.03 OUTLIER 'General case' 0 C--N 1.262 -3.203 0 CA-C-N 113.473 -1.694 . . . . 0.0 109.999 -179.796 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.544 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.0 p-10 -51.93 105.1 0.1 Allowed 'General case' 0 C--N 1.303 -1.451 0 CA-C-O 121.49 0.662 . . . . 0.0 111.088 -179.05 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.95 6.66 6.96 Favored Glycine 0 N--CA 1.486 1.983 0 C-N-CA 119.18 -1.486 . . . . 0.0 113.194 177.518 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.749 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.6 t -105.14 -174.45 2.54 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 121.437 2.618 . . . . 0.0 109.922 179.709 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.782 HG22 HG22 ' A' ' 68' ' ' THR . 21.6 t -127.02 135.94 62.2 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.579 -1.191 . . . . 0.0 110.955 -178.778 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.622 ' CG1' HD13 ' A' ' 13' ' ' LEU . 32.5 m -109.54 154.79 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 178.795 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.514 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -110.56 109.25 19.5 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.198 -0.939 . . . . 0.0 108.825 179.776 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.871 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -104.32 140.46 22.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.943 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.951 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.18 160.32 38.73 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 118.74 -1.184 . . . . 0.0 109.857 179.649 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.59 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.44 143.55 15.2 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 108.021 -2.032 . . . . 0.0 108.021 179.789 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.578 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.12 125.26 12.91 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 120.843 -1.386 . . . . 0.0 108.846 179.289 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.53 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.98 26.8 25.5 Favored Glycine 0 N--CA 1.488 2.124 0 C-N-CA 119.371 -1.395 . . . . 0.0 109.704 -179.698 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.5 mt -86.27 175.83 8.25 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 120.921 -1.341 . . . . 0.0 108.557 -179.813 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.44 96.9 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.028 -1.045 . . . . 0.0 109.556 -179.771 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.637 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.26 76.32 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.715 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.541 -178.989 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.32 33.93 0.3 Allowed Glycine 0 N--CA 1.484 1.876 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.304 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.558 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 1.2 t -148.64 114.97 5.87 Favored 'General case' 0 C--N 1.308 -1.21 0 O-C-N 120.774 -1.427 . . . . 0.0 111.333 179.955 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.57 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.13 130.05 3.65 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.798 178.376 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.553 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 7.7 m-85 -121.41 147.93 45.06 Favored 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.583 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.498 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.96 156.71 17.24 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.626 -1.296 . . . . 0.0 107.771 178.719 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.644 HG13 ' O ' ' A' ' 34' ' ' VAL . 5.5 p -140.27 117.27 9.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.066 -1.021 . . . . 0.0 109.867 -177.789 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.518 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.29 -176.92 39.06 Favored Glycine 0 N--CA 1.494 2.514 0 C-N-CA 118.354 -1.879 . . . . 0.0 111.942 -179.739 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.64 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.4 pt20 -99.83 109.96 22.35 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-O 121.874 0.845 . . . . 0.0 109.02 -179.648 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.497 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.2 m -130.35 150.12 51.73 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.223 -0.923 . . . . 0.0 109.679 179.703 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.457 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.69 138.29 54.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.197 -0.94 . . . . 0.0 110.968 -178.945 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.38 115.0 26.83 Favored 'General case' 0 N--CA 1.491 1.6 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 177.982 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.458 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 19.8 m -105.77 14.72 7.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 120.993 -1.067 . . . . 0.0 110.646 -178.732 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.756 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.32 -174.71 0.09 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.04 -1.037 . . . . 0.0 110.011 179.614 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.84 97.03 1.73 Allowed 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.439 -0.788 . . . . 0.0 109.709 -179.77 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.28 27.8 32.3 Favored Glycine 0 N--CA 1.493 2.492 0 C-N-CA 120.149 -1.024 . . . . 0.0 111.481 178.849 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.756 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -116.32 106.45 20.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 O-C-N 120.688 -1.477 . . . . 0.0 107.252 178.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.5 tp -115.38 104.8 12.15 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.4 -1.437 . . . . 0.0 110.019 -177.715 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.986 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.68 109.71 22.41 Favored 'General case' 0 N--CA 1.486 1.372 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.801 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.51 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -109.08 168.34 9.44 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.059 -1.026 . . . . 0.0 110.365 -178.744 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.55 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 22.3 t-20 -118.09 135.08 23.32 Favored Pre-proline 0 N--CA 1.499 2.01 0 O-C-N 121.353 -0.842 . . . . 0.0 110.101 -179.438 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.589 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 3.5 Cg_endo -73.66 23.33 0.33 Allowed 'Trans proline' 0 CA--C 1.545 1.045 0 C-N-CA 122.223 1.949 . . . . 0.0 112.181 179.901 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.55 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -108.82 1.99 21.31 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.345 -1.472 . . . . 0.0 109.079 179.406 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.53 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.11 17.41 2.27 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.643 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -81.06 90.37 6.0 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.524 -0.735 . . . . 0.0 110.891 -178.606 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.69 -166.87 1.19 Allowed 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 178.145 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.448 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.72 134.92 0.09 Allowed 'General case' 0 C--N 1.306 -1.311 0 O-C-N 120.524 -1.36 . . . . 0.0 111.666 -179.356 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.803 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.5 p -150.94 157.38 5.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 177.862 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.57 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.19 146.07 25.44 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.496 -1.377 . . . . 0.0 109.741 -179.648 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.09 108.55 3.15 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 122.302 1.048 . . . . 0.0 109.589 179.009 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.541 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 1.7 t70 -63.69 -139.03 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.999 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.663 179.938 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.637 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.92 -51.74 49.11 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.343 -0.848 . . . . 0.0 110.679 -178.672 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 -102.58 -32.7 9.78 Favored 'General case' 0 C--N 1.287 -2.14 0 N-CA-C 106.517 -1.66 . . . . 0.0 106.517 178.662 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.006 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 105.36 66.32 0.67 Allowed Glycine 0 C--N 1.297 -1.591 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.18 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.59 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 58.0 p -98.66 131.96 44.42 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 121.378 -1.072 . . . . 0.0 109.097 179.006 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.803 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.43 108.32 6.32 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 119.319 -0.953 . . . . 0.0 109.52 -179.642 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.6 m -124.67 119.13 28.1 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.094 -1.004 . . . . 0.0 109.701 -179.939 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.593 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.33 144.16 29.6 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.448 -0.782 . . . . 0.0 109.363 179.853 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.8 p -99.12 141.51 31.8 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.316 -0.865 . . . . 0.0 109.191 179.838 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.827 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.83 167.94 20.94 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.449 -0.782 . . . . 0.0 109.551 -179.23 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.782 HG22 HG22 ' A' ' 18' ' ' VAL . 2.0 p -98.18 126.82 43.8 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.094 -1.004 . . . . 0.0 109.319 -179.761 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.502 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 15.4 m -134.44 140.53 45.67 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.879 -1.138 . . . . 0.0 110.091 -179.198 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.544 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 52.2 mtt180 -127.56 -165.52 1.49 Allowed 'General case' 0 N--CA 1.485 1.315 0 O-C-N 120.676 -1.265 . . . . 0.0 111.255 -179.821 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.574 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 1.0 OUTLIER -80.48 -79.64 0.15 Allowed 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.209 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.511 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -68.85 136.45 52.7 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 177.9 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.573 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.03 137.64 9.76 Favored 'General case' 0 C--N 1.294 -1.831 0 C-N-CA 117.803 -1.559 . . . . 0.0 110.735 -177.325 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.526 ' HB3' ' CD1' ' A' ' 76' ' ' PHE . 8.0 mm-40 -33.72 119.2 0.37 Allowed 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 121.638 0.732 . . . . 0.0 110.58 -178.69 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.986 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -87.92 48.4 3.67 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -179.316 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.589 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 19.0 m-85 -39.21 113.92 0.36 Allowed 'General case' 0 N--CA 1.507 2.385 0 O-C-N 121.157 -1.202 . . . . 0.0 110.136 179.591 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.746 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -87.67 127.04 35.29 Favored 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.993 -1.067 . . . . 0.0 109.474 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.588 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.1 t80 -64.51 58.29 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.967 0 O-C-N 120.753 -1.217 . . . . 0.0 110.056 179.674 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.7 t70 -159.52 19.0 0.17 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.042 -1.036 . . . . 0.0 109.721 179.948 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.68 -26.56 5.8 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 179.84 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 72.4 p -95.15 160.56 14.5 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.021 -1.281 . . . . 0.0 110.417 -179.343 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.482 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 1.3 ptt180 -105.63 134.84 48.1 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.66 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.746 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.0 t90 -81.21 -20.01 42.03 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.823 -1.173 . . . . 0.0 110.234 -178.623 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.26 173.64 18.25 Favored Glycine 0 N--CA 1.486 2.008 0 N-CA-C 108.739 -1.745 . . . . 0.0 108.739 -179.572 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.67 111.45 2.09 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 179.251 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.653 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.7 t -83.1 103.91 11.02 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.685 0 O-C-N 121.35 -0.844 . . . . 0.0 108.798 -179.062 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.542 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -65.8 111.41 3.24 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.448 -0.783 . . . . 0.0 109.971 -179.094 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.57 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -63.96 -5.12 4.03 Favored 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 118.426 -1.31 . . . . 0.0 109.834 179.372 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 4.9 p -87.89 2.09 52.41 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.841 -1.162 . . . . 0.0 109.052 179.415 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.542 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -116.72 -51.23 2.59 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.329 -0.857 . . . . 0.0 108.939 -179.99 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.1 179.5 4.25 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.512 -0.742 . . . . 0.0 109.371 179.869 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.34 116.52 32.58 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.362 -0.836 . . . . 0.0 108.925 179.917 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.505 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.9 m -96.73 120.71 37.56 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.894 -1.129 . . . . 0.0 109.357 -179.41 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.616 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.67 145.56 28.92 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 122.373 1.083 . . . . 0.0 111.283 -179.12 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.427 ' CG1' HG11 ' A' ' 7' ' ' VAL . 62.6 t -101.71 109.81 26.92 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.037 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 177.537 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.451 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.85 -170.91 16.33 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 118.174 -1.965 . . . . 0.0 111.851 -177.467 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.526 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -121.6 178.98 4.61 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -178.859 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.553 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.7 OUTLIER -179.56 176.86 0.77 Allowed 'General case' 0 C--N 1.297 -1.704 0 O-C-N 121.564 -0.71 . . . . 0.0 109.562 179.999 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.459 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -124.32 -157.31 0.76 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.054 -1.029 . . . . 0.0 109.101 -179.896 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.459 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.77 36.17 4.41 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.76 -1.213 . . . . 0.0 109.2 -179.965 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.47 -32.67 6.62 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.312 -0.868 . . . . 0.0 109.8 -179.735 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.77 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.43 -35.92 0.26 Allowed Glycine 0 N--CA 1.481 1.698 0 N-CA-C 107.946 -2.061 . . . . 0.0 107.946 -179.765 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.421 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.99 -177.0 3.6 Favored 'General case' 0 C--N 1.307 -1.263 0 O-C-N 121.609 -0.936 . . . . 0.0 109.756 179.367 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.25 -161.36 17.96 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 108.27 -1.932 . . . . 0.0 108.27 -179.396 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.532 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.6 Cg_exo -46.6 176.5 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.664 0 CA-C-N 118.841 1.32 . . . . 0.0 110.203 179.287 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -93.85 -168.88 1.97 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.118 -0.989 . . . . 0.0 110.39 -178.927 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.451 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -123.88 163.47 17.51 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 -179.736 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.14 129.67 49.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.409 -1.054 . . . . 0.0 109.123 -179.679 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.616 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.58 118.97 16.15 Favored 'General case' 0 C--N 1.288 -2.085 0 O-C-N 121.703 -0.623 . . . . 0.0 109.759 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.66 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.4 pt -98.07 168.0 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.386 0 O-C-N 121.249 -0.907 . . . . 0.0 109.065 179.803 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.505 ' CB ' ' HB3' ' A' ' 11' ' ' SER . 0.2 OUTLIER -132.28 156.89 45.74 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.281 -0.887 . . . . 0.0 109.666 -179.876 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.617 ' CE2' HD12 ' A' ' 110' ' ' ILE . 41.4 m-85 -131.72 117.35 18.51 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.272 -0.893 . . . . 0.0 109.357 -179.852 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.7 p30 . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 118.021 -0.99 . . . . 0.0 109.496 179.931 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.77 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.466 -0.568 . . . . 1.0 109.466 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.16 149.0 50.59 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.309 -0.869 . . . . 1.0 109.569 179.922 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.581 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.4 Cg_exo -59.94 158.76 28.01 Favored 'Trans proline' 0 C--N 1.309 -1.505 0 C-N-CA 122.241 1.961 . . . . 1.0 110.606 179.969 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.49 -169.65 0.15 Allowed 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.092 -1.077 . . . . 1.0 108.092 179.233 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.565 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . -165.99 133.81 2.89 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 120.735 -1.228 . . . . 1.0 110.961 -179.277 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.005 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.4 p -102.0 104.52 15.19 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 122.408 1.099 . . . . 1.0 110.088 -179.84 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 1.018 HG22 HG23 ' A' ' 21' ' ' VAL . 5.9 t -119.5 123.55 71.33 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.448 0 CA-C-N 115.521 -0.763 . . . . 1.0 110.516 179.822 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.48 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -170.95 150.02 2.9 Favored Pre-proline 0 N--CA 1.488 1.451 0 N-CA-C 108.086 -1.079 . . . . 1.0 108.086 -179.649 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.48 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.0 Cg_endo -76.79 151.37 94.16 Favored 'Cis proline' 0 C--N 1.311 -1.434 0 C-N-CA 123.658 -1.393 . . . . 1.0 109.533 -0.526 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.683 ' HA ' HG22 ' A' ' 110' ' ' ILE . 95.2 p -95.4 -21.47 18.34 Favored 'General case' 0 C--N 1.293 -1.888 0 O-C-N 121.649 -0.657 . . . . 1.0 109.643 179.954 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.489 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.3 m -131.54 157.11 44.45 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.256 -0.903 . . . . 1.0 110.221 -179.583 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.39 37.11 25.04 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 108.794 -1.722 . . . . 1.0 108.794 -179.719 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.807 ' HA ' HG21 ' A' ' 17' ' ' THR . 35.4 mt -92.1 -44.78 8.63 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 123.201 1.477 . . . . 1.0 110.542 -178.59 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.442 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.1 t 63.8 147.52 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.25 0 CA-C-N 113.562 -1.654 . . . . 1.0 110.045 -179.815 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.521 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.5 p-10 -51.65 105.16 0.1 Allowed 'General case' 0 C--N 1.303 -1.438 0 CA-C-O 121.665 0.745 . . . . 1.0 111.106 -178.997 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 123.31 7.39 7.02 Favored Glycine 0 N--CA 1.485 1.954 0 C-N-CA 119.319 -1.42 . . . . 1.0 113.318 177.323 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.807 HG21 ' HA ' ' A' ' 13' ' ' LEU . 14.9 t -106.42 -177.46 3.37 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 121.468 2.634 . . . . 1.0 110.325 179.654 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.858 HG22 HG22 ' A' ' 68' ' ' THR . 21.9 t -128.3 139.69 51.22 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.374 0 CA-C-N 114.076 -1.42 . . . . 1.0 111.091 -178.717 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.671 HG11 HD11 ' A' ' 13' ' ' LEU . 15.7 m -117.19 154.68 18.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 N-CA-C 108.35 -0.981 . . . . 1.0 108.35 178.739 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.545 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -104.1 108.79 20.32 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.139 -0.975 . . . . 1.0 109.304 -179.886 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 1.018 HG23 HG22 ' A' ' 7' ' ' VAL . 2.4 p -106.34 123.27 61.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 N-CA-C 108.299 -1.001 . . . . 1.0 108.299 179.571 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.005 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -117.67 167.21 11.55 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 120.681 -1.262 . . . . 1.0 109.22 -179.831 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.617 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.77 139.1 10.61 Favored Glycine 0 C--N 1.294 -1.779 0 N-CA-C 107.282 -2.327 . . . . 1.0 107.282 179.51 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.581 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -145.39 125.35 13.56 Favored 'General case' 0 C--N 1.293 -1.866 0 O-C-N 120.522 -1.575 . . . . 1.0 108.991 179.613 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.533 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.23 26.35 28.62 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 119.013 -1.565 . . . . 1.0 109.952 -179.798 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.566 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.3 mt -86.5 174.34 9.02 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 120.885 -1.362 . . . . 1.0 108.29 179.743 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.021 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -47.41 99.28 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.412 0 O-C-N 120.855 -1.153 . . . . 1.0 109.743 -179.605 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.585 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.11 77.74 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.304 -0.862 . . . . 1.0 110.246 -179.271 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.9 34.47 0.3 Allowed Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.464 -1.454 . . . . 1.0 109.464 179.587 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 53.4 p -142.82 108.75 5.17 Favored 'General case' 0 C--N 1.308 -1.221 0 O-C-N 121.039 -1.271 . . . . 1.0 111.214 -179.416 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.594 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.92 109.92 0.34 Allowed 'General case' 0 N--CA 1.497 1.9 0 N-CA-C 109.393 -0.595 . . . . 1.0 109.393 177.807 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.583 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 4.7 m-30 -104.9 155.4 18.96 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.119 -0.988 . . . . 1.0 108.878 179.874 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.82 162.01 13.33 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.804 -1.185 . . . . 1.0 108.077 178.934 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.63 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.9 p -141.91 120.36 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.166 -0.959 . . . . 1.0 109.307 -178.217 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' HB2' ' A' ' 51' ' ' ASP . . . -171.88 -176.48 40.83 Favored Glycine 0 N--CA 1.495 2.571 0 C-N-CA 118.412 -1.851 . . . . 1.0 111.583 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.657 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -101.15 109.19 21.03 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 108.909 -0.774 . . . . 1.0 108.909 -179.908 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.492 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.0 m -130.14 149.06 52.02 Favored 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.277 -0.89 . . . . 1.0 109.682 179.585 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.525 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -123.54 138.72 54.51 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.236 -0.915 . . . . 1.0 110.793 -178.93 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.2 114.77 26.6 Favored 'General case' 0 N--CA 1.492 1.672 0 N-CA-C 107.532 -1.284 . . . . 1.0 107.532 178.047 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 m -104.85 14.72 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.931 -1.106 . . . . 1.0 110.481 -178.793 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.75 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.1 -175.24 0.09 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.98 -1.075 . . . . 1.0 110.049 179.748 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.51 97.79 2.17 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.519 -0.738 . . . . 1.0 109.577 -179.75 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.46 27.75 31.94 Favored Glycine 0 N--CA 1.492 2.414 0 C-N-CA 120.214 -0.993 . . . . 1.0 111.399 178.94 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.75 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -117.22 106.48 20.18 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.558 -1.554 . . . . 1.0 107.357 178.81 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.4 104.72 11.74 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.475 -1.391 . . . . 1.0 109.954 -177.629 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.007 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.65 109.53 22.27 Favored 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 107.812 -1.181 . . . . 1.0 107.812 178.871 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.6 t -108.05 166.74 10.5 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.869 -1.145 . . . . 1.0 110.727 -178.455 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.487 ' OD1' ' HB2' ' A' ' 74' ' ' GLU . 46.4 t30 -118.51 136.72 24.2 Favored Pre-proline 0 N--CA 1.498 1.971 0 C-N-CA 120.098 -0.641 . . . . 1.0 109.64 -179.497 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.587 ' HD3' ' CE1' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -74.03 26.41 0.33 Allowed 'Trans proline' 0 C--N 1.317 -1.111 0 C-N-CA 122.437 2.092 . . . . 1.0 112.01 -179.89 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.447 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -98.54 -9.55 24.78 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.319 -1.488 . . . . 1.0 109.164 179.735 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.801 ' HB3' HD22 ' A' ' 67' ' ' LEU . 0.8 OUTLIER -135.68 7.4 3.26 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.383 -0.823 . . . . 1.0 108.872 -179.81 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -60.75 84.1 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.427 -0.796 . . . . 1.0 110.898 -178.569 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.63 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.78 -167.02 1.17 Allowed 'General case' 0 N--CA 1.49 1.539 0 N-CA-C 107.852 -1.166 . . . . 1.0 107.852 178.33 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.477 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.7 t 179.1 135.25 0.09 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.569 -1.332 . . . . 1.0 111.43 -179.364 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.789 HG11 ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -150.46 157.77 5.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 N-CA-C 107.537 -1.283 . . . . 1.0 107.537 177.914 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.63 142.1 30.63 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.734 -1.229 . . . . 1.0 110.051 -179.747 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.021 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.36 107.68 1.41 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 122.331 1.062 . . . . 1.0 109.38 178.524 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.558 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.6 p-10 -62.04 -138.81 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.057 0 CA-C-N 115.612 -0.722 . . . . 1.0 110.861 -179.778 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.585 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.87 -51.82 37.5 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.344 -0.847 . . . . 1.0 110.737 -178.599 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -104.57 -32.91 8.72 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 106.261 -1.755 . . . . 1.0 106.261 178.508 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.988 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.57 69.88 0.67 Allowed Glycine 0 C--N 1.298 -1.574 0 N-CA-C 110.299 -1.12 . . . . 1.0 110.299 178.104 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.617 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 63.7 m -104.07 129.98 51.75 Favored 'General case' 0 N--CA 1.483 1.175 0 O-C-N 121.259 -1.142 . . . . 1.0 109.275 179.14 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.789 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.4 108.96 8.46 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.535 -0.866 . . . . 1.0 109.484 -179.638 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 97.2 p -116.21 117.02 28.87 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.117 -0.989 . . . . 1.0 109.492 -179.747 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.61 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.27 139.93 26.13 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.385 -0.822 . . . . 1.0 110.077 -179.84 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 27.2 p -99.61 135.26 41.29 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.822 -0.807 . . . . 1.0 108.822 179.432 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.94 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -136.22 168.52 19.24 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.292 -0.88 . . . . 1.0 110.057 -178.931 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.858 HG22 HG22 ' A' ' 18' ' ' VAL . 1.2 p -104.06 126.26 51.04 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.192 -0.942 . . . . 1.0 109.329 -179.653 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.735 HG13 ' OD2' ' A' ' 51' ' ' ASP . 12.3 m -129.41 139.99 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 120.922 -1.111 . . . . 1.0 110.209 -179.26 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.521 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 52.4 mtt180 -125.67 -168.57 1.86 Allowed 'General case' 0 N--CA 1.484 1.23 0 O-C-N 120.676 -1.265 . . . . 1.0 111.304 179.823 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.588 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 40.0 mtt180 -78.5 -75.71 0.22 Allowed 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.2 -1.037 . . . . 1.0 108.2 179.284 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.493 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -72.67 137.06 45.79 Favored 'General case' 0 N--CA 1.485 1.296 0 O-C-N 120.14 -1.6 . . . . 1.0 106.812 178.107 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -157.66 135.51 10.73 Favored 'General case' 0 C--N 1.295 -1.784 0 C-N-CA 118.08 -1.448 . . . . 1.0 110.308 -177.903 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.601 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 9.5 mm-40 -34.78 121.62 0.52 Allowed 'General case' 0 N--CA 1.487 1.41 0 CA-C-O 121.582 0.706 . . . . 1.0 110.364 -178.259 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.007 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -87.76 47.94 3.64 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 110.986 -0.846 . . . . 1.0 110.986 -179.377 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.601 ' CE1' ' HB3' ' A' ' 74' ' ' GLU . 36.2 m-85 -39.76 112.95 0.3 Allowed 'General case' 0 N--CA 1.504 2.263 0 O-C-N 121.07 -1.253 . . . . 1.0 110.001 179.614 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.738 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -87.03 126.64 34.88 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.995 -1.066 . . . . 1.0 109.493 -179.912 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.594 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.3 t80 -63.99 58.34 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.998 0 O-C-N 120.735 -1.228 . . . . 1.0 110.315 179.674 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.26 19.15 0.15 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.01 -1.056 . . . . 1.0 109.765 179.854 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.31 -26.18 5.81 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 110.097 -1.201 . . . . 1.0 110.097 179.78 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -94.07 160.0 14.91 Favored 'General case' 0 N--CA 1.485 1.311 0 O-C-N 121.011 -1.288 . . . . 1.0 110.49 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.476 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -105.89 133.39 50.69 Favored 'General case' 0 C--N 1.299 -1.592 0 N-CA-C 108.581 -0.896 . . . . 1.0 108.581 179.701 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.738 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.1 t90 -80.93 -20.28 42.4 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.809 -1.182 . . . . 1.0 110.256 -178.701 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.92 174.19 18.62 Favored Glycine 0 N--CA 1.486 1.973 0 N-CA-C 108.9 -1.68 . . . . 1.0 108.9 -179.59 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.06 110.04 1.69 Allowed 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.143 -1.21 . . . . 1.0 107.743 179.269 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.678 HG21 ' HB3' ' A' ' 46' ' ' ALA . 44.4 t -82.32 104.45 10.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.696 0 N-CA-C 108.715 -0.846 . . . . 1.0 108.715 -179.098 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.529 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -67.11 111.07 3.69 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.322 -0.861 . . . . 1.0 109.893 -179.119 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.588 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -64.04 -5.23 4.33 Favored 'General case' 0 N--CA 1.501 2.083 0 C-N-CA 118.465 -1.294 . . . . 1.0 109.869 179.394 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -86.69 2.04 49.92 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.757 -1.214 . . . . 1.0 108.923 179.363 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.529 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -117.05 -51.11 2.56 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.478 -0.764 . . . . 1.0 108.967 -179.977 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -102.57 -179.92 4.11 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.498 -0.751 . . . . 1.0 109.381 179.883 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.84 115.25 29.98 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.349 -0.845 . . . . 1.0 108.979 179.923 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.56 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.88 122.25 39.63 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.807 -1.183 . . . . 1.0 109.464 -179.278 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.618 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -101.75 145.35 29.26 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 122.449 1.119 . . . . 1.0 111.184 -179.3 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.614 ' HB ' HG11 ' A' ' 7' ' ' VAL . 65.2 t -102.68 110.59 29.76 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.939 0 N-CA-C 106.892 -1.521 . . . . 1.0 106.892 177.815 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.491 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.11 -169.63 18.47 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 118.177 -1.963 . . . . 1.0 111.75 -177.712 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.52 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -120.02 177.06 5.13 Favored 'General case' 0 N--CA 1.489 1.485 0 CA-C-O 121.69 0.757 . . . . 1.0 109.113 -178.931 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.581 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -168.84 173.45 7.1 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 109.276 -0.639 . . . . 1.0 109.276 179.801 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.583 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -116.06 -159.92 0.74 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.103 -0.998 . . . . 1.0 108.86 179.662 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.407 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.2 36.44 4.23 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.674 -1.266 . . . . 1.0 109.152 -179.95 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -115.17 -32.67 5.61 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.404 -0.81 . . . . 1.0 110.173 -179.724 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.952 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 164.68 -35.53 0.28 Allowed Glycine 0 N--CA 1.481 1.677 0 N-CA-C 107.703 -2.159 . . . . 1.0 107.703 -179.573 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.31 -178.08 6.69 Favored 'General case' 0 C--N 1.305 -1.326 0 O-C-N 121.554 -0.968 . . . . 1.0 109.749 179.322 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.487 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.35 -161.31 18.01 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.326 -1.91 . . . . 1.0 108.326 -179.293 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.487 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.4 Cg_exo -47.33 179.82 0.0 OUTLIER 'Trans proline' 0 C--O 1.215 -0.627 0 CA-C-N 118.783 1.292 . . . . 1.0 110.368 179.322 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -95.59 -170.82 2.23 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.053 -1.029 . . . . 1.0 110.236 -179.075 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.491 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -125.37 164.53 18.91 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.693 -1.363 . . . . 1.0 109.693 -179.846 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.56 128.55 49.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 O-C-N 121.436 -1.038 . . . . 1.0 109.103 -179.535 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.618 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.56 120.91 19.81 Favored 'General case' 0 C--N 1.289 -2.036 0 O-C-N 121.735 -0.603 . . . . 1.0 109.835 179.957 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.683 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.4 pt -98.03 168.11 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.315 -0.866 . . . . 1.0 109.037 179.722 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.489 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.4 OUTLIER -134.98 158.6 43.9 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.305 -0.872 . . . . 1.0 109.428 179.976 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.548 ' CE2' HD12 ' A' ' 110' ' ' ILE . 42.2 m-85 -132.33 119.62 20.99 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.191 -0.943 . . . . 1.0 109.392 -179.786 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 23.7 p30 . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.172 -0.955 . . . . 1.0 109.423 179.954 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.952 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.328 0.585 . . . . 1.0 109.481 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.564 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -101.24 160.75 25.72 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.225 -0.922 . . . . 1.0 109.496 179.956 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.591 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 2.4 Cg_endo -61.79 155.22 55.66 Favored 'Trans proline' 0 C--N 1.311 -1.447 0 C-N-CA 122.185 1.924 . . . . 1.0 110.556 -179.99 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.636 HG23 ' HB3' ' A' ' 24' ' ' ALA . 0.0 OUTLIER 179.85 -169.6 0.13 Allowed 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 108.055 -1.091 . . . . 1.0 108.055 179.063 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.557 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -167.82 132.54 1.82 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 120.655 -1.278 . . . . 1.0 111.098 -179.412 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.023 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -99.7 104.3 16.02 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 122.353 1.073 . . . . 1.0 109.918 -179.965 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.945 HG22 HG23 ' A' ' 21' ' ' VAL . 4.0 t -121.6 117.1 51.5 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.386 0 CA-C-O 121.603 0.716 . . . . 1.0 110.341 179.587 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.518 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -165.94 150.04 7.21 Favored Pre-proline 0 N--CA 1.487 1.41 0 N-CA-C 108.213 -1.032 . . . . 1.0 108.213 -179.646 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.518 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.8 Cg_endo -77.72 151.76 92.04 Favored 'Cis proline' 0 C--N 1.31 -1.463 0 C-N-CA 123.608 -1.413 . . . . 1.0 109.512 -0.615 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.712 ' HA ' HG22 ' A' ' 110' ' ' ILE . 85.7 p -92.85 -25.66 18.0 Favored 'General case' 0 C--N 1.293 -1.857 0 O-C-N 121.435 -0.791 . . . . 1.0 108.895 179.42 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 111' ' ' SER . 3.0 m -131.9 161.37 33.2 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.455 -0.778 . . . . 1.0 109.413 -179.912 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.59 36.55 33.19 Favored Glycine 0 N--CA 1.496 2.639 0 N-CA-C 108.627 -1.789 . . . . 1.0 108.627 -179.566 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.772 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.6 mt -91.19 -42.69 10.29 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 123.298 1.523 . . . . 1.0 110.37 -178.505 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.5 143.62 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.284 0 CA-C-N 113.292 -1.776 . . . . 1.0 109.809 -179.585 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.602 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.1 p-10 -50.76 105.59 0.1 Allowed 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.596 0.712 . . . . 1.0 111.31 -178.655 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.47 13.64 8.02 Favored Glycine 0 N--CA 1.485 1.945 0 C-N-CA 119.316 -1.421 . . . . 1.0 113.041 177.497 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.772 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -104.8 -171.96 2.01 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 121.28 2.54 . . . . 1.0 109.755 179.28 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.739 HG13 ' C ' ' A' ' 67' ' ' LEU . 14.9 t -130.11 138.51 53.8 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.345 0 CA-C-N 114.857 -1.065 . . . . 1.0 111.261 -178.855 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.537 HG11 HD11 ' A' ' 13' ' ' LEU . 34.1 m -115.85 154.82 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.585 -0.894 . . . . 1.0 108.585 178.888 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.559 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -109.19 109.18 20.07 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.121 -0.987 . . . . 1.0 109.35 -179.903 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.945 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.4 123.16 62.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 N-CA-C 108.357 -0.979 . . . . 1.0 108.357 179.67 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.023 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -120.85 167.24 12.73 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 120.721 -1.237 . . . . 1.0 109.386 -179.744 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.609 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -131.24 144.33 15.86 Favored Glycine 0 C--N 1.295 -1.723 0 N-CA-C 107.711 -2.155 . . . . 1.0 107.711 179.691 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.636 ' HB3' HG23 ' A' ' 4' ' ' THR . . . -148.18 123.19 10.08 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 120.96 -1.317 . . . . 1.0 108.532 179.105 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.481 ' CA ' ' HA ' ' A' ' 3' ' ' PRO . . . 90.66 27.95 17.98 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.269 -1.443 . . . . 1.0 109.722 -179.464 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.539 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.0 OUTLIER -90.52 175.37 7.09 Favored 'General case' 0 C--N 1.308 -1.213 0 O-C-N 120.832 -1.393 . . . . 1.0 108.602 179.947 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.012 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -48.6 100.4 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.903 -1.123 . . . . 1.0 109.859 -179.817 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.55 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.43 78.57 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.679 0 CA-C-N 115.355 -0.839 . . . . 1.0 110.116 -179.375 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.573 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.81 34.44 0.3 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.283 -1.527 . . . . 1.0 109.283 179.711 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.548 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 21.4 p -139.75 105.69 5.19 Favored 'General case' 0 C--N 1.307 -1.252 0 O-C-N 121.185 -1.185 . . . . 1.0 111.155 -179.381 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.584 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.47 109.8 0.28 Allowed 'General case' 0 N--CA 1.497 1.896 0 N-CA-C 109.579 -0.526 . . . . 1.0 109.579 178.057 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.491 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 8.4 m-85 -104.34 153.23 21.3 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.055 -1.028 . . . . 1.0 108.994 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.435 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -103.2 155.35 18.49 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.859 -1.15 . . . . 1.0 108.246 179.054 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.728 HG23 HD23 ' A' ' 97' ' ' LEU . 0.8 OUTLIER -126.91 127.89 70.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.228 -0.92 . . . . 1.0 108.973 -178.079 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.513 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -175.6 174.36 46.8 Favored Glycine 0 N--CA 1.495 2.581 0 C-N-CA 117.726 -2.178 . . . . 1.0 112.342 -179.926 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.606 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -101.09 108.84 20.63 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 107.964 -1.124 . . . . 1.0 107.964 179.577 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.461 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.0 m -129.67 147.87 51.5 Favored 'General case' 0 C--N 1.294 -1.81 0 O-C-N 121.212 -0.93 . . . . 1.0 109.969 -179.654 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.44 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.58 139.13 54.26 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.362 -0.837 . . . . 1.0 110.523 -179.133 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.876 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.08 114.72 26.56 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.411 -1.329 . . . . 1.0 107.411 178.282 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -106.11 15.35 7.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.051 -1.031 . . . . 1.0 110.541 -178.614 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.77 -175.99 0.09 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.931 -1.106 . . . . 1.0 110.02 179.761 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.79 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.29 97.09 1.19 Allowed 'General case' 0 N--CA 1.488 1.457 0 CA-C-O 121.782 0.801 . . . . 1.0 109.993 -179.631 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.56 28.23 36.43 Favored Glycine 0 N--CA 1.492 2.384 0 C-N-CA 120.278 -0.963 . . . . 1.0 111.413 178.856 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.18 106.27 20.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 O-C-N 120.623 -1.516 . . . . 1.0 107.186 178.846 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.876 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.5 tp -116.88 104.77 11.64 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.463 -1.398 . . . . 1.0 109.869 -177.614 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.044 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.01 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 120.782 -1.199 . . . . 1.0 108.219 178.815 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.5 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.0 t -106.35 164.85 11.7 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.945 -1.097 . . . . 1.0 110.288 -178.897 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.749 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 8.9 t-20 -107.52 134.29 20.05 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.386 -0.821 . . . . 1.0 109.648 -179.301 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.593 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.3 Cg_endo -74.96 22.88 0.41 Allowed 'Trans proline' 0 CA--C 1.544 0.998 0 C-N-CA 122.327 2.018 . . . . 1.0 111.811 -179.813 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.749 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -115.82 7.04 14.46 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.398 -1.439 . . . . 1.0 108.912 179.534 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.546 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.99 15.16 2.86 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.385 -1.339 . . . . 1.0 107.385 179.522 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -78.3 88.19 4.34 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.984 -0.686 . . . . 1.0 111.522 -178.132 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' HG12 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -97.97 -167.49 1.52 Allowed 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 107.718 -1.215 . . . . 1.0 107.718 177.941 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.445 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.93 135.99 0.09 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.565 -1.335 . . . . 1.0 111.542 -179.331 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.953 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -163.47 154.19 2.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 107.526 -1.287 . . . . 1.0 107.526 178.419 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.584 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.6 141.92 30.83 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.833 -1.167 . . . . 1.0 109.59 -179.945 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.012 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -61.82 105.69 0.59 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 122.493 1.139 . . . . 1.0 109.281 178.541 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.552 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.8 p-10 -58.55 -138.63 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.982 0 CA-C-N 115.443 -0.799 . . . . 1.0 110.966 -179.862 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.55 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -53.79 -49.4 68.37 Favored 'General case' 0 N--CA 1.5 2.042 0 CA-C-O 121.675 0.75 . . . . 1.0 110.409 -178.672 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 74.7 m-80 -102.38 -37.29 8.11 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 106.066 -1.827 . . . . 1.0 106.066 178.382 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.986 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 110.16 65.84 0.55 Allowed Glycine 0 C--N 1.297 -1.596 0 CA-C-N 114.774 -1.103 . . . . 1.0 110.438 177.964 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.609 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.7 m -104.43 127.3 52.09 Favored 'General case' 0 N--CA 1.483 1.179 0 O-C-N 121.563 -0.963 . . . . 1.0 109.07 179.05 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.953 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -136.54 109.02 7.38 Favored 'General case' 0 C--N 1.297 -1.678 0 C-N-CA 119.519 -0.872 . . . . 1.0 109.764 -179.443 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 53.3 p -115.3 119.57 36.74 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.105 -0.997 . . . . 1.0 109.373 179.97 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.5 ' CG2' HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.33 142.21 30.25 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.48 -0.762 . . . . 1.0 109.844 179.935 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 54.8 p -99.44 149.02 23.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.414 -0.803 . . . . 1.0 109.156 179.751 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.739 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.2 OUTLIER -149.87 163.71 37.31 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.265 -0.897 . . . . 1.0 109.763 -178.93 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.71 HG22 HG22 ' A' ' 18' ' ' VAL . 2.5 p -96.57 126.1 41.51 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.125 -0.984 . . . . 1.0 109.259 -179.987 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.547 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.0 m -137.44 143.19 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 120.904 -1.123 . . . . 1.0 109.856 -179.102 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.602 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.9 ptt180 -147.3 -176.51 5.26 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 120.519 -1.363 . . . . 1.0 111.081 -179.774 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.596 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -53.04 -100.19 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 109.155 -0.683 . . . . 1.0 109.155 -179.714 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.52 139.97 51.96 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.779 -1.201 . . . . 1.0 107.801 179.208 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.591 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -162.45 138.79 7.62 Favored 'General case' 0 C--N 1.293 -1.89 0 C-N-CA 118.525 -1.27 . . . . 1.0 110.074 -177.819 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.564 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.8 mm-40 -34.7 120.82 0.5 Allowed 'General case' 0 N--CA 1.491 1.6 0 CA-C-O 121.395 0.617 . . . . 1.0 110.246 -178.713 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.044 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.18 50.8 1.9 Allowed Glycine 0 N--CA 1.492 2.402 0 C-N-CA 120.477 -0.868 . . . . 1.0 111.136 -179.101 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.593 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.6 m-30 -39.39 113.35 0.32 Allowed 'General case' 0 N--CA 1.507 2.424 0 O-C-N 121.057 -1.26 . . . . 1.0 109.916 179.488 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.643 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -85.73 126.78 34.23 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.835 -1.166 . . . . 1.0 109.504 -179.915 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.585 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 30.7 t80 -64.36 58.23 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.018 0 O-C-N 120.859 -1.151 . . . . 1.0 110.104 179.764 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -160.05 19.49 0.16 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.019 -1.051 . . . . 1.0 109.674 179.905 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.38 -26.71 5.52 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.154 -1.178 . . . . 1.0 110.154 179.856 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.451 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.4 OUTLIER -94.27 154.81 17.33 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.06 -1.259 . . . . 1.0 110.42 -179.431 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.479 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -102.11 134.54 45.19 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 108.176 -1.046 . . . . 1.0 108.176 179.476 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.643 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.2 t90 -81.49 -16.6 51.41 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.784 -1.197 . . . . 1.0 110.506 -178.34 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 108.17 175.52 22.04 Favored Glycine 0 N--CA 1.485 1.921 0 N-CA-C 108.768 -1.733 . . . . 1.0 108.768 -179.675 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.44 104.32 0.61 Allowed 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 107.615 -1.254 . . . . 1.0 107.615 179.07 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.615 HG21 ' HB3' ' A' ' 46' ' ' ALA . 38.1 t -76.03 106.37 5.82 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.316 -0.865 . . . . 1.0 109.059 -178.862 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.37 110.65 2.33 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.507 -0.746 . . . . 1.0 109.835 -179.268 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.596 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.61 -5.08 4.88 Favored 'General case' 0 N--CA 1.498 1.938 0 C-N-CA 118.261 -1.375 . . . . 1.0 109.752 179.357 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.5 p -85.57 -1.44 57.11 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.806 -1.184 . . . . 1.0 109.216 179.606 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.81 -48.36 3.07 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.299 -0.875 . . . . 1.0 109.051 -179.984 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.31 -178.57 3.64 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.57 -0.706 . . . . 1.0 109.491 179.905 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.46 115.36 30.12 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.429 -0.794 . . . . 1.0 109.096 -179.956 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.76 120.99 38.12 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.894 -1.129 . . . . 1.0 109.239 -179.514 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.61 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -99.26 145.54 27.16 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 122.328 1.061 . . . . 1.0 111.105 -179.338 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.545 ' HB ' HG11 ' A' ' 7' ' ' VAL . 97.5 t -103.21 110.51 29.97 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 106.958 -1.497 . . . . 1.0 106.958 177.858 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.544 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -154.09 -169.68 19.2 Favored Glycine 0 N--CA 1.486 1.996 0 C-N-CA 118.173 -1.965 . . . . 1.0 111.579 -177.635 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.728 HD23 HG23 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -117.87 173.92 6.48 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 108.532 -0.914 . . . . 1.0 108.532 -179.506 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.596 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 7.3 t 176.13 163.93 0.38 Allowed 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 109.235 -0.654 . . . . 1.0 109.235 -179.808 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.491 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -108.61 -160.84 0.74 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.923 -1.111 . . . . 1.0 109.092 -179.997 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -118.03 36.49 4.31 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.705 -1.247 . . . . 1.0 109.167 -179.954 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -110.18 -30.32 7.79 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.37 -0.831 . . . . 1.0 109.809 -179.713 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.525 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . 170.79 -38.45 0.18 Allowed Glycine 0 N--CA 1.482 1.757 0 N-CA-C 108.115 -1.994 . . . . 1.0 108.115 -179.82 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -172.61 -176.69 1.56 Allowed 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.526 -0.985 . . . . 1.0 109.715 179.467 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.23 -160.8 16.73 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.159 -1.976 . . . . 1.0 108.159 -179.383 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.2 Cg_exo -46.84 176.41 0.01 OUTLIER 'Trans proline' 0 C--N 1.326 -0.656 0 CA-C-N 118.973 1.386 . . . . 1.0 109.998 179.127 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -95.21 -176.88 3.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.027 -1.046 . . . . 1.0 110.376 -178.814 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.544 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.62 167.19 13.38 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.741 -1.343 . . . . 1.0 109.741 -179.963 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -101.55 129.55 52.54 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.417 -1.049 . . . . 1.0 109.143 -179.381 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.61 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -68.91 115.86 8.72 Favored 'General case' 0 C--N 1.289 -2.041 0 N-CA-C 109.47 -0.567 . . . . 1.0 109.47 179.474 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.827 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.8 pt -97.8 168.49 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.262 -0.899 . . . . 1.0 108.59 179.857 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.422 ' O ' ' HA ' ' A' ' 11' ' ' SER . 2.8 t -142.36 158.49 43.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.022 -1.049 . . . . 1.0 110.302 -179.375 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.827 ' CE1' HD12 ' A' ' 110' ' ' ILE . 84.8 m-85 -133.67 98.86 4.31 Favored 'General case' 0 N--CA 1.484 1.259 0 O-C-N 121.374 -0.829 . . . . 1.0 109.324 -179.856 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 20.0 p30 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 118.033 -0.984 . . . . 1.0 109.517 -179.935 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.864 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 121.319 0.58 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 033 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.783 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -110.65 167.82 8.5 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.218 -0.926 . . . . 0.0 109.503 -179.99 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.783 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 3.3 Cg_exo -60.82 157.49 37.79 Favored 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.256 1.971 . . . . 0.0 110.464 -179.936 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.672 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.1 p -159.68 160.14 33.81 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 -179.309 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.483 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.82 121.97 9.53 Favored 'General case' 0 C--N 1.296 -1.73 0 CA-C-O 122.333 1.063 . . . . 0.0 110.388 -179.672 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.755 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.3 t -114.54 109.35 18.13 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 123.01 1.386 . . . . 0.0 109.768 -179.929 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.83 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -115.58 139.03 44.0 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.721 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.763 179.913 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.51 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -172.42 150.71 2.31 Favored Pre-proline 0 N--CA 1.487 1.403 0 O-C-N 121.154 -0.966 . . . . 0.0 108.948 -179.533 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.51 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.1 Cg_endo -75.38 152.77 98.03 Favored 'Cis proline' 0 C--N 1.313 -1.316 0 C-N-CA 123.498 -1.459 . . . . 0.0 109.533 -0.674 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.641 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.5 m -89.89 -25.42 20.99 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.763 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.494 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.5 m -136.83 166.43 23.63 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.483 -0.76 . . . . 0.0 109.435 179.935 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.28 37.72 35.99 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.522 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.837 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.9 mt -92.77 -44.68 8.39 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 123.153 1.454 . . . . 0.0 110.767 -178.272 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.84 145.56 0.03 OUTLIER 'General case' 0 C--N 1.258 -3.392 0 CA-C-N 113.721 -1.581 . . . . 0.0 110.045 -179.819 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.593 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.6 p-10 -50.64 108.34 0.23 Allowed 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 121.562 0.696 . . . . 0.0 111.727 -178.678 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.06 15.56 9.82 Favored Glycine 0 N--CA 1.484 1.895 0 C-N-CA 119.619 -1.277 . . . . 0.0 112.78 177.263 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.837 HG21 ' CA ' ' A' ' 13' ' ' LEU . 8.8 t -103.56 -173.12 2.24 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 121.056 2.428 . . . . 0.0 109.839 179.348 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.77 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.9 t -126.8 135.71 62.91 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.944 -178.771 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.549 HG13 ' CG2' ' A' ' 69' ' ' VAL . 27.4 m -112.37 154.75 13.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 O-C-N 121.348 -0.845 . . . . 0.0 108.883 178.789 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.517 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -111.24 109.43 19.45 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.219 -0.926 . . . . 0.0 108.987 179.947 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.83 HG23 HG22 ' A' ' 7' ' ' VAL . 2.2 p -105.11 140.2 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -179.972 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.755 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.43 161.39 36.47 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.793 -1.192 . . . . 0.0 110.004 179.583 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -134.54 140.44 11.74 Favored Glycine 0 C--N 1.299 -1.518 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 179.793 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.583 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -141.74 127.04 18.66 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.563 -1.551 . . . . 0.0 109.489 179.294 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.489 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 87.47 29.26 22.35 Favored Glycine 0 N--CA 1.488 2.16 0 C-N-CA 118.915 -1.612 . . . . 0.0 109.681 -179.821 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.551 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.9 mt -89.08 173.21 8.57 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.006 -1.291 . . . . 0.0 108.334 -179.85 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.022 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.21 98.85 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.015 -1.053 . . . . 0.0 109.797 -179.715 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.549 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.38 77.02 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.251 -179.199 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.05 33.35 0.28 Allowed Glycine 0 N--CA 1.486 1.991 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.533 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.55 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.7 p -142.81 110.57 5.87 Favored 'General case' 0 C--N 1.308 -1.216 0 O-C-N 120.981 -1.306 . . . . 0.0 111.028 -179.832 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.588 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.95 112.68 0.65 Allowed 'General case' 0 N--CA 1.495 1.814 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.99 178.366 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.504 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 21.6 m-85 -101.33 155.3 18.12 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.127 -0.983 . . . . 0.0 108.88 179.665 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.517 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.4 OUTLIER -102.7 150.19 23.7 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.862 -1.149 . . . . 0.0 108.205 179.014 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.71 ' CG1' HD21 ' A' ' 67' ' ' LEU . 1.1 t -126.34 129.97 71.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 O-C-N 121.117 -0.989 . . . . 0.0 109.121 -178.074 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.47 ' O ' ' H29' ' A' ' 114' ' ' CHR . . . -178.56 172.67 45.06 Favored Glycine 0 N--CA 1.495 2.573 0 C-N-CA 117.812 -2.137 . . . . 0.0 112.201 179.866 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.609 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -101.02 109.1 20.97 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 179.364 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.1 m -130.05 148.93 51.96 Favored 'General case' 0 C--N 1.295 -1.765 0 O-C-N 120.96 -1.087 . . . . 0.0 110.27 -179.496 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.52 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.54 138.34 54.34 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.364 -0.835 . . . . 0.0 110.537 -179.307 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.892 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.34 114.79 26.61 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 178.249 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.5 m -104.46 14.57 6.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.069 -1.02 . . . . 0.0 110.518 -178.915 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.763 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.55 -175.0 0.08 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.902 -1.124 . . . . 0.0 109.974 179.702 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -73.6 98.79 2.91 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.441 -0.787 . . . . 0.0 109.539 -179.814 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.99 27.62 30.86 Favored Glycine 0 N--CA 1.492 2.392 0 C-N-CA 120.161 -1.018 . . . . 0.0 111.362 179.09 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.763 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -118.11 105.99 18.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 O-C-N 120.597 -1.531 . . . . 0.0 107.231 178.967 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.892 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.6 tp -118.12 104.73 11.11 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 120.496 -1.378 . . . . 0.0 109.917 -177.801 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.013 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.64 109.33 22.11 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.729 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -105.64 165.87 10.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.915 -1.116 . . . . 0.0 110.674 -178.479 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.504 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 7.8 t30 -110.32 130.25 23.07 Favored Pre-proline 0 N--CA 1.497 1.906 0 O-C-N 121.601 -0.687 . . . . 0.0 109.247 -179.486 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -71.59 23.28 0.24 Allowed 'Trans proline' 0 CA--C 1.545 1.055 0 C-N-CA 122.054 1.836 . . . . 0.0 111.804 179.623 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.504 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -103.32 -3.07 26.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.448 -1.408 . . . . 0.0 109.074 179.641 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.863 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.6 m-20 -134.93 10.41 3.6 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.943 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -63.34 81.99 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.251 -178.905 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.648 ' HB2' HG12 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -98.34 -169.57 1.82 Allowed 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.096 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.435 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.1 t 179.27 132.94 0.09 Allowed 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.865 -1.147 . . . . 0.0 111.126 -179.532 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.855 HG11 ' HB1' ' A' ' 63' ' ' ALA . 1.1 p -156.32 152.61 8.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 178.367 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.588 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.91 142.29 29.83 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.696 -1.253 . . . . 0.0 109.872 -179.64 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.022 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.02 106.11 0.78 Allowed 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 122.447 1.117 . . . . 0.0 109.497 178.792 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.6 p-10 -57.92 -139.22 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.727 -179.978 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.549 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -55.13 -49.27 72.2 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.331 -0.856 . . . . 0.0 110.093 -178.95 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.7 p-10 -100.22 -39.03 8.25 Favored 'General case' 0 C--N 1.286 -2.183 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 178.482 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.978 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.94 66.36 0.58 Allowed Glycine 0 C--N 1.297 -1.619 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 178.288 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.584 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.0 m -101.48 129.81 47.61 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 121.601 -0.941 . . . . 0.0 109.056 179.103 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.855 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -138.13 108.95 6.66 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 119.31 -0.956 . . . . 0.0 109.498 -179.554 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.7 m -126.0 120.92 31.58 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.205 -0.934 . . . . 0.0 109.627 -179.774 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.08 144.78 30.24 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.482 -0.761 . . . . 0.0 109.391 179.871 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.437 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 32.1 p -98.83 141.12 32.02 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.368 -0.832 . . . . 0.0 109.115 179.894 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.863 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.0 OUTLIER -140.56 174.69 10.27 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.333 -0.854 . . . . 0.0 109.65 -178.818 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.528 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -102.34 122.37 44.11 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.019 -1.051 . . . . 0.0 109.622 -179.751 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.671 HG13 ' OD2' ' A' ' 51' ' ' ASP . 16.9 m -133.47 143.17 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 120.911 -1.118 . . . . 0.0 110.159 -179.411 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.593 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.0 ptt180 -142.68 -166.87 2.38 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.663 -1.273 . . . . 0.0 110.09 179.568 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.565 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -72.32 -85.91 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.321 -0.862 . . . . 0.0 108.841 -179.575 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.62 138.81 58.58 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.291 -1.506 . . . . 0.0 107.362 178.799 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -164.48 139.08 5.49 Favored 'General case' 0 C--N 1.294 -1.82 0 C-N-CA 117.982 -1.487 . . . . 0.0 110.542 -177.496 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.507 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.6 mm-40 -34.09 120.55 0.44 Allowed 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.47 0.653 . . . . 0.0 110.612 -178.625 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.013 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.15 50.57 1.91 Allowed Glycine 0 N--CA 1.494 2.563 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.226 -179.418 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-85 -41.05 114.18 0.46 Allowed 'General case' 0 N--CA 1.508 2.45 0 O-C-N 120.868 -1.372 . . . . 0.0 109.964 179.453 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.637 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.3 tp -84.32 126.92 33.64 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.742 -1.224 . . . . 0.0 109.624 -179.951 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.592 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 26.4 t80 -64.05 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.812 -1.18 . . . . 0.0 110.275 179.688 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' LEU . 8.7 t0 -161.35 20.0 0.12 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.944 -1.098 . . . . 0.0 109.806 179.731 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.19 -26.88 5.31 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 110.041 -1.223 . . . . 0.0 110.041 179.963 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.475 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 5.9 p -92.38 152.78 19.56 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.056 -1.261 . . . . 0.0 110.386 -179.442 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.515 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 5.4 ptt180 -101.93 133.06 47.32 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.597 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.637 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.0 OUTLIER -81.24 -20.96 39.9 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 120.713 -1.242 . . . . 0.0 110.527 -178.269 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.88 176.04 20.45 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 108.725 -1.75 . . . . 0.0 108.725 -179.629 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.49 109.42 1.37 Allowed 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 179.148 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.591 HG21 ' HB3' ' A' ' 46' ' ' ALA . 31.1 t -81.83 105.74 12.05 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 121.341 -0.849 . . . . 0.0 108.94 -178.934 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.651 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -65.3 111.82 3.19 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.446 -0.783 . . . . 0.0 109.845 -179.357 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.549 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.56 -5.09 7.13 Favored 'General case' 0 N--CA 1.499 1.984 0 C-N-CA 118.285 -1.366 . . . . 0.0 109.648 179.369 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 p -83.76 -2.18 55.74 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.876 -1.14 . . . . 0.0 108.901 179.318 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.651 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -111.98 -49.81 2.95 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.347 -0.846 . . . . 0.0 109.013 -179.998 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.62 -178.34 3.62 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.551 -0.718 . . . . 0.0 109.517 179.919 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.3 116.29 31.68 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.43 -0.794 . . . . 0.0 108.99 -179.971 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.568 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.1 m -96.88 124.21 40.8 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.814 -1.179 . . . . 0.0 109.747 -179.168 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.614 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.0 147.32 26.71 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 122.33 1.062 . . . . 0.0 111.202 -179.44 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.527 ' CG1' HG11 ' A' ' 7' ' ' VAL . 43.8 t -104.75 111.53 34.65 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.567 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.496 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.35 -169.81 17.47 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 117.906 -2.092 . . . . 0.0 111.845 -177.481 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.494 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.57 -179.07 3.57 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 -179.094 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.586 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.0 OUTLIER -171.34 173.55 4.81 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.277 -0.889 . . . . 0.0 109.438 -179.73 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.413 ' OD1' ' C ' ' A' ' 99' ' ' ASP . 0.6 OUTLIER -118.43 -160.38 0.79 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.078 -1.014 . . . . 0.0 108.993 179.937 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -118.91 35.5 4.79 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.673 -1.267 . . . . 0.0 109.347 -179.824 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.78 -32.55 4.49 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.403 -0.811 . . . . 0.0 110.239 -179.542 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 1.018 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 168.32 -37.56 0.21 Allowed Glycine 0 N--CA 1.481 1.658 0 N-CA-C 107.676 -2.17 . . . . 0.0 107.676 -179.493 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.55 -178.16 6.91 Favored 'General case' 0 C--N 1.306 -1.296 0 O-C-N 121.534 -0.98 . . . . 0.0 109.671 179.253 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -166.5 -162.04 17.06 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 108.356 -1.897 . . . . 0.0 108.356 -179.494 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.484 ' CD ' ' CE1' ' A' ' 32' ' ' TYR . 6.8 Cg_exo -46.12 174.16 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 CA-C-N 118.784 1.292 . . . . 0.0 110.022 179.387 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -92.82 -177.69 4.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.107 -0.996 . . . . 0.0 110.528 -178.588 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.496 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.8 167.44 13.1 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -179.946 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -104.06 131.19 53.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 O-C-N 121.325 -1.103 . . . . 0.0 109.095 -179.269 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.614 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.99 122.63 22.03 Favored 'General case' 0 C--N 1.29 -2.001 0 O-C-N 121.612 -0.68 . . . . 0.0 109.529 179.707 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.848 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.72 169.84 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 O-C-N 121.225 -0.922 . . . . 0.0 109.226 -179.982 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.494 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -135.48 155.33 50.7 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.233 -0.917 . . . . 0.0 109.721 -179.753 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.848 ' CE2' HD12 ' A' ' 110' ' ' ILE . 74.9 m-85 -131.19 109.28 10.31 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.247 -0.908 . . . . 0.0 109.547 -179.767 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.2 p30 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 117.98 -1.01 . . . . 0.0 109.443 179.99 . . . . . . . . 0 0 . 1 . 033 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 1.018 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.489 0 CA-C-O 121.316 0.579 . . . . 0.0 109.459 . . . . . . . . . 0 0 . 1 . 034 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -119.88 152.84 54.44 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.181 -0.949 . . . . 0.0 109.524 179.969 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.701 ' HB3' HD23 ' A' ' 26' ' ' LEU . 2.7 Cg_endo -61.33 156.03 48.45 Favored 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.343 2.029 . . . . 0.0 110.514 -179.941 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.602 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -146.75 161.56 40.37 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 -179.739 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -146.9 128.92 15.51 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-O 122.475 1.131 . . . . 0.0 110.618 -179.725 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.006 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.8 p -106.89 104.95 14.75 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-O 122.503 1.144 . . . . 0.0 110.331 -179.43 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.955 HG22 HG23 ' A' ' 21' ' ' VAL . 10.6 t -117.25 119.16 61.02 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.478 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.303 179.582 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.501 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.61 148.38 12.67 Favored Pre-proline 0 N--CA 1.487 1.415 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -179.602 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.501 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.49 152.85 97.95 Favored 'Cis proline' 0 C--N 1.31 -1.497 0 C-N-CA 123.603 -1.415 . . . . 0.0 109.728 -0.445 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.676 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.7 m -92.53 -24.94 18.6 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.505 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.517 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 1.2 m -136.53 166.05 24.43 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.656 -0.652 . . . . 0.0 109.351 179.847 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.39 37.98 39.95 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 108.38 -1.888 . . . . 0.0 108.38 -179.723 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.786 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.6 mt -91.7 -43.34 9.64 Favored 'General case' 0 C--N 1.297 -1.707 0 CA-C-O 123.344 1.545 . . . . 0.0 110.649 -178.31 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.472 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.02 144.43 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.376 -1.738 . . . . 0.0 109.853 -179.653 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.611 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 6.1 p-10 -51.13 107.78 0.2 Allowed 'General case' 0 C--N 1.302 -1.492 0 CA-C-O 121.586 0.708 . . . . 0.0 111.527 -178.534 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.12 14.26 9.33 Favored Glycine 0 N--CA 1.484 1.86 0 C-N-CA 119.406 -1.378 . . . . 0.0 112.822 177.486 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.786 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.3 t -105.0 -172.6 2.13 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 121.13 2.465 . . . . 0.0 109.713 179.287 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.75 HG13 ' C ' ' A' ' 67' ' ' LEU . 15.0 t -130.68 139.18 51.88 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.332 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.324 -178.793 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.472 HG23 ' CD1' ' A' ' 67' ' ' LEU . 31.7 m -114.72 154.91 16.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 179.037 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.541 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.6 tptm -110.45 109.36 19.7 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.148 -0.97 . . . . 0.0 109.337 180.0 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.955 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -105.1 123.95 59.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 179.948 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.006 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.38 166.16 11.55 Favored 'General case' 0 N--CA 1.485 1.279 0 O-C-N 120.927 -1.108 . . . . 0.0 108.94 179.594 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.622 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.19 108.1 0.48 Allowed Glycine 0 N--CA 1.482 1.763 0 N-CA-C 108.41 -1.876 . . . . 0.0 108.41 179.917 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.602 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -117.19 136.81 52.78 Favored 'General case' 0 N--CA 1.501 2.078 0 CA-C-N 119.432 1.616 . . . . 0.0 110.38 -179.287 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.466 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 87.61 28.11 25.2 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 118.895 -1.621 . . . . 0.0 109.806 179.68 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.701 HD23 ' HB3' ' A' ' 3' ' ' PRO . 0.8 OUTLIER -93.4 170.6 9.49 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.988 -1.301 . . . . 0.0 108.309 179.852 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.008 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.9 100.8 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.068 -1.02 . . . . 0.0 110.018 -179.495 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.541 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.75 78.17 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.675 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.018 -179.36 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.32 34.48 0.28 Allowed Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.735 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 18.8 p -139.56 105.67 5.23 Favored 'General case' 0 C--N 1.307 -1.278 0 O-C-N 121.162 -1.199 . . . . 0.0 111.273 -179.258 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.592 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.74 109.88 0.36 Allowed 'General case' 0 N--CA 1.496 1.849 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 177.824 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.535 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 5.2 m-30 -106.38 156.11 18.85 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.049 -1.032 . . . . 0.0 108.886 179.89 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.512 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -100.36 164.51 11.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.902 -1.124 . . . . 0.0 108.081 179.035 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.682 HG22 HG11 ' A' ' 21' ' ' VAL . 4.2 p -144.23 117.21 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.152 -0.967 . . . . 0.0 109.61 -178.1 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.9 -176.9 38.83 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 118.364 -1.874 . . . . 0.0 111.876 -179.717 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.601 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.3 OUTLIER -101.48 109.21 20.99 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.837 0.827 . . . . 0.0 109.13 -179.572 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.475 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.21 148.44 52.04 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.192 -0.943 . . . . 0.0 109.511 179.579 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.509 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.7 138.52 54.58 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.179 -0.951 . . . . 0.0 110.815 -178.969 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.37 114.97 26.8 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 178.112 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.9 m -105.64 15.07 7.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 120.994 -1.066 . . . . 0.0 110.534 -178.84 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.754 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.11 -175.38 0.09 Allowed 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.857 -1.152 . . . . 0.0 110.064 179.724 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 64.0 p -72.24 97.44 1.99 Allowed 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.428 -0.795 . . . . 0.0 109.64 -179.784 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.56 27.54 32.24 Favored Glycine 0 N--CA 1.493 2.47 0 C-N-CA 120.154 -1.022 . . . . 0.0 111.419 178.877 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.754 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.65 106.21 19.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.526 -1.573 . . . . 0.0 107.221 178.93 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.8 tp -117.06 104.69 11.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.52 -1.362 . . . . 0.0 109.854 -177.659 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.072 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.08 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.299 0 O-C-N 120.842 -1.161 . . . . 0.0 107.887 178.77 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -106.87 163.99 12.49 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.015 -1.053 . . . . 0.0 110.44 -178.771 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.743 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 47.0 t30 -109.59 131.04 22.12 Favored Pre-proline 0 N--CA 1.502 2.173 0 O-C-N 121.59 -0.694 . . . . 0.0 109.618 -179.345 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.3 Cg_endo -71.61 20.76 0.25 Allowed 'Trans proline' 0 C--N 1.318 -1.029 0 C-N-CA 122.21 1.94 . . . . 0.0 112.243 -179.813 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.743 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -110.53 5.68 21.39 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.379 -1.451 . . . . 0.0 108.846 179.166 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.543 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.01 16.82 2.64 Favored 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.157 -1.423 . . . . 0.0 107.157 179.339 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -81.74 88.82 6.26 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.868 -0.733 . . . . 0.0 111.285 -178.302 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.637 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.79 -167.25 1.23 Allowed 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 177.93 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.65 136.24 0.09 Allowed 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.479 -1.388 . . . . 0.0 111.395 -179.341 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.881 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -152.67 157.29 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.169 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.592 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.89 141.76 31.25 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.732 -1.23 . . . . 0.0 109.859 -179.772 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.008 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.17 107.51 1.06 Allowed 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 122.43 1.109 . . . . 0.0 109.399 178.199 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.562 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 14.4 p-10 -61.75 -138.91 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.001 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.812 -179.997 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.541 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.49 -51.62 53.55 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.374 -0.828 . . . . 0.0 110.664 -178.665 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -102.23 -33.75 9.5 Favored 'General case' 0 C--N 1.287 -2.138 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 178.473 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.008 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.28 64.56 0.57 Allowed Glycine 0 C--N 1.299 -1.511 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.671 178.009 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.622 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 92.7 p -98.89 128.91 45.2 Favored 'General case' 0 N--CA 1.482 1.168 0 O-C-N 121.859 -0.789 . . . . 0.0 108.92 178.804 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.881 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.28 108.78 7.4 Favored 'General case' 0 C--N 1.296 -1.742 0 C-N-CA 119.67 -0.812 . . . . 0.0 109.416 -179.524 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 80.9 p -120.5 117.44 27.65 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.298 -0.876 . . . . 0.0 109.368 -179.906 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.569 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.31 140.83 28.04 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.418 -0.801 . . . . 0.0 109.609 -179.836 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 12.6 p -100.69 136.24 40.88 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.377 -0.827 . . . . 0.0 109.494 -179.947 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.75 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -133.84 165.85 24.03 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.423 -0.798 . . . . 0.0 109.392 -179.473 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.729 HG22 HG22 ' A' ' 18' ' ' VAL . 2.2 p -96.22 125.33 40.66 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.956 -1.09 . . . . 0.0 109.349 -179.946 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.601 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.4 m -135.82 143.49 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 120.919 -1.113 . . . . 0.0 109.929 -179.116 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.611 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.63 -175.9 4.98 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 120.495 -1.378 . . . . 0.0 110.984 179.957 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.599 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.56 -101.73 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.762 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.514 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -57.29 142.0 44.84 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 120.731 -1.23 . . . . 0.0 108.187 179.424 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.585 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -162.65 136.85 6.39 Favored 'General case' 0 C--N 1.294 -1.83 0 C-N-CA 118.775 -1.17 . . . . 0.0 109.637 -177.961 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.498 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 1.6 mp0 -34.46 121.89 0.5 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 121.431 0.634 . . . . 0.0 110.306 -178.402 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.072 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.58 49.91 2.34 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.236 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.5 m-85 -39.3 113.85 0.36 Allowed 'General case' 0 N--CA 1.507 2.382 0 O-C-N 121.204 -1.174 . . . . 0.0 109.992 179.555 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.7 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -85.81 126.46 34.04 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 120.944 -1.098 . . . . 0.0 109.55 -179.797 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.576 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 19.9 t80 -64.28 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.05 0 O-C-N 120.869 -1.144 . . . . 0.0 110.052 179.665 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.539 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.4 t70 -159.96 19.49 0.16 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.157 -0.964 . . . . 0.0 109.66 179.764 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.96 -27.45 5.47 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 179.75 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.4 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 19.5 p -94.49 160.46 14.64 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.033 -1.275 . . . . 0.0 110.362 -179.361 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.48 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.75 136.62 46.24 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.689 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.7 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -82.89 -17.96 41.93 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.765 -1.21 . . . . 0.0 110.526 -178.487 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.94 175.6 19.89 Favored Glycine 0 N--CA 1.485 1.955 0 N-CA-C 108.778 -1.729 . . . . 0.0 108.778 -179.632 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -65.05 104.74 0.92 Allowed 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 179.134 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.633 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.5 t -76.48 106.3 6.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.388 -0.82 . . . . 0.0 109.258 -178.913 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -66.02 111.28 3.28 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.47 -0.769 . . . . 0.0 109.892 -179.41 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.599 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.75 -5.49 4.27 Favored 'General case' 0 N--CA 1.5 2.068 0 C-N-CA 118.256 -1.377 . . . . 0.0 109.816 179.484 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.6 p -86.82 -0.14 55.89 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 120.708 -1.245 . . . . 0.0 109.111 179.585 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.33 -50.59 2.85 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.398 -0.814 . . . . 0.0 108.945 179.96 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.07 -179.95 4.09 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.484 -0.76 . . . . 0.0 109.392 179.845 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.97 115.86 31.2 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.333 -0.854 . . . . 0.0 108.964 179.917 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.559 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.84 121.32 38.57 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.993 -1.067 . . . . 0.0 109.308 -179.421 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.595 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.92 145.7 28.3 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 122.355 1.074 . . . . 0.0 111.2 -179.306 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.648 ' HB ' HG11 ' A' ' 7' ' ' VAL . 58.6 t -103.12 109.78 27.83 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 177.675 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.478 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.26 -170.73 16.47 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 118.271 -1.919 . . . . 0.0 111.663 -177.738 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.503 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -114.36 -179.55 3.66 Favored 'General case' 0 N--CA 1.487 1.377 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 -178.95 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.562 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 37.1 p -170.85 168.33 7.23 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.337 -0.852 . . . . 0.0 109.321 -179.235 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.535 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -120.06 -158.83 0.76 Allowed 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.079 -1.013 . . . . 0.0 108.845 179.663 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.427 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.45 36.13 4.39 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.706 -1.246 . . . . 0.0 109.314 179.943 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -117.8 -32.76 4.72 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.452 -0.78 . . . . 0.0 110.262 -179.509 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 1.023 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 164.9 -36.25 0.28 Allowed Glycine 0 N--CA 1.483 1.771 0 N-CA-C 107.572 -2.211 . . . . 0.0 107.572 -179.513 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.61 -178.01 6.79 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 121.538 -0.977 . . . . 0.0 109.793 179.253 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -164.75 -163.0 16.93 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -179.321 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.503 ' HB2' HD12 ' A' ' 97' ' ' LEU . 6.4 Cg_exo -46.71 175.69 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.643 0 CA-C-N 118.77 1.285 . . . . 0.0 110.1 179.325 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -90.06 -176.04 4.75 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.019 -1.05 . . . . 0.0 110.599 -178.787 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.478 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.82 167.0 13.88 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.896 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.89 132.66 49.84 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.373 -1.075 . . . . 0.0 109.174 -179.334 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.595 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.27 118.88 17.73 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.547 -0.72 . . . . 0.0 109.685 179.675 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.911 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -98.02 170.07 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 O-C-N 121.211 -0.93 . . . . 0.0 108.999 179.72 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.517 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 34.4 m -140.95 156.85 45.99 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.167 -0.958 . . . . 0.0 110.094 -179.674 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.911 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.3 m-85 -131.97 106.33 7.98 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.333 -0.855 . . . . 0.0 109.541 -179.754 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 p30 . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 117.986 -1.007 . . . . 0.0 109.4 -179.928 . . . . . . . . 0 0 . 1 . 034 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 1.023 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.322 0.582 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -113.09 150.11 42.42 Favored Pre-proline 0 N--CA 1.49 1.554 0 O-C-N 121.217 -0.927 . . . . 0.0 109.444 179.984 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.61 ' HB3' HD23 ' A' ' 26' ' ' LEU . 5.6 Cg_exo -58.67 154.04 45.57 Favored 'Trans proline' 0 C--N 1.305 -1.728 0 C-N-CA 124.821 3.681 . . . . 0.0 110.086 -179.935 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.594 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -150.16 160.63 43.53 Favored 'General case' 0 C--N 1.293 -1.858 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -179.419 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.488 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.01 122.48 10.37 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 122.486 1.136 . . . . 0.0 110.397 -179.589 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.763 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.5 t -113.52 109.17 18.21 Favored 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 123.15 1.452 . . . . 0.0 109.266 179.954 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.889 HG22 HG23 ' A' ' 21' ' ' VAL . 4.4 t -116.25 127.38 73.87 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.709 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.94 -179.847 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.512 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.44 148.11 12.7 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.286 -0.884 . . . . 0.0 108.874 -179.696 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.512 ' HA ' HG23 ' A' ' 8' ' ' THR . 7.1 Cg_endo -79.96 147.65 77.46 Favored 'Cis proline' 0 C--N 1.31 -1.451 0 O-C-N 123.778 1.409 . . . . 0.0 109.35 -0.797 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.681 ' HA ' HG22 ' A' ' 110' ' ' ILE . 79.8 p -89.27 -25.8 21.5 Favored 'General case' 0 C--N 1.295 -1.785 0 O-C-N 121.563 -0.71 . . . . 0.0 109.203 179.788 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.476 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.0 OUTLIER -132.23 162.03 31.97 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.405 -0.81 . . . . 0.0 109.55 -179.927 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.9 37.29 29.98 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 108.65 -1.78 . . . . 0.0 108.65 -179.661 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.773 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.5 mt -92.39 -42.81 9.57 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 123.295 1.521 . . . . 0.0 110.516 -178.388 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 67.42 144.69 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.283 0 CA-C-N 113.321 -1.763 . . . . 0.0 109.936 -179.649 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.591 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 11.3 p-10 -51.2 106.11 0.12 Allowed 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.647 0.737 . . . . 0.0 111.494 -178.513 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.98 14.67 8.35 Favored Glycine 0 N--CA 1.485 1.929 0 C-N-CA 119.354 -1.403 . . . . 0.0 113.006 177.358 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.773 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.9 t -104.87 -171.2 1.88 Allowed 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 121.143 2.471 . . . . 0.0 109.516 179.218 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.732 HG13 ' C ' ' A' ' 67' ' ' LEU . 17.0 t -127.63 135.88 61.95 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.367 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.128 -179.119 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.642 HG13 ' CG2' ' A' ' 69' ' ' VAL . 29.2 m -109.18 155.27 10.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.835 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.533 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -110.35 109.23 19.57 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.264 -0.897 . . . . 0.0 108.834 179.804 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.889 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -105.01 139.5 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.399 -0.813 . . . . 0.0 108.832 179.997 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.763 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.58 161.13 37.25 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.804 -1.185 . . . . 0.0 109.945 179.631 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -134.05 141.57 12.93 Favored Glycine 0 C--N 1.297 -1.623 0 N-CA-C 108.318 -1.913 . . . . 0.0 108.318 179.768 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.594 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.64 125.98 16.6 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.706 -1.467 . . . . 0.0 109.294 179.369 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.49 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.11 28.2 21.19 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 118.873 -1.632 . . . . 0.0 109.599 -179.625 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.61 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.8 mt -88.84 174.59 7.88 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 120.988 -1.301 . . . . 0.0 108.365 179.953 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.66 98.45 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.365 0 O-C-N 120.887 -1.133 . . . . 0.0 109.823 -179.521 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.579 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 77.71 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.724 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.248 -179.253 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.563 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.73 34.37 0.31 Allowed Glycine 0 N--CA 1.486 2.014 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.525 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 66.6 p -144.24 109.73 5.19 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.005 -1.291 . . . . 0.0 111.211 -179.585 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.566 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -43.8 127.01 4.97 Favored 'General case' 0 N--CA 1.491 1.599 0 CA-C-N 115.835 -0.621 . . . . 0.0 109.43 178.02 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.541 ' CD2' ' O ' ' A' ' 30' ' ' THR . 15.3 m-85 -116.98 153.48 32.56 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.388 -0.82 . . . . 0.0 108.834 179.844 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.5 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.5 OUTLIER -105.24 148.97 26.38 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.816 -1.177 . . . . 0.0 108.264 179.059 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.648 HG13 HD21 ' A' ' 67' ' ' LEU . 0.9 OUTLIER -125.82 126.46 70.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.169 -0.957 . . . . 0.0 109.071 -178.103 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -172.77 173.29 45.47 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 117.707 -2.187 . . . . 0.0 112.527 -179.915 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.578 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.36 110.31 22.52 Favored 'General case' 0 C--N 1.314 -0.938 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 179.368 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 63.1 m -129.35 152.11 49.26 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 121.196 -0.94 . . . . 0.0 110.156 -179.612 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.67 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -126.47 135.45 51.37 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.632 -0.668 . . . . 0.0 110.046 179.585 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.905 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.71 114.43 26.35 Favored 'General case' 0 N--CA 1.494 1.764 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.579 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 m -106.86 15.15 7.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.915 -1.115 . . . . 0.0 110.713 -178.633 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.788 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.4 -174.52 0.07 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.819 -1.175 . . . . 0.0 110.135 179.63 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 29.5 p -70.14 96.32 1.07 Allowed 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.407 -0.808 . . . . 0.0 110.013 -179.468 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.04 28.4 34.4 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 120.166 -1.016 . . . . 0.0 111.532 178.749 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.788 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.32 106.04 19.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 O-C-N 120.58 -1.541 . . . . 0.0 107.327 178.83 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.905 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.7 tp -116.47 106.54 13.71 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.59 -1.319 . . . . 0.0 109.775 -177.65 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.116 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -96.13 109.76 22.14 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 120.697 -1.252 . . . . 0.0 108.381 179.281 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.41 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 86.8 m -101.48 147.59 26.2 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.346 -0.847 . . . . 0.0 110.48 -178.371 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.655 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 31.1 t30 -96.66 137.87 21.43 Favored Pre-proline 0 N--CA 1.502 2.169 0 O-C-N 121.01 -1.056 . . . . 0.0 108.826 178.878 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.582 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 8.0 Cg_endo -75.76 26.71 0.4 Allowed 'Trans proline' 0 N--CA 1.496 1.649 0 C-N-CA 125.188 3.925 . . . . 0.0 111.507 -179.068 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.655 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -126.1 9.12 7.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.424 -1.423 . . . . 0.0 109.576 179.881 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.54 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.83 15.97 2.49 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 179.502 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -77.91 87.14 4.11 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.059 -178.675 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.611 ' CB ' HG12 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -98.98 -168.22 1.6 Allowed 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 178.569 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.43 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 179.13 133.98 0.09 Allowed 'General case' 0 N--CA 1.486 1.329 0 O-C-N 120.766 -1.209 . . . . 0.0 111.42 -179.428 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.879 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -159.14 153.62 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.525 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.493 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.566 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.51 144.63 27.02 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.683 -1.261 . . . . 0.0 109.645 -179.86 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.002 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.67 107.42 1.41 Allowed 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 122.525 1.155 . . . . 0.0 109.502 178.7 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.556 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 p-10 -61.39 -139.97 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.782 179.98 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.579 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.06 -50.73 58.1 Favored 'General case' 0 N--CA 1.5 2.031 0 O-C-N 121.382 -0.824 . . . . 0.0 110.664 -178.799 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -103.48 -32.64 9.39 Favored 'General case' 0 C--N 1.286 -2.165 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 178.713 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.994 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.0 65.72 0.65 Allowed Glycine 0 C--N 1.296 -1.652 0 N-CA-C 110.304 -1.118 . . . . 0.0 110.304 178.309 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.1 m -100.54 128.96 46.43 Favored 'General case' 0 N--CA 1.484 1.245 0 O-C-N 121.523 -0.987 . . . . 0.0 108.808 178.856 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.879 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -137.9 108.65 6.64 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.242 -0.983 . . . . 0.0 109.588 -179.516 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.462 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 27.3 p -123.82 120.24 32.04 Favored 'General case' 0 C--N 1.305 -1.33 0 O-C-N 121.246 -0.909 . . . . 0.0 109.513 -179.982 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.76 146.05 31.06 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.485 -0.759 . . . . 0.0 109.321 179.819 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 55.4 p -98.57 144.56 27.75 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.295 -0.878 . . . . 0.0 109.287 179.945 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.732 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -144.02 165.01 28.97 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.434 -0.791 . . . . 0.0 109.413 -179.216 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.657 HG22 HG22 ' A' ' 18' ' ' VAL . 3.8 p -95.04 123.71 38.68 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.127 -0.983 . . . . 0.0 109.329 -179.887 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.642 ' CG2' HG13 ' A' ' 19' ' ' VAL . 16.6 m -137.89 142.49 35.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 120.963 -1.085 . . . . 0.0 109.701 -179.292 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.591 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 5.4 ptt180 -140.71 -166.79 2.21 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 120.677 -1.264 . . . . 0.0 109.968 -179.989 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.549 ' HA ' ' CB ' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -71.66 -80.41 0.06 Allowed 'General case' 0 N--CA 1.487 1.404 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.809 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.504 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.3 OUTLIER -64.87 135.79 56.13 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 178.648 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.67 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -161.08 133.6 6.09 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 117.862 -1.535 . . . . 0.0 110.563 -177.643 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.556 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.4 OUTLIER -33.64 120.74 0.41 Allowed 'General case' 0 N--CA 1.493 1.694 0 CA-C-O 121.615 0.722 . . . . 0.0 110.391 -178.472 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.116 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.4 50.52 2.4 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.456 -0.878 . . . . 0.0 111.611 -178.916 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.582 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.7 OUTLIER -38.42 116.88 0.58 Allowed 'General case' 0 N--CA 1.51 2.567 0 O-C-N 121.094 -1.239 . . . . 0.0 110.053 179.41 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.627 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.28 125.71 34.38 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 120.8 -1.187 . . . . 0.0 109.455 179.855 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.575 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.0 t80 -64.14 58.6 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.819 -1.176 . . . . 0.0 110.086 179.82 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.9 t70 -160.51 20.02 0.14 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.059 -1.026 . . . . 0.0 109.668 179.898 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.46 -28.64 5.19 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 179.813 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.468 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 40.7 p -94.23 160.57 14.63 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.066 -1.255 . . . . 0.0 110.293 -179.52 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.49 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -108.02 136.8 47.11 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.794 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.627 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.9 t90 -80.74 -20.34 42.97 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.809 -1.182 . . . . 0.0 110.351 -178.688 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.43 176.24 20.22 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 108.644 -1.782 . . . . 0.0 108.644 -179.565 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -62.55 109.97 1.55 Allowed 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.166 -1.196 . . . . 0.0 107.779 179.168 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.63 HG21 ' CB ' ' A' ' 46' ' ' ALA . 37.1 t -83.22 103.53 10.62 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -179.104 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.575 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -65.77 111.71 3.37 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.383 -0.823 . . . . 0.0 109.894 -179.257 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.549 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -65.83 -3.67 5.43 Favored 'General case' 0 N--CA 1.5 2.055 0 C-N-CA 118.334 -1.346 . . . . 0.0 109.886 179.457 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.4 p -86.93 11.61 13.08 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.739 -1.225 . . . . 0.0 108.794 179.487 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.575 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -127.25 -48.22 1.45 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.428 -0.795 . . . . 0.0 108.989 179.944 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.36 -179.85 4.04 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.559 -0.713 . . . . 0.0 109.504 -179.948 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.1 113.66 27.32 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.318 -0.864 . . . . 0.0 109.079 -179.986 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.522 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.6 m -97.12 124.89 41.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.879 -1.138 . . . . 0.0 109.438 -179.512 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.567 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -104.87 147.15 28.06 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 122.403 1.097 . . . . 0.0 111.38 -179.27 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.497 ' CG1' HG11 ' A' ' 7' ' ' VAL . 43.4 t -103.53 112.04 35.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.977 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 177.577 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.417 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.06 -170.44 16.73 Favored Glycine 0 N--CA 1.488 2.137 0 C-N-CA 118.076 -2.011 . . . . 0.0 111.738 -177.607 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.485 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -117.08 -179.43 3.7 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 -179.126 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.559 ' HB2' ' C20' ' A' ' 114' ' ' CHR . 4.5 p -166.83 167.25 15.12 Favored 'General case' 0 C--N 1.293 -1.885 0 O-C-N 121.337 -0.852 . . . . 0.0 109.287 -179.523 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.7 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 4.7 m-20 -101.6 -12.54 18.38 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.134 -0.979 . . . . 0.0 109.452 179.891 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.7 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 74.77 38.15 0.48 Allowed 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.451 -0.781 . . . . 0.0 109.283 179.89 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -138.85 -34.28 0.61 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.525 -0.734 . . . . 0.0 110.636 -179.382 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.607 ' HA2' H192 ' A' ' 114' ' ' CHR . . . -177.82 -42.87 0.06 OUTLIER Glycine 0 N--CA 1.482 1.75 0 N-CA-C 107.59 -2.204 . . . . 0.0 107.59 -179.627 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.54 -178.74 7.49 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 121.62 -0.929 . . . . 0.0 109.355 178.9 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -173.29 -165.97 30.97 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 108.737 -1.745 . . . . 0.0 108.737 -179.471 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.596 ' HG3' HD22 ' A' ' 26' ' ' LEU . 4.6 Cg_exo -46.39 -175.86 0.0 OUTLIER 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 123.57 2.847 . . . . 0.0 109.923 179.512 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -94.78 172.13 8.35 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.975 -1.078 . . . . 0.0 110.574 -178.957 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.417 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -110.47 159.71 13.71 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 179.897 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.36 128.17 55.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.36 -1.082 . . . . 0.0 109.29 -179.378 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.567 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.75 119.49 17.06 Favored 'General case' 0 C--N 1.289 -2.042 0 O-C-N 121.591 -0.693 . . . . 0.0 109.358 179.569 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.852 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.99 171.07 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.228 -0.92 . . . . 0.0 109.116 -179.945 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.476 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.86 154.91 48.46 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.088 -1.007 . . . . 0.0 109.811 -179.763 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.852 ' CE2' HD12 ' A' ' 110' ' ' ILE . 76.1 m-85 -133.11 94.25 3.32 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 121.1 -1.0 . . . . 0.0 109.467 -179.752 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.434 ' O ' ' OD1' ' A' ' 113' ' ' ASN . 19.7 p30 . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 117.988 -1.006 . . . . 0.0 109.44 -179.967 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.853 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 036 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -109.69 148.86 39.03 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.227 -0.921 . . . . 0.0 109.504 179.982 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.575 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 4.8 Cg_exo -60.38 157.23 36.84 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 C-N-CA 122.321 2.014 . . . . 0.0 110.581 -179.988 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.549 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.76 -169.69 0.14 Allowed 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 179.146 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.549 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -167.4 130.69 1.74 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 120.872 -1.143 . . . . 0.0 110.613 -179.16 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.954 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -113.19 108.66 17.58 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 123.166 1.46 . . . . 0.0 109.227 179.418 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.911 HG22 HG23 ' A' ' 21' ' ' VAL . 4.3 t -116.89 141.37 35.37 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.717 0 CA-C-N 114.185 -1.371 . . . . 0.0 109.953 -179.716 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.47 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -178.07 150.61 0.76 Allowed Pre-proline 0 N--CA 1.487 1.415 0 O-C-N 121.248 -0.907 . . . . 0.0 108.668 -179.613 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.47 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -75.67 152.24 96.92 Favored 'Cis proline' 0 C--N 1.312 -1.39 0 C-N-CA 123.485 -1.465 . . . . 0.0 109.679 -0.699 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.545 ' HA ' HG22 ' A' ' 110' ' ' ILE . 0.8 OUTLIER -90.75 -24.85 20.25 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.768 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.507 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 15.7 m -136.71 164.15 28.92 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.451 -0.781 . . . . 0.0 109.482 179.856 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.39 37.47 31.38 Favored Glycine 0 N--CA 1.497 2.702 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 -179.717 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.776 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.6 mt -92.18 -43.2 9.47 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 123.203 1.477 . . . . 0.0 110.421 -178.348 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.91 144.45 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.312 0 CA-C-N 113.459 -1.7 . . . . 0.0 109.929 -179.657 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.611 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.1 p-10 -50.79 107.56 0.18 Allowed 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.521 0.677 . . . . 0.0 111.458 -178.583 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.32 13.5 9.77 Favored Glycine 0 N--CA 1.485 1.938 0 C-N-CA 119.435 -1.364 . . . . 0.0 112.935 177.342 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.776 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.6 t -104.45 -172.61 2.13 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 121.213 2.507 . . . . 0.0 109.734 179.261 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.748 HG13 ' C ' ' A' ' 67' ' ' LEU . 15.9 t -129.37 138.3 54.7 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.371 0 CA-C-N 114.761 -1.109 . . . . 0.0 111.019 -179.014 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.556 HG23 ' CD1' ' A' ' 67' ' ' LEU . 27.8 m -113.67 154.62 15.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.922 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.504 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -108.55 109.38 20.6 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.208 -0.932 . . . . 0.0 108.996 179.936 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.911 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -103.49 140.89 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 179.789 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.954 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -136.35 160.54 38.42 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 118.659 -1.216 . . . . 0.0 109.89 179.734 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.589 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.18 143.81 15.46 Favored Glycine 0 C--N 1.293 -1.814 0 N-CA-C 108.001 -2.04 . . . . 0.0 108.001 179.716 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.575 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.26 124.96 12.55 Favored 'General case' 0 C--N 1.294 -1.821 0 O-C-N 120.908 -1.348 . . . . 0.0 108.882 179.185 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.525 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.86 27.58 23.59 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 119.339 -1.41 . . . . 0.0 109.659 -179.68 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.7 mt -86.72 175.53 8.21 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 120.909 -1.348 . . . . 0.0 108.62 -179.781 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.54 97.12 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.047 -1.033 . . . . 0.0 109.58 -179.821 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.585 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.22 76.19 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.495 -178.978 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.569 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.21 33.27 0.28 Allowed Glycine 0 N--CA 1.486 1.985 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.26 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.61 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.4 t -148.13 115.32 6.18 Favored 'General case' 0 C--N 1.308 -1.214 0 O-C-N 120.831 -1.394 . . . . 0.0 111.276 179.973 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.3 127.84 5.88 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.781 178.367 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.61 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.8 m-85 -119.09 149.03 42.38 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 179.51 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.5 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.62 163.86 12.31 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.61 -1.307 . . . . 0.0 107.518 178.631 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.707 HG11 HG21 ' A' ' 65' ' ' THR . 9.2 p -149.08 114.62 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.045 -1.035 . . . . 0.0 110.143 -177.74 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.14 -175.41 37.16 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 118.365 -1.874 . . . . 0.0 111.731 -179.865 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.581 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.4 OUTLIER -100.34 109.01 21.19 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-O 121.829 0.823 . . . . 0.0 108.819 -179.695 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.7 m -130.47 149.04 52.33 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.231 -0.918 . . . . 0.0 109.6 179.751 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.448 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.48 139.24 54.07 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.301 -0.875 . . . . 0.0 110.732 -179.041 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 114.78 26.6 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.174 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.4 m -105.53 15.29 6.97 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.999 -1.063 . . . . 0.0 110.573 -178.639 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.757 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.09 -175.42 0.09 Allowed 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.955 -1.091 . . . . 0.0 110.003 179.734 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 56.8 p -71.95 97.45 1.86 Allowed 'General case' 0 N--CA 1.485 1.305 0 O-C-N 121.364 -0.835 . . . . 0.0 109.748 -179.73 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.65 27.71 34.5 Favored Glycine 0 N--CA 1.492 2.404 0 C-N-CA 120.235 -0.983 . . . . 0.0 111.423 178.985 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.757 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.05 106.24 19.98 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 O-C-N 120.59 -1.536 . . . . 0.0 107.29 178.829 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -116.71 104.55 11.47 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 120.478 -1.388 . . . . 0.0 109.81 -177.715 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.088 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.2 109.45 22.21 Favored 'General case' 0 N--CA 1.485 1.276 0 O-C-N 120.834 -1.166 . . . . 0.0 107.945 178.828 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -107.4 163.9 12.65 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.964 -1.085 . . . . 0.0 110.297 -178.73 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.754 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 38.8 t30 -108.56 128.77 24.98 Favored Pre-proline 0 N--CA 1.501 2.111 0 O-C-N 121.46 -0.775 . . . . 0.0 109.503 -179.386 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -70.14 19.76 0.19 Allowed 'Trans proline' 0 CA--C 1.544 1.017 0 C-N-CA 122.088 1.859 . . . . 0.0 112.386 -179.867 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.754 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -108.96 4.85 23.75 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.388 -1.445 . . . . 0.0 108.868 179.157 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.578 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.79 16.7 2.68 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 179.497 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -81.67 90.58 6.33 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.974 -0.691 . . . . 0.0 111.088 -178.446 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.623 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.39 -171.08 1.77 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 178.015 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.446 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.85 134.99 0.09 Allowed 'General case' 0 C--N 1.305 -1.356 0 O-C-N 120.403 -1.435 . . . . 0.0 111.554 -179.357 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.777 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.5 p -150.07 159.11 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 N-CA-C 107.094 -1.447 . . . . 0.0 107.094 177.894 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.57 146.05 25.66 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.543 -1.348 . . . . 0.0 109.726 -179.724 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.24 108.71 3.28 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 122.31 1.052 . . . . 0.0 109.629 178.999 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.547 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 3.5 t0 -63.02 -138.65 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.526 179.858 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.585 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -53.7 -51.45 63.2 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.289 -0.882 . . . . 0.0 110.21 -178.931 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 9.8 p-10 -98.58 -37.08 9.68 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 178.563 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.987 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.06 65.62 0.64 Allowed Glycine 0 C--N 1.297 -1.588 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.412 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.589 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 53.7 p -98.49 132.62 43.77 Favored 'General case' 0 N--CA 1.483 1.215 0 O-C-N 121.426 -1.043 . . . . 0.0 109.245 179.28 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.777 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.02 108.53 6.55 Favored 'General case' 0 C--N 1.296 -1.754 0 C-N-CA 119.235 -0.986 . . . . 0.0 109.52 -179.708 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.432 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 21.8 p -124.82 120.75 32.61 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.147 -0.97 . . . . 0.0 109.797 -179.803 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.707 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -148.04 146.72 28.99 Favored 'General case' 0 C--N 1.3 -1.587 0 O-C-N 121.581 -0.7 . . . . 0.0 109.304 179.648 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.4 p -100.61 138.88 37.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.322 -0.861 . . . . 0.0 109.404 179.975 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.748 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -138.03 165.54 26.32 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.404 -0.81 . . . . 0.0 109.529 -179.405 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.724 HG22 HG22 ' A' ' 18' ' ' VAL . 2.2 p -96.8 125.7 41.44 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.068 -1.02 . . . . 0.0 109.354 -179.857 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.572 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -136.8 144.42 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.99 -1.069 . . . . 0.0 109.888 -179.26 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.611 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.0 OUTLIER -149.0 -174.93 4.77 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 120.455 -1.403 . . . . 0.0 110.998 -179.845 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.61 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.94 -101.84 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 -179.766 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -57.05 140.46 49.06 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.815 -1.178 . . . . 0.0 108.052 179.43 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.58 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -161.79 137.13 7.45 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 118.642 -1.223 . . . . 0.0 109.759 -178.118 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.522 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 10.3 mm-40 -34.97 122.06 0.55 Allowed 'General case' 0 N--CA 1.49 1.546 0 CA-C-O 121.387 0.613 . . . . 0.0 110.351 -178.468 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.088 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.29 51.25 1.86 Allowed Glycine 0 N--CA 1.493 2.458 0 C-N-CA 120.548 -0.835 . . . . 0.0 111.06 -179.268 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -39.24 115.39 0.49 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.04 -1.271 . . . . 0.0 110.108 179.572 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.691 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.49 126.46 34.45 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 120.928 -1.108 . . . . 0.0 109.495 -179.895 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.586 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.8 t80 -64.38 58.46 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.989 0 O-C-N 120.876 -1.14 . . . . 0.0 110.091 179.685 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.53 ' N ' ' O ' ' A' ' 77' ' ' LEU . 17.0 t0 -160.19 19.65 0.15 Allowed 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.987 -1.07 . . . . 0.0 109.664 179.83 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.05 -28.03 5.26 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.999 -1.241 . . . . 0.0 109.999 179.931 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.414 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 10.3 p -94.27 161.0 14.43 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.034 -1.274 . . . . 0.0 110.384 -179.446 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.48 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -107.97 138.13 44.77 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.84 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.691 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -83.61 -17.96 39.82 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.71 -1.244 . . . . 0.0 110.674 -178.411 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.0 176.43 19.99 Favored Glycine 0 N--CA 1.485 1.941 0 N-CA-C 108.644 -1.783 . . . . 0.0 108.644 -179.648 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.53 104.45 1.01 Allowed 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 179.188 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.658 HG21 ' HB3' ' A' ' 46' ' ' ALA . 41.0 t -76.09 106.62 6.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.287 -0.883 . . . . 0.0 109.133 -178.926 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.546 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.7 OUTLIER -65.68 111.24 3.1 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.493 -0.755 . . . . 0.0 110.026 -179.352 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.61 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -63.47 -5.71 4.07 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.813 179.353 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 13.5 p -86.58 -0.93 57.14 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 120.747 -1.221 . . . . 0.0 109.202 179.681 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.546 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -112.87 -50.1 2.9 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.29 -0.881 . . . . 0.0 108.995 179.977 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.94 -179.04 3.83 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.488 -0.757 . . . . 0.0 109.42 179.782 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.06 115.75 30.8 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.386 -0.821 . . . . 0.0 108.905 179.992 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.531 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -96.87 121.43 38.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.851 -1.156 . . . . 0.0 109.483 -179.455 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.619 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.85 146.29 28.5 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.437 1.113 . . . . 0.0 111.215 -179.32 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 97.3 t -102.46 109.77 27.35 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 N-CA-C 106.552 -1.647 . . . . 0.0 106.552 177.632 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.439 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -147.6 -173.11 18.38 Favored Glycine 0 N--CA 1.486 2.016 0 C-N-CA 118.142 -1.98 . . . . 0.0 111.709 -177.601 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.5 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -113.71 -178.95 3.5 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.069 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.589 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.0 OUTLIER -175.88 170.62 2.76 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.219 -0.926 . . . . 0.0 109.711 -179.203 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.423 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -122.46 -159.33 0.82 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.025 -1.047 . . . . 0.0 108.856 179.786 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.423 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.86 36.08 4.34 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.685 -1.259 . . . . 0.0 109.2 -179.926 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.55 -33.07 5.68 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.359 -0.838 . . . . 0.0 110.034 -179.669 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.965 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 164.89 -35.64 0.27 Allowed Glycine 0 N--CA 1.481 1.696 0 N-CA-C 107.776 -2.13 . . . . 0.0 107.776 -179.673 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.61 -177.72 5.76 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-O 122.007 0.908 . . . . 0.0 109.785 179.279 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.38 -161.85 15.27 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 108.35 -1.9 . . . . 0.0 108.35 -179.44 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.504 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.3 Cg_exo -47.08 177.98 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.693 0 CA-C-N 118.874 1.337 . . . . 0.0 110.202 179.324 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -92.27 -175.17 3.96 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.06 -1.025 . . . . 0.0 110.511 -178.83 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.439 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.24 163.46 14.68 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.944 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.422 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.9 128.92 52.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.426 -1.044 . . . . 0.0 109.222 -179.441 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.619 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.22 123.22 23.26 Favored 'General case' 0 C--N 1.29 -2.015 0 O-C-N 121.687 -0.633 . . . . 0.0 109.562 179.672 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.917 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.72 167.69 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 O-C-N 121.221 -0.924 . . . . 0.0 109.193 -179.925 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.507 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -134.73 154.26 51.65 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.277 -0.889 . . . . 0.0 109.565 -179.873 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.917 ' CE1' HD12 ' A' ' 110' ' ' ILE . 30.3 m-85 -122.98 117.43 25.48 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.15 -0.969 . . . . 0.0 109.566 -179.729 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.418 ' C ' ' O ' ' A' ' 112' ' ' PHE . 20.9 p30 . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 118.018 -0.992 . . . . 0.0 109.479 -179.972 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.965 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 121.301 0.572 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 037 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.819 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -120.58 168.36 10.83 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.966 . . . . 0.0 109.516 -179.94 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.819 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.4 Cg_exo -59.89 158.34 29.62 Favored 'Trans proline' 0 C--N 1.309 -1.537 0 C-N-CA 122.355 2.037 . . . . 0.0 110.577 179.971 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.537 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.42 -169.81 0.15 Allowed 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.147 -1.057 . . . . 0.0 108.147 179.239 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.593 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -166.5 131.46 2.2 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 120.771 -1.206 . . . . 0.0 110.863 -179.111 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.949 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.6 t -112.46 108.58 17.76 Favored 'General case' 0 C--N 1.296 -1.738 0 CA-C-O 123.084 1.421 . . . . 0.0 109.117 179.357 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.79 HG22 HG23 ' A' ' 21' ' ' VAL . 2.4 t -115.31 140.38 36.99 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.699 0 CA-C-N 114.275 -1.329 . . . . 0.0 110.102 -179.521 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.496 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -176.04 149.82 1.03 Allowed Pre-proline 0 N--CA 1.487 1.375 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.772 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.496 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.2 Cg_endo -77.43 152.57 93.88 Favored 'Cis proline' 0 C--N 1.312 -1.353 0 C-N-CA 123.572 -1.428 . . . . 0.0 109.313 -0.813 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.639 ' HA ' HG22 ' A' ' 110' ' ' ILE . 3.5 m -89.76 -26.51 20.58 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 179.761 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.48 ' HB3' ' HB2' ' A' ' 111' ' ' SER . 5.3 m -135.23 164.31 27.99 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.587 -0.696 . . . . 0.0 109.609 179.858 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.3 37.03 29.14 Favored Glycine 0 N--CA 1.496 2.664 0 N-CA-C 108.767 -1.733 . . . . 0.0 108.767 -179.841 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.766 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.6 mt -93.23 -42.69 9.21 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-O 123.242 1.496 . . . . 0.0 110.405 -178.406 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.83 145.3 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.277 0 CA-C-N 113.322 -1.763 . . . . 0.0 109.954 -179.735 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.613 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 14.2 p-10 -51.26 106.81 0.15 Allowed 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.493 0.663 . . . . 0.0 111.513 -178.749 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.54 13.16 9.01 Favored Glycine 0 N--CA 1.483 1.823 0 C-N-CA 119.401 -1.38 . . . . 0.0 112.986 177.317 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.766 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -105.31 -172.4 2.09 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 121.242 2.521 . . . . 0.0 109.673 179.167 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.738 HG13 ' O ' ' A' ' 67' ' ' LEU . 20.2 t -126.6 135.56 63.39 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 114.866 -1.061 . . . . 0.0 111.097 -178.897 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.66 ' CG1' HD13 ' A' ' 13' ' ' LEU . 17.3 m -109.04 156.82 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.664 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -114.06 109.27 18.18 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.091 -1.005 . . . . 0.0 109.16 179.949 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.79 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -104.07 140.01 23.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 179.749 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.949 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.77 160.4 38.29 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 118.605 -1.238 . . . . 0.0 109.85 179.856 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.595 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -131.4 144.96 16.6 Favored Glycine 0 C--N 1.293 -1.807 0 N-CA-C 108.179 -1.968 . . . . 0.0 108.179 179.751 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.571 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.88 124.53 11.79 Favored 'General case' 0 C--N 1.295 -1.792 0 O-C-N 120.901 -1.352 . . . . 0.0 108.785 179.182 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.53 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.99 26.7 23.47 Favored Glycine 0 N--CA 1.487 2.086 0 C-N-CA 119.337 -1.411 . . . . 0.0 109.631 -179.623 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.603 HD22 ' HG3' ' A' ' 105' ' ' PRO . 1.9 mt -87.43 174.57 8.44 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 120.897 -1.355 . . . . 0.0 108.445 -179.901 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.42 96.96 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.04 -1.037 . . . . 0.0 109.674 -179.714 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.659 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.05 76.83 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.45 -179.091 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.01 33.77 0.32 Allowed Glycine 0 N--CA 1.486 2.027 0 N-CA-C 109.731 -1.347 . . . . 0.0 109.731 179.347 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.554 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 1.2 t -148.15 114.88 6.03 Favored 'General case' 0 C--N 1.309 -1.181 0 O-C-N 120.869 -1.371 . . . . 0.0 111.098 179.899 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.45 129.86 3.93 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.996 178.55 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.553 ' CE1' ' OD1' ' A' ' 99' ' ' ASP . 10.7 m-85 -119.47 150.84 39.55 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.368 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.506 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -102.05 159.39 15.41 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.703 -1.248 . . . . 0.0 107.856 178.728 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.645 HG22 HG11 ' A' ' 21' ' ' VAL . 5.1 p -144.03 117.27 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.075 -1.016 . . . . 0.0 109.852 -177.914 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.523 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.12 -178.73 40.18 Favored Glycine 0 N--CA 1.494 2.518 0 C-N-CA 118.324 -1.893 . . . . 0.0 111.849 -179.86 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.592 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -100.43 108.88 20.98 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -179.862 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.24 148.34 52.06 Favored 'General case' 0 C--N 1.296 -1.731 0 O-C-N 121.286 -0.884 . . . . 0.0 109.704 179.777 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.512 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.96 138.63 54.34 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.274 -0.891 . . . . 0.0 110.776 -179.005 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.867 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.45 114.75 26.55 Favored 'General case' 0 N--CA 1.493 1.684 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 178.137 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -106.12 14.79 7.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.934 -1.104 . . . . 0.0 110.64 -178.716 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.61 -175.65 0.08 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 120.926 -1.109 . . . . 0.0 110.101 179.694 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.775 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.3 97.53 1.26 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 121.799 0.809 . . . . 0.0 110.031 -179.605 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.26 27.11 37.64 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 120.261 -0.971 . . . . 0.0 111.429 178.785 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -114.85 106.14 20.03 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 O-C-N 120.617 -1.519 . . . . 0.0 107.375 178.818 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.867 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -117.01 104.71 11.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.459 -1.401 . . . . 0.0 109.629 -177.803 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.058 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.94 109.55 22.28 Favored 'General case' 0 N--CA 1.485 1.316 0 O-C-N 120.808 -1.183 . . . . 0.0 108.415 179.093 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.6 t -105.98 162.83 13.25 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.952 -1.092 . . . . 0.0 110.115 -179.254 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.548 HD22 ' HB3' ' A' ' 50' ' ' ALA . 17.0 t30 -107.01 140.89 21.84 Favored Pre-proline 0 N--CA 1.504 2.259 0 O-C-N 121.348 -0.845 . . . . 0.0 110.13 -179.218 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.573 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 8.2 Cg_endo -76.36 27.65 0.41 Allowed 'Trans proline' 0 C--N 1.318 -1.029 0 C-N-CA 122.662 2.241 . . . . 0.0 111.636 -179.665 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.548 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -121.49 3.57 10.21 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.394 -1.441 . . . . 0.0 109.522 -179.869 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.523 ' O ' ' HA2' ' A' ' 35' ' ' GLY . 0.0 OUTLIER -138.48 15.41 2.75 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 179.435 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -80.11 91.68 5.55 Favored 'General case' 0 C--N 1.305 -1.356 0 O-C-N 121.508 -0.745 . . . . 0.0 110.815 -178.675 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.59 -168.53 1.33 Allowed 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.387 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.98 135.2 0.09 Allowed 'General case' 0 N--CA 1.486 1.349 0 O-C-N 120.633 -1.292 . . . . 0.0 111.486 -179.381 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.872 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -149.02 157.53 6.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 177.935 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.567 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.28 146.61 24.96 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.636 -1.29 . . . . 0.0 109.897 -179.489 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.26 108.31 2.68 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-O 122.361 1.077 . . . . 0.0 109.622 178.847 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.533 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.6 t0 -62.95 -138.94 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.005 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.822 -179.867 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.659 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.9 -51.99 36.42 Favored 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.349 -0.845 . . . . 0.0 110.676 -178.657 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.06 -32.36 9.24 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.714 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.0 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.07 64.89 0.61 Allowed Glycine 0 C--N 1.298 -1.583 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 178.262 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 50.5 m -99.57 129.31 45.72 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 121.465 -1.021 . . . . 0.0 108.664 178.772 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.872 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.74 108.63 6.69 Favored 'General case' 0 C--N 1.296 -1.722 0 C-N-CA 119.144 -1.022 . . . . 0.0 109.805 -179.329 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 51.8 p -122.15 119.45 31.32 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.259 -0.901 . . . . 0.0 109.455 179.936 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.571 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.22 143.46 30.29 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.519 -0.738 . . . . 0.0 109.417 179.894 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 15.9 p -100.01 140.63 33.96 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.406 -0.809 . . . . 0.0 109.406 179.961 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.789 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.37 168.82 18.97 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.405 -0.809 . . . . 0.0 109.382 -179.426 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.716 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -96.82 124.86 40.92 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.03 -1.044 . . . . 0.0 109.424 -179.823 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.598 ' CG2' HG13 ' A' ' 19' ' ' VAL . 15.9 m -137.05 143.54 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.932 -1.105 . . . . 0.0 109.728 -179.259 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.613 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.1 ptt180 -148.79 -175.34 4.91 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.519 -1.363 . . . . 0.0 110.9 -179.835 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.612 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.76 -101.2 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.7 -179.413 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.507 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -56.86 142.03 42.61 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.812 -1.18 . . . . 0.0 108.319 179.785 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.582 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.93 134.59 4.38 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 118.783 -1.167 . . . . 0.0 109.64 -178.209 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.554 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -33.81 122.82 0.46 Allowed 'General case' 0 N--CA 1.493 1.697 0 CA-C-O 121.519 0.676 . . . . 0.0 110.465 -178.138 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.058 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.2 49.15 2.7 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.273 -179.187 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.573 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -38.47 115.0 0.42 Allowed 'General case' 0 N--CA 1.509 2.519 0 O-C-N 121.096 -1.237 . . . . 0.0 109.909 179.615 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.726 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -86.72 126.42 34.55 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 120.938 -1.101 . . . . 0.0 109.357 179.972 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.585 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 24.5 t80 -63.48 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.97 0 O-C-N 120.902 -1.124 . . . . 0.0 110.307 179.912 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.548 ' N ' ' O ' ' A' ' 77' ' ' LEU . 22.2 t0 -162.04 20.18 0.1 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.992 -1.068 . . . . 0.0 109.786 179.736 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.65 -27.76 5.17 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 179.821 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.445 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 14.3 p -93.15 160.23 14.94 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.047 -1.267 . . . . 0.0 110.26 -179.466 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.479 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.4 OUTLIER -107.63 136.69 46.96 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.835 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.726 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -82.56 -19.1 39.19 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.848 -1.158 . . . . 0.0 110.407 -178.667 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.54 175.41 19.14 Favored Glycine 0 N--CA 1.485 1.908 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.613 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -64.84 107.14 1.37 Allowed 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 179.271 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.622 HG21 ' HB3' ' A' ' 46' ' ' ALA . 47.2 t -79.62 106.71 11.11 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.362 -0.836 . . . . 0.0 109.262 -179.014 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.54 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -67.69 111.67 4.37 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.407 -0.808 . . . . 0.0 109.805 -179.554 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.612 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -63.16 -5.69 3.49 Favored 'General case' 0 N--CA 1.5 2.046 0 C-N-CA 118.189 -1.404 . . . . 0.0 109.826 179.414 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -86.14 0.02 54.58 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.644 -1.285 . . . . 0.0 109.158 179.51 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.54 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.66 -49.72 2.87 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.366 -0.834 . . . . 0.0 109.007 -179.98 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.77 179.63 4.21 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.433 -0.792 . . . . 0.0 109.482 179.944 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.94 116.13 31.95 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.445 -0.785 . . . . 0.0 108.922 179.908 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.85 121.8 39.11 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.86 -1.15 . . . . 0.0 109.371 -179.381 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.6 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.68 146.51 27.63 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.411 1.101 . . . . 0.0 111.359 -179.213 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 65.7 t -102.95 110.06 28.53 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.003 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 177.502 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.76 -173.01 17.61 Favored Glycine 0 N--CA 1.487 2.063 0 C-N-CA 118.041 -2.028 . . . . 0.0 111.828 -177.441 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.593 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -115.98 -178.11 3.32 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 -179.057 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.554 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 1.0 OUTLIER -172.28 166.46 5.9 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.234 -0.916 . . . . 0.0 109.331 -179.527 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.719 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 7.9 m-20 -99.46 -13.41 19.53 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.173 -0.955 . . . . 0.0 109.402 179.882 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.719 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 75.47 36.9 0.46 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.451 -0.78 . . . . 0.0 109.222 179.9 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.09 -33.51 0.83 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.53 -0.731 . . . . 0.0 110.704 -179.399 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.476 ' HA2' H192 ' A' ' 114' ' ' CHR . . . -177.59 -42.62 0.06 OUTLIER Glycine 0 N--CA 1.481 1.695 0 N-CA-C 107.687 -2.165 . . . . 0.0 107.687 -179.636 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.43 -178.49 7.18 Favored 'General case' 0 C--N 1.307 -1.245 0 O-C-N 121.527 -0.984 . . . . 0.0 109.431 179.05 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.64 -166.18 33.36 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -179.554 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.603 ' HG3' HD22 ' A' ' 26' ' ' LEU . 4.3 Cg_exo -49.09 -177.37 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.677 0 CA-C-N 118.7 1.25 . . . . 0.0 110.288 179.525 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -94.54 -176.85 4.04 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.082 -1.011 . . . . 0.0 110.419 -179.02 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -120.45 161.3 14.73 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 -179.969 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.409 ' O ' HG12 ' A' ' 108' ' ' VAL . 1.2 t -100.87 126.37 54.59 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 O-C-N 121.349 -1.089 . . . . 0.0 109.188 -179.472 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.6 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.1 119.76 16.75 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.745 -0.597 . . . . 0.0 109.431 179.669 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.766 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.96 168.53 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.201 -0.937 . . . . 0.0 109.303 -179.956 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB2' ' HB3' ' A' ' 11' ' ' SER . 2.4 m -138.2 151.31 47.57 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.384 -0.823 . . . . 0.0 109.542 -179.955 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.766 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 22.8 m-85 -126.38 104.91 8.42 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.146 -0.971 . . . . 0.0 109.531 -179.674 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 19.7 p30 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.502 -179.98 . . . . . . . . 0 0 . 1 . 037 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.659 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 0 0 . 1 . 038 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.63 143.99 39.42 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.206 -0.934 . . . . 0.0 109.222 179.781 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.612 ' HB3' HD23 ' A' ' 26' ' ' LEU . 3.2 Cg_exo -60.85 156.52 43.07 Favored 'Trans proline' 0 C--N 1.31 -1.468 0 C-N-CA 122.063 1.842 . . . . 0.0 110.415 179.984 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.607 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -146.62 159.24 43.7 Favored 'General case' 0 C--N 1.292 -1.899 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 -179.617 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -146.51 125.36 12.7 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-O 122.43 1.109 . . . . 0.0 110.129 -179.715 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.903 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.1 t -116.28 109.02 16.83 Favored 'General case' 0 C--N 1.293 -1.858 0 CA-C-O 123.129 1.442 . . . . 0.0 109.622 179.968 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.948 HG22 HG23 ' A' ' 21' ' ' VAL . 8.0 t -116.92 137.84 49.51 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.709 0 CA-C-N 114.074 -1.421 . . . . 0.0 109.862 -179.874 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.49 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -174.37 151.02 1.57 Allowed Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.331 -0.856 . . . . 0.0 108.804 -179.617 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.49 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.3 Cg_endo -77.47 150.94 91.85 Favored 'Cis proline' 0 C--N 1.312 -1.383 0 C-N-CA 123.539 -1.442 . . . . 0.0 109.392 -0.907 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.677 ' HA ' HG22 ' A' ' 110' ' ' ILE . 89.6 p -92.52 -23.08 19.21 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 121.433 -0.792 . . . . 0.0 109.27 179.692 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.499 ' CB ' ' HB3' ' A' ' 111' ' ' SER . 7.0 m -132.16 159.97 37.41 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.484 -0.76 . . . . 0.0 109.542 -179.859 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.73 37.61 29.76 Favored Glycine 0 N--CA 1.496 2.637 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.633 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.773 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.4 mt -91.1 -43.69 9.74 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-O 123.146 1.45 . . . . 0.0 110.641 -178.273 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.35 144.88 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.298 0 CA-C-N 113.471 -1.695 . . . . 0.0 110.224 -179.72 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.594 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.0 p-10 -50.2 106.11 0.11 Allowed 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.494 0.664 . . . . 0.0 111.626 -178.548 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.81 15.0 8.92 Favored Glycine 0 N--CA 1.484 1.894 0 C-N-CA 119.426 -1.368 . . . . 0.0 113.037 177.05 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.773 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -105.8 -174.02 2.44 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 121.29 2.545 . . . . 0.0 109.837 179.227 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.733 HG13 ' O ' ' A' ' 67' ' ' LEU . 15.7 t -130.71 138.56 53.35 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 CA-C-N 114.702 -1.135 . . . . 0.0 111.178 -178.721 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.568 HG12 HD21 ' A' ' 13' ' ' LEU . 33.8 m -113.06 155.16 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 178.75 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -103.96 108.82 20.33 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.021 -1.05 . . . . 0.0 109.167 179.971 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.948 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.51 140.06 21.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.893 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.903 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -133.76 159.18 41.37 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.866 -1.146 . . . . 0.0 109.638 179.484 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.581 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -141.08 108.8 0.57 Allowed Glycine 0 N--CA 1.482 1.76 0 N-CA-C 108.753 -1.739 . . . . 0.0 108.753 179.97 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.607 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.28 140.35 49.42 Favored 'General case' 0 N--CA 1.501 2.12 0 CA-C-N 119.259 1.529 . . . . 0.0 110.426 -179.461 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.471 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 85.48 26.9 34.32 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 118.945 -1.598 . . . . 0.0 109.946 179.57 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.612 HD23 ' HB3' ' A' ' 3' ' ' PRO . 0.8 OUTLIER -93.0 169.88 10.09 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 120.933 -1.333 . . . . 0.0 108.534 -179.946 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.58 101.32 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.117 -0.989 . . . . 0.0 109.777 -179.426 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.92 77.88 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.864 -179.327 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.89 33.83 0.28 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 179.77 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.55 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 18.8 p -138.79 106.35 5.58 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.279 -1.13 . . . . 0.0 110.93 -179.465 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.583 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.39 109.91 0.39 Allowed 'General case' 0 N--CA 1.497 1.903 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.532 178.181 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.483 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 32.6 m-85 -102.81 155.8 18.08 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.147 -0.971 . . . . 0.0 108.901 179.74 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.407 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.46 158.42 15.92 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 178.696 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.63 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 3.3 p -139.83 120.07 13.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.189 -0.944 . . . . 0.0 109.472 -177.818 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -169.89 -178.34 40.86 Favored Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.23 -1.938 . . . . 0.0 111.796 -179.742 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.729 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.21 109.78 22.03 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.918 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 68.1 m -127.16 152.77 46.9 Favored 'General case' 0 C--N 1.293 -1.86 0 O-C-N 121.22 -0.925 . . . . 0.0 109.819 179.619 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.654 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -126.87 135.66 51.27 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.535 -0.728 . . . . 0.0 110.452 179.965 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.902 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.94 114.69 26.55 Favored 'General case' 0 N--CA 1.493 1.717 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.231 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 20.1 m -104.97 14.42 7.21 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 120.851 -1.155 . . . . 0.0 110.809 -178.65 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.785 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 173.73 -174.5 0.06 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.81 -1.181 . . . . 0.0 110.158 179.65 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 24.5 p -71.69 97.67 1.79 Allowed 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.467 -0.77 . . . . 0.0 109.827 -179.67 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.85 27.63 31.22 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 120.285 -0.959 . . . . 0.0 111.487 178.836 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.785 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.3 t -116.35 106.09 19.63 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 O-C-N 120.538 -1.566 . . . . 0.0 107.372 179.001 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.902 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.7 tp -116.85 106.37 13.38 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.548 -1.345 . . . . 0.0 109.989 -177.703 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.105 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -95.72 109.78 22.02 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.803 -1.185 . . . . 0.0 108.161 179.137 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.4 ' O ' ' HB2' ' A' ' 76' ' ' PHE . 66.5 m -100.12 145.88 27.47 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.225 -0.922 . . . . 0.0 110.415 -178.354 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.502 ' HB3' ' HG2' ' A' ' 36' ' ' GLN . 7.4 t30 -99.23 129.23 29.8 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.217 -0.927 . . . . 0.0 108.673 179.097 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.4 Cg_endo -71.41 23.05 0.23 Allowed 'Trans proline' 0 C--N 1.317 -1.108 0 C-N-CA 122.102 1.868 . . . . 0.0 111.968 179.923 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.494 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -103.35 -5.86 22.54 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.4 -1.437 . . . . 0.0 109.106 179.68 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.696 ' OD2' HG13 ' A' ' 69' ' ' VAL . 5.6 m-20 -134.13 6.39 3.62 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.351 -0.843 . . . . 0.0 108.89 -179.961 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -62.42 84.18 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.336 -0.852 . . . . 0.0 110.655 -178.672 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.63 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.5 -167.87 1.32 Allowed 'General case' 0 N--CA 1.49 1.535 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 178.605 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.47 135.73 0.08 Allowed 'General case' 0 C--N 1.304 -1.404 0 O-C-N 120.68 -1.262 . . . . 0.0 111.383 -179.321 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.925 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -150.83 156.13 6.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 177.94 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.583 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.69 142.0 30.8 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.721 -1.237 . . . . 0.0 110.162 -179.525 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.011 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.26 106.4 0.73 Allowed 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 122.559 1.171 . . . . 0.0 109.45 178.316 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.2 p-10 -59.7 -139.51 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.862 179.962 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.539 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.75 -50.87 59.78 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.454 -0.778 . . . . 0.0 110.715 -178.711 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -102.94 -33.79 9.18 Favored 'General case' 0 C--N 1.286 -2.188 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 178.462 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.43 65.9 0.61 Allowed Glycine 0 C--N 1.298 -1.548 0 CA-C-N 114.937 -1.029 . . . . 0.0 110.575 177.941 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.581 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 23.2 m -102.81 126.49 49.97 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 178.631 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.925 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.24 109.17 8.68 Favored 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 119.457 -0.897 . . . . 0.0 109.296 -179.29 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.407 ' HB3' ' HE3' ' A' ' 20' ' ' LYS . 1.4 m -123.35 119.42 30.04 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.412 -0.805 . . . . 0.0 109.646 -179.73 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.55 150.31 36.17 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.698 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 28.2 p -98.04 136.7 37.92 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.196 -0.94 . . . . 0.0 109.484 -179.785 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.912 HD11 HG11 ' A' ' 21' ' ' VAL . 0.2 OUTLIER -128.99 160.65 32.06 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.442 -0.786 . . . . 0.0 109.485 -178.913 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.665 HG22 HG22 ' A' ' 18' ' ' VAL . 1.3 p -100.95 123.23 44.82 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.03 -1.044 . . . . 0.0 108.861 179.525 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.729 HG12 ' HB3' ' A' ' 36' ' ' GLN . 17.6 m -135.25 142.81 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 120.872 -1.143 . . . . 0.0 110.486 -178.579 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.594 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.4 ptt180 -145.5 -171.81 3.75 Favored 'General case' 0 N--CA 1.484 1.263 0 O-C-N 120.582 -1.324 . . . . 0.0 110.825 179.55 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.588 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -57.34 -99.67 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.197 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.513 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.79 142.23 50.8 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 120.343 -1.473 . . . . 0.0 108.218 179.517 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.654 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.4 OUTLIER -162.07 135.09 6.05 Favored 'General case' 0 C--N 1.295 -1.771 0 C-N-CA 118.581 -1.248 . . . . 0.0 110.027 -178.05 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.544 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 20.5 mt-10 -35.22 120.99 0.55 Allowed 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.458 0.647 . . . . 0.0 110.231 -178.723 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.105 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -94.74 51.22 2.01 Favored Glycine 0 N--CA 1.494 2.55 0 C-N-CA 120.476 -0.869 . . . . 0.0 111.665 -178.793 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -38.32 115.88 0.48 Allowed 'General case' 0 N--CA 1.507 2.396 0 O-C-N 121.04 -1.271 . . . . 0.0 110.012 179.26 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.767 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -86.78 126.06 34.35 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 120.816 -1.177 . . . . 0.0 109.594 -179.623 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 30.9 t80 -64.34 58.93 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.006 0 O-C-N 120.842 -1.161 . . . . 0.0 109.837 179.519 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.6 t70 -159.68 19.76 0.17 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.984 -1.072 . . . . 0.0 109.715 179.936 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.6 -27.91 5.59 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 179.811 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.467 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 73.1 p -98.49 162.6 13.07 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.142 -1.21 . . . . 0.0 110.39 -179.439 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.486 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 2.1 ptt180 -106.54 142.13 36.7 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.859 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.767 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.6 t90 -85.19 -19.77 31.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.635 -1.291 . . . . 0.0 110.601 -178.505 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.1 177.12 18.77 Favored Glycine 0 N--CA 1.484 1.883 0 N-CA-C 108.631 -1.788 . . . . 0.0 108.631 -179.424 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -66.4 105.33 1.43 Allowed 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 179.198 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.591 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 44.3 t -76.13 104.83 4.52 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 O-C-N 121.24 -0.913 . . . . 0.0 109.048 -179.058 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.529 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.05 111.17 3.24 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.46 -0.775 . . . . 0.0 109.686 -179.508 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.588 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -64.77 -4.85 4.76 Favored 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 118.245 -1.382 . . . . 0.0 109.71 179.51 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -86.83 1.81 51.15 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.782 -1.199 . . . . 0.0 109.017 179.341 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.529 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -117.01 -51.14 2.56 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.376 -0.828 . . . . 0.0 108.951 179.975 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.31 -179.92 4.09 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.479 -0.763 . . . . 0.0 109.383 179.914 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.25 115.7 30.85 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.446 -0.784 . . . . 0.0 108.935 179.807 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.527 ' O ' ' CG1' ' A' ' 110' ' ' ILE . 2.7 m -97.03 124.53 41.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.84 -1.162 . . . . 0.0 109.582 -179.264 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.57 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -102.97 147.73 26.57 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.344 1.069 . . . . 0.0 111.405 -179.241 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.496 ' CG1' HG11 ' A' ' 7' ' ' VAL . 44.8 t -104.6 113.12 40.78 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 177.498 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.509 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -155.08 -169.77 19.99 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 117.886 -2.102 . . . . 0.0 111.802 -177.766 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.46 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -120.56 177.59 5.0 Favored 'General case' 0 N--CA 1.484 1.245 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -179.138 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.584 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 2.1 t 177.52 163.57 0.57 Allowed 'General case' 0 C--N 1.294 -1.833 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 179.907 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -107.44 -162.61 0.85 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.916 -1.115 . . . . 0.0 109.138 -179.79 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -115.82 35.83 4.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.697 -1.252 . . . . 0.0 109.112 -179.969 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -112.31 -32.23 6.58 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.458 -0.776 . . . . 0.0 109.864 -179.633 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.703 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.1 -35.34 0.27 Allowed Glycine 0 N--CA 1.481 1.654 0 N-CA-C 107.96 -2.056 . . . . 0.0 107.96 -179.656 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.53 -177.65 6.08 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-O 122.1 0.952 . . . . 0.0 109.839 179.263 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.496 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.31 -161.34 21.77 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 108.176 -1.97 . . . . 0.0 108.176 -179.361 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.501 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.3 Cg_exo -47.73 -178.77 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.671 0 CA-C-N 118.96 1.38 . . . . 0.0 110.313 179.206 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.8 mt-10 -96.69 178.04 5.45 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.979 -1.075 . . . . 0.0 110.364 -178.958 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.509 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -116.7 172.64 14.32 Favored Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 -179.983 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -110.87 153.55 12.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.495 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.57 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -95.75 122.45 38.55 Favored 'General case' 0 C--N 1.291 -1.959 0 O-C-N 121.217 -0.927 . . . . 0.0 109.392 179.79 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.852 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.99 168.98 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 121.091 -1.005 . . . . 0.0 109.032 -179.905 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.499 ' HB3' ' CB ' ' A' ' 11' ' ' SER . 13.0 t -138.92 157.9 45.18 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.175 -0.953 . . . . 0.0 109.68 -179.91 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.852 ' CE2' HD12 ' A' ' 110' ' ' ILE . 82.0 m-85 -134.02 93.76 3.15 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.23 -0.919 . . . . 0.0 109.488 -179.706 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 17.5 p30 . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 118.065 -0.969 . . . . 0.0 109.464 -179.957 . . . . . . . . 0 0 . 1 . 038 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.859 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 121.305 0.574 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 039 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.708 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -89.19 164.97 28.56 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.194 -0.942 . . . . 0.0 109.458 179.979 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.708 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 4.3 Cg_exo -60.58 157.03 38.8 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.256 1.971 . . . . 0.0 110.495 179.94 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.609 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -147.0 160.64 42.12 Favored 'General case' 0 C--N 1.295 -1.797 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -179.6 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.505 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.55 122.39 9.33 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 122.366 1.079 . . . . 0.0 110.28 -179.715 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.861 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.6 t -115.9 109.16 17.22 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 123.122 1.439 . . . . 0.0 109.829 -179.827 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.817 HG22 HG23 ' A' ' 21' ' ' VAL . 2.2 t -114.78 133.7 60.1 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.19 -1.368 . . . . 0.0 109.787 179.855 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.513 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -169.26 150.17 4.15 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.232 -0.917 . . . . 0.0 108.809 -179.604 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.513 ' HA ' HG23 ' A' ' 8' ' ' THR . 1.2 Cg_endo -75.33 155.31 99.56 Favored 'Cis proline' 0 C--N 1.312 -1.35 0 C-N-CA 123.521 -1.45 . . . . 0.0 109.399 -0.873 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.5 ' O ' ' HB ' ' A' ' 110' ' ' ILE . 15.4 m -99.62 -19.83 16.63 Favored 'General case' 0 C--N 1.294 -1.847 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.754 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.502 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 19.2 m -136.02 159.07 42.84 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.426 -0.796 . . . . 0.0 109.678 -179.945 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.37 37.78 30.67 Favored Glycine 0 N--CA 1.494 2.55 0 N-CA-C 108.526 -1.829 . . . . 0.0 108.526 -179.688 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.794 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.1 mt -89.75 -44.31 10.08 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 123.056 1.407 . . . . 0.0 110.599 -178.383 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.462 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.0 144.39 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.363 0 CA-C-N 113.633 -1.622 . . . . 0.0 109.935 -179.638 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.605 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.1 p-10 -50.86 105.0 0.09 Allowed 'General case' 0 C--N 1.301 -1.504 0 CA-C-O 121.632 0.729 . . . . 0.0 111.435 -178.565 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 116.04 14.77 7.61 Favored Glycine 0 N--CA 1.485 1.902 0 C-N-CA 119.396 -1.383 . . . . 0.0 113.055 177.383 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.794 HG21 ' CA ' ' A' ' 13' ' ' LEU . 13.7 t -104.48 -173.55 2.33 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 121.264 2.532 . . . . 0.0 109.717 179.116 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.748 HG13 ' O ' ' A' ' 67' ' ' LEU . 18.1 t -127.65 135.99 61.64 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.89 -1.05 . . . . 0.0 111.424 -178.598 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.594 HG23 ' CD1' ' A' ' 67' ' ' LEU . 34.7 m -111.2 154.6 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.529 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 5.4 tttt -110.31 109.28 19.66 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.161 -0.962 . . . . 0.0 108.894 179.875 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.817 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -101.27 139.17 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.347 -0.846 . . . . 0.0 108.734 -179.929 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.861 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.0 162.38 32.22 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 118.819 -1.153 . . . . 0.0 110.107 179.656 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.603 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.71 140.35 11.39 Favored Glycine 0 C--N 1.299 -1.525 0 N-CA-C 107.899 -2.08 . . . . 0.0 107.899 179.694 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.609 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.94 124.96 15.24 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.514 -1.58 . . . . 0.0 109.409 179.299 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.46 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.55 28.62 18.81 Favored Glycine 0 N--CA 1.488 2.107 0 C-N-CA 118.776 -1.678 . . . . 0.0 109.678 -179.705 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.659 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.2 mt -89.79 171.86 9.32 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.006 -1.291 . . . . 0.0 108.249 179.875 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.008 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.92 99.6 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.969 -1.082 . . . . 0.0 109.926 -179.498 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.5 77.05 0.01 OUTLIER 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.136 -179.333 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.91 33.83 0.22 Allowed Glycine 0 N--CA 1.486 2.022 0 N-CA-C 109.311 -1.515 . . . . 0.0 109.311 179.634 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 40.4 p -141.38 107.32 5.16 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 121.09 -1.241 . . . . 0.0 111.399 -179.35 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.599 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.83 109.79 0.36 Allowed 'General case' 0 N--CA 1.496 1.835 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.621 177.828 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.593 ' CE1' ' CB ' ' A' ' 99' ' ' ASP . 4.4 m-30 -105.42 157.54 17.27 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.119 -0.988 . . . . 0.0 108.798 179.745 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.49 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -100.45 167.52 10.33 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.762 -1.211 . . . . 0.0 108.048 179.209 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.704 HG22 HG11 ' A' ' 21' ' ' VAL . 2.7 p -148.13 119.59 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.132 -0.98 . . . . 0.0 109.648 -178.094 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -171.26 -176.74 40.59 Favored Glycine 0 N--CA 1.496 2.638 0 C-N-CA 118.369 -1.872 . . . . 0.0 111.5 -179.763 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.685 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.71 108.3 20.13 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 -179.979 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -130.01 148.32 51.85 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.306 -0.872 . . . . 0.0 109.833 179.685 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.25 139.84 53.53 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.227 -0.921 . . . . 0.0 110.739 -179.024 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.88 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.12 114.93 26.78 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 178.119 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.7 m -106.21 15.49 7.13 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.035 -1.041 . . . . 0.0 110.526 -178.724 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.77 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.7 -176.66 0.09 Allowed 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.948 -1.095 . . . . 0.0 110.068 179.739 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.794 HG23 ' O ' ' A' ' 42' ' ' THR . 15.2 t -69.78 96.72 1.01 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.503 -0.748 . . . . 0.0 110.009 -179.61 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.93 28.82 33.39 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 120.15 -1.024 . . . . 0.0 111.355 178.892 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.77 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.25 106.42 20.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.228 0 O-C-N 120.586 -1.538 . . . . 0.0 107.221 178.769 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.88 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.7 tp -116.89 104.68 11.55 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.427 -1.421 . . . . 0.0 109.706 -177.545 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.989 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.23 109.54 22.28 Favored 'General case' 0 N--CA 1.484 1.244 0 O-C-N 120.827 -1.171 . . . . 0.0 108.295 178.928 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -106.27 166.13 10.75 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.956 -1.09 . . . . 0.0 110.209 -179.073 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.684 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 12.6 t-20 -108.22 134.45 20.18 Favored Pre-proline 0 N--CA 1.498 1.952 0 O-C-N 121.376 -0.827 . . . . 0.0 109.599 -179.411 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.627 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.1 Cg_endo -73.93 24.29 0.34 Allowed 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 122.452 2.102 . . . . 0.0 112.108 -179.655 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.684 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -113.75 -0.69 14.17 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.322 -1.486 . . . . 0.0 109.183 179.643 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.898 ' HB3' HD22 ' A' ' 67' ' ' LEU . 2.2 m-20 -136.38 18.26 3.15 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 179.651 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -78.04 83.96 4.32 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.66 -0.816 . . . . 0.0 110.62 -178.525 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -106.27 -170.51 1.74 Allowed 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 178.523 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.458 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.61 136.39 0.09 Allowed 'General case' 0 C--N 1.305 -1.351 0 O-C-N 120.705 -1.247 . . . . 0.0 111.008 -179.273 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.776 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.7 p -148.58 159.07 6.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 178.259 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.599 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.56 141.6 31.2 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 120.729 -1.232 . . . . 0.0 109.802 -179.923 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.008 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.09 108.04 1.72 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 122.305 1.05 . . . . 0.0 109.651 178.57 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.567 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.0 t0 -64.08 -139.44 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.027 0 CA-C-O 121.377 0.608 . . . . 0.0 110.809 179.864 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -49.95 -52.0 36.91 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.386 -0.821 . . . . 0.0 110.821 -178.706 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -102.49 -32.17 10.08 Favored 'General case' 0 C--N 1.286 -2.156 0 N-CA-C 106.442 -1.688 . . . . 0.0 106.442 178.633 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.995 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 103.3 66.6 0.73 Allowed Glycine 0 C--N 1.298 -1.572 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.262 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.603 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 52.6 m -98.82 130.73 45.26 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.603 -0.939 . . . . 0.0 108.764 178.866 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.776 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.09 109.13 8.74 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 119.299 -0.96 . . . . 0.0 109.335 -179.576 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 15.9 m -123.08 116.86 24.19 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.237 -0.914 . . . . 0.0 109.498 -179.803 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.616 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.24 143.58 29.31 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.385 -0.822 . . . . 0.0 109.523 -179.993 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.0 p -99.83 147.33 25.62 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.363 -0.835 . . . . 0.0 109.469 -179.892 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.898 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -147.56 168.43 21.98 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.441 -0.787 . . . . 0.0 109.398 -179.155 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.696 HG22 HG22 ' A' ' 18' ' ' VAL . 2.5 p -100.19 121.81 42.03 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.84 -1.163 . . . . 0.0 110.098 -178.937 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.823 HG13 ' OD2' ' A' ' 51' ' ' ASP . 15.5 m -129.08 144.17 38.99 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 120.897 -1.127 . . . . 0.0 110.162 -179.404 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.605 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 4.7 ptt180 -149.1 -177.47 5.84 Favored 'General case' 0 N--CA 1.482 1.145 0 O-C-N 120.576 -1.327 . . . . 0.0 110.838 179.722 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.578 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.6 -102.58 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.702 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.508 ' OG ' ' NH1' ' A' ' 71' ' ' ARG . 0.7 OUTLIER -57.56 140.41 50.96 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 120.712 -1.242 . . . . 0.0 108.161 179.388 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.41 136.69 8.66 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 118.79 -1.164 . . . . 0.0 109.934 -178.124 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.522 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 8.9 mm-40 -32.28 120.15 0.29 Allowed 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.47 0.652 . . . . 0.0 110.6 -178.591 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.989 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.84 47.19 2.95 Favored Glycine 0 N--CA 1.492 2.422 0 C-N-CA 120.573 -0.823 . . . . 0.0 111.175 -179.195 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.627 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.0 m-85 -38.38 113.99 0.33 Allowed 'General case' 0 N--CA 1.508 2.428 0 O-C-N 121.168 -1.195 . . . . 0.0 110.085 179.607 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.724 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -87.56 126.33 34.87 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.869 -1.145 . . . . 0.0 109.509 -179.816 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.594 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 16.4 t80 -64.26 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 120.856 -1.153 . . . . 0.0 110.035 179.693 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.532 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.0 t0 -159.87 19.25 0.16 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.982 -1.073 . . . . 0.0 109.735 179.895 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.93 -27.02 5.64 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.837 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.403 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 1.3 p -95.17 161.47 14.1 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.006 -1.29 . . . . 0.0 110.361 -179.491 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.475 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -107.66 136.32 47.61 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.832 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.724 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -83.03 -17.61 42.68 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.858 -1.151 . . . . 0.0 110.502 -178.649 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.71 174.02 19.65 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 108.862 -1.695 . . . . 0.0 108.862 -179.632 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.97 105.97 0.95 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.08 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.641 HG21 ' HB3' ' A' ' 46' ' ' ALA . 46.1 t -76.94 105.46 5.83 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 121.385 -0.822 . . . . 0.0 109.45 -178.682 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.558 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.9 m-20 -64.01 110.61 2.19 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.43 -0.793 . . . . 0.0 109.7 -179.624 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.578 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.3 t -65.0 -4.48 4.65 Favored 'General case' 0 N--CA 1.499 2.024 0 C-N-CA 118.289 -1.364 . . . . 0.0 109.969 179.505 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 38.7 p -86.82 -1.14 57.54 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.712 -1.242 . . . . 0.0 109.239 179.579 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.558 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -112.28 -50.27 2.91 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.34 -0.85 . . . . 0.0 108.917 -179.99 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.39 -178.27 3.61 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.596 -0.69 . . . . 0.0 109.301 179.724 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.29 115.51 30.33 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.349 -0.844 . . . . 0.0 109.14 -179.989 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.558 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.77 121.62 38.82 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.848 -1.158 . . . . 0.0 109.244 -179.578 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.656 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.31 145.26 30.22 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 122.424 1.107 . . . . 0.0 111.16 -179.176 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.502 ' HB ' HG11 ' A' ' 7' ' ' VAL . 49.1 t -101.73 109.88 27.1 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.999 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 177.68 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.489 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.7 -170.57 16.62 Favored Glycine 0 N--CA 1.486 2.012 0 C-N-CA 118.26 -1.924 . . . . 0.0 111.666 -177.569 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.49 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -112.91 179.61 3.92 Favored 'General case' 0 N--CA 1.486 1.359 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 -179.197 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.567 ' HB3' ' C26' ' A' ' 114' ' ' CHR . 33.8 p -168.66 166.43 11.81 Favored 'General case' 0 C--N 1.295 -1.762 0 O-C-N 121.381 -0.824 . . . . 0.0 109.585 -179.328 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.593 ' CB ' ' CE1' ' A' ' 32' ' ' TYR . 0.6 OUTLIER -116.71 -159.25 0.72 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.229 -0.919 . . . . 0.0 108.864 179.629 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.401 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -118.37 36.01 4.54 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.667 -1.271 . . . . 0.0 109.286 -179.911 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.66 -33.03 4.39 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.369 -0.832 . . . . 0.0 110.311 -179.572 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 1.002 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.07 -36.8 0.23 Allowed Glycine 0 N--CA 1.483 1.772 0 N-CA-C 107.657 -2.177 . . . . 0.0 107.657 -179.562 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.448 ' ND2' ' O9 ' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -159.58 -178.04 6.83 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 122.104 0.954 . . . . 0.0 109.768 179.206 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.46 -162.65 14.65 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 -179.404 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.481 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.3 Cg_exo -47.09 177.09 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.608 0 CA-C-N 118.807 1.304 . . . . 0.0 110.042 179.258 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -91.81 -178.57 5.07 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.015 -1.053 . . . . 0.0 110.409 -178.704 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.489 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.74 165.29 12.95 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.954 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.456 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.83 129.51 51.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 O-C-N 121.458 -1.025 . . . . 0.0 109.249 -179.413 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.656 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.31 126.6 30.49 Favored 'General case' 0 C--N 1.291 -1.972 0 O-C-N 121.677 -0.639 . . . . 0.0 109.791 179.756 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.697 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 20.8 pt -97.43 177.2 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 O-C-N 121.226 -0.921 . . . . 0.0 109.473 -179.884 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.502 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.3 m -144.2 150.96 38.81 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.464 -0.772 . . . . 0.0 109.54 179.851 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.697 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 94.9 m-85 -130.16 92.83 3.36 Favored 'General case' 0 N--CA 1.485 1.297 0 O-C-N 121.115 -0.991 . . . . 0.0 109.506 -179.636 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.419 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 13.4 p30 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.527 179.969 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 1.002 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 040 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.08 154.98 58.42 Favored Pre-proline 0 N--CA 1.489 1.476 0 O-C-N 121.231 -0.918 . . . . 0.0 109.503 179.991 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.736 ' O ' HG23 ' A' ' 4' ' ' THR . 3.4 Cg_exo -60.76 157.37 38.09 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 C-N-CA 122.252 1.968 . . . . 0.0 110.486 -179.948 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.736 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.1 p -162.04 160.71 27.85 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -179.327 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.511 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.34 128.23 14.45 Favored 'General case' 0 C--N 1.298 -1.636 0 C-N-CA 118.989 -1.084 . . . . 0.0 110.599 -179.707 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.015 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -104.82 104.72 14.55 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 122.456 1.122 . . . . 0.0 110.243 -179.495 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.928 HG22 HG23 ' A' ' 21' ' ' VAL . 14.7 t -119.51 115.4 47.5 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.443 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.265 179.704 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -160.72 148.94 12.95 Favored Pre-proline 0 N--CA 1.488 1.451 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -179.547 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.5 Cg_endo -78.59 149.77 86.21 Favored 'Cis proline' 0 C--N 1.31 -1.497 0 C-N-CA 123.726 -1.364 . . . . 0.0 109.558 -0.609 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.657 ' HA ' HG22 ' A' ' 110' ' ' ILE . 77.6 p -91.7 -24.06 19.6 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 179.543 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.479 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 0.9 OUTLIER -131.28 162.18 30.63 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.45 -0.781 . . . . 0.0 109.513 -179.921 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.17 38.37 34.78 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 -179.536 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.809 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.5 mt -91.51 -44.28 9.19 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 123.142 1.448 . . . . 0.0 110.691 -178.233 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.472 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.7 144.87 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.274 0 CA-C-N 113.587 -1.642 . . . . 0.0 109.915 -179.629 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.577 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 9.2 p-10 -50.81 106.29 0.12 Allowed 'General case' 0 C--N 1.302 -1.46 0 CA-C-O 121.492 0.663 . . . . 0.0 111.674 -178.575 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.55 15.51 8.77 Favored Glycine 0 N--CA 1.485 1.918 0 C-N-CA 119.523 -1.323 . . . . 0.0 112.944 177.178 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.809 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.9 t -103.93 -172.3 2.08 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 121.156 2.478 . . . . 0.0 109.835 179.304 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.761 HG22 HG22 ' A' ' 68' ' ' THR . 15.1 t -131.56 140.23 48.75 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.301 0 CA-C-N 114.873 -1.058 . . . . 0.0 111.186 -178.817 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.638 HG22 HG22 ' A' ' 69' ' ' VAL . 4.1 m -117.86 154.72 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 178.948 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.549 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.0 tttt -106.91 108.74 20.39 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.078 -1.014 . . . . 0.0 109.311 179.927 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.928 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -106.23 122.16 59.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 N-CA-C 108.674 -0.862 . . . . 0.0 108.674 179.775 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.015 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.54 165.97 12.2 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 120.913 -1.117 . . . . 0.0 109.068 179.933 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.16 108.1 0.5 Allowed Glycine 0 N--CA 1.483 1.778 0 N-CA-C 108.586 -1.806 . . . . 0.0 108.586 179.848 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.585 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.58 140.31 49.53 Favored 'General case' 0 N--CA 1.498 1.954 0 CA-C-N 119.192 1.496 . . . . 0.0 110.282 -179.274 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.452 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.73 28.1 33.07 Favored Glycine 0 N--CA 1.489 2.184 0 C-N-CA 119.025 -1.559 . . . . 0.0 109.845 179.777 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.3 mt -92.55 175.08 6.96 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.931 -1.335 . . . . 0.0 108.352 179.929 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.998 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.94 98.84 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.448 0 O-C-N 120.878 -1.139 . . . . 0.0 109.601 -179.625 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.663 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.3 77.48 0.0 OUTLIER 'General case' 0 C--N 1.294 -1.807 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.269 -179.131 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.31 34.35 0.32 Allowed Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.457 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.564 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 59.7 p -145.42 112.08 5.87 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.075 -1.25 . . . . 0.0 111.196 -179.691 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.552 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -44.42 126.84 5.56 Favored 'General case' 0 N--CA 1.491 1.615 0 CA-C-O 121.458 0.647 . . . . 0.0 109.523 178.098 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.493 ' HA ' ' O ' ' A' ' 98' ' ' SER . 12.1 m-85 -118.09 150.26 39.63 Favored 'General case' 0 N--CA 1.492 1.663 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.736 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.512 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.1 OUTLIER -100.84 159.0 15.56 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.652 -1.28 . . . . 0.0 107.729 178.535 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.68 HG13 ' O ' ' A' ' 34' ' ' VAL . 7.4 p -144.27 116.04 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.085 -1.009 . . . . 0.0 110.045 -177.637 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.519 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.2 -178.78 39.74 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.414 -1.85 . . . . 0.0 111.857 -179.919 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.598 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -100.31 109.01 21.2 Favored 'General case' 0 C--N 1.317 -0.848 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -179.872 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.48 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 1.9 m -130.58 148.02 52.33 Favored 'General case' 0 C--N 1.294 -1.81 0 O-C-N 121.357 -0.84 . . . . 0.0 109.835 179.873 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.466 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.9 138.94 54.21 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.375 -0.828 . . . . 0.0 110.702 -179.082 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.874 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.55 114.67 26.45 Favored 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 178.187 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.42 ' O ' ' OD2' ' A' ' 41' ' ' ASP . 17.1 m -105.71 14.72 7.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.971 -1.081 . . . . 0.0 110.576 -178.679 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.761 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.92 -175.17 0.08 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.923 -1.111 . . . . 0.0 110.086 179.749 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 46.2 p -71.85 97.54 1.83 Allowed 'General case' 0 N--CA 1.486 1.364 0 O-C-N 121.428 -0.795 . . . . 0.0 109.717 -179.655 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.33 27.13 34.05 Favored Glycine 0 N--CA 1.493 2.477 0 C-N-CA 120.293 -0.956 . . . . 0.0 111.487 178.921 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.761 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.93 106.13 19.81 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.222 0 O-C-N 120.566 -1.549 . . . . 0.0 107.337 178.872 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.874 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.6 tp -117.24 104.67 11.4 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.531 -1.356 . . . . 0.0 109.669 -177.839 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.077 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.76 109.36 22.13 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 120.787 -1.196 . . . . 0.0 108.331 178.956 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 2.8 t -105.39 164.51 11.81 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.05 -1.031 . . . . 0.0 110.123 -179.055 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.695 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 13.6 t-20 -106.76 138.9 19.91 Favored Pre-proline 0 N--CA 1.501 2.087 0 O-C-N 121.333 -0.854 . . . . 0.0 110.095 -179.031 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.576 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 6.9 Cg_endo -75.88 25.9 0.41 Allowed 'Trans proline' 0 C--N 1.319 -1.012 0 C-N-CA 122.537 2.158 . . . . 0.0 111.705 179.987 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.695 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -121.43 3.54 10.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.403 -1.436 . . . . 0.0 109.312 -179.915 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.538 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.09 14.36 3.06 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.285 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -80.18 91.83 5.61 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.799 -178.644 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.617 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -112.53 -169.23 1.44 Allowed 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 178.356 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 179.03 135.56 0.09 Allowed 'General case' 0 C--N 1.306 -1.325 0 O-C-N 120.517 -1.364 . . . . 0.0 111.439 -179.351 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.899 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -151.98 157.75 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 178.102 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.552 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.41 145.31 26.29 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 120.595 -1.316 . . . . 0.0 109.976 -179.578 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.998 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.6 107.39 1.71 Allowed 'General case' 0 C--N 1.3 -1.582 0 CA-C-O 122.375 1.083 . . . . 0.0 109.418 178.716 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 15.7 p-10 -60.37 -139.25 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.019 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.019 -179.914 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.663 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.21 -50.43 59.11 Favored 'General case' 0 N--CA 1.5 2.041 0 O-C-N 121.316 -0.865 . . . . 0.0 110.564 -178.71 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -104.7 -33.71 8.38 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 106.249 -1.759 . . . . 0.0 106.249 178.529 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.982 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.01 66.99 0.61 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 178.205 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.8 m -104.3 124.84 49.89 Favored 'General case' 0 N--CA 1.485 1.28 0 O-C-N 121.674 -0.898 . . . . 0.0 108.686 178.818 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.899 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.15 109.21 8.76 Favored 'General case' 0 C--N 1.296 -1.733 0 C-N-CA 119.699 -0.8 . . . . 0.0 109.479 -179.412 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 81.2 p -117.87 118.64 32.57 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.348 -0.845 . . . . 0.0 109.448 -179.924 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.636 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.02 141.24 30.01 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.513 -0.742 . . . . 0.0 109.631 179.92 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.1 p -100.46 131.65 46.27 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.436 -0.79 . . . . 0.0 109.352 179.955 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.746 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -130.05 166.98 19.03 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.416 -0.803 . . . . 0.0 109.477 -179.512 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.761 HG22 HG22 ' A' ' 18' ' ' VAL . 1.7 p -97.94 124.69 42.49 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.109 -0.994 . . . . 0.0 109.365 -179.834 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.638 HG22 HG22 ' A' ' 19' ' ' VAL . 16.0 m -135.45 143.28 37.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.082 -1.011 . . . . 0.0 109.767 -179.292 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.577 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 4.6 ptt180 -141.1 -165.62 2.0 Allowed 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.657 -1.277 . . . . 0.0 110.494 -179.912 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.597 ' HG2' ' CG ' ' A' ' 112' ' ' PHE . 17.5 mtp180 -72.4 -80.24 0.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.367 -0.833 . . . . 0.0 109.217 -179.498 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.5 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -68.65 138.3 54.89 Favored 'General case' 0 N--CA 1.485 1.282 0 O-C-N 120.051 -1.655 . . . . 0.0 107.284 178.874 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.567 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -162.21 133.99 5.41 Favored 'General case' 0 C--N 1.295 -1.788 0 C-N-CA 117.766 -1.573 . . . . 0.0 110.414 -177.559 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.55 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -33.83 121.95 0.44 Allowed 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.44 0.638 . . . . 0.0 110.234 -178.766 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.077 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.86 51.66 2.27 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 120.512 -0.852 . . . . 0.0 111.392 -178.98 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.576 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.5 OUTLIER -38.97 116.17 0.55 Allowed 'General case' 0 N--CA 1.511 2.615 0 O-C-N 121.075 -1.25 . . . . 0.0 109.933 179.519 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.693 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -87.32 126.63 34.96 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.875 -1.14 . . . . 0.0 109.328 -179.946 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.586 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.1 t80 -64.15 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.001 0 O-C-N 120.772 -1.205 . . . . 0.0 110.025 179.741 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.537 ' N ' ' O ' ' A' ' 77' ' ' LEU . 20.4 t70 -160.18 19.48 0.15 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.984 -1.072 . . . . 0.0 109.705 179.895 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.0 -27.39 5.51 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 179.785 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.41 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 2.3 p -95.22 160.93 14.32 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.004 -1.292 . . . . 0.0 110.318 -179.425 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.479 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.86 137.48 44.84 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 179.822 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.693 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.3 t90 -82.27 -19.2 40.03 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.748 -1.22 . . . . 0.0 110.437 -178.596 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.51 176.27 19.73 Favored Glycine 0 N--CA 1.484 1.85 0 N-CA-C 108.682 -1.767 . . . . 0.0 108.682 -179.485 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -63.82 108.8 1.55 Allowed 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 179.13 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.628 HG21 ' HB3' ' A' ' 46' ' ' ALA . 38.2 t -81.72 105.41 11.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 121.361 -0.837 . . . . 0.0 108.786 -179.144 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.531 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -67.68 112.16 4.63 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.39 -0.819 . . . . 0.0 109.931 -179.108 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.546 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -64.28 -5.09 4.41 Favored 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.286 -1.366 . . . . 0.0 109.97 179.437 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.404 HG22 ' NH2' ' A' ' 71' ' ' ARG . 41.0 p -85.63 1.44 49.24 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.769 -1.207 . . . . 0.0 109.021 179.361 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -115.73 -49.34 2.73 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.432 -0.792 . . . . 0.0 109.08 179.971 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.64 -179.63 4.0 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.458 -0.776 . . . . 0.0 109.536 179.961 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.99 115.36 30.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.338 -0.851 . . . . 0.0 109.102 179.958 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.507 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.7 m -96.94 123.73 40.73 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.082 -1.011 . . . . 0.0 109.54 -179.358 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.582 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.28 147.48 27.44 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-O 122.515 1.15 . . . . 0.0 111.356 -179.318 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.64 ' HB ' HG11 ' A' ' 7' ' ' VAL . 59.1 t -103.09 109.62 27.36 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.038 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 177.351 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -146.09 -174.06 17.9 Favored Glycine 0 N--CA 1.484 1.855 0 C-N-CA 118.203 -1.951 . . . . 0.0 111.815 -177.414 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.503 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -117.1 -177.59 3.24 Favored 'General case' 0 C--N 1.304 -1.373 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -178.835 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.549 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.8 OUTLIER -170.3 157.36 6.15 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 121.182 -0.949 . . . . 0.0 109.389 -179.344 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.696 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 3.6 m-20 -85.32 -14.91 45.04 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.133 -0.98 . . . . 0.0 109.483 179.959 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.696 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 76.16 35.5 0.46 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.513 -0.742 . . . . 0.0 109.328 -179.943 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -138.73 -34.05 0.63 Allowed 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.636 -0.665 . . . . 0.0 110.651 -179.463 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.802 ' HA2' H192 ' A' ' 114' ' ' CHR . . . -176.13 -44.03 0.06 OUTLIER Glycine 0 N--CA 1.482 1.73 0 N-CA-C 107.468 -2.253 . . . . 0.0 107.468 -179.69 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -154.98 -179.66 8.27 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 121.509 -0.995 . . . . 0.0 109.406 178.786 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -179.23 -167.78 37.22 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 -179.488 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.449 ' HG3' HD22 ' A' ' 26' ' ' LEU . 5.8 Cg_exo -48.38 175.1 0.03 OUTLIER 'Trans proline' 0 C--O 1.215 -0.665 0 CA-C-N 118.888 1.344 . . . . 0.0 110.002 179.523 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 pt-20 -92.48 -175.4 3.98 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.163 -0.96 . . . . 0.0 110.435 -178.778 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -120.52 166.54 13.77 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 -179.908 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -106.65 131.82 55.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.452 -1.028 . . . . 0.0 109.069 -179.358 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.582 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.16 125.11 27.65 Favored 'General case' 0 C--N 1.29 -2.018 0 O-C-N 121.48 -0.762 . . . . 0.0 109.782 179.733 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.86 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.72 172.18 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.158 -0.964 . . . . 0.0 108.948 179.81 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.479 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.81 158.25 44.74 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.305 -0.872 . . . . 0.0 109.605 -179.837 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.86 ' CE2' HD12 ' A' ' 110' ' ' ILE . 70.8 m-85 -135.75 86.16 2.21 Favored 'General case' 0 C--N 1.306 -1.297 0 O-C-N 121.19 -0.944 . . . . 0.0 109.52 -179.585 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 17.4 p30 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 118.013 -0.994 . . . . 0.0 109.441 -179.959 . . . . . . . . 0 0 . 1 . 040 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.802 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.508 ' HB3' ' OD1' ' A' ' 60' ' ' ASN . . . . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.321 0.581 . . . . 0.0 109.479 . . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -117.66 152.06 49.26 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.203 -0.935 . . . . 0.0 109.512 179.981 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.589 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 4.6 Cg_exo -60.46 157.38 36.58 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.301 2.001 . . . . 0.0 110.625 -179.924 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.535 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.69 -169.57 0.14 Allowed 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.204 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.572 ' HB1' ' O ' ' A' ' 22' ' ' ALA . . . -167.82 133.63 1.98 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.661 -1.274 . . . . 0.0 111.252 -179.27 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.01 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.2 p -100.36 104.03 15.45 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.377 1.084 . . . . 0.0 109.783 179.982 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.937 HG22 HG23 ' A' ' 21' ' ' VAL . 6.9 t -120.32 116.72 51.1 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.421 0 CA-C-O 121.726 0.774 . . . . 0.0 110.466 179.863 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.508 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.81 148.7 8.86 Favored Pre-proline 0 N--CA 1.486 1.339 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.707 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.508 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.0 Cg_endo -77.94 150.32 89.18 Favored 'Cis proline' 0 C--N 1.307 -1.65 0 C-N-CA 123.604 -1.415 . . . . 0.0 109.513 -0.425 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.674 ' HA ' HG22 ' A' ' 110' ' ' ILE . 80.1 p -91.3 -24.69 19.75 Favored 'General case' 0 C--N 1.292 -1.916 0 O-C-N 121.498 -0.751 . . . . 0.0 108.985 179.518 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.519 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 17.0 m -133.92 161.9 33.51 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.521 -0.737 . . . . 0.0 109.367 -179.931 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.77 37.06 31.05 Favored Glycine 0 N--CA 1.494 2.563 0 N-CA-C 108.571 -1.811 . . . . 0.0 108.571 -179.657 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.725 ' CA ' HG21 ' A' ' 17' ' ' THR . 42.8 mt -91.12 -42.13 10.64 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-O 123.374 1.559 . . . . 0.0 110.22 -178.548 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.468 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 67.65 142.31 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.238 -1.801 . . . . 0.0 109.838 -179.488 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.61 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.3 p-10 -49.94 106.86 0.13 Allowed 'General case' 0 C--N 1.298 -1.656 0 CA-C-O 121.562 0.696 . . . . 0.0 111.324 -178.588 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 117.16 10.64 9.57 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.132 177.449 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.725 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.7 t -105.48 -171.31 1.89 Allowed 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 121.286 2.543 . . . . 0.0 109.905 179.471 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.81 HG13 ' C ' ' A' ' 67' ' ' LEU . 16.8 t -132.93 143.42 39.55 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.284 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.851 -178.952 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.599 HG11 HD11 ' A' ' 13' ' ' LEU . 32.2 m -118.98 155.34 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.28 -0.887 . . . . 0.0 108.707 179.21 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.547 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -105.08 108.77 20.47 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.152 -0.967 . . . . 0.0 109.441 -179.897 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.937 HG23 HG22 ' A' ' 7' ' ' VAL . 1.8 p -106.74 121.76 59.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.434 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -118.07 167.16 11.72 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 120.688 -1.257 . . . . 0.0 109.292 -179.604 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.602 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -132.55 143.47 15.11 Favored Glycine 0 C--N 1.294 -1.78 0 N-CA-C 107.774 -2.131 . . . . 0.0 107.774 179.735 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.589 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -147.82 123.01 10.2 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 120.929 -1.336 . . . . 0.0 108.589 179.175 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.51 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 90.18 27.39 21.0 Favored Glycine 0 N--CA 1.487 2.063 0 C-N-CA 119.201 -1.476 . . . . 0.0 109.755 -179.448 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.542 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.0 mt -87.9 175.85 7.62 Favored 'General case' 0 C--N 1.308 -1.224 0 O-C-N 120.846 -1.384 . . . . 0.0 108.403 179.964 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.996 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.24 96.85 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.029 -1.044 . . . . 0.0 109.6 -179.91 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.679 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.24 76.48 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.448 -178.847 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.25 33.44 0.27 Allowed Glycine 0 N--CA 1.486 1.994 0 N-CA-C 109.899 -1.281 . . . . 0.0 109.899 179.179 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.626 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.6 t -148.45 115.46 6.09 Favored 'General case' 0 C--N 1.309 -1.178 0 O-C-N 120.797 -1.414 . . . . 0.0 111.252 179.932 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.565 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.98 129.18 4.43 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 115.452 -0.795 . . . . 0.0 109.657 178.221 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.626 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 6.8 m-85 -121.5 146.82 46.54 Favored 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 179.727 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.508 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -98.95 164.31 12.24 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 107.429 -1.323 . . . . 0.0 107.429 178.54 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.948 HG11 HG21 ' A' ' 65' ' ' THR . 7.1 p -148.95 115.11 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.979 -1.076 . . . . 0.0 110.133 -177.673 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -168.15 -174.29 36.85 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 118.541 -1.79 . . . . 0.0 111.563 -179.938 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.568 ' O ' ' CG ' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -100.77 108.89 20.83 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -179.718 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.26 148.76 52.12 Favored 'General case' 0 C--N 1.296 -1.73 0 O-C-N 121.19 -0.944 . . . . 0.0 109.934 179.765 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -125.33 139.1 53.98 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.276 -0.89 . . . . 0.0 110.613 -179.03 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.882 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.17 114.89 26.74 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 178.116 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.2 m -106.17 15.57 7.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.014 -1.054 . . . . 0.0 110.587 -178.676 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.3 -175.59 0.09 Allowed 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.933 -1.105 . . . . 0.0 110.021 179.739 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -72.0 97.47 1.88 Allowed 'General case' 0 N--CA 1.486 1.33 0 O-C-N 121.423 -0.798 . . . . 0.0 109.724 -179.765 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.64 27.93 33.89 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 120.164 -1.017 . . . . 0.0 111.399 178.973 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.52 106.33 20.07 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.235 0 O-C-N 120.612 -1.522 . . . . 0.0 107.289 178.928 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.882 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -116.88 104.74 11.61 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.501 -1.374 . . . . 0.0 109.684 -177.626 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.068 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.13 109.57 22.3 Favored 'General case' 0 N--CA 1.485 1.294 0 O-C-N 120.739 -1.226 . . . . 0.0 108.213 178.797 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -108.12 164.53 12.21 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.977 -1.077 . . . . 0.0 110.081 -178.929 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.62 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 7.5 t30 -108.62 130.02 23.27 Favored Pre-proline 0 N--CA 1.5 2.069 0 O-C-N 121.357 -0.84 . . . . 0.0 109.69 -179.284 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.614 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -71.01 19.83 0.23 Allowed 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 122.178 1.919 . . . . 0.0 112.044 179.502 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.634 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -108.32 1.12 21.66 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.364 -1.46 . . . . 0.0 108.883 179.305 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.576 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.07 19.27 2.99 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 179.462 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -83.0 90.9 7.07 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.876 -0.73 . . . . 0.0 111.005 -178.439 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.66 -171.02 1.76 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.944 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.437 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.3 OUTLIER 178.53 137.96 0.09 Allowed 'General case' 0 C--N 1.304 -1.372 0 O-C-N 120.501 -1.374 . . . . 0.0 111.544 -179.16 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.822 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.8 OUTLIER -154.79 159.51 3.03 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 107.055 -1.461 . . . . 0.0 107.055 178.07 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.565 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.28 145.78 25.76 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 120.59 -1.319 . . . . 0.0 109.722 -179.676 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.996 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.66 108.09 2.78 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-O 122.353 1.073 . . . . 0.0 109.582 179.037 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.541 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.0 t0 -63.03 -139.21 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.015 0 CA-C-N 115.617 -0.719 . . . . 0.0 110.874 -179.917 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.679 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.04 -51.83 28.88 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 121.411 -0.806 . . . . 0.0 110.759 -178.572 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.508 ' OD1' ' HB3' ' A' ' 1' ' ' ALA . 0.8 OUTLIER -105.09 -32.07 8.87 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 178.585 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.963 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 106.25 67.96 0.69 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 178.391 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.602 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.2 m -103.42 128.88 50.46 Favored 'General case' 0 N--CA 1.484 1.266 0 O-C-N 121.37 -1.077 . . . . 0.0 109.143 179.202 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.822 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.25 108.65 6.89 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 119.321 -0.952 . . . . 0.0 109.949 -179.486 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.494 ' HB3' ' CE ' ' A' ' 20' ' ' LYS . 3.4 m -114.48 116.58 29.07 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.995 -1.066 . . . . 0.0 109.409 179.85 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.948 HG21 HG11 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -143.08 142.19 31.46 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 110.013 -179.971 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 38.9 p -100.71 136.32 40.76 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.466 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.81 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -141.08 156.82 45.93 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.935 . . . . 0.0 109.808 -179.129 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.634 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 12.9 t -87.04 138.76 31.22 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.062 -1.023 . . . . 0.0 110.676 -179.608 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.564 HG12 ' HB3' ' A' ' 36' ' ' GLN . 20.7 m -149.27 143.55 18.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.508 -0.745 . . . . 0.0 109.232 -179.852 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.61 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.4 OUTLIER -147.52 -178.01 6.01 Favored 'General case' 0 N--CA 1.486 1.326 0 O-C-N 120.487 -1.383 . . . . 0.0 111.206 -179.68 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.697 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -47.52 -98.92 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -179.616 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.523 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -64.02 145.01 56.65 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.389 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.599 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 1.0 OUTLIER -163.95 143.2 7.85 Favored 'General case' 0 C--N 1.291 -1.952 0 C-N-CA 118.045 -1.462 . . . . 0.0 110.268 -177.419 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.538 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 29.4 mm-40 -37.29 120.46 0.77 Allowed 'General case' 0 N--CA 1.489 1.477 0 CA-C-O 121.457 0.646 . . . . 0.0 110.304 -178.888 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.068 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -96.5 52.45 1.54 Allowed Glycine 0 N--CA 1.495 2.632 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 -179.477 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.614 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.8 m-85 -39.76 114.96 0.47 Allowed 'General case' 0 N--CA 1.508 2.465 0 O-C-N 121.181 -1.188 . . . . 0.0 110.113 179.65 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.656 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.13 126.55 34.3 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.866 -1.146 . . . . 0.0 109.511 -179.986 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.576 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.6 t80 -64.1 58.17 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.004 0 O-C-N 120.845 -1.159 . . . . 0.0 110.25 179.767 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.58 19.68 0.14 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.025 -1.047 . . . . 0.0 109.709 179.892 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.88 -27.5 5.4 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 179.871 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.419 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 11.9 p -93.36 158.53 15.69 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 121.02 -1.282 . . . . 0.0 110.434 -179.455 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.487 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -106.35 136.28 46.35 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.627 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.656 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.1 t90 -83.08 -16.72 45.81 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 120.669 -1.269 . . . . 0.0 110.647 -178.194 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.57 175.94 21.18 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 108.709 -1.756 . . . . 0.0 108.709 -179.618 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -64.84 103.07 0.66 Allowed 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 179.106 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.656 HG21 ' HB3' ' A' ' 46' ' ' ALA . 37.2 t -73.78 107.97 4.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.396 -0.815 . . . . 0.0 109.483 -178.755 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.523 ' HA ' ' HA ' ' A' ' 72' ' ' SER . 0.8 OUTLIER -65.11 112.09 3.22 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.462 -0.774 . . . . 0.0 109.706 -179.58 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.697 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 4.0 m -62.81 -4.98 2.4 Favored 'General case' 0 N--CA 1.497 1.919 0 C-N-CA 118.422 -1.311 . . . . 0.0 110.228 179.608 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 20.5 p -89.25 -2.94 58.67 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.566 -1.334 . . . . 0.0 109.555 -179.983 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.522 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -106.31 -48.65 3.52 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 121.071 -1.018 . . . . 0.0 108.861 179.885 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.42 -177.86 3.4 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.631 -0.668 . . . . 0.0 109.297 179.726 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.59 115.98 31.51 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.454 -0.779 . . . . 0.0 108.927 179.834 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.544 ' HB2' HD11 ' A' ' 110' ' ' ILE . 3.2 m -96.48 120.32 36.58 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.913 -1.117 . . . . 0.0 109.615 -179.245 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.93 145.28 30.37 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-O 122.409 1.099 . . . . 0.0 111.282 -179.392 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.582 ' HB ' HG11 ' A' ' 7' ' ' VAL . 92.4 t -102.22 109.86 27.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.945 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 177.788 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.494 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.49 -173.22 19.82 Favored Glycine 0 N--CA 1.486 2.028 0 C-N-CA 118.112 -1.995 . . . . 0.0 111.695 -177.608 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.538 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -111.93 -178.61 3.47 Favored 'General case' 0 N--CA 1.485 1.288 0 N-CA-C 108.647 -0.871 . . . . 0.0 108.647 -179.345 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.586 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.1 p -175.1 167.47 3.48 Favored 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.197 -0.939 . . . . 0.0 109.751 -179.132 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -117.67 -161.46 0.82 Allowed 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.032 -1.042 . . . . 0.0 108.901 179.906 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -117.38 35.67 4.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.598 -1.314 . . . . 0.0 109.453 -179.955 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -114.26 -31.19 6.37 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.374 -0.829 . . . . 0.0 109.955 -179.705 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.868 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 164.22 -35.12 0.29 Allowed Glycine 0 N--CA 1.482 1.723 0 N-CA-C 107.75 -2.14 . . . . 0.0 107.75 -179.558 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.11 -177.6 5.85 Favored 'General case' 0 C--N 1.307 -1.246 0 O-C-N 121.578 -0.954 . . . . 0.0 109.713 179.242 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.31 -161.5 14.41 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 -179.345 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.485 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.5 Cg_exo -47.97 -179.36 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.612 0 CA-C-N 118.877 1.339 . . . . 0.0 110.304 179.328 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -93.59 -173.95 3.34 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.002 -1.061 . . . . 0.0 110.298 -178.974 . . . . . . . . 1 1 . 1 . 041 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.494 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.76 164.18 14.97 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.946 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -100.86 129.41 51.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.367 -1.078 . . . . 0.0 109.0 -179.46 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.79 119.25 15.7 Favored 'General case' 0 C--N 1.288 -2.101 0 O-C-N 121.746 -0.596 . . . . 0.0 109.73 179.759 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.813 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -98.09 170.04 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.188 -0.945 . . . . 0.0 108.861 179.821 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.519 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -138.46 155.08 48.78 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.085 -1.01 . . . . 0.0 109.6 -179.908 . . . . . . . . 3 3 . 1 . 041 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.813 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 77.6 m-85 -129.67 99.11 5.03 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.271 -0.893 . . . . 0.0 109.424 -179.686 . . . . . . . . 2 2 . 1 . 041 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 14.3 p30 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 118.011 -0.995 . . . . 0.0 109.463 179.992 . . . . . . . . 0 0 . 1 . 041 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.868 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 042 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -111.62 152.64 44.19 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.296 -0.878 . . . . 0.0 109.498 179.933 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.497 ' O ' HG23 ' A' ' 4' ' ' THR . 2.6 Cg_endo -61.43 156.83 44.25 Favored 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 122.271 1.981 . . . . 0.0 110.534 179.981 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.6 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -155.01 160.96 41.45 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 -179.511 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -146.8 127.98 14.74 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 119.011 -1.075 . . . . 0.0 110.594 -179.731 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.012 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -104.72 104.85 14.72 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-O 122.532 1.158 . . . . 0.0 110.142 -179.519 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.974 HG22 HG23 ' A' ' 21' ' ' VAL . 12.5 t -119.48 120.0 62.25 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.438 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.355 179.616 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.519 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.67 150.3 8.84 Favored Pre-proline 0 N--CA 1.489 1.492 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 -179.621 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.519 ' HA ' HG23 ' A' ' 8' ' ' THR . 1.3 Cg_endo -74.22 153.98 99.42 Favored 'Cis proline' 0 C--N 1.31 -1.493 0 C-N-CA 123.621 -1.408 . . . . 0.0 109.927 -0.482 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.628 ' HA ' HG22 ' A' ' 110' ' ' ILE . 4.5 m -93.64 -23.94 18.08 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.646 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.495 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 3.1 m -137.12 166.14 24.41 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.61 -0.681 . . . . 0.0 109.424 179.919 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.14 38.09 40.93 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 108.346 -1.902 . . . . 0.0 108.346 -179.6 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.852 ' CA ' HG21 ' A' ' 17' ' ' THR . 29.9 mt -91.42 -45.21 8.68 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 123.131 1.444 . . . . 0.0 110.676 -178.316 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 65.28 146.16 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.763 -1.562 . . . . 0.0 109.942 -179.704 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.592 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.5 p-10 -51.44 110.14 0.42 Allowed 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 121.532 0.682 . . . . 0.0 111.664 -178.614 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 111.52 13.97 12.23 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.557 -1.306 . . . . 0.0 112.731 177.345 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.852 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.0 t -102.66 -173.38 2.31 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 120.929 2.364 . . . . 0.0 109.632 179.365 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.73 HG13 ' C ' ' A' ' 67' ' ' LEU . 12.7 t -132.15 137.75 53.96 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.866 -1.061 . . . . 0.0 111.14 -178.995 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.498 HG13 ' CG2' ' A' ' 69' ' ' VAL . 29.2 m -114.57 154.48 15.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.351 -0.843 . . . . 0.0 109.07 178.934 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.555 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.3 tttt -109.33 108.93 19.68 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.266 -0.896 . . . . 0.0 109.126 179.83 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.974 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -107.25 122.92 62.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 -179.954 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.012 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.48 165.96 12.19 Favored 'General case' 0 C--N 1.306 -1.283 0 O-C-N 120.761 -1.212 . . . . 0.0 109.136 179.694 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.58 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.15 107.84 0.49 Allowed Glycine 0 N--CA 1.483 1.793 0 N-CA-C 108.683 -1.767 . . . . 0.0 108.683 179.865 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.6 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.49 141.15 48.56 Favored 'General case' 0 N--CA 1.5 2.051 0 CA-C-N 119.248 1.524 . . . . 0.0 110.273 -179.389 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.44 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.28 28.37 33.75 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 118.943 -1.598 . . . . 0.0 109.767 179.621 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.523 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -94.54 173.66 7.51 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.941 -1.329 . . . . 0.0 108.553 179.971 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.005 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.72 98.74 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.006 -1.059 . . . . 0.0 109.703 -179.885 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.622 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.41 76.6 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.644 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.188 -179.21 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 135.06 33.35 0.28 Allowed Glycine 0 N--CA 1.486 1.993 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.483 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.627 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -142.49 111.83 6.6 Favored 'General case' 0 C--N 1.309 -1.174 0 O-C-N 120.928 -1.336 . . . . 0.0 111.075 -179.929 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.579 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.5 113.34 0.8 Allowed 'General case' 0 N--CA 1.497 1.922 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.915 178.67 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.627 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 11.9 m-85 -107.14 153.06 23.21 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.263 -0.898 . . . . 0.0 108.592 179.441 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.482 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -101.66 159.55 15.22 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.729 -1.232 . . . . 0.0 107.994 178.884 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.002 HG11 HG21 ' A' ' 65' ' ' THR . 6.4 p -139.84 114.66 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 109.667 -178.086 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.96 -179.51 37.55 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 118.384 -1.865 . . . . 0.0 111.733 -179.449 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.633 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.1 pt20 -101.92 109.39 21.12 Favored 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 -179.889 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.472 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.69 149.37 52.37 Favored 'General case' 0 C--N 1.296 -1.751 0 O-C-N 121.14 -0.975 . . . . 0.0 110.087 -179.867 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.07 138.2 54.73 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.276 -0.89 . . . . 0.0 110.809 -178.976 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.887 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.26 115.0 26.85 Favored 'General case' 0 N--CA 1.493 1.688 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 178.055 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -104.36 14.3 7.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 121.044 -1.035 . . . . 0.0 110.491 -178.853 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.758 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.29 -174.86 0.07 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.977 -1.077 . . . . 0.0 110.095 179.765 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -72.96 98.68 2.54 Favored 'General case' 0 N--CA 1.485 1.3 0 O-C-N 121.387 -0.821 . . . . 0.0 109.606 -179.803 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.61 27.41 32.5 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 120.251 -0.975 . . . . 0.0 111.394 179.011 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.758 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -117.64 105.96 19.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 O-C-N 120.571 -1.547 . . . . 0.0 107.335 178.849 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.887 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.4 tp -117.95 104.38 10.84 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.408 -1.433 . . . . 0.0 109.741 -177.772 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.908 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.15 109.36 22.13 Favored 'General case' 0 N--CA 1.484 1.239 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 178.829 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.4 t -105.56 165.82 10.88 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.029 -1.044 . . . . 0.0 110.277 -178.612 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.614 HD22 ' HB3' ' A' ' 50' ' ' ALA . 50.8 t30 -110.66 134.93 20.77 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 121.49 -0.756 . . . . 0.0 109.885 -179.409 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.602 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -75.32 25.46 0.39 Allowed 'Trans proline' 0 C--N 1.319 -1.011 0 C-N-CA 122.328 2.019 . . . . 0.0 111.404 179.591 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.614 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -112.74 0.1 15.18 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.484 -1.385 . . . . 0.0 109.373 179.944 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.524 ' O ' ' CD2' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.67 16.1 2.71 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 179.601 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -78.8 91.66 4.75 Favored 'General case' 0 C--N 1.304 -1.407 0 C-N-CA 119.872 -0.731 . . . . 0.0 110.952 -178.648 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -110.1 -166.58 1.1 Allowed 'General case' 0 N--CA 1.49 1.56 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.281 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.448 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.7 136.44 0.09 Allowed 'General case' 0 N--CA 1.486 1.336 0 O-C-N 120.546 -1.346 . . . . 0.0 111.502 -179.289 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.957 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.4 OUTLIER -154.39 157.15 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 178.174 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.579 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.37 143.95 28.28 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.772 -1.205 . . . . 0.0 109.91 -179.827 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.005 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.58 106.64 1.2 Allowed 'General case' 0 C--N 1.299 -1.587 0 CA-C-O 122.478 1.132 . . . . 0.0 109.325 178.556 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.9 p-10 -59.28 -139.53 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.937 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.918 -179.928 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.622 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.01 -50.0 62.25 Favored 'General case' 0 N--CA 1.5 2.035 0 O-C-N 121.434 -0.791 . . . . 0.0 110.731 -178.703 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.418 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.5 t-20 -103.77 -34.35 8.59 Favored 'General case' 0 C--N 1.287 -2.136 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 178.379 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.004 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.76 66.13 0.61 Allowed Glycine 0 C--N 1.297 -1.599 0 N-CA-C 110.459 -1.056 . . . . 0.0 110.459 178.126 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.8 m -104.36 124.23 48.83 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.683 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.957 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.89 109.2 8.9 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 119.692 -0.803 . . . . 0.0 109.506 -179.278 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.2 m -116.88 116.35 27.27 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.3 -0.875 . . . . 0.0 109.353 -179.93 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 1.002 HG21 HG11 ' A' ' 34' ' ' VAL . 1.2 t -140.78 139.08 34.53 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.507 -0.745 . . . . 0.0 109.762 179.998 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.6 p -99.02 138.38 36.2 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.38 -0.825 . . . . 0.0 108.982 179.631 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.809 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.56 166.44 24.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.269 -0.894 . . . . 0.0 109.547 -179.15 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.66 HG22 HG22 ' A' ' 18' ' ' VAL . 2.8 p -95.3 125.02 39.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.061 -1.025 . . . . 0.0 109.44 -179.818 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.609 HG23 HD13 ' A' ' 13' ' ' LEU . 15.0 m -133.29 143.32 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.847 0 O-C-N 120.955 -1.091 . . . . 0.0 109.798 -179.207 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.592 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.59 -170.7 3.58 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.484 -1.385 . . . . 0.0 111.092 179.992 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.606 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -63.12 -101.87 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.954 -0.466 . . . . 0.0 110.309 -179.034 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.535 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -58.95 137.98 57.64 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 120.595 -1.316 . . . . 0.0 108.534 -180.0 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.633 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.8 OUTLIER -156.62 156.59 33.79 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 118.807 -1.157 . . . . 0.0 109.746 -178.864 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.545 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 10.3 mm-40 -48.35 122.28 5.21 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.273 -0.892 . . . . 0.0 109.587 -178.603 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.908 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.32 46.78 3.41 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -179.555 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.602 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -38.59 112.92 0.26 Allowed 'General case' 0 N--CA 1.506 2.351 0 O-C-N 121.22 -1.164 . . . . 0.0 110.537 -179.795 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.753 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.8 tp -86.79 126.89 34.92 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.986 -1.071 . . . . 0.0 109.366 179.945 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.588 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.8 t80 -63.68 58.41 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.017 0 O-C-N 120.851 -1.156 . . . . 0.0 110.21 179.761 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.533 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.1 t0 -161.1 19.52 0.12 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.927 -1.108 . . . . 0.0 109.786 179.816 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.28 -26.73 5.46 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 179.798 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 47.2 p -93.88 160.72 14.61 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.958 -1.319 . . . . 0.0 110.275 -179.508 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.486 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.9 OUTLIER -107.23 134.92 49.61 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 179.895 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.753 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.2 t90 -81.74 -17.46 47.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.956 -1.09 . . . . 0.0 110.327 -178.608 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 113.12 173.46 18.76 Favored Glycine 0 N--CA 1.485 1.936 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 -179.544 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -63.77 107.34 1.17 Allowed 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 179.093 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.645 HG21 ' HB3' ' A' ' 46' ' ' ALA . 44.5 t -78.7 104.61 6.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 121.398 -0.814 . . . . 0.0 109.275 -178.686 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.557 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.2 m-20 -64.88 108.86 1.89 Allowed 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.545 -0.722 . . . . 0.0 110.032 -179.377 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.606 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.6 t -60.3 -5.52 1.15 Allowed 'General case' 0 N--CA 1.501 2.113 0 C-N-CA 118.164 -1.414 . . . . 0.0 110.343 179.302 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 33.1 p -89.51 0.83 56.61 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.486 -1.384 . . . . 0.0 109.528 179.987 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.557 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -111.67 -48.61 3.06 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.201 -0.937 . . . . 0.0 109.129 -179.894 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.31 179.38 4.27 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.592 -0.693 . . . . 0.0 109.539 -179.896 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.28 113.31 26.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.369 -0.832 . . . . 0.0 108.925 179.826 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.515 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.8 m -96.55 121.07 37.98 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.035 -1.041 . . . . 0.0 109.43 -178.854 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.589 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.82 148.11 25.7 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-O 122.416 1.103 . . . . 0.0 111.301 -179.375 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.625 ' HB ' HG11 ' A' ' 7' ' ' VAL . 47.7 t -104.41 109.96 29.03 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 N-CA-C 106.697 -1.594 . . . . 0.0 106.697 177.607 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.457 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.51 -171.15 17.79 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 118.15 -1.976 . . . . 0.0 111.589 -177.686 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.541 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -115.08 -178.54 3.39 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -178.888 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.574 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.2 p 178.65 171.03 0.81 Allowed 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.224 -0.923 . . . . 0.0 109.65 -179.113 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.451 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -122.26 -159.58 0.83 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 120.902 -1.124 . . . . 0.0 108.934 179.801 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.404 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.62 36.58 4.08 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.673 -1.267 . . . . 0.0 109.134 179.985 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -116.27 -34.04 4.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.374 -0.829 . . . . 0.0 110.099 -179.686 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.791 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.4 -37.03 0.23 Allowed Glycine 0 N--CA 1.481 1.692 0 N-CA-C 107.915 -2.074 . . . . 0.0 107.915 -179.72 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.23 -177.47 5.73 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 121.542 -0.975 . . . . 0.0 110.09 179.419 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.37 -163.69 23.82 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 108.17 -1.972 . . . . 0.0 108.17 -179.512 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.541 ' HB2' HD12 ' A' ' 97' ' ' LEU . 7.2 Cg_exo -46.09 172.78 0.02 OUTLIER 'Trans proline' 0 C--O 1.214 -0.693 0 CA-C-N 119.084 1.442 . . . . 0.0 109.938 179.332 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -91.16 -177.2 4.82 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.071 -1.018 . . . . 0.0 110.701 -178.632 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.457 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.27 168.36 13.81 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.842 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.47 133.57 51.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.43 -1.041 . . . . 0.0 109.176 -179.202 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.589 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.68 123.48 24.14 Favored 'General case' 0 C--N 1.291 -1.976 0 O-C-N 121.55 -0.719 . . . . 0.0 109.874 179.72 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.837 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.97 172.77 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.137 -0.977 . . . . 0.0 108.969 179.711 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.495 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -139.97 157.74 45.18 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.036 -1.04 . . . . 0.0 110.094 -179.627 . . . . . . . . 3 3 . 1 . 042 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.837 ' CE1' HD12 ' A' ' 110' ' ' ILE . 88.0 m-85 -133.23 93.36 3.15 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.224 -0.922 . . . . 0.0 109.444 -179.825 . . . . . . . . 2 2 . 1 . 042 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.468 ' OD1' ' OXT' ' A' ' 113' ' ' ASN . 6.9 p30 . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 118.049 -0.977 . . . . 0.0 109.55 -179.904 . . . . . . . . 1 1 . 1 . 042 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.791 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 043 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.934 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -122.27 173.07 4.47 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.256 -0.903 . . . . 0.0 109.406 -179.925 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.934 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 6.0 Cg_exo -59.52 158.66 26.58 Favored 'Trans proline' 0 C--N 1.31 -1.475 0 C-N-CA 122.212 1.941 . . . . 0.0 110.522 179.932 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.546 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.38 -169.7 0.15 Allowed 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 179.403 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.553 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -165.37 130.46 2.51 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 120.818 -1.176 . . . . 0.0 110.751 -179.083 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.936 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.6 t -111.75 108.54 18.01 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-O 123.099 1.428 . . . . 0.0 109.053 179.339 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.897 HG22 HG23 ' A' ' 21' ' ' VAL . 5.6 t -117.71 137.39 51.78 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.716 0 CA-C-N 114.284 -1.326 . . . . 0.0 109.935 -179.616 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.493 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -172.85 149.11 1.8 Allowed Pre-proline 0 N--CA 1.485 1.316 0 O-C-N 121.241 -0.912 . . . . 0.0 108.815 -179.717 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.493 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -76.63 151.08 94.07 Favored 'Cis proline' 0 C--N 1.311 -1.439 0 C-N-CA 123.478 -1.468 . . . . 0.0 109.467 -0.865 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.685 ' HA ' HG22 ' A' ' 110' ' ' ILE . 65.3 p -90.17 -25.18 20.79 Favored 'General case' 0 C--N 1.294 -1.842 0 O-C-N 121.564 -0.71 . . . . 0.0 109.123 179.686 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.511 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 13.5 m -134.16 165.04 26.01 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.459 -0.776 . . . . 0.0 109.534 -179.904 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.22 38.28 34.79 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 -179.61 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.76 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.0 mt -92.4 -42.92 9.5 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 123.236 1.493 . . . . 0.0 110.525 -178.322 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.0 143.86 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.468 -1.696 . . . . 0.0 109.686 -179.534 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.583 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 6.0 p-10 -50.98 107.19 0.16 Allowed 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 121.625 0.726 . . . . 0.0 111.608 -178.437 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.46 11.61 11.59 Favored Glycine 0 N--CA 1.485 1.902 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.087 177.254 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.76 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -102.3 -169.8 1.72 Allowed 'General case' 0 C--N 1.312 -1.043 0 CA-C-N 121.111 2.455 . . . . 0.0 109.615 179.397 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.765 HG13 ' C ' ' A' ' 67' ' ' LEU . 12.0 t -134.17 142.23 41.56 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.702 -179.255 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.579 HG12 HD21 ' A' ' 13' ' ' LEU . 35.0 m -119.88 155.21 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.276 -0.89 . . . . 0.0 108.853 179.313 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 11.1 tttt -103.96 109.24 20.93 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.207 -0.933 . . . . 0.0 109.158 -179.965 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.897 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -101.94 140.87 19.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.607 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.936 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.3 160.15 39.89 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 118.62 -1.232 . . . . 0.0 109.949 179.795 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.594 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -130.19 143.89 15.16 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 179.578 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.576 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -145.73 125.93 13.83 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 120.87 -1.371 . . . . 0.0 108.911 179.296 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.531 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 88.73 26.39 27.24 Favored Glycine 0 N--CA 1.488 2.137 0 C-N-CA 119.296 -1.43 . . . . 0.0 109.777 -179.692 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.554 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.0 mt -86.84 175.3 8.26 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.918 -1.342 . . . . 0.0 108.364 -179.933 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.85 97.33 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.961 -1.087 . . . . 0.0 109.737 -179.61 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.675 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.53 77.32 0.0 OUTLIER 'General case' 0 C--N 1.294 -1.813 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.42 -179.134 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.12 34.4 0.33 Allowed Glycine 0 N--CA 1.486 2.005 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.381 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.549 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 38.4 p -147.78 113.26 5.63 Favored 'General case' 0 C--N 1.307 -1.251 0 O-C-N 121.045 -1.267 . . . . 0.0 111.236 -179.819 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.569 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -43.53 128.41 5.06 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.823 178.263 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.49 ' CD2' ' O ' ' A' ' 30' ' ' THR . 11.3 m-85 -121.38 149.8 42.43 Favored 'General case' 0 N--CA 1.492 1.657 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.596 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.509 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.49 156.35 17.33 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.642 -1.286 . . . . 0.0 107.854 178.84 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.649 HG13 ' O ' ' A' ' 34' ' ' VAL . 5.6 p -138.53 114.79 10.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.062 -1.024 . . . . 0.0 109.713 -178.06 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.08 -178.3 35.86 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.249 -1.929 . . . . 0.0 111.908 -179.529 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.568 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -101.03 112.55 25.04 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 -179.941 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 66.8 m -130.64 153.11 49.27 Favored 'General case' 0 C--N 1.294 -1.841 0 O-C-N 121.365 -0.834 . . . . 0.0 109.615 179.746 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.694 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -127.43 135.91 51.1 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.482 -0.761 . . . . 0.0 110.491 -179.957 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.885 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.6 OUTLIER -94.83 114.37 26.24 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 107.243 -1.391 . . . . 0.0 107.243 178.137 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 m -106.27 14.86 7.47 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 O-C-N 120.966 -1.084 . . . . 0.0 110.763 -178.473 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.776 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.21 -175.47 0.08 Allowed 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.856 -1.152 . . . . 0.0 110.222 179.655 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 42' ' ' THR . 15.2 t -69.75 97.09 1.04 Allowed 'General case' 0 N--CA 1.488 1.447 0 CA-C-O 121.83 0.824 . . . . 0.0 109.952 -179.445 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.66 27.15 36.09 Favored Glycine 0 N--CA 1.494 2.546 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.515 178.679 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.776 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.4 t -114.48 106.18 20.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.233 0 O-C-N 120.6 -1.53 . . . . 0.0 107.483 178.901 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.92 HD22 H182 ' A' ' 114' ' ' CHR . 11.7 tp -116.94 106.54 13.54 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.574 -1.329 . . . . 0.0 109.662 -177.724 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.096 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -95.99 111.97 23.83 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 120.676 -1.265 . . . . 0.0 108.256 179.445 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.545 ' HB3' ' CE1' ' A' ' 52' ' ' PHE . 66.8 m -101.67 147.76 26.06 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.33 -0.856 . . . . 0.0 110.71 -178.291 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.696 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 24.4 t30 -103.45 126.11 33.06 Favored Pre-proline 0 N--CA 1.503 2.198 0 O-C-N 121.248 -0.908 . . . . 0.0 108.838 179.053 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.586 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 1.5 Cg_endo -70.58 23.85 0.2 Allowed 'Trans proline' 0 CA--C 1.545 1.031 0 C-N-CA 122.108 1.872 . . . . 0.0 112.561 -179.657 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.696 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -110.15 2.15 19.21 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.252 -1.53 . . . . 0.0 109.317 179.346 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.562 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.54 16.18 2.55 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 179.628 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.545 ' CE1' ' HB3' ' A' ' 47' ' ' CYS . 0.8 OUTLIER -79.08 91.51 4.91 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.579 -0.701 . . . . 0.0 110.885 -178.568 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.625 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -108.67 -165.71 1.05 Allowed 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.284 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 179.04 135.3 0.09 Allowed 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.514 -1.366 . . . . 0.0 111.564 -179.339 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.899 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -153.2 157.83 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 107.116 -1.438 . . . . 0.0 107.116 178.024 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.569 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.71 145.92 25.86 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.658 -1.276 . . . . 0.0 109.865 -179.73 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.38 107.98 2.2 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 122.368 1.08 . . . . 0.0 109.478 178.733 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.526 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.2 t0 -62.02 -139.11 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.045 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.931 -179.948 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.675 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.84 -51.62 38.71 Favored 'General case' 0 N--CA 1.5 2.046 0 O-C-N 121.477 -0.764 . . . . 0.0 110.733 -178.614 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.73 -32.39 8.89 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 178.726 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.978 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.15 65.38 0.59 Allowed Glycine 0 C--N 1.297 -1.59 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 178.307 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.594 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 48.4 m -101.77 127.99 48.31 Favored 'General case' 0 C--N 1.309 -1.187 0 O-C-N 121.468 -1.019 . . . . 0.0 108.711 178.858 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.899 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.92 108.77 7.08 Favored 'General case' 0 C--N 1.295 -1.768 0 C-N-CA 119.316 -0.953 . . . . 0.0 109.819 -179.214 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 40.2 p -121.95 120.11 33.47 Favored 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.322 -0.861 . . . . 0.0 109.481 179.945 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.438 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -145.74 147.97 32.49 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.482 -0.761 . . . . 0.0 109.245 179.845 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 24.3 p -98.64 139.74 33.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.355 -0.84 . . . . 0.0 109.593 -179.876 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.765 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -143.75 157.45 44.38 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.366 -0.834 . . . . 0.0 109.202 -179.466 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.641 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 14.4 t -86.25 137.73 32.39 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.056 -1.028 . . . . 0.0 110.427 -179.645 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.539 HG23 HD13 ' A' ' 13' ' ' LEU . 24.1 m -148.6 141.43 18.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.467 -0.771 . . . . 0.0 109.525 -179.444 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.583 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -143.63 -170.68 3.36 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.563 -1.335 . . . . 0.0 110.368 -179.984 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.577 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -64.4 -94.61 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 -179.812 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.524 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.77 137.73 56.27 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.776 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.694 ' HZ ' ' HB2' ' A' ' 38' ' ' ALA . 0.3 OUTLIER -162.19 137.96 7.49 Favored 'General case' 0 C--N 1.293 -1.886 0 C-N-CA 118.3 -1.36 . . . . 0.0 110.473 -177.683 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.541 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 0.8 OUTLIER -32.42 118.91 0.28 Allowed 'General case' 0 N--CA 1.493 1.682 0 CA-C-O 121.5 0.667 . . . . 0.0 110.6 -178.497 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.096 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.97 49.42 1.76 Allowed Glycine 0 N--CA 1.492 2.403 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.542 -179.028 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.586 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.8 m-85 -40.0 115.55 0.55 Allowed 'General case' 0 N--CA 1.509 2.517 0 O-C-N 121.029 -1.277 . . . . 0.0 109.731 179.347 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.709 HD11 HG12 ' A' ' 44' ' ' VAL . 7.6 tp -85.81 127.21 34.5 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 120.943 -1.098 . . . . 0.0 109.66 -179.673 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.579 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 22.1 t80 -64.55 57.97 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.856 -1.153 . . . . 0.0 110.182 179.664 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -160.47 19.62 0.14 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.929 -1.107 . . . . 0.0 109.718 179.885 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.07 -28.12 5.23 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.952 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.454 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 34.6 p -92.59 156.28 17.21 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.06 -1.259 . . . . 0.0 110.309 -179.439 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.481 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -105.04 134.73 47.65 Favored 'General case' 0 C--N 1.3 -1.581 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.664 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.616 ' HB2' HD13 ' A' ' 77' ' ' LEU . 0.6 OUTLIER -82.55 -17.21 45.76 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 120.655 -1.278 . . . . 0.0 110.518 -178.372 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 106.67 176.42 23.14 Favored Glycine 0 N--CA 1.485 1.904 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -179.791 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.72 105.38 0.65 Allowed 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 179.095 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.581 HG21 ' CB ' ' A' ' 46' ' ' ALA . 36.8 t -76.43 104.08 4.26 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.421 -0.799 . . . . 0.0 109.046 -178.816 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.545 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -62.39 109.51 1.38 Allowed 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.546 -0.721 . . . . 0.0 110.027 -179.343 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.577 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.8 t -65.85 -4.49 6.86 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 120.565 -1.335 . . . . 0.0 109.728 179.256 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.5 p -85.37 3.78 38.31 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.848 -1.158 . . . . 0.0 108.989 179.499 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.545 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -119.37 -49.08 2.38 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.409 -0.807 . . . . 0.0 109.026 -179.999 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.91 -178.88 3.78 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.491 -0.756 . . . . 0.0 109.474 179.826 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.55 115.26 29.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.366 -0.833 . . . . 0.0 109.138 -179.924 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.547 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.85 124.88 40.95 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.845 -1.16 . . . . 0.0 109.201 -179.628 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.572 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -104.12 146.77 28.27 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 122.379 1.085 . . . . 0.0 111.709 -179.027 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.525 ' CG1' HG11 ' A' ' 7' ' ' VAL . 84.1 t -100.4 109.81 25.97 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 177.348 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -145.87 -174.2 17.83 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 118.064 -2.017 . . . . 0.0 111.782 -177.426 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.553 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -117.62 -178.8 3.56 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 -178.95 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.548 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 1.2 p -173.28 170.19 4.33 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 121.423 -0.798 . . . . 0.0 109.094 -179.425 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.671 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 1.7 m-20 -106.07 -9.34 17.04 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.107 -0.996 . . . . 0.0 109.542 179.917 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.671 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 72.72 39.76 0.66 Allowed 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.443 -0.785 . . . . 0.0 109.121 179.991 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -137.44 -34.47 0.7 Allowed 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.629 -0.669 . . . . 0.0 110.646 -179.427 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.693 ' HA2' H192 ' A' ' 114' ' ' CHR . . . -177.09 -42.8 0.06 OUTLIER Glycine 0 N--CA 1.482 1.709 0 N-CA-C 107.867 -2.093 . . . . 0.0 107.867 -179.712 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.61 -178.11 6.36 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 121.504 -0.998 . . . . 0.0 109.626 179.209 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -176.13 -165.89 32.62 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.473 -1.851 . . . . 0.0 108.473 -179.479 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.539 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.7 Cg_exo -49.53 -175.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.646 0 CA-C-N 118.874 1.337 . . . . 0.0 110.371 179.572 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 16.5 mm-40 -95.89 -178.85 4.5 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.093 -1.004 . . . . 0.0 110.248 -179.094 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -115.64 158.74 14.2 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 -179.906 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.94 128.35 50.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.421 -1.046 . . . . 0.0 108.982 -179.555 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.572 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.32 119.26 16.27 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.589 -0.695 . . . . 0.0 109.959 179.964 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.914 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -97.97 172.61 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.241 -0.912 . . . . 0.0 108.677 179.544 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.511 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.3 OUTLIER -140.7 156.91 46.09 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.945 -1.097 . . . . 0.0 110.012 -179.761 . . . . . . . . 3 3 . 1 . 043 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.914 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.6 m-85 -132.8 114.63 14.32 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.289 -0.882 . . . . 0.0 109.506 -179.749 . . . . . . . . 2 2 . 1 . 043 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.42 ' C ' ' O ' ' A' ' 112' ' ' PHE . 23.5 p30 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.036 -0.983 . . . . 0.0 109.491 -179.984 . . . . . . . . 1 1 . 1 . 043 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.92 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 044 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.756 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -93.93 165.91 16.85 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.347 -0.846 . . . . 0.0 109.535 179.995 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.756 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.2 Cg_exo -59.97 157.53 33.49 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.371 2.048 . . . . 0.0 110.667 179.969 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.605 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -147.12 160.58 42.26 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 -179.681 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.44 122.42 9.43 Favored 'General case' 0 C--N 1.297 -1.705 0 CA-C-O 122.427 1.108 . . . . 0.0 110.278 -179.659 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.793 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.1 t -116.21 109.22 17.14 Favored 'General case' 0 C--N 1.297 -1.716 0 CA-C-O 123.09 1.424 . . . . 0.0 109.767 -179.992 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.836 HG22 HG23 ' A' ' 21' ' ' VAL . 2.4 t -112.87 136.26 49.71 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.745 0 CA-C-N 114.24 -1.345 . . . . 0.0 109.776 179.909 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.462 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.65 148.23 5.6 Favored Pre-proline 0 N--CA 1.487 1.396 0 O-C-N 121.184 -0.947 . . . . 0.0 108.855 -179.557 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.462 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.4 Cg_endo -76.46 151.18 94.44 Favored 'Cis proline' 0 C--N 1.312 -1.352 0 C-N-CA 123.38 -1.508 . . . . 0.0 109.422 -0.812 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.648 ' HA ' HG22 ' A' ' 110' ' ' ILE . 2.1 m -88.35 -26.73 22.06 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.593 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.484 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 13.4 m -136.73 165.14 26.61 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.616 -0.678 . . . . 0.0 109.446 179.807 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.31 37.69 31.12 Favored Glycine 0 N--CA 1.497 2.735 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 -179.631 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.742 ' CA ' HG21 ' A' ' 17' ' ' THR . 38.7 mt -92.84 -41.98 9.78 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-O 123.362 1.553 . . . . 0.0 110.418 -178.342 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.476 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.45 143.24 0.05 OUTLIER 'General case' 0 C--N 1.261 -3.279 0 CA-C-N 113.297 -1.774 . . . . 0.0 109.808 -179.57 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.601 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.3 p-10 -50.79 104.75 0.08 Allowed 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 121.462 0.649 . . . . 0.0 111.432 -178.369 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.4 15.19 7.76 Favored Glycine 0 N--CA 1.485 1.963 0 C-N-CA 119.317 -1.421 . . . . 0.0 113.086 177.311 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.742 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -104.72 -170.33 1.75 Allowed 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 121.165 2.482 . . . . 0.0 109.579 179.09 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.736 HG13 ' C ' ' A' ' 67' ' ' LEU . 17.4 t -127.4 137.41 57.81 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.357 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.116 -179.133 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.633 HG13 ' CG2' ' A' ' 69' ' ' VAL . 11.7 m -111.28 156.32 12.47 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.315 -0.866 . . . . 0.0 108.852 178.932 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.504 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.4 tttt -111.55 109.48 19.42 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.214 -0.929 . . . . 0.0 108.843 179.854 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.836 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -102.91 138.8 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 179.975 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.793 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -132.61 161.76 33.06 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.861 -1.135 . . . . 0.0 109.941 179.689 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.588 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.92 140.75 11.85 Favored Glycine 0 C--N 1.298 -1.547 0 N-CA-C 108.144 -1.983 . . . . 0.0 108.144 179.776 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.605 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.54 125.4 16.09 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.606 -1.526 . . . . 0.0 109.296 179.374 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.46 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.2 28.51 20.06 Favored Glycine 0 N--CA 1.489 2.187 0 C-N-CA 118.69 -1.719 . . . . 0.0 109.807 -179.808 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.681 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.4 mt -89.53 171.95 9.34 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 120.936 -1.332 . . . . 0.0 108.301 179.852 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.013 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.0 99.33 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.96 -1.087 . . . . 0.0 109.892 -179.385 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.549 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.23 77.66 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.212 -179.337 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.19 34.02 0.3 Allowed Glycine 0 N--CA 1.487 2.099 0 N-CA-C 109.444 -1.463 . . . . 0.0 109.444 179.57 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.557 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 48.2 p -141.94 108.57 5.35 Favored 'General case' 0 C--N 1.306 -1.284 0 O-C-N 121.048 -1.266 . . . . 0.0 111.252 -179.527 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.59 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.16 109.71 0.32 Allowed 'General case' 0 N--CA 1.496 1.843 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.584 177.944 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.484 ' CE1' ' OG1' ' A' ' 30' ' ' THR . 4.6 m-30 -104.26 156.14 18.15 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.145 -0.972 . . . . 0.0 108.774 179.752 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.509 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -99.7 165.36 11.64 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.978 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.05 HG11 HG21 ' A' ' 65' ' ' THR . 4.5 p -146.66 116.23 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.085 -1.009 . . . . 0.0 109.759 -178.15 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.515 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -166.73 -176.89 38.17 Favored Glycine 0 N--CA 1.494 2.52 0 C-N-CA 118.175 -1.964 . . . . 0.0 111.709 -179.608 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.649 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.3 pt20 -101.47 109.77 21.65 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.979 0.895 . . . . 0.0 109.055 -179.653 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.488 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.99 150.46 52.13 Favored 'General case' 0 C--N 1.296 -1.719 0 O-C-N 121.224 -0.922 . . . . 0.0 109.554 179.846 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.48 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.78 139.0 54.24 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.079 -1.013 . . . . 0.0 110.775 -178.949 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.884 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.16 114.64 26.45 Favored 'General case' 0 N--CA 1.493 1.678 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 178.196 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m -105.46 15.19 7.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.068 -1.02 . . . . 0.0 110.561 -178.688 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.746 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 175.42 -175.38 0.1 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.894 -1.128 . . . . 0.0 110.114 179.631 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -71.6 96.81 1.6 Allowed 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.426 -0.796 . . . . 0.0 109.743 -179.696 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.01 27.5 33.89 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 120.194 -1.003 . . . . 0.0 111.482 178.877 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.746 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -115.42 106.29 20.23 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 O-C-N 120.523 -1.575 . . . . 0.0 107.443 178.861 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.884 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -115.75 104.67 11.9 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 120.389 -1.445 . . . . 0.0 109.967 -177.658 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.833 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.18 109.24 22.03 Favored 'General case' 0 N--CA 1.484 1.24 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.709 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.7 t -107.26 167.93 9.57 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.985 -1.072 . . . . 0.0 110.564 -178.397 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.74 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 49.9 t30 -112.61 130.9 22.97 Favored Pre-proline 0 N--CA 1.5 2.043 0 O-C-N 121.454 -0.779 . . . . 0.0 109.585 -179.435 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.51 ' CD ' ' HB3' ' A' ' 74' ' ' GLU . 2.8 Cg_endo -72.41 23.76 0.27 Allowed 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 122.189 1.926 . . . . 0.0 112.124 179.966 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.74 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -113.41 3.53 15.88 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.333 -1.479 . . . . 0.0 109.192 179.526 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.525 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.45 17.36 2.74 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 179.259 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -80.84 88.87 5.82 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.577 -0.702 . . . . 0.0 111.011 -178.593 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.618 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -107.27 -167.19 1.24 Allowed 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 178.266 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.8 OUTLIER 178.96 135.06 0.09 Allowed 'General case' 0 C--N 1.305 -1.353 0 O-C-N 120.496 -1.377 . . . . 0.0 111.372 -179.418 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.843 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.4 p -150.3 157.72 5.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 178.176 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.56 142.24 30.4 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.74 -1.225 . . . . 0.0 110.054 -179.847 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.13 107.73 1.36 Allowed 'General case' 0 C--N 1.298 -1.646 0 CA-C-O 122.469 1.128 . . . . 0.0 109.416 178.436 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.555 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.0 p-10 -61.2 -139.17 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 115.635 -0.712 . . . . 0.0 110.762 179.893 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.549 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.29 -51.07 60.66 Favored 'General case' 0 N--CA 1.499 1.996 0 O-C-N 121.431 -0.793 . . . . 0.0 110.454 -178.691 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -101.75 -34.95 9.24 Favored 'General case' 0 C--N 1.285 -2.221 0 N-CA-C 106.287 -1.745 . . . . 0.0 106.287 178.342 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.28 65.87 0.59 Allowed Glycine 0 C--N 1.298 -1.565 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.082 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 49.5 m -98.71 130.83 45.21 Favored 'General case' 0 N--CA 1.485 1.319 0 O-C-N 121.503 -0.998 . . . . 0.0 108.482 178.729 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.843 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.76 108.86 7.7 Favored 'General case' 0 C--N 1.299 -1.596 0 C-N-CA 118.956 -1.098 . . . . 0.0 109.796 -179.272 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 60.0 p -121.51 117.72 27.52 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.36 -0.838 . . . . 0.0 109.421 179.949 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 1.05 HG21 HG11 ' A' ' 34' ' ' VAL . 0.7 OUTLIER -144.99 142.17 29.57 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.489 -0.757 . . . . 0.0 109.593 179.981 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 34.0 p -99.87 141.59 32.48 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.436 -0.79 . . . . 0.0 109.287 179.815 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.736 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -142.04 166.18 25.42 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.354 -0.841 . . . . 0.0 109.418 -179.355 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.701 HG22 HG22 ' A' ' 18' ' ' VAL . 3.4 p -95.49 124.47 39.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.118 -0.989 . . . . 0.0 109.398 -179.852 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.633 ' CG2' HG13 ' A' ' 19' ' ' VAL . 18.8 m -139.76 142.56 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 120.946 -1.096 . . . . 0.0 109.964 -179.183 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.601 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.3 ptt180 -140.09 -166.35 2.08 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 120.627 -1.295 . . . . 0.0 109.897 179.903 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.594 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -71.93 -80.68 0.06 Allowed 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 179.952 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.507 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.5 OUTLIER -64.13 135.97 56.83 Favored 'General case' 0 N--CA 1.488 1.432 0 N-CA-C 107.197 -1.409 . . . . 0.0 107.197 178.579 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.591 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.3 OUTLIER -161.98 138.68 8.14 Favored 'General case' 0 C--N 1.294 -1.836 0 C-N-CA 118.07 -1.452 . . . . 0.0 110.252 -177.692 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.51 ' HB3' ' CD ' ' A' ' 49' ' ' PRO . 0.1 OUTLIER -31.04 121.39 0.22 Allowed 'General case' 0 N--CA 1.492 1.634 0 CA-C-O 121.479 0.657 . . . . 0.0 110.851 -178.31 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.833 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.95 50.62 2.83 Favored Glycine 0 N--CA 1.496 2.667 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 -179.489 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.47 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.5 OUTLIER -52.97 114.13 1.33 Allowed 'General case' 0 N--CA 1.51 2.55 0 O-C-N 120.934 -1.333 . . . . 0.0 110.645 -179.886 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.685 HD13 ' HB2' ' A' ' 83' ' ' TRP . 0.4 OUTLIER -78.94 151.95 31.37 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 120.864 -1.148 . . . . 0.0 108.231 178.114 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.575 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 63.7 t80 -74.68 5.5 4.83 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 120.69 -1.256 . . . . 0.0 110.563 -179.98 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -105.16 -2.49 24.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.905 -1.122 . . . . 0.0 109.701 -179.879 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.21 -19.45 51.42 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.998 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.49 ' O ' ' HB2' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -76.35 151.56 36.61 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.147 -1.207 . . . . 0.0 109.5 -179.947 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.512 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -96.82 123.08 40.42 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.896 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.685 ' HB2' HD13 ' A' ' 77' ' ' LEU . 0.7 OUTLIER -85.27 -16.68 39.33 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.968 -1.083 . . . . 0.0 110.046 -179.121 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 103.19 173.15 26.24 Favored Glycine 0 N--CA 1.483 1.829 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 -179.757 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -60.09 108.93 0.85 Allowed 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 178.853 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.635 HG23 ' HA3' ' A' ' 75' ' ' GLY . 25.5 t -78.88 101.27 4.16 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -178.844 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.531 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -62.14 110.41 1.6 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.548 -0.72 . . . . 0.0 110.046 -178.985 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.548 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -65.14 -4.78 5.38 Favored 'General case' 0 N--CA 1.499 1.993 0 C-N-CA 118.413 -1.315 . . . . 0.0 109.727 179.378 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.6 p -83.66 2.82 35.73 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.712 -1.242 . . . . 0.0 108.911 179.328 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.0 p -117.91 -48.53 2.55 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.406 -0.809 . . . . 0.0 108.974 -179.976 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.67 179.97 4.08 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.542 -0.724 . . . . 0.0 109.394 179.931 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.47 114.75 29.18 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.368 -0.832 . . . . 0.0 109.22 179.964 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.569 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.7 120.89 37.86 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.887 -1.133 . . . . 0.0 109.532 -179.305 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.611 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -100.91 148.25 25.2 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-O 122.38 1.086 . . . . 0.0 111.308 -179.322 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.507 ' CG1' HG11 ' A' ' 7' ' ' VAL . 43.2 t -105.06 111.56 35.04 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.012 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 177.66 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.427 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.47 -170.84 17.45 Favored Glycine 0 N--CA 1.486 2.025 0 C-N-CA 118.18 -1.962 . . . . 0.0 111.667 -177.65 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.495 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.68 178.81 4.2 Favored 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.016 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.584 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.0 OUTLIER -171.59 168.7 6.28 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.473 -0.767 . . . . 0.0 109.347 -179.517 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.464 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -118.1 -158.28 0.71 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.067 -1.021 . . . . 0.0 108.948 179.811 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.464 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.39 36.63 4.18 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.72 -1.238 . . . . 0.0 109.156 179.999 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -115.87 -32.74 5.35 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.262 -0.899 . . . . 0.0 110.225 -179.624 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.983 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 164.13 -35.49 0.29 Allowed Glycine 0 N--CA 1.482 1.763 0 N-CA-C 107.661 -2.175 . . . . 0.0 107.661 -179.648 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.28 -177.76 6.24 Favored 'General case' 0 C--N 1.305 -1.332 0 O-C-N 121.561 -0.964 . . . . 0.0 109.715 179.28 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -165.82 -161.78 15.63 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 108.41 -1.876 . . . . 0.0 108.41 -179.344 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.504 ' HG3' HD22 ' A' ' 26' ' ' LEU . 5.7 Cg_exo -47.22 178.97 0.0 OUTLIER 'Trans proline' 0 C--O 1.214 -0.678 0 CA-C-N 118.721 1.261 . . . . 0.0 110.345 179.378 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -92.97 -172.64 3.05 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.198 -0.939 . . . . 0.0 110.357 -178.866 . . . . . . . . 1 1 . 1 . 044 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.427 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -123.45 161.94 17.56 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -179.891 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.424 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -99.73 130.53 48.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.415 -1.05 . . . . 0.0 109.244 -179.514 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.611 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.22 120.81 19.36 Favored 'General case' 0 C--N 1.289 -2.043 0 O-C-N 121.716 -0.615 . . . . 0.0 109.646 179.684 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.878 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.6 pt -98.14 169.67 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 O-C-N 121.138 -0.976 . . . . 0.0 109.331 -179.956 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.484 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -136.96 151.16 48.69 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.256 -0.903 . . . . 0.0 109.694 -179.973 . . . . . . . . 3 3 . 1 . 044 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.878 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 36.7 m-85 -128.56 100.8 5.89 Favored 'General case' 0 C--N 1.305 -1.33 0 O-C-N 121.099 -1.001 . . . . 0.0 109.539 -179.727 . . . . . . . . 2 2 . 1 . 044 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 20.1 p30 . . . . . 0 N--CA 1.49 1.527 0 CA-C-O 117.987 -1.006 . . . . 0.0 109.417 -179.986 . . . . . . . . 0 0 . 1 . 044 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.983 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 045 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -110.31 155.48 41.86 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.239 -0.913 . . . . 0.0 109.558 179.918 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.656 ' HB3' HD23 ' A' ' 26' ' ' LEU . 3.5 Cg_exo -60.8 156.38 43.65 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.313 2.009 . . . . 0.0 110.62 -179.872 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.601 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -148.05 160.53 42.76 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.901 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -145.64 127.05 14.96 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 120.984 -1.072 . . . . 0.0 110.469 -179.67 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.016 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.4 p -105.56 105.04 14.89 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 122.501 1.143 . . . . 0.0 110.46 -179.352 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 1.127 HG22 HG23 ' A' ' 21' ' ' VAL . 3.5 t -118.12 117.82 56.09 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.426 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.267 179.426 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.485 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -161.34 148.49 11.83 Favored Pre-proline 0 N--CA 1.487 1.412 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 -179.588 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.485 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.2 Cg_endo -78.3 149.93 87.38 Favored 'Cis proline' 0 C--N 1.31 -1.491 0 C-N-CA 123.533 -1.445 . . . . 0.0 109.563 -0.573 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.66 ' HA ' HG22 ' A' ' 110' ' ' ILE . 88.5 p -92.23 -23.38 19.36 Favored 'General case' 0 C--N 1.291 -1.962 0 O-C-N 121.618 -0.676 . . . . 0.0 109.209 179.584 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.472 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -132.7 161.15 34.75 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.52 -0.737 . . . . 0.0 109.47 -179.91 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.01 37.76 32.07 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 -179.556 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.789 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.8 mt -90.83 -43.78 9.83 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 123.303 1.525 . . . . 0.0 110.674 -178.233 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.47 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.39 143.94 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.282 0 CA-C-N 113.508 -1.678 . . . . 0.0 109.899 -179.618 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.596 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -50.72 107.19 0.15 Allowed 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.683 0.754 . . . . 0.0 111.653 -178.611 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.26 15.46 8.99 Favored Glycine 0 N--CA 1.483 1.829 0 C-N-CA 119.557 -1.306 . . . . 0.0 112.801 177.461 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.789 HG21 ' CA ' ' A' ' 13' ' ' LEU . 14.7 t -105.3 -173.82 2.39 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 121.106 2.453 . . . . 0.0 109.914 179.309 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.756 HG13 ' O ' ' A' ' 67' ' ' LEU . 19.0 t -130.18 138.94 52.68 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 114.666 -1.152 . . . . 0.0 111.24 -178.61 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.518 HG12 HD21 ' A' ' 13' ' ' LEU . 34.6 m -115.92 155.65 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.367 -0.833 . . . . 0.0 108.817 178.725 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.541 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 12.4 tttt -107.72 109.33 20.89 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.03 -1.043 . . . . 0.0 109.66 -179.789 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 1.127 HG23 HG22 ' A' ' 7' ' ' VAL . 6.5 p -104.36 125.08 59.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.528 -0.732 . . . . 0.0 109.193 179.759 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.016 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -115.53 165.21 13.26 Favored 'General case' 0 C--N 1.305 -1.343 0 O-C-N 120.741 -1.224 . . . . 0.0 108.911 179.348 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.614 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.39 107.95 0.49 Allowed Glycine 0 N--CA 1.481 1.686 0 N-CA-C 108.242 -1.943 . . . . 0.0 108.242 -179.97 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.601 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -118.23 139.84 50.69 Favored 'General case' 0 N--CA 1.5 2.035 0 CA-C-N 119.635 1.718 . . . . 0.0 110.464 -179.171 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.48 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 83.76 28.46 35.06 Favored Glycine 0 N--CA 1.489 2.219 0 C-N-CA 118.739 -1.696 . . . . 0.0 109.948 179.387 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.656 HD23 ' HB3' ' A' ' 3' ' ' PRO . 0.9 OUTLIER -92.4 171.96 8.7 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.935 -1.332 . . . . 0.0 108.429 179.793 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.016 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.23 100.43 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.473 0 O-C-N 120.933 -1.104 . . . . 0.0 109.781 -179.664 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.06 77.6 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.679 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.982 -179.245 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.1 33.99 0.27 Allowed Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.721 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 24.5 p -139.53 106.98 5.55 Favored 'General case' 0 C--N 1.307 -1.276 0 O-C-N 121.17 -1.194 . . . . 0.0 111.261 -179.577 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.582 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -52.37 110.4 0.49 Allowed 'General case' 0 N--CA 1.497 1.901 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.93 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.588 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 30.0 m-85 -106.68 157.4 17.73 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.06 -1.025 . . . . 0.0 109.079 179.892 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -100.58 165.29 11.49 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.781 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.652 HG22 HG11 ' A' ' 21' ' ' VAL . 4.6 p -144.57 121.3 4.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.13 -0.981 . . . . 0.0 109.535 -177.623 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.39 -178.53 42.62 Favored Glycine 0 N--CA 1.496 2.681 0 C-N-CA 118.114 -1.993 . . . . 0.0 111.86 -179.814 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.619 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.2 OUTLIER -100.73 108.86 20.81 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.874 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -129.85 149.29 51.65 Favored 'General case' 0 C--N 1.294 -1.811 0 O-C-N 121.142 -0.974 . . . . 0.0 110.11 179.849 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.34 138.73 54.35 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.363 -0.836 . . . . 0.0 110.757 -179.128 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.25 115.03 26.89 Favored 'General case' 0 N--CA 1.494 1.737 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.146 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 m -105.9 15.52 7.0 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 O-C-N 120.95 -1.094 . . . . 0.0 110.55 -178.895 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.772 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 173.97 -176.26 0.08 Allowed 'General case' 0 C--N 1.303 -1.417 0 O-C-N 120.902 -1.124 . . . . 0.0 110.192 179.775 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.777 HG23 ' O ' ' A' ' 42' ' ' THR . 15.0 t -71.16 98.45 1.69 Allowed 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.426 -0.796 . . . . 0.0 109.827 -179.672 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.7 28.77 34.25 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.312 179.006 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.772 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -117.5 106.11 19.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 O-C-N 120.608 -1.525 . . . . 0.0 107.16 178.853 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.3 tp -117.6 104.74 11.33 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 120.49 -1.381 . . . . 0.0 109.756 -177.613 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.072 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.95 109.52 22.26 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.809 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.3 t -106.74 166.49 10.54 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.928 -1.108 . . . . 0.0 110.422 -178.761 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.833 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 3.0 t-20 -107.88 133.34 20.51 Favored Pre-proline 0 N--CA 1.499 1.988 0 O-C-N 121.526 -0.734 . . . . 0.0 109.511 -179.247 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.595 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.3 Cg_endo -74.61 25.12 0.36 Allowed 'Trans proline' 0 C--N 1.319 -0.99 0 C-N-CA 122.376 2.05 . . . . 0.0 111.99 -179.973 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.833 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -107.12 -4.87 18.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.342 -1.474 . . . . 0.0 109.306 179.848 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.663 ' HB3' HD22 ' A' ' 67' ' ' LEU . 5.4 m-20 -133.24 5.94 3.83 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.264 -0.898 . . . . 0.0 108.683 179.918 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -60.35 80.06 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.239 -0.913 . . . . 0.0 110.5 -178.797 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.636 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -105.31 -169.6 1.62 Allowed 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 178.55 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.46 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 177.88 135.67 0.07 Allowed 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.626 -1.296 . . . . 0.0 111.149 -179.249 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.783 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -149.58 157.83 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 N-CA-C 107.572 -1.269 . . . . 0.0 107.572 177.907 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.582 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.31 140.1 33.1 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 120.837 -1.164 . . . . 0.0 110.038 -179.7 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.016 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -62.45 106.61 0.79 Allowed 'General case' 0 C--N 1.298 -1.673 0 CA-C-O 122.438 1.113 . . . . 0.0 109.448 178.418 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.561 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 8.5 p-10 -59.8 -139.38 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.031 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.882 -179.944 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.01 -50.4 61.46 Favored 'General case' 0 N--CA 1.5 2.064 0 O-C-N 121.344 -0.848 . . . . 0.0 110.485 -178.782 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -103.21 -35.0 8.62 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 106.194 -1.78 . . . . 0.0 106.194 178.433 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.974 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.34 69.86 0.71 Allowed Glycine 0 C--N 1.298 -1.555 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 178.123 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.614 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 48.3 m -105.1 127.68 53.0 Favored 'General case' 0 N--CA 1.485 1.299 0 O-C-N 121.517 -0.99 . . . . 0.0 108.96 179.256 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.783 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.96 109.27 8.9 Favored 'General case' 0 C--N 1.298 -1.644 0 C-N-CA 119.789 -0.765 . . . . 0.0 109.076 -179.765 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 42.5 m -120.46 115.84 24.26 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.282 -0.886 . . . . 0.0 109.452 -179.656 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -145.82 143.82 29.89 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.4 -0.813 . . . . 0.0 109.502 179.967 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.436 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 21.8 p -98.76 137.21 37.69 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.467 -0.771 . . . . 0.0 109.407 179.977 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.927 HD11 HG12 ' A' ' 21' ' ' VAL . 0.1 OUTLIER -131.26 167.81 18.58 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.408 -0.808 . . . . 0.0 110.027 -178.673 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.529 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.2 p -102.62 123.6 46.62 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.051 -1.031 . . . . 0.0 108.863 179.396 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.619 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.7 m -135.99 143.99 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 120.899 -1.126 . . . . 0.0 109.868 -179.023 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.596 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.8 ptt180 -144.75 -176.79 5.21 Favored 'General case' 0 N--CA 1.484 1.251 0 O-C-N 120.637 -1.289 . . . . 0.0 111.046 -179.891 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.727 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.97 -94.72 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.276 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.533 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -65.32 148.28 51.98 Favored 'General case' 0 N--CA 1.485 1.282 0 O-C-N 120.566 -1.334 . . . . 0.0 107.543 178.63 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.602 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -167.44 140.66 3.45 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 117.942 -1.503 . . . . 0.0 110.126 -177.459 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.523 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 5.1 mm-40 -36.49 122.06 0.75 Allowed 'General case' 0 N--CA 1.489 1.509 0 CA-C-O 121.421 0.629 . . . . 0.0 110.235 -178.708 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.072 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -96.61 51.83 1.54 Allowed Glycine 0 N--CA 1.495 2.571 0 C-N-CA 120.496 -0.859 . . . . 0.0 111.148 -179.252 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.595 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -39.16 114.74 0.43 Allowed 'General case' 0 N--CA 1.509 2.476 0 O-C-N 121.104 -1.233 . . . . 0.0 110.18 179.446 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.724 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -85.53 126.55 33.95 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 120.791 -1.193 . . . . 0.0 109.594 -179.841 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 32.3 t80 -64.5 58.5 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.028 0 O-C-N 120.852 -1.155 . . . . 0.0 109.951 179.527 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.2 t70 -159.55 19.41 0.17 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.007 -1.058 . . . . 0.0 109.624 179.873 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.4 -27.45 5.71 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 110.095 -1.202 . . . . 0.0 110.095 179.929 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.471 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 63.1 p -97.01 158.5 15.4 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 120.963 -1.316 . . . . 0.0 110.366 -179.375 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.498 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 2.6 ptt180 -104.28 140.21 38.19 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.672 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.724 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.7 t90 -84.93 -17.51 37.54 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.683 -1.261 . . . . 0.0 110.787 -178.077 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.41 176.58 19.83 Favored Glycine 0 N--CA 1.485 1.923 0 N-CA-C 108.617 -1.793 . . . . 0.0 108.617 -179.45 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -65.91 104.51 1.12 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 179.198 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.649 HG21 ' HB3' ' A' ' 46' ' ' ALA . 39.9 t -75.93 107.92 7.53 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.295 -0.878 . . . . 0.0 109.387 -178.767 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.711 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -68.24 113.14 5.6 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.435 -0.791 . . . . 0.0 109.575 -179.777 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.727 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 8.2 m -62.48 -5.07 2.24 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 120.424 -1.423 . . . . 0.0 110.235 179.717 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 p -88.35 -2.82 58.82 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.542 -1.349 . . . . 0.0 109.489 179.825 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.711 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -106.45 -47.95 3.67 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.237 -0.914 . . . . 0.0 108.804 179.837 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -111.1 -177.67 3.27 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.642 -0.662 . . . . 0.0 109.295 179.724 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.75 116.19 31.87 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.933 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.621 ' HB2' HD11 ' A' ' 110' ' ' ILE . 3.4 m -96.67 122.23 39.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.823 -1.173 . . . . 0.0 109.794 -179.167 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.561 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -104.36 148.71 26.09 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 122.393 1.092 . . . . 0.0 111.458 -179.374 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.556 ' HB ' HG11 ' A' ' 7' ' ' VAL . 48.4 t -106.3 111.51 35.55 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 106.873 -1.529 . . . . 0.0 106.873 177.534 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.508 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -153.51 -170.68 19.9 Favored Glycine 0 N--CA 1.488 2.106 0 C-N-CA 118.104 -1.998 . . . . 0.0 111.625 -177.743 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.488 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -115.92 175.15 5.67 Favored 'General case' 0 C--N 1.307 -1.268 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.269 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.6 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 3.3 t 175.34 153.1 0.14 Allowed 'General case' 0 C--N 1.291 -1.957 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -179.857 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.588 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -99.72 -161.26 0.86 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.765 -1.21 . . . . 0.0 109.115 -179.819 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -115.63 35.76 4.28 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.716 -1.24 . . . . 0.0 109.15 -179.929 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -110.78 -32.17 6.94 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.358 -0.839 . . . . 0.0 109.658 -179.733 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.559 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.63 -36.82 0.22 Allowed Glycine 0 N--CA 1.481 1.672 0 N-CA-C 108.048 -2.021 . . . . 0.0 108.048 -179.823 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -165.83 -177.16 4.15 Favored 'General case' 0 C--N 1.307 -1.282 0 O-C-N 121.501 -0.999 . . . . 0.0 109.98 179.476 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.488 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.71 -161.62 20.48 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 108.204 -1.958 . . . . 0.0 108.204 -179.368 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.488 ' HB2' HD12 ' A' ' 97' ' ' LEU . 6.4 Cg_exo -47.55 -179.55 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.694 0 CA-C-N 118.921 1.36 . . . . 0.0 110.442 179.239 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -96.51 174.71 6.71 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.069 -1.019 . . . . 0.0 110.361 -179.056 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.508 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -114.65 175.69 16.29 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.674 -1.371 . . . . 0.0 109.674 179.95 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -110.01 153.45 11.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 -179.545 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.561 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -94.21 123.94 37.92 Favored 'General case' 0 C--N 1.29 -2.01 0 O-C-N 121.337 -0.852 . . . . 0.0 109.413 179.796 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.75 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.4 pt -97.91 169.72 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.413 0 O-C-N 121.092 -1.005 . . . . 0.0 109.159 -179.923 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.472 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.44 154.99 48.87 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.333 -0.854 . . . . 0.0 109.455 179.93 . . . . . . . . 3 3 . 1 . 045 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.75 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 59.6 m-85 -131.39 87.85 2.51 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.084 -1.01 . . . . 0.0 109.598 -179.609 . . . . . . . . 2 2 . 1 . 045 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.407 ' C ' ' O ' ' A' ' 112' ' ' PHE . 18.6 p30 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.428 -179.971 . . . . . . . . 1 1 . 1 . 045 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.707 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 121.274 0.559 . . . . 0.0 109.492 . . . . . . . . . 0 0 . 1 . 046 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.493 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -117.8 158.41 45.71 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.18 -0.95 . . . . 0.0 109.484 179.977 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.577 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.2 Cg_exo -59.98 157.44 33.95 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.185 1.923 . . . . 0.0 110.606 -179.979 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.539 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.83 -169.75 0.14 Allowed 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 179.218 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.652 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -166.87 133.87 2.44 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.634 -1.291 . . . . 0.0 111.055 -179.529 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.01 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.3 p -101.22 104.71 15.77 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-O 122.453 1.121 . . . . 0.0 109.959 -179.843 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 1.131 HG22 HG23 ' A' ' 21' ' ' VAL . 3.2 t -118.54 124.54 73.3 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.419 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.509 179.716 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.478 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -170.8 149.96 2.99 Favored Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 -179.509 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.478 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.0 Cg_endo -75.02 152.55 98.32 Favored 'Cis proline' 0 C--N 1.309 -1.504 0 C-N-CA 123.553 -1.436 . . . . 0.0 109.714 -0.476 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.622 ' HA ' HG22 ' A' ' 110' ' ' ILE . 9.3 m -93.31 -23.07 18.61 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.61 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.469 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 3.2 m -135.32 163.38 30.14 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.46 -0.775 . . . . 0.0 109.345 179.764 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.83 38.1 32.11 Favored Glycine 0 N--CA 1.495 2.579 0 N-CA-C 108.387 -1.885 . . . . 0.0 108.387 -179.513 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.795 ' CA ' HG21 ' A' ' 17' ' ' THR . 32.8 mt -91.94 -44.14 9.07 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 123.122 1.439 . . . . 0.0 110.7 -178.201 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 68.14 145.24 0.04 OUTLIER 'General case' 0 C--N 1.259 -3.338 0 CA-C-N 113.578 -1.646 . . . . 0.0 110.081 -179.707 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.583 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 5.5 p-10 -50.45 106.81 0.13 Allowed 'General case' 0 C--N 1.302 -1.474 0 CA-C-O 121.437 0.637 . . . . 0.0 111.793 -178.54 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.05 16.38 9.15 Favored Glycine 0 N--CA 1.484 1.844 0 C-N-CA 119.502 -1.332 . . . . 0.0 112.905 177.137 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.795 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.1 t -105.05 -173.73 2.37 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 121.069 2.434 . . . . 0.0 109.982 179.276 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.762 HG13 ' O ' ' A' ' 67' ' ' LEU . 19.3 t -130.33 138.84 52.86 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.287 0 CA-C-N 114.593 -1.185 . . . . 0.0 111.183 -178.613 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.532 HG12 HD21 ' A' ' 13' ' ' LEU . 27.2 m -115.95 155.52 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.75 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.567 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 4.7 tttm -104.84 109.15 21.0 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.08 -1.013 . . . . 0.0 109.355 -179.954 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 1.131 HG23 HG22 ' A' ' 7' ' ' VAL . 7.2 p -106.64 124.2 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 179.671 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.01 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -118.89 166.94 12.21 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 120.65 -1.281 . . . . 0.0 109.296 179.848 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.603 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -133.76 141.8 13.2 Favored Glycine 0 C--N 1.296 -1.676 0 N-CA-C 107.594 -2.203 . . . . 0.0 107.594 179.727 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.577 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -147.42 123.21 10.59 Favored 'General case' 0 C--N 1.291 -1.956 0 O-C-N 120.832 -1.393 . . . . 0.0 108.624 179.19 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.528 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.68 26.36 25.12 Favored Glycine 0 N--CA 1.488 2.112 0 C-N-CA 119.222 -1.466 . . . . 0.0 109.884 -179.724 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.544 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 2.3 mt -85.69 176.01 8.4 Favored 'General case' 0 C--N 1.307 -1.281 0 O-C-N 120.695 -1.473 . . . . 0.0 108.245 179.908 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.002 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.76 96.87 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 O-C-N 121.013 -1.055 . . . . 0.0 109.671 -179.891 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.722 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.69 76.61 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.762 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.547 -178.91 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.01 34.59 0.33 Allowed Glycine 0 N--CA 1.486 1.984 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 179.334 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.561 ' CG2' ' CB ' ' A' ' 27' ' ' GLN . 1.2 t -149.23 115.4 5.77 Favored 'General case' 0 C--N 1.308 -1.213 0 O-C-N 120.94 -1.329 . . . . 0.0 111.263 179.949 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -42.68 129.54 4.15 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.819 178.262 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.541 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 7.4 m-85 -120.45 149.85 41.74 Favored 'General case' 0 N--CA 1.492 1.645 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 179.614 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.549 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -100.07 164.79 11.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.651 -1.281 . . . . 0.0 107.685 178.73 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.648 HG13 ' O ' ' A' ' 34' ' ' VAL . 7.0 p -147.86 118.22 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.139 -0.976 . . . . 0.0 109.855 -177.831 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -170.77 -178.61 41.52 Favored Glycine 0 N--CA 1.494 2.526 0 C-N-CA 118.432 -1.842 . . . . 0.0 111.537 -179.864 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.707 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -99.16 108.48 21.09 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.822 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.19 148.31 52.02 Favored 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.257 -0.902 . . . . 0.0 110.109 179.992 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.44 139.5 53.83 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.39 -0.819 . . . . 0.0 110.736 -179.167 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.878 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.22 114.82 26.65 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.129 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.454 ' O ' ' OD1' ' A' ' 41' ' ' ASP . 13.6 m -105.92 15.46 7.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.029 -1.044 . . . . 0.0 110.583 -178.698 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.5 OUTLIER 175.32 -175.66 0.09 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.858 -1.151 . . . . 0.0 110.095 179.688 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -71.5 97.14 1.61 Allowed 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.47 -0.769 . . . . 0.0 109.754 -179.744 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.26 27.81 35.49 Favored Glycine 0 N--CA 1.491 2.325 0 C-N-CA 120.181 -1.009 . . . . 0.0 111.394 179.006 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 2.0 t -116.1 106.6 20.69 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 O-C-N 120.625 -1.515 . . . . 0.0 107.295 178.814 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.927 HD22 H182 ' A' ' 114' ' ' CHR . 12.4 tp -116.21 104.66 11.74 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.483 -1.386 . . . . 0.0 109.738 -177.745 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.925 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.63 109.36 22.13 Favored 'General case' 0 N--CA 1.483 1.221 0 O-C-N 120.887 -1.133 . . . . 0.0 107.947 178.916 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.492 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.8 t -108.29 167.09 10.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.98 -1.075 . . . . 0.0 110.589 -178.535 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.496 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 43.6 t30 -114.7 128.22 26.09 Favored Pre-proline 0 N--CA 1.499 1.977 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 -179.554 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.603 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.2 Cg_endo -69.96 19.89 0.19 Allowed 'Trans proline' 0 CA--C 1.545 1.065 0 C-N-CA 122.005 1.803 . . . . 0.0 112.294 -179.804 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.496 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -93.79 -7.51 43.22 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.384 -1.448 . . . . 0.0 108.802 179.122 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.608 ' HB3' HD22 ' A' ' 67' ' ' LEU . 4.2 m-20 -131.24 2.22 4.24 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.369 -0.832 . . . . 0.0 108.802 -179.869 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -58.15 83.53 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.39 0 O-C-N 121.336 -0.853 . . . . 0.0 111.147 -178.247 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -110.97 -170.89 1.72 Allowed 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 178.087 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.62 134.7 0.08 Allowed 'General case' 0 C--N 1.305 -1.363 0 O-C-N 120.446 -1.409 . . . . 0.0 111.621 -179.345 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.708 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.9 p -145.95 158.78 11.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 107.071 -1.455 . . . . 0.0 107.071 177.744 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.568 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.13 145.44 26.01 Favored 'General case' 0 N--CA 1.487 1.414 0 O-C-N 120.448 -1.407 . . . . 0.0 109.944 -179.613 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.002 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -68.04 108.84 3.23 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 122.272 1.034 . . . . 0.0 109.568 179.036 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.54 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.3 t0 -62.8 -138.89 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.979 -179.888 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.722 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -49.95 -51.53 40.59 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.393 -0.817 . . . . 0.0 110.559 -178.732 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -104.46 -33.54 8.55 Favored 'General case' 0 C--N 1.287 -2.134 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 178.493 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.971 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.75 70.08 0.7 Allowed Glycine 0 C--N 1.299 -1.512 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 178.482 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.603 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 70.9 m -103.57 130.81 51.05 Favored 'General case' 0 N--CA 1.484 1.255 0 O-C-N 121.248 -1.148 . . . . 0.0 109.208 179.324 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.708 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.57 108.86 7.79 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.471 -0.891 . . . . 0.0 109.841 -179.588 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 4.2 m -115.4 115.38 26.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.117 -0.99 . . . . 0.0 109.328 179.998 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.44 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.09 144.87 30.29 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.413 -0.804 . . . . 0.0 109.829 -179.91 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.426 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 24.7 p -98.99 140.8 32.61 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.55 -0.718 . . . . 0.0 109.169 179.66 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 1.128 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -135.46 165.37 25.64 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.322 -0.862 . . . . 0.0 110.065 -178.924 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.587 HG22 HG22 ' A' ' 18' ' ' VAL . 1.2 p -104.38 123.06 46.75 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.127 -0.983 . . . . 0.0 108.807 179.463 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.707 HG12 ' HB3' ' A' ' 36' ' ' GLN . 18.9 m -136.06 143.48 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.838 -1.164 . . . . 0.0 110.359 -178.898 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.583 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.2 ptt180 -141.64 -166.19 2.15 Favored 'General case' 0 N--CA 1.485 1.323 0 O-C-N 120.686 -1.259 . . . . 0.0 110.331 179.688 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.571 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 1.3 mtp180 -68.98 -78.21 0.07 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.57 -0.706 . . . . 0.0 109.128 -179.419 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -71.92 139.25 48.65 Favored 'General case' 0 C--N 1.306 -1.319 0 O-C-N 120.122 -1.611 . . . . 0.0 107.822 179.39 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.595 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -160.32 136.36 8.52 Favored 'General case' 0 C--N 1.295 -1.78 0 C-N-CA 118.276 -1.37 . . . . 0.0 110.058 -178.501 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.483 ' O ' ' O ' ' A' ' 47' ' ' CYS . 20.4 mm-40 -32.84 122.36 0.36 Allowed 'General case' 0 N--CA 1.491 1.598 0 CA-C-O 121.557 0.694 . . . . 0.0 110.776 -178.248 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.925 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.51 44.37 3.05 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 -179.502 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.603 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.2 m-85 -39.12 112.3 0.24 Allowed 'General case' 0 N--CA 1.507 2.384 0 O-C-N 121.156 -1.202 . . . . 0.0 110.27 179.954 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.696 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.5 tp -87.41 127.73 35.21 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 120.837 -1.165 . . . . 0.0 109.412 -179.926 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.586 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.5 t80 -64.35 57.96 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 120.91 -1.119 . . . . 0.0 110.24 179.9 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.52 ' N ' ' O ' ' A' ' 77' ' ' LEU . 2.0 t70 -160.68 19.06 0.13 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.049 -1.032 . . . . 0.0 109.817 179.813 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.06 -26.01 5.73 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.161 -1.175 . . . . 0.0 110.161 179.865 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.424 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -92.54 153.65 18.93 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.906 -1.35 . . . . 0.0 110.384 -179.463 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.482 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.3 OUTLIER -101.34 132.45 46.89 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.493 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.696 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -80.66 -17.44 51.2 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.813 -1.179 . . . . 0.0 110.278 -178.624 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.6 173.55 20.16 Favored Glycine 0 N--CA 1.486 1.995 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -179.682 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.38 108.05 1.03 Allowed 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 179.04 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.676 HG21 ' CB ' ' A' ' 46' ' ' ALA . 39.8 t -79.01 105.64 8.64 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 O-C-N 121.43 -0.794 . . . . 0.0 108.882 -178.834 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.631 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -67.93 111.23 4.25 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.427 -0.795 . . . . 0.0 109.874 -179.151 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.571 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 1.9 t -63.88 -5.45 4.43 Favored 'General case' 0 N--CA 1.501 2.095 0 C-N-CA 118.438 -1.305 . . . . 0.0 109.862 179.529 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.424 HG23 ' HB3' ' A' ' 71' ' ' ARG . 69.7 p -84.49 0.22 50.53 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.744 -1.222 . . . . 0.0 108.909 179.324 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.631 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -114.2 -49.06 2.86 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.469 -0.77 . . . . 0.0 109.147 179.952 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.17 -178.65 3.7 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.386 -0.821 . . . . 0.0 109.58 -179.943 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.16 114.78 29.18 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.452 -0.78 . . . . 0.0 109.022 -179.991 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.563 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -97.04 122.12 39.68 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 120.919 -1.113 . . . . 0.0 109.49 -179.375 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.637 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -102.28 144.7 30.46 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 122.444 1.116 . . . . 0.0 111.151 -179.336 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.567 ' HB ' HG11 ' A' ' 7' ' ' VAL . 99.4 t -100.9 110.02 26.84 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.604 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.483 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.39 -172.63 19.19 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 117.899 -2.096 . . . . 0.0 111.83 -177.611 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.652 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -111.63 -177.51 3.21 Favored 'General case' 0 N--CA 1.485 1.308 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -179.268 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.578 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.0 OUTLIER -178.07 174.63 1.35 Allowed 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.137 -0.977 . . . . 0.0 110.143 -179.134 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.724 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 27.1 p-10 -107.47 -33.08 7.46 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-O 122.148 0.975 . . . . 0.0 108.773 179.621 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.724 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 86.96 13.0 0.12 Allowed 'General case' 0 C--N 1.296 -1.759 0 CA-C-N 115.079 -0.964 . . . . 0.0 110.171 -179.944 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -107.36 -21.34 12.97 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.237 -0.915 . . . . 0.0 109.395 179.385 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.593 ' N ' H193 ' A' ' 114' ' ' CHR . . . -178.44 -43.71 0.07 OUTLIER Glycine 0 N--CA 1.483 1.793 0 N-CA-C 107.978 -2.049 . . . . 0.0 107.978 179.745 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.49 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -171.24 -179.12 2.58 Favored 'General case' 0 C--N 1.307 -1.254 0 O-C-N 121.517 -0.99 . . . . 0.0 109.567 179.156 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.36 -165.42 28.61 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 108.685 -1.766 . . . . 0.0 108.685 -179.548 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.472 ' O ' ' O ' ' A' ' 104' ' ' GLY . 3.0 Cg_exo -49.3 -178.19 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.641 0 CA-C-N 118.857 1.328 . . . . 0.0 110.076 179.556 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -96.88 -179.67 4.64 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.079 -1.013 . . . . 0.0 110.313 -179.056 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.483 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -117.87 163.79 12.8 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 179.994 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.84 127.6 51.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.287 -1.125 . . . . 0.0 109.165 -179.53 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.637 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.02 121.11 18.61 Favored 'General case' 0 C--N 1.289 -2.053 0 CA-C-O 121.323 0.582 . . . . 0.0 109.743 179.825 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.861 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.98 168.76 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.238 -0.914 . . . . 0.0 109.387 179.952 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.469 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.0 OUTLIER -138.34 157.63 45.86 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.289 -0.882 . . . . 0.0 109.78 -179.875 . . . . . . . . 3 3 . 1 . 046 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.861 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.6 m-85 -129.89 72.27 1.48 Allowed 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.202 -0.936 . . . . 0.0 109.565 -179.756 . . . . . . . . 2 2 . 1 . 046 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.426 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 12.6 p30 . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.481 -179.986 . . . . . . . . 1 1 . 1 . 046 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.927 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 047 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -118.42 152.68 51.25 Favored Pre-proline 0 N--CA 1.49 1.538 0 O-C-N 121.273 -0.892 . . . . 0.0 109.422 179.975 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.615 ' HB3' HD23 ' A' ' 26' ' ' LEU . 2.5 Cg_endo -61.42 155.59 51.5 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.271 1.98 . . . . 0.0 110.489 -179.901 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.596 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -148.66 161.12 42.38 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 -179.825 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.526 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -147.4 128.92 15.0 Favored 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 118.923 -1.111 . . . . 0.0 110.609 -179.697 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.005 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.9 p -105.42 104.72 14.5 Favored 'General case' 0 C--N 1.295 -1.77 0 CA-C-O 122.57 1.176 . . . . 0.0 110.173 -179.585 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.944 HG22 HG23 ' A' ' 21' ' ' VAL . 20.5 t -119.29 122.56 69.39 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.474 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.317 179.804 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.477 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -166.59 150.64 6.76 Favored Pre-proline 0 N--CA 1.489 1.511 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.294 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.477 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.6 Cg_endo -74.62 151.9 97.54 Favored 'Cis proline' 0 C--N 1.309 -1.512 0 C-N-CA 123.651 -1.395 . . . . 0.0 110.016 -0.621 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.635 ' HA ' HG22 ' A' ' 110' ' ' ILE . 6.0 m -93.73 -23.07 18.34 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.518 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.501 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -135.67 160.86 37.22 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.474 -0.766 . . . . 0.0 109.446 -179.97 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.09 37.7 31.93 Favored Glycine 0 N--CA 1.494 2.541 0 N-CA-C 108.517 -1.833 . . . . 0.0 108.517 -179.624 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.829 ' CA ' HG21 ' A' ' 17' ' ' THR . 31.0 mt -89.9 -44.7 9.73 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 123.188 1.47 . . . . 0.0 110.608 -178.439 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.47 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.4 OUTLIER 65.89 146.26 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.271 0 CA-C-N 113.626 -1.624 . . . . 0.0 110.151 -179.931 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.588 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 4.1 p-10 -51.33 107.52 0.19 Allowed 'General case' 0 C--N 1.302 -1.485 0 CA-C-O 121.68 0.752 . . . . 0.0 111.678 -178.601 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.24 15.08 9.27 Favored Glycine 0 N--CA 1.484 1.848 0 C-N-CA 119.511 -1.328 . . . . 0.0 112.847 177.348 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.829 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.9 t -103.72 -172.77 2.17 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 121.146 2.473 . . . . 0.0 109.776 179.358 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.721 HG13 ' C ' ' A' ' 67' ' ' LEU . 13.6 t -132.81 140.42 47.45 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.351 0 CA-C-N 114.937 -1.028 . . . . 0.0 111.136 -178.829 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.525 HG23 ' CD1' ' A' ' 67' ' ' LEU . 31.3 m -117.76 154.16 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.392 0 O-C-N 121.355 -0.841 . . . . 0.0 108.968 179.144 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.551 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -108.03 108.95 20.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.886 . . . . 0.0 109.148 179.966 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.944 HG23 HG22 ' A' ' 7' ' ' VAL . 2.3 p -106.1 122.44 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.978 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.005 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.84 166.23 11.57 Favored 'General case' 0 C--N 1.306 -1.3 0 O-C-N 120.857 -1.152 . . . . 0.0 108.737 179.502 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.605 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -144.41 108.37 0.49 Allowed Glycine 0 N--CA 1.482 1.752 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 179.952 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.596 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.94 138.83 51.28 Favored 'General case' 0 N--CA 1.5 2.033 0 CA-C-N 119.366 1.583 . . . . 0.0 110.21 -179.454 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.48 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 84.88 28.92 30.29 Favored Glycine 0 N--CA 1.491 2.306 0 C-N-CA 118.941 -1.6 . . . . 0.0 109.888 179.549 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.615 HD23 ' HB3' ' A' ' 3' ' ' PRO . 2.0 mt -91.67 176.13 6.65 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.979 -1.307 . . . . 0.0 108.449 179.956 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.65 96.91 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.052 -1.03 . . . . 0.0 109.61 -179.905 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.7 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.07 76.61 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.798 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.341 -178.857 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 133.52 34.17 0.32 Allowed Glycine 0 N--CA 1.486 1.985 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 179.383 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.568 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.1 t -148.44 115.32 6.06 Favored 'General case' 0 C--N 1.309 -1.193 0 O-C-N 120.931 -1.335 . . . . 0.0 111.113 -179.935 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.559 ' HA ' ' OG1' ' A' ' 56' ' ' THR . . . -43.36 128.83 4.94 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.777 178.38 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.568 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 8.0 m-85 -120.58 147.35 45.31 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.486 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.469 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -99.61 159.65 14.88 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.507 -1.371 . . . . 0.0 107.666 178.648 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.8 HG11 HG21 ' A' ' 65' ' ' THR . 9.8 p -144.36 116.33 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.08 -1.012 . . . . 0.0 110.198 -177.543 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.522 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.89 -175.33 38.81 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.477 -1.82 . . . . 0.0 111.654 -179.995 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.587 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.5 OUTLIER -100.91 109.22 21.14 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-O 121.845 0.831 . . . . 0.0 108.973 -179.717 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.79 149.44 52.43 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.254 -0.904 . . . . 0.0 110.05 179.796 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.34 139.07 54.26 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.38 -0.825 . . . . 0.0 110.813 -179.064 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 115.05 26.92 Favored 'General case' 0 N--CA 1.493 1.709 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 177.98 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 10.8 m -106.05 15.59 7.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 O-C-N 120.969 -1.082 . . . . 0.0 110.534 -178.796 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.777 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 173.79 -176.36 0.07 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 120.897 -1.127 . . . . 0.0 110.127 179.835 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.781 HG23 ' O ' ' A' ' 42' ' ' THR . 15.0 t -70.79 98.58 1.57 Allowed 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.416 -0.803 . . . . 0.0 109.914 -179.69 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.13 28.52 36.84 Favored Glycine 0 N--CA 1.492 2.427 0 C-N-CA 120.265 -0.969 . . . . 0.0 111.238 179.027 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.777 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.9 106.31 19.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.304 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.839 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.6 tp -116.94 104.83 11.68 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 120.409 -1.432 . . . . 0.0 109.749 -177.55 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.895 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.62 109.46 22.21 Favored 'General case' 0 N--CA 1.485 1.276 0 O-C-N 120.806 -1.184 . . . . 0.0 108.29 178.938 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.504 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.2 t -107.38 167.46 9.91 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.959 -1.088 . . . . 0.0 110.078 -178.959 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.743 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 15.2 t-20 -109.31 136.45 20.18 Favored Pre-proline 0 N--CA 1.5 2.06 0 O-C-N 121.369 -0.832 . . . . 0.0 109.97 -179.296 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 4.4 Cg_endo -75.25 23.27 0.42 Allowed 'Trans proline' 0 CA--C 1.544 0.976 0 C-N-CA 122.369 2.046 . . . . 0.0 111.798 179.994 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.743 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -117.68 3.9 12.33 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.429 -1.42 . . . . 0.0 108.974 179.593 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.583 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.58 17.87 2.9 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 107.122 -1.436 . . . . 0.0 107.122 179.214 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -83.71 90.13 7.26 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.925 -178.473 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.624 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.6 OUTLIER -109.81 -170.41 1.65 Allowed 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 178.042 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.445 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.81 135.36 0.09 Allowed 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.402 -1.436 . . . . 0.0 111.508 -179.245 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.788 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.3 p -151.88 158.73 4.34 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.037 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.559 ' OG1' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.49 145.77 25.89 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.642 -1.286 . . . . 0.0 109.799 -179.621 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -67.22 108.01 2.55 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-O 122.389 1.09 . . . . 0.0 109.681 178.879 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.553 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 11.8 p-10 -61.23 -139.56 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.941 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.811 -179.898 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.7 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.96 -50.89 57.16 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.296 -0.877 . . . . 0.0 110.498 -178.858 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.406 ' ND2' ' HA2' ' A' ' 25' ' ' GLY . 0.2 OUTLIER -103.98 -34.02 8.61 Favored 'General case' 0 C--N 1.286 -2.184 0 N-CA-C 106.414 -1.698 . . . . 0.0 106.414 178.481 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.947 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.11 70.36 0.73 Allowed Glycine 0 C--N 1.297 -1.583 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 178.278 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.605 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 38.9 m -104.05 127.4 51.61 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.69 -0.888 . . . . 0.0 108.936 179.165 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.788 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.06 109.04 8.15 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.679 -0.808 . . . . 0.0 109.415 -179.682 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.469 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.4 m -118.69 117.07 27.94 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.264 -0.898 . . . . 0.0 109.349 -179.934 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.8 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -145.46 142.0 28.88 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.452 -0.78 . . . . 0.0 109.772 179.99 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 23.3 p -100.91 135.06 42.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.497 -0.752 . . . . 0.0 109.231 179.742 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.721 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -133.39 165.52 24.65 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.314 -0.866 . . . . 0.0 109.526 -179.449 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.679 HG22 HG22 ' A' ' 18' ' ' VAL . 2.3 p -96.76 125.23 41.07 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.27 -0.894 . . . . 0.0 109.342 -179.903 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.562 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.3 m -136.13 144.54 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.959 -1.088 . . . . 0.0 109.584 -179.312 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.588 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 3.4 ptt180 -139.95 -166.37 2.08 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 120.593 -1.317 . . . . 0.0 110.338 -179.927 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.688 ' HA ' ' HB2' ' A' ' 88' ' ' CYS . 40.9 mtm180 -69.83 -73.91 0.15 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.51 -0.744 . . . . 0.0 109.298 -179.113 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.52 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -76.87 145.74 38.13 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 178.534 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.587 ' CE1' ' SG ' ' A' ' 88' ' ' CYS . 1.0 OUTLIER -166.23 140.06 4.23 Favored 'General case' 0 C--N 1.293 -1.887 0 C-N-CA 117.507 -1.677 . . . . 0.0 110.464 -177.737 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.537 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 2.2 mm-40 -33.98 122.32 0.46 Allowed 'General case' 0 N--CA 1.49 1.533 0 CA-C-O 121.593 0.711 . . . . 0.0 110.664 -178.479 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.895 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.09 45.82 3.03 Favored Glycine 0 N--CA 1.495 2.601 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 -179.338 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 2.9 m-30 -39.63 113.19 0.31 Allowed 'General case' 0 N--CA 1.508 2.472 0 O-C-N 121.083 -1.245 . . . . 0.0 110.169 179.673 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.737 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.2 tp -87.23 128.17 35.15 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 120.868 -1.145 . . . . 0.0 109.379 -179.928 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.576 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 24.8 t80 -64.47 57.89 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.04 0 O-C-N 120.809 -1.182 . . . . 0.0 110.328 179.882 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.518 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.1 t70 -161.0 18.92 0.12 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.946 -1.096 . . . . 0.0 109.779 179.844 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 84.79 -25.85 5.65 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 179.952 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 3.4 p -91.55 153.27 19.87 Favored 'General case' 0 N--CA 1.486 1.339 0 O-C-N 120.895 -1.356 . . . . 0.0 110.387 -179.351 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.508 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 8.5 ptt180 -100.95 131.93 46.6 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.544 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.737 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.0 t90 -81.74 -18.61 43.65 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.729 -1.232 . . . . 0.0 110.495 -178.47 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.61 173.65 19.6 Favored Glycine 0 N--CA 1.486 2.014 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 -179.624 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -62.07 109.27 1.24 Allowed 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 179.133 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.681 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.5 t -80.87 104.51 9.47 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 O-C-N 121.339 -0.851 . . . . 0.0 109.058 -178.859 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.573 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -68.07 112.69 5.19 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.628 -0.67 . . . . 0.0 109.648 -179.551 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.688 ' HB2' ' HA ' ' A' ' 71' ' ' ARG . 6.8 m -56.83 -8.4 0.6 Allowed 'General case' 0 N--CA 1.496 1.867 0 C-N-CA 118.309 -1.356 . . . . 0.0 110.466 179.816 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 p -84.52 -12.44 54.19 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.366 -1.459 . . . . 0.0 109.53 179.981 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.573 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -92.97 -47.86 6.8 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.286 -0.884 . . . . 0.0 109.032 179.934 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -117.12 -178.24 3.4 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.547 -0.72 . . . . 0.0 109.477 179.937 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.48 117.76 35.59 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.462 -0.774 . . . . 0.0 108.922 179.888 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.496 ' O ' HG12 ' A' ' 110' ' ' ILE . 3.2 m -96.41 121.41 38.19 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.761 -1.212 . . . . 0.0 109.791 -179.202 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.597 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.78 146.92 27.92 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-O 122.445 1.117 . . . . 0.0 111.022 -179.486 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.707 ' HB ' HG11 ' A' ' 7' ' ' VAL . 42.5 t -102.93 109.81 27.82 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.99 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 177.442 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.482 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.68 -170.0 16.65 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 118.263 -1.922 . . . . 0.0 111.697 -177.4 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.526 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -122.2 -179.41 4.16 Favored 'General case' 0 N--CA 1.486 1.326 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.608 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.55 ' HB2' ' C27' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -179.26 176.96 0.81 Allowed 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.362 -0.836 . . . . 0.0 109.593 -179.739 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.455 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -123.82 -157.88 0.78 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 120.923 -1.111 . . . . 0.0 109.067 -179.96 . . . . . . . . 3 3 . 1 . 047 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.455 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.46 35.79 4.4 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.819 -1.176 . . . . 0.0 109.223 -179.991 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -112.96 -33.08 6.17 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.363 -0.836 . . . . 0.0 109.882 -179.705 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.707 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 163.57 -35.52 0.31 Allowed Glycine 0 N--CA 1.481 1.696 0 N-CA-C 107.713 -2.155 . . . . 0.0 107.713 -179.755 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -162.52 -177.6 5.72 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.626 -0.926 . . . . 0.0 109.967 179.311 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.53 -161.55 21.31 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.147 -1.981 . . . . 0.0 108.147 -179.41 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.494 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.2 Cg_exo -45.83 173.12 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.628 0 CA-C-N 118.919 1.359 . . . . 0.0 109.936 179.263 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -92.81 -174.87 3.74 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.127 -0.983 . . . . 0.0 110.526 -178.751 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.482 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.0 166.14 13.55 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.953 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -103.97 130.42 54.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.349 -1.089 . . . . 0.0 109.075 -179.39 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.597 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.81 123.68 23.85 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 121.494 -0.753 . . . . 0.0 109.642 179.728 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.761 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.78 168.42 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 C-N-CA 119.555 -0.858 . . . . 0.0 108.912 179.893 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.501 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 2.3 m -134.12 153.76 51.62 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.295 -0.878 . . . . 0.0 109.448 -179.882 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.761 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 65.9 m-85 -127.35 98.17 5.16 Favored 'General case' 0 N--CA 1.485 1.314 0 O-C-N 121.193 -0.942 . . . . 0.0 109.397 -179.783 . . . . . . . . 2 2 . 1 . 047 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.467 ' O ' ' O ' ' A' ' 112' ' ' PHE . 12.4 p30 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 117.962 -1.018 . . . . 0.0 109.664 -179.905 . . . . . . . . 1 1 . 1 . 047 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.789 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 048 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.645 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -79.67 162.97 60.94 Favored Pre-proline 0 N--CA 1.489 1.521 0 O-C-N 121.329 -0.857 . . . . 0.0 109.48 -179.982 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.865 ' O ' HG23 ' A' ' 4' ' ' THR . 4.1 Cg_exo -60.24 158.07 32.39 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.167 1.912 . . . . 0.0 110.443 179.921 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.865 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.2 p -165.95 160.48 16.73 Favored 'General case' 0 C--N 1.296 -1.753 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 -179.265 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -147.9 128.5 14.15 Favored 'General case' 0 C--N 1.297 -1.701 0 CA-C-O 122.359 1.076 . . . . 0.0 110.696 -179.782 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.009 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -105.11 104.8 14.61 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 122.609 1.195 . . . . 0.0 110.141 -179.505 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.931 HG22 HG23 ' A' ' 21' ' ' VAL . 16.7 t -120.17 119.91 61.4 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.44 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.325 179.662 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.523 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.0 150.06 9.54 Favored Pre-proline 0 N--CA 1.488 1.466 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 -179.587 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.523 ' HA ' HG23 ' A' ' 8' ' ' THR . 3.1 Cg_endo -75.11 153.57 99.06 Favored 'Cis proline' 0 C--N 1.31 -1.471 0 C-N-CA 123.721 -1.366 . . . . 0.0 109.933 -0.637 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.646 ' HA ' HG22 ' A' ' 110' ' ' ILE . 8.0 m -95.04 -23.51 17.32 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.461 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.461 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 3.4 m -134.24 164.21 27.89 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.583 -0.698 . . . . 0.0 109.649 179.95 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.36 36.85 43.39 Favored Glycine 0 N--CA 1.496 2.668 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 -179.73 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.885 ' CA ' HG21 ' A' ' 17' ' ' THR . 21.9 mt -90.03 -46.18 8.67 Favored 'General case' 0 C--N 1.297 -1.705 0 CA-C-O 123.151 1.453 . . . . 0.0 110.6 -178.532 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.45 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 2.1 t 61.45 148.25 0.02 OUTLIER 'General case' 0 C--N 1.259 -3.341 0 CA-C-N 113.917 -1.492 . . . . 0.0 109.913 -179.766 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.625 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 3.9 p-10 -51.35 109.61 0.36 Allowed 'General case' 0 C--N 1.301 -1.535 0 CA-C-O 121.574 0.702 . . . . 0.0 111.683 -178.834 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.94 12.68 10.95 Favored Glycine 0 N--CA 1.485 1.945 0 C-N-CA 119.403 -1.38 . . . . 0.0 112.915 177.42 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.885 HG21 ' CA ' ' A' ' 13' ' ' LEU . 7.9 t -101.45 -175.25 2.8 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 121.0 2.4 . . . . 0.0 109.717 179.511 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.673 HG13 ' O ' ' A' ' 67' ' ' LEU . 9.4 t -132.75 137.72 53.41 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.906 -179.414 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.485 ' O ' HD12 ' A' ' 67' ' ' LEU . 28.5 m -116.97 153.88 18.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.348 -0.845 . . . . 0.0 109.214 179.219 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.54 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.3 OUTLIER -110.31 109.23 19.6 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.29 -0.882 . . . . 0.0 108.977 179.715 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.931 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -105.95 122.5 59.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.766 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.009 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -113.4 165.84 12.07 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 120.886 -1.134 . . . . 0.0 108.954 179.554 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.52 108.23 0.5 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 108.806 -1.717 . . . . 0.0 108.806 -179.976 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.589 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.31 140.8 48.95 Favored 'General case' 0 N--CA 1.499 1.98 0 CA-C-N 119.204 1.502 . . . . 0.0 110.281 -179.38 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.451 ' CA ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.08 28.46 34.05 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.077 -1.535 . . . . 0.0 109.964 179.653 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.535 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.2 mt -92.91 175.01 6.95 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.942 -1.328 . . . . 0.0 108.367 179.977 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.54 99.19 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.913 -1.117 . . . . 0.0 109.572 -179.743 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.647 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.69 76.85 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.272 -179.101 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.17 34.26 0.29 Allowed Glycine 0 N--CA 1.486 2.005 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.574 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.563 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 68.9 p -145.11 111.98 5.91 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.958 -1.319 . . . . 0.0 111.167 -179.683 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -45.7 125.66 6.21 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.574 178.107 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.489 ' CD2' ' O ' ' A' ' 30' ' ' THR . 14.2 m-85 -117.33 151.11 37.67 Favored 'General case' 0 N--CA 1.492 1.638 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 179.682 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.516 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.6 OUTLIER -101.39 153.23 19.85 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.76 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.002 HG11 HG21 ' A' ' 65' ' ' THR . 6.2 p -136.31 115.05 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.105 -0.997 . . . . 0.0 109.756 -177.928 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -165.09 -178.45 38.35 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 118.474 -1.822 . . . . 0.0 111.696 -179.68 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.618 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.9 OUTLIER -102.47 109.27 20.86 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -179.729 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -130.87 149.08 52.67 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.128 -0.982 . . . . 0.0 110.117 -179.878 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -122.78 138.72 54.55 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.399 -0.813 . . . . 0.0 110.609 -179.111 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.883 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.2 114.88 26.72 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 178.005 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 14.7 m -105.24 15.05 6.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.986 -1.071 . . . . 0.0 110.579 -178.72 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.759 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.59 -175.88 0.08 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.916 -1.115 . . . . 0.0 110.044 179.686 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.786 HG23 ' O ' ' A' ' 42' ' ' THR . 15.0 t -71.81 98.34 1.96 Allowed 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.418 -0.801 . . . . 0.0 109.794 -179.704 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.76 27.43 34.94 Favored Glycine 0 N--CA 1.492 2.425 0 C-N-CA 120.077 -1.058 . . . . 0.0 111.518 179.084 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.759 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -116.76 106.42 20.19 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 O-C-N 120.548 -1.56 . . . . 0.0 107.288 178.929 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.883 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -117.36 104.64 11.33 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 120.38 -1.45 . . . . 0.0 109.796 -177.757 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.89 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.77 109.5 22.24 Favored 'General case' 0 N--CA 1.485 1.296 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 178.698 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.495 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -105.49 166.96 10.07 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.043 -1.036 . . . . 0.0 110.493 -178.641 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.465 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 36.8 t-20 -110.35 129.61 23.77 Favored Pre-proline 0 N--CA 1.499 1.998 0 O-C-N 121.668 -0.645 . . . . 0.0 109.499 -179.393 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.612 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.1 Cg_endo -72.39 22.34 0.28 Allowed 'Trans proline' 0 CA--C 1.545 1.026 0 C-N-CA 122.091 1.861 . . . . 0.0 111.808 179.581 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -110.76 2.6 18.5 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.41 -1.431 . . . . 0.0 108.997 179.626 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.531 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.58 17.83 2.71 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 179.447 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -80.73 93.11 6.13 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.916 -0.714 . . . . 0.0 111.086 -178.496 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.627 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -113.15 -167.78 1.24 Allowed 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 178.113 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.7 OUTLIER 178.73 136.82 0.09 Allowed 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.619 -1.301 . . . . 0.0 111.524 -179.248 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.918 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.7 OUTLIER -154.45 157.1 4.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.113 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.84 144.82 27.03 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 120.665 -1.272 . . . . 0.0 109.893 -179.636 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.6 107.07 1.61 Allowed 'General case' 0 C--N 1.301 -1.506 0 CA-C-O 122.353 1.073 . . . . 0.0 109.428 178.772 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.549 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 5.4 t0 -60.47 -139.29 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.051 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.956 -179.895 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.647 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.01 -50.72 57.98 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.401 -0.812 . . . . 0.0 110.733 -178.749 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -104.02 -34.06 8.58 Favored 'General case' 0 C--N 1.286 -2.182 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.461 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.985 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.23 66.17 0.62 Allowed Glycine 0 C--N 1.295 -1.704 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 178.243 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 20.3 m -103.5 125.02 49.82 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.758 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.918 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.6 109.19 8.5 Favored 'General case' 0 C--N 1.296 -1.749 0 C-N-CA 119.631 -0.827 . . . . 0.0 109.649 -179.28 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 97.3 p -116.44 116.51 27.8 Favored 'General case' 0 N--CA 1.486 1.356 0 O-C-N 121.345 -0.847 . . . . 0.0 109.441 -179.987 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 1.002 HG21 HG11 ' A' ' 34' ' ' VAL . 1.1 t -141.3 138.5 33.21 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.438 -0.789 . . . . 0.0 109.816 179.982 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.444 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 23.4 p -99.12 141.22 32.16 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.446 -0.784 . . . . 0.0 109.127 179.814 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.776 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -142.34 169.44 17.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.33 -0.856 . . . . 0.0 109.523 -179.24 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.561 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 2.5 p -96.57 126.26 41.62 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.055 -1.028 . . . . 0.0 109.519 -179.712 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.676 HG23 HD13 ' A' ' 13' ' ' LEU . 15.6 m -133.14 142.74 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 120.916 -1.115 . . . . 0.0 109.738 -179.346 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.625 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -146.84 -170.68 3.59 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 120.517 -1.364 . . . . 0.0 110.731 -179.877 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.6 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -66.6 -102.23 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.807 -0.558 . . . . 0.0 110.171 -179.04 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -57.12 136.29 56.38 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.388 -1.445 . . . . 0.0 108.198 179.845 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.618 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -155.86 158.52 38.18 Favored 'General case' 0 C--N 1.295 -1.793 0 C-N-CA 118.722 -1.191 . . . . 0.0 109.894 -178.853 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.515 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 12.1 mm-40 -50.01 121.9 6.01 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.296 -0.878 . . . . 0.0 109.561 -178.651 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.89 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.12 48.32 3.43 Favored Glycine 0 N--CA 1.495 2.578 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 -179.514 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.612 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -40.11 113.38 0.35 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.046 -1.267 . . . . 0.0 110.286 179.919 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.756 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -86.94 127.1 35.07 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 120.913 -1.117 . . . . 0.0 109.47 179.987 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.577 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 21.5 t80 -63.88 58.52 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.865 -1.147 . . . . 0.0 110.167 179.8 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.531 ' N ' ' O ' ' A' ' 77' ' ' LEU . 14.3 t0 -161.02 19.23 0.12 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.09 -1.006 . . . . 0.0 109.92 179.842 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -25.6 5.96 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.15 -1.18 . . . . 0.0 110.15 179.802 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 67.4 p -94.09 159.22 15.25 Favored 'General case' 0 N--CA 1.486 1.362 0 O-C-N 120.979 -1.307 . . . . 0.0 110.384 -179.35 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.483 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 2.7 ptt180 -104.97 133.33 49.94 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 179.796 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.756 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -82.38 -18.37 42.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.845 -1.159 . . . . 0.0 110.406 -178.694 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.29 174.04 19.36 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 -179.671 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -63.56 108.7 1.44 Allowed 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 179.137 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.642 HG21 ' CB ' ' A' ' 46' ' ' ALA . 42.9 t -80.28 104.38 8.53 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 O-C-N 121.469 -0.77 . . . . 0.0 109.278 -178.771 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.561 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -63.78 108.35 1.42 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.517 -0.739 . . . . 0.0 110.137 -179.231 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.597 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.6 t -60.76 -5.14 1.17 Allowed 'General case' 0 N--CA 1.501 2.084 0 C-N-CA 118.141 -1.424 . . . . 0.0 110.282 179.214 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 73.2 p -89.87 2.08 55.42 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.486 -1.383 . . . . 0.0 109.495 179.965 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.561 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.7 p -113.06 -49.04 2.94 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.236 -0.915 . . . . 0.0 109.149 -179.975 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.57 179.55 4.23 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.432 -0.792 . . . . 0.0 109.48 -179.974 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -101.65 112.99 25.74 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.791 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.506 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.55 121.39 38.32 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.008 -1.058 . . . . 0.0 109.373 -179.004 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.594 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.61 147.03 27.3 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.369 1.08 . . . . 0.0 111.341 -179.117 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.626 ' HB ' HG11 ' A' ' 7' ' ' VAL . 54.0 t -102.82 109.24 26.15 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 177.309 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.467 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.1 -170.96 16.56 Favored Glycine 0 N--CA 1.485 1.947 0 C-N-CA 118.179 -1.962 . . . . 0.0 111.53 -177.378 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.516 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -118.33 -178.52 3.54 Favored 'General case' 0 C--N 1.304 -1.399 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -178.612 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.559 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.1 OUTLIER -173.7 172.57 3.54 Favored 'General case' 0 C--N 1.295 -1.783 0 O-C-N 121.423 -0.798 . . . . 0.0 109.38 -179.352 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.429 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -118.85 -157.87 0.7 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.188 -0.945 . . . . 0.0 108.796 179.676 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.429 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -118.07 36.34 4.38 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.705 -1.247 . . . . 0.0 109.24 179.988 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.23 -33.51 4.37 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.345 -0.847 . . . . 0.0 110.185 -179.552 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 1.024 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 166.26 -36.98 0.25 Allowed Glycine 0 N--CA 1.482 1.735 0 N-CA-C 107.645 -2.182 . . . . 0.0 107.645 -179.519 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.18 -178.39 7.17 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.581 -0.953 . . . . 0.0 109.809 179.229 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.12 -162.08 19.32 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 108.209 -1.957 . . . . 0.0 108.209 -179.398 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 7.3 Cg_exo -45.68 171.99 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.632 0 CA-C-N 118.855 1.327 . . . . 0.0 109.932 179.366 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -90.6 -173.07 3.62 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.092 -1.005 . . . . 0.0 110.544 -178.567 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.467 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -122.68 168.26 15.04 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.874 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -105.33 131.44 54.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 O-C-N 121.414 -1.051 . . . . 0.0 109.143 -179.313 . . . . . . . . 1 1 . 1 . 048 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.594 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.16 122.51 21.13 Favored 'General case' 0 C--N 1.289 -2.053 0 O-C-N 121.662 -0.648 . . . . 0.0 109.736 179.767 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.906 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -97.95 170.99 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.279 -0.888 . . . . 0.0 108.898 179.766 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.461 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.1 OUTLIER -137.07 162.29 33.76 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.216 -0.927 . . . . 0.0 109.856 -179.78 . . . . . . . . 3 3 . 1 . 048 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.906 ' CE1' HD12 ' A' ' 110' ' ' ILE . 48.3 m-85 -133.37 144.75 49.79 Favored 'General case' 0 N--CA 1.485 1.277 0 O-C-N 121.244 -0.91 . . . . 0.0 109.495 -179.817 . . . . . . . . 2 2 . 1 . 048 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.8 p30 . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.454 -179.978 . . . . . . . . 0 0 . 1 . 048 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 1.024 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 121.258 0.551 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 049 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.733 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -117.0 165.94 14.18 Favored Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.231 -0.918 . . . . 0.0 109.514 -179.957 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.733 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 4.2 Cg_exo -60.2 157.76 33.58 Favored 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.277 1.985 . . . . 0.0 110.54 179.932 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -153.65 160.72 42.47 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 -179.402 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.23 122.53 9.62 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-O 122.431 1.11 . . . . 0.0 110.262 -179.705 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.879 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.0 t -115.82 109.16 17.25 Favored 'General case' 0 C--N 1.298 -1.651 0 CA-C-O 123.058 1.409 . . . . 0.0 109.867 -179.893 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.921 HG22 HG23 ' A' ' 21' ' ' VAL . 1.6 t -114.5 136.68 50.32 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.733 0 CA-C-N 114.236 -1.347 . . . . 0.0 109.557 179.781 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.486 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -170.55 149.68 3.09 Favored Pre-proline 0 N--CA 1.488 1.432 0 O-C-N 121.135 -0.978 . . . . 0.0 109.001 -179.591 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.486 ' HA ' HG23 ' A' ' 8' ' ' THR . 4.9 Cg_endo -77.02 150.78 92.94 Favored 'Cis proline' 0 C--N 1.313 -1.302 0 C-N-CA 123.436 -1.485 . . . . 0.0 109.455 -0.931 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.656 ' HA ' HG22 ' A' ' 110' ' ' ILE . 79.1 p -91.31 -23.81 20.01 Favored 'General case' 0 C--N 1.292 -1.928 0 O-C-N 121.589 -0.695 . . . . 0.0 109.292 179.971 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.493 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -131.57 162.05 31.22 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.284 -0.885 . . . . 0.0 109.733 -179.839 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.76 38.38 31.72 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 108.434 -1.866 . . . . 0.0 108.434 -179.666 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.781 ' CA ' HG21 ' A' ' 17' ' ' THR . 35.0 mt -91.88 -44.07 9.13 Favored 'General case' 0 C--N 1.299 -1.592 0 CA-C-O 123.12 1.438 . . . . 0.0 110.759 -178.226 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.468 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 67.87 144.22 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.317 0 CA-C-N 113.568 -1.651 . . . . 0.0 109.938 -179.526 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.618 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.6 p-10 -50.55 108.43 0.23 Allowed 'General case' 0 C--N 1.3 -1.568 0 CA-C-O 121.64 0.734 . . . . 0.0 111.759 -178.483 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 112.72 14.24 10.52 Favored Glycine 0 N--CA 1.484 1.841 0 C-N-CA 119.555 -1.307 . . . . 0.0 112.895 177.255 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.781 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -105.29 -173.71 2.36 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 121.011 2.406 . . . . 0.0 110.162 179.435 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.779 HG13 ' O ' ' A' ' 67' ' ' LEU . 21.8 t -130.62 141.39 46.36 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.273 0 CA-C-N 114.45 -1.25 . . . . 0.0 111.069 -178.714 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.572 HG12 HD21 ' A' ' 13' ' ' LEU . 34.5 m -118.53 155.29 20.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.661 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 2.9 tttt -102.07 109.19 20.84 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.127 -0.983 . . . . 0.0 109.176 -179.871 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.921 HG23 HG22 ' A' ' 7' ' ' VAL . 10.5 p -99.05 139.6 20.45 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.785 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.879 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -134.84 161.49 35.05 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 120.729 -1.232 . . . . 0.0 109.94 179.45 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.586 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.98 138.01 9.46 Favored Glycine 0 C--O 1.207 -1.551 0 N-CA-C 107.839 -2.104 . . . . 0.0 107.839 179.669 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.597 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -141.04 126.89 19.19 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-N 119.484 1.642 . . . . 0.0 109.547 179.52 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.476 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 87.36 28.64 24.35 Favored Glycine 0 N--CA 1.488 2.132 0 C-N-CA 118.832 -1.651 . . . . 0.0 109.745 -179.984 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.56 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.7 mt -88.27 173.06 8.99 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.913 -1.345 . . . . 0.0 108.235 179.894 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.021 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.56 99.26 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.492 0 O-C-N 120.954 -1.091 . . . . 0.0 109.809 -179.482 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.545 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.43 77.31 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.698 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.254 -179.221 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.62 34.18 0.28 Allowed Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 179.591 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 50.7 p -142.35 108.55 5.24 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.092 -1.24 . . . . 0.0 111.367 -179.52 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.597 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.23 109.71 0.33 Allowed 'General case' 0 N--CA 1.495 1.821 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 177.826 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.536 ' CE1' ' OG1' ' A' ' 30' ' ' THR . 4.3 m-30 -103.13 155.53 18.34 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.094 -1.004 . . . . 0.0 108.987 179.94 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.523 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.2 OUTLIER -98.99 161.82 13.42 Favored 'General case' 0 N--CA 1.49 1.534 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.855 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.696 HG22 HG11 ' A' ' 21' ' ' VAL . 2.7 p -142.66 121.61 8.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.117 -0.99 . . . . 0.0 109.538 -178.018 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -172.64 -176.9 41.63 Favored Glycine 0 N--CA 1.496 2.645 0 C-N-CA 118.516 -1.802 . . . . 0.0 111.548 -179.77 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.756 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -100.17 108.94 21.18 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 -179.937 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.463 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -128.66 148.53 50.82 Favored 'General case' 0 C--N 1.295 -1.767 0 O-C-N 121.229 -0.919 . . . . 0.0 109.884 179.738 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.502 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.92 139.51 53.76 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.24 -0.912 . . . . 0.0 110.674 -179.071 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.891 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.13 114.93 26.78 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 178.19 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.8 m -105.24 15.26 6.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.982 -1.074 . . . . 0.0 110.53 -178.883 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 174.7 -176.39 0.09 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.997 -1.064 . . . . 0.0 110.067 179.682 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.774 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.4 97.37 1.26 Allowed 'General case' 0 N--CA 1.487 1.42 0 CA-C-O 121.817 0.818 . . . . 0.0 109.901 -179.656 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.13 28.23 34.62 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 120.198 -1.001 . . . . 0.0 111.387 178.833 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.03 106.41 20.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 O-C-N 120.562 -1.552 . . . . 0.0 107.278 178.891 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.891 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -115.98 104.77 11.93 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.465 -1.397 . . . . 0.0 109.942 -177.552 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.041 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.3 109.65 22.37 Favored 'General case' 0 N--CA 1.484 1.246 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 178.656 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.49 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -109.06 161.9 14.75 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.863 -1.148 . . . . 0.0 110.462 -178.585 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.479 ' HB2' ' HB2' ' A' ' 73' ' ' PHE . 29.8 t-20 -108.44 131.04 22.02 Favored Pre-proline 0 N--CA 1.5 2.038 0 O-C-N 121.582 -0.699 . . . . 0.0 109.391 -179.659 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.607 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.7 Cg_endo -72.19 22.15 0.27 Allowed 'Trans proline' 0 CA--C 1.545 1.074 0 C-N-CA 121.958 1.772 . . . . 0.0 111.892 179.523 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.664 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -97.08 -7.26 33.2 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.434 -1.417 . . . . 0.0 108.994 179.555 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.881 ' HB3' HD22 ' A' ' 67' ' ' LEU . 1.8 m-20 -132.63 5.22 3.97 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.999 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -59.84 78.61 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.355 -0.841 . . . . 0.0 110.938 -178.385 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.632 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -101.07 -167.91 1.49 Allowed 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 178.238 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.451 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.57 134.84 0.08 Allowed 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.55 -1.344 . . . . 0.0 111.363 -179.391 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.771 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.5 p -149.03 156.99 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.067 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.597 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.4 141.22 31.54 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 120.706 -1.246 . . . . 0.0 110.012 -179.776 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.021 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.26 107.54 1.34 Allowed 'General case' 0 C--N 1.298 -1.669 0 CA-C-O 122.484 1.135 . . . . 0.0 109.571 178.76 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.565 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.8 p-10 -61.04 -139.42 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.709 179.95 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -52.35 -50.68 61.87 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.393 -0.817 . . . . 0.0 110.481 -178.798 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.416 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 6.2 t-20 -101.95 -35.15 9.09 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 178.404 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.998 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.42 68.19 0.66 Allowed Glycine 0 C--N 1.298 -1.535 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 178.07 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.586 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 56.4 m -99.54 131.54 45.47 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.421 -1.046 . . . . 0.0 108.836 178.917 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.771 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -135.2 108.87 7.98 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.182 -1.007 . . . . 0.0 109.452 -179.517 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 2.0 m -123.97 117.92 25.86 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.297 -0.877 . . . . 0.0 109.651 -179.798 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.525 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -146.61 145.34 30.04 Favored 'General case' 0 C--N 1.3 -1.551 0 O-C-N 121.433 -0.792 . . . . 0.0 109.411 179.879 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 25.0 p -98.56 136.6 38.43 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.273 -0.892 . . . . 0.0 109.22 179.894 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.881 HD22 ' HB3' ' A' ' 51' ' ' ASP . 0.1 OUTLIER -140.69 165.9 26.23 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.396 -0.815 . . . . 0.0 109.909 -178.9 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.664 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 10.9 t -99.56 129.61 45.73 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.955 -1.09 . . . . 0.0 111.437 -178.753 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.83 HG13 ' OD2' ' A' ' 51' ' ' ASP . 17.3 m -136.61 143.86 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.459 -0.776 . . . . 0.0 109.956 179.68 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.618 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 0.0 OUTLIER -148.45 -175.46 4.93 Favored 'General case' 0 N--CA 1.484 1.239 0 O-C-N 120.445 -1.409 . . . . 0.0 110.6 179.25 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.59 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.13 -102.44 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -179.539 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.4 OUTLIER -56.41 139.93 47.26 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.789 -1.194 . . . . 0.0 108.206 179.494 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.581 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.4 OUTLIER -159.68 138.3 10.64 Favored 'General case' 0 C--N 1.296 -1.745 0 C-N-CA 118.717 -1.193 . . . . 0.0 109.91 -178.403 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.477 ' O ' ' O ' ' A' ' 47' ' ' CYS . 4.4 mm-40 -35.22 120.81 0.55 Allowed 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.473 0.654 . . . . 0.0 110.662 -178.496 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.041 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -92.6 48.27 2.57 Favored Glycine 0 N--CA 1.493 2.467 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 -179.428 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.607 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.9 m-30 -39.12 114.98 0.44 Allowed 'General case' 0 N--CA 1.509 2.489 0 O-C-N 121.152 -1.205 . . . . 0.0 110.064 179.598 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.734 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.4 tp -87.3 126.48 34.87 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 120.796 -1.19 . . . . 0.0 109.597 -179.78 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.584 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 24.1 t80 -64.42 58.31 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.023 0 O-C-N 120.871 -1.143 . . . . 0.0 110.188 179.704 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 14.0 t0 -160.35 19.6 0.15 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.049 -1.032 . . . . 0.0 109.739 179.865 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.83 -27.43 5.41 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 179.935 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.491 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 68.1 p -95.13 157.05 16.06 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 120.978 -1.307 . . . . 0.0 110.313 -179.446 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.536 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -103.94 139.94 38.4 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.673 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.734 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.1 t90 -85.89 -19.71 30.15 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.588 -1.32 . . . . 0.0 110.766 -178.129 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.23 174.59 18.62 Favored Glycine 0 N--CA 1.487 2.036 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -179.419 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -65.99 104.17 1.08 Allowed 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 179.159 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.665 HG21 ' HB3' ' A' ' 46' ' ' ALA . 48.9 t -74.49 106.64 4.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.388 -0.82 . . . . 0.0 109.55 -178.769 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.544 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -64.74 110.67 2.46 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.443 -0.786 . . . . 0.0 109.654 -179.735 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.59 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 2.4 t -64.32 -4.98 4.29 Favored 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 118.334 -1.346 . . . . 0.0 109.891 179.58 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 3.0 p -87.03 0.56 55.01 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.701 -1.25 . . . . 0.0 109.111 179.511 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.544 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -114.16 -50.07 2.83 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.275 -0.891 . . . . 0.0 109.047 179.905 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -104.22 -178.09 3.56 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.54 -0.725 . . . . 0.0 109.495 179.769 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.09 114.94 29.38 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.395 -0.816 . . . . 0.0 108.998 179.937 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.567 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.5 m -97.05 122.98 40.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.911 -1.118 . . . . 0.0 109.722 -179.233 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.632 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -104.23 146.83 28.22 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-O 122.345 1.069 . . . . 0.0 111.224 -179.414 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.658 ' CG1' HG11 ' A' ' 7' ' ' VAL . 58.9 t -101.5 110.18 27.69 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.987 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 177.695 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.476 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.06 -171.28 16.85 Favored Glycine 0 N--CA 1.485 1.964 0 C-N-CA 118.236 -1.935 . . . . 0.0 111.78 -177.592 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.476 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.63 177.66 5.15 Favored 'General case' 0 N--CA 1.488 1.466 0 CA-C-O 121.625 0.726 . . . . 0.0 109.047 -179.161 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.585 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -175.18 176.3 2.1 Favored 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.641 -0.662 . . . . 0.0 109.455 179.937 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.5 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -124.46 -157.13 0.75 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.004 -1.06 . . . . 0.0 109.0 179.802 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.476 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.22 35.9 4.46 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.746 -1.221 . . . . 0.0 109.288 -179.982 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.88 -32.9 6.46 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.349 -0.844 . . . . 0.0 109.833 -179.765 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.812 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.1 -36.28 0.27 Allowed Glycine 0 N--CA 1.481 1.668 0 N-CA-C 107.817 -2.113 . . . . 0.0 107.817 -179.738 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -166.06 -177.09 4.02 Favored 'General case' 0 C--N 1.306 -1.317 0 O-C-N 121.596 -0.944 . . . . 0.0 109.795 179.336 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.18 -161.88 17.52 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 108.247 -1.941 . . . . 0.0 108.247 -179.379 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.521 ' HG3' HD22 ' A' ' 26' ' ' LEU . 6.4 Cg_exo -46.56 176.34 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.686 0 CA-C-N 118.778 1.289 . . . . 0.0 110.203 179.325 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 22.9 mt-10 -95.19 -177.3 4.08 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.121 -0.987 . . . . 0.0 110.417 -178.896 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.476 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -115.37 161.63 12.75 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.871 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.448 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -98.8 130.55 47.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.383 -1.069 . . . . 0.0 109.041 -179.461 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.632 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.65 124.33 25.06 Favored 'General case' 0 C--N 1.291 -1.975 0 O-C-N 121.724 -0.61 . . . . 0.0 110.059 -179.937 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.894 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.65 171.21 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.298 -0.876 . . . . 0.0 108.954 179.639 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.493 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -137.05 158.06 45.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.209 -0.932 . . . . 0.0 109.632 179.97 . . . . . . . . 3 3 . 1 . 049 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.894 ' CE1' HD12 ' A' ' 110' ' ' ILE . 77.7 m-85 -129.49 79.27 1.9 Allowed 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.26 -0.9 . . . . 0.0 109.517 -179.551 . . . . . . . . 2 2 . 1 . 049 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.407 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 13.6 p30 . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.439 -179.924 . . . . . . . . 1 1 . 1 . 049 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.812 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 050 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.922 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -88.8 172.97 6.68 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.267 -0.896 . . . . 0.0 109.491 -179.951 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.922 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 2.7 Cg_endo -61.31 155.63 50.7 Favored 'Trans proline' 0 C--N 1.31 -1.463 0 C-N-CA 122.304 2.002 . . . . 0.0 110.544 179.992 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.61 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -141.25 161.56 37.59 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 -179.866 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.566 ' HB2' HD11 ' A' ' 97' ' ' LEU . . . -145.77 128.67 16.4 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 118.846 -1.142 . . . . 0.0 110.702 -179.682 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.015 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.8 p -104.05 104.71 14.7 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-O 122.39 1.09 . . . . 0.0 110.271 -179.566 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.912 HG22 HG23 ' A' ' 21' ' ' VAL . 11.2 t -119.68 119.19 59.65 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.514 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.244 179.625 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.516 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -163.51 150.51 10.49 Favored Pre-proline 0 N--CA 1.488 1.44 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 -179.561 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.516 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.49 153.24 99.06 Favored 'Cis proline' 0 C--N 1.309 -1.537 0 C-N-CA 123.663 -1.39 . . . . 0.0 110.014 -0.578 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.618 ' HA ' HG22 ' A' ' 110' ' ' ILE . 7.2 m -94.44 -23.57 17.68 Favored 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.495 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.481 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.3 m -136.18 163.12 31.1 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.516 -0.74 . . . . 0.0 109.33 179.825 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.41 37.66 35.49 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 -179.523 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.796 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.1 mt -90.47 -44.12 9.82 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-O 123.18 1.467 . . . . 0.0 110.486 -178.289 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.467 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.97 144.71 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.265 0 CA-C-N 113.613 -1.63 . . . . 0.0 109.903 -179.665 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.625 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 8.1 p-10 -51.11 106.18 0.12 Allowed 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 121.471 0.653 . . . . 0.0 111.509 -178.592 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.46 12.31 9.78 Favored Glycine 0 N--CA 1.488 2.126 0 C-N-CA 119.324 -1.417 . . . . 0.0 113.121 177.261 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.796 HG21 ' CA ' ' A' ' 13' ' ' LEU . 11.6 t -101.51 -169.55 1.71 Allowed 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 121.135 2.467 . . . . 0.0 109.665 179.362 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.74 HG13 ' C ' ' A' ' 67' ' ' LEU . 11.4 t -136.14 142.94 37.32 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 CA-C-N 115.204 -0.907 . . . . 0.0 110.953 -179.015 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.538 HG22 HG22 ' A' ' 69' ' ' VAL . 13.3 m -120.47 154.72 23.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.221 -0.924 . . . . 0.0 109.255 179.438 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.538 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 7.3 tttt -106.28 109.08 20.9 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.233 -0.917 . . . . 0.0 109.28 179.955 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.912 HG23 HG22 ' A' ' 7' ' ' VAL . 1.6 p -105.61 122.26 58.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 179.885 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.015 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.43 165.81 12.35 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 120.886 -1.134 . . . . 0.0 109.129 179.885 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.579 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.1 107.7 0.48 Allowed Glycine 0 N--CA 1.482 1.751 0 N-CA-C 108.572 -1.811 . . . . 0.0 108.572 179.792 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.61 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.6 141.24 48.45 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 120.598 -1.53 . . . . 0.0 110.16 -179.439 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.483 ' O ' ' CA ' ' A' ' 3' ' ' PRO . . . 85.31 27.88 32.0 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 118.833 -1.651 . . . . 0.0 109.718 179.726 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.874 HD23 ' HB3' ' A' ' 3' ' ' PRO . 0.6 OUTLIER -95.67 170.88 9.02 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.018 -1.284 . . . . 0.0 108.45 179.831 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.003 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.07 101.18 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.407 0 O-C-N 120.947 -1.095 . . . . 0.0 109.948 -179.607 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.85 77.98 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.685 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.993 -179.411 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.42 34.15 0.29 Allowed Glycine 0 N--CA 1.486 2.021 0 N-CA-C 109.316 -1.513 . . . . 0.0 109.316 179.818 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 22.6 p -139.78 106.9 5.46 Favored 'General case' 0 C--N 1.308 -1.233 0 O-C-N 121.186 -1.185 . . . . 0.0 111.154 -179.514 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.582 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.67 110.0 0.34 Allowed 'General case' 0 N--CA 1.496 1.839 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.8 178.131 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.525 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 28.8 m-85 -103.89 154.51 19.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.111 -0.993 . . . . 0.0 108.95 179.8 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -102.18 158.09 16.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.767 -1.208 . . . . 0.0 107.821 178.784 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.945 HG11 HG21 ' A' ' 65' ' ' THR . 6.0 p -139.23 115.11 9.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.165 -0.959 . . . . 0.0 109.722 -178.12 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.495 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -162.73 -178.36 36.5 Favored Glycine 0 N--CA 1.494 2.561 0 C-N-CA 118.326 -1.892 . . . . 0.0 111.729 -179.468 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.635 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.1 pt20 -103.32 109.75 21.49 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 121.8 0.81 . . . . 0.0 108.9 -179.764 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.478 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -131.3 149.2 52.66 Favored 'General case' 0 C--N 1.297 -1.684 0 O-C-N 121.005 -1.06 . . . . 0.0 110.261 -179.805 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.37 138.8 54.52 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.319 -0.863 . . . . 0.0 110.777 -179.167 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.876 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.25 114.55 26.35 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 178.108 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.6 m -104.83 14.69 7.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.026 -1.046 . . . . 0.0 110.663 -178.757 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.746 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.7 OUTLIER 175.25 -175.17 0.09 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.923 -1.111 . . . . 0.0 110.125 179.758 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -72.0 97.64 1.92 Allowed 'General case' 0 N--CA 1.485 1.317 0 O-C-N 121.413 -0.804 . . . . 0.0 109.677 -179.757 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.3 26.76 35.31 Favored Glycine 0 N--CA 1.494 2.531 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.475 178.934 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.746 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.92 106.66 20.85 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 O-C-N 120.549 -1.56 . . . . 0.0 107.396 178.875 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.876 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.7 tp -117.05 104.62 11.43 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.488 -1.382 . . . . 0.0 109.629 -177.747 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.871 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.61 109.42 22.18 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 120.808 -1.182 . . . . 0.0 107.914 178.678 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.494 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -105.95 167.83 9.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.928 -1.107 . . . . 0.0 110.483 -178.68 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.53 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 11.6 t-20 -111.94 129.33 24.33 Favored Pre-proline 0 N--CA 1.499 1.986 0 O-C-N 121.532 -0.73 . . . . 0.0 109.649 -179.118 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.582 ' HG3' ' CE2' ' A' ' 76' ' ' PHE . 2.2 Cg_endo -72.72 23.06 0.29 Allowed 'Trans proline' 0 CA--C 1.545 1.059 0 C-N-CA 122.056 1.837 . . . . 0.0 111.815 179.61 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.611 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -110.57 -0.7 17.2 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.462 -1.399 . . . . 0.0 109.145 179.545 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.567 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -136.37 16.81 3.17 Favored 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 179.489 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.6 m-85 -79.75 89.94 5.22 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.709 -178.678 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.26 -166.26 1.14 Allowed 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 107.948 -1.131 . . . . 0.0 107.948 178.34 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.76 136.43 0.09 Allowed 'General case' 0 C--N 1.305 -1.332 0 O-C-N 120.594 -1.316 . . . . 0.0 111.314 -179.256 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 1.016 HG11 ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -154.74 156.63 4.9 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.084 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.582 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.49 142.1 30.52 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.669 -1.269 . . . . 0.0 109.977 -179.621 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.013 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -62.08 106.12 0.68 Allowed 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 122.467 1.127 . . . . 0.0 109.341 178.208 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.545 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.8 p-10 -59.29 -138.79 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.029 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.052 -179.881 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.85 -50.33 61.13 Favored 'General case' 0 N--CA 1.5 2.058 0 O-C-N 121.412 -0.805 . . . . 0.0 110.744 -178.633 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -104.08 -34.57 8.37 Favored 'General case' 0 C--N 1.286 -2.178 0 N-CA-C 106.004 -1.85 . . . . 0.0 106.004 178.505 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.013 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.41 64.34 0.54 Allowed Glycine 0 C--N 1.296 -1.646 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 177.928 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.579 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 18.5 m -103.85 124.05 48.23 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.501 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 1.016 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.01 109.48 9.01 Favored 'General case' 0 C--N 1.293 -1.868 0 C-N-CA 119.821 -0.752 . . . . 0.0 109.673 -179.081 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.7 m -116.5 116.69 28.11 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.329 -0.857 . . . . 0.0 109.373 -179.959 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.945 HG21 HG11 ' A' ' 34' ' ' VAL . 1.3 t -140.85 140.19 34.57 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.374 -0.829 . . . . 0.0 109.822 179.908 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.1 p -98.88 137.61 37.19 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.49 -0.756 . . . . 0.0 109.242 179.849 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.806 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -140.43 159.01 43.15 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.382 -0.824 . . . . 0.0 109.452 -179.129 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.611 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 12.7 t -87.55 135.77 33.22 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.162 -0.961 . . . . 0.0 110.21 -179.837 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.573 HG23 HD13 ' A' ' 13' ' ' LEU . 18.0 m -145.51 140.36 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.74 -179.39 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.625 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.5 ptt180 -140.25 -163.83 1.59 Allowed 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.595 -1.315 . . . . 0.0 109.877 179.814 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.603 ' O ' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -78.79 -81.81 0.1 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.055 -1.028 . . . . 0.0 109.6 -179.15 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.524 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -67.12 134.66 52.24 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.334 -1.479 . . . . 0.0 107.488 179.273 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.635 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.8 OUTLIER -157.7 156.58 31.94 Favored 'General case' 0 C--N 1.293 -1.851 0 C-N-CA 117.965 -1.494 . . . . 0.0 110.568 -178.257 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.514 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 2.2 mm-40 -48.71 121.66 4.83 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.497 -0.752 . . . . 0.0 109.676 -178.574 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.871 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -89.08 48.78 3.48 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 -179.39 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.582 ' CE2' ' HG3' ' A' ' 49' ' ' PRO . 0.2 OUTLIER -40.39 114.6 0.47 Allowed 'General case' 0 N--CA 1.514 2.774 0 O-C-N 121.029 -1.277 . . . . 0.0 109.972 179.908 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.704 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -87.25 126.95 35.14 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.959 -1.088 . . . . 0.0 109.289 179.729 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.578 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 23.2 t80 -64.09 58.11 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.99 0 O-C-N 120.8 -1.187 . . . . 0.0 110.307 179.897 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.531 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -160.86 19.34 0.13 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.961 -1.087 . . . . 0.0 109.785 179.91 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.3 -26.74 5.45 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 179.913 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 39.7 p -91.88 159.32 15.83 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.12 -1.223 . . . . 0.0 110.389 -179.403 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.513 ' HG3' ' NH1' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -106.56 133.46 51.21 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.716 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.704 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.8 t90 -82.6 -18.13 42.35 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.88 -1.137 . . . . 0.0 110.411 -178.469 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 110.32 174.79 20.6 Favored Glycine 0 N--CA 1.486 1.991 0 N-CA-C 108.68 -1.768 . . . . 0.0 108.68 -179.525 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.0 112.06 2.18 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 179.14 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.664 HG21 ' CB ' ' A' ' 46' ' ' ALA . 38.7 t -83.44 102.39 9.35 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 -178.916 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.547 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -64.49 108.53 1.68 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.659 -0.651 . . . . 0.0 109.971 -179.153 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.579 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 3.7 t -62.48 -4.25 1.82 Allowed 'General case' 0 N--CA 1.499 1.979 0 C-N-CA 118.361 -1.336 . . . . 0.0 110.34 179.341 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 23.6 p -88.24 10.39 19.76 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.621 -1.299 . . . . 0.0 109.097 179.622 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.547 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -124.25 -47.66 1.87 Allowed 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.399 -0.813 . . . . 0.0 109.08 -179.994 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.85 179.58 4.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.604 -0.685 . . . . 0.0 109.536 179.905 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.88 112.41 25.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.36 -0.838 . . . . 0.0 108.799 179.783 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.497 ' O ' HG12 ' A' ' 110' ' ' ILE . 2.1 m -96.64 121.85 38.93 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.083 -1.01 . . . . 0.0 109.667 -178.786 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.583 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.34 149.2 24.98 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 122.482 1.134 . . . . 0.0 111.368 -179.199 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.561 ' HB ' HG11 ' A' ' 7' ' ' VAL . 47.4 t -105.42 109.94 29.42 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 177.465 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.449 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.89 -171.3 17.51 Favored Glycine 0 N--CA 1.485 1.95 0 C-N-CA 118.154 -1.974 . . . . 0.0 111.663 -177.641 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.602 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -115.16 -179.02 3.51 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -178.899 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.576 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.5 p -178.65 169.31 1.7 Allowed 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.332 -0.855 . . . . 0.0 109.545 -179.06 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.43 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.5 OUTLIER -121.31 -158.8 0.78 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.961 -1.087 . . . . 0.0 108.976 179.895 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.43 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.13 36.05 4.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.663 -1.273 . . . . 0.0 109.093 -179.982 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -115.33 -33.65 5.23 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.469 -0.77 . . . . 0.0 109.994 -179.707 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.863 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 164.36 -36.06 0.29 Allowed Glycine 0 N--CA 1.48 1.627 0 N-CA-C 107.753 -2.139 . . . . 0.0 107.753 -179.7 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.35 -178.09 6.69 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 122.159 0.98 . . . . 0.0 109.898 179.326 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -168.42 -163.04 21.72 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 108.191 -1.963 . . . . 0.0 108.191 -179.46 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.602 ' HB2' HD12 ' A' ' 97' ' ' LEU . 7.4 Cg_exo -45.93 172.76 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.647 0 CA-C-N 119.013 1.406 . . . . 0.0 109.937 179.325 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -90.19 -177.42 5.14 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.997 -1.064 . . . . 0.0 110.695 -178.566 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.449 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -120.03 167.9 13.66 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.816 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -107.47 132.56 54.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.393 -1.063 . . . . 0.0 109.23 -179.285 . . . . . . . . 1 1 . 1 . 050 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.583 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.57 124.42 25.86 Favored 'General case' 0 C--N 1.29 -1.984 0 O-C-N 121.637 -0.664 . . . . 0.0 109.732 179.757 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.842 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.5 pt -97.97 171.81 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.228 -0.92 . . . . 0.0 109.227 179.794 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.481 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -138.23 155.96 48.15 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.209 -0.932 . . . . 0.0 109.769 -179.896 . . . . . . . . 3 3 . 1 . 050 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.842 ' CE2' HD12 ' A' ' 110' ' ' ILE . 71.6 m-85 -133.25 95.05 3.44 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.178 -0.952 . . . . 0.0 109.533 -179.733 . . . . . . . . 2 2 . 1 . 050 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 14.8 p30 . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 118.077 -0.963 . . . . 0.0 109.462 -179.997 . . . . . . . . 0 0 . 1 . 050 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.863 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.307 0.575 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 051 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.856 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -71.21 169.73 14.11 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.239 -0.913 . . . . 0.0 109.422 179.962 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.856 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.6 Cg_exo -60.1 156.76 37.82 Favored 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.253 1.969 . . . . 0.0 110.642 -179.928 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.574 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -177.75 -169.42 0.21 Allowed 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 179.016 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.574 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.7 132.6 3.28 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.76 -1.212 . . . . 0.0 110.63 -179.135 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.02 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.9 p -104.54 104.4 14.23 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-O 122.453 1.12 . . . . 0.0 110.156 179.96 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.952 HG22 HG23 ' A' ' 21' ' ' VAL . 12.0 t -120.15 119.76 60.98 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.366 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.309 179.738 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.512 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.64 149.88 6.34 Favored Pre-proline 0 N--CA 1.486 1.326 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -179.674 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.512 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.1 Cg_endo -76.68 151.62 94.61 Favored 'Cis proline' 0 C--N 1.309 -1.523 0 C-N-CA 123.637 -1.401 . . . . 0.0 109.501 -0.433 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.674 ' HA ' HG22 ' A' ' 110' ' ' ILE . 77.4 p -93.19 -23.53 18.53 Favored 'General case' 0 C--N 1.293 -1.865 0 O-C-N 121.595 -0.691 . . . . 0.0 109.305 179.765 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.48 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.2 m -133.89 158.2 44.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.316 -0.865 . . . . 0.0 109.957 -179.693 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 80.36 36.46 23.71 Favored Glycine 0 N--CA 1.495 2.594 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 -179.777 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.763 ' HA ' HG21 ' A' ' 17' ' ' THR . 39.2 mt -92.54 -44.36 8.66 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 123.24 1.495 . . . . 0.0 110.284 -178.634 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.447 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 64.1 147.03 0.03 OUTLIER 'General case' 0 C--N 1.263 -3.189 0 CA-C-N 113.549 -1.66 . . . . 0.0 110.138 -179.758 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.552 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.0 p-10 -51.65 104.81 0.09 Allowed 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.644 0.735 . . . . 0.0 111.048 -178.939 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 124.52 6.39 6.72 Favored Glycine 0 N--CA 1.486 2.031 0 C-N-CA 119.148 -1.501 . . . . 0.0 113.33 177.312 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.763 HG21 ' HA ' ' A' ' 13' ' ' LEU . 14.9 t -106.31 -175.97 2.94 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 121.491 2.646 . . . . 0.0 110.166 179.693 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.861 HG22 HG22 ' A' ' 68' ' ' THR . 21.8 t -128.05 138.2 55.36 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.383 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.068 -178.697 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.652 HG11 HD11 ' A' ' 13' ' ' LEU . 34.6 m -114.39 154.66 15.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 178.827 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.553 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -107.1 108.9 20.59 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.14 -0.975 . . . . 0.0 109.314 -179.885 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.952 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.59 123.34 62.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.751 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.02 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -116.72 165.33 13.41 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 120.873 -1.142 . . . . 0.0 109.14 179.922 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.563 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.46 107.55 0.53 Allowed Glycine 0 C--O 1.207 -1.577 0 N-CA-C 108.433 -1.867 . . . . 0.0 108.433 179.875 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.582 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -116.23 143.83 45.0 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.787 -1.419 . . . . 0.0 110.676 -178.964 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.52 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 80.48 27.45 51.51 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 119.576 -1.297 . . . . 0.0 109.993 179.193 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.571 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -91.95 172.25 8.58 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.086 -1.244 . . . . 0.0 108.556 -179.984 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.005 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.58 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.116 -0.99 . . . . 0.0 109.652 -179.987 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.578 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.63 76.74 0.0 OUTLIER 'General case' 0 C--N 1.299 -1.606 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.206 -179.059 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.568 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 135.96 32.96 0.26 Allowed Glycine 0 N--CA 1.486 2.008 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.512 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.628 ' CG2' ' CE2' ' A' ' 32' ' ' TYR . 1.2 t -141.98 111.45 6.54 Favored 'General case' 0 C--N 1.308 -1.208 0 O-C-N 120.935 -1.332 . . . . 0.0 111.027 -179.96 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.572 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.64 120.4 4.67 Favored 'General case' 0 N--CA 1.493 1.715 0 CA-C-N 115.488 -0.778 . . . . 0.0 109.674 178.7 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.628 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 9.7 m-85 -114.27 152.82 30.74 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.238 -0.914 . . . . 0.0 108.923 179.807 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.483 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.2 OUTLIER -100.68 154.18 18.81 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 178.622 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.693 HG13 ' O ' ' A' ' 34' ' ' VAL . 9.7 p -137.42 115.41 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.023 -1.048 . . . . 0.0 109.882 -177.753 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.51 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.87 -176.85 36.16 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 118.372 -1.87 . . . . 0.0 111.792 -179.717 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.624 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.9 OUTLIER -101.21 109.86 21.79 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -179.803 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.498 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.9 m -129.61 149.38 51.39 Favored 'General case' 0 C--N 1.296 -1.74 0 O-C-N 121.221 -0.924 . . . . 0.0 109.748 179.81 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.531 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.66 137.73 54.81 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.254 -0.904 . . . . 0.0 110.907 -178.847 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.887 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.9 OUTLIER -95.49 114.86 26.67 Favored 'General case' 0 N--CA 1.493 1.708 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.048 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 m -105.05 14.67 7.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 120.931 -1.105 . . . . 0.0 110.501 -178.947 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.774 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 173.9 -175.54 0.07 Allowed 'General case' 0 C--N 1.302 -1.468 0 O-C-N 120.949 -1.094 . . . . 0.0 110.128 179.73 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.779 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.92 98.17 1.55 Allowed 'General case' 0 N--CA 1.487 1.416 0 CA-C-O 121.828 0.823 . . . . 0.0 109.969 -179.669 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.28 27.98 34.92 Favored Glycine 0 N--CA 1.493 2.441 0 C-N-CA 120.325 -0.94 . . . . 0.0 111.444 178.949 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.774 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -116.54 106.29 19.99 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 O-C-N 120.569 -1.548 . . . . 0.0 107.198 178.782 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.887 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.4 tp -117.02 104.64 11.47 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.487 -1.383 . . . . 0.0 109.942 -177.527 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.011 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.9 109.56 22.29 Favored 'General case' 0 N--CA 1.485 1.303 0 O-C-N 120.847 -1.158 . . . . 0.0 107.919 178.7 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.501 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -106.58 167.05 10.11 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.907 -1.12 . . . . 0.0 110.41 -178.699 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.585 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 20.7 t-20 -114.67 137.71 22.87 Favored Pre-proline 0 N--CA 1.5 2.048 0 O-C-N 121.299 -0.876 . . . . 0.0 110.359 -179.149 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.464 ' HD2' ' ND2' ' A' ' 48' ' ' ASN . 6.1 Cg_endo -75.55 25.8 0.39 Allowed 'Trans proline' 0 C--N 1.318 -1.039 0 C-N-CA 122.346 2.031 . . . . 0.0 111.966 179.859 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.585 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -113.82 2.13 15.03 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.266 -1.521 . . . . 0.0 109.482 179.833 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.533 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.22 16.72 2.42 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 179.423 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -79.38 91.74 5.12 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.598 -0.689 . . . . 0.0 111.016 -178.678 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -109.08 -166.9 1.15 Allowed 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.171 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.455 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.97 136.62 0.09 Allowed 'General case' 0 N--CA 1.485 1.301 0 O-C-N 120.519 -1.363 . . . . 0.0 111.327 -179.298 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.964 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -156.75 157.0 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 178.213 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.572 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.6 144.23 28.13 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.884 -1.135 . . . . 0.0 109.835 -179.759 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.005 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -63.84 105.82 0.9 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 122.436 1.112 . . . . 0.0 109.38 178.546 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.546 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.8 p-10 -58.69 -138.87 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.044 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.029 -179.869 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.578 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.32 -50.26 62.62 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.453 -0.779 . . . . 0.0 110.576 -178.718 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.463 ' OD1' ' HA2' ' A' ' 25' ' ' GLY . 1.7 t-20 -103.75 -35.19 8.3 Favored 'General case' 0 C--N 1.286 -2.195 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 178.442 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.977 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 109.28 67.36 0.59 Allowed Glycine 0 C--N 1.297 -1.627 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 177.936 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.563 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.0 m -106.76 123.12 47.68 Favored 'General case' 0 N--CA 1.482 1.137 0 O-C-N 121.559 -0.965 . . . . 0.0 108.623 178.829 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.964 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -132.6 109.15 9.54 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 -179.443 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.495 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 2.1 m -118.95 120.39 37.13 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.211 -0.93 . . . . 0.0 109.606 -179.474 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.662 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.71 141.62 29.42 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.567 -0.708 . . . . 0.0 109.691 179.779 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 17.7 p -99.93 135.89 40.66 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.395 -0.815 . . . . 0.0 109.112 179.702 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.843 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -135.59 167.84 20.35 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.941 . . . . 0.0 109.618 -179.29 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.861 HG22 HG22 ' A' ' 18' ' ' VAL . 1.5 p -99.4 126.89 45.38 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.077 -1.014 . . . . 0.0 109.276 -179.802 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.491 HG12 ' HB3' ' A' ' 36' ' ' GLN . 12.6 m -132.39 140.8 46.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 120.868 -1.145 . . . . 0.0 109.93 -179.134 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.552 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 56.7 mtt180 -127.61 -166.96 1.68 Allowed 'General case' 0 N--CA 1.485 1.322 0 O-C-N 120.68 -1.263 . . . . 0.0 111.328 -179.674 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.578 ' HG2' ' CD1' ' A' ' 112' ' ' PHE . 46.4 mtt180 -80.59 -79.02 0.16 Allowed 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 178.946 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -69.11 136.66 52.58 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 106.386 -1.709 . . . . 0.0 106.386 177.766 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.575 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.4 OUTLIER -160.35 136.51 8.6 Favored 'General case' 0 C--N 1.294 -1.844 0 C-N-CA 117.666 -1.614 . . . . 0.0 110.891 -177.191 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.47 ' C ' ' O ' ' A' ' 73' ' ' PHE . 2.0 mm-40 -33.43 118.78 0.34 Allowed 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.47 0.652 . . . . 0.0 110.427 -178.742 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.011 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.26 48.07 3.57 Favored Glycine 0 N--CA 1.493 2.463 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.148 -179.312 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.487 ' O ' ' HA ' ' A' ' 46' ' ' ALA . 0.2 OUTLIER -36.99 115.93 0.41 Allowed 'General case' 0 N--CA 1.513 2.685 0 O-C-N 121.109 -1.23 . . . . 0.0 110.11 179.828 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.727 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.3 tp -87.59 126.41 34.92 Favored 'General case' 0 N--CA 1.499 1.982 0 O-C-N 120.987 -1.071 . . . . 0.0 109.121 179.742 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 25.8 t80 -63.64 58.4 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.954 0 O-C-N 120.836 -1.165 . . . . 0.0 110.228 179.824 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.543 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.1 t70 -160.89 19.72 0.13 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.989 -1.069 . . . . 0.0 109.846 179.924 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.2 -28.01 5.34 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.812 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.2 OUTLIER -94.67 163.38 13.4 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.061 -1.258 . . . . 0.0 110.184 -179.438 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.478 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -108.55 137.71 46.05 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.987 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.727 ' HB2' HD13 ' A' ' 77' ' ' LEU . 5.6 t90 -81.62 -20.93 38.71 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.896 -1.127 . . . . 0.0 110.157 -178.956 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 116.36 173.55 17.07 Favored Glycine 0 N--CA 1.486 1.968 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 -179.44 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.25 111.81 2.41 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 179.069 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.652 HG21 ' HB3' ' A' ' 46' ' ' ALA . 46.0 t -83.67 104.25 11.9 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 121.378 -0.826 . . . . 0.0 108.981 -179.001 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.531 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -66.15 111.3 3.34 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.355 -0.84 . . . . 0.0 109.845 -179.295 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.572 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.4 t -64.25 -4.8 4.04 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 120.587 -1.321 . . . . 0.0 109.896 179.4 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 31.6 p -87.81 2.18 52.01 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 120.694 -1.253 . . . . 0.0 109.097 179.325 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.531 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -116.52 -51.16 2.61 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.362 -0.836 . . . . 0.0 108.935 -179.998 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.22 -179.9 4.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.53 -0.731 . . . . 0.0 109.493 179.745 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.75 116.07 31.64 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.365 -0.834 . . . . 0.0 108.925 179.91 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.557 ' HB2' HD11 ' A' ' 110' ' ' ILE . 2.7 m -96.97 123.3 40.65 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.828 -1.17 . . . . 0.0 109.477 -179.298 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.582 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -103.15 149.17 24.9 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.344 1.069 . . . . 0.0 111.356 -179.142 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.639 ' HB ' HG11 ' A' ' 7' ' ' VAL . 43.2 t -104.88 112.1 37.12 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 177.552 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -151.77 -172.02 20.14 Favored Glycine 0 N--CA 1.487 2.085 0 C-N-CA 118.218 -1.944 . . . . 0.0 111.747 -177.785 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.483 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.01 178.67 4.64 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 -178.845 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.558 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 3.2 m 177.19 178.56 0.27 Allowed 'General case' 0 C--N 1.295 -1.786 0 O-C-N 121.581 -0.699 . . . . 0.0 109.432 -179.806 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.423 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -124.74 -158.64 0.84 Allowed 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.935 -1.103 . . . . 0.0 109.063 179.796 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.422 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -116.72 36.02 4.34 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.696 -1.252 . . . . 0.0 109.134 -179.966 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -113.12 -33.94 5.85 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.42 -0.8 . . . . 0.0 109.855 -179.732 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.8 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 166.19 -36.35 0.25 Allowed Glycine 0 N--CA 1.482 1.7 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 -179.805 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.82 -177.48 5.15 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.544 -0.974 . . . . 0.0 109.9 179.438 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -171.88 -161.83 23.1 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.462 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.478 ' O ' ' O ' ' A' ' 104' ' ' GLY . 8.0 Cg_exo -45.51 173.73 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.643 0 CA-C-N 119.003 1.401 . . . . 0.0 110.232 179.251 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 25.9 pt-20 -92.7 -173.83 3.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.072 -1.017 . . . . 0.0 110.302 -178.824 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -124.67 174.86 17.15 Favored Glycine 0 N--CA 1.488 2.122 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 -179.89 . . . . . . . . 1 1 . 1 . 051 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -111.02 153.71 12.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -179.552 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.582 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -95.02 123.07 38.3 Favored 'General case' 0 C--N 1.292 -1.93 0 O-C-N 121.303 -0.873 . . . . 0.0 109.605 179.922 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.674 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.4 pt -98.08 168.32 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.209 -0.932 . . . . 0.0 109.073 179.942 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.2 OUTLIER -135.1 156.65 48.65 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.29 -0.881 . . . . 0.0 109.456 -179.98 . . . . . . . . 3 3 . 1 . 051 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.658 ' CE2' HD12 ' A' ' 110' ' ' ILE . 44.6 m-85 -131.97 78.46 1.82 Allowed 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.2 -0.937 . . . . 0.0 109.543 -179.767 . . . . . . . . 2 2 . 1 . 051 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 20.1 p30 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 118.003 -0.999 . . . . 0.0 109.497 179.995 . . . . . . . . 0 0 . 1 . 051 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.8 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 052 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.527 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -122.07 159.29 52.4 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.309 -0.869 . . . . 0.0 109.446 -179.939 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.637 ' HB3' HD23 ' A' ' 26' ' ' LEU . 5.0 Cg_exo -59.88 157.42 33.55 Favored 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.332 2.021 . . . . 0.0 110.619 179.938 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.604 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.8 OUTLIER -147.29 160.37 42.58 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.6 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.495 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.59 122.44 9.33 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-O 122.288 1.042 . . . . 0.0 110.333 -179.673 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.908 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.8 t -115.63 109.26 17.5 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-O 123.158 1.456 . . . . 0.0 109.838 -179.866 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.795 HG13 ' CA ' ' A' ' 21' ' ' VAL . 0.8 OUTLIER -115.5 136.12 53.32 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.632 0 CA-C-N 114.271 -1.331 . . . . 0.0 109.604 179.763 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.465 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -173.72 150.64 1.75 Allowed Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.181 -0.95 . . . . 0.0 109.04 -179.621 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.465 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.0 Cg_endo -77.2 151.18 92.99 Favored 'Cis proline' 0 C--N 1.313 -1.335 0 C-N-CA 123.484 -1.465 . . . . 0.0 109.26 -0.902 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.686 ' HA ' HG22 ' A' ' 110' ' ' ILE . 72.4 p -94.43 -22.55 18.22 Favored 'General case' 0 C--N 1.293 -1.89 0 O-C-N 121.511 -0.743 . . . . 0.0 109.623 179.878 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.466 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 1.1 m -130.88 155.18 47.18 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.214 -0.929 . . . . 0.0 110.233 -179.602 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 81.33 35.59 22.96 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 109.002 -1.639 . . . . 0.0 109.002 179.996 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.713 ' CA ' HG21 ' A' ' 17' ' ' THR . 40.4 mt -92.8 -44.19 8.63 Favored 'General case' 0 C--N 1.301 -1.529 0 CA-C-O 123.214 1.483 . . . . 0.0 110.635 -178.713 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.433 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 63.17 145.19 0.02 OUTLIER 'General case' 0 C--N 1.261 -3.247 0 CA-C-N 113.558 -1.655 . . . . 0.0 109.201 -178.939 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.533 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.6 m-20 -53.82 114.68 1.65 Allowed 'General case' 0 C--N 1.299 -1.627 0 CA-C-O 121.764 0.792 . . . . 0.0 110.436 -178.946 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 121.67 0.71 10.99 Favored Glycine 0 N--CA 1.484 1.865 0 C-N-CA 119.495 -1.336 . . . . 0.0 112.404 178.334 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.713 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.8 t -106.7 -177.34 3.33 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 121.069 2.434 . . . . 0.0 110.474 -179.944 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.774 HG13 ' O ' ' A' ' 67' ' ' LEU . 25.9 t -127.48 139.09 52.88 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 CA-C-N 114.113 -1.403 . . . . 0.0 110.878 -178.865 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.603 ' CG1' HD13 ' A' ' 13' ' ' LEU . 4.2 m -113.01 158.37 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 178.907 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.51 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.2 OUTLIER -106.45 108.77 20.44 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.088 -1.007 . . . . 0.0 109.115 179.947 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.878 ' CG1' HD11 ' A' ' 67' ' ' LEU . 13.0 p -101.23 140.02 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 N-CA-C 108.423 -0.955 . . . . 0.0 108.423 179.651 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.908 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -137.37 161.86 35.16 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.675 -1.266 . . . . 0.0 110.154 179.642 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.591 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.6 139.32 10.53 Favored Glycine 0 C--N 1.298 -1.546 0 N-CA-C 107.882 -2.087 . . . . 0.0 107.882 179.529 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.604 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.4 125.31 16.13 Favored 'General case' 0 N--CA 1.496 1.828 0 CA-C-N 119.411 1.606 . . . . 0.0 109.434 179.446 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.465 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.67 27.77 21.01 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 118.8 -1.667 . . . . 0.0 109.634 -179.756 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.637 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.2 mt -89.01 169.63 11.36 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.033 -1.275 . . . . 0.0 108.188 179.942 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.007 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -43.59 98.67 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.015 -1.053 . . . . 0.0 110.042 -179.354 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.552 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.29 77.83 0.0 OUTLIER 'General case' 0 C--N 1.298 -1.648 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.255 -179.285 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.571 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.23 33.44 0.27 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.393 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.542 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 59.0 p -141.73 108.67 5.43 Favored 'General case' 0 C--N 1.307 -1.264 0 O-C-N 121.102 -1.234 . . . . 0.0 111.316 -179.474 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.79 111.49 0.61 Allowed 'General case' 0 N--CA 1.497 1.896 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.717 178.067 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.539 ' CE1' ' HB2' ' A' ' 99' ' ' ASP . 5.3 m-30 -105.65 160.04 15.5 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.068 -1.02 . . . . 0.0 108.817 179.662 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.502 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -100.23 167.34 10.49 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.738 -1.226 . . . . 0.0 108.003 179.061 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.625 HG22 HG11 ' A' ' 21' ' ' VAL . 2.9 p -149.48 120.81 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.112 -0.992 . . . . 0.0 109.531 -178.136 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -174.9 -176.63 43.36 Favored Glycine 0 N--CA 1.493 2.434 0 C-N-CA 118.297 -1.906 . . . . 0.0 111.702 -179.941 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.711 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -98.83 108.87 21.66 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -179.997 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 3.1 m -130.45 148.93 52.32 Favored 'General case' 0 C--N 1.295 -1.796 0 O-C-N 121.315 -0.866 . . . . 0.0 109.461 179.389 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.494 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.38 138.72 54.34 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.154 -0.966 . . . . 0.0 110.849 -178.872 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.886 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.14 114.64 26.46 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 178.103 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.6 m -105.16 15.14 6.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.08 -1.012 . . . . 0.0 110.466 -178.609 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.75 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.42 -175.48 0.1 Allowed 'General case' 0 N--CA 1.488 1.44 0 O-C-N 120.864 -1.148 . . . . 0.0 109.998 179.705 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -71.65 96.83 1.63 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.473 -0.767 . . . . 0.0 109.735 -179.739 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.03 28.03 32.32 Favored Glycine 0 N--CA 1.493 2.449 0 C-N-CA 120.223 -0.989 . . . . 0.0 111.493 178.933 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.75 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.9 t -116.18 106.57 20.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 O-C-N 120.577 -1.543 . . . . 0.0 107.302 178.845 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.886 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.2 tp -116.23 104.45 11.52 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.449 -1.407 . . . . 0.0 110.022 -177.5 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.095 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.25 109.45 22.21 Favored 'General case' 0 N--CA 1.484 1.248 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 178.525 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 5.1 t -108.5 165.49 11.48 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.826 -1.171 . . . . 0.0 110.648 -178.468 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.48 ' OD1' ' HD2' ' A' ' 49' ' ' PRO . 52.4 t30 -115.84 134.45 22.71 Favored Pre-proline 0 N--CA 1.499 2.019 0 O-C-N 121.545 -0.722 . . . . 0.0 109.394 -179.624 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.531 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 2.5 Cg_endo -72.08 22.96 0.26 Allowed 'Trans proline' 0 C--N 1.317 -1.124 0 C-N-CA 122.289 1.993 . . . . 0.0 112.106 -179.802 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.443 ' HB3' HD22 ' A' ' 48' ' ' ASN . . . -95.28 -9.76 32.2 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.355 -1.466 . . . . 0.0 109.045 179.408 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.65 ' OD2' HG13 ' A' ' 69' ' ' VAL . 3.4 m-20 -134.06 6.77 3.66 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -179.903 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -59.72 84.04 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.495 -0.753 . . . . 0.0 110.589 -178.775 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.612 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -111.47 -168.89 1.36 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.516 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.464 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.3 t 179.01 135.17 0.09 Allowed 'General case' 0 C--N 1.305 -1.358 0 O-C-N 120.656 -1.278 . . . . 0.0 110.967 -179.476 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.79 HG11 ' HB1' ' A' ' 63' ' ' ALA . 1.6 p -147.29 157.4 9.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.288 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.598 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.53 142.01 30.66 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 120.696 -1.252 . . . . 0.0 110.024 -179.699 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.007 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.17 107.54 1.32 Allowed 'General case' 0 C--N 1.297 -1.675 0 CA-C-O 122.5 1.143 . . . . 0.0 109.533 178.462 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.558 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.2 p-10 -61.19 -139.39 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.976 -179.99 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.552 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.77 -50.83 55.0 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.399 -0.813 . . . . 0.0 110.641 -178.764 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -104.36 -33.27 8.69 Favored 'General case' 0 C--N 1.285 -2.221 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 178.498 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.996 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.47 66.49 0.62 Allowed Glycine 0 C--N 1.299 -1.498 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 178.132 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.591 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 51.6 m -100.68 130.09 46.67 Favored 'General case' 0 N--CA 1.486 1.334 0 O-C-N 121.491 -1.006 . . . . 0.0 108.883 178.974 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.79 ' HB1' HG11 ' A' ' 55' ' ' VAL . . . -134.49 109.51 8.76 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.217 -0.993 . . . . 0.0 109.307 -179.594 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 18.2 m -124.31 118.33 26.52 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.359 -0.838 . . . . 0.0 109.789 -179.781 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -148.36 148.26 30.17 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.436 -0.79 . . . . 0.0 109.218 179.808 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.412 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 28.2 p -98.38 136.23 38.83 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.33 -0.856 . . . . 0.0 109.47 179.923 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.878 HD11 ' CG1' ' A' ' 21' ' ' VAL . 0.2 OUTLIER -129.68 164.91 22.91 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.313 -0.867 . . . . 0.0 109.874 -179.023 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.713 HG22 HG22 ' A' ' 18' ' ' VAL . 1.1 p -104.29 127.16 51.89 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.157 -0.964 . . . . 0.0 108.679 179.529 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.711 HG12 ' HB3' ' A' ' 36' ' ' GLN . 16.0 m -134.53 140.21 46.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.722 -1.236 . . . . 0.0 110.471 -178.659 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.533 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 46.8 mtt180 -126.48 -168.2 1.83 Allowed 'General case' 0 N--CA 1.484 1.226 0 O-C-N 120.703 -1.248 . . . . 0.0 111.015 179.937 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.583 ' O ' ' HB2' ' A' ' 88' ' ' CYS . 27.9 mtm180 -77.87 -75.5 0.22 Allowed 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 179.326 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.0 OUTLIER -73.79 136.39 43.58 Favored 'General case' 0 C--N 1.306 -1.288 0 O-C-N 120.006 -1.684 . . . . 0.0 106.829 178.017 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.594 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -156.15 136.88 13.36 Favored 'General case' 0 C--N 1.295 -1.766 0 C-N-CA 117.987 -1.485 . . . . 0.0 110.481 -177.861 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.479 ' O ' ' O ' ' A' ' 47' ' ' CYS . 6.6 mm-40 -37.37 120.45 0.78 Allowed 'General case' 0 N--CA 1.487 1.385 0 CA-C-O 121.589 0.709 . . . . 0.0 110.129 -178.584 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.095 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -88.91 48.88 3.53 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.273 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.531 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 26.3 m-85 -38.22 113.44 0.29 Allowed 'General case' 0 N--CA 1.505 2.276 0 O-C-N 121.165 -1.197 . . . . 0.0 110.138 179.561 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.717 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.0 tp -86.07 126.93 34.54 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.003 -1.061 . . . . 0.0 109.455 -179.819 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.595 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 19.6 t80 -63.62 58.44 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.994 0 O-C-N 120.984 -1.073 . . . . 0.0 110.21 179.599 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.542 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -160.89 19.62 0.13 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.038 -1.038 . . . . 0.0 109.824 179.926 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.72 -27.14 5.47 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 179.767 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.446 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 15.5 p -95.57 158.91 15.24 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.994 -1.297 . . . . 0.0 110.258 -179.457 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.461 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.8 OUTLIER -105.03 136.68 44.06 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.717 -0.845 . . . . 0.0 108.717 179.699 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.717 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.7 t90 -80.72 -20.13 43.5 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.914 -1.116 . . . . 0.0 110.274 -178.644 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 114.76 174.43 18.31 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 108.669 -1.772 . . . . 0.0 108.669 -179.392 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -63.53 108.73 1.44 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.011 -1.287 . . . . 0.0 107.771 179.21 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.674 HG21 ' HB3' ' A' ' 46' ' ' ALA . 41.5 t -81.41 105.59 11.5 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 O-C-N 121.375 -0.828 . . . . 0.0 108.796 -179.256 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.526 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.92 111.14 3.63 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.342 -0.849 . . . . 0.0 110.051 -179.085 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.583 ' HB2' ' O ' ' A' ' 71' ' ' ARG . 2.5 t -63.99 -5.21 4.22 Favored 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 118.587 -1.245 . . . . 0.0 109.924 179.456 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.7 p -87.43 1.46 53.35 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 120.804 -1.185 . . . . 0.0 109.08 179.446 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.526 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -116.05 -51.18 2.65 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.393 -0.817 . . . . 0.0 108.965 179.868 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.401 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . -102.2 -178.96 3.85 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.544 -0.722 . . . . 0.0 109.384 179.736 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -105.49 115.61 30.54 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.389 -0.82 . . . . 0.0 109.077 179.975 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.52 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.8 m -96.76 121.39 38.55 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.833 -1.167 . . . . 0.0 109.324 -179.438 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.632 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.02 144.93 30.0 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 122.323 1.059 . . . . 0.0 111.262 -179.278 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.586 ' CG1' HG11 ' A' ' 7' ' ' VAL . 96.1 t -102.14 109.86 27.36 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 177.663 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.476 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.89 -171.29 17.49 Favored Glycine 0 N--CA 1.487 2.092 0 C-N-CA 118.018 -2.039 . . . . 0.0 111.894 -177.54 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.502 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -110.51 -179.21 3.7 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 -179.221 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.554 ' HB3' ' C21' ' A' ' 114' ' ' CHR . 36.8 p -162.67 173.78 13.43 Favored 'General case' 0 C--N 1.295 -1.766 0 O-C-N 121.464 -0.772 . . . . 0.0 109.379 -179.366 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.539 ' HB2' ' CE1' ' A' ' 32' ' ' TYR . 0.8 OUTLIER -123.59 -160.93 0.94 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.197 -0.939 . . . . 0.0 108.782 179.569 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -120.73 34.01 5.37 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.511 -1.368 . . . . 0.0 109.572 -179.859 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -121.48 -29.12 4.48 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.355 -0.841 . . . . 0.0 110.578 -179.63 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.983 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 167.28 -37.31 0.23 Allowed Glycine 0 N--CA 1.482 1.763 0 N-CA-C 107.601 -2.199 . . . . 0.0 107.601 -179.42 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.501 ' ND2' ' O9 ' ' A' ' 114' ' ' CHR . 0.4 OUTLIER -160.34 -178.3 6.84 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 121.568 -0.96 . . . . 0.0 109.587 179.202 . . . . . . . . 3 3 . 1 . 052 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -158.92 -163.42 13.0 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 108.3 -1.92 . . . . 0.0 108.3 -179.558 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 104' ' ' GLY . 5.0 Cg_exo -47.72 178.89 0.01 OUTLIER 'Trans proline' 0 C--O 1.214 -0.705 0 CA-C-N 118.819 1.31 . . . . 0.0 110.132 179.331 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -91.75 -175.79 4.26 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.047 -1.033 . . . . 0.0 110.415 -178.879 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.476 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.83 168.2 14.56 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 -179.865 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.6 130.49 51.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.405 -1.056 . . . . 0.0 109.073 -179.363 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.632 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.58 121.39 21.5 Favored 'General case' 0 C--N 1.29 -1.979 0 O-C-N 121.578 -0.701 . . . . 0.0 109.914 179.85 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.686 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.5 pt -98.0 166.91 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 O-C-N 121.279 -0.888 . . . . 0.0 109.04 179.765 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.466 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 1.4 m -135.25 156.52 48.83 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.322 -0.862 . . . . 0.0 109.597 -179.96 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.648 ' CE2' HD12 ' A' ' 110' ' ' ILE . 53.7 m-85 -128.08 89.33 2.9 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.215 -0.928 . . . . 0.0 109.434 -179.885 . . . . . . . . 2 2 . 1 . 052 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.406 ' OD1' ' C ' ' A' ' 113' ' ' ASN . 14.4 p30 . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.456 -179.998 . . . . . . . . 1 1 . 1 . 052 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.983 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 053 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -122.56 108.81 33.1 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.266 -0.896 . . . . 0.0 109.407 -179.917 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.572 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 6.3 Cg_exo -58.77 156.66 31.59 Favored 'Trans proline' 0 C--N 1.311 -1.406 0 C-N-CA 122.119 1.879 . . . . 0.0 110.64 179.954 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.542 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -176.85 -169.41 0.26 Allowed 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 179.083 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.542 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.28 132.84 3.02 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.81 -1.181 . . . . 0.0 110.717 -179.059 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.017 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 1.7 p -104.16 104.38 14.3 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 122.585 1.183 . . . . 0.0 109.835 179.901 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.965 HG22 HG23 ' A' ' 21' ' ' VAL . 14.2 t -119.59 121.49 66.43 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.395 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.398 179.806 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.479 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -166.73 149.75 6.18 Favored Pre-proline 0 N--CA 1.486 1.354 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.557 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.479 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.8 Cg_endo -78.63 149.54 85.67 Favored 'Cis proline' 0 C--N 1.308 -1.563 0 C-N-CA 123.663 -1.39 . . . . 0.0 109.697 -0.722 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.641 ' HA ' HG22 ' A' ' 110' ' ' ILE . 88.7 p -91.0 -24.63 20.03 Favored 'General case' 0 C--N 1.293 -1.88 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 179.34 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 111' ' ' SER . 0.8 OUTLIER -131.23 161.17 32.85 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.381 -0.825 . . . . 0.0 109.733 -179.949 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.63 38.47 32.19 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 -179.574 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.825 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.9 mt -92.08 -44.46 8.82 Favored 'General case' 0 C--N 1.298 -1.665 0 CA-C-O 123.111 1.434 . . . . 0.0 110.736 -178.26 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.464 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.67 145.72 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.308 0 CA-C-N 113.658 -1.61 . . . . 0.0 110.05 -179.818 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.607 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 5.4 p-10 -51.2 107.35 0.18 Allowed 'General case' 0 C--N 1.303 -1.453 0 CA-C-O 121.502 0.668 . . . . 0.0 111.597 -178.693 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.25 14.36 9.91 Favored Glycine 0 N--CA 1.484 1.883 0 C-N-CA 119.335 -1.412 . . . . 0.0 112.953 177.227 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.825 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.7 t -102.78 -172.31 2.1 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 121.012 2.406 . . . . 0.0 109.643 179.239 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.738 HG13 ' C ' ' A' ' 67' ' ' LEU . 11.8 t -131.71 137.93 54.0 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.372 0 CA-C-N 115.001 -0.999 . . . . 0.0 111.229 -179.113 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.427 HG23 ' CD1' ' A' ' 67' ' ' LEU . 33.7 m -114.69 154.4 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.965 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.564 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -109.05 109.29 20.28 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.158 -0.964 . . . . 0.0 109.186 -179.993 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.965 HG23 HG22 ' A' ' 7' ' ' VAL . 2.0 p -107.7 123.11 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 -179.968 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.017 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.43 165.12 13.07 Favored 'General case' 0 C--N 1.306 -1.309 0 O-C-N 120.829 -1.169 . . . . 0.0 108.873 179.55 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.574 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.85 107.67 0.53 Allowed Glycine 0 C--N 1.297 -1.614 0 N-CA-C 108.825 -1.71 . . . . 0.0 108.825 179.944 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.572 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -115.73 142.84 46.21 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 120.876 -1.367 . . . . 0.0 110.676 -179.213 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.521 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 81.78 27.35 46.77 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 179.207 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.561 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -92.11 174.26 7.41 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.061 -1.258 . . . . 0.0 108.589 179.967 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.004 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.44 99.43 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.025 -1.047 . . . . 0.0 109.732 -179.79 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.656 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.06 77.4 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.246 -179.116 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.67 34.02 0.32 Allowed Glycine 0 N--CA 1.487 2.067 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.379 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.559 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 80.3 p -144.23 111.6 5.98 Favored 'General case' 0 C--N 1.306 -1.291 0 O-C-N 120.996 -1.297 . . . . 0.0 111.096 -179.803 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.568 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -47.09 124.5 6.53 Favored 'General case' 0 N--CA 1.493 1.691 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.845 178.355 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.494 ' CE2' ' OG1' ' A' ' 30' ' ' THR . 17.8 m-85 -117.69 150.4 39.13 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.493 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.479 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.64 155.42 17.89 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 178.675 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.012 HG11 HG21 ' A' ' 65' ' ' THR . 7.0 p -138.17 114.96 11.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.025 -1.047 . . . . 0.0 109.807 -177.81 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.505 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -163.58 -177.67 36.62 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 118.507 -1.806 . . . . 0.0 111.638 -179.648 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.642 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 1.2 pt20 -102.3 109.83 21.62 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-O 121.836 0.826 . . . . 0.0 108.917 -179.781 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.483 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.0 150.34 51.32 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.157 -0.964 . . . . 0.0 110.166 -179.869 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -124.77 139.7 53.61 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.255 -0.903 . . . . 0.0 110.633 -179.212 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.883 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.05 114.44 26.25 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 178.178 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.4 m -105.37 15.82 6.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.006 -1.059 . . . . 0.0 110.661 -178.821 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.748 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.98 -175.94 0.11 Allowed 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.928 -1.108 . . . . 0.0 110.043 179.741 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 71.8 p -71.23 96.35 1.39 Allowed 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.37 -0.831 . . . . 0.0 109.759 -179.714 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.38 27.98 34.59 Favored Glycine 0 N--CA 1.492 2.388 0 C-N-CA 120.234 -0.984 . . . . 0.0 111.402 178.873 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.748 HG21 ' CB ' ' A' ' 41' ' ' ASP . 2.1 t -115.46 105.97 19.59 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 O-C-N 120.481 -1.599 . . . . 0.0 107.417 178.951 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.883 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.0 tp -114.9 104.63 12.12 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.533 -1.355 . . . . 0.0 110.062 -177.658 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.745 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.21 109.52 22.26 Favored 'General case' 0 N--CA 1.483 1.225 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 178.447 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.7 t -105.49 170.47 7.87 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.968 -1.082 . . . . 0.0 110.734 -178.108 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.474 ' HB2' ' HB2' ' A' ' 73' ' ' PHE . 21.1 t-20 -114.14 126.07 28.5 Favored Pre-proline 0 N--CA 1.498 1.962 0 O-C-N 121.54 -0.725 . . . . 0.0 109.546 -179.471 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.602 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 0.9 OUTLIER -70.57 21.15 0.2 Allowed 'Trans proline' 0 CA--C 1.545 1.062 0 C-N-CA 122.098 1.865 . . . . 0.0 112.118 179.589 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.445 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -107.86 2.59 23.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.42 -1.425 . . . . 0.0 108.964 179.385 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.544 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.39 16.4 2.57 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.563 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -80.35 91.16 5.63 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.747 -0.781 . . . . 0.0 110.974 -178.537 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.621 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -107.35 -166.37 1.15 Allowed 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.23 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.442 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.68 137.57 0.09 Allowed 'General case' 0 N--CA 1.486 1.345 0 O-C-N 120.55 -1.344 . . . . 0.0 111.369 -179.38 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 1.012 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -156.86 156.94 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.171 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.568 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -98.17 144.7 27.36 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 120.717 -1.239 . . . . 0.0 109.944 -179.616 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.004 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.22 106.39 1.08 Allowed 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 122.408 1.099 . . . . 0.0 109.29 178.466 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.536 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.6 p-10 -59.04 -138.49 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.992 -179.816 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.656 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -52.19 -50.27 62.22 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.445 -0.784 . . . . 0.0 110.618 -178.567 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 28.9 t30 -104.16 -35.53 8.0 Favored 'General case' 0 C--N 1.284 -2.241 0 N-CA-C 106.093 -1.817 . . . . 0.0 106.093 178.376 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.993 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 111.1 64.82 0.51 Allowed Glycine 0 C--N 1.298 -1.548 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 177.924 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.574 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 18.6 m -104.72 123.11 47.06 Favored 'General case' 0 N--CA 1.484 1.254 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.545 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 1.012 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.27 109.23 9.25 Favored 'General case' 0 C--N 1.294 -1.819 0 C-N-CA 119.894 -0.722 . . . . 0.0 109.544 -179.052 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 3.6 m -114.0 115.77 28.15 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.349 -0.845 . . . . 0.0 109.358 -179.981 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 1.012 HG21 HG11 ' A' ' 34' ' ' VAL . 1.5 t -139.18 140.0 37.7 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.399 -0.813 . . . . 0.0 109.85 179.971 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 45.4 p -99.24 145.82 26.86 Favored 'General case' 0 C--N 1.303 -1.42 0 O-C-N 121.496 -0.753 . . . . 0.0 109.17 179.718 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.738 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -146.63 162.7 37.88 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.354 -0.842 . . . . 0.0 109.6 -179.134 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.714 HG22 HG22 ' A' ' 18' ' ' VAL . 3.2 p -93.94 124.76 38.16 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.203 -0.936 . . . . 0.0 109.276 -179.913 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.553 HG23 HD13 ' A' ' 13' ' ' LEU . 15.4 m -134.66 141.94 41.87 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 120.861 -1.149 . . . . 0.0 109.99 -179.101 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.607 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.5 ptt180 -141.9 -163.7 1.64 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 120.473 -1.392 . . . . 0.0 110.601 -179.802 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.615 ' HD2' ' CD1' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -75.74 -92.59 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.343 -0.848 . . . . 0.0 109.79 -179.029 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.539 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -60.92 133.07 55.73 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.255 -1.528 . . . . 0.0 107.726 179.478 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.642 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -153.95 156.91 38.35 Favored 'General case' 0 C--N 1.293 -1.874 0 C-N-CA 118.367 -1.333 . . . . 0.0 110.179 -178.716 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.596 ' HB3' ' CE1' ' A' ' 76' ' ' PHE . 30.3 mm-40 -47.99 121.66 4.41 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.35 -0.844 . . . . 0.0 109.94 -178.292 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.745 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -86.79 49.89 4.1 Favored Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 -179.4 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.602 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 29.7 m-85 -52.29 110.37 0.49 Allowed 'General case' 0 N--CA 1.505 2.301 0 O-C-N 121.014 -1.286 . . . . 0.0 110.743 179.753 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.775 HD13 ' HB2' ' A' ' 83' ' ' TRP . 0.5 OUTLIER -78.67 151.57 32.14 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 120.801 -1.187 . . . . 0.0 108.748 178.64 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.55 ' HA ' ' C6 ' ' A' ' 114' ' ' CHR . 40.4 t80 -63.41 -5.5 3.71 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 120.691 -1.256 . . . . 0.0 110.863 179.954 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 30.5 m-20 -99.18 7.63 45.59 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.723 -1.236 . . . . 0.0 109.593 179.938 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.447 ' HA2' ' O11' ' A' ' 114' ' ' CHR . . . 82.59 -9.81 57.77 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.967 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.55 ' O ' ' HB2' ' A' ' 77' ' ' LEU . 0.3 OUTLIER -78.86 133.56 36.98 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.115 -1.227 . . . . 0.0 109.917 -179.8 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.508 ' NH1' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -75.74 114.66 14.6 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.294 -0.879 . . . . 0.0 109.702 179.75 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.775 ' HB2' HD13 ' A' ' 77' ' ' LEU . 4.0 t90 -80.91 -20.16 42.73 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.036 -1.04 . . . . 0.0 109.426 -179.97 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.44 172.48 18.82 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 -179.725 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -62.44 110.61 1.72 Allowed 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 179.192 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.616 HG23 ' HA3' ' A' ' 75' ' ' GLY . 41.1 t -80.84 101.17 5.55 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.989 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.727 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -61.98 108.21 1.0 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.671 -0.643 . . . . 0.0 110.066 -179.176 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.56 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 4.1 t -60.36 -5.07 1.0 Allowed 'General case' 0 N--CA 1.501 2.124 0 C-N-CA 118.334 -1.346 . . . . 0.0 110.339 179.385 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 60.8 p -89.6 0.26 57.05 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.461 -1.399 . . . . 0.0 109.588 179.994 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.727 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -110.24 -48.46 3.18 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.172 -0.955 . . . . 0.0 109.068 179.994 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.78 -178.07 3.54 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.604 -0.685 . . . . 0.0 109.507 179.997 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.36 112.94 26.17 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.784 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.497 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.7 m -96.48 122.2 39.13 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.107 -0.995 . . . . 0.0 109.675 -178.731 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.3 mt-30 -104.02 148.92 25.66 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 122.428 1.109 . . . . 0.0 111.339 -179.42 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.549 ' HB ' HG11 ' A' ' 7' ' ' VAL . 57.7 t -103.98 109.78 28.25 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.989 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 177.566 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.46 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.13 -171.46 17.83 Favored Glycine 0 N--CA 1.486 1.995 0 C-N-CA 118.239 -1.934 . . . . 0.0 111.605 -177.625 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.49 HD11 ' HB2' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -122.05 178.92 4.7 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -178.812 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.571 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 3.4 m 178.37 177.32 0.44 Allowed 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.571 -0.705 . . . . 0.0 109.393 -179.841 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.481 ' CG ' ' N ' ' A' ' 100' ' ' ALA . 0.4 OUTLIER -125.05 -156.95 0.75 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.058 -1.026 . . . . 0.0 109.033 179.877 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.481 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.48 36.22 4.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.781 -1.2 . . . . 0.0 109.091 179.925 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -112.19 -32.84 6.41 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.301 -0.875 . . . . 0.0 109.946 -179.671 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.725 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 165.89 -36.86 0.26 Allowed Glycine 0 N--CA 1.482 1.71 0 N-CA-C 107.883 -2.087 . . . . 0.0 107.883 -179.704 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.413 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -167.0 -177.17 3.67 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 122.079 0.942 . . . . 0.0 109.755 179.427 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -169.87 -162.23 21.77 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 108.265 -1.934 . . . . 0.0 108.265 -179.431 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.508 ' HG3' HD22 ' A' ' 26' ' ' LEU . 7.5 Cg_exo -45.27 171.91 0.02 OUTLIER 'Trans proline' 0 C--N 1.326 -0.629 0 CA-C-N 118.95 1.375 . . . . 0.0 110.035 179.319 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -93.17 -176.69 4.23 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.049 -1.032 . . . . 0.0 110.501 -178.583 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.46 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.07 166.28 12.77 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 -179.908 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.1 t -106.11 132.91 52.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.399 -1.059 . . . . 0.0 109.162 -179.251 . . . . . . . . 1 1 . 1 . 053 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -72.58 126.08 29.0 Favored 'General case' 0 C--N 1.289 -2.038 0 O-C-N 121.534 -0.729 . . . . 0.0 109.741 179.873 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.822 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.6 pt -97.91 172.44 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.248 -0.907 . . . . 0.0 108.979 179.683 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.48 ' HB3' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -137.59 158.73 43.76 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.077 -1.014 . . . . 0.0 109.462 -179.948 . . . . . . . . 3 3 . 1 . 053 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.822 ' CE2' HD12 ' A' ' 110' ' ' ILE . 56.0 m-85 -136.8 81.09 1.85 Allowed 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.24 -0.913 . . . . 0.0 109.636 -179.639 . . . . . . . . 2 2 . 1 . 053 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 16.6 p30 . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 118.0 -1.0 . . . . 0.0 109.516 -179.985 . . . . . . . . 0 0 . 1 . 053 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.811 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 0 0 . 1 . 054 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -119.42 152.95 53.52 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.371 -0.83 . . . . 0.0 109.49 179.969 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.583 ' HB3' HD23 ' A' ' 26' ' ' LEU . 5.1 Cg_exo -59.96 157.44 33.87 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.23 1.953 . . . . 0.0 110.642 -179.985 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.598 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -149.04 160.22 43.51 Favored 'General case' 0 C--N 1.294 -1.842 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 -179.542 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.494 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.41 122.69 9.61 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-O 122.43 1.11 . . . . 0.0 110.234 -179.728 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.863 HG22 ' HB3' ' A' ' 22' ' ' ALA . 5.9 t -115.14 109.04 17.43 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 123.127 1.441 . . . . 0.0 109.812 -179.863 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.795 HG22 HG23 ' A' ' 21' ' ' VAL . 2.2 t -116.18 134.18 60.36 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.659 0 CA-C-N 114.229 -1.35 . . . . 0.0 109.486 179.795 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.472 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -169.53 150.39 4.03 Favored Pre-proline 0 N--CA 1.487 1.413 0 O-C-N 121.183 -0.948 . . . . 0.0 108.876 -179.509 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.472 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.5 Cg_endo -75.52 152.32 97.24 Favored 'Cis proline' 0 C--N 1.313 -1.315 0 C-N-CA 123.488 -1.463 . . . . 0.0 109.785 -0.963 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.625 ' HA ' HG22 ' A' ' 110' ' ' ILE . 5.8 m -93.05 -23.52 18.63 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.447 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.513 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 69.0 m -134.99 159.62 40.93 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.564 -0.71 . . . . 0.0 109.382 179.912 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.28 36.29 27.61 Favored Glycine 0 N--CA 1.495 2.626 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.736 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.745 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.7 mt -90.94 -42.65 10.45 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 123.391 1.567 . . . . 0.0 110.393 -178.482 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.48 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.11 144.34 0.05 OUTLIER 'General case' 0 C--N 1.261 -3.267 0 CA-C-N 113.282 -1.781 . . . . 0.0 110.08 -179.746 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.599 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 7.3 p-10 -50.46 104.75 0.08 Allowed 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.556 0.693 . . . . 0.0 111.655 -178.451 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 115.51 14.4 8.2 Favored Glycine 0 N--CA 1.485 1.91 0 C-N-CA 119.33 -1.414 . . . . 0.0 113.154 177.18 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.745 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.0 t -105.76 -172.99 2.19 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 121.352 2.576 . . . . 0.0 109.821 179.181 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.731 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.5 t -129.59 138.21 54.82 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.333 0 CA-C-N 114.67 -1.15 . . . . 0.0 111.136 -178.711 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.633 HG11 HD11 ' A' ' 13' ' ' LEU . 29.4 m -113.61 155.48 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.357 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.863 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.505 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 3.2 tttm -104.32 109.05 20.75 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.208 -0.933 . . . . 0.0 109.213 -179.962 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.944 HG11 HD11 ' A' ' 67' ' ' LEU . 2.2 p -100.64 140.05 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.627 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.863 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -136.61 162.67 32.49 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 120.733 -1.229 . . . . 0.0 110.179 179.666 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.588 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -136.64 139.82 10.95 Favored Glycine 0 C--N 1.299 -1.527 0 N-CA-C 108.244 -1.942 . . . . 0.0 108.244 179.728 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.598 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -142.32 125.6 16.51 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.491 -1.593 . . . . 0.0 109.355 179.301 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.469 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 88.85 28.32 21.52 Favored Glycine 0 N--CA 1.49 2.264 0 C-N-CA 118.685 -1.722 . . . . 0.0 109.731 -179.824 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.583 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.4 mt -88.72 171.95 9.6 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.885 -1.362 . . . . 0.0 108.278 179.835 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.02 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.03 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 O-C-N 120.96 -1.087 . . . . 0.0 109.872 -179.476 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.547 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -56.57 77.54 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.677 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.178 -179.345 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.578 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 134.65 33.97 0.28 Allowed Glycine 0 N--CA 1.486 2.007 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 179.618 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.563 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 41.2 p -141.51 108.05 5.32 Favored 'General case' 0 C--N 1.307 -1.244 0 O-C-N 121.144 -1.209 . . . . 0.0 111.236 -179.476 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -51.04 109.8 0.36 Allowed 'General case' 0 N--CA 1.497 1.904 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.488 177.866 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.511 ' CE1' ' HB2' ' A' ' 99' ' ' ASP . 5.3 m-30 -103.89 157.99 16.71 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.054 -1.029 . . . . 0.0 108.87 179.741 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.489 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.5 OUTLIER -99.81 166.54 11.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.844 -1.16 . . . . 0.0 107.969 179.007 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.628 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 2.8 p -148.09 120.28 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.108 -0.995 . . . . 0.0 109.605 -178.038 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -174.02 -177.02 42.89 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 118.403 -1.856 . . . . 0.0 111.641 -179.927 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.701 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.0 OUTLIER -99.16 108.24 20.79 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.95 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.3 m -130.25 148.5 52.08 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.212 -0.93 . . . . 0.0 109.985 179.708 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.427 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -124.71 139.58 53.73 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.298 -0.877 . . . . 0.0 110.634 -179.099 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.888 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.21 114.76 26.59 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 178.207 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -104.83 15.02 6.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 120.92 -1.112 . . . . 0.0 110.58 -178.795 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.768 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 174.41 -175.96 0.08 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.872 -1.142 . . . . 0.0 110.074 179.757 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.781 HG23 ' O ' ' A' ' 42' ' ' THR . 15.0 t -71.36 98.0 1.7 Allowed 'General case' 0 N--CA 1.488 1.434 0 CA-C-O 121.729 0.776 . . . . 0.0 109.808 -179.696 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.48 27.86 34.64 Favored Glycine 0 N--CA 1.492 2.405 0 C-N-CA 120.174 -1.012 . . . . 0.0 111.427 178.97 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.768 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.8 t -116.71 106.25 19.87 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 O-C-N 120.587 -1.537 . . . . 0.0 107.192 178.887 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.888 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -116.96 104.53 11.37 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 120.478 -1.389 . . . . 0.0 109.773 -177.75 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.098 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.99 109.28 22.06 Favored 'General case' 0 N--CA 1.485 1.315 0 O-C-N 120.833 -1.167 . . . . 0.0 108.152 178.92 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.0 t -106.67 164.8 11.79 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.913 -1.117 . . . . 0.0 110.233 -179.115 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.793 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 3.7 t-20 -106.56 136.21 19.42 Favored Pre-proline 0 N--CA 1.498 1.966 0 O-C-N 121.386 -0.821 . . . . 0.0 109.622 -179.179 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.592 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.0 Cg_endo -74.85 23.79 0.39 Allowed 'Trans proline' 0 CA--C 1.543 0.968 0 C-N-CA 122.384 2.056 . . . . 0.0 111.943 -179.83 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.793 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -109.76 -4.59 15.99 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.33 -1.481 . . . . 0.0 109.143 179.615 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.665 ' OD2' HG13 ' A' ' 69' ' ' VAL . 6.0 m-20 -131.73 6.05 4.33 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.658 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -64.47 84.94 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.732 -178.502 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.628 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -110.76 -170.49 1.65 Allowed 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.448 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.58 135.22 0.08 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 120.622 -1.298 . . . . 0.0 111.136 -179.286 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.767 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.6 p -146.8 158.28 10.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 N-CA-C 107.623 -1.251 . . . . 0.0 107.623 178.169 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.598 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.49 141.51 31.25 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 120.703 -1.248 . . . . 0.0 110.061 -179.791 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.02 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.21 107.91 1.43 Allowed 'General case' 0 C--N 1.298 -1.641 0 CA-C-O 122.438 1.114 . . . . 0.0 109.537 178.596 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.57 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 9.1 p-10 -61.46 -139.45 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.97 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.864 179.849 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.547 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -51.89 -50.87 60.17 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.427 -0.796 . . . . 0.0 110.487 -178.843 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -102.24 -34.71 9.13 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 178.46 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.984 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.27 67.31 0.64 Allowed Glycine 0 C--N 1.299 -1.499 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 178.073 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 57.5 m -100.06 130.86 46.26 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.482 -1.011 . . . . 0.0 108.803 178.962 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.767 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.48 109.42 9.27 Favored 'General case' 0 C--N 1.299 -1.612 0 C-N-CA 119.19 -1.004 . . . . 0.0 109.321 -179.648 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 73.2 m -121.85 117.0 25.43 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.313 -0.867 . . . . 0.0 109.61 -179.678 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.589 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -147.54 149.32 32.37 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.452 -0.78 . . . . 0.0 109.291 179.879 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.434 ' O ' HD23 ' A' ' 67' ' ' LEU . 56.3 p -98.47 145.08 27.13 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.401 -0.812 . . . . 0.0 109.284 179.969 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.944 HD11 HG11 ' A' ' 21' ' ' VAL . 0.3 OUTLIER -138.96 159.62 41.7 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.334 -0.854 . . . . 0.0 109.826 -178.717 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.652 HG22 HG22 ' A' ' 18' ' ' VAL . 1.4 p -101.29 124.0 46.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.011 -1.056 . . . . 0.0 108.483 179.319 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.701 HG12 ' HB3' ' A' ' 36' ' ' GLN . 21.1 m -137.92 143.16 34.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.744 -1.222 . . . . 0.0 110.783 -178.47 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.599 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 6.9 ptt180 -147.45 -175.14 4.73 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 120.711 -1.243 . . . . 0.0 110.742 179.68 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.595 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -52.43 -101.93 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -179.597 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.503 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.7 OUTLIER -57.08 140.85 47.98 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.741 -1.224 . . . . 0.0 108.205 179.459 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.5 OUTLIER -161.83 136.67 7.16 Favored 'General case' 0 C--N 1.294 -1.811 0 C-N-CA 118.611 -1.235 . . . . 0.0 109.733 -178.1 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.532 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.4 mp0 -35.87 122.36 0.68 Allowed 'General case' 0 N--CA 1.491 1.576 0 CA-C-O 121.466 0.65 . . . . 0.0 110.094 -178.615 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.098 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -95.85 52.67 1.7 Allowed Glycine 0 N--CA 1.494 2.522 0 C-N-CA 120.539 -0.838 . . . . 0.0 111.22 -179.109 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.592 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.1 m-85 -39.57 114.05 0.38 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.094 -1.239 . . . . 0.0 110.133 179.463 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.733 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -82.79 126.19 32.14 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 120.843 -1.161 . . . . 0.0 109.313 179.787 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.585 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 51.8 t80 -64.02 58.59 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.955 0 O-C-N 120.89 -1.131 . . . . 0.0 110.042 179.724 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.541 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.3 t0 -160.22 20.03 0.15 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.094 -1.004 . . . . 0.0 109.608 179.942 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 86.54 -28.35 5.36 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 179.871 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.481 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.5 OUTLIER -96.72 160.42 14.38 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.058 -1.26 . . . . 0.0 110.207 -179.532 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.508 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.7 OUTLIER -106.13 141.69 37.07 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 179.896 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.733 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.6 t90 -85.15 -19.35 31.92 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.679 -1.263 . . . . 0.0 110.689 -178.289 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 115.42 177.5 18.59 Favored Glycine 0 N--CA 1.485 1.957 0 N-CA-C 108.508 -1.837 . . . . 0.0 108.508 -179.359 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -67.02 105.79 1.75 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.146 -1.208 . . . . 0.0 107.785 179.183 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.65 HG21 ' HB3' ' A' ' 46' ' ' ALA . 42.7 t -77.2 106.33 7.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.326 -0.858 . . . . 0.0 109.232 -178.879 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.55 ' HB3' HG23 ' A' ' 90' ' ' THR . 1.1 m-20 -65.96 111.63 3.42 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.363 -0.836 . . . . 0.0 109.69 -179.643 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.595 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.5 -5.36 5.26 Favored 'General case' 0 N--CA 1.5 2.045 0 C-N-CA 118.195 -1.402 . . . . 0.0 109.721 179.567 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -86.4 -0.41 55.91 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.716 -1.24 . . . . 0.0 109.079 179.482 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.55 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -113.6 -50.88 2.83 Favored 'General case' 0 N--CA 1.486 1.348 0 O-C-N 121.287 -0.883 . . . . 0.0 108.972 179.9 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.69 -178.73 3.74 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.509 -0.744 . . . . 0.0 109.271 179.815 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.17 115.37 30.11 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.437 -0.789 . . . . 0.0 108.888 -179.949 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.527 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.3 m -97.06 121.1 38.56 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.94 -1.1 . . . . 0.0 109.714 -179.271 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.614 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -102.21 146.94 27.27 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 122.449 1.119 . . . . 0.0 111.024 -179.562 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.548 ' CG1' HG11 ' A' ' 7' ' ' VAL . 61.6 t -104.23 111.72 34.94 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 177.858 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.497 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -152.91 -169.86 18.59 Favored Glycine 0 N--CA 1.487 2.089 0 C-N-CA 118.124 -1.989 . . . . 0.0 111.848 -177.71 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.489 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -114.32 179.43 3.96 Favored 'General case' 0 N--CA 1.486 1.345 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 -179.173 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.576 ' HB2' ' C20' ' A' ' 114' ' ' CHR . 25.0 p -160.64 167.59 26.69 Favored 'General case' 0 C--N 1.295 -1.792 0 O-C-N 121.467 -0.771 . . . . 0.0 109.363 -179.513 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.511 ' HB2' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -110.25 -160.5 0.72 Allowed 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.025 -1.047 . . . . 0.0 108.646 179.554 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . . . . . . . . . . . -116.86 37.07 3.92 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.552 -1.342 . . . . 0.0 109.09 179.866 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -123.53 -36.74 2.74 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.275 -0.89 . . . . 0.0 110.449 -179.473 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.977 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 162.43 -30.9 0.3 Allowed Glycine 0 N--CA 1.476 1.34 0 N-CA-C 106.717 -2.553 . . . . 0.0 106.717 -179.348 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.451 ' O ' ' OD1' ' A' ' 99' ' ' ASP . 0.0 OUTLIER -146.7 170.74 16.35 Favored 'General case' 0 C--N 1.307 -1.256 0 O-C-N 121.709 -0.877 . . . . 0.0 109.943 -179.775 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -163.15 -165.01 19.55 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 108.163 -1.975 . . . . 0.0 108.163 -179.857 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.474 ' O ' ' O ' ' A' ' 104' ' ' GLY . 4.9 Cg_exo -48.22 179.39 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.649 0 CA-C-N 118.889 1.344 . . . . 0.0 110.164 179.446 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.5 pt-20 -92.86 -177.71 4.61 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.183 -0.948 . . . . 0.0 110.438 -178.894 . . . . . . . . 1 1 . 1 . 054 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.497 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.61 165.62 14.53 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.923 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -103.0 130.13 53.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 O-C-N 121.293 -1.122 . . . . 0.0 109.209 -179.269 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.614 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.05 121.92 21.85 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.569 -0.707 . . . . 0.0 109.528 179.668 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.827 HD12 ' CZ ' ' A' ' 112' ' ' PHE . 1.5 pt -97.9 167.25 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 121.188 -0.945 . . . . 0.0 109.243 179.913 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.513 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 0.9 OUTLIER -137.33 151.24 48.42 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.237 -0.914 . . . . 0.0 109.62 -179.97 . . . . . . . . 3 3 . 1 . 054 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.827 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 25.2 m-85 -126.32 108.06 10.89 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.163 -0.961 . . . . 0.0 109.51 -179.693 . . . . . . . . 2 2 . 1 . 054 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 16.0 p30 . . . . . 0 N--CA 1.489 1.48 0 CA-C-O 117.941 -1.028 . . . . 0.0 109.461 179.997 . . . . . . . . 0 0 . 1 . 054 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.977 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 121.327 0.584 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 055 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.656 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -105.56 162.99 18.03 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.199 -0.938 . . . . 0.0 109.497 179.967 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.656 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 3.2 Cg_exo -60.87 156.24 44.8 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.262 1.975 . . . . 0.0 110.672 -179.996 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.561 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -179.95 -169.65 0.13 Allowed 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.237 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.561 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -166.8 129.01 1.76 Allowed 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.837 -1.164 . . . . 0.0 110.71 -179.164 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.968 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.7 t -110.93 108.77 18.65 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.079 1.418 . . . . 0.0 109.078 179.276 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.768 HG22 HG23 ' A' ' 21' ' ' VAL . 2.3 t -119.62 136.7 55.89 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.672 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.023 -179.637 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.488 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.8 OUTLIER -177.0 150.96 0.92 Allowed Pre-proline 0 N--CA 1.487 1.421 0 O-C-N 121.286 -0.884 . . . . 0.0 108.785 -179.72 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.488 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -78.46 150.76 88.4 Favored 'Cis proline' 0 C--N 1.312 -1.35 0 C-N-CA 123.481 -1.466 . . . . 0.0 109.301 -0.828 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.689 ' HA ' HG22 ' A' ' 110' ' ' ILE . 77.9 p -89.34 -25.99 21.33 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.518 -0.739 . . . . 0.0 109.056 179.527 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.504 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 0.7 OUTLIER -132.99 162.69 31.01 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.528 -0.733 . . . . 0.0 109.529 -179.922 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.31 36.93 29.37 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.749 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.771 ' CA ' HG21 ' A' ' 17' ' ' THR . 37.5 mt -92.78 -42.97 9.27 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-O 123.24 1.495 . . . . 0.0 110.488 -178.327 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.477 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 68.29 144.35 0.04 OUTLIER 'General case' 0 C--N 1.261 -3.265 0 CA-C-N 113.479 -1.691 . . . . 0.0 109.936 -179.521 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.591 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 15.5 p-10 -50.9 106.49 0.13 Allowed 'General case' 0 C--N 1.3 -1.551 0 CA-C-O 121.515 0.674 . . . . 0.0 111.556 -178.542 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.28 14.22 9.23 Favored Glycine 0 N--CA 1.484 1.854 0 C-N-CA 119.331 -1.414 . . . . 0.0 113.007 177.311 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.771 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.71 -172.01 2.02 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 121.143 2.471 . . . . 0.0 109.67 179.144 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.748 HG13 ' C ' ' A' ' 67' ' ' LEU . 17.2 t -127.92 135.97 61.53 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.404 0 CA-C-N 114.976 -1.011 . . . . 0.0 111.182 -178.93 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.591 HG11 HD11 ' A' ' 13' ' ' LEU . 23.0 m -110.79 155.15 12.24 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 N-CA-C 108.507 -0.923 . . . . 0.0 108.507 178.77 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.523 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.8 OUTLIER -109.93 109.18 19.71 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.173 -0.954 . . . . 0.0 108.973 179.958 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.768 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -105.16 141.73 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.675 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.968 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -141.0 160.2 40.59 Favored 'General case' 0 C--N 1.304 -1.397 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.144 179.886 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.593 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -129.95 144.72 15.91 Favored Glycine 0 C--N 1.294 -1.769 0 N-CA-C 107.996 -2.041 . . . . 0.0 107.996 179.666 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.579 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -146.4 125.73 13.1 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 120.884 -1.362 . . . . 0.0 108.789 179.244 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.496 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 89.46 27.16 23.36 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.315 -1.421 . . . . 0.0 109.608 -179.568 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.551 HD22 ' HG3' ' A' ' 105' ' ' PRO . 1.5 mt -88.8 175.33 7.53 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 120.946 -1.326 . . . . 0.0 108.446 -179.941 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.998 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -48.42 99.49 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.013 -1.055 . . . . 0.0 109.83 -179.623 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.562 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.11 77.98 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.759 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.149 -179.325 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.559 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.69 34.2 0.31 Allowed Glycine 0 N--CA 1.487 2.085 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 179.614 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.549 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 62.9 p -143.21 109.09 5.18 Favored 'General case' 0 C--N 1.307 -1.261 0 O-C-N 121.034 -1.274 . . . . 0.0 111.142 -179.591 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.552 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -44.99 126.01 5.57 Favored 'General case' 0 N--CA 1.493 1.71 0 CA-C-O 121.403 0.62 . . . . 0.0 109.56 178.129 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.566 ' CE1' ' OD2' ' A' ' 99' ' ' ASP . 19.8 m-85 -117.35 152.98 33.82 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.349 -0.844 . . . . 0.0 108.923 179.808 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.523 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -103.14 152.66 21.17 Favored 'General case' 0 N--CA 1.492 1.652 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 178.627 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.637 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 5.0 p -136.82 116.96 16.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 120.885 -1.134 . . . . 0.0 109.856 -177.904 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.502 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -167.1 -178.28 39.35 Favored Glycine 0 N--CA 1.493 2.49 0 C-N-CA 118.462 -1.828 . . . . 0.0 111.828 -179.799 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.59 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -101.74 109.56 21.36 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.928 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.485 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.4 m -130.53 148.4 52.33 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.098 -1.001 . . . . 0.0 110.081 179.852 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -123.04 138.53 54.66 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.394 -0.816 . . . . 0.0 110.701 -179.025 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.862 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.39 114.6 26.39 Favored 'General case' 0 N--CA 1.493 1.676 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 178.137 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 m -105.22 15.16 6.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.006 -1.059 . . . . 0.0 110.705 -178.596 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.757 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.3 OUTLIER 175.14 -175.09 0.09 Allowed 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.952 -1.093 . . . . 0.0 110.097 179.736 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 35.1 p -72.0 97.54 1.9 Allowed 'General case' 0 N--CA 1.486 1.35 0 O-C-N 121.404 -0.81 . . . . 0.0 109.727 -179.673 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.13 26.53 36.61 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 120.173 -1.013 . . . . 0.0 111.446 178.859 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.757 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.7 t -115.21 106.3 20.28 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 O-C-N 120.547 -1.561 . . . . 0.0 107.482 178.93 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.862 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.9 tp -117.51 104.07 10.7 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.47 -1.393 . . . . 0.0 109.6 -177.815 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.014 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.32 109.24 22.03 Favored 'General case' 0 N--CA 1.483 1.179 0 O-C-N 120.767 -1.208 . . . . 0.0 107.753 178.603 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.491 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.5 t -103.5 166.01 10.69 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.924 -1.11 . . . . 0.0 110.411 -178.532 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.677 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 17.1 t-20 -106.35 129.72 24.07 Favored Pre-proline 0 N--CA 1.501 2.084 0 C-N-CA 119.945 -0.702 . . . . 0.0 109.757 -179.202 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.598 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 2.6 Cg_endo -72.94 23.81 0.3 Allowed 'Trans proline' 0 CA--C 1.544 0.98 0 C-N-CA 122.089 1.86 . . . . 0.0 111.813 179.634 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.677 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -115.51 3.63 14.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.498 -1.376 . . . . 0.0 109.197 179.738 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.543 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.89 17.24 2.66 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 179.49 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -80.64 91.1 5.8 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.842 -0.743 . . . . 0.0 110.814 -178.696 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.637 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -109.51 -166.71 1.12 Allowed 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 178.297 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 1.0 OUTLIER 178.94 137.03 0.09 Allowed 'General case' 0 C--N 1.306 -1.311 0 O-C-N 120.526 -1.358 . . . . 0.0 111.404 -179.271 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.932 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.5 OUTLIER -154.9 156.15 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.211 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.552 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.68 144.87 26.88 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.694 -1.254 . . . . 0.0 109.907 -179.534 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.003 ' HB1' ' HA3' ' A' ' 61' ' ' GLY . . . -63.83 107.22 1.16 Allowed 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 122.431 1.11 . . . . 0.0 109.409 178.586 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.542 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 7.2 p-10 -61.07 -139.34 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.027 0 CA-C-N 115.466 -0.788 . . . . 0.0 110.903 -179.909 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.562 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.9 -50.91 56.38 Favored 'General case' 0 N--CA 1.5 2.028 0 O-C-N 121.397 -0.814 . . . . 0.0 110.68 -178.713 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -103.94 -33.18 8.92 Favored 'General case' 0 C--N 1.286 -2.166 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 178.576 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.003 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 107.96 64.91 0.58 Allowed Glycine 0 C--N 1.299 -1.498 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 178.206 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.593 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 47.7 m -103.44 127.07 50.9 Favored 'General case' 0 N--CA 1.483 1.176 0 O-C-N 121.57 -0.959 . . . . 0.0 108.83 178.901 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.932 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -137.04 108.96 7.1 Favored 'General case' 0 C--N 1.296 -1.751 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.659 -179.396 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.473 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.1 m -122.44 121.01 35.6 Favored 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.359 -0.838 . . . . 0.0 109.303 -179.898 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.525 HG21 HG11 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -144.83 144.84 31.34 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.426 -0.796 . . . . 0.0 109.565 179.886 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 22.1 p -99.0 141.0 32.3 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.38 -0.825 . . . . 0.0 109.297 -179.945 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.777 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -140.99 166.7 24.07 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.413 -0.804 . . . . 0.0 109.39 -179.327 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.728 HG22 HG22 ' A' ' 18' ' ' VAL . 2.7 p -95.96 124.38 39.95 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.005 -1.06 . . . . 0.0 109.416 -179.883 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.587 HG22 HG22 ' A' ' 19' ' ' VAL . 13.3 m -136.42 141.86 40.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 120.907 -1.121 . . . . 0.0 109.937 -179.12 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.591 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 7.3 ptt180 -144.35 -170.32 3.34 Favored 'General case' 0 N--CA 1.485 1.317 0 O-C-N 120.546 -1.346 . . . . 0.0 110.884 -179.882 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.598 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -62.45 -101.42 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.77 -0.581 . . . . 0.0 110.206 -179.125 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.541 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -58.94 137.15 58.0 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.574 -1.329 . . . . 0.0 108.209 179.957 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD2' ' O ' ' A' ' 71' ' ' ARG . 1.7 p90 -157.53 154.04 27.96 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.646 -1.222 . . . . 0.0 110.198 -178.514 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.5 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 5.1 mm-40 -47.15 120.8 3.32 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.359 -0.838 . . . . 0.0 109.263 -179.124 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.014 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.5 51.34 3.01 Favored Glycine 0 N--CA 1.495 2.59 0 C-N-CA 120.414 -0.898 . . . . 0.0 111.116 -179.224 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.598 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.5 m-30 -39.0 114.0 0.36 Allowed 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.114 -1.227 . . . . 0.0 110.31 179.62 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.765 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.21 126.94 34.63 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 120.919 -1.113 . . . . 0.0 109.782 -179.917 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.585 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 29.2 t80 -64.25 58.44 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.033 0 O-C-N 120.911 -1.118 . . . . 0.0 110.059 179.702 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.534 ' N ' ' O ' ' A' ' 77' ' ' LEU . 0.6 OUTLIER -160.33 19.52 0.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.031 -1.043 . . . . 0.0 109.733 179.824 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.74 -26.96 5.57 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 179.866 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.404 ' O ' ' HB3' ' A' ' 77' ' ' LEU . 0.0 OUTLIER -95.34 161.42 14.09 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 120.998 -1.295 . . . . 0.0 110.315 -179.383 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.482 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.0 OUTLIER -107.24 136.78 46.49 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.813 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.765 ' HB2' HD13 ' A' ' 77' ' ' LEU . 3.0 t90 -83.64 -16.89 43.44 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.784 -1.198 . . . . 0.0 110.562 -178.423 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.14 174.27 20.0 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 108.827 -1.709 . . . . 0.0 108.827 -179.553 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -63.66 107.0 1.06 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.141 -1.211 . . . . 0.0 107.759 179.218 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.662 HG21 ' HB3' ' A' ' 46' ' ' ALA . 44.3 t -78.94 106.05 9.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 O-C-N 121.307 -0.871 . . . . 0.0 109.243 -178.877 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.553 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -65.16 108.35 1.84 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.652 -0.655 . . . . 0.0 110.113 -179.408 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.598 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.5 t -61.34 -4.72 1.32 Allowed 'General case' 0 N--CA 1.502 2.133 0 O-C-N 120.479 -1.388 . . . . 0.0 110.417 179.391 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.2 p -90.43 3.68 53.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.597 -1.314 . . . . 0.0 109.481 179.944 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.553 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -114.96 -48.32 2.84 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.282 -0.886 . . . . 0.0 109.107 -179.976 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.72 -179.05 3.82 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.573 -0.704 . . . . 0.0 109.526 179.997 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.97 112.15 24.83 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.382 -0.824 . . . . 0.0 108.812 179.838 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.505 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.4 m -96.98 122.06 39.54 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.104 -0.997 . . . . 0.0 109.399 -178.922 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.575 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.08 148.66 25.45 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-O 122.439 1.114 . . . . 0.0 111.577 -179.157 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.499 ' CG1' HG11 ' A' ' 7' ' ' VAL . 84.8 t -104.22 110.78 31.43 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.908 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 177.643 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.412 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -149.84 -172.01 18.87 Favored Glycine 0 N--CA 1.486 2.005 0 C-N-CA 118.034 -2.031 . . . . 0.0 111.802 -177.604 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.523 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.1 OUTLIER -114.57 -179.04 3.52 Favored 'General case' 0 N--CA 1.485 1.3 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -178.94 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.563 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 0.8 OUTLIER -170.93 168.26 7.12 Favored 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.394 -0.816 . . . . 0.0 109.033 -179.418 . . . . . . . . 3 3 . 1 . 055 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.7 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 2.1 m-20 -103.66 -11.16 17.84 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.021 -1.05 . . . . 0.0 109.485 179.961 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.7 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 74.29 37.67 0.58 Allowed 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.411 -0.806 . . . . 0.0 109.246 179.783 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -137.24 -33.61 0.74 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.533 -0.729 . . . . 0.0 110.715 -179.44 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.515 ' N ' H193 ' A' ' 114' ' ' CHR . . . -179.88 -41.93 0.08 OUTLIER Glycine 0 N--CA 1.481 1.688 0 N-CA-C 107.636 -2.185 . . . . 0.0 107.636 -179.573 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.3 -178.81 7.56 Favored 'General case' 0 C--N 1.307 -1.26 0 O-C-N 121.542 -0.975 . . . . 0.0 109.623 179.022 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -177.63 -167.01 35.17 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 108.39 -1.884 . . . . 0.0 108.39 -179.584 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.551 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.7 Cg_exo -49.11 -179.57 0.01 OUTLIER 'Trans proline' 0 C--O 1.216 -0.618 0 CA-C-N 118.83 1.315 . . . . 0.0 110.07 179.529 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -93.87 -179.81 5.1 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.012 -1.055 . . . . 0.0 110.521 -178.765 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.412 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -118.99 162.65 13.42 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.973 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . . . . . . . . . 1.2 t -103.55 130.62 53.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.318 -1.107 . . . . 0.0 109.216 -179.347 . . . . . . . . 1 1 . 1 . 055 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.575 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -71.98 121.21 18.75 Favored 'General case' 0 C--N 1.289 -2.035 0 O-C-N 121.641 -0.662 . . . . 0.0 109.606 179.62 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.859 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -98.04 171.43 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.239 -0.913 . . . . 0.0 109.174 179.947 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.504 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 1.4 m -141.1 156.55 45.96 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.151 -0.968 . . . . 0.0 109.895 -179.841 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.859 ' CE2' HD12 ' A' ' 110' ' ' ILE . 82.8 m-85 -134.36 94.22 3.18 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.243 -0.911 . . . . 0.0 109.549 -179.74 . . . . . . . . 2 2 . 1 . 055 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 23.0 p30 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 118.003 -0.998 . . . . 0.0 109.459 179.931 . . . . . . . . 0 0 . 1 . 055 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.676 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.345 0.593 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 056 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.911 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -95.42 172.17 5.66 Favored Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.224 -0.922 . . . . 0.0 109.509 179.995 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.911 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 3.7 Cg_exo -60.42 158.08 33.15 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.266 1.977 . . . . 0.0 110.55 -179.98 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.873 HG23 ' O ' ' A' ' 3' ' ' PRO . 1.1 p -166.43 160.79 15.87 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -179.341 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.505 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.11 128.61 14.03 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-O 122.409 1.1 . . . . 0.0 110.565 -179.705 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.011 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.4 p -106.31 104.86 14.65 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 122.461 1.124 . . . . 0.0 110.199 -179.476 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.967 HG22 HG23 ' A' ' 21' ' ' VAL . 12.1 t -118.53 118.69 58.8 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.439 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.364 179.596 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.499 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -162.87 149.17 10.28 Favored Pre-proline 0 N--CA 1.487 1.38 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 -179.65 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.499 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.7 Cg_endo -77.83 151.23 91.09 Favored 'Cis proline' 0 C--N 1.31 -1.494 0 C-N-CA 123.606 -1.414 . . . . 0.0 109.51 -0.578 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.704 ' HA ' HG22 ' A' ' 110' ' ' ILE . 16.5 p -93.52 -23.85 18.2 Favored 'General case' 0 C--N 1.292 -1.892 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.639 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.463 ' HB3' ' OG ' ' A' ' 111' ' ' SER . 20.2 m -132.38 162.22 31.64 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.438 -0.789 . . . . 0.0 109.585 -179.927 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.2 37.24 37.72 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 -179.733 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.83 ' CA ' HG21 ' A' ' 17' ' ' THR . 30.2 mt -90.41 -44.64 9.51 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 123.127 1.441 . . . . 0.0 110.652 -178.428 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.469 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.2 OUTLIER 66.99 145.83 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.325 0 CA-C-N 113.699 -1.591 . . . . 0.0 109.963 -179.701 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.63 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 7.3 p-10 -51.35 106.26 0.13 Allowed 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.598 0.713 . . . . 0.0 111.794 -178.471 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.45 15.7 8.71 Favored Glycine 0 N--CA 1.485 1.946 0 C-N-CA 119.438 -1.363 . . . . 0.0 112.98 177.302 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.83 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.0 t -102.72 -171.66 1.99 Allowed 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 121.13 2.465 . . . . 0.0 109.84 179.31 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.755 HG13 ' O ' ' A' ' 67' ' ' LEU . 17.2 t -129.45 139.01 52.83 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.289 0 CA-C-N 114.861 -1.063 . . . . 0.0 111.195 -178.699 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.533 HG22 HG22 ' A' ' 69' ' ' VAL . 31.2 m -118.08 155.04 20.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.733 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.548 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 6.2 tttt -113.08 109.13 18.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.126 -0.984 . . . . 0.0 109.413 -179.854 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.967 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -105.33 122.97 59.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 179.833 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.011 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -112.88 166.09 11.71 Favored 'General case' 0 C--N 1.307 -1.243 0 O-C-N 120.799 -1.188 . . . . 0.0 109.073 179.634 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.607 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -143.67 108.46 0.5 Allowed Glycine 0 N--CA 1.481 1.678 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 -179.886 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.583 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -116.36 139.11 50.76 Favored 'General case' 0 N--CA 1.5 2.03 0 CA-C-N 119.396 1.598 . . . . 0.0 110.424 -179.485 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.452 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 84.56 29.04 30.86 Favored Glycine 0 N--CA 1.49 2.262 0 C-N-CA 119.079 -1.534 . . . . 0.0 109.941 179.56 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.523 ' HG ' ' O ' ' A' ' 61' ' ' GLY . 1.5 mt -92.47 176.07 6.6 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.986 -1.302 . . . . 0.0 108.562 179.935 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.39 96.98 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.023 -1.048 . . . . 0.0 109.621 -179.909 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.711 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.94 77.18 0.0 OUTLIER 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.36 -178.93 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.564 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 131.8 34.87 0.37 Allowed Glycine 0 N--CA 1.486 2.02 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.465 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.636 ' CG2' ' CE1' ' A' ' 32' ' ' TYR . 0.7 OUTLIER -146.51 114.4 6.51 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 120.931 -1.335 . . . . 0.0 111.109 -179.948 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -48.17 122.9 5.66 Favored 'General case' 0 N--CA 1.493 1.697 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.181 178.669 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.636 ' CE1' ' CG2' ' A' ' 30' ' ' THR . 2.0 m-30 -116.93 151.77 35.96 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 179.267 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.515 ' N ' ' O ' ' A' ' 98' ' ' SER . 0.3 OUTLIER -98.91 163.75 12.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.539 -1.351 . . . . 0.0 108.216 179.247 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.003 HG11 HG21 ' A' ' 65' ' ' THR . 3.8 p -144.59 117.98 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.106 -0.997 . . . . 0.0 109.643 -177.963 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.511 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -169.66 -179.08 41.22 Favored Glycine 0 N--CA 1.494 2.516 0 C-N-CA 118.411 -1.852 . . . . 0.0 111.738 -179.804 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.636 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 0.6 OUTLIER -100.95 109.24 21.15 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 -179.922 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.5 m -130.03 149.21 51.85 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.21 -0.931 . . . . 0.0 109.74 179.891 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.552 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.36 137.75 54.75 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.178 -0.951 . . . . 0.0 110.736 -178.993 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.883 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.8 OUTLIER -95.28 114.61 26.41 Favored 'General case' 0 N--CA 1.492 1.67 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 178.038 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 18.1 m -104.59 14.47 7.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 120.973 -1.079 . . . . 0.0 110.585 -178.708 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.766 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.57 -174.84 0.08 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.941 -1.099 . . . . 0.0 109.988 179.747 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -72.92 98.22 2.43 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.379 -0.826 . . . . 0.0 109.653 -179.753 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.28 26.95 31.96 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 120.302 -0.952 . . . . 0.0 111.534 178.943 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.766 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -116.85 106.16 19.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 O-C-N 120.499 -1.589 . . . . 0.0 107.298 178.922 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.883 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.1 tp -118.17 104.37 10.75 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.358 -1.464 . . . . 0.0 109.885 -177.795 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.023 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -98.45 109.36 22.13 Favored 'General case' 0 N--CA 1.485 1.284 0 O-C-N 120.821 -1.174 . . . . 0.0 108.156 178.905 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.509 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.3 t -104.42 166.63 10.27 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.844 -1.16 . . . . 0.0 110.353 -178.961 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.677 ' OD1' ' HB3' ' A' ' 50' ' ' ALA . 15.8 t-20 -109.53 137.89 20.44 Favored Pre-proline 0 N--CA 1.501 2.082 0 O-C-N 121.445 -0.785 . . . . 0.0 110.146 -179.081 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.601 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 5.8 Cg_endo -74.82 25.2 0.37 Allowed 'Trans proline' 0 C--N 1.318 -1.027 0 C-N-CA 122.465 2.11 . . . . 0.0 111.939 179.903 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.677 ' HB3' ' OD1' ' A' ' 48' ' ' ASN . . . -117.27 2.35 12.54 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.278 -1.514 . . . . 0.0 109.294 179.788 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.551 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -139.73 18.71 2.51 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 179.297 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -80.58 89.73 5.69 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.88 -0.728 . . . . 0.0 110.489 -179.078 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.622 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.5 OUTLIER -113.65 -168.7 1.38 Allowed 'General case' 0 N--CA 1.49 1.543 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 178.647 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.454 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.5 OUTLIER 178.5 134.96 0.08 Allowed 'General case' 0 C--N 1.305 -1.34 0 O-C-N 120.653 -1.28 . . . . 0.0 111.286 -179.337 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.856 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 1.3 p -149.09 158.71 6.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 177.966 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.19 145.69 26.35 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.75 -1.219 . . . . 0.0 109.908 -179.723 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -66.88 107.87 2.36 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-O 122.443 1.116 . . . . 0.0 109.369 178.577 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.551 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 10.9 p-10 -59.87 -139.47 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.0 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.829 179.996 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.711 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -51.64 -50.68 59.84 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 121.386 -0.821 . . . . 0.0 110.467 -178.775 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.5 t30 -103.63 -34.65 8.56 Favored 'General case' 0 C--N 1.285 -2.225 0 N-CA-C 106.379 -1.711 . . . . 0.0 106.379 178.481 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.986 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.5 67.92 0.62 Allowed Glycine 0 C--N 1.297 -1.584 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.055 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 22.8 m -103.36 126.16 50.37 Favored 'General case' 0 N--CA 1.484 1.254 0 O-C-N 121.717 -0.873 . . . . 0.0 108.677 178.817 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.856 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -134.87 108.86 8.14 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 119.714 -0.794 . . . . 0.0 109.511 -179.327 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 93.0 p -117.89 117.2 28.62 Favored 'General case' 0 N--CA 1.486 1.357 0 O-C-N 121.17 -0.956 . . . . 0.0 109.436 -179.99 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 1.003 HG21 HG11 ' A' ' 34' ' ' VAL . 0.5 OUTLIER -141.85 135.31 29.44 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.467 -0.771 . . . . 0.0 109.957 179.979 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 20' ' ' LYS . 10.0 p -100.36 133.13 45.23 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.423 -0.798 . . . . 0.0 108.848 179.511 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.817 ' H ' HD12 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -134.3 175.19 9.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.316 -0.865 . . . . 0.0 109.683 -178.917 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.548 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.7 p -100.16 125.0 46.23 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.006 -1.059 . . . . 0.0 109.702 -179.612 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.533 HG22 HG22 ' A' ' 19' ' ' VAL . 16.5 m -136.87 142.15 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 120.94 -1.1 . . . . 0.0 109.761 -179.495 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.63 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.4 ptt180 -138.43 -165.3 1.79 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.652 -1.28 . . . . 0.0 110.129 -179.911 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.579 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -74.87 -83.61 0.05 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.142 -0.974 . . . . 0.0 108.782 -179.615 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.501 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.8 OUTLIER -62.82 138.86 58.64 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 120.361 -1.462 . . . . 0.0 107.228 178.668 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.579 ' CD1' ' O ' ' A' ' 71' ' ' ARG . 0.3 OUTLIER -164.54 135.11 4.1 Favored 'General case' 0 C--N 1.293 -1.862 0 C-N-CA 117.933 -1.507 . . . . 0.0 110.533 -177.443 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.51 ' HB3' ' HD3' ' A' ' 49' ' ' PRO . 0.6 OUTLIER -31.82 121.02 0.28 Allowed 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.463 0.649 . . . . 0.0 110.483 -178.76 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.023 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.28 49.87 2.42 Favored Glycine 0 N--CA 1.494 2.537 0 C-N-CA 120.353 -0.927 . . . . 0.0 111.396 -179.062 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.601 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.4 m-30 -39.68 112.46 0.26 Allowed 'General case' 0 N--CA 1.508 2.442 0 O-C-N 121.027 -1.278 . . . . 0.0 109.998 179.306 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.668 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -84.62 127.18 33.94 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.906 -1.121 . . . . 0.0 109.791 -179.804 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.573 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 42.0 t80 -63.66 58.35 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.03 0 O-C-N 120.978 -1.077 . . . . 0.0 110.195 179.58 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.536 ' N ' ' O ' ' A' ' 77' ' ' LEU . 7.4 t0 -161.26 19.51 0.12 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.022 -1.049 . . . . 0.0 109.816 179.878 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.3 -26.68 5.49 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 179.866 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.419 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 22.8 p -93.9 157.53 16.08 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 120.975 -1.309 . . . . 0.0 110.302 -179.442 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.497 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 4.5 ptt180 -104.73 135.54 45.92 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 179.701 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.668 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -82.57 -17.76 43.74 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.716 -1.24 . . . . 0.0 110.423 -178.55 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.6 175.68 21.14 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.664 -1.774 . . . . 0.0 108.664 -179.57 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -62.59 109.14 1.3 Allowed 'General case' 0 C--N 1.3 -1.556 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 179.037 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.574 HG21 ' HB3' ' A' ' 46' ' ' ALA . 35.2 t -81.39 104.77 10.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 -178.864 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.529 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.09 111.9 3.61 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.448 -0.782 . . . . 0.0 109.885 -179.146 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.543 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -65.98 -4.44 7.1 Favored 'General case' 0 N--CA 1.499 1.992 0 C-N-CA 118.366 -1.334 . . . . 0.0 109.839 179.324 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 1.1 p -85.02 1.18 48.76 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 120.835 -1.166 . . . . 0.0 108.872 179.336 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.529 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.3 p -116.13 -49.86 2.68 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.401 -0.812 . . . . 0.0 109.047 -179.957 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -105.7 -179.49 3.95 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.512 -0.743 . . . . 0.0 109.464 179.916 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -104.99 115.46 30.31 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.883 . . . . 0.0 109.104 179.976 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.55 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.9 m -96.8 122.54 39.87 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.909 -1.12 . . . . 0.0 109.391 -179.5 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.592 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -101.31 146.28 27.76 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-O 122.393 1.092 . . . . 0.0 111.368 -179.216 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.722 ' HB ' HG11 ' A' ' 7' ' ' VAL . 53.4 t -102.5 109.64 27.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.995 0 N-CA-C 106.432 -1.692 . . . . 0.0 106.432 177.419 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.438 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.64 -169.99 16.0 Favored Glycine 0 N--CA 1.485 1.932 0 C-N-CA 118.009 -2.043 . . . . 0.0 111.729 -177.362 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.498 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.0 OUTLIER -117.75 -177.89 3.36 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -178.786 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.584 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 1.1 p -173.15 174.28 3.45 Favored 'General case' 0 C--N 1.295 -1.765 0 O-C-N 121.35 -0.844 . . . . 0.0 109.302 -179.251 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.551 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.5 OUTLIER -121.36 -159.23 0.8 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.105 -0.997 . . . . 0.0 108.839 179.663 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.406 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.63 36.01 4.46 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.63 -1.293 . . . . 0.0 109.267 179.966 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -118.99 -33.28 4.22 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.426 -0.796 . . . . 0.0 110.299 -179.532 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 1.03 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 166.76 -37.18 0.24 Allowed Glycine 0 N--CA 1.482 1.707 0 N-CA-C 107.599 -2.201 . . . . 0.0 107.599 -179.579 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.94 -178.15 7.03 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.617 -0.931 . . . . 0.0 109.826 179.288 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -167.87 -162.6 20.13 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 108.239 -1.945 . . . . 0.0 108.239 -179.433 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.609 ' CD ' ' CE2' ' A' ' 32' ' ' TYR . 7.3 Cg_exo -45.59 172.07 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.652 0 CA-C-N 118.92 1.36 . . . . 0.0 109.926 179.354 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -90.36 -171.43 3.09 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.107 -0.995 . . . . 0.0 110.42 -178.746 . . . . . . . . 1 1 . 1 . 056 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.438 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -124.65 169.65 16.67 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.751 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.445 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.81 133.95 47.55 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.48 -1.012 . . . . 0.0 109.061 -179.314 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.592 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -74.82 119.42 18.98 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.513 -0.742 . . . . 0.0 109.696 179.791 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.896 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.6 pt -98.14 168.58 1.64 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 O-C-N 121.272 -0.892 . . . . 0.0 108.845 179.708 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.463 ' OG ' ' HB3' ' A' ' 11' ' ' SER . 0.3 OUTLIER -139.7 157.63 45.44 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.017 -1.052 . . . . 0.0 109.853 -179.717 . . . . . . . . 3 3 . 1 . 056 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.896 ' CE1' HD12 ' A' ' 110' ' ' ILE . 96.7 m-85 -130.64 142.79 50.45 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.236 -0.915 . . . . 0.0 109.506 -179.672 . . . . . . . . 2 2 . 1 . 056 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 22.7 p30 . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 117.971 -1.014 . . . . 0.0 109.524 179.983 . . . . . . . . 0 0 . 1 . 056 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 1.03 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 057 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -125.22 98.86 34.84 Favored Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.26 -0.9 . . . . 0.0 109.311 -179.935 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.566 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 6.2 Cg_exo -58.78 156.7 31.42 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.111 1.874 . . . . 0.0 110.496 -179.992 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.584 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -176.65 -169.52 0.28 Allowed 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.222 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.584 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -165.81 129.87 2.24 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 120.952 -1.092 . . . . 0.0 110.32 -178.983 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.95 HG22 ' HB3' ' A' ' 22' ' ' ALA . 4.3 t -116.36 108.71 16.4 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-O 123.167 1.46 . . . . 0.0 109.23 179.29 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.791 HG22 HG23 ' A' ' 21' ' ' VAL . 2.5 t -117.04 138.26 48.29 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.654 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.944 -179.604 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.494 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -174.5 149.88 1.39 Allowed Pre-proline 0 N--CA 1.485 1.308 0 O-C-N 121.298 -0.877 . . . . 0.0 108.757 -179.782 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.494 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -77.86 150.91 90.56 Favored 'Cis proline' 0 C--N 1.311 -1.427 0 C-N-CA 123.507 -1.455 . . . . 0.0 109.461 -0.786 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.673 ' HA ' HG22 ' A' ' 110' ' ' ILE . 71.1 p -88.31 -26.2 22.39 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 108.903 -0.776 . . . . 0.0 108.903 179.564 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.543 ' OG ' ' CB ' ' A' ' 111' ' ' SER . 0.8 OUTLIER -132.75 168.74 17.8 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.449 -0.782 . . . . 0.0 109.499 179.649 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 73.93 38.79 48.11 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 108.36 -1.896 . . . . 0.0 108.36 -179.801 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.772 ' CA ' HG21 ' A' ' 17' ' ' THR . 34.3 mt -94.11 -43.04 8.68 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 123.285 1.517 . . . . 0.0 110.67 -178.111 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.48 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 69.08 143.5 0.04 OUTLIER 'General case' 0 C--N 1.26 -3.283 0 CA-C-N 113.408 -1.723 . . . . 0.0 109.766 -179.398 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.568 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 10.8 p-10 -49.95 105.47 0.09 Allowed 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 121.57 0.7 . . . . 0.0 111.753 -178.397 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.403 ' H ' ' HB3' ' A' ' 70' ' ' ARG . . . 113.23 15.68 8.86 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.33 -1.414 . . . . 0.0 113.081 177.158 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.772 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.3 t -104.24 -171.15 1.88 Allowed 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 121.235 2.517 . . . . 0.0 109.733 179.153 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.859 HG22 HG22 ' A' ' 68' ' ' THR . 15.9 t -129.98 139.26 51.95 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.289 0 CA-C-N 114.943 -1.026 . . . . 0.0 111.309 -178.97 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.566 HG12 HD21 ' A' ' 13' ' ' LEU . 33.6 m -115.59 155.74 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 178.881 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.499 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.0 OUTLIER -106.9 109.76 21.74 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.117 -0.989 . . . . 0.0 109.187 -179.929 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.791 HG23 HG22 ' A' ' 7' ' ' VAL . 1.9 p -103.35 139.74 23.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.404 -0.81 . . . . 0.0 108.842 179.978 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.95 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -132.55 157.8 43.79 Favored 'General case' 0 C--N 1.306 -1.293 0 O-C-N 120.829 -1.169 . . . . 0.0 109.608 179.426 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -138.99 108.71 0.62 Allowed Glycine 0 N--CA 1.482 1.74 0 N-CA-C 108.688 -1.765 . . . . 0.0 108.688 -179.964 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.566 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -114.36 142.04 46.85 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 120.889 -1.359 . . . . 0.0 110.858 -179.059 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 81.84 27.36 46.47 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.701 -1.237 . . . . 0.0 110.131 178.942 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.574 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.6 mt -89.52 173.99 8.02 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.008 -1.289 . . . . 0.0 108.705 -179.848 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.009 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.97 99.64 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.965 -1.085 . . . . 0.0 109.579 -179.598 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.554 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -56.24 77.22 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.196 -179.144 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.561 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 133.9 34.09 0.31 Allowed Glycine 0 N--CA 1.487 2.043 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.549 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.554 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 78.0 p -144.04 111.02 5.73 Favored 'General case' 0 C--N 1.307 -1.274 0 O-C-N 120.965 -1.315 . . . . 0.0 111.045 -179.741 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.567 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -46.27 125.09 6.28 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 115.651 -0.704 . . . . 0.0 109.689 178.158 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.493 ' CD2' ' O ' ' A' ' 30' ' ' THR . 16.9 m-85 -116.11 150.82 36.75 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.277 -0.889 . . . . 0.0 108.97 179.699 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.509 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.4 OUTLIER -101.86 151.77 21.69 Favored 'General case' 0 N--CA 1.491 1.594 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 178.547 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.622 HG13 ' O ' ' A' ' 34' ' ' VAL . 4.5 p -136.17 117.63 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.957 -1.09 . . . . 0.0 109.787 -177.904 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.499 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -165.01 -179.35 38.93 Favored Glycine 0 N--CA 1.494 2.5 0 C-N-CA 118.348 -1.882 . . . . 0.0 111.69 -179.576 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.629 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.6 pt20 -100.44 110.79 23.0 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.927 0.87 . . . . 0.0 108.744 -179.872 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.481 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.1 m -131.08 148.98 52.8 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.265 -0.897 . . . . 0.0 109.781 -179.756 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.478 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -122.39 138.19 54.61 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.261 -0.9 . . . . 0.0 110.675 -179.047 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.867 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.63 114.64 26.41 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 178.209 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 m -105.23 14.56 7.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 O-C-N 121.028 -1.045 . . . . 0.0 110.65 -178.693 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.769 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 173.98 -175.67 0.07 Allowed 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.912 -1.118 . . . . 0.0 110.198 179.706 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.777 HG23 ' O ' ' A' ' 42' ' ' THR . 15.1 t -70.34 97.99 1.34 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 121.755 0.788 . . . . 0.0 110.001 -179.633 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.62 26.47 38.62 Favored Glycine 0 N--CA 1.493 2.494 0 C-N-CA 120.252 -0.975 . . . . 0.0 111.522 178.825 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.769 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.5 t -114.89 106.31 20.35 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 O-C-N 120.572 -1.546 . . . . 0.0 107.382 178.931 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.867 HD13 ' NE1' ' A' ' 39' ' ' TRP . 12.8 tp -118.05 104.69 11.1 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.494 -1.379 . . . . 0.0 109.77 -177.793 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.943 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.87 109.69 22.4 Favored 'General case' 0 N--CA 1.484 1.265 0 O-C-N 120.796 -1.19 . . . . 0.0 108.246 178.903 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.9 t -107.13 166.54 10.55 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.93 -1.106 . . . . 0.0 110.525 -178.692 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.496 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 12.4 t-20 -114.0 129.81 24.45 Favored Pre-proline 0 N--CA 1.499 2.005 0 O-C-N 121.424 -0.797 . . . . 0.0 109.697 -179.236 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.614 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.1 Cg_endo -71.28 21.08 0.23 Allowed 'Trans proline' 0 CA--C 1.546 1.082 0 C-N-CA 121.953 1.769 . . . . 0.0 111.969 179.274 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.496 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -107.08 1.45 24.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.442 -1.411 . . . . 0.0 108.82 179.293 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.532 ' HA ' ' CB ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -137.92 15.47 2.87 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 179.372 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -79.25 85.76 5.08 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.069 -178.49 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.601 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.0 OUTLIER -101.59 -166.72 1.33 Allowed 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 178.128 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.432 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.4 OUTLIER 178.36 138.35 0.09 Allowed 'General case' 0 C--N 1.305 -1.348 0 O-C-N 120.504 -1.373 . . . . 0.0 111.417 -179.178 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.936 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -157.47 156.7 4.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 178.135 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.567 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.1 m -97.88 144.75 27.13 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.747 -1.221 . . . . 0.0 109.884 -179.664 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.009 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.46 106.69 1.19 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 122.47 1.129 . . . . 0.0 109.44 178.61 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.543 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 16.9 p-10 -58.87 -138.62 0.0 OUTLIER 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.621 179.848 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.554 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -56.38 -49.45 74.42 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.39 -0.819 . . . . 0.0 110.103 -178.976 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.406 ' CG ' ' N ' ' A' ' 61' ' ' GLY . 10.8 p-10 -98.21 -39.84 8.66 Favored 'General case' 0 C--N 1.285 -2.202 0 N-CA-C 106.066 -1.827 . . . . 0.0 106.066 178.372 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.989 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 110.19 64.33 0.53 Allowed Glycine 0 C--N 1.296 -1.694 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.38 178.054 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.584 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 88.6 p -100.28 128.47 46.34 Favored 'General case' 0 C--N 1.309 -1.167 0 O-C-N 121.618 -0.93 . . . . 0.0 108.945 178.915 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.936 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -136.26 108.47 7.26 Favored 'General case' 0 C--N 1.292 -1.893 0 C-N-CA 119.604 -0.839 . . . . 0.0 108.952 -179.814 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -128.64 121.33 28.37 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.288 -0.883 . . . . 0.0 109.977 -179.358 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.06 148.08 31.28 Favored 'General case' 0 C--N 1.299 -1.59 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.62 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 9.5 p -98.28 131.01 44.96 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.173 -0.955 . . . . 0.0 109.486 -179.737 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.767 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -127.23 164.52 21.51 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.507 -0.746 . . . . 0.0 109.338 -179.347 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.859 HG22 HG22 ' A' ' 18' ' ' VAL . 1.9 p -96.51 124.05 40.37 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.986 -1.071 . . . . 0.0 109.333 179.969 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.539 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 17.5 m -137.33 143.38 34.5 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 120.997 -1.064 . . . . 0.0 109.968 -179.211 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.568 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 3.6 ptt180 -141.52 -166.54 2.22 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 120.558 -1.338 . . . . 0.0 110.214 179.986 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.595 ' HA ' ' CE2' ' A' ' 112' ' ' PHE . 0.0 OUTLIER -69.44 -89.13 0.02 OUTLIER 'General case' 0 N--CA 1.497 1.88 0 C-N-CA 119.687 -0.805 . . . . 0.0 108.837 -179.737 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.52 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -59.67 138.27 57.79 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 120.426 -1.421 . . . . 0.0 107.451 178.89 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.565 ' CD1' ' N ' ' A' ' 73' ' ' PHE . 0.3 OUTLIER -163.12 141.09 7.99 Favored 'General case' 0 C--N 1.294 -1.819 0 C-N-CA 118.148 -1.421 . . . . 0.0 110.351 -177.682 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.489 ' HB2' ' HD2' ' A' ' 49' ' ' PRO . 4.5 mm-40 -33.95 120.24 0.42 Allowed 'General case' 0 N--CA 1.491 1.62 0 CA-C-O 121.561 0.696 . . . . 0.0 110.7 -178.473 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.943 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.33 45.21 2.79 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.713 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.614 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 3.3 m-30 -39.24 113.34 0.31 Allowed 'General case' 0 N--CA 1.508 2.474 0 O-C-N 121.099 -1.236 . . . . 0.0 110.298 179.782 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.634 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.6 tp -86.43 127.36 34.83 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 120.857 -1.152 . . . . 0.0 109.556 -179.972 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 18.5 t80 -64.23 58.09 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.955 0 O-C-N 120.815 -1.178 . . . . 0.0 110.286 179.849 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.527 ' N ' ' O ' ' A' ' 77' ' ' LEU . 10.7 t0 -160.92 19.57 0.13 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.983 -1.073 . . . . 0.0 109.833 179.771 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.05 -26.78 5.28 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.918 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.422 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 0.7 OUTLIER -91.72 154.44 18.97 Favored 'General case' 0 N--CA 1.484 1.275 0 O-C-N 121.031 -1.276 . . . . 0.0 110.387 -179.471 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.489 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -102.87 131.91 49.45 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 179.634 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.634 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -79.89 -19.15 48.89 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.758 -1.214 . . . . 0.0 110.238 -178.635 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.24 175.05 20.13 Favored Glycine 0 N--CA 1.485 1.966 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 -179.529 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.499 ' CG2' ' HB3' ' A' ' 72' ' ' SER . 0.9 OUTLIER -63.49 110.29 1.91 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 106.903 -1.518 . . . . 0.0 106.903 178.851 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.57 HG21 ' HB3' ' A' ' 46' ' ' ALA . 40.1 t -81.28 104.36 9.71 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.702 0 O-C-N 121.345 -0.847 . . . . 0.0 109.162 -178.642 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.655 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -63.98 110.64 2.2 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.479 -0.763 . . . . 0.0 109.735 -179.414 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.534 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -64.61 -5.13 4.98 Favored 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 118.137 -1.425 . . . . 0.0 109.839 179.42 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -84.41 -0.7 53.73 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.834 -1.166 . . . . 0.0 108.932 179.306 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.655 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.4 p -112.66 -50.02 2.91 Favored 'General case' 0 N--CA 1.487 1.382 0 O-C-N 121.346 -0.847 . . . . 0.0 108.995 179.911 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.12 -179.88 4.06 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.491 -0.756 . . . . 0.0 109.572 179.96 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -103.91 116.12 31.68 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.365 -0.834 . . . . 0.0 109.103 -179.954 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.562 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 3.0 m -96.83 122.24 39.57 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.884 -1.135 . . . . 0.0 109.555 -179.484 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.575 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.0 OUTLIER -102.76 149.59 24.32 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 122.383 1.087 . . . . 0.0 111.421 -179.149 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.494 ' CG1' HG11 ' A' ' 7' ' ' VAL . 47.2 t -102.07 111.12 30.73 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 177.194 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -145.18 -174.96 17.91 Favored Glycine 0 N--CA 1.486 1.975 0 C-N-CA 118.49 -1.814 . . . . 0.0 111.46 -177.56 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.509 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -121.12 -179.83 4.16 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -178.779 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.584 ' CB ' ' C20' ' A' ' 114' ' ' CHR . 0.0 OUTLIER -173.48 172.46 3.68 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.501 -0.749 . . . . 0.0 109.063 -179.498 . . . . . . . . 3 3 . 1 . 057 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.69 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 1.5 m-20 -106.87 -9.44 16.33 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.036 -1.04 . . . . 0.0 109.425 179.947 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.69 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 73.81 39.41 0.54 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.365 -0.834 . . . . 0.0 109.135 179.927 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.61 -33.84 0.78 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.696 -0.627 . . . . 0.0 110.631 -179.4 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.563 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 178.26 -40.4 0.09 OUTLIER Glycine 0 N--CA 1.482 1.755 0 N-CA-C 107.823 -2.111 . . . . 0.0 107.823 -179.625 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -159.17 -178.58 7.3 Favored 'General case' 0 C--N 1.308 -1.222 0 O-C-N 121.484 -1.01 . . . . 0.0 109.573 179.074 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -178.63 -166.45 34.8 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 108.495 -1.842 . . . . 0.0 108.495 -179.457 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.5 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.0 Cg_exo -50.22 -175.15 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.63 0 CA-C-N 118.843 1.321 . . . . 0.0 110.279 179.561 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.61 -173.66 2.81 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.119 -0.988 . . . . 0.0 110.076 -179.179 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -125.25 169.95 17.2 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.817 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.516 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -109.25 154.23 10.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -179.597 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.575 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -97.42 122.82 40.9 Favored 'General case' 0 C--N 1.291 -1.945 0 O-C-N 121.318 -0.864 . . . . 0.0 109.703 -179.888 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.673 HG22 ' HA ' ' A' ' 10' ' ' SER . 1.6 pt -98.26 168.97 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.213 -0.929 . . . . 0.0 109.033 179.83 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.543 ' CB ' ' OG ' ' A' ' 11' ' ' SER . 1.7 m -142.52 155.91 45.08 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.05 -1.031 . . . . 0.0 109.811 179.979 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.669 ' CZ ' HD12 ' A' ' 110' ' ' ILE . 31.4 m-85 -129.48 75.61 1.66 Allowed 'General case' 0 N--CA 1.486 1.327 0 O-C-N 121.138 -0.976 . . . . 0.0 109.539 -179.642 . . . . . . . . 2 2 . 1 . 057 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.427 ' O ' ' OD1' ' A' ' 113' ' ' ASN . 21.6 p30 . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 118.022 -0.989 . . . . 0.0 109.481 -179.979 . . . . . . . . 1 1 . 1 . 057 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.674 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 058 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.645 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -65.63 163.23 36.27 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.188 -0.945 . . . . 0.0 109.337 179.848 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.645 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 5.0 Cg_exo -60.17 155.27 46.46 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.213 1.942 . . . . 0.0 110.646 179.965 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.545 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.0 OUTLIER -175.41 -169.6 0.38 Allowed 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.996 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.545 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.8 133.29 3.4 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.767 -1.208 . . . . 0.0 110.81 -179.0 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.016 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.2 p -105.01 104.4 14.13 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-O 122.435 1.112 . . . . 0.0 109.997 179.833 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.978 HG22 HG23 ' A' ' 21' ' ' VAL . 13.1 t -118.85 119.75 61.97 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.543 179.841 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.506 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -164.75 148.55 7.68 Favored Pre-proline 0 N--CA 1.486 1.352 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 -179.695 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.506 ' HA ' HG23 ' A' ' 8' ' ' THR . 5.5 Cg_endo -77.54 150.72 91.21 Favored 'Cis proline' 0 C--N 1.31 -1.476 0 C-N-CA 123.552 -1.437 . . . . 0.0 109.495 -0.458 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.668 ' HA ' HG22 ' A' ' 110' ' ' ILE . 80.4 p -89.29 -26.18 21.28 Favored 'General case' 0 C--N 1.293 -1.882 0 O-C-N 121.467 -0.77 . . . . 0.0 108.993 179.625 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.539 ' HB2' ' CB ' ' A' ' 111' ' ' SER . 4.3 p -133.47 165.91 23.77 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.474 -0.766 . . . . 0.0 109.419 -179.941 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 75.7 38.27 37.51 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 108.418 -1.873 . . . . 0.0 108.418 -179.505 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.772 ' CA ' HG21 ' A' ' 17' ' ' THR . 36.8 mt -92.56 -43.24 9.24 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 123.203 1.478 . . . . 0.0 110.624 -178.167 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.482 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.1 OUTLIER 70.54 143.31 0.05 Allowed 'General case' 0 C--N 1.26 -3.291 0 CA-C-N 113.453 -1.703 . . . . 0.0 109.774 -179.54 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.625 ' HA ' ' HB3' ' A' ' 70' ' ' ARG . 7.4 p-10 -50.57 104.59 0.08 Allowed 'General case' 0 C--N 1.301 -1.516 0 CA-C-O 121.558 0.694 . . . . 0.0 111.772 -178.447 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.89 16.61 7.85 Favored Glycine 0 N--CA 1.485 1.939 0 C-N-CA 119.476 -1.345 . . . . 0.0 112.97 177.272 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.772 HG21 ' CA ' ' A' ' 13' ' ' LEU . 15.2 t -104.8 -171.23 1.88 Allowed 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 121.146 2.473 . . . . 0.0 109.693 179.11 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.845 HG22 HG22 ' A' ' 68' ' ' THR . 16.4 t -130.37 140.02 49.9 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.339 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.246 -178.845 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.559 HG12 HD21 ' A' ' 13' ' ' LEU . 35.1 m -117.25 155.33 18.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 178.933 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.555 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 1.1 tttt -106.73 108.97 20.75 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.047 -1.033 . . . . 0.0 109.414 -179.817 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.978 HG23 HG22 ' A' ' 7' ' ' VAL . 2.1 p -107.47 123.13 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 179.723 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.016 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.67 164.49 13.97 Favored 'General case' 0 C--N 1.306 -1.301 0 O-C-N 120.745 -1.222 . . . . 0.0 108.938 179.82 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.583 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.56 107.51 0.53 Allowed Glycine 0 C--N 1.297 -1.628 0 N-CA-C 108.595 -1.802 . . . . 0.0 108.595 179.8 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.566 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -115.72 142.67 46.44 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.978 -1.307 . . . . 0.0 110.445 -179.134 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.524 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 82.03 27.26 45.97 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 119.577 -1.297 . . . . 0.0 109.93 179.357 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.568 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 1.3 mt -90.84 174.24 7.56 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.069 -1.254 . . . . 0.0 108.574 179.974 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.0 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -46.42 99.57 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.966 -1.084 . . . . 0.0 109.517 -179.65 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.688 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -55.82 77.21 0.0 OUTLIER 'General case' 0 C--N 1.295 -1.77 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.409 -178.97 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.553 ' N ' ' O ' ' A' ' 27' ' ' GLN . . . 132.7 34.66 0.34 Allowed Glycine 0 N--CA 1.487 2.066 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.407 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.562 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 70.0 p -145.0 112.54 6.2 Favored 'General case' 0 C--N 1.307 -1.272 0 O-C-N 121.031 -1.276 . . . . 0.0 111.083 -179.676 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.555 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -45.83 125.34 6.05 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-N 115.67 -0.695 . . . . 0.0 109.606 178.096 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.508 ' CZ ' ' OD2' ' A' ' 99' ' ' ASP . 11.8 m-85 -118.13 149.87 40.31 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.325 -0.86 . . . . 0.0 108.697 179.692 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.511 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.1 OUTLIER -100.27 158.35 15.93 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.614 -1.304 . . . . 0.0 107.742 178.635 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.722 HG13 ' O ' ' A' ' 34' ' ' VAL . 7.2 p -142.12 112.24 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.035 -1.041 . . . . 0.0 109.897 -177.798 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.508 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -160.57 -178.86 34.93 Favored Glycine 0 N--CA 1.494 2.538 0 C-N-CA 118.524 -1.798 . . . . 0.0 111.722 -179.62 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.635 ' HG3' ' O ' ' A' ' 36' ' ' GLN . 1.1 pt20 -101.31 110.75 22.81 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.82 0.819 . . . . 0.0 108.922 -179.82 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.479 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.2 m -131.45 148.69 52.67 Favored 'General case' 0 C--N 1.295 -1.791 0 O-C-N 121.286 -0.884 . . . . 0.0 109.672 179.893 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.533 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -120.97 137.59 54.55 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.174 -0.954 . . . . 0.0 110.803 -178.936 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.866 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.73 114.57 26.32 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.096 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 m -104.78 14.11 7.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 120.979 -1.076 . . . . 0.0 110.65 -178.738 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.761 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.4 OUTLIER 174.17 -174.53 0.07 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.942 -1.099 . . . . 0.0 110.081 179.725 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.8 p -72.73 98.66 2.43 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.504 -0.748 . . . . 0.0 109.622 -179.729 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 86.11 26.37 34.26 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 120.222 -0.99 . . . . 0.0 111.553 178.939 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.761 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.3 t -116.64 106.04 19.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 O-C-N 120.47 -1.606 . . . . 0.0 107.413 178.918 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.866 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.4 tp -118.98 104.47 10.53 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 120.517 -1.365 . . . . 0.0 109.681 -177.896 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.042 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.93 109.57 22.3 Favored 'General case' 0 N--CA 1.485 1.279 0 O-C-N 120.852 -1.155 . . . . 0.0 108.063 178.9 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.493 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 3.8 t -105.88 165.06 11.46 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.966 -1.084 . . . . 0.0 110.599 -178.699 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.677 ' ND2' ' HB3' ' A' ' 50' ' ' ALA . 50.2 t30 -113.18 130.87 23.19 Favored Pre-proline 0 N--CA 1.499 2.023 0 O-C-N 121.558 -0.714 . . . . 0.0 109.714 -179.3 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.61 ' HG3' ' CZ ' ' A' ' 76' ' ' PHE . 1.8 Cg_endo -71.85 22.2 0.26 Allowed 'Trans proline' 0 CA--C 1.545 1.067 0 C-N-CA 122.188 1.926 . . . . 0.0 112.288 -179.986 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.677 ' HB3' ' ND2' ' A' ' 48' ' ' ASN . . . -108.65 2.02 21.67 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.39 -1.444 . . . . 0.0 108.929 179.393 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.544 ' HB2' HD22 ' A' ' 67' ' ' LEU . 0.0 OUTLIER -138.05 14.43 2.85 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 179.475 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.7 m-85 -78.13 91.28 4.3 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.908 -0.717 . . . . 0.0 110.974 -178.475 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.641 ' C ' HG12 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -114.09 -173.11 2.22 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 178.198 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.533 ' N ' ' OG ' ' A' ' 53' ' ' SER . 12.3 t 179.68 139.35 0.12 Allowed 'General case' 0 C--N 1.306 -1.285 0 O-C-N 120.534 -1.354 . . . . 0.0 111.303 -179.134 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.934 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -152.71 160.59 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 178.123 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.555 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -97.61 144.53 27.19 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.593 -1.317 . . . . 0.0 110.168 -179.387 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.0 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.7 107.2 1.36 Allowed 'General case' 0 C--N 1.301 -1.537 0 CA-C-O 122.44 1.114 . . . . 0.0 109.338 178.415 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.529 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 13.6 p-10 -58.53 -138.16 0.0 OUTLIER 'General case' 0 C--N 1.29 -1.998 0 CA-C-N 115.521 -0.763 . . . . 0.0 110.852 -179.8 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.688 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -54.58 -49.74 69.67 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.348 -0.845 . . . . 0.0 110.202 -178.771 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.404 ' CG ' ' N ' ' A' ' 61' ' ' GLY . 9.9 p-10 -101.41 -38.97 7.78 Favored 'General case' 0 C--N 1.285 -2.2 0 N-CA-C 106.21 -1.774 . . . . 0.0 106.21 178.454 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.991 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 111.74 65.74 0.51 Allowed Glycine 0 C--N 1.297 -1.587 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 178.211 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.583 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 21.0 m -105.42 124.03 48.87 Favored 'General case' 0 N--CA 1.483 1.214 0 O-C-N 121.686 -0.89 . . . . 0.0 108.734 179.005 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.934 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -133.52 109.35 9.2 Favored 'General case' 0 C--N 1.295 -1.788 0 C-N-CA 119.899 -0.72 . . . . 0.0 109.388 -179.395 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 1.5 m -116.5 118.28 32.23 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.178 -0.951 . . . . 0.0 109.273 -179.901 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.544 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -143.68 141.08 30.38 Favored 'General case' 0 C--N 1.299 -1.605 0 O-C-N 121.405 -0.809 . . . . 0.0 109.679 -179.907 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 21.3 p -99.36 130.75 45.66 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.441 -0.787 . . . . 0.0 109.277 179.9 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.762 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.1 OUTLIER -128.18 165.56 20.2 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.332 -0.855 . . . . 0.0 109.376 -179.503 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.845 HG22 HG22 ' A' ' 18' ' ' VAL . 1.8 p -96.75 123.23 40.38 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.103 -0.998 . . . . 0.0 109.213 179.953 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.535 ' CG1' ' HB3' ' A' ' 36' ' ' GLN . 16.3 m -135.96 142.13 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.118 -0.989 . . . . 0.0 109.899 -179.232 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.625 ' HB3' ' HA ' ' A' ' 15' ' ' ASP . 8.2 ptt180 -137.6 -166.12 1.89 Allowed 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.62 -1.3 . . . . 0.0 110.097 -179.946 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.583 ' O ' ' CD1' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -73.92 -83.57 0.05 OUTLIER 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.27 -0.894 . . . . 0.0 108.665 -179.686 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.501 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -62.54 138.68 58.53 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.343 -1.473 . . . . 0.0 107.185 178.631 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.583 ' CD1' ' O ' ' A' ' 71' ' ' ARG . 0.2 OUTLIER -164.04 137.05 5.19 Favored 'General case' 0 C--N 1.294 -1.835 0 C-N-CA 117.879 -1.528 . . . . 0.0 110.459 -177.434 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.508 ' OE1' ' N ' ' A' ' 75' ' ' GLY . 0.6 OUTLIER -34.29 121.49 0.48 Allowed 'General case' 0 N--CA 1.491 1.595 0 CA-C-O 121.478 0.656 . . . . 0.0 110.302 -178.584 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.042 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -93.73 50.34 2.3 Favored Glycine 0 N--CA 1.494 2.544 0 C-N-CA 120.451 -0.881 . . . . 0.0 111.205 -179.223 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.61 ' CZ ' ' HG3' ' A' ' 49' ' ' PRO . 4.1 m-30 -39.81 113.34 0.33 Allowed 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.032 -1.275 . . . . 0.0 110.025 179.468 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.631 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.7 tp -84.7 127.1 33.93 Favored 'General case' 0 N--CA 1.5 2.032 0 O-C-N 120.884 -1.135 . . . . 0.0 109.638 -179.845 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.577 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 29.7 t80 -63.54 58.33 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.004 0 O-C-N 120.874 -1.141 . . . . 0.0 110.405 179.611 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.538 ' N ' ' O ' ' A' ' 77' ' ' LEU . 3.5 t0 -161.54 19.78 0.11 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.008 -1.057 . . . . 0.0 109.807 179.849 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.22 -26.91 5.31 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 110.171 -1.172 . . . . 0.0 110.171 179.937 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.43 ' O ' ' CB ' ' A' ' 77' ' ' LEU . 37.0 p -92.95 156.26 17.04 Favored 'General case' 0 N--CA 1.486 1.36 0 O-C-N 121.031 -1.276 . . . . 0.0 110.332 -179.489 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.471 ' O ' ' HD2' ' A' ' 82' ' ' ARG . 0.1 OUTLIER -104.49 133.75 48.83 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.707 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.631 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.6 t90 -80.26 -18.71 48.6 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.823 -1.173 . . . . 0.0 110.41 -178.566 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 109.93 175.93 20.97 Favored Glycine 0 N--CA 1.485 1.93 0 N-CA-C 108.667 -1.773 . . . . 0.0 108.667 -179.589 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -62.43 109.59 1.41 Allowed 'General case' 0 C--N 1.3 -1.568 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 179.138 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.577 HG21 ' HB3' ' A' ' 46' ' ' ALA . 31.4 t -82.54 105.39 12.33 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.967 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.656 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.3 OUTLIER -65.76 112.32 3.66 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.402 -0.811 . . . . 0.0 109.904 -179.215 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.557 ' CB ' ' HA ' ' A' ' 71' ' ' ARG . 2.0 t -64.97 -4.79 4.96 Favored 'General case' 0 N--CA 1.5 2.03 0 C-N-CA 118.208 -1.397 . . . . 0.0 109.863 179.398 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 p -85.71 -0.08 54.19 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.774 -1.204 . . . . 0.0 109.0 179.348 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.656 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.5 p -113.03 -49.71 2.91 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.297 -0.877 . . . . 0.0 109.063 179.949 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.8 179.77 4.13 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.581 -0.7 . . . . 0.0 109.505 179.93 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.93 115.7 31.11 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.301 -0.874 . . . . 0.0 109.219 -180.0 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.547 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.7 m -96.92 123.7 40.7 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.87 -1.143 . . . . 0.0 109.358 -179.469 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.574 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -103.52 148.46 25.93 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-O 122.446 1.117 . . . . 0.0 111.457 -179.171 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.548 ' HB ' HG11 ' A' ' 7' ' ' VAL . 61.8 t -102.4 109.66 27.03 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 N-CA-C 106.282 -1.748 . . . . 0.0 106.282 177.249 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -144.11 -175.41 17.22 Favored Glycine 0 N--CA 1.483 1.831 0 C-N-CA 118.318 -1.896 . . . . 0.0 111.563 -177.395 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.537 HD12 ' HB2' ' A' ' 105' ' ' PRO . 0.1 OUTLIER -117.22 -177.82 3.3 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 -178.853 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.56 ' HB3' ' C27' ' A' ' 114' ' ' CHR . 1.1 p -173.72 169.45 4.2 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.235 -0.916 . . . . 0.0 109.143 -179.26 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.714 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 1.7 m-20 -106.91 -9.34 16.33 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.141 -0.975 . . . . 0.0 109.487 179.92 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.714 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 75.18 37.61 0.46 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.41 -0.806 . . . . 0.0 109.116 179.947 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -136.11 -34.69 0.79 Allowed 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.572 -0.705 . . . . 0.0 110.616 -179.434 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.614 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 179.85 -41.95 0.08 OUTLIER Glycine 0 N--CA 1.482 1.712 0 N-CA-C 107.699 -2.16 . . . . 0.0 107.699 -179.665 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -158.59 -178.68 7.44 Favored 'General case' 0 C--N 1.308 -1.198 0 O-C-N 121.415 -1.05 . . . . 0.0 109.866 179.118 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -177.67 -166.52 34.43 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 108.194 -1.962 . . . . 0.0 108.194 -179.477 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.537 ' HB2' HD12 ' A' ' 97' ' ' LEU . 5.4 Cg_exo -48.42 179.26 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.659 0 CA-C-N 118.94 1.37 . . . . 0.0 110.148 179.483 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -91.85 -175.2 4.06 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.055 -1.028 . . . . 0.0 110.516 -178.717 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -122.05 161.7 16.1 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.848 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -104.62 133.09 49.71 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.364 -1.08 . . . . 0.0 109.278 -179.242 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.574 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -76.04 122.09 23.73 Favored 'General case' 0 C--N 1.289 -2.054 0 O-C-N 121.485 -0.76 . . . . 0.0 109.716 179.703 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.91 HD12 ' CE2' ' A' ' 112' ' ' PHE . 1.7 pt -97.99 174.0 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.222 -0.924 . . . . 0.0 109.23 179.837 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.539 ' CB ' ' HB2' ' A' ' 11' ' ' SER . 0.6 OUTLIER -140.21 158.19 44.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.048 -1.032 . . . . 0.0 109.838 -179.778 . . . . . . . . 3 3 . 1 . 058 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.91 ' CE2' HD12 ' A' ' 110' ' ' ILE . 96.5 m-85 -135.08 131.18 36.64 Favored 'General case' 0 N--CA 1.485 1.282 0 O-C-N 121.22 -0.925 . . . . 0.0 109.431 -179.808 . . . . . . . . 2 2 . 1 . 058 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.407 ' C ' ' O ' ' A' ' 112' ' ' PHE . 21.4 p30 . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.533 -179.967 . . . . . . . . 1 1 . 1 . 058 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.74 ' H8 ' HD23 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.491 ' HB1' HD21 ' A' ' 60' ' ' ASN . . . . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 121.296 0.57 . . . . 0.0 109.5 . . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.438 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -113.06 157.03 41.92 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.245 -0.909 . . . . 0.0 109.471 -179.993 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.545 ' HA ' ' O ' ' A' ' 24' ' ' ALA . 5.7 Cg_exo -59.98 157.95 31.72 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 C-N-CA 122.314 2.01 . . . . 0.0 110.608 179.948 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.557 ' OG1' ' N ' ' A' ' 5' ' ' ALA . 0.1 OUTLIER -173.71 -169.23 0.48 Allowed 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 178.989 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.557 ' N ' ' OG1' ' A' ' 4' ' ' THR . . . -164.6 133.84 3.68 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 120.745 -1.222 . . . . 0.0 110.757 -179.156 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 1.016 ' OG1' ' HB3' ' A' ' 22' ' ' ALA . 2.1 p -105.41 104.62 14.38 Favored 'General case' 0 C--N 1.296 -1.747 0 CA-C-O 122.558 1.17 . . . . 0.0 109.911 179.983 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 1.012 HG22 HG23 ' A' ' 21' ' ' VAL . 14.5 t -118.97 126.34 75.27 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.407 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.535 179.875 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.478 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -170.57 149.37 2.99 Favored Pre-proline 0 N--CA 1.486 1.361 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 -179.642 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.478 ' HA ' HG23 ' A' ' 8' ' ' THR . 2.2 Cg_endo -74.64 153.23 99.05 Favored 'Cis proline' 0 C--N 1.31 -1.465 0 C-N-CA 123.678 -1.384 . . . . 0.0 109.894 -0.522 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.626 ' HA ' HG22 ' A' ' 110' ' ' ILE . 6.6 m -95.73 -22.6 17.43 Favored 'General case' 0 C--N 1.294 -1.846 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 179.564 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.459 ' OG ' ' HB2' ' A' ' 111' ' ' SER . 2.9 m -135.59 162.85 31.55 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.491 -0.756 . . . . 0.0 109.496 179.921 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.11 37.6 37.23 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 108.503 -1.839 . . . . 0.0 108.503 -179.556 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.862 ' CA ' HG21 ' A' ' 17' ' ' THR . 27.3 mt -90.59 -45.47 8.89 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-O 123.116 1.436 . . . . 0.0 110.644 -178.373 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.463 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 1.2 t 63.82 147.24 0.03 OUTLIER 'General case' 0 C--N 1.26 -3.325 0 CA-C-N 113.69 -1.596 . . . . 0.0 109.974 -179.699 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.616 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 8.4 p-10 -51.48 109.33 0.34 Allowed 'General case' 0 C--N 1.301 -1.514 0 CA-C-O 121.556 0.694 . . . . 0.0 111.721 -178.652 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 113.04 12.98 11.42 Favored Glycine 0 N--CA 1.485 1.966 0 C-N-CA 119.478 -1.344 . . . . 0.0 112.873 177.339 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.862 HG21 ' CA ' ' A' ' 13' ' ' LEU . 9.7 t -101.42 -174.35 2.58 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 121.057 2.428 . . . . 0.0 109.763 179.479 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.728 HG13 ' O ' ' A' ' 67' ' ' LEU . 14.8 t -131.28 138.48 53.14 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.38 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.813 -178.982 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.581 HG13 ' CG2' ' A' ' 69' ' ' VAL . 35.0 m -117.43 154.4 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.365 -0.835 . . . . 0.0 109.135 179.082 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.551 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 0.1 OUTLIER -110.12 109.25 19.71 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.168 -0.957 . . . . 0.0 109.149 179.881 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 1.012 HG23 HG22 ' A' ' 7' ' ' VAL . 2.4 p -107.39 124.6 63.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.964 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 1.016 ' HB3' ' OG1' ' A' ' 6' ' ' THR . . . -114.08 165.08 13.0 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.845 -1.159 . . . . 0.0 108.858 179.489 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.615 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -140.39 107.5 0.53 Allowed Glycine 0 C--N 1.296 -1.692 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 179.971 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.545 ' O ' ' HA ' ' A' ' 3' ' ' PRO . . . -116.41 141.09 48.63 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 120.743 -1.445 . . . . 0.0 110.796 -179.072 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.542 ' O ' ' CB ' ' A' ' 3' ' ' PRO . . . 83.09 26.5 44.29 Favored Glycine 0 N--CA 1.489 2.203 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.033 179.145 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.564 ' HB2' ' HB2' ' A' ' 57' ' ' ALA . 0.9 OUTLIER -90.35 172.29 8.85 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.028 -1.278 . . . . 0.0 108.575 -179.992 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.01 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -45.18 99.97 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.081 -1.012 . . . . 0.0 109.652 -179.685 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.566 ' HB1' ' O ' ' A' ' 59' ' ' ALA . . . -57.0 76.96 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.118 -179.036 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.57 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 135.41 33.39 0.27 Allowed Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.517 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.553 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 54.1 p -141.14 109.47 5.88 Favored 'General case' 0 C--N 1.307 -1.25 0 O-C-N 121.015 -1.285 . . . . 0.0 111.152 -179.714 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.584 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -50.94 110.08 0.39 Allowed 'General case' 0 N--CA 1.496 1.858 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.909 178.314 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.555 ' CE1' ' HB3' ' A' ' 99' ' ' ASP . 18.6 m-85 -104.25 154.76 19.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.146 -0.971 . . . . 0.0 108.74 179.396 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.45 ' HA ' ' OG ' ' A' ' 54' ' ' SER . 0.3 OUTLIER -98.96 165.23 11.85 Favored 'General case' 0 N--CA 1.489 1.496 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 178.545 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.62 ' CG1' ' CB ' ' A' ' 53' ' ' SER . 4.0 p -143.4 120.47 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.092 -1.005 . . . . 0.0 109.493 -177.807 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -168.75 179.91 41.32 Favored Glycine 0 N--CA 1.491 2.312 0 C-N-CA 118.264 -1.922 . . . . 0.0 111.614 -179.806 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.618 ' NE2' ' CD2' ' A' ' 73' ' ' PHE . 0.0 OUTLIER -101.96 109.79 21.6 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.715 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 58.2 m -128.87 152.75 48.17 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.347 -0.846 . . . . 0.0 110.319 -179.828 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -127.52 136.36 51.63 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.64 -0.662 . . . . 0.0 110.126 179.65 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.901 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -94.4 114.73 26.81 Favored 'General case' 0 N--CA 1.493 1.687 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 178.369 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m -106.6 15.3 7.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 120.964 -1.085 . . . . 0.0 110.762 -178.636 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.785 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.6 OUTLIER 174.24 -175.63 0.08 Allowed 'General case' 0 N--CA 1.488 1.47 0 O-C-N 120.894 -1.129 . . . . 0.0 110.112 179.604 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.799 HG23 ' O ' ' A' ' 42' ' ' THR . 15.3 t -69.63 97.0 0.99 Allowed 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.741 0.781 . . . . 0.0 110.02 -179.404 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 83.8 28.46 34.95 Favored Glycine 0 N--CA 1.492 2.415 0 C-N-CA 120.225 -0.988 . . . . 0.0 111.38 178.694 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.785 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.6 t -115.09 106.09 19.9 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 O-C-N 120.531 -1.57 . . . . 0.0 107.432 178.836 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.901 HD13 ' NE1' ' A' ' 39' ' ' TRP . 11.8 tp -116.31 106.66 13.9 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.541 -1.349 . . . . 0.0 109.941 -177.552 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 1.1 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -95.93 110.12 22.38 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 120.759 -1.213 . . . . 0.0 108.028 179.186 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 68.2 m -98.91 144.91 27.56 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.259 -0.901 . . . . 0.0 110.846 -178.132 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.513 ' ND2' ' HG2' ' A' ' 36' ' ' GLN . 0.1 OUTLIER -85.48 131.08 48.95 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.415 -0.803 . . . . 0.0 109.076 179.299 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.589 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 6.8 Cg_endo -75.68 31.02 0.38 Allowed 'Trans proline' 0 C--N 1.314 -1.266 0 C-N-CA 122.267 1.978 . . . . 0.0 111.323 179.898 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.465 ' O ' ' OD1' ' A' ' 51' ' ' ASP . . . -122.14 -1.69 9.23 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.42 -1.425 . . . . 0.0 110.299 -179.231 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.796 ' HB3' HD22 ' A' ' 67' ' ' LEU . 20.4 m-20 -137.55 10.31 2.93 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.039 -1.038 . . . . 0.0 109.115 -179.68 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -64.0 84.1 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.594 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.292 -179.108 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.62 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.3 OUTLIER -110.82 -169.0 1.38 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.164 -0.96 . . . . 0.0 108.557 179.081 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.455 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.6 OUTLIER 178.32 135.22 0.08 Allowed 'General case' 0 N--CA 1.486 1.328 0 O-C-N 120.783 -1.198 . . . . 0.0 111.288 -179.348 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.877 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 0.9 OUTLIER -147.48 159.29 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 177.915 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.584 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.29 142.96 29.29 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 120.707 -1.245 . . . . 0.0 110.246 -179.52 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.01 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -64.75 107.08 1.34 Allowed 'General case' 0 C--N 1.299 -1.593 0 CA-C-O 122.404 1.097 . . . . 0.0 109.367 178.323 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.55 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 6.5 t0 -60.59 -138.97 0.0 OUTLIER 'General case' 0 C--N 1.289 -2.039 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.022 -179.889 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.566 ' O ' ' HB1' ' A' ' 28' ' ' ALA . . . -50.72 -51.11 53.06 Favored 'General case' 0 N--CA 1.5 2.06 0 O-C-N 121.427 -0.796 . . . . 0.0 110.66 -178.552 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . 0.491 HD21 ' HB1' ' A' ' 1' ' ' ALA . 11.9 t30 -104.19 -34.28 8.43 Favored 'General case' 0 C--N 1.286 -2.185 0 N-CA-C 106.182 -1.785 . . . . 0.0 106.182 178.472 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.976 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 108.72 67.93 0.61 Allowed Glycine 0 C--N 1.296 -1.647 0 N-CA-C 110.467 -1.053 . . . . 0.0 110.467 178.182 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 19.8 m -104.67 124.48 49.44 Favored 'General case' 0 N--CA 1.483 1.194 0 O-C-N 121.612 -0.934 . . . . 0.0 108.739 179.004 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.877 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -132.88 109.21 9.45 Favored 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.906 -0.718 . . . . 0.0 109.223 -179.609 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 14.7 m -118.37 118.77 32.66 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.302 -0.874 . . . . 0.0 109.611 -179.621 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.56 HG21 HG11 ' A' ' 34' ' ' VAL . 0.1 OUTLIER -144.86 140.29 28.27 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.505 -0.747 . . . . 0.0 109.684 179.805 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . 0.434 ' C ' ' HG ' ' A' ' 67' ' ' LEU . 19.2 p -98.83 136.05 39.4 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.466 -0.771 . . . . 0.0 109.079 179.758 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.84 HD11 HG12 ' A' ' 21' ' ' VAL . 0.0 OUTLIER -133.35 173.79 11.09 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.339 -0.851 . . . . 0.0 109.687 -178.887 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.533 ' HA ' ' HA ' ' A' ' 18' ' ' VAL . 1.6 p -100.18 125.01 46.27 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.933 -1.105 . . . . 0.0 109.01 179.918 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.778 HG23 HD13 ' A' ' 13' ' ' LEU . 15.9 m -132.19 142.13 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 120.764 -1.21 . . . . 0.0 110.06 -178.986 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.616 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 2.9 ptt180 -147.71 -170.48 3.58 Favored 'General case' 0 N--CA 1.485 1.313 0 O-C-N 120.563 -1.336 . . . . 0.0 110.827 -179.945 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.624 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -67.22 -102.68 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.821 -0.549 . . . . 0.0 109.932 -179.329 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.552 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.9 OUTLIER -58.08 134.98 56.92 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 120.359 -1.463 . . . . 0.0 108.152 179.714 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.618 ' CD2' ' NE2' ' A' ' 36' ' ' GLN . 0.7 OUTLIER -153.78 156.92 38.6 Favored 'General case' 0 C--N 1.295 -1.781 0 C-N-CA 118.584 -1.246 . . . . 0.0 110.298 -178.683 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.564 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 1.6 mm-40 -53.15 119.4 4.67 Favored 'General case' 0 N--CA 1.486 1.367 0 O-C-N 121.277 -0.889 . . . . 0.0 109.368 -178.736 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 1.1 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -90.39 54.04 3.5 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.311 -178.9 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.589 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 5.3 m-30 -40.35 115.92 0.61 Allowed 'General case' 0 N--CA 1.504 2.271 0 O-C-N 120.947 -1.325 . . . . 0.0 110.173 179.487 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.72 HD13 ' HB2' ' A' ' 83' ' ' TRP . 8.1 tp -87.46 126.85 35.14 Favored 'General case' 0 N--CA 1.5 2.072 0 O-C-N 120.806 -1.184 . . . . 0.0 109.488 -179.834 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.589 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 24.8 t80 -64.18 58.38 0.02 OUTLIER 'General case' 0 N--CA 1.498 1.972 0 O-C-N 120.837 -1.165 . . . . 0.0 110.132 179.702 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.529 ' N ' ' O ' ' A' ' 77' ' ' LEU . 15.4 t70 -160.37 19.66 0.15 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.028 -1.045 . . . . 0.0 109.717 179.772 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.75 -27.44 5.36 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.151 -1.18 . . . . 0.0 110.151 179.856 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 46.4 p -94.9 162.44 13.75 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 120.98 -1.306 . . . . 0.0 110.402 -179.46 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.481 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 2.2 ptm180 -108.14 138.0 45.15 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.921 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.72 ' HB2' HD13 ' A' ' 77' ' ' LEU . 2.9 t90 -83.4 -18.6 38.21 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.769 -1.207 . . . . 0.0 110.443 -178.656 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 111.99 175.05 19.79 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 108.766 -1.734 . . . . 0.0 108.766 -179.632 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -63.94 106.2 0.98 Allowed 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.119 -1.224 . . . . 0.0 107.898 179.227 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.64 HG21 ' CB ' ' A' ' 46' ' ' ALA . 40.7 t -78.25 104.35 6.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.343 -0.848 . . . . 0.0 109.021 -179.041 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.655 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -62.99 107.9 1.1 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.55 -0.719 . . . . 0.0 110.164 -179.141 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.624 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 3.4 t -61.42 -4.26 1.23 Allowed 'General case' 0 N--CA 1.501 2.105 0 C-N-CA 118.255 -1.378 . . . . 0.0 110.38 179.298 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 17.2 p -90.98 7.09 42.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.562 -1.336 . . . . 0.0 109.407 -179.933 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.655 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.2 p -119.35 -47.76 2.44 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.292 -0.88 . . . . 0.0 109.16 179.941 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.6 -178.4 3.64 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.562 -0.711 . . . . 0.0 109.589 179.988 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.81 111.99 24.58 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.381 -0.824 . . . . 0.0 108.856 179.859 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.494 ' O ' HG12 ' A' ' 110' ' ' ILE . 1.5 m -97.22 121.06 38.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.036 -1.04 . . . . 0.0 109.445 -178.966 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.606 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.2 mt-30 -103.17 147.36 27.12 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-O 122.474 1.13 . . . . 0.0 111.646 -179.05 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.584 ' HB ' HG11 ' A' ' 7' ' ' VAL . 92.3 t -102.95 109.65 27.38 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 177.259 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.496 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -151.84 -169.45 17.37 Favored Glycine 0 N--CA 1.484 1.88 0 C-N-CA 118.073 -2.013 . . . . 0.0 111.628 -177.258 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.485 ' O ' ' HB2' ' A' ' 98' ' ' SER . 0.0 OUTLIER -121.24 176.8 5.43 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -178.897 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.592 ' CB ' ' C21' ' A' ' 114' ' ' CHR . 6.9 t 176.84 159.71 0.36 Allowed 'General case' 0 C--N 1.292 -1.897 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 -179.963 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.555 ' HB3' ' CE1' ' A' ' 32' ' ' TYR . 0.4 OUTLIER -103.49 -158.49 0.67 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 120.91 -1.119 . . . . 0.0 109.29 -179.855 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.442 ' N ' ' CG ' ' A' ' 99' ' ' ASP . . . -117.22 36.22 4.33 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 120.788 -1.195 . . . . 0.0 109.238 179.984 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -111.89 -32.6 6.56 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.366 -0.834 . . . . 0.0 109.796 -179.736 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.572 ' HA2' H192 ' A' ' 114' ' ' CHR . . . 169.02 -37.94 0.2 Allowed Glycine 0 N--CA 1.481 1.666 0 N-CA-C 107.992 -2.043 . . . . 0.0 107.992 -179.78 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 102' ' ' GLY . 0.3 OUTLIER -166.54 -177.08 3.82 Favored 'General case' 0 C--N 1.307 -1.262 0 O-C-N 121.574 -0.957 . . . . 0.0 109.984 179.395 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -170.56 -161.41 21.1 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 108.068 -2.013 . . . . 0.0 108.068 -179.397 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.467 ' O ' ' O ' ' A' ' 104' ' ' GLY . 6.9 Cg_exo -45.77 172.63 0.02 OUTLIER 'Trans proline' 0 C--O 1.215 -0.632 0 CA-C-N 118.978 1.389 . . . . 0.0 109.933 179.194 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -92.9 -174.49 3.61 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.092 -1.005 . . . . 0.0 110.56 -178.772 . . . . . . . . 1 1 . 1 . 059 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.496 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -121.48 166.31 14.35 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -179.876 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -102.0 131.16 50.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.416 -1.049 . . . . 0.0 109.124 -179.428 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.606 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -73.61 123.77 24.63 Favored 'General case' 0 C--N 1.29 -1.983 0 O-C-N 121.594 -0.691 . . . . 0.0 109.519 179.713 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.916 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.7 pt -97.84 171.74 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.232 -0.917 . . . . 0.0 109.183 179.901 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.459 ' HB2' ' OG ' ' A' ' 11' ' ' SER . 0.1 OUTLIER -138.15 157.78 45.62 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.279 -0.888 . . . . 0.0 109.92 -179.712 . . . . . . . . 3 3 . 1 . 059 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.916 ' CE1' HD12 ' A' ' 110' ' ' ILE . 38.8 m-85 -129.77 98.62 4.86 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.273 -0.892 . . . . 0.0 109.543 -179.741 . . . . . . . . 2 2 . 1 . 059 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . . . . . . . . . 24.7 p30 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 118.048 -0.977 . . . . 0.0 109.462 -179.97 . . . . . . . . 0 0 . 1 . 059 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.794 H182 HD22 ' A' ' 45' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 060 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.6 ' HB1' ' HD2' ' A' ' 3' ' ' PRO . . . -103.41 161.75 22.12 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.268 -0.895 . . . . 0.0 109.446 -179.978 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.6 ' HD2' ' HB1' ' A' ' 2' ' ' ALA . 4.1 Cg_exo -60.5 157.25 37.38 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.322 2.014 . . . . 0.0 110.52 -179.987 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.597 ' N ' ' O ' ' A' ' 24' ' ' ALA . 0.9 OUTLIER -149.82 160.59 43.44 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 -179.532 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 22' ' ' ALA . . . -148.63 122.57 9.39 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 122.454 1.121 . . . . 0.0 110.452 -179.675 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.829 HG22 ' HB3' ' A' ' 22' ' ' ALA . 6.3 t -115.58 109.24 17.5 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-O 123.123 1.44 . . . . 0.0 109.72 -179.935 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.834 HG22 HG23 ' A' ' 21' ' ' VAL . 1.1 t -114.53 135.75 53.35 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.657 0 CA-C-N 114.285 -1.325 . . . . 0.0 109.582 179.886 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.487 HG23 ' HA ' ' A' ' 9' ' ' PRO . 0.9 OUTLIER -171.69 150.42 2.62 Favored Pre-proline 0 N--CA 1.487 1.407 0 O-C-N 121.151 -0.968 . . . . 0.0 108.95 -179.639 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.487 ' HA ' HG23 ' A' ' 8' ' ' THR . 6.0 Cg_endo -78.63 150.2 86.86 Favored 'Cis proline' 0 C--N 1.313 -1.305 0 C-N-CA 123.392 -1.503 . . . . 0.0 109.341 -0.965 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.672 ' HA ' HG22 ' A' ' 110' ' ' ILE . 84.6 p -92.91 -22.65 19.11 Favored 'General case' 0 C--N 1.292 -1.905 0 O-C-N 121.552 -0.718 . . . . 0.0 109.306 179.894 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . 0.495 ' CB ' ' HB2' ' A' ' 111' ' ' SER . 4.3 m -130.91 159.64 36.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.345 -0.847 . . . . 0.0 109.644 -179.838 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.55 37.34 31.13 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 108.542 -1.823 . . . . 0.0 108.542 -179.676 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.8 ' CA ' HG21 ' A' ' 17' ' ' THR . 33.6 mt -90.92 -44.29 9.46 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 123.14 1.447 . . . . 0.0 110.691 -178.479 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.459 ' HB3' ' O ' ' A' ' 13' ' ' LEU . 0.3 OUTLIER 66.26 144.41 0.03 OUTLIER 'General case' 0 C--N 1.261 -3.249 0 CA-C-N 113.555 -1.657 . . . . 0.0 109.687 -179.538 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.607 ' HA ' ' CB ' ' A' ' 70' ' ' ARG . 12.4 p-10 -51.54 109.24 0.33 Allowed 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.495 0.664 . . . . 0.0 111.483 -178.612 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 114.43 10.85 12.56 Favored Glycine 0 N--CA 1.485 1.955 0 C-N-CA 119.391 -1.385 . . . . 0.0 112.83 177.374 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.8 HG21 ' CA ' ' A' ' 13' ' ' LEU . 12.9 t -101.97 -171.37 1.96 Allowed 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 121.051 2.425 . . . . 0.0 109.876 179.575 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.753 HG13 ' C ' ' A' ' 67' ' ' LEU . 19.1 t -131.19 142.41 43.53 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.281 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.76 -179.058 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.417 HG11 HD11 ' A' ' 13' ' ' LEU . 35.4 m -118.55 155.58 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.277 -0.889 . . . . 0.0 108.764 179.209 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.489 ' O ' ' HA ' ' A' ' 7' ' ' VAL . 6.1 tttt -108.02 109.23 20.64 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.162 -0.961 . . . . 0.0 109.288 -179.984 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.834 HG23 HG22 ' A' ' 7' ' ' VAL . 10.4 p -101.36 138.92 23.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 179.71 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.829 ' HB3' HG22 ' A' ' 6' ' ' THR . . . -135.68 161.24 36.11 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 118.698 -1.201 . . . . 0.0 110.127 179.689 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . 0.604 ' O ' ' HA ' ' A' ' 62' ' ' SER . . . -135.94 140.92 12.0 Favored Glycine 0 C--O 1.209 -1.444 0 N-CA-C 107.928 -2.069 . . . . 0.0 107.928 179.621 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.597 ' O ' ' N ' ' A' ' 4' ' ' THR . . . -143.06 125.05 15.21 Favored 'General case' 0 N--CA 1.494 1.756 0 CA-C-N 119.266 1.533 . . . . 0.0 109.395 179.387 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.465 ' C ' ' HA ' ' A' ' 3' ' ' PRO . . . 89.64 28.22 19.75 Favored Glycine 0 N--CA 1.489 2.194 0 C-N-CA 118.755 -1.688 . . . . 0.0 109.619 -179.728 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.595 HD23 ' HB3' ' A' ' 3' ' ' PRO . 1.6 mt -88.74 171.32 10.06 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 120.866 -1.373 . . . . 0.0 108.089 179.906 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 1.014 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.0 OUTLIER -44.79 100.25 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.901 -1.124 . . . . 0.0 109.981 -179.424 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.542 ' CB ' ' O ' ' A' ' 59' ' ' ALA . . . -57.58 77.21 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.946 -179.347 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 57' ' ' ALA . . . 136.01 33.88 0.24 Allowed Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 179.717 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.557 ' CG2' ' HB3' ' A' ' 27' ' ' GLN . 36.3 p -141.26 107.47 5.23 Favored 'General case' 0 C--N 1.308 -1.234 0 O-C-N 121.082 -1.246 . . . . 0.0 111.311 -179.422 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 56' ' ' THR . . . -49.49 109.78 0.31 Allowed 'General case' 0 N--CA 1.496 1.842 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 177.93 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . 0.58 ' CG ' ' O ' ' A' ' 98' ' ' SER . 4.4 m-30 -101.24 156.1 17.63 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.168 -0.957 . . . . 0.0 109.009 179.83 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.499 ' O ' ' HA ' ' A' ' 97' ' ' LEU . 0.3 OUTLIER -99.98 163.71 12.32 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 107.545 -1.279 . . . . 0.0 107.545 178.503 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.752 HG22 HG11 ' A' ' 21' ' ' VAL . 2.4 p -147.77 117.85 1.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.891 -1.131 . . . . 0.0 110.05 -177.928 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.497 ' HA2' ' O ' ' A' ' 51' ' ' ASP . . . -171.28 -175.91 40.04 Favored Glycine 0 N--CA 1.494 2.501 0 C-N-CA 118.346 -1.883 . . . . 0.0 111.724 -179.862 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.573 ' HB3' HG12 ' A' ' 69' ' ' VAL . 0.1 OUTLIER -100.42 108.87 20.97 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.748 0.785 . . . . 0.0 108.946 -179.818 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.489 ' HA ' ' HA ' ' A' ' 47' ' ' CYS . 2.8 m -130.39 148.27 52.19 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.269 -0.894 . . . . 0.0 109.676 179.431 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.556 ' HB2' ' HZ ' ' A' ' 73' ' ' PHE . . . -121.19 137.55 54.62 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.265 -0.897 . . . . 0.0 110.932 -178.839 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 39' ' ' TRP . . . . . 0.869 ' NE1' HD13 ' A' ' 45' ' ' LEU . 0.7 OUTLIER -95.64 114.68 26.45 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.114 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.0 m -105.03 14.4 7.24 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 120.95 -1.094 . . . . 0.0 110.573 -178.715 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.76 ' CB ' HG21 ' A' ' 44' ' ' VAL . 0.2 OUTLIER 174.03 -175.36 0.07 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.987 -1.071 . . . . 0.0 110.091 179.729 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.788 HG23 ' O ' ' A' ' 42' ' ' THR . 15.0 t -71.69 99.05 2.04 Favored 'General case' 0 N--CA 1.486 1.347 0 CA-C-O 121.829 0.823 . . . . 0.0 109.812 -179.641 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 84.77 26.57 37.71 Favored Glycine 0 N--CA 1.494 2.549 0 C-N-CA 120.179 -1.01 . . . . 0.0 111.46 178.957 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.76 HG21 ' CB ' ' A' ' 41' ' ' ASP . 1.4 t -116.16 106.25 19.98 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 O-C-N 120.576 -1.544 . . . . 0.0 107.356 178.891 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . 0.869 HD13 ' NE1' ' A' ' 39' ' ' TRP . 13.2 tp -117.93 104.34 10.82 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 120.471 -1.393 . . . . 0.0 109.73 -177.694 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.976 ' HB1' ' CA ' ' A' ' 75' ' ' GLY . . . -97.73 109.66 22.37 Favored 'General case' 0 N--CA 1.485 1.311 0 O-C-N 120.776 -1.203 . . . . 0.0 108.07 178.88 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 36' ' ' GLN . 4.1 t -107.26 163.35 13.09 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.016 -1.053 . . . . 0.0 110.467 -178.705 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.528 HD22 ' HB3' ' A' ' 50' ' ' ALA . 17.0 t30 -111.29 136.77 20.91 Favored Pre-proline 0 N--CA 1.502 2.136 0 O-C-N 121.414 -0.803 . . . . 0.0 109.75 -179.463 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.588 ' HG3' ' CE1' ' A' ' 76' ' ' PHE . 4.7 Cg_endo -73.57 25.67 0.32 Allowed 'Trans proline' 0 C--N 1.319 -1.007 0 C-N-CA 122.463 2.109 . . . . 0.0 112.335 -179.63 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . 0.631 ' HB1' ' CG2' ' A' ' 68' ' ' THR . . . -112.66 3.07 16.41 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.272 -1.518 . . . . 0.0 109.326 179.588 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.534 ' HA ' ' HB3' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -141.45 18.97 2.22 Favored 'General case' 0 C--N 1.298 -1.632 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 179.592 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -79.94 92.06 5.5 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.867 -0.733 . . . . 0.0 110.866 -178.867 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 53' ' ' SER . . . . . 0.618 ' CB ' ' CG1' ' A' ' 34' ' ' VAL . 0.4 OUTLIER -114.47 -168.85 1.43 Allowed 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 178.367 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' O ' ' A' ' 53' ' ' SER . 0.9 OUTLIER 178.9 134.88 0.09 Allowed 'General case' 0 C--N 1.304 -1.372 0 O-C-N 120.597 -1.315 . . . . 0.0 111.214 -179.402 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.763 ' CG1' ' HB1' ' A' ' 63' ' ' ALA . 2.0 p -148.98 157.2 7.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 178.233 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 31' ' ' ALA . 1.2 m -98.26 142.62 29.69 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 120.709 -1.244 . . . . 0.0 109.874 -179.85 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 1.014 ' HB3' ' O ' ' A' ' 27' ' ' GLN . . . -65.36 108.15 1.86 Allowed 'General case' 0 C--N 1.299 -1.626 0 CA-C-O 122.337 1.065 . . . . 0.0 109.649 178.706 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.561 ' N ' ' HA2' ' A' ' 61' ' ' GLY . 12.1 t0 -63.84 -138.8 0.0 OUTLIER 'General case' 0 C--N 1.29 -2.003 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.816 179.888 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.542 ' O ' ' CB ' ' A' ' 28' ' ' ALA . . . -50.81 -52.04 45.07 Favored 'General case' 0 N--CA 1.499 2.016 0 O-C-N 121.361 -0.837 . . . . 0.0 110.697 -178.677 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -101.74 -33.6 9.78 Favored 'General case' 0 C--N 1.287 -2.15 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 178.517 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 1.011 ' HA3' ' HB1' ' A' ' 57' ' ' ALA . . . 104.51 65.92 0.69 Allowed Glycine 0 C--N 1.298 -1.532 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 178.221 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.604 ' HA ' ' O ' ' A' ' 23' ' ' GLY . 55.9 p -98.53 132.41 43.98 Favored 'General case' 0 N--CA 1.482 1.153 0 O-C-N 121.489 -1.007 . . . . 0.0 109.177 179.074 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.763 ' HB1' ' CG1' ' A' ' 55' ' ' VAL . . . -138.63 108.57 6.33 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 119.255 -0.978 . . . . 0.0 109.567 -179.658 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.482 ' HA ' ' HA ' ' A' ' 22' ' ' ALA . 6.0 m -127.11 120.32 28.6 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.272 -0.892 . . . . 0.0 109.681 -179.878 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.535 HG21 HG11 ' A' ' 34' ' ' VAL . 0.3 OUTLIER -146.09 142.72 28.81 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.55 -0.719 . . . . 0.0 109.277 179.794 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.9 p -98.81 131.69 44.74 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.287 -0.883 . . . . 0.0 109.212 179.985 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.753 ' C ' HG13 ' A' ' 18' ' ' VAL . 0.0 OUTLIER -135.6 169.4 17.59 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.288 -0.882 . . . . 0.0 109.569 -179.349 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . 0.631 ' CG2' ' HB1' ' A' ' 50' ' ' ALA . 11.3 t -95.29 137.74 33.93 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.091 -1.006 . . . . 0.0 110.559 -179.425 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.573 HG12 ' HB3' ' A' ' 36' ' ' GLN . 18.3 m -148.24 143.55 19.13 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.381 -0.824 . . . . 0.0 109.536 -179.891 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.607 ' CB ' ' HA ' ' A' ' 15' ' ' ASP . 1.0 OUTLIER -149.95 -174.65 4.77 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.497 -1.377 . . . . 0.0 110.807 -179.863 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 71' ' ' ARG . . . . . 0.62 ' HA ' ' HB3' ' A' ' 88' ' ' CYS . 0.0 OUTLIER -51.86 -102.06 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.414 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.637 -179.458 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.5 ' HA ' ' HA ' ' A' ' 87' ' ' ASP . 0.6 OUTLIER -56.49 141.89 40.97 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 120.831 -1.168 . . . . 0.0 108.577 179.814 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 73' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' A' ' 86' ' ' VAL . 0.3 OUTLIER -163.34 137.26 5.91 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 118.836 -1.146 . . . . 0.0 109.633 -178.402 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.52 ' HB2' ' CD ' ' A' ' 49' ' ' PRO . 17.4 mm-40 -33.56 122.1 0.42 Allowed 'General case' 0 N--CA 1.49 1.571 0 CA-C-O 121.559 0.695 . . . . 0.0 110.78 -178.12 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.976 ' CA ' ' HB1' ' A' ' 46' ' ' ALA . . . -91.32 46.91 2.83 Favored Glycine 0 N--CA 1.493 2.472 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.321 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 76' ' ' PHE . . . . . 0.588 ' CE1' ' HG3' ' A' ' 49' ' ' PRO . 6.1 m-85 -39.64 112.02 0.23 Allowed 'General case' 0 N--CA 1.507 2.404 0 O-C-N 121.073 -1.251 . . . . 0.0 109.856 179.568 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.696 HD13 ' HB2' ' A' ' 83' ' ' TRP . 7.9 tp -85.46 126.44 33.82 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 120.895 -1.128 . . . . 0.0 109.37 -179.927 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.588 ' CD2' ' H15' ' A' ' 114' ' ' CHR . 37.5 t80 -63.89 58.39 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.977 0 O-C-N 120.933 -1.104 . . . . 0.0 110.168 179.833 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' LEU . 4.9 t70 -160.38 19.3 0.14 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.037 -1.039 . . . . 0.0 109.709 179.913 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 85.51 -26.5 5.74 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.163 -1.175 . . . . 0.0 110.163 179.808 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 60.5 p -94.06 158.63 15.53 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.033 -1.275 . . . . 0.0 110.418 -179.346 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.477 ' O ' ' HG2' ' A' ' 82' ' ' ARG . 0.2 OUTLIER -105.08 133.43 49.87 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.698 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 83' ' ' TRP . . . . . 0.696 ' HB2' HD13 ' A' ' 77' ' ' LEU . 1.9 t90 -81.43 -18.9 43.76 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 120.883 -1.135 . . . . 0.0 110.37 -178.573 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 112.34 174.83 19.57 Favored Glycine 0 N--CA 1.485 1.962 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.653 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.1 105.96 0.97 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.112 -1.228 . . . . 0.0 107.72 179.085 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.644 HG21 ' HB3' ' A' ' 46' ' ' ALA . 43.6 t -76.95 105.99 6.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.306 -0.871 . . . . 0.0 109.27 -178.824 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . 0.539 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.4 OUTLIER -66.4 111.14 3.39 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.359 -0.838 . . . . 0.0 109.821 -179.524 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 88' ' ' CYS . . . . . 0.62 ' HB3' ' HA ' ' A' ' 71' ' ' ARG . 1.9 t -62.74 -6.09 3.34 Favored 'General case' 0 N--CA 1.501 2.104 0 C-N-CA 118.225 -1.39 . . . . 0.0 109.875 179.42 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 43.4 p -86.13 -1.26 57.24 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.716 -1.24 . . . . 0.0 109.163 179.63 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.539 HG23 ' HB3' ' A' ' 87' ' ' ASP . 2.6 p -111.47 -49.6 2.99 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.338 -0.851 . . . . 0.0 109.005 179.905 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.27 179.15 4.34 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.415 -0.803 . . . . 0.0 109.438 179.924 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -102.54 116.22 32.16 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.322 -0.861 . . . . 0.0 108.952 179.928 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 93' ' ' CYS . . . . . 0.564 ' SG ' ' CZ ' ' A' ' 73' ' ' PHE . 2.6 m -96.72 124.7 40.78 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.815 -1.178 . . . . 0.0 109.535 -179.478 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 94' ' ' GLN . . . . . 0.594 ' HG3' ' HA ' ' A' ' 109' ' ' ALA . 1.1 mt-30 -105.15 147.87 27.49 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-O 122.515 1.15 . . . . 0.0 111.451 -179.152 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.595 ' CG1' HG11 ' A' ' 7' ' ' VAL . 57.6 t -104.49 110.55 30.93 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.04 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 177.43 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.408 ' HA3' ' HA2' ' A' ' 107' ' ' GLY . . . -148.47 -171.29 17.18 Favored Glycine 0 N--CA 1.488 2.157 0 C-N-CA 118.123 -1.989 . . . . 0.0 111.89 -177.562 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.499 ' HA ' ' O ' ' A' ' 33' ' ' ASP . 0.0 OUTLIER -116.77 -179.62 3.74 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.023 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.58 ' O ' ' CG ' ' A' ' 32' ' ' TYR . 1.5 p -156.1 177.19 11.71 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.367 -0.833 . . . . 0.0 109.715 -179.524 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 99' ' ' ASP . . . . . 0.708 ' O ' ' HB3' ' A' ' 100' ' ' ALA . 0.7 OUTLIER -107.25 -16.27 14.45 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.387 -0.821 . . . . 0.0 109.274 179.811 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 100' ' ' ALA . . . . . 0.708 ' HB3' ' O ' ' A' ' 99' ' ' ASP . . . 76.77 36.02 0.37 Allowed 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.55 -0.718 . . . . 0.0 109.218 -179.83 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . -143.13 -34.68 0.42 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.588 -0.695 . . . . 0.0 110.802 -179.411 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 102' ' ' GLY . . . . . 0.758 ' HA2' H192 ' A' ' 114' ' ' CHR . . . -178.79 -42.67 0.07 OUTLIER Glycine 0 N--CA 1.483 1.783 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 -179.642 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.471 ' O ' ' HB2' ' A' ' 99' ' ' ASP . 0.4 OUTLIER -153.88 -179.62 8.01 Favored 'General case' 0 C--N 1.307 -1.279 0 O-C-N 121.466 -1.02 . . . . 0.0 109.345 178.8 . . . . . . . . 3 3 . 1 . 060 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 105' ' ' PRO . . . -172.45 -166.28 30.79 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 108.631 -1.788 . . . . 0.0 108.631 -179.44 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . 0.517 ' HG3' HD22 ' A' ' 26' ' ' LEU . 3.0 Cg_exo -49.93 -175.64 0.01 OUTLIER 'Trans proline' 0 C--O 1.215 -0.668 0 CA-C-N 118.759 1.279 . . . . 0.0 110.32 179.603 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 15.5 pt-20 -94.43 -179.27 4.85 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.059 -1.026 . . . . 0.0 110.506 -178.843 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.408 ' HA2' ' HA3' ' A' ' 96' ' ' GLY . . . -119.95 162.64 14.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.992 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 108' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 94' ' ' GLN . 1.2 t -101.17 128.42 53.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.334 -1.098 . . . . 0.0 109.165 -179.389 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 109' ' ' ALA . . . . . 0.594 ' HA ' ' HG3' ' A' ' 94' ' ' GLN . . . -75.71 124.02 26.56 Favored 'General case' 0 C--N 1.289 -2.047 0 O-C-N 121.59 -0.694 . . . . 0.0 109.552 179.669 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 110' ' ' ILE . . . . . 0.758 HD12 ' CE1' ' A' ' 112' ' ' PHE . 1.5 pt -97.75 167.79 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.21 -0.931 . . . . 0.0 109.234 -179.913 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.495 ' HB2' ' CB ' ' A' ' 11' ' ' SER . 15.2 m -137.0 156.33 48.58 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.276 -0.89 . . . . 0.0 109.481 -179.931 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 112' ' ' PHE . . . . . 0.758 ' CE1' HD12 ' A' ' 110' ' ' ILE . 17.5 m-85 -122.18 126.9 49.3 Favored 'General case' 0 N--CA 1.486 1.347 0 O-C-N 121.204 -0.935 . . . . 0.0 109.523 -179.787 . . . . . . . . 2 2 . 1 . 060 nuclear nobuild full ' A' A ' 113' ' ' ASN . . . . . 0.457 ' OXT' ' O ' ' A' ' 112' ' ' PHE . 20.1 p30 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 117.969 -1.015 . . . . 0.0 109.502 -179.938 . . . . . . . . 1 1 . 1 . 060 nuclear nobuild full ' A' A ' 114' ' ' CHR . . . . . 0.758 H192 ' HA2' ' A' ' 102' ' ' GLY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_